REGISTRY,SITE,GROUP,PATIENT_DISPLAY_ID,TUMOR_RECORD_NUMBER,RECORD_DOCUMENT_ID,TEXT_PATH_CLINICAL_HISTORY,TEXT_PATH_COMMENTS,TEXT_PATH_FORMAL_DX,TEXT_PATH_FULL_TEXT,TEXT_PATH_GROSS_PATHOLOGY,TEXT_PATH_MICROSCOPIC_DESC,TEXT_PATH_NATURE_OF_SPECIMENS,TEXT_PATH_STAGING_PARAMS,TEXT_PATH_SUPP_REPORTS_ADDENDA
REG3,COLON,0,PAT-00451455,2,REC-5000719522,,,,"<CLINICAL INFO>
A. RULE OUT SPRUE, GIARDIA AND CROHN's DISEASE
B. RULE OUT ADENOMA
C. RULE OUT CARCINOMA


<GROSS>
The specimen, labeled on container as **NAME[BBB], is received in three parts. (csc)
A. Part A, designated random proximal small bowel biopsy, is one formalin-fixed, irregular, tan soft tissue fragment, 0.3 cm in greatest dimension. The specimen is inked. All embedded, one block. 
B. Part B, designated biopsy, ascending colon and transverse colon polyps, is four formalin-fixed, irregular, tan soft tissue fragments varying up to 0.3 cm in greatest dimension. The specimen is inked. All embedded, one block.
C. Part C, designated sigmoid colon ulcerated mass biopsy, is four formalin-fixed, irregular, tan soft tissue fragments averaging 0.2 cm in greatest dimension. The specimen is inked. All embedded, one block.


<MICROSCOPIC>
See diagnosis.


<FINAL DX>
A. RANDOM BIOPSY, PROXIMAL SMALL BOWEL: BENIGN DUODENAL MUCOSA WITH NO SIGNIFICANT HISTOPATHOLOGIC CHANGES. No significant inflammatory process is present. No villous blunting or intraepithelial lymphocytosis is present. Negative for Giardia. Negative for dysplasia and malignancy.
B. BIOPSY, POLYPS, ASCENDING COLON, TRANSVERSE COLON: MULTIPLE TUBULAR ADENOMATA. Negative for high-grade dysplasia and invasive malignancy.
C. BIOPSY, ULCERATED MASS, SIGMOID COLON: SUPERFICIALLY INVASIVE, MODERATELY DIFFERENTIATED COLONIC ADENOCARCINOMA, WITH FOCAL MUCINOUS FEATURES. THE CARCINOMA IS ARISING WITHIN AN ADENOMATOUS POLYP WITH FOCAL HIGH-GRADE DYSPLASIA. NO DEFINITIVE ANGIOLYMPHATIC INVASION IS IDENTIFIED. See comment.


<DX COMMENT>
B. As part of the routine quality assurance program, selected slides have been reviewed by Dr. **NAME[ZZZ] who concurs with the diagnosis.",,,,,
REG3,COLON,0,PAT-00541798,3,REC-5000720380,,,,"<CLINICAL INFO>
HISTORY OF POLYP


<GROSS>
The specimen, labeled on container as **NAME[BBB], 972975, designated ascending colon polyp, is multiple formalin-fixed, irregular, tan soft tissue fragments varying up to 0.7 cm in greatest dimension. These are filtered and inked. All embedded, one block. (csc)


<MICROSCOPIC>
See diagnosis.


<FINAL DX>
ASCENDING COLON POLYP: 
 INFILTRATING ADENOCARCINOMA WITH MUCINOUS FEATURES. 


<DX COMMENT>
As part of the routine quality assurance program, selected slides have been reviewed by Dr. **NAME[ZZZ], who concurs with the diagnosis.
RESULT OF CONSULTATION
Immunocytochemical studies done at PhenoPath Laboratories are positive for loss of expression of mismatch repair gene products. Please see their accompanying report (***PATH-NUMBER[1]).",,,,,
REG3,COLON,0,PAT-00347923,2,REC-5000728853,,,,"CASE: GAO11-003406
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A. Ileocecal Valve, Biopsy:
     Mild active ileitis.

B. Colon, Ascending Colon Mass, Biopsy:
     Invasive adenocarcinoma, well differentiated.

C. Colon, Ascending Colon Polyps x2, Biopsy:
     Invasive adenocarcinoma, one piece (SEE COMMENT).
     Inflammatory polyp, two pieces.
     Normal colonic mucosa, two pieces.

<COMMENT>
The active ileitis seen at the ileocecal valve may be related to NSAIDs
or mass effect. Part C is designated ""ascending colon polyps x2"" with
three tissue fragments identified grossly. The slide shows five pieces
of tissue including a fragment of invasive adenocarcinoma. This may
represent tissue contamination from part B; Endoscopic correlation
needed.

<CLINICAL INFO>
Not provided. ICD9 Code(s): 211.3, 153.6

<GROSS>
Part A: Received in formalin; container labeled with **NAME[BBB, AAA
M] and Ileocecal Valve Biopsy. Number of tissue fragments 3,
total/aggregate size 2-3 mm. Entirely submitted: number of cassettes 1.

Part B: Received in formalin; container labeled with **NAME[BBB, AAA
M] and Ascending Colon Mass. Number of tissue fragments Aggregate,
total/aggregate size 1-2 mm. Entirely submitted: number of cassettes 1.

Part C: Received in formalin; container labeled with **NAME[BBB, AAA
M] and Ascending Colon Polyps x2. Number of tissue fragments 3,
total/aggregate size 1-5 mm. Entirely submitted: number of cassettes 1.
Largest piece inked black and bisected. (TLH)

<MICROSCOPIC>
A. Sections of ileocecal valve show three pieces of small bowel mucosa,
all three of which are involved by mild active ileitis with a
superficial neutrophil-rich infiltrate. Pseudopyloric metaplasia is not
present. There is no granulomatous inflammation, dysplasia, or
malignancy.

INTRADEPARTMENTAL CONSULTATION:
**NAME[ZZZ M. YYY], M.D.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[May 28 2012]",,,,,
REG3,COLON,0,PAT-00405167,3,REC-5000730121,,,,"<CLINICAL INFO>
 Cecal carcinoma, lap right colectomy.<FINAL DX>
 A) Right colon and ileum, right hemicolectomy:
  Adenocarcinoma; refer to summary cancer data.SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Colon resection, segmental for tumor
  Specimen and Tumor Location
  Specimen type: Right hemicolectomy
  Specimen length: 22cm
  Tumor site: Right (ascending) colon (C18.2)
  Characteristics and Extent of Neoplasm
  Histologic type: Adenocarcinoma (81403)
  Histologic grade: Low-grade (well to moderately differentiated; >50% gland
  formation)
  Tumor size: Greatest diameter: 2.5cm
  Tumor perforation (macroscopic): Not identified
  Microscopic tumor extent:
  Tumor invades through muscularis propria but does not penetrate any peritoneal
  surface
  Tumor deposits: Not identified
  Lymphatic [small vessel] Invasion  (L): Indeterminate
  Venous [large vessel] Invasion (V): Not identified
  Perineural invasion: Absent
  Comment about Local Extent:
  There is a nest of carcinoma separated from the main mass next to a vessel
  suggestive of lymphatic space invasion.
  Final Surgical Resection Margins
  Grossly positive margin(s): None
  Microscopically positive margin(s): None
  Lymph Node Status
  Node summary: Nodes with carcinoma: 0    / Total nodes examined: 11
  Comment about lymph nodes: An extensive search for lymph nodes was performed.
  Minimum Pathologic Stage (AJCC, 7th ed., 2010)
  Primary tumor (pT): pT3: Tumor invades through the muscularis propria into
  pericolorectal tissues
  Regional lymph nodes (pN): pN0: No regional lymph node metastasis
  Other Findings
  Tumor-Infiltrating Lymphocytes per high-power field: 0
  Peri-tumoral lymphocytic response (Crohn-like reaction): Mild/Moderate (0-
  2/hpf)
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received fresh labeled with the patient's
  name ""**NAME[BBB, AAA CCC]"" and designated ""A) right colon"" is an ileocolectomy
  specimen (colon - 15 cm, ileum - 6.5 cm), with an abundant amount of
  pericolonic fat.  For intraoperative consultation, the specimen is partially
  opened along the lateral aspect to reveal a 2.5 cm ulcerated lesion with
  rolled edges and a firm 0.4 cm nodule within the ulcer bed.  The lesion is 2.5
  cm from the ileocecal valve and 7.5 cm from the distal colonic margin.  The
  uninvolved colonic mucosa is grossly unremarkable with normal intestinal
  folds.  The small bowel is also grossly unremarkable.  There is a 5.5 cm
  attached appendix with no gross abnormalities.  The overlying serosal fat is
  inked green in the area of the ulcer and the lesion is blocked out and
  serially sectioned.  Cut surfaces show an invasive lesion to a depth of 0.6
  cm, encroaching the subserosal adipose tissue, coming to 1.5 cm of the inked
  margin.  Representative sections are submitted as follows:  A1 - A3 - areas of
  deepest invasion; A4 - normal colonic mucosa with polyp; A5 - normal small
  bowel margin; A6 - appendix (base inked green); A7 - A11 - lymph node
  candidates. Additional search for lymph nodes is performed by the pathology
  assistant and no additional lymph nodes are found.  (MS/**INITIALS)<FROZEN SECTION DX>
 A)  Colon with approximately 2 cm
  carcinoma widely free of margin. (MS/RAS, **DATE[Jan 12 12], 11:19 a.m.)(MS/jps)",,,,,
REG3,COLON,0,PAT-00411395,2,REC-5000732122,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Right Colon, (19 cm in length), Resection:
   Invasive carcinoma of the cecum with the following features:
      Size:    5.7 x 5.5 x 4 cm.
      Histologic type:   Mucinous adenocarcinoma.
      Histologic grade:  Low grade/Well differentiated.
      Depth/extent of invasion:    Into subserosa, not penetrating
through serosa.
      Margins: Negative.
         Mucosal:   9 cm to proximal mucosal margin.
         Radial:    4.5 cm.
      Extramural vein (large vessel) invasion:    Absent.
      Lymphatic (small vessel) invasion:     Not identified.
      Regional lymph nodes:   21 total lymph nodes identified, 9 nodes
with metastatic carcinoma (9/21).
     Pathologic stage:   IIIC: pT3, pN2b (AJCC 7th Edition).

   Additional findings:                 Separate tubular adenoma.
                              Subserosal abscess possibly associated
with
                               diverticulum or fissure.

B.  Gallbladder, Cholecystectomy:
     Chronic cholecystitis with cholelithasis.
     One benign lymph node.

<CLINICAL INFO>
A - vessel loop on ileocolic pedicle. B - cholelithiasis.

<GROSS>
A.  Received in formalin, labeled ""**NAME[BBB, AAA M]."" and designated ""A.
Cecal cancer"", is a right colectomy consisting of an 11.5 cm long and 3
cm in diameter terminal ileum continuous with a 19 cm long and 3.5 cm in
diameter cecum and distal colon, stapled at both ends. The proximal
margin is inked blue and the distal margin is inked black. The attached
mesenteric and pericolic fat is 25 x 5 x 4 cm. A 6.5 cm long and 0.7 cm
in diameter appendix is identified. The serosa is dusky and hemorrhagic
with an abundant amount of adhesions/adherent clot surrounding the
cecum. There is a 3.2 x 1.5 x 0.6 cm edematous/cystic looking area with
central puckering at the cecum. This area is inked green. The radial fat
margin is inked orange. A 5.7 x 5.5 x 4 cm cecal mass is identified,
involving the ileocecal valve and the proximal end of the appendix. The
mass occupies the entire cecum and extends through the wall and into the
underlying fat. It is 4.5 cm from the radial fat margin (mesenteric), 9
cm from the proximal margin, and 11.5 cm from the distal margin. The
mass is circumferential and constricts the lumen up to 1 cm in diameter.
There is a 1 x 0.9 x 0.9 cm polypoid lesion identified distal to the
mass. The lesion is 2.5 cm distal to the mass, 3 cm distal to the
ileocecal valve, 13 cm from the proximal margin, and 10 cm from the
distal margin. The cut surface of the polyp appears to possibly extend
focally into the wall. The wall within this area is up to 0.8 cm in
thickness. No other tumors, polyps, or lesions are identified. The
mucosa distal to the mass and polypoid lesion is slightly edematous but
otherwise unremarkable. The fat is thoroughly searched for lymph nodes
and 22 nodes are identified up to 2 cm. Representative sections are
submitted as follows: A1 - longitudinal margins; A2 - radial fat margin
closest to mass, en face; A3 - mass in relation to appendiceal orifice
and proximal appendix; A4 - appendix (including distal tip, bisected);
A5 - mass in relation to appendical orifice; A6 - mass in relation to
puckered/edematous serosa, bisected; A7 - mass in relation to underlying
fat; A8 - mass in relation to colon wall; A9, A10 - entire polyp,
bisected; A11 - eight possible nodes; A12 - five possible nodes; A13 -
two nodes, inked and bisected; A14 - three nodes, inked and bisected;
A15, A16 - cluster of four possible nodes, bisected.

B.  Received in formalin, labeled ""**NAME[BBB, AAA M]."" and designated ""B.
Gallbladder"", is a 8.5 x 3 x 2.7 cm nonintact gallbladder. The serosa is
smooth is tinged-green. There is a 0.8 x 0.7 x 0.4 cm lymph node within
the fat adjacent to the cystic duct. The wall is up to 0.4 cm in
thickness. The mucosa is dark green and velvety. The lumen contains
green, viscous bile and a 1.7 cm black granular stone. Representative
sections, including the cystic duct margin and lymph node, bisected, are
submitted in cassette B1. (jo/jmk)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

**NAME[ZZZ M YYY], M.D.  Electronically signed **DATE[Apr 01 2012]",,,,,
REG3,COLON,0,PAT-00448865,2,REC-5000734084,,,,"PART / DESCRIPTION - SEQ# 
Colon, other/ RIGHT COLON- 1<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONE<MICROSCOPIC>
RIGHT COLON
Ten slides reviewed. The specimen shows evidence of a previous biopsy site without a residual malignancy. A tubular adenoma is also identified.<CLINICAL INFO>
Ascending colon polyp; colon cancer.<FINAL DX>

MASS, RIGHT COLON, RESECTION (15 CM): SEGMENT OF COLON SHOWING INFLAMMATION AND FIBROSIS CONSISTENT WITH A PREVIOUS BIOPSY SITE. NO RESIDUAL MALIGNANT NEOPLASM. SURROUNDING COLON SHOWS A TUBULAR ADENOMA. 0 OF 6 LYMPH NODES SHOW METASTATIC CARCINOMA.
**INITIALS<GROSS>
RIGHT COLON: 
(GF:ab) Received in formalin labeled """"**NAME[CCC BBB AAA],"""" designated """"right colon,"""" is a previously opened partial colectomy specimen which includes the cecum and portion of ascending colon in continuity to a segment of terminal ileum. The cecum and ascending colon measures 12 cm in length and the segment of terminal ileum measures 3 cm. Examination of the colon reveals a stellate, firm, pink-red area of interest which is suggestive of an old biopsy site measuring 0.5 x 0.5 cm. This area of interest is 3 cm from the ileocecal valve area and 8 cm to the distal margin of resection. This area of interest is blocked, sectioned and entirely submitted. The radial margin is marked blue. Further examination of the colon reveals a tiny red-brown, slightly raised mucosal lesion measuring 0.3 cm in greatest dimension. The rest of the mucosa, along with the ileocecal valve and terminal ileum, are grossly unremarkable. Thorough examination of the attached pericolonic fat reveals several nodes ranging from 0.2 up to 0.5 cm. Also attached is grossly unremarkable omental fat. No appendix is attached.

Summary of sections: 1a-surgical margins; 1b-cut mesenteric margin; 1c, 1d-colon apparent biopsy site, entirely submitted; 1e-slightly raised mucosal lesion, colon; 1f-sections nonlesional colon; 1g-sections ileocecal valve and terminal ileum; 1h-multiple intact pericolonic fatty lymph nodes; 1i, 1j-sections omental fatPATHOLOGIST:
**NAME[ZZZ YYY M]",,,,,
REG3,COLON,0,PAT-00585233,4,REC-5000736984,,,,"<CLINICAL INFO>
HISTORY OF COLON CANCER / COLONOSCOPY


<GROSS>
The specimen, labeled on container as **NAME[BBB], designated proximal colon, is four formalin-fixed, irregular, tan soft tissue fragments, 0.2 to 0.3 cm in greatest dimension. The specimen is inked. All embedded, one block. (nh)


<MICROSCOPIC>
See diagnosis.


<FINAL DX>
BIOPSY, PROXIMAL COLON: 
 INVASIVE MODERATELY-DIFFERENTIATED ADENOCARCINOMA.


<DX COMMENT>
The adenocarcinoma does not appear to be arising within a background adenomatous lesion. Several sections show only involvement of the submucosa. These features are suggestive of recurrence or metastasis. 
As part of the routine quality assurance program, the case has been reviewed by Dr. **NAME[ZZZ] who concurs with the diagnosis.
The results have been called to the physician's office on **DATE[Jan 26 2012].",,,,,
REG3,COLON,0,PAT-00173516,3,REC-5000751267,,,,"<FINAL DX>
  A) RIGHT COLON, RESECTION: HIGH-GRADE COLONIC ADENOCARCINOMA WITH THE
FOLLOWING FEATURES: 
1. TUMOR SIZE: 5.0 CM IN THE GREATEST DIMENSION. 
2. TUMOR SITE: CECUM.
3. EXTENT OF INVASION: INVADES THROUGH MUSCULARIS PROPRIA INTO SUBSEROSA. 
4. RESECTION MARGIN: ALL SURGICAL MARGINS UNINVOLVED BY CARCINOMA. 
5. REGIONAL LYMPH NODES: TWENTY SIX LYMPH NODES IDENTIFIED; TWO OF THE
TWENTY SIX LYMPH NODES ARE POSITIVE FOR METASTATIC CARCINOMA. 
6. LYMPH-VASCULAR INVASION: PRESENT. 
7. TUMOR DEPOSITS: NOT IDENTIFIED. 
8. TREATMENT EFFECT: NO PRIOR TREATMENT. 
9. ADDITIONAL FINDINGS: ONE SESSILE SERRATED ADENOMA; TWO TUBULAR ADENOMAS. 
10. HISTOLOGIC FEATURES SUGGESTIVE OF MICROSATELLITE INSTABILITY INCLUDING
MUCINOUS TUMOR COMPONENT, HIGH HISTOLOGIC GRADE AND RIGHT SIDED LOCATION. 
11. PATHOLOGIC STAGE: pT3, pN1b, pM1
B) LIVER BIOPSY:  INFILTRATING ADENOCARCINOMA, MORPHOLOGICALLY CONSISTENT
WITH METASTATIC COLONIC ADENOCARCINOMA.

<PATHOLOGIST>
   Zhu, Lee-Ching              Electronically Signed: **DATE[Dec 24 2011]
<SPECIMEN(S)>
  A) R. COLON
B) LIVER Bx
<GROSS>
  A) Received in a container labeled with the patient's name and ""#1"",
requisition additionally stating ""right colon"" is a 3.5 cm long, 2.5 cm in
diameter portion of terminal ileum contiguous with a 17.5 cm long by 4.0
cm in average diameter segment of large bowel which includes cecum and
ascending colon, with a moderate amount of attached mesenteric adipose
tissue. The appendix is surgically absent. The serosa is purple-tan,
focally dusky with numerous membranous adhesions and is remarkable for a
2.5 x 2.5 cm focus of retraction and puckering 6.0 cm from the distal
resection margin. This focus is marked with silver nitrate. The specimen
is opened to demonstrate a 5.0 x 5.0 x 1.7 cm plaque-like mass lesion with
central ulceration and heaped-up borders. This mass lesion corresponds to
the aforementioned focus of serosal retraction and comes to within 3.8 cm
of the distal resection margin at closest approach and is grossly clear of
the proximal resection margin. Sectioning reveals gray-tan homogenous,
indurated cut surfaces and the maximum tumor thickness is 2.0 cm. The
lesion extends into and through the bowel muscularis and into the adjacent
mesenteric adipose tissue, grossly abutting the silver nitrate-marked
puckered, retracted serosa. Additionally, the specimen demonstrates four
brown-tan, granular, sessile mucosal polyps ranging from 0.4 cm up to 2.8
cm in greatest dimension which are located within the cecum.  The largest
lesion (2.8 x 1.1 x 0.6 cm) focally abuts the ileocecal valve and
sectioning reveals brown-tan granular cut surfaces which are grossly
confined to the mucosa. No additional discrete lesions are noted and the
remaining, uninvolved bowel mucosa is tan, focally granular and
convoluted. The attached mesenteric adipose tissue is palpated, dissected
for lymph node candidates and thirty are identified ranging from 0.3 cm up
to 0.9 cm in greatest dimension. Representative sections are submitted as
follows: 
A1) Proximal resection margin. 
A2) Distal resection margin. 
A3) Ileocecal valve. 
A4-A6) Representative mass lesion. 
A7) Representative largest mucosal polyp. 
A8) Smaller mucosal polyps. 
A9) Uninvolved bowel wall. 
A10-A14) Six lymph node candidates submitted in toto, each. 
Also received in the container are two bowel segments which are
arbitrarily designated ""A and B"". Bowel segment ""A"" is 2.6 cm long by 1.7
cm in diameter with a small amount of attached mesenteric adipose tissue
with no palpable lymph nodes. The focally intact serosa is pink-tan,
smooth, glistening and grossly unremarkable. The specimen demonstrates one
stapled resection margin and one opened margin. The staple line is
removed, the underlying parenchyma is inked orange and the specimen is
opened to demonstrate grossly unremarkable tan, granular and convoluted
mucosa. No discrete lesions are grossly appreciated. 
Bowel segment ""B"" is 4.0 cm long by approximately 4.0 cm in diameter with
a scant amount of attached mesenteric adipose tissue. The serosa is tan,
smooth, glistening and grossly unremarkable. The bowel segment
demonstrates two stapled resection margins which are removed and the
underlying parenchyma is differentially inked. The specimen is opened to
demonstrate grossly unremarkable pink-tan granular and convoluted mucosa
throughout. No discrete lesions are grossly appreciated. Representative
sections are submitted as follows:
A15) Bowel segment A. 
A16) Bowel segment B. 
B) Received in a container labeled with the patient's name and ""#2"",
requisition additionally stating ""liver biopsy"" are four white and tan
soft tissue needle cores, 5.0 cm in aggregate length, AE/(4).
<MICROSCOPIC>
  A) Features are of a high-grade colonic adenocarcinoma with mucinous
differentiation (representing approximately 20% tumor component in
sections examined).  Carcinoma invades through muscularis propria into
subserosa.  
B) In a background of non-cirrhotic liver parenchyma, sections demonstrate
invasive adenocarcinoma with morphologic similarity to the identified
colonic adenocarcinoma.",,,,,
REG3,COLON,0,PAT-00588600,2,REC-5000751934,,,,"PART / DESCRIPTION - SEQ# 
Colon, total resection (incl lymph nodes)/ Colon, Total Resection- 1
<INTRAOPERATIVE DX>
NONE
<MICROSCOPIC>
NONESynoptic Diagnosis
COLON, TOTAL RESECTION 
SPECIMEN: Terminal ileum
 Cecum
 Appendix
 Ascending colon
 Transverse colon
 Other: colostomy stoma revision, omentum
PROCEDURE: Total abdominal colectomy
SPECIMEN LENGTH: 80 cm
PRIMARY TUMOR SITE: Right (ascending) colon
ADDITIONAL SITES INVOLVED BY TUMOR: None identified
MACROSCOPIC TUMOR PERFORATION: Not identified:
INTACTNESS OF MESORECTUM: Not applicable:
HISTOLOGIC TYPE: Adenocarcinoma
HISTOLOGIC GRADE: Low-grade (well to moderately differentiated)
INTRATUMORAL LYMPHOCYTIC RESPONSE: None
PERITUMOR LYMPHOCYTIC RESPONSE: None
TUMOR SUBTYPE AND DIFFERENTIATION: Mucinous tumor component: 50 %
TUMOR SIZE: Greatest dimension: 2.5 cm
MICROSCOPIC TUMOR EXTENSION: Tumor invades through the muscularis propria into the subserosal adipose tissue or the nonperitonealized pericolic or perirectal soft tissues but does not extend to the serosal surface
PROXIMAL MARGIN: Uninvolved by invasive carcinoma
Intramucosal carcinoma /adenoma not identified at proximal margin
DISTAL MARGIN: Uninvolved by invasive carcinoma
Intramucosal carcinoma /adenoma not identified at distal margin
CIRCUMFERENTIAL MARGIN: Uninvolved by invasive carcinoma
TREATMENT EFFECT: Not known
LYMPH-VASCULAR INVASION: Not identified
PERINEURAL INVASION: Not identified
TUMOR DEPOSITS: Tumor Deposits Not identified
TYPE OF POLYP IN WHICH INVASIVE CARCINOMA AROSE: Tubular adenoma
TNM DESCRIPTORS: Not identified:
PATHOLOGIC STAGING (pTNM): pT3: Tumor invades through the muscularis propria into pericolorectal tissues
REGIONAL LYMPH NODES (pN): pN0: No regional lymph node metastasis
 Number of nodes examined: 14
 Number of nodes involved: 0
DISTANT METASTASIS (pM): Not identified:
ADDITIONAL PATHOLOGIC FINDINGS: Other polyps:submucosal lipoma
--------------------------------------------------------


<FINAL DX>
Colon (right hemicolectomy specimen and revision of colostomy): A). invasive moderately differentiated adenocarcinoma with mucinous features arising from a tubular adenoma with high-grade dysplasia. B). tumor invades through the muscularis propria into subserosal connective tissue, no perforation identified. C). proximal, distal and radial surgical margins negative for malignancy. D). fourteen (14) lymph nodes, negative for malignancy. E). skin and anastomosed bowel consistent with colostomy revision. F). please see CAP protocol summary for more complete details.

**DATE[Jul 1 2012] SMC
<GROSS>
The specimen is received in one formalin filled container labeled with the patient's name, sublabeled """"colon"""" and consists of a right hemicolectomy specimen. The proximal margin of resection measures 4.5 cm in diameter. The distal margin of resection measures 4 cm in diameter. A portion of terminal ileum is present measuring 3 cm in length and portion of cecum and right colon is present measuring 80 cm in length. A pale tan vermiform appendix is identified measuring 6 x 0.6 x 0.5 cm. Attached is yellow periappendiceal adipose tissue measuring 7 x 2.2 x 0.9 cm. Upon sectioning no fecaliths are identified. The serosal surface is smooth and tan. The mucosal surface is pale tan and retained is rugose folds. A mass lesion is identified measuring 2 x 2 x 1 cm. The mass lesion is located at the terminal ileum cecum junction 3 cm from the proximal margin of resection and 72 cm from the distal margin of resection. The mass lesion does not extend through the muscularis propria. A second fungating tan mass lesion is identified measuring 2.5 x 2.5 x 1 cm. The mass lesion does not extend through the muscularis propria. No additional mass lesions, areas of hemorrhage, ulcerations, or perforations are identified. The mass lesion is located 22 cm from the terminal ileum and 43 cm from the distal margin of resection. Attached to the bowel wall is pericolonic adipose tissue measuring 80 x 8 x 4 cm. Sections through the adipose tissue reveal multiple pale tan lymph nodes ranging up to 0.9 x 0.5 x 0.3 cm. Representative sections are submitted as follows: Cassette A: Appendix, cassettes B - C colon proximal margin resection, cassettes D - E colon distal margin resection, cassettes F - G: First described mass lesion, cassettes H - I: Second described mass lesion, cassette J: Uninvolved colon cassette K: 2 lymph nodes, cassette L: 2 lymph nodes, cassette M: 2 lymph nodes, cassette N: 4 lymph nodes, cassettes O - V: Possible lymph nodes

 Also present in the container is a portion of small bowel measuring 14 x 3 x 2.5 cm. The first margin of resection measures 4 cm and the opposite margin of resection measures 3 cm. The serosal surface is smooth and pale tan. The mucosal surface is tan and retained is rugose folds. No mass lesions, areas of hemorrhage, ulcerations, or perforations are identified. Representative sections are submitted as follows: cassette W: First margin of resection, cassette X: Second margin of resection, cassette Y: Small bowel.

 A second portion of small bowel is present measuring 3.5 x 2 x 1.5 cm. The first margin of resection measures 3 cm in diameter the opposite margin of resection measures 2.5 cm in diameter. The serosal surface is smooth and pale tan. The mucosal surface is tan and retained is rugose folds. No mass lesions, areas of hemorrhage, ulcerations, or perforations are identified. Representative sections are submitted as follow:, cassette Z: First margin of resection, cassette AA: Opposite margin of resection, cassette BB: Small bowel.

 A stoma and ellipse of surrounding skin is present in the container. The skin measures 14 x 9 x 1.3 cm. The surface is smooth and pale tan. The stoma measures 8.5 x 5 x 3 cm. A second portion of skin is identified measuring 2.5 x 1.5 x 0.3 cm. The underlying tissue is yellow-tan and measures 5.5 x 5 x 2.5 cm. The cut surface is smooth, yellow-tan and homogeneous. Representative sections are submitted as follows: cassette CC: Stoma and skin, cassette DD: Additional portion of skin.

2 portions of omentum are present in the container ranging up to 45 x 17 x 2 cm. Sections through the omentum reveal no areas of necrosis or hemorrhage. Representative sections are submitted as cassettes EE - FF. **DATE[Jul 1 2012] **INITIALS
<CLINICAL INFO>
Colon cancer
1). Colon<PATHOLOGIST>
**NAME[ZZZ YYY M] 

<SNOMED Code(s)>
T67965T67080T67040T1X200P1100M84803M82110M821032T67950T50500T08000P1452M18200M09400M74000",,,,,
REG3,COLON,0,PAT-00432475,3,REC-5000764520,,,,"**NAME[ZZZ,YYY M] MD

   **NAME[XXX,WWW VVV]









H/o colon cancer.



   

   BIOPSIES OF SIGMOID COLON LESION:  MODERATELY DIFFERENTIATED ADENOCARCINOMA.





   This case was seen in consultation with Dr. **NAME[UUU].  Results were telephoned to Dr. **NAME[ZZZ] at 1140 on **DATE[Oct 13 11].





   Several 2 mm tan biopsies are submitted together.",,,,,
REG3,COLON,0,PAT-00563035,2,REC-5000768657,,,,"PART / DESCRIPTION - SEQ# 
Colon, other/ RIGHT COLON- 1Comment
Several findings in this case suggest the likely possibility that this represents a microsatellite instable (MSI) tumor. These findings include the poorly differentiated/dedifferentiated histologic appearance of the tumor with accompanying mucinous and medullary features, the absence of identifiable lymph node metastases in a tumor of this size and differentiation, and the presence of several separate sessile serrated adenomas in the cecum.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONE<FINAL DX>

TERMINAL ILEUM (4 CM), ASCENDING/RIGHT COLON (19 CM), AND APPENDIX, SEGMENTAL EXCISION: PROCEDURE: RIGHT HEMICOLECTOMY. 
 TUMOR SITE: CECUM. 
 TUMOR SIZE: LUMINAL DIMENSIONS = 11.0 X 6.5 CM. 
 MACROSCOPIC TUMOR PERFORATION: NOT IDENTIFIED. 
 HISTOLOGIC TYPE: ADENOCARCINOMA, POORLY DIFFERENTIATED, WITH AREAS OF MUCINOUS, SIGNET-RING AND MEDULLARY DIFFERENTIATION (SEE COMMENT). 
 HISTOLOGIC GRADE: HIGH GRADE (POORLY DIFFERENTIATED). 
 HISTOLOGIC FEATURES SUGGESTIVE OF MICROSATELLITE INSTABILITY (SEE COMMENT). INTRATUMORAL LYMPHOCYTIC RESPONSE- MILD TO MODERATE. PERITUMOR LYMPHOCYTIC RESPONSE- MILD TO MODERATE. TUMOR SUBTYPE AND DIFFERENTIATION- HIGH HISTOLOGIC GRADE (POORLY DIFFERENTIATED) WITH MUCINOUS AND MEDULLARY TUMOR COMPONENTS. 
 MICROSCOPIC TUMOR EXTENSION: TUMOR INVADES THROUGH MUSCULARIS PROPRIA INTO NON-PERITONEALIZED PERICOLIC SOFT TISSUES BUT DOES NOT EXTEND TO SEROSAL SURFACE. 
 SURGICAL MARGINS: PROXIMAL MARGIN- UNINVOLVED BY INVASIVE CARCINOMA. DISTAL MARGIN- UNINVOLVED BY INVASIVE CARCINOMA. CIRCUMFERENTIAL AND MESENTERIC MARGIN- UNINVOLVED BY INVASIVE CARCINOMA. DISTANCE OF INVASIVE CARCINOMA FROM CLOSEST MARGIN- ~3 CM (PROXIMAL END MARGIN). 
 LYMPH-VASCULAR TUMOR INVASION: NOT IDENTIFIED. 
 PERINEURAL TUMOR INVASION: NOT IDENTIFIED. 
 TUMOR DEPOSITS/DISCONTINUOUS EXTRAMURAL EXTENSION: NOT IDENTIFIED.
 TUMOR BUDDING: NOT PROMINENT. 
 LYMPH NODE STATUS: 20 BENIGN LYMPH NODES. 
 MINIMUM PATHOLOGIC STAGING: pT3 pN0
 ADDITIONAL PATHOLOGIC FINDINGS: TWO SESSILE SERRATED ADENOMAS OF CECUM. 
3260F
MJF:cr<MICROSCOPIC>
RIGHT COLON: 
Sections examined. See final diagnosis.<GROSS>
RIGHT COLON: 
(**INITIALS:cr) The specimen is received fresh from the operating room labeled with the patient's name and designated """"right colon."""" The specimen consists of an apparent hemicolectomy with 4 cm of terminal ileum resected in continuity with 19 cm of proximal colon. Both end surgical margins are open. The external surface of the bowel does not show definite tumor penetration. An unremarkable 4 x 0.4 cm appendix is present in its normal position. A variable amount of peribowel fatty tissue, mesentery and omentum is present. The bowel is opened longitudinally. Present in the cecum is an ulcered necrotic appearing tumor mass with maximum luminal dimension of 11.0 x 6.5 cm. The tumor appears to extend into the ileocecal valve. The distance from the tumor to the distal colonic and margin of resection is approximately 9 cm. On cut section the tumor shows invasion into and through the muscularis propria. The cecum also demonstrates 2 separate polyps measuring 0.4 cm in and 1.0 cm respectively. The terminal ileal mucosa does not evidence of polyps. The mesenteric and omental tissues appear unremarkable. Multiple pericolonic lymph nodes are isolated. 

Summary of sections: 1a-end surgical margins; 1b-cut mesenteric margin; 1c-appendix; 1d through 1h-tumor; 1i-cecal polyps; 1j-random colon; 1k-ileocecal valve and random terminal ileum; 1l-omentum; 1m, 1n-multiple intact lymph nodes; 1o-three bisected lymph nodes. 

Note: Portions of the colonic mass were taken fresh and submitted for a BiospeciFX studies.<CLINICAL INFO>
Colon carcinoma.PATHOLOGIST:
**NAME[ZZZ YYY]",,,,,
REG3,COLON,0,PAT-00481783,3,REC-5000775691,,,,"<CLINICAL INFO>
SIGMOID COLON CARCINOMA.
<SPECIMEN(S)>
A. RECTO SIGMOID COLON.
B. ANASTOMOTIC DONUTS X2, PROXIMAL AND DISTAL.
C. LEFT TUBE AND OVARY. ADHERENT TO SIGMOID COLON, QUERY METASTATIC CA.
<GROSS>
Received in formalin labeled with the patient's name in three parts.
A. Labeled ""1. Sigmoid colon"" is a segment of colon measuring 20.0 cm in length and 3.2 cm in diameter, with attached yellow to red pericolic adipose tissue. The serosal surface is smooth, red to purple, with a firm depressed area measuring 4.0 x 2.2 cm, which is 4.0 cm away from the stapled end. This firm area is inked blue. There is attached red tissue present in this depressed firm area, measuring 3.5 x 2.5 x 1.0 cm. One end is open and the other end is stapled closed. Opening the colon reveals a circumferential pink to tan tumor with heaped up borders and a central gray ulceration, measuring 6.0 x 3.2 x 1.9 cm. The tumor is approximately 3.0 cm away from the stapled end (closest end). Sectioning through the tumor reveals that tumor grossly penetrates through the muscularis propria, extending into the underlying adipose tissue and abutting both inked serosa and the attached red tissue. The rest of the mucosa is soft tan to pink folds.
Sectioning through the pericolic adipose tissue reveals thirteen pink to red possible lymph nodes ranging from 0.2 to 1.0 cm in greatest dimension. 
Representative sections submitted in nine cassettes: A1-A3: tumor, including ink, A4-A5: tumor, including ink and attached red tissue, A6: tumor showing relation to adjacent mucosa towards the stapled end, A7: five intact nodes, A8: five intact nodes, A9: three intact nodes. 
B. Labeled ""2. Anastomotic donuts x 2 proximal and distal"" are two rings of intestine with red to tan mucosa, measuring 2.0 cm in diameter by 0.7 cm in length and 2.2 cm in diameter by 1.1 cm in length. Sectioning reveals tan to red cut surface, with suture material and staples present in the second ring of intestine. Gross only.
C. Labeled ""3. Left tube and ovary"" is lobulated purple to red tissue with possible ovarian tissue, measuring 2.5 x 2.0 x 1.2 cm, with a surface defect, measuring 1.5 x 1.0 cm, and some attached yellow adipose tissue. Sectioning reveals tan tissue and yellow adipose tissue. There is attached red to purple possible fallopian tube which measures 2.5 cm in length and 1.0 cm in diameter. Representative sections submitted in three cassettes (cassettes C2-C3 include possible fallopian tube). LS/IA:pro **DATE[Jan 20 12]
<FINAL DX>
A. Rectosigmoid colon: Invasive colonic adenocarcinoma with the following characteristics:
1. Tumor size: 6.0 cm.
2. Histologic grade: Intermediate (G2).
3. Depth of invasion: Neoplasm penetrates completely through the muscularis propria into subserosal connective tissue, focally penetrating the serosal surface. 
4. Vascular/lymphatic invasion: Not identified. 
5. Margin status (proximal/distal): Negative for tumor.
6. Distance to nearest margin: 3.0 cm (stapled end).
7. Radial margin status (if rectal tumor): Not applicable.
8. Other lesions present: Adherent fallopian tube tissue - neoplasm does not extend into this adherent tissue. 
9. Lymph node status: 
Number of positive lymph nodes: Zero.
Total number of lymph nodes examined: Thirteen
10. AJCC/pTN classification: T4aN0 - stage IIB, if no distant metastases.
B. (Gross) Anastomotic donuts x2 (proximal and distal): Segments of intestine, as described. 
C. Specimen designated ""left tube and ovary, adherent to sigmoid colon"": 
1. Ovarian tissue with benign epithelial inclusion cysts (see comment). 
2. Fibrovascular connective tissue containing large blood vessels, consistent with adnexal connective tissue. 
3. No neoplasm identified. 
Comment: Most of the third specimen is connective tissue with large blood vessels, consistent with adnexal connective tissue. Sections of the attached tissue, which grossly appeared to be fallopian tube, show ovarian tissue with benign epithelial inclusion cysts.
 
<PATHOLOGIST>
**NAME[ZZZ YYY], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,COLON,0,PAT-00343332,4,REC-5000780986,,,,"**NAME[ZZZ,YYY M] MD

   **NAME[XXX,WWW M] DO









Liver mass.  H/o breast cancer.



   

   LIVER CORE BIOPSIES:  POSITIVE FOR METASTATIC CARCINOMA WITH

   IMMUNOHISTOCHEMICAL FEATURES TYPICAL FOR METASTATIC

   COLORECTAL CARCINOMA.





   

   Markers for breast carcinoma (ER, CK 7, and GCDFP-15) are

   negative as is the marker for adenocarcinoma of lung origin

   (TTF-1).  Markers of colorectal carcinoma (CK 20 and CDX-2)

   are both strongly positive. Dr. **NAME[VVV] was consulted.  Results

   telephoned to Dr. **NAME[ZZZ] at 9:00 a.m. on **DATE[Sep 30 12].





   Three cores of yellowish tan to pink-white tissue are

   submitted together.





   

   The core biopsies show liver parenchyma containing nests of

   moderately differentiated carcinoma showing extensive dirty

   necrosis and tubular villous formation of adenocarcinoma

   characterized by _ columnar cells with nuclear pleomorphism

   and mitotic activity.  Immunohistochemical stains on the

   tumor are as follows:  CK 7 negative, CK 20 strongly

   positive, ER negative, CDX-2 strongly positive, GCDFP-15

   negative, TTF-1 negative.",,,,,
REG3,COLON,0,PAT-00398952,2,REC-5000784527,,,,"<CLINICAL INFO>
 **AGE[in 80s]-year-old female with cecal adenocarcinoma.
  Endoscopic findings:  Large sigmoid polyps, status post hot snare.<FINAL DX>
 A) Sigmoid polyp, biopsy:  Tubulovillous adenoma,
  completely excised.  A HEABS stain highlights the altered mucin profile.
  **INITIALS
  Procedures used to establish the diagnosis:
  A    GI Hematoxylin, eosin, Alcian blue stain, USE ONLY FOR GI LAB CASE<GROSS>
 A) Received in neutral buffered formalin and
  labeled with the patient's name is a specimen designated ""sigmoid polyp"",
  comprising 1 piece(s) of tan white tissue measuring 2.3 cm. Submitted in total
  in 1 cassette(s).  GQ",,,,,
REG3,COLON,0,PAT-00531863,2,REC-5000790056,,,,"<SPECIMEN(S)> 
B. Colon -Right colon 
A. Other -Mesentery nodule 
<ADDENDUM> 
Addendum 1 Entered: **DATE[Jan 03 12]-1527 
Addendum Following Submission of Additional Material 
Subsequently seven further possible lymph nodes are submitted in Bx1 
Diagnosis 

 
<ADDENDUM> (Continued) 
Five mesenteric lymph nodes negative for malignancy. 
DN/ab 
<CLINICAL INFO> 
Colon cancer 

<FINAL DX> 
A. Mesentery nodule, resection: 
Fibrofatty tissue containing suture material with wide area of organized fat necrosis 
with 
extensive calcifications; negative for metastatic malignancy. 
B. Segment of terminal ileum in continuity with cecum and ascending colon: 
Invasive adenocarcinoma 
Specimen: Terminal ileum, cecum and ascending colon with appendix. 
Procedure: Right hemicolectomy. 
Tumor site: Cecum. 
Tumor size: 2.5 cm in greatest dimension. 
Macroscopic tumor perforation: Not identified. 
Histologic type: Intestinal, NOS. 
Histologic grade: Moderately differentiated (2/3). 
Microscopic tumor extension: Through muscularis propria and the pericolonic soft 
tissues. 

 

<FINAL DX> (Continued) 
Margins: Free (proximal, 7.0 cm; distal, 15.5 cm). 
Treatment effect: Not applicable. 
Lymph-vascular invasion: Not identified. 
Perineural invasion: Not identified. 
Tumor deposits: Not identified. 
Lymph nodes: Ten mesenteric lymph node negative for metastatic malignancy (0-10). 
Other: Multiple tubular adenomata; one sessile serrated polyp. 
AJCC (7th ed.) pathologic stage: pT3 pN0. 
This case has been subjected to review by a second pathologist per departmental quality 
assurance (QA) policy. 
**INITIALS 

<GROSS> 
Received in two formalin-filled containers labeled '**NAME[BBB, AAA M]. H000730173' and a 
requisition with '**NAME[BBB, AAA M]. H000730173'. 
The first is designated 'mesentery nodule' and is a tan-red, firm nodule with attached 
yellow, roughened fat. The nodule measures 2.5 x 1.7 x 1.0 cm. The specimen is inked blue 
on the external surface and is quadrisected revealing yellow-brown, granular cut surfaces. 
Sectioning and palpation through the remaining fat reveals three tan-yellow, firm nodules 
measuring 0.5, 0.6 and 1.1 cm in greatest dimension. Representative sections submitted in 
five cassettes. 
Summary of Sections: 
A1-A4 Quadrisected firm large nodule, blue-inked 
A5 Three smaller nodules found in attached fat 
The second is designated 'right colon' and consists of a segment of colon with attached 
terminal ileum. The colon measures 20.0 cm in length and up to 8.5 cm in circumference. 
The terminal ileum measures 6.5 cm in length and up to 3.0 cm in circumference. There is 
attached yellow-red pericolic fat. The serosal surface is smooth and purple. Both ends are 
stapled closed. The proximal margin is inked blue, the distal margin is inked green. 
Opening the colon reveals a well-circumscribed, tan-pink tumor with rolled up borders 
measuring 2.5 x 2.5 cm which is 7.0 cm from the proximal margin and 15.5 cm from the distal 
margin. The fat overlying the tumor is inked black. Sectioning through the tumor reveals 
that the tumor involves but does not grossly extend through the muscularis propria. The 
tumor abuts the ileocecal valve. The remaining mucosa is soft, tan-pink mucosal folds with 
approximately eight tan-pink possible polyps ranging from 0.3 to 1.0 cm in greatest 
dimension. These polyps are found throughout the colon, the closest one approximately 3.5 
cm from the distal margin. Sectioning and palpation of the attached pericolic fat reveals 
15 possible lymph nodes. The lymph nodes range from 1.1 cm to 0.3 cm in greatest dimension. 
Eight lymph nodes are found adjacent to the tumor toward the proximal margin. 
Attached to the cecum is a vermiform appendix measuring 4.0 cm in length and 0.5 cm in 
diameter. Sectioning reveals a lumen containing light tan, pale-pink fecal material. No 

 

<GROSS> (Continued) 
fecalith or perforations are grossly identified. 
Summary of Sections: 
B1-B3 Sections of tumor 
B4 Section of tumor showing adjacent mucosa toward proximal margin 
B5 Section of tumor showing adjacent ileocecal valve 
B6-B8 Polyps (B6 contains bisected largest polyp) 
B9 Representative sections of grossly normal mucosa 
B10 Sections of resection margin 
B11 Appendix 
B12 Bisected lymph node adjacent to tumor 
B13 Bisected lymph node adjacent to tumor 
B14 Two intact nodes adjacent to tumor, one inked blue 
B15 Bisected lymph node adjacent to tumor 
B16 Bisected lymph node adjacent to tumor and one intact node (intact node inked 
blue) 
B17 Trisected lymph node adjacent to tumor 
B18 Four intact lymph nodes away from tumor 
B19 Two intact lymph nodes away from tumor (one node inked blue) 
B20 Bisected lymph node away from tumor 
**INITIALS 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis.",,,,,
REG3,COLON,0,PAT-00462918,2,REC-5000793074,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Colon (31 cm in length and Additional Separate Segment 21.5 cm in
length), Resection:
   Invasive carcinoma with the following features:
      Size:    4.3 x 3.5 x 0.9 cm.
      Histologic type:                  Adenocarcinoma.
      Histologic grade:                 Low-grade (moderately
differentiated).
      Depth/extent of invasion:    Tumor invades through the muscularis
propria into
            the subserosal adipose tissue.
      Margins:      Negative for tumor.
         Mucosal:   11.5 and 15 cm.
         Radial:    8 cm. 
      Extramural vein (large vessel) invasion:    Present.
      Lymphatic (small vessel) invasion:     Absent.
      Regional lymph nodes:
         Total nodes identified:             14.
         Nodes with metastases:              None (0/14).
      Discontinuous extramural extension:    Absent.
      Pathologic stage:  pT3 (AJCC 7th Edition).
     pN0 (AJCC 7th Edition).
   Additional findings:  Tubular adenoma, negative for high-grade
       dysplasia.
     Hyperplastic polyp.
     Diverticulosis.
     No evidence of microsatellite instability (see    coment).

<COMMENT>
There is no evidence of microsatellite instability (MSI-H) by
immunohistochemistry (IHC) which reveals intact nuclear expression of",,,,,
REG3,COLON,0,PAT-00404575,1,REC-5000801105,,,,"<CLINICAL INFO>
 History of colon cancer.  Three small colon polyps.<FINAL DX>
 A) Rectal sigmoid polyps x 3, biopsies:  Tubular
  adenoma in three of five fragments.  A HEABS stain highlights the decreased
  mucin profile.
  **INITIALS
  Procedures used to establish the diagnosis:
  A    GI Hematoxylin, eosin, Alcian blue stain, USE ONLY FOR GI LAB CASE<GROSS>
 A) Received in neutral buffered formalin and
  labeled with the patient's name is a specimen designated ""rectal sigmoid
  polyps"", comprising 5 piece(s) of tan white tissue measuring 0.4 cm to 1.2 cm.
  Submitted in total in 1 cassette.  LCB",,,,,
REG3,COLON,0,PAT-00360744,2,REC-5000808459,,,,"<CLINICAL HX>
Obstructing colon lesion. A biopsy performed the day before this procedure (***PATH-NUMBER[1]) has shown adenocarcinoma.  

<HISTOLOGY COMMENT>



<GROSS>
The specimen is labeled ""left colon"" and is received in formalin. It consists of a previously opened segment of colon measuring 21 cm in length. Roughly in the center the colon is constricted and there is a circumferential 4.5 cm (in circumference) x 3 cm sessile polypoid tan to red-tan tumor mass which protrudes up to 1.5 cm above the surrounding mucosa. In the center of the mass there is an 8 mm perforation and the attached mesentery also has an adjacent 2 cm perforation. The colon on one side of the mass is dilated and its mucosal folds are markedly edematous; this side will be treated as proximal. The tumor is 10 cm from the proximal margin and 8 cm from the distal margin. Distal to the tumor the circumference measures up to 4.5 cm and the mucosal folds are also slightly edematous. Located 1.5 cm from the distal margin there is an additional small 2.2 cm firm ulcerated tan mass. Four small 2-3 mm tan sessile polyps are present in the distal portion of the colon, located from 3 to 4 cm from the main tumor mass, and on the proximal side there are approximately eight white to tan 2 up to 10 mm sessile polyps. The mesentery measures up to 7 cm in width, and there is also a 9 x 7.5 cm piece of attached finely lobulated adipose tissue which may represent omentum. On sectioning, the tumor appears to infiltrate transmurally, and is possibly present on the serosal surface in the area of the perforation. In areas where the wall is intact tumor is located approximately 5 cm from the mesenteric margin. Representative sections are submitted. Cassette summary: A1 - adjacent to stapled proximal margin; A2 - adjacent to stapled distal margin; A3 - entire small ulcerated mass near distal margin; A4 - polyps in distal portion of colon; A5  A6 - polyps in proximal portion of colon; A7 - tumor adjacent to perforation (two sections, one on either side of the perforation); A8 - tumor, intact; A9  A10 - tumor in area of possible attached omentum, with possible serosal nodule in A10; A11 - tumor-uninvolved colon interface; A12 - three lymph node candidates. The remainder of the mesenteric and possible omental fat is removed from the specimen and fixed overnight in lymph node-clearing fixative. Multiple lymph node candidates are then dissected out of the fat and submitted as five lymph node candidates each in cassettes A13-A16.


<COMMENT>


<MICROSCOPIC>
The small ulcerated area near the distal margin shows no malignancy or adenomatous change and may represent a recent polypectomy site.

<FINAL DX>
LEFT COLON (RESECTION):  ADENOCARCINOMA, MODERATELY DIFFERENTIATED.  THE TUMOR INVADES TRANSMURALLY AND IS PRESENT ON THE SEROSAL SURFACE.  NO METASTATIC CARCINOMA IDENTIFIED IN 9/9 REGIONAL LYMPH NODES BUT EXTRATUMORAL  DEPOSITS PRESENT.  PLEASE SEE SYNOPTIC REPORT/CHECKLIST SECTION.

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>


<NOTIFICATION>
I discussed the preliminary findings with Dr. **NAME[ZZZ], **DATE[Nov 21 12].

<PRELIM DX>


<CHECKLIST>
CANCER CHECKLIST:  COLON RESECTION  AJCC 7TH ED.  SPECIMEN:  Left colon. PROCEDURE:  Resection. SPECIMEN LENGTH:  21 cm. TUMOR SITE:  35-40 cm (sigmoid) per previous biopsy; splenic flexure per operative note in hospital information system. TUMOR SIZE:  4.5 cm in greatest dimension. MACROSCOPIC TUMOR PERFORATION:  Present. HISTOLOGIC TYPE:  Adenocarcinoma. HISTOLOGIC GRADE:  Low-grade. HISTOLOGIC FEATURES SUGGESTIVE OF MICROSATELLITE INSTABILITY:  Mucinous component (but less than 50%  of the tumor); sessile serrated adenomas also noted. MICROSCOPIC TUMOR EXTENSION:  Tumor invades transmurally and penetrates to the surface of the  visceral peritoneum (serosa). MARGINS:  Proximal Margin:  Invasive carcinoma not identified (10 cm from margin).  Distal Margin:  Invasive carcinoma not identified (8 cm from margin).  Radial/Mesenteric Margin:  Invasive carcinoma not identified (5 cm from mesenteric margin). TREATMENT EFFECT:  No prior treatment. LYMPH-VASCULAR INVASION:  Not identified. PERINEURAL INVASION:  Present (see slide ***PATH-NUMBER[2]). TUMOR DEPOSITS (discontinuous extramural extension):  Present; 3 identified. ADDITIONAL PATHOLOGIC FINDINGS:  Tubular adenoma, sessile serrated adenoma, and hyperplastic polyps. PATHOLOGIC STAGING:  Primary Tumor: pT4a.  Regional Lymph Nodes: pN1c.  Number of Lymph Nodes Examined: 9  Number of Lymph Nodes Involved: 0.  Distant Metastasis (pM):  Not applicable.

<IMMUNOHISTOCHEMISTRY>


<INDICATIORS>


<SPECIAL STAINS>",,,,,
REG3,COLON,0,PAT-00088748,3,REC-5000808485,,,,"<CLINICAL HX>
A) Cecal mass bxs.
B) Rectal p. i. Adenoma vs hyperplasia. Submitted ICD9 codes 211.4, 211.3. STAT reading requested.  

<HISTOLOGY COMMENT>




<GROSS>
A.  In formalin labeled with the patient's name and ""A"" are approximately seven 1-3 mm pieces of tan tissue. Submitted as received in cassette A.
B.  In formalin labeled with the patient's namd and ""B"" is a 5 mm piece of tan tissue. Submitted as received in cassette B.


<COMMENT>


<MICROSCOPIC>
Six slides are examined (block A was exhausted).

<FINAL DX>
 A.  CECUM, BIOPSIES DESIGNATED MASS:  ADENOCARCINOMA, INVASIVE, LOW-GRADE (WELL TO MODERATELY DIFFERENTIATED)  IN THIS MATERIAL. 
B.  RECTAL POLYP:  TUBULAR ADENOMA. 

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>
The case was reviewed intradepartmentally.

<NOTIFICATION>


<PRELIM DX>


<CHECKLIST>


<IMMUNOHISTOCHEMISTRY>


<INDICATIORS>


<SPECIAL STAINS>",,,,,
REG3,OTHER,0,PAT-00516411,1,REC-5000712160,,,,"<CLINICAL INFO>
 The patient is a **AGE[in 60s]-year-old woman with a history
  of relapsed secondary AML s/p transplant.  A bone marrow evaluation is
  obtained Day 14 after re-induction with 7+3.
  PERIPHERAL BLOOD COUNTS from electronic medical record (**DATE[Apr 06 2012]):
      WBC                 *  1.05     [4.3-10.0]    THOU/uL
      RBC                 *  3.06     [3.80-5.00]   mil/uL
      Hemoglobin          *  9.4      [11.5-15.5]   g/dL
      Hematocrit          *  28       [36-45]       %
      MCV                    90       [81-98]       fL
      MCH                    30.7     [27.3-33.6]   pg
      MCHC                   34.2     [32.2-36.5]   g/dL
      Platelet Count      *  38       [150-400]     THOU/uL
      RDW-CV              *  15.2     [11.6-14.4]   %
      Neutrophils         ^  0.01     [1.80-7.00]   THOU/uL
      Lymphocytes            1.02     [1.00-4.80]   THOU/uL
      Monocytes              0.00     [0.00-0.80]   THOU/uL
      Eosinophils            0.00     [0.00-0.50]   THOU/uL
      Basophils              0.00     [0.00-0.20]   THOU/uL
      Blasts              *  0.02     [0]           THOU/uL<FINAL DX>
 BONE MARROW BIOPSY,  ASPIRATE SMEARS, AND
  PERIPHERAL BLOOD:  Hypercellular marrow with trilineage hematopoiesis, limited
  myeloid and erythroid maturation, numerous small hypolobated megakaryocytes,
  and markedly increased blasts, consistent with persistent acute myeloid
  leukemia (see comment).<DIAGNOSIS COMMENT(S)>
  The peripheral blood is pancytopenic with circulating blasts.  The marrow is
  hypercellular for age and for this time point post-chemotherapy, at roughly
  70% cellularity.  Numerous small, hypolobated megakaryocytes are seen.  The
  morphologic blast count is challenging due the marked left shift in both
  myeloid and erythroid maturation as well as the hypogranular nature of the
  myeloid precursors, but blasts are estimated at approximately 40% by
  morphology.  Mature myeloid and erythroid elements are rare.  Concurrent flow
  cytometry on the core biopsy (see ***PATH-NUMBER[1]) identified approximately 35%
  abnormal myeloid blasts.   These findings are consistent with extensive
  involvement by persistent acute myeloid leukemia.  Clinical correlation is
  recommended.

  ------------------------------------------------------------------------<GROSS>
 A) Received are 2 Wright-Giemsa stained bone
  marrow aspirate slides.
  B) Received in  formalin labeled ""**NAME[BBB, AAA], bm bx RPIC"" are two tan-red
  cores of cancellous bone measuring 1.0 and 1.5 cm in length.  The specimen is
  wrapped and entirely submitted in cassette B1 following decalcification.
  (**INITIALS)
  C) Received are 2 Wright-Giemsa stained peripheral blood smears.
  Procedures used to establish the diagnosis:
  B    Submit tissue for decalcification<MICROSCOPIC>
 PERIPHERAL BLOOD DIFFERENTIAL:
  Neutrophils:   1%
  Lymphocytes:   89%
  Monocytes:   5%
  Blasts  5 %
  Total cells counted: 100
  PERIPHERAL BLOOD MORPHOLOGY:
  WBC:   predominantly lymphocytes, circulating blasts seen
  RBC:    Normal
  Platelets:  Decreased numbers, normal morphology
  BONE MARROW ASPIRATE SMEARS:
  Sample:   Right posterior iliac crest
  Quality:   Adequate particles, good quality
  Blasts:   Markedly increased
  Myeloids:   Proportionately decreased, minimal maturation, no dysplastic
  features
  Erythroids:   Proportionately decreased, minimal maturation, no dysplastic
  features
  Megakaryocytes:  Increased numbers, dysplastic features with numerous small
  hypolobated forms.
  Lymphocytes:   Not increased, no aggregates identified
  Plasma cells:   Not increased
  BONE MARROW DIFFERENTIAL:
  Preparation:  Aspirate smears
  Myeloids:   41.5%
  Erythroids:   4.5%
  Blasts:   40%
  Lymphocytes:   12.5%
  Plasma cells:   1.5%
  M:E Ratio:  8 to 1 (may not be reliable based on limited cellularity)
  Total cells counted:  200
  BONE MARROW BIOPSY:
  Sample:   Right posterior iliac crest
  Biopsy length:   1 cm
  Quality:   Adequate
  Cellularity:   70%
  Myeloids:   Proportionately increased and left-shifted, including numerous
  immature myeloid forms/blasts
  Erythroids:   Proportionately decreased
  Megakaryocytes:  Increased numbers, dysplastic features
  Infiltrate:   Scattered lymphocytes and plasma cells seen, no lymphoid
  aggregates identified
  FLOW CYTOMETRY (see ***PATH-NUMBER[1]):
  ""An abnormal myeloid blast population is identified by flow cytometry with an
  immunophenotype similar to that identified previously (***PATH-NUMBER[2]).  The
  abnormal blasts represent 35.0% of the white cells following erythrocyte lysis
  and abnormally express CD7 (subset), CD13 (increased), CD33 (increased), CD34
  (increased), CD38 (increased), CD56 (small subset), CD117 (increased), CD123
  (increased), and HLA-DR (variably decreased) with normal expression of CD45,
  and CD71 without CD4, CD5, CD14, CD15, CD16, CD19, or CD64.  Analysis of the
  bone marrow aspirate shows significant hemodilution and a lower percentage of
  abnormal myeloid blasts.  These findings are consistent with
  persistent/recurrent acute myeloid leukemia, depending on the clinical
  context.  Clinical and morphologic correlation is recommended.""",,,,,
REG3,OTHER,0,PAT-00608909,2,REC-5000714980,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.-C. Bone Marrow Aspirate, Peripheral Smears, Clot Section and Core
Biopsy:
  Chronic myeloid stem cell neoplasm, consistent with chronic
myelomonocytic leukemia-1.
  The peripheral blood smear shows moderate normocytic anemia with a
dimorphic erythroid population, left-shifted neutrophilia with
dysgranulopoiesis, monocytosis, and thrombocytopenia with atypical
platelets.
  Less than 1% peripheral blood blasts; 1-4% bone marrow blasts.
  Storage iron present; negative for ring sideroblasts.
  Cytogenetics pending.

<COMMENT>
This patient's bone marrow shows a persistent myeloid stem cell
neoplasm. The last biopsy (***PATH-NUMBER[2]; **DATE[Aug 05 2009]) showed mixed
myelodysplastic/myeloproliferative features with prevailing
myelodysplastic clinical features. The current case can be considered
chronic myelomonocytic leukemia-1.

<CLINICAL INFO>
MDS, CRF, low platelets. ICD-9 Code(s): 238.75, 287.5

CBC:
WBC: 36.4 x 10K/ul  DIFFERENTIAL:       ABSOLUTE:
RBC: 3.11 x 10M/ul  Neutrophils:   51%       Neutrophils:   18.6#
Hgb: 9.6 g/dL  Lymphocytes:   7%        Lymphocytes:   2.5#
Hct: 28.8%     Monocytes:     37%       Monocytes:     13.5#
MCV: 92.8 fl
RDW  17.7%
Platelets 29 x 10K/ul

PERIPHERAL SMEAR:
RBC: There is a moderate normocytic anemia with a dimorphic population.
WBC: There is neutrophilia with left shift. The granulocytes show
hypergranularity and abnormal segmentation. There is monocytosis. The
monocytes are maturing appearing. There is no increase in blasts.
Platelets:     There is thrombocytopenia. Large hypogranular platelets
are present.

BONE MARROW ASPIRATE:
SPECIMEN ADEQUACY: Adequate
DIFFERENTIAL (500 cells counted):
Segs/bands:                   46.0%
Myelocytes/metamyelocytes:    22.4%
Erythroid:                         8.3%
Blasts:                       3.9%
Lymphocytes:                  3.3%
Monocytes:                    15.3%
M:E ratio:                         10:1

Erythroid precursors are proportionally reduced and show mild
dyserythropoiesis. Granulocyte precursors are proportionally increased
and show left-shifted expanded maturation. Monocytes appear increased.
Blasts are increased at 4%. Auer rods are not present. The
megakaryocytes show cytologic atypia. Lymphocytes and plasma cells are
normal.

Iron: An iron stain was performed on the bone marrow aspirate smear.
Storage iron is present. Sideroblasts are present. Ring sideroblasts are
not seen.

BONE MARROW BIOPSY / CLOT SECTION:
SPECIMEN ADEQUACY: Adequate
CELLULARITY: Approximately 75%, away from aspiration effect.

Erythroid precursors are numerically normal and show nuclear
irregularity. There is marked granulocytic hyperplasia, which shows
maturation to the terminal phase. The megakaryocytes show
hyperchromasia. Rare loose megakaryocyte aggregates are seen. There is
no bone marrow fibrosis. Lymphocytes and plasma cells are normal.

PROCEDURE PERFORMED BY:
**NAME[ZZZ M. YYY], M.D.

FLOW CYTOMETRY:

<FINAL DX>

Abnormal myeloid antigen expression, see comment.

COMMENT:
CD34-positive blasts comprise 0.52% of the total WBC and express CD34,
HLA-DR, CD117, CD13 (decreased), CD38, and do not express CD33, CD11b,
CD15, CD2, CD5, CD7, CD56, or CD64. The maturing myeloid population
shows reduced side scatter and mild dyssynchronous antigen expression
with respect to CD13 and CD16. The myelomonocytic population shows
increased CD56 expression.

By flow, the myeloid population comprises 91.2% of the total WBC, and
the monocyte population comprises 4.1% of the total WBC. Erythroid
precursors are reduced at 4.58% CD71-positive. B cells comprise only
0.1% of the total WBC and show polytypic surface immunoglobulin
expression. Hematogones are numerically reduced.

Flow Cytometry Images

  fd
Antibodies tested: CD2, CD5, CD7, CD10, CD11b, CD13, CD14, CD15, CD16,
CD19, CD20, CD33, CD34, CD38, CD45, CD56, CD64, CD71, CD117, HLA-DR,
kappa and lambda.

These tests were developed and the performance characteristics
determined by Cellnetix Pathology and Laboratories. They have not been
cleared or approved by the US Food and Drug Administration. The FDA has
determined that such clearance or approval is not necessary. This
laboratory is certified under CLIA-88 and is qualified to perform high
complexity clinical testing. Prognostic and predictive testing should be
interpreted in the context of additional clinical and/or
histopathological findings.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block C1

Antibody  Result    Comment
CD34sq    Positive  Approximately 1% cells

Impression:
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:  A CD34 immunostain was used to evaluate the
immunoarchitecture. There are no CD34-positive blast clusters.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

<GROSS>
A. Received fresh, labeled ""**NAME[AAA BBB]"", are multiple unstained bone
marrow aspirate smears and a peripheral blood smear.

B. Received in formalin, labeled ""**NAME[AAA BBB]"" and designated ""bone
marrow clot"", is a 0.5 cm aggregate of clotted blood, which is submitted
in one cassette.

C. Received in formalin, labeled ""**NAME[AAA BBB]"" and designated ""bone
marrow core"", is a 1.1 cm cylindrical fragment of osseous material,
which is submitted for brief decalcification in one cassette. (ke/gdb)

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Jul 01 2012]",,,,,
REG3,OTHER,0,PAT-00369617,3,REC-5000724899,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Colon, Segmental Resection:
     Inflammatory polyp with associated hyperplastic change (0.5 cm).
     Appendix with fibrous luminal obliteration.
     Fifteen lymph nodes with no specific histopathologic features.
     No evidence of malignancy.

<CLINICAL INFO>
Right colon with evaluation of cecal mass. Newly diagnosed cancer
involving cecum. History of lung plus prostate cancer.

INTRAPROCEDURAL EVALUATION:
Right colon (gross examination): ""5 mm mucosal polyp in cecum. No gross
invasion. If microscopic
  invasion is present, it is likely to be superficial. No obvious mass
in pericolic fat.""
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
Received fresh, labeled ""**NAME[BBB, AAA M]"" and designated ""right
colon"", and is submitted for rapid evaluation yielding the above
intraprocedural evaluation by Dr. **NAME[YYY]. The above intraprocedural
evaluation was called in to Dr. **NAME[XXX] in the operating room by Dr.
**NAME[YYY]. The specimen is a segment of colon consisting of the following:
1) A 3.2 cm long by 2 cm in diameter segment of terminal ileum; 2) a
15.5 cm long by 3.5-4 cm in diameter cecum and colon; 3) an 18 x 6.5 x 4
cm segment of pericolic-mesenteric fat; and 4) a 4.5 cm long by 0.4 cm
in diameter vermiform appendix with adhesions at the distal tip. The
proximal and distal ends are closed with surgical staples. Proximal is
inked green and distal is inked black. The serosa has focal adhesions.
The cecum contains a 0.5 cm domed red polyp. The polyp is 1.5 cm from
the ileocecal valve, 5 cm from the proximal margin, and 13.5 cm from the
distal margin. The polyp appears superficial. No discrete tumors or
ulcers are found within the colon. The fat is sectioned and does no
contain any nodules or masses. The fat is thoroughly searched for lymph
nodes. Fifteen possible nodes ranging in size from 0.3-1.5 cm are found
within the fat. Representative sections are submitted as follows: A1 -
longitudinal sections of proximal and distal margins; A2 - ileocecal
valve; A3 - polyp entirely submitted; A4 - appendix including the distal
tip bisected longitudinally; A5 - three possible nodes; A6 - six
possible nodes; A7 - two nodes bisected; A8 - two possible nodes
bisected; A9 - two possible nodes, one trisected and one bisected.
(kjh/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Jan 21 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,OTHER,0,PAT-00434143,2,REC-5000734056,,,,"PART / DESCRIPTION - SEQ# 
Vaginal/ VAGINAL CUFF- 1<MICROSCOPIC>
VAGINAL CUFF: 
Sections show squamous mucosa with the subjacent soft tissues showing involvement by poorly differentiated adenocarcinoma, morphologically compatible with the previously diagnosed uterine carcinoma. A squamous intraepithelial lesion is not identified.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONEComment
The features are morphologically compatible with recurrence of the previously diagnosed carcinosarcoma of the uterus (***PATH-NUMBER[1]). The findings on the current vaginal cuff biopsy explain the atypical glandular cells seen on prior Pap smear (***PATH-NUMBER[2]).<FINAL DX>

VAGINAL CUFF, BIOPSY: POSITIVE FOR INVOLVEMENT BY POORLY DIFFERENTIATED ADENOCARCINOMA.
**INITIALS<GROSS>
VAGINAL CUFF: 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"vaginal cuff biopsy,"""" are three pieces of pink-red tissue ranging from 0.3 up to 0.4 cm. Entirely submitted in a single cassette.<CLINICAL INFO>
Malignant mixed mullerian tumor of uterus with involvement of bilateral ovaries, peritoneum, lymph nodes (***PATH-NUMBER[1]).PATHOLOGIST:
Austin G.David",,,,,
REG3,OTHER,0,PAT-00213161,2,REC-5000749226,,,,"<CLINICAL INFO>
 Pancreatic mass.  Patient to be seen by Dr. **NAME[ZZZ
  YYY] on **DATE[Aug 08 2012].<FINAL DX>
 **INSTITUTION., P.S., Lynnwood,
  WA; ***PATH-NUMBER[1] (**DATE[Mar 14 2012])
  Duodenum, second part, biopsy:  Duodenal mucosa with no diagnostic alteration,
  including no increased intraepithelial lymphocytes, and no villous blunting.
  **INSTITUTION, **PLACE, WA; ***PATH-NUMBER[2] (**DATE[Jul 18 2012])
  Pancreatic mass, needle aspirate:  Malignant cells present consistent with
  adenocarcinoma.
  **INSTITUTION, **PLACE, WA; ***PATH-NUMBER[3] (**DATE[Jul 18 2012])
  Pancreatic mass, core biopsy:  Invasive adenocarcinoma, moderately
  differentiated.
  **INITIALS
  Procedures used to establish the diagnosis:
  RoutineMATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[1]  0B,1S  Second part duodenum
   B VC11 639  0B,4S  Pancreas mass aspirate
   C VS11 4523  0B,1S  Pancreatic mass core biopsy",,,,,
REG3,OTHER,0,PAT-00621508,3,REC-5000753276,,,,"PART / DESCRIPTION - SEQ 
Pleural Fluid Cyto/ LEFT LUNG PIGTAIL ATRIUM DRAINAGE- A
INTRAOPERATIVE DX:
NONE
MICROSCOPIC:
NONEConsult
Dr. **NAME[ZZZ]
PHYSICIAN NOTIFICATION:
Dr. **NAME[YYY] telephoned with the preliminary diagnosis on **DATE[Feb 20 12], and updated on **DATE[Feb 23 12].
FINAL DX:
Pleural fluid cytology (cell block and ThinPrep slide): -Positive for malignant cells, consistent with metastatic adenocarcinoma (see concurrent pleural biopsy ***PATH-NUMBER[1] for characterization of the neoplasm). -Lymphocytes, histiocytes, neutrophils, reactive mesothelial cells are also present.GROSS:
Received fresh on **DATE[Feb 20 2012] is approximately 1900 cc of hemorrhagic fluid, labeled ''**NAME[BBB, CCC]'. Prepared are one cell block and one ThinPrep slide. (ESP: ra). The specimen was reprocessed on 8/22; prepared are a second cell block and 2 more ThinPrep slides.
CLINICAL INFO:
Lung cancer. ICD-9 CODE: V10.9
PATHOLOGIST:
**NAME[XXX WWW] S  

SNOMED Code(s)",,,,,
REG3,OTHER,0,PAT-00531681,3,REC-5000759276,,,,"<CLINICAL INFO>

<GROSS>


<MICROSCOPIC SECTION>

<FINAL DX>
WHOLE BLOOD FOR LYMPHOCYTE ANALYSIS:
1.          Monoclonal B lymphocytosis with immunophenotypic features seen in CLL/SLL (see flow cytometry report below).
2.          Absolute lymphocyte count of abnormal B cells =3202/ L.

Preliminary results are discussed with Dr. **NAME[ZZZ] on **DATE[Mar 2 12] at 1700.
Reviewed by: Dr. **NAME[YYY XXX]



Review of the peripheral smear shows a modest absolute lymphocytosis with many of the cells having increased cytoplasm that molds to adjacent red blood cells.  There is also a suggestion of a mild increase in parachromatin clearing.  
Flow studies show a population of CD19 positive cells co-expressing CD5, CD23 and dim monoclonal lambda light chain.  The cells are also positive with CD20 and CD22 and negative with all other antibodies utilized including CD38.  
These features are consistent with a monoclonal B lymphocytosis since the total absolute lymphocyte count is < 5,000 per  L (3202/ L).  Correlation with the clinical picture is suggested to determine whether there is any extramedullary tissue involvement.



<SPECIMEN(S)>
Whole Blood",,,,,
REG3,OTHER,0,PAT-00372093,2,REC-5000760024,,,,"<ADDENDUM>
EXTRADEPARTMENTAL REVIEW DIAGNOSIS* 
Right bone marrow biopsy, aspirate smears, clot section, and peripheral blood: 
1. Hypercellular marrow with extensive involvement by a low grade B cell lymphoma. 
2. Increased myeloid blasts with an abnormal immunophenotype by flow cytometry. 
3. Peripheral blood with pancytopenia and relative lymphocytosis. 
*Studies performed at **INSTITUTION 
See full report LP-11-10804 from: 
**INSTITUTION 

A scanned copy of the report can be found in the Documents tab section in Powerchart.",,,,,
REG3,OTHER,0,PAT-00572094,1,REC-5000767693,,,,"Clinical Indication:     MDS
  Previous Tests:
  ***PATH-NUMBER[1] **DATE[Jun 08 2007] 47,XY,+8[12]/46,XY[8]Diagnosis and Comments:   There was no growth in the one culture
  set up from this specimen.  Other specimens set up the same day had adequate
  growth.
  Reported By: **NAME[ZZZ YYY], PhD
  Signed By: cd
  Procedures Performed:
  88237 Cytogenetics Tissue culture, bone marrow/bloodISCN Diagnosis:   No growth or insufficient growth
  Summary:  No growth",,,,,
REG3,OTHER,0,PAT-00720203,1,REC-5000781059,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Ascites Fluid Cytology:
Rare atypical cells, see Comment.
Histiocytes, mesothelial cells and blood cells identified.

<COMMENT>
The ThinPrep slide shows rare groups of atypical cells with features
concerning for possible neoplasm.  The patient's history of gastric
carcinoma was noted, so immunohistochemical (IHC) stains for antibodies
that are typically positive in gastric carcinoma were performed.  All of
those stains were negative as was the stain for mesothelial cells.  Thus
the numbers of atypical cells in this preparation are too small to be
diagnostic. Follow-up is recommended as clinically indicated.

<CLINICAL INFO>
Renal insufficiency.  History of gastric signet ring cell carcinoma.

<GROSS>
Received on **DATE[Feb 24 2012] is 150 ml of clear, yellow, clotted fluid labeled
""**NAME[BBB, AAA]"" and designated ""ascites"" per specimen label. Prepared
are one ThinPrep Pap-stained slide, one air-dried cytocentrifuge
Diff-Quik-stained slide and one cell block.  (rc/gdb)

<MICROSCOPIC>
One Diff-Quik-stained cytospin slide, one Papanicolaou-stained ThinPrep
slide, and one cell block slide are examined. These show mesothelial
cells and blood cells. Rare groups of cells with prominent nucleoli and
higher nuclear/cytoplasmic ratios are identified.  These are best seen
on the Thin-Prep slide.
Immunohistochemical stains are performed to further characterize the
cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
Calretinin     Negative
Villin    Negative
BerEP4    Negative
CDX-2     Negative

Impression:  These stains do not show any staining typical for gastric
carcinoma.
Interpreted by:  **NAME[ZZZ M. YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION: **NAME[XXX WWW], M.D.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Feb 26 2012]",,,,,
REG3,OTHER,0,PAT-00720504,2,REC-5000783789,,,,"Clinical Indication:     AML
  Previous Tests:
  ***PATH-NUMBER[1] **DATE[Jun 14 2012] PendingDiagnosis and Comments:   No evidence of a translocation between
  chromosomes 8 and 21 was found by interphase fluorescence in situ
  hybridization (IFISH) using a dual color probe designed to detect the fusion
  of the RUNX1 (AML1) gene at 21q22 with the RUNX1T1 (ETO) gene at 8q22.  The
  percentage of abnormal configurations of the signals suggestive of fusion
  events in 200 nuclei screened was not significantly different from that found
  in a series of normal control samples.  The ISCN description of these normal
  results is nuc ish(RUNX1T1,RUNX1)x2[200/200].  This diagnosis is consistent
  with the absence of the 8;21 translocation or fusion product associated with
  AML M2.
  No evidence of a translocation between chromosomes 15 and 17 was found by
  IFISH using a dual color probe designed to detect the fusion of PML
  (promyelocytic leukemia gene) at 15q22 and RARA (retinoic acid receptor alpha
  gene) at 17q21.  The percentage of abnormal configurations of the signals
  suggestive of fusion events in 200 nuclei screened was not significantly
  different from that found in a series of normal control samples.  The ISCN
  description of these normal results is nuc ish(PML,RARA)x2[200/200].  This
  diagnosis is consistent with the absence of the 15;17 translocation or fusion
  product associated with APL (AML M3).
  No evidence of an inversion in chromosome 16 was detected by IFISH using a
  dual color probe designed to detect the inversion.  The percentage of abnormal
  configurations of the signals suggestive of an inversion in 200 nuclei
  screened was not significantly different from that found in a series of normal
  control samples.  The ISCN description of these normal results is nuc
  ish(CBFBx2)[200/200].  This result is consistent with the absence of the
  inv(16) associated with AML-M4.ISCN Diagnosis:   Normal IFISH
  Summary:  NEGATIVE for rearrangements common in AML by IFISHCell Analysis:
  STAIN/probe MICRO PHOTO KTYPE
  FISH 0 0 0 complete
   597 3 0 partial
  Procedures Performed:
  88271 Cytogenetics FISH probe
  88271 Cytogenetics FISH probe
  88271 Cytogenetics FISH probe
  88275 Cytogenetics Interphase FISH analysis 100-300NOTE:   The FISH test was developed and its performance
  characteristics determined by the UWMC Cytogenetics Laboratory.  Pursuant to
  the requirements of CLIA 1988, this laboratory has established and verified
  the test's accuracy and precision.  The test has not been cleared or approved
  by the US Food and Drug Administration.  The FDA has determined that such
  clearance or approval is not necessary.  This test is used for clinical
  purposes.
  Please see ***PATH-NUMBER[2] for karyotype results.
  Reported By: **NAME[ZZZ YYY], MD
  Signed By: thn",,,,,
REG3,OTHER,0,PAT-00328925,2,REC-5000787493,,,,"<CLINICAL INFO>
H/O endometrial cancer, adnexal mass
<GROSS>
95cc pink fluid received, 1 liquid based slide and 1 cell block are prepared.

<MICROSCOPIC SECTION>

<FINAL DX>

Pelvic  Washing: Final Cytology Diagnosis
MALIGNANT EPITHELIAL CELLS PRESENT.  
Specimen Adequacy
Satisfactory for interpretation.

Malignant epithelial cells present, morphologically similar to those in the concurrent hysterectomy specimen showing poorly differentiated endometrioid adenocarcinoma, FIGO 3.

Reviewed by: Dr. **NAME[ZZZ YYY].





<SPECIMEN(S)>
Peritoneal Washing",,,,,
REG3,OTHER,0,PAT-00719830,1,REC-5000800405,,,,"<CLINICAL INFO>
 The patient is a **AGE[in 50s]-year-old woman with a history
  of Hodgkin lymphoma diagnosed in 2010.  Pathology review of a recent bone
  marrow biopsy performed **DATE[Jul 09 2012] is requested by Dr. **NAME[ZZZ YYY].<FINAL DX>
 **INSTITUTION of
  **PLACE, WA; ***PATH-NUMBER[1] (**DATE[Jul 09 2012])
  Left posterior iliac crest, aspirate, core biopsy, touch preparations and
  peripheral blood smear:
  1. Normocellular marrow with trilineage hematopoiesis with maturation.
  2. No morphologic evidence of Hodgkin lymphoma.
  3. Concurrent flow cytometry is reportedly negative for abnormal B cell, T
  cell, or NK cell populations.
  ------------------------------------------------------------------------<GROSS>
 Received from Franciscan Health System Regional
  **INSTITUTION of **PLACE, WA; and
  labeled ""***PATH-NUMBER[1]"" are 17 glass slides, corresponding to a left iliac crest
  bone marrow aspirate and core biopsy procedure performed on **DATE[Jul 09 2012]
  according to the accompanying pathology report bearing the patient s name and
  date of birth.  Also received is a flow cytometry report from **PLACE, WA, and a cytogenetics report from **INSTITUTION., **PLACE, WA, both bearing the patient s name and date of
  birth.
  CD/ch
  Procedures used to establish the diagnosis:
  Routine<MICROSCOPIC>
 A) ***PATH-NUMBER[1] (**DATE[Jul 09 2012]):
  Outside CBC results from **DATE[May 11 2012]:  WBC 7.9, RBC 4.07, HGB 11.6, HCT 34, MCV
  83, RDW 16.3, platelets 241.
  Review of the peripheral blood smear shows normal white cell quantity and
  morphology.  Red cells are normocytic and normochromic without significant
  anisopoikilocytosis or polychromasia.  Platelets have normal quantity and
  morphology.
  The bone marrow aspirate smears and some core biopsy touch preparations are
  largely hemodilute.  Focally, there is a spicule with adequate morphology.
  There is demonstrable trilineage hematopoiesis with full maturation.  There is
  no dyserythropoiesis or dysmyelopoiesis.  Megakaryocytes have appropriate
  nuclear segmentation.  Blasts are not increased.
  The bone marrow aspirate clot section shows abundant marrow particles with
  cellularity and morphology similar to the core biopsy.  Both show
  approximately normocellular marrow, 30% overall, with evidence of trilineage
  hematopoiesis.  No atypical lymphoid infiltrates are present.  No evidence of
  collagenous or reticulin fibrosis is present.  Myeloid and erythroid
  maturation appear complete with appropriate M:E ratio.  Iron stains performed
  on the clot section and the core biopsy shows scattered apparently normal
  storage iron.
  FLOW CYTOMETRY:
  **PLACE, WA (***PATH-NUMBER[2])
  Bone marrow, left PIC, CT-guided aspirate:  No abnormal B cell, T cell, or NK
  cell populations identified.<DIAGNOSIS COMMENT(S)>   No evidence of non-Hodgkin lymphoma is identified by
  flow cytometry.
  CYTOGENETICS:
  **INSTITUTION., **PLACE, WA, (***PATH-NUMBER[3])
  Routine cytogenetic studies results:  46, XX[20]; normal female karyotype
  without demonstrable abnormalities.",,,,,
REG3,OTHER,0,PAT-00645915,2,REC-5000800802,,,,"<FINAL DX>
 A) Stomach anastomosis, biopsy:
  - Gastric and small intestinal mucosa with active inflammation and reactive
  epithelial changes, consistent with anastomotic site.
  B) Distal greater curvature, biopsy:
  - Adenocarcinoma with signet ring cell features, consistent with the patient's
  history of gastric adenocarcinoma.
  C) Stomach, distal, lesser curvature, biopsy:
  - Rare atypical glandular cells worrisome for adenocarcinoma with signet ring
  cell features.
  - Small bowel mucosa with reactive epithelial changes.
  D) Proximal body, biopsy:
  - Gastric body-type mucosa with no diagnostic alterations.
  E) Proximal fundus, biopsy:
  - Adenocarcinoma with signet ring cell features, consistent with the patient's
  history of gastric adenocarcinoma.
  F) Ascending colon, 1.0 mm polyp, biopsy:
  - Tubular adenoma.
  G) Sigmoid, two 1.0 mm polyps, biopsy:
   - Tubular adenoma.
   - Fragments of colonic mucosa with surface hyperplastic change.<GROSS>
 A) Received in neutral buffered formalin and
  labeled with the patient's name is a specimen designated ""anastomosis
  stomach"", comprising 5 pieces of tan white tissue measuring 0.1 cm to 0.8 cm.
  Submitted in total in 1 cassette.
  B) Received in neutral buffered formalin and labeled with the patient's name
  is a specimen designated ""distal greater curvature"", comprising 5 pieces of
  tan white tissue measuring 0.3 cm to 0.5 cm. Submitted in total in 1 cassette.
  C) Received in neutral buffered formalin and labeled with the patient's name
  is a specimen designated ""distal lesser curvature"", comprising 4 pieces of tan
  white tissue measuring 0.4 cm to 0.7 cm. Submitted in total in 1 cassette.
  D) Received in neutral buffered formalin and labeled with the patient's name
  is a specimen designated ""proximal body"", comprising 5 pieces of tan white
  tissue measuring 0.1 cm to 0.5 cm. Submitted in total in 1 cassette.
  E) Received in neutral buffered formalin and labeled with the patient's name
  is a specimen designated ""proximal fundus"", comprising 4 pieces of tan white
  tissue measuring 0.4 cm to 0.5 cm. Submitted in total in 1 cassette.
  F) Received in neutral buffered formalin and labeled with the patient's name
  is a specimen designated ""1mm polyp descending colon"", comprising 1 piece of
  tan white tissue measuring 0.5 cm. Submitted in total in 1 cassette.
  G) Received in neutral buffered formalin and labeled with the patient's name
  is a specimen designated ""1mm polyp sigmoid"", comprising 3 pieces of tan white
  tissue measuring 0.3 cm to 0.4 cm. Submitted in total in 1 cassette.  GQ<DIAGNOSIS COMMENT(S)> Dr. **NAME[ZZZ YYY] has also reviewed this case and agrees
  with the cancer diagnosis.
  A-E):  No Helicobacter pylori-type organisms are identified on Genta stain in
  each part, with an appropriately positive control.
  F-G):  A HEABS stain in each part highlights the architecture and mucin
  profile.
  DM/ch
  Procedures used to establish the diagnosis:
  A    GI Genta stain, USE ONLY FOR GI LAB CASE
  B    GI Genta stain, USE ONLY FOR GI LAB CASE
  C    GI Genta stain, USE ONLY FOR GI LAB CASE
  D    GI Genta stain, USE ONLY FOR GI LAB CASE
  E    GI Genta stain, USE ONLY FOR GI LAB CASE
  F    GI Hematoxylin, eosin, Alcian blue stain, USE ONLY FOR GI LAB CASE
  G    GI Hematoxylin, eosin, Alcian blue stain, USE ONLY FOR GI LAB CASE",,,,,
REG3,OTHER,0,PAT-00703225,2,REC-5000802085,,,,"PART / DESCRIPTION - SEQ# 
Skin, biopsy/ SKIN LEFT THIGH- 1
PART / DESCRIPTION - SEQ# 
Skin, biopsy/ SKIN LEFT  BREAST- 2<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
Comment
Both lesions (left thigh and left breast) show features worrisome for malignant melanoma. These cases will be sent in consultation to Dermatopathology Northwest. 

Of note is a prior history of malignant melanoma with spitzoid/nevoid features, involving the left arm (***PATH-NUMBER[1]). This case was seen in consultation at Dermatopathology Northwest and as well at the **INSTITUTION at San Francisco.<FINAL DX>

1) SKIN, LEFT THIGH: ATYPICAL MELANOCYTIC PROLIFERATION (SEE COMMENT). 

2) SKIN, LEFT BREAST: ATYPICAL MELANOCYTIC PROLIFERATION (SEE COMMENT). 
GDA:cr<GROSS>
PART 1: SKIN LEFT THIGH 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"left thigh,"""" is a shaved portion of tan-brown fine granular skin measuring 0.3 cm. Marked blue and submitted as is in cassette 1a.
 
PART 2: SKIN LEFT BREAST 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"left breast,"""" is an elliptoid portion of tan unoriented skin measuring 1.2 x 0.6 cm. The skin is smooth and almost occupied by a gray-brown fine granular flat lesion measuring 0.8 x 0.4 cm. The lesion approaches one cutaneous margin. The skin tips are marked blue and black respectively. Sectioned and entirely submitted in cassette 2a.<CLINICAL INFO>
Suspicious lesion left thigh and left breast. History of melanoma.<MICROSCOPIC>
PART 1: SKIN LEFT THIGH
Sections demonstrate skin with an atypical melanocytic proliferation, with pagetoid epidermal ascent, atypical junctional nests, and atypical nested melanocytes in the papillary dermis. 
 
PART 2: SKIN LEFT BREAST 
Sections demonstrate an atypical melanocytic proliferation. Nests of atypical melanocytes are present at the junction as well as filling and apparently expanding the papillary dermis. There are infrequent atypical individual melanocytes in the epidermis.PATHOLOGIST:
Austin G.David",,,,,
REG3,OTHER,0,PAT-00475692,1,REC-5000804994,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Parotid Lymph Node, Fine Needle Aspiration (Cytology and Cell
Block):
  Abnormal B-cell population identified on flow cytometry with
immunophenotypic features
    (by flow cytometry and immunohistochemistry) consistent with
recurrent mantle cell lymphoma.

<COMMENT>
This case has been reviewed by Dr. **NAME[ZZZ M. YYY], who specializes in
hematopathology. This has been done as part of our quality assurance
policy, and she concurs with the diagnosis.

<CLINICAL INFO>
History of mantle cell lymphoma in 2003 with recurrence in 2009. ICD-9
Code(s): 785.6

<GROSS>
A. A specimen labeled ""**NAME[BBB, AAA]"" and designated ""right parotid
mass/lymph node"" per requisition is received in 30 ml of CytoLyt on
**DATE[Mar 30 2012]. Prepared are one alcohol-fixed cytocentrifuge Pap-stained
slide and one cell block. Also received on **DATE[Mar 30 2012] are three
alcohol-fixed direct smears and three air-dried direct smears unlabeled
and designated ""right parotid mass/lymph node"" per requisition. The
alcohol-fixed smears are Papanicolaou stained and the air-dried smears
are Diff-Quik-stained. (rc/gdb)

B. A specimen labeled ""**NAME[BBB, AAA]"" and designated ""right parotid
mass lymph node"" is received in tissue media for flow cytometry analysis
on **DATE[Mar 30 2012]. Flow cytometry analysis is performed on that material.
(acb/jmk)

<MICROSCOPIC>
A.  Examination of the smears and cytospins reveals a cellular sample
with predominantly lymphocytes present. No epithelial cells are seen.
Occasional stromal fibrous tissue fragments are identified. Occasional
other inflammatory cells to include histiocytes and neutrophils are
present. The lymphocytes appear to be predominantly small
well-differentiated and occasional intermediate-sized lymphocytes
showing slight nuclear membrane irregularities. There is a small
population of large atypical lymphoid cells with nuclei containing
granular chromatin and no significant or prominent nucleoli.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
Cyclin D1 Positive

Impression:
Interpreted by:  **NAME[ZZZ M. YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

FLOW CYTOMETRY:

<FINAL DX>

Right parotid mass/lymph node: Abnormal B-cell population identified
with immunophenotypic features consistent with Mantle cell lymphoma.
(see comment)

COMMENT:
Flow cytometry reveals an abnormal B-cell population expressing CD5,
CD19, and CD20, with kappa surface light chain restriction, without
CD23.  The abnormal B-cell population comprises 93.7% of the white blood
cells.  The immunophenotypic findings are consistent with recurrent
mantle cell lymphoma. However, documentation of cyclin D1 expression by
immunocytochemistry, or the t(11;14) by FISH could be considered for
confirmation.

Flow cytometry histograms interpreted by **NAME[ZZZ YYY], M.D.

Flow Cytometry Images

Antibodies tested: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD16, CD19, CD20,
CD23, CD25, CD38, CD45, CD56, CD57, Kappa and Lambda.

These tests were developed and the performance characteristics
determined by Cellnetix Pathology and Laboratories. They have not been
cleared or approved by the US Food and Drug Administration. The FDA has
determined that such clearance or approval is not necessary. This
laboratory is certified under CLIA-88 and is qualified to perform high
complexity clinical testing. Prognostic and predictive testing should be
interpreted in the context of additional clinical and/or
histopathological findings.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Apr 02 2012]",,,,,
REG3,OTHER,0,PAT-00596543,2,REC-5000810425,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Bladder Tumor, Biopsy:
Invasive papillary urothelial carcinoma:
Grade:    High grade (WHO/ISUP Classification, 1998).
Invasion:      Present, with foci consistent with invasion to muscularis
propria.
Muscularis propria:      Present.

<CLINICAL INFO>
Bladder cancer.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA M]"", and designated
""bladder tumor"" per requisition, are multiple irregular pieces of dusky,
rubbery tissue admixed with a scant amount of clot, altogether
aggregating to 3.8 x 3 x 1.5 cm. It is entirely submitted in A1-A3.
(kjh/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

PHYSICIAN NOTIFICATION:
-Dr. **NAME[ZZZ]'s medical office.

INTRADEPARTMENTAL CONSULTATION:
CellNetix pathologist, Dr. **NAME[YYY XXX], also reviewed this case and
agrees with the above diagnosis.

**NAME[WWW M VVV], M.D.  Electronically signed **DATE[Feb 09 2012]",,,,,
REG1,BREAST,0,114431,3,,"Clinical Diagnosis and History\X0D\\X0A\LEFT CHEST WALL MASS, HISTORY OF BREAST CANCER S/P MASTECTOMY\X0D\\X0A\OPER  EXC MASS LEFT CHEST WALL","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: MASS LEFT CHEST WALL REMOVED 09:35 FORMALIN 09:48-ag\X0D\\X0A\2: TISSUE DEEP MARGIN LEFT CHEST WALL-REMOVED 09:35 FORMALIN 09:48- ag","Final Diagnosis\X0D\\X0A\1: ""MASS LEFT CHEST WALL"":\X0D\\X0A\     POORLY DIFFERENTIATED CARCINOMA CONSISTENT WITH MAMMARY CARCINOMA \X0D\\X0A\          INVOLVING FIBROADIPOSE TISSUE AND SKELETAL MUSCLE (SEE COMMENT).\X0D\\X0A\     TUMOR SIZE: 3.8 X 3.0 X 1.8 CM.\X0D\\X0A\     TUMOR EXTENSION TO INKED DEEP (SKELETAL MUSCLE) MARGIN.\X0D\\X0A\     FOCAL TUMOR EXTENSION TO WITHIN LESS THAN 0.5 MM OF CLOSEST OVERLYING\X0D\\X0A\          ANTERIOR SOFT TISSUE MARGIN.\X0D\\X0A\     SKIN: NEGATIVE.\X0D\\X0A\COMMENT: Our records indicate a history of breast invasive lobular carcinoma in\X0D\\X0A\1995 (slides not available for comparison).  This current tumor shows focal\X0D\\X0A\areas with single cell infiltration pattern (lobular pattern) carcinoma with\X0D\\X0A\other areas showing diffuse sheets of carcinoma.  A limited panel of\X0D\\X0A\immunostains with appropriate controls show: mammoglobin (+), GCDFP (+), CK7\X0D\\X0A\(+), AE1/3 (+) with e-cadherin showing focal areas of positive staining. This\X0D\\X0A\pattern is supportive of mammary carcinoma with mixed ductal and lobular\X0D\\X0A\immunophenotype. Hormone receptors and Her2 are pending. \X0D\\X0A\2: ""TISSUE DEEP MARGIN LEFT CHEST WALL"":\X0D\\X0A\     INVASIVE CARCINOMA.\X0D\\X0A\**INITIALS IHC/a/CMK  \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY",,"Gross Description\X0D\\X0A\1:  Received in formalin labeled ""mass left chest wall"" is an unoriented 7.5 x\X0D\\X0A\6.5 x 3.8 cm portion of yellow red fibrofatty tissue which includes a small\X0D\\X0A\amount of skeletal muscle attached along one edge of the specimen.  Overlying\X0D\\X0A\the specimen is a wrinkled tan pink 9.0 cm strip of skin which varies in width\X0D\\X0A\from 0.5 cm up to 2.0 cm.  Initially, the margin with the attached skeletal\X0D\\X0A\muscle is inked in blue and the opposite marginal side of the specimen is inked\X0D\\X0A\in green.  On serially sectioning the specimen across its short axis, situated\X0D\\X0A\deep within the underlying soft tissue and grossly in continuity with the margin\X0D\\X0A\with the attached skeletal muscle (blue) and approximately 0.7 cm away from the\X0D\\X0A\opposite margin (green) is a well defined tan pink and focally hemorrhagic 3.8 x\X0D\\X0A\3.0 x 1.8 cm mass.  This mass is situated approximately 3.2 cm subjacent to the\X0D\\X0A\skin.  Each of the long axis soft tissue margins of the specimen grossly appear\X0D\\X0A\to be at least 1 cm away from the edge of the mass.  Sections are submitted as\X0D\\X0A\follows: \X0D\\X0A\1A, 1B:  Representative cross-sections of the skin to include the immediate\X0D\\X0A\underlying superficial soft tissue.\X0D\\X0A\1C through 1F:  Representative sections of the mass within the deeper soft\X0D\\X0A\tissue, taken through the short specimen axis to include each of the inked close\X0D\\X0A\margins.\X0D\\X0A\1G, 1H:  A perpendicular section of each of the long axis skin margins.\X0D\\X0A\1I, 1J:  Additional representative sections of the mass to include close inked\X0D\\X0A\margins.\X0D\\X0A\2:  Received in formalin labeled ""tissue deep margin left"" is an unoriented firm\X0D\\X0A\tan pink 3.0 x 0.7 x 0.3 cm strip of tissue which is inked in blue and submitted\X0D\\X0A\in toto in block 2A.\X0D\\X0A\The specimens were removed from the patient at 9:35 hours and placed in formalin\X0D\\X0A\at 9:48 hours on **DATE[Jan 12 12].  The tissue was sectioned, placed in cassettes in\X0D\\X0A\formalin at 19:50 hours on **DATE[Jan 12 12].  DH/**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 19 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 19 2012]     By:  **NAME[WWW, VVV]\X0D\\X0A\     Date Reported:     **DATE[Jan 19 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding Breast Cancer Biomarker Analysis.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **NAME[YYY"
REG1,BREAST,0,118420,5,,CLINICAL HISTORY:\X0D\\X0A\History of bilateral breast cancer. Specimen excised at 7:57 a.m. and\X0D\\X0A\placed in formalin at 8:10 a.m. for an approximate ischemic time of 13\X0D\\X0A\minutes and total formalin fixation time of 10 hours.,"AP SPECI\X0D\\X0A\**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\ADDENDUM I\X0D\\X0A\**DATE[Dec 25 2011]\X0D\\X0A\ \X0D\\X0A\SPECIAL STAINS: (Estrogen Receptor, Progesterone Receptor)\X0D\\X0A\ \X0D\\X0A\Hormone receptor studies using immunohistochemistry were performed on\X0D\\X0A\the invasive tumor.  The results and information regarding the stains\X0D\\X0A\are as follows:\X0D\\X0A\ \X0D\\X0A\ESTROGEN RECEPTOR\X0D\\X0A\ \X0D\\X0A\Vendor:  Vision biosystems\X0D\\X0A\         bond-Leica\X0D\\X0A\Clone:   6F11\X0D\\X0A\Processing: FFPE*\X0D\\X0A\Estimation of % positive: 80%\X0D\\X0A\**NAME[ZZZ] Score: 8/8\X0D\\X0A\RESULTS:  POSITIVE\X0D\\X0A\ \X0D\\X0A\PROGESTERONE RECEPTOR\X0D\\X0A\ \X0D\\X0A\Vendor:  Vision Biosystems\X0D\\X0A\         Bond-Leica\X0D\\X0A\Clone:   16\X0D\\X0A\Processing: FFPE*\X0D\\X0A\Estimation of % positive: 99%\X0D\\X0A\**NAME[ZZZ] Score: 8/8\X0D\\X0A\RESULTS: POSITIVE\X0D\\X0A\ \X0D\\X0A\Her2/neu studies will be performed by FISH technique at Quest\X0D\\X0A\Diagnostics.  Their results will be reported in an addendum. (*FFPE  \X0D\\X0A\Formalin-Fixed paraffin-embedded.)\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\ADDENDUM II\X0D\\X0A\**DATE[Dec 29 11]\X0D\\X0A\ \X0D\\X0A\SPECIAL STAINS:  (Her/2 neu)\X0D\\X0A\ \X0D\\X0A\Her2/neu studies were performed using a FISH technique. These studies\X0D\\X0A\were performed at Quest Diagnostics.  The results are as follows:\X0D\\X0A\ \X0D\\X0A\RESULT:  NEGATIVE FOR HER/2 (ERBB2) AMPLIFICATION.\X0D\\X0A\ \X0D\\X0A\RATIO OF ERBB2/D17z1:  1.1\X0D\\X0A\A ratio of <1.8 is considered negative for amplification.\X0D\\X0A\A ratio of 1.8-2.2 is considered equivocal for amplification (Guidelines\X0D\\X0A\suggest retesting or testing with IHC.  Those with a ratio greater than\X0D\\X0A\2.0 have been eligible for Herceptin trials).\X0D\\X0A\A ratio of >2.2 is considered positive for amplification.\X0D\\X0A\ \X0D\\X0A\AVERAGE COUNT ERBB2:  2.0\X0D\\X0A\AVERAGE COUNT D17z1:  1.8\X0D\\X0A\ \X0D\\X0A\COMMENT:   Please refer to a copy of the outside consultant's report\X0D\\X0A\dated **DATE[Dec 18 2011].\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\The previous value GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   SKIN AND SOFT TISSUE, LEFT CHE was corrected by IF on **DATE[Jan 03 12]\X0D\\X0A\07:43\X0D\\X0A\\X0D\\X0A\The previous value GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'left chest wall, recurrent  was\X0D\\X0A\corrected by IF on **DATE[Jan 03 12] 07:43\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Dec 25 11] 13:04\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Dec 25 11] 13:04\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Jan 03 12] 07:43\X0D\\X0A\\X0D\\X0A\The previous value **NAME[YYY:  XXX M. WWW] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Dec 22]/ was corrected by IF on **DATE[Dec 25 11] 13:04\X0D\\X0A\\X0D\\X0A\The previous value **NAME[YYY:  XXX M. WWW] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\**NAME[YYY:  VVV M. UUU] was corrected by IF on **DATE[Jan 03 12] 07:43","GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   SKIN AND SOFT TISSUE, LEFT CHEST WALL, EXCISION: INVASIVE\X0D\\X0A\ADENOCARCINOMA CONSISTENT WITH BREAST  PRIMARY.\X0D\\X0A\1.   HISTOLOGIC FEATURES:\X0D\\X0A\a.   Histologic Type: mucinous adenocarcinoma.\X0D\\X0A\b.   Grade: Nottingham Grade I (histologic grade 2,\X0D\\X0A\    nuclear grade 1, mitotic grade 1).\X0D\\X0A\2.   TUMOR SIZE: Tumor measures up to 1.9 cm. on the\X0D\\X0A\   slide.\X0D\\X0A\3.   MARGINS OF RESECTION AND EXTENT:\X0D\\X0A\a.   Tumor comes within 1.3 mm. of the deep margin.\X0D\\X0A\b.   No capillary lymphatic invasion.\X0D\\X0A\c.   No perineural invasion.\X0D\\X0A\d.   No dermal lymphatic invasion.\X0D\\X0A\e.   No intraductal component.\X0D\\X0A\4.   ADDITIONAL FINDINGS:\X0D\\X0A\a.   Fat necrosis.\X0D\\X0A\b.   Area of hemorrhage adjacent to the tumor (questionable previous\X0D\\X0A\biopsy site).\X0D\\X0A\5.   PATHOLOGIC STAGING: p,T1c,NX,MX,G1\X0D\\X0A\ \X0D\\X0A\COMMENT: Hormone receptors will be performed and the results will be\X0D\\X0A\reported in an addendum.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[YYY:  XXX M. WWW] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\**NAME[YYY:  VVV M. CCC] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jan 03 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'left chest wall, recurrent mass with\X0D\\X0A\pectoralis muscle attached' is a 5.4 x 1.2 cm. tan skin ellipse\X0D\\X0A\surmounting a 5.5 x 4.3 x 2.7 cm. fibrofatty nodule.  The margin is\X0D\\X0A\inked.  There is a palpable nodule of subcutaneous tissue.  The specimen\X0D\\X0A\is serially sectioned, to reveal a well demarcated 2 cm. nodule with\X0D\\X0A\hemorrhage and fat necrosis.  Definitive tumor is not identified.  The\X0D\\X0A\entire lesion is submitted in cassettes (A1-A3) with representative\X0D\\X0A\sections of grossly benign appearing skin and subcutaneous tissue in\X0D\\X0A\cassettes (A4-A6).   (MC/kd)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 6\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Breast\X0D\\X0A\Specimen Type: Other\X0D\\X0A\Chest Wall biopsy\X0D\\X0A\Lymph Node Sampling:     No lymph node sampling\X0D\\X0A\Specimen size: Greatest dimension: 5.5cm x 4.3cm x 3.7cm\X0D\\X0A\Laterality:    Left\X0D\\X0A\Tumor Site:    Not specified\X0D\\X0A\Size of Invasive Component:   Greatest dimension: 1.9cm\X0D\\X0A\Histologic Type:    Mucinous\X0D\\X0A\Grading System:     Nottingham\X0D\\X0A\Tubule Formation:   Moderate 10% to 75% (score = 2)\X0D\\X0A\Nuclear Pleomorphism:    Small regular nuclei (score = 1)\X0D\\X0A\Mitotic Count: 40 x objective field with a field area of 0.152 mm2:   0\X0D\\X0A\to 5 mitoses per 10 HPF (score = 1)\X0D\\X0A\Total Nottingham Score:  Grade I\X0D\\X0A\Margins:  Margins uninvolved by invasive carcinoma\X0D\\X0A\Distance from closest margin: 1.3mm\X0D\\X0A\Deep\X0D\\X0A\Venous/Lymphatic [Large/Small]  Invasion:    Absent\X0D\\X0A\Microcalcifications:     Not identified\X0D\\X0A\Additional Findings:     Include\X0D\\X0A\Specify:  Area of hemmorhage and fat necrosis\X0D\\X0A\Primary Tumor [pT]: pT1c\X0D\\X0A\Regional Nodes [pN]:     pNX\X0D\\X0A\Number involved:    0\X0D\\X0A\Number examined:    0\X0D\\X0A\Distant Metastasis [pM]: pMX",,SPECIMEN(S): A LEFT CHEST WALL,,
REG1,BREAST,0,206013,3,,Clinical History:\X0D\\X0A\None Given,**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\Frozen Section:\X0D\\X0A\A) Gross margin evaluation:  Tumor present at deep margin.  (ES).\X0D\\X0A\Results given directly to Dr. **NAME[ZZZ].\X0D\\X0A\B) Touch prep Dx:  No tumor identified.  (Touch preps only done as\X0D\\X0A\discussed with Dr. **NAME[ZZZ]).  (ES).  Results RBV by **NAME[YYY].,"Pre-Operative Diagnosis:\X0D\\X0A\Right Breast Cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A) Right breast, mass, needle-localized lumpectomy:\X0D\\X0A\-    Infiltrating moderately differentiated ductal carcinoma with focal\X0D\\X0A\lobular features, 2.5 cm, with associated prior biopsy site changes (see\X0D\\X0A\synoptic and microscopic description).\X0D\\X0A\-    Minor component of intermediate grade ductal carcinoma in situ,\X0D\\X0A\intermediate grade, representing 5% of the tumor volume.\X0D\\X0A\-    Infiltrating tumor focally involves the deep resection margin, with\X0D\\X0A\all remaining peripheral margins and overlying medial skin free of\X0D\\X0A\tumor.\X0D\\X0A\-    Focal angiolymphatic invasion identified.\X0D\\X0A\-    Pathologic Stage:  pT2; pN0(sn); pMx.\X0D\\X0A\-    Background proliferative fibrocystic changes, intraductal\X0D\\X0A\papillomas, focal atypical ductal hyperplasia, and sclerosing adenosis\X0D\\X0A\with associated luminal microcalcifications.\X0D\\X0A\B) Sentinel lymph node #1, right, excision:\X0D\\X0A\-    One benign lymph node; no tumor seen.\X0D\\X0A\C) Sentinel lymph node #2, right, excision:\X0D\\X0A\-    One benign lymph node; no tumor seen.\X0D\\X0A\Comment:  Immunohistochemical studies for estrogen and progesterone\X0D\\X0A\receptors and HER-2/neu status will be performed on block A10, with\X0D\\X0A\results to be issued in an addendum.",,"Gross Description:\X0D\\X0A\Received are three parts, each labeled with the patient's name.\X0D\\X0A\Part A is received fresh on a Specboard for gross margin evaluation and\X0D\\X0A\additionally labeled ""right breast mass"".  The specimen consists of an 8\X0D\\X0A\x 7 x 3.5 cm portion of yellow-tan fibrofatty soft tissue.  The medial\X0D\\X0A\aspect of the specimen is partially surfaced by a pink-tan skin ellipse\X0D\\X0A\which is 3 x 0.5 cm.  The epidermal surface is pink-tan and grossly\X0D\\X0A\unremarkable.  There is a radiograph included with the specimen, and an\X0D\\X0A\indwelling needle localization wire is present.  The specimen is\X0D\\X0A\oriented on the Specboard with respect to the superior, inferior,\X0D\\X0A\medial, and lateral margins.  The specimen is also oriented with black\X0D\\X0A\ink on the anterior surface, and blue ink on the posterior surface.  The\X0D\\X0A\specimen is now further inked deep = blue, superficial = black.\X0D\\X0A\Sectioning the specimen reveals a 1.9 x 1.4 x 1.2 cm relatively\X0D\\X0A\well-circumscribed indurated mass within the medial half of the\X0D\\X0A\specimen.  The lesion has a solid white-tan cut surface.  The mass is\X0D\\X0A\0.7 cm from the superficial margin, 1 cm from the inferior margin, 1.5\X0D\\X0A\cm from the superior margin, 1.5 cm from the medial margin, and greater\X0D\\X0A\than 2 cm from the lateral margin.  Posterior to the main mass, there is\X0D\\X0A\a separate stellate lesion which is 0.6 x 0.5 x 0.4 cm.  This smaller\X0D\\X0A\lesion is possibly connected to the main mass, giving the lesional area\X0D\\X0A\an overall greatest dimension of 2.5 cm.  The separate small lesion\X0D\\X0A\abuts the deep margin.  There are no other distinct lesions identified.\X0D\\X0A\The lateral half of the specimen is notable for a moderate amount of\X0D\\X0A\dense white-tan fibrous tissue and abundant blue-domed cystic\X0D\\X0A\structures.  An intraoperative gross consult is performed.\X0D\\X0A\Representative sections are submitted as follows:\X0D\\X0A\A1 - medial margin\X0D\\X0A\A2 - lateral margin\X0D\\X0A\A3 and A4 - superior margin\X0D\\X0A\A5 and A6 - inferior margin\X0D\\X0A\A7 - superficial margin\X0D\\X0A\A8 through A12 - lesional area entirely submitted to include deep margin\X0D\\X0A\(nodule at deep margin included in cassettes A8 through A10);\X0D\\X0A\A13 through A14 - representative sections of dense fibrous tissue\X0D\\X0A\lateral to the mass.\X0D\\X0A\NOTE:  Part A sections are placed in formalin at 11:40 a.m. on **DATE[Nov 7 2011].\X0D\\X0A\Part B is received fresh additionally labeled ""sentinel node #1"".  The\X0D\\X0A\specimen consists of a 4 x 2 x 1 cm yellowish-tan largely fatty replaced\X0D\\X0A\lymph node.  The lymph node is serially sectioned and touch preps are\X0D\\X0A\obtained.  There is no frozen section performed.  The lymph node is\X0D\\X0A\submitted entirely in cassette B.\X0D\\X0A\Part C is received fresh additionally labeled ""sentinel node #2"".  The\X0D\\X0A\specimen consists of a 1.2 x 0.8  x0.7 cm pink-tan partially fatty\X0D\\X0A\replaced lymph node.  The lymph node is sectioned and submitted entirely\X0D\\X0A\in cassette C.\X0D\\X0A\JAB:jck","Microscopic Description:\X0D\\X0A\A)   The initial peripheral resections margins as designated are each\X0D\\X0A\benign, with the medial skin showing subcutaneous prior biopsy site\X0D\\X0A\changes.  The background breast shows proliferative fibrocystic changes\X0D\\X0A\with a few foci of columnar cell hyperplasia without atypia, and a small\X0D\\X0A\focus of intraductal papilloma formation.  Foci of sclerosing adenosis\X0D\\X0A\and scattered benign luminal microcalcifications are noted.  Sections of\X0D\\X0A\the tumor in relation to the deep margin show the smaller described\X0D\\X0A\nodular focus deep to the main tumor mass, to focally involve the inked\X0D\\X0A\and cauterized margin of resection (as noted grossly).  The majority of\X0D\\X0A\the tumor in this peripheral distribution shows small aggregates and\X0D\\X0A\single file linear arrays, focally circumscribing benign ductal\X0D\\X0A\elements, suggestive of lobular features.  However, the main tumor mass\X0D\\X0A\demonstrates areas of true tubule formation, overall compatible with a\X0D\\X0A\ductal morphology.  Prior biopsy site changes are again noted.  The\X0D\\X0A\majority of the tumor shows moderate to focally marked nuclear\X0D\\X0A\pleomorphism, with mitoses estimated at up to 2-3 in 10 high-power\X0D\\X0A\fields.  The tumor nests occasionally show retraction artifact with the\X0D\\X0A\surrounding stroma with a few scattered foci of angiolymphatic invasion\X0D\\X0A\identified.  A minor component of background ductal carcinoma in situ is\X0D\\X0A\noted, primarily of a cribriform morphology and of intermediate nuclear\X0D\\X0A\features.  The in situ tumor is seen spreading in adjacent and distant\X0D\\X0A\segmental ducts.  Slide ***PATH-NUMBER[1] also shows an adjacent intraductal\X0D\\X0A\papilloma, appearing partially sclerosed.  A few separated foci of\X0D\\X0A\atypical ductal hyperplasia are also noted, with a few separate < 1\X0D\\X0A\millimeter satellite tumor foci seen in slide ***PATH-NUMBER[2].  The dense breast\X0D\\X0A\tissue lateral to the mass shows similar proliferative fibrocystic\X0D\\X0A\changes with features suggestive of a very small, < 0.3 cm early radial\X0D\\X0A\scar noted.\X0D\\X0A\B)   Review of the touch preparation and permanent sentinel lymph node\X0D\\X0A\step-level sections shows a single benign serially divided lymph node\X0D\\X0A\with no evidence of metastatic tumor.\X0D\\X0A\C)   Review of the permanent sentinel lymph node levels shows a single\X0D\\X0A\serially divided benign lymph node with no evidence of metastatic tumor.\X0D\\X0A\Tissue Code:  T1.\X0D\\X0A\CASE SUMMARY FOR INVASIVE CARCINOMA OF THE BREAST\X0D\\X0A\Specimen:  Breast\X0D\\X0A\Procedure:  Needle localized lumpectomy\X0D\\X0A\Lymph node sampling:  Sentinel nodes x 2\X0D\\X0A\Specimen laterality:  Right\X0D\\X0A\Specimen integrity:  Single intact specimen, margins can be assessed\X0D\\X0A\Specimen size:  8 x 7 x 3.5 cm\X0D\\X0A\Tumor site:  3:00 position (per ***PATH-NUMBER[3])\X0D\\X0A\Tumor size:  2.5 x 1.4 x 1.2 cm\X0D\\X0A\Tumor focality:  Multifocal (separate <1 mm satellite tumor foci noted)\X0D\\X0A\Histologic type of invasive carcinoma:  Ductal\X0D\\X0A\Histologic grade (Nottingham histologic score):\X0D\\X0A\Glandular/tubular differentiation:  3\X0D\\X0A\Nuclear pleomorphism:  2-3\X0D\\X0A\Mitotic count:  1\X0D\\X0A\Total score:  7\X0D\\X0A\Overall grade:  Moderately differentiated\X0D\\X0A\Extent of tumor:\X0D\\X0A\Skin:  Benign\X0D\\X0A\Nipple:  N/A\X0D\\X0A\Skeletal muscle:  N/A\X0D\\X0A\Ductal carcinoma in situ (DCIS):\X0D\\X0A\Size (extent) of DCIS:  \R\5% of tumor volume\X0D\\X0A\DCIS architectural patterns:  Cribriform\X0D\\X0A\DCIS nuclear grade:  Intermediate\X0D\\X0A\Necrosis:  Not observed\X0D\\X0A\Lobular carcinoma in situ (LCIS):  Not identified\X0D\\X0A\Microcalcifications:  Yes - benign zones\X0D\\X0A\Margins:  Invasive tumor extends to focally involve the deeper resection\X0D\\X0A\margin only\X0D\\X0A\Lymph-vascular invasion:  Identified\X0D\\X0A\Dermal lymph-vascular invasion:  Not identified\X0D\\X0A\Lymph nodes:\X0D\\X0A\Number of sentinel lymph nodes examined:  2\X0D\\X0A\Total number of lymph nodes examined (sentinel and non-sentinel):  2\X0D\\X0A\Number of lymph nodes with macrometastases:  0\X0D\\X0A\Number of lymph nodes with micrometastases:  0\X0D\\X0A\Number of lymph nodes with isolated tumor cells:  0\X0D\\X0A\Size of largest metastatic deposit:  N/A\X0D\\X0A\Extranodal extension:  N/A\X0D\\X0A\Additional pathologic findings:  Proliferative fibrocystic changes,\X0D\\X0A\focal atypical ductal hyperplasia, intraductal papillomas, sclerosing\X0D\\X0A\adenosis\X0D\\X0A\Receptor studies:  To be performed on block A10, with the results to\X0D\\X0A\follow in an addendum\X0D\\X0A\Pathologic Staging:  pT2; pN0(sn); pMx.\X0D\\X0A\DRJ:jck\X0D\\X0A\D\T\T:  **DATE[Nov 08 2011].\X0D\\X0A\Addendum:\X0D\\X0A\Immunohistochemical studies for estrogen (ER) and progesterone receptors\X0D\\X0A\(PR), and HER-2/neu status were performed on block A10, with the\X0D\\X0A\following results obtained (adequate immunostain controls):\X0D\\X0A\Estrogen Receptor (ER) (semiquantitative) / Progesterone Receptor (PR)\X0D\\X0A\(semiquantitative)\X0D\\X0A\ER:  Positive   >95%; staining intensity (strong)\X0D\\X0A\PR:  Positive     80%; staining intensity (mild/moderate)\X0D\\X0A\Method and Scoring Guide for ER/PR:\X0D\\X0A\Performed upon routinely formalin fixed and paraffin embedded tissue.\X0D\\X0A\ER clone SP1\X0D\\X0A\PR clone 1E2.\X0D\\X0A\Scoring Guide:  A positive result is based specifically upon positive\X0D\\X0A\nuclear staining within tumor cells, with an intensity graded from\X0D\\X0A\weak-mild to strong as noted above.  If the count is greater than 0% by\X0D\\X0A\IHC manual morphometry, of any intensity, the result is considered\X0D\\X0A\POSITIVE, with only 0% staining considered NEGATIVE.\X0D\\X0A\HER-2/neu Status (semiquantitative):  (1+) Negative.\X0D\\X0A\Method and Interpretation Guide for HER-2/neu (C-erB-2):\X0D\\X0A\Performed upon routinely formalin fixed and paraffin embedded tissue\X0D\\X0A\(subject to false-negative results with improper and/or delayed\X0D\\X0A\fixation).\X0D\\X0A\Specimen identification:\X0D\\X0A\CASE #:  ***PATH-NUMBER[4] BLOCK #:  A10\X0D\\X0A\-    Specimen site and type:  Breast\X0D\\X0A\-    Time to fixation (if available):  11:40 a.m.\X0D\\X0A\-    Duration of fixation (if available):  > 6 hours\X0D\\X0A\HER-2/neu clone 4B5.\X0D\\X0A\Method used:  VENTANA i VIEW PATHWAYS (FDA approved, controls high\X0D\\X0A\protein expression, low level protein expression, negative protein\X0D\\X0A\expression, internal).\X0D\\X0A\Adequacy of sample for evaluation:  Adequate\X0D\\X0A\Result interpretation:  (1+) Negative\X0D\\X0A\Percentage of invasive tumor cells exhibiting complete membrane\X0D\\X0A\staining:  0%\X0D\\X0A\Uniformity of staining present or absent:  Absent\X0D\\X0A\Homogeneous dark circumferential pattern present or absent:  Absent\X0D\\X0A\Scoring Guide:\X0D\\X0A\Staining Pattern                   Result\X0D\\X0A\     0    No membrane staining observed      Negative\X0D\\X0A\          (or membrane staining observed\X0D\\X0A\          in a count of less than 10% of tumor cells).\X0D\\X0A\     1+   Faint/partial membrane staining         Negative\X0D\\X0A\          (detected in a count of more than 10% of\X0D\\X0A\          tumor cells.  Staining may not\X0D\\X0A\          encircle entire cell membrane).\X0D\\X0A\     2+   Weak complete membrane staining,        Equivocal\X0D\\X0A\          observed in a count of more than 10%\X0D\\X0A\of tumor cells (encircling entire cell\X0D\\X0A\membrane).\X0D\\X0A\     3+   Moderate to strong (intense) complete   Positive\X0D\\X0A\          membrane staining observed in a count\X0D\\X0A\of more than 10% of tumor cells (encircling\X0D\\X0A\          entire cell membrane).\X0D\\X0A\NOTE:  The immunohistochemical methods utilized for the evaluation of\X0D\\X0A\ER/PR receptor status are considered semiquantitative with results\X0D\\X0A\expressed as detailed above.   Despite an FDA approved scoring guide\X0D\\X0A\that classifies 2+ immunohistochemistry results as equivocal, the\X0D\\X0A\literature suggests that up to 70% of these cases may be actually the\X0D\\X0A\fluorescence in situ hybridization (FISH) negative.  As such, a reflex\X0D\\X0A\to HER-2/neu FISH testing could be considered before administration of\X0D\\X0A\Herceptin therapy.\X0D\\X0A\The immunohistochemistry methods utilized for the evaluation of ER/PR\X0D\\X0A\receptor and HER-2/neu status are considered semiquantitative, with\X0D\\X0A\results expressed as detailed above.  These tests were developed and\X0D\\X0A\their performance characteristics determined by the **NAME[XXX WWW]\X0D\\X0A\Hospital Pathology Department.  This laboratory is regulated under the\X0D\\X0A\Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), as\X0D\\X0A\qualified to perform high complexity testing.\X0D\\X0A\DRJ:jlj\X0D\\X0A\D\T\T:  **DATE[Nov 12 2011].\X0D\\X0A\**NAME[VVV UUU:  TTT M SSS] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Nov 12 2011]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right Breast Mass\X0D\\X0A\SOURCE OF SPECIMEN: B Sentinel Node #1 (3436)\X0D\\X0A\SOURCE OF SPECIMEN: C Sentinel Node #2 (917),,
REG1,BREAST,0,268629,3,,"Clinical Diagnosis and History\X0D\\X0A\LT BREAST CALCS AND DENSITY\X0D\\X0A\OPER:   LT BREAST MAMMOTOME BIOPSY X 2 SITES\X0D\\X0A\SITE #1 CHECK FOR CALCIFICATIONS, CALCIFICATIONS INDICATED WITH WAX PENCIL MARK\X0D\\X0A\SITE #2 NOT FOR CALCIFICATIONS, CALCIFICATIONS NOT INDICATED","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **PLACE F.\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LT BREAST #1 SITE FOR CALCS-REMOVED FROM PATIENT 2:00, PLACED IN FORMALIN\X0D\\X0A\2:10-ls\X0D\\X0A\2: LT BREAST #2 SITE NOT FOR CALCS-REMOVED FROMT PATIENT 2:20, PLACED IN\X0D\\X0A\FORMALIN 2:40-ls","Final Diagnosis\X0D\\X0A\1: LEFT BREAST, SITE #1, MAMMOTOME DIRECTED NEEDLE BIOPSIES:\X0D\\X0A\     DUCTAL CARCINOMA IN SITU, HIGH NUCLEAR GRADE WITH FOCAL COMEDO NECROSIS, \X0D\\X0A\          CRIBRIFORM TYPE.\X0D\\X0A\     FOCAL CALCIFICATIONS.\X0D\\X0A\2: LEFT BREAST, SITE #2, MAMMOTOME DIRECTED NEEDLE BIOPSIES:\X0D\\X0A\     FOCAL DUCT CARCINOMA IN SITU, HIGH NUCLEAR GRADE WITH NECROSIS, IN A \X0D\\X0A\          BACKGROUND OF ATYPICAL DUCT HYPERPLASIA.\X0D\\X0A\COMMENT: Hormone receptor studies are pending on one block from each biopsy\X0D\\X0A\site.  Additionally, stains to exclude invasion are being performed.  A\X0D\\X0A\supplemental report will follow.\X0D\\X0A\MER/jsh\X0D\\X0A\IHC/a/CLS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\1: Received in formalin in a CoreTainer designated ""left breast for\X0D\\X0A\calcifications site #1"" are multiple fragments of gray and tan tissue.  These\X0D\\X0A\range in diameter from 0.2 to 0.3 cm and in length from 1.5 to 4.5 cm.  An\X0D\\X0A\accompanying specimen x-ray shows two red wax pencil marks over the 9 region. \X0D\\X0A\All tissue is submitted as follows:\X0D\\X0A\1A  12 region  2 cores\X0D\\X0A\1B  3 region  3 cores\X0D\\X0A\1C  6 region  1 core\X0D\\X0A\1D  9 region  5 cores\X0D\\X0A\All tissue has been processed.\X0D\\X0A\2: In the second container in formalin in a CoreTainer designated ""left breast\X0D\\X0A\not for calcs site #2"" are fourteen cores of gray and tan tissue ranging in\X0D\\X0A\diameter from 0.2 to 0.3 cm and in length from 0.5 to 4.0 cm.  An accompanying\X0D\\X0A\specimen x-ray shows no markings.  All tissue is submitted as follows:\X0D\\X0A\1A  12 region  2 cores\X0D\\X0A\2B  3 region  4 cores\X0D\\X0A\2C  6 region  4 cores\X0D\\X0A\2D  9 region  4 cores\X0D\\X0A\All tissue has been processed.\X0D\\X0A\MER/jsh",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Dec 23 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Dec 23 2011]     By:  **NAME[XXX,WWW]\X0D\\X0A\     Date Reported:     **DATE[Dec 24 2011]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding immunohistochemical analysis.\X0D\\X0A\INTERPRETATION, in part, reads:\X0D\\X0A\Block 1D  These results support ductal carcinoma in situ with a focus of\X0D\\X0A\microinvasion.\X0D\\X0A\Block 2B  These results support ductal carcinoma in situ.\X0D\\X0A\Signed:  **NAME[VVV UUU], M.D.    /ap\X0D\\X0A\HER2/NEU TESTING ON BLOCK 1/D TO FOLLOW.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[YYY], M.D.,  MARK E."
REG1,BREAST,0,273579,3,,"CLINICAL HISTORY\X0D\\X0A\Preop diagnosis: breast cancer recurrent (right). Intraoperative findings:\X0D\\X0A\breast cancer. Operative procedure: right partial mastectomy with needle\X0D\\X0A\localization and sentinel lymph node injection, possible axillary dissection.\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Mar 30 1951] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Apr 2 2012] 14:03\X0D\\X0A\Receipt Date: **DATE[Apr 2 2012] 14:03\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: BCC     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Apr 8 2012] 15:55\X0D\\X0A\RESIDENTS(**NAME[M): VVV UUU], DO\X0D\\X0A\Comment:\X0D\\X0A\This patient had a T1, N0, M0 mammary carcinoma resected in 2002.  The\X0D\\X0A\current tumor is apparently a recurrence at the same location.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\The primary antibody clone used for estrogen receptor analysis is Neomarker\X0D\\X0A\clone SP1 and Dako PgR636 for progesterone receptor analysis.  The detection\X0D\\X0A\system for both is Dakocytoenvision (+) R System HRP (DAB).  Only nuclear\X0D\\X0A\staining is counted and any value +/> 1% tumor cell nuclear staining is\X0D\\X0A\considered a positive test.\X0D\\X0A\HER-2/neu (c-erbB-2) Immunohistochemistry\X0D\\X0A\Using appropriate positive and negative controls, the test for the presence\X0D\\X0A\of this oncoprotein is performed by the immunoperoxidase method, and reported\X0D\\X0A\according to the American Society of Clinical Oncology (ASCO)/College of\X0D\\X0A\American Pathologists (CAP) Guideline Recommendations (2006).\X0D\\X0A\IMMUNOHISTOCHEMICAL INTERPRETATION:  CELL MEMBRANE STAINING ONLY (DAKO\X0D\\X0A\Polyclonal Rabbit Anti-Human c-erB-2 Oncoprotein Antibody)\X0D\\X0A\NEGATIVE:  Score 0 (No staining is observed or membrane staining is observed\X0D\\X0A\in less than 10% of the tumor cells).\X0D\\X0A\NEGATIVE:  Score 1+ (A faint/barely perceptible membrane staining is seen in\X0D\\X0A\more than 10% of the tumor cells.  The cells are only stained in part of\X0D\\X0A\their membrane).\X0D\\X0A\WEAK POSITIVE:  Score 2+ (A weak to moderate complete membrane staining is\X0D\\X0A\observed in more than 10% of the tumor cells).\X0D\\X0A\STRONG POSITIVE:  Score 3+ (A strong complete membrane staining is observed\X0D\\X0A\in more than 30% of the tumor cells).\X0D\\X0A\The results of this test are for investigational purposes as its performance\X0D\\X0A\characteristics have not been established.  It should be noted that according\X0D\\X0A\to the literature, the sensitivity for immunohistochemical HER-2/neu\X0D\\X0A\determination is no greater than 80% when compared to molecular or FISH\X0D\\X0A\methods.\X0D\\X0A\Primary antibody:  C-erb B.2 oncoprotein (polyclonal rabbit Dako ID# A0485)\X0D\\X0A\Detection system:  Dakocytoenvision (+) R System HRP (DAB)\X0D\\X0A\The results of this test are for investigational purposes as its performance\X0D\\X0A\characteristics have not been established.  It should be noted that according\X0D\\X0A\to the literature, the sensitivity for immunohistochemical HER-2/neu\X0D\\X0A\determination is no greater than 80% when compared to molecular or FISH\X0D\\X0A\methods.\X0D\\X0A\Primary antibody:  C-erb B.2 oncoprotein (polyclonal rabbit Dako ID# A0485)\X0D\\X0A\Detection system:  Dakocytoenvision (+) R System HRP (DAB)","DIAGNOSIS\X0D\\X0A\SPECIMEN SUBMITTED AS RIGHT LATERAL BREAST TISSUE (A):\X0D\\X0A\   - RECURRENT INTRADUCTAL AND INFILTRATING DUCT ADENOCARCINOMA OF THE\X0D\\X0A\BREAST, SUPERFICIAL\X0D\\X0A\     MARGIN POSITIVE FOR TUMOR.\X0D\\X0A\SPECIMEN SUBMITTED AS EXTENDED SUPERFICIAL MARGIN, RIGHT LATERAL BREAST (B):\X0D\\X0A\   - DENSE SCAR TISSUE, NO RESIDUAL CARCINOMA IDENTIFIED.\X0D\\X0A\SPECIMEN SUBMITTED AS RIGHT AXILLARY CONTENTS (C):\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, NO TUMOR SEEN, TWELVE LYMPH NODES.\X0D\\X0A\rpT1c, N0\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 7 2012] **NAME[TTT M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: T08000\X0D\\X0A\B: M85002 M8500\X0D\\X0A\C: M09400 M4906\X0D\\X0A\D: M09450 T0800 \X0D\\X0A\F: A: 88307, 76098 XRAY, 67030-ER, S 88360, 67031-PR, S 88360, S 67669, S\X0D\\X0A\88360\X0D\\X0A\B: 88305\X0D\\X0A\C: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Three specimens are received.\X0D\\X0A\Specimen A is received fresh labeled right lateral breast tissue (specimen\X0D\\X0A\radiographed, ink and cut) and consists of yellow white fragments of\X0D\\X0A\fibroadipose tissue with a needle that extends to the superficial margin.  An\X0D\\X0A\x-ray is taken and the presence of a clip \X0D\\X0A\is confirmed in the lateral aspect of the specimen.  It is serially sectioned\X0D\\X0A\and shows a poorly circumscribed white tan speculated mass.  There is a small\X0D\\X0A\0.3 x 0.3 x 0.3 firm nodule in the tissue that is submitted also.\X0D\\X0A\Note: the tissue is placed in formalin at 12:40.\X0D\\X0A\Measurements:\X0D\\X0A\Specimen dimensions: 8.5 cm from lateral to medial, 5.5 cm from superior to\X0D\\X0A\inferior, and 3 cm from superficial to deep\X0D\\X0A\Mass dimensions: 1.5 cm medial to lateral, 0.7 superior to inferior and 0.5\X0D\\X0A\cm\X0D\\X0A\Distance to closest lateral margin 0.6 cm, distance to medial margin 4.5 cm,\X0D\\X0A\distance to superficial margin grossly abuts, distance to the distal margin\X0D\\X0A\0.5 cm\X0D\\X0A\Inking:\X0D\\X0A\Superficial margin: black\X0D\\X0A\Deep margin: blue\X0D\\X0A\Superior/Inferior/Medial/Lateral edge: green.\X0D\\X0A\Cassette summary:\X0D\\X0A\A1- lateral margin\X0D\\X0A\A2 mass to the superficial margin with clip\X0D\\X0A\A3 mass to deep margin\X0D\\X0A\A4-A6 serial sections of the mass to the margin superficial black inked\X0D\\X0A\margin\X0D\\X0A\A7 superior margin\X0D\\X0A\A8 inferior margin closest to tumor\X0D\\X0A\A9 section of normal breast tissue near medial margin\X0D\\X0A\A10 section of normal breast tissue near superior margin\X0D\\X0A\A11 area lateral to the mass\X0D\\X0A\A12 and A13 small fibrous nodule 4 mm from the superficial margin\X0D\\X0A\Specimen B is labeled extended superficial margin right lateral breast, new\X0D\\X0A\margin is up and consists of a single oriented fragments of yellow tan\X0D\\X0A\fibrofatty tissue measuring 3 cm from lateral to medial, 1.6 cm from superior\X0D\\X0A\to inferior and 1 cm from superficial to deep. The black ink denotes the new\X0D\\X0A\margin. The green ink denotes superior part of the resection. The specimen is\X0D\\X0A\serially sectioned and submitted in its'  entirety from lateral to medial.\X0D\\X0A\Note tissue placed in formalin at 1:55.\X0D\\X0A\Specimen label:  C) right axillary contents                 \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: rubbery\X0D\\X0A\Size(s): 4 x 2 cm which is dissected to reveal seven candidate lymph nodes. \X0D\\X0A\Cassette summary: C1 candidate lymph node bisected, C2 candidate lymph node\X0D\\X0A\trisected, C3 candidate lymph node trisected, C4 three possible candidate\X0D\\X0A\nodes, C5 candidate node bisected, C6-12 additional candidate nodes. \X0D\\X0A\ksl/**DATE[Apr 6 2012] **NAME[VVV UUU], DO\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST (template #26)\X0D\\X0A\Last updated **DATE[Jan 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Specimen/procedure:  right partial mastectomy, needle localization and\X0D\\X0A\sentinel lymph node injection, right axillary dissection\X0D\\X0A\Specimen integrity:  main specimen with separate margins \X0D\\X0A\\X0D\\X0A\Specimen size:   8.5 x 5.5 x 3 cm\X0D\\X0A\Specimen laterality:   right \X0D\\X0A\Tumor site for invasive carcinoma:    right breast\X0D\\X0A\Tumor size (largest one):   1.5 x 0.7 x 0.5 cm\X0D\\X0A\Tumor focality:   unifocal\X0D\\X0A\Histologic type:   ductal\X0D\\X0A\Histologic grade (Nottingham histologic score):\X0D\\X0A\    Glandular (acinar)/tubular differentiation:  2 \X0D\\X0A\     Nuclear pleomorphism:  2\X0D\\X0A\     Mitotic Count:   2\X0D\\X0A\     Overall Grade:  Grade 2 (score of 6)\X0D\\X0A\\X0D\\X0A\Ductal carcinoma in situ (DCIS):   present, less than 25%\X0D\\X0A\\X0D\\X0A\      DCIS architectural pattern(s):  cribriform type\X0D\\X0A\      DCIS nuclear grade:   Grade II (intermediate) \X0D\\X0A\Lobular carcinoma in situ (LCIS):   not identified \X0D\\X0A\Lymph-vascular Invasion:   not identified \X0D\\X0A\Dermal lymph-vascular Invasion:  no skin present \X0D\\X0A\Microcalcifications:   no  \X0D\\X0A\Skin:    no skin present \X0D\\X0A\Nipple:    no nipple present \X0D\\X0A\Skeletal muscle:    no skeletal muscle \X0D\\X0A\Margins:    ultimate margins free of tumor \X0D\\X0A\Lymph nodes (if present in current specimen):  0/12\X0D\\X0A\Pathologic staging (pTNM) (m: multiple foci of invasive carcinoma)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\       rpT1c:             >10 mm but =20 mm \X0D\\X0A\REGIONAL LYMPH NODES (pN) \X0D\\X0A\     Note:  (sn): only sentinel node(s) evaluated.  If 6 or more sentinel\X0D\\X0A\nodes and/or nonsentinel nodes are \X0D\\X0A\          removed, this modifier should not be used.\X0D\\X0A\          pN0:                No metastasis identified\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (M)  \X0D\\X0A\                         Not applicable\X0D\\X0A\Ancillary studies:\X0D\\X0A\Estrogen Receptor)   performed on this specimen \X0D\\X0A\         Results:  positive, quantitation: >95%, strong\X0D\\X0A\Progesterone Receptor)   performed on this specimen \X0D\\X0A\         Results:  positive, quantitation: 5-10%, strong\X0D\\X0A\HER2/neu) \X0D\\X0A\   Immunostain)   performed on this specimen \X0D\\X0A\          Results:   negative (Score 0) \X0D\\X0A\    Fluorescence In Situ Hybridization (FISH) for HER2/neu) not performed\X0D\\X0A\",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right lateral breast tissue (specimen readiograph; ink and cut)\X0D\\X0A\B: Extended superficial margin right lateral breast; new margin is up\X0D\\X0A\C: Right axillary contents,,
REG1,BREAST,0,287461,3,,"CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\LEFT BREAST MASS (PREVIOUS - PCA SOUTHEAST **INITIALS-1259, **INITIALS-1398)\X0D\\X0A\","A.    SPECIMEN/PROCEDURE:  LEFT BREAST LUMPECTOMY (WITH NEEDLE LOCALIZATION).\X0D\\X0A\    TUMOR TYPE:  INVASIVE DUCTAL CARCINOMA.\X0D\\X0A\    TUMOR GRADE:  2.\X0D\\X0A\    NOTTINGHAM HISTOLOGIC SCORE:  3+2+1=6.\X0D\\X0A\    INVASIVE CARCINOMA SIZE:  1.2 X 1.1 X 0.8 CM IN GREATEST DIMENSION.\X0D\\X0A\    TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\    DUCTAL CARCINOMA IN SITU:  NOT IDENTIFIED.\X0D\\X0A\    MARGINS:  ALL MARGINS ARE FREE OF TUMOR\X0D\\X0A\THE INVASIVE CARCINOMA IS WITHIN 0.9 CM FROM CLOSEST (SUPERIOR) MARGIN.\X0D\\X0A\LYMPHVASCULAR INVASION:  NOT IDENTIFIED.\X0D\\X0A\MICROCALCIFICATION:  NOT IDENTIFIED.\X0D\\X0A\SPECIMEN SIZE:  7.5 X 7.0 X 2.6 CM IN GREATEST DIMENSION.\X0D\\X0A\SPECIMEN INTEGRITY:  INTACT.\X0D\\X0A\LOBULAR CARCINOMA IN SITU:  NOT PRESENT.\X0D\\X0A\LYMPH NODE SAMPLING:  SEE SPECIMEN B.\X0D\\X0A\ANCILLARY STUDIES:  SEE PCA SOUTHEAST LABORATORY REPORT.\X0D\\X0A\ESTIMATED COLD ISCHEMIC TIME (<1 HOUR).\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME IN FORMALIN:  6-72 HOURS.\X0D\\X0A\\X0D\\X0A\TUMOR STAGE:  pT1c N(sl)0 MX\X0D\\X0A\\X0D\\X0A\B.      LEFT AXILLARY (SENTINEL) LYMPH NODE:\X0D\\X0A\    NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   315 E **PLACE, **ROOM\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   Irick,Max L\X0D\\X0A\   1169 Eastern Parkway\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX] II,Art J\X0D\\X0A\   4004 DUPOINT CIRCLE\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\   **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS/2\X0D\\X0A\\X0D\\X0A\",FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.    SPECIMEN/PROCEDURE:  LEFT BREAST LUMPECTOMY (WITH NEEDLE LOCALIZATION).\X0D\\X0A\TUMOR TYPE:  INVASIVE DUCTAL CARCINOMA.\X0D\\X0A\TUMOR GRADE:  2.\X0D\\X0A\NOTTINGHAM HISTOLOGIC SCORE:  3+2+1=6.\X0D\\X0A\INVASIVE CARCINOMA SIZE:  1.2 X 1.1 X 0.8 CM IN GREATEST DIMENSION.\X0D\\X0A\TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\DUCTAL CARCINOMA IN SITU:  NOT IDENTIFIED.\X0D\\X0A\MARGINS:  ALL MARGINS ARE FREE OF TUMOR\X0D\\X0A\THE INVASIVE CARCINOMA IS WITHIN 0.9 CM FROM CLOSEST (SUPERIOR) MARGIN.\X0D\\X0A\LYMPHVASCULAR INVASION:  NOT IDENTIFIED.\X0D\\X0A\MICROCALCIFICATION:  NOT IDENTIFIED.\X0D\\X0A\SPECIMEN SIZE:  7.5 X 7.0 X 2.6 CM IN GREATEST DIMENSION.\X0D\\X0A\SPECIMEN INTEGRITY:  INTACT.\X0D\\X0A\LOBULAR CARCINOMA IN SITU:  NOT PRESENT.\X0D\\X0A\LYMPH NODE SAMPLING:  SEE SPECIMEN B.\X0D\\X0A\ANCILLARY STUDIES:  SEE PCA SOUTHEAST LABORATORY REPORT.\X0D\\X0A\ESTIMATED COLD ISCHEMIC TIME (<1 HOUR).\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME IN FORMALIN:  6-72 HOURS.\X0D\\X0A\\X0D\\X0A\TUMOR STAGE:  pT1c N(sl)0 MX\X0D\\X0A\\X0D\\X0A\B.      LEFT AXILLARY (SENTINEL) LYMPH NODE:\X0D\\X0A\NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\,,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  Received fresh labeled ""left breast mass"" is 63 gram previously inked lumpectomy\X0D\\X0A\measuring 7.5 x 7.0 x 2.6 cm (anterior to posterior, medial to lateral, superior to\X0D\\X0A\inferior).  The specimen is inked as follows:  anterior-red, superior-blue, inferior-green,\X0D\\X0A\medial-orange, lateral-yellow and posterior-black.  There is a penetrating needle\X0D\\X0A\localization wire at the anterior aspect.  Sectioning reveals a 1.2 x 1.1 x 0.8 cm tan\X0D\\X0A\indurated stellate mass.  The distance of each margin from the mass is as follows:\X0D\\X0A\inferior-1.1 cm, medial-1.2 cm, superior-0.9 cm, lateral-4.8 cm, anterior-2.1 cm and\X0D\\X0A\posterior >3 cm.  The remaining parenchyma is yellow, lobulated and glistening and composed\X0D\\X0A\of approximately 10% pink tan fibrous tissue.  Representative sections are submitted as\X0D\\X0A\follows:\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\A1-3.  mass submitted entirely\X0D\\X0A\A4.  fibrous area of tissue\X0D\\X0A\A5.  representative deep and lateral margins\X0D\\X0A\A6.  representative section of inferior margin\X0D\\X0A\\X0D\\X0A\Time received in Lab - 1:58\X0D\\X0A\Time placed in formalin - 2:00\X0D\\X0A\Time sectioned and replaced in formalin - 2:41         /pb/as\X0D\\X0A\\X0D\\X0A\B. Received in formalin labeled ""sentinel lymph node left axilla"" is a 4 x 3.5 x 1 cm\X0D\\X0A\lobular portion of fibroadipose tissue.  Sectioning reveals a 2.5 cm lymph node.  The fatty\X0D\\X0A\tissue is trimmed.  Blue dye is identified.  The lymph node is bisected and entirely\X0D\\X0A\submitted in a cassette labeled B.  /st/as\X0D\\X0A\",,"SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\LEFT BREAST MASS - TIME SPECIMEN REMOVED 13:30\X0D\\X0A\SENTINEL LYMPH NODE, 719-BLUE, LEFT AXILLA\X0D\\X0A\",,
REG1,BREAST,0,389610,3,,"Clinical Diagnosis and History\X0D\\X0A\Right sternal mass, left breast mass \X0D\\X0A\Clinical history  Status post mastectomy for breast cancer 2004",Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Right sternal mass\X0D\\X0A\2: Left Breast mass,"Final Diagnosis\X0D\\X0A\1.     Biopsy right sternal mass with needle localization and margin evaluation;\X0D\\X0A\     A.     Infiltrating ductal carcinoma of breast, grade 1 (three adjacent\X0D\\X0A\foci).  \X0D\\X0A\     B.     Maximum linear diameter of largest focus of invasive carcinoma is 6\X0D\\X0A\x 5 mm. \X0D\\X0A\          C.     Adjacent foci of low to intermediate grade ductal carcinoma in\X0D\\X0A\situ, with focal comedonecrosis. \X0D\\X0A\     D.     Foci of invasive malignancy abut against inked surgical margins of\X0D\\X0A\the biopsy specimen.  \X0D\\X0A\     E.     Adjacent areas of benign breast parenchyma, focally demonstrating\X0D\\X0A\benign fibrocystic mastopathy.  \X0D\\X0A\2.     Biopsy left breast mass, with needle localization and margin evaluation; \X0D\\X0A\     A.     Focal benign fibrocystic mastopathy within otherwise unremarkable\X0D\\X0A\fatty breast parenchyma.  \X0D\\X0A\     B.     Changes include stromal fibrosis, microcystic duct dilatation, and\X0D\\X0A\blunt duct adenosis. \X0D\\X0A\     C.     No histologic evidence of malignancy within the inked margins of the\X0D\\X0A\biopsy specimen.  \X0D\\X0A\                    1 \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\Ben **NAME[M. ZZZ], MD\X0D\\X0A\Surgical Pathology Cancer Case Summary (Checklist)\X0D\\X0A\Protocol web posting date: **DATE[Jul 2010]\X0D\\X0A\     INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total\X0D\\X0A\Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy,\X0D\\X0A\and Partial Mastectomy With or Without Axillary Contents) and Mastectomy (Total,\X0D\\X0A\Modified Radical, Radical With or Without Axillary Contents)\X0D\\X0A\Select a single response unless otherwise indicated.\X0D\\X0A\Specimen (Note A)\X0D\\X0A\___ Partial breast\X0D\\X0A\___ Total breast (including nipple and skin)\X0D\\X0A\_x__ Other (specify): __peristernal soft tissue_________________________\X0D\\X0A\___ Not specified\X0D\\X0A\Procedure (Note A)\X0D\\X0A\___ Excision without wire-guided localization\X0D\\X0A\_x__ Excision with wire-guided localization\X0D\\X0A\___ Total mastectomy (including nipple and skin)\X0D\\X0A\___ Other (specify): ____________________________\X0D\\X0A\___ Not specified\X0D\\X0A\Lymph Node Sampling (select all that apply) (Note B)\X0D\\X0A\_x__ No lymph nodes present\X0D\\X0A\___ Sentinel lymph node(s) \X0D\\X0A\___ Axillary dissection (partial or complete dissection)\X0D\\X0A\___ Lymph nodes present within the breast specimen (ie, intramammary lymph\X0D\\X0A\nodes)\X0D\\X0A\___ Other lymph nodes (eg, supraclavicular or location not identified)\X0D\\X0A\     Specify location, if provided:  _________________________\X0D\\X0A\Specimen Integrity (Note C)\X0D\\X0A\_x__ Single intact specimen (margins can be evaluated)\X0D\\X0A\___ Multiple designated specimens (eg, main excision and identified margins)\X0D\\X0A\___ Fragmented (margins cannot be evaluated with certainty)\X0D\\X0A\___ Other (specify): _____________________________\X0D\\X0A\Specimen Size (for excisions less than total mastectomy) (Note C)\X0D\\X0A\Greatest dimension: _3.7__ cm\X0D\\X0A\*Additional dimensions: ___ x ___ cm\X0D\\X0A\___ Cannot be determined \X0D\\X0A\Specimen Laterality\X0D\\X0A\_x__ Right\X0D\\X0A\___ Left\X0D\\X0A\___ Not specified\X0D\\X0A\*Tumor Site: Invasive Carcinoma (select all that apply) (Note D)\X0D\\X0A\*___ Upper outer quadrant\X0D\\X0A\*___ Lower outer quadrant\X0D\\X0A\*___ Upper inner quadrant\X0D\\X0A\*___ Lower inner quadrant\X0D\\X0A\*___ Central\X0D\\X0A\*___ Nipple\X0D\\X0A\*Position: ___ o'clock\X0D\\X0A\*_x__ Other (specify): ___peristernal__________________\X0D\\X0A\*___ Not specified\X0D\\X0A\Tumor Size: Size of Largest Invasive Carcinoma (Note E) \X0D\\X0A\___ Microinvasion only (d0.1 cm)\X0D\\X0A\Greatest dimension of largest focus of invasion over 0.1 cm: 0.6___ cm\X0D\\X0A\     *Additional dimensions: ___ x ___ cm\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Cannot be determined (see Comment)\X0D\\X0A\Note: The size of the invasive carcinoma should take into consideration the\X0D\\X0A\gross findings correlated with themicroscopicexamination. In some cases, it may\X0D\\X0A\be helpful to use information about tumor size from imaging studies.  If\X0D\\X0A\multiple foci of invasion are present, the size listed is the size of the\X0D\\X0A\largest contiguous area of invasion. The size of multiple invasive carcinomas\X0D\\X0A\should not be added together.  The size does not include adjacent DCIS.\X0D\\X0A\If there has been a prior core needle biopsy or incisional biopsy showing a\X0D\\X0A\larger area of invasion than in the excisional specimen, the largest dimension\X0D\\X0A\of the invasive carcinoma in the prior specimen should be used for T\X0D\\X0A\classification, if known.\X0D\\X0A\If there has been prior treatment and no invasive carcinoma is present, the\X0D\\X0A\cancer is classified as Tis if there is residual DCIS and T0 if there is no\X0D\\X0A\remaining carcinoma.\X0D\\X0A\Tumor Focality (Note F) \X0D\\X0A\___ Single focus of invasive carcinoma\X0D\\X0A\_x__ Multiple foci of invasive carcinoma\X0D\\X0A\     *Number of foci:  ___3_____\X0D\\X0A\     *Sizes of individual foci:  _______\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Indeterminate\X0D\\X0A\Note:  If there are multiple invasive carcinomas, size, grade, histologic type,\X0D\\X0A\and the results of studies for estrogen receptor (ER), progesterone receptor\X0D\\X0A\(PR), and HER2/neu should pertain to the largest invasive carcinoma.  If smaller\X0D\\X0A\invasive carcinomas differ in any of these features, this information may be\X0D\\X0A\included in the ""Comments"" section.\X0D\\X0A\Macroscopic and Microscopic Extent of Tumor (select all that apply) (Note G) \X0D\\X0A\Skin\X0D\\X0A\     _x__ Skin is not present\X0D\\X0A\___ Invasive carcinoma does not invade into the dermis or epidermis\X0D\\X0A\___ Invasive carcinoma directly invades into the dermis or epidermis without\X0D\\X0A\skin ulceration\X0D\\X0A\___ Invasive carcinoma directly invades into the dermis or epidermis with skin\X0D\\X0A\ulceration (classified as T4b)\X0D\\X0A\     ___ Satellite skin foci of invasive carcinoma are present (ie, not\X0D\\X0A\contiguous with the invasive carcinoma in the breast) (classified as T4b)\X0D\\X0A\Nipple\X0D\\X0A\     ___ DCIS does not involve the nipple epidermis\X0D\\X0A\___ DCIS involves nipple epidermis (Paget disease of the nipple)\X0D\\X0A\Note: This finding does not change the T classification.\X0D\\X0A\Skeletal Muscle\X0D\\X0A\     _x__ No skeletal muscle present\X0D\\X0A\     ___ Skeletal muscle is present and is free of carcinoma\X0D\\X0A\___ Carcinoma invades skeletal muscle\X0D\\X0A\___ Carcinoma invades into skeletal muscle and into the chest wall (classified\X0D\\X0A\as T4a)\X0D\\X0A\Note: Invasion into pectoralis muscle is not considered chest wall invasion, and\X0D\\X0A\cancers are not classified as T4a unless there is invasion deeper than this\X0D\\X0A\muscle.\X0D\\X0A\Ductal Carcinoma In Situ (DCIS) (select all that apply) (Note G)\X0D\\X0A\___ No DCIS is present \X0D\\X0A\_x__ DCIS is present\X0D\\X0A\     _x__ Extensive intraductal component (EIC) negative\X0D\\X0A\___ EIC positive \X0D\\X0A\___ Only DCIS is present after presurgical (neoadjuvant) therapy\X0D\\X0A\*Size (Extent) of DCIS \X0D\\X0A\     *Estimated size (extent) of DCIS (greatest dimension using gross and\X0D\\X0A\microscopic evaluation) is at least ___ cm\X0D\\X0A\     *Additional dimensions: ___  x ___ cm\X0D\\X0A\     *Number of blocks with DCIS: ___\X0D\\X0A\*Number of blocks examined: ___\X0D\\X0A\Note: The size (extent) of DCIS is an estimation of the volume of breast tissue\X0D\\X0A\occupied by DCIS. This information may be helpful for cases with a predominant\X0D\\X0A\component of DCIS (eg, DCIS with microinvasion) but may not be necessary for\X0D\\X0A\cases of EIC negative invasive carcinomas.\X0D\\X0A\*Architectural Patterns  \X0D\\X0A\*___ Comedo \X0D\\X0A\*___ Paget disease (DCIS involving nipple skin)\X0D\\X0A\*___ Cribriform\X0D\\X0A\*___ Micropapillary\X0D\\X0A\*___ Papillary\X0D\\X0A\*___ Solid\X0D\\X0A\*___ Other (specify): ________________________\X0D\\X0A\*Nuclear Grade \X0D\\X0A\*_x__ Grade I (low)\X0D\\X0A\*___ Grade II (intermediate) \X0D\\X0A\*___ Grade III (high) \X0D\\X0A\*Necrosis \X0D\\X0A\*___ Not identified\X0D\\X0A\*_x__ Present, focal (small foci or single cell necrosis)\X0D\\X0A\*___ Present, central (expansive ""comedo"" necrosis)\X0D\\X0A\Lobular Carcinoma In Situ (LCIS)\X0D\\X0A\__x_ Not identified\X0D\\X0A\___ Present\X0D\\X0A\Histologic Type of Invasive Carcinoma (Note H)\X0D\\X0A\___ Ductal carcinoma in situ with microinvasion\X0D\\X0A\___ Lobular carcinoma in situ with microinvasion\X0D\\X0A\___ Ductal carcinoma in situ involving nipple skin (Paget disease) with\X0D\\X0A\microinvasion\X0D\\X0A\_x__ Invasive ductal carcinoma (no special type or not otherwise specified)\X0D\\X0A\___ Invasive lobular carcinoma\X0D\\X0A\___ Invasive carcinoma with ductal and lobular features (""mixed type carcinoma"")\X0D\\X0A\___ Invasive mucinous carcinoma\X0D\\X0A\___ Invasive medullary carcinoma\X0D\\X0A\___ Invasive papillary carcinoma\X0D\\X0A\___ Invasive micropapillary carcinoma\X0D\\X0A\___ Invasive tubular carcinoma\X0D\\X0A\___ Invasive cribriform carcinoma\X0D\\X0A\___ Invasive carcinoma, type cannot be determined\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other(s) (specify): ____________________________\X0D\\X0A\Note: The histologic type corresponds to the largest area of invasion.  If there\X0D\\X0A\are smaller foci of invasion of a different type, this information should be\X0D\\X0A\included under ""Additional Pathologic Findings.""\X0D\\X0A\Histologic Grade: Nottingham Histologic Score (Note I)\X0D\\X0A\Glandular (Acinar)/Tubular Differentiation\X0D\\X0A\_x__ Score 1: >75% of tumor area forming glandular/tubular structures\X0D\\X0A\___ Score 2: 10% to 75% of tumor area forming glandular/tubular structures\X0D\\X0A\___ Score 3: <10% of tumor area forming glandular/tubular structures\X0D\\X0A\___ Only microinvasion present (not graded)\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined\X0D\\X0A\Nuclear Pleomorphism\X0D\\X0A\     ___ Score 1: Nuclei small with little increase in size in comparison with\X0D\\X0A\normal breast epithelial cells, regular outlines, uniform nuclear chromatin,\X0D\\X0A\little variation in size\X0D\\X0A\_x__ Score 2: Cells larger than normal with open vesicular nuclei, visible\X0D\\X0A\nucleoli, and moderate variability in both size and shape\X0D\\X0A\___ Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked\X0D\\X0A\variation in size and shape, occasionally with very large and bizarre forms\X0D\\X0A\     ___ Only microinvasion present (not graded)\X0D\\X0A\     ___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined\X0D\\X0A\Mitotic Count\X0D\\X0A\___ Score 1 (see Table 2)\X0D\\X0A\_x__ Score 2 (see Table 2)\X0D\\X0A\___ Score 3 (see Table 2)\X0D\\X0A\___ Only microinvasion present (not graded)\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined\X0D\\X0A\*Number of mitoses per 10 high-power fields: ___\X0D\\X0A\*Diameter of microscope field: ___ mm\X0D\\X0A\Overall Grade\X0D\\X0A\_x__ Grade 1: scores of 3, 4, or 5 \X0D\\X0A\___ Grade 2: scores of 6 or 7 \X0D\\X0A\___ Grade 3: scores of 8 or 9 \X0D\\X0A\___ Only microinvasion present (not graded)\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined.\X0D\\X0A\Note: The grade corresponds to the largest area of invasion. If there are\X0D\\X0A\smaller foci of invasion of a different grade, this information should be\X0D\\X0A\included under ""Additional Pathologic Findings.""\X0D\\X0A\Margins (select all that apply) (Note J)\X0D\\X0A\     ___ Margins cannot be assessed\X0D\\X0A\___ Margins uninvolved by invasive carcinoma\X0D\\X0A\     Distance from closest margin: ___ mm\X0D\\X0A\     *Specify margins: \X0D\\X0A\     *Distance from superior margin: ___ mm\X0D\\X0A\*Distance from inferior margin: ___ mm\X0D\\X0A\*Distance from anterior margin: ___ mm\X0D\\X0A\*Distance from posterior margin: ___ mm\X0D\\X0A\*Distance from medial margin: ___ mm\X0D\\X0A\*Distance from lateral     margin: ___ mm\X0D\\X0A\*Distance from other specified margin: ___ mm\X0D\\X0A\          *Designation of margin: _________________\X0D\\X0A\_x__ Margins uninvolved by DCIS (if present)\X0D\\X0A\     Distance from closest margin: ___ mm\X0D\\X0A\     *Specify margins: \X0D\\X0A\     *Distance from superior margin: ___ mm\X0D\\X0A\*Distance from inferior margin: ___ mm\X0D\\X0A\*Distance from anterior margin: ___ mm\X0D\\X0A\*Distance from posterior margin: ___ mm\X0D\\X0A\*Distance from medial margin: ___ mm\X0D\\X0A\*Distance from lateral     margin: ___ mm\X0D\\X0A\*Distance from other specified margin: ___ mm\X0D\\X0A\     *Designation of margin: _________________\X0D\\X0A\_x__ Margin(s) positive for invasive carcinoma \X0D\\X0A\     *Specify margin(s): _____________________________\X0D\\X0A\     *Specify margin(s) and extent of involvement:\X0D\\X0A\          *___ Superior margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Inferior margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Anterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Posterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Medial margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\     *___ Extensive\X0D\\X0A\          *___ Lateral margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\___ Margin(s) positive for DCIS\X0D\\X0A\     *Specify margin(s): _____________________________\X0D\\X0A\     *Specify margin(s) and extent of involvement:\X0D\\X0A\          *___ Superior     margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Inferior margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Anterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Posterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\               *___ Extensive \X0D\\X0A\          *___ Medial margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Lateral margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\*Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy (Note K)\X0D\\X0A\*In the Breast\X0D\\X0A\     *___ No known presurgical therapy\X0D\\X0A\*___ No definite response to presurgical therapy in the invasive carcinoma\X0D\\X0A\*___ Probable or definite response to presurgical therapy in the invasive\X0D\\X0A\carcinoma\X0D\\X0A\*___ No residual invasive carcinoma is present in the breast after presurgical\X0D\\X0A\therapy \X0D\\X0A\*In the Lymph Nodes\X0D\\X0A\     *___ No known presurgical therapy\X0D\\X0A\*___ No lymph nodes removed\X0D\\X0A\*___ No definite response to presurgical therapy in metastatic carcinoma\X0D\\X0A\     *___ Probable or definite response to presurgical therapy in metastatic\X0D\\X0A\carcinoma\X0D\\X0A\*___ No lymph node metastases.  Fibrous scarring, possibly related to prior\X0D\\X0A\lymph node metastases with pathologic complete response\X0D\\X0A\*___ No lymph node metastases and no prominent fibrous scarring in the nodes\X0D\\X0A\*Lymph-Vascular Invasion (Note L)\X0D\\X0A\*___ Not identified\X0D\\X0A\*___ Present\X0D\\X0A\*___ Indeterminate\X0D\\X0A\*Dermal Lymph-Vascular Invasion\X0D\\X0A\     *___ No skin present\X0D\\X0A\*___ Not identified\X0D\\X0A\*___ Present\X0D\\X0A\*___ Indeterminate\X0D\\X0A\Lymph Nodes (required only if lymph nodes are present in the specimen) (Note B)\X0D\\X0A\Number of sentinel lymph nodes examined: __0_\X0D\\X0A\Total number of lymph nodes examined (sentinel and nonsentinel): ___\X0D\\X0A\Number of lymph nodes with macrometastases (>0.2 cm):  ___\X0D\\X0A\     Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or\X0D\\X0A\>200cells):___\X0D\\X0A\Number of lymph nodes with isolated tumor cells (d0.2 mm and d200 cells): ___\X0D\\X0A\Size of largest metastatic deposit (if present): ___\X0D\\X0A\Note: The sentinel node is usually the first involved lymph node. In the unusual\X0D\\X0A\situation in which a sentinel node is not involved by metastatic carcinoma, but\X0D\\X0A\a nonsentinel node is involved, this information should be included in a note.\X0D\\X0A\*Extranodal Extension\X0D\\X0A\*___ Present\X0D\\X0A\*___ Not identified\X0D\\X0A\*___ Indeterminate\X0D\\X0A\*Method of Evaluation of Sentinel Lymph Nodes (select all that apply)\X0D\\X0A\*___ Hematoxylin and eosin (H\E\T\E\E), one level\X0D\\X0A\*___ H\E\T\E\E, multiple levels\X0D\\X0A\*___ Immunohistochemistry\X0D\\X0A\*___ Sentinel lymph node biopsy not performed\X0D\\X0A\*___ Other (specify): _______________________________\X0D\\X0A\Pathologic Staging (based on information available to the pathologist) (pTNM)\X0D\\X0A\(Note M)\X0D\\X0A\TNM Descriptors (required only if applicable) (select all that apply)\X0D\\X0A\_xx__ m (multiple foci of invasive carcinoma)\X0D\\X0A\___ r (recurrent)\X0D\\X0A\___ y (posttreatment)\X0D\\X0A\Primary Tumor (Invasive Carcinoma) (pT) \X0D\\X0A\     ___ pTX:     Primary tumor cannot be assessed\X0D\\X0A\___ pT0:     No evidence of primary tumor#\X0D\\X0A\___ pTis (DCIS):     Ductal carcinoma in situ#\X0D\\X0A\___ pTis (LCIS):     Lobular carcinoma in situ#\X0D\\X0A\___ pTis (Paget):     Paget disease of the nipple not associated with invasive\X0D\\X0A\carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in the underlying breast\X0D\\X0A\parenchyma#\X0D\\X0A\pT1: Tumor d20 mm in greatest dimension\X0D\\X0A\     ___ pT1mi:      Tumor d1 mm in greatest dimension (microinvasion)\X0D\\X0A\___ pT1a:     Tumor >1 mm but d5 mm in greatest dimension\X0D\\X0A\__x_ pT1b:     Tumor >5 mm but d10 mm in greatest dimension\X0D\\X0A\___ pT1c:     Tumor >10 mm but d20 mm in greatest dimension\X0D\\X0A\___ pT2:     Tumor >20 mm but d50 mm in greatest dimension\X0D\\X0A\___ pT3:     Tumor >50 mm in greatest dimension\X0D\\X0A\     pT4:  Tumor of any size with direct extension to the chest wall and/or to\X0D\\X0A\the skin (ulceration or skin nodules). Note: Invasion of the dermis alone does\X0D\\X0A\not qualify as pT4.\X0D\\X0A\___ pT4a:     Extension to chest wall, not including only pectoralis muscle\X0D\\X0A\adherence/invasion\X0D\\X0A\     ___ pT4b:     Ulceration and/or ipsilateral satellite nodules and/or edema\X0D\\X0A\(including peau d'orange) of the skin which do not meet the criteria for\X0D\\X0A\inflammatory carcinoma\X0D\\X0A\___ pT4c:     Both T4a and T4b\X0D\\X0A\___ pT4d:     Inflammatory carcinoma##\X0D\\X0A\# For the purposes of this checklist, these categories should only be used in\X0D\\X0A\the setting of preoperative (neoadjuvant) therapy for which a previously\X0D\\X0A\diagnosed invasive carcinoma is no longer present after treatment.\X0D\\X0A\## Inflammatory carcinoma is a clinical-pathologic entity characterized by\X0D\\X0A\diffuse erythema and edema (peau d'orange) involving one-third or more of the\X0D\\X0A\skin of the breast.  The skin changes are due to lymphedema caused by tumor\X0D\\X0A\emboli within dermal lymphatics, which may or may not be obvious in a small skin\X0D\\X0A\biopsy.  However, a tissue diagnosis is still necessary to demonstrate an\X0D\\X0A\invasive carcinoma in the underlying breast parenchyma or at least in the dermal\X0D\\X0A\lymphatics, as well as to determine biological markers, such as ER, PR, and HER2\X0D\\X0A\status.  Tumor emboli in dermal lymphatics without the clinical skin changes\X0D\\X0A\described above do not qualify as inflammatory carcinoma.  Locally advanced\X0D\\X0A\breast cancers directly invading the dermis or ulcerating the skin without the\X0D\\X0A\clinical skin changes and tumor emboli in dermal lymphatics also do not qualify\X0D\\X0A\as inflammatory carcinoma.  Thus the term inflammatory carcinoma should not be\X0D\\X0A\applied to neglected locally advanced cancer of the breast presenting late in\X0D\\X0A\the course of a patient's disease.  The rare case that exhibits all the features\X0D\\X0A\of inflammatory carcinoma, but in which skin changes involve less than one-third\X0D\\X0A\of the skin, should be classified by the size and extent of the underlying\X0D\\X0A\carcinoma. \X0D\\X0A\Regional Lymph Nodes (pN) (choose a category based on lymph nodes received with\X0D\\X0A\the specimen; immunohistochemistry and/or molecular studies are not required)\X0D\\X0A\If internal mammary lymph nodes, infraclavicular nodes, or supraclavicular lymph\X0D\\X0A\nodes are included in the specimen, consult the AJCC Cancer Staging Manual1 for\X0D\\X0A\additional lymph node categories.\X0D\\X0A\Modifier (required only if applicable)\X0D\\X0A\     ___ (sn):     Only sentinel node(s) evaluated.  If 6 or more sentinel nodes\X0D\\X0A\and/or nonsentinel nodes are removed, this modifier should not be used.\X0D\\X0A\Category (pN)\X0D\\X0A\     _x__ pNX:     Regional lymph nodes cannot be assessed (eg, previously\X0D\\X0A\removed, or not removed for pathologic study)\X0D\\X0A\___ pN0:     No regional lymph node metastasis identified histologically\X0D\\X0A\     Note: Isolated tumor cell (ITC) clusters are defined as small clusters of\X0D\\X0A\cells not greater than 0.2 mm or single tumor cells, or a cluster of fewer than\X0D\\X0A\200 cells in a single histologic cross-section.#   ITCs may be detected by\X0D\\X0A\routine histology or by immunohistochemical (IHC) methods.  Nodes containing\X0D\\X0A\only ITCs are excluded from the total positive node count for purposes of N\X0D\\X0A\classification but should be included in the total number of nodes evaluated.\X0D\\X0A\     ___ pN0 (i-):     No regional lymph node metastases histologically,\X0D\\X0A\negative IHC\X0D\\X0A\___ pN0 (i+):     Malignant cells in regional lymph node(s) no greater than 0.2\X0D\\X0A\mm and no more than 200 cells (detected by H\E\T\E\E or IHC including ITC)\X0D\\X0A\___ pN0 (mol-):     No regional lymph node metastases histologically, negative\X0D\\X0A\molecular findings (reverse transcriptase polymerase chain reaction [RT-PCR])\X0D\\X0A\___ pN0 (mol+):     Positive molecular findings (RT-PCR), but no regional lymph\X0D\\X0A\node metastases detected by histology or IHC\X0D\\X0A\___ pN1mi:     Micrometastases (greater than 0.2 mm and/or more than 200 cells,\X0D\\X0A\but none greater than 2.0 mm).\X0D\\X0A\___ pN1a:     Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis\X0D\\X0A\greater than 2.0 mm\X0D\\X0A\___ pN2a:     Metastases in 4 to 9 axillary lymph nodes (at least 1 tumor\X0D\\X0A\deposit greater than 2.0 mm)\X0D\\X0A\___ pN3a:     Metastases in 10 or more axillary lymph nodes (at least 1 tumor\X0D\\X0A\deposit greater than 2.0 mm)\X0D\\X0A\# Approximately 1000 tumor cells are contained in a 3-dimensional 0.2-mm\X0D\\X0A\cluster.  Thus, if more than 200 individual tumor cells are identified as single\X0D\\X0A\dispersed tumor cells or as a nearly confluent elliptical or spherical focus in\X0D\\X0A\a single histologic section of a lymph node, there is a high probability that\X0D\\X0A\more than 1000 cells are present in the node.  In these situations, the node\X0D\\X0A\should be classified as containing a micrometastasis (pN1mi).  Cells in\X0D\\X0A\different lymph node cross-sections or longitudinal sections or levels of the\X0D\\X0A\block are not added together; the 200 cells must be in a single node profile\X0D\\X0A\even if the node has been thinly sectioned into multiple slices.  It is\X0D\\X0A\recognized that there is substantial overlap between the upper limit of the ITC\X0D\\X0A\and the lower limit of the micrometastasis categories because of inherent\X0D\\X0A\limitations in pathologic nodal evaluation and detection of minimal tumor burden\X0D\\X0A\in lymph nodes.  Thus, the threshold of 200 cells in a single cross-section is a\X0D\\X0A\guideline to help pathologists distinguish between these 2 categories.  The\X0D\\X0A\pathologist should use judgment regarding whether it is likely that the cluster\X0D\\X0A\of cells represents a true micrometastasis or is simply a small group of\X0D\\X0A\isolated tumor cells.\X0D\\X0A\Distant Metastasis (M)  \X0D\\X0A\_x__ Not applicable\X0D\\X0A\     ___ cM0(i+):     No clinical or radiographic evidence of distant\X0D\\X0A\metastasis, but deposits of molecularly or microscopically detected tumor cells\X0D\\X0A\in circulating blood, bone marrow, or other nonregional nodal tissue that are\X0D\\X0A\d0.2 mm in a patient without symptoms or signs of metastasis\X0D\\X0A\     ___ pM1:          Distant detectable metastasis as determined by classic\X0D\\X0A\clinical and radiographic means and/or histologically proven >0.2 mm\X0D\\X0A\*Additional Pathologic Findings (Note N)\X0D\\X0A\*Specify: ____________________________\X0D\\X0A\Ancillary Studies (Note O) \X0D\\X0A\Estrogen Receptor (immunohistochemical results on invasive carcinoma performed\X0D\\X0A\on this specimen or a prior core needle biopsy or incisional biopsy)\X0D\\X0A\___ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\__x_ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify): _____________________\X0D\\X0A\Results: \X0D\\X0A\___ Immunoreactive tumor cells present (d1%)\X0D\\X0A\     Quantitation: ____________\X0D\\X0A\___ Less than 1% immunoreactive cells present\X0D\\X0A\___ No immunoreactive tumor cells present\X0D\\X0A\___ Results unknown\X0D\\X0A\___ Other (specify): _____________________\X0D\\X0A\*Antibody vendor and clone: ___________\X0D\\X0A\*Type of fixative (if other than neutral buffered formalin): ____________\X0D\\X0A\Progesterone Receptor (immunohistochemical results for invasive carcinoma\X0D\\X0A\performed on this specimen or a prior core needle biopsy or incisional biopsy)\X0D\\X0A\___ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\_x__ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\Results:\X0D\\X0A\___ Immunoreactive tumor cells present (d1%)\X0D\\X0A\     Quantitation:  ____________\X0D\\X0A\___ Less than 1% immunoreactive cells present\X0D\\X0A\___ No immunoreactive tumor cells present\X0D\\X0A\___ Results unknown\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\*Antibody vendor and clone: __________________\X0D\\X0A\HER2/neu (results for invasive carcinoma performed on this specimen or a prior\X0D\\X0A\core needle biopsy or incisional biopsy) \X0D\\X0A\Immunoperoxidase Studies\X0D\\X0A\___ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\_x__ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify): _____________________\X0D\\X0A\Results:\X0D\\X0A\___ Negative (Score 0)\X0D\\X0A\___ Negative (Score 1+)\X0D\\X0A\___ Equivocal (Score 2+)\X0D\\X0A\___ Positive (Score 3+)\X0D\\X0A\___ Other \X0D\\X0A\     Specify: _________________________\X0D\\X0A\___ Results unknown\X0D\\X0A\*Antibody vendor and clone: ______________________\X0D\\X0A\Fluorescence In Situ Hybridization (FISH) for HER2/neu\X0D\\X0A\___ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number):  _________________\X0D\\X0A\_x__ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\Results:\X0D\\X0A\___ Not amplified (HER2 gene copy <4.0 or ratio <1.8)\X0D\\X0A\___ Equivocal (HER2 gene copy 4.0 to 6.0 or ratio 1.8 to 2.2)\X0D\\X0A\___ Amplified (HER2 gene copy >6.0 or ratio >2.2)\X0D\\X0A\     *Average number of HER2 gene copies per cell: ___\X0D\\X0A\     *Average number of chromosome 17 per cell: ___\X0D\\X0A\     *Ratio: ___\X0D\\X0A\___ Results unknown\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\* Name of assay:  _____________________\X0D\\X0A\*Other Ancillary Studies (results for invasive carcinoma performed on this\X0D\\X0A\specimen or a prior core needle biopsy or incisional biopsy) \X0D\\X0A\*___ Performed on this specimen\X0D\\X0A\*___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\*Name of test:  _____________________________________\X0D\\X0A\*Results:  _______________________________________\X0D\\X0A\*Microcalcifications (select all that apply) (Note P)\X0D\\X0A\*___ Not identified \X0D\\X0A\*___ Present in DCIS\X0D\\X0A\*___ Present in invasive carcinoma\X0D\\X0A\*___ Present in non-neoplastic tissue\X0D\\X0A\*___ Present in both carcinoma and non-neoplastic tissue\X0D\\X0A\*Clinical History (select all that apply) (Note Q)\X0D\\X0A\*The current clinical/radiologic breast findings for which this surgery is\X0D\\X0A\performed include:\X0D\\X0A\*___ Palpable mass\X0D\\X0A\*___ Radiologic finding\X0D\\X0A\     *___ Mass or architectural distortion\X0D\\X0A\     *___ Calcifications\X0D\\X0A\     *___ Other (specify): _________________________\X0D\\X0A\*___ Nipple discharge\X0D\\X0A\*___ Other (specify): _______________________________\X0D\\X0A\*___ Prior history of breast cancer\X0D\\X0A\     *Specify site, diagnosis, and prior treatment: ________________________\X0D\\X0A\*___ Prior presurgical (neoadjuvant) therapy for this diagnosis of invasive\X0D\\X0A\carcinoma\X0D\\X0A\     *Specify type: _______________________________\X0D\\X0A\*Comment(s)\X0D\\X0A\     *     Data elements with asterisks are not required. However, these\X0D\\X0A\elements may be clinically important but are not yet validated or regularly used\X0D\\X0A\in patient management. \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\HER 2 - by FISH     Date Ordered:     **DATE[Jun 20 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jun 20 2012]     By:  **NAME[YYY XXX]\X0D\\X0A\     Date Reported:     **DATE[Jun 20 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,"Gross Description\X0D\\X0A\Specimen #1 is received fresh labeled with the patient's name and designated\X0D\\X0A\""right sternal mass"".  The specimen consists of a fragment of yellow-pink soft\X0D\\X0A\fatty tissue measuring 3.7 x 3 x 1.4 cm.  The external surface is yellow-pink\X0D\\X0A\and slightly lobulated.  A wire guide is present. The external surface is inked\X0D\\X0A\black.  Sectioning reveals a slightly stellate fibrous mass measuring 0.8 cm in\X0D\\X0A\greatest dimension. The mass extends to within 0.1 cm of the undesignated\X0D\\X0A\resection margin.  The remaining tissue is yellow-pink, soft and fatty. Section\X0D\\X0A\of mass is submitted for frozen section. The frozen section remnant is submitted\X0D\\X0A\in (block 1A).  Sections surrounding the mass are submitted in (blocks 1B and\X0D\\X0A\1C).   The remaining specimen is submitted in (blocks 1D-1G).\X0D\\X0A\Specimen #2 is received fresh on a radiology spec board labeled with the\X0D\\X0A\patient's name and designated ""left breast mass"".  The specimen consists of a\X0D\\X0A\fragment of fibroadipose tissue measuring 3.1 x 2.8 x 1.4 cm.  The external\X0D\\X0A\surface is yellow-pink, slightly lobulated. A wire guide is in place.  A\X0D\\X0A\radiograph does not accompany the specimen.  The external surface is inked blue.\X0D\\X0A\Sectioning reveals yellow-pink, soft and lobulated fatty tissue with no discrete\X0D\\X0A\nodules or masses identified.  A slightly more firm fatty lobe is noted on the\X0D\\X0A\peripheral measuring 0.6 cm in greatest dimension.   The specimen is totally\X0D\\X0A\submitted in (blocks 2A-2F).\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\     1.     Sections of biopsy of right sternal mass reveal involvement by a\X0D\\X0A\nodular implant of low grade infiltrating ductal carcinoma of breast with\X0D\\X0A\associated foci of adjacent low to intermediate grade ductal carcinoma in situ,\X0D\\X0A\focally showing comedonecrosis.  Three closely approximated but apparently\X0D\\X0A\separate foci of invasive carcinoma are observed within the biopsy fragment, the\X0D\\X0A\largest of which is 5 x 6 mm in size.  The tumor demonstrates extensive tubule\X0D\\X0A\formation with elongated irregular branching tubular structures lined by cells\X0D\\X0A\showing intermediate nuclear enlargement, small nucleoli and varying amounts of\X0D\\X0A\pinkish-gray cytoplasm.  Less than 10 mitoses are observed per 10 high power\X0D\\X0A\fields.  The adjacent foci of ductal carcinoma in situ demonstrate a combination\X0D\\X0A\of solid and cribriform architectures with many showing central comedonecrosis. \X0D\\X0A\Foci of invasive carcinoma abut against the inked surgical margins of excision. \X0D\\X0A\Small amounts of adjacent benign breast parenchyma are observed with changes of\X0D\\X0A\cystic dilatation, apocrine metaplasia and lobular sclerosis. \X0D\\X0A\Microcalcifications are identified associated with areas of ductal carcinoma in\X0D\\X0A\situ.  Patchy chronic inflammatory infiltrates are present surrounding areas of\X0D\\X0A\invasive malignancy as well as a reactive stromal fibrosis.  \X0D\\X0A\2.     Sections of needle-localized left breast mass reveal benign fatty breast\X0D\\X0A\parenchyma demonstrating a few scattered, crescent-shaped areas of benign\X0D\\X0A\fibrocystic mastopathy with stromal fibrosis, microcystic duct dilatation and\X0D\\X0A\focal blunt duct adenosis.  Benign duct and lobular elements are also identified\X0D\\X0A\within the otherwise fatty parenchyma.  Multiple sections reveal no evidence of\X0D\\X0A\malignancy within the inked margins of the biopsy specimen.  \X0D\\X0A\BHT/js",,,Procedures/Addenda\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Jun 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jun 16 2012]     By:  **NAME[WWW VVV]\X0D\\X0A\     Date Reported:     **DATE[Jun 16 2012]
REG1,BREAST,0,418346,3,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Right breast mass,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\RE      011\X0D\\X0A\PHYSICIAN:       OON LEEDHANACHO  SIGN OUT DATE:   **DATE[May 01 2012]\X0D\\X0A\COPIES TO:          OON\X0D\\X0A\LEEDHANACHO,"DIAGNOSIS\X0D\\X0A\BREAST MASS, RIGHT:  INFILTRATING DUCTAL CARCINOMA WITH GREATEST\X0D\\X0A\DIMENSION 1 CM.\X0D\\X0A\CPT4 88305//ICD9 174.9\X0D\\X0A\ANCILLARY STUDIES (Performed at US Labs) See outside report.\X0D\\X0A\ESTROGEN RECEPTOR:  0%\X0D\\X0A\PROGESTERONE RECEPTOR: 0%\X0D\\X0A\HER-2/neu: 1+",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled ""core needle biopsy\X0D\\X0A\of right breast"" and consists of two thin yellow-tan cylindrical cores\X0D\\X0A\with the smallest measuring 0.8 cm in length and the largest 1 cm in\X0D\\X0A\length; each x 0.1 cm diameter.  Two smaller yellow-tan fatty appearing\X0D\\X0A\fragments are present each measuring 0.1 cm.  The specimen is entirely\X0D\\X0A\submitted in cassette A.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of the core needle biopsy of the right breast mass shows small\X0D\\X0A\cylinders of breast tissue measuring 0.8 cm to 1 cm x 0.1 cm each.\X0D\\X0A\Invasive ductular carcinoma extends from one end to the other and given\X0D\\X0A\an overall dimension of 1 cm of this infiltrating ductular carcinoma\X0D\\X0A\with dense desmoplastic response identified.  Deeper sections show\X0D\\X0A\similar features.  Once again the largest fragment shows a length of 1\X0D\\X0A\cm with diameter of 0.1 cm.\X0D\\X0A\<Sign Out Dr. **NAME[ZZZ]>\X0D\\X0A\**NAME[YYY XXX], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  BREAST MASS, RIGHT, SURGICAL EXCISION\X0D\\X0A\Right breast biopsy\X0D\\X0A\(core needle)",,
REG1,BREAST,0,427196,3,,Clinical History:\X0D\\X0A\Rt breast cancer,"**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\Frozen Section:\X0D\\X0A\Part A)  Lymph node, sentinel, right axilla - TP\T\FSDx:  Benign.  (JW)\X0D\\X0A\     -Results rbv by **NAME[ZZZ].\X0D\\X0A\CPT Code(s):   88307.26;  88331.26;  88309.26;  88360.26 x 3.\X0D\\X0A\JES:jlj\X0D\\X0A\Dct:Trs:  **DATE[Jan 15 2012]\X0D\\X0A\Addendum:\X0D\\X0A\Estrogen Receptor (ER) (semiquantitative) /  Progesterone Receptor (PR)\X0D\\X0A\(semiquantitative)\X0D\\X0A\ER:  Positive, strong staining in greater than 90% of tumor cells.\X0D\\X0A\PR:  Positive, moderate staining in greater than 90% of tumor cells.\X0D\\X0A\Method and Scoring Guide for ER/PR:\X0D\\X0A\Performed upon routinely formalin fixed and paraffin embedded tissue.\X0D\\X0A\ER clone SP1\X0D\\X0A\PR clone 1E2.\X0D\\X0A\Scoring Guide:  A positive result is based specifically upon positive\X0D\\X0A\nuclear staining within tumor cells, with an intensity graded from\X0D\\X0A\weak-mild to strong as noted above.  If the count is greater than 0% by\X0D\\X0A\IHC manual morphometry, of any intensity, the result is considered\X0D\\X0A\POSITIVE, with only 0% staining considered NEGATIVE.\X0D\\X0A\HER-2/neu Status (semiquantitative):  0, negative.\X0D\\X0A\Method and Interpretation Guide for HER-2/neu (C-erB-2):\X0D\\X0A\Performed upon routinely formalin fixed and paraffin embedded tissue\X0D\\X0A\(subject to false-negative results with improper and/or delayed\X0D\\X0A\fixation).\X0D\\X0A\Specimen identification:\X0D\\X0A\BLOCK #:  B3\X0D\\X0A\-    Specimen site and type:  Right breast\X0D\\X0A\-    Time to fixation (if available):  Not given\X0D\\X0A\-    Duration of fixation (if available):  8 hours\X0D\\X0A\HER-2/neu clone 4B5.\X0D\\X0A\Method used:  VENTANA i VIEW PATHWAYS (FDA approved, controls high\X0D\\X0A\protein expression, low level protein expression, negative protein\X0D\\X0A\expression, internal).\X0D\\X0A\Adequacy of sample for evaluation:  Adequate\X0D\\X0A\Result interpretation:  Negative\X0D\\X0A\Percentage of invasive tumor cells exhibiting complete membrane\X0D\\X0A\staining:  0%\X0D\\X0A\Uniformity of staining present or absent:  Absent\X0D\\X0A\Homogeneous dark circumferential pattern present or absent:   Absent\X0D\\X0A\Scoring Guide:\X0D\\X0A\Staining Pattern                   Result\X0D\\X0A\     0    No membrane staining observed      Negative\X0D\\X0A\          (or membrane staining observed\X0D\\X0A\          in a count of less than 10% of tumor cells).\X0D\\X0A\     1+   Faint/partial membrane staining         Negative\X0D\\X0A\          (detected in a count of more than 10% of\X0D\\X0A\          tumor cells.  Staining may not\X0D\\X0A\          encircle entire cell membrane).\X0D\\X0A\     2+   Weak complete membrane staining,        Equivocal\X0D\\X0A\          observed in a count of more than 10%\X0D\\X0A\of tumor cells (encircling entire cell\X0D\\X0A\membrane).\X0D\\X0A\     3+   Moderate to strong (intense) complete   Positive\X0D\\X0A\          membrane staining observed in a count\X0D\\X0A\of more than 10% of tumor cells (encircling\X0D\\X0A\          entire cell membrane).\X0D\\X0A\NOTE:  The immunohistochemical methods utilized for the evaluation of\X0D\\X0A\ER/PR receptor status are considered semiquantitative with results\X0D\\X0A\expressed as detailed above.   Despite an FDA approved scoring guide\X0D\\X0A\that classifies 2+ immunohistochemistry results as equivocal, the\X0D\\X0A\literature suggests that up to 70% of these cases may be actually the\X0D\\X0A\fluorescence in situ hybridization (FISH) negative.  As such, a reflex\X0D\\X0A\to HER-2/neu FISH testing could be considered before administration of\X0D\\X0A\Herceptin therapy.\X0D\\X0A\The immunohistochemistry methods utilized for the evaluation of ER/PR\X0D\\X0A\receptor and HER-2/neu status are considered semiquantitative, with\X0D\\X0A\results expressed as detailed above.  These tests were developed and\X0D\\X0A\their performance characteristics determined by the **NAME[YYY XXX]\X0D\\X0A\Hospital Pathology Department.  This laboratory is regulated under the\X0D\\X0A\Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), as\X0D\\X0A\qualified to perform high complexity testing.\X0D\\X0A\JES:jlj\X0D\\X0A\Dct:Trs:  **DATE[Jan 15 2012]\X0D\\X0A\**NAME[WWW VVV:  UUU M TTT] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jan 16 2012]","Pre-Operative Diagnosis:\X0D\\X0A\Rt breast cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Pending path\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Right sentinel lymph node:\X0D\\X0A\  -   No tumor identified (0/1) lymph node.\X0D\\X0A\B)  Right breast, mastectomy:\X0D\\X0A\  -   1.3 cm invasive well-differentiated ductal adenocarcinoma,\X0D\\X0A\modified EBR Score\X0D\\X0A\      2+2+1=5 of 9.\X0D\\X0A\  -   Previous biopsy site changes.\X0D\\X0A\  -   Radial scar formation with proliferative fibrocystic change.\X0D\\X0A\  -   Deep margin negative.\X0D\\X0A\  -   No specific pathologic alteration, nipple.\X0D\\X0A\  -   No tumor identified (0/1), right axillary lymph node.",,"Gross Description:\X0D\\X0A\Received are two parts, each labeled with the patient's name.\X0D\\X0A\Part A is received fresh for frozen section additionally labeled\X0D\\X0A\""sentinel node, right axilla"".  The specimen consists of a 1.5 x 1.5 x 1\X0D\\X0A\cm portion of yellow lobulated soft tissue, within which is a 1.1 cm\X0D\\X0A\pink-tan nodule.  The nodule is bisected, touch prepped, and submitted\X0D\\X0A\entirely for frozen section in one block.  The specimen is now\X0D\\X0A\resubmitted in toto for permanents in cassette A-FSc.\X0D\\X0A\Part B is received in formalin additionally labeled ""right breast\X0D\\X0A\tissue"".  The specimen consists of a 354 gram, 15 x 15 x 3.5 cm simple\X0D\\X0A\mastectomy specimen.  There is no orientation provided, thus the aspect\X0D\\X0A\of the specimen with the larger flap of fibrofatty tissue will be\X0D\\X0A\designated superior.  The specimen is partially surfaced by an 11 x 8 cm\X0D\\X0A\pink-tan skin ellipse.  There is a central 2.5 cm in diameter areola\X0D\\X0A\with a 0.7 x 0.7 x 0.2 cm everted nipple.  The epidermal surface is\X0D\\X0A\pink-tan and smooth with no distinct biopsy sites, scars, or lesions.\X0D\\X0A\The skin surface is notable for an abundant amount of injected Methylene\X0D\\X0A\blue dye.  The posterior aspect of the specimen is inked blue.\X0D\\X0A\Sectioning the specimen reveals a very ill-defined focus of indurated\X0D\\X0A\white-tan fibrous breast tissue within the upper inner quadrant of the 2\X0D\\X0A\o'clock position.  The indurated area measures 1.3 x 1.3 x 1 cm.  At the\X0D\\X0A\medial edge of the indurated area, there is a 0.4 x 0.4 x 0.3 cm biopsy\X0D\\X0A\cavity which is filled with Gelfoam material and contains an indwelling\X0D\\X0A\metal radiographic clip.  The biopsy cavity and indurated area is 0.4 cm\X0D\\X0A\from the nearest deep margin and 0.5 cm from the nearest superficial\X0D\\X0A\margin.  The biopsy site is surrounded by punctate foci of hemorrhage\X0D\\X0A\and fat necrosis.  At 0.8 cm inferior to the indurated area and biopsy\X0D\\X0A\site, there is a separate 0.6 x 0.5 x 0.5 cm indurated white-tan nodule.\X0D\\X0A\The solid nodule is 1.5 cm from the nearest deep margin.  There are no\X0D\\X0A\other lesions identified.  The remainder of the specimen is notable for\X0D\\X0A\a moderate amount of central white-tan fibrous breast tissue.  There are\X0D\\X0A\no distinct cystic structures seen.  There is a 0.4 cm pink-tan lymph\X0D\\X0A\node identified within the lateral breast tissue.  Representative\X0D\\X0A\sections are submitted as follows:\X0D\\X0A\Cassette B1 - nipple base and bisected nipple,\X0D\\X0A\Cassette B2 - deep margin overlying biopsy site at 2 o'clock,\X0D\\X0A\Cassette B3-B6  - biopsy site and adjacent indurated fibrous breast\X0D\\X0A\tissue entirely submitted from medial to lateral,\X0D\\X0A\Cassette B7 - deep margin overlying solid nodule inferior to biopsy\X0D\\X0A\site,\X0D\\X0A\Cassette B8 - solid nodule inferior to biopsy site, entirely submitted,\X0D\\X0A\Cassette B9 - random uninvolved upper inner quadrant,\X0D\\X0A\Cassette B10 - random uninvolved lower inner quadrant,\X0D\\X0A\Cassette B11 - random uninvolved upper outer quadrant,\X0D\\X0A\Cassette B12 - random uninvolved lower outer quadrant,\X0D\\X0A\Cassette B13 - one bisected lymph node.\X0D\\X0A\Sections are placed in formalin at 1:35 p.m. on **DATE[Jan 12 2012].   JAB:vsg","Microscopic Description:\X0D\\X0A\CASE SUMMARY FOR INVASIVE CARCINOMA OF THE BREAST\X0D\\X0A\Specimen:   Right breast.\X0D\\X0A\Procedure:  Mastectomy.\X0D\\X0A\Lymph node sampling:  Sentinel lymph node (1);  additional right\X0D\\X0A\axillary lymph node (1).\X0D\\X0A\Specimen laterality:  Right.\X0D\\X0A\Specimen integrity:  Intact.\X0D\\X0A\Specimen size:  15 x 15 x 3.5 cm.\X0D\\X0A\Tumor site:  Approximately 2 o'clock.\X0D\\X0A\Tumor size:  1.3 x 1.3 x 1.0 cm.\X0D\\X0A\Tumor focality:  Single focus.\X0D\\X0A\Histologic type of invasive carcinoma:  Ductal adenocarcinoma.\X0D\\X0A\Histologic grade (Nottingham histologic score):\X0D\\X0A\Glandular/tubular differentiation:  2.\X0D\\X0A\Nuclear pleomorphism:  2.\X0D\\X0A\Mitotic count:  1.\X0D\\X0A\Total score:  5 of 9.\X0D\\X0A\Overall grade:  I\X0D\\X0A\Extent of tumor:\X0D\\X0A\Nipple:  Negative.\X0D\\X0A\Skeletal muscle:  Not applicable.\X0D\\X0A\Ductal carcinoma in situ (DCIS):  Definitive DCIS not identified.  Rare\X0D\\X0A\focus of atypical ductal hyperplasia, focally approaching DCIS.\X0D\\X0A\Microcalcifications:  Present.\X0D\\X0A\Margins:  Negative.\X0D\\X0A\Lymph-vascular invasion:  Not identified.\X0D\\X0A\Lymph nodes:\X0D\\X0A\Number of sentinel lymph nodes examined:  1.\X0D\\X0A\Total number of lymph nodes examined (sentinel and non-sentinel):  2.\X0D\\X0A\Number of lymph nodes with macrometastases:  0.\X0D\\X0A\Number of lymph nodes with micrometastases:  0.\X0D\\X0A\Additional pathologic findings:  Focal atypical ductal hyperplasia,\X0D\\X0A\radial scar, proliferative fibrocystic changes.\X0D\\X0A\Receptor studies:\X0D\\X0A\Pending.  Additional report to follow.\X0D\\X0A\Pathologic staging:  pT1c;  N0;  MX.\X0D\\X0A\ Tissue Code:  T1.",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Sentinel node\X0D\\X0A\SOURCE OF SPECIMEN: B Right Breast Tissue,,
REG1,BREAST,0,431571,3,,"Clinical Diagnosis and History\X0D\\X0A\The working history is right nipple retraction, history of left lumpectomy.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]  :14A\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast Needle Biopsy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Mar 20 10]:  ADDENDUM COMMENT: HER-2/neu by FISH negative.  1.  SENTINEL\X0D\\X0A\NODE BIOPSY, LEFT AXILLA, EXCISION:No tumor seen.  2.   LEFT BREAST MASS,\X0D\\X0A\LUMPECTOMY:  High grade ductal carcinoma in-situ with focal microinvasion, deep\X0D\\X0A\and superior margins less than 1.0 mm.  (See Template).  (DGD)","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT: Positive for Estrogen receptors and Progesterone receptors,\X0D\\X0A\and negative (1+) for HER2/Neu by immunohistochemistry.\X0D\\X0A\MHB/mbc \X0D\\X0A\RIGHT BREAST, MRI GUIDED BIOPSY: \X0D\\X0A\     Microscopic foci of infiltrating lobular carcinoma with occasional foci of\X0D\\X0A\lobular carcinoma in situ. See comment. \X0D\\X0A\COMMENT:  This report was faxed to the Radiologist at the Breast Imaging\X0D\\X0A\Services on **DATE[May 5 12]. \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received and placed in formalin at 2 p.m. labeled right breast MRI biopsy and\X0D\\X0A\consists of multiple red and tan fragments measuring in aggregate 1.5 x 1.5 x\X0D\\X0A\1.5 cm. The specimen is submitted in toto in A-C.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections show breast and adipose tissue with stromal fibrosis, ductal dilatation\X0D\\X0A\and areas of intraductal hyperplasia. Some dense fibrosis is seen with\X0D\\X0A\surrounding chronic inflammation. The inflammatory process appears to surround\X0D\\X0A\dilated ducts in some areas. Calcification is identified in the dense fibrous\X0D\\X0A\stroma as well. Occasional foci of lobular carcinoma in situ are seen and in\X0D\\X0A\block B, occasional small foci of infiltrating lobular are identified as well,\X0D\\X0A\measuring approximately 1 mm in diameter on the slide. **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: This tumor shows POSITIVE nuclear staining\X0D\\X0A\for Estrogen Receptor (100% of tumor nuclei) and POSITIVE staining for\X0D\\X0A\Progesterone Receptor (over 50% of tumor nuclei). The tumor shows incomplete\X0D\\X0A\weak membrane staining for HER2/Neu in the tumor cells (1+ on a scale of 1 to 3)\X0D\\X0A\and is there fore negative. Note: All controls stain appropriately including\X0D\\X0A\external positive, internal negative and external negative controls as required.\X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\MHB/mbc",,,"Amendments:\X0D\\X0A\Amended:  **DATE[May 6 2012] by **NAME[XXX WWW VVV]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     ER/PR/H2N\X0D\\X0A\Previous Signout Date:  **DATE[May 5 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[UUU, TTT M].\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,472406,1,,Clinical Diagnosis and History\X0D\\X0A\Left breast mass.,Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Left breast mass,"Final Diagnosis\X0D\\X0A\Left breast mass, excisional biopsy of frozen section:\X0D\\X0A\A.          Infiltrating ductal carcinoma, intermediate to high grade.\X0D\\X0A\B.     Tumor approaches to within 3 mm of the inked surgical margin.\X0D\\X0A\                                             1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Mar 15 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 20 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Mar 21 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\HER 2 - by FISH     Date Ordered:     **DATE[Mar 22 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 22 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Mar 22 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\Oncotype DX N/C     Date Ordered:     **DATE[Apr 17 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 23 2012]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Apr 23 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ M. YYY], MD",,"Gross Description\X0D\\X0A\Received fresh in a container labeled with the patient's name and medical record\X0D\\X0A\number and designated as ""left breast mass"" with a long suture superficial and a\X0D\\X0A\short suture deep is a mass of fibrofatty breast tissue weighing 73.9 grams. \X0D\\X0A\The biopsy measures 10 cm from superficial to deep stitch.  At the superficial\X0D\\X0A\end of the specimen cross-sectional dimensions are 4 x 2.5 cm.  At the deep end\X0D\\X0A\of the biopsy cross-sectional dimensions are 6 x 3 cm.  The margins of the\X0D\\X0A\superficial one-half are marked with blue ink and the margins of the deep\X0D\\X0A\one-half are marked with black ink.  Cross-sectioning through the breast tissue\X0D\\X0A\reveals, within the deep one-half of the specimen is a firm pink-gray to\X0D\\X0A\gray-white tumor which has overall dimensions of 1.8 x 1.3 x 1.4 cm.  This tumor\X0D\\X0A\measures 1.4 cm from the tag of the deep margin and 5 cm from the tagged\X0D\\X0A\superficial margin.  The tumor is seen at 0.3 cm from the closest lateral\X0D\\X0A\margin.  Representative sections are submitted for frozen section and following\X0D\\X0A\this procedure resubmitted in (block A).   Additional sections of the tumor are\X0D\\X0A\submitted in (blocks B through D). A section through the closest deep margin is\X0D\\X0A\submitted in (block E).  Section through the superficial margin submitted in\X0D\\X0A\(block F).  A section through an area of fibrocystic changes and the superficial\X0D\\X0A\aspect is submitted in (block F).  An additional section through an area of\X0D\\X0A\fibrocystic changes is submitted in (block G).  \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Sections of the left breast mass reveal an infiltrating low grade ductal\X0D\\X0A\carcinoma of the breast.  Approximately 50% of the infiltrate displays ductal\X0D\\X0A\differential.  There is a central area of fibroelastic proliferation associated\X0D\\X0A\with the infiltrating carcinoma.  Lymphatic of vascular invasion is not\X0D\\X0A\identified.  A very few small foci of ductal carcinoma in fact are seen in\X0D\\X0A\association with the infiltrating carcinoma.  There is a moderate degree of\X0D\\X0A\nuclear atypia with enlarged nuclei with many nuclei containing distinct\X0D\\X0A\nucleoli.  Although the tumor shows good evidence of ductal differentiation, the\X0D\\X0A\nuclei are enlarged pleomorphic and vesicular with most nuclei containing a\X0D\\X0A\prominent nucleus.  There is a high mitotic rate with up to 6 mitotic figures in\X0D\\X0A\a single high power field.  Mitotic rate greater than 17 per 10 high power\X0D\\X0A\fields is seen.  The infiltrating carcinoma is seen within 3 mm of the inked\X0D\\X0A\margins.  Fibrocystic changes are seen elsewhere in the breast tissue.  No other\X0D\\X0A\sites of infiltrating carcinoma are identified.  \X0D\\X0A\**INITIALS",,,Procedures/Addenda\X0D\\X0A\Clarient DNA     Date Ordered:     **DATE[Mar 15 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 20 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Mar 20 2012]
REG1,BREAST,0,472434,3,,Clinical Diagnosis and History,"Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Left Breast, Core Biopsy\X0D\\X0A\2: Left Breast\X0D\\X0A\3: Left sentinel node axilla","Final Diagnosis\X0D\\X0A\1.     Left breast, Mammotome biopsies:   \X0D\\X0A\     A.     Ductal carcinoma in situ, cribriform and papillary, intermediate\X0D\\X0A\nuclear grade.\X0D\\X0A\            B.         Changes consistent with prior biopsy site.\X0D\\X0A\            C.         Microcalcifications associated with the DCIS.\X0D\\X0A\2.     Submitted left simple mastectomy:  \X0D\\X0A\          A.     Invasive mammary carcinoma, grade 2, predominantly lobular,\X0D\\X0A\with focal ductal differentiation, arising in the upper outer quadrant.   \X0D\\X0A\     B.     Greatest dimension of invasive carcinoma equals 1.9 cm.  \X0D\\X0A\     C.     Tumor measures 2.9 mm from the posterior (deep) margin.  \X0D\\X0A\     D.     Ductal carcinoma in situ arising in the upper outer quadrant and\X0D\\X0A\subareolar area.  \X0D\\X0A\     E.     Florid fibrocystic disease. \X0D\\X0A\3.     Left axillary sentinel lymph node, biopsy:  \X0D\\X0A\          A.     Two (2) lymph nodes displaying benign fatty infiltration, no\X0D\\X0A\metastatic carcinoma seen in serial sections stained with Hematoxylin and Eosin.\X0D\\X0A\     B.     Pankeratin immunoperoxidase stain negative for metastatic carcinoma.\X0D\\X0A\                    1\X0D\\X0A\Pathologic classification of the tumor equals pT1c pN0(i-) pMX.  AJCC\X0D\\X0A\classification equals IA.  \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Surgical Pathology Cancer Case Summary (Checklist)\X0D\\X0A\     INVASIVE CARCINOMA OF THE BREAST: Mastectomy (Total With or Without\X0D\\X0A\Axillary Contents)\X0D\\X0A\Specimen \X0D\\X0A\_x__ Total breast (including nipple and skin)\X0D\\X0A\Procedure \X0D\\X0A\__x_ Total mastectomy (including nipple and skin)\X0D\\X0A\Lymph Node Sampling \X0D\\X0A\_x__ Sentinel lymph node\X0D\\X0A\Specimen Integrity \X0D\\X0A\__x_ Single intact specimen (margins can be evaluated)\X0D\\X0A\Specimen Laterality\X0D\\X0A\__x_ Left\X0D\\X0A\*Tumor Site: Invasive Carcinoma \X0D\\X0A\*_x__ Upper outer quadrant\X0D\\X0A\*___ Central\X0D\\X0A\*Position: _10__ o'clock\X0D\\X0A\Tumor Size: Size of Largest Invasive Carcinoma \X0D\\X0A\Greatest dimension of largest focus of invasion over 0.1 cm: __1.9_ cm\X0D\\X0A\     *Additional dimensions: ___ x ___ cm\X0D\\X0A\Tumor Focality \X0D\\X0A\_x__ Single focus of invasive carcinoma\X0D\\X0A\Macroscopic and Microscopic Extent of Tumor \X0D\\X0A\     _x__ Invasive carcinoma does not invade into the dermis or epidermis\X0D\\X0A\Nipple\X0D\\X0A\     __x_ DCIS does not involve the nipple epidermis\X0D\\X0A\___ DCIS involves nipple epidermis (Paget disease of the nipple)\X0D\\X0A\Note: This finding does not change the T classification.\X0D\\X0A\Skeletal Muscle\X0D\\X0A\     _x__ Skeletal muscle is present and is free of carcinoma\X0D\\X0A\Ductal Carcinoma In Situ (DCIS) (select all that apply) (Note G)\X0D\\X0A\_x__ DCIS is present\X0D\\X0A\     _x__ Extensive intraductal component (EIC) negative\X0D\\X0A\*Size (Extent) of DCIS \X0D\\X0A\     *Estimated size (extent) of DCIS (greatest dimension using gross and\X0D\\X0A\microscopic evaluation) is at least __1.6_ cm\X0D\\X0A\*Architectural Patterns  \X0D\\X0A\*_x__ Cribriform\X0D\\X0A\*Nuclear Grade \X0D\\X0A\*_x__ Grade I (low)\X0D\\X0A\*Necrosis \X0D\\X0A\*__x_ Present, focal (small foci or single cell necrosis)\X0D\\X0A\Lobular Carcinoma In Situ (LCIS)\X0D\\X0A\__x_ Not identified\X0D\\X0A\Histologic Type of Invasive Carcinoma \X0D\\X0A\__x_ Invasive carcinoma with ductal and lobular features (""mixed type\X0D\\X0A\carcinoma"")\X0D\\X0A\Histologic Grade: Nottingham Histologic Score \X0D\\X0A\Glandular (Acinar)/Tubular Differentiation\X0D\\X0A\_x__ Score 3: <10% of tumor area forming glandular/tubular structures\X0D\\X0A\Nuclear Pleomorphism\X0D\\X0A\     __x_ Score 2: Cells larger than normal with open vesicular nuclei, visible\X0D\\X0A\nucleoli, and moderate variability in both size and shape\X0D\\X0A\Mitotic Count\X0D\\X0A\_x__ Score 1 (see Table 2)\X0D\\X0A\*Number of mitoses per 10 high-power fields: _1__\X0D\\X0A\Overall Grade\X0D\\X0A\_x__ Grade 2: scores of 6 or 7 \X0D\\X0A\Margins \X0D\\X0A\_x__ Margins uninvolved by invasive carcinoma\X0D\\X0A\     Distance from closest margin: _2.9__ mm\X0D\\X0A\     *Distance from posterior margin: _2.9__ mm\X0D\\X0A\__x_ Margins uninvolved by DCIS (if present)\X0D\\X0A\     Distance from closest margin: __>50_ mm     \X0D\\X0A\Lymph-Vascular Invasion \X0D\\X0A\_x__ Not identified\X0D\\X0A\Dermal Lymph-Vascular Invasion\X0D\\X0A\     __x_ Not identified\X0D\\X0A\Lymph Nodes \X0D\\X0A\Number of sentinel lymph nodes examined: _2__\X0D\\X0A\Total number of lymph nodes examined (sentinel and nonsentinel): _2__\X0D\\X0A\Number of lymph nodes with macrometastases (>0.2 cm):  _0__\X0D\\X0A\     Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or\X0D\\X0A\>200cells):_0__\X0D\\X0A\Number of lymph nodes with isolated tumor cells (d0.2 mm and d200 cells): _0__\X0D\\X0A\*Method of Evaluation of Sentinel Lymph Nodes (select all that apply)\X0D\\X0A\*_x__ H\E\T\E\E, multiple levels\X0D\\X0A\*_x_ Immunohistochemistry\X0D\\X0A\Pathologic Staging (based on information available to the pathologist) (pTNM) \X0D\\X0A\Primary Tumor (Invasive Carcinoma) (pT) \X0D\\X0A\pT1: Tumor d20 mm in greatest dimension\X0D\\X0A\     _x__ pT1c:     Tumor >10 mm but d20 mm in greatest dimension\X0D\\X0A\Regional Lymph Nodes (pN) \X0D\\X0A\Modifier (required only if applicable)\X0D\\X0A\     _x__ (sn):     Only sentinel node(s) evaluated.  If 6 or more sentinel\X0D\\X0A\nodes and/or nonsentinel nodes are removed, this modifier should not be used.\X0D\\X0A\Category (pN)\X0D\\X0A\     __x_ pN0:     No regional lymph node metastasis identified histologically\X0D\\X0A\_x__ pN0 (i-):     No regional lymph node metastases histologically, negative\X0D\\X0A\IHC\X0D\\X0A\Distant Metastasis (M)  \X0D\\X0A\_x__ Not applicable\X0D\\X0A\Ancillary Studies  \X0D\\X0A\Estrogen Receptor (immunohistochemical results on invasive carcinoma performed\X0D\\X0A\on this specimen or a prior core needle biopsy or incisional biopsy)\X0D\\X0A\_x__ Pending\X0D\\X0A\Progesterone Receptor (immunohistochemical results for invasive carcinoma\X0D\\X0A\performed on this specimen or a prior core needle biopsy or incisional biopsy)\X0D\\X0A\_x_ Pending\X0D\\X0A\Results:\X0D\\X0A\___ Immunoreactive tumor cells present (d1%)\X0D\\X0A\     Quantitation:  ____________\X0D\\X0A\___ Less than 1% immunoreactive cells present\X0D\\X0A\___ No immunoreactive tumor cells present\X0D\\X0A\___ Results unknown\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\*Antibody vendor and clone: __________________\X0D\\X0A\HER2/neu (results for invasive carcinoma performed on this specimen or a prior\X0D\\X0A\core needle biopsy or incisional biopsy) \X0D\\X0A\Immunoperoxidase Studies\X0D\\X0A\_x__ Pending\X0D\\X0A\Results:\X0D\\X0A\___ Negative (Score 0)\X0D\\X0A\___ Negative (Score 1+)\X0D\\X0A\___ Equivocal (Score 2+)\X0D\\X0A\___ Positive (Score 3+)\X0D\\X0A\___ Other \X0D\\X0A\     Specify: _________________________\X0D\\X0A\___ Results unknown\X0D\\X0A\*Antibody vendor and clone: ______________________\X0D\\X0A\Fluorescence In Situ Hybridization (FISH) for HER2/neu\X0D\\X0A\__x_ Pending\X0D\\X0A\Results:\X0D\\X0A\___ Not amplified (HER2 gene copy <4.0 or ratio <1.8)\X0D\\X0A\___ Equivocal (HER2 gene copy 4.0 to 6.0 or ratio 1.8 to 2.2)\X0D\\X0A\___ Amplified (HER2 gene copy >6.0 or ratio >2.2)\X0D\\X0A\     *Average number of HER2 gene copies per cell: ___\X0D\\X0A\     *Average number of chromosome 17 per cell: ___\X0D\\X0A\     *Ratio: ___\X0D\\X0A\___ Results unknown\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\* Name of assay:  _____________________\X0D\\X0A\*Microcalcifications \X0D\\X0A\*_x__ Present in DCIS\X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Clarient DNA     Date Ordered:     **DATE[Feb 22 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Feb 27 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Feb 27 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Feb 22 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Feb 29 2012]     By:  **NAME[VVV UUU,TTT](ASCP),Pathology\X0D\\X0A\Supervisor\X0D\\X0A\     Date Reported:     **DATE[Feb 29 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\HER 2 - by FISH     Date Ordered:     **DATE[Mar 1 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 1 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Mar 3 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,"Gross Description\X0D\\X0A\     1.     Received fresh in the laboratory and hand-delivered by Dr. **NAME[SSS]\X0D\\X0A\labeled ""left breast ultrasound Mammotome biopsies"" are segments of yellow,\X0D\\X0A\tan-white, reddish, and mucinous core biopsy segments measuring up to 3 cm in\X0D\\X0A\length.  One of these cores is submitted for frozen section and following this\X0D\\X0A\procedure resubmitted in (block 1A).   The remainder of the core biopsies are\X0D\\X0A\submitted in (blocks 1B and 1C).  \X0D\\X0A\2.  Received fresh and hand delivered by Dr. **NAME[SSS] to the pathology department\X0D\\X0A\in a container labeled with the patient name and medical record number and Dr.\X0D\\X0A\**NAME[SSS] designates as a left simple mastectomy.  Dr. **NAME[SSS] orients the specimen\X0D\\X0A\identifying a suture in the left axillary tail.  The specimen weighs is 968\X0D\\X0A\grams.  Blue ink is placed on the posterior retromammary fascia margin.  Black\X0D\\X0A\ink is placed on the superior margin.  Dr. **NAME[SSS] identifies in the upper outer\X0D\\X0A\quadrant at approximately 2 o'clock at the site of the previous Mammo tone\X0D\\X0A\biopsies with a surgical incision measuring 0.7 cm in length.  Dr. **NAME[SSS] also\X0D\\X0A\identifies a parenchymal mass of interest. This mass is located in the upper\X0D\\X0A\outer quadrant and is felt very close to the posterior retromammary fascia\X0D\\X0A\margin.  Cross sectioning through the breast tissue reveals a gritty firm tumor\X0D\\X0A\measuring 1.9 x 1.5 x 1.4 cm. The tumor displays retracted edges and has a\X0D\\X0A\gray-white cut surface. The tumor measures 3 mm from the posterior margin. \X0D\\X0A\Tumor measures 2 cm from the superior margin, 7 cm from the inferior margin, 7\X0D\\X0A\cm from the lateral margin and 15 cm from the medial margin.  A section of the\X0D\\X0A\tumor is submitted for frozen section and following this procedure resubmitted\X0D\\X0A\in (block 2A).  A portion of the fresh tumor is sent to Mammo print.  It is\X0D\\X0A\noted that on the skin surface .3 cm  immediately superior to the nipple is a\X0D\\X0A\well healed white surgical scar 6 cm in length. The nipple is everted and shows\X0D\\X0A\no scaling or erosion.  Cross sectioning through the breast tissue reveals the\X0D\\X0A\gritty gray firm tumor as described above measuring 1.9 cm in greatest\X0D\\X0A\dimension.  The Mammo tone biopsy tract extends into the breast tissue\X0D\\X0A\superficial or anterior to the tumor and then biopsy tract extends in a medial\X0D\\X0A\and inferior direction with the biopsy gel located approximately 1-2 cm medial,\X0D\\X0A\1 cm inferior and 1 cm anterior to the tumor.  The biopsy cavity itself extends\X0D\\X0A\in a medial direction with the edge of the biopsy cavity extending to the\X0D\\X0A\subareolar tissues.  The biopsy cavity measures 2.5 x 2.5 cm.  The hydrogel\X0D\\X0A\measures 1.7 cm in length and contains a metal coil within its center.  In cross\X0D\\X0A\sectioning through the breast tissue there are no other tumors identified. \X0D\\X0A\Fibrocystic changes are seen throughout.  There is approximately 50% fibrous\X0D\\X0A\parenchyma in the central fibrous band region which measures 9 x 9 cm. \X0D\\X0A\Key to  microscopic sections:  (block 2A) section of tumor for frozen section\X0D\\X0A\including posterior margin.  (blocks 2B-2C) remainder of tumor. (block\X0D\\X0A\2D-nipple). (blocks 2E-2F) sections from the wall of the biopsy cavity in a\X0D\\X0A\subareolar location.  (block 2G) section from upper outer quadrant along the\X0D\\X0A\edge of the Mammo tone biopsy tract.  (block 2H) representative section of outer\X0D\\X0A\quadrant.  (block 2I) representative section of lower inner quadrant.  (block\X0D\\X0A\2J) representative section of upper inner quadrant.  (block 2K) upper outer\X0D\\X0A\quadrant breast tissue superior to the tumor site. (block 2L) subareolar tissue.\X0D\\X0A\ (blocks 2M through 2O) slightly medial and inferior to the site of invasive\X0D\\X0A\carcinoma.  (block 2P) anterior to the invasive carcinoma in the area of the\X0D\\X0A\Mammotome biopsy track.  \X0D\\X0A\3.  Received in formalin and labeled with the patient name and designated ""left\X0D\\X0A\sentinel (axillary) lymph node"" is a mass of adipose tissue with overall\X0D\\X0A\dimensions of 4 x 3 x 2.5 cm.  There are two apparent lymph nodes included in\X0D\\X0A\the fatty tissue both of which is tan pink measuring 3.1 x 2 x 0.9 cm.  The\X0D\\X0A\second segment measures 3.1 x 1.5 x 0.7 cm.  The larger lymph node is serially\X0D\\X0A\sectioned and revealing yellow fatty infiltration.  This lymph node is serially\X0D\\X0A\sectioned and submitted in toto in (blocks 3A-3B).  The smaller lymph node is\X0D\\X0A\also serially sectioned and submitted in toto in (blocks 3C-3D).\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\     1.     Sections of the Mammotome biopsies of the left breast reveal ductal\X0D\\X0A\carcinoma in situ.  There are dilated ductular structures displaying a\X0D\\X0A\cribriform proliferation of ductal epithelial cells. There is also a papillary\X0D\\X0A\and solid pattern There is focal central luminal necrosis.  Microcalcifications\X0D\\X0A\are present within the center of the areas of central necrosis. There is mucus\X0D\\X0A\spillage, granulation tissue, and hemosiderin macrophages consistent with the\X0D\\X0A\previous biopsy.  . Invasive carcinoma is not seen.\X0D\\X0A\2.     Sections of the left breast cancer reveal invasive mammary carcinoma\X0D\\X0A\characterized by a proliferation of malignant epithelial cells which tend to\X0D\\X0A\form cords and small nests with a tendency to single file pattern of\X0D\\X0A\infiltration.  Tumor is seen in association with a fibroelastic scar.  The tumor\X0D\\X0A\is seen to approach to 2.9 mm from the deep margin of resection which includes\X0D\\X0A\skeletal muscle.  Ductular differentiation is focally  identified.  The tumor\X0D\\X0A\nuclei display moderate pleomorphism with nuclear enlargement, vesicular\X0D\\X0A\chromatin and many nuclei containing distinct nucleoli.  Occasional signet ring\X0D\\X0A\cell forms are seen.  There is a mild lymphocytic infiltrate associated with the\X0D\\X0A\infiltrating carcinoma.  One mitotic figure is seen in ten high powered fields. \X0D\\X0A\Medial and inferior to the invasive carcinoma and corresponding to the site of\X0D\\X0A\the Mammotome biopsy, there is low grade ductal carcinoma in situ.  A cribriform\X0D\\X0A\pattern is seen.  A micropapillary pattern is seen.  A solid pattern is seen. \X0D\\X0A\The carcinoma in situ demonstrates rare mitotic figures.  The residual colloid\X0D\\X0A\carcinoma as noted on the Mammotome biopsy is not demonstrated.  Fibrocystic\X0D\\X0A\changes are prominent throughout.  There are also foci of atypical ductal\X0D\\X0A\hyperplasia with solid proliferation of ductal cells seen slightly expanding\X0D\\X0A\ductular spaces. \X0D\\X0A\3.     Sections of the left axillary sentinel lymph node reveal no evidence of\X0D\\X0A\metastatic carcinoma within either lymph node on the H\E\T\E\E stained sections. \X0D\\X0A\There is extensive benign fatty infiltration.  Pankeratin immunoperoxidase stain\X0D\\X0A\is performed on the sentinel lymph nodes along with the appropriate negative\X0D\\X0A\control and positive control staining 3+.  There is no metastatic carcinoma\X0D\\X0A\demonstrated with the pankeratin stain.  \X0D\\X0A\**INITIALS",,,Procedures/Addenda\X0D\\X0A\Mammaprint     Date Ordered:     **DATE[Feb 21 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 26 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Mar 31 2012]
REG1,BREAST,0,472443,1,,Clinical Diagnosis and History\X0D\\X0A\Right breast mass with a 1.25 cm solid irregular mass at 11 o'clock.,Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Right breast cores,"Final Diagnosis\X0D\\X0A\Right breast, Mammotome core biopsies:  \X0D\\X0A\     A.     Infiltrating ductal carcinoma, grade 2.  \X0D\\X0A\     B.     Greatest tumor length equals 14 millimeters.  \X0D\\X0A\                    1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Clarient DNA     Date Ordered:     **DATE[Mar 28 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 2 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Apr 3 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Mar 28 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 2 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Apr 3 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\HER 2 - by FISH     Date Ordered:     **DATE[Apr 4 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 4 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Apr 4 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,Gross Description\X0D\\X0A\Received on a Petri dish and labeled with the patient name and medical record\X0D\\X0A\number are four gray-white and yellow core biopsy segments which vary from 1.5\X0D\\X0A\to 2 cm in length.  Dr. **NAME[VVV] requests that a portion of the probable tumor be\X0D\\X0A\sent for Mammo print. The remaining cores are submitted in (block A).\X0D\\X0A\**INITIALS,"Microscopic Description\X0D\\X0A\Sections of the right breast Mammotome core biopsies reveal an infiltrating\X0D\\X0A\mammary carcinoma extending up to 1.4 cm in length.  The tumor arises in\X0D\\X0A\association with fibroelastic scar.  The tumor infiltrates as nests of varying\X0D\\X0A\size and shape.  There is less than 10% ductular differentiation.  A few\X0D\\X0A\distinct ductular shapes are seen.  There are only a few cords of cells seen in\X0D\\X0A\a single file pattern to suggest any lobular differentiation.  There appear to\X0D\\X0A\be a few dilated ductal-type structures displaying a pattern of a solid\X0D\\X0A\carcinoma in situ.  However, focal central necrosis is also seen in the involved\X0D\\X0A\ductal structures.  Microcalcifications are not seen in these core biopsies. \X0D\\X0A\The tumor nuclei display a moderate pleomorphism with irregular nuclear borders\X0D\\X0A\with only an occasional nucleus showing a small distinct nucleolus.  Mitotic\X0D\\X0A\count reveals no greater than three mitotic figures per 10 high power fields.  \X0D\\X0A\**INITIALS",,,Procedures/Addenda\X0D\\X0A\Mammaprint     Date Ordered:     **DATE[Mar 27 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 6 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[May 9 2012]
REG1,BREAST,0,472452,1,,Clinical Diagnosis and History\X0D\\X0A\Breast mass radiologically suspicious for malignancy.,"Copy To: **NAME[ZZZ M. YYY], M.D. \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Fine Needle Core Biopsy, Right Breast\X0D\\X0A\2: Fine Needle Aspiration, Right Breast","Final Diagnosis\X0D\\X0A\1.          Breast, right breast fine needle biopsy:\X0D\\X0A\           Infiltrating mammary carcinoma with lobular features, favor grade 1.\X0D\\X0A\Comment:  The histopathologic features present favor a low grade carcinoma\X0D\\X0A\however the tumor grade is based on a relatively limited amount of tumor and may\X0D\\X0A\change upon receipt upon the final specimen. Clinical correlation is suggested. \X0D\\X0A\A representative sample has been submitted for Immunoprognostic markers.\X0D\\X0A\2.          Breast, right breast fine needle aspiration, smears:\X0D\\X0A\A.          Positive for malignancy.\X0D\\X0A\B.     Atypical epithelial cells consistent with mammary carcinoma.\X0D\\X0A\                                        1  \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX M. WWW], M.D.\X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Aug 3 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 8 2012]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Aug 8 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[XXX M. WWW], M.D.\X0D\\X0A\HER 2 - by FISH     Date Ordered:     **DATE[Aug 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 9 2012]     By:  **NAME[TTT SSS]\X0D\\X0A\     Date Reported:     **DATE[Aug 9 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin and labeled with the patient name and\X0D\\X0A\designated ""FNA right breast"". The specimen consists of two yellow-pink to gray\X0D\\X0A\soft tissue core biopsies each measuring 1.3 cm in length x 0.2 cm in diameter,\X0D\\X0A\totally submitted in (block 1A).\X0D\\X0A\Specimen #2 ""FNA right breast"" consists of four fixed smears.\X0D\\X0A\Preliminary exam: Atypical cells, many discohesive, suspicious for malignancy. \X0D\\X0A\Carcinoma versus lymphoma.  Cores obtained (CSW).\X0D\\X0A\cb",Microscopic Description\X0D\\X0A\Microscopic examination reveal sections of cores of breast parenchyma displaying\X0D\\X0A\an infiltrative epithelial lesion comprised of solid nests to single file\X0D\\X0A\infiltrating strands of atypical epithelial cells with high nuclear to\X0D\\X0A\cytoplasmic ratios and mildly pleomorphic enlarged angular hyperchromatic nuclei\X0D\\X0A\with occasional nucleoli.  The cells demonstrate a scant amount of eccentrically\X0D\\X0A\located eosinophilic cytoplasm.  The lesion measures 0.9 cm in greatest linear\X0D\\X0A\dimension and 4 mitotic figures are identified per 10 high power field examined.\X0D\\X0A\Microscopic examination of smear preparations of the right breast lesion fine\X0D\\X0A\needle aspiration specimen reveals numerous epithelial cells with high nuclear\X0D\\X0A\to cytoplasmic rations and mildly pleomorphic hyperchromatic nuclei with\X0D\\X0A\occasional nucleoli.  \X0D\\X0A\CBG/sj,,,Procedures/Addenda\X0D\\X0A\Flow Cytometry     Date Ordered:     **DATE[Aug 2 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 2 2012]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Aug 2 2012]
REG1,BREAST,0,476151,1,,Clinical Diagnosis and History\X0D\\X0A\Left breast mass.  Left breast cancer.,"Copy To: **NAME[ZZZ M. YYY], M.D. \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Left Breast mass\X0D\\X0A\2: Left Breast","Final Diagnosis\X0D\\X0A\1.     Biopsy left breast mass with needle localization and margin evaluation; \X0D\\X0A\     A.     Infiltrating ductal carcinoma of breast, grade 2 (maximum tumor\X0D\\X0A\diameter 2.1 x 1.5 cm).  \X0D\\X0A\     B.     Tumor focally abuts against the inked surgical margin of biopsy\X0D\\X0A\specimen.  \X0D\\X0A\     C.     No histologic evidence of angiolymphatic invasion by tumor. \X0D\\X0A\     D.     Numerous microcalcifications observed associated with tumor.  \X0D\\X0A\2.     Left modified radical mastectomy;  \X0D\\X0A\     A.     Nipple and subareolar ducts negative for Paget's disease or tumor\X0D\\X0A\involvement.  \X0D\\X0A\     B.     Overlying skin of the breast negative for tumor involvement.  \X0D\\X0A\     C.     Benign seborrheic keratosis and dermal cicatrix observed within\X0D\\X0A\overlying skin of the breast. \X0D\\X0A\          D.     No evidence of residual tumor within the breast parenchyma\X0D\\X0A\surrounding previous biopsy site.\X0D\\X0A\     E.     Florid benign fibrocystic mastopathy surrounding previous biopsy\X0D\\X0A\site and within adjacent breast quadrants including;  \X0D\\X0A\          1.     Stellate scar with complex sclerosing lesion. \X0D\\X0A\          2.     Duct ectasia with stasis.  \X0D\\X0A\          3.     Florid sclerosing adenosis.  \X0D\\X0A\          4.     Apocrine papillomatosis. \X0D\\X0A\          5.     Blunt duct adenosis. \X0D\\X0A\          6.     Multiple microcalcifications associated with fibrocystic\X0D\\X0A\mastopathy. \X0D\\X0A\          7.     No additional foci of tumor observed within adjacent breast\X0D\\X0A\quadrants.  \X0D\\X0A\     F.     Previous biopsy site is 1.5 cm from inked deep surgical margin of\X0D\\X0A\mastectomy specimen.  \X0D\\X0A\     G.     Axillary lymph nodes (seven) all negative for involvement by\X0D\\X0A\metastatic tumor.  \X0D\\X0A\                    1  \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\Ben **NAME[M. XXX], MD\X0D\\X0A\Surgical Pathology Cancer Case Summary (Checklist)\X0D\\X0A\Protocol web posting date: **DATE[Aug 2010]\X0D\\X0A\     INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total\X0D\\X0A\Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy,\X0D\\X0A\and Partial Mastectomy With or Without Axillary Contents) and Mastectomy (Total,\X0D\\X0A\Modified Radical, Radical With or Without Axillary Contents)\X0D\\X0A\Select a single response unless otherwise indicated.\X0D\\X0A\Specimen (Note A)\X0D\\X0A\___ Partial breast\X0D\\X0A\_x__ Total breast (including nipple and skin)\X0D\\X0A\___ Other (specify): ____________________________\X0D\\X0A\___ Not specified\X0D\\X0A\Procedure (Note A)\X0D\\X0A\___ Excision without wire-guided localization\X0D\\X0A\_x__ Excision with wire-guided localization\X0D\\X0A\__x_ Total mastectomy (including nipple and skin)\X0D\\X0A\___ Other (specify): ____________________________\X0D\\X0A\___ Not specified\X0D\\X0A\Lymph Node Sampling (select all that apply) (Note B)\X0D\\X0A\___ No lymph nodes present\X0D\\X0A\___ Sentinel lymph node(s) \X0D\\X0A\_x__ Axillary dissection (partial or complete dissection)\X0D\\X0A\___ Lymph nodes present within the breast specimen (ie, intramammary lymph\X0D\\X0A\nodes)\X0D\\X0A\___ Other lymph nodes (eg, supraclavicular or location not identified)\X0D\\X0A\     Specify location, if provided:  _________________________\X0D\\X0A\Specimen Integrity (Note C)\X0D\\X0A\_x__ Single intact specimen (margins can be evaluated)\X0D\\X0A\___ Multiple designated specimens (eg, main excision and identified margins)\X0D\\X0A\___ Fragmented (margins cannot be evaluated with certainty)\X0D\\X0A\___ Other (specify): _____________________________\X0D\\X0A\Specimen Size (for excisions less than total mastectomy) (Note C)\X0D\\X0A\Greatest dimension: ___ cm\X0D\\X0A\*Additional dimensions: ___ x ___ cm\X0D\\X0A\___ Cannot be determined \X0D\\X0A\Specimen Laterality\X0D\\X0A\___ Right\X0D\\X0A\__x_ Left\X0D\\X0A\___ Not specified\X0D\\X0A\*Tumor Site: Invasive Carcinoma (select all that apply) (Note D)\X0D\\X0A\*___ Upper outer quadrant\X0D\\X0A\*___ Lower outer quadrant\X0D\\X0A\*___ Upper inner quadrant\X0D\\X0A\*___ Lower inner quadrant\X0D\\X0A\*x__ Central\X0D\\X0A\*___ Nipple\X0D\\X0A\*Position: ___ o'clock\X0D\\X0A\*___ Other (specify): _____________________\X0D\\X0A\*___ Not specified\X0D\\X0A\Tumor Size: Size of Largest Invasive Carcinoma (Note E) \X0D\\X0A\___ Microinvasion only (d0.1 cm)\X0D\\X0A\Greatest dimension of largest focus of invasion over 0.1 cm: _2.1__ cm\X0D\\X0A\     *Additional dimensions: _1.5__ x ___ cm\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Cannot be determined (see Comment)\X0D\\X0A\Note: The size of the invasive carcinoma should take into consideration the\X0D\\X0A\gross findings correlated with themicroscopicexamination. In some cases, it may\X0D\\X0A\be helpful to use information about tumor size from imaging studies.  If\X0D\\X0A\multiple foci of invasion are present, the size listed is the size of the\X0D\\X0A\largest contiguous area of invasion. The size of multiple invasive carcinomas\X0D\\X0A\should not be added together.  The size does not include adjacent DCIS.\X0D\\X0A\If there has been a prior core needle biopsy or incisional biopsy showing a\X0D\\X0A\larger area of invasion than in the excisional specimen, the largest dimension\X0D\\X0A\of the invasive carcinoma in the prior specimen should be used for T\X0D\\X0A\classification, if known.\X0D\\X0A\If there has been prior treatment and no invasive carcinoma is present, the\X0D\\X0A\cancer is classified as Tis if there is residual DCIS and T0 if there is no\X0D\\X0A\remaining carcinoma.\X0D\\X0A\Tumor Focality (Note F) \X0D\\X0A\_x__ Single focus of invasive carcinoma\X0D\\X0A\___ Multiple foci of invasive carcinoma\X0D\\X0A\     *Number of foci:  ________\X0D\\X0A\     *Sizes of individual foci:  _______\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Indeterminate\X0D\\X0A\Note:  If there are multiple invasive carcinomas, size, grade, histologic type,\X0D\\X0A\and the results of studies for estrogen receptor (ER), progesterone receptor\X0D\\X0A\(PR), and HER2/neu should pertain to the largest invasive carcinoma.  If smaller\X0D\\X0A\invasive carcinomas differ in any of these features, this information may be\X0D\\X0A\included in the ""Comments"" section.\X0D\\X0A\Macroscopic and Microscopic Extent of Tumor (select all that apply) (Note G) \X0D\\X0A\Skin\X0D\\X0A\     ___ Skin is not present\X0D\\X0A\_x__ Invasive carcinoma does not invade into the dermis or epidermis\X0D\\X0A\___ Invasive carcinoma directly invades into the dermis or epidermis without\X0D\\X0A\skin ulceration\X0D\\X0A\___ Invasive carcinoma directly invades into the dermis or epidermis with skin\X0D\\X0A\ulceration (classified as T4b)\X0D\\X0A\     ___ Satellite skin foci of invasive carcinoma are present (ie, not\X0D\\X0A\contiguous with the invasive carcinoma in the breast) (classified as T4b)\X0D\\X0A\Nipple\X0D\\X0A\     __x_ DCIS does not involve the nipple epidermis\X0D\\X0A\___ DCIS involves nipple epidermis (Paget disease of the nipple)\X0D\\X0A\Note: This finding does not change the T classification.\X0D\\X0A\Skeletal Muscle\X0D\\X0A\     _x__ No skeletal muscle present\X0D\\X0A\     ___ Skeletal muscle is present and is free of carcinoma\X0D\\X0A\___ Carcinoma invades skeletal muscle\X0D\\X0A\___ Carcinoma invades into skeletal muscle and into the chest wall (classified\X0D\\X0A\as T4a)\X0D\\X0A\Note: Invasion into pectoralis muscle is not considered chest wall invasion, and\X0D\\X0A\cancers are not classified as T4a unless there is invasion deeper than this\X0D\\X0A\muscle.\X0D\\X0A\Ductal Carcinoma In Situ (DCIS) (select all that apply) (Note G)\X0D\\X0A\_x__ No DCIS is present \X0D\\X0A\___ DCIS is present\X0D\\X0A\     ___ Extensive intraductal component (EIC) negative\X0D\\X0A\___ EIC positive \X0D\\X0A\___ Only DCIS is present after presurgical (neoadjuvant) therapy\X0D\\X0A\*Size (Extent) of DCIS \X0D\\X0A\     *Estimated size (extent) of DCIS (greatest dimension using gross and\X0D\\X0A\microscopic evaluation) is at least ___ cm\X0D\\X0A\     *Additional dimensions: ___  x ___ cm\X0D\\X0A\     *Number of blocks with DCIS: ___\X0D\\X0A\*Number of blocks examined: ___\X0D\\X0A\Note: The size (extent) of DCIS is an estimation of the volume of breast tissue\X0D\\X0A\occupied by DCIS. This information may be helpful for cases with a predominant\X0D\\X0A\component of DCIS (eg, DCIS with microinvasion) but may not be necessary for\X0D\\X0A\cases of EIC negative invasive carcinomas.\X0D\\X0A\*Architectural Patterns  \X0D\\X0A\*___ Comedo \X0D\\X0A\*___ Paget disease (DCIS involving nipple skin)\X0D\\X0A\*___ Cribriform\X0D\\X0A\*___ Micropapillary\X0D\\X0A\*___ Papillary\X0D\\X0A\*___ Solid\X0D\\X0A\*___ Other (specify): ________________________\X0D\\X0A\*Nuclear Grade \X0D\\X0A\*___ Grade I (low)\X0D\\X0A\*___ Grade II (intermediate) \X0D\\X0A\*___ Grade III (high) \X0D\\X0A\*Necrosis \X0D\\X0A\*___ Not identified\X0D\\X0A\*___ Present, focal (small foci or single cell necrosis)\X0D\\X0A\*___ Present, central (expansive ""comedo"" necrosis)\X0D\\X0A\Lobular Carcinoma In Situ (LCIS)\X0D\\X0A\_x__ Not identified\X0D\\X0A\___ Present\X0D\\X0A\Histologic Type of Invasive Carcinoma (Note H)\X0D\\X0A\___ Ductal carcinoma in situ with microinvasion\X0D\\X0A\___ Lobular carcinoma in situ with microinvasion\X0D\\X0A\___ Ductal carcinoma in situ involving nipple skin (Paget disease) with\X0D\\X0A\microinvasion\X0D\\X0A\_x__ Invasive ductal carcinoma (no special type or not otherwise specified)\X0D\\X0A\___ Invasive lobular carcinoma\X0D\\X0A\___ Invasive carcinoma with ductal and lobular features (""mixed type carcinoma"")\X0D\\X0A\___ Invasive mucinous carcinoma\X0D\\X0A\___ Invasive medullary carcinoma\X0D\\X0A\___ Invasive papillary carcinoma\X0D\\X0A\___ Invasive micropapillary carcinoma\X0D\\X0A\___ Invasive tubular carcinoma\X0D\\X0A\___ Invasive cribriform carcinoma\X0D\\X0A\___ Invasive carcinoma, type cannot be determined\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other(s) (specify): ____________________________\X0D\\X0A\Note: The histologic type corresponds to the largest area of invasion.  If there\X0D\\X0A\are smaller foci of invasion of a different type, this information should be\X0D\\X0A\included under ""Additional Pathologic Findings.""\X0D\\X0A\Histologic Grade: Nottingham Histologic Score (Note I)\X0D\\X0A\Glandular (Acinar)/Tubular Differentiation\X0D\\X0A\___ Score 1: >75% of tumor area forming glandular/tubular structures\X0D\\X0A\_x__ Score 2: 10% to 75% of tumor area forming glandular/tubular structures\X0D\\X0A\___ Score 3: <10% of tumor area forming glandular/tubular structures\X0D\\X0A\___ Only microinvasion present (not graded)\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined\X0D\\X0A\Nuclear Pleomorphism\X0D\\X0A\     ___ Score 1: Nuclei small with little increase in size in comparison with\X0D\\X0A\normal breast epithelial cells, regular outlines, uniform nuclear chromatin,\X0D\\X0A\little variation in size\X0D\\X0A\_x__ Score 2: Cells larger than normal with open vesicular nuclei, visible\X0D\\X0A\nucleoli, and moderate variability in both size and shape\X0D\\X0A\___ Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked\X0D\\X0A\variation in size and shape, occasionally with very large and bizarre forms\X0D\\X0A\     ___ Only microinvasion present (not graded)\X0D\\X0A\     ___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined\X0D\\X0A\Mitotic Count\X0D\\X0A\___ Score 1 (see Table 2)\X0D\\X0A\__x_ Score 2 (see Table 2)\X0D\\X0A\___ Score 3 (see Table 2)\X0D\\X0A\___ Only microinvasion present (not graded)\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined\X0D\\X0A\*Number of mitoses per 10 high-power fields: ___\X0D\\X0A\*Diameter of microscope field: ___ mm\X0D\\X0A\Overall Grade\X0D\\X0A\___ Grade 1: scores of 3, 4, or 5 \X0D\\X0A\__x_ Grade 2: scores of 6 or 7 \X0D\\X0A\___ Grade 3: scores of 8 or 9 \X0D\\X0A\___ Only microinvasion present (not graded)\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Score cannot be determined.\X0D\\X0A\Note: The grade corresponds to the largest area of invasion. If there are\X0D\\X0A\smaller foci of invasion of a different grade, this information should be\X0D\\X0A\included under ""Additional Pathologic Findings.""\X0D\\X0A\Margins (select all that apply) (Note J)\X0D\\X0A\     ___ Margins cannot be assessed\X0D\\X0A\_x__ Margins uninvolved by invasive carcinoma\X0D\\X0A\     Distance from closest margin: _15__ mm\X0D\\X0A\     *Specify margins: \X0D\\X0A\     *Distance from superior margin: ___ mm\X0D\\X0A\*Distance from inferior margin: ___ mm\X0D\\X0A\*Distance from anterior margin: ___ mm\X0D\\X0A\*Distance from posterior margin: ___ mm\X0D\\X0A\*Distance from medial margin: ___ mm\X0D\\X0A\*Distance from lateral     margin: ___ mm\X0D\\X0A\*Distance from other specified margin: ___ mm\X0D\\X0A\          *Designation of margin: _________________\X0D\\X0A\NA___ Margins uninvolved by DCIS (if present)\X0D\\X0A\     Distance from closest margin: ___ mm\X0D\\X0A\     *Specify margins: \X0D\\X0A\     *Distance from superior margin: ___ mm\X0D\\X0A\*Distance from inferior margin: ___ mm\X0D\\X0A\*Distance from anterior margin: ___ mm\X0D\\X0A\*Distance from posterior margin: ___ mm\X0D\\X0A\*Distance from medial margin: ___ mm\X0D\\X0A\*Distance from lateral     margin: ___ mm\X0D\\X0A\*Distance from other specified margin: ___ mm\X0D\\X0A\     *Designation of margin: _________________\X0D\\X0A\___ Margin(s) positive for invasive carcinoma \X0D\\X0A\     *Specify margin(s): _____________________________\X0D\\X0A\     *Specify margin(s) and extent of involvement:\X0D\\X0A\          *___ Superior margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Inferior margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Anterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Posterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Medial margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\     *___ Extensive\X0D\\X0A\          *___ Lateral margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\___ Margin(s) positive for DCIS\X0D\\X0A\     *Specify margin(s): _____________________________\X0D\\X0A\     *Specify margin(s) and extent of involvement:\X0D\\X0A\          *___ Superior     margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Inferior margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Anterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Posterior margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\               *___ Extensive \X0D\\X0A\          *___ Medial margin\X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\          *___ Lateral margin     \X0D\\X0A\     *___ Focal\X0D\\X0A\*___ Minimal/moderate\X0D\\X0A\*___ Extensive\X0D\\X0A\*Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy (Note K)\X0D\\X0A\*In the Breast\X0D\\X0A\     *___ No known presurgical therapy\X0D\\X0A\*___ No definite response to presurgical therapy in the invasive carcinoma\X0D\\X0A\*___ Probable or definite response to presurgical therapy in the invasive\X0D\\X0A\carcinoma\X0D\\X0A\*___ No residual invasive carcinoma is present in the breast after presurgical\X0D\\X0A\therapy \X0D\\X0A\*In the Lymph Nodes\X0D\\X0A\     *___ No known presurgical therapy\X0D\\X0A\*___ No lymph nodes removed\X0D\\X0A\*___ No definite response to presurgical therapy in metastatic carcinoma\X0D\\X0A\     *___ Probable or definite response to presurgical therapy in metastatic\X0D\\X0A\carcinoma\X0D\\X0A\*___ No lymph node metastases.  Fibrous scarring, possibly related to prior\X0D\\X0A\lymph node metastases with pathologic complete response\X0D\\X0A\*___ No lymph node metastases and no prominent fibrous scarring in the nodes\X0D\\X0A\*Lymph-Vascular Invasion (Note L)\X0D\\X0A\*_x_ Not identified\X0D\\X0A\*___ Present\X0D\\X0A\*___ Indeterminate\X0D\\X0A\*Dermal Lymph-Vascular Invasion\X0D\\X0A\     *___ No skin present\X0D\\X0A\*__x_ Not identified\X0D\\X0A\*___ Present\X0D\\X0A\*___ Indeterminate\X0D\\X0A\Lymph Nodes (required only if lymph nodes are present in the specimen) (Note B)\X0D\\X0A\Number of sentinel lymph nodes examined: _0__\X0D\\X0A\Total number of lymph nodes examined (sentinel and nonsentinel): __7_\X0D\\X0A\Number of lymph nodes with macrometastases (>0.2 cm):  _0__\X0D\\X0A\     Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or\X0D\\X0A\>200cells):0__\X0D\\X0A\Number of lymph nodes with isolated tumor cells (d0.2 mm and d200 cells): _0__\X0D\\X0A\Size of largest metastatic deposit (if present): ___\X0D\\X0A\Note: The sentinel node is usually the first involved lymph node. In the unusual\X0D\\X0A\situation in which a sentinel node is not involved by metastatic carcinoma, but\X0D\\X0A\a nonsentinel node is involved, this information should be included in a note.\X0D\\X0A\*Extranodal Extension\X0D\\X0A\*___ Present\X0D\\X0A\*___ Not identified\X0D\\X0A\*___ Indeterminate\X0D\\X0A\*Method of Evaluation of Sentinel Lymph Nodes (select all that apply)\X0D\\X0A\*___ Hematoxylin and eosin (H\E\T\E\E), one level\X0D\\X0A\*___ H\E\T\E\E, multiple levels\X0D\\X0A\*___ Immunohistochemistry\X0D\\X0A\*___ Sentinel lymph node biopsy not performed\X0D\\X0A\*___ Other (specify): _______________________________\X0D\\X0A\Pathologic Staging (based on information available to the pathologist) (pTNM)\X0D\\X0A\(Note M)\X0D\\X0A\TNM Descriptors (required only if applicable) (select all that apply)\X0D\\X0A\___ m (multiple foci of invasive carcinoma)\X0D\\X0A\___ r (recurrent)\X0D\\X0A\___ y (posttreatment)\X0D\\X0A\Primary Tumor (Invasive Carcinoma) (pT) \X0D\\X0A\     ___ pTX:     Primary tumor cannot be assessed\X0D\\X0A\___ pT0:     No evidence of primary tumor#\X0D\\X0A\___ pTis (DCIS):     Ductal carcinoma in situ#\X0D\\X0A\___ pTis (LCIS):     Lobular carcinoma in situ#\X0D\\X0A\___ pTis (Paget):     Paget disease of the nipple not associated with invasive\X0D\\X0A\carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in the underlying breast\X0D\\X0A\parenchyma#\X0D\\X0A\pT1: Tumor d20 mm in greatest dimension\X0D\\X0A\     ___ pT1mi:      Tumor d1 mm in greatest dimension (microinvasion)\X0D\\X0A\___ pT1a:     Tumor >1 mm but d5 mm in greatest dimension\X0D\\X0A\___ pT1b:     Tumor >5 mm but d10 mm in greatest dimension\X0D\\X0A\___ pT1c:     Tumor >10 mm but d20 mm in greatest dimension\X0D\\X0A\_x__ pT2:     Tumor >20 mm but d50 mm in greatest dimension\X0D\\X0A\___ pT3:     Tumor >50 mm in greatest dimension\X0D\\X0A\     pT4:  Tumor of any size with direct extension to the chest wall and/or to\X0D\\X0A\the skin (ulceration or skin nodules). Note: Invasion of the dermis alone does\X0D\\X0A\not qualify as pT4.\X0D\\X0A\___ pT4a:     Extension to chest wall, not including only pectoralis muscle\X0D\\X0A\adherence/invasion\X0D\\X0A\     ___ pT4b:     Ulceration and/or ipsilateral satellite nodules and/or edema\X0D\\X0A\(including peau d'orange) of the skin which do not meet the criteria for\X0D\\X0A\inflammatory carcinoma\X0D\\X0A\___ pT4c:     Both T4a and T4b\X0D\\X0A\___ pT4d:     Inflammatory carcinoma##\X0D\\X0A\# For the purposes of this checklist, these categories should only be used in\X0D\\X0A\the setting of preoperative (neoadjuvant) therapy for which a previously\X0D\\X0A\diagnosed invasive carcinoma is no longer present after treatment.\X0D\\X0A\## Inflammatory carcinoma is a clinical-pathologic entity characterized by\X0D\\X0A\diffuse erythema and edema (peau d'orange) involving one-third or more of the\X0D\\X0A\skin of the breast.  The skin changes are due to lymphedema caused by tumor\X0D\\X0A\emboli within dermal lymphatics, which may or may not be obvious in a small skin\X0D\\X0A\biopsy.  However, a tissue diagnosis is still necessary to demonstrate an\X0D\\X0A\invasive carcinoma in the underlying breast parenchyma or at least in the dermal\X0D\\X0A\lymphatics, as well as to determine biological markers, such as ER, PR, and HER2\X0D\\X0A\status.  Tumor emboli in dermal lymphatics without the clinical skin changes\X0D\\X0A\described above do not qualify as inflammatory carcinoma.  Locally advanced\X0D\\X0A\breast cancers directly invading the dermis or ulcerating the skin without the\X0D\\X0A\clinical skin changes and tumor emboli in dermal lymphatics also do not qualify\X0D\\X0A\as inflammatory carcinoma.  Thus the term inflammatory carcinoma should not be\X0D\\X0A\applied to neglected locally advanced cancer of the breast presenting late in\X0D\\X0A\the course of a patient's disease.  The rare case that exhibits all the features\X0D\\X0A\of inflammatory carcinoma, but in which skin changes involve less than one-third\X0D\\X0A\of the skin, should be classified by the size and extent of the underlying\X0D\\X0A\carcinoma. \X0D\\X0A\Regional Lymph Nodes (pN) (choose a category based on lymph nodes received with\X0D\\X0A\the specimen; immunohistochemistry and/or molecular studies are not required)\X0D\\X0A\If internal mammary lymph nodes, infraclavicular nodes, or supraclavicular lymph\X0D\\X0A\nodes are included in the specimen, consult the AJCC Cancer Staging Manual1 for\X0D\\X0A\additional lymph node categories.\X0D\\X0A\Modifier (required only if applicable)\X0D\\X0A\     ___ (sn):     Only sentinel node(s) evaluated.  If 6 or more sentinel nodes\X0D\\X0A\and/or nonsentinel nodes are removed, this modifier should not be used.\X0D\\X0A\Category (pN)\X0D\\X0A\     ___ pNX:     Regional lymph nodes cannot be assessed (eg, previously\X0D\\X0A\removed, or not removed for pathologic study)\X0D\\X0A\__x_ pN0:     No regional lymph node metastasis identified histologically\X0D\\X0A\     Note: Isolated tumor cell (ITC) clusters are defined as small clusters of\X0D\\X0A\cells not greater than 0.2 mm or single tumor cells, or a cluster of fewer than\X0D\\X0A\200 cells in a single histologic cross-section.#   ITCs may be detected by\X0D\\X0A\routine histology or by immunohistochemical (IHC) methods.  Nodes containing\X0D\\X0A\only ITCs are excluded from the total positive node count for purposes of N\X0D\\X0A\classification but should be included in the total number of nodes evaluated.\X0D\\X0A\     ___ pN0 (i-):     No regional lymph node metastases histologically,\X0D\\X0A\negative IHC\X0D\\X0A\___ pN0 (i+):     Malignant cells in regional lymph node(s) no greater than 0.2\X0D\\X0A\mm and no more than 200 cells (detected by H\E\T\E\E or IHC including ITC)\X0D\\X0A\___ pN0 (mol-):     No regional lymph node metastases histologically, negative\X0D\\X0A\molecular findings (reverse transcriptase polymerase chain reaction [RT-PCR])\X0D\\X0A\___ pN0 (mol+):     Positive molecular findings (RT-PCR), but no regional lymph\X0D\\X0A\node metastases detected by histology or IHC\X0D\\X0A\___ pN1mi:     Micrometastases (greater than 0.2 mm and/or more than 200 cells,\X0D\\X0A\but none greater than 2.0 mm).\X0D\\X0A\___ pN1a:     Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis\X0D\\X0A\greater than 2.0 mm\X0D\\X0A\___ pN2a:     Metastases in 4 to 9 axillary lymph nodes (at least 1 tumor\X0D\\X0A\deposit greater than 2.0 mm)\X0D\\X0A\___ pN3a:     Metastases in 10 or more axillary lymph nodes (at least 1 tumor\X0D\\X0A\deposit greater than 2.0 mm)\X0D\\X0A\# Approximately 1000 tumor cells are contained in a 3-dimensional 0.2-mm\X0D\\X0A\cluster.  Thus, if more than 200 individual tumor cells are identified as single\X0D\\X0A\dispersed tumor cells or as a nearly confluent elliptical or spherical focus in\X0D\\X0A\a single histologic section of a lymph node, there is a high probability that\X0D\\X0A\more than 1000 cells are present in the node.  In these situations, the node\X0D\\X0A\should be classified as containing a micrometastasis (pN1mi).  Cells in\X0D\\X0A\different lymph node cross-sections or longitudinal sections or levels of the\X0D\\X0A\block are not added together; the 200 cells must be in a single node profile\X0D\\X0A\even if the node has been thinly sectioned into multiple slices.  It is\X0D\\X0A\recognized that there is substantial overlap between the upper limit of the ITC\X0D\\X0A\and the lower limit of the micrometastasis categories because of inherent\X0D\\X0A\limitations in pathologic nodal evaluation and detection of minimal tumor burden\X0D\\X0A\in lymph nodes.  Thus, the threshold of 200 cells in a single cross-section is a\X0D\\X0A\guideline to help pathologists distinguish between these 2 categories.  The\X0D\\X0A\pathologist should use judgment regarding whether it is likely that the cluster\X0D\\X0A\of cells represents a true micrometastasis or is simply a small group of\X0D\\X0A\isolated tumor cells.\X0D\\X0A\Distant Metastasis (M)  \X0D\\X0A\_x__ Not applicable\X0D\\X0A\     ___ cM0(i+):     No clinical or radiographic evidence of distant\X0D\\X0A\metastasis, but deposits of molecularly or microscopically detected tumor cells\X0D\\X0A\in circulating blood, bone marrow, or other nonregional nodal tissue that are\X0D\\X0A\d0.2 mm in a patient without symptoms or signs of metastasis\X0D\\X0A\     ___ pM1:          Distant detectable metastasis as determined by classic\X0D\\X0A\clinical and radiographic means and/or histologically proven >0.2 mm\X0D\\X0A\*Additional Pathologic Findings (Note N)\X0D\\X0A\*Specify: ____________________________\X0D\\X0A\Ancillary Studies (Note O) \X0D\\X0A\Estrogen Receptor (immunohistochemical results on invasive carcinoma performed\X0D\\X0A\on this specimen or a prior core needle biopsy or incisional biopsy)\X0D\\X0A\_x__ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\_x__ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify): _____________________\X0D\\X0A\Results: \X0D\\X0A\___ Immunoreactive tumor cells present (d1%)\X0D\\X0A\     Quantitation: ____________\X0D\\X0A\___ Less than 1% immunoreactive cells present\X0D\\X0A\___ No immunoreactive tumor cells present\X0D\\X0A\_x__ Results unknown\X0D\\X0A\___ Other (specify): _____________________\X0D\\X0A\*Antibody vendor and clone: ___________\X0D\\X0A\*Type of fixative (if other than neutral buffered formalin): ____________\X0D\\X0A\Progesterone Receptor (immunohistochemical results for invasive carcinoma\X0D\\X0A\performed on this specimen or a prior core needle biopsy or incisional biopsy)\X0D\\X0A\_x__ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\_x__ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\Results:\X0D\\X0A\___ Immunoreactive tumor cells present (d1%)\X0D\\X0A\     Quantitation:  ____________\X0D\\X0A\___ Less than 1% immunoreactive cells present\X0D\\X0A\___ No immunoreactive tumor cells present\X0D\\X0A\_x__ Results unknown\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\*Antibody vendor and clone: __________________\X0D\\X0A\HER2/neu (results for invasive carcinoma performed on this specimen or a prior\X0D\\X0A\core needle biopsy or incisional biopsy) \X0D\\X0A\Immunoperoxidase Studies\X0D\\X0A\_x__ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\_x__ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify): _____________________\X0D\\X0A\Results:\X0D\\X0A\___ Negative (Score 0)\X0D\\X0A\___ Negative (Score 1+)\X0D\\X0A\___ Equivocal (Score 2+)\X0D\\X0A\___ Positive (Score 3+)\X0D\\X0A\___ Other \X0D\\X0A\     Specify: _________________________\X0D\\X0A\_x__ Results unknown\X0D\\X0A\*Antibody vendor and clone: ______________________\X0D\\X0A\Fluorescence In Situ Hybridization (FISH) for HER2/neu\X0D\\X0A\_x__ Performed on this specimen\X0D\\X0A\___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number):  _________________\X0D\\X0A\_x_ Pending\X0D\\X0A\___ Not performed\X0D\\X0A\___ No residual invasive carcinoma after presurgical (neoadjuvant) therapy\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\Results:\X0D\\X0A\___ Not amplified (HER2 gene copy <4.0 or ratio <1.8)\X0D\\X0A\___ Equivocal (HER2 gene copy 4.0 to 6.0 or ratio 1.8 to 2.2)\X0D\\X0A\___ Amplified (HER2 gene copy >6.0 or ratio >2.2)\X0D\\X0A\     *Average number of HER2 gene copies per cell: ___\X0D\\X0A\     *Average number of chromosome 17 per cell: ___\X0D\\X0A\     *Ratio: ___\X0D\\X0A\x___ Results unknown\X0D\\X0A\___ Other (specify):  _____________________\X0D\\X0A\* Name of assay:  _____________________\X0D\\X0A\*Other Ancillary Studies (results for invasive carcinoma performed on this\X0D\\X0A\specimen or a prior core needle biopsy or incisional biopsy) \X0D\\X0A\*___ Performed on this specimen\X0D\\X0A\*___ Performed on another specimen\X0D\\X0A\     *Specify specimen (accession number): _________________\X0D\\X0A\*Name of test:  _____________________________________\X0D\\X0A\*Results:  _______________________________________\X0D\\X0A\*Microcalcifications (select all that apply) (Note P)\X0D\\X0A\*___ Not identified \X0D\\X0A\*___ Present in DCIS\X0D\\X0A\*___ Present in invasive carcinoma\X0D\\X0A\*___ Present in non-neoplastic tissue\X0D\\X0A\*___ Present in both carcinoma and non-neoplastic tissue\X0D\\X0A\*Clinical History (select all that apply) (Note Q)\X0D\\X0A\*The current clinical/radiologic breast findings for which this surgery is\X0D\\X0A\performed include:\X0D\\X0A\*___ Palpable mass\X0D\\X0A\*___ Radiologic finding\X0D\\X0A\     *___ Mass or architectural distortion\X0D\\X0A\     *___ Calcifications\X0D\\X0A\     *___ Other (specify): _________________________\X0D\\X0A\*___ Nipple discharge\X0D\\X0A\*___ Other (specify): _______________________________\X0D\\X0A\*___ Prior history of breast cancer\X0D\\X0A\     *Specify site, diagnosis, and prior treatment: ________________________\X0D\\X0A\*___ Prior presurgical (neoadjuvant) therapy for this diagnosis of invasive\X0D\\X0A\carcinoma\X0D\\X0A\     *Specify type: _______________________________\X0D\\X0A\*Comment(s)\X0D\\X0A\     *     Data elements with asterisks are not required. However, these\X0D\\X0A\elements may be clinically important but are not yet validated or regularly used\X0D\\X0A\in patient management. \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\Clarient DNA     Date Ordered:     **DATE[Jun 25 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jun 30 2012]     By:  **NAME[WWW VVV]\X0D\\X0A\     Date Reported:     **DATE[Jun 30 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\Oncotype DX     Date Ordered:     **DATE[Jul 12 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jul 20 2012]     By:  **NAME[WWW VVV]\X0D\\X0A\     Date Reported:     **DATE[Jul 20 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,"Gross Description\X0D\\X0A\Specimen #1 is received fresh for frozen section on a Radiology Specboard,\X0D\\X0A\labeled with the patient's name and designated ""left breast biopsy.""  The\X0D\\X0A\specimen consists of a fragment of fibroadipose tissue measuring 5.4 x 3.6 x 1.5\X0D\\X0A\cm. The external surface is yellow-pink, soft and lobulated.  A wire guide is in\X0D\\X0A\place.  The specimen is accompanied by radiographs indicating a stellate mass in\X0D\\X0A\the center of the specimen with focal calcification. The wire guide appears to\X0D\\X0A\pass through the mass.  The external surface is inked blue.  Sectioning reveals\X0D\\X0A\a yellow-gray stellate mass in the central aspect measuring 2.2 x 1.7 x 1.2 cm. \X0D\\X0A\Focal necrosis is noted.  The mass has a gritty cut surface consistent with\X0D\\X0A\microcalcification.  The mass extends to multiple resection margins.  The\X0D\\X0A\remaining cut surface is yellow-pink, soft and lobulated.  A representative\X0D\\X0A\section of the stellate mass is submitted for frozen section.  The frozen\X0D\\X0A\section remnant is submitted in (block A).  Representative sections of tumor are\X0D\\X0A\submitted in (blocks B and C). Representative section of unremarkable breast\X0D\\X0A\tissue is submitted in (block D). \X0D\\X0A\Specimen #2 is received in formalin, labeled with the patient's name and\X0D\\X0A\designated ""left breast.""  The specimen consists of a left breast with attached\X0D\\X0A\axillary tail.  The breast measures 22.4 x 16.5 x 4.2 cm and weighs 1,031 grams.\X0D\\X0A\The attached skin ellipse measures 24.8 x 14.0 cm.  The skin surface is tan-pink\X0D\\X0A\with a stapled incision superior of the nipple measuring 5.5 cm in length. \X0D\\X0A\Lateral to the incision is a pink-gray round to oval possible scar measuring 1.0\X0D\\X0A\x 1.0 cm.  Two tan-pink slightly elevated lesions are noted along the\X0D\\X0A\superior-medial aspect measuring 0.8 cm in greatest dimension and 0.7 cm in\X0D\\X0A\greatest dimension.  The nipple appears unremarkable.  The deep margin is\X0D\\X0A\yellow-pink and intact. The deep margin is inked black.  Serial sectioning\X0D\\X0A\reveals a recent biopsy cavity in the center of the specimen measuring 5.1 x 3.9\X0D\\X0A\x 3.5 cm.  The walls of the cavity are ragged. The tissue surrounding the cavity\X0D\\X0A\shows changes of fibrocystic disease.  Biopsy cavity extends to within 1.5 cm of\X0D\\X0A\the deep margin.  \X0D\\X0A\The axillary tail is dissected and reveals multiple lymph node candidates\X0D\\X0A\measuring up to 2.1 cm in greatest dimension.  \X0D\\X0A\Representative section of nipple is submitted in (block 2A). Representative\X0D\\X0A\sections of skin lesions are submitted in (block 2B). Representative sections of\X0D\\X0A\deep margin overlying biopsy cavity submitted in (block 2C).  Random sections of\X0D\\X0A\biopsy cavity are submitted in (blocks 2D through 2F). Representative section of\X0D\\X0A\fibrocystic disease is submitted in (block 2G). Random upper outer quadrant\X0D\\X0A\submitted in (block 2H). Random lower outer quadrant submitted in (block 2I). \X0D\\X0A\Random upper inner quadrant submitted in (block 2J). Random lower inner quadrant\X0D\\X0A\submitted in (block 2K).  Representative sections of lymph nodes are submitted\X0D\\X0A\in (blocks 2L and 2M).  \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\     1.     Sections of biopsy of left breast reveals, adjacent to the marker\X0D\\X0A\wire, an infiltrating ductal carcinoma of breast, grade 2.  The tumor\X0D\\X0A\demonstrates a dense desmoplastic stroma with tumor infiltrating the stroma in\X0D\\X0A\irregular solid nests, ribbons as well as moderate tubular formation.  Nuclei\X0D\\X0A\are moderately enlarged with most showing a distinct nucleolus and stippled to\X0D\\X0A\slightly vesicular chromatin pattern.  The tumor demonstrates an intermediate\X0D\\X0A\mitotic index with an average of 1 to 2 mitoses per high power field.  Multiple\X0D\\X0A\microcalcifications are observed associated with the tumor.  No definitive\X0D\\X0A\angiolymphatic invasion by tumor is observed.  Tumor focally abuts against the\X0D\\X0A\inked surgical margin of the biopsy specimen.  \X0D\\X0A\2.     Sections of nipple and areola of mastectomy specimen reveal an\X0D\\X0A\unremarkable nipple epidermis showing no evidence of Paget's disease or\X0D\\X0A\involvement by tumor.  Subareolar lactiferous ducts are also negative for tumor\X0D\\X0A\involvement.  Superficial dermal lymphatics demonstrate no evidence of tumor. \X0D\\X0A\Sections of overlying skin of the breast reveal no evidence of involvement of\X0D\\X0A\the epidermis with superficial dermal lymphatics by tumor.  A small seborrheic\X0D\\X0A\keratosis is noted.  Also present is an area demonstrating old healed dermal\X0D\\X0A\cicatrix.  Sections of the inked deep surgical margin below biopsy site reveals\X0D\\X0A\a minimum of 1.5 cm of uninvolved fatty breast parenchyma from the inked margin\X0D\\X0A\to the site of previous biopsy.  Sections of breast tissue surrounding the\X0D\\X0A\previous biopsy site reveal florid fibrocystic mastopathy including duct ectasia\X0D\\X0A\with stasis, cystic duct dilatation with apocrine metaplasia, sclerosing\X0D\\X0A\adenosis, blunt duct adenosis, and duct papillomatosis with focal apocrine\X0D\\X0A\change.  Multiple microcalcifications are identified associated with fibrocystic\X0D\\X0A\mastopathy.  A stellate scar is observed with surrounding complex sclerosing\X0D\\X0A\lesion. Adjacent areas of apocrine papillomatosis are identified.  Multiple\X0D\\X0A\microcalcifications are observed.  Multiple sections of all adjacent breast\X0D\\X0A\quadrants reveal no evidence of additional foci of malignancy.  Sections of\X0D\\X0A\seven axillary lymph nodes reveal benign lymph nodes showing no evidence of\X0D\\X0A\involvement by primary or metastatic malignancy. \X0D\\X0A\BHT/js",,,Procedures/Addenda\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Jun 25 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jul 1 2012]     By:  **NAME[WWW VVV]\X0D\\X0A\     Date Reported:     **DATE[Jul 1 2012]
REG1,BREAST,0,478753,1,,Clinical Diagnosis and History\X0D\\X0A\Left breast mass 3 o'clock position. 0.85 cm solid irregular mass.,"Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, Core Biopsy","Final Diagnosis\X0D\\X0A\Core biopsies, left breast:  \X0D\\X0A\     Infiltrating ductal carcinoma of the breast, grade 3 (approximately 0.8 cm\X0D\\X0A\in greatest extent) involving four (4) out of 5 (five) biopsy segments.  \X0D\\X0A\Comment:  Fresh tissue has been submitted for Mammaprint studies.  Results of\X0D\\X0A\these studies will be forwarded upon receipt from the reference laboratory. \X0D\\X0A\Estrogen and progesterone receptor analyses, as well as other prognostic\X0D\\X0A\indicator studies, will be performed on tissue from the paraffin block.  Results\X0D\\X0A\of these studies will be forwarded upon completion.  \X0D\\X0A\AJCC stage:   pTX pNX.  \X0D\\X0A\               1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[May 9 2012]     Status:  Ordered\X0D\\X0A\Clarient DNA     Date Ordered:     **DATE[May 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 13 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[May 22 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,"Gross Description\X0D\\X0A\Specimen #1 is received fresh in a Petri dish labeled with the patient's name\X0D\\X0A\and designated ""left breast"".  The specimen consists of five yellow-pink soft\X0D\\X0A\tissue core biopsies ranging from 0.6 cm in length to 2.9 cm in length and each\X0D\\X0A\measuring 0.4 cm in diameter.  The cores appear predominantly fatty with focal\X0D\\X0A\areas of pink-gray fibrous tissue measuring up to 0.8 cm in length.  This\X0D\\X0A\largest area of fibrous tissue is inked black.  A representative section from\X0D\\X0A\this area is submitted in transport media and held for Mammaprint studies as\X0D\\X0A\needed.  A radiograph does not accompany the specimen.  The cores are totally\X0D\\X0A\submitted in (blocks A and B).\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Step sections of the core biopsies from the left breast reveal infiltrating\X0D\\X0A\ductal carcinoma of the breast, high-grade, involving four out of five core\X0D\\X0A\biopsy segments.  The tumor is approximately 0.8 cm in greatest extent.  There\X0D\\X0A\is essentially no tubule formation.  The tumor consists predominantly of solid\X0D\\X0A\nests of cells which often coalesce.  The nuclei are enlarged and prominent\X0D\\X0A\nucleoli are seen.  Moderate to abundant amounts of amphophilic cytoplasm are\X0D\\X0A\present.  There is brisk mitotic activity with atypical mitotic figures\X0D\\X0A\observed. There is a prominent lymphocytic inflammatory response to the tumor.  \X0D\\X0A\**INITIALS",,,Procedures/Addenda\X0D\\X0A\Mammaprint     Date Ordered:     **DATE[May 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 20 2012]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[May 22 2012]
REG1,BREAST,0,479878,3,,"Clinical Diagnosis and History\X0D\\X0A\RIGHT BREAST CANCER\X0D\\X0A\OPER:   RIGHT LUMPECTOMY, SENTINEL NODE","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **PLACE F.\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: MEDIAL MARGIN RIGHT BREAST TISSUE REMOVED FROM PATIENT @ 13:45  PLACED IN\X0D\\X0A\FORMALIN @ 13:55. jl\X0D\\X0A\2: DEEP MARGIN RIGHT BREAST TISSUE REMOVED FROM PATIENT @ 13:45  PLACED IN\X0D\\X0A\FORMALIN @ 13:55. jl\X0D\\X0A\3: SUPERIOR MARGIN RIGHT BREAST TISSUE REMOVED FROM PATIENT @ 13:45  PLACED IN\X0D\\X0A\FORMALIN @ 13:55  STITCH MARKS TRUE MARGIN. jl\X0D\\X0A\4: RIGHT LUMPECTOMY - LONG = LATERAL  SHORT = SUPERIOR  DOUBLE = DEEP  REMOVED\X0D\\X0A\FROM PATIENT @ 13:42  PLACED IN FORMALIN @ 14:05. jl:\X0D\\X0A\5: #1 SENTINEL NODE RIGHT BREAST (NO FS DONE). REM 14:18; FMLN 14:20 jl\X0D\\X0A\6: #2 SENTINEL NODE RIGHT BREAST (NO FS DONE). REM 14:24; FMLN 14:26 jl\X0D\\X0A\7: #3 SENTINEL NODE RIGHT BREAST (NO FS DONE). REM 14:34, FMLN 14:35 jl","Final Diagnosis\X0D\\X0A\1:  ""MEDIAL MARGIN RIGHT BREAST"":\X0D\\X0A\     FOCAL NON-ATYPICAL DUCT HYPERPLASIA/COLUMNAR CELL CHANGE.\X0D\\X0A\     BACKGROUND OF FIBROCYSTIC CHANGES WITH SCLEROSING ADENOSIS, \X0D\\X0A\     DUCT ECTASIA.\X0D\\X0A\     DESIGNATED MARGIN  NO ATYPIA SEEN.\X0D\\X0A\2:  ""DEEP MARGIN RIGHT BREAST"":\X0D\\X0A\     BENIGN BREAST TISSUE.\X0D\\X0A\     DESIGNATED MARGIN  NO ATYPIA SEEN.\X0D\\X0A\3:  ""SUPERIOR MARGIN RIGHT BREAST"":\X0D\\X0A\     BENIGN BREAST TISSUE.\X0D\\X0A\     DESIGNATED MARGIN  NO ATYPIA SEEN.\X0D\\X0A\4:  ""RIGHT LUMPECTOMY"":\X0D\\X0A\     CAP TUMOR REPORTING PROTOCOL:\X0D\\X0A\     SPECIMEN: PARTIAL BREAST.\X0D\\X0A\     PROCEDURE:  LUMPECTOMY, WIRE-GUIDED.\X0D\\X0A\     LYMPH NODE SAMPLING: SENTINEL LYMPH NODES (SPECIMENS 5, 6 AND 7).\X0D\\X0A\     SPECIMEN INTEGRITY: \X0D\\X0A\          SPECIMEN SIZE: 5.9 x 5.4 x 3.3 CM.\X0D\\X0A\          SPECIMEN LATERALITY: RIGHT.\X0D\\X0A\     HISTOLOGIC TYPE:  INVASIVE DUCTAL CARCINOMA.\X0D\\X0A\     GRADE: I (WELL DIFFERENTIATED).\X0D\\X0A\     NOTTINGHAM HISTOLOGIC SCORE: 5 (TUBULES = 2; NUCLEI = 2; MITOSES = 1).\X0D\\X0A\     TUMOR SIZE:  INDETERMINATE; 0.5 CM RESIDUAL FOCUS OF TUMOR AS MEASURED\X0D\\X0A\     MICROSCOPICALLY ADJACENT TO A 2.0 x 1.0 x 0.9 CM BIOPSY SITE. CORRELATION\X0D\\X0A\WITH IMAGING STUDIES AND PRIOR BIOPSY SUGGESTED.\X0D\\X0A\     TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\     NIPPLE:  NOT PRESENT.\X0D\\X0A\     SKIN: UNINVOLVED.\X0D\\X0A\     DERMAL/LYMPH/VASCULAR INVASION:  NOT IDENTIFIED. \X0D\\X0A\     SKELETAL MUSCLE: NOT PRESENT.\X0D\\X0A\     DUCTAL CARCINOMA IN SITU:  PRESENT.\X0D\\X0A\          GRADE: LOW GRADE, CRIBRIFORM PATTERN.\X0D\\X0A\          NECROSIS:  NOT IDENTIFIED.\X0D\\X0A\          EXTENT:  MICROSCOPIC FOCI ADJACENT TO FOCUS OF INVASIVE TUMOR.\X0D\\X0A\     LOBULAR CARCINOMA IN SITU:  NOT IDENTIFIED. \X0D\\X0A\     LYMPHOVASCULAR INVASION:  NOT IDENTIFIED.\X0D\\X0A\     MARGINS:  UNINVOLVED.\X0D\\X0A\     DISTANCE OF INVASIVE TUMOR FROM CLOSEST MARGIN: 0.6 CM (SUPERIOR).\X0D\\X0A\     DISTANCE OF DCIS FROM CLOSEST MARGIN: 0.6 CM (SUPERIOR).\X0D\\X0A\     LYMPH NODES:\X0D\\X0A\          NUMBER OF SENTINEL LYMPH NODES EXAMINED: 3.\X0D\\X0A\          TOTAL NUMBER OF LYMPH NODES: 3.\X0D\\X0A\          NUMBER OF LYMPH NODES INVOLVED: 0.\X0D\\X0A\     ANCILLARY STUDIES:  HORMONE RECEPTORS AND HER2-neu APPARENTLY REPORTED\X0D\\X0A\     **INSTITUTION, ***PATH-NUMBER[1].\X0D\\X0A\     ADDITIONAL PATHOLOGIC FINDINGS:  BIOPSY SITE CHANGES. FOCAL NON-ATYPICAL\X0D\\X0A\     DUCT HYPERPLASIA.  BACKGROUND OF FIBROCYSTIC CHANGES WITH\X0D\\X0A\SCLEROSING ADENOSIS, APOCRINE METAPLASIA, DUCT ECTASIA.\X0D\\X0A\5:  ""#1 SENTINEL NODE RIGHT BREAST"":\X0D\\X0A\     LYMPH NODE  MULTIPLE STEP SECTIONS: NO METASTATIC CARCINOMA SEEN.\X0D\\X0A\6:  ""#2 SENTINEL NODE RIGHT BREAST"":\X0D\\X0A\     LYMPH NODE  MULTIPLE STEP SECTIONS: NO METASTATIC CARCINOMA SEEN.\X0D\\X0A\7:  ""#3 SENTINEL NODE RIGHT BREAST"":\X0D\\X0A\     LYMPH NODE  MULTIPLE STEP SECTIONS: NO METASTATIC CARCINOMA SEEN.\X0D\\X0A\**INITIALS IHC/a/CLS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **NAME[XXX]",,"Gross Description\X0D\\X0A\1: In formalin labeled ""medial margin right breast tissue"" is a flattened\X0D\\X0A\fragment of yellow fatty tissue 3.9 x 2.5 cm ranging to 0.8 cm in thickness.  A\X0D\\X0A\suture is present designated true margin.  This aspect is marked with black ink.\X0D\\X0A\ Sectioning reveals unremarkable lobulated yellow fatty tissue.  Divided and\X0D\\X0A\totally submitted in blocks 1A and B.\X0D\\X0A\2: In formalin labeled ""deep margin breast tissue, stitch marks true margin"" is\X0D\\X0A\a 3.0 x 2.0 x 1.3 cm lobulated fragment of yellow fatty tissue with a stitch on\X0D\\X0A\one surface.  This aspect is marked with black ink.  Sectioning reveals\X0D\\X0A\unremarkable lobulated yellow fatty tissue.  Divided and submitted in blocks 2A\X0D\\X0A\and B.\X0D\\X0A\3: In formalin labeled ""superior margin breast tissue, stitch marks true margin""\X0D\\X0A\is an angulated fragment of yellow fatty tissue 3.0 x 2.0 cm ranging to 0.8 cm\X0D\\X0A\in thickness.  A stitch is present on one surface.  This is marked with black\X0D\\X0A\ink.  Sectioning reveals unremarkable lobulated yellow fatty tissue.  Divided\X0D\\X0A\and totally submitted in blocks 3A and B.  **INITIALS\X0D\\X0A\4: Received in formalin labeled ""right lumpectomy, long lateral, short superior,\X0D\\X0A\double deep"" is a 45 gram oriented lumpectomy specimen pierced by metallic\X0D\\X0A\guidewire and having a 2.2 x 0.7 x 0.2 cm ellipse of skin on the mid superficial\X0D\\X0A\surface.  The guidewire enters the specimen through the ellipse of skin.  The\X0D\\X0A\specimen is 5.9 cm from superficial to deep, 5.4 cm from medial to lateral and\X0D\\X0A\3.3 cm from superior to inferior.  The lateral border is inked yellow.  The\X0D\\X0A\superior half of the specimen is inked blue and the inferior half is inked\X0D\\X0A\black.  The medial superficial and deep margins are represented by the junction\X0D\\X0A\of blue and black ink.  An accompanying specimen radiograph shows a highlighted\X0D\\X0A\density along the path of the guidewire with a clip within.  The specimen is\X0D\\X0A\serial sectioned in the medial/lateral axis from superficial to deep.  This\X0D\\X0A\reveals a paracentral hemorrhagic biopsy site located 1.7 cm below the\X0D\\X0A\superficial margin.  This region is 2.0 x 1.0 x 0.9 cm in overall dimension. \X0D\\X0A\The lesional area is 0.6 cm from the mid superior margin, 1.0 cm from the mid\X0D\\X0A\inferior margin, 1.8 cm from the medial margin, 2.0 cm from the lateral margin\X0D\\X0A\and 2 cm from the deep margin.  The remainder of the specimen is grossly fatty. \X0D\\X0A\Sections are submitted as follows:\X0D\\X0A\4A through 4E  entire lesional area superficial to deep and relationship to\X0D\\X0A\superior and inferior margins\X0D\\X0A\4F through 4H  lateral margin closest to lesion\X0D\\X0A\4I through 4K  medial margin closest to lesion\X0D\\X0A\4L  superficial margin\X0D\\X0A\4M  deep margin\X0D\\X0A\4N  representative section superficial to lesion\X0D\\X0A\4O  representative section deep to lesion\X0D\\X0A\Note: The specimen is removed from the patient at 13:42 hours, **DATE[Jan 17 12], and\X0D\\X0A\initially placed into formalin at 14:05 hours, **DATE[Jan 17 12].  The specimen is\X0D\\X0A\described, sectioned and resubmitted into formalin at 16:08, **DATE[Jan 17 12].\X0D\\X0A\**INITIALS\X0D\\X0A\5:  In formalin labeled ""sentinel node #1 right breast"" is a partially\X0D\\X0A\fat-replaced tan apparent lymph node, 1.7 x 1.3 x 1.0 cm, which is divided and\X0D\\X0A\totally submitted in blocks 5A and B.\X0D\\X0A\6:  In formalin labeled ""sentinel node #2 right breast"" is a 1.7 x 1.5 x 1.4 cm\X0D\\X0A\ovoid fragment of yellow fatty tissue with a slight nodular configuration, which\X0D\\X0A\is divided and totally submitted in block 6A.\X0D\\X0A\7:  In formalin labeled ""sentinel node #3 right breast"" is a 1.7 x 1.5 x 1.6 cm\X0D\\X0A\vaguely nodular portion of yellow fatty tissue which is divided and totally\X0D\\X0A\submitted in block 7A.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,BREAST,0,479880,1,,"Clinical Diagnosis and History\X0D\\X0A\RIGHT BREAST CANCER\X0D\\X0A\OPER:   RIGHT BREAST LUMPECTOMY WITH MAMMO NEEDLE LOC, SENT. NODE BX\X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\FS#1: NO TUMOR IDENTIFIED.  MER/jsh **DATE[Jan 26 12]","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RIGHT AXILLARY SENTINEL NODE (FROZEN SECTION)   tb\X0D\\X0A\2: RIGHT BREAST LUMPECTOMY; CAN GO IN FORMALIN  AFTER MAMMO, AND DOES NOT NEED\X0D\\X0A\TO COME BACK TO OR.  REMOVED 15:30, IN FORMALIN @ 15:40, NOT FOR\X0D\\X0A\CALCIFICATIONS/bi\X0D\\X0A\3: RIGHT BREAST LUMPECTOMY MARGIN, REMOVED 15:35, FORMALIN @ 15:40/bi","Final Diagnosis\X0D\\X0A\1. SENTINEL LYMPH NODE #1, RIGHT AXILLA, EXCISIONAL SPECIMEN (ONE NODE):\X0D\\X0A\     NO TUMOR IDENTIFIED WITH STEP SECTIONS AND ROUTINE STAINS.\X0D\\X0A\     KERATIN STAINS AVAILABLE IF REQUESTED.\X0D\\X0A\MER/ap \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\Received in the fresh state designated ""right axillary sentinel node"" is a 2.2 x\X0D\\X0A\1.7 x 0.7 cm piece of lobulated gray and tan fibrofatty tissue which on\X0D\\X0A\sectioning contains a single possible lymph node 0.7 cm in greatest dimension. \X0D\\X0A\Serially sectioned in the short axis and completely submitted for frozen section\X0D\\X0A\and then as frozen section control labeled 1AFSC.  MER/jsh",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 27 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 27 2012]     By:  **NAME[YYY,XXX]\X0D\\X0A\     Date Reported:     **DATE[Jan 29 2012]         \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\2: PARTIAL BREAST:\X0D\\X0A\     PROCEDURE: EXCISION, WIRE GUIDED.\X0D\\X0A\     LYMPH NODE SAMPLING: ONE BENIGN SENTINEL LYMPH NODE (SPECIMEN 1).\X0D\\X0A\     SPECIMEN INTEGRITY: MULTIPLE DESIGNATED SPECIMENS.\X0D\\X0A\     SPECIMEN SIZE: MAIN LUMPECTOMY (SPECIMEN 2) MEASURES 4.5 X 4.0 X 3.5 CM.\X0D\\X0A\     SPECIMEN LATERALITY: RIGHT.\X0D\\X0A\     TUMOR SIZE: INVASIVE CARCINOMA PRESENT ON SLIDES FROM TWO BLOCKS\X0D\\X0A\         ADJACENT TO BIOPSY SITE WITH LARGER FOCUS MEASURING 8 MM AND\X0D\\X0A\        SMALLER FOCUS MEASURING 2 MM ON A SLIDE.\X0D\\X0A\     TUMOR FOCALITY; SINGLE FOCUS OF INVASIVE CARCINOMA.\X0D\\X0A\     MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR:\X0D\\X0A\          SKIN: SKIN IS NOT PRESENT.\X0D\\X0A\          SKELETAL MUSCLE: NO SKELETAL MUSCLE IDENTIFIED.\X0D\\X0A\     DUCT CARCINOMA IN-SITU: DUCT CARCINOMA IN-SITU IS FOCALLY PRESENT, \X0D\\X0A\         LOW TO NUCLEAR GRADE WITH ABSENCE OF NECROSIS.\X0D\\X0A\     LOBULAR CARCINOMA IN-SITU: NOT IDENTIFIED.\X0D\\X0A\     HISTOLOGIC TYPE OF INVASIVE CARCINOMA: INVASIVE MUCINOUS CARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE (NOTTINGHAM SCORE): \X0D\\X0A\          GLANDULAR DIFFERENTIATION: SCORE 3.\X0D\\X0A\          NUCLEAR PLEOMORPHISM: SCORE 1.\X0D\\X0A\          MITOTIC COUNT: SCORE 1.\X0D\\X0A\          OVERALL GRADE: GRADE 1 (SCORE 5).\X0D\\X0A\     MARGINS:  INVASIVE CARCINOMA IS LESS THAN 0.5 MM FROM MARGIN OF SPECIMEN 2\X0D\\X0A\         AND CARCINOMA IN-SITU IS 2 MM FROM MARGIN IN SPECIMEN 2.\X0D\\X0A\     ADDITIONAL MARGIN (SPECIMEN 3): FREE OF IN-SITU AND INVASIVE CARCINOMA.\X0D\\X0A\     LYMPH/VASCULAR INVASION: NOT IDENTIFIED.\X0D\\X0A\     LYMPH NODES: ONE BENIGN SENTINEL LYMPH NODE ONLY (SPECIMEN 1).\X0D\\X0A\     PATHOLOGIC STAGING:\X0D\\X0A\          PRIMARY TUMOR: Tx (MAXIMUM DIMENSION OF TUMOR ON A SINGLE SLIDE IS\X0D\\X0A\                  8 MM, HOWEVER, DUE TO THE SMALL SIZE OF TUMOR I FEEL THE\X0D\\X0A\MAXIMUM\X0D\\X0A\              DIMENSION OF TUMOR MAY BE BEST OBTAINED FROM CLINICAL AND\X0D\\X0A\              RADIOGRAPHIC DATA).\X0D\\X0A\          REGIONAL LYMPH NODES: N0\X0D\\X0A\          DISTANT METASTASIS: NOT APPLICABLE. \X0D\\X0A\     ANCILLARY STUDIES: \X0D\\X0A\          ESTROGEN RECEPTOR: PRESUMABLY PERFORMED ON ELSEWHERE ON PRIOR\X0D\\X0A\               BIOPSY MATERIAL).\X0D\\X0A\          PROGESTERONE RECEPTOR: PRESUMABLY PERFORMED ON ELSEWHERE ON\X0D\\X0A\              PRIOR BIOPSY MATERIAL).\X0D\\X0A\          HER-2/NEU: PRESUMABLE PERFORMED ON ELSEWHERE ON PRIOR BIOPSY\X0D\\X0A\               MATERIAL).\X0D\\X0A\COMMENT: It is not known whether hormone receptor and HER-2/neu studies have\X0D\\X0A\been performed on prior biopsy material.  If those studies are desired on the\X0D\\X0A\current specimen, please contact the laboratory. \X0D\\X0A\**INITIALS\X0D\\X0A\IHC/MER\X0D\\X0A\Addendum Comment\X0D\\X0A\GROSS DESCRIPTION, continued:\X0D\\X0A\2:  Received fresh on a grid, labeled ""right breast lumpectomy obtained from the\X0D\\X0A\patient at 15:30 and placed in formalin at 15:55 on **DATE[Jan 26 12]"" is a yellow white\X0D\\X0A\indurated unoriented 4.5 x 4.0 x 3.5 cm portion of fibrofatty breast tissue. \X0D\\X0A\There is no attached skin.  There is an inserted localizing wire including tip. \X0D\\X0A\The specimen margins are inked in blue.  Also received is a specimen radiograph\X0D\\X0A\of the circled area of concern which includes an inserted marker clips near the\X0D\\X0A\hook of the wire.  On sectioning, situated within the area of concern, is a 1.3\X0D\\X0A\x 1.0 x 0.5 cm firm yellow and focally hemorrhagic region.  There is also a\X0D\\X0A\small amount of surrounding indurated white fibrous areas.  This area of\X0D\\X0A\induration extends to within less than 1 mm of the inked margins.  The entire\X0D\\X0A\area of concern, to include the surrounding inked resection margins, is\X0D\\X0A\submitted in blocks 2A through 2I.  The remaining specimen consists of soft\X0D\\X0A\yellow fat with a small amount of scattered fibrous tissue.  The remainder of\X0D\\X0A\the tissue, which is not situated at the area of concern, is submitted in blocks\X0D\\X0A\2J through 2M.  The entire specimen has been submitted.  The specimen is\X0D\\X0A\sectioned and placed in cassettes in formalin at 10:10 hours on **DATE[Jan 27 12].  \X0D\\X0A\3:  Received in formalin labeled ""right breast lumpectomy margins"" are two\X0D\\X0A\unoriented fragments of yellow red fibrofatty breast tissue, obtained from the\X0D\\X0A\patient at 15:35 and placed in formalin at 15:40 on **DATE[Jan 26 12].  Fragments measure\X0D\\X0A\2.5 x 2.0 x 1.5 cm and 4.0 x 2.5 x 1.9 cm.  One of the surfaces on each fragment\X0D\\X0A\is more convex and yellow and presumed to represent the outermost margin.  The\X0D\\X0A\surface on each fragment will be inked in blue.  The opposite side of each\X0D\\X0A\fragment is more roughened, flat, and hemorrhagic, presumed to represent the\X0D\\X0A\margin nearest to the previous excision.  This surface will be inked in yellow. \X0D\\X0A\Each fragment is then serially sectioned and the cut surface consists of areas\X0D\\X0A\of firm, white fibrous tissue and soft and yellow adipose tissue.  No discrete\X0D\\X0A\suspicious nodule or mass is identified.  The entire smaller fragment is\X0D\\X0A\submitted in blocks 3A and 3B and the entire larger fragment submitted in blocks\X0D\\X0A\3C through 3F.  DH/USO/MER/ap \X0D\\X0A\PREOP DIAGNOSIS AND HISTORY:  RIGHT BREAST CANCER\X0D\\X0A\OPER:  RIGHT BREAST LUMPECTOMY WITH MAMMO NEEDLE LOC SENT NODE BIOPSY \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **PLACE"
REG1,BREAST,0,479905,3,,Clinical Diagnosis and History\X0D\\X0A\BREAST CA LEFT\X0D\\X0A\OPER:  B.L. MASTECTOMY WITH LEFT SENTINEL NODES\X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX:  METASTATIC CARCINOMA TO 1 OF 2 LYMPH NODES. CLS/in  Reported at 10:29\X0D\\X0A\am\X0D\\X0A\#2FSDX:  2 SEPARATE BENIGN LYMPH NODES.  CLS/in  Reported at 10:29 am,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT  SENTINEL NODE -FRESH FOR FS  REMOVED @09:55  rd\X0D\\X0A\2: LEFT SENTINEL NODE -FRESH FOR FS  -REMOVED @09:55  rd\X0D\\X0A\3: LEFT BREAST  -REMOVED @10:45 ,IN FIRMALIN @10:46  rd\X0D\\X0A\4: RIGHT BREAST  -REMOVED @10:33 , IN FORMALIN @10:34   rd","Final Diagnosis\X0D\\X0A\1: LEFT SENTINEL LYMPH NODES:\X0D\\X0A\     MICROMETASTATIC CARCINOMA TO ONE OF TWO LYMPH NODES.\X0D\\X0A\     MICROMETASTATIC FOCUS MEASURES 0.1 CM. \X0D\\X0A\     NO EXTRANODAL EXTENSION IDENTIFIED.\X0D\\X0A\2: LEFT SENTINEL LYMPH NODES:\X0D\\X0A\     TWO BENIGN LYMPH NODES, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\     FOLLOWING THE SENTINEL LYMPH NODE PROTOCOL, ADDITIONAL H\E\T\E\E RECUTS ARE\X0D\\X0A\NEGATIVE\X0D\\X0A\          FOR MALIGNANCY.\X0D\\X0A\3: LEFT BREAST, MASTECTOMY WITH LOW AXILLARY LYMPH NODE:\X0D\\X0A\     TUMOR #1 UPPER INNER QUADRANT:\X0D\\X0A\     TUMOR HISTOLOGIC TYPE: INVASIVE DUCTAL CARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: WELL DIFFERENTIATED/GRADE I OUT OF III (NOTTINGHAM SCORE \X0D\\X0A\TUBULE\X0D\\X0A\          FORMATION 2/3, NUCLEAR PLEOMORPHISM 2/3, MITOTIC ACTIVITY 1/3; TOTAL\X0D\\X0A\SCORE 5/9).\X0D\\X0A\     IN SITU COMPONENT: INTERMEDIATE NUCLEAR GRADE DUCTAL CARCINOMA IN SITU\X0D\\X0A\WITHOUT\X0D\\X0A\          CENTRAL NECROSIS, SOLID AND CRIBRIFORM PATTERNS, EXTENDS BEYOND THE \X0D\\X0A\          INVASIVE COMPONENT.\X0D\\X0A\     INVASIVE TUMOR SIZE: 0.5 CM (SEE COMMENT).\X0D\\X0A\     NIPPLE: NEGATIVE PAGET's DISEASE.\X0D\\X0A\     LYMPH/VASCULAR SPACE INVASION: NOT IDENTIFIED.\X0D\\X0A\     MARGIN STATUS: WIDELY NEGATIVE FOR MALIGNANCY (CLOSEST DEEP MARGIN\X0D\\X0A\          MEASURES 2.5 CM).\X0D\\X0A\     TUMOR #2 LOWER INNER QUADRANT:\X0D\\X0A\     TUMOR TYPE: INVASIVE DUCTAL CARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: MODERATELY DIFFERENTIATED/GRADE II OUT OF III (NOTTINGHAM\X0D\\X0A\SCORE  \X0D\\X0A\          TUBULE FORMATION 3/3, NUCLEAR PLEOMORPHISM 2/3, MITOTIC ACTIVITY 1/3; \X0D\\X0A\          TOTAL SCORE 6/9).\X0D\\X0A\     IN SITU COMPONENT: INTERMEDIATE NUCLEAR GRADE DUCTAL CARCINOMA IN SITU\X0D\\X0A\WITHOUT\X0D\\X0A\          CENTRAL NECROSIS, CRIBRIFORM PATTERN, EXTENDS BEYOND THE INVASIVE\X0D\\X0A\          COMPONENT.\X0D\\X0A\     INVASIVE TUMOR SIZE: 0.3 CM (SEE COMMENT).\X0D\\X0A\     LYMPH/VASCULAR SPACE INVASION: NOT IDENTIFIED.\X0D\\X0A\     MARGIN STATUS: WIDELY NEGATIVE FOR MALIGNANCY (CLOSEST SUPERFICIAL/INFERIOR\X0D\\X0A\SOFT\X0D\\X0A\          TISSUE MARGIN MEASURES 1.5 CM).\X0D\\X0A\     LOW AXILLARY LYMPH NODE: SINGLE BENIGN LOW AXILLARY LYMPH NODE.\X0D\\X0A\     OTHER FINDINGS: CHANGES ASSOCIATED WITH PRIOR BIOPSY SITES X2; HEMANGIOMA\X0D\\X0A\OF SKIN.\X0D\\X0A\     ESTROGEN AND PROGESTERONE RECEPTORS, HER/2-NEU: SEE PRIOR BIOPSY RESULTS \X0D\\X0A\          (***PATH-NUMBER[1], ***PATH-NUMBER[2]).\X0D\\X0A\4: RIGHT BREAST, SIMPLE MASTECTOMY:\X0D\\X0A\     TUMOR TYPE: INTERMEDIATE NUCLEAR GRADE DUCTAL CARCINOMA IN SITU WITHOUT\X0D\\X0A\CENTRAL\X0D\\X0A\          NECROSIS, SOLID PATTERN; NEGATIVE FOR INVASIVE MALIGNANCY.\X0D\\X0A\     TUMOR SIZE: SINGLE MICROSCOPIC FOCUS MEASURING 0.3 CM.\X0D\\X0A\     MARGIN STATUS: NEGATIVE FOR MALIGNANCY.\X0D\\X0A\     OTHER FINDINGS: SKIN WITH SEVERAL SEBORRHEIC KERATOSES.\X0D\\X0A\COMMENT: The sizes of these two invasive tumors identified in the left breast\X0D\\X0A\are difficult to determine with absolute certainty due to disruption from the\X0D\\X0A\prior biopsies:  Final staging must be performed by the oncologist/surgeon in\X0D\\X0A\correlation with all pathologic, imaging, surgical and clinical information. \X0D\\X0A\See microscopic section below for summary of CAP Tumor Reporting protocol.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\1:  Received fresh designated 'left sentinel lymph node' is fat containing two\X0D\\X0A\nodules consistent with lymph nodes measuring 2.5 x 2.0 x 1.2 cm and 2.6 x 2.0 x\X0D\\X0A\1.2 cm.  Each nodule is sectioned through the short axis and frozen in separate\X0D\\X0A\blocks with controls submitted as FSC1A and FSC1B.  CLS/in\X0D\\X0A\2:  Received fresh designated ""left sentinel node"" is fat containing two\X0D\\X0A\separate nodules consistent with lymph nodes, measuring 1.0 x 1.0 x 0.6 cm, and\X0D\\X0A\3.0 x 2.5 x 1.4 cm.  The smaller nodule is sectioned and entirely frozen in one\X0D\\X0A\block with control submitted as FSC2A.  The remaining nodule is sectioned and\X0D\\X0A\frozen in two blocks with controls submitted as FSC2B, and 2C.   **INITIALS\X0D\\X0A\3:  Received in formalin labeled 'left breast is a 755 gram unoriented left\X0D\\X0A\simple mastectomy specimen having a small amount of contiguous axillary fat. \X0D\\X0A\The axillary fat is utilized to orient the specimen.  The specimen is 21.1 cm\X0D\\X0A\from medial to lateral, 18.4 cm from superior to inferior and 5.4 cm from\X0D\\X0A\anterior to posterior.  The anterior surface is partially covered by 22.1 x 9.3\X0D\\X0A\cm ellipse of white tan skin which includes a 3.9 cm pale areola and a 1.0 x 1.0\X0D\\X0A\x 0.5 cm nipple.  The nipple and areola are partially discolored by a blue dye. \X0D\\X0A\8.8 cm lateral and slightly superior to the nipple there is a 0.3 x 0.3 x 0.3 cm\X0D\\X0A\purple red skin lesion.  3.3 cm superior to the nipple in the midline there is a\X0D\\X0A\0.2 cm hyperemic area which may be a site of previous mammotome biopsy entry. \X0D\\X0A\The skin is otherwise unremarkable.  The superior inferior soft tissue margins\X0D\\X0A\are composed of lobulated fatty tissue.  The deep margin is partially covered by\X0D\\X0A\fascia and shows no apparent skeletal muscle.  The superior soft tissue margin\X0D\\X0A\is inked blue the inferior soft tissue margin is inked yellow and the deep soft\X0D\\X0A\tissue margin is inked black.  The specimen is serially sectioned.  Two separate\X0D\\X0A\areas of previous biopsy are identified.  Within the medial inferior aspect of\X0D\\X0A\the upper inner quadrant there is a 1.0 cm in greatest dimension surgigel filled\X0D\\X0A\biopsy site having a metal clip within.  The adjacent tissue is mildly indurated\X0D\\X0A\but there is no grossly apparent residual tumor.  This biopsy site is 2.5 cm\X0D\\X0A\from the deep margin which is the closest margin.  Within the inferior medial\X0D\\X0A\aspect of the lower inner quadrant there is a 1.0 cm in greatest dimension\X0D\\X0A\surgigel filled biopsy site having an adjacent 1.0 x 0.8 x 0.7 cm area of\X0D\\X0A\induration.  This biopsy site is 1.5 cm from the inferior soft tissue margin\X0D\\X0A\which is the closest margin.  Although the tissue adjacent to the biopsy site is\X0D\\X0A\indurated there is no grossly apparent residual tumor.  The remainder of the\X0D\\X0A\breast is composed primarily of fat with focal strands of white fibrous-like. \X0D\\X0A\Thorough examination of the tissues at what appears to be the upper outer\X0D\\X0A\quadrant reveals a solitary 1 cm lymph node candidate.  This is the only\X0D\\X0A\apparent lymph node with the specimen.  Detached but within the same container\X0D\\X0A\are four pieces of skin and unremarkable fatty tissue ranging from 6.1  11.7 cm\X0D\\X0A\in greatest dimension.  These weigh an additional 41 grams.  Sections are\X0D\\X0A\submitted as follows:\X0D\\X0A\3A  nipple and areola\X0D\\X0A\3B  skin lesion\X0D\\X0A\3C  punctate area superior to nipple\X0D\\X0A\3D through 3G  upper inner quadrant biopsy site with metal marker removed from\X0D\\X0A\block 3D\X0D\\X0A\3H  deep margin closest to upper inner quadrant biopsy site\X0D\\X0A\3I, J  tissue between upper inner quadrant and lower inner quadrant biopsy sites\X0D\\X0A\3K through 3P  lower inner quadrant biopsy site and adjacent indurated tissue\X0D\\X0A\3Q  inferior soft tissue margin closest to lower inner quadrant biopsy site\X0D\\X0A\3R  representative section upper inner quadrant 2 cm from upper inner quadrant\X0D\\X0A\biopsy site\X0D\\X0A\3S  representative section lower inner quadrant 1 cm medial to lower inner\X0D\\X0A\quadrant biopsy site\X0D\\X0A\3T  representative section upper outer quadrant\X0D\\X0A\3U  representative section lower outer quadrant\X0D\\X0A\3V  serially sectioned axillary lymph node candidate\X0D\\X0A\The specimen was removed from the patient at 10:45 hr **DATE[Mar 9 12] and initially\X0D\\X0A\placed into formalin at 10:46 hrs 9/9 11.  The specimen is described sectioned\X0D\\X0A\and resubmitted into formalin at 12:59 hr **DATE[Mar 9 12]. LW/USO/CLS/in \X0D\\X0A\4:  Received in formalin labeled ""right breast"" is a 21.1 x 18.3 x 5.3 cm,\X0D\\X0A\736-gram unoriented simple mastectomy specimen.  The anterior surface is\X0D\\X0A\partially covered by a 21 x 11.5 cm ellipse of white tan skin which includes a\X0D\\X0A\4.0 cm in greatest dimension pale areola with a central 1.0 x 1.0 x 0.7 cm\X0D\\X0A\nipple.  The skin shows a few purple red to waxy tan skin lesions ranging from\X0D\\X0A\0.2 to 0.8 cm in greatest dimension.  Several of the skin lesions come to within\X0D\\X0A\0.4 cm of the skin margins. The exposed superficial soft tissue margins are\X0D\\X0A\composed of lobulated fatty tissue.  The deep margin is covered by fascia and\X0D\\X0A\shows a few thin and delicate strands of skeletal muscle.  The superficial\X0D\\X0A\margins are inked blue and the deep margin is inked black.  The specimen is then\X0D\\X0A\serially sectioned.  This shows predominantly fat with areas of white mammary\X0D\\X0A\tissue scattered within, primarily in the central portion of the breast.  No\X0D\\X0A\lesions are seen.  No lymph nodes are included with the specimen.  Sections are\X0D\\X0A\submitted as follows:\X0D\\X0A\4A:  Nipple and areola.\X0D\\X0A\4B, 4C:  Representative skin lesions and relationship to closest skin margin.\X0D\\X0A\4D through 4K:  Two random sections from each quadrant.\X0D\\X0A\4L:  Random section, central deep margin.\X0D\\X0A\The specimen was removed from the patient at 10:33 hours, **DATE[Mar 9 12], and initially\X0D\\X0A\placed into formalin at 10:34 hours, **DATE[Mar 9 12].  The specimen is described,\X0D\\X0A\sectioned and resubmitted into formalin at 14:02 hours, **DATE[Mar 9 12].   **INITIALS\X0D\\X0A\On **DATE[Mar 10 12], additional random sections of breast parenchyma are submitted in six\X0D\\X0A\blocks.\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Incorporated in diagnosis.\X0D\\X0A\SUMMARY OF CAP TUMOR REPORTING PROTOCOL:\X0D\\X0A\Specimen: Left breast.\X0D\\X0A\Procedure: Mastectomy.\X0D\\X0A\Lymph Node Sampling: Sentinel lymph nodes and single low axillary lymph node in\X0D\\X0A\mastectomy.\X0D\\X0A\Specimen Integrity: Intact mastectomy.\X0D\\X0A\Tumor Focality: Two separate invasive tumors.\X0D\\X0A\Macroscopic and Microscopic Extent of Tumor: \X0D\\X0A\     Skin:  Carcinoma does not invade into the dermis or epidermis of skin.\X0D\\X0A\     Nipple: DCIS does not involve the nipple.\X0D\\X0A\               Skeletal Muscle: No skeletal muscle is present.\X0D\\X0A\Tumor Histologic Type / Upper Inner Quadrant: Invasive ductal carcinoma.\X0D\\X0A\Histologic Grade: Well differentiated/Grade I out of III (Nottingham score -\X0D\\X0A\tubule formation 2/3, nuclear pleomorphism 2/3,          mitotic activity 1/3;\X0D\\X0A\total score 5/9).\X0D\\X0A\Ductal Carcinoma In Situ: Intermediate nuclear grade ductal carcinoma in situ\X0D\\X0A\without central necrosis, solid and cribriform \X0D\\X0A\     patterns, extends beyond the invasive component to involve the upper and\X0D\\X0A\lower inner quadrants.\X0D\\X0A\Size of Invasive Tumor: 0.5 cm (see Comment).\X0D\\X0A\Tumor Histologic Type / Lower Inner Quadrant: Invasive ductal carcinoma.\X0D\\X0A\Histologic Grade: Moderately differentiated/Grade II out of III (Nottingham\X0D\\X0A\score - tubule formation 3/3, nuclear pleomorphism 2/3,          mitotic\X0D\\X0A\activity 1/3; total score 6/9).\X0D\\X0A\Size of Invasive Tumor: 0.3 cm (see Comment).\X0D\\X0A\Lymph/Vascular Space Invasion: Not identified.\X0D\\X0A\Margin Status: Margins are widely negative for malignancy (closest deep and\X0D\\X0A\superficial inferior margins measure 2.5 and 1.5 cm\X0D\\X0A\     respectively).\X0D\\X0A\Number of Sentinel Lymph Nodes Examined: 4. \X0D\\X0A\Number of Non-sentinel Lymph Nodes Examined: 1. \X0D\\X0A\Number of Sentinel Lymph Nodes with Micrometastasis: 1.\X0D\\X0A\Number of Sentinel Lymph Nodes with Macrometastasis: 0.\X0D\\X0A\Size of Largest Metastatic Deposit (0.1 cm).\X0D\\X0A\Extranodal Extension: Not identified.\X0D\\X0A\Estrogen and Progesterone Receptors, and Her/2-neu: See prior biopsy results\X0D\\X0A\(***PATH-NUMBER[1], ***PATH-NUMBER[2]).\X0D\\X0A\AJCC Pathologic Tumor Stage: T1a N1mi Mx\X0D\\X0A\Specimen: Right breast.\X0D\\X0A\Procedure: Simple mastectomy.\X0D\\X0A\Lymph Node Sampling: No lymph nodes sampled.\X0D\\X0A\Specimen Integrity: Intact mastectomy.\X0D\\X0A\Tumor Site: Indeterminant.\X0D\\X0A\Tumor Size: Single microscopic focus identified in random section- 0.3 cm in\X0D\\X0A\diameter.\X0D\\X0A\Histologic Type: Intermediate nuclear grade ductal carcinoma in situ without\X0D\\X0A\central necrosis, solid pattern; negative for invasive malignancy.\X0D\\X0A\Margins: Margins are uninvolved by DCIS.\X0D\\X0A\Estrogen and Progesterone Receptors: Available upon request.\X0D\\X0A\AJCC Pathologic Tumor Stage: Tis (DCIS).\X0D\\X0A\Comment: The sizes of these invasive tumors identified in the left breast are\X0D\\X0A\difficult to determine with absolute certainty due to disrupt ion from the prior\X0D\\X0A\biopsies. Final staging must be performed by the oncologist/surgeon in\X0D\\X0A\correlation with all pathologic, imaging, surgical and clinical information.\X0D\\X0A\**INITIALS",,,
REG1,BREAST,0,479908,1,,"Clinical Diagnosis and History\X0D\\X0A\LEFT BREAST CANCER\X0D\\X0A\OPER:   LEFT BREAST LUMPECTOMY WITH MAMMO NEEDLE LOC, SENT NODE BIOPSY\X0D\\X0A\FROZEN SECTION\X0D\\X0A\NOT FOR CALCIFICATIONS \X0D\\X0A\6 BLOCKS FOR FROZEN\X0D\\X0A\DR. **NAME[ZZZ] OF POSSIBLE DELAY \X0D\\X0A\Intraoperative Consult\X0D\\X0A\FS#1: NO TUMOR IDENTIFIED.  MER/jsh **DATE[Dec 26 11]\X0D\\X0A\Reported directly by phone/intercom to Dr. **NAME[YYY] at 2:16 PM","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT AXILLARY SENTINEL NODE FOR FROZEN SECTION. jl\X0D\\X0A\2: LEFT BREAST LUMPECTOMY; CAN GO TO FORMALIN AFTER MAMMO.  NOT FOR\X0D\\X0A\CALCIFICATIONS  REMOVED FROM PATIENT @ 13:49. jl\X0D\\X0A\3: LEFT BREAST LUMPECTOMY MARGINS  tb","Final Diagnosis\X0D\\X0A\1:  SENTINEL LYMPH NODE #1, LEFT AXILLA, EXCISIONAL SPECIMEN (ONE NODE):\X0D\\X0A\     NO TUMOR IDENTIFIED WITH STEP SECTIONS AND ROUTINE STAINS.\X0D\\X0A\     KERATIN STAINS AVAILABLE IF REQUESTED.\X0D\\X0A\2: LEFT BREAST, LUMPECTOMY SPECIMEN:\X0D\\X0A\     INVASIVE DUCT CARCINOMA.\X0D\\X0A\     NOTTINGHAM HISTOLOGIC GRADE 2 (TUBULES=3,NUCLEAR PLEOMORPHISM=2,\X0D\\X0A\        MITOSES=1).\X0D\\X0A\     FOCAL ANGIOLYMPHATIC INVASION PRESENT.\X0D\\X0A\     MAXIMUM DIMENSION OF INVASIVE TUMOR (MEASURED ON A SLIDE)  1.4 CM.\X0D\\X0A\     ASSOCIATED IN-SITU DUCT CARCINOMA, MINOR COMPONENT, LOW TO \X0D\\X0A\        INTERMEDIATE NUCLEAR GRADE WITHOUT NECROSIS.\X0D\\X0A\     INVASIVE AND IN-SITU CARCINOMA EXTEND TO WITHIN 3 MM OF THE CLOSEST \X0D\\X0A\        RESECTION MARGIN.\X0D\\X0A\     NEGATIVE SKIN.\X0D\\X0A\3: LEFT BREAST, ""LUMPECTOMY MARGINS"", ADDITIONAL RESECTION SPECIMEN (THREE\X0D\\X0A\FRAGMENTS);\X0D\\X0A\     BENIGN FIBROFATTY TISSUE WITH ONLY RARE BREAST DUCTS AND LOBULES.\X0D\\X0A\MER/cb \X0D\\X0A\IHC/a/CMK\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\1: Received in the fresh state designated ""left axillary sentinel node"" is a 5.6\X0D\\X0A\x 2.5 x 1.2 cm piece of fibrofatty tissue which on section contains a possible\X0D\\X0A\lymph node with marked fatty infiltration 3.5 cm in greatest dimension. \X0D\\X0A\Serially sectioned in the short axis.  Completely submitted for frozen section\X0D\\X0A\and then as frozen section control in six cassettes labeled 1.  MER/jsh\X0D\\X0A\2:  Received fresh on a radiology grid board labeled ""left breast lumpectomy"" is\X0D\\X0A\an 8.3 x 7.3 x 2.4 cm partially flattened piece of mammary tissue and fat,\X0D\\X0A\pierced by a metallic guidewire.  The guidewire enters the specimen through the\X0D\\X0A\central portion of a 3.2 x 0.5 x 0.4 cm ellipse of white tan skin located at one\X0D\\X0A\edge of the specimen.  The portion of the specimen furthest from the skin is\X0D\\X0A\partially discolored by a blue dye.  An accompanying specimen radiograph shows a\X0D\\X0A\density with an adjacent highlighted clip within the region of the specimen\X0D\\X0A\discolored by the dye.  The surface of the specimen is inked black and the\X0D\\X0A\tissue is then serially sectioned.  This reveals a 1.2 x 1.0 x 1.0 cm stellate\X0D\\X0A\mass of firm and slightly gritty white tan tissue, having a 0.8 x 0.5 x 0.5 cm\X0D\\X0A\Surgigel-filled biopsy cavity immediately adjacent to it.  The metal marker seen\X0D\\X0A\on specimen radiograph is identified within this cavity.  The mass focally comes\X0D\\X0A\to within 0.4 cm of the closest surgical margin.  The breast away from the\X0D\\X0A\lesion is composed primarily of fat and shows no other focal lesions. \X0D\\X0A\Representative sections are submitted as follows: \X0D\\X0A\2A through 2E:  Entire lesion and adjacent biopsy cavity and relationship to\X0D\\X0A\closest surgical margins.\X0D\\X0A\2F, 2G:  Representative sections of parenchyma between lesion and skin.\X0D\\X0A\2H:  Perpendicular sections through margin and adjacent skin.\X0D\\X0A\2I:  Perpendicular sections through margin furthest from skin.\X0D\\X0A\2J:  Representative section between lesion and margin furthest from skin.\X0D\\X0A\The specimen was removed from the patient at 13:49 hours, **DATE[Dec 26 11].  It is\X0D\\X0A\described, sectioned and initially placed into formalin at 14:48 hours, **DATE[Dec 26 11].\X0D\\X0A\ LW/USO/MER/ap\X0D\\X0A\3:  Received in formalin labeled ""left breast lumpectomy margins"" are three\X0D\\X0A\irregular and unoriented pieces of grossly unremarkable-appearing fatty tissue. \X0D\\X0A\These are 3.0 x 2.5 x 1.0 cm, 3.7 x 3.0 x 1.3 cm, and 5.0 x 3.3 x 1.1 cm.  All\X0D\\X0A\three pieces are inked black and sectioned, showing no grossly apparent tumor. \X0D\\X0A\They are entirely submitted as follows:\X0D\\X0A\3A, 3B:  Smallest piece.\X0D\\X0A\3C through 3F:  Midsize piece.\X0D\\X0A\3G through 3K:  Largest piece.\X0D\\X0A\This specimen is removed from the patient at 13:51 hours, and initially placed\X0D\\X0A\into formalin at 13:56 hours.  The specimen is described, sectioned and\X0D\\X0A\resubmitted into formalin at 15:53 hours, **DATE[Dec 26 11].   LW/USO/MER/ap","Microscopic Description\X0D\\X0A\Incorporated in diagnosis.\X0D\\X0A\CAP REPORTING:\X0D\\X0A\Specimen: partial breast\X0D\\X0A\Procedure: excision with wire guided localization\X0D\\X0A\Lymph node sampling: sentinel lymph node\X0D\\X0A\Specimen integrity: single intact specimen (margins can be evaluated)\X0D\\X0A\Specimen size, greatest dimension: 8.3 cm\X0D\\X0A\Specimen laterality: left\X0D\\X0A\Tumor size, greatest dimension of invasive carcinoma: 1.4 cm (measured on the\X0D\\X0A\slide)\X0D\\X0A\Tumor focality: single focus of invasive carcinoma\X0D\\X0A\Skin: present and not involved\X0D\\X0A\Nipple: not identified\X0D\\X0A\Skeletal muscle: not identified\X0D\\X0A\Ductal carcinoma in situ: DCIS is present (minor component)\X0D\\X0A\Lobular carcinoma in situ: not identified\X0D\\X0A\Histologic type of invasive carcinoma: invasive ductal carcinoma, no special\X0D\\X0A\type\X0D\\X0A\Histologic grade: Nottingham Histologic grade (tubules = 3, nuclear pleomorphism\X0D\\X0A\= 2, mitoses = 1)\X0D\\X0A\Margins: margins uninvolved by invasive or in situ carcinoma\X0D\\X0A\Distance from closest margin: 3 mm\X0D\\X0A\Lymph nodes: number of sentinel lymph nodes examined: 1\X0D\\X0A\Total number of lymph nodes examined: 1 \X0D\\X0A\Number involved by metastatic carcinoma: 0 \X0D\\X0A\Pathologic staging:\X0D\\X0A\     Primary tumor: pT1c (at least, specimen previously biopsied)\X0D\\X0A\     Regional lymph nodes: (sn)N0\X0D\\X0A\     Distant metastasis: not applicable\X0D\\X0A\Ancillary studies: estrogen receptor, progesterone receptor, HER/2-neu and\X0D\\X0A\florescence in situ hybridization for HER/2-neu studies: not performed on\X0D\\X0A\current material, please see prior biopsy material, outside report, if available\X0D\\X0A\for testing and testing results.\X0D\\X0A\MER/pkm",,,
REG1,BREAST,0,479965,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT BREAST INVASIVE DUCT CARCINOMA \X0D\\X0A\OPER:  LEFT BREAST LUMPECTOMY WITH LEFT SENTINEL NODE BIOPSY \X0D\\X0A\FROZEN SECTION\X0D\\X0A\CALCIFICATIONS NOT INDICATED  \X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX:  BENIGN LYMPH NODE.  **INITIALS  (REPORTED AT 11:23AM)\X0D\\X0A\#2 INTRAOPERATIVE GROSS EVALUATION:  TUMOR AT BIOPSY SITE CLOSELY APPROACHES\X0D\\X0A\(1-2 MM) SUPERIOR/POSTERIOR MARGIN AS WELL AS INFERIOR MARGIN.  **INITIALS \X0D\\X0A\(REPORTED AT 11:15AM)\X0D\\X0A\#3FSDX:  BENIGN LYMPH NODE.  **INITIALS  (REPORTED AT 11:23AM),"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **PLACE F.\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT SENTINEL NODE BX FOR FROZEN SECTION. jl\X0D\\X0A\2: LEFT BREAST LUMPECTOMY REMOVED FROM PATIENT @ 10:43 - SINGLE SHORT = SUPERIOR\X0D\\X0A\ SINGLE LONG = LATERAL, SKIN = ANATERIOR FOR INTRA-OPERATIVE CONSULTATION -\X0D\\X0A\GROSS  CALCIFICATIONS NOT INDICATED. jl\X0D\\X0A\3: LEFT SENTINEL NODE BX FOR FROZEN SECTION. jl\X0D\\X0A\4: LEFT BREAST LUMPECTOMY NEW SUPERIOR/POSTERIOR MARGIN (SUTURE MARKS NEW\X0D\\X0A\MARGIN) REMOVED FROM PATIENT @ 11:20 PLACED IN FORMALIN @ 11:22. jl\X0D\\X0A\5: LEFT BREAST LUMPECTOMY NEW INFERIOR MARGIN SUTURE MARKS NEW MARGIN. REMOVED\X0D\\X0A\FROM PATIENT @ 11:24  PLACED IN FORMALIN @ 11:26. jl","Final Diagnosis\X0D\\X0A\1:  LEFT SENTINEL LYMPH NODE #1:\X0D\\X0A\     SINGLE BENIGN LYMPH NODE, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\     FOLLOWING THE SENTINEL LYMPH NODE PROTOCOL, ADDITIONAL H \E\T\E\ E RECUTS ARE\X0D\\X0A\          NEGATIVE FOR MALIGNANCY.\X0D\\X0A\2:  LEFT BREAST, LUMPECTOMY, NEEDLE LOCALIZATION PROCEDURE:\X0D\\X0A\     TUMOR HISTOLOGIC TYPE:  INVASIVE MAMMARY CARCINOMA, DUCTAL TYPE.\X0D\\X0A\     HISTOLOGIC GRADE:  POORLY DIFFERENTIATED/GRADE 3 OUT OF 3 \X0D\\X0A\          (NOTTINGHAM SCORE  TUBULE FORMATION 3/3, NUCLEAR PLEOMORPHISM 3/3, \X0D\\X0A\          MITOTIC ACTIVITY 3/3; TOTAL SCORE 9/9).\X0D\\X0A\     INVASIVE TUMOR SIZE:  1.5 CM (AS MEASURED ON A MICROSCOPIC SLIDE).\X0D\\X0A\     IN SITU COMPONENT:  RARE FOCUS OF HIGH NUCLEAR GRADE DUCTAL CARCINOMA IN\X0D\\X0A\SITU\X0D\\X0A\          WITHOUT CENTRAL NECROSIS, SOLID PATTERN, EXTENDS BEYOND THE \X0D\\X0A\          INVASIVE COMPONENT.\X0D\\X0A\     LYMPH/VASCULAR SPACE INVASION:  NOT IDENTIFIED. \X0D\\X0A\     MARGIN STATUS: \X0D\\X0A\          INVASIVE CARCINOMA MEASURES 0.1  0.2 CM FROM THE CLOSEST\X0D\\X0A\               SUPERIOR/POSTERIOR MARGIN OF EXCISION.\X0D\\X0A\          INVASIVE CARCINOMA MEASURES 1.3 CM FROM THE NEXT CLOSEST INFERIOR \X0D\\X0A\               MARGIN OF EXCISION.\X0D\\X0A\          REMAINING MARGINS ARE WIDELY NEGATIVE FOR MALIGNANCY.\X0D\\X0A\     ESTROGEN AND PROGESTERONE RECEPTORS, HER/2-neu:  AVAILABLE UPON REQUEST.\X0D\\X0A\3:  LEFT SENTINEL LYMPH NODE #2:\X0D\\X0A\     SINGLE BENIGN LYMPH NODE, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\     FOLLOWING THE SENTINEL LYMPH NODE PROTOCOL, ADDITIONAL H \E\T\E\ E RECUTS ARE\X0D\\X0A\          NEGATIVE FOR MALIGNANCY.\X0D\\X0A\4:  LEFT BREAST LUMPECTOMY, NEW SUPERIOR/POSTERIOR MARGIN:\X0D\\X0A\     BENIGN FAT AND SKELETAL MUSCLE, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\5:  LEFT BREAST LUMPECTOMY, NEW INFERIOR MARGIN:\X0D\\X0A\     BENIGN BREAST TISSUE DISPLAYING FIBROCYSTIC CHANGES, NEGATIVE FOR\X0D\\X0A\MALIGNANCY.\X0D\\X0A\COMMENT:  The size of tumor, and therefore T stage, is difficult to determine\X0D\\X0A\with absolute certainty due to disruption from the prior biopsy.  Final staging\X0D\\X0A\must be performed by the oncologist/surgeon in correlation with all pathologic,\X0D\\X0A\imaging, surgical and clinical information.  See microscopic section below for\X0D\\X0A\Summary CAP Tumor Reporting Protocol.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **NAME[XXX]",,"Gross Description\X0D\\X0A\1:  Received fresh for frozen section designated ""#1 left sentinel node biopsy""\X0D\\X0A\is a fatty nodule consistent with fatty lymph node measuring 3.0 x 1.5 x 1.0 cm.\X0D\\X0A\ Sectioned through the short axis and entirely frozen in one block with control\X0D\\X0A\submitted as FSC1A.  **INITIALS\X0D\\X0A\2: Received fresh on an Accugrid designated ""left breast lumpectomy (single\X0D\\X0A\short = superior, single long = lateral, skin = anterior) is an Accugrid with an\X0D\\X0A\overlying lumpectomy with sutures as designated measuring 11.0 cm in lateral\X0D\\X0A\dimension, 9.0 cm in anterior posterior dimension and 4.2 cm in superior\X0D\\X0A\inferior dimension.  The anterior surface is a tan skin ellipse measuring 6.5 x\X0D\\X0A\1.1 cm in cross dimensions.  Other than the purple ink markings, the skin\X0D\\X0A\surface is unremarkable.  The superior surface is inked blue and the inferior\X0D\\X0A\surface is inked black.  Sectioning adjacent to the short suture and superior\X0D\\X0A\margin reveals a poorly defined but palpable mass measuring 2.5 x 2.0 x 2.0 cm. \X0D\\X0A\Within the mass is a hemorrhagic area suggestive of prior biopsy site.  The\X0D\\X0A\palpable mass and biopsy site measures within millimeters of the superior\X0D\\X0A\posterior margin of excision and possibly within 5 mm of the inferior margin of\X0D\\X0A\excision.  The mass measures 3.5 cm from the anterior margin, 2.5 cm from the\X0D\\X0A\medial margin and 3.0 cm from the lateral margin.  No other discrete focal\X0D\\X0A\lesion is identified.  \X0D\\X0A\SUMMARY OF SECTIONS:\X0D\\X0A\2A-2C  tumor in closest proximity to superior posterior margin of excision\X0D\\X0A\2D-2H  tumor/biopsy site in closest proximity to inferior margin\X0D\\X0A\2I  additional breast tissue adjacent to biopsy site without margins\X0D\\X0A\2J  posterior margin \X0D\\X0A\2K  superior margin\X0D\\X0A\2L  anterior and lateral margins\X0D\\X0A\2M  medial margin\X0D\\X0A\The specimen was blocked in and placed in formalin at 1:47 p.m. on **DATE[Jan 14 12]. \X0D\\X0A\**INITIALS \X0D\\X0A\3:  Received in formalin designated ""#2 left sentinel node biopsy"" is fatty\X0D\\X0A\tissue containing a 1.3 x 1.0 x 0.8 cm nodule consistent with lymph node. \X0D\\X0A\Sectioned through the short axis and entirely frozen in one block with control\X0D\\X0A\submitted as FSC3A.  **INITIALS\X0D\\X0A\4: Received in formalin designated ""left breast lumpectomy new superior\X0D\\X0A\posterior margin"" is a portion of breast tissue measuring 9.0 x 4.5 x 2.3 cm.  A\X0D\\X0A\suture indicates the new margin which will be inked black.  Sectioning reveals\X0D\\X0A\fat only.  Alternating sections are submitted in blocks 4A-4G.\X0D\\X0A\5: Received in formalin designated ""left breast lumpectomy new inferior margin""\X0D\\X0A\is a portion of breast tissue measuring 7.0 x 5.0 x 2.5 cm.  A suture indicates\X0D\\X0A\the new margin which will be inked black.  Sectioning reveals fat and intermixed\X0D\\X0A\tan rubbery fibrous tissue.  No suspicious lesion is grossly identified. \X0D\\X0A\Alternating sections are submitted in block 5A-5H.  The specimens were blocked\X0D\\X0A\in and placed in formalin at 1:00 p.m. on **DATE[Jan 14 12].  **INITIALS","Microscopic Description\X0D\\X0A\Incorporated in diagnosis. \X0D\\X0A\SPECIMEN:  Left breast.\X0D\\X0A\PROCEDURE:  Lumpectomy, needle localization.\X0D\\X0A\LYMPH NODE SAMPLING:  Sentinel lymph nodes.\X0D\\X0A\SPECIMEN INTEGRITY:  Single intact specimen and additional separate margins (see\X0D\\X0A\specimens #4 and #5).\X0D\\X0A\SPECIMEN SIZE:  11.0 x 9.0 x 4.2 cm.\X0D\\X0A\SPECIMEN LATERALITY:  Left.\X0D\\X0A\TUMOR SIZE:  1.5 cm (see Comment).\X0D\\X0A\TUMOR FOCALITY:  Unifocal.\X0D\\X0A\MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR:\X0D\\X0A\     Skin: Invasive carcinoma does not invade into the dermis or epidermis.\X0D\\X0A\     Nipple:  Nipple not present.\X0D\\X0A\     Skeletal muscle:  No skeletal muscle present.\X0D\\X0A\DUCTAL CARCINOMA IN SITU:  High nuclear grade ductal carcinoma in situ without\X0D\\X0A\central necrosis, solid pattern, \X0D\\X0A\     extends beyond the invasive component.\X0D\\X0A\LOBULAR CARCINOMA IN SITU:  Not identified.\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive mammary carcinoma, ductal type.\X0D\\X0A\HISTOLOGIC GRADE:  Poorly differentiated/grade 3 out of 3 (Nottingham score \X0D\\X0A\tubule formation 3/3, nuclear pleomorphism 3/3,\X0D\\X0A\     mitotic activity 3/3; total score 9/9).\X0D\\X0A\MARGINS:  \X0D\\X0A\     Invasive carcinoma measures 0.1-0.2 cm from the closest superior/posterior\X0D\\X0A\margin of excision.\X0D\\X0A\     Invasive carcinoma measures 1.3 cm from the next closest inferior margin of\X0D\\X0A\excision.\X0D\\X0A\     Remaining margins are widely negative for malignancy. \X0D\\X0A\     Margins uninvolved by DCIS.\X0D\\X0A\     Also see separately submitted margins (specimens #4 and #5).\X0D\\X0A\NUMBER OF SENTINEL LYMPH NODES EXAMINED: 2.\X0D\\X0A\NUMBER OF NONSENTINEL LYMPH NODES EXAMINED: 0.\X0D\\X0A\NUMBER OF LYMPH NODES WITH METASTASIS: 0.\X0D\\X0A\ESTROGEN AND PROGESTERONE RECEPTORS, HER/2-neu:  Available upon request.\X0D\\X0A\AJCC PATHOLOGIC TUMOR STAGE:  T1cN0snMX.  \X0D\\X0A\COMMENT:The size of tumor, and therefore T stage, is difficult to determine with\X0D\\X0A\absolute certainty due to disruption from the prior biopsy.  Final staging must\X0D\\X0A\be performed by the oncologist/surgeon in correlation with all pathologic,\X0D\\X0A\imaging, surgical and clinical information.\X0D\\X0A\**INITIALS",,,
REG1,BREAST,0,481629,1,,"CLINICAL HISTORY:\X0D\\X0A\Abnormal mammogram, nipple discharge.  Tissue obtained 15:27 placed in\X0D\\X0A\formalin 15:40, **DATE[Nov 14 11].",AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   LEFT BREAST NEEDLE LOCALIZATION LUMPECTOMY/RESECTION: DUCTAL\X0D\\X0A\CARCINOMA IN-SITU.\X0D\\X0A\1.   SIZE/EXTENT OF DCIS:\X0D\\X0A\a.   Largest focus measures 0.9 cm. maximally.\X0D\\X0A\b.   Low grade DCIS is multifocal.\X0D\\X0A\2.   HISTOLOGY OF DCIS:\X0D\\X0A\a.   DCIS is of solid and cribriform types.\X0D\\X0A\b.   Nuclear grade: intermediate/grade II.\X0D\\X0A\c.   Necrosis: not identified.\X0D\\X0A\d.   Microcalcifications are identified in association with DCIS.\X0D\\X0A\3.   MARGINS:\X0D\\X0A\a.   DCIS is present at multiple inked cauterized margins of excision.\X0D\\X0A\4.   PATHOLOGIC STAGE: pTisNXMXG2.\X0D\\X0A\5.   ADDITIONAL PATHOLOGIC FINDINGS:\X0D\\X0A\a.   Duct ectasia, apocrine metaplasia, small duct papillomas, duct\X0D\\X0A\hyperplasia of the usual type and atypical intraductal hyperplasia.\X0D\\X0A\B.   LEFT BREAST, BIOPSY: BREAST TISSUE WITH:\X0D\\X0A\1.   Duct hyperplasia of the usual type, apocrine metaplasia and duct\X0D\\X0A\ectasia.\X0D\\X0A\2.   No evidence of in-situ or invasive malignancy.\X0D\\X0A\ \X0D\\X0A\COMMENT: Utilizing appropriate positive and negative controls a P63\X0D\\X0A\stain is performed. The P63 stain shows positivity around nets of DCIS.\X0D\\X0A\An invasive component is not identified. This case is shared in internal\X0D\\X0A\consultation with Dr. **NAME[ZZZ] who concurs.  Hormone receptors are\X0D\\X0A\performed on a section of the in-situ tumor.\X0D\\X0A\ \X0D\\X0A\ESTROGEN RECEPTOR\X0D\\X0A\ \X0D\\X0A\Vendor:  Vision biosystems\X0D\\X0A\         bond-Leica\X0D\\X0A\Clone:   6F11\X0D\\X0A\Processing: FFPE*\X0D\\X0A\Estimation of % positive: 95%\X0D\\X0A\**NAME[YYY] Score: 8/8\X0D\\X0A\RESULTS:  Positive.\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (MC/dkv)\X0D\\X0A\**NAME[XXX:  WWW M VVV] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Nov 19 2011]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Submitted in formalin in a compression device is a markedly\X0D\\X0A\compressed fragmented 5.4 x 4.2 x 1.1 cm. fibrofatty soft tissue\X0D\\X0A\fragment with a centrally embedded stainless steel wire including hook.\X0D\\X0A\The smaller fragment is inked in red, bisected revealing a firm tan\X0D\\X0A\solid central core.  The entire smaller nodule is submitted in A1.  The\X0D\\X0A\larger fragment is likewise inked in red and serially sectioned\X0D\\X0A\perpendicular to the wire revealing a firm tan and fatty yellow central\X0D\\X0A\core with no grossly discernible tumor nodularity.  Scattered unilocular\X0D\\X0A\cysts ranging up to 4.0 mm. are identified.  The specimen is embedded en\X0D\\X0A\toto in A2-A6.\X0D\\X0A\Specimen (B) Submitted in formalin and designated 'left breast biopsy'\X0D\\X0A\is a firm tan and fatty yellow 2.6 x 1.4 x 0.4 cm. aggregate of soft\X0D\\X0A\tissue embedded en toto in a single cassette.  (DA/dkv)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 7\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Breast\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: LEFT BREAST NEEDLE LOCALIZATION\X0D\\X0A\ \X0D\\X0A\Histologic Type:    Ductal carcinoma in situ\X0D\\X0A\Margins:  Margin[s] involved by DCIS\X0D\\X0A\Microcalcifications:     Present in DCIS\X0D\\X0A\Primary Tumor [pT]: pTis\X0D\\X0A\Regional Nodes [pN]:     pNX\X0D\\X0A\Number involved:    0\X0D\\X0A\Number examined:    0\X0D\\X0A\Distant Metastasis [pM]: pMX",,"SPECIMEN(S): A LEFT BREAST NEEDLE LOCALIZATION\X0D\\X0A\SPECIMEN(S): B BREAST BIOPSY, LEFT",,
REG1,BREAST,0,482109,1,,CLINICAL HISTORY:. \X0D\\X0A\ \X0D\\X0A\PREOPERATIVE CLINICAL DIAGNOSIS:. \X0D\\X0A\Left breast mass.\X0D\\X0A\ \X0D\\X0A\POSTOPERATIVE CLINICAL DIAGNOSIS:. \X0D\\X0A\Same as pre-op,"**INSTITUTION\X0D\\X0A\Surgical Pathology Laboratory Report\X0D\\X0A\NUMBER: ***PATH-NUMBER[1]                                      PATIENT: **NAME[BBB],\X0D\\X0A\ANNA C\X0D\\X0A\RECEIVED: 07 **DATE[Dec 2011]                                 MRN: **ID-NUM\X0D\\X0A\COLLECTED: 07 **DATE[Dec 2011]                                DOB: 27 **DATE[Mar 1943]\X0D\\X0A\PHYSICIAN: **NAME[ZZZ(YYY), XXX]\X0D\\X0A\CC: Medical Record\X0D\\X0A\--------------------------------------------------------------------------\X0D\\X0A\*** SUPPLEMENTARY REPORT ***","DIAGNOSIS:. \X0D\\X0A\ \X0D\\X0A\(A) Breast, Left, needle Localization Lumpectomy:\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST:  SYNOPTIC REPORT\X0D\\X0A\-  Tumor Histologic Type of Invasive Carcinoma: Invasive ductal\X0D\\X0A\carcinoma.\X0D\\X0A\-  Tumor Histologic Grade: Moderately differentiated, Nottingham\X0D\\X0A\Histologic Score: II/III (tubules = 3, nuclear pleomorphism = 2,\X0D\\X0A\mitosis =1).\X0D\\X0A\-  Specimen Integrity: Intact\X0D\\X0A\-  Specimen Size: 7.0 x 5.8 x 1.7 cm.\X0D\\X0A\-  Lymph Node Sampling: Sentinel lymph nodes are sampled. Please see\X0D\\X0A\parts B-D.\X0D\\X0A\-  Tumor Laterality: Left\X0D\\X0A\-  Tumor Size: 0.7 cm.\X0D\\X0A\-  Tumor Focality: Single focus.\X0D\\X0A\-  Ductal Carcinoma In Situ (DCIS): Present, is admixed with the\X0D\\X0A\tumor and comprises less than 10% of the tumor mass.\X0D\\X0A\Architectural Patterns: Cribriform and solid\X0D\\X0A\Nuclear Grade: Intermediate.\X0D\\X0A\Necrosis: Minimal\X0D\\X0A\-  Margins:\X0D\\X0A\Margins uninvolved by invasive carcinoma\X0D\\X0A\Distance from closest margin: 0.5 cm from the anterior margin\X0D\\X0A\Margins uninvolved by DCIS\X0D\\X0A\Distance from closest margin: 0.7 cm\X0D\\X0A\-  Lymph-Vascular Invasion: Not present\X0D\\X0A\-  Perineural Invasion: Not seen.\X0D\\X0A\-  Number of sentinel lymph nodes examined: 3\X0D\\X0A\Number of lymph nodes with macrometastases (>0.2 cm):  0\X0D\\X0A\Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm\X0D\\X0A\and/or >200cells):0\X0D\\X0A\Number of lymph nodes with isolated tumor cells (=0.2 mm and\X0D\\X0A\=200 cells): 0\X0D\\X0A\Method of Evaluation of Sentinel Lymph Nodes: Three H\T\E levels on\X0D\\X0A\each.\X0D\\X0A\-  Ancillary Studies: ER, PR, Her2/neu and Ki67 immunostains are\X0D\\X0A\ordered and the results will be reported as an addendum.\X0D\\X0A\-  Microcalcifications: Present, associated with invasive and in\X0D\\X0A\situ carcinoma and benign breast parenchyma.\X0D\\X0A\-  Additional Pathologic Findings: Previous biopsy site, columnar\X0D\\X0A\cell changes and sclerosing adenosis.\X0D\\X0A\-  Pathologic Tumor Staging (pTNM): pT1b, N(sn) 0, MX\X0D\\X0A\ \X0D\\X0A\(B) Lymph node, Left Axilla Sentinel#1, Count 193 not blue,\X0D\\X0A\Excision:\X0D\\X0A\-  One lymph node, negative for metastatic carcinoma (0/1).\X0D\\X0A\ \X0D\\X0A\(C) Lymph node, Left Axilla Sentinel#2, Count 68 not blue, Excision:\X0D\\X0A\-  One lymph node, negative for metastatic carcinoma (0/1).\X0D\\X0A\ \X0D\\X0A\(D) Lymph node, Left Axilla Sentinel#3, not blue, Excision:\X0D\\X0A\-  One lymph node, negative for metastatic carcinoma (0/1).",,,,,,"*** ADDENDUM REPORT #2 **\X0D\\X0A\ \X0D\\X0A\CPA LAB (MO11-521):\X0D\\X0A\ \X0D\\X0A\FISH Analysis Her-2/neu Amplification (S11-8152-A1):\X0D\\X0A\ \X0D\\X0A\Her-2/neu: NOT AMPLIFIED\X0D\\X0A\ \X0D\\X0A\Number of Her2/neu copies:  4.2\X0D\\X0A\ \X0D\\X0A\Number of CEP17 copies:  3.0\X0D\\X0A\ \X0D\\X0A\Ratio of Her2/CEP17:  1.4\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\INTERPRETATION:\X0D\\X0A\Amplification of the HER-2 gene is not detected.\X0D\\X0A\ \X0D\\X0A\**NAME[WWW VVV], M.D.\X0D\\X0A\ \X0D\\X0A\Electronically signed by Pathologist: **NAME[UUU TTT SSS], RRR], PhD, 22 **DATE[Dec 20]\X0D\\X0A\11\X0D\\X0A\*** ADDENDUM REPORT #1 **\X0D\\X0A\Immunohistochemistry was performed with the following results for\X0D\\X0A\invasive carcinoma:\X0D\\X0A\ \X0D\\X0A\Estrogen Receptor:  Positive (> 95%, strong; **NAME[QQQ] score = 8)\X0D\\X0A\Progesterone Receptor:  Positive (80%, strong)\X0D\\X0A\HER2/neu: Equivocal (2+)\X0D\\X0A\Ki-67:  12%\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\NOTE:  HER2/neu FISH analysis will be performed and results will\X0D\\X0A\follow as an addendum.\X0D\\X0A\ \X0D\\X0A\Immunohistochemical studies for estrogen receptor, progesterone\X0D\\X0A\receptor, and HER2/neu were evaluated by manual morphometric\X0D\\X0A\analysis using the following criteria:\X0D\\X0A\Hormone receptor analysis:  The percent of immunoreactive nuclei in\X0D\\X0A\the carcinoma is reported as follows:\X0D\\X0A\Positive > 1% of nuclei immunoreactive\X0D\\X0A\Negative   < 1% of nuclei immunoreactive\X0D\\X0A\**NAME[QQQ] Score for Estrogen Receptor status:\X0D\\X0A\Positive 3-8\X0D\\X0A\Negative 0-2\X0D\\X0A\**NAME[QQQ] Score is calculated based on the sum of the proportion score\X0D\\X0A\and the intensity score as referenced in Journal of Clinical\X0D\\X0A\Oncology, **ID-NUM, 1999.\X0D\\X0A\Her2/neu analysis:\X0D\\X0A\ \X0D\\X0A\Negative (0):  No immunoreactivity or immunoreactivity in <10% of\X0D\\X0A\tumor cells.\X0D\\X0A\Negative (1+):  Faint weak immunoreactivity in >10% of tumor cells\X0D\\X0A\but only a portion of the membrane is positive.\X0D\\X0A\Equivocal (2+):  Weak to moderate complete membrane immunoreactivity\X0D\\X0A\in >10% of tumor cells or moderate to strong complete membrane\X0D\\X0A\immunoreactivity in <30% of tumor cells.\X0D\\X0A\Positive (3+):  Moderate to strong complete membrane\X0D\\X0A\immunoreactivity in >30% of tumor cells.\X0D\\X0A\ \X0D\\X0A\Cytoplasmic immunoreactivity alone is scored as a negative result.\X0D\\X0A\ \X0D\\X0A\External controls are evaluated and show appropriate\X0D\\X0A\immunoreactivity.\X0D\\X0A\ \X0D\\X0A\The Her2/neu testing, reporting and interpretation follow the\X0D\\X0A\ASCO/CAP guidelines as referenced in Archives of Pathology and\X0D\\X0A\Laboratory Medicine, 131, 18-43, 2007.\X0D\\X0A\ \X0D\\X0A\Electronically signed by Pathologist: **NAME[UUU TTT SSS], RRR], PhD, 14 **DATE[Dec 20]\X0D\\X0A\11\X0D\\X0A\ \X0D\\X0A\SPECIMEN SOURCE:\X0D\\X0A\ \X0D\\X0A\(A) Left Breast Needle LOC\X0D\\X0A\(B) Left Breast Sentinel Lymph Node Biopsy\X0D\\X0A\(C) Left Axillary Sentinel Lymph Node Biopsy\X0D\\X0A\(D) Left Axillary Sentinel Lymph Node Biopsy\X0D\\X0A\ \X0D\\X0A\GROSS:\X0D\\X0A\(A)  Received fresh on an Accugrid with an accompanying radiograph\X0D\\X0A\labeled ""left breast needle loc, short stitch superior, long stitch\X0D\\X0A\lateral"" is an irregular portion of breast tissue measuring 7.0 cm\X0D\\X0A\from superior to inferior, 5.8 cm from medial to lateral and 1.7 cm\X0D\\X0A\from anterior to posterior.  There is a short stitch denoting the\X0D\\X0A\superior margin and a long stitch denoting the lateral margin.\X0D\\X0A\There is a needle localization wire inserted into the lateral\X0D\\X0A\margin.  A single area of concern is circled on the accompanying\X0D\\X0A\radiograph marked by a clip and the needle localization wire which\X0D\\X0A\is located in coordinates C1-D1-C2-D2 which corresponds to the\X0D\\X0A\superior half of the breast lumpectomy specimen.  The specimen is\X0D\\X0A\differentially inked as follows: superior/inferior - yellow, medial\X0D\\X0A\- orange, lateral - green, anterior - blue, posterior - black.  The\X0D\\X0A\specimen is serially sectioned from superior to inferior to reveal a\X0D\\X0A\1.5 x 0.6 x 0.3 cm tan-white slightly hemorrhagic spiculated area\X0D\\X0A\which has the  central spring/clip identified.  The mass appears to\X0D\\X0A\come within 0.3 cm of the anterior margin, 0.7 cm of the lateral\X0D\\X0A\margin, 1.2 cm of the medial margin and 0.6 cm of the posterior\X0D\\X0A\margin. The inferior margin is clear by 3.5 cm and the superior\X0D\\X0A\margin is clear by at least 1.0 cm.  The remaining breast tissue is\X0D\\X0A\primarily yellow lobulated adipose tissue with less than 5% white\X0D\\X0A\fibrous tissue.  Representative sections are submitted as follows:\X0D\\X0A\ \X0D\\X0A\Cassette Review:\X0D\\X0A\A1 - Central mass containing spring/clip\X0D\\X0A\A2 - Lateral margin of central mass\X0D\\X0A\A3 - Medial margin of central mass\X0D\\X0A\A4-A5 - Superior portion of mass bisected\X0D\\X0A\A6-A8 - Tissue superior to mass trisected\X0D\\X0A\A9 - Inferior mass\X0D\\X0A\A10-A11 - Tissue inferior to mass bisected\X0D\\X0A\A12 - Superior margin perpendicular\X0D\\X0A\A13 - Inferior margin perpendicular\X0D\\X0A\Dr. **NAME[PPP OOO NNN]:  Pathology Resident/lap\X0D\\X0A\ \X0D\\X0A\(B) Received in formalin labeled ""left breast sentinel lymph node\X0D\\X0A\biopsy #1, count 193 not blue"" is a 1.1 x 0.6 x 0.5 cm tan-pink\X0D\\X0A\lymph node which is serially sectioned and entirely submitted as\X0D\\X0A\""B"".\X0D\\X0A\ \X0D\\X0A\(C) Received in formalin labeled ""left axillary sentinel lymph node\X0D\\X0A\biopsy #2, count 68 not blue"" is a 1.7 x 1.0 x 0.8 cm tan-pink lymph\X0D\\X0A\node which is serially sectioned and entirely submitted as ""C"".\X0D\\X0A\ \X0D\\X0A\(D) Received in formalin labeled ""sentinel lymph node #3 left\X0D\\X0A\axillary, not blue no count"" is a 4.4 x 2.0 x 2.0 cm aggregate of\X0D\\X0A\fibrofatty tissue containing a 2.5 x 2.2 x 1.5 cm tan-pink lymph\X0D\\X0A\node which is serially sectioned and entirely submitted as ""D1-D3"".\X0D\\X0A\Pathology Assistant:  **NAME[KKK JJJ]/mcw\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\**NAME[M. OOO NNN], MD\X0D\\X0A\ \X0D\\X0A\**NAME[MMM LLL], M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed   12 **DATE[Dec 2011]\X0D\\X0A\ \X0D\\X0A\CPT: 88307#4\X0D\\X0A\ICD-9: 174.1"
REG1,BREAST,0,482660,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT AXILLARY NODE VIABLE ON ULTRASOUND \X0D\\X0A\OPER: PERCUTANEOUS ULTRASOUND GUIDED VACUUM ASSISTED CORE AXILLARY\X0D\\X0A\ NODE BIOPSY LEFT AXILLA\X0D\\X0A\NOT FOR CALCIFICATIONS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: CORE AXILLARY NODE LEFT AXILLA-NOT FOR CALCS-ls","Final Diagnosis\X0D\\X0A\LEFT AXILLARY LYMPH NODE, NEEDLE BIOPSIES \X0D\\X0A\     ADENOCARCINOMA.\X0D\\X0A\Comment:  Tumor is seen to involve fragments of tissue having a patchy lymphoid\X0D\\X0A\component and in areas without lymphoid tissue showing sclerosis.  A fragment of\X0D\\X0A\unremarkable skin is also present.  Additional marker studies are pending.\X0D\\X0A\MER/in \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\Received in formalin designated ""left axillary node core"" are a few strips and\X0D\\X0A\pieces of tan and yellow tissue which are 2.0 x 0.7 x 0.2 cm in aggregate. \X0D\\X0A\These are totally submitted in one cassette.  The specimen is removed from the\X0D\\X0A\patient at 8:50 hrs and initially placed in formalin at 0900 hrs.  The specimen\X0D\\X0A\is described, transferred to a cassette and resubmitted into formalin at 12:58\X0D\\X0A\hrs.\X0D\\X0A\LW/USO/MER\X0D\\X0A\/cb",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Sep 22 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 22 2012]     By:  **NAME[YYY, XXX]\X0D\\X0A\     Date Reported:     **DATE[Sep 22 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Immunohistochemical stains have been performed using appropriate controls, on\X0D\\X0A\block 1A, and show the following results:\X0D\\X0A\Mammaglobin positive, GCDFP-15 equivocal, TTF-1 negative, pancytokeratin\X0D\\X0A\positive.  \X0D\\X0A\These staining results support a diagnosis of metastatic carcinoma of probable\X0D\\X0A\mammary origin.  Receptor studies are being performed at Genzyme Laboratories\X0D\\X0A\and are pending.\X0D\\X0A\MER/cb  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Sep 24 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 24 2012]     By:  **NAME[WWW,VVV]\X0D\\X0A\     Date Reported:     **DATE[Sep 24 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding biomarker analysis.  /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D.,  MARK E."
REG1,BREAST,0,483752,3,,Clinical Diagnosis and History\X0D\\X0A\The working history is invasive lobular CA right breast and second area of\X0D\\X0A\lobular CA in situ.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\**NAME[ZZZ, YYY]\X0D\\X0A\**NAME[XXX, WWW M]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, simple mastectomy with lymph nodes\X0D\\X0A\2: Lymph Node, Sentinel Node\X0D\\X0A\3: Breast, simple mastectomy with lymph nodes\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[May 24 12]: 1.  RIGHT BREAST ULTRASOUND GUIDED BIOPSY AT 8 O'CLOCK: \X0D\\X0A\Lobular carcinoma in-situ involving ductal and lobular units, invasive carcinoma\X0D\\X0A\not identified.  2.  RIGHT BREAST ULTRASOUND GUIDED BIOPSY AT 12 O'CLOCK: \X0D\\X0A\Infiltrating lobular carcinoma with ductal involvement.  (DGD)","Final Diagnosis\X0D\\X0A\IMMUNOHISTOCHEMICAL RESULTS:  :  HER-2/neu immunohistochemistry on the left\X0D\\X0A\breast is strongly positive (3+), testing performed on Block 1C. \X0D\\X0A\Immunohistochemistry for HER-2/neu in the right breast is negative, testing\X0D\\X0A\performed on Block 3J.  These findings were discussed with Dr. **NAME[VVV UUU] by Dr.\X0D\\X0A\Daron **PLACE on **DATE[Aug 9 2012] at approximately **ID-NUMam.  **INITIALS\X0D\\X0A\COMMENT:  The findings concur with the FISH studies and Oncotype studies. \X0D\\X0A\**INITIALS\X0D\\X0A\ADDENDUM COMMENT:  See Microscopic Description for immunohistochemistry results\X0D\\X0A\of ER/PR. **INITIALS\X0D\\X0A\1.  LEFT BREAST SIMPLE MASTECTOMY: \X0D\\X0A\     Infiltrating lobular carcinoma (infiltrating tumor size 7 x 4 x 4 mm) and\X0D\\X0A\multifocal lobular carcinoma in situ, margins of excision free of tumor, no\X0D\\X0A\lymphvascular invasion identified, skin of breast and nipple negative for tumor.\X0D\\X0A\See TEMPLATE. \X0D\\X0A\2.  RIGHT SENTINEL NODE BIOPSY: \X0D\\X0A\     Lymph node x1 no tumor seen. \X0D\\X0A\3.  RIGHT BREAST, SIMPLE MASTECTOMY: \X0D\\X0A\     Invasive lobular carcinoma (infiltrating tumor size 22mm x 12mm x 12mm)\X0D\\X0A\with multifocal lobular carcinoma in situ, margins of excision free of tumor;\X0D\\X0A\however, deep margin less than 1 mm. No lymphvascular invasion identified. Skin\X0D\\X0A\of nipple and breast pending immunohistochemistry. See TEMPLATE. \X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  LEFT simple mastectomy. \X0D\\X0A\LYMPH NODE SAMPLING:  None. \X0D\\X0A\SPECIMEN INTEGRITY:  Intact. \X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  576 grams, 25 x 18 x\X0D\\X0A\4.5 cm. \X0D\\X0A\LATERALITY:  Left \X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number And Size):  Unifocal for\X0D\\X0A\infiltrating tumor; multifocal for LCIS. \X0D\\X0A\TUMOR SITE:  Deep central breast close to deep margin. \X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  7 x 4 x 4 mm. \X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  0%\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  90%; multifocal. \X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Lobular. \X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  \X0D\\X0A\     TUBULAR FORMATION:  3\X0D\\X0A\     MITOTIC ACTIVITY:  1\X0D\\X0A\     PLEOMORPHISM:  2\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  None. \X0D\\X0A\SENTINEL NODE STATUS:  No nodes submitted. \X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  Absent. \X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  No nodes submitted. \X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  Not applicable. \X0D\\X0A\SURGICAL MARGINS:  Negative for tumor. \X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  1.4 cm. \X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  No skin or nipple involvement. \X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Pending\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Pending\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  Pending\X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  \X0D\\X0A\TREATMENT EFFECT:  None. \X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Small tubular adenoma (4 mm) and extensive\X0D\\X0A\sclerosing adenosis. \X0D\\X0A\OTHER STUDIES:  None. \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=1b\X0D\\X0A\pN=X\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IA\X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  RIGHT simple mastectomy. \X0D\\X0A\LYMPH NODE SAMPLING:  One sentinel node. \X0D\\X0A\SPECIMEN INTEGRITY:  Intact. \X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  653.7; 25 x 19 x 5.5\X0D\\X0A\cm. \X0D\\X0A\LATERALITY:  Right. \X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number And Size):  Unifocal invasive;\X0D\\X0A\multifocal LCIS. \X0D\\X0A\TUMOR SITE:  Inferior quadrant. \X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  22mm x 12mm x 12 mm. \X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  0 \X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  Approximately 60%. \X0D\\X0A\MACRO EXTENT:  Indistinct. \X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Lobular. \X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  \X0D\\X0A\     TUBULAR FORMATION:  3\X0D\\X0A\     MITOTIC ACTIVITY:  1\X0D\\X0A\     PLEOMORPHISM:  2\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  One\X0D\\X0A\sentinel node\X0D\\X0A\SENTINEL NODE STATUS:  Negative. \X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  Negative. \X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  One sentinel node\X0D\\X0A\negative for tumor. \X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  N/A \X0D\\X0A\SURGICAL MARGINS:  Negative but close deep margin < 1 mm. \X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  Deep < 1 mm. \X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  Immunos pending will add when available. \X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Pending\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Pending\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  Pending \X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  \X0D\\X0A\TREATMENT EFFECT:  None. \X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Extensive sclerosing adenosis, proliferative\X0D\\X0A\fibrocystic change with atypia, micro intraductal papilloma. \X0D\\X0A\OTHER STUDIES:  \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=2  \X0D\\X0A\pN=0   \X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIA \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled left breast is a 576 gram, per the\X0D\\X0A\operating room scale, 25.0 x 18.0 x 4.5 cm intact left simple mastectomy\X0D\\X0A\specimen. The specimen is partially surfaced by a 12.0 x 7.0 cm tan wrinkled\X0D\\X0A\skin ellipse. The everted nipple measures 1 cm in diameter. Sectioning reveals\X0D\\X0A\approximately equal proportions of yellow adipose tissue and dense white fibrous\X0D\\X0A\breast tissue. No masses, suspicious lesions or previous biopsy sites are\X0D\\X0A\identified. Representative sections are submitted. Summary of sections: 1A-1H \X0D\\X0A\representative sections of fibrous breast tissue; 1I  representative section of\X0D\\X0A\nipple. \X0D\\X0A\Specimen 2 received fresh for frozen section labeled right sentinel node biopsy\X0D\\X0A\is a 1.5 cm in greatest dimension tan/pink lymph node which is submitted\X0D\\X0A\entirely for frozen section, now resubmitted in cassette 2. \X0D\\X0A\Specimen 3 received in formalin labeled right breast is a 653.1 gram, 25.0 x\X0D\\X0A\19.0 x 5.5 cm intact right simple mastectomy specimen. The specimen is partially\X0D\\X0A\surfaced by a 12.5 x 7.5 cm tan wrinkled skin ellipse. The everted nipple\X0D\\X0A\measures 1 cm in diameter. The margins are inked as follows: superficial margin\X0D\\X0A\blue, deep margin black, and sectioning reveals a 1.0 x 0.8 x 0.8 cm area of\X0D\\X0A\ill-defined slightly firm breast tissue with a central metal clip. This area is\X0D\\X0A\located in the inferior quadrant of the breast and is 1.3 cm from the\X0D\\X0A\superficial margin and 2.8 cm from the deep margin. There is a second firm mass\X0D\\X0A\identified in the central aspect of the breast with overall dimensions of 2.8 x\X0D\\X0A\2.8 x 2.5 cm. The secondary mass is approximately 3.5 cm away from the metal\X0D\\X0A\clip. The mass is 2.7 cm from the deep margin and 2 cm from the superficial\X0D\\X0A\margin. There appears to be an area of normal breast tissue between the biopsy\X0D\\X0A\site and the invasive mass. The remaining cut surface shows predominantly yellow\X0D\\X0A\adipose tissue with focal areas of dense white fibrous breast tissue. No\X0D\\X0A\involvement of the skin or nipple is identified. No lymph nodes are present.\X0D\\X0A\Representative sections are placed in formalin at 11:35 a.m. Summary of\X0D\\X0A\sections: 3A-3B  deep margin closest to clip; 3C-3D  representative sections of\X0D\\X0A\breast tissue containing clip; 3E-3H  representative sections of breast tissue\X0D\\X0A\between the clip and invasive mass; 3I-3K  representative sections of invasive\X0D\\X0A\mass to include blue-inked superficial margin; 3L  representative section of\X0D\\X0A\deep margin closest to invasive mass; 3M  representative section of nipple. \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Sections of the left breast show extensive lobular carcinoma in situ\X0D\\X0A\characterized by lobular and ductal elements that have been overfilled by\X0D\\X0A\proliferation of neoplastic lobular elements. Lobules are frequently filled and\X0D\\X0A\the neoplasm extends up the adjacent ducts. Scattered microcalcifications are\X0D\\X0A\seen. The invasive lobular carcinoma is noted focally and measures 7 mm x 4 mm x\X0D\\X0A\4 mm. The in situ component comprises approximately 90% of the neoplasm present\X0D\\X0A\and its size is difficult to estimate because of its presence in multiple tissue\X0D\\X0A\blocks and is estimated at between 15mm x 5mm x 5 mm.  There are extensive\X0D\\X0A\calcifications within the breast and these appear to be associated predominantly\X0D\\X0A\with two small tubular adenomatous proliferation one of which measures\X0D\\X0A\approximately 5mm x 5mm x 5 mm. Sclerosing adenosis is extensively seen within\X0D\\X0A\the breast tissue. Sections of the breast skin and nipple show no definite\X0D\\X0A\pagetoid intraepithelial spread and no involvement of the dermal lymphatics. \X0D\\X0A\Sections of the right sentinel lymph node which has been bisected shows mild\X0D\\X0A\sinus histiocytosis. There is no tumor noted in the subcapsular spaces. The node\X0D\\X0A\is immunostained with estrogen and pankeratin which confirms no tumor identified\X0D\\X0A\in the lymph node. \X0D\\X0A\Sections of the right simple mastectomy show a lobular carcinoma that is\X0D\\X0A\infiltrative and extensively present in situ. The infiltrating component of the\X0D\\X0A\tumor measures 22mm x 12mm x approximately 12 mm. There is no lymphvascular\X0D\\X0A\invasion identified. Lobular carcinoma in situ is extensively seen and\X0D\\X0A\approximates at least 60% of the tumor. The margins of excision are free of\X0D\\X0A\tumor; however, the deep margin is close and less than 1 mm (see block 3J).\X0D\\X0A\Calcifications are also abundantly noted throughout the sampled breast sections.\X0D\\X0A\Sclerosing adenosis is extensively seen within the breast tissue. Duct elements\X0D\\X0A\show only focal hyperplasia without atypia.  **INITIALS\X0D\\X0A\IMMUNOHISTOCHEMISTRY RESULTS:  All controls stain appropriately including\X0D\\X0A\external positive, internal negative and external negative controls as required.\X0D\\X0A\ This tumor shows POSITIVE nuclear staining for Estrogen Receptor (over 95% of\X0D\\X0A\tumor nuclei) in the right sided tumor and left sided tumor and WEAKLY POSITIVE\X0D\\X0A\staining for Progesterone Receptor in the tumor and STRONGLY POSITIVE in the\X0D\\X0A\in-situ elements.  Controls stain appropriately. \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\ **INITIALS\X0D\\X0A\ADDITIONAL IMMUNOHISTOCHEMISTRY RESULTS (dictated **DATE[Aug 9 12]):  HER-2/neu\X0D\\X0A\immunohistochemistry on the left breast is strongly positive (3+), testing\X0D\\X0A\performed on Block 1C.  Immunohistochemistry for HER-2/neu in the right breast\X0D\\X0A\is negative, testing performed on Block 3J.  **INITIALS",,,Amendments:\X0D\\X0A\Amended:  **DATE[Jul 18 2012] by Ruthanne Walker\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Jul 14 2012]\X0D\\X0A\Amended:  **DATE[Aug 9 2012] by Ruthanne Walker\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Jul 18 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Oncotype - Genomic Dx     Date Ordered:     **DATE[Jul 27 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 6 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Aug 8 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\ONCOTYPE RESULTS BREAST CANCER ASSAY:  Breast Cancer Recurrence Score = 13 with\X0D\\X0A\an Average Rate of Distant Recurrence of 9% (95% CI: 6%-11%).  SEE SCANNED\X0D\\X0A\REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Jul 27 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 3 2012]     By:  **NAME[TTT SSS]\X0D\\X0A\     Date Reported:     **DATE[Aug 3 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\HER2/CEP17 FISH: \X0D\\X0A\     No HER2/Neu gene amplification was observed for this specimen. \X0D\\X0A\HER2/CEP17 RATIO   1.05. \X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE\X0D\\X0A\Oncotype - Genomic Dx     Date Ordered:     **DATE[Aug 10 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 10 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Aug 18 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\ONCOTYPE RESULTS FOR LEFT BREAST:  Breast Cancer Recurrence Score = 40 with\X0D\\X0A\Average Rate of Distant Recurrence of 27% (95% CI: 20%-34%)  SEE SCANNED\X0D\\X0A\REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Aug 10 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 10 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Aug 10 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\HER-2/neu FISH RESULTS FOR LEFT BREAST:  Positive.  HER-2/neu gene amplification\X0D\\X0A\was positive for this specimen.  HER-2/CEP17 Ratio:  3.66   SEE SCANNED\X0D\\X0A\REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,BREAST,0,484400,1,,"CLINICAL HISTORY:. \X0D\\X0A\ \X0D\\X0A\PREOPERATIVE CLINICAL DIAGNOSIS:. \X0D\\X0A\Left breast microcalcifications. ER, PR, and Her-2/neu if positive.\X0D\\X0A\ \X0D\\X0A\POSTOPERATIVE CLINICAL DIAGNOSIS:. \X0D\\X0A\Same","**INSTITUTION\X0D\\X0A\Surgical Pathology Laboratory Report\X0D\\X0A\NUMBER: ***PATH-NUMBER[1]                                      PATIENT: **NAME[BBB], EN\X0D\\X0A\ILE\X0D\\X0A\RECEIVED: 01 **DATE[Oct 2011]                                 MRN: **ID-NUM\X0D\\X0A\COLLECTED: 01 **DATE[Oct 2011]                                DOB: 26 **DATE[Oct 1956]\X0D\\X0A\PHYSICIAN: MIZUGUCHI(BCC), **NAME[ZZZ]\X0D\\X0A\CC: Medical Record\X0D\\X0A\--------------------------------------------------------------------------\X0D\\X0A\*** SUPPLEMENTARY REPORT ***","DIAGNOSIS:. \X0D\\X0A\Left Breast, Stereotactic core biopsy:\X0D\\X0A\- Well differentiated invasive ductal carcinoma, (tubular\X0D\\X0A\carcinoma), Nottingham Histologic grade: I/III ( Tubules:1,\X0D\\X0A\pleomorphism:1 and mitosis:1)\X0D\\X0A\- Fibrocystic change.\X0D\\X0A\- Microcalcifications identified.\X0D\\X0A\- ER, PR and Her-2 neu are pending.\X0D\\X0A\- Immunostains for p63 and SMA are negative around the invasive\X0D\\X0A\ducts, confirming their neoplastic nature.\X0D\\X0A\ \X0D\\X0A\Note: This case was reviewed at the daily AP Division QA conference.\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\This test was developed and its performance characteristics\X0D\\X0A\determined by **INSTITUTION\X0D\\X0A\Laboratory.  It has not been cleared or approved by the U.S. Food\X0D\\X0A\and Drug Administration.\X0D\\X0A\ \X0D\\X0A\The FDA has determined that such clearance or approval is not\X0D\\X0A\necessary.  This test is used for clinical purposes.  It should not\X0D\\X0A\be regarded as investigational or for research. This laboratory is\X0D\\X0A\certified under the Clinical Laboratory Improvement Amendments\X0D\\X0A\(CLIA) as qualified to perform high complexity clinical laboratory\X0D\\X0A\testing.",,,,,,"*** ADDENDUM REPORT #2 **\X0D\\X0A\The estrogen receptors are strongly positive in 100% of tumor cells\X0D\\X0A\and the progesterone receptors are positive in 90% of the tumor\X0D\\X0A\cells.\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\This test was developed and its performance characteristics\X0D\\X0A\determined by **INSTITUTION\X0D\\X0A\Laboratory.  It has not been cleared or approved by the U.S. Food\X0D\\X0A\and Drug Administration.\X0D\\X0A\ \X0D\\X0A\The FDA has determined that such clearance or approval is not\X0D\\X0A\necessary.  This test is used for clinical purposes.  It should not\X0D\\X0A\be regarded as investigational or for research. This laboratory is\X0D\\X0A\certified under the Clinical Laboratory Improvement Amendments\X0D\\X0A\(CLIA) as qualified to perform high complexity clinical laboratory\X0D\\X0A\testing.\X0D\\X0A\ \X0D\\X0A\Electronically signed by **NAME[YYY XXX], MD, 16 **DATE[Oct 2011]\X0D\\X0A\*** ADDENDUM REPORT #1 **\X0D\\X0A\ \X0D\\X0A\Immunohistochemical stains were performed to evaluate HER-2/neu\X0D\\X0A\(HercepTest) onco protein overexpression via an automated\X0D\\X0A\immunohistochemical technique utilizing appropriate epitope\X0D\\X0A\enhancement.\X0D\\X0A\ \X0D\\X0A\Immunostain for HER2/neu onco protein is negative for\X0D\\X0A\overexpression.  Controls reacted appropriately.\X0D\\X0A\ \X0D\\X0A\Note: The Her2/neu testing, reporting and interpretation follow the\X0D\\X0A\ASCO/CAP guidelines as referenced in Archives of Pathology and\X0D\\X0A\Laboratory Medicine, 131, 18-43, 2007.\X0D\\X0A\ \X0D\\X0A\Electronically signed by **NAME[WWW VVV], MD, 16 **DATE[Oct 2011]\X0D\\X0A\ \X0D\\X0A\SPECIMEN SOURCE:\X0D\\X0A\ \X0D\\X0A\(A) Left Breast Stereotactic Biopsy\X0D\\X0A\GROSS:\X0D\\X0A\(A) Received fresh in a Petri dish with an accompanying radiograph\X0D\\X0A\labeled with the patient's name are eight fibrofatty cylindrical\X0D\\X0A\tissues ranging from 0.4 x 0.3 - 3.6 x 0.5 cm. There are nine cores\X0D\\X0A\encircled on the radiograph. The specimen is submitted in toto as\X0D\\X0A\follows.\X0D\\X0A\ \X0D\\X0A\Cassette Review:\X0D\\X0A\A1-A3 - cores marked on radiograph\X0D\\X0A\A4 - remaining cores\X0D\\X0A\ \X0D\\X0A\Specimen was submitted in formalin at 4:15 p.m.\X0D\\X0A\Dr. **NAME[UUU TTT]: Pathology Resident/mcw\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Resident:  **NAME[SSS RRR]\X0D\\X0A\ \X0D\\X0A\**NAME[YYY XXX], MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed   09 **DATE[Oct 2011]\X0D\\X0A\ \X0D\\X0A\CPT: 88342; 88307\X0D\\X0A\ICD-9: 611.72"
REG1,BREAST,0,484425,3,,Clinical Diagnosis and History\X0D\\X0A\The working history is lobular carcinoma in situ right breast.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY\X0D\\X0A\**INSTITUTION - COPY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, simple mastectomy w/o lymph nodes\X0D\\X0A\2: Breast, simple mastectomy with lymph nodes\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Nov 22 11]:  MEDIAL RIGHT BREAST, STEREOTACTIC CORE BIOPSIES: Lobular\X0D\\X0A\carcinoma in situ with ductal involvement, focally involving a micropapilloma.\X0D\\X0A\Background proliferative fibrocystic changes with extensive apocrine metaplasia.\X0D\\X0A\Negative for invasive carcinoma.  (JFJ)","Final Diagnosis\X0D\\X0A\1. LEFT BREAST, SIMPLE MASTECTOMY: \X0D\\X0A\     Focal microscopic lobular carcinoma in situ.\X0D\\X0A\Negative for invasive carcinoma.\X0D\\X0A\2. RIGHT BREAST WITH AXILLARY LYMPH NODES: \X0D\\X0A\     Focal atypical lobular hyperplasia with ductal involvement by atypical\X0D\\X0A\lobular hyperplasia.\X0D\\X0A\No residual in situ or invasive carcinoma identified. \X0D\\X0A\Biopsy cavity present.\X0D\\X0A\Three lymph nodes negative metastatic carcinoma. See Comment.\X0D\\X0A\COMMENT: As noted in the diagnosis, a focal microscopic area of LCIS is\X0D\\X0A\identified in the left breast. The right breast showed only residual atypical\X0D\\X0A\lobular hyperplasia with areas of ductal involvement. Both breasts were\X0D\\X0A\generously sampled. A template will not be dictated as templates are only for\X0D\\X0A\invasive carcinoma or ductal carcinoma in situ.\X0D\\X0A\JFJ/mbc",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled left breast is a 1240 gram, per the\X0D\\X0A\operating room scale, 23.0 x 18.0 x 4.5 cm intact simple mastectomy specimen.\X0D\\X0A\The specimen is partially surfaced by a 12.5 x 4.5 cm tan wrinkled skin ellipse.\X0D\\X0A\There is a large circular defect in the middle of the skin consistent with the\X0D\\X0A\previous nipple and areolar site. Sectioning reveals approximately equal\X0D\\X0A\proportions of yellow adipose tissue and dense white fibrous breast tissue. No\X0D\\X0A\masses, suspicious lesions or previous biopsy sites are identified.\X0D\\X0A\Representative sections of fibrous breast tissue are submitted in cassettes\X0D\\X0A\1A-1G.  \X0D\\X0A\Specimen 2 received in formalin labeled right breast is a 1520 gram, per the\X0D\\X0A\operating room scale, 29.0 x 18.0 x 7.0 cm right simple mastectomy specimen. The\X0D\\X0A\specimen is partially surfaced by a 13.0 x 4.0 cm tan wrinkled skin ellipse.\X0D\\X0A\There is a large central defect measuring 3.5 x 3.0 cm consistent with the\X0D\\X0A\previous site of the areolar and nipple. The deep margin is inked black and\X0D\\X0A\sectioning reveals a 1.3 x 1.1 x 1.1 cm tan healed biopsy cavity, 6.5 cm from\X0D\\X0A\the deep margin and 5 cm from the superficial margin. The remaining cut surface\X0D\\X0A\shows nearly exclusively yellow adipose tissue. A few lymph nodes are identified\X0D\\X0A\in the outer quadrant. Representative sections are placed in formalin at 2:45\X0D\\X0A\p.m. Summary of sections: A- deep margin closest to biopsy site; B  superficial\X0D\\X0A\margin closest to biopsy site; C-H  entire biopsy site to include surrounding\X0D\\X0A\breast tissue; I  bisected lymph node; J - two intact lymph nodes.  **INITIALS","Microscopic Description\X0D\\X0A\Sections from the left breast show primarily fibrocystic changes with cystic\X0D\\X0A\dilatation of multiple ducts with areas of ductal epithelial hyperplasia. There\X0D\\X0A\is a focal area of lobular carcinoma in situ. There is no evidence of invasive\X0D\\X0A\carcinoma. \X0D\\X0A\Sections from specimen 2 show evidence of prior biopsy cavity with areas of\X0D\\X0A\cystic hemorrhage with foreign body reaction and background scarring. There are\X0D\\X0A\multiple areas of atypical lobular hyperplasia with ductal involvement by\X0D\\X0A\atypical lobular hyperplasia. There is no evidence of in situ or invasive\X0D\\X0A\carcinoma. Sections through three axillary lymph nodes show no evidence of\X0D\\X0A\metastatic neoplasm. \X0D\\X0A\All controls stain appropriately including external positive, internal negative\X0D\\X0A\and external negative controls as required. Antibody E-cadherin shows positive\X0D\\X0A\stain of the background ductal elements and a lack of staining in the area of\X0D\\X0A\putative LCIS. Similarly, block 2F shows a lack of staining of the lobular\X0D\\X0A\component noted previously.\X0D\\X0A\**INITIALS:mbc",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,484867,3,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is right breast DCIS, left side is ADH. Operative\X0D\\X0A\procedure: left NL, right NL and bilateral lumpectomy to follows. \X0D\\X0A\\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[May 8 1959] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Jan 20 2012] 14:06\X0D\\X0A\Receipt Date: **DATE[Jan 20 2012] 14:06\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD: P.C. **NAME[YYY], MD     Service: XRY     Location: MAMM\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jan 25 2012] 17:40\X0D\\X0A\RESIDENTS(S): S.R. **NAME[WWW], MD\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Comment: The case was prospectively reviewed in consultation with Dr. **NAME[VVV]\X0D\\X0A\who concurs to the above diagnosis. \X0D\\X0A\Protocol for the Examination of Specimens from Patients with Ductal Carcinoma\X0D\\X0A\In Situ (DCIS) of the Breast (Protocol applies to DCIS without invasive\X0D\\X0A\carcinoma or microinvasion) (template #37)\X0D\\X0A\Last updated **DATE[Jan 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\     Specimen/procedure:\X0D\\X0A\\X0D\\X0A\Specimen integrity:  single intact specimen (margins can be evaluated) \X0D\\X0A\                                     \X0D\\X0A\Specimen size:  3.2 x 2.5 x 1.8 cm\X0D\\X0A\\X0D\\X0A\Specimen laterality:  left\X0D\\X0A\\X0D\\X0A\Tumor site:  left breast 9 o' clock  \X0D\\X0A\\X0D\\X0A\Size (extent) of DCIS: \X0D\\X0A\                 estimated size (greatest dimension using gross and\X0D\\X0A\microscopic evaluation): at least 0.4 cm \X0D\\X0A\            number of blocks with DCIS:  4; Number of blocks examined: 8\X0D\\X0A\\X0D\\X0A\Architectural patterns (select all that apply):  solid  \X0D\\X0A\\X0D\\X0A\Nuclear grade:  grade I (low) to grade II (intermediate)\X0D\\X0A\\X0D\\X0A\Necrosis:  focally present (small foci or single cell necrosis) \X0D\\X0A\\X0D\\X0A\Microcalcifications:   not identified \X0D\\X0A\\X0D\\X0A\Margins:  uninvolved by DCIS (distance from closest margin: <0.1 mm from\X0D\\X0A\superficial margin). In the same area, one small detached fragment of tumoral\X0D\\X0A\cells is identified, outsite from the inked margin of the specime, which is\X0D\\X0A\consider to be a floater. \X0D\\X0A\\X0D\\X0A\Additional pathologic findings:  clustered micropapillomas invoved by DCIS,\X0D\\X0A\fibrocystic changes with apocrine metaplasia  \X0D\\X0A\\X0D\\X0A\Ancillary studies:\X0D\\X0A\\X0D\\X0A\Estrogen Receptor)   performed on this specimen \X0D\\X0A\\X0D\\X0A\         Results:  positive (quantitation: 70 - 80 %) \X0D\\X0A\\X0D\\X0A\Progesterone Receptor)   performed on this specimen \X0D\\X0A\\X0D\\X0A\         Results:  positive (quantitation: 10 -15 %) \X0D\\X0A\\X0D\\X0A\Protocol for the Examination of Specimens from Patients with Ductal Carcinoma\X0D\\X0A\In Situ (DCIS) of the Breast (Protocol applies to DCIS without invasive\X0D\\X0A\carcinoma or microinvasion) (template #37)\X0D\\X0A\Last updated **DATE[Jan 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\     Specimen/procedure:\X0D\\X0A\\X0D\\X0A\Specimen integrity:  single intact specimen (margins can be evaluated) \X0D\\X0A\                                     \X0D\\X0A\Specimen size:  4 x 3.4 x 1.8 cm\X0D\\X0A\\X0D\\X0A\Specimen laterality:  right\X0D\\X0A\\X0D\\X0A\Tumor site:  right breast 3 o' clock    \X0D\\X0A\\X0D\\X0A\Size (extent) of DCIS: \X0D\\X0A\                 estimated size (greatest dimension using gross and\X0D\\X0A\microscopic evaluation): at least 0.2 cm \X0D\\X0A\            number of blocks with DCIS:  8; Number of blocks examined: 16\X0D\\X0A\\X0D\\X0A\Architectural patterns (select all that apply):  solid\X0D\\X0A\\X0D\\X0A\Nuclear grade:  grade I (low) to grade II (intermediate)\X0D\\X0A\\X0D\\X0A\Necrosis:  not identified \X0D\\X0A\\X0D\\X0A\Microcalcifications:   present, associated with blood vessels. \X0D\\X0A\\X0D\\X0A\Margins:  uninvolved by DCIS (distance from closest margin:  1 mm from\X0D\\X0A\inferior margin)\X0D\\X0A\              \X0D\\X0A\Additional pathologic findings:  fibrocystic changes with apocrine\X0D\\X0A\metaplasia.\X0D\\X0A\\X0D\\X0A\Ancillary studies:\X0D\\X0A\\X0D\\X0A\Estrogen Receptor)   performed on another specimen (accession number: \X0D\\X0A\***PATH-NUMBER[2])\X0D\\X0A\\X0D\\X0A\         Results:  positive (quantitation: >95 %) \X0D\\X0A\\X0D\\X0A\Progesterone Receptor)   performed on another specimen (accession:  ***PATH-NUMBER[2])\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\         Results:  positive (quantitation: >90 %) \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\BREAST, LEFT, NEEDLE LOCALIZATION LUMPECTOMY (A):\X0D\\X0A\   - LOW TO INTERMEDIATE NUCLEAR GRADE DUCTAL CARCINOMA IN-SITU INVOLVING\X0D\\X0A\CLUSTERED MICROPAPILLOMAS AND  SURROUNDING DUCTS WITH FOCAL CENTRAL NECROSIS.\X0D\\X0A\   - NO INVASIVE CARCINOMA IDENTIFIED.\X0D\\X0A\   - PREVIOUS BIOPSY SITE CHANGES. \X0D\\X0A\   - POSITIVE ER AND PR\X0D\\X0A\   - SEE TEMPLATE AND COMMETN\X0D\\X0A\\X0D\\X0A\BREAST, RIGHT, NEEDLE LOCALIZATION LUMPECTOMY (B):\X0D\\X0A\   - LOW TO INTERMEDIATE NUCLEAR GRADE DUCTAL CARCINOMA IN-SITU (SEE\X0D\\X0A\TEMPLATE).\X0D\\X0A\   - PREVIOUS BIOPSY SITE CHANGES.\X0D\\X0A\   - NO INVASIVE CARCINOMA IDENTIFIED.\X0D\\X0A\   - SEE TEMPLATE AND COMMETN  \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jan 22 2012] **NAME[M. UUU], MD\X0D\\X0A\ \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M85002 P1100\X0D\\X0A\B: M85002 P1100 \X0D\\X0A\\X0D\\X0A\F: A: 88307, 76098 XRAY, 67030-ER, S 88360, 67031-PR, S 88360\X0D\\X0A\B: 88307, 76098 XRAY, 76098 XRAY \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Two specimens are received. \X0D\\X0A\\X0D\\X0A\Specimen A is received fresh labeled left breast needle loc lumpectomy,\X0D\\X0A\stitch long lateral, short superior and consists of a yellow white fragment\X0D\\X0A\of fibroadipose tissue with a needle that extends from the superior medial\X0D\\X0A\edge.  An x-ray is taken and the presence of a probable mass is confirmed (no\X0D\\X0A\clip identified) in the lateral aspect of the specimen.  It is serially\X0D\\X0A\sectioned and shows no discrete gross mass is identified, only hemorrhagic\X0D\\X0A\fibrous tissue at the lateral aspect of the specimen. The hemorrhagic area\X0D\\X0A\measures 6 x 4 x 4 mm and is located at a distance of 0.1 cm from the closest\X0D\\X0A\deep margin. The remaining parts of the specimen are grossly unremarkable.\X0D\\X0A\\X0D\\X0A\Note: the tissue is placed in formalin by 1:10 pm.\X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Specimen dimensions: 3.2 cm from lateral to medial, 2.5 cm from superior to\X0D\\X0A\inferior and 1.8 cm from superficial to deep. \X0D\\X0A\\X0D\\X0A\Inking:\X0D\\X0A\Superficial margin: black\X0D\\X0A\Deep margin: blue\X0D\\X0A\Additional green ink is applied to the superior margin\X0D\\X0A\\X0D\\X0A\Sections (entirely submitted):\X0D\\X0A\Entirely submitted from lateral to medial as follows: \X0D\\X0A\A1  lateral margin perpendicular sections\X0D\\X0A\A2  A7  sections from lateral to medial \X0D\\X0A\A3  A4  hemorrhagic fibrous tissue \X0D\\X0A\A8  medial margin perpendicular sections\X0D\\X0A\\X0D\\X0A\Specimen B is received fresh labeled right breast needle loc lumpectomy,\X0D\\X0A\stitch long lateral, short superior and consists of a yellow white fragment\X0D\\X0A\of fibroadipose tissue with a needle that extends from the medial to lateral\X0D\\X0A\edge.  An x-ray is taken and calcifications are seen in slightly inferiorly\X0D\\X0A\from the tip of the inserted wire in lateral inferior aspect of the specimen.\X0D\\X0A\The specimen is serially sectioned and shows predominately white, soft\X0D\\X0A\fibrous tissue admixed with minimal yellow fatty tissue.  No lesions or\X0D\\X0A\masses are seen grossly.  The sections are x-rayed and the calcifications are\X0D\\X0A\located in (cassettes B11).\X0D\\X0A\\X0D\\X0A\Note: the tissue is placed in formalin at 1:45 pm.\X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Specimen dimensions: 4 cm from superior to inferior, 3.4 cm from medial to\X0D\\X0A\lateral and 2.5 cm from superficial to deep. \X0D\\X0A\\X0D\\X0A\Inking:\X0D\\X0A\Superficial margin: black\X0D\\X0A\Deep margin: blue\X0D\\X0A\\X0D\\X0A\Sections (entirely submitted)\X0D\\X0A\Entirely submitted from superior to inferior as follows: \X0D\\X0A\B1  superior margins, sections are made perpendicular to margin\X0D\\X0A\B2  lateral half\X0D\\X0A\B3  medial half\X0D\\X0A\B4  lateral half\X0D\\X0A\B5  medial half\X0D\\X0A\B6  lateral third of the specimen \X0D\\X0A\B7  mid third of the specimen\X0D\\X0A\B8  medial third of the specimen\X0D\\X0A\B9  lateral half\X0D\\X0A\B10  medial half\X0D\\X0A\B11  lateral half of the specimen with microcalcifications\X0D\\X0A\B12  medial half of the specimen\X0D\\X0A\B13  lateral half of the specimen \X0D\\X0A\B14  medial half\X0D\\X0A\B15  lateral half of the inferior margin \X0D\\X0A\B16  medial half of the inferior margin (sections are taken perpendicular to\X0D\\X0A\margin)\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\rgc/**DATE[Jan 21 2012] S.R. **NAME[WWW], MD\X0D\\X0A\A.H. Aroutiounian,  \X0D\\X0A\\X0D\\X0A\",MICROSCOPIC DESCRIPTION,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left breast needle localization\X0D\\X0A\B: Right breast needle localization\X0D\\X0A\,,
REG1,BREAST,0,485362,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is breast cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: LeVAN, THERESE-ANNE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, simple mastectomy w/o lymph nodes\X0D\\X0A\2: Lymph Node, Sentinel Node\X0D\\X0A\3: Breast, simple mastectomy w/o lymph nodes\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Dec 05 2011]. ER positive, PR positive, HER2/Neu by FISH negative\X0D\\X0A\(1.05). 1. RIGHT BREAST STEREOTACTIC BIOPSY SITE #1: Intermediate grade in situ\X0D\\X0A\ductal adenocarcinoma with central comedonecrosis and focal dystrophic\X0D\\X0A\calcification; small focus suspicious for Infiltrating carcinoma. 2. RIGHT\X0D\\X0A\BREAST STEREOTACTIC BIOPSY SITE #2: Nonproliferative fibrocystic change, no in\X0D\\X0A\situ or invasive carcinoma identified. (DGD)\X0D\\X0A\***PATH-NUMBER[2], **DATE[Sep 08 2008]. LEFT BREAST, STEREOTACTIC CORE BIOPSIES: Fibrocystic\X0D\\X0A\change with focal adenosis. Microcalcifications present. Negative for in-situ\X0D\\X0A\and invasive carcinoma. (JFJ)\X0D\\X0A\***PATH-NUMBER[3], **DATE[Feb 12 2009]. RIGHT BREAST, ULTRASOUND GUIDED BIOPSIES: Tiny fragments\X0D\\X0A\consistent with fibroadenoma. (DGD)","Final Diagnosis\X0D\\X0A\1.          LEFT BREAST TISSUE, SIMPLE MASTECTOMY:\X0D\\X0A\     Nonproliferative fibrocystic change with small sclerotic intraductal\X0D\\X0A\papilloma; no in situ or invasive carcinoma identified.\X0D\\X0A\Skin and subareolar zone unremarkable.\X0D\\X0A\2.          SENTINEL LYMPH NODES:\X0D\\X0A\     Lymph nodes x2; no tumor or granulomatous inflammation identified.\X0D\\X0A\3.          RIGHT BREAST TISSUE, SIMPLE MASTECTOMY:\X0D\\X0A\     Focal residual intermediate-grade ductal carcinoma in situ; tumor size\X0D\\X0A\7x3x3 mm; margins of excision negative for tumor; no invasive carcinoma\X0D\\X0A\identified; lymphvascular invasion absent.\X0D\\X0A\Skin and nipple unremarkable.\X0D\\X0A\DGD/mbc\X0D\\X0A\     BREAST DCIS (LUMPECTOMY/MASTECTOMY)\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  Simple mastectomy.\X0D\\X0A\LYMPH NODE SAMPLING:  Yes.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\SPECIMEN SIZE (3 DIMENSIONS):  422.2 grams, 18.0x15.0x4.0 cm. \X0D\\X0A\LATERALITY:  Right.\X0D\\X0A\TUMOR SITE:  Right breast, not otherwise specified.\X0D\\X0A\SIZE (Extent) OF DCIS COMPONENT (greatest dimension):  7x3x3 mm.\X0D\\X0A\HISTOLOGIC TYPE:  Ductal.\X0D\\X0A\NUCLEAR GRADE:  Grade 2.\X0D\\X0A\NECROSIS (PRESENT/ABSENT):  Focally present.\X0D\\X0A\MARGIN STATUS (SPECIFY MARGIN):  Negative.\X0D\\X0A\     DISTANCE FROM MARGIN:  Greater than 1 cm from the superficial margin and\X0D\\X0A\best approximation is 0.5 cm from the deep margin.\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  Lymph nodes x2; negative for tumor.\X0D\\X0A\ESTROGEN RECEPTOR STATUS (IHC):  Positive per previous biopsy ***PATH-NUMBER[1].\X0D\\X0A\PROGESTERONE RECEPTOR STATUS (IHC):  Positive per previous biopsy ***PATH-NUMBER[1].\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:   None.\X0D\\X0A\OTHER STUDIES:  HER2/Neu by FISH negative (1.05) per previous biopsy ***PATH-NUMBER[1].\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  DCIS\X0D\\X0A\pN=   0\X0D\\X0A\AJCC PATHOLOGIC STAGE:    0.\X0D\\X0A\DGD/mbc",,"Gross Description\X0D\\X0A\Specimen 1 labeled left breast tissue, received in formalin, consists of a 471\X0D\\X0A\gram, 18.0x16.0x4.0 cm intact simple mastectomy specimen. The specimen is\X0D\\X0A\partially surfaced by a 5.5x3.8 cm tan wrinkled skin ellipse. The everted nipple\X0D\\X0A\measures 1.4 cm in diameter. The deep margin is inked black and sectioning\X0D\\X0A\reveals approximately equal proportions of yellow adipose tissue and dense white\X0D\\X0A\fibrocystic breast tissue. No masses, suspicious lesions or previous biopsy\X0D\\X0A\sites are identified. Representative sections are submitted. Summary of\X0D\\X0A\sections: 1A-1I  representative sections of fibrocystic breast tissue; 1J \X0D\\X0A\representative section of nipple. \X0D\\X0A\Specimen 2 labeled #1 sentinel node and #2 sentinel node, received fresh for\X0D\\X0A\frozen section, consists of two tan/pink lymph nodes measuring 0.8 and 1.5 cm in\X0D\\X0A\greatest dimension which are submitted entirely for frozen section, now\X0D\\X0A\resubmitted in cassette 2. \X0D\\X0A\Specimen 3 labeled right breast tissue, received in formalin, consists of a\X0D\\X0A\422.2 gram intact simple mastectomy specimen with overall dimensions of\X0D\\X0A\18.0x15.0x4.0 cm. The specimen is partially surfaced by a 6.0x3.5 cm tan\X0D\\X0A\wrinkled skin ellipse. The everted nipple measures 1.4 cm in diameter. There is\X0D\\X0A\a suture designating the superior aspect. The margins are inked as follows:\X0D\\X0A\superficial margin blue, deep margin black, and sectioning reveals a 0.8x0.8x0.7\X0D\\X0A\cm tan/pink biopsy cavity, 1.5 cm from the deep margin and 1.7 cm from the\X0D\\X0A\superficial margin. Located 3.3 cm lateral from this site is a 1.1x0.8x0.8 cm\X0D\\X0A\tan biopsy site containing a metal clip. The more lateral biopsy site is 0.8 cm\X0D\\X0A\from the deep margin and 1.9 cm from the superficial margin. The tissue between\X0D\\X0A\the two biopsy sites is tan/pink and fibrocystic. The two biopsy sites are\X0D\\X0A\located in the upper central to outer quadrant. Sectioning through the remaining\X0D\\X0A\breast tissue reveals dense white fibrocystic breast tissue. No other definitive\X0D\\X0A\masses or biopsy sites are identified. Representative sections are submitted.\X0D\\X0A\Summary of sections: 3A-3D  central upper quadrant biopsy cavity submitted in\X0D\\X0A\its entirety to include deep and superficial margins; 3E-3F  breast tissue\X0D\\X0A\between the two biopsy sites; 3G-3H  second more lateral biopsy site to include\X0D\\X0A\deep and superficial margin; 3I  large cyst/suspicious area directly adjacent\X0D\\X0A\second more lateral biopsy site; 3J-3K  representative sections of fibrous\X0D\\X0A\breast tissue from the upper inner quadrant located approximately 3  3.5 cm from\X0D\\X0A\the first more central biopsy cavity; 3L-3M  representative sections of fibrous\X0D\\X0A\breast tissue from the central aspect of the breast located approximately 1.5  2\X0D\\X0A\cm from the more central biopsy cavity; 3N-3O  representative sections of breast\X0D\\X0A\tissue from the lower inner quadrant approximately 4.5  5 cm from the first more\X0D\\X0A\central biopsy cavity; 3P-3Q  representative sections of fibrous breast tissue\X0D\\X0A\from the lower outer quadrant approximately 5 cm from the biopsy cavity; 3R \X0D\\X0A\representative section of nipple. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Multiple representative sections of the breast show numerous dilated ducts,\X0D\\X0A\scattered benign lobular units and focal microcalcifications. The ducts show no\X0D\\X0A\epithelial proliferation and occasional ducts show apocrine metaplastic change.\X0D\\X0A\One of the ducts shows a small sclerotic intraductal papilloma. Sections of the\X0D\\X0A\skin of nipple are remarkable for benign squamous epithelium without atypia and\X0D\\X0A\no evidence of lymphvascular infiltration in the dermal lymphatics. There is a\X0D\\X0A\small fibroadenoma less than 1 mm in size in block 1I. \X0D\\X0A\Sections of the two lymph nodes show mildly reactive nodes with a modest degree\X0D\\X0A\of sinus histiocytosis. There is no evidence of granulomatous inflammation or\X0D\\X0A\metastatic tumor.\X0D\\X0A\Sections of the right breast show a single small focus of residual\X0D\\X0A\intermediate-grade ductal carcinoma in situ. The tumor shows a focus where duct\X0D\\X0A\epithelium is overfilling the ducts and the nuclear features of the epithelium\X0D\\X0A\are relatively pleomorphic with prominent macronucleoli compatible with DCIS.\X0D\\X0A\Numerous calcifications are seen within the affected ducts. Also noted in the\X0D\\X0A\background breast tissue are large areas of proliferative fibrocystic change and\X0D\\X0A\some of the dilated ducts show apocrine metaplastic alterations. No\X0D\\X0A\lymphvascular invasion is identified. \X0D\\X0A\DGD/mbc",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,BREAST,0,485587,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RIGHT BREAST MASS\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\    RIGHT BREAST AXILLARY TAIL, EXCISIONAL BIOPSY.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\    WELL-DIFFERENTIATED INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 1             (SCORE:\X0D\\X0A\TUBULE FORMATION 3/3 + PLEOMORPHISM 1/3 + MITOTIC COUNT\X0D\\X0A\        1/3=5/9).\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   3430 Newburg Rd.\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Sep 23 11]                 **PLACE Clinical Associates                    PAGE:   8\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA] L              DOB: **DATE[Aug 02 1961]   Sex: F\X0D\\X0A\Add:4312 **PLACE,KY **ZIP-CODE  **PHONE                                                            \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  REG SDC   Location:  D.SURG                 \X0D\\X0A\Reg:   **DATE[Aug 05 11]     Disch:           SS: **ID-NUM    Race: BL        \X0D\\X0A\**NAME[CCC:DDD,EEE M] XXX], MD   Submit:**NAME[DDD,EEE M] XXX], MD        MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS Dr.             **PLACE                     KY           \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:  (Continued)\X0D\\X0A\\X0D\\X0A\   **NAME[DDD,EEE M] XXX], MD\X0D\\X0A\   **STREET-ADDRESS Dr.\X0D\\X0A\   **PLACE, KY\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88360GS/2, 88307GS, 88342GS/2\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[WWW M VVV] MD **DATE[Aug 07 11]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Sep 23 11]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST SYNOPTIC REPORT\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\RIGHT BREAST AXILLARY TAIL, EXCISIONAL BIOPSY.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\WELL-DIFFERENTIATED INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 1             (SCORE:\X0D\\X0A\TUBULE FORMATION 3/3 + PLEOMORPHISM 1/3 + MITOTIC COUNT\X0D\\X0A\1/3=5/9).\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\GREATEST DIMENSION OF INVASIVE CARCINOMA IS 2.2 CM (MICROSCOPIC\X0D\\X0A\MEASUREMENT).\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\RIGHT BREAST UPPER OUTER QUADRANT.\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS):\X0D\\X0A\NON-EXTENSIVE DCIS, INTERMEDIATE GRADE, CRIBRIFORM TYPE WITH FOCAL\X0D\\X0A\NECROSIS.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\DCIS IS MULTIFOCAL (TWO FOCI).\X0D\\X0A\FOCI OF DCIS RANGE FROM 1.6 TO 2.2 MM IN GREATEST DIMENSION.\X0D\\X0A\MARGINS:\X0D\\X0A\NO TUMOR IDENTIFIED ON THE INKED EXCISION MARGINS.\X0D\\X0A\DISTANCE FROM INVASIVE CARCINOMA TO CLOSEST MARGIN IS 2.0 MM.\X0D\\X0A\DISTANCE FROM DCIS TO CLOSEST MARGIN IS 3.7 MM.\X0D\\X0A\MACROSCOPIC AND MICROSCOPIC TUMOR EXTENT:\X0D\\X0A\SKIN - NOT PRESENT.\X0D\\X0A\NIPPLE - NOT PRESENT.\X0D\\X0A\SKELETAL MUSCLE - NOT PRESENT.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\MICROCALCIFICATIONS:\X0D\\X0A\IDENTIFIED ASSOCIATED WITH DCIS.\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\NO PRIOR TREATMENT.\X0D\\X0A\SPECIMEN SIZE:\X0D\\X0A\8.5 X 7.0 X 3.0 CM.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\INTACT.\X0D\\X0A\LOBULAR CARCINOMA IN SITU:\X0D\\X0A\IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\NONE SAMPLED.\X0D\\X0A\ADDITIONAL FINDINGS:\X0D\\X0A\FLAT EPITHELIAL ATYPIA.\X0D\\X0A\ATYPICAL DUCT HYPERPLASIA.\X0D\\X0A\PROLIFERATIVE FIBROCYSTIC CHANGES.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\REPORT ON HORMONE RECEPTOR, HER-2/NEU AND KI-67 ANALYSIS TO FOLLOW AS AN\X0D\\X0A\ADDENDUM.\X0D\\X0A\ESTIMATED COLD ISCHEMIA TIME:\X0D\\X0A\LESS THAN 1 HOUR.\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME IN FORMALIN:\X0D\\X0A\6-72 HOURS.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  pT2 pNX pMn/a.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual 7th edition\X0D\\X0A\guidelines.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Reviewed for QA(LK).\X0D\\X0A\\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received fresh designated ""right breast axillary tail"" is an ovoid fragment of yellow-tan,\X0D\\X0A\lobulated, adipose tissue measuring 8.5 x 7.0 x 3.0 cm.  The specimen is marked with black\X0D\\X0A\ink and serially sectioned across the short axis to reveal unremarkable, yellow-tan,\X0D\\X0A\lobulated adipose tissue with focal hemorrhage.  Focal areas of dense white fibrous soft\X0D\\X0A\tissue are noted.  A distinct mass is not grossly identified.  Multiple representative\X0D\\X0A\sections, to include full cross-sections of the dense, white, fibrous areas, are submitted\X0D\\X0A\as follows:\X0D\\X0A\\X0D\\X0A\1.    representative section of white fibrous tissue\X0D\\X0A\2-5.    one complete cross-section, sectioned\X0D\\X0A\6-11.    one complete cross-section, sectioned\X0D\\X0A\12-17.    one complete cross-section, sectioned\X0D\\X0A\18-23.    one complete cross-section, sectioned\X0D\\X0A\24.    representative section\X0D\\X0A\\X0D\\X0A\Following microscopic examination, the remaining specimen is entirely submitted as follows:\X0D\\X0A\\X0D\\X0A\25.    one complete cross-section\X0D\\X0A\26\T\27.    one complete cross-section, bisected\X0D\\X0A\28\T\29.    remaining cross-section associated with cassette #1\X0D\\X0A\30-32.    remaining cross-section associated with cassette #24\X0D\\X0A\33-35.    one complete cross-section, sectioned\X0D\\X0A\36\T\37.    one complete cross-section, bisected\X0D\\X0A\38.    one complete cross-section, bisected\X0D\\X0A\\X0D\\X0A\NOTE:  Time tissue removed from patient - 9:22 a.m.; time received in pathology - 9:27 a.m.;\X0D\\X0A\time tissue cut into 5 mm sections - 9:50 a.m.  **INITIALS\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\38 H\T\E\X0D\\X0A\,"SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\RIGHT BREAST AXILLARY TAIL, FRESH AT 0922\X0D\\X0A\",,"ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #3              Entered: **DATE[Sep 22 11]-1611\X0D\\X0A\\X0D\\X0A\REPORT FROM GENOMIC HEALTH\X0D\\X0A\ONCOTYPE DX BREAST CANCER ASSAY\X0D\\X0A\REDWOOD CITY, CA 94063\X0D\\X0A\\X0D\\X0A\The specimen was sent at the request of Dr. **NAME[UUU TTT] with **PLACE Oncology.\X0D\\X0A\\X0D\\X0A\RESULTS\X0D\\X0A\\X0D\\X0A\Breast Cancer Recurrence Score = 14\X0D\\X0A\\X0D\\X0A\CLINICAL EXPERIENCE:  PROGNOSIS FOR NODE NEGATIVE, ER-POSITIVE PATIENTS\X0D\\X0A\The Clinical Validation study included female patients with Stage I or II, Node Negative,\X0D\\X0A\ER-Positive breast cancer treated with 5 years of tamoxifen.  Those patients who had a\X0D\\X0A\Recurrence Score of 14 had an Average Rate of Distant Recurrence of 9% (95%CI: 6%-12%)\X0D\\X0A\\X0D\\X0A\Please see scanned report for more detailed information, graphs and references.\X0D\\X0A\\X0D\\X0A\RESULTS\X0D\\X0A\\X0D\\X0A\Breast Cancer Recurrence Score = 14\X0D\\X0A\\X0D\\X0A\CLINICAL EXPERIENCE:  CHEMOTHERAPY BENEFIT\X0D\\X0A\FOR NODE NEGATIVE, ER-POSITIVE PATIENTS\X0D\\X0A\\X0D\\X0A\Please see graphs on scanned report, page 2.\X0D\\X0A\\X0D\\X0A\QUANTITATIVE SINGLE GENE REPORT\X0D\\X0A\\X0D\\X0A\ER Score = 8.5        Positive\X0D\\X0A\\X0D\\X0A\PR Score = 8.7        Positive\X0D\\X0A\\X0D\\X0A\HER2 Score = 8.7    Negative\X0D\\X0A\\X0D\\X0A\Please see graphs on scanned report, page 3.\X0D\\X0A\\X0D\\X0A\Laboratory Director:  **NAME[SSS RRR], M.D.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Addendum #2              Entered: **DATE[Aug 13 11]-1244\X0D\\X0A\\X0D\\X0A\FISH Analysis Her-2/neu Amplification\X0D\\X0A\(***PATH-NUMBER[1] / MO11-248)\X0D\\X0A\\X0D\\X0A\Interpretation\X0D\\X0A\\X0D\\X0A\Amplification of the HER-2 gene is not detected.\X0D\\X0A\\X0D\\X0A\Results\X0D\\X0A\\X0D\\X0A\Her-2         CEP17           Ratio\X0D\\X0A\(red)         (green)\X0D\\X0A\\X0D\\X0A\Number of copies:                  2.2            2.2                   1.0\X0D\\X0A\\X0D\\X0A\Specimen Data\X0D\\X0A\\X0D\\X0A\There are 20 invasive tumor cells present for evaluation with 1 observers.\X0D\\X0A\\X0D\\X0A\Principle\X0D\\X0A\\X0D\\X0A\HER-2/neu FISH testing is performed in compliance with the ASCO/CAP guidelines. The\X0D\\X0A\procedure in use has been modified from the FDA approved procedure (PathVysion from Vysis)\X0D\\X0A\by increasing the enzyme digestion to 20 minutes and using DAPI II as a counterstain.  The\X0D\\X0A\Flow Cytometry Laboratory takes responsibility for test performance, and the validation\X0D\\X0A\performed has proven extremely high between IHC and FISH.  Tissue sections are\X0D\\X0A\deparaffinized, pretreated and digested, then probed and incubated overnight, along with\X0D\\X0A\appropriate controls.  Two separate probes are used from Vysis:  a Spectrum Orange Her-2\X0D\\X0A\probe that is locus-specific and a Spectrum Green centromere probe for Chromosome 17.  The\X0D\\X0A\slides are counterstained with DAPI to produce an enhanced visualization of probe\X0D\\X0A\reactivity.\X0D\\X0A\\X0D\\X0A\Analysis\X0D\\X0A\\X0D\\X0A\The slides are viewed under a fluorescent microscope. The level of HER-2 gene amplification\X0D\\X0A\is measured as a ratio of orange (Her-2) fluorescent foci to green (CEP 17) fluorescent\X0D\\X0A\foci. A positive result is a ratio >2.2, and a negative result is a ratio <1.8.  A ratio\X0D\\X0A\between 1.8-2.2 is considered equivocal amplification.\X0D\\X0A\\X0D\\X0A\References\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\1) Wolff A.C. et al. (2007); JCO 25: 118-145.\X0D\\X0A\2) J.H.J.M. van Krieken et al. (2007); Leukemia 21: 201-206.\X0D\\X0A\3) Gonzalez-Angulo A.M. et al. (2006); The Oncologist 11: 857-867.\X0D\\X0A\4) Yaziji H. et al. (2004); JAMA **PHONE-1977.\X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Aug 08 11]-0907\X0D\\X0A\\X0D\\X0A\ER/PR and Ki-67 Results\X0D\\X0A\\X0D\\X0A\INTERPRETATION:     Positive for ER.\X0D\\X0A\Positive for PR.\X0D\\X0A\Ki-67 = 3%.\X0D\\X0A\\X0D\\X0A\NOTE:  FISH HER2/neu study to follow as an additional addendum.\X0D\\X0A\\X0D\\X0A\Materials Received:\X0D\\X0A\\X0D\\X0A\Block #: DS11=3593, block 15\X0D\\X0A\**INSTITUTION\X0D\\X0A\Fixative: Neutral Buffered Formalin\X0D\\X0A\Duration of Fixation (> 6 hours and < 72 hours):  Yes\X0D\\X0A\Cold Ischemia time:  < 1 hour\X0D\\X0A\\X0D\\X0A\Modified **NAME[QQQ] Score\X0D\\X0A\\X0D\\X0A\Antibody/Clone\X0D\\X0A\Proportion Score*\X0D\\X0A\Intensity Score+\X0D\\X0A\Results\X0D\\X0A\\X0D\\X0A\ER/6F11\X0D\\X0A\5\X0D\\X0A\2\X0D\\X0A\Positive\X0D\\X0A\\X0D\\X0A\PR/1P4\X0D\\X0A\5\X0D\\X0A\2\X0D\\X0A\Positive\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\*Proportion Score\X0D\\X0A\\X0D\\X0A\+Intensity Score\X0D\\X0A\\X0D\\X0A\Score\X0D\\X0A\% Tumor Cells Stained\X0D\\X0A\\X0D\\X0A\Score\X0D\\X0A\Value\X0D\\X0A\\X0D\\X0A\0\X0D\\X0A\0\X0D\\X0A\\X0D\\X0A\0\X0D\\X0A\Negative\X0D\\X0A\\X0D\\X0A\1\X0D\\X0A\1\X0D\\X0A\\X0D\\X0A\1\X0D\\X0A\Weak\X0D\\X0A\\X0D\\X0A\2\X0D\\X0A\10\X0D\\X0A\\X0D\\X0A\2\X0D\\X0A\Intermediate\X0D\\X0A\\X0D\\X0A\3\X0D\\X0A\33\X0D\\X0A\\X0D\\X0A\3\X0D\\X0A\Strong\X0D\\X0A\\X0D\\X0A\4\X0D\\X0A\66\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\5\X0D\\X0A\100\X0D\\X0A\\X0D\\X0A\Detection System: Polymer\X0D\\X0A\Internal and External Controls: Adequate\X0D\\X0A\\X0D\\X0A\Technique description:\X0D\\X0A\Using appropriate positive and negative controls this specimen is stained for the presence\X0D\\X0A\of immunoreactive estrogen and progesterone receptor, and Ki-67 via an automated\X0D\\X0A\immunohistochemical technique utilizing appropriate epitope enhancement.\X0D\\X0A\\X0D\\X0A\References:\X0D\\X0A\Arch Pathol Lab Med 2007; 131:1-26\X0D\\X0A\Arch Pathol Lab Med 2010; **ID-NUM\X0D\\X0A\\X0D\\X0A\ADDENDUM.\X0D\\X0A\ESTIMATED COLD ISCHEMIA TIME:\X0D\\X0A\LESS THAN 1 HOUR.\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME IN FORMALIN:\X0D\\X0A\6-72 HOURS.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  pT2 pNX pMn/a.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual 7th edition\X0D\\X0A\guidelines.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS    \X0D\\X0A\\X0D\\X0A\Reviewed for QA(LK).\X0D\\X0A\\X0D\\X0A\CLINICAL HISTORY       \X0D\\X0A\\X0D\\X0A\RIGHT BREAST MASS\X0D\\X0A\\X0D\\X0A\SPECIMEN INFORMATION     \X0D\\X0A\\X0D\\X0A\RIGHT BREAST AXILLARY TAIL, FRESH AT 0922\X0D\\X0A\\X0D\\X0A\GROSS DESCRIPTION       \X0D\\X0A\\X0D\\X0A\Received fresh designated ""right breast axillary tail"" is an ovoid fragment of yellow-tan,\X0D\\X0A\lobulated, adipose tissue measuring 8.5 x 7.0 x 3.0 cm.  The specimen is marked with black\X0D\\X0A\ink and serially sectioned across the short axis to reveal unremarkable, yellow-tan,\X0D\\X0A\lobulated adipose tissue with focal hemorrhage.  Focal areas of dense white fibrous soft\X0D\\X0A\tissue are noted.  A distinct mass is not grossly identified.  Multiple representative\X0D\\X0A\sections, to include full cross-sections of the dense, white, fibrous areas, are submitted\X0D\\X0A\as follows:\X0D\\X0A\\X0D\\X0A\1.    representative section of white fibrous tissue\X0D\\X0A\2-5.    one complete cross-section, sectioned\X0D\\X0A\6-11.    one complete cross-section, sectioned\X0D\\X0A\12-17.    one complete cross-section, sectioned\X0D\\X0A\18-23.    one complete cross-section, sectioned\X0D\\X0A\24.    representative section\X0D\\X0A\\X0D\\X0A\Following microscopic examination, the remaining specimen is entirely submitted as follows:\X0D\\X0A\\X0D\\X0A\25.    one complete cross-section\X0D\\X0A\26\T\27.    one complete cross-section, bisected\X0D\\X0A\28\T\29.    remaining cross-section associated with cassette #1\X0D\\X0A\30-32.    remaining cross-section associated with cassette #24\X0D\\X0A\33-35.    one complete cross-section, sectioned\X0D\\X0A\36\T\37.    one complete cross-section, bisected\X0D\\X0A\38.    one complete cross-section, bisected\X0D\\X0A\\X0D\\X0A\NOTE:  Time tissue removed from patient - 9:22 a.m.; time received in pathology - 9:27 a.m.;\X0D\\X0A\time tissue cut into 5 mm sections - 9:50 a.m.  **INITIALS\X0D\\X0A\\X0D\\X0A\MICROSCOPIC DESCRIPTION    \X0D\\X0A\\X0D\\X0A\38 H\T\E\X0D\\X0A\\X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[ZZZ,YYY M]\X0D\\X0A\3430 Newburg Rd.\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\**NAME[DDD,EEE M] XXX], MD\X0D\\X0A\**STREET-ADDRESS Dr.\X0D\\X0A\**PLACE, KY\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88360GS/2, 88307GS, 88342GS/2\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[WWW M VVV] MD **DATE[Aug 07 11]\X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Sep 23 11]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\"
REG1,BREAST,0,486021,1,,Clinical Diagnosis and History\X0D\\X0A\MASS\X0D\\X0A\NOT FOR CALCIFICATIONS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LT BREAST BX-NOT FOR CALCS-ls-REMOVED 1032, IN FORMALIN 1033","Final Diagnosis\X0D\\X0A\LEFT BREAST:\X0D\\X0A\     INVASIVE MAMMARY CARCINOMA, FAVOR DUCTAL TYPE.\X0D\\X0A\     PREDICTED NOTTINGHAM HISTOLOGIC GRADE 3 (TUBULES=3, NUCLEAR\X0D\\X0A\        PLEOMORPHISM=3, MITOSES=3).\X0D\\X0A\     NO DEFINITE ANGIOLYMPHATIC INVASION.\X0D\\X0A\     INVASIVE CARCINOMA IS PRESENT IN FOUR CORES, MAXIMUM DIMENSION OF INVASION\X0D\\X0A\        1.6 CM.\X0D\\X0A\COMMENT: Hormone receptor studies are pending.  E-cadherin is also being\X0D\\X0A\performed.\X0D\\X0A\MER/cb \X0D\\X0A\IHC/a/CLS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D.,  MARK E.",,Gross Description\X0D\\X0A\Received in formalin designated 'left breast' are four slivers of tan tissue\X0D\\X0A\each 0.1 cm in diameter and ranging in length from 0.4  1.9 cm.  All are\X0D\\X0A\submitted labeled 1A.  Processed and resubmitted into formalin at 11: 22 am on\X0D\\X0A\**DATE[Aug 27 11].  MER/in,Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Aug 28 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 28 2011]     By:  **NAME[YYY, XXX]\X0D\\X0A\     Date Reported:     **DATE[Aug 28 2011]         \X0D\\X0A\Addendum Comment\X0D\\X0A\An immunohistochemical stain has been performed for e-cadherin, on block 1A,\X0D\\X0A\using appropriate controls, and is strongly positive supporting classification\X0D\\X0A\of this invasive neoplasm as ductal type.\X0D\\X0A\MER/cb \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Sep 1 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 1 2011]     By:  **NAME[YYY, XXX]\X0D\\X0A\     Date Reported:     **DATE[Sep 1 2011]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding Breast Cancer Biomarker Analysis.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D.,  MARK E."
REG1,BREAST,0,486098,1,,"Clinical Diagnosis and History\X0D\\X0A\LEFT PLEURAL EFFUSION, BREAST CA\X0D\\X0A\OPER:  LEFT VAT\X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX#1:  METASTATIC CARCINOMA.  **INITIALS","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D.,  **NAME[YYY]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: PLEURAL BIOPSY, FROZEN SECTION    bmc\X0D\\X0A\2: PLEURAL BIOPSY, FRESH     bmc","Final Diagnosis\X0D\\X0A\1\E\T\E\2:  ""PLEURA BIOPSY"":\X0D\\X0A\         MALIGNANT EPITHELIOD NEOPLASM (SEE COMMENT).\X0D\\X0A\Comment:  A limited panel of immunostains with appropriate controls is performed\X0D\\X0A\on block 2A and is inconclusive: negative for mammoglobin, calretinin (tumor\X0D\\X0A\cells) and TTF1. Tumor cells show focal staining for CK7. A more complete panel\X0D\\X0A\to include hormone receptors and her2 will be performed (Genzyme Labs) with\X0D\\X0A\separate report to follow.   \X0D\\X0A\THM/in IHC/a/CMK, CLS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D., **NAME[WWW",,"Gross Description\X0D\\X0A\1:  Received fresh for frozen section evaluation labeled ""pleural biopsy"" are\X0D\\X0A\multiple fragments of friable tan white soft tissue, 0.9 x 0.7 x 0.6 cm in\X0D\\X0A\aggregate.  Totally submitted as frozen section.  **INITIALS\X0D\\X0A\2: Received fresh with request for additional to Precision Laboratories labeled\X0D\\X0A\""core biopsy"" are multiple friable fragments of tan gray soft tissue 1.0 x 1.0 x\X0D\\X0A\1.0 cm in aggregate.  Representative portions are submitted to Precision\X0D\\X0A\Laboratories with remaining tissue submitted for routine permanent sections\X0D\\X0A\block 2A.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 14 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 14 2012]     By:  **NAME[UUU, TTT]\X0D\\X0A\     Date Reported:     **DATE[Mar 14 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding Breast Cancer Biomarker Analysis.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[SSS], M.D., **NAME[RRR]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 15 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 15 2012]     By:  **NAME[UUU, TTT]\X0D\\X0A\     Date Reported:     **DATE[Mar 15 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding Breast Cancer Biomarker Analysis.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[QQQ], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 19 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 19 2012]     By:  **NAME[PPP,OOO]\X0D\\X0A\     Date Reported:     **DATE[Mar 19 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\`See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding breast cancer biomarker analysis.   /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **NAME[WWW]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 22 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 22 2012]     By:  **NAME[NNN, MMM LLL]\X0D\\X0A\     Date Reported:     **DATE[Mar 22 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned immunohistochemistry analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file. \X0D\\X0A\Their report in part: These results support interpretation of metastatic breast\X0D\\X0A\carcinoma. Signed **NAME[M KKK] M.D.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **NAME[WWW]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 1 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 1 2012]     By:  **NAME[UUU, TTT]\X0D\\X0A\     Date Reported:     **DATE[Apr 1 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Precision\X0D\\X0A\regarding termination report.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[SSS], M.D., **NAME[RRR"
REG1,BREAST,0,486919,1,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Left breast mass,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\RE      011\X0D\\X0A\PHYSICIAN:       **NAME[ZZZ YYY]    SIGN OUT DATE:   **DATE[Sep 15 2011]\X0D\\X0A\COPIES TO:          **NAME[XXX]\X0D\\X0A\**NAME[WWW]\X0D\\X0A\**NAME[ZZZ YYY,"DIAGNOSIS\X0D\\X0A\LEFT BREAST MASS, NEEDLE BIOPSY:  INFILTRATING LOBULAR CARCINOMA.\X0D\\X0A\CPT4 88305 / ICD9 174.9\X0D\\X0A\ANCILLARY STUDIES (Performed at US Labs) See outside report.\X0D\\X0A\ESTROGEN RECEPTOR: 50%\X0D\\X0A\PROGESTERONE RECEPTOR: 30%\X0D\\X0A\HER-2/NEU RESULT:  0+",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is labeled ""left breast, needle biopsy"" and consists of\X0D\\X0A\four cylinders of fibro-fatty tissue measuring 0.5 x 0.1 cm each.  The\X0D\\X0A\specimen is entirely submitted in one cassette.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of the left breast needle biopsy show an infiltrative\X0D\\X0A\carcinoma with lobular characteristics measuring 0.5 cm greatest\X0D\\X0A\dimension.  The entire process is filled with infiltrative lobular\X0D\\X0A\carcinoma.\X0D\\X0A\<Sign Out Dr. **NAME[VVV]>\X0D\\X0A\**NAME[UUU TTT], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  BREAST MASS, LEFT, SURGICAL EXCISION\X0D\\X0A\U/S guided needle\X0D\\X0A\biopsy",,
REG1,BREAST,0,487816,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is breast cancer. Intraoperative findings: none\X0D\\X0A\provided. Operative procedure: bilateral mastectomy with left sided sentinel\X0D\\X0A\lymph node. Ultrasound and mammogram report from the SCM says 1.8 cm\X0D\\X0A\spiculated mass @ 12:00, 5 cm from nipple on the left breast.\X0D\\X0A\Cf. ***PATH-NUMBER[1] (CNB left breast 12:00 1.8 cm mass 6 cm from nipple):  Invasive\X0D\\X0A\ductal adenocarcinoma, nuclear grade 1, with extensive cribriform DCIS with\X0D\\X0A\focal necrosis\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1A-B/SP1/TP1:  ""NO TUMOR SEEN""---WOC. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Aug 9 1969] (Age: **AGE[in 40s])  FW\X0D\\X0A\Collect Date: **DATE[Mar 12 2012] 15:29\X0D\\X0A\Receipt Date: **DATE[Mar 12 2012] 15:29\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[2]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: P.C. **NAME[WWW], MD     Service: BCC     Location: CASR\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Mar 16 2012] 15:18\X0D\\X0A\RESIDENTS(S): R.K. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\LEFT BREAST, TOTAL MASTECTOMY (C):     INVASIVE DUCTAL ADENOCARCINOMA, WELL\X0D\\X0A\DIFFERENTIATED (pT1c / N0)\X0D\\X0A\SENTINEL LYMPH NODE (16922), LEFT AXILLA (A):\X0D\\X0A\     NO TUMOR SEEN (0/1)\X0D\\X0A\LYMPH NODE, LEFT AXILLA (D):     NO TUMOR SEEN (0/1)\X0D\\X0A\RIGHT BREAST, TOTAL MASTECTOMY (B):     FIBROCYSTIC CHANGES\X0D\\X0A\     NO TUMOR SEEN\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dw/**DATE[Mar 15 2012] **NAME[TTT SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 174.9     MALIGNANT NEOPLASM BREAST NOS (FEMALE)\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: **ID-NUM P110\X0D\\X0A\B: M09450 T0871\X0D\\X0A\C: M09450 T0871\X0D\\X0A\D: M09450 M7432 \X0D\\X0A\F: A: 88331 FS1, 88332 ADD'L FS, 88307\X0D\\X0A\B: 88309\X0D\\X0A\C: 88309, S 67669, S 88360",,"GROSS DESCRIPTION\X0D\\X0A\Four specimens are received. \X0D\\X0A\Specimen A is received fresh for frozen section labeled as sentinel node #1 \X0D\\X0A\left and consists of a red tan soft tissue fragment measuring 2.5 x 2 x 0.8\X0D\\X0A\cm. A single lymph node measures 1.9 x 1.3 x 0.6 cm is identified and\X0D\\X0A\embedded within the adipose tissue. Entire lymph node is serially sectioned.\X0D\\X0A\**INITIALS and entire lymph node is prepared.  Entire lymph node is submitted for\X0D\\X0A\frozen section (FS1A and B). A1  FS1A resubmitted; A2  FS1B resubmitted; A3 \X0D\\X0A\unfrozen adipose tissue entirely.\X0D\\X0A\Specimen B is received fresh then placed in formalin at 2:35 pm labeled as\X0D\\X0A\right breast, suture at 12:00, consists of a right total non-skin sparing\X0D\\X0A\total mastectomy with a black suture at 12:00 weighing 335 grams measuring 16\X0D\\X0A\cm from medial to lateral, 12 cm from superior to inferior and 3.5 cm from\X0D\\X0A\superficial to deep. Deep margin inked black. The specimen is serially\X0D\\X0A\sectioned to reveal tan yellow lobulated fibroadipose breast parenchyma.\X0D\\X0A\Fibrous area present about 40 to 50% of the breast parenchyma. Some fibrous\X0D\\X0A\areas are firm. No definite nodules are identified. The attached portion of\X0D\\X0A\skin measures 20.5 cm from medial to lateral, 9.5 cm from superior to\X0D\\X0A\inferior. The nipple measures 1.4 cm in diameter. The areola measures 3 cm in\X0D\\X0A\diameter. The skin, nipple and areola are grossly unremarkable.\X0D\\X0A\Representative sections: B1  upper inner quadrant 5.5 cm from nipple\X0D\\X0A\representative; B2  area adjacent to B1; B3  B4  lower inner quadrant, 4 cm\X0D\\X0A\and 5 cm from nipple respectively; B5  B6  upper outer quadrant; 10 and 11:00\X0D\\X0A\5.5 cm from nipple; B7  B8  inner outer quadrant 7 and 8:00, 4 cm and 5 cm\X0D\\X0A\from nipple; representative; B9  areola 12 to 3:00 en face; B10  areola 3 to\X0D\\X0A\6:00 en face; B11  areola 6 to 9:00 en face; B12  areola 9 to 12:00 en face;\X0D\\X0A\B13  nipple entirely. \X0D\\X0A\Specimen C is received fresh then placed in formalin at 3 pm labeled as left\X0D\\X0A\breast, stitch at 12:00, consists of a left total non-skin sparing mastectomy\X0D\\X0A\weighing 488 grams, measuring 25 cm from medial to lateral, 12.5 cm from\X0D\\X0A\superior to inferior and 4 cm from superficial to deep. The ellipse of skin\X0D\\X0A\measures 20.5 cm from medial to lateral and 10.5 cm from superior to\X0D\\X0A\inferior. The nipple measures 1.1 cm in diameter. The areola measures 3 cm in\X0D\\X0A\diameter. The skin is tan pink and unremarkable. The nipple and areola is\X0D\\X0A\grossly unremarkable. The deep surface is inked black. No tumor is identified\X0D\\X0A\at the inked surface. The specimen is serially sectioned and reveals an\X0D\\X0A\irregular tan to tan white speculated mass with a metal clip that is\X0D\\X0A\identified at 12:00 5 cm from the nipple. The mass measures 2 x 1.5 x 1.5 cm.\X0D\\X0A\It is located approximately 1.5 cm from the superficial skin surface, 2 cm\X0D\\X0A\from closest deep surface, 3 cm from closest superior margin and 5.5 cm from\X0D\\X0A\closest inferior margin, 6 cm from the closest lateral margin and 6.5 cm from\X0D\\X0A\closest medial margin. The uninvolved breast parenchyma shows multiple\X0D\\X0A\diffuse area of tan white fibrous thickening occupying 30 to 40% of the\X0D\\X0A\breast parenchyma. No other definite mass or abnormality is identified.\X0D\\X0A\Cassette summary: C1  tumor with clip; C2  C4  tumor additional section,\X0D\\X0A\entirely; C5  corresponding closest superficial margin with skin; C6-\X0D\\X0A\corresponding deep margin; C 7  corresponding closest medial margin with skin\X0D\\X0A\ellipse tip; C8  corresponding closest lateral margin with skin ellipse tip;\X0D\\X0A\C9  corresponding closest superior margin; C10  corresponding closest\X0D\\X0A\inferior margin; C11  C12  upper outer quadrant representative; C13  C14 \X0D\\X0A\lower outer quadrant representative; C15  C16  upper inner quadrant\X0D\\X0A\representative; C17  C18  lower inner quadrant representative; C19 \X0D\\X0A\additional section 12:00 4 cm from nipple, inferior and adjacent to the\X0D\\X0A\tumor; C20  areola 12:00 to 3:00 en face; C21  areola 3:00 to 6:00 en face;\X0D\\X0A\C22  areola 6 to 9:00 en face; C23  areola 9 to 12:00 en face; C24  nipple\X0D\\X0A\bisected entirely. \X0D\\X0A\Specimen D is received in formalin labeled as left axillary node and consists\X0D\\X0A\of a tan red soft tissue fragment measuring 3.5 x 1.8 x 1 cm. A single lymph\X0D\\X0A\node measures 3.5 x 1 x 1 cm is identified and embedded within the adipose\X0D\\X0A\tissue. The entire specimen is submitted as follows: D1  D2  lymph node\X0D\\X0A\serially sectioned. D3  remaining adipose tissue entirely.\X0D\\X0A\rgc/**DATE[Mar 15 2012] R.K. **NAME[UUU], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST (template #26)\X0D\\X0A\Last updated **DATE[Jan 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Specimen/procedure:  total mastectomy; SLN biopsy\X0D\\X0A\Specimen integrity:  intact\X0D\\X0A\\X0D\\X0A\Specimen size (for excisions less than total mastectomy):  n/a\X0D\\X0A\Specimen laterality:  left\X0D\\X0A\Tumor site for invasive carcinoma:  12:00, 5 to 6 cm from nipple       \X0D\\X0A\Tumor size (largest one):   2 x 1.5 x 1.5 cm.\X0D\\X0A\Tumor focality:  unifocal    \X0D\\X0A\Histologic type:  ductal adenocarcinoma \X0D\\X0A\Histologic grade (Nottingham histologic score):  1 (tubule formation) + 2\X0D\\X0A\(nuclear atypia) + 1 (mitoses) = score 4 (grade 1)\X0D\\X0A\Ductal carcinoma in situ (DCIS):  >25%; predominantly cribriform /\X0D\\X0A\micropapillary; focal solid with central necrosis; \X0D\\X0A\    low-to-intermediate grade \X0D\\X0A\Lobular carcinoma in situ (LCIS):  not identified\X0D\\X0A\Lymph-vascular invasion: not identifed\X0D\\X0A\Dermal lymph-vascular Invasion (if skin present):  not identified\X0D\\X0A\Microcalcifications:  not identified\X0D\\X0A\Skin:  no tumor involvement \X0D\\X0A\Nipple:  no DCIS present\X0D\\X0A\Skeletal muscle:  no skeletal muscle present \X0D\\X0A\Margins:  negative; closest, 1.5 cm (superficial)\X0D\\X0A\Lymph nodes (if present in current specimen):  \X0D\\X0A\    Number of sentinel lymph nodes examined: 1\X0D\\X0A\    Total number of lymph nodes examined (sentinel and nonsentinel):  2\X0D\\X0A\    Number of lymph nodes with macrometastases (>0.2 cm):  0\X0D\\X0A\    Number of lymph nodes with micrometastases (>0.2 mm-0.2 cm): 0\X0D\\X0A\    Number of lymph nodes with isolated tumor cells (=0.2 mm):  0\X0D\\X0A\    Size of largest metastatic deposit (if present):  n/a\X0D\\X0A\    Extranodal extension:  n/a\X0D\\X0A\Pathologic staging (pTNM) (m: multiple foci of invasive carcinoma)\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\T1c:             >10 mm but =20 mm \X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\N0:                No metastasis identified\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\Not applicable\X0D\\X0A\Ancillary studies:\X0D\\X0A\ ***PATH-NUMBER[1] (core-needle biopsy, left breast) \X0D\\X0A\ER:  positive (>90%)\X0D\\X0A\PR:  positive (>90%)\X0D\\X0A\ On this specimen: \X0D\\X0A\Results of immunostain for HER-2/neu (c-erbB-2):  2+  (Recommend FISH assay) \X0D\\X0A\HER-2/neu (c-erbB-2) immunohistochemical interpretation (based exclusively on\X0D\\X0A\cell-membrane staining)\X0D\\X0A\  Negative                            \X0D\\X0A\         Score 0       No staining or membrane-staining in <10% of tumor\X0D\\X0A\cells\X0D\\X0A\         Score 1+     Faint incomplete membrane-staining in >10% of tumor\X0D\\X0A\cells\X0D\\X0A\ Weak positive\X0D\\X0A\        Score 2+     Weak to moderate complete membrane-staining in >10% of\X0D\\X0A\tumor cells\X0D\\X0A\ Strong positive\X0D\\X0A\        Score 3+     Strong complete membrane-staining in >30% of tumor cells\X0D\\X0A\Comment re HER-2/neu (c-erbB-2) immunostaining\X0D\\X0A\Using appropriate positive and negative controls, the test for the presence\X0D\\X0A\of this oncoprotein is performed by the immunoperoxidase method [primary\X0D\\X0A\antibody:  DAKO polyclonal rabbit anti-human c-erB-2 oncoprotein antibody ID#\X0D\\X0A\A0485; detection system:  Dakocytoenvision (+) R System HRP (DAB) ].  The\X0D\\X0A\results are reported according to the American Society of Clinical Oncology\X0D\\X0A\(ASCO)/College of American Pathologists (CAP) Guideline Recommendations\X0D\\X0A\(2006).\X0D\\X0A\The results of this test are for investigational purposes as its performance\X0D\\X0A\characteristics have not been established.  It should be noted that according\X0D\\X0A\to the literature, the sensitivity for immunohistochemical HER-2/neu\X0D\\X0A\determination is no greater than 80% when compared to molecular or FISH\X0D\\X0A\methods.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\\X0D\\X0A\A resident has participated in this service.  The electronic signature\X0D\\X0A\denotes the pathologist performing and responsible for the pathologic\X0D\\X0A\evaluation.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Sentinel lymph node # 1 left (16922)\X0D\\X0A\B: Right breast\X0D\\X0A\C: Left breast\X0D\\X0A\D: Left axillary node,,
REG1,BREAST,0,487846,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is breast cancer. The operative procedure: left breast\X0D\\X0A\lumpectomy, following needle localization and sentinel node biopsy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION / SP / TP DIAGNOSIS #1-3:  ""NO TUMOR""---WOC. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Jan 12 1949] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Oct 10 2011] 12:32\X0D\\X0A\Receipt Date: **DATE[Oct 10 2011] 12:32\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: P.C. **NAME[WWW], MD     Service: BCC     Location: CAS\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Oct 15 2011] 16:37\X0D\\X0A\RESIDENTS(S): K.K. **NAME[UUU], DO","DIAGNOSIS\X0D\\X0A\LEFT BREAST, NEEDLE LOCALIZATION LUMPECTOMY (D):\X0D\\X0A\   - TWO FOCI OF INFILTRATING DUCTAL CARCINOMA, NOTTINGHAM SCORE 8/9 (see\X0D\\X0A\template).\X0D\\X0A\   - TUMOR SIZE 0.8 CM AND 0.4 CM IN GREATEST DIMENSIONS, RESPECTIVELY.\X0D\\X0A\   - RESECTION MARGINS NEGATIVE FOR TUMOR (0.4 CM FROM CLOSEST SUPERFICIAL\X0D\\X0A\MARGIN, LARGER FOCUS).\X0D\\X0A\   - DUCTAL CARCINOMA IN-SITU, NUCLEAR GRADE 3, SOLID TYPE WITH\X0D\\X0A\COMEDONECROSIS AND ASSOCIATED  \X0D\\X0A\     EPITHELIAL MICROCALCIFICATIONS.\X0D\\X0A\   - PATHOLOGIC STAGE:  pT1b, N0. \X0D\\X0A\   - INVASIVE TUMOR CELLS NEGATIVE FOR ER/PR AND HER-2/NEU ONCOPROTEIN (SCORE\X0D\\X0A\0).\X0D\\X0A\EXTENDED SUPERFICIAL MARGIN, EXCISION (E):\X0D\\X0A\   - BENIGN BREAST TISSUE; NO TUMOR SEEN.\X0D\\X0A\SENTINEL LYMPH NODE #1, EXCISION (A):\X0D\\X0A\   - ONE LYMPH NODE NEGATIVE FOR METASTATIC TUMOR (0/1).\X0D\\X0A\SENTINEL LYMPH NODE #2, EXCISION (B):\X0D\\X0A\   - TWO LYMPH NODES NEGATIVE FOR METASTATIC TUMOR (0/2).\X0D\\X0A\SENTINEL LYMPH NODE #3, EXCISION (C):\X0D\\X0A\   - TWO LYMPH NODES NEGATIVE FOR METASTATIC TUMOR (0/2).\X0D\\X0A\AXILLARY TISSUE, EXCISION (F):\X0D\\X0A\   - ONE LYMPH NODE NEGATIVE FOR METASTATIC TUMOR (0/1).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Oct 12 2011] R.G. **NAME[TTT], MD\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  six\X0D\\X0A\Specimen label:  A) sentinel lymph node #1               \X0D\\X0A\Fixation: fresh for frozen section \X0D\\X0A\Number of pieces: 1\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow pink \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 2 x 2 x 1 cm. A probable node is identified measuring 2 x 0.8 x 0.4\X0D\\X0A\cm. \X0D\\X0A\**INITIALS are done. The node is entirely frozen and the specimen is entirely\X0D\\X0A\submitted as follows: FS1 is submitted in A1; remainder of the specimen is\X0D\\X0A\submitted in A2. \X0D\\X0A\Specimen label:  B) sentinel lymph node #2                 \X0D\\X0A\Fixation: fresh for frozen section \X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow pink \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 3.1 x 2 x 1 cm \X0D\\X0A\A probable node is identified measuring 3 x 0.8 x 0.4 cm. The node is cut\X0D\\X0A\sectioned. \X0D\\X0A\**INITIALS are done. The node is entirely frozen as entirely submitted as follows:\X0D\\X0A\FS2  resubmitted in B1; remaining of specimen is submitted in B2. \X0D\\X0A\Specimen label:  C) sentinel node #3                  \X0D\\X0A\Fixation: fresh for frozen section \X0D\\X0A\Number of pieces: 1\X0D\\X0A\Shape(s): irregular  \X0D\\X0A\Color(s): yellow pink \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 2.7 x 1.3 x 0.6 cm \X0D\\X0A\One probable node is identified measuring 1.8 x 1.2 x 0.6 cm. The node is cut\X0D\\X0A\sectioned.\X0D\\X0A\**INITIALS are done. The node is entirely frozen as FS3. It is entirely submitted\X0D\\X0A\in two cassettes. FS3 is submitted in C1; remainder of specimen  C2. \X0D\\X0A\Specimen D is received fresh labeled left breast lumpectomy needle\X0D\\X0A\localization, short stitch superior, long lateral  ink and cut        and\X0D\\X0A\consists of a yellow white fragment of fibroadipose tissue with two needles\X0D\\X0A\that extend from the lateral to medial edge.  An x-ray is taken and shows a\X0D\\X0A\presence of two probable masses, larger mass adjacent to more peripheral\X0D\\X0A\clip, and smaller mass in posterior inferior aspect of the specimen. Two\X0D\\X0A\clips are confirmed. Cut sectioning of the specimen reveals first mass\X0D\\X0A\adjacent to more peripheral clip, located in lateral superior superficial\X0D\\X0A\aspect of the specimen measuring 1 x 0.7 x 0.6 cm. The mass grossly abuts\X0D\\X0A\superficial margin. Cut sectioning of the mass reveals yellow and red\X0D\\X0A\congested cut surfaces. A second mass is located towards to the second clip,\X0D\\X0A\at medial/inferior posterior aspect of the specimen measuring 0.7 x 0.6 x 0.5\X0D\\X0A\cm. Cut sectioning of the second mass reveals pink tan firm ill-defined cut\X0D\\X0A\surfaces. The second smaller mass is located at the distance of 1 cm\X0D\\X0A\inferiorly and medially from the larger mass.\X0D\\X0A\Note: the tissue is placed in formalin at 11:20 am. \X0D\\X0A\Measurements:\X0D\\X0A\Specimen dimensions: 6.6 cm from medial to lateral, 5.8 cm from superior to\X0D\\X0A\inferior and 2.5 cm from superficial to deep. First mass in the superior\X0D\\X0A\lateral aspect of the specimen measures 1 x 0.7 x 0.6 cm. The first mass\X0D\\X0A\abuts superficial margin and is located at the distance of 0.8 cm from\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.","MICROSCOPIC DESCRIPTION\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST (template #26)\X0D\\X0A\Last updated **DATE[Aug 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Specimen/procedure:  left breast lumpectomy\X0D\\X0A\Specimen integrity:  single intact specimen\X0D\\X0A\\X0D\\X0A\Specimen size:  6.6 x 5.8 x 2.5 cm\X0D\\X0A\Specimen laterality:   left breast \X0D\\X0A\Tumor site for invasive carcinoma:  larger focus (adjacent to more peripheral\X0D\\X0A\clip), smaller focus (towards the second clip)     \X0D\\X0A\Tumor size (largest one):  larger focus 0.8 x 0.6 x 2.5 cm (more peripheral),\X0D\\X0A\smaller focus 0.4 x 0.3 x 0.3 cm\X0D\\X0A\Tumor focality:  two foci  \X0D\\X0A\Histologic type: infiltrating ductal carcinoma\X0D\\X0A\Histologic grade (Nottingham histologic score): \X0D\\X0A\    Glandular (acinar)/tubular differentiation:  2 \X0D\\X0A\     Nuclear pleomorphism:  3 \X0D\\X0A\     Mitotic Count:  3\X0D\\X0A\     Overall Grade:  Grade 3 (score 8)\X0D\\X0A\\X0D\\X0A\Ductal carcinoma in situ (DCIS):  yes, high-grade with epithelial\X0D\\X0A\microcalcifications (associated with larger tumor focus), <25%\X0D\\X0A\                              (DCIS present in 2 blocks out of total 26\X0D\\X0A\\X0D\\X0A\      DCIS architectural pattern(s):  solid type with comedonecrosis \X0D\\X0A\      DCIS nuclear grade:  Grade III (high) \X0D\\X0A\Lobular carcinoma in situ (LCIS):  absent\X0D\\X0A\Lymph-vascular Invasion:  absent \X0D\\X0A\Dermal lymph-vascular Invasion:  no skin present\X0D\\X0A\Microcalcifications:  associated with high-grade DCIS\X0D\\X0A\Skin:    no skin present \X0D\\X0A\Nipple:  no nipple present\X0D\\X0A\Skeletal muscle:  no skeletal muscle present \X0D\\X0A\Margins:  uninvolved, closet margin 0.4 mm from superficial margin (larger\X0D\\X0A\peripheral tumor) and 0.7 mm from superficial margin   \X0D\\X0A\\X0D\\X0A\                       (smaller tumor)\X0D\\X0A\Lymph nodes (if present in current specimen): \X0D\\X0A\    Number of sentinel lymph nodes examined: 5\X0D\\X0A\    Total number of lymph nodes examined (sentinel and nonsentinel): 5 + 1\X0D\\X0A\(axillary) \X0D\\X0A\    Number of lymph nodes with macrometastases (>0.2 cm):  0\X0D\\X0A\         Number of lymph nodes with micrometastases (>0.2 mm-0.2 cm): 0\X0D\\X0A\    Number of lymph nodes with isolated tumor cells (=0.2 mm): 0\X0D\\X0A\    Size of largest metastatic deposit (if present): not applicable\X0D\\X0A\    Extranodal Extension:  not applicable\X0D\\X0A\Clinical history (If available, clinical presentation, radiologic findings,\X0D\\X0A\prior history, etc.): high grade invasive and in-situ carcinoma\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\           pT1b:             >5 mm but =10 mm \X0D\\X0A\REGIONAL LYMPH NODES (pN) \X0D\\X0A\     Note:  (sn): only sentinel node(s) evaluated.  If 6 or more sentinel\X0D\\X0A\nodes and/or nonsentinel nodes are \X0D\\X0A\          removed, this modifier should not be used.\X0D\\X0A\          pN0:                No metastasis identified\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (M)  \X0D\\X0A\                         Not applicable\X0D\\X0A\Additional pathologic findings: biopsy site changes with fibrosis\X0D\\X0A\Ancillary studies:\X0D\\X0A\Estrogen Receptor performed on this specimen (D6, larger focus)\X0D\\X0A\         Results:  negative (0%) \X0D\\X0A\Progesterone Receptor performed on this specimen (D6) \X0D\\X0A\         Results: negative (0%) \X0D\\X0A\HER2/neu \X0D\\X0A\   Immunostain performed on this specimen (D6) \X0D\\X0A\          Results: negative (score 0)\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\The primary antibody clone used for estrogen receptor analysis is Neomarker\X0D\\X0A\clone SP1 and Dako PgR636 for progesterone receptor analysis.  The detection\X0D\\X0A\system for both is Dakocytoenvision (+) R System HRP (DAB).  Only nuclear\X0D\\X0A\staining is counted and any value +/> 1% tumor cell nuclear staining is\X0D\\X0A\considered a positive test.\X0D\\X0A\HER-2/neu (c-erbB-2) Immunohistochemistry\X0D\\X0A\Using appropriate positive and negative controls, the test for the presence\X0D\\X0A\of this oncoprotein is performed by the immunoperoxidase method, and reported\X0D\\X0A\according to the American Society of Clinical Oncology (ASCO)/College of\X0D\\X0A\American Pathologists (CAP) Guideline Recommendations (2006).\X0D\\X0A\IMMUNOHISTOCHEMICAL INTERPRETATION:  CELL MEMBRANE STAINING ONLY (DAKO\X0D\\X0A\Polyclonal Rabbit Anti-Human c-erB-2 Oncoprotein Antibody)\X0D\\X0A\NEGATIVE:  Score 0 (No staining is observed or membrane staining is observed\X0D\\X0A\in less than 10% of the tumor cells).\X0D\\X0A\NEGATIVE:  Score 1+ (A faint/barely perceptible membrane staining is seen in\X0D\\X0A\more than 10% of the tumor cells.  The cells are only stained in part of\X0D\\X0A\their membrane).\X0D\\X0A\WEAK POSITIVE:  Score 2+ (A weak to moderate complete membrane staining is\X0D\\X0A\observed in more than 10% of the tumor cells).\X0D\\X0A\STRONG POSITIVE:  Score 3+ (A strong complete membrane staining is observed\X0D\\X0A\in more than 30% of the tumor cells).\X0D\\X0A\The results of this test are for investigational purposes as its performance\X0D\\X0A\characteristics have not been established.  It should be noted that according\X0D\\X0A\to the literature, the sensitivity for immunohistochemical HER-2/neu\X0D\\X0A\determination is no greater than 80% when compared to molecular or FISH\X0D\\X0A\methods.\X0D\\X0A\Primary antibody:  C-erb B.2 oncoprotein (polyclonal rabbit Dako ID# A0485)\X0D\\X0A\Detection system:  Dakocytoenvision (+) R System HRP (DAB)\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Sentinel lymph node # 1 (no count)\X0D\\X0A\B: Sentinel lymph node # 2 (no count)\X0D\\X0A\C: Sentinel lymph node # 3 (6665)\X0D\\X0A\D: Left breast lumpectomy needle localized\X0D\\X0A\E: Extended superficial medial\X0D\\X0A\F: Axillary tissue,,
REG1,BREAST,0,487858,3,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is right breast palpable lump 10:00, 1 cm from nipple,\X0D\\X0A\6.2 cm irregular hypoechoic mass. Operative procedure: right breast biopsy on\X0D\\X0A\area listed 10:00, 1 cm from nipple, with 14 g core needle, 6 passes, marker\X0D\\X0A\clip placed, ribbon shaped. No core tissue from pass 2 and 3. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\TP #1: ""ATYPICAL""---KA.\X0D\\X0A\TP#2-3: ""BLOOD""---KA.\X0D\\X0A\TP#4: ""SCANT""---KA. \X0D\\X0A\TP #5: ""SUSPICIOUS""---KA. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jun 17 1942] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Apr 7 2012] 11:26\X0D\\X0A\Receipt Date: **DATE[Apr 7 2012] 11:26\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: M.M. **NAME[WWW], MD     Service: FM     Location: MAMM\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Apr 11 2012] 14:47\X0D\\X0A\RESIDENTS(S): J.W. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\RIGHT BREAST, 10 O' CLOCK, 1 CM FROM NIPPLE, 14-GAUGE MAMMOTOME BIOPSY X 6:\X0D\\X0A\   - INFILTRATING LOBULAR CARCINOMA WITH ASSOCIATED MICROCALCIFICATIONS.\X0D\\X0A\   - ER/PR POSITIVE, SEE COMMENT.\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 11 2012] Y.M. **NAME[TTT], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\IMMUNOHISTOCHEMICAL KI-67 INDEX IS ABOUT 30% (SEE COMMENT).\X0D\\X0A\Addendum Comment\X0D\\X0A\Per Dr. **NAME[SSS]' s request immunohistochemical stains for Ki-67 on this biopsy\X0D\\X0A\(***PATH-NUMBER[1]) and subsequent biopsy (post treatment biopsy) (***PATH-NUMBER[2]) are\X0D\\X0A\performed.  Ki-67 index on this biopsy (***PATH-NUMBER[1]) is about 30% and Ki-67 on\X0D\\X0A\the post treatment biopsy (***PATH-NUMBER[2]) is less than 2%.  Therefore, post\X0D\\X0A\treatment biopsy (***PATH-NUMBER[2]) shows much lower Ki-67 index that that of this\X0D\\X0A\biopsy (***PATH-NUMBER[1]).\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\dlf/**DATE[Jun 12 2012] **NAME[RRR QQQ], MD \X0D\\X0A\ICD 9: 174.4     MALIGNANT NEOPLASM UPPER OUTER QUADRANT, FEMALE BREAST\X0D\\X0A\V86.0     ESTROGEN RECEPTOR POSITIVE STATUS (ER POSITIVE)\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M55400 M8520 \X0D\\X0A\F:  C 88333, 67405, C 88334, 67404(4)\X0D\\X0A\A: 88305, 67030-ER, S 88360, 67031-PR, S 88360, 67043 IMHC2, S 88342 (PROF),\X0D\\X0A\S 67693, S 88342 (PROF)",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) right breast biopsy 10:00, 1 cm from nipple              \X0D\\X0A\\X0D\\X0A\Fixation: formalin; time in formalin 11:05 am \X0D\\X0A\Number of pieces: 4\X0D\\X0A\Shape(s): core   \X0D\\X0A\Color(s): yellow to white \X0D\\X0A\Consistency: soft to fatty \X0D\\X0A\Size(s): 1.5 to 0.8 cm in length x 0.2 cm in diameter each\X0D\\X0A\TP were performed by cytology as TP1-5.   \X0D\\X0A\Cassette summary: entirely submitted in screened A1.   \X0D\\X0A\rgc/**DATE[Apr 8 2012] J.W. **NAME[UUU], MD\X0D\\X0A\**NAME[PPP M. OOO","MICROSCOPIC DESCRIPTION\X0D\\X0A\Immunohistochemical stains for E-cadherin, Estrogen and Progesterone\X0D\\X0A\receptors are performed.  The tumor cells are e-cadherin negative supporting\X0D\\X0A\the diagnosis of lobular carcinoma.  Over 90% of tumor nuclei demonstrate\X0D\\X0A\strong positive ER receptor staining.  Approximately 65% of tumor nuclei\X0D\\X0A\demonstrate strong progesterone receptor staining.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\The primary antibody clone used for estrogen receptor analysis is Neomarker\X0D\\X0A\clone SP1 and Dako PgR636 for progesterone receptor analysis.  The detection\X0D\\X0A\system for both is Dakocytoenvision (+) R System HRP (DAB).  Only nuclear\X0D\\X0A\staining is counted and any value +/> 1% tumor cell nuclear staining is\X0D\\X0A\considered a positive test.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: right breast @ 10:00,,PROCEDURES/ADDENDA
REG1,BREAST,0,487935,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is left breast 11:00, 4 cm from nipple, 1.28 x 1.26 x\X0D\\X0A\1.26 cm hypoechoic, irregular shadowing mass. Operative procedure: 5 passes\X0D\\X0A\with a 14 g needle and X-shaped marker clip placement. \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Oct 4 1966] (Age: **AGE[in 40s])  FU\X0D\\X0A\Collect Date: **DATE[Jun 15 2012] 12:00\X0D\\X0A\Receipt Date: **DATE[Jun 15 2012] 12:00\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: M.M. **NAME[YYY], MD     Service: PAT     Location: MAMM\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jun 16 2012] 14:03\X0D\\X0A\RESIDENTS(S): R.K. **NAME[WWW], MD","DIAGNOSIS\X0D\\X0A\LEFT BREAST, 11 O' CLOCK, 4CM FROM NIPPLE, ULTRASOUND GUIDED NEEDLE CORE\X0D\\X0A\BIOPSY (SUSPICIOUS MASS):\X0D\\X0A\- MODERATELY TO POORLY DIFFERENTIATED DUCTAL ADENOCARCINOMA WITH MINIMAL\X0D\\X0A\ASSOCIATED LOW TO INTERMEDIATE GRADE DUCTAL CARCINOMA IN-SITU. TUMOR\X0D\\X0A\IDENTIFIED IN 80% OR ALL 3 CORES. (SEE COMMENT). \X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\lms/**DATE[Jun 16 2012] **NAME[VVV M. UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 174.9     MALIGNANT NEOPLASM BREAST NOS (FEMALE)\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M85002 M8500 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) left breast 11:00, 4 cm from nipple                 \X0D\\X0A\Fixation: formalin; time in formalin 10:15 am\X0D\\X0A\Number of pieces: 5\X0D\\X0A\Shape(s): core   \X0D\\X0A\Color(s): yellow tan to red \X0D\\X0A\Consistency: firm to soft friable and fatty\X0D\\X0A\Size(s): 1.6 x 0.2 x 0.2 cm to 0.5 x 0.1 x 0.1 cm \X0D\\X0A\Cassette summary: entirely submitted in screened A1.  \X0D\\X0A\rgc/**DATE[Jun 16 2012] R.K. **NAME[WWW], MD\X0D\\X0A\**NAME[TTT M. SSS","MICROSCOPIC DESCRIPTION\X0D\\X0A\Block A1, is enclosed for ancillary studies (not performed at this\X0D\\X0A\institution). Patient is being seen at **PLACE' s **INSTITUTION in Miami\X0D\\X0A\Florida. We are keeping one slide for our files.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left breast 11 o'clock 4 cm from nipple,,
REG1,BREAST,0,487944,1,,Clinical History:\X0D\\X0A\None Given,CPT Code(s):   88305.26;  88342.26 ( x 2).\X0D\\X0A\DBC:jlj\X0D\\X0A\Dct:Trs:  **DATE[Mar 08 2012]\X0D\\X0A\**NAME[ZZZ YYY:  XXX WWW VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Mar 08 2012],"Pre-Operative Diagnosis:\X0D\\X0A\Suspect lobular cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Right breast mass, core biopsy:  Intermediate to high grade ductal\X0D\\X0A\carcinoma in situ (DCIS) with focal central comedo necrosis.  Minute\X0D\\X0A\focus of microinvasive carcinoma is present.",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled ""right breast"".  The specimen consists of six\X0D\\X0A\white-tan fibrofatty tissue cores, which are each 0.2 cm in diameter,\X0D\\X0A\and range in length from 0.2 to 1.3 cm.  The specimen is submitted in\X0D\\X0A\toto in a single cassette.  The following times are given on the\X0D\\X0A\requisition:  S     9:35 a.m., E     9:45 a.m., F     9:35 a.m. on **DATE[Mar 7 2012].\X0D\\X0A\**INITIALS","Microscopic Description:\X0D\\X0A\Sections of the core biopsy material demonstrate intermediate to high\X0D\\X0A\grade intraductal carcinoma (DCIS) with predominant solid and cribriform\X0D\\X0A\patterns.  The DCIS is markedly distorted by sclerotic and elastotic\X0D\\X0A\stroma.   Immunohistochemical staining with smooth muscle myosin heavy\X0D\\X0A\chain and p63 shows preservation of myoepithelial cells in the areas of\X0D\\X0A\DCIS.  However, there is a limited focus of small tumor nests which lack\X0D\\X0A\a myoepithelial cell population on immunohistochemical staining.  These\X0D\\X0A\findings are compatible with DCIS with associated microinvasion.\X0D\\X0A\This case has been reviewed by two other pathologists who agree with the\X0D\\X0A\above interpretation.\X0D\\X0A\Tissue Code:  T1.",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right Breast Masses,,
REG1,BREAST,0,488029,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is breast CA right 5-6 mm spiculated mass left breast;\X0D\\X0A\infiltrating well differentiated ductal carcinoma.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ] HALL\X0D\\X0A\**INSTITUTION - COPY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, simple mastectomy w/o lymph nodes\X0D\\X0A\2: Lymph node, regional resection\X0D\\X0A\3: Lymph Node, Sentinel Node\X0D\\X0A\4: Breast, simple mastectomy with lymph nodes\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Nov 20 11]. LEFT BREAST NODULE AT 9:30, STEREOTACTIC BIOPSIES:\X0D\\X0A\Proliferative fibrocystic changes with microcalcifications.  (MHB)\X0D\\X0A\***PATH-NUMBER[2], **DATE[Nov 11 11]. ADDENDUM DIAGNOSIS:  This tumor shows POSITIVE nuclear\X0D\\X0A\staining for Estrogen Receptor (over 90% of tumor nuclei) and POSITIVE staining\X0D\\X0A\for Progesterone Receptor (over 70% of tumor nuclei). Controls stain\X0D\\X0A\appropriately.  COMMENT: 1% or greater numbers of nuclei staining of any\X0D\\X0A\intensity is considered a positive test in our laboratory. ER clone Ventana SPI,\X0D\\X0A\PR clone IE2, IVD approved immunohistochemical stains on formalin fixed,\X0D\\X0A\paraffin embedded tissue.  BREAST, LEFT ULTRASOUND-GUIDED NEEDLE BIOPSY:\X0D\\X0A\Infiltrating well-differentiated ductal carcinoma. (MHB)","Final Diagnosis\X0D\\X0A\1. RIGHT BREAST, SIMPLE MASTECTOMY:\X0D\\X0A\     Proliferative fibrocystic changes with multifocal sclerosing adenosis.\X0D\\X0A\     Calcified cystic fat necrosis compatible with old biopsy cavity.\X0D\\X0A\     No evidence of in situ or invasive carcinoma.\X0D\\X0A\2. RIGHT AXILLARY LYMPH NODES, REGIONAL DISSECTION:\X0D\\X0A\     Four lymph nodes negative for metastatic carcinoma.\X0D\\X0A\3. LEFT AXILLARY SENTINEL LYMPH NODES:\X0D\\X0A\     No metastatic carcinoma identified in three lymph nodes.\X0D\\X0A\4. LEFT BREAST, MASTECTOMY WITH LYMPH NODES:\X0D\\X0A\     No residual carcinoma identified.\X0D\\X0A\     Two biopsy cavities identified, one with adjacent multifocal sclerosing\X0D\\X0A\adenosis.\X0D\\X0A\     No evidence of angiolymphatic permeation by neoplasm.\X0D\\X0A\     Six additional lymph nodes negative for metastatic carcinoma.\X0D\\X0A\**INITIALS\X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE: Mastectomy  \X0D\\X0A\LYMPH NODE SAMPLING:  yes\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  mastectomy\X0D\\X0A\LATERALITY:  left\X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number And Size):  unifocal\X0D\\X0A\TUMOR SITE: left breast central segment \X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  estimated 6 mm per previous\X0D\\X0A\biopsy\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  None\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  none\X0D\\X0A\MACRO EXTENT: no residual \X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  ductal\X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  1 (B-R 4 of 9)\X0D\\X0A\     TUBULAR FORMATION: 1 \X0D\\X0A\     MITOTIC ACTIVITY: 1  \X0D\\X0A\     PLEOMORPHISM:  2\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  nine\X0D\\X0A\SENTINEL NODE STATUS:  0/3\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  no\X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  0/9\X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  n/a\X0D\\X0A\SURGICAL MARGINS: free \X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  5.5 cm. from\X0D\\X0A\superficial\X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  no\X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD: positive per previous biopsy \X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  positive per previous biopsy\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD: N/A\X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  Negative (per ***PATH-NUMBER[2]) with ratio\X0D\\X0A\of 1.14\X0D\\X0A\TREATMENT EFFECT:  none\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  multifocal sclerosing adenosis\X0D\\X0A\OTHER STUDIES: not requested \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  1b\X0D\\X0A\pN=  0 \X0D\\X0A\AJCC PATHOLOGIC STAGE:  1A\X0D\\X0A\JFJ",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled right breast is a 2060 gram, 30.0 x 26.0\X0D\\X0A\x 6.0cm intact simple mastectomy specimen.  The specimen is partially surfaced\X0D\\X0A\by a 24.0 x 17.0 cm tan wrinkled skin ellipse.  The inverted nipple measures\X0D\\X0A\1.0cm in diameter.  The deep margin is inked black and sectioning reveals\X0D\\X0A\predominately yellow fatty adipose tissue with focal areas of dense white\X0D\\X0A\fibrous breast tissue.  No masses or previous biopsy sites are identified.  In\X0D\\X0A\the upper quadrant, there is a cyst identified surrounded by a calcified wall. \X0D\\X0A\No invasive tumor is identified.  Representative sections are submitted. \X0D\\X0A\Summary of Sections: 1A  calcified cyst submitted following decalcification, B-C\X0D\\X0A\ representative sections from upper outer quadrant, D  representative sections\X0D\\X0A\from upper inner quadrant, F-G  representative sections from lower outer\X0D\\X0A\quadrant, H-I  representative sections from lower inner quadrant, J \X0D\\X0A\representative sections of nipple.\X0D\\X0A\Specimen 2 received in formalin labeled right axillary node is a 4.0 x 4.0 x\X0D\\X0A\2.0cm aggregate of fatty soft tissue.  Four lymph nodes are identified ranging\X0D\\X0A\from 0.8 to 2.0cm in greatest dimension.  The nodes are submitted in their\X0D\\X0A\entirety.  Summary of Sections: 2  three intact lymph nodes, B  one bisected\X0D\\X0A\lymph node.\X0D\\X0A\Specimen 3 received fresh for frozen section labeled left sentinel node are\X0D\\X0A\three tan/pink lymph nodes ranging from 0.6 to 1.5cm in greatest dimension which\X0D\\X0A\are submitted entirely for frozen section, now resubmitted in cassette 3.\X0D\\X0A\Specimen 4 received in formalin labeled left breast is a 1830 gram per the\X0D\\X0A\operating room scale, 30.0 x 18.0 breast with an inverted nipple measuring 1.0cm\X0D\\X0A\in diameter.  The deep margin is inked black and sectioning reveals a 1.5 x 1.0\X0D\\X0A\x 1.0cm hemorrhagic biopsy cavity in the central aspect of the breast, 9.0cm\X0D\\X0A\from the deep margin, and 5.5cm from the superficial margin.  No definitive\X0D\\X0A\invasive tumor is identified at the smaller biopsy cavity.  Located\X0D\\X0A\approximately at 9 o'clock aspect is a large hemorrhagic biopsy cavity measuring\X0D\\X0A\2.5 x 2.5 x 2.0cm.  No invasive tumor or suspicious breast tissue is identified\X0D\\X0A\surrounding the second biopsy site.  The remaining cut surface shows nearly\X0D\\X0A\exclusive yellow adipose tissue.  Several lymph nodes are identified in the\X0D\\X0A\upper quadrant.  Representative sections are submitted.  Summary of Sections:\X0D\\X0A\A-B  deep margin closest to smaller biopsy site, C  superficial skin closest to\X0D\\X0A\smaller biopsy site, D-G  entire smaller more central biopsy site, H  larger\X0D\\X0A\hemorrhagic biopsy site, I  nipple, J-K  one bisected lymph node per cassette,\X0D\\X0A\L-M  intact lymph nodes.  **INITIALS","Microscopic Description\X0D\\X0A\Sections from the right breast show in block A an area of cystic degenerative\X0D\\X0A\change with calcification and fat necrosis.  There is no area of surrounding in\X0D\\X0A\situ or invasive carcinoma.  Additional representative sections through breast\X0D\\X0A\parenchyma show areas of fibrosis that change with cystic dilatation of ducts\X0D\\X0A\and dense stromal fibrosis.  Multifocal sclerosing adenosis is noted.  Some of\X0D\\X0A\those areas show microcalcifications.  Sections through nipple and skin show no\X0D\\X0A\evidence of in situ or invasive carcinoma.  The skin shows no dermal lymphatic\X0D\\X0A\involvement by neoplasm.\X0D\\X0A\Sections from right axillary lymph node show four lymph nodes with sinus\X0D\\X0A\histiocytosis and no evidence of primary or metastatic neoplasm.\X0D\\X0A\Sections from the left axillary sentinel lymph node shows similar findings with\X0D\\X0A\sinus histiocytosis and no evidence of primary or metastatic neoplasm.\X0D\\X0A\Sections of specimen 4 show in the central area multifocal areas of sclerosing\X0D\\X0A\adenosis.  With appropriate control, P63 stain in these areas does show a basal\X0D\\X0A\layer around most of the cell groups.  The area from the central region also\X0D\\X0A\shows evidence of biopsy cavity immediately adjacent.  The additional sections\X0D\\X0A\from that area show no additional findings.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY M. XXX], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488035,2,,"Clinical Diagnosis and History\X0D\\X0A\The working history is abnormal mammogram and ultrasound, left breast mass mixed\X0D\\X0A\echogenicity mass in 11 o'clock position may be fibrocystic changes.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\LEFT BREAST AT 11 O'CLOCK, ULTRASOUND GUIDED BIOPSY:\X0D\\X0A\LEFT BREAST ULTRASOUND-GUIDED BIOPSY AT 11 O'CLOCK: \X0D\\X0A\     Infiltrating ductal carcinoma. See COMMENT. \X0D\\X0A\DGD/mbc\X0D\\X0A\PROVISIONAL DIAGNOSIS PENDING IMMUNOHISTOCHEMISTRY:\X0D\\X0A\LEFT BREAST ULTRASOUND-GUIDED BIOPSY AT 11 O'CLOCK: \X0D\\X0A\     Infiltrating mammary carcinoma. See COMMENT. \X0D\\X0A\COMMENT:  This report was faxed to the Radiologist at the Breast Imaging\X0D\\X0A\Services on **DATE[Dec 20 11]. \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled left breast ultrasound biopsy is a 1.5 x 1.0 x 0.3\X0D\\X0A\cm aggregate of tan/pink fibroadipose breast tissue fragments which were placed\X0D\\X0A\in formalin at 2:26 p.m. and are now submitted in one cassette.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections of the left breast fibroadipose connective tissues are infiltrated by a\X0D\\X0A\raggedly advancing ductal carcinomatous lesion. The tumor shows nuclei which are\X0D\\X0A\intermediate in their degree of pleomorphism. Occasional tubule formation is\X0D\\X0A\seen; however, the majority of the lesion in these sections is infiltrating\X0D\\X0A\raggedly. Immunohistochemistry for E-cadherin and the routine tumor markers are\X0D\\X0A\in process. **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: Immunohistochemistry for E-cadherin is\X0D\\X0A\positive. This tumor shows POSITIVE nuclear staining for Estrogen Receptor (over\X0D\\X0A\95% of tumor nuclei) and POSITIVE staining for Progesterone Receptor (over 95%\X0D\\X0A\of tumor nuclei). All controls stain appropriately including external positive,\X0D\\X0A\internal negative and external negative controls as required. \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\DGD/mbc",,,Amendments:\X0D\\X0A\Amended:  **DATE[Dec 22 2011] by **NAME[XXX WWW VVV]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     ER/PR/E-cadherin\X0D\\X0A\Previous Signout Date:  **DATE[Dec 20 2011]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Dec 20 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Dec 29 2011]     By:  **NAME[UUU TTT]\X0D\\X0A\     Date Reported:     **DATE[Dec 29 2011]         \X0D\\X0A\Interpretation\X0D\\X0A\HER2/CEP17 FISH: \X0D\\X0A\     No HER2/Neu gene amplification was observed for this specimen. \X0D\\X0A\HER2/CEP17 RATIO: 1.20 SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,BREAST,0,488043,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is breast CA.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY\X0D\\X0A\**NAME[ZZZ YYY], M.D. \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, simple mastectomy w/o lymph nodes\X0D\\X0A\2: Lymph Node, Sentinel Node\X0D\\X0A\3: Breast, simple mastectomy with lymph nodes\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Jul 27 12]. ADDENDUM COMMENT: This tumor shows POSITIVE nuclear staining\X0D\\X0A\for Estrogen Receptor (over 90% of tumor nuclei) and POSITIVE staining for\X0D\\X0A\Progesterone Receptor (over 90% of tumor nuclei).  Controls stain appropriately.\X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\ HER-2/neu by FISH RESULTS: Negative with ratio of 1.30. 1.  LEFT BREAST\X0D\\X0A\ULTRASOUND-GUIDED BIOPSY AT 12 O'CLOCK:  Infiltrating intermediate grade ductal\X0D\\X0A\adenocarcinoma with focal mucinous features. 2.  LEFT BREAST MASS AT 2 O'CLOCK \X0D\\X0A\ULTRASOUND-GUIDED BIOPSY:  Infiltrating and in situ ductal adenocarcinoma, low\X0D\\X0A\to intermediate grade, lymphvascular invasion not identified.  (DGD)","Final Diagnosis\X0D\\X0A\1. RIGHT BREAST, SIMPLE MASTECTOMY:\X0D\\X0A\     Proliferative fibrocystic changes.  No in situ or invasive carcinoma\X0D\\X0A\identified.\X0D\\X0A\2. LEFT AXILLARY SENTINEL LYMPH NODES:\X0D\\X0A\     No metastasis identified (0/2).\X0D\\X0A\3. LEFT BREAST, SIMPLE MASTECTOMY WITH LYMPH NODE SAMPLING:\X0D\\X0A\     Three separate foci of invasive low and intermediate grade ductal carcinoma\X0D\\X0A\with multifocal ductal \X0D\\X0A\      carcinoma in situ and lobular carcinoma in situ.  Margins free.  See\X0D\\X0A\TEMPLATE.\X0D\\X0A\     No metastasis identified in two axillary lymph nodes.\X0D\\X0A\**INITIALS\X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Mastectomy with lymph node sampling\X0D\\X0A\LYMPH NODE SAMPLING:  Yes\X0D\\X0A\SPECIMEN INTEGRITY:  Intact\X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  N/A\X0D\\X0A\LATERALITY:  Unilateral\X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number and Size):  Multifocal, 2.2,\X0D\\X0A\1.5, and 0.6cm\X0D\\X0A\TUMOR SITE:  Left breast\X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  Largest is 2.2 x 1.8 x 1.8cm\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  Moderate\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  Moderate\X0D\\X0A\MACRO EXTENT:  Multifocal with largest tumor 2.2cm\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Ductal\X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  Intermediate grade, 7/9 (for largest tumor)\X0D\\X0A\     TUBULAR FORMATION:     3\X0D\\X0A\     MITOTIC ACTIVITY:          2\X0D\\X0A\     PLEOMORPHISM:          2\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  0/4\X0D\\X0A\SENTINEL NODE STATUS:  0/2\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  None seen\X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  0/4\X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  N/A\X0D\\X0A\SURGICAL MARGINS:  Free\X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  Approximately\X0D\\X0A\0.9 cm from deep margin\X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  No\X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Positive per biopsy\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Positive per biopsy\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  N/A\X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  Negative (ratio 1.30) per biopsy\X0D\\X0A\TREATMENT EFFECT:  N/A\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  N/A\X0D\\X0A\OTHER STUDIES:  N/A\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  2\X0D\\X0A\pN=  0\X0D\\X0A\AJCC PATHOLOGIC STAGE: IIA\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled right breast for permanent is a 525 gram\X0D\\X0A\per the operating room scale, 17.5 x 17.0 x 4.0cm intact simple mastectomy\X0D\\X0A\specimen.  The specimen is partially surfaced by a 6.0 x 3.5cm tan wrinkled skin\X0D\\X0A\ellipse.  The everted nipple measures 2.0cm in diameter.  The deep margin is\X0D\\X0A\black and sectioning reveals nearly exclusively dense white fibrous breast\X0D\\X0A\tissue.  No masses or suspicious lesions are appreciated.  Representative\X0D\\X0A\sections are submitted.  Summary of Sections: 1A-1I  representative sections of\X0D\\X0A\random fibrous breast tissue, 1J  representative section of nipple.  \X0D\\X0A\Specimen 2 received fresh for frozen section labeled left sentinel node for\X0D\\X0A\frozen section is a 3.0 x 3.0 x 1.8cm aggregate of tan/pink adipose tissue. \X0D\\X0A\Sectioning reveals a single lymph node measuring 1.5cm in greatest dimension. \X0D\\X0A\The node is submitted entirely for frozen section, now resubmitted in cassettes\X0D\\X0A\2A-2B.  The remaining fatty tissue is submitted in cassettes 2C-2D.\X0D\\X0A\Specimen 3 received in formalin labeled left breast is a 675 gram per the\X0D\\X0A\operating room scale, 20.0 x 18.5 x 5.0cm intact left simple mastectomy\X0D\\X0A\specimen.  The specimen is partially surfaced by a 7.5 x 3.5cm tan wrinkled skin\X0D\\X0A\ellipse.  The everted nipple measures 2.1cm in diameter.  The margins are inked\X0D\\X0A\as follows: superior aspect  blue, inferior aspect  green, and deep margin \X0D\\X0A\black.  The specimen is sent to mammography for radiographing.  There are two\X0D\\X0A\needles inserted into the radiographically identified biopsy site.  The needles\X0D\\X0A\are 6.5cm apart.  The biopsy sites are arbitrarily designated as #1 and #2 on\X0D\\X0A\the radiograph.  The first needle is surrounded by a 2.2 x 1.8 x 1.8cm\X0D\\X0A\well-circumscribed tan firm mass, 0.9cm from the deep margin and 1.0cm from the\X0D\\X0A\superficial margin.  Located between the two needles is a small firm nodule\X0D\\X0A\measuring 0.6 x 0.5 x 0.5cm.  This nodule grossly appears to be completely\X0D\\X0A\separate isolated nodule.  The nodule is 3.0cm from the #1 needle biopsy site\X0D\\X0A\and 2.5cm from the #2 needle biopsy site.  There is fibrocystic breast tissue\X0D\\X0A\between the needles and the small nodule.  The small nodule is greater than\X0D\\X0A\1.0cm from both the deep and superficial margins.  The second needle biopsy site\X0D\\X0A\has a 1.5 x 1.2 x 1.2cm well-circumscribed tan nodule, 2.0cm from the\X0D\\X0A\superficial margin, and 0.9cm from the deep margin.  Located approximately 2.5cm\X0D\\X0A\lateral to the second needle biopsy site is a 0.6 x 0.6 x 0.4cm\X0D\\X0A\well-circumscribed tan firm nodule which appears to be fourth area of separate\X0D\\X0A\tumor.  The skin and nipple are unremarkable and grossly free of tumor.  There\X0D\\X0A\are two lymph nodes identified in the outer quadrant.  Representative sections\X0D\\X0A\are submitted.  Summary of Sections: 3A  superficial margin closest to biopsy\X0D\\X0A\site #1, 3B-3C  mass at biopsy site #1 to include deep margin, 3D-3E  breast\X0D\\X0A\tissue between site #1 and nodule #1, 3F-3G  nodule #1, 3H-3J  breast tissue\X0D\\X0A\between nodule #1 and biopsy site #2, 3K  superficial margin closest to biopsy\X0D\\X0A\#2, 3L-3M  biopsy site #2 to include deep margin, 3N  breast tissue between\X0D\\X0A\biopsy site #2 and nodule #2, 3O  nodule #2 submitted in its entirety, 3P \X0D\\X0A\nipple, 3Q-3R  one bisected lymph node per cassette, 3S  suspicious peripheral\X0D\\X0A\nodule.   **INITIALS",Microscopic Description\X0D\\X0A\Multiple sections from the right breast show stromal fibrosis with some\X0D\\X0A\sclerosing adenosis and some ductal dilatation.  Areas of intraductal\X0D\\X0A\hyperplasia are seen and some calcifications are identified in benign ducts.  No\X0D\\X0A\atypical hyperplasia or malignancy is identified.  Focal fibroadenomatoid change\X0D\\X0A\is seen as well.  The nipple shows no pathologic changes.\X0D\\X0A\The two sentinel lymph nodes show no metastasis.\X0D\\X0A\Sections from the first identified tumor show an invasive ductal carcinoma. \X0D\\X0A\Occasional foci of in situ tumor are seen with central necrosis as well.  No\X0D\\X0A\marginal involvement is identified.  Occasional calcifications are identified\X0D\\X0A\within the tumor.  Sections between the identified biopsy site and the separate\X0D\\X0A\nodule show proliferative fibrocystic changes but no invasive tumor.  The second\X0D\\X0A\separately identified nodule does show in situ and invasive low grade carcinoma.\X0D\\X0A\ Some fibroadenomatoid change is seen adjacent to this nodule.  The tissue\X0D\\X0A\between the newly identified nodule and biopsy site 2 show occasional foci of\X0D\\X0A\lobular carcinoma in situ but no invasive lobular or ductal carcinoma is seen. \X0D\\X0A\No marginal involvement is identified.  The second biopsy site shows in situ and\X0D\\X0A\invasive carcinoma.  The tumor has low grade histology.  No marginal involvement\X0D\\X0A\is seen.  The breast tissue between the nodule second biopsy site and second\X0D\\X0A\nodule shows both ductal and lobular in situ carcinoma.  The nodule #2 shows a\X0D\\X0A\small biopsy site with foci of in situ carcinoma but no invasive carcinoma is\X0D\\X0A\seen.  The nipple is free of in situ or invasive tumor.  The two submitted lymph\X0D\\X0A\nodes show no metastasis.  The peripheral nodule shows dense fibrosis but no\X0D\\X0A\atypical hyperplasia or malignancy is identified.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX, WWW M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Oncotype - Genomic Dx     Date Ordered:     **DATE[Sep 13 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 20 2012]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Sep 20 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\Breast Cancer Recurrence Score = 54. SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE"
REG1,BREAST,0,488056,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is right breast cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lymph Node, Sentinel Node\X0D\\X0A\2: Breast, Lumpectomy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[May 15 2012]. COMMENT: ER positive, PR positive, E-cadherin negative,\X0D\\X0A\HER2/CEP17 Ratio = 1.16 (negative). FINAL DIAGNOSIS RIGHT BREAST, UPPER INNER\X0D\\X0A\QUADRANT, STEREOTACTIC BIOPSY: Infiltrating intermediate-grade lobular\X0D\\X0A\carcinoma. (DGD)","Final Diagnosis\X0D\\X0A\1.          RIGHT BREAST SENTINEL NODE:\X0D\\X0A\     Lymph node x 1; no tumor or granulomatous inflammation identified.\X0D\\X0A\2.          RIGHT BREAST, LUMPECTOMY WITH NEEDLE LOCALIZATION:\X0D\\X0A\     Infiltrating lobular carcinoma; tumor size estimated 2.5x1.5x1.5 cm;\X0D\\X0A\inferior and anterior margins of excision less than 1 mm; extensive ductal\X0D\\X0A\involvement by lobular carcinoma but no evidence of lymphvascular invasion. See\X0D\\X0A\Template.\X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Needle localized lumpectomy.\X0D\\X0A\LYMPH NODE SAMPLING:  Yes.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  41.6 grams, 6.5x5.5x4.0\X0D\\X0A\cm.\X0D\\X0A\LATERALITY:  Right breast.\X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number And Size):  Unifocal.\X0D\\X0A\TUMOR SITE:  Right breast, NOS.\X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  2.5x1.5x1.5 cm approximately.\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  0.\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  0.\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Lobular carcinoma.\X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  6/9.\X0D\\X0A\     TUBULAR FORMATION:  3\X0D\\X0A\     MITOTIC ACTIVITY:  1\X0D\\X0A\     PLEOMORPHISM:  2\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  One.\X0D\\X0A\SENTINEL NODE STATUS:  One sentinel lymph node sampled, negative for tumor.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  Negative.\X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  One sentinel node,\X0D\\X0A\negative for tumor.\X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  N/A.\X0D\\X0A\SURGICAL MARGINS:  Free, however, inferior and anterior margins less than 1 mm.\X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  inferior and\X0D\\X0A\anterior margins less than 1 mm\X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  No skin involvement identified.\X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Positive per previous biopsy ***PATH-NUMBER[1].\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Positive per previous biopsy\X0D\\X0A\***PATH-NUMBER[1].\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  \X0D\\X0A\     HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  Negative (HER2/CEP17 Ratio =\X0D\\X0A\1.16) per previous biopsy ***PATH-NUMBER[1].\X0D\\X0A\TREATMENT EFFECT:  none\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  none\X0D\\X0A\OTHER STUDIES:  none\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  2\X0D\\X0A\pN=  0 \X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIA.\X0D\\X0A\DGD/mbc",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled right breast sentinel node\X0D\\X0A\is a 1 cm in greatest dimension tan/pink lymph node which is submitted entirely\X0D\\X0A\for frozen section, now resubmitted in cassette one. \X0D\\X0A\Specimen 2 received fresh labeled right breast lumpectomy with needle loc is a\X0D\\X0A\41.6 gram, 6.5 x 5.5 x 4.0 cm intact, needle localized lumpectomy specimen. The\X0D\\X0A\specimen is partially surfaced by tan wrinkled skin ellipse measuring 2.5 x 1.0\X0D\\X0A\cm. The specimen is oriented by the surgeon and inked as follows: superior\X0D\\X0A\margin blue, inferior margin green, anterior margin red, posterior margin black,\X0D\\X0A\medial margin yellow, and lateral margin orange. Sectioning reveals a 0.8 x 0.6\X0D\\X0A\x 0.6 cm ill-defined gray/white firm area, 1.5 cm from the superior margin and\X0D\\X0A\greater than 2 cm from the remaining margins. The remaining cut surface shows\X0D\\X0A\predominantly yellow adipose tissue. No other masses or suspicious lesions are\X0D\\X0A\appreciated. Representative sections are placed in formalin at 10 a.m. Summary\X0D\\X0A\of sections: 2A  lateral margin; 2B medial margin; 2C  anterior margin; 2D \X0D\\X0A\posterior margin; 2E-2H  mass and surrounding tissue to include superior and\X0D\\X0A\inferior margins.  **INITIALS",Microscopic Description\X0D\\X0A\Sections of the bisected node show no evidence of metastatic deposits within the\X0D\\X0A\node on H\E\T\E\E;  Immunohistochemistry on the lymph node with pankeratin and\X0D\\X0A\estrogen on deeper sections also show no tumor in the lymph node. There is no\X0D\\X0A\evidence of granulomatous inflammation seen. Mild sinus histiocytosis is noted\X0D\\X0A\focally. \X0D\\X0A\Sections of the submitted lumpectomy specimen show the site previous biopsy\X0D\\X0A\which is filled with multinucleate foreign body giant cells and an inflammatory\X0D\\X0A\infiltrate. Adjacent to the zone there is a lobular carcinomatous infiltrate\X0D\\X0A\that is approximately 2.5x1.5x1.5 cm in size. The infiltrate involves a number\X0D\\X0A\of the ducts and is seen approaching the anterior and inferior margins to within\X0D\\X0A\less than 1 mm. Tumor is not noted directly on the cut inked surface in any of\X0D\\X0A\the sections examined. No true lymphvascular invasion is seen. \X0D\\X0A\DGD/mbc,,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,BREAST,0,488059,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is moderately differentiated infiltrating high-grade ductal\X0D\\X0A\carcinoma in situ.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ] HALL\X0D\\X0A\**NAME[YYY, XXX]  :14B\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\**NAME[WWW VVV]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lymph Node, Sentinel Node\X0D\\X0A\2: Breast, simple mastectomy with lymph nodes\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Jul 19 2012]. HER2/NEU BY FISH: Negative at 1.26. ADDENDUM COMMENT: This\X0D\\X0A\tumor shows POSITIVE nuclear staining for Estrogen Receptor (over 95% of tumor\X0D\\X0A\nuclei) and POSITIVE staining for Progesterone Receptor (over 95% of tumor\X0D\\X0A\nuclei). All controls stain appropriately including external positive, internal\X0D\\X0A\negative and external negative controls as required. COMMENT: 1% or greater\X0D\\X0A\numbers of nuclei staining of any intensity is considered a positive test in our\X0D\\X0A\laboratory. ER clone Ventana SPI, PR clone IE2, IVD approved immunohistochemical\X0D\\X0A\stains on formalin fixed, paraffin embedded tissue. RIGHT BREAST\X0D\\X0A\ULTRASOUND-GUIDED BIOPSY FOR MASS AND CALCIFICATIONS: Intermediate grade\X0D\\X0A\infiltrating and high-grade in situ ductal adenocarcinoma. Calcifications\X0D\\X0A\identified. (DGD)","Final Diagnosis\X0D\\X0A\1.          RIGHT SENTINEL NODE, BIOPSY:\X0D\\X0A\     No tumor or granulomatous inflammation identified; mild sinus\X0D\\X0A\histiocytosis.\X0D\\X0A\2.          RIGHT BREAST, SIMPLE MASTECTOMY:\X0D\\X0A\     Infiltrating and in situ high-grade ductal adenocarcinoma; tumor size\X0D\\X0A\1.5x1.5x1.0 cm; no lymphvascular invasion identified; margins of excision free\X0D\\X0A\of tumor; skin and nipple free of tumor. See Template.\X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Simple mastectomy.\X0D\\X0A\LYMPH NODE SAMPLING:  Sentinel nodes only.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  626.9 grams,\X0D\\X0A\18.0x15.0x4.5 cm.\X0D\\X0A\LATERALITY:  Right.\X0D\\X0A\TUMOR FOCALITY (f Multiple Foci, Include Number And Size):  Unifocal.\X0D\\X0A\TUMOR SITE:  Central upper quadrant.\X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  1.5x1.5x1.0 cm.\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  Approximately 25%.\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  0%.\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Ductal.\X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  8/9.\X0D\\X0A\     TUBULAR FORMATION:  3\X0D\\X0A\     MITOTIC ACTIVITY:  2\X0D\\X0A\     PLEOMORPHISM:  3\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  One\X0D\\X0A\sentinel node negative for tumor.\X0D\\X0A\SENTINEL NODE STATUS:  One node negative for tumor.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  Absent.\X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  One sentinel node\X0D\\X0A\negative for tumor.\X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  N/A.\X0D\\X0A\SURGICAL MARGINS:  Free of tumor.\X0D\\X0A\     DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  The\X0D\\X0A\invasive tumor is 2.7 cm from the deep margin and 1.8 cm from the superficial\X0D\\X0A\margin.\X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  No skin or nipple involved by tumor.\X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Positive per previous biopsy ***PATH-NUMBER[1].\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Positive per previous biopsy\X0D\\X0A\***PATH-NUMBER[1].\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  N/A.\X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  Negative per previous biopsy\X0D\\X0A\***PATH-NUMBER[1].\X0D\\X0A\TREATMENT EFFECT:  None.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Small fibroadenoma less than 6 mm in diameter.\X0D\\X0A\OTHER STUDIES:  none\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  1a\X0D\\X0A\pN=  X \X0D\\X0A\AJCC PATHOLOGIC STAGE:  IA.\X0D\\X0A\DGD/mbc",,"Gross Description\X0D\\X0A\Specimen 1 labeled right sentinel node, received fresh for frozen section,\X0D\\X0A\consists of a single tan/pink lymph node measuring 1.5 cm in greatest dimension\X0D\\X0A\which is submitted entirely for frozen section, now resubmitted in cassette 1. \X0D\\X0A\Specimen 2 labeled right breast, received in formalin, consists of a 626.9 gram,\X0D\\X0A\18.0x15.0x4.5 cm intact simple mastectomy specimen. The specimen is partially\X0D\\X0A\surfaced by a 13.5x9.0 cm tan wrinkled skin ellipse. The everted nipple measures\X0D\\X0A\1.5 cm in diameter. The margins are inked as follows: superficial margin blue,\X0D\\X0A\deep margin black, and sectioning reveals a 1.5x1.5x1.0 cm ill defined tan/gray\X0D\\X0A\firm mass with a central biopsy cavity and clip. The mass is 2.7 cm from the\X0D\\X0A\deep margin and 1.8 cm from the superficial margin. This area is located in the\X0D\\X0A\central upper quadrant. There is a second area of suspicious breast tissue\X0D\\X0A\located 7 cm medial and inferior to the biopsy cavity. No definitive invasive\X0D\\X0A\tumor is identified in the secondary area. The remaining cut surface shows\X0D\\X0A\approximately equal proportions of yellow adipose tissue and dense white fibrous\X0D\\X0A\breast tissue. No lymph nodes are identified. Representative sections are placed\X0D\\X0A\in formalin at 10:50 am. Summary of sections: 2A-2B  deep margin closest to\X0D\\X0A\biopsy site; 2C  superficial margin closest to biopsy site; 2D-2G  entire biopsy\X0D\\X0A\site and mass; 2H-2I  secondary area; 2J  representative section of nipple. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections of the submitted sentinel node shows mild sinus histiocytosis and no\X0D\\X0A\evidence of metastatic carcinoma in the subcapsular sinuses or medullary regions\X0D\\X0A\of the node. \X0D\\X0A\Sections of the sampled breast neoplasm show it to be a high-grade infiltrating\X0D\\X0A\and in situ ductal adenocarcinoma. The tumor shows no propensity to form\X0D\\X0A\tubules, has a high nuclear degree of pleomorphism and mitoses number greater\X0D\\X0A\than 10 per 10 HPF for a Bloom-Richardson score of 8/9. Centralized comedo\X0D\\X0A\necrosis is seen in many of the ducts involved by in situ carcinoma. The margins\X0D\\X0A\of excision are widely free of tumor. The secondary lesion noted grossly\X0D\\X0A\consists of fibrocystic changes without evidence of infiltrating or in situ\X0D\\X0A\neoplasia. \X0D\\X0A\DGD/mbc",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Oncotype - Genomic Dx     Date Ordered:     **DATE[Aug 31 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 10 2012]     By:  **NAME[UUU TTT SSS]\X0D\\X0A\     Date Reported:     **DATE[Sep 12 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\ONCOTYPE:\X0D\\X0A\     Breast Cancer Recurrence Score = 24\X0D\\X0A\Those patients who had a Recurrence Score of 24 had an Average Rate of Distance\X0D\\X0A\Recurrence of 16% (95% CI: 12%  19%). SEE SCANNED REFERENCE REPORT.  \X0D\\X0A\mbc\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,BREAST,0,488062,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is 7-8 o'clock mass large ulcerating cancer, axillary lymph\X0D\\X0A\node, and 12 o'clock hypoechoic tissue right breast.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, needle biopsy\X0D\\X0A\2: Lymph node biopsy, (axillary)\X0D\\X0A\3: Breast, needle biopsy","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT:  This tumor shows POSITIVE nuclear staining for Estrogen\X0D\\X0A\Receptor (over 95% of tumor nuclei) and POSITIVE staining for Progesterone\X0D\\X0A\Receptor (over 95% of tumor nuclei).  Controls stain appropriately. \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\  **INITIALS \X0D\\X0A\1.  RIGHT BREAST ULTRASOUND-GUIDED BIOPSY AT 7-8 O'CLOCK: \X0D\\X0A\     Low-grade infiltrating and in situ ductal adenocarcinoma, perineural\X0D\\X0A\invasion identified. \X0D\\X0A\2.  RIGHT AXILLARY LYMPH NODE: \X0D\\X0A\     Fibrous tissue with infiltrating ductal adenocarcinoma. \X0D\\X0A\3.  RIGHT BREAST BIOPSY AT 12 O'CLOCK: \X0D\\X0A\     Dense fibrous connective tissue with benign ducts, no in situ or invasive\X0D\\X0A\carcinoma identified.  See Comment. \X0D\\X0A\COMMENT:  This report was faxed to the Radiologist at the Breast Imaging\X0D\\X0A\Services on **DATE[Nov 28 11]. \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled right breast 7-8 o'clock ultrasound\X0D\\X0A\biopsy is a 1.0 x 1.0 x 0.3 cm aggregate of tan/pink fibroadipose breast tissue\X0D\\X0A\fragments and blood which were placed in formalin at 3:45 p.m. and are now\X0D\\X0A\submitted in cassette 1. \X0D\\X0A\Specimen 2 received in formalin labeled axillary lymph node right breast\X0D\\X0A\ultrasound biopsy is a 1.0 x 1.0 x 0.3 cm aggregate of fatty soft tissue which\X0D\\X0A\was placed in formalin at 3:50 p.m. and is now submitted in cassette 2. \X0D\\X0A\Specimen 3 received in formalin labeled right breast 12 o'clock ultrasound\X0D\\X0A\biopsy is a 1.2 x 1.0 x 0.3 cm aggregate of tan/pink fibroadipose breast tissue\X0D\\X0A\fragments which were placed in formalin at 3:55 p.m. and are now submitted in\X0D\\X0A\cassette 3.  **INITIALS,Microscopic Description\X0D\\X0A\Sections show an infiltrating ductal adenocarcinoma in the breast fibrous\X0D\\X0A\connective tissue inciting a desmoplastic response. In addition the tumor is\X0D\\X0A\infiltrating the perineural spaces of small peripheral nerve segments in the\X0D\\X0A\area. Also noted are several foci of in situ ductal adenocarcinoma. \X0D\\X0A\Sections of the tissue show no evidence of lymph node. Instead there is fibrous\X0D\\X0A\connective tissue with an infiltrating ductal adenocarcinoma that appears\X0D\\X0A\identical to specimen 1. Focal microcalcifications are seen.\X0D\\X0A\Sections of the 12 o'clock biopsy show dense fibrous and scattered benign\X0D\\X0A\somewhat dilated ducts. There is no evidence of duct epithelial hyperplasia or\X0D\\X0A\carcinoma in this section. The lobular elements are unremarkable.  **INITIALS,,,Amendments:\X0D\\X0A\Amended:  **DATE[Nov 29 2011] by **NAME[XXX WWW]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Nov 28 2011]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Nov 29 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Dec 8 2011]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Dec 8 2011]         \X0D\\X0A\Interpretation\X0D\\X0A\HER-2/neu by FISH RESULTS:  No HER-2/neu Gene Amplification was observed. \X0D\\X0A\HER-2/CEP!\E\T\E\ Ratio:  1.08  SEE SCANNED REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,BREAST,0,488072,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is 4.0 cm irregular mass 10 o'clock right breast; worrisome\X0D\\X0A\for an invasive carcinoma.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT: This tumor shows POSITIVE nuclear staining for Estrogen\X0D\\X0A\Receptor (less than 5% of tumor nuclei) and POSITIVE staining for Progesterone\X0D\\X0A\Receptor (5% of tumor nuclei).  Controls stain appropriately. \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\ **INITIALS \X0D\\X0A\RIGHT BREAST AT 10 O'CLOCK, ULTRASOUND GUIDED BIOPSY:\X0D\\X0A\     Infiltrating and in situ high-grade ductal adenocarcinoma.\X0D\\X0A\DGD/mbc\X0D\\X0A\COMMENT:  This report was faxed to the radiologist at Central Baptist Breast\X0D\\X0A\Imaging Services on **DATE[Aug 01 2012].",,"Gross Description\X0D\\X0A\The specimen, labeled right breast ultrasound guided biopsy, received in\X0D\\X0A\formalin, consists of a 1.8x1.0x0.3 cm aggregate of tan/pink fibroadipose breast\X0D\\X0A\tissue cores which were placed in formalin at 11:55 am and are now submitted in\X0D\\X0A\one cassette.\X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections show a needle core biopsy in which there is extensive infiltrating and\X0D\\X0A\in situ ductal adenocarcinoma. The tumor shows focal comedo necrosis in the in\X0D\\X0A\situ tumor and a desmoplastic response in the fibrous connective tissue\X0D\\X0A\intimately associated with the invasive carcinoma. The tumor is high-grade with\X0D\\X0A\marked nuclear pleomorphism, single cell necrosis, prominent nucleoli and no\X0D\\X0A\propensity to form tubules. Cancerization of lobules by the DCIS is noted. \X0D\\X0A\Lymphvascular invasion is not identified.    \X0D\\X0A\DGD/mbc \X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: Immunohistochemistry for estrogen receptor\X0D\\X0A\shows focal nuclear positivity in less than 5% of the tumor nuclei.\X0D\\X0A\Immunohistochemistry for progesterone receptor shows a similar approximately 5%\X0D\\X0A\positivity in the tumor. There is very good staining of the adjacent normal\X0D\\X0A\neoplastic breast tissue. All controls stain appropriately including external\X0D\\X0A\positive, internal negative and external negative controls as required.   \X0D\\X0A\**INITIALS",,,Amendments:\X0D\\X0A\Amended:  **DATE[Aug 3 2012] by **NAME[XXX WWW]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Aug 1 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Aug 1 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 8 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Aug 8 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\HER-2/neu by FISH RESULTS:  No HER-2/neu Gene Amplification was observed for\X0D\\X0A\this specimen.  SEE SCANNED REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,BREAST,0,488079,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is left breast 2:30 position with 2.1cm irregular mass\X0D\\X0A\palpable.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY M]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\LEFT BREAST MASS AT 2:30, ULTRASOUND GUIDED NEEDLE BIOPSIES:\X0D\\X0A\     Invasive intermediate-grade ductal carcinoma. Positive for estrogen and\X0D\\X0A\progesterone receptors by immunohistochemistry.\X0D\\X0A\COMMENT: Immunostains support the ductal origin of this tumor. HER2/Neu will be\X0D\\X0A\performed by FISH and reported as an addendum.\X0D\\X0A\MHB/mbc \X0D\\X0A\PROVISIONAL DIAGNOSIS:\X0D\\X0A\LEFT BREAST MASS AT 2:30, ULTRASOUND GUIDED NEEDLE BIOPSIES:\X0D\\X0A\     Invasive intermediate grade mammary carcinoma.\X0D\\X0A\     Immunostains will be performed to determine ductal vs lobular origin prior\X0D\\X0A\to issuing a final report.\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT: This report was faxed to the Radiologists at the Breast Imaging\X0D\\X0A\Services on **DATE[Sep 10 2011].  **INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled left breast ultrasound biopsy is a 2.5 x 2.5 x\X0D\\X0A\0.4cm aggregate of tan/pink fibroadipose breast tissue fragments which were\X0D\\X0A\placed in formalin at 2:22pm and are now submitted in one cassette.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections show invasive carcinoma with infiltrating nests of malignant cells with\X0D\\X0A\moderately pleomorphic nuclei and scant mitotic activity.  The tumor infiltrates\X0D\\X0A\within a dense fibrotic stroma.  **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: This tumor shows POSITIVE nuclear staining\X0D\\X0A\for Estrogen Receptor (over 90% of tumor nuclei) and POSITIVE staining for\X0D\\X0A\Progesterone Receptor (over 50% of tumor nuclei). The E-cadherin shows positive\X0D\\X0A\staining supporting a ductal origin of this tumor. All controls stain\X0D\\X0A\appropriately including external positive, internal negative and external\X0D\\X0A\negative controls as required.  \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\MHB/mbc",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Sep 12 2011] by **NAME[XXX WWW VVV]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     ER/PR, E-Cadherin\X0D\\X0A\Previous Signout Date:  **DATE[Sep 10 2011]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[UUU, TTT M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Sep 10 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 18 2011]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Sep 18 2011]         \X0D\\X0A\Interpretation\X0D\\X0A\HER-2/neu by FISH RESULTS:  No HER-2/neu gene amplification was observed for\X0D\\X0A\this specimen.  HER-2/CEP17 Ratio 1.14\X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[UUU, TTT M."
REG1,BREAST,0,488085,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is core biopsy right breast category 5 mammogram.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT:  The tumor is Positive for Estrogen and Progesterone\X0D\\X0A\receptors. Dr. **NAME[ZZZ] relayed the results to **NAME[YYY XXX], RN at 2:10pm on\X0D\\X0A\**DATE[Nov 7 2011].  See Additional Microscopic Description for details.  **INITIALS\X0D\\X0A\RIGHT BREAST UPPER OUTER QUADRANT, NEEDLE CORE BIOPSIES: \X0D\\X0A\     Invasive moderately to poorly differentiated ductal carcinoma. \X0D\\X0A\Angiolymphatic permeation present. \X0D\\X0A\Hormone receptors pending. SEE COMMENT.     **INITIALS \X0D\\X0A\COMMENT: Dr. **NAME[ZZZ] discussed this case with Dr. **NAME[WWW] on **DATE[Oct 26 11] at 9:10 a.m.\X0D\\X0A\This report was faxed to the Radiologist at the Breast Imaging Services on\X0D\\X0A\**DATE[Oct 26 11]. \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled core biopsy right breast are a few yellow/tan\X0D\\X0A\fibroadipose breast tissue cores aggregating 1.6 x 0.6 x 0.3 cm which are\X0D\\X0A\submitted in toto in one cassette.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections show an invasive poorly differentiated ductal carcinoma arranged as\X0D\\X0A\rounded nests, cords and sheets of malignant cells invading into a fibrous\X0D\\X0A\stroma. It is also noted infiltrating into surrounding fat. Angiolymphatic\X0D\\X0A\permeation by neoplasm is present. In-situ carcinoma is not identified.  **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION:  All controls stain appropriately including\X0D\\X0A\external positive, internal negative and external negative controls as required.\X0D\\X0A\ This tumor shows POSITIVE nuclear staining for Estrogen Receptor (strong 3+\X0D\\X0A\staining in greater than 95% of tumor nuclei) and POSITIVE staining for\X0D\\X0A\Progesterone Receptor (strong 3+ staining in greater than 60% of tumor nuclei). \X0D\\X0A\Controls stain appropriately.  NOTE: 1% or greater numbers of nuclei staining of\X0D\\X0A\any intensity is considered a positive test in our laboratory. ER clone Ventana\X0D\\X0A\SPI, PR clone IE2, IVD approved immunohistochemical stains on formalin fixed,\X0D\\X0A\paraffin embedded tissue.  **INITIALS",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Nov 7 2011] by Ruthanne Walker\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Oct 26 2011]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. ZZZ], M.D.\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Oct 29 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Nov 6 2011]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Nov 7 2011]         \X0D\\X0A\Interpretation\X0D\\X0A\HER2/CEP17 FISH: \X0D\\X0A\     No HER2/Neu gene amplification was observed for this specimen.  \X0D\\X0A\HER 2/CEP17 RATIO 1.10    \X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[CCC M. ZZZ], M.D."
REG1,BREAST,0,488087,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is left breast mass.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, biopsy with Margins","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT: Template updated to reflect ER/PR results of Negative. MHB/mbc\X0D\\X0A\LEFT BREAST MASS, NEEDLE LOCALIZED EXCISIONAL BIOPSY: \X0D\\X0A\     High-grade ductal carcinoma in situ with necrosis and microcalcifications.\X0D\\X0A\See template and comment:\X0D\\X0A\COMMENT:  I have discussed this with **NAME[YYY XXX] in Dr. **NAME[ZZZ]' office on\X0D\\X0A\**DATE[Mar 17 12]. \X0D\\X0A\**INITIALS\X0D\\X0A\BREAST DCIS (LUMPECTOMY/MASTECTOMY)\X0D\\X0A\SPECIMEN TYPE/PROCEDURE: needle localized excisional biopsy \X0D\\X0A\LYMPH NODE SAMPLING:  no\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\SPECIMEN SIZE (3 DIMENSIONS):  7.0 x 4.0 x 1.4 cm\X0D\\X0A\LATERALITY:  unilateral\X0D\\X0A\TUMOR SITE:  left breast\X0D\\X0A\SIZE (Extent) OF DCIS COMPONENT (greatest dimension): 1.2 cm \X0D\\X0A\HISTOLOGIC TYPE:  ductal\X0D\\X0A\NUCLEAR GRADE:  high grade\X0D\\X0A\NECROSIS (PRESENT/ABSENT): present \X0D\\X0A\MARGIN STATUS (SPECIFY MARGIN):  free\X0D\\X0A\DISTANCE FROM MARGIN:  1mm\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  n/a\X0D\\X0A\ESTROGEN RECEPTOR STATUS (IHC):  Negative.  \X0D\\X0A\PROGESTERONE RECEPTOR STATUS (IHC):  Negative\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:   n/a\X0D\\X0A\OTHER STUDIES:  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=is  \X0D\\X0A\pN=x   \X0D\\X0A\AJCC PATHOLOGIC STAGE:  0",,"Gross Description\X0D\\X0A\Received in formalin labeled left breast mass is a 13.1 gram, 7.0 x 4.0 x 1.4 cm\X0D\\X0A\intact, unoriented needle localized breast biopsy. The unoriented margins are\X0D\\X0A\inked black and sectioning reveals approximately equal proportions of yellow\X0D\\X0A\adipose tissue and delicate tan/pink fibrous breast tissue. No masses, invasive\X0D\\X0A\tumor, or definitive biopsy site is identified. The specimen is placed in\X0D\\X0A\formalin at 1 p.m. and submitted in its entirety in cassettes A-J.  **INITIALS","Microscopic Description\X0D\\X0A\Sections show breast and adipose tissue with stromal fibrosis, ductal dilatation\X0D\\X0A\and cyst formation. Some calcifications are seen within benign ducts. In\X0D\\X0A\addition, there are areas of ductal carcinoma in situ with some necrosis and\X0D\\X0A\calcifications as well. No definite invasion is seen.  The tumor extends very\X0D\\X0A\close to the inked excisional margins but no marginal involvement is identified.\X0D\\X0A\**INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: This tumor is NEGATIVE for both Estrogen and\X0D\\X0A\Progesterone Receptors. There is no staining of tumor nuclei (0+). All controls\X0D\\X0A\stain appropriately including external positive, internal negative and external\X0D\\X0A\negative controls as required. \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone Ventana IE2,\X0D\\X0A\IVD approved immunohistochemical stains on formalin fixed, paraffin embedded\X0D\\X0A\tissue.   \X0D\\X0A\MHB/mbc",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Mar 18 2012] by **NAME[WWW VVV UUU]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     ER/PR\X0D\\X0A\Previous Signout Date:  **DATE[Mar 17 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[TTT, SSS M].\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488088,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is abnormal right breast mammogram.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY\X0D\\X0A\**NAME[ZZZ YYY], M.D. \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT:  The tumor is positive for estrogen and progesterone receptors\X0D\\X0A\(see additional microscopic description for semiquantitative details).  **INITIALS\X0D\\X0A\RIGHT BREAST, NEEDLE CORE BIOPSIES: \X0D\\X0A\     Infiltrating intermediate grade ductal carcinoma. \X0D\\X0A\Hormone receptors pending. See Comment. \X0D\\X0A\COMMENT:  Dr. **NAME[XXX] discussed this case with Dr. **NAME[WWW] on **DATE[Aug 5 12] at 9:15 AM.  \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled right breast core biopsies are a few tan soft\X0D\\X0A\tissue cores aggregating 1.0 x 1.0 x 0.3 cm which are submitted in toto in one\X0D\\X0A\cassette.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections show an infiltrating neoplasm composed of cords, rounded nests, and\X0D\\X0A\tubules. The constituent nuclei are hyperchromatic with small nucleoli. Mitotic\X0D\\X0A\activity is counted at less than 10 per 10 HPF. In some areas this is present in\X0D\\X0A\a dense collagenous background. In that area, there is much retraction artifact.\X0D\\X0A\Definitive angiolymphatic permeation is not identified. **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION:  All controls stain appropriately including\X0D\\X0A\external positive, internal negative and external negative controls as required.\X0D\\X0A\  With appropriate controls, tumor cells stain strongly (3+) in greater than 90%\X0D\\X0A\of cells when stained with antibody to estrogen receptor.  The tumor cells show\X0D\\X0A\a similar reaction when stained with antibody to progesterone receptor (3+,\X0D\\X0A\>90%).  **INITIALS",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Aug 8 2012] by Ruthanne Walker\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Aug 5 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. XXX], M.D.\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Her2Neu **INSTITUTION     Date Ordered:     **DATE[Aug 5 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 18 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Aug 18 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\HER-2/neu by FISH RESULTS:  No HER-2/neu gene amplification was observed for\X0D\\X0A\this specimen.  HER-2/CEP17 ratio 1.31\X0D\\X0A\SEE SCANNED REFERENCE REPORT.  \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[CCC M. XXX], M.D."
REG1,BREAST,0,488095,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is 3.5 cm lobulated hypoechoic mass right 1 o'clock.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\RIGHT BREAST MASS AT 1 O'CLOCK, ULTRASOUND-GUIDED CORE BIOPSIES: \X0D\\X0A\     Poorly differentiated ductal carcinoma with foci suspicious for\X0D\\X0A\angiolymphatic permeation. See COMMENT. \X0D\\X0A\COMMENT:  Stains for hormone receptors can be performed on any subsequent\X0D\\X0A\resection specimen. This report was faxed to the Radiologist at the Breast\X0D\\X0A\Imaging Services on **DATE[Feb 18 12]. \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled right breast ultrasound biopsy is a 2.5 x 2.5 x 0.3\X0D\\X0A\cm aggregate of tan/pink fibroadipose breast tissue fragments which were placed\X0D\\X0A\in formalin at 2:55 p.m. and are now submitted in one cassette.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections show an infiltrating ductal carcinoma arranged primarily as sheets and\X0D\\X0A\rounded nests of cells with large nuclei, prominent nucleoli with some multiple\X0D\\X0A\nucleoli, and mitotic activity. These are present in a desmoplastic stroma.\X0D\\X0A\Areas suspicious for angiolymphatic permeation by neoplasm are noted. Focal\X0D\\X0A\areas of fibrosis and hemorrhage are present as well. **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX M. WWW], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488105,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is breast CA.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, simple mastectomy with lymph nodes\X0D\\X0A\2: Lymph Node, Sentinel Node\X0D\\X0A\Previous Pertinent History\X0D\\X0A\S11023119, **DATE[Aug 29 12]. CORE BIOPSIES OF LEFT BREAST: Invasive well-differentiated\X0D\\X0A\(tubular) carcinoma. No lymphvascular or perineural invasion. Estrogen and\X0D\\X0A\progesterone receptors by immunohistochemistry both positive. HER-2/neu by\X0D\\X0A\immunohistochemistry negative. (JLB)","Final Diagnosis\X0D\\X0A\1.          LEFT BREAST, MASTECTOMY WITH AXILLARY LYMPH NODE SAMPLING:\X0D\\X0A\     Invasive low-grade ductal carcinoma. Three lymph nodes negative for\X0D\\X0A\metastasis. See Template.\X0D\\X0A\2.          LEFT AXILLARY SENTINEL LYMPH NODES:\X0D\\X0A\     No metastasis identified (0/2).\X0D\\X0A\INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Mastectomy with axillary and sentinel lymph node\X0D\\X0A\sampling.\X0D\\X0A\LYMPH NODE SAMPLING:  Yes.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  N/A.\X0D\\X0A\LATERALITY:  Unilateral.\X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number And Size):  Unifocal.\X0D\\X0A\TUMOR SITE:  Left breast.\X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  1.8x1.5x1.5 cm.\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  Slight.\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  N/A.\X0D\\X0A\MACRO EXTENT:  1.8 cm.\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Ductal.\X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  Well differentiated 4/9.\X0D\\X0A\     TUBULAR FORMATION:  2\X0D\\X0A\     MITOTIC ACTIVITY:  1\X0D\\X0A\     PLEOMORPHISM:  1\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  Five.\X0D\\X0A\SENTINEL NODE STATUS:  0/2.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  None seen.\X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  0/5.\X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  N/A..\X0D\\X0A\SURGICAL MARGINS:  Free.\X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  2.4 cm from\X0D\\X0A\superficial margin.\X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  No.\X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Positive per previous biopsy **ID-NUM\X0D\\X0A\PCL.\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Positive per previous biopsy\X0D\\X0A\S11023119 PCL.\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  Negative (0+) per previous biopsy\X0D\\X0A\S11023119 PCL.\X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  N/A.\X0D\\X0A\TREATMENT EFFECT:  N/A.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  N/A.\X0D\\X0A\OTHER STUDIES:  N/A.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  1\X0D\\X0A\pN=  0 \X0D\\X0A\AJCC PATHOLOGIC STAGE:  I.\X0D\\X0A\MHB/mbc",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled left breast is a 960 gram, 24.0 x 19.0 x\X0D\\X0A\6.0cm intact left simple mastectomy specimen.  The specimen is partially\X0D\\X0A\surfaced by 17.0 x 9.0cm tan wrinkled skin ellipse.  The everted nipple measures\X0D\\X0A\1.5cm in diameter.  The margins are inked as follows: superficial margin  black,\X0D\\X0A\deep margin  blue, and sectioning reveals a 1.8 x 1.5 x 1.5cm ill-defined tan\X0D\\X0A\firm mass, 2.8cm from the deep margin and 2.4cm from the superficial margin. \X0D\\X0A\The mass is located in the upper inner quadrant.  There is an area of firm\X0D\\X0A\nodular fibrocystic breast tissue located in the lower outer quadrant.  This\X0D\\X0A\area is greater than 12.0cm from the primary mass.  No definitive invasive tumor\X0D\\X0A\is identified in this area.  There are a few small lymph nodes identified in the\X0D\\X0A\upper outer quadrant.  Representative sections are placed in formalin at\X0D\\X0A\10:30am.  Summary of Sections: 1A-1B  deep margin closest to mass, 1C \X0D\\X0A\superficial margin closest to mass, 1D-1F  representative sections of primary\X0D\\X0A\mass, 1G-1H  representative sections of suspicious breast tissue in lower outer\X0D\\X0A\quadrant, 1I  representative section of nipple, 1J  intact axillary lymph nodes.\X0D\\X0A\Specimen 2 received in formalin labeled sentinel node are two pieces of fatty\X0D\\X0A\tissue each containing a single lymph node.  The smaller node measures 0.8cm in\X0D\\X0A\greatest dimension and the larger node measures 1.7cm in greatest dimension. \X0D\\X0A\The nodes are submitted in their entirety separately in cassettes 2A-2B.  **INITIALS",Microscopic Description\X0D\\X0A\Sections show invasive ductal carcinoma. The tumor shows low-grade histology\X0D\\X0A\with foci of low-grade DCIS. No vascular invasion or marginal involvement is\X0D\\X0A\seen. Sections from the separately submitted suspicious area show proliferative\X0D\\X0A\fibrocystic changes with prominent intraductal hyperplasia and papillomatosis.\X0D\\X0A\No carcinoma is seen.  A few calcifications are seen. The nipple is\X0D\\X0A\unremarkable. The three axillary tail lymph nodes show no metastasis.\X0D\\X0A\The two sentinel lymph nodes are also free of tumor. \X0D\\X0A\MHB/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488111,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is abnormal mammogram; calcifications.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY M].\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle bx","Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\BREAST, LEFT, BIOPSY: \X0D\\X0A\     Intermediate-grade ductal carcinoma in situ, apocrine type, 4 mm in\X0D\\X0A\greatest extent, involving multiple cores.\X0D\\X0A\COMMENT: This diagnosis was rendered by Dr. **NAME[XXX M. WWW] at **NAME[VVV]\X0D\\X0A\**INSTITUTION and I concur with this diagnosis.\X0D\\X0A\DGD/mbc \X0D\\X0A\PROVISIONAL DIAGNOSIS\X0D\\X0A\LEFT BREAST STEREOTACTIC BIOPSY FOR CALCIFICATIONS: \X0D\\X0A\     Atypical micropapillary hyperplasia, case forwarded for consultation to Dr.\X0D\\X0A\**NAME[UUU] Page. See Comment. \X0D\\X0A\COMMENT:  This report was faxed to the Radiologist at the Breast Imaging\X0D\\X0A\Services on **DATE[May 16 12]. \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\The specimen, labeled left breast stereotactic biopsy, received in formalin,\X0D\\X0A\consists of two cassettes one of which is designated with a Steri-Strip. The\X0D\\X0A\undesignated cassette contains a 2.5x2.5x0.3 cm aggregate of tan/pink\X0D\\X0A\fibroadipose breast tissue fragments which were placed in formalin at 11:45 am\X0D\\X0A\and are now submitted in cassette A. The taped, designated cassette contains a\X0D\\X0A\2.5x2.3x0.3 cm aggregate of tan/pink fibroadipose breast tissue fragments which\X0D\\X0A\were placed in formalin at 11:45 am and are now submitted in cassette B.    \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections of the left breast show fibrous and adipose tissue with essentially\X0D\\X0A\unremarkable lobular units; however, the ducts show modest dilatation in several\X0D\\X0A\with a micropapillary apocrine appearing hyperplasia. These ducts occasional\X0D\\X0A\show small foci of central necrosis in the ducts containing the micropapillary\X0D\\X0A\atypical hyperplastic change. The biopsy also shows focal dystrophic\X0D\\X0A\calcification within these ducts. \X0D\\X0A\NOTE: The ductal changes are suspicious for a micropapillary ductal carcinoma in\X0D\\X0A\situ; the case will be forwarded to Dr. **NAME[UUU] Page and his colleagues for\X0D\\X0A\review.  **INITIALS",,,"Amendments:\X0D\\X0A\Amended:  **DATE[May 21 2012] by **NAME[TTT SSS RRR]\X0D\\X0A\Reason: OUTSIDE CONSULTATION RESULTS\X0D\\X0A\     Dr. **NAME[XXX M. WWW, QQQ]\X0D\\X0A\Previous Signout Date:  **DATE[May 16 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\External Consultation     Date Ordered:     **DATE[May 20 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 20 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[May 20 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE"
REG1,BREAST,0,488114,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is right breast cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION - COPY\X0D\\X0A\**INSTITUTION\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lymph node, regional resection\X0D\\X0A\2: Breast, Lumpectomy","Final Diagnosis\X0D\\X0A\1.          RIGHT AXILLARY LYMPH NODES, DISSECTION:\X0D\\X0A\     Metastatic ductal carcinoma involving eight of fourteen lymph nodes (8/14).\X0D\\X0A\2.          RIGHT BREAST, LUMPECTOMY:\X0D\\X0A\     Infiltrating poorly differentiated ductal carcinoma with background ductal\X0D\\X0A\carcinoma in situ (B-R score 8/9).\X0D\\X0A\Gross tumor size estimated 8.0x3.5x2.5 cm.\X0D\\X0A\Angiolymphatic and perineural invasion by tumor identified. \X0D\\X0A\Tumor present at anterior margin near medial aspect. See Template and Comment.\X0D\\X0A\COMMENT: Dr. **NAME[ZZZ] discussed this case with Dr. **NAME[YYY] on **DATE[Feb 15 12] at 3:30 p.m.\X0D\\X0A\The tumor has some variability in appearance with some areas consisting of\X0D\\X0A\tubules while others are more solid and show even single file pattern. Likewise,\X0D\\X0A\areas of in situ carcinoma range from low-grade ductal carcinoma in situ to\X0D\\X0A\high-grade comedo carcinoma in situ are noted. For purposes of grading, the\X0D\\X0A\least differentiated areas are taken into consideration.\X0D\\X0A\     INVASIVE BREAST CANCER STAGING\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Lumpectomy.\X0D\\X0A\LYMPH NODE SAMPLING:  Yes.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\SPECIMEN SIZE (If Excision Less Than Total Mastectomy):  11.5x9.5x4.5 cm.\X0D\\X0A\LATERALITY:  Right breast.\X0D\\X0A\TUMOR FOCALITY (If Multiple Foci, Include Number And Size):  Unifocal.\X0D\\X0A\TUMOR SITE:  Right breast, NOS.\X0D\\X0A\TUMOR SIZE: (Size of Largest Invasive Carcinoma):  8.0x3.0x2.8\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS) EXTENT:  10% of total volume.\X0D\\X0A\LOBULAR CARCINOMA IN SITU (LCIS) EXTENT:  None.\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Ductal with focal lobular features.\X0D\\X0A\GRADE (BLOOM-RICHARDSON SCORE):  3\X0D\\X0A\     TUBULAR FORMATION:  3\X0D\\X0A\     MITOTIC ACTIVITY:  2\X0D\\X0A\     PLEOMORPHISM:  3\X0D\\X0A\LYMPH NODES (required only if lymph nodes are present in the specimen):  14.\X0D\\X0A\SENTINEL NODE STATUS:  N/A.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  Present.\X0D\\X0A\AXILLARY LYMPH NODE STATUS (INCLUDES SENTINEL NODES):  8/14 positive for\X0D\\X0A\metastatic carcinoma.\X0D\\X0A\EXTRANODAL EXTENSION OF TUMOR:  None.\X0D\\X0A\SURGICAL MARGINS:  Medial/anterior margin positive for carcinoma.\X0D\\X0A\DISTANCE FROM SURGICAL MARGIN (INVASIVE/DCIS, SPECIFY MARGIN):  See above.\X0D\\X0A\SKIN/NIPPLE INVOLVEMENT:  No.\X0D\\X0A\ESTROGEN RECEPTOR STATUS BY IHC METHOD:  Positive per outside biopsy.\X0D\\X0A\PROGESTERONE RECEPTOR STATUS BY IHC METHOD:  Positive per outside biopsy.\X0D\\X0A\HER-2/neu ONCOPROTEIN STATUS BY IHC METHOD:  Negative (0+) per outside biopsy.\X0D\\X0A\HER-2/neu ONCOGENE STATUS BY FISH ANALYSIS:  N/A.\X0D\\X0A\TREATMENT EFFECT:  None.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  None.\X0D\\X0A\OTHER STUDIES:  Not requested.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  3\X0D\\X0A\pN=  2a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIIA.\X0D\\X0A\JFJ/mbc",,"Gross Description\X0D\\X0A\Specimen 1 labeled right axillary lymph node, received in formalin, consists of\X0D\\X0A\a 10.0x10.0x5.0 cm aggregate of fatty soft tissue. Several enlarged firm lymph\X0D\\X0A\nodes are identified ranging from 0.8 to 3.5 cm in greatest dimension.\X0D\\X0A\Sectioning through the largest lymph node reveals a gray/white firm cut surface\X0D\\X0A\consistent with metastatic tumor. The lymph nodes are submitted in their\X0D\\X0A\entirety. Summary of sections: 1A-1H  one bisected lymph node per cassette; 1I \X0D\\X0A\intact lymph nodes; 1J  representative section from largest grossly positive\X0D\\X0A\lymph node. \X0D\\X0A\Specimen 2 labeled right breast tissue short superior long lateral, received\X0D\\X0A\fresh for frozen section, consists of a 257.2 gram, 11.5x9.5x4.5 cm intact\X0D\\X0A\lumpectomy specimen. The margins are inked as follows: superior margin blue,\X0D\\X0A\lateral margin green, and remaining margins black. A representative section of\X0D\\X0A\the medial and central anterior aspect are submitted for frozen section.\X0D\\X0A\Sectioning from the medial toward the lateral aspect reveals a 6.5x3.0x2.8 cm\X0D\\X0A\ill defined firm tan mass, 3.5 cm from the inferior margin, 1.8 cm from the\X0D\\X0A\superior margin, 4 cm from the lateral margin, 1.3 cm from the deep margin. The\X0D\\X0A\mass abuts the medial and anterior margins. There is an area in the central\X0D\\X0A\aspect of the breast which is extremely firm and slightly more well\X0D\\X0A\circumscribed. This area measures approximately 3.5x2.8x2.5 cm. The breast\X0D\\X0A\tissue coursing toward the medial aspect of the breast continues to have a firm\X0D\\X0A\slightly nodular appearance and is suspicious for invasive tumor. Representative\X0D\\X0A\sections are submitted for frozen section. Summary of sections: 2A  frozen\X0D\\X0A\section residue; 2B  lateral margin; 2C  inferior margin; 2D  superior margin;\X0D\\X0A\2E  deep margin; 2F  mass taken perpendicularly to include the medial margin,\X0D\\X0A\2G-2N  representative sections of breast tissue to include probable tumor\X0D\\X0A\submitted sequentially from the medial toward the lateral aspect every 1 cm for\X0D\\X0A\a total area of 8 cm. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections through specimen 1 show multiple lymph nodes with evidence of\X0D\\X0A\metastatic carcinoma. In total, eight of fourteen lymph nodes are positive for\X0D\\X0A\metastatic carcinoma. These do not show extracapsular extension. \X0D\\X0A\Sections from the right breast lumpectomy show frozen section margin to have\X0D\\X0A\infiltrating neoplasm involving both the anterior and antero-medial margins.\X0D\\X0A\Sections through margins designated lateral, inferior, and superior show no\X0D\\X0A\evidence of neoplasm. Section taken designated deep margin show neoplasm well\X0D\\X0A\away from the margin. Sections taken from the neoplasm show a ductal carcinoma\X0D\\X0A\with lobular features. The pattern and focal single file appearance of the tumor\X0D\\X0A\cells is noted; however, there are rounded nests and tubules of tumor. At areas\X0D\\X0A\of worst differentiation, the cells show large vesicular nuclei with nucleoli.\X0D\\X0A\Mitotic activity is counted between 10 and 20 per 10 HPF. Some of the cells do\X0D\\X0A\show lobular features including cytoplasmic lumina. All of the sections\X0D\\X0A\submitted show evidence of neoplasm. Focal areas of ductal carcinoma in situ are\X0D\\X0A\noted. There are foci of low-grade ductal carcinoma in situ with solid and\X0D\\X0A\cribriform areas as well as areas of high-grade with high-grade cytology,\X0D\\X0A\luminal necrosis, and calcification. There is cancerization of lobules in these\X0D\\X0A\areas. The in situ carcinoma comprises approximately 10% of the total tumor\X0D\\X0A\volume. There is a perineural invasion and lymphvascular invasion noted.  \X0D\\X0A\JFJ/mbc",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. ZZZ], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488117,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is spiculated 10 o'clock mass right, 3 mm nodule 12 o'clock\X0D\\X0A\right.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, needle biopsy\X0D\\X0A\2: Breast, needle biopsy","Final Diagnosis\X0D\\X0A\1. RIGHT BREAST AT 10 O'CLOCK, ULTRASOUND GUIDED CORE BIOPSIES:\X0D\\X0A\     Infiltrating lobular carcinoma.\X0D\\X0A\     Hormone receptors pending.\X0D\\X0A\2. RIGHT BREAST NODULE AT 12 O'CLOCK, ULTRASOUND GUIDED CORE BIOPSIES:\X0D\\X0A\     Infiltrating lobular carcinoma.\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT: This report was faxed to the Radiologists at the Breast Imaging\X0D\\X0A\Services on **DATE[Feb 6 2012].  **INITIALS",,Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled right breast 10 o'clock ultrasound\X0D\\X0A\biopsy is a 1.5 x 1.5 x 0.3 cm aggregate of tan/pink fibroadipose breast tissue\X0D\\X0A\fragments which were placed in formalin at 10:25 a.m. and are now submitted in\X0D\\X0A\cassette 1. \X0D\\X0A\Specimen 2 received in formalin labeled right breast 12 o'clock ultrasound\X0D\\X0A\biopsy is a 1.0 x 0.8 x 0.2 cm aggregate of tan/pink fibroadipose breast tissue\X0D\\X0A\fragments which were placed in formalin at 10:30 a.m. and are now submitted in\X0D\\X0A\cassette 2.  **INITIALS,Microscopic Description\X0D\\X0A\Sections show infiltrating neoplasm composed primarily of tumor cells arranged\X0D\\X0A\in a single file pattern in a dense fibrous stroma. \X0D\\X0A\Sections from specimen 2 show a small area of similar infiltrating carcinoma\X0D\\X0A\present with background cystic dilatation of ducts with a mild degree of\X0D\\X0A\epithelial hyperplasia.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY M. CCC], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488119,3,,"Clinical Diagnosis and History\X0D\\X0A\The working history is known right breast CA, abnormal MRI, left breast, 11 to\X0D\\X0A\12 o'clock clumped linear enhancement.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, M. YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Breast, needle biopsy\X0D\\X0A\2: Breast, needle bx\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Oct 16 11]. RIGHT BREAST STEREOTACTIC BREAST BIOPSY: Proliferative\X0D\\X0A\fibrocystic change without atypia, sclerosing adenosis, and fibroadenomatoid\X0D\\X0A\change.  Microcalcifications identified.  No invasive or in-situ carcinoma\X0D\\X0A\noted.  (DGD)\X0D\\X0A\***PATH-NUMBER[2], **DATE[Oct 02 11]. ADDENDUM COMMENT:  The tumor is positive for estrogen and\X0D\\X0A\progesterone receptors; negative for HER2/Neu (0+). See additional microscopic\X0D\\X0A\description for semiquantitative details. 1. RIGHT BREAST AT 10 O'CLOCK,\X0D\\X0A\ULTRASOUND GUIDED CORE BIOPSIES: Infiltrating well differentiated ductal\X0D\\X0A\carcinoma.  2. RIGHT AXILLARY LYMPH NODE, BIOPSY: Negative for metastatic\X0D\\X0A\carcinoma.  COMMENT: Although reference was made to flow cytometry on the\X0D\\X0A\requisition sheet, there was no specimen received for flow cytometry.\X0D\\X0A\Correlation with clinical findings is recommended. (JFJ)","Final Diagnosis\X0D\\X0A\1.          LEFT BREAST AT 11  12 O'CLOCK, MRI GUIDED CORE BIOPSIES:\X0D\\X0A\     Lobular carcinoma in situ.\X0D\\X0A\Negative for invasive carcinoma.\X0D\\X0A\2.          RIGHT BREAST, UPPER OUTER QUADRANT, MRI GUIDED CORE BIOPSIES:\X0D\\X0A\     Proliferative fibrocystic change with sclerosing adenosis.\X0D\\X0A\JFJ/mbc \X0D\\X0A\COMMENT: This report was faxed to the radiologist at Central Baptist Breast\X0D\\X0A\Imaging Services on **DATE[Oct 22 2011].",,Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled left breast MRI guided biopsy is a 2.5 x\X0D\\X0A\2.5 x 0.3cm aggregate of tan/pink fibroadipose breast tissue fragments which\X0D\\X0A\were placed in formalin at 2pm and are now submitted in cassette 1.\X0D\\X0A\Specimen 2 received in formalin labeled right breast MRI guided biopsy is a 3.0\X0D\\X0A\x 3.0 x 0.5cm aggregate of tan/pink fibroadipose breast tissue fragments which\X0D\\X0A\were placed in formalin at 2:10pm and are now submitted in cassette 2A-2B. \X0D\\X0A\**INITIALS,Microscopic Description\X0D\\X0A\Sections from the left breast biopsies show multiple areas of expansion of\X0D\\X0A\lobules with filling of ductal-lobular units by lobular type epithelial cells.\X0D\\X0A\There is focal background sclerosing adenosis. There is no evidence of invasive\X0D\\X0A\carcinoma.\X0D\\X0A\Sections from the right breast biopsies show an area of adenosis with background\X0D\\X0A\sclerotic stroma. There is intervening pseudoangiomatous stromal hyperplasia.\X0D\\X0A\There is no evidence of in situ or invasive carcinoma.\X0D\\X0A\JFJ/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX M. WWW], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,488127,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is palpable left 2 o'clock, 2.3cm irregular mass with\X0D\\X0A\associated pleomorphic calcifications, highly suspicious.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY] :\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy",Final Diagnosis\X0D\\X0A\LEFT BREAST ULTRASOUND-GUIDED BIOPSY AT 2 O'CLOCK: \X0D\\X0A\     Infiltrating intermediate grade ductal adenocarcinoma with focal in situ\X0D\\X0A\carcinoma. See Comment.\X0D\\X0A\COMMENT:  This report was faxed to the Radiologist at the Breast Imaging\X0D\\X0A\Services on **DATE[May 26 12]. \X0D\\X0A\**INITIALS,,Gross Description\X0D\\X0A\Received in formalin labeled left breast ultrasound biopsy is a 2.5 x 2.0 x\X0D\\X0A\0.3cm aggregate of tan/pink fibroadipose breast tissue fragments placed in\X0D\\X0A\formalin at 11:30am and are now submitted in one cassette.  **INITIALS,Microscopic Description\X0D\\X0A\Sections of the breast fibrous and adipose tissue show an infiltrating neoplasm\X0D\\X0A\with cells having moderate nuclear pleomorphism; some of the nuclei do show\X0D\\X0A\nucleoli visible. The tumor is raggedly infiltrating the fibrous connective\X0D\\X0A\tissue and advancing into the adipose. Focal in situ ductal carcinoma is also\X0D\\X0A\present. No definite lymphvascular invasion is seen. Immunohistochemistry is\X0D\\X0A\pending for ER/PR's and Her-2 by FISH. **INITIALS,,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,BREAST,0,488434,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RIGHT BREAST CANCER\X0D\\X0A\,"SPECIMEN/PROCEDURE/LATERALITY:\X0D\\X0A\        RIGHT BREAST, SIMPLE MASTECTOMY.\X0D\\X0A\    HISTOLOGIC TYPE OF INVASIVE CARCINOMA:\X0D\\X0A\        SMALL CELL CARCINOMA.\X0D\\X0A\        SEE COMMENT SECTION FOR IMMUNOSTAINING RESULTS.\X0D\\X0A\    HISTOLOGIC GRADE:\X0D\\X0A\        POORLY DIFFERENTIATED, NOTTINGHAM HISTOLOGIC GRADE:  TUBULE\X0D\\X0A\FORMATION 3; NUCLEAR PLEOMORPHISM 3; MITOSES 3; TOTAL SCORE 9/9.\X0D\\X0A\    INVASIVE CARCINOMA SIZE:\X0D\\X0A\        8.0 CM.\X0D\\X0A\    TUMOR FOCALITY:\X0D\\X0A\        UNIFOCAL.\X0D\\X0A\    EXTENT OF TUMOR:\X0D\\X0A\        TUMOR EXTENDS INTO SKIN BY DIRECT INVASION, WITHOUT ULCERATION.\X0D\\X0A\        NO INVOLVEMENT OF NIPPLE.\X0D\\X0A\        SKELETAL MUSCLE IS PRESENT AND NOT INVOLVED.\X0D\\X0A\    DUCTAL CARCINOMA IN SITU:\X0D\\X0A\        NON-EXTENSIVE HIGH GRADE DUCT CARCINOMA IN SITU WITH COMEDO\X0D\\X0A\   NECROSIS.\X0D\\X0A\    LOBULAR CARCINOMA IN SITU:\X0D\\X0A\        NOT IDENTIFIED.\X0D\\X0A\    MARGINS:\X0D\\X0A\        ALL MARGINS UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\        INVASIVE AND IN SITU CARCINOMA ARE 3.8 CM FROM THE DEEP MARGIN.\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 11 12]                 **PLACE Clinical Associates                    PAGE:   6\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA] C                  DOB: **DATE[Mar 26 1948]   Sex: F\X0D\\X0A\Add:1002 **PLACE,KY **ZIP-CODE  **PHONE                                                               \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS INo   Location:  D.6WS      D.6103-1    \X0D\\X0A\Reg:   **DATE[May 21 12]     Disch: **DATE[May 23 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[ZZZ:YYY,XXX] B       Submit:**NAME[YYY,XXX] B            MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS Dr #530         **PLACE                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[WWW,VVV M]\X0D\\X0A\   2355 Poplar Level Rd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 11 12]                 **PLACE Clinical Associates                    PAGE:   8\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA] C                  DOB: **DATE[Mar 26 1948]   Sex: F\X0D\\X0A\Add:1002 **PLACE,KY **ZIP-CODE  **PHONE                                                               \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS INo   Location:  D.6WS      D.6103-1    \X0D\\X0A\Reg:   **DATE[May 21 12]     Disch: **DATE[May 23 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[ZZZ:YYY,XXX] B       Submit:**NAME[YYY,XXX] B            MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS Dr #530         **PLACE                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:  (Continued)\X0D\\X0A\\X0D\\X0A\   Sheth,Bakula R\X0D\\X0A\   1001 Trevilian Way\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\   **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[YYY,XXX M]\X0D\\X0A\   **STREET-ADDRESS Dr #530\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88360GS/2, 88307GS/2, 88331GS, 88342GS\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[UUU M TTT] MD **DATE[May 25 12]                \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 11 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FROZEN SECTION DIAGNOSIS\X0D\\X0A\\X0D\\X0A\ALL NODAL TISSUE FROZEN, NO METASTATIC TUMOR IDENTIFIED (LIMITED SECTIONS).  REPORTED TO DR.\X0D\\X0A\**NAME[YYY] ON **DATE[May 21 2012] AT APPROXIMATELY 12:40 P.M.  LWF\X0D\\X0A\\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.    SENTINEL LYMPH NODE #1:\X0D\\X0A\BENIGN LYMPH NODE TISSUE (TWO PIECES).\X0D\\X0A\\X0D\\X0A\B.    CARCINOMA OF THE BREAST SYNOPTIC REPORT\X0D\\X0A\\X0D\\X0A\SPECIMEN/PROCEDURE/LATERALITY:\X0D\\X0A\RIGHT BREAST, SIMPLE MASTECTOMY.\X0D\\X0A\HISTOLOGIC TYPE OF INVASIVE CARCINOMA:\X0D\\X0A\SMALL CELL CARCINOMA.\X0D\\X0A\SEE COMMENT SECTION FOR IMMUNOSTAINING RESULTS.\X0D\\X0A\HISTOLOGIC GRADE:\X0D\\X0A\POORLY DIFFERENTIATED, NOTTINGHAM HISTOLOGIC GRADE:  TUBULE\X0D\\X0A\FORMATION 3; NUCLEAR PLEOMORPHISM 3; MITOSES 3; TOTAL SCORE 9/9.\X0D\\X0A\INVASIVE CARCINOMA SIZE:\X0D\\X0A\8.0 CM.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\EXTENT OF TUMOR:\X0D\\X0A\TUMOR EXTENDS INTO SKIN BY DIRECT INVASION, WITHOUT ULCERATION.\X0D\\X0A\NO INVOLVEMENT OF NIPPLE.\X0D\\X0A\SKELETAL MUSCLE IS PRESENT AND NOT INVOLVED.\X0D\\X0A\DUCTAL CARCINOMA IN SITU:\X0D\\X0A\NON-EXTENSIVE HIGH GRADE DUCT CARCINOMA IN SITU WITH COMEDO\X0D\\X0A\NECROSIS.\X0D\\X0A\LOBULAR CARCINOMA IN SITU:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\MARGINS:\X0D\\X0A\ALL MARGINS UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\INVASIVE AND IN SITU CARCINOMA ARE 3.8 CM FROM THE DEEP MARGIN.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\LYMPHATIC/VASCULAR INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\LYMPH NODE SAMPLING:\X0D\\X0A\TWO BENIGN SENTINEL LYMPH NODES (SEE PART A).\X0D\\X0A\AJCC PATHOLOGIC STAGE:  pT3 pN0(sn) Mn/a.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\BREAST PANEL TO INCLUDE ER, PR, KI-67 AND HER-2/NEU WILL BE REPORTED\X0D\\X0A\AS ADDENDA.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:\X0D\\X0A\CARCINOMA PARTIALLY INVOLVES A SENESCENT FIBROADENOMA.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\INTACT.\X0D\\X0A\COLD ISCHEMIA TIME:  LESS THAN 1 HOUR.\X0D\\X0A\TOTAL FIXATION TIME IN FORMALIN:  BETWEEN 6 AND 72 HOURS.\X0D\\X0A\IMAGING STUDIES:\X0D\\X0A\NO IMAGING STUDIES OF THE BREAST ARE FOUND IN THE **PLACE COMPUTER\X0D\\X0A\SYSTEM.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual seventh edition\X0D\\X0A\guidelines.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\IMMUNOSTAIN REPORT\X0D\\X0A\\X0D\\X0A\A panel of immunostains is performed with results as follows:\X0D\\X0A\Tumor cells are positive for CD56, CK7, and synaptophysin.\X0D\\X0A\Tumor cells are negative for chromogranin A, mammoglobin, and CD45.\X0D\\X0A\All controls stain appropriately.\X0D\\X0A\\X0D\\X0A\Staining results are consistent with small cell carcinoma.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  Received fresh for frozen section designated ""sentinel node #1"" are two irregular\X0D\\X0A\fragments of yellow-tan lobulated adipose tissue measuring 1.5 to 2.5 cm in greatest\X0D\\X0A\dimension.  Section and palpation reveals two fragments of lymph node measuring up to 1.4 cm\X0D\\X0A\in greatest dimension.  Further sectioning of the lymph node fragments reveals partial\X0D\\X0A\adipose replacement.  A touch prep is prepared and the sectioned fragmented lymph node is\X0D\\X0A\submitted on a single block for frozen section.  Following frozen section, the specimen is\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\submitted in cassette A-FSC.\X0D\\X0A\\X0D\\X0A\B.  Received in formalin designated ""right breast"" is a 550 gram simple mastectomy specimen\X0D\\X0A\measuring 18.5 x 16.0 x up to 7.2 cm.  There is an overlying ellipse of skin measuring 18.5\X0D\\X0A\x 12.0 cm.  The skin is taut and discolored by blue injection dye.  The areola is identified\X0D\\X0A\on the medial aspect of the specimen measuring 5.0 x 4.5 cm.  The 1.0 cm nipple is flush\X0D\\X0A\with the skin surface without definite retraction.  A bulky firm mass is identified within\X0D\\X0A\the breast tissue.\X0D\\X0A\\X0D\\X0A\The deep margin consists of a fascial plane with focal wisps of red-tan skeletal muscle.\X0D\\X0A\The deep margin is marked with black ink.  The specimen is serially sectioned across the\X0D\\X0A\short axis to reveal a centrally located, well circumscribed tan-white fibrocystic nodule.\X0D\\X0A\The nodule is central and extends to involve all four quadrants of the breast, is well\X0D\\X0A\defined and measures 6.0 x 5.5 x 4.8 cm.  Immediately adjacent and possibly associated with\X0D\\X0A\the fibrous lesion is an additional lobulated tan fleshy nodule measuring 3.0 x 2.2 x 8.0\X0D\\X0A\cm.  The nodule abuts the taut skin surface within less than 0.1 cm and is located 3.8 cm\X0D\\X0A\from the closest overlying inked deep margin.\X0D\\X0A\\X0D\\X0A\The remaining breast tissue is yellow-tan and lobulated.  There are no additional nodules or\X0D\\X0A\masses identified within the remaining breast tissue.\X0D\\X0A\\X0D\\X0A\Axilla is not attached.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\B1.    nipple\X0D\\X0A\B2\T\B3.    representative sections of skin overlying described nodule\X0D\\X0A\B4.    closest overlying inked deep margin\X0D\\X0A\B5\T\B6.    additional representative sections of deep margin\X0D\\X0A\B7-B10.    representative sections of fibrous nodule with fibrocystic change,\X0D\\X0A\submitted from\X0D\\X0A\medial to lateral\X0D\\X0A\B11\T\B12.    representative sections of transitional tissue of nodule\X0D\\X0A\B13-B18.    multiple representative sections of second described nodule submitted from\X0D\\X0A\medial to lateral\X0D\\X0A\B19.    representative sections of upper inner quadrant\X0D\\X0A\B20.    representative sections of upper outer quadrant\X0D\\X0A\B21.    representative sections of lower outer quadrant\X0D\\X0A\B22.    representative sections of lower inner quadrant\X0D\\X0A\\X0D\\X0A\Note:  The specimen is removed from the patient at 12:28 and placed into formalin at 12:35\X0D\\X0A\p.m.  The specimen is received in pathology at 12:44 p.m. and sectioned and placed into\X0D\\X0A\formalin at 1:15 p.m. on **DATE[May 21 12].  **INITIALS\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A.  SENTINEL NODE #1 - FROZEN (OUT AT 1216)\X0D\\X0A\B.  RIGHT BREAST\X0D\\X0A\,,"ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #3              Entered: **DATE[Jun 10 12]-1217\X0D\\X0A\\X0D\\X0A\**INSTITUTION **INSTITUTION\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\**PLACE, TN\X0D\\X0A\\X0D\\X0A\Specimen:  Sentinel lymph node #1 and right breast simple mastectomy (VUMC #***PATH-NUMBER[1]).\X0D\\X0A\\X0D\\X0A\The specimen was sent at the request of Dr. **NAME[VVV WWW, SSS] Oncology.\X0D\\X0A\\X0D\\X0A\DIAGNOSIS:\X0D\\X0A\\X0D\\X0A\A.  LYMPH NODE, SENTINEL NODE #1, EXCISION:\X0D\\X0A\BENIGN LYMPH NODE TISSUE.\X0D\\X0A\\X0D\\X0A\B.  BREAST, RIGHT, SIMPLE MASTECTOMY:\X0D\\X0A\SMALL CELL CARCINOMA; 8 CM IN GREATEST EXTENT, SURGICAL MARGINS WIDELY     NEGATIVE FOR\X0D\\X0A\TUMOR (PER REPORT).  (SEE COMMENT).\X0D\\X0A\\X0D\\X0A\COMMENT:\X0D\\X0A\There is an in situ component that indicates this is a primary tumor.  The tumor is positive\X0D\\X0A\for CD56, synaptophysin, CK7, and estrogen receptor, while it is negative for CD45,\X0D\\X0A\progesterone receptor, chromogranin, and mammoglobin, all consistent with the above\X0D\\X0A\diagnosis.  We concur with the original pathologist's diagnosis.\X0D\\X0A\\X0D\\X0A\Report signed by **NAME[RRR QQQ], M.D.\X0D\\X0A\\X0D\\X0A\Addendum #2              Entered: **DATE[May 27 12]-1522\X0D\\X0A\\X0D\\X0A\FISH Analysis Her-2/neu Amplification\X0D\\X0A\***PATH-NUMBER[2]/MO11-315\X0D\\X0A\\X0D\\X0A\Interpretation\X0D\\X0A\\X0D\\X0A\Amplification of the HER-2 gene is not detected\X0D\\X0A\\X0D\\X0A\Results\X0D\\X0A\\X0D\\X0A\Her-2         CEP17           Ratio\X0D\\X0A\(red)         (green)\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Number of copies:               2.6            2.2                   1.3\X0D\\X0A\\X0D\\X0A\Specimen Data\X0D\\X0A\\X0D\\X0A\The specimen was fixed in 10% NBF for 6-72 hrs.\X0D\\X0A\Cold Ischemic Time:  less than 1 hr.\X0D\\X0A\There are 100 invasive tumor cells present for evaluation with 1 observer.\X0D\\X0A\\X0D\\X0A\Principle\X0D\\X0A\\X0D\\X0A\HER-2/neu FISH testing is performed in compliance with the ASCO/CAP guidelines. The\X0D\\X0A\procedure in use has been modified from the FDA approved procedure (PathVysion from Vysis)\X0D\\X0A\by increasing the enzyme digestion to 20 minutes and using DAPI II as a counterstain.  The\X0D\\X0A\Flow Cytometry Laboratory takes responsibility for test performance, and the validation\X0D\\X0A\performed has proven extremely high between IHC and FISH.  Tissue sections are\X0D\\X0A\deparaffinized, pretreated and digested, then probed and incubated overnight, along with\X0D\\X0A\appropriate controls.  Two separate probes are used from Vysis:  a Spectrum Orange Her-2\X0D\\X0A\probe that is locus-specific and a Spectrum Green centromere probe for Chromosome 17.  The\X0D\\X0A\slides are counterstained with DAPI to produce an enhanced visualization of probe\X0D\\X0A\reactivity.\X0D\\X0A\\X0D\\X0A\Analysis\X0D\\X0A\\X0D\\X0A\The slides are viewed under a fluorescent microscope. The level of HER-2 gene amplification\X0D\\X0A\is measured as a ratio of orange (Her-2) fluorescent foci to green (CEP 17) fluorescent\X0D\\X0A\foci. A positive result is a ratio >2.2, and a negative result is a ratio <1.8.  A ratio\X0D\\X0A\between 1.8-2.2 is considered equivocal amplification.\X0D\\X0A\\X0D\\X0A\References\X0D\\X0A\\X0D\\X0A\1) Wolff A.C. et al. (2007); JCO 25: 118-145.\X0D\\X0A\2) J.H.J.M. van Krieken et al. (2007); Leukemia 21: 201-206.\X0D\\X0A\3) Gonzalez-Angulo A.M. et al. (2006); The Oncologist 11: 857-867.\X0D\\X0A\4) Yaziji H. et al. (2004); JAMA **PHONE-1977.\X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[May 25 12]-1319\X0D\\X0A\\X0D\\X0A\ER/PR and Ki-67 Results\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\INTERPRETATION: This tumor must be considered strongly positive for immunoreactive estrogen\X0D\\X0A\receptor but negative for immunoreactive progesterone receptor.\X0D\\X0A\\X0D\\X0A\HER-2/neu determination via FISH to follow as an additional addendum.\X0D\\X0A\\X0D\\X0A\Ki-67 - 70%.\X0D\\X0A\\X0D\\X0A\Materials Received:\X0D\\X0A\\X0D\\X0A\Block #: DS11-3926-B8\X0D\\X0A\**INSTITUTION\X0D\\X0A\Fixative: Neutral Buffered Formalin\X0D\\X0A\Duration of Fixation (> 6 hours and < 72 hours):  Yes\X0D\\X0A\\X0D\\X0A\Modified **NAME[PPP] Score\X0D\\X0A\\X0D\\X0A\Antibody/Clone\X0D\\X0A\Proportion Score*\X0D\\X0A\Intensity Score+\X0D\\X0A\Results\X0D\\X0A\\X0D\\X0A\ER/6F11\X0D\\X0A\5\X0D\\X0A\2\X0D\\X0A\Positive\X0D\\X0A\\X0D\\X0A\PR/1P4\X0D\\X0A\0\X0D\\X0A\0\X0D\\X0A\Negative\X0D\\X0A\\X0D\\X0A\*Proportion Score\X0D\\X0A\\X0D\\X0A\+Intensity Score\X0D\\X0A\\X0D\\X0A\Score\X0D\\X0A\% Tumor Cells Stained\X0D\\X0A\\X0D\\X0A\Score\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Value\X0D\\X0A\\X0D\\X0A\0\X0D\\X0A\0\X0D\\X0A\\X0D\\X0A\0\X0D\\X0A\Negative\X0D\\X0A\\X0D\\X0A\1\X0D\\X0A\1\X0D\\X0A\\X0D\\X0A\1\X0D\\X0A\Weak\X0D\\X0A\\X0D\\X0A\2\X0D\\X0A\10\X0D\\X0A\\X0D\\X0A\2\X0D\\X0A\Intermediate\X0D\\X0A\\X0D\\X0A\3\X0D\\X0A\33\X0D\\X0A\\X0D\\X0A\3\X0D\\X0A\Strong\X0D\\X0A\\X0D\\X0A\4\X0D\\X0A\66\X0D\\X0A\\X0D\\X0A\5\X0D\\X0A\100\X0D\\X0A\\X0D\\X0A\Detection System: Polymer\X0D\\X0A\Internal and External Controls: Adequate\X0D\\X0A\\X0D\\X0A\Technique description:\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Using appropriate positive and negative controls this specimen is stained for the presence\X0D\\X0A\of immunoreactive estrogen and progesterone receptor, and Ki-67 via an automated\X0D\\X0A\immunohistochemical technique utilizing appropriate epitope enhancement.\X0D\\X0A\\X0D\\X0A\References:\X0D\\X0A\Arch Pathol Lab Med 2007; 131:1-26\X0D\\X0A\Arch Pathol Lab Med 2010; **ID-NUM\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\"
REG1,BREAST,0,488463,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RIGHT BREAST CANCER\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\        RIGHT BREAST, MASTECTOMY.\X0D\\X0A\    TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\        POORLY DIFFERENTIATED, INVASIVE DUCTAL CARCINOMA, NOTTINGHAM                 GRADE 3\X0D\\X0A\(SCORE:  TUBULE FORMATION 3/3 + PLEOMORPHISM 3/3 +\X0D\\X0A\            MITOTIC COUNT 3/3= 9/9).\X0D\\X0A\        TUMOR IS ASSOCIATED WITH A LYMPHOCYTIC INFILTRATE AND IS ASSOCIATED\X0D\\X0A\WITH CENTRAL HYALINIZED FIBROSIS.\X0D\\X0A\    TUMOR SIZE:\X0D\\X0A\        GREATEST DIMENSION OF INVASIVE CARCINOMA IS 3.0 CM.\X0D\\X0A\    DUCTAL CARCINOMA IN SITU (DCIS):\X0D\\X0A\        NON-EXTENSIVE DCIS, HIGH-GRADE, SOLID AND CRIBRIFORM TYPES WITH\X0D\\X0A\            FOCAL NECROSIS INTERMIXED WITH TUMOR AND AT TUMOR\X0D\\X0A\            PERIPHERY.\X0D\\X0A\    TUMOR SITE:\X0D\\X0A\        UPPER OUTER QUADRANT.\X0D\\X0A\    TUMOR FOCALITY:\X0D\\X0A\        UNIFOCAL.\X0D\\X0A\    MARGINS:\X0D\\X0A\        DEEP RESECTION MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\        DISTANCE FROM TUMOR TO CLOSEST DEEP MARGIN IS 2.0 CM.\X0D\\X0A\COPIES TO:\X0D\\X0A\   Arla,Mohana R\X0D\\X0A\   170 Doctor Arla Way\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   **STREET-ADDRESS Dr #530\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS/2, 88331GS\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[XXX M WWW] MD **DATE[Aug 06 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Aug 07 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FROZEN SECTION DIAGNOSIS\X0D\\X0A\\X0D\\X0A\ONE LYMPH NODE, NEGATIVE FOR METASTATIC TUMOR.  REPORTED TO DR. **NAME[ZZZ] ON **DATE[Aug 02 12] AT 11:06\X0D\\X0A\A.M.  LWF\X0D\\X0A\\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.    RIGHT SENTINEL NODE, EXCISION:\X0D\\X0A\ONE LYMPH NODE, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\\X0D\\X0A\B.    INVASIVE CARCINOMA OF THE BREAST SYNOPTIC REPORT, AJCC/UICC TNM,\X0D\\X0A\7TH EDITION\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\RIGHT BREAST, MASTECTOMY.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\POORLY DIFFERENTIATED, INVASIVE DUCTAL CARCINOMA, NOTTINGHAM                 GRADE 3\X0D\\X0A\(SCORE:  TUBULE FORMATION 3/3 + PLEOMORPHISM 3/3 +\X0D\\X0A\MITOTIC COUNT 3/3= 9/9).\X0D\\X0A\TUMOR IS ASSOCIATED WITH A LYMPHOCYTIC INFILTRATE AND IS ASSOCIATED\X0D\\X0A\WITH CENTRAL HYALINIZED FIBROSIS.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\GREATEST DIMENSION OF INVASIVE CARCINOMA IS 3.0 CM.\X0D\\X0A\DUCTAL CARCINOMA IN SITU (DCIS):\X0D\\X0A\NON-EXTENSIVE DCIS, HIGH-GRADE, SOLID AND CRIBRIFORM TYPES WITH\X0D\\X0A\FOCAL NECROSIS INTERMIXED WITH TUMOR AND AT TUMOR\X0D\\X0A\PERIPHERY.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\UPPER OUTER QUADRANT.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\MARGINS:\X0D\\X0A\DEEP RESECTION MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\DISTANCE FROM TUMOR TO CLOSEST DEEP MARGIN IS 2.0 CM.\X0D\\X0A\MACROSCOPIC AND MICROSCOPIC TUMOR EXTENT:\X0D\\X0A\SKIN - NOT INVOLVED.\X0D\\X0A\NIPPLE - NOT INVOLVED.\X0D\\X0A\SKELETAL MUSCLE - NOT INVOLVED.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\NO DEFINITE ANGIOLYMPHATIC INVASION IDENTIFIED.\X0D\\X0A\MICROCALCIFICATIONS:\X0D\\X0A\MICROCALCIFICATIONS ARE IDENTIFIED ASSOCIATED WITH INVASIVE\X0D\\X0A\CARCINOMA AND DCIS.\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\NO PRIOR TREATMENT.\X0D\\X0A\SPECIMEN SIZE:\X0D\\X0A\25.0 X 17.0 X UP TO 5.8 CM.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\INTACT.\X0D\\X0A\LOBULAR CARCINOMA IN SITU:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\SEE SPECIMEN A.\X0D\\X0A\ADDITIONAL FINDINGS:\X0D\\X0A\NONPROLIFERATIVE FIBROCYSTIC CHANGES.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\HORMONE RECEPTOR, HER2/NEU AND KI-67 ANALYSIS WERE PERFORMED ON\X0D\\X0A\PATIENT's PRIOR BIOPSY SPECIMEN (***PATH-NUMBER[1]).\X0D\\X0A\ESTIMATED COLD ISCHEMIA TIME:\X0D\\X0A\LESS THAN ONE HOUR.\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME IN FORMALIN:\X0D\\X0A\6-72 HOURS.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  PLEASE SEE COMMENTS.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Pathologic stage:  pT2 pN0(sn) pMn/a.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  Received fresh for frozen section designated ""right sentinel node"" is an irregular\X0D\\X0A\fragment of yellow-tan lobulated adipose tissue measuring 3.5 x 1.7 x 1.0 cm.  Sectioning\X0D\\X0A\and palpation reveals a single blue discolored lymph node candidate measuring 1.1 cm.  The\X0D\\X0A\specimen is serially sectioned to reveal a tan-blue homogeneous cut surface.  A touch prep\X0D\\X0A\is prepared and the specimen is entirely submitted on a single block for frozen section.\X0D\\X0A\Following frozen section, the specimen is submitted in cassette A-FSC.  Sentinel lymph node\X0D\\X0A\protocol is observed.\X0D\\X0A\\X0D\\X0A\B.  Received in formalin designated ""right breast"" is a 780 gram simple mastectomy measuring\X0D\\X0A\25.0 x 17.0 x up to 5.8 cm.  The overlying ellipse of white skin measures 19.5 x 12.0 cm.\X0D\\X0A\Blue discoloration is noted lateral to the areola.  The areola is located on the inferior\X0D\\X0A\aspect of the skin surface measuring 3.5 x 2.2 cm.  The unretracted central nipple measures\X0D\\X0A\1.1 cm in greatest dimension.  A fullness is palpated within the upper outer quadrant of the\X0D\\X0A\breast.\X0D\\X0A\\X0D\\X0A\The deep margin consists of a fascial plane with focal wispy skeletal muscle.  The deep\X0D\\X0A\margin is marked with black ink and the specimen is serially sectioned from medial to\X0D\\X0A\lateral.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Sectioning reveals a partially well circumscribed tan-white tumor mass within the upper\X0D\\X0A\outer quadrant at the 11:00 position.  The tumor mass measures 3.0 x 2.5 x 2.2 cm.  The\X0D\\X0A\tumor is located 2.0 cm from the overlying inked deep margin and 2.0 cm from the overlying\X0D\\X0A\skin surface.  Blue injection dye is noted within the breast tissue surrounding the tumor\X0D\\X0A\mass.  A central biopsy site is noted within the tumor.\X0D\\X0A\\X0D\\X0A\The remaining breast tissue consists of yellow-tan lobulated adipose tissue and pink-tan to\X0D\\X0A\white fibrous banding.  There are no additional nodules or masses within the breast.  An\X0D\\X0A\axilla is not attached.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\B1.    nipple\X0D\\X0A\B2.    skin overlying tumor\X0D\\X0A\B3.    skeletal muscle\X0D\\X0A\B4.    inked deep margin closest to tumor\X0D\\X0A\B5\T\B6.    largest gross section of tumor, bisected (dimension is superior to inferior)\X0D\\X0A\B7-B10.    additional representative sections of tumor to include multiple biopsy sites\X0D\\X0A\B11.        representative sections of upper inner quadrant\X0D\\X0A\B12.        representative sections of upper outer quadrant\X0D\\X0A\B13.        representative sections of lower outer quadrant\X0D\\X0A\B14.        representative sections of lower inner quadrant\X0D\\X0A\\X0D\\X0A\Note:  The specimen is removed from the patient at 11:03 a.m. and placed in to formalin at\X0D\\X0A\11:10 a.m.  The specimen is received in pathology at 11:11 a.m. and sectioned and placed\X0D\\X0A\into formalin at 11:58 a.m. on **DATE[Aug 02 12].  **INITIALS\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  3 FROZEN H\T\E, 3 PERMANENT H\T\E.    B.  14 H\T\E.\X0D\\X0A\","SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A.  RIGHT SENTINEL NODE - FROZEN\X0D\\X0A\B.  RIGHT BREAST, PERMANENT\X0D\\X0A\",,
REG1,BREAST,0,488709,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is abnormal ultrasound; left breast mass 1.6 cm mass 2\X0D\\X0A\o'clock left breast; rule out malignancy.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS (FOLLOWING IMMUNOHISTOCHEMISTRY RESULTS DETAILED IN MICROSCOPIC\X0D\\X0A\DESC):\X0D\\X0A\LEFT BREAST MASS AT 2 O'CLOCK, ULTRASOUND GUIDED BIOPSY:\X0D\\X0A\     Infiltrating lobular carcinoma.\X0D\\X0A\**INITIALS\X0D\\X0A\PRELIMINARY DIAGNOSIS PENDING IMMUNOHISTOCHEMISTRY:\X0D\\X0A\LEFT BREAST MASS AT 2 O'CLOCK, ULTRASOUND GUIDED BIOPSY:\X0D\\X0A\     Infiltrating mammary carcinoma.\X0D\\X0A\Immunohistochemistry pending.\X0D\\X0A\DGD/mbc\X0D\\X0A\COMMENT:  This report was faxed to the radiologist at Central Baptist Breast\X0D\\X0A\Imaging Services on **DATE[Aug 22 2012].",,"Gross Description\X0D\\X0A\The specimen, labeled left breast ultrasound guided biopsy, received in\X0D\\X0A\formalin, consists of a 2.0x2.0x0.3 cm aggregate of tan/pink fibroadipose breast\X0D\\X0A\tissue fragments which were placed in formalin at 5:05 pm and are now submitted\X0D\\X0A\in one cassette. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections of the needle core biopsy show a ragged infiltrate of neoplastic cells\X0D\\X0A\focally showing linear Indian file pattern infiltration suggestive of lobular\X0D\\X0A\carcinoma. E-cadherin, Estrogen and Progesterone receptors by\X0D\\X0A\immunohistochemistry are pending. No lymphvascular invasion is identified in the\X0D\\X0A\planes of section examined.  DGD/mbc\X0D\\X0A\IMMUNOHISTOCHEMISTRY RESULTS:  E-Cadherin immunohistochemistry is completely\X0D\\X0A\negative in the infiltrating tumor cells while the non-neoplastic ducts provide\X0D\\X0A\a strongly positive interim control.  Immunohistochemistry for estrogen receptor\X0D\\X0A\is strongly positive in greater than 95% of the tumor cells and a similar\X0D\\X0A\finding is seen with the progesterone receptor immunohistochemistry.  **INITIALS",,,Amendments:\X0D\\X0A\Amended:  **DATE[Aug 24 2012] by Ruthanne Walker\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Aug 22 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,BREAST,0,489007,1,,CLINICAL HISTORY: ***PATH-NUMBER[1] Left breast 10:00 FNA: Hypocellular specimen with atypical cells suspicious for malignancy.,"Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[DDD M BBB], XXX] PhD **DATE[Jan 01 12]","FINAL DIAGNOSIS: A.    LEFT BREAST **ID-NUM, LUMPECTOMY INVASIVE MODERATELY DIFFERENTIATED DUCTAL ADENOCARCINOMA OF BREAST. NO LYMPHOVASCULAR INVASION IDENTIFIED. SURGICAL MARGINS FREE OF TUMOR. SEE COMMENT. B.    LEFT AXILLARY SENTINEL LYMPH NODE LYMPH NODE, NO EVIDENCE OF METASTATIC CARCINOMA. SEE COMMENT. C.    LEFT BREAST, ADDITIONAL SUPERIOR DEEP MARGIN BREAST TISSUE, NO EVIDENCE OF MALIGNANCY. FINAL MARGIN WIDELY FREE OF TUMOR. SEE COMMENT.",,"GROSS DESCRIPTION: A.    The specimen is received in a Transpec container labeled with the patient's name, number, date and ""left breast.""  The specimen is accompanied by a mammographic film and is found to contain a localization needle.  The film demonstrates a dense mass, fairly well-delineated lying adjacent to the midportion of the localization needle. The surgical margins are inked beginning with the superior lateral and proceeding in a clockwise fashion with red, green, orange and black.  The deep margin is inked with purple.  The breast tissue is found to contain a 1.2 cm. firm glistening white-tan mass.  Grossly the mass lies approximately 1 cm. or more from all margins except for the superior deep where it lies approximately 5 mm. or less from the inked surface.  The mass and this nearest margin are represented in Blocks A1 and 2.  The breast tissue shows evidence of blue dye discoloration consistent with tracer dye injection.  The nearest margins from the anterior inferior lateral quadrant are placed in Block A3, the anterior superior lateral quadrant margin in Block A4, the anterior inferior medial quadrant in Block A5 and the anterior superior medial quadrant in Block A6. B.    The specimen is received in a container labeled with the patient's name, number, date and ""left axillary sentinel lymph node.""  The specimen is received in formalin and consists of a portion of lobulated yellow-red tissue, measuring 3 x 1.5 x 1 cm.  The specimen is bisected revealing an encapsulated structure grossly consistent with lymph node.  The outer edge has a peripheral rim of tan-pink tissue while most of the tissue consists of adipose tissue consistent with fatty infiltrate.  No gross evidence of metastatic disease is identified.  The specimen is totally submitted in Block B. C.    The specimen is received in a container labeled with the patient's name, number, date and ""additional superior and deep margin left breast.""  The specimen is received in formalin and consists of a lobulated portion of yellow adipose tissue, measuring 5.5 x 3.5 x 1 cm.  A surgical suture indicates the new margin.  The new margin is inked and the tissues are serially sectioned and are uniform lobulated yellow glistening throughout.  Multiple full thickness sections are placed in Blocks C1-4. Specimen A BREAST TISSUE WITH MASS GROSSLY CONSISTENT WITH ADENOCARCINOMA CLOSELY APPROXIMATING SUPERIOR DEEP QUADRANT MARGIN. REMAINING MARGINS WIDELY FREE OF TUMOR BY 1 CM. OR MORE. Specimen B LYMPH NODE, NO GROSS EVIDENCE OF METASTATIC CARCINOMA IDENTIFIED.","COMMENT WORD: The left breast lumpectomy **ID-NUM (Specimen A) is found to contain a 1.2 cm. firm glistening white-tan mass.  Microscopically this mass is composed of atypical epithelial cells forming an infiltrating pattern of tubules surrounded by a desmoplastic reaction.  The cells are mildly pleomorphic and the mitotic rate is low.  No lymphovascular invasion is identified.  Grossly and microscopically, the neoplasm is noted to extend to within approximately 5 mm. of the superior deep margin.  The remaining margins are widely free of tumor by 1 cm. or more.   The additional superior deep margin submitted as Specimen C shows no evidence of carcinoma, therefore, all final margins are felt to be widely free of tumor. There is no evidence of metastatic carcinoma in the left axillary sentinel lymph node (Specimen B).  Staging criteria: T1c, N0 probable Stage IA.  Histopathologic grade: tubule formation 1, nuclear pleomorphism 2 and mitotic count 1 for a total score of 4 points, designated as a Grade I, G1 low histologic grade neoplasm.  Histopathologic type: invasive ductal carcinoma.  The breast tumor profile analysis will be performed and reported separately.","Specimen Number: ***PATH-NUMBER[2]. Tissues: A. Left breast - 10-12:00, Lumpectomy, Single stitch superior, double lateral B. Axillary lymph node - Left sentinel C. Left breast - Additional superior deep margin. Specimen Comments:",,
REG1,BREAST,0,489017,1,,CLINICAL HISTORY: Preop diagnosis right breast mass.,"Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX M WWW], VVV] PhD **DATE[Nov 12 11]","FINAL DIAGNOSIS: RIGHT BREAST, CORE BIOPSY INVASIVE POORLY DIFFERENTIATED DUCTAL CARCINOMA OF BREAST. NO LYMPHOVASCULAR INVASION IDENTIFIED. SEE COMMENT.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, date of birth, and ""right breast biopsy.""  The specimen is received in formalin and consists of multiple longitudinal, cylindrically-shaped portions of yellow-white tissue, measuring 3 x 0.2 cm. The specimen is totally submitted in one block.","COMMENT WORD: The microscopic sections of core biopsy from the right breast reveal an atypical epithelial proliferation forming variably sized clusters.  The neoplasm extends into adipose tissues and there is chronic inflammation as well as desmoplastic reaction.  The cells contain large, moderately pleomorphic nuclei with variably clumped chromatin patterns, irregular outlines and variably sized nucleoli.  Mitoses are easily identified, oftentimes multiple per high-power field.  The biopsy is felt to demonstrate the presence of invasive poorly differentiated ductal carcinoma.  The longest continuous segment of neoplasm in the submitted biopsy tissue measures 8 mm. in length.  Staging criteria will be completed if additional tissue is received.  Histopathologic grade: tubule formation 3, nuclear pleomorphism 2 and mitotic count 3 for a total score of 8 points, a Grade III, G3 high histologic grade neoplasm.  Histopathologic type: invasive ductal carcinoma.  The breast tumor profile analysis will be performed and reported separately.",Specimen Number: ***PATH-NUMBER[1]. Tissues: Right breast. Specimen Comments:,,
REG1,BREAST,0,489288,1,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Abnormal calcifications,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\RE      011\X0D\\X0A\PHYSICIAN:       **NAME[ZZZ YYY]   SIGN OUT DATE:   **DATE[May 08 2012]\X0D\\X0A\COPIES TO:          **NAME[ZZZ]\X0D\\X0A\**NAME[YYY,"DIAGNOSIS\X0D\\X0A\1. STEREOTACTIC RIGHT BREAST DENSITY: INFILTRATING DUCTULAR CARCINOMA\X0D\\X0A\(GREATEST DIMENSION 0.5 CM DIAMETER).\X0D\\X0A\CPT4 88305 / ICD9 174.9 / PC 851.1, 873.7 / M85003\X0D\\X0A\ANCILLARY STUDIES (Performed at GenPath, read by Dr. **NAME[XXX])  See\X0D\\X0A\separate outside report.\X0D\\X0A\ESTROGEN RECEPTOR:   Positive, 97.57%\X0D\\X0A\PROGESTERONE RECEPTOR:  Positive, 97.91%\X0D\\X0A\HER-2/NEU RESULTS:  Negative, 1+",,"GROSS DESCRIPTION\X0D\\X0A\Specimen one is labeled ""right breast density"" and consists of a\X0D\\X0A\cluster of yellow-tan rubbery breast tissue measuring 4 x 3 x 0.5 cm.\X0D\\X0A\The specimen is entirely submitted in cassettes A and B.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Section A of the right breast density show infiltrating ductal\X0D\\X0A\carcinoma in two distinct nodules.  Deeper sections show similar\X0D\\X0A\features with dense sclerosis present and infiltrating ductal carcinoma\X0D\\X0A\with three distinct nodular clusters, greatest dimension 0.5 cm\X0D\\X0A\diameter.  Section B shows similar features with dense fibrosis and\X0D\\X0A\collagenous fiber proliferation in a single nodule. Deeper section show\X0D\\X0A\similar features and another focus of tumor is present.  One duct is\X0D\\X0A\filled with a cribriform pattern of ductular carcinoma.\X0D\\X0A\<Sign Out Dr. **NAME[WWW]>\X0D\\X0A\**NAME[DDD XXX], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  BREAST SPECIMEN, SURGICAL EXCISION\X0D\\X0A\Stereotactic right\X0D\\X0A\breast density",,
REG1,BREAST,0,490123,1,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: BREAST, LEFT UPPER OUTER QUADRANT, EXCISION: INVASIVE MAMMARY CARCINOMA, FAVOR DUCTAL CARCINOMA WITH LOBULAR FEATURES. COLD ISCHEMIC TIME:  LESS THAN 10 MINUTES. FIXATION TIME IN 10% BUFFERED FORMALIN - GREATER THAN 6 HOURS, BUT LESS THAN 48 HOURS. SPECIMEN INTEGRITY - INTACT. SPECIMEN SIZE - 2.7 X 2.5 CM. TUMOR SITE OF INVASIVE CARCINOMA - LEFT UPPER OUTER QUADRANT. TUMOR SIZE - 1.6 X 1.3 X 1.1 CM. HISTOLOGIC TYPE - MAMMARY CARCINOMA, FAVOR DUCTAL CARCINOMA WITH LOBULAR FEATURES. HISTOLOGIC GRADE (NOTTINGHAM SCORE) - GLANDULAR DIFFERENTIATION 3. NUCLEAR PLEOMORPHISM - 3. MITOTIC COUNT - 23 PER MITOSES PER 10 HIGH-POWER FIELDS - SCORE 3. OVERALL GRADE - 3 (HIGH GRADE). DUCTAL CARCINOMA IN SITU, EXTENSIVE INVOLVING EACH OF THE FOUR BLOCKS. DCIS ARCHITECTURAL PATTERN - SOLID AND CLINGING PATTERN. GRADE - HIGH GRADE. NECROSIS - CENTRAL NECROSIS PRESENT. LOBULAR CARCINOMA IN SITU - NOT IDENTIFIED. LYMPHVASCULAR INVASION - PRESENT. MICROCALCIFICATIONS - PRESENT. SKIN - TUMOR INVADES THE DERMAL LYMPHATICS AND INFILTRATES INTO THE DERMIS. MARGINS OF EXCISION - TRANSVERSE AND DEEP MARGINS OF EXCISION - POSITIVE. NOTE:  Ancillary studies - tissue is submitted for a breast panel, to include an E-cadherin and p120 catenin.  These findings will be reported in a supplemental report.. Final Signout: **NAME[XXX], MD **DATE[Sep 18 11]",,"GROSS DESCRIPTION: A single specimen is received in formalin labeled left breast mass.  The specimen consists of a 2.7 x 2.5 x 1.3 cm. epithelial ellipse and underlying firm, circumscribed, gray-tan nodular lesion.  The nodule measures 1.6 x 1.3 x 1.1 cm.  The specimen is serially sectioned in a breadloaf fashion to reveal no areas of necrosis or hemorrhage.  The tissue is entirely submitted in cassettes ""A"" through ""D"".  The specimen is processed to assure fixation in formalin does not exceed 48 hours.",,Tissues: BREAST BIOPSY. Specimen Comments:,,
REG1,BREAST,0,490129,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is right breast mass. 9:00, 7 cm FN. 3.56 cm x 3.04 cm\X0D\\X0A\x 2.5 cm hypoechoic irregular. Operative procedure: six passes with 14 gauge\X0D\\X0A\BARD with placement of x-shaped clip. 6 passes with 14 g BARD with placement\X0D\\X0A\of x-shaped clip. \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Nov 12 1951] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Oct 15 2011] 00:00\X0D\\X0A\Receipt Date: **DATE[Oct 16 2011] 07:36\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: M.M. **NAME[YYY], MD     Service: BCC     Location: MAMM\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Oct 18 2011] 18:20\X0D\\X0A\RESIDENTS(S): R.G. **NAME[WWW], MD","DIAGNOSIS\X0D\\X0A\RIGHT BREAST, 9 O' CLOCK, 14-GAUGE CORE BIOPSIES:\X0D\\X0A\   - INFILTRATING POORLY DIFFERENTIATED DUCTAL ADENOCARCINOMA.\X0D\\X0A\   - ER/PR NEGATIVE. (SEE COMMENT)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Oct 18 2011] Y.M. **NAME[VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: **ID-NUM P114 \X0D\\X0A\F: A: 88305, 67030-ER, S 88360, 67031-PR, S 88360",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) ER/PR for receptors, Her-2-neu                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 3 \X0D\\X0A\Shape(s): tubular   \X0D\\X0A\Color(s): white tan \X0D\\X0A\Consistency: firm \X0D\\X0A\Size(s): first two fragments the size is 1.5 x 0.2 x 0.2 cm, third smallest\X0D\\X0A\fragment is 0.9 x 0.2 x 0.2 cm\X0D\\X0A\Cassette summary: all the three fragments are submitted entirely in screened\X0D\\X0A\A1.  \X0D\\X0A\rgc/**DATE[Oct 16 2011] R.G. **NAME[WWW], MD\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\The tumor cells show no positive nuclear staining for either estrogen or\X0D\\X0A\progesterone receptor stains.\X0D\\X0A\The primary antibody clone used for estrogen receptor analysis is Neomarker\X0D\\X0A\clone SP1 and Dako PgR636 for progesterone receptor analysis.  The detection\X0D\\X0A\system for both is Dakocytoenvision (+) R System HRP (DAB).  Only nuclear\X0D\\X0A\staining is counted and any value +/> 1% tumor cell nuclear staining is\X0D\\X0A\considered a positive test.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right breast mass 9 o'clock 7 cm from nipple hypoechoic/irregular 3.56 x\X0D\\X0A\3.04 x 2.5 cm,,
REG1,BREAST,0,490131,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is breast cancer. Operative procedure: right partial\X0D\\X0A\mastectomy with sentinel node biopsy. Possible axillary dissection. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1: ""NO TUMOR SEEN""---VC.  \X0D\\X0A\FROZEN SECTION DIAGNOSIS # 2A-B:  ""NO TUMOR SEEN""---VC. \X0D\\X0A\\X0D\\X0A\     **NAME[M. ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jan 15 1952] (Age: **AGE[in 50s])  FB\X0D\\X0A\Collect Date: **DATE[Oct 19 2011] 14:58\X0D\\X0A\Receipt Date: **DATE[Oct 19 2011] 14:58\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: **NAME[M. XXX], MD     Service: SGO     Location: CAS\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Oct 23 2011] 15:13\X0D\\X0A\RESIDENTS(S): R.K. **NAME[VVV], MD\X0D\\X0A\Comment:  A micrometastasis measuring less than 0.5mm is present on the\X0D\\X0A\permanent section of sentinel node #1. This focus is not seen on\X0D\\X0A\retrospective review of the frozen section, and definite tumor cells are not\X0D\\X0A\identified on the touch and scrape preps. This case was reviewed at the\X0D\\X0A\Intradepartmental Consensus Conference.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\BREAST, RIGHT, PARTIAL MASTECTOMY (C):\X0D\\X0A\   - INFILTRATING LOBULAR CARCINOMA, GRADE 2 (pT2, pN1mi), SEE TEMPLATE.\X0D\\X0A\   - TUMOR WITHIN 1 MM OF DEEP MARGIN; ALL OTHER RESECTION MARGINS WIDELY\X0D\\X0A\FREE OF TUMOR.\X0D\\X0A\   - LOBULAR CARCINOMA IN SITU (LCIS) FOCALLY PRESENT WITHIN THE TUMOR.\X0D\\X0A\LYMPH NODE, SENTINEL #1, RIGHT BREAST, DISSECTION (A):\X0D\\X0A\   - MICROSCOPIC FOCUS OF METASTATIC CARCINOMA IN ONE LYMPH NODE IDENTIFIED\X0D\\X0A\ON PERMANENT SECTION \X0D\\X0A\     (1/1).\X0D\\X0A\LYMPH NODE, SENTINEL #2, RIGHT BREAST, DISSECTION (B):\X0D\\X0A\   - NO METASTATIC CARCINOMA SEEN (0/1).\X0D\\X0A\BREAST, RIGHT, EXTENDED MEDIAL MARGIN (D):\X0D\\X0A\   - NO TUMOR SEEN.\X0D\\X0A\LYMPH NODE, RIGHT AXILLARY, DISSECTION (E):\X0D\\X0A\   - NO METASTATIC CARCINOMA SEEN (0/1).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Oct 23 2011] M.V. **NAME[UUU], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\SEE COMMENT\X0D\\X0A\Addendum Comment\X0D\\X0A\Immunohistochemistry for HER-2/neu overexpression is negative (score 0).\X0D\\X0A\HER-2/neu (c-erbB-2) Immunohistochemistry\X0D\\X0A\Using appropriate positive and negative controls, the test for the presence\X0D\\X0A\of this oncoprotein is performed by the immunoperoxidase method, and reported\X0D\\X0A\according to the American Society of Clinical Oncology (ASCO)/College of\X0D\\X0A\American Pathologists (CAP) Guideline Recommendations (2006).\X0D\\X0A\IMMUNOHISTOCHEMICAL INTERPRETATION:  CELL MEMBRANE STAINING ONLY (DAKO\X0D\\X0A\Polyclonal Rabbit Anti-Human c-erB-2 Oncoprotein Antibody)\X0D\\X0A\NEGATIVE:  Score 0 (No staining is observed or membrane staining is observed\X0D\\X0A\in less than 10% of the tumor cells).\X0D\\X0A\NEGATIVE:  Score 1+ (A faint/barely perceptible membrane staining is seen in\X0D\\X0A\more than 10% of the tumor cells.  The cells are only stained in part of\X0D\\X0A\their membrane).\X0D\\X0A\WEAK POSITIVE:  Score 2+ (A weak to moderate complete membrane staining is\X0D\\X0A\observed in more than 10% of the tumor cells).\X0D\\X0A\STRONG POSITIVE:  Score 3+ (A strong complete membrane staining is observed\X0D\\X0A\in more than 30% of the tumor cells).\X0D\\X0A\The results of this test are for investigational purposes as its performance\X0D\\X0A\characteristics have not been established.  It should be noted that according\X0D\\X0A\to the literature, the sensitivity for immunohistochemical HER-2/neu\X0D\\X0A\determination is no greater than 80% when compared to molecular or FISH\X0D\\X0A\methods.\X0D\\X0A\Primary antibody:  C-erb B.2 oncoprotein (polyclonal rabbit Dako ID# A0485)\X0D\\X0A\Detection system:  Dakocytoenvision (+) R System HRP (DAB)\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\dlf/**DATE[Oct 24 2011] M.V. **NAME[UUU], MD \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M85203 P1100\X0D\\X0A\B: M09450 T0402\X0D\\X0A\C: M09450 T0402\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.",,"GROSS DESCRIPTION\X0D\\X0A\Five specimens are received. \X0D\\X0A\Specimen A is received fresh for frozen section (FS1) labeled sentinel node\X0D\\X0A\#1, right breast, (7532) and consists of a single yellow tan soft tissue\X0D\\X0A\fragment measuring 1.2 x 0.8 x 0.6 cm. A single node is identified measuring\X0D\\X0A\0.9 x 0.6 x 0.3 cm. Entire lymph node is serially sectioned and submitted for\X0D\\X0A\frozen section as FS1. The entire specimen is submitted in A1  FS1\X0D\\X0A\resubmitted; A2  unfrozen fragment of adipose tissue. \X0D\\X0A\Specimen B is received fresh for frozen section (FS2A-B) labeled as sentinel\X0D\\X0A\node #2, right breast, palpable and consists of a single yellow tan soft\X0D\\X0A\tissue fragment measuring 3.5 x 2.5 x 1.4 cm. A lymph node measuring 2.8 x\X0D\\X0A\2.1 x 1.3 cm is identified. The lymph node is serially sectioned and\X0D\\X0A\submitted for frozen section. Entire specimen is submitted as follows: B1 \X0D\\X0A\FS2A resubmitted; B2  FS2B resubmitted. \X0D\\X0A\Specimen C is received fresh labeled as right partial mastectomy, suture\X0D\\X0A\short superior, long lateral and consists of a right aforementioned weighing\X0D\\X0A\61.4 grams (fresh), measuring 6.5 cm superior to inferior, 6.5 cm medial to\X0D\\X0A\lateral and 3.2 cm superficial to deep. Ellipse of tan pink skin measures 4.5\X0D\\X0A\cm medial to lateral and 0.7 cm from superior to inferior. The skin is tan\X0D\\X0A\brown and slightly wrinkled or else unremarkable. Superficial surface is\X0D\\X0A\inked blue and deep surface black. The specimen is longitudinally sectioned\X0D\\X0A\from medial to lateral and reveals a tan irregular fairly circumscribed mass\X0D\\X0A\measuring 2.2 x 1.5 x 1 cm located in the center of the specimen 0.4 cm from\X0D\\X0A\the closest deep margin, 2.2 cm from closest inferior margin; 3.5 cm from\X0D\\X0A\closest superior margin, 2.5 cm from closest medial margin and 2 cm from\X0D\\X0A\closest lateral margin and 1.1 cm from closest skin/superficial surface. The\X0D\\X0A\fibrous breast parenchyma comprises less than 10% of the specimen.  The\X0D\\X0A\specimen was radiographed, clip was identified. Cassette summary: C1  tumor\X0D\\X0A\half with closest superficial surface and clip; C2  tumor half with closest\X0D\\X0A\deep surface corresponding half in C1; C3  tumor with anterior margin and\X0D\\X0A\closest skin; C4  tumor with closest posterior margin; C5  tumor with closest\X0D\\X0A\posterior margin; C6  remaining of the tumor entirely; C7  closest\X0D\\X0A\superficial margin corresponding to section in C1 and C2; C8  corresponding\X0D\\X0A\closest inferior margin corresponding to C1 and C2. C9  skin medial\X0D\\X0A\one-third; C10  skin central one-third; C11  skin medial one-third; C12 \X0D\\X0A\closest lateral margin shaved, and placed, representative; C13  closest\X0D\\X0A\medial margin, shaved, en face representative; C14  C15  uninvolved breast\X0D\\X0A\parenchyma representative.  \X0D\\X0A\Specimen D is received in formalin labeled as extended medial margin, short\X0D\\X0A\superior, long superficial, ink marks new margin. It consists of a fragment\X0D\\X0A\of tan yellow lobulated tissue measuring 2 cm from superior to inferior, 2.5\X0D\\X0A\cm from superficial to deep and 1 cm from medial to lateral. New margins are\X0D\\X0A\inked black, surface opposite to new margin is inked blue. The superior\X0D\\X0A\margin is inked green. The specimen is sectioned from the deep to superficial\X0D\\X0A\and submitted entirely as follows: D1  deep shaved en face; D2  D3  deep to\X0D\\X0A\superficial; D4  superficial, shaved, en face. \X0D\\X0A\Specimen E is received in formalin labeled as additional axillary contents\X0D\\X0A\and contains a tan yellow lobulated tissue measuring 1.5 x 1 x 0.5 cm. A tan\X0D\\X0A\pink lymph node measuring 1 x 1 x 0.5 cm is identified. Lymph node is\X0D\\X0A\serially sectioned and submitted entirely in E1. \X0D\\X0A\rgc/**DATE[Oct 22 2011] R.K. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\Frozen section diagnosis (specimen A and B) is confirmed on permanent\X0D\\X0A\section.\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST (template #26)\X0D\\X0A\Last updated **DATE[Aug 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Specimen/procedure:  partial mastectomy\X0D\\X0A\Specimen integrity:    single intact specimen (margins can be evaluated) \X0D\\X0A\\X0D\\X0A\Specimen size:  6.5 x 6.5 x 3.2 cm\X0D\\X0A\Specimen laterality:  right \X0D\\X0A\Tumor site for invasive carcinoma:  6 o' clock, 11 cm from nipple    \X0D\\X0A\Tumor size (largest one):  2.2 x 1.5 x 1 cm  \X0D\\X0A\Tumor focality: unifocal \X0D\\X0A\Histologic type:  infiltrating lobular carcinoma\X0D\\X0A\Histologic grade (Nottingham histologic score):\X0D\\X0A\    Glandular (acinar)/tubular differentiation:  3 \X0D\\X0A\     Nuclear pleomorphism: 2  \X0D\\X0A\     Mitotic Count:  1 \X0D\\X0A\     Overall Grade:  Grade 2 (score of 6)\X0D\\X0A\\X0D\\X0A\Ductal carcinoma in situ (DCIS):  no DCIS is present \X0D\\X0A\Lobular carcinoma in situ (LCIS):  present, focal within tumor\X0D\\X0A\Lymph-vascular Invasion:   no definite\X0D\\X0A\Dermal lymph-vascular Invasion:  not identified \X0D\\X0A\Microcalcifications:  not identified \X0D\\X0A\Skin:  no tumor involvement \X0D\\X0A\Nipple:  no nipple present.\X0D\\X0A\Skeletal muscle: no skeletal muscle present \X0D\\X0A\Margins:  uninvolved by invasive carcinoma (distance to closest deep margin: \X0D\\X0A\less than 1 mm) \X0D\\X0A\Lymph nodes (if present in current specimen): \X0D\\X0A\    Number of sentinel lymph nodes examined: 2\X0D\\X0A\    Total number of lymph nodes examined (sentinel and nonsentinel): 3\X0D\\X0A\    Number of lymph nodes with macrometastases (>0.2 cm): 0\X0D\\X0A\         Number of lymph nodes with micrometastases (>0.2 mm-0.2 cm):1\X0D\\X0A\    Number of lymph nodes with isolated tumor cells (=0.2 mm): 0\X0D\\X0A\    Size of largest metastatic deposit (if present): not applicable\X0D\\X0A\    Extranodal Extension:   not applicable\X0D\\X0A\Pathologic staging (pTNM) (m: multiple foci of invasive carcinoma)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\    pT2:               > 2 cm but =5 cm\X0D\\X0A\REGIONAL LYMPH NODES (pN) \X0D\\X0A\     Note:  (sn): only sentinel node(s) evaluated.  If 6 or more sentinel\X0D\\X0A\nodes and/or nonsentinel nodes are \X0D\\X0A\          removed, this modifier should not be used.\X0D\\X0A\          pN1mi:         Micrometastasis (greater than 0.2 mm but not larger\X0D\\X0A\than 2 mm)\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (M)  \X0D\\X0A\                         Not applicable\X0D\\X0A\Additional pathologic findings:  focal usual ductal hyperplasia and DIALH\X0D\\X0A\Ancillary studies:  \X0D\\X0A\Estrogen Receptor performed on another specimen (accession number: \X0D\\X0A\***PATH-NUMBER[2])\X0D\\X0A\         Results:  positive (quantitation: 100% strong) \X0D\\X0A\Progesterone Receptor performed on another specimen (accession number: \X0D\\X0A\***PATH-NUMBER[2])\X0D\\X0A\         Results:  positive (quantitation: 75% strong) \X0D\\X0A\HER2/neu \X0D\\X0A\   Immunostain performed on this specimen \X0D\\X0A\          Results: pending; an addendum will follow",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Sentinel lymph node #1 right breast (count 7532)\X0D\\X0A\B: Sentinel lymph node #2 right breast/palpable\X0D\\X0A\C: right partial mastectomy/suture short superior; long lateral\X0D\\X0A\D: extended medial margin/short suture superior; long superficial. Ink marks\X0D\\X0A\new margin\X0D\\X0A\E: additional axillary cotents,,PROCEDURES/ADDENDA
REG1,BREAST,0,490261,1,,Clinical History:\X0D\\X0A\Mass 611.72,,"Pre-Operative Diagnosis:\X0D\\X0A\Suspect Invasive CA With Met Adenopathy\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Left breast, needle core biopsies at the 12:00 position:\X0D\\X0A\-    Infiltrating ductal carcinoma with apocrine features, favor\X0D\\X0A\moderately differentiated (see microscopic description).",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled ""left breast"".  The specimen consists of five\X0D\\X0A\white-tan tissue cores, which are each 0.1 cm in diameter x 1.5 cm in\X0D\\X0A\length.  The specimen is submitted in toto in a single cassette.  The\X0D\\X0A\following times are given on the requisition:  S - 10:50 a.m., E - 10:59\X0D\\X0A\a.m., F - 10:52 a.m. on **DATE[Apr 7 2012].\X0D\\X0A\JAB:jck","Microscopic Description:\X0D\\X0A\Sections show core biopsies of breast tissue each appearing at least\X0D\\X0A\partially effaced by an infiltrating ductal carcinoma.  The tumor shows\X0D\\X0A\very rare attempts at true tubule formation with the majority invading\X0D\\X0A\as irregular nested aggregates, occasionally showing retraction artifact\X0D\\X0A\in broad zones suggestive of a micropapillary growth pattern.  In\X0D\\X0A\addition, some clusters show a mixture of both apocrine features with\X0D\\X0A\eosinophilic cytoplasm, with still others demonstrating occasional tumor\X0D\\X0A\cells with cytoplasmic vacuolization or clearing.  Tumor cell nuclei\X0D\\X0A\range from generally moderate to marked for cytologic atypia, some\X0D\\X0A\demonstrating prominent nucleoli and irregular nuclear membranes.\X0D\\X0A\Mitotic activity is generally scant (<5 in 10 high power fields).  A\X0D\\X0A\rare focus suspicious for angiolymphatic invasion is noted.  The tumor\X0D\\X0A\approaches 1.2 cm in greatest dimension within an individual core\X0D\\X0A\biopsy.  A background minor component of at least intermediate grade\X0D\\X0A\ductal carcinoma in situ is noted favoring a solid type within a rare\X0D\\X0A\duct.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\DRJ:vsg\X0D\\X0A\D\T\T:  **DATE[Apr 08 2012].\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 08 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Left Breast Core Biopsy 12:00,,
REG1,BREAST,0,490412,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is focal asymmetry.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Breast, needle biopsy","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT: The invasive neoplasm is positive for estrogen and\X0D\\X0A\progesterone receptors. It is negative (0+) for HER2/Neu. See additional\X0D\\X0A\microscopic description for semiquantitative results. **INITIALS\X0D\\X0A\LEFT BREAST, STEREOTACTIC CORE BIOPSIES:\X0D\\X0A\     Microscopically invasive ductal carcinoma arising in small focus of ductal\X0D\\X0A\carcinoma in situ. \X0D\\X0A\Microcalcifications present.\X0D\\X0A\Hormone receptors pending.\X0D\\X0A\JFJ/mbc \X0D\\X0A\COMMENT:  This report was faxed to the radiologist at Central Baptist Breast\X0D\\X0A\Imaging Services on **DATE[Aug 30 2012].",,"Gross Description\X0D\\X0A\The specimen, labeled left breast stereotactic biopsy, received in formalin,\X0D\\X0A\consists of a 2.5x2.5x0.3 cm aggregate of tan/pink fibroadipose breast tissue\X0D\\X0A\fragments which were placed in formalin at 1:45 and are now submitted in one\X0D\\X0A\cassette. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections show focal area of intraductal proliferation of cells with enlarged\X0D\\X0A\nuclei with inconspicuous nucleoli with a variable solid and cribriform\X0D\\X0A\architecture. This is present as several 1 mm foci. Focal involvement of\X0D\\X0A\adjacent lobules is noted. There is no evidence of luminal necrosis. A tiny\X0D\\X0A\focus of microinvasive carcinoma is seen as well. \X0D\\X0A\JFJ/mbc \X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: All controls stain appropriately including\X0D\\X0A\external positive, internal negative and external negative controls as required.\X0D\\X0A\ This tumor shows POSITIVE 3+ nuclear staining for Estrogen Receptor (over 90%\X0D\\X0A\of tumor nuclei) and POSITIVE 2+ staining for Progesterone Receptor (over 70% of\X0D\\X0A\tumor nuclei).  HER2/Neu antibody shows absolutely no staining in any of the\X0D\\X0A\tumor with a membranous pattern (0+, negative).  \X0D\\X0A\COMMENT: 1% or greater numbers of nuclei staining of any intensity is considered\X0D\\X0A\a positive test in our laboratory. ER clone Ventana SPI, PR clone IE2, IVD\X0D\\X0A\approved immunohistochemical stains on formalin fixed, paraffin embedded tissue.\X0D\\X0A\**INITIALS",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Sep 8 2012] by **NAME[XXX WWW]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Aug 30 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[VVV M. UUU], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,BREAST,0,490595,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\LEFT BREAST MASS (PREVIOUS PCA SOUTHEAST **INITIALS-1258)\X0D\\X0A\,"SPECIMEN/PROCEDURE:\X0D\\X0A\LEFT LUMPECTOMY (WITH WIRE LOCALIZATION)\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\INTACT.\X0D\\X0A\SPECIMEN SIZE:\X0D\\X0A\4.1 X 3.8 X 1.8 CM IN GREATEST DIMENSION.\X0D\\X0A\               TUMOR HISTOLOGIC TYPE:\X0D\\X0A\DUCTAL CARCINOMA IN-SITU, INTERMEDIATE NUCLEAR GRADE WITH FOCAL MUCIN PRODUCTION INVOLVING A\X0D\\X0A\PAPILLOMA AND ADJACENT DUCTS.\X0D\\X0A\ESTIMATED TUMOR SIZE:\X0D\\X0A\1.2 CM.\X0D\\X0A\ARCHITECTURAL PATTERN:\X0D\\X0A\CRIBRIFORM AND FOCALLY MICROPAPILLARY.\X0D\\X0A\NECROSIS:\X0D\\X0A\NOT PRESENT.\X0D\\X0A\MARGINS:\X0D\\X0A\ALL MARGINS ARE FREE OF LESIONS (CARCINOMA IS WITHIN 2 MM OF SUPERIOR\X0D\\X0A\    MARGIN OF THE SPECIMEN).\X0D\\X0A\LYMPH NODES:\X0D\\X0A\NOT SUBMITTED.\X0D\\X0A\ADDITIONAL PATHOLOGICAL FINDINGS:\X0D\\X0A\FIBROCYSTIC CHANGES WITH CHRONIC INFLAMMATION AND FAT NECROSIS AT THE PREVIOUS BIOPSY SITE.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\THE RESULTS OF HER-2/NEU AND HORMONE RECEPTOR STUDIES WILL\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   315 E **PLACE, **ROOM\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX] II,Art J\X0D\\X0A\   4004 DUPOINT CIRCLE\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\   **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[WWW,VVV M] MD\X0D\\X0A\   4950 **PLACE Healthcare Blvd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\SPECIMEN/PROCEDURE:\X0D\\X0A\LEFT LUMPECTOMY (WITH WIRE LOCALIZATION)\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\INTACT.\X0D\\X0A\SPECIMEN SIZE:\X0D\\X0A\4.1 X 3.8 X 1.8 CM IN GREATEST DIMENSION.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:\X0D\\X0A\DUCTAL CARCINOMA IN-SITU, INTERMEDIATE NUCLEAR GRADE WITH FOCAL MUCIN PRODUCTION INVOLVING A\X0D\\X0A\PAPILLOMA AND ADJACENT DUCTS.\X0D\\X0A\ESTIMATED TUMOR SIZE:\X0D\\X0A\1.2 CM.\X0D\\X0A\ARCHITECTURAL PATTERN:\X0D\\X0A\CRIBRIFORM AND FOCALLY MICROPAPILLARY.\X0D\\X0A\NECROSIS:\X0D\\X0A\NOT PRESENT.\X0D\\X0A\MARGINS:\X0D\\X0A\ALL MARGINS ARE FREE OF LESIONS (CARCINOMA IS WITHIN 2 MM OF SUPERIOR\X0D\\X0A\MARGIN OF THE SPECIMEN).\X0D\\X0A\LYMPH NODES:\X0D\\X0A\NOT SUBMITTED.\X0D\\X0A\ADDITIONAL PATHOLOGICAL FINDINGS:\X0D\\X0A\FIBROCYSTIC CHANGES WITH CHRONIC INFLAMMATION AND FAT NECROSIS AT THE PREVIOUS BIOPSY SITE.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\THE RESULTS OF HER-2/NEU AND HORMONE RECEPTOR STUDIES WILL\X0D\\X0A\BE SUBMITTED AS AN ADDENDUM.\X0D\\X0A\ESTIMATED COLD ISCHEMIC TIME:\X0D\\X0A\LESS THAN 1 HOUR.\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME:\X0D\\X0A\6-72 HOURS.\X0D\\X0A\LOBULAR CARCINOMA IN-SITU:\X0D\\X0A\NOT PRESENT.\X0D\\X0A\\X0D\\X0A\AJCC Stage: PTis NX MX\X0D\\X0A\\X0D\\X0A\As required by the American College of Surgeons, the American Joint Cancer Committee Staging\X0D\\X0A\is included in this report.  However, this stage should only be considered preliminary and\X0D\\X0A\incomplete; final staging can only be accomplished by the oncologist/surgeon after\X0D\\X0A\evaluation of all clinical and surgical/pathologic information.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\See Microscopic Description\X0D\\X0A\\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received fresh labeled ""left breast mass"" is an 11.5 gram oriented portion of yellow,\X0D\\X0A\lobulated, partially disrupted adipose tissue measuring 4.1 x 3.8 x 1.8 cm (medial to\X0D\\X0A\lateral, anterior to posterior, superior to inferior).  A short suture denotes superior and\X0D\\X0A\a long suture denotes lateral per requisition.  There is a penetrating needle localization\X0D\\X0A\wire near one of the partially disrupted area at the anterior aspect.\X0D\\X0A\\X0D\\X0A\The specimen is inked as follows:  superior - blue, inferior - green, medial - orange,\X0D\\X0A\lateral - violet, anterior - red and posterior - black. /pb/kb\X0D\\X0A\\X0D\\X0A\Sectioning of the tissue reveals yellow lobulated glistening cut surfaces.  There is a 1.1 x\X0D\\X0A\0.8 x 0.3 cm hemorrhagic cavity possibly representing a prior biopsy site.  The cavity is\X0D\\X0A\focally surrounded by pink tan fibrous tissue.  The fibrous areas are within 0.2 cm of the\X0D\\X0A\anterior resection margin.  The specimen is sequentially submitted entirely as follows:\X0D\\X0A\\X0D\\X0A\1.  perpendicular sections of deep margin\X0D\\X0A\2-7.  one whole cross section in each cassette with cassettes 5 through 7 containing the\X0D\\X0A\fibrous areas\X0D\\X0A\8.  remainder of anterior margin\X0D\\X0A\9.  remainder of medial margin\X0D\\X0A\\X0D\\X0A\Time received in Lab - 11:39\X0D\\X0A\Time placed in formalin - 11:40\X0D\\X0A\Time sectioned and replaced in formalin - 2:00\X0D\\X0A\\X0D\\X0A\The specimen is accompanied by a radiograph            /pb/as\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\Sections show the site of previous breast biopsy showing fibrosis with fat necrosis and\X0D\\X0A\chronic inflammation. Microscopic foci of intraductal carcinoma intermediate nuclear grade\X0D\\X0A\is identified, one of which appears to involve a pre-existing papilloma. No stromal invasion\X0D\\X0A\is seen. There is focal mucin production present. The material has been reviewed in\X0D\\X0A\consultation with Dr. **NAME[UUU TTT] at the department of pathology at **INSTITUTION\X0D\\X0A\**INSTITUTION who agrees with the above interpretation (see scanned report).\X0D\\X0A\\X0D\\X0A\",SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\LEFT BREAST MASS - TIME SPECIMEN REMOVED:  11:20\X0D\\X0A\,,"BE SUBMITTED AS AN ADDENDUM.\X0D\\X0A\ESTIMATED COLD ISCHEMIC TIME:\X0D\\X0A\LESS THAN 1 HOUR.\X0D\\X0A\ESTIMATED TOTAL FIXATION TIME:\X0D\\X0A\6-72 HOURS.\X0D\\X0A\LOBULAR CARCINOMA IN-SITU:\X0D\\X0A\NOT PRESENT.\X0D\\X0A\\X0D\\X0A\AJCC Stage: PTis NX MX\X0D\\X0A\\X0D\\X0A\As required by the American College of Surgeons, the American Joint Cancer Committee Staging\X0D\\X0A\is included in this report.  However, this stage should only be considered preliminary and\X0D\\X0A\incomplete; final staging can only be accomplished by the oncologist/surgeon after\X0D\\X0A\evaluation of all clinical and surgical/pathologic information.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS    \X0D\\X0A\\X0D\\X0A\See Microscopic Description\X0D\\X0A\\X0D\\X0A\CLINICAL HISTORY       \X0D\\X0A\\X0D\\X0A\LEFT BREAST MASS (PREVIOUS PCA SOUTHEAST **INITIALS-1258)\X0D\\X0A\\X0D\\X0A\SPECIMEN INFORMATION     \X0D\\X0A\\X0D\\X0A\LEFT BREAST MASS - TIME SPECIMEN REMOVED:  11:20\X0D\\X0A\\X0D\\X0A\GROSS DESCRIPTION       \X0D\\X0A\\X0D\\X0A\Received fresh labeled ""left breast mass"" is an 11.5 gram oriented portion of yellow,\X0D\\X0A\lobulated, partially disrupted adipose tissue measuring 4.1 x 3.8 x 1.8 cm (medial to\X0D\\X0A\lateral, anterior to posterior, superior to inferior).  A short suture denotes superior and\X0D\\X0A\a long suture denotes lateral per requisition.  There is a penetrating needle localization\X0D\\X0A\wire near one of the partially disrupted area at the anterior aspect.\X0D\\X0A\\X0D\\X0A\The specimen is inked as follows:  superior - blue, inferior - green, medial - orange,\X0D\\X0A\lateral - violet, anterior - red and posterior - black. /pb/kb\X0D\\X0A\\X0D\\X0A\Sectioning of the tissue reveals yellow lobulated glistening cut surfaces.  There is a 1.1 x\X0D\\X0A\0.8 x 0.3 cm hemorrhagic cavity possibly representing a prior biopsy site.  The cavity is\X0D\\X0A\focally surrounded by pink tan fibrous tissue.  The fibrous areas are within 0.2 cm of the\X0D\\X0A\anterior resection margin.  The specimen is sequentially submitted entirely as follows:\X0D\\X0A\\X0D\\X0A\1.  perpendicular sections of deep margin\X0D\\X0A\2-7.  one whole cross section in each cassette with cassettes 5 through 7 containing the\X0D\\X0A\fibrous areas\X0D\\X0A\8.  remainder of anterior margin\X0D\\X0A\9.  remainder of medial margin\X0D\\X0A\\X0D\\X0A\Time received in Lab - 11:39\X0D\\X0A\Time placed in formalin - 11:40\X0D\\X0A\Time sectioned and replaced in formalin - 2:00\X0D\\X0A\\X0D\\X0A\The specimen is accompanied by a radiograph            /pb/as\X0D\\X0A\\X0D\\X0A\MICROSCOPIC DESCRIPTION    \X0D\\X0A\\X0D\\X0A\Sections show the site of previous breast biopsy showing fibrosis with fat necrosis and\X0D\\X0A\chronic inflammation. Microscopic foci of intraductal carcinoma intermediate nuclear grade\X0D\\X0A\is identified, one of which appears to involve a pre-existing papilloma. No stromal invasion\X0D\\X0A\is seen. There is focal mucin production present. The material has been reviewed in\X0D\\X0A\consultation with Dr. **NAME[UUU TTT] at the department of pathology at **INSTITUTION\X0D\\X0A\**INSTITUTION who agrees with the above interpretation (see scanned report).\X0D\\X0A\\X0D\\X0A\**NAME[ZZZ,YYY M]\X0D\\X0A\315 E **PLACE, **ROOM, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\**NAME[XXX] II,Art J\X0D\\X0A\4004 DUPOINT CIRCLE\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\\X0D\\X0A\**NAME[WWW,VVV M] MD\X0D\\X0A\4950 **PLACE Healthcare Blvd\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS\X0D\\X0A\\X0D\\X0A\Signed __________(signature on file)___________ **NAME[SSS M RRR] MD **DATE[Apr 22 12]\X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Apr 23 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\"
REG1,BREAST,0,491654,1,,Clinical History:\X0D\\X0A\Left breast cancer,"Frozen Section:\X0D\\X0A\A)  Lymph node, sentinel, left - TP\T\FSDx:   Benign.  **INITIALS **NAME[ZZZ]\X0D\\X0A\Benavidez.","Pre-Operative Diagnosis:\X0D\\X0A\Left breast cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Lymph node, sentinel, left:  Benign lymph node.\X0D\\X0A\B)  Left breast:  Infiltrating duct carcinoma, moderately\X0D\\X0A\differentiated, 1.0 x 1.0 x 0.4 cm, EBR score 3+3+1=7, without\X0D\\X0A\lymphvascular invasion.  Duct carcinoma in situ component, intermediate\X0D\\X0A\grade, cribriform type with central comedonecrosis.  Multiple radial\X0D\\X0A\scars, papillomatosis, stromal fibrosis, and marked sclerosing adenosis\X0D\\X0A\with luminal microcalcifications in remainder of breast parenchyma.\X0D\\X0A\Benign nipple.  Benign deep soft tissue resection margin.",,"Gross Description:\X0D\\X0A\A)  Received fresh designated ""left sentinel node"" is a 2.5 x 1 x 0.9 cm\X0D\\X0A\aggregate of yellow lobulated adipose tissue, within which is a 0.4 x\X0D\\X0A\0.3 x 0.2 cm pink-tan nodule.  The nodule is bisected, touch prepped,\X0D\\X0A\and submitted entirely for frozen section in one block.  The specimen is\X0D\\X0A\now re-submitted for permanents in cassette A-FSC.\X0D\\X0A\B)  Received in formalin designated ""left breast"" is a 588 gm, 20 x 20 x\X0D\\X0A\4 cm total mastectomy specimen.  The specimen is partially surfaced by a\X0D\\X0A\10.5 x 6 cm pink-tan skin ellipse.  There is a central 2.5 cm in\X0D\\X0A\diameter areola with a 0.7 x 0.7 x 0.3 cm slightly retracted black\X0D\\X0A\inverted nipple.  The epidermal surface is notable for a 0.2 cm prior\X0D\\X0A\biopsy site at the 9-10 o'clock position, 4 cm from the center of the\X0D\\X0A\nipple.  There is no orientation provided, thus the aspect of the\X0D\\X0A\specimen with the larger flap of fibro-fatty tissue will be designated\X0D\\X0A\superior.  The posterior surface of the specimen is inked blue.\X0D\\X0A\Sectioning the specimen reveals a 1 x 1 x 0.4 cm biopsy cavity within\X0D\\X0A\the upper inner quadrant at the 11:00 o'clock position.  The biopsy\X0D\\X0A\cavity is packed with white pebble-like biopsy seed material.  The\X0D\\X0A\biopsy cavity is 0.5 cm from the nearest deep margin.  The biopsy cavity\X0D\\X0A\is surrounded by punctate foci of hemorrhage and fat necrosis, as well\X0D\\X0A\as a very ill-defined area of indurated dense white-tan fibrous breast\X0D\\X0A\tissue.  The indurated fibrous tissue surrounding the biopsy site\X0D\\X0A\measures approximately 2 x 1.5 x 1.5 cm.  There is also a small amount\X0D\\X0A\of indurated slightly granular fibrous tissue noted extending superiorly\X0D\\X0A\from the biopsy site.  There are no distinct well-circumscribed masses\X0D\\X0A\seen.  There are no other lesional areas identified.  The remainder of\X0D\\X0A\the specimen is notable for a moderate amount of dense white-tan fibrous\X0D\\X0A\breast tissue and multiple blue-domed cystic structures.  There are no\X0D\\X0A\lymph nodes identified.  Representative sections are submitted and\X0D\\X0A\placed in formalin at 1430 hours on **DATE[Jun 29 12].\X0D\\X0A\Summary of sections:  B1 - nipple base and remainder of nipple; B2-B9 -\X0D\\X0A\biopsy site entirely submitted, lateral to medial to include the deep\X0D\\X0A\margin in cassettes B4 and B5; B10\T\B11 - representative sections of\X0D\\X0A\granular fibrous tissue extending superiorly from biopsy site; B12 -\X0D\\X0A\random upper outer quadrant; B13 - random lower outer quadrant; B14 -\X0D\\X0A\random lower inner quadrant.  JAB:jlj","Microscopic Description:\X0D\\X0A\A)  The lymph node shows a normal architecture and an intact capsule.\X0D\\X0A\There are mild reactive changes but no evidence of primary or metastatic\X0D\\X0A\neoplasm.\X0D\\X0A\B)  Numerous sections from around the circumference of the biopsy site\X0D\\X0A\reveal very complicated radial scars with complex papillomatosis.  In\X0D\\X0A\the center of this area, there is both an intraductal and infiltrating\X0D\\X0A\duct carcinoma present.  The intraductal component which makes up\X0D\\X0A\approximately 50% of the tumor shows very large duct structures\X0D\\X0A\distended by atypical epithelial cells in very complicated\X0D\\X0A\cribriform-type patterns with central areas of eosinophilic\X0D\\X0A\comedonecrosis.  The invasive portion of the tumor shows small fairly\X0D\\X0A\solid aggregates of epithelial cells with focal lumen formations but\X0D\\X0A\without well-formed tubular structures present.  These cells show small\X0D\\X0A\to moderate amounts of cytoplasm and contain nuclei which vary markedly\X0D\\X0A\from small and pyknotic up to giant vesicular nuclei with variably\X0D\\X0A\prominent nucleoli.  Occasional mitoses can be identified averaging 2\X0D\\X0A\per 10 high-power fields.  These microscopic findings would score a 3\X0D\\X0A\for tubule formation, 3 for nuclear pleomorphism, and 1 for mitotic\X0D\\X0A\count for a combined EBR score of 7, which is moderately differentiated.\X0D\\X0A\No definite lymphvascular invasion can be identified.  The neoplasm\X0D\\X0A\shows numerous microcalcifications.  An immunoperoxidase stain for\X0D\\X0A\e-cadherin reveals marked cytoplasmic positivity of the invasive\X0D\\X0A\neoplastic cells indicative of ductal origin.  The uninvolved breast\X0D\\X0A\tissue shows a localized area of stromal fibrosis in association with\X0D\\X0A\focal papillomatosis and fairly extensive sclerosing adenosis with\X0D\\X0A\numerous luminal microcalcifications.  The deep soft tissue resection\X0D\\X0A\margin is free by approximately 0.6 cm from the deeper most aspect of\X0D\\X0A\the biopsy site scar.  The nipple is unremarkable.  Tissue Code:  T1\X0D\\X0A\Synoptic Template for Primary Invasive Breast Carcinoma:\X0D\\X0A\Specimen:  Total breast.\X0D\\X0A\Procedure:  Total mastectomy.\X0D\\X0A\Lymph node sampling:  Sentinel lymph node.\X0D\\X0A\Specimen laterality:  Left.\X0D\\X0A\Specimen integrity:  Single intact specimen.\X0D\\X0A\Specimen size:  20 x 20 x 4 cm, 588 gms.\X0D\\X0A\Tumor site:  Upper inner quadrant, 10-11 o'clock.\X0D\\X0A\Tumor size:  1.0 x 1.0 x 0.4 cm.\X0D\\X0A\Tumor focality:  Single focus of invasive carcinoma.\X0D\\X0A\Histologic type of invasive carcinoma:  Invasive ductal carcinoma.\X0D\\X0A\Histologic grade (Nottingham histologic score):\X0D\\X0A\Glandular/tubular differentiation:  3.\X0D\\X0A\Nuclear pleomorphism:  3.\X0D\\X0A\Mitotic count:  1.\X0D\\X0A\Total score:  7.\X0D\\X0A\Overall grade:  Moderately differentiated.\X0D\\X0A\Extent of tumor:\X0D\\X0A\Skin:  Not involved.\X0D\\X0A\Nipple:  Not involved.\X0D\\X0A\Skeletal muscle:  Not involved.\X0D\\X0A\Ductal carcinoma in situ (DCIS):  Present.\X0D\\X0A\Size (extent) of DCIS:  Approximately 50% of tumor.\X0D\\X0A\DCIS architectural patterns:  Cribriform.\X0D\\X0A\DCIS nuclear grade:  2.\X0D\\X0A\Necrosis:  Present, central comedonecrosis.\X0D\\X0A\Lobular carcinoma in situ (LCIS):  Not present.\X0D\\X0A\Microcalcifications:  Present in non-neoplastic tissue and in carcinoma.\X0D\\X0A\Margins:  Margins uninvolved by carcinoma with closest deep margin 0.6\X0D\\X0A\cm.\X0D\\X0A\Lymphvascular invasion:  Not identified.\X0D\\X0A\Dermal lymphvascular invasion:  Not identified.\X0D\\X0A\Lymph nodes:\X0D\\X0A\Number of sentinel lymph nodes examined:  1.\X0D\\X0A\Total number of lymph nodes examined (sentinel and non-sentinel):  1.\X0D\\X0A\Number of lymph nodes with macrometastases:  0.\X0D\\X0A\Number of lymph nodes with micrometastases:  0.\X0D\\X0A\Number of lymph nodes with isolated tumor cells:  0.\X0D\\X0A\Size of largest metastatic deposit:  Not applicable\X0D\\X0A\Extranodal extension:  Not applicable\X0D\\X0A\Additional pathologic findings:  Multiple radial scars, papillomatosis,\X0D\\X0A\stromal fibrosis, and extensive sclerosing adenosis with luminal\X0D\\X0A\microcalcifications.\X0D\\X0A\Pathologic staging:  pT1b pN0(sn) MX\X0D\\X0A\Receptor studies:\X0D\\X0A\Estrogen Receptor (ER) (semiquantitative) /  Progesterone Receptor (PR)\X0D\\X0A\(semiquantitative)\X0D\\X0A\ER:  Positive:  99% of cells; staining intensity strong\X0D\\X0A\PR:  Positive:  80% of cells; staining intensity moderate to strong\X0D\\X0A\Method and Scoring Guide for ER/PR:\X0D\\X0A\Performed upon routinely formalin fixed and paraffin embedded tissue.\X0D\\X0A\ER clone SP1\X0D\\X0A\PR clone 1E2.\X0D\\X0A\Scoring Guide:  A positive result is based specifically upon positive\X0D\\X0A\nuclear staining within tumor cells, with an intensity graded from\X0D\\X0A\weak-mild to strong as noted above.  If the count is greater than 0% by\X0D\\X0A\IHC manual morphometry, of any intensity, the result is considered\X0D\\X0A\POSITIVE, with only 0% staining considered NEGATIVE.\X0D\\X0A\HER-2/neu Status (semiquantitative):  0; Negative\X0D\\X0A\Method and Interpretation Guide for HER-2/neu (C-erB-2):\X0D\\X0A\Performed upon routinely formalin fixed and paraffin embedded tissue\X0D\\X0A\(subject to false-negative results with improper and/or delayed\X0D\\X0A\fixation).\X0D\\X0A\Specimen identification:\X0D\\X0A\-    CASE #:  5227            BLOCK #:  B4\X0D\\X0A\-    Specimen site and type:  Left mastectomy\X0D\\X0A\-    Time to fixation:  45 minutes\X0D\\X0A\-    Duration of fixation:  7 hours\X0D\\X0A\HER-2/neu clone 4B5.\X0D\\X0A\Method used:  VENTANA i VIEW PATHWAYS (FDA approved, controls high\X0D\\X0A\protein expression, low level protein expression, negative protein\X0D\\X0A\expression, internal).\X0D\\X0A\Adequacy of sample for evaluation:  Adequate\X0D\\X0A\Result interpretation:  Negative\X0D\\X0A\Percentage of invasive tumor cells exhibiting complete membrane\X0D\\X0A\staining:  0%\X0D\\X0A\Uniformity of staining present or absent:  Absent\X0D\\X0A\Homogeneous dark circumferential pattern present or absent:  Absent\X0D\\X0A\Scoring Guide:\X0D\\X0A\Staining Pattern                   Result\X0D\\X0A\     0    No membrane staining observed      Negative\X0D\\X0A\          (or membrane staining observed\X0D\\X0A\          in a count of less than 10% of tumor cells).\X0D\\X0A\     1+   Faint/partial membrane staining         Negative\X0D\\X0A\          (detected in a count of more than 10% of\X0D\\X0A\          tumor cells.  Staining may not\X0D\\X0A\          encircle entire cell membrane).\X0D\\X0A\     2+   Weak complete membrane staining,        Equivocal\X0D\\X0A\          observed in a count of more than 10%\X0D\\X0A\of tumor cells (encircling entire cell\X0D\\X0A\membrane).\X0D\\X0A\     3+   Moderate to strong (intense) complete   Positive\X0D\\X0A\          membrane staining observed in a count\X0D\\X0A\of more than 10% of tumor cells (encircling\X0D\\X0A\          entire cell membrane).\X0D\\X0A\NOTE:  The immunohistochemical methods utilized for the evaluation of\X0D\\X0A\ER/PR receptor status are considered semiquantitative with results\X0D\\X0A\expressed as detailed above.   Despite an FDA approved scoring guide\X0D\\X0A\that classifies 2+ immunohistochemistry results as equivocal, the\X0D\\X0A\literature suggests that up to 70% of these cases may be actually the\X0D\\X0A\fluorescence in situ hybridization (FISH) negative.  As such, a reflex\X0D\\X0A\to HER-2/neu FISH testing could be considered before administration of\X0D\\X0A\Herceptin therapy.  The immunohistochemistry methods utilized for the\X0D\\X0A\evaluation of ER/PR receptor and HER-2/neu status are considered\X0D\\X0A\semiquantitative, with results expressed as detailed above.  These tests\X0D\\X0A\were developed and their performance characteristics determined by the\X0D\\X0A\**INSTITUTION Pathology Department.  This laboratory is\X0D\\X0A\regulated under the Clinical Laboratory Improvement Amendments of 1988\X0D\\X0A\(CLIA '88), as qualified to perform high complexity testing.\X0D\\X0A\**NAME[YYY XXX:  WWW M VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jun 31 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Left sentinal node\X0D\\X0A\SOURCE OF SPECIMEN: B Left breast,,
REG1,BREAST,0,491664,1,,Clinical History:\X0D\\X0A\None Given,"Frozen Section:\X0D\\X0A\Part A)  TP/FS Dx:  One lymph node, no tumor identified.  (DBC).\X0D\\X0A\Results given directly to Dr. **NAME[ZZZ].\X0D\\X0A\CPT Code(s):\X0D\\X0A\A:  88307.26;  88331.26;  88334.26.\X0D\\X0A\B:  88307.26, 88342.26 X 3\X0D\\X0A\**NAME[YYY XXX:  WWW M VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 02 2012]","Pre-Operative Diagnosis:\X0D\\X0A\Right Breast Cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Right sentinel lymph node:  Negative for malignancy.\X0D\\X0A\B)  Right breast, mastectomy:  Residual multifocal high grade ductal\X0D\\X0A\carcinoma in situ with luminal necrosis, prior biopsy sites,\X0D\\X0A\proliferative fibrocystic changes, and small hyalinized fibroadenoma,\X0D\\X0A\see Case summary below.\X0D\\X0A\      Lymph node:  Negative for malignancy.",,"Gross Description:\X0D\\X0A\Received are two parts, each labeled with the patient's name.\X0D\\X0A\Part A is received fresh for frozen section, additionally labeled ""right\X0D\\X0A\sentinel node"".  The specimen consists of a 1.5 x 1.0 x 0.8 cm pink-tan\X0D\\X0A\lymph node which is notable for blue-green localization dye.  The lymph\X0D\\X0A\node is serially sectioned and touch preps are obtained.  The specimen\X0D\\X0A\is submitted entirely for frozen section in one block.  The specimen is\X0D\\X0A\now resubmitted in toto for permanents in cassette A-FSC.\X0D\\X0A\Part B is received in formalin, additionally labeled ""right breast"".\X0D\\X0A\The specimen consists of a 690 gram, 20 x 17 x 5 cm simple mastectomy\X0D\\X0A\specimen.  The specimen is partially surfaced by a 13.5 x 7.5 cm\X0D\\X0A\pink-tan skin ellipse.  There is no orientation provided, such the\X0D\\X0A\aspect of the specimen would be larger, thus the fibrofatty tissue will\X0D\\X0A\be designated ""superior"".  The epidermal surface is pink-tan and smooth\X0D\\X0A\with no distinct biopsy sites, scars or lesions.  There is a 2 x 2 cm\X0D\\X0A\focus of reddish-purple bruising at the 7:00 to 8:00 o'clock position\X0D\\X0A\4.5 cm from the center of the nipple. There is an eccentric 3.8 cm in\X0D\\X0A\diameter areola with a 0.8 x 0.8 x 0.5 cm everted nipple.  The posterior\X0D\\X0A\surface of the specimen is inked blue.  Sectioning the specimen reveals\X0D\\X0A\two distinct separate biopsy sites and a separate solid nodule.  The\X0D\\X0A\first biopsy site is located within the lower outer quadrant at\X0D\\X0A\approximately the 8:00-9:00 o'clock position and is 1.2 x 0.6 x 0.5 cm.\X0D\\X0A\This first biopsy site is filled with clotted blood and pebble white\X0D\\X0A\biopsy seed material.  The first biopsy site is 2.0 cm from the nearest\X0D\\X0A\deep margin.  The first biopsy site is also approximately 1 cm deep to\X0D\\X0A\the overlying skin.  The second biopsy site is located within the upper\X0D\\X0A\outer quadrant 2.0 cm superior to the first biopsy site.  The second\X0D\\X0A\biopsy site is approximately 1.5 x 0.6 x 0.6 cm and is located at the\X0D\\X0A\10:00 o'clock position.  The second biopsy site contains no biopsy seed\X0D\\X0A\material.  The second biopsy site is also 2.0 cm from the nearest deep\X0D\\X0A\margin and 1.0 cm from the overlying skin.  Directly lateral to the\X0D\\X0A\second biopsy site within the upper outer quadrant, there is a 0.6 x 0.5\X0D\\X0A\x 0.5 cm solid white-tan nodule.  The nodule is also located at the\X0D\\X0A\10:00 o'clock position and is 1.5 cm from the nearest deep margin.  The\X0D\\X0A\nodule has a solid white-tan cut surface.  There is a moderate amount of\X0D\\X0A\intervening slightly granular dense white fibrous tissue between the\X0D\\X0A\solid nodule and the two biopsy sites.  There are no other distinct\X0D\\X0A\lesions identified.  There is a single 0.5 cm possible pink-tan lymph\X0D\\X0A\node identified within the lateral breast tissue.  The remainder of the\X0D\\X0A\specimen is predominantly composed of dense white-tan fibrous tissue.\X0D\\X0A\There are occasional small cystic structures seen.  Additional received\X0D\\X0A\in the same container is a separate small fragment of fibrofatty tissue,\X0D\\X0A\which is 6.0 x 4.0 x 1.5 cm.  Sectioning through this additional tissue\X0D\\X0A\fragment reveals a grossly unremarkable cut surface with no additional\X0D\\X0A\lesions.  Representative sections are submitted as follows:\X0D\\X0A\Cassette B1     nipple base and remainder of nipple\X0D\\X0A\Cassette B2     deep margin overlying biopsy site #1 at 8:00 o'clock\X0D\\X0A\Cassettes B3-B6     biopsy site #1 at 8:00 o'clock submitted entirely from\X0D\\X0A\medial to lateral\X0D\\X0A\Cassette B7     deep margin overlying biopsy site #2 at 10:00 o'clock\X0D\\X0A\Cassettes B8 \T\ B9     biopsy site #2 at 10:00 o'clock, entirely\X0D\\X0A\submitted\X0D\\X0A\from medial to lateral\X0D\\X0A\Cassette B10     deep margin overlying solid nodule from upper outer\X0D\\X0A\quadrant\X0D\\X0A\Cassettes B11 \T\ B12     bisected solid nodule from upper outer quadrant\X0D\\X0A\Cassette B13     granular fibrous tissue inferior to solid nodule\X0D\\X0A\Cassette B14     fibrous tissue superficial to solid nodule\X0D\\X0A\Cassette B15     random uninvolved upper inner quadrant\X0D\\X0A\Cassette B16     random uninvolved lower inner quadrant\X0D\\X0A\Cassette B17     one whole lymph node.\X0D\\X0A\Sections are placed in formalin at 1:05 p.m. on **DATE[Feb 1 2012].  **INITIALS","Microscopic Description:\X0D\\X0A\A)  Right sentinel lymph node:  Sections reveal a lymph node\X0D\\X0A\demonstrating sinus histiocytosis.  Within the sections examined, there\X0D\\X0A\is no evidence of malignancy.\X0D\\X0A\B)  Right breast:  Sections of the biopsy site from the 8 o'clock\X0D\\X0A\position, and sections through the tissue surrounding the solid nodules\X0D\\X0A\show foci of residual high grade duct carcinoma in situ characterized by\X0D\\X0A\expanded ducts which are filled with markedly atypical epithelial cells\X0D\\X0A\with focal central necrosis.  Definite invasion is not identified.  A\X0D\\X0A\smooth muscle myosin heavy chain immunohistochemical stain is performed\X0D\\X0A\on multiple slides and no definitive evidence of invasion is identified.\X0D\\X0A\A lateral single lymph node is also seen which is negative for\X0D\\X0A\malignancy.  For further information see Case Summary below.\X0D\\X0A\CASE SUMMARY FOR DUCTAL CARCINOMA IN SITU (DCIS) OF THE BREAST\X0D\\X0A\Specimen:  Breast.\X0D\\X0A\Procedure:   Mastectomy.\X0D\\X0A\Lymph node sampling:  Yes.\X0D\\X0A\Specimen laterality:  Right.\X0D\\X0A\Specimen integrity:  Intact.\X0D\\X0A\Specimen size:  690 grams, 20 x 17 x 5 cm.\X0D\\X0A\Tumor site:  8-9 o'clock and upper outer quadrant surrounding solid\X0D\\X0A\nodule.\X0D\\X0A\Size (extent) of DCIS:\X0D\\X0A\Number of blocks with DCIS: Present focally in Blocks B3, B4, B5, B13,\X0D\\X0A\and B14.\X0D\\X0A\Number of blocks examined:  16.\X0D\\X0A\Architectural pattern(s):  Solid.\X0D\\X0A\Nuclear grade:    3.\X0D\\X0A\Necrosis:  Present.\X0D\\X0A\Microcalcifications:  Yes, focal.\X0D\\X0A\Margins:  Negative for malignancy;\X0D\\X0A\          Closest margin:  1.5 cm.\X0D\\X0A\Lymph nodes:\X0D\\X0A\Number of sentinel lymph nodes examined:  1.\X0D\\X0A\Total number of lymph nodes examined (sentinel and non-sentinel):  2.\X0D\\X0A\Number of lymph nodes with macrometastases:  0.\X0D\\X0A\Number of lymph nodes with micrometastases:  0.\X0D\\X0A\Number of lymph nodes with isolated tumor cells:  0.\X0D\\X0A\Additional pathologic findings:  Proliferative fibrocystic changes and\X0D\\X0A\small hyalinized fibroadenoma.\X0D\\X0A\Receptor studies:  See receptor studies below.\X0D\\X0A\Pathologic staging:  pTis;  pN0;  pMX.\X0D\\X0A\ER/PR SEMIQUANTITATIVE\X0D\\X0A\ER: (Negative): 0 %\X0D\\X0A\PR: (Negative): 0%\X0D\\X0A\Method and Scoring Guide for ER/PR:\X0D\\X0A\*    Performed upon routinely formalin fixed and paraffin embedded\X0D\\X0A\tissue.\X0D\\X0A\*    ER clone 6F11.\X0D\\X0A\*    PR clone 16.\X0D\\X0A\*    Scoring Guide: A positive result is based specifically upon\X0D\\X0A\positive nuclear staining within tumor cells, with an intensity graded\X0D\\X0A\from weak-mild to strong as noted above. If the result is >0% of any\X0D\\X0A\intensity, the result is considered POSITIVE, with only 0% staining\X0D\\X0A\considered NEGATIVE.\X0D\\X0A\NOTE  The immunohistochemistry methods utilized for the evaluation of\X0D\\X0A\ER/PR receptor and HER-2/neu status are considered semiquantitative,\X0D\\X0A\with results expressed as detailed above. These tests were developed and\X0D\\X0A\their performance characteristics determined by the **NAME[UUU TTT]\X0D\\X0A\Hospital Pathology Department. ER and PR receptor tests have not been\X0D\\X0A\cleared or approved by the U.S. Food and Drug Administration (FDA). The\X0D\\X0A\FDA has determined that such clearance or approval is not necessary.\X0D\\X0A\These tests are used solely for clinical purposes. They should not be\X0D\\X0A\regarded as investigational or for research. This laboratory is\X0D\\X0A\regulated under the Clinical Laboratory Improvement Amendments of 1988\X0D\\X0A\(CLIA '88), as qualified to perform high complexity testing. Tissue\X0D\\X0A\Code:  T1.",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right Sentinel Node\X0D\\X0A\SOURCE OF SPECIMEN: B Right Breast,,
REG1,BREAST,0,491711,2,,Clinical History:\X0D\\X0A\14G U/S guided biopsy; 15mm spiculated mass at 9:00. Suspect invasive\X0D\\X0A\cancer.,"CPT Code(s):  88305.26, 88342.26(x 3)\X0D\\X0A\DBC:jck\X0D\\X0A\Dct:Trs:  **DATE[Feb 02 2012]\X0D\\X0A\**NAME[ZZZ YYY:  XXX WWW VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 02 2012]","Pre-Operative Diagnosis:\X0D\\X0A\311.72 Right breast mass\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Right breast mass at 9 o'clock, ultrasound guided core biopsy:\X0D\\X0A\Infiltrating well differentiated ductal carcinoma with associated ductal\X0D\\X0A\carcinoma in situ (DCIS).",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled ""right breast"".  The specimen consists of three\X0D\\X0A\yellow-tan fibro-fatty tissue cores, which are each 0.1 cm in diameter x\X0D\\X0A\0.5, 1 and 1.1 cm in length.  The specimen is submitted in toto in a\X0D\\X0A\single cassette.   The following times are given on the requisition:\X0D\\X0A\S-9:55 a.m.;  E-9:59 a.m.;   F-10:01 a.m. on **DATE[Feb 01 2012].   JAB:jlj","Microscopic Description:\X0D\\X0A\Sections from all submitted core biopsy tissue samples demonstrate\X0D\\X0A\infiltrating cords and small nests of tumor cells embedded within a\X0D\\X0A\moderately sclerotic stroma.  There is no tubule formations and focal\X0D\\X0A\single-file infiltration pattern is seen.  Tumor nuclei show mild\X0D\\X0A\pleomorphism and no significant mitotic activity.  E-cadherin\X0D\\X0A\immunostain is diffusely positive, indicative of ductal phenotype.  The\X0D\\X0A\infiltrating tumor shows no immunoreactivity with smooth muscle myosin\X0D\\X0A\heavy chain (SMM-HC) and p63 immunostains, confirming the diagnosis of\X0D\\X0A\infiltrating carcinoma.  The tumor is associated with low to\X0D\\X0A\intermediate grade ductal carcinoma in situ (DCIS) with solid pattern.\X0D\\X0A\The foci of DCIS show preservation of myoepithelial cells with p63 and\X0D\\X0A\SMM-HC.  No lymph-vascular invasion is observed.  The infiltrating tumor\X0D\\X0A\measures up to 1 cm in greatest linear extent in this material.\X0D\\X0A\Tissue Code:  T1",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right breast core 9:00,,
REG1,BREAST,0,493916,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is breast cancer. Intraoperative findings: right breast\X0D\\X0A\cancer. Operative procedure: right mastectomy with sentinel node biopsy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION / TP / SP DIAGNOSIS #1A-C:  ""(RIGHT SENTINEL LYMPH NODE #1):\X0D\\X0A\NO TUMOR SEEN""---VC.\X0D\\X0A\FROZEN SECTION / TP / SP DIAGNOSIS #2:  ""(SENTINEL LYMPH NODE #2): NO TUMOR\X0D\\X0A\SEEN""---VC.\X0D\\X0A\\X0D\\X0A\     **NAME[M. ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Oct 13 1966] (Age: **AGE[in 40s])  FW\X0D\\X0A\Collect Date: **DATE[Mar 16 2012] 11:50\X0D\\X0A\Receipt Date: **DATE[Mar 16 2012] 11:50\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: **NAME[M. XXX], MD     Service: SGO     Location: 7W\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Mar 21 2012] 17:28\X0D\\X0A\RESIDENTS(**NAME[M): M. VVV], MD\X0D\\X0A\Comment: For specimen ' A"" the tumor is not present on the frozen section,\X0D\\X0A\but is seen on permanent staining sections which are deeper level in the\X0D\\X0A\specimen.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\BREAST, RIGHT, MASTECTOMY WITH SENTINEL NODE BIOPSY (B):    - INVASIVE DUCTAL\X0D\\X0A\CARCINOMA, INTERMEDIATE HISTOLOGIC GRADE.   - TUMOR MEASURES 1.3 CM IN\X0D\\X0A\GREATEST DIMENSION.   - DUCTAL CARCINOMA IN SITU PRESENT.   - NO PERINEURAL\X0D\\X0A\OR LYMPHVASCULAR INVASION IDENTIFIED.   - ALL MARGINS NEGATIVE.   -\X0D\\X0A\PATHOLOGIC STAGE pT1c pN1mi (SEE TEMPLATE, SEE COMMENT).\X0D\\X0A\SENTINEL LYMPH NODE, RIGHT, EXCISION (A):\X0D\\X0A\  - ONE LYMPH NODE WITH MICROMETASTATIC TUMOR, MEASURING 1 MM IN DIMENSION\X0D\\X0A\(1/1) (SEE COMMENT)\X0D\\X0A\ SENTINEL LYMPH NODE, RIGHT, EXCISION (C):\X0D\\X0A\  - ONE LYMPH NODE, NO TUMOR SEEN(0/1)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\rxa/**DATE[Mar 20 2012] **NAME[M. ZZZ], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M85002 P1100 \X0D\\X0A\F: A: 88332 ADD'L FS(2), 88307\X0D\\X0A\A,C: 88331 FS1(2)\X0D\\X0A\B: 88309\X0D\\X0A\C: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Three specimens are received.\X0D\\X0A\Specimen label:  A) right sentinel node #1                 \X0D\\X0A\Fixation: fresh for frozen (FS1)\X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular     \X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 3 x 2 x 1 cm, one lymph node measuring 2.7 x 2 x 1 cm is identified \X0D\\X0A\Cassette summary: the entire lymph node is frozen as FS1A  C. FS1A is\X0D\\X0A\entirely resubmitted as A1; FS1B is resubmitted as A2 and FS1C is resubmitted\X0D\\X0A\as A3; A4  unfrozen surrounding fatty tissue.    \X0D\\X0A\Specimen B is received fresh and then added to formalin at 9:20 am labeled\X0D\\X0A\right breast, short superior, long lateral. It consists of a single oriented,\X0D\\X0A\yellow tan breast with an attached light tan skin ellipse. The breast\X0D\\X0A\measures 22 cm from medial to lateral end, 17 cm from superior to inferior\X0D\\X0A\and 4 cm in thickness. The attached hairbearing skin elipse measures 18 cm\X0D\\X0A\from medial to lateral end, 6.5 cm from superior to inferior end and 0.2 cm\X0D\\X0A\in thickness. The surface of the skin appears grossly unremarkable with no\X0D\\X0A\lesions or peau d' Orange. The superficial part is inked blue and the deep\X0D\\X0A\margin is inked black. The breast is serially sectioned to reveal a dense and\X0D\\X0A\firm, pink tan fibrous area measuring 1.5 x 1 x 1 cm. The area in the center\X0D\\X0A\of the mass appears to be dense and a clip is identified in this area. The\X0D\\X0A\mass is at a distance of 5 cm from the medial margin, 5 cm from the inferior\X0D\\X0A\margin, 11 cm from the superior margin and 10 cm from the lateral margin. It\X0D\\X0A\is 1.4 cm from the deep margin and 4 cm from the nipple. The mass is at a\X0D\\X0A\distance of 0.6 cm from the superficial margin. There is an adjacent\X0D\\X0A\hemorrhagic and thickened area adjacent to this mass measuring 1.5 cm in\X0D\\X0A\greatest dimension. B1  section of the nipple; B2  subareola. A clip is\X0D\\X0A\recognized at approximately 9:00 position which in the mass. B3  B4 - section\X0D\\X0A\around the clip; B5- B6  more tumor section; B7  B9  sections through the\X0D\\X0A\adjacent hemorrhagic area; B10 - more sections through fibrous areas in the\X0D\\X0A\breast; B11  outer lower quadrant, representative sections; B12  outer upper\X0D\\X0A\quadrant, representative sections; B13  inner lower quadrant representative\X0D\\X0A\sections; B14  inner upper quadrant for representative section.\X0D\\X0A\Specimen label:  C) right sentinel node #1                 \X0D\\X0A\Fixation: fresh for frozen (FS2)\X0D\\X0A\Number of pieces: 1\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): red tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): a single lymph node is identified measuring approximately 2.5 x 2 x\X0D\\X0A\0.5 cm. It is frozen as FS2\X0D\\X0A\Cassette summary: FS2 is entirely resubmitted as C1; remaining fatty tissue\X0D\\X0A\which was not frozen is submitted as C2.   \X0D\\X0A\rgc/**DATE[Mar 19 2012] **NAME[M. VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\INVASIVE CARCINOMA OF THE BREAST (template #26)\X0D\\X0A\Last updated **DATE[Dec 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Specimen/procedure: right mastectomy with sentinel node biopsy\X0D\\X0A\Specimen integrity:    single intact specimen (margins can be evaluated) \X0D\\X0A\\X0D\\X0A\Specimen size:     22 x 17 x 4 cm\X0D\\X0A\Specimen laterality:     right \X0D\\X0A\Tumor site for invasive carcinoma:    9 o' clock\X0D\\X0A\Tumor size (largest one):    1.3 x 1 x 1 cm\X0D\\X0A\Tumor focality:    unifocal \X0D\\X0A\\X0D\\X0A\Histologic type: invasive ductal carcinoma\X0D\\X0A\Histologic grade (Nottingham histologic score): 5\X0D\\X0A\    Only microinvasion present (not graded): not applicable\X0D\\X0A\    Glandular (acinar)/tubular differentiation:   3 \X0D\\X0A\     Nuclear pleomorphism:  2 \X0D\\X0A\     Mitotic Count:  1 \X0D\\X0A\     Overall Grade:  Grade 2 (score 6)\X0D\\X0A\\X0D\\X0A\Ductal carcinoma in situ (DCIS):    extensive intraductal component (EIC:\X0D\\X0A\>25%) in association with the invasive component             (estimated size:\X0D\\X0A\at least 0.6 cm; number of blocks with DCIS: 4; number of blocks examined:\X0D\\X0A\14)\X0D\\X0A\\X0D\\X0A\      DCIS architectural pattern(s):   cribriform with necrosis\X0D\\X0A\      DCIS nuclear grade:   Grade II (intermediate) \X0D\\X0A\Lobular carcinoma in situ (LCIS):   not identified \X0D\\X0A\Lymph-vascular Invasion:   not identified \X0D\\X0A\Dermal lymph-vascular Invasion:  not identified \X0D\\X0A\Microcalcifications:    not identified \X0D\\X0A\Skin:    no tumor involvement \X0D\\X0A\Nipple:    no DCIS present \X0D\\X0A\Skeletal muscle:    no skeletal muscle present \X0D\\X0A\Margins:     uninvolved by invasive carcinoma (distance to closest margin: 14\X0D\\X0A\mm from deep margin) \X0D\\X0A\              Uninvolved by DCIS, DCIS with extensive cautery artifact within\X0D\\X0A\1 mm from the superficial margin of resection\X0D\\X0A\Lymph nodes (if present in current specimen): no\X0D\\X0A\    Number of sentinel lymph nodes examined: 2\X0D\\X0A\    Total number of lymph nodes examined (sentinel and nonsentinel): 2\X0D\\X0A\    Number of lymph nodes with macrometastases (>0.2 cm):  0\X0D\\X0A\         Number of lymph nodes with micrometastases (>0.2 mm-0.2 cm):1\X0D\\X0A\    Number of lymph nodes with isolated tumor cells (=0.2 mm): 0\X0D\\X0A\    Size of largest metastatic deposit (if present): 1 mm\X0D\\X0A\    Extranodal Extension:   not identified \X0D\\X0A\Clinical history (If available, clinical presentation, radiologic findings,\X0D\\X0A\prior history, etc.):  history of invasive ductal carcinoma on biopsy. \X0D\\X0A\Pathologic staging (pTNM) (m: multiple foci of invasive carcinoma)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\           pT1c:             >10 mm but =20 mm \X0D\\X0A\REGIONAL LYMPH NODES (pN) \X0D\\X0A\     Note:  (sn): only sentinel node(s) evaluated.  If 6 or more sentinel\X0D\\X0A\nodes and/or nonsentinel nodes are \X0D\\X0A\          removed, this modifier should not be used.\X0D\\X0A\            pN1mi:          Micrometastasis (greater than 0.2 mm but not\X0D\\X0A\larger than 2 mm)\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (M)  \X0D\\X0A\                         Not applicable\X0D\\X0A\Additional pathologic findings: fibrocystic changes with columnar cell\X0D\\X0A\changes.\X0D\\X0A\Ancillary studies:\X0D\\X0A\Estrogen Receptor)   performed on another specimen (accession number:\X0D\\X0A\***PATH-NUMBER[2]  \X0D\\X0A\         Results:  positive (quantitation: 90%) \X0D\\X0A\Progesterone Receptor)   performed on another specimen (accession ***PATH-NUMBER[2] \X0D\\X0A\         Results:  positive (quantitation: 90%) \X0D\\X0A\HER2/neu) \X0D\\X0A\   Immunostain)   not performed on this specimen (accession number: \X0D\\X0A\***PATH-NUMBER[2]\X0D\\X0A\    Fluorescence In Situ Hybridization (FISH) for HER2/neu)  performed on\X0D\\X0A\another specimen : ***PATH-NUMBER[2]\X0D\\X0A\          Results:   not amplified (HER2 gene copy <4.0 or ratio <1.8)",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Sentinel lymph node #1 (count 18519)\X0D\\X0A\B: right breast-short stitch superior; long lateral\X0D\\X0A\C: Sentinel lymph node #2 (count 6408),,
REG1,BREAST,0,495164,1,,PRE-OPERATIVE DIAGNOSIS: RIGHT BREAST CALCIFICATIONS.,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT. COMMENT:. **INSTITUTION, Department of Pathology, Histology Laboratory. performs proper fixation of breast specimens submitted for estrogen and progesterone. receptor and HER-2-NEU testing by IHC by allowing at least 6 hours and no more than 48 hours. of fixation time in 10% buffered formalin of all breast specimens processed in this. laboratory. Addendum Final Signout: **NAME[XXX WWW], MD **DATE[May 13 12]. CPT CODES:. 88305 x 1,  88361 x 2","MICROSCOPIC INTERPRETATION: RIGHT STEREOTACTIC BREAST BIOPSY: CRIBRIFORMING AND COMEDO-TYPE DUCTAL CARCINOMA IN SITU OF HIGH NUCLEAR GRADE. ASSOCIATED INTRADUCTAL MICROCALCIFICATIONS. NEGATIVE FOR DEFINITIVE INVASIVE TUMOR. NOTE:  The DICS will be further characterized per ER and PR immunostains. These results will follow in an addendum report.. Final Signout: **NAME[XXX WWW], MD **DATE[May 12 12]",,"GROSS DESCRIPTION: The specimen is received within formalin in one container labeled right stereotactic breast biopsy.  It consists of multiple lobulated cylindrical portions of yellow-pink soft tissue, which measure 5.5 x 3.5 x 0.4 cm. in aggregate.  The specimen is entirely submitted in blocks ""A"" through ""C"".",,Tissues: BREAST BIOPSY. Specimen Comments:,,ADDENDUM: Addendum Date: **DATE[May 13 12] ESTROGEN  RECEPTORS:  BORDERLINE        (1.41% of  tumor cell nuclei). PROGESTERONE RECEPTORS:  UNFAVORABLE    (0.00% of  tumor cell nuclei). NOTE:  Immunohistochemical stains are quantitated with computer digital imaging assistance. All controls work appropriately (see Genzyme report for further testing details).
REG1,BREAST,0,495413,1,,Clinical History\X0D\\X0A\Right breast mass.\X0D\\X0A\Pre-Operative Diagnosis\X0D\\X0A\Not given.\X0D\\X0A\Post-Operative Diagnosis\X0D\\X0A\Not given.,"Bon Secours Kentucky Health System\X0D\\X0A\**INSTITUTION\X0D\\X0A\St. **PLACE Drive\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\Tel:  **PHONE    Fax:  **PHONE\X0D\\X0A\**NAME[ZZZ M. YYY], MD, Director\X0D\\X0A\Patient Name: **NAME[BBB, AAA M]          Specimen #:***PATH-NUMBER[1]\X0D\\X0A\Patient ID: **ID-NUM          Account #:**ID-NUM\X0D\\X0A\DOB/Gender: **DATE[Dec 20 1937] (Age: **AGE[in 70s])/F          Location: SP (OLB)\X0D\\X0A\Collect: **DATE[Aug 12 2011]   Rec'd: **DATE[Aug 12 2011]   Reported: **DATE[Aug 14 2011]\X0D\\X0A\Physician(s):\X0D\\X0A\**NAME[XXX, WWW] MD\X0D\\X0A\**NAME[VVV, UUU]\X0D\\X0A\RADIOLOGY COPY\X0D\\X0A\SURGICAL PATHOLOGY REPORT","FINAL PATHOLOGIC DIAGNOSIS\X0D\\X0A\Right breast mass, needle core biopsies:\X0D\\X0A\1.          Invasive ductal carcinoma\X0D\\X0A\a.          Histologic grade 1 (Combined Nottingham histologic grade):\X0D\\X0A\i.  Nuclear pleomorphism:  Moderate (score 2)\X0D\\X0A\ii.  Tubule formation:  Moderate (score 2)\X0D\\X0A\iii:  Mitotic count (40X objective):   0/10 high powered fields\X0D\\X0A\(score 1)\X0D\\X0A\iv.  Combined Nottingham score:   5\X0D\\X0A\b.   Extent of associated ductal carcinoma in situ:  Not identified\X0D\\X0A\c.   Microcalcifications:  Not identified\X0D\\X0A\d.   Lymphovascular invasion:  Not identified\X0D\\X0A\2.          Results of special studies (Immunoperoxidase stains):\X0D\\X0A\a.   Estrogen receptor:  Strongly, diffusely positive\X0D\\X0A\b.   Progesterone receptor:  Strongly, diffusely positive\X0D\\X0A\c.   Her2/neu:  Specimen block forwarded to reference laboratory for\X0D\\X0A\fluorescent in situ\X0D\\X0A\hybridization (FISH) analysis with a\X0D\\X0A\separate report to follow\X0D\\X0A\3.   Additional pathologic findings:  Focal atypical ductal hyperplasia.\X0D\\X0A\CPT:   88305 (x1), 88342 (x3), 88360 (x2)\X0D\\X0A\aw1/**DATE[Aug 14 2011]\X0D\\X0A\***Electronically Signed Out By **NAME[TTT, SSS M]., M.D.***",,Gross Description\X0D\\X0A\Submitted in formalin specimen is labeled RIGHT BREAST CORE BIOPSIES X 4\X0D\\X0A\and consists of four intact and fragments pieces of yellow white and dark\X0D\\X0A\maroon fibrous and adipose tissue measuring from 0.9 up to 1.1 cm in\X0D\\X0A\length x 0.1 cm in diameter each.  Specimen is totally embedded in one\X0D\\X0A\cassette.\X0D\\X0A\GAR,"Microscopic Description\X0D\\X0A\Multiple sections of the right breast needle core biopsy show fibrotic\X0D\\X0A\pressed tissue with extensive malignant cell population displaying a\X0D\\X0A\glandular and focal solid growth pattern with moderate nuclear\X0D\\X0A\pleomorphism exhibited by oval nuclei with pseudonuclear inclusions,\X0D\\X0A\minimal cytoplasm, and no mitotic figures.  Occasional nests of ductal\X0D\\X0A\cells displaying a cellular proliferation with focal myoepithelial cells\X0D\\X0A\are noted somewhat suggestive of at least atypical ductal hyperplasia.\X0D\\X0A\Immunoperoxidase stains are performed with appropriate controls and the\X0D\\X0A\results are as follows:\X0D\\X0A\1.  Actin:   Negative for a myoepithelial cell layer with extensive\X0D\\X0A\positivity for fibroblast\X0D\\X0A\2.  CD34:   Positive for occasional myoepithelial cells and blood\X0D\\X0A\vessels without evidence of lymphovascular\X0D\\X0A\invasion\X0D\\X0A\3.   Estrogen receptor:  Strongly positive\X0D\\X0A\4.   KCAM:  Strongly diffusely positive\X0D\\X0A\5.   Progesterone receptor:  Moderate to strongly positive\X0D\\X0A\The overall staining pattern confirms the presence of invasive ductal\X0D\\X0A\carcinoma.  No microcalcifications or lymphovascular invasion is seen.","Specimen Source: \X0D\\X0A\ \S\core biopsy, right breast x 4\S\\S\0 \X0D\\X0A\",,
REG1,BREAST,0,500422,1,,PRE-OPERATIVE DIAGNOSIS: CALCIFICATIONS.,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT. COMMENT:. **INSTITUTION, Department of Pathology, Histology Laboratory,. performs proper fixation of breast specimens submitted for estrogen and progesterone. receptors and HER-2-NEU testing by IHC by allowing at least 6 hours and no more than 48. hours of fixation time in 10% buffered formalin of all breast specimens processed in this. laboratory. Addendum Final Signout: **NAME[XXX WWW], MD **DATE[Feb 26 12]. CPT CODES:. 88305; 88361 x 2","MICROSCOPIC INTERPRETATION: LEFT STEREOTACTIC BREAST BIOPSY: COMEDO TYPE DUCTAL CARCINOMA IN SITU. HIGH NUCLEAR GRADE. ASSOCIATED INTRADUCTAL MICROCALCIFICATIONS. NEGATIVE FOR DEFINITIVE INVASIVE TUMOR. BACKGROUND NONPROLIFERATIVE FIBROCYSTIC CHANGES. NOTE:  Dr. **NAME[VVV M]. Jackson agrees with the diagnosis.  DCIS will be further characterized per ER and PR immunohistochemical stains.  The results will follow in an addendum report.. Final Signout: **NAME[XXX WWW], MD **DATE[Feb 25 12]",,"GROSS DESCRIPTION: Submitted in a single container of formalin labeled left stereotactic breast biopsy are core biopsy fragments of soft tissue ranging measuring 4 x 3.5 x 0.4cm in aggregate.  The specimen is entirely submitted in cassettes ""A"" through ""D"".",,Tissues: BREAST BIOPSY. Specimen Comments:,,ADDENDUM: Addendum Date: **DATE[Feb 26 12] ESTROGEN RECEPTORS:  FAVORABLE        (12.30% of tumor cell nuclei). PROGESTERONE RECEPTORS:  UNFAVORABLE    (0.43% of tumor cell nuclei). NOTE:  Immunohistochemical stains are quantitated with computer digital imaging assistance. All controls work appropriately (see Genzyme report for further testing details).
REG1,BREAST,0,500425,1,,PRE-OPERATIVE DIAGNOSIS: LEFT BREAST CALCIFICATIONS.,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT. COMMENT:. **INSTITUTION, Department of Pathology, Histology Laboratory. performs proper fixation of breast specimens submitted for estrogen and progesterone. receptor and HER-2-NEU testing by IHC by allowing at least 6 hours and no more than 48 hours. of fixation time in 10% buffered formalin of all breast specimens processed in this. laboratory. Addendum Final Signout: **NAME[XXX WWW], MD **DATE[Jan 15 12]. CPT CODES:. 88305 x 1;88361 x 2","MICROSCOPIC INTERPRETATION: LEFT STEREOTACTIC BREAST BIOPSY: SOLID TO CRIBIFORMING DUCTAL CARCINOMA IN SITU OF LOW NUCLEAR GRADE. ASSOCIATED INTRADUCTAL MICROCALCIFICATIONS. NEGATIVE FOR DEFINITIVE INVASIVE TUMOR. BACKGROUND MILDLY TO MODERATELY PROLIFERATIVE FIBROCYSTIC CHANGE. NOTE:  Dr. **NAME[M. VVV UUU] agrees with the diagnosis.  The DCIS will be further characterized per ER and PR immunostains.  These results will follow in an addendum report.. Final Signout: **NAME[XXX WWW], MD **DATE[Jan 10 12]",,"GROSS DESCRIPTION: The specimen is received within formalin in one container labeled left stereotactic breast biopsy.  It consists of multiple cylindrical lobulated portions of pink-yellow-red soft tissue measuring 6 x 4 x 0.4 cm. in aggregate.  The specimen is entirely submitted in blocks ""A"" through ""D"".",,Tissues: BREAST BIOPSY. Specimen Comments:,,ADDENDUM: Addendum Date: **DATE[Jan 15 12] ESTROGEN  RECEPTORS:  FAVORABLE        (78.22% of  tumor cell nuclei). PROGESTERONE RECEPTORS:  FAVORABLE    (73.46% of  tumor cell nuclei). NOTE:  Immunohistochemical stains are quantitated with computer digital imaging assistance. All controls work appropriately (see Genzyme report for further testing details).
REG1,BREAST,0,502014,1,,Clinical Diagnosis and History\X0D\\X0A\**AGE[in 80s]-year-old female with right breast mass/NUB.,Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Right breast NUB,"Final Diagnosis\X0D\\X0A\Right breast NUB:\X0D\\X0A\A.          Infiltrating high grade mammary carcinoma.\X0D\\X0A\B.     9 points on Nottingham scale.\X0D\\X0A\C.     Specimen previously partially incised (see gross and microscopic\X0D\\X0A\descriptions).\X0D\\X0A\D.     Tumor measures 1.7 cm in greatest dimension.\X0D\\X0A\                                   1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\DNA Analysis     Date Ordered:     **DATE[Jun 27 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jun 27 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Jun 27 2012]         \X0D\\X0A\Results\X0D\\X0A\{Not Entered}\X0D\\X0A\Interpretation-Comments\X0D\\X0A\{Not Entered}",,"Gross Description\X0D\\X0A\The specimen is submitted fixed in a container labeled with the patient name and\X0D\\X0A\designated ""right breast NUB.""  Within the container is a previously partially\X0D\\X0A\sectioned fibroadipose specimen measuring 3 x 2.2 x 1.8 cm.  Because of the\X0D\\X0A\previous partial sectioning, no marking for margin identification can be\X0D\\X0A\performed.  Cross-sectioning the specimen shows a 1.7 cm in greatest dimension\X0D\\X0A\gray-white nodule present.  The entire nodule is sectioned and submitted in\X0D\\X0A\(cassettes A through E). \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\The sections are of breast and show inflammation, fibrosis, duct ectasia, and an\X0D\\X0A\infiltrating neoplasm composed of cells with virtually no lumen formation (3\X0D\\X0A\points), anisonucleosis and nuclear hyperchromasia (3 points), and a high\X0D\\X0A\mitotic rate of greater than 10 per 10 high power fields (3 points).  The\X0D\\X0A\findings are those of an infiltrating high grade mammary carcinoma and based on\X0D\\X0A\the gross measurement the lesion is at least 1.7 cm in dimension.  As noted\X0D\\X0A\grossly, the specimen has previously been incised and no inking for margins was\X0D\\X0A\possible.  The lesion does not appear to be present at the cauterized margins of\X0D\\X0A\excision but clinical correlation is recommended.  At the time of this report,\X0D\\X0A\special studies (estrogen receptor, progesterone receptor, Her-2 neu receptor,\X0D\\X0A\and DNA, etc) are pending and an addendum report will be issued.  \X0D\\X0A\**INITIALS",,,Procedures/Addenda\X0D\\X0A\ER-PR-Her2 Analysis     Date Ordered:     **DATE[Jun 25 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jun 28 2012]     By:  **NAME[VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Jun 28 2012]
REG1,BREAST,0,506697,1,,Clinical History:\X0D\\X0A\None Given,CPT Code(s):   88305.26;  88342.26 (x2).\X0D\\X0A\DBC:jlj\X0D\\X0A\Dct:Trs:  **DATE[Jul 05 2012]\X0D\\X0A\**NAME[ZZZ YYY:  XXX WWW VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jul 05 2012],"Pre-Operative Diagnosis:\X0D\\X0A\C/W small invasive cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Axillary tail of right breast, core biopsy:  Infiltrating ductal\X0D\\X0A\carcinoma, well differentiated.",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled ""right axillary tail"".  The specimen consists of\X0D\\X0A\five yellow-tan fibrofatty tissue cores, which are each 0.1 cm in\X0D\\X0A\diameter, and range in length from 0.6 to 1.5 cm.  The specimen is\X0D\\X0A\submitted in toto in single cassette.  The following times are given on\X0D\\X0A\the requisition:  S - 11:05 a.m., E - 11:20 a.m., F - 11:10 a.m. on\X0D\\X0A\**DATE[Jul 04 2012].  JAB:jck",Microscopic Description:\X0D\\X0A\Sections of the core biopsy demonstrate infiltrating malignant glands\X0D\\X0A\set within hyalinized stroma (tubular score: 2) which exhibit mild to\X0D\\X0A\moderate nuclear atypia (nuclear score: 2).  Mitotic activity is sparse\X0D\\X0A\(mitotic score: 1).  No in situ carcinoma is seen.  The diagnosis of\X0D\\X0A\carcinoma is supported by the failure of immunoperoxidase staining for\X0D\\X0A\smooth muscle myosin heavy chain and P63 to demonstrate myoepithelial\X0D\\X0A\cells.  A few scattered microcalcifications are noted within the tumor.\X0D\\X0A\No lymph-vascular space invasion is seen.  The tumor measures up to 0.7\X0D\\X0A\cm in greatest linear extent in this material.\X0D\\X0A\A second pathologist has reviewed this case and agrees with the above\X0D\\X0A\interpretation.\X0D\\X0A\Tissue Code:  T1.,Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right Breast axillary tail Core Biopsy,,
REG1,BREAST,0,506706,1,,Clinical History:\X0D\\X0A\Left 2:00 Suspicious Mass With Calcification,**** THIS IS AN ADDENDUM REPORT ****,"Pre-Operative Diagnosis:\X0D\\X0A\Expect Cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Left breast, needle core biopsies at the 2:00 position:\X0D\\X0A\-    Infiltrating mammary carcinoma, favor moderately differentiated,\X0D\\X0A\with associated microcalcifications (see microscopic description).",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled ""left breast"".  The specimen consists of six\X0D\\X0A\yellow-tan fibrofatty tissue cores, which are each 0.1 cm in diameter,\X0D\\X0A\and range in length from 0.5 to 1.8 cm.  The specimen is submitted in\X0D\\X0A\toto in a single cassette.  The following times are given on the\X0D\\X0A\requisition:  S - 8:35 a.m., E - 8:36 a.m., F - 8:40 a.m. on **DATE[Nov 08 2011].\X0D\\X0A\JAB:vsg","Microscopic Description:\X0D\\X0A\Sections show multiple core biopsies of breast tissue, the majority\X0D\\X0A\demonstrating an infiltrating mammary carcinoma.  The tumor grows\X0D\\X0A\predominately in irregular cords and small sheets with very rare\X0D\\X0A\attempts at possible tubule formation.  Tumor nuclei generally\X0D\\X0A\demonstrate moderate atypia, and only a few scattered mitoses are\X0D\\X0A\present (<5 in 10 high power fields).  Occasionally, the tumor assumes\X0D\\X0A\single file linear arrays within the background desmoplastic stroma,\X0D\\X0A\possibly indicating differentiation towards a lobular phenotype.\X0D\\X0A\However; a minor component is favored to represent a background ductal\X0D\\X0A\carcinoma in situ component of low to intermediate nuclear grade with\X0D\\X0A\partial cribriforming noted, involving only a few scattered ducts.  An\X0D\\X0A\E-cadherin immunostain is pending to further type this tumor, and\X0D\\X0A\results will be reported in an addendum.  No angiolymphatic invasion is\X0D\\X0A\appreciated.  The largest tumor measurement within an individual core\X0D\\X0A\biopsy approaches 1.2 cm.  Scattered associated microcalcifications are\X0D\\X0A\noted.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\DRJ:vsg\X0D\\X0A\D\T\T:  **DATE[Nov 09 2011].\X0D\\X0A\Addendum:\X0D\\X0A\An E-cadherin immunostain shows diffuse positive staining within both\X0D\\X0A\the in situ and infiltrating components of this mammary carcinoma,\X0D\\X0A\consistent with a ductal phenotype (adequate E-cadherin immunostain\X0D\\X0A\controls).\X0D\\X0A\DRJ:jlj\X0D\\X0A\D\T\T:  **DATE[Nov 12 2011].\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Nov 12 2011]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Left Breast Core Biopsy,,
REG1,BREAST,0,514005,1,,PRE-OPERATIVE DIAGNOSIS: 611.72,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: BREAST, RIGHT, MAMMOTOME BIOPSIES: INVASIVE DUCTAL ADENOCARCINOMA. COLD ISCHEMIC TIME - LESS THAN 5 SECONDS. FIXATION TIME IN 10% BUFFERED FORMALIN - GREATER THAN 6 HOURS BUT LESS THAN 48 HOURS. TUMOR SIZE - AT LEAST PARTIALLY INVOLVING EACH OF 4 CORE BIOPSIES. HISTOLOGIC GRADE (NOTTINGHAM SCORE) - GLANDULAR DIFFERENTIATION SCORE 2. NUCLEAR PLEOMORPHISM SCORE 3. MITOTIC FIGURE COUNT - SCORE 2 (16 MITOSES PER 10 HIGH POWER FIELDS). OVERALL GRADE - GRADE 2. DUCTAL CARCINOMA IN SITU - NON-EXTENSIVE, HIGH NUCLEAR GRADE WITH SOLID AND CLINGING PATTERNS PRESENT. CENTRAL NECROSIS - NOT IDENTIFIED. LOBULAR CARCINOMA IN SITU - NOT IDENTIFIED. LYMPHVASCULAR PRESENT - FOCALLY PRESENT. MICROCALCIFICATIONS - NOT IDENTIFIED. NOTE:  A quantitative breast panel will be performed and rendered in a supplemental report.. Preliminary Signout: **NAME[XXX], MD **DATE[Apr 10 12]. Final Signout: **NAME[XXX], MD **DATE[Apr 08 12]",,"GROSS DESCRIPTION: A single specimen is received in formalin labeled right breast mass. The specimen consists of multiple, variegated, yellow-gray core biopsies - numbering four and measuring, in aggregate, 2.7 x 1.6 x 0.4 cm.  The tissue is entirely submitted in mesh cassettes ""A"" and ""B"".",,Tissues: BREAST BIOPSY. Specimen Comments:,,"ADDENDUM: Addendum Date: **DATE[Apr 10 12] ER: 98.7% FAVORABLE PR: 0.00% UNFAVORABLE Ki-67: 26.05% UNFAVORABLE P53:  9.37%  FAVORABLE HER2: 1+ NEGATIVE Note: Immunohistochemical stains are quantitated with computer digital imaging assistance. All controls work appropriately (See Genzyme Report).  The panel was performed on tissue which was processed according to ASCO/CAP guidelines. Addendum Final Signout: **NAME[XXX], MD **DATE[Apr 10 12] CPT CODES: 88305 x 1;88361 x 5"
REG4,OTHER,0,PAT-10040746,1,REC-3000637052,"ClinicalHistory:
569.9
Procedure->Biopsy
Clinical History/Diagnosis/Condition->HX of chronic rectal bleeding/rectal pain: (a) Circumferential indurated rectal mass @ 5 cm from anal canal consistent with malignancy./r/n",,"FinalDiagnosis:
Rectal mass at 5cm biopsy:  Adenocarcinoma./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ] on **DATE[Jun 2 12].  Dr. **NAME[YYY] notified via voice message and email on **DATE[Jun 2 12]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated rectum biopsy Specimen:    Multiple, tan pieces of tissue (formalin)
Aggregate:    1.2 x 0.6 x 0.3 cm
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Rectal mass @ 5 cm, biopsy",,
REG4,OTHER,0,PAT-10039923,1,REC-3000637732,,"CytologyReview:

FNA right inguinal node

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Malignant neoplasm consistent with malignant lymphoma, see comment.","FinalDiagnosis:

FNA right inguinal node

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Malignant neoplasm consistent with malignant lymphoma, see comment

  

DiagnosisComment:
Adequacy is performed.  This demonstrates an infiltrate of small to intermediate sized cells with atypical cytologic features.  The core needle biopsy demonstrates replacement of the usual lymph node architecture by sheets of intermediate sized cells.  There are no definite organoid or cohesive elements.

This case is referred to Dr. **NAME[ZZZ YYY] for further review and work-up.  \X0A|",,,,A: FNA right inguinal node,,
REG4,OTHER,0,PAT-10039082,1,REC-3000638113,"ClinicalHistory:
Rectal cancer of left posterior quadrant.",,"FinalDiagnosis:
RECTUM, LEFT POSTERIOR QUADRANT; TRANSANAL EXCISION: 
- ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
- RESECTION MARGINS NEGATIVE FOR TUMOR.
- LYMPHVASCULAR INVASION IDENTIFIED.

Colon and rectal cancer information
Operative procedure:  Transanal excision.
Tumor-histologic type:  Rectal adenocarcinoma.
Histologic grade:  Moderately differentiated (G2).
Anatomic site:  Rectum, left posterior quadrant.
Size:  2.3 x 1.9 cm (macroscopic measurement).
Depth of invasion:  Into muscularis propria.
Perforation:  Not identified.
Crohn's-like lymphoid infiltrate:  Not identified.
Tumor infiltrating lymphocytes:  Not increased.
Pattern of growth at tumor periphery:  Infiltrating.
Perineural invasion:  Focal perineural invasion identified.
Lymphatic invasion:  Present.
Venous invasion:  Not identified.
Resection margins:  Clear.
Distance to mucosal margin:  
- 0.4 cm from the superior and 0.7 cm from the inferior margin.
Distance to closest radial margin:  0.3 cm.
Regional lymph nodes:  Not assessed.
Distant metastasis:  Not assessed.
Indications for MMR (MSI) testing: Not indicated.  
Special procedures:  None.
Other findings:  None.
Pathologic grade and stage:  G2, pT2, pNX, Stage I (if N0 M0).",,"GrossDescription:
Specimen:  Oriented, irregular segment of mucosal tissue.
Weight:  5 gm.
Number of segments:  1.
Size:  4.2 x 3.5 x 1.4 cm.
Orientation/inked margins:  
   Suture - inferior margin
   Superior   green
   Inferior   blue
   Right   red
   Left   yellow
   Deep - black
Gross findings:  2.3 x 1.9 cm tan-red ulcerated lesion with raised edges 0.4 cm from superior, 0.7 cm from inferior, 0.8 cm from right and 0.7 cm from left margins.
Submitted for microscopic evaluation:  All.
Cassettes:  8, right to left respectively.",,A: LEFT POSTERIOR QUADRANT,,
REG4,OTHER,0,PAT-10037660,1,REC-3000638137,"ClinicalHistory:
Papillary cancer left lobe left thyroid.
Post-OperativeDiagnosis:
Papillary cancer left lobe left thyroid.
Pre-OperativeDiagnosis:
Bilateral total thyroidectomy.",,"PreOperativeDiagnosis:
Bilateral total thyroidectomy
PostOperativeDiagnosis:
Papillary cancer left lobe left thyroid
FinalDiagnosis:
A-B.  PAPILLARY CARCINOMA OF THYROID.
Tumor information:
Type of specimen:      Left thyroid lobectomy/part of sternothyroid muscle; right thyroid lobectomy
Tumor location:      Bilateral
Tumor size:        Left lobe - 2.5 cm
          Right lobe - 0.5 cm
Histologic type:      Papillary carcinoma
Histologic grade:      Low grade
Capsular penetration:      Present, invasion of adjacent perithyroidal soft tissue and microscopic invasion of adjacent sternothyroid muscle
Invasion of contiguous structures:  Microscopic invasion of adjacent sternothyroid muscle
Lymphovascular invasion:    Not evident
Perineural invasion:      Not evident
Resection margins:      Focal microscopic (<1.0 mm) tumor at inked surgical margin, left
Lymph node involvement:    Positive for metastasis (3 of 3 left perithyroidal nodes positive)
Stage:          pT3 N1a\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""left lobe thyroid (part of sternal thyroid muscle)"" is an excision of tan-pink to red thyroid tissue measuring 4.5 x 3.0 x 2.5 cm.  Adherent to the capsule is a fragment of tan-red skeletal muscle.  The capsule is inked blue.  Sectioning reveals a tan-red, granular cut surface with a central, poorly circumscribed tan-white nodule measuring 2.5 x 2.1 x 2.0 cm.  The nodule abuts the capsule under the overlying adherent skeletal muscle.  Further sectioning reveals a second tan-white nodule measuring 0.2 cm in greatest dimension in one pole of the specimen.  The specimen is serially sectioned and submitted entirely in blocks A1-A9.

B.  Received in formalin labeled ""right thyroid lobe"" is a tan-pink thyroid lobe measuring 4.9 x 3.0 x 2.9 cm.  The capsule appears grossly intact.  Sectioning reveals a tan-red, granular cut surface.  In the mid-portion of the specimen are two tan-pink to yellow well circumscribed nodules measuring up to 0.5 cm in greatest dimension.  Representative sections are submitted in blocks B1-B4.","MicroscopicDescription:
A.  Sections of thyroid demonstrate a papillary carcinoma with papillary architecture and atypical nuclear features of papillary neoplasia.  Carcinoma exhibits focal invasion through the thyroid capsule into adjacent perithyroidal fibrofatty soft tissue and focal microscopic invasion and adherence to adjacent skeletal muscle.  The inked margins of excision exhibit rare microscopic, <1.0 mm foci of margin involvement.  A total of three perithyroidal nodes are present, all exhibiting small foci of metastatic papillary carcinoma.  No parathyroid tissue is identified.  In addition to the main tumor, several smaller foci of papillary carcinoma are seen within other areas of the thyroid lobe.  

B.  Sections of thyroid demonstrate a focus of papillary carcinoma.  No additional lymph nodes are identified.  No parathyroid tissue is evident.","A: Left lobe thyroid (part of sternal thyroid muscle)
B: Right thyroid lobe",,
REG4,OTHER,0,PAT-10012832,2,REC-3000638199,"ClinicalHistory:
Malignant melanoma left shoulder
A. melanoma left scapula area
B. cyst.",,"FinalDiagnosis:
A.  LEFT SHOULDER LYMPH NODE (***PATH-NUMBER[1]):  
- BENIGN FIBROADIPOSE TISSUE; NO LYMPHOID TISSUE OR MALIGNANCY IDENTIFIED (229.0).
 
B.  LEFT BACK (***PATH-NUMBER[2]):  
- RECURRENT MALIGNANT MELANOMA (172.5).",,"GrossDescription:
A. Specimen:  Case received for consultation.

Materials received:
Original pathology report no.:  ***PATH-NUMBER[1].
Name of laboratory:  Pan **PLACE Pathologists, LLC.
Date of specimen:  **DATE[Dec 14 08].
Original diagnosis:  Fibrofatty tissue.
Number of slides:  2.
Number of blocks:  None.

B. Specimen:  Case received for consultation.

Materials received:
Original pathology report no.:  ***PATH-NUMBER[2].
Name of laboratory:  Pan **PLACE Pathologists, LLC.
Date of specimen:  **DATE[Oct 27 11].
Original diagnosis:  Recurrent malignant melanoma.
Number of slides:  3.
Number of blocks:  None.

Five slides returned to Clinical Laboratories of Hawaii, Department of Pathology.  One block requested for molecular studies.","MicroscopicDescription:
A.  Sections of fibroadipose soft tissue show patchy areas of fibrosis.  No lymphoid tissues identified.  No melanocytic lesion or malignancy is observed.
 
B.  Sections show a nodular, circumscribed area which sheets of epithelioid, atypical melanocytes. The lesion measures 9 mm in greatest dimension. Immunohistochemical studies mark epithelioid cells positive for S100 and Melan-A.  No overlying epidermis is identified.  The lesion extends to the edges of the biopsy.","A: LEFT SHOULDER LYMPH NODE (SLIDE REVIEW ***PATH-NUMBER[1])
B: LEFT BACK (SLIDE REVIEW ***PATH-NUMBER[2])",,"Interpretation:

Specimen request made on ***PATH-NUMBER[2] on **DATE[Dec 13 11].
By:  **NAME[ZZZ YYY], MD
Request:  BRAF Mutation Analysis and C-Kit send to Clarient."
REG4,OTHER,0,PAT-10043134,1,REC-3000639827,"ClinicalHistory:
Lymphoma.",,"FinalDiagnosis:

A, B.  Left iliac crest, bone marrow biopsy and aspirate:
  Marrow positive for involvement by a CD5-negative, CD10-negative mature B-cell Lymphoma   (see comments).


Comment:  The marrow shows numerous CD20-positive, non-paratrabecular lymphoid aggregates composed predominantly of small round lymphocytes.  

The flow cytometric analysis shows a surface kappa light chain restricted B-cell population compatible with a CD5-negative, CD10-negative B-cell lymphoproliferative disorder.  The clonal B-cells are CD20-positive, partially express CD22 and comprise 58%of the lymphocytes and 15-16% of the total cells.  They have light scatter of small lymphocytes.

The differential diagnoses includes, but is not limited to, a marginal zone lymphoma.  Rare antigenic variants of chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, and follicular lymphoma cannot be excluded by this study alone.  The degree of marrow involvement is estimated at 50% of the cellular elements.  Thorough systemic evaluation and correlation with molecular studies, if available, is recommended.  

This case discussed with Dr. **NAME[ZZZ].\X0A|",,"GrossDescription:
(A)  Received labeled with the patient's name is a blue top Vacutainer tube containing approximately 1.5 cc of blood.  The blood is centrifuged and the resulting cell pellet is submitted in one cassette.

(B)  Received in formalin labeled with the patient's name, ""bone marrow biopsy"" is a 1.5 x 0.3 x 0.3 cm core of bone.  Also present is a 1.6 x 1.6 x 0.2 cm aggregate of clotted blood.   Entirely submitted in one cassette after decalcification of bone core.","MicroscopicDescription:
Automated Blood Count
WBC      5.3    
RBC      4.69    
Hemoglobin    13.3 L    
Hematocrit    40.2    
MCV      85.8    
MCH      28.4    
MCHC      33.1    
RDW      18.3 H    
Platelet Count    89 L    

Peripheral Blood Differential 
Diff Method    Auto
Neutrophils    45
Lymphs      48 H
Monocytes    6
Eosinophils    1
Basophils    0
Neutrophils, Absolute  2.40    
Lymphs, Absolute    2.50    
Monocytes, Absolute  0.30    
Eosinophils, Absolute  0.00    
Basophils, Absolute  0.00    

Reticulocyte Count Automated
Reticulocytes    0.9    
Absolute Retic Count  0.041    
Retic, Corrected    0.8    

Peripheral blood:  The peripheral blood smear reveals normochromic, normocytic erythrocytes with unremarkable morphology.  No rouleau formation is seen.  Leukocytes are present in usual numbers in a distribution corresponding to the reported differential.  The lymphocyte population is small and large (monocytoid).   Platelets appear numerically decreased and morphologically consist of normal and large forms.

Bone marrow:  The core biopsy and particle sections show marrow with an overall estimated cellularity of 30-35%.  The marrow shows numerous collection of lymphoid aggregates (focal nonparatrabecular) composed of small round lymphocytes.  There other portions shows granulocytic and erythroid precursors showing terminal maturation.  The M:E ratio is approximately 1.  There are frequent megakaryocytes of usual appearance.  

No clusters or sheets of blasts, granulomas, fibrosis, or metastatic tumor are seen.  

The aspirate smears corroborate the histologic findings.  Granulocytic and erythroid progenitors are present at all stages without morphologic abnormality.   Lymphocytes are small and round.   Megakaryocytes are morphologically unremarkable.  There is no increase in blasts.  The bone marrow differential is as follows:

Normal (%)Patient0-1Blasts1%1-5Promyelocytes0%5-15Myelocytes, neutrophilic2%10-15Metamyelocytes, neutrophilic6%10-40Bands, neutrophilic8%10-30Segmented neutrophils12%0-3Eosinophils1%0-1Basophils0%5-15Lymphocytes39%0-1Plasma cells1%0-2Monocytes2%16-34Normoblasts29%
Iron stains show adequate stainable iron.  No ring sideroblasts are seen.

Immunohistochemical stains:
CD3     Interstitial and less than 10% in aggregates
CD5    Interstitial and in less than 5-10% in aggregates
CD10    Negative in aggregates
CD20    Positive in aggregates
CD23    Positive in aggregates
Cyclin D1  Negative.","A: Bone marrow, aspiration with iron, L iliac crest
B: Bone marrow, biopsy, L iliac crest",,
REG4,OTHER,0,PAT-10011596,1,REC-3000639967,"ClinicalHistory:
**AGE[in 70s]-year old female with multiple myeloma (***PATH-NUMBER[1], **DATE[Jul 22 11]).",,"FinalDiagnosis:
BONE MARROW, LEFT ILIAC, ASPIRATE AND BIOPSY:  PLASMA CELL MYELOMA.
DiagnosisComment:
Flow cytometric analysis reveals a kappa clonal plasma cell population (74% of all cells).  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Feb 21 2012].",,"GrossDescription:
The specimen consists of 3 grams of clotted blood and a core biopsy measuring 0.4 cm in length, and 0.2 cm in diameter.  The specimen is fixed in formalin and totally submitted.","MicroscopicDescription:
Peripheral blood:  Shows an estimated WBC count of 6-8,000, with unremarkable morphology.  No plasma cells are seen.  RBCs show mild anisopoikilocytosis with occasional dacryocytes; moderate rouleaux is present.  Platelets are decreased.

Bone marrow aspirate and biopsy touch imprint:  Smears show cellular particles, with a predominance of atypical plasma cells having prominent nucleoli (89% of all nucleated cells); binucleated and multinucleated forms are noted.  Maturing granulocytic and erythrocytic precursors are markedly decreased.

Bone marrow clot and biopsy:  Shows an estimated cellularity of > 90%, with sheets of atypical plasma cells.  Hematopoietic precursors including megakaryocytes are markedly decreased to absent.  The bony trabeculae are unremarkable.  There is no evidence of amyloid, granuloma, or metastatic tumor.
  
Iron stain:  Positive; no ring sideroblasts are seen.","A: BONE MARROW BIOPSY/ASPIRATE, LEFT ILIAC",,"Interpretation:
BONE MARROW:  KAPPA LIGHT CHAIN RESTRICTED PLASMA CELL POPULATION IDENTIFIED.

                         IMMUNOPHENOTYPIC ANALYSIS

%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
NEG   CD2    (39C1.5)  E-rosette T-cells, thymocytes, some NK cells,
                       LFA-3 receptor.
NEG   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
NEG   CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
NEG   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
NEG   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
NEG   CD14     (MY4)   Monocytes, few granulocytes.
NEG   CD19   (J3-119)  Pan B-cell, pre-B ALL.
NEG   CD20    (B9E9)   Pan B-cell.
NEG   CD22  (SJ10.1H11)Pan B-cell.
POS+  CD38  (LS198-4-3)Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
NEG   CD45    (J.33)   Pan leukocytes, LCA.
POS***CD3-56+ (NKH-1)  Natural killer cells (CD3-).
POS*  Kappa            Kappa light chain.
NEG   Lambda           Lambda light chain.
  #   cKappa           Cytoplasmic kappa light chain.
  #   cLambda          Cytoplasmic lambda light chain.

  * dim intensity
  + dim-moderate intensity
*** strong intensity
  # see comment

POPULATION REPORTED:  CD45-NEGATIVE PLASMA CELLS

COMMENT:  Flow cytometric evaluation shows an abnormal CD45-negative plasma cell population (larger in size by light scatter; 74% of all cells) which expresses CD38 and CD56, with a kappa clonal excess (dim intensity).  There is no significant expression for B-cell markers CD19, CD20, or CD22.  The immunophenotype is similar to a previous bone marrow specimen (***PATH-NUMBER[1]), and shows a clonal population of plasma cells.

Lymphocytes (3% of all cells) show a predominance of T-cells with no T-aberrancy (inverted CD4:CD8 ratio = 0.2).  B-lymphocytes (2% of lymphocytes) show no evidence of monoclonality.

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research.

46,XX(20); NORMAL FEMALE KARYOTYPE.

MYELOMA FISH PANEL:  ABNORMAL.

Fluorescence in situ hybridization (FISH) analysis of at least 200 interphase nuclei per probe was performed using a multiple myeloma specific set of FISH probes (**PLACE, IL). This study revealed multiple FISH abnormalities including: Hyperdiploidy (an increase in select chromosome copy numbers), loss of both 13q14 and 13q34 (i.e. monosomy 13 or 13q-) and 17p13.1 (p53 gene) deletion.

In addition, other signal patterns were identified for which a reference range has not been established; however, the findings are suggestive of del(5q) and loss of 14q32.
ResultsComments:
See NeoGenomics Laboratories report for additional information."
REG4,OTHER,0,PAT-01019629,3,REC-3000640031,"ClinicalHistory:
Endometrial cancer.",,"IntraoperativeDiagnosis:
A. FROZEN SECTION: Endometrial carcinoma greater than   myometrial thickness. Assessed by K. Hirata/**INITIALS.
FinalDiagnosis:
A.  UTERUS WITH CERVIX AND BILATERAL ADNEXA:
    CERVIX:  NEGATIVE FOR MALIGNANCY
    ENDOMETRIUM AND MYOMETRIUM:
1.  ENDOMETRIOID ADENOCARCINOMA, GRADE I (WELL DIFFERENTIATED) WITH DEEP MYOMETRIAL INVASION
2.  LEIOMYOMATA
    ADNEXA:  NEGATIVE FOR MALIGNANCY 
 
B.  CUL DE SAC:  NEGATIVE FOR MALIGNANCY  
 
C.  RIGHT PELVIC LYMPH NODE BIOPSY:  NEGATIVE FOR METASTASIS (0/4)  
 
D.  LEFT PELVIC LYMPH NODE BIOPSY:  POSITIVE FOR METASTASIS (1/1)  

Endometrial carcinoma information
Operative procedure:  Hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node biopsies
Tumor-histologic type:  Endometrioid adenocarcinoma
Histologic grade (FIGO I-III):  I (well differentiated)
Anatomic site:  Fundus, anterior and posterior body
Size:  5.0 x 4.5 cm
Depth of myometrial invasion:  18 mm
Myometrial thickness in area of invasion:  19 mm 
Percent of myometrial involvement:  95%
Cervical involvement:  None
Pelvic extension/metastasis:  Positive for left pelvic lymph node metastasis
Vaginal or parametrial extension/metastasis:  None
Invasion of bladder and/or bowel mucosa:  None
Peritoneal extension/metastasis beyond pelvis:  None
Vascular invasion:  None
Resection margins:  Clear
Regional lymph nodes:  1 of 5 pelvic lymph nodes positive for metastasis (1/5) (maximal dimension 2 cm, extranodal extension present)
Distant metastasis:  Unknown
Indications for MMR (MSI) testing:  None
Special procedures:  Estrogen and progesterone receptor analyses pending
Other findings:  Leiomyomata
Pelvic/peritoneal cytology results:  Negative for malignant cells (***PATH-NUMBER[1]) 
Pathologic grade and stage:  G1 pT1b pN1 (Stage IIIC1, if M0).",,"GrossDescription:
A. Specimen:  Uterus with attached cervix and bilateral adnexa, received fresh.
Weight of uterus:  124 gm.
Measurements of uterus:  8.5 x 6.5 x 3.5 cm.
Appearance of cervix:  Unremarkable.
External appearance of uterus:  Deformed.
Endometrium:
  Tumor: 
     Size:  5.0 x 4.5 cm.
     Location:  Fundus, anterior and posterior body of uterus.
     Appearance:  Tan, soft and polypoid.
     Depth of myometrial invasion (in mm):  25 mm.
     Myometrial thickness (in mm) area of invasion:  28 mm.
     Involvement of cervix:  Absent.
     Other findings:  None.
Uninvolved mucosa:  
  Thickness:  0.2 cm.
  Appearance:  Unremarkable.
Myometrium:
  Thickness:  2.8 cm.
  Appearance:  Unremarkable.
  Leiomyomas: Two leiomyomas identified measuring up to 1.3 x 0.8 cm, no hemorrhage or necrosis identified on sectioning.
Fallopian tubes:  
  Right:  9.5 x 0.6 cm, unremarkable.
  Left:  7.5 x 0.6 cm, unremarkable.
Ovaries:
  Right:  2.5 x 1.6 x 1.6 cm, multiple clear fluid-filled cysts measuring up to 0.4-cm.
  Left:  1.8 x 1.5 x 1.2 cm, 3 clear fluid-filled cysts measuring up to 0.3-cm.
Lymph nodes:  None.
Special studies:  None.
Photos: Taken.
Description of blocks for microscopic evaluation:
1  frozen section, tumor
2  cervix
3-6  tumor, full thickness sections
7-8  uninvolved endomyometrium with leiomyomas
9  right adnexa
10  left adnexa

B. Specimen:  Irregular segments of clotted blood.  
Weight:  11 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 5.0 x 4.0 cm.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  2.

C. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  5 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 3.7 x 2.5 x 1.4 cm.
Gross findings: Three lymph nodes identified measuring up to 1.7 x 1.0 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, (1-single bisected lymph node, 2-lymph nodes and fat).

D. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  6 gm.
Number of segments:  1.  
Size:  4.2 x 2.0 x 2.0 cm.
Gross findings: Single lymph node identified measuring 4.0 x 2.0 x 1.5 cm, appear entirely involved by tumor.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  1, full thickness representative section of lymph node.",,"A: UTERUS, CERVIX, BILATERAL TUBES AND OVARIES
B: CUL DE SAC
C: RIGHT PELVIC LYMPH BIOPSY
D: LEFT PELVIC LYMPH NODE BIOPSY",,"Interpretation:
ER/PR (IMMUNOPEROXIDASE, POLYMER) DakoACIS3 COMPUTER-ASSISTED MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
----------------------------------------------------------------- 
ESTROGEN RECEPTOR (1D5):             99%          STRONG POSITIVE
PROGESTERONE RECEPTOR (PGR636):      95%          STRONG POSITIVE
-----------------------------------------------------------------
Specimen/Block (Formalin-fixed Paraffin Embedded Section): A6

ER/PR studies are reported as average %positive:  Negative 0-1%;  Borderline 2-3%;  Low Positive 4-15%;  Positive 16-35%;  Strong Positive 36-100%.
These tests were developed and their performance characteristics were determined by the **INSTITUTION Pathology Laboratory.  Tests have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary."
REG4,OTHER,0,PAT-10038504,1,REC-3000640042,"ClinicalHistory:
**AGE[in 50s]-year-old female with a clinical diagnosis of acute myeloid leukemia.",,"FinalDiagnosis:
BONE MARROW (BIOPSY/ASPIRATE RIGHT ILIAC CREST):  
ACUTE MYELOID LEUKEMIA WITH t(8;21).
DiagnosisComment:
Unfortunately, no metaphases were obtained for cytogenetic analysis.

Subsequent material submitted for FISH analysis showed positive result in probe 8;21 (AML1/ETO fusion).",,"GrossDescription:
The specimen consists of 1 gram of clotted blood and a core biopsy specimen measuring 2.1 cm in length, and 0.2 cm in diameter.  The specimen is totally submitted.","MicroscopicDescription:
Peripheral blood smear:  
Shows an estimated WBC count of 2-4,000, with a 100 cell differential revealing 25 segs, 5 bands, 2 metas, 1  myelo, 1 pro, 27 blasts, 26 lymphs, and 3 monos.  Some of the blasts contain azurophilic granules, but no Auer rods are seen.  The RBCs are unremarkable.  Platelets are slightly decreased.

Bone marrow aspirate smear and touch prep:
Shows poorly-spread, poorly-stained cellular particles, with scattered megakaryocytes, including apparent atypical forms.  Due to the poor quality of the smears, a differential count could not performed.  However, scanning the slides reveals numerous blasts which appear to comprise about half of the total nucleated population.  A few maturing granulocytic and erythrocytic precursors are present.  Due to the poor quality of preparation, dyspoiesis is difficult to assess. There is no evidence of opportunistic microorganisms, granulomata, or metastatic tumor.

Bone marrow biopsy and clot section:  
Sections reveal a bone marrow biopsy that is adequate for evaluation.  Both clot and biopsy show an estimated cellularity of 70-80%, with adequate numbers of megakaryocytes.  A heterogeneous population of granulocytic and erythrocytic precursors is present, with no focal accumulation of blasts.  The bony trabeculae are thin.  There is no evidence of opportunistic microorganisms, granulomata, or metastatic tumor.

Special stains:  
Iron- Positive; no ring sideroblasts seen.",A: BONE MARROW BIOPSY/ASPIRATE RIGHT ILIAC,,"Interpretation:
POSITIVE result seen in probe 8;21
Normal results seen in probes 5,7,8,11 (MLL), 15;17, and 16(CBFB)
Nuc ish (D5S721-D5S23,CSFI5)x2(206)
Nuc ish (CEP7,D7S486)x2(200)
Nuc ish (CEP88x2)(203)
Nuc ish ETOx2),(AML1x3)(ETO con AML 1x1)(165/200)
Nuc ish (MLLx2)(241)
Nuc ish (PML,RARA)x2(205)
Nuc ish (CBFBx2)(200).

RESULT (NPM1): NEGATIVE
- NEGATIVE FOR NPM1 MUTATION BY PCR.
RESULT (FLT ITD AND FLT3 D835): NEGATIVE 
- NEGATIVE FOR FLT3 ITD MUTATION AND FLT3 D835 MUTATION BY PCR.

MOLECULAR RESULTS: NEGATIVE FOR CEBPA MUTATION BY PCR.

BONE MARROW:  
- IMMUNOPHENOTYPE CONSISTENT WITH CD33 POSITIVE ACUTE MYELOID LEUKEMIA.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
  9   CD2    (39C1.5)  E-rosette T-cells, thymocytes, some NK cells,
                       LFA-3 receptor.
  9   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 68*  CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
  4   CD5     (BL1a)   All mature T-cells, mature thymocytes, B-cell 
                       subsets.
  3   CD7     (8H8.1)  T-cells and NK cells.
  2   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  8   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
 15*  CD11b   (Bear1)  Granulocytes, monocytes, LGL, C3bi receptor.
 54*  CD13     (MY7)   Monocytes, granulocytes, CFU-C.
  3   CD14     (MY4)   Monocytes, few granulocytes.
  2   CD14     (Mo2)   Monocytes, few granulocytes.
 52+  CD15    (80H5)   Mature granulocytes, seen in Hodgkins and 
                       Reed-Sternberg cells.
  8   CD16     (3G8)   Fc gamma receptor III expressed on natural 
                       killer cells, neutrophils, basophils (CD3-).
 49*  CD19    (HD37)   Pan B-cell, pre-B ALL.
  8   CD20    (B9E9)   Pan B-cell.
 18   CD22  (SJ10.1H11)Pan B-cell.
 71** CD33 (D3HL60.251)Early myeloid progenitors, myeloid cells, AML.
 86** CD34     (581)   HPCA-2, Bone marrow progenitor cells, TdT+ 
                       cells some acute leukemias.
 13   CD36   (FA6.152) Platelets, megakaryocytes, monocytes, early 
                       erythroid cells.
 87** CD38     (T16)   Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
100*  CD45    (J.33)   Pan leukocytes, LCA.
  5   CD56    (NKH-1)  Natural killer cells (CD3-).
 19*  CD64     (22)    Monocytes, macrophages, GCSF induced 
                       neutrophils.
 82** CD71  (YDJ1.2.2) Activated T and B-lymphocytes, macrophages,
                       and erythroblasts.
 73** CD117  (104D2D1) c-Kit, AML, CML in blast crisis, absent in ALL.
  5   CD235a  (JC159)  Normal erythroid cells at all stages of 
      GlycophorinA     differentiation, neoplastic erythroblasts.
 89** HLADR (Immu-357) MHC Class II HLA-DR, B-cells, monocytes, 
                       activated T-cells.
NEG   Kappa            Kappa light chain.
NEG   Lambda           Lambda light chain.
NEG   cCD3             Cytoplasmic CD3.
NEG   cCD22            Cytoplasmic CD22.
POS*  TdT   (HT1,4,8,9)T and B lymphocyte precursors in bone marrow
                       but not in peripheral blood.
POS** MPO     (MPO-7)  Myeloperoxidase cells of granulocytic series,
                       acute myeloid leukemia.
  *dim intensity
  +dim-moderate intensity
 **moderate intensity

POPULATION REPORTED:  CD45-DIM IMMATURE MONONUCLEAR POPULATION

COMMENT:  Flow cytometric evaluation shows a CD45-dim immature mononuclear population (moderate in size by light scatter; 77% of mononuclear cells) which expresses myeloid antigens, CD13 (partial), CD33, CD117, and myeloperoxidase and the progenitor cell antigen, CD34, as well as CD11b (partial, mostly negative), CD15, CD38, CD64 (partial, mostly negative), CD71 and HLA-DR.  In addition, there is dim, partial expression for T cell marker CD4, B cell marker CD19, and TdT (partial).  There no significant expression for other surface or cytoplasmic antigens associated with T- or B-lineage differentiation.  

Peripheral blood shows that 49% of all cells are myeloblasts expressing CD34, CD117 and CD19. 

In summary, the described immunophenotypic findings are consistent with a blast population of myeloid lineage with aberrant coexpression of CD19 and a diagnosis of acute myeloid leukemia.  

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research.

KARYOTYPE: No metaphase is available for analysis.
ResultsComments:
Sent purple top for FLT-3, CEBPA, NPM 1 to Clarient."
REG4,OTHER,0,PAT-10037534,1,REC-3000640045,"ClinicalHistory:
Abnormal Pap, glandular; postmenopausal bleeding; **AGE[in 60s]-year-old female, menopausal with episode postmenopausal bleeding.  Not on hormones.  Abnormal Pap ***PATH-NUMBER[1].  Suspicious for adeno CA.  Pathologist recommended colp with bx.  CX without lesion.  ECC done.  ATTN: Dr. **NAME[ZZZ], this is a follow-up to your evaluation of her Pap.",,"FinalDiagnosis:
Endocervical curettings:    SEROUS CARCINOMA (See Comment)
 
DiagnosisComment:
The curettage shows a high grade carcinoma with a serous morphology.  Immunostains for p53 are strongly positive.  Stains for vimentin and estrogen receptor are also positive.  CEA stains are negative.

These findings support the diagnosis of a serous carcinoma.  While primary serous carcinomas of the cervix do occur, the staining pattern present, as well as the lack of any fragments showing direct involvement of cervical tissue, are more suggestive of an endometrial primary.

The biopsy findings correlate with the recent abnormal Pap smear (***PATH-NUMBER[1]).\X0A|",,"GrossDescription:
Received in formalin labeled as ""XXXXXX, ECC"" are fragments of hemorrhagic tissue and mucoid material measuring 3.0 x 1.1 x 0.2 cm in aggregate dimension.  Submitted in toto in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Endocervical curettings,,
REG4,OTHER,0,PAT-01218221,1,REC-3000640144,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->LEFT NECK MASS./r/n",,"FinalDiagnosis:
Left neck, lymph node: Metastatic papillary thyroid carcinoma./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[Nov 28 2011]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated left neck mass
Specimen:    Red-pink lobulated rubbery encapsulated portion of soft tissue (formalin)
Size:      3 x 2 x 1.8 cm
Findings:    Sectioning reveals a 1.5 x 1.5 x 1.5 cm pink-yellow lobulated lesion. Subjacent to the lesion is a 
      0.3 x 0.3 x 0.1 cm cystic cavity grossly free of any material.
Submitted/Blocks:  Entirely/5./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left neck mass, excision",,
REG4,OTHER,0,PAT-10041763,1,REC-3000640253,"ClinicalHistory:
211.3.",,"FinalDiagnosis:

A.  HEPATIC FLEXURE COLON POLYP:  TUBULAR ADENOMA. 
 
B.  TRANSVERSE COLON POLYP:  TUBULAR ADENOMA. 
 
C.  SIGMOID COLON POLYP:  TUBULAR ADENOMA. 
 
D.  RECTAL MASS BIOPSY:  MODERATELY DIFFERENTIATED ADENOCARCINOMA.",,"GrossDescription:
A. Specimen:  Pedunculated, polypoid, tan mucosal tissue.
Number of segments:  1.
Size:  1.1 x 1.0 cm.
Submitted for microscopic evaluation:  All.
Cassettes:  1, bisected.

B. Specimen:  Sessile, polypoid, tan mucosal tissue.
Number of segments:  1.
Size:  0.6 x 0.5 cm.
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Sessile, polypoid, tan mucosal tissue.
Number of segments:  1.
Size:  0.9 x 0.7 cm.
Submitted for microscopic evaluation:  All.
Cassettes:  1, bisected.

D. Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
A-C. Sections of polypoid colonic mucosa show foci of abnormal glands lined by columnar cells with high N:C ratio and nuclear pseudostratification.  There is no evidence of malignancy. 

D. Sections of ulcerated mucosa show infiltration by irregularly shaped glands lined by atypical polygonal cells with nuclear hyperchromasia, increased N:C ratio, and high mitotic activity.  The stroma is desmoplastic.","A: HEPATIC FLEXURE POLYP
B: TRANSVERSE POLYP
C: SIGMOID POLYP
D: RECTAL MASS",,
REG4,OTHER,0,PAT-10030472,1,REC-3000640308,"ClinicalHistory:
Ovarian cancer.",,"FinalDiagnosis:
PERITONEAL PORT AND CHEMO PORT (GROSS IDENTIFICATION).",,"GrossDescription:
Specimen:  White plastic Mediport with one port and attached 28.3 cm plastic tubing. Purple plastic Mediport with one port and attached 28.0 cm plastic tubing.
Weight:  22 gm.
Size:  White port   3.5 x 3.5 cm, Purple port   2.7 x 1.5 cm. 
Inscriptions:  White port   BARD 3462, Purple port   BARD 3067.
Submitted:  None, object will be saved for storage.",,A: PERITONEAL PORT AND CHEMO PORT,,
REG4,OTHER,0,PAT-10030092,2,REC-3000640384,"ClinicalHistory:
Procedure->Other (specify in Comments)
*** FNA
Clinical History/Diagnosis/Condition->FNA of bilat. thyroid nodules.  Calcified nodule LT mid thyroid, complex nodule RT mid/inf thyroid./r/n",,"FinalDiagnosis:
A.  Thyroid, left mid:  Papillary carcinoma.  
 
B.  Thyroid, right mid/inferior:  Follicular lesion, favor hyperplastic nodule./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[Dec 30 2011].  **NAME[WWW VVV], NP, was notified of the diagnosis via e-mail on **DATE[Dec 30 2011]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left thyroid   Specimen:    Multiple, tan-brown pieces of tissue (formalin)
  Aggregate:    1 x 0.3 x 0.2 cm
  Submitted/Block:    Entirely/1  

B.  Labeled:      Patient name and medical record number, designated right thyroid   Specimen:    Multiple, tan pieces of tissue (formalin)
  Aggregate:    0.7 x 0.3 x 0.2 cm
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A-B.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left mid thyroid
B: Right mid/inf thyroid",,
REG4,OTHER,0,PAT-10021356,1,REC-3000640799,"ClinicalHistory:
History of thyroid cancer, post-thyroidectomy; left thyroid bed nodule.",,"FinalDiagnosis:
LEFT THYROID BED FNA:  PAPILLARY THYROID CARCINOMA.",,"GrossDescription:
Received:  6 fixed smears for Pap stain.","MicroscopicDescription:
Cytologic preparations show a cellular yield of epithelial cells in papillary groups.  The epithelial cells contain enlarged nuclei with occasional nuclear inclusions and grooves.",A: LEFT THYROID BED FNA,,
REG4,OTHER,0,PAT-10036658,1,REC-3000653439,,,,,,,A: PERIPHERAL BLOOD,,"Interpretation:
MOLECULAR ANALYSIS FLT3 INTERNAL TANDEM DUPLICATION (ITD):
-HETEROZYOUS FOR FLT3 ITD GENE MUTATIONS (POSITIVE FOR ITD).

MOLECULAR ANALYSIS FLT3 D835 AND I836 MUTATION:
-WILD TYPE FOR FLT3 D835 AND I836 MUTATIONS (NEGATIVE FOR D835 AND I836). 

RESULTS COMMENTS

DNA was isolated and analyzed for the presence of an internal tandem duplication (ITD) in the ""juxtamembrane domain-coding region"" and mutations at the D835 and I836 codons in exon 20 in the FMS-Like Tyrosine Kinase 3 (FLT3) gene using the polymerase chain reaction and restriction enzyme digestion    

This patient is positive and heterozygous for an internal tandem duplication but negative for mutations in codons 835 and 836. The presence of this mutation has been recognized as an independent poor prognostic factor in AML.  The presence of this mutation has been recognized as an independent poor prognostic factor in AML.  Genetics counseling is recommended.  

The sensitivity of this assay for detecting a FLT3 mutation in the background of a normal population, using these primers sets, is 1 in 100 cells.  

Kottardis et al, Blood **ID-NUM, 2001  

This assay was developed and its performance characteristics were determined by The Queen's Molecular Diagnostic Laboratory.  This assay has not been cleared or approved by the U.S. Food and Drug Administration, as the FDA has determined that such clearance or approval is not necessary.  This test is for clinical purposes and should not be regarded as investigational or for research only.  This laboratory is certified under the Clinical Laboratory Improvements Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing."
REG4,OTHER,0,PAT-10037581,1,REC-3000653983,"ClinicalHistory:
Endometrial cancer.",,"FinalDiagnosis:
A.  PERITONEAL IMPLANT:  EPIPLOIC APPENDAGE WITH FAT NECROSIS
    AND CALCIFICATION; NO MALIGNANCY IDENTIFIED.

B.  RIGHT PELVIC LYMPH NODES:  8 LYMPH NODES NEGATIVE FOR
    METASTASIS.

C.  LEFT PELVIC LYMPH NODES:  10 LYMPH NODES NEGATIVE FOR
    METASTASIS.

D.  RIGHT PERIAORTIC LYMPH NODES:  2 LYMPH NODES NEGATIVE FOR
    METASTASIS.

E.  LEFT PERIAORTIC LYMPH NODES:  1 LYMPH NODE NEGATIVE FOR
    METASTASIS.
 
F.  UTERUS, CERVIX, BILATERAL ADNEXA:

    CERVIX:  CHRONIC INFLAMMATION.
    ENDOMETRIUM:  SEROUS ADENOCARCINOMA, GRADE III; ATROPHIC
      ENDOMETRIUM.
    MYOMETRIUM:  ADENOMYOSIS; LEIOMYOMA, 0.8 CM.
    OVARIES AND TUBES:  ATROPHIC CHANGES; NEGATIVE FOR MALIGNANCY.

G.  OMENTUM:  BENIGN ADIPOSE TISSUE; NO MALIGNANCY IDENTIFIED.

Endometrial carcinoma and uterine adenosarcoma information
Operative procedure:  TAH BSO, lymph node dissection, omentectomy.
Tumor-histologic type:  Serous adenocarcinoma.
Histologic grade (FIGO I-III):  Grade III.
Anatomic site:  Fundus and body.
Size:  3.2 x 2.2 cm.
Depth of myometrial invasion:  No invasion identified.
Myometrial thickness in area of invasion:  Not applicable.
Percent of myometrial involvement:  0.
Cervical involvement:  Not identified.
Pelvic extension/metastasis:  Not identified.
Vaginal or parametrial extension/metastasis:  Not identified.
Invasion of bladder and/or bowel mucosa:  Not identified.
Peritoneal extension/metastasis beyond pelvis:  Not identified.
Vascular invasion:  Not identified.
Resection margins:  Clear.
Regional lymph nodes:  0/21.
Distant metastasis:  Not assessed.
Indications for MMR (MSI) testing:  None. 
Special procedures:  ER, PR ordered.
Other findings:  None.
Pelvic/peritoneal cytology results:  Negative (***PATH-NUMBER[1]).
Pathologic grade and stage:  G3, T1a N0, stage IA.",,"GrossDescription:
A. Specimen:  Firm tan-yellow polypoid tissue.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  1.2 x 1.0 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  6 gm.
Number of segments:  2.  
Size:  Aggregating to 3.5 x 2.8 x 1.5 cm.
Gross findings: Multiple lymph nodes identified measuring up to 1.7 x 0.7 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  3, (1-2 lymph nodes, 3-fat).

C. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  8 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 4.3 x 3.3 x 1.6 cm.
Gross findings: Multiple lymph nodes identified measuring up to 2.7 x 1.1 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  3, (1-2 lymph nodes, 3-fat).

D. Specimen:    Irregular segments of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  3.  
Size:  Aggregating to 2.1 x 1.5 x 0.9 cm.
Gross findings: Two lymph nodes identified measuring up to 1.3 x 0.8 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

E. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  2 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 2.5 x 1.3 x 0.9 cm.
Gross findings: Single lymph node identified measuring 1.2 x 0.8 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

F. Specimen:  Uterus with attached cervix and bilateral adnexa.
Weight of uterus:  48 gm.
Measurements of uterus:  7.0 x 4.0 x 2.8 cm.
Appearance of cervix:  Unremarkable.
External appearance of uterus:  Unremarkable.
Endometrium:
  Tumor: 
     Size:  3.2 x 2.2 cm.
     Location:  Fundus, anterior and posterior body of uterus.
     Appearance:  Tan-pink, soft and friable.
     Depth of myometrial invasion (in mm):  No obvious myometrial invasion grossly identified.
     Myometrial thickness (in mm) area of invasion:  Not applicable.
     Involvement of cervix:  Absent.
     Other findings:  None.
Uninvolved mucosa:  
  Thickness:  0.1 cm.
  Appearance:  Unremarkable.
Myometrium:
  Thickness:  1.1 cm.
  Appearance:  Unremarkable.
  Leiomyomas: Single apparent leiomyoma identified measuring 0.8 x 0.6 cm, no hemorrhage or necrosis identified on sectioning.
Fallopian tubes:  
  Right:  3.4 x 0.4 cm, unremarkable.
  Left:  3.6 x 0.6 cm, unremarkable.
Ovaries:
  Right:  2.1 x 1.0 x 1.0 cm, unremarkable.
  Left:  1.7 x 1.1 x 0.7 cm, unremarkable.
Lymph nodes:  None identified.
Special studies:  None.
Photos: Taken.
Description of blocks for microscopic evaluation:
1  cervix
2-5  tumor, full thickness sections
6  uninvolved endomyometrium and leiomyoma
7  right adnexa
8  left adnexa

G. Specimen:  Irregular segment of omental tissue.  
Weight:  72 gm.
Number of segments:  1.  
Size:  12.0 x 8.7 x 2.2 cm.
Gross findings: No obvious mass/lesions grossly identified.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  2.",,"A: PERITONEAL IMPLANT
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE
D: RIGHT PERIAORTIC LYMPH NODE
E: LEFT PERIAORTIC LYMPH NODE
F: UTERUS, CERVIX, BILATERAL FALLOPIAN TUBES AND OVARIES
G: OMENTUM",,"Interpretation:
NO MLH1, MSH2, MSH6 OR PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA NUCLEI.

- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Normal expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

METHODS:  MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block F5.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.

ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                72%  **   STRONG POSITIVE
PROGESTERONE RECEPTOR (PGR636):         40%  **   STRONG POSITIVE
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): F5

ER/PR studies are reported as average %positive:  Negative 0-1%;  Borderline
2-3%;  Low Positive 4-15%;  Positive 16-35%;  Strong Positive 36-100%.
**The tumor cells show variable estrogen and progesterone receptor stain, ranging
from negative to strong positive.  The result given is an average of stain
intensity.
ER/PR tests were developed and their performance characteristics were determined by the **INSTITUTION Pathology Laboratory.  Tests have not been cleared or approved by the U.S. Food and Drug Administration. The FDA does not require this test to go through premarket FDA review.
ResultsComments:
Based on the four-antibody panel, there is no immunohistochemical evidence to suggest a mismatch repair deficiency or microsatellite unstable carcinoma."
REG4,OTHER,0,PAT-10039882,1,REC-3000654021,"ClinicalHistory:
Irregular bleeding.
Post-OperativeDiagnosis:
Pending pathology exam.
Pre-OperativeDiagnosis:
Endometrial curettings:.",,"PreOperativeDiagnosis:
Endometrial curettings:  
 
PostOperativeDiagnosis:
Pending pathology exam
FinalDiagnosis:
Endometrial curettings:  Endometrioid adenocarcinoma, grade I
 
DiagnosisComment:
This case will be sent for additional internal review.

A message was left at Dr. **NAME[ZZZ]'s office.\X0A|",,"GrossDescription:
Endometrial curettings:  Approximately 8 cc's of hemorrhagic and tan tissue fragments are entirely submitted in 5 cassettes.","MicroscopicDescription:
Endometrial curettings:  Sections demonstrate a mixture of architectural patterns.  A few cribriform glandular elements are noted as well as irregularly shaped glands.  Other areas demonstrate complex glands lying back to back with little to no intervening stroma.  Solid tumor areas are not appreciated.  Nuclei are large and elongated and stratified with coarse chromatin.  A few areas of well-differentiated squamous cells are also noted.",A: Endometrial curettings,,
REG4,OTHER,0,PAT-01338409,2,REC-3000654113,"ClinicalHistory:
Left retroperitoneal mass.",,"FinalDiagnosis:

Left upper quadrant retroperitoneal mass, image-guided core needle biopsy:
  PLEOMORPHIC SARCOMA (see comment).
  

Comment:  The tumor consists of highly pleomorphic cells with brisk mitotic activity.  The tumor cells are positive for vimentin (strong), CK AE1/AE3, EMA (focal), desmin (occasional cells only) and CD68 stains; negative for LCA, CD3, PAX-5, CD30, CD31, CD34, S-100 protein, Melan-A, CD117, CD1a, and calretinin stains.  PAS stain is negative for cytoplasmic inclusions.

Case discussed with Dr. **NAME[ZZZ YYY] on **DATE[Mar 9 2012].   \X0A|",,"GrossDescription:
Received in formalin labeled with the patient's name are three tan-pink and soft tissue cores measuring up to 1.8 cm in length by 
0.1 cm in diameter.  All in.  One cassette.  Also received in RPMI is a single tan-pink and soft tissue core measuring 1.5 cm in length by 0.1 cm in diameter.  Entirely submitted for Flow Cytometry.","MicroscopicDescription:
Microscopic findings support the diagnosis.",A: LUQ Mass vascular,,
REG4,OTHER,0,PAT-10008387,2,REC-3000654355,,,,,"GrossDescription:
Received:  Peripheral blood in heparin, EDTA.
From: DLS Central Lab. 
Request:  Immunophenotyping by flow cytometry.",,A: PERIPHERAL BLOOD,,"Interpretation:
PERIPHERAL BLOOD:  IMMUNOPHENOTYPE CONSISTENT WITH CD33 POSITIVE ACUTE MYELOID LEUKEMIA.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
 <1   CD2    (39C1.5)  E-rosette T-cells, thymocytes, some NK cells,
                       LFA-3 receptor.
  3   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 51*  CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
 <1   CD5     (BL1a)   All mature T-cells, mature thymocytes, B-cell 
                       subsets.
 71+  CD7     (8H8.1)  T-cells and NK cells.
  1   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  1   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
  6   CD11b   (Bear1)  Granulocytes, monocytes, LGL, C3bi receptor.
100** CD13     (MY7)   Monocytes, granulocytes, CFU-C.
  1   CD14     (MY4)   Monocytes, few granulocytes.
  1   CD14     (Mo2)   Monocytes, few granulocytes.
  9   CD15    (80H5)   Mature granulocytes, seen in Hodgkins and 
                       Reed-Sternberg cells.
  3   CD16     (3G8)   Fc gamma receptor III expressed on natural 
                       killer cells, neutrophils, basophils (CD3-).
 <1   CD19    (HD37)   Pan B-cell, pre-B ALL.
 <1   CD20    (B9E9)   Pan B-cell.
  1   CD22  (SJ10.1H11)Pan B-cell.
100** CD33 (D3HL60.251)Early myeloid progenitors, myeloid cells, AML.
 68+  CD34     (581)   HPCA-2, Bone marrow progenitor cells, TdT+ 
                       cells some acute leukemias.
 12*  CD36   (FA6.152) Platelets, megakaryocytes, monocytes, early 
                       erythroid cells.
 99** CD38     (T16)   Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
100*  CD45    (J.33)   Pan leukocytes, LCA.
  1   CD56    (NKH-1)  Natural killer cells (CD3-).
  7   CD64     (22)    Monocytes, macrophages, GCSF induced 
                       neutrophils.
 31*  CD71  (YDJ1.2.2) Activated T and B-lymphocytes, macrophages,
                       and erythroblasts.
 96** CD117  (104D2D1) c-Kit, AML, CML in blast crisis, absent in ALL.
  1   CD235a  (JC159)  Normal erythroid cells at all stages of 
      GlycophorinA     differentiation, neoplastic erythroblasts.
 98   HLADR (Immu-357) MHC Class II HLA-DR, B-cells, monocytes, 
                       activated T-cells.
NEG   Kappa            Kappa light chain.
NEG   Lambda           Lambda light chain.
NEG   cCD3             Cytoplasmic CD3.
NEG   TdT   (HT1,4,8,9)T and B lymphocyte precursors in bone marrow
                       but not in peripheral blood.
POS** MPO     (MPO-7)  Myeloperoxidase cells of granulocytic series,
                       acute myeloid leukemia.
  *dim intensity
  +dim-moderate intensity
 **moderate intensity

POPULATION REPORTED:  CD45-DIM IMMATURE MONONUCLEAR POPULATION

COMMENT:  Flow cytometric evaluation shows a CD45 (dim intensity) myeloblast population (smaller in size by light scatter, 32% of all cells) which expresses expresses myeloid antigens, CD13, CD33, CD117, and myeloperoxidase and the progenitor cell antigen, CD34 (partial), as CD38, C71 (dim, partial) and HLA-DR.  In addition, there is dim, partial expression for T cell marker, CD7 and no significant expression for TdT or other surface or cytoplasmic antigens associated with T- or B-lineage differentiation.  

There is also a CD45 (moderate intensity) abnormal monocyte population (moderate in size by light scatter; with higher side scatter characteristics, 56% of all cells) which expresses CD4 (dim), CD11b (strong), CD13 (strong), CD14 (My4, partial), CD15 (moderate), CD16 (partial), CD33, CD36 (dim-moderate), CD38, CD56 (dim, partial), CD64 (moderate), and myeloperoxidase.  There is no significant expression for CD7, CD14 (Mo2), CD34, and CD117.  

The overall findings are interpreted as showing a CD33 positive acute myeloid leukemia with monocytic features.

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research."
REG4,OTHER,0,PAT-01084870,1,REC-3000654506,"ClinicalHistory:
Bone marrow cancer.",,"FinalDiagnosis:

T11 VERTEBRAL BODY TISSUE:  METASTATIC MODERATELY DIFFERENTIATED ADENOCARCINOMA, COMPATIBLE WITH COLORECTAL PRIMARY.",,"GrossDescription:
Specimen:  Fragments of bone and soft tissue.  
Weight:  35 gm.
Number of segments:  Multiple.  
Size:  Up to 2.1 x 2 x 0.9 cm.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  3, for decalcification.",,A: T11 VERTEBRAL BODY,,
REG4,OTHER,0,PAT-01063148,2,REC-3000655169,"ClinicalHistory:
Pancreatic mass, EUS/FNA
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Pancreatic mass, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Atypical
Cytology and cell block: Atypical ductal epithelium, cannot role out malignancy.
Abundant acute inflammation.


Pancreas, endoscopic ultrasound guided fine needle aspiration biopsy:

  Specimen Adequacy:    Satisfactory for evaluation

  Interpretation:      Positive for malignancy
          Cytology and cell block: Well-differentiated adenocarcinoma (see comment).","FinalDiagnosis:

Pancreas, endoscopic ultrasound guided fine needle aspiration biopsy:

  Specimen Adequacy:    Satisfactory for evaluation

  Interpretation:      Positive for malignancy
          Cytology and cell block: Well-differentiated adenocarcinoma (see comment) 

DiagnosisComment:
The specimen is moderately cellular and shows a population of malignant glandular epithelial cells characterized by enlarged nuclei, nuclear crowding, irregular nuclear membranes and significant variation in nuclear size. The background shows abundant acute inflammatory cells and necrotic debris. These findings are diagnostic of well-differentiated adenocarcinoma. Clinical and radiographic correlation is recommended.\X0A|",,"GrossDescription:
Specimen consists of 1 air-dried and 1 fixed slides prepared by physician along with 6cc of grossly bloody, fixed fluid.

2 Physician prepped slide(s):    1 Air-dried (Diff-quik stained),    1 Fixed (Pap stained)
2 CLH/PPPL prepped slide(s):   1 Pap stained,    1 Cell block
0 Review(s) by Pathologist:.",,"A: Pancreatic mass, FNA",,
REG4,OTHER,0,PAT-10039510,1,REC-3000655250,"ClinicalHistory:
Tongue mass.",,"IntraoperativeDiagnosis:
A. FROZEN SECTION AND TOUCH PREP: Invasive squamous cell carcinoma.  Assessed by **NAME[M. ZZZ]/**INITIALS.

C. GROSS EXAM: No obvious residual tumor.  Assessed by **NAME[M. ZZZ/CCC]/RK.
FinalDiagnosis:
A.  LEFT POSTERIOR LATERAL TONGUE:  
- SQUAMOUS CELL CARCINOMA, POORLY DIFFERENTIATED.
 
B.  LEFT EPIGLOTTAL LESION, LINGUAL SURFACE:  
- LINGUAL TONSIL; NEGATIVE FOR MALIGNANCY.
 
C.  LEFT POSTERIOR LATERAL TONGUE:  
- SQUAMOUS CELL CARCINOMA, POORLY DIFFERENTIATED.
 
Oral cavity cancer information
Operative procedure:  Partial glossectomy.
Tumor-Histologic type:  Squamous cell carcinoma.
Histologic grade:  G3 - Poorly differentiated.
Anatomic site:  Left posterolateral tongue.
Size:  3.3 x 2.85 x 1.55 cm (estimated size based upon microscopic correlation with the macroscopic findings in parts A and C).
Extent of invasion:  Into the intrinsic muscles of the tongue to a depth of approximately 1.4 cm (estimated depth based upon microscopic correlation with the macroscopic findings in parts A and C).
Perineural invasion:  Present.
Vascular invasion:  Absent.
Resection margins:  Uninvolved by carcinoma (includes parts A and C).
  Superior   0.1 cm.
  Inferior   0.25 cm.
  Anterior   0.2 cm.
  Posterior   >0.5 cm.
  Deep - 0.25 cm.
Regional lymph nodes:  Not applicable.
Distant metastasis:  Not applicable.
Pathologic grade and stage:  G3 pT2 NX (stage II if N0 M0).
DiagnosisComment:
Case discussed with Dr. **NAME[YYY] on **DATE[Oct 20 2011].",,"GrossDescription:
A. Specimen:  Oriented irregular segment of soft tan tissue, received fresh.
Weight:  3 gm.
Number of segments:  1.
Dimensions:  
  Superior-inferior:  1.4 cm.
  Superficial-deep:  1 cm.
  Anterior-posterior:  2.2 cm.
Orientation/inked margins:  Specimen oriented by surgeon.
  Superior   green
  Inferior   blue
  Anterior   orange
  Posterior   black
  Deep - yellow 
Gross findings:  0.9 cm ulcerated lesion, 0.2 cm from the inferior margin, 0.3 cm from the superior margin, 0.6 cm from the anterior margin, and 1 cm from the posterior margin.
Submitted for microscopic evaluation:  All.
Cassettes:  5.
1  frozen section (superior, inferior, and deep margins)
2  frozen section (anterior and posterior margins)
3-5  remaining tissue, anterior to posterior respectively

B. Specimen:  Irregular segments of tan mucosal tissue, received in formalin.  
Weight:  Less than 1 gm.
Number of segments:  2.  
Size:  Up to 1.5 x 0.5 x 0.3 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Oriented irregular segment of soft tan tissue, received fresh.
Weight:  4 gm.
Number of segments:  1.
Dimensions:  
  Superior-inferior:  3.2 cm.
  Anterior-posterior:  4.9 cm.
  Superficial-deep:  1.8 cm.
Orientation/inked margins:  Specimen oriented by surgeon.
  Superior   green
  Inferior   blue
  Anterior   orange
  Posterior   black
  Deep - yellow
Gross findings:  3.7 x 2.5 cm crater (previous excision site).
Submitted for microscopic evaluation:  All.
Cassettes:  8, anterior to posterior; cross sections through end margins in 1, 2, 7, and 8.",,"A: LEFT POSTERIOR LATERAL TONGUE
B: LEFT EPIGLOTTAL LESION, LINGUAL SURFACE
C: LEFT POSTERIOR LATERAL TONGUE",,"ResultsComments:
Specimen request made on A4 on **DATE[Oct 22 11].
By: DR. **NAME[XXX YYY], MD
Request:  HPV High Risk to Clarient."
REG4,OTHER,0,PAT-10038554,1,REC-3000655504,Rectal bleeding.,,"A. Rectum, ""Polyp"": - LOW GRADE NEUROENDOCRINE (CARCINOID) TUMOR.    Comment: The carcinoid tumor measures 0.4 cm in greatest dimension and is present at the margins. The carcinoid cells stain positive with synaptophysin and negative with chromgranin.  No high-grade features are present.    Dr. **NAME[ZZZ YYY] was notified of the diagnosis per telephone conversation at 11:56 MST on **DATE[Mar 14 11].",,"Received is a formalin filled specimen container labeled with the patient's name, medical record number and ""colon-rectum polyp"".  It contains one portion of light tan polypoid tissue 0.5 cm. in greatest dimension.  The specimen is bisected and entirely submitted in one cassette.  (MW/mwatr **DATE[Mar 13 11] 08:06 AM)",,Gastrointestinal,,
REG4,OTHER,0,PAT-10042629,1,REC-3000655886,"ClinicalHistory:
Multiple chronic skin lesions in patient with T-cell lymphoma.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Skin punch biopsy right thigh.",,"PreOperativeDiagnosis:
Skin punch biopsy right thigh
PostOperativeDiagnosis:
Same
FinalDiagnosis:
Skin lesion right thigh:  Skin with diffuse lymphocytic infiltration (see comment)
DiagnosisComment:
The finding is suggestive of known T-cell lymphoma.  The case is sent to Dr. **NAME[ZZZ YYY] for consultation, result is pending.\X0A|",,"GrossDescription:
Specimen received I n fixative labeled with the patient's name and ""skin lesion right thigh"" consists of a 3-mm punch biopsy of white skin and a fragment of underlying tan soft tissue measuring up to 0.4 cm in maximum dimension.  The punch biopsy is bisected and along with the smaller tan fragment of tissue totally submitted in one cassette.","MicroscopicDescription:
The punch biopsy of skin shows diffuse lymphocytic infiltration in the dermis.  The lymphocytes appear monotonous.  The epidermis is not involved.","A: Right thigh, punch biopsy of skin",,"AddendumDiagnosis:
""Right Thigh Tissue ***PATH-NUMBER[1]:  Clonal Rearrangement Detected"".

Skin lesion right thigh:  CD30-positive T-cell lymphoproliferative disorder (see comments).

Comments:  The majority of the lymphoid cells are of T-cell lineage (CD2+, CD3+, CD4+, CD5+, CD7-neg, CD8-neg, CD30+, CD56-neg, ALK-neg and EMA-neg), admixed with rare B-cells (PAX-5+).  CD10 and CD21 are negative.  S-100, Melan-A, and pankeratin are negative as well.

Histologic differential diagnosis:
  Primary cutaneus ALCL (ALK-negative, EMA-negative, CD4-positive)
  Secondary ALCL from MF, Hodgkin's, etc (ALK-negative, EMA-negative)
  Lymphomatoid papulosis (ALK-negative, EMA-negative, CD4-positive)

  Less likely Peripheral T-cell lymphoma, NOS and CD30-positive mycosis fungoides (tumor stage)

Clinicopathologic correlation is suggested.
AddendumComment:
Both Dr. **NAME[XXX WWW] and Dr. **NAME[ZZZ YYY] reviewed the slides and agree with the above diagnosis.

""Comment:  A clonal T cell receptor gene rearrangement was identified by PCR.  T cell clonality can be seen in neoplastic as well as reactive processes, particularly in the setting of restricted immune responses.  The diagnosis of lymphoma cannot be made solely on this result; therefore, these results should be interpreted in the context of clinical, histologic and immunophenotypic findings.""

Addendum Diagnosis and Comment were given on the Clarient T-Cell Clonality Detection by PCR (TCR-beta and TCR-gamma PCR) Report of **DATE[May 20 2012] (Accession No. **ID-NUM)."
REG4,OTHER,0,PAT-01569318,1,REC-3000655970,"ClinicalHistory:
TRACHEOSTOMY **DATE[Jan 25 2012]
Procedure->Other (specify in Comments)
Clinical History/Diagnosis/Condition-> HX THYROID CA./r/n",,"FinalDiagnosis:
Tracheal mass:  Sclerotic tissue with a small focus of metastatic papillary thyroid carcinoma (see comment)./r/nDiagnosisComment:
The H\T\E-stained sections demonstrate fibrofatty connective tissue fragments; a focal epithelial lesion is present with cytologic details obscured by thermal artifact.  Immunohistochemical staining for thyroglobulin and TTF-1 is performed (block A2; all controls react appropriately).  The lesion demonstrates immunopositivity for both markers, supporting the diagnosis of metastatic papillary thyroid carcinoma.  Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Jan 26 12]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated tracheal mass
Specimen:    Several, pieces of red-brown tissue (formalin)
Size (aggregate):    1.8 x 1.4 x 0.4 cm
Section code:   
  Block 1:    Largest piece of tissue trisected
  Block 2:    Three remaining pieces of name./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: TRACHAEL MASS, excision",,
REG4,OTHER,0,PAT-10038787,1,REC-3000655977,"ClinicalHistory:
Lymphoma.",,"FinalDiagnosis:
CEREBROSPINAL FLUID CYTOLOGY:  FINDINGS NOT DIAGNOSTIC FOR MALIGNANCY.",,"GrossDescription:
Received:  2 ml of clear colorless fluid.
Prepared:  2 cytospin slides for DQ/Pap stain.",,A: CEREBROSPINAL FLUID CYTOLOGY,,
REG4,OTHER,0,PAT-10037852,1,REC-3000655988,"ClinicalHistory:
Bladder tumor.",,"FinalDiagnosis:
URINARY BLADDER TISSUE (TUR):  PAPILLARY UROTHELIAL CARCINOMA, LOW GRADE, WITH NO EVIDENCE OF INVASION; MUSCULARIS PROPRIA PRESENT.",,"GrossDescription:
Specimen:  Irregular segments of tan-pink rubbery tissue, received in formalin.  
Weight:  Less than 1 gm.
Number of segments:  Multiple.  
Size:  Up to 0.9 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.",,A: BLADDER TUMOR,,
REG4,OTHER,0,PAT-10032149,1,REC-3000656184,"ClinicalHistory:
Results to Dr. **NAME[ZZZ YYY]
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Greater omental mass, suspicious for mets./r/n",,"FinalDiagnosis:
Omentum:  Metastatic adenocarcinoma (see comment)./r/nDiagnosisComment:
The H\T\E-stained sections demonstrate tumor cells which form small glandular structures.  They are surrounded by fibrotic stroma; little residual adipose tissue is present.  Immunohistochemical stains are performed with appropriately reacting controls.  The tumor cells are positive for CDX2, cytokeratin 20, and focally for cytokeratin 7.  They are negative for PSA and TTF-1.  The morphology is consistent with metastatic carcinoma and, based on the staining pattern, the differential diagnosis includes a GI, pancreatic, or biliary primary.  Clinical correlation is required.

Case reviewed in Pathology Staff Conference on **DATE[Mar 30 11].  Shanella Valu MA, of Dr. **NAME[ZZZ YYY] s office, notified of the findings on **DATE[Mar 30 11].  Dr. **NAME[ZZZ YYY] also notified via e-mail communication on **DATE[Mar 30 11]./r/n",,"GrossDescription:
Labeled:      patient name and medical record number, designated omental biopsy per requisition only
Specimen:    pale, tan-gray cylindrical pieces of tissue (formalin)
Number:      two
Size:           measuring up to 2 x 0.1 x 0.1 cm 
Submitted/Block:    entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Omental, biopsy",,"AddendumDiagnosis:
Omentum Tissue ***PATH-NUMBER[1]:  KRAS Mutation Not Detected./r/nAddendumComment:
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA and reported by **NAME[XXX WWW], M.D. on **DATE[Nov 29 2011].   

KRAS Mutation Analysis

Genotype Results:  
Wild-type (No mutation identified)

Reference RangeMutation Detected:
Unlikely to respond to anti-EGFR therapy.Mutation Not Detected:
May respond to anti-EGFR therapy.
Comment:  No KRAS mutations were detected by PCR.  Activating mutations in BRAF (V600E), a downstream effector in the KRAS pathway, have also been described to identify patients who are unlikely to respond to anti-EGFR therapy (D. Nicolantonio et al., J Clin Oncol **DATE[Feb 10 2009]).  Additional BRAF mutational analysis can be performed, if clinically indicated (please call  **PHONE to order this test).

Methodology:  Tumor areas were identified, selectively microdissected and lysed, and DNA extracted.  Real-time PCR using eight primer sets was used to amplify the region of the KRAS gene containing codons 12 and 13.  A set of eight probes was used to specifically detect the wild-type and mutant sequences.

Intended Use:  The KRAS mutation analysis by real-time PCR detects the wild-type sequence and seven known mutations associated with codons 12 and 13 of the KRAS oncogene.  This assay is capable of detecting a mutation to 1% in a background of wild-type alleles.  The intended use of this assay is to aid the treating physician in the selection of the appropriate therapy for the patient.  Tumors harboring a KRAS mutation show relative insensitivity to anti-tyrosine kinase receptor therapies that signal through the RAS/RAF pathway.  The results of this study are to be interpreted in context with other clinical findings in patient care management

Prognostic and predictive testing should be interpreted in the context of additional clinical and/or histopathological findings.

This assay was developed and its performance characteristics were determined by **INSTITUTION.  Pursuant to the requirements of CLIA  88, this laboratory has established the test s accuracy and precision.  It has not been cleared or approved by the U.S. Food and Drug Administration, as the FDA has determined that such approval is not necessary.  This test is used for clinical purposes.  The results of this study are to be interpreted in the context of all other clinical findings./r/n"
REG4,OTHER,0,PAT-10038501,1,REC-3000659189,"ClinicalHistory:
**AGE[in 60s]-year old male with AML with myelodysplasia-related changes and deletion 7 (***PATH-NUMBER[1], **DATE[Aug 15 12]).",,"FinalDiagnosis:
BONE MARROW, RIGHT ILIAC, ASPIRATE AND BIOPSY:  PERSISTENT LEUKEMIA.
DiagnosisComment:
Flow cytometric analysis cofirms an abnormal myeloblast population (21% of all nucleated cells).  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Sep 1 2012].",,"GrossDescription:
The specimen consists of 1 gram of clotted blood and a core biopsy measuring 2.7 cm in length, and 0.2 cm in diameter.  The specimen is fixed in formalin and totally submitted.","MicroscopicDescription:
Peripheral blood:  Shows an estimated WBC count of less than 1,000; no blasts are identified.  RBCs show mild non-specific anisopoikilocytosis.  Platelets are markedly decreased.

Bone marrow aspirate and biopsy touch imprint:  Smears show cellular particles, with an increase in blasts (52% of all nucleated cells).  Maturing granulocytic precursors are present including an increase in eosinophils with abnormal granules.  Erythrocytic precursors are markedly decreased to absent.

Bone marrow clot and biopsy:  Shows an estimated cellularity of 70%, with a predominance of immature mononuclear cells and granulocytic precursors including numerous eosinophils.  Erythrocytic precursors are markedly decreased to absent.  Megakaryocytes are present, but decreased.  The bony trabeculae are unremarkable.  There is no evidence of granuloma or metastatic tumor.
  
Iron stain:  Positive; no ring sideroblasts are seen.",A: BONE MARROW BIOPSY/ASPIRATE RIGHT ILIAC,,
REG4,OTHER,0,PAT-01311323,2,REC-3000659340,"ClinicalHistory:
Follicular thyroid carcinoma.",,"FinalDiagnosis:

A.  Completion of right thyroid:  PAPILLARY THYROID CARCINOMA.
  
Tumor information
Procedure:        Completion thyroidectomy
Tumor focality:      Single focus
Tumor laterality:      Right lobe
Tumor size:        0.4 cm
Histologic type:      Papillary carcinoma
Margins:        Not involved
Extrathyroid extension:    Not identified
AJCC TNM stage:      pT1
Other:          Benign parathyroid gland
          Thyroiditis and Adenomatous nodules
  

B.  Anterior neck dissection level 6:  Four benign lymph nodes.\X0A|",,"GrossDescription:
(A)  Received in formalin labeled ""completion of right thyroid"" is a 4.0 x 2.0 x 1.4 cm un-oriented red-tan and firm tissue with disrupted portions.  The external surfaces are inked black.  Sections show multiple tan and firm nodules ranging in size from
0.2 - 0.4 cm.  The rest of thyroid tissue is red-tan and soft to firm.  Sections are cut and submitted sequentially from one end to the opposite end.  
Entirely submitted in cassettes A1 - A5.  A 3.0 x 3.0 x 0.5 cm aggregate of red-tan and firm tissue fragments that are grossly consistent with tan and firm nodules (ranging in size from 0.5 - 0.9 cm) is separately identified.  Entirely submitted in cassettes A6 and A7.

(B)  Received in formalin labeled ""anterior neck dissection level 6"" is a single tan-pink and rubbery to firm tissue fragment measuring 2.2 x 1.2 x 0.8 cm.  The external surfaces are inked black.  Sections are tan-pink with tan and firm areas.  Entirely submitted in two cassettes.","MicroscopicDescription:
A, B.  Confirmed.","A: Completion of right thyroid
B: Anterior neck dissection level 6",,
REG4,OTHER,0,PAT-10041047,1,REC-3000659517,"ClinicalHistory:
A) Colon polyp, B) Colon tumor.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same 
FinalDiagnosis:
MICROSCOPIC DIAGNOSES:

A. Colon biopsy, 80 cm (0.5 cm sessile clinically):
  TUBULAR ADENOMA   (SEE COMMENT)

B. Rectal biopsy, 10 cm:
  MODERATELY DIFFERENTIATED ADENOCARCINOMA
DiagnosisComment:
The specimen at 80 cm has a suggestion of adenomatous enlargement of the surface nuclei, but is compromised by either cautery of crush artifact.  The specimen at 10 cm is an infiltrating adenocarcinoma with a glandular pattern predominating, lacking mucin production.  There is an inflammatory desmoplastic tissue response.  These results were called to Dr. **NAME[ZZZ] on **DATE[Jul 6 12]. \X0A|",,"GrossDescription:
Specimen A.  Received in formalin, labeled ""0.5 cm sessile at 80 cm"" are three irregular pieces of rubbery tan tissue (0.5 x 0.3 x 0.1 cm in aggregate, 0.1 to 0.3 cm in greatest dimension).  The entire specimen is submitted in A.

Specimen B.  Received in formalin, labeled ""biopsy 10 cm"" are multiple irregular pieces of rubbery tan-red tissue (0.7 x 0.6 x 0.1 cm in aggregate, 0.1 to 0.3 cm in greatest dimension).  The entire specimen is submitted in B.","MicroscopicDescription:
A-B. The microscopic findings support the diagnoses.","A: 0.5 cm sessile at 80 cm
B: Bx at 10 cm",,
REG4,OTHER,0,PAT-00925248,2,REC-3000678757,"ClinicalHistory:
782.1.",,"FinalDiagnosis:
A.  RIGHT ARM INFERIOR:  PLASMABLASTIC LYMPHOMA.
 
B.  RIGHT ARM SUPERIOR:  PLASMABLASTIC LYMPHOMA.",,"GrossDescription:
A.  Specimen:  Irregular segment of tan skin.
Weight:  Less than 1 gm.
Number of segments:  1.
Size:  0.3 x 0.3 cm.
Gross findings:  0.3 x 0.3 cm gray-tan papule, abutting margins.
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Cylindrical segment of tan skin.
Weight:  Less than 1 gm.
Number of segments:  1.
Size:  0.3 x 0.3 cm.
Gross findings:  0.3 x 0.3 cm gray-tan papule, abutting margins.
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
A,B.  Punch biopsy of skin shows a superficial and deep diffuse infiltrate composed of atypical large lymphocytes exhibiting eccentric, vesicular nuclei with central prominent nucleoli.  Scattered mitotic figures are noted (MIB-1 shows a high proliferative index).  

Immunoperoxidase stains show positivity for LCA, CD138, MUM-1, and kappa (vs lambda) predominance.  They are negative for B-cell markers (CD20, PAX-5, CD79a), CD10, bcl-6, CD3, CD56, CD163, ALK-1, cytokeratin AE1/AE3, and melanoma markers (S-100, melan-A).  EBV (RISH) and HHV8 stains are negative.","A: RIGHT ARM INFERIOR
B: RIGHT ARM SUPERIOR",,"Interpretation:
**INSTITUTION PATHOLOGY:

A,B.  SKIN, RIGHT ARM INFERIOR AND SUPERIOR:

      - CUTANEOUS PLASMABLASTIC INFILTRATE.
      - IMMUNOSTAINS REVEAL THE MALIGNANT CELLS TO BE POSITIVE FOR CD45, CD138, CD56 
        (SMALL SUBSET), AND DEMONSTRATE KAPPA LIGHT CHAIN RESTRICTION.  Ki-67 INDICATES 
        A PROLIFERATION RATE OF APPROXIMATELY 90%."
REG4,OTHER,0,PAT-10040996,1,REC-3000678793,"ClinicalHistory:
Liver mass, left lobe; suspect pancreas CA with metastasis.
Post-OperativeDiagnosis:
Liver mass, left lobe.",,"PostOperativeDiagnosis:
Liver mass, left lobe.
FinalDiagnosis:
Liver, core needle biopsy, clinically left lobe mass :
  Moderate to poorly differentiated adenocarcinoma (see comment).
DiagnosisComment:
The patient reportedly has a pancreatic mass, and metastasis of pancreatic carcinoma is suspected clinically.  Although  other primary sites such as intrahepatic/extrahepatic biliary tract and stomach cannot be totally excluded, the histopathologic features and immunohistochemical staining pattern would be compatible with metastasis of pancreatic adenocarcinoma.",,"GrossDescription:
Received in formalin labeled ""XXXXXX, liver"" are four cores of tan to tan-white tissue measuring up to 2.0 cm in length and less than 0.1 cm in diameter.  Submitted in toto in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.

By immunohistochemical staining, the tumor is positive for cytokeratin 7 (CK7) and cytokeratin 20 (CK20), with CK20 slightly less than CK7; cytokeratin 19 (CK19), Ca19-9, and polyclonal carcinoembryonic antigen (pCEA).  The pCEA stain is membrane/cytoplasmic and does not show a canalicular pattern.  Hepar-1 shows homogenous light cytoplasmic staining with no granular staining seen.  The tumor is negative for TTF-1 (nuclear and cytoplasmic), napsin A, CDX2, prostate specific antigen, and prostatic acid phosphatase.

Note:  The slides have been referred for internal concurrence.  Dr. **NAME[ZZZ YYY] was informed of the diagnosis on **DATE[Nov 12 2011], 0845 hrs.  Dr. **NAME[XXX] Tan was informed of the diagnosis on **DATE[Nov 12 2011], 0901 hrs.",A: Liver,,
REG4,OTHER,0,PAT-10038975,1,REC-3000678801,"ClinicalHistory:
Right neck lymphoma.",Other Case Numbers: ***PATH-NUMBER[1].,"FinalDiagnosis:
Right neck lymph node:
  1.  Lymphocytes comprise 88% of the total events.
  2.  Majority population of phenotypically unremarkable peripheral T-cells having light scatter features of small to intermediate and few large cells, with an increased CD4/CD8 ratio of 17 to 1.
  3.  Minority population of surface light chain polytypic B-cells with light scatter features of small lymphocytes.
DiagnosisComment:
Similar findings may be seen in reactive/inflammatory conditions, Hodgkin s lymphoma, non-hematolymphoid lesions, and non-representative sampling.  Infrequently, peripheral T-cell lymphoma may display a ""normal"" phenotype.  Lymphomas composed of phenotypically non-descript cells or comprising a small proportion of the specimen may not appear abnormal due to obscuring of the neoplastic population by non-neoplastic cells.",,,,A: Right neck lymph node,,
REG4,OTHER,0,PAT-10041901,1,REC-3000678960,"ClinicalHistory:
R/O malignancy
Hematochezia.",,"FinalDiagnosis:

Rectum at 10 cm, biopsy:  ADENOCARCINOMA, MODERATELY DIFFERENTIATED.



Case discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jun 13 2012].",,"GrossDescription:
Received in formalin labeled ""rectal at 10 cm"" are seven tan-pink and soft tissue fragments measuring up to 0.5 cm.  Entirely submitted in one cassette.","MicroscopicDescription:
Microscopic findings support the diagnosis.",A: rectal @ 10 cm,,
REG4,OTHER,0,PAT-10041724,1,REC-3000679020,"ClinicalHistory:
Hx of pancreatic tail mass and multiple liver mets.","PhysicianNotification:
Result faxed to Dr **NAME[ZZZ] on signout (TN).","IntraoperativeDiagnosis:
Positive for tumor cells; assessed by T Namiki.
FinalDiagnosis:
LIVER MASS CT-GUIDED CNB:  METASTATIC POORLY DIFFERENTIATED ADENOCARCINOMA.
DiagnosisComment:
The staining pattern is non-specific but compatible with tumor of pancreatic primary.  Immunohistochemical staining result:
  Cytokeratin 7 - positive
  Cytokeratin 20 - negative
  CEA - negative
  CDX-2 - negative
  TTF-1 - negative
  Hepatocyte - negative
  WT-1 - negative
  GCDFP-15 - negative.",,"GrossDescription:
Received:  2 DQ stained smears.
       Tissue fragments in formalin soln. 
Submitted:  3 tissue fragments measuring up to 5 mm in length for a cell block.",,A: LIVER MASS CT-GUIDED CNB,,
REG4,OTHER,0,PAT-01492792,2,REC-3000679182,"ClinicalHistory:
Result to **NAME[ZZZ YYY]
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Liver mass right lobe./r/n",,"FinalDiagnosis:
Liver:  Established cirrhosis with hepatocellular carcinoma./r/nDiagnosisComment:
Case reviewed at Pathology Staff Conference on **DATE[Mar 14]-14/2011.  Clinical correlation is needed as to etiologic factors for the established cirrhosis which appears micronodular without fatty changes.  There is some inflammation in the thickened bridging septae without bile stasis, granulomas or other specific etiologic agents identifiable with recent hepatitis serology apparently been negative.  While there is only limited neoplastic areas represented for evaluation, the mean immunohistochemistry and morphologic features are consistent with hepatocellular carcinoma which is a risk factor for development given a background of cirrhosis.  Findings reported to Dr. **NAME[ZZZ YYY] on **DATE[Mar 14]-14/2011 at 3:30 PM./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated liver biopsy
Specimen:    Cylindrical threadlike cores of tissue (formalin)
Number:      Two
Size:           Each measuring 1.5 x 0.1 x 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
The liver core needle biopsy fragments have mostly cirrhotic liver with established cirrhosis with broad prominent bridging fibrous bands highlighted with blue staining on a trichrome stain with bile ductular proliferation separating mostly micronodular islands of hepatocytes outlined on a reticulin stain with focally thickened cords and mild anisonucleosis of hepatocytes with focal lipofuscin pigment present with scant iron on an iron stain.  Focal lymphocytes are seen at the limiting plates with focal neutrophils and rare eosinophils.  Limited small nodular focus and a scant rim of a second focus of neoplastic cells with nuclear atypia and eosinophilic to amphophilic cytoplasm are seen with suggestion of some cords of cells with rare mitotic form.   The neoplastic area appears negative for Hepar-1 and  Alpha-fetoprotein protein (AFP) but has a canalicular pattern of polyclonal CEA and CD10 expression in conjunction with increased sinusoidal staining pattern on a CD 34 preparation consistent with hepatocellular carcinoma.  The neoplastic cells are negative for MOC-31, cytokeratin 7, cytokeratin 20, TTF-1 and mucin with a mucicarmine stain examined./r/n","A: Liver, biopsy",,
REG4,OTHER,0,PAT-10040653,1,REC-3000679337,"ClinicalHistory:
Anemia, pancytopenia.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:

Peripheral blood, bone marrow aspirate, clot section and core biopsy:
  1.  Peripheral blood with pancytopenia
  2.  Mildly hypercellular marrow (40-50%) positive for morphological involvement 
       by a B-cell lymphoproliferative disorder co-expressing CD5 and CD23 (please see Comments)

Comments:
The morphological and immunophenotypic features demonstrate involvement by a monoclonal B-cell lymphoproliferative disorder, co-expressing CD5 and CD23, consistent with Small Lymphocytic Lymphoma (SLL).  The degree of involvement is estimated at approximately 5-10%.  Immunohistochemical stains for CD3, CD20, PAX5, CD5, CD10, CD23, BCL-2 and cyclin-D1 are performed on the aspirate clot section and core biopsy and are supportive.  Iron stains are also performed on the aspirate and core biopsy.  Flow cytometric analysis of the bone marrow aspirate (***PATH-NUMBER[1]) reveals a monoclonal population of B-cells with similar co-expression of CD5 and CD23.  Please see separate report for details.  Clinical correlation, with systemic evaluation for lymphadenopathy and/or flow cytometric analysis of the peripheral blood is recommended.  The results of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 17 2012].",,"GrossDescription:
Specimen A:  Received in formalin, labeled ""Rt il"" is a moderately firm tan-red core (0.7 x 0.2 x 0.2 cm).  The entire specimen is submitted in A following decalcification.

Specimen B:  Received in the fresh state, labeled ""Rt il"" are soft tan-red spicules and red material (1.7 x 0.9 x 0.5 cm in aggregate).  The entire specimen is submitted in B.",,"A: Bone marrow biopsy right iliac crest
B: Bone marrow aspirate right iliac crest with flow cytometry",,
REG4,OTHER,0,PAT-10040642,1,REC-3000679607,"ClinicalHistory:
789.5 Ascites, 401.1 Benign essential hypertension, 311 Depressive disorder not elsewhere classified, 250.52 Diabetes with ophthalmic manifestations type II or unspecified type uncontrolled, 747.61 Gastrointestinal vessel anomaly, 578.9 Hemorrhage of gastrointestinal tract unspecified, 157.9 Malignant neoplasm of pancreas part unspecified, 272.2 Mixed hyperlipidemia, 263.2 Neoplasm of uncertain behavior of ovary, 785.2 Undiagnosed cardiac murmurs.","CytologyReview:

Paracentesis fluid

  Specimen Adequacy:
Satisfactory for evaluation.

  Interpretation:
  Paracentesis fluid:
    Malignant cells present consistent with adenocarcinoma.

Comment:  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 18 2012].  

SV:dn.","FinalDiagnosis:

Paracentesis fluid

  Specimen Adequacy:
Satisfactory for evaluation.

  Interpretation:
  Paracentesis fluid:
    Malignant cells present consistent with adenocarcinoma.

Comment:  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 18 2012].  

SV:dn.",,"GrossDescription:
Same.",,A: Paracentesis fluid,,
REG4,OTHER,0,PAT-10043054,1,REC-3000679810,"ClinicalHistory:
Enlarged lymph node.",Other Case Numbers: ***PATH-NUMBER[1].,"FinalDiagnosis:
Lymph node, left axillary, biopsy:
  1.   Sample viability is suboptimal (87%), which may result in non-random cell loss, antigen       deterioration, and/or non-specific staining.

  2.  Surface kappa light chain-restricted, CD5-dim positive, CD10-negative B cell population,       comprising 8% of the total cells (see Comment).  The cells are predominantly small in size by 
    forward angle light scatter.

  Phenotype:   CD45+ / CD5+(dim) / CD19+ / CD20+ / FMC-7+ / surface kappa light chain+ 

  T cell antigens negative:    CD2, CD3, CD4, CD7, CD8
  B cell antigens negative:    Surface lambda light chain
  Other antigens negative:    CD10, CD23, CD38
  Equivocal expression:  CD22

  3.  Remaining cells are T, NK, and CD5-negative B cells, which comprise 81-85% of the total cells
    a.  Minor subset of CD4-negative, CD8-negative, CD3+ T cells (3% of total cells).
DiagnosisComment:
The surface kappa light chain-restricted B cells of the current specimen have a similar immunophenotype seen in the prior bone marrow specimen (***PATH-NUMBER[2]).  This clonal B cell population may represent chronic lymphocytic leukemia / small lymphocytic lymphoma or mantle cell lymphoma.  Please correlate with the concurrent specimen (***PATH-NUMBER[1]).",,,,A: Left axillary node,,
REG4,OTHER,0,PAT-10040591,1,REC-3000682562,"ClinicalHistory:
238.2
**AGE[in 30s]-year-old male with 2.5 year HX of slowly growing tender red lesion R anterior thigh 17 mm x 22 mm  irregular shaped nodular lesion, full thickness  sample taken from medial edge of lesion to fat.
5 mm punch biopsy to fat, 3-0 nylon suture x 1 mattress suture, blood loss less than 1 Ml.
DDX: BCC, vs Keloid vs benign lesion R/O B-cell lymphoma.
Procedure->Punch
Clinical History/Diagnosis/Condition->**AGE[in 30s]-year-old male with 2.5 year HX of slowly growing tender red lesion R anterior thigh 
17 mm X 22 mm, 5 mm punch biopsy medial edge irregular shaped nodular lesion, DDX: BCC, vs Keloid vs benign lesion R/O 
B-cell lymphoma./r/n",,"FinalDiagnosis:
Skin, right anterior thigh:  Atypical infiltrate consistent with cutaneous involvement by classical Hodgkin lymphoma (see comment)./r/nDiagnosisComment:
The morphologic features and immunoprofile of this case are consistent with cutaneous involvement by classical Hodgkin lymphoma.  Given the rarity of this diagnosis, the case has been forwarded to Dr. **NAME[ZZZ YYY], Professor and **NAME[CCC] of **NAME[DDD] at Oregon Health and **INSTITUTION, for her expert opinion.  Once received, her consultative report will be issued as an addendum to this report

Case reviewed in Pathology Staff Conference on **DATE[Feb 16 12] and **DATE[Feb 21 12].  The findings were discussed with **NAME[XXX WWW], PA-C on **DATE[Feb 21 12] at 3:41 a.m./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right anterior thigh
Specimen:    0.5 x 0.5 cm excised to a depth of 0.4 cm punch biopsy (formalin)
Lesion:      Ill-defined 0.3 x 0.2 x 0.1 cm pale gray focus present at the margin
Submitted/Block:    Entirely bisected/1./r/n","MicroscopicDescription:
The H\T\E-stained sections demonstrate an atypical dermal infiltrate comprised of widely scattered large atypical lymphoid cells admixed with small, mature lymphocytes, scattered histiocytes, and rare eosinophils. The atypical cells have abundant cytoplasm and nuclei with irregular contours, pale chromatin, and prominent eosinophilic nucleoli.  

To further investigate, immunohistochemical stains are performed on sections from block A1 with appropriately staining positive and negative controls.  The large atypical lymphoid cells are positive for CD30 (membranous and Golgi-staining patterns), CD15 (membranous and Golgi-staining patterns), PAX-5 (dim), and CD20 (membranous).  They are negative for BCL6, BCL2, CD10, CD45, EMA, CD3, and CD5.  No significant staining with CD21 is identified.  The interspersed small lymphocytes are a mixture of CD20-positive B-cells and CD3-positive T-cells (with a subset co-expressing CD5)./r/n","A: Right anterior thigh, punch biopsy",,"AddendumDiagnosis:
Skin, right anterior thigh, punch biopsy (**PLACE, HI, ***PATH-NUMBER[1], **DATE[Feb 14 2012]):
        Atypical lymphoid proliferation (see Note)./r/nAddendumComment:
The following results were performed at **INSTITUTION Department of Pathology and reported by 
**NAME[ZZZ YYY], M.D. on **DATE[Mar 13 2012].  The results were discussed with **NAME[EEE WWW] on **DATE[Mar 19 12] at 10:15 a.m.


Note:  We agree that the histologic appearance of the dermal infiltrate is highly suggestive of cutaneous involvement by classical Hodgkin lymphoma (CHL).  However, there are a number of features that prevent us from making a definitive diagnosis.  Both the site and the clinical history are extremely unusual for CHL, but the major impediment to establishing a definitive diagnosis is that the immunophenotype is also not completely characteristic.  All of the large cells show strong CD20 and PAX5-positivity, as well as some CD45 positivity.  CD30 staining is positive but somewhat weak for CHL, and CD15 is almost completely negative.

This is an extremely challenging case.  Since there are multiple infectious/inflammatory processes that can mimic many features of CHL, in the absence of a classic immunophenotype and in conjunction with the unusual site and clinical presentation, we are unable to make a definitive diagnosis of CHL.  There are numerous small background T-cells, as well as numerous variably-sized B-cells, but, in our opinion, the atypical lymphoid infiltrate does not meet the criteria for peripheral T-cell lymphoma or B-cell non-Hodgkin lymphoma either.  Antigen receptor PCR analyses for B-cell and T-cell clonality were performed in consideration of non-Hodgkin lymphoma and both were negative.  The case was reviewed at the **NAME[DDD FFF] Conference on **DATE[Mar 5 2012] by Drs. **NAME[VVV, UUU, TTT] and **NAME[SSS]: they concur with this interpretation.

Microscopic Description:  Hematoxylin and eosin stained sections of the skin punch biopsy show skin with a superficial to deep dense lymphocytic infiltrate restricted to the dermis and not involving the overlying epidermis.  Scattered large atypical cells with prominent nucleoli and cytoplasmic clearing/retraction resembling classical Hodgkin lymphoma lacunar cells are present.  The background infiltrate is composed of numerous small lymphocytes, histiocytes, and occasional plasma cells.

Immunohistochemical Stains:  The following immunostains were received for review from the referring institution:  CD3, CD5, CD10, CD15, CD20, CD21, CD30, CD45, BCL2, BCL6, PAX 5 and EMA.  Limited additional immunostaining were performed at OHSU, using the CD3, CD15, CD20, CD30 and PAX 5 antibodies, which showed similar staining to the outside immunostains.  The large atypical cells show the following immunophenotype:
  CD3  negative
  CD5  negative
  CD10  negative
  CD15  rare positive cells
  CD20  strongly and homogenously positive
  CD30  variably positive
  CD45  variably positive
  BCL2  negative
  BCL6  occasional positive cell
  PAX 5  strongly positive

The background small lymphocytes are mainly CD3 and CD5-positive T-cells, but there are also numerous, variably-sized B-cells in the infiltrate, highlighted by staining with the CD20 and PAX 5 antibodies.

In Situ Hybridization:  Molecular probes were used in an in situ hybridization analysis for **NAME[RRR QQQ] virus encoded mRNA.  Appropriate controls, including RNA controls, were performed and test validity confirmed.  The large atypical cells are negative for Epstein-Barr virus on the in situ hybridization analysis.

(Analyte specific reagents are used in many laboratory tests necessary for standard medical care and generally do not require FDA approval.  This test was developed and its performance characteristics determined by OHSU laboratories.  It has not been cleared or approved by the U.S. Food and Drug Administration)./r/n"
REG4,OTHER,0,PAT-10023677,1,REC-3000682794,"ClinicalHistory:
Left neck mass, 2.18 x 1.95 x 1.38 cm; history of nasopharyngeal cancer.",,"IntraoperativeDiagnosis:
Malignant; assessed and supervised by **INITIALS.
FinalDiagnosis:
LEFT NECK MASS, U/S-GUIDED FNA AND CORE NEEDLE BIOPSY:  METASTATIC NASOPHARYNGEAL CARCINOMA (CYTOKERATIN AE1/AE3 IMMUNOPEROXIDASE STAIN POSITIVE).
DiagnosisComment:
Tumor shows histologic features similar to a left nasopharyngeal mass biopsy (***PATH-NUMBER[1]).",,"GrossDescription:
Received:  1 air dried smear for DQ stain.
       6 DQ stained smears.
       tissue fragments in formalin.
Submitted:  tissue fragments for a cell block.",,A: LEFT NECK MASS U/S-GUIDED FNA/CNB,,
REG4,OTHER,0,PAT-10039021,1,REC-3000683200,"ClinicalHistory:
**AGE[in 40s]-year old male with a recent diagnosis of tonsillar follicular lymphoma (***PATH-NUMBER[1], **DATE[Mar 12 12]).",,"FinalDiagnosis:
BONE MARROW, RIGHT ILIAC, ASPIRATE AND BIOPSY:  50-60% CELLULAR MARROW WITH TRILINEAGE HEMATOPOIESIS; NEGATIVE FOR MALIGNANT LYMPHOMA.
DiagnosisComment:
Flow cytometric analysis is negative for a clonal B or abnormal T-cell population.  Plasma cells are polyclonal.",,"GrossDescription:
The specimen consists of 1 gram of clotted blood and a core biopsy measuring 2.0 cm in length, and 0.2 cm in diameter.  The specimen is fixed in formalin and totally submitted.","MicroscopicDescription:
                                     Differential count

                     Percent                                     Percent
Myeloblasts             0                Lymphocytes               6.4
Promyelocytes          2.8               Monocytes                 0.8
Myelocytes            18.4               Plasma cells             14.0
Metamyelocytes        17.2               Rubriblasts                0
Bands                 13.2               Prorubricytes             0.8
PMN's                  7.2               Rubricytes                6.0
Eosinophils            1.6               Metarubricytes           11.6
Basophils               0                Other                      0
                                         M:E ratio               3.2:1

Peripheral blood:  Shows an estimated WBC count of 6-7,000, with a 100-cell differential revealing 69 segs, 24 lymphs, 5 monos, 1 eos, and 1 baso.  No abnormal cells are seen.  RBCs show mild non-specific anisopoikilocytosis.  Platelets are numerically adequate.

Bone marrow aspirate and biopsy touch imprint:  Smears show cellular particles, with scattered megakaryocytes.  Maturing granulocytic and erythrocytic precursors show no significant dyspoiesis.  Blasts are less than 5%.  Plasma cells are mildly increased (14% of all nucleated cells), with mature morphology.

Bone marrow clot and biopsy:  Shows an estimated cellularity of 50-60%, with adequate numbers of megakaryocytes.  A heterogeneous population of granulocytic and erythrocytic precursors is present, with no focal accumulation of blasts.  No significant lymphoid infiltrates/aggregates are seen (CD20 vs CD3 immunoperoxidase stains).  Plasma cells are mildly increased (CD138 stain), without kappa or lambda predominance.  The bony trabeculae are variably thinned.  There is no evidence of granuloma or metastatic tumor.
  
Iron stain:  Positive; no ring sideroblasts are seen.","A: BONE MARROW BIOPSY/ASPIRATE, RIGHT ILIAC",,"Interpretation:
BONE MARROW:
-NO MONOCLONAL B-CELL OR IMMUNOPHENOTYPICALLY ABNORMAL T-CELL POPULATION IDENTIFIED.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
 56   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 24   CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
 39   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  4   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
 20   CD19   (J3-119)  Pan B-cell, pre-B ALL.
 19   CD20    (B9E9)   Pan B-cell.
 18   CD22  (SJ10.1H11)Pan B-cell.
 30   CD38  (LS198-4-3)Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
100***CD45    (J.33)   Pan leukocytes, LCA.
 19   CD3-56+ (NKH-1)  Natural killer cells (CD3-).
 11   Kappa            Kappa light chain.
  7   Lambda           Lambda light chain.
  #   cKappa           Cytoplasmic kappa light chain.
  #   cLambda          Cytoplasmic lambda light chain.
***strong intensity
  #see comment

POPULATION REPORTED:  CD45-BRIGHT LYMPHOID POPULATION

COMMENT:  Flow cytometric evaluation of the CD45-bright lymphoid population shows a predominance of T-lymphocytes with both CD4 and CD8 subsets (CD4:CD8 ratio=0.77), limited panel.  There is no obvious evidence of B-monoclonality.  CD3-/CD56+ natural killer cells comprise 19% of the lymphocytes.

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research."
REG4,OTHER,0,PAT-10040606,1,REC-3000683212,"ClinicalHistory:
Rule out melanoma, patient has history of melanoma.",,"FinalDiagnosis:
CENTRAL LUMBAR BACK SHAVE:  COMPOUND MELANOCYTIC NEVUS (216.5).",,"GrossDescription:
Specimen:  Irregular segment of shaved tan skin.
Weight:  Less than 1 gm.  Size:  0.8 x 0.7 cm.
Number of segments:  1.
Gross findings:  0.5 x 0.5 cm rubbery, ovoid tan papule budding margin.
Cassettes submitted for microscopic evaluation:  1, all.","MicroscopicDescription:
Sections show nests of melanocytes without significant cytologic atypia or mitotic figures are present both at the dermal-epidermal junction and in the dermis.  There is no significant architectural disorder or inflammatory response.  The melanocytes mature with depth.  The lesion extends to the edges of the biopsy.",A: CENTRAL LUMBAR BACK SHAVE,,
REG4,OTHER,0,PAT-10042941,1,REC-3000685103,"ClinicalHistory:
Rt retroperitoneal mass.  Recent bone marrow biopsy with concurrent flow noted (***PATH-NUMBER[1], ***PATH-NUMBER[2]).","CytologyReview:

FNA, Right Retroperitoneal Mass, Pap stain, Diff-Quik stain, Cellblock:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
FNA, Retroperitoneal mass:

B-CELL LYMPHOMA (SEE COMMENT).","FinalDiagnosis:

FNA, Right Retroperitoneal Mass, Pap stain, Diff-Quik stain, Cellblock:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
FNA, Retroperitoneal mass:

B-CELL LYMPHOMA (SEE COMMENT).
DiagnosisComment:
Immunohistochemistry stains are positive for LCA, CD20 and bcl-2.  Stains are negative for keratin (OSCAR), CD3, and CD10.  The findings, in concert with those noted in concurrent flow cytometry study ***PATH-NUMBER[3], are consistent with B-cell lymphoma.  

This case will be sent for confirmatory hematopathology review.",,"GrossDescription:
Cell block: 1.0 x 1.0 x 0.3 cm red/tan and soft.

Intraprocedural Assessment:
Lymphoid. Recommend flow cytometry. (**DATE[Nov 24 2011], ss).",,"A: FNA, Right retroperitoneal mass",,
REG4,OTHER,0,PAT-10043081,1,REC-3000685485,"ClinicalHistory:

Lentigo maligna melanoma.",,"IntraoperativeDiagnosis:
A. Frozen section interpretation:  Upper margin:  Free of tumor/YC
B. Frozen section interpretation:  Lower margin:  Free of tumor/YC.
FinalDiagnosis:
A.  Skin, left cheek upper margin, excision:  No atypical melanocytic proliferation
 
B.  Skin, left cheek lower margin, excision:  No atypical melanocytic proliferation.
DiagnosisComment:
Specimen signed out at **INSTITUTION **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.",,"GrossDescription:
A.  Received fresh for frozen section examination labeled ""XXXXXX, left cheek upper margin"" is an unoriented skin ellipse, measuring up to 0.8 x 0.4 x 0.2 cm in greatest dimensions.  The specimen is inked black, bisected.  Submitted entirely for frozen section examination, and subsequently submitted in cassette A.

B.  Received fresh for frozen section examination labeled ""XXXXXX, left cheek lower margin"" is an unoriented skin ellipse, measuring up to 0.7 x 0.3 x 0.2 cm in greatest dimensions.  The specimen is inked blue on the deep margin, bisected.  Submitted entirely in cassette B.","MicroscopicDescription:
A-B.  The microscopic description supports the above diagnoses.","A: Skin, left cheek upper margin
B: Skin, left cheek lower margin",,
REG4,OTHER,0,PAT-10037914,1,REC-3000696423,"ClinicalHistory:
Biliary stricture
ERCP
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS., **ROOM.","CytologyReview:

Brushing distal CBD

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Moderately differentiated adenocarcinoma.


Brushing distal CBD

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Adenocarcinoma.","FinalDiagnosis:

Brushing distal CBD

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Adenocarcinoma.
DiagnosisComment:
The specimen is mildly cellular and shows a population of cytologically atypical cells with enlarged, hyperchromatic nuclei, irregular nuclear membranes and variation in nuclear size. The concurrent bile duct biopsy shows adenocarcinoma.",,"GrossDescription:
Specimen consists of one fiber optic brush in saline.

3 CLH/PPPL prepped slide(s):  2 Pap stained,    1 Cell block.",,A: Brushing distal CBD,,
REG4,OTHER,0,PAT-10042944,1,REC-3000696588,"ClinicalHistory:
Multiple myeloma.",Other Case Numbers: ***PATH-NUMBER[1].,"FinalDiagnosis:
Bone marrow, aspirate:
  1.  Cytoplasmic kappa light chain-restricted, plasma cell population, comprising less than 0.5% of the
    total cells (see Comment).  

  Phenotype:   CD38+ / CD138+(partial) / CD19+(partial) / CD20+(partial) / cytoplasmic kappa light
    chain+ / CD10- / CD45- / CD56-

  2.  Lymphocytes comprise 14-17% of the total cells and include mixed T, NK, and polytypic B cells     without aberrant antigen co-expression or loss.
DiagnosisComment:
The flow cytometry study demonstrates a clonal plasma cell population.  If indicated, please correlate with serum M-protein levels and examine for any myeloma-related organ or tissue impairment (i.e., hypercalcemia, renal insufficiency, anemia, bone lesions) to aid with the proper plasma cell neoplasm classification.

Of note, the yield of plasma cells by flow cytometry is typically underestimated;1 and, thus, the total percentage of plasma cells should be determined via the bone marrow biopsy and aspirate.  Please also see the concurrent bone marrow biopsy (***PATH-NUMBER[1]).

Reference:
1.  Paiva B, Vidriales M, P rez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more   prognostic information than morphological assessment in myeloma patients. Haematologica. 2009;**ID-NUM.",,,,A: Bone marrow aspirate,,
REG4,OTHER,0,PAT-01041060,2,REC-3000696694,"ClinicalHistory:
Liver mass.","CytologyReview:

FNA, liver, left lower, mass, Pap stain, Diff-Quik stain, Cellblock:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
FNA, Liver mass:

POSITIVE FOR MALIGNANCY
POORLY DIFFERENTIATED CARCINOMA.","FinalDiagnosis:

FNA, liver, left lower, mass, Pap stain, Diff-Quik stain, Cellblock:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
FNA, Liver mass:

POSITIVE FOR MALIGNANCY
POORLY DIFFERENTIATED CARCINOMA.
DiagnosisComment:
Immunohistochemistry stains are positive if keratin (OSCAR) and CK7.  Stains are negative for CK20, S-100, panmelanoma marker, and LCA.  The findings are suggestive of a poorly differentiated carcinoma.  Additional stains will be examined in attempts to further characterize the malignancy.  Addendum to follow.",,"GrossDescription:
Received cell block: 0.4 x 0.5 x 0.2 cm red and soft.

INTRAPROCEDURAL ASSESSMENT:  Adequate.  (bs, **DATE[Jan 3 2012]).",,A: FNA (L) lower liver,,"AddendumDiagnosis:
FINAL DIAGNOSIS:

FNA, Liver mass:
  POORLY DIFFERENTIATED CARCINOMA (SEE COMMENT).
AddendumComment:
The findings are that of a poorly differentiated carcinoma NOS.  Adenocarcinoma is favored, however, the site of origin is not classifiable on the basis of histology.  Clinical correlation is suggested.  

In addition to the previously reported stains, immunohistochemistry staining is positive for CK7, and negative for CK20, TTF-1, ERA, CDX2 and Hepar-1.  

The findings were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jan 9 12].  Dr. **NAME[XXX WWW] is in agreement with the malignant diagnosis."
REG4,OTHER,0,PAT-10039584,1,REC-3000696705,"ClinicalHistory:
Liver mets.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Liver biopsy with US guidance.",,"PreOperativeDiagnosis:
Liver biopsy with US guidance.
PostOperativeDiagnosis:
Same, Pending pathology.
FinalDiagnosis:
Nodules, liver, US needle biopsy:  POORLY-DIFFERENTIATED ADENOCARCINOMA;
          consistent with pancreatobiliary primary (Ca19-9 positive)

Comment:  This immunoprofile is supportive of metastatic pancreatic carcinoma, or, less likely, primary hepatic cholangiocarcinoma.  A pancreatic mass is noted by imaging studies.",,"GrossDescription:
Received in formalin labeled ""liver"" are 6 cores of tan-brown to white soft tissue measuring up to 1.7 x 0.1 cm.  Submitted entirely in one block.","MicroscopicDescription:
Needle biopsies of liver exhibit scattered foci of poorly-differentiated adenocarcinoma, consisting of irregular glandular formations with prominent nuclear atypia and nuclear hyperchromasia.  Tumor cells are focally positive for intracytoplasmic mucin (Mucicarmine stain).  Immunostains are evaluated.  Malignant cells are strongly positive for CA19-9 and appear negative for Hepar-1 and CDX2.",A: Liver,,
REG4,OTHER,0,PAT-01156280,2,REC-3000696828,"ClinicalHistory:
Bladder tumor.",,"FinalDiagnosis:
URINARY BLADDER TISSUE (TUR):  UROTHELIAL CARCINOMA, HIGH GRADE, WITH INVASION OF THE LAMINA PROPRIA; MUSCULARIS PROPRIA NOT IDENTIFIED.",,"GrossDescription:
Specimen:  Multiple irregular tan?pink fragments, received in formalin. 
Weight:  3 gm.
Submitted for microscopic evaluation:  All.
Cassettes:  2.",,A: BLADDER TUMOR,,
REG4,OTHER,0,PAT-10042379,1,REC-3000696881,"ClinicalHistory:
ALL.",Other Case Numbers: ***PATH-NUMBER[1].,"FinalDiagnosis:
Bone marrow, aspirate:
  1.  CD45-partial dim positive, CD19-positive lymphoid blast population, comprising 80% of the
    total cells.  These cells are small to large in size with low side angle light scatter (see Comment).

    Phenotype:   CD45+(partial, dim) / CD34+(partial) / CD10+(partial) / CD19+ / CD20+(partial) / 
          cytoplasmic CD79a+ / cytoplasmic mu heavy chain+ / HLA-DR+

              T cell antigens negative:      CD2, CD3, CD5, CD7
              B cell antigens negative:       CD22, surface kappa and lambda light chains
              Myeloid antigens negative:     CD11c, CD13, CD14, CD33, CD41, CD42b, CD61, CD64, 
                myeloperoxidase
              Other antigens negative:        CD56, CD117


       2.  CD45-dim positive, CD19-negative blast population, comprising 2% of the total cells.  
    These cells are small to intermediate in size with low to intermediate side angle light scatter.

    Phenotype:   CD45+(dim) / CD34+(partial) / CD11c+(partial) / CD13+(partial) / CD33+(partial) / 
          CD64+ / myeloperoxidase+(heterogeneous) / cytoplasmic mu heavy chain+.

    T cell antigens negative:       CD2, CD3, CD5, CD7
              B cell antigens negative:       CD19, CD20, CD22, cytoplasmic CD79a, surface kappa and lambda
                light chains
    Myeloid antigens negative:    CD14, CD41, CD42b, CD61
    Other antigens negative:        CD10, CD56, CD117


  3.  CD45-dim positive, CD19-dim positive blast population, comprising 4% of the total cells. 
    These cells are small to intermediate in size with low to intermediate side angle light scatter.

    Phenotype:   CD45+(dim) / CD34+(partial) / CD11c+(partial) / CD13+(partial) / CD19+(dim) / 
          CD33+(partial) / CD64+ / myeloperoxidase+(heterogeneous) / cytoplasmic mu 
          heavy chain+.

    T cell antigens negative:    CD2, CD3, CD5, CD7
    B cell antigens negative:    CD20, CD22, cytoplasmic CD79a, surface kappa and lambda 
                light chains
    Myeloid antigens negative:    CD14, CD41, CD42b, CD61
    Other antigens negative:        CD10, CD56, CD117


  4.  Lymphocytes comprise 4-5% of the total cells and include mixed T, NK, NK/T, and polytypic B 
    cells without aberrant antigen co-expression or loss.
DiagnosisComment:
There are three abnormal populations detected in this bone marrow specimen.  The majority blast population (#1) comprises 32-80% of the total cells and has an immunophenotype consistent with a B lymphoblastic leukemia / lymphoma.  The remaining two populations (#2 and #3) are fewer in number (2% and 4% of the total cells, respectively) and have mixed immunophenotypic characteristics of myeloid cells and B cells.  (Population #2 co-expresses myeloperoxidase and cytoplasmic mu heavy chain.  Population #3 co-expresses myeloperoxidase, cytoplasmic mu heavy chain, and dim surface CD19.)

Collectively, the flow cytometric findings may represent 1) a B lymphoblastic leukemia / lymphoma with concurrent immature, aberrant myeloid blast populations or 2) an ""acute leukemia of ambiguous lineage,"" as defined by the 2008 World Health Organization.  If indicated, consider correlation with cytogenetics to possibly aid in classification for an acute leukemia of ambiguous lineage [i.e., mixed phenotype acute leukemia with t(9;22)(q34;q11.2); mixed phenotype acute leukemia with t(v;11q23); mixed phenotype acute leukemia, B/myeloid, NOS).

The findings are similar to the previous flow cytometric analysis of the peripheral blood (***PATH-NUMBER[2]).

***NOTE:  THIS IS AN AMENDED REPORT TO CORRECT A TYPOGRAPHICAL ERROR IN THE FIRST SENTENCE OF THE COMMENTS SECTION.  THE ORIGINAL DIAGNOSES REMAIN UNCHANGED.***.",,,,A: Bone marrow aspirate,,
REG4,OTHER,0,PAT-10039879,1,REC-3000697009,"ClinicalHistory:
BRBPR.
Post-OperativeDiagnosis:
Colon polyp.",,"PostOperativeDiagnosis:
Colon polyp.
FinalDiagnosis:
A.   Descending colon polyp, biopsy:    Tubular adenoma

B.   Rectosigmoid colon mass, biopsy:  INVASIVE ADENOCARCINOMA, Moderately differentiated.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, biopsy polyp at descending"" are 2 tan-pink fragments of mucosal lined soft tissue measuring up to 0.3 cm in greatest dimension.  Entirely in one block. 

B.  Received in formalin labeled ""XXXXXX, biopsy mass at rectosigmoid"" are multiple tan-pink fragments of mucosal lined soft tissue measuring up to 0.3 cm in greatest dimension.  Entirely in one block.","MicroscopicDescription:
A-B.   The microscopic findings support the above diagnoses. For part B, Dr. **NAME[ZZZ] concurs. Dr. **NAME[YYY] has been notified.","A: Descending colon polyp
B: Rectosigmoid colon mass biopsy",,
REG4,OTHER,0,PAT-10042300,1,REC-3000697128,"ClinicalHistory:
Leukemia.
Post-OperativeDiagnosis:
Pending pathology exam.",,"PostOperativeDiagnosis:
Pending pathology exam.
FinalDiagnosis:
Bone marrow, biopsy and aspirate:  100% CELLULAR MARROW WITH B-LYMPHOBLASTIC LEUKEMIA, 
          73% BLASTS (see comment).
DiagnosisComment:
Flow cytometric analysis performed on the bone marrow aspirate (FL11- 912), shows an increased CD34/CD19/TdT-positive, CD10/CD117-negative lymphoid blast population, consistent with B-lymphoblastic leukemia/lymphoma.",,"GrossDescription:
A.  Received in bone marrow fixative labeled ""right posterior superior iliac, **NAME[AAA] XXXXXX"" is a 2.7 x 0.5 x 0.3 cm aggregate of tan to red-brown material which is submitted entirely in one cassette.

B.  Received in bone marrow fixative labeled ""right posterior superior iliac bone biopsy, **NAME[AAA] XXXXXX"" is a 1.5 cm in length x 0.15 cm in diameter core of bone which is submitted in toto in one cassette, after decalcification.","MicroscopicDescription:
Peripheral Blood:  CBC performed on **DATE[Aug 10 2012] shows a WBC count of 12.6 K/mm3.  The differential shows 18% segs, 43% lymphocytes, 3% atypical lymphocytes, 1% monocytes, 2% eosinophils, 1% basophils, 1% metamyelocytes, and 31% blasts.  The RBC count is 4.41 M/mm3, hemoglobin 13.3 gm/dl, hematocrit 38.1%, MCV 86.4 fl, MCH 30.3 pg, MCHC 35.0 gm/dl, and platelet count 129 K/mm3.  The peripheral blood smear reveals normochromic, normocytic erythrocytes with unremarkable morphology.  No rouleau formation is seen.  Leukocytes and blasts are present in a distribution corresponding to the reported differential.  Platelets appear numerically decreased and morphologically unremarkable.  

Bone Marrow:  The aspirate smears show well-stained particles with adequate megakaryocytes.  Hematopoiesis is minimal.  The cells largely consist of blasts.  The morphology of the blast cells ranges from small, round blasts with dispersed chromatin and scanty cytoplasm, typical of L1 lymphoblasts, to larger blasts with oval to irregular hyperchromatic nuclei, and scanty deeply basophilic cytoplasm with cytoplasmic blebbing.  Single nucleoli are present in some of these larger blasts.  The core biopsy and clot section show an average cellularity of 100%.  Scattered megakaryocytes are present.  The bone marrow biopsy and clot sections are largely replaced with sheets of small blasts with round nuclei, inconspicuous nucleoli, and scanty cytoplasm.  No extrinsic cells or granulomas are seen.  The bone marrow differential is as follows (300 cells counted):
 
%Blasts73Promyelocytes/myelocytes1Metamyelocytes/bands/segs3Monocytes0Eosinophils<1Basophils0Red cell precursors6Lymphocytes17
The iron stain was unevaluable due to absent spicules.","A: Right posterior superior iliac bone marrow aspiration
B: Right posterior superior bone biopsy",,
REG4,OTHER,0,PAT-10031318,1,REC-3000697290,"ClinicalHistory:
Pancreatic CA.",,"FinalDiagnosis:
PANCREATIC STENT FOR CYTOLOGY:  FINDINGS NOT DIAGNOSTIC FOR MALIGNANCY.",,"GrossDescription:
Received:  1 stent with multiple tissue material in formalin soln.
Submitted:  Tissue material measuring up to 6 mm in length submitted for a cell block.",,A: PANCREATIC STENT FOR CYTOLOGY,,
REG4,OTHER,0,PAT-10036242,1,REC-3000697291,"ClinicalHistory:
Left inguinal lymph node 4.3 x 3.2 x 1.7 cm.",,"IntraoperativeDiagnosis:
Rare atypical cells in lymphoid background; assessed and supervised by KK/SB.
Specimen saved for FCM.
FinalDiagnosis:
LEFT INGUINAL LYMPH NODE, US-GUIDED FINE NEEDLE ASPIRATION BIOPSY:
- RARE ATYPICAL CELLS IN A BACKGROUND OF POLYMORPHOUS LYMPHOID TISSUE (SEE COMMENT).
DiagnosisComment:
The findings may represent a T-cell lymphoproliferative disorder or Hodgkin lymphoma.  Partial involvement of a lymph node by metastatic disease with associated reactive T-cell proliferation is also a consideration.  An excisional biopsy is necessary for further classification.  Dr. **NAME[ZZZ] discussed the case with Dr. **NAME[YYY] by phone on **DATE[Feb 11 12].",,"GrossDescription:
Received:  2 DQ stained smears.","MicroscopicDescription:
Cytologic preparations demonstrate abundant polymorphous lymphoid tissue with obscuring ultrasound gel.  Scattered atypical cells are identified with prominent nucleomegaly and macronucleoli.",A: LEFT INGUINAL LYMPH NODE US-GUIDED FNA,,"Interpretation:
LEFT INGUINAL LYMPH NODE:  MINUTE POPULATION OF ABNORMAL T-CELLS IDENTIFIED.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
 75   CD2    (39C1.5)  E-rosette T-cells, thymocytes, some NK cells,
                       LFA-3 receptor.
 80   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 63   CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
 73   CD5     (BL1a)   All mature T-cells, mature thymocytes, B-cell 
                       subsets.
 73   CD7     (8H8.1)  T-cells and NK cells.
 15   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  3   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
 <1   CD14     (MY4)   Monocytes, few granulocytes.
  2   CD3-16+  (3G8)   Fc gamma receptor III expressed on natural 
                       killer cells, neutrophils, basophils (CD3-).
 13   CD19   (J3-119)  Pan B-cell, pre-B ALL.
 11   CD20    (B9E9)   Pan B-cell.
 13   CD22  (SJ10.1H11)Pan B-cell.
 17   CD38     (T16)   Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
 99   CD45    (J.33)   Pan leukocytes, LCA.
  1   CD3-56+ (NKH-1)  Natural killer cells (CD3-).
 10   Kappa            Kappa light chain.
  6   Lambda           Lambda light chain.

POPULATION REPORTED:  ENTIRE LYMPHOID POPULATION

COMMENT:  Flow cytometric evaluation of the lymphoid population shows a predominance of immunophenotypically normal T-lymphocytes with both CD4 and CD8 subsets (CD4:CD8 ratio=4.2), without loss of pan-T-cells antigens.  There is also a minute abnormal T-lymphoid population (smaller in size by light scatter; 5% of all cells) which expresses CD4, CD5, and CD7 with no significant expression of CD3, CD8 or natural killer cell markers (CD3-16+, or CD3-56+).  The significance of this immunophenotypic finding is uncertain.  

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research."
REG4,OTHER,0,PAT-10040641,1,REC-3000697558,"ClinicalHistory:
577.9
Procedure->Core
Clinical History/Diagnosis/Condition->Pancreatic mass with liver lesions and adenopathy./r/n",,"FinalDiagnosis:
Liver:  Moderately differentiated adenocarcinoma./r/nDiagnosisComment:
A panel of immunohistochemical stains will be performed in an attempt to determine the primary site of origin.  An addendum report will follow.  Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Aug 12 2012].  Dr. **NAME[XXX WWW] was notified of the diagnosis via e-mail on **DATE[Aug 12 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated liver biopsy
Specimen:    Cylindrical gray-white to brown cores (formalin)
Number:      Three
Size:           Up to 1.8 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Liver, core biopsy",,"AddendumComment:
Immunohistochemical stains have been performed.  The tumor cells express cytokeratin 7, cytokeratin 20, cytokeratin 19, CA 19-9 and focally express CDX-2.  An immunostain for TTF-1 appears negative.  The morphologic and immunohistochemical findings are consistent with a pancreaticobiliary primary.  Clinical correlation is recommended.  Intradepartmental consultation with Dr. **NAME[VVV UUU TTT] on **DATE[Aug 15 2012]./r/n"
REG4,OTHER,0,PAT-10035293,1,REC-3000697562,"ClinicalHistory:
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Left upper lobe mass./r/n",,"FinalDiagnosis:
A. Lung, left upper lobe: Metastatic melanoma with extensive necrosis and hemorrhage.

  One lymph node with no definite evidence of metastatic melanoma.

  See comment.

B. Lymph nodes, left pulmonary artery region: Two lymph nodes with no definite evidence of metastatic melanoma (see comment).

C. Lymph node, hilar region: One lymph node with no definite evidence of metastatic melanoma (see comment).

D. Lymph node, left inferior pulmonary ligament region: One lymph node with no definite evidence of metastatic melanoma (see comment)./r/nDiagnosisComment:
Immunohistochemical staining for Melan A (with Giemsa counterstain) as well as melanin bleach and iron special stains, are performed on sections from blocks A5, A10, and B2. All controls react appropriately.  The lung tumor is largely necrotic with peripheral rims of intact Melan-A-positive melanoma cells, which lose their pigment with the melanin bleach stain.  Scattered iron-positive histiocytes are also present.  Lymph nodes demonstrate anthracotic pigmentation and have reactive features which include abundant sinusoidal histiocytes with bland cytologic features. Many of the histiocytes contain melanin pigments, likely acquired draining the necrotic melanotic tumor in the lung. No unequivocal melanoma cells (e.g. pigmented cells with cytologic atypia consistent with metastatic tumor) are identified in any of the lymph nodes. The lymph nodes also contain scattered histiocytes with iron pigments.

Case reviewed in Pathology Staff Conference on **DATE[Dec 14 11] and case further seen in intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Dec 15 11]./r/n",,"GrossDescription:
A.   Labeled:        Patient name and medical record number, designated left upper lobe
Specimen:      Lobe of lung  
Size:        16.1 x 10.9 x 3.7 cm  
Weight:        130.6 grams  
Description:      Purple-gray smooth to wrinkled pleura.  
Orientation:      Base and apex discernible  
Tumor:        
  Location:      Adjacent to base  
  Size:        4.5 x 3.7 x 3.3 cm  
  Description:      Solid red-brown to gray-yellow, ill-defined, focally hemorrhagic
  Extent of invasion:  
  Bronchial involvement:    None, 4.1 cm from bronchial resection margin
  Visceral pleural involvement:  None    
  Mediastinal pleural involvement:  None  
  Interlobar fissure extension:  None    
  Blood vessel invasion:    None
  Invasion of attached tissues:  None  
Additional tumors:    None
Margins:        Bronchial:      4.1 cm
  Vascular:      4.1 cm
  Parenchymal surfaces:    Pink to red-brown and spongy
  Other tissues:      Purple-gray smooth to wrinkled pleura 
Additional findings:    The tumor measures 0.5 cm from the stapled parenchymal margin. 
Lymph nodes:      One, perihilar
Section code:    
  Block A1:      Bronchial and vascular margins
  Block A2:      Stapled parenchymal margin
  Block A3:      Tumor, closest proximity to base, pleura
  Block A4:      Tumor, closest proximity to medial aspect, pleura
  Blocks A5-A8:      Tumor
  Block A9:      Uninvolved parenchyma
     Block A10:      One whole perihilar lymph node

B.   Labeled:      Patient name and medical record number, designated left pulmonary artery
Specimen:    Two, gray-black lymph nodes (formalin)
Size:      0.6 x 0.4 x 0.3 cm and 1.3 x 1.2 x 0.5 cm
Findings:    Gray-black cut surface
Submitted:     Entirely
Section code:
  Block B1:    One whole lymph node
  Block B2:     One whole lymph node, bisected

C.  Labeled:      Patient name and medical record number, designated hilar lymph node
  Specimen:    One, gray-black node (formalin)
  Size:      0.8 x 0.6 x 0.2 cm
  Submitted/Block:    Entirely/1

D.  Labeled:      Patient name and medical record number, designated left inferior pulmonary ligament
  Specimen:    One, gray-black irregular soft tissue fragment (formalin)
  Size:      1 x 0.8 x 0.3 cm
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A-D.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left upper lobe fresh, biopsy
B: Left pulmonary artery lymph node perm, biopsy
C: Hilar lymph node perm, biopsy
D: Left inferior pulmonary ligament perm, biopsy",,
REG4,OTHER,0,PAT-10016716,2,REC-3000697563,"ClinicalHistory:
172.9
Procedure->Excision
Clinical History/Diagnosis/Condition->RT sideburn melanoma, wide excision 12:00 margin./r/n",,"FinalDiagnosis:
Skin, sideburn:  Residual melanoma in situ, ulceration and scar, not involving the section edges./r/nDiagnosisComment:
The melanoma appears to be completely excised in the sections available for review./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated sideburn Specimen:    4 x 2.7 x 0.5 cm skin ellipse (formalin)
Lesion:      0.6 x 0.6 x 0.1 cm firm, gray, circumscribed slightly elevated, gray lesion
Suture:      12:00
Colors:      
  Black:      Deep and 3:00
  Blue:      9:00
Submitted/Blocks:  Entirely in several pieces, from 12:00 to 6:00/3./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right sideburn, excision",,
REG4,OTHER,0,PAT-10027102,1,REC-3000697565,,,"FinalDiagnosis:
Left superior neck lymph node, biopsy:  Minute fragments of lymph node tissue with variable crush artifact (see comment)./r/nDiagnosisComment:
The lymphoid tissue cellular constituents appear benign.  The clinical history of thyroid cancer is noted.  There is no evidence of a hematopoietic or epithelial malignancy; however, the minute size of the biopsy fragments limits evaluation.  

Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Jan 15 12]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated left superior neck node
Specimen:    Cylindrical (formalin)
Number:      Several
Size:           Measuring up to 0.1 x 0.1 x 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left superior neck node, biopsy",,
REG4,OTHER,0,PAT-10033905,2,REC-3000697594,"ClinicalHistory:
Enlarged lymph node right groin
R/O malignant lymphoma.",,"FinalDiagnosis:
RIGHT GROIN LYMPH NODE, EXCISIONAL BIOPSY:
- PARTIAL NODAL INVOLVEMENT BY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL
  LYMPHOCYTIC LYMPHOMA (CLL/SLL).
- NO MORPHOLOGIC EVIDENCE OF LARGE CELL/HIGH-GRADE TRANSFORMATION.

Lymphoma information
Operative procedure: Excisional biopsy.
Tumor histologic type: Chronic lymphocytic leukemia/small lymphocytic lymphoma.
Anatomic site: Right groin lymph node.
Immunohistochemical studies:  Performed - see microscopic description for details.
Flow cytometric analysis:  CD5/CD23-positive B-cell population with lambda light chain restriction - see addendum.
Cytogenetic studies:  Conventional karyotype and CLL FISH panel pending.
Molecular genetic studies:  Not performed.",,"GrossDescription:
Specimen:  Irregular segment of soft tan-white tissue.  
Weight:  Less than 1 gm.
Number of segments:  2.  
Size:  1.7 x 1.3 x 1 .5 cm, 1.5 x 1.0 x 0.8 cm.
Submitted for microscopic evaluation:  A portion of the specimen is saved for flow cytometric analysis and possible cytogenetic studies.  The remainder of the specimen is submitted entirely.  
Cassettes:  2.","MicroscopicDescription:
The lymph node appears to exhibit maintenance of the overall architecture including patent sinuses.  Clusters of histiocytes and foci of dendritic cell aggregates are identified, the latter with pigment consistent with dermatopathic lymphadenopathy.  No diffuse areas of transformed/large cells or significant mitotic activity is identified.

Immunohistology:  CD20 and PAX5 highlight a population of B-cells expressing BCL2, CD23 and Ki67 (10-15% of cells; higher in germinal centers) with aberrant expression of CD5 and CD43.  Cyclin D1 is negative as are CD10 and BCL6, which highlight germinal centers/follicular center cells that are BCL2 negative.  CD68 (PGM1) and S100 highlight macrophages and dendritic cells, respectively, and there is no evidence of metastatic carcinoma (cytokeratin AE1/AE3).  CD3 stains small T-cells.  Special stains for acid-fast bacilli (Kinyoun) and fungal organisms (GMS-F) are negative in the histiocytic foci.",A: RIGHT GROIN LYMPH NODE,,"Interpretation:
RIGHT GROIN LYMPH NODE:  
- CD5-POSITIVE/CD10-NEGATIVE B-CELL NON-HODGKIN LYMPHOMA CONSISTENT
  WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
 55   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 46   CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
 66*  CD5     (BL1a)   All mature T-cells, mature thymocytes, B-cell 
                       subsets.
  6   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  6   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
 <1   CD3-16+  (3G8)   Fc gamma receptor III expressed on natural 
                       killer cells, neutrophils, basophils (CD3-).
 44** CD19   (J3-119)  Pan B-cell, pre-B ALL.
 38+  CD20    (B9E9)   Pan B-cell.
 30*  CD22  (SJ10.1H11)Pan B-cell.
 15** CD23    (9P25)   Activated B-cells, B-cell subsets.
  5   CD38  (LS198-4-3)Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
 98***CD45    (J.33)   Pan leukocytes, LCA.
  1   CD3-56+ (NKH-1)  Natural killer cells (CD3-).
 11   Kappa            Kappa light chain.
 27*  Lambda           Lambda light chain.
 16   FMC7             Pan B-cell, B-cell leukemias other than CLL.
  *dim intensity
  +dim-moderate intensity
 **moderate intensity
***strong intensity

POPULATION REPORTED:  ENTIRE LYMPHOID POPULATION

COMMENT:  Flow cytometric evaluation shows an abnormal CD45-bright lymphoid population (smaller in size by light scatter; 15% of lymphocytes) that expresses CD5 (dim, partial), CD19, CD20, CD22 (dim) and CD23 with a lambda clonal excess (dim intensity).  There is no significant expression of CD10 or FMC7.  Polyclonal B-cells are also present.  The immunophenotype is similar to the previous specimen ***PATH-NUMBER[1] and is consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma.

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research.

NEOGENOMICS LABORATORIES: CLL FISH ANALYSIS

11q22.3 (ATM gene) deletion:  Negative.
17p13.1 (p53 gene) deletion:  Negative.
Trisomy 12:  Negative.
13q14.3 (RB1 gene) deletion:  Negative.
13q14.3 (homozygous RB1 gene) deletion:  Negative.
13q34 (LAMP1) deletion:  Negative.
Whole arm deletion or monosomy 13:  Negative.
CCND1(BCL1)/IGH translocation:  Negative.

FISH ANALYSIS CLL (TISSUE): NORMAL.

See NeoGenomics Laboratories report for additional information.
ResultsComments:
See NeoGenomics Laboratories report for additional information."
REG4,OTHER,0,PAT-10040120,1,REC-3000697942,"ClinicalHistory:

1. Re-ex left neck
2. Irritated nevus lipomatosus vs. skin tag at buttocks.",,"FinalDiagnosis:
A.  Skin, left neck behind left ear, re-excision:  1.  No residual lymphoma   
              2.  Resection margins are free in the planes of the sections examined. 
              3.  Healing surgical site
              4.  Suture material 

B.  Skin, left buttock, biopsy:        Consistent with nevus lipomatosus.
DiagnosisComment:
Specimen signed out at **INSTITUTION **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, left neck behind left ear"" is a roughly elliptical excision of skin with attached soft tissue, measuring up to 2.0 x 0.6 x 0.5 cm.  No orientation is provided.  Also submitted is a detached portion of fibrinous, tan to dark brown material measuring up to 1.5 x 0.8 x 0.1 cm.  The elliptical fragment is inked and sectioned.  Submitted in toto in three cassettes, with the end pieces of the ellipse in cassette #1, the remainder of the ellipse in cassette #2, and the fibrinous fragment in cassette #3.

B.    Received in formalin labeled ""XXXXXX, left buttock"" is an irregular to polypoid fragment of skin measuring up to 0.9 x 0.8 x 0.5 cm.  The apparent base of the specimen is marked with black ink.  The specimen is trisected, and submitted in toto in one cassette.","MicroscopicDescription:
A-B.  The microscopic findings support the above diagnoses.","A: Skin, left neck behind left ear
B: Skin, left buttock",,
REG4,OTHER,0,PAT-10040003,1,REC-3000698092,"ClinicalHistory:
Rectal mass, R/O malignancy.",,"FinalDiagnosis:

A.  Ascending colon polyp at 105 cm, biopsy:    Fragments of tubulovillous adenoma with focal high-
              grade dysplasia on the surface.

B.  Colon polyp at 80 cm, biopsy:      Fragments of tubulovillous adenoma.

C.  Colon polyp at 18 cm, biopsy:      Tubular adenoma.

D.  Colon mass at 14 cm, biopsy:      Tubulovillous adenoma with adenocarcinoma in situ, 
              suspicious for invasive carcinoma.",,"GrossDescription:
(A)  Received in formalin labeled ""pieces of polyp ascending colon 105 cm"" are twenty-eight tan-pink and soft tissue fragments ranging in size from 0.2 cm - 1.2 x 0.8 x 0.4 cm.  Entirely submitted in three cassettes.

(B) Received in formalin labeled ""polyp at 80 cm"" are eight tan-pink and soft tissue fragments measuring up to 0.9 cm.  Entirely submitted in one cassette.

(C)  Received in formalin labeled ""polyp at 18 cm"" is a single tan-pink and soft tissue fragment measuring 0.5 cm.  Entirely submitted in one cassette.

(D)  Received in formalin labeled ""mass starting at 14 cm"" are six tan-pink and soft tissue fragments measuring up to 0.6 cm.  Entirely submitted in one cassette.","MicroscopicDescription:
A - D.  Microscopic findings support the diagnosis.","A: Pieces of polyp ascending colon 105 cm
B: Polyp at 80 cm
C: Polyp at 18cm
D: Mass starting at 14 cm biopsy",,
REG4,OTHER,0,PAT-10000260,1,REC-3000698192,"ClinicalHistory:
SCCA thyroid.",,"FinalDiagnosis:
SPECIMEN FROM RETROPHARYNGEAL SPACE:  
METASTATIC PAPILLARY THYROID CARCINOMA X4 (UP TO 2 CM.) INVOLVING FIBROMUSCULAR TISSUE AND EXTENDING TO THE EXCISIONAL MARGIN (SEE COMMENT).
DiagnosisComment:
The metastases may represent nodal involvement.  However, no residual lymph node tissue is identified.",,"GrossDescription:

A. Specimen:  Irregular segments of rubbery tan tissue.  
Weight:  7 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 4.0 x 3.6 x 1.8 cm.
Gross findings: Four nodules measuring up to 2 cm, largest lymph node appears matted, firm and fibrotic.
Submitted for microscopic evaluation:  All.  
Cassettes:  6, (1-2 contains a bisected matted nodule, 3-4 single bisected nodules, 5-6 remaining tan tissue and smallest nodule).",,A: RETROPHARYNGEAL SPACE NODES,,
REG4,OTHER,0,PAT-10037470,1,REC-3000698428,"ClinicalHistory:
569.3 
154.1
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Rectal neoplasm./r/n",,"FinalDiagnosis:
Rectum:  Poorly differentiated adenocarcinoma with ulceration./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Nov 22 2012].  The diagnosis was called to Dr. **NAME[XXX WWW] s office (**NAME[VVV]) on **DATE[Nov 22 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated rectum Specimen:    Multiple, pale gray-tan irregular pieces of tissue (formalin)
Aggregate:    1.2 x 1 x 0.4 cm
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Rectal neoplasm, biopsy",,
REG4,OTHER,0,PAT-10041857,1,REC-3000698433,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->OTHER
*** ABDOMINAL LESION./r/n",,"FinalDiagnosis:
Pancreatic cyst, tail of pancreas, transverse colon, and spleen:

  Mucinous cystadenocarcinoma (7.8 cm); all margins negative.

  Five lymph nodes negative for metastasis (0/5).

  Pathologic stage: pT3 N0.

  See microscopic description for additional tumor information./r/nDiagnosisComment:
Case seen in intradepartmental consultation (select glass slides and the gross specimen) with Dr. **NAME[ZZZ YYY] on **DATE[Aug 21 12], and the case is further reviewed in Pathology Staff Conference on **DATE[Aug 22 12].  The findings were discussed with Dr.  **NAME[XXX WWW] on **DATE[Aug 22 12] at 4:40 p.m./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated pancreatic cyst, tail of pancreas, spleen, and 
      transverse colon
Specimen:    Distal pancreas, spleen, transverse colon, and omentum (formalin)
Size:      
  Pancreas:      9 x 6 x 2.5 cm
  Spleen:      9.1 x 7.2 x 4.5 cm
  Colon:      Length = 16.8 cm, maximal circumference = 9.1 cm 
Colors:      
  Black:      Proximal colonic margin, colonic serosa
  Blue:      Distal colonic margin  
  Red:      External pancreas
  Yellow:      Parenchymal margin
  Green:      Retroperitoneal margin.
Findings:    7.8 x 6 x 5.2 cm unilocular cystic cavity with a smooth-appearing pale inner surface without evidence of papillations or excrescences; arises from the distal pancreas.  Also present is a hematoma (approximately 5.5 x 4.5 x 2.0 cm), located immediately adjacent to the colon and cystic cavity; the hematoma shows evidence of some organization and hemorrhage into the colonic serosa with dissection of blood also into the muscularis propria and submucosa.  The colonic mucosa appears diffusely dusky and edematous; no lesions are identified.  Serial sections through the cystic cavity demonstrate a fibrotic wall with extension of fibrotic tissue into the surrounding tissues between the cavity and spleen and between the cavity and the colon segment.  Sections through the spleen are grossly unremarkable; no lesions are identified.  Several possible peripancreatic lymph nodes are identified.
Section code:
  Block 1:    Proximal and distal colonic margins
  Block 2:    Pancreatic parenchyma margin
  Blocks 3-5:    Pancreatic cyst wall
  Blocks 6-8:    Pancreatic cyst with adjacent pancreas
  Blocks 9-11:    Pancreatic cyst with adjacent colon
  Blocks 12-13:    Representative colon
  Blocks 14-15:    Pancreatic cyst with adjacent spleen
  Block 16:    Representative spleen
  Block 17:    Additional tumor and pancreas, including pancreas margin.
  Block 18-19:    Tumor closest to retroperitoneal margin.
  Block  20:    Additional representative section between cyst and spleen
  Block 21-22:    Tumor closest to retroperitoneal margin.
  Block 23:    Splenic hilar tissue including splenic artery and vein.
  Block 24-25:    Representative sections, hematoma, colon, and closest tumor.
  Block 26-27:    Possible lymph nodes
 Block 28-30:    Representative sections of the peripancreatic and pericolic fat./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.  

Carcinoma of the Endocrine Pancreas Information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Pancreatic tail/cyst.
Tumor Size: 7.8 x 6.0 x 5.2 cm.
Histologic Type: Mucinous cystadenocarcinoma.
Histologic Grade: G2   Moderately differentiated.
Microscopic Tumor Extension:  
     Tumor invades into peripancreatic soft tissues between cyst wall and spleen; spleen itself uninvolved by tumor.
     Tumor invades into peripancreatic soft tissues between cyst wall and colon; colon itself uninvolved by tumor.
Margins: Margins uninvolved by invasive carcinoma.
     Distance of invasive carcinoma from closest retroperitoneal margin: 4 mm.
Lymph-Vascular Invasion: Indeterminant; tumor is noted to invade into, but not go through, the splenic vein muscular wall.
Perineural Invasion: Present.

Pathologic Staging:
     Primary Tumor: pT3 (tumor extends beyond the pancreas but without known involvement of the celiac axis or the superior mesenteric artery)
     Regional Lymph Nodes: pN0 (no region lymph node metastasis).
          Number examined: 5
          Number involved:  0
     Distant Metastasis: Not applicable.

Additional Pathologic Findings: 
     Chronic pancreatitis with fibrosis closely surrounding the tumor; further out the pancreas is without significant histopathologic abnormality including the ducts.
     Adjacent hematoma (approximately 5.5 cm) with evidence of dissection into the muscularis propria and submucosa.
     Spleen with no significant histopathologic abnormality.
     Benign colonic mucosa with patchy submucosal hemorrhage; colonic muscular wall with patchy areas of fibrosis and inflammation./r/n","A: Pancreatic cyst, tail of pancreas, transverse colon, spleen, excision",,
REG4,OTHER,0,PAT-10041221,1,REC-3000698615,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->HEPATOCELLULAR CARCINOMA./r/n",,"IntraoperativeDiagnosis:
FS:  Atypical hepatocellular lesion C/W hepatocellular carcinoma (JME/CR)./r/nFinalDiagnosis:
A. Liver: Hepatocellular carcinoma.

B. Gallbladder: Chronic cholecystitis and cholelithiasis./r/nDiagnosisComment:
Immunohistochemical stains for CD34 and polyclonal CEA results are compatible with hepatocellular carcinoma. Case reviewed in Pathology Staff Conference on **DATE[Jun 22 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left lobe liver nodule
  Specimen:    Two, cylindrical cores of tissue (fresh)
  Size:      Aggregating to 1.2 x 0.2 x 0.1 cm
  Findings:    Frozen section done
  Submitted/Block:    Entirely as frozen section residue/1  

B.  Labeled:      Patient name and medical record number, designated gallbladder and stone
  Specimen:    Partial fragment of gallbladder tissue and black granular stone (formalin)
  Size:      
    Tissue:      2 x 2 x 0.9 cm 
    Gallbladder stone:  1 x 1 x 1 cm
  Findings:    No suspicious nodules or lesions grossly identified on the tissue.
  Submitted/Blocks:  Tissue entirely submitted/2./r/n","MicroscopicDescription:
A-B.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left liver lobe nodule frozen, excision
B: Gallbladder and stone, excision",,
REG4,OTHER,0,PAT-10041410,1,REC-3000698679,"ClinicalHistory:
Stomach ulcer.
Post-OperativeDiagnosis:
Pending.",,"PostOperativeDiagnosis:
Pending.
FinalDiagnosis:
A.  Gastric biopsy, greater curvature:    1. Mild chronic gastritis 
            2. Diff-Quik and H and E stains negative for Helicobacter
            3. Intestinal metaplasia absent
            4. Dysplasia absent
 
B.  Gastric biopsy, lesser curvature:      1. Mild chronic gastritis 
            2. Diff-Quik and H and E stains negative for Helicobacter
            3. Intestinal metaplasia absent
            4. Dysplasia absent
 
C.  Gastric biopsy, cardia:        POORLY DIFFERENTIATED NEUROENDOCRINE NEOPLASM, 
            FAVOR SMALL CELL CARCINOMA.
DiagnosisComment:
Specimen signed out at **INSTITUTION for **STREET-ADDRESS, **PLACE, HI **ZIP-CODE.",,"GrossDescription:
A.  Received in Excell tissue fixative labeled ""XXXXXX, gastric mass greater curvature"" are two pieces of tan tissue measuring up to 0.4 x 0.2 x 0.2 cm in greatest dimension.  The larger specimen is bisected, and submitted in toto in one cassette.

B.  Received in Excell tissue fixative labeled ""XXXXXX, gastric mass lesser curvature"" are four pieces of tan tissue measuring up to 0.3 x 0.2 x 0.1 cm in greatest dimension.  Submitted in toto in one cassette.

C.  Received in Excell tissue fixative labeled ""XXXXXX, gastric mass cardia lesser curvature"" are three pieces of tan tissue measuring up to 0.4 x 0.2 x 0.2 cm in greatest dimension.  The largest specimen is bisected, and submitted in toto in one cassette.","MicroscopicDescription:
A.  The microscopic description supports the above diagnoses.

B.  The microscopic description supports the above diagnoses.

C.  The hematoxylin and eosin-stained sections demonstrate fragments of oxyntic mucosa.  The lamina propria shows a mild increase in neutrophils with rare neutrophils found in the superficial epithelium.  There is an abnormal infiltrate of intermediate-sized cells with hyperchromatic nuclei found in the deeper aspect of the mucosa of one fragment.  These abnormal cells have varying nuclear contour shapes and scant cytoplasm.  Adjacent and interspersed small lymphocytes are present among the abnormal cells.  No mucosal ulceration or necrosis is seen.  Immunohistochemical stains were conducted. The abnormal cells label with CD56 and synaptophysin (weak).  The abnormal cells do not stain with chromogranin A, neuron specific enolase (NSE), Ber-EP4, cytokeratin AE1/AE3, cytokeratin 7, cytokeratin 20, polyclonal CEA, TTF-1, CDX2, PSA, CD45 (LCA), CD3, and CD138 (positive controls intact).  

Note:  Preliminary results were discussed with Dr. **NAME[M. ZZZ] on **DATE[May 22 2012].","A: Gastric biopsy mass, greater curvature
B: Gastric biopsy mass, lesser curvature
C: Gastric biopsy mass, cardia lesser curvature",,"AddendumComment:
This Addendum is created to incorporate additional immunohistochemical staining results for part C.

For Part C (cardia lesser curvature), additional immunohistochemical stains were conducted in an attempt to further characterize the neoplasm.  Unfortunately, the small amount of neoplastic cells in the original hematoxylin and eosin-stained sections does not appear in the deeper, immunohistochemically stained tissue sections (conducted for this Addendum), thereby precluding further characterization.  

The morphologic features and the prior immunohistochemical stains (i.e., CD56 and synaptophysin) suggest a poorly-differentiated neuroendocrine neoplasm, favoring small cell carcinoma.  However, in the absence of a full immunohistochemical work-up, other malignancies (i.e., atypical forms of hematopoietic neoplasms, gastrointestinal stromal tumor) cannot be definitively excluded.

If indicated, consider submission of more tissue/sampling of tumor to aid the diagnosis.  


Addendum Microscopic Description
For Part C, additional immunohistochemical staining was conducted to further characterize the neoplasm.  PAX-5, CD20, CD34, CD99 (MIC 2), CD117, TdT, S100, and Ki-67 (positive controls intact) were conducted.  However, no neoplastic cells are present for staining in the deeper tissue sections."
REG4,OTHER,0,PAT-10034777,1,REC-3000703845,"ClinicalHistory:
Bladder tumor
Multifocal transitional cell carcinoma of the bladder
[***PATH-NUMBER[1] **DATE[Jul 16 2012] - Right lung mass, FNA: Poorly differentiated carcinoma with necrotic debris. 
[***PATH-NUMBER[2] **DATE[Jul 16 2012] - Right lung mass CT needle biopsy: Poorly differentiated carcinoma. Comments: The biopsies contain fragments of a poorly differentiated carcinoma. Initial immunostain evaluation is not definite as to whether this represents primary lung carcinoma vs. metastatic urinary bladder carcinoma. Addendum comment: An additional immunostain (UroplakinIII) is evaluated. Tumor cells are negative . In final evaluation, there is no definitive immunostain support for primary lung carcinoma vs. metastatic urinary bladder carcinoma. Morphologic comparison to the previous bladder tumor (***PATH-NUMBER[3]) demonstrates similar features of poorly-differentiated, high grade carcinoma. Based on clinical presentation of a large bladder tumor with probable pelvic lymph node involvement, the current lung carcinoma is considered most consistent with metastatic urinary bladder carcinoma
[***PATH-NUMBER[3] **DATE[Jun 25 2012] - Urinary bladder tumor: Predominately hemorrhagic and necrotic material with small fragments of high-grade, poorly differentiated carcinoma, consistent with high grade urothelial carcinoma.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
Bladder tumor, transurethral resection:    High-grade urothelial carcinoma with extensive 
               necrosis.
DiagnosisComment:
The depth of invasion cannot be assessed due to extensive necrosis.",,"GrossDescription:
Received in formalin labeled ""XXXXXX, bladder tumor"" are multiple pieces of soft tan tissue, 150.0 gm, aggregating 11.4 x 11.0 x 4.3 cm.  Representative sections are submitted in eight cassettes (one cassette/20 gm of tissue).","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Bladder tumor,,
REG4,OTHER,0,PAT-10036410,1,REC-3000703963,"ClinicalHistory:
Right liver solid mass 10.5 x 10 x 9 cm seen on CT/MRI.","PhysicianNotification:
Discussed with Dr. **NAME[ZZZ] on **DATE[Aug 7 12].","IntraoperativeDiagnosis:
Atypical cells present; assessed by AOL/SB.
FinalDiagnosis:
RIGHT LIVER MASS, US-GUIDED CORE NEEDLE BIOPSY:  HEPATOCELLULAR CARCINOMA, MODERATELY DIFFERENTIATED, WITH EXTENSIVE STEATOSIS.
DiagnosisComment:
Tumor shows abnormal trabecular architecture (reticulin stain) and extensive fatty change.  Tumor cells stain positive for Hepatocyte A1.  Stains are negative for cytokeratin 20, cytokeratin 7 and CEA.  Findings discussed with hospitalist team on **DATE[Aug 7 12].",,"GrossDescription:
Received:  2 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  10 tissue fragments measuring up to 3 mm in length for a cell block.",,A: RIGHT LIVER SOLID MASS US-GUIDED CNB,,
REG4,OTHER,0,PAT-10040101,1,REC-3000704016,"ClinicalHistory:
GI bleed.
Post-OperativeDiagnosis:
Same, pending pathology.
Pre-OperativeDiagnosis:
Needle biopsies of liver masses:.",,"PreOperativeDiagnosis:
Needle biopsies of liver masses:.
PostOperativeDiagnosis:
Same, pending pathology.
FinalDiagnosis:
Liver biopsies:  Malignant neoplasm consistent with metastatic small cell carcinoma, see comment.
DiagnosisComment:
Synaptophysin and TTF1 IHC staining is requested and the results will be reported in an amendment.",,"GrossDescription:
GI bleed:  Two brown 0.2 cm tissue fragments are entirely submitted in one cassette.","MicroscopicDescription:
Liver biopsies:  Sections demonstrate groups of groups of intermediate sized cells with dark cytoplasm reminiscent of the malignancy noted in the prior esophageal biopsy (***PATH-NUMBER[1]).  Neither glandular formations nor keratin production is noted.",A: GI bleed,,
REG4,OTHER,0,PAT-10041442,1,REC-3000704135,"ClinicalHistory:
238.2
Procedure->Shave
*** Saucerization biopsy followed by thorough curettage and electrodesiccation
Clinical History/Diagnosis/Condition->Pearly pinkish telangiectatic papule with erosion
*** Rule-out BCC./r/n",,"FinalDiagnosis:
Skin, right cheek:  Melanoma, measuring approximately 1.62 mm in Breslow thickness, ulcerated, with 3 mitoses/mm2, involving the peripheral section edge (see comment)./r/nDiagnosisComment:
There is a broad, asymmetric and poorly circumscribed melanocytic neoplasm composed of nests of varying size as well as single melanocytes distributed irregularly along and above the hyperpigmented basal layer with prominent involvement of adnexal epithelium.  There are similar appearing small nests as well as single melanocytes in the adjacent fibrotic papillary dermis where there is a moderately dense superficial perivascular infiltrate of lymphocytes and scattered melanophages.  The melanocytic nuclei are large and pleomorphic and the cells have abundant pale staining cytoplasm containing melanin.   Antibodies to Melan-A, S100, and cytokeratin were examined.  There is prominent hemorrhage and telangiectatic blood vessels in the superficial dermis.  Precise Breslow thickness is difficult due to overlying epidermal disruption, prominent adnexal involvement, and inflammation.

Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[May 8 2012].
Dr. **NAME[XXX WWW] notified of results via KPHC staff message on **DATE[May 8 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right cheek
Specimen:    1.2 x 1 x 0.4 cm shaving of skin (formalin)
Lesion:      0.9 x 0.8 x 0.3 cm gray-brown elevated crusted lesion
Submitted/Blocks:  Entirely serially sectioned/2./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.  

Melanoma Information Protocol
Based on AJCC/UICC TNM, 7th edition

Tumor Site: Right cheek
Tumor Size (required only if tumor is grossly present)
  Greatest dimension: 0.9 cm
Macroscopic Satellite Nodule(s): Not present
Histologic Type: Superficial spreading
Maximum Tumor Thickness: 1.62 mm
Anatomic Level: Mid reticular dermis
Ulceration: Not present
Margin:
  Peripheral margins: Involved
  Deep margin: Not involved
Mitotic index: 3/mm2
Microsatellitosis: Not present
Lymph-Vascular Invasion: Not present
Perineural Invasion: Not present
Tumor-Infiltrating lymphocytes: Brisk
Tumor Regression: Not present
Growth Phase: Vertical
Pathologic Staging:
  Primary tumor: pT2b./r/n","A: Right cheek, shave biopsy",,
REG4,OTHER,0,PAT-10040077,1,REC-3000704183,"ClinicalHistory:

Pigmented irregular lesion
SCC.
Post-OperativeDiagnosis:
Pigmented irregular lesion.",,"PostOperativeDiagnosis:
Pigmented irregular lesion.
FinalDiagnosis:
Skin, left cheek, excision:            1.  Lentigo maligna melanoma, non-ulcerated, invasive of the dermis to a depth of 0.415 mm, coming to within 1.58 mm of the peripheral resection margin at the 2:30 position and 6.5 mm of the deep resection margin (see Synoptic Report)
                                 2.  Adjacent scar
     
SYNOPTIC REPORT:  
Histologic Type:       Lentigo maligna melanoma
Ulceration:       Absent
Depth of Invasion:       0.415 mm
Clark's Level:        IV
Primary Tumor (pT):       pT1a
Microsatellitosis:       Absent in the specimen
Lymph-Vascular Invasion:       Absent
Perineural Invasion:       Absent
Tumor Infiltrating Lymphocytes:       Focally non-brisk
Tumor Regression:       Present, involving less than 75% of lesion
Mitotic Figures:       0 (zero) mitotic figure per mm2
Additional Pathologic Findings:       None.
DiagnosisComment:
The case will be referred to Dr. **NAME[ZZZ YYY] for further consultation.

Testing performed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.",,"GrossDescription:
Received in formalin labeled ""XXXXXX, left cheek"" is an irregular to ovoid excision of skin with attached soft tissue, measuring up to 3.5 x 3.3 x 0.8 cm.  An attached suture identifies the 12 o'clock margin.  The tissue is oriented with the skin surface facing up, and inked as follows: 12-3-6 o'clock-blue, **DATE[Jan 9 13]-orange.  An irregular, pigmented lesion measuring up to 3.3 x 2.9 cm across is present along the epidermal surface.  The specimen is sectioned along the 9-3 o'clock axis, from 12 o'clock to 6 o'clock, and submitted in toto.

KEY TO CASSETTES: 
1  -  12 o'clock end piece
2-7  -  Remainder of 12 o'clock half, submitted sequentially from 12 o'clock to central
8-13  -  6 o'clock half, submitted sequentially from central to 6 o'clock
14  -  6 o'clock end piece.","MicroscopicDescription:
Sections reveal a non-ulcerated lentiginous compound melanocytic proliferation with single junctional melanocytes predominating over irregularly shaped nests.  There is focally prominent confluence of single junctional melanocytes with upward migration in focal areas. The lesional melanocytes are pleomorphic with enlarged hyperchromatic nuclei.  This is associated with lichenoid lymphocytic infiltrate, fibroplasia of papillary dermis, and scattered melanophages.  Rare small nests of melanocytes of similar cytology as the junctional component are noted within this area of dermal fibroplasia. Superficial adnexal involvement is noted. The lesion is invasive of the dermis to a depth of 0.415 mm.  It comes to within 1.58 mm of the peripheral resection margin at the 2:30 position and 6.5 mm of the deep resection margin.  Melan-A (red) and S-100 stains are confirmatory.  In addition, there is an adjacent scar.","A: Skin, left cheek, 12 o'clock marked with suture",,"AddendumDiagnosis:
SKIN (LEFT CHEEK) EXCISION:Malignant melanoma in situ, lentigo maligna type, with focus suspicious for early superficial invasion (0.25 mm, Clark's level II, non-ulcerated, no mitotic activity), the margins appear uninvolved in the sections examined. (see note)
Note: I entirely agree with your interpretation of this case. Focal single cell invasion is seen on immunohistochemical stains, S100 and Mart1.
AddendumComment:
The above diagnosis was provided by **NAME[ZZZ YYY] M.D., **STREET-ADDRESS, **PLACE, MA, **ZIP-CODE (Report #**ID-NUM)."
REG4,OTHER,0,PAT-01534809,2,REC-3000704822,"ClinicalHistory:
Bladder tumor.",,"FinalDiagnosis:
URINARY BLADDER TISSUE:  PAPILLARY UROTHELIAL CARCINOMA, HIGH GRADE, WITH NO EVIDENCE OF INVASION; MUSCULARIS PROPRIA NOT IDENTIFIED.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.4 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: BLADDER TUMOR,,
REG4,OTHER,0,PAT-10042812,1,REC-3000704847,"ClinicalHistory:
Pelvic abscess, infection probable colontero fistula, uterine infection.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
IntraoperativeDiagnosis:
A.  Touch Prep/Frozen Section Diagnosis:  MALIGNANT; FAVOR CARCINOMA.  (ss, **DATE[Apr 25 12], 2:00).
FinalDiagnosis:
A.  Recto-uterus junction, excision:
  Poorly-differentiated adenocarcinoma          

B.  Uterus, right ovary and fallopian tube, supracervical hysterectomy and right salpingo-oophorectomy:
  1. POORLY-DIFFERENTIATED ADENOCARCINOMA (see Comment)
  2. Ovary with metastatic adenocarcinoma
  3. Fallopian tube with serosal adhesions and acute inflammation
  4. Proliferative endometrium, negative for malignancy

C.  Large intestine, sigmoid, partial colectomy:
  POORLY-DIFFERENTIATED ADENOCARCINOMA (see Comment)
  20 lymph nodes, negative for metastasis(0/20).
DiagnosisComment:
In part B, the tumor is present from the lower uterine segment/endocervix myometrium extending to the endocervical canal.  The tumor is present at the posterior supracervical margin of excision.  

In part C, there is transmural extension of the tumor.  The tumor extends to the distal margin.  Lymphovascular space invasion by tumor is present. 

Immunohistochemical stains show the tumor to be positive for cytokeratin 7 and estrogen receptor.  The tumor is negative for cytokeratin 20, CDX2, WT-1, Oscar, LCA and p63.  The cytokeratin 7+/ cytokeratin 20- phenotype is seen in tumors of the gynecologic tract and are not consistent with a gastrointestinal primary.  The ER positivity lends further support for a gynecologic primary.  The tumor does not appear to be arising from the endometrium or the ovaries and is predominately located within the cervical/endocervical region.  Additional immunohistochemical stains to further classify this tumor are pending and will be reported separately.

Specimen signed out at **INSTITUTION for **STREET-ADDRESS, **PLACE, HI **ZIP-CODE.",,"GrossDescription:
Specimen A:  Received in the fresh state, labeled ""recto-uterus junction"" is an irregular piece of rubbery pink-tan tissue (2 x 2 x 1.4 cm).  The specimen is sectioned.  Touch preps were made and frozen section was taken from a portion of the specimen.  The entire specimen is submitted as follows:

Block summary:
A1.  -  Piece from frozen section.
A2-A4.  -  Remainder.

Specimen B:  Received in formalin, labeled ""uterus and right fallopian tube and ovary"" is a supracervical hysterectomy specimen (70.5 grams) consisting of a uterus with an attached right fallopian tube and right ovary.  The right fallopian tube is tan-red with a fimbriated end and measures 6.5 x 1.1 x 1 cm and has multiple adherent paratubal cysts ranging from 0.2 to 0.7 cm in greatest dimension.  The right ovary is tan-red and measures 3.2 x 2.5 x 1.5 cm and upon sectioning reveals a few cystic cavities measuring up to 1.5 cm in greatest dimension.  The uterus measures 5.5 x 5.5 x 4 cm and has a smooth, tan-red serosal surface.  The uterus is bivalved and sectioned.  Endometrium (0.1 to 0.2 cm in thickness) is soft, tan-red.  Myometrium (1.2 to 1.7 cm in thickness) is pink-tan and reveals two rubbery white nodules (0.6 and 0.9 cm in greatest dimension).  Representative sections are submitted as follows:

Block Summary:
B1.    -  Cross sections of right fallopian tube.
B2-B4.    -  Sections of right ovary.
B5.    -  Section of supracervical margin, anterior.
B6.    -  Section of supracervical margin, posterior.
B7.    -  Lower uterine section, anterior.
B8.    -  Lower uterine section, posterior.
B9-B10.    -  Full thickness sections of endometrium, myometrium and serosa, anterior.
B11-B14.  -  Full thickness sections of endometrium, myometrium and serosa, posterior.
B15.    -  Sections of nodules, posterior. 

Specimen C:  Received in formalin, labeled ""sigmoid colon staple end rectum"" is a partially previously opened segment of large bowel and rectum (10 cm in length by 2 to 2.5 cm in diameter).  The distal end of the specimen is left open and inked black.  The proximal end of the specimen is stapled.  The staples are removed and the revised proximal resection margin is inked red.  The radial/mesenteric resection margin is inked green.  The circumferential serosal margin is inked yellow.  An apparent circumferential ulcerated tan-red polypoid mass (approximately 7 x 5 x 1.2 cm) with a tan-white exudate is found at the distal aspect of the specimen.  The mass possibly extends to the distal resection margin on the circumferential serosal aspect and grossly approaches 2.5 cm within the distal resection margin on the mucosal aspect.  The mass is also found 3.5 cm away from the proximal resection margin and 0.5 cm away from the radial/mesenteric resection margin.  The mass grossly appears to protrude through the muscularis propria.  Also found in the same container is an additional piece of tan-red tissue/probable mass (3.3 x 2 x 1.2 cm).  Representative sections are submitted as follows:

Block summary:
C1-C3.    -  Perpendicular sections of distal resection margin and circumferential serosal margin.
C4.    -  Perpendicular section of proximal resection margin.
C5.    -  Additional section of circumferential serosal margin and possible mass.
C6-C11.    -  Sections of mass with radial/mesenteric resection margin.
C12-C16.  -  Additional sections of mass.
C17.    -  Section of grossly uninvolved large bowel proximal to the mass.
C18.    -  Section of grossly uninvolved large bowel distal to the mass.
C19.    -  Six possible lymph nodes.
C20.    -  Six possible lymph nodes.
C21.    -  Six possible lymph nodes.
C22.    -  One possible lymph node.
C23-C25.  -  Sections of additional piece of tissue/probable mass, entirely submitted.","MicroscopicDescription:
The microscopic findings support the diagnosis.","A: Recto-uterus junction frozen section
B: Uterus and right fallopian tube and ovary
C: Sigmoid colon/stapled end is rectum",,"AddendumComment:
HPV in situ hybridization was performed by **INSTITUTION. The results are negative for high-risk HPV.

Immunohistochemical stain for progesterone receptor (PR) is focally positive (approximately 10% of the cells).

Additional stains show the tumor within the endocervical region to be positive for cytokeratin 7, estrogen receptor and p16 and focally positive for p63. The cells are negative for thrombomodulin (provides support for non-urothelial neoplasm) and cytokeratin 20. These results are non-specific, but are consistent with a cervical/endocervical primary."
REG4,OTHER,0,PAT-10039775,1,REC-3000704880,"ClinicalHistory:
Nasopharyngeal and left neck mass.",,"IntraoperativeDiagnosis:
A.  Malignant per KH/SB

B.  Malignant per KH/SB

25G FNA x 2.
FinalDiagnosis:
A.  BIOPSY, NASOPHARYNGEAL MASS:  SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED.
 
B.  LEFT NECK LYMPH NODE, FNA:  METASTATIC SQUAMOUS CELL CARCINOMA (CYTOKERATIN 
    AE1/AE3 POSITIVE, LCA NEGATIVE).
DiagnosisComment:
Tumor (specimen A) shows keratinization, and is immunopositive for squamous markers (p63 and cytokeratins AE1/AE3 and 5/6); p16 is also positive, and EBER RISH is negative.  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jan 14 2012].",,"GrossDescription:
A)  Received:  1 DQ stained smear.
       tissue fragments in formalin.
    Submitted:  tissue fragments for a cell block.

B)  Received:  5 DQ stained smears.
               bloody material in formalin.
    Submitted:  bloody material for a cell block.",,"A: NASOPHARYNGEAL MASS FNA
B: LEFT NECK LYMPH NODE FNA",,
REG4,OTHER,0,PAT-01424886,1,REC-3000705000,"ClinicalHistory:
**AGE[in 50s] y/o female with a clinical diagnosis of CML.",,"FinalDiagnosis:
PERIPHERAL BLOOD:
-LEUKOPENIA.
-THROMBOCYTOPENIA.

BONE MARROW (BIOPSY/ASPIRATE, LEFT ILIAC CREST):  
- 80% CELLULAR MARROW WITH A MILD TO MODERATE ERYTHROID PREPONDERANCE AND LESS THAN 5% BLASTS.",,"GrossDescription:
The specimen consists of 2 grams of clotted blood and a core biopsy measuring 4.3 cm in length, and 0.2 cm in diameter.  The specimen is fixed in formalin and totally submitted.","MicroscopicDescription:
Peripheral blood smear:  
Shows an estimated WBC count of 3-5,000, with a 100 cell differential revealing 53 segs, 35 lymphs, 7 monos, and 5 eos.  No abnormal cells are seen.  The RBCs are unremarkable.  Platelets are numerically decreased.

Bone marrow aspirate smear and touch prep (250 cell differential count):
                     Percent                               Percent
Myeloblasts           3.6           Lymphocytes              2.8
Promyelocytes         4.0           Monocytes                0.4
Myelocytes            8.8           Plasma cells             3.2
Metamyelocytes       10.4           Rubriblasts              2.8
Bands                 4.4           Prorubricytes            3.2
PMN's                 8.8           Rubricytes               9.2
Eosinophils           2.8           Metarubricytes          35.6
Basophils             0.0           Other                    0.0
                                    M:E ratio              0.7:1

Shows well-spread, well-stained cellular particles, with scattered megakaryocytes.  A heterogeneous population of maturing granulocytic and erythrocytic precursors is present, with an M:E ratio of 0.7:1 and less than 5% blasts.  Mild dyspoiesis is seen.  There is no evidence of opportunistic microorganisms, granulomata, or metastatic tumor.

Bone marrow biopsy and clot section:  
Sections reveal a bone marrow biopsy that is adequate for evaluation.  Both clot and biopsy show an estimated cellularity of 80%, with adequate numbers of megakaryocytes.  A heterogeneous population of granulocytic and erythrocytic precursors is present, with no focal accumulation of blasts.  The bony trabeculae are unremarkable.  There is no evidence of opportunistic microorganisms, granulomata, or metastatic tumor.

Special stains:  
Iron- Positive; rare ring sideroblasts seen.","A: BONE MARROW BIOPSY/ASPIRATE, LEFT ILIAC",,"Interpretation:
BONE MARROW BIOPSY/ASPIRATE:  
- NO MONOCLONAL B-CELL OR IMMUNOPHENOTYPICALLY ABNORMAL T-CELL POPULATION IDENTIFIED.
- CD34+ BLASTS COMPRISING 2% OF ALL CELLS.
- PLASMA CELLS COMPRISING 1% OF ALL CELLS.  NO MONOCLONAL PLASMA CELL POPULATION DETECTED.
- MATURING GRANULOCYTES SHOWING DYSSYNCHRONOUS ACQUISITION OF 
  CD16 RELATIVE TO CD13 AND CD11b.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
 10   CD2    (39C1.5)  E-rosette T-cells, thymocytes, some NK cells,
                       LFA-3 receptor.
 54   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 24   CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
 51   CD5     (BL1a)   All mature T-cells, mature thymocytes, B-cell 
                       subsets.
 33   CD7     (8H8.1)  T-cells and NK cells.
 29   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  2   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
  #   CD11b   (Bear1)  Granulocytes, monocytes, LGL, C3bi receptor.
  #   CD13     (MY7)   Monocytes, granulocytes, CFU-C.
 19   CD16     (3G8)   Fc gamma receptor III expressed on natural 
                       killer cells, neutrophils, basophils.
 26   CD19    (HD37)   Pan B-cell, pre-B ALL.
 26   CD20    (B9E9)   Pan B-cell.
 24   CD22  (SJ10.1H11)Pan B-cell.
  #   CD33 (D3HL60.251)Early myeloid progenitors, myeloid cells, AML.
  #   CD34     (581)   HPCA-2, Bone marrow progenitor cells, TdT+ 
                       cells some acute leukemias.
 14   CD38     (T16)   Thymocytes, activated T-cells, plasma cells, 
                       early and terminally differentiated B-cells, 
                       granulocytes.
100***CD45    (J.33)   Pan leukocytes, LCA.
 18   CD3-56+ (NKH-1)  Natural killer cells (CD3-).
  #   HLADR (Immu-357) MHC Class II HLA-DR, B-cells, monocytes, 
                       activated T-cells.
 15   Kappa            Kappa light chain.
 10   Lambda           Lambda light chain.
  #   cKappa           Cytoplasmic kappa light chain.
  #   cLambda          Cytoplasmic lambda light chain.
***strong intensity
  #see comment

POPULATION REPORTED:  CD45-BRIGHT LYMPHOID POPULATION

COMMENT:  By flow cytometric analysis, approximately 20% of cells in the specimen display the phenotypic and light scatter properties of lymphocytes.  Most of these are T cells, without obvious phenotypic abnormality, including CD4+ and CD8+ subsets (CD4/CD8 ratio of 1.0).  There is a relatively distinct population of B cells, which are phenotypically immature, with a composite immunophenotype consistent with that seen in normal B-cell precursors (hematogones; 4% of all cells).  Phenotypically mature B cells comprise approximately 26% of lymphocytes and show a mixture of kappa- and lambda-bearing cells, without evidence of light chain restriction.  Cells with bright CD38 expression, dim CD45 expression, and light scatter properties characteristic of plasma cells comprise 1% of all cells, and include a mixture of cytoplasmic kappa- and lambda-bearing cells.  No distinct light chain-restricted plasma cell population is detectable.  

CD34+ myeloblasts comprise 2% of all cells in the specimen and express myeloid antigens, CD13 and CD33 as well as HLA-DR and CD38.  A subset of the cells with immunophenotypic and light scatter characteristics of monocytes shows weak aberrant expression for CD56.  A subset of the granulocytes also shows weak CD56 expression.  The aberrant expression of CD56 by the maturing myelomonocytic cells may be seen in conditions which include reactive/regenerative marrow, myelodysplasia and after chemotherapy and/or cytokine treatment.  Granulocytes show a normal pattern of phenotypic maturation with respect to CD11b, CD13 and CD16.     

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research.

KARYOTYPE: 46,XX(20) Normal female karyotype."
REG4,OTHER,0,PAT-10039179,1,REC-3000706283,"ClinicalHistory:
GI bleed.",,"FinalDiagnosis:
A.  SIGMOID COLON/RECTUM:

    1.  RECTAL ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
    2.  11 NODES NEGATIVE FOR METASTASIS (0/11).

B.  GALLBLADDER:  CHRONIC CHOLECYSTITIS AND CHOLELITHIASIS.

Rectal cancer information
Operative procedure:  Removal of rectosigmoid colon/anus.
Tumor-histologic type:  Rectal adenocarcinoma.
Histologic grade:  Moderately differentiated.
Anatomic site:  Rectum.
Size:  4.9 x 4.5 cm.
Depth of invasion:  Into perirectal fat.
Perforation:  Not identified.
Crohn's-like lymphoid infiltrate:  Present.
Tumor infiltrating lymphocytes:  Mild.
Pattern of growth at tumor periphery:  Infiltrative.
Perineural invasion:  Not identified.
Lymphatic invasion:  Not identified.
Venous invasion:  Not identified.
Resection margins:  Clear.
Distance to closest mucosal margin:  2.5-cm.
Distance to closest radial margin:  < 0.1 cm.
Regional lymph nodes:  0/11.
Distant metastasis:  Not assessed.
Indications for MMR (MSI) testing:  Age < **AGE[in 60s] w/Crohn s-like lymphocytic reaction.
Special procedures:  MSI IHC pending.
Other findings:  None.
Pathologic grade and stage:  G2, pT3 N0 (Stage IIA if M0).",,"GrossDescription:
A. Specimen:  Sigmoid colon, rectum and anus, received partially opened.
Weight:  531 gm.
Measurements:  
   Length:  30.0 cm.
   Circumference:  Up to 7.0 cm.
Appearance of adventitia:  Adventitia grossly appears complete and unremarkable.
Tumor:
   Location:  Rectum.
   Appearance:  Tan-pink, raised and slightly centrally ulcerated.
   Size:  4.9 x 4.5 cm.
   Depth of invasion:  Grossly involving the muscularis propria with apparent adventitial fat involvement.
   Distance from proximal margin:  24.0 cm.
   Distance from distal margin:  2.5 cm.
   Distance from dentate line:  1.5 cm.
   Distance from radial (adventitial) margin (inked blue):  Grossly abuts.
   Relationship to peritoneal reflection:  At the level, and extending 4.5 cm below the peritoneal reflection.
Appearance of uninvolved mucosa:  Unremarkable.
Other findings:  None.
Mesentery
   Lymph nodes:  Multiple lymph nodes identified measuring up to 1.4 x 0.8 cm.
   Other findings:  None.
Photos:  Taken.
Description of blocks for microscopic evaluation:
1-2  distal margin
3  proximal margin
4  mesenteric margin
5-9  tumor (5-with dentate line, 6-8 with adventitial margin)
10  uninvolved mucosa
11  lymph nodes within 3-cm of tumor
12-13  lymph nodes greater than 3-cm of tumor
14-16  representative fatty tissue

B. Specimen:  Gallbladder, received previously cut into.
Weight:  13 gm. 
Size:  7.0 x 3.0 x 2.9 cm. 
Gross findings:  Serosal surface appears tan and smooth.  No surface appears tan-yellow and slightly fibrotic. 
Gallstones:  Single irregular black stone measuring 0.6-cm; stone saved for storage. 
Submitted for microscopic evaluation:  Representative.  
Cassettes:  1.",,"A: SIGMOID COLON, RECTUM, AND ANUS (TUMOR AT THE RECTUM)
B: GALLBLADDER",,"Interpretation:
NO MLH1, MSH2, MSH6 OR PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA NUCLEI.

- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Normal expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

METHODS:  MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block A9.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.
ResultsComments:
Based on the four-antibody panel, there is no immunohistochemical evidence to suggest a mismatch repair deficiency or microsatellite unstable carcinoma."
REG4,OTHER,0,PAT-10024482,1,REC-3000706305,"ClinicalHistory:
Right breast mass.","Other Case Numbers: **ID-NUM

cc:  Dr **NAME[ZZZ YYY].","FinalDiagnosis:
Breast, right, ultrasound-guided fine needle aspiration:
  1.   Sample viability is suboptimal (84%), which may result in non-random cell loss, antigen       deterioration, and/or non-specific staining.

  2.  Surface lambda light chain-restricted, CD5-positive, CD10-partial positive B cell population,       comprising 66% of the total cells (see Comment).  The cells are small to large in size by forward 
    angle light scatter and have low to intermediate internal complexity by side angle light scatter.

  Phenotype:   CD45+(dim to bright) / CD5+(dim to bright) / CD10+(partial, dim) / CD19+ / CD20+ / 
    FMC-7+(partial) / surface lambda light chain+ 

  T cell antigens negative:    CD2, CD3, CD4, CD7, CD8
  B cell antigens negative:    CD22, surface kappa light chain
  Other antigens negative:    CD23, CD38

  3.  Remaining cells are T and NK cells, which comprise 5-6% of the total cells
    a.  Inverted CD4:CD8 T cell ratio (1:2.1).
DiagnosisComment:
The clonal B cell population supports a mature B cell lymphoma.  The differential diagnoses include diffuse large B cell lymphoma, mantle cell lymphoma, and possibly small lymphocytic lymphoma / chronic lymphocytic leukemia.  Please also see the concurrent biopsy (***PATH-NUMBER[1]). 

Of note, the current B cell population has a similar immunophenotype as the abnormal B cell populations observed in the previous flow cytometry studies (***PATH-NUMBER[2], right abdominal wall; ***PATH-NUMBER[3], ascites).",,,,A: FNA US guided right breast biopsy,,
REG4,BREAST,0,PAT-10037406,1,REC-3000636443,"ClinicalHistory:
Malignancy.",,"FinalDiagnosis:
RIGHT BREAST MASS 12:00 4 CM FN:  INVASIVE DUCTAL CARCINOMA.
DiagnosisComment:
Though a definitive histologic grade cannot be given on a needle biopsy, the tumor exhibits features of at least intermediate grade (nuclear pleomorphism score of 2, glandular (acinar)/tubular differentiation score of 3 and mitotic score of 1-2).  ER/PR and Her2/neu studies are pending.  The results were conveyed to Dr. **NAME[ZZZ YYY]'s office on **DATE[Jun 28 12].",,"GrossDescription:
Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Jun 27 12] 10:30 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  2.
Size:  0.1 cm in diameter and up to 2 cm in length.
Formalin fixation (Start):  Date  **DATE[Jun 27 12] Time  10:30 a.m.
Formalin fixation (End):  Date  **DATE[Jun 27 12] Time  5:35 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,A: RIGHT BREAST MASS 12:00 4 CM FN,,
REG4,BREAST,0,PAT-10033857,1,REC-3000636657,"ClinicalHistory:
Calcifications.",Other Case Numbers: MR# **ID-NUM.,"FinalDiagnosis:
Left breast core biopsies:  1.  Ductal carcinoma in situ
        2.  Microcalcifications present


Breast Tumor Information:

Operative procedure:    Left breast core biopsies
Histologic type:      Ductal carcinoma in situ
Nuclear grade:      Grade 3
Necrosis:        Present
Architectural pattern(s):    Solid and cribriform
Size:          0.3 cm
Microcalcifications:      Present
Special studies:      ER/PR to be reported separately
  
DiagnosisComment:
Dr. **NAME[ZZZ YYY] concurs.  Dr. **NAME[XXX WWW] notified on **DATE[Oct 23 11] at 0925 hrs. \X0A|",,"GrossDescription:
Received in fixative labeled ""XXXXXX, left breast"" are multiple cores of yellowish-white tissue measuring up to 3.2 cm in length and 0.3 cm in diameter.  Submitted in toto in two cassettes.  The specimen was removed from patient on **DATE[Oct 21 11] at 1050 and placed in formalin for a total fixation time of 8 hours and 10 minutes.  Cold ischemic time information was not provided.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Left breast,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    POSITIVE
Progesterone receptor (clone PgR 636):  POSITIVE


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-00916056,1,REC-3000637110,"ClinicalHistory:
Patient hx of breast CA 1993.",,"IntraoperativeDiagnosis:
Malignant; assessed and supervised by CF/CM/MG.
FinalDiagnosis:
RIGHT AXILLA (ANTERIOR SHOULDER) CT-GUIDED CORE NEEDLE BIOPSY:
- POORLY DIFFERENTIATED CARCINOMA.",,"GrossDescription:
Received:  1 DQ stained smear.
       Tissue fragments in formalin soln.
Submitted:  8 tissue fragments measuring up to 1 cm in length for a cell block.",,A: RIGHT AXILLA AREA (ANTERIOR SHOULDER) CT-GUIDED CNB,,
REG4,BREAST,0,PAT-00916056,1,REC-3000637298,"ClinicalHistory:
Patient hx of breast CA 1993.",,"IntraoperativeDiagnosis:
Malignant; assessed and supervised by CF/CM/MG.
FinalDiagnosis:
RIGHT AXILLA (ANTERIOR SHOULDER) CT-GUIDED CORE NEEDLE BIOPSY:
- POORLY DIFFERENTIATED CARCINOMA.
DiagnosisComment:
Immunoreactivity is noted with estrogen receptor and GCDFP-15.  Mammaglobin is negative.  The composite findings are consistent with metastatic breast carcinoma.  ER/PR (stain and morphometry) and Her2/neu studies are pending.",,"GrossDescription:
Received:  1 DQ stained smear.
       Tissue fragments in formalin soln.
Submitted:  8 tissue fragments measuring up to 1 cm in length for a cell block.",,A: RIGHT AXILLA AREA (ANTERIOR SHOULDER) CT-GUIDED CNB,,
REG4,BREAST,0,PAT-10037406,1,REC-3000637583,"ClinicalHistory:
Malignancy.",,"FinalDiagnosis:
RIGHT BREAST MASS 12:00 4 CM FN:  INVASIVE DUCTAL CARCINOMA.
DiagnosisComment:
Though a definitive histologic grade cannot be given on a needle biopsy, the tumor exhibits features of at least intermediate grade (nuclear pleomorphism score of 2, glandular (acinar)/tubular differentiation score of 3 and mitotic score of 1-2).  ER/PR and Her2/neu studies are pending.  The results were conveyed to Dr. **NAME[ZZZ YYY]'s office on **DATE[Apr 28 12].",,"GrossDescription:
Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Apr 27 12] 10:30 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  2.
Size:  0.1 cm in diameter and up to 2 cm in length.
Formalin fixation (Start):  Date  **DATE[Apr 27 12] Time  10:30 a.m.
Formalin fixation (End):  Date  **DATE[Apr 27 12] Time  5:35 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,A: RIGHT BREAST MASS 12:00 4 CM FN,,"Interpretation:
ER/PR (IMMUNOPEROXIDASE, POLYMER) DakoACIS3 COMPUTER-ASSISTED MORPHOMETRY
HercepTest (IMMUNOPEROXIDASE, POLYMER) DakoACIS3 COMPUTER-ASSISTED MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
----------------------------------------------------------------- 
ESTROGEN RECEPTOR (1D5):              100%        STRONG POSITIVE
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):       100%        STRONG POSITIVE
 INTENSITY:                         Strong
 Internal Control:                Negative
 External Control:                Positive
HER2 HercepTest (TM):              PENDING
-----------------------------------------------------------------
Specimen/Block (Formalin-fixed Paraffin Embedded Section): A1

ER/PR studies are reported as average %positive:  Negative 0%;  Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
These tests were developed and their performance characteristics were determined by the **INSTITUTION Pathology Laboratory.  Tests have not been cleared or approved by the U.S. Food and Drug Administration. The FDA does not require this test to go through premarket FDA review.
               
STANDARD ASSAY CONDITIONS:
Cold ischemic less than 1 hr.:  within limits
Fixation time Estrogen-Progesterone 6-72 hrs.:  within limits."
REG4,BREAST,0,PAT-10037285,1,REC-3000637605,"ClinicalHistory:
Right breast mass.
Pre-OperativeDiagnosis:
Ultrasound guided right breast biopsy, time collected at 835, Tech JD.",,"PreOperativeDiagnosis:
Ultrasound guided right breast biopsy, time collected at 835, Tech JD
FinalDiagnosis:
RIGHT BREAST INVASIVE DUCTAL CARCINOMA. 
Breast Tumor Information:
Operative procedure:    US needle biopsy, right breast mass 10:00 6 cm FN
Histologic type:    Invasive ductal carcinoma 
Histologic grade (MBR):  Poorly-differentiated 
Nuclear score:      3
Mitotic score:      3
Tubule score:      2
Invasive tumor size:    1.0 cm in core biopsy material
Necrosis:      Not evident
Lymphovascular invasion:  Not evident
In situ component:    Not evident
Microcalcifications:    Not evident
Special studies:    ER/PR/HER2-neu/Ki-67 pending
Staging information:    Tentative pT1\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, **NAME[AAA], right breast 10 o'clock, 6.0 cm FN"" are three cores of tan-white, focally hemorrhagic soft tissue measuring up to 1.4 x 0.1 cm.  The specimens are placed in formalin at 8:35 on **DATE[Dec 08 11] for a total fixation time of approximately 10.5 hours.  Submitted entirely in one cassette.","MicroscopicDescription:
Needle biopsies of breast demonstrate an invasive, poorly-differentiated ductal carcinoma.",A: Right breast 1000 6 cm FN,,
REG4,BREAST,0,PAT-10036115,1,REC-3000638589,"ClinicalHistory:
Ca++ in cage
Mass, Size of lesion-4 mm.",,"FinalDiagnosis:

RIGHT BREAST US-GUIDED CORE BIOPSY AT 9:30 2CFN (4MM MASS AND CA++):

1. INVASIVE DUCTAL CARCINOMA WITH MICROPAPILLARY FEATURES.
2. FIBROCYSTIC CHANGES (CYSTS, APOCRINE METAPLASIA, COLUMNAR CELL
   CHANGE, FIBROSIS).
3. MICROCALCIFICATIONS NOT IDENTIFIED.
DiagnosisComment:
ER/PR/Her2 results pending.  The invasive tumor measures up to 0.25 cm and shows grade II features (architectural score 3; nuclear score 2; mitotic score 1) with micropapillary pattern.",,"GrossDescription:
Specimen:  Free-floating elongated segments of fibrofatty tissue
  and caged elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Sep 6 11] 7:46 a.m..
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  Multiple.
Size:  0.2 cm in diameter and up to 1.9 cm in length.
Notes/comments:  Ca++ in cage.
Formalin fixation (Start):  Date  **DATE[Sep 6 11] Time  8:02 a.m..
Formalin fixation (End):  Date  **DATE[Sep 6 11] Time  10:50 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  2
  1  free-floating cores
  2  caged cores.",,A: RIGHT BREAST 9:30 2 CFN,,"Interpretation:
ER/PR (IMMUNOPEROXIDASE, POLYMER) DakoACIS3 COMPUTER-ASSISTED MORPHOMETRY
HercepTest (IMMUNOPEROXIDASE, POLYMER) DakoACIS3 COMPUTER-ASSISTED MORPHOMETRY
HER-2/neu gene (FISH) MetaSystems Metafer

TEST                               RESULTS        INTERPRETATION
----------------------------------------------------------------- 
ESTROGEN RECEPTOR (1D5):              100%        STRONG POSITIVE
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):       100%        STRONG POSITIVE
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:                 2.5        EQUIVOCAL
HER-2/neu gene (FISH)***:              1.1        NEGATIVE
-----------------------------------------------------------------
Specimen/Block (Formalin-fixed Paraffin Embedded Section): A2

ER/PR studies are reported as average %positive:  Negative 0%;  Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
These tests were developed and their performance characteristics were determined by the **INSTITUTION Pathology Laboratory.  Tests have not been cleared or approved by the U.S. Food and Drug Administration. The FDA does not require this test to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation
1.5-2.69: (2+) Equivocal.               

***PathVysion HER-2 DNA probe kit fluorescence in situ hybidization (FISH), a trademark of Abbot. 
<1.8: (Negative)
Report REISSUED to add HER-2/neu gene (FISH) results.

STANDARD ASSAY CONDITIONS:
Cold ischemic less than 1 hr.:  within limits
Fixation time Estrogen-Progesterone 6-72 hrs.:  within limits
Fixation time Her-2 6-48 hrs.:  within limits."
REG4,BREAST,0,PAT-10038877,1,REC-3000638955,"ClinicalHistory:
Right breast, masses at 10:00 and 2:00
**DATE[Dec 28 11] - Right breast ultrasound reveals two highly suspicious nodules in the right breast, one at 10:00 and one at 2:00
BIRAD 5 - Highly suspicious of malignancy.",,"FinalDiagnosis:
A.  Right breast, @10:00,core biopsy:    
  INVASIVE DUCTAL CARCINOMA, GRADE 2, WITH LYMPHOVASCULAR INVASION (See Tumor information).

B.  Right breast, @2:00, core biopsy:    
INVASIVE DUCTAL CARCINOMA, GRADE 2(See Tumor information).


Breast Tumor Information: (AJCC/UICC TNM, 7th edition).

Operative procedure:    Core biopsy
Histologic type:    Invasive Ductal Carcinoma
Histologic grade (MBR):    
Nuclear score:    2
Mitotic score:    1
Tubule score:    3
Overall grade  Grade 2
Invasive tumor size:    0.7 cm in greatest dimension in 12 of 15 cores (part A);  0.4 cm in greatest dimension and in 4 of 12 cores (part B).
Necrosis:    Yes
Lymphovascular invasion:    Yes (block A1)
In situ component:    Not present
Microcalcifications:    Yes
Special studies:    Pending

Comment:
Prognostic and predictive markers for both parts A and B are ordered and will be reported in an addendum. Immunohistochemical stains for E-cadherin, thrombomodulin, and D2-40 are performed and support the above diagnosis.  Dr. **NAME[ZZZ] concurs.
\X0A|",,"GrossDescription:
(A)  Received in formalin labeled ""right breast core biopsy, mass at 10:00"" are fifteen white-tan, yellow and cylindrical, fibro-fatty tissue fragments ranging in size from 0.4 x 0.2 x 0.1 cm to 2.2 x 0.3 x 0.2 cm.  The specimen was collected on **DATE[Jan 12 12] at 8:30 a.m. and placed in formalin at 8:35 a.m. for a total fixation time of approximately 10 hours.  Entirely submitted in four cassettes.

(B)  Received in formalin labeled ""right breast core biopsy, mass at 2:00"" are twelve white-tan, yellow and cylindrical, fibro-fatty tissue fragments ranging in size from 0.4 x 0.2 x 0.1 cm to 1.7 x 0.3 x 0.2 cm.  The specimen was collected on **DATE[Jan 12 12] at 
8:50 a.m. and placed in formalin at 8:55 a.m. for a total fixation time of approximately 9.5 hours. Entirely submitted in four cassettes.","MicroscopicDescription:
Confirmed.","A: Right breast core bx @ 10:00
B: Right breast core bx @ 2:00",,"AddendumDiagnosis:
A. Right breast, 10:00:
  
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive
HER-2/neu (HercepTest):      Equivocal, FISH testing pending
Ki-67 (clone Ki-S5):      Low cell proliferation
p53 (clone DO7):        Normal

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results.


B. Right breast, 2:00:
  
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (clone Ki-S5):      Low cell proliferation
p53 (clone DO7):        Normal

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10037309,1,REC-3000639290,"ClinicalHistory:
Mass, left 10 o'clock.",Other Case Numbers: MR# 431857.,"FinalDiagnosis:
Left breast core biopsy, mass:  INFILTRATING DUCTAL CARCINOMA

Breast Tumor Information:

Operative procedure:      Ultrasound-guided core biopsy
Histologic type:      Ductal, usual type
Histologic grade (MBR):      Grade 3
Nuclear score:      3
Mitotic score:      3
Tubule score:      3
Invasive tumor size:      At least 0.8 cm (3.3 cm on imaging studies)
Necrosis:      Present
Lymphovascular invasion:      Not identified
In situ component:      Absent
Microcalcifications:      Absent
Special studies:      ER, PR, HER-2 and Ki-67 pending
DiagnosisComment:
Specimen signed out at **INSTITUTION for **STREET-ADDRESS, **PLACE, HI **ZIP-CODE.\X0A|",,"GrossDescription:
Received in fixative labeled ""XXXXXX, left breast"" are 3 cores of yellowish-white tissue measuring up to 1.3 cm in length and 0.2 cm in diameter.  Submitted in toto in one cassette.  The specimen was removed from patient on **DATE[Mar 20 12] at 8:48am and placed in formalin for a total fixation time of 10 hours and 21 minutes.  Cold ischemic time information was not provided.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Left breast, 10 o'clock",,
REG4,BREAST,0,PAT-10040762,1,REC-3000639415,"ClinicalHistory:
Specimen ID:  A1 - RIGHT BREAST TISSUE
* Type: Permanent Fresh
* Site: Breast
* Comments:  Sutures - Short:  Base of nipple; Medium:  1:00; Long: 10:00
* Sent To: Pathology
Specimen ID:  A2 - RIGHT BREAST TISSUE @ 9:00
* Type: Permanent Fresh
* Site: Breast
* Sent To: Pathology
Procedure->Excision
Clinical History/Diagnosis/Condition->RIGHT BREAST LUMPS./r/n",,"FinalDiagnosis:
A. Breast, right: Ductal carcinoma in situ with multiple foci of microinvasive ductal carcinoma, superior and superficial margins involved and lesion present within 1 mm focally of all margins (see template below).

B. Breast, right 9:00: Ductal carcinoma in situ seen within 1 mm of the surgical margins./r/nDiagnosisComment:
Immunohistochemical stains for p63 and SMMS-1 were performed on blocks A5, A6, A7, A8, and B2. p63 only was performed on block A10.  Based on the current findings the lesion would be stage pT1mi.  Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block A7 and reported in an addendum.  Case reviewed at Pathology Staff Conference on **DATE[Jul 11 12] and **DATE[Jul 12 12].  Case discussed with Dr. **NAME[ZZZ] on **DATE[Jul 11 12]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right breast tissue 
  Specimen:    Irregular lobulated portion of fibroadipose tissue (formalin)
  Size:      
    Superior-inferior:  1.5 cm
    Medial-lateral:     6 cm
    Superficial-deep:  2.5 cm
  Skin:      None
  Skeletal muscle:    None
  Orientation:    
    Short:      Base of nipple
    Medium:    1:00
    Long:       10:00
  Colors:
      Black:      Deep
      Orange:    Superficial (base of nipple)
      Green:      Superior
      Blue:      Inferior
      Red:      Medial (1:00)
      Yellow:      Lateral (10:00)
  Radiographic findings:  None provided
  Findings:      
      Size:      Measuring from 0.2 x 0.2 x 0.2 cm up to 0.8 x 0.8 x 0.7 cm
      Description:    Multiple, circular cavities containing hemorrhagic material 
    Skin dermal invasion:    Not applicable
      Skin ulceration:    Not applicable
      Margins:    The largest cavity abuts the superior-anterior (superficial) margin
  Additional findings:  No additional lesions identified.
  Section code:    
      Block A1:    QuadrIsected lateral end piece (10:00)
      Blocks A2-10:    Entire specimen including hemorrhagic cavities
      Block A11:    Trisected medial end piece (1:00)
  
B.  Labeled:      Patient name and medical record number, designated right breast tissue at 9:00
  Specimen:    Two, roughened lobulated portions of fibroadipose tissue (formalin)
  Size:      0.9 x 0.7 x 0.5 cm (black) and 1.2 x 1 x 0.7 cm (blue)
  Submitted/Blocks:  Entirely/2./r/n","MicroscopicDescription:
A. Ductal carcinoma in situ is seen involving the entire specimen with multiple foci (4) of microinvasive (less than or equal to 1 mm) ductal carcinoma. The ductal carcinoma in situ is seen focally involving the superior and superficial surgical margins and is within a millimeter of all other surgical margins.  In addition there is crush artifact at the surgical margins and additional margin involvement cannot be entirely excluded.  The DCIS shows clinging/micropapillary and papillary patterns with an intermediate nuclear grade (Grade II).   Focal reaction compatible with previous biopsy site is seen.

B.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right breast tissue, excision (fresh)
B: Right breast tissue at 9 o'clock, excision (fresh)",,"ResultsComments:
The following results were performed at **PLACE, NV and reported by **NAME[YYY M. XXX], M.D. on **DATE[Jul 21 2012].  

INTERPRETATION:

BREAST CANCER PROGNOSTIC PANEL:  
***PATH-NUMBER[1], BLOCK # A7 (INVASIVE CARCINOMA)

            ESTROGEN RECEPTOR:                   90%
            PROGESTERONE RECEPTOR:            83%
            HER-2/neu (ACIS score):                   0.8 (NO OVEREXPRESSION)

COMMENT:
ERPR     
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical methods on the Ventana Benchmark XT automated stainer 
  using antibodies against ER (SP1 IVD), PR (clone IE2 IVD).  Though the largest studies have used 10% as a 
  threshold for positivity, others have recommended a cutoff as low as 1%. 

HER-2/neu
  Analysis is performed using Chromavision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu 
  (4B5)  Rabbit Monoclonal Antibody.

  Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and 
  equivocal) were appropriate.

  The results obtained from the ChromaVision ACIS correspond to the ASCO/CAP scoring criteria in the following 
  manner, as determined by in-house studies:

  ChromaVision:         ASCO/CAP 
  Result:          Score:

  Less than 1.5         0       (No staining)

  Less than 1.5         1+        (Weak, incomplete membrane staining)

  1.5 to 3.4              2+        (Complete membrane staining that is either nonuniform or weak in 
                       intensity, but with obvious circumferential distribution in at least 10% of the 
                       cells, or intense complete membrane staining in less than 30% of invasive 
                       tumor cells)

  Greater than 3.4       3+       (Uniform, intense membrane staining in greater or lesser than 30% 
                       invasive tumor cells)

  A ChromaVision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise 
  specified.  This is in accordance with CAP recommendations (Strategic Science I Meeting, **DATE[May 2003], **PLACE, 
  IL).

  Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American 
  Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered 
  formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 
  48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  
  
References:
  1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
  2.  **NAME[WWW] JM, et. al. Mod Path **ID-NUM.
  3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
  4.  **NAME[VVV M], et. al. Am J Clin Pathol 2001;**ID-NUM.
  5.  **NAME[UUU, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
  6.  Wolff, AC, et al.  ""American Society of Clinical Oncology/College of American Pathologists Guideline
       Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.""  Arch Pathol 
       Lab Med 2007; **ID-NUM.
  (BLS/mab)./r/n"
REG4,BREAST,0,PAT-10037351,1,REC-3000639455,"ClinicalHistory:
611.72

**DATE[Mar 28 12] - Abnormal mammogram with a 1.9 cm dense mass in the left breast at approximately 2:00 position. BIRAD 5 - findings highly suspicious of malignancy.",,"FinalDiagnosis:

Left breast, 2:00, needle core biopsy:        INVASIVE DUCTAL CARCINOMA (please see Tumor Information)

Tumor Information: (Based on AJCC/UICC TNM, 7th edition)
Histologic type:    Invasive ductal carcinoma
Histologic grade: Nottingham Histologic Score
     Tubule score:      3
     Nuclear score:      3
     Mitotic count:      3
     Overall grade:    Grade 3  
Invasive tumor size:    At least 9mm
Necrosis:      Not identified
Lymphovascular invasion:  Not identified
In situ component:    Not identified
Microcalcifications:    Not identified
Ancillary studies:    Pending (please see Comments)

Comments:  
The tumor is high-grade and present in all three needle core biopsies.  
Prognostic and predictive markers will be performed and issued as an addendum to this report at a later date. \X0A|",,"GrossDescription:
Received in formalin labeled ""left 2, 8 cm FN"" are three tan-pink, yellow and fibrofatty tissue fragments that range in size from 
1.7 x 0.4 x 0.3 cm to 2.5 x 0.6 x 0.4 cm.  The specimen was collected on **DATE[Apr 20 12] at 8:18 a.m. and placed in formalin at 
8:19 a.m. for a total fixation time of approximately 10 hours.  Submitted in one cassette.","MicroscopicDescription:
Confirmed.",A: L 2   8 cm FN,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    #
Progesterone receptor (clone PgR 636):  #
HER-2/neu (HercepTest):      #
Ki-67 (clone Ki-S5):      #
p53 (clone DO7):        #

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results.
AddendumComment:
The results of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 22 2012]."
REG4,BREAST,0,PAT-10016409,2,REC-3000639485,"ClinicalHistory:
Left inflammatory breast cancer.",,"FinalDiagnosis:
A.  Left breast with long stitch lateral, short stitch superior:  INVASIVE DUCTAL CARCINOMA
                
  Location:        Left breast
  Histologic type:      Ductal carcinoma, NOS
  Histologic grade:      Grade II (7/9)
     Tubular formation:         3/3
     Nuclear pleomorphism:       3/3
     Mitotic count:         1/3
  In situ carcinoma:      Present
              -Solid and cribriform types
  Microcalcifications:      Present possibly in neoplastic tissue
  Lymphovascular invasion:    Present
  Perineural invasion:      Not seen
  Necrosis:        Not seen
  Tumor size:        1.4 cm in maximal dimension
  Skin involvement:      Present (present in dermis)
  Surgical margins:      Negative
  Regional lymph nodes:    Positive in ten out of twenty-six lymph nodes (13/26)
              (combined with B)
  Special studies:      ER, PR, HER2-neu and Ki67 performed on prior biopsy
              specimen (***PATH-NUMBER[1])
  Stage:          See comment
  Additional pathologic findings:  Healing scar at the prior biopsy site

B. Left axillary contents:  METASTASIS TO THIRTEEN OUT OF TWENTY SIX NODES (13/26)
          -Metastatic tumor foci 2.8 mm in maximal dimension    
DiagnosisComment:
Though pathologically the tumor size is ypT1c {postneoadjuvant therapy TNM (ypTNM) is ypT1c, ypN3a, cM0}, since there is known clinical diagnosis of inflammatory carcinoma, the tumor size will be cT4d. 
Dr. **NAME[ZZZ] reviewed the slides and concurred with the diagnosis.\X0A|",,"GrossDescription:
Two specimens are received labeled with the patient's name.
A.  Specimen received in fresh status labeled ""left breast with long stitch lateral, short stitch superior"" consists of a mastectomy specimen with two suture labelings.  The breast tissue measures 19.5 x 18 x 5.5 cm, the skin measures 16.5 x 9 cm and the nipple measures 1.5 cm in diameter.  On the skin surface above the nipple there is a healing scar 3 cm in length.  Dissection reveals no mass lesion.  The skin and nipple are grossly unremarkable.  The representative tissues are initially submitted in nine cassettes and additional tissue is submitted in seven more cassettes.
  A1-A5)  Tissue near the previous biopsy site
  A6-A7)  Random sampling
  A8)  Skin at previous biopsy site
  A9)  Nipple
  ***PATH-NUMBER[2])  Additional tissue

       Specimen is received in Excell fixative (replaced with formalin at 1630 on **DATE[Aug 11 2011]).

B.  Specimen received in Excell fixative (replaced with formalin at 1320 on **DATE[Aug 12 2011]) labeled ""left axillary contents"" consists of a fragment of fibroadipose tissue, 11 x 6 x 3 cm.  Dissection reveals multiple lymph nodes.  The entire nodes are submitted in eleven cassettes.
              B1-B11) Left axillary contents.","MicroscopicDescription:
A.  The microscopic findings and immunostains (panCK, heavy chain myosin and p63) support the above diagnosis.
B.  There is metastasis in thirteen out of 26 nodes. The metastatic tumor is present as small isolated tumor cell clusters in each
      node. The largest one in the nodes measures 2.8 mm in maximal dimension.","A: Left breast, long stitch lateral margin, short stitch superior margin
B: Left axillary contents",,"AddendumComment:
Pancytokeratin immunohistochemical stain was conducted on B4, B6, B8 and B9 which supports the diagnosis."
REG4,BREAST,0,PAT-01149582,2,REC-3000639492,"ClinicalHistory:
Left breast cancer.
Post-OperativeDiagnosis:
Left breast cancer.
Pre-OperativeDiagnosis:
Left breast lumpectomy, sentinel node, possible mastectomy.",,"PreOperativeDiagnosis:
Left breast lumpectomy, sentinel node, possible mastectomy
PostOperativeDiagnosis:
Left breast cancer
IntraoperativeDiagnosis:
A.  Frozen Section:  Node, negative for metastasis/MP
FinalDiagnosis:
A.     Sentinel node, left axilla, biopsy:    Lymph node, negative for metastasis (0/1)

B-C.  LEFT BREAST INVASIVE LOBULAR CARCINOMA
   Breast Tumor Information:
  Operative procedure:      Needle localized wide excision, left breast mass; additional inferior lateral margin extension
  Histologic type:      Invasive lobular carcinoma
  Histologic grade (MBR):    Low grade
  Nuclear score:        1
  Mitotic score:        1
  Tubule score:        3
  Invasive tumor size:       1.0 cm invasive component
  Necrosis:        Not evident
  Margins:        1. Anterior/subareolar margin with minimal 0.1 cm clearance
            2. Other margins with greater than 0.5 cm clearance
  Lymphovascular invasion:    Not evident
  In situ component:      Present, minor component, lobular carcinoma in situ
  Microcalcifications:      Rare
  Axillary  lymph nodes:      Negative for metastasis (0/1 sentinel node) !      
  Special studies:      Performed on prior needle biopsy (***PATH-NUMBER[1]; ER positive, PR-positive, Her2-negative, KI67-low proliferation)
  Stage:          pT1b N0(i-)(sn)\X0A|",,"GrossDescription:
A.  Received fresh for intraoperative consultation labeled ""left breast mass (stitch is sentinel node)"" is an excision of tan-yellow fibrofatty soft tissue measuring 4.0 x 2.8 x 1.0 cm.  A suture is provided for orientation.  By palpation there is a firm nodule grossly consistent with a lymph node measuring 1.0 cm in greatest dimension.  The lymph node is submitted for frozen section subsequently submitted in block A.

B.  Received fresh labeled ""left breast mass (2 long stitch is nipple 1 long stitch is lateral)"" is an excision of tan-yellow fibrofatty soft tissue measuring 4.0 x 3.0 x 2.3 cm.  Sutures are provided for orientation and there is a centrally placed needle.  The needle approaches the lateral inferior margin.  The specimen is inked.  The superior aspect orange, inferior yellow, lateral red, medial green, anterior blue, posterior black.  The sutures marking the nipple area on the anterior aspect of the specimen in the superior medial quadrant.  Sections reveal a tan-yellow to white fibrofatty cut surface.  In the anterior lateral aspect of the specimen is a cystic, hemorrhagic lesion measuring 0.6 x 0.5 x 0.5 cm and located 0.4 cm from the anterior margin.  Specimen is serially sectioned from medial and lateral and submitted entirely in blocks B1-B11.  Note:  The sections beneath the nipple are submitted in blocks 2-4.  The specimen is placed in formalin at 1300 on **DATE[May 15 12] for a total fixation time of 6.0 hours.

C.  Received in formalin labeled ""additional inferior lateral breast tissue one long suture posterior long lateral short medial"" the specimen is inked.  The superior aspect orange, inferior yellow, lateral red, medial green, anterior blue, posterior black.  Sections reveal a tan-yellow fibrofatty cut surface with no grossly identifiable masses or lesions.  The specimen is placed in formalin at 1300 on **DATE[May 15 12] for a total fixation time of 6.0 hours.  The specimen is serially sectioned from inferior to superior and submitted entirely in blocks C1-C6.","MicroscopicDescription:
A.  Sections of lymph node are negative for metastasis on routine stain.  Immunostain (Pan Keratin) is negative for micrometastasis. 

B.  An excision of breast demonstrates a previous needle biopsy site with adjacent residual invasive lobular carcinoma.  Tumor focally extends to within 1.0 mm of the anterior/subareolar margin of resection.  Other margins exhibit wider clearance, and are partially extended by additional excision (part C).  Immunostain (pan keratin) is used to differentiate inflammatory infiltrate from the lobular carcinoma infiltrate.  These stains support minimal 1.0 mm clearance from the anterior/subareolar margin of resection.  

C.  Additional sections of breast exhibit fibrofatty breast tissue with mild proliferative and non-proliferative fibrocystic change.  There is a focus of atypical duct epithelial hyperplasia with prominent biopsy/cautery artifact.","A: Left axillary node, Stitch is Sentinel node, sent 1141 (FS)
B: Left breast mass, 2 long stitch marks nipple, 1 long stitch is lateral, sent at 1205
C: Additional inferior lateral breast tissue, long suture - lateral, short suture - medial, 1 long suture - posterior",,"AddendumComment:
Please see attached Oncotype DX."
REG4,BREAST,0,PAT-10037231,1,REC-3000639924,"ClinicalHistory:
Mass/calcifications; R/O malignancy.",Other Case Numbers: MR# **ID-NUM.,"FinalDiagnosis:
Right breast core biopsy:    MUCINOUS CARCINOMA

Breast Tumor Information:

Operative procedure:      Stereotactic core biopsy
Histologic type:      Mucinous
Histologic grade (MBR):      Grade 1
Nuclear score:      1
Mitotic score:      1
Tubule score:      2
Invasive tumor size:      At least 1.0 cm
Necrosis:      Absent
Lymphovascular invasion:      Not identified
In situ component:      10%, low grade
Microcalcifications:      Absent
Special studies:      ER, PR, HER-2 and Ki-67 pending\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, right breast"" are multiple cores of yellowish-white pieces of tissue measuring up to 2.4 cm in length and 0.3 cm in diameter.  Submitted in toto in two cassettes.  The specimen removed from patient on **DATE[Jan 30 12] at 8:40 a.m. and placed in formalin for a total fixation time of 10 hours and 20 minutes.  Cold ischemic time information was not provided.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right breast,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Low cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results.
AddendumComment:
Attached is a copy of the InsightDx Mammostrat Report rendered by Dr **NAME[ZZZ YYY] of **NAME[XXX] Diagnostic Services."
REG4,BREAST,0,PAT-10037444,1,REC-3000640547,"ClinicalHistory:
Left breast cancer.
Post-OperativeDiagnosis:
Pending pathology exam.",,"PostOperativeDiagnosis:
Pending pathology exam
IntraoperativeDiagnosis:
Touch Preparation:  Positive for metastasis
FinalDiagnosis:
A.  Left sentinel node # 1:        POSITIVE FOR METASTASIS, 1.3 CM, NO PERINODAL EXTENSION
 
B.  Left breast mass:         INFILTRATING DUCTAL CARCINOMA
 
C.  Left axillary lymph node dissection:    METASTASIS TO THREE OF ELEVEN LYMPH NODES

Breast Tumor Information:

Operative procedure:        Wide excision with sentinel node biopsy and axillary dissection
Histologic type:        Ductal, usual type
Histologic grade (MBR):      Grade 1
   Nuclear score:        2
   Mitotic score:        1
   Tubule score:        2
Invasive tumor size:        1.5 x 1.4 x 1.0  cm (macroscopic)
Necrosis:          Absent
Lymphovascular invasion:      Not identified
In situ component:        10%, intermediate grade
Resection margins:        All margins clear by greater than 0.5 cm
Microcalcifications:        Absent in tumor
Lymph nodes:          Metastasis to 4 of 12 lymph nodes (4/12)
Special studies:        ER, PR, HER-2 and Ki-67 pending
Staging information:        pT1c N2a
\X0A|",,"GrossDescription:
A.  Received unfixed for touch imprint labeled ""left sentinel lymph node #1, **NAME[AAA] XXXXXX"" is a yellow-red 2.3 x 1.9 x 1.0 cm piece of tissue that contains a 1.5 x 1.3 x 0.8 cm firm gray lymph node.  A touch imprint was done.  The node is submitted entirely in one cassette.

B.  Received in formalin labeled ""left breast cancer, **NAME[AAA] XXXXXX"" is an ovoid gray to yellow piece of breast tissue with an attached gray skin ellipse.  The specimen weighs 23.0 gm and measures 5.5 cm from medial to lateral x 4.2 cm superior to inferior x 2.1 cm from anterior to deep.  The skin appears grossly unremarkable and measures 3.3 x 0.6 x 0.3 cm.  There is a short suture at the superior margin, a long suture at the lateral margin and a double suture at the deep margin.  The specimen is differentially inked: orange = anterior, black = deep, green = superior, blue = inferior, red = medial and yellow = lateral.  The specimen was removed from the patient at 1304 hours and immediately placed in formalin resulting in total formalin fixation time of 6 hours.  Sectioning reveals a firm ill-defined gray mass within the center of the specimen that measures 1.5 x 1.4 x 1.0 cm and is situated 0.5 cm from the closest deep margin, approximately 1.0 cm from the closest superior margin, 1.2 cm from the closest inferior margin and not in proximity to any other surface margins.  There is dense fibrous breast tissue that extends to the inferior margin.  

  KEY TO CASSETTES: 
B1-B2    -  Sections that include the tumor and all margins in proximity to the tumor 
      except the inferior margin  
B3-B4    -  Sections that represent all margins in proximity to the tumor including 
      the inferior margin and excluding the superior margin
  B5    -  The superior margin not represented by the sections in blocks B3 and 
        B4
  B6    -  Firm dense tissue extending to the inferior margin within the medial 
        portion of the specimen
  B7    -  Medial margin
  B8    -  Additional medial margin
  B9-B10    -  Lateral margin

C.  Received in formalin labeled ""left axillary lymph node dissection and **NAME[AAA] XXXXXX"" is a yellow to pink piece of tissue that measures 7.3 x 6.8 x 1.4 cm and contains 11 lymph nodes that vary in greatest dimension from 0.2 cm to 1.8 cm.  

  KEY TO CASSETTES: 
  C1    -  Three nodes
  C2    -  Four nodes
  C3    -  The four smallest nodes.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Left sentinel node # 1
B: Left breast cancer
C: Left axillary lymph node dissection",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Low cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10037306,1,REC-3000640664,"ClinicalHistory:
Cancer of the left breast.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Left mastectomy and sentinel node biopsy.",,"PreOperativeDiagnosis:
Left mastectomy and sentinel node biopsy
PostOperativeDiagnosis:
Same
IntraoperativeDiagnosis:
A.  Touch Prep:  Node, negative for metastasis/MP
FinalDiagnosis:
A.  Sentinel node, left axilla, biopsy:  Lymph node, negative for metastasis (0/1).

B.  LEFT BREAST INVASIVE DUCTAL CARCINOMA.
Breast Tumor Information:
Operative procedure:    Left breast mastectomy
Histologic type:    Invasive ductal carcinoma 
Histologic grade (MBR):  Moderately-differentiated 
Nuclear score:      2
Mitotic score:      2
Tubule score:      2
Invasive tumor size:    2.8 x 1.5 x 1.4 cm
Necrosis:      Not evident
Lymphovascular invasion:  Not evident
In situ component:    Present, extensive duct carcinoma in-situ, intermediate grade 
Resection margins:    Free of carcinoma (minimum 1.0 cm deep margin clearance)
Microcalcifications:    Rare
Lymph nodes:      Negative for metastasis (0/8 total nodes, including 0/1 sentinel node/part A and 
        0/7 main specimen nodes/part B)
Special studies:    Performed on previous needle biopsy (***PATH-NUMBER[1]; ER-positive, PR-positive, 
        HER2-neu-positive)
Staging information:    pT2 N0\X0A|",,"GrossDescription:
A.  Received fresh for intraoperative consultation labeled ""sentinel node biopsy left axillary"" is an excision of tan-yellow fatty soft tissue measuring 1.5 x 1.0 x 0.7 cm.  By palpation there is a firm nodule grossly consistent with a lymph node measuring 1.1 x 0.8 x 0.6 cm.  Touch preparation is performed.  The lymph node is submitted entirely in block A.

B.  Received in formalin labeled ""left breast tissue suture marks at axillary tail"" is a mastectomy specimen with attached tan-white skin ellipse having overall dimensions of 22.5 x 15.0 x 7.5 cm.  The attached skin ellipse measures 10.1 x 4.0 cm.  In the medial aspect of the ellipse is an intact tan-brown nipple and areola measuring 4.3 x 3.0 cm.  In the inferior portion of the specimen there is a previously blue inked area.  The deep margin is inked red.  Sectioning reveals a tan-yellow to white fibrofatty cut surface.  In the superior medial aspect of the specimen is a poorly circumscribed tan-white, firm stellate nodule measuring 2.8 x 1.5 x 1.4 cm.  The cut surface is tan-white with multiple hemorrhagic areas grossly consistent with previous biopsy.  The lesion is located 1.0 cm from the deep margin.  By palpation there are multiple firm nodules grossly consistent with lymph nodes present in the axillary tail measuring up to 1.3 cm in greatest dimension.  Representative sections are submitted in blocks B1-B12.","MicroscopicDescription:
A.  Sections of lymph node exhibit mild reactive hyperplasia.  There is no metastasis on routine stain.  Immunostain evaluation deferred due to additional nodes present in part B.

B.  Sections of breast demonstrate an invasive, moderately-differentiated ductal carcinoma with prominent adjacent duct carcinoma in-situ of intermediate nuclear grade.  Margins of the mastectomy are free of tumor involvement.  Within the axillary portion, an additional 7 nodes are present, exhibiting areas of reactive lymphoid hyperplasia and sinus histiocytosis, however, all nodes are negative for metastasis.","A: Sentinel node biopsy, left axillary tail
B: Left breast tissue, suture marks at axillary tail",,
REG4,BREAST,0,PAT-10039788,1,REC-3000640753,"ClinicalHistory:
Left breast calcifications.
Post-OperativeDiagnosis:
Pending pathology.",,"PostOperativeDiagnosis:
Pending pathology
FinalDiagnosis:
Breast, left, excisional biopsy:    DUCTAL CARCINOMA IN SITU, GRADE 2
      
  Breast Tumor Information:

  Type of specimen(s):      Excisional biopsy
  Histologic Type:      Ductal carcinoma in situ
  Size:      1.5 cm (present on 5 consecutive sections)
  Architectural pattern(s):      Micropapillary and cribriform
  Nuclear grade:      Nuclear grade 2 out of 3
  Necrosis:      Present, comedo type
  Microcalcifications:      Present, associated with malignant and benign tissue
  Resection margins:      Involved by DCIS (anterior and deep margins)
        Present less than 0.5 mm from the inferior margin
        All other margins clear by at least 3 mm
  Other findings:      Atypical and usual ductal hyperplasia, radial scar
  Ancillary studies:      ER and PR are pending and will be reported separately\X0A|",,"GrossDescription:
Received fresh, labeled ""XXXXXX, XXXXXX, left breast mass"" is a discoid portion of rubbery and focally firm yellow to gray-tan tissue weighing up to 11.2 gm and measuring 5.1 x 3.6 x 1.5 cm in greatest dimension.  The specimen is oriented: short suture - superior, long suture - lateral, double suture - deep.  The specimen is inked: blue - superior, green - inferior, yellow - lateral, orange - medial, red - anterior, black - deep.  A metal localizing wire is inserted through the lateral aspect of the specimen.  Sectioning reveals a largely white-tan and fibrous cut surface with apparent fibrocystic changes.  There is an ill-defined gray-tan zone of increased firmness at the medial margin that measures up to 1.3 cm in greatest dimension.  The remaining cut surface is soft and yellow-tan.  Out of patient: unspecified, in formalin: (**DATE[Jun 1 12]) 16:40 hours, total fixation: approximately 26 hours.  Submitted entirely in 9 cassettes as serial, sequential sections beginning with the lateral margin in cassette 1.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Left breast biopsy, microcalcifications",,
REG4,BREAST,0,PAT-10033828,1,REC-3000640767,"ClinicalHistory:
Mass.",Other Case Numbers: MR# **ID-NUM.,"FinalDiagnosis:
Left breast core biopsy, mass:  INFILTRATING DUCTAL CARCINOMA 

Breast Tumor Information:

Operative procedure:      Stereotactic core biopsy
Histologic type:      Ductal, usual type
Histologic grade (MBR):      Grade 2
Nuclear score:      1
Mitotic score:      3
Tubule score:      3
Invasive tumor size:      At least 0.5 cm
Necrosis:      Absent
Lymphovascular invasion:      Not identified
In situ component:      10%, low grade
Microcalcifications:      Absent
Special studies:      ER, PR, HER-2 and Ki-67 pending
DiagnosisComment:
Specimen signed out at **INSTITUTION for **STREET-ADDRESS, **PLACE, HI **ZIP-CODE.\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, left breast"" are multiple cores of yellowish-white tissue measuring up to 2.2 x 0.2 cm in diameter.  Submitted in toto in four cassettes.  Specimen removed from patient for a total fixation time of 9 hours 30 minutes.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Left breast,,
REG4,BREAST,0,PAT-10040581,1,REC-3000640877,,,"IntraoperativeDiagnosis:
Malignant; performed and assessed by CF.
FinalDiagnosis:
RIGHT BREAST MASS AT MASTECTOMY SITE, FINE AND CORE NEEDLE BIOPSY:
- POORLY DIFFERENTIATED CARCINOMA CONSISTENT WITH BREAST PRIMARY.
DiagnosisComment:
ER/PR and HER2/neu are pending.  

The following stains were performed in the evaluation of this case (see microscopic description for complete details): GCDFP-15, mammaglobin and CD31.",,"GrossDescription:
Received:  3 DQ stained smears.
       1.5 ml of cloudy reddish fluid in a syringe.
       Tissue fragments in formalin soln.
Prepared:  1 cytospin slide for Pap stain, treated with CytoLyt x1.
Submitted:  4 tissue fragments measuring up to 6 mm in length for a cell block.","MicroscopicDescription:
Cytologic preparations demonstrate a poorly differentiated carcinoma.  Focally, the tumor appears to exhibit a vascular growth pattern, however, CD31 is negative.  Despite the negative GCDFP-15 and mammaglobin, the composite findings in conjunction with the patient's history are compatible with recurrent mammary carcinoma.",A: RIGHT BREAST MASS @ MASTECTOMY SITE FNA AND CNB,,
REG4,BREAST,0,PAT-01447861,2,REC-3000653420,,,"IntraoperativeDiagnosis:
25G FNA x 1.
16G CNB x 3.
Malignant; performed and assessed by **INITIALS.
FinalDiagnosis:
RIGHT BREAST FNA AND CNB:  INVASIVE DUCTAL CARCINOMA.
DiagnosisComment:
Though a definitive histologic grade cannot be given on a needle biopsy, the tumor exhibits features of intermediate to high grade (nuclear pleomorphism score of 3, glandular (acinar)/tubular differentiation score of 3 and mitotic score of 1-2).  ER/PR and Her2/neu studies are pending.  The results have been conveyed to Dr. **NAME[ZZZ YYY]'s office on **DATE[Aug 4 12].",,"GrossDescription:
Received:  3 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  3 tissue fragments measuring up to 9 mm in length for a cell block.",,A: RIGHT BREAST FNA AND CNB,,
REG4,BREAST,0,PAT-10041038,1,REC-3000653441,"ClinicalHistory:
A. Mass, size of lesion-15.5 mm
B. Mass, size of lesion-6.5 mm.",,"FinalDiagnosis:

A.  LEFT BREAST US-GUIDED CORE BIOPSY AT 3:00 5CFN (15.5MM MASS):
    - INVASIVE DUCTAL CARCINOMA.  
 
B.  LEFT BREAST US-GUIDED CORE BIOPSY AT 2:30 5CFN (6.5MM MASS):  
    - INVASIVE DUCTAL CARCINOMA.
DiagnosisComment:
A,B. ER/PR/Her2 results pending (block A1).  The tumor in both specimens shows grade II features (architectural score 3; nuclear score 2; mitotic score 1).",,"GrossDescription:
A. Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Oct 3 11] 8:45 a.m..
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  5.
Size:  0.2 cm in diameter and up to 2.0 cm in length.
Formalin fixation (Start):  Date  **DATE[Oct 3 11] Time  8:52 a.m..
Formalin fixation (End):  Date  **DATE[Oct 3 11] Time  10:30 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B. Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Oct 3 11] 8:30 a.m..
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  Multiple.
Size:  0.2 cm in diameter and up to 1.7 cm in length.
Formalin fixation (Start):  Date  **DATE[Oct 3 11] Time  8:40 a.m..
Formalin fixation (End):  Date  **DATE[Oct 3 11] Time  10:30 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT 3:00 5 CFN
B: LEFT 2:30 5 CFN",,
REG4,BREAST,0,PAT-10037283,1,REC-3000653486,"ClinicalHistory:
Left breast cancer.",,"FinalDiagnosis:
LEFT BREAST (NEEDLE LOCALIZATION) BIOPSY:  DUCTAL CARCINOMA IN-SITU

Breast in-situ carcinoma information
Specimen:  Left breast tissue
Operative Procedure:  Left breast needle localization biopsy
Tumor histologic type:  Ductal carcinoma in-situ
Anatomic site:  Left breast
Focality:  Unifocal in specimen  
Architectural pattern:  Solid
Nuclear grade:  3
Necrosis:  Comedonecrosis present
Size:  2.8 x 1.4 x 1.2 cm (macroscopic)
Paget s disease:  Nipple not submitted
Microcalcifications:  Present in DCIS
Resection margins:
  Superior:  > 1 cm  
  Inferior:  > 1 cm  
  Lateral:  > 1 cm  
  Medial:  > 1 cm  
  Superficial:  < 1 mm  
  Deep:  1 mm    
Axillary lymph nodes:  None submitted
Special procedures:
1.  Estrogen and progesterone receptor analysis pending
2.  Immunohistochemical staining with smooth muscle actin and p63 on slides A7 and A9 fail to reveal invasive carcinoma
Other findings:  Foci of atypical ductal hyperplasia, sclerosing adenosis, fibroadenoma (3 mm), fibrocystic change with apocrine metaplasia, focal hemorrhage and granulation tissue consistent with previous biopsy 

Pathologic stage:  pTis NX (Stage 0, if N0 and M0).",,"GrossDescription:
A. Specimen:  Oriented, irregular segment of fibrofatty tissue received fresh with a single localization wire.
Collection date/time:  **DATE[Jun 3 12]; 9:01 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  41 gm.
Dimensions:  
Superior-inferior:  7.0 cm.
Medial-lateral:  6.5 cm.
Superficial-deep:  2.3 cm. 
Orientation/inking of margins:
Long suture - lateral
Medium suture - anterior
Short suture - superior
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  2.8 x 1.4 x 1.2 cm pink tan lesion with biopsy clip, < 0.1 cm from superficial and 0.1 cm from the deep margins.  Remaining margins are greater than 1.0 cm away.
Ancillary studies:  Faxitron performed and reviewed by pathologist.  Biopsy clip and microcalcifications identified within mass.
Special studies:  To be done off paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[Jun 3 12] Time  10:00 a.m.
Formalin fixation (End):  Date  **DATE[Jun 3 12] Time  6:00 p.m.
Submitted for microscopic evaluation:  Representative as indicated on photograph.
Cassettes:  13, interior to superior respectively. Cassettes 1 and 13 contain cross sections through end margins. Cassettes 3 contains biopsy clip. Cassettes 3-5, 7-12 contain microcalcifications.",,A: LEFT NEEDLE LOCALIZATION,,
REG4,BREAST,0,PAT-10037448,1,REC-3000653690,"ClinicalHistory:
Left breast cancer.",,"FinalDiagnosis:
LEFT BREAST TISSUE, ORIENTED:  
1.  INTRADUCTAL PAPILLOMA WITH DUCTAL CARCINOMA IN SITU, 1 CM.
2.  FIBROCYSTIC CHANGES WITH FOCAL FLORID DUCTAL EPITHELIAL
    HYPERPLASIA AND MICROCALCIFICATIONS.
3.  HYALINIZED FIBROADENOMA, 0.4 CM.

Breast in-situ carcinoma information
Specimen:  Left breast tissue.
Operative Procedure:  Left breast lumpectomy.
Tumor histologic type:  Ductal carcinoma in situ in intraductal
  papilloma.
Anatomic site:  Left breast.
Focality:  Unifocal.
Architectural pattern:  Solid and papillary.
Nuclear grade:  Grade 1.
Necrosis:  Not identified.
Size:  1 x 1 x 0.8 cm (macroscopic).
Paget s disease:  Not assessed.
Microcalcifications:  Present in benign breast.
Resection margins:
  Superior:  >10 mm.
  Inferior:  2 mm.
  Lateral:  >10 mm.
  Medial:  4 mm.
  Superficial:  >10 mm.
  Deep:  >10 mm. 
Axillary lymph nodes:  Not assessed.
Special procedures:  ER+, PR+ on previous needle biopsy
  (WO11-3558, **DATE[Nov 18 11], Pan **PLACE Pathologists).
Other findings:  None.

Pathologic stage:  Tis NX, stage 0.
DiagnosisComment:
p63 and smooth muscle myosin stains show myoepithelial cells at the periphery and focally within the lesion. CK5/6 stain shows absence of staining. The findings support the diagnosis of DCIS.",,"GrossDescription:
Specimen:  Oriented irregular segment of fibrofatty tissue, received fresh with single localization wire.
Collection date/time:  **DATE[Dec 5 11]; 9:08 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  34 gm.
Dimensions:  
Superior-inferior:  3 cm.
Medial-lateral:  4.5 cm.
Superficial-deep:  7.4 cm. 
Orientation/inking of margins:
Long suture - lateral
Short suture - superior
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  1 x 1 x 0.8 cm circumscribed, soft, tan lesion with associated biopsy cavity containing filler material and clip.  Lesions measure 0.2 cm from the inferior margin, 0.4 cm from the medial margin, and greater than 1 cm from the remaining margins.  No other lesions grossly identified.  Remaining tissue has a predominantly fatty cut surface with focal hemorrhage.
Ancillary studies:  Faxitron performed and reviewed by pathologist.  Biopsy clip and lesion identified on Faxitron.
Special studies:  To be done off paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[Dec 5 11] Time  9:55 a.m.
Formalin fixation (End):  Date  **DATE[Dec 5 11] Time  6:00 p.m.
Submitted for microscopic evaluation:  Representative.
Cassettes:  12, superficial to deep.  Lesion in 3 and 7; cross sections through end margins in 1 and 12.",,A: LEFT BREAST TISSUE,,
REG4,BREAST,0,PAT-10034746,1,REC-3000654115,"ClinicalHistory:
Right breast cancer.
Pre-OperativeDiagnosis:
Re-excision of right breast margin.",,"PreOperativeDiagnosis:
Re-excision of right breast margin
FinalDiagnosis:
New lateral posterior margin, stitch marks new margin:  No evidence of residual carcinoma
                Fat necrosis and chronic granulomatous
                  inflammation at prior biopsy site
                Proliferative fibrocystic change\X0A|",,"GrossDescription:
Specimen received in fixative labeled with the patient's name and ""new lateral posterior margin, stitch marks new margin"" consists of one yellow soft tissue measuring 4 x 3 x 1.2 cm.  There is a stitch labeling lateral on one side of the specimen.  The side with the suture is labeled with green ink and the opposite side is labeled with yellow ink.  Specimen is serially sectioned and totally submitted in five cassettes.
  1-5) New lateral posterior margin

Specimen was removed from patient on **DATE[Apr 5 2012] at 0748 and placed in formalin at 0750 for a total fixation time of approximately 9 hours.","MicroscopicDescription:
Five slides are reviewed.  At the prior biopsy site there are fat necrosis and chronic granulomatous inflammation.  The rest of breast tissue shows ductal dilatation, mild adenosis, apocrine metaplasia and mild ductal hyperplasia with microcalcifications.  There is no evidence of residual carcinoma.","A: New lateral posterior margin, stitch marks new margin",,
REG4,BREAST,0,PAT-10039788,1,REC-3000654225,"ClinicalHistory:
Left breast calcifications.
Post-OperativeDiagnosis:
Pending pathology.",,"PostOperativeDiagnosis:
Pending pathology
FinalDiagnosis:
Breast, left, excisional biopsy:    DUCTAL CARCINOMA IN SITU, GRADE 2
      
  Breast Tumor Information:

  Type of specimen(s):      Excisional biopsy
  Histologic Type:      Ductal carcinoma in situ
  Size:      1.5 cm (present on 5 consecutive sections)
  Architectural pattern(s):      Micropapillary and cribriform
  Nuclear grade:      Nuclear grade 2 out of 3
  Necrosis:      Present, comedo type
  Microcalcifications:      Present, associated with malignant and benign tissue
  Resection margins:      Involved by DCIS (anterior and deep margins)
        Present less than 0.5 mm from the inferior margin
        All other margins clear by at least 3 mm
  Other findings:      Atypical and usual ductal hyperplasia, radial scar
  Ancillary studies:      ER and PR are pending and will be reported separately\X0A|",,"GrossDescription:
Received fresh, labeled ""XXXXXX, XXXXXX, left breast mass"" is a discoid portion of rubbery and focally firm yellow to gray-tan tissue weighing up to 11.2 gm and measuring 5.1 x 3.6 x 1.5 cm in greatest dimension.  The specimen is oriented: short suture - superior, long suture - lateral, double suture - deep.  The specimen is inked: blue - superior, green - inferior, yellow - lateral, orange - medial, red - anterior, black - deep.  A metal localizing wire is inserted through the lateral aspect of the specimen.  Sectioning reveals a largely white-tan and fibrous cut surface with apparent fibrocystic changes.  There is an ill-defined gray-tan zone of increased firmness at the medial margin that measures up to 1.3 cm in greatest dimension.  The remaining cut surface is soft and yellow-tan.  Out of patient: unspecified, in formalin: (**DATE[Feb 1 12]) 16:40 hours, total fixation: approximately 26 hours.  Submitted entirely in 9 cassettes as serial, sequential sections beginning with the lateral margin in cassette 1.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Left breast biopsy, microcalcifications",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10031154,1,REC-3000671352,"ClinicalHistory:
Right breast mass 1 o clock./r/n",,"FinalDiagnosis:
Right breast at 1:00:  Invasive ductal carcinoma./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[May 31 2012].  Findings reported to Phyllis Lum of the breast team on **DATE[May 31 2012] at 5:45 PM.   Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block 1 and reported in an addendum./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right breast 100
Specimen:    Cylindrical cores of fibrofatty tissue (formalin)
Number:      Five
Size:           Up to 2 x 0.1 x 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Most of the breast needle cores are involved by invasive ductal carcinoma with thin cords of infiltrating cells with stromal desmoplasia with accompanying ductal carcinoma in situ with solid and cribriform patterns extending slightly further away from the invasive component with overall low nuclear grade and low mitotic rate.  Focal lymphocytes are seen in the background breast tissue./r/n","A: Right breast 100, core biopsy",,"ResultsComments:
The following results were performed at Quest Diagnostics and reported by **NAME[ZZZ M. YYY], M.D. on **DATE[Jun 08 2012].   

INTERPRETATION:
***PATH-NUMBER[1] (INVASIVE CARCINOMA)

ESTROGEN RECEPTOR:      99%
PROGESTERONE RECEPTOR:    97%
HER-2/neu    (ACIS score)       1.6          (REFLEXED TO SISH TESTING)

COMMENT:
ERPR:  
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on   formalin-  fixed paraffin-embedded section stained by immunohistochemical methods on the Ventana Benchmark XT 
  automated stainer using antibodies against ER (SP1 IVD) and PR (clone IE2 IVD).  Though the largest 
  studies have used 10% as a threshold for positivity, others have recommended a cutoff as low as 1%.

HER-2/neu:
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on   formalin-  fixed paraffin-embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu (4B5) Rabbit Monoclonal Antibody.

Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and equivocal) were appropriate.

The results obtained from the ChromaVision ACIS correspond to the ASCO/CAP scoring criteria in the following manner, as determined by in-house studies:

ChromaVision       ASCO/CAP
Result:          Score:

Less than 1.5      0
(No staining)

Less than 1.5      1+
(Weak, incomplete membrane staining)

1.5 to 3.4      2+
(Complete membrane staining that is either nonuniform or weak in intensity, but with obvious circumferential distribution in at least 10% of the cells, or intense complete membrane staining in less than or equal to 30% of invasive tumor cell)

Greater than 3.4      3+
(Uniform, intense membrane staining in greater than 30% of invasive tumor cells)

A ChromaVision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise specified.  This is in accordance with CAP recommendations (Strategic Science I meeting, **DATE[Feb 2003], **PLACE, IL).

Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  

References:
1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
2.  **NAME[XXX] JM, et. al. Mod Path **ID-NUM.
3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
4.  **NAME[WWW M], et. al. Am J Clin Pathol 2001;**ID-NUM.
5.  **NAME[VVV, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
6.  Wolff, AC, et al.  American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.  Arch Pathol Lab Med 2007; **ID-NUM./r/n"
REG4,BREAST,0,PAT-10038123,1,REC-3000671395,"ClinicalHistory:
DCIS proven, possible METs.",,"FinalDiagnosis:
LEFT BREAST LEFT AXILLA:  
BENIGN LYMPH NODE, NO EVIDENCE OF METASTASIS.",,"GrossDescription:
Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Mar 7 12]; 11:20 a.m..
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  Multiple.
Size:  0.2 cm in diameter and up to 1.5 cm in length.
Formalin fixation (Start):  Date  **DATE[Mar 7 12] Time  11:20 a.m..
Formalin fixation (End):  Date  **DATE[Mar 7 12] Time  6:00 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,A: LEFT BREAST LEFT AXILLA,,
REG4,BREAST,0,PAT-10035364,1,REC-3000671685,"ClinicalHistory:
Bilateral breast masses.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
US guided bilateral core biopsies. Tech: RMS.",,"PreOperativeDiagnosis:
US guided bilateral core biopsies. Tech: RMS
PostOperativeDiagnosis:
Same, Pending pathology
FinalDiagnosis:
A.  LEFT BREAST INVASIVE DUCTAL CARCINOMA
Breast Tumor Information:
Operative procedure:      US needle biopsy, left breast mass 1:00, 2 cm FN
Histologic type:        Invasive ductal carcinoma
Histologic grade (MBR):      Moderately-differentiated
Nuclear score:        2
Mitotic score:        1
Tubule score:        3
Invasive tumor size:      1.0 cm in core biopsy material
Necrosis:          Not evident
Lymphovascular invasion:      Not evident
In situ component:        Present, minimal component ductal carcinoma in situ, 
          low-grade
Microcalcifications:        Few
Special studies:        ER/PR/HER2-neu/Ki67 pending
Staging information:      pT1

B.  Mass, right breast 12:00, 2 cm FN, US needle biopsy:  
              Fibroadenoma. \X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, **NAME[AAA], left breast 1:00, 2 cm FN"" are four cores of tan-white, focally hemorrhagic soft tissue measuring up to 2.0 x 0.1 cm.  The specimens are placed in formalin at 8:18 on **DATE[Aug 06 12], for a total fixation time of approximately 9.75 hours.  Submitted entirely in block A.

B.  Received in formalin labeled ""XXXXXX, **NAME[AAA], right breast 12:00, 2 cm FN"" are three cores of tan-white, focally hemorrhagic soft tissue measuring up to 1.7 x 0.1 cm.  The specimens are placed in formalin at 8:18 on **DATE[Aug 06 12], for a total fixation time of approximately 9.75 hours.  Submitted entirely in block B.","MicroscopicDescription:
A.  Needle biopsies of breast demonstrate an invasive mammary carcinoma.  An immunostain for E-cadherin demonstrates strong positive tumor staining, supporting ductal differentiation.

B.  Needle biopsies of breast contain fragments of fibroadenoma.","A: Left breast 1:00 2cm FN 10x13x18mm
B: Right breast 12:00 2cm FN 3x4x11mm",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Elevated cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10037315,1,REC-3000671982,"ClinicalHistory:
Breast lump.",,"FinalDiagnosis:

Left breast mass, core needle biopsy:    DUCTAL CARCINOMA, HIGH-GRADE (see comment).



Comment:  The biopsy shows cyst-like areas lined by highly atypical cells.  The myoepithelial markers (myosin heavy chain and p63 stains) are negative in these areas.  Although there is no characteristic infiltrative pattern of invasive tumor, the absence of myoepithelial cell staining is highly suspicious for invasive carcinoma.  Prior core needle biopsy of the left breast mass (***PATH-NUMBER[1]) showed a minute focus of invasive ductal carcinoma. 

Case discussed with Dr. **NAME[M. ZZZ YYY] on **DATE[May 12 2012].  Reviewed in concurrence with Dr. **NAME[XXX WWW] at the **INSTITUTION for Women and Children, Oahu.     
            \X0A|",,"GrossDescription:
Received in formalin labeled ""left breast mass"" are nine white-tan, yellow and fibro-fatty tissue fragments ranging in size from 
2.4 x 0.8 x 0.3 cm to 3.5 x 0.4 x 0.4 cm.  Entirely submitted in three cassettes.

The specimen was collected on **DATE[May 10 12] at 3:47 p.m. and immediately placed in formalin for a total fixation time of approximately 
27 hours.","MicroscopicDescription:
Microscopic findings support the diagnosis.",A: Lt breast mass,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Negative
Progesterone receptor (clone PgR 636):  Negative
HER-2/neu (HercepTest):      Equivocal
Ki-67 (clone Ki-S5):      Elevated cell proliferation
p53 (clone DO7):        Elevated

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results.

HER-2/neu (FISH):  Negative for amplification, chromosome 17 aneusomy present.
AddendumComment:
Fish2HER-2/neu analysis by fluorescence in situ hybridization shows a HER-2/chromosome 17 ratio of 0.9.  There is aneusomy of chromosome 17 with an average copy number of 4.3.


Testing performed at Clarient Diagnostic Services, **PLACE, CA."
REG4,BREAST,0,PAT-10034852,1,REC-3000672043,"ClinicalHistory:
Left breast cancer.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Needle localized wide excision left breast and left breast sentinel node biopsy.",,"PreOperativeDiagnosis:
Needle localized wide excision left breast and left breast sentinel node biopsy
PostOperativeDiagnosis:
Same, Pending pathology
IntraoperativeDiagnosis:
A.  Touch Prep:  Node, negative for metastasis/MP
FinalDiagnosis:
A.  Sentinel node, left axilla, biopsy:    Lymph node, negative for metastasis (0/1)

B.  LEFT BREAST INVASIVE DUCTAL CARCINOMA
  Breast Tumor Information:
  Operative procedure:      Needle localized wide excision, left breast mass
  Histologic type:      Invasive ductal carcinoma
  Histologic grade (MBR):    Well-differentiated 
  Nuclear score:        2
  Mitotic score:        1
  Tubule score:        2
  Invasive tumor size:      1.5 x 1.0 x 0.9 cm
  Necrosis:        Not evident
  Lymphovascular invasion:    Not evident
  In situ component:      Minimal, low-grade duct carcinoma in-situ
  Resection margins:      Tumor present at deep margin of excision (3.0 mm area of 
            involvement)
  Microcalcifications:      Rare
  Lymph nodes:        Negative for metastasis (0/1 sentinel node/part A)
  Special studies:      Performed on previous needle biopsy (***PATH-NUMBER[1]; ER-positive, 
            PR-positive, HER2-neu (FISH)-negative)
  Staging information:      pT1c N0(i-)(sn)\X0A|",,"GrossDescription:
A.  Received fresh for intraoperative consultation labeled ""left breast sentinel node"" is an excision of tan-yellow soft tissue measuring 2.3 x 1.8 x 1.0 cm.  By palpation there is a single firm nodule grossly consistent with lymph node measuring 1.7 cm in greatest dimension.  A touch preparation is performed and the lymph node is submitted entirely in block A.

B.  Received fresh labeled ""left breast tissue long lateral short superior"" is an excision of tan-yellow fibrofatty soft tissue with attached tan-white skin ellipse having overall dimensions of 7.5 x 7.0 x 2.8 cm.  The skin ellipse measures 4.5 x 1.9 cm.  Sutures are provided for orientation and the specimen is inked.  The superior aspect orange, inferior yellow, lateral red, medial blue, deep green.  There is a centrally placed needle.  Sectioning reveals a tan-yellow fibrofatty cut surface.  in the deep aspect of the specimen is a poorly circumscribed tan-white firm nodule measuring  1.5 x 1.0 x 0.9 cm.  The lesion is located at the tip of the localizing wire at the deep margin.  No further masses or lesions are grossly identified.  Representative sections are submitted in blocks B1-B8.","MicroscopicDescription:
A.  Sections of lymph node are negative for metastasis on routine stain.  Immunostain (keratin) demonstrates no evidence of micrometastasis.  

B.  An excision of breast demonstrates an invasive, well-differentiated ductal carcinoma.  There is focal tumor involvement of the deep margin of excision, involving an area of approximately 3.0 mm.","A: Sentinel node biopsy left breast
B: Left breast mass short superior long lateral",,
REG4,BREAST,0,PAT-10036085,1,REC-3000672277,"ClinicalHistory:
Left breast mass.",,"IntraoperativeDiagnosis:

A.  INTRAOPERATIVE CONSULTATION:  MASS GROSSLY INVOLVES THE ANTERIOR MARGIN.  (JM)
FinalDiagnosis:

A.  Left breast mass, excision:    INVASIVE DUCTAL CARCINOMA, GRADE 2, 
          measuring 2.2 x 1.4 x 1.3 cm, with mucinous component (20%).

Tumor Information:
Operative procedure:    Lumpectomy
Histologic type:    Ductal
Histologic grade (MBR):  Grade 2
  Nuclear score:    3
  Mitotic score:    1
  Tubule score:    3
  Total score    7 out of 9
Invasive tumor size:    2.2 x 1.4 x 1.3 cm
Necrosis:      Yes
Lymphovascular invasion:  No
In situ component:    Yes, DCIS minor component 
Resection margins:    Final margin free in part B, 0.2 mm clearance to margin in part A.
Microcalcifications:    No
Lymph nodes:      N/A
Special studies:    E-cadherin and myosin heavy chain, prognostic markers reported in an addendum.
Staging information:    pT2, pNx, pMx


B.  Anterior margin, excision:    Skin and benign breast tissue, negative for carcinoma.

Comment: The immunohistochemical markers E-Cadherin and myosin heavy chain support the above diagnosis.\X0A|",,"GrossDescription:
(A)  Received fresh labeled ""left breast mass"" is a 9.0 x 6.0 x 3.0 cm oriented yellow and fatty tissue with attached metallic tags demarcating superficial, deep, medial, lateral, superior and inferior margins.  The margins are inked as follows:  superior - blue, inferior - green, lateral - violet, medial - red, superficial - orange and deep - black.  The specimen is serially cut into ten lamella from lateral to medial margin.  There is a 2.2 x 1.4 x 1.3 cm tan-pink and firm tumor grossly involving the nearest anterior margin, and is 1.5 cm from lateral margin, 2.3 cm from medial margin, 2.0 cm from nearest inferior margin, 2.5 cm from nearest superior margin and 0.6 cm from nearest deep margin.  The tumor is located at lamella 3 - 6.  The rest of breast tissue is fatty with a little amount of white-tan, pink and rubbery tissue.  The specimen was collected on **DATE[Jan 13 12] at 8:33 am and placed in formalin at 8:55 am, for a total fixation time of approximately 9-1/2 hours.  Representative sections are submitted in eleven cassettes.

Cassette Key:
A1  Lamella 1 (lateral margin)
A2  Representative section from lamella 2
A3  Representative section from lamella 3
A4  Representative section from lamella 4 (deep margin nearest to tumor)
A5  Representative section from lamella 4 (grossly involved superficial margin)
A6  Representative section from lamella 5 (grossly involved superficial margin)
A7  Representative section from lamella 5 (inferior margin nearest to tumor)
A8  Representative section from lamella 5 (superior margin nearest to tumor)
A9  Representative section from lamella 9 (grossly involved superficial margin)
A10  Representative section from lamella 7
A11  Lamella 10 (medial margin)

(B)  Received in formalin labeled ""anterior margin"" is a 4.2 x 1.5 x 0.7 cm tan-pink ellipse of skin with a centrally located, possible scar measuring 0.8 cm.  The margins are entirely inked green.  Sections are cut and submitted sequentially from one tip to the opposite tip.  Entirely submitted in two cassettes.","MicroscopicDescription:
A, B.  Confirmed.","A: Left breast mass (specimen marked with margin map)
B: Anterior margin",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (clone Ki-S5):      Low cell proliferation
p53 (clone DO7):        Normal

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-01486232,1,REC-3000672288,"ClinicalHistory:
Right and left femur, pathologic impending fractures.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Intramedullary nailing, right and left femur.",,"PreOperativeDiagnosis:
Intramedullary nailing, right and left femur
PostOperativeDiagnosis:
Same
FinalDiagnosis:
A.  Right femur, reamings:  METASTATIC CARCINOMA, consistent with metastatic breast carcinoma

B.  Left femur, reamings:  METASTATIC CARCINOMA, consistent with metastatic breast carcinoma
DiagnosisComment:
The patient's previous breast carcinoma (***PATH-NUMBER[1]) is reviewed in conjunction with the current bone metastases.  There is similar morphology between both specimens, supporting the current bony metastases as representing metastatic breast carcinoma.  Estrogen receptor staining on the current metastases shows equivocal, to very faint estrogen receptor staining.  HER-2/neu assessment of the current metastatic tumor is pending.\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""right femur reamings"" are fragments of tan-red soft tissue and hemorrhagic material measuring, in aggregate, 3.5 x 3.2 x 1.0 cm.  A large representative portion is submitted in blocks A1-A2.

B.  Received in formalin labeled ""left femur reamings"" are fragments of tan-red soft tissue and hemorrhagic material measuring, in aggregate, 6.0 x 4.5 x 2.0 cm.  A large representative portion is submitted in blocks B1-B2.","MicroscopicDescription:
A.  Sections contain small fragments of bone and fragments of soft tissue exhibiting metastatic carcinoma.  Immunostains (pan keratin, ER, PR) are evaluated and demonstrates positive staining for epithelial differentiation, and faint positive staining for ER receptors.  PR receptor is negative.  An immunostain for BRST-2 is negative in tumor.   

B.  Sections contain small fragments of bone with occasional small foci of metastatic carcinoma.  Immunostains (ER, BRST-2) are evaluated and demonstrates negative BRST-2 staining and very weak, to equivocal, staining for estrogen receptor.","A: Femur reamings, right
B: Femur reamings, left",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


HER-2/neu (HercepTest):      Positive for overexpression


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10029255,1,REC-3000672534,"ClinicalHistory:
Recurrent left breast mass.
Post-OperativeDiagnosis:
Same, pending pathology.
Pre-OperativeDiagnosis:
A.  Left breast mass, excision:
 
B.  Left axillary mass, excision:.",,"PreOperativeDiagnosis:
A.  Left breast mass, excision:
 
B.  Left axillary mass, excision:
 
PostOperativeDiagnosis:
Same, pending pathology 
FinalDiagnosis:
A.  Left breast mass:  Recurrent high grade invasive ductal carcinoma, see comment

Breast Tumor Information:

Operative procedure:    Left breast biopsy
Histologic type:    Invasive ductal carcinoma
Histologic grade (MBR):    Grade 3
Nuclear score:    Grade 3
Mitotic score:    Grade 3
Tubule score:    Grade 3
Invasive tumor size:    2 x 2 x 1.8 cm
Necrosis:    Present
Lymphovascular invasion:    Not identified
In situ component:    Entirely invasive
Resection margins:    Clear
Microcalcifications:    Not identified
Special studies:    Receptor studies requested
Staging information:    Recurrent tumor

B.  Left axillary mass:  Invasive ductal carcinoma replacing axillary lymph node
 
**NAME[ZZZ:
YYY XXX], the left breast mass is removed at 11:17 am on **DATE[Mar 14 12] and immediately placed in formalin.  The specimen is sectioned and submitted for processing to begin at 7:30 pm on **DATE[Mar 14 12].

Receptor studies are requested on block A1.\X0A|",,"GrossDescription:
A.  Left breast mass:  Received is a breast biopsy measuring up to 6.2 x 4.5 x 3.0 cm.  It is partially covered by an intact skin ellipse that measures up to 5 x 2.5 cm.  The skin and fatty margins are grossly free of tumor.  On section, a movable well defined complex nodule measures up to 2 x 2 x 1.8 cm.  The margins of the nodule are well-defined and do not appear infiltrative.  The nodule is both cystic and solid.  Representative sections submitted in cassettes A1 and A2.
 
B.  Left axillary mass:  This consists of a firm yellow-tan tissue fragment measuring up to 5 x 3 x 1.8 cm.  On section, a complex mass similar to that seen in the left breast is identified.  This occupies most of the specimen.  Two representative sections are submitted in cassettes B1 and B2.","MicroscopicDescription:
A.  Left breast mass:  Sections demonstrate a tumor nodule composed of large nests of tumor cells with areas of necrosis.  Tumor sheets are solid.  Nuclei are high grade with frequent mitoses.  The surgical margins are free of tumor.
 
B.  Left axillary mass:  Sections demonstrate tumor similar to that seen in the left breast mass.  Residual lymph node tissue is not appreciated in the sections examined.  There is, however, a small lymph node in the adjacent fatty tissue.  Metastatic tumor is not noted in this small lymph node.","A: Left breast mass
B: Left axillary mass",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Negative
Progesterone receptor (PgR 636):    Negative
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Elevated cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10035008,1,REC-3000672714,,,"FinalDiagnosis:
Breast, right:  Invasive ductal carcinoma./r/nDiagnosisComment:
Immunoperoxidase stains for estrogen and progesterone receptors and Her-2/neu will be performed on block 1 and the results will be reported in an addendum.  Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Sep 13 2012].  The diagnosis was called to **NAME[ZZZ YYY] (voicemail), Breast Surgery Team, on **DATE[Sep 13 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right breast
Specimen:    Cylindrical cores of fibrofatty tissue, blood clot (formalin)
Number:      Multiple
Size:           Up to 1.7 x 0.2 x 0.2 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right breast, biopsy",,"ResultsComments:
The following results were performed at **PLACE, NV and reported by 
**NAME[XXX M. WWW], M.D. on **DATE[Sep 17 2012].  

INTERPRETATION:

BREAST CANCER PROGNOSTIC PANEL:  
***PATH-NUMBER[1], BLOCK # A1 (INVASIVE CARCINOMA)

            ESTROGEN RECEPTOR:                   100%
            PROGESTERONE RECEPTOR:            100%
            HER-2/neu (ACIS score):                   0.3 (NO OVEREXPRESSION)

COMMENT:
ERPR     
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical methods on the Ventana Benchmark XT automated stainer 
  using antibodies against ER (SP1 IVD), PR (clone IE2 IVD).  Though the largest studies have used 10% as a 
  threshold for positivity, others have recommended a cutoff as low as 1%. 

HER-2/neu
  Analysis is performed using Chromavision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu 
  (4B5)  Rabbit Monoclonal Antibody.

  Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and 
  equivocal) were appropriate.

  The results obtained from the ChromaVision ACIS correspond to the ASCO/CAP scoring criteria in the following 
  manner, as determined by in-house studies:

  ChromaVision:         ASCO/CAP 
  Result:          Score:

  Less than 1.5         0       (No staining)

  Less than 1.5         1+        (Weak, incomplete membrane staining)

  1.5 to 3.4              2+        (Complete membrane staining that is either nonuniform or weak in 
                       intensity, but with obvious circumferential distribution in at least 10% of the 
                       cells, or intense complete membrane staining in less than 30% of invasive 
                       tumor cells)

  Greater than 3.4       3+       (Uniform, intense membrane staining in greater or lesser than 30% 
                       invasive tumor cells)

  A ChromaVision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise 
  specified.  This is in accordance with CAP recommendations (Strategic Science I Meeting, **DATE[May 2003], **PLACE, 
  IL).

  Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American 
  Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered 
  formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 
  48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  
  
References:
  1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
  2.  **NAME[VVV] JM, et. al. Mod Path **ID-NUM.
  3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
  4.  **NAME[UUU M], et. al. Am J Clin Pathol 2001;**ID-NUM.
  5.  **NAME[TTT, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
  6.  Wolff, AC, et al.  ""American Society of Clinical Oncology/College of American Pathologists Guideline
       Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.""  Arch Pathol 
       Lab Med 2007; **ID-NUM.
  (DTW/mab)./r/n"
REG4,BREAST,0,PAT-10031154,1,REC-3000672828,"ClinicalHistory:
Right breast mass 1 o clock./r/n",,"FinalDiagnosis:
Right breast at 1:00:  Invasive ductal carcinoma./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[May 31 2012].  Findings reported to Phyllis Lum of the breast team on **DATE[May 31 2012] at 5:45 PM.   Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block 1 and reported in an addendum./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right breast 100
Specimen:    Cylindrical cores of fibrofatty tissue (formalin)
Number:      Five
Size:           Up to 2 x 0.1 x 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Most of the breast needle cores are involved by invasive ductal carcinoma with thin cords of infiltrating cells with stromal desmoplasia with accompanying ductal carcinoma in situ with solid and cribriform patterns extending slightly further away from the invasive component with overall low nuclear grade and low mitotic rate.  Focal lymphocytes are seen in the background breast tissue./r/n","A: Right breast 100, core biopsy",,"Interpretation:
HER2 SISH INTERPRETATION (***PATH-NUMBER[1]);

  NEGATIVE FOR HER2 ONCOGENE AMPLIFICATION./r/nResultsComments:
The following results were performed at **PLACE, NV and reported by **NAME[ZZZ M. YYY] M.D. on **DATE[Jun 20 2012].   

Average ratio of HER2 to CHROMOSOME 17 centromere is 1.

Average number of HER2 signals/nucleus is 2.

Average number of CHROMOSOME 17 centromeres/nucleus is 2.

The SISH (silver in situ hybridization) HER2 assay is performed at **PLACE, Nevada Business Unit.  The SISH assay uses the Ventana Benchmark automated stainer and Ventana INFORM HER2 and chromosome 17 (Chr17) probes on formalin?fixed, paraffin-embedded tissue.  Results are scored by a pathologist as follows:  negative for amplification (HER2:Chr17 less than 1.8), equivocal for amplification (1.8 greater than or equal to HER2:Chr17 less than or equal to 2.2), and positive for amplification (HER2:Chr17 greater than 2.2).  Controls stain appropriately.  This test fulfills the ASCO/CAP guidelines for HER2 testing that mandate that a new test should demonstrate a high (greater than or equal to 95%) concordance with another validated test (i.e. FISH) for positive (amplified) and negative (nonamplified) results.

FDA Disclaimer:  This test was performed using a kit/reagent that has not been cleared or approved by the FDA.  The analytical performance characteristics of this test have been determined by Quest Diagnostics.  This test should not be used for diagnosis without confirmation by other medically established means.

**INITIALS./r/n
The following results were performed at Quest Diagnostics and reported by **NAME[ZZZ M. YYY], M.D. on **DATE[Jun 08 2012].   

INTERPRETATION:
***PATH-NUMBER[1] (INVASIVE CARCINOMA)

ESTROGEN RECEPTOR:      99%
PROGESTERONE RECEPTOR:    97%
HER-2/neu    (ACIS score)       1.6          (REFLEXED TO SISH TESTING)

COMMENT:
ERPR:  
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on   formalin-  fixed paraffin-embedded section stained by immunohistochemical methods on the Ventana Benchmark XT 
  automated stainer using antibodies against ER (SP1 IVD) and PR (clone IE2 IVD).  Though the largest 
  studies have used 10% as a threshold for positivity, others have recommended a cutoff as low as 1%.

HER-2/neu:
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on   formalin-  fixed paraffin-embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu (4B5) Rabbit Monoclonal Antibody.

Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and equivocal) were appropriate.

The results obtained from the ChromaVision ACIS correspond to the ASCO/CAP scoring criteria in the following manner, as determined by in-house studies:

ChromaVision       ASCO/CAP
Result:          Score:

Less than 1.5      0
(No staining)

Less than 1.5      1+
(Weak, incomplete membrane staining)

1.5 to 3.4      2+
(Complete membrane staining that is either nonuniform or weak in intensity, but with obvious circumferential distribution in at least 10% of the cells, or intense complete membrane staining in less than or equal to 30% of invasive tumor cell)

Greater than 3.4      3+
(Uniform, intense membrane staining in greater than 30% of invasive tumor cells)

A ChromaVision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise specified.  This is in accordance with CAP recommendations (Strategic Science I meeting, **DATE[Feb 2003], **PLACE, IL).

Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  

References:
1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
2.  **NAME[XXX] JM, et. al. Mod Path **ID-NUM.
3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
4.  **NAME[WWW M], et. al. Am J Clin Pathol 2001;**ID-NUM.
5.  **NAME[VVV, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
6.  Wolff, AC, et al.  American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.  Arch Pathol Lab Med 2007; **ID-NUM./r/n"
REG4,BREAST,0,PAT-10035124,1,REC-3000672874,"ClinicalHistory:
Right breast cancer.",,"IntraoperativeDiagnosis:

B.  INTRAOPERATIVE CONSULTATION:  GROSSLY 1mm TO LATERAL MARGIN.  (LK).
FinalDiagnosis:

A.  Right axillary contents, excision:    Eight benign lymph nodes (0/8).

B.  Right breast mass, lumpectomy:    1.  INVASIVE DUCTAL CARCINOMA (see Tumor Information).
            2.  Healing biopsy site.

Tumor Information:
Histologic grade:    Grade 2 out of 3 (Nottingham combined histologic score 7 out of 9)
          Tubule score:  3 out of 3
          Nuclear score:  3 out of 3
          Mitotic score:  1 out of 3
Invasive tumor size:    Up to 0.5 cm
Tumor focality:    Unifocal
In-situ component:    Lobular carcinoma in situ
Lymph-vascular invasion:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:    Negative - invasive tumor is 2 mm from the anterior margin 
Lymph node metastasis:  Not identified - eight benign lymph nodes      
Ancillary studies:    See addendum below
Stains:        Tumor is positive for E-cadherin stain, supporting the ductal differentiation; 
        myosin heavy chain and p63 stains are negative
AJCC (7th edition) stage:  pT1a  pN0  Mx
        Note:  Tumor size in prior biopsy is not known

C.  Right breast, lateral margin, excision:  Negative for malignancy.",,"GrossDescription:
(A)  Received in formalin labeled ""right axillary contents"" is a yellow-red and soft fibrofatty tissue fragment measuring 10 x 5.7 x 2.1 cm.  At least ten possible lymph nodes are noted.  The largest measures 0.8 cm in greatest dimension.  The lymph nodes are submitted as whole in cassettes A1 - A6.  

(B)  Received fresh labeled ""right breast cancer"" is an oriented breast mass excision specimen measuring 7.5 x 7 x 2.5 cm.  The specimen is oriented with metallic margin markers, and is inked as follows:  cranial - blue, lateral - violet, medial - red, deep - black, caudal - green and skin - orange.  There is an anteriorly inserted localization wire that terminates within the caudal medial aspect of the specimen.  The guide wire tip shows breast tissue that is yellow and fatty.  No suspicious lesions or nodules surrounding the hook wire.  Within the middle aspect of the specimen on the anterior and lateral portion is a tan-white and firm gritty nodule (possible biopsy site) that measures 0.5 cm in greatest dimension.  It is within 0.3 cm under the violet inked lateral margin.  About 1.5 cm medially and anteriorly of the nodule is a 0.4 cm tan-white and firm nodule that appears to be grossly consistent with tumor.  It is within 0.8 cm of the nearest orange inked anterior surface, 1.5 cm from the violet inked lateral margin and more than 2 cm from the remaining margins.  Some areas surrounding the suspicious lesion are tan-pink and rubbery, suggestive of fibrocystic change.  All remaining breast tissue is yellow and fatty.  All margins appear grossly clear of the nodule.  Representative sections are submitted sequentially from caudal to cranial in fourteen cassettes.  Sections suspicious for cancer are submitted in cassettes B4 and B5.  

Also received is a yellow-pink and soft fatty tissue fragment measuring 3.3 x 2.5 x 1 cm.  The specimen is inked black.  All sections are yellow and fatty with some areas of hemorrhage.  No gross lesions or suspicious nodules noted.  Random sections of separate fatty tissue fragment in cassettes B13 and B14.  

The specimen was collected on **DATE[Apr 16 12] at 12:17 pm and placed in formalin at 1:00 pm, for a total fixation time of approximately 
6 hours.

(C)  Received in formalin labeled ""re-excision lateral margin, right breast"" is an unoriented yellow-pink, red and soft, fibrofatty tissue fragment measuring 5.8 x 4.1 x 2.5 cm.  The specimen is inked black.  Sections reveal a predominantly yellow, fatty breast specimen with some areas of focal hemorrhage noted along the margins.  No sections reveal any suspicious nodules or residual tumor.  Submitted entirely and sequentially in seventeen cassettes.

The specimen was collected on **DATE[Apr 16 12] at 12:51 pm and placed in formalin at 12:52 pm, for a total fixation time of approximately 
6 hours.","MicroscopicDescription:
A - C.  Microscopic findings support the diagnosis.","A: Right axillary contents
B: Right breast cancer
C: Reexcision lateral margin, Right breast",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive
HER-2/neu (HercepTest):      Positive for overexpression
Ki-67 (clone Ki-S5):      Elevated cell proliferation
p53 (clone DO7):        Normal

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10038165,1,REC-3000673215,,,"FinalDiagnosis:

RIGHT BREAST US-GUIDED CORE BIOPSY AT 9:00 3CFN (7MM MASS):  INVASIVE DUCTAL CARCINOMA.
DiagnosisComment:
ER/PR/Her2 results pending.  The invasive tumor shows architectural score 3, nuclear score 2 to 3, and mitotic score deferred.  The tumor cells are positively stained with cytokeratin 7 and E-cadherin.",,"GrossDescription:
Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Nov 6 11] 9:25 am.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  Multiple.
Size:  Up to 0.3 cm in diameter and up to 1.2 cm in length.
Formalin fixation (Start):  Date  **DATE[Nov 6 11]  Time  9:35 am.
Formalin fixation (End):  Date  **DATE[Nov 6 11]  Time  10:30 pm.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT BREAST U/S BIOPSY 9:00, 3 CFN, 7 MM",,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HercepTest(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HER-2/neu gene (FISH) MetaSystems Metafer

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                 0%       NEGATIVE
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          0%       NEGATIVE
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
Ki-67 (MIB-1):                           9%       LOW
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:                 1.8        EQUIVOCAL
HER-2/neu gene (FISH)***:              1.0        NEGATIVE
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section):A1

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
Ki67 is reported as average %positive:  Low <10%.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation
1.5-2.69:  (2+) Equivocal
Report REISSUED to add HER2 HercepTest Results.

***PathVysion HER-2 DNA probe kit fluorescence in situ
hybidization (FISH), a trademark of Abbot
<1.8:  Negative
Report REISSUED to add HER-2/neu gene (FISH) results.

STANDARD ASSAY CONDITIONS ER/PR Her2:
Cold ischemic time less than 1 hr.: within limits
Fixation time Estrogen-Progesterone 6-72 hrs: within limits
Fixation time Her-2 6-48 hrs: within limits."
REG4,BREAST,0,PAT-10040685,1,REC-3000675831,"ClinicalHistory:
Calcifications; R/O malignancy.",,"FinalDiagnosis:
Right breast core biopsy, calcifications:  DUCTAL CARCINOMA IN-SITU

Breast Tumor Information:

Operative procedure:      Stereotactic core biopsy
Histologic type:      High grade
Nuclear grade:        3
Necrosis:        Absent
Architectural pattern(s):    Micropapillary
Size:          At least 0.4 cm (0.8 cm on imaging studies)
Microcalcifications:      Present in involved ducts
Special studies:      ER, PR pending.
DiagnosisComment:
Specimen signed out at **INSTITUTION for **STREET-ADDRESS, **PLACE, HI **ZIP-CODE.",,"GrossDescription:
Received in fixative labeled ""XXXXXX, right breast"" are multiple cores of yellowish-white tissue measuring up to 3.1 cm in length and 0.3 cm in diameter.  Submitted in toto in three cassettes.  The specimen was removed from patient on **DATE[Aug 22 12] at 8:30am and placed in formalin for a total fixation time of 10 hours and 30 minutes.  Cold ischemic time information was not provided.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right breast,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10035128,1,REC-3000675907,"ClinicalHistory:
Right breast cancer, LMP postmeno.
Post-OperativeDiagnosis:
Same, pending pathology examination.",,"PostOperativeDiagnosis:
Same, pending pathology examination.
FinalDiagnosis:
A.  Left breast:          Breast tissue with no evidence of malignancy  
 
B.  Right breast and axillary dissection:    INVASIVE DUCTAL CARCINOMA

Breast Tumor Information:

Operative procedure:        Bilateral mastectomy, right axillary dissection
Histologic type:        Usual type
Histologic grade (MBR):      Grade 3
  Nuclear score:        3
  Mitotic score:        3
  Tubule score:        3
Invasive tumor size:        2.4 x 1.7 x 0.7 cm
Necrosis:            Absent  
Resection margins:        All margins clear by >0.5 cm.
Lymphovascular invasion:      Not definitively identified (CD31 and D2-40 stains performed)
In situ component:        Absent
Microcalcifications:        Absent
Chest wall involvement:      Absent
Nipple/Skin involvement:      Absent
Lymph nodes:          36 lymph nodes negative for metastasis (0/36).
Special studies:        Previously performed, (ER neg, PR neg, Her-2 neg), repeat analysis pending
Staging information:        ypT2 ypN0.
DiagnosisComment:
The tumor bed shows chemotherapy effect but considerable viable tumor is present.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, left breast stitch at axillary tail (weight = 1kg - no formalin)"" is an oriented soft tan tissue, 990.0 gm, 21.0 x 18.6 x 7.1 cm.  There is a suture indicating the axillary tail.  There is a skin ellipse, 17.4 x 9.6 cm on the anterior surface.  There is a nipple, 1.2 x 0.9 x 0.7 cm, surrounded by an areola, 4.8 x 4.1 cm.  No previous biopsy scar is identified on the skin surface.  

The specimen is oriented and inked as follows:
         Upper outer quadrant         -             Red
        Lower outer quadrant         -             Blue
         Lower inner quadrant         -             Orange
         Upper inner quadrant         -             Green
         Posterior (deep)                 -              Black

Sectioning shows no masses, lesions, areas of ulceration, hemorrhage, or calcifications grossly identified.  

Multiple possible lymph nodes are identified, largest up to 0.3 cm.  

Representative sections are submitted in 22 cassettes as follows:

KEY TO CASSETTES:
A1               -            Nipple
A2                 -            Areola
A3                 -            Representative of upper outer quadrant (red)
A4                 -            Representative of lower outer quadrant (blue)
A5                 -            Representative of lower inner quadrant (orange)
A6                 -            Representative of upper inner quadrant (green)
A7-A8           -            Upper outer quadrant margin (red)
A9-A10         -            Lower outer quadrant margin (blue)
A11-A12       -            Lower inner quadrant margin (orange)
A13-A14       -            Upper inner quadrant margin (green)
A15              -            Posterior (deep - black) margin
A16-A22       -            Lymph nodes

B.  Received in formalin labeled ""XXXXXX, right breast and axillary node dissection (single stitch at axillary tail, double stitch at axillary node dissection, weight = 1.08 kg - formalin)"" is an oriented soft tan to yellow tissue, 1112 gm, 26.4 x 23.1 x 7.6 cm.  There is a skin ellipse on the anterior surface, 17.7 x 6.6 cm, with a nipple, 1.4 x 1.2 x 1.0 cm surrounded by an areola, 4.3 x 4.2 cm.  No biopsy scar is identified on the skin surface. 

The specimen is oriented and inked as follows:
  Upper inner quadrant  -  Red
  Lower inner quadrant  -  Blue
  Lower outer quadrant  -  Orange
  Upper outer quadrant  -  Green
  Posterior (deep)    -  Black

Sectioning reveals an irregular firm to hard white mass, 2.4 x 1.7 x1.4 cm, 0.7 cm from the deep (posterior - black) and 0.7 cm 
from the lower inner quadrant margin (blue).  The tumor is located in the lower inner quadrant, 4.5 cm from the nipple.  The 
tumor shows stellate borders.  

Sectioning through the remainder of the specimen shows no other lesions or masses.

Multiple possible lymph nodes are identified, largest up to 0.4 cm in greatest dimension.

Representative sections are submitted in 31 cassettes as follows:

KEY TO CASSETTES:
B1    -  Nipple
B2    -  Areola
B3-B6  -  Tumor
B7    -  Representative of upper inner quadrant (red)
B8    -  Representative of lower outer quadrant (orange)
B9    -  Representative of upper outer quadrant (green)
B10-B11  -  Representative of upper inner quadrant margin (red)
B12-B13  -  Representative of lower outer quadrant margin (orange)
B14-B15  -  Representative of upper outer quadrant margin (green)
B16    -  Posterior (deep - black) margin
B17-B31  -  Possible lymph nodes.","MicroscopicDescription:
A-B. The microscopic findings support the above diagnoses.","A: Left breast
B: Right breast and axillary node dissection",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Negative
Progesterone receptor (PgR 636):    Negative
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Low cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-00759001,2,REC-3000675938,"ClinicalHistory:
Invasive cancer left breast.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Needle localized wide excision CA left breast, and sentinel node biopsy.",,"PreOperativeDiagnosis:
Needle localized wide excision CA left breast, and sentinel node biopsy.
PostOperativeDiagnosis:
Same, Pending pathology.
IntraoperativeDiagnosis:
A.  Frozen Section:  Node, negative for metastasis/MP
B.  Frozen Section:  Node, positive for metastasis/MP
C.  Touch Prep:        Margins free/MP.
FinalDiagnosis:
A.  Sentinel node #1, left axilla, excision:  Lymph node, negative for metastasis (0/1)
 
B.  Sentinel node #2, left axilla, biopsy:  Lymph node, positive for metastasis 
            (1/1 node; 0.9 cm focus; focal extranodal extension)
 
C.  LEFT BREAST INVASIVE DUCTAL CARCINOMA  
Breast Tumor Information:
Operative procedure:      Needle localized wide excision, left breast mass
Histologic type:        Invasive ductal carcinoma 
Histologic grade (MBR):      Moderately-differentiated 
Nuclear score:        2
Mitotic score:        2
Tubule score:        2
Invasive tumor size:      1.4 cm
Necrosis:          Not evident
Margins:          Negative for tumor involvement 
            (0.4 cm minimal clearance, inferior) 
Lymphovascular invasion:    Not evident 
In situ component:        Present, minor component low-grade DCIS
Microcalcifications:      Rare
Axillary lymph nodes:      Positive for metastasis (total 1 of 2 nodes positive; including 0/1 sentinel node/part A, 1/1 sentinel node/part B, and 0/0 nodes/part D)
Other:          Fibroadenoma
Special studies:        Performed on previous needle biopsy 
            (***PATH-NUMBER[1]; ER-positive, PR-positive, HER-2/neu-negative)
Staging information:      pT1cN1a(sn)

D.   Tissue, left axilla, additional dissection:  Benign fibrofatty soft tissue; no additional nodes identified.",,"GrossDescription:
A.  Received fresh for intraoperative consultation, labeled ""left sentinel node,"" are fragments of tan-pink to yellow, fatty soft tissue measuring, in aggregate, 2.5 x 2.0 x 1.0 cm.  By palpation, there is a single firm nodule roughly consistent with a lymph nodule measuring 1.6 x 1.0 x 0.7 cm.  The lymph node is submitted for a frozen section and subsequently submitted in block A.

B.  Received fresh for intraoperative consultation, labeled ""left sentinel node #2,"" is an excision of tan-pink to yellow, lymphoid soft tissue measuring 1.0 x 0.8 x 0.5 cm.  The specimen has been previously stained blue.  Sectioning reveals a tan-yellow to white cut surface roughly consistent with a lymph node.  The node is submitted for a frozen section and subsequently submitted in block B.

C.  Received fresh for intraoperative consultation, labeled ""left breast needle-localized mass, suture long-lateral, short-superior,"" is an excision of tan-yellow, fibrofatty soft tissue with attached tan-white skin ellipse, having overall dimensions of 6.9 x 6.5 x 3.0 cm.  The skin ellipse measures 4.5 x 1.5 cm.  Sutures are provided for orientation and there is a centrally placed needle.  The specimen is inked: superior aspect-orange, inferior-green, lateral-red, medial-black, deep-blue.  Sectioning reveals a tan-yellow to white, fibrofatty cut surface.  In the inferior/deep portion of the specimen is a poorly-circumscribed, tan-white firm nodule measuring 1.4 x 1.3 x 1.0 cm, located 0.4 cm from the nearest (inferior) margin.  Further sectioning reveals a second nodule, measuring 1.0 x 1.0 x 0.9 cm, located at the superior margin.  The cut surface is tan-white and lobular.  No further masses or lesions are grossly identified.  Representative sections are submitted in blocks C1-C9.

  SECTION SUMMARY:
  C1-C6  -  Poorly-circumscribed nodule
  C7-C8  -  Nodule at superior margin
  C9  -  Grossly normal skin and soft tissue

D.   Received in formalin labeled ""left axillary contents"" are three fragments of tan-pink to yellow, fatty soft tissue measuring, in aggregate, 8.5 x 6.5 x 3.0 cm.  Sectioning reveals a tan-yellow, fatty cut surface with no identifiable lymph nodes.  Representative sections are submitted in blocks D1-D4.","MicroscopicDescription:
A.  Sections of lymph node are negative for metastasis on routine stain.  

B.  Sections of lymph node exhibit metastatic breast ductal carcinoma replacing approximately 80% of the node, and exhibiting focal extranodal extension into perinodal fibrofatty soft tissue.

C.  An excision of breast demonstrates an invasive, moderately-differentiated ductal carcinoma.  Margins of resection are free of tumor involvement.  There is a minor component of low-grade duct carcinoma in-situ.  Surrounding breast tissues exhibit moderate proliferative and non-proliferative fibrocystic change.  Also present is a small, 1.0 cm lobulated fibroadenoma.

D.  Additional axillary dissection exhibits predominately fatty breast tissue with a few areas of benign breast parenchyma.  Despite extensive dissection, no additional lymph nodes are identified.","A: Left sentinel node #1
B: Left sentinel node #2
C: Left breast needle localized mass long lateral short superior
D: Left axillary contents",,
REG4,BREAST,0,PAT-10039952,1,REC-3000676221,"ClinicalHistory:
Right breast mass.",,"FinalDiagnosis:

Right breast biopsy:        INVASIVE DUCTAL CARCINOMA

Breast Tumor Information:
Operative procedure:  Needle biopsy
Histologic type:    Invasive ductal carcinoma
Histologic grade (MBR):    1
Nuclear score:    2
Mitotic score:    1
Tubule score:    2
Invasive tumor size:    0.15 cm on sampling
Necrosis:    Negative
Lymphovascular invasion:    Not identified
In situ component:    Not identified
Microcalcifications:    Not identified
Special studies:    P63 and heavy chain myosin stains are supportive.  
Other:    Dr. **NAME[ZZZ] concurs.",,"GrossDescription:
Received in formalin labeled ""biopsy right breast"" are three tan-yellow, pink and soft, fibro-fatty tissue cores measuring up to 
0.5 x 0.1 x 0.1 cm.  All in.  One cassette.  The specimen was collected on **DATE[Dec 26 11] at 2:20 p.m. and placed in formalin immediately for a fixation time of approximately 9.5 hours.","MicroscopicDescription:
Confirmed.",A: Right breast biopsy,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive
HER-2/neu (HercepTest):      Negative for overexpression


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10038621,1,REC-3000676455,"ClinicalHistory:
Lt breast increasing microcalcification.",,"FinalDiagnosis:

Left breast microcalcifications:    DUCTAL CARCINOMA IN SITU

Breast Tumor Information:
  Type of specimen(s):  Biopsy
Histologic Type:  Ductal carcinoma in situ
Size:  1.3 cm
Architectural pattern(s):  Solid with comedonecrosis
Nuclear grade:  Nuclear grade 3 out of 3
Necrosis:  Present
Microcalcifications:  Present
Resection margins:  Involved
Other findings:  N/A
Ancillary studies:  Pending.",,"GrossDescription:
Received fresh labeled ""left breast microcalcifications"" is an unoriented tan-yellow and fatty tissue fragment measuring 
5.5 x 4.3 x 2.8 cm.  The specimen is inked entirely black.  There is a guide wire that terminates within the middle of the specimen.  Approximately 25% of the specimen is tan-pink and fibrous, suggestive of fibrocystic change.  The remaining breast parenchyma is yellow and fatty.  No suspicious lesions noted grossly.  Submitted entirely in sixteen cassettes.  Section containing guide wire tip in cassette 8.

The specimen was collected on **DATE[Sep 30 12] at 3:24 pm and placed in formalin at 3:45 pm, for a total fixation time of approximately
6.25 hours.","MicroscopicDescription:
Confirmed.",A: Lt breast microcalcifications,,
REG4,BREAST,0,PAT-10039368,1,REC-3000677808,"ClinicalHistory:
Left breast cancer.
Pre-OperativeDiagnosis:
A.  Node, left axilla:  
 
B.  Left breast mass:.",,"PreOperativeDiagnosis:
A.  Node, left axilla:  
 
B.  Left breast mass:.
FinalDiagnosis:
A.  Node, left axilla:  No evidence of metastatic carcinoma
 
B.  Left breast mass:  

Breast Tumor Information:

Type of specimen(s):  Left breast biopsy
Histologic Type:  Ductal carcinoma-in-situ, see comment
Size:  High grade dysplasia and in-situ carcinoma extend over an area estimated at 1.3 cm in greatest dimension
Architectural pattern(s):  Predominantly solid
Nuclear grade:  Nuclear grade 3 out of 3
Necrosis:  Not identified
Microcalcifications:  Not identified
Resection margins:  Margins free of in-situ ductal carcinoma
Additional findings:  Receptor studies requested.
DiagnosisComment:
The specimen is removed at 15:55 on **DATE[Aug 7 2011] and placed in formalin at 16:28 on **DATE[Aug 7 2011].  It is submitted for processing to begin at 10:30 pm on **DATE[Aug 8 2011].

Please correlate with prior biopsy.

ADDENDUM:  Outside slides from initial core needle biopsy (***PATH-NUMBER[1]) shows definite invasive ductal carcinoma.  Dr. **NAME[ZZZ] has reviewed both the initial core needle biopsy and the excisional biopsy.",,"GrossDescription:
A.  Node, left axilla:  Received fresh for frozen section is a fatty lymph node.  On section, it is grossly free of tumor.  Touch preps are performed:  NO EVIDENCE OF METASTATIC CARCINOMA.  DLW 3:30 pm.  Specimen submitted for permanent sections.
 
B.  Left breast mass:  Received is a fatty breast biopsy measuring up to 9 x 7 x 2.5 cm.  The specimen is oriented with a double suture, a single suture, and a wire.  The specimen is roughly pancake in shape.  The double suture is located on the superficial aspect of the biopsy (inked red).  The opposite bottom aspect is inked green.  A single suture is located at one medial edge (inked black) and the opposite edge is (inked blue).  The wire is located 90 degrees from the single suture.  This edge is (inked yellow) and the edge opposite to the wire is (inked orange).  On section, an ill-defined area of hemorrhagic discoloration extends over an area of 2 cm in greatest dimension.  The closest surgical margin is inked green.  Representative sections submitted through cassette B9.","MicroscopicDescription:
A.  Node, left axilla:  Sections of the lymph node are free of metastatic carcinoma.  Cytokeratin stains are also negative for metastatic carcinoma.
 
B.  Left breast mass:  Slides B8 and B9 demonstrate areas suggestive of a prior biopsy with granulation tissue formation, inflammation, fibrosis, and hemorrhage.  The adjacent stroma demonstrates a duct with in-situ ductal carcinoma and comedonecrosis as well as a few small nests in which a clear myoepithelial layer is not appreciated on H and E stain.  However on myosin staining, these nests do demonstrate a myoepithelial layer.  Nuclei appear high grade.  Throughout this section as well as much of the remainder of the sampled breast, there is evidence of fat necrosis.  Slide B2 also demonstrates areas of high grade ductal carcinoma-in-situ as well as a few nests of invasive ductal carcinoma.  Definite vascular or neural invasion is not appreciated.","A: Node, left axilla
B: Left breast mass",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Negative
HER-2/neu (HercepTest):      Equivocal


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results.

HER-2/neu (FISH):  Positive for amplification.
AddendumComment:
HER-2/neu analysis by fluorescence in situ hybridization shows a HER-2/chromosome 17 ratio of 3.3.


Testing performed at Clarient Diagnostic Services, **PLACE, CA."
REG4,BREAST,0,PAT-10038122,1,REC-3000677923,"ClinicalHistory:
Right breast cancer.",,"IntraoperativeDiagnosis:
A-D.  IMPRINT:  Negative; assessed by K. Hirata/RK.
FinalDiagnosis:
A.  RIGHT AXILLA SENTINEL LYMPH NODE(S) #1:  3 LYMPH NODES NEGATIVE FOR METASTASIS 
    (DEEPER LEVELS).
 
B.  RIGHT AXILLA SENTINEL LYMPH NODE(S) #2:  2 LYMPH NODES NEGATIVE FOR METASTASIS 
    (DEEPER LEVELS).
 
C.  RIGHT AXILLA SENTINEL LYMPH NODE #3:  1 LYMPH NODE NEGATIVE FOR METASTASIS (DEEPER 
    LEVELS).
 
D.  RIGHT AXILLA SENTINEL LYMPH NODE #4:  1 LYMPH NODE NEGATIVE FOR METASTASIS (DEEPER 
    LEVELS).
 
E.  RIGHT BREAST TISSUE (ORIENTED):  INVASIVE DUCTAL (PAPILLARY) CARCINOMA, GRADE I.
 
F.  LATERAL INFERIOR MARGIN (UNORIENTED):  NEGATIVE FOR MALIGNANCY.

Breast-invasive carcinoma information
Operative procedure:  Lumpectomy and sentinel lymph node(s) biopsy.
Tumor histologic type:  Invasive ductal (papillary) carcinoma.
Anatomic site:  Right breast, 1:00.
Focality:  Unifocal.
Histologic grade:  Grade I.
   Tubule score:  2.
   Nuclear score:  1.
   Mitotic score:  1.
Size of invasive carcinoma:  0.7 cm (microscopic).
Necrosis of invasive component:  None.
Lymphatic involvement:  None.
Vascular involvement:  None.
Skin involvement:  Not applicable,
Chest wall involvement:  None.
In situ component:  
   Histologic type:  Ductal carcinoma in situ.
   Architectural pattern:  Cribriform.
   % of tumor:  Less than 5%.  
   Nuclear grade:  Grade 1.
   Comedonecrosis:  None.
   Paget s disease:  Not applicable.
Microcalcifications:  Present, within tumor and non-neoplastic breast.
Resection margins: 
   Invasive component:
      Superior:  > 1 cm.
      Inferior:  > 1 cm.
      Lateral:  > 1 cm.
      Medial:  > 1 cm.
      Superficial:  0.4 cm.
      Deep:  0.6 cm.
   In situ component:
      Superior:  > 1 cm.
      Inferior:  > 1 cm.
      Lateral:  > 1 cm.
      Medial:  > 1 cm.
      Superficial:  0.9 cm.
      Deep:  0.6 cm.
Axillary lymph nodes:  7 negative, sentinel.
Distant metastasis:  Unknown.
Special procedures:  ER/PR - strong positive; Her2 (FISH) - negative; MIB-1 - high 
   (***PATH-NUMBER[1]).
Other findings:  Immunoperoxidase stains (p63, smooth muscle myosin heavy chain) show 
   absence of myoepithelial cells within tumor.  Focal atypical ductal hyperplasia; 
   radial scar, fibrocystic and post-biopsy changes including clip.
Pathologic grade and stage:  G1; pT1b N0 (Stage IA).",,"GrossDescription:
A.  Specimen:  Irregular segment of fibrofatty tissue, received fresh.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.5 x 1.5 x 1.1 cm.
Gross findings:  Three lymph nodes, up to 1.4 x 0.7 x 0.3 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B.  Specimen:  Irregular segment of fibrofatty tissue, received fresh.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.5 x 2.0 x 0.7 cm.
Gross findings:  Two lymph nodes, up to 0.4 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C.  Specimen:  Irregular segment of fibrofatty tissue, received fresh.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  1.5 x 0.7 x 0.7 cm.
Gross findings:  Single lymph node, 1.5 x 0.5 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D.  Specimen:  Single lymph node, received fresh.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  0.7 x 0.4 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

E.  Specimen:  Oriented, irregular segment of fibrofatty tissue, received fresh with 
       single localization wire.
Weight:  47 gm.
Dimensions:  
   Superior-inferior:  7.2 cm.
   Medial-lateral:  7.2 cm.
   Superficial-deep:  3 cm. 
Orientation/Inking of margins:  Long suture - lateral; short suture - superior.
   Superior - green; inferior - blue; medial - red; lateral - yellow; superficial - 
   orange; deep - black.
Gross findings:  1.4 x 1.2 x 1.2 cm hemorrhagic biopsy site containing filler material 
   and biopsy clip, 0.3 cm from the superficial margin, 0.7 cm from the deep margin, 
   and > 1 cm from remaining margins.  Lesion #1   0.6 x 0.6 x 0.5 cm firm, white-tan, 
   nodule adjacent to biopsy cavity, > 1 cm from all margins (nearest is deep   1.4 
   cm).  Lesion #2   0.5 x 0.5 x 0.4 cm firm, white-tan nodule 2 cm from lesion #1, 
   0.7 cm from the deep margin, 0.8 cm from the superficial margin, 1 cm from the 
   lateral margin, and > 1 cm from remaining margins.  Remaining tissue is 
   predominantly fatty.   
Ancillary studies:  None.
Special studies:  Off paraffin block as needed.
Collection date/time:  **DATE[Jun 30 12]; 1:05 pm.
Fixative:  10x volume, neutral buffered formalin.
Formalin fixation (start date/time):  **DATE[Jun 30 12]; 1:45 pm.
Formalin fixation (end date/time):  **DATE[Jun 30 12]; 9:30 pm.
Submitted for microscopic evaluation:  Representative, superior to inferior per 
   photograph.
Cassettes:  13 (lesion #1 and biopsy cavity in 8 and 11; lesion #2 in 3; cross-
   sections through end margins in 1 and 13). 

F.  Specimen:  Unoriented, irregular segment of fibrofatty tissue, received in 
       formalin.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  1.7 x 0.7 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.",,"A: RIGHT AXILLARY SENTINEL NODE #1
B: RIGHT AXILLA TISSUE #2
C: AXILLARY NODE #3
D: RIGHT AXILLARY NODE #4
E: RIGHT BREAST
F: LATERAL INFERIOR MARGIN",,
REG4,BREAST,0,PAT-10039963,1,REC-3000677931,"ClinicalHistory:
Bilateral breast CA.",,"IntraoperativeDiagnosis:
FROZEN SECTION:  Tissue adequate (malignant and benign).  Assessed by **NAME[M. ZZZ] MD/CA.
FinalDiagnosis:
A.  LEFT PARTIAL MASTECTOMY:  DUCTAL CARCINOMA IN-SITU

Breast in-situ carcinoma information
Specimen:  Left breast partial mastectomy
Operative procedure:  Left breast partial mastectomy
Tumor histologic type:  Ductal carcinoma in-situ
Anatomic site:  Left breast
Focality:  Unifocal  
Architectural pattern:  Solid
Nuclear grade:  3
Necrosis:  Comedonecrosis present
Size:  1.8 x 1.2 x 1.0 cm (macroscopic)
Paget s disease:  Nipple not submitted
Microcalcifications:  Present in DCIS and non-neoplastic breast
Resection margins:
  Superior:  > 1 cm    
  Inferior:  < 1 mm  
  Lateral:  > 1 cm  
  Medial:  < 1 mm  
  Superficial:  Positive  
  Deep:  < 1 mm    
Axillary lymph nodes:  None
Special procedures:  Estrogen and progesterone receptor analyses pending
Other findings:  None
Pathologic stage:  pTis NX (Stage 0, if N0 and M0)

B.  RIGHT PARTIAL MASTECTOMY:  INVASIVE LOBULAR CARCINOMA

Breast-invasive carcinoma information
Specimen:  Right breast partial mastectomy  
Operative Procedure:   Right breast partial mastectomy 
Tumor histologic type:  Invasive lobular carcinoma  
Anatomic site:  Right breast  
Focality:  Unifocal  
Histologic grade:  I (well differentiated)    
  Tubule score:  3  
  Nuclear score:  1  
  Mitotic score:  1  
Size of invasive carcinoma:  3.0 x 2.5 x 1.6 cm (macroscopic)  
Necrosis of invasive component:  Not identified  
Lymphatic involvement:  Not identified  
Vascular involvement:  Not identified  
Skin involvement:  Skin not submitted  
Chest wall involvement:  Not identified  
In situ component:  
  Histologic type:  Lobular carcinoma in-situ  
  % of tumor:  < 20% 
Microcalcifications:  Present in normal tissue and LCIS
Resection margins:
  In situ component:
    Superior:  1 mm  
    Inferior:  > 1 cm  
    Lateral:  > 1 cm  
    Medial:  3 mm  
    Superficial:  > 1 cm  
    Deep:  > 1 cm   
  Invasive component:
    Superior:  Positive in specimen B; however, specimen C (additional superior margin) is negative for malignancy  
    Inferior:  > 1 cm  
    Lateral:  0.3 cm  
    Medial:  0.2 cm  
    Superficial:  > 1 cm  
    Deep:  0.7 cm    
Axillary lymph nodes:  1 of 2 right axillary sentinel lymph nodes positive for metastasis (1/2)  
Distant metastasis:  Unknown  
Special procedures:
1.  Immunohistochemical staining of the invasive tumor with e-cadherin is negative
2.  Estrogen receptor positive, progesterone receptor positive, Her-2/Neu gene FISH negative (previously performed on previous right breast biopsy, ***PATH-NUMBER[1], **DATE[Apr 16 12])
3.  MIB-1 pending on current specimen  
Other findings:  None    
Pathologic grade and stage:  G1 pT2 pN1a(sn) (Stage IIB, if M0)  

C.  RIGHT LYMPH SENTINEL NODES:  ONE OF TWO LYMPH NODES POSITIVE FOR METASTASIS BY H+E DEEPER AND IMMUNOHISTOCHEMICAL KERATIN STAINED SECTIONS (1/2)

Axillary lymph node information
# Sentinel nodes examined:  2
  Method of evaluation:  3 H+E deepers, immunohistochemical stain for cytokeratin AE1/AE3
Total # of nodes examined (sentinel and nonsentinel):  2
# with metastasis:  1
#  nodes with macrometastases (> 2 mm.):  1
Size of largest metastasis:  4 mm
Extranodal extension:  None
Other findings:  None

D.  RIGHT BREAST ADDITIONAL SUPERIOR MARGIN:  NEGATIVE FOR ATYPICAL HYPERPLASIA OR MALIGNANCY.",,"GrossDescription:
A. Specimen:  Oriented, irregular segment of fibrofatty tissue received fresh with two localization wires.
Collection date/time:  **DATE[May 29 12]; 11:35 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  22 gm.
Dimensions:  
Superior-inferior:  6.5 cm.
Medial-lateral:  4.5 cm.
Superficial-deep:  2.5 cm. 
Orientation/inking of margins:
Long suture - lateral
Short suture - superior
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  1.8 x 1.2 x 1.0 cm ill-defined, firm tan mass 0.1 cm from medial, 0.1 cm from superficial and inferior, and abutting deep margins.
Ancillary studies:  Faxitron performed and reviewed by pathologist.  Mass with microcalcifications identified on Faxitron. 
Special studies:  To be performed on paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[May 29 12]  Time  1:00 p.m.
Formalin fixation (End):  Date  **DATE[May 29 12]  Time  9:30 p.m.
Submitted for microscopic evaluation:  Representative as indicated on photograph.
Cassettes:  8, superior to inferior respectively.  Cassettes 1 and 8 contain cross-sections through end margins.  Cassettes 4 through 8 contain mass.

B. Specimen:  Oriented, irregular segment of fibrofatty tissue received fresh with a single localization wire.
Collection date/time:  **DATE[May 29 12]; 12:40 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  27 gm.
Dimensions:  
Superior-inferior:  5.0 cm.
Medial-lateral:  3.5 cm.
Superficial-deep:  4.4 cm. 
Orientation/inking of margins:
Long suture - lateral
Short suture - superior
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  Sectioning reveals a 3.0 x 2.5 x 1.6 cm ill-defined, firm tan-white stellate mass, abutting superior and lateral, 0.7 cm from the deep margins, and greater than 1.0 cm from remaining margins. Biopsy clip identified within mass.
Ancillary studies:  None.
Special studies:  To be performed on paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[May 29 12]  Time  1:20 p.m.
Formalin fixation (End):  Date  **DATE[May 29 12]  Time  9:30 p.m.
Submitted for microscopic evaluation:  Representative as indicated on photograph.
Cassettes:  11, superior to inferior respectively.  Cassettes 1 and 11 contain cross-sections through end margins.  Cassettes 1 through 9 contain mass.

C. Specimen:  Unoriented segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.0 x 1.0 to 1.0 cm.
Gross findings:  Two lymph nodes identified measuring up to 0.8 x 0.7 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2 (larger lymph node inked green).

D. Specimen:  Oriented, irregular segment of fibrofatty tissue received in formalin.
Collection date/time:  **DATE[May 29 12]; 12:43 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  3 gm.
Dimensions:  
Orientation/inking of margins:
Suture - inferior
Short suture - superior
     Superior - green
     Inferior - blue
Gross findings:  No obvious mass/lesions grossly identified.
Ancillary studies:  None.
Special studies:  To be performed on paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[May 29 12]  Time  2:55 p.m.
Formalin fixation (End):  Date  **DATE[May 29 12]  Time  9:30 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  5.",,"A: LEFT PARTIAL MASTECTOMY
B: RIGHT PARTIAL MASTECTOMY
C: RIGHT SENTINEL NODES
D: RIGHT BREAST ADDITIONAL SUPERIOR MARGIN, SUTURE IN INFERIOR MARGIN",,
REG4,BREAST,0,PAT-10039996,1,REC-3000677947,"ClinicalHistory:
Right breast mass.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
US guided breast biopsy. Tech: NC.",,"PreOperativeDiagnosis:
US guided breast biopsy. Tech: NC.
PostOperativeDiagnosis:
Same, Pending pathology.
FinalDiagnosis:
RIGHT BREAST INVASIVE DUCTAL CARCINOMA 
Breast Tumor Information:
Operative procedure:    US needle biopsy, right breast mass 7:00, 5 cm FN
Histologic type:    Invasive ductal carcinoma
Histologic grade (MBR):  Poorly-differentiated 
Nuclear score:      3
Mitotic score:      3
Tubule score:      2
Invasive tumor size:    0.5 cm in core biopsy material
Necrosis:      Minimal
Lymphovascular invasion:  Not evident
In situ component:    Present, minor component duct carcinoma in-situ
Microcalcifications:    Rare
Special studies:    ER/PR/HER2-neu/Ki-67 pending
Staging information:    pT1.",,"GrossDescription:
Received in formalin labeled ""XXXXXX, right breast 7 o'clock 5 cm FN"" are approximately six cores of yellow to pink-gray tissue measuring up to 3.3 cm in length and 0.3 cm in diameter.  The specimen is collected on **DATE[Jul 30 12] at 1320 hours, placed in formalin at 1343 hours, for a total fixation time of approximately 51.0 hours.  Submitted in toto in two cassettes.","MicroscopicDescription:
Needle biopsies of breast demonstrate foci of carcinoma with areas of infiltrative pattern.  Immunostain for myoepithelial cells (p63, Myosin) are evaluated and demonstrate significant areas lacking a myoepithelial layer, especially with myosin staining, supporting areas of invasive ductal carcinoma.  An immunostain (E-cadherin) is evaluated and demonstrates positive tumor cell staining, supporting ductal differentiation.",A: Right breast 7:00 5 cm FN,,
REG4,BREAST,0,PAT-10036447,1,REC-3000677959,"ClinicalHistory:
Lt breast cancer.",,"IntraoperativeDiagnosis:

B.  INTRAOPERATIVE CONSULTATION:  MASS LOCATED 1mm FROM DEEP AND SUPERIOR MARGINS.  (JM).
FinalDiagnosis:

A.  Left breast sentinel node #1, biopsy:   One benign lymph node

B.  Left breast mass, excision:      INVASIVE LOBULAR CARCINOMA

Breast Tumor Information:
Operative procedure:        Biopsy
Histologic type:        Invasive lobular carcinoma
Histologic grade (MBR):      2
  Nuclear score:        3
  Mitotic score:        1
  Tubule score:        3
Invasive tumor size:        5+ cm
Necrosis:          Not identified
Resection margins:        Involved deep margin
Lymphovascular invasion:      Not identified
In situ component:        Present (lobular carcinoma in situ)
Microcalcifications:        Not identified
Chest wall involvement:      Not identified
Nipple/Skin involvement:      N/A
Special studies:        Pending studies.  
            E-cadherin stains are supportive.
Staging information:        pT3  pN0  Mx
          

C.  Left breast, superior border, excision:       Benign breast parenchyma

Comment:  Pancytokeratin stains on the lymph node are negative.",,"GrossDescription:
(A)  Received in formalin labeled ""sentinel node #1"" is an aggregate of yellow, red-brown and soft, fibrofatty tissue fragments measuring 2.5 x 2 x 1 cm.  A single lymph node measuring 1.1 x 1 x 0.8 cm is noted.  All remaining tissue is yellow and fatty.  Submitted entirely in two cassettes, with one bisected lymph node in cassette A1 and remaining tissue sections in cassette A2.



(B)  Received fresh labeled ""left breast cancer and margins"" is an oriented breast mass excision specimen measuring 7 x 5 x 2.5 cm.  It is oriented with margin tags, and is inked as follows:  superior - blue, inferior - green, medial - red, lateral - violet, deep - black, anterior - orange.  

Sections reveal a tan-white and poorly circumscribed nodule within the upper inner quadrant of the specimen.  It is adjacent to a slightly hemorrhagic area, suggestive of prior biopsy site.  Another tan-white and firm, poorly circumscribed area is noted in the middle region.  It appears to be grossly within 0.3 cm of the nearest superior and deep margins.  

All remaining sections are tan-white and fibrocystic.  Otherwise, the breast parenchyma is predominantly yellow and fatty.  

Representative sections submitted sequentially from medial to lateral in sixteen cassettes, with areas suspicious for carcinoma in cassettes B2 - B12.  

The specimen was collected on **DATE[Sep 30 12] at 12:26 pm and placed in formalin at 1:30 pm, for a total fixation time of approximately 8.5 hours.



(C)  Received in formalin labeled ""superior border"" are four yellow-red and soft, fatty tissue fragments measuring up to 4.5 x 2 x 1 cm.  Submitted entirely in five cassettes.

The specimen was collected on **DATE[Sep 30 12] at 12:26 pm and placed in formalin at 1:30 pm, for a total fixation time of approximately 
8.5 hours.","MicroscopicDescription:
A - C.  Confirmed.","A: Sentinel node biopsy #1
B: FS-Lt breast cancer with margins
C: Superior border",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Positive
HER-2/neu (HercepTest):      Equivocal, FISH testing pending


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-00935411,2,REC-3000678205,"ClinicalHistory:
Right breast cancer; Hypothyroid, shingles (history), HTN, appendectomy.",,"IntraoperativeDiagnosis:
Same, pending pathology.
FinalDiagnosis:
Breast, right, mastectomy:    1.  Residual ductal carcinoma in-situ
          2.  Resection margins free of tumor

  Breast Tumor Information:

Histologic Type:  Ductal
Size:  0.5 cm
Architectural pattern(s):  Solid with comedonecrosis
Nuclear grade:  Nuclear grade 2 out of 3
Necrosis:  Present
Microcalcifications:  Present
Resection margins:  Free of tumor (all margins clear by >1.0 cm)
Other findings:  1.  Partially calcified dense fibrosis
    2.  Prior procedure-related changes.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] concurs with the diagnosis.",,"GrossDescription:
Received fresh labeled ""**NAME[BBB], right breast"" is a mastectomy which measures 13.3 x 12.6 x 4.0 cm.  The anterior surface is covered by an 11.3 x 3.9 cm skin ellipse centrally occupied by a nipple and areola which measures 2.7 cm in diameter.  The specimen is oriented, the margins are inked.  The specimen is serially sectioned (""bread-loafed"") at 1.0 cm intervals revealing a white, partially calcified, firm region which measures 2.4 x 1.8 x 1.4 cm.  The edge of this region comes to within 0.2 cm of the closest adjacent resected specimen margin, which is the posterior margin (black).  The distances of this region to the margins are as follows:
Medial-orange-9.2 cm; Lateral-yellow-1.6 cm; Posterior-black-0.2 cm; Superior-blue-8.3 cm; Inferior-green-2.6 cm; Skin-no color- 2.4 cm.

Sectioning through the remainder of the specimen shows a rubbery, white, fibrotic area, up to 5.1 x 3.2 x 2.8 cm, 0.7 cm from the closest adjacent resected specimen margin, which is the inferior (green) margin.  This white area is in the 6 to 9 o clock position, 0.8 cm from the nipple.  There are areas of hemorrhage which appear to be previous core biopsy site.  

The specimen is placed in formalin on 09:00 hours, **DATE[Jun 30 2012], for a total fixation time of 10.0 hours.  

Representative sections are submitted in 34 cassettes as follows:

KEY TO CASSETTES1  -  Nipple
2  -  Areola
3-6  -  Calcified area after decalcification, entirely submitted, with closest adjacent resected specimen margin (posterior)
7-9  -  Representative of rubbery white fibrotic area described above
10  -  Representative of medial margin (orange-shave)
11  -  Representative of lateral margin (yellow-perpendicular)
12  -  Representative of anterior-superior margin (blue-shave)
13  -  Representative of anterior- inferior margin (green-shave)
14-15  -  Possible area of previous core biopsy site with posterior (black) tumor
16-34  -  Additional sections of rubbery white fibrotic area described above.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right breast,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Positive
Progesterone receptor (clone PgR 636):  Negative


Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10039963,2,REC-3000678314,"ClinicalHistory:
Bilateral breast CA.",,"IntraoperativeDiagnosis:
FROZEN SECTION:  Tissue adequate (malignant and benign).  Assessed by **NAME[M. ZZZ] MD/CA.
FinalDiagnosis:
A.  LEFT PARTIAL MASTECTOMY:  DUCTAL CARCINOMA IN-SITU

Breast in-situ carcinoma information
Specimen:  Left breast partial mastectomy
Operative procedure:  Left breast partial mastectomy
Tumor histologic type:  Ductal carcinoma in-situ
Anatomic site:  Left breast
Focality:  Unifocal  
Architectural pattern:  Solid
Nuclear grade:  3
Necrosis:  Comedonecrosis present
Size:  1.8 x 1.2 x 1.0 cm (macroscopic)
Paget s disease:  Nipple not submitted
Microcalcifications:  Present in DCIS and non-neoplastic breast
Resection margins:
  Superior:  > 1 cm    
  Inferior:  < 1 mm  
  Lateral:  > 1 cm  
  Medial:  < 1 mm  
  Superficial:  Positive  
  Deep:  < 1 mm    
Axillary lymph nodes:  None
Special procedures:  Estrogen and progesterone receptor analyses pending
Other findings:  None
Pathologic stage:  pTis NX (Stage 0, if N0 and M0)

B.  RIGHT PARTIAL MASTECTOMY:  INVASIVE LOBULAR CARCINOMA

Breast-invasive carcinoma information
Specimen:  Right breast partial mastectomy  
Operative Procedure:   Right breast partial mastectomy 
Tumor histologic type:  Invasive lobular carcinoma  
Anatomic site:  Right breast  
Focality:  Unifocal  
Histologic grade:  I (well differentiated)    
  Tubule score:  3  
  Nuclear score:  1  
  Mitotic score:  1  
Size of invasive carcinoma:  3.0 x 2.5 x 1.6 cm (macroscopic)  
Necrosis of invasive component:  Not identified  
Lymphatic involvement:  Not identified  
Vascular involvement:  Not identified  
Skin involvement:  Skin not submitted  
Chest wall involvement:  Not identified  
In situ component:  
  Histologic type:  Lobular carcinoma in-situ  
  % of tumor:  < 20% 
Microcalcifications:  Present in normal tissue and LCIS
Resection margins:
  In situ component:
    Superior:  1 mm  
    Inferior:  > 1 cm  
    Lateral:  > 1 cm  
    Medial:  3 mm  
    Superficial:  > 1 cm  
    Deep:  > 1 cm   
  Invasive component:
    Superior:  Positive in specimen B; however, specimen C (additional superior margin) is negative for malignancy  
    Inferior:  > 1 cm  
    Lateral:  0.3 cm  
    Medial:  0.2 cm  
    Superficial:  > 1 cm  
    Deep:  0.7 cm    
Axillary lymph nodes:  1 of 2 right axillary sentinel lymph nodes positive for metastasis (1/2)  
Distant metastasis:  Unknown  
Special procedures:
1.  Immunohistochemical staining of the invasive tumor with e-cadherin is negative
2.  Estrogen receptor positive, progesterone receptor positive, Her-2/Neu gene FISH negative (previously performed on previous right breast biopsy, ***PATH-NUMBER[1], **DATE[Apr 16 12])
3.  MIB-1 pending on current specimen  
Other findings:  None    
Pathologic grade and stage:  G1 pT2 pN1a(sn) (Stage IIB, if M0)  

C.  RIGHT LYMPH SENTINEL NODES:  ONE OF TWO LYMPH NODES POSITIVE FOR METASTASIS BY H+E DEEPER AND IMMUNOHISTOCHEMICAL KERATIN STAINED SECTIONS (1/2)

Axillary lymph node information
# Sentinel nodes examined:  2
  Method of evaluation:  3 H+E deepers, immunohistochemical stain for cytokeratin AE1/AE3
Total # of nodes examined (sentinel and nonsentinel):  2
# with metastasis:  1
#  nodes with macrometastases (> 2 mm.):  1
Size of largest metastasis:  4 mm
Extranodal extension:  None
Other findings:  None

D.  RIGHT BREAST ADDITIONAL SUPERIOR MARGIN:  NEGATIVE FOR ATYPICAL HYPERPLASIA OR MALIGNANCY.",,"GrossDescription:
A. Specimen:  Oriented, irregular segment of fibrofatty tissue received fresh with two localization wires.
Collection date/time:  **DATE[May 29 12]; 11:35 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  22 gm.
Dimensions:  
Superior-inferior:  6.5 cm.
Medial-lateral:  4.5 cm.
Superficial-deep:  2.5 cm. 
Orientation/inking of margins:
Long suture - lateral
Short suture - superior
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  1.8 x 1.2 x 1.0 cm ill-defined, firm tan mass 0.1 cm from medial, 0.1 cm from superficial and inferior, and abutting deep margins.
Ancillary studies:  Faxitron performed and reviewed by pathologist.  Mass with microcalcifications identified on Faxitron. 
Special studies:  To be performed on paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[May 29 12]  Time  1:00 p.m.
Formalin fixation (End):  Date  **DATE[May 29 12]  Time  9:30 p.m.
Submitted for microscopic evaluation:  Representative as indicated on photograph.
Cassettes:  8, superior to inferior respectively.  Cassettes 1 and 8 contain cross-sections through end margins.  Cassettes 4 through 8 contain mass.

B. Specimen:  Oriented, irregular segment of fibrofatty tissue received fresh with a single localization wire.
Collection date/time:  **DATE[May 29 12]; 12:40 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  27 gm.
Dimensions:  
Superior-inferior:  5.0 cm.
Medial-lateral:  3.5 cm.
Superficial-deep:  4.4 cm. 
Orientation/inking of margins:
Long suture - lateral
Short suture - superior
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  Sectioning reveals a 3.0 x 2.5 x 1.6 cm ill-defined, firm tan-white stellate mass, abutting superior and lateral, 0.7 cm from the deep margins, and greater than 1.0 cm from remaining margins. Biopsy clip identified within mass.
Ancillary studies:  None.
Special studies:  To be performed on paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[May 29 12]  Time  1:20 p.m.
Formalin fixation (End):  Date  **DATE[May 29 12]  Time  9:30 p.m.
Submitted for microscopic evaluation:  Representative as indicated on photograph.
Cassettes:  11, superior to inferior respectively.  Cassettes 1 and 11 contain cross-sections through end margins.  Cassettes 1 through 9 contain mass.

C. Specimen:  Unoriented segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.0 x 1.0 to 1.0 cm.
Gross findings:  Two lymph nodes identified measuring up to 0.8 x 0.7 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2 (larger lymph node inked green).

D. Specimen:  Oriented, irregular segment of fibrofatty tissue received in formalin.
Collection date/time:  **DATE[May 29 12]; 12:43 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  3 gm.
Dimensions:  
Orientation/inking of margins:
Suture - inferior
Short suture - superior
     Superior - green
     Inferior - blue
Gross findings:  No obvious mass/lesions grossly identified.
Ancillary studies:  None.
Special studies:  To be performed on paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[May 29 12]  Time  2:55 p.m.
Formalin fixation (End):  Date  **DATE[May 29 12]  Time  9:30 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  5.",,"A: LEFT PARTIAL MASTECTOMY
B: RIGHT PARTIAL MASTECTOMY
C: RIGHT SENTINEL NODES
D: RIGHT BREAST ADDITIONAL SUPERIOR MARGIN, SUTURE IN INFERIOR MARGIN",,"Interpretation:
LEFT BREAST A5:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                 0%       NEGATIVE#
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          0%       NEGATIVE#
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): A5 LEFT BREAST

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
# Although internal controls are positive, cold ischemic time was
slightly greater than 1 hour which is not optimal.  Repeat
testing on appropriately fixed tissue may be warranted.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

STANDARD ASSAY CONDITIONS ER/PR:
Cold ischemic time less than 1 hr.: not within limits, 1.4 hrs.
Fixation time Estrogen-Progesterone 6-72 hrs: within limits

RIGHT BREAST B3:
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
Ki-67 (MIB-1):                           8%       LOW
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): RIGHT BREAST B3

Ki67 is reported as average %positive:  Low <10%.
Ki67 tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration. The FDA does not require this test
to go through premarket FDA review."
REG4,BREAST,0,PAT-01307651,2,REC-3000678488,"ClinicalHistory:
Left breast mass.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
U/S guided left breast biopsy, Tech: RMS.",,"PreOperativeDiagnosis:
U/S guided left breast biopsy, Tech: RMS.
PostOperativeDiagnosis:
Same.
FinalDiagnosis:
LEFT BREAST INVASIVE DUCTAL CARCINOMA
Breast Tumor Information:
Operative procedure:    US needle biopsy, left breast mass 1:00, 5 cm FN
Histologic type:      Invasive ductal carcinoma
Histologic grade (MBR):    Poorly-differentiated
Nuclear score:      3
Mitotic score:      3
Tubule score:      3
Invasive tumor size:    0.6 cm in core biopsy material
Necrosis:      Present
Lymphovascular invasion:  Not evident
In situ component:    Not evident
Microcalcifications:    Few
Special studies:      ER/PR/HER2-neu/Ki67 pending
Staging information:    pT1.",,"GrossDescription:
Received in formalin, labeled ""XXXXXX, left breast 1:00 5 cm FN"" are three cores of yellow-white tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.   The specimens were received on **DATE[Aug 7 2012] and placed in formalin at approximately 10:30, for a total fixation time of approximately 8 hours and 30 minutes.","MicroscopicDescription:
Needle biopsies of breast demonstrate an invasive, poorly-differentiated ductal carcinoma.",A: Left breast mass 1:00 5 cm FN,,
REG4,BREAST,0,PAT-10038084,1,REC-3000678507,,,,,"GrossDescription:
Specimen request made on 45***PATH-NUMBER[1] (A1) from **DATE[Aug 19 2012].
By:  **NAME[ZZZ YYY], MD- **NAME[XXX] PATHOLOGY
Request: ER/PR (IPOX/Morphometry), Her2 HercepTest TM, MIB 
DIAGNOSIS:  LEFT BREAST MASS, 1:00, U/S GUIDED CORE NEEDLE BIOPSY:
- INVASIVE DUCTAL CARCINOMA, HIGH GRADE.  (**NAME[XXX] **INSTITUTION Diagnosis).",,A: LEFT BREAST 1:00,,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HercepTest(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HER-2/neu gene (FISH) MetaSystems Metafer

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                 0%       NEGATIVE
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          0%       NEGATIVE
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
Ki-67 (MIB-1):                          78%       HIGH
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:                 2.0        EQUIVOCAL
HER-2/neu gene (FISH)***:              1.4        NEGATIVE
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section):A1

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
Ki67 is reported as average %positive:  High >20%.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation
1.5-2.69:  (2+) Equivocal

***PathVysion HER-2 DNA probe kit fluorescence in situ
hybidization (FISH), a trademark of Abbot
<1.8:  Negative
Report REISSUED to add HER-2/neu gene (FISH) results.

STANDARD ASSAY CONDITIONS ER/PR Her2:
Cold ischemic time less than 1 hr.: within limits
Fixation time Estrogen-Progesterone 6-72 hrs: within limits
Fixation time Her-2 6-48 hrs: within limits."
REG4,BREAST,0,PAT-00127878,2,REC-3000678684,"ClinicalHistory:
Inflammatory ulcerating cancer; metastasis.",,"FinalDiagnosis:
A.  RIGHT BREAST:  INVASIVE DUCTAL CARCINOMA.
 
B.  AXILLARY NODE:  
    - INVASIVE DUCTAL CARCINOMA.
    - NO RESIDUAL LYMPH NODE STRUCTURE IDENTIFIED.
DiagnosisComment:
A.B.
Though a definitive histologic grade cannot be given on a needle biopsy, the tumor exhibits features of high grade (nuclear pleomorphism score of 3, glandular (acinar)/tubular differentiation score of 3 and mitotic score of 2-3).  ER/PR, Her2/neu and Ki67 (MIB1) studies (performed on part A) are pending.",,"GrossDescription:

A. Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Jun 30 12] 12:10 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  5.
Size:  0.1 cm in diameter and up to 1.9 cm in length.
Formalin fixation (Start):  Date  **DATE[Jun 30 12] Time  12:10 p.m.
Formalin fixation (End):  Date  **DATE[Jun 30 12] Time  10:30 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B. Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Jun 30 12] 12:15 p.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  1.
Size:  0.1 cm in diameter and up to 1.3 cm in length.
Formalin fixation (Start):  Date  **DATE[Jun 30 12] Time  12:15 p.m.
Formalin fixation (End):  Date  **DATE[Jun 30 12] Time  10:30 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT BREAST
B: AXILLARY NODE",,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HercepTest(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                 0%       INDETERMINATE#
 INTENSITY:
 Internal Control:             Not Present
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          0%       INDETERMINATE#
 INTENSITY:
 Internal Control:             Not Present
 External Control:                Positive
Ki-67 (MIB-1):                          57%       HIGH
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:                 4.7        POSITIVE
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): A1

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
Ki67 is reported as average %positive:  High >20%.
# Intrinsic epithelial elements not present or negative in a
specimen that appears negative for estrogen and progesterone.
Assay conditions were optimal, but proper fixation cannot be
evaluated and result is indeterminate.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation
=>2.7: (3+) Positive
Report REISSUED to add HER2 HercepTest Results.

STANDARD ASSAY CONDITIONS ER/PR Her2:
Cold ischemic time less than 1 hr.: within limits
Fixation time Estrogen-Progesterone 6-72 hrs: within limits
Fixation time Her-2 6-48 hrs: within limits."
REG4,BREAST,0,PAT-10032163,3,REC-3000696810,"ClinicalHistory:
Left breast nodule./r/n",,"FinalDiagnosis:
Left breast, stereotactic core biopsy: Invasive lobular carcinoma.

  Lobular carcinoma in situ.

  Fibrocystic changes with microcalcifications./r/nDiagnosisComment:
The invasive lobular carcinoma is seen in several core fragments measuring up to 5 mm on the slide. No lymph vascular invasion is identified. E-cadherin stain on blocks A1 and A3 examined which show the tumor to be negative consistent with lobular differentiation. Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block A1 and reported in an addendum. Intradepartmental consultation with Dr. **NAME[ZZZ] and the Breast Surgery Team (Phyllis Lum) was contacted on **DATE[Nov 3 12] at 11:00 am./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated left breast
Specimen:    Cylindrical cores of fibrous fatty tissue (formalin)
Number:      Multiple
Size:           Aggregating to 4 x 3 x 0.7 cm 
Submitted/Blocks:  Entirely/3./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left breast, stereotactic core biopsy",,"Interpretation:
***PATH-NUMBER[1], Block #A1 (Invasive Carcinoma)

Estrogen Receptor  99%
Progesterone Receptor    0%
Her-2/neu (ACIS Score)    0.0   (No overexpression)./r/nResultsComments:
The above diagnosis and following results are performed at **PLACE, NV, and reported by **NAME[YYY M. XXX], M.D., on **DATE[Nov 9 12].

ERPR:  
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on   formalin-  fixed paraffin-embedded section stained by immunohistochemical methods on the Ventana Benchmark XT 
  automated stainer using antibodies against ER (SP1 IVD) and PR (clone IE2 IVD).  Though the largest 
studies have used 10% as a threshold for positivity, others have recommended a cutoff as low as 1%.

HER-2/neu:
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on   formalin-  fixed paraffin-embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu (4B5) Rabbit Monoclonal Antibody.

Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and equivocal) were appropriate.

The results obtained from the Chromavision ACIS correspond to the ASCO/CAP scoring criteria in the following manner, as determined by in-house studies:

Chromavision       ASCO/CAP
Result:          Score:

Less than 1.5      0
(No staining)

Less than 1.5      1+
(Weak, incomplete membrane staining)

1.5 to 3.4      2+
(Complete membrane staining that is either nonuniform or weak in intensity, but with obvious circumferential distribution in at least 10% of the cells, or intense complete membrane staining in less than or equal to 30% of invasive tumor cell)

Greater than 3.4      3+
(Uniform, intense membrane staining in greater than 30% of invasive tumor cells)

A Chromavision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise specified.  This is in accordance with CAP recommendations (Strategic Science I meeting, **DATE[May 2003], **PLACE, IL).

Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  

References:
  1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
  2.  **NAME[WWW] JM, et. al. Mod Path **ID-NUM.
3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
  4.  **NAME[VVV M], et. al. Am J Clin Pathol 2001;**ID-NUM.
5.  **NAME[UUU, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
6.  Wolff, AC, et al.  American Society of Clinical Oncology/College of American Pathologists  
     Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in 
     Breast Cancer.  Arch Pathol Lab Med 2007; **ID-NUM.

(DTW/mab)./r/n"
REG4,BREAST,0,PAT-10038260,1,REC-3000697004,"ClinicalHistory:
Left breast calcifications.",Other Case Numbers: MR# **ID-NUM.,"FinalDiagnosis:
Left breast core biopsy, calcification:    DUCTAL CARCINOMA IN-SITU WITH EARLY STROMAL INVASION (SEE COMMENT).
DiagnosisComment:
Immunostains for keratin, p63, and HC-myosin were performed to evaluate the area of possible invasion.  Although the area measures less than 0.5 mm in size, there appears to be true early stromal invasion.  In addition, the tumor cells show some p63 positivity which suggests a ""basal"" immunophenotype.  There is insufficient invasive tumor to perform prognostic marker testing.  The prognostic report to follow will represent the in situ component.  The case has been discussed with Dr. **NAME[ZZZ].",,"GrossDescription:
Received in formalin labeled ""XXXXXX, left breast"" are multiple cores of pinkish-yellow tissue measuring up to 2.5 cm in length and 0.3 cm in diameter.  Submitted in toto in three cassettes.  Specimen removed from patient on **DATE[Mar 08 12] at 8:30 a.m. and placed in formalin, for a total fixation time of 10 hours 30 minutes.  Cold ischemic time information not provided.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Left breast,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (clone 1D5):    Insufficient residual tumor for evaluation
Progesterone receptor (clone PgR 636):  Negative


Formalin-fixed, paraffin-embedded sections.
AddendumComment:
The sections cut for hormone receptor staining containing only scant tumor in the progesterone receptor slide and no residual tumor in the estrogen receptor slide.  Repeat testing on an excisional specimen is recommended."
REG4,BREAST,0,PAT-10034252,1,REC-3000697039,"ClinicalHistory:
Hx Rt breast CA **DATE[Sep 2011].",,"FinalDiagnosis:

Left axillary lymph node, image-guided core needle biopsy:  
  Minute fragment of benign-appearing lymphoid tissue and fibro-fatty tissue.



Comment:  No definitive metastatic carcinoma is identified.   The fragment of lymphoid tissue may not be representative of the entire lymph node.",,"GrossDescription:
Received in formalin labeled ""left axillary lymph node"" are tiny pieces of white and soft material measuring 0.3 cm in aggregate.  Entirely submitted in one cassette.","MicroscopicDescription:
Microscopic findings support the diagnosis.",A: Left axillary lymph node,,
REG4,BREAST,0,PAT-10037233,1,REC-3000697435,"ClinicalHistory:
174.9
Procedure->Core
Clinical History/Diagnosis/Condition->Enlarging L1 lesion, R/O metastatic breast CA./r/n",,"FinalDiagnosis:
L1 bone lesion:  Metastatic carcinoma consistent with metastatic lobular carcinoma (see comment)./r/nDiagnosisComment:
The H\T\E-stained sections of the bone biopsy show that most of the marrow space is overrun by a desmoplastic stromal reaction with associated reactive bone formation.  Within the desmoplastic stroma are scattered round to oval cells which stain positively with both cytokeratin AE1/AE3 (establishing an epithelial origin) and estrogen receptor (ER).  The findings are consistent with metastatic lobular carcinoma.  The immunohistochemical stains were performed on sections of the decalcified, formalin-fixed, and paraffin-embedded bone biopsy; all controls react appropriately.  Of note, the small amount of residual background marrow that is present demonstrates trilineage hematopoiesis.

Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Oct 14 12].  Preliminary findings were discussed with Dr. **NAME[XXX WWW] on **DATE[Oct 14 12] at 8:55 a.m. and the final findings were communicated to Dr. **NAME[WWW] on **DATE[Oct 14 12] at 4:39 p.m./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated bone core per requisition slip onlySpecimen:    Two, cylindrical gray-pink bone core biopsy and dark brown blood clots (formalin)
Aggregate:    1.5 x 0.7 x 0.4 cm
Section code:
  Block 1:    Bone biopsy after decalcification
  Block 2:    Blood clots./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: L1 lesion, biopsy",,"AddendumComment:
Per request of Dr. **NAME[WWW], estrogen receptor (ER), progesterone receptor (PR), and Her-2/Neu studies will be attempted on the decalcified, formalin-fixed, and paraffin-embedded bone biopsy material.  The results will be reported as an addendum./r/n"
REG4,BREAST,0,PAT-10039836,1,REC-3000697883,"ClinicalHistory:
Right breast microcalcifications./r/n",,"FinalDiagnosis:
Breast, right:  Invasive ductal carcinoma (1.7 millimeter).

  Ductal carcinoma in situ.

  Microcalcifications./r/nDiagnosisComment:
Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block A1 and reported in an addendum.  The breast surgery team was notified of the diagnosis via message phone on **DATE[Sep 9 2012] at 4:19 p.m.  Case reviewed in Pathology Staff Conference on **DATE[Sep 9 2012].  Immunoperoxidase stain for SMMS-1 performed on sections A1 and A2 shows an absence of myoepithelial cells within the invasive ductal carcinoma in A1 and the presence of myoepithelial cells in the DCIS in sections A1 and A2.  Step x 2 on sections A1-2./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right breast
Specimen:    Cylindrical gray-white to yellow cores some of which are inked (formalin)
Number:      Multiple
Size:           2.5 x 2 x 0.6 cm 
Submitted/Blocks:  Entirely/2 (inked cores in #1 and remainder #2)./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right breast, stereotactic core biopsy",,"ResultsComments:
The following results were performed at **PLACE, NV and reported by **NAME[ZZZ M. YYY], M.D. on **DATE[Sep 17 2012].

INTERPRETATION:

BREAST CANCER PROGNOSTIC PANEL:  
***PATH-NUMBER[1], BLOCK # 1 (INVASIVE CARCINOMA)

            ESTROGEN RECEPTOR:                   91%
            PROGESTERONE RECEPTOR:            93%
            HER-2/neu (ACIS score):                   0.4 (NO OVEREXPRESSION)

COMMENT:
ERPR     
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical methods on the Ventana Benchmark XT automated stainer 
  using antibodies against ER (SP1 IVD), PR (clone IE2 IVD).  Though the largest studies have used 10% as a 
  threshold for positivity, others have recommended a cutoff as low as 1%. 

HER-2/neu
  Analysis is performed using Chromavision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu 
  (4B5)  Rabbit Monoclonal Antibody.

  Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and 
  equivocal) were appropriate.

  The results obtained from the ChromaVision ACIS correspond to the ASCO/CAP scoring criteria in the following 
  manner, as determined by in-house studies:

  ChromaVision:         ASCO/CAP 
  Result:          Score:

  Less than 1.5         0       (No staining)

  Less than 1.5         1+        (Weak, incomplete membrane staining)

  1.5 to 3.4              2+        (Complete membrane staining that is either nonuniform or weak in 
                       intensity, but with obvious circumferential distribution in at least 10% of the 
                       cells, or intense complete membrane staining in less than 30% of invasive 
                       tumor cells)

  Greater than 3.4       3+       (Uniform, intense membrane staining in greater or lesser than 30% 
                       invasive tumor cells)

  A ChromaVision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise 
  specified.  This is in accordance with CAP recommendations (Strategic Science I Meeting, **DATE[Mar 2003], **PLACE, 
  IL).

  Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American 
  Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered 
  formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 
  48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  
  
References:
  1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
  2.  **NAME[XXX] JM, et. al. Mod Path **ID-NUM.
  3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
  4.  **NAME[WWW M], et. al. Am J Clin Pathol 2001;**ID-NUM.
  5.  **NAME[VVV, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
  6.  Wolff, AC, et al.  ""American Society of Clinical Oncology/College of American Pathologists Guideline
       Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.""  Arch Pathol 
       Lab Med 2007; **ID-NUM.
  (BLS/mab)./r/n"
REG4,BREAST,0,PAT-10040127,1,REC-3000697904,"ClinicalHistory:
Bloody right nipple discharge.",,"FinalDiagnosis:
A.  ADDITIONAL RIGHT BREAST TISSUE, DEEP MARGIN:  
    NEGATIVE FOR MALIGNANCY.
 
B.  ADDITIONAL RIGHT BREAST TISSUE, LATERAL MARGIN:  
    INTRADUCTAL PAPILLARY CARCINOMA.
 
C.  RIGHT BREAST TISSUE (ORIENTED): 
    INTRADUCTAL PAPILLARY CARCINOMA.

Breast in-situ carcinoma information
Operative Procedure:  Removal right breast tissue.
Tumor histologic type:  Intraductal papillary carcinoma.
Anatomic site: Right breast.
Focality:  Unifocal
Architectural pattern: Papillary
Nuclear grade: Grade 2
Necrosis: Not identified.
Size:  Difficult to assess; estimate tumor spans 5.5 cm.
Paget s disease:  Not assessed.
Microcalcifications: Present in non-neoplastic tissue.
Resection margins (specify distance to margins up to 1 cm):
  Superior: < 0.1 cm.
  Inferior: < 0.1 cm.
  Lateral:  Tumor involves lateral margin (specimen B).
  Medial:   < 0.1 cm.
  Spf:      0.5 cm.
  Deep:     > 1 cm.
Axillary lymph nodes: Not assessed.
Special procedures: 
  1.  p63 and heavy chain myosin negative.
  2.  ER/PR pending.
Other findings: None

Pathologic stage: Tis (Stage 0 if N0 M0).
DiagnosisComment:
The case was discussed with Dr. **NAME[ZZZ] on **DATE[Aug 14 2012].",,"GrossDescription:
A. Specimen:  Irregular, unoriented segment of fibrofatty tissue, received in formalin.
Collection date/time:  8:53 a.m. on **DATE[Aug 10 12].
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  1.
Size:  2.0 x 1.0 x 0.7 cm.
Formalin fixation (Start):  Date  **DATE[Aug 10 12] Time  10:50 a.m..
Formalin fixation (End):  Date  **DATE[Aug 10 12] Time  6:00 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  2.

B. Specimen:  Irregular, unoriented segment of fibrofatty tissue, received in formalin.
Collection date/time:  8:55 a.m. on **DATE[Aug 10 12].
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  1.
Size:  1.6 x 1.6 x 0.5 cm.
Formalin fixation (Start):  Date  **DATE[Aug 10 12] Time  10:52 a.m..
Formalin fixation (End):  Date  **DATE[Aug 10 12] Time  6:00 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Irregular, oriented segment of fibrofatty tissue, received in formalin.
Collection date/time:  8:53 a.m. on **DATE[Aug 10 12].
Fixative:  10x volume, neutral buffered formalin.
Weight:  14 gm.
Dimensions:  
Superior-inferior:  4.1 cm.
Medial-lateral:  1.5 cm.
Superficial-deep:  7.0 cm. 
Orientation/inking of margins:
Long suture - medial
Single short suture - superior
Double short sutures - proximal nipple/superficial
     Superior - green
     Inferior - blue
     Medial - red
     Lateral - yellow
     Superficial - orange
     Deep - black
Gross findings:  Predominantly fatty cut surface with an irregular, ill-defined firm tan-white mass measuring 1.9 x 0.3 x 0.3 cm, grossly abutting the lateral and medial margins, 0.6 cm away from the superficial margin, 0.9 cm away from the inferior margin, greater than 1.0 cm away from all remaining margins.
Ancillary studies:  None.
Special studies:  To be done off paraffin block as needed.
Formalin fixation (Start):  Date  **DATE[Aug 10 12] Time  11:25 a.m..
Formalin fixation (End):  Date  **DATE[Aug 10 12] Time  6:00 p.m..
Submitted for microscopic evaluation:  All as per photo.
Cassettes:  22 (1-2, 10 cross-sections through end margins; 5-9 lesion).",,"A: ADDITIONAL DEEP RIGHT BREAST TISSUE
B: ADDITIONAL LATERAL MARGIN RIGHT BREAST
C: RIGHT BREAST TISSUE",,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):               100%       STRONG POSITIVE
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          0%       NEGATIVE#
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): C8

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
# Although internal controls are positive, cold ischemic time was
greater than 1 hour which is not optimal.  Repeat testing on
appropriately fixed tissue may be warranted.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

STANDARD ASSAY CONDITIONS ER/PR:
Cold ischemic time less than 1 hr.: not within limits, 2.5 hrs.
Fixation time Estrogen-Progesterone 6-72 hrs: within limits."
REG4,BREAST,0,PAT-10039942,1,REC-3000698027,,,"FinalDiagnosis:
Right breast, 10:00, biopsy:  Invasive ductal carcinoma (see comment)./r/nDiagnosisComment:
Histologic sections of the needle core biopsy fragments demonstrate extensive invasive ductal carcinoma.  Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block A1 and reported as an addendum.  

Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Mar 18 12].  **NAME[XXX WWW] RN notified of the findings via voicemail communication on **DATE[Mar 18 12] at 8:52 a.m./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated right breast 10:00
Specimen:    Cylindrical pale gray-tan cores of fibroadipose tissue (formalin)
Number:      Five and fragments
Size:           Measuring up to 1.2 x 0.2 x 0.2 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right breast 10:00, biopsy",,
REG4,BREAST,0,PAT-10039935,1,REC-3000698095,"ClinicalHistory:
Cancer of the right breast.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Right mastectomy and sentinel node biopsy.",,"PreOperativeDiagnosis:
Right mastectomy and sentinel node biopsy.
PostOperativeDiagnosis:
Same, Pending pathology.
FinalDiagnosis:
A.   RIGHT BREAST DUCT CARCINOMA IN-SITU 
Breast Tumor Information:
Operative procedure:    Right breast mastectomy
Histologic Type:    Duct carcinoma in-situ
Nuclear grade:    Intermediate (2) with focal high-grade comedo carcinoma (3)
Necrosis:    Focal comedo necrosis present
Architectural pattern(s):    Cribriform, solid and focal comedo carcinoma patterns
Margins:    Widely free of tumor
Size:    1.2 cm area residual duct carcinoma in-situ 
Microcalcifications:    Few, present within DCIS and adjacent fibrocystic changes
Special studies:    Performed on previous needle biopsy 
    (***PATH-NUMBER[1]; ER-positive/weak, PR-negative)
Other:    Overlying skin with seborrheic keratosis
Stage:    pTis N0(i-)(sn)

B.  Sentinel node #1, right axilla, biopsy:  Lymph node, negative for metastasis (0/1)

C.  Sentinel node #2, right axilla, biopsy:  Lymph node, negative for metastasis (0/1).",,"GrossDescription:
A.  Received fresh labeled ""right breast"" is a mastectomy specimen with attached tan-white skin ellipse having overall dimensions of 17.0 x 16.0 x 4.0 cm.  The skin ellipse measures 10.4 x 5.2 cm.  Centrally located on the skin ellipse is an intact tan-brown nipple and areola measuring 3.5 cm in greatest dimension.  Adjacent to the nipple and areola are two papillomatous tan-brown to black nodules measuring 0.9 cm in greatest dimension.  The deep margin is inked black.  Sectioning reveals a tan-yellow to white fibrofatty cut surface.  In the mid inferior aspect of the specimen is a poorly-circumscribed tan-white, stellate nodule measuring 1.5 x 1.3 x 1.0 cm, located 1.6 cm from the deep margin.  No further masses or lesions are grossly identified.  Representative sections are submitted in blocks A1-8.  Section summary:  block A1 nipple and areola, block A2 papillomatous nodule, block A3 deep margin, blocks A4-7 stellate nodule, block A8 axillary contents.

B.  Received in formalin labeled ""right axillary sentinel node #1"" is an excision of tan-pink to yellow, previously blue stained soft tissue measuring 0.9 x 0.7 x 0.6 cm.  Bisected and submitted entirely in block B.

C.  Received in formalin labeled ""right sentinel node #2"" is an excision of tan-pink to yellow, previously blue stained soft tissue measuring 0.7 x 0.5 x 0.4 cm.  Submitted entirely in block C.","MicroscopicDescription:
A.  Sections of skin demonstrate a seborrheic keratosis.  Underlying breast tissue demonstrates areas of duct carcinoma in-situ of intermediate and focal high nuclear grade, with scattered associated microcalcifications.  Areas of sclerosis and questionable infiltrative pattern are evaluated for myoepithelial cells (p63, myosin).  These demonstrate an apparent intact myoepithelial layer, with no evidence of invasive neoplasia. 

B.  Sections of lymph node exhibit no evidence of metastasis on routine stain.  Immunostain (keratin) demonstrates no evidence of micrometastasis.  

C.  Sections of lymph node demonstrate no metastasis on routine stain.  Immunostain (keratin) shows no evidence of micrometastasis.","A: Right breast
B: Right axillary sentinel node #1
C: Right axillary sentinel node #2",,
REG4,BREAST,0,PAT-10040995,1,REC-3000698390,"ClinicalHistory:
Right breast calcifications; R/O malignancy.",Other Case Numbers: MR# **ID-NUM.,"FinalDiagnosis:
Right breast core biopsy, calcifications:  INFILTRATING DUCTAL CARCINOMA

Breast Tumor Information:

Operative procedure:      Stereotactic core biopsy
Histologic type:      Ductal, usual type
Histologic grade (MBR):      Grade 1
Nuclear score:      1
Mitotic score:      1
Tubule score:      3
Invasive tumor size:      At least 0.2 cm
Necrosis:      Absent
Lymphovascular invasion:    Not identified
In situ component:      Extensive, intermediate grade
Microcalcifications:      Present in in situ component
Special studies:      ER, PR, HER-2 and Ki-67 pending.
DiagnosisComment:
Specimen(s) signed out at **INSTITUTION for **STREET-ADDRESS., **PLACE, Hawaii **ZIP-CODE.",,"GrossDescription:
Received in fixative labeled ""XXXXXX, right breast"" are multiple cores of pink-yellow tissue measuring up to 2.2 cm in length and 0.2 cm in diameter.  Submitted in toto in two cassettes.  The specimen was removed from patient on **DATE[Jul 17 12] at 10:06am and placed in formalin for a total fixation time of 8 hours and 54 minutes.  Cold ischemic time information was not provided.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right breast,,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Low cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10038877,1,REC-3000698499,"ClinicalHistory:
Rt liver mass, Hx Ca breast. R/O malignancy.",,"FinalDiagnosis:

Right costal angle/right lower lobe lung mass, core needle biopsy:  
  1.  Spindle cell tumor (see comment).
  2.  Benign liver parenchyma and skeletal muscle; no pulmonary parenchyma present.

Comment:   Scant fragments with spindle cells show moderate cellularity and are without increased mitotic 
activity, significant pleomorphism, and necrosis.  These fragments are covered by mesothelial lining (pleura 
vs. peritoneum).  The spindle cells are positive for CD34 and bcl-2 stains, and negative for CK AE1/AE3,
calretinin (which highlights the mesothelial lining), smooth muscle actin, desmin, and S-100 protein stains.
Ki-67 stain show low proliferative index (1 - 2% of nuclear positivity).  Favor solitary fibrous tumor. The 
biopsy sample is limited and complete examination of the tumor is suggested.
Case discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jun 21 2012].",,"GrossDescription:
Received in formalin labeled with the patient's name, ""right COST. angle"" are three tan and soft, cylindrical tissue fragments ranging in size from 0.3 - 0.9 cm in length by less than 0.1 cm in diameter, and a 0.4 cm aggregate of white, tan and soft tiny pieces of material.  Entirely submitted in one cassette.","MicroscopicDescription:
Microscopic findings support the diagnosis.",A: Rt lung (lower lobe),,
REG4,BREAST,0,PAT-10038641,1,REC-3000698661,"ClinicalHistory:
Left breast cancer.
Post-OperativeDiagnosis:
Pending pathology.",,"PostOperativeDiagnosis:
Pending pathology.
IntraoperativeDiagnosis:
A. and B.  Touch Preparation:  Neg. for metastasis.
FinalDiagnosis:
A.   Sentinel lymph node #1, biopsy:  One (1) lymph node, negative for metastasis

B.   Sentinel lymph node #2, biopsy:  One (1) lymph node, negative for metastasis

C.   Left breast mass, lumpectomy:  INFILTRATING DUCTAL CARCINOMA

D.   Additional deep margin:    Benign adipose tissue and skeletal muscle

Breast Tumor Information:

Operative procedure:      Wide excision with sentinel node biopsy
Histologic type:      Ductal, usual type
Histologic grade (MBR):    Grade 3
Nuclear score:        2
Mitotic score:        3
Tubule score:        3
Invasive tumor size:      2.3 x 1.8 x 1.4 cm (gross)
Necrosis:        Absent
Lymphovascular invasion:    Not identified
In situ component:      20%, high grade
Resection margins:      All final margins clear by at least 0.3 cm
Microcalcifications:      Present in in situ component
Lymph nodes:        2 sentinel nodes negative for metastasis (0/2)
Special studies:      Previously performed on core biopsies (ER+, PR-, HER-2 negative, elevated cell proliferation)
Staging information:      pT2, N0[sn].
DiagnosisComment:
Sentinel node analysis includes three levels of H&E stained slides with corresponding cytokeratin immunohistochemical staining (AE1/AE3) at levels 2 and 3.  Grossly suspicious nodes are confirmed intraoperatively by imprint cytology and/or frozen section.",,"GrossDescription:
A.  Received unfixed for touch imprint labeled ""sentinel lymph node #1, **NAME[AAA] XXXXXX"" is a 3.8 x 1.5 x 1.2 cm yellow-red piece of tissue that contains a 1.5 x 1.0 x 0.8 cm gray-yellow lymph node.  A touch imprint was done.  The node is submitted entirely in one cassette.   
 
B.  Received unfixed for touch imprint labeled ""sentinel lymph node #2, **NAME[AAA] XXXXXX"" is a 2.8 x 1.5 x 1.0 cm yellow-red piece of tissue that contains a 1.2 x 0.8 x 0.7 cm  gray lymph node.  A touch imprint was done.  The node is submitted entirely in one cassette.

C.  Received unfixed labeled ""left breast mass, **NAME[AAA] XXXXXX"" is an oblong yellow to pink piece of tissue that weighs 77.0 gm and measures 5 cm from anterior to deep by 8.8 cm from medial to lateral by 3.5 cm from superior to inferior.  There is a short suture at the superior margin, a long suture at the lateral margin and a double suture at the deep margin.  The specimen is differentially inked:  orange-anterior, black-deep, green-superior, blue-inferior, red-medial and yellow-lateral.  There are two localizing wires inserted into the specimen about 3 cm apart.  The specimen was removed from the patient at 1052 hours on **DATE[Apr 22 12] and submitted for radiographic examination.  The mass was received in pathology and placed in formalin at 1100 hours.  Prosection was done the following day resulting in 32 hours of formalin fixation.  Sectioning the specimen reveals a hard white mass within the anterior superior portion of the specimen that measures 2.3 x 1.8 x 1.4 cm and appears to be several millimeters away from the superior margin and about 0.7 cm from the anterior margin.  Proceeding medially, there is an additional firm gray zone that is in proximity to the superior and deep margins that measures about 1.5 x 1.3 x 1 cm.  The two masses appear to be just over 1 cm apart.  

        KEY TO CASSETTES:
        C1-C2  -  Lateral margin
        C3-C4  -  Medial margin
        C5  -  A representative section of benign appearing breast tissue between the more medial firm zone
               and the medial margin
        C6-C7  -  Sections from the more medial firm lesional area 
        C8-C10  -  Sections from the entire region of the hard white mass
        C11-C13  -  Additional representative sections of the lateral portion of the specimen between the hard mass and the 
    lateral margin

D.  Received unfixed labeled ""additional deep margin, **NAME[AAA] XXXXXX"" is a discoid yellow-red piece of tissue that weighs 9.0 gm and measures 4.5 cm from medial to lateral x 4.5 cm from superior to inferior x 1.3 cm from anterior to deep.  There is a short suture at the superior margin, a long suture at the lateral margin, and a double suture at the deep margin.  The specimen is differentially inked:  orange-anterior, black-deep, green-superior, blue-inferior, red-medial and yellow-lateral.  The specimen was placed in formalin at 11:04 hours resulting in 8 hours of formalin fixation.  Cut surfaces are yellow to red and show no gross lesions.  Submitted entirely in five cassettes serially from medial to lateral.","MicroscopicDescription:
A-C.   The microscopic findings support the above diagnoses.","A: Sentinel lymph node #1, (TP)
B: Sentinel lymph node #2, (TP)
C: Left breast mass
D: Additional deep margin",,
REG4,BREAST,0,PAT-10041949,1,REC-3000702880,"ClinicalHistory:
A1 LONG-LATERAL, SHORT-SUPERIOR, LONG/SHORT-DEEP.  SENT TO RADIOLOGY
A2 SUTURE AT NEW MARGIN
Procedure->Excision
Clinical History/Diagnosis/Condition->OTH
*** LEFT BREAST PAPILLARY NEOPLASM./r/n",,"FinalDiagnosis:
A. Breast lump, left :  Low grade ductal carcinoma in situ arising within an intraductal papilloma (see complete below).

B. Breast, additional anterior superior tissue: Negative for tumor./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ] on **DATE[Oct 26 12].  Dr. **NAME[YYY] s office (**PLACE) notified on **DATE[Oct 28 12].  Immunoperoxidase stains for estrogen/progesterone receptors will be performed on block A4 and reported in an addendum./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left breast lump 
Specimen:    Lobulated yellow-gray piece of tissue (formalin)
Size:      6 cm medial-lateral, 2 cm superior-inferior, 1 cm superficial-deep
Skeletal muscle:    None
Orientation:    Long suture = lateral, short = superior, long/short = deep
Colors:
  Black:    Deep
  Orange:    Superficial
  Green:    Superior
  Blue:    Inferior
  Red:    Medial
  Yellow:    Lateral
Findings:  The end of the localizing needle is found within the methylene blue dyed zone at the medial aspect of the specimen. The cut surfaces are focally firm, no obvious gross lesions.
Section code:    
  Block A1:    Medial margin
  Blocks A2-7:    Sections of the entire midportion of the specimen starting from medial to lateral
  Block A8:    Lateral margin

B.  Labeled:      Patient name and medical record number, designated additional anterior superior tissue
  Specimen:    Lobulated yellow tan piece of tissue (formalin)
  Size:      1.5 x 1.5 x 0.8 cm
  Orientation:    Suture = new margin
  Colors:      Orange = new margin, black = towards previous biopsy
  Submitted/Block:    Entirety in 4 pieces/1./r/n","MicroscopicDescription:
A-B.  Breast Cancer Information (Based on AJCC/UICC TNM, 7th edition)

Size (extent) of DCIS: Focally within an intraductal papilloma into blocks.
Histologic Type: Ductal carcinoma in situ
Histologic Grade: Grade I (low)
Necrosis: Not identified
Margins: Margins uninvolved by DCIS
    Distance from closest margin(s): Focally close (within 1 mm) to the deep margin
Pathologic Staging (pTNM):
    Primary tumor: pTis
    Regional lymph nodes: pNX
    Distant metastasis: Not applicable./r/n","A: A1-Left breast lump, excision
B: A2-Additional anterior superior tissue to pathology, excision",,
REG4,BREAST,0,PAT-10040990,1,REC-3000702902,"ClinicalHistory:
Carcinoma, left breast.",,"FinalDiagnosis:
Left breast:    1. Residual intravascular ductal carcinoma
      2. Granulation tissue and foreign body reaction, consistent with previous biopsy
      3. No residual invasive ductal carcinoma identified
      4. Metastatic carcinoma in 2 of 10 axillary lymph nodes

Breast Tumor Information:  (Below information based on previous excision   ***PATH-NUMBER[1])

Operative procedure:    Left mastectomy and axillary contents  
Histologic type:    Invasive ductal carcinoma 
Histologic grade (MBR):  Grade 3
  Nuclear score:    3
  Mitotic score:    3  
  Tubule score:    3
Invasive tumor size:    2.3 x 2.3 x 2.0 cm
Necrosis:      Present
Resection margins:    Clear
Lymphovascular invasion:  Present (residual tumor is only present within vascular spaces)
In situ component:    Not identified
Microcalcifications:    Not identified
Chest wall involvement:  Not identified
Nipple/Skin involvement:  Not identified
Lymph nodes:      Metastasis to 2 of 10 lymph nodes (largest focus 1.2 cm)
Special studies:    Receptor studies done on previous specimen
        Estrogen receptor:    Negative
        Progesterone receptor:  Negative
        HER-2/neu:      Equivocal
        Ki-67:        Elevated cell proliferation
Staging information:    pT2, pN1, cN0.
DiagnosisComment:
The tumor that is present is entirely intravascular.  No residual invasive ductal carcinoma is seen within the wall of the biopsy cavity.  The staging information is based on the original biopsy (***PATH-NUMBER[1]).

Specimen signed out at **STREET-ADDRESS, **ROOM, **PLACE, HI   **ZIP-CODE.",,"GrossDescription:
Received in formalin, labeled ""XXXXXX, left breast"" is a breast with attached axillary tissue, measuring up to 26.0 x 16.0 x 3.8 cm.  The axillary contents measure up to 8.5 x 7.5 x 3.3 cm.  The overlying, attached segment of skin measures up to 13.0 cm in length and 7.5 cm in width.  The nipple and areola measure 1.2 and 2.2 cm in diameter, respectively, and are unremarkable.  Present approximately 1.5 cm superior to the nipple, and extending along the upper outer and upper inner quadrant is a sutured, roughly linear incision measuring up to 4.5 cm in length.  The specimen is inked as follows: superior anterior - orange, inferior anterior - blue, posterior (deep) - black.  Deep to the incision, sectioning reveals a biopsy cavity that measures up to 5.7 x 5.5 x 4.0 cm.  The biopsy cavity is located approximately 1.0 cm from the skin surface and extends to within 0.3 cm of the posterior (deep) margin and measures up to 5.7 x 5.5 x 4.0 cm.  A biopsy cavity is lined by slightly firm, tan to pink-tan tissue.  No definite residual tissue is grossly identified.  Elsewhere, sections through the remainder of the breast reveals lobulated fatty tissue, and scant amounts of rubbery breast parenchyma.  The axillary tissue is arbitrarily divided into thirds, designated as ""lower, mid, and upper"".  Embedded within the soft tissue are multiple non-matted lymph nodes, ranging from a few millimeters up to 2.0 cm.  The cut surfaces are pink-gray to gray-white, rubbery to slightly firm.  The specimen is placed in formalin on **DATE[Mar 28 12] at 12:30pm for a total fixation time of approximately 6.5 hours.  Cold ischemic time information was not provided.  Representative sections and all identified lymph nodes are submitted.

KEY TO CASSETTES:
1  -  Nipple and areola
2  -  Sutured incision along skin
3-7  -  Biopsy cavity, including posterior (deep) margin
8  -  Upper outer quadrant
9  -  Upper inner quadrant 
10  -  Lower outer quadrant 
11  -  Lower inner quadrant 
12  -  2 possible ""lower third"" axillary lymph nodes
13  -  1 possible ""low"" axillary lymph node (representative section)
14  -  1 possible ""low"" axillary lymph node, bisected 
15  -  3 possible ""middle third"" lymph nodes
16  -  1 possible ""middle third"" lymph node, bisected
17  -  1 possible ""middle third"" axillary lymph node (representative section)
18  -  2 possible ""upper third"" axillary lymph node.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Left breast,,
REG4,BREAST,0,PAT-01477421,2,REC-3000703140,"ClinicalHistory:
Recurrent left breast carcinoma; right lateral thigh lesion.
Post-OperativeDiagnosis:
Same, pending pathology.
Pre-OperativeDiagnosis:
A.  Left breast lumpectomy:  
 
B.  Right lateral thigh lesion:.",,"PreOperativeDiagnosis:
A.  Left breast lumpectomy:  
 
B.  Right lateral thigh lesion:.
PostOperativeDiagnosis:
Same, pending pathology.
FinalDiagnosis:
A.  Left breast lumpectomy:  Malignant neoplasm suggestive of inflammatory malignant fibrous histiocytoma, see comment
 
B.  Right lateral thigh lesion:  Basal cell carcinoma, margins free.
DiagnosisComment:
The specimen is removed at 11:55 am on **DATE[Mar 16 2012] and immediately placed in formalin.  It is submitted for processing to begin at 7:30 pm on **DATE[Mar 17 2012].

Dr. **NAME[ZZZ]'s office was notified of a malignancy involving the breast that may be metastatic melanoma on **DATE[Mar 19].  Further work up would be required.  Block A1 is sent for melanA, HMB45 and S100.  Additional IHC's are requested on block A1.

Special stains and controls worked appropriately.

The histology and IHC's are consistent with a sarcoma.  Inflammatory malignant fibrous histiocytoma is in the differential.  This case will be sent for external review to Mayo Medical Laboratories in **PLACE, MN.

Lysozyme is sent to Clarient.",,"GrossDescription:
A.  Left breast lumpectomy:  Received is a breast biopsy that is covered by an ellipse of skin measuring up to 7 x 4 cm.  The skin is tan without gross evidence of Pagetoid changes.  The underlying specimen measures 9 x 8 x 2.5 cm.  On section, a well-defined yellow-white firm nodule with sharp borders measures up to 1 cm in dimension.  This is submitted in cassettes A1 and A2.  A second centrally located area of increased stromal fibrosis is noted.  Well-defined margins are not appreciated in this specimen.  This is nearly entirely submitted in cassettes A3 and A4.  On sectioning, this second area contains palpable small 0.3 cm areas of firmness.  The surgical margins are grossly widely free from both nodules.
 
B.  Right lateral thigh lesion:  An elliptical biopsy of skin measuring up to 1.3 x 1 x 0.3 cm surrounds a central ulceration.  The center is submitted in cassette B1 and the tails are submitted in cassette B2.","MicroscopicDescription:
A.  Left breast lumpectomy:  The well-defined lesion that is submitted in cassettes A1 and A2 demonstrate a mixture of large very atypical cells intermixed with acute and chronic inflammatory cells with a few xanthomatous-like cells.  The nuclei of some of these cells are up to 5 to 7 times the diameter of a poly.  Chromatin is coarse with occasional single to multiple eosinophilic nucleoli.  Pigmentation is not appreciated.  The palpable smaller nodules within the fibrous stroma that are submitted in cassettes B1 and B2 contain similar nodules of atypical cells.   Atypical cells are negative for melanA, HMB45, S100, cytokeratin A1/A3, cytokeratin 8/18, LCA, vimentin, desmin, and CD30.  Atypical cells are positive for CD31 and are questionably positive for collagen IV.  The histology is similar to that seen in the prior biopsy ***PATH-NUMBER[1].
 
B.  Right lateral thigh lesion:  The epidermis is ulcerated by a tumor composed of solid and cystic irregular nests of basaloid cells with peripheral palisading.  Neither vascular nor neural invasion is noted.  The surgical margins are free of tumor.","A: Left breast lumpectomy
B: Right lateral thigh lesion",,
REG4,BREAST,0,PAT-10035219,1,REC-3000703154,"ClinicalHistory:
A-D. Right breast cancer.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A.  ""Right breast sentinel lymph node #1"":  One benign lymph node

B.  ""Right breast sentinel lymph node #2"":  One benign lymph node

C.  ""Right breast sentinel lymph node #3"":  One benign lymph node

D.  ""Right breast, segment"":      INVASIVE DUCTAL CARCINOMA

Breast Tumor Information:
Operative procedure:        Lumpectomy
Histologic type:        Invasive ductal carcinoma
Histologic grade (MBR):      2
  Nuclear score:        3
  Mitotic score:        1
  Tubule score:        3
Invasive tumor size:        2.2 cm
Necrosis:          Present
Resection margins:        Not involved
Lymphovascular invasion:      Not identified
In situ component:        Not extensive, cribriform low nuclear grade
Microcalcifications:        Not identified in tumor, present in adjacent breast
Chest wall involvement:      N/A
Nipple/Skin involvement:      N/A
Special studies:        N/A
Staging information:        pT2  pN0  Mx.
DiagnosisComment:
Specimen signed out at **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.",,"GrossDescription:
Specimen A.  Received in formalin labeled ""right breast sentinel lymph node #1"" is an irregular piece of rubbery tan-yellow tissue (2.2 x 1.6 x 0.9 cm).  The specimen is bisected to reveal a single blue-stained sentinel node.  The entire specimen is submitted in A.

Specimen B.  Received in formalin labeled ""right breast sentinel lymph node #2"" is an irregular piece of rubbery tan-yellow tissue (3 x 1.5 x 0.6 cm).  The specimen is bisected to reveal a single sentinel node.  The entire specimen is submitted in B.

Specimen C.  Received in formalin labeled ""right breast sentinel lymph node #3"" is an irregular piece of rubbery tan-yellow tissue (1.1 x 0.8 x 0.4 cm).  The specimen is bisected to reveal a single sentinel node.  The entire specimen is submitted in C.

Specimen D.  Received in formalin labeled ""segment of right breast"" is a lumpectomy specimen consisting of an ellipse of tan and blue-stained skin (4.5 x 1.7 x 0.3 cm) and attached tan-yellow and blue-stained tissue (8.3 x 6.5 x 3.7 cm).  A short suture marks the superior margin, a long suture marks the lateral margin and a double suture marks the deep/posterior margin.  Surgical margins are differentially inked as follows:  superior-blue ink, inferior-yellow ink, anterior-black ink, posterior-green ink, medial and lateral-red ink.  The specimen is serially sectioned into fifteen lamellae from medial (lamella 1) to lateral (lamella 15) direction.  Lamellae 4 through 7 reveal a firm and well-circumscribed tan-red mass (2.2 x 1.5 x 1.1 cm).  The mass grossly approaches 2.5 cm within the superior margin, 1.7 cm within the inferior margin, 1 cm within the anterior/skin margin, 0.6 cm within the posterior margin, 1.7 cm within the medial margin and 4.4 cm within the lateral margin.  The remainder of the specimen consists of fatty yellow tissue with an area of blue-stained fibrous tissue in the lateral half of the specimen.  Representative sections are submitted as follows:

Block summary:
D1  -  Lamella 1, representative perpendicular sections of medial margin
D2  -  Lamella 3, skin, anterior and posterior sections
D3  -  Lamella 4, skin, anterior and posterior sections, mass
D4  -  Lamella 4, inferior, anterior and posterior sections, mass
D5  -  Lamella 5, skin, anterior and posterior sections, mass
D6  -  Lamella 6, skin, anterior and posterior sections, mass
D7  -  Lamella 7, superior, anterior and posterior sections
D8  -  Lamella 7, skin, anterior and posterior sections, mass
D9  -  Lamella 8, superior, anterior and posterior sections
D10  -  Lamella 8, skin, anterior and posterior sections
D11  -  Lamella 10, superior, anterior and posterior sections
D12  -  Lamella 10, anterior and posterior sections
D13  -  Lamella 11, anterior sections
D14  -  Lamella 13, superior, anterior and posterior sections
D15  -  Lamella 13, anterior and posterior sections
D16  -  Lamella 14, superior and anterior sections
D17  -  Lamella 14, anterior sections
D18  -  Lamella 14, inferior and anterior sections
D19  -  Lamella 15, representative perpendicular sections of lateral margin

The entire mass is submitted.  The specimen was placed into formalin on **DATE[Mar 29 12] at approximately 1300 hours, for a total fixation time of approximately 31.5 hours.","MicroscopicDescription:
A-D.  The microscopic findings support the diagnoses.  Immunohistochemical stains (A, B, C) are negative.","A: Right breast sentinel lymph node #1
B: Right breast sentinel lymph node #2
C: Right breast sentinel lymph node #3
D: Right breast, segment of: short stitch-superior margin, long stitch-lateral margin, double stitch-deep margin",,
REG4,BREAST,0,PAT-10041199,1,REC-3000703177,"ClinicalHistory:
Left breast mass 9:00, 2 cm FN.",Other Case Numbers: MR **ID-NUM.,"FinalDiagnosis:
Left breast core biopsy, 9:00 mass:  INFILTRATING DUCTAL CARCINOMA

  Breast Tumor Information:

Operative procedure:      Ultrasound-guided core biopsy
Histologic type:      Ductal, usual type
Histologic grade (MBR):    Grade 2
Nuclear score:      2
Mitotic score:      2
Tubule score:      3
Invasive tumor size:      At least 0.8 cm (3.5 cm on imaging studies)
Necrosis:      Absent
Lymphovascular invasion:    Not identified
In situ component:      20%
Microcalcifications:      Absent
Special studies:      ER, PR, HER-2 and Ki-67 pending.
DiagnosisComment:
Specimen signed out at **INSTITUTION for **STREET-ADDRESS, **PLACE, HI **ZIP-CODE.",,"GrossDescription:
Received in fixative labeled ""XXXXXX, left breast, 9:00, 2 cm FN"" are 4 cores of tan-white tissue measuring up to 2.1 cm in length and 0.2 cm in diameter.  Submitted in toto in one cassette.  The specimen is placed in formalin on 08:15 hours **DATE[Jan 29 2012] for a total fixation time of 10.75 hours.","MicroscopicDescription:
The microscopic description supports the above diagnosis.","A: Left breast 9:00, 2 cm FN",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Low cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10038177,1,REC-3000703261,"ClinicalHistory:
Left breast upper outer breast mass with suspicious microcalcifications.",,"FinalDiagnosis:
ULTRASOUND-GUIDED CORE NEEDLE BIOPSY, LEFT BREAST AT 2:00, 6 CM FROM NIPPLE:  INVASIVE DUCTAL CARCINOMA, HISTOLOGIC GRADE III (SEE COMMENT).
DiagnosisComment:
The core needle biopsy sections infiltration by irregular nests (tubule score 3) of markedly pleomorphic tumor cells (nuclear score 3) with frequent mitotic activity (mitotic score 2).  The invasive tumor exhibits extensive necrosis.  There is also a minor intraductal component with high grade nuclear features and comedonecrosis.

Estrogen and progesterone receptor, Her-2-Neu, and MIB-1 analyses will be performed, and an addendum report will follow.",,"GrossDescription:
Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Dec 23 11]; 11:30 a.m..
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  4.
Size:  Up to 0.2 cm in diameter and up to 2.3 cm in length.
Formalin fixation (Start):  Date  **DATE[Dec 23 11] Time  11:30 a.m..
Formalin fixation (End):  Date  **DATE[Dec 23 11] Time  6:00 p.m..
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,A: LEFT BREAST 2:00 6 CM FN,,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HercepTest(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                 0%       NEGATIVE
 INTENSITY:
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          1%       LOW POSITIVE
 INTENSITY:                           Weak
 Internal Control:             Not Present
 External Control:                Positive
Ki-67 (MIB-1):                          64%       HIGH
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:                 1.0        NEGATIVE
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): A1

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
Ki67 is reported as average %positive:  High >20%.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation
0.5-1.49:  (1+) Negative
Report REISSUED to add HER2 HercepTest Results.

STANDARD ASSAY CONDITIONS ER/PR Her2:
Cold ischemic time less than 1 hr.: within limits
Fixation time Estrogen-Progesterone 6-72 hrs: within limits
Fixation time Her-2 6-48 hrs: within limits."
REG4,BREAST,0,PAT-10034636,1,REC-3000703445,"ClinicalHistory:
Right breast mass.
Post-OperativeDiagnosis:
Same, pending pathology.
Pre-OperativeDiagnosis:
US guided breast biopsy. Tech: NC.",,"PreOperativeDiagnosis:
US guided breast biopsy. Tech: NC.
PostOperativeDiagnosis:
Same, pending pathology.
FinalDiagnosis:
RIGHT BREAST INVASIVE DUCTAL CARCINOMA
Breast Tumor Information:
Operative procedure:    US needle biopsy, right breast mass, 4:00, 3 cm FN
Histologic type:    Invasive ductal carcinoma 
Histologic grade (MBR):  Well-differentiated 
Nuclear score:      1
Mitotic score:      1
Tubule score:      2
Invasive tumor size:    0.8 cm in core biopsy material 
Necrosis:      Not evident 
Lymphovascular invasion:  Not evident 
In situ component:    Not evident 
Microcalcifications:    Not evident 
Special studies:    ER/PR/HER2-neu/Ki-67 pending
Staging information:    pT1.",,"GrossDescription:
Received in formalin labeled ""XXXXXX, **NAME[AAA], right breast 4:00 3.0 cm FN""  are three cores of tan-white soft tissue measuring up to 1.8 cm in length x 0.2 cm average outside diameter.  Specimens are placed in formalin at 8:38 on **DATE[Jan 1 12] for a total fixation time of approximately 10.25 hours.  Submitted entirely in one block.","MicroscopicDescription:
Needle biopsies of breast demonstrate an invasive mammary carcinoma.  There is prominent background lymphocytic inflammation.  Immunostains for myoepithelial cells (p63, myosin) and E-cadherin immunostain are evaluated.  These demonstrate a diffuse absence of myoepithelial cells, and positive staining for E-Cadherin, supporting invasive ductal carcinoma.",A: Right breast mass 4:00 3cm FN,,
REG4,BREAST,0,PAT-10039959,1,REC-3000703699,"ClinicalHistory:
233.0
A1) Short stitch superior, double short stitch medial, long stitch lateral
A2) Long stitch lateral, short stitch superior
Procedure->Biopsy
Procedure->Excision
Clinical History/Diagnosis/Condition->DCIS./r/n",,"FinalDiagnosis:
A.  Left breast, lumpectomy:  Invasive ductal carcinoma, Grade 2, multifocal (two foci; 5 mm and 1 mm).

  Ductal carcinoma in situ (DCIS), Grade 3.

  DCIS is focally positive at the superficial, superior, deep, and inferior margins; larger focus of invasive ductal carcinoma is less than 1 mm from the closest superior margin.
  
  Pathologic stage pT1a NX
  
  See comment and microscopic description for additional tumor information. 

B.  Left breast, deep margin:  Benign breast parenchyma with fibrocystic changes; negative for malignancy./r/nDiagnosisComment:
The H\T\E-stained sections demonstrate widespread foci of ductal carcinoma in situ (DCIS), focally present at several margins (see microscopic description), as well as two foci of invasive ductal carcinoma that are confirmed with an immunohistochemical stain for smooth muscle myosin.  The stains are performed on sections from blocks A11, A13, A16, A17, and A19; all controls react appropriately.

Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block A13 with the 5 mm focus of invasive carcinoma; the results will be reported in an addendum.  

Case reviewed in Pathology Staff Conference on **DATE[Feb 5 12].  **NAME[ZZZ YYY] RN was notified of the findings via voicemail communication on **DATE[Feb 5 12] at 4:39 p.m./r/n",,"GrossDescription:
A.  
Labeled:      Patient name and medical record number, designated left breast biopsy
Specimen:    Slightly firm pale yellow, lobulated tissue (formalin)
Size:      9 x 2.3 x 1 cm
Orientation:    Short stitch = superior, double short stitch = medial, long stitch = lateral
Colors:  
    Black:    Deep
    Orange:    Superficial
    Green:    Superior
   Blue:    Inferior
    Red:    Medial
    Yellow:    Lateral

Findings  :  Sections reveal white fibrous tissue, including a 1 x 0.9 x 0.3 cm firm focus located on the superior margin. Specimen is serial sections from medial to lateral into 20 slabs. 
Section code:    
    Block 1-4:  Medial margin and adjacent slabs
   Block 5-15:  Specimen entirely submitted from medial to lateral, firm focus at the superior margin in  B12.  
    Block 16-20:  Lateral margin and adjacent slabs

B.  
Labeled:      Patient name and medical record number, designated left breast, deep margin at 1300
Specimen:    Slightly firm, pale, yellow, lobulated portion of tissue (formalin)
Size:      3.3 cm medial-lateral, 1.7 cm superior-inferior, 1.4 cm superficial-deep
Orientation:    Long stitch = lateral, short stitch = superior, and a long day only area meeting
Colors:
    Black:    Deep
    Orange:    Superficial
    Green:    Superior
    Blue:    Inferior
    Red:    Medial
    Yellow:    Lateral
Findings  : 0.2 x 0.2 x 0.1 cm firm focus, present at the lateral margin.  0.2 x 0.1 x 0.1 cm, firm focus present at the superior superficial margin
Section code:    
    Block 1:    Medial margin
    Block 2 -3:  Full thickness sections
    Block 5:    Superior superficial margin containing firm focus
    Block 6:    Full thickness sections
    Block 7:    Lateral margin containing firm focus./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.  

Breast Cancer Information (Based on AJCC/UICC TNM, 7th edition)

Tumor Focality: Multiple foci of invasive carcinoma.
    Number of foci: One larger and one smaller focus.
    Sizes of individual foci:  5 mm (microscopic measurement, block A13 at mid portion of specimen) and 1 mm (microscopic measurement, block A17 at approximate halfway point between middle and lateral end of specimen) 
Macroscopic and Microscopic Extent of Tumor:   
    Skin: Not present.
    Nipple: Not present
    Skeletal muscle: Not present.

Ductal carcinoma in Situ (DCIS): DCIS is present.
     Extent of DCIS:    
     Number of blocks with DCIS: 14 
     Number of blocks examined: 20 (part A) + 7 (part B) = 27
     Architectural Patterns: Solid, cribriform, comedo.
     Nuclear Grade: Grade III (high grade).
     Necrosis:  Present, central.
Lobular carcinoma in situ:  Not identified.

Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma.
    Glandular (acinar)/tubular differentiation: Score 3
    Nuclear pleomorphism: Score 2
    Mitotic count: Score 2
    Total score: 7
    Overall Grade: Grade 2
Margins:
    Margins uninvolved by invasive carcinoma. 
        Distance from closest margin(s): 1 mm to closest superior margin (larger 5 mm focus) and 2 mm to closest lateral margin (smaller 1 mm focus).
    Margins positive for ductal carcinoma in situ.
        Tumor focally positive at the superficial, superior, deep, and inferior margins.
        Tumor is less than 1 mm from the closest lateral margin, and is 1 mm from the closest medial margin.   
Lymph-Vascular Invasion: Indeterminate.
Lymph nodes:  Not present.

 Pathologic Staging (pTNM):
    Primary tumor: pT1a (tumor greater than 1 mm but less than or equal to 5 mm in greatest dimension)
    Regional lymph nodes: NX  (Regional lymph nodes cannot be assessed)
    Distant metastasis: Not applicable.

Ancillary Studies:
    Estrogen receptor: 0%
    Progesterone receptor: 0%
    Ancillary studies performed on previous left breast biopsy (surgical pathology case ***PATH-NUMBER[1]; **DATE[Dec 26 11]).
Microcalcifications: Present in ductal carcinoma in situ.
Additional pathologic findings:  
   Prior biopsy site changes.
   Proliferative fibrocystic changes including scattered foci of mild ductal epithelial hyperplasia./r/n","A: Left breast biopsy, biopsy
B: Left breast deep margin, excision",,
REG4,BREAST,0,PAT-10017477,1,REC-3000703700,"ClinicalHistory:
174.9
Long stitch lateral, short stitch superior.
Procedure->Excision
Clinical History/Diagnosis/Condition->Left chest wall mass./r/n",,"FinalDiagnosis:
Left chest wall mass: Compatible with a recurrent invasive ductal carcinoma, tumor involves the 6:00 margin and comes to within 1 mm of the deep margin (block 9).

  Prior biopsy site reaction present./r/nDiagnosisComment:
The tumor is histologically similar to the patient's prior left breast recurrence (***PATH-NUMBER[1]). The tumor involves the dermis and the underlying skeletal muscle. Dr. **NAME[ZZZ] s office (**NAME[YYY]) contacted on **DATE[Feb 5 12] at 9:42 am./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated left chest wall mass Specimen:    6 x 2 x 2 cm skin ellipse and adjacent tissue (formalin)
Lesion:      4 cm long apparent linear scar on the skin surface; 3 x 2.5 x 1.7 cm pink-tan mass within the subcutaneous tissue; cut surfaces are homogeneous gray-white.
Sutures:      
  Long:      Lateral (3:00)
  Short:      Superior (12:00)
Colors:      
  Black:      Deep and 12:00
  Blue:      6:00
Submitted/Blocks:  Entirely in several pieces, from 3:00 to 9:00/14./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left chest wall mass, excision",,"AddendumComment:
Intradepartmental consultation with Dr. **NAME[XXX] on **DATE[Feb 3 12]./r/n"
REG4,BREAST,0,PAT-10038182,1,REC-3000703724,"ClinicalHistory:
A. palpable, firm, oval solid mass at right 8 o'clock-suspicious for CA or DCIS

B. complex mass with calcifications palpable right 8:30 lobulated mass with numerous amorphous calcifications adjacent to site A-suspicious for carcinoma or DCIS.",,"FinalDiagnosis:
A.  BREAST CORE NEEDLE BIOPSY FOR MASS:  
    INVASIVE DUCTAL CARCINOMA.
 
B.  RIGHT BREAST MASS 8:30 6 CM FN:  
    - INVASIVE DUCTAL CARCINOMA.
    - DUCTAL CARCINOMA IN SITU, NUCLEAR GRADE 3 WITH 
      COMEDONECROSIS AND MICROCALCIFICATION.
DiagnosisComment:
Though a definitive histologic grade cannot be given on a needle biopsy, the tumor (both A and B) exhibits features of high grade (nuclear pleomorphism score of 3, glandular (acinar)/tubular differentiation score of 3 and mitotic score of 2-3.  ER/PR, Her2/neu and Ki67 (MIB1) studies are pending.",,"GrossDescription:
A. Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Jun 29 12], 10:40 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  4.
Size:  0.3 cm in diameter and up to 1.4 cm in length.
Formalin fixation (Start):  Date  **DATE[Jun 29 12] Time  10:40 a.m.
Formalin fixation (End):  Date  **DATE[Jun 29 12] Time  6:00 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B. Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Jun 29 12], 11:00 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  3.
Size:  0.3 cm in diameter and up to 2.0 cm in length.
Formalin fixation (Start):  Date  **DATE[Jun 29 12] Time  11:00 a.m.
Formalin fixation (End):  Date  **DATE[Jun 29 12] Time  6:00 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: BREAST CORE NEEDLE BIOPSY FOR MASS
B: RIGHT BREAST MASS 8:30 6 CM FN",,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HercepTest(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                17%  **   POSITIVE
 INTENSITY:                  Weak-Moderate
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          2%  **   LOW POSITIVE
 INTENSITY:                           Weak
 Internal Control:                Positive
 External Control:                Positive
Ki-67 (MIB-1):                          83%       HIGH
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:             PENDING
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): B1

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
Ki67 is reported as average %positive:  High >20%.
**The tumor cells show variable estrogen and progesterone
receptor stain, ranging from negative to positive.  The
result given is an average of stain intensity.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation

STANDARD ASSAY CONDITIONS ER/PR Her2:
Cold ischemic time less than 1 hr.: within limits
Fixation time Estrogen-Progesterone 6-72 hrs: within limits
Fixation time Her-2 6-48 hrs: within limits."
REG4,BREAST,0,PAT-10038181,1,REC-3000703729,"ClinicalHistory:
1.4-cm lobulated firm left lobulated nodule suspicious for carcinoma.",,"FinalDiagnosis:
LEFT BREAST 4:00 4 CM FN:  INVASIVE DUCTAL CARCINOMA.
DiagnosisComment:
Though a definitive histologic grade cannot be given on a needle biopsy, the tumor exhibits features of intermediate to high grade (nuclear pleomorphism score of 3, glandular (acinar)/tubular differentiation score of 3 and mitotic score of 1-2).  ER/PR, Her2/neu and Ki67 (MIB1) studies are pending.",,"GrossDescription:
Specimen:  Elongated segments of fibrofatty tissue.
Collection date/time:  **DATE[Dec 29 11], 11:20 a.m.
Fixative:  10x volume, neutral buffered formalin.
Weight:  Less than 1 gm.
Number of segments:  5.
Size:  0.2 cm in diameter and up to 1.3 cm in length.
Formalin fixation (Start):  Date  **DATE[Dec 29 11] Time  11:20 a.m.
Formalin fixation (End):  Date  **DATE[Dec 29 11] Time  6:00 p.m.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,A: LEFT BREAST 4:00 4 CM FN,,"Interpretation:
ER/PR(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
Ki67(IMMUNOPEROXIDASE, POLYMER)DakoACIS3 COMPUTER-ASSIST MORPHOMETRY
HercepTest(IMMUNOPEROXIDASE,POLYMER) DakoACIS3 COMPUTER-ASSIST MORPHOMETRY

TEST                               RESULTS        INTERPRETATION
-----------------------------------------------------------------
ESTROGEN RECEPTOR (1D5):                89%  **   STRONG POSITIVE
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
PROGESTERONE RECEPTOR (PGR636):          1%       LOW POSITIVE
 INTENSITY:                       Moderate
 Internal Control:                Positive
 External Control:                Positive
Ki-67 (MIB-1):                          24%       HIGH
 INTENSITY:                         Strong
 Internal Control:                Positive
 External Control:                Positive
HER2 HercepTest (TM)*:             PENDING
-----------------------------------------------------------------
Block (Formalin-fixed Paraffin Embedded Section): A1

ER/PR studies are reported as average %positive:  Negative 0%;
Low Positive 1-15%;  Positive 16-35%;  Strong Positive 36-100%.
Ki67 is reported as average %positive:  High >20%.
**The tumor cells show variable estrogen receptor stain, ranging
from negative to strong positive.  The result given is an average
of stain intensity.
These tests were developed and their performance characteristics
were determined by the **INSTITUTION Pathology
Laboratory.  Tests have not been cleared or approved by the U.S.
Food and Drug Administration.  The FDA does not require this test
to go through premarket FDA review.

*HercepTest, a trademark of the DAKO Corporation

STANDARD ASSAY CONDITIONS ER/PR Her2:
Cold ischemic time less than 1 hr.: within limits
Fixation time Estrogen-Progesterone 6-72 hrs: within limits
Fixation time Her-2 6-48 hrs: within limits."
REG4,BREAST,0,PAT-10039959,1,REC-3000704551,"ClinicalHistory:
233.0
A1) Short stitch superior, double short stitch medial, long stitch lateral
A2) Long stitch lateral, short stitch superior
Procedure->Biopsy
Procedure->Excision
Clinical History/Diagnosis/Condition->DCIS./r/n",,"FinalDiagnosis:
A.  Left breast, lumpectomy:  Invasive ductal carcinoma, Grade 2, multifocal (two foci; 5 mm and 1 mm).

  Ductal carcinoma in situ (DCIS), Grade 3.

  DCIS is focally positive at the superficial, superior, deep, and inferior margins; larger focus of invasive ductal carcinoma is less than 1 mm from the closest superior margin.
  
  Pathologic stage pT1a NX
  
  See comment and microscopic description for additional tumor information. 

B.  Left breast, deep margin:  Benign breast parenchyma with fibrocystic changes; negative for malignancy./r/nDiagnosisComment:
The H\T\E-stained sections demonstrate widespread foci of ductal carcinoma in situ (DCIS), focally present at several margins (see microscopic description), as well as two foci of invasive ductal carcinoma that are confirmed with an immunohistochemical stain for smooth muscle myosin.  The stains are performed on sections from blocks A11, A13, A16, A17, and A19; all controls react appropriately.

Immunoperoxidase stains for estrogen/progesterone receptors and Her2 Neu studies will be performed on block A13 with the 5 mm focus of invasive carcinoma; the results will be reported in an addendum.  

Case reviewed in Pathology Staff Conference on **DATE[Aug 5 12].  **NAME[ZZZ YYY] RN was notified of the findings via voicemail communication on **DATE[Aug 5 12] at 4:39 p.m./r/n",,"GrossDescription:
A.  
Labeled:      Patient name and medical record number, designated left breast biopsy
Specimen:    Slightly firm pale yellow, lobulated tissue (formalin)
Size:      9 x 2.3 x 1 cm
Orientation:    Short stitch = superior, double short stitch = medial, long stitch = lateral
Colors:  
    Black:    Deep
    Orange:    Superficial
    Green:    Superior
   Blue:    Inferior
    Red:    Medial
    Yellow:    Lateral

Findings  :  Sections reveal white fibrous tissue, including a 1 x 0.9 x 0.3 cm firm focus located on the superior margin. Specimen is serial sections from medial to lateral into 20 slabs. 
Section code:    
    Block 1-4:  Medial margin and adjacent slabs
   Block 5-15:  Specimen entirely submitted from medial to lateral, firm focus at the superior margin in  B12.  
    Block 16-20:  Lateral margin and adjacent slabs

B.  
Labeled:      Patient name and medical record number, designated left breast, deep margin at 1300
Specimen:    Slightly firm, pale, yellow, lobulated portion of tissue (formalin)
Size:      3.3 cm medial-lateral, 1.7 cm superior-inferior, 1.4 cm superficial-deep
Orientation:    Long stitch = lateral, short stitch = superior, and a long day only area meeting
Colors:
    Black:    Deep
    Orange:    Superficial
    Green:    Superior
    Blue:    Inferior
    Red:    Medial
    Yellow:    Lateral
Findings  : 0.2 x 0.2 x 0.1 cm firm focus, present at the lateral margin.  0.2 x 0.1 x 0.1 cm, firm focus present at the superior superficial margin
Section code:    
    Block 1:    Medial margin
    Block 2 -3:  Full thickness sections
    Block 5:    Superior superficial margin containing firm focus
    Block 6:    Full thickness sections
    Block 7:    Lateral margin containing firm focus./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.  

Breast Cancer Information (Based on AJCC/UICC TNM, 7th edition)

Tumor Focality: Multiple foci of invasive carcinoma.
    Number of foci: One larger and one smaller focus.
    Sizes of individual foci:  5 mm (microscopic measurement, block A13 at mid portion of specimen) and 1 mm (microscopic measurement, block A17 at approximate halfway point between middle and lateral end of specimen) 
Macroscopic and Microscopic Extent of Tumor:   
    Skin: Not present.
    Nipple: Not present
    Skeletal muscle: Not present.

Ductal carcinoma in Situ (DCIS): DCIS is present.
     Extent of DCIS:    
     Number of blocks with DCIS: 14 
     Number of blocks examined: 20 (part A) + 7 (part B) = 27
     Architectural Patterns: Solid, cribriform, comedo.
     Nuclear Grade: Grade III (high grade).
     Necrosis:  Present, central.
Lobular carcinoma in situ:  Not identified.

Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma.
    Glandular (acinar)/tubular differentiation: Score 3
    Nuclear pleomorphism: Score 2
    Mitotic count: Score 2
    Total score: 7
    Overall Grade: Grade 2
Margins:
    Margins uninvolved by invasive carcinoma. 
        Distance from closest margin(s): 1 mm to closest superior margin (larger 5 mm focus) and 2 mm to closest lateral margin (smaller 1 mm focus).
    Margins positive for ductal carcinoma in situ.
        Tumor focally positive at the superficial, superior, deep, and inferior margins.
        Tumor is less than 1 mm from the closest lateral margin, and is 1 mm from the closest medial margin.   
Lymph-Vascular Invasion: Indeterminate.
Lymph nodes:  Not present.

 Pathologic Staging (pTNM):
    Primary tumor: pT1a (tumor greater than 1 mm but less than or equal to 5 mm in greatest dimension)
    Regional lymph nodes: NX  (Regional lymph nodes cannot be assessed)
    Distant metastasis: Not applicable.

Ancillary Studies:
    Estrogen receptor: 0%
    Progesterone receptor: 0%
    Ancillary studies performed on previous left breast biopsy (surgical pathology case ***PATH-NUMBER[1]; **DATE[Jun 26 12]).
Microcalcifications: Present in ductal carcinoma in situ.
Additional pathologic findings:  
   Prior biopsy site changes.
   Proliferative fibrocystic changes including scattered foci of mild ductal epithelial hyperplasia./r/n","A: Left breast biopsy, biopsy
B: Left breast deep margin, excision",,"ResultsComments:
The following results were performed at **PLACE, NV and reported by **NAME[XXX M. WWW], M.D. on **DATE[Aug 10 2012].  

INTERPRETATION:

BREAST CANCER PROGNOSTIC PANEL:  
***PATH-NUMBER[2], BLOCK # A13 (INVASIVE CARCINOMA)

            ESTROGEN RECEPTOR:                   0%
            PROGESTERONE RECEPTOR:            0%
            HER-2/neu (ACIS score):                   4.1 (OVEREXPRESSION)

COMMENT:
ERPR     
  Analysis is performed using ChromaVision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical methods on the Ventana Benchmark XT automated stainer 
  using antibodies against ER (SP1 IVD), PR (clone IE2 IVD).  Though the largest studies have used 10% as a 
  threshold for positivity, others have recommended a cutoff as low as 1%. 

HER-2/neu
  Analysis is performed using Chromavision Automated Cellular Imaging System (ACIS) on formalin-fixed paraffin-
  embedded section stained by immunohistochemical on the Ventana Benchmark XT automated stainer using HER-2/neu 
  (4B5)  Rabbit Monoclonal Antibody.

  Slides were reviewed by an in-house pathologist and deemed adequate for analysis.  All controls (negative, positive, and 
  equivocal) were appropriate.

  The results obtained from the ChromaVision ACIS correspond to the ASCO/CAP scoring criteria in the following 
  manner, as determined by in-house studies:

  ChromaVision:         ASCO/CAP 
  Result:          Score:

  Less than 1.5         0       (No staining)

  Less than 1.5         1+        (Weak, incomplete membrane staining)

  1.5 to 3.4              2+        (Complete membrane staining that is either nonuniform or weak in 
                       intensity, but with obvious circumferential distribution in at least 10% of the 
                       cells, or intense complete membrane staining in less than 30% of invasive 
                       tumor cells)

  Greater than 3.4       3+       (Uniform, intense membrane staining in greater or lesser than 30% 
                       invasive tumor cells)

  A ChromaVision ACIS score of 1.5 to 3.4 is reflexed to Her-2/neu testing by FISH methods, unless otherwise 
  specified.  This is in accordance with CAP recommendations (Strategic Science I Meeting, **DATE[Jan 2003], **PLACE, 
  IL).

  Per the 2007 joint guidelines of the American Society of Clinical Oncology (ASCO) and the College of American 
  Pathologists (CAP) on HER2 testing in breast cancer, specimens should be fixed in 10% neutral buffered 
  formalin for intervals ranging from 6 hours to no more than 48 hours.  Prolonged fixation, for example more than 
  48 hours, may result in false-negative results.  Fixation times for needle biopsies have not been addressed.  
  
References:
  1.  Fitzgibbons PL, et. al. Arch Pathol Lab Med 2000;**ID-NUM.
  2.  **NAME[VVV] JM, et. al. Mod Path **ID-NUM.
  3.  Baddoura FK, et. al. Mod Path 1991;4(1):91-95.
  4.  **NAME[UUU M], et. al. Am J Clin Pathol 2001;**ID-NUM.
  5.  **NAME[TTT, M], et al. J Clin Pathol 2000; 53 (**ID-NUM.
  6.  Wolff, AC, et al.  ""American Society of Clinical Oncology/College of American Pathologists Guideline
       Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.""  Arch Pathol 
       Lab Med 2007; **ID-NUM.
  (BLS/mab)./r/n"
REG4,BREAST,0,PAT-10039850,1,REC-3000704578,"ClinicalHistory:
A) Right breast mass, 6 o'clock, 3 cm FN; B) right breast mass, inferior, 10 o'clock, 4 cm FN; C) right breast mass, superior, 10 o'clock, 4 cm FN; D) right breast mass, 10 o'clock, 6 cm FN.",Other Case Numbers: MR# 560940.,"FinalDiagnosis:
A.  Right breast, 6 o'clock, 3 cm fn, ultrasound guided core biopsy:    
          Intraductal papilloma without atypia

B.  Right breast, 10 o'clock, 4 cm fn inferior, ultrasound guided biopsy:    
          Invasive LOBULAR carcinoma

C.  Right breast, 10 o'clock, 4.0 cm fn superior, ultrasound guided core biopsy:
          Benign breast tissue  

D.  Right breast, 10 o'clock, 6.0 cm fn, ultrasound guided core biopsy:  
          Invasive LOBULAR carcinoma

Breast Tumor Information:

Operative procedure:    Ultrasound guided core biopsy
Histologic type:    LOBULAR
Nottingham grade:    2 of 3 (nuclear score 2, mitotic score 1, tubular score 3)
Invasive tumor size:    At least 1.0 cm 
Necrosis:      Absent
Lymphovascular invasion:  Not identified
In-situ component:    Atypical lobular hyperplasia, minor component
Microcalcifications:    Absent
Special studies:    ER, PR, Her2 and Ki67 pending.
DiagnosisComment:
The invasive tumor seen in parts B and D show similar histologic features and given the proximity of lesions they likely represent sampling of a single invasive tumor. Please correlate with radiographic findings.

E-cadherin immunohistochemical stain shows absent membranous reactivty in the neoplastic cells confirming the lobular phenotype.",,"GrossDescription:
A.  Received in fixative labeled ""XXXXXX, right breast A"" are multiple cores of pink-white tissue measuring up to 1.9 cm in length and 0.1 cm in diameter.  Submitted in toto in one cassette.  The specimen was removed from patient on **DATE[Jul 5 12] at 8:25am and placed in formalin for a total fixation time of 10 hours and 35 minutes.  The specimen has a cold ischemic time of 5 minutes.  

B.  Received in fixative labeled ""XXXXXX, right breast B"" are 5 cores of pink-white tissue measuring up to 0.8 cm in length and 0.2 cm in diameter.  Submitted in toto in one cassette.  The specimen was removed from patient on **DATE[Jul 5 12] at 8:50am and placed in formalin for a total fixation time of 10 hours and 10 minutes.  The specimen has a cold ischemic time of 2 minutes.  

C.  Received in fixative labeled ""XXXXXX, right breast C"" are 5 cores of pink-white tissue measuring up to 0.5 cm in length and 0.1 cm in diameter.  Submitted in toto in one cassette.  The specimen was removed from patient on **DATE[Jul 5 12] at 8:20am and placed in formalin for a total fixation time of 9 hours and 40 minutes.  The specimen has a cold ischemic time of 5 minutes.  

D.  Received in fixative labeled ""XXXXXX, right breast D"" are 5 cores of pink-white tissue measuring up to 1.8 cm in length and 0.2 cm in diameter.  Submitted in toto in one cassette.  The specimen was removed from patient on **DATE[Jul 5 12] at 9:27am and placed in formalin for a total fixation time of 9 hours and 33 minutes.  The specimen has a cold ischemic time of 2 minutes.","MicroscopicDescription:
A-D.  The microscopic findings support the above diagnoses.","A: Right breast, 6 o'clock, 3 cm FN
B: Right breast, inferior, 10 o'clock, 4 cm FN
C: Right breast, superior, 10 o'clock, 4 cm FN
D: Right breast, 10 o'clock, 6 cm FN",,"AddendumDiagnosis:
D.  Right breast, 10 o'clock, 6 cm FN:  
 

PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Equivocal, FISH testing pending
Ki-67 (Ki-S5):        Elevated cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results.

HER-2/neu (FISH):  Negative for amplification.
AddendumComment:
HER-2/neu analysis by fluorescence in situ hybridization shows a HER-2/chromosome 17 ratio of 1.1.


Testing performed at Clarient Diagnostic Services, **PLACE, CA."
REG4,BREAST,0,PAT-10040780,1,REC-3000704717,"ClinicalHistory:
A-E.  Redo right breast lumpectomy.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A. Right breast, superior margin, excision:                PAS 4  
  Benign breast tissue with biopsy site changes

B. Right breast, inferior margin, excision:                PAS 4
  Benign fibroadipose tissue with biopsy site changes

C. Skin, right breast, anterior margin, excision:                PAS 4
  Skin with scar, negative for malignancy

D. Right breast, lateral margin, excision:                PAS 4
  Benign breast tissue with biopsy site changes

E. Right breast, medial margin, excision:                PAS 4
  Benign fibroadipose tissue with biopsy site changes.",,"GrossDescription:
Specimen A:  Received in formalin, labeled ""superior margin, stitch marks new margin at 1012"" is an irregular piece of rubbery pink-tan and yellow tissue (7 x 5.3 x 1.8 cm) with a suture attached to one side of the specimen marking the new margin.  The specimen is differentially inked as follows:  new margin-black ink and old margin-green ink.  The specimen is serially sectioned and entirely submitted in A1 through A12.

Specimen B:  Received in formalin, labeled ""inferior margin at 1025"" are multiple irregular pieces of rubbery pink-tan and yellow tissue (4.5 x 4 x 1.6 cm in aggregate, 0.7 to 4 cm in greatest dimension).  The specimen is sectioned and entirely submitted in B1 through B6.

Specimen C:  Received in formalin, labeled ""anterior margin (skin)"" is an elongated piece of pink-tan skin with attached underlying rubbery tan-yellow tissue (4.5 x 0.7 x 0.5 cm).  The surgical margin is inked black.  The specimen is sectioned and entirely submitted in C1 through C5.

Specimen D:  Received in formalin, labeled ""lateral margin, stitch marks new margin"" is an irregular piece of rubbery pink-tan and yellow tissue (6.5 x 4.5 x 1.9 cm) with a suture attached to one side of the specimen marking the new margin.  The specimen is differentially inked as follows:  new margin-black ink and old margin-green ink.  The specimen is serially sectioned and entirely submitted in D1 through D11.

Specimen E:  Received in formalin, labeled ""medial margin, stitch marks new margin at 1016"" is an irregular piece of rubbery pink-tan and yellow tissue (2.5 x 1.7 x 1.1 cm) with a suture attached to one side of the specimen marking the new margin.  The specimen is differentially inked as follows:  new margin-black ink and old margin-green ink.  Also received in the same container is an additional piece of rubbery tan-yellow tissue (1 x 0.8 x 0.4 cm).  Both pieces are sectioned and the entire specimen is submitted as follows:

Block summary:
E1-E2.  -  Sections of larger inked piece of tissue with suture.
E3.  -  Sections of additional piece of separate tissue.

The specimen was placed into formalin on **DATE[Jun 13 12] between the hours of 1004 and 1033, for a total fixation time of approximately 10.25 hours.","MicroscopicDescription:
A-E. The microscopic findings support the diagnoses.","A: Rt breast superior margin stitch marks new margin at 1012
B: Rt breast inferior margin in formalin at 1025
C: Rt breast anterior margin (skin) out at 1001/in formalin at 1004
D: Rt breast lateral margin stitch marks new margin at 1033
E: Rt breast medial margin stitch marks new margin at 1016",,
REG4,BREAST,0,PAT-10034382,1,REC-3000705087,"ClinicalHistory:
Left breast cancer, post chemotherapy.
Post-OperativeDiagnosis:
Left partial mastectomy, axillary node dissection.
Pre-OperativeDiagnosis:
Left partial mastectomy, axillary node dissection.",,"PreOperativeDiagnosis:
Left partial mastectomy, axillary node dissection.
PostOperativeDiagnosis:
Left partial mastectomy, axillary node dissection.
FinalDiagnosis:
A.   LEFT BREAST DUCT CARCINOMA IN-SITU (12:00)
Breast Tumor Information:
Operative procedure:  Needle localized excision, left breast mass 12:00
Histologic Type:  Duct carcinoma in-situ (residual, post chemotherapy)
Nuclear grade:  High-grade (3)
Necrosis:  Moderate
Architectural pattern(s):  Comedocarcinoma and cribriform 
Margins:  Free of carcinoma (1.0 cm minimum clearance)
Size:  0.5 cm aggregate dimension of residual DCIS; no residual invasive carcinoma identified
Microcalcifications:  Present
Special studies:  Defer to previous biopsy (pre-chemotherapy)
Stage:  Post chemotherapy ypTisN0

B.  Lesion, left breast 10:00, needle localized excision:   
          1. No residual carcinoma identified (post chemotherapy)
          2. Mild-moderate fibrocystic changes with fibroadenoma
 
C.  Lymph nodes, left axilla, disection:
          Lymph nodes, negative for metastasis (0/13 nodes, post chemotherapy).
DiagnosisComment:
No residual invasive carcinoma is identified.  A few scattered foci of high-grade duct carcinoma are present within the 12:00 lesion.  Lymph nodes, post chemotherapy, are negative for metastasis.",,"GrossDescription:
A.  Received fresh labeled ""left breast 12 o'clock position"" is an excision of tan-yellow fibrofatty soft tissue measuring 6.5 x 5.4 x 3.2 cm.  Sutures are provided for orientation.  The specimen is inked: superior aspect-orange, inferior-yellow, lateral-red, medial-green, anterior-blue, posterior-black.  The specimen is serially sectioned from medial to lateral revealing a tan-yellow to white fibrofatty cut surface.  A portion of the specimen has an area of hemorrhage grossly consistent with a previous needle biopsy site.  By palpation, adjacent to the previous needle biopsy site are multiple firm nodules measuring up to 0.3 cm in greatest dimension.  No further masses or lesions are grossly identified.  Representative sections are submitted in blocks A1-8.

The specimen is collected at 1055 on **DATE[Apr 16 12], and placed in formalin at 1130 for a cold ischemic time of approximately 35 minutes and a total fixation time of approximately 7.5 hours.

B.  Received fresh labeled ""breast mass left 10 o'clock position"" is an excision of tan-yellow fibrofatty soft tissue measuring 4.6 x 3.5 x 2.5 cm.  Sutures are provided for orientation.  There is a centrally placed needle.  The specimen is inked: superior aspect-orange, inferior-yellow, lateral-red, medial-green, anterior-blue, posterior-black.  Sectioning reveals a tan-yellow to white fibrofatty cut surface with no grossly identifiable masses or lesions.  Representative sections are submitted in blocks B1-8.  

The specimen is collected at 1055 on **DATE[Apr 16 12], and placed in formalin at 1130 for a total cold ischemic time of approximately 35 minutes and a total fixation time of approximately 7.5 hours.

C.  Received in formalin labeled ""left axillary contents"" is an excision of tan-pink to yellow fatty soft tissue measuring 7.0 x 4.3 x 2.0 cm.  By palpation, there are multiple firm nodules closely consistent with lymph nodes.  Five nodes in total are grossly identified measuring up to 1.5 cm in greatest dimension.  Submitted in blocks C1-4.","MicroscopicDescription:
A.  An excision of breast demonstrates several residual foci of high-grade duct carcinoma in-situ.  No residual invasive carcinoma is identified (post chemotherapy).  Scattered involutional/post chemotherapy effects are noted, represented by areas of fibrosis and hyalinization, and scattered dystrophic microcalcifications.  Margins of excision are free of residual DCIS.

B.  An excision of breast demonstrates no evidence of residual carcinoma (post chemotherapy).  There are areas of mild involutional/post chemotherapy change, represented by areas of collagenous fibrosis and dystrophic calcifications.  The breast exhibits mild proliferative and non-proliferative fibrocystic changes and focal fibroadenoma formation.

C.  A total of 13 lymph nodes are evident, all negative for metastasis (post chemotherapy).","A: Breast mass, left, 12:00 position (fresh)
B: Breast mass, left, 10:00 position, long suture lateral, short suture superior (fresh)
C: Left axillary contents",,
REG4,BREAST,0,PAT-10039942,1,REC-3000705335,"ClinicalHistory:
Right breast cancer.
Pre-OperativeDiagnosis:
Single stitch anterior margin
Double stitch superior margin.",,"PreOperativeDiagnosis:
Single stitch anterior margin
Double stitch superior margin.
FinalDiagnosis:
A.  Right axillary node:  No evidence of metastatic carcinoma by H and E stain, see comment
 
B.  Right axillary tissue:  Fatty tissue without evidence of metastatic carcinoma
 
C.  Right breast lumpectomy: 

Breast Tumor Information:

Operative procedure:    Right breast lumpectomy
Histologic type:    Invasive ductal carcinoma
Histologic grade (MBR):    Moderate to poorly differentiated
Nuclear score:    2
Mitotic score:    2
Tubule score:    3
Invasive tumor size:    1.2 cm in greatest dimension
Necrosis:    Present
Lymphovascular invasion:  Not identified
In situ component:    Small amount of in-situ tumor noted
Resection margins:    Clear (see microscopic description)
Microcalcifications:    Present
Lymph nodes:      One sentinel node without evidence of metastasis on H and E
Special studies:    Receptor studies requested
Staging information:    T1c, N0

D.  Posterior deep margin:  No evidence of carcinoma.
DiagnosisComment:
The specimen is removed at 1325 on **DATE[Jun 17]/ 2011 and placed in formalin at 1344.  It is further sectioned and submitted for processing to begin on **DATE[Jun 18 2012] at 10:15 pm.

The sentinel node will be additionally sent for keratin stains.  Receptor studies performed on block C3.

This report is faxed to Dr. **NAME[ZZZ]'s office on **DATE[Jun 19 2012] at 1:45 pm.",,"GrossDescription:
A.  Right axillary node:  A lymph node and surrounding fatty tissue in aggregate measuring up to 1.7 x 1.2 x 1.0 cm is sectioned and entirely submitted in cassette A.
 
B.  Right axillary tissue:  Fatty tissue measuring up to 2.8 x 2.5 x 1.0 cm is sectioned and entirely submitted in cassettes B1 and B2.
 
C.  Right breast lumpectomy:  Received is a fatty breast biopsy measuring up to 7 x 5 x 2.5 cm.  It is oriented with a single suture, a guidewire and a double suture.  The surgical margins are inked as follows:  double suture (black); opposite double suture (blue); single suture and guidewire (green); opposite single suture and guidewire (red); with double suture anterior and the single suture anterior, the lateral margin is inked yellow and the medial margin is inked orange.  On section, an area of induration grossly suggestive of invasive carcinoma measures approximately 1 cm in dimension.  All margins appear free of tumor.  However, the closest surgical margin appears to be the red inked or posterior margin.  Nearly the entire tumor is submitted in cassettes C1 through C4.  No additional tumor nodules are noted on further sectioning of the breast.  It is fatty and otherwise unremarkable.
 
D.  Posterior deep margin:  Received is a fatty breast biopsy measuring up to 7 x 4 x 1.5 cm.  Sutures mark the new true surgical margins and this surface is inked.  They are inked as follows:  single suture, right lateral (green); double suture, superior anterior (black).  On section, gross carcinoma is not appreciated.  Representative sections submitted in cassettes D1 through D3.","MicroscopicDescription:
A.  Right axillary node:  Sections demonstrate a lymph node without evidence of metastatic carcinoma by H and E stain.
 
B.  Right axillary tissue:  Sections demonstrate axillary fatty tissue.  Lymphoid tissue is not appreciated.
 
C.  Right breast lumpectomy:  Sections demonstrate an invasive tumor surrounding a central scar.  Tumor is characterized by small invasive solid nests as well as glands with glandular lumens.  In the least differentiated areas, tumor is predominantly solid.  Nuclei demonstrate moderate nuclear enlargement and atypia.  10 mitoses are noted per 10 hpf.  A small amount of necrosis is noted and there are small areas of in-situ ductal carcinoma.  Neither vascular nor neural invasion is noted.  Calcifications are noted.  The surgical margins on the primary resection are free of tumor although surgical coagulation artifact is note within 1 mm of tumor.  Although there are deep surgical coagulative areas close to the tumor, it is estimated that the true surgical margin is at least 0.7 cm from tumor. On the slide, tumor measures 1.2 cm in greatest dimension.
 
D.  Posterior deep margin:  The additional representative sections are free of tumor.","A: Right axillary node
B: Right axillary tissue
C: Right breast lumpectomy
D: Posterior deep margin",,"AddendumDiagnosis:
PROGNOSTIC PANEL SUMMARY


Estrogen receptor (1D5):      Positive
Progesterone receptor (PgR 636):    Positive
HER-2/neu (HercepTest):      Negative for overexpression
Ki-67 (Ki-S5):        Elevated cell proliferation

Formalin-fixed, paraffin-embedded sections, see image analysis report for complete analytic results."
REG4,BREAST,0,PAT-10038949,1,REC-3000705742,"ClinicalHistory:
Left breast cancer.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
IntraoperativeDiagnosis:
Frozen Section Diagnosis C:  MOSTLY FIBROSIS,  DEFER FINAL TO PERMANENT SECTIONS.  (mb, **DATE[Feb 20 12], 1412).
FinalDiagnosis:
A.  Sentinel node #1 (460 hot not blue):
  One lymph node, negative for metastatic carcinoma by multi-level H&E and keratin IHC  PAS 1

B.  Sentinel node #2 (1900 hot not blue):
  METASTATIC LOBULAR CARCINOMA, MICROMETASTASIS  (0.6 MM IN LENGTH, WITH A     DIFFUSE SCATTERING OF SINGLE CELLS THROUGHOUT THE NODE)                 PAS 9

C.  Left breast nodule for frozen section:
  STROMAL FIBROSIS, ISOLATED CANCER CELLS NOT EXCLUDED   (SEE COMMENT)  PAS 9

D.  Left breast mass, local excision:
  INFILTRATING LOBULAR CARCINOMA, EXTENDING TO SUPERIOR MEDIAL INKED MARGIN
                          PAS 9
E.  Additional medial margin:
  Atypical lobular hyperplasia, focal, with fibrocystic changes, negative for lobular carcinoma
                          PAS 4

TUMOR INFORMATION:
  Type of specimen:  Left breast, excisional biopsy
  Specimen integrity:  Part E (additional medial margin) appears to correlate with the positive margin
          in part D
  Histologic grade:  Grade 2 out of 3
        Modified **NAME[ZZZ YYY] (Nottingham) score of 7 of 9
   Tubular score:    3 out of 3
  Nuclear score:    2 out of 3
  Mitotic score:    2 out of 3
  Tumor location:  Left breast, 8 o'clock, 8 cm from nipple (on prior biopsy)
  Tumor size:    The largest mass grossly was 4.8 cm with at least 1 cm of contiguous 
        microscopic extension along neurovascular septa
  Tumor focality:  Multiple intramammary metastases are seen in the surrounding fat
  In situ component:  Lobular carcinoma in situ is also multifocal (less than 10%)
  Lymph-vascular invasion:
        The tumor extension along neurovascular septa is suspicious for both
         perineural and vascular invasion
  Tumor microcalcifications:
        Not identified
  Skin involvement:  Not identified
  Resection margins:  Invasive tumor extends to the superior medial inked margin, but is not seen
         on the additional revision in part E.  Invasive tumor approaches to less than
         2 mm of the lateral inked margin, 3 mm of the anterior margin, 4mm of the
         superior margin, and 5 mm of the inferior margin microscopially.
         In situ lobular carcinoma is seen within 1 mm of the anterior margin and 
         superior margin.
  Lymph node metastasis:
        1 of 2 sentinel nodes has subcapsular tumor measuring up to 0.6 mm in 
          length (micrometastasis) with isolated diffuse single cells scattered 
          throughout the node as identified by PCK immunohistochemistry.
  Ancillary studies:  The receptor studies are reported on the addendum to the needle biopsy
         (***PATH-NUMBER[1] from **DATE[Jan 18 2012])
  AJCC tumor stage:       pT3,  pN1 mi,  cMX   (Pathologic stage IIIA)



COMMENT:  The infiltrating lobular carcinoma in this specimen appears to be spreading more widely than the 4.8 cm mass palpated grossly upon dissection of this excisional specimen. It appears to spread within and along neurovascular septa greater than the 5cm size for a T3 category. The sampling in part C shows a few  ""indian-file"" cells on the frozen amidst  stromal fibrosis that remain suspicious for tumor after the permanent H&E and IHC for keratin stains are reviewed. Multiple intramammary foci of infiltrating and in situ lobular carcinoma are found on the slides in areas not identified grossly. The tumor is close to multiple inked margins as detailed above. These findings were discussed with Dr. **NAME[XXX] on **DATE[Feb 22 12].",,"GrossDescription:
Specimen A:  Received in formalin, labeled ""SN #1 460 hot not blue"" is an irregular piece of rubbery tan-yellow tissue (1.7 x 1.2 x 1 cm).  The specimen is bisected to reveal a single node.  The entire specimen is submitted in A.

Specimen B:  Received in formalin, labeled ""#2 sentinel node 1900 hot not blue"" is an irregular piece of rubbery tan-yellow tissue (2.8 x 2 x 1.2 cm).  The specimen is bisected to reveal a single node.  The entire specimen is submitted in B.

Specimen C:  Received in the fresh state, labeled ""breast nodule frozen"" is an irregular piece of rubbery pink-tan tissue (0.7 x 0.4 x 0.4 cm).  The specimen is submitted for a frozen section and then entirely submitted in cassette C.

Specimen D:  Received in formalin, labeled ""L breast mass, skin-anterior, short-superior, long-lateral, long/short-medial"" is a lumpectomy specimen consisting of an ellipse of tan skin (3.5 x 1.2 x 0.4 cm) and attached tan-yellow tissue (8.3 cm superior to inferior by 6.7 cm lateral to medial by 3.8 cm anterior to posterior).  The skin designates the anterior margin, a short suture marks the superior margin, a long suture marks the lateral margin and one short and one long suture marks the medial margin.  Surgical margins are differentially inked as follows: superior-blue ink, inferior-yellow ink, anterior-black ink, posterior-green ink, lateral and medial-red ink.  The specimen is serially sectioned into fourteen lamellae from lateral (lamella 1) to medial (lamella 14) direction.  Lamellae 1 through 10 grossly reveal a firm, pink-tan mass (4.8 x 2.4 x 2.1 cm).  The mass grossly approaches 1.5 cm within the superior margin, 1.5 cm within the inferior margin, 0.2 cm within the anterior margin, 1 cm within the posterior margin, 0.5 cm within the lateral margin and 1.9 cm within the medial margin.  An apparent pink-tan to white fibrous area is found within the specimen near the superior aspect.  Grossly unable to determine whether the fibrous area is part of the mass, and therefore is not included in the gross measurement of the mass.  The remainder of the specimen consists of adipose tissue.  Representative sections are submitted as follows:

Block Summary:
D1-D3.    -  Lamella 1, perpendicular sections of lateral margin, mass.
D4.    -  Lamella 2, superior half, mass.
D5.    -  Lamella 2, inferior half, mass.
D6.    -  Lamella 3, superior half, mass.
D7.    -  Lamella 3, inferior half, mass.
D8.    -  Lamella 4, anterior and posterior section, mass.
D9.    -  Lamella 5, superior and anterior section, mass.
D10.    -  Lamella 5, posterior section, mass.
D11.    -  Lamella 6, superior and anterior section, fibrous area.
D12.    -  Lamella 6, anterior section, mass.
D13.    -  Lamella 6, posterior section, mass.
D14.    -  Lamella 7, anterior section, mass.
D15.    -  Lamella 7, posterior section, mass.
D16.    -  Lamella 8, anterior section, mass and location of biopsy clip.
D17.    -  Lamella 8, posterior section, mass.
D18.    -  Lamella 9, superior, anterior and posterior section, mass.
D19-D20.  -  Lamella 9, anterior section, mass.
D21.    -  Lamella 9, posterior section, mass.
D22.    -  Lamella 10, superior and anterior section, fibrous tissue.
D23.    -  Lamella 10, anterior section, mass.
D24.    -  Lamella 10, posterior section, mass.
D25.    -  Lamella 11, superior and anterior section, fibrous tissue.
D26.    -  Lamella 11, superior and posterior section, fibrous tissue.
D27.    -  Lamella 12, superior, anterior and posterior section, fibrous tissue.
D28.    -  Lamella 12, posterior section.
D29.    -  Lamella 12, inferior, skin, anterior and posterior section.
D30.    -  Lamella 13, superior and anterior section, fibrous tissue.
D31-D34.  -  Lamella 14, perpendicular sections of medial margin.

The specimen was taken out of the patient on **DATE[Feb 20 12] at approximately 13:45 hours and placed into formalin on **DATE[Feb 20 12] at approximately 14:00 hours, for a total fixation time of approximately 30.5 hours.  

Specimen E:  Received in formalin, labeled ""additional medial margin"" is an irregular piece of rubbery pink-tan and yellow tissue (2.2 x 1.6 x 1.3 cm).  The surface is inked, the specimen is serially sectioned and entirely submitted in E1 and E2.","MicroscopicDescription:
The microscopic findings support the diagnoses.
The immunohistochemical stain controls were satisfactory.","A: Sentinel node #1 460 hot not blue
B: Sentinel node #2 1900 hot not blue
C: Breast nodule frozen 1355
D: Left breast mass, skin-ant, long lateral, short-superior, long-short-medial
E: Additional medial margin 1420",,
REG4,BREAST,0,PAT-10034656,1,REC-3000705794,"ClinicalHistory:
C.  Suture on axillary tail

Procedure->Excision
Clinical History/Diagnosis/Condition->LEFT BREAST CANCER DCIS.",,"FinalDiagnosis:
A.  Sentinel lymph node #1, left axilla:  One lymph node negative for metastases (0/1).

B.  Sentinel lymph node #2, left axilla:  One lymph node negative for metastases (0/1).

C.  Left breast:  Ductal carcinoma in situ (DCIS), intermediate to high grade with focal comedo necrosis.

  DCIS focally abuts the superficial/anterior margin.

  Pathologic Stage:  pTis (DCIS) N0(i-) (sn).

   See comment and microscopic description for additional tumor information.

D.  Right breast:  Benign breast parenchyma; no evidence of malignancy.
DiagnosisComment:
One section with DCIS demonstrates a focal area with distortion of the lesional tissue border.  To investigate for a possible focus of microinvasion, immunohistochemical stains for smooth muscle myosin and p63 are performed (block C19; all controls react appropriately).  The results show the lesional tissue retains immunopositivity of surrounding myoepithelial cells, consistent with ductal carcinoma in situ.  No invasion is identified.

Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Dec 13]-14/11.  Dr. **NAME[XXX WWW] was notified of the preliminary findings via e-mail communications on **DATE[Dec 12 12] at 5:16 p.m. and **DATE[Dec 13 12] at 2:13 p.m.",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated sentinel node 1
  Specimen:    Lobulated yellow-red piece of tissue (unfixed)
  Size:      2.5 x 1.7 x 0.8 cm
  Findings:    2.3 x 1.5 x 0.8cm lymph node, bisected
  Section code:
    Block A1:    Sentinel node
    Block A2:    Remaining tissue  

B.   Labeled:      Patient name and medical record number, designated sentinel node 2
  Specimen:    Lobulated yellow-red piece of tissue (unfixed)
  Size:      1.3 x 0.8 x 0.6 cm
  Findings:    1.1 x 0.7 x 0.5 cm lymph node bisected, touch imprint and frozen section done.
  Section code:
    Block B1:    Sentinel node
    Block B2:    Remaining tissue  

C.  Labeled:      Patient name and medical record number, designated left breast mastectomy
Specimen:    Tan-yellow-pink fatty tissue with nipple 
Size:      18.4 x 12.8 x 1.4 cm  
Skin:      4.4 x 2 x 1.9 cm
Skeletal muscle:    Absent.
Nipple:      1.5 x 1.1 x 1.1 cm
Orientation:    Suture at axillary tail
Colors:
    Black:      Deep
    Orange:    Superficial
    Green:      Superior
    Blue:      Inferior
    Red:      Medial
    Yellow:      Lateral
Tumor:      
  Size:      No palpable mass.  A small 7 mm biopsy cavity is identified, 2.5 cm lateral and superior to the
nipple; the cavity contains small white pellets.  
  Skin dermal invasion:    Not identified.
  Skin ulceration:    Not identified.
  Margins:    0.9 cm from the margin
Additional findings:  Marking dye visualized lateral and deep to nipple.  A small area of hemorrhage measuring 0.4
x 0.4 x 0.4 centimeters; located approximately 1.3 cm from nipple
  Lymph nodes:    None submitted.
  Section code     (Attached labeled picture):    
    Block C1:    Cross-section of the nipple
    Block C2:    Area of hemorrhage
    Block C3-4:    Lower right quadrant
    Block C5-6:    Upper right quadrant
    Block C7-8:    Upper left quadrant
    Block C9:    Tissue lateral to nipple.
    Block C10:    Lower outer quadrant
    Block C11:    Additional right upper quadrant
    Block ***PATH-NUMBER[1]:    Remaining nipple with surrounding lateral-superior tissue.
    Block C15-16:    Remaining subareolar tissue.
    Block C17-19:    Biopsy cavity.
    Block C20-23:    Deep margin adjacent to nipple and biopsy cavity (lateral-superior).

D.  Labeled:      Patient name and medical record number, designated right breast mastectomy
Specimen:    Tan-pink fatty tissue
Size:      2.5 x 11 .0 x 2.5 cm  
Skin:      2.3 x 1.7 x 0.2 cm
Skeletal muscle:    Absent
Nipple:      2 x 2 x 1.5 cm
Orientation:    Suture arbitrarily 12:00
Colors:
    Black:      Deep
    Green:      Superior
    Blue:      Inferior
    Red:      Medial
    Yellow:      Lateral
Tumor:      
  Description:    No focal lesion identified.
  Skin dermal invasion:    Absent
  Skin ulceration:    Absent
  Margins:    Clear
  Section code     (Attached labeled picture):    
    Block D1:    Cross-section through nipple
    Blocks D2-3:    Lower right quadrant
    Blocks D4-5:    Lower left quadrant
    Blocks D6-7:    Upper right quadrant
    Blocks D8-9:    Upper left quadrant.","MicroscopicDescription:
A-D.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.

Breast Cancer Information (Based on AJCC/UICC TNM, 7th edition)

Specimen Integrity:  Single intact specimen (margins can be evaluated)
Lymph Node Sampling:  Sentinel lymph nodes.
Specimen Laterality:  Left
Tumor Site: Central to upper outer quadrant.
Size (Extent) of DCIS
        Estimated size:  Multifocal.  Small foci of DCIS are seen in blocks C1, C3, C9, C15-16, C18-20; individual foci range from 2.8 mm up to 20 mm in greatest dimension (microscopic measurement, block C19).
        Number of blocks with DCIS:   8
        Number of blocks examined: 23
Histologic Type
        Ductal carcinoma in situ - Tis (DCIS)
Architectural Patterns
        Solid
        Cribriform
        Micropapillary
        Comedo
Nuclear Grade
        Grade II-III (intermediate to high)
Necrosis
        Present, central (occasional foci of expansive ""comedo"" cell necrosis).
Margins
        DCIS focally abuts the superficial margin (block C19), and approaches to less than 1 mm of the superficial margin in blocks C1 and C9)
        Closest deep margin is 2 mm distant (block C19)  
Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy
        No known presurgical therapy specific for breast cancer. 

Lymph Nodes
        Number of sentinel nodes examined:  2
        Total number of nodes examined (sentinel and nonsentinel): 2
        Number of lymph nodes with macrometastasis (>0.2 cm): 0
        Number of lymph nodes with micrometastasis (>0.2 mm ro .2 cm and/or >200 cells): 0
        Number of lymph nodes with isolated tumor cells (< or = 0.2 mm and < or = 200 cells): 0
Method of Evaluation of Sentinel Lymph Nodes:
        Hematoxylin and eosin, multiple levels.
        Immunohistochemistry (cytokeratin Ae1/AE3, performed on blocks A1 and B1; all controls react appropriately).

Primary Tumor (pT)
        pTis (DCIS): Ductal carcinoma in situ
Regional Lymph Nodes (pN)
        Modifier: (sn)   only sentinel lymph nodes(s) evaluated.
        Category:  pN0(i-)   No regional lymph node metastases histologically, negative IHC.
Distant Metastasis (pM)
        Not applicable (MX)

Additional Pathologic Findings
        Proliferative fibrocystic changes.
        Previous biopsy site changes.
Microcalcifications: Not identified.

Ancillary Studies (performed on previous left breast biopsy ***PATH-NUMBER[2], **DATE[Nov 22 12]):
    Estrogen Receptor: 97%
    Progesterone Receptor: 35%.","A: Left axillary sentinel node #1 (fresh)
B: Left axillary sentinel node #2 (fresh)
C: Left breast mastectomy, excision
D: Right breast mastectomy, excision",,
REG4,BREAST,0,PAT-10039921,1,REC-3000706204,"ClinicalHistory:
Right breast cancer.
Post-OperativeDiagnosis:
Pending pathology exam.",,"PostOperativeDiagnosis:
Pending pathology exam.
FinalDiagnosis:
Right breast, segmental mastectomy:    DUCTAL CARCINOMA IN SITU (see tumor information)

Breast Tumor Information:

Type of specimen(s):  Right breast, segmental mastectomy
Histologic Type:  Ductal carcinoma in situ, high-grade
Size:  2.4 cm (present on 8 consecutive sections)
Architectural pattern(s):  Solid and cribriform
Nuclear grade:  Nuclear grade 3 out of 3
Necrosis:  Comedonecrosis
Microcalcifications:  Present within DCIS and benign tissue  
Resection margins:  Superior, medial and deep margins involved by DCIS
  Remaining margins free by >3 mm
Other findings:  Biopsy site changes
Ancillary studies:  ER +, PR + on core biopsy (***PATH-NUMBER[1]).",,"GrossDescription:
Received unfixed labeled ""right breast, **NAME[AAA] XXXXXX"" is an ovoid yellow-red piece of tissue that weighs 14.2 gm and measures 5.2 cm from medial to lateral x 3.6 cm from superior to inferior x 1.8 cm from anterior to deep.  There is a short suture at  the superior margin, a long suture at the lateral margin, and a double suture at the deep margin.  The specimen is differentially inked:  Orange ink marks the anterior margin, black ink the deep margin, green ink the superior margin, blue ink the inferior margin, red ink the medial margin, and yellow ink the lateral margin.  There is a localizing wire inserted into the medial aspect of the specimen that extends to the lateral breast.  The specimen was removed from the patient at 09:23 hours and placed in formalin at 0936 resulting in approximately 9 hours and 30 minutes of formalin fixation.  Sectioning the specimen reveals a firm pale appearing zone within the medial portion of the specimen that abuts the deep margin and measures 1.4 x 1.0 x 0.7 cm.  Proceeding laterally there is a focally hemorrhagic pale appearing zone within the mid portion of the specimen that also extends toward the deep margin and is not firm.  No discrete lesions are seen.  The specimen is submitted entirely in 12 cassettes as serial sections from medial to lateral.","MicroscopicDescription:
The microscopic description supports the above diagnoses.",A: Right breast,,
REG4,COLON,0,PAT-01267590,1,REC-3000636773,,,,,"GrossDescription:
Specimen request made on ***PATH-NUMBER[1] #1 from **DATE[Nov 28 10].
By:  **NAME[ZZZ YYY], MD
Request: K-RAS Mutation Analysis sent to Clarient  
DIAGNOSIS: LEFT NECK/SUPRACLAVICULAR NODE, UTZ-GUIDED CORE NEEDLE BIOPSY: METASTATIC ADENOCARCINOMA.",,A: LEFT NECK/SUPRACLAVICULAR CNB-UTZ GUIDED,,"Interpretation:
NEGATIVE (KRAS MUTATION NOT DETECTED)."
REG4,COLON,0,PAT-10038907,1,REC-3000636826,"ClinicalHistory:
Mass in ascending colon on CT, malignant neoplasm of ascending colon.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSES:

A. Colon biopsy, clinically ""ascending colon mass"":
  WELL TO MODERATELY DIFFERENTIATED ADENOCARCINOMA, WITH MUCINOUS FEATURES

B. Colon biopsy, clinically ""transverse colon mass at 70 cm"":
  AT LEAST ADENOMATOUS POLYP WITH FOCAL SEVERE DYSPLASIA (SEE COMMENT)
DiagnosisComment:
The clinical history is noted of two large colon masses- one in the proximal ascending colon, and one in the transverse colon.  The small biopsies taken from the transverse colon mass show dysplasia with at least focal severe dysplasia.  It is noted that considering the highly suspicious clinical history and the small biopsy size, the likelihood of an unsampled invasive carcinoma is strongly considered.  Clinical correlation is suggested.  Multiple deeper levels are examined.

Specimen signed out at **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.\X0A|",,"GrossDescription:
Specimen A.  Received in formalin, labeled ""XXXXXX, XXXXXX"" and ""A, bx mass ascending colon"" are multiple irregular pieces of soft tan tissue (0.8 x 0.5 x 0.2 cm in aggregate, 0.2 to 0.4 cm in greatest dimension).  The entire specimen is submitted in A.

Specimen B.  Received in formalin, labeled ""XXXXXX, XXXXXX"" and ""B, bx mass transverse colon at 70 cm"" is an irregular-shaped piece of rubbery tan tissue (0.4 x 0.3 x 0.2 cm).  The specimen is bisected and entirely submitted in B.","MicroscopicDescription:
A-B. The microscopic findings support the diagnoses.","A: Bx mass ascending colon
B: Bx mass transverse colon at 70 cm",,
REG4,COLON,0,PAT-10034030,1,REC-3000636837,"ClinicalHistory:
Sigmoid cancer.",,"FinalDiagnosis:
Sigmoid colon, stitch marks distal margin:  INVASIVE ADENOCARCINOMA ARISING FROM 
              A PRE-EXISTING TUBULAR ADENOMA
  
  Tumor Information
  Type of specimen:    Resection
  Tumor location:    Sigmoid colon
  Tumor size:      Pending
  Histologic type:    Adenocarcinoma, NOS
  Histologic grade:    Moderately differentiated
  Level of invasion:    Tumor invades submucosa 
  Lymphovascular invasion:  None
  Perineural invasion:    None
  Resections margins:    Negative
  Lymph node involvement:  None (0/4)
  Stage:        Stage I  (pT1, pN0, cM0)\X0A|",,"GrossDescription:
Specimen received in fresh status labeled with the patient's name and ""sigmoid colon with stitch for distal margin"" consists of a segment of colon and attached mesentery and a suture labeling at one side.  The colon is partially opened. The colon measures 10.5 cm in length and 4.5 cm in maximum circumference.  Approximately 3.5 cm away from the distal margin there is a pedunculated polypoid lesion identified.  The mass measures 3 x 3 x 1.8 cm.  The tumor occupies approaching half circumference of the colon.  The rest of the colon is grossly unremarkable.  Both proximal and distal margins are not involved.  Dissection of pericolic tissue reveals multiple small lymph nodes.  The representative tissues are submitted in eight cassettes.
  1, 2)  Tumor
  3)  Colonic tissue adjacent to the tumor
  4)  Surgical margin (black - distal margin, green - proximal margin)
  5-8)  Pericolic lymph nodes.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Sigmoid colon, stitch distal margin",,
REG4,COLON,0,PAT-10041672,1,REC-3000637551,"ClinicalHistory:


Procedure:->Other (Specify in Comments)
*** LAPAROSCOPIC DRAINAGE
Examine for:->Cancer
History/Clinical Impressions:->ABDOMINAL ASCITES, OMENTAL MASS./r/n","CytologyReview:
NEGATIVE FOR MALIGNANT CELLS
Admixture of mesothelial cells, macrophages, and lymphocytes./r/n
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with adenocarcinoma./r/n","FinalDiagnosis:
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with adenocarcinoma./r/nDiagnosisComment:
The patient s clinical history of poorly differentiated adenocarcinoma with signet ring features is noted (see surgical pathology case ***PATH-NUMBER[1], **DATE[Mar 6 12] for further details).  Immunohistochemical stains are performed on sections of the cell block (block 1); all controls react appropriately.  Scattered clusters of MOC-31-positive and CDX-2-positive tumor cells are identified.  The findings are  consistent with involvement by adenocarcinoma./r/n",,"GrossDescription:
50cc of bloody fluid with clot
Preparation:
2 cytospins:     1 giemsa stain, 1 papanicolaou stain
2 pull smears:  1 giemsa stain, 1 papanicolaou stain
2 cell block./r/n",,"A: Abdominal ascites, laparoscopic drainage",,
REG4,COLON,0,PAT-10021305,1,REC-3000638338,,,,,"GrossDescription:
Specimen request made on ***PATH-NUMBER[1] A5 from **DATE[Oct 9 09].
By:  **NAME[ZZZ YYY], MD
Request: MSI 
DIAGNOSIS: RIGHT COLON WITH TERMINAL ILEUM:
-COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.",,A: RIGHT COLON WITH TERMINAL ILEUM,,"Interpretation:
NO MLH1, MSH2, MSH6 OR PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA NUCLEI.

- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Normal expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

METHODS:  MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block ***PATH-NUMBER[1] A5.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.
ResultsComments:
Based on the four-antibody panel, there is no immunohistochemical evidence to suggest a mismatch repair deficiency or microsatellite unstable carcinoma."
REG4,COLON,0,PAT-10031862,2,REC-3000638536,"ClinicalHistory:
R/O H.pylori w/ abnormal histology, Hx of colon CA.",,"FinalDiagnosis:

A.  Gastric antrum, biopsy:        1.  Mild chronic gastritis.
              2.  Negative for Helicobacter Pylori.

B.  Pylorus, biopsy:          1.  Mild chronic gastritis.
              2. Negative for Helicobacter Pylori.

C.  Anastomosis site in colon, biopsy:    Benign small intestinal and colonic mucosa.

D.  Transverse colon ulcerated mass, biopsy:    ADENOCARCINOMA, MODERATELY DIFFERENTIATED,               INVASIVE.

Comment:  Dr. **NAME[ZZZ] concurs.  This case discussed with Dr. **NAME[YYY].\X0A|",,"GrossDescription:
(A)  Received in formalin labeled ""antrum"" is a single tan-pink and soft tissue fragment measuring 0.3 cm.  Submitted in toto in one cassette. 

(B)  Received in formalin labeled ""pylorus"" is a single tan-pink and soft tissue fragment measuring 0.3 cm.  Submitted in toto in one cassette. 

(C)  Received in formalin labeled ""anastomosis site in colon"" is a single tan-pink and soft tissue fragment measuring 0.5 cm.  Submitted in toto in one cassette. 

(D)  Received in formalin labeled ""transverse colon ulcerated mass"" are six tan-pink and soft tissue fragments measuring up to 
0.6 cm.  Submitted in toto in one cassette.","MicroscopicDescription:

A, B.  Gastric biopsies:  
Location:    A.  Antrum; B.  Pylorus
Helicobacter pylori:  Negative 
Chronic inflammation:  Mild
Lymphoid aggregates:  Negative
Acute inflammation:  Negative
Atrophy:      Negative
Intestinal metaplasia:  Negative
Other findings:    Fibrosis

C, D.  Confirmed.","A: Antrum (cold)
B: Pylorus (cold)
C: Anastamosis site in colon (cold)
D: Trans colon - ulcerated mass (cold)",,
REG4,COLON,0,PAT-01355189,1,REC-3000638737,"ClinicalHistory:
197.0 
153.9
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Colon Ca Met to bronchus./r/n",,"FinalDiagnosis:
Bronchus biopsy:  Extensive necrosis with focal adenocarcinoma consistent with colonic primary./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ] on **DATE[Jan 16 12].  Dr. **NAME[YYY] notified via email on **DATE[Jan 16 12]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated bronchus per requisition slip onlySpecimen:    Several, gray-pink pieces of tissue (formalin)
Aggregate:    1.1 x 1 x 0.7 cm
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Bronchus, biopsy",,
REG4,COLON,0,PAT-10034391,1,REC-3000639082,"ClinicalHistory:
Sigmoid mass.",,"FinalDiagnosis:
SIGMOID COLON BIOPSIES: 
COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
DiagnosisComment:
The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Feb 19 2012].",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  3.    
Size:  Up to 0.5 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
Small superficial sections of colonic mucosa show partial replacement and invasion by irregular glands lined by abnormal columnar epithelium.  Surrounding granulation tissue and inflammation are present.",A: SIGMOID MASS,,
REG4,COLON,0,PAT-10036143,1,REC-3000639237,"ClinicalHistory:
Colon CA.",,"FinalDiagnosis:
RIGHT COLON: 
- COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
- ONE OF FORTY ONE LYMPH NODES POSITIVE FOR METASTASIS (1/41).  

Colon and rectal cancer information
Operative procedure:  Right hemicolectomy.
Tumor-histologic type:  Adenocarcinoma.
Histologic grade:  Grade 2 (moderately differentiated).
Anatomic site:  Right colon (clinically ascending colon).
Size: 7.1 X 4.2 CM (macroscopic measurement).
Depth of invasion:  Into subserosal fat.
Perforation:  Not identified.
Crohn's-like lymphoid infiltrate:  Not identified.
Tumor infiltrating lymphocytes:  Not increased.
Pattern of growth at tumor periphery:  Infiltrating.
Perineural invasion:  Not identified.
Lymphatic invasion:  Not identified.
Venous invasion:  Not identified.
Resection margins:  Clear.
Distance to closest mucosal margin:  3.0 cm (proximal margin).
Distance to closest radial margin:  2.1 cm.
Regional lymph nodes:  One of forty one lymph nodes positive for metastasis.
Distant metastasis:  Not assessed.
Indications for MMR (MSI) testing: Not indicated.  
Special procedures:  Will be done upon request.
Other findings:  None.
Pathologic grade and stage:  G2, pT3, pN1a, Stage IIIB (if M0).",,"GrossDescription:
Specimen:  Right colon with attached terminal ileum and appendix.  
Weight:  193 gm.  
Measurements:  
   Length:  Colon-11.6 cm, terminal ileum-2.6 cm.  
   Circumference:  Colon-up to 8.7 cm, terminal ileum-3.7 cm.  
Appearance of serosa:  Slightly retracted over tumor.  
Tumor
   Location: Proximal right colon.  
   Appearance:  Tan-red, ulcerated with central necrosis and raised edges.  
   Size:  7.1 x 4.2 cm.  
   Depth of invasion:  Into subserosal fat.  
   Distance from proximal margin:  3.0 cm.  
   Distance from distal margin:  6.5 cm.  
   Distance from mesenteric margin:  7.2 cm.  
   Distance from radial margin:  2.1 cm.  
Appearance of uninvolved mucosa:  Two tan-red polyps distal to tumor measuring up to 1.0 x 0.9 cm.  Larger polyp is 1.1 cm from distal margin.
Other findings:  Attached appendix measures 6.8 x 1.0 cm.  
Mesentery
   Lymph nodes:  Multiple mesenteric lymph nodes identified measuring up to 1.3 x 0.9 x 0.8 cm.  
   Other findings:  None.
Description of blocks for microscopic evaluation:
1-2  shaved proximal and distal margins, respectively
3  mesenteric margin
4  radial margin
5  tumor with uninvolved mucosa
6-8  tumor
9  appendix
10  larger polyp
11  smaller polyp, bisected
12  uninvolved mucosa
13  single bisected mesenteric lymph node within 3 cm of tumor
14-20  remaining mesenteric lymph nodes within 3 cm of tumor
21-22  mesenteric lymph nodes greater than 3 cm distal to tumor.",,A: RIGHT COLON,,
REG4,COLON,0,PAT-10039969,1,REC-3000653426,"ClinicalHistory:
History of ulcerative colitis.",,"FinalDiagnosis:

A.  CECUM AND ASCENDING COLON BIOPSY:  NEGATIVE FOR ACTIVE COLITIS
    AND DYSPLASIA.
 
B.  SCAR IN ASCENDING COLON:  NEGATIVE FOR ACTIVE COLITIS AND 
    DYSPLASIA.
 
C.  TRANSVERSE COLON BIOPSIES:  NEGATIVE FOR ACTIVE COLITIS AND
    DYSPLASIA.
 
D.  PREVIOUS COLON CANCER ANASTOMOSIS BIOPSIES:  NEGATIVE FOR 
    ACTIVE COLITIS AND DYSPLASIA.
 
E.  DESCENDING AND SIGMOID COLON BIOPSIES:  NEGATIVE FOR ACTIVE 
    COLITIS AND DYSPLASIA.
 
F.  RECTUM BIOPSIES:  MILD CHRONIC PROCTITIS PATTERN, NEGATIVE 
    FOR ATYPIA.",,"GrossDescription:
A. Specimen:  Soft tan tissue.
Number of segments:  5.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.

B. Specimen:  Soft tan tissue.
Number of segments:  5.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.

C. Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  2.

D. Specimen:  Soft tan tissue.
Number of segments:  4.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.

E. Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  2.

F. Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.2 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
A-E. Sections of colonic mucosa show normal crypt architecture without a significant increase in inflammatory cells of the lamina propria.  No lymphocytic or neutrophilic exocytosis is seen in the surface and crypt epithelium.  Dysplastic changes and malignant tumor are not identified.

F. Sections of rectal mucosa show a few of the fragments with mild expansion of the lamina propria with mixture of chronic inflammatory cells.  The glands show focal architectural distortion.  No appreciable neutrophilic infiltration is identified.  Dysplastic changes are not identified.","A: CECUM AND ASCENDING COLON BIOPSY
B: SCAR IN ASCENDING COLON
C: TRANSVERSE COLON BIOPSIES
D: PREVIOUS COLON CANCER ANASTOMOSIS BIOPSIES
E: DESCENDING AND SIGMOID BIOPSIES
F: RECTUM BIOPSIES",,
REG4,COLON,0,PAT-10039773,1,REC-3000653504,"ClinicalHistory:
Gastritis.",,"FinalDiagnosis:
A.  STOMACH, RANDOM, BIOPSY:
- MILD CHRONIC INACTIVE GASTRITIS.
- HELICOBACTER PYLORI NEGATIVE (GENTA STAIN).
- NO EVIDENCE OF INTESTINAL METAPLASIA, DYSPLASIA OR MALIGNANCY.

B.  COLON, POLYPS X2 AT 40 CM AND 35 CM PROXIMAL SIGMOID, HOT
    BIOPSY AND SNARE POLYPECTOMY:
- TUBULAR ADENOMAS.
 
C.  COLON, POLYP AT 30 CM, SNARE POLYPECTOMY:
- COLORECTAL ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
- ADENOCARCINOMA ARISES IN A TUBULOVILLOUS ADENOMA WITH HIGH-GRADE DYSPLASIA.
 
D.  COLON, POLYP AT 10 CM, SNARE POLYPECTOMY:
- TUBULAR ADENOMA.

E.  COLON, POLYP AT RECTOSIGMOID, HOT BIOPSY:
- HYPERPLASTIC POLYP.
 
Colon and rectal malignant polyp information
Operative procedure:  Excisional Biopsy (Polypectomy).
Specimen integrity:  Fragmented.
Tumor-histologic type:  Adenocarcinoma.
Histologic grade:  Low-grade (moderately differentiated).
Anatomic site:  30 cm.
Polyp configuration:  Pedunculated vs sessile requires endoscopic correlation.
Size of polyp:  2.4 x 1.7 x 1.1 cm.
Size of invasive carcinoma:  0.75 x 0.4 cm.
Depth of invasion:  pT1 - Tumor invades submucosa.
Lymphatic invasion:  Not identified.
Resection margins:  Cauterized deeper margin appears uninvolved by invasive carcinoma at a distance of 0.1 cm; however, correlation with the endoscopic impression is recommended.
Indications for MMR (MSI) testing:  Not identified.
Special procedures:  None.
Distant metastasis:  Not applicable.
Other findings:  None.
Pathologic grade and stage:  G2 pT1 NX (stage I if M0).",,"GrossDescription:
A. Specimen:  Soft tan tissue.
Number of segments:  4.    
Size:  Up to 0.4 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.

B. Specimen:  Soft tan tissue.
Number of segments:  3.    
Size:  Up to 0.5 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.

C. Specimen:  Sessile polypoid tan-pink mucosal tissue.
Number of segments:  3.    
Size:  2.4 x 1.7 x 1.1 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  2.

D. Specimen:  Soft tan tissue.
Number of segments:  2.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.

E. Specimen:  Soft tan tissue.
Number of segments:  1.    
Size:  0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,"A: BIOPSY RANDOM STOMACH
B: HOT BIOPSY POLYP AT 40 CM, SNARE POLYP AT 35 CM PROXIMAL SIGMOID
C: SNARE POLYP AT 30 CM ON WAY OUT
D: SNARE POLYP AT 10 CM
E: HOT BIOPSY POLYP AT RECTOSIGMOID",,
REG4,COLON,0,PAT-10022932,1,REC-3000653793,"ClinicalHistory:
Colon cancer.",,"FinalDiagnosis:
A.  SIGMOID COLON:  

    1.  DISTAL SIGMOID COLON MUCINOUS ADENOCARCINOMA, MODERATELY
        DIFFERENTIATED, WITH PORTION OF SEROSAL TUMOR NODULE.
    2.  METASTASIS TO 10 OF 22 LYMPH NODES (**DATE[Jun 23]).
    3.  MUCOSAL AND MESENTERIC MARGINS CLEAR.

    GREATER OMENTUM LESION:  SEROSAL MUCINOUS ADENOCARCINOMA, 
    WITH MICROSCOPIC FEATURES CONSISTENT WITH DIRECT EXTENSION 
    OF TUMOR FROM THE PRIMARY SITE.
 
B.  HERNIA SAC:  BENIGN FIBROFATTY TISSUE.
DiagnosisComment:
COLON CANCER INFORMATION
Operative procedure:  Segmental resection.
Tumor-histologic type:  Mucinous adenocarcinoma (>50% mucinous
  features).
Histologic grade:  Grade II.
Anatomic site:  Distal sigmoid colon.
Size:  7.5 x 6.5 cm.
Depth of invasion:  To serosa - the greater omentum lesion is
  consistent with direct extension of the primary tumor.
Perforation:  Absent.
Crohn's-like lymphoid infiltrate:  Absent.
Intratumoral or peritumoral lymphocytic response:  Sparse.
Pattern of growth at tumor periphery:  Pushing pattern.
Perineural invasion:  Absent.
Lymphatic invasion:  Absent.
Venous invasion:  Absent.
Resection margins:  Clear.
Distance to closest mucosal margin:  3.0 cm.
Distance to closest radial margin:  5.7 cm.
Regional lymph nodes:  Metastasis to 10 of 22 nodes (**DATE[Jun 23]).
Distant metastasis:  Not applicable.
Other findings:  None.
Special studies:  MSI testing results pending.
Pathologic grade and stage:  G2; pT4 N2 MX (Stage IIIC if M0).",,"GrossDescription:
A. Specimen:  Segment of sigmoid colon.  
Weight:  517 gm.  
Measurements:  
   Length:  27.0 cm.  
   Circumference:  10.0 cm.  
Appearance of serosa:  Dusky.  
Tumor
   Location: Sigmoid colon.  
   Appearance:  Soft tan polypoid mass.  
   Size:  7.5 x 6.5 cm.  
   Depth of invasion:  Into muscularis propria.  
   Distance from proximal margin:  18.5 cm.  
   Distance from distal margin:  3.0 cm.  
   Distance from mesenteric margin:  10.5 cm.  
   Distance from adventitial margin:  5.7 cm.  
Appearance of uninvolved mucosa:  Fattened and distended.  
Other findings:  Separate omental nodule received measuring 2.7 x 1.7 x 1.0 knee cm.  
Mesentery
   Lymph nodes:  Multiple mesenteric lymph nodes identified measuring up to 2.2 x 1.8 x 1.7 cm. Larger lymph nodes have a mucinous cut surface.  
   Other findings:  None.
Description of blocks for microscopic evaluation:
1  shaved proximal margin
2-3  shaved distal margin
4  mesenteric margin
5  adventitial margin
6  tumor with uninvolved mucosa
7-9  tumor
10  uninvolved mucosa
11  omental lesion
12  single bisected mesenteric lymph node within 3-cm of tumor
13  two bisected mesenteric lymph nodes within 3-cm of tumor
14-15  remaining mesenteric lymph nodes within 3 cm of tumor
16-17  each cassette contains a single bisected mesenteric lymph node greater than 3-cm proximal of tumor
18-20  each cassette contains two bisected mesenteric lymph nodes greater than 3-cm proximal of tumor
21  remaining mesenteric lymph nodes greater than 3 cm of tumor proximal of tumor

B. Specimen:  A segment of fibrofatty tissue covered by a thin smooth membrane.
Weight:  20 gm.
Number of segments:  1. 
Size:  5.1 x 4.0 x 2.6 cm.
Submitted for microscopic evaluation:  Representative.
Cassettes: 1.",,"A: SIGMOID COLON AND GREATER OMENTUM LESION
B: HERNIA SAC",,"Interpretation:

Immunohistochemical stains for gene mismatch repair defects are 
performed.  The results are as follows:

MLH1: No loss of expression (2+)
PMS2: No loss of expression (3+)
MSH6: No loss of expression (2+)
MSH2: No loss of expression (3+)

Findings are consistent with NO DNA repair defect.

GENOTYPE RESULT (CLARIENT):  MUTATION Gly12Asp (GGT->GAT).
ResultsComments:
Specimen request made on ***PATH-NUMBER[1] A8 on **DATE[Jan 11 10].
By:  **NAME[ZZZ YYY], M.D.
Request:  K-RAS Sent to Clarient."
REG4,COLON,0,PAT-10007734,1,REC-3000653805,"ClinicalHistory:
Head of pancreas mass.",,"IntraoperativeDiagnosis:
Lesional tissue present, per CF/KK

assessed by, KK/CF
supervised by, KK/CF.
FinalDiagnosis:
HEAD OF PANCREAS MASS, FINE NEEDLE ASPIRATION BIOPSY:
- MUCINOUS NEOPLASM.
DiagnosisComment:
Main diagnostic considerations include an intraductal papillary mucinous neoplasm with cytologic features suggesting high-grade dysplastic epithelium or an invasive ductal carcinoma with abundant mucin (eg. colloid carcinoma).",,"GrossDescription:
Received:  9 DQ stained smears.
           7 red and white elongated tissue fragments in formalin up to approx. 
           3 cm. in length (A1).
           8 red tissue fragments in formalin up to approx. 0.5 cm. in length (A2).
Submitted:  All tissue fragments for a cell block (A1).
            All tissue fragments for a cell block (A2).",,A: HEAD OF PANCREAS MASS FNA,,
REG4,COLON,0,PAT-10016110,2,REC-3000654002,"Post-OperativeDiagnosis:
Colon polyp.",,"PostOperativeDiagnosis:
Colon polyp
FinalDiagnosis:
Colon, right, snare biopsy:      INVASIVE ADENOCARCINOMA, MODERATELY-DIFFERENTIATED 
          (see Comments)
DiagnosisComment:
The biopsy shows dysplastic glands in the background of desmoplastic stroma.  Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnosis.  The result was discussed with Dr. **NAME[XXX WWW] on **DATE[Jul 12 2012].\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, bx colon polyp"" are multiple fragments of tan tissue measuring up to 0.4 cm in greatest dimension.  Submitted in toto in one block.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right colon polyp biopsy and snare,,
REG4,COLON,0,PAT-10038872,1,REC-3000654093,"ClinicalHistory:
GIB/ mass @ 60 cm.",,"FinalDiagnosis:

Colon mass at 50 cm, biopsy:    POSITIVE FOR ADENOCARCINOMA 
          (please see Comments)

Comments:  
The results of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Oct 9 2011].\X0A|",,"GrossDescription:
Received in formalin labeled ""50 cm mass"" are two tan-pink and soft tissue fragments measuring 0.3 and 0.4 cm.  
Entirely submitted in one cassette.","MicroscopicDescription:
Confirmed.",A: 50 cm mass,,
REG4,COLON,0,PAT-10041035,1,REC-3000654097,"ClinicalHistory:
Internal bleeding.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Colon biopsy, clinically ""rectosigmoid mass"":               PAS 9
  MODERATELY DIFFERENTIATED ADENOCARCINOMA (AT LEAST IN-SITU) \X0A|",,"GrossDescription:
Received in formalin, labeled ""rectosigmoid colon mass biopsies"" are multiple irregular pieces of rubbery tan tissue (0.6 x 0.6 x 0.2 cm in aggregate, 0.1 to 0.4 cm in greatest dimension).  The entire specimen is submitted in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Rectosigmoid colon mass biopsies,,
REG4,COLON,0,PAT-10033936,2,REC-3000654145,"ClinicalHistory:
Colon CA- sigmoid.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same 
FinalDiagnosis:

Large intestine, sigmoid, partial colectomy:
  MODERATELY DIFFERENTIATED ADENOCARCINOMA

Tumor Information:

Specimen:  Sigmoid colon
Procedure:  Segmental colectomy
Tumor site:  Sigmoid colon  
Tumor size:  3.5 x 3.3 x 2.5 cm
Macroscopic tumor perforation:  Not identified
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Microscopic tumor extension:  Tumor invades into, but not through the muscularis propria
Margins:
    Proximal:  Uninvolved by invasive carcinoma
  Distal:  Uninvolved by invasive carcinoma
  Mesenteric:  Uninvolved by invasive carcinoma
Treatment effect:  No prior treatment
Lymph-vascular invasion:  Present
Perineural invasion:  Not identified
Tumor deposits (discontinuous extramural 
  extension):  Present
  Specify number of tumor deposits:  6
Lymph nodes (pericolonic):  6 out of 11 mesenteric nodes positive for metastasis
Pathologic staging (pTNM):   pT2, pN2a

DiagnosisComment:
Specimen signed out at **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.\X0A|",,"GrossDescription:
Received in formalin, labeled ""sigmoid colon"" is a segment of large bowel (11.5 cm in length by 2.5 to 3 cm in diameter) with a suture marking the distal end of the specimen.  The proximal resection margin is left open and inked black.  The distal resection margin is stapled.  The staples are removed and the revised distal resection margin is inked red.  The mesenteric resection margin is inked green.  Serosa is smooth, tan-red.  The specimen is opened to reveal a rubbery to firm tan-red well circumscribed mass (3.5 x 3.3 x 2.5 cm).  The mass is found 6 cm away from the proximal resection margin, 2.5 cm away from the distal resection margin and 4 cm away from the mesenteric resection margin.  The mass does not grossly appear to penetrate through the muscularis propria.  The remainder of the specimen appears grossly normal.  Representative sections are submitted as follows:  

Block summary:
1.  -  Perpendicular section of proximal resection margin.
2.  -  Perpendicular section of distal resection margin.
3.  -  En face section of mesenteric resection margin.
4-8.  -  Sections of mass.
9.  -  Sections of grossly uninvolved large bowel proximal to the mass.
10.  -  Sections of grossly uninvolved large bowel distal to the mass.
11.  -  Four possible lymph nodes.
12.  -  Three possible lymph nodes.
13.  -  Two possible lymph nodes.
14-16.  -  Sections of fat.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Sigmoid colon- suture at distal end of specimen (sigmoid),,
REG4,COLON,0,PAT-10039067,1,REC-3000654180,"ClinicalHistory:
Sigmoid carcinoma

Previous biopsy
[***PATH-NUMBER[1] **DATE[Dec 20 2011] - Biopsy polyp 25 cm: Adenocarcinoma, at least intraepithelial/intramucosal, with ulceration.  More invasive carcinoma not sampled in the biopsy cannot be excluded.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
Sigmoid colon, partial colectomy:  INVASIVE ADENOCARCINOMA, MODERATELY-DIFFERENTIATED

Tumor Information:

Histologic type:  Adenocarcinoma
Histologic grade:  Moderately-differentiated
Tumor site:  Sigmoid
Tumor size:  1.7 x 0.9 x 0.9 cm 
Extent of invasion:  Tumor invades submucosa
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:  Free of tumor
  Proximal:  10.0 cm (macroscopic)
  Distal:  4.5 cm (macroscopic)
Lymph node metastasis:
  Total nodes:  0 out of 13 mesenteric nodes
Other findings:  Hyperplastic polyp
AJCC Pathologic Stage:  Stage I [pT1, pN0, cM0]
DiagnosisComment:
The tumor arises in a pedunculated tubular adenoma.  Dr. **NAME[ZZZ YYY] concurs with the diagnosis.\X0A|",,"GrossDescription:
Received fresh labeled ""XXXXXX, sigmoid colon adenocarcinoma biopsy long silk high point lymph node dissection, stitch distal margin sigmoid colon"" is an oriented segment of intestinal tissue, measuring up to 15.0 cm in length.  The specimen was received previously opened.  The distal end (marked with a suture) measures 6.5 cm in circumference, and is inked blue; the proximal margin, which measures 5.0 cm in circumference, is inked orange.  The remainder of the specimen is opened to reveal a pedunculated polypoid structure measuring up to 1.7 x 0.9 x 0.9 cm.  The polyp elevates the mucosa by approximately 0.4 cm.  The polyp is 4.5 cm from the distal end and 10.0 cm from the proximal end.  The polyp appears to be confined within the mucosa, and does not extend to the muscularis propria or serosal surface.  The area underlying the polyp is inked black.  Approximately 2.0 cm away in the proximal direction of the polyp is a tattooed area (1.5 x 1.1 cm).  Two smaller polypoid structures are also present, measuring up to 0.3 cm.  Multiple soft tan lymph nodes are identified, measuring up to 0.3 cm in greatest dimension.  

KEY TO CASSETTES: 
1  -  Distal margin (shaved)
2  -  Proximal margin (shaved)
3-6  -  The largest polyp submitted entirely
7-9  -  The tattooed area submitted entirely
10  -  Two smaller polypoid structures
11-12  -  Nodes, 0.3 cm in greatest dimension (beginning with the high point in cassette 11)
13  -  Lymph node immediately below the polypoid structure
14-34  -  The lymph node dissection beginning with the high point in cassette 14.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Sigmoid colon,,
REG4,COLON,0,PAT-10040630,1,REC-3000654300,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->Other (use Comments)
*** Pelvic mass./r/n",,"IntraoperativeDiagnosis:
FS:  A\T\B.  Mucinous neoplasm on limited FS pieces at least borderline but given clinical and operative features, may just likely be malignant as bilateral ovaries are involved, metastatic mucinous malignancy involving ovaries cannot be ruled out versus primary mucinous ovarian neoplasm.  Deferred to additional specimens.  SL/JME/SB./r/nFinalDiagnosis:
A.  Left ovary:  Metastatic adenocarcinoma.

B.  Right tube and ovary:  

  Ovary:  Metastatic adenocarcinoma.

  Fallopian tube:  Serosa with metastatic adenocarcinoma; lumen uninvolved by tumor.

C.  Left fallopian tube:  Serosa with metastatic adenocarcinoma; tumor focally closely approaches the lumen, which is uninvolved by tumor.

D.  Uterus and cervix:

  Cervix:  Mild chronic inflammation and benign endocervical polyp.

  Endometrium:  Proliferative endometrium.

  Myometrium:  Benign leiomyomata (up to 3 cm).

  Serosa and peritoneum:  Benign subserosal leiomyomata (up to 3 cm) and scattered metastatic adenocarcinoma deposits.

E.  Sigmoid colon:  Moderately differentiated adenocarcinoma, pT4a N1b M1b (see comment and microscopic description for additional tumor information). 

F.  Small bowel:  Metastatic colonic adenocarcinoma./r/nDiagnosisComment:
Immunohistochemical stains for cytokeratin 7, cytokeratin 20, and CDX2 are performed on sections from the left ovary (block A9, right ovary (block B9), sigmoid colon (block E4), and small bowel (block F2).  All controls react appropriately.  The tumor in each of these four locations stain uniformly positive for cytokeratin 20 and CDX2, and all are negative for cytokeratin 7.  These findings support the diagnosis of a colonic primary with metastases to the ovaries and small bowel.

Case reviewed in Pathology Staff Conference on **DATE[Dec 12 11].  Dr. **NAME[ZZZ YYY] was notified of the findings on **DATE[Dec 12 11] at 4:14 p.m.  Microsatelite instability (MSI) testing will be performed and reported as an addendum.  Dr. **NAME[XXX WWW] notified of the findings via e-mail communication on **DATE[Dec 12 11] at 6:35 p.m./r/n",,"GrossDescription:
A.  Labeled:        Patient name and medical record number, designated left ovary
Specimen:      Partially opened bosselated gray-pink ovarian mass with attached portion of fallopian tube (unfixed)
  Weight:        317 grams
  Size:        Ovarian mass: 15 x 14.5 x 3.7 cm
          Fallopian tube: 4 x 0.8 x 0.8 cm
  Findings:      The mass has a smooth gray-pink external surface, roughened, lobulated, and multiloculated inner surface with thick mucinous contents (frozen section); normal?appearing fallopian tube.
  Section code:  
    Blocks A1-2:      Frozen section residue
    Blocks A3-10:      Sections from the ovarian mass
    Blocks ***PATH-NUMBER[1]:      Fallopian tube

B.  Labeled:        Patient name and medical record number, designated right tube and ovary
  Specimen:      Tan-gray-pink ovarian mass with attached fimbriated fallopian tube (formalin)
  Weight:        1600 grams
  Size:        Ovarian mass: 30 x 25 x 6 cm
          Fallopian tube: 6.5 x 1 x 1 cm
  Findings:      The mass has a smooth gray-pink external surface, roughened, lobulated inner surface with thick mucinous contents (frozen section); normal-appearing fallopian tube.
  Section code:  
    Blocks B1-2:       Frozen section residue
    Blocks B3-17:      Sections from the ovarian mass
    Blocks B18-20:      Fallopian tube

C.  Labeled:        Patient name and medical record number, designated left tube
  Specimen:      Grossly unremarkable portion of fimbriated fallopian tube (formalin)
  Size:        3.7 x 1 x 0.8 cm
  Submitted/Blocks:    Entirely/2
  
D.  Labeled:        Patient name and medical record number, designated uterus and cervix
Specimen:      Uterus, cervix (formalin)
Weight:        178.8 grams
Size:        10.5 x 8 x 5.5 cm
Serosa:  Gray-pink with several elevated foci measuring up to 3 x 3 x 1.6 cm; a 
12 x 2.5 x 0.4 cm gray?brown piece of peritoneum includes a 7 x 3 x 1.5 cm focally firm yellow-gray tissue grossly consistent with tumor.
  Cervix:        Two nabothian cysts measuring up to 0.4 x 0.4 x 0.4 cm; 2 x 0.5 x 0.4 cm yellow-gray           endocervical polyp.
  Endometrium:      Soft, gray-pink, measures 0.2 cm in thickness, no gross lesions attached.
Myometrium:  Gray-pink, 2 cm in thickness, several fibroids, up to 3 x 3 x 1.9 cm; the largest fibroid is focally calcified, a smaller fibroid contains a hemorrhagic focus.
  Section code:
    Blocks D1-2:      Tumor on serosal surface
    Block D3:      Cervix, endocervical polyp
    Block D4:      Endometrium and myometrium
    Blocks D5-7:      Intramural fibroids
      Block D8:      Subserosal fibroids

E.  Labeled:        Patient name and medical record number, designated sigmoid colon
Specimen:      Unopened segment of sigmoid colon (unfixed)
Size:        9 cm in length, 6 cm in circumference
Orientation:      Not given
Colors:
  Black:        One resection margin and serosal margin
  Blue:        Opposite resection margin
  Green:        Radial margin
Tumor:      
  Location:      Sigmoid colon, centrally located
  Size:        5 x 4 x 0.6 cm
  Description:      Gray-pink, firm, centrally depressed lesion with rolled borders
  Ulceration/perforation:      Possible
  Distance from margins:     2 cm from both resection margins, appears to abut the radial margin
  Estimated depth of invasion:  Extends through the muscular layer and into the pericolic fat.
Other lesions:      1 x 1 x 0.4 cm firm elevated focus on the serosa
Regional lymph nodes:    Three, up to 0.7 x 0.7 x 0.7 cm
Section code:    
  Block E1:      Proximal and distal margins
  Block E2:      Radial margin
  Blocks E3-4:      Tumor
  Block E5:      Lymph nodes
  Block E6-10:      Fat with possible lymph nodes
  
F.  Labeled:        Patient name and medical record number, designated small bowel
Specimen:      Segment of small bowel
Size:        9 x 7 x 1.5 cm
Orientation:      None provided
Colors:
  Black:        One margin
  Blue:        Opposite margin
  Green:        Radial margin
Tumor:      
  Location:      Small bowel, centrally located lesion
  Size:        3 x 2.7 x 0.8 cm
  Description:      Tan-pink to dark gray-brown somewhat friable fungating lesion
  Ulceration/perforation:      None
  Distance from margins:    3 cm from blue ink margin, 4 cm from black ink margin, possibly abuts radial margin
Estimated depth of invasion:  Tumor includes the mucosa, muscularis propria and possibly invades into the pericolic fat abutting the radial margin.
Other lesions:      No additional lesions identified.
Regional lymph nodes:    No lymph node identified.
Section code:    
  Block F1:      Proximal and distal margins
  Blocks F2-4:      Representative sections of tumor including radial margin
  Blocks F5-6:      Remaining pericolic fat including remaining green inked radial margin./r/n","MicroscopicDescription:
A-F.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.

Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Sigmoid colon
Tumor Size: 5 x 4 x 0.6 cm
Macroscopic Tumor Perforation: Cannot be determined.
Histologic Type: Adenocarcinoma
Histologic Grade: Low-grade (well- to moderately differentiated).
Microscopic Tumor Extension: Tumor penetrates to the surface of the visceral peritoneum (serosa)
Margins (specimen received unoriented):
     First margin:  Involved by invasive carcinoma.
     Second margin: Uninvolved by invasive carcinoma.
     Circumferential/radial margin: Involved by invasive carcinoma (tumor present 0-1 mm from margin).
Treatment Effect (if applicable): Not applicable.
Lymph-Vascular Invasion: Present.
Perineural Invasion: Present.
Tumor Deposits: Present (3 deposits identified in pericolonic fatty tissue).
Type of Polyp in Which Invasive Carcinoma Arose:  Indeterminant.
Pathologic Staging (pTNM):
      Primary tumor: pT4a (tumor penetrates the visceral peritoneum).
      Regional lymph nodes: pN1b (metastasis in 2 to 3 regional lymph nodes).
         Number examined: 2
         Number involved: 2
      Distant metastasis: pM1b (metastasis to more than one organ/site or to the peritoneum)
Ancillary Studies:
     Microsatellite instability testing will be ordered; the results will be reported as an addendum./r/n","A: A1 Left ovary-FS, excision
B: A2 Right tube and ovary-fresh, excision
C: A3 Left tube-perm, excision
D: A4 Uterus and cervix-permanent, excision
E: A6 Sigmoid colon fresh, excision
F: A5 Small bowel perm, excision",,
REG4,COLON,0,PAT-10040201,1,REC-3000654514,"ClinicalHistory:
Sigmoid CA.",,"FinalDiagnosis:
A.  SIGMOID COLON:  
- MODERATE TO POORLY DIFFERENTIATED COLONIC ADENOCARCINOMA, MIXED
  CONVENTIONAL AND MICROPAPILLARY TYPE.
- 20 BENIGN LYMPH NODES.
 
B.  PROXIMAL AND DISTAL DONUT:
- COLONIC TISSUE WITH NO SIGNIFICANT DIAGNOSTIC ALTERATIONS.

Colon cancer information
Operative procedure:  Laparoscopic sigmoid resection.
Tumor-histologic type:  Adenocarcinoma.
Histologic grade:  High-grade (moderate to poorly differentiated).
Anatomic site:  Sigmoid colon.
Size:  5 x 3.4 cm.
Depth of invasion:  pT3 - Tumor invades through the muscularis propria into pericolorectal tissues.
Perforation:  Not identified.
Crohn's-like lymphoid infiltrate:  Not identified.
Tumor infiltrating lymphocytes:  Not identified.
Pattern of growth at tumor periphery:  Infiltrative.
Perineural invasion:  Not identified.
Lymphatic invasion:  Not identified.
Venous invasion:  Not identified.
Resection margins:  Uninvolved by invasive carcinoma.
  Distance from proximal margin:  7.0 cm.  
  Distance from distal margin:  6.5 cm.  
  Distance from mesenteric margin:  6.5 cm.  
Regional lymph nodes:  0/20 (pN0: No regional lymph node metastasis).
Indications for mismatch repair protein (MMR) immunohistochemistry/microsatellite instability (MSI) testing:  Not identified.
Special procedures:  None.
Distant metastasis:  Not applicable.
Other findings:  None.
Pathologic grade and stage:  G2-3 pT3 pN0 (stage IIA if M0).
DiagnosisComment:
Micropapillary adenocarcinoma is a rare variant of colonic adenocarcinoma that can occur in a pure form or in association with a conventional colorectal adenocarcinoma (i.e. adenocarcinoma not otherwise specified), as in this case.  At the current time, the significance of this component remains uncertain though some authors have speculated that it may be an adverse prognostic marker.",,"GrossDescription:
A.  Specimen:  Oriented sigmoid colon, received fresh.  
Weight:  298 gm.  
Measurements:  
   Length:  17.0 cm.  
   Circumference:  6.9 cm.  
Appearance of serosa:  Appears slightly retracted over tumor with apparent fat wrapping.  
Tumor
   Location: Sigmoid colon.  
   Appearance:  Raised tan, polypoid.  
   Size:  5.0 x 3.4 cm.  
   Depth of invasion:  Into subserosal fat.  
   Distance from proximal margin:  7.0 cm.  
   Distance from distal margin:  6.5 cm.  
   Distance from mesenteric margin:  6.5 cm.  
   Distance from radial margin:  6.5 cm.  
Appearance of uninvolved mucosa:  Appears edematous adjacent to tumor.  Remaining mucosa appears unremarkable.  
Other findings:  None.  
Mesentery
   Lymph nodes:  Multiple measuring up to 1.0 x 0.6 x 0.6 cm.  
   Other findings:  None.
Description of blocks for microscopic evaluation:
1  shaved proximal margin
2  shaved distal margin
3  mesenteric margin
4  radial margin
5-10  tumor (5-7 with invasion into subserosal fat; 10 with adjacent edematous mucosa)
11  uninvolved
12  mesenteric lymph nodes 3.0 cm proximal from tumor
13-17  mesenteric lymph nodes within 3.0 cm of tumor (13-15 contain multiple lymph 
      nodes, on of which is inked and bisected; 17 - 3 bisected lymph nodes)
18  mesenteric lymph nodes 3.0 cm distal from tumor 

B.  Specimen:   Doughnut segment of proximal and distal colon.  
Weight:  2 gm.
Number of segments:  2.  
Size:  up to 1.5 x 1.2 x 0.8 cm.
Gross description:  Firm tan/brown un-oriented segment of sigmoid colon. 
Submitted for microscopic evaluation:  representative.  
Cassettes:  
  1 - inked section (originally sutured without orientation).
  2 - uninked section.",,"A: SIGMOID COLON
B: PROXIMAL AND DISTAL DONUT",,
REG4,COLON,0,PAT-10039052,1,REC-3000654533,"ClinicalHistory:
573.8 Liver mass.","CytologyReview:

Liver core biopsy

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:      POSITIVE FOR MALIGNANCY
          Metastatic adenocarcinoma
          Immunostain pending.","FinalDiagnosis:

Liver core biopsy

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:      POSITIVE FOR MALIGNANCY
          Metastatic adenocarcinoma
          Immunostain pending.\X0A|",,"GrossDescription:
Specimen consists of 2 ""passes"" = 2 air-dried & 2 fixed smears prepared by physician, along with 40cc of clear, colorless, formalin fixed fluid containing cores.

Physician prepped slide(s):  2 Air-dried (Diff-quik stained), 2 Fixed (Pap stained)
CLH/PPPL prepped slide(s):  1 Pap stained, 1 Cell block
Review(s) by Pathologist:

Adequacy evaluation #1 (pass # 1) = _x_  Adequate
88172                 ___  Insufficient.",,A: Liver core biopsy,,"AddendumDiagnosis:
The tumor cells are positive for CDX2 and CK20; negative for CK7, CK19 and TTF1, consistent with metastatic colorectal adenocarcinoma.  Dr. **NAME[ZZZ] concurs."
REG4,COLON,0,PAT-10040832,1,REC-3000654545,"ClinicalHistory:
Right colon CA

Previous biopsy
[***PATH-NUMBER[1] **DATE[Mar 02 2012]: Cecum: Invasive adenocarcinoma poorly differentiated.",,"FinalDiagnosis:
Colon, right colectomy:      INVASIVE ADENOCARCINOMA, MODERATELY-DIFFERENTIATED


Tumor Information:

Histologic type:  Adenocarcinoma
Histologic grade:  Moderately-differentiated, with mucinous features
Tumor site:  Cecum
Tumor size:  3.5 x 2.8 x 2.2 cm
Tumor configuration:  Fungating
Extent of invasion:  Tumor penetrates to the serosa surface 
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Mucinous feature present
Neoadjuvant treatment effect:  N/A
Resection margins:  Free of tumor
  Proximal:  8.5 cm
  Distal:  13.3 cm
Lymph node metastasis:
  Total nodes:  3 out of 23 mesenteric nodes (see Comments)
Other findings:  Benign small bowel
AJCC Pathologic Stage:  Stage IIIB [pT4a, pN1b, cM0]

DiagnosisComment:
The tumor penetrates to the serosal surface, confirmed by AE1/AE3 immunostains.  Three out of twenty-three mesenteric nodes contain small clusters of tumor cells in the periphery or the lymphatic space, confirmed by AE1/A3 immunostains.  One of the positive lymph node is located within 3.0 cm from the mass, and the remaining two positive nodes are > 3.0 cm from the mass.  

Dr. **NAME[ZZZ YYY] concurs with the diagnosis.  \X0A|",,"GrossDescription:
Received unopened and unfixed, labeled ""XXXXXX, right colectomy,"" is a segment of unoriented bowel, 21.3 cm in length x 3.7 cm in circumference at the proximal margin (smooth), and 7.5 cm in circumference  at the distal margin (orange).  There is a 7.4 cm long segment of terminal ileum and 13.9 cm long segment of colon.  No appendix is identified.  There is a fungating white firm mass at the cecum, 3.5 x 2.8 x 2.2 cm, 8.5 cm from the proximal margin, 1.1 cm from the ileocecal valve, and 13.3 cm from the distal margin (orange).  The tumor appears to penetrate the muscularis propria.  There are areas of serosal retraction, deep to the mass.  The remaining mucosa of the small and large bowel is tan and grossly unremarkable, with no areas of ulceration, polyps, or diverticula.  Multiple lymph nodes are identified, the largest up to 1.1 cm in greatest dimension.

There is a second unoriented segment of bowel, 4.5 x 2.0 x 1.5 cm.  Both margins are closed by the metallic staples.  One staple line is inked red, remaining staple line inked green.  The segment is opened and reveals grossly unremarkable tan mucosa, with no diverticula, masses, polyps or areas of ulceration.  


Representative sections are submitted in 26 cassettes as follows:

  KEY TO CASSETTES:
  1  -  Blue margin
  2  -  Orange margin
  3-7  -  Firm, hard mass described above, in cecum 
  8  -  Uninvolved mucosa of small and large bowel
  9  -  Ileocecal valve
  10-13  -  Lymph nodes within 3.0 cm of mass
  14-25  -  Lymph nodes >3.0 cm from mass
  26  -  Separately received segment of bowel described above.","MicroscopicDescription:
The microscopic description supports the above diagnosis.",A: Right colectomy,,
REG4,COLON,0,PAT-10039301,1,REC-3000654639,"ClinicalHistory:
Colon CA.","PhysicianNotification:
Case discussed with Dr. **NAME[ZZZ] on **DATE[Oct 15 2011].","FinalDiagnosis:
COLON, MASS AT CECUM, COLD BIOPSY:
- COLONIC ADENOCARCINOMA, WELL DIFFERENTIATED.
- CARCINOMA ARISES FROM A TUBULOVILLOUS ADENOMA WITH FOCAL HIGH-GRADE DYSPLASIA.
DiagnosisComment:
Given the patient's age, mismatch repair protein immunohistochemical stains will be performed and reported in an addendum.  Deeper levels examined in the evaluation of this case.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: COLD BIOPSY MASS AT CECUM,,"Interpretation:
PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA AND ADENOMA NUCLEI (SEE COMMENT).
NO MLH1, MSH2 OR MSH6 PROTEIN LOSS OF EXPRESSION IN CARCINOMA OR ADENOMA NUCLEI.

CARCINOMA
- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Loss of expression.
- MSH6 (CLONE **INITIALS):  Normal expression.
- MSH2 (CLONE FE11):  Normal expression.

ADENOMA
- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Loss of expression.
- MSH6 (CLONE **INITIALS):  Normal expression.
- MSH2 (CLONE FE11):  Normal expression.


METHODS: MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block A1.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.
ResultsComments:
Loss of PMS2 protein expression is noted in the carcinoma and adenoma without evidence of MLH1 loss; however, since MLH1 is much more frequently implicated than PMS2 in DNA mismatch repair defects, a primary deficiency of MLH1 is still a strong consideration.  Correlation with additional molecular genetic testing, particularly PMS2 gene mutation analysis, may be helpful and further evaluation by a genetics counselor at the **INSTITUTION (phone: **PHONE) is highly recommended.

Reference:  de Jong AE et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer.  Clin Cancer Res. 2004 **DATE[Apr 1];**ID-NUM."
REG4,COLON,0,PAT-10029879,1,REC-3000655249,"ClinicalHistory:
Colostomy.",,"FinalDiagnosis:
A.  COLOSTOMY:  NO MALIGNANCY IDENTIFIED.
 
B.  PROXIMAL DONUT:  COLONIC ADENOCARCINOMA INVOLVING LYMPHOVASCULAR SPACES, 
    EXTENSIVE.
 
C.  DISTAL DONUT:  COLONIC ADENOCARCINOMA INVOLVING LYMPHOVASCULAR SPACES, EXTENSIVE.
DiagnosisComment:
Tumor shows histologic features similar to a sigmoid colectomy specimen (***PATH-NUMBER[1]).  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jul 20 2012].",,"GrossDescription:
A.  Specimen:  Segment of large bowel with attached ring of tan skin (colostomy).  
Weight:  27 gm.
Number of segments:  1.  
Size:  4.3 x 4.3 x 2.9 cm.
Gross findings:  No focal lesion identified.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  3 (1,2 - margins).

B.  Specimen:  Irregular segments of pink-tan mucosal tissue.  
Weight:  2 gm.
Number of segments:  2.  
Size:  Up to 3.2 x 0.8 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2.

C.  Specimen:  Mucosal donut.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.4 x 1.5 x 1.0 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.",,"A: COLOSTOMY
B: PROXIMAL DONUT
C: DISTAL DONUT",,
REG4,COLON,0,PAT-10038751,1,REC-3000655269,"ClinicalHistory:

Partial obstruction due to sigmoid colon mass.  DMII, uncontrolled, HTN, hyperlipidemia, gout, osteoarthritis.

Previous biopsy
[***PATH-NUMBER[1] **DATE[Mar 15 2012] - Rectal mass biopsy at 18 cm: Invasive adenocarcinoma, moderately-differentiated.
Post-OperativeDiagnosis:
Partial obstruction due to sigmoid colon mass.",,"PostOperativeDiagnosis:
Partial obstruction due to sigmoid colon mass.
FinalDiagnosis:
A.   Sigmoid colon, resection:      MODERATELY DIFFERENTIATED ADENOCARCINOMA

B.   Colon, donut anastomosis:    Benign colonic tissue


Tumor Information:
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately-differentiated
Tumor site:  Sigmoid colon
Tumor size:  5.3 x 4.2 x 0.5 cm
Tumor configuration:  Centrally ulcerated, with necrosis
Extent of invasion:  Tumor penetrates to the surface of the visceral peritoneum (pT4a)
Lymphovascular invasion:  Present
Discontinuous extramural extension:  Present
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Minimal
  Peritumoral (Crohn-like):  Minimal
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  N/A
Resection margins:  Uninvolved by tumor
  Proximal and distal:  5.5 and 2.7 cm
Lymph node metastasis:
  Total nodes:  6 out of 15 mesenteric nodes
  Largest nodal metastatic focus:  0.8 cm
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  0 nodes
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  0 nodes
  Nodes with metastases > 2.0 mm:  6 nodes
Other findings:  Tattoo identified
AJCC Pathologic Stage:  Stage IIIC (pT4a, pN2a, cM0)\X0A|",,"GrossDescription:
A.  Received fresh, previously opened and unoriented, labeled ""XXXXXX, **NAME[AAA], sigmoid colon"" is an unoriented segment of pink-tan, intestinal tissue measuring up to 13.5 cm in length x 9.0 cm in greatest circumference. There is a well-circumscribed, centrally ulcerated and necrotic tumor measuring 5.3 x 4.2 x 0.5 cm.  The tumor is approximately 2.7 cm away from one margin, which has been inked blue, and approximately 5.5 cm away from the opposite margin, which has been inked orange.  The mass is nearly circumferential.  The underlying fat and serosal surface is inked black beneath the tumor.  Sectioning of the tumor reveals that it penetrates through the muscularis propria and does extend to the serosa and fat.  There are two suspicious, shaggy-appearing areas at the blue margin.  Examination of the fat reveals multiple lymph nodes, ranging from 0.7 cm to 0.2 cm in greatest dimension.  

  KEY TO CASSETTES:
  A1    -  Orange shave margin
  A2    -  Blue shave margin and one perpendicular representative section of the margin
  A3-A7    -  Tumor and deepest penetrating area through the serosa
  A8-A10    -  Tumor and extension into the fat
  A11, A12  -  Shaggy area #1
  A13, A14  -  Shaggy area #2
  A15    -  Three lymph nodes
  A16    -  Three lymph nodes
  A17    -  Two lymph nodes
  A18    -  One lymph node (trisected)
  A19    -  One lymph node
  A20    -  Two lymph nodes
  A21    -  Three lymph nodes
  A22    -  Two lymph nodes 

        Lymph nodes within cassettes within A15-A19 are lymph nodes underlying the tumor, and lymph nodes in cassettes A20-A22 
        are lymph nodes present closer to the orange-inked margin.  

B.  Received in formalin, labeled ""XXXXXX, colon donut anastomosis"" are two soft, tan-gray, unoriented segments of intestinal tissue, the larger of which measures up to 2.0 x 2.0 x 1.6 cm in greatest dimension.  The smaller piece measures approximately 2.9 x 1.3 x 0.9 cm in greatest dimension.  Both specimens appear to be unoriented and are partially lined by mucosa-line soft tissue.  Representative sections of the larger specimen are submitted in cassette B1.  Representative sections of the smaller specimen are submitted in cassette B2.","MicroscopicDescription:
A-B.   The microscopic findings support the above diagnoses.

Note:  Dr. **NAME[ZZZ YYY] concurs with the diagnosis.","A: Sigmoid colon
B: Donut colon anastomosis",,
REG4,COLON,0,PAT-10039881,1,REC-3000655341,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->Right colon polyps./r/n",,"FinalDiagnosis:
A.  Right colon:  Moderately differentiated adenocarcinoma; two separate tumors identified.

   Tumor #1:  7.5 cm in cecal pouch, 3.5 cm from proximal margin; focally invades into the submucosa (pT1).  

Tumor #2:  1.5 cm in ascending colon, 6.5 cm from distal margin; invades into muscularis propria (pT2).

  See microscopic description and comment.

B.  Liver:  Liver capsule and underlying thin strip of benign hepatic parenchyma (see comment)./r/nDiagnosisComment:
A.  Two separate tumors are identified.  The tumor in the cecum (tumor #1) has a prominent component of tubulovillous adenoma with areas of high grade dysplasia, and only focally invades into the submucosa (multiple H\T\E-stained step sections examined).  The second tumor focus (tumor #2) arises from a tubular adenoma in the ascending portion of the colon, and shows more extensive invasion into the muscularis propria.  The pathologic staging is thus based on tumor #2 (pT2 N0).

Case reviewed at Pathology Staff Conference on **DATE[Jul 19 11].  The findings were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jul 19 11] at 5:06 p.m./r/n",,"GrossDescription:
A.  Labeled:        Patient name and medical record number, designated right colon
Specimen:      Right colon segment with attached appendix
Size:        23 x 8.5 x 1.5 cm
Orientation:      None provided
Colors:
  Black:        Proximal
  Blue:        Distal
Tumor:      
  Location:      Cecal pouch
  Size:        7.5 x 7 x 3 cm
  Description:      Tan-gray dome-shaped multilobulated friable lesion
  Ulceration/perforation:      None
  Distance from margins:    3.5 cm from proximal margin, 14 cm from distal margin, proximally 8.5 cm from radial margin
Estimated depth of invasion:  Lobulated lesion appears to involve the mucosa, muscularis propria and possibly abuts the serosal margin.
Other lesions:  There is a 7 x 3 cm tattoo area present 4 cm from the distal margin. Adjacent to attached to the area is a 1.5 x 1 x 0.5 cm tan slightly umbilicated lesion measuring 
6.5 cm from the distal margin and approximately 6 cm from the large, elevated lobulated lesion.
Regional lymph nodes:    Several lymph nodes identified measuring from 0.1 x 0.1 x 0.1 to 1.3 x 1 x 0.9 cm
Section code:    
    Block A1:      Proximal and distal margins
    Block A2:      Radial margin
    Blocks A3-6:      Tumor (large lobulated in cecum)
    Blocks A7-8:      Entire secondary lesion with representative sections of a adjacent tattooed area
    Block A9      Representative sections of unremarkable appendix
    Blocks ***PATH-NUMBER[1]:      Each cassette containing several possible lymph nodes
    Block A16:      Three lymph nodes
    Block A17:       One trisected lymph node 

B.  Labeled:        Patient name and medical record number, designated liver biopsy
  Specimen:      Single, brown roughened piece of tissue (formalin)
  Size:        0.3 x 0.2 x 0.1 cm
  Submitted/Block:      Entirely/1./r/n","MicroscopicDescription:
A. Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site # 1:  Cecum
Tumor Size: 7.5 x 7.0 x 3.0 cm
Macroscopic Tumor Perforation: Not identified.
Histologic Type: Adenocarcinoma.
Histologic Grade: Low-grade (moderately differentiated).
Microscopic Tumor Extension: Tumor focally invades the submucosa.

Tumor Site # 2:  Ascending colon.
Tumor Size: 1.5 x 1.0 x 0.5 cm
Macroscopic Tumor Perforation: Not identified.
Histologic Type: Adenocarcinoma.
Histologic Grade: Low-grade (moderately differentiated).
Microscopic Tumor Extension: Tumor invades muscularis propria.

Margins:
    Proximal margin: Uninvolved by invasive carcinoma.
    Distal margin: Uninvolved by invasive carcinoma.
    Circumferential/radial margin: Uninvolved by invasive carcinoma.
    Distance of invasive carcinoma from closest margin: 3.5 cm (proximal, tumor #1)

Treatment Effect (if applicable): No prior treatment
Lymph-Vascular Invasion: Not identified.
Perineural Invasion: Not identified.
Tumor Deposits: Not identified.
Type of Polyp in Which Invasive Carcinoma Arose:
    Tumor #1:  Tubulovillous adenoma.
    Tumor #2:  Tubular adenoma.

Pathologic Staging (pTNM):
    Primary tumor (#2): pT2
    Regional lymph nodes: N0 
       Number examined: 32 
       Number involved: 0
    Distant metastasis: Not applicable.

Other pathologic findings:
  - Appendix with no significant histopathologic abnormality.

B.  Microscopic evaluation of multiple H\T\E-stained step levels was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: A2 Right colon, excision (fresh)
B: A1 Liver, biopsy",,
REG4,COLON,0,PAT-10038513,1,REC-3000655502,Rectal bleeding.,,"Colon, at 25 cm, ""Polyp"": - INVASIVE COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.  See comment.  Comment: Due to the diagnosis of adenocarcinoma, immunohistochemical stains for DNA mismatch repair proteins will be performed and reported in an addendum. This case was reviewed in intradepartmental consensus conference.  Dr. **NAME[ZZZ] was notified of the diagnosis per telephone conversation at 5:40 p.m. on Thursday, **DATE[Feb 6 2011].",,"Received is a formalin filled specimen container labeled with the patient's name, medical record number and ""colonoscopy at 25 cm"".  It contains five portions of light tan mucosal tissue ranging from 0.6 cm. to 0.2 cm. in greatest dimension.  The specimen is entirely submitted in one cassette.  (HB/hbrya **DATE[Feb 6 11] 07:58 AM)",,Gastrointestinal,,
REG4,COLON,0,PAT-10039498,1,REC-3000655752,,,"FinalDiagnosis:
COLON MASS AT 55 CM:  COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
DiagnosisComment:
MSI studies will be reported in an addendum.  The case was discussed with Dr. **NAME[ZZZ] on **DATE[Feb 24 2012].",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
Small superficial sections of colonic mucosa show ulceration with marked inflammation.  There are invasive nests and strands of crowded glands lined by cells with enlarged irregularly shaped nuclei.  Scattered mitoses are present.  Surrounding granulation tissue and inflammation are noted.",A: COLON MASS AT 55 CM,,"Interpretation:
NO MLH1, MSH2, MSH6 OR PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA NUCLEI.

- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Normal expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

METHODS:  MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block A1.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.
ResultsComments:
Based on the four-antibody panel, there is no immunohistochemical evidence to suggest a mismatch repair deficiency or microsatellite unstable carcinoma; however, further evaluation by a genetics counselor at the **INSTITUTION (phone: **PHONE) is highly recommended given the patient's age."
REG4,COLON,0,PAT-10035195,1,REC-3000655900,"ClinicalHistory:
Abnormal polyp right colon with severe dysplasia.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:

""Right colon"":          ADENOCARCINOMA (see tumor information).

Tumor Information:
Type of specimen(s):  Right colon
Histologic type:  Adenocarcinoma with medullary features.
Histologic grade:  Moderately-poorly differentiated
Tumor site:  Cecal
Tumor size:  2.5 cm
Tumor configuration:  Sessile
Extent of invasion:  Into submucosa
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Present
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:  Present
Mucinous/signet ring/medullary pattern:  Present
Neoadjuvant treatment effect:  No known pre-surgical treatment
Resection margins:  Negative
  Proximal:  4 cm
  Distal:  16.5 cm
  Circumferential/radial:  6 cm
Lymph node metastasis:
  Total nodes:  2 out of 25 mesenteric nodes (medullary type).
  Largest nodal metastatic focus:  0.6 cm
  Nodes with metastases > 2.0 mm:  0 nodes
Other findings:  N/A
AJCC Pathologic Stage:  pT1, pN1, Mx    
DiagnosisComment:
The cecal neoplasm shows both adenocarcinomatous and medullary features.  It arises from a tubular adenoma and invades into the submucosa.  Two lymph nodes are positive (2/25).  Medullary carcinoma is a distinctive histologic type strongly associated with high levels of microsatellite instability (MSI-H), indicative of defects in the normal DNA repair gene function.  MSI testing is generally recommended in cases that show the MSI-H phenotype.

Specimen signed out at **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.\X0A|",,"GrossDescription:
Received in formalin, labeled ""right colon"" is a segment of small bowel (3 cm in length by 2 cm in diameter) and a segment of large bowel (18 cm in length by 3 cm in diameter).  A smooth pink-tan appendix (8 x 0.8 x 0.6 cm) is attached to the cecum of the large bowel.  Both proximal and distal resection margins are inked black and the radial resection margin is inked green.  

The specimen is opened to reveal a tan-red mass (2.5 x 2.5 x 0.9 cm) which is found in the cecum at the appendiceal orifice.  The mass is grossly located 4 cm away from the proximal resection margin, 16.5 cm away from the distal resection margin and 6 cm away from the radial resection margin.  The mass does not grossly appear to penetrate through the muscularis propria.  

Also found in the large bowel are two possible polyps measuring 0.2 and 0.4 cm in greatest dimension and found 9 cm and 6 cm away from the distal resection margin respectively.  

The remainder of the specimen appears grossly normal.  

Representative sections are submitted as follows:

Block summary:
1.  -  Perpendicular section of proximal resection margin.
2.  -  Perpendicular section of distal resection margin.
3.  -  En face section of radial resection margin.
4.  -  Cross section of proximal end of appendix.
5.  -  Additional cross sections of appendix.
6.  -  Distal tip of appendix.
7-9.  -  Sections of mass, entirely submitted.
10.  -  Two possible polyps.
11.  -  Section of ileocecal valve.
12.  -  Sections of small bowel.
13-14.  -  Sections of large bowel.
15.  -  Six possible lymph nodes.
16.  -  Six possible lymph nodes.
17.  -  Three possible lymph nodes.
18.  -  Six possible lymph nodes.
19.  -  Three possible lymph nodes.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Right colon,,
REG4,COLON,0,PAT-10041661,1,REC-3000655969,"ClinicalHistory:
569.9
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Hepatic flexure mass./r/n",,"FinalDiagnosis:
Colon, hepatic flexure region:  Moderately differentiated adenocarcinoma./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[May 26 2012].  Dr. **NAME[WWW VVV] was notified of the diagnosis (voicemail) on **DATE[May 26 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated hepatic flexure mass Specimen:    Multiple, tan pieces of tissue (formalin)
Aggregate:    1 x 0.5 x 0.3 cm
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Hepatic flexure mass, biopsy",,
REG4,COLON,0,PAT-10039878,1,REC-3000656011,"ClinicalHistory:
Colon polyp.",,"FinalDiagnosis:
A.  Large intestine, transverse colon polyp, snare biopsy:  Fragments of tubulovillous adenoma

B.  Large intestine, cecal mass, biopsy:      Fragments of dysplastic colonic mucosa, 
                suspicious for adenocarcinoma (see Comment)

C.  Large intestine, descending colon polyp, biopsy:    Villous adenoma

D.  Large intestine, rectum polyp, biopsy:      Hyperplastic polyp
DiagnosisComment:
For part B (cecal mass), the biopsy shows small, superficial, acutely inflamed fragments of colonic mucosa with dysplastic epithelium.  While no definitive invasion is seen in this biopsy, the architectural and abnormal cytologic features raise the suspicion of invasive adenocarcinoma.  The superficial nature of the biopsy precludes examination of a deeper lesion.  Please correlate clinically and with the endoscopic findings.  \X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, biopsy/snare colon polyp transverse"" are multiple tan-pink fragments of mucosal lined soft tissue measuring up to 0.4 cm in greatest dimension.  Submitted entirely in one cassette.

B.  Received in formalin labeled ""XXXXXX, biopsy cecal mass"" are multiple minute, tan-pink fragments of mucosal lined soft tissue, the largest of which measures up to 0.2 cm in greatest dimension.  Submitted entirely in one cassette.

C.   Received in formalin labeled ""XXXXXX, colon polyp snare descending"" is a polypoid piece of pink-tan tissue measuring up to 1.0 x 1.0 x 0.8 cm in greatest dimensions.  The specimen is inked black at the base and sectioned.  Submitted entirely in one cassette.

D.   Received in formalin labeled ""XXXXXX, biopsy colon polyp rectum"" are two tan-pink fragments of mucosal lined soft tissue measuring up to 0.3 cm in greatest dimension.  Submitted entirely in one cassette.","MicroscopicDescription:
A-D.   The microscopic findings support the above diagnoses.  For part B, multiple deeper sections were conducted to confirm the diagnosis.","A: Transverse colon polyp snare
B: Cecal mass biopsy
C: Descending colon polyp
D: Rectum polyp",,
REG4,COLON,0,PAT-10016110,2,REC-3000659250,"ClinicalHistory:
Colon cancer

Previous biopsy
[***PATH-NUMBER[1] **DATE[Jun 11 2012] - Right colon polyp biopsy and snare: Invasive adenocarcinoma, moderately-differentiated.
Post-OperativeDiagnosis:
Colon cancer.",,"PostOperativeDiagnosis:
Colon cancer
FinalDiagnosis:
A.  Transverse colon, partial colectomy:      INVASIVE ADENOCARCINOMA, moderately-differentiated
                    Fourteen benign lymph nodes (0/14)

B.  Colon, right hemicolectomy:    Tubular adenoma
            Benign small bowel and appendix
            Fourteen benign lymph nodes (0/14)  
            

                                                    Tumor Information:

Histologic type:  Adenocarcinoma
Histologic grade:  Moderately-differentiated
Tumor site:  Part A (transverse colon)
Tumor size:  1.2 x 0.5 x 0.3 cm 
Tumor configuration:  Ulcerated
Extent of invasion:  Tumor invades submucosa
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Resection margins:  Free of tumor
  Proximal:  Far (extended by part B)
  Distal:  At lease 4.5 cm (part A)
Lymph node status:  Twenty-eight benign lymph nodes (0/28)
Other findings:  Tattoo in the area of carcinoma
      Benign small bowel and appendix (part B)  
AJCC Pathologic Stage:  Stage I [pT1, pN0, cM0]
    
DiagnosisComment:
Dr. **NAME[ZZZ YYY] concurs with the diagnoses.\X0A|",,"GrossDescription:
A.  Received fresh labeled ""**NAME[CCC] Jr, XXXXXX, colon transverse"" is an unoriented segment of intestinal tissue measuring 15.0 cm in length x 10.0 cm in greatest circumference.  The specimen is inked blue at one margin, and the opposite margin is inked orange.  Opening of the specimen reveals a mass lesion measuring 1.2 x 0.5 x 0.3 cm.  The mass lesion is approximately 4.5 cm away from the orange margin and approximately 9.2 cm away from the blue margin.  The area underlying the mass lesion is inked black.  Sectioning reveals no definitive invasion into the muscularis propria.  No other lesions are grossly identified.  Examination of the pericolonic fat reveals at least three lymph nodes measuring up to 0.3 cm in greatest dimension.  All three lymph nodes are within 2.0 cm of the mass lesion.  

KEY TO CASSETTES:
A1    -  Blue margin
A2    -  Orange margin
A3-A6  -  Mass, submitted entirely 
A7    -  Representative unremarkable intestinal tissue
A8-A10  -  One lymph node per cassette, bisected
A11-A24  -  Representative sections of fat, beginning with the orange margin in cassette 1

B.  Received fresh labeled ""**NAME[CCC] Jr, **NAME[CCC], right colon"" is an oriented segment of intestinal tissue measuring up to 25.5 cm in length x 12.0 cm in greatest circumference.  The specimen includes terminal ileum, the ileocecal valve, cecum, appendix, and ascending colon.  The proximal terminal ileum margin is inked green, and the distal colonic margin is inked red.  The specimen is opened to reveal no masses/lesions.  One small polyp is grossly identified in the colon, measuring 0.4 cm, and is approximately 10.0 cm away from the red margin.  The appendix appears unremarkable, and measures 5.5 cm in length x 0.4 cm in diameter.  The terminal ileum appears unremarkable.  Examination of the pericolonic fat reveals at least four lymph nodes, ranging from 0.5 cm to 0.3 cm.  

KEY TO CASSETTES:
B1    -  Proximal (green) margin
B2    -  Distal (red) margin
B3    -  Polyp submitted entirely
B4    -  Representative unremarkable terminal ileum
B5    -  Representative sections of the appendix
B6    -  Iliocecal valve
B7-B8  -  Lymph nodes (one each, bisected)
B9-B25  -  Representative sections of fat, beginning with the green margin in cassette B9.","MicroscopicDescription:
A-B.  The microscopic findings support the above diagnoses.","A: Transverse colon
B: Right colon",,
REG4,COLON,0,PAT-10037387,1,REC-3000659367,"ClinicalHistory:
Colon mass ? CA.",,"FinalDiagnosis:
COLON MASS AT 40 CM LEVEL BIOPSY:  CONSISTENT WITH MODERATELY 
DIFFERENTIATED ADENOCARCINOMA.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  4.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
Sections of colonic mucosa show infiltration by irregularly 
shaped glands lined by atypical polygonal cells with nuclear 
hyperchromasia, increased N:C ratio, and high mitotic 
activity.  The stroma is desmoplastic.  Findings are 
consistent with moderately differentiated adenocarcinoma. 
MSI studies will be performed and reported in an addendum.",A: COLON MASS AT 40 CM LEVEL BIOPSY,,"Interpretation:
NO MLH1, MSH2, MSH6 OR PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA NUCLEI.

- MLH1 (CLONE **ID-NUM):  Normal expression.
- PMS2 (CLONE A16-4):  Normal expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

METHODS:  MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block A1.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.
ResultsComments:
Based on the four-antibody panel, there is no immunohistochemical evidence to suggest a mismatch repair deficiency or microsatellite unstable carcinoma."
REG4,COLON,0,PAT-10038684,1,REC-3000659412,Colon cancer screening in patient at increased risk: Colorectal cancer in mother.,,"A. Colon, Sigmoid, ""Polyp"": - INFLAMMATORY-TYPE POLYP. - No dysplasia or malignancy identified.  B. Colon, Sigmoid, ""Polyp"": - TUBULAR ADENOMA. - MARGINS FREE OF ADENOMATOUS EPITHELIUM. - No high-grade dysplasia or malignancy.  C. Colon, Sigmoid, Biopsy: - INVASIVE COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.  See comment.  Comment: Due to the presence of adenocarcinoma, immunohistochemical stains for DNA mismatch repair proteins will be performed and reported in an addendum.  This case was reviewed in intradepartmental consultation.  The diagnosis was discussed with Dr. **NAME[ZZZ] per telephone conversation at 2:05 PM on **DATE[Oct 05 2011].",,"The specimens are received in three formalin-filled containers labeled with the patient's name and medical record number. A.  The first container is further labeled ""sigmoid polyp"".  It contains three portions of light tan mucosal tissue ranging from 0.2 cm. to less than 0.1 cm. The smallest fragment(s) may not survive processing.  The specimen is entirely submitted in A.   B.  The second container is further labeled ""sigmoid polyp"".  It contains one portion of light tan polypoid tissue 1.2 x 1.0 x 0.6 cm. The specimen is inked blue, bisected with fragmentation occurring and entirely submitted in B1 - B2.   C.  The third container is further labeled ""sigmoid mass"".  It contains multiple portions of light tan mucosal tissue ranging from 0.3 cm. to less than 0.1 cm. The smallest fragment(s) may not survive processing.  The specimen is entirely submitted in C.  (CJ/cjenn **DATE[Oct 5 11] 07:53 AM)",,Gastrointestinal,,
REG4,COLON,0,PAT-10039034,1,REC-3000659416,Generalized abdominal pain.  Hematochezia.,,"A. Colon, Cecum, ""Polyp"": - FRAGMENTS OF TUBULOVILLOUS ADENOMA.  - No high-grade dysplasia or malignancy.   B. Colon, Hepatic Flexure, ""Polyp"": - HYPERPLASTIC POLYP.   C. Colon, Transverse, ""Polyp"": - TUBULAR ADENOMA.  - No high-grade dysplasia or malignancy.   D. Colon, Descending, ""Mass"": - INVASIVE COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED. See comment.  - IMMUNOHISTOCHEMICAL STAINS FOR MLH1, MSH2, MSH6 AND PMS2 ARE INTACT (NORMAL). See comment.  Comment: This case was reviewed in intradepartmental consensus conference. Dr. **NAME[ZZZ] was notified of the diagnosis per telephone conversation at 4:31 pm on **DATE[Oct 23 11].   There is no evidence of DNA mismatch repair deficiency in the carcinoma, indicating that the tumor is most likely microsatellite stable, and that Lynch syndrome (a common cause of hereditary non-polyposis colorectal cancer or HNPCC) is very unlikely.  Lynch syndrome cannot be completely excluded because some germline mismatch repair gene mutations may rarely have intact expression of a non-functional mismatch repair protein. Additional testing (MSI and/or germline) should be considered if the patient meets high risk criteria for Lynch syndrome. If MSI testing is desired, please call Caris Life Sciences at **PHONE. In addition, about one half of HNPCC is caused by alterations in other unknown genes (so-called familial colorectal cancer type X), for which no testing is currently available.   DNA mismatch repair intact cancers, such as this example, are associated with decreased overall patient survival when compared to patients with mismatch repair deficient cancers. Studies also demonstrate that mismatch repair intact cancers are often sensitive to 5-fluorouracil based chemotherapy, but typically resistant to irinotecan (CPT-11).  References:  1) **NAME[YYY] HT, **NAME[YYY] PM, Lanspa SJ, **PLACE CL, **NAME[YYY] JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009;76:1-18.   2) Ribic CM, **NAME[XXX] DJ, **NAME[WWW] MJ, Thibodeau SN, French **NAME[VVV, UUU] RM, **PLACE SR, **NAME[TTT M, SSS M, RRR] LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. NEJM 2003;**PHONE-1257.   3) Bertagnolli MM, **NAME[QQQ M, PPP] CC, **NAME[OOO] HP, Hall **NAME[M, NNN M, MMM] SD, **NAME[LLL] RJ, **NAME[UUU] RM, Saltz LB, **PLACE RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;**ID-NUM.  Type of specimen fixation and processing: formalin-fixed paraffin-embedded sections.  Clones used: MLH1 (ES05), MSH2 (**ID-NUM). MSH6 (BC-44), PMS2 (A16-4).  Detection system used: avidin biotin peroxidase. Criteria for scoring: staining was scored as either intact, absent (complete loss of nuclear staining in all neoplastic cells), or markedly reduced (less than 20% of neoplastic cells with 2-3+ nuclear positivity) in the presence of appropriate positive non-neoplastic internal control cells.  E. Rectum, ""Polyp"": - FRAGMENTS OF TUBULOVILLOUS ADENOMA. See comment.  - No high-grade dysplasia or malignancy.  - Additional deeper sections examined.   Comment:  Due to the fragmented nature of the specimen and the architectural features of the lesion, complete removal of the adenomatous lesion is recommended, if not already performed. Invasive neoplasm is not present.",,"The specimens are received in five formalin-filled containers labeled with the patient's name and medical record number. A.  The first container is further labeled ""cecum polyp"".  It contains two portions of light tan polypoid tissue ranging from 0.6 cm. to 0.5 cm. in greatest dimension.   The specimen is entirely submitted in A.   B.  The second container is further labeled ""hepatic flexure polyp"".  It contains one portion of light tan polypoid tissue 0.3 cm. in greatest dimension.   The specimen is entirely submitted in B. C.  The third container is further labeled ""transverse polyp"".  It contains one portion of light tan polypoid tissue 0.8 cm. in greatest dimension.  The specimen is bisected and entirely submitted in C.   D.  The fourth container is further labeled ""descending mass"".  It contains multiple portions of light tan mucosal tissue ranging from 0.4 cm. to less than 0.1 cm. The smallest fragment(s) may not survive processing.  The specimen is entirely submitted in cassettes D1 - D2.   E.  The fifth container is further labeled ""rectum polyp"".  It contains two portions of light tan polypoid tissue ranging from 1.2 x 0.7 x 0.7 cm. to 0.8 x 0.6 x 0.4 cm. Portion one is bisected and entirely submitted in cassette E1.  Portion two is bisected with fragmentation and entirely submitted in cassette E2.  (HB/hbrya **DATE[Oct 23 11] 08:04 AM)",,Gastrointestinal,,
REG4,COLON,0,PAT-10040912,1,REC-3000665276,"ClinicalHistory:
Procedure->Other (specify in Comments)
Clinical History/Diagnosis/Condition->COLON MASS./r/n",,"FinalDiagnosis:
Right colon:  Moderately differentiated adenocarcinoma extending through muscularis propria into pericolonic tissues, margins and 
                      14 lymph nodes are negative (0/14)./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[May 06 2012].  Findings reported to Dr. **NAME[ZZZ YYY] s office (**NAME[XXX]) on **DATE[May 06 2012] at 4:00PM./r/n",,"GrossDescription:
Labeled:        Patient name and medical record number, designated right colon
Specimen:      Colon with attached appendix
Size:        
  Length:        34.5 cm
  Circumference:      6.5   8 cm
Appendix:      
  Length:        **ID-NUM cm
  Diameter:      0.9 cm
Colors:
  Black:        Distal
  Blue:        Proximal
  Green:        Radial margin
Tumor:      
  Location:      Right colon
  Size:        6 x 5.5 x 1.2 cm
  Description:      White-tan firm fungated mass
  Ulceration/perforation:      None
  Distance from margins:      21 cm from proximal margin
9.5 cm from distal margin
1.5 cm from radial margin
  Estimated depth of invasion:  Through muscularis propria into pericolonic fat.
Regional lymph nodes:    Small lymph nodes measuring up to 1.2 x 1.2 x 0.6 cm
Section code:    
  Blocks 1-2:      Proximal margin
  Blocks 3-4:      Distal margin
  Block 5:      Tumor with radial margin
  Blocks 6-10:      Tumor
  Block 11:      Uninvolved mucosa
  Block 12:      Appendix
  Blocks 13-16:      Lymph nodes
  Block 17:      Two bisected lymph nodes./r/n","MicroscopicDescription:
The invasive adenocarcinoma has associated ulceration with invasion through the muscular propria into the adjoining pericolonic tissues without involvement of the serosa or margins with a proximal margin of terminal ileum.  There are neutrophils around the malignant glands without intratumoral lymphocytic response with occasional small lymphoid aggregates in the pericolonic tissue in a limited pericolic peri-tumor distribution without evidence of a mucinous or medullary tumor component.  The appendix is unremarkable.  The pericolonic lymph nodes have focal reactive sinus histiocytes and scant foamy histocytes without metastasis.

Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site:  Right (ascending, nearer hepatic flexure) colon
Tumor Size:  Greatest dimension:  6 cm 
Macroscopic Tumor Perforation:  Not identified 
Histologic Type:  Adenocarcinoma 
Histologic Grade:  Low grade (moderately differentiated).
Microscopic Tumor Extension:  Tumor invades through the muscularis propria into the subserosal adipose tissue or 
                       non-peritonealized pericolic soft tissues but does not extend to the serosal surface 
Margins:
     Proximal margin:  Uninvolved by invasive carcinoma 
     Distal margin:  Uninvolved by invasive carcinoma 
     Circumferential/radial margin:  Uninvolved by invasive carcinoma 
     Distance of invasive carcinoma from closest margin:  1.5 cm from radial margin
Treatment Effect (if applicable):  No prior treatment 
Lymph-Vascular Invasion:  Not identified 
Perineural Invasion:  Not identified
Tumor Deposits (discontinuous extramural extension):  Not identified
Pathologic Staging (pTNM):
     Primary tumor:  pT3:  Tumor invades through the muscularis propria into pericolonic tissues 
     Regional lymph nodes:  pN0:  No regional lymph node metastasis
          Number examined:  14
          Number involved:  0
     Distant metastasis:  Not applicable 
Additional Pathologic Findings:  None identified./r/n",A: Right colon,,
REG4,COLON,0,PAT-10038922,1,REC-3000671250,"ClinicalHistory:
Distal sigmoid colon carcinoma, *suture at distal margin.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Colon, partial colectomy, rectal-sigmoid:
  1.   MODERATE TO POORLY DIFFERENTIATED ADENOCARCINOMA
  2.   CARCINOMA INVASIVE THROUGH MUSCULARIS PROPRIA INTO SUBSEROSAL TISSUE
  3.   THREE OF SEVEN LYMPH NODES POSITIVE FOR CARCINOMA (3/7), SEE COMMENT
  4.   RESECTION MARGINS NEGATIVE FOR CARCINOMA

Tumor Information:
Type of specimen(s):  Colectomy, rectal sigmoid
Histologic type:  Adenocarcinoma
Histologic grade:  Moderate, to focally poorly differentiated
Tumor site:  Rectal/sigmoid
Tumor size:  3.7 x 3 x 1.5 cm
Tumor configuration:  Exophytic and ulcerated
Extent of invasion:  Into and through muscularis propria, into subserosal soft tissue
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Presumed positive due to nodal metastasis
Venous invasion:  Not identified
Perineural invasion:  Present
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Resection margins:  All Negative
  Proximal:  >0.8 cm
  Distal:  >1 cm
  Circumferential/radial:  Negative
Lymph node metastasis:
  Total nodes:  3 out of 7 mesenteric nodes positive for carcinoma, (3/7)
  Size:  Nodal metastases range from approximately 1 to 5 MM
      Extracapsular extension not seen
AJCC Pathologic Stage:  pT3, pN1b

DiagnosisComment:
The small number of lymph nodes retrieved is noted.  The reason for this is the relative small specimen size with scant adipose tissue.  It is also noted that of the seven nodes examined, three of them exhibited metastatic carcinoma.  \X0A|",,"GrossDescription:
Received in a container, labeled ""XXXXXX, XXXXXX, rectal sigmoid colon"" is a 6.2 cm length of colon with a diameter of 4.1 by approximately 5 cm.  There is a suture designating the distal resection margin.  Additionally, two donuts of tissue are also present in the container (2.2 x 2.2 x 0.9 and 2.2 x 1.8 x 1.2 cm).  The stapled resection margins are removed and inked as follow:  black-proximal, yellow-distal.  An exophytic, fungating tumor (3.7 x 3 x 1.5 cm) is present approximately 1 cm from the distal mucosal resection margin and 0.8 cm from the proximal mucosal resection margin.  Serial sectioning of the tumor shows gross extension at least to the muscularis propria.  Extension to subserosal soft tissue is not grossly evident.  Representative sections are submitted as follows:    

Block summary:
1-2.  -  Donut, unoriented.
3.  -  Donut, unoriented.
4-5.  -  Distal margin, totally submitted en face.
6-7.  -  Radial sections of tumor and proximal resection margin.
8.  -  Tumor.
9-10.  -  Adjacent sections of tumor up to block 14.
11-24.  -  Possible lymph node tissue.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Rectal - sigmoid colon,,
REG4,COLON,0,PAT-10041337,1,REC-3000671351,"ClinicalHistory:
211.3
Procedure->Excision
Clinical History/Diagnosis/Condition->(+)IFOBT: (a) Pedunculated polyp @ 20 cm./r/n",,"FinalDiagnosis:
Colon at 20 cm:  Adenocarcinoma arising in a tubulovillous adenoma./r/nDiagnosisComment:
Step x 3 on section A1.  Dr. **NAME[ZZZ YYY] s office (**NAME[XXX]) was notified of the diagnosis on **DATE[Sep 8 2012] at 9:59 A.M.  Case reviewed in Pathology Staff Conference on **DATE[Sep 7 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated colon polyp at 20 cm
Specimen:    Single, brown lobulated piece of tissue (formalin)
Size:      1.3 x 1 x 0.8 cm
Submitted/Block:    Entirely trisected/1./r/n","MicroscopicDescription:
Colon and Rectum Cancer Excisional Biopsy (Polypectomy) Information
Based on AJCC/UICC TNM, 7th edition

Tumor site:  Distal sigmoid.  
Size of invasive carcinoma:  Up to 3 mm in greatest dimension.
Histologic type:  Adenocarcinoma.
Histologic grade:  Low-grade (well to moderately differentiated).
Microscopic tumor extension:  Submucosa.
Margins:  
   Deep stalk:  Uninvolved by invasive carcinoma.
   Mucosal/lateral margin:  Uninvolved by invasive carcinoma.
      Distance of carcinoma from margin:  Invasive carcinoma is 3 mm from the deep stalk margin.
Lymph-vascular invasion:  Not identified./r/n","A: Colon polyp @ 20 cm, excision",,
REG4,COLON,0,PAT-10035205,1,REC-3000671442,"ClinicalHistory:
Perforated viscus.","CytologyReview:

LLQ sigmoid colon mass aspiration

  Specimen Adequacy:
Satisfactory for evaluation.

  Interpretation:
  MICROSCOPIC DIAGNOSIS:

  LLQ sigmoid colon mass aspiration:
    ABUNDANT MUCOPURULENT DEBRIS IS IDENTIFIED, WITH FOCAL ATYPICAL CELLS
      POSITIVE FOR CDX2, CONSISTENT WITH THE MUCINOUS ADENOCARCINOMA
      OF ***PATH-NUMBER[1] IN THE SIGMOID COLON

MB:mk.","FinalDiagnosis:

LLQ sigmoid colon mass aspiration

  Specimen Adequacy:
Satisfactory for evaluation.

  Interpretation:
  MICROSCOPIC DIAGNOSIS:

  LLQ sigmoid colon mass aspiration:
    ABUNDANT MUCOPURULENT DEBRIS IS IDENTIFIED, WITH FOCAL ATYPICAL CELLS
      POSITIVE FOR CDX2, CONSISTENT WITH THE MUCINOUS ADENOCARCINOMA
      OF ***PATH-NUMBER[1] IN THE SIGMOID COLON

MB:mk


  
\X0A|",,"GrossDescription:
Received with fixative 10 ml tan (in formalin), cloudy.
Cell block: 1.0 x 1.0 x 0.3 cm tan and mucoid.",,A: LLQ sigmoid colon mass aspiration,,
REG4,COLON,0,PAT-10039369,1,REC-3000671444,"ClinicalHistory:
Sigmoid colon stricture.
Pre-OperativeDiagnosis:
Sigmoid colectomy:.",,"PreOperativeDiagnosis:
Sigmoid colectomy:
FinalDiagnosis:
Sigmoid colon:  

Tumor Information:

Type of specimen(s):  Sigmoid colectomy
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Sigmoid colon
Tumor size:  2 x1 x 1 cm
Tumor configuration:  Ulcerated
Extent of invasion:  Tumor extends through the wall into peri-colic fat
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Present
Venous invasion:  
  Intramural:  Not identified
  Extramural:  Present
Perineural invasion:  Present
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Resection margins:  Clear
  Proximal:  4 to 5 cm
  Distal:  4 to 5 cm
  Circumferential/radial:  Clear
Lymph node metastasis:
  Total nodes:  1 out of 17 mesenteric nodes
  Largest nodal metastatic focus:  less than 0.2 cm
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  1 node
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  0 nodes
  Nodes with metastases > 2.0 mm:  0 nodes
Other findings:  MSI testing requested
AJCC Pathologic Stage:  pT3, pN1, MX
      Pathologic stage:  IIIB

DiagnosisComment:
The diagnosis of adenocarcinoma involving at least one lymph node was discussed with Dr. **NAME[ZZZ] on **DATE[Jun 8 2012].  Block 3 is sent for KRAS reflex to BRAF.\X0A|",,"GrossDescription:
Sigmoid colon:  Received is a segment of large bowel which measures in its fixed state up to 9 cm in length.  The central portion of the specimen is narrowed.  On section, a 2 x 1 cm ulceration is centrally identified with wide proximal and distal margins.  On section, the wall is thickened and fibrosis extends into the peri-colic fat.  Representative sections of ulcer are submitted in cassettes 1 through 5.  The tumor is between 4 to 5 cm from the distal and proximal margins of resection.  A representative section of each margin is submitted in cassette 6.  Possible lymph nodes are submitted through cassette 13.","MicroscopicDescription:
Sigmoid colon:  Sections demonstrate an invasive adenocarcinoma.  Complex glands invade through the muscularis into the peri-colic fat.  Solid tumor areas are noted with bizarre tumor cells. Solid areas of tumor are felt to represent less than 50% of tumor mass.  1 of 17 regional nodes demonstrates evidence of metastatic carcinoma.  In this particular node, the node is located in the immediate peri-colic fat and the tumor is less 2 mm in dimension.  Peri-vascular tumor invasion is noted.  Perineural invasion is also appreciated.   The surgical margins are free of tumor.",A: Sigmoid colon,,
REG4,COLON,0,PAT-10038927,1,REC-3000671455,"ClinicalHistory:
Malignancy in colon/rectum.",,"FinalDiagnosis:

A.  Colon, flat lesion at 30 cm, biopsy:  Flat adenoma with focal high-grade dysplasia (see 
            comment).

B.  Sigmoid colon polyps, biopsy:    Hyperplastic polyps.

C.  Rectum, biopsy:        Benign rectal mucosa with hyperplastic changes.


Comment:  
A.   Adenomatous features are present in 3 out of 4 biopsies at 30 cm.  High-grade dysplasia is identified 
      focally in few glands in the form of nuclear pleomorphism.\X0A|",,"GrossDescription:
(A)  Received in formalin labeled ""30 cm flat lesion"" are four tan-pink and soft tissue fragments measuring up to 0.5 cm.  Entirely submitted in one cassette. 

(B)  Received in formalin labeled ""hyperplastic polyps, sigmoid"" are two tan-pink and soft tissue fragments measuring up to 0.3 cm.  Entirely submitted in one cassette. 

(C)  Received in formalin labeled ""biopsy rectum"" are two tan-pink and soft tissue fragments measuring up to 0.4 cm.  Entirely submitted in one cassette.","MicroscopicDescription:
A - C. Microscopic findings support the diagnosis.","A: Bx 30 cm (flat lesion)
B: Hyperplastic polyps Sigmoid
C: Rectum, biopsy",,
REG4,COLON,0,PAT-10035205,1,REC-3000671457,"ClinicalHistory:
A-D.  Sigmoid colon mass.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same 
FinalDiagnosis:
MICROSCOPIC DIAGNOSES:

A. Jejunum, B. Left colon, C. Sigmoid and transverse colon, and D. Additional distal margin:
  1.  INVASIVE ADENOCARCINOMA, MUCINOUS TYPE, LOW GRADE
  2.  CARCINOMA EXTENDS THROUGH THE VISCERAL PERITONEUM (X2)
             3.  FOCAL TUMOR SEEDING NOTED IN THE ADHESION TO THE TRANSVERSE COLON
  3.  RESECTION MARGINS NEGATIVE
  4.  NONE OF 27 LYMPH NODES CONTAIN METASTATIC ADENOCARCINOMA

Tumor Information:

Type of specimen(s):  Segmental resections of sigmoid, transverse, and distal colon
      with a portion of jejunum
Histologic type:  Adenocarcinoma, with mucinous features
Histologic grade:  Low grade
Tumor site:  Sigmoid colon
Tumor size:                                                         7 cm x 6 cm
Tumor focality:                                                   Unifocal
Tumor configuration:  Polypoid
Extent of invasion:  Through the visceral peritoneum into the peritoneal cavity (x2)
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Present in the adhesion to the transverse colon
Marked lymphocytic response:  Not identified
Mucinous/signet ring/medullary pattern:  Mucinous pattern present

Margins
  Proximal:  5 cm on the initial segment
  Distal:  5 cm on the initial segment
  Radial mesenteric:  1 cm on the initial segment
  Circumferential serosal:  Perforated at two sites
Lymph node metastasis:  0 out of 27 lymph nodes have carcinoma

  Other findings:  There are multiple areas of acute and chronic granulomatous, desmoplastic serositis. Focal discontinuous tumor extension is documented in the adhesion to the transverse colon.  An additional tubular adenoma and a hyperplastic polyp are seen in part B, with a second tubular adenoma in part C.  Residual villous adenoma is suggested at the edge of the carcinoma.
AJCC Pathologic Stage:  pT4, pN0      (see comments)   
DiagnosisComment:
The invasive tumor appears to be low grade with many areas of partial thickness pseudo stratification arising in a large villous adenoma.  It has substantial mucin production without a significant signet ring component.  The tumor perforates the sigmoid colon at two sites, inciting a desmoplastic, often granulomatous, serositis with adhesions to the transverse colon, jejunum, anterior adominal wall and pelvic brim noted at operation. Focal discontinuous tumor is documented in the adhesion to the transverse colon, but not in any of the 27 lymph nodes identified.\X0A|",,"GrossDescription:
Specimen A.  Received in formalin, labeled ""jejunum"" is a segment of small bowel (4.5 cm in length by 2 cm in diameter).  The serosal surface reveals a tan-red ulcer (2 x 1.1 x 0.4 cm) found 1 cm away from the nearest resection margin and 1 cm away from the mesenteric resection margin.  Both resection margins are inked black and the mesenteric resection margin is inked green.  The specimen is opened to reveal tan mucosa with normal rugal folds.  The mucosa adjacent to the serosal ulcer appears slightly reddened.  No masses are grossly identified.  Representative sections are submitted as follows:

Block summary:
A1.    -  Perpendicular sections of both resection margin.
A2-A7.    -  Sections of serosal ulcer, entirely submitted with adjacent mucosa and mesenteric resection margin.

Specimen B.  Received in formalin, labeled ""left colon, stitch marks proximal end"" is a segment of large bowel (17 cm in length by 3 cm in diameter) with a suture marking the proximal end of the specimen.  The proximal resection margin is inked black and the distal resection margin is inked red.  Serosa is smooth, pink-tan.  The specimen is opened to reveal tan mucosa with normal rugal folds.  One possible tan polyp (0.4 x 0.3 x 0.2 cm) is found 4 cm away from the proximal resection margin.  A second possible tan polyp (0.4 x 0.4 x 0.1 cm) is found 2 cm away from the distal resection margin.  No other lesions or masses are grossly identified.  Representative sections are submitted as follows:

Block summary:
B1.    -  Perpendicular section of proximal resection margin.
B2.    -  Perpendicular section of distal resection margin.
B3.    -  Possible polyp #1.
B4.    -  Possible polyp #2.
B5.    -  Four possible lymph nodes.
B6.    -  Six possible lymph nodes.
B7.    -  Six possible lymph nodes.

Specimen C.  Received in formalin, labeled ""perforated sigmoid colon"" is a segment of large bowel/sigmoid colon (16 cm in length by 3.5 cm in diameter) with metal clips marking the distal resection margin.  The proximal resection margin is inked black and the distal resection margin is inked red.  The radial/mesenteric resection margin is inked green.  The circumferential serosal margin is also inked black.  Two perforations are found on the sigmoid colon measuring 3.8 x 3 cm in greatest dimension and 2.5 x 2 cm in greatest dimension.  The two perforations are found within the inked circumferential serosal margin.  Adhered midway through the sigmoid colon is a second horizontal segment of large bowel (6.5 cm in length by 2.5 cm in diameter).  Both resection margins on the second segment of large bowel are inked black and the radial/mesenteric resection margin is inked green.  The serosal surface of the interface between both segments of bowel is inked yellow.  The sigmoid colon is opened to reveal a large and circumferential mucinous and polypoid tan-red to white mass measuring 7 cm in circumference by 6 cm in length.  The mass grossly approaches 5 cm within the proximal resection margin, 5 cm within the distal resection margin and 1 cm within the radial/mesenteric resection margin.  The mass extends to the circumferential serosal margin and protrudes through at both perforation site.  The mass does not grossly appear to invade the second smaller segment of large bowel.  No grossly abnormal findings are found within the second smaller segment of large bowel.  A tan polyp measuring 0.5 x 0.3 x 0.2 cm is found in the sigmoid colon located 1 cm away from the proximal resection margin.  The remainder of the sigmoid colon appears grossly normal.  Representative sections are submitted as follows:

Block summary:
C1.    -  Perpendicular section of proximal resection margin.
C2.    -  Perpendicular section of distal resection margin.
C3.    -  Polyp.
C4-C5.    -  Sections of mass at perforated site #1 with radial/mesenteric resection margin.
C6.    -  Additional section of mass at perforated site #1.
C7.    -  Section of mass at perforated site #2.
C8-C11.    -  Additional sections of mass.
C12.    -  Sections of interface between both adhered segments of bowel.
C13.    -  Section of second smaller segment of large bowel with one resection margin and adjacent fat.
C14.    -  Additional section of second smaller segment of large bowel with adjacent fat.
C15.    -  Section of fat between both segments of adhered bowel.
C16.    -  Five possible lymph nodes.
C17.    -  Six possible lymph nodes.

Specimen D.  Received in formalin, labeled ""additional distal margin, stitch marks proximal end"" is a portion of large bowel (3.5 cm in length by 3 cm in diameter).  The proximal resection margin is stapled and the distal resection margin is left open.  The proximal resection margin is inked black and the distal resection margin is inked red.  The specimen is opened and appears grossly normal.  No masses or lesions are grossly identified.  Representative sections are submitted as follows:

Block summary:
D1.    -  Perpendicular sections of proximal resection margin.
D2.    -  Perpendicular sections of distal resection margin.","MicroscopicDescription:
A-D. The microscopic findings support the diagnoses.","A: Jejunum
B: Left colon- stitch marks proximal
C: Perforated sigmoid colon, adjacent adhesed transverse colon- clips mark distal end
D: Additional distal margin- stitch marks proximal",,
REG4,COLON,0,PAT-10036864,1,REC-3000671785,"ClinicalHistory:
Colon cancer.
Post-OperativeDiagnosis:
Pending Pathology.",,"PostOperativeDiagnosis:
Pending Pathology 
FinalDiagnosis:
Sigmoid colon, stitch at distal margin:  INVASIVE ADENOCARCINOMA
  
  Tumor Information:
  Type of specimen:    Resection
  Tumor location:      Sigmoid colon
  Tumor size:        2.1 cm in maximum dimension
  Histologic type:      Adenocarcinoma, polypoid
  Histologic grade:      Moderately differentiated
  Level of invasion:      Tumor invades submucosa (pT1)
  Lymphovascular invasion:  None
  Perineural invasion:    None
  Resection margins:      Negative
  Lymph node involvement:    No metastasis in seventeen nodes (0/17)
  Stage:          Stage I (pT1 pN0 cM0)      \X0A|",,"GrossDescription:
Received in fresh status labeled with the patient's name and ""sigmoid colon with stitch for distal margin"" is a segment of colon with a suture labeled at one side.  The colon measures 11.0 cm in length and 3.0 cm in circumference.  Upon opening there is a pedunculated polypoid mass at the distal portion of the colon, which measures 2.1 x 1.7 x1.0 cm, and the stalk measures 1.75 cm in length.  The tumor is about 2.0 cm away from the distal margin.  The rest of the colon is grossly unremarkable.  Dissection of pericolic soft tissue reveals multiple lymph nodes.  Representative sections submitted in 7 cassettes.

KEY TO CASSETTES:
1  -  Pedunculated tumor and distal margin
2-3  -  Tumor
4  -  Distal margin (inked black) and proximal margin (inked green)
5-7  -  Pericolic lymph nodes.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Sigmoid colon, stitch, distal margin",,
REG4,COLON,0,PAT-10038667,1,REC-3000671792,"ClinicalHistory:
Mass? (CA).",,"FinalDiagnosis:

Colon, 50 cm:      COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED, WITH FIBROPURULENT EXUDATE. (see comment).

Comment:  The findings of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jun 13 2012].\X0A|",,"GrossDescription:
Received in formalin labeled ""50 cm"" are two tan-pink and soft tissue fragments measuring up to 0.4 cm.  Entirely submitted in one cassette.","MicroscopicDescription:
Confirmed.",A: 50 cm,,
REG4,COLON,0,PAT-10039953,1,REC-3000671795,"ClinicalHistory:
Cecal polyp.",,"FinalDiagnosis:

Cecum, partial colectomy:    1.  COLONIC ADENOCARCINOMA, arising from a tubular adenoma,
               with submucosal invasion.
          2.  Ileocecal valve, proximal margin, distal resection and radial margin               negative for carcinoma.
          3.  Appendix, negative for carcinoma
          4.  Thirteen lymph nodes, negative for carcinoma (0/13).
Tumor Information:

Type of specimen(s):  Partial colectomy
Histologic type:  Adenocarcinoma
Histologic grade:  Moderate
Tumor site:  Cecum
Tumor size:  3.5 cm x 2.5 cm. x 1.3 cm  
Tumor configuration:  Polypoid
Extent of invasion:  Submucosa
Macroscopic tumor perforation:  No 
Lymph-vascular invasion:  No
Venous invasion:  No
Perineural invasion:  No
Discontinuous extramural extension:  No
Mucinous/signet ring/medullary pattern:  No
Resection margins:  
  Proximal:  1 cm
  Distal:  1.5 cm
  Circumferential/radial:  2 cm
Lymph node metastasis:  No (0/13)
Other findings:  See above
AJCC Pathologic Stage:  pT1, pN0, Mx
\X0A|",,"GrossDescription:
The specimen is received in formalin labeled ""cecum"" and consists of a segment of cecum measuring 6 x 3 x 3 cm, with an attached vermiform appendix measuring 4 x 0.5 x 0.5 cm.  The specimen is received opened, revealing a polypoid mass at the base of the cecum measuring 3.5 x 2.5 cm, which is raised approximately 1.3 cm above the mucosal surface.  The remainder of the cecal mucosa is brown-tan, smooth and grossly unremarkable, containing the usual rugal folding.  There is adipose tissue attached measuring approximately 5 x 1 x 1 cm.  The polypoid mass is located approximately 1 cm from the proximal resection margin and 1.5 cm from the distal resection margin.  The polypoid mass is located approximately 2 cm from the radial margin.  Upon further sectioning, the polypoid mass does not grossly invade the muscularis propria and is located superficial to and involves the ileocecal valve.  The polypoid mass does not appear to grossly involve the appendiceal orifice.  Sectioning the appendix reveals no gross abnormalities and a pinpoint lumen.  Representative sections are submitted for microscopic examination.

Summary of sections
1, 2  Polypoid mass, one contiguous piece
3, 4  Polypoid mass, one contiguous piece
5, 6  Polypoid mass, at the junction of the ileocecal valve, one contiguous piece (not a margin)
7  Proximal resection margin
8  Distal resection margin
9  Radial margin
10  Appendix
11  Two bisected lymph nodes (smaller lymph node is inked black, larger lymph node is uninked)
12  All possible lymph nodes.","MicroscopicDescription:
Confirmed.",A: Cecum,,
REG4,COLON,0,PAT-10040099,1,REC-3000671952,"ClinicalHistory:
Sigmoid colon tumor.",,"FinalDiagnosis:
SIGMOID COLON:  
- COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
- CARCINOMA ARISES FROM A VILLOUS ADENOMA WITH HIGH-GRADE DYSPLASIA.
- METASTATIC CARCINOMA TO ONE (1) OF 13 LYMPH NODES.

Colon cancer information
Operative procedure:  Sigmoidectomy.
Tumor-histologic type:  Adenocarcinoma.
Histologic grade:  Low-grade (moderately differentiated).
Anatomic site:  Sigmoid colon.
Size:  6.8 x 3.3 cm.
Depth of invasion:  pT3 - Tumor invades through the muscularis propria into pericolorectal tissues.
Perforation:  Not identified.
Crohn's-like lymphoid infiltrate:  Not identified.
Tumor infiltrating lymphocytes:  Not identified.
Pattern of growth at tumor periphery:  Infiltrative.
Perineural invasion:  Not identified.
Lymphatic invasion:  Not identified.
Venous invasion:  Not identified.
Resection margins:  Uninvolved by invasive carcinoma.
  Distance from margin 1:  2.7 cm. 
  Distance from margin 2:  1.6 cm.  
  Distance from mesenteric margin:  6.5 cm.  
Regional lymph nodes:  1/13 (pN1a).
Indications for mismatch repair protein (MMR) immunohistochemistry/microsatellite instability (MSI) testing:  Not identified.
Special procedures:  None.
Distant metastasis:  Not applicable.
Other findings:  None.
Pathologic grade and stage:  G2 pT3 pN1a (stage IIIB if M0).",,"GrossDescription:
Specimen:  Unoriented segment of sigmoid colon.  
Weight:  181 gm.  
Measurements:  
   Length:  7.6 cm.  
   Circumference:  7.5 cm.  
Appearance of serosa:  Unremarkable.  
Tumor
   Location: Sigmoid colon.  
   Appearance:  Tan-red, circumferential with raised edges.  
   Size:  6.8 x 3.3 cm.  
   Depth of invasion:  Into subserosal fat.  
   Distance from margin 1:  2.7 cm.  
   Distance from margin 2:  1.6 cm.  
   Distance from mesenteric margin:  6.5 cm.  
Appearance of uninvolved mucosa:  Unremarkable.  
Other findings:  None.  
Mesentery
   Lymph nodes:  Multiple mesenteric lymph nodes identified ranging from 0.2 cm to 1.0 
   cm.  
   Other findings:  None.
Description of blocks for microscopic evaluation:
1-2  shaved margins 1 and 2, respectively
3  mesenteric margin
4  tumor with uninvolved mucosa
5-8  tumor
9  uninvolved mucosa
10  two bisected mesenteric lymph nodes (larger inked green)
11-14  remaining mesenteric lymph nodes
15-20  mesenteric fat.",,A: SIGMOID COLON,,
REG4,COLON,0,PAT-10036478,2,REC-3000671966,"ClinicalHistory:
Diarrhea, history polyp.",,"FinalDiagnosis:
COLON, SIGMOID MASS, BIOPSY:
- POORLY DIFFERENTIATED MALIGNANCY (SEE COMMENT).
DiagnosisComment:
The tumor exhibits an epithelioid morphology and a non-specific immunophenotype (focal cytokeratin, EMA and DOG1 immunoreactivity).  The overall features are not those of a conventional colonic adenocarcinoma.  Though a primary colonic carcinoma remains a consideration, metastatic carcinoma and other non-epithelial malignancies (including GIST) are a consideration.  Case discussed with Dr. **NAME[ZZZ] on **DATE[Sep 12 2012] and **DATE[Sep 13 2012].

The following stains were performed in the evaluation of this case (see microscopic description for complete details): vimentin, cytokeratin 8/18, EMA, cytokeratin AE1/AE3, DOG1, CD45, S100, CDX2, cytokeratin 7, cytokeratin 20, ER, PR, GCDFP15, mammaglobin, PAX2, PAX8, WT1, CA125, p63, cytokeratin 5/6, CD138, CD43, TTF1, thyroglobulin, HMB45, melan-A, CD30, desmin, CD117, PASD.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
The biopsy consists of multiple fragments of colonic mucosa, some involved by a proliferation/infiltrate a poorly differentiated epithelioid cells.  In areas, a rhabdoid morphology is noted.  No associated in situ lesion (ie. adenoma) is identified.

Immunoreactivity is noted with vimentin and focal immunoreactivity is identified on cytokeratin 8/18, EMA, cytokeratin AE1/AE3 and DOG1 (weak) stained sections.  CD45, S100, CDX2, cytokeratin 7, cytokeratin 20, ER, PR, GCDFP15, mammaglobin, PAX2, PAX8, WT1, CA125, p63, cytokeratin 5/6, CD138, CD43, TTF1, thyroglobulin, HMB45, melan-A, CD30, desmin and CD117 are noted.  No intracytoplasmic mucin production is identified on a PAS stain following diastase digestion.",A: BIOPSY SIGMOID MASS,,
REG4,COLON,0,PAT-10041698,1,REC-3000672122,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->OTHER
*** COLON POLYP./r/n",,"FinalDiagnosis:
Colon: Intramucosal noninvasive adenocarcinoma arising within a tubular adenoma, margins free.

  25 lymph nodes negative for metastasis.

  Tubular adenoma.

Appendix: Mucosal hyperplasia with mucocele.

Terminal ileum: No significant histologic abnormality./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[Sep 14 12]. Step sections on blocks 8, 9, 12 and 13 examined./r/n",,"GrossDescription:
Labeled:        Patient name and medical record number, designated right colon
Specimen:      Terminal ileum and right colon (unopened, unfixed)
Size:        Terminal ileum: 7 cm in length, 6 cm in circumference
        Colon: 19 cm in length, 13 cm in circumference
Orientation:      None
Colors:
  Black:        Serosal and distal margin
  Blue:        Proximal and radial margins
Tumor:      
  Location:      Cecum
  Size:        7.2 x 3 x 0.6 cm
  Description:      Gray-tan, circumscribed, slightly elevated, focally lobulated
  Ulceration/perforation:      None
  Distance from margins:    7.5 cm from the proximal margin, 15 cm from the distal margin, and 4 cm from the radial margin
  Estimated depth of invasion:  No gross extension of tumor into the submucosa.
Other lesions:  2.2 x 0.6 x 0.2 cm slightly elevated light brown lesion in the cecum, about 1.2 cm from the large tumor and about 1.6 cm from the cecal pouch
Other findings:   3.7 x 0.5 x 0.5 cm grossly unremarkable appendix
Regional lymph nodes:    Several, up to 0.6 x 0.6 x 0.4 cm
Section code:    
  Block 1:      Proximal and distal margins
  Block 2:      Radial margin
  Blocks 3-11:      Tumor entirely
  Block 12:      Smaller elevated lesion adjacent to the larger tumor, entirely
  Block 13:      Appendix
  Blocks 14-19:      Lymph nodes
  Block 20:      Remainder  of appendix./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings. 

Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Cecum
Tumor Size: approximately 1.5 cm within a 7.2 x 3 x 0.6 cm tubular adenoma
Macroscopic Tumor Perforation: Absent
Histologic Type: Adenocarcinoma
Histologic Grade: Moderately differentiated
Microscopic Tumor Extension: Intramucosal carcinoma. No invasion of the submucosa is identified.
Margins:
  Proximal margin: Uninvolved
  Distal margin: Uninvolved
  Circumferential/radial margin: Uninvolved
  Distance of invasive carcinoma from closest margin: 4 cm from the radial margin
Treatment Effect (if applicable): Not applicable
Lymph-Vascular Invasion: Not identified
Perineural Invasion: Not identified
Tumor Deposits: Not identified
Pathologic Staging (pTNM):
  Primary tumor: pTis: Carcinoma in situ (no invasion)
  Regional lymph nodes: pN0
    Number examined: 25
    Number involved: 0
  Distant metastasis: Not applicable
Ancillary Studies: None./r/n","A: Right colon, excision",,
REG4,COLON,0,PAT-10041030,1,REC-3000672891,"ClinicalHistory:
Malignant neoplasm rectosigmoid junction.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:

Colectomy, ""sigmoid colon and anastomotic segment"":          PAS 9
  1.  MODERATELY DIFFERENTIATED INVASIVE ADENOCARCINOMA, EXTENDING THROUGH 
    MUSCULARIS PROPRIA INTO SUBSEROSAL SOFT TISSUE
  2.  Resection margins negative for carcinoma
  3.  Thirty-three lymph nodes, all negative for metastatic carcinoma (0/33)

Tumor Information:
Type of specimen(s):  Colectomy
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Sigmoid
Tumor size:  3.5 x 3 x 1.4 cm
Tumor configuration:  Exophytic
Extent of invasion:  Through muscular propria into subserosal soft tissue
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:  Negative
  Mucosal margin #1:  3.5 cm
  Mucosal margin #2:  2.5 cm
  Circumferential/radial:  1.5 cm
Lymph node metastasis:  Negative; Thirty-three nodes all negative for carcinoma (0/33)
AJCC Pathologic Stage:  pT3, pN0.
DiagnosisComment:
This case will be sent for routine intradepartmental consensus review.",,"GrossDescription:
Received in formalin, labeled ""sigmoid colon and anastomotic segment"" is a rectosigmoid segment (9 cm in length by 2 by 2.5 cm in diameter).  The specimen is unoriented.  One resection margin is stapled and inked red.  The other resection margin is left opened and inked black.  The mesenteric/radial resection margin is inked green.  The specimen was received partially opened.  A tan-red mass (3.5 x 3 x 1.4 cm) is found 3.5 cm away from the red inked resection margin, 2.5 cm away from the black inked resection margin and 1.5 cm away from the mesenteric/radial resection margin.  The mass grossly appears to penetrate through the muscularis propria.  The remainder of the specimen appears grossly uninvolved.  Representative sections are submitted as follows:

1  -  Perpendicular section of red inked resection margin
2  -  Perpendicular section of black inked resection margin
3  -  Perpendicular section of mesenteric/radial resection margin
4-6  -  Sections of closest approaching mass to mesenteric/radial resection margin
7-11  -  Sections of mass grossly appearing to penetrate through muscularis propria
12-13  -  Additional sections of mass
14  -  Section of grossly uninvolved bowel adjacent to mass, closest to red inked resection margin
15  -  Section of grossly uninvolved bowel adjacent to mass, closest to black inked resection margin
16  -  Six possible lymph nodes
17  -  Six possible lymph nodes
18  -  Six possible lymph nodes
19  -  Six possible lymph nodes
20  -  Six possible lymph nodes
21  -  Four possible lymph nodes.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Sigmoid colon and anastomotic segment,,
REG4,COLON,0,PAT-10013494,1,REC-3000672970,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->METASTATIC BRAIN TUMOR./r/n",,"IntraoperativeDiagnosis:
A.  Frozen Section: Metastatic carcinoma (BK)./r/nFinalDiagnosis:
A-C. Left parietal occipital and frontal brain: Metastatic adenocarcinoma consistent with colonic primary./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY]. Patient with history of colonic adenocarcinoma./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left parietal occipital brain tumor   Specimen:    Multiple, soft tan pieces of tissue (fresh)
  Aggregate:    0.9 x 0.9 x 0.4 cm (one piece of tissue is for frozen)
  Submitted/Blocks:  Entirely/2 (1 frozen section residue, 2 remainder tissue)

B.  Labeled:      Patient name and medical record number, designated left parietal occipital brain tumor   Specimen:    Multiple, gray-white to pink pieces of tissue (formalin)
  Aggregate:    3.5 x 2 x 1.8 cm
  Submitted/Blocks:  Representative/2

C.  Labeled:      Patient name and medical record number, designated left frontal brain tumor   Specimen:    Multiple, gray-white to pink pieces of tissue (formalin)
  Aggregate:    2.5 x 1.5 x 0.9 cm
  Submitted/Blocks:  Entirely larger 2 pieces section/2./r/n","MicroscopicDescription:
A-C.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left parieto-occipital brain tumor, excision (frozen)
B: Left parieto-occipital brain tumor, excision (permanent)
C: Left frontal tumor, excision (permanent)",,
REG4,COLON,0,PAT-10036869,1,REC-3000673005,"ClinicalHistory:
Rectal bleeding.
Post-OperativeDiagnosis:
Pending.",,"PostOperativeDiagnosis:
Pending.
FinalDiagnosis:
A.  Colon polyp at 50 cm:    Tubular adenoma

B.  Ascending colon polyp:    Tubular adenoma

C.  Cecal polyp:      Tubular adenoma

D.  Colon polyp at 30 cm:    Tubular adenoma

E.  Colon polyp at 25 cm:    TUBULAR ADENOMA WITH FOCAL HIGH GRADE DYSPLASIA

F.  Rectal polyp:      Tubular adenoma

G.  Polyp at 15 cm:      MODERATELY-DIFFERENTIATED ADENOCARCINOMA ARISING IN A 
          TUBULAR ADENOMA.
DiagnosisComment:
Dr. **NAME[ZZZ] notified on **DATE[Feb 22 12] at 0910 hrs.   The stalk margin of the polyp at 15 cm could not be well visualized.  Dr. **NAME[YYY XXX] concurs with the diagnosis of adenocarcinoma.  

Specimen signed out at **INSTITUTION **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.",,"GrossDescription:
A.  Received in Excell labeled ""XXXXXX, colon polyp 5.0 cm"" are four pieces of tan tissue measuring up to 0.4 x 0.2 x 0.1 cm in 
  greatest dimension.  The larger specimens are bisected, and submitted in toto in one cassette.

B.  Received in Excell labeled ""XXXXXX, ascending colon polyp"" is a piece of tan tissue measuring 0.2 x 0.2 x 0.2 cm in greatest 
  dimension.  Submitted in toto in one cassette.

C.  Received in Excell labeled ""XXXXXX, cecum polyp"" are multiple pieces of tan tissue measuring up to 0.4 x 0.3 x 0.2 cm in 
  greatest dimension.  The larger specimen is bisected, and submitted in toto in one cassette.

D.  Received in Excell labeled ""XXXXXX, colon polyp 30 cm"" is a nodular piece of tan tissue measuring up to 1.5 x 0.9 x 0.4 cm in greatest dimension.  The specimen is sectioned, and submitted in toto in one cassette.

E.  Received in Excell labeled ""XXXXXX, colon polyp 25 cm"" are two nodular pieces of tan tissue measuring up to 1.5 x 1.2 x 0.9 
  cm in greatest dimension.  Specimens are sectioned, and submitted in toto in two cassettes.

F.  Received in Excell labeled ""XXXXXX, rectal polyp"" are multiple pieces of tan tissue measuring up to 0.6 x 0.6 x 0.4 cm in 
  greatest dimension.  The larger specimens are bisected and submitted in toto in one cassette.

G.  Received in Excell labeled ""XXXXXX, 15 cm polyp"" are two nodular pieces of tan tissue measuring up to 1.5 x 1.4 x 0.9 cm in 
  greatest dimensions.  Specimens are sectioned, and submitted in toto in two cassettes.","MicroscopicDescription:
A-G.  The microscopic findings support the above diagnoses.","A: Colon polyp, 50 cm
B: Colon polyp, ascending
C: Cecum polyp
D: Colon polyp, 30 cm
E: Colon polyp, 25 cm
F: Rectum, polyp
G: Colon polyp, 15 cm",,
REG4,COLON,0,PAT-10038803,1,REC-3000673007,"ClinicalHistory:
Colon cancer.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A.  Right colon mesentery:  Benign lymph node

B.  Colon segment:    Moderately differentiated mucinous adenocarcinoma

Tumor Information:

Type of specimen(s):  Terminal ileum and cecum
Histologic type:  Mucinous adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Cecum
Tumor size:  6.5 x 6.0 x 1.7 cm
Tumor configuration:  Endophytic
Extent of invasion:  Through muscularis propria
Macroscopic tumor perforation:  Absent
Lymph-vascular invasion:  Absent
Venous invasion:  Absent
    Intramural:  Absent
    Extramural:  Absent
Perineural invasion:  Absent
Discontinuous extramural extension:  Present
Marked lymphocytic response:
    Intratumoral (tumor infiltrating):  Absent
    Peritumoral (Crohn-like):  Present, focal
Mucinous/signet ring/medullary pattern:  Mucinous patter present
Neoadjuvant treatment effect:  Absent
Resection margins:  Clear
    Proximal:  9.1 cm
    Distal:  21.2 cm
    Circumferential/radial:  Clear
    Mesenteric:  Clear
Lymph node metastasis:
    Total nodes:  7 out of 19 mesenteric nodes
    Largest nodal metastatic focus:  2.2 cm
    Nodes with Isolated Tumor Cells
        (ITC) only (< 0.2 mm):  0 nodes
    Nodes with micrometastases
        (> 0.2 mm, < 2.0 mm):  2 nodes
    Nodes with metastases > 2.0 mm:  5 nodes
Other findings:  Unremarkable appendix
AJCC Pathologic Stage:  pT3, pN2b, cM0
  Pathologic stage:  IIIC

C.  Omentum:                              Congestion and hemorrhages

D.  Terminal ileum segment:      1.  No evidence of malignancy
                                              2,  4 benign lymph nodes.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right colon mesentery"" is soft tan tissue, <1.0 gm, 1.4 x 1.3 x 0.3 cm.  

Sectioning reveals firm, hard, white nodules, largest up to 0.5 cm in greatest dimension.  Submitted entirely in one cassette.

B.  Received unfixed, unopened is a segment of bowel, unoriented, 34.1 cm in length x 3.1 cm in circumference at the proximal margin (inked orange), and 5.0 cm in circumference at the distal margin (inked green).  There is a portion of terminal ileum, up to 9.1 cm in length.  There is an appendix 5.9 x 0.7 x 0.6 cm.  The appendix is grossly unremarkable.

There is a firm, hard tan to white mass, with rolled borders and a central area of necrosis, at the ileocecal valve, 9.1 cm from 
the proximal (orange) margin, and 21.2 cm from the distal margin (green).  The mass is 6.5 x 6.0 x 1.7 cm.  The serosal surface 
overlying the mass is inked blue.  The mass appears to involve the muscularis propria.  There is serosal retraction.  

The remaining portion of bowel shows grossly unremarkable mucosa, with no areas of perforation, ulceration, diverticula, 
polyps or masses.  

Multiple lymph nodes are identified, largest up to 4.4 cm.  The largest apparent lymph node contains a suture.  

Representative sections are submitted in # cassettes as follows:

KEY TO CASSETTES:
B1  -  Proximal margin (orange)
B2  -  Distal margin (green)
B3-B6  -  Representative of mass described above
B7  -  Appendix
B8  -  Uninvolved mucosa
B9-B15  -  Lymph nodes, with B9 representative of largest lymph node described above

C.  Received unfixed labeled ""XXXXXX, omentum"" is a segment of soft tan to yellow tissue, 19.3 x 6.4 x 1.1 cm.  

Sectioning reveals no identifiable lesions.  Representative sections are submitted in 18 cassettes.

D.  Received in formalin labeled ""XXXXXX, terminal ileum, suture on lymph nodes"" is an unoriented, unopened segment of bowel, 
  8.3 cm in length x 4.1 cm in circumference at one margin (inked green) and 3.0 cm in circumference at the remaining margin 
  (inked orange).  

The bowel is opened revealing grossly unremarkable tan mucosa with no areas of ulcerations, perforations, diverticulum, 
polyps, or masses.  There is a suture indicating lymph nodes, largest up to 0.6 cm in greatest dimension.  

Representative sections are submitted in 7 cassettes as follows:

KEY TO CASSETTES:
D1      -  Green margin
D2      -  Orange margin
D3      -  Representative of mucosa
D4-D7    -  Possible lymph nodes and mesentery.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Right colon mesentary
B: Right colon
C: Omentum
D: Terminal ileum, suture on lymph nodes",,
REG4,COLON,0,PAT-10039616,2,REC-3000673010,"ClinicalHistory:

Mesenteric mass.
Post-OperativeDiagnosis:
Pending.",,"PostOperativeDiagnosis:
Pending.
FinalDiagnosis:
A.  Soft tissue, excision, clinically mesenteric nodule:
    1.  Metastatic well differentiated neuroendocrine carcinoma
    2.  No underlying lymph node identified

B.  Soft tissue, excision, clinically peritoneal clot:
    1.  Organizing blood clot
    2.  No neuroendocrine carcinoma seen

C.  Segment of small intestine, resection:
    1.  Well differentiated neuroendocrine carcinoma, multifocal (greater than 20 foci)
    2.  Metastasis to the mesentery, peritoneal surface, and 3 out of 3 identifiable lymph nodes
    3.  No involvement of the small intestinal resection margins seen

D.  Appendix and mass, resection:
    1.  Well differentiated neuroendocrine carcinoma
    2.  No involvement of the proximal appendiceal margin seen

Tumor Information:
Type of specimen:  Excision of mesenteric nodule (A); excision of peritoneal clot (B); resection of segment of small intestine (C); resection of appendix (D) 
Specimen Integrity:  Not applicable
Histologic type:  Well differentiated neuroendocrine carcinoma
Histologic grade:  Low grade malignant potential
Tumor location:  Multiple tumors (greater than 20) arising in the small intestine; one tumor arising in the appendix.
Tumor size:  1.  Small intestinal tumors ranging from 0.3 cm to 6.0 x 4.2 x 4.0 cm.
  2.  Appendix tumor measuring 2.0 x 2.0 x 1.5 cm
Extent of invasion:  1.  Small intestine tumor invades through the muscularis propria without serosal penetration.
  2.  Appendiceal tumor invades through the appendiceal muscularis propria with serosal penetration.
Lymphvascular invasion:  Present
Perineural invasion:  Present
Mitotic count:  Less than 1 mitosis/10 hpf
Ki-67 labeling:  Less than 1%
Resection margins:  No involvement of the proximal/distal small intestinal margin or the proximal appendiceal margin, however because of the degree of multifocality and the presence of mesenteric/peritoneal metastasis, the presence of residual tumor cannot be excluded.
Lymph node metastasis:  3 out of 3 identifiable small intestine mesenteric lymph nodes.
Other findings:  Immunohistochemical stains on the previous abdominal FNA specimen (**DATE[Apr 06 2012], ***PATH-NUMBER[1]) showed that the tumor was positive for synaptophysin, chromogranin, and CD56, consistent with neuroendocrine origin.
AJCC Pathologic Stage:  Small intestine tumors:  pT3, pN1, pM1
  Appendix tumor:    pT1b, pNX, pM1                  Pathologic stage:  IV.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, mesenteric nodule"" is a soft, tan-white piece of tissue measuring up to 0.9 x 0.6 x 0.3 cm in greatest dimension.  The specimen is inked black and trisected.  Submitted entirely in one cassette.  

B.  Received in formalin labeled ""XXXXXX, peritoneal clot"" is a soft, dark red-brown piece of irregular tissue measuring up to 2.7 x 3.2 x 1.0 cm in greatest dimensions.  The specimens are inked black and submitted entirely in cassettes B1-B3.

C.  Received fresh labeled ""XXXXXX, small bowel"" is an unoriented segment of pink-tan intestinal tissue measuring up to 42.0 cm in length x 5.5 cm in greatest diameter.  One end is inked blue and the opposite end is inked orange.  Within the mesentery of the specimen is a mass measuring up to 6.0 x 4.2 x 4.0 cm.  The mass lesion is 9.0 cm away from the blue end and 24.0 cm away from the orange end.  The surface of the largest mass is inked black and the specimen is serially sectioned.  The cut surface appears fleshy and peach in color.  There appear to be focal areas of hemorrhage.  4.0 cm away from the mass, in the direction of the orange margin, is a second mass measuring up to 3.5 cm.  The cut surface of the second mass is white and well-circumscribed.  10.0 cm away from the second mass is a third mass, in the direction of the blue margin, measuring up to 1.2 cm.  The cut surface of the third mass is white and well-circumscribed.  There are numerous smaller nodules below the mucosal lining of the entire specimen.  These nodules number up to greater than 20.  No lymph nodes are identified.  One nodule is present on the mesentery surface, measuring up to 0.3 cm in greatest dimension.  

  Key to Cassettes:
  C1  -  Blue margin
  C2  -  Orange margin
  C3-C4  -  Largest mass, with sections of the small bowel
  C5-C9  -  Random representative sections of the largest mass
  C10-C12  -  Representative sections of the second largest mass
  C13-C14  -  Third largest mass, submitted entirely
  C15-C19  -  Random representative sections of the smaller nodules
  C20  -  Nodule present on the mesentery, submitted entirely

D.  Received in formalin labeled ""XXXXXX, appendix with mass"" is an appendix measuring 3.5 cm in length x1.3 cm in greatest diameter.  At the distal tip there is a white, well circumscribed mass measuring up to 2.0 x 2.0 x 1.5 cm in greatest dimension.  The proximal end in inked black, and the mass at the distal rip is inked blue.  The specimen is serially sectioned, and submitted entirely in cassettes D1-D9, beginning with the most proximal  in cassette D1.","MicroscopicDescription:
A-D.  The microscopic findings support the above diagnosis.

Note:  Discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 21 2012], 0905 hrs.","A: Mesenteric nodule
B: Peritoneal clot
C: Small bowel
D: Appendix with mass",,
REG4,COLON,0,PAT-01355189,1,REC-3000673275,"ClinicalHistory:
197.0
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Met Colon Ca to Main Bronchi; Y stent in place; tissue at distal LMS limb of stent ? CA vs granulation tissue./r/n",,"FinalDiagnosis:
Bronchus, LMS: Bronchial mucosa with squamous metaplasia and underlying granulation tissue. No malignancy identified./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated bronchus per requisition Specimen:    Two, pale gray irregular pieces of tissue (formalin)
Aggregate:    0.4 x 0.2 x 0.2 cm
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Bronchus LMS, biopsy",,
REG4,COLON,0,PAT-10038803,1,REC-3000675917,"ClinicalHistory:
Colon cancer.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A.  Right colon mesentery:  Benign lymph node

B.  Colon segment:    Moderately differentiated mucinous adenocarcinoma

Tumor Information:

Type of specimen(s):  Terminal ileum and cecum
Histologic type:  Mucinous adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Cecum
Tumor size:  6.5 x 6.0 x 1.7 cm
Tumor configuration:  Endophytic
Extent of invasion:  Through muscularis propria
Macroscopic tumor perforation:  Absent
Lymph-vascular invasion:  Absent
Venous invasion:  Absent
    Intramural:  Absent
    Extramural:  Absent
Perineural invasion:  Absent
Discontinuous extramural extension:  Present
Marked lymphocytic response:
    Intratumoral (tumor infiltrating):  Absent
    Peritumoral (Crohn-like):  Present, focal
Mucinous/signet ring/medullary pattern:  Mucinous patter present
Neoadjuvant treatment effect:  Absent
Resection margins:  Clear
    Proximal:  9.1 cm
    Distal:  21.2 cm
    Circumferential/radial:  Clear
    Mesenteric:  Clear
Lymph node metastasis:
    Total nodes:  7 out of 19 mesenteric nodes
    Largest nodal metastatic focus:  2.2 cm
    Nodes with Isolated Tumor Cells
        (ITC) only (< 0.2 mm):  0 nodes
    Nodes with micrometastases
        (> 0.2 mm, < 2.0 mm):  2 nodes
    Nodes with metastases > 2.0 mm:  5 nodes
Other findings:  Unremarkable appendix
AJCC Pathologic Stage:  pT3, pN2b, cM0
  Pathologic stage:  IIIC

C.  Omentum:                              Congestion and hemorrhages

D.  Terminal ileum segment:      1.  No evidence of malignancy
                                              2,  4 benign lymph nodes.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right colon mesentery"" is soft tan tissue, <1.0 gm, 1.4 x 1.3 x 0.3 cm.  

Sectioning reveals firm, hard, white nodules, largest up to 0.5 cm in greatest dimension.  Submitted entirely in one cassette.

B.  Received unfixed, unopened is a segment of bowel, unoriented, 34.1 cm in length x 3.1 cm in circumference at the proximal margin (inked orange), and 5.0 cm in circumference at the distal margin (inked green).  There is a portion of terminal ileum, up to 9.1 cm in length.  There is an appendix 5.9 x 0.7 x 0.6 cm.  The appendix is grossly unremarkable.

There is a firm, hard tan to white mass, with rolled borders and a central area of necrosis, at the ileocecal valve, 9.1 cm from 
the proximal (orange) margin, and 21.2 cm from the distal margin (green).  The mass is 6.5 x 6.0 x 1.7 cm.  The serosal surface 
overlying the mass is inked blue.  The mass appears to involve the muscularis propria.  There is serosal retraction.  

The remaining portion of bowel shows grossly unremarkable mucosa, with no areas of perforation, ulceration, diverticula, 
polyps or masses.  

Multiple lymph nodes are identified, largest up to 4.4 cm.  The largest apparent lymph node contains a suture.  

Representative sections are submitted in # cassettes as follows:

KEY TO CASSETTES:
B1  -  Proximal margin (orange)
B2  -  Distal margin (green)
B3-B6  -  Representative of mass described above
B7  -  Appendix
B8  -  Uninvolved mucosa
B9-B15  -  Lymph nodes, with B9 representative of largest lymph node described above

C.  Received unfixed labeled ""XXXXXX, omentum"" is a segment of soft tan to yellow tissue, 19.3 x 6.4 x 1.1 cm.  

Sectioning reveals no identifiable lesions.  Representative sections are submitted in 18 cassettes.

D.  Received in formalin labeled ""XXXXXX, terminal ileum, suture on lymph nodes"" is an unoriented, unopened segment of bowel, 
  8.3 cm in length x 4.1 cm in circumference at one margin (inked green) and 3.0 cm in circumference at the remaining margin 
  (inked orange).  

The bowel is opened revealing grossly unremarkable tan mucosa with no areas of ulcerations, perforations, diverticulum, 
polyps, or masses.  There is a suture indicating lymph nodes, largest up to 0.6 cm in greatest dimension.  

Representative sections are submitted in 7 cassettes as follows:

KEY TO CASSETTES:
D1      -  Green margin
D2      -  Orange margin
D3      -  Representative of mucosa
D4-D7    -  Possible lymph nodes and mesentery.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Right colon mesentary
B: Right colon
C: Omentum
D: Terminal ileum, suture on lymph nodes",,
REG4,COLON,0,PAT-10030090,1,REC-3000676224,"ClinicalHistory:

Colon cancer with liver lesion
Previous biopsy
[***PATH-NUMBER[1] **DATE[Sep 7 2012] - Liver FNA: Metastatic adenocarcinoma
[***PATH-NUMBER[2] **DATE[Sep 13 2011] - Descending and upper sigmoid colon: Invasive adenocarcinoma, moderately-differentiated, extending into pericolic fat, margins free of tumor.
Post-OperativeDiagnosis:
Pending final pathology report.",,"PostOperativeDiagnosis:
Pending final pathology report.
IntraoperativeDiagnosis:
A. Frozen Section Interpretation:  Segment 4 - liver mass:  Margin negative for tumor/DG
B. Frozen Section Interpretation:  Proximal margin:    Negative for tumor/DG
C. Intraoperative Gross Interpretation:  Partial right hepatectomy margins:  Margin negative for malignancy/DG.
FinalDiagnosis:
A.  Liver, segment #4, resection:      1. METASTATIC ADENOCARCINOMA compatible 
                  With colorectal primary (see comment)
              2. Tumor size: 2.2 x 1.7 x 1.0 cm
              3. Resection margin free of tumor (0.3 cm clearance)

B.  Liver, proximal margin, biopsy:      Benign fibrous, vascular, and neural tissue

C.  Liver, right partial hepatectomy:      1. METASTATIC ADENOCARCINOMA compatible 
                  With colorectal primary (see comment)
              2. Tumor size: 1.8 x 1.6 x 1.5 cm
              3. Resection margin free of tumor (0.3 cm clearance)

D.  Gallbladder and contents, cholecystectomy:  1. Chronic cholecystitis and mucosa denudation
              2. No tumor seen.
DiagnosisComment:
The tumor cells in parts A and C are morphologically identical.  Immunohistochemical stains performed on part A show that the tumor cells are positive for CK20 and CDX-2 while negative for CK7.  The morphology and immunoprofile is compatible with a metastatic colorectal adenocarcinoma.  Dr. **NAME[ZZZ YYY] concurs with the diagnoses.",,"GrossDescription:
A.  Received fresh for intraoperative frozen section labeled ""XXXXXX, segment #4 liver mass"" is soft tan tissue, 5.4 x 2.2 x 2.1 cm.  The surgical margin is inked green.  Sectioning reveals a firm, white to tan nodule, up to 2.2 x 1.7 x .0 cm, 0.4 cm from the nearest inked margin.  Representative sections are submitted in 7 cassettes as follows:  A1 as frozen section, A2-A5 nodule, submitted entirely, serially, A6-A7 representative of remainder of the specimen.

B.  Received fresh for intraoperative frozen section labeled ""XXXXXX, proximal margin"" is soft tan tissue, 0.4 x 0.2 x 0.3 cm.  Submitted entirely in one cassette after frozen section, with B as frozen section.

C.  Received fresh for intraoperative frozen section labeled ""XXXXXX, partial right hepatectomy margins"" is soft tan tissue, 6.5 x 4.8 x 2.9 cm.  The surgical margin is inked black.  Sectioning reveals a firm, white to tan nodule, up to 1.8 x 1.6 x 1.5 cm, 0.4 cm from the nearest inked margin.  Representative sections are submitted in 7 cassettes after gross examination as follows:  C1-C6 nodule, C7 representative sections from the remainder of the specimen.

D.  Received in formalin labeled ""XXXXXX, gallbladder and contents is an unopened, unoriented tan gallbladder, 7.6 cm in length x 3.1 cm in diameter.  The serosa is tan, smooth.  The wall measures 0.3 cm in thickness and is slightly edematous.  The mucosa is velvety, gold to light yellow.  No stones are grossly identified.   There is 30 cc of viscous dark green to brown sludge.  Representative sections are submitted in one cassette.","MicroscopicDescription:
A-D.   The microscopic findings support the above diagnoses.","A: Segment #4 - liver mass
B: Proximal margin - liver
C: Partial right hepatectomy margins for FS
D: Gallbladder and contents",,
REG4,COLON,0,PAT-01521012,2,REC-3000676331,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->COLON CANCER./r/n",,"FinalDiagnosis:
Colon, right and transverse colon: Low grade adenocarcinoma with invasion through the muscularis propria into pericolic tissues, margins are free (see complete below).

  Incidental appendectomy./r/nDiagnosisComment:
Case discussed with Dr. **NAME[ZZZ] on **DATE[Oct 27 11].  Additional blocks will be submitted to evaluate for more nodes showed no additional lymph nodes.  But deeper sections of block 17 revealed 1 additional lymph node negative for tumor thus bringing the total number of lymph nodes to 10./r/n",,"GrossDescription:
Labeled:        Patient name and medical record number, designated right and transverse colon
Specimen:      Right and transverse colon with attached terminal ileum and appendix
Size:        Terminal ileum - 5 cm in length, 3 cm in circumference
        Colon - 34 cm in length, 5-8 cm in circumference
        Appendix - 5.5 cm, 0.5 cm diameter appears unremarkable
Tumor:      
  Location:      Splenic flexure
  Size:        1.5 x 1.5 x 0.5 cm
  Description:      Crater-like lesion with elevated edge and possible ulcer centrally
  Perforation:        Absent
  Distance from margins:      5.5 cm from distal margin, 32 cm from proximal margin, 6 cm from radial margin
  Estimated depth of invasion:  Through muscularis propria into pericolonic fat
Other lesions:      Three, polyps at right colon measuring up to 0.9 x 0.5 x 0.4 cm
Regional lymph nodes:    Multiple minute lymph nodes measuring up to 0.4 cm
Section code:    
  Block 1:      Proximal margin (terminal ileum)
  Block 2:      Distal margin (transverse colon)
  Block 3:      Radial margin
  Blocks 4-6:      Tumor
  Block 7:      Bisected three polyps (inked different color)
  Block 8:      Uninvolved mucosa
  Block 9:      Appendix
  Blocks 10-11:      Multiple minute lymph nodes within 3 cm from tumor
  Blocks 12-13:      Pericolonic fat within 3 cm from tumor
  Block 14:      Possible four lymph nodes
  Block 15-18:      Additional pericolonic fat within 3 cm from tumor
  Block 19:      Additional lymph nodes more than 3 cm from tumor
  Block 20-35:      Additional pericolonic fat more than 3 cm from tumor./r/n","MicroscopicDescription:
Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Splenic flexure 
Tumor Size: 1.5 x 1.5 x 0.5 cm
Macroscopic Tumor Perforation: Not identified
Histologic Type: Adenocarcinoma
Histologic Grade: Low grade
Microscopic Tumor Extension: Tumor invades through the muscularis propria into the subserosal adipose tissue but does not extend to the serosal surface
Margins:
  Proximal margin: Uninvolved by invasive carcinoma
  Distal margin: Uninvolved by invasive carcinoma
  Circumferential/radial margin: Uninvolved by invasive carcinoma
  Distance of invasive carcinoma from closest margin: 5.5 cm from the distal margin
Treatment Effect (if applicable): No prior treatment
Lymph-Vascular Invasion: Not identified
Perineural Invasion: Not identified
Tumor Deposits: Not identified
Pathologic Staging (pTNM):
  Primary tumor: pT3
  Regional lymph nodes: pN0
    Number examined: 10 (see comment)
    Number involved: 0
  Distant metastasis: No applicable
Other: Incidental appendectomy./r/n","A: Right and transverse colon, excision",,
REG4,COLON,0,PAT-10039770,1,REC-3000676373,"ClinicalHistory:
Colon cancer.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Partial colectomy.",,"PreOperativeDiagnosis:
Partial colectomy.
PostOperativeDiagnosis:
Same, Pending pathology.
IntraoperativeDiagnosis:
A.  Gross Only:     Margins free; closest margin 4.0 cm clearance/MP
B.  Frozen Section:      Sessile hyperplastic polyp/MP.
FinalDiagnosis:
A, C.  SIGMOID COLON ADENOCARCINOMA
Tumor information:
Type of specimen:      Sigmoid colon resection; donuts
Tumor location:      Sigmoid colon
Tumor size:        4.0 x 2.5 x 1.3 cm
Histologic type:      Adenocarcinoma 
Histologic grade:      Moderately-differentiated 
Level of invasion:      Muscularis propria
Peritoneal involvement:    Not evident
Lymphovascular invasion:    Not evident 
Perineural invasion:      Not evident
Invasion of contiguous structures:  Not evident
Resection margins:      Free of carcinoma (>4.0 cm minimum clearance)
Lymph node involvement:    Negative for metastasis (0/15)
Mesenteric involvement:    Not evident
Stage:          pT2 N0

B.  Polyp, cecum, excision:    Sessile hyperplastic polyp 

D.  Appendix, appendectomy:    Appendix, negative for acute inflammation 

E.  Cecum, staple line resection:  Small (0.3 cm) adenomatous polyp.",,"GrossDescription:
A.  Received fresh for intraoperative consultation, labeled ""sigmoid colon,"" is a resected segment of tan-pink intestinal tissue measuring 15.5 cm in length x 3.0 cm average outside diameter.  One margin is received stapled.  The serosal surface is smooth and tan-pink, with a retracted area on the antimesenteric side, measuring 1.3 cm in greatest dimension.  Opening reveals a tan-pink mucosa with a tan-pink to red lesion measuring 4.0 x 2.5 x 1.3 cm, located 4.0 cm from the stapled margin, >7.0 cm from the open margin.  Sectioning through the lesion reveals gross invasion of the muscle layer with no gross invasion of the surrounding fat.  No further masses or lesions are grossly identified.  Representative sections are submitted in blocks A1-A14.  

  SECTION SUMMARY:
  A1  -  Stapled margin
  A2  -  Open margin  
  A3-A6  -  Sections through lesion
  A7-A10  -  Lymph nodes
  A11-A14-  Additional node dissection

B.  Received fresh for intraoperative consultation, labeled ""cecal polyp,"" is an excision of tan-pink soft tissue measuring 1.4 x 10 x 0.3 cm.  The specimen is submitted for a frozen section and subsequently submitted in block B.

C.  Received in formalin labeled ""colon donuts"" are two ring-shaped fragments of tan-pink intestinal tissue measuring, in aggregate, 2.4 x 2.2 x 2.2 cm. Representative sections are submitted in blocks C1-C2.

D.  Received in formalin labeled ""appendix"" is a tan-pink appendix measuring 5.3 cm in length x 0.7 cm average outside diameter.  The serosal surface is smooth and tan-pink.  Sectioning reveals a constricted lumen and grossly normal mucosa.  Representative sections are submitted in block D.

E.  Received in formalin labeled ""cecum staple line"" is a segment of tan-pink intestinal tissue measuring 3.5 x 1.1 x 1.1 cm.  There is a suture line seen along the long axis of the specimen.  A representative section is submitted in block E.","MicroscopicDescription:
A.  Proximal and distal margins are free of carcinoma.  The mucosal mass is an invasive, moderately-differentiated adenocarcinoma invading into, but not through, the muscularis propria.  Some nests of tumor exhibit surrounding retraction artifact, but distinct lymphovascular invasion is not identified.  Initial dissection demonstrates only eight small lymph nodes/lymphoid aggregates, all negative for metastasis.  Additional dissection for nodes demonstrates seven additional nodes, all negative for metastasis, for a total of 15 nodes, all negative for metastasis. 

B.  Sections of colonic mucosa and submucosa demonstrate a sessile hyperplastic polyp.  Margins of the mucosal resection appear free of polyp.  There is moderate chronic inflammation with scattered reactive lymphoid aggregates.  

C.  Sections of donuts demonstrate benign colonic mucosa.  

D.  Sections of appendix are free of acute inflammation.  

E.  Sections of colon exhibit a small, 0.3 cm adenomatous polyp.","A: Sigmoid colon
B: Cecal polyp
C: Colon donuts
D: Appendix
E: Cecum staple line",,
REG4,COLON,0,PAT-10041758,1,REC-3000677958,"ClinicalHistory:
Right colon tumor.
Pre-OperativeDiagnosis:
Open right colon placement of central line.",,"PreOperativeDiagnosis:
Open right colon placement of central line.
FinalDiagnosis:
Right colon, segmental resection:  ADENOCARCINOMA
  
  Tumor information:
  Tumor site:      Right colon
  Tumor type:      Adenocarcinoma
  Tumor grade:      Poorly-differentiated
  Tumor size:      12.0 cm
  Depth of invasion:    Tumor invades through muscularis propria into pericolonic fat, but 
          does not extend to serosal surface (T3) (see Comment)
  Satellite tumor deposits:  None
  Margins of resection:    Proximal and distal margins of resection widely free of tumor (7.0 and 
          8.0 cm)
  Lymph nodes:      1 of 17 lymph nodes positive for metastatic neoplasm 
  Surrounding colonic tissue:  Tubular adenomas x2
  Preliminary AJCC staging:  T3 N1a Mx.
DiagnosisComment:
Although reactive changes are identified, no extension of tumor to serosal surface is identified and no extension of tumor into omental fat is identified.  KRAS is pending.",,"GrossDescription:
Received labeled ""XXXXXX, right colon"" consists of a 24.0 cm long segment of colon with a central apple core mass.  The mass measures 12.0 x 7.0 x 2.6 cm and extends through the muscularis propria near the serosal surface and possibly into omental fat.  The margins are grossly free of tumor (7 and 8 cm, respectively (proximal and distal)).  Two polyps are identified arising within normal mucosa measuring 2.0 and 6.0 mm in maximum dimension.  

KEY TO CASSETTES:
1-5  -  Sections of firm pericolonic fat and tumor 
6-7  -  Representative sections of tumor 
8  -  Polyps
9-10  -  Proximal and distal margins of resection
11-16  -  Lymph nodes.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right colon,,"AddendumComment:
Please see the attached Clarient KRAS and BRAF Mutation Analysis reports for results of testing (***PATH-NUMBER[1]; **DATE[Jan 25 12] and ***PATH-NUMBER[2]; **DATE[Jan 23 12]).

Focal lymphovascular invasion is identified, no perineural invasion is present."
REG4,COLON,0,PAT-10030122,1,REC-3000678002,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->Colon polyps./r/n",,"FinalDiagnosis:
Colon, right colon: Intramucosal adenocarcinoma arising in a tubular adenoma, margins free.

Pericolic lymph nodes: Negative for metastasis (0/24)./r/n",,"GrossDescription:
Labeled:      patient name and medical record number, designated right colon
Specimen:    short segment of terminal ileum and right colon (unopened, unfixed)
Size:      terminal ileum:  2 cm in length, 5 cm in circumference
      right colon:  25 cm in length, 10 cm in circumference
Orientation:    not given
Colors:
  Black:      proximal and serosal margins
  Blue:      distal and radial margins
Tumor:      
  Location:    right colon
  Size:      2.5 x 1.6 x 1 cm
  Description:    Focally firm, lobulated, tan sessile lesion.
  Ulceration/perforation:    none
  Distance from margins:    21 cm from the proximal margin, 5.5 cm from the distal margin, and 4 cm from the medial margin
  Estimated depth of invasion:  The tumor appears to be confined to the mucosa.
Other lesions:  0.5 x 0.4 x 0.2 cm pale gray, sessile mucosal bump about 6 cm from the distal margin; a 
0.6 x 0.5 x 0.4 cm lobulated, elevated, pale gray polyp located about 4.5 cm from the cecal pouch; 
1.3 x 1 x 0.5 cm yellow-gray elevated mucosal bump located about 7 cm from the proximal margin.
Regional lymph nodes:  several, up to 0.6 x 0.6 x 0.5 cm
Section code:    
  Block 1:    proximal and distal margins
  Block 2:    radial margin
  Blocks 3-6:    entire lobulated sessile lesion
  Block 7:    sessile submucosal bump 6 cm from the distal margin
  Block 8:    lobulated pale gray polyp 4.5 cm from the cecal pouch
  Block 9:    elevated yellow-gray mucosal bump 7 cm from the proximal margin
  Block 10:    random mucosa
  Blocks 11-14:    lymph nodes./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right colon, excision",,"AddendumDiagnosis:
Right Colon Tissue ***PATH-NUMBER[1]:  Microsatellite Stable

BAT-26:StableNR-21:StableBAT-25:StableMONO-27:StableNR-24:Stable./r/nAddendumComment:
Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Right colon
Tumor Size: 2.5cm
Macroscopic Tumor Perforation: Not identified
Histologic Type: Adenocarcinoma
Histologic Grade: Low grade, well-differentiated
Microscopic Tumor Extension: Confined to the mucosa
Margins:
  Proximal margin: Free of tumor
  Distal margin: Free of tumor
  Circumferential/radial margin: Free of tumor
  Distance of invasive carcinoma from closest margin: 4cm from the radial margin
Treatment Effect (if applicable): NA
Lymph-Vascular Invasion: Absent
Perineural Invasion: Absent
Tumor Deposits: Absent
Pathologic Staging (pTNM):
  Primary tumor: pTis (carcinoma in situ)
  Regional lymph nodes: pN0
    Number examined: 24
    Number involved: None
  Distant metastasis: NA
Ancillary Studies: NA./r/n
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA and reported by **NAME[ZZZ YYY], M.D. on **DATE[Aug 4 2012].   

Microsatellite Instability PCR

Comment:  This tumor showed no evidence of microsatellite instability by PCR.  It is unlikely that this patient has Lynch syndrome (hereditary non-polyposis colorectal cancer, or HNPCC), however, 5% of patients with HNPCC have MSS colorectal adenocarcinomas.  Microsatellite stability in this neoplasm is associated with the presence of the mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2).  Microsatellite stability by PCR in cases with complete or equivocal loss of one or more mismatch repair proteins indicates the immunohistochemistry results were due to fixation or tissue processing factors or other unrelated epigenomic alteration.

Identification of microsatellite stable (MSS) and unstable (MSI) subsets of adenocarcinomas is important, as published data suggests microsatellite instability status is associated with prognosis and response to 5-FU based chemotherapy.

REFERENCES:
Ruczkiewicz AR and Jass JR. Pathol Case Rev 9:163-72, 2004
Popat S et al., J Clin Oncol **ID-NUM, 2005
Southey MC et al., J Clin Oncol **ID-NUM, 2005.

Methodology:  Non-tumor/normal and tumor areas were identified and selectively microdissected.  The collected cells were lysed and genomic DNA was extracted.  A multiplex PCR was used to amplify five mononucleotide repeat regions from both tumor and matched non-tumor/normal DNA and amplified products were evaluated by capillary electrophoresis.  Tumors containing DNA that generated novel products and/or demonstrated a size shift of three or more base pairs when compared to products generated from matched non-tumor/normal DNA were determined to exhibit microsatellite instability.

Intended Use:  Repetitive DNA is particularly sensitive to errors in replication and therefore dysfunctional mismatch repair genes result in widespread alterations in microsatellite regions.  Microsatellite instability (MSI) testing is used to evaluate five different microsatellite loci for instability.  MSI has been found in over 90% of Hereditary Non-Polyposis Colorectal Cancer (HNPCC)-associated colorectal tumors and is a hallmark of this syndrome.  MSI has also been found in 10-20% of sporadic colorectal carcinomas and 5-FU therapy has been reported not to improve survival in these tumors in some studies (Benatti P et al., Clin Cancer Res **ID-NUM 2005)./r/n"
REG4,COLON,0,PAT-10035665,1,REC-3000678063,"ClinicalHistory:
Sigmoid colon cancer.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Sigmoid colectomy.",,"PreOperativeDiagnosis:
Sigmoid colectomy.
PostOperativeDiagnosis:
Same.
IntraoperativeDiagnosis:
A.  Gross only:  Distal margin with 1.5 cm clearance/MP.
FinalDiagnosis:
A-B.  SIGMOID COLON ADENOCARCINOMA 
Tumor Information:
Type of specimen(s):      Sigmoid colon resection; donuts
Tumor location:      Sigmoid colon
Tumor size:        4.0 x 2.0 x 1.6 cm
Histologic type:      Adenocarcinoma
Histologic grade:      Poorly-differentiated
Level of invasion:      Subserosal fat
Peritoneal involvement:    Not evident
Lymphovascular invasion:    Present
Perineural invasion:      Present
Invasion of contiguous structures:  Not evident
Resection margins:      Free of carcinoma (>2.5 cm distal clearance and >15.0 cm 
          proximal clearance with donuts)
Lymph node involvement:    Positive for metastasis (11 of 14 nodes positive for metastasis)
Mesenteric involvement:    Not evident
Stage:          pT3 N2b.",,"GrossDescription:
A.  Received fresh for intraoperative consultation labeled ""sigmoid colon from margins"" is a resected segment of tan-pink 
  intestinal tissue measuring 22.0 cm in length x 4.0 cm average outside diameter.  The serosal surface is smooth and tan-pink.  
  Opening reveals a tan-pink mucosa with a centrally ulcerated tan-pink to red mass lesion measuring 4.0 x 2.0 x 1.6 cm, 
  located 1.5 cm from the distal margin and greater 15.0 cm from proximal margin.  Sectioning of the lesion reveals gross 
  invasion of the muscle area and invasion into surrounding fat.  Sectioning through fat overlying the lesion reveals the multiple 
  matted nodes measuring up to 2.5 cm in greatest dimension.  No further masses or lesions are grossly identified.  
  Representative sections are submitted in blocks A1-A10.

  KEY TO CASSETTES:
  A1  -  Proximal margin
  A2  -  Distal margin
  A3-A6  -  Sections through lesion
  A7-A10  -  Lymph nodes

B.  Received in formalin labeled ""colon donuts"" are two ringed shaped fragments of tan-pink intestinal tissue measuring in 
  aggregate 2.5 x 2.4 x 1.5 cm.  Representative sections are submitted in blocks B1-B2.","MicroscopicDescription:
A.  Proximal and distal margins of resection are free of tumor.  The mucosal mass is an invasive, poorly-differentiated adenocarcinoma extending through the muscularis propria into subserosal fat.  Areas of lymphovascular tumor infiltration are noted.  There is a large focus of necrotic tumor, probably representing matted nodes, present overlying the mucosal mass.  11 of 14 identified nodes are positive for metastatic carcinoma.

B.  Additional sections of colon are negative for malignancy.","A: Sigmoid colon for margins
B: Colon donuts",,
REG4,COLON,0,PAT-10039049,1,REC-3000678214,"Post-OperativeDiagnosis:
1. Colon polyp
2. Colon mass.",,"PostOperativeDiagnosis:
1. Colon polyp
2. Colon mass.
FinalDiagnosis:
A.  Cecum, polyp, biopsy:        Tubular adenoma 

B.  Descending colon, proximal, mass, biopsy:  INVASIVE ADENOCARCINOMA, well to moderately 
              differentiated

C.  Sigmoid colon, polyp, snare biopsy:    Tubular adenoma.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] concurs with the diagnosis.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, biopsy cecal polyp"" is a tan-pink fragment of mucosal lined soft tissue measuring up to 0.3 cm in greatest dimension.  Submitted entirely in one cassette.

B.  Received in formalin labeled ""XXXXXX, biopsy colon mass proximal descending"" are multiple tan-pink fragments of mucosal lined soft tissue measuring up to 0.4 cm in greatest dimension.  Submitted entirely in one cassette.

C.  Received in formalin labeled ""XXXXXX, snare sigmoid polyp"" are multiple tan-pink fragments of mucosal lined soft tissue, the largest of which measures up to 0.5 x 0.4 x 0.4 cm in greatest dimension.  The largest piece is inked black at the base, and bisected.  Submitted entirely in cassettes C1 and C2, with the largest piece in cassette C1.","MicroscopicDescription:
A-C.  The microscopic findings support the above diagnoses.","A: Biopsy cecal polyp
B: Biopsy colon mass proximal descending
C: Snare sigmoid polyp",,
REG4,COLON,0,PAT-10036481,1,REC-3000678306,"ClinicalHistory:
Abnormal GI Xray.",,"FinalDiagnosis:
CECAL BIOPSIES:  POORLY DIFFERENTIATED COLONIC ADENOCARCINOMA.
DiagnosisComment:
Immunoperoxidase stains show that the tumor is positive for cytokeratin 7, cytokeratin 20, CDX-2, and SATB2.  It is negative for WT1 and PAX-8.  

The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Mar 6 2012].  K-Ras will be performed and reported in an addendum.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: COLD BIOPSY MASS - CECUM,,
REG4,COLON,0,PAT-10041676,1,REC-3000678427,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->Left colon cancer./r/n",,"FinalDiagnosis:
Left colon: Moderately differentiated adenocarcinoma infiltrating pericolic fat, margins free.

Lymph nodes: Negative for metastasis (0/15)./r/n",,"GrossDescription:
Labeled:        Patient name and medical record number, designated left colon
Specimen:      Pink-red segment of colon (unopened, unfixed)
Size:        15 cm in length, varying in circumference from 5-8 cm
Orientation:      None provided
Colors:
  Black:        One removed, stapled margin, serosal margin
  Blue:        Opposite removed, stapled margin
  Green:        Radial margin
Tumor:      
  Location:      Left colon
  Size:        5 x 5 x 1.3 cm
  Description:      Gray-tan, lobulated, circumferential centrally depressed with rolled edges
  Ulceration/perforation:      No grossly identifiable ulceration/perforation.
  Distance from margins:      5.5 cm away from the black margin, 6 cm away from the blue margin
  Estimated depth of invasion:  Upon sectioning, the tumor appears to extend past the muscle layer into the pericolic fat.
Other findings:  1 x 0.7 cm hemorrhagic area on serosa 4 cm from the black margin and 11.2 cm from the blue margin.
Regional lymph nodes:    Several possible lymph nodes identified measuring from 0.3 x 0.3 x 0.2 cm up to 
1.3 x 1 x 0.8 cm.
Section code:    
  Block 1:      Proximal and distal margins
  Block 2:      Radial margin
  Blocks 3-6:      Tumor
  Blocks 7-9:      Lymph nodes, 5 per cassette
  Blocks 10-11:      Lymph nodes, 2 per cassette inked and bisected./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.
Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Left colon
Tumor Size: 5 CM
Macroscopic Tumor Perforation: Not identified
Histologic Type: Adenocarcinoma
Histologic Grade: Moderately differentiated, G1
Microscopic Tumor Extension: Tumor invades pericolic fat
Margins:
  Proximal margin: Free of tumor
  Distal margin: Free of tumor
  Circumferential/radial margin: Free of tumor
  Distance of invasive carcinoma from closest margin: 2 cm from radial margin
Treatment Effect (if applicable): N A
Lymph-Vascular Invasion: Present
Perineural Invasion: Absent
Tumor Deposits: Absent
Pathologic Staging (pTNM):
  Primary tumor: pT3
  Regional lymph nodes: pN0
    Number examined: 15
    Number involved: None
  Distant metastasis: pMX
Ancillary Studies: N A./r/n","A: Left colon (fresh), excision",,
REG4,COLON,0,PAT-10040992,1,REC-3000678734,"ClinicalHistory:
Abnormal abdominal X-ray.
Post-OperativeDiagnosis:
Colon mass.",,"PostOperativeDiagnosis:
Colon mass.
FinalDiagnosis:
Colon biopsy, clinically mass at 16 cm:
  Moderately differentiated adenocarcinoma.",,"GrossDescription:
Received in formalin labeled ""XXXXXX"" are three fragments of tan to tan-pink tissue measuring up to 0.3 x 0.3 x 0.3 cm.  Submitted in toto in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.

Note:  The slides have been referred for internal concurrence.  Dr. **NAME[ZZZ YYY] was informed on **DATE[Mar 11 2012], 0952 hrs.  Dr. **NAME[XXX WWW]'s office was informed on **DATE[Mar 11 2012], 0954 hrs.",A: Colon mass @ 16 cm,,
REG4,COLON,0,PAT-10040895,1,REC-3000678824,"ClinicalHistory:
Adenocarcinoma, ascending colon.",,"IntraoperativeDiagnosis:
Gross Diagnosis:     Tumor 8 cm from the proximal margin, 7 cm from the distal margin/SK/TM.
FinalDiagnosis:
Right colon, cecum with appendix, and terminal ileum, resection:
  1.  Moderately differentiated colonic adenocarcinoma
    a.  No involvement of the resection margins
    b.  27 mesenteric lymph nodes, negative for metastatic carcinoma
  2.  Tubular adenomas x 2 (0.9 cm and 0.3 cm), ascending colon
  3.  Colonic diverticulum
  4.  Fibrofatty lumenal obliteration of distal appendix

Tumor Information:
Type of specimen(s):  Resection of right colon, cecum with appendix, and terminal ileum
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Ascending colon
Tumor size:  3.7 x 2.7 x 0.8 cm
Tumor configuration:  Sessile
Extent of invasion:  Into but not through the muscularis propria
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not marked
  Peritumoral (Crohn-like):  Not marked
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Prior neoadjuvant treatment unknown
Resection margins:  Not involved
  Proximal:  8.0 cm from the tumor
  Distal:  7.0 cm from the tumor
  Circumferential/radial:  1.3 cm from the tumor
  Mesenteric:  Greater than 5.0 cm from the tumor
Lymph node metastasis:
  Total nodes:  0 out of 27 mesenteric nodes
  Largest nodal metastatic focus:  Not applicable
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  None
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  Not applicable
  Nodes with metastases > 2.0 mm:  Not applicable
Other findings:  Colonic tubular adenomas x 2 (0.9 cm and 0.3 cm)
AJCC Pathologic Stage:  pT2, pN0, cM0
      Pathologic stage:  I.",,"GrossDescription:
Type of specimen:    Segment of right colon, cecum with appendix, and terminal ileum, with stapled proximal and distal margins
How received:      Fresh
Labeled:        ""XXXXXX, right colon""
Orientation:      None
Measurements:  
  Colon:      Up to 14.0 cm in length and 8.0 cm in circumference, in the fixed state
  Cecum:      6.5 cm in circumference
  Terminal ileum:    Up to 2.3 cm in length and 5.5 cm in circumference
  Appendix:      The attached appendix measures up to 6.5 cm in length and 1.0 cm in diameter
Tumor location:      Ascending colon, approximate mid-portion of specimen
Tumor size:      2.7 cm axially, 3.7 cm transversely, and up to 0.8 cm in thickness
Appearance:      Sessile
% involvement of circumference:  Approximately 35%
Distance of margins:
  Proximal:      8.0 cm
  Distal:      7.0 cm
  Circumferential:    1.3 cm 
  Mesenteric:      Greater than 5.0 cm 
Depth/extent of invasion:    Into the muscularis propria
Serosa adjacent to tumor:    Unremarkable
Obstruction:      None
Perforation:      None
Lymph nodes:      Multiple circumscribed, tan, possible lymph nodes measuring up to 0.6 cm are identified.  The cut surfaces are unremarkable.
Mesenteric tumor deposits:  None identified
Other findings:      Present 4.5 cm lateral to the tumor is a sessile mucosal polyp measuring up to 0.9 cm. Present 2.0 cm distal to the tumor is an apparent intact diverticulum measuring up to 0.8 cm.
Intraoperative consultation:  Gross evaluation of the margins
Submitted for histology:    Representative sections, and all identified lymph nodes
  Total cassettes:    14
  Frozen section cassettes:  None
Key to inked margins:    Circumferential/radial - blue, mesenteric - orange
Key to cassettes:
  1  -  Proximal and distal margin
  2  -  Mesenteric margin
  3  -  Tumor and circumferential/radial margin
  4-6  -  Representative sections of tumor
  7  -  Sessile mucosal polyp lateral to tumor
  8  -  Diverticulum and adjacent mucosa
  9  -  Representative section of large bowel
  10  -  Sections of appendix
  11-14  -  Possible individual, mesenteric lymph nodes.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right colon,,
REG4,COLON,0,PAT-10040992,1,REC-3000678965,"ClinicalHistory:
Sigmoid colon with obstruction.
Post-OperativeDiagnosis:
Pending.",,"PostOperativeDiagnosis:
Pending.
IntraoperativeDiagnosis:
A.  Frozen Section Diagnosis:  Benign cysts/SK/TM
B.  Frozen Section Diagnosis:  Tumor is 8 cm from proximal margin, 4.5 cm from distal margin/SK/TM.
FinalDiagnosis:
A.  Soft tissue, biopsy, clinically uterus, peritoneal:
    Benign mesothelial microcysts, no malignancy seen

B.  Segment of colon, resection, clinically sigmoid:
    1.  Moderately differentiated adenocarcinoma
    2.  No involvement of the resection margins
    3.  17 mesenteric lymph nodes, negative for metastatic tumor

C.  Colonic tissue (two), excision, clinically distal staple line:
    1.  Benign colonic tissue, no involvement by carcinoma
    2.  No lymph nodes identified

Tumor Information:
Type of specimen(s):  Biopsy of uterine peritoneal tissue; resection of sigmoid colon; excision of distal colonic staple line tissue.
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Sigmoid colon
Tumor size:  6.8 x 5.3 x 2.7 cm
Tumor configuration:  Sessile, ulcerated
Extent of invasion:  Through the muscularis propria into pericolonic fat.  No serosal penetration identified.
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not marked
  Peritumoral (Crohn-like):  Not marked
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Prior neoadjuvant treatment unknown
Resection margins:  Not involved
  Proximal:  8.0 cm from the tumor
  Distal:  4.5 cm from the tumor
  Circumferential/radial:  None
  Mesenteric:  0.7 cm from the tumor
Lymph node metastasis:
  Total nodes:  0 out of 17 mesenteric nodes
  Largest nodal metastatic focus:  Not applicable
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  None
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  Not applicable
  Nodes with metastases > 2.0 mm:  Not applicable
Other findings:  Uterine peritoneal biopsy and distal colonic staple line tissue negative for malignancy
AJCC Pathologic Stage:  pT3, pN0, cM0
      Pathologic stage:  IIA.",,"GrossDescription:
A.  Received fresh, labeled ""XXXXXX, peritoneal biopsy of uterus"" is an irregular fragment of tan to pink-tan, fibromembranous tissue measuring up to 0.9 x 0.6 x 0.3 cm.  Submitted in toto for frozen section, with the residual tissue submitted in one cassette labeled ""AFS"".

B.  Type of specimen:      Segment of large bowel, with stapled margins
  How received:      Fresh
  Labeled:        ""XXXXXX, sigmoid colon""
  Orientation:        Stitch = distal
  Measurements:      Up to 16.0 cm in length and ranging from 6.8 cm in circumference at the level of the tumor, up to 11.0 cm in circumference along the proximal aspect
Tumor location:      Distal half of specimen
Tumor size:        5.3 cm axially, 6.8 cm transversely and up to 2.7 cm in thickness
Appearance:        Sessile, focally ulcerated
% involvement of circumference:  100%
Distance from the margins:    
  Proximal:      8.0 cm
  Distal:        4.5 cm
  Circumferential:         None
  Mesenteric:      0.7 cm 
Depth/extent of invasion:    Through the muscularis propria, into the subserosal fat
Serosa adjacent to tumor:    Focally retracted, grossly intact
Obstruction:        Present, approximately 95%
Perforation:        None identified 
Lymph nodes:      Multiple circumscribed, possible lymph nodes measuring up to 0.8 cm are identified.  The cut surfaces are pink-gray, rubbery to slightly firm.
Mesenteric tumor deposits:    None identified 
Other findings:      None
Intraoperative consultation:    Gross evaluation of the margins
Submitted for histology:    Representative sections and all identified lymph nodes
  Total cassettes:      10
  Frozen section cassettes:    None
Key to inked colors:      Distal margin - green, mesenteric margin - orange, serosal surface - blue
Key to cassettes:
  1  -  Proximal and distal margin
  2  -  Mesenteric margin
  3-6  -  Representative sections of tumor, including serosal surface
  7, 8  -  Multiple individual, possible mesenteric lymph nodes
  9  -  One possible mesenteric lymph node, bisected
  10  -  One possible mesenteric lymph node, bisected 
  
C.  Received in formalin, labeled ""XXXXXX, distal staple line sigmoid"" are two irregular portions of tan to pink-tan tissue, with multiple embedded staples, measuring up to 3.8 x 0.4 x 0.3 cm.  The cut surfaces are grossly unremarkable.  The staples are removed and representative sections are submitted in one cassette.","MicroscopicDescription:
A-C.  The microscopic findings support the above diagnosis.","A: Peritoneal biopsy of uterus
B: Sigmoid colon - stitch = distal sigmoid colon
C: Distal staple line sigmoid",,
REG4,COLON,0,PAT-10039366,1,REC-3000679161,"ClinicalHistory:
R colon cancer.
Pre-OperativeDiagnosis:
Right colectomy:.",,"PreOperativeDiagnosis:
Right colectomy:.
FinalDiagnosis:
Right colon:  

Tumor Information:

Type of specimen(s):  Right colectomy with terminal ileum
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Cecum
Tumor size:  5 x 5 x 1 cm
Tumor configuration:  Circumferential and ulcerated
Extent of invasion:  Through the wall into peri-colic fat
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:  Clear
  Proximal:  Clear by at least 15 cm
  Distal:  Clear by at least 15 cm
Lymph node metastasis:
  Total nodes:  5 out of 12 mesenteric nodes, see comment
  Largest nodal metastatic focus:  1.5 cm
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  0 nodes
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  1 nodes
  Nodes with metastases > 2.0 mm:  4 nodes
Other findings:  MSI testing requested on block 4
    KRAS/BRAF testing requested on block 4
AJCC Pathologic Stage:  pT3, pN2a      
    Pathologic stage:  IIIb.
DiagnosisComment:
Additional lymph nodes will be sought and the results will be reported in an addendum.",,"GrossDescription:
Right colon:  Received is an intestinal resection that includes the cecum, a portion of the right colon, terminal ileum, and vermiform appendix.  In aggregate the fixed specimen measures 45 cm in length.  In the cecum is an ulcerated apple core lesion that extends 5 cm in length and up to 5 cm around.  The bowel has previously been opened.  On further sectioning, there is gross invasion through the wall into the peri-colic fat.  Firm white regional nodes are noted.  The surgical margins are widely free by at least 15 cm.  No other additional mucosal lesions are noted.  The vermiform appendix measures up to 3.5 x 0.7 x 0.7 cm and is grossly free of tumor.  Specimen representatively submitted as follows:  representative sections of tumor, 1 through 4; representative sections of both margins, 5; vermiform appendix, 6; possible lymph nodes 7 through 1o.","MicroscopicDescription:
Right colon:  The tumor is characterized by nests of well to moderately differentiated glands that invade through the muscularis into the peri-colic fat.  Neither vascular nor peri-neural invasion is appreciated.  The surgical margins are free of tumor.  A section of vermiform appendix is free of both primary appendiceal neoplasia and metastatic tumor.  Five of 12 regional nodes are positive for metastatic carcinoma.",A: Right colon,,
REG4,COLON,0,PAT-10041703,1,REC-3000683034,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->RIGHT COLON MASS./r/n",,"FinalDiagnosis:
Colon, right:  Moderately differentiated adenocarcinoma of cecum, surgical margins free of tumor.

  Metastatic carcinoma involving four of twenty pericolic lymph nodes (4/20)./r/nDiagnosisComment:
Testing for microsatellite instability/mismatch repair proteins is available upon request.  Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[Dec 22 2011].  Dr. **NAME[WWW VVV] was notified of the diagnosis via e-mail on **DATE[Dec 22 2011]./r/n",,"GrossDescription:
Labeled:        Patient name and medical record number, designated right colon mass
Specimen:      Right hemicolectomy specimen
Size:        Terminal ileum 5.5 cm, cecum with colon 14 cm, appendix 9.5 cm
Orientation:      Not required
Colors:
  Black:        Proximal margin
  Blue:        Distal margin and circumferential meso-colonic margin
Tumor:      
  Location:      Cecum
  Size:        4.5 x 4 x 2 cm
  Description:      Fungating polypoid ulcerated lesion abutting the ileocecal valve.
  Ulceration/perforation:      Lesion is centrally ulcerated, perforation not seen on gross.
  Distance from margins:      5.3 cm from proximal margin, 10.5 cm from distal margin
  Estimated depth of invasion:  Into the subserosal adipose tissue
Other lesions:  0.3 cm polyp in the ascending colon, 4 .5 cm from the main lesion, multiple polyps in the terminal ileum, appendix is grossly unremarkable.
Regional lymph nodes:    Multiple lymph nodes present measuring up to 1.7 cm
Section code:    
  Block 1:      Proximal and distal margins
  Block 2:      Radial margin
  Blocks 3-5:      Tumor
  Block 6:      Representative appendix
  Block 7:      Representative terminal ileum
  Block 8:      Representative colon with polyp
  Blocks 9-12:      Single bisected lymph node in each
  Blocks 13-16:      Multiple lymph nodes (#16 has one bisected and 2 more lymph nodes)./r/n","MicroscopicDescription:
Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Cecum/ileocecal valve
Tumor Size: 4.5 x 4 x 2 cm
Macroscopic Tumor Perforation: Absent
Histologic Type: Adenocarcinoma, intestinal type, with focal mucinous features
Histologic Grade: Moderately differentiated (low-grade)
Microscopic Tumor Extension: Through muscularis propria into subserosal adipose tissue
Margins:
  Proximal margin: Free of tumor
  Distal margin: Free of tumor
  Circumferential/radial margin: Free of tumor
  Distance of invasive carcinoma from closest mucosal margin: 5.3 cm 
Treatment Effect: Not applicable 
Lymph-Vascular Invasion: Present
Perineural Invasion: Not identified
Pathologic Staging (pTNM):
  Primary tumor: pT3
  Regional lymph nodes: pN2a
    Number examined: 20
    Number involved: 4
  Distant metastasis: pMX
Ancillary Studies: None./r/n","A: Right colon mass, excision",,
REG4,COLON,0,PAT-10039366,1,REC-3000683162,"ClinicalHistory:
R colon cancer.
Pre-OperativeDiagnosis:
Right colectomy:.",,"PreOperativeDiagnosis:
Right colectomy:.
FinalDiagnosis:
Right colon:  

Tumor Information:

Type of specimen(s):  Right colectomy with terminal ileum
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Cecum
Tumor size:  5 x 5 x 1 cm
Tumor configuration:  Circumferential and ulcerated
Extent of invasion:  Through the wall into peri-colic fat
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:  Clear
  Proximal:  Clear by at least 15 cm
  Distal:  Clear by at least 15 cm
Lymph node metastasis:
  Total nodes:  5 out of 15 mesenteric nodes
  Largest nodal metastatic focus:  1.5 cm
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  0 nodes
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  1 nodes
  Nodes with metastases > 2.0 mm:  4 nodes
Other findings:  MSI testing requested on block 4
    KRAS/BRAF testing requested on block 4
AJCC Pathologic Stage:  pT3, pN2a      
    Pathologic stage:  IIIb.
DiagnosisComment:
Additional lymph nodes will be sought and the results will be reported in an addendum.",,"GrossDescription:
Right colon:  Received is an intestinal resection that includes the cecum, a portion of the right colon, terminal ileum, and vermiform appendix.  In aggregate the fixed specimen measures 45 cm in length.  In the cecum is an ulcerated apple core lesion that extends 5 cm in length and up to 5 cm around.  The bowel has previously been opened.  On further sectioning, there is gross invasion through the wall into the peri-colic fat.  Firm white regional nodes are noted.  The surgical margins are widely free by at least 15 cm.  No other additional mucosal lesions are noted.  The vermiform appendix measures up to 3.5 x 0.7 x 0.7 cm and is grossly free of tumor.  Specimen representatively submitted as follows:  representative sections of tumor, 1 through 4; representative sections of both margins, 5; vermiform appendix, 6; possible lymph nodes 7 through 1o.","MicroscopicDescription:
Right colon:  The tumor is characterized by nests of well to moderately differentiated glands that invade through the muscularis into the peri-colic fat.  Neither vascular nor peri-neural invasion is appreciated.  The surgical margins are free of tumor.  A section of vermiform appendix is free of both primary appendiceal neoplasia and metastatic tumor.  Five of 12 regional nodes are positive for metastatic carcinoma.  ADDENDUM:  Three additional lymph nodes are negative for metastatic carcinoma.  DLW **DATE[May 17 2012].",A: Right colon,,
REG4,COLON,0,PAT-10042597,1,REC-3000685102,"ClinicalHistory:
Large tubulovillous adenoma.
Post-OperativeDiagnosis:
Pending.",,"PostOperativeDiagnosis:
Pending.
FinalDiagnosis:
Transverse colon segment:  Tubular adenoma with focal high grade dysplasia and focal invasive 
        well differentiated adenocarcinoma


Tumor Information:

Type of specimen(s):    Transverse colon
Histologic type:    Adenocarcinoma arising out of a tubular adenoma  
Histologic grade:    Well differentiated
Tumor site:    7.5 cm from distal margin
Tumor size:    0.2 cm, invasive component
Tumor configuration:    Exophytic (tubular adenoma portion)
Extent of invasion:    into submucosa but not into muscularis propria
Macroscopic tumor perforation:    Not identified
Lymph-vascular invasion:    Not identified
Venous invasion:    Not identified
Perineural invasion:    Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
   Intratumoral (tumor infiltrating):    Not identified
   Peritumoral (Crohn-like):    Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:    Not identified
Resection margins:    Clear
   Proximal:    7.6 cm
   Distal:    7.5 cm
   Circumferential/radial:    Clear
   Mesenteric:    Clear
Lymph node metastasis:
   Total nodes:    0 out of 22 mesenteric nodes
Other findings:  None
AJCC Pathologic Stage:  pT1, pN0, cM0
  Pathologic stage:  I.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] concurs with the diagnosis of adenocarcinoma.

Specimen signed out at **INSTITUTION **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.",,"GrossDescription:
Received in formalin is an unoriented, unopened segment of bowel, 22.9 cm in length, and 4.9 cm in circumference at the proximal margin (orange), and 4.9 cm circumference at the distal margin (blue-marked with a suture).

There is a pedunculated, irregular, tan to pink polypoid mass, up to 4.1 x 2.4 x 2.0 cm, 13.2 cm from the proximal (blue) margin, and 7.5 cm from the distal (orange) margin.  The polypoid mass does not appear to involve the underlying lamina propria.  The polypoid mass encompasses >75% of the lumen.  

There is an area of narrowing of the lumen, starting 7.6 cm from the proximal margin, and ending at the polypoid mass described above.  This area of decreased lumen coincides with an area of adhesion of the mesentery on the serosal surface.  The mesentery encompasses the entire circumference of the bowel at the area of narrowing.  The mesentery surrounding the segment of bowel is grossly unremarkable, with no masses.  

Multiple possible lymph nodes are identified, largest up to 0.4 cm.  

Representative sections are submitted in 26 cassettes, as follows:

KEY TO CASSETTES:
1  -  Proximal (blue)
2  -  Distal (orange) 
3-10  -  Tan polypoid mass described above en block (serosal surface inked black)
11  -  Uninvolved mucosa 
12  -  Representative of mesentery that is adherent/surrounds the bowel at the area of narrowing 
13-26  -  Possible lymph nodes and surrounding adipose tissue.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Transverse colon splenic flexure, suture marks distal margin",,
REG4,COLON,0,PAT-10038737,1,REC-3000685112,"ClinicalHistory:
Cecal mass, carcinomatosis.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Laparoscopic, biopsy.",,"PreOperativeDiagnosis:
Laparoscopic, biopsy.
PostOperativeDiagnosis:
Same.
IntraoperativeDiagnosis:
A. Frozen Section:  Mucinous adenocarcinoma/MP.
FinalDiagnosis:
A and B.  Peritoneal nodules, biopsies:  Metastatic mucinous adenocarcinoma.
DiagnosisComment:
The metastatic mucinous carcinoma is positive for CDX2, supporting primary colorectal or appendiceal primary origin.
Per request (Dr. **NAME[ZZZ YYY]), tumor material will be submitted for KRAS and BRAF testing (Clarient Labs, pending).",,"GrossDescription:
A.  Received fresh for intraoperative consultation labeled ""carcinoma peritoneal"" is an excision of tan-pink to yellow mucinous soft tissue measuring 0.7 x 0.4 x 0.2 cm.  Specimen is submitted for frozen section and subsequently submitted in block A.

B.  Received in formalin labeled ""peritoneal biopsy"" are multiple fragments of tan-pink to yellow, mucinous soft tissue measuring in aggregate 2.1 x 1.6 x 0.4 cm.  Submitted entirely in block B.","MicroscopicDescription:
A and B.    Sections contain fragments of atypical, malignant epithelial cells floating in large pools of mucus material.  
    CDX2 is positive in tumor cells.","A: Peritoneal biopsy
B: Peritoneal biopsy",,"AddendumComment:
Please see attached Clarient KRAS report #***PATH-NUMBER[1]."
REG4,COLON,0,PAT-10039057,1,REC-3000685118,"ClinicalHistory:

Previous biopsy
[***PATH-NUMBER[1] **DATE[Apr 6 2012] - Right colon: Invasive adenocarcinoma, moderately-differentiated.
Post-OperativeDiagnosis:
1. Gastritis, R/O H. pylori
2. S/O colon CA surgery.",,"PostOperativeDiagnosis:
1. Gastritis, R/O H. pylori
2. S/O colon CA surgery.
FinalDiagnosis:
A.  Biopsy antrum:          1. Mild chronic gastritis
            2. Negative for Helicobacter pylori 
 
B.  Random colon ileo-colic anastomosis:    Benign small intestinal and colonic mucosa

Comment:  The anastomotic biopsies show mild non-specific inflammatory changes.  It is negative for dysplasia or malignancy.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, EGD biopsy antrum"" are 2 tan-pink fragments of mucosal lined soft tissue measuring up to 0.4 cm in greatest dimension.  Entirely in one block. 

B.  Received in formalin labeled ""XXXXXX, colon ileocolic anastomosis random biopsy"" are 5 tan-pink fragments of mucosal lined soft tissue measuring up to 0.4 cm in greatest dimension.  Entirely in one block.","MicroscopicDescription:
A.   Location:     Antrum
  Helicobacter pylori:   Negative 
  Chronic inflammation:  Mild
  Lymphoid aggregates:   Negative 
  Acute inflammation:  Negative 
  Atrophy:     Negative 
  Intestinal metaplasia:   Negative 
  Other findings:   Negative 

B.  The microscopic findings support the above diagnosis.","A: Biopsy antrum
B: Random colon ileo-colic anastomosis",,
REG4,COLON,0,PAT-10038962,1,REC-3000685128,"ClinicalHistory:
Appendix cancer.
Post-OperativeDiagnosis:
Same as pre-op.
Pre-OperativeDiagnosis:
Laparoscopic right colectomy.",,"PreOperativeDiagnosis:
Laparoscopic right colectomy.
PostOperativeDiagnosis:
Same as pre-op.
FinalDiagnosis:
Right colon, laparoscopic colectomy:    1. Appendiceal stump with focal high-grade epithelial dysplasia;
                no residual carcinoma evident
            2. Lymph nodes, negative for metastasis (0/22)
            3. Margins free of atypia.
DiagnosisComment:
Based on the previous appendectomy, with appendiceal mucinous carcinoma (***PATH-NUMBER[1]), the stage of this appendicial carcinoma is pT3 N0.",,"GrossDescription:
Received in formalin labeled ""right colon"" is a resected segment of tan-pink intestinal tissue measuring 11.0 cm in length x 4.5 cm average outside diameter.  The serosal surface is smooth and tan-pink. The proximal margin is a length of ileum measuring 2.0 cm in length x 2.0 cm average outside diameter.  Opening reveals a grossly normal tan-pink mucosa with no grossly identifiable masses or lesions.  Representative sections are submitted in blocks 1-9.  Section summary: block 1 proximal margin, block 2 distal margin, block 3 random sections of intestine, blocks 4-6 appendiceal orifice and stump, blocks 7-9 lymph node.","MicroscopicDescription:
Proximal and distal margins of resection are unremarkable.  Sections of the appendiceal stump area exhibit foci of high-grade intraepithelial dysplasia, but no residual invasive carcinoma.  There are foci of adjacent mixed acute and chronic inflammation and reactive fibrosis, consistent with recent appendectomy.  There is a small simple mesothelial cyst present.  A total of 22 lymph nodes are identified, all negative for metastatic carcinoma.",A: Right colon,,
REG4,COLON,0,PAT-10039714,1,REC-3000685256,"ClinicalHistory:

Colon cancer.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A.  Transverse colon with splenic flexure:     INVASIVE ADENOCARCINOMA
             Three out of thirteen nodes, positive for metastasis (3/13)
 
B.  Additional proximal colon:       Segment of colon, no tumor present
             One benign lymph node, no tumor present (0/1)
 
C.  Additional mesenteric transverse colon:  Three benign lymph nodes, no tumor present (0/3)
 
D.  Omentum:           Adipose tissue, no tumor present

Tumor Information:

Type of specimen(s):  Segmental colectomy
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Splenic flexure
Tumor size:  4.5 cm
Extent of invasion:  Invades through muscularis propria into pericolonic tissue
Macroscopic tumor perforation:  Not present
Lymphovascular invasion:  Not present
Perineural invasion:  Not present
Discontinuous extramural extension:  Not present
Marked lymphocytic response:  Not present
  Intratumoral (tumor infiltrating):  Not present
  Peritumoral (Crohn-like):  Not present
Mucinous/signet ring/medullary pattern:  Not present
Neoadjuvant treatment effect:  N/A
Resection margins:  Negative for tumor
  Proximal:  Clear by 2.6 cm
  Distal:  Clear by 11.2 cm
  Circumferential/radial:  Negative for tumor
  Mesenteric:  Negative for tumor
Lymph node metastasis:
  Total nodes:  3 out of 17 mesenteric nodes, positive for metastasis (3/17)
  Largest nodal metastatic focus:  0.2 cm
  Nodes with Isolated Tumor Cells
    (ITC) only (< 0.2 mm):  1 node
  Nodes with micrometastases
    (> 0.2 mm, < 2.0 mm):  2 nodes
  Nodes with metastases > 2.0 mm:  0 node
Other findings:  Tubular adenoma
AJCC Pathologic Stage:  Stage IIIB (pT3, pN1b, cM0).",,"GrossDescription:
A.  Received fresh labeled ""XXXXXX, transverse colon with splenic flexure"" is an unopened, unoriented segment of bowel, 15.4 cm in length x 5.9 cm in circumference at one margin (inked blue), and 5.5 cm in circumference at the remaining margin (inked orange).  The specimen is not oriented.  

  The bowel is opened showing a firm, white to tan centrally ulcerated mass with rolled borders, occupying >90% of the lumen, 4.5 x 3.5 x 1.0 cm.  The mass is 0.6 cm from the proximal (blue margin), and 11.2 cm from the distal (orange margin).  No serosal retraction is identified.  The serosal surface is inked black.  The tumor appears to involve the muscularis propria.

  There is a soft tan polyp, 0.6 x 0.5 x 0.4 cm, 6.5 cm from the ulcerated tumor, and 9.3 cm from the blue margin, and 4.8 cm from the orange margin.  

  Multiple lymph nodes are identified, largest up to 0.4 cm in greatest dimension.  

  Representative sections are submitted in 21 cassettes as follows:
  
  KEY TO CASSETTES: 
A1    -  Blue margin
A2    -  Orange margin
  A3-A7  -  Ulcerated tumor described above (A5-A6 one full thickness section; A7 tumor with blue margin)
A8    -  Polyp described above en block
A9    -  Uninvolved mucosa
A10-A15  -  Lymph nodes, <3.0 cm from the bowel wall
A16-A21  -  Lymph nodes, >3.0 cm from the bowel wall

B.  Received in formalin, labeled ""XXXXXX, additional proximal colon"" is an unremarkable segment of bowel, unoriented, 2.0 
  cm in length by 6.9 cm in circumference at one margin (inked blue), and 6.6 cm in circumference at the remaining margin 
     (inked orange). Possible lymph nodes are identified, largest up to 0.3 cm in greatest dimension.

    Submitted entirely in seven cassettes as follows:
  
  KEY TO CASSETTES:
  B1-B3  -  Segment of bowel wall, submitted entirely
  B4-B7  -  Possible lymph nodes

C.  Received in formalin, labeled ""XXXXXX, additional mesenteric transverse colon"" is a soft tan tissue, unoriented, 9.5 x 4.4 x 1.9 cm.  No segment of bowel is identified.  Sectioning reveals no masses or lesions.  Possible lymph nodes are identified, the largest up to 0.3 cm in greatest dimension. Submitted entirely in seven cassettes. 

D.    Received in formalin, labeled ""XXXXXX, omentum"" is an unoriented soft tan tissue, 29.9 x 12.6 x 2.1 cm.  Sectioning
     reveals no lesions or masses.  Representative sections are submitted in 15 cassettes.","MicroscopicDescription:
A-D.  The microscopic description supports the above diagnoses.","A: Transverse colon with splenic flexure
B: Additional proximal colon
C: Additional mesenteric transverse colon
D: Omentum",,
REG4,COLON,0,PAT-10036479,1,REC-3000696417,"ClinicalHistory:
Bleed.",,"FinalDiagnosis:
RIGHT COLON, LESION, BIOPSY:
- COLONIC ADENOCARCINOMA, POORLY DIFFERENTIATED.
DiagnosisComment:
The tumor expresses an intestinal immunophenotype (CDX2/SATB2-positive) while PAX8 and WT1 are negative, supporting the above diagnosis.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.6 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: BIOPSY LESION RIGHT COLON,,
REG4,COLON,0,PAT-10040500,1,REC-3000696547,"ClinicalHistory:
197.7
Procedure->Core
Clinical History/Diagnosis/Condition->Liver masses./r/n",,"FinalDiagnosis:
Liver:  Metastatic adenocarcinoma consistent with gastrointestinal tract/colonic primary./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Nov 29 2011].  Findings reported to Dr. **NAME[XXX WWW] s office (**NAME[VVV]) on **DATE[Nov 31 2011] at 12:00 PM.  These findings are consistent with the clinical mass noted at 30 cm of the colon with the prior colonic biopsy (***PATH-NUMBER[1]) being superficial and limited in sampling the mass which is the likely primary site of the adenocarcinoma./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated liver core per the requisition only 
Specimen:    Cylindrical (formalin)
Number:      Five
Size:           Range from 0.4-1.9 cm length, each less than 0.1 cm diameter
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
The liver needle core has a large area with apparent metastatic adenocarcinoma with a fibrotic stromal reaction with infiltrating gland forming malignant columnar cells displacing the hepatic parenchyma cells. The adjoining liver has focal limited leukocytes including some neutrophils with reactive changes with focal hemosiderin bordering the tumor involved areas with focal reactive portal triad changes. The adenocarcinoma expresses cytokeratin 20 and CDX-2 and appears negative for cytokeratin 7 consistent with a colorectal primary./r/n","A: Liver, core biopsy",,"AddendumDiagnosis:
Liver tissue ***PATH-NUMBER[2]:  KRAS Mutation Detected

Genotype Result:    Mutation Gly12Asp (GGT->GAT)

Reference Range:  Mutation Detected:  Unlikely to respond to anti-EGFR therapy.
      Mutation Not Detected:  May respond to anti-EGFR therapy./r/nAddendumComment:
The results were reported by **NAME[UUU TTT], M.D. of Clarient Diagnostics Services, Aliso Viejo, CA on **DATE[Dec 6 2011].


Methodology:  Tumor areas were identified, selectively microdissected and lysed, and DNA extracted.  Real-time PCR was using eight primer sets was used to amplify the region of the KRAS gene containing codons 12 and 13.  A set of eight probes was used to specifically detect the wild-type and mutant sequences.

Intended Use:  The KRAS mutation analysis by real-time PCR detects the wild-type sequence and seven known mutations associated with codons 12 and 13 of the KRAS oncogene.  This assay is capable of detecting a mutation to 1% in a background of wild-type alleles.  The intended use of this assay is to aid the treating physician in the selection of the appropriate therapy for the patient.  Tumors harboring a KRAS mutation show relative insensitivity to anti-tyrosine kinase receptor therapies that signal through the RAS/RAF pathway.  The results of this study are to be interpreted in context with other clinical findings in patient care management

Prognostic and predictive testing should be interpreted in the context of additional clinical and/or histopathological findings.

This assay was developed and its performance characteristics were determined by **INSTITUTION.  Pursuant to the requirements of CLIA  88, this laboratory has established the test s accuracy and precision.  It has not been cleared or approved by the U.S. Food and Drug Administration, as the FDA has determined that such approval is not necessary.  This test is used for clinical purposes.  The results of this study are to be interpreted in the context of all other clinical findings./r/n"
REG4,COLON,0,PAT-10037542,2,REC-3000696680,"ClinicalHistory:
Cecal CA.",,"FinalDiagnosis:
RIGHT COLON:  
- TWO (2) COLONIC ADENOCARCINOMAS WITH MUCINOUS COMPONENT.
- CARCINOMAS ARISE FROM A VILLOUS AND TUBULAR ADENOMA.
- 19 BENIGN LYMPH NODES.

Colon cancer information
Operative procedure:  Laparoscopic right hemicolectomy.
  Tumor 1:
    Tumor-histologic type:  Adenocarcinoma with mucinous component.
    Histologic grade:  Low-grade (moderately differentiated).
    Anatomic site:  Cecum.
    Size:  3.7 x 3.4 x 1.3 cm (macroscopic).
    Depth of invasion:  pT2 - Tumor invades muscularis propria
    (deeper levels examined).
    Perforation:  Not identified.
    Crohn's-like lymphoid infiltrate:  Present.
    Tumor infiltrating lymphocytes:  Present.
    Pattern of growth at tumor periphery:  Infiltrative.
    Perineural invasion:  Not identified.
    Lymphatic invasion:  Not identified.
    Venous invasion:  Not identified.
    Resection margins:  Uninvolved by invasive carcinoma.
      Distance from proximal margin:  2.6 cm.  
      Distance from distal margin:  17.5 cm.  
      Distance from mesenteric margin:  2.5 cm.  
      Distance from radial margin:  2.3 cm.
  Tumor 2:
    Tumor-histologic type:  Adenocarcinoma with mucinous component.
    Histologic grade:  Low-grade (moderately differentiated).
    Anatomic site:  Ascending colon.
    Size:  0.4 x 0.3 cm (microscopic).
    Depth of invasion:  pT1 - Tumor invades submucosa.
    Perforation:  Not identified.
    Crohn's-like lymphoid infiltrate:  Present.
    Tumor infiltrating lymphocytes:  Present.
    Pattern of growth at tumor periphery:  Infiltrative.
    Perineural invasion:  Not identified.
    Lymphatic invasion:  Not identified.
    Venous invasion:  Not identified.
    Resection margins:  Uninvolved by invasive carcinoma.
      Distance from proximal margin:  9.1 cm.  
      Distance from distal margin:  11 cm.  
      Distance from mesenteric margin:  7 cm.  
      Distance from radial margin:  2.3 cm.
Regional lymph nodes:  0/19 (pN0).
Indications for mismatch repair protein (MMR) immunohistochemistry/microsatellite instability (MSI) testing:  Present.
Special procedures:  Both carcinomas and their respective adenomas exhibit loss of MLH1 and PMS2 (see addendum).
Distant metastasis:  Not applicable.
Other findings:  
- Terminal ileum with focal pyloric gland metaplasia consistent
  with prior mucosal injury.
- Tumor infiltrating lymphocytes within both adenomas.
- Pigment consistent with tattoo.
- Appendix without significant diagnostic alterations.
Pathologic stage:  
  Tumor 1:  pT2 pN0 (stage I if M0).
  Tumor 2:  pT1 pN0 (stage I if M0).",,"GrossDescription:
Specimen:  Right colon with attached segment of terminal ileum and appendix, received in formalin.  
Weight:  618 gm.  
Measurements:
Right colon  
   Length:  19.0 cm.  
   Circumference:  Up to 9.6 cm.
Terminal ileum
   Length:  4.5 cm.  
   Circumference:  Up to 6.5 cm.  
Appendix: 6.5 x 0.6 x 0.5 cm.  
Appearance of serosa:  Apparent serosal exudate around cecal pouch.  6.0 cm linear incision involving the serosal and mucosal surfaces, secured with sutures and vascular clips.  
Tumor
   Location: Cecum.  
   Appearance:  Soft tan-pink polypoid mass.  
   Size:  3.7 x 3.4 x 1.3 cm.  
   Depth of invasion:  Possible invasion into subserosal fat.  
   Distance from proximal margin:  2.6 cm.  
   Distance from distal margin:  17.5 cm.  
   Distance from mesenteric margin:  2.5 cm.  
   Distance from radial margin:  2.3 cm.
   Distance from appendiceal orifice: 0.7 cm.  
Appearance of uninvolved mucosa:  Raised tan polyploid lesion measuring 1.4 x 1.0 x 0.5 cm, 6.5 cm distal to tumor.
   Distance from proximal margin:  9.1 cm.  
   Distance from distal margin:  11 cm.  
   Distance from mesenteric margin:  7 cm.  
   Distance from radial margin:  2.3 cm.  
Other findings:  Sectioning of the appendix appears unremarkable.  
Mesentery
   Lymph nodes:  Multiple lymph nodes grossly identified measuring 2.6 x 1.3 x 0.8 cm.  
   Largest lymph node appears matted.  
   Other findings:  None.
Description of blocks for microscopic evaluation:
1  shaved proximal margin
2  shaved distal margin
3  mesenteric margin
4  radial margin
5-8  tumor
9  tumor with appendiceal orifice
10  polyploid lesion
11  intervening tissue
12  serosal exudate with linear incision
13  uninvolved
14  appendix with bisected tip
15-20  mesenteric lymph nodes within 3.0 cm of tumor (16-17 includes a single bisected lymph node, 18-19 each includes a single bisected lymph node, 20 includes two bisected lymph nodes inked black and orange)
21-25  mesenteric lymph nodes 3.0 cm distal from tumor
26-37 remainder of tumor.",,A: RIGHT COLON,,"Interpretation:
TUMOR 1:  MLH1 AND PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA AND ADENOMA NUCLEI;  NO MSH2 OR MSH6 PROTEIN LOSS OF EXPRESSION IN CARCINOMA OR ADENOMA NUCLEI.

CARCINOMA
- MLH1 (CLONE **ID-NUM):  Loss of expression.
- PMS2 (CLONE A16-4):  Loss of expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

ADENOMA
- MLH1 (CLONE **ID-NUM):  Loss of expression.
- PMS2 (CLONE A16-4):  Loss of expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.


TUMOR 2:  MLH1 AND PMS2 PROTEIN LOSS OF EXPRESSION IN CARCINOMA AND ADENOMA NUCLEI;  NO MSH2 OR MSH6 PROTEIN LOSS OF EXPRESSION IN CARCINOMA OR ADENOMA NUCLEI.

CARCINOMA
- MLH1 (CLONE **ID-NUM):  Loss of expression.
- PMS2 (CLONE A16-4):  Loss of expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

ADENOMA
- MLH1 (CLONE **ID-NUM):  Loss of expression.
- PMS2 (CLONE A16-4):  Loss of expression.
- MSH6 (CLONE **INITIALS):  Normal expression.- MSH2 (CLONE FE11):  Normal expression.

METHODS:  MISMATCH REPAIR PROTEIN IMMUNOHISTOCHEMISTRY

Formalin-fixed and paraffin-embedded tissue from block A6 and A10.

Controls were appropriately positive for each immunohistochemical stain.  Loss of protein expression for any of the mismatch repair genes helps to identify the causative gene and makes further mutation testing more efficient, if indicated following genetic counseling.  Immunohistochemical results are not definitive evidence of a germline versus a tumor-acquired alteration.
ResultsComments:
Concurrent loss of both MLH1 and PMS2 expression is typical as they are binding partners and this pattern suggests the mutation is within the MLH1 gene.  Thus, the immunohistochemical profile suggests microsatellite unstable carcinomas and their respective adenomas related to loss of MLH1 mismatch repair protein function.  Given the synchronous nature of the lesions and loss of MMR proteins in both the adenoma and carcinoma, further evaluation by a genetics counselor at the **INSTITUTION (phone: **PHONE) is highly recommended."
REG4,COLON,0,PAT-10027372,1,REC-3000696699,"ClinicalHistory:
Abdominal mass, post menopausal bleeding.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A.  Endocervical curettings:  Benign endocervical tissue and scant endometrial glands 
 
B.  Endometrial curettings:    Disordered proliferative endometrium
 
C.  Omental mass, biopsy:    Metastatic mucinous adenocarcinoma, favor colorectal 
          or appendiceal primary.
DiagnosisComment:
For part A and B, Dr. **NAME[ZZZ] concurs.
For part C, the tumor cells are positive for CK20 and CDX2; while negative for CK7, TTF1, WT1 and ER. The morphologic features and immunostaining patter are consistent with metastatic mucinous adenocarcinoma from colorectal or appendiceal primary.
Dr. **NAME[YYY] concurs.",,"GrossDescription:
A.  Received in formalin labeled as ""**NAME[BBB], endocervical curettage"" are fragments of hemorrhagic tissue and mucoid material measuring 2.0 x 2.0 x 0.3 cm in aggregate dimension.  Submitted entirely in one cassette. 

B.  Submitted in formalin labeled ""**NAME[BBB], endometrial curettage"" are fragments of hemorrhagic tissue measuring 3.1 x 1.9 x 0.5 cm in aggregate dimensions.  Submitted entirely in two cassettes. 

C.  Received in formalin labeled ""**NAME[BBB], omental mass"" is soft tan to yellow tissue, 3.0 x 2.6 x 0.6 cm.  sectioning reveals a firm, white nodule, largest up to 1.6 x 0.5 x 0.5 cm.  Submitted entirely, serially in three cassettes.","MicroscopicDescription:
A-C.  The microscopic description supports the above diagnoses.","A: Endocervical curettings
B: Endometrial curettings
C: Omental mass biopsy",,
REG4,COLON,0,PAT-10040093,1,REC-3000697126,"ClinicalHistory:
R/O Ulcer vs cancer.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Colonoscopy with biopsy.",,"PreOperativeDiagnosis:
Colonoscopy with biopsy.
PostOperativeDiagnosis:
Same, Pending pathology.
FinalDiagnosis:
Lesion, ascending colon/cecum, biopsy:  ADENOCARCINOMA, moderately-differentiated.",,"GrossDescription:
Received in formalin labeled ""biopsy at ascending colon/cecum"" are five pieces of tan tissue measuring up to 0.3 cm in greatest dimension.  Submitted entirely in one block.","MicroscopicDescription:
Fragments of colonic mucosa exhibit an invasive, moderately-differentiated carcinoma exhibiting large areas of ulceration and necrosis.  Foci of invasion are supported by irregular, neoplastic glands surrounded by desmoplastic fibrous stroma.  A histochemical stain for mucin is focally positive in malignant glands.  An immunostain (pankeratin) focally delineates infiltrative glands.",A: Ascending colon/cecum biopsy,,
REG4,COLON,0,PAT-10037880,1,REC-3000697455,"ClinicalHistory:
Sigmoid colon CA.",,"IntraoperativeDiagnosis:
GROSS:  Tumor present, margins clear.  Assessed by **NAME[M. ZZZ] MD/KC.
FinalDiagnosis:
SEGMENT OF SIGMOID COLON:
1.  COLONIC ADENOCARCINOMA
2.  2 OF 21 LYMPH NODES POSITIVE FOR METASTASES (2/21)

Colon cancer information
Operative procedure:  Sigmoid colectomy
Tumor-histologic type:  Colonic adenocarcinoma
Histologic grade:  Moderately to poorly differentiated
Anatomic site:  Sigmoid colon
Size:  4.8 x 4.0 cm  
Depth of invasion:  Tumor invades through muscularis propria into pericolic tissues
Perforation:  None
Crohn's-like lymphoid infiltrate:  Not identified
Tumor infiltrating lymphocytes:  Present
Pattern of growth at tumor periphery:  Infiltrative
Perineural invasion:  Present
Lymphatic invasion:  Not identified
Venous invasion:  Not identified
Resection margins:  Clear
Distance to closest mucosal margin:  5.1 cm
Distance to closest radial margin:  5.3 cm
Regional lymph nodes:  2 of 21 lymph nodes positive for metastases (2/21), maximal size of metastasis 0.9 cm, extranodal extension present
Distant metastasis:  Unknown
Indications for MMR (MSI) testing:  None
Special procedures:  None
Other findings:  None
Pathologic grade and stage:  G2-3 pT3 pN1 (Stage IIIB, if M0).",,"GrossDescription:
Specimen:  Undesignated segment of sigmoid colon, received fresh and subsequently placed in formalin.  
Weight:  136 gm.  
Measurements:  
   Length:  16.0 cm.  
   Circumference:  6.7 cm.  
Appearance of serosa:  Unremarkable.  
Tumor
   Location: Sigmoid colon.  
   Appearance:  Tan-red, ulcerated with raised edges.  
   Size:  4.8 x 4.0 cm.  
   Depth of invasion:  Involving the muscularis propria with apparent fat invasion.  
   Distance from margin 1 (stitched margin, inked green):  7.0 cm.  
   Distance from margin 2:  5.1 cm.  
   Distance from mesenteric margin:  5.3 cm.  
Appearance of uninvolved mucosa:  Unremarkable.  
Other findings:  None.  
Mesentery
   Lymph nodes:  Multiple lymph nodes identified measuring up to 1.5 x 1.4 x 1.0 cm.  
   Other findings:  None.
Photos:  Taken.
Description of blocks for microscopic evaluation:
1  margin 1
2  margin 2
3  mesenteric margin
4-7  tumor
8  uninvolved mucosa
9  single bisected lymph node, within 3-cm of tumor
10-12  lymph nodes within 3-cm of tumor
13  lymph nodes greater than 3 cm towards margin 1
14  lymph nodes greater than 3 cm towards margin 2.",,A: SIGMOID COLON,,
REG4,COLON,0,PAT-10041030,1,REC-3000697764,"ClinicalHistory:
Malignant neoplasm rectosigmoid junction.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same.
FinalDiagnosis:

Colectomy, ""sigmoid colon and anastomotic segment"":          PAS 9
  1.  MODERATELY DIFFERENTIATED INVASIVE ADENOCARCINOMA, EXTENDING THROUGH 
    MUSCULARIS PROPRIA INTO SUBSEROSAL SOFT TISSUE
  2.  Resection margins negative for carcinoma
  3.  Thirty-three lymph nodes, all negative for metastatic carcinoma (0/33)

Tumor Information:
Type of specimen(s):  Colectomy
Histologic type:  Adenocarcinoma
Histologic grade:  Moderately differentiated
Tumor site:  Sigmoid
Tumor size:  3.5 x 3 x 1.4 cm
Tumor configuration:  Exophytic
Extent of invasion:  Through muscular propria into subserosal soft tissue
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
Perineural invasion:  Not identified
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:  Negative
  Mucosal margin #1:  3.5 cm
  Mucosal margin #2:  2.5 cm
  Circumferential/radial:  1.5 cm
Lymph node metastasis:  Negative; Thirty-three nodes all negative for carcinoma (0/33)
AJCC Pathologic Stage:  pT3, pN0.
DiagnosisComment:
This case will be sent for routine intradepartmental consensus review.",,"GrossDescription:
Received in formalin, labeled ""sigmoid colon and anastomotic segment"" is a rectosigmoid segment (9 cm in length by 2 by 2.5 cm in diameter).  The specimen is unoriented.  One resection margin is stapled and inked red.  The other resection margin is left opened and inked black.  The mesenteric/radial resection margin is inked green.  The specimen was received partially opened.  A tan-red mass (3.5 x 3 x 1.4 cm) is found 3.5 cm away from the red inked resection margin, 2.5 cm away from the black inked resection margin and 1.5 cm away from the mesenteric/radial resection margin.  The mass grossly appears to penetrate through the muscularis propria.  The remainder of the specimen appears grossly uninvolved.  Representative sections are submitted as follows:

1  -  Perpendicular section of red inked resection margin
2  -  Perpendicular section of black inked resection margin
3  -  Perpendicular section of mesenteric/radial resection margin
4-6  -  Sections of closest approaching mass to mesenteric/radial resection margin
7-11  -  Sections of mass grossly appearing to penetrate through muscularis propria
12-13  -  Additional sections of mass
14  -  Section of grossly uninvolved bowel adjacent to mass, closest to red inked resection margin
15  -  Section of grossly uninvolved bowel adjacent to mass, closest to black inked resection margin
16  -  Six possible lymph nodes
17  -  Six possible lymph nodes
18  -  Six possible lymph nodes
19  -  Six possible lymph nodes
20  -  Six possible lymph nodes
21  -  Four possible lymph nodes.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Sigmoid colon and anastomotic segment,,
REG4,COLON,0,PAT-10040093,1,REC-3000697953,"ClinicalHistory:
Colon cancer cecum.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Laparoscopic right colectomy.",,"PreOperativeDiagnosis:
Laparoscopic right colectomy.
PostOperativeDiagnosis:
Same, Pending pathology.
FinalDiagnosis:
RIGHT COLON ADENOCARCINOMA
Tumor information:
Type of specimen:      Laparoscopic right colectomy 
Tumor location:      Right colon/cecum
Tumor size:        5.5 x 3.5 x 1.5 cm
Histologic type:      Adenocarcinoma
Histologic grade:      Moderately-differentiated 
Level of invasion:      Subserosal fat
Peritoneal involvement:    Not evident
Lymphovascular invasion:    Not evident
Perineural invasion:      Not evident
Invasion of contiguous structures:  Not evident
Resection margins:      Free of carcinoma (6.0 cm proximal clearance, >9.0 cm distal clearance)
Lymph node involvement:    Positive for metastasis (3 of 18 nodes positive for metastasis)
Mesenteric involvement:    Not evident
Stage:          pT3 N1b.",,"GrossDescription:
Received fresh labeled ""right  colon"" is a resected segment of colon measuring 18.0 cm in length x 10.0 cm average outside diameter.  The proximal margin is comprised of a length of ileum measuring 6.5 x 2.5 cm.  The serosal surface is smooth and tan-pink.  Opening reveals a tan-pink mucosa with a tan-pink to red, centrally ulcerated mass lesion measuring 5.5 x 3.5 x 1.5 cm, located at the ileocecal junction, 6.0 cm from the proximal margin, >9 cm from the distal margin.  Sectioning through the lesion reveals gross invasion of the muscle layer and possible invasion of the surrounding fat.  A tan-pink appendix, measuring 2.5 cm in length x 0.8 cm in average outside diameter, is grossly identified  No further masses or lesions are grossly identified.  Representative sections are submitted in blocks 1-10.  
   
  SECTION SUMMARY:
  1  -  Proximal margin
  2  -  Distal margin
  3-6  -  Sections through lesion
  7  -  Appendiceal base
  8-10  -  Lymph node.","MicroscopicDescription:
Proximal and distal margins are free of tumor.  The mucosal mass is an invasive, moderately-differentiated adenocarcinoma extending through the muscular wall into subserosal fat.  The appendix is normal.  3 of 18 identified nodes are positive for metastasis.",A: Right colon,,
REG4,COLON,0,PAT-10040834,1,REC-3000703522,"ClinicalHistory:
153.4 
211.3 
562.10
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Cecal neoplasm.  Colon polyps./r/n",,"FinalDiagnosis:
A. Cecal mass, biopsy: Adenocarcinoma; depth of invasion cannot be determined (see comment).

B. Proximal transverse colon, polyp: Tubular adenoma.

C. Colon, splenic flexure, polyps: Tubular adenomas; largest (0.7 cm) with focal high grade dysplasia.

D. Rectum, polyp: Sessile serrated adenoma./r/nDiagnosisComment:
A.  The H\T\E-stained sections demonstrate several fragments of tubulovillous adenoma with focal areas of adenocarcinoma.  The size of the tissue fragments and the orientation precludes accurate assessment of depth of invasion.  Please correlate with the endoscopic and radiologic findings.  

Intradepartmental consultation (part A and C) with Dr. **NAME[ZZZ YYY] on **DATE[Apr 3 12].  Dr. **NAME[XXX WWW] notified of the findings via e-mail communication on **DATE[Apr 3 12] at 5:00 p.m./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated cecal mass   Specimen:    Four, firm ovoid gray-pink pieces of tissue (formalin)
  Aggregate:    0.8 x 0.5 x 0.3 cm
  Submitted/Block:    Entirely/1  

B.  Labeled:      Patient name and medical record number, designated proximal transverse
  Specimen:    Single, ovoid pale gray piece of tissue (formalin)
  Size:      0.4 x 0.4 x 0.3 cm
  Submitted/Block:    Entirely/1

C.  Labeled:      Patient name and medical record number, designated splenic flexure x3   Specimen:    Three, ovoid firm dark pink pieces of tissue (formalin)
  Aggregate:    1.1 x 1 x 0.4 cm
  Submitted/Block:    Entirely/1
  
D.  Labeled:      Patient name and medical record number, designated rectal polyp
  Specimen:    Single, ovoid gray-pink piece of tissue (formalin)
  Size:      0.3 x 0.3 with 0.2 cm
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A-D.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Cecal mass, biopsy
B: Proximal colon polyp, biopsy
C: Splenic flexure polyps, biopsy
D: Rectal polyp, excision",,
REG4,COLON,0,PAT-01355189,1,REC-3000703523,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->OTH
*** METASTATIC COLON CANCER TO THE BRONCHUS./r/n",,"FinalDiagnosis:
Airway tumor, excision: Metastatic adenocarcinoma consistent with colonic primary, tumor present at tissue edges./r/nDiagnosisComment:
The tumor is histologically similar to the patients prior bronchial metastasis (***PATH-NUMBER[1]). Intradepartmental consultation with Dr. **NAME[ZZZ]. Dr. **NAME[YYY] contacted via e-mail message on **DATE[Mar 3 12] at 3:45 pm./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated airway tumor Specimen:    Multiple, tan hemorrhagic pieces of tissue (formalin)
Aggregate:    3.5 x 2 x 1 cm
Submitted/Blocks    Entirely/2./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Airway tumor, excision",,
REG4,COLON,0,PAT-10039812,1,REC-3000703539,"ClinicalHistory:
Colonic mass.",,"FinalDiagnosis:
COLON, MASS AT DESCENDING, BIOPSY:
- COLONIC ADENOCARCINOMA, MODERATELY DIFFERENTIATED.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  4.    
Size:  Up to 0.5 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: BIOPSY - COLONIC MASS AT DESCENDING,,
REG4,COLON,0,PAT-10039975,1,REC-3000703623,"ClinicalHistory:
History of colon cancer stage III
Previous
[***PATH-NUMBER[1] **DATE[Feb 22 2012]: Right colon, ileum, and transverse colon: COLONIC ADENOCARCINOMA, MULTIFOCAL.
Post-OperativeDiagnosis:
Colon polyp.",,"PostOperativeDiagnosis:
Colon polyp.
FinalDiagnosis:
A.  Colon, anastomosis, biopsy:  Colonic mucosa with inflammation, edema, and hyperplastic change
 
B.  Colon, 40 cm, polyp, biopsy:    Tubular adenoma.
DiagnosisComment:
A-B.  No malignancy is noted.
Dr. **NAME[ZZZ YYY] concurs with the diagnoses.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, bx anastomoses"" are three fragments of tan tissue measuring up to 0.3 cm in greatest dimension.  Submitted in toto in block A.

B.  Received in formalin labeled ""XXXXXX, snare polyp at 40 cm"" is a soft tan polypoid tissue, 1.1 x 0.7 x 0.6 cm.  Submitted entirely in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: Biopsy anastomosis
B: Snare colon polyp at 40 cm",,
REG4,COLON,0,PAT-10039891,1,REC-3000703751,"ClinicalHistory:
Large polyp in descending colon.",,"FinalDiagnosis:

A.  Descending colon mass, resection:  1.  TUBULAR ADENOMA WITH ADENOCARCINOMA IN SITU.
              Polyp size: 3.0 x 2.8 x 2.4 cm; 20% - 30% of the polyp is 
              involved by adenocarcinoma in situ 
            2.  Margins negative.
            3.  Eight benign lymph nodes (0/8).

B.  Liver, core needle biopsy:      1.  Mild macrovesicular and microvesicular steatosis (involving 
              approximately 10% - 20% of the hepatocytes).
            2.  Mild portal mixed inflammation (grade 1 out of 3).
            3.  Mild portal fibrosis (stage 1 out of 4).
            4.  No increase in hepatocyte stainable iron.

Case discussed with Dr. **NAME[M. ZZZ YYY] on **DATE[Aug 5 2012].",,"GrossDescription:
(A)  Received in formalin labeled ""descending colon mass"" is a previously opened colon resection specimen measuring 10.5 cm in length by up to 3 cm in diameter.  The intact adipose tissue is yellow with central areas of focal hemorrhage noted.  The serosal surfaces are tan-red and knotted.  The staple line at the resection margin appears grossly unremarkable.  The intact lumen shows unremarkable rugal folds with an area 3.5 cm from the nearest staple line appearing to be previously inked black.  There is a large red-tan colon polyp measuring 3 x 2.8 x 2.4 cm (with a 4.3 x 1.6 x 0.8 cm extended mucosal lining attached to the base of the polyp).  The polyp is within 5.5 cm from the nearest staple line.  No other suspicious masses or lesions noted.  Representative sections submitted sequentially in fourteen cassettes.  The staple line nearest polyp is inked black and the opposite resection line is uninked.    The polyp is submitted in cassettes A3 - A5 and random sections A2, A6, A7, and opposite resection margin in A8. Possible lymph nodes (each submitted as whole) and random fatty tissue sections in cassettes A9 - A14.

(B)  Received in formalin labeled ""liver biopsy"" is a yellow-brown and soft tissue core biopsy measuring 1.2 x 0.2 x 0.2 cm.  All in.  One cassette.","MicroscopicDescription:
A, B.  Microscopic findings and special stains (iron, trichrome, and reticulin performed on B) support the diagnosis.","A: Descending colon mass
B: Liver biopsy",,
REG4,COLON,0,PAT-10039017,1,REC-3000703763,"ClinicalHistory:
Large bowel obstruction due to colon mass.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Exploratory laparotomy.",,"PreOperativeDiagnosis:
Exploratory laparotomy.
PostOperativeDiagnosis:
Same.
FinalDiagnosis:
A.  Nodule, peritoneum, biopsy:    Benign fibrofatty soft tissue with lymphocytic infiltrate; 
            negative for malignancy 

B.  LEFT COLON ADENOCARCINOMA
Tumor information:
Operative procedure:      Left colectomy
Tumor location:        Left colon
Tumor size:        6.0 x 5.5 x 1.2 cm (circumferential)
Histologic type:        Adenocarcinoma
Histologic grade:        Poorly-differentiated 
Level of invasion:        Subserosal adipose tissue
Peritoneal involvement:      Not evident
Lymphovascular invasion:    Present, extensive
Perineural invasion:      Present
Invasion of contiguous structures:  Not evident 
Resection margins:      Free of carcinoma (4.0 cm minimum clearance) 
Lymph node involvement:      Positive for metastasis (6 of 21 nodes positive for metastatic              carcinoma)
Other:          Small tubulovillous adenoma 
Mesenteric involvement:      Not evident 
Stage:          pT3 N2a.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, peritoneal biopsy"" is soft, white, irregular piece of tissue measuring up to 1.0 x 0.3 x 0.3 cm in greatest dimension.  The specimen is inked black, and trisected.  Submitted entirely in one cassette.

B.  Received fresh labeled ""XXXXXX, left colon"" are two unoriented segments of colon, the larger of which measures up to 32.0 cm in greatest length x 13.2 cm in greatest circumference.  

The smaller segment of bowel measures up to 11.0 cm in length x 5.0 cm in greatest diameter.  The smaller segment consists 
of two segments sutured together, with a small amount of fibrous adhesions at the center.  

The larger segment is opened to reveal a circumferential tumor measuring up to 5.5 x 6.0 x 1.25 cm in greatest dimension.  The 
mass lesion has a central area of ulceration, and necrosis.  The mass is approximately 4.0 cm from one end of the bowel, and 
approximately 32.0 cm away from the opposite end.  The overlying surface of the tumor is inked black, and the margin closest 
to the tumor is inked blue.  

Sectioning of the tumor reveals that it invades through the  muscularis propria, and possibly into the fat.  No other mass 
lesions are present within the larger segment of bowel. 

Opening of the smaller segment of bowel reveals multiple red polyps, the largest of which measures up to 1.2 x 0.7 x 0.5 cm in 
greatest dimension.  

Palpation of the pericolonic fat reveals at least 12 lymph nodes, ranging from 0.5 cm in greatest dimension to 0.2 cm in greatest 
dimension.  

KEY TO CASSETTES:
B1    -  Margins of the larger colon segment
B2-B13    -  Representative sections of the tumor, including the area as deep as penetration
B14    -  Normal colonic tissue from the larger segment
B15-B17    -  Lymph nodes
B18    -  Representative section of the largest polypoid structure present within the smaller segment of 
      colon
B19    -  Representative sections of smaller colon segment.","MicroscopicDescription:
A.  Sections contain a small fragment of fibrous and fibrofatty soft tissue with focal chronic lymphocytic inflammation.   There is no evidence of malignancy.  A CDX2 immunostain is negative for evidence of metastatic carcinoma.  

B.  Proximal and distal margins are free of carcinoma.  The circumferential mucosal mass is an invasive malignancy extending through the muscular wall into subserosal areas.  Tumor closely approaches the overlying serosa.  Tumor is composed of nests and sheets of fairly monotonous cells exhibiting areas of necrosis.  There is extensive lymphovascular tumor infiltration.  6 of 21 lymph nodes are positive for metastatic tumor.  Additional sections of bowel demonstrate a small pedunculated tubulovillous adenoma.  Based on the monotony of the main tumor, special stains are evaluated (CDX2, LCA, CD56, Synaptophysin, Chromogranin, mucin).  These demonstrate no evidence of intracytoplasmic mucin staining.  Tumor cells are positive for CDX2 and negative for LCA, CD56, Chromogranin and Synaptophysin.  While cells have a monotonous, possible neuroendocrine appearance, immunostaining does not support neuroendocrine differentiation.","A: Peritoneal biopsy
B: Left colon",,
REG4,COLON,0,PAT-10039926,1,REC-3000703865,"ClinicalHistory:
Mass ileocecal valve.
Pre-OperativeDiagnosis:
Right colectomy:.",,"PreOperativeDiagnosis:
Right colectomy:.
FinalDiagnosis:
Right colon:  

Tumor Information:

Type of specimen(s):  Right colectomy
Histologic type:  Adenocarcinoma
Histologic grade:  Low grade 
Tumor site:  Cecum
Tumor size:  3.5 x 2.5 x 1.0
Tumor configuration:  Flat
Extent of invasion:  Tumor extends through muscularis to serosal surface
Macroscopic tumor perforation:  Not identified
Lymph-vascular invasion:  Not identified
Venous invasion:  Not identified
  Intramural:  Not identified
  Extramural:  Not identified
Perineural invasion:  Present
Discontinuous extramural extension:  Not identified
Marked lymphocytic response:
  Intratumoral (tumor infiltrating):  Not identified
  Peritumoral (Crohn-like):  Not identified
Mucinous/signet ring/medullary pattern:  Not identified
Neoadjuvant treatment effect:  Not identified
Resection margins:  Clear
  Proximal:  Clear by approximately 4 cm
  Distal:  Widely clear 
Lymph node metastasis:  16 regional nodes negative for metastatic carcinoma
Other findings:  KRAS reflex to BRAF requested, MSI testing requested
AJCC Pathologic Stage:  pT3, pN0
      Pathologic stage:  IIa.",,"GrossDescription:
Right colon:  Received is a right colectomy that includes the cecum.  The specimen measures 60 cm in length.  At the ileo-cecal valve is a flat tumor that measures up to 3.5 x 2.5 x 1.0 cm.  On section, it appears to extend through the thickness of the wall.  The proximal margin is approximately 4 cm from the tumor and the distal margin is widely free.  The vermiform appendix is grossly free of tumor and inflammation.  It measures 7 x 0.6 x 0.6 cm.  Representative sections submitted as follows:  tumor, 1-4; margins, 5; vermiform appendix, 6; possible lymph nodes, 7 through 12.","MicroscopicDescription:
Right colon:  The sections of cecal mass demonstrate a tumor characterized by back-to-back glands.  In areas nuclei are large and hyperchromatic with loss of polarity.  The tumor is entirely glandular without solid areas.  Tumor invades through the muscularis propria into the peri-colic soft tissue and to the serosal surface.  Neural invasion is noted.  Definite vascular invasion is not appreciated.  The surgical margins are free of tumor.  A section of vermiform appendix demonstrates acute peri-appendiceal inflammation.  Neoplastic changes are not noted in the vermiform appendix.  Sixteen regional nodes are identified and these are negative for metastatic carcinoma.",A: Right colon,,
REG4,COLON,0,PAT-10038773,1,REC-3000704148,"ClinicalHistory:
Abnormal CT.",,"FinalDiagnosis:

BIOPSY- SIGMOID MASS AT 15 CM:  
-MODERATELY DIFFERENTIATED ADENOCARCINOMA.",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  2.    
Size:  Up to 0.4 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: BIOPSY- SIGMOID MASS AT 15 CM,,
REG4,COLON,0,PAT-10037723,2,REC-3000705441,"ClinicalHistory:
Lynch syndrome, colon cancer.",,"FinalDiagnosis:
PELVIC WASHING:  NEGATIVE FOR MALIGNANT CELLS.",,"GrossDescription:
Received:  45 cc of turbid, red fluid.
Prepared:  2 cytospin slides for Pap and DQ stains (treated with NH4Cl x 2).
Submitted:  cell button for a cell block.",,A: PELVIC WASHING,,
REG4,COLON,0,PAT-10040263,2,REC-3000705963,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->Colon cancer.",,"FinalDiagnosis:
Terminal ileum and right colon:  Moderately differentiated adenocarcinoma confined to polyp (2.7 cm); margins uninvolved.

  Thirteen lymph nodes negative for metastases (0/13).
 
  Pathologic stage pT1 N0 

  See microscopic description for additional tumor information.
DiagnosisComment:
Intradepartmental consultation (select slides) with Dr. **NAME[ZZZ YYY] on **DATE[May 15 12].  The amended report (updating the lymph node count) was discussed with Dr. **NAME[XXX WWW] on **DATE[May 16 12] at 4:20 p.m.",,"GrossDescription:
Labeled:        Patient name and medical record number, designated sigmoid colon
Specimen:      Tan-brown section of colon with pedunculated tumor and associated fat.  
Size:        27.7 x 14.2 x 4.2  cm
Orientation:      Stapled line at distal end
Colors:
  Black:        Distal   
  Blue:        Proximal
Tumor:      
  Location:      9 cm from distal end
  Size:        2.7 x 2.5 x 1.4 cm
  Description:      Brown lobulated pedunculated polyp appearance with stalk    
  Ulceration/perforation:      Not identified  
  Distance from margins:      9 cm from distal margin
        14.7 cm from proximal margin
        7.4 cm from radial margin        
  Estimated depth of invasion:  0.7 cm
Other lesions:      Not identified
Regional lymph nodes:    10 possible
Section code:    
  Block 1:      Proximal and distal margins
  Block 2:      Radial margin
  Blocks 3-4:      Tumor
  Block 5:      Uninvolved colon
  Blocks6-9:      Single bisected lymph nodes
  Blocks 10-11:      Possible lymph nodes
  Blocks 12-17:      Random sections of fat (contiguous to tumor)
  Blocks 18-20:      Remaining tumor
  Block 21:      Fat with possible lymph nodes
  Block 22:      Fat with possible lymph nodes
  Blocks 23-24:      Fat with possible lymph nodes
  Blocks 25-26:      Fat with possible lymph nodes
  Blocks 27-31:      Contiguous fat 
  Blocks 32-42:      Contiguous fat.","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings. 

Colon and Rectum Cancer information (Based on AJCC/UICC TNM, 7th edition)

Tumor Site: Sigmoid colon.
Tumor Size: 2.7 x 2. x 1.4 cm (polyp)
Macroscopic Tumor Perforation: None
Histologic Type: Adenocarcinoma
Histologic Grade: Low-grade (well-differentiated to moderately differentiated).
Microscopic Tumor Extension: Tumor invades into the submucosa of the polyp (and remains confined to the polyp).
Margins:
     Proximal margin: Uninvolved by invasive carcinoma; 14.2 cm distant.
     Distal margin: Uninvolved by invasive carcinoma; 9.0 cm distant.
     Circumferential/radial margin: Uninvolved by invasive carcinoma; 7.4 cm distant.
     Distance of invasive carcinoma from closest margin (circumferential): at least 7.4 cm
Treatment Effect (if applicable): Not applicable.
Lymph-Vascular Invasion: Not identified.
Perineural Invasion: Not identified.
Tumor Deposits: Not identified.
Type of Polyp in Which Invasive Carcinoma Arose:  Tubular adenoma.
Pathologic Staging (pTNM):
      Primary tumor: pT1 (tumor invades the submucosa)
      Regional lymph nodes: pN0 (No regional lymph node metastasis).
         Number examined: 13
         Number involved: 0
      Distant metastasis: Not applicable.","A: Sigmoid, excision",,
REG2,LUNG,0,PAT-40160298,1,REC-100000926619,"ClinicalHistory:
Lung mass.","CytologyReview:
 Malignant cells consistent with Non Small Cell Carcinoma.

Malignant cells consistent with Squamous Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.

FINAL DIAGNOSIS:
Lung, Left Upper Lobe, CT Guided Fine Needle Aspiration Specimen:
Malignant Cells Present, Consistent with Squamous Cell Carcinoma. 
See Comment.

COMMENT:
  Sections of the CT guided fine needle aspiration from the left upper lobe show a cellular sample for evaluation consisting of multiple clusters and single cells of multiple malignant cells-?? arranged in cohesive clusters and as single cells having large nuclei, hyperchromatic chromatin, indistinct nucleoli, and abundang cytoplasm.  A cell block preparation is made and immunohistochemical stains are performed.  In the cell block there is cytoplasmic eosinophilia and intercytoplasmic bridges are seen.  Immunohistochemical stains document CK56 immunoreactivity and p63 staining, while TTF1 and napsin A are nonimmunoreactive.  These cytololgic and immunohistochemical findings are interpreted as a poorly differentiated keratinizing squamous cell carcinoma.  

NOTE:
  This case is reviewed at the Departmental Surgical Pathology Conference.","FinalDiagnosis:

FINAL DIAGNOSIS:
Lung, Left Upper Lobe, CT Guided Fine Needle Aspiration Specimen:
Malignant Cells Present, Consistent with Squamous Cell Carcinoma. 
See Comment.

COMMENT:
  Sections of the CT guided fine needle aspiration from the left upper lobe show a cellular sample for evaluation demonstrating malignant cells arranged in cohesive clusters and as single cells having large nuclei, hyperchromatic chromatin, indistinct nucleoli, and abundant cytoplasm.  A cell block is made prepared and immunohistochemical stains are performed.  Cytoplasmic eosinophilia and intercytoplasmic bridges are seen.  Immunohistochemical stains document CK5 6 and p63 staining, while TTF1 and napsin A are nonimmunoreactive.  These cytololgic and immunohistochemical findings are interpreted as a poorly differentiated keratinizing squamous cell carcinoma.  

NOTE:
  This case is reviewed at the Departmental Surgical Pathology Conference.",,"GrossDescription:

Received:  30cc bloody cytolyt for ThinPrep and Cell Block
2 Air-Dried Smears, 2 Fixed Smears
Specimen examined in Radiology suite with rapid cytologic stain: found to have sufficient cellular material for pathologic examination.",,"A: Lung Left Upper Lobe, Fine Needle Aspiration",,
REG2,LUNG,0,PAT-40084695,3,REC-100000926882,"ClinicalHistory:
  Left lower lobe lung caner.",,"FinalDiagnosis:
1.  Lymph Node, Level 9, Excisional Biopsy:
No Carcinoma Identified in One (1) Lymph Node (0 of 1). 

2.  Lymph Node, Level 10, Excisional Biopsy:
No Carcinoma Identified in One (1) Lymph Node (0 of 1). 

3.  Lymph Node, Level 8, Excisional Biopsy:
No Carcinoma Identified in One (1) Lymph Node (0 of 1). 

4.  Lymph Node, Level 11, Excisional Biopsy:
No Carcinoma Identified in One (1) Lymph Node (0 of 1). 

5.  Lymph Node, Level 12, Left Lower Lobe, Excisional Biopsy:
No Carcinoma Identified in One (1) Lymph Node (0 of 1). 

6.  Lung, Left, Lower Lobe, Lobectomy:
Adenocarcinoma, Well to Moderately Differentiated, 2.1 x 2.0 x 1.1cm. 
No Carcinoma Identified on Surgical Margins of Excision. 
See Note. 

NOTE: 
  The supplied clinical information is noted.  Previous specimens, including N12 3435, S12 20165, N12 3194, S08 12289, S08 8378, N08 693, and S08 243, are noted 

  In specimens #1 through #5, lymph nodes, no carcinoma is identified in a combined total of five (5) lymph nodes (0 of 5) in the sections examined.  

  In specimen #6, lung, left, lower lobe, lobectomy, sections show a well to moderately differentiated adenocarcinoma of the lung.  The carcinoma measures 2.1 x 2.0 x 1.1cm grossly.  No definite lymphatic invasion, blood vessel invasion, or perineural invasion by carcinoma is identified in the sections examined.  No definite histopathologic evidence of invasion into or through the visceral pleura is identified in the sections examined.  No carcinoma is identified on the marked bronchial, vascular, staple line, or any other surgical margin of excision in the sections examined.  

  Based on the pathologic findings in the present specimen and the patient's previous specimens, including N12 3435, S12 20165, and N12 3194, alone, the TNM stage for this adenocarcinoma of the lower lobe of the left lung would be:  pT1b  pN0  pMX  (Stage IA) (AJCC, 7th edition). 

SYNOTIC REPORT:
LUNG: Resection

Specimen  :  Lobe of lung: left lung, lower lobe
Procedure  :  Lobectomy
Specimen Integrity  :  Intact
Specimen Laterality  :  Left

Tumor Site  :  Lower lobe

Tumor Size  :  Greatest dimension: 2.1cm
      Additional dimensions: 2.0 x 1.1cm

Tumor Focality  :  Unifocal

Histologic Type  :  Adenocarcinoma 
Histologic Grade  :  G1, Well differentiated 
      G2, Moderately differentiated
 
Visceral Pleura  :  Not identified (no involvement by tumor identified)
 
Tumor Extension  :  Not applicable

Margins
  If all margins uninvolved by invasive carcinoma
    :  Distance of invasive carcinoma from closest margin: 20mm
      Specify margin: Vascular and staple line
  Bronchial Margin  :  Uninvolved by invasive carcinoma and carcinoma in situ 
  Vascular Margin  :  Uninvolved by invasive carcinoma
  Parenchymal Margin  :  Uninvolved by invasive carcinoma
  Parietal Margin  :  Not applicable
  Chest Wall Margin  :  Not applicable
  Other Attached Tissue Margin  :  Not applicable

Treatment Effect  :  Not applicable

Lymph Vascular Invasion  :  Not identified
 

Pathologic Staging (pTNM)
  Primary Tumor  :  pT1b  Tumor greater than 2cm, but 3cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (ie, not in the main bronchus)
  Regional Lymph Nodes  :  pN0  No regional lymph node metastasis
          Number of lymph nodes examined: 5
          Number of lymph nodes involved: 0
  Distant Metastasis  :  Not applicable

Additional Pathologic Findings  :  None identified
 
Comments  :  See N12 3435, S12 20165, and N12 3194;
      See report.",,"GrossDescription:
  Container 1:  Received in formalin labeled level 9 is a 0.3cm in greatest dimension tan to gray, presumed lymph node with a moderate amount of attached yellow, lobulated adipose tissue.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled level 10 lymph node is a 0.9cm in greatest dimension tan to gray, rubbery, presumed lymph node.  The specimen is submitted in toto as 2A.

  Container 3:  Received in formalin labeled level 8 lymph node is a 1.0cm in greatest dimension tan to gray, rubbery, presumed lymph node.  The specimen is submitted in toto as 3A.

  Container 4:  Received in formalin labeled level 11 lymph node is a 1.2cm in greatest dimension tan to gray, rubbery lymph node, which is bisected and submitted in its entirety as 4A.

  Container 5:  Received in formalin labeled level 12 left lower lobe lymph node is a 1.0cm in greatest dimension tan to gray, rubbery lymph node, which is bisected and submitted in its entirety as 5A.

  Container 6:  Received fresh labeled left lower lung lobe is a 183.6 gram, 15.2 x 11.0 x 3.8cm lung lobe displaying multiple linear staple lines along one aspect, which are removed to reveal a 1.5cm segment of bronchus measuring up to 1.5cm in diameter.  In addition, there are several vascular segments, averaging 0.5cm in length and measuring up to 1.0cm in diameter.  Neither the bronchus nor vessels appear to be involved by tumor.  The remaining staple lines are inked blue.  There is a 2.0 x 2.0cm area of umbilication along the medial aspect of the lateral basal segment.  The area of umbilication is marked with silver nitrate.  The remaining pleural surface is red and unremarkable.  On sectioning, there is a 2.1 x 2.0 x 1.1cm tan, rubbery to indurated and slightly lobulated lesion corresponding to the aforementioned area of pleural umbilication.  The lesion comes to within 2.0cm of the closest vascular and staple line margin and 2.5cm from the closest bronchial margin.  The remaining cut surfaces are red and spongy with no additionally noted lesions.  Representative tissue is submitted as follows:  6A, en face vascular and bronchial margins; 6B, en face staple line closest to lesions; 6C and 6D, lesion to pleural surface; 6E, lesion to uninvolved parenchyma; 6F, uninvolved parenchyma.  Gross photographs are taken.
AC:lefb **DATE[Sep 14 2013].","MicroscopicDescription:
  Slides reviewed.",1: Lymph node(not regional resection)2: Lymph node(not regional resection)3: Lymph node(not regional resection)4: Lymph node(not regional resection)5: Lymph node(not regional resection)6: Left lower lobe of lung,,
REG2,LUNG,0,PAT-40160295,2,REC-100000927144,"ClinicalHistory:
  Left upper lobe lung mass.",,"FinalDiagnosis:
Lung, Left Upper Lobe, Core Biopsies:
Poorly Differentiated Nonkeratinizing Squamous Cell Carcinoma.",,"GrossDescription:
  Received in formalin labeled left upper lobe mass core biopsy is a 1.0 x 0.9 x 0.3cm aggregate of dark red clotted blood and tan to gray, soft tissue.  The specimen is submitted in toto as 1A.
AC:lefb **DATE[Jan 8 2013].","MicroscopicDescription:
  The core biopsies of the lung and left upper lobe consist of lung tissue with a malignant neoplasm consistent with non small cell carcinoma with features of squamous cell carcinoma nonkeratinizing.  Immunoperoxidase stains for show the tumor cells to be strongly positive for CK5 and 6 and p63,  and negative for TTF1 and napsin A, consistent with the diagnosis.",1: Fine needle core biopsy of lung,,
REG2,LUNG,0,PAT-40136866,2,REC-100000927196,"ClinicalHistory:
  Left lung carcinoma.
IntraoperativeDiagnosis:
Frozen Section Diagnosis:
  FS1.  Left lung bronchial margin:  Margin negative; diagnosis given to Dr. **NAME[ZZZ].  (ASJ).",,"FinalDiagnosis:
1.  Lung, Left, Pneumonectomy (Specimen #10):
Squamous Cell Carcinoma, Poorly Differentiated, Size 5.3 x 4.1 x 4.0cm. No Evidence of Visceral Pleura Invasion. Vascular Invasion Present. Margins Negative for Carcinoma. Three of Fifteen Peribronchial Lymph Nodes with Metastatic Squamous Cell Carcinoma. 

2.  Lymph Node, Level 10 Hilar (Specimen #1):
One Lymph Node with Anthracosis. No Evidence of Metastatic Carcinoma. 

3.  Lymph Node, Level 5 AP Window (Specimen #2):
One Lymph Node with Anthracosis. No Evidence of Metastatic Carcinoma.

4.  Lymph Node, Level 10 Hilar (Specimen #3):
One Lymph Node with Reactive Follicular Hyperplasia and Anthracosis. No Evidence of Metastatic Carcinoma. 

5.  Lymph Node, Level 12 (Specimen #4):
One Lymph Node with Metastatic Squamous Cell Carcinoma. 

6.  Lymph Node, Level 8 Periesophageal (Specimen #5):
Portion of Vascular Fibroadipose Tissue and Peripheral Nerve. No Lymphoid Tissue Seen. No Evidence of Malignancy. 

7.  Lymph Node, Level 7 (Specimen #6):
Benign Vascular Fibroadipose Tissue with Minute Lymph Node. No Evidence of Metastatic Carcinoma. 

8.  Lymph Node, Level 7 Permanent Number 2:
Portion of Benign Vascular Fibroadipose Tissue with Peripheral Nerve. No Lymphoid Tissue Seen. No Evidence of Malignancy. 

9.  Lymph Node, Level 8 (Specimen #8):
One Lymph Node with Anthracosis and Fibrosis with Hyalinization. No Evidence of Metastatic Carcinoma. 

10.  Lymph Node, Level 9 (Specimen #9):
One Lymph Node with Reactive Follicular Hyperplasia and Anthracosis. No Evidence of Metastatic Carcinoma. 



LUNG: Resection Synoptic Report


Specimen        : Lung
Procedure         : Pneumonectomy
Specimen Integrity      : Intact
Specimen Laterality      : Left
Tumor Site        : Upper lobe, lower lobe
Tumor Size        : 5.3cm in greatest dimension; 4.1 x 4.0cm additional dimensions
Tumor Focality      : Unifocal
Histologic Type       : Squamous cell carcinoma
Histologic Grade       : G3: Poorly differentiated
Visceral Pleura Invasion     : Not identified
Tumor Extension       : Not applicable
Margins 

Bronchial Margin      : Uninvolved by invasive carcinoma and carcinoma in situ
Vascular Margin      : Uninvolved by invasive carcinoma
Parenchymal Margin      : Not applicable
Parietal Pleural Margin    : Not applicable
Chest Wall Margin      : Not applicable
Other Attached Tissue Margin   : Not applicable

If all margins uninvolved by invasive carcinoma:
Distance of invasive carcinoma from closest margin: 6.0 mm
Specify margin      : bronchial
Treatment Effect       : Not applicable
Lymph-Vascular Invasion    : Present
Lymph Nodes       : Not identified

Pathologic Staging (pTNM)

Primary Tumor (pT)                          : pT2b: Tumor greater than 5.0cm, but 7.0cm or less in greatest
  dimension. 
Regional Lymph Nodes (pN)           : pN1: Metastasis in ipsilateral peribronchial and or ipsilateral hilar
  lymph nodes, and intrapulmonary nodes, including involvement by
  direct extension. 
Specify:     Number examined  : 21
         Number involved  : 4 
Distant Metastasis (pM)    : Not applicable
Additional Pathologic Findings  : Emphysema.",,"GrossDescription:
  Container 1:  Received in formalin labeled level 10 hilar lymph node is a 1.0cm in greatest dimension red, rubbery, possible lymph node with a moderate amount of attached yellow, lobulated adipose tissue.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled level 5 AP window is a 0.5cm in greatest dimension tan to gray, rubbery lymph node with a moderate amount of attached yellow, lobulated adipose tissue.  The specimen is submitted in toto as 2A.

  Container 3:  Received in formalin labeled level 10 hilar lymph node is a 2.0cm in greatest dimension tan to red, rubbery, presumed lymph node.  The specimen is submitted in toto as 3A.

  Container 4:  Received in formalin labeled level 12 lymph node is a 1.0cm in greatest dimension tan, rubbery lymph node, which is submitted in toto as 4A.

  Container 5:  Received in formalin labeled level 8 periesophageal lymph node is a 1.0cm in greatest dimension irregular portion of tan to pink, rubbery tissue, possibly consistent with a lymph node.  The specimen is submitted in toto as 5A.

  Container 6:  Received in formalin labeled level 7 lymph node are two irregular portions of tan to pink, rubbery tissue averaging 1.3cm in greatest dimension.  Both tissue portions are submitted in toto as 6A.

  Container 7:  Received in formalin labeled level 7 lymph node permanent #2 is a 2.0 x 1.5 x 0.6cm irregular portion of tan to pink, rubbery tissue.  The specimen is bisected and submitted in its entirety as 7A.

  Container 8:  Received in formalin labeled level 8 lymph node is a 2.0cm in greatest dimension irregular portion of tan to pink, rubbery tissue, possibly consistent with a lymph node.  The specimen is bisected and submitted in its entirety as 8A.

  Container 9:  Received in formalin labeled level 9 lymph node is a 0.8cm in greatest dimension tan to gray, rubbery lymph node with scant attached yellow, lobulated adipose tissue.  The specimen is submitted in toto as 9A.
AC:lefb **DATE[Sep 25 2013]

  Container 10:  Received fresh labeled left lung is a 600.4 gram, 23.5 x 17.5 x 7.5cm left pneumonectomy specimen with 2.3cm of exposed, stapled bronchus, measuring 2.0cm in diameter.  The pleural surface is red to pink, focally congested and predominantly smooth, displaying a few fibrous adhesions on the medial aspect.  Sectioning reveals a 5.3 x 4.1 x 4.0cm tan, granular, ill defined, obstructing endobronchial tumor, within the hilum, which extends to within 0.6cm of the bronchial margin of resection.  The tumor invades through the bronchial wall into the surrounding parenchyma and surrounds the pulmonary artery and vein with no evidence of invasion.  The tumor involves the superior and inferior segments of the upper lobe and the medial basal and posterior basal segments of the lower lobe.  The tumor extends to within 0.4cm of the pleural surface.  The remaining parenchyma is diffusely congested and subcrepitant.  No discrete areas of consolidation are identified.  The bronchi distal to the aforementioned tumor are filled with thick gray mucus.  Multiple, black to gray, peribronchial lymph nodes are identified, ranging from 0.4cm to 2.5cm in greatest dimension.  Several of the lymph nodes display a soft, friable cut surface, grossly consistent with metastatic tumor.  Representative sections are submitted as follows:  10A, bronchial margin of resection; 10B and 10C, en face vascular margins; 10D through 10I, representative sections of tumor to include bronchus and surrounding parenchyma and vasculature; 10J through 10N, peribronchial lymph nodes; 10O, random upper lobe; 10P, random lower lobe.  Photographs are taken.
CH:lefb **DATE[Sep 25 2013].","MicroscopicDescription:
  Slides reviewed.",1: Lymph node(not regional resection)2: Lymph node(not regional resection)3: Lymph node(not regional resection)4: Lymph node(not regional resection)5: Lymph node(not regional resection)6: Lymph node(not regional resection)7: Lymph node(not regional resection)8: Lymph node(not regional resection)9: Lymph node(not regional resection)10: Left lung,,
REG2,LUNG,0,PAT-40084695,3,REC-100000927229,"ClinicalHistory:
  Left lower lobe lung cancer.",,"FinalDiagnosis:
Lymph Node, 4R:
One (1) Lymph Node with Anthracosis and Sinus Histiocytosis. 
No Evidence of Metastatic Carcinoma.",,"GrossDescription:
  Received in formalin labeled 4R lymph node is a tan, pink, firm lymph node, which measures 0.5 x 0.5 x 0.3cm.  The specimen is bisected and submitted in its entirety as 1A.
MD:lefb **DATE[Jun 24 2013].","MicroscopicDescription:
  Slides reviewed.",1: Lymph node(not regional resection),,
REG2,LUNG,0,PAT-40160114,1,REC-100000927238,"ClinicalHistory:
  Right middle lobe nodule.",,"FinalDiagnosis:
  Lung, Right Middle Lobe, Biopsy:  Fragments of Lung Tissue and Bronchial Mucosa with
     Well Differentiated Adenocarcinoma.
DiagnosisComment:",,"GrossDescription:
  Received in formalin labeled right middle lobe biopsy is a 2.0 x 0.5 x 0.1cm aggregate of tan to red, soft and delicate tissue, admixed with dark red clotted blood.  The specimen is submitted in toto as 1A.
AC:lefb **DATE[Aug 22 2013].","MicroscopicDescription:
  The core biopsies from the right middle lobe of lung consists of several fragments of lung tissue with alveolated lung parenchyma as well as several fragments of bronchial mucosa. The alveolated lung parenchyma shows numerous pigmented macrophages in the alveolar spaces. The fragments of bronchial mucosa show intense acute and chronic inflammation. One of the biopsy fragments shows groups of atypical cells lining acinar structures in the subepithelial tissue. The atypical cells show pleomorphic hyperchromatic nuclei and show a small amount of eosinophilic cytoplasm. Immunoperoxidase stain shows the atypical cells to be negative for Cytokeratin CK5 and 6 and strongly positive for CK7 and TTF1. The morphologic features in conjunction with this immunophenotype are consistent with an adenocarcinoma of lung primary site.",1: Fine needle core biopsy of lung,,
REG2,LUNG,0,PAT-40159986,1,REC-100000927373,"ClinicalHistory:
  Right lung mass.
IntraoperativeDiagnosis:
Frozen Section Diagnosis:
  FS1.  Superior segment R:  Well differentiated adenocarcinoma.  (TM)
FS2.  Apical segment right upper lobe:  Poorly differentiated adenocarcinoma.  Results given to Dr. **NAME[ZZZ].  (TM).",,"FinalDiagnosis:
1.  Lung, Right Lower Lobe, Superior Segment, Excision (Specimen #4):
Well Differentiated Adenocarcinoma, Acinar Type, Size 1.5 x 1.0 x 0.6cm with Visceral Pleura Invasion.
Margins Negative for Carcinoma.
Vascular Invasion Present.
Lung Tissue with Emphysema and Subpleural Fibrosis.


2.  Lung, Right Upper Lobe, Apical Segment, Excision (Specimen #5):
Moderately Differentiated Adenocarcinoma, Mixed Solid and Acinar Type, Size 1.9 x 1.5 x 1.2cm.
Margins Negative for Carcinoma. 
Lung Tissue with Emphysema with Pleural Bleb and Subpleural Scarring.

3.  Lymph Node, Level 10 Hilar (Specimen #1):
Two Lymph Nodes with Anthracosis and Marked Thermal Artifact.
No Evidence of Metastatic Carcinoma.

4.  Lymph Node, Level 11 (Specimen #2):
One Lymph Node with Anthracosis.
No Evidence of Metastatic Carcinoma.

5.  Lymph Node, Level 13 Superior Segment (Specimen #3):
One Lymph Node with Anthracosis.
No Evidence of Metastatic Carcinoma.

6.  Soft Tissue, Mediastinal (Specimen #6):
Benign Fibroadipose Tissue with Three Lymph Nodes with Anthracosis.
No Evidence of Metastatic Carcinoma.

7.  Lymph Node, Level 4R (Specimen #7):
Scant Fragments of Benign Vascular Connective Tissue.
No Lymphoid Tissue Seen.
No Evidence of Malignancy.

8.  Lymph Node, Level 9 (Specimen #8):
Lymph Node with Anthracosis.
No Evidence of Metastatic Carcinoma.

Note: Although both lobes show an adenocarcinoma, the tumor in the right lower lobe which is smaller, is more well differentiated with acinar type of adenocarcinoma pattern in contrast to the tumor in the right upper lobe which is less differentiated with solid areas of adenocarcinoma. Consequently these tumors have been staged as two synchronous primaries.


LUNG: Resection

Right Lower Lobe Tumor

Specimen        :Lobe(s) of lung; superior segment of right lower lobe
Procedure         :Segmentectomy
Specimen Integrity      :Intact
Specimen Laterality      :Right
Tumor Site        :Lower lobe, superior segment
Tumor Size        :
Greatest dimension      :1.5cm
Additional dimensions      :1.0 x 0.6cm
Tumor Focality      :Unifocal
Histologic Type       :Acinar adenocarcinoma
Histologic Grade       :G1: Well differentiated
Visceral Pleura Invasion     :Present
Tumor Extension       :Not applicable
Margins 
If all margins uninvolved by invasive carcinoma:
Distance of invasive carcinoma 
From closest margin      :10mm
Specify margin      :Stapled margin
Bronchial Margin      :Not applicable
Vascular Margin      :Not applicable
Parenchymal Margin      :Uninvolved by invasive carcinoma
Parietal Pleural Margin    :Not applicable
Chest Wall Margin      :Not applicable
Other Attached Tissue Margin 
(specify)        :Not applicable
Treatment Effect       :Not applicable 
Lymph Vascular Invasion    :Present
Pathologic Staging (pTNM)
Primary Tumor (pT)      :pT2a: Tumor 5.0cm or less in greatest dimension with
          :invasion of the visceral pleura
Additional Pathologic Findings  :Emphysema
          :subpleural scarring


LUNG: Resection

Right Upper Lobe Tumor

Specimen        :Lobe(s) of lung (specify): apical segment of right upper lobe
Procedure         :Segmentectomy
Specimen Integrity      :Intact
Specimen Laterality      :Right
Tumor Site        :Upper lobe, apical segment
Tumor Size        :
Greatest dimension      :1.9cm
Additional dimensions      1.5 x 1.2cm
Tumor Focality      :Unifocal
Histologic Type       :Adenocarcinoma, mixed subtype
Histologic Grade       :G2: Moderately differentiated
Visceral Pleura Invasion     :Present
Tumor Extension       :Not applicable
Margins 
If all margins uninvolved by invasive carcinoma:
Distance of invasive carcinoma 
From closest margin      :12mm
Specify margin      :Stapled
Bronchial Margin      :Not applicable
Vascular Margin      :Not applicable
Parenchymal Margin      :Not applicable
Parietal Pleural Margin    :Not applicable
Chest Wall Margin      :Not applicable
Other Attached Tissue Margin 
(specify)        :Not applicable
Treatment Effect       :Not applicable
Lymph Vascular Invasion    :Not identified
Pathologic Staging (pTNM)
Primary Tumor (pT)      :pT2a:Tumor 5.0cm or less in greatest dimension with
          :invasion of the visceral pleura
Distant Metastasis (pM)    :Not applicable
Additional Pathologic Findings  :Emphysema
          :Pleural blebs and subpleural scarring.",,"GrossDescription:
  Container 1:  Received in formalin labeled level 10 hilar lymph node are two tan, irregular, soft to rubbery tissues, both measuring 0.4 x 0.2 x 0.2cm.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled level 11 lymph node is a red, tan, irregular, soft to rubbery tissue, which measures 0.7 x 0.4 x 0.3cm.  The specimen is submitted in toto as 2A.

  Container 3:  Received in formalin labeled level 13 superior segment lymph node is a red, tan, irregular, soft to rubbery tissue, which measures 0.5 x 0.4 x 0.2cm.  The specimen is submitted in toto as 3A.

  Container 4:  Received fresh for intraoperative consultation and subsequently placed in formalin labeled superior segment RLL is a 56 gram, 9.2 x 9.5 x 3.5cm wedge of lung.  There are two staple lines measuring 4.5cm and 11.0cm in length.  The pleural surface is tan, pink to purple and smooth, displaying a focal 0.5 x 0.4cm tan, white, puckered lesion.  The external surface is marked with silver nitrate and the short staple line is removed and inked black.  The long staple line is removed and inked blue.  Upon sectioning, the cut surface displays a 1.5 x 1.0 x 0.6cm subpleural, tan, white, firm mass, which is located 1.0cm from the short, black margin and 2.2cm from the long blue margin.  A representative section of the mass and margin is submitted for frozen section analysis as FS1.  (See Frozen Section Diagnosis #1).  The remaining cut surfaces display a red, tan, spongy parenchyma.  Representative sections are submitted as follows:  4A, FS1 remnants; 4B through 4D, additional sections of subpleural mass with adjacent uninvolved lung parenchyma; 4E, section of the short black margin; 4F, section of the long blue margin; 4G, sections displaying pleural lesion (uninvolved with subpleural mass); 4H and 4I, random sections of uninvolved lung parenchyma.

  Container 5:  Received fresh for intraoperative diagnosis and subsequently placed in formalin labeled apical segment right upper lobe is a 39 gram, 9.8 x 5.5 x 2.5cm wedge of lung.  The pleural surface is tan, pink to purple and smooth, displaying pleural retraction.  The external surface is marked with silver nitrate and there is an 11.1cm staple line, which is removed and the resection margin is inked blue.  Upon sectioning, the cut surface display lung blebs, which measure up to 2.5cm and is associated with the previously mentioned pleural retractions.  There is also a 1.9 x 1.5 x 1.2cm mass, which approaches the pleura and is 1.2cm from the stapled margin.  A representative section is submitted for frozen section analysis as FS2.  (See Frozen Section Diagnosis #2).  The remaining cut surfaces display a red, brown, spongy and focally congested lung parenchyma.  Representative sections are submitted as follows:  5A, FS2 remnants; 5B through 5E, sections of mass lesion to adjacent lung parenchyma; 5F, sections displaying pleura adjacent to mass; 5G and 5H, sections displaying resection margin; 5I and 5J, random sections of uninvolved lung parenchyma.

  Container 6:  Received in formalin labeled mediastinal fat pad is a 1.5 x 1.0 x 0.3cm irregular portion of tan, yellow, soft to cauterized adipose tissue, which is submitted in toto as 6A.

  Container 7:  Received in formalin labeled level 4R are two red, tan, irregular, soft, rubbery tissues, both measuring 0.4 x 0.2 x 0.1cm.  The specimen is submitted in toto as 7A.

  Container 8:  Received in formalin labeled level 9 is a tan, brown, irregular, soft to rubbery tissue, which measures 0.7 x 0.3 x 0.2cm.  The specimen is submitted in toto as 8A.
MD:lefb **DATE[Jun 12 2013].","MicroscopicDescription:
  Slides Reviewed.",1: Lymph node(not regional resection)2: Lymph node(not regional resection)3: Lymph node(not regional resection)4: Wedge right lower lobe lung5: Wedge right upper lobe lung6: Fat (? tumor)7: Lymph node(not regional resection)8: Lymph node(not regional resection),,
REG2,LUNG,0,PAT-40160232,1,REC-100000927375,"ClinicalHistory:
Multiple Right Lung Nodules.","CytologyReview:
 Malignant cells consistent with Non Small Cell Carcinoma.

 Malignant cells consistent with Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
 Malignant cells consistent with Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.
 
Note: Immunohistochemical stains pending and results will follow as an addendum.",,"GrossDescription:
Received:  30cc bloody CytoLyt for ThinPrep and Cell Block
3 Air-Dried Smears, 3 Fixed Smears
Specimen examined in Radiology suite with rapid cytologic stain: found to have sufficient cellular material for pathologic examination.",,"A: Right Lung, Fine Needle Aspiration",,"AddendumComment:
 The tumor cells are positive for pan keratin, TTF1, Napsin A, and BerEp4 and negative for p63 consistent with adenocarcinoma of lung origin."
REG2,LUNG,0,PAT-40160232,1,REC-100000927393,"ClinicalHistory:
Multiple Right Lung Nodules.","CytologyReview:
 Malignant cells consistent with Non Small Cell Carcinoma.

 Malignant cells consistent with Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
 Malignant cells consistent with Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.
 
Note: Immunohistochemical stains pending and results will follow as an addendum.",,"GrossDescription:
Received:  30cc bloody CytoLyt for ThinPrep and Cell Block
3 Air-Dried Smears, 3 Fixed Smears
Specimen examined in Radiology suite with rapid cytologic stain: found to have sufficient cellular material for pathologic examination.",,"A: Right Lung, Fine Needle Aspiration",,"AddendumComment:
 The tumor cells are positive for pan keratin, TTF1, Napsin A, and BerEp4 and negative for p63 consistent with adenocarcinoma of lung origin."
REG2,LUNG,0,PAT-40159677,1,REC-100000927498,"ClinicalHistory:
2 cm left lung mass.
IntraoperativeDiagnosis:
B: FNA Immediate Evaluation-SFH: Cellular material present. Per  **NAME[ZZZ YYY], MD. **DATE[Jul 6 13].","CytologyReview:
 Atypical cells suspicious for Malignancy.

 Malignant cells consistent with Squamous Cell Carcinoma.","FinalDiagnosis:
 Malignant cells consistent with non keratinizing Squamous Cell Carcinoma.
The tumor cells are best seen in the cell block.

This case was reviewed at the pathology departmental conference.  Case discussed with **PLACE, PA on **DATE[Jul 8 2013] at 8:30 AM and with Dr. **NAME[M. XXX] on **DATE[Jul 8 2013] at 4:30 PM.",,"GrossDescription:

A. Left Lung, Fine Needle Aspiration:  Received: 30cc pink CytoLyt for ThinPrep and Cell Block
4 Air-Dried Smears, 4 Fixed Smears.",,"A: Left Lung, Fine Needle AspirationB: FNA Immediate Evaluation-SFH",,
REG2,LUNG,0,PAT-40146555,1,REC-100000927524,"ClinicalHistory:
  Left upper lobe bleb; Lung cancer.",,"FinalDiagnosis:
Lung, Left Upper Lobe, Bleb Resection:
Benign Lung Tissue with Pleural Fibrosis with Subpleural Scarring with Pleural Bleb and Reactive Pleuritis. 
Lung Parenchyma with Peribronchial Fibrosis and with Alveoli with Pigmented Macrophages. 
No Evidence of Malignancy.",,"GrossDescription:
  Received in formalin labeled left upper lobe bleb are three irregular portions of lung tissue weighing an aggregate of 30 grams and ranging from 4.2 x 1.5 x 0.8cm to 5.5 x 4.0 x 2.0cm.  Each fragment displays a tan, pink to purple, smooth pleural surface with an irregular staple line, which extends the entire length of each fragment.  The external surfaces are marked with silver nitrate and the stapled margins are removed and inked blue.  Upon sectioning, the cut surfaces display a red, tan, spongy parenchyma with no discrete lesions identified.  Also received in the same container is a 1.6 x 1.3 x 0.3cm irregular portion of pale yellow, soft, lobulated adipose tissue, which contains a staple line measuring 1.2cm.  The staple line is removed and the specimen is bisected.  Representative sections are submitted as follows:  1A, sections displaying smallest fragment of lung; 1B and 1C, sections displaying the second largest fragment of lung; 1D through 1F, sections displaying largest fragment of lung; 1G, bisected portion of adipose tissue.
MD:lefb **DATE[Nov 11 2012].","MicroscopicDescription:
  Slides reviewed.",1: Bleb in lung,,
REG2,LUNG,0,PAT-40160213,1,REC-100000927571,"ClinicalHistory:
  Left lung mass; Endobronchial biopsy.",,"FinalDiagnosis:
Lung, Left, Endobronchial Biopsy:
Bronchial Mucosa with Poorly Differentiated Focally Keratinizing Squamous Cell 
  Carcinoma.",,"GrossDescription:
  Received in formalin labeled biopsy left lower lobe are seven irregular portions of white to pink, soft and delicate tissue averaging 0.2cm in greatest dimension.  The specimen is submitted in toto as 1A.
AC:lefb **DATE[Sep 4 2013].","MicroscopicDescription:
  The endobronchial biopsy from the left lung consists of multiple fragments of bronchial mucosa with an invasive poorly differentiated non small cell carcinoma.  Foci of keratinization seen in the tumor cells consistent with a poorly differentiated focally keratinizing squamous cell carcinoma.  Areas of necrosis are seen within the tumor. Immunoperoxidase stains for show the tumor cells to be strongly positive for p63 and CK5 6,  and negative for TTF1 and napsin A, consistent with a squamous cell carcinoma.",1: Biopsy left lower lobe lung,,
REG2,LUNG,0,PAT-40128833,1,REC-100000927670,"ClinicalHistory:
  History of right lung cancer adeno.",,"FinalDiagnosis:
1.  Lung, Right Lower Lobe, Core Biopsies:
 Lung Tissue with Scarring with Rare Atypical Cells.    
 See Description.


2.  Lung, Left Lower Lobe, Core Biopsies:
Lung Tissue with Atypical Mucinous Proliferation.   
See Description.",,"GrossDescription:
  Container 1. Received in formalin labeled ""right lower lobe biopsy"" are two cylindrical portions of tan to pink soft tissue averaging 0.2 x 0.1cm. The specimen is submitted in toto in 1A. 

  Container 2. Received in formalin labeled ""left lower lobe biopsy"" are two cylindrical portions of tan soft tissue ranging from 0.2 x 0.1cm to 0.5 x 0.1cm. The specimen is submitted in toto in 2A. 
AC:fmg **DATE[Apr 5 2013].","MicroscopicDescription:
  The specimen from the right lower lobe of lung consists of lung parenchyma with focal scarring with scattered alveolar lining cells with reactive changes with rare atypical cells present.  These findings although they may be associated with the history of radiation, they can not exclude a persistent or recurrent adenocarcinoma. Clinical correlation is recommended.  

  The specimen from the left lower lobe of lung consists of lung parenchyma with fragments of detached mucin containing atypical single cells.  Included is portion of lung tissue with squamous metaplasia.  Although the atypical cells present in the background of mucin are highly suspicious for a mucinous adenocarcinoma, the quantity of the atypical cells is scant and not sufficient for the definite diagnosis of malignancy.  Clinical correlation and appropriate follow up are recommended.",1: Fine needle core biopsy of lung2: Fine needle core biopsy of lung,,
REG2,LUNG,0,PAT-40084695,3,REC-100000927870,"ClinicalHistory:
Breast cancer, Prostate cancer.","CytologyReview:
 Malignant cells noted.

 Malignant cells consistent with Non Small Cell Carcinoma.","FinalDiagnosis:
Malignant cells consistent with Non Small Cell Carcinoma.
Immunohistochemically consistent with Primary Lung Adenocarcinoma. (Please see comment.)

Comment:
Note is made of the provided clinical information and the patient's previous history of invasive mammary ductal carcinoma and prostate carcinoma. The patient's previous specimens (N08 693, S08 243 and S08 8378) are reviewed for morphologic comparison. Immunohistochemical stains are performed on the cellblock of the current fine needle aspiration specimen of the left lung and show the following results in the tumor cells: strong diffuse positivity for TTF1 and NapsinA; negative for ER, mammaglobin, GCDFP, PSA and PSAP. This immunohistochemical profile, in conjunction with the morphology, is consistent with a primary lung adenocarcinoma. Clinical and imaging correlation is recommended.

This case was reviewed at the daily intradepartmental conference for consensus diagnosis on **DATE[Jun 5 2013]. Results given to Dr. **NAME[M. ZZZ] via phone by Dr. **NAME[M. YYY] on **DATE[Jun 5 2013].",,"GrossDescription:
Received:  30cc blood tinged cytolyt for ThinPrep and Cell Block; 3 Air-Dried Smears, 3 Fixed Smears.
Specimen examined in Radiology suite with rapid cytologic stain: found to have sufficient cellular material for pathologic examination.",,"A: Lung Left, Fine Needle Aspiration",,
REG2,LUNG,0,PAT-40152464,1,REC-100000927979,"ClinicalHistory:
  Right mainstem bronchial mass.
IntraoperativeDiagnosis:
  Frozen Section Diagnosis: 
    1. Malignant; Consistent with SCC. Given to Dr. **NAME[ZZZ] (TM).",,"FinalDiagnosis:
1.  Lung, Right Mainstem Bronchus, Biopsy:    
Minute Fragment of Nonkeratinizing Squamous Cell Carcinoma.

2.  Lung, Carina, Biopsy:
Multiple Fragments of Bronchial Mucosa with In Situ and Invasive Moderately
  Differentiated Nonkeratinizing Squamous Cell Carcinoma.",,"GrossDescription:
  Container 1. Received fresh for frozen section diagnosis and subsequently placed in formalin labeled ""right mainstem bronchial biopsy"" is a 0.2cm in greatest dimension aggregate of tan to pink, soft, minute tissue portions. The specimen is submitted in toto for frozen section analysis as FS1 (see frozen section diagnosis #1). The remaining specimen is submitted in its entirety in 1A.

  Container 2. Received in formalin labeled ""biopsy carinal mass"" is a 3.0 x 2.0 x 0.3cm aggregate of dark red clotted blood and tan to red soft tissue. The specimen is submitted in toto in 2A.  
AC:fmg **DATE[Aug 8 2013].","MicroscopicDescription:
  The first from the right mainstem bronchial biopsy and the second specimen from the carinal mass both show a moderately differentiated nonkeratinizing squamous cell carcinoma.  The specimen from the right mainstem bronchus biopsy consists of a minute fragment of squamous cell carcinoma.  The second specimen from the carinal mass consists of multiple fragments of bronchial mucosa with invasive moderately differentiated nonkeratinizing squamous cell carcinoma.  The bronchial mucosa shows foci of squamous cell carcinoma in situ.  Immunoperoxidase stains show the tumor cells to be strongly positive for CK5 and 6 and P63, focally positive for CK7,  and negative for Napsin A, TTF1, consistent with the diagnosis.",1: Bronchial biopsy2: Carinal bronchial biopsy,,
REG2,LUNG,0,PAT-22697403,2,REC-100000928022,,,"FinalDiagnosis:
  Lung, Right Middle Lobe, Biopsies:
    Lung Tissue with Non Small Cell Carcinoma with Extensive Lymphatic Vascular
      Invasion.",,"GrossDescription:
  Received from the **INSTITUTION, Department of Pathology, are 2 H and E slides labeled S12 6258 and with the patient's name and 7 slides  from immunoperoxidase stains labeled S12 6258.  The accompanying report is also received.","MicroscopicDescription:
  The slides are from the right middle lobe biopsies per the accompanied report and consist of several fragments of bronchial mucosa as well as portion of alveolated lung parenchyma.  Both the bronchial mucosa and the alveolated lung parenchyma show several groups of malignant cells with features consistent with poorly differentiated carcinoma present in lymphatic vessels.  The tumor cells have large pleomorphic hyperchromatic nuclei and eosinophilic, slightly vacuolated cytoplasm.  The immunoperoxidase stains which are received show the tumor cells to be strongly positive for CK7 and negative for CK20, CDX2, P63 and TTF1.  The morphologic features, in conjunction with this immunophenotype, are consistent with a non small cell carcinoma with features favoring an adenocarcinoma and although a primary lung adenocarcinoma cannot be ruled out, other sites should also be considered.  Clinical and imaging correlation is recommended.",1: Outside slide consult charge,,
REG2,LUNG,0,PAT-40146537,1,REC-100000928084,"ClinicalHistory:
Right Lower Lobe Lung Mass.","CytologyReview:
 Highly suspicious for Non Small Cell Carcinoma.

 Atypical cells suspicious for Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
 Atypical cells seen suspicious for Non Small Cell Carcinoma.

Note: This case was seen at the Pathology Departmental Conference on **DATE[Aug 30 2012], and a consensus diagnosis is rendered.",,"GrossDescription:
Received:  40cc blood tinged cytolyt for ThinPrep and Cell Block.",,A: Right Lower Lobe Bronchial Lavage,,
REG2,LUNG,0,PAT-40146883,1,REC-100000928275,"ClinicalHistory:
Right Upper Lobe Lung Mass.","CytologyReview:
 Malignant cells consistent with Non Small Cell Carcinoma.

 Malignant cells consistent with Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
 Malignant cells consistent with Non Small Cell Carcinoma.
This case was seen in the Pathology Departmental Conference.

Note: Immunohistochemical stains pending and results will follow as an addendum.",,"GrossDescription:
Received:  30cc bloody cytolyt for ThinPrep and Cell Block
4 Air-Dried Smears, 4 Fixed Smears
Specimen examined in Radiology suite with rapid cytologic stain: found to have sufficient cellular material for pathologic examination.",,"A: RUL Lung, Fine Needle Aspiration",,"AddendumDiagnosis:

Immunohistochemical stains favor adenocarcinoma of lung origin.
AddendumComment:

The tumor cells are positive for pan keratin, BerEp4 and CK7, and some cells are positive for TTF1 and Napsin A. They are negative for CK20, CK5 6, and p63."
REG2,LUNG,0,PAT-40144916,1,REC-100000928402,"ClinicalHistory:
History of Lung cancer and pancreatic cancer.","CytologyReview:
 No Evidence of Malignancy.
Acute inflammation present.
Reactive cellular changes noted.

 No Evidence of Malignancy.
Acute inflammation present.
Reactive mesothelial cells noted.","FinalDiagnosis:
No Evidence of Malignancy.
Acute inflammation present.
Occasional reactive mesothelial cells noted.",,"GrossDescription:

Received: 70cc dark bloody fluid for ThinPrep and Cell Block.",,A: Right Pleural Fluid,,
REG2,LUNG,0,PAT-40146827,1,REC-100000928464,"ClinicalHistory:
Pneumonia, hypoxia.","CytologyReview:
 Malignant cells noted.

 Malignant cells consistent with Adenocarcinoma.
Consistent with metastasis from patient's known primary.
Recommend clinical correlation.
Appropriate follow-up recommended.","FinalDiagnosis:
Malignant cells consistent with Metastatic Adenocarcinoma.
Consistent with metastasis from adenocarcinoma of probable primary pulmonary origin.
See Note.

Note: Immunohistochemical stains, performed on the cell block, show the tumor cells to be positive for CK7, TTF-1, and Napsin A, and negative for CK20. These results are felt to support the diagnostic interpretation that the tumor represents a metastatic adenocarcinoma, whose most likely primary site is in the lung.
Recommend clinical and imaging correlation.
Appropriate follow-up recommended.",,"GrossDescription:
Received    1200cc dark bloody fluid for ThinPrep and Cell Block.",,A: Right Pleural Fluid,,
REG2,LUNG,0,PAT-21759561,2,REC-100000928684,"ClinicalHistory:
History of Lung Ca.","CytologyReview:
A   No Evidence of Malignancy. lymphocytes and ciliated bronchial cells.
  
B   No Evidence of Malignancy.

A   No Evidence of Malignancy. lymphocytes and ciliated bronchial cells.
  
B   No Evidence of Malignancy.","FinalDiagnosis:
A.  Lymph node, level 5 AP window, FNA:
No Evidence of Malignancy. 
Few bronchial epithelial cells and small lymphocytes noted.
 
B.  Lymph node, level 5, FNA:
No Evidence of Malignancy.
Bronchial epithelial cells, small lymphocytes and fragments of anthracotic lymphoid tissue.

This case was seen at the pathology departmental conference.  Dr. **NAME[M. ZZZ] was notified of these results on **DATE[Jun 11 2013] at 12:10 PM.",,"GrossDescription:

A.  Level 5 AP Window Lymph Node, Fine Needle Aspiration:  Received:  30cc slightly bloody cytolyt for ThinPrep and Cell Block.  

B.  Level 5 Lymph Node, Fine Needle Aspiration:  Received:  30cc slightly bloody cytolyt for ThinPrep and Cell Block.",,"A: Level 5 AP Window Lymph Node, Fine Needle AspirationB: Level 5 Lymph Node, Fine Needle Aspiration",,
REG2,LUNG,0,PAT-40151693,1,REC-100000928756,"ClinicalHistory:
  Lung mass.
IntraoperativeDiagnosis:
Frozen Section Diagnosis:
  FS1.  4R:  Metastatic adenocarcinoma to lymph node.  Report given to Dr. **NAME[ZZZ].  (PDHK).",,"FinalDiagnosis:
1.  Lymph Nodes, Mediastinal 4R, Mediastinoscopy and Biopsy:
Lymph Nodes (Fragments of Lymph Node Tissue) Showing Features of Metastatic Non Small Cell Carcinoma. 

2.  Lymph Node, Mediastinal 4R, Mediastinoscopy and Biopsy:
Lymph Nodes (Fragments of Lymph Node Tissue) Showing Features of Metastatic Non Small Cell Carcinoma.

3.  Lymph Nodes, Mediastinal 2R, Mediastinoscopy and Biopsy:
Lymph Nodes (Fragments of Lymph Node Tissue) Showing Features of Metastatic Non Small Cell Carcinoma.

4.  Lymph Nodes, Mediastinal Level 7, Mediastinoscopy and Biopsy:
Lymph Nodes (Fragments of Lymph Node Tissue) Showing Features of Metastatic Non Small Cell Carcinoma.

Comment:
  All four mediastinal lymph node biopsies reveal features of metastatic non small cell carcinoma. Immunohistochemical studies are in progress to include markers for metastatic adenocarcinoma and squamous cell carcinoma. These results will be issued in an addendum with additional subclassification upon completion. This case was reviewed for a consensus diagnosis through intradepartmental consultation (Dr. **NAME[YYY XXX]) on **DATE[Aug 25 2012].",,"GrossDescription:
  Container 1:  Received fresh for frozen section diagnosis and subsequently placed in formalin labeled 4R is a 0.8 x 0.3 x 0.2cm tan to black, partially disrupted, rubbery tissue portion, which is submitted for frozen section analysis as FS1.  (See Frozen Section Diagnosis #1).  The remaining specimen is submitted in its entirety as 2A.

  Container 2:  Received in formalin labeled level 4R are two irregular portions of tan to gray, rubbery tissue ranging from 0.3cm to 1.0cm in greatest dimension.  The specimen is submitted in toto as 2A.

  Container 3:  Received in formalin labeled level 2R is a 0.4cm in greatest dimension irregular portion of tan to gray, rubbery tissue.  The specimen is submitted in toto as 3A.

  Container 4:  Received in formalin labeled level 7 are three irregular portions of tan to yellow, soft to rubbery tissue and adipose tissue ranging from 0.3cm to 1.2cm in greatest dimension.  The specimen is submitted in toto as 4A.
AC:lefb **DATE[Aug 24 2012].","MicroscopicDescription:

  Slides reviewed.",1: Lymph node(not regional resection)2: Lymph node(not regional resection)3: Lymph node(not regional resection)4: Lymph node(not regional resection),,"AddendumDiagnosis:
.
AddendumComment:
  Immunohistochemical Studies:  Immunohistochemical stains are performed on a selected node for further subclassification of this metastatic tumor (napsin, p63, TTF1, CK5 6, CA19.9, CDX2, CK7, CK20, p16, PSA, PSAP, and CEA.  Tumor cells are positive for CK7 and show focal expression of CK20.  They appear essentially negative for CDX2, CA9, PSA and PSAP.  Significant expression of TTF1 or napsin are not noted.  The metastatic tumor appears negative for mucin. 

  The immunohistochemical findings are not specific or diagnostic in assessment of potential primary sites.  The differential diagnosis includes, but is not limited to, possible upper gastrointestinal primary, genitourinary (bladder), and others.  While the differential diagnosis could include poorly differentiated non small cell carcinoma of pulmonary primary, there is no evidence of expression of TTF1 and Napsin in this case.  

The immunostain interpretations were reviewed for consensus diagnosis through intradepartmental consultation (Dr. **NAME[YYY XXX]) on **DATE[Aug 30 2012].


  Fluorescence in situ hybridization studies for expression of ALK are performed at PhenoPath Laboratories.  Tissue submitted from block 2A (specimen 2, lymph node mediastinal 4R) is reported as POSITIVE for an ALK rearrangement by FISH.  A copy of the PhenoPath report is enclosed with this addendum."
REG2,LUNG,0,PAT-40002330,2,REC-100000928778,"ClinicalHistory:
Lung mass.","CytologyReview:
 Atypical cells suspicious for Malignancy.

 Malignant cells noted.","FinalDiagnosis:
 Malignant cellspresent, consistent with poorly differentiated carcinoma.
See also biopsy S12 13742.",,"GrossDescription:
Received:  15cc very bloody cytolyt for ThinPrep and Cell Block.",,A: Bronchial Washing Right Main Stem,,
REG2,LUNG,0,PAT-40144987,1,REC-100000928832,"ClinicalHistory:
Left lung Mass, Smoker.","CytologyReview:
A   No Evidence of Malignancy.
  
 B  Malignant  cells consistent with Small Cell Carcinoma.

A   No Evidence of Malignancy.
  
 B  Malignant  cells consistent with Small Cell Carcinoma.","FinalDiagnosis:
A:  Left Bronchial Lavage, Pre Biopsy: 
No Evidence of Malignancy. Benign bronchial cells and macrophages are noted.
  
B: Left Bronchial Lavage, Post Biopsy: 
Positive for Malignant cells, consistent with Small Cell Carcinoma.
(Please also see S12 13494 and N12 2215.)

This case was reviewed at the daily intradepartmental conference for consensus diagnosis on **DATE[Aug 18 2012].",,"GrossDescription:
A.  Pre Biopsy Left Bronchial Lavage:  Received:  50cc mucoid cytolyt for ThinPrep and Cell Block.  

B.  Post Biopsy Left Bronchial Lavage:  Received:  130cc bloody cytolyt for ThinPrep and Cell Block.",,A: Pre Biopsy Left Bronchial LavageB: Post Biopsy Left Bronchial Lavage,,
REG2,LUNG,0,PAT-40145320,1,REC-100000928871,"ClinicalHistory:
  Right lung CA.",,"FinalDiagnosis:
  Lung, Right Upper Lobe, Lobectomy (Specimen #8):
    Moderately to Poorly Differentiated Keratinizing Squamous Cell Carcinoma, Size 1.8 x  
      1.8 x 1.0cm.
    No Evidence of Visceral Pleural Invasion.
    Margins Negative for Carcinoma.
    Lung Tissue with Subpleural Fibrosis and Scarring with Pleural Blebs and Scattered 
      Foci of Organizing Pneumonia.

   Lymph Node, Level 10 Hilar (Specimen #1):
    Three Lymph Nodes with Anthracosis.
    No Evidence of Metastatic Carcinoma.

   Lymph Node, Level 12 Right Upper Lobe (Specimen #2):
    Four Lymph Nodes with Anthracosis.
    No Evidence of Metastatic Carcinoma.

  Lymph Node, Level 12 Right Upper Lobe (Specimen #3):
    Three Lymph Nodes with Anthracosis.
    No Evidence of Metastatic Carcinoma.

  Lymph Node, Level 11 (Specimen #4):
    One Lymph Node with Anthracosis.
    No Evidence of Metastatic Carcinoma.

  Lymph Node, Level 11 (Specimen #5):
    One Lymph Node with Anthracosis.    No Evidence of Metastatic Carcinoma.

  Lymph Node,  Level 4R (Specimen #6):
    One Lymph Node with Anthracosis.
    No Evidence of Metastatic Carcinoma.

  Lymph Node, Level 4R (Specimen #7):
    One Lymph Node with Anthracosis.
    No Evidence of Metastatic Carcinoma.


LUNG: Resection

Specimen        : Lobe(s) of lung
Procedure         : Lobectomy
Specimen Integrity      : Intact
Specimen Laterality      : Right
Tumor Site        : Upper lobe
Tumor Size        : Greatest dimension: 1.8cm
            Additional dimensions: 1.8 x 1.0cm
Tumor Focality      : Unifocal
Histologic Type       : Squamous cell carcinoma 
Histologic Grade       : G3: Poorly differentiated
Visceral Pleura Invasion     : Not identified 
Tumor Extension       : Not identified 
Margins 

Bronchial Margin      : Uninvolved by invasive carcinoma; squamous cell carcinoma in situ
            (CIS) not identified at bronchial margin
Vascular Margin      : Uninvolved by invasive carcinoma 
Parenchymal Margin      : Not applicable
Parietal Pleural Margin    : Not applicable
Chest Wall Margin      : Not applicable
Other Attached Tissue Margin (specify): Not applicable

If all margins uninvolved by invasive carcinoma:
Distance of invasive carcinoma from closest margin: 28mm
  Specify margin: Bronchial

Treatment Effect       : Not applicable

Pathologic Staging (pTNM)

Primary Tumor (pT)      : pT1a: Tumor 2cm or less in greatest dimension, surrounded by lung               or visceral pleura, without bronchoscopic evidence of
              invasion more proximal than the lobar bronchus (ie, not               in the main bronchus); or 
             Superficial spreading tumor of any size with its invasive  
              component limited to the bronchial wall, which may                 extend proximally to the main bronchus
Regional Lymph Nodes (pN)    : pN0: No regional lymph node metastasis
Distant Metastasis (pM)    : Not applicable
Additional Pathologic Findings  : Emphysema with pleural blebs.",,"GrossDescription:
  Container 1:  Received in formalin labeled level 10 hilar lymph node are three irregular, tan to black, anthracotic, rubbery lymph nodes measuring 0.5 x 0.3 x 0.3cm to 0.9 x 0.4 x 0.4cm.  The specimen is submitted in its entirety as 1A.

  Container 2:  Received in formalin labeled level 12 right upper lobe are five irregular, tan to black, anthracotic, rubbery lymph nodes ranging from 0.3 x 0.2 x 0.1cm to 0.5 x 0.4 x 0.3cm.  The specimen is submitted in its entirety as 2A.

  Container 3:  Received in formalin labeled level 12 right upper lobe are three irregular, tan to black, anthracotic, rubbery lymph nodes ranging from 0.2 x 0.2 x 0.1cm to 0.8 x 0.7 x 0.3cm.  The specimen is submitted in its entirety as 3A.

  Container 4:  Received in formalin labeled level 11 is a 1.0 x 0.6 x 0.5cm tan to black, anthracotic, rubbery lymph node.  The specimen is submitted in its entirety as 4A.

  Container 5:  Received in formalin labeled level 11 is a 1.5 x 1.1 x 0.7cm tan to black, anthracotic, rubbery lymph node.  The specimen is bisected and submitted in its entirety as 5A.

  Container 6:  Received in formalin labeled level 4R is a 0.4 x 0.3 x 0.3cm irregular, tan to black, anthracotic, rubbery lymph node.  The specimen is submitted in its entirety as 6A.

  Container 7:  Received in formalin labeled level 4R is a 1.0 x 0.7 x 0.5cm tan to black, anthracotic, rubbery lymph node.  The specimen is bisected and submitted in its entirety as 7A.

  Container 8:  Received in formalin labeled right upper lobe is a 15.0 x 12.0 x 4.0cm portion of lung, which weighs 169 grams.  The pleural surface is tan, pink to red and nodular.  There is a 1.0 x 1.0cm tan, white, stellate plaque opposite the surgical resection margin.  Sectioning of the specimen reveals a 1.8 x 1.8 x 1.0cm tan, white, indurated tumor.  There is a tan, white, soft material present within the tumor.  The tumor is adjacent to a 5.5 x 5.0 x 2.0cm cystic cavity.  The cystic cavity has a tan, white to red, smooth to trabeculated surface.  The cystic area and tumor corresponds to the previously mentioned pleural plaque.  Further sectioning reveals a moderate amount of emphysematous change.  The remaining lung parenchyma is tan, pink to red and spongy.  Dissection of the hilum reveals the bronchial and vascular margins to be grossly free of tumor.  There are two possible, hilar lymph nodes averaging 1.0 x 0.8 x 0.8cm.  The tumor is 2.8cm from the bronchial margin.  The specimen is entirely marked with silver nitrate and representative sections are submitted as follows:  8A, bronchial margin en face; 8B, vascular margins en face; 8C, two possible hilar lymph nodes, both bisected and one inked blue; 8D through 8G, tumor serially sectioned and submitted in its entirety; 8H, pleural plaque; 8I and 8J, emphysematous change; 8K and 8L, random sections of uninvolved lung parenchyma.
MM:lefb **DATE[Sep 13 2012].","MicroscopicDescription:
  Slides Reviewed.",1: Lymph node(not regional resection)2: Lymph node(not regional resection)3: Lymph node(not regional resection)4: Lymph node(not regional resection)5: Lymph node(not regional resection)6: Lymph node(not regional resection)7: Lymph node(not regional resection)8: Right upper lobe of lung,,
REG2,LUNG,0,PAT-40146389,1,REC-100000928874,"ClinicalHistory:
Lung Ca.","CytologyReview:
  No Evidence of Malignancy.
Acute inflammation present.

  No Evidence of Malignancy.
Acute inflammation present.","FinalDiagnosis:
  No Evidence of Malignancy.
 Acute inflammation present.",,"GrossDescription:

Received:  30cc slightly bloody cytolyt with brush for ThinPrep and Cell Block.",,A: Right Upper Lobe Bronchial Brush,,
REG2,LUNG,0,PAT-40152429,1,REC-100000928910,"ClinicalHistory:
Lung mass LUL.","CytologyReview:
Rare group of Atypical cells suspicious for malignancy.

 Atypical cells seen.
 Appropriate follow-up recommended.","FinalDiagnosis:
Rare group of  Atypical cells seen.
 Appropriate follow-up recommended.

Note: Dr. **NAME[M. ZZZ] is consulted on this case and agrees with the diagnosis.",,"GrossDescription:
Received:  30cc clear cytolyt for ThinPrep with a brush and Cell Block.",,A: Bronchial Brushing Left Upper Lobe,,
REG2,LUNG,0,PAT-40145309,1,REC-100000928926,"ClinicalHistory:
  Right lung cancer.",,"FinalDiagnosis:
1.  Lymph Node, Level 4R, Biopsy:
Fragments of Lymph Node with Anthracosis; No Evidence of Metastatic Carcinoma. 

2.  Lymph Node, Level 7, Biopsy:
Fragments of Lymph Node with Anthracosis; No Evidence of Metastatic Carcinoma. 

3.  Lymph Node, Level 4L, Biopsy:
Fragments of Lymph Node with Anthracosis; No Evidence of Metastatic Carcinoma. 

4.  Lymph Node, Level 10R, Fine Needle Aspiration Biopsy:
Blood Clot with Small Amount of Lymph Node Tissue with Anthracosis; No Evidence of Metastatic Carcinoma.",,"GrossDescription:
  
  Container 1:  Received in formalin labeled level 4R lymph node permanent are six irregular portions of tan to gray, rubbery tissue ranging from 0.2cm to 0.5cm in greatest dimension.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled level 7 lymph node permanent are six irregular portions of tan to pink to gray, rubbery tissue ranging from 0.5cm to 0.8cm in greatest dimension.  The specimen is submitted in toto as 2A and 2B.

  Container 3:  Received in formalin labeled level 4L permanent are two irregular portions of tan to gray, rubbery tissue ranging from 0.5cm to 0.9cm in greatest dimension.  The specimen is submitted in toto as 3A. 

Container 4:  Received in CytoLite solution labeled level 10R per the container and mediastinal level 10R lymph node tissue for Cytology per the requisition is a 2.0 x 0.6 x 0.1cm aggregate of tan to pink, soft tissue and dark red clotted blood.  The specimen is submitted in toto as 4A and the surrounding fluid is forwarded to Cytology.

AC:lefb **DATE[May 12 2013].","MicroscopicDescription:
  Slides reviewed.",1: Lymph node(not regional resection)2: Lymph node(not regional resection)3: Lymph node(not regional resection)4: Lymph node biopsy,,
REG2,LUNG,0,PAT-40146389,1,REC-100000928946,"ClinicalHistory:
  Lung cancer.
IntraoperativeDiagnosis:
Frozen Section Diagnosis:
  FS1.  Level 4R lymph node:  Benign lymph node.  Given to Dr. **NAME[ZZZ].  (TM).",,"FinalDiagnosis:
1.  Lymph Node, Level 4R:
Lymph Node with Sinus Histiocytosis.
No Evidence of Malignancy.

2.  Lung, Right Upper Lobe, Biopsy:
Benign Bronchial Mucosa with Subacute and Chronic Inflammation.
No Evidence of Malignancy.

3.  Lymph Node, Level 4R:
Lymph Node with Sinus Histiocytosis.
No Evidence of Malignancy.

4.  Lymph Node, Level 4L:
Lymph Node with Sinus Histiocytosis and Anthracosis and Focal Reactive Follicular Hyperplasia.
No Evidence of Malignancy.

5.  Lymph Node, Level 2R:
Lymph Node with Sinus Histiocytosis and Anthracosis.
No Evidence of Malignancy.

6.  Lymph Node, Level 7:
Lymph Node with Sinus Histiocytosis and Anthracosis and Reactive Follicular Hyperplasia.
No Evidence of Malignancy.",,"GrossDescription:
  Container 1:  Received fresh for intraoperative consultation and subsequently placed in formalin labeled level 4R lymph node is a 0.5 x 0.2 x 0.2cm tan lymph node, which is submitted for frozen section analysis as FS1.  (See Frozen Section Diagnosis #1).  The specimen is submitted in its entirety as 1A, FS1.

  Container 2:  Received in formalin labeled biopsy right upper lobe are five tan to red, irregular soft tissues ranging from minute to 0.2cm in greatest dimension, which are submitted in toto as 2A.

  Container 3:  Received in formalin labeled level 4R permanent is a 0.8cm in greatest dimension tan, presumed lymph node, which is submitted in toto as 3A.

  Container 4:  Received in formalin labeled level 4L permanent is a 0.7cm in greatest dimension tan, presumed lymph node, which is submitted in toto as 4A.

  Container 5:  Received in formalin labeled level 2R permanent is a 0.4cm in greatest dimension anthracotic lymph node, which is submitted in toto as 5A.

  Container 6:  Received in formalin labeled level 7 permanent are three tan, presumed lymph nodes ranging from 0.3cm to 0.7cm in greatest dimension, which are submitted in toto as 6A.
GH:lefb **DATE[Jul 12 2013].","MicroscopicDescription:
  The bronchial biopsy consists of bronchial mucosa with intact bronchial epithelium. The subepithelial tissue shows chronic inflammation with a mixture of plasma cells, lymphocytes and scattered eosinophils. No granulomatous process is seen. No neoplastic proliferation is seen. No evidence of malignancy is seen. 

  The multiple lymph nodes from 4R, 4L, 2R and level 7, show lymph nodes with sinus histiocytosis. No evidence of malignancy is seen.",1: Lymph node(not regional resection)2: Biopsy right upper lobe lung3: Lymph node(not regional resection)4: Lymph node(not regional resection)5: Lymph node(not regional resection)6: Lymph node(not regional resection),,
REG2,LUNG,0,PAT-40145309,1,REC-100000928948,"ClinicalHistory:
Lung Ca.","CytologyReview:
  No Evidence of Malignancy.

  No Evidence of Malignancy.","FinalDiagnosis:
  No Evidence of Malignancy.
  No lymphoid tissue seen.",,"GrossDescription:

Received:  45cc bloody cytolyt for ThinPrep and Cell Block.",,"A: Mediastinum Level 10 R Lymph Node, Fine Needle Aspiration",,
REG2,LUNG,0,PAT-40080797,1,REC-100000929092,"ClinicalHistory:
AMS, Brain Mets.","CytologyReview:
 Malignant cells consistent with Metastatic Carcinoma. Suspect adeno from lung.

 Malignant cells consistent with Metastatic Carcinoma. Suspect adeno from lung.","FinalDiagnosis:
 Malignant cells consistent with Metastatic Adenocarcinoma and patient's known lung primary.
  

Note: Dr. **NAME[M. ZZZ] is notified of the results.",,"GrossDescription:
Received:  2cc clear fluid for ThinPrep.",,A: Cerebrospinal Fluid,,
REG2,LUNG,0,PAT-40152525,1,REC-100000929299,"ClinicalHistory:
Left Lung Mass.","CytologyReview:
 Malignant cells consistent with Metastatic adenocarcinoma.

 Malignant cells consistent with Metastatic adenocarcinoma.","FinalDiagnosis:
 Groups of Malignant cells present, consistent with adenocarcinoma and previous history.",,"GrossDescription:
Received    25cc bloody fluid for ThinPrep and Cell Block.",,A: Left Pleural Fluid,,
REG2,LUNG,0,PAT-40108030,2,REC-100000929336,"ClinicalHistory:
  Tumor right temporal lobe.",,"FinalDiagnosis:
Brain, Right Upper Lobe, Craniotomy:
Metastatic Adenocarcinoma Consistent with Lung Primary Site.",,"GrossDescription:
  Received in formalin labeled right temporal lobe metastasis is a 2.2 x 1.7 x 0.6cm red, soft, rubbery tissue.  The external surface is inked blue prior to sectioning.  Sectioning reveals a central 1.5cm cystic area containing red, friable material.  The specimen is serially sectioned and entirely submitted as 1A through 1C.
CH:lefb **DATE[Jun 29 2013].","MicroscopicDescription:
  The biopsy from the craniotomy specimen and from the right temporal lobe shows a metastatic malignant neoplasm consistent with metastatic carcinoma.  Adjacent organizing hemorrhage is seen.  Compared to previous adenocarcinoma of lung (S11 14391) the morphologic features are similar. Intact brain tissue is not seen.  Immunoperoxidase stains show the malignant cells to be positive for TTF1 and napsin A and negative for the estrogen and progesterone receptors.  The morphologic findings and immunophenotype of the tumor are consistent with a metastatic adenocarcinoma of lung and previous history.",1: Brain tumor,,
REG2,LUNG,0,PAT-40102239,2,REC-100000929349,"ClinicalHistory:
Right lung nodules with history of breast cancer.","CytologyReview:
 Malignant cells noted.

 Malignant cells noted.","FinalDiagnosis:
 Malignant cells present, consistent with a adenocarcinoma of lung primary site.

Note
Immunoperoxidase stains show the malignant cells to be positive for TTF-1 and Napsin A, and negative for the estrogen and progesterone receptors and the Herceptest. These results in conjunction with the morphologic features of the tumor are compatible with a primary adenocarcinoma of lung and not a metastasis from the patient?s mammary carcinoma.",,"GrossDescription:

Received:  30cc bloody cytolyt for ThinPrep and Cell Block
2 Air-Dried Smears, 2 Fixed Smears


Specimen examined in Radiology suite with rapid cytologic stain: found to have sufficient cellular material for pathologic examination.",,"A: Right Lung, Fine Needle Aspiration",,"AddendumComment:
  EGFR mutation analysis by PCR and ALK rearrangement by FISH were performed at PhenoPath Laboratories, per Dr. **NAME[ZZZ]'s request.  The result is as follows: The tumor is negative for EGFR mutation by Real Time PCR and is also negative for ALK rearrangement by FISH.  See also reports from PhenoPath Laboratories, PP2012 **ID-NUM and PP2012 **ID-NUM."
REG2,LUNG,0,PAT-40145193,1,REC-100000929519,"ClinicalHistory:
Right upper lobe lesion.","CytologyReview:
 Atypical cells seen.

 Atypical cells seen.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
Bronchial epithelial cells and a rare atypical cell seen, suspicious for malignancy.

Comment: This case was seen at the Pathology Departmental Conference on **DATE[Mar 19 2013].",,"GrossDescription:

Received:  30cc clear cytolyt with brush for ThinPrep.",,A: Right Upper Lobe Bronchial Brush,,
REG2,LUNG,0,PAT-10933751,2,REC-100000930212,"ClinicalHistory:
Liver Masses, Pancreatic Mass, History of Breast CA.","CytologyReview:
 Malignant cells noted.

 Malignant cells consistent with Metastatic Carcinoma.
 Recommend clinical correlation.
Appropriate follow-up recommended.","FinalDiagnosis:
Malignant cells consistent with Metastatic Carcinoma.
See needle core biopsy specimen, ***PATH-NUMBER[1], for further evaluation and diagnosis, including results of immunohistochemical stains.
Recommend clinical and imaging correlation.
Appropriate follow-up recommended.",,"GrossDescription:
Received:  3 Air-Dried Smears
Tissue Cores in formalin.",,A: Liver Core Biopsy Touch Prep,,
REG1,PROSTATE,0,34598,3,,HISTORY: suspect cancer,"ICD9 CODES: 185, 595.2, \X0D\\X0A\COMMENTS: Eosinophils are noted in the inflammatory infiltrate of the bladder biopsy.  However, the number of eosinophils is not sufficient to warrant the diagnosis eosinophilic cystitis.  The slides were seen in consultation with Dr. **NAME[ZZZ YYY], who agrees with the above diagnosis.","DIAGNOSIS: 1 -  BLADDER, BIOPSY:             SEVERE CHRONIC CYSTITIS.             NEGATIVE FOR UROTHELIAL LESION.             MUSCLE IS PRESENT ON THIS BIOPSY SPECIMEN.             SEE COMMENT.  2 -  PROSTATE, RIGHT BASE, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 4+4=8, 10% INVOLVED.  3 -  PROSTATE, RIGHT MID, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 3+4=7, 50% INVOLVED.             PERINEURAL INVASION IS IDENTIFIED.  4 -  PROSTATE, RIGHT APEX, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 4+4=8, LESS THAN 5%             INVOLVED.  5 -  PROSTATE, RIGHT LATERAL, BIOPSY:             BENIGN PROSTATIC TISSUE.             NEGATIVE FOR ADENOCARCINOMA.  6 -  PROSTATE, LEFT BASE, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 4+5=9, 30% INVOLVED.             PERINEURAL INVASION IS IDENTIFIED.  7 -  PROSTATE, LEFT MID, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 5+4=9, 50% INVOLVED.             PERINEURAL INVASION IS IDENTIFIED.  8 -  PROSTATE, LEFT APEX, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 5+4=9, 60% INVOLVED.             PERINEURAL INVASION IS IDENTIFIED.  9 -  PROSTATE, LEFT LATERAL, BIOPSY:             ADENOCARCINOMA, GLEASON GRADE 4+5=9, 90% INVOLVED.             PERINEURAL INVASION IS IDENTIFIED.",,"GROSS: Received in formalin and labeled with patient's name are nine specimens. First is labeled ""bladder biopsy"" and consists of a single tan fragment of tissue up to 0.3 cm. Specimen is submitted for TE as #1. Second specimen is labeled ""prostate biopsy right base"" and consists of two gray needle core biopsies with the largest measuring up to 1 cm. Specimen is submitted for TE as #2. Third specimen is labeled ""right mid"" and consists of two gray needle core biopsies with the largest measuring up to 0.8 cm. Specimen is submitted for TE as #3. Fourth specimen is labeled ""right apex"" and consists of two gray needle core biopsies with the largest measuring up to 1.2 cm. Specimen is submitted for TE as #4. Fifth specimen is labeled ""right lateral"" and consists of a single gray needle core biopsy measuring up to 0.7 cm. Specimen is submitted for TE as #5. Sixth specimen is labeled ""left base"" and consists of two gray needle core biopsies with the largest measuring up to 1.5 cm. Specimen is submitted for TE as #6. Seventh specimen is labeled ""left mid"" and consists of three gray needle core biopsies with the largest measuring up to 2 cm. Specimen is submitted for TE as #7. Eighth specimen is labeled ""left apex"" and consists of a single needle core biopsy measuring up to 1.7 cm. Specimen is submitted for TE as #8. Ninth specimen is labeled ""left lateral"" and consists of two gray needle core biopsies with the largest measuring up to 1.2 cm. Specimen is submitted for TE as #9. DT: **DATE[Feb 12 2012]","MICRO: Sections of the bladder biopsy demonstrate benign urothelial mucosa with an extensive inflammatory infiltrate involving both the mucosa and submucosa.  The inflammatory infiltrate is composed of plasma cells, lymphocytes, eosinophils, and rare neutrophils.  Muscularis propria is identified.  Sections of the prostate biopsies from both sides of the gland demonstrate adenocarcinoma as described in the above diagnosis.  Perineural invasion is identified.  DT:  **DATE[Feb 15 12] (DRB, bsp)",PROCEDURE: Cystoscopy. Ultrasound guided prostate biopsy.\X0D\\X0A\SPECIMEN(S): 1) bladder biopsy 2) right base  3) right mid  4) right apex  5) right lateral 6) left base 7) left mid  8) left apex  9) left lateral,,
REG1,PROSTATE,0,341883,3,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Intraoperative findings: none\X0D\\X0A\given. Operative procedure: robotic laparoscopic prostatectomy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  ""NO TUMOR SEEN, NO PROSTATE GLAND\X0D\\X0A\IDENTIFIED""---YMB. \X0D\\X0A\\X0D\\X0A\     Y.M. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Jul 17 1949] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Oct 19 2011] 13:41\X0D\\X0A\Receipt Date: **DATE[Oct 19 2011] 13:41\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: **NAME[XXX WWW], MD     Service: URO     Location: REC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Oct 21 2011] 17:19\X0D\\X0A\RESIDENTS(S): J.D. **NAME[UUU], MD\X0D\\X0A\COMMENT:  In one of the sections of the left apex, tumor is noted approaching\X0D\\X0A\the inked and cauterized margin.  However, few benign glands are present\X0D\\X0A\admixed with the tumor.  While there are glands noted at the inked margin,\X0D\\X0A\due to the marked cautery artifact, it is unable to be determined with\X0D\\X0A\certainty whether this represents benign glands or tumor.  This focus is less\X0D\\X0A\than 1 mm in size.  Dr. **NAME[TTT] has reviewed this slide and concurs.  \X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\POSTERIOR BLADDER NECK MARGIN, EXCISION (A):\X0D\\X0A\   - NO TUMOR SEEN; NO PROSTATE TISSUE IDENTIFIED.\X0D\\X0A\PROSTATE AND SEMINAL VESICLES, ROBOTIC LAPAROSCOPIC PROSTATECTOMY (B):   -\X0D\\X0A\PROSTATIC ADENOCARCINOMA, GLEASON SCORE 3 + 4 = 7 (pT2c, pNX), SEE TEMPLATE.\X0D\\X0A\   - LEFT APICAL MARGIN INDETERMINANT DUE TO MARKED CAUTERY ARTIFACT, SEE\X0D\\X0A\COMMENT.     - REMAINING MARGINS OF RESECTION FREE OF TUMOR.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Oct 21 2011] **NAME[SSS M. RRR], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09400 M8140 \X0D\\X0A\F: A: 88331 FS1, 88305\X0D\\X0A\B: 88309",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  two\X0D\\X0A\Specimen label:   A) posterior bladder neck margin               \X0D\\X0A\Fixation: fresh for frozen section\X0D\\X0A\Number of pieces: 1\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): red tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.9 x 0.3 x 0.2 cm \X0D\\X0A\It is entirely frozen as FS1\X0D\\X0A\Cassette summary: FS1 is entirely resubmitted in A1.  \X0D\\X0A\Specimen B is received in formalin labeled ""prostate and seminal vesicles""\X0D\\X0A\and consists of the aforementioned.  The external surface is dull red-brown. \X0D\\X0A\The cut surface varies from firm to rubbery and is nodular, light tan to\X0D\\X0A\yellow.  No discrete masses or lesions are noted.  The vas deferens and\X0D\\X0A\seminal vesicle are unremarkable and grossly free of tumor.  The urethral\X0D\\X0A\mucosa and margins are unremarkable.\X0D\\X0A\Ink code: anterior blue, posterior black\X0D\\X0A\Measurements:\X0D\\X0A\Weight: 62 gm\X0D\\X0A\Prostate size: Apex to base 4.5 cm; Left to right 6.2 cm; Anterior to\X0D\\X0A\posterior 4.5 cm\X0D\\X0A\Right seminal vesicle: 3.5 x 1.5 x 0.5 cm\X0D\\X0A\Left seminal vesicle: 3 x 1 x 0.5 cm\X0D\\X0A\Right vas deferens: 2.6 cm in length and 0.4 cm in diameter\X0D\\X0A\Left vas deferens: 3.9 cm in length and 0.4 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\B1  B2  right urethral apex margin\X0D\\X0A\B3  B4  left urethral apex margin\X0D\\X0A\B5  B6  right urethral base margin\X0D\\X0A\B7  B8  left urethral base margin\X0D\\X0A\B9  right vas deferens margin\X0D\\X0A\B10  B12  right seminal vesicle/vas deferens\X0D\\X0A\B13  left vas deferens margin\X0D\\X0A\B14  B16  left seminal vesicle/vas deferens\X0D\\X0A\B17  B24  alternating sections right prostate apex to base (same plane split\X0D\\X0A\sections in B18 and B19, B20 and B21, and B22 and B23).\X0D\\X0A\B25  B35  alternating sections left prostate, apex to base (same plane split\X0D\\X0A\sections in B26 and B27, B28 and B29, B30 and B31, B32 and B33, \T\ B34 and\X0D\\X0A\B35). \X0D\\X0A\rgc/**DATE[Oct 20 2011] J.D. **NAME[UUU], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Sep 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate/seminal vesicles \X0D\\X0A\Type of procedure: robotic laparoscopic prostatectomy\X0D\\X0A\Weight of prostate: 62 grams\X0D\\X0A\Histologic type: prostate adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 3/5\X0D\\X0A\              Secondary (next most prevalent) 4/5\X0D\\X0A\              Score 7/10\X0D\\X0A\Tumor location:  right and left\X0D\\X0A\Tumor amount (percentage): 5%\X0D\\X0A\Size of largest tumor nodule:  11 mm (block B17)\X0D\\X0A\Involvement of seminal vesicle:   no\X0D\\X0A\Extension into soft tissue: no\X0D\\X0A\Extracapsular extension: no\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:    negative\X0D\\X0A\     Apical (inferior):  indeterminate on left side due to marked cautery\X0D\\X0A\artifact, see comment (block B4)\X0D\\X0A\Inked surgical margins:  see above, remaining margins negative\X0D\\X0A\Inked surgical margins:  negative with the exception of left apex margin\X0D\\X0A\which is indeterminant due to marked cautery artifact\X0D\\X0A\Vascular invasion: not identified\X0D\\X0A\Perineural invasion: present\X0D\\X0A\High grade PIN:  present (quantity: small), bilateral \X0D\\X0A\Lymph node involvement:  none submitted\X0D\\X0A\Additional pathologic findings (list):  acute \T\ chronic inflammation,\X0D\\X0A\benign prostate hypertrophy\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\           pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNX:     Cannot be assessed   \X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Posterior bladder neck margin/rule out prostate/prostate cancer\X0D\\X0A\B: Prostate gland,,
REG1,PROSTATE,0,385015,4,,Clinical History:\X0D\\X0A\None Given,**** THIS IS AN ADDENDUM REPORT ****,"Pre-Operative Diagnosis:\X0D\\X0A\Prostate CA\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Prostate, bilateral seminal vesicles and vas deferens, radical\X0D\\X0A\prostatectomy:\X0D\\X0A\-    Infiltrating prostatic adenocarcinoma involving approximately 15%\X0D\\X0A\of the gland volume, largest tumor focus 1.4 cm - left side; Gleason's\X0D\\X0A\score 3+4 = 7 (see synoptic and microscopic description).\X0D\\X0A\- Tumor extends multifocally to involve the left apical, bilateral\X0D\\X0A\bladder base, and bilateral peripheral capsular margins (left side >\X0D\\X0A\than right).\X0D\\X0A\-    Bilateral seminal vesicles, and shaved bilateral vas deferens\X0D\\X0A\resection margins are free of tumor.\X0D\\X0A\-    Pathologic Stage:  pT2c; pNx; pMx.\X0D\\X0A\-    Background foci of high-grade prostatic intraepithelial neoplasia,\X0D\\X0A\and focal chronic active prostatitis.",,"Gross Description:\X0D\\X0A\Received is a single formalin container labeled with the patient's name\X0D\\X0A\and demographics and designated ""prostate tissue"".  The specimen\X0D\\X0A\consists of a radical prostatectomy with attached segments of seminal\X0D\\X0A\vesicles and apparent detached tubular segments of vas deferens.  The\X0D\\X0A\main prostatectomy specimen body measures 5.3 x 4.0 x 4.0 cm.  The right\X0D\\X0A\seminal vesicle measures 2.8 x 2.0 x 1.2 cm, and the left measures 3.0 x\X0D\\X0A\1.6 x 1.4 cm.  The short stump-like segment of possible right and left\X0D\\X0A\vas deferens is noted on the base near the insertion point of the\X0D\\X0A\seminal vesicles.  The outer surface is shaggy gray-tan over the body of\X0D\\X0A\the prostate.  The right side is inked black, and the left side is inked\X0D\\X0A\blue over the anterior and posterior capsular surfaces.  The right\X0D\\X0A\seminal vesicle is also inked black, and the left seminal vesicle is\X0D\\X0A\also inked blue.  A small amount of irregular rubbery tissue is noted\X0D\\X0A\anterior to the seminal vesicles over both the right and left sides,\X0D\\X0A\bordering the bladder neck margin.  This tissue is included in the\X0D\\X0A\differential inking.  The seminal vesicles and vas deferens are then\X0D\\X0A\amputated at their bases, and the body of the prostate overall weighs\X0D\\X0A\49.3 grams.  The apex and bladder base margins are both removed in a\X0D\\X0A\conical fashion, and both are submitted in a radial sectioned pattern as\X0D\\X0A\follows:\X0D\\X0A\1 - right side apex\X0D\\X0A\2 - left side apex\X0D\\X0A\3 - right side bladder base\X0D\\X0A\4 - left side bladder base.\X0D\\X0A\The gland is then divided into the right and left halves, and the right\X0D\\X0A\half is serially sectioned from apex to base to reveal generally\X0D\\X0A\heterogeneous pink to yellow-tan rubbery tissue with a few cystic spaces\X0D\\X0A\between 0.2 to 0.3 cm, and a gray-tan nodule measuring up to 0.6 cm near\X0D\\X0A\the mid point between the anterior and posterior lobes.  No necrosis is\X0D\\X0A\observed.  The superior soft tissues show dense rubbery white-tan\X0D\\X0A\indurated tissue and softer amounts of lobulated yellow adipose tissue.\X0D\\X0A\The left side of the prostate is serially sectioned to reveal a rubbery\X0D\\X0A\similar consistency throughout with a few white-tan nodules between 0.3\X0D\\X0A\to 1.2 cm noted.  No necrosis is observed.  Sectioning through the right\X0D\\X0A\and left seminal vesicles shows no focal lesions.  Four additional\X0D\\X0A\detached fragments of rubbery soft tissue are noted ranging in size from\X0D\\X0A\1.2 to 3.6 x 1.2 x 1.0 cm.  These appear to represent possible\X0D\\X0A\additional portions of either seminal vesicle or vas deferens.\X0D\\X0A\Additional representative sections including the vast majority of the\X0D\\X0A\gland, are submitted as follows:\X0D\\X0A\5 through 10 - right side of the prostate\X0D\\X0A\11 - rubbery soft tissue superior to the right prostate\X0D\\X0A\12 - shaved right vas deferens margin, and right seminal vesicle\X0D\\X0A\representative\X0D\\X0A\13 through 18 - left side of the prostate\X0D\\X0A\19 - rubbery soft tissue superior to the left prostate\X0D\\X0A\20 - shaved left vas deferens margin, and left seminal vesicle\X0D\\X0A\representative\X0D\\X0A\21 and 22 - random sections of additional four separate soft tissue\X0D\\X0A\fragments.\X0D\\X0A\DRJ:jlj","Microscopic Description:\X0D\\X0A\Sections show infiltrating Gleason pattern 3 prostatic adenocarcinoma\X0D\\X0A\within one high-power field of the right side apical margin, with tumor\X0D\\X0A\foci extending to involve the inked left side apical margin (slide\X0D\\X0A\A2-1).  The right bladder base margin is focally involved by\X0D\\X0A\adenocarcinoma, and the left bladder base margin appears more\X0D\\X0A\extensively involved by adenocarcinoma with a few foci representing\X0D\\X0A\Gleason pattern 4.  Sections from the right side of the prostate show\X0D\\X0A\multiple scattered foci of mixed Gleason pattern 3 and focal Gleason\X0D\\X0A\pattern 4 adenocarcinoma, the largest up to 0.8 cm in greatest nodular\X0D\\X0A\dimension.  The tumor focally involves the right peripheral soft tissue\X0D\\X0A\margin, at the anterior aspect.  No definitive perineural invasion is\X0D\\X0A\identified.  Sections of the soft tissue described on the right bladder\X0D\\X0A\base side show a portion of benign urinary bladder wall with patchy mild\X0D\\X0A\chronic inflammation and an intact urothelium.  No tumor involvement is\X0D\\X0A\seen in these sections.  A large dystrophic calcification possibly\X0D\\X0A\representing a phlebolith is noted, and will require further\X0D\\X0A\decalcification.  The results of this additionally processed block will\X0D\\X0A\be reported in a separate addendum (block 11).  The right seminal\X0D\\X0A\vesicle, and the right shaved vas deferens resection margin are both\X0D\\X0A\free of tumor.\X0D\\X0A\Sections from the left side of the prostate show larger foci of mixed\X0D\\X0A\Gleason pattern 3 and focal Gleason pattern 4 adenocarcinoma.\X0D\\X0A\Background scattered foci of high-grade prostatic intraepithelial\X0D\\X0A\neoplasia (PIN) are noted.  The infiltrating tumor multifocally extends\X0D\\X0A\to the left side peripheral capsular margin of resection.  No perineural\X0D\\X0A\invasion is identified.  The largest tumor focus on the left side\X0D\\X0A\measures up to 1.4 cm.  Slide A19-1 represents the additional tissue\X0D\\X0A\superior to the left prostate, and show infiltrating adenocarcinoma\X0D\\X0A\extending to this peripheral soft tissue margin, which includes a small\X0D\\X0A\amount of muscle appearing to represent additional bladder neck tissue.\X0D\\X0A\Clinical correlation with the intraoperative impression is recommended.\X0D\\X0A\Sections of the left shaved vas deferens margin and left seminal vesicle\X0D\\X0A\show each to be free of tumor.  Sections of the additionally submitted\X0D\\X0A\soft tissue fragments show benign seminal vesicle tissue, additional vas\X0D\\X0A\deferens, and benign fibromuscular connective tissue.  No tumor is\X0D\\X0A\identified in these sections.\X0D\\X0A\Tissue Code:  T1.\X0D\\X0A\CASE SUMMARY FOR PROSTATE CARCINOMA (PROSTATECTOMY)\X0D\\X0A\Specimen:  Prostate, bilateral seminal vesicles, vas deferens\X0D\\X0A\Procedure:  Radical prostatectomy\X0D\\X0A\Weight of prostate:  49.3 grams\X0D\\X0A\Lymph node sampling:  N/A\X0D\\X0A\Histologic type:  Adenocarcinoma\X0D\\X0A\Gleason grade:\X0D\\X0A\Primary (predominant) pattern:  3\X0D\\X0A\Secondary (worst remaining) pattern:  4\X0D\\X0A\Tertiary pattern:  N/A\X0D\\X0A\Total Gleason score:  7\X0D\\X0A\Size of largest tumor nodule:  1.4 cm - left side\X0D\\X0A\Extraprostatic extension:  Not identified (peripheral resection margins\X0D\\X0A\involved     see below)\X0D\\X0A\Seminal vesicle invasion:  Not identified\X0D\\X0A\Surgical margins:  Involved multifocally (left apical, bilateral bladder\X0D\\X0A\base, bilateral peripheral capsular margins)\X0D\\X0A\Perineural invasion:  Not identified\X0D\\X0A\Lymph-vascular invasion:  Not identified\X0D\\X0A\Treatment effect on carcinoma:  No known treatment effect\X0D\\X0A\Lymph node status:  N/A\X0D\\X0A\Right pelvic:\X0D\\X0A\Left pelvic:\X0D\\X0A\Additional pathologic findings:  Focal high-grade PIN, chronic active\X0D\\X0A\prostatitis\X0D\\X0A\Pathologic Staging:  pT2c; pNx; pMx.\X0D\\X0A\DRJ:jck\X0D\\X0A\D\T\T:  **DATE[Jul 31 2012].\X0D\\X0A\Addendum:\X0D\\X0A\Block 11 following routine decalcification shows a small phlebolith with\X0D\\X0A\partial metaplastic ossification, within a segmental vessel.\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Aug 01 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Prostate,,
REG1,PROSTATE,0,388988,3,,,,,,,,,,
REG1,PROSTATE,0,453634,3,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: PROSTATE, TRANSURETHRAL RESECTION: PROSTATIC ADENOCARCINOMA GLEASONS GRADE 3 + 3 = 6 PERINEURAL INVASION - NOT IDENTIFIED INVOLVING APPROXIMATELY 1% OF EXAMINED TISSUE. HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA - PRESENT. MARKED CHRONIC ACTIVE PROSTATITIS NOTE:  A prostate triple stain is performed utilizing appropriate positive and negative controls.  The tumor shows lack of basal staining with p63 and HMW cytokeratin. The proliferation is positive for P504S. The immunophenotypic signature in conjunction with morphology is consistent with a prostatic adenocarcinoma. Dr. **NAME[XXX] has reviewed the case and concurs with this diagnosis.. Final Signout: **NAME[WWW], MD **DATE[Jul 02 12]",,"GROSS DESCRIPTION: A single specimen is received in formalin labeled prostate tissue.  The specimen consists of 22.9 grams of prostate chips measuring in aggregate 7.5 x 6.9 x 4.6 cm.  The tissue is examined to reveal pink-tan vaguely nodular prostatic chips.  Representative sections are submitted in cassettes ""A"" through ""T"".",,Tissues: PROSTATE. Specimen Comments: CPT CODES: 88342 x 3;88305 x 1,,
REG1,PROSTATE,0,469077,3,,,,,,,,,,
REG1,PROSTATE,0,482885,1,,,,,,,,,,
REG1,PROSTATE,0,483042,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Intraoperative findings: prostate\X0D\\X0A\cancer. Operative procedure: laparoscopic prostatectomy with possible cysto. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Sep 31 1944] (Age: **AGE[in 60s])  MU\X0D\\X0A\Collect Date: **DATE[Jun 5 2012] 13:27\X0D\\X0A\Receipt Date: **DATE[Jun 5 2012] 13:27\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: 2OR\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Jun 7 2012] 16:53\X0D\\X0A\RESIDENTS(S): M.H. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\PROSTATE AND SEMINAL VESICLES (C), LAPAROSCOPIC PROSTATECTOMY:\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON' S 4 + 3 = 7 (pT2c, pN0), SEE\X0D\\X0A\TEMPLATE.\X0D\\X0A\   - PERINEURAL INVASION IDENTIFIED.\X0D\\X0A\   - SURGICAL MARGINS FREE OF TUMOR IN PLANES OF SECTION.\X0D\\X0A\LYMPH NODES, RIGHT PELVIC (A), DISSECTION:\X0D\\X0A\   - NO TUMOR SEEN IN FOUR LYMPH NODES (0/4).\X0D\\X0A\LYMPH NODES, LEFT PELVIC (B), DISSECTION:\X0D\\X0A\   - NO TUMOR SEEN IN TWO LYMPH NODES (0/2).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jun 7 2012] **NAME[UUU M. TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09450 T0860\X0D\\X0A\B: M09450 T0860\X0D\\X0A\C: M09400 M8140 \X0D\\X0A\F: A: 88307\X0D\\X0A\B: 88307\X0D\\X0A\C: 88309",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  three\X0D\\X0A\Specimen label:   A) right pelvic node              \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple  \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): tan \X0D\\X0A\Consistency: soft and fibrofatty\X0D\\X0A\Size(s): 6 x 2 x 0.8 cm in aggregate \X0D\\X0A\Cassette summary: it is sectioned to reveal two lymph nodes which are fatty\X0D\\X0A\and infiltrative. The largest measures 2.5 cm in greatest dimension. The\X0D\\X0A\smaller measures 1.4 cm in greatest dimension. No gross tumor is identified\X0D\\X0A\in either node. The remaining tissue is fatty and unremarkable. The specimen\X0D\\X0A\is submitted entirely in A1  A4 with the smaller lymph node in A1, trisected\X0D\\X0A\and the larger lymph node in A2  A3, serially sectioned; A4  reminder of soft\X0D\\X0A\tissue.  \X0D\\X0A\Specimen label:  B) left pelvic nodes               \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces:  \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 4.5 x 1 x 0.5 cm \X0D\\X0A\The specimen is palpated to reveal a single lymph node measuring 3.5 cm in\X0D\\X0A\greatest dimension. It is serially sectioned to reveal an unremarkable lymph\X0D\\X0A\node with no gross tumor seen. The specimen is submitted entirely as follows:\X0D\\X0A\B1  B2  lymph node, serially sectioned; B3  remainder of specimen. \X0D\\X0A\Specimen C is received in formalin labeled ""prostate and seminal vesicles""\X0D\\X0A\and consists of the aforementioned.  The external surface is dull red-brown. \X0D\\X0A\The cut surface varies from firm to rubbery and is nodular, light tan to\X0D\\X0A\yellow.  No discrete masses or lesions are noted.  The vas deferens and\X0D\\X0A\seminal vesicle are unremarkable and grossly free of tumor.  The urethral\X0D\\X0A\mucosa and margins are unremarkable.\X0D\\X0A\Ink code: anterior blue and posterior black \X0D\\X0A\Measurements:\X0D\\X0A\Weight: 47 gm\X0D\\X0A\Prostate size: Apex to base 4.6 cm; Left to right 4.6 cm; Anterior to\X0D\\X0A\posterior 3.5 cm\X0D\\X0A\Right seminal vesicle: 3 x 1 x 0.8 cm\X0D\\X0A\Left seminal vesicle: 2.5 x 1.1 x 0.6 cm \X0D\\X0A\Right vas deferens: 2.4 cm in length and 0.6 cm in diameter\X0D\\X0A\Left vas deferens: 2.4 cm in length and 0.5 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\C1  right vas deferens margin\X0D\\X0A\C2  left vas deferens margin\X0D\\X0A\C3  C4  right urethral base margin\X0D\\X0A\C5  C6 - left urethral base margin\X0D\\X0A\C7  right urethral apex margin\X0D\\X0A\C8  left urethral apex margin\X0D\\X0A\C9  C11  entire right seminal vesicle and vas deferens\X0D\\X0A\C12  C13  entire left vas deferens and seminal vesicle \X0D\\X0A\C14  C21  right prostate from apex to base, every other section, with\X0D\\X0A\sections divided in C16  C21 (no block C20) \X0D\\X0A\C22  C27  left lobe of prostate from apex to base with sections divided in\X0D\\X0A\C24  C27\X0D\\X0A\rgc/**DATE[Jun 6 2012] M.H. **NAME[VVV], MD\X0D\\X0A\C.M. **NAME[SSS], MD","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Apr 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate/seminal vesicles \X0D\\X0A\Type of procedure:  laparoscopic prostatectomy with bilateral lymph node\X0D\\X0A\sampling\X0D\\X0A\Weight of prostate:  47 grams\X0D\\X0A\Histologic type:  prostatic adenocarcinoma \X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 4/5\X0D\\X0A\              Secondary (next most prevalent) 3/5\X0D\\X0A\              Score 7/10\X0D\\X0A\Tumor location: right and left sides  \X0D\\X0A\Tumor amount (percentage):  right side  8%; left side  3%\X0D\\X0A\Size of largest tumor nodule:  7 mm\X0D\\X0A\Involvement of seminal vesicle:  no\X0D\\X0A\Extension into soft tissue:  no\X0D\\X0A\Extracapsular extension:  no\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:  negative\X0D\\X0A\     Apical (inferior):  negative\X0D\\X0A\Inked surgical margins:  negative\X0D\\X0A\Vascular invasion:  not identified\X0D\\X0A\Perineural invasion:  yes\X0D\\X0A\High grade PIN:  present, small to moderate amount, bilateral location\X0D\\X0A\Lymph node involvement:  0 positive / 6 total\X0D\\X0A\                    Right pelvic:  0/4\X0D\\X0A\                    Left pelvic:  0/2\X0D\\X0A\Additional pathologic findings (list):  BPH and chronic prostatitis\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\        pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:     No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Lymph node dissection-right pelvic nodes\X0D\\X0A\B: Lymph node dissection-left pelvic nodes\X0D\\X0A\C: Prostate and seminal vessicles,,
REG1,PROSTATE,0,484053,1,,CLINICAL HISTORY:\X0D\\X0A\Prostate ca.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   RIGHT PELVIC LYMPH NODES:\X0D\\X0A\1.   Three benign lymph nodes.\X0D\\X0A\B.   LEFT PELVIC LYMPH NODES:\X0D\\X0A\1.   Five benign lymph nodes.\X0D\\X0A\C.   RADICAL PROSTATECTOMY (46.0 GRAMS) WITH ADJOINING BILATERAL SEMINAL\X0D\\X0A\VESICLES AND VAS DEFERENS:\X0D\\X0A\1.   INVASIVE MODERATE TO POORLY DIFFERENTIATED (GLEASON's SCORE 4+3=7)\X0D\\X0A\PROSTATIC ADENOCARCINOMA, ACINIC CELL TYPE.\X0D\\X0A\2.   The tumor diffusely involves the right lobe (40%) with microscopic\X0D\\X0A\perineural extension into the left lobe.\X0D\\X0A\3.   Multiple foci of capsular invasion are identified in the right lobe\X0D\\X0A\with perineural extension to the right periprostatic soft tissue margin\X0D\\X0A\of excision (2.0 mm. focus).\X0D\\X0A\4.   A single microscopic focus (2.0 mm) extends to the prostatic\X0D\\X0A\urethral margin of excision.\X0D\\X0A\5.   The bilateral seminal vesicles and vas deferens are negative for\X0D\\X0A\tumor.\X0D\\X0A\6.   The bladder neck and left periprostatic soft tissue margins of\X0D\\X0A\excision are negative for tumor.\X0D\\X0A\7.   Background of benign adenofibromatous hyperplasia.\X0D\\X0A\ \X0D\\X0A\COMMENT: T3a,N0,MX.  Although the dominant Gleason components are 4 and\X0D\\X0A\3, a significant tertiary component of Gleason score 5 is identified as\X0D\\X0A\well.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (DA/dkv)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jul 20 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Submitted in formalin and designated 'right pelvic lymph\X0D\\X0A\nodes' is a 3 x 2.5 x 0.5 cm aggregate of fibrofatty soft tissue\X0D\\X0A\embedded en toto in A.\X0D\\X0A\Specimen (B) Submitted in formalin and designated 'left pelvic lymph\X0D\\X0A\nodes' is a 2.8 x 2.5 x 0.4 cm aggregate of fibrofatty soft tissue\X0D\\X0A\embedded en toto in B.\X0D\\X0A\Specimen (C) Submitted in formalin is an intact 46 gram walnut shaped\X0D\\X0A\4.8 x 4.2 x 3.8 cm radical prostatectomy with adjoining bilateral\X0D\\X0A\seminal vesicles and vas deferens.  The vas deferens approximate 3.2 x\X0D\\X0A\0.8 cm bilaterally and appear grossly unremarkable.  The vas deferens\X0D\\X0A\margins of excision are submitted in C1 with the right inked in red. The\X0D\\X0A\seminal vesicles approximate 3.3 x 2.1 x 1.1 cm bilaterally and appear\X0D\\X0A\grossly unremarkable.  The bladder neck margin of excision appears\X0D\\X0A\grossly unremarkable. The bladder neck margin of excision is submitted\X0D\\X0A\in C2.  The prostatic urethral margin of excision appears grossly\X0D\\X0A\unremarkable.  The prostatic urethral margin of excision is submitted in\X0D\\X0A\C3. The right and left perirectal soft tissue margins of excision appear\X0D\\X0A\grossly unremarkable.  The right perirectal and lateral soft tissue\X0D\\X0A\margins of excision are submitted in C4 with the left in C5.  The right\X0D\\X0A\lobe is inked in red and the specimen is serially sectioned from\X0D\\X0A\inferior/anterior to superior/posterior.  The anterior most aspect of\X0D\\X0A\both lobes is submitted in C6.  An irregular central nodularity is\X0D\\X0A\identified compressing the prostatic urethral consistent with\X0D\\X0A\adenofibromatous hyperplasia.  An irregular yellowish discoloration is\X0D\\X0A\noted throughout the right lobe approximating 1.5 cm in greatest\X0D\\X0A\dimension.  No yellow discoloration is identified within the confines of\X0D\\X0A\the left lobe.  The bulk of the right lobe is embedded in C7 through C10\X0D\\X0A\with the bulk of the left lobe in C11 through C14.  The base of the\X0D\\X0A\right seminal vesicle is submitted in C15 with the base of the left\X0D\\X0A\seminal vesicle in C16.  (DA/cm)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 18,,"SPECIMEN(S): A RIGHT PELVIC LYMPH NODE\X0D\\X0A\SPECIMEN(S): B LEFT PELVIC LYMPH NODE\X0D\\X0A\SPECIMEN(S): C Prostate, radical",,
REG1,PROSTATE,0,484887,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Intraoperative findings: prostate\X0D\\X0A\cancer. Operative procedure: robotic laparoscopic prostatectomy. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jun 9 1954] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[Jul 7 2012] 14:29\X0D\\X0A\Receipt Date: **DATE[Jul 7 2012] 14:29\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Jul 9 2012] 14:27\X0D\\X0A\RESIDENTS(S): J.D. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\LYMPH NODES, RIGHT PELVIC, EXCISION (A):\X0D\\X0A\   - NO TUMOR SEEN IN THREE LYMPH NODES (0/3).\X0D\\X0A\LYMPH NODES, LEFT PELVIC, EXCISION (B):\X0D\\X0A\   - NO TUMOR SEEN IN THREE LYMPH NODES (0/3).\X0D\\X0A\PROSTATE AND SEMINAL VESICLES, ROBOTIC LAPAROSCOPIC PROSTATECTOMY (C):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON SCORE 3 + 4 = 7 (pT2c, pN0; SEE\X0D\\X0A\TEMPLATE).\X0D\\X0A\   - EXTRAPROSTATIC EXTENSION IDENTIFIED.\X0D\\X0A\   - SURGICAL RESECTION MARGIN FOCALLY POSITIVE.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jul 9 2012] **NAME[UUU M. TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09450 P1100\X0D\\X0A\B: M09450 P1100\X0D\\X0A\C: M81403 P1100 \X0D\\X0A\F: A: 88307\X0D\\X0A\B: 88307\X0D\\X0A\C: 88309",,"**NAME[BBB] DESCRIPTION\X0D\\X0A\Total specimen number:  three\X0D\\X0A\Specimen label:   A) right pelvic lymph nodes               \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s): irregular     \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): 4.2 x 3.5 x 2 cm \X0D\\X0A\Three candidate lymph node are identified measuring 0.9 and 1.1 cm and 6 cm\X0D\\X0A\in greatest dimension respectively. \X0D\\X0A\Cassette summary: A1  two candidate lymph nodes; A2  A5  largest candidate\X0D\\X0A\lymph node serially sectioned. \X0D\\X0A\Specimen label:  B) left pelvic lymph nodes                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple  \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft and fatty\X0D\\X0A\Size(s): 5 x 3.5 x 2 cm\X0D\\X0A\Three candidate lymph nodes are identified. The largest measures 3 x 2 x 1.5\X0D\\X0A\cm; the second measures 3 x 1 x 0.5 cm; the third measures 1.1 x 0.4 x 0.3 cm\X0D\\X0A\\X0D\\X0A\Cassette summary: B1  one candidate lymph node serially sectioned; B2  one\X0D\\X0A\candidate lymph node; B3  B5  largest candidate lymph node serially\X0D\\X0A\sectioned. \X0D\\X0A\Specimen C is received in formalin labeled ""prostate and seminal vesicles""\X0D\\X0A\and consists of the aforementioned.  The external surface is dull red-brown. \X0D\\X0A\The cut surface varies from firm to rubbery and is nodular, light tan to\X0D\\X0A\yellow.  No discrete masses or lesions are noted.  The vas deferens and\X0D\\X0A\seminal vesicle are unremarkable and grossly free of tumor.  The urethral\X0D\\X0A\mucosa and margins are unremarkable. **NAME[BBB] examination of the left half of\X0D\\X0A\the prostate shows a well circumscribed 1.4 cm round nodule. \X0D\\X0A\Ink code: anterior is inked blue; posterior is inked black  \X0D\\X0A\Measurements:\X0D\\X0A\Weight: 52 gm\X0D\\X0A\Prostate size: Apex to base 4.2 cm; Left to right 5.4 cm; Anterior to\X0D\\X0A\posterior 4 cm\X0D\\X0A\Right seminal vesicle: 3 x 2 x 0.7 cm\X0D\\X0A\Left seminal vesicle: 3.5 x 2 x 0.6 cm \X0D\\X0A\Right vas deferens: 2.2 cm in length and 0.6 cm in diameter\X0D\\X0A\Left vas deferens: 2.2 cm in length and 0.6 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\C1  right vas deferens margin\X0D\\X0A\C2  left vas deferens margin\X0D\\X0A\C3  C4  right urethral apex margin\X0D\\X0A\C5  C6  left urethral apex margin\X0D\\X0A\C7  C8  right urethral base margin\X0D\\X0A\C9  C10  left urethral base margin\X0D\\X0A\C11  C13  right seminal vesicle and vas deferens submitted entirely\X0D\\X0A\C14  C16  left seminal vesicle and vas deferens\X0D\\X0A\C17  C22  right side from apex to base (alternating sections)\X0D\\X0A\C23  C30  left side from apex to base (alternating sections)\X0D\\X0A\rgc/**DATE[Jul 8 2012] J.D. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Jun 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate/seminal vesicles \X0D\\X0A\Type of procedure:  robotic laparoscopic prostatectomy\X0D\\X0A\Weight of prostate:  52 grams\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 3/5\X0D\\X0A\              Secondary (next most prevalent) 4/5\X0D\\X0A\              Score 7/10\X0D\\X0A\Tumor location:  right and left\X0D\\X0A\Tumor amount (percentage):  5%\X0D\\X0A\Size of largest tumor nodule:  15 mm\X0D\\X0A\Involvement of seminal vesicle:   no\X0D\\X0A\Extension into soft tissue:  no\X0D\\X0A\Extracapsular extension:  yes (block C20 \T\ C22)\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:  negative\X0D\\X0A\     Apical (inferior):   negative\X0D\\X0A\Inked surgical margins:  positive on right side near base (block C22)\X0D\\X0A\    If inked surgical margins are positive, the length of the invasive focus\X0D\\X0A\abutting the inked margin is  5 mm.\X0D\\X0A\    Gleason grade of tumor at inked margin:  3\X0D\\X0A\Vascular invasion:  not identified\X0D\\X0A\Perineural invasion: present\X0D\\X0A\High grade PIN:  present\X0D\\X0A\Lymph node involvement:  \X0D\\X0A\                    Right pelvic:  0/3\X0D\\X0A\                    Left pelvic:  0/3\X0D\\X0A\Additional pathologic findings (list):  focal acute and chronic inflammation\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\       pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:     No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: right pelvic lymph nodes\X0D\\X0A\B: left pelvic lymph nodes\X0D\\X0A\C: Prostate,,
REG1,PROSTATE,0,487013,1,,,,,,,,,,
REG1,PROSTATE,0,487892,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is elevated PSA. Operative procedure: TRUS biopsy, base\X0D\\X0A\ blue, mid  green, apex  eosin.\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[May 1 1934] (Age: **AGE[in 70s])  MW\X0D\\X0A\Collect Date: **DATE[May 22 2012] 13:58\X0D\\X0A\Receipt Date: **DATE[May 22 2012] 13:58\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], MD     Service: URO     Location: URCT\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 27 2012] 14:48\X0D\\X0A\RESIDENTS(**NAME[M): WWW VVV], DO","DIAGNOSIS\X0D\\X0A\PROSTATE GLAND, RIGHT (base; mid-gland; apex), NEEDLE BIOPSY (A):\X0D\\X0A\     PROSTATIC ADENOCARCINOMA\X0D\\X0A\            Gleason grade:  3 + 4 = 7 (of 10)\X0D\\X0A\            number of positive tissue cores:  5/6\X0D\\X0A\            greatest percentage involvement of single core (approximate):  15\X0D\\X0A\to 20%\X0D\\X0A\            perineurial invasion:  not identified\X0D\\X0A\PROSTATE GLAND, LEFT (base; mid-gland; apex), NEEDLE BIOPSY (B):\X0D\\X0A\     PROSTATIC ADENOCARCINOMA\X0D\\X0A\            Gleason grade:  3 + 4 = 7 (of 10)\X0D\\X0A\            number of positive tissue cores:  2/6\X0D\\X0A\            greatest percentage involvement of single core (approximate):  20\X0D\\X0A\to 25%\X0D\\X0A\            perineurial invasion:  not identified\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dw/**DATE[May 27 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 185     MALIGNANT NEOPLASM PROSTATE\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M81403 P1143\X0D\\X0A\B: M81403 P1143 \X0D\\X0A\F: A: 88305(3)\X0D\\X0A\B: 88305(3)",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  two\X0D\\X0A\Specimen label: A) right prostate               \X0D\\X0A\Fixation: formalin\X0D\\X0A\Shape(s): cores    \X0D\\X0A\Number, Inked Color(s)/Size(s): two blue cores which measure 1.2 and 0.7 cm\X0D\\X0A\in length x less than 0.1 cm in diameter; two green cores which measure 1 and\X0D\\X0A\0.8 cm in length x less than 0.1 cm in diameter; two eosin cores which\X0D\\X0A\measure 0.8 and 0.5 cm in length less than 0.1 cm in diameter.\X0D\\X0A\Cassette summary:  Blue cores are submitted in screened A1; green cores \X0D\\X0A\screened A2; eosin cores  screened A3. \X0D\\X0A\Specimen label: B) left prostate               \X0D\\X0A\Fixation: formalin\X0D\\X0A\Shape(s): cores \X0D\\X0A\Number, Color(s)/Size(s): two blue cores which measure 1.2 and 0.8 cm in\X0D\\X0A\length x less than 0.1 cm in diameter, three green cores which range from 1.5\X0D\\X0A\to 0.5 cm in length x less than 0.1 cm in diameter and two eosin cores which\X0D\\X0A\measure 0.7 cm in length x less than 0.1 cm in diameter each.  \X0D\\X0A\Cassette summary: Blue cores are submitted in screened B1; green cores \X0D\\X0A\screened B2; eosin cores  screened B3. \X0D\\X0A\rgc/**DATE[May 23 2012] **NAME[WWW VVV], DO\X0D\\X0A\J.G. Combs",MICROSCOPIC DESCRIPTION\X0D\\X0A\A resident has participated in this service.  The electronic signature\X0D\\X0A\denotes the pathologist performing and responsible for the pathologic\X0D\\X0A\evaluation.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right prostate biopsy\X0D\\X0A\B: Left prostate biopsy,,
REG1,PROSTATE,0,487933,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is elevated PSA, prostate nodule. Operative procedure:\X0D\\X0A\TRUS biopsy  (base  blue; mid  green; apex  eosin). \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 24 1939] (Age: **AGE[in 70s])  MW\X0D\\X0A\Collect Date: **DATE[Sep 9 2012] 15:30\X0D\\X0A\Receipt Date: **DATE[Sep 9 2012] 15:30\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: P.L. **NAME[YYY], MD     Service: URO     Location: URCT\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Sep 14 2012] 10:29\X0D\\X0A\RESIDENTS(S): J.P. **NAME[WWW], MD","DIAGNOSIS\X0D\\X0A\PROSTATE, LEFT, TRUS BIOPSY (APEX, MID, BASE) (B):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON GRADE 3 + 4 = 7 INVOLVING SIX OF SIX\X0D\\X0A\CORES (60% OF\X0D\\X0A\     MATERIAL EXAMINED INVOLVED WITH TUMOR).\X0D\\X0A\PROSTATE, RIGHT, TRUS BIOPSY (APEX, MID, BASE) (A):\X0D\\X0A\   - ATYPICAL SMALL ACINAR PROLIFERATION INVOLVING MID CORE (SEE COMMENT).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Sep 13 2012] M.S. **NAME[VVV], M.D.\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09450 P1140\X0D\\X0A\B: M81403 P1140 \X0D\\X0A\F: A: 88305(3)\X0D\\X0A\B: 88305(3)",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  two\X0D\\X0A\Specimen label: A) right prostate               \X0D\\X0A\Fixation: formalin\X0D\\X0A\Shape(s): cores    \X0D\\X0A\Number, Inked Color(s)/Size(s): two blue measuring 1.1 and 1 cm in length x\X0D\\X0A\less than 0.1 cm in diameter, two green measuring 1.3 and 1.1 cm in length x\X0D\\X0A\less than 0.1 cm in diameter, and two eosin measuring 1 and 0.8 cm in length\X0D\\X0A\x less than 0.1 cm in diameter. \X0D\\X0A\Cassette summary:  Cores are submitted in screened blue  A1; green  A2; eosin\X0D\\X0A\ A3, entirely.\X0D\\X0A\Specimen label: B) left prostate               \X0D\\X0A\Fixation: formalin\X0D\\X0A\Shape(s): cores \X0D\\X0A\Number, Color(s)/Size(s): two blue measuring 1.5 and 1.1 cm in length x less\X0D\\X0A\than 0.1 cm in diameter, two green measuring 1.7 and 1.3 cm in length x less\X0D\\X0A\than 0.1 cm in diameter and two eosin measuring 1.1 and 0.9 cm in length x\X0D\\X0A\less than 0.1 cm in diameter. \X0D\\X0A\Cassette summary:  Cores are submitted in screened blue  B1; green  B2; eosin\X0D\\X0A\ B3, entirely.\X0D\\X0A\rgc/**DATE[Sep 12 2012] J.P. **NAME[WWW], MD\X0D\\X0A\**NAME[UUU M. TTT","MICROSCOPIC DESCRIPTION\X0D\\X0A\Given the presence of overt tumor in the contralateral side,\X0D\\X0A\immunohistochemical stains (PIN4) were not performed on the focus of atypical\X0D\\X0A\small acinar proliferation identified.  If clinically relevant, stains can be\X0D\\X0A\attempted.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right prostate biopsy\X0D\\X0A\B: Left prostate biopsy,,
REG1,PROSTATE,0,488067,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is BPH.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Prostate, TUR","Final Diagnosis\X0D\\X0A\PROSTATE TISSUE, TUR:\X0D\\X0A\     Adenocarcinoma, Gleason's grade 3+3 (with focal 3+4) involving 30% of the\X0D\\X0A\curetting sample.\X0D\\X0A\     See TEMPLATE and COMMENT.\X0D\\X0A\COMMENT:  I have discussed this with **PLACE Grizzle in Dr. **NAME[ZZZ]' office on\X0D\\X0A\**DATE[Oct 28 11].\X0D\\X0A\**INITIALS\X0D\\X0A\PROSTATE TUR TEMPLATE:\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  TUR\X0D\\X0A\SPECIMEN SIZE (grams):  6.9 grams\X0D\\X0A\HISTOLOGIC TYPE:  adenocarcinoma\X0D\\X0A\PRIMARY (Predominant) PATTERN:  3\X0D\\X0A\SECONDARY (Worst Remaining) PATTERN:  4\X0D\\X0A\TOTAL GLEASON SCORE:  7\X0D\\X0A\TUMOR QUANTITATION - TUR Specimens:  approximately 30%\X0D\\X0A\PERIPROSTATIC FAT INVASION (document if identified):   none seen\X0D\\X0A\SEMINAL VESICLE INVASION (document if identified):  none seen\X0D\\X0A\LYMPH-VASCULAR INVASION:   none seen\X0D\\X0A\PERINEURAL INVASION:  none seen\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS: high grade PIN\X0D\\X0A\OTHER STUDIES:  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 1b  \X0D\\X0A\pN= x   \X0D\\X0A\AJCC PATHOLOGIC STAGE:  I\X0D\\X0A\MHB",,Gross Description\X0D\\X0A\Received in formalin labeled prostate tissue is a 6.9 gram aggregate of tan/pink\X0D\\X0A\rubbery prostate chips which are submitted entirely in cassettes A-E.  **INITIALS,Microscopic Description\X0D\\X0A\The prostate tissue shows areas of hyperplasia but also shows infiltrating\X0D\\X0A\carcinoma.  The tumor shows infiltrating individual glands in many areas but\X0D\\X0A\some gland fusion is seen.  The individual cells show prominent nucleoli in some\X0D\\X0A\areas.  Occasional foci of high grade PINs are also seen.  The tumor involves\X0D\\X0A\approximately 30% of the curetting sampled.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY, XXX M].\X0D\\X0A\Procedures/Addenda"
REG1,PROSTATE,0,488226,1,,CLINICAL HISTORY:\X0D\\X0A\BPH with obstruction.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'PROSTATE CHIPS, TURP':\X0D\\X0A\1.   FOCAL PROSTATIC ADENOCARCINOMA (GLEASON's PATTERN 3+3=6)\X0D\\X0A\a.   Adenocarcinoma identified focally in one of sixty four cores (1/64)\X0D\\X0A\(see comment).\X0D\\X0A\2.   Associated prostatic hypertrophy.\X0D\\X0A\3.   Moderate mixed acute and chronic prostatitis.\X0D\\X0A\4.   Focal atrophy.\X0D\\X0A\ \X0D\\X0A\COMMENT: A p63 immunostain was performed on the core confirming a single\X0D\\X0A\focus of atypical acinar glands in a pattern most consistent with\X0D\\X0A\Gleason's 3+3=6 adenocarcinoma. This case was shared in internal\X0D\\X0A\consultation with Dr. **NAME[ZZZ], who concurred.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[YYY:  XXX M. WWW] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Dec 14 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'prostate chips' are multiple cores of\X0D\\X0A\indurated tan tissue measuring 4.5 x 4.5 x 2.5 cm and weighing 15.6\X0D\\X0A\grams in total aggregate weight. The entire specimen is submitted in\X0D\\X0A\cassettes A1 through A7.  (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 7,,SPECIMEN(S): A Prostate chips,,
REG1,PROSTATE,0,488244,1,,CLINICAL HISTORY:\X0D\\X0A\prostate ca,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   RIGHT PELVIC LYMPH NODES:\X0D\\X0A\1.   Three benign lymph nodes.\X0D\\X0A\B.   LEFT PELVIC LYMPH NODES:\X0D\\X0A\1.   Three benign lymph nodes.\X0D\\X0A\C.   RADICAL PROSTATECTOMY (62.0 GRAMS) WITH BILATERAL ADJOINING SEMINAL\X0D\\X0A\VESICLES AND VAS DEFERENS:\X0D\\X0A\1.   DIFFUSELY INVADING POORLY DIFFERENTIATED (GLEASON's SCORE 4+5=9)\X0D\\X0A\PROSTATIC ADENOCARCINOMA.\X0D\\X0A\2.   Tumor diffusely involves both glands and approximates 70% of the\X0D\\X0A\prostatic parenchyma.\X0D\\X0A\3.   Extensive bilateral capsular invasion.\X0D\\X0A\4.   Extensive perineural and lymphatic invasion.\X0D\\X0A\5.   Tumor extends to the prostatic urethral, bladder neck, and left vas\X0D\\X0A\deferens margins of excision.\X0D\\X0A\6.   Tumor diffusely involves the bilateral seminal vesicles.\X0D\\X0A\7.   Tumor extends to the left perirectal soft tissue margin of\X0D\\X0A\excision.\X0D\\X0A\D.   ANTERIOR BLADDER PACKET:\X0D\\X0A\1.   Benign fibrofatty soft tissue.\X0D\\X0A\ \X0D\\X0A\COMMENT: T4,N0,MX\X0D\\X0A\ \X0D\\X0A\Shavings from the bladder neck margin of excision are positive for tumor\X0D\\X0A\warranting a T4 pathologic staging.  The dominant Gleason components are\X0D\\X0A\4 and 5 with a tertiary component of Grade 3.  Extensive perineural,\X0D\\X0A\lymphatic and extracapsular tumor invasion is identified.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (DA/dkv)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Dec 21 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Submitted in formalin and designated 'right pelvic lymph\X0D\\X0A\node' is a firm tan and fatty yellow 4.1 x 1.2 x 0.8 cm. soft tissue\X0D\\X0A\fragment that is bisected and embedded en toto in a single cassette.\X0D\\X0A\Specimen (B) Submitted in formalin and designated 'left pelvic lymph\X0D\\X0A\node' is a 2.6 x 1.4 x 0.3 cm. aggregate of firm tan and fatty yellow\X0D\\X0A\soft tissue embedded en toto in a single cassette.\X0D\\X0A\Specimen (C) Submitted in formalin is an intact 62.0 gram walnut-shaped\X0D\\X0A\5.8 x 5.4 x 4.4 cm. radical prostatectomy with bilateral adjoining\X0D\\X0A\seminal vesicles.  The vas deferens approximate 2.8 x 0.5 cm.\X0D\\X0A\bilaterally and appear grossly normal.  The vas deferens margins of\X0D\\X0A\excision are submitted in C1 with the right inked in red.  The proximal\X0D\\X0A\aspects of both seminal vesicles is present each approximating 1.8 x 1.2\X0D\\X0A\x 0.9 cm.  No grossly discernible tumor nodularity is identified.  The\X0D\\X0A\bladder dome margin of excision appears grossly unremarkable.  The\X0D\\X0A\bladder neck margin of excision is submitted in C2.  The prostatic\X0D\\X0A\urethral margin of excision appears grossly unremarkable.  The prostatic\X0D\\X0A\urethral margin of excision is submitted in C3.  The right and left\X0D\\X0A\perirectal soft tissue margins of excision appear unremarkable.  The\X0D\\X0A\right perirectal soft tissue margins of excision are submitted in C4\X0D\\X0A\with left perirectal soft tissue margins in C5.  The right lobe is inked\X0D\\X0A\in red and the specimen is serially sectioned from anterior to posterior\X0D\\X0A\revealing a central irregular nodularity consistent with\X0D\\X0A\adenofibromatous hyperplasia.  The anterior most aspect of both lobes is\X0D\\X0A\submitted in C6 and C7.  No definitive tumor nodularity is grossly\X0D\\X0A\identified.  An ill-defined palpable nodularity is noted in the right\X0D\\X0A\posterior lobe.  The bulk of the right lobe is submitted in C8-C12 with\X0D\\X0A\the bulk of the left lobe in C13-C17.  Multiple gritty black phleboliths\X0D\\X0A\are identified throughout and are attempted to be removed.  The base of\X0D\\X0A\the right seminal vesicle with adjoining prostate is submitted in C18\X0D\\X0A\with the base of the left seminal vesicle and adjacent prostate in C19.\X0D\\X0A\Specimen (D) Submitted in formalin and designated 'anterior bladder\X0D\\X0A\lymph node packet' is a 3.8 x 3.2 x 0.5 cm. aggregate of fatty soft\X0D\\X0A\tissue embedded en toto in a single cassette.  (DA/dkv)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 22\X0D\\X0A\Prostate Gland\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     C: Prostate, radical\X0D\\X0A\ \X0D\\X0A\PROSTATE GLAND: Radical Prostatectomy\X0D\\X0A\Histologic Type:    Adenocarcinoma (conventional, not otherwise\X0D\\X0A\specified)\X0D\\X0A\Histologic Grade:   Primary Pattern Grade:   4\X0D\\X0A\Secondary Pattern Grade: 5\X0D\\X0A\Tertiary Pattern Grade:  3\X0D\\X0A\Total Gleason Score:     9\X0D\\X0A\Tumor Quantitation: Proportion (percent) of prostate involved by tumor:\X0D\\X0A\70%\X0D\\X0A\Primary Tumor (pT): pT4\X0D\\X0A\Regional Lymph Nodes (pN):    pN0\X0D\\X0A\Number of nodes examined:     6\X0D\\X0A\Number of nodes involved:     0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Extraprostatic Extension:     Present\X0D\\X0A\Seminal Vesicle Invasion:     Present\X0D\\X0A\Perineural Invasion:     Present\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Lymphatic (Small Vessel) Invasion (L):  Present",,"SPECIMEN(S): A RIGHT PELVIC LYMPH NODE\X0D\\X0A\SPECIMEN(S): B LEFT PELVIC LYMPH NODE\X0D\\X0A\SPECIMEN(S): C Prostate, radical\X0D\\X0A\SPECIMEN(S): D ANTERIOR BLADDER LYMPH NODE PACKET",,
REG1,PROSTATE,0,488730,1,,HISTORY: elevated PSA,"ICD9 CODES: 185, 233.4, 601.0\X0D\\X0A\COMMENTS: Results communicated to **NAME[VVV UUU] in Dr. **NAME[ZZZ YYY]'s office by Dr. **NAME[XXX WWW] at 11:37 a.m. on **DATE[Mar 22 12].","DIAGNOSIS: 1 -  PROSTATE, LEFT LATERAL BASE, BIOPSY:             INVASIVE PROSTATIC ADENOCARCINOMA \X0D\\X0A\GLEASON GRADE 3+4=7 \X0D\\X0A\            TUMOR INVOLVES 40% OF THE SPECIMEN \X0D\\X0A\PERINEURAL INVASION IS             IDENTIFIED.  2 -  PROSTATE, LEFT LATERAL MID, BIOPSY:             INVASIVE PROSTATIC ADENOCARCINOMA \X0D\\X0A\GLEASON GRADE 3+4=7 \X0D\\X0A\            TUMOR INVOLVES 60% OF THE SPECIMEN \X0D\\X0A\NO PERINEURAL             INVASION IDENTIFIED.  3 -  PROSTATE, LEFT LATERAL APEX, BIOPSY:             INVASIVE PROSTATIC ADENOCARCINOMA \X0D\\X0A\GLEASON GRADE 4+3=7 \X0D\\X0A\            TUMOR INVOLVES 50% OF THE SPECIMEN \X0D\\X0A\NO PERINEURAL             INVASION IDENTIFIED.  4 -  PROSTATE, LEFT BASE, BIOPSY:             BENIGN PROSTATE TISSUE.             NO EVIDENCE OF MALIGNANCY.  5 -  PROSTATE, LEFT MID, BIOPSY:             INVASIVE PROSTATIC ADENOCARCINOMA \X0D\\X0A\GLEASON GRADE 4+3=7 \X0D\\X0A\            TUMOR INVOLVES 80% OF THE SPECIMEN \X0D\\X0A\NO PERINEURAL             INVASION IDENTIFIED.  6 -  PROSTATE, LEFT APEX, BIOPSY:             INVASIVE PROSTATIC ADENOCARCINOMA \X0D\\X0A\GLEASON GRADE 4+4=8 \X0D\\X0A\            TUMOR INVOLVES 90% OF THE SPECIMEN \X0D\\X0A\PERINEURAL INVASION IS             IDENTIFIED.  7 -  PROSTATE, LEFT TRANSITIONAL, BIOPSY:             BENIGN PROSTATE TISSUE.             NO EVIDENCE OF MALIGNANCY.  8 -  PROSTATE, RIGHT LATERAL BASE, BIOPSY:             SMALL FOCUS CONSISTENT WITH HIGH-GRADE PROSTATIC             INTRAEPITHELIAL NEOPLASM.  9 -  PROSTATE, RIGHT LATERAL MID, BIOPSY:             INVASIVE PROSTATIC ADENOCARCINOMA \X0D\\X0A\GLEASON GRADE 3+3=6 \X0D\\X0A\            TUMOR INVOLVES 50% OF THE SPECIMEN \X0D\\X0A\NO PERINEURAL             INVASION IDENTIFIED.  10 - PROSTATE, RIGHT LATERAL APEX, BIOPSY:             BENIGN PROSTATE TISSUE.             NO EVIDENCE OF MALIGNANCY.  11 - PROSTATE, RIGHT BASE, BIOPSY:             BENIGN PROSTATE TISSUE.             NO EVIDENCE OF MALIGNANCY.  12 - PROSTATE, RIGHT MID, BIOPSY:             BENIGN PROSTATE TISSUE WITH ACUTE AND CHRONIC PROSTATITIS.             NO EVIDENCE OF MALIGNANCY.  13 - PROSTATE, RIGHT APEX, BIOPSY:             BENIGN PROSTATE TISSUE.             NO EVIDENCE OF MALIGNANCY.  14 - PROSTATE, RIGHT TRANSITIONAL, BIOPSY:             BENIGN PROSTATE TISSUE.             NO EVIDENCE OF MALIGNANCY.",,"GROSS: Received in formalin and labeled with patient's name are fourteen specimens. All are labeled ""prostate biopsy"". First specimen is labeled ""left lateral base"" and consists of a single tan needle core biopsy measuring up to 1 cm. Specimen is submitted for TE as #1. Second specimen is labeled ""left lateral mid"" and consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as #2. Third specimen is labeled ""left lateral apex"" and consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as #3. Fourth specimen is labeled ""left base"" and consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as #4. Fifth specimen is labeled ""left mid"" and consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as #5. Sixth specimen is labeled ""left apex"" and consists of a single gray needle core biopsy measuring up to 2.5 cm. Specimen is submitted for TE as #6. Seventh specimen is labeled ""left transitional"" and consists of two gray needle core biopsies with the largest measuring up to 0.7 cm. Specimen is submitted for TE as #7. Eighth specimen is labeled ""right lateral base"" and consists of a single gray needle core biopsy measuring up to 1.5 cm. Specimen is submitted for TE as #8. Ninth specimen is labeled ""right lateral mid"" and consists of a single gray needle core biopsy measuring up to 1.5 cm. Specimen is submitted for TE as #9. Tenth specimen is labeled ""right lateral apex"" and consists of a single gray needle core biopsy measuring 1.7 cm. Specimen is submitted for TE as #10. Eleventh specimen is labeled ""right base"" and consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as #11. Twelfth specimen is labeled ""right mid"" and consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as #12. Specimen #13 labeled ""right apex"" consists of a single gray needle core biopsy measuring up to 2 cm. Specimen is submitted for TE as  #13. Specimen #14 labeled ""right transitional"" consists of a single gray needle core biopsy measuring up to 1.5 cm. Specimen is submitted for TE as #14. DT: **DATE[Mar 21 2012]","MICRO: A microscopic examination has been performed.  DT:  **DATE[Mar 22 12] (KSB, bsp)",PROCEDURE: Prostate biopsy\X0D\\X0A\SPECIMEN(S): 1) left lateral base 2) left lateral mid 3) left lateral apex 4) left base 5) left mid 6) left apex 7) left transitional 8) right lateral base 9) right lateral mid 10) right lateral apex 11) right base 12) right mid 13) right apex 14) right transitional,,
REG1,PROSTATE,0,489068,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\elevated psa\X0D\\X0A\,PROSTATE BIOPSY WITH TRANSRECTAL GUIDE\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3062 - SUR PATH IV\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH IV/6\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH IV (**DATE[Nov 03 11]-0936)\X0D\\X0A\,"DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\A.  NEEDLE CORE BIOPSY, RIGHT LOBE OF PROSTATE - APEX:\X0D\\X0A\BENIGN PROSTATIC PARENCHYMA.\X0D\\X0A\B.  NEEDLE CORE BIOPSY, RIGHT LOBE OF PROSTATE - MID:\X0D\\X0A\BENIGN PROSTATIC PARENCHYMA WITH FOCAL CORPORA AMYLACEA.\X0D\\X0A\C.  NEEDLE CORE BIOPSY, RIGHT LOBE OF PROSTATE - BASE:\X0D\\X0A\BENIGN PROSTATIC PARENCHYMA WITH CORPORA AMYLACEA.\X0D\\X0A\D.  NEEDLE CORE BIOPSY, LEFT LOBE OF PROSTATE - APEX:\X0D\\X0A\BENIGN PROSTATIC PARENCHYMA WITH FOCAL CORPORA AMYLACEA.\X0D\\X0A\E.  NEEDLE CORE BIOPSY, LEFT LOBE OF PROSTATE - MID:\X0D\\X0A\BENIGN PROSTATIC PARENCHYMA WITH FOCAL CORPORA AMYLACEA.\X0D\\X0A\F.  NEEDLE CORE BIOPSY, LEFT LOBE OF PROSTATE - BASE:\X0D\\X0A\MODERATELY DIFFERENTIATED ADENOCARCINOMA INVOLVING 40% OF THE\X0D\\X0A\NEEDLE BIOPSY WITH ASSOCIATED EXTENSIVE HIGH GRADE PROSTATIC\X0D\\X0A\INTRAEPITHELIAL NEOPLASIA.\X0D\\X0A\COMBINED GLEASON SCORE OF 6 (3+3).\X0D\\X0A\NEGATIVE FOR PERINEURAL LYMPHOVASCULAR INVASION.\X0D\\X0A\ \X0D\\X0A\88305 x6\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\The specimen is received in six containers.  The first container is received designated as\X0D\\X0A\""prostate biopsy of right apex"" and consists of two (2) cylindrical segments of white soft\X0D\\X0A\tissue.  These measure 1.8 and 2.0 cm. in length, respectively.  They are submitted in toto\X0D\\X0A\in cassette A.\X0D\\X0A\ \X0D\\X0A\The second container is received designated as ""prostate biopsy of right mid"" and consists\X0D\\X0A\of two (2) cylindrical segments of white soft tissue.  These measure 1.6 and 1.9 cm. in\X0D\\X0A\length, respectively.  Each measures less than 0.1 cm. in diameter.  The specimen is\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\GROSS DESCRIPTION          (Continued)\X0D\\X0A\ \X0D\\X0A\submitted in toto in cassette B.\X0D\\X0A\ \X0D\\X0A\The third container is received designated as ""prostate biopsy right base"" and consists of\X0D\\X0A\two (2) cylindrical segments of white soft tissue.  These measure 1.4 and 1.8 cm. in length,\X0D\\X0A\respectively.  Each measures less than 0.1 cm. in diameter.  The specimen is submitted in\X0D\\X0A\toto in cassette C.\X0D\\X0A\ \X0D\\X0A\The fourth container is received designated as ""prostate biopsy of left apex"" and consists\X0D\\X0A\of two (2) cylindrical segments of white soft tissue.  These measure 1.5 and 1.9 cm. in\X0D\\X0A\length, respectively.  Each measures less than 0.1 cm. in diameter.  They are submitted in\X0D\\X0A\toto in cassette D.\X0D\\X0A\ \X0D\\X0A\The fifth container is received designated as ""prostate biopsy of left mid"" and consists of\X0D\\X0A\two (2) cylindrical segments of white soft tissue.  These measure 1.5 and 1.7 cm. in length,\X0D\\X0A\respectively.  The specimen is submitted in toto in cassette E.\X0D\\X0A\ \X0D\\X0A\The remaining container is received designated as ""prostate biopsy of left base"" and\X0D\\X0A\consists of two (2) cylindrical segments of white soft tissue.  These measure 1.6 and 1.9\X0D\\X0A\cm. in length, respectively.  They are submitted in toto in cassette F.\X0D\\X0A\",MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\A-F.  Microscopic review was performed.\X0D\\X0A\,"SPECIMEN\X0D\\X0A\ \X0D\\X0A\A.  PROSTATE, RIGHT APEX, BIOPSY\X0D\\X0A\B.  PROSTATE, RIGHT MID, BIOPSY\X0D\\X0A\C.  PROSTATE, RIGHT BASE, BIOPSY\X0D\\X0A\D.  PROSTATE, LEFT APEX, BIOPSY\X0D\\X0A\E.  PROSTATE, LEFT MID, BIOPSY\X0D\\X0A\F.  PROSTATE, LEFT BASE, BIOPSY\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT",,
REG1,PROSTATE,0,489231,1,,CLINICAL HISTORY:  NONE GIVEN\X0D\\X0A\PRE-OP DIAGNOSIS:  ACUTE PROSTATITIS\X0D\\X0A\POST-OP DIAGNOSIS:  SAME,"CASE: SUR-11-11985\X0D\\X0A\PATIENT: **NAME[AAA BBB]\X0D\\X0A\PROCEDURE:  CYSTO, TURP","FINAL DIAGNOSIS:\X0D\\X0A\PROSTATE, TURP:  Malignant.\X0D\\X0A\HISTOLOGIC TYPE:    Prostatic adenocarcinoma\X0D\\X0A\HISTOLOGIC GLEASON SCORE:\X0D\\X0A\-Primary Grade:     3\X0D\\X0A\-Secondary Grade:   3\X0D\\X0A\-Gleason Score:     6\X0D\\X0A\TUMOR QUANTITATION:\X0D\\X0A\Percent of tissue involved by tumor:    Less than 5%\X0D\\X0A\ANGIOLYMPHATIC INVASION: Not identified\X0D\\X0A\PERINEURAL INVASION:     Not identified\X0D\\X0A\HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA:   Not identified\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:\X0D\\X0A\-Nodular hyperplasia\X0D\\X0A\-Focal acute prostatitis",,"GROSS:\X0D\\X0A\Received designated prostate tissue are multiple fragments of pink and\X0D\\X0A\tan tissue that are 15 grams.  Representative sections will be submitted\X0D\\X0A\as A1 through A6.          (AEE)\X0D\\X0A\IMMUNOHISTOCHEMISTRY REPORT\X0D\\X0A\Using formalin fixed paraffin embedded tissue with the appropriate\X0D\\X0A\positive and negative controls, the specimen designated prostate TURP\X0D\\X0A\(blocks A1, A2, A5) are stained for immunoreactive CK-HMW, p63, and\X0D\\X0A\P504S using an automated immunohistochemical technique.  A single 2 mm\X0D\\X0A\aggregate of atypical glands lack identifiable basal layer\X0D\\X0A\immunoreactivity for p63/CK-HMW; there is concomitant well developed\X0D\\X0A\circumferential overexpression of P504S.  All internal and external\X0D\\X0A\controls react appropriately.\X0D\\X0A\INTERPRETATION:  Prostatic adenocarcinoma (\R\2 mm).\X0D\\X0A\Preliminary Diagnosis performed by\X0D\\X0A\**NAME[M. M. ZZZ], M.D.\X0D\\X0A\Electronically signed **DATE[Oct 31 2012] 1:12PM Final Diagnosis performed by\X0D\\X0A\**NAME[M. M. ZZZ], M.D.\X0D\\X0A\Electronically signed **DATE[Nov 1 2012] 1:37PM",,SPECIMEN:  A. PROSTATE TISSUE,,
REG1,PROSTATE,0,489469,1,,CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis is prostate cancer.  Intraoperative findings: \X0D\\X0A\prostate cancer.  Operative procedure:  robotic laparoscopic prostatectomy.\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Dec 5 1952] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[Jul 22 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Jul 23 2012] 07:28\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], MD     Service: URO     Location: 2PAC\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jul 30 2012] 19:55\X0D\\X0A\RESIDENTS(S): J.P. **NAME[WWW], MD\X0D\\X0A\Comment:  P4 immunostain has been performed on sections A20, A23, A24 and\X0D\\X0A\A46, and supports the diagnosis.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.","DIAGNOSIS\X0D\\X0A\PROSTATE AND SEMINAL VESICLES, ROBOTIC LAPAROSCOPIC PROSTATECTOMY:\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON SCORE 4 + 3 = 7 (see template and\X0D\\X0A\comment).\X0D\\X0A\   - TUMOR INVOLVES RIGHT AND LEFT LOBES AND COMPRISES APPROXIMATELY 3% OF\X0D\\X0A\THE TOTAL TISSUE.\X0D\\X0A\   - RESECTION MARGINS NEGATIVE FOR TUMOR.   - PATHOLOGIC STAGE: pT2c, NX.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Jul 28 2012] R.G. **NAME[VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M81403 P1100 \X0D\\X0A\F: A: 88309, 67044 IMHC3, S 88342 (PROF)(3), 67044 IMHC3, S 88342 (PROF)(3),\X0D\\X0A\67044 IMHC3, S 88342 (PROF)(3), 67044 IMHC3, S 88342 (PROF)(3)",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled ""prostate and seminal\X0D\\X0A\vesicles"" and consists of the aforementioned.  The external surface is dull\X0D\\X0A\red-brown.  The cut surface varies from firm to rubbery and is nodular, light\X0D\\X0A\tan to yellow.  Upon cutting the prostate into left and right halves a mass\X0D\\X0A\is revealed that measures 1.2 cm in length.  The mass is tan/yellow and is\X0D\\X0A\approximately 1.8 cm from the base of the prostate. The vas deferens and\X0D\\X0A\seminal vesicle are unremarkable and grossly free of tumor.  The urethral\X0D\\X0A\mucosa and margins are unremarkable.\X0D\\X0A\Ink code: right inked blue, left inked black\X0D\\X0A\Measurements:\X0D\\X0A\Weight:  56.3 grams\X0D\\X0A\Prostate size: Apex to base 5 cm; Left to right 6.5 cm; Anterior to posterior\X0D\\X0A\3 cm\X0D\\X0A\Right seminal vesicle: 5 x 1.5 x 0.5 cm\X0D\\X0A\Left seminal vesicle: 5.7 x 1.6 x 0.7 cm\X0D\\X0A\Right vas deferens : 5 cm in length and 0.5 cm in diameter\X0D\\X0A\Left vas deferens: 2 cm in length and 0.5 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\A1  right urethral apex margin\X0D\\X0A\A2-A3  left urethral apex margin\X0D\\X0A\A4-A5  right urethral base margin\X0D\\X0A\A6-A7  left urethral base margin\X0D\\X0A\A8  left and right vas deferens margin\X0D\\X0A\A9-A10  right vas deferens\X0D\\X0A\A11-A12  right seminal vesicle\X0D\\X0A\A13  left vas deferens\X0D\\X0A\A14-A18  left seminal vesicle\X0D\\X0A\A19-A31  right anterior side from apex to base\X0D\\X0A\A32-A42  right posterior side apex to base\X0D\\X0A\A43-A53  left anterior side apex to base\X0D\\X0A\A54-A64  left posterior side apex to base\X0D\\X0A\dlf/**DATE[Jul 23 2012] J.P. **NAME[WWW], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Apr 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:   prostate/seminal vesicles \X0D\\X0A\Type of procedure: robotic laparoscopic prostatectomy\X0D\\X0A\Weight of prostate: 56.3 grams\X0D\\X0A\Histologic type: prostatic adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 4/5\X0D\\X0A\              Secondary (next most prevalent) 3/5\X0D\\X0A\              Score 7/10\X0D\\X0A\              Tertiary pattern if present: not present\X0D\\X0A\Tumor location:  right and left lobes\X0D\\X0A\Tumor amount (percentage): 3% right lobe and 3% left lobe\X0D\\X0A\Size of largest tumor nodule:  1.5 cm (left lobe)\X0D\\X0A\Involvement of seminal vesicle:  no\X0D\\X0A\Extension into soft tissue: no\X0D\\X0A\Extracapsular extension: no\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:     negative\X0D\\X0A\     Apical (inferior):   negative\X0D\\X0A\Inked surgical margins:   negative\X0D\\X0A\Vascular invasion: not identified\X0D\\X0A\Perineural invasion: not identified\X0D\\X0A\High grade PIN:  present, moderate\X0D\\X0A\Lymph node involvement:  not submitted\X0D\\X0A\Additional pathologic findings (list): glandular hyperplasia\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\\X0D\\X0A\           pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNX:     Cannot be assessed",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Prostate/seminal vessicles,,
REG1,PROSTATE,0,490201,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Intraoperative findings: prostate\X0D\\X0A\cancer. Operative procedure: robotic laparoscopic prostatectomy. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Oct 21 1964] (Age: **AGE[in 40s])  MW\X0D\\X0A\Collect Date: **DATE[Dec 22 2011] 00:00\X0D\\X0A\Receipt Date: **DATE[Dec 23 2011] 08:02\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: 2MCC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Dec 25 2011] 16:36\X0D\\X0A\RESIDENTS(S): J.M. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\PROSTATE AND SEMINAL VESICLES, PROSTATECTOMY (C):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON SCORE 4 + 3 = 7 (pT3a, N0) (SEE\X0D\\X0A\TEMPLATE).\X0D\\X0A\   - PERINEURAL INVASION IDENTIFIED.\X0D\\X0A\   - INKED MARGINS NEGATIVE; TUMOR <1 MM FROM INKED MARGIN MULTIFOCALLY.\X0D\\X0A\LYMPH NODES, LEFT PELVIC, EXCISION (A):\X0D\\X0A\   - NO TUMOR SEEN IN ONE (0/1) LYMPH NODE.\X0D\\X0A\LYMPH NODES, RIGHT PELVIC, EXCISION (B):\X0D\\X0A\   - NO TUMOR SEEN IN TWO (0/2) LYMPH NODES.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Dec 25 2011] M.V. **NAME[UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M81403 P1100\X0D\\X0A\B: M09450 P1100\X0D\\X0A\C: M09450 P1100 \X0D\\X0A\F: A: 88307\X0D\\X0A\B: 88307\X0D\\X0A\C: 88309",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  three\X0D\\X0A\Specimen label:   A) left pelvic lymph node             \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow fatty\X0D\\X0A\Consistency: semi-firm \X0D\\X0A\Size(s): 3.5 x 2.5 x 1.0 cm \X0D\\X0A\It is palpated to reveal one potential lymph node measuring 4.5 x 0.5 x 0.5\X0D\\X0A\cm. \X0D\\X0A\Cassette summary: the lymph node is serially sectioned and submitted entirely\X0D\\X0A\in A1. \X0D\\X0A\Specimen label:  B) right pelvic lymph node               \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow fatty\X0D\\X0A\Consistency: semi-firm \X0D\\X0A\Size(s): 4.0 x 3.5 x 1.5 cm \X0D\\X0A\Two potential lymph nodes 2.5 x 1.0 x 1.0 cm and 3.5 x 1.0 x 0.5 cm \X0D\\X0A\Cassette summary: B1  first described lymph node serially sectioned; B2 \X0D\\X0A\second described lymph node serially sectioned. \X0D\\X0A\Specimen C is received fresh placed in formalin labeled ""prostate and seminal\X0D\\X0A\vesicles"" and consists of the aforementioned.  The external surface is dull\X0D\\X0A\red-brown.  The cut surface varies from firm to rubbery and is nodular, light\X0D\\X0A\tan to yellow.  No discrete masses or lesions are noted.  The vas deferens\X0D\\X0A\and seminal vesicle are unremarkable and grossly free of tumor.  The urethral\X0D\\X0A\mucosa and margins are unremarkable.\X0D\\X0A\Ink code: anterior half blue, posterior half black \X0D\\X0A\Measurements:\X0D\\X0A\Weight: 47 gm\X0D\\X0A\Prostate size: Apex to base 4.0 cm; Left to right 4.1 cm; Anterior to\X0D\\X0A\posterior 3.1 cm\X0D\\X0A\Right seminal vesicle: 3.0 x 1.7 x 0.5 cm \X0D\\X0A\Left seminal vesicle: 3.5 x 1.5 x 0.7 cm\X0D\\X0A\Right vas deferens: 3 cm in length and 0.3 cm in diameter\X0D\\X0A\Left vas deferens: 3.0 cm in length and 0.2 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\C1  right half of the apex urethral margin\X0D\\X0A\C2  left half of apex urethral margin\X0D\\X0A\C3  right half of base urethral margin \X0D\\X0A\C4  left half of base urethral margin\X0D\\X0A\C5  vas deferens margin right inked green\X0D\\X0A\C6  C10  right seminal vesicles and vas deferens\X0D\\X0A\C11  C16  left half of the seminal vesicles and vas deferens\X0D\\X0A\C17  C30 right half of the prostate submitted entirely from apex to base\X0D\\X0A\C31- C44  left half of the prostate submitted from apex to base\X0D\\X0A\rgc/**DATE[Dec 24 2011] J.M. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Dec 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate/seminal vesicles\X0D\\X0A\Type of procedure:  robotic laparoscopic prostatectomy\X0D\\X0A\Weight of prostate:  47 grams\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 4/5\X0D\\X0A\              Secondary (next most prevalent) 3/5\X0D\\X0A\              Score 7/10\X0D\\X0A\              Tertiary pattern if present:  not applicable\X0D\\X0A\Tumor location:  right  and left\X0D\\X0A\Tumor amount (percentage):  21% on right; 8% on left\X0D\\X0A\Size of largest tumor nodule:  12 mm\X0D\\X0A\Involvement of seminal vesicle:   no\X0D\\X0A\Extracapsular extension: yes, focal (blocks C24 and C30)\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:  negative\X0D\\X0A\     Apical (inferior):  negative\X0D\\X0A\Inked surgical margins:  negative, but <1 mm to the margin at multiple points\X0D\\X0A\    invasion through prostate capsule into periprostatic soft tissue but not\X0D\\X0A\to surgical margin.\X0D\\X0A\Vascular invasion: no\X0D\\X0A\Perineural invasion:  yes, extensive (C22)\X0D\\X0A\High grade PIN:  present, moderate amount, bilateral\X0D\\X0A\Lymph node involvement:  positive/total\X0D\\X0A\                    Right pelvic:  0/2\X0D\\X0A\                    Left pelvic:  0/1\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\        pT3a:  Extraprostatic extension or microscopic invasion of bladder\X0D\\X0A\neck\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:     No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable\X0D\\X0A\A portion of this case was reviewed at the Intradepartmental Consensus\X0D\\X0A\Conference (to confirm focal extracapsular extension).\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left pelvic lymph nodes\X0D\\X0A\B: Right pelvic lymph nodes\X0D\\X0A\C: Prostate and seminal vesicles,,
REG1,PROSTATE,0,490207,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Intraoperative findings: prostate\X0D\\X0A\cancer. Operative procedure: robotic laparoscopic prostatectomy.\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Apr 9 1953] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[May 13 2012] 13:44\X0D\\X0A\Receipt Date: **DATE[May 13 2012] 13:44\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: P.L. **NAME[YYY], MD     Service: URO     Location: 2OR\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 15 2012] 14:56\X0D\\X0A\RESIDENTS(S): R.K. **NAME[WWW], MD","DIAGNOSIS\X0D\\X0A\PROSTATE AND SEMINAL VESICLES, ROBOTIC LAPAROSCOPIC PROSTATECTOMY (C):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON GRADE 3 + 4 = 7/10 (pT2c, pN0), WITH\X0D\\X0A\TERTIARY PATTERN OF GRADE 5 \X0D\\X0A\    (<5%) SEE TEMPLATE.\X0D\\X0A\   - RESECTION MARGIN FREE OF TUMOR.\X0D\\X0A\LYMPH NODE, LEFT PELVIC, DISSECTION (A):\X0D\\X0A\   - NO METASTATIC CARCINOMA IN THREE LYMPH NODES (0/3).\X0D\\X0A\LYMPH NODE, RIGHT PELVIC, DISSECTION (B):\X0D\\X0A\  - NO METASTATIC CARCINOMA IN FOUR LYMPH NODES (0/4).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 15 2012] **NAME[VVV M. UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M81403 P1100\X0D\\X0A\B: M09450 T0860\X0D\\X0A\C: M09450 T0860 \X0D\\X0A\F: A: 88307\X0D\\X0A\B: 88307\X0D\\X0A\C: 88309",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  three\X0D\\X0A\Specimen label:   A) left pelvic lymph node              \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: firm\X0D\\X0A\Size(s): 4.5 x 2 x 1 cm\X0D\\X0A\The fibrofatty tissue is palpated to reveal multiple possible lymph nodes\X0D\\X0A\Cassette summary: A1  contains one large possible lymph node measuring 2.8 x\X0D\\X0A\1 x 0.3 cm. The lymph node is bisected and submitted entirely in A1; A2 \X0D\\X0A\multiple possible lymph nodes (at least 3). A3  fibrofatty tissue in search\X0D\\X0A\of lymph nodes. \X0D\\X0A\Specimen label:  B) right pelvic lymph node                \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): yellow tan \X0D\\X0A\Consistency: firm\X0D\\X0A\Size(s): 3.5 x 1.5 x 1.2 cm\X0D\\X0A\The fibrofatty tissue is palpated to reveal two possible lymph nodes \X0D\\X0A\Cassette summary: B1  contains one possible lymph node measuring 1.6 x 1 x\X0D\\X0A\0.4 cm. It is bisected and submitted in B1; B2  contains second possible\X0D\\X0A\lymph node measuring 1.6 x 0.7 x 0.3 cm. The lymph node is bisected and\X0D\\X0A\submitted entirely in B2; B3  contains fibrofatty tissue in search of lymph\X0D\\X0A\nodes.\X0D\\X0A\Specimen C is received fresh and placed in formalin labeled ""prostate and\X0D\\X0A\seminal vesicles"" and consists of the aforementioned.  The external surface\X0D\\X0A\is dull red-brown.  The cut surface varies from firm to rubbery and is\X0D\\X0A\nodular, light tan to yellow.  No discrete masses or lesions are noted.  The\X0D\\X0A\vas deferens and seminal vesicle are unremarkable and grossly free of tumor. \X0D\\X0A\The urethral mucosa and margins are unremarkable.\X0D\\X0A\Ink code: anterior half blue, posterior half black\X0D\\X0A\Measurements:\X0D\\X0A\Weight: 57 grams\X0D\\X0A\Prostate size: Apex to base 3.7 cm; Left to right 4.8 cm; Anterior to\X0D\\X0A\posterior 3.5 cm\X0D\\X0A\Right seminal vesicle: 2.5 x 1.5 x 1 cm\X0D\\X0A\Left seminal vesicle: 2.8 x 1.5 x 1 cm\X0D\\X0A\Right vas deferens : 3.8 cm in length and .7 cm in diameter\X0D\\X0A\Left vas deferens:  3 cm in length and .7 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\C1:  right apex, shaved, radially sectioned\X0D\\X0A\C2: left apex, shaved, radially sectioned\X0D\\X0A\C3-C4:  right base margin, shaved, radially sectioned\X0D\\X0A\C5-C6  left base margin, shaved, radially sectioned\X0D\\X0A\C7:  right vas deferens margin and right base of seminal vesicle\X0D\\X0A\C8:  left vas deferens margin and base of left seminal vesicle\X0D\\X0A\C9-C23:  right, apex to base, section in C13-C22 sections divided into\X0D\\X0A\anterior and posterior half\X0D\\X0A\C24:  right vas deferens entirely\X0D\\X0A\C25-C26:  right seminal vesicle entirely, bisected\X0D\\X0A\C27-C41:  left, apex to base, C30-C41 sections divided into anterior and\X0D\\X0A\posterior half\X0D\\X0A\C42:  left vas deferens entirely\X0D\\X0A\C43-C44:  left seminal vesicle entirely, bisected\X0D\\X0A\dlf/**DATE[May 14 2012] R.K. **NAME[WWW], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Jan 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate/seminal vesicles \X0D\\X0A\Type of procedure:  robotic laparoscopic prostatectomy with pelvic lymph node\X0D\\X0A\dissection\X0D\\X0A\Weight of prostate:  57 grams\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 3/5\X0D\\X0A\              Secondary (next most prevalent) 4/5\X0D\\X0A\              Score 7/10\X0D\\X0A\              Tertiary pattern if present:  grade 5 (< 5%)\X0D\\X0A\Tumor location:  right and left\X0D\\X0A\Tumor amount (percentage):  70 to 80% (extensive involvement on right and\X0D\\X0A\left side)\X0D\\X0A\Size of largest tumor nodule:  2.5 mm (microscopic)\X0D\\X0A\Involvement of seminal vesicle:   not seen\X0D\\X0A\Extension into soft tissue:  not seen\X0D\\X0A\Extracapsular extension:  not seen\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:  negative\X0D\\X0A\     Apical (inferior):   negative (less than 1 mm from inked margin)\X0D\\X0A\Inked surgical margins:  negative (less than 1 cm from inked capsular margin)\X0D\\X0A\Vascular invasion: not seen\X0D\\X0A\Perineural invasion:  present (extensive)\X0D\\X0A\High grade PIN:  present, quantity (moderate amount), right and left\X0D\\X0A\Lymph node involvement:  0 positive / 7 total\X0D\\X0A\                    Right pelvic:  0/4\X0D\\X0A\                    Left pelvic:  0/3\X0D\\X0A\Additional pathologic findings: High grade PIN and glandular hypertrophy.\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\        pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:     No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: left pelvic lymph nodes\X0D\\X0A\B: right pelvic lymph nodes\X0D\\X0A\C: Prostate,,
REG1,PROSTATE,0,490333,1,,CLINICAL HISTORY\X0D\\X0A\Elevated PSA level 4.6\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jul 29 1943] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Jul 25 2012] 10:01\X0D\\X0A\Receipt Date: **DATE[Jul 25 2012] 10:01\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY  REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **STREET-ADDRESS. **NAME[YYY], MD     Service: PAT     Location: OUTS\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jul 25 2012] 13:14\X0D\\X0A\RESIDENTS(S): \X0D\\X0A\CONSULTATION:\X0D\\X0A\**INSTITUTION","DIAGNOSIS\X0D\\X0A\PROSTATIC ADENOCARCINOMA, GLEASON SCORE 3 + 4 = 7 INVOLVING ONE OF FOUR (1/4)\X0D\\X0A\LEFT PROSTATE NEEDLE CORE BIOPSIES  TUMOR INVOLVES 100% OF ONE CORE (EQUALS\X0D\\X0A\25% OF SAMPLED LEFT PROSTATE TISSUE).\X0D\\X0A\FOCUS OF ATYPICAL SMALL ACINAR PROLIFERATION (ASAP), RIGHT PROSTATE, NEEDLE\X0D\\X0A\CORE BIOPSIES, **DATE[Jul 8 2012], SEE COMMENT.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jul 25 2012] **NAME[WWW M. VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M81403 P1143\X0D\\X0A\B: M76000 M7600 \X0D\\X0A\F: A: S 88321 CONSULT",,,"MICROSCOPIC DESCRIPTION\X0D\\X0A\Unequivocal tumor is noted on the left side involving one core throughout\X0D\\X0A\with no perineural invasion.  Primary pattern is 3 with second worse pattern\X0D\\X0A\being 4, for a total Gleason score of 7.  One of the four cores is involved\X0D\\X0A\completely in a 1.2 cm long core.  The right sided cores show a single focus\X0D\\X0A\of atypical small acinar proliferation which is inclusive.  An immunostain is\X0D\\X0A\available on the left sided core confirming malignant glands with no\X0D\\X0A\myoepithelial layer.\X0D\\X0A\SLIDE/BLOCK DESCRIPTION\X0D\\X0A\Received from **INSTITUTION 3 slides ***PATH-NUMBER[2] (date collected **DATE[Jul 8 12]) and\X0D\\X0A\a copy of corresponding pathology report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Outside slide(s) only,,
REG1,PROSTATE,0,490338,1,,CLINICAL HISTORY\X0D\\X0A\Elevated PSA\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Nov 11 1948] (Age: **AGE[in 60s])  MB\X0D\\X0A\Collect Date: **DATE[Apr 27 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Apr 28 2012] 07:57\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY  REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **STREET-ADDRESS. **NAME[YYY], MD     Service: RAD     Location: RDMD\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 1 2012] 13:05\X0D\\X0A\RESIDENTS(S): \X0D\\X0A\CONSULTATION:\X0D\\X0A\Pathology \T\ Cytology Laboratory","DIAGNOSIS\X0D\\X0A\RECEIVED SIX OUTSIDE SLIDES (LABELED ***PATH-NUMBER[2] 1-6, COLLECTED **DATE[Mar 16 12]),\X0D\\X0A\DESIGNATED AS FOLLOWS:\X0D\\X0A\PROSTATE, RIGHT APEX, NEEDLE CORE BIOPSIES (1):\X0D\\X0A\   - PROSTATIC TISSUE WITH NO TUMOR PRESENT.\X0D\\X0A\PROSTATE, RIGHT MID, NEEDLE CORE BIOPSIES (2):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON SCORE 7 (4 +3) INVOLVING ONE OF TWO\X0D\\X0A\CORES AND LESS THAN\X0D\\X0A\    5% OF SUBMITTED TISSUE.\X0D\\X0A\PROSTATE, RIGHT BASE, NEEDLE CORE BIOPSIES (3):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON SCORE 6 (3 + 3), INVOLVING ONE OF\X0D\\X0A\THREE TISSUE FRAGMENTS (LESS \X0D\\X0A\     THAN 1% OF SUBMITTED TISSUE).\X0D\\X0A\PROSTATE, LEFT APEX, NEEDLE CORE BIOPSIES (4):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON' S SCORE 7 (4 + 3), INVOLVING TWO OF\X0D\\X0A\THREE TISSUE FRAGMENTS \X0D\\X0A\     AND APPROXIMATELY 60% OF THE SUBMITTED TISSUE. \X0D\\X0A\   - FOCAL PERINEURAL INVASION IDENTIFIED.\X0D\\X0A\PROSTATE, LEFT MID, NEEDLE CORE BIOPSIES (5):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON' S SCORE 7 (4 + 3), INVOLVING TWO OF\X0D\\X0A\FOUR TOTAL TISSUE\X0D\\X0A\    FRAGMENTS AND APPROXIMATELY 75% OF THE SUBMITTED TISSUE.\X0D\\X0A\PROSTATE, LEFT BASE, NEEDLE CORE BIOPSY (6):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON' S SCORE 7 (4 + 3), INVOLVING ONE OF\X0D\\X0A\FOUR TISSUE FRAGMENTS\X0D\\X0A\    AND APPROXIMATELY 80% OF THE SUBMITTED TISSUE.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 31 2012] D.L. **NAME[WWW], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\B: M09450 P1140\X0D\\X0A\C: M81403 P1143\X0D\\X0A\D: M81403 P1143\X0D\\X0A\E: M81403 P1140\X0D\\X0A\F: M81403 P1143\X0D\\X0A\G: M81403 P1143 \X0D\\X0A\F: A: S 88321 CONSULT",,,,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Outside slide(s) only\X0D\\X0A\SLIDE/BLOCK DESCRIPTION\X0D\\X0A\Received from Pathology \T\ Cytology Laboratory 6 slides ***PATH-NUMBER[3] (date\X0D\\X0A\collected **DATE[Mar 16 12]) and a copy of corresponding pathology report.,,
REG1,PROSTATE,0,490346,1,,,"Patient Age: **AGE[in 70s].\X0A\ PATHOLOGY CODES: **INITIALS  88305 (x 2) COMMENT: Case discussed with Dr. **NAME[ZZZ] by Dr. **NAME[YYY] and completed report faxed to Dr. **NAME[ZZZ]'s office on **DATE[Feb 6 12]. ** Original Signature on File ** **NAME[CCC M. YYY], M.D. **ID-NUM  **NAME[BBB,AAA] **DATE[Feb 02 2012]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ PROSTATE, RIGHT, CORE NEEDLE BIOPSY: \X0D\\X0A\ Benign prostatic tissue \X0D\\X0A\ PROSTATE, LEFT, CORE NEEDLE BIOPSY: \X0D\\X0A\ Prostatic adenocarcinoma, Gleason's score 4 + 3 = 7, involving 4 of 8 \X0D\\X0A\ cores, approximately 20% of submitted tissue \X0D\\X0A\ No Gleason's pattern 5 identified \X0D\\X0A\ No lymphvascular invasion, perineural invasion, or extraprostatic \X0D\\X0A\ extension noted in the core biopsies (see COMMENT)",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is elevated PSA, benign prostatic hypertrophy, \X0D\\X0A\ prostatism, and bladder outlet obstruction. \X0D\\X0A\ Specimen 1 consists of multiple tan soft cylindrical tissue fragments \X0D\\X0A\ ranging in size from 0.3 to 2.2 cm in length and measuring 0.1 cm in \X0D\\X0A\ diameter each. The specimen is submitted in its entirety in two \X0D\\X0A\ cassettes. \X0D\\X0A\ Specimen 2 consists of multiple tan soft cylindrical tissue fragments \X0D\\X0A\ ranging in size from 0.5 to 1.8 cm in length and measuring 0.1 cm in \X0D\\X0A\ diameter each.  The specimen is submitted in its entirety in two \X0D\\X0A\ cassettes.  **INITIALS",MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Tissue blocks are prepared and slides are examined microscopically. \X0D\\X0A\ See diagnosis for details. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:,TISSUE SUBMITTED: \X0D\\X0A\ 1. Right side prostate biopsy \X0D\\X0A\ 2. Left side prostate biopsy,,
REG1,PROSTATE,0,490506,1,,CLINICAL HISTORY:\X0D\\X0A\Prostate cancer.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'PROSTATE, TOTAL PROSTATECTOMY':  PROSTATIC ADENOCARCINOMA\X0D\\X0A\1.   TUMOR SIZE AND EXTENT:  Adenocarcinoma focally present in two of\X0D\\X0A\ten representative slides (2/10) involving the left mid gland and left\X0D\\X0A\base regions.\X0D\\X0A\2.   TUMOR GRADE:  Overall Gleason's score 3+3=6.\X0D\\X0A\3.   MARGINS OF EXCISION AND EXTENT:  All margins of excision are\X0D\\X0A\negative for involvement by carcinoma.\X0D\\X0A\a.   Apical urethral margin is negative for involvement by carcinoma.\X0D\\X0A\b.   Bladder neck margin is negative for involvement by carcinoma.\X0D\\X0A\c.   All periprostatic soft tissue margins are negative for involvement\X0D\\X0A\by carcinoma.\X0D\\X0A\d.   No definitive perineural invasion identified.\X0D\\X0A\e.   No definitive capillary lymphatic space invasion by carcinoma is\X0D\\X0A\identified.\X0D\\X0A\f.   Right and left seminal vesicles are negative for involvement by\X0D\\X0A\carcinoma.\X0D\\X0A\g.   Right and left vas deferens are negative for involvement by\X0D\\X0A\carcinoma.\X0D\\X0A\4.   LYMPH NODES:  Not available for review.\X0D\\X0A\5.   ADDITIONAL FINDINGS:\X0D\\X0A\a.   Extensive high-grade PIN.\X0D\\X0A\b.   Scattered acute and chronic prostatitis.\X0D\\X0A\6.   PATHOLOGIC STAGE:  pT2a, NX, MX (Gleason's 3+3=6).\X0D\\X0A\ \X0D\\X0A\Prostate Gland\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: Prostate, radical\X0D\\X0A\ \X0D\\X0A\PROSTATE GLAND: Radical Prostatectomy\X0D\\X0A\Histologic Type:    Adenocarcinoma (conventional, not otherwise\X0D\\X0A\specified)\X0D\\X0A\Histologic Grade:   Primary Pattern Grade:   3\X0D\\X0A\Secondary Pattern Grade: 3\X0D\\X0A\Total Gleason Score:     6\X0D\\X0A\Primary Tumor (pT): pT2\X0D\\X0A\Portion of lobe involved:     pT2a\X0D\\X0A\Regional Lymph Nodes (pN):    pNX\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Can be assessed\X0D\\X0A\Margin involvement: Margins uninvolved by invasive carcinoma\X0D\\X0A\Extraprostatic Extension:     Absent\X0D\\X0A\Seminal Vesicle Invasion:     Seminal Vesicle Invasion absent\X0D\\X0A\Perineural Invasion:     Absent\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Lymphatic (Small Vessel) Invasion (L):  Absent\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Aug 06 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'prostate' is a 42.a gram prostate with\X0D\\X0A\attached seminal vesicles and vas deferens. The right seminal vesicle\X0D\\X0A\measures 3.0 x 1.8 x 0.5 cm.  The associated portion of vas measures 3.1\X0D\\X0A\cm in length by up to 0.4 cm in diameter.  Sections of the right seminal\X0D\\X0A\vesicle and vas are submitted in cassette A1.  The left seminal vesicle\X0D\\X0A\measures 4.0 x 2.0 x 0.1 cm.  No grossly discernible masses are\X0D\\X0A\identified.  The associated portion of vas measures 2.0 cm in length and\X0D\\X0A\has a maximum diameter of 0.4 cm.  Representative sections of the left\X0D\\X0A\seminal vesicle and vas are submitted in cassette A2. The right side of\X0D\\X0A\the specimen is inked green and the left side is inked blue.  The apical\X0D\\X0A\urethral and bladder neck margins appear grossly free of tumor.\X0D\\X0A\Sections from the apical margin are submitted in cassette A3.  Sections\X0D\\X0A\from the bladder neck margin are submitted in cassette A4.  Sectioning\X0D\\X0A\through the prostate gland discloses focal areas of nodularity without\X0D\\X0A\discrete mass.  Sections are submitted in cassettes A5 through A12.\X0D\\X0A\Cassette A5 right apex, cassettes A6-A7 right mid gland, cassette A8\X0D\\X0A\right base, cassette A9 left apex, cassettes A10-A11 left mid gland and\X0D\\X0A\cassette A12 left base.   (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 12",,"SPECIMEN(S): A Prostate, radical",,
REG1,PROSTATE,0,491873,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is prostate CA.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Prostate, radical resection","Final Diagnosis\X0D\\X0A\PROSTATE, RADICAL PROSTATECTOMY:\X0D\\X0A\     Bilateral involvement with prostatic adenocarcinoma.\X0D\\X0A\     Gleason's Grade 3+4=7 involving 15% of the right lobe and 10% of the left\X0D\\X0A\lobe.\X0D\\X0A\     Focal extraprostatic extension is seen, but no marginal involvement\X0D\\X0A\identified.\X0D\\X0A\     See TEMPLATE.\X0D\\X0A\**INITIALS\X0D\\X0A\PROSTATE RADICAL/ENUCLEATION\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Radical prostatectomy\X0D\\X0A\PROSTATE SIZE:  150 grams\X0D\\X0A\SPECIMEN INTEGRITY:  Intact\X0D\\X0A\LOCATION OF TUMOR:  Bilateral\X0D\\X0A\TUMOR SIZE/ % PROSTATE GLAND INVOLVED:  15% of right lobe and 10% of left lobe \X0D\\X0A\LOBES INVOLVED (RIGHT, LEFT, BILATERAL):  Bilateral\X0D\\X0A\PRIMARY PATTERN:  3+4=7\X0D\\X0A\SECONDARY PATTERN:  3+3=6\X0D\\X0A\TERTIARY PATTERN:  N/A\X0D\\X0A\TOTAL GLEASON SCORE:  7\X0D\\X0A\CAPSULAR INVASION:  Present\X0D\\X0A\EXTRAPROSTATIC EXTENSION:  Present.\X0D\\X0A\VASCULAR/LYMPHVASCULAR INVASION:  None seen\X0D\\X0A\PERINEURAL INVASION:  None seen\X0D\\X0A\MARGINS INVOLVED:  No\X0D\\X0A\HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA:  No\X0D\\X0A\SEMINAL VESICLE INVOLVEMENT:  No\X0D\\X0A\BLADDER OR RECTAL INVOLVEMENT:  No\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  N/A\X0D\\X0A\EXTRANODAL EXTENSION:  N/A\X0D\\X0A\OTHER METASTATIC SITES:  Unknown\X0D\\X0A\OTHER NEOPLASM SITES:  Unknown\X0D\\X0A\SPECIAL STUDIES:  N/A\X0D\\X0A\THERAPY RELATED CHANGES:  N/A\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  N/A\X0D\\X0A\OTHER STUDIES:  N/A\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  3a\X0D\\X0A\pN=  x\X0D\\X0A\AJCC PATHOLOGIC STAGE:  III\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Received in formalin labeled prostate gland is a 150 gram, 8.0 x 7.0 x 6.0cm\X0D\\X0A\intact, enlarged radical prostatectomy specimen.  The bilateral vas averages\X0D\\X0A\3.5cm in length and bilateral seminal vesicles average 2.0 x 1.5 x 1.0cm.  The\X0D\\X0A\prostate gland is inked as follows:  right lobe  blue, left lobe  black.  The\X0D\\X0A\proximal and distal urethral resection margins are taken en face and submitted\X0D\\X0A\in their entirety.  The prostate gland is sectioned from the distal toward the\X0D\\X0A\proximal aspect to reveal tan, glistening, prostatic parenchyma with numerous\X0D\\X0A\tan nodules which bulge from the cut surface.  The nodules are in both the right\X0D\\X0A\and left lobes and compress the surrounding probe patent urethra.  No single\X0D\\X0A\discrete area of tumor is grossly identified.  Representative sections are\X0D\\X0A\submitted.  Summary of Sections: A  right vas margin, B  left vas margin, C \X0D\\X0A\distal urethra, D  proximal urethra, E-T  right lobe of prostate submitted every\X0D\\X0A\other slice sequentially from the distal toward the proximal aspect, U-JJ  left\X0D\\X0A\lobe of prostate submitted every other slice sequentially from the distal toward\X0D\\X0A\the proximal aspect.  **INITIALS","Microscopic Description\X0D\\X0A\The right and left vas margins and the distal and proximal urethra margins are\X0D\\X0A\free of tumor.  Multiple sections from the right lobe show involvement with\X0D\\X0A\adenocarcinoma.  The tumor shows infiltrating glands with large hyperchromatic\X0D\\X0A\nuclei with some gland fusion.  The tumor infiltrates into the prostatic capsule\X0D\\X0A\with focal extraprostatic extension on the right side, but no marginal\X0D\\X0A\involvement is seen.  The tumor involves approximately 15% of the right lobe. \X0D\\X0A\The left lobe shows similar tumor involvement with infiltrating glands with some\X0D\\X0A\gland fusion.  No extraprostatic extension or marginal involvement is identified\X0D\\X0A\on this side.  The tumor involves approximately 10% of the left lobe.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\PREVIOUS HISTORY     Date Ordered:     **DATE[Aug 6 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 6 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Aug 7 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ, YYY M."
REG1,PROSTATE,0,491941,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is prostate cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Bladder neck (margin)\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\4: Prostate, radical resection","Final Diagnosis\X0D\\X0A\1. BLADDER NECK:\X0D\\X0A\     Smooth muscle, no tumor seen.\X0D\\X0A\2. LEFT OBTURATOR LYMPH NODE:\X0D\\X0A\     Benign lymph node with partial fatty replacement, no tumor identified.\X0D\\X0A\3. RIGHT OBTURATOR NODE:\X0D\\X0A\     Benign lymph node with sinus histiocytosis and focal dystrophic\X0D\\X0A\calcification, no tumor seen.\X0D\\X0A\4. PROSTATE:\X0D\\X0A\     Infiltrating poorly differentiated prostatic adenocarcinoma involving right\X0D\\X0A\and left lobe, approximately 40% of \X0D\\X0A\      right lobe involved by Gleason Grade 4+5; left lobe approximately 10%\X0D\\X0A\involved by Gleason Grade 3+3;\X0D\\X0A\      tumor present in prostatic capsule on the right without extension into\X0D\\X0A\extraprostatic tissues.\X0D\\X0A\     Perineural infiltration identified.\X0D\\X0A\     No involvement of seminal vesicles, proximal or distal urethral margins.\X0D\\X0A\     All surgical margins negative for tumor\X0D\\X0A\     See TEMPLATE.\X0D\\X0A\**INITIALS\X0D\\X0A\PROSTATE TEMPLATE: \X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Total prostatectomy\X0D\\X0A\PROSTATE SIZE:  45 grams\X0D\\X0A\SPECIMEN INTEGRITY:  Intact\X0D\\X0A\LOCATION OF TUMOR:  Right and left lobes\X0D\\X0A\TUMOR SIZE/ % PROSTATE GLAND INVOLVED:  Approximately 40% of right lobe and\X0D\\X0A\approximately 10% of left lobe involved\X0D\\X0A\LOBES INVOLVED (RIGHT, LEFT, BILATERAL):  Bilateral\X0D\\X0A\PRIMARY PATTERN:  Gleason Grade 4-right; Gleason Grade 3-left\X0D\\X0A\SECONDARY PATTERN:  Gleason Grade 5-right; Gleason Grade3-left\X0D\\X0A\TERTIARY PATTERN:  N/A\X0D\\X0A\TOTAL GLEASON SCORE:  4+5=9 on right; 3+3=6 on left\X0D\\X0A\CAPSULAR INVASION:  Present on right\X0D\\X0A\EXTRAPROSTATIC EXTENSION:  Absent\X0D\\X0A\VASCULAR/LYMPHVASCULAR INVASION:  Absent\X0D\\X0A\PERINEURAL INVASION:  Present on right\X0D\\X0A\MARGINS INVOLVED:  All margins free of tumor\X0D\\X0A\HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA:  Present in both lobes\X0D\\X0A\SEMINAL VESICLE INVOLVEMENT:  Absent on both right and left sides\X0D\\X0A\BLADDER OR RECTAL INVOLVEMENT:  Bladder neck margin is negative\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  Right and left obturator nodes negative for tumor\X0D\\X0A\EXTRANODAL EXTENSION:  Absent\X0D\\X0A\OTHER METASTATIC SITES:  Unknown\X0D\\X0A\OTHER NEOPLASM SITES:  Unknown\X0D\\X0A\SPECIAL STUDIES:  None\X0D\\X0A\THERAPY RELATED CHANGES:  None\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Focal chronic prostatitis\X0D\\X0A\OTHER STUDIES:  None\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  2c\X0D\\X0A\pN=  0\X0D\\X0A\pM=  x\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIB\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled bladder neck is a 1.0 x 0.4\X0D\\X0A\x 0.4 cm tan soft tissue which is submitted entirely for frozen section, now\X0D\\X0A\resubmitted in cassette 1.  \X0D\\X0A\Specimen 2 received in formalin labeled left obturator lymph node are two\X0D\\X0A\tan/pink lymph nodes each averaging 1.5 cm in greatest dimension which are\X0D\\X0A\submitted in toto in cassette 2.  \X0D\\X0A\Specimen 3 received in formalin labeled right obturator lymph node is a 1.6 cm\X0D\\X0A\in greatest dimension tan/pink lymph node which is submitted in toto in cassette\X0D\\X0A\3. \X0D\\X0A\Specimen 4 received in formalin labeled prostate is a 45.5 gram intact\X0D\\X0A\prostatectomy specimen with overall dimensions of 5.5 x 4.5 x 4.0 cm. The\X0D\\X0A\bilateral vas are identified and average 3 cm in length and the bilateral\X0D\\X0A\seminal vesicles average 3.0 x 1.5 x 1.5 cm. There is a 2 cm in greatest\X0D\\X0A\dimension cyst located between the right and left vas. The cyst is filled with\X0D\\X0A\tan thick fluid. The prostatic ureter is probe patent. The prostate is inked as\X0D\\X0A\follows: right lobe black, left lobe blue and sectioning reveals tan/pink\X0D\\X0A\glistening nodular prostatic parenchyma. No single discrete area of tumor is\X0D\\X0A\identified. There is a diffuse yellow infiltrate involving both the right and\X0D\\X0A\left lobes of the prostate. The prostate gland is submitted in its entirety.\X0D\\X0A\Summary of sections: 4A  distal prostatic urethral resection margin and right\X0D\\X0A\vas; 4B  proximal prostatic urethra resection margin and left vas; 4C-4L  right\X0D\\X0A\lobe of prostate submitted sequentially from the distal toward the proximal\X0D\\X0A\aspect; 4M-4V  left lobe of prostate submitted sequentially from the distal\X0D\\X0A\toward the proximal aspect. **INITIALS","Microscopic Description\X0D\\X0A\Sections of the bladder neck show sections of smooth muscle without evidence of\X0D\\X0A\prostatic neoplasia.\X0D\\X0A\Sections of the left obturator node show partial fatty replacement and foci of\X0D\\X0A\dystrophic calcification within the node.  There is no evidence of neoplasia\X0D\\X0A\within the node.  \X0D\\X0A\Sections of the right obturator node show sinus histiocytosis and multiple foci\X0D\\X0A\of dystrophic calcification without evidence of metastatic carcinoma.  \X0D\\X0A\Sections of the proximal and distal urethral margins are free of tumor as are\X0D\\X0A\the seminal vesicles.  The right lobe of the prostate shows much more extensive\X0D\\X0A\prostatic adenocarcinomatous infiltration and by higher grade of tumor.  The\X0D\\X0A\tumor represents approximately 40% of the right lobe by volume and shows\X0D\\X0A\infiltrating carcinoma that is Gleason Grade 4+5.  The Gleason Grade 5 areas\X0D\\X0A\show very ragged single cell infiltration.  Also noted on the right side (block\X0D\\X0A\4H) is prominent in areas of perineural infiltration as well as prostatic\X0D\\X0A\capsular infiltration.  The tumor infiltrating the capsule does not pass through\X0D\\X0A\the capsule or into the periprostatic tissues.  The left lobe of prostate shows\X0D\\X0A\only approximately 10% of the gland involved by tumor and the tumor is of lower\X0D\\X0A\grade (3+(3) .  No infiltration of the tumor capsule, perineural infiltration or\X0D\\X0A\lymphvascular infiltration is seen in the left lobe.  All surgical margins of\X0D\\X0A\excision are negative for tumor.  **INITIALS",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,PROSTATE,0,491966,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is prostate cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Prostate, radical resection","Final Diagnosis\X0D\\X0A\PROSTATE, RADICAL PROSTATECTOMY:\X0D\\X0A\     Moderately differentiated prostatic adenocarcinoma involving right and left\X0D\\X0A\lobes; Gleason grade 3+3=6; perineural invasion identified.\X0D\\X0A\No lymphvascular invasion; tumor infiltrating prostatic capsule but does not\X0D\\X0A\extend into periprostatic tissues.\X0D\\X0A\All surgical margins of excision negative for tumor.\X0D\\X0A\Seminal vesicles, proximal and distal urethral margins, right and left vas\X0D\\X0A\deferens margins negative for tumor. See Template.\X0D\\X0A\DGD/mbc \X0D\\X0A\     PROSTATE RADICAL/ENUCLEATION\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Radical prostatectomy\X0D\\X0A\PROSTATE SIZE:  64 grams\X0D\\X0A\SPECIMEN INTEGRITY:  Intact\X0D\\X0A\LOCATION OF TUMOR:  Both lobes involved\X0D\\X0A\TUMOR SIZE/ % PROSTATE GLAND INVOLVED:     Right lobe 30% of lobe involved by\X0D\\X0A\tumor\X0D\\X0A\                                   Left lobe 15% of lobe involved by tumor\X0D\\X0A\LOBES INVOLVED (RIGHT, LEFT, BILATERAL):  Bilateral\X0D\\X0A\PRIMARY PATTERN:  Gleason Grade 3\X0D\\X0A\SECONDARY PATTERN:  Gleason Grade 3\X0D\\X0A\TERTIARY PATTERN:  N/A\X0D\\X0A\TOTAL GLEASON SCORE:  3+3=6\X0D\\X0A\CAPSULAR INVASION:  Present\X0D\\X0A\EXTRAPROSTATIC EXTENSION:  Absent\X0D\\X0A\VASCULAR/LYMPHVASCULAR INVASION:  Absent\X0D\\X0A\PERINEURAL INVASION:  Present on right and left sides\X0D\\X0A\MARGINS INVOLVED:  No surgical margin of excision is involved by tumor.\X0D\\X0A\HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA:  Present\X0D\\X0A\SEMINAL VESICLE INVOLVEMENT:  Absent\X0D\\X0A\BLADDER OR RECTAL INVOLVEMENT:  Unknown\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  No nodes submitted\X0D\\X0A\EXTRANODAL EXTENSION:  N/A\X0D\\X0A\OTHER METASTATIC SITES:  Unknown\X0D\\X0A\OTHER NEOPLASM SITES:  Unknown\X0D\\X0A\SPECIAL STUDIES:  None\X0D\\X0A\THERAPY RELATED CHANGES:  None\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Focal chronic prostatitis\X0D\\X0A\OTHER STUDIES:  None\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  2c\X0D\\X0A\pN=  x\X0D\\X0A\pM=  unknown\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIB\X0D\\X0A\DGD",,"Gross Description\X0D\\X0A\Received in formalin labeled prostate gland consists of a 64.4 gram intact\X0D\\X0A\radical prostatectomy specimen. The prostate gland measures 6.5x5.0x5.0 cm.\X0D\\X0A\There is a bulging nodule exuding from the urethra measuring 3.5x3.0x2.5 cm. The\X0D\\X0A\bilateral vas are present and average 3 cm in length and bilateral seminal\X0D\\X0A\vesicles average 3.5x2.0x1.0 cm. The prostatic urethra is probe patent. The\X0D\\X0A\prostate is inked as follows: right lobe black, left lobe blue, and sectioning\X0D\\X0A\reveals tan glistening nodular parenchyma. There is a large dominant nodule\X0D\\X0A\surrounding and compressing the urethra. The prostate gland is submitted in its\X0D\\X0A\entirety. Summary of sections: A  right vas margin; B  left vas margin; C \X0D\\X0A\proximal urethra margin; D  distal urethra margin; E-Q  right lobe of prostate\X0D\\X0A\submitted sequentially from the distal toward the proximal aspect; R-EE  left\X0D\\X0A\lobe of prostate submitted sequentially from the distal toward the proximal\X0D\\X0A\aspect. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections of the radical prostatectomy specimen show negative urethral margins\X0D\\X0A\and right and left vas deferens margins. The right lobe shows approximately 30%\X0D\\X0A\of the lobe replaced by prostatic moderately differentiated adenocarcinoma,\X0D\\X0A\Gleason grade 3+3=6. The left lobe shows approximately 15% of the gland replaced\X0D\\X0A\by tumor which is Gleason grade 3+3=6. There is tumor infiltrating the prostatic\X0D\\X0A\capsule, however, it does not perforate the capsule and no evidence of\X0D\\X0A\extraprostatic tumor is seen. Focally carcinoma is seen in the perineural zone\X0D\\X0A\of several nerves. Lymph nodes were not received with this specimen.\X0D\\X0A\DGD/mbc",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\PREVIOUS HISTORY     Date Ordered:     **DATE[May 3 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 3 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[May 3 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\**INSTITUTION.  SEE SCANNED REFERENCE REPORT. \X0D\\X0A\/rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,PROSTATE,0,491986,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is prostate cancer.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Prostate, Radical resection\X0D\\X0A\2: Lymph node, regional resection\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\S11029094, **DATE[Feb 15 2012]. CORE BIOPSIES OF RIGHT APEX, RIGHT MID PROSTATE, AND\X0D\\X0A\RIGHT BASE: Invasive prostate adenocarcinoma, Gleason's 3 + 4 = 7. No Gleason's\X0D\\X0A\5 pattern present. In each, two of two cores are involved with 75%, 75%, and 25%\X0D\\X0A\respectively of total volume involved. Perineural invasion identified in the mid\X0D\\X0A\prostate. CORE BIOPSIES OF LEFT APEX: Invasive prostate adenocarcinoma,\X0D\\X0A\Gleason's 3 + 4 = 7. No Gleason's 5 pattern present. Tumor in one of two cores,\X0D\\X0A\occupying approximately 5% of the total volume. CORE BIOPSIES OF LEFT MID\X0D\\X0A\PROSTATE: Single atypical small acinar proliferative focus. CORE BIOPSIES OF\X0D\\X0A\LEFT PROSTATE BASE: Negative for tumor. (JLB)","Final Diagnosis\X0D\\X0A\1.          PROSTATE GLAND, RADICAL PROSTATECTOMY:\X0D\\X0A\     Bilateral involvement with prostatic adenocarcinoma, Gleason grade 3+4=7\X0D\\X0A\involving 40% of right lobe and 30% of left lobe.  Proximal and distal urethral\X0D\\X0A\margins involved.  No extraprostatic extension identified. See Template.\X0D\\X0A\2.          RIGHT OBTURATOR LYMPH NODES:\X0D\\X0A\     No metastasis identified (0/3).\X0D\\X0A\3.          LEFT OBTURATOR LYMPH NODES:\X0D\\X0A\     No metastasis identified (0/2).\X0D\\X0A\MHB/mbc\X0D\\X0A\     PROSTATE RADICAL/ENUCLEATION\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  radical prostatectomy with node sampling \X0D\\X0A\PROSTATE SIZE:  31.4 gm\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\LOCATION OF TUMOR:  bilateral\X0D\\X0A\TUMOR SIZE/ % PROSTATE GLAND INVOLVED:   40% of right lobe and 30% of left lobe \X0D\\X0A\LOBES INVOLVED (RIGHT, LEFT, BILATERAL):  bilateral\X0D\\X0A\PRIMARY PATTERN:  3\X0D\\X0A\SECONDARY PATTERN:  4\X0D\\X0A\TERTIARY PATTERN:  n/a\X0D\\X0A\TOTAL GLEASON SCORE:  7\X0D\\X0A\CAPSULAR INVASION:  present\X0D\\X0A\EXTRAPROSTATIC EXTENSION:  no\X0D\\X0A\VASCULAR/LYMPHVASCULAR INVASION: none seen \X0D\\X0A\PERINEURAL INVASION:  present\X0D\\X0A\MARGINS INVOLVED:  proximal and distal urethral margins involved\X0D\\X0A\HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA:  n/a\X0D\\X0A\SEMINAL VESICLE INVOLVEMENT:  no\X0D\\X0A\BLADDER OR RECTAL INVOLVEMENT:  no\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  right and left obturator nodes negative\X0D\\X0A\EXTRANODAL EXTENSION:  n/a\X0D\\X0A\OTHER METASTATIC SITES:  unknown\X0D\\X0A\OTHER NEOPLASM SITES:  unknown\X0D\\X0A\SPECIAL STUDIES:  n/a\X0D\\X0A\THERAPY RELATED CHANGES:  n/a\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS: n/a \X0D\\X0A\OTHER STUDIES:  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  2c\X0D\\X0A\pN= 0    \X0D\\X0A\AJCC PATHOLOGIC STAGE:    IIB\X0D\\X0A\MHB",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled prostate gland consists of an intact\X0D\\X0A\prostatectomy specimen with attached bilateral vas and bilateral seminal\X0D\\X0A\vesicles. The specimen weighs 31.4 grams and the prostate has the overall\X0D\\X0A\dimensions of 4.5x3.0x3.0 cm. The bilateral vas average 3 cm in length and the\X0D\\X0A\bilateral seminal vesicles average 3.0x1.0x1.0 cm. The prostatic urethra is\X0D\\X0A\probe patent. The prostate gland is inked as follows: right lobe black, left\X0D\\X0A\lobe blue and sectioning reveals tan glistening prostatic parenchyma with a\X0D\\X0A\focal area of a golden yellow infiltrate predominantly on the right side of the\X0D\\X0A\prostate. The prostate gland is submitted in its entirety. Summary of sections:\X0D\\X0A\1A  right vas margin taken en face; 1B  left vas margin taken en face; 1C \X0D\\X0A\proximal urethra; 1D  distal urethra; 1E-1K  right lobe of prostate submitted\X0D\\X0A\sequentially from the distal toward the proximal aspect; 1L-1R  left lobe of\X0D\\X0A\prostate submitted sequentially from the distal toward the proximal aspect.\X0D\\X0A\Specimen 2 received in formalin labeled right obturator node consists of a\X0D\\X0A\2.5x2.0x0.5 cm aggregate of fatty soft tissue which is submitted entirely in\X0D\\X0A\cassette 2.\X0D\\X0A\Specimen 3 received in formalin labeled left obturator node consists of a\X0D\\X0A\2.5x2.5x0.6 cm aggregate of fatty soft tissue which is submitted in toto in\X0D\\X0A\cassette 3.\X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\The right and left vas margins are free of tumor. The proximal urethral margin\X0D\\X0A\is involved with adenocarcinoma as is the distal urethral margin. The right lobe\X0D\\X0A\shows infiltrating variably sized glands with perineural invasion. Some gland\X0D\\X0A\fusion is seen. Tumor is seen approximately 1 mm from the inked margins but no\X0D\\X0A\extraprostatic extension is seen. Tumor involves 40% of the right lobe. The left\X0D\\X0A\lobe shows similar tumor involvement of approximately 30%. Again, extraprostatic\X0D\\X0A\involvement is seen. \X0D\\X0A\Specimen 2 shows three small lymph nodes without metastasis.\X0D\\X0A\Specimen 3 shows two lymph nodes without metastasis.\X0D\\X0A\MHB/mbc",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,PROSTATE,0,492560,1,,CLINICAL HISTORY:\X0D\\X0A\Prostate cancer.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   RIGHT PELVIC LYMPH NODE:\X0D\\X0A\1.   Two benign lymph nodes, negative for metastatic carcinoma (0/2).\X0D\\X0A\B.   LEFT PELVIC LYMPH NODE:\X0D\\X0A\1.   Two benign lymph nodes, negative for metastatic carcinoma (0/2).\X0D\\X0A\C.   PROSTATE, RADICAL PROSTATECTOMY/RESECTION (71.4 GRAMS): PROSTATIC\X0D\\X0A\ADENOCARCINOMA, ACINAR TYPE/NOS.\X0D\\X0A\1.   HISTOLOGIC GRADE: Gleason pattern 4+3=7 with a substantial tertiary\X0D\\X0A\component of Gleason pattern 5.\X0D\\X0A\2.   TUMOR QUANTITATION:\X0D\\X0A\a.   Tumor occupies an estimated 12% of the prostate parenchyma.\X0D\\X0A\b.   Maximal area of tumor confluence measures 2.3 cm.\X0D\\X0A\c.   Tumor is present in 6 of 15 submitted slides of the prostate gland.\X0D\\X0A\3.   MARGINS AND EXTENT:\X0D\\X0A\a.   Tumor involves the right mid gland and base.\X0D\\X0A\b.   Seminal vesicle invasion: Present on the right.\X0D\\X0A\c.   Tumor comes to within less than 0.1 mm. in the area of the right\X0D\\X0A\posterior lateral margin.\X0D\\X0A\d.   All margins are free of tumor.\X0D\\X0A\e.   Treatment effect on carcinoma: not identified.\X0D\\X0A\f.   Lymphovascular space invasion: not identified.\X0D\\X0A\g.   Perineural invasion: Present, extensive.\X0D\\X0A\4.   PATHOLOGIC STAGE: pT3bN0MX\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (MC/dkv)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 10 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received in formalin designated 'right pelvic lymph nodes'\X0D\\X0A\is a 4.5 x 1.5 x 0.4 cm. fibrofatty tissue aggregate.  The adipose is\X0D\\X0A\bluntly dissected.  The entirety is submitted in cassette (A).\X0D\\X0A\Specimen (B) Received in formalin designated 'left pelvic lymph node' is\X0D\\X0A\a 6.3 x 2.0 x 0.8 cm. fibrofatty tissue aggregate.  The adipose is\X0D\\X0A\bluntly dissected.  The entirety is submitted in cassette (B).\X0D\\X0A\Specimen (C) Received in formalin designated 'prostate' is a 71.4-gram\X0D\\X0A\radical prostatectomy specimen with the following measurements:\X0D\\X0A\Superior/inferior 4.9 cm., anterior posterior 3.8 cm., horizontal 5.5\X0D\\X0A\cm. with attached seminal vesicles (3.2 x 0.9 x 0.8 cm. and 3.4 x 1.4 x\X0D\\X0A\0.7 cm. right and left respectively) and attached vas deferens (2.0 and\X0D\\X0A\3.5 cm. in length right and left respectively) each with an average\X0D\\X0A\tubal diameter of 0.5 cm.  The specimen has tan suture anteriorly, the\X0D\\X0A\right half is inked in green; the left half is inked in blue.  The\X0D\\X0A\distal urethral margin is marked by silver nitrate.  The specimen is\X0D\\X0A\serially sectioned to reveal marked central nodular hyperplasia.  No\X0D\\X0A\definitive mass lesion or tumor nodularity is identified.  The lobes are\X0D\\X0A\approximately symmetric.  Sections are submitted as follows:  C1 right\X0D\\X0A\vas deferens and seminal vesicle, C2 left vas deferens and seminal\X0D\\X0A\vesicle, C3 proximal urethral margin, C4 distal urethral margin, C5\X0D\\X0A\right and left apex, C6-C10 right mid gland, C11 right base, C12-C16\X0D\\X0A\left mid gland, C17 left base.   (MC/kd)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 19\X0D\\X0A\Prostate Gland\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: RIGHT PELVIC LYMPH NODE\X0D\\X0A\B: LEFT PELVIC LYMPH NODE\X0D\\X0A\C: Prostate, radical\X0D\\X0A\ \X0D\\X0A\PROSTATE GLAND: Radical Prostatectomy\X0D\\X0A\Histologic Type:    Adenocarcinoma (conventional, not otherwise\X0D\\X0A\specified)\X0D\\X0A\Histologic Grade:   Primary Pattern Grade:   4\X0D\\X0A\Secondary Pattern Grade: 3\X0D\\X0A\Tertiary Pattern Grade:  5\X0D\\X0A\Total Gleason Score:     7\X0D\\X0A\Tumor Quantitation: Proportion (percent) of prostate involved by tumor:\X0D\\X0A\12%\X0D\\X0A\Tumor Size:    Greatest dimension: 2.3cm\X0D\\X0A\Tumor is present in:     6 slides of 15\X0D\\X0A\Primary Tumor (pT): pT3\X0D\\X0A\Extension/Invasion: pT3b\X0D\\X0A\Number of nodes examined:     4\X0D\\X0A\Number of nodes involved:     0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Can be assessed\X0D\\X0A\Margin involvement: Margins uninvolved by invasive carcinoma\X0D\\X0A\Extraprostatic Extension:     Present\X0D\\X0A\Seminal Vesicle Invasion:     Present\X0D\\X0A\Perineural Invasion:     Present\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Lymphatic (Small Vessel) Invasion (L):  Absent\X0D\\X0A\Additional Pathologic Findings:    Are identified\X0D\\X0A\High-grade prostatic intraepithelial neoplasia (PIN)\X0D\\X0A\Atypical adenomatous hyperplasia\X0D\\X0A\Benign prostatic hyperplasia",,"SPECIMEN(S): A RIGHT PELVIC LYMPH NODE\X0D\\X0A\SPECIMEN(S): B LEFT PELVIC LYMPH NODE\X0D\\X0A\SPECIMEN(S): C Prostate, radical",,
REG1,PROSTATE,0,492625,1,,,"Patient Age: **AGE[in 70s].\X0A\ COMMENT:  Revised diagnosis called and report faxed to Dr. **NAME[ZZZ]'s office on **DATE[Feb 15 12]. PATHOLOGY CODES: RLL/dls88305 COMMENT: Report called and faxed to **NAME[YYY] in Dr. **NAME[ZZZ]'s office on **DATE[Feb 13 12] at 11:45. ** Original Signature on File ** **NAME[XXX M. WWW], M.D. **ID-NUM  **NAME[BBB,AAA M] **DATE[Feb 09 2012]  *** FINAL REPORT ***","REVISED PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ TRANSURETHRAL RESECTION OF PROSTATE: \X0D\\X0A\ Poorly differentiated prostatic adenocarcinoma (Gleasons' grade 4 + 5 \X0D\\X0A\ = 9/10) \X0D\\X0A\ Tumor involves multiple chips but accounts for less than 5% of the \X0D\\X0A\ tissue volume \X0D\\X0A\ Grade 5 tumor represents 10% of the tumor volume \X0D\\X0A\ **INITIALS \X0D\\X0A\ PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ PROSTATE, TUR: \X0D\\X0A\ Poorly differentiated prostatic adenocarcinoma, Gleason's grade 4 + 4 \X0D\\X0A\ = 8/10",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is BPH. \X0D\\X0A\ Specimen consists of multiple tan soft cylindrical tissue fragments \X0D\\X0A\ measuring 6.0 x 5.0 x 1.5 cm in aggregate and weighing 14.1 grams. \X0D\\X0A\ Representative sections are submitted in five cassettes. **INITIALS \X0D\\X0A\ Remaining tissue fragments entirely submitted in cassettes F-L. \X0D\\X0A\ **INITIALS \X0D\\X0A\ **PLACE, KY **ZIP-CODE",MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Tissue blocks are prepared and slides are examined microscopically. \X0D\\X0A\ See diagnosis for details. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:,TISSUE SUBMITTED: \X0D\\X0A\ Prostate chips,,
REG1,PROSTATE,0,493867,1,,CLINICAL HISTORY\X0D\\X0A\Elevated PSA 790.93\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[May 26 1950] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Oct 14 2012] 13:56\X0D\\X0A\Receipt Date: **DATE[Oct 14 2012] 13:56\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY  REPORT\X0D\\X0A\Phone: **PHONE Fax:  **PHONE          ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: PAT     Location: LABH\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Oct 14 2012] 17:28\X0D\\X0A\CONSULTATION:\X0D\\X0A\Dianon Systems","DIAGNOSIS\X0D\\X0A\PROSTATE, LEFT LATERAL BASE, NEEDLE CORE BIOPSY (G):\X0D\\X0A\   - ADENOCARCINOMA (GLEASON SCORE OF 7 = 4 + 3, INVOLVEMENT OF ONE OF ONE\X0D\\X0A\CORE, ABOUT 50%\X0D\\X0A\    INVOLVEMENT) NO EVIDENCE OF PERINEURAL INVASION (SEE COMMENT).\X0D\\X0A\PROSTATE, LEFT LATERAL MID, NEEDLE CORE BIOPSY (H):\X0D\\X0A\   - SMALL FOCUS OF ADENOCARCINOMA OF GLEASON SCORE 3 (LESS THAN 5%); NO\X0D\\X0A\EVIDENCE OF\X0D\\X0A\     PERINEURAL INVASION.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Oct 14 2012] **NAME[VVV UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:   SNOMED CODES:\X0D\\X0A\A: M81403 P1143\X0D\\X0A\B: M81403 P1143 \X0D\\X0A\F: A: S 88321 CONSULT",,,"MICROSCOPIC DESCRIPTION/COMMENT\X0D\\X0A\Only two biopsies (specimens G and H) are submitted for this review.  Per the\X0D\\X0A\pathology report specimen K (right lateral mid) showed atypical small acinar\X0D\\X0A\proliferation (ASAP) and specimen J (right lateral base) showed high-grade\X0D\\X0A\PIN.  The remaining specimens (A for left base, B for left mid, C for left\X0D\\X0A\apex, D for right base, E for right mid, F for right apex, I for left lateral\X0D\\X0A\apex, and L for right lateral apex) were negative for malignancy.  \X0D\\X0A\SLIDE/BLOCK DESCRIPTION\X0D\\X0A\Received from Dianon Systems 2 slides PA7055 (date collected **DATE[Aug 19 12]) and a\X0D\\X0A\copy of corresponding pathology report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Outside slide(s) only,,
REG1,PROSTATE,0,493897,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Operative procedure: robotic\X0D\\X0A\laparoscopic prostatectomy. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Dec 20 1945] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Mar 8 2012] 13:41\X0D\\X0A\Receipt Date: **DATE[Mar 8 2012] 13:41\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Mar 12 2012] 15:51\X0D\\X0A\RESIDENTS(S): V.V. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\PROSTATE AND SEMINAL VESICLE, ROBOTIC LAPAROSCOPIC PROSTATECTOMY (A):\X0D\\X0A\   - PROSTATIC ADENOCARCINOMA, GLEASON GRADE 3 + 4 = 7, INVOLVING RIGHT AND\X0D\\X0A\LEFT LOBES\X0D\\X0A\     (pT2c, pN0, SEE TEMPLATE).\X0D\\X0A\   - PERINEURAL INVASION IDENTIFIED.\X0D\\X0A\   - MARGINS OF RESECTION FREE OF TUMOR.\X0D\\X0A\LYMPH NODES, LEFT PELVIC, EXCISION (B):\X0D\\X0A\   - NO TUMOR SEEN IN FOUR LYMPH NODES (0/4).\X0D\\X0A\LYMPH NODES, RIGHT PELVIC, EXCISION (C):\X0D\\X0A\   - NO TUMOR SEEN IN FOUR LYMPH NODES (0/4).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Mar 12 2012] **NAME[UUU M. TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09400 M8140\X0D\\X0A\B: M09450 P1100\X0D\\X0A\C: M09450 P1100 \X0D\\X0A\F: A: 88309\X0D\\X0A\B: 88307\X0D\\X0A\C: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Three specimens are received. \X0D\\X0A\Specimen A is received in formalin labeled ""prostate and seminal vesicles""\X0D\\X0A\and consists of the aforementioned.  The external surface is dull red-brown. \X0D\\X0A\The cut surface varies from firm to rubbery and is nodular, light tan to\X0D\\X0A\yellow.  No discrete masses or lesions are noted.  The vas deferens and\X0D\\X0A\seminal vesicle are unremarkable and grossly free of tumor.  The urethral\X0D\\X0A\mucosa and margins are unremarkable.\X0D\\X0A\Ink code: anterior blue, posterior black\X0D\\X0A\Measurements:\X0D\\X0A\Weight: 120 gm\X0D\\X0A\Prostate size: Apex to base 7.0 cm; Left to right 6.5 cm; Anterior to\X0D\\X0A\posterior 5.0 cm\X0D\\X0A\Right seminal vesicle: 3.5 x 1.2 x 0.5 cm \X0D\\X0A\Left seminal vesicle: 2.5 x 1.5 x 0.5 cm\X0D\\X0A\Right vas deferens: 3.5 cm in length and 0.5 cm in diameter\X0D\\X0A\Left vas deferens: 2.5 cm in length and 0.4 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\A1  right urethral apex margin\X0D\\X0A\A2  left urethral apex margin\X0D\\X0A\A3  right urethral base margin\X0D\\X0A\A4  left urethral base margin\X0D\\X0A\A5  right vas deferens\X0D\\X0A\A6  left vas deferens\X0D\\X0A\A7  A9  right vas deferens and seminal vesicle\X0D\\X0A\A10  A11  left vas deferens and seminal vesicle\X0D\\X0A\A12  A40  right prostate entirely submitted apex to base\X0D\\X0A\A41  A69  left prostate left side entirely submitted apex to base \X0D\\X0A\Specimen label:   B) left pelvic node               \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): yellow\X0D\\X0A\Consistency: adipose \X0D\\X0A\Size(s): in aggregate 5.0 x 4.0 x 2.5 cm \X0D\\X0A\Five probable lymph nodes are identified \X0D\\X0A\Cassette summary: B1  three probable lymph nodes; B2  B3  one probable lymph\X0D\\X0A\node; B4  B5  one probable lymph node\X0D\\X0A\Specimen label:  C) right pelvic node                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow\X0D\\X0A\Consistency: adipose tissue \X0D\\X0A\Size(s): in aggregate 5.0 x 3.5 x 2.5 cm \X0D\\X0A\Four probable nodes are identified \X0D\\X0A\Cassette summary: C1  one probable lymph node; C2  two probable lymph nodes;\X0D\\X0A\C3  one probable lymph node \X0D\\X0A\rgc/**DATE[Mar 9 2012] V.V. **NAME[VVV], MD\X0D\\X0A\J.P. **NAME[SSS], MD","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Nov 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate/seminal vesicles\X0D\\X0A\Type of procedure:  robotic laparoscopic prostatectomy\X0D\\X0A\Weight of prostate:  120 grams\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 3/5\X0D\\X0A\              Secondary (next most prevalent) 4/5\X0D\\X0A\              Score 7/10\X0D\\X0A\Tumor location:  right and left\X0D\\X0A\Tumor amount (percentage):  right  4%; left  1%\X0D\\X0A\Size of largest tumor nodule:  6 mm (block A14)\X0D\\X0A\Involvement of seminal vesicle:  no\X0D\\X0A\Extension into soft tissue:  no\X0D\\X0A\Extracapsular extension:  no\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:   negative\X0D\\X0A\     Apical (inferior):  negative\X0D\\X0A\Inked surgical margins: negative\X0D\\X0A\Vascular invasion:  no\X0D\\X0A\Perineural invasion:  yes (block A12)\X0D\\X0A\High grade PIN:  present (quantity  large amount, right and left sides)\X0D\\X0A\Lymph node involvement:  \X0D\\X0A\                    Right pelvic:  0/4\X0D\\X0A\                    Left pelvic:  0/4\X0D\\X0A\Additional pathologic findings (list):  marked benign prostatic hypertrophy\X0D\\X0A\and acute and chronic prostatitis\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\        pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:     No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Prostate and seminal vessicles\X0D\\X0A\B: Left pelvic lymph nodes\X0D\\X0A\C: Right pelvic lymph nodes,,
REG1,PROSTATE,0,494555,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\prostate ca\X0D\\X0A\,"DaVINCI LAPAROSCOPIC PROSTATECTOMY\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3063 - SUR PATH V\X0D\\X0A\ \X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[XXX,WWW]\X0D\\X0A\1791 **NAME[VVV UUU]\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\**NAME[ZZZ,YYY M]., M.D.\X0D\\X0A\**INSTITUTION\X0D\\X0A\201 PARK STREET\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI, SUR PATH V/2\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI (**DATE[May 13 12]-1709)\X0D\\X0A\SUR PATH V (**DATE[May 13 12]-1709)\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\A.  RADICAL PROSTATECTOMY:\X0D\\X0A\INFILTRATING MODERATELY DIFFERENTIATED ADENOCARCINOMA INVOLVING\X0D\\X0A\LESS THAN 20% OF THE TOTAL GLAND, WITH TUMOR CONFINED WITHIN THE\X0D\\X0A\RIGHT LOBE WITH SPECIMEN MARGINS FREE OF MALIGNANCY.\X0D\\X0A\TUMOR HAS A COMBINED GLEASON's SCORE OF 7 (4+3).\X0D\\X0A\FOCAL PERINEURAL INVASION.\X0D\\X0A\NEGATIVE FOR LYMPHOVASCULAR INVASION.\X0D\\X0A\SEMINAL VESICLES AND VAS DEFERENS ARE UNINVOLVED BY TUMOR.\X0D\\X0A\BENIGN PROSTATIC HYPERPLASIA AND FOCI OF ACUTE AND CHRONIC\X0D\\X0A\INFLAMMATION.\X0D\\X0A\B.  RIGHT PELVIC LYMPH NODES:\X0D\\X0A\TWO REGIONAL LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA.\X0D\\X0A\C.  LEFT PELVIC LYMPH NODES:\X0D\\X0A\FIVE REGIONAL LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA.\X0D\\X0A\ \X0D\\X0A\CAP CHECKLIST:\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\DIAGNOSIS              (Continued)\X0D\\X0A\ \X0D\\X0A\Procedure:  Radical prostatectomy.\X0D\\X0A\Specimen Weight:  41 grams.\X0D\\X0A\Specimen Size:  3.3 x 5.5 x 3.5 cm.\X0D\\X0A\Lymph Node Sampling:  Pelvic lymph node dissection.\X0D\\X0A\Histologic Type:  Adenocarcinoma (acinar, not otherwise specified).\X0D\\X0A\Histologic Grade (Gleason Pattern):\X0D\\X0A\Primary Grade:  Grade 4.\X0D\\X0A\Secondary Grade:  Grade 3.\X0D\\X0A\Total Gleason Score:  7.\X0D\\X0A\Tumor Quantitation:  Tumor involves less than 20% of the total gland and is confined within\X0D\\X0A\the right lobe.\X0D\\X0A\Tumor Size (Dominant Nodule):  Greatest dimension is 13 millimeters.\X0D\\X0A\Extraprostatic Extension:  Not identified.\X0D\\X0A\Seminal Vesicle Invasion:  Not identified.\X0D\\X0A\Margins:  Margins are uninvolved by invasive carcinoma.\X0D\\X0A\Treatment Effect on Carcinoma:  Not identified.\X0D\\X0A\Lymphovascular Invasion:  Not identified.\X0D\\X0A\Perineural Invasion:  Present.\X0D\\X0A\Pathologic Staging (pTNM):\X0D\\X0A\Primary Tumor:  pT2a.\X0D\\X0A\Regional Lymph Nodes:  pN0.\X0D\\X0A\Distant Metastasis:  Not applicable.\X0D\\X0A\Additional Pathologic Findings:  Acute and chronic inflammation.\X0D\\X0A\Nodular prostatic hyperplasia.\X0D\\X0A\88309, 88307 x2\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\A.  Received in formalin designated as ""prostate"" is a 41 gram, 3.3 cm. in length x 5.5 by\X0D\\X0A\up to 3.5 cm. radical prostatectomy with attached seminal vesicles and vas deferens.  The\X0D\\X0A\right vas deferens is 3 cm. in length and the left is 3.7 cm. in length.  Both average 0.4\X0D\\X0A\cm. in diameter.  The right seminal vesicle is 3.3 x 1 by up to 0.25 cm. and the left is 3.5\X0D\\X0A\x 1 by up to 0.25 cm.  There is adherent soft tissue and cautery distortion along the\X0D\\X0A\anterior surface of the specimen.  There is a separate detached portion of vas deferens\X0D\\X0A\which is 1.5 cm. in length by up to 0.35 cm. in diameter.  A representative section is\X0D\\X0A\submitted in cassette A.  The gland is differentially stained with ink within the laboratory\X0D\\X0A\for orientation purposes.  The right anterior lobe is marked with yellow ink, the right\X0D\\X0A\posterior lobe with black ink, the left anterior lobe with blue ink, and the left posterior\X0D\\X0A\lobe with red ink.  The proximal portion of the right seminal vesicle and vas deferens are\X0D\\X0A\submitted in cassette A1 and of the left seminal vesicle and vas deferens are submitted in\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\GROSS DESCRIPTION          (Continued)\X0D\\X0A\ \X0D\\X0A\cassette A2.  Breadloaf-sectioning of the gland reveals a well-demarcated yellowish-tan\X0D\\X0A\nodule which is found in the right apex and mid portion of the gland.  It is up to 1 cm. in\X0D\\X0A\maximal diameter with a slightly wedge-shaped configuration.  Within the central portion of\X0D\\X0A\the right lobe and extending superficially into the left lobe is an ill-defined area of\X0D\\X0A\yellowish-tan discoloration which is 3.6 x 2.2 cm. in diameter.  Representative sections of\X0D\\X0A\the right lobe are submitted in cassettes A3-A15.  A3-A5 represent the apex and A12-A15\X0D\\X0A\represent the base extending from anterior to posterior.  Representative sections from the\X0D\\X0A\left lobe are submitted in cassettes A16-A28.  The areas of discoloration extend close to\X0D\\X0A\the margins at the base of the gland.  Representative sections of the apex are submitted in\X0D\\X0A\cassettes A16-A18.  Sections of the base extending from anterior to posterior are submitted\X0D\\X0A\in cassettes A25-A28.\X0D\\X0A\ \X0D\\X0A\B.  Received in formalin designated as ""right pelvic lymph node"" is an ovoid portion of\X0D\\X0A\fibroadipose tissue which is 2.7 x 2 by up to 0.8 cm.  There are lobules of greasy\X0D\\X0A\yellow-tan adipose tissue along the external surface.  There is a single plastic clip along\X0D\\X0A\one edge of the specimen.  The specimen is bisected and reveals a greasy yellow-tan to light\X0D\\X0A\tan cut surface.  The specimen is submitted in toto in cassettes B1 and B2.\X0D\\X0A\ \X0D\\X0A\C.  Received in formalin designated as ""left pelvic lymph node"" is an ovoid portion of\X0D\\X0A\fibroadipose tissue which is 5 x 2 by up to 1.2 cm.  The external surface is covered by\X0D\\X0A\lobules of greasy yellow-tan adipose tissue.  There is a central firm nodule suggestive of a\X0D\\X0A\lymph node which is 3.2 cm. in length by up to 0.4 cm. in diameter and an adjacent similar\X0D\\X0A\appearing nodule which is up to 0.4 cm. in diameter.  The tissue is submitted in toto in\X0D\\X0A\cassettes C1 and C2 with both representing different portions of the tissue.\X0D\\X0A\",MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\A-C.  Microscopic review was performed.\X0D\\X0A\,SPECIMEN\X0D\\X0A\ \X0D\\X0A\A.  PROSTATE\X0D\\X0A\B.  RIGHT PELVIC LYMPH NODE\X0D\\X0A\C.  LEFT PELVIC LYMPH NODE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT,,
REG1,PROSTATE,0,494664,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\prostate cancer\X0D\\X0A\,"DaVINCI LAPAROSCOPY PROSTATECTOMY\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3063 - SUR PATH V\X0D\\X0A\ \X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[XXX,WWW]\X0D\\X0A\1791 **NAME[VVV UUU]\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\**NAME[ZZZ,YYY M]., M.D.\X0D\\X0A\**INSTITUTION\X0D\\X0A\201 PARK STREET\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI, SUR PATH V/2\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI (**DATE[Dec 08 11]-1633)\X0D\\X0A\SUR PATH V (**DATE[Dec 08 11]-1633)\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\*****AMENDED DIAGNOSIS*****\X0D\\X0A\A.  RADICAL PROSTATECTOMY:\X0D\\X0A\INFILTRATING ADENOCARCINOMA INVOLVING APPROXIMATELY 30% OF THE\X0D\\X0A\LEFT LOBE WITH FOCI OF SUPERFICIAL EXTRACAPSULAR EXTENSION IN THE\X0D\\X0A\APEX AND BASE WITH SPECIMEN MARGINS FREE OF MALIGNANCY.\X0D\\X0A\COMBINED GLEASON SCORE OF 9 (4+5) WITH ADMIXED FOCI OF GLEASON\X0D\\X0A\PATTERN 3.\X0D\\X0A\POSITIVE FOR LYMPHOVASCULAR AND EXTENSIVE PERINEURAL INVASION.\X0D\\X0A\BENIGN GLANDULAR AND STROMAL HYPERPLASIA WITH FOCI OF CHRONIC\X0D\\X0A\INFLAMMATION.\X0D\\X0A\SEMINAL VESICLES:\X0D\\X0A\NO SIGNIFICANT HISTOPATHOLOGIC CHANGES.\X0D\\X0A\VAS DEFERENS:\X0D\\X0A\NO SIGNIFICANT HISTOPATHOLOGIC CHANGES.\X0D\\X0A\B.  RIGHT PELVIC REGIONAL LYMPH NODES:\X0D\\X0A\FUSED CHAIN OF REGIONAL LYMPH NODES COMPOSED OF AT LEAST TWO\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\DIAGNOSIS              (Continued)\X0D\\X0A\ \X0D\\X0A\REGIONAL LYMPH NODES\X0D\\X0A\NEGATIVE FOR METASTATIC CARCINOMA.\X0D\\X0A\C.  LEFT PELVIC REGIONAL LYMPH NODES:\X0D\\X0A\FUSED CHAIN OF REGIONAL LYMPH NODES COMPOSED OF AT LEAST TWO\X0D\\X0A\REGIONAL LYMPH NODES\X0D\\X0A\NEGATIVE FOR METASTATIC CARCINOMA.\X0D\\X0A\ \X0D\\X0A\CAP CHECKLIST:\X0D\\X0A\Procedure:  Radical prostatectomy.\X0D\\X0A\Specimen Weight:  46 grams.\X0D\\X0A\Size:  4 x 5 x 3.5 cm.\X0D\\X0A\Lymph Node Sampling:  Pelvic regional lymph node dissection.\X0D\\X0A\Histologic Type:  Adenocarcinoma (not otherwise specified).\X0D\\X0A\Histologic Grade:  Gleason pattern.\X0D\\X0A\Primary Pattern:  Grade 4.\X0D\\X0A\Secondary Pattern:  Grade 5.\X0D\\X0A\Tertiary Pattern:  Grade 3.\X0D\\X0A\Total Gleason Score:  9.\X0D\\X0A\Tumor Quantitation:  Tumor involves less than 20% of the total gland.\X0D\\X0A\Tumor involves approximately 30% of the left lobe and 0%\X0D\\X0A\of the right lobe.\X0D\\X0A\Extraprostatic Extension:  Present focally in the apex and base of the left lobe.\X0D\\X0A\Seminal Vesicle Invasion:  Not identified.\X0D\\X0A\Margins:  Uninvolved by invasive carcinoma.\X0D\\X0A\Treatment Effect on Carcinoma:  Not identified.\X0D\\X0A\Lymphovascular Invasion:  Present.\X0D\\X0A\Perineural Invasion:  Present, extensive.\X0D\\X0A\Pathologic Staging (pTNM):\X0D\\X0A\Primary Tumor:  pT3a.\X0D\\X0A\Regional Lymph Nodes:  pN0.\X0D\\X0A\Distant Metastasis:  Not applicable.\X0D\\X0A\Additional Pathologic Findings:  Focal chronic inflammation.\X0D\\X0A\Nodular prostatic hyperplasia.\X0D\\X0A\ \X0D\\X0A\88309, 88307 x2\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\A.  Received in formalin designated as ""prostate gland, seminal vesicles and vas deferens""\X0D\\X0A\is a radical prostatectomy which weighs 46.0 grams.  The right vas deferens is 4.5 cm. in\X0D\\X0A\length.  The left vas deferens is 4.9 cm. in length.  Both are up to 0.5 cm. in diameter.\X0D\\X0A\The right seminal vesicle is 2.7 x 1.5 x 0.6 cm.  The left is 2.2 x 1.8 by up to 0.6 cm.\X0D\\X0A\The prostate gland is 4 x 5 x 3.5 cm.  There is a prominent median lobe predominantly along\X0D\\X0A\the left base of the gland.  The gland is marked with multiple inks for orientation\X0D\\X0A\purposes.  The right anterior lobe is marked with yellow ink, the right posterior lobe with\X0D\\X0A\black ink, the left anterior lobe is marked with green ink, and the left posterior lobe with\X0D\\X0A\blue ink.  The proximal seminal vesicle and vas deferens margin is submitted in cassette A1\X0D\\X0A\with an additional section in cassette A2.  The gland is breadloaf-sectioned and reveals a\X0D\\X0A\multinodular cut surface with areas of yellowish-white discoloration predominantly along the\X0D\\X0A\left lobe in the lateral aspect of the mid portion of the gland extending posteriorly.\X0D\\X0A\Representative sections of the right lobe extending from the apex to the base are submitted\X0D\\X0A\in cassettes A3-A15 with cassettes A12-A15 representing the base extending from anterior to\X0D\\X0A\posterior.  The left lobe is submitted in cassettes A16-A32 with the apex in cassettes\X0D\\X0A\A16-A18 and the base in cassettes A27-A32 extending from anterior to posterior.\X0D\\X0A\ \X0D\\X0A\B.  Received in formalin designated as ""right pelvic lymph node"" is a solitary strip of\X0D\\X0A\fibroadipose tissue which is 6 x 1.5 by up to 1 cm.  Palpation reveals this appears to be\X0D\\X0A\composed predominantly of a fused chain of apparent lymph nodes which are bisected\X0D\\X0A\longitudinally and reveal no gross evidence of metastatic disease.  This fragment is\X0D\\X0A\submitted as paired sections with one half submitted in cassettes B1 and B2 and the opposite\X0D\\X0A\half submitted in cassettes B3 and B4.\X0D\\X0A\ \X0D\\X0A\C.  Received in formalin designated as ""left pelvic lymph node"" is a portion of fibroadipose\X0D\\X0A\tissue which is 5 x 2 by up to 0.6 cm.  There is a scant amount of adipose tissue adherent\X0D\\X0A\along the surface of the specimen.  The specimen appears to be composed of a single long\X0D\\X0A\fused chain of lymph nodes.  The tissue is bisected and reveals no gross evidence of\X0D\\X0A\metastatic disease.  The specimen appears to be composed of at least two (2) separate lymph\X0D\\X0A\nodes.  Representative sections for count are submitted in cassettes C1 and C2.  Additional\X0D\\X0A\sections of the remainder of the lymph node are submitted in cassette C3.\X0D\\X0A\",MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\A.  Sections of the right lobe of the prostate reveal benign glandular and stromal\X0D\\X0A\hyperplasia and are negative for malignancy.  Sections of the left lobe of the prostate\X0D\\X0A\reveal multiple foci of malignancy ranging from well-formed microacinar structures diffusely\X0D\\X0A\infiltrating the gland (Gleason pattern 3) to areas of fused glands and cribriform\X0D\\X0A\structures (Gleason pattern 4) to foci of poorly differentiated tumor composed predominantly\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\MICROSCOPIC EXAMINATION       (Continued)\X0D\\X0A\ \X0D\\X0A\of infiltrating single cells with marked nuclear atypia.  The majority of the tumor is\X0D\\X0A\composed of Gleason patterns 4 and 5 with smaller areas of admixed Gleason pattern 3.  Tumor\X0D\\X0A\is found predominantly along the peripheral aspects of the gland and focally extends through\X0D\\X0A\the capsule in both apex and the base of the gland with specimen margins free of malignancy.\X0D\\X0A\There are extensive foci of perineural invasion.  There are multiple foci of lymphovascular\X0D\\X0A\invasion.  Tumor involves approximately 30% of the left lobe.  There is no extension to the\X0D\\X0A\seminal vesicles.  The seminal vesicles and vas deferens are unremarkable.  The remainder of\X0D\\X0A\the left lobe reveals areas of glandular and nodular hyperplasia with multiple foci of\X0D\\X0A\atrophy and chronic inflammation.\X0D\\X0A\ \X0D\\X0A\B-C.  Microscopic review was performed.\X0D\\X0A\,"SPECIMEN\X0D\\X0A\ \X0D\\X0A\*****AMENDED DIAGNOSIS*****\X0D\\X0A\A.  PROSTATE GLAND, SEMINAL VESICLES, VAS DEFERENS\X0D\\X0A\B.  RIGHT PELVIC LYMPH NODE\X0D\\X0A\C.  LEFT PELVIC LYMPH NODE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT",,
REG1,PROSTATE,0,495172,1,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: PROSTATE CHIPS AND BLADDER STONE: LOW-GRADE PROSTATIC ADENOCARCINOMA. GLEASON's GRADE: 1 + 3 =4. INVOLVING LESS THAN 1% OF EVALUATED TISSUE. MARKED CHRONIC ACTIVE PROSTATITIS. Final Signout: **NAME[XXX], MD **DATE[Aug 01 12]",,"GROSS DESCRIPTION: A single specimen is received in formalin labeled prostate chips and bladder stone.  The specimen consists of 25 grams of prostatic chips and small bosselated black stones.  The tissue in aggregate measures 8.4 x 7.3 x 2.2 cm.  The tissue is inspected and representative sections are submitted in cassettes ""A"" through ""T"".",,Tissues: PROSTATE. Specimen Comments: CPT CODES: 88305 X 1,,
REG1,PROSTATE,0,495462,1,,CLINICAL HISTORY:  NONE GIVEN\X0D\\X0A\PRE-OP DIAGNOSIS:  PROSTATE CANCER\X0D\\X0A\POST-OP DIAGNOSIS:  SAME,CASE: SUR-11-13093\X0D\\X0A\PATIENT: **NAME[AAA BBB]\X0D\\X0A\PROCEDURE:  ROBOTIC PROSTATECTOMY,"FINAL DIAGNOSIS:\X0D\\X0A\PROSTATECTOMY SPECIMEN:  Invasive carcinoma.\X0D\\X0A\HISTOLOGIC TYPE:    Adenocarcinoma (conventional, not otherwise\X0D\\X0A\specified)\X0D\\X0A\HISTOLOGIC GLEASON SCORE:\X0D\\X0A\-Primary Grade:     3\X0D\\X0A\-Secondary Grade:   3\X0D\\X0A\-Gleason Score:     6\X0D\\X0A\TUMOR QUANTITATION:\X0D\\X0A\Percent involved by tumor:    1%\X0D\\X0A\MARGINS:  Free of neoplasm\X0D\\X0A\BILATERAL INVOLVEMENT:   Present\X0D\\X0A\EXTRAPROSTATIC EXTENSION:     Not identified\X0D\\X0A\SEMINAL VESICLE INVASION:     Not identified\X0D\\X0A\PERINEURAL INVASION:     Not identified\X0D\\X0A\ANGIOLYMPHATIC INVASION: Not identified\X0D\\X0A\PATHOLOGIC STAGING (pTNM):\X0D\\X0A\-Primary Tumor (pT):     pT2c\X0D\\X0A\-Regional Lymph Nodes (pN):   pNX\X0D\\X0A\-Distant Metastasis (pM):     pMX",,"GROSS:\X0D\\X0A\Received is a prostatectomy specimen with attached seminal vesicles. The\X0D\\X0A\specimen is 45 grams and 5.2 x 3.5 x 4.5 cm. The outer surface is\X0D\\X0A\somewhat granular and reddish brown. The right half of the prostate is\X0D\\X0A\marked with green ink and the left with yellow. The specimen is serially\X0D\\X0A\sectioned in the coronal plane. The cut surface demonstrates a slightly\X0D\\X0A\nodular appearance with diffuse yellowish discoloration which is\X0D\\X0A\bilateral and covers \R\60% of the parenchyma.\X0D\\X0A\A section of right anterior prostate is submitted labeled as A1, right\X0D\\X0A\anterior lateral A2, right mid lateral A3, right posterior A4, 5, 6 and\X0D\\X0A\7, and right seminal vesicle A8.\X0D\\X0A\A section of the left anterior is submitted labeled A9, the left\X0D\\X0A\anterior lateral A10, the left mid lateral A11, the left posterior A12,\X0D\\X0A\13, 14 and 15, and the left seminal vesicle A16.","MICROSCOPIC:\X0D\\X0A\Sections from the right portion of the prostate demonstrate nodular\X0D\\X0A\hyperplasia with a 2 mm area of prostatic adenocarcinoma present in\X0D\\X0A\slide A2 which corresponds to the right anterolateral aspect.  This does\X0D\\X0A\not extend to any margin and does not penetrate the capsule.  No other\X0D\\X0A\tumor is identified in the right.  In the slides of the left prostate,\X0D\\X0A\prostatic carcinoma is identified in slide A13 only and this is present\X0D\\X0A\in the posterior aspect.  Again, there is no tumor present at the\X0D\\X0A\margin.  This area is also \R\2 mm in greatest dimension.  Perineural\X0D\\X0A\invasion is not identified.  Overall, the amount of submitted tissue\X0D\\X0A\shows tumor in less than 1% of the material.\X0D\\X0A\Final Diagnosis performed by\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\Electronically signed **DATE[Apr 30 2012] 9:49AM",SPECIMEN:  A. PROSTATE,,
REG1,PROSTATE,0,495798,3,,,,,,,,,,
REG1,PROSTATE,0,497026,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is elevated PSA. Operative procedure: TRUS biopsy (base\X0D\\X0A\ blue, mid  green, apex  eosin).\X0D\\X0A\AMENDMENTS\X0D\\X0A\Amended:  **DATE[Jul 3 2012] by **NAME[ZZZ YYY XXX]\X0D\\X0A\Reason:     Typographical Error\X0D\\X0A\     Typographical error in Gleason score\X0D\\X0A\Previous Signout Date:  **DATE[May 8 2012]\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jul 4 1949] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[May 6 2012] 15:16\X0D\\X0A\Receipt Date: **DATE[May 6 2012] 15:16\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\* Amended *\X0D\\X0A\**NAME[WWW] MD: **NAME[VVV UUU], MD     Service: URO     Location: URCT\X0D\\X0A\**NAME[TTT] MD(S):      Reported: **DATE[May 8 2012] 16:56\X0D\\X0A\RESIDENTS(S): E.A. Pirruccello, DO","DIAGNOSIS\X0D\\X0A\RIGHT PROSTATE, NEEDLE CORE BIOPSIES (A):\X0D\\X0A\    BASE: \X0D\\X0A\   - INFILTRATING POORLY DIFFERENTIATED PROSTATIC ADENOCARCINOMA, GLEASON\X0D\\X0A\SCORE 3 + 5 = 8.\X0D\\X0A\   - NO HIGH-GRADE PIN OR PERINEURAL INVASION SEEN.\X0D\\X0A\  MID LOBE: \X0D\\X0A\   -INFILTRATING MODERATELY DIFFERENTIATED PROSTATIC ADENOCARCINOMA, GLEASON\X0D\\X0A\SCORE 3 + 4 = 7.\X0D\\X0A\   - NO PERINEURAL INVASION OR HIGH-GRADE PIN SEEN.\X0D\\X0A\  APEX:  INFILTRATING MODERATE TO POORLY DIFFERENTIATED PROSTATIC\X0D\\X0A\ADENOCARCINOMA, GLEASON\X0D\\X0A\    SCORE 3 + 4 = 7.\X0D\\X0A\   - NO PERINEURAL INVASION OR HIGH-GRADE PIN SEEN.\X0D\\X0A\LEFT PROSTATE, NEEDLE CORE BIOPSIES (B):\X0D\\X0A\  BASE: \X0D\\X0A\   - MODERATE TO POORLY DIFFERENTIATED PROSTATIC ADENOCARCINOMA, GLEASON\X0D\\X0A\SCORE 4 + 3 = 7.\X0D\\X0A\   - FOCAL PERINEURAL INVASION IDENTIFIED, NO HIGH-GRADE PIN SEEN.\X0D\\X0A\ MID LOBE: \X0D\\X0A\   - INFILTRATING MODERATE TO POORLY DIFFERENTIATED PROSTATE ADENOCARCINOMA,\X0D\\X0A\GLEASON\X0D\\X0A\    SCORE 3 + 4 = 7. \X0D\\X0A\   - NO PERINEURAL INVASION OR HIGH-GRADE PIN SEEN.\X0D\\X0A\ APEX: \X0D\\X0A\  - INFILTRATING MODERATE TO POORLY DIFFERENTIATED PROSTATIC ADENOCARCINOMA,\X0D\\X0A\GLEASON\X0D\\X0A\    SCORE 3 + 4 = 7.\X0D\\X0A\   - NO PERINEURAL INVASION OR HIGH-GRADE PIN SEEN.  \X0D\\X0A\SEE TEMPLATE.\X0D\\X0A\NOTE\X0D\\X0A\This amended report corrects a typographical error in the Gleason score of\X0D\\X0A\right base in diagnosis.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 8 2012] **NAME[M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 185     MALIGNANT NEOPLASM PROSTATE\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: P1143 T77101\X0D\\X0A\B: P1143 T77101 \X0D\\X0A\F: A: 88305(3)\X0D\\X0A\B: 88305(3)",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  two\X0D\\X0A\Specimen label: A) right prostate               \X0D\\X0A\Fixation: formalin\X0D\\X0A\Shape(s): cores    \X0D\\X0A\Number, Inked Color(s)/Size(s): two blue measuring 1.3 and 1.2 cm x less than\X0D\\X0A\0.1 cm in diameter, two green measuring 1.7 and 1.4 cm in length x less than\X0D\\X0A\0.1 cm in diameter, and two eosin measuring 1.5 and 1.2 cm x less than 0.1 cm\X0D\\X0A\in diameter. \X0D\\X0A\Cassette summary:  Cores are submitted in screened blue  A1; green  A2; eosin\X0D\\X0A\ A3, entirely.\X0D\\X0A\Specimen label: B) left prostate               \X0D\\X0A\Fixation: formalin\X0D\\X0A\Shape(s): cores \X0D\\X0A\Number, Color(s)/Size(s): two blue measuring 1.7 and 1.5 cm in length x less\X0D\\X0A\than 0.1 cm in diameter, two green measuring 1.6 and 1.5 cm in length x less\X0D\\X0A\than 0.1 cm in diameter, and two eosin measuring 1.4 and 1.1 cm in length x\X0D\\X0A\less than 0.1 cm in diameter.\X0D\\X0A\Cassette summary:  Cores are submitted in screened blue  B1; green  B2; eosin\X0D\\X0A\ B3, entirely. \X0D\\X0A\rgc/**DATE[May 7 2012] E.A. Pirruccello, DO\X0D\\X0A\**NAME[RRR M. QQQ","MICROSCOPIC DESCRIPTION\X0D\\X0A\NEEDLE BIOPSY FOR PROSTATE CANCER (template #7)\X0D\\X0A\Last updated **DATE[Jun 2010] (AJCC 7th Edition \T\ 2009 CAP checklist))\X0D\\X0A\Consensus conference review with agreement is obtained on the right base\X0D\\X0A\biopsy.\X0D\\X0A\Histologic type:  prostatic adenocarcinoma\X0D\\X0A\Side of tumor:  bilateral involving base, mid lobe and apex\X0D\\X0A\Gleason grade:    \X0D\\X0A\        Primary (most prevalent pattern) 3/5\X0D\\X0A\        Secondary (worst remaining pattern) 5 /5 \X0D\\X0A\        Score) 8/10\X0D\\X0A\\X0D\\X0A\     Note)  For needle biopsies the worst remaining rather than second most\X0D\\X0A\extensive is utilized as the \X0D\\X0A\                secondary score.\X0D\\X0A\Number of cores involved/total number of cores:  11 of 12\X0D\\X0A\% of tumor in biopsy cores:  60%\X0D\\X0A\Presence of high grade PIN:  no\X0D\\X0A\Presence of perineural invasion:  yes\X0D\\X0A\Presence of extraprostatic extension of tumor:  cannot be assessed\X0D\\X0A\Other significant findings:  not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right prostate biopsy\X0D\\X0A\B: Left prostate biopsy,,
REG1,PROSTATE,0,498192,1,,PRE-OPERATIVE DIAGNOSIS: PROSTATE CANCER.,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: #1 - RIGHT OBTURATOR NODE: THREE BENIGN REACTIVE LYMPH NODES. NEGATIVE FOR MALIGNANCY. #2 - LEFT OBTURATOR NODE: FIVE BENIGN REACTIVE LYMPH NODES. NEGATIVE FOR MALIGNANCY. #3 - PROSTATE: INVASIVE PROSTATIC ADENOCARCINOMA, CONVENTIONAL TYPE. GLEASON SCORE: 3 + 4 = 7. LOCATION:  TUMOR INVOLVES RIGHT AND LEFT PROSTATE GLAND (SEE NOTE). EXTENT OF LOCAL INVASION:  NEGATIVE FOR EXTRA PROSTATIC SOFT TISSUE INVASION AND BILATERAL SEMINAL VESICLE INVASION. PERINEURAL INVASION:  EXTENSIVELY POSITIVE. LYMPHOVASCULAR INVASION:  NOT IDENTIFIED. SURGICAL MARGINS:  NEGATIVE FOR TUMOR (SEE NOTE). BACKGROUND MULTIFOCAL HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA. NOTE:  The tumor appears centered within the left mid apical prostate with extension into the left base, and right apical, mid and basal regions.  Tumor involves approximately 50% of the left prostate and 20% of the right prostate.  Tumor     approaches to within 1 mm. or less of the inked posterior margins of the right prostate in the basal and mid regions. Tumor approaches to within 1 mm. or less of the posterior margins of the left prostate within both the mid and apical regions.  Tumor also approaches to within 1 mm. of the left anterior apical margin.  Tumor appears completely excised. Overall, the findings result in a TNM classification of pT2c, pN0, pMX.. Final Signout: **NAME[XXX WWW], MD **DATE[Dec 22 12]",,"GROSS DESCRIPTION: The specimens are received within formalin in three separate containers. Specimen #1 - is labeled right obturator node and consists of two lobulated portions of yellow-gray-tan soft tissue - measuring 4.0 x 3.5 x 1.6 cm. in aggregate.  Dissection reveals two apparent lymph nodes which are variably replaced by fat.  They range from 3.1 - 3.5 cm. in diameter.  The smaller lymph node is entirely submitted in block ""1A"" with the larger lymph node submitted in blocks ""1B"" through ""1D"". Specimen #2 - is labeled left obturator node and consists of a lobulated portion of yellow-gray-tan soft tissue measuring 3.3 x 2.5 x 1.5 cm.  Dissection demonstrates four apparent lymph nodes which are variably replaced by fat and range from 0.3 cm. - 3.0 cm. in diameter.  The three small lymph nodes are submitted in block ""2A"".  The largest lymph node is submitted in blocks ""2B"" and ""2C"". Specimen #3 - is labeled prostate and consists of a gray-tan prostate gland with attached bilateral seminal vesicles and vas deferens stumps.  It weighs 35.4 grams and measures 3.4 cm. superior to inferior, 4.6 cm. left to right, and 3.2 cm. anterior to posterior.  The right seminal vesicle stump measures 2.0 cm. in diameter x 1.4 cm. long.  The left seminal vesicle stump measures 1.5 cm. in diameter x 1.6 cm. long.  The margins are inked as follows:  black - right posterior, violet - left posterior, blue - right anterior, and green - left anterior. The prostate gland is bisected and serially sectioned.  The right proximal base is submitted in block ""3A"".  The right distal apex is submitted in block ""3B"".  The right seminal vesicle stump is sampled in block ""3C"".  The right prostate gland is extensively sampled from proximal/base to distal/apex in blocks ""3D"" through ""3K"".  The left proximal base is submitted in block ""3L"".  The left distal apex is submitted in block ""3M"". The left seminal vesicle stump is sampled in block ""3M"".  The left prostate is extensively sampled from proximal to distal in blocks ""3O"" through ""3U'.",,Tissues: 1. LYMPH NODE - RT OBTURATOR 2. LYMPH NODE - LT OBTURATOR 3. PROSTATE -. Specimen Comments: CPT CODES: 88307 x 2;88309 x 1,,
REG1,PROSTATE,0,498616,1,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: #1 - RIGHT OBTURATOR NODE, EXCISION: FIVE BENIGN LYMPH NODES. NO METASTATIC CARCINOMA PRESENT (0/5). #2 - LEFT OBTURATOR LYMPH NODE, EXCISION: ONE BENIGN LYMPH NODE. NO METASTATIC CARCINOMA PRESENT (0/1). SMALL NON-CASEATING EPITHELIOID GRANULOMAS PRESENT. (AFB AND PAS SPECIAL STAINS ARE NEGATIVE - WITH POSITIVE CONTROLS WORKING WELL). #3 - PROSTATE, RADICAL PROSTATECTOMY: INVASIVE ADENOCARCINOMA, CONVENTIONAL TYPE, WELL DIFFERENTIATED. TOTAL GLEASON SCORE - 6 (PRIMARY PATTERN GRADE 3; SECONDARY PATTERN GRADE 3). TUMOR INVOLVES BOTH RIGHT AND LEFT LOBES, LESS THAN 50%. EXTRAPROSTATIC EXTENSION - NOT IDENTIFIED. SEMINAL VESICLE INVASION - NOT IDENTIFIED. PERINEURAL INVASION - PRESENT. LYMPHOVASCULAR INVASION - NOT IDENTIFIED. SURGICAL MARGINS: INVASIVE CARCINOMA IS PRESENT AT THE INKED/CAUTERIZED MARGIN OF THE RIGHT LOBE (DEEPER LEVELS EXAMINED). BLADDER NECK MARGIN: NOT INVOLVED APICAL MARGIN: NOT INVOLVED. SEMINAL VESICLE AND VAS DEFERENS MARGINS: NOT INVOLVED PATHOLOGIC STAGING - pT2c (BILATERAL DISEASE), N0, MX. ADDITIONAL PATHOLOGIC FINDINGS: HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN). NODULAR PROSTATIC HYPERPLASIA. CHRONIC-ACTIVE INFLAMMATION.. Final Signout: **NAME[XXX WWW], MD **DATE[Sep 09 12]",,"GROSS DESCRIPTION: The specimens are received within formalin in three containers. Specimen #1 - is  labeled right obturator node and consists of three pieces of fibroadipose tissue, ranging in size from 1 to 3.5 cm. in greatest dimension.  On sectioning, there are multiple lymph nodes ranging from 0.3 to 2.5 cm. in greatest dimension.  The specimen is entirely submitted in two cassettes, as follows:  ""1A"" - larger lymph node bisected, ""1B"" - smaller lymph nodes. Specimen #2 - is labeled left obturator node and consists of one piece of fibroadipose tissue that measures 3.3 x 1.2 x 0.7 cm.  On sectioning, there is one lymph node that measures 3 x 1.5 x 0.8 cm.  The lymph node is sectioned and the specimen is entirely submitted in two cassettes, labeled ""2A"" and ""2B"". Specimen #3 - is labeled prostate and consists of a radical prostatectomy specimen, weighing 42 grams and measuring 4.8 cm. from anterior to posterior, 5.6 cm. from right to left, and 3.6 cm. from superior to inferior.  The specimen is inked as follows:  red - right lobe, orange - left lobe, and black - inferior/posterior.  The left vas deferens measures 1 x 0.7 x 0.7 cm.  The left seminal vesicle measures 0.9 x 0.6 x 0.5 cm.  The right vas deferens measures 0.8 x 0.8 x 0.5 cm. and the right seminal vesicle measures 1 x 0.5 x 0.5 cm.  On sectioning, there is a diffuse spongy cut-surface with scattered white-yellow areas. Representative sections are submitted in 32 cassettes - labeled ""3A"" through ""3FF"", as follows:  ""3A"" - right seminal vesicle margin and right vas deferens margin; ""3B"" - left seminal vesicle margin and left vas deferens margin; ""3C"" - right base; ""3D"" - left base; ""3E"" - right parabase, circumferential sections; ""3F"" and ""3G"" - left parabase, circumferential sections; ""3H"" - right apex;  ""3I"" - left apex; ""3J"" - right paraapex, circumferential sections;  ""3K"" - left paraapex, circumferential sections; ""3L"" through ""3U"" - representative sections, approximately 70% submitted from the right lobe from anterior to posterior; ""3V"" through ""3FF, approximately 80% of the left lobe submitted from anterior to posterior.",,"Tissues: 1. LYMPH NODE - RIGHT OBTURATOR 2. LYMPH NODE - LEFT OBTURATOR 3. PROSTATE -. Specimen Comments: CPT CODES: 88305 X 2,  88309 X 1,  88312 X 2",,
REG1,PROSTATE,0,499723,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is prostate cancer.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Prostate, Radical resection\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, biopsy","Final Diagnosis\X0D\\X0A\1. PROSTATE, ROBOTIC PROSTATECTOMY:\X0D\\X0A\     Prostatic adenocarcinoma, Gleason grade 4+3=7 with a small component of\X0D\\X0A\Gleason grade 5 tumor, tumor \X0D\\X0A\      widely infiltrative in both lobes with approximately 80% of each lobe\X0D\\X0A\involved by infiltrating neoplasm.\X0D\\X0A\     Extensive perineural infiltration and extensive extraprostatic tumor\X0D\\X0A\spread, focal positive surgical margin on       right, bilateral seminal vesicle\X0D\\X0A\involvement by infiltrating prostatic adenocarcinoma and involvement of  \X0D\\X0A\      proximal urethral margin by carcinoma.\X0D\\X0A\     Left vas deferens shows glandular elements highly suspicious for carcinoma.\X0D\\X0A\     Lymphvascular invasion present. See TEMPLATE.\X0D\\X0A\2. RIGHT PELVIC LYMPH NODE:\X0D\\X0A\     No tumor seen, no definite lymph node identified; \X0D\\X0A\3. LEFT PELVIC LYMPH NODE:\X0D\\X0A\     Lymph node x 1, no tumor seen. \X0D\\X0A\**INITIALS\X0D\\X0A\PROSTATE RADICAL/ENUCLEATION TEMPLATE:\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE: Robotic radical prostatectomy\X0D\\X0A\PROSTATE SIZE: 40 grams, 6.5 x 3.5 x 3.5cm\X0D\\X0A\SPECIMEN INTEGRITY: Intact\X0D\\X0A\LOCATION OF TUMOR: Both lobes\X0D\\X0A\TUMOR SIZE/ % PROSTATE GLAND INVOLVED: Approximately 80% of the glands is\X0D\\X0A\involved\X0D\\X0A\LOBES INVOLVED (RIGHT, LEFT, BILATERAL): Both right and left lobes are involved\X0D\\X0A\PRIMARY PATTERN: Gleason grade 4\X0D\\X0A\SECONDARY PATTERN: Gleason grade 3\X0D\\X0A\TERTIARY PATTERN: Gleason grade 5\X0D\\X0A\TOTAL GLEASON SCORE: 4+3=7 with a minor component of Gleason grade 5\X0D\\X0A\CAPSULAR INVASION: Present\X0D\\X0A\EXTRAPROSTATIC EXTENSION: Present\X0D\\X0A\VASCULAR/LYMPHVASCULAR INVASION: Present\X0D\\X0A\PERINEURAL INVASION: Present\X0D\\X0A\MARGINS INVOLVED: Yes\X0D\\X0A\HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA: Present\X0D\\X0A\SEMINAL VESICLE INVOLVEMENT: Tumor is present bilaterally in the seminal\X0D\\X0A\vesicles\X0D\\X0A\BLADDER OR RECTAL INVOLVEMENT: Unknown\X0D\\X0A\REGIONAL LYMPH NODE STATUS: Tissue submitted as right pelvic node is\X0D\\X0A\fibroadipose and does not contain tumor, tissue submitted as left pelvic lymph\X0D\\X0A\node is a lymph node that is also free of tumor\X0D\\X0A\EXTRANODAL EXTENSION: Absent\X0D\\X0A\OTHER METASTATIC SITES: Unknown\X0D\\X0A\OTHER NEOPLASM SITES: Unknown\X0D\\X0A\SPECIAL STUDIES: None\X0D\\X0A\THERAPY RELATED CHANGES: None\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS: None\X0D\\X0A\OTHER STUDIES: Not performed\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 3b\X0D\\X0A\pN= x\X0D\\X0A\pM= x\X0D\\X0A\AJCC PATHOLOGIC STAGE: III\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled prostate is a 40.9 gram intact radical\X0D\\X0A\prostatectomy specimen. The prostate measures 6.5 x 3.5 x 3.5 cm, the bilateral\X0D\\X0A\seminal vessels average 1.5 x 1.0 x 1.0 cm and bilateral vas average 0.6 cm in\X0D\\X0A\length. The prostatic urethra is probe patent. The prostate is inked as follows:\X0D\\X0A\right lobe black, left lobe blue, and sectioning reveals tan/pink glistening\X0D\\X0A\focally nodular prostatic parenchyma with focal areas of a yellowish infiltrate.\X0D\\X0A\No single area of tumor is identified. The prostate gland is submitted in its\X0D\\X0A\entirety. Summary of sections: 1A - distal urethral resection margin; 1B -\X0D\\X0A\proximal urethral resection margin; 1C - right vas; 1D - left vas; 1E-1O - right\X0D\\X0A\lobe of prostate submitted sequentially from the distal toward the proximal\X0D\\X0A\aspect; 1P-1V - left lobe of prostate submitted sequentially from the distal\X0D\\X0A\toward the proximal aspect. \X0D\\X0A\Specimen 2 received in formalin labeled right pelvic lymph node is a 3.0 x 2.5 x\X0D\\X0A\0.5 cm aggregate of fatty soft tissue. No definitive lymph node is identified.\X0D\\X0A\The specimen is submitted entirely in cassette 2.  \X0D\\X0A\Specimen 3 received in formalin labeled left pelvic lymph node is a 2.5 x 2.0 x\X0D\\X0A\0.6 cm aggregate of fatty soft tissue. A single probable lymph node is present\X0D\\X0A\measuring 1 cm in greatest dimension. The specimen is submitted entirely in\X0D\\X0A\cassette 3.  **INITIALS","Microscopic Description\X0D\\X0A\Sections of the prostatic resection show no carcinoma in the distal urethral\X0D\\X0A\margin; however, the proximal urethral margin is positive for infiltrating\X0D\\X0A\prostatic adenocarcinoma.  The left vas deferens is also seen to be involved by\X0D\\X0A\a small acinar glands which are poorly preserved but the pattern is highly\X0D\\X0A\suspicious for infiltrating prostatic adenocarcinoma.  Both seminal vesicles are\X0D\\X0A\infiltrated heavily by tumor.  The prostate shows both lobes involved by Gleason\X0D\\X0A\grade 4+3 pattern of infiltration with small foci of Gleason grade 5 seen in\X0D\\X0A\each prostatic lobe.  Both lobes show extensive perineural infiltration, focal\X0D\\X0A\lymphvascular infiltration and extensive extraprostatic carcinomatous\X0D\\X0A\infiltration of the tissues.  Only one of the blocks shows tumor close to the\X0D\\X0A\surgical line of excision and it is less than 0.5mm (block O).\X0D\\X0A\Specimen 2 does not show definitive lymph node,  the tissue consists of adipose\X0D\\X0A\and fibrovascular connective tissues. No tumor is seen.\X0D\\X0A\Specimen 3 is a single lymph node free of tumor.  **INITIALS",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,PROSTATE,0,500087,1,,CLINICAL HISTORY AND DATA:\X0D\\X0A\PREOP/POSTOP DX: BPH,"\X0D\\X0A\          \X0D\\X0A\ANATOMIC PATHOLOGY REPORT\X0D\\X0A\\X0D\\X0A\     \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\PATIENT:               **NAME[BBB, AAA M]. SR\X0D\\X0A\RECEIVED:               **DATE[Aug 14 2012]     \X0D\\X0A\REPORTED:               **DATE[Aug 16 2012]     \X0D\\X0A\SPECIMEN NO:             ***PATH-NUMBER[1]\X0D\\X0A\DOB/AGE:                 **AGE[birth-12]/**DATE[May 1946] (Age: **AGE[in 60s])\X0D\\X0A\LOCATION:                DISCH\X0D\\X0A\HOSP NO:                 **ID-NUM\X0D\\X0A\PHYSICIAN:                **NAME[ZZZ M. YYY], M.D.\X0D\\X0A\REFERRAL:             \X0D\\X0A\\X0D\\X0A\PATHOLOGIST: **NAME[XXX M. WWW], M.D.  ***Electronically Signed Out***\X0D\\X0A\ **PHONE  FAX  **PHONE\X0D\\X0A\CAW / rle / DATE:**DATE[Aug 15 2012] \X0D\\X0A\\X0D\\X0A\CPT CODE:   **ID-NUM, **ID-NUM x2","INTERPRETATION:\X0D\\X0A\\X0D\\X0A\PROSTATE TISSUE, TURP:\X0D\\X0A\1.     TUMOR HISTOLOGIC TYPE:  INVASIVE PROSTATIC ADENOCARCINOMA. \X0D\\X0A\2.     GLEASON SCORE:  7 (3+4). \X0D\\X0A\3.     TUMOR EXTENT:  3 OR 4 FOCI MEASURING UP TO 6 MM IN GREATEST DIMENSION INVOLVING LESS\X0D\\X0A\     THAN 5% OF THE TOTAL TISSUE.  \X0D\\X0A\4.     ADDITIONAL FINDINGS:  EXTENSIVE FIBROMUSCULAR AND GLANDULAR HYPERPLASIA CONSISTENT           WITH BENIGN PROSTATIC HYPERTROPHY\X0D\\X0A\COMMENTS:\X0D\\X0A\\X0D\\X0A\Immunostains for basal cells (p63 and 34BE12) were performed on a focus supicious for carcinoma in block A5.  The immunostains reveal a total lack of basal cells in the periphery of the suspicious glands confirming invasive prostatic adenocarcinoma. All controls are appropriate. \X0D\\X0A\\X0D\\X0A\Reviewed for QA.\X0D\\X0A\\X0D\\X0A\",,GROSS DESCRIPTION:\X0D\\X0A\\X0D\\X0A\Received in formalin labeled with the patient's name and date of birth are multiple rubbery fragments of pink-brown tissue measuring 6 x 5.5 x 1 cm in aggregate and weighing 14 grams.  The entire specimen is submitted in eight blocks. \X0D\\X0A\\X0D\\X0A\GM / bl / DATE:**DATE[Aug 14 2012],MICROSCOPIC DESCRIPTION:\X0D\\X0A\MICROSCOPIC EXAMINATION PERFORMED.,SPECIMEN REMOVED:\X0D\\X0A\PROSTATE TISSUE,,
REG1,PROSTATE,0,501289,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is prostate cancer. Intraoperative findings: prostate\X0D\\X0A\cancer. Operative procedure: robotic laparoscopic prostatectomy. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Oct 31 1948] (Age: **AGE[in 60s])  MB\X0D\\X0A\Collect Date: **DATE[Apr 20 2012] 13:08\X0D\\X0A\Receipt Date: **DATE[Apr 20 2012] 13:08\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: 2OR\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Apr 22 2012] 13:06\X0D\\X0A\RESIDENTS(S): R.K. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\PROSTATE AND SEMINAL VESICLES, ROBOTIC LAPAROSCOPIC PROSTATECTOMY (A):\X0D\\X0A\    - PROSTATIC ADENOCARCINOMA (GLEASON SCORE 7=3+4, pT2c, pN0), PROSTATE\X0D\\X0A\(SEE TEMPLATE).\X0D\\X0A\    - NO TUMOR SEEN, SEMINAL VESICLES.\X0D\\X0A\LYMPH NODE, RIGHT PELVIC, DISSECTION (B):\X0D\\X0A\   - NO TUMOR SEEN (0/5).\X0D\\X0A\LYMPH NODE, LEFT PELVIC, DISSECTION (C):\X0D\\X0A\   - NO TUMOR SEEN (0/8).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 22 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09400 M8140\X0D\\X0A\B: M09450 T0800\X0D\\X0A\C: M09450 T0800 \X0D\\X0A\F: A: 88309\X0D\\X0A\B: 88307\X0D\\X0A\C: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Three specimens are received. \X0D\\X0A\Specimen A is received fresh and placed in formalin labeled ""prostate and\X0D\\X0A\seminal vesicles"" and consists of the aforementioned.  The external surface\X0D\\X0A\is dull red-brown.  The cut surface varies from firm to rubbery and is\X0D\\X0A\nodular, light tan to yellow.  No discrete masses or lesions are noted.  The\X0D\\X0A\vas deferens and seminal vesicle are unremarkable and grossly free of tumor. \X0D\\X0A\The urethral mucosa and margins are unremarkable.\X0D\\X0A\Ink code: anterior black, posterior blue\X0D\\X0A\Measurements:\X0D\\X0A\Weight: 47 gm\X0D\\X0A\Prostate size: Apex to base 3.5 cm; Left to right 5 cm; Anterior to posterior\X0D\\X0A\3 cm\X0D\\X0A\Right seminal vesicle: 3.5 x 1.5 x 1 cm \X0D\\X0A\Left seminal vesicle: 3.5 x 2 x 1 cm\X0D\\X0A\Right vas deferens: 5.5 cm in length and 0.6 cm in diameter\X0D\\X0A\Left vas deferens: 4.5 cm in length and 0.6 cm in diameter\X0D\\X0A\Sections:\X0D\\X0A\A1  right and left vas deferens (right black, left blue)\X0D\\X0A\A2  A3  right urethral apex margin \X0D\\X0A\A4  A5  left urethral apex margin\X0D\\X0A\A6  right urethral base margin \X0D\\X0A\A7  left urethral base margin\X0D\\X0A\A8  A20  right lobe, apex to base (same plane split section in A10  A19)\X0D\\X0A\A21  A24  right seminal vesicle and vas deferens, base to apex, entire\X0D\\X0A\A25  A38  left lobe, apex to base (same plane split sections in A26  A37)\X0D\\X0A\A39  A42  left vas deferens and seminal vesicles from base to apex, entire\X0D\\X0A\Specimen B is received in formalin labeled as right pelvic lymph node and\X0D\\X0A\consist of a single fragment of soft tan and yellow tissue measuring 5 x 3 x\X0D\\X0A\1.2 cm. Multiple fatty lymph nodes are identified ranging in size from 0.3 cm\X0D\\X0A\to 4.5 cm in greatest dimension. All the lymph nodes are submitted entirely\X0D\\X0A\as follows: B1  B4  largest fatty lymph node serially sectioned; B5  multiple\X0D\\X0A\lymph nodes, not modified. \X0D\\X0A\Specimens C is received in formalin labeled as left pelvic lymph nodes and\X0D\\X0A\consist of a single fragment of soft tan yellow tissue measuring 4.5 x 3 x 1\X0D\\X0A\cm. A single fatty lymph node is identified measuring 3 cm in greatest\X0D\\X0A\dimension. Cassette summary: C1  C2 - largest lymph node bisected; C3  C5 \X0D\\X0A\remaining of the adipose tissue entirely. \X0D\\X0A\\X0D\\X0A\rgc/**DATE[Apr 21 2012] R.K. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Oct 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  prostate with seminal vesicles and right and left pelvic\X0D\\X0A\lymph nodes\X0D\\X0A\Type of procedure:  robotic laparoscopic prostatectomy \X0D\\X0A\Weight of prostate:  47 grams\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 3/5\X0D\\X0A\              Secondary (next most prevalent) 4/5\X0D\\X0A\              Score 7/10\X0D\\X0A\Tumor location:  right and left\X0D\\X0A\Tumor amount (percentage):  approximately 10-15% \X0D\\X0A\Size of largest tumor nodule:  15 mm (microscopic, slide A14 + A15)\X0D\\X0A\Involvement of seminal vesicle:   right and left  not seen\X0D\\X0A\Extension into soft tissue:  not seen\X0D\\X0A\Extracapsular extension:  not seen\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:      negative\X0D\\X0A\     Apical (inferior):    negative\X0D\\X0A\Inked surgical margins:  negative (tumor within 1 mm of inked capsular\X0D\\X0A\surface)\X0D\\X0A\Vascular invasion:  not seen\X0D\\X0A\Perineural invasion:  present\X0D\\X0A\High grade PIN:  present (quantity  small, right and left)\X0D\\X0A\Lymph node involvement:  0 positive / 13 total\X0D\\X0A\                    Right pelvic:  0/5\X0D\\X0A\                    Left pelvic:  0/8\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\        pT2c:   Bilateral disease\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:    No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                 Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Prostate/seminal vessicles\X0D\\X0A\B: Right pelvic lymph nodes\X0D\\X0A\C: Left pelvic lymph nodes,,
REG1,PROSTATE,0,502264,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\PROSTATE CANCER - ALLIED UROLOGY ***PATH-NUMBER[1]\X0D\\X0A\,"C.    SPECIMEN TYPE/PROCEDURE:  RADICAL PROSTATECTOMY.\X0D\\X0A\    PROSTATE WEIGHT/SIZE:  38 GRAMS, 4.5 X 3.8 X 3.6 CM IN GREATEST DIMENSION.\X0D\\X0A\    TUMOR TYPE:  ADENOCARCINOMA.\X0D\\X0A\    GLEASON GRADE:  3+3=6.\X0D\\X0A\    TUMOR QUANTITATION:  ADENOCARCINOMA INVOLVES APEX (12-3 AND\X0D\\X0A\        6-9 O'CLOCK), RIGHT AND LEFT SUBAPEX AND LEFT ANTERIOR AND\X0D\\X0A\        POSTERIOR LOBE OF PROSTATE (ESTIMATED SIZE OF TUMOR\X0D\\X0A\        2 X 1.5 X 1 CM IN GREATEST DIMENSION).\X0D\\X0A\    EXTRAPROSTATIC EXTENSION:  NOT IDENTIFIED.\X0D\\X0A\    MARGINS:  MARGINS ARE FREE OF TUMOR (TUMOR CLOSELY APPROACHES\X0D\\X0A\        THE MARGIN OF APEX BUT DOES NOT INVOLVE THE INKED SURGICAL\X0D\\X0A\        MARGIN).\X0D\\X0A\    ANGIOLYMPHATIC INVASION:   NOT IDENTIFIED.\X0D\\X0A\    PERINEURAL INVASION:  NOT IDENTIFIED.\X0D\\X0A\    SEMINAL VESICLES:  NOT INVOLVED.\X0D\\X0A\    VAS DEFERENS:  NOT INVOLVED.\X0D\\X0A\PROCEDURES: 88305GS, 88307GS/2\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A, B.  LEFT PELVIC LYMPH NODES:\X0D\\X0A\NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\\X0D\\X0A\C.    SPECIMEN TYPE/PROCEDURE:  RADICAL PROSTATECTOMY.\X0D\\X0A\PROSTATE WEIGHT/SIZE:  38 GRAMS, 4.5 X 3.8 X 3.6 CM IN GREATEST DIMENSION.\X0D\\X0A\TUMOR TYPE:  ADENOCARCINOMA.\X0D\\X0A\GLEASON GRADE:  3+3=6.\X0D\\X0A\TUMOR QUANTITATION:  ADENOCARCINOMA INVOLVES APEX (12-3 AND\X0D\\X0A\6-9 O'CLOCK), RIGHT AND LEFT SUBAPEX AND LEFT ANTERIOR AND\X0D\\X0A\POSTERIOR LOBE OF PROSTATE (ESTIMATED SIZE OF TUMOR\X0D\\X0A\2 X 1.5 X 1 CM IN GREATEST DIMENSION).\X0D\\X0A\EXTRAPROSTATIC EXTENSION:  NOT IDENTIFIED.\X0D\\X0A\MARGINS:  MARGINS ARE FREE OF TUMOR (TUMOR CLOSELY APPROACHES\X0D\\X0A\THE MARGIN OF APEX BUT DOES NOT INVOLVE THE INKED SURGICAL\X0D\\X0A\MARGIN).\X0D\\X0A\ANGIOLYMPHATIC INVASION:   NOT IDENTIFIED.\X0D\\X0A\PERINEURAL INVASION:  NOT IDENTIFIED.\X0D\\X0A\SEMINAL VESICLES:  NOT INVOLVED.\X0D\\X0A\VAS DEFERENS:  NOT INVOLVED.\X0D\\X0A\ADDITIONAL FINDINGS:  NODULAR PROSTATIC HYPERPLASIA WITH MICROSCOPIC\X0D\\X0A\FOCI OF HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA.\X0D\\X0A\LYMPH NODES:  SEE SPECIMENS A AND B.\X0D\\X0A\\X0D\\X0A\AJCC Stage:  pT2c  NO  MX\X0D\\X0A\\X0D\\X0A\As required by the American College of Surgeons, the American Joint Cancer Committee Staging\X0D\\X0A\is included in this report.  However, this stage should only be considered preliminary and\X0D\\X0A\incomplete; final staging can only be accomplished by the oncologist/surgeon after\X0D\\X0A\evaluation of all clinical and surgical/pathologic information.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A. Received in formalin labeled ""right pelvic lymph node"" is a 3 x 2 x 0.5 cm mostly fatty\X0D\\X0A\lymph node.  It is serially sectioned and entirely submitted in two cassettes labeled A1 and\X0D\\X0A\A2.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\B.  Received in formalin labeled ""left pelvic lymph node"" are multiple irregular lobular\X0D\\X0A\portions of fibroadipose tissue which measure in aggregate 4.5 x 3.5 x 1.0 cm.  Sectioning\X0D\\X0A\reveals four possible lymph nodes ranging in size from 1.7 cm through 2.7 cm.  The lymph\X0D\\X0A\nodes are entirely submitted as:\X0D\\X0A\\X0D\\X0A\B1.  two whole lymph nodes\X0D\\X0A\B2.  one whole lymph node bisected\X0D\\X0A\B3.  one whole (largest) lymph node                  /st/as\X0D\\X0A\\X0D\\X0A\C. Received in formalin labeled ""prostate"" is a prostatectomy specimen with an overall\X0D\\X0A\weight of 38 grams. It is inked as follows:  right - black, left - blue, mid anterior -\X0D\\X0A\orange. The prostate measures 3.8 cm from the anterior to the posterior aspect, 3.8 cm from\X0D\\X0A\the right to the left and 3.6 cm from the superior to the inferior aspect. A 4.5 cm, clear,\X0D\\X0A\plastic, tubular catheter is in place within the prostatic urethra. The urethra is dilated\X0D\\X0A\and measures 1 cm in diameter. The posterior bladder base is protuberant. Sectioning reveals\X0D\\X0A\a 2 x 1.5 x 1 cm, dusky yellow, well demarcated, rubbery, firm tumor within the left lateral\X0D\\X0A\prostate which extends from the sub apex to the base. The remaining parenchyma is rubbery,\X0D\\X0A\tan and uniform.\X0D\\X0A\\X0D\\X0A\The right seminal vesicle measures 3.2 x 1.8 x 1.3 cm. The right vas deferens measures 1.0 x\X0D\\X0A\0.3 cm. The left seminal vesicle measures 3.2 x 1.6 x 1.1 cm. The left vas deferens measures\X0D\\X0A\1.4 x 0.4 cm. Each is unremarkable. Representative sections are submitted as:\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\\X0D\\X0A\C1. - apex 12-3:00\X0D\\X0A\C2. - apex 3-6:00\X0D\\X0A\C3. - apex 6-9:00\X0D\\X0A\C4. - apex 9-12:00\X0D\\X0A\C5\T\6. - left bladder base\X0D\\X0A\C7\T\8. - right bladder base\X0D\\X0A\C9. - right sub apex with tumor\X0D\\X0A\C10. - left sub apex\X0D\\X0A\C11. - right anterior prostate, mid portion\X0D\\X0A\C12. - right posterior prostate, mid portion\X0D\\X0A\C13. - left anterior prostate with tumor at base\X0D\\X0A\C14. - left posterior prostate from base\X0D\\X0A\C15. - right seminal vesicle/prostate interface\X0D\\X0A\C16. - right vas deferens\X0D\\X0A\C17. - left seminal vesicle/prostate interface\X0D\\X0A\C18. - left vas deferens                                        /st/sk\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A. RIGHT PELVIC LYMPH NODES\X0D\\X0A\B. LEFT PELVIC LYMPH NODES\X0D\\X0A\C. PROSTATE\X0D\\X0A\,,
REG1,PROSTATE,0,502287,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\NOT PROVIDED\X0D\\X0A\,"PROCEDURE:  RADICAL PROSTATECTOMY.\X0D\\X0A\PROSTATE SIZE AND WEIGHT:   5.1 X 4.2 X 3.8 CM, 54 GRAMS.\X0D\\X0A\TUMOR TYPE:  ADENOCARCINOMA.\X0D\\X0A\GLEASON SCORE:  4+5=9.\X0D\\X0A\TUMOR QUANTITATION:  INVASIVE TUMOR IS PRESENT IN THE RIGHT, INFERIOR AND SUPERIOR,\X0D\\X0A\POSTERIOR LOBE.  INVASIVE TUMOR IS PRESENT IN 9 OF 28 TISSUE CASSETTES.\X0D\\X0A\EXTRAPROSTATIC EXTENSION:   NONE.\X0D\\X0A\MARGINS:   ALL MARGINS ARE UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\ANGIOLYMPHATIC INVASION:  ABSENT.\X0D\\X0A\PERINEURAL INVASION:  ABSENT.\X0D\\X0A\SEMINAL VESICLES:  UNINVOLVED.\X0D\\X0A\ADDITIONAL FINDINGS:    HIGH GRADE PIN.\X0D\\X0A\LYMPH NODES:  NO LYMPH NODES SUBMITTED.\X0D\\X0A\\X0D\\X0A\TREATMENT EFFECT:  NO KNOWN PRESURGICAL THERAPY.\X0D\\X0A\PATHOLOGIC STAGING (pT2b, pN0, pMX)\X0D\\X0A\*ANCILLARY STUDIES:  NONE.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual seventh edition\X0D\\X0A\guidelines.\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS/2, 88309GS\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.  RIGHT PELVIC LYMPH  NODES:\X0D\\X0A\FOUR BENIGN LYMPH NODES.\X0D\\X0A\NO MALIGNANCY IDENTIFIED.\X0D\\X0A\\X0D\\X0A\B.  LEFT PELVIC LYMPH NODES:\X0D\\X0A\THREE BENIGN LYMPH NODES.\X0D\\X0A\NO MALIGNANCY IDENTIFIED.\X0D\\X0A\\X0D\\X0A\C.  ADENOCARCINOMA OF THE PROSTATE, SYNOPTIC REPORT AJCC/UICC TNM, 7th edition\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE:  PROSTATE.\X0D\\X0A\PROCEDURE:  RADICAL PROSTATECTOMY.\X0D\\X0A\PROSTATE SIZE AND WEIGHT:   5.1 X 4.2 X 3.8 CM, 54 GRAMS.\X0D\\X0A\TUMOR TYPE:  ADENOCARCINOMA.\X0D\\X0A\GLEASON SCORE:  4+5=9.\X0D\\X0A\TUMOR QUANTITATION:  INVASIVE TUMOR IS PRESENT IN THE RIGHT, INFERIOR AND SUPERIOR,\X0D\\X0A\POSTERIOR LOBE.  INVASIVE TUMOR IS PRESENT IN 9 OF 28 TISSUE CASSETTES.\X0D\\X0A\EXTRAPROSTATIC EXTENSION:   NONE.\X0D\\X0A\MARGINS:   ALL MARGINS ARE UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\ANGIOLYMPHATIC INVASION:  ABSENT.\X0D\\X0A\PERINEURAL INVASION:  ABSENT.\X0D\\X0A\SEMINAL VESICLES:  UNINVOLVED.\X0D\\X0A\ADDITIONAL FINDINGS:    HIGH GRADE PIN.\X0D\\X0A\LYMPH NODES:  NO LYMPH NODES SUBMITTED.\X0D\\X0A\\X0D\\X0A\TREATMENT EFFECT:  NO KNOWN PRESURGICAL THERAPY.\X0D\\X0A\PATHOLOGIC STAGING (pT2b, pN0, pMX)\X0D\\X0A\*ANCILLARY STUDIES:  NONE.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual seventh edition\X0D\\X0A\guidelines.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A. Received in formalin labeled ""right pelvic lymph node"" is a 4.5 x 3.1 x 0.9 cm aggregate\X0D\\X0A\of red-pink, lobulated, adipose tissue. Within the tissue four red-pink, rubbery possible\X0D\\X0A\nodes are identified ranging from 0.5 cm in greatest dimension to the largest measuring 3.1\X0D\\X0A\x 2.1 x 0.6 cm. The nodes are submitted as follows:\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\\X0D\\X0A\1. - two whole possible nodes\X0D\\X0A\2\T\3. - one trisected node\X0D\\X0A\4\T\5. - one trisected node\X0D\\X0A\\X0D\\X0A\B. Received in formalin labeled ""left pelvic lymph nodes"" is a 4.6 x 2.9 x 0.9 cm portion of\X0D\\X0A\yellow-pink, lobulated, adipose tissue. Within the tissue, three red-pink, rubbery nodes are\X0D\\X0A\identified ranging from 1.3 cm in greatest dimension to the largest measuring 3.1 x 2.5 x\X0D\\X0A\0.5 cm. The nodes are submitted as follows:\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\\X0D\\X0A\1 - one trisected node\X0D\\X0A\2. - one bisected node\X0D\\X0A\3-4. - largest serially sectioned node    /pb/sk\X0D\\X0A\\X0D\\X0A\C. Received in formalin labeled ""prostate"" is a 54 gram prostatectomy measuring 5.1 x 4.2 x\X0D\\X0A\3.8 cm (lateral to lateral, anterior to posterior, superior to inferior).  There is an\X0D\\X0A\attached right vas deferens and seminal vesicle that measure 0.6 x 0.4 cm and 2.5 x 1.8 x\X0D\\X0A\0.8 cm, respectively.  There is also attached left vas deferens and seminal vesicle\X0D\\X0A\measuring 0.5 x 0.5 cm and 2.2 x 1.7 x 1.0 cm, respectively.  The remaining prostate is\X0D\\X0A\covered by a thin intact fibrous capsule.  The right half is inked black and the left half\X0D\\X0A\is inked green and the anterior aspect is inked orange.  Sectioning reveals a multinodular\X0D\\X0A\focally hemorrhagic and focally gritty cut surface.  The urethra at the apex is distended\X0D\\X0A\due to a protruding nodule on the left half.  A suspicious pink indurated gritty nodule\X0D\\X0A\measuring 2.1 x 1.8 x 1.8 cm is located on the right posterior aspect of the mid prostate.\X0D\\X0A\A 1.9 x 1.7 x 1.1 cm firm nodule also is within 0.2 cm of the left posterior aspect of the\X0D\\X0A\mid prostate.  The remaining parenchyma contains multiple additional pink glistening rubbery\X0D\\X0A\nodules.  Representative sections are submitted as follows:\X0D\\X0A\\X0D\\X0A\1.  right seminal vesicle and right vas deferens\X0D\\X0A\2.  left seminal vesicle and left vas deferens\X0D\\X0A\3-6.  left base\X0D\\X0A\7-10.right base\X0D\\X0A\11.  apex 12-3 o'clock\X0D\\X0A\12.  apex 3-6 o'clock\X0D\\X0A\13.  apex 6-9 o'clock\X0D\\X0A\14.  apex 9-12 o'clock\X0D\\X0A\15-23.  entire right posterior quadrant submitted sequentially from apex to base\X0D\\X0A\24-27.  suspicious nodular area of left posterior aspect of prostate\X0D\\X0A\28,29.  representative sections of left anterior prostate        /pb/as\X0D\\X0A\\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\38 H\T\E\X0D\\X0A\,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A. RIGHT PELVIC LYMPH NODE\X0D\\X0A\B. LEFT PELVIC LYMPH NODE\X0D\\X0A\C. PROSTATE\X0D\\X0A\\X0D\\X0A\,,
REG1,PROSTATE,0,503982,1,,"Clinical History:\X0D\\X0A\Prostate Cancer, Prostate Biopsy, 11 Positive Cores, Gleason Grade 7\X0D\\X0A\Stage T1b",,"Pre-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Prostate and seminal vesicles, radical prostatectomy:  Prostatic\X0D\\X0A\adenocarcinoma, Gleason grade 3+4=7, involving both sides of the gland.\X0D\\X0A\No extraprostatic extension or seminal vesicle invasion identified.\X0D\\X0A\Extensive perineural invasion is present.  Surgical resection margins,\X0D\\X0A\free of tumor.  See template.\X0D\\X0A\B)  Right obturator lymph node:  One lymph node, no tumor present.\X0D\\X0A\C)  Left obturator lymph node:  Fibroadipose tissue.  No lymph node or\X0D\\X0A\tumor identified.",,"Gross Description:\X0D\\X0A\Three containers.\X0D\\X0A\Container A is labeled ""prostate and seminal vesicles"".  The specimen is\X0D\\X0A\received in fixative and consists of a 54 gram, 7 x 4.5 x 4 cm prostate\X0D\\X0A\gland with attached bilateral seminal vesicles and vas deferens.  The\X0D\\X0A\vas deferens each measure approximately 5.4 cm in length.  The prostate\X0D\\X0A\surface is shaggy and tan.  The prostatic urethra is 3.1 cm in length\X0D\\X0A\and is patent.  The margins are inked posterior orange, right black, and\X0D\\X0A\left blue.  The cut surface is nodular and tan with areas of hemorrhage.\X0D\\X0A\Discrete mass lesions are not evident.  Representative sections are\X0D\\X0A\submitted as follows:\X0D\\X0A\A1 - right apex,\X0D\\X0A\A2 - left apex,\X0D\\X0A\A3-A7 - representative sections of the right aspect of the prostate\X0D\\X0A\extending apex to base,\X0D\\X0A\A8 - right bladder base,\X0D\\X0A\A9 - right seminal vesicle and vas deferens,\X0D\\X0A\A10-A16 - left aspect of prostate extending apex to base,\X0D\\X0A\A17 - left bladder base,\X0D\\X0A\A18 - left seminal vesicles and vas deferens.\X0D\\X0A\Specimen B is labeled ""right obturator node"".  The specimen is received\X0D\\X0A\in fixative and consists of a piece of soft yellow lobulated tissue\X0D\\X0A\containing a 2 x 1.2 x 0.8 cm lymph node.  The node is serially\X0D\\X0A\sectioned and entirely submitted in one cassette.\X0D\\X0A\Specimen C is labeled ""left obturator node"".  This specimen is received\X0D\\X0A\in fixative and consists of a 1.6 x 1.5 x 0.4 cm aggregate of soft\X0D\\X0A\yellow-pink tissue.  No lymph node is identified.  The specimen is\X0D\\X0A\entirely submitted in one cassette.  JMM:vsg",Microscopic Description:\X0D\\X0A\CASE SUMMARY FOR PROSTATE CARCINOMA (PROSTATECTOMY)\X0D\\X0A\Specimen:  Prostate and bilateral seminal vesicles.\X0D\\X0A\Procedure:  Radical prostatectomy.\X0D\\X0A\Weight of prostate:  54 grams.\X0D\\X0A\Lymph node sampling:  Right obturator lymph node.\X0D\\X0A\Histologic type:  Prostatic adenocarcinoma (usual type).\X0D\\X0A\Gleason grade:\X0D\\X0A\Primary (predominant) pattern:  3.\X0D\\X0A\Secondary (worst remaining) pattern:  4.\X0D\\X0A\Total Gleason score:  7.\X0D\\X0A\Size of largest tumor nodule:  2.0 cm.\X0D\\X0A\Extraprostatic extension:  Not identified.\X0D\\X0A\Seminal vesicle invasion:  Not identified.\X0D\\X0A\Surgical margins:  Free of tumor.\X0D\\X0A\Perineural invasion:  Present (extensive).\X0D\\X0A\Lymph-vascular invasion:  Not identified.\X0D\\X0A\Treatment effect on carcinoma:  No known prior therapy.\X0D\\X0A\Lymph node status:\X0D\\X0A\Right obturator:  0 positive/1 total.\X0D\\X0A\Additional pathologic findings:  Focal high-grade PIN.\X0D\\X0A\Pathologic staging:\X0D\\X0A\     pT2c Tumor involves both lobes.\X0D\\X0A\     pN0  No regional lymph node metastasis.\X0D\\X0A\     MX\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\DBC:jck\X0D\\X0A\Dct:Trs:  **DATE[Apr 11 2012]\X0D\\X0A\**NAME[ZZZ YYY:  XXX WWW VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 12 2012],Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Prostate and Seminal Vesicles\X0D\\X0A\SOURCE OF SPECIMEN: B Right Obturator Nodes\X0D\\X0A\SOURCE OF SPECIMEN: C Left Obturator Node,,
REG1,PROSTATE,0,506682,1,,Clinical History:\X0D\\X0A\Prostate CA,,"Pre-Operative Diagnosis:\X0D\\X0A\Prostate CA\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Prostate gland with attached bilateral seminal vesicles and bilateral\X0D\\X0A\vasa deferentia:  Multifocal bilateral prostatic adenocarcinoma, Gleason\X0D\\X0A\score 3+4=7, with extensive perineural invasion and invasion into but\X0D\\X0A\not through prostate capsule.  Glandular and stromal hyperplasia with\X0D\\X0A\mild chronic prostatitis and bilateral high grade prostatic\X0D\\X0A\intraepithelial neoplasia in remainder of prostate parenchyma.  Benign\X0D\\X0A\circumferential soft tissue margin.  Benign urinary bladder base margin.\X0D\\X0A\Benign but close urethral/apical margin (0.2 cm).  Benign bilateral\X0D\\X0A\seminal vesicles.  Benign bilateral vasa deferentia.",,"Gross Description:\X0D\\X0A\Received in formalin designated ""prostate and seminal vesicles"" is a\X0D\\X0A\prostate gland with attached bilateral seminal vesicles and apparent\X0D\\X0A\bilateral vasa deferentia.  The apparent right vas is 1.2 cm in length\X0D\\X0A\and the left is 5.0 cm in length.  The prostate gland is 34 grams and\X0D\\X0A\measures 5.0 x 4.5 x 3.0 cm.  The prostatic urethra is 3.5 cm in length\X0D\\X0A\and is patent.  The surface of the prostate is shaggy and tan.  The\X0D\\X0A\margins are inked as follows:  posterior orange, right black, left blue.\X0D\\X0A\The cut surface is nodular, tan and firm.  Discrete mass lesions are not\X0D\\X0A\present.   The entire prostate is submitted.\X0D\\X0A\Summary of sections:  1 - right apex; 2 - left apex; 3-16 - right aspect\X0D\\X0A\of prostate extending apex to base; 17 - right bladder base; 18 - right\X0D\\X0A\seminal vesicle; 19 - right vas deferens; 20-33 - left aspect of\X0D\\X0A\prostate extending apex to base; 34 - left bladder base; 35 - left\X0D\\X0A\seminal vesicle;\X0D\\X0A\36 - left vas deferens.  **INITIALS","Microscopic Description:\X0D\\X0A\The majority of the prostate gland shows glandular and stromal\X0D\\X0A\hyperplasia with scattered foci of chronic prostatitis and bilateral\X0D\\X0A\foci of high grade prostatic intraepithelial neoplasia.  In addition,\X0D\\X0A\there is an invasive glandular neoplasm fragment focally on the right\X0D\\X0A\side and fairly extensively on the left side.  The neoplasm is mainly\X0D\\X0A\growing as well-formed individual glands with readily identifiable\X0D\\X0A\lumina.  These glands are extending between preexisting benign glands\X0D\\X0A\and are lined by cuboidal to low columnar cells with moderate amounts of\X0D\\X0A\cytoplasm and enlarged vesicular nuclei with focally prominent nucleoli\X0D\\X0A\(Gleason grade 3).  There is a minority component consisting of large\X0D\\X0A\fused glands into complicated cribriform-type structures with very\X0D\\X0A\irregular circumferences lined by similar appearing neoplastic cells\X0D\\X0A\(Gleason grade 4).  The neoplasm is extending into but not through the\X0D\\X0A\prostate capsule.  The neoplasm shows extensive perineural invasion even\X0D\\X0A\down within the prostate parenchyma itself in addition to out near the\X0D\\X0A\capsule.  The circumferential soft tissue margin is benign.  The urinary\X0D\\X0A\bladder base margin is benign.  The urethral apical margin is benign but\X0D\\X0A\close on the left side (0.2 cm).  The seminal vesicles and vasa\X0D\\X0A\deferentia are unremarkable bilaterally.  Tissue Code:  T1\X0D\\X0A\Synoptic Template for Primary Prostate Carcinoma:\X0D\\X0A\Specimen:  Prostate gland with attached bilateral seminal vesicles and\X0D\\X0A\bilateral vasa deferentia.\X0D\\X0A\Procedure:  Radical prostatectomy.\X0D\\X0A\Weight of prostate:  34 gms.\X0D\\X0A\Lymph node sampling:  None.\X0D\\X0A\Histologic type:  Adenocarcinoma.\X0D\\X0A\Gleason grade:\X0D\\X0A\Primary (predominant) pattern:  3.\X0D\\X0A\Secondary (worst remaining) pattern:  4.\X0D\\X0A\Tertiary pattern:  Not identified.\X0D\\X0A\Total Gleason score:  7.\X0D\\X0A\Size of largest tumor nodule:  2.1 x 0.5 cm.\X0D\\X0A\Extraprostatic extension:  Not identified.\X0D\\X0A\Seminal vesicle invasion:  Not identified.\X0D\\X0A\Surgical margins:\X0D\\X0A\     Apical/urethral margin:  Negative with close left side margin (0.2\X0D\\X0A\cm).\X0D\\X0A\     Urinary bladder base margin:  Negative.\X0D\\X0A\     Circumferential soft tissue margin:  Negative.\X0D\\X0A\Perineural invasion:  Yes, extensive.\X0D\\X0A\Lymph-vascular invasion:  Not identified.\X0D\\X0A\Treatment effect on carcinoma:  Unknown.\X0D\\X0A\Lymph node status:  Not sampled.\X0D\\X0A\Additional pathologic findings:  Glandular and stromal hyperplasia with\X0D\\X0A\mild chronic prostatitis and bilateral foci of high grade prostatic\X0D\\X0A\intraepithelial neoplasia.\X0D\\X0A\Pathologic staging:  pT2c pNX MX\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jan 23 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Prostate and seminal vesicles,,
REG1,PROSTATE,0,506723,2,,Clinical History:\X0D\\X0A\None Given,"CPT Code(s):  88305.26, 88342.26.\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Aug 12 2012]","Pre-Operative Diagnosis:\X0D\\X0A\Prostatic Hypertrophy\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Prostate, transurethral resection:  Focal adenocarcinoma, 3+4=7,\X0D\\X0A\involving small foci in less than 6% of the chips examined.",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled ""prostate tissue"".  The specimen consists of\X0D\\X0A\multiple irregular pink-tan morcellated tissue fragments, which have\X0D\\X0A\aggregate dimensions of 12.0 x 9.0 x 1.5 cm, and aggregate weight of 44\X0D\\X0A\grams.  There are no distinct lesions or areas of yellowish\X0D\\X0A\discoloration grossly identified.  Representative sections are submitted\X0D\\X0A\in cassettes 1-7.  **INITIALS","Microscopic Description:\X0D\\X0A\Prostate, transurethral resection:  Sections reveal prostate tissue\X0D\\X0A\demonstrating glandular and stromal elements.  Patchy chronic\X0D\\X0A\inflammation is noted.  Cautery-type artifact is seen.  Rare glands show\X0D\\X0A\focal crowding.  Immunohistochemical stains for 34betaE12/p63 cocktail\X0D\\X0A\demonstrate a lack of basal cells focally within the cluster of atypical\X0D\\X0A\glands.  Additionally, there is a second focus of adenocarcinoma\X0D\\X0A\characterized by atypical glands infiltrating the stroma, some of which\X0D\\X0A\in a syncytial pattern.  Small foci of tumor are noted in 2 of 35 chips\X0D\\X0A\examined.\X0D\\X0A\Tissue Code:  T1.\X0D\\X0A\CASE SUMMARY FOR PROSTATE CARCINOMA (TURP)\X0D\\X0A\Procedure:  Transurethral prostate resection (TUR)\X0D\\X0A\Specimen size:    44grams\X0D\\X0A\Histologic type:  Adenocarcinoma\X0D\\X0A\Gleason grade:\X0D\\X0A\Primary (predominant) pattern:  3\X0D\\X0A\Secondary (worst remaining) pattern:  4\X0D\\X0A\Total Gleason score:  7\X0D\\X0A\Tumor quantitation:  Focal involvement in less than 6% of examined chips\X0D\\X0A\Perineural invasion:  Not identified\X0D\\X0A\Additional pathologic findings:  Chronic active inflammation.",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Prostate Tissue,,
REG1,PROSTATE,0,511783,1,,HISTORY: BPH,"ICD9 CODES: 185, , \X0D\\X0A\COMMENTS: Multiple foci of glandular crowding are present. A few of these are associated with small and mildly dilated glands with mild nuclear atypia. Immunoperoxidase stains confirm three of these foci to be diagnostic of malignancy (two on slide 1G, one on slide 1H).  This pathology could be consistent with stage pT1a, and clinical correlation is required.  This result is called to Dr. **NAME[M. ZZZ]'s nurse **NAME[YYY] at 9:30 a.m. on **DATE[May 16 12].  This case will be submitted to Associated Pathologists for retrospective quality assurance review.\X0D\\X0A\LAB_COMM: cut all IP's superficial since small atypical foci.  Dr **NAME[XXX]/JSMC","DIAGNOSIS: Prostate gland, transurethral resection:     Focal prostatic adenocarcinoma, Gleason score 5 (2+3), involving three of         approximately one-hundred prostate chips (approximately 1% of tissue area) \X0D\\X0A\        no perineural invasion identified.     Multiple foci of adenosis.     Changes consistent with benign prostatic hypertrophy.",,"GROSS: The specimen is received in formalin in a single container labeled ""prostate tissue"". It consists of a 18 gram, 6 x 6 x 1.3 cm aggregate of white-tan to pink fibrous soft tissue fragments.  Specimen entirely submitted in nine cassettes.","MICRO: Multiple foci of glandular crowding are noted, and some of these are associated with mild nuclear atypia. Triple immunoperoxidase stain for p63, cytokeratin 903, and P504s are performed on blocks 1E and 1G \X0D\\X0A\and immunoperoxidase stain for p63 is performed on blocks 1D and 1H. Two foci on slide 1G shows small, irregular to focally mildly dilated glands that are P504s positive and lack a basal cell layer. An additional focus on slide 1H includes an area of medium and focally dilated glands with mild atypia showing an absence of a basal cell layer.",PROCEDURE: TURP\X0D\\X0A\SPECIMEN(S): Prostate tissue,,
REG1,PROSTATE,0,521784,1,,"HISTORY: Prostate cancer, PSA in 30's\X0D\\X0A\OR CONSULT: FROZEN SECTION DIAGNOSIS (performed at **INSTITUTION, **STREET-ADDRESS, **PLACE, KY **ZIP-CODE):  1,2. Right (2) and left (5) pelvic lymph nodes:             Negative for tumor.                     _x0015_William Farthing, MD_x0015_","ICD9 CODES: 185, , \X0D\\X0A\LAB_COMM: rc's to see ink fill in around edges of these pieces to see all margin.  Dr **NAME[ZZZ]/JSM","CANCER CHECKLIST: Tumor Site              Prostatic structure      SPECIMEN          Procedure              Radical prostatectomy          Prostate Size            Weight (g): 19            Size (cm): 4.6            Size (cm): 3.4            Size (cm): 2.1          Lymph Node Sampling              Pelvic lymph node dissection      TUMOR          Histologic Type              Adenocarcinoma (acinar, not otherwise specified)          Histologic Grade                    Primary Pattern                        Grade 4                    Secondary Pattern                        Grade 3                    Tertiary Pattern                        Not applicable                    Total Gleason Score: 7      EXTENT          Tumor Quantitation              Proportion (percentage) of Prostate Involved by Tumor: 50      MARGINS              Margin(s) involved by invasive carcinoma                Focality of Tumor                    Multifocal                    Apical                    Posterior      ACCESSORY FINDINGS          Extraprostatic Extension              Present                    Focal                      Specify Site(s): posterior base and apparent bladder base          Seminal Vesicle Invasion (invasion of muscular wall required)              Not identified          Lymph-Vascular Invasion              Not Identified          Perineural Invasion              Present      STAGE (pTNM)          Regional Lymph Nodes (pN)              pN0: No regional lymph node metastasis              Number Examined: 8              Number Involved: 0          Distant Metastasis (pM)              Not applicable      ADDITIONAL NON-TUMOR          Additional Pathologic Findings              High-grade prostatic intraepithelial neoplasia (PIN) (Note F)\X0D\\X0A\DIAGNOSIS: 1. Lymph nodes, right pelvic, lymphadenectomy:         Three lymph nodes, negative for tumor (0/3).  2. Lymph nodes, left pelvic, lymphadenectomy:         Five lymph nodes, negative for tumor (0/5).  3. Prostate gland, radical retropubic prostatectomy:         Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 50%             of gland, right and left lobes, with rare area of periprostatic spread at posterior             bladder base, and also involving bladder base margin over 1.0 x 0.4 cm area \X0D\\X0A\            apical margin and focal posterior margins also positive for adenocarcinoma \X0D\\X0A\            extensive peripheral perineural invasion identified.         Multifocal high grade prostatic intraepithelial neoplasia of prostate gland.         19 gm prostate gland.         Bilateral seminal vesicles and vasa deferentia, negative for tumor.         (See microscopic description)  AJCC stage consistent with III (pT3a N0 MX G7)",,"GROSS: The specimen is received in three containers.  1. Specimen #1 is labeled ""right pelvic lymph nodes"". It consists of a 3.5 x 3.5 x 0.8 cm portion of adipose tissue. Dissection reveals two small portions of apparent lymph node, and both of these are frozen. The remaining frozen tissue is submitted as frozen section control in cassette 1FSA (2). After formalin fixation, the fibroadipose tissue is further dissected, and an additional 0.5 cm pink-tan apparent lymph node is identified. This lymph node is entirely submitted for permanent section in cassette 1A. Total two cassettes.  2. Specimen #2 is labeled ""left pelvic lymph nodes"". It consists of a 3.0 x 2.2 x 1.0 cm portion of adipose tissue. Dissection reveals several rather small fragments of apparent lymph node. The lymph node fragments are entirely frozen. The remainder of the frozen tissue is submitted as frozen section control in cassette 2FSA (5).  3. Specimen #3 is received in formalin labeled ""prostate"". It consists of a radical prostatectomy with bilateral seminal vesicles and vas deferentia attached. A large tan suture is attached to the superior midline of the specimen. The specimen weighs 29 gm. The right superior apex shows an underlying tan-white nodule that measures 0.9 cm. The prostate gland measures 4.6 cm medial to lateral, 3.4 cm anterior to posterior, and 2.1 cm proximal to distal. The right seminal vesicle measures 2.6 x 2.0 x 0.8 cm. The right vas deferens measures 2.0 x 0.5 cm. The left vas deferens measures 1.6 x 0.5 cm. The left seminal vesicle measures 3.5 x 2.0 x 1.0 cm. Margins are inked black. Sectioning of right vas deferens and seminal vesicle reveal pink-tan glandular tissue with some tan mucoid material, and this is sampled in cassette 3A. Sectioning of left seminal vesicle and vas deferens reveals pink-tan glandular tissue with some mucoid tissue, and this is sampled in cassette 3B. After removal of seminal vesicles and vas deferentia, the prostate gland weighs 19 gm. The apex is shaved from the specimen, and the right apex includes a 1.0 cm tan-pink to yellow nodular area. 3C-right apex, 3D-left apex. The bladder base portion is granular, and it is shaved from the specimen and sampled en fas in cassettes 3E, F. Sectioning of the remaining prostate gland includes a 1.5 x 1.0 cm yellow nodular area of the right posterior prostate gland, abutting the inked area. 3G-right anterior, 3H-left anterior \X0D\\X0A\3I-K-right posterior, proceeding from apex to base \X0D\\X0A\3L-N-left posterior, proceeding from apex to base. The posterior base shows additional focal yellow-tan coloration, more so on the right, and a section is cut in half to include left and right and submitted in cassette 3O. Approximately 90% of the gland was submitted. Total fifteen cassettes.","MICRO: 1, 2. Microscopic examination performed.  3. Bilateral posterior lobes of prostate gland are extensively involved with adenocarcinoma, the largest focus on the slide approximating 2.0 cm. The apical margin (3C) is involved over 4 mm area. The left apical margin (3D) is involved over a 1.0 x 1.0 cm area. The bladder base margin was shaved from the specimen and is involved over a 1.0 x 0.4 cm area. One slide (3I) shows right posterior margin involvement over a 3-4 mm area. One slide (3L) shows left posterior margin involvement over a 1.1 cm area. The tumor invades into the prostate capsule in many areas, often associated with perineural invasion. Slide 3O includes a single focus of tumor with perineural invasion present in periprostatic adipose tissue.",PROCEDURE: Radical retropubic prostatectomy \X0D\\X0A\bil. pelvic node dissection\X0D\\X0A\SPECIMEN(S): 1.  Right pelvic lymph node F.S. 2.  Left pelvic lymph node F.S. 3.  Prostate,,
REG1,PROSTATE,0,526573,1,,HISTORY: Elevated PSA,"ICD9 CODES: 185, 601.0, 602.2\X0D\\X0A\COMMENTS: 12.  The focus of adenocarcinoma shows positive staining among the surface epithelial cells and no staining of a myoepithelial layer.  The features are congruent with a diagnosis of prostatic adenocarcinoma.\X0D\\X0A\LAB_COMM: Do immunostain on""Held 4"" on block 6A.  Do immunostain on ""Held 1"" on block 9A.   Item C Pin 4-3 deleted from 8-A via SSR2 by KSA  Item C Pin 4 deleted from 8-A via SSR2 by KSA  Item C Pin 4-2 deleted from 8-A via SSR2 by KSA  **NAME[YYY] at Dr. **NAME[ZZZ]'s office was notified of the diagnosis of prostatic adenocarcinoma on **DATE[Nov 14 2011] at 12:50 pm.","DIAGNOSIS: 1. Prostate, left lateral base, needle core biopsy:         Benign prostatic tissue.  2. Prostate, left lateral mid, needle core biopsy:         Benign prostatic tissue.         Minimal chronic inflammation.  3. Prostate, left lateral apex, needle core biopsy:         Benign prostatic tissue.  4. Prostate, left base, needle core biopsy:         Benign prostatic tissue.         Focal mild chronic inflammation.  5. Prostate, left mid, needle core biopsy:        Benign prostatic tissue.  6. Prostate, left apex, needle core biopsy:         Benign prostatic tissue.  7. Prostate, right base, needle core biopsy:         Benign prostatic tissue.  8. Prostate, right mid, needle core biopsy:         Benign prostatic tissue.         Atrophic changes and mild chronic inflammation.  9. Prostate, right apex, needle core biopsy:         Benign prostatic tissue.         Focal mild acute and chronic inflammation.  10. Prostate, right lateral base, needle core biopsy:         Benign prostatic tissue.         Minimal focal chronic inflammation.  11. Prostate, right lateral mid, needle core biopsy:         Atypical small acinar proliferation.         Minimal focal acute and chronic inflammation.  12. Prostate, right lateral apex, needle core biopsy:         Adenocarcinoma, Gleason grade 3+3= score of 6, involving 1 out of 3 tissue             cores, measuring 1 mm in length and occupying 4% of the needle core tissue.         Negative for perineural invasion.         See comment.  13. Prostate, left lateral, needle core biopsy:         Benign prostatic tissue.",,"GROSS: Washington: 1LLB:6,10   2LLM:8,8   3LLA:14   4LB:2,2,10   5LM:10,12   6LA:7,16 7RB:4,8   8**ROOM   9RA:10,15   10RLB:13   11RLM:13,14   12RLA:2,6,9   13LLP:17 21/245","MICRO: Microscopic examination is performed.  Immunohistochemical PIN-4 staining performed on Parts 3, 6 and 9 shows basal staining in the groups of atypical glands which is congruent with benign prostatic glands.",PROCEDURE: Prostate biopsy\X0D\\X0A\SPECIMEN(S): 1. Left lateral base   2. Left lateral mid   3. Left lateral apex   4. Left base prostate   5. Left mid   6. Left apex prostate   7. Right base   8. Right mid   9. Right apex prostate 10. Right lateral base 11. Right lateral mid 12. Right lateral apex 13. Left lateral,,
REG2,COLON,0,PAT-40097367,1,REC-100000927575,"ClinicalHistory:
  Right upper lobe mass.",,"FinalDiagnosis:
Lung, Right Upper Lobe, Bronchial Biopsy Specimen:
Portions of Bronchial Mucosa and Detached Fragments of Poorly Differentiated Adenocarcinoma.
See Comment.

COMMENT: 
  Sections of the right upper lobe mass show portions of bronchial mucosa and fragments of blood containing poorly differentiated adenocarcinoma.  The tumor cells form abortive glandular structures and show intracytoplasmic vacuoles with extracellular mucin noted.  In view of the patient's history of colonic adenocarcinoma, a panel of immunohistochemical stains is performed.  The CK7 is nonimmunoreactive as is CK20. CDX2 and CEA show are positive.  TTF1 and Napsin A (markers typically positive in adenocarcinomas of the lung) are negative.  These histologic and immunohistochemical findings are interpreted as adenocarcinoma, compatible with a metastasis from the patient?s previously diagnosed and treated adenocarcinoma of the colon. 
 

NOTE: This case is reviewed at the Departmental Surgical Pathology Conference on **DATE[Jun 31 2013] and a consensus diagnosis is rendered.",,"GrossDescription:
  Received in formalin labeled right upper lobe biopsy are four cylindrical portions of white to pink, soft tissue averaging 0.2 x 0.1cm.  The specimen is submitted in toto as 1A.
AC:lefb **DATE[Jun 28 2013].","MicroscopicDescription:
  Slides reviewed.",1: Biopsy right upper lobe lung,,"AddendumComment:
  At the request of the attending medical oncologist, Dr. **NAME[ZZZ YYY], the specimen is sent for special molecular studies.

Interpretation: 
  Lung, right upper lobe, bronchial biopsy specimen: Wild Type KRAS (no mutation detected by PCR).

  Please see the complete report from PhenoPath Laboratories, case number: **ACCESSION-NUMBER[1] **STREET-ADDRESS, **PLACE, Washington **ZIP-CODE."
REG2,COLON,0,PAT-40097367,1,REC-100000930407,"ClinicalHistory:
  Right upper lobe mass.",,"FinalDiagnosis:
Lung, Right Upper Lobe, Bronchial Biopsy Specimen:
Portions of Bronchial Mucosa and Detached Fragments of Poorly Differentiated Adenocarcinoma.
See Comment.

COMMENT: 
  Sections of the right upper lobe mass show portions of bronchial mucosa and fragments of blood containing poorly differentiated adenocarcinoma.  The tumor cells form abortive glandular structures and show intracytoplasmic vacuoles with extracellular mucin noted.  In view of the patient's history of colonic adenocarcinoma, a panel of immunohistochemical stains is performed.  The CK7 is nonimmunoreactive as is CK20. CDX2 and CEA show are positive.  TTF1 and Napsin A (markers typically positive in adenocarcinomas of the lung) are negative.  These histologic and immunohistochemical findings are interpreted as adenocarcinoma, compatible with a metastasis from the patient?s previously diagnosed and treated adenocarcinoma of the colon. 
 

NOTE: This case is reviewed at the Departmental Surgical Pathology Conference on **DATE[Jan 31 2013] and a consensus diagnosis is rendered.",,"GrossDescription:
  Received in formalin labeled right upper lobe biopsy are four cylindrical portions of white to pink, soft tissue averaging 0.2 x 0.1cm.  The specimen is submitted in toto as 1A.
AC:lefb **DATE[Jan 28 2013].","MicroscopicDescription:
  Slides reviewed.",1: Biopsy right upper lobe lung,,
REG3,BREAST,0,PAT-00740844,1,REC-5000708722,,,,"<SPECIMEN(S)> 
A. Breast -Left skin sparing mastectomy 
B. Lymph Node Biopsy -Left axillary dissection 

 
<CLINICAL INFO> 
Left breast cancer -A) Specimen collection and fixation done on **DATE[Feb 16 12] at 10:16, B) 
Specimen collection and fixation done on **DATE[Feb 16 12] at 12:30 

<FINAL DX> 
A. Left breast, skin sparing mastectomy and axillary dissection: 
Invasive carcinoma 
Tumor size: 4.0 cm in greatest dimension. 
Tumor Site: 4 o'clock, 4.0 cm from nipple. 
Tumor focality: Single focus. 
Histologic type: Infiltrating ductal. 
Histologic grade: Nottingham grade 3 of 3 (Tubule score 3 of 3; nuclear score 
3 of 3; mitotic count 12 per 10 hpf, score 2 of 3). 
Lymph-vascular invasion: Extensively present. 
Skin: Focal involvement of deep dermis, epidermis not involved. 
Nipple: Free of involvement. 
Skeletal muscle: Not submitted. 
Ductal carcinoma in situ: Focally present (nuclear grade 3 of 3 without necrosis, 
comprising less than 5% of tumor). 
Lobular carcinoma in situ: Not identified. 
Margins (invasive carcinoma): Black/deep at 0.7 cm, remaining margins greater 
than 1.0 cm free of involvement. 
Margins (ductal carcinoma in situ): All margins greater than 1.0 cm free of 
involvement. 
Hormone receptor, HER2 studies (done on previous biopsy ***PATH-NUMBER[1]): 
ER positive (91%), PR positive (40%), negative for HER2 by IHC. 
Microcalcifications: Not identified. 
Lymph nodes: 1 of 1 intraparenchymal lymph node positive for metastatic 
carcinoma; 8 of 19 axillary lymph nodes positive for metastatic carcinoma, 
up to 1.4 cm in diameter with focal extranodal extension. 
Other: Changes consistent with previous biopsy. 
AJCC (7th ed.) pathologic stage: pT2 pN2a. 
Specimen: Total breast. 
Procedure: Skin sparing mastectomy with axillary dissection. 
Lymph node sampling: Axillary dissection. 
Specimen integrity: Two intact specimens. 
Specimen laterality: Left. 
B. Left axillary dissection: 
8 of 19 lymph nodes positive for metastatic carcinoma; up to 1.4 cm in diameter with 
focal extranodal extension. 
This case has been subjected to review by a second pathologist per departmental quality 
assurance (QA) policy. 
DN/ab 

 

<FINAL DX> (Continued) 

<GROSS> 
Received are two containers labeled '**NAME[BBB, AAA M]. H000599655' and a requisition with 
'**NAME[BBB, AAA M]. H000599655'. The specimens are placed in formalin between 1016 and 1230, 
**DATE[Feb 16 12], for a total fixation time of between 10.5 and 12.5 hours. 
The first is designated 'left skin-sparing mastectomy' and is received without fixative. It 
is a 758 gm skin-sparing breast 21.0 cm from medial to lateral, 22.0 cm from superior to 
inferior, and 4.0 cm from superficial to deep. There is an attached 11.5 x 5.3 cm skin 
ellipse which has an everted unremarkable nipple. At 6.5 cm inferolateral to the nipple's 
edge is a 1.7 cm healed incision. The deep margin has no attached muscle. Orientation is 
short suture superior and long lateral. The specimen is inked: 2.0 cm band superior to 
skin ellipse -green, 2.0 cm band inferior to skin ellipse -yellow, remaining 
superoanterior margin -orange, remaining inferoanterior margin -blue, deep margin -black. 
The specimen is sectioned from medial to lateral into 18 slices. The cut surface has two 
gross areas of interest which are separate. The first gross area of interest is in slices 
8-15 at approximately 4:00 to 5:00, 4.0 cm from the nipple, in the lower outer quadrant. 
This is what appears to be a single irregular mass which is somewhat ill-defined and has 
gross evidence of biopsy. The mass is 3.5 x 2.5 x an estimated 4.0 cm on the medial to 
lateral axis. The mass is 0.4 cm from the blue inferoanterior margin and 0.4 cm from the 
black deep margin. It is over 2.0 cm from the orange superoanterior margin, 1.5 cm from the 
yellow band inferior to the skin ellipse, and 0.8 cm from the green band superior to the 
skin ellipse. Intraoperative gross margin consultation by Dr. **NAME[ZZZ YYY] of: `4.0 cm mass 
in lower outer quadrant, 4 mm from deep and anteroinferior margins'. 
The second gross area of interest is in slices 15 and 16 at approximately 2:00. This is a 
1.5 x 0.8 cm firm, circumscribed area which appears consistent with an interparenchymal 
lymph node. This is over 2.0 cm from all margins. 
Summary of Sections: 
A1 Slice 6 -nipple 
A2 Slice 14 -healed incision on skin which corresponds to more lateral portion of 
mass 
A3 First gross area of interest -slice 8, yellow band inferior to skin ellipse 
A4 Slice 9 -first gross area of interest, blue inferoanterior 
A5 Slice 10 -first gross area of interest, apparent biopsy site, blue and yellow 
band inferior to skin ellipse 
A6 Slice 13 -green band superior to skin ellipse and mass 
A7 Slice 14 -black deep 
A8 Slice 15 second gross area of interest -what appears to be an intrarparenchymal lymph 
node, no marginal ink 
The second is designated 'left axillary dissection' and is received in formalin. It is 
unoriented orange-yellow adipose tissue 15.0 x 8.0 x 4.0 cm. This has tentatively 
identified lymph nodes up to 2.5 cm with several of these lymph nodes white and firm. One 
of the lymph nodes appears to have gross evidence of biopsy. 
Summary of Sections: 

 

<GROSS> (Continued) 
B1 One lymph node subsectioned 
B2-B3 One lymph node subsectioned 
B4 Two lymph nodes subsectioned 
B5 Three lymph nodes subsectioned 
B6 Three lymph nodes subsectioned 
B7-B8 One lymph node subsectioned 
B9-B10 One lymph node subsectioned 
B11 One lymph node subsectioned 
B12 Three lymph nodes subsectioned 
B13 Two lymph nodes subsectioned 
B14-B15 One lymph node subsectioned 
(**INITIALS) 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis.",,,,,
REG3,BREAST,0,PAT-00739693,1,REC-5000712937,,,,"<CLINICAL INFO>
 Left breast density in upper inner quadrant.<FINAL DX>
 A) Left breast, upper inner quadrant density,
  stereotactic core needle biopsy: Invasive ductal carcinoma with the following
  features
   1. Nottingham grade 2 of 3: poor tubule formation - 3, intermediate nuclear
  grade - 2, low mitotic activity - 1.
   2. Extent/Size: Involving multiple tissue cores with a maximum contiguous
  length of 0.5 cm.
   3. Associated in situ component: Focal intermediate grade ductal carcinoma
  without necrosis.
   4. No microcalcifications identified.
   5. No angiolymphatic invasion identified.
   6. Prognostic markers will be performed and the results reported as an
  addendum.
  Procedures used to establish the diagnosis:
  Routine<ADDENDUM FINAL DX>
 A) Left breast, upper inner quadrant
  density, stereotactic core needle biopsy: Invasive ductal carcinoma with the
  following immunohistochemical features
   1. Positive for estrogen and progesterone receptor expression (**NAME[ZZZ] scores
  of 8 and 7 of 8, respectively).
   2. Intermediate for Her2/neu over-expression (2+); FISH studies will be
  performed and the results reported in an addendum.
   3. Ki-67 proliferative index - 20% of nuclei positive.<ADDENDUM FINAL DX>
 A) Left breast, upper inner quadrant
  density, stereotactic core needle biopsy: Invasive ductal carcinoma, negative
  for gene amplification of Her-2/neu by fluorescence in situ hybridization
  technique.


  A2-17: Her2 FISHADDENDUM REASON:
  This addendum is issued to report the results of immunohistochemistry.<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[YYY M XXX] MD and **NAME[WWW M. VVV] MD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): A2
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  ER Estrogen Receptor [SP1] 99 % positive cells Intensity: Strong
  PR88 Progesterone Receptor [PR88] 95 % positive cells Intensity: Intermediate
  to strong
  C-erbB-2 m C-erbB-2,  (w/ HIER)  Intermediate over-expression
  Ki-67 Ki-67 [MIB-1] 20 % positive cellsDNA ANALYSIS: (Interpreted by: **NAME[UUU M. TTT] MD and **PLACE
  **NAME[SSS] MD)
  Unstained sections are prepared and regions of invasive carcinoma are marked
  by comparison with H&E-stained sections from the same block.  Fluorescence in
  situ hybridization for the Her-2/neu gene is then carried out using the FDA-
  approved Vysis Path Vysion HER-2 DNA probe kit.  The prepared slides are then
  viewed under a fluorescent microscope with appropriate filters for the
  chromosome 17 probe (green), the Her-2/neu probe (orange) and DNA (blue) to
  localize nuclei.  Signals are counted from up to 60 cells and the ratio of
  Her-2/neu to chromosome 17 signals is computed.  Control slides from non-
  amplified and low-level amplified tumor cells are prepared simultaneously to
  ensure reproducibility between assays.  Results are listed in the table below:
  Block (Original Label): A2
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  FISH H2N/17 ICC FISH Chromosome 17 PROBE 2.1 signals/cell
  FISH H2N/17 ICC FISH Her2Neu PROBE 2.0 signals/cell
            Ratio: 0.9  Interpretation: Not amplified<GROSS>
 A) Received in formalin labeled ""Brown, left
  UIQ density"" is a 2.6 x 2.4 x 0.3 cm aggregate of yellow-tan fibrofatty soft
  tissue fragments that are inked blue and entirely submitted in cassettes A1-
  A3.  (**INITIALS)NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.<MICROSCOPIC>
 A recut slide confirms residual invasive
  carcinoma in the block.NOTE:  Per the ASCO/CAP Guideline Recommendations for Her-2/neu
  testing in breast cancer (Arch Pathol Lab Med 131: 18-43, 2007), ratios of
  less than 1.8 are interpreted as negative, ratios of more than 2.2 are
  interpreted as positive, and ratios between 1.8 and 2.2 are interpreted as
  equivocal for gene amplification.  Alternatively, cancers having > 6 signals
  of Her-2 per nucleus are considered positive, < 4 signals per cell are
  negative and 4-6 signals/cell are equivocal.",,,,,
REG3,BREAST,0,PAT-00742126,1,REC-5000713294,,,,"<CLINICAL INFO>
 Right breast mass 12:00.  Per Powerpath: Patient
  has carcinoma in left breast.<FINAL DX>
 A)  Right breast mass 12:00, ultrasound-guided
  core biopsy:  Fibroadenoma with sclerosing adenosis; no atypical hyperplasia,
  in situ or invasive carcinoma identified.
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received in formalin labeled ""**NAME[BBB,
  AAA], right 12:00 mass"" are four tan-yellow cores of fibroadipose tissue
  ranging from 0.5 to 2.2 cm in length.  The specimen is wrapped, inked green
  and entirely submitted in cassette A1.  (**INITIALS)",,,,,
REG3,BREAST,0,PAT-00067792,3,REC-5000713692,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Left Breast, Simple Mastectomy:
Infiltrating carcinoma with the following features:
Histologic type:              Ductal.
Size:               1.4 cm (histologic measurement)
Histologic grade:             2 of 3.
Nottingham grade:             6 of 9.
Tubule formation:        Intermediate (2 of 3).
Nuclear grade:      High (3 of 3).
Mitotic rate:            Low (1 of 3).
Lymph-vascular invasion:           Not identified.
Ductal carcinoma in situ (DCIS) with the following features:
Histologic type:              Solid.
Nuclear grade:           High.
Necrosis:           Absent.
Calcifications:               Focally present.
Estimated size/extent of DCIS:     1 cm.
Surgical margins: (histologic measurement)
Infiltrating carcinoma:
Anterior (superficial):            10 mm. (histologic measurement)
Posterior (deep):             >10 mm.
Superior:           >10 mm.
Inferior:           >10 mm.
Medial:             >10 mm.
Lateral:            >10 mm.
Ductal carcinoma in situ:
Anterior (superficial):            7 mm. (histologic measurement)
Posterior (deep):             >10 mm.
Superior:           >10 mm.
Inferior:           >10 mm.
Medial:             >10 mm.
Lateral:            >10 mm.
   Lymph nodes:               Not present. (see comment)
Pathologic stage:             pT1c, pNX (AJCC 7th edition).
Additional findings:                        No pagetoid involvement of
lactiferous sinuses, nipple skin, or other skin identified.
Immunohistochemistry staining for estrogen and progesterone receptor
expression and HER-2/neu overexpression have previously been performed
(***PATH-NUMBER[2]), with the following results:  ER 99%, PR 60%, HER-2/neu
equivocal (score of 2+), negative for overexpression by FISH studies.

B.  Residual Breast Tissue, Excision:
Benign fibroadipose tissue.
No ductal epithelium present.
Negative for atypia or malignancy.

<COMMENT>
Review of the medical record indicates that the patient had a left
breast lumpectomy for cancer in 1993 that included axillary lymph node
dissection and radiation therapy. DCIS is intermixed within and
extending slightly beyond the infiltrating carcinoma, and it measures
approximately 1 cm across. A separate hemorrhagic focus in the 1 o'clock
region appears to be fat necrosis and inflammatory response. No
malignancy is identified in that site.

<CLINICAL INFO>
Collection date:  **DATE[Aug 28 2011] at 4:30 p.m. Total fixation time 23 hours.
Left breast cancer.

INTRAPROCEDURAL EVALUATION:
A.  Left breast (gross exam): ""Hematoma, makes difficult assessment of
tumor in relation to margin"".
Performed by:  **NAME[ZZZ M. YYY], M.D.

<GROSS>
A.  Received fresh, labeled ""**NAME[BBB, AAA M]"", and designated ""left
breast"" and is submitted for rapid evaluation yielding the above
intraprocedural evaluation by Dr. **NAME[ZZZ M. YYY]. The above
intraprocedural evaluation is called into Dr. **NAME[XXX] in the operating
room by Dr. **NAME[YYY]. It consists of an oriented simple mastectomy
specimen with a single suture designated as marking medial. It is 418
grams, 16 cm superior to inferior, by 12.5 cm medial to lateral, by 5 cm
superficial to deep. It is without an axillary tail. It is partially
covered by a 6.5 x 5 cm ellipse of unremarkable skin with a 1.2 x 1 cm
everted nipple. Prior to dissection, it is inked as follows:  Superior
superficial orange, inferior superficial green, and deep black. It Is
then sectioned from medial to lateral into 19 cross-sectional slices
numbered respectively. The cut surfaces are 30% fibrous and 70% fatty.
Slices 3-7 (mid to superior) have a 2.3 x 2 x 1.8 cm ill-defined
hemorrhagic area that is less than 0.1 cm from the superior superficial
surface, 5.3 cm from the nipple, 1.8 cm from the deep margin, and 4 cm
from the superior skin margin. Within this hemorrhagic area in slices 5
and 6 is a 1.5 x 1.1 x 1 cm ill-defined, firm, white-pink nodular area
that is 1.2 cm from the deep margin, 1.1 cm from the superior
superficial margin, 5.5 cm from the nipple, and 6 cm from the superior
skin margin. The tumor has a centrally placed M-clip. This hemorrhagic
area and nodular area correlate with the prior biopsy at 11 o'clock.
Slices 7-10 (mid to superior) have a 1.5 x 1 x 0.7 cm ill-defined,
hemorrhagic, fibrous area with calcified material. This area is 3 cm
from the superior skin margin, less than 0.1-0.2 cm from the superior
superficial margin, 2.8 cm from the hemorrhagic area, 3 cm from the
nipple, and 5 cm from the deep margin. This biopsy has a metallic clip.
This second area correlates with the prior 1 o'clock biopsy site.

Representative sections are submitted as follows: A1- nipple; A2- middle
of slice 1 medial aspect-uninked, superior and inferior slice 2; A3-
medial aspect of hemorrhagic area in slice 3 including superficial
margin; A4- hemorrhagic area from slice 4; A5, A6- nodular area within
hemorrhagic area of slices 5 and 6 (A6 includes superficial margin); A7-
deep margin from slices 5 and 6; A8- hemorrhagic area from slice 7 (most
lateral aspect of larger hemorrhagic area); A9- tissue from the middle
of slice 7 between hemorrhagic area in slices 3-7 and ill-defined
hemorrhagic fibrous area with calcified material in slices 7-10; A10-
superior and inferior slice 7; A11-A13- second ill-defined hemorrhagic
fibrous area with calcified material from slices 7 through 10; A14- mid
deep, superior, and inferior slice 10; A15- middle uninked, superior,
and inferior slice 13; A16- superior and inferior slice 16 and
middle-uninked slice 19. kjh/ct

B.  Received in formalin, labeled ""**NAME[BBB, AAA M]."" and designated
""residual breast tissue"", are three irregular, unoriented pieces of
fibrofatty tissue, 4 x 1.5 x 0.6 cm (green ink), 5.3 x 4 x 0.9 cm (blue
ink), and 5.5 x 4.6 x 1 cm (black ink). Each piece is serially
sectioned. The cut surfaces are 98% fatty and 2% fibrous. No discrete
tumors of nodules are identified. Representative sections are submitted
in B1-B3. (kjh/jmk)

<MICROSCOPIC>
The final diagnosis for each specimen is based on a microscopic
examination of the tissues.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Aug 30 2011]",,,,,
REG3,BREAST,0,PAT-00737767,1,REC-5000714040,,,,"<CLINICAL INFO>
 Left breast CA.  Needle loc lumpectomy.  SLN
  biopsy.<CLINICAL INFO>
 Left breast CA.  Needle loc lumpectomy.  SLN
  biopsy.<CLINICAL INFO>
 Left breast CA.  Needle loc lumpectomy.  SLN
  biopsy.<FINAL DX>
 A,B,C)  Lymph nodes, left sentinel #1 - #3,
  excisions:  No carcinoma identified in 3 lymph nodes.
  D) Left breast, lumpectomy:  Invasive ductal carcinoma; see summary cancer
  data.
  E, F) Left breast, margins, superior-medial-inferior segment and deep,
  excisions: Breast parenchyma with no evidence of atypical hyperplasia, in situ
  or invasive carcinoma.<FINAL DX>
 A,B,C)  Lymph nodes, left sentinel #1 - #3,
  excisions:  No carcinoma identified in 3 lymph nodes.
  D) Left breast, lumpectomy:  Invasive ductal carcinoma; see summary cancer
  data.
  E, F) Left breast, margins, superior-medial-inferior segment and deep,
  excisions: Breast parenchyma with no evidence of atypical hyperplasia, in situ
  or invasive carcinoma.<FINAL DX>
 A,B,C)  Lymph nodes, left sentinel #1 - #3,
  excisions:  No carcinoma identified in 3 lymph nodes.
  D) Left breast, lumpectomy:  Invasive ductal carcinoma; see summary cancer
  data.
  E, F) Left breast, margins, superior-medial-inferior segment and deep,
  excisions: Breast parenchyma with no evidence of atypical hyperplasia, in situ
  or invasive carcinoma.<DIAGNOSIS COMMENT(S)> SU-11-12694
  Estrogen receptor: Positive (**NAME[ZZZ] score = 8 of 8)
  Progesterone receptor: Positive (**NAME[ZZZ] score = 7 of 8)
  c-erb-B2 (Her-2/neu) by IHC: Negative for Her-2/neu overexpression by IHC
  Her-2/neu by FISH: Not performed/reported
  Skin status: Not involved
  Nipple status: Cannot assess (nipple not present)
  Skeletal muscle status: Skeletal muscle not present
  Ductal carcinoma in-situ (DCIS): Present (85002)
  Nuclear grade of DCIS: Low
  DCIS qualifies as ""extensive intraductal component""?: No
  Lobular carcinoma in-situ (LCIS): Absent
  Final surgical resection margins (including separately submitted margins):
  Invasive carcinoma margins:
  In the main lumpectomy specimen, the carcinoma is 0.3 cm from the superior
  margin and 0.7 cm from the inferior margin.
  The separately submitted superior-medial-inferior and deep margins are free of
  carcinoma.
  DCIS Margins: DCIS is widely free of margins.
  Lymph node involvement
  Sentinel nodes: Sentinel nodes with carcinoma 0    / Total sentinel nodes 3
  Non-sentinel nodes: Non-sentinel nodes with carcinoma: 0    / Total non-
  sentinel nodes: 0
        - Total number of nodes with macrometastases: 0
        - Total number of nodes with micrometastases: 0
        - Total number of nodes with isolated tumor cells: 0
  Minimum pathologic stage (AJCC, 7th ed., 2010)
  Primary tumor [pT]: pT1b: Tumor > 0.5 cm and <= 1.0 cm - greatest dimension
  Regional nodes [pN]: pN0: No regional lymph node metastasis histologically
  (ITCs may be present)
  N stage modifier: (sn): Only sentinel node(s) evaluated.
  Distant metastasis [pM]: Not applicable or no pathologic information
  Procedures used to establish the diagnosis:
  Routine<DIAGNOSIS COMMENT(S)> SU-11-12694
  Estrogen receptor: Positive (**NAME[ZZZ] score = 8 of 8)
  Progesterone receptor: Positive (**NAME[ZZZ] score = 7 of 8)
  c-erb-B2 (Her-2/neu) by IHC: Negative for Her-2/neu overexpression by IHC
  Her-2/neu by FISH: Not performed/reported
  Skin status: Not involved
  Nipple status: Cannot assess (nipple not present)
  Skeletal muscle status: Skeletal muscle not present
  Ductal carcinoma in-situ (DCIS): Present (85002)
  Nuclear grade of DCIS: Low
  DCIS qualifies as ""extensive intraductal component""?: No
  Lobular carcinoma in-situ (LCIS): Absent
  Final surgical resection margins (including separately submitted margins):
  Invasive carcinoma margins:
  In the main lumpectomy specimen, the carcinoma is 0.3 cm from the superior
  margin and 0.7 cm from the inferior margin.
  The separately submitted superior-medial-inferior and deep margins are free of
  carcinoma.
  DCIS Margins: DCIS is widely free of margins.
  Lymph node involvement
  Sentinel nodes: Sentinel nodes with carcinoma 0    / Total sentinel nodes 3
  Non-sentinel nodes: Non-sentinel nodes with carcinoma: 0    / Total non-
  sentinel nodes: 0
        - Total number of nodes with macrometastases: 0
        - Total number of nodes with micrometastases: 0
        - Total number of nodes with isolated tumor cells: 0
  Minimum pathologic stage (AJCC, 7th ed., 2010)
  Primary tumor [pT]: pT1b: Tumor > 0.5 cm and <= 1.0 cm - greatest dimension
  Regional nodes [pN]: pN0: No regional lymph node metastasis histologically
  (ITCs may be present)
  N stage modifier: (sn): Only sentinel node(s) evaluated.
  Distant metastasis [pM]: Not applicable or no pathologic information
  Procedures used to establish the diagnosis:
  Routine<DIAGNOSIS COMMENT(S)> SU-11-12694
  Estrogen receptor: Positive (**NAME[ZZZ] score = 8 of 8)
  Progesterone receptor: Positive (**NAME[ZZZ] score = 7 of 8)
  c-erb-B2 (Her-2/neu) by IHC: Negative for Her-2/neu overexpression by IHC
  Her-2/neu by FISH: Not performed/reported
  Skin status: Not involved
  Nipple status: Cannot assess (nipple not present)
  Skeletal muscle status: Skeletal muscle not present
  Ductal carcinoma in-situ (DCIS): Present (85002)
  Nuclear grade of DCIS: Low
  DCIS qualifies as ""extensive intraductal component""?: No
  Lobular carcinoma in-situ (LCIS): Absent
  Final surgical resection margins (including separately submitted margins):
  Invasive carcinoma margins:
  In the main lumpectomy specimen, the carcinoma is 0.3 cm from the superior
  margin and 0.7 cm from the inferior margin.
  The separately submitted superior-medial-inferior and deep margins are free of
  carcinoma.
  DCIS Margins: DCIS is widely free of margins.
  Lymph node involvement
  Sentinel nodes: Sentinel nodes with carcinoma 0    / Total sentinel nodes 3
  Non-sentinel nodes: Non-sentinel nodes with carcinoma: 0    / Total non-
  sentinel nodes: 0
        - Total number of nodes with macrometastases: 0
        - Total number of nodes with micrometastases: 0
        - Total number of nodes with isolated tumor cells: 0
  Minimum pathologic stage (AJCC, 7th ed., 2010)
  Primary tumor [pT]: pT1b: Tumor > 0.5 cm and <= 1.0 cm - greatest dimension
  Regional nodes [pN]: pN0: No regional lymph node metastasis histologically
  (ITCs may be present)
  N stage modifier: (sn): Only sentinel node(s) evaluated.
  Distant metastasis [pM]: Not applicable or no pathologic information
  Procedures used to establish the diagnosis:
  RoutineIHC INTERPRETATION: Ki67 stains 1% of carcinoma cells.IHC INTERPRETATION: Ki67 stains 1% of carcinoma cells.IHC INTERPRETATION: Ki67 stains 1% of carcinoma cells.SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Sentinel lymph node
  B: Sentinel lymph node
  C: Sentinel lymph node
  D: Breast biopsy, lump
  E: Breast biopsy, lump
  F: Surgical margins
  Invasive carcinoma with the following features:
  Histologic type: Invasive ductal carcinoma, NOS (85003)
  Size (largest focus): 0.9cm
      Comment about size determination: Carcinoma is present in 3 slices
  Focality of invasive carcinoma: Single contiguous focus
  Nottingham Grade: Grade I: 3-5 points
      - Tubule Formation: 2  points (10 - 75%)
      - Nuclear Pleomorphism: 2 points (moderate)
      - Mitotic Activity: 1 point
  Ancillary Studies
  Source: Outside pathology lab (slides reviewed)SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Sentinel lymph node
  B: Sentinel lymph node
  C: Sentinel lymph node
  D: Breast biopsy, lump
  E: Breast biopsy, lump
  F: Surgical margins
  Invasive carcinoma with the following features:
  Histologic type: Invasive ductal carcinoma, NOS (85003)
  Size (largest focus): 0.9cm
      Comment about size determination: Carcinoma is present in 3 slices
  Focality of invasive carcinoma: Single contiguous focus
  Nottingham Grade: Grade I: 3-5 points
      - Tubule Formation: 2  points (10 - 75%)
      - Nuclear Pleomorphism: 2 points (moderate)
      - Mitotic Activity: 1 point
  Ancillary Studies
  Source: Outside pathology lab (slides reviewed)SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Sentinel lymph node
  B: Sentinel lymph node
  C: Sentinel lymph node
  D: Breast biopsy, lump
  E: Breast biopsy, lump
  F: Surgical margins
  Invasive carcinoma with the following features:
  Histologic type: Invasive ductal carcinoma, NOS (85003)
  Size (largest focus): 0.9cm
      Comment about size determination: Carcinoma is present in 3 slices
  Focality of invasive carcinoma: Single contiguous focus
  Nottingham Grade: Grade I: 3-5 points
      - Tubule Formation: 2  points (10 - 75%)
      - Nuclear Pleomorphism: 2 points (moderate)
      - Mitotic Activity: 1 point
  Ancillary Studies
  Source: Outside pathology lab (slides reviewed)ADDENDUM REASON: This addendum is being issued to report the
  results of immunohistochemistry studies.ADDENDUM REASON: This addendum is being issued to report the
  results of immunohistochemistry studies.ADDENDUM REASON: This addendum is being issued to report the
  results of immunohistochemistry studies.<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[YYY XXX] WWW], PhD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): D8
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  Ki-67 Ki-67 [MIB-1] 1 % positive cells<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[YYY XXX] WWW], PhD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): D8
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  Ki-67 Ki-67 [MIB-1] 1 % positive cells<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[YYY XXX] WWW], PhD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): D8
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  Ki-67 Ki-67 [MIB-1] 1 % positive cellsADDENDUM REASON: This addendum is to document pathology effort to
  support additional testing.  There is no change to the previous diagnoses.
  Oncotype DX  testing was requested by Dr **NAME[VVV] on this case after the original
  report was issued. Slides were retrieved from archives storage and  re-
  examined along with the original report to select the most appropriate block
  containing invasive carcinoma for this additional molecular testing (block
  D8). After the selected block was retrieved from storage and appropriate
  slides cut, material was sent to Genomic Health for testing and the results
  were reported as follows:
  The OncotypeDX recurrence score is: 17 (11% rate of distant recurrence at 10
  years for node negative, ER-positive cancers treated with tamoxifen).
  The OncotypeDX quantitative Estrogen Receptor score is: 9.3 (with positive >
  6.5).
  The OncotypeDX quantitative Progesterone Receptor score is: 6.0 (with positive
  > 5.5).
  The OncotypeDX quantitative Her2 score is: 9.6 (with positive >11.5 and
  negative < 10.7).ADDENDUM REASON: This addendum is to document pathology effort to
  support additional testing.  There is no change to the previous diagnoses.
  Oncotype DX  testing was requested by Dr **NAME[VVV] on this case after the original
  report was issued. Slides were retrieved from archives storage and  re-
  examined along with the original report to select the most appropriate block
  containing invasive carcinoma for this additional molecular testing (block
  D8). After the selected block was retrieved from storage and appropriate
  slides cut, material was sent to Genomic Health for testing and the results
  were reported as follows:
  The OncotypeDX recurrence score is: 17 (11% rate of distant recurrence at 10
  years for node negative, ER-positive cancers treated with tamoxifen).
  The OncotypeDX quantitative Estrogen Receptor score is: 9.3 (with positive >
  6.5).
  The OncotypeDX quantitative Progesterone Receptor score is: 6.0 (with positive
  > 5.5).
  The OncotypeDX quantitative Her2 score is: 9.6 (with positive >11.5 and
  negative < 10.7).ADDENDUM REASON: This addendum is to document pathology effort to
  support additional testing.  There is no change to the previous diagnoses.
  Oncotype DX  testing was requested by Dr **NAME[VVV] on this case after the original
  report was issued. Slides were retrieved from archives storage and  re-
  examined along with the original report to select the most appropriate block
  containing invasive carcinoma for this additional molecular testing (block
  D8). After the selected block was retrieved from storage and appropriate
  slides cut, material was sent to Genomic Health for testing and the results
  were reported as follows:
  The OncotypeDX recurrence score is: 17 (11% rate of distant recurrence at 10
  years for node negative, ER-positive cancers treated with tamoxifen).
  The OncotypeDX quantitative Estrogen Receptor score is: 9.3 (with positive >
  6.5).
  The OncotypeDX quantitative Progesterone Receptor score is: 6.0 (with positive
  > 5.5).
  The OncotypeDX quantitative Her2 score is: 9.6 (with positive >11.5 and
  negative < 10.7).NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.<GROSS>
 A) Received in a container of formalin labeled
  ""**NAME[BBB], left axillary sentinel lymph node #1"" is a 1.5 x 1.0 x 0.5 cm tan-
  pink, rubbery lymph node which has a scant amount of attached adipose tissue.
  Lymph node is bisected and has tan, focally nodular-appearing cut surfaces.
  No obvious masses are appreciated.  The lymph node, minus the attached adipose
  tissue, is entirely submitted in cassette A1.  (**INITIALS)
  B) Received in a container of formalin labeled ""**NAME[BBB], left axillary
  sentinel lymph node #2"" is a 1.0 x 1.0 x 0.5 cm tan, rubbery lymph node which
  has a scant amount of attached adipose tissue.  Lymph node is bisected and has
  tan-pink, congested cut surfaces.  The lymph node is entirely submitted in
  cassette B1.  (**INITIALS)
  C) Received in a container of formalin labeled ""**NAME[BBB], left axillary
  sentinel lymph node #3"" is a 1.8 x 1.0 x 0.5 cm tan, rubbery lymph node which
  has a scant amount of attached adipose tissue.  The lymph node is bisected and
  has tan-pink, rubbery cut surfaces.  Lymph node is entirely submitted in
  cassette C1.  (**INITIALS)
  D) Received fresh labeled ""**NAME[BBB], left breast lumpectomy"" is a 26 g, 5.3 cm
  ML x 4.3 cm AP x 4.0 cm SI lumpectomy.  There is an attached 2.4 x 0.6 cm
  ellipse of tan-pink skin.  The lumpectomy has been previously inked by the
  surgeons are follows:  superior red, inferior blue, lateral orange, medial
  yellow, anterior green and posterior black.  It is serially sectioned into ten
  slices, with slices #1 and #10 measuring 0.8 cm in thickness and the
  intervening slices measuring 0.3 cm in thickness.  It is placed into formalin
  at 4:30 p.m. on **DATE[Jun 1 2012].  After fixation, a tan-white fibrous area with
  central area of hemorrhage is present located in slices 2 - 10.  There is a
  metal clip present in slice 8.  In slice #5, the white fibrous area measures
  1.5 x 1.0 cm and is located 0.3 cm from the red margin.  In slice #7, the firm
  yellow-red area measures 1.2 x 1.0 cm and is located 0.2 cm from the superior
  margin, 0.2 cm from the inferior margin, and 1  cm from the anterior margin.
  Representative sections are submitted labeled as follows:  D1 -slice 1,
  perpendicularly sectioned; D2 - biopsy site slice 2; D3 - biopsy site slice 3;
  D4 - biopsy site slice 4; D5 - biopsy site slice 5; D6 - biopsy site slice 6;
  D7 - biopsy site slice 7; D8, D9 - entire slice 8 with clip in D8; D10 -
  biopsy site slice 9; D11, D12 - slice 10, perpendicularly sectioned.  (**INITIALS)
  E) Received in a container of formalin labeled ""**NAME[BBB], left breast superior
  medial inferior segment"" is a 14 g, 7.8 SI x 3.8 x 1.4 cm yellow, lobulated
  portion of fibrofatty breast tissue.  One side of the margin has been
  previously inked red, blue, and yellow by the surgeon.  The opposing surface
  is marked with black ink.  There is a suture attached to the side of the
  specimen inked by the surgeon.  The specimen is serially sectioned and has
  yellow, lobulated, fatty cut surfaces.  No obvious breast tissue is grossly
  appreciated.  Every other section is submitted sequentially in eight
  cassettes.  (**INITIALS)
  F) Received in a container of formalin labeled ""**NAME[BBB], deep left breast
  margin"" is a 1 g, 2.5 x 2.5 x 0.3 cm yellow, lobulated portion of fibrofatty
  breast tissue.  One margin has been inked black by the surgeon.  This margin
  also has an attached metallic clip.  The specimen is quadrisected and has
  unremarkable cut surfaces and is entirely submitted into two cassettes.
  (**INITIALS)<GROSS>
 A) Received in a container of formalin labeled
  ""**NAME[BBB], left axillary sentinel lymph node #1"" is a 1.5 x 1.0 x 0.5 cm tan-
  pink, rubbery lymph node which has a scant amount of attached adipose tissue.
  Lymph node is bisected and has tan, focally nodular-appearing cut surfaces.
  No obvious masses are appreciated.  The lymph node, minus the attached adipose
  tissue, is entirely submitted in cassette A1.  (**INITIALS)
  B) Received in a container of formalin labeled ""**NAME[BBB], left axillary
  sentinel lymph node #2"" is a 1.0 x 1.0 x 0.5 cm tan, rubbery lymph node which
  has a scant amount of attached adipose tissue.  Lymph node is bisected and has
  tan-pink, congested cut surfaces.  The lymph node is entirely submitted in
  cassette B1.  (**INITIALS)
  C) Received in a container of formalin labeled ""**NAME[BBB], left axillary
  sentinel lymph node #3"" is a 1.8 x 1.0 x 0.5 cm tan, rubbery lymph node which
  has a scant amount of attached adipose tissue.  The lymph node is bisected and
  has tan-pink, rubbery cut surfaces.  Lymph node is entirely submitted in
  cassette C1.  (**INITIALS)
  D) Received fresh labeled ""**NAME[BBB], left breast lumpectomy"" is a 26 g, 5.3 cm
  ML x 4.3 cm AP x 4.0 cm SI lumpectomy.  There is an attached 2.4 x 0.6 cm
  ellipse of tan-pink skin.  The lumpectomy has been previously inked by the
  surgeons are follows:  superior red, inferior blue, lateral orange, medial
  yellow, anterior green and posterior black.  It is serially sectioned into ten
  slices, with slices #1 and #10 measuring 0.8 cm in thickness and the
  intervening slices measuring 0.3 cm in thickness.  It is placed into formalin
  at 4:30 p.m. on **DATE[Jun 1 2012].  After fixation, a tan-white fibrous area with
  central area of hemorrhage is present located in slices 2 - 10.  There is a
  metal clip present in slice 8.  In slice #5, the white fibrous area measures
  1.5 x 1.0 cm and is located 0.3 cm from the red margin.  In slice #7, the firm
  yellow-red area measures 1.2 x 1.0 cm and is located 0.2 cm from the superior
  margin, 0.2 cm from the inferior margin, and 1  cm from the anterior margin.
  Representative sections are submitted labeled as follows:  D1 -slice 1,
  perpendicularly sectioned; D2 - biopsy site slice 2; D3 - biopsy site slice 3;
  D4 - biopsy site slice 4; D5 - biopsy site slice 5; D6 - biopsy site slice 6;
  D7 - biopsy site slice 7; D8, D9 - entire slice 8 with clip in D8; D10 -
  biopsy site slice 9; D11, D12 - slice 10, perpendicularly sectioned.  (**INITIALS)
  E) Received in a container of formalin labeled ""**NAME[BBB], left breast superior
  medial inferior segment"" is a 14 g, 7.8 SI x 3.8 x 1.4 cm yellow, lobulated
  portion of fibrofatty breast tissue.  One side of the margin has been
  previously inked red, blue, and yellow by the surgeon.  The opposing surface
  is marked with black ink.  There is a suture attached to the side of the
  specimen inked by the surgeon.  The specimen is serially sectioned and has
  yellow, lobulated, fatty cut surfaces.  No obvious breast tissue is grossly
  appreciated.  Every other section is submitted sequentially in eight
  cassettes.  (**INITIALS)
  F) Received in a container of formalin labeled ""**NAME[BBB], deep left breast
  margin"" is a 1 g, 2.5 x 2.5 x 0.3 cm yellow, lobulated portion of fibrofatty
  breast tissue.  One margin has been inked black by the surgeon.  This margin
  also has an attached metallic clip.  The specimen is quadrisected and has
  unremarkable cut surfaces and is entirely submitted into two cassettes.
  (**INITIALS)<GROSS>
 A) Received in a container of formalin labeled
  ""**NAME[BBB], left axillary sentinel lymph node #1"" is a 1.5 x 1.0 x 0.5 cm tan-
  pink, rubbery lymph node which has a scant amount of attached adipose tissue.
  Lymph node is bisected and has tan, focally nodular-appearing cut surfaces.
  No obvious masses are appreciated.  The lymph node, minus the attached adipose
  tissue, is entirely submitted in cassette A1.  (**INITIALS)
  B) Received in a container of formalin labeled ""**NAME[BBB], left axillary
  sentinel lymph node #2"" is a 1.0 x 1.0 x 0.5 cm tan, rubbery lymph node which
  has a scant amount of attached adipose tissue.  Lymph node is bisected and has
  tan-pink, congested cut surfaces.  The lymph node is entirely submitted in
  cassette B1.  (**INITIALS)
  C) Received in a container of formalin labeled ""**NAME[BBB], left axillary
  sentinel lymph node #3"" is a 1.8 x 1.0 x 0.5 cm tan, rubbery lymph node which
  has a scant amount of attached adipose tissue.  The lymph node is bisected and
  has tan-pink, rubbery cut surfaces.  Lymph node is entirely submitted in
  cassette C1.  (**INITIALS)
  D) Received fresh labeled ""**NAME[BBB], left breast lumpectomy"" is a 26 g, 5.3 cm
  ML x 4.3 cm AP x 4.0 cm SI lumpectomy.  There is an attached 2.4 x 0.6 cm
  ellipse of tan-pink skin.  The lumpectomy has been previously inked by the
  surgeons are follows:  superior red, inferior blue, lateral orange, medial
  yellow, anterior green and posterior black.  It is serially sectioned into ten
  slices, with slices #1 and #10 measuring 0.8 cm in thickness and the
  intervening slices measuring 0.3 cm in thickness.  It is placed into formalin
  at 4:30 p.m. on **DATE[Jun 1 2012].  After fixation, a tan-white fibrous area with
  central area of hemorrhage is present located in slices 2 - 10.  There is a
  metal clip present in slice 8.  In slice #5, the white fibrous area measures
  1.5 x 1.0 cm and is located 0.3 cm from the red margin.  In slice #7, the firm
  yellow-red area measures 1.2 x 1.0 cm and is located 0.2 cm from the superior
  margin, 0.2 cm from the inferior margin, and 1  cm from the anterior margin.
  Representative sections are submitted labeled as follows:  D1 -slice 1,
  perpendicularly sectioned; D2 - biopsy site slice 2; D3 - biopsy site slice 3;
  D4 - biopsy site slice 4; D5 - biopsy site slice 5; D6 - biopsy site slice 6;
  D7 - biopsy site slice 7; D8, D9 - entire slice 8 with clip in D8; D10 -
  biopsy site slice 9; D11, D12 - slice 10, perpendicularly sectioned.  (**INITIALS)
  E) Received in a container of formalin labeled ""**NAME[BBB], left breast superior
  medial inferior segment"" is a 14 g, 7.8 SI x 3.8 x 1.4 cm yellow, lobulated
  portion of fibrofatty breast tissue.  One side of the margin has been
  previously inked red, blue, and yellow by the surgeon.  The opposing surface
  is marked with black ink.  There is a suture attached to the side of the
  specimen inked by the surgeon.  The specimen is serially sectioned and has
  yellow, lobulated, fatty cut surfaces.  No obvious breast tissue is grossly
  appreciated.  Every other section is submitted sequentially in eight
  cassettes.  (**INITIALS)
  F) Received in a container of formalin labeled ""**NAME[BBB], deep left breast
  margin"" is a 1 g, 2.5 x 2.5 x 0.3 cm yellow, lobulated portion of fibrofatty
  breast tissue.  One margin has been inked black by the surgeon.  This margin
  also has an attached metallic clip.  The specimen is quadrisected and has
  unremarkable cut surfaces and is entirely submitted into two cassettes.
  (**INITIALS)",,,,,
REG3,BREAST,0,PAT-00725751,1,REC-5000714057,,,,"<CLINICAL INFO>
 **AGE[in 40s] yo W with Dx Left breast cancer clinical T2,
  Grade III (SU-10-32562); Her left breast mass measured 24 x 29 x 29 mm on
  imaging and is located at the 9:00 position about 3 cm from the nipple;
  neoadjuvant chemo on **DATE[Nov 31 11] and completed 4 cycles of AC.  Left total
  mastectomy.<FINAL DX>
 Left breast, total mastectomy (497 g):  Invasive
  ductal carcinoma (2.4 cm); see Summary Cancer Data below.SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Breast, total mastectomy
  Residual invasive carcinoma S/P neoadjuvant therapy
  Histologic type: Invasive ductal carcinoma, NOS (85003)
  Extent/focality of carcinoma: Single contiguous residual mass/focus
  Span of residual invasive carcinoma (tumor bed): 2.4cm   x 2cm
  Size of largest residual focus of carcinoma: 2.4cm
      Comment about size determination:
  A discrete dense fibrous mass variably infiltrated by carcinoma; invasive
  carcinoma size is measured on composite section (A2-A3).
  Overall cellularity (invasive carcinoma only): 15%
  Cellularity comment:
  Variable carcinoma cellularity: from dense fibrosis centrally (0% cellularity)
  to variably cellular carcinoma, with mostly 5-10% scattered and some 20-30%
  grouped pattern, with estimated average ~15%.
  Grade of residual carcinoma: Deferred because of prior therapy
  Pre-treatment tumor characteristics
  Source of pre-treatment data: SU-10-32562
  Pre-treatment Nottingham grade: Grade III: 8-9 points
  Pre-treatment ER: Positive (**NAME[ZZZ] score = 8 of 8)
  Pre-treatment PR: Positive (**NAME[ZZZ] score = 6 of 8)
  Pre-treatment Her-2/neu by IHC: Intermediate for Her-2/neu overexpression by
  IHC
  Pre-treatment Her-2/neu by FISH: Negative for Her-2/neu gene amplification by
  FISH
  Pre-treatment Ki-67: 50%
  Residual DCIS present (85002)
  Nuclear grade of DCIS: High
  Necrosis in DCIS: Not identified
         Comment about DCIS: Very minimal, focal (A4)
  Angiolymphatic space invasion: Not identified
  Skin status: Carcinoma invades dermal stroma of skin
  Nipple status: Not involved
      Comment about skin/nipple: Deep dermis invasion (A2)
  Skeletal muscle status: Skeletal muscle not present
  Lobular carcinoma in-situ (LCIS): Absent
  Additional findings: Other finding(s)
  Stromal fibrosis, adenosis, fibroadenoma
  Microcalcifications: Present in invasive carcinoma
  Final surgical resection margins (including separately submitted margins):
  Invasive carcinoma margins:
  deep margin is >1 cm; anterior-inferior soft tissue margin=0.5 cm;  anterior-
  superior soft tissue margin = 0.8 cm.
  DCIS Margins: widely clear >1 cm
  Lymph node involvement (S/P neoadjuvant therapy)
  No lymph nodes to examine post-therapy
  Minimum pathologic stage (AJCC, 7th ed., 2010)
  Primary tumor [pT]: ypT2: Tumor > 2.0 cm and <= 5.0 cm - greatest dimension
  Regional nodes [pN]: ypNX: Cannot be assessed
  Distant metastasis [pM]: Not applicable or no pathologic information
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received unfixed labeled ""**NAME[BBB], left
  breast"" is a 497 g, 18 cm SI x 19 cm ML x 7 cm AP skin-sparing mastectomy.
  There is a 6.2 x 3.7 cm attached ellipse of tan-pink skin with a 1.3 x 1.0 x
  0.3 cm everted nipple.  Located at 9 o'clock, 2 cm from the nipple, there is
  an approximately 1.0 x 0.6 cm area of skin retraction/dimpling.  The breast is
  serially sectioned from medial to lateral and placed into formalin at 20:24 on
  **DATE[Apr 2 2012].  Located at 9 o'clock, 3 cm from the nipple, there is a tan-white,
  firm, stellate mass.  The mass is located underneath the of skin surface
  puckering.  The mass is located 2 cm from the posterior margin and 1 cm from
  the anterior-inferior soft tissue margin.  The mass measures 2.8 x 2.0 cm and
  spans four slices for a total medial to lateral distance of 3.2 cm.
  Representative sections:  A1 - section lateral to mass; A2-A3 - composite
  section mass, lateral slice; A4-A5 - composite section of a 3.6 x 3.1 cm area
  of next slice of mass; A6-A7-A8 - composite section next slice mass; A9 - next
  slice of mass; A10 - cassette submitted empty; A11 - slice medial to mass; A12
  - uninvolved upper inner quadrant; A13 - uninvolved lower inner quadrant; A14
  - uninvolved lower outer quadrant; A15 - uninvolved upper outer quadrant; A16-
  A17 - nipple.  (**INITIALS)",,,,,
REG3,BREAST,0,PAT-00739687,1,REC-5000714172,,,,"<CLINICAL INFO>
 Patient to see Dr. **NAME[ZZZ YYY] at Breast Cancer
  **INSTITUTION on **DATE[Aug 21 2011].<FINAL DX>
 **PLACE, WA; ***PATH-NUMBER[1]
  (**DATE[Jul 5 2011])
  Right breast retro-areolar central mass, needle biopsy:  Invasive ductal
  carcinoma with the following features (immunohistochemical stains performed at
  Skagit Pathology and available for review):
  1. Positive for estrogen and progesterone receptor with **NAME[XXX] scores 8 of 8
  for each.
  2. Negative for Her2 overexpression  by IHC.
  3. Ki-67 proliferative index 5-10%.
  4. Positive for E-Cadherin consistent with ductal phenotype.
  5. Smooth muscle myosin and p63 confirm the absence of myoepithelial cells
  around nests of invasive carcinoma.
  **PLACE, WA; ***PATH-NUMBER[2] (**DATE[Aug 7 2011])
  Right breast mass, lumpectomy (part 2):  Invasive ductal carcinoma with the
  following features:
  1. Nottingham grade I of III derived as follows:  Intermediate tubule
  formation, intermediate nuclear grade, low mitotic
   activity.
  2. Size/extent:  0.9 cm, based on extent in a single slide.
  3. Associated in situ component:  Minor component of intermediate grade ductal
  carcinoma in situ without necrosis.
  4. Microcalcifications:  Present in association with invasive carcinoma, DCIS,
  and nonneoplastic epithelium.
  5. Angiolymphatic invasion:  Focus suspicious.
  6. Margins:  Invasive carcinoma and DCIS are approximately 0.9 cm from the
  lateral margin, and >1 cm from remaining
   margins.
  Right axillary sentinel lymph node, excision (part 1):  One lymph node with no
  carcinoma identified on H&E or immunostained sections (IHC performed at Skagit
  pathology and available for review).
  CP/jps
  Procedures used to establish the diagnosis:
  RoutineMATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[1]  0B,10S  R breast retroareolar central mass, needle bx
   B ***PATH-NUMBER[2]  0B,17S  R axillary sentinel node, R breast mass",,,,,
REG3,BREAST,0,PAT-00742153,1,REC-5000714748,,,,"3261 NW Mount Vintage Way **ROOM
**PLACE, WA **ZIP-CODE
REPORT
FLUORESCENCE IN SITU HYBRIDIZATION REPORT
<FINAL DX>
Pathology Associates of Kitsap County ***PATH-NUMBER[1], A1 
Right breast, 8:00: Infiltrating ductal carcinoma
NEGATIVE for HER2 gene amplification by FISH
***PATH-NUMBER[1], A1 (Procedure Date: **DATE[Mar 25 2012]) 
HER2:CEP17 Ratio      1.4 
Number of nuclei counted:     70     
HER2 (SpectrumOrange)     5.7 mean signals per nuclei
CEP17 (SpectrumGreen)     4.0 mean signals per nuclei
Block ***PATH-NUMBER[1], A1 (Procedure Date: **DATE[Mar 25 2012])
Number of nuclei counted:          40
SMS (SpectrumOrange)     4.80 mean signals per nuclei
RARA (SpectrumGreen)     3.90 mean signals per nuclei
Block ***PATH-NUMBER[1], A1 (Procedure Date: **DATE[Mar 25 2012])
Number of nuclei counted:          60
P53 (SpectrumOrange)     4.38 mean signals per nuclei
COMMENTS
In a subset of breast carcinoma cases showing increased CEP17 signal copy
number by FISH, studies have shown that calculating the HER2:CEP17 ratio may
not reflect the actual HER2 amplification status (Troxell, ML et al., AJCP
2006;**ID-NUM). Because both the HER2 and CEP17 signals were significantly
elevated in this case, we assessed this tumor for alternative chromosome 17
loci (SMS, RARA, and P53 genes) in order to determine if evaluation of the
copy number for these alternative chromosome 17 loci, could lead to a
significantly increased HER2:Chromosome 17 ratio. The results for these
additional FISH studies demonstrated that these loci were elevated to a
similar degree as the CEP17 copy number. Therefore, the HER2:chromosome 17
ratio is not elevated and this case should be considered NEGATIVE for HER2
amplification.
MATERIAL RECEIVED
A1 = ***PATH-NUMBER[1], A1, 1 Block (**DATE[Apr 07 2012])
Fixative: Formalin
Duration of fixation >6 and <48 hours?: YES
CLIENT REQUEST/CLINICAL HISTORY
HER2 FISH.
METHODOLOGY
HER2 FISH testing is performed according to ASCO-CAP guidelines (Wolff AC et
al., J Clin Oncol 25:**PHONE). FISH testing for the purpose of alternative
chromosome 17 enumeration using probes to the SMS, RARA, and P53 loci has been
independently validated. Methods: Deparaffinized sections of tissue,
following pretreatment, are incubated with PathVysion    HER2 probe kit (**NAME[ZZZ]
**PLACE, IL) containing 2 separate probes: a locus-specific HER2
gene probe (17p11.2-q12 ) and a reference chromosome 17 centromere probe
(CEP17; 17p11.1-q11.1). Separate, similarly treated tissue section slides are
incubated with an **PLACE, IL) and a P53 (**PLACE, IL) probe, the later also containing a CEP17 probe.
Morphometric image analysis is performed using a MetaSystems    platform and
Metafer 4    application software. The HER2 and CEP17 signals are counted per
tile/nucleus and the HER2:CEP17 ratio is calculated. Similarly, the SMS/**NAME[CCC]
and P53 signals are also enumerated per nucleus. FISH Scoring: 
Results are scored as positive, negative, or equivocal for amplification based on
evaluation of the signal copy numbers for the alternative chromosome 17 loci.
Test Validation: The test methodology for HER2/CEP17 FISH testing employed in
this laboratory has demonstrated an extremely high concordance rate between
IHC and FISH (Gown AM et al., Mod Pathol **ID-NUM, 2008; Yaziji H et al.,
JAMA **ID-NUM, 2004). In the most recent study of 6604 patients, a 99.2%
concordance was demonstrated between negative (0 or 1+) HER2 IHC and
non-amplified HER2 FISH, and a 94.7% concordance was demonstrated between
positive (3+) HER2 IHC and amplified HER2 FISH. Quality Assurance: PhenoPath
Laboratories has in place a quality assurance program for HER2 FISH, which
includes daily controls (cell lines and tissues), Levy-Jennings analysis of
HER2 controls, and ongoing concordance studies between IHC and FISH, to ensure
high levels of interobserver and methodology concordance. . *PhenoPath
Laboratories' HER2 validation and ongoing monitoring of IHC and FISH assays
demonstrate extremely high concordance (>95%) that is independent of the
reported duration of fixation.
Chief Pathologist
Per CMS regulations, the pathologist's signature above indicates that this
case has been reviewed and the diagnosis made or confirmed by said
pathologist.
Note: Some of the tests reported here may have been developed and performance
characteristics determined by PhenoPath Laboratories. They have not been
cleared or approved by the U.S. Food and Drug Administration (FDA). However,
the FDA has determined that such clearance or approval is not necessary.
Pursuant to the requirements of CLIA, this laboratory has established and
verified the accuracy and precision of all tests, and additional information
about these tests is available upon request. PhenoPath Laboratories is
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
as qualified to perform high complexity clinical laboratory testing.",,,,,
REG3,BREAST,0,PAT-00739892,1,REC-5000715025,,,,"<CLINICAL INFO>
Right breast cancer.

<GROSS>
Received in a TranSpec container containing formalin, labeled with the patient's name and designated 'right breast lump,' is an unoriented 7.5 x 5.5 x 1.5 cm right breast lumpectomy with an inserted localization wire.  The accompanying radiograph reveals a metallic clip adjacent to the tip of the wire.  The outer surface of the breast tissue is inked blue in order to allow for the microscopic evaluation of the surgical resection margins.  Sectioning of the breast tissue reveals a hemorrhagic biopsy cavity measuring 1.0 x 0.5 x 0.5 cm.  This prior biopsy cavity comes to within 0.2 cm of the nearest resection margin.  Additional distinct masses or nodules are not identified.  The remainder of the lumpectomy grossly appears to be comprised of approximately 60% yellow glistening adipose tissue and 40% white to pink fibrous tissue.  The breast tissue is submitted in its entirety in cassettes A1-A22.  The prior biopsy site is found within cassettes A6-A11.
**INITIALS  **DATE[Aug 22 11]

<MICROSCOPIC>
Sections examined.  Patchy atypical lobular hyperplasia is present and focally the changes are consistent with lobular carcinoma in situ.  No LCIS is seen at the excision margins.  A focus of atypical ductal hyperplasia is also seen adjacent to the healing biopsy site, but it does not cross a threshold for a diagnosis of DCIS.  Block A16 has a sclerosing duct proliferation, as well as the in situ lobular proliferation, and that block is marked with immunohistochemical stains, which demonstrate that the sclerosing lesion has maintenance of myoepithelial smooth muscle myosin heavy chain expression indicative of a benign lesion.  The in situ lobular process has loss of E-cadherin expression indicating it is lobular rather than ductal. 
The findings are correlated with the operative report in ACIS EMR, which states this patient had a 'Newly diagnosed right breast cancer which is lobular carcinoma in situ on the extensive background of atypical ductal hyperplasia.  The patient was taken for surgery for lumpectomy to ensure there is no more lobular carcinoma in situ as well as no other carcinoma beyond the lobular carcinoma in situ, with intention of obtaining a good margin.'  No prior pathology is available in FHS pathology system for comparison.  
This case has undergone prospective intradepartmental departmental quality assurance review prior to verification.  
BAF/sls  **DATE[Aug 23 11]


<FINAL DX>
RIGHT BREAST, WIRE-LOCALIZED EXCISION:  
1.  FOCAL LOBULAR CARCINOMA IN SITU (LCIS) IN A BACKGROUND OF PATCHY ATYPICAL
LOBULAR HYPERPLASIA (ALH); NO INVASIVE CARCINOMA IDENTIFIED.
2.  FOCAL ATYPICAL DUCTAL HYPERPLASIA (ADH) BUT NO DCIS IDENTIFIED.
3.  ORGANIZING PRIOR BIOPSY SITE PRESENT.
4.  BACKGROUND OF EXTENSIVE FIBROPROLIFERATIVE CHANGES INCLUDING ADENOSIS,
CYSTIC DUCT DILATION, USUAL DUCTAL HYPERPLASIA, CALCIFICATIONS AND 
APOCRINE METAPLASIA.",,,,,
REG3,BREAST,0,PAT-00610527,2,REC-5000715435,,,,"PART / DESCRIPTION - SEQ# 
Breast, needle biopsy/ RIGHT STEREOTACTIC BREAST BIOPSY- 1Addendum Diagnosis
<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
<FINAL DX>

RIGHT BREAST, STEREOTACTIC NEEDLE BIOPSIES: A. DUCTAL CARCINOMA IN SITU WITH THE FOLLOWING FEATURES: 1. SIZE (EXTENT OF DCIS): DCIS INVOLVES MULTIPLE CORES WITH A  MAXIMUM LINEAR EXTENT OF 0.4 CM. 
 2. LOCATION: RIGHT BREAST (NOT OTHERWISE SPECIFIED). 3. NUCLEAR GRADE: G I.
 4. ARCHITECTURAL PATTERN: PREDOMINANTLY MICROPAPILLARY  AND CLINGING.
 5. NECROSIS: NOT IDENTIFIED.
 6. MICROCALCIFICATIONS: PRESENT IN DCIS AND NON-NEOPLASTIC  TISSUE.
 7. SPECIAL STUDIES: PENDING.
 B. ADDITIONAL FINDINGS: SENESCENT FIBROADENOMA WITH MICROCALCIFICATIONS.
**INITIALS

This case was reviewed by Dr. **NAME[ZZZ YYY], who concurs with the diagnosis.<MICROSCOPIC>
RIGHT STEREOTACTIC BREAST BIOPSY: 
Sections through the stereotactic needle biopsies from the right breast are reviewed on three levels. See diagnosis.<CLINICAL INFO>
Microcalcifications.<GROSS>
RIGHT STEREOTACTIC BREAST BIOPSY: 
(**INITIALS) Received in formalin, labeled **NAME[AAA BBB] and designated """"right breast,"""" are multiple yellow-tan needle core tissue portions ranging in size from 0.2 to 4.0 cm. Wrapped and entirely submitted in cassette 1a. Also in the same container is a green cassette containing multiple yellow-tan needle core tissue portions ranging in size from 0.5 to 3.0 cm. Entirely submitted in cassettes 1b. TE 1a, 1b<ADDENDUM COMMENTS>
Immunohistochemical studies performed at Laboratories Northwest show the following:
 Estrogen receptor   Positive (**NAME[XXX] score 5+3=8) Progesterone receptor  Positive (**NAME[XXX] score 5+2=7)

(**INITIALS **DATE[Aug 28 2011]) 






NOTE: Immunohistochemical evaluation of the estrogen receptor is performed using Ventana rabbit antihuman estrogen clone SP1. Immunohistochemical evaluation of the progesterone receptor is performed using Ventana rabbit antihuman progesterone receptor clone IE2.        
Our policy is to fix all breast tumors for at least 6 hours and <48 hours.
 



PATHOLOGIST:
**NAME[WWW VVV M.",,,,,
REG3,BREAST,0,PAT-00741857,1,REC-5000715460,,,,"PART / DESCRIPTION - SEQ# 
Biopsy, NOS/ RIGHT BREAST LOWER OUTER QUADRANT- 2
PART / DESCRIPTION - SEQ# 
Biopsy, NOS/ LEFT BREAST APPROXIMATELY 9:00- 1<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
<ADDENDUM COMMENTS>
Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. 

These studies showed the invasive tumor in the left breast (part 1) to be estrogen receptor positive (intensity score 3+ positivity score 5 = total **NAME[ZZZ] score 8) and progesterone receptor positive (intensity score 3+ positivity score 5 = total **NAME[ZZZ] score 8). The Ki-67-defined cell proliferation index was low (<10% of tumor cells positive). 

These studies showed the invasive tumor in the right breast (part 2) to be estrogen receptor positive (intensity score 3+ positivity 5 = total **NAME[ZZZ] score 8) and progesterone receptor positive (intensity score 3+ positivity score 5 = total **NAME[ZZZ] score 8). The Ki-67-defined cell proliferation index was low (<10% of tumor cells positive).

Additional testing regarding the HER2 status of these tumors is pending. Another addendum report will follow.
(**INITIALS **DATE[Jan 1 2012])






NOTE: Immunohistochemical evaluation of the estrogen receptor is performed using Ventana rabbit antihuman estrogen clone SP1. Immunohistochemical evaluation of the progesterone receptor is performed using Ventana rabbit antihuman progesterone receptor clone IE2.        
Our policy is to fix all breast tumors for at least 6 hours and <48 hours.






NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.Comment
Additional testing regarding the hormone receptor status, HER2 status and proliferative rate of the invasive carcinoma identified in both breast biopsies is pending. Addendum reports will follow. 

This case was reviewed by Dr. **NAME[YYY], who concurs.<MICROSCOPIC>
PART 1: LEFT BREAST APPROXIMATELY 9:00
Sections examined. See final diagnosis. 

Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. Antibodies utilized to evaluate the patient's breast carcinoma were estrogen receptor, progesterone receptor and KI-67. 

Special stains: Immunostains for estrogen receptor, progesterone receptor and Ki-67. 
 
PART 2: RIGHT BREAST LOWER OUTER QUADRANT 
Sections examined. See final diagnosis. 

Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. Antibodies utilized to evaluate the patient's breast carcinoma were estrogen receptor, progesterone receptor and KI-67. 

Special stains: Immunostains for estrogen receptor, progesterone receptor and Ki-67.<CLINICAL INFO>
Mass.<FINAL DX>

1) LEFT BREAST, """"APPROXIMATELY 9 O'CLOCK,"""" CORE BIOPSIES: A. INVASIVE LOBULAR CARCINOMA, CLASSIC-TYPE. 1. NOTTINGHAM HISTOLOGIC SCORE: 5 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR GRADE: 1.  c. MITOTIC COUNT: 1. 
 2. SIZE/EXTENT OF CARCINOMA: INVASIVE CARCINOMA INVOLVES MULTIPLE CORES WITH A MAXIMUM LINEAR EXTENT OF 1.1 CM. 
 3. FOCAL LOBULAR NEOPLASIA PRESENT. 
 4. ANGIOLYMPHATIC TUMOR INVASION: NOT IDENTIFIED. 
 5. MICROCALCIFICATIONS PRESENT IN NON-NEOPLASTIC FIBROCYSTIC TISSUE. 
 6. SPECIAL STUDIES PENDING (SEE COMMENT). 

2) RIGHT BREAST, LOWER OUTER QUADRANT, CORE BIOPSIES: A. INVASIVE LOBULAR CARCINOMA, CLASSIC-TYPE. 1. NOTTINGHAM HISTOLOGIC SCORE: 5 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR GRADE: 1.  c. MITOTIC COUNT: 1. 
 2. SIZE/EXTENT OF CARCINOMA: INVASIVE CARCINOMA INVOLVES ONE OF MULTIPLE CORES WITH A MAXIMUM LINEAR EXTENT OF 0.1 CM. 
 3. EXTENSIVE LOBULAR NEOPLASIA PRESENT. 
 4. ANGIOLYMPHATIC TUMOR INVASION: NOT IDENTIFIED. 
 5. MICROCALCIFICATIONS PRESENT IN LOBULAR NEOPLASIA. 
 6. SPECIAL STUDIES PENDING (SEE COMMENT). 
MJF:cr<GROSS>
PART 1: LEFT BREAST APPROXIMATELY 9:00
(**INITIALS) Received in formalin, labeled **NAME[AAA BBB] and designated """"left breast,"""" are multiple yellow-white and brown needle core tissue portions measuring up to 3.6 cm in length. Entirely submitted in cassettes 1a, 1b. TE 1a, 1b
 
PART 2: RIGHT BREAST LOWER OUTER QUADRANT
(**INITIALS) Received in formalin, labeled **NAME[AAA BBB] and designated """"right breast,"""" are multiple yellow-white and brown needle core tissue portions measuring up to 3.5 cm in length. Entirely submitted in cassette 2a. TE 2aAddendum Diagnosis
PATHOLOGIST:
**NAME[XXX WWW]",,,,,
REG3,BREAST,0,PAT-00476969,2,REC-5000716065,,,,"PART / DESCRIPTION - SEQ 
breast mass, oriented/ LEFT BREAST, EXCISIONAL BIOPSY- A
PART / DESCRIPTION - SEQ 
Lymph node, Sentinel/ LEFT AXILLARY SENTINEL NODE #1- D
PART / DESCRIPTION - SEQ 
breast mass, oriented/ LEFT BREAST FINAL INFERIOR AND LATERAL MARGIN- C
PART / DESCRIPTION - SEQ 
breast mass, oriented/ LEFT BREAST, LUMPECTOMY- B
PART / DESCRIPTION - SEQ 
Lymph node, Sentinel/ LEFT AXILLARY SENTINLE NODE #2- E
INTRAOPERATIVE DX:
NONEConsult
Dr. **NAME[ZZZ], selected slides, Part A.
FINAL DX:
A. LEFT BREAST, EXCISIONAL BIOPSY: 
  -Benign breast tissue with: -Biopsy site. -Radial scar. -Columnar cell alteration, ductal hyperplasia without atypia, microcysts. -No in situ or invasive carcinoma identified; margins evaluated.

B. LEFT BREAST, ORIENTED EXCISION WITH WIRE LOCALIZATION: Infiltrating carcinoma with the following features:  Histologic type:    Ductal.
Size:     1.0 cm.  Histologic grade:   2 of 3.  Nottingham grade:   6 of 9.   Tubule formation:    poor (3 of 3).   Nuclear grade:   intermediate (2 of 3).   Mitotic rate:    low (1 of 3).  Lymph-vascular invasion:  Not identified. No ductal carcinoma in situ (DCIS) identified.
Surgical margins, Infiltrating carcinoma:   Inferior:   negative (8 mm).   All other margins:  negative (>10 mm). Summary of lymph node status (including all lymph nodes from parts D and E):       Two lymph nodes, negative for tumor on step sections (0/2). Pathologic stage:  pT1b, pN0(sn) (AJCC 7th edition). Additional findings:  Biopsy site.   Immunohistochemistry staining for estrogen and progesterone receptor expression and Her-2/neu overexpression have previously been performed (***PATH-NUMBER[1]), with the following results: ER 100%, PR 100%, HER-2/neu negative (score of 1+).

C. LEFT BREAST FINAL INFERIOR AND LATERAL MARGIN: 
  -Benign breast tissue. -No in situ or invasive carcinoma identified; margin evaluated.

D. LEFT AXILLARY SENTINEL NODE #1: 
  -One lymph node, negative for tumor on step sections.

LEFT AXILLARY SENTINLE NODE #2: -One lymph node, negative for tumor on step sections.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''A. left breast wire-guided excisional biopsy'', is an oriented breast specimen with localization wire inserted through the lateral margin and exiting out the medial margin, designated anterior wire at 3 o'clock. Please note the ink key is different - red ink is toward nipple, yellow ink is toward armpit more posterior lesion. It has dimensions as follows: 2.7 cm from medial to lateral, 2.1 cm from superior to inferior, 3 cm from anterior to posterior. It is inked as follows: deep - black, anterior - blue, toward nipple - red, toward armpit - yellow, superior - orange, inferior - green. The specimen is sectioned from anterior to posterior into ten slices. Within slices 4-6, there is a 0.9 x 0.7 x 0.6 cm hemorrhagic previous biopsy site, which is at the lateral margin and is 1.5 cm of the medial margin, 1 cm of the superior margin, 1.2 cm of the inferior margin and is widely free of the anterior and posterior margins. The uninvolved parenchyma is 80% fibrous tissue interspersed between 20% fatty tissue. The specimen is submitted in its entirety as follows: A1 - slice 1; A2 - slice 2; A3 - slice 3; A4 - slice 4; A5 - slice 5; A6-A7 - slice 6, composite section; A8-A9 - slice 7, composite section; A10-A11 - slice 8, composite section; A12 - slice 9; A13 - slice 10. Please note the specimen was placed in formalin on **DATE[Oct 27 2011] at 12:39 p.m. and formalin fixation time is 7 hours 51 minutes.
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''B. left breast wire guided lumpectomy'', is an oriented breast specimen received previously inked. There is a localization wire inserted at the anterior margin and exiting out the inferior medial margin. Overlying the anterior margin, there is a C-shaped 3 x 0.6 cm unremarkable skin ellipse. The localization wire is oriented as entering lateral and exiting medial. It has dimensions as follows: 4.8 cm from medial to lateral, 4.5 cm from superior to inferior and 3.7 cm from anterior to posterior. It is inked as follows: deep - black, anterior - blue, toward nipple - red, toward armpit- yellow, superior - orange, inferior - green. The specimen is sectioned from toward nipple to toward armpit into 17 slices. Within slices 7-8, there is a spiculated, firm 1 x 1 x 0.8 cm mass which is 1.2 cm of the inferior margin, 2.5 cm of the superior margin, 1.5 cm of the posterior margin and 1.5 cm of the anterior margin and is widely free of the medial and lateral margins. The uninvolved parenchyma is 20% fibrous tissue interspersed between 20% fatty tissue. Representative sections are submitted as follows: B1 - slice 1; B2-B3 - slice 3 composite section; B4-B7 - slice 6 composite section submitted from superior to inferior; B8-B12 - slice 7, composite section submitted from superior to inferior, further sectioned from posterior to anterior; B13-B15 - slice 8, composite section; B16-B18 - slice 9, composite section submitted from superior to inferior; B19-B20 - slice 11, composite section; B21 - slice 17. Please note the specimen is placed in formalin on **DATE[Oct 27 2011] at 1:38 p.m. and formalin fixation time is 6 hours 52 minutes.
C. Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''C. left breast final inferior and lateral margin'', is a previously inked, 3.5 x 3 x 0.5 cm fibrofatty tissue. The inside of the lumpectomy cavity is inked blue. The new margin is inked black. The specimen is sectioned into 6 slices. No masses are identified. The parenchyma is mainly fatty tissue with scant fibrous tissue present. The specimen is submitted in contiguous order in C1-C6. Please note the specimen was placed in formalin on **DATE[Oct 27 2011] at 1:38 p.m. and formalin fixation time is 6 hours 52 minutes.
D. Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''D. level blue normal, 8551, left axillary sentinel lymph node no.1'', is a 2.5 x 1 x 1 cm portion of fibrofatty tissue with a 2.2 x 1 x 1 cm lymph node. The lymph node is sectioned and submitted in its entirety in one cassette. 
E. Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''E. left axillary sentinel lymph node no.2, blue level 1 normal, 3262'', is a 2.7 x 1.5 x 1.1 cm blue-dyed node, which is sectioned and submitted in its entirety in two cassettes. (ESP/es:cmc78 277965)
CLINICAL INFO:
Left breast carcinoma, left breast radial scar. **AGE[in 50s]-year-old with left breast carcinoma and left breast radial scar.
ICD-9 code: 239.83.
PATHOLOGIST:
**NAME[YYY XXX] S  

SNOMED Code(s)",,,,,
REG3,BREAST,0,PAT-00742410,1,REC-5000716321,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Left Anterior Breast, Core Needle Biopsies for Calcifications:
Ductal carcinoma in situ with the following features:
Histologic type:         Solid and cribriform.
Nuclear grade:           High.
Necrosis:                Present.
Associated calcification:     Present.
Invasive carcinoma: Not identified.
Additional findings:     Immunohistochemical studies for estrogen and
progesterone receptor expression will be performed and reported in an
addendum.

B.  Left Posterior Breast, Core Needle Biopsies:
Benign fibrocystic changes.
No definite calcifications identified (see comment).
No evidence of atypia or malignancy.

<COMMENT>
Per Dr. **NAME[ZZZ M. YYY] (radiology), no definite calcifications were
identified radiographically within the left posterior core needle biopsy
specimen (part B).

<CLINICAL INFO>
Suspicious calcifications involving left inferior breast.  Collection
date **DATE[May 05 2012] at A. 1:30 p.m., B. 2:30 p.m. resulting in a fixation
time for A. 9.5 hours and B. 7.5 hours.

<GROSS>
A.  Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated ""left
anterior breast needle core"", per requisition, is a cassette that per
requisition contains the calcs which consists of two hemorrhagic
fibrofatty needle cores with a diameter of 0.3 cm and a maximum length
of 2 cm.  These calcs are submitted in cassette A1.  There is also a 3 x
1.5 x 0.5 cm aggregate of yellow-tan fibrofatty soft tissue fragments,
each with a diameter of 0.3 cm that are entirely submitted in cassettes
A2 and A3.

B.  Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated ""left
posterior breast needle core"", per requisition, is a 4.2 x 2.5 x 0.6 cm
aggregate of yellow-tan fibrofatty soft tissue fragments, each with a
diameter of no greater than 0.3 cm.  The specimens are entirely
submitted in cassettes B1 and B2.  (ps/bas)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

PHYSICIAN NOTIFICATION:
Case discussed with Dr. **NAME[ZZZ M. YYY] on **DATE[May 06 2012]

INTRADEPARTMENTAL CONSULTATION:
**NAME[XXX M. WWW], M.D.

**NAME[VVV M. UUU], MD.  Electronically signed **DATE[May 06 2012]",,,,,
REG3,BREAST,0,PAT-00745750,1,REC-5000717409,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Immunohistochemistry results

<FINAL DX>     

Left Upper Quadrant Breast 2 o'clock:
Ductal carcinoma in situ with the following features:
Histologic type:         solid
Nuclear grade:           High.
Necrosis:                Present.
Associated calcification:     Present.
Invasive carcinoma: Not identified.
Additional findings:     Focal cancerization of the lobules and
scattered dense periductal lymphocytic infiltrates noted.
          Immunohistochemical studies for estrogen and progesterone
receptor expression will be performed and reported in an addendum
report.

Consult:**NAME[ZZZ] YYY]/PhD.

<CLINICAL INFO>
An 8.3 cm segmental area left breast calcs. BIRADS 4C. The tissue was
collected on **DATE[Aug 30 2011] at 9:20 a.m. Total formalin fixation time is 11
hours 40 minutes.

<GROSS>
The specimen is received in formalin, in two containers, each labeled
""**NAME[BBB, AAA]"" and designated ""left breast 2 o'clock"", per container,
and further designated, ""left upper-outer quadrant"" per requisition. The
first container is designated ""calcs"" and contains six 0.2 cm in
diameter elongated portions of tissue from 0.3 to 1.1 cm in length. They
are inked blue and entirely submitted in A1. Also received in formalin,
labeled ""**NAME[BBB, AAA]"" and designated ""left breast 2 o'clock"", per
container, and further designated, ""left upper-outer quadrant"" per
requisition, are eleven 0.2 cm in diameter elongated portions of tissue
from 0.4 to 1.2 cm in length along with a 0.25 cc aggregate of pink-tan
tissue fragments, less than 0.2 cm in greatest individual dimension.
They are inked blue and entirely submitted in cassettes A2 and A3.
(rkg/do)

<MICROSCOPIC>
Reviewed are 12 HE-stained slides including levels. Please see
diagnosis.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Sep 01 2011]

<ADDENDUM> #1

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
ER   5 %  See Comment
PR   0 %  Negative

Impression:  The tumor is positive for estrogen receptors and negative
for progesteron receptors.
Interpreted by:  **NAME[XXX M. WWW] M.D. and **NAME[VVV M. UUU] M.D.
Comment:  Focally positive for ER,estimated 5%of tumor cells.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

Addendum #1 performed by **NAME[XXX M. WWW], M.D.  Electronically signed
**DATE[Sep 07 2011]",,,,,
REG3,BREAST,0,PAT-00738400,1,REC-5000718132,,,,"<CLINICAL INFO> 
Left breast cancer 
<GROSS>: 
The specimen is received without fixative for intraoperative consult, labeled '**NAME[BBB, AAA]' and 
designated 'left breast partial mastectomy'. It consists of an oriented fibrofatty tissue fragment 
weighing 87 grams and measuring 9.5 cm from medial to lateral, 6.5 cm from superior and 3 cm 
from anterior to posterior. On the anterior aspect there is a 6.5 x 1.5 cm skin ellipse running 
from medial to lateral. 
With the provided orientation the specimen is inked as follows: 
Medial-Red 
Lateral-Yellow 
Superior-Orange 
Inferior-Green 
Anterior-Blue 
Deep-Black 

The tissue is serially sectioned from lateral to medial into 11 slices revealing a firm indurated 
irregular mass occupying slices 6-9 and grossly measuring 3.1 x 3 x 3.2 cm. The mass is 0.5 
cm from the deep margin, 0.5 cm from the inferior margin, 1.2 cm from the anterior margin, 1.5 
cm from the superior margin, 1.5 cm from the overlying skin, 1.8 cm from the medial margin and 
3.2 cm from the lateral margin. Additionally, the mass is located within a field of rubbery to 
dense fibrocystic tissue occupying slices 6-11. The remainder of the specimen shows soft tan-
yellow fibrofatty cut surfaces with no additional lesions or abnormalities. 
Representative sections are submitted as follows: 
1-Perpendicular sections of slice 1 with yellow-inked lateral margin. 
2-Representative fibrous tissue, slice 3. 
3-Representative section from slice 6, lateral extent of mass. 
4-Slice 7, representative section of dense fibrocystic tissue superiorly adjacent to mass. 
5-6-Slice 7, representative sections of mass with deep and inferior margins. 
7-10-Slice 8, mass in this slice submitted sequentially from superior towards inferior with 
nearest inked margins. 
11-Slice 8, anterior margin and skin nearest to mass. 
12-Slice 9. mass with nearest inferior margin. 

15-Representative perpendicular section of slice 11 with medial margin. 
<FINAL DX> 
LEFT BREAST, PARTIAL MASTECTOMY (9.5 x 6.5 x 3 cm, 87 gms): 
Invasive mammary carcinoma with the following features: 
1. HISTOLOGIC TYPE: Infiltrating ductal carcinoma. 
2. TUMOR SIZE: 32 x 31 x 30 mm. 
3. 
HISTOLOGIC GRADE: III of III. 
Nottingham Histologic Score: 9 of 9. 
Nuclear pleomorphism score: 3 of 3. 
Tubular differentiation score: 3 of 3. 
Mitotic score: 3 of 3 (28 per 10 hpf). 
4. IN SITU CARCINOMA: Present, solid type, high grade nuclei, no evident comedo necrosis 
less than 5% of tumor. 
5. RESECTION MARGINS: 
Medial-Red: 18 mm. 
Lateral-Yellow: 32 mm. 
Superior-Orange: 15 mm. 
Inferior-Green: 3 mm. 
Anterior-Blue: 12 mm. 
Deep-Black: 5 mm. 
6. CALCIFICATIONS: Not observed. 
7. LYMPHOVASCULAR INVOLVEMENT: One suspicious focus (slide 4). 
8. ADDITIONAL FINDINGS: Surrounding breast tissue with fibrocystic changes and sclerosing 
adenosis. 
9. HORMONE RECEPTOR STUDIES AND HER-2/NEU STUDIES: Performed on this patient's 
prior biopsy(Outside report) and show the following by written report: 
ER: Positive >95%. 
PR: Positive >95%. 
HER-2/neu: Negative +1 by IHC. 
th
10. AJCC (7 ed.) PATHOLOGIC TUMOR STAGE: pT2 pNX. 
This case has been subjected to review by a second pathologist per departmental quality assurance policy.",,,,,
REG3,BREAST,0,PAT-00743812,1,REC-5000718354,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  BREAST, RIGHT, ULTRASOUND GUIDED CORE BIOPSY:  INVASIVE WELL
DIFFERENTIATED DUCTAL CARCINOMA, HISTOLOGIC GRADE 1 OF 3. 
1. TUBULE FORMATION: MAJORITY
2. NUCLEAR GRADE: LOW TO INTERMEDIATE
3. MITOTIC ACTIVITY: LOW
4. LONGEST CONTIGUOUS LENGTH: 0.8 CM 
5. IN-SITU COMPONENT: ABSENT
6. CALCIFICATIONS: ABSENT IN THIS SPECIMEN
7. CAPILLARY LYMPHATIC SPACE INVASION: ABSENT IN THIS SPECIMEN.
8. BREAST MARKERS: ER POSITIVE, PR POSITIVE, HER2/NEU 1+, NEGATIVE. 
9. ADDITIONAL FINDINGS: MINUTE FOCI OF ATYPICAL DUCTAL HYPERPLASIA. 
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. HER2-NEU (4B5): 1+, NEGATIVE
2. ESTROGEN RECEPTOR (SP1): POSITIVE (**NAME[ZZZ] Score 8)
3. PROGESTERONE RECEPTOR (IE2): POSITIVE (**NAME[ZZZ] Score 8)
4. CALPONIN (EP798Y): NEGATIVE IN GLANDS OF INTEREST
5. SMOOTH MUSCLE MYOSIN (SMMS-1): NEGATIVE IN GLANDS OF INTEREST
6. p63 (BC4A4): NEGATIVE IN GLANDS OF INTEREST
Fixation Time: Within Guideline Limits (See comment).
: Negative estrogen and progesterone receptors and Her-2/neu
results may be unreliable in cases where fixation time is shorter than
guideline limits suggest. 
Interpretation: Estrogen/progesterone receptor evaluation is based on the
**NAME[ZZZ] Scoring system.  An **NAME[ZZZ] score of 3 to 8 is considered positive.
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.

<PATHOLOGIST>
   **NAME[YYY] MD, **NAME[XXX]               Electronically Signed: **DATE[Oct 13 2011]
<SPECIMEN(S)>
  A) US biopsy - 3 core spec - right breast
<CLINICAL INFO>
  Right breast mass
<GROSS>
  Received in a container labeled with the patient's name and no site are
three needle cores 1.2 to 1.6 cm, AE/(3).
<MICROSCOPIC>
  Sections show an invasive well differentiated ductal carcinoma, histologic
grade 1 of 3.  The tumor shows greater than 75% tubule formation (score
1), is composed of malignant cells with grade 1-2 nuclear features (score
2) and has a low mitotic rate (score 1).  The small infiltrating glands
are lined by cuboidal malignant cells with either eosinophilic or clear
cytoplasm with glands set within edematous appearing fibrous stroma. There
are rare cribriform glands. No in-situ component is identified. There is
no evidence of capillary lymphatic space invasion. No calcifications are
identified. The longest contiguous length of tumor is 0.8 cm. There is
focal atypical ductal hyperplasia.",,,,,
REG3,BREAST,0,PAT-00742862,1,REC-5000718380,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  RIGHT BREAST, UPPER OUTER QUADRANT, CORE BIOPSIES: DUCTAL CARCINOMA IN
SITU. 
1. NUCLEAR GRADE: LOW. 
2. CENTRAL NECROSIS: ABSENT. 
3. CALCIFICATIONS: PRESENT, ASSOCIATED WITH IN SITU CARCINOMA. 
4. NO INVASIVE CARCINOMA IDENTIFIED.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Jun 14 2012]
<SPECIMEN(S)>
  A) right upper outer breast stereotactic biopsy
<CLINICAL INFO>
  abnormal mammogram
<GROSS>
  Received in a container labeled with the patient's name and ""right stereo
breast biopsy"" are ten needle core fragments ranging from 0.4 to 2.5 cm,
green cassette, all embedded seven pieces in cassette 1; three pieces in
cassette 2. 
Received floating free within the container are multiple needle core
fragments less than 0.1 up to 3 cm. all embedded five pieces in cassette
3; multiple in cassette 4.
<MICROSCOPIC>
  Sections show cores of breast parenchyma and fatty soft tissues. Two cores
show foci of low grade ductal carcinoma in situ. The largest single span
of DCIS measures 1.5 mm. The cells show a low nuclear grade in a solid
growth pattern. One area of the lesion has disassociated from surrounding
stromal tissues. Associated microcalcifications are present. No invasive
carcinoma is seen.",,,,,
REG3,BREAST,0,PAT-00743814,1,REC-5000718383,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  BREAST MASS, RIGHT LOWER OUTER QUADRANT, ULTRASOUND GUIDED CORE BIOPSY: 
INVASIVE DUCTAL CARCINOMA WITH THE FOLLOWING FEATURES: 
1. NOTTINGHAM GRADE 2/3, DERIVED AS FOLLOWS: POOR TUBULE FORMATION-3,
INTERMEDIATE NUCLEAR GRADE-2, LOW MITOTIC ACTIVITY-1. 
2. CARCINOMA INVOLVED 95% OF FOUR OF FOUR CORE BIOPSY TISSUE. 
3. MICROCALCIFICATIONS: NOT IDENTIFIED. 
4. DUCTAL CARCINOMA IN-SITU: NOT IDENTIFIED IN THE CURRENT BIOPSY.
5. ANGIOLYMPHATIC INVASION: NOT IDENTIFIED IN THE CURRENT BIOPSY.
6. BREAST MARKER STUDIES WERE PERFORMED AT GROUP HEALTH PATHOLOGY
LABORATORY WITH THE FOLLOWING RESULTS: 
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. HER2-NEU (4B5): 0-1+, NEGATIVE 
2. ESTROGEN RECEPTOR (SP1): POSITIVE (**NAME[ZZZ] Score 8 of 8)
3. PROGESTERONE RECEPTOR (IE2): POSITIVE (**NAME[ZZZ] Score 8 of 8)
Fixation Time: Within Guideline Limits (See comment).
: Negative estrogen and progesterone receptors and Her-2/neu
results may be unreliable in cases where fixation time is shorter than
guideline limits suggest. 
Interpretation: Estrogen/progesterone receptor evaluation is based on the
**NAME[ZZZ] Scoring system.  An **NAME[ZZZ] score of 3 to 8 is considered positive.
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.


<PATHOLOGIST>
   Zhu, Lee-Ching              Electronically Signed: **DATE[Feb 15 2012]
<SPECIMEN(S)>
  A) highly suspicious  solid mass   Rt breast LOQ    US guided core biopsy
rt breast 
<CLINICAL INFO>
  r/o breast cancer
<GROSS>
  Received in a container labeled with the patient's name and ""right breast""
are four fine needle core fragments ranging from 0.2 to 1 cm, AE/(4).
<MICROSCOPIC>
  Cores of breast parenchyma are subtotally replaced by an invasive ductal
carcinoma, eliciting desmoplastic reaction.",,,,,
REG3,BREAST,0,PAT-00743457,1,REC-5000723173,,,,"<SPECIMEN(S)> 
A. Breast -Ultrasound guided core biopsy, left breast 9:00 (4 cores) 
B. Breast -Ultrasound guided core biopsy, left breast 12:00 (4 cores) 
<CLINICAL INFO> 
Left breast 611.72, A) Left breast 9:00, 2 cm from nipple -specimen collection and fixation 
done on **DATE[Jul 14 12] at 11:00, B) Left breast 12:00, 1 cm from nipple -specimen collection and 
fixation done on **DATE[Jul 14 12] at 11:00 

<FINAL DX> 
A. Left breast ultrasound-guided needle core biopsy, 9:00, 2 cm from the nipple: 
Ductal carcinoma in situ (DCIS) 
Size (extent): Largest focus measures 0.6 cm on slide; tumor involves 4 of 4 cores. 
Histologic pattern: Cribriform. 
Nuclear grade: 2 of 3. 
Necrosis: Present. 
Microcalcifications: Not identified. 
Hormone receptor studies: Estrogen receptor pending, addendum report to follow. 
B. Left breast ultrasound-guided needle core biopsy, 12:00, 1 cm from the nipple: 
Florid adenosis with focal area of atypical sclerosis (see comment). 

<COMMENT>: In the area of florid adenosis present in part B, there is an atypical area of 
sclerosis which probably represents sclerosis adenosis. In order to rule out the 
possibility of invasive carcinoma in this area, immunohistochemistry is performed. An 
addendum report will be issued at the conclusion of those studies. 
This case has been subjected to review by a second pathologist per departmental quality 
assurance (QA) policy. 
DB/dh 

 

<GROSS> 
Received are two formalin-filled containers labeled '**NAME[AAA BBB] 75597' and a requisition 
with '**NAME[BBB, AAA] 75597'. The specimens are placed in formalin at 1100, **DATE[Jul 14 2012], for a 
total fixation time of 12 hours. 
The first specimen is designated 'left breast site one 9:00, 2 cm from nipple 
ultrasound-guided core biopsy 14-gauge Achieve'. It consists of four needle cores measuring 
up to 1.6 cm in length with a diameter of 0.1 cm. Entirely submitted in A1 and A2. 
The second specimen is designated 'left breast site two 12:00, 1 cm from nipple 
ultrasound-guided core biopsy 14-gauge Achieve' (labeled 'left breast 12:00, 1 cm from 
nipple'). It consists of four needle cores measuring up to 1.5 cm in length with a diameter 
of 0.1 cm. Entirely submitted in B1 and B2. 
**INITIALS 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis.",,,,,
REG3,BREAST,0,PAT-00743103,1,REC-5000723177,,,,"<SPECIMEN(S)> 
A. Breast -Left breast mass 2:00, upper outer quadrant 
B. Sentinel Lymph Node -Left sentinel lymph node 
C. Breast -Additional superior margin 
D. Breast -Additional inferior margin 
88307 (**DATE[Sep 13 11]-1421 SWHITING) 
3260F (**DATE[Sep 13 11]-1421 SWHITING) 
**DATE[Sep 13 11] -1421 SWHITING 
**DATE[Sep 13 11] -1421 SWHITING 

 
<CLINICAL INFO> 
Left breast carcinoma 174.9 -A) Specimen collection and fixation done on **DATE[Sep 12 11] at 13:25, 
B -D) Specimen collection and fixation done on **DATE[Sep 12 11] at 13:14 

<FINAL DX> 
Left breast excisional specimen: 
Invasive carcinoma 
Tumor size: 1.2 cm in maximum dimension. 
Tumor focality: Single focus. 
Tumor site: Upper outer quadrant (2:00 o'clock). 
Histologic type: Ductal carcinoma. 
Histologic grade: Nottingham grade 2 of 3 (Tubule score 3 of 3; nuclear 
score 2 of 3; mitotic count less than 1 per 10 hpf, score 1 of 3). 
Lymph-vascular invasion: Not identified. 
Skin: Negative for tumor. 
Nipple: Absent. 
Skeletal muscle: Absent. 
Ductal carcinoma in situ: Focally present; nuclear grade 1 of 3 without 
necrosis, comprising less than 5% of tumor. 
Lobular carcinoma in situ: Not identified (a single small focus of atypical 
lobular hyperplasia present). 
Margins (invasive carcinoma): Negative for tumor, 0.4 cm from the 
superior (orange) margin and 0.6 cm from the inferior (green) margin (See 
parts C and D for re-excision of these margins). 
Estrogen receptor: Positive. Progesterone receptor: Positive. HER2: 
Negative by FISH. All performed on previous needle core biopsy. 
Microcalcifications: Focally present within blood vessels. 
Lymph nodes: 
Number of sentinel nodes: 2. 
Total number of nodes (sentinel, non-sentinel): 2. 
Number of nodes with macrometastases (>0.2 cm): 0. 
Number of nodes with micrometastases (>0.2 mm to 0.2 cm): 0. 
Number of nodes with isolated tumor cells (<0.2 mm): 0. 
AJCC (7th ed.) pathologic stage: pT1c pN0 (sn). 
Specimen: Partial breast. 
Procedure: Excision with guidewire localization. 
Lymph node sampling: Two sentinel lymph nodes (see Part B). Specimen 
integrity: Three separate specimens (Parts A, C and D). 
Specimen size (for excisions less than total mastectomy): 6.0 x 4.7 x 2.8 
cm. (Part A), 3.5 x 2.5 x 1.5 cm (Part C) and 4.0 x 2.5 x 1.5 cm (Part D). 
Specimen laterality: Left. 
B. Left axilla sentinel lymph node: 
Two lymph nodes identified, both negative for metastatic carcinoma by serial H&E 
sections. 
C. Left breast additional superior margin: 

 

<FINAL DX> (Continued) 
Negative for malignancy and significant atypia. 
D. Left breast additional inferior margin: 
Negative for malignancy and significant atypia. 
This case has been subjected to review by a second pathologist per departmental quality 
assurance (QA) policy. 
**INITIALS 

<GROSS> 
Received are four formalin-filled containers labeled `**NAME[BBB, AAA M]., H000449616' and a 
requisition with `**NAME[BBB, AAA M]., H000449616'. The specimens are placed in formalin 
between 1325 and 1314 on **DATE[Sep 12 2011], for a total fixation time of approximately 9.5 hours. 
The first is designated `left breast mass, 2:00, upper outer quadrant' and is a 29.0 gram 
yellow tissue, 6.0 cm from medial to lateral, 4.7 cm from superficial to deep and 2.8 cm 
from superior to inferior. There is an attached blue-stained skin ellipse, 3.9 x 0.7 cm. 
Extending into the lateral end of the skin ellipse is a hooked 14.0 cm in length guidewire. 
Orientation is short suture superior and long lateral. The specimen is inked as follows: 
superior -orange, inferior -green, superficial -blue, deep -black, lateral -yellow, and 
medial -red. The specimen is sectioned from lateral to medial into eleven slices. On the 
cut surfaces of slices 3 through 5, there is a circumscribed firm mass. This mass is 1.2 x 
1.0 x 1.0 cm. The mass is within 0.5 cm of the orange superior and 1.0 cm or greater from 
all other margins. This area approximately corresponds to the hook of the guidewire. 

Summary of sections: 
A1 Slice 1, lateral margin represented, section perpendicular to margin, two pieces in 
cassette. 
A2 Slice 2, orange superior. 
A3 Slice 3, orange superior green inferior, apparent beginning of mass. 
A4 Slice 4, mass or superior green inferior. 
A5 Slice 4, skin and blue superficial. 
A6 Slice 5, mass and orange superior, greatest size of mass, orange-inked seepage has 
occurred, 
only black over orange is true superior margin. 
A7 Slice 5, black deep. 
A8 Slice 6, mass and green inferior. 
A9 Slice 11, medial margin represented, section perpendicular to margin, three pieces in 
cassette. 
The second is designated `left sentinel lymph node' and is an unoriented yellow-pink tissue 
measuring 2.5 x 2.0 x 1.5 cm. This has a 1.5 cm yellow-pink lymph node. In addition to the 
distinct lymph node there is a firm gray-pink loosely attached piece of tissue, 0.3 x 0.3 x 
0.2 cm. 

 

<GROSS> (Continued) 

Summary of sections: 
B1-B3 One lymph node submitted for special handling. 
B4 Piece of loosely-attached gray fibrous tissue not for special handling. 
The third is designated `additional superior margin' and is an unoriented 7 gram yellow 
tissue, 3.5 x 2.5 x 1.5 cm. One aspect is convex. The other is concave. The convex aspect 
is inked orange. The concave aspect is inked black and the specimen is sectioned 
perpendicular to the long axis into eleven slices. The cut surface is yellow tissue with no 
grossly suspicious features. 

Summary of sections: 
C1 Slice 1. 
C2 Slice 3. 
C3 Slice 6. 
C4 Slice 8. 
C5 Slice 10. 
The fourth is designated `additional inferior margin' and is a 6.7 gram unoriented yellow 
tissue which is 4.0 x 2.5 x 1.5 cm. One aspect of this tissue is convex. This aspect is 
inked green. The opposite concave aspect is inked black. The specimen is sectioned 
perpendicular to the long axis into fifteen slices. The cut surface has a moderate white 
component, but no grossly suspicious features. 

Summary of sections: 
D1 Slices 1 and 2. 
D2 Slice 3. 
D3 Slice 4. 
D4 Slice 5. 
D5 Slice 6. 
D6 Slice 7. 
D7 Slices 14 and 15, all grossly evident fibrous tissue submitted. 
**INITIALS 
**DATE[Sep 13 11] -1421 SWHITING 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis.",,,,,
REG3,BREAST,0,PAT-00740473,1,REC-5000725010,,,,"<CLINICAL INFO>
Right breast cancer

<GROSS>
     1.     Received fresh, labeled **NAME[BBB, AAA], #1, is a soft, partially fatty lymph node, 1.8 x 0.8 x 0.7 cm.  SECTIONS:  A1 and A2 = in total.
2.     Received fresh, labeled **NAME[BBB, AAA], #2, is a single fatty lymph node, approximately 2.2 x 0.9 x 0.4 cm.  SECTIONS:  B1 and B2 = in total.
3.     Received fresh, labeled **NAME[BBB, AAA], #3, is a partially fatty lymph node, 2.2 x 1.2 x 1.0 cm.  SECTIONS:  C1 and C2 = in total.
4.     Received fresh, labeled **NAME[BBB, AAA], #4, is a soft, fatty lymph node, 2.0 x 1.1 x 1.0 cm.  SECTIONS:  D1 and D2 = in total.
5.     Received fresh, labeled **NAME[BBB, AAA], #5, is a soft, tan lymph node, 0.6 x 0.3 x 0.3 cm.  SECTIONS:  E1 = in total, bisected.
6.     Received fresh, labeled **NAME[BBB, AAA], #6, is a soft, partially fatty, hemorrhagic lymph node, 1.6 x 1.0 x 0.7 cm.  SECTIONS:  F1 and F2 = in total, serially sectioned.
     7.     Received fresh, labeled **NAME[BBB, AAA], #7, is a soft, tan lymph node, 0.6 x 0.5 x 0.3 cm.  SECTIONS:  G1 = in total, bisected.
8.     Received fresh, labeled **NAME[BBB, AAA], #8, is an oriented, fibrous and fatty portion of tissue, 7.1 x 6.6 x 2.4 cm, with a long suture marking lateral and a short suture marking superior.  Specimen radiograph is performed and calcifications and biopsy clip are present.  The margins are inked as follows:  anterior = blue; posterior = black; superior = yellow; inferior = red; medial = green; lateral = orange.  Specimen is serially sectioned in nine slices proceeding from lateral to medial margins and a localizing radiograph was performed.  A HydroMARK clip is located in the middle of slice five.  An area of microcalcifications is identified around the biopsy cavity and central in slices four, five, six, seven, eight and nine.  The remaining breast consists of both fibrous and fatty tissue without a discrete mass.  A second clip was identified at the medial margin and was displaced per consultation with surgeon.  A specimen radiograph was performed and no calcifications were present.  SECTIONS:  H1 = slice four; H2 and H3 = slice five; H4-H9 = slice six; H10-H14 = slice seven; H15-H18 = slice eight; H19-H21 = perpendicular sections of medial margin, slice nine (H1-H21= entire biopsy cavity and microcalcifications proceeding from mid specimen toward specimen proceeding medially); H22 and H23 = representative sections slice three; H24 and H25 = representative perpendicular sections of lateral margin.  All representative samples include margins.  Sections were placed in formalin at approximately 1515 on **DATE[Sep 11 11] for a total fixation time of 8 hours, 45 minutes.
9.     Received fresh, labeled **NAME[BBB, AAA], #9, is an oriented reexcision of fibrous and fatty tissue, 5.9 x 4.3 x 1.8 cm, with a short suture marking superior, a long suture marking anterior, and a double suture marking the new margin.  The new margins were inked by the surgeon as follows:  superior = yellow; inferior = red; medial = green; anterior = blue; posterior = black.  Specimen is serially sectioned perpendicular to the superior to inferior axis in six slices and a localizing radiograph is performed.  No identifiable calcifications are identified.  A majority of the specimen consists of dense, fibrous tissue without a discrete mass.  SECTIONS:  I1-I12 = entire specimen submitted sequentially proceeding from superior to inferior as follows:  I1 and I2 = perpendicular sections of superior margin, slice one; I3-I5 = slice two; I6 and I7 = slice three; I8 and I9 = slice four; I10 and I11 = slice five; I12 = perpendicular sections inferior margin, slice six.  Sections were placed in formalin at approximately 1545 on **DATE[Sep 11 11] for a total fixation time of 8 hours 15 minutes.


<MICROSCOPIC SECTION>

<FINAL DX>
1-4,6,7.     RIGHT AXILLARY SENTINEL LYMPH NODES #1, #2, #3, #4, #5, #6:
     Six fatty lymph nodes without evidence of malignancy (0/6).
5.     TISSUE DESIGNATED RIGHT AXILLARY NONSENTINEL LYMPH NODE #1:
     Fatty soft tissue; no node or malignancy identified.
8.     EXCISIONAL BIOPSY OF RIGHT BREAST:
          A.     Status post needle biopsies demonstrating both in-situ as well as infiltrating ductal carcinoma (see ***PATH-NUMBER[1]).
     B.     Current excision demonstrates biopsy site changes but no residual invasive ductal carcinoma (invasive carcinoma measured 3.0 mm in maximum dimension on previous biopsy, histologic grade II).
     C.     Residual in-situ ductal carcinoma present on 5 of 25 cassettes (5/25), intermediate nuclear grade, with areas of central necrosis.
     D.     Microcalcifications associated with DCIS as well as focally in benign ducts.
     E.     No lymphatic/vascular space invasion identified.
     F.     Resection margins:  In-situ ductal carcinoma focally extends to 9.0 mm of designated superior margin, remaining margins are widely free of tumor (greater than 1 cm).
     G.     ER/PR receptor analysis (see previous biopsy ***PATH-NUMBER[1]):  Positive for both ER and PR receptor protein.
     H.     HER2 status (see previous biopsy ***PATH-NUMBER[1]):  Negative for protein expression by IHC.
     I.     Remaining breast demonstrates cyst formation, apocrine metaplasia, and areas of florid duct hyperplasia of usual type.
     J.     Pathologic stage:  T1a, N0.
     9.     REEXCISION OF RIGHT BREAST TISSUE, ALL MARGINS AT SITE OF ANTERIOR CLIP:
     Biopsy site changes but no residual in-situ or invasive carcinoma identified.







<SPECIMEN(S)>
Lymph node, sentinel
<SPECIMEN(S)>
Lymph node, sentinel
<SPECIMEN(S)>
Lymph node, sentinel
<SPECIMEN(S)>
Lymph node, sentinel
<SPECIMEN(S)>
Lymph node, sentinel
<SPECIMEN(S)>
Lymph node, sentinel
<SPECIMEN(S)>
lymph node
<SPECIMEN(S)>
Breast excision, oriented
<SPECIMEN(S)>
Breast excision, oriented",,,,,
REG3,BREAST,0,PAT-00742127,1,REC-5000725150,,,,"<CLINICAL INFO>
Right breast cancer.

<GROSS>
A.  Received fresh, labeled with the patient's name and designated 'sentinel lymph node,' is a 0.8 x 0.8 x 0.5 cm tan to gray-pink ovoid lymph node surrounded by yellow glistening adipose tissue.  The lymph node is bisected and a touch prep is performed yield the following diagnosis Dr. **NAME[ZZZ]:  'No metastatic carcinoma identified on touch prep'.  The bisected lymph node is submitted in its entirety for permanent section in cassette A1.
B.  Received fresh in a TranSpec container, labeled with the patient's name and without a specimen source designation, is an oriented right breast lumpectomy measuring 5.0 cm medial to lateral, 4.5 cm superior to inferior, and 0.6 cm anterior to posterior.  The specimen has been received oriented per the surgeon with a short suture designating the superior resection margin and a long suture designating the lateral resection margin.  Entering the medial-anterior aspect of the breast is a localization wire.  A radiograph is not received with the specimen.  The lumpectomy is differentially inked in order to allow for the microscopic evaluation of the surgical resection margins in the following manner:  the superior resection margin is inked blue, the inferior resection margin is inked green, the medial resection margin is inked violet, the lateral resection margin is inked orange, the anterior resection margin is inked yellow, and the posterior resection margin is inked black.  Sectioning of the lumpectomy reveals a 1.0 x 0.8 x 0.5 cm gritty white-gray mass within the medial half of the breast.  This mass abuts the posterior resection margin and comes to within 0.2 cm of the anterior resection margin.  The mass is 1.0 cm from the inferior resection margin and 2.0 cm from the superior resection margin.  A metallic spring-like clip is present within the central aspect of the mass.  Additional distinct masses or nodules are not grossly identified.  The remainder of the lumpectomy grossly appears to be comprised of approximately 60% yellow glistening adipose tissue and 40% white to pink fibrous tissue.  The lumpectomy is submitted in its entirety in a sequential fashion from the medial resection margin in cassette B1 to the lateral resection margin in cassette B12.
**INITIALS  **DATE[Feb 30 12]

<MICROSCOPIC>
A.  H&E-stained levels are performed on the tissue block in this case and the final diagnosis confirms the intraoperative touch prep interpretation.  A pan-cytokeratin immunohistochemical stain is also performed in block A1, as per current FHS sentinel lymph node protocol, and it is negative, with appropriate controls.
B.  Sections examined.
**INITIALS  **DATE[Mar 1 12]

<INTRAOPERATIVE CONSULT>

<FINAL DX>
A.  RIGHT AXILLARY SENTINEL LYMPH NODE BIOPSY:
  NEGATIVE FOR METASTATIC CARCINOMA WITHIN ONE SENTINEL LYMPH NODE.
B.  RIGHT BREAST, WIRE-LOCALIZED EXCISION:
  INFILTRATING DUCTAL CARCINOMA WITH THE FOLLOWING FEATURES:
  1.  SOLITARY 1.0 CM TUMOR ASSOCIATED WITH PRIOR BIOPSY SITE AND CLIP.
  2.  NOTTINGHAM HISTOLOGIC GRADE 1 (OUT OF 3, DERIVED AS FOLLOWS: NUCLEAR
    SCORE 2, TUBULE SCORE 2, MITOTIC SCORE 1).
  3.  FOCAL LYMPHATIC SPACE INVASION IDENTIFIED; NO PERINEURAL INVASION,
    NO BLOOD VESSEL INVASION, AND NO SKIN, NIPPLE OR SKELETAL MUSCLE
PRESENT FOR EVALUATION.
  4.  INVASIVE CARCINOMA EXTENDS TO WITHIN 0.15 CM OF POSTERIOR MARGIN AND
    WITHIN 0.15 CM OF ANTERIOR MARGIN; ALL OTHER MARGINS MORE WIDELY
    NEGATIVE FOR CARCINOMA (>0.8 CM).
  5.  NO IN SITU CARCINOMA (DCIS OR LCIS) IDENTIFIED.
  6.  PROGNOSTIC/PREDICTIVE IMMUNOPHENOTYPE:  ANALYSIS PRESUMABLY PERFORMED
    ON BIOPSY SPECIMEN (NOT AVAILABLE), BUT CAN BE PERFORMED ON TUMOR
    FROM THIS CASE IF REQUESTED.
  7.  PATHOLOGIC STAGE:  pT1b, pN0(sn)(i-).



<ADDENDUM>
This addendum is issued on receipt of Oncotype DX breast cancer RT-PCR assay results from **INSTITUTION. in Redwood City, CA.  Per their report, the 'Breast Cancer Recurrence Score' is 22.  Please see separate report from Genomic Health regarding specific RT-PCR results and their estimation of stage selective average rate of distant recurrence.
BAF/vrb  **DATE[Mar 20 12],",,,,,
REG3,BREAST,0,PAT-00739447,1,REC-5000729844,,,,"<CLINICAL INFO>
 **AGE[in 50s]-year-old woman with right breast mass.<CLINICAL INFO>
 **AGE[in 50s]-year-old woman with right breast mass.<FINAL DX>
 **PLACE, WA; ***PATH-NUMBER[1] (**DATE[Jan 18 2012])
  Right breast, 10:00, ultrasound-guided core biopsies (part A): Invasive ductal
  carcinoma with the following features:
  1. Nottingham grade 3 of 3 derived as follows:  Poor tubule formation (3),
  high nuclear grade (3), moderate mitotic activity (2).
  2. Extent/size:  Involving three of three tissue cores with a maximum
  contiguous length of 0.5 cm.
  3. Associated in situ component:  High grade ductal carcinoma in situ with
  central necrosis.
  4. Microcalcifications:  Identified associated with invasive carcinoma.
  5. Angiolymphatic invasion:  No definite.
  6. Prognostic markers were performed at CellNetix and immunostains are
  available for review:
  a. Invasive carcinoma is negative for estrogen receptor expression (**NAME[ZZZ]
  score 0 of 8, with positive internal controls). DCIS has focal, weak ER
  staining (**NAME[ZZZ] score 3 of 8).
  b. Invasive carcinoma is negative for progesterone receptor expression (**NAME[ZZZ]
  score 0 of 8, with positive internal controls).  DCIS is negative for PR
  expression (**NAME[ZZZ] score 0 of 8).
  c. Invasive carcinoma is positive for Her2/neu over-expression by
  immunohistochemistry.
  Right breast, 8:00, ultrasound-guided core biopsy (part B): Invasive ductal
  carcinoma with the following features:
  1. Nottingham grade 3 of 3 derived as follows:  Poor tubule formation (3),
  high nuclear grade (3), moderate mitotic activity (2).
  2. Extent/size:  Involving two of two tissue cores with a maximum contiguous
  length of 0.4 cm.
  3. Associated in situ component:  Not identified.
  4. Microcalcifications:  Not identified.
  5. Angiolymphatic invasion:  No definite.
  6. Prognostic markers were performed at CellNetix and immunostains are
  available for review:
  a. Negative for estrogen reception expression (**NAME[ZZZ] score 0 of 8, with
  positive internal controls).
  b. Negative for progesterone receptor expression (**NAME[ZZZ] score 0 of 8, with
  positive internal controls).
  c. Positive for Her2/neu over-expression by IHC.
  MS/jps
  Procedures used to establish the diagnosis:
  Routine
  Per discussion with Drs. **NAME[YYY] and **NAME[XXX] at BCSC conference on 7/5/2100, if
  additional surgical material is received in the future, repeat hormonal
  studies are requested.<FINAL DX>
 **PLACE, WA; ***PATH-NUMBER[1] (**DATE[Jan 18 2012])
  Right breast, 10:00, ultrasound-guided core biopsies (part A): Invasive ductal
  carcinoma with the following features:
  1. Nottingham grade 3 of 3 derived as follows:  Poor tubule formation (3),
  high nuclear grade (3), moderate mitotic activity (2).
  2. Extent/size:  Involving three of three tissue cores with a maximum
  contiguous length of 0.5 cm.
  3. Associated in situ component:  High grade ductal carcinoma in situ with
  central necrosis.
  4. Microcalcifications:  Identified associated with invasive carcinoma.
  5. Angiolymphatic invasion:  No definite.
  6. Prognostic markers were performed at CellNetix and immunostains are
  available for review:
  a. Invasive carcinoma is negative for estrogen receptor expression (**NAME[ZZZ]
  score 0 of 8, with positive internal controls). DCIS has focal, weak ER
  staining (**NAME[ZZZ] score 3 of 8).
  b. Invasive carcinoma is negative for progesterone receptor expression (**NAME[ZZZ]
  score 0 of 8, with positive internal controls).  DCIS is negative for PR
  expression (**NAME[ZZZ] score 0 of 8).
  c. Invasive carcinoma is positive for Her2/neu over-expression by
  immunohistochemistry.
  Right breast, 8:00, ultrasound-guided core biopsy (part B): Invasive ductal
  carcinoma with the following features:
  1. Nottingham grade 3 of 3 derived as follows:  Poor tubule formation (3),
  high nuclear grade (3), moderate mitotic activity (2).
  2. Extent/size:  Involving two of two tissue cores with a maximum contiguous
  length of 0.4 cm.
  3. Associated in situ component:  Not identified.
  4. Microcalcifications:  Not identified.
  5. Angiolymphatic invasion:  No definite.
  6. Prognostic markers were performed at CellNetix and immunostains are
  available for review:
  a. Negative for estrogen reception expression (**NAME[ZZZ] score 0 of 8, with
  positive internal controls).
  b. Negative for progesterone receptor expression (**NAME[ZZZ] score 0 of 8, with
  positive internal controls).
  c. Positive for Her2/neu over-expression by IHC.
  MS/jps
  Procedures used to establish the diagnosis:
  Routine
  Per discussion with Drs. **NAME[YYY] and **NAME[XXX] at BCSC conference on 7/5/2100, if
  additional surgical material is received in the future, repeat hormonal
  studies are requested.AMENDMENT REASON: This amendment is issued to correct the date of
  specimen receipt.  The final diagnosis remains unchanged.AMENDMENT REASON: This amendment is issued to correct the date of
  specimen receipt.  The final diagnosis remains unchanged.MATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[1]  0B,18S  Right breast mass, right axillary LNMATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[1]  0B,18S  Right breast mass, right axillary LN",,,,,
REG3,BREAST,0,PAT-00739884,2,REC-5000730195,,,,"<CLINICAL INFO>
 Bilateral breast cancer/bilateral mastectomy.  DIEP
  flap.<FINAL DX>
 A)  Left breast, mastectomy: Breast with biopsy
  site changes and no residual invasive or in situ carcinoma identified.
  B)  Right breast, mastectomy: Breast with focal lobular carcinoma in situ,
  changes consistent with previous excision site and no residual invasive
  carcinoma identified.
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received fresh labeled ""**NAME[BBB, AAA
  CCC], left breast, long stitch = lateral, short stitch = superior"" is a
  1124 g, 24 ML x 25 SI x 7 AP cm stated left breast with an overlying 3.5 x 4.5
  cm tan-pink unremarkable areola and a 1.0 x 1.0 cm protruding tan-pink
  unremarkable nipple.  The specimen is inked as follows:  anterior-superior -
  orange, anterior-inferior - blue, posterior - black.  After inking, the
  specimen is serially sectioned from medial to lateral into 16 slices ranging
  in size from 1.0 to 2.0 cm in greatest thickness (slice #1 = most lateral,
  slice #16 = most medial).  The specimen is placed in fixative at 6:30 p.m. on
  **DATE[May 14 12] and allowed to fix overnight.  After fixation, the cut surfaces are
  tan-yellow and fibrofatty, with a biopsy cavity and clip in the 4 o'clock
  region approximately 5 cm from the nipple.  No other obvious discrete masses
  or lesions are identified.  The remainder of the breast tissue is
  approximately 90% adipose tissue and 10% fibrous tissue.  The specimen is
  reviewed with Dr. **NAME[ZZZ YYY] on **DATE[May 15 12].  Representative sections are
  submitted as follows:  A1 - biopsy site in slice #6 (clip); A2 - adjacent
  tissue in slice #7; A3 - adjacent tissue in slice #8; A4 - adjacent tissue in
  slice #5; A5 - random upper outer quadrant; A6 - random upper inner quadrant;
  A7 - random lower outer quadrant; A8 - random lower inner quadrant; A9 random
  central breast; A10 - nipple.  (**INITIALS)
  B) Received fresh labeled ""**NAME[BBB, AAA CCC], right breast, long =
  lateral, single = superior"" is an 819 g, 20.0 ML x 16.0 SI x 7.5 AP cm stated
  right breast with an overlying 5.5 x 3.5 cm tan-pink unremarkable areola and a
  1.0 x 1.0 cm tan-pink protruding unremarkable nipple.  The specimen is inked
  as follows:  anterior superior orange, anterior inferior blue, posterior
  black.  The specimen is sliced from medial to lateral into 14 approximately
  1.0 cm thick slices (slice 1 = most medial, slice 14 = most lateral).  The
  specimen is placed in fixative at 6:00 p.m. on **DATE[May 14 12] and allowed to fix
  overnight.  After fixation, cut surfaces are tan-yellow and fibrofatty with a
  2.0 x 1.5 x 2.0 cm apparent excisional cavity in the 10:00 position, with two
  metal clips identified at this location.  The excisional cavity margin is
  within 0.5 cm of the black (posterior) margin.  All other margins are grossly
  free.  There is also a 1.1 x 0.9 x 1.0 cm tan-yellow firm area of apparent fat
  necrosis 1.0 cm superior and immediately posterior to the nipple.  No other
  obvious discrete masses or lesions are identified.  The remainder of the
  breast is approximately 80% adipose tissue and 20% fibrous tissue.  The
  specimen is reviewed with Dr. **NAME[ZZZ YYY] on **DATE[May 15 12].  Representative
  sections are submitted as follows:  B1 - excision cavity slice 7, B2 -
  excision cavity slice 8, B3 - excision cavity slice 9, B4 - area of fat
  necrosis, B5 - random upper inner quadrant, B6 - random lower inner quadrant,
  B7 - random upper outer quadrant, B8 - random lower outer quadrant, B9 -
  nipple.  (**INITIALS)",,,,,
REG3,BREAST,0,PAT-00744865,1,REC-5000733102,,,,"<CLINICAL INFO>
1) L BREAST MASS, 11:00 AND 2) L AXILLARY LYMPH NODE, US GUIDED BIOPSY.
<SPECIMEN(S)>
A. L BREAST MASS, 11:00, NEEDLE CORE.
B. L AXILLARY LYMPH NODE NEEDLE CORE.
  Formalin added at: 1400
*****The case is amended to correct patient name.*****
<GROSS>
Received in formalin labeled with the patient's name in two parts.
A. Labeled ""1. L breast 11:00"" are three tan to yellow fibroadipose needle core tissue fragments measuring 0.5, 1.7, and 1.8 cm in length and 0.2 cm in diameter. Wrapped and entirely submitted in one cassette.
B. Labeled ""2. L axilla L node"" are seven red to yellow fibroadipose needle core tissue fragments ranging from 0.1 to 1.5 cm in length and 0.1 cm in diameter. Wrapped and entirely submitted in one cassette. LS:pro **DATE[Sep 21 11]
<FINAL DX>
A. Breast mass at 11:00, left, ultrasound-guided needle core biopsy:  Invasive mammary carcinoma with the following characteristics:
1. Tumor type: Infiltrating ductal carcinoma. 
2. Histologic grade: High grade.
Modified Bloom-Richardson Score: 9.
Tubular score: 3
Nuclear score: 3
Mitotic score: 3 (greater than 20 per ten high-power fields).
3. In situ carcinoma: Not identified.
4. Lymphatic/blood vascular invasion: Possible lymphovascular involvement is present.
5. Estrogen/progesterone receptor and HER-2 studies: Pending; results will be reported as an addendum. 
B. Left axillary lymph node, ultrasound-guided needle core biopsy: Multiple fragments of lymph node, negative for metastatic carcinoma by H&E stain. 
IC:  IA
 
<PATHOLOGIST>
**NAME[ZZZ YYY], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,BREAST,0,PAT-00741992,1,REC-5000733791,,,,"PART / DESCRIPTION - SEQ 
BREAST,MASTECTOMY w/o lymph nodes/ LEFT WIRE LOCALIZED PARTIAL MASTECTOMY- A
INTRAOPERATIVE DX:
NONE
DIAGNOSIS COMMENTS:
A small focus of ductal carcinoma in situ is present in slice 5 and larger area in slices 8 and 9, bridged by the biopsy site. It assumed that these are part of the same unifocal process and therefore the size is determined by the aggregate length from slices 5 to 9. Clinical correlation is recommended.
FINAL DX:
A. Left breast, partial mastectomy: Ductal carcinoma in situ (DCIS) with the following features:  Histologic type:   Solid.  Nuclear grade:   High.  Necrosis:    Focally present. Size/Extent of DCIS:   Residual size estimated 1.7 x 0.9 cm. Distribution of DCIS in specimen: Slices 5, 8 and 9. Microcalcifications:   Absent. Surgical margins:  Anterior (superficial):  Negative (greater than 10 mm).  Posterior (deep):   Negative (greater than 10 mm).  Superior:    Negative (greater than 10 mm).  Inferior:    Negative (7.5 mm).  Medial:    Negative (4 mm).  Lateral:    Negative (greater than 10 mm). No invasive carcinoma identified. Pathologic stage:    pTis, pNX (AJCC 7th edition). Additional findings: Immunohistochemistry staining for estrogen and progesterone receptor expression has been previously performed (**INSTITUTION ***PATH-NUMBER[1], not reviewed here), with the following results: ER 75%, PR (not performed). Intraductal papillomas with epithelial hyperplasia.  Florid duct epithelial hyperplasia of the usual type. Evidence of prior biopsy.
MICROSCOPIC:
The final diagnosis is based on a microscopic examination of the tissue(s)/cells.GROSS:
Received in formalin, labeled ''**NAME[BBB, AAA] L'' and designated ''A. left wire-localized partial mastectomy'', is an oriented breast specimen with a localizing wire protruding from the anterior aspect. It has dimensions as follows: 3.2 cm anterior-posterior, 3.6 cm medial-lateral and 4.5 cm superior-inferior. It has been previously inked as follows: posterior - black, anterior - blue, medial - red, lateral - yellow, superior - orange, inferior - green. It is sectioned superior to inferior into 13 cross-sectional slices numbered respectively. Slices 6, 7 and 8 have a 1.4 x 0.9 x 0.9 cm fibrous hemorrhagic biopsy site with a central metal clip (in slice 7). The biopsy site is 0.2 cm from the anterior and medial margins, 1.0 cm from the posterior margin, 1.5 cm from the superior margin, 1.7 cm from the inferior margin, and 2.0 cm from the lateral margin. The surrounding parenchyma is 70% lobular fatty tissue and 30% firm fibrous tissue. No other mass or lesion is identified. There are a few scattered smooth-walled cysts up to 0.3 cm filled with tan watery material. Representative sections are submitted as follows: A1 - slice 1 (superior edge of breast); A2-A3 - composite slice 3; A4-A5 - composite slice 5 (adjacent to biopsy site); A6-A7 - composite slice 6 (superior biopsy site); A8-A9 - composite slice 7; A10-A11 - composite slice 8 (inferior biopsy site); A12-A13 - composite slice 9 (adjacent to biopsy site); A14-A15 - composite slice 11 and A16 - slice 13 bisected (inferior aspect of breast specimen). The biopsy site is entirely submitted. The specimen submitted in formalin at 1:00 p.m. on **DATE[May 26 2012]. Total fixation time: 7-1/2 hours. (**INITIALS:cmc40 285265)
CLINICAL INFO:
Carcinoma in situ of breast. This is a **AGE[in 60s]-year-old post menopausal woman with ER positive, intermediate to high nuclear grade, apparently unifocal DCIS marked by microcalcifications at 9 o'clock in the left breast.
ICD-9 code: 233.0.
PATHOLOGIST:
**NAME[ZZZ YYY M]. 

SNOMED Code(s)",,,,,
REG3,BREAST,0,PAT-00742247,2,REC-5000733973,,,,"PART / DESCRIPTION - SEQ# 
Lymph node, biopsy/ HIGHEST LEFT AXILLARY NODE- 3
PART / DESCRIPTION - SEQ# 
Breast, other/ RIGHT BREAST- 2
PART / DESCRIPTION - SEQ# 
Breast, modified radical mastectomy (includiing lymph nodes)/ LEFT MODIFIED MASTECTOMY- 4
PART / DESCRIPTION - SEQ# 
sentinel node/ RIGHT SENTINEL NODE BIOPSY- 1Comment
The right breast contains invasive carcinoma with lobular and ductal features. The left breast contains invasive ductal carcinoma. The differing morphologies and distinct immunohistochemical staining patterns are compatible with two distinct primary carcinomas. If marker studies (ER/PR/Ki-67/HER2) are desired, please contact the pathologist of record. 
Dr. **NAME[ZZZ] reviewed this case and agrees.<FINAL DX>

1) RIGHT SENTINEL NODE, BIOPSY: ONE LYMPH NODE, NEGATIVE FOR CARCINOMA. 

2) RIGHT BREAST, 430 GRAM MASTECTOMY: A. MODERATELY DIFFERENTIATED (MODIFIED B&R GRADE II OF III) INVASIVE CARCINOMA WITH MIXED DUCTAL AND LOBULAR FEATURES. 1. TUMOR SIZE: 1.9 CM (SLIDE MEASUREMENT, 2E). 
 2. TUMOR LOCATION: RIGHT BREAST. 
 3. NOTTINGHAM HISTOLOGIC SCORE: 6 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR PLEOMORPHISM: 2.  c. MITOTIC COUNT: 1. 

 4. ASSOCIATED CARCINOMA IN SITU IS PRESENT WITH THE FOLLOWING FEATURES:  a. THE IN SITU DISEASE HAS LOBULAR FEATURES.  b. IN SITU CARCINOMA COMPRISES AROUND 25% OF TUMOR   VOLUME.  c. NUCLEAR GRADE: INTERMEDIATE.  c. NECROSIS: NEGATIVE. 
 5. SPECIMEN MARGINS: NEGATIVE (>2 CM FREE). 
 6. ANGIOLYMPHATIC SPACE INVASION: NEGATIVE. 
 7. NIPPLE AND SKIN INVOLVEMENT: NEGATIVE. 8. MICROCALCIFICATIONS: NEGATIVE. 
 9. SPECIAL STAINS: SEE COMMENT. 

3) HIGHEST LEFT AXILLARY NODE, EXCISION: TWO LYMPH NODES, NEGATIVE FOR CARCINOMA. 

4) LEFT MODIFIED MASTECTOMY, SUTURE MARKS AXILLA, 457 GRAMS: A. MODERATELY DIFFERENTIATED INVASIVE DUCTAL CARCINOMA WITH THE FOLLOWING FEATURES: 1. SIZE: 2.2 CM. 
 2. LOCATION: LEFT BREAST. 
 3. NOTTINGHAM HISTOLOGIC SCORE: 6 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR PLEOMORPHISM: 2.  c. MITOTIC RATE: 1. 
 4. ASSOCIATED DUCTAL CARCINOMA IN SITU IS PRESENT WITH THE FOLLOWING FEATURES:  a. DCIS COMPRISES <10% OF THE MASS.  b. NUCLEAR GRADE: INTERMEDIATE.  c. NECROSIS: NEGATIVE. 
 5. SPECIMEN MARGINS: NEGATIVE (>2 CM FREE). 
 6. ANGIOLYMPHATIC SPACE INVASION NEGATIVE. 
 7. NIPPLE AND SKIN INVOLVEMENT: NEGATIVE. 
 8. TWO OF NINE LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA (2/9).  a. 0.8 CM METASTASIS.  b. EXTRACAPSULAR SPREAD PRESENT.  c. ONE NODE SHOWS CHANGES COMPATIBLE WITH SITE OF   PRIOR BIOPSY. 
 9. MARKER STUDIES: SEE COMMENT. 
c6
Minimum pathologic stage based on the above findings is:
7th Edition AJCC right breast: pT1 pN0  left breast:  pT2 pN1  3260F   grade 2 of 3
JEL:crAddendum Diagnosis
NONE<CLINICAL INFO>
Bilateral breast cancer.<GROSS>
PART 1: RIGHT SENTINEL NODE BIOPSY 
Received fresh is a 4 cm packet of adipose tissue containing material grossly compatible with a lymph node. Touch preps were performed. The node was entirely submitted.

TOUCH PREP DIAGNOSIS: NEGATIVE FOR CARCINOMA

PART 2: RIGHT BREAST
(**INITIALS) Received in formalin labeled **NAME[AAA BBB], designated """"right breast, suture marks axillary"""" is an apparent simple mastectomy specimen weighing 430 grams and measuring 20 cm medial-lateral, 16.5 cm superior-inferior and up to 3 cm anterior-posterior. The axillary area of the excision is marked with a suture on the container label and requisition form. The specimen is also surmounted by an elliptoid portion of yellow-pink skin measuring 15.5 x 8.5 cm. The nipple is everted measuring 1.4 cm. The skin is notable for two red-maroon, flat, discolored lesions, each measuring 0.2 cm in greatest dimension. The specimen is inked as follows: superior-green, inferior-orange, medial-red, lateral-purple, and deep posterior-black. Sectioning the breast reveals a solid, firm, suspicious-appearing neoplasm in the central superior aspect of the excision. The lesion measures 2.2 x 2 cm. It is removed from the cutaneous and inked soft tissue margin. The nearest inked margin to the lesion are the green and black inked soft tissue margin at a distance of 1.5 cm each. The lesion on cut section features solid hemorrhagic areas, along with a deeply embedded metallic clip. The remainder of the breast tissue parenchyma is composed mainly of bright yellow fatty tissue with strips of pink-white fibrous tissue. No other suspicious mass is grossly appreciated. Thorough examination of the superior-lateral most aspect of the excision reveals two lymph node/nodules measuring 0.6 and 1.9 cm in greatest dimension which are fat replaced on cut section. 

Summary of sections: 2a-sections skin and nipple; 2b-green inked soft tissue margin close to breast lesion; 2c-black inked soft tissue margin close to breast lesion; 2d through 2f-representative sections breast lesion central superior breast; 2g, 2h-sections upper outer quadrant of breast; 2i, 2j-sections lower outer quadrant of breast; 2k, 2l-sections upper inner quadrant of breast; 2m, 2n-sections lower inner quadrant of breast; 2o-two bisected axillary lymph nodes/nodules
 
PART 3: HIGHEST LEFT AXILLARY NODE 
(**INITIALS) Received in formalin labeled **NAME[AAA BBB], designated """"highest left axillary node"""" is a portion of fatty yellow tissue measuring 1.4 x 1 x 0.3 cm. Trimming of this fatty tissue reveals two somewhat matted lymph nodes. Entirely submitted in cassette 3a. 
 
PART 4: LEFT MODIFIED MASTECTOMY 
(**INITIALS) Received in formalin labeled **NAME[AAA BBB], designated """"left modified mastectomy, suture marks axilla"""" is a modified radical mastectomy specimen weighing 457 grams. The axillary tail is marked with a suture. The breast tissue portion measures 15.5 cm medial-lateral, 15 cm superior-inferior and up to 4 cm anterior-posterior. The axillary tail measures 8 x 6 x 1.5 cm. The specimen is surmounted by an elliptoid portion of yellow-pink skin measuring 16 x 8.5 cm. The nipple is everted measuring 1.3 cm. The 4 to 8 o'clock aspect of the areola complex has a purple-red discoloration. Otherwise, no skin lesion is grossly appreciated. The specimen is inked as follows: superior-green, inferior-orange, medial-red, lateral-purple, deep posterior-black. Sectioning the breast reveals an ill-defined malignant appearing neoplasm in the central upper outer quadrant of the breast. The lesion measures 3 x 2.2 cm. The lesion has a solid, smooth, yellow-white cut surface with strips of hemorrhagic areas. The lesion is also remote from the cutaneous and inked soft tissue margins. The nearest inked margins of the lesion are the green and black inked soft tissue margins with a distance of 1 cm each. The rest of the breast tissue parenchyma is composed of bright yellow fatty tissue alternating with pink-white, fibrous tissue. No other suspicious mass is grossly appreciated. Thorough examination of the attached axillary tail reveals several lymph nodes ranging from 0.3 up to 2.8 cm in greatest dimension. 

Summary of sections: 4a-sections of skin and nipple; 4b-sections green and black inked soft tissue margins close to breast lesion; 4c, 4d-representative sections breast lesion; 4e, 4f-additional representative section of breast lesion divided in two blocks; 4g, 4h-section upper inner quadrant of breast; 4i, 4j-sections lower inner quadrant of breast; 4k, 4l-upper outer quadrant of breast away from breast lesion; 4m, 4n-sections lower outer quadrant of breast; 4o-multiple intact lymph nodes; 4p-two bisected nodes; 4q, 4r-one bisected lymph node each block; 4s-representative cross section largest axillary node.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONE<MICROSCOPIC>
PART 1: RIGHT SENTINEL NODE BIOPSY 
Touch preps and H&E stained slides examined. 
 
PART 2: RIGHT BREAST 
H&E stained slides and one immunohistochemical stain examined. The slides contain multiple representative sections of a mastectomy. A carcinoma is present with associated in situ disease. Immunohistochemistry shows the in situ component to lack E-cadherin and the invasive component to have patchy E-cadherin reactivity. 
 
PART 3: HIGHEST LEFT AXILLARY NODE 
Slide examined. 
 
PART 4: LEFT MODIFIED MASTECTOMY 
Slides examined. An invasive carcinoma is present which measures 2.3 cm. This carcinoma is similar to the previous but shows more ductal morphologic features and has a small component of ductal carcinoma in situ. E-cadherin is positive. 



NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.<ADDENDUM COMMENTS>
This addendum issued to measure the extracapsular spread in part 4. One of the lymph nodes contains extracapsular spread that measures at most 1 mm in greatest dimension. 
(JEL:cr **DATE[Nov 27 2011])
____________________________________________________________________________________

<ADDENDUM COMMENTS>
#1
This addendum is issued to report on immunohistochemical stains performed at Laboratories Northwest. 

The invasive carcinoma in the right breast stains as follows:
 Estrogen receptor   Positive (**NAME[YYY] score: IS3+PS5=8) Progesterone receptor  Negative (**NAME[YYY] score: 0) Ki-67 defined proliferative rate Low (<10%)

The left sided breast carcinoma stains as follows:
 Estrogen receptor   Positive (**NAME[YYY] score: IS3+PS5=8) Progesterone receptor  Positive (**NAME[YYY] score: IS2+PS5=7) Ki-67 defined proliferative rate Low (<5%)

Blocks 4c and 2d will be submitted for HER2 analysis.
(**INITIALS **DATE[Nov 27 2011]) 






NOTE: Immunohistochemical evaluation of the estrogen receptor is performed using Ventana rabbit antihuman estrogen clone SP1. Immunohistochemical evaluation of the progesterone receptor is performed using Ventana rabbit antihuman progesterone receptor clone IE2.        
Our policy is to fix all breast tumors for at least 6 hours and <48 hours.
 


PATHOLOGIST:
Love **NAME[XXX M.",,,,,
REG3,BREAST,0,PAT-00272267,2,REC-5000734000,,,,"PART / DESCRIPTION - SEQ# 
Breast, other/ SUB Q TISSUE, HIGH READ- 4
PART / DESCRIPTION - SEQ# 
sentinel node/ LEFT BREAST SENTINEL NODE- 2
PART / DESCRIPTION - SEQ# 
Breast, other/ LEFT BREAST- 6
PART / DESCRIPTION - SEQ# 
sentinel node/ LEFT BREAST SENTINEL NODE- 1
PART / DESCRIPTION - SEQ# 
Breast, other/ RIGHT BREAST- 5
PART / DESCRIPTION - SEQ# 
sentinel node/ SENTINEL NODE- 3<CLINICAL INFO>
Biopsy proven carcinoma, left breast invasive lobular carcinoma.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
PART 1: LEFT BREAST SENTINEL NODE
RAPID DIAGNOSIS:
TOUCH PREP: DEFINITE MALIGNANT CELLS NOT IDENTIFIED.
**NAME[ZZZ M. YYY], MD  **DATE[Jul 15 2012]

PART 2: LEFT BREAST SENTINEL NODE
RAPID DIAGNOSIS:
TOUCH PREP: DEFINITE MALIGNANT CELLS NOT IDENTIIFED.
**NAME[ZZZ M. YYY], MD  **DATE[Jul 15 2012]

PART 3: SENTINEL NODE
RAPID DIAGNOSIS:
TOUCH PREP: DEFINITE MALIGNANT CELLS NOT IDENTIFIED.
**NAME[ZZZ M. YYY], MD  **DATE[Jul 15 2012]

PART 4: SUB Q TISSUE, HIGH READ
RAPID DIAGNOSIS:
TOUCH PREP: DEFINITE MALIGNANT CELLS NOT IDENTIFIED.
**NAME[ZZZ M. YYY], MD  **DATE[Jul 15 2012]<MICROSCOPIC>
PART 1: LEFT BREAST SENTINEL NODE
Sections examined. See final diagnosis.

Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. An immunostain for pancytokeratin was utilized to look for occult tumor cells in the lymph node.

Special stain: Immunostain for pancytokeratin. 
 
PART 2: LEFT BREAST SENTINEL NOD
Sections examined. See final diagnosis.

Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. An immunostain for pancytokeratin was utilized to look for occult tumor cells in the lymph node.

Special stain: Immunostain for pancytokeratin. 
 
PART 3: SENTINEL NODE
Sections examined. See final diagnosis.

Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. An immunostain for pancytokeratin was utilized to look for occult tumor cells in the lymph node.

Special stain: Immunostain for pancytokeratin. 
 
PART 4: SUB Q TISSUE, HIGH READ 
Sections examined. See final diagnosis.
 
PART 5: RIGHT BREAST 
Sections examined. See final diagnosis. 
 
PART 6: LEFT BREAST
Sections examined. See final diagnosis.

Immunocytochemical studies were performed at Laboratories Northwest using antibody staining with appropriate control tissue staining. These studies showed the tumor cells from the focus of solid type ILC to be positive for estrogen receptor (positivity score 5 + intensity score 3 = total **NAME[XXX] score 8/8) and positive for estrogen receptor (intensity score 3 + positivity score 4 = total **NAME[XXX] score 7/8). The tumor cells were negative for e-cadherin. The tumor cells show a low Ki67-defined cell proliferation index (<10% of tumor cells positive).<ADDENDUM COMMENTS>
The patient's previously uncharacterized breast carcinoma was further evaluated at PhenoPath Laboratories in **PLACE, Washington. An initial report from Dr. **NAME[WWW] indicated that the tumor was equivocal (2+) for HER2 by IHC. A subsequent follow-up report from Dr. **NAME[VVV] indicates that the tumor is negative for HER2 gene amplification by FISH (HER2:CEP17 Ratio=1.2). 

Please see a full copy of these reports (***PATH-NUMBER[1]/02) for additional details.
(**INITIALS **DATE[Jul 26 2012])Addendum Diagnosis
NONEComment
Within the left breast (Part 6) two discrete, grossly separate, areas of invasive lobular carcinoma were identified. The larger tumor shows features of classic type ILC and appears to have been recently biopsied and evaluated. The slightly smaller tumor shows features of solid type ILC and does not appear to have been previously biopsied. Studies regarding the HER2 status of the second tumor are underway and an addendum report will follow.<GROSS>
PART 1: LEFT BREAST SENTINEL NODE
(MF:mm) Part 1 is received fresh from the operating rom, labeled with the patient's name and designated """"sentinel node, left breast."""" The specimen consists of a 1 cm portion of dye stained tissue, which is sectioned. A touch preparation is made. All tissue is submitted in cassette 1a. 

PART 2: LEFT BREAST SENTINEL NODE
(MF:mm) Part 2 is received fresh from the operating rom, labeled with the patient's name and designated """"sentinel node, left breast."""" The specimen consists of a 1 cm portion of fatty tissue, which is sectioned. A touch preparation is made. Tissue is submitted in entirety in cassette 2a.

PART 3: SENTINEL NODE
(MF:mm) Part 3 is received fresh from the operating rom, labeled with the patient's name and designated """"sentinel node."""" The specimen consists of a 1.5 cm portion of fatty tissue, which is sectioned. A touch preparation is made. The tissue is submitted in entirety in cassette 3a. 

PART 4: SUB Q TISSUE, HIGH READ
MF:mm) Part 4 is received fresh from the operating rom, labeled with the patient's name and designated """"sub Q tissue, high read."""" The specimen consists of a 1 cm portion of fatty tissue, which is sectioned. A touch preparation is made, and the specimen is submitted in entirety in cassette 4a.

PART 5: RIGHT BREAST
(**INITIALS) Received in formalin labeled with the patient's name and designated """"right breast, stitch lateral, other stitch axillary tail."""" The specimen consists of a simple mastectomy which weighs 630 grams and measures 25 x 22 x 5 cm. Present is a 10.4 x 5.7 cm ellipse of tan-brown skin containing its 4 cm areolar and a 1.2 cm nipple. With the specimen oriented per the sutures placed by the surgeon, the specimen is inked as follows: superior-green, inferior-orange, medial-red, lateral-purple, and deep/posterior-black. The specimen is sectioned from medial to lateral and shows a non-descript fibrofatty tissue without localizing lesions suspicious for neoplasm. In the region of the axillary tail two lymph nodes are identified measuring 0.5 and 0.8 cm in greatest dimension. 

Summary of sections: 5a-nipple and skin; 5b-one lymph node, trisected; 5c-other lymph node bisected; 5d, 5e-upper outer quadrant; 5f, 5g-upper inner quadrant; 5h, 5i-lower outer quadrant; 5j, 5k, lower inner quadrant.

PART 6: LEFT BREAST
(**INITIALS) The specimen is received in formalin labeled with the patient's name and designated """"left breast."""" The specimen consists of a simple mastectomy which weighs 690 grams and measures 27 x 23 x 5 cm. The specimen includes a 10.5 x 6.0 cm ellipse of tan-brown skin with a 3.5 cm areola and 1 cm everted nipple. The skin and nipple appear grossly unremarkable. The specimen is oriented by several sutures placed by the surgeon. The specimen is inked as follows: superior-green, inferior-orange, medial-red, lateral-purple, and deep/posterior-black. The specimen is sectioned from medial to lateral and the slices are numbered 1-12 from medial to lateral. Identified in slice #5 is a 0.9 cm circumscribed tumor nodule which is grossly situated 1.5 from the posterior margin, 4.5 cm from the nipple and greater than 5 cm from the medial, superior, inferior, and lateral margins. Situated approximately 1 cm from this mass lesion is a second area of parenchymal abnormality which measures approximately 1.0 cm in dimension and has a firm and hemorrhagic cut surface. Grossly, this appears to be consistent with a previous biopsy site. This lesion is situated 2 cm from the posterior margin and greater than 5 cm from the other margins. This lesion is located in slices #6 and #7. The remainder of the breast tissue has a non-descript fibrofatty appearance without other identifiable mass lesions. No definite lymph nodes are identified in the region of the axillary breast. 

Summary of sections: 6a-nipple and skin; 6b, 6c-circumscribed lesion in slice #5; 6d-closest (posterior) margin in slice #5, 6e through 6h-slice #6; 6i, 6j-slice #7; 6k, 6l-upper outer quadrant; 6m, 6n-upper inner quadrant; 6o, 6p-lower outer quadrant; 6q, 6r-lower inner quadrant<FINAL DX>

1) LEFT BREAST SENTINEL LYMPH NODE: ONE BENIGN LYMPH NODE. IHC STAINING FOR OCCULT TUMOR CELLS IS NEGATIVE.

2) LEFT BREAST SENTINEL LYMPH NODE: ONE BENIGN LYMPH NODE. IHC STAINING FOR OCCULT TUMOR CELLS IS NEGATIVE. 

3) LEFT BREAST SENTINEL LYMPH NODE: ONE BENIGN LYMPH NODE. IHC STAINING FOR OCCULT TUMOR CELLS IS NEGATIVE.

4) """"SUBCUTANEOUS TISSUE, HIGH READ"""": BENIGN STROMAL TISSUE.

5) RIGHT BREAST (630 GRAMS): MULTIFOCAL ATYPICAL LOBULAR HYPERPLASIA AND FIBROCYSTIC CHANGES. INVASIVE CARCINOMA NOT IDENTIFIED. TWO BENIGN LYMPH NODES.

6) LEFT BREAST (690 GRAMS): A. INVASIVE LOBULAR CARCINOMA, CLASSICAL TYPE. 1. TUMOR SIZE: 1.0 CM.
 2. TUMOR LOCATION: CENTRAL BREAST, 3 O'CLOCK AXIS.
 3. NOTTINGHAM HISTOLOGIC SCORE: 5 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR PLEOMORPHISM: 1.  c. MITOTIC COUNT: 1. 4. FOCAL ASSOCIATED LOBULAR NEOPLASIA PRESENT.
 5. SPECIMEN MARGINS: MARGINS UNINVOLVED BY INVASIVE CARCINOMA.  a. DISTANCE FROM CLOSEST MARGIN= 2.0 CM (POSTERIOR   MARGIN). 6. ANGIOLYMPHATIC TUMOR INVASION: NOT IDENTIFIED.
 7. NIPPLE AND SKIN TUMOR INVOLVEMENT: NOT IDENTIFIED.
 8. TUMOR PREVIOUSLY SHOWN ON NEEDLE BIOPSY (***PATH-NUMBER[2]) TO BE ESTROGEN RECEPTOR POSITIVE, PROGESTERONE RECEPTOR 
 POSITIVE, E-CADHERIN NEGATIVE AND HER2 NEGATIVE WITH A 
 LOW KI-67 PROLIFERATION INDEX. B. INVASIVE LOBULAR CARCINOMA, SOLID TYPE. 1. TUMOR SIZE: 0.9 CM.
 2. TUMOR LOCATION: CENTRAL BREAST, 12 O'CLOCK AXIS.
 3. NOTTINGHAM HISTOLOGIC SCORE: 5 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR PLEOMORPHISM: 1.  c. MITOTIC COUNT: 1.
 4. FOCAL ASSOCIATED LOBULAR NEOPLASIA PRESENT.
 5. SPECIMEN MARGINS: MARGINS UNINVOLVED BY INVASIVE CARCINOMA.  a. DISTANCE FROM CLOSEST MARGIN= 1.5 CM (POSTERIOR   MARGIN).
 6. ANGIOLYMPHATIC TUMOR INVASION: NOT IDENTIFIED.
 7. NIPPLE AND SKIN TUMOR INVOLVEMENT: NOT IDENTIFIED.
 8. SPECIAL STUDIES:  TUMOR IS ESTROGEN RECEPTOR POSITIVE, PROGESTERONE  RECEPTOR POSITIVE, E-CADHERIN NEGATIVE AND SHOWS  A LOW KI67-CELL PROLIFERATION INDEX. 
 C. ADDITIONAL PATHOLOGIC FINDINGS: LOBULAR NEOPLASIA AND FIBROCYSTIC CHANGES. 
Minimum pathologic stage based on the above findings is:
7th Edition AJCC; pT1b pN0 3260F
**INITIALS  PATHOLOGIST:
**NAME[YYY ZZZ]",,,,,
REG3,BREAST,0,PAT-00741968,1,REC-5000734067,,,,"PART / DESCRIPTION - SEQ# 
sentinel node/ RIGHT SENTINEL LYMPH NODE #2- 2
PART / DESCRIPTION - SEQ# 
sentinel node/ RIGHT SENTINEL LYMPH NODE #1- 1
PART / DESCRIPTION - SEQ# 
Breast, other/ RIGHT BREAST LUMPECTOMY- 4
PART / DESCRIPTION - SEQ# 
sentinel node/ RIGHT SENTINEL LYMPH NODE #3- 3
PART / DESCRIPTION - SEQ# 
Breast, other/ RIGHT BREAST, NEW POSTEROMEDIAL MARGIN- 5<CLINICAL INFO>
Right breast cancer.<FINAL DX>

1) RIGHT SENTINEL LYMPH NODE BIOPSY #1: ONE BENIGN LYMPH NODE SHOWING NO METASTATIC CARCINOMA.

2) RIGHT SENTINEL LYMPH NODE BIOPSY #2: ONE BENIGN LYMPH NODE SHOWING NO METASTATIC CARCINOMA.

3) RIGHT SENTINEL LYMPH NODE BIOPSY #3: ONE BENIGN LYMPH NODE SHOWING NO METASTATIC CARCINOMA.

4) RIGHT BREAST TISSUE EXCISION: A. POORLY DIFFERENTIATED (MODIFIED B&R GRADE III OF III) INVASIVE DUCTAL CARCINOMA WITH GEOGRAPHIC NECROSIS. 1. TUMOR SIZE: 1 CM (HISTOLOGIC MEASUREMENT).
 2. TUMOR LOCATION: RIGHT BREAST.
 3. NOTTINGHAM HISTOLOGIC SCORE: 9 OF 9.  a. TUBULE FORMATION: 3.  b. NUCLEAR PLEOMORPHISM: 3.  c. MITOTIC COUNT: 3 (34 MITOSES PER 10 HIGH POWER FIELDS). 4. ASSOCIATED DUCTAL CARCINOMA IN SITU: NOT IDENTIFIED.
 5. SPECIMEN MARGINS:  a. MARGINS UNINVOLVED BY INVASIVE CARCINOMA.  b. DISTANCE OF INVASIVE CARCINOMA FROM CLOSEST   (MEDIAL) MARGIN: 0.3 CM.   6. LYMPH-VASCULAR INVASION: NOT IDENTIFIED.
 7. MICROCALCIFICATIONS: NOT IDENTIFIED.
 8. ORGANIZING BIOPSY SITE.
 9. NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES WITH  USUAL DUCT HYPERPLASIA AND APOCRINE METAPLASIA. 10. SPECIAL STUDIES PERFORMED ON PREVIOUS BIOPSY (***PATH-NUMBER[1]):  ESTROGEN RECEPTOR   NEGATIVE  PROGESTERONE RECEPTOR   NEGATIVE  KI-67      HIGH (50%)  HER2      NEGATIVE FOR         OVEREXPRESSION (1+) BY         ICC

5) RIGHT BREAST POSTEROMEDIAL MARGIN EXCISION: BENIGN FIBROFATTY TISSUE. NO CARCINOMA IDENTIFIED.
Minimum pathologic stage based on the above findings is:
7th Edition AJCC: G3, pT1b, pN0, 3260F
**INITIALS<GROSS>
PART 1: RIGHT SENTINEL LYMPH NODE #1 
(RRR:ab) Container identified as """"**NAME[AAA BBB]"""" and labeled """"right sentinel node #1."""" Submitted fresh are approximately 4 grams of fat containing a single lymph node 1.9 cm. This is thinly sectioned and no malignant tumor cells are identified on a cytology touch preparation. Lymph node TE3 1a levels
 
PART 2: RIGHT SENTINEL LYMPH NODE #2 
(RRR:ab) Container identified as """"**NAME[AAA BBB]"""" and labeled """"right sentinel node #2."""" Submitted fresh is a 1.3 cm lymph node. This is thinly sectioned and no malignant tumor cells are identified on a cytology touch preparation. Lymph node TE3 2a levels

PART 3: RIGHT SENTINEL LYMPH NODE #3
(RRR:ab) Container identified as """"**NAME[AAA BBB]"""" and labeled """"right sentinel node #3."""" Submitted fresh is a 1.5 cm lymph node. It is thinly sectioned and no malignant tumor cells are identified on a cytology touch preparation. TE3 3a levels
 
PART 4: RIGHT BREAST LUMPECTOMY
(GF:ab) Received fresh from the operating room labeled """"**NAME[AAA BBB],"""" designated """"right breast lumpectomy,"""" is a localized lumpectomy specimen weighing 35 grams and measuring 5.1 cm anterior-posterior, 3.5 cm medial-lateral and 4.4 cm superior-inferior. The anterior, superior and lateral aspects are marked with double, short and long sutures respectively, as noted on the requisition form and container label. The lateral aspect of the excision is also the entrance site of the localization wire. No accompanying radiograph is submitted. The specimen is inked as follows: superior-green, inferior-orange, anterior-blue, deep posterior-black, medial-red and lateral-purple. The specimen is now serially sectioned progressing from anterior to posterior. A solid, firm, pink-white, suspicious-appearing nodule is noted in the posterior medial aspect of the excision, measuring 1.5 x 1.5 cm. The lesion has a distance of approximately 0.3 cm to the nearest inked soft tissue margin, which is the red-inked soft tissue margin. The lesion, on cut section, also harbors a tiny silver metallic clip. Representative sections of the lesion are submitted in cassetes 4a-4c. The remainder of the breast tissue parenchyma is composed of firmer fibroglandular tissue alternating with bright-yellow fatty tissue. Additional representative sections throughout the specimen are submitted sequentially in cassettes 4d-4m. 

PART 5: RIGHT BREAST, NEW POSTEROMEDIAL MARGIN
 (GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"new posteromedial margin, suture marks the same,"""" is a portion of fibrofatty breast tissue weighing 8 grams and measuring 4 x 3.1 x 1.1 cm. The unaltered margin is marked with a suture. This new margin is now marked black. The opposing margin, which is consistent with an old surgical margin, is left unmarked. Sectioning reveals mainly fatty yellow tissue with firmer fibrous tissue. Representative sections are submitted in cassettes 5a-5f.<MICROSCOPIC>
PART 1: RIGHT SENTINEL LYMPH NODE #1
Levels examined. 
 
PART 2: RIGHT SENTINEL LYMPH NODE #2
Levels examined. 
 
PART 3: RIGHT SENTINEL LYMPH NODE #3
Levels examined. 
 
PART 4: RIGHT BREAST LUMPECTOMY
Sections examined. 
 
PART 5: RIGHT BREAST, NEW POSTEROMEDIAL MARGIN
Sections examined.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
PART 1: RIGHT SENTINEL LYMPH NODE #1
RAPID DIAGNOSIS:
CYTOLOGY TOUCH PREPARATION: NO MALIGNANT TUMOR CELLS IDENTIFIED.
**NAME[ZZZ M. YYY], M.D.  1445 HOURS  26 **DATE[May 2012]
 
PART 2: RIGHT SENTINEL LYMPH NODE #2
RAPID DIAGNOSIS:
CYTOLOGY TOUCH PREPARATION: NO MALIGNANT TUMOR CELLS IDENTIFIED.
**NAME[ZZZ M. YYY], M.D.  1445 HOURS  26 **DATE[May 2012]

PART 3: RIGHT SENTINEL LYMPH NODE #3
RAPID DIAGNOSIS:
CYTOLOGY TOUCH PREPARATION: NO MALIGNANT TUMOR CELLS IDENTIFIED.
**NAME[ZZZ M. YYY], M.D.  1517 HOURS  26 JULY 2011PATHOLOGIST:
**NAME[YYY ZZZ]",,,,,
REG3,BREAST,0,PAT-00745537,1,REC-5000735237,,,,"1 ST HISALERT^ALERT   
<SUPPLEMENTAL>
  An immunostain for Her-2/neu has been performed. The invasive neoplastic
cells are negative  (0-1+) with that antibody.
SUPPLEMENTING
<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Mar 26 2012]
<FINAL DX>
  ADDENDED REPORT
RIGHT BREAST, 10 O'CLOCK, 5 CFN, CORE BIOPSIES: INFILTRATING DUCTAL
CARCINOMA ADJACENT TO AREA OF SCAR AND FAT NECROSIS; WELL DIFFERENTIATED
(NOTTINGHAM GRADE I/III). 
1. NUCLEAR GRADE: INTERMEDIATE.
2. MITOTIC RATE: LOW.
3. TUBULAR DIFFERENTIATION: INTERMEDIATE. 
4. INTRADUCTAL CARCINOMA COMPONENT: ABSENT. 
5. CALCIFICATIONS: ABSENT. 
6. INTRAMAMMARY LYMPHATIC SPACE INVASION: ABSENT IN THIS SPECIMEN. 
7. ESTROGEN RECEPTOR STATUS: POSITIVE. 
8. PROGESTERONE RECEPTOR STATUS: POSITIVE. 
9. HER2 STATUS: PENDING. 
: Grading of this neoplasm is limited by the small amount of tumor
present and by crush artifact of some neoplastic cells.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Mar 25 2012]
<SPECIMEN(S)>
  A) right breast mass, 10:00, 5 cfn - adjacent to scar
<CLINICAL INFO>
  hx right breast ca, 10 yrs ago, s/p chemo/radiation, r/o ca
<GROSS>
  Received in a container labeled with the patient's name and ""right breast
10:00 5 CFN"" are four irregular yellow-tan fibroadipose needle cores, 4.5
cm in aggregate length, AE/(4).
<MICROSCOPIC>
  Sections show several cores of breast tissues with areas of fat necrosis
and dense fibrosis. On three of the core biopsies, in areas of dense
fibrosis, there are nests of invasive ductal breast carcinoma. The
presence of these epithelial cells is confirmed with an immunostain for
pancytokeratin (AE1/AE3). Invasive tumor spans a greatest area of up to
2.8 mm on a single core. 
Slides from the previous breast cancer are not in our files for a direct
histologic comparison but given the location within scar tissues and the
adjacent fat necrosis this is likely near the site of a previous surgical
procedure and could be recurrent tumor. The possibility of a new primary
carcinoma arising at this site can not be completely excluded. 
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. HER2-NEU (4B5): PENDING
2. ESTROGEN RECEPTOR (SP1): POSITIVE (**NAME[XXX] Score 8)
3. PROGESTERONE RECEPTOR (IE2): NEGATIVE
4. PANCYTOKERATIN (AE1/AE3): POSITIVE
Fixation Time:  Within Guideline Limits (See comment).
: Negative estrogen and progesterone receptors and Her-2/neu
results may be unreliable in cases where fixation time is shorter than
guideline limits suggest. 
Interpretation: Estrogen/progesterone receptor evaluation is based on the
**NAME[XXX] Scoring system.  An **NAME[XXX] score of 3 to 8 is considered positive.
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.",,,,,
REG3,BREAST,0,PAT-00593135,2,REC-5000735437,,,,"<CLINICAL INFO>
Left breast cancer, previous right breast CA with mastectomy.  Per outside report (**ID-NUM), immunohistochemistry stains were performed on the biopsy from **DATE[Mar 19 2012] and the tumor is negative for estrogen receptor, progesterone receptor and Her-2.  Ki-67 demonstrated a high proliferative index of >50%.

<GROSS>
Received in formalin, labeled with the patient's name and designated 'left breast tissue, short suture at Tail of **NAME[ZZZ], long suture marks tumor skin boundary,' is a 160 gm simple left mastectomy specimen with short suture designating Tail of **NAME[ZZZ] and long suture marking tumor skin boundary, per the requisition.  The breast measures 9.1 cm from superior to inferior, 2.5 cm from anterior to posterior, 15.3 cm from medial to lateral.  A tan-pink skin ellipse is present on the anterior surface measuring 13.8 cm from medial to lateral x 8.1 cm from superior to inferior.  A V-shaped incision is present on the left tip of the skin ellipse, which measures 7.2 cm from superior to inferior, and is located 1.5 cm from the most lateral skin tip.  An everted nipple measuring 1.1 cm in diameter x 0.9 cm in length is located in the central aspect of the skin, with a 3.1 cm areolar surrounding the nipple.  The specimen is differentially inked to allow for the microscopic evaluation of surgical resection margins as follows:  anterior-superior resection margin   blue, anterior-inferior resection margin   green, and posterior resection margin   black.  Sectioning reveals a firm, round, well-circumscribed mass measuring 1.5 cm from medial to lateral, 1.3 cm from superior to inferior, and 1.3 cm from anterior to posterior.  The mass is located 0.1 cm from the closest black-inked posterior resection margin, 0.9 cm from the closest blue-inked anterior-superior resection margin, 2.0 cm from the closest green-inked anterior-inferior resection margin, 0.8 cm deep to the skin, and 7.0 cm from the nipple.  The mass is located in the lower-outer quadrant.  The mass has a tan-white homogeneous and rubbery cut surface.  The mass is located 0.9 cm deep to the skin incision.  Located 1.0 cm from the mass is an ill-defined nodule area of tan-white dense fibrous tissue, measuring 2.5 x 1.0 x 1.0 cm.  A localization clip is identified within the central portion of the mass.  The breast immediately deep to the nipple is tan-white to chalky white soft and friable, grossly appearing to be necrotic.  The remaining uninvolved breast tissue consists of approximately 40% tan-white dense fibrous tissue admixed with 60% tan-yellow, glistening and lobulated unremarkable breast tissue.  Representative sections are submitted.  Summary of sections:  A1 nipple, A2 full thickness section through mass with closest black-inked posterior resection margin, A3 full thickness section through mass with closest blue inked anterior-superior resection margin and closest skin, A4 closest green-inked anterior-inferior margin, A5-A6 remainder of mass, A7 nodular fibrous tissue adjacent to mass, A8 soft and friable tissue deep to nipple, A9 representative upper-outer quadrant, A10 representative lower-outer quadrant, A11 representative upper-inner quadrant, A12 representative lower-inner quadrant.
JF/cs  **DATE[May 22 12]

<MICROSCOPIC>
Sections examined.  Immunohistochemistry stains were performed to evaluate for myoepithelial cells.  Stains for both p63 and smooth muscle cell myosin heavy chain demonstrate incomplete myoepithelial cells supporting a diagnosis of invasive ductal carcinoma within the mass.   This case has undergone intradepartmental review for quality assurance prior to sign-out.  
**INITIALS  **DATE[May 25 12]


<FINAL DX>
LEFT BREAST, MASTECTOMY:  
INVASIVE DUCTAL CARCINOMA WITH THE FOLLOWING FEATURES:  
1.  NOTTINGHAM GRADE III OF III (TUBULES 3, NUCLEAR PLEOMORPHISM 3, 
MITOSES 2).  
2.  TUMOR SIZE:  1.5 CM IN GREATEST DIMENSION.  
3.  FOCALITY:  SINGLE FOCUS OF INVASIVE CARCINOMA. 
4.  MULTIPLE FOCI OF LOW GRADE DUCTAL CARCINOMA IN SITU AND ATYPICAL 
DUCTAL HYPERPLASIA.
  a.  NUCLEAR GRADE:  GRADE I OF III (LOW) NUCLEAR GRADE.
  b.  ARCHITECTURAL PATTERN:  CRIBRIFORM WITHOUT NECROSIS.
  c.  MULTIFOCAL.
  d.  EXTENSIVE INTRADUCTAL COMPONENT NEGATIVE.  
5.  FOCAL ATYPICAL LOBULAR HYPERPLASIA PRESENT. 
6.  MARGINS OF INVASIVE CARCINOMA:  NEGATIVE FOR INVASIVE CARCINOMA, TUMOR 
EXTENDS TO 0.4 CM FROM POSTERIOR RESECTION MARGIN, 0.5 CM 
FROM ANTERIOR-SUPERIOR RESECTION MARGIN, AND GREATER THAN 0.5 CM
FROM REMAINING RESECTION MARGINS. 
  7.  MARGINS OF DUCTAL CARCINOMA IN SITU:  DUCTAL CARCINOMA IN SITU EXTENDS 
TO 0.2 CM FROM POSTERIOR MARGIN, AND IS GREATER THEN 0.5 CM FROM REMAINING RESECTION MARGINS.  
  8.  TREATMENT EFFECT:  NOT APPLICABLE.   
  9.  LYMPHOVASCULAR INVASION:  NOT IDENTIFIED. 
10.  SKIN AND NIPPLE PRESENT AND NEGATIVE FOR INVASIVE CARCINOMA. 
11.  SKELETAL MUSCLE NOT PRESENT.  
  12.  LYMPH NODES:  NOT IDENTIFIED.  
  13.  PATHOLOGIC STAGE:  pT1c, pNX.  
  14.  OTHER PATHOLOGIC FINDINGS:  
    a.  MARKED FIBROCYSTIC CHANGES WITH USUAL TYPE DUCTAL HYPERPLASIA. 
    b.  MICROCALCIFICATION ASSOCIATED WITH DUCTAL CARCINOMA IN SITU.
c.  VASCULAR CALCIFICATIONS.
    d.  BIOPSY SITE CHANGES.
    e.  INCIDENTAL FIBROADENOMA.",,,,,
REG3,BREAST,0,PAT-00745205,1,REC-5000735502,,,,"<CLINICAL INFO>
Suspicious mass.

<GROSS>
Received in formalin labeled with the patient's name, specimen identification number HH68896 and designated 'right breast' are five delicate yellow-tan soft tissue cores which range from 0.5 cm to 1.4 cm in length x an average diameter of 0.1 cm.  The cores, specimen container and requisition are inked red.  The tissue is wrapped and submitted entirely in A1.
RA/jw  **DATE[Mar 27 12]

<MICROSCOPIC>
Sections examined.
PB/cs  **DATE[Mar 28 12]


<FINAL DX>
RIGHT BREAST, 1:00, CORE BIOPSY:
INVASIVE DUCT CARCINOMA WITH THE FOLLOWING FEATURES:
  1.  NOTTINGHAM GRADE 3 OF 3 (TUBULE FORMATION SCORE 3,
    NUCLEAR PLEOMORPHISM SCORE 3, MITOTIC RATE SCORE 3).
  2.  TYPE:  THIS INVASIVE DUCT CARCINOMA HAS FEATURES OF INVASIVE 
    MICROPAPILLARY CARCINOMA.
  3.  FOCI SUSPICIOUS FOR LYMPHATIC SPACE INVASION ARE PRESENT.
  4.  NO IN SITU COMPONENT IDENTIFIED.
  5.  BREAST PANEL OF HORMONE RECEPTOR IMMUNOHISTOCHEMISTRY STUDIES PENDING;
THESE RESULTS WILL BE ISSUED AS AN ADDENDUM.



<ADDENDUM>
IMMUNOCYTOCHEMICAL CANCER MARKER STUDIES REPORT
ESTROGEN RECEPTOR:    NEGATIVE  
*Percent cells positive:  Less than 1%.
  Internal Controls:    Positive  
PROGESTERONE RECEPTOR:  NEGATIVE
  *Percent cells positive:  Less than 1%.
  Internal Controls:    Positive  
CerbB2 (HER-2 NEU) ONCOGENE OVEREXPRESSION:  
          NEGATIVE
  ***Score:        0 (1% faint partial membranous staining).
  Internal Controls:    Present
Ki-67 Antigen:****      High (>20%)
Percent cells positive:    37%    
_____________________________________________________________________
Immunohistochemical evaluation is performed by manual quantitative/semiquantitative morphometric analysis.
Immunohistochemical evaluation of estrogen receptor is performed is using DAKO monoclonal  mouse antihuman estrogen receptor alpha clone 1D5.  Progesterone receptor evaluation is performed using DAKO monoclonal mouse antihuman progesterone receptor clone PgR636.  Ki-67 evaluation is performed using DAKO monoclonal mouse antihuman  Ki-67 antigen clone MIB-1.  Her-2 neu evaluation is performed using DAKO polyclonal rabbit antihuman c-erbB-2 oncoprotein code No. A 0485.  Unless otherwise indicated, these studies are performed using the DAKO auto stainer used with paraffin embedded formalin-fixed sections which have undergone heat-induced epitope retrieval in Target Retrieval Solution.  DAKO Envision+/HRP kit is used for visualization.
*  If less than 1% of tumor cells are positive for estrogen or progesterone receptor, the tumor is considered to be negative for hormone receptor expression per ASCO-CAP 2010 guidelines.
**  A false negative cannot be ruled out in the presence of inadequate controls.
*** Negative (0) - no staining or membrane staining < 10% tumor cells.
   Negative (1+) - faint partial membrane staining > 10% tumor cells.
   Weak positive (2+) - weak to moderate complete membrane staining > 10% tumor cells.
   Strong positive (3+) -  uniform intense complete membrane staining > 30% tumor cells.
****  When discordance exists between cell proliferation as determined by ki-67 antigen and histologic mitotic count, the           
higher of the two determinations should be used.  Ki-67 antigen is sensitive to tissue fixation and may show a falsely low  proliferation index.",,,,,
REG3,BREAST,0,PAT-00745976,1,REC-5000735542,,,,"<CLINICAL INFO>
A.  Mass with calcs at 2 o'clock N+7.  B.  Mass at 6 o'clock N+4.  C.  Left axilla abnormal lymph node.

<GROSS>
A.  Received in formalin labeled with the patient's name and designated 'left breast 2 o'clock' are three pieces of pale tan tissue ranging in size from 0.9 x 0.1 x 0.5 x 0.1 cm.  Specimens are inked red and totally submitted in cassette A1.
B.  Received in formalin labeled with the patient's name and designated HH88934 'left breast 6 o'clock' are three pieces of pale tan tissue ranging in size from 1.7 x 0.1 and 1.6 x 0.1 cm.  Specimens are inked yellow and totally submitted in cassette B1.
C.  Received in formalin labeled with the patient's name and designated HH88790 'left axilla' are two pieces of pale tan tissue ranging in size from 2.1 x 0.1 cm.  Specimens are inked orange and submitted in cassette C1.
**INITIALS  **DATE[Jul 29 12]

<MICROSCOPIC>
Sections examined.
**INITIALS  **DATE[Jul 29 12]


<FINAL DX>
A.  LEFT BREAST MASS AT 2 O'CLOCK, N+7 (BIOPSY):
  DUCT CARCINOMA IN SITU SHOWING THE FOLLOWING FEATURES:
  1.  NUCLEAR GRADE:  2 OF 3.
  2.  SOLID TYPE WITH NECROSIS.
  3.  NO EVIDENCE OF INVASIVE CARCINOMA.
  4.  HORMONE RECEPTOR STUDIES ARE PENDING.
B.  LEFT BREAST MASS AT 6 O'CLOCK, N+4 (BIOPSY):
  INVASIVE MAMMARY CARCINOMA SHOWING THE FOLLOWING FEATURES:
  1.    HISTOLOGIC SCORE:  2 OF 3 (NOTTINGHAM HISTOLOGIC SCORE: 3 FOR
    TUBULE FORMATION, 2 FOR NUCLEAR GRADE, AND 1 FOR MITOTIC RATE
    FOR A TOTAL SCORE OF 6 OF 9).
  2.    FOCAL IN SITU CARCINOMA IS PRESENT, POSSIBLY ASSOCIATED WITH
    NECROSIS (SEE COMMENT).
  3.    GREATEST LINEAR EXTENT OF TUMOR:  1.3 CM.
  4.    HORMONE RECEPTOR STUDIES ARE PENDING AND WILL BE REPORTED IN AN
    ADDENDUM.
C.  LEFT AXILLA, LYMPH NODE (BIOPSY):
  INVASIVE DUCT AND DUCT CARCINOMA IN SITU ASSOCIATED WITH LYMPHOID TISSUE
  CONSISTENT WITH LYMPH NODE METASTASES.

<DX COMMENT>
 The histologic features of the tumor within specimen B, representing the mass at 6 o clock, show a single file pattern of infiltration suggesting lobular carcinoma. An E-cadherin immunohistochemical stain is pending for more definitive evaluation. Prominent calcifications are present within invasive tumor and within circumscribed foci of necrosis, possibly representing an in situ component.


<ADDENDUM>
An E-cadherin stain is performed on specimen B, representing invasive carcinoma and possible in situ, showing strong membranous staining for E-cadherin, supporting the diagnosis of invasive duct carcinoma.  
**INITIALS  **DATE[Aug 01 12],   PART A DCIS BREAST PANEL
IMMUNOCYTOCHEMICAL CANCER MARKER STUDIES REPORT
ESTROGEN RECEPTOR:    Negative   
*Percent cells positive:  0%
  Internal Controls:    Positive
PROGESTERONE RECEPTOR:  Negative 
  *Percent cells positive:  0%
  Internal Controls:    Positive
_____________________________________________________________________
Immunohistochemical evaluation is performed by manual quantitative/semiquantitative morphometric analysis.
Immunohistochemical evaluation of estrogen receptor is performed is using DAKO monoclonal  mouse antihuman estrogen receptor alpha clone 1D5.  Progesterone receptor evaluation is performed using DAKO monoclonal mouse antihuman progesterone receptor clone PgR636.  Ki-67 evaluation is performed using DAKO monoclonal mouse antihuman  Ki-67 antigen clone MIB-1.  Her-2 neu evaluation is performed using DAKO polyclonal rabbit antihuman c-erbB-2 oncoprotein code No. A 0485.  Unless otherwise indicated, these studies are performed using the DAKO auto stainer used with paraffin embedded formalin-fixed sections which have undergone heat-induced epitope retrieval in Target Retrieval Solution.  DAKO Envision+/HRP kit is used for visualization.
*  If less than 1% of tumor cells are positive for estrogen or progesterone receptor, the tumor is considered to be negative for hormone receptor expression per ASCO-CAP 2010 guidelines.
**  A false negative cannot be ruled out in the presence of inadequate controls.
*** Negative (0) - no staining or membrane staining < 10% tumor cells.
   Negative (1+) - faint partial membrane staining > 10% tumor cells.
   Weak positive (2+) - weak to moderate complete membrane staining > 10% tumor cells.
   Strong positive (3+) -  uniform intense complete membrane staining > 30% tumor cells.
****  When discordance exists between cell proliferation as determined by ki-67 antigen and histologic mitotic count, the           
higher of the two determinations should be used.  Ki-67 antigen is sensitive to tissue fixation and may show a falsely low  proliferation index.   PART B INFILTRATING CARCINOMA  
IMMUNOCYTOCHEMICAL CANCER MARKER STUDIES REPORT
ESTROGEN RECEPTOR:    Negative.    
*Percent cells positive:  0%
  Internal Controls:    Positive  
PROGESTERONE RECEPTOR:  Negative 
  *Percent cells positive:  0%
  Internal Controls:    Positive  Negative**  Not Present**
CerbB2 (HER-2 NEU) ONCOGENE OVEREXPRESSION:  
          Strong positive 
 
      ***Score:    3+ (78% of cells demonstrate strong complete 
          membranous staining)  
    Internal Controls:  Present  
Ki-67 Antigen:****      High (>20%)
Percent cells positive:  31%      
_____________________________________________________________________
Immunohistochemical evaluation is performed by manual quantitative/semiquantitative morphometric analysis.
Immunohistochemical evaluation of estrogen receptor is performed is using DAKO monoclonal  mouse antihuman estrogen receptor alpha clone 1D5.  Progesterone receptor evaluation is performed using DAKO monoclonal mouse antihuman progesterone receptor clone PgR636.  Ki-67 evaluation is performed using DAKO monoclonal mouse antihuman  Ki-67 antigen clone MIB-1.  Her-2 neu evaluation is performed using DAKO polyclonal rabbit antihuman c-erbB-2 oncoprotein code No. A 0485.  Unless otherwise indicated, these studies are performed using the DAKO auto stainer used with paraffin embedded formalin-fixed sections which have undergone heat-induced epitope retrieval in Target Retrieval Solution.  DAKO Envision+/HRP kit is used for visualization.
*  If less than 1% of tumor cells are positive for estrogen or progesterone receptor, the tumor is considered to be negative for hormone receptor expression per ASCO-CAP 2010 guidelines.
**  A false negative cannot be ruled out in the presence of inadequate controls.
*** Negative (0) - no staining or membrane staining < 10% tumor cells.
   Negative (1+) - faint partial membrane staining > 10% tumor cells.
   Weak positive (2+) - weak to moderate complete membrane staining > 10% tumor cells.
   Strong positive (3+) -  uniform intense complete membrane staining > 30% tumor cells.
****  When discordance exists between cell proliferation as determined by ki-67 antigen and histologic mitotic count, the           
higher of the two determinations should be used.  Ki-67 antigen is sensitive to tissue fixation and may show a falsely low  proliferation index.",,,,,
REG3,BREAST,0,PAT-00743455,1,REC-5000735608,,,,"<CLINICAL INFO>
Right breast cancer.
INTRAOPERATIVE CYTOLOGIC EVALUATION:
A1TP:  Lymph node, one; negative for carcinoma (Dr. **NAME[ZZZ]).

<GROSS>
A.  Received fresh labeled with the patient's name designated 'right axillary sentinel node' is a 2.5 x 1.5 x 1.0 cm fat replaced tan to pink-yellow ovoid lymph node.  This lymph node is bisected and a touch prep is performed yielding the following diagnosis by Dr. **NAME[ZZZ]:  Lymph node, one; negative for carcinoma.  The bisected lymph node is submitted in its entirety for permanent sectioning in cassette A1.
B.  Received in formalin labeled with the patient's name and designated 'right breast tissue' is an oriented right breast lumpectomy measuring 10.5 cm medial to lateral, 7.0 cm superior to inferior, and up to 4.5 cm anterior to posterior.  The specimen has been received oriented per the surgeon with a double suture designating the posterior resection margin, a single suture designating the lateral resection margin, and a localization wire and skin representing the anterior margin.  The overlying ellipse of lightly pigmented skin is 4.5 cm medial to lateral x 1.0 cm superior to inferior.  The skin surface is grossly unremarkable.  A skin mass or lesion is not identified.  The lumpectomy is differentially inked in order to allow for the microscopic evaluation of the surgical resection margins in the following manner:  The superior resection margin is inked blue, the inferior resection margin is inked green, the medial resection margin is inked violet, the lateral resection margin is inked orange, the anterior resection margin is inked yellow, the posterior resection margin is inked black.  Sectioning of the lumpectomy reveals a gritty white to pink-gray 1.0 x 0.8 x 0.7 cm mass within the anterior-inferior aspect of the lumpectomy.  A spring-like metallic clip is embedded within the mass.  The mass comes to within 0.8 cm of the anterior resection margin, 1.0 cm of the inferior resection margin, 1.5 cm of the superior resection margin, and 2.0 cm of the posterior resection margin.  The mass does not grossly appear to involve the overlying skin ellipse.  Additional distinct breast masses or lesions are not grossly identified.  The remainder of the lumpectomy is comprised of approximately 75% yellow glistening adipose tissue and 25% white to pink fibrous tissue.  The identified mass is submitted in its entirety.  Summary of sections:  B1 medial resection margin, B2 and B3 bicomposite section of uninvolved breast medial to mass, B4 and B5 breast mass with anterior and inferior resection margins, B6 breast mass with anterior, skin, and superior resection margin, B7 and B8 bicomposite section of uninvolved breast tissue lateral to breast mass, B9 lateral resection margin.
**INITIALS  **DATE[Jun 4 12]

<MICROSCOPIC>
A-B.  Sections examined (including a cytokeratin immunohistochemical stain on part A).
This case has undergone prospective intradepartmental quality assurance review prior to verification.
AK/cs  **DATE[Jun 05 12]


<FINAL DX>
A.  LYMPH NODE, RIGHT AXILLARY SENTINEL, BIOPSY:
  ONE LYMPH NODE NEGATIVE FOR CARCINOMA ON ROUTINE H&E LEVELS AND A 
  CYTOKERATIN IMMUNOHISTOCHEMICAL STAIN.
B.  BREAST, RIGHT, LUMPECTOMY:
  INVASIVE DUCTAL CARCINOMA WITH THE FOLLOWING FEATURES:
  1.  SIZE:  1.0 X 0.8 X 0.7 CM (GROSS MEASUREMENT).
  2.  TUMOR FOCALITY:  SINGLE FOCUS OF INVASIVE CARCINOMA.
  3.  HISTOLOGIC GRADE:  NOTTINGHAM GRADE 3 OF 3 (DERIVED AS FOLLOWS:
    TUBULE FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY-2; 
    TOTAL SCORE 8).
  4.  DUCTAL CARCINOMA IN SITU (DCIS):  NOT IDENTIFIED.
  5.  LOBULAR CARCINOMA IN SITU (LCIS):  NOT IDENTIFIED.
  6.  MARGINS:  INVASIVE CARCINOMA IS 0.4 CM FROM THE CLOSEST ANTERIOR 
    MARGIN, 0.6 CM FROM THE CLOSEST INFERIOR MARGIN, AND GREATER THAN
    1.0 CM FROM ALL OTHER MARGINS (MICROSCOPIC MEASUREMENTS).
  7.  LYMPHOVASCULAR INVASION:  NOT IDENTIFIED.
  8.  SKIN WITH NO DIAGNOSTIC ABNORMALITY RECOGNIZED.  
  9.  ADDITIONAL PATHOLOGIC FINDINGS:  PRIOR BIOPSY SITE CHANGES.
  10. ANCILLARY STUDIES:  HORMONE RECEPTOR STUDIES WERE PERFORMED ON THE
    PRIOR CORE BIOPSY SPECIMEN(FH-11-12522)(ER+,PR+,HER-2 NEGATIVE).  
  11. PATHOLOGIC STAGE:  pT1b N0(sn)(i-).",,,,,
REG3,BREAST,0,PAT-00497714,2,REC-5000736249,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Breast, 9:00, Ultrasound Guided Core Biopsy:
   Infiltrating carcinoma with the following features:
      Histologic type:   Lobular.
      Histologic grade:  1.
      Nottingham grade:  5 of 9.
         Tubule formation:    Low (3 of 3).
         Nuclear grade:  Low (1 of 3).
         Mitotic rate:   Low (1 of 3).
      Lymph-vascular space invasion:    Not identified.
   Ductal carcinoma in situ (DCIS):     Not identified.
   Additional findings:  Immunohistochemical studies for estrogen and
progesterone receptor expression and HER-2/neu will be performed and
reported in an addendum.

<CLINICAL INFO>
Right breast mass 9 o'clock. ?papilloma. Fixation time: **DATE[Oct 05 2011] at
1430 hours. Total fixation time 6 hours 30 minutes.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""right
breast needle core biopsy at 9 o'clock"" per requisition, are four 0.3 cm
in diameter, elongated portions of fibrofatty tissue, 0.3-1.1 cm in
lengths; submitted in A1.  (pcs/jkb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

INTRADEPARTMENTAL CONSULATION:
Cellnetix pathologist **NAME[ZZZ YYY] M.D. agrees with the diagnosis of
invasive carcinoma.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Oct 08 2011]
**PHONE  (Physician to Physician Only)",,,,,
REG3,BREAST,0,PAT-00743375,1,REC-5000736584,,,,"<SPECIMEN(S)> 
A. Breast -Left breast core biopsy 12:00 / 5 cm from nipple 
<ADDENDUM> 
Addendum 1 Entered: **DATE[Feb 05 12]-0825 
Immunohistochemical Studies Performed 
B. Left breast, 6:00, MRI-guided needle core biopsy: 
Invasive mammary carcinoma with the following immunohistochemical features 1. 
Estrogen receptor expression: Positive (59% of cells, moderate staining 
intensity). 
2. Progesterone receptor expression: Positive (2% of cells, strong staining 
intensity). 
3. HER2 oncogene protein overexpression: Negative. 

 
<ADDENDUM> (Continued) 
IMMUNOHISTOCHEMICAL RESULTS 
Deparaffinized tissue sections undergo optimized epitope retrieval prior to incubation with 
the appropriate antibody. Visualization is provided by an immunoperoxidase technique. 
Immunohistochemical staining is evaluated by visual examination of slides using a 
conventional light microscope and by computer-assisted morphometric analysis where noted. 
The positive and negative control slides for each immunohistochemical test are reviewed and 
found to exhibit the appropriate staining pattern. Results on the invasive carcinoma are as 
indicated in the table below 
Tests performed on formalin-fixed, paraffin-embedded block: B1 
Antibody (clone): Result 
Estrogen receptor (ER) (SP1): 59% *** 
Progesterone receptor (PR) (PgR 636): 2% *** 
HER2 (HerceptTest Dako) 1+ **** 
***Hormone receptor scoring is performed quantitatively by computer-assisted morphometric 
analysis with an Applied Imaging Ariol system. Results are reported as positive for the 
percentage of neoplastic cells that exhibit the expected staining pattern when the 
percentage is greater than or equal to 1%. Results are reported as negative when the 
percentage of neoplastic cells that exhibit the expected staining pattern is less than 1%. 
****HER2 immunohistochemical slides are prepared with the Dako HercepTest (FDA method) 
following the procedures as outlined in the test kit. Separate 1+, 2+, and 3+ staining 
controls are provided for each run. Analysis is performed by quantitative computer-assisted 
morphometric analysis based on an appropriately trained Ariol (Applied Imaging) system. The 
immunostained signal is analyzed for each selected area of the invasive tumor. The final 
results are scored according to CAP-ASCO HER2 testing guidelines (Wolff et al., 2007) as 
negative (either 0 or 1+), equivocal (2+, requiring a calculated signal of at least 2+ in 
>10% of the selected tumor), or positive (3+, requiring a calculated signal of 3+ in >30% of 
the selected tumor). Validation studies are performed on a set of tumors for which 
immunohistochemical and fluorescence in situ hybridization (FISH) results are known from 
outside studies performed by an external laboratory using validated methods. The validation 
set consists of 97 immunohistochemical results (which includes 33 external 3+ scores and 35 
external negative scores) and 49 FISH results (which consists of 16 positive results and 33 
negative results). Comparison of the internal immunohistochemical scores obtained by 
computer-assisted morphometric analysis with the external immunohistochemical scores reveals 
no discordance between immunohistochemical internal (negative, 3+) scores and external (3+, 
negative) scores, respectively. Specifically, identical results are found with all 33 of the 
externally scored 3+ cases and with 34 of the 35 externally scored negative cases, with one 
of the externally scored negative cases given an internal score of 2+ (equivocal). Cases 
possessing internal scores of negative or 3+ but which are externally scored as 2+ are found 
to possess negative and positive FISH results which are 100% concordant with the internal 
negative and 3+ immunohistochemical scores, respectively. Comparison of the internal 
immunohistochemical scores obtained by computer-assisted morphometric analysis with the 
external FISH scores reveals no discordance between immunohistochemical (negative, 3+) 
scores and FISH results. Specifically, all 22 internal negative immunohistochemical scores 
correspond to negative FISH results and all 14 internal 3+ immunohistochemical scores 
correspond to positive FISH results. The remaining 13 FISH results correspond to internal 2+ 
immunohistochemical scores. 

 
<ADDENDUM> (Continued) 
Breast specimens are allowed to fix in 10% neutral buffered formalin for at least 6 hours 
and complete processing within 36 hours of receipt unless otherwise noted. 
This laboratory participates in external HER2 proficiency testing as specified in the 
CAP-ASCO HER2 testing guidelines (Wolff et al., 2007). 
The performance characteristics of these immunohistochemical tests have been determined by 
**INSTITUTION. Some of these tests have been developed by **INSTITUTION. 
**INSTITUTION. is certified under the Clinical Laboratory Improvement Amendments 
of 1988 as qualified to perform high complexity clinical laboratory testing. Some of these 
tests may use analyte specific reagents; they have not been cleared or approved by the U.S. 
Food & Drug Administration (FDA). The FDA has determined that such clearance or approval is 
not necessary. These tests are used for clinical purposes. They should not be regarded as 
investigational or for research. 
REFERENCES 
Wolff et al. American Society of Clinical Oncology/College of American Pathologists 
Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast 
Cancer. Arch Pathol Lab Med. 2007 **DATE[Jul 1];**ID-NUM. 
AH/dh 
88305 (**DATE[Feb 02 12]-1442 SWHITING) 

 
**DATE[Feb 02 12] -1442 SWHITING 
**DATE[Feb 02 12] -1442 SWHITING 
<CLINICAL INFO> 
A) Left breast core biopsy 12:00 / 5 cm from nipple, ICD: 611.72,, B) Left breast history of 
breast cancer, Left breast mass at 6 o'clock, A ) specimen collection and fixation done 07/ 
29/2011 at 2:49, B) Specimen collection and fixation done **DATE[Jan 29 2012] at 12:00 

<FINAL DX> 
A. Left breast needle core biopsy, 12:00, 5 cm from the nipple: 
-Focal microcalcifications associated with benign breast ducts. 
-Dense hyalinized stromal fibrosis. 
-Negative for significant atypia and malignancy. 
B. Left breast MRI-guided needle core biopsy, 6:00: 
Invasive carcinoma 
Tumor size: At least 0.4 cm in greatest dimension. 
Histologic type: Ductal carcinoma (tubular carcinoma). 
Histologic grade: Nottingham grade 1 of 3 (Tubule score 1 of 3; nuclear score 1 of 
3; mitotic count less than 1 per 10 hpf, score 1 of 3). 
Lymph-vascular invasion: Not identified. 
Ductal carcinoma in situ: Present, cribriform pattern, nuclear grade 1 of 3 without 
necrosis. 
Hormone receptor, HER2 studies: Pending, addendum report to follow. 
Microcalcifications: Not identified. 
This case has been subjected to review by a second pathologist per departmental quality 
assurance (QA) policy. 
**INITIALS 

<GROSS> 
Received are two formalin-filled containers labeled '**NAME[AAA BBB] 75733' and a 
requisition with '**NAME[CCC, AAA M]. 75733'. The specimens are placed in formalin at 
1449, **DATE[Jan 29 12], for a total fixation time of 29.5 hours. 
The first specimen is designated 'left breast core biopsy, 12:00, 5 cm from nipple'. It 
consists of five needle cores measuring up to 2.0 cm in length with a diameter of 0.1 cm. 
Entirely submitted in A1 and A2. 

 

<GROSS> (Continued) 
The second is designated `left breast mass MRI-guided biopsy, 6.00' and is multiple friable 
cores of tissue up to 1.7 cm in length with a diameter of 0.5 cm. Entirely submitted in 
B1-B6. 
IMMUNOHISTOCHEMICAL RESULTS 
Deparaffinized tissue sections undergo optimized epitope retrieval prior to incubation with 
the appropriate antibody. Visualization is provided by an immunoperoxidase technique. 
Immunohistochemical staining is evaluated by visual examination of slides using a 
conventional light microscope. The positive and negative control slides for each 
immunohistochemical test are reviewed and found to exhibit the appropriate staining pattern. 
Tests performed on three-fixed, paraffin-embedded blocks: ***PATH-NUMBER[1] B1, B2 and B3. 
ANTIBODY (CLONE): RESULT 
Smooth muscle myosin heavy chain (SMMS-1): Areas of DCIS positive; areas of invasive 
carcinoma negative 
The performance characteristics of these immunohistochemical tests have been determined by 
**INSTITUTION. Some of these tests have been developed by **INSTITUTION. 
**INSTITUTION. is certified under the Clinical Laboratory Improvement Amendments 
of 1988 as qualified to perform high complexity clinical laboratory testing. 
**Technical component performed at US LABS, **STREET-ADDRESS, **PLACE, CA 92612. The 
performance characteristics of these immunohistochemical tests have been determined by US 
Labs. Some of these tests have been developed by US Labs. US Labs is certified under the 
Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high complexity 
clinical laboratory testing. 
Some of these tests may use analyte specific reagents; they have not been cleared or 
approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such 
clearance or approval is not necessary. These tests are used for clinical purposes. They 
should not be regarded as investigational or for research. 
JR/dh 
**DATE[Feb 02 12] -1442 SWHITING 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis. 

 
DATE: **DATE[Feb 08 12] @ 0954 
PTH SPECIMEN INTERNAL INQUIRY 
PAGE 6 
**NAME[ZZZ YYY] 
**NAME[XXX M WWW], MD 
**NAME[XXX M WWW], MD 
**NAME[XXX M WWW], MD 
DATE TYPE ESIG ADDEN SEC ACTION 
ENTERED BY DATE TIME",,,,,
REG3,BREAST,0,PAT-00734951,1,REC-5000737520,,,,"<CLINICAL HX>
Preop: Previous lumpectomy - right breast. Breast Ca UOQ. Right breast re-excision for margins (stitch medial aspect with skin anterior). The patient's surgical pathology record documents an outside biopsy with grade 1, ER and PR positive, HER2 negative, invasive ductal carcinoma, with subsequent excisional biopsy containing a 1.5 cm grade 1 invasive carcinoma, extending to within less than 0.5 mm of margin; sentinel lymph node biopsy showed a micrometastasis (***PATH-NUMBER[1]; selected slides reviewed).  

<HISTOLOGY COMMENT>



<GROSS>
The specimen is labeled ""right breast re-excision for margins"" and is received in formalin. It consists of an ovoid piece of fat-covered tissue surfaced by a skin ellipse which has a suture at one apex to indicate medial, and the skin ellipse itself is anterior. The skin ellipse measures 3.7 x 1.2 cm and has a linear scar running parallel to its long axis along most of its length. The specimen measures 4 cm in length from anterior to posterior including the skin ellipse, 3.5 cm from medial to lateral, and 3 cm from superior to inferior. The external surface is now inked as follows: Medial - blue, lateral - green, posterior - black, anterior surrounding skin ellipse - yellow, superior - orange, and inferior - violet. The specimen is serially sectioned from lateral to medial perpendicular to the skin ellipse into thirteen slices. This reveals a central biopsy cavity measuring up to 1.5 x 0.5 cm (slice #6), surrounded by fibrotic-appearing white tissue. Residual tumor is not grossly apparent. The entire specimen is submitted sequentially from lateral to medial in cassettes A1-A13 (the medial tip of the skin ellipse is in A10). lj


<COMMENT>


<MICROSCOPIC>


<FINAL DX>
 RIGHT BREAST, ORIENTED RE-EXCISION WITH EXAMINATION OF MARGINS:  SKIN AND BREAST TISSUE SHOWING A HEALING BIOPSY SITE WITH FIBROSIS, FAT NECROSIS,  HEMORRHAGE, AND FOREIGN BODY REACTION; NO RESIDUAL INVASIVE OR IN-SITU CARCINOMA  IS IDENTIFIED.  PROLIFERATIVE FIBROCYSTIC CHANGE WITH INTRADUCTAL HYPERPLASIA AND SCLEROSING  ADENOSIS; MICROCALCIFICATIONS.  INCIDENTAL SMALL LYMPH NODE; METASTATIC CARCINOMA IS NOT IDENTIFIED. 

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>


<NOTIFICATION>


<PRELIM DX>


<CHECKLIST>


<IMMUNOHISTOCHEMISTRY>


<INDICATIORS>


<SPECIAL STAINS>",,,,,
REG3,BREAST,0,PAT-00744791,1,REC-5000737577,,,,"<CLINICAL HX>
Poorly defined, slightly hypoechoic lesion. Fam hx with sister.  7 slides sent to Virginia Mason per their request, UPS 1Z9864970393750402, **DATE[Jan 22 12] CC  

<HISTOLOGY COMMENT>



<GROSS>
In formalin labeled ""right breast"" are eight 2 mm in diameter and 2-17 mm in length yellow-white fibrofatty biopsy cores. Entirely submitted in cassette A1. as


<COMMENT>
 

<MICROSCOPIC>
 

<FINAL DX>
 BREAST, RIGHT, ""9 O'CLOCK 7 CM FROM NIPPLE"", ENCOR BIOPSY:  DUCTAL CARCINOMA-IN-SITU.  ARCHITECTURAL TYPE: CRIBRIFORM.  GRADE: INTERMEDIATE.  NECROSIS: PRESENT.  MICROCALCIFICATIONS: PRESENT.  EXTENT: DUCTAL CARCINOMA-IN-SITU INVOLVES ALL SUBMITTED TISSUE CORES.  NO INVASIVE MALIGNANCY IS IDENTIFIED.  SUMMARY OF PREDICTIVE AND PROGNOSTIC ASSAYS:  ESTROGEN RECEPTOR: POSITIVE.  PROGESTERONE RECEPTOR: POSITIVE. 

<ANCILLARY STUDIES>
 

<EXTERNAL CONSULTATION>
 

<INTRADEPARTMENTAL CONSULTATION>
 Dr. **NAME[ZZZ YYY] has reviewed this case and concurs with this diagnosis.

<NOTIFICATION>
 Dr. **NAME[ZZZ YYY] discussed this diagnosis with Dr. **NAME[XXX] on **DATE[Dec 18 11].

<PRELIM DX>
 

<CHECKLIST>
 

<IMMUNOHISTOCHEMISTRY>
Semi-quantitative immunohistochemical stains using DAB Chromogen detection were performed on formalin-fixed paraffin-embedded tissue sections with the following results below. Specimen fixation time was 26 hours, 30 minutes. Current CAP/ASCO recommended fixation times are 6-48 hours for Her2 testing and 6-72 hours for estrogen and progesterone receptor testing.

<INDICATIORS>
 

<SPECIAL STAINS>",,,,,
REG3,BREAST,0,PAT-00636561,2,REC-5000738099,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Left Superficial Lymph Node, Not Hot or Blue:
     No evidence of malignancy in a single identified lymph node (0 of
1).

B.  Left Superficial Lymph Node, Not Hot or Blue:
     No evidence of malignancy in a single identified lymph node (0 of
1).

C.  Left Inferior Lymph Node, Not Hot or Blue:
     No evidence of malignancy in a single identified lymph node (0 of
1).

D.  Left Sentinel Lymph Node, Counts 75/33:
     No evidence of malignancy in a single identified lymph node (0 of
1).

E.  Left Deep Chest Wall Sentinel Lymph Node, Counts 31/19:
     No evidence of malignancy in a single identified lymph node (0 of
1).

F.  Left Breast, 1 o'clock Re-Excision, Partial Mastectomy: 
     Ductal carcinoma in situ (DCIS) with the following features:
          Histologic type:
Micropapillary/cribriform.
          Nuclear grade:                     Low to intermediate.
          Necrosis:                     Not identified.
          Size/Extent of DCIS:                         5.5 mm in
greatest extent.
          Distribution of DCIS in specimen:  Single focus in slice 4
(block F5).
          Microcalcifications:                         Not identified.
          Surgical margins:
          Anterior (superficial):                 0.5 mm.
          Posterior (deep):                       10 mm. 
          Superior:                     >10 mm. 
          Inferior:                     >10 mm. 
          Medial:                       43 mm. 
          Lateral:                 12 mm. 
     Lymph nodes:                  No lymph nodes identified in specimen
F.
                         Zero of five lymph nodes (including all
specimens A-E)
                           (0 of 5).
          No invasive carcinoma identified.
     Pathologic stage:                  pTis, pN0 (AJCC 7th Edition).
     Additional findings:
     Focal fat necrosis and reactive changes are identified consistent
with previous
       excisional biopsy.
     Immunohistochemistry staining for estrogen and progesterone
receptor
       expression has been previously performed (***PATH-NUMBER[2]), with the
following results:
       ER 99%, PR 95%.

<CLINICAL INFO>
Left breast cancer. Part F was placed into formalin at 3 p.m. on
**DATE[Feb 05 2012]. Total formalin-fixation time is 72.5 hours.

INTRAPROCEDURAL EVALUATION:
D. Left sentinel lymph node, count 75/33 (touch prep): ""No carcinoma
identified. Final diagnosis to await
    complete study.""
E. Left deep chest wall sentinel node, 31/19 (touch prep): ""No carcinoma
identified. Final diagnosis to
    await complete study.""
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A. Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated
""superficial lymph node, not hot or blue"" per container, further
designated ""left"" per requisition, is a portion of yellow adipose tissue
containing metal clips from which a 0.8 cm possible lymph node is
retrieved. The fat is retained in formalin. The node is bisected and
entirely submitted in A1.

B. Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated
""superficial lymph node, not hot or blue #2"" per container, further
designated ""left"" per requisition, is a 0.7 cm possible lymph node with
scant adherent adipose tissue. It is bisected and entirely submitted in
B1.

C. Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated
""inferior lymph node, not hot or blue"" per container, further designated
""left"" per requisition, is a portion of yellow adipose tissue from which
a 1 cm possible lymph node is retrieved. The adipose tissue is retained
in formalin. The lymph node is bisected and entirely submitted in C1.

D. Taken fresh from the operating room, labeled ""**NAME[BBB, AAA]""
and designated ""sentinel lymph node ct 75/33"" per container, further
designated ""left"" per requisition, is 0.6 cm possible lymph node. It is
bisected and a touch prep is performed. Following formalin fixation, the
remaining tissue is entirely submitted in D1.

E. Taken fresh from the operating room, labeled ""**NAME[BBB, AAA]""
and designated ""deep chest wall sentinel node, 31/19"" per container,
further designated ""left"" per requisition, is 0.3 cm blue-tinted lymph
node. It is entirely submitted for touch prep evaluation. It is entirely
submitted in E1.

F. Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated
""left 1 o'clock re-excision partial mastectomy"", is an 18-gram portion
of fibroadipose tissue oriented by a short black superior suture, a long
black lateral suture, a short white inferior suture and a long white
medial suture. It is 5.5 cm from medial to lateral, 4.5 cm from superior
to inferior and 1.3 cm from superficial to deep. There is a 2.5 cm
full-thickness defect from anterior to posterior. The anterior surface
is covered by granulation tissue. It is inked as follows: anterior -
blue, posterior - black, medial - red, lateral - yellow, superior -
orange, inferior - green, defect - violet. It is sectioned from lateral
to medial into 19 slices revealing no discrete masses and some fat
necrosis along the anterior margin. The specimen is entirely submitted
as follows:
Block Key:
F1, F2    slice 1
F3        slice 2
F4        slice 3
F5        slice 4
F6        slice 5
F7        slice 6
F8        slice 7
F9        slice 8
F10       slice 9
F11       slice 10
F12       slice 11
F13       slice 12
F14       slice 13
F15       slice 14
F16       slice 15
F17       slice 16
F18       slice 17
F19       slice 18
F20       slice 19. (rkg/gdb)

<MICROSCOPIC>
A.  One HE stained slide examined. Please see diagnosis.

B.  One HE stained slide examined. Please see diagnosis.

C.  One HE stained slide examined. Please see diagnosis.

D.  Five HE stained slides examined including touch preps and multiple
levels. Please see diagnosis.

E.  Five HE stained slides examined including touch preps and multiple
levels. Please see diagnosis.

F.  Twenty HE stained slides examined. Please see diagnosis.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block D1

Antibody  Result    Comment
Pan CK    Negative

Block E1

Antibody  Result    Comment
Pan CK    Negative

Impression:  Immunohistochemical stains shows no evidence of metastatic
carcinoma.
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Feb 10 2012]",,,,,
REG3,BREAST,0,PAT-00745896,1,REC-5000738116,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Omitted information

<FINAL DX>     

A. Left Breast, 5:00, Wire-Localized Oriented Partial Mastectomy:
   Ductal carcinoma in situ (DCIS) with the following features:
      Histologic type:        Solid.
      Nuclear grade:          High.
      Necrosis:          Present.
      Size/Extent of DCIS:         Approximately 0.9 cm.
      Distribution of DCIS in specimen: Near biopsy site in the
mid-inferior half (slices 10-12 of 16).
      Microcalcifications:         Present, and associated with DCIS.
      Surgical margins:
         Anterior (superficial):        Negative (3 mm).
         Posterior (deep):         Negative (9mm).
         Superior:       Negative (>10 mm).
         Inferior:       Negative (>5 mm). (slide A19, See Comment)
         Medial:         Negative (>10 mm).
         Lateral:        Close (1 mm) (slides A15, A19).

      No invasive carcinoma identified.
   Additional findings:
Immunohistochemistry staining for estrogen and progesterone receptor
expression has been previously performed (***PATH-NUMBER[2]), with the following
results: ER 5%, PR 0%

B. Left Breast, 5:00, New Inferior Margin, Oriented Resection:
       Benign fatty breast tissue.

<COMMENT>
In part A (partial mastectomy), there is focally DCIS 1 mm from the
green inked (marks inferior) cauterized surface at its junction with the
yellow inked (marks lateral) surface in slice 12 of 16 (slice 16 most
inferior).  This would place it approximately 12 mm from the absolute
inferior-most edge of the specimen.  Thus while the DCIS is focally
close to green ink, I interpret that this ink extends beyond what might
best be considered the inferior margin. Therefore, I consider that this
focus of DCIS is at least 5 mm from what would be considered the
inferior specimen margin.  The final inferior margin seems widely free,
as no DCIS was identified in the additional margin tissue (part B).

<CLINICAL INFO>
Left breast DCIS. Hydromarker fell out. The tissue was placed in
formalin at approximately 12:30 p.m. on **DATE[Dec 01 2011]. Total formalin
fixation time is 27 hours.

<GROSS>
A.  Received fresh, labeled ""**NAME[BBB, AAA]"" and designated ""left breast 5
o'clock, partial mastectomy"", is a 35-gram portion of fibroadipose
tissue oriented by short - superior and long - lateral sutures, and
containing two localizing wires. It is 5 cm from superior to inferior, 5
cm from medial to lateral, and 2 cm from anterior to posterior. There is
a 0.5 cm cavity at the lateral margin extruding gelatinous material and
a spiral-shaped metal clip. The specimen is inked as follows: superior -
orange, inferior - green, medial - red, lateral - yellow, anterior -
blue, posterior - black, cavity - violet. It is sectioned from superior
to inferior into 16 slices. The gel-filled cavity adjacent to the
lateral margin is present in slices 8-11. It measures 1 cm in greatest
dimension and is located 1.1 cm from the anterior, 0.6 cm from the
posterior, 3.3 cm from the medial, 2 cm from the inferior, and widely
clear of the superior margins. The remaining cut surface consists of 85%
yellow adipose tissue and 15% fibrous parenchyma with areas of focal
hemorrhage. No discrete mass are identified. Representative sections are
submitted as follows:
     Block key:
     A1, A2.   Slice 1;
     A3, A4.   Composite slice 3;
     A5-A7.    Composite slice 5;
     A8-A10.   Composite slice 7;
     A11, A12. Composite slice 8 with cavity;
     A13, A14.      Composite slice 9 with cavity;
     A15, A16.      Composite slice 10 with cavity;
     A17, A18. Composite slice 11 with cavity;
     A19, A20.      Composite slice 12;
     A21.      Slice 14;
     A22.      Slice 16;

Following initial slide review additional tissue was submitted as
follows.
     A23, A24. Composite slice 13.

B.  Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated ""new
inferior margin, left breast 5 o'clock"", is a 4-gram portion of yellow
adipose tissue oriented by short - superior and long - lateral sutures.
It is 1.8 cm from superior to inferior, 1.5 cm from medial to lateral,
and 4 cm from anterior to posterior. It is inked as follows: superior -
orange, inferior - green, medial - red, lateral - yellow, anterior -
blue, posterior - black. It is sectioned from anterior to posterior into
14 slices. These are entirely submitted as follows:
     Block key:
     B1.       Slice 1;
     B2.       Slices 2-4;
     B3.       Slices 5 and 6;
     B4.       Slices 7 and 8;
     B5.       Slices 9 and 10;
     B6.       Slices 11-13;
     B7.       Slice 14. (rkg/jmk)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

**NAME[ZZZ M. YYY] XXX], Ph.D.  Electronically signed **DATE[Dec 05 2011]

<ADDENDUM> #1
This addendum is issued to report the pathologic stage for the ductal
carcinoma in situ. The pathologic stage was inadvertently omitted from
the original report. The remainder of the report is correct and remains
unchanged.

ADDENDUM DIAGNOSIS:

A.  Left Breast, 5 o'clock, Wire-Localized Oriented Partial Mastectomy:
Pathological stage:      pTis(DCIS), pNX (per AJCC 7th edition.)

Addendum #1 performed by **NAME[ZZZ M. YYY] XXX], Ph.D.  Electronically
signed **DATE[Dec 10 2011]",,,,,
REG3,BREAST,0,PAT-00746650,1,REC-5000738139,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Breast, Mass at 12:00, Ultrasound-Guided Core Biopsy:
   Infiltrating carcinoma with the following features:
      Histologic type:   Ductal.
      Histologic grade:  2.
      Nottingham grade:  7 of 9.
         Tubule formation:    Low (3 of 3).
         Nuclear grade:  Intermediate (2 of 3).
         Mitotic rate:   Intermediate (2 of 3).
      Lymph-vascular space invasion:    Not identified.
   Ductal carcinoma in situ (DCIS):     Focally present.
      Histologic type:   Cribriform.
      Nuclear grade:     Intermediate, with focal necrosis, without
calcifications.
   Additional findings:  Immunohistochemical studies for estrogen and
progesterone receptor expression and HER-2/neu will be performed and
reported in an addendum.

<CLINICAL INFO>
Right breast, 5 BIRADS. 17 mm target size. Collection date: **DATE[Dec 09 2011]
at 10 a.m. Total fixation time: 8.5 hours.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA M]"" and designated ""right
breast ultrasound core biopsy mass 12 o'clock"", are two 0.2 cm in
diameter elongated pieces of blood-tinged fibrofatty tissue 1.4 and 2.4
cm in length, entirely submitted in A1. (kjh/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

INTRADEPARTMENTAL CONSULTATION:
Cellnetix pathologist **NAME[ZZZ YYY] M.D. agrees with the diagnosis of
invasive carcinoma.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Dec 10 2011]
**PHONE  (Physician to Physician Only)",,,,,
REG3,BREAST,0,PAT-00743368,1,REC-5000738217,,,,"<CLINICAL INFO> 
Right breast cancer 
<GROSS>: 
Five specimens are received without fixative, each labeled '**NAME[BBB, AAA]'. 
Part A is designated 'right breast partial mastectomy, long stitch medial, short stitch superior, 
wire is anterior'. It consists of an oriented fibrofatty tissue fragment weighing 66 grams and 
measuring 8.5 cm from superior to inferior, 6.5 cm from medial to lateral and 2.5 cm from 
anterior to posterior. The tail end of a localization guidewire extends centrally from the anterior 
aspect. 
WIth the provided orientation the specimen is inked as follows: 
Medial-Red 
Lateral-Yellow 
Superior-Orange 
Inferior-Green 
Anterior-Blue 
Deep-Black 

The specimen is serially sectioned from superior towards inferior into 12 slices with the hooked 
end of the guidewire terminating in slice 3. Sectioning reveals an indurated tan-white slightly ill-
defined mass occupying slices 6-8 and grossly measuring 1.2 x 1.2 x 1.5 cm. Grossly the 
mass is 0.1 cm from the anterior margin (slice 6), 1.5 cm from the lateral margin, 1.5 cm from 
the medial margin, 2 cm from the deep margin, 2 cm from the inferior margin and 2.5 cm from 
the superior margin. The remainder of the specimen shows soft yellow fatty cut surfaces with a 
minimal fibrous component, although there is some dense fibrous tissue laterally adjacent to the 
mass in slice 8 which abuts the inked margin. There are otherwise no definite areas of 
abnormality. 
Sections are submitted as follows:A1-Perpendicular sections of slice 1 with superior margin. 
A2-Representative fibrous tissue in slice 4. 
A3-Fibrous tissue superiorly adjacent to mass, slice 5. 
A4-Slice 6, superior extent of mass with nearest inked anterior margin. 
A5-Slice 6, tissue and deep margin posterior adjacent to mass. 
A6-Tissue and medial margin adjacent to mass. 

A9-A10-Slice 8, mass in this slice with anterior and lateral margins (one section bisected). 
A11-Slice 9, fibrous tissue inferiorly adjacent to mass. 
A12-Representative perpendicular sections of slice 12 with inferior margin. 

Part B is designated 'sentinel nodes 1-3'. It consists of a soft to rubbery yellow-red fatty tissue 
fragment measuring 6 x 3.8 x 1.3 cm. Palpation and dissection of this tissue reveals three soft 
to rubbery yellow-red probable lymph nodes ranging from 1-2.5 cm in maximum dimension. 

The nodes are submitted as follows: 
B1-One node bisected. 
B2-One node bisected. 
B3-B4-One node quadrisected. 

Part C is designated 'additional right anterior margin'. It consists of an unoriented rubbery 
yellow-red fatty tissue fragment weighing 4.2 grams and measuring 4 x 3.5 x 1 cm. One aspect 
is slightly coarse and is the assumed old margin and the opposite lobulated assumed new 
margin is inked blue. The tissue is serially sectioned revealing uniform soft yellow-red fatty cut 
surfaces with no gross masses or areas of abnormality. The tissue is entirely submitted in C1C3. 

Part D is designated 'right breast anterior lateral'. It consists of two unoriented yellow-red fatty 
tissue fragments together weighing 6.6 grams. The fragments measure 3.5 x 1.5 x 0.4 cm and 
5.3 x 2.5 x 1 cm. Each has a slightly coarse flat assumed old margin and the opposite lobulated 
assumed new margin is inked blue. Each fragment is serially sectioned revealing uniform soft 
yellow-red fibrofatty cut surfaces with no gross lesions or areas of induration. The specimen is 
entirely submitted in D1-D5. 
Part E is designated 'right anterior margin'. It consists of a tissue fragment weighing 3.3 grams 
and consists of an elliptical skin fragment measuring 5 x 2 x 1 cm with a 1 cm everted nipple 
centrally though at one edge. The skin is the new margin and the opposite old/deep margin is 
inked black. The tissue is serially sectioned revealing uniform rubbery tan-white cut surfaces. 
The tissue is entirely submitted in E1-E3. 
<FINAL DX> 
A. BREAST, RIGHT, PARTIAL MASTECTOMY WITH WIRE LOCALIZATION (weight 66 
grams, 85 x 65 x 25 mm): 
Invasive mammary carcinoma with the following features: 
1. HISTOLOGIC TYPE: Infiltrating ductal carcinoma. 
2. TUMOR SIZE: 15 x 12 x 12 mm. 
3. 
HISTOLOGIC GRADE: I of III. 
Nottingham Histologic Score: 5 of 9. 
Nuclear pleomorphism score: 2 of 3. 
Tubular differentiation score: 2 of 3. 
Mitotic score: 1 of 3 (3 per 10 hpf). 
4. IN SITU CARCINOMA: Ductal carcinoma in-situ present, solid and cribriform types, and 
possibly solid papillary type, with lobular extension, very focal necrosis, low to intermediate 
nuclear grade. DCIS is present adjacent to tumor and constitutes approximately 15-20% of the 
 Medial-Red: 15 mm.
 Lateral-Yellow: 15 mm.
 Superior-Orange: 25 mm.
 Inferior-Green: 20 mm.
 Anterior-Blue: 6 mm. (DCIS present 2 mm from margin. Please see parts C, D, and E, 
below.
 Deep-Black: 20 mm. 
6. CALCIFICATIONS: Present and are associated with infiltrating tumor. 
7. LYMPHOVASCULAR INVOLVEMENT: Not definitively identified. 
8. ADDITIONAL FINDINGS: Changes consistent with previous instrumentation. 
9. HORMONE RECEPTOR STUDIES AND HER-2/NEU STUDIES: Performed on this patient's 
prior biopsy (***PATH-NUMBER[1]; **DATE[Oct 13 11]) and show the following by written report: 
ER: Positive (99% cells positive, strong staining intensity). 
PR: Positive (92% cells positive, moderate staining intensity). 
HER-2/neu: Negative by FISH. 
th
10. AJCC (7 ed.) PATHOLOGIC TUMOR STAGE: pT1c pN0. 
B. SENTINEL NODES 1-3, EXCISION: 
Three lymph nodes negative for metastatic tumor by histomorphology and 
immunohistochemistry studies (0/3). Please see comment. 
C. ADDITIONAL RIGHT ANTERIOR MARGIN (weight 4.2 grams, 40 x 35 x 10 mm): 
Benign breast parenchyma. 
D. RIGHT BREAST, ANTERIOR LATERAL, EXCISION (weight 6.6 grams, fragments 
measure 35 x 15 x 4 mm and 53 x 25 x 10 mm): 
Ductal carcinoma in situ (DCIS) with the following features: 
1. ESTIMATED TUMOR SIZE: 2 mm and 4 mm in greatest dimension. 
2. NUCLEAR GRADE AND ARCHITECTURAL PATTERNS: Low to intermediate nuclear 
grade with a solid architectural pattern. 
3. NECROSIS: Absent. 
4. RESECTION MARGINS: New blue-inked resection margin measures 8 mm. 
5. MICROCALCIFICATIONS: Not identified. 
6. ADDITIONAL FINDINGS: Changes consistent with previous instrumentation are present. 
Please see comment. 
E. RIGHT ANTERIOR MARGIN, EXCISION (weight 3.3 grams, 50 x 20 x 10 mm): 
1. Skin and nipple with no histomorphologic abnormality. 
2. Benign breast parenchyma. 
This case has been subjected to review by a second pathologist per departmental quality assurance policy. 
<DIAGNOSIS COMMENTS>: 
Part D: E-cadherin: Positive. 
COMMENT: The positive expression of e-cadherin confirms the ductal nature of the neoplastic cells. 

an immunoperoxidase technique. Immunohistochemical staining is evaluated by visual examination of slides using a conventional light 
microscope. The positive and negative control slides for each immunohistochemical test are reviewed and found to exhibit the appropriate 

staining pattern. Results on the neoplastic cell population are as indicated in the table below. 
Tests performed on formalin fixed, paraffin-embedded block D2 
ANTIBODY (CLONE) RESULT 
E-cadherin (4A2C7): Positive 
*The performance characteristics of these immunohistochemical tests have been determined by **INSTITUTION. Some 
of these tests have been developed by **INSTITUTION. Eastside Pathology is certified under the Clinical Laboratory 
Improvement Amendments of 1988 as qualified to perform high complexity clinical laboratory testing. 
Some of the above tests may use analyte specific reagents; they have not been cleared or approved by the U.S. Food & Drug 
Administration (FDA). The FDA has determined that such clearance or approval is not necessary. These tests are used for 
clinical purposes. They should not be regarded as investigational or for research. 
IMMUNOHISTOCHEMICAL RESULTS: 
Deparaffinized tissue sections undergo optimized epitope retrieval prior to incubation with the appropriate antibody. Visualization is provided by 
an immunoperoxidase technique. Immunohistochemical staining is evaluated by visual examination of slides using a conventional light 
microscope. The positive and negative control slides for each immunohistochemical test are reviewed and found to exhibit the appropriate 
staining pattern. Results on the lymph node population are as indicated in the table below. 
Tests performed on formalin fixed, paraffin-embedded blocks B1-B4 
ANTIBODY(CLONE): RESULT 
Cytokeratin AE1/AE3: Negative 
The performance characteristics of these immunohistochemical tests have been determined by **INSTITUTION. Some of these tests 
have been developed by Eastside Pathology, Inc.Eastside Pathology is certified under the Clinical Laboratory Improvement Amendments of 
1988 as qualified to perform high complexity clinical laboratory testing. 
Some of the above tests may use analyte specific reagents; they have not been cleared or approved by the U.S. Food & Drug Administration 
(FDA). The FDA has determined that such clearance or approval is not necessary.These tests are used for clinical purposes.They should not 
be regarded as investigational or for research.",,,,,
REG3,BREAST,0,PAT-00745899,1,REC-5000739409,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Left Breast, 12 o'clock Ultrasound-Guided Needle Core Biopsy:
   Infiltrating carcinoma with the following features:
      Histologic type:   Ductal.
      Histologic grade:  1 of 3.
      Nottingham grade:  5 of 9.
         Tubule formation:    2 (of 3).
         Nuclear grade:  2 (of 3).
         Mitotic rate:   1 (of 3).
      Lymph-vascular space invasion:    Not identified.
   Ductal carcinoma in situ (DCIS):     Positive, minimal.
      Histologic type:   Cribriform.
      Nuclear grade:     Intermediate, negative for necrosis, and
positive for                    associated calcifications.
   Additional findings:  Multiple needle cores are positive for
carcinoma with a maximum microscopic linear extent 3 mm.
          Immunohistochemical study for HER2/neu will be performed and
reported in an addendum.

<CLINICAL INFO>
Ultrasound core biopsy, 5 mm mass, BIRADS 4B. The tissue was placed into
formalin at 9:30 a.m. on **DATE[Oct 10 2011]. Total formalin-fixation time is
11.5 hours.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated ""left
breast 12 o'clock"", are seven 0.1 cm diameter elongated portions of
tissue from 0.1 to 1.3 cm in length. They are inked blue and entirely
submitted in one cassette. (rkg/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block A1

Antibody  Result    Comment
ERsq 100 % Positive
PRsq 100 % Positive

 Infiltrating carcinoma cells are 3+ positive for both estrogen and
progesterone receptor assay.
Interpreted by:  **NAME[ZZZ M. YYY] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Oct 12 2011]",,,,,
REG3,BREAST,0,PAT-00745162,1,REC-5000739882,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Breast, Left Breast Calcs Upper-Outer Quadrant Core Biopsy:
Ductal carcinoma in situ with the following features:
Histologic type:         Solid and comedo.
Nuclear grade:           Intermediate.
Necrosis:                Present.
Associated calcification:     Present.
Invasive carcinoma: No invasive carcinoma.
Additional findings:     Ductal hyperplasia of the usual type.
          Columnar cell changes and columnar cell hyperplasia.
          Apocrine metaplasia.
          Immunohistochemical studies for estrogen and progesterone
receptor expression will be performed and reported in an addendum
report.

<CLINICAL INFO>
Left breast calcifications, posterior upper-outer. Collection date/time:
**DATE[Aug 10 2012] at 2:10 p.m. Total fixation time: 8 hours 50 minutes.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""left
breast calcs upper-outer quadrant"", is a cassette with two portions of
fibrofatty tissue, 2.5 x 1 x 0.6 cm in aggregate dimension; submitted in
A1. Also received in the same container wrapped in filter paper are
multiple portions of fibrofatty tissue, 4 x 2.1 x 0.5 cm in aggregate;
submitted in A2.  (pcs/cm)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

INTRADEPARTMENTAL CONSULTATION:
**NAME[ZZZ M. YYY], M.D.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Aug 11 2012]",,,,,
REG3,BREAST,0,PAT-00745889,1,REC-5000740389,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Left Breast Mass at 2:30, Ultrasound-Guided Core Biopsy:
Infiltrating carcinoma with the following features:
Histologic type:    Infiltrating ductal carcinoma, no special type.
Nottingham combined histologic grade:   2 of 3.
Modified Bloom-Richardson score:   6 of 9.
Tubule formation:   3 (of 3).
Nuclear grade: 2 (of 3).
Mitotic rate:  1 (of 3).
Lymph-vascular space invasion:     Not identified.
Ductal carcinoma in situ (DCIS):   Not identified.
Additional findings:     Immunohistochemical studies for estrogen and
progesterone receptor expression and HER-2/neu will be performed and
reported in an addendum.

<CLINICAL INFO>
Ultrasound-guided core needle biopsy 3.4 cm mass. Collected on
**DATE[Jun 16 2012] at 2:17 PM. Total formalin fixation time 6 hours 43 minutes.
ICD9 code: 793.00

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""left breast
2:30"" per container and further designated ""subareolar position"" per
requisition, are six 0.1 cm in diameter, elongated portions of tissue
from 0.4 to 1.3 cm in lengths. They are inked blue and entirely
submitted in A1.  (rg/jkb)

<MICROSCOPIC>
Four HE stained slides examined including multiple levels. Please see
diagnosis.

PHYSICIAN NOTIFICATION:
This diagnosis is discussed with Dr. **NAME[M. ZZZ] at 9:45 a.m. **DATE[Jun 17 2012].

INTRADEPARTMENTAL CONSULTATION:
**NAME[YYY M. XXX], WWW], Ph.D. and **NAME[VVV M. UUU], M.D.

**NAME[TTT M. SSS], M.D.  Electronically signed **DATE[Jun 17 2012]",,,,,
REG3,BREAST,0,PAT-00744011,1,REC-5000743119,,,,"**** THIS IS AN AMENDED REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Amendment ****

Reason for Addendum #1:  Immunohistochemistry results
Reason for Addendum #2:  Immunohistochemistry results
Reason for Addendum #3:  Molecular results
Reason for Amendment #1: Typographical Error

AMENDMENT COMMENT:  This amendment corrects the pathologic stage.  The
original report incorrectly staged the tumor as pT1c pN1c.  The staging
has been corrected to pT1c pN1a.  The remainder of the diagnosis is
unchanged.

<FINAL DX>     

A. Sentinel Lymph Node:
     Metastatic carcinoma involving one of one lymph node (1/1).

B. Left Breast, Lumpectomy (4.7 x 2.5 x 1.8 cm):
     Infiltrating carcinoma with the following features:
          Histologic type:    Ductal.
          Size:     1.5 cm
          Histologic grade:   3 of 3.
          Nottingham grade:   9 of 9.
          Tubule formation:   Low (3 of 3).
          Nuclear grade: High (3 of 3).
          Mitotic rate:  High (3 of 3).
          Lymph-vascular invasion: Present.
     Ductal carcinoma in situ (DCIS) with the following features:
          Histologic type:    Solid and cribriform.
          Nuclear grade: High.
          Necrosis: Present.
          Calcifications:     Present.
          Estimated size/extent of DCIS: 1.5 cm, closely associated with
infiltrating component but with extension beyond infiltrating component.
     Surgical margins:
          Infiltrating carcinoma:
          Anterior (superficial):  Close, <1 mm.
          Posterior (deep):   Negative, 4 mm.
          Superior: Close, <1 mm.
          Inferior: Close, <1 mm.
          Medial:   Negative, >10 mm.
          Lateral:  Negative, >10 mm.
     Ductal carcinoma in situ:
          Anterior (superficial):  Positive.
          Posterior (deep):   Close, <1 mm.
          Superior: Positive.
          Inferior: Close, 1.2 mm.
          Medial:   Negative, >10 mm.
          Lateral:  Negative, >10 mm.
          Lymph nodes (including Specimen A):
          3 of 15 lymph nodes positive for metastatic carcinoma (3/15);
largest metastatic deposit 1.0 cm, extranodal extension is not
identified.
     Pathologic stage:   pT1c, pN1a (AJCC 7th edition).
Hormone Receptors:             Immunohistochemistry studies for estrogen
and progesterone receptor expression and Her-2/neu overexpression will
be performed and reported in an addendum.
Additional Findings:     Fibrocystic change.

<CLINICAL INFO>
Left breast mass. Placed in formalin on **DATE[Jan 22 2012] at approximately 1:10
PM. Formalin fixation time 8 hours 50 minutes. ICD9 code: 17.9 -
neoplasm female breast.

INTRAPROCEDURAL EVALUATION:
A.  Left sentinel lymph node (frozen): ""Positive for metastatic
carcinoma"".
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A.  Received fresh, labeled ""**NAME[BBB, AAA]"", and designated ""A. Sentinel
node"", is a 1.5 x 1 x 0.8 cm, white, firm node. A portion of the node
was submitted for frozen section and submitted in A1. The remaining
tissue is submitted in A2.

B.  Received fresh, labeled ""**NAME[BBB, AAA]"", and designated ""left breast
excisional biopsy"", is an oriented breast specimen received previously
inked. There is a 4 x 1.4 cm of unremarkable skin. The specimen has
dimensions as follows: 4.7 cm from medial to lateral, 2.5 cm from
superior to inferior and 1.8 cm from anterior to posterior. The specimen
is inked as follows: deep - black, superficial - blue, medial - red,
lateral - yellow, superior - orange, inferior - green. The specimen is
sectioned from medial to lateral into thirteen slices. Within slices
6-9, there is a spiculated white, firm mass, 1.5 x 1.2 x 0.8 cm and is
0.2 cm from the superior margin, 1 cm from the inferior margin, 1 cm
from the anterior margin, 0.3 cm of the deep margin, and is greater than
1 cm from the medial lateral margins.  The uninvolved parenchyma is 10%
fibrous tissue and dispersed between 90% fatty tissue. The specimen is
submitted in its entirety as follows:
Block Key:
B1.       Slice 1.
B2.       Slice 2.
B3.       Slice 3.
B4.       Slice 4.
B5, B6.   Composite slice 5.
B7, B8.   Composite slice 6.
B9, B10.  Composite slice 7.
B11, B12. Composite slice 8.
B13.      Slice 9.
B14.      Slice 10.
B15.      Slice 11.
B16.      Slice 12.
B17.      Slice 13.

C.  Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""C. Left
axillary node dissection"", is an unoriented 10 x 9.2 x 1.5 cm aggregate
of fibrofatty tissue with fifteen probable nodes, 0.7 cm to 2 cm in
greatest dimension. One of the nodes (1 cm in greatest dimension) is
white and firm.  Lymph nodes are submitted in their entirety as follows:

Block Key:
C1.       Eight lymph nodes.
C2.       Five lymph nodes.
C3.       One possible lymph node candidate, white, bisected.
C4.       One lymph node candidate, trisected.  (es/jkb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

INTRADEPARTMENTAL CONSULTATION:
**NAME[XXX M. WWW], M.D.

<ADDENDUM> #1

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block B9

Antibody  Result    Comment
ERsq 100 % of tumor cells positive,            strong nuclear staining.

PRsq 20 % of tumor cells positive,             moderate nuclear staining

Interpreted by:  **NAME[ZZZ M YYY] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

ADDENDUM #2:

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for detection of the HER2 oncogene product
(using **INSTITUTION. Pathway Anti-HER2 rabbit monoclonal
antibody, clone 4B5) are carried out on formalin-fixed,
paraffin-embedded tissue sections.  Positive and negative controls show
appropriate reactivity. Interpretation of Ventana Pathway for HER2
immunostain is performed according to guidelines recommended by ASCO/CAP
in 2007 (see comment below).  Results are as follows:
Block B9

Antibody  Result    Comment
HER2 2 +  Equivocal for overexpression

Impression:In-situ hybridization for HER-2 neu will be performed and the
results will be reported in an addendum.
Interpreted by:  **NAME[ZZZ M YYY] M.D.
Comment:

1.  The guideline recommendations by ASCO/CAP in 2007 is as follows:  A
score of 3+ (positive HER2 test) is defined by uniform intense membrane
staining in >30% of tumor cells.  A score of 2+ (equivocal HER2 test) is
defined by complete membrane staining that is either nonuniform or weak
in intensity but with obvious circumferential distribution in at least
10% of tumor cells, or less commonly, intense completemembrane staining
but in only 30% or fewer tumor cells.  A score of 0 or 1+ (negative HER2
test) is defined by no or weak and incomplete membrane staining in any
proportion of tumor cells.
2.  The correlation between HER2 protein overexpression by
immunohistochemistry and HER2/neu gene amplification by fluorescence in
situ hybridization (FISH) is not 100%.  Rare cases interpreted as
negative (0 and 1+) for HER2 protein overexpression may demonstrate low
level HER2/neu gene amplification by FISH.  Approximately 10-20% of
cases interpreted as 2+ may show gene amplification by FISH, while the
vast majority of cases, if not all, interpreted as 3+ show gene
amplification by FISH.  Therefore, additional testing for HER2/neu gene
amplification by fluorescence in situ hybridization (FISH) may be
considered on individual cases, if clinically warranted.  Reflexive
testing for HER2/neu gene amplification by FISH will be performed on all
cases interpreted as 2+ (equivocal for protein overexpression) by
immunohistochemistry.   Performed at CellNetix Pathology  **PLACE, WA.  **ZIP-CODE.

FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) STUDIES:
Fluorescence in situ hybridization (FISH) for HER-2/neu gene
amplification (using PathVysion probes and the MetaSystems Metafer
automated scanning fluorescent microscope) is performed at CellNetix,
**PLACE, WA. **ZIP-CODE. Results are as follows:
Block B9

Name **NAME[CCC]     Result
HER2 FISH 4.9
CEP-17    4.7
Tiles Used     202
HER2 FISH Estimated Ratio     1    Negative for Amplification

Interpretation:

Comment:There are numerous copies of the HER2 gene and CEP-17 in this
case that are a result of aneusomy of chromosome 17 (the ratio of HER2
to CEP-17 is <1.8 and the number of CEP-17 signals per nucleus is >2.5).
Using CAP-ASCO guidelines (1) for assessing HER2 without an internal
reference gene, this case would be considered ""equivocal"" for HER2 gene
amplification ( 4-6 HER2 copies per non-overlapping nucleus). Aneusomy
of chromosome 17 is not uncommon, can occur in up to 29.6% of patients
(2) and can result in overexpression of HER2 protein. Response to
trastuzumab in this cohort of patients has not been well studied (3).

1.        Wolff et al., J Clin Oncol **ID-NUM, 2007
2.        Yaziji H et al. HER-2 testing in breast cancer using parallel
tissue-based methods.JAMA. **ID-NUM, 2004
3.        Downs-Kelly E et al. Am J Surg Pathol. **ID-NUM, 2005

According to the CAP/ASCO guidelines, amplification is defined as a
signal ratio greater than 2.2 (JCO 25:1-28, 2007).  The results of this
test are meant to be used as an adjunct to other prognostic indicators.
Interpreted by: **NAME[VVV UUU], Ph.D.

FISH Image(s)

A-1: 4
A-1: 5
A-1: 6

**NAME[ZZZ M YYY], M.D.  Electronically signed **DATE[Jan 25 2012]
Addendum #1 performed by **NAME[ZZZ M YYY], M.D.  Electronically signed
**DATE[Jan 26 2012]
Addendum #3 performed by **NAME[TTT SSS], M.D.  Electronically signed
**DATE[Feb 02 2012]
Amendment #1 performed by **NAME[ZZZ M YYY], M.D.  Electronically signed
**DATE[Feb 23 2012]",,,,,
REG3,BREAST,0,PAT-00744815,1,REC-5000747380,,,,"<CLINICAL HX>
Previous demonstration of ductal carcinoma-in-situ, intermediate grade, on Encor biopsy (see case ***PATH-NUMBER[1]).  Short suture - 12:00  Long suture - 9:00  

<HISTOLOGY COMMENT>



<GROSS>
In formalin labeled ""left breast mass"" is a 5.0 x 6.2 x 3.2 cm oriented yellow-white fibrofatty piece of tissue. There are two sutures present designated as follows: Short suture - 12 o'clock; long suture - 9 o'clock. There is also a metal guide wire coursing through the anterior aspect to the medial-posterior aspect. The margins are inked as follows: 12 o'clock (superior) - orange; 3 o'clock (lateral) - green; 6 o'clock (inferior) - magenta; 9 o'clock (medial) - blue; anterior - yellow; posterior - black. The specimen is serially sectioned revealing an ill-defined dark red-brown area that covers the majority of the specimen. There is also a 6 x 7 x 7 mm possible traumatic biopsy cavity filled with hard white structures consistent with calculi, ranging from 2-5 mm in greatest dimension. The specimen is serially sectioned and submitted sequentially as follows: A1  A2 - horizontal sections of lateral margin; A3  A4 - bisected cross-section (A3 anterior, A4 posterior); A5-A7 - trisected cross-section (A5 anterior, A6 mid, A7 posterior); A8  A9 - bisected cross-section (A8 anterior with possible traumatic biopsy cavity and calculi; A9 - posterior); A10  A11 - bisected cross-section (A10 anterior with possible calculi; A11 posterior); A12  A13 - bisected cross-section (A12 anterior, A13 posterior); A14  A15 - representative horizontal sections of medial margin. as


<COMMENT>
The pattern of the ductal carcinoma-in-situ is mixed, in areas showing a classic solid pattern, admixed with a pattern which is best termed columnar cell or flat epithelial atypia type. Immunohistochemical stain for cytokeratin 5/6 performed on a representative tissue block supports the diagnosis of ductal carcinoma-in-situ in this specimen (see immunohistochemistry).

<MICROSCOPIC>


<FINAL DX>
 BREAST, LEFT, ""MASS"", WIRE NEEDLE-LOCALIZED ORIENTED EXCISIONAL BIOPSY:  DUCTAL CARCINOMA-IN-SITU, MIXED ARCHITECTURAL PATTERN, INTERMEDIATE NUCLEAR GRADE.  THE DUCTAL CARCINOMA-IN-SITU INVOLVES 8 OF 15 SUBMITTED TISSUE BLOCKS, AND HAS A  MAXIMUM LINEAR MICROSCOPIC DIMENSION OF 1.1 CM (MEASURED IN SLIDE A1).  THE DUCTAL CARCINOMA-IN-SITU EXTENDS TO THE LATERAL AND 12 O'CLOCK SURGICAL MARGINS.  NO EVIDENCE OF INVASIVE MALIGNANCY IS PRESENT.  SEE IMMUNOHISTOCHEMISTRY AND COMMENT. 

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>


<NOTIFICATION>
This diagnosis was discussed with Dr. **NAME[ZZZ] on **DATE[Aug 24 12].

<PRELIM DX>


<CHECKLIST>
CANCER CHECKLIST: DCIS OF BREAST  AJCC 7TH ED.  SPECIMEN:  Partial breast. PROCEDURE:  Wire needle-localized oriented excisional biopsy. SPECIMEN INTEGRITY:  Intact. SPECIMEN SIZE:  5.0 x 6.2 x 3.2 cm. SPECIMEN LATERALITY:  Left. TUMOR SITE:  Not designated. SIZE (EXTENT) OF DCIS:  DCIS is present in 8 of 15 submitted blocks.  Maximum linear measured dimension of DCIS is 1.1 cm.  This extent of DCIS is indicative of ""extensive DCIS"". HISTOLOGIC TYPE:  Ductal carcinoma-in-situ. ARCHITECTURAL PATTERN:  Mixed. NUCLEAR GRADE: Intermediate. MICROCALCIFICATIONS:  Present. NECROSIS:  None identified. MARGINS:  The lateral and 12 o'clock surgical margins are positive for DCIS. TREATMENT EFFECT:  None identified. LYMPH NODES:  None sampled. PATHOLOGIC STAGE (pTNM):  Primary Tumor:  pTis.  Regional Lymph Nodes:  pNX.  Distant Metastasis:  pMX.  ADDITIONAL PATHOLOGIC FINDINGS:  Changes of previous core biopsy site are identified.  SUMMARY OF PREDICTIVE AND PROGNOSTIC ASSAYS (performed on diagnostic core biopsy case ***PATH-NUMBER[1]):  Estrogen Receptor:  Positive.  Progesterone Receptor:  Positive.

<IMMUNOHISTOCHEMISTRY>
Immunohistochemical stain for cytokeratin 5/6 was performed on the paraffin-embedded tissue in block A1, and the results of this analysis are shown in the table below.  INTERPRETATION: The negative cytokeratin 5/6 staining within the atypical ductal epithelial proliferation confirms the diagnosis of ductal carcinoma-in-situ over the other major differential diagnostic possibility of a benign usual epithelial hyperplasia.

<INDICATIORS>


<SPECIAL STAINS>",,,,,
REG3,BREAST,0,PAT-00744446,1,REC-5000747834,,,,"<CLINICAL INFO>
 Diagnosis:  DCIS left breast.  Protocol:  left
  breast lumpectomy with wire localization and sentinel node biopsy.<CLINICAL INFO>
 Diagnosis:  DCIS left breast.  Protocol:  left
  breast lumpectomy with wire localization and sentinel node biopsy.<ADDENDUM FINAL DX>
 A)  Left breast, lumpectomy: Foci of
  invasive ductal carcinoma, negative for gene amplification of Her-2/neu by
  fluorescence in situ hybridization technique.


  ***PATH-NUMBER[1]: HER2 FISH<ADDENDUM FINAL DX>
 A)  Left breast, lumpectomy: Foci of
  invasive ductal carcinoma, negative for gene amplification of Her-2/neu by
  fluorescence in situ hybridization technique.


  ***PATH-NUMBER[1]: HER2 FISH<FINAL DX>
 A) Left breast, lumpectomy:  2.2 cm of ductal
  carcinoma in situ with multiple foci of invasion, largest measuring 0.3 cm in
  greatest dimension; see cancer summary below.
  B) Left sentinel lymph node #1, excision:  1 lymph node with no metastatic
  carcinoma identified on H&E sections (0/1).<FINAL DX>
 A) Left breast, lumpectomy:  2.2 cm of ductal
  carcinoma in situ with multiple foci of invasion, largest measuring 0.3 cm in
  greatest dimension; see cancer summary below.
  B) Left sentinel lymph node #1, excision:  1 lymph node with no metastatic
  carcinoma identified on H&E sections (0/1).NOTE:  Per the ASCO/CAP Guideline Recommendations for Her-2/neu
  testing in breast cancer (Arch Pathol Lab Med 131: 18-43, 2007), ratios of
  less than 1.8 are interpreted as negative, ratios of more than 2.2 are
  interpreted as positive, and ratios between 1.8 and 2.2 are interpreted as
  equivocal for gene amplification.  Alternatively, cancers having > 6 signals
  of Her-2 per nucleus are considered positive, < 4 signals per cell are
  negative and 4-6 signals/cell are equivocal.NOTE:  Per the ASCO/CAP Guideline Recommendations for Her-2/neu
  testing in breast cancer (Arch Pathol Lab Med 131: 18-43, 2007), ratios of
  less than 1.8 are interpreted as negative, ratios of more than 2.2 are
  interpreted as positive, and ratios between 1.8 and 2.2 are interpreted as
  equivocal for gene amplification.  Alternatively, cancers having > 6 signals
  of Her-2 per nucleus are considered positive, < 4 signals per cell are
  negative and 4-6 signals/cell are equivocal.<GROSS>
 A) Received fresh and labeled ""left breast
  lumpectomy, short = superior, long = lateral"" and ""**NAME[AAA BBB]"" is an
  11 g, 4.5 ML x 3.1 SI x 1.3 AP wire localized lumpectomy specimen with two
  localization wires.  The specimen has previously been inked per protocol by
  the surgeon as follows:  red superior, blue inferior, orange lateral, yellow
  medial, green anterior and  black posterior.  The specimen is sliced medial to
  lateral into nine slices, 0.4 cm in thickness with slices one and nine 1 cm in
  thickness.  The specimen is placed in formalin at 5:45 p.m. on **DATE[Mar 27 12].  In
  slice seven there is a biopsy clip and a 0.8 x 0.7 x 0.5 cm well-circumscribed
  white, firm, gritty mass.  This mass appears to abut the red superior margin
  and is 0.2 cm to the black posterior margin, 0.6 cm to the green anterior
  margin, 1 cm to the blue inferior margin, 1 cm to the orange lateral margin
  and >1  cm to the yellow medial margin.  Focal hemorrhage is apparent in slice
  six consistent with biopsy site.  There is a band of fibrosis extending
  superior to inferior completely across slices three, four,  five, six, seven
  and eight and partially across slice two.  The remaining tissue is yellow,
  fatty adipose tissue.  No other masses or lesions are identified.  The
  specimen is entirely submitted as follows:  A1 - perpendicular sections of
  slice one; A2 -  slice two; A3 - slice three; A4 and 5 - composite of slice
  four; A6 and 7 - composite of slice five; A8 and 9 - composite of slice six;
  A10 - slice seven; A11 - slice eight; A12 - perpendicular sections of slice
  nine.   (**INITIALS)
  B) Received in formalin labeled ""**NAME[BBB]"", and designated ""left sentinel lymph
  node #1"" is a 1.5 x 1.0 x 0.5 cm tan lymph node with attached fat.  The lymph
  node is bisected and entirely submitted in cassette B1.  (CR/pwt)<GROSS>
 A) Received fresh and labeled ""left breast
  lumpectomy, short = superior, long = lateral"" and ""**NAME[AAA BBB]"" is an
  11 g, 4.5 ML x 3.1 SI x 1.3 AP wire localized lumpectomy specimen with two
  localization wires.  The specimen has previously been inked per protocol by
  the surgeon as follows:  red superior, blue inferior, orange lateral, yellow
  medial, green anterior and  black posterior.  The specimen is sliced medial to
  lateral into nine slices, 0.4 cm in thickness with slices one and nine 1 cm in
  thickness.  The specimen is placed in formalin at 5:45 p.m. on **DATE[Mar 27 12].  In
  slice seven there is a biopsy clip and a 0.8 x 0.7 x 0.5 cm well-circumscribed
  white, firm, gritty mass.  This mass appears to abut the red superior margin
  and is 0.2 cm to the black posterior margin, 0.6 cm to the green anterior
  margin, 1 cm to the blue inferior margin, 1 cm to the orange lateral margin
  and >1  cm to the yellow medial margin.  Focal hemorrhage is apparent in slice
  six consistent with biopsy site.  There is a band of fibrosis extending
  superior to inferior completely across slices three, four,  five, six, seven
  and eight and partially across slice two.  The remaining tissue is yellow,
  fatty adipose tissue.  No other masses or lesions are identified.  The
  specimen is entirely submitted as follows:  A1 - perpendicular sections of
  slice one; A2 -  slice two; A3 - slice three; A4 and 5 - composite of slice
  four; A6 and 7 - composite of slice five; A8 and 9 - composite of slice six;
  A10 - slice seven; A11 - slice eight; A12 - perpendicular sections of slice
  nine.   (**INITIALS)
  B) Received in formalin labeled ""**NAME[BBB]"", and designated ""left sentinel lymph
  node #1"" is a 1.5 x 1.0 x 0.5 cm tan lymph node with attached fat.  The lymph
  node is bisected and entirely submitted in cassette B1.  (CR/pwt)NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.
  IHC <DIAGNOSIS COMMENT(S)>
  SMHC and AE1/AE3 stains were performed on multiple blocks to assess for small
  foci of invasion in the above 4 separate blocks that had areas suspicious for
  invasion on H&E.NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.
  IHC <DIAGNOSIS COMMENT(S)>
  SMHC and AE1/AE3 stains were performed on multiple blocks to assess for small
  foci of invasion in the above 4 separate blocks that had areas suspicious for
  invasion on H&E.<MICROSCOPIC>
 A recut slide confirms residual invasive
  carcinoma in the block.<MICROSCOPIC>
 A recut slide confirms residual invasive
  carcinoma in the block.DNA ANALYSIS: (Interpreted by: **NAME[ZZZ YYY] XXX], PhD and **PLACE
  **NAME[WWW] MD)
  Unstained sections are prepared and regions of invasive carcinoma are marked
  by comparison with H&E-stained sections from the same block.  Fluorescence in
  situ hybridization for the Her-2/neu gene is then carried out using the FDA-
  approved Vysis Path Vysion HER-2 DNA probe kit.  The prepared slides are then
  viewed under a fluorescent microscope with appropriate filters for the
  chromosome 17 probe (green), the Her-2/neu probe (orange) and DNA (blue) to
  localize nuclei.  Signals are counted from up to 60 cells and the ratio of
  Her-2/neu to chromosome 17 signals is computed.  Control slides from non-
  amplified and low-level amplified tumor cells are prepared simultaneously to
  ensure reproducibility between assays.  Results are listed in the table below:
  Block (Original Label): A11
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  FISH H2N/17 ICC FISH Chromosome 17 PROBE 2.1 signals/cell
  FISH H2N/17 ICC FISH Her2Neu PROBE 2.8 signals/cell
            Ratio: 1.3  Interpretation: Not AmplifiedDNA ANALYSIS: (Interpreted by: **NAME[ZZZ YYY] XXX], PhD and **PLACE
  **NAME[WWW] MD)
  Unstained sections are prepared and regions of invasive carcinoma are marked
  by comparison with H&E-stained sections from the same block.  Fluorescence in
  situ hybridization for the Her-2/neu gene is then carried out using the FDA-
  approved Vysis Path Vysion HER-2 DNA probe kit.  The prepared slides are then
  viewed under a fluorescent microscope with appropriate filters for the
  chromosome 17 probe (green), the Her-2/neu probe (orange) and DNA (blue) to
  localize nuclei.  Signals are counted from up to 60 cells and the ratio of
  Her-2/neu to chromosome 17 signals is computed.  Control slides from non-
  amplified and low-level amplified tumor cells are prepared simultaneously to
  ensure reproducibility between assays.  Results are listed in the table below:
  Block (Original Label): A11
  Population: Invasive carcinoma

  Label Marker For  Results Special Pattern or Comments
  FISH H2N/17 ICC FISH Chromosome 17 PROBE 2.1 signals/cell
  FISH H2N/17 ICC FISH Her2Neu PROBE 2.8 signals/cell
            Ratio: 1.3  Interpretation: Not Amplified<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[ZZZ YYY] XXX], PhD and **NAME[CCC WWW] MD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): A10
  Population: Areas suspicous for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  consistent with invasion
  AE1/AE3 Pan-Cytokeratin Cocktail [AE1/AE3]  Positive, 3+ (> 75% of cells)
  Block (Original Label): A11
  Population: Areas suspicious for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  ER Estrogen Receptor [SP1] 95 % positive cells Intensity: Strong
  PR88 Progesterone Receptor [PR88] 1 % positive cells Intesity: Weak
  C-erbB-2 m C-erbB-2,  (w/ HIER)  Intermediate over-expression
  Ki-67 Ki-67 [MIB-1] 20 % positive cells
  Block (Original Label): A8
  Population: Areas suspicious for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  AE1/AE3 Pan-Cytokeratin Cocktail [AE1/AE3]  Positive, 3+ (> 75% of cells)
  Block (Original Label): A9
  Population: Areas suspicious for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  AE1/AE3 Pan-Cytokeratin Cocktail [AE1/AE3]  Positive, 3+ (> 75% of cells)<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[ZZZ YYY] XXX], PhD and **NAME[CCC WWW] MD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): A10
  Population: Areas suspicous for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  consistent with invasion
  AE1/AE3 Pan-Cytokeratin Cocktail [AE1/AE3]  Positive, 3+ (> 75% of cells)
  Block (Original Label): A11
  Population: Areas suspicious for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  ER Estrogen Receptor [SP1] 95 % positive cells Intensity: Strong
  PR88 Progesterone Receptor [PR88] 1 % positive cells Intesity: Weak
  C-erbB-2 m C-erbB-2,  (w/ HIER)  Intermediate over-expression
  Ki-67 Ki-67 [MIB-1] 20 % positive cells
  Block (Original Label): A8
  Population: Areas suspicious for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  AE1/AE3 Pan-Cytokeratin Cocktail [AE1/AE3]  Positive, 3+ (> 75% of cells)
  Block (Original Label): A9
  Population: Areas suspicious for invasion

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  Absent around tumor nests
  AE1/AE3 Pan-Cytokeratin Cocktail [AE1/AE3]  Positive, 3+ (> 75% of cells)SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: L Breast lumpectomy
  B: L Sentinel lymph node
  Invasive carcinoma with the following features:
  Histologic type: Invasive ductal carcinoma, NOS (85003)
  Size (largest focus): 0.3cm
      Comment about size determination:
  There are multiple foci of invasion with the largest focus of contiguous
  invasive carcinoma measuring 0.3 cm
  Focality of invasive carcinoma: Extensive carcinoma in situ with multiple foci
  of invasion
  Nottingham Grade: Grade II: 6-7 points
      - Tubule Formation: 3 points (< 10%)
      - Nuclear Pleomorphism: 3 points (severe)
      - Mitotic Activity: 1 point
  Ancillary Studies
  Source: This case (included in this report)
  Estrogen receptor: Positive (**NAME[VVV] score = 8 of 8)
  Progesterone receptor: Weakly positive (**NAME[VVV] score = 3 of 8)
  c-erb-B2 (Her-2/neu) by IHC:
  Intermediate for Her-2/neu overexpression by IHC; FISH studies will be ordered
  and reported in an addendum
  Ki-67 proliferative index: 20%
  Her-2/neu by FISH: See Comment
  Ancillary studies comment: Will be performed and reported in an addendum
  Angiolymphatic Space Invasion: Not identified
  Skin status: Cannot assess (skin not present)
  Nipple status: Cannot assess (nipple not present)
  Skeletal muscle status: Skeletal muscle not present
  Ductal carcinoma in-situ (DCIS): Present (85002)
  Nuclear grade of DCIS: High
  Necrosis associated with DCIS:
  Present and central (expansive ""comedo"" necrosis)
  Distance spanned by DCIS: 2.2cm
  DCIS qualifies as ""extensive intraductal component""?: Yes
  Lobular carcinoma in-situ (LCIS): Absent
  Changes consistent with previous biopsy site: Present
  Microcalcifications: Not identified
  Final surgical resection margins (including separately submitted margins):
  Invasive carcinoma margins:
  Invasive carcinoma is 0.3 cm from superior margin, 0.4 cm from lateral margin,
  0.5 cm from posterior margin, 0.8 cm from inferior margin and >1 cm from
  medial and anterior margins.
  DCIS Margins:
  DCIS is <0.1 cm from superior and posterior margins,  0.2 cm from inferior
  margin, 0.3 cm from anterior and lateral  margins, and > 1 cm from medial
  margin.
  Lymph node involvement
  Sentinel nodes: Sentinel nodes with carcinoma 0    / Total sentinel nodes 1
  Non-sentinel nodes: Non-sentinel nodes with carcinoma: 0    / Total non-
  sentinel nodes: 0
        - Total number of nodes with macrometastases: 0
        - Total number of nodes with micrometastases: 0
        - Total number of nodes with isolated tumor cells: 0
  Minimum pathologic stage (AJCC, 7th ed., 2010)
  Primary tumor [pT]: PT1a: Tumor > 0.1 cm and <= 0.5 cm - greatest dimension
  Regional nodes [pN]: pN0: No regional lymph node metastasis histologically
  (ITCs may be present)
  N stage modifier: (sn): Only sentinel node(s) evaluated.
  Distant metastasis [pM]: Not applicable or no pathologic information
  Procedures used to establish the diagnosis:
  RoutineSUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: L Breast lumpectomy
  B: L Sentinel lymph node
  Invasive carcinoma with the following features:
  Histologic type: Invasive ductal carcinoma, NOS (85003)
  Size (largest focus): 0.3cm
      Comment about size determination:
  There are multiple foci of invasion with the largest focus of contiguous
  invasive carcinoma measuring 0.3 cm
  Focality of invasive carcinoma: Extensive carcinoma in situ with multiple foci
  of invasion
  Nottingham Grade: Grade II: 6-7 points
      - Tubule Formation: 3 points (< 10%)
      - Nuclear Pleomorphism: 3 points (severe)
      - Mitotic Activity: 1 point
  Ancillary Studies
  Source: This case (included in this report)
  Estrogen receptor: Positive (**NAME[VVV] score = 8 of 8)
  Progesterone receptor: Weakly positive (**NAME[VVV] score = 3 of 8)
  c-erb-B2 (Her-2/neu) by IHC:
  Intermediate for Her-2/neu overexpression by IHC; FISH studies will be ordered
  and reported in an addendum
  Ki-67 proliferative index: 20%
  Her-2/neu by FISH: See Comment
  Ancillary studies comment: Will be performed and reported in an addendum
  Angiolymphatic Space Invasion: Not identified
  Skin status: Cannot assess (skin not present)
  Nipple status: Cannot assess (nipple not present)
  Skeletal muscle status: Skeletal muscle not present
  Ductal carcinoma in-situ (DCIS): Present (85002)
  Nuclear grade of DCIS: High
  Necrosis associated with DCIS:
  Present and central (expansive ""comedo"" necrosis)
  Distance spanned by DCIS: 2.2cm
  DCIS qualifies as ""extensive intraductal component""?: Yes
  Lobular carcinoma in-situ (LCIS): Absent
  Changes consistent with previous biopsy site: Present
  Microcalcifications: Not identified
  Final surgical resection margins (including separately submitted margins):
  Invasive carcinoma margins:
  Invasive carcinoma is 0.3 cm from superior margin, 0.4 cm from lateral margin,
  0.5 cm from posterior margin, 0.8 cm from inferior margin and >1 cm from
  medial and anterior margins.
  DCIS Margins:
  DCIS is <0.1 cm from superior and posterior margins,  0.2 cm from inferior
  margin, 0.3 cm from anterior and lateral  margins, and > 1 cm from medial
  margin.
  Lymph node involvement
  Sentinel nodes: Sentinel nodes with carcinoma 0    / Total sentinel nodes 1
  Non-sentinel nodes: Non-sentinel nodes with carcinoma: 0    / Total non-
  sentinel nodes: 0
        - Total number of nodes with macrometastases: 0
        - Total number of nodes with micrometastases: 0
        - Total number of nodes with isolated tumor cells: 0
  Minimum pathologic stage (AJCC, 7th ed., 2010)
  Primary tumor [pT]: PT1a: Tumor > 0.1 cm and <= 0.5 cm - greatest dimension
  Regional nodes [pN]: pN0: No regional lymph node metastasis histologically
  (ITCs may be present)
  N stage modifier: (sn): Only sentinel node(s) evaluated.
  Distant metastasis [pM]: Not applicable or no pathologic information
  Procedures used to establish the diagnosis:
  RoutineADDENDUM REASON: HER2 FISH ResultsADDENDUM REASON: HER2 FISH Results",,,,,
REG3,BREAST,0,PAT-00746251,1,REC-5000748097,,,,"<CLINICAL INFO>
 Patient to be seen by Dr. **NAME[ZZZ YYY] at BCSC
  on **DATE[Jun 19 12].<FINAL DX>
 **INSTITUTION of Pathology, **PLACE,
  Washington; PT-11-5490 (**DATE[Jun 08 2012])
  Right breast, mass at 1 o'clock, core biopsy:  Invasive ductal carcinoma with
  the following features:
  1. Nottingham grade 1 of 3 derived as follows:  Intermediate tubule formation
  (3), low to intermediate nuclear grade (1-2), low mitotic rate (1).
  2. Extent/size:  Involving three of three needle cores with a contiguous
  length of at least 1.3 cm.
  3. Associated in situ component:  Focal low-grade ductal carcinoma in situ
  present, without necrosis.
  4. Microcalcifications:  Present, associated with invasive ductal carcinoma.
  5. Angiolymphatic invasion:  Not identified.
  6. Immunohistochemical stains performed at PSIP and available for review at
  UWMC:
   a. Positive for estrogen and progesterone receptor expression (**NAME[XXX] 8 and 8
  of 8, respectively).
   b. Negative for HER2 over-expression by immunohistochemical technique.
   c. Ki-67 proliferative index:  5%.
  **INITIALS
  Procedures used to establish the diagnosis:
  RoutineMATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A PT-11-5490  0B,7S  R Breast",,,,,
REG3,BREAST,0,PAT-00747088,1,REC-5000750183,,,,"<CLINICAL INFO>
LEFT BREAST DUCTAL CARCINOMA IN SITU


<GROSS>
The specimen is received in three parts, each in formalin. 
A. Part A, designated left breast tissue, is a 6.0 x 5.0 x 3.0-cm oval mass of fibrofatty tissue with two localization wires protruding from one end. A specimen radiogram accompanies the tissue showing numerous microcalcifications and two radiologic markers between the two localization wires. The margins have been inked as follows: superior - black, lateral - blue, medial - green, inferior - orange, deep - yellow, and anterior - purple. The localization wires protrude from the lateral margin. The specimen consists predominately of yellow adipose tissue. Scattered foci of fat necrosis are found. No distinct masses are identified. The area between the two localization wires is entirely submitted in cassettes 1 through 25. Sections from the remaining tissue are submitted in cassette 26.
B. Part B, designated new posterior margin, left breast, is a 5.0 x 3.0 x up to 1.0-cm oval mass of soft, yellow adipose tissue. Yellow ink covers one surface. No masses are identified. The specimen is entirely submitted sequentially in five cassettes. 
C. Part C, designated new medial margin, left breast, is a 6.5 x 4.5 x 1.2-cm oval mass of soft, yellow adipose tissue. Green ink covers one surface. No masses are found. The specimen is entirely submitted sequentially in eight cassettes.",,,,,
REG3,BREAST,0,PAT-00747382,1,REC-5000751602,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Breast Mass, Excisional Biopsy:
   Infiltrating carcinoma with the following features:
      Histologic type:   Ductal (see comment).
      Size:    0.7 cm (measured microscopically).
      Histologic grade:  1 of 3 (well differentiated).
      Nottingham grade:  5 of 9.
         Tubule formation:    3 of 3.
         Nuclear grade:  1 of 3.
         Mitotic rate:   1 of 3.
      Lymph-vascular invasion:     Not identified.
      Perineural invasion:    Present.
   Ductal carcinoma in situ (DCIS):     No definite DCIS identified.
   Surgical margins:
      Infiltrating carcinoma: Very close (tumor is <0.1 cm from the
unoriented resection margin across a broad front).
   Pathologic stage:     pT1b, pNX (AJCC 7th edition).
   Additional findings:
ER positive (95%), PR positive (50%), HER-2/neu 3+ (positive for
overexpression).

<COMMENT>
The tumor shows some morphologic features of lobular carcinoma but the
positive (retained) E-cadherin immunostain supports a ductal phenotype.

<CLINICAL INFO>
Right breast mass.  The specimen was placed in formalin at 12:00 PM on
**DATE[Jun 31 2012] and has an approximate formalin fixation time of 61/2 hours.

<GROSS>
Received in formalin, labeled ""**NAME[AAA BBB]"", and designated ""right
breast mass"", are two fragments of fibrous tissue, 0.5 and 0.8 cm in
maximal dimension. Both specimens are inked and the larger fragment is
bisected. The tissue is entirely submitted in one cassette.  (ke/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
E-Cadherin     Positive  Retained/intact membranous immunoreactivity in
tumor cells.

Impression:  The immunohistochemical results supports the diagnosis.
Interpreted by:  **NAME[ZZZ M. YYY] MD
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block A1

Antibody  Result    Comment
ERsq 95 % of tumor cells positive,            strong nuclear staining.
Non-neoplastic internal control present (positive internal control).

PRsq 50 % of tumor cells positive,            strong nuclear staining.
Non-neoplastic internal control present (positive internal control).

Interpreted by:  **NAME[ZZZ M. YYY] MD
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for detection of the HER2 oncogene product
(using **INSTITUTION. Pathway Anti-HER2 rabbit monoclonal
antibody, clone 4B5) are carried out on formalin-fixed,
paraffin-embedded tissue sections.  Positive and negative controls show
appropriate reactivity. Interpretation of Ventana Pathway for HER2
immunostain is performed according to guidelines recommended by ASCO/CAP
in 2007 (see comment below).  Results are as follows:
Block A1

Antibody  Result    Comment
HER2 3 +  Positive for overexpression

Impression:
Interpreted by:  **NAME[XXX M WWW] M.D.
Comment:

1.  The guideline recommendations by ASCO/CAP in 2007 is as follows:  A
score of 3+ (positive HER2 test) is defined by uniform intense membrane
staining in >30% of tumor cells.  A score of 2+ (equivocal HER2 test) is
defined by complete membrane staining that is either nonuniform or weak
in intensity but with obvious circumferential distribution in at least
10% of tumor cells, or less commonly, intense complete membrane staining
but in only 30% or fewer tumor cells.  A score of 0 or 1+ (negative HER2
test) is defined by no or weak and incomplete membrane staining in any
proportion of tumor cells.
2.  The correlation between HER2 protein overexpression by
immunohistochemistry and HER2/neu gene amplification by fluorescence in
situ hybridization (FISH) is not 100%.  Rare cases interpreted as
negative (0 and 1+) for HER2 protein overexpression may demonstrate low
level HER2/neu gene amplification by FISH.  Approximately 10-20% of
cases interpreted as 2+ may show gene amplification by FISH, while the
vast majority of cases, if not all, interpreted as 3+ show gene
amplification by FISH.  Therefore, additional testing for HER2/neu gene
amplification by fluorescence in situ hybridization (FISH) may be
considered on individual cases, if clinically warranted.  Reflexive
testing for HER2/neu gene amplification by FISH will be performed on all
cases interpreted as 2+ (equivocal for protein overexpression) by
immunohistochemistry.   Performed at CellNetix Pathology  **PLACE, WA.  **ZIP-CODE.

PHYSICIAN NOTIFICATION:
Case discussed with Dr. **NAME[VVV], who confirmed that the specimen
represents an excisional biopsy of a palpable breast mass, on
**DATE[Jul 06 2012].

**NAME[ZZZ M. YYY], MD.  Electronically signed **DATE[Jul 06 2012]",,,,,
REG3,BREAST,0,PAT-00741747,1,REC-5000751660,,,,"<CLINICAL INFO>
Left breast cancer.

<GROSS>
NOTE:  After the specimen was grossed in, the surgeon, Dr. **NAME[ZZZ], called and asked for the tissue to be imaged by Outpatient Radiology.  The tissue was imaged and the clip was identified in cassette A8.
RA/jw  **DATE[Jun 26 12]

<MICROSCOPIC>
A-B.  Sections examined (including a cytokeratin immunohistochemical stain on block B1 and SMMHC on block A6).  The smooth muscle myosin heavy chain stain performed on block A6 confirms the presence of myoepithelial cells surrounding foci of DCIS and shows the absence of myoepithelial cells surrounding the invasive component.  
This case has undergone prospective intradepartmental quality assurance review prior to verification.
AK/cs  **DATE[Jun 29 12]

<INTRAOPERATIVE CONSULT>

<FINAL DX>
A.  BREAST, LEFT, LUMPECTOMY:
  INVASIVE MUCINOUS CARCINOMA (COLLOID CARCINOMA), WITH THE FOLLOWING 
  FEATURES:
  1.  SIZE:  1.0 CM (MICROSCOPIC MEASUREMENT).
  2.  TUMOR FOCALITY:  SINGLE FOCUS OF INVASIVE CARCINOMA.
  3.  HISTOLOGIC GRADE:  NOTTINGHAM GRADE 1 OF 3 (DERIVED AS FOLLOWS:
    TUBULE FORMATION 3, NUCLEAR PLEOMORPHISM 1, MITOTIC ACTIVITY-1; 
    TOTAL SCORE 5 OF 9).
  4.  DUCTAL CARCINOMA IN SITU (DCIS):  PRESENT; SHOWING LOW NUCLEAR 
    GRADE AND SOLID AND CRIBRIFORM PATTERNS; COMPRISING LESS THAN 25%
    OF THE TOTAL TUMOR.
  5.  LOBULAR CARCINOMA IN SITU (LCIS):  NOT IDENTIFIED.
  6.  MARGINS:  
    a.  INVASIVE CARCINOMA IS 0.8 CM FROM THE CLOSEST ANTERIOR MARGIN,
      1.0 CM FROM THE CLOSEST POSTERIOR MARGIN, AND GREATER THAN 
      1.0 CM FROM ALL OTHER MARGINS.
    b.  DCIS IS 0.1 CM FROM THE CLOSEST INFERIOR MARGIN, 0.6 CM FROM
      CLOSEST POSTERIOR MARGIN, AND GREATER THAN 1.0 CM FROM ALL
OTHER MARGINS.
  7.  LYMPHOVASCULAR:  NOT IDENTIFIED.
  8.  ADDITIONAL PATHOLOGIC FINDINGS:  PRIOR BIOPSY SITE CHANGES.
  9.  ANCILLARY STUDIES:  HORMONE RECEPTOR STUDIES WERE PERFORMED ON THE 
    PRIOR CORE BIOPSY SPECIMEN (FH-11-11570)(ER+, PR+, HER2 NEGATIVE).
  10. PATHOLOGIC STAGE:  pT1b N0(sn)(i-)(INCLUDES SPECIMEN B).
B.  LYMPH NODE, LEFT AXILLARY SENTINEL, EXCISIONAL BIOPSY:
  ONE LYMPH NODE NEGATIVE FOR CARCINOMA ON ROUTINE H&E-STAINED LEVELS AND 
  A CYTOKERATIN IMMUNOHISTOCHEMICAL STAIN (0/1).",,,,,
REG3,BREAST,0,PAT-00730728,1,REC-5000751882,,,,"PART / DESCRIPTION - SEQ# 
Breast, modified radical mastectomy (includiing lymph nodes)/ Breast, Modified Radical Mastectomy (including lymph nodes)- 1Interpretation
IMMUNOHISTOCHEMISTRY REPORT:

Deparaffinized sections of formalin fixed tissue (along with appropriate positive and negative controls) are incubated with the following antibody(s). Using the automated Ventana stainer, tissue is incubated with the designated antibody which is then localized by a non-biotin, dual polymer detection system. The controls are reviewed for appropriate reactivity and found to be adequate. Slides are reviewed using the Ventana Image Analysis System (VIAS), an adjunctive computer-assisted image analysis method intended to aid in the detection, classification and counting of cells of interest. Results on the target cell population are indicated below:

 ANTIBODIES TO:     CLONE: RESULTS:

HER2/NEU GENE PRODUCT (fda approved) 4B5  negative (1+, 0)

DIAGNOSIS:
1). Left breast invasive carcinoma: No overexpression of HER-2 oncogene product (1+).
2). Lymph node metastasis: No overexpression of HER-2 oncogene product (0).

**DATE[Jun 30 2012] SMC
<INTRAOPERATIVE DX>
NONE
<MICROSCOPIC>
NONESynoptic Diagnosis
BREAST, MODIFIED RADICAL MASTECTOMY (INCLUDING LYMPH NODES) 
SPECIMEN: Modified radical mastectomy
PROCEDURE: Total mastectomy (including nipple and skin)
LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection)
SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated)
SPECIMEN SIZE: Not applicable (total mastectomy)
SPECIMEN LATERALITY: Left
TUMOR SITE OF INVASIVE CARCINOMA: Central
DUCTAL CARCINOMA IN SITU: DCIS is present
 Extensive intraductal component (EIC) negative
 Size (Extent) of DCIS: Estimated size of DCIS is at least 0.3 cm
 DCIS Architectural Patterns: Solid
 DCIS Nuclear Grade: Grade III (high)
 DCIS Necrosis: Present, focal (small foci or single cell necrosis)
LOBULAR CARCINOMA IN SITU (LCIS): Not identified
HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified)
HISTOLOGIC GRADE: Tubule formation: Score 3: <10% of tumor area forming glandular/tubular structures
 Nuclear pleomorphism: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms
 Mitotic Count: Score 1
 Nottingham Histologic Score-Grade II: 6-7 points
TUMOR SIZE/TUMOR FOCALITY: Greatest dimension of largest focus of invasion over 0.1 cm: 0.7 cm
SKIN: Invasive carcinoma does not invade into the dermis or epidermis
NIPPLE: DCIS does not involve the nipple epidermis.
SKELETAL MUSCLE: No skeletal muscle present
INVASIVE CARCINOMA MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: 1.6 mm
 Distance of invasive carcinoma to posterior margin: 1.6 mm
DCIS MARGINS: Margins uninvolved by DCIS. Distance from closest margin: 1.6 mm
 Distance of DCIS to posterior margin: 1.6 mm
LYMPH-VASCULAR INVASION: Not identified
DERMAL LYMPH-VASCULAR INVASION: Not identified
MICROCALCIFICATIONS: Present in DCIS
 Response to Presurgical (Neoadjuvant) Therapy in the Breast: Probable or definite response to presurgical therapy in the invasive carcinoma
RESPONSE TO PRESURGICAL (NEOADJUVANT) THERAPY IN THE LYMPH NODES: Probable or definite response to presurgical therapy in metastatic carcinoma
LYMPH NODES: Total number of nodes examined (sentinel and nonsentinel): 20
 Micro / Macro Metastases present
 Number of lymph nodes with macrometastases (>0.2 cm): 9
 Extranodal extension not identified
 Estrogen Receptor: Performed on another specimen
 Progesterone Receptor: Performed on another specimen
 HER2/neu Immunoperoxidase Studies: Performed on another specimen
 Fluorescence In Situ Hybridization (FISH) for HER2/neu: Not performed
PRIMARY TUMOR (INVASIVE CARCINOMA) (pT): pT1b: Tumor >5 mm but <= 10 mm in greatest dimension
 Category (pN): pN2a: Metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm)
DISTANT METASTASIS (pM): Not applicable
--------------------------------------------------------


<FINAL DX>
Left breast (modified radical mastectomy specimen): A). invasive poorly differentiated ductal carcinoma, 0.7 cm in greatest dimension. B). focal ductal carcinoma in situ, solid type, with microcalcifications. C). nine (9) of twenty (20) lymph nodes positive for metastatic carcinoma. D). focal extranodal lymphatic space invasion identified. E). surgical margins negative for malignancy. F). please see CaP protocol summary for more complete details.

**DATE[Jun 19 2012] SMC
<GROSS>
The specimen is received in one formalin filled container labeled with the patient's name and sublabeled """"left breast"""". The specimen has been fixed in formalin for greater than 6 hours and less than 48 hours. The specimen consists of a modified radical mastectomy specimen which includes a skin ellipse measuring 23.4 x 10.7 x 0.2 cm. Centrally located is a nipple and areola measuring 3.7 x 3.5 x 0.8 cm. The skin surface is light tan and smooth with one brown macule measuring 0.4 cm in greatest dimension. The edges are regular and extend to within 2.1 cm of the inferior surgical margin. Underlying the skin ellipse is fibrofatty breast tissue measuring 22.5 x 18.9 x 5.2 cm. The specimen is serially sectioned revealing yellow adipose tissue with grey-white breast tissue marbling through it. An ill-defined gray-white mass lesion is present located centrally in the breast measuring 1.1 x 1 x 0.7 cm. The mass lesion is associated with a metal marking pellet and extends to within 1.6 cm of the posterior inked surgical margin. Sections through the remaining tissue reveal no additional mass lesions or areas of hemorrhage. Attached to the breast is an axillary tail measuring 8 x 7.7 x 2 cm. Sections through the adipose tissue reveal several dark tan to pale tan lymph nodes ranging up to 1.5 x 1.1 x 0.9 cm. Lymph nodes are dissected away from the adipose tissue and submitted. Representative sections are submitted as follows: Cassette A: Nipple, cassette B: Skin, cassette C: Mass lesion located closest to posterior inked surgical margin, cassettes D - F: Mass lesion, cassette G: Upper inner quadrant, cassette H: Lower inner quadrant, cassette I: Upper outer quadrant, cassette J: Lower outer quadrant, cassette K: 2 lymph nodes, cassette L: 2 lymph nodes, cassette M: 4 lymph nodes, cassette N: 2 lymph nodes, cassette O: 2 lymph nodes, cassette P: 3 lymph nodes, cassette Q: 2 lymph nodes, cassette R: 2 lymph nodes, cassette S: One lymph node. **DATE[Jun 19 2012] SMC/AO
<CLINICAL INFO>
left breast cancer
1). Left breast<PATHOLOGIST>
**NAME[ZZZ YYY M] 

<SNOMED Code(s)>
T09010M09400T08000T04030P1121P1100M850033M80106M55400",,,,,
REG3,BREAST,0,PAT-00592042,2,REC-5000752143,,,,"<GROSS>
 #SLIDES MADE (BY PATHOLOGY): PAP STAIN-3DIFF QUIK- H&E-6

 submitted in formalin are 6 yellow and white needle core biopsies
 each measuring approximately 0.4cm in diameter and up to 2.5cm in
 length.Levels.2CE. Date and Time tissue removed: **DATE[Oct 16 2011] at
 0845. Date and Time tissue placed in formalin: **DATE[Oct 16 2011] at 0905.
 <CYTO FINAL DX>
 RIGHT BREAST, 2 O'CLOCK, CORE BIOPSY AND SCRAPE CYTOLOGY:
 -- INVASIVE DUCTAL CARCINOMA, GRADE 3, NOTTINGHAM SCORE 8/9.
- TUBULES - 3, PLEOMORPHISM - 3, MITOTIC ACTIVITY - 2.
 -- EXTENSIVE LYMPHATIC-VASCULAR INVASION PRESENT.
 -- ASSOCIATED DUCTAL CARCINOMA IN SITU PRESENT.

 COMMENT:
 Hormone receptor and Her2 amplification studies will be reported in
 an addendum.

 The findings were discussed with Ms. **NAME[CCC], Breast Pathway Service,
 on **DATE[Oct 17 2011].
 This case received prospective Quality Control review.",,,,,
REG3,BREAST,0,PAT-00270023,2,REC-5000752144,,,,"<GROSS>
 #SLIDES MADE (BY PATHOLOGY): PAP STAIN-2DIFF QUIK-1 H&E-3

 submitted in formalin are 3 yellow and white needle core biopsies
 each measuring approximately 0.3 cm in diameter and up to 1.5 cm in
 length.Levels.1CE. Date and Time tissue removed:**DATE[Oct 16 2011] at
 10:05. Date and Time tissue placed in formalin:**DATE[Oct 16 2011] at 10:15.
 <CYTO FINAL DX>
 RIGHT BREAST, 6 O'CLOCK, CORE BIOPSY AND IMPRINT CYTOLOGY:
 -- DUCTAL CARCINOMA IN SITU, INTERMEDIATE GRADE, ARISING IN A
SCLEROSED PAPILLOMA.
 -- FOCAL AREAS SUSPICIOUS FOR MICROINVASION.

 COMMENT:
 Immunohistochemical stains for E-cadherin, smooth muscle myosin heavy
 chain, and p63 were performed with the appropriate controls. The
 intraductal tumor cells strongly express E-cadherin, compatible with
 a ductal carcinoma in situ. Focal areas lack myoepithelial cells,
 which is suspicious for invasion.

 The findings were discussed with Dr. **NAME[ZZZ] on **DATE[Oct 17 2011].
 This case received intradepartmental consultation.",,,,,
REG3,BREAST,0,PAT-00745574,1,REC-5000752891,,,,"PART / DESCRIPTION - SEQ 
BREAST,,MASTECTOMY WITH NODES/ RIGHT BREAST AND AXILLARY CONTENTS- A
INTRAOPERATIVE DX:
NONE
DIAGNOSIS COMMENTS:
The clinical impression of a possible satellite nodule is noted. Sampling of the presumed area shows marked lymphocytic lobulitis. Although it is of some interest that the in-situ and the invasive carcinoma are accompanied by marked lymphocytic infiltrate, the lobules in the presumed area of satellite nodule do not exhibit convincing cytomorphologic or histoarchitectural features of carcinoma (or atypical ductal hyperplasia), although some reactive changes are appreciated. 

The larger positive node was extensively sampled to evaluate for extranodal extension. It is extensively replaced by carcinoma which for the most part appears surrounded by dense fibrosis In one area (A20), this fibrosis is much more abundant, appears eccentric, contains a nest of carcinoma, as well as possible entrapped adipocytes; these features are interpreted as extranodal extension.
FINAL DX:

Breast and axillary contents, right, mastectomy with axillary dissection: Infiltrating carcinoma with the following features:  Histologic type:   Ductal.
Size:     4.5 x 3.5 x 3 cm.  Histologic grade:   High, G3 of 3.  Nottingham grade:   9 of 9.   Tubule formation:    Poor (3 of 3).   Nuclear grade:   High (3 of 3).   Mitotic rate:    High (3 of 3).  Lymph-vascular invasion:  Identified, focal. Ductal carcinoma in situ (DCIS) with the following features:  Histologic type:   Solid.  Nuclear grade:    High.  Necrosis:    Present.  Calcifications:    Rare.  Estimated size/extent of DCIS: Rare ducts with DCIS are seen in association with infiltrating        carcinoma.      Separate incidental microscopic focus of DCIS with features      similar to those reported above, identified in upper inner      quadrant at 3 cm medial and superior from main mass.
Extensive intraductal component: Not identified. Surgical margins:  Infiltrating carcinoma:   Widely free (distance greater than 1 cm, all margins).  Ductal carcinoma in situ:   Widely free (distance greater than 1 cm, all margins). Lymph nodes:    Twenty-five lymph nodes identified.         Two lymph nodes with metastatic carcinoma (2/25).         Largest metastatic deposit: 3.5 cm.         Focal features consistent with extranodal extension identified. Pathologic stage:   pT2, pN1a (AJCC 7th edition). Additional findings:      Immunohistochemistry staining for estrogen and progesterone receptor expression and Her-2/neu overexpression have previously been performed (as per report ***PATH-NUMBER[1], slides not concurrently reviewed), with the following results: ER positive, 100% of tumor cell nuclei with strong staining, PR positive, 20-25% of tumor cell nuclei with moderate to strong staining, HER-2/neu equivocal by immunohistochemistry (score of 2+), negative for HER-2/neu gene amplification by FISH.    Nipple and skin with focal changes consistent with involvement by carcinoma at the base of the    nipple and at the deepest parts of the dermis of skin.    Two hemangiomas of skin, up to 0.4 cm.    Previous biopsy site with associated changes.    Striated muscle with no histologic abnormality is seen in some of the samples from the deep margin.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''right breast and axillary contents'', is an 1178-g right breast with the letter R and an arrow pointing toward axilla written on the skin with an attached 9 x 8.5 x 3.5 cm axillary tail. It has dimensions as follows: medial to lateral - 23 cm, superior to inferior - 25 cm superficial to deep - 5.5 cm. There is a 20 x 13.5 cm ellipse of skin with a 1 cm, retracted nipple. There are two, 0.4 cm in diameter, red-brown macules within the 5 and 7 o'clock skin regions, respectively, and coming to within 0.3 cm of the nearest skin margin. The specimen is inked as follows: superior superficial - orange, inferior superficial- blue, deep - black. The breast is sectioned from medial to lateral into 30 slices, numbered respectively (nipple between slices 11-12). There is a 4.5 x 3.5 x 3 cm firm white mass in slices 11-14, 4 cm from the deep margin, 4 cm from the superior superficial margin, 7 cm from the inferior superficial margin, 4 cm from the nearest skin margin, and 0.3 cm from the nipple. The remainder of the specimen consists of 90% yellow lobulated adipose tissue and 10% white fibrous tissue. There are 26 possible lymph nodes and one grossly positive lymph node identified within the axillary tail, up to 3.5 cm in diameter. Representative sections are submitted as follows: A1 - nipple, bisected and subareolar tissue; A2 - slice 10, area immediately medial to mass with separate superficial and deep; A3 - slice 11, mass with attached overlying skin and separate deep; A4 - slice 12, representative section of mass with attached subareolar tissue and skin near nipple and separate deep; A5-A6 - slice 13, mass with separate superficial and deep; A7 - slice 14, mass, with separate superficial and deep; A8 - slice 15, area immediately lateral to mass, with separate superficial and deep; A9 - slice 18, upper outer quadrant, with separate superficial and deep; A10 - slice 22, lower outer quadrant, with separate superficial and deep; A11 - slice 8, lower inner quadrant, with separate superficial and deep; A12 - slice 6, upper inner quadrant, with separate superficial and deep (3 cm medial and superior to mass, 1.5 cm from the deep margin, 2.5 cm from the superior superficial margin, 8 cm from the inferior superficial margin, 2.5 cm from the nearest skin margin, and 3.3 cm from the nipple); A13 - six possible axillary lymph nodes; A14 - six possible axillary lymph nodes; A15 - five possible axillary lymph nodes; A16 - four possible axillary lymph nodes; A17 - two possible axillary lymph nodes; A18 - two possible axillary lymph nodes; A19 - one possible axillary lymph node, serially sectioned; A20 - representative sections of grossly positive lymph node; A21 - slice 5, upper inner quadrant, directly medial to section from cassette A12, with separate superficial and deep; A22 - slice 7, immediately lateral to section from cassette A12, with separate superficial and deep; A23 - slice 16, possible satellite nodule; A24 - slice 17, possible satellite nodule; A25 - slice 15, possible satellite nodule; A26-A27 - representative additional sections of grossly positive lymph node; A28 - representative sections of skin macules. Specimen was put into formalin at approximately 4 p.m. on **DATE[Feb 02 2012] and will have a total time in formalin of 20-1/2 hours. (**INITIALS:cmc10 287542) (RDR:cmc131 288629) (**INITIALS:cmc40 288785)
CLINICAL INFO:
Malignant neoplasm of breast (female), unspecified site.
ICD-9 code: 174.9.
PATHOLOGIST:
Ranguelov Rostislav D  

SNOMED Code(s)
M55400M54000TY8110TY8100T04020T04010T04000T13000M00100T04100T01200T01000P1140P1100M80103M80001E8550T08000M80106M55000T00100M85003M80103M80103M85002",,,,,
REG3,BREAST,0,PAT-00748363,1,REC-5000753042,,,,"PART / DESCRIPTION - SEQ 
Breast, biopsy (core/incisional)/ RIGHT BREAST CORES 12 O'CLOCK- A
INTERPRETATION:


Fluorescence in situ hybridization (FISH) for HER-2/neu gene amplification has been performed per Dr. **NAME[ZZZ] request. The invasive carcinoma of RIGHT BREAST is reported to show a HER-2/neu to CEP-17 ratio of 3.55, which is interpreted as POSITIVE for HER-2/neu gene amplification by FISH.

Please see the separate report from the Dynacare Cytogenetics laboratory report ***PATH-NUMBER[1] (LCLS: **ID-NUM).
INTERPRETATION:


Immunohistochemistry studies for ER/PR receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone 1E2 for PR from Ventana) and for detection of the C-erb B-2 (Her2/Neu) oncogene product (using FDA-approved DAKO HercepTest) are carried out on formalin fixed and paraffin embedded tissue sections (A1). Routine histologic examination of the RIGHT BREAST demonstrates invasive carcinoma. Positive and negative controls show appropriate reactivity. 
Determination of ER/PR reactivity is based on manual estimation of the percentage of positive nuclei in tumor cells, and interpretation of HercepTest for Her2/neu is by following guidelines recommended by ASCO/CAP in 2007 (see comment below). A positive internal control is identified. 
Results are as follows: 

ER:  Negative (0% of tumor cells showing nuclear staining), invasive carcinoma.
PR:  Negative (0% of tumor cells showing nuclear staining), invasive carcinoma.
c-erb B-2: Equivocal (score of 2-3) for overexpression of c-erb B-2 (Her2/Neu) protein, invasive carcinoma.

PENDING FISH HER2/NEU STUDIES, to be reported in an addendum report.

STUDY REQUESTED BY: Dr. **NAME[YYY M. ZZZ] 

COMMENT: 
Some immunohistochemistry studies have suggested that as few as 1% positive tumor cells for ER/PR may correlate with a significantly improved clinical response of patients to therapeutic and adjuvant hormonal therapy. Based on this information, tumors showing greater than 1% of tumor cell nuclear staining for ER/PR may be considered positive.
The guideline recommendations by ASCO/CAP in 2007 is as follows: A score of 3+ (positive Her2 test) is defined by uniform intense membrane staining in >30% of tumor cells. A score of 2+ (equivocal Her2 test) is defined by complete membrane staining that is either nonuniform or weak in intensity but with obvious circumferential distribution in at least 10% of tumor cells, or less commonly, intense complete membrane staining but in only 30% or fewer tumor cells. A score of 0 or 1+ (negative Her2 test) is defined by no or weak and incomplete membrane staining in any proportion of tumor cells.
The correlation of Her2/neu protein overexpression by the DAKO HercepTest and Her2/neu gene amplification by fluorescence in-situ hybridization (FISH) is not 100%. Rare cases interpreted as negative (0 and 1+) for Her2/neu protein over-expression may demonstrate Her2/neu gene amplification by FISH. Approximately 10% of cases interpreted as 2+ show gene amplification by FISH, and the vast majority, but not all cases interpreted as 3+ show gene amplification by FISH. Therefore, testing for c-erb B-2 (Her2/neu) gene amplification by fluorescence in situ hybridization (FISH) may be considered if clinically warranted. Reflexive testing for Her2/neu gene amplification by FISH will be performed on all cases interpreted as 2+ on immunohistochemistry.

The immunohistochemical tests (for ER/PR) reported were developed and performance characteristics determined by Dynacare Laboratories, **PLACE Wa. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests may be used for clinical purposes. They should not be regarded as investigational or for research use only. Dynacare Laboratories certified is under the Clinical Laboratory Improvement Amendments of 1988(CLIA) as qualified to perform high complexity clinical laboratory testing
INTRAOPERATIVE DX:
NONEConsult
Dr. **NAME[XXX WWW VVV], UUU], PhD (cancer QA)
FINAL DX:

Right breast, 12 o'clock, ultrasound-guided core biopsies:
 Infiltrating carcinoma with the following features:
 Histologic type: Ductal carcinoma.
 Histologic grade: 3 of 3. 
 Nottingham grade: 9 of 9. 
 Tubule formation: Poor (3 of 3).
 Nuclear grade: High (3 of 3).
 Mitotic rate: High (3 of 3).
 Lymph-vascular space invasion: Not identified.
 Ductal carcinoma in situ (DCIS): Not identified.
 Additional findings:    Immunohistochemical studies for estrogen and progesterone receptor expression and HER-2/neu will be performed and reported in an addendum.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''right breast 12 o'clock'', are two, 0.2 cm in diameter cores of yellow-white fibroadipose tissue up to 2.5 cm in length. The specimen is submitted entirely in cassette A1. (**INITIALS:cmc40 289264) (TKL:cmc131 289334)
CLINICAL INFO:
Ultrasound-guided core biopsy of mass in right breast 12 o'clock. Clinical impression: Cancer. The specimen was put into formalin at 8:50 a.m. on **DATE[Aug 9 2012] and will have a total time in formalin of 11 hours and 40 minutes.
ICD-9 code: 793.89.
PATHOLOGIST:
**NAME[TTT SSS M]. 

SNOMED Code(s)
M85002E8550T04020P1140M85003M80103",,,,,
REG3,BREAST,0,PAT-00744511,1,REC-5000754324,,,,"PART / DESCRIPTION - SEQ# 
Breast, biopsy (GSH)/ Lateral right breast tumor- 4
PART / DESCRIPTION - SEQ# 
Breast, biopsy (GSH)/ Superior right breast tumor- 3
PART / DESCRIPTION - SEQ# 
Breast, biopsy (GSH)/ Right breast biopsy tumor- 2
PART / DESCRIPTION - SEQ# 
Breast, biopsy (GSH)/ Inferior margin right breast tumor- 1
PART / DESCRIPTION - SEQ# 
Lymph node biopsy, sentinel (GSH)/ Right breast sentinel lymph node- 5<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
Comment
The needle biopsy of this tumor (GSH ***PATH-NUMBER[1]) was extensively evaluated at PhenoPath Laboratories, revealing a phenotype most compatible with a skin adnexal-type carcinoma in the breast. Review of the entire lesion, shows features which support that interpretation, demonstrating a malignancy with features suggestive of eccrine differentiation. This case will be returned to PhenoPath Laboratories in follow-up, and an addendum report will be issued when their study is complete.
**INITIALS<FINAL DX>

1) """"INFERIOR MARGIN"""" - ONE MICROSCOPIC FOCUS OF INTTRALYMPHATIC  TUMOR APPROXIMATELY 0.3 CM FROM THE SURGICAL MARGIN.
 SECOND SEPARATE 0.2 CM PORTION OF CAUTERIZED TUMOR CONTAINING TISSUE; CANNOT EXCLUDE INVOLVEMENT OF THE SURGICAL MARGIN.

2) RIGHT BREAST TUMOR (ORIENTED LUMPECTOMY, 122 GM) - POORLY DIFFERENTIATED CARCINOMA WITH HISTOPATHOLOGIC FEATURES SUGGESTIVE OF A SKIN ADNEXAL-TYPE CARCINOMA.

 SIZE: 2.9 CM.

 NEOPLASM IS CONFINED TO THE EXCISION; NEAREST RESECTION SURFACE: INFERIOR, 0.2 CM. 

 SKIN INVOLVEMENT: NOT IDENTIFIED.

 ANGIOLYMPHATIC INVASION: PRESENT.

 CHANGES RELATED TO PRIOR BIOPSY.

3) SUPERIOR MARGIN, RIGHT BREAST - BENIGN BREAST TISSUE.

4) """"LATERAL BREAST TUMOR"""" - BENIGN BREAST TISSUE AND FAT.

5) """"RIGHT BREAST SENTINEL LYMPH NODE"""" - ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA.

<MICROSCOPIC>
1) Six slides examined.

2) Ten slides examined.

3) Six slides examined.

4) Four slides examined.

5) Sections from two blocks are examined on six slides.<GROSS>
1) Received in formalin labeled """"**NAME[AAA BBB], inferior margin"""" is a 16 cm., 5 x 4.5 x 1.4 cm. ovoid fragment of yellow-tan fibrofatty tissue with a suture on one side. This side is inked black. The specimen is transversely sliced to reveal unremarkable yellow fatty tissue. Every other section is submitted in 1a-1f. 

2) Received in formalin labeled """"**NAME[AAA BBB], long lateral short superior right breast tumor"""" is a 122 gm. breast lumpectomy specimen with a long suture on one slide facing lateral and a short suture on the adjacent side for superior. It is overlying 5.5 x 2.7 cm. ellipse of blue-dyed, other unremarkable, skin. The specimen is 11.5 cm. anterior to posterior, 8 cm. medial to lateral, and 4.3 cm. superior to inferior. It is inked: superior - green, medial - red, inferior - orange, lateral - purple, anterior - blue, posterior - black. The specimen is sliced from anterior to posterior to reveal a 2.9 x 2.7 x 0.5 cm. well delineated rubbery lesion with a rubbery, white-grey cut surface with lobulated border. It is centrally hemorrhage. The roughly inferior margin, is 0.5 cm. nearest the medial margin, 0.6 cm. to the superior margin, 1.5 cm. to the lateral margin. 2 cm. to the posterior margin, and 5 cm. to the overlying skin. The remainder of the breast parenchyma is yellow, chalky and fatty with intervening soft white fibrous strands. Representative sections are submitted from anterior to posterior in 2a-2i. Approximately 10% of the specimen is submitted.

3) Received in formalin labeled """"**NAME[AAA BBB], superior breast tumor"""" is a 16 gm., 5.3 x 4.3 x 1.8 cm. ovoid fragment of yellow-tan fibrofatty tissue with a suture on one side. The side is inked green and the specimen is transversely sliced to reveal unremarkable yellow, soft, fibrofatty tissue. Every other section is submitted in 3a-3f.

4) Received in formalin labeled """"**NAME[AAA BBB], lateral breast tumor"""" is a 9 gm., 5 x 3 x 1.2 cm. ovoid fragment of yellow-tan fibrofatty tissue with a suture on one side. This side is inked blue. The specimen is transversely sliced to reveal unremarkable soft, yellow, fibrofatty tissue. Every other slice is submitted in 4a-4d.

5) Received in formalin labeled """"**NAME[AAA BBB], right breast sentinel lymph node"""" is a 3.5 x 2.5 x 1.2 cm. aggregate of two fragments of yellow-tan, fibrofatty tissue which contains a 2 x 1.1 x 0.7 cm. tan, rubbery, matted lymph node. The lymph node is sliced and entirely submitted in 5a and 5b.
**INITIALS<CLINICAL INFO>
Adnexal tumor, right breastPATHOLOGIST:
**NAME[ZZZ YYY M]",,,,,
REG3,BREAST,0,PAT-00470177,2,REC-5000754360,,,,"<CLINICAL HX>
According to the ultrasound core breast biopsy protocol data sheet, there was no evidence of abnormality on mammogram. An ultrasound demonstrates a hypoechoic oval mass with vascularity present, which appears to be adherent to underlying muscle. The mass is palpable. The Bi-Rad code is 5. Ultrasound demonstrates an oval lobular mass with indistinct margins and hypoechoic echogenicity with posterior acoustic shadowing. It measures 1.3 x 0.8 x 1.5 cm and is present at the right breast at 10 o'clock position, mid depth. A localization clip was placed.  

<HISTOLOGY COMMENT>



<GROSS>
In formalin labeled ""Rt breast cores"", ""Rt breast Tru-cut bx at 10:00"" on the lid, are four 1 mm in diameter and 5-13 mm in length yellow-white fibrofatty biopsy cores. Entirely submitted in cassette A1. as


<COMMENT>


<MICROSCOPIC>


<FINAL DX>
 BREAST, RIGHT 10 O'CLOCK, TRU-CUT BIOPSY:  INVASIVE DUCTAL CARCINOMA (SEE SYNOPTIC REPORT). 

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>
This case was seen in intradepartmental consultation (new malignancy).

<NOTIFICATION>


<PRELIM DX>


<CHECKLIST>
CANCER CHECKLIST:  INVASIVE CARCINOMA OF BREAST  AJCC 7th ED.  SPECIMEN:  Breast. PROCEDURE:  Ultrasound-guided Tru-cut biopsy. SPECIMEN LATERALITY:  Right. TUMOR SITE:  10 o'clock, mid depth. SPECIMEN INTEGRITY:  Multiple fragments. HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  Invasive ductal carcinoma. NOTTINGHAM HISTOLOGIC SCORE:  Glandular/Tubular Differentiation:  Score = 3.  Nuclear Pleomorphism:  Score = 2.  Mitotic Count:  Cannot be ascertained from this specimen.  Overall Grade:  2. ANCILLARY STUDIES:  Estrogen Receptor:  Positive.  Progesterone Receptor:  Negative.  Her2/neu:  Negative.  Proliferation Index:  Intermediate.

<IMMUNOHISTOCHEMISTRY>


<INDICATIORS>
Semi-quantitative immunohistochemical stains using DAB Chromogen detection were performed on formalin-fixed paraffin-embedded tissue sections with the following results below.  Specimen fixation time was 9 hours, 5 minutes.  Current CAP/ASCO recommended fixation times are 6-48 hours for Her2 testing and 6-72 hours for estrogen and progesterone receptor testing.

<SPECIAL STAINS>",,,,,
REG3,BREAST,0,PAT-00744394,1,REC-5000755905,,,,"<CLINICAL INFO>
DUCTAL CARCINOMA IN SITU BY PRIOR EXCISION WITH CLOSE MARGINS (***PATH-NUMBER[1]).
<SPECIMEN(S)>
LEFT BREAST LUMP.
  Formalin added at: 1200 ON **DATE[May 7 12] AND CASSETTES SENT TO HISTOLOGY **DATE[May 8 12].
<GROSS>
Received in formalin labeled with the patient's name and ""left breast lump long suture lateral"" is a oriented breast lumpectomy specimen which contains two sutures. A short suture which is not designated and a long suture designated lateral. The specimen has been inked in the operating room by Dr. **NAME[ZZZ] as follows: superior orange, lateral yellow, inferior green, medial red, anterior blue, and posterior black. The specimen measures 3.5 cm from superior to inferior, 3.2 cm from medial to lateral, and 1.7 cm from anterior to posterior. There is a hooked guidewire which enters the specimen on the anterior/superior aspect and exits the posterior/inferior and measures 15.0 cm in length. 
The specimen is cross-sectioned from medial to lateral into ten slices. Sectioning reveals rubbery off-white to light tan fibrous tissue with minimal ill-defined adipose tissue. In slices six and seven is a red slightly hemorrhagic cavity measuring 0.3 x 0.2 cm which is 0.4 cm from the anterior margin, 0.6 cm from the posterior margin, 1.0 cm from the inferior margin, and 1.5 cm from the superior margin. No discrete nodules are grossly identified. 
Separate in the container is a tan wrinkled skin fragment measuring 1.9 x 0.3 cm and excised up to 1.0 cm. This fragment is inked purple at the resection margin and serially cross sectioned. 
The specimen is entirely submitted sequentially into twelve cassettes.
Summary of sections
1: slice 1, lateral margin perpendicular sections
2: slice 2, including superior, inferior, anterior, and posterior margins
3: slice 3, including superior, inferior, anterior, and posterior margins
4: slice 4, including superior, inferior, anterior, and posterior margins
5: slice 5, including superior, inferior, anterior, and posterior margins
6: slice 6, cavity, including superior, inferior, anterior, and posterior margins
7: slice 7, cavity, including superior, inferior, anterior, and posterior margins
8: slice 8, including superior, inferior, anterior, and posterior margins
9: slice 9, including superior, inferior, anterior, and posterior margins
10-11: medial margin perpendicular sections
12: skin fragment 
**INITIALS:pro **DATE[May 8 12]
<FINAL DX>
Left breast lump (wire localization excision): Invasive mammary carcinoma arising in a setting of ductal carcinoma in situ, with the following characteristics:
1. Primary tumor size: 0.4 cm. Please see comment.
2. Tumor type: Invasive ductal carcinoma.
3. Histologic grade: Low to intermediate grade. 
Modified Bloom-Richardson score: 5-6.
Tubular score: 3
Nuclear score: 1-2
Mitotic score: 1
4. In situ carcinoma: Positive for ductal carcinoma in situ involving all ten slices with solid and cribriform architectural pattern, intermediate nuclear grade and focal necrosis.
5. Lymphatic/vascular invasion: Not present.
6. Resection margins: Positive medial margin for invasive carcinoma.
a. Distance to next closest margin (DCIS): 0.2 mm (posterior-black).
b. Distance to next closest margin (DCIS): 0.3 mm (lateral-yellow).
c. Distance to next closest margin (DCIS): 0.4 mm (anterior-blue).
d. Distance to next closest margin (DCIS): 1.5 mm (inferior-green).
e. Distance to remaining margin (DCIS): 4.0 mm (superior-orange).
f. Invasive carcinoma is more than 5.0 mm to remaining margins.
7. Estrogen/progesterone receptors and HER-2 studies: Pending, separate report to follow. 
8. Other lesions present: 
a. Ductal hyperplasia, columnar cell change and microcalcifications.
b. Foreign body-type inflammation consistent with changes related to prior excisional procedure.
c. Segment of skin with underlying dermal cicatrix.
9. Lymph nodes: Not removed.
10. AJCC/pTNM classification: T1a,pNX (not removed). 
 
Comment: Invasive carcinoma with marked electrocautery artifact is found in slide eleven representing the medial surgical margin. Here, the tumor measures 0.4 cm in dimension but involves the medial (red) painted margin and therefore may actually be larger if invasive carcinoma remains. Immunohistochemistry studies which support invasion include absence of staining for myoepithelial markers p63 and smooth muscle myosin heavy chain.  ER, PR and Her-2 studies will be attempted on the invasive component. Ductal carcinoma in situ is found to some degree in all sections of the breast excision and is very close to several margins. Slides with immunohistochemistry of the invasive component reviewed by Dr. **NAME[YYY XXX]. I have discussed the findings with **NAME[WWW], Dr. **NAME[ZZZ]'s nurse on **DATE[May 12 12].
<IMMUNOHISTOCHEMISTRY RESULTS>
Deparaffinized tissue sections undergo optimized epitope retrieval prior to incubation with the appropriate antibody.  Visualization is provided by an immunoperoxidase technique.  Immunohistochemical staining is evaluated by visual examination of slides using a conventional light microscope.  The positive and negative control slides for each immunohistochemical test are reviewed and found to exhibit the appropriate staining pattern.  Results on the targeted cell population are as indicated in the table below.  
Tests performed on formalin fixed, paraffin-embedded block 11.
ANTIBODY TO (CLONE ): RESULT.
1. SMOOTH MUSCLE MYOSIN HC (SMMS-1)*: Negative staining around cell groups in question.
2. p63 (4A4)*: Negative staining around cell groups in question.
 
*The performance characteristics of these immunohistochemical tests have been determined by **INSTITUTION.  Some of these tests have been developed by **INSTITUTION. Eastside pathology is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high complexity clinical laboratory testing.
_____________________________________________________________________________________
Some of the above tests may use analyte specific reagents; they have not been cleared or approved by the U.S. Food & Drug Administration (FDA).  The FDA has determined that such clearance or approval is not necessary.  These tests are used for clinical purposes.  They should not be regarded as investigational or for research.  
 
<PATHOLOGIST>
**NAME[VVV UUU], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,BREAST,0,PAT-00737329,1,REC-5000757209,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A. Left Breast and Level 1 Lymph Nodes, Mastectomy and Partial Lymph
Node Dissection:
   Residual infiltrating carcinoma with the following features:
      Histologic type:   Ductal.
      Size:    Stromal-invasive focus measures 0.4 cm.
      Histologic grade:  At least grade 2; defer to pre-treatment biopsy
for more
           definitive grading.
      Nottingham grade:  At least 7 of 9; defer to pre-treatment biopsy
for more
           definitive grading.
         Tubule formation:    Low (3 of 3).
         Nuclear grade:  High (3 of 3).
         Mitotic rate:   Low (1 of 3).
      Lymph-vascular invasion:     Present in random sections of breast
parenchyma, nipple
            and dermis.

   Ductal carcinoma in situ (DCIS) with the following features:
      Histologic type:   Solid.
      Nuclear grade:     High.
      Necrosis:     Not identified.
      Calcifications:    Not identified.
      Estimated size/extent of DCIS:    Small focus measuring 0.1 cm
associated with invasive
            tumor.
   Surgical margins:
      Infiltrating carcinoma:
         Anterior (superficial):   Negative; distance >5 mm.
         Posterior (deep):    Negative; distance >5 mm.
   Ductal carcinoma in situ:
         Anterior (superficial):   Negative; distance >5 mm.
         Posterior (deep):    Negative; distance >5 mm.
      Lymph nodes (including part B):
            Total number of nodes identified:          17
            Number of nodes positive for metastatic carcinoma:   4.
            Largest metastatic deposit:           >2 mm.
            Extranodal extension:            Not identified.
   Pathologic stage:     ypT1a.
          ypN2a (AJCC 7th edition).
   Additional findings:  Multiple areas of nonspecific fibrosis,
possibly areas of tumor regression.

B. Level 2 Lymph Nodes, Regional Resection:
     7 lymph nodes identified.
     1 lymph node positive for metastatic carcinoma. (see part A for
combined level 1 and level 2
       node status)

<COMMENT>
The patient's prior biopsy is not present in our files. I have not
performed ER, PR and Her-2 neu analysis since this testing was likely
performed on the patient's previous biopsy.

<CLINICAL INFO>
Excerpt from Dr. **NAME[ZZZ]'s operative note: The patient is a truly
pleasant **AGE[in 40s]-year-old woman with a history of left breast inflammatory
cancer for which she underwent systemic therapy with good response. She
has stage IV disease. Because of the good control on systemic therapy,
mastectomy is indicated. She presents for mastectomy and lymph node
surgery.

<GROSS>
Collection date: **DATE[Mar 09 2012], placed in formalin at 11:00 p.m. Total
fixation time: Approximately 14 hours.
A.  Received in formalin, labeled ""**NAME[BBB, AAA M]"", and
designated ""left breast including level 1 lymph node"", is a 924 gram
left breast with axilla. It has dimensions as follows: 20 cm medial to
lateral, 22 cm superior to inferior, 7 cm superficial to deep. There is
a 16 x 7.5 cm ellipse of skin with a normal nipple. There is a 0.6 x 0.6
x 0.1 cm tan-brown, slightly raised lesion, 0.2 cm from the inferior
skin margin. It is inked as follows: superior superficial - orange,
inferior superficial - blue, deep - black. It is sectioned from medial
to lateral into twenty-three slices, numbered respectively. The nipple
is in slice 9. There is an 8 x 5 x 4 cm tan-white, firm, nodular area in
slices 9-14, with a metal clip in inferior slice 9, consistent with a
previous biopsy site. There are a few additional focal areas of
hemorrhage. No other discrete mass or lesion is identified. The
remaining tissue consists of yellow, lobulated adipose tissue (95%)
intermixed with firm, white, nodular fibrous tissue (5%). Representative
sections are submitted as follows: A1- nipple; A2- superior, mid and
inferior slice 5 with attached superior superficial, deep and inferior
superficial margins, respectively; A3- mid slice 8, tissue adjacent to
firm area with detached deep margin; A4- inferior slice 8, tissue
adjacent to firm area with metal clip, with detached inferior
superficial margin; A5- firm area in superior slice 9 with detached
superior superficial margin; A6- firm tissue with metal clip in inferior
slice 9 with attached inferior superficial margin; A7- firm area in mid
slice 10 with detached deep margin; A8- firm area in inferior slice 10,
adjacent to metal clip with detached inferior superficial margin; A9-
firm area in inferior slice 11 with attached skin and inferior
superficial margin; A10- firm area in superior slice 12 with attached
superior superficial margin; A11- firm area in superior slice 13 with
detached superior superficial margin; A12- firm area in superior slice
14 with attached superior superficial margin; A13- superior, mid and
inferior slice 15 with attached superior superficial, deep and inferior
superficial margins, respectively; A14- superior, mid and inferior slice
18 with attached superior superficial, deep and inferior superficial
margins, respectively; A15- superior, mid and inferior slice 21 with
attached superior superficial, deep and inferior superficial margins,
respectively; A16- three possible lymph nodes; A17- six possible lymph
nodes; A18- two possible lymph nodes, differentially inked and bisected;
A19- one possible lymph node trisected.

B.  Received in formalin, labeled ""**NAME[BBB, AAA M]"", and
designated ""level 2 nodes"", is a 5 x 4.8 x 2.3 cm portion of adipose
tissue containing five possible lymph nodes, 0.2-1.2 cm in greatest
dimension. The tissue is entirely submitted as follows: B1- five
possible lymph nodes; B2- remaining adipose tissue. (axp/cm)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A9

Antibody  Result    Comment
SMM  Focally positive
D2-40     Indeterminate
Pan CK    Positive

Impression:  Smooth muscle myosin stain demonstrates positive staining
around DCIS in block A9 and negative staining around invasive tumor
cells. Pan-cytokeratin highlights the carcinoma cells including few
clusters within lymphatic channels. D2-40 stain shows nonspecific
staining and does not appear to stain lymphatic endothelium
appropriately and therefore is non-contributory.
Interpreted by:  **NAME[YYY M. XXX] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
Cellnetix pathologist **NAME[WWW M. VVV] agrees with the diagnosis of
malignancy.

**NAME[YYY M. XXX], M.D.  Electronically signed **DATE[Mar 14 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,BREAST,0,PAT-00749321,1,REC-5000757825,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Left Breast, 10 o'clock Ultrasound-Guided Core Biopsies:
Infiltrating carcinoma with the following features:
Histologic type:    Lobular, pleomorphic.
Histologic grade:   3 of 3.
Nottingham grade:   8 of 9.
Tubule formation:   Poor (3 of 3).
Nuclear grade: High (3 of 3).
Mitotic rate:  Intermediate (2 of 3).
Lymph-vascular space invasion:     Not identified.
Ductal carcinoma in situ (DCIS):   Not identified.
Additional findings:     Immunohistochemical studies for hormone
receptors demonstrate the following: ER 100%, PR 100%.
          Immunohistochemical study for HER-2/neu will be performed and
reported in an addendum.

<COMMENT>
This case has been reviewed by Dr. **NAME[ZZZ YYY], as part of our
quality assurance policy, and he concurs with the diagnosis.

<CLINICAL INFO>
Ultrasound biopsy, solid mass left breast at 10 o'clock. Clinical
impression: Cancer. Postmenopausal. Collection date/time: **DATE[May 14 2012] at
1:45 p.m. Total fixation time: 7 hours 15 minutes.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA M]"", designated ""left
breast 10 o'clock"", are four 0.2 cm diameter elongated portions of
fibrofatty tissue, 0.6-1.3 cm in lengths; entirely submitted in A1.
(rtb/cm)

<MICROSCOPIC>
The final diagnosis for this specimen is based on a microscopic
examination of the tissues.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
E-Cadherin     Negative  lobular immunophenotype.

Impression:
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block A1

Antibody  Result    Comment
ERsq 100 % of tumor cells positive,            strong nuclear staining.
No internal control.
PRsq 100 % of tumor cells positive,             moderate nuclear
staining  No internal control.

Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[May 16 2012]",,,,,
REG3,BREAST,0,PAT-00748540,1,REC-5000757865,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Immunohistochemistry results
Reason for Addendum #2:  Immunohistochemistry results

<FINAL DX>     

Core Biopsy, Left Breast:
Infiltrating carcinoma with the following features:
Histologic type:    Ductal.
Histologic grade:   1/3.
Nottingham grade:   4 of 9.
Tubule formation:   2 (of 3).
Nuclear grade: 1 (of 3).
Mitotic rate:  1 (of 3).
Lymph-vascular space invasion:     Not identified.
Ductal carcinoma in situ (DCIS):
Histologic type:    Solid / cribriform.
Nuclear grade: Low.
Necrosis: Absent.
Associated calcifications:    Not identified.
Additional findings:
Immunohistochemical studies for estrogen and progesterone receptor
expression and HER-2/neu will be performed and reported in an addendum.

<CLINICAL INFO>
Palpable lump anteriorly in the left breast at the 12 o'clock position.
Fixation time: **DATE[Sep 13 2012] at 1130 hours for a total fixation time of
91/2 hours.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""left"", are
four 0.3 cm in diameter elongated portions of fibrofatty tissue, 0.5-2.2
cm in length, entirely submitted in A1.  (pcs/dg)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

INTRADEPARTMENTAL CONSULTATION:
**NAME[ZZZ M. YYY], M.D.

**NAME[M. XXX WWW], M.D.  Electronically signed **DATE[Sep 14 2012]

<ADDENDUM> #1

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block A1

Antibody  Result    Comment
ERsq 100 %
PRsq 100 %

Interpreted by:  **NAME[M. XXX WWW] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

Addendum #1 performed by **NAME[M. XXX WWW], M.D.  Electronically signed
**DATE[Sep 15 2012]

<ADDENDUM>  #2

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for detection of the HER2 oncogene product
(using **INSTITUTION. Pathway Anti-HER2 rabbit monoclonal
antibody, clone 4B5) are carried out on formalin-fixed,
paraffin-embedded tissue sections.  Positive and negative controls show
appropriate reactivity. Interpretation of Ventana Pathway for HER2
immunostain is performed according to guidelines recommended by ASCO/CAP
in 2007 (see comment below).  Results are as follows:
Block A1

Antibody  Result    Comment
HER2 1+   Negative for overexpression

Impression:
Interpreted by:  **NAME[VVV M. UUU] MD
Comment:

1.  The guideline recommendations by ASCO/CAP in 2007 is as follows:  A
score of 3+ (positive HER2 test) is defined by uniform intense membrane
staining in >30% of tumor cells.  A score of 2+ (equivocal HER2 test) is
defined by complete membrane staining that is either nonuniform or weak
in intensity but with obvious circumferential distribution in at least
10% of tumor cells, or less commonly, intense complete membrane staining
but in only 30% or fewer tumor cells.  A score of 0 or 1+ (negative HER2
test) is defined by no or weak and incomplete membrane staining in any
proportion of tumor cells.
2.  The correlation between HER2 protein overexpression by
immunohistochemistry and HER2/neu gene amplification by fluorescence in
situ hybridization (FISH) is not 100%.  Rare cases interpreted as
negative (0 and 1+) for HER2 protein overexpression may demonstrate low
level HER2/neu gene amplification by FISH.  Approximately 10-20% of
cases interpreted as 2+ may show gene amplification by FISH, while the
vast majority of cases, if not all, interpreted as 3+ show gene
amplification by FISH.  Therefore, additional testing for HER2/neu gene
amplification by fluorescence in situ hybridization (FISH) may be
considered on individual cases, if clinically warranted.  Reflexive
testing for HER2/neu gene amplification by FISH will be performed on all
cases interpreted as 2+ (equivocal for protein overexpression) by
immunohistochemistry.   Performed at CellNetix Pathology  **PLACE, WA.  **ZIP-CODE.

Addendum #2 performed by **NAME[M. XXX WWW], M.D.  Electronically signed
**DATE[Sep 16 2012]",,,,,
REG3,BREAST,0,PAT-00748173,1,REC-5000757986,,,,"<CLINICAL INFO>
Right DCIS.

<GROSS>
A.  Received in formalin, labeled with the patient's name and designated 'anterior margin right breast,' are two separate portions of yellow-tan lobulated fibrofatty breast tissue.  The smaller unoriented portion of breast tissue measures 6.5 x 3.5 x 1.3 cm and the larger oriented portion of right breast measures 10.5 cm from medial to lateral x 9 cm from superior to inferior x 2.4 cm from anterior to posterior.  The external surface of the larger portion of oriented breast tissue is slightly disrupted and is now differentially inked to allow for the microscopic evaluation of the surgical resection margins as follows:  superior   blue, inferior   green, anterior   yellow, posterior   black, medial   purple, and lateral   orange.  The external surface of the smaller unoriented portion of breast tissue is intact and is now inked blue, to allow for the microscopic evaluation of the surgical resection margins.  Sectioning through the larger oriented portion of breast tissue from medial to lateral reveals primarily yellow-tan lobulated adipose tissue and a small amount of scattered white-tan firm fibrous tissue.  No distinct masses, nodules, or biopsy sites are identified.  Sectioning through the unoriented portion of breast tissue reveals primarily yellow-tan lobulated adipose tissue and a small amount of scattered white-tan fibrous tissue.  No distinct masses, nodules or biopsy sites are identified.  The breast tissue is submitted entirely and sequentially as follows:  A1-A42 oriented right breast lumpectomy submitted from medial to lateral as follows: A1-A5 medial margin perpendicular, A6-A20 tricomposite sections with the superior third in the first even cassettes, middle third in the odd cassettes, and inferior third in the second even cassettes, A21-A38 bicomposite sections with the superior half in the odd cassettes, A39-A42 lateral margin perpendicular, A43-A49 entire smaller unoriented breast tissue.  
B.  Received in formalin, labeled with the patient's name and designated 'superior margin right breast,' is an unoriented right breast lumpectomy designated with a short suture marking superior and a long suture marking lateral, per the requisition form and specimen container.  The breast tissue measures 7.2 cm from medial to lateral x 4.8 cm from anterior to posterior x 3 cm from superior to inferior.  The external surface is slightly disrupted and is now differentially inked to allow for the microscopic evaluation of the surgical resection margins as follows:  superior   blue, inferior   green, anterior   yellow, posterior   black, medial   purple, and lateral   orange.  Sectioning from medial to lateral reveals primarily yellow-tan lobulated adipose tissue with a small amount of scattered white-tan fibrous tissue.  No distinct masses, nodules, or biopsy sites are identified.  The breast tissue is submitted entirely and sequentially from medial to lateral as follows:  B1-B3 medial margin perpendicular, B4-B23 bicomposite sections with the anterior half in the even cassettes, and the posterior half in the odd cassettes, B24-B28 lateral margin perpendicular.
RA/cs  **DATE[Nov 06 11]

<MICROSCOPIC>
Sections examined.
**INITIALS  **DATE[Nov 8 11]


<FINAL DX>
A.  RIGHT BREAST ANTERIOR MARGIN, ORIENTED EXCISION:
  1.  FOCAL (0.3CM) ATYPICAL DUCTAL HYPERPLASIA IS SEEN IN ASSOCIATION     WITH THE PREVIOUS BIOPSY SITE (BLOCK A1); MARGINS REMOTE FROM FOCAL ADH.
  2.  FLORID USUAL DUCTAL HYPERPLASIA WITHOUT ATYPIA AND MICROCYST   FORMATION IS NOTED.
  3.  MICROCALCIFICATIONS ARE IDENTIFIED IN ASSOCIATION WITH DUCTAL
    HYPERPLASIA AND MICROCYSTS.
  4.  NEGATIVE FOR IN SITU AND INVASIVE CARCINOMA.
B.  RIGHT BREAST SUPERIOR MARGIN, ORIENTED EXCISION:
  1.  CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE IDENTIFIED.
  2.  FLORID USUAL DUCTAL HYPERPLASIA WITHOUT ATYPIA AND MICROCYST
    FORMATION NOTED.
  3.  MICROCALCIFICATIONS ARE IDENTIFIED IN ASSOCIATION WITH BENIGN BREAST
    EPITHELIUM AND MILDLY SCLEROTIC STROMA.
  4.  NEGATIVE FOR ATYPICAL HYPERPLASIA, IN SITU AND INVASIVE CARCINOMA.",,,,,
REG3,BREAST,0,PAT-00745749,1,REC-5000758016,,,,"<CLINICAL INFO>
**AGE[in 60s]-year-old female with recent diagnosis of invasive ductal carcinoma from right breast biopsy at 10:00 (FH-11-14062).

<GROSS>
Received in formalin labeled with the patient's name and designated 'right axilla 9:30' are four tan-yellow soft tissue cores ranging from 0.2 to 0.6 cm in length x 0.1 cm in diameter.  The container, requisition and specimen are marked with yellow ink and the specimen is wrapped and submitted entirely in cassette A1.
**INITIALS  **DATE[Mar 7 12]

<MICROSCOPIC>
Sections examined.
**INITIALS  **DATE[Mar 8 12]


<FINAL DX>
RIGHT AXILLA AT 9:30, N+12 (ULTRASOUND-GUIDED CORE BIOPSY):
1.  PORTION OF LYMPH NODE; NEGATIVE FOR METASTATIC CARCINOMA.
2.  PORTION OF BENIGN BREAST TISSUE; NEGATIVE FOR ATYPICAL DUCTAL HYPERPLASIA,
  IN SITU OR INVASIVE CARCINOMA.",,,,,
REG3,BREAST,0,PAT-00743626,1,REC-5000758083,,,,"<CLINICAL INFO>
Left breast cancer.

<GROSS>
Received in formalin, labeled with the patient's name and designated 'left breast re-excision,' is an oriented left breast lumpectomy measuring 5.5 cm medial to lateral, 4.5 cm superior to inferior, and up to 1.5 cm anterior to posterior.  The specimen has been received oriented per the surgeon with a short black suture representing the anterior resection margin, a long black suture designating the medial resection margin, a long white suture representing the superior resection margin, and a short white suture representing the inferior resection margin.  The posterior surface of the specimen is concave and remarkable for extensive cautery artifact, hemorrhage, and necrosis.  The anterior surface of the specimen is convex and without cautery artifact.  The lumpectomy is differentially inked in order to allow for the microscopic evaluation of the surgical resection margins in the following manner:  the superior resection margin is inked blue, the inferior resection margin is inked green, the medial resection margin is inked violet, the lateral resection margin is inked orange, the anterior resection margin is inked yellow, and the posterior resection margin is inked black.  The lumpectomy is sectioned perpendicular to the old surgical margin to reveal a cut surface, which grossly appears to be comprised of approximately 90% yellow glistening adipose tissue and 10% white to pink fibrous tissue.  A distinct mass or lesion is not grossly identified.  The breast tissue is submitted in its entirety in a sequential fashion from the lateral resection margin in cassette A1 to the medial resection margin in cassette A8.  
**INITIALS  **DATE[Jan 14 12]

<MICROSCOPIC>
Sections examined.  
LVT/cs  **DATE[Jan 15 12]


<FINAL DX>
LEFT BREAST, RE-EXCISION OF LUMPECTOMY SITE:
1.  HEMORRHAGE, INFLAMMATION, ORGANIZING FAT NECROSIS, AND REACTIVE FIBROSIS,
  CONSISTENT WITH  PREVIOUS LUMPECTOMY SITE.
2.  FOCAL MICROCALCIFICATIONS IDENTIFIED, ASSOCIATED WITH BENIGN EPITHELIUM.
3.  NO RESIDUAL IN SITU OR INVASIVE CARCINOMA IDENTIFIED.",,,,,
REG3,BREAST,0,PAT-00746388,1,REC-5000758106,,,,"<CLINICAL INFO>
Left breast cancer.  Right breast MRI abnormality.

<GROSS>
Received in formalin are three specimens each labeled with the patient's name.
A.  The specimen designated 'right subareolar (long lateral, short superior),' is an oriented fibrofatty tissue fragment weighing 7 gm and measuring 5.3 cm from medial to lateral, 2.3 cm from anterior to posterior, and 1.2 cm from superior to inferior.  The tail-end of the localization guidewire extends from the lateral aspect.  With the provided orientation, the specimen is differentially inked to allow for microscopic evaluation of surgical resection margins as follows:  superior-blue, inferior-green, posterior-black, anterior-yellow, medial-purple, lateral-orange.  The tissue is serially sectioned from medial toward lateral into nine slices with the hooked end of the guidewire terminating in slice 8.  Sectioning reveals uniform rubbery fibrofatty cut surfaces throughout with a hemorrhagic cavity in slices 4-6.  There is no discrete mass identified.  The specimen is entirely submitted sequentially in cassettes A1-A6.  
B.  The specimen designated 'left breast, stitch superior,' consists of an unoriented breast specimen weighing 765 gm and measuring 23 cm from superior to inferior, 21 cm from medial to lateral and up to 5.3 cm from superficial to deep.  There is an overlying 15.5 x 7 cm horizontal tan-pink skin ellipse, with a central to slightly medial 3.5 x 3.3 cm everted nipple and areolar complex, grossly without ulceration.  At 12:00, 2 cm from the nipple, there is a 0.7 cm tan-brown lesion with similar lesions from 0.4-0.8 cm are identified at 5:00, 3 cm from the nipple, 7:00, 2 cm from the nipple, and 11:00, 2.5 cm from the nipple.  The specimen is inked as follows:  superior/superficial   blue, inferior/superficial   green, and posterior   black.  
The specimen is serially sectioned from medial towards lateral into 19 slices, with the nipple aligned between slices 7-8.  Sectioning reveals an indurated tan-white mass in the upper-outer quadrant, grossly approximately 2:00, 3-4 cm from the nipple.  This mass occupies slices 8-10, and measures 2.3 cm from superior to inferior, 1.3 cm from anterior to posterior, and 2.6 cm from medial to lateral.  Centrally within the mass, there is gel-foam filler, consistent with a previous biopsy site.  The mass is 3 cm from the nearest superior margin, 3.5 cm from the deep margin, and 5 cm from the inferior margin.  This discrete mass is surrounded superiorly and inferiorly, as well as anterior/medially, by rubbery to dense irregular fibrocystic tissue, which occupies slices 6-10.  The greatest extent of this irregular tissue, including mass is 7.3 cm from superior to inferior, 2.5 cm from anterior to posterior, and 4 cm from medial to lateral.  The remainder of the breast shows soft tan-yellow lobulated fatty cut surfaces, with a minimal to moderate fibrous component.  There are no additional discrete masses, lesions or areas of induration identified.  Palpation and dissection of the most lateral slices reveals no additional attached axillary nodes.  
Sections are submitted as follows:  B1 representative section of central nipple, section of described lesions, random section of skin, B2 central breast, slice 5, fibrocystic tissue lateral to field of described irregular tissue (no margins shown), B3 slice 6, retroareolar tissue, at medial extent of irregularity, B4 slice 7, tissue medially adjacent to discrete mass, B5-B8, slice 7, sections submitted sequentially from superior toward inferior showing greatest extent of mass with surrounding irregular tissue (no margins shown), B9 slice 7, superior margin, adjacent to tissue in B5, B10 slice 7, deep margin nearest to mass, B11 slice 7 inferior margin nearest to tissue in B8, B12 slice 9, mass in this slice with inferiorly adjacent fibrous tissue, B13 slice 10, lateral extent of mass, B14 slice 11, tissue laterally adjacent to mass, B15 upper-outer quadrant, B16 lower-outer quadrant, B17 lower-inner quadrant, B18 upper-inner quadrant.
C.  The specimen designated 'axillary contents, left' is an 8.5 x 8.5 x 1.5 cm portion of soft rubbery tan-yellow fatty tissue.  Palpation and dissection of this tissue reveals 16 soft and rubbery tan-pink probable lymph nodes ranging from 0.5-2.4 cm in maximum dimension.  The nodes are entirely submitted as follows:  C1 two nodes bisected (one inked blue), C2 six nodes intact, C3 one node trisected, C4 one node bisected, C5 one node bisected, C6 one node bisected, C7 two nodes intact, C8 one node bisected, C9-C10 one node sectioned.
JG/cs  **DATE[Jan 02 12]

<MICROSCOPIC>
Sections examined.  
**INITIALS  **DATE[Jan 06 12]  
Right Breast Infiltrating Ductal Carcinoma


<FINAL DX>
A.  RIGHT BREAST MASS, WIRE-LOCALIZED ORIENTED EXCISION:  
  1.  INFILTRATING DUCTAL CARCINOMA.  
  2.  SIZE:  0.4 CM.
  3.  TUMOR FOCALITY: SINGLE FOCUS.
  4.  NOTTINGHAM GRADE:  I/III (GOOD TUBULE FORMATION = 1; MINIMAL 
    NUCLEAR PLEOMORPHISM = 1; LOW MITOTIC COUNT = 1; FOR A 
    TOTAL SCORE OF 3/9).  
  5.  SURGICAL MARGINS:  NEGATIVE (CARCINOMA EXTENDS 0.5 MM 
    FROM INFERIOR MARGIN, 5 MM FROM POSTERIOR MARGIN, 9 MM 
FROM SUPERIOR MARGIN, 10 MM FROM ANTERIOR MARGIN, AND
GREATER THAN 10 MM FROM THE MEDIAL AND LATERAL MARGINS).    
  6.  DUCTAL CARCINOMA IN SITU IS NOT IDENTIFIED.  
  7.  ANGIOLYMPHATIC INVASION IS NOT IDENTIFIED. 
  8.  FOCAL MICROCALCIFICATIONS ARE IDENTIFIED IN ASSOCIATION 
WITH INFILTRATING CARCINOMA. 
  9.  BREAST IMMUNOHISTOCHEMICAL PANEL PENDING AND WILL 
    BE REPORT AS AN ADDENDUM.  
  10.  OTHER FINDINGS:  FIBROCYSTIC CHANGE. 
  11. PATHOLOGIC STAGE:  pT1a, pNX.  
B.  LEFT BREAST, SIMPLE MASTECTOMY:  
  1.  INFILTRATING DUCTAL CARCINOMA. 
  2.  SIZE:  2.6 X 2.3 X 1.3 CM. 
  3.  TUMOR FOCALITY:  SINGLE FOCUS.  
  4.  NOTTINGHAM GRADE:  II/III (POOR TUBULE FORMATION = 3; 
    INTERMEDIATE NUCLEAR GRADE = 2; LOW MITOTIC RATE = 1; 
    FOR A TOTAL SCORE OF 6/9).  
  5.  DUCTAL CARCINOMA IN SITU IS NOT IDENTIFIED. 
  6.  MARGINS:  NEGATIVE (CARCINOMA EXTENDS TO 3 CM FROM SUPERIOR 
    MARGIN, 3.5 CM FROM DEEP MARGIN, AND 5 CM FROM INFERIOR 
    MARGIN). 
  7.  ANGIOLYMPHATIC INVASION IS NOT IDENTIFIED.  
  8.  NO INVOLVEMENT OF THE DERMIS, NIPPLE, OR DEEP SKELETAL MUSCLE IS   NOTED. 
  9.  MICROCALCIFICATIONS ARE IDENTIFIED IN ASSOCIATION WITH THE
INFILTRATING CARCINOMA AND ALSO BENIGN BREAST EPITHELIUM.  
  10. ADDITIONAL FINDINGS:  CHANGES CONSISTENT WITH PREVIOUS BIOPSY 
    SITE NOTED IN ASSOCIATION WITH INFILTRATING CARCINOMA; 
    FIBROCYSTIC CHANGE AND SEBORRHEIC KERATOSES ARE ADDITIONALLY
    NOTED. 
  11. PATHOLOGIC STAGE:  pT2, pN1a.  
C.  LEFT AXILLARY LYMPH NODE DISSECTION:  
1.  3 OF 15 AXILLARY LYMPH NODES POSITIVE FOR METASTATIC 
ADENOCARCINOMA.  
  2.  SIZE OF LARGEST METASTATIC FOCUS = 1.2 CM.  
  3.  FOCAL EXTRACAPSULAR EXTENSION BY CARCINOMA IS NOTED.



<ADDENDUM>
IMMUNOCYTOCHEMICAL CANCER MARKER STUDIES REPORT
ESTROGEN RECEPTOR:    POSITIVE    
*Percent cells positive:    82%
Staining intensity:     Moderate to Strong
  Internal Controls:    Positive
PROGESTERONE RECEPTOR:  POSITIVE
  *Percent cells positive:    71%
  Staining intensity:          Moderate to Strong
  Internal Controls:    Positive
CerbB2 (HER-2 NEU) ONCOGENE OVEREXPRESSION:  
          NEGATIVE
      ***Score:    0 (6.5% faint partial membranous staining)  
    Internal Controls:  Present
Ki-67 Antigen:****      Low (<10%)
Percent cells positive:      2%
_____________________________________________________________________
Immunohistochemical evaluation is performed by manual quantitative/semiquantitative morphometric analysis.
Immunohistochemical evaluation of estrogen receptor is performed is using DAKO monoclonal  mouse antihuman estrogen receptor alpha clone 1D5.  Progesterone receptor evaluation is performed using DAKO monoclonal mouse antihuman progesterone receptor clone PgR636.  Ki-67 evaluation is performed using DAKO monoclonal mouse antihuman  Ki-67 antigen clone MIB-1.  Her-2 neu evaluation is performed using DAKO polyclonal rabbit antihuman c-erbB-2 oncoprotein code No. A 0485.  Unless otherwise indicated, these studies are performed using the DAKO auto stainer used with paraffin embedded formalin-fixed sections which have undergone heat-induced epitope retrieval in Target Retrieval Solution.  DAKO Envision+/HRP kit is used for visualization.
*  If less than 1% of tumor cells are positive for estrogen or progesterone receptor, the tumor is considered to be negative for hormone receptor expression per ASCO-CAP 2010 guidelines.
**  A false negative cannot be ruled out in the presence of inadequate controls.
*** Negative (0) - no staining or membrane staining < 10% tumor cells.
   Negative (1+) - faint partial membrane staining > 10% tumor cells.
   Weak positive (2+) - weak to moderate complete membrane staining > 10% tumor cells.
   Strong positive (3+) -  uniform intense complete membrane staining > 30% tumor cells.
****  When discordance exists between cell proliferation as determined by ki-67 antigen and histologic mitotic count, the           
higher of the two determinations should be used.  Ki-67 antigen is sensitive to tissue fixation and may show a falsely low  proliferation index.",,,,,
REG3,BREAST,0,PAT-00748531,1,REC-5000758158,,,,"<CLINICAL INFO>
Left breast cancer.

<GROSS>
Received in formalin labeled with the patient's name and designated 'left lumpectomy, stitch on inferior margin' and per the surgeon's operative report the skin is designated as anterior lateral and consists of an oriented fibrofatty tissue fragment weighing 51.2 gm and measuring 8.5 cm from superior to inferior, 6.2 cm from anterior to posterior and 2.3 cm from medial to lateral.  On the anterior/lateral aspect there is a vertical 3.5 x 0.6 cm partially disrupted tan-pink skin ellipse with a central linear 3.3 cm well-healed vertical scar.  With the provided orientation per the requisition and operative report, the specimen is differentially inked to allow for microscopic evaluation of surgical resection margins as follows:  superior - yellow, inferior - green, posterior - black, anterior - blue, medial - purple, lateral - orange.  On the anterior aspect there is a vertical 8 cm open defect exposing a central cavity approximately 7.5 cm in maximum dimension.  The tissue is serially sectioned from superior towards inferior into fifteen slices revealing a cavity occupying slices 1-14.  Grossly the cavity is opened at the anterior margin throughout and is 0.2 cm from the green inked inferior margin, 0.3 cm from the black inked deep margin, 0.1 cm from the orange inked lateral margin, 0.2 cm from the purple inked medial margin and approximately 0.5 cm from the yellow inked superior margin.  Surrounding the cavity is a minimal amount of rubbery opaque yellow tissue as well as a minimal amount of rubbery to nodular fibrous tissue occupying slices 6-14 at the inferior, posterior, lateral and medial aspects of the cavity although there are no discrete masses identified.  Representative sections are submitted as follows:  A1 perpendicular sections of slice 1 with yellow inked superior margin, A2 representative sections of slice 3 with lateral and deep margins, A3 slice 6 representative sections of medial and deep margins, A4 slice 8 representative lateral and deep margins, A5 slice 10, representative medial and deep margins, A6-A8 slice 12 entirely submitted, A9-A10 slice 13 inferior lateral and posterior medial margins, A11-A12 slice 14 inferior lateral and posterior medial margins, A13-A14 perpendicular sections of slice 15 entirely submitted, A15 additional yellow-inked superior margin (slice 2), A16 additional blue-inked anterior margin with skin (slice 10-11), A17 additional medial margin (slices 9 and 11), A18 additional lateral margin (slices 5, 8-9).
JG/gk/cs  **DATE[Jul 14 12]

<MICROSCOPIC>
Slide section/s examined.
**INITIALS  **DATE[Jul 15 12]


<FINAL DX>
LEFT BREAST, RE-EXCISION LUMPECTOMY:
  RESIDUAL DUCTAL CARCINOMA IN SITU, WITH THE FOLLOWING FEATURES:
  1.  HIGH NUCLEAR GRADE, WITH FOCAL NECROSIS.
  2.  SOLID AND MICROPAPILLARY PATTERNS.
  3.  NO ASSOCIATED CALCIFICATIONS SEEN IN THIS SAMPLE.
4.  RESIDUAL DUCTAL CARCINOMA IN SITU IS ESTIMATED TO SPAN AT LEAST 2.0 CM IN LINEAR EXTENT, BASED ON THE NUMBER OF TISSUE SECTIONS INVOLVED.
5.  DUCTAL CARCINOMA IN SITU EXTENDS IN MULTIPLE FOCI TO WITHIN LESS THAN 0.1 CM OF THE POSTERIOR SURGICAL MARGIN, AND FOCALLY TO WITHIN LESS THAN 0.1 CM OF THE INFERIOR SURGICAL MARGIN; MEDIAL, LATERAL, SUPERIOR, AND ANTERIOR SURGICAL MARGINS APPEAR WIDELY (GREATER THAN 1.0 CM) CLEAR OF DUCTAL CARCINOMA IN SITU.
  6.  NO RESIDUAL INVASIVE CARCINOMA IDENTIFIED.
  7.  FOCAL ATYPICAL LOBULAR HYPERPLASIA IS ALSO PRESENT.
  8.  PRIOR SURGERY-RELATED CHANGES ARE PRESENT.
  9.  NO SKIN INVOLVEMENT IDENTIFIED.
  10. NO SKELETAL MUSCLE OR NIPPLE TISSUE PRESENT.
  11. SPECIMEN INTEGRITY:  INTACT.
  12. PRIOR TREATMENT-RELATED EFFECT:  NOT APPLICABLE (NO PRIOR TREATMENT).
  13. NO LYMPH NODES IDENTIFIED IN THIS SPECIMEN.",,,,,
REG3,BREAST,0,PAT-00736636,1,REC-5000759285,,,,"<CLINICAL INFO>
Left breast cancer
<GROSS>
     1.     Received in formalin, labeled **NAME[BBB, AAA], #1, is a 1,336 gram, 29.0 x 27.0 x 5.4 cm mastectomy specimen with an attached, 8.5 x 7.0 x 2.8 cm axillary tail.  Specimen is surfaced in part on the anterior aspect by a 23.0 x 10.0 cm, elliptical portion of grossly unremarkable, tan skin with a centrally located nipple.  The deep surface is covered by fascia with a 7.5 x 3.5 cm area of attached skeletal muscle on the upper outer aspect of specimen.  The margins are marked as follows:  superior anterior margin = blue; inferior anterior margin = red; posterior = black.  Specimen is serially sectioned proceeding from medial to lateral revealing a 7.0 x 4.0 x 4.0 cm smooth lined cyst in the upper outer quadrant that grossly abuts the overlying posterior fascia and overlying skin on the anterior surface.  The cyst is extends to a 4.5 x 3.0 x 2.0 cm, firm, tan mass 0.9 cm from the nearest superior anterior surgical margin and also deep to overlying skin.  Twenty lymph nodes are identified in the axillary tail, up to 2.0 cm in maximum dimension.  Also received in the same container is an 8.0 x 3.5 x 1.5 cm, unattached portion of adipose tissue.  Serial cuts through the smaller specimen reveal grossly unremarkable, lobulated adipose tissue.  No discrete lesions or areas of nodularity are identified.  SECTIONS:  A1 = posterior cystic mass and posterior surgical margin; A2 = cyst and overlying skin; A3 and A4 = density at nearest anterior superior surgical margin and overlying skin; A5 = nipple and subjacent tissue; A6, A7 and A8 = additional representative sections tumor; A9 = representative sections upper inner quadrant; A10 = representative sections lower inner quadrant; A11 = representative sections lower outer quadrant; A12-A16 = lymph nodes, in total, as follows:  A12 = six lymph nodes; A13 = seven lymph nodes; A14 = two bivalved lymph nodes; A15 = four lymph nodes; A16 = largest lymph node, bisected; A17-A21 = additional representative sections 4.5 cm mass.
     2.      Received in formalin, labeled **NAME[BBB, AAA], #2, is an irregular portion of grossly unremarkable, tan skin, up to 11.0 cm in length by up to 3.8 cm in diameter.  The specimen is excised to a depth of 1.3 cm.  A short stitch is attached to the superior aspect and a long suture the lateral.  Margins are marked as follows:  superior = yellow; inferior = red; lateral = orange; medial = green; posterior = black.  On cut section, the subcutaneous tissue consists of grossly unremarkable adipose tissue in which no discrete lesions or areas of firmness or nodularity are identified.  SECTIONS:  B1 = representative sections.


<MICROSCOPIC SECTION>

<FINAL DX>
     
1.     BREAST, LEFT AND AXILLARY PACKET, MASTECTOMY:
     A.     History of infiltrating ductal carcinoma, grade III (***PATH-NUMBER[1]).
B.     Status post neoadjuvant therapy.
C.     Current specimen shows no residual viable carcinoma.  The irregular 4.5 x 3.0 x 2.0 cm, firm mass with associated cystic change consists of irregular fibrosis and entirely necrotic tumor.  See comment.
D.     Remainder of breast parenchyma with mild patchy fibrosis.
E.     Axillary lymph node status:  Twenty axillary lymph nodes free of metastatic carcinoma (0/20).  See comment.
F.     Pathologic stage:  ypT0 ypN0.  See comment.
     
2.     LEFT LATERAL SKIN:
     Skin with no diagnostic abnormality.

     1.     The left breast resection shows an irregular, 4.5 x 3.0 x 2.0 cm mass with associated cystic change consistent with the location of the prior tumor.  On histologic examination, no residual viable tumor is present.  The mass consists entirely of irregular fibrosis with areas of tumor which is completely necrotic consistent with response to therapy.  






<SPECIMEN(S)>
Breast excision, oriented
<SPECIMEN(S)>
Skin, scar/plastic repair",,,,,
REG3,BREAST,0,PAT-00478234,2,REC-5000759326,,,,"<CLINICAL INFO>
Right breast ductal carcinoma in situ
<GROSS>
     1.     Received fresh, labeled **NAME[BBB, AAA], #1, is an oriented, 12.5 x 7.5 x 4.0 cm, fibrous and fatty portion of tissue with a long suture marking lateral and a short suture marking superior.  There is an overlying portion of skin, 5.8 x 1.2 cm.  A specimen radiograph is performed, and a metallic marker and calcifications are present within the specimen.  The margins are inked as follows:  anterior = blue; posterior = black; superior = yellow; inferior = red; medial = green; lateral = orange.  The specimen is serially sectioned perpendicular to the inferior to superior axis into 12 slices.  In slices 5-8 are clustered areas of calcifications.  In slice 7 is a disrupted, coiled HydroMARK clip 0.8 cm to the closest anterior margin and well-excised by all other margins.  Most of the specimen consists of yellow-tan, lobulated adipose tissue with very little fibrous tissue.  No discrete mass is noted.  SECTIONS:  A1-A44 = representative sections as follows:  A1 and A2 = microcalcifications, slice 5; A3-A10 = representative majority of remaining slice 5; A11-A13 = microcalcifications, slice 6; A14-A18 = majority of remaining slice 6; A19 and A20 = microcalcifications and HydroMARK clip; A21-A29 = majority of remaining slice 7; A30 and A31 = microcalcifications, slice 8; A32-A37 = majority of remaining slice 8; A38-A40 = specimen adjacent to area of microcalcifications, representatively sampled, slice 4; A41 and A42 = representative section immediately adjacent to area of calcification, slice 9; A43 = representative perpendicular sections inferior margin; A44 = representative perpendicular sections superior margin, slice 12.  The specimen is placed in formalin at approximately 1440 on **DATE[Jan 06 12] for a total fixation time of 29 hours, 15 minutes; A45 and A46 = additional section, slice 2; A47 and A48 = additional section, slice 3; A49-A51 = additional section, slice 4; A52-A54 = additional section, slice 5; A55-A57 = additional section, slice 6; A58-A60 = additional section, slice 7; A61-A63 = additional section, slice 8; A64-A66 = additional section, slice 9; A67 and A68 = additional section, slice 10; A69 and A70 = additional section, slice 11.
     2.      Received in formalin, labeled **NAME[BBB, AAA], #2, right breast tissue reexcision anterior margin, is an oriented reexcision of mostly fatty tissue, 4.0 x 2.5 x 1.2 cm, with a short suture marking superior, a long suture marking lateral, and a double suture marking the new anterior margin.  The new margins are inked as follows:  superior = yellow; inferior = red; medial = green; lateral = orange; anterior = blue.  The surface opposite the new margin is marked with black ink and is not a true margin.  The specimen is serially sectioned perpendicular to the superior to inferior axis.  The specimen consists of yellow-tan adipose tissue without residual tumor.  SECTIONS:  B1-B6 = in total, proceeding from superior to inferior, as follows:  B1 = perpendicular sections, superior margin; B2-B5 = entire body; B6 = perpendicular sections, inferior margin.  Specimen is placed in formalin at 1535 on **DATE[Jan 06 12] for a total fixation time of 28 hours, 30 minutes.


<MICROSCOPIC SECTION>
BREAST MARKER STUDIES BY IMMUNOHISTOCHEMISTRY:
ER, PR and HER2 assessment by immunohistochemistry (IHC) are performed in this laboratory in accordance with guidelines issued by the American Society of Clinical Oncologists-College of American Pathologists (ASCO-ASCP) (Wolff et al., J Clin Oncol 2007;**ID-NUM; **PLACE et al. J Clin Oncol 2010;**ID-NUM).
All specimens are fixed in 10% neutral buffered formalin.  See gross description for cold ischemic time and fixation time for the specimen.  Formalin-fixed paraffin-embedded tissue sections are deparaffinized and incubated with the following validated antibodies: Biocare medical clone SP1, a rabbit monoclonal anti-ER antibody; Dako clone PgR 636, a mouse monoclonal anti-PR antibody; and Dako polyclonal antibody Cerb A0485, a rabbit polyclonal anti-HER2 antibody.  Detection:  a highly sensitive, biotin-free, polymer-based immunoperoxidase technique is employed according to an optimized protocol (Envision Plus HRP, Dako).  Controls:  for ER, PR and HER2, external controls are reviewed for appropriate positive and negative immunoreactivity and fount to be satisfactory.
Scoring results:  For ER and PR, a cutoff of 1% positive tumor cells, as determined by semiquantitative assessment, is employed for determination of assay results.  For HER2, results are scored as follows:  Negative for overexpression:  no membrane staining (0) or weak/incomplete membrane staining in any proportion of tumor cells (1+); Equivocal for protein expression: complete membrane staining that, either nonuniform or weak in intensity but with obvious circumferential distribution in at least 10% of tumor cells, or intense, complete membrane staining of 30% or fewer tumor cells (2+).
Fluorescence in-situ hybridization (FISH) for the HER2 gene is performed on all of these cases scored as 2+.  Positive for protein expression:  uniform intense membrane staining of >30% of invasive tumor cells (3+).
Quality assurance:  **INSTITUTION Department of Pathology has in place quality assurance programs for ER, PR and HER2, in accordance with ASCO-CAP guidelines.  This includes case review by Pathologists dedicated to interpreting these marker studies and ongoing concordance studies within the Virginia Mason Laboratory as well as external validation with a reference laboratory (**PLACE, WA).

<FINAL DX>
     
     1.     RIGHT BREAST TISSUE:
     Invasive ductal carcinoma, histologic grade II.
     A.     Tumor size:  two foci: 2.5 mm (block A34) and 1.5mm (block A63).
     B.     Nuclear grade:  Intermediate.
     C.     Mitotic rate:  Low.
     D.     Tubule formation:  None.
     E.     Ductal carcinoma in situ:  Extensively present on slides of 22 tissue blocks spanning tissue slices 4-9 (an area of approximately 6.2 cm).  Ductal carcinoma in situ is of high nuclear grade with central necrosis.
     F.     Calcifications:  Present in ductal carcinoma in situ and focally in benign breast tissue.
     G.     Intramammary lymphatic space invasion:  Not identified.
     H.     Resection margins:  
               i.     Invasive carcinoma:  1.5mm from the medial/green margin (block A63).  Remaining margins are negative by greater than 10 mm for invasive carcinoma.
          ii.     Ductal carcinoma in situ:  Present less than 0.5 mm from the medial/green margin (see comments).  Remaining margins are negative by greater than 10 mm for ductal carcinoma in situ.
          I.     Estrogen receptor status:  Positive (% tumor cells staining:  greater than 95%, staining intensity:  strong).
     J.     Progesterone receptor status:  Positive (% tumor cells staining:  90%; staining intensity:  moderate to strong).
     K.     HER2 status:  Negative for protein expression by immunohistochemistry (0).
     L.     Axillary lymph node status:  None submitted.
     M.     Pathologic stage:  T1a NX.
2.     RIGHT BREAST TISSUE, REEXCISION OF ANTERIOR MARGIN:
     Benign breast tissue and fibroadipose tissue.

Ductal carcinoma in situ is present less than 0.5 mm focally from the medial/green margin on blocks A5 and A63.  A cauterized ductal space highly suspicious for ductal carcinoma in situ is present microns from the medial/green margin on block A14.  Ductal carcinoma in situ is also present 1.8 mm from the medial/green margin on block A21.  
The diagnosis of invasive carcinoma on slides from block A34 is supported by the absence of immunostaining for smooth muscle myosin heavy chain (SMM) and p63 surrounding the nests of carcinoma.  






<SPECIMEN(S)>
Breast excision, oriented
<SPECIMEN(S)>
Breast excision, oriented",,,,,
REG3,BREAST,0,PAT-00748535,1,REC-5000759989,,,,"CASE: NS-11-19727
PATIENT: **NAME[AAA BBB]

<COMMENT>
Prognostic indicator studies will be performed.  Results will be promptly submitted as an amended report.
**NAME[XXX] in Dr. **NAME[ZZZ YYY]'s office was verbally notified of the **NAME[WWW] final diagnosis on Wednesday, **DATE[May 21 2012] at 11:25 a.m.
**NAME[M. VVV UUU], MD
Pathologist
**INITIALS **DATE[May 21 12]


<GROSS>
One specimen is received in a container of formalin labeled **NAME[M. BBB] and designated ""left breast.""  The specimen consists of unoriented elliptical excision of gray skin measuring 1.3 x 0.5 x 0.7 cm.  Located on the skin surface is a gray-pale purple lesion measuring 0.4 x 0.3 cm.  The margin is inked green and the specimen is serially sectioned.  Sectioning reveals a gray homogenous inner cut surface.  The entire specimen is submitted in one cassette.  (**INITIALS **DATE[May 20 12])


<MICROSCOPIC>
The serially-sectioned skin wedge biopsy demonstrates a solid and diffuse proliferation of malignant epithelial cells involving deep dermal tissue.  No dermal lymphatic invasion or Paget's disease is apparent.  Malignant cells are characterized by moderate-marked variation in nuclear size and shape with large nucleoli, increased chromatin and diminished amphophilic cytoplasm.  A moderate mitotic rate is noted.  Foam cells are intimately distributed throughout viable invasive tumor.  Small foci of coagulation necrosis are noted.  No vascular invasion or intraductal carcinoma is apparent.
**NAME[VVV UUU], MD
Pathologist
Electronically signed **DATE[May 21 2012] 11:49:17AM


<FINAL DX>
Left breast, wedge biopsy:  Invasive carcinoma with contiguous involvement of deep dermis.
     A.  Histologic type:  Invasive duct carcinoma.
     B.  Histologic grade (Nottingham):  Poorly differentiated.
          1.  Nuclear grade:  Intermediate-high (score 3 of 3).
          2.  Mitotic rate:  Intermediate (score 2 of 3).
          3.  Tubule formation:  Low (score 3 of 3).
          4.  Composite score:  8 of 9.
     C.  One of one wedge biopsy fragments involved by carcinoma.
     D.  Greatest length of carcinoma in a single fragment:  5 mm.
     E.  Vascular space invasion:  Not identified.
     F.  Mammographic correlation:  Unknown.
     G.  Intraductal component:  Not identified.
     H.  Prognostic indicators:  Pending.
     I.  Additional findings:
          1.  Negative for dermal lymphatic invasion.
          2.  Negative for Paget's disease.


<CLINICAL INFO>
Advanced left breast cancer.  174.",,,,,
REG3,BREAST,0,PAT-00747326,1,REC-5000764514,,,,"Left breast cancer.



   LEFT SIMPLE MASTECTOMY:  INVASIVE CARCINOMA OF THE BREAST WITH THE FOLLOWING FEATURES;

        1.  SPECIMEN:  TOTAL BREAST INCLUDING NIPPLE AND SKIN AND SMALL AXILLARY TAIL.

        2.  PROCEDURE:  TOTAL MASTECTOMY.

        3.  LYMPH NODE SAMPLING:  PARTIAL AXILLARY DISSECTION.

        4.  SPECIMEN INTEGRITY:  SINGLE INTACT SPECIMEN (MARGINS CAN BE EVALUATED).

        5.  SPECIMEN SIZE:  17 X 19 X 3.5 CM.

        6.  SPECIMEN LATERALITY:  LEFT.

        7.  TUMOR SITE:  CENTRAL.

        8.  TUMOR SIZE:  1.7 CM (READ OFF HISTOLOGIC SLIDE 12).

        9.  TUMOR FOCALITY:  MULTIPLE FOCI OF INVASIVE CARCINOMA.

       10. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR.

            a.  SKIN:  NEGATIVE FOR CARCINOMA.

            b.  NIPPLE:  NEGATIVE FOR CARCINOMA.

            c.  SKELETAL MUSCLE:  NEGATIVE FOR CARCINOMA.

            d.  SCATTERED MICROSCOPIC FOCI OF INVASIVE LOBULAR CARCINOMA (1.7 CM LARGEST DIMENSION), LOBULAR CARCINOMA IN SITU, AND DUCTAL CARCINOMA IN SITU (SOLID AND MICROPAPILLARY GROWTH PATTERNS) ARE DISTRIBUTED AROUND THE PREVIOUS BIOPSY SITE.

   e.  SIZE OF DCIS AND LCIS CAN NOT BE DETERMINED BECAUSE OF WIDELY SCATTERED NATURE OF FOCI.

       11. HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  INVASIVE LOBULAR CARCINOMA.

       12. HISTOLOGIC GRADE:  BLOOM-RICHARDSON SCORE 6/9, NOTTINGHAM GRADE 2 (TUBULE FORMATION - 3, NUCLEAR PLEOMORPHISM - 2, MITOTIC RATE - 1).

       13. SURGICAL MARGINS:

             a.  ALL SURGICAL MARGINS ARE NEGATIVE FOR INVASIVE AND IN SITU CARCINOMAS.

             b.  DISTANCE TO CLOSEST MARGIN CAN NOT BE DETERMINED BECAUSE ALL SECTIONS OF SURGICAL MARGINS DO NOT CONTAIN CARCINOMA AND CARCINOMA CAN NOT BE DISCERNED GROSSLY.

       14.  LYMPH NODES:  FOUR AXILLARY LYMPH NODES INCLUDED WITH SPECIMEN ARE NEGATIVE FOR CARCINOMA (0/4).

       15.  PATHOLOGIC STAGING:  pT1c, pN1a, (STAGE IIA)  (SEE COMMENT).

       16.  ANCILLARY STUDIES:  ER, PR AND HER2 IMMUNOSTAINS WERE PERFORMED ON THE PREVIOUS LUMPECTOMY SPECIMEN (11S-3056) AND ARE ER - POSITIVE, PR - NEGATIVE,  HER2 - NEGATIVE.





   Please see also the previous breast biopsy and lumpectomy reports (11S-2634 and 11S-3056)

          













   .

   The staging is an attempt to combine the information from the lumpectomy and the mastectomy

   specimens. The exact size of the various carcinomas is difficult to determine because of

   their diffuse and multifocal distribution, but the stage is based on a maximum dimension of

   1.7 cm read off the histologic slides(s)..  The previous lumpectomy specimen (11S-3056) had

   one positive sentinel lymph node, and 1 out of 3 positive axillary lymph nodes (total 2/4).

   This mastectomy specimen has 4 lymph nodes, all negative for carcinoma (even on pankeratin

   immunostain, there was a small suspicious focus that proved negative on immunostain) (0/4).

   Total lymph node count for this patient is **AGE[birth-12] out of 8 lymph nodes positive for carcinoma

  (2/8), which is pN1a.  Dr. **NAME[ZZZ] was telephoned with a brief discussion of the findings on **DATE[Oct 15 11].





   The left simple mastectomy specimen measures 17 cm superior to inferior, 19 cm medial to

   lateral, and up to 3.5 cm thick centrally.  The inferior half of the superficial surface is

   covered by a 17 x 8 cm skin ellipse with a central 3.5 cm areola and normal 1 cm nipple.

   1.5 cm superior medial from the nipple there is an oblique longitudinal partially healed

   scar 3 cm long running from approximately 9:30 to the 12 o'clock position at the edge of the

   areola.  The superior superficial surgical margin is grossly unremarkable fat and extends up

   to 9 cm superior to the superior edge of the ellipse.  The inferior surgical margin is

   unremarkable fat.  The deep surface is a transected fascial plane with bits of attached

   skeletal muscle.  The superior superficial margin is inked blue, inferior superficial margin

   green and the deep surface black.  Bread loafing reveals a 5 cm seroma  lined by pink tan

   granulation tissue in the central and medial portions of the breast directly underneath the

   skin incision.  The specimen is fixed over night.  Sections are submitted as follows:

   cassette ""1"" nipple and and healing skin incision, cassette ""2"" healing skin incision,

   cassette ""3"" margins deep to seroma, cassette ""4"" margins deep to seroma, cassette ""5""

   closest superior superficial margin, cassette ""6"" closest superficial inferior margin,

   cassettes ""3"" through ""13"" specimens from around seroma.  A 4 x 1 x 0.3 cm portion of fat

   attached in the direction of the axillary tail contains three lymph nodes.  They are

   differentially inked,  bisected and submitted in cassettes ""14"" and ""15"".  Additional

   sections from around seroma are submitted in cassettes 16 and 17.  Random sections away from

          













   the seroma are submitted: 18 - upper outer quadrant, 19 - lower outer quadrant, 20 - upper inner quadrant, and 21 - lower inner quadrant.",,,,,
REG3,BREAST,0,PAT-00746323,1,REC-5000765279,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Breast, Right, Wire-Localized Excision for a Mass:
Infiltrating carcinoma with the following features:
Histologic type:    Ductal.
Size:     0.9 x 0.9 x 0.7 cm.
Histologic grade:   2 of 3.
Nottingham grade:   7 of 9.
Tubule formation:   3 (of 3).
Nuclear grade: 2 (of 3).
Mitotic rate:  2 (of 3).
Lymph-vascular invasion: Not identified.
Ductal carcinoma in situ (DCIS) with the following features:
Histologic type:    Solid and cribriform.
Nuclear grade: Intermediate.
Necrosis: Present.
Calcifications:     Present.
Estimated size/extent of DCIS:     Present associated with the main
tumor spanning up to 0.9 cm, EIC (extensive intraductal component)
negative.
Surgical margins:
Infiltrating carcinoma:
Anterior (superficial):  Negative (>5 mm from margin).
Posterior (deep):   Negative (>5 mm from margin).
Superior: Negative (>5 mm from margin).
Inferior: Negative (>5 mm from margin.
Medial:   Negative (>5 mm from margin).
Lateral:  Negative (>5 mm from margin).
Ductal carcinoma in situ:
Anterior (superficial):  Negative (>5 mm from margin).
Posterior (deep):   Negative (>5 mm from margin).
Superior: Negative (>5 mm from margin).
Inferior: Negative (>5 mm from margin).
Medial:   Negative (>5 mm from margin).
Lateral:  Negative (>5 mm from margin).
Lymph nodes:
Total number of nodes identified in part A:  Zero.
Summary of lymph node status (including all lymph nodes from part(s) B,
C, and D:
Total number of lymph nodes identified:  Three.
Lymph nodes positive for metastatic carcinoma:    Zero, (i-).
Pathologic stage:   pT1b (AJCC 7th edition).
          pN0(sn)(i-) (AJCC 7th edition).
Additional findings:
Immunohistochemistry staining for estrogen and progesterone receptor
expression and HER-2/neu overexpression have previously been performed
(***PATH-NUMBER[2]), with the following results:  ER 100% of tumor cells
positive, PR 95% of tumor cells positive, HER-2/neu 1+, negative for
overexpression.
Atypical ductal hyperplasia.
Intraductal papilloma.
Sclerosing adenosis and other fibrocystic changes including usual ductal
hyperplasia.
Calcifications associated with benign epithelium.
Biopsy site changes.
Skin and skeletal muscle are not identified within the specimen.

B.  Sentinel Lymph Node, Right, Hot and Blue 48 counts per second,
Biopsy:
Number of lymph nodes identified:  One.
Number of lymph nodes positive for metastatic carcinoma:  Zero.
Immunohistochemical staining for pankeratin was performed in evaluation
of the specimen.

C.  Lymph Node, Right Axilla, Nonsentinel, Biopsy:
Mature fibroadipose tissue.
No lymph node tissue is identified.

D.  Sentinel Lymph Node, Right Axilla, Hot and Blue, 182 counts per
second, Biopsy:
Number of lymph nodes identified:  One.
Number of lymph nodes positive for metastatic carcinoma:  Zero.
Immunohistochemical staining for pankeratin was performed in evaluation
of the specimen.

E.  Breast, Right, Additional Anterior-Inferior Medial Excision:
Atypical ductal hyperplasia.
Flat epithelial atypia.
Sclerosing adenosis and usual ductal hyperplasia.

<CLINICAL INFO>
Right breast mass. Collection date: **DATE[Jul 27 2012] at 6:15 PM. Total
fixation time of 21 hours and 15 minutes. ICD9 Code(s): 174.2.

<GROSS>
A. Received fresh, labeled ""**NAME[BBB, AAA M]"" and designated ""right
needle localized breast mass"", is an oriented breast specimen with two
sutures designated as ""short - superior and long - lateral"". The
localizing wire is protruding from the superficial surface. The specimen
is accompanied by a specimen radiograph with an attached note by the
reviewing radiologist Dr. **NAME[ZZZ] stating that ""the targeted mass and clip
are included in the specimen radiograph at coordinate 6D"". It has
dimensions as follows: 8 cm superficial-deep x 6.5 cm medial-lateral x
2.1 cm superior-inferior, in its compressed state. It is inked as
follows: deep - black, superficial - blue, medial - red, lateral -
yellow, superior - orange, inferior - green. It is sectioned from
superficial to deep into 18 cross-sectional slices, numbered
respectively. The cut surfaces are 10% fibrous and 90% fatty. Slices 6-8
have a 0.9 x 0.9 x 0.7 cm ill-defined, firm, white nodule which is 0.3
cm from the inferior margin, 0.6 cm from the superior margin, 0.9 cm
from the lateral margin; and greater than 2 cm from all other margins.
It correlates with the coordinate listed on the attached note from the
reviewing radiologist. The biopsy clip is found within the nodule in
slice 7. No other discrete tumors or nodules are identified.
Representative sections are submitted as follows: A1- perpendicular
sections of slice 1 superficial aspect; A2-A3- slice 3; A4-A5- slice 5;
A6- the lateral third of slice 6; A7-A9- slice 7; A10- the lateral third
of slice 8 (A6-A7 and A10 contain the entire nodule); A11- the lateral
third of slice 9; A12-A14- slice 10; A15-A17- slice 13; A18-A20- slice
16; A21- perpendicular sections from the middle slice 18 deep aspect.
Please note all composite sections are submitted lateral to medial.

B. Received in formalin, labeled ""**NAME[BBB, AAA M]"", and designated
""right sentinel lymph node hot and blue, 488 cnt"", is a 2 x 1.5 x 1.3 cm
piece of fatty tissue containing a 0.6 cm lymph node with faint blue
discoloration. It is bisected and entirely submitted with the remaining
fatty tissue in B1.

C. Received in formalin, labeled ""**NAME[BBB, AAA M]"", and designated
""right axillary non sentinel node"", is a 1.6 x 1.1 x 0.5 cm piece of
fatty tissue without an obvious lymph node. The tissue is entirely
submitted in C1.

D. Received in formalin, labeled ""**NAME[BBB, AAA M]"", and designated
""right axilla sentinel node hot and blue, 182 cnt"", is a 1.2 x 0.7 x 0.6
cm piece of fatty tissue with a central 0.5 cm blue lymph node. The
tissue is bisected and entirely submitted in D1.

E. Received in formalin, labeled ""**NAME[BBB, AAA M]"" and designated
""additional anterior, inferior, medial right breast margins"", is an
oriented breast specimen with two sutures and clips designated as ""short
- superior, long - lateral, and clips - marks new margins"". It has
dimensions as follows: 7 cm medial-lateral x 5 cm superior-inferior x
1.5 cm anterior-posterior. It is inked as follows: posterior - black,
anterior - blue, medial - red, lateral - yellow, superior - orange,
inferior - green. It is sectioned from medial to lateral into 18
cross-sectional slices, numbered respectively. The cut surfaces are 10%
fibrous and 90% fatty. No discrete tumors or nodules are identified.
Representative sections are submitted as follows: E1- perpendicular
sections from the middle of slice 1 medial aspect; E2- slice 3; E3-E4-
slice 7; E5-E6- slice 9; E7- the superior half of slice 10; E8- the
superior half of slice 11; E9-E10- slice 12; E11- slice 15; E12-
perpendicular sections from the middle of slice 18 lateral aspect.
(kjh/dg)

    The following day, additional representative sections are submitted
as follows: E13 - the inferior half of slice 10; E14 - inferior half of
slice 11; E15 - inferior half of slice 13; E16 - inferior half of slice
14. (kjh/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A7

Antibody  Result    Comment
E-Cadherin     Positive

Block A10

Antibody  Result    Comment
p63  Positive
Calponin  Positiv

Block A16

Antibody  Result    Comment
p63  Positive
Calponin  Positive

Block B1

Antibody  Result    Comment
Pan CK    Negative

Block D1

Antibody  Result    Comment
Pan CK    Negative

Block E10

Antibody  Result    Comment
CK 5/6    Positive

Impression:  E-cadherin staining is positive in invasive carcinoma,
supporting a ductal phenotype.  p63 and calponin staining are positive
in myoepithelial cells in the foci in question, supporting a benign
diagnosis.  Pan-keratin staining is negative in the sentinel lymph
nodes.  CK5/6 staining is partially present in the focus of atypical
ductal hyperplasia in part E.
Interpreted by:  **NAME[YYY M XXX] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
CellNetix pathologist Dr. **NAME[M. WWW] reviewed selected slides of part E
(E10 and IHC stain) and concurs with a diagnosis of atypical ductal
hyperplasia in that focus.

**NAME[YYY M XXX], M.D.  Electronically signed **DATE[Jul 30 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,BREAST,0,PAT-00730277,2,REC-5000765340,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A. Breast, Right, 10 o'clock, Ultrasound-Guided Core Needle Biopsy for a
Mass:
     Infiltrating carcinoma with the following features:
             Histologic type:           Ductal.
             Histologic grade:               Intermediate.
             Nottingham grade:               6 of 9.
                Tubule formation:            3 of 3.
                Nuclear grade:               2 of 3.
                Mitotic rate:           1 of 3.
             Lymph-vascular space invasion:  Not identified.
     Ductal carcinoma in situ (DCIS):        Present.
             Histologic type:           Solid.
             Nuclear grade:             Intermediate, without necrosis
but with associated calcifications.
     Additional findings:               Immunohistochemical studies for
HER-2/neu will be performed and reported in an addendum.

B. Axilla, Right, Ultrasound-Guided Core Needle Biopsy of Lymph Node:
     Metastatic ductal adenocarcinoma involving lymph node tissue.
     Lymphovascular invasion is also present.

<COMMENT>
The tumor in parts A and B are morphologically similar.  The tumor in
part B involves a lymph node.

<CLINICAL INFO>
1. Right breast, lesion mass, BIRADS 5 10 o'clock, UCB needle core,
14-gauge 4 cores. Highly suspicious mass. 2. Right breast, lesion, LN,
BIRADS 5 axilla, UCB needle core, 14-gauage, 1 core. Moderately
suspicious LN  Collection date: **DATE[Jul 29 2012] at 8:30 AM (specimen 1) and
8:45 AM (specimen 2). Total fixation time: 10 hours (specimen 1); 9
hours 45 minutes (specimen 2).

<GROSS>
A.  Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""right 10
o'clock"" per specimen container and ""right breast, mass, BIRADS 5, 10
o'clock, UCB"" per requisition, are four 0.2 cm diameter, elongated
portions of fibrofatty tissue, 0.5-1.5 cm in lengths and a 0.4 x 3 x 0.2
cm aggregate of clotted blood; entirely submitted in A1.

B.  Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""right
axilla"" per specimen container and ""right breast, LN, BIRADS 5, axilla,
UCB"" per requisition, is a 0.2 cm diameter, elongated portion of
fibrofatty tissue, 1.5 cm in length; entirely submitted in B1.
(jws/jkb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
p63  Focally positive
D2-40     Focally positive
Calponin  Focally positive

Block B1

Antibody  Result    Comment
p63  Negative
Calponin  Negative

Impression:  p63 and calponin expression are present in myoepithelial
cells underlying ductal carcinoma in situ in part A.  No myoepithelial
cell layer is present in part B.  D2-40 highlights lymphatics in part A,
but no lymphovascular invasion is identified.
Interpreted by:  **NAME[ZZZ M YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block A1

Antibody  Result    Comment
ERsq 98 % of tumor cells positive,            strong nuclear staining.

PRsq 95 % of tumor cells positive,            strong nuclear staining.

Interpreted by:  **NAME[ZZZ M YYY] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
CellNetix pathologist Dr. **NAME[M. XXX] also reviewed this case and concurs.

**NAME[ZZZ M YYY], M.D.  Electronically signed **DATE[Jul 30 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,BREAST,0,PAT-00335758,3,REC-5000766794,,,,"<CLINICAL INFO>
 History of breast cancer.  Per MINDscape:  Invasive
  ductal carcinoma.<FINAL DX>
 A) Designated, ""left breast explant"", removal:
  Tissue expander; gross only.
  B) Right breast, excision:
  1. Lobular carcinoma in situ involving sclerosing adenosis.
  2. Focal atypical ductal hyperplasia.
  3. Cystic and papillary apocrine metaplasia and associated
  microcalcifications.
  4. No invasive carcinoma identified.
  5. Reactive lymph node; no metastatic carcinoma identified.
  C) Left breast, excision: Fat necrosis and foreign-body giant cell reaction;
  no atypical hyperplasia, in situ, or invasive carcinoma identified.
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received unfixed designated ""left breast
  explant for disposal"" is a 16 x 10.5 x 2 cm deflated tissue expander.  There
  is a 4 cm defect in the side of the expander.  The markings on the back side
  say ""MENTOR"" and possibly ""LH, 550 cc"".  There are additional numbers, but
  they are illegible.  A photograph is taken and the specimen is reviewed by Dr.
  **NAME[ZZZ YYY].  (**INITIALS)
  B) Received unfixed designated ""right breast tissue"" is a 394 g, 15 x 12 x 6
  cm aggregate of breast tissue with multiple pieces.  Two pieces contain pale
  tan, wrinkled skin measuring 18 x 5 cm and 3 x 2 cm.  Specimen is serially
  sectioned revealing mostly tan-yellow, lobular fatty tissue with minimal
  fibrous breast tissue.  There is a 1 x 0.5 cm area of possible cysts with dark
  brown-green material focally.  Representative sections are submitted as
  follows:  B1 - skin and possible intraparenchymal lymph node; B2-B3 -
  additional representative sections of breast tissue.  (**INITIALS)
  C) Received in formalin designated ""left breast tissue"" is a 2 x 1.5 x 1.5 cm
  round, unoriented piece of tissue which has minimal amount of pale tan fat
  attached.  Cut sections show yellow, lobular architecture most likely
  representing fat necrosis.  Representative sections are submitted in one
  cassette.  (**INITIALS)",,,,,
REG3,BREAST,0,PAT-00749325,1,REC-5000767065,,,,"<CLINICAL INFO>
 **AGE[in 60s]-year-old female with left breast calcifications
  at 7 o'clock.  Per Mindscape: three clusters of coarse heterogeneous
  calcifications at 7 o'clock.<FINAL DX>
 A) Left breast, 7 o'clock posterior, stereotactic
  core needle biopsy:  Ductal carcinoma in-situ with the following features:
  1. Nuclear grade: intermediate
  2. Necrosis: present, central comedo-type
  3. Microcalcifications: present in association with DCIS
  4. No invasion identified by smooth muscle heavy chain stain.
  B) Left breast, 7 o'clock adjacent tissue posterior, stereotactic core needle
  biopsy:
  1. Calcifications present in association with benign stroma.
  2. No definitive evidence of atypical hyperplasia, in situ, or invasive
  carcinoma.
  C) Left breast, 7 o'clock anterior, stereotactic core needle biopsy:  Ductal
  carcinoma in-situ with the following features:
  1. Nuclear grade: intermediate
  2. Necrosis: present, central comedo-type
  3. Microcalcifications: present in association with DCIS and in benign stroma
  4. No invasion identified by smooth muscle heavy chain stain.
  5. Estrogen receptor status: Negative (**NAME[ZZZ] score 0 of 8).<DIAGNOSIS COMMENT(S)> Because of the common histologic features of this in-situ
  neoplasm in both the anterior (C) and posterior (A) samples at 7 o'clock, only
  the anterior biopsy was assessed for estrogen receptor protein content.  No
  (micro)invasive disease was identified in either sample using
  immunohistochemical analyses for smooth muscle myosin heavy chain.  Both block
  C1 and C2 were analyzed to ensure that this architecturally complex in-situ
  lesion was evaluated appropriately.
  Procedures used to establish the diagnosis:
  Routine<PROCEDURE INTERP>
IMMUNOHISTOCHEMISTRY REPORT:
  (Interpreted by: **NAME[YYY XXX WWW] VVV], PhD and **NAME[UUU M. TTT] MD)
  Formalin-fixed, deparaffinized sections are incubated with the following panel
  of monoclonal and/or polyclonal antibodies. Localization is via an avidin
  biotin or streptavidin biotin immunoperoxidase method, with or without the use
  of heat induced epitope retrieval techniques.  Results on the population(s) of
  interest are as indicated in the table(s) below.
  Block (Original Label): A1
  Population: Neoplastic cells

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  No loss of expression
  Block (Original Label): C1
  Population: Neoplastic cells

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  No loss of expression
  ER Estrogen Receptor [SP1]  Negative
  Block (Original Label): C2
  Population: Neoplastic cells

  Label Marker For  Results Special Pattern or Comments
  SMHC Smooth Muscle Myosin Heavy Chain [SMMS-1]  No loss of expression<GROSS>
 A) Received in formalin labeled ""**NAME[BBB, AAA],
  left 7 o'clock calcs posterior"" are multiple tan-yellow cores and core-like
  fragments of fibroadipose ranging from 0.2 to 3.0 cm in length.  The larger
  specimens are sectioned.  The specimen is wrapped, inked green and entirely
  submitted in cassettes A1-A4.  (**INITIALS)
  B) Received in formalin labeled ""**NAME[BBB, AAA], left 7 o'clock posterior
  adjacent tissue"" are multiple yellow-brown core-like fragments of fibroadipose
  tissue ranging from 0.1 to 0.4 cm in greatest dimension.  The specimen is
  wrapped, inked yellow and entirely submitted in cassette B1.  (**INITIALS)
  C) Received in formalin labeled ""**NAME[BBB, AAA], left 7 o'clock anterior calcs""
  are multiple yellow-brown cores and core-like fragments of soft tissue ranging
  from 0.2 to 2.4 cm in length.  The specimen is wrapped, not inked, touched
  with hematoxylin and entirely submitted in cassettes C1-C3.  (**INITIALS)NOTE:   The performance characteristics of all immunohistochemical
  stains cited in this report were determined by the Immunohistochemistry
  Laboratory at the **INSTITUTION, as part of an ongoing quality assurance program and in compliance
  with federally mandated regulations drawn from the Clinical Laboratory
  Improvement Amendments of 1988 (CLIA  88).  Some of these tests rely on the
  use of ""analyte specific reagents"" and are subject to specific labeling
  requirements by the US Food and Drug Administration.  Such diagnostic tests
  may only be performed in a facility that is certified by the Centers for
  Medicare and Medicaid Services (formerly HCFA) as a high complexity laboratory
  under CLIA  88.  These tests need not be cleared or approved by the FDA prior
  to their use.  Nevertheless, federal rules concerning the medical use of
  analyte specific reagents require that the following disclaimer be attached to
  this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.",,,,,
REG3,BREAST,0,PAT-00749073,1,REC-5000767371,,,,"**NAME[ZZZ,YYY M] MD

   **NAME[XXX,WWW] MD

   Highline Diagnostics at 160th









Right breast lump.



FISH RESULT:  NEGATIVE FOR AMPLIFICATION OF HER2 NEU.



Her2 FISH assay was performed at LabCorp.  Please see their report dated **DATE[Aug 1 12].





















































          













The  tissue block  of this patient's breast carcinoma is submitted for Estrogen and

Progesterone Receptors and Her 2 Oncogene expression via Immunohistochemistry.  Positive and

Negative controls stain appropriately.  Results are as follows:



     ESTROGEN RECEPTOR:     0% OF TUMOR CELLS STAIN POSITIVE.



     PROGESTERONE RECEPTOR:  < 5% OF TUMOR CELLS STAIN WEAKLY POSITIVE.



     HER 2 RESULTS:          10% OF THE INVASIVE TUMOR CELLS EXHIBIT WEAK INCOMPLETE MEMBRANE STAINING AND OTHER DIFFERENT FOCI COMPRISING 2% OF THE BIOPSY MATERIAL EXHIBIT STRONG, COMPLETE MEMBRANE STAINING.



HER 2 INTERPRETATION:  EQUIVOCAL  FOR HER 2 PROTEIN EXPRESSION.



(FISH ANALYSIS FOR HER2 AMPLIFICATION WILL BE PERFORMED AND REPORT APPENDED)



TIME TO FIXATION :  5

DURATION OF FIXATION:  8 hrs



""Note:  Some of the immunostains reported here may have been developed and performance

characteristics determined by LabCorp histology lab in **PLACE, WA.  They have not been

cleared or approved by the U.S. Food and Drug Administration (FDA).  However, the FDA has

determined that such clearance and approval is not necessary.  Pursuant to the requirements

of CLIA, LabCorp has established and verified the accuracy and precision of all tests.  The

Her 2 test from DAKO uses an affinity purified rabbit anti-human Her 2 antibody.



Additional information is available on request.""

































          













   

   CORE BIOPSIES OF RIGHT BREAST LUMP:

        1.  INFILTRATING DUCTAL CARCINOMA.

        2.  BLOOM-RICHARDSON SCORE 8/9, NOTTINGHAM GRADE III (TUBULE FORMATION - 3, NUCLEI - 2, MITOSES - 3 (23 MITOTIC FIGURES PER 10 HIGH POWER FIELDS)).

        3.  ER/PR AND HER2 STUDIES PENDING.





   This case was seen in consultation with Dr. **NAME[VVV].  The

   diagnosis was telephoned to Dr. **NAME[UUU] for Dr. **NAME[ZZZ] at

   10:30 AM  on **DATE[Jul 21 12].





   Four core fragments of firm gray tissue are each 2 mm in

   diameter and range from 3 - 8 mm long.

   Submitted entirely.",,,,,
REG3,BREAST,0,PAT-00616894,1,REC-5000768859,,,,"**STREET-ADDRESS NE
**PLACE, WA **ZIP-CODE
REPORT
HER2 FLUORESCENCE IN SITU HYBRIDIZATION REPORT
<FINAL DX>
**INSTITUTION **INSTITUTION ***PATH-NUMBER[1], A 
Right breast, 10:00: Infiltrating carcinoma
NEGATIVE for HER2 gene amplification by FISH
***PATH-NUMBER[1], A (Procedure Date: **DATE[Dec 25 2011]) 
HER2:CEP17 Ratio      1.3 
Number of nuclei counted:     80     
HER2 (SpectrumOrange)     1.6 mean signals per nuclei
CEP17 (SpectrumGreen)     1.3 mean signals per nuclei
MATERIAL RECEIVED
A1 = ***PATH-NUMBER[1], A, 1 Block (**DATE[Dec 30 2011])
Fixative: Formalin
Duration of fixation >6 and <48 hours?: YES
CLIENT REQUEST/CLINICAL HISTORY
HER2 by FISH (if equivocal, IHC will be performed); invasive mammary
carcinoma
METHODOLOGY
HER2 FISH testing is performed according to ASCO-CAP guidelines (Wolff AC et
al., J Clin Oncol 25:**PHONE). Methods: Deparaffinized sections of tissue,
following pretreatment, are incubated with PathVysion    HER2 probe kit (**NAME[ZZZ]
**PLACE, IL) containing 2 separate probes: a locus-specific HER2
gene probe (17p11.2-q12 ) and a reference chromosome 17 centromere probe
(CEP17; 17p11.1-q11.1). Morphometric image analysis is performed using a
MetaSystems    platform and Metafer 4    application software. The HER2 and CEP17
signals are counted per tile/nucleus and the HER2:CEP17 ratio is calculated.
FISH Scoring: Results are scored as positive (HER2:CEP17 ratio > 2.2),
negative (HER2:CEP17 ratio <1.8), or equivocal for amplification (HER2:CEP17
ratio     1.8 and     2.2). Test Validation: The test methodology employed in this
laboratory has demonstrated an extremely high concordance rate between IHC
and FISH (Gown AM et al., Mod Pathol **ID-NUM, 2008; Yaziji H et al., JAMA
**ID-NUM, 2004). In the most recent study of 6604 patients, a 99.2%
concordance was demonstrated between negative (0 or 1+) HER2 IHC and
non-amplified HER2 FISH, and a 94.7% concordance was demonstrated between
positive (3+) HER2 IHC and amplified HER2 FISH. Quality Assurance: PhenoPath
Laboratories has in place a quality assurance program for HER2 FISH, which
includes daily controls (cell lines and tissues), Levy-Jennings analysis of
HER2 controls, and ongoing concordance studies between IHC and FISH, to ensure
high levels of interobserver and methodology concordance. (*PhenoPath
Laboratories' HER2 validation and ongoing monitoring of IHC and FISH assays
demonstrate extremely high concordance (>95%) that is independent of the
reported duration of fixation.)
    Electronically signed **DATE[Jan 01 2012]: 
**NAME[YYY XXX], MD-Pathologist, IHC Fellow, Pathologist
Per CMS regulations, the pathologist's signature above indicates that this
case has been reviewed and the diagnosis made or confirmed by said
pathologist.
Note: Some of the tests reported here may have been developed and performance
characteristics determined by PhenoPath Laboratories. They have not been
cleared or approved by the U.S. Food and Drug Administration (FDA). However,
the FDA has determined that such clearance or approval is not necessary.
Pursuant to the requirements of CLIA, this laboratory has established and
verified the accuracy and precision of all tests, and additional information
about these tests is available upon request. PhenoPath Laboratories is
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
as qualified to perform high complexity clinical laboratory testing.
Copy to: **NAME[WWW, VVV M. (UUU] Pathology)",,,,,
REG3,BREAST,0,PAT-00580538,2,REC-5000769546,,,,"PART / DESCRIPTION - SEQ 
Lymph nodes, regional resection/ RIGHT AXILLARY CONTENTS- A
INTRAOPERATIVE DX:
**NAME[ZZZ
M. YYY XXX], M.D. (slides prepared from block A8; slide A2).
**NAME[WWW M. VVV], M.D. (slides prepared from block A8; slide A2).
DIAGNOSIS COMMENTS:
NONE
FINAL DX:

''Right axillary contents'':
9 of 24 lymph nodes positive for metastatic carcinoma (9/24).

Summary of lymph node status [including all lymph nodes from current specimen and from previous
 specimen (***PATH-NUMBER[1])]: 12 of 29 lymph nodes positive for metastatic carcinoma (**DATE[Oct 30]).
 Largest metastatic deposit identified: 7.2 mm.
 Extranodal extension focally present.

Pathologic stage: pT2, pN3a (AJCC 7th Edition).
MICROSCOPIC:
The pathology diagnosis is based on microscopic examination of the tissue(s)/cells.
An immunohistochemistry study of block A8 for pankeratin supports the diagnosis of carcinoma in a lymph node. 

The immunohistochemical test reported was developed and performance characteristics determined by Dynacare Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test may be used for clinical purposes. It should not be regarded as investigational or for research use only. Dynacare Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988(CLIA) as qualified to perform high complexity clinical laboratory testing. 








GROSS:
Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''A. right axillary contents'', is an unoriented 12.5 x 7.5 x 3 cm portion of adipose tissue which yields twenty-two 0.3-4.5 cm tan-pink possible lymph nodes. The remaining cut surface is composed of fibroadipose tissue with focal areas of bright yellow possible fat necrosis. Representative sections are submitted as follows: A1 - five possible lymph nodes; A2 - seven possible lymph nodes; A3 - axillary tissue; A4 - three possible lymph nodes; A5 - five possible lymph nodes; A6-A7 - one possible lymph node, sectioned; subsequent exam consistent with smaller second node; A8-A9 - one possible lymph node, sectioned; A10-A13 - one area, sectioned, with possible fat necrosis; A14 - possible fat necrosis. (**INITIALS:cmc131 296759) (RHK:cmc10 297884)


CLINICAL INFO:
Patient diagnosis: **DATE[Jun 09 2012], right diagnostic mammogram: Known cancer at 1 o'clock, measuring 3.7 cm with loosely grouped calcifications and segmental distribution. More focal group of indeterminate calcifications noted 2 cm anteriorly spanning 9 mm. A **AGE[in 60s]-year-old woman with right palpable upper outer quadrant T2 (up to 5 cm) ILC, Nottingham 6/9, ER 95%, PR 95%, HER-2 negative MRI. Comorbidities include hypertension and a history of hemochromatosis. Paternal aunt with postmenopausal breast cancer. Malignant neoplasm of breast (female), unspecified site. 
ICD-9 code: 174.9.
PATHOLOGIST:
**NAME[UUU TTT M]. 

SNOMED Code(s)
M80006M55000TY8110T08000M80106",,,,,
REG3,BREAST,0,PAT-00720293,1,REC-5000769732,,,,"PART / DESCRIPTION - SEQ 
Skin, biopsy/ SKIN FROM LEFT CHEST WALL, PUNCH BIOPSY- A
INTRAOPERATIVE DX:
NONE
FINAL DX:

 SKIN OF LEFT CHEST WALL, PUNCH BIOPSY: - Skin without significant abnormality. - Subcutis and breast tissue are not present for evaluation. - No evidence of malignancy (multiple levels were examined).
MICROSCOPIC:
The final diagnosis is based on a microscopic examination of the tissue.GROSS:
Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''left chest wall nodule'', is a 0.2 cm punch biopsy of skin with a depth of 0.4 cm. The punch is inked and entirely submitted in one cassette. (nr:cmc40 298963)
CLINICAL INFO:
Breast cancer status post mastectomy. Now getting chest wall radiation therapy. New chest wall nodule. Fat necrosis? Rule out recurrent cancer. Please note: Formalin fixation time: 13.5 hours. 
ICD-9 code: V10.3, 238.3. Personal history of malignant neoplasm of breast. Neoplasm of uncertain behavior.
PATHOLOGIST:
**NAME[ZZZ YYY M]. 

SNOMED Code(s)",,,,,
REG3,BREAST,0,PAT-00747848,1,REC-5000769877,,,,"PART / DESCRIPTION - SEQ 
breast mass, oriented/ LEFT BREAST TISSUE- A
INTRAOPERATIVE DX:
NONE
FINAL DX:
Breast, left, lumpectomy:  Ductal carcinoma in situ (DCIS) with the following features:  Histologic type:   Cribriform.  Nuclear grade:   Intermediate.  Necrosis:    Absent. Size/Extent of DCIS:   Two residual foci (0.3cm each) located at each end of biopsy            cavity. Distribution of DCIS in specimen: At inferior and superior borders of biopsy cavity. Microcalcifications:   Present. Surgical margins:  Anterior (superficial):  Negative (7 mm).  Posterior (deep):   Negative (3 mm).  Superior:    Negative (4 mm).  Inferior:    Negative (10 mm).  Medial:    Negative (10 mm).  Lateral:    Negative (10 mm). No invasive carcinoma identified. Pathologic stage:    pTis, pNX (AJCC 7th edition). Additional findings: Immunohistochemistry staining for estrogen and progesterone receptor expression has been previously performed (***PATH-NUMBER[1]), with the following results: ER 100%, PR 100%.

MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''left breast wire localized biopsy'', is an oriented left breast biopsy specimen with a needle localization wire entering superficial-superiorly. It has dimensions as follows: superior to inferior - 7.5 cm, medial to lateral - 6.5 cm, superficial to deep - 3 cm. It is inked as follows: deep - black, anterior - blue, medial - red, lateral - yellow, superior - orange, inferior - green. It is sectioned inferior to superior into 17 slices, numbered respectively. There is a 2 x 1 x 0.7 cm previous biopsy site in slices 10-14, 0.8 cm from the superficial margin, 1.2 cm from the deep margin, 1.7 cm from the medial margin, and 1.2 cm from the lateral margin. The remainder of the specimen consists of 95% yellow lobulated adipose tissue and 5% white fibrous tissue. Sections are submitted as follows: A1 - slice 1; A2-A3 - slice 4, bisected from medial to lateral; A4-A6 - slice 7, trisected from medial to lateral; A7-A9 - slice 9, immediately inferior to previous biopsy site; A10-A12 - slice 10, with biopsy site, trisected from medial to lateral; A13-A15 - slice 12, with biopsy site, trisected from medial to lateral; A16-A17 - slice 14, with biopsy site, bisected from medial to lateral; A18-A19 - slice 15, immediately superior to biopsy site, bisected from medial to lateral; A20 - slice 16; A21 - slice 17; A22-A24 - slice 11, trisected from medial to lateral; A25-A27 - slice 13 with biopsy site, trisected from medial to lateral. The specimen was received previously inked. The specimen is not entirely submitted. The specimen was put into formalin at 8:50 a.m. on **DATE[Mar 21 2012] and will have a total time in formalin of 11 hours and 40 minutes. (MPH/nr:cmc31 300815) (MPH/nr:cmc94 301329)
CLINICAL INFO:
Carcinoma in situ of breast. Patient diagnosis: DCIS left breast. Patient history: Abnormal left mammograms. **DATE[Feb 30 2012] stereotactic left breast biopsy, Pathology: Ductal carcinoma in situ. Histologic type: Solid focal cribriform. Nuclear grade: Low to intermediate. Necrosis: Present. Associated calcifications: Present. Invasive carcinoma: Not identified. ER 100% positive. PR 100% positive. 
ICD-9 code: 233.0.
PATHOLOGIST:
**NAME[ZZZ YYY M]. 

SNOMED Code(s)",,,,,
REG3,BREAST,0,PAT-00557838,2,REC-5000770103,,,,"PART / DESCRIPTION - SEQ 
Breast, biopsy (core/incisional)/ LEFT BREAST CORES WITH CALCIFICATIONS- A
INTRAOPERATIVE DX:
NONEConsult
Dr. **NAME[ZZZ].
FINAL DX:

Calcifications in upper outer left breast, stereotactic -guided core biopsy:
 Ductal carcinoma in situ with the following features:
 Histologic type:   Solid.
 Nuclear grade:   High.
 Necrosis:    Absent.
 Associated calcification:  Present.
 Invasive carcinoma: Absent.
 Additional findings:  Immunohistochemical studies for estrogen and progesterone receptor    expression cannot be performed as DCIS has been sectioned through.

MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''left breast UO'', are nine 0.3 cm diameter elongated portions of fibrofatty tissue, 0.6-1.5 cm in length, submitted entirely in a single cassette. (**INITIALS:cmc94 303817)
CLINICAL INFO:
Left breast core biopsy stereotactic guided UO. Description: Calcifications. Clinical impression: Indeterminate. Collection date **DATE[Jan 30 12]. Fixation time 9:17 a.m. resulting in an approximately 11 hour 15 minute fixation in formalin.
ICD-9 code: 793.81.
PATHOLOGIST:
**NAME[YYY XXX M]. 

SNOMED Code(s)",,,,,
REG3,BREAST,0,PAT-00747213,1,REC-5000770438,,,,"<FINAL DX>
  A) RIGHT BREAST, EXCISION: INFILTRATING DUCTAL CARCINOMA, WELL TO
MODERATELY DIFFERENTIATED (NOTTINGHAM GRADE I/II OUT OF III). 
1. TUMOR SIZE (INFILTRATING COMPONENT) 0.2 MM BY MICROSCOPIC MEASUREMENT;
TUMOR ON ORIGINAL BIOPSY SAMPLE MEASURING 0.4 CM BY MICROSCOPIC
MEASUREMENT. 
2. NUCLEAR GRADE: INTERMEDIATE. 
3. MITOTIC RATE: LOW. 
4. TUBULAR DIFFERENTIATION: INTERMEDIATE TO LITTLE. 
5. INTRADUCTAL CARCINOMA COMPONENT: PRESENT OF INTERMEDIATE NUCLEAR GRADE
WITHOUT CENTRAL NECROSIS. 
6. CALCIFICATIONS: PRESENT, ASSOCIATED WITH IN SITU CARCINOMA. 
7. INTRAMAMMARY LYMPHATIC SPACE INVASION: NOT IDENTIFIED. 
8. RESECTION MARGINS: NEGATIVE (0.6 CM TO LATERAL MARGIN). 
9. PATHOLOGIC STAGE: pT1A, pN0 (sn), pMX. 
B,C) LYMPH NODE, RIGHT AXILLA, SENTINEL #1 AND #2, BIOPSIES: TWO LYMPH
NODES IDENTIFIED, NO EVIDENCE OF MALIGNANCY.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[May 19 2012]
<SPECIMEN(S)>
  A) R. Breast lumpectomy
B) R. axilla SENTINEL LYMPH NODE #1
C) R. axilla SENTINEL LYMPH NODE #2
<GROSS>
  A) Received in a container labeled with the patient's name and ""right
breast, lump SS LL"" is a 38 gram, 6.2 x 5.0 x 2.3 cm portion of fatty
breast tissues with sutures marking: short-superior, long-lateral. A
localization wire exits toward medial-superior. A radiograph is viewed in
EPIC and shows a dense process with biopsy clip in place, all in relation
to the needle localization wire. The specimen is inked: superior-blue,
inferior-green, anterior-purple, deep-black, lateral-yellow, medial-orange. 
The specimen is serially sectioned from lateral to medial to demonstrate a
2.6 x 0.8 x 0.7 cm pink indurated lesion with biopsy clip in place. This
approaches the superior-anterior margin, is 0.4 cm from deep, is 1.5 cm
from inferior, is within 0.4 cm of lateral, and approximately 4.0 cm from
medial. This lesion demonstrates lateral fat necrosis and hemorrhage. No
additional mass lesions are identified and the cut surfaces are yellow
glistening lobulated adipose tissue with minimal areas of membranous
parenchymous septae. 
Representative sections are submitted sequentially from lateral to medial
as follows: 
A1) Lateral margin, serially sectioned. 
A2) Lesion and fat necrosis to nearest lateral and deep margin. 
A3) Representative lesion. 
A4) Biopsy clip section to nearest (superior and anterior) margins. 
A5) Additional margins at the lesion. 
A6) Representative uninvolved section. 
A7) Medial margin, serially sectioned. 
B) Received in a container labeled with the patient's name and ""right
axilla sentinel node #1"" is a 1.8 cm in greatest dimension ovoid slightly
firm fatty tissue, which is sectioned to demonstrate a 1.2 cm tan lymph
node candidate, within. The specimen is entirely submitted in B1-2. 
C) Received in a container labeled with the patient's name and ""left
axilla sentinel node #2"" is a 2.5 cm shaggy and fatty tissue, which is
palpated and dissected to demonstrate a 1.5 cm partially fat-replaced
lymph node candidate. The entire specimen is submitted in C1-2.
<MICROSCOPIC>
  A) Sections through the breast confirm the presence of an infiltrating
ductal carcinoma. Microscopic evaluation shows that the gross estimation
of the maximal tumor size is an over-estimate. Most of what was noted
grossly consists of a tract of scar and reactive changes from the previous
biopsy. Only a small amount of residual invasive and in situ carcinoma is
noted. This is best seen on slide A2. The residual focus of invasive tumor
spans an area of 2.0 mm. On the original biopsy sample (**ID-NUMS) tumor
spans an area of at least 4.0 mm. This biopsy measurement will be used for
staging purposes. Nests of invasive tumor come to within 0.6 cm of the
lateral margin with other margins being widely clear. The tissue that was
noted approaching the superior anterior margin on gross evaluation is a
tract of scar and fibrous tissues from the biopsy and does not represent
neoplasia near this margin. There are surrounding breast ducts with
fibrocystic changes including cysts, columnar cell change and stromal
fibrosis. Other findings are as listed in the diagnosis section of this
report. 
B,C) Sections from each sentinel lymph node are benign. No metastatic
carcinoma is identified. Multiple levels have been cut according to the
sentinel lymph node protocol.",,,,,
REG3,BREAST,0,PAT-00745747,1,REC-5000773366,,,,"**** THIS IS AN AMENDED REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Amendment ****

Reason for Addendum #1:  Immunohistochemistry results
Reason for Amendment #1: Typographical Error

AMENDMENT COMMENT: This amendment corrects a typographical error in
pathologic staging, originally reported as pNX(sn).  The correct stage
is pN0(sn).

<FINAL DX>     

A.  Right Sentinel Lymph Node (#1):
One lymph node, negative for carcinoma (0/1).

B.  Right Sentinel Lymph Node (#2):
One lymph node, negative for carcinoma (0/1).

C.  Right Sentinel Lymph Node (#3):
One lymph node, negative for carcinoma (0/1).

D.  Right Breast, Lumpectomy (6.5 x 5.5 x 3 cm):
Infiltrating carcinoma with the following features:
Histologic type:    Ductal (NOS) and micropapillary (see comment).
Size:     Two foci, 1.3 cm and 0.5 cm (see comment).
Tumor #1 (1.3 cm, micropapillary):
        Histologic grade:     2 of 3.
        Nottingham grade:     6 of 9.
   Tubule formation:     Intermediate (2 of 3).
   Nuclear grade:   Intermediate (2 of 3).
   Mitotic rate:    Intermediate (2 of 3).
     Tumor #2 (0.5 cm, ductal, NOS):
        Histologic grade:     1 of 3.
        Nottingham grade:     5 of 9.
           Tubule formation:  Low (3 of 3).
          Nuclear grade: Low (1 of 3).
          Mitotic rate:  Low (1 of 3).
Lymph-vascular invasion: Present (micropapillary).
Ductal carcinoma in situ:     Present.
     Histologic type:    Solid and cribriform.
   Nuclear grade:   Low.
   Necrosis:   Absent.
     Calcifications:                    Absent.
   Estimated size:  Scattered foci within and outside of infiltrating
carcinoma covering an area of approximately 3.4 cm.
Surgical margins (infiltrating carcinoma):
Anterior (superficial):  Close, 1 mm (see comment).
Posterior (deep):   Negative, >10 mm.
Superior: Close, <1 mm (see comment).
Inferior: Negative, >10 mm.
Medial:   Negative, 4 mm.
Lateral:  Negative, >10 mm.
     Surgical margins (in-situ carcinoma):
Anterior (superficial):  Negative, at least 5 mm.
Posterior (deep):   Negative, >10 mm.
Superior: Negative, 4 mm.
Inferior: Negative, >10 mm.
Medial:   Negative, at least 4 mm.
Lateral:  Negative, >10 mm.
Lymph nodes:   Summary of lymph node status (including all lymph nodes
from part(s) A-C: Three lymph nodes negative for carcinoma (0/3).
Pathologic stage:        pT1c(m), pN0(sn) (AJCC 7th edition).
Additional findings:
Immunohistochemistry staining for estrogen and progesterone receptor
expression and Her-2/neu overexpression have been performed on a prior
biopsy (Group Health #**ID-NUM) with the following results: ER positive
(**NAME[ZZZ] score 8), PR positive (**NAME[ZZZ] 6-7), HER-2/neu negative for
amplification (FISH). The immunohistochemistry results are by report
only (not reviewed).
Additional immunohistochemistry staining for estrogen and progesterone
receptor expression was performed on the smaller lesion (0.5 cm, ductal
NOS) with the following results:  ER 100% tumor cells positive, PR 100%
tumor cells positive.  Immunohistochemistry for Her-2/neu is pending and
the results will be reported in an addendum.

<COMMENT>
The excision contains two morphologically discrete foci of infiltrating
carcinoma.  One focus (1.3 cm) is associated with the prior biopsy site
and shows morphologic features of micropapillary carcinoma. The second
focus (0.4 cm) is located more laterally within the specimen, closely
associated with low grade in-situ carcinoma, and shows morphologic
features most closely resembling ductal carcinoma, NOS.  Although both
foci show a similar ER/PR expression profile, the distinct morphologic
profiles favors two separate primaries over intramammary spread.

The micropapillary carcinoma shows multifocal lymphatic involvement.
The invasive carcinoma that is close to the anterior and superior
margins is micropapillary type and appears to be related to lymphatic
spread.

<CLINICAL INFO>
Right breast cancer. Specimen placed in formalin at 1700 hours on
**DATE[Sep 01 2012] for an approximate formalin-fixation time of 6 hours.

<GROSS>
A.  Received in formalin, labeled ""**NAME[AAA BBB]"" and designated
""sentinel node #1 right"", is a 2.7 x 1.5 x 1 cm partially fat-replaced
lymph node, which is sectioned and entirely submitted in two cassettes.

B.  Received in formalin, labeled ""**NAME[AAA BBB]"" and designated
""sentinel node #2 right"", is a 0.8 cm tissue fragment, which is
submitted as received in one cassette.

C.  Received in formalin, labeled ""**NAME[AAA BBB]"" and designated
""sentinel node #3 right"", is a 3 x 1.3 x 0.7 cm lymph node, which is
bisected and entirely submitted in one cassette.

D.  Received fresh, labeled ""**NAME[AAA BBB]"" and designated ""right
breast lumpectomy"", is an oriented breast biopsy, 6.5 cm lateral to
medial, 5.5 cm anterior to deep, and 3 cm superior to inferior. There is
a short suture attached to one surface designating the ""superior margin""
and a long stitch attached to one edge designates the ""lateral margin"".
The specimen is inked as follows: superior orange, inferior green,
lateral yellow, medial red, anterior blue and deep black. The specimen
is serially sectioned lateral to medial into fifteen slices. There is a
previous needle biopsy site within slices 13 and 14, which consists of a
0.5 cm cavity filled with soft brown material. The biopsy site grossly
extends to within less than 0.1 cm of the anterior margin, 0.5 cm of the
superior margin, 0.4 cm of the medial margin, and is at least 1 cm from
all other margins. The remaining specimen consists of a homogeneous
adipose tissue. No tumors or additional biopsy sites are grossly
identified. Representative material is submitted as follows:
Block Key:
D1.  Section from slice 1 at lateral edge;
D2.  Section from slice 5;
D3.  Section from slice 8;
D4.  Section from slice 10;
D5.  Section from slice 12, just lateral to biopsy site;
D6.  Section from slice 13, including lateral edge of biopsy site;
D7.  Section from slice 14, including medial half of biopsy site;
D8.  Section from slice 15 at medial edge. (ke/cm)
D9.  Additional tissue from slice 6.
D10. Additional tissue from slice 7.
D11. Additional tissue from slice 9.  (ke/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
Pan CK    Negative

Block A2

Antibody  Result    Comment
Pan CK    Negative

Block B1

Antibody  Result    Comment
Pan CK    Negative

Block C1

Antibody  Result    Comment
Pan CK    Negative

Block D3

Antibody  Result    Comment
E-Cadherin     Positive

Block D6

Antibody  Result    Comment
EMA  Positive

Impression:  These findings support the diagnosis.
Interpreted by:  **NAME[YYY M XXX] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

IMMUNOHISTOCHEMISTRY STUY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block D3

Antibody  Result    Comment
ERsq 100 % of tumor cells positive,            strong nuclear staining.

PRsq 100 % of tumor cells positive,            strong nuclear staining.

Interpreted by:  **NAME[YYY M XXX] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[WWW M. VVV], M.D. (select slides from specimen D).

<ADDENDUM> #1

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for detection of the HER2 oncogene product
(using **INSTITUTION. Pathway Anti-HER2 rabbit monoclonal
antibody, clone 4B5) are carried out on formalin-fixed,
paraffin-embedded tissue sections.  Positive and negative controls show
appropriate reactivity. Interpretation of Ventana Pathway for HER2
immunostain is performed according to guidelines recommended by ASCO/CAP
in 2007 (see comment below).  Results are as follows:
Block D3

Antibody  Result    Comment
HER2 0    Negative for overexpression

Impression:
Interpreted by:  **NAME[YYY M XXX] M.D.
Comment:

1.  The guideline recommendations by ASCO/CAP in 2007 is as follows:  A
score of 3+ (positive HER2 test) is defined by uniform intense membrane
staining in >30% of tumor cells.  A score of 2+ (equivocal HER2 test) is
defined by complete membrane staining that is either nonuniform or weak
in intensity but with obvious circumferential distribution in at least
10% of tumor cells, or less commonly, intense complete membrane staining
but in only 30% or fewer tumor cells.  A score of 0 or 1+ (negative HER2
test) is defined by no or weak and incomplete membrane staining in any
proportion of tumor cells.
2.  The correlation between HER2 protein overexpression by
immunohistochemistry and HER2/neu gene amplification by fluorescence in
situ hybridization (FISH) is not 100%.  Rare cases interpreted as
negative (0 and 1+) for HER2 protein overexpression may demonstrate low
level HER2/neu gene amplification by FISH.  Approximately 10-20% of
cases interpreted as 2+ may show gene amplification by FISH, while the
vast majority of cases, if not all, interpreted as 3+ show gene
amplification by FISH.  Therefore, additional testing for HER2/neu gene
amplification by fluorescence in situ hybridization (FISH) may be
considered on individual cases, if clinically warranted.  Reflexive
testing for HER2/neu gene amplification by FISH will be performed on all
cases interpreted as 2+ (equivocal for protein overexpression) by
immunohistochemistry.   Performed at CellNetix Pathology  **PLACE, WA.  **ZIP-CODE.

**NAME[YYY M XXX], M.D.  Electronically signed **DATE[Sep 07 2012]
Addendum #1 performed by **NAME[YYY M XXX], M.D.  Electronically signed
**DATE[Sep 07 2012]
Amendment #1 performed by **NAME[YYY M XXX], M.D.  Electronically signed
**DATE[Oct 11 2012]",,,,,
REG3,BREAST,0,PAT-00751675,1,REC-5000774765,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Immunohistochemistry results
Reason for Addendum #2:  Immunohistochemistry results

<FINAL DX>     

A.  Right Breast, 10 o'clock, Ultrasound-Guided Core Biopsies:
Infiltrating carcinoma with the following features:
Histologic type:              Ductal.
Histologic grade:             3 of 3.
Nottingham grade:             8 of 9.
Tubule formation:             Poor (3 of 3).
Nuclear grade:           High (3 of 3).
Mitotic rate:            Intermediate (2 of 3).
Lymph-vascular space invasion:     Not identified.
Ductal carcinoma in situ (DCIS):        Not identified.
Additional findings:
Immunohistochemical studies for estrogen and progesterone receptor
expression and HER-2/neu will be performed and reported in an addendum.

B.  Right Axilla Lymph Node, Core Biopsy:
Metastatic carcinoma.

<COMMENT>
The tumor has some features that raise the possibility of neuroendocrine
differentiation. Immunostaining will be performed to evaluate for that
with results to be reported in an addendum.  This case was reviewed with
Dr. **NAME[ZZZ M. YYY], as part of our quality assurance policy, and he
concurs with the diagnoses.

<CLINICAL INFO>
Ultrasound biopsy, right breast irregular with shadowing mass at 10
o'clock and right axilla abnormal lymph node. Clinical impression:
Cancer. Postmenopausal. Collection date/time: **DATE[Aug 10 2012] at A) 9:25 and
B) 9:50. Total fixation times: A) 11 hours 35 minutes, B) 11 hours 10
minutes.  ICD-9 Code(s): 611.72

<GROSS>
A.  Received in formalin, labeled ""**NAME[BBB, AAA M]"", and designated
""right breast mass 10 o'clock"", are multiple 0.2 cm diameter elongated
portions of fibrofatty tissue, 0.2-1.7 cm in lengths; entirely submitted
in A1.

B.  Received in formalin, labeled ""**NAME[BBB, AAA M]"", and designated
""right axilla abnormal lymph node"", are multiple 0.2 cm diameter
elongated portions of fibrofatty tissue, 0.2-1.1 cm in lengths; entirely
submitted in B1. (jws/cm)

<MICROSCOPIC>
The final diagnosis for each specimen is based on a microscopic
examination of the tissues.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Aug 11 2012]

<ADDENDUM> #1

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for estrogen and progesterone (ER/PR)
receptors (using rabbit monoclonal antibodies clone SP1 for ER and clone
1E2 for PR from Ventana) are carried out on formalin fixed and paraffin
embedded tissue sections.  Positive and negative controls show
appropriate reactivity.  Determination of ER/PR reactivity is based on
manual estimation of the percentage of positive nuclei in tumor cells.
Results are as follows:
Block A1

Antibody  Result    Comment
ERsq 80 % of tumor cells positive,            strong nuclear staining.
No non-neoplastic epithelium is identified (no internal control).

PRsq 0 % of tumor cells positive   No non-neoplastic epithelium is
identified (no internal control).

Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

Some immunohistochemistry studies have suggested that as few as 1%
positive tumor cells for ER/PR may correlate with a significantly
improved clinical response of patients to therapeutic and adjuvant
hormonal therapy.  Based on this information, tumors showing greater
than 1% of tumor cell nuclear staining for ER/PR may be considered
positive.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  They have not been
cleared or approved by the U.S. Food and Drug Administration.  The FDA
has determined that such clearance or approval is not necessary.  These
tests may be used for clinical purposes.  They should not be regarded as
investigational or for research use only.  CellNetix Labs, LLC is
certified under the Clinical Laboratory Improvement Amendments of
1988(CLIA) as qualified to perform high complexity clinical laboratory
testing.

Addendum #1 performed by **NAME[XXX M. WWW], M.D.  Electronically
signed **DATE[Aug 11 2012]

<ADDENDUM> #2

ADDENDUM DIAGNOSIS:

Right Breast, 10 o'clock, Core Biopsies:
  Infiltrating ductal carcinoma with neuroendocrine features.
  ER 80%, PR 0%, HER-2/neu negative (1+ staining).

ADDENDUM <COMMENT>
Immunostaining for neuroendocrine markers (chromogranin and
synaptophysin) indicate there is neuroendocrine differentiation in this
tumor.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
Chromogranin   Positive  Moderately positivity
Synaptophysin  Diffusely positive  Strong staining

Impression:
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

IMMUNOHISTOCHEMISTRY STUDY:
Immunohistochemistry studies for detection of the HER2 oncogene product
(using **INSTITUTION. Pathway Anti-HER2 rabbit monoclonal
antibody, clone 4B5) are carried out on formalin-fixed,
paraffin-embedded tissue sections.  Positive and negative controls show
appropriate reactivity. Interpretation of Ventana Pathway for HER2
immunostain is performed according to guidelines recommended by ASCO/CAP
in 2007 (see comment below).  Results are as follows:
Block A1

Antibody  Result    Comment
HER2 1 +  Negative for overexpression

Impression:
Interpreted by:  **NAME[VVV M. UUU] M.D.
Comment:

1.  The guideline recommendations by ASCO/CAP in 2007 is as follows:  A
score of 3+ (positive HER2 test) is defined by uniform intense membrane
staining in >30% of tumor cells.  A score of 2+ (equivocal HER2 test) is
defined by complete membrane staining that is either nonuniform or weak
in intensity but with obvious circumferential distribution in at least
10% of tumor cells, or less commonly, intense complete membrane staining
but in only 30% or fewer tumor cells.  A score of 0 or 1+ (negative HER2
test) is defined by no or weak and incomplete membrane staining in any
proportion of tumor cells.
2.  The correlation between HER2 protein overexpression by
immunohistochemistry and HER2/neu gene amplification by fluorescence in
situ hybridization (FISH) is not 100%.  Rare cases interpreted as
negative (0 and 1+) for HER2 protein overexpression may demonstrate low
level HER2/neu gene amplification by FISH.  Approximately 10-20% of
cases interpreted as 2+ may show gene amplification by FISH, while the
vast majority of cases, if not all, interpreted as 3+ show gene
amplification by FISH.  Therefore, additional testing for HER2/neu gene
amplification by fluorescence in situ hybridization (FISH) may be
considered on individual cases, if clinically warranted.  Reflexive
testing for HER2/neu gene amplification by FISH will be performed on all
cases interpreted as 2+ (equivocal for protein overexpression) by
immunohistochemistry.   Performed at CellNetix Pathology  **PLACE, WA.  **ZIP-CODE.

Addendum #2 performed by **NAME[XXX M. WWW], M.D.  Eectronically
signed **DATE[Aug 13 2012]",,,,,
REG3,BREAST,0,PAT-00722933,1,REC-5000775747,,,,"<CLINICAL INFO>
RIGHT BREAST CANCER WITH METASTASIS WITH CLINICAL RESPONSE TO CHEMOTHERAPY AND HORMONAL THERAPY.
<SPECIMEN(S)>
RIGHT BREAST AND AXILLARY CONTENTS.
  Formalin added at: 1302
<GROSS>
Received in formalin labeled with the patient's name and ""right breast and axillary contents"" is an 864 gram mastectomy specimen. There is a clip present on the edge of the overlying skin designated superior margin. The specimen measures 24.0 cm from medial to lateral, 19.0 cm from superior to inferior and 5.5 cm from anterior to posterior. There is overlying tan-pink skin measuring 22.5 x 11.5 cm. Centrally located is a nipple, which is located between slice 9 and 10 of the breast tissue, measuring 1.4 cm in greatest dimension. Centrally located on the nipple is a light tan friable area measuring 0.5 x 0.2 cm. 3.0 cm from the nipple at 8:00 is a 0.6 cm in greatest dimension red area. 8.0 cm from the nipple at 10:00 is a 3.5 cm in greatest dimension tan-pink depression, possible scar. This is present towards the lateral margin, upper outer quadrant. Specimen is inked as follows: superior superficial blue, inferior superficial green, and deep surface black. The axilla is unlinked. The specimen is cross sectioned from medial to lateral into seventeen slices.
 Sectioning reveals a light tan to pink ill-defined fibrous area with retracted adipose tissue surrounding it, in slice 13 and measures up to 3.0 x 1.5 x approximately 3.5 cm. This area abuts the depression on the upper outer quadrant of the skin. It also abuts the deep margin (black ink), is 4.5 cm from the superior tip, 7.5 cm from the inferior tip. 
Sectioning and palpation through the axillary tissue reveals a 4.2 x 3.2 x 1.5 cm firm nodule which is approximately 1.0 cm from the first described area of interest. Sectioning through the nodule reveals tan pink firm cut surface. Further palpation reveals no lymph nodes grossly identified.
 Sectioning through the remaining tissue reveals yellow adipose tissue with minimal ill-defined tan-pink fibrous tissue. Representative sections in nine cassettes. 
Summary of Sections
1: nipple and red skin lesions
2: slice 14, first described fibrous area including skin with skin lesion and deep margin
3: slice 15, first described fibrous area with overlying skin lesion and deep margin
4: slice 13, first described fibrous area including deep margin
5-6: firm nodule in axilla
7: fibrous tissue slice 5, upper outer quadrant
8: fibrous tissue slice 9, upper outer quadrant
9: fibrous tissue, slices 10 and 11, mid lower breast
AOH/VT:pem **DATE[Nov 29 11]
<FINAL DX>
Right breast and axillary contents (mastectomy): Invasive mammary carcinoma with the following characteristics:
1. Primary tumor size: 3.5 cm (post treatment).
2. Tumor type: Invasive ductal carcinoma.
3. Histologic grade: Low grade.
Modified Bloom-Richardson Score: 3
Tubular score: 1
Nuclear score: 1
Mitotic score: 1
4. In situ carcinoma: Not present.
5. Lymphatic/blood vascular invasion: Not present.
6. Resection margins: 
a. Focally positive deep surgical margin for invasive carcinoma. 
b. Distance to remaining margins: More than 4.5 cm. 
7. Estrogen/progesterone receptor and HER-2 studies: Not available but may be performed if requested. 
8. Other lesions present: 
a. Neoplasm invades underlying skeletal muscle, overlying skin (dermis) and nipple. 
b. Positive for axillary perineural invasion by neoplasm.
c. Dermal hemangioma. 
9. Lymph nodes: 
a. Metastatic carcinoma to a 4.2 cm fibrotic axillary nodule consistent with involvement of matted lymph nodes.  
b. Positive for extracapsular extension by neoplasm.
10. AJCC/pTN classification: ypT2,pN1,M1(based on imaging and clinical). Stage IV. 
Comment: Both the primary tumor and particularly the nodular axillary mass show fairly extensive fibrosis possibly representing chemotherapeutic effect. However there is still viable neoplasm microscopically. The axillary mass is consistent with matted lymph nodes involved by metastatic carcinoma but the number of nodes cannot be determined. 
 
<PATHOLOGIST>
**NAME[ZZZ YYY], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,BREAST,0,PAT-00746645,1,REC-5000775877,,,,"<SPECIMEN(S)> 
A. Breast -Left breast central milk ducts 
B. Sentinel Lymph Node -Sentinel node 1, left breast 
C. Breast -Left nipple sparing mastectomy 
D. Breast -Central milk duct, right breast 
E. Breast -Right breast nipple sparing mastectomy 
<CLINICAL INFO> 
Left breast cancer 174.4, V10.3 -A & B) Specimen collection and fixation done on **DATE[Apr 6 12] at 
14:40, C) Specimen collection and fixation don eon **DATE[Apr 6 12] at 15:00, D) Specimen collection 
and fixation done on **DATE[Apr 6 12] at 16:50, E) Specimen collection and fixation done on **DATE[Apr 6 12] 
at 16:40 

<FINAL DX> 
A. Left breast central milk ducts, excision (1.5 x 1.0 x 
0.8 cm, 1.1 gm): 
Benign breast tissue and lactiferous ducts. Negative 
for cytologic atypia or malignancy. 
B. Central lymph node #1, left axilla, excision: 
One lymph node negative for metastatic carcinoma on 
multiple H&E level sections. 
C. Left breast, nipple-sparing mastectomy (operative weight 
662 gm): 
Invasive carcinoma 
Tumor size: 2.2 cm in greatest dimension. 
Tumor site: 2-3:00. 
Tumor focality: Single focus. 
Histologic type: Infiltrating ductal carcinoma. 
Histologic grade: Nottingham grade 3 of 3 (tubule 
score 3 of 3; nuclear score 3 of 3; 
mitotic count 47 per 10 hpf, score 3 of 3). 
Lymph-vascular invasion: Not identified. 
Skin: Negative for tumor. 
Nipple: Not present. 
Skeletal muscle: Not present. 
Ductal carcinoma in situ: Not identified. 
Lobular carcinoma in situ: Not identified. 
Margins (invasive carcinoma): All margins are 
greater than 1.0 cm. 
Hormone receptor, HER2 studies: Performed on 

 
PAGE 3 

<FINAL DX> (Continued) 
previous biopsy at Cellnetix Laboratory 
and reported as ER positive (5% of tumor cells with weak 
nuclear staining), PR negative, HER2 positive for 
overexpression (3+). 
Microcalcifications: Not identified. 
Lymph nodes: 
Number of sentinel nodes: 1. 
Total number of nodes (sentinel, non-sentinel): 
1. 
Number of nodes with macrometastases (>0.2 cm): 
0. 
Number of nodes with micrometastases (>0.2 mm to 
0.2 cm): 0. 
Number of nodes with isolated tumor cells (<0.2 
mm): 0. 
Size of largest metastatic deposit: N/A. 
Other: Biopsy site change within the tumor. 
AJCC (7th ed.) pathologic stage: pT2 pN0 (sn). 
Specimen: Total breast. 
Procedure: Nipple-sparing mastectomy. 
Lymph node sampling: One sentinel lymph node 
present, negative for metastatic 
carcinoma. 
Specimen integrity: Single intact specimen. 
Specimen laterality: Left. 
D. Right breast central milk ducts, excision (1.5 x 1.3 x 
1.0 cm, 1.7 gm): 
Benign breast tissue and lactiferous ducts. Negative 
for cytologic atypia or malignancy. 
E. Right breast, nipple-sparing mastectomy (operative weight 
544 gm): 
Benign breast tissue with a biopsy cavity at 9:00 with 
associated changes. No cytologic atypia 
or malignancy identified. 
This case has been subjected to review by a second 
pathologist per departmental quality assurance (QA) policy. 
HJ/dh 

 
PAGE 4 

<GROSS> 
Received are five containers labeled '**NAME[BBB, AAA M]., 
H000817126' and a requisition with '**NAME[BBB, AAA M]., 
H000817126'. The specimens are placed in formalin between 
1440 and 1640 on **DATE[Apr 6 2012], for a total fixation time of 
over 48 hours. 
The first is designated 'left breast central milk duct' and 
is received in formalin. It consists of an unoriented 1.1 
gram yellow tissue 1.5 x 1.0 x 0.8 cm. It is inked an 
sectioned perpendicular to the long axis into six pieces. 
The cut surface is yellow-pink tissue without grossly 
suspicious features. Entirely sequentially submitted in 
cassettes A1 and A3 with three slices in each cassette. 
The second specimen is designated 'SN1 left breast' and is 
received without fixative. It consists of a 1.7 x 0.8 cm 
yellow-grey lymph node. Intraoperative touch prep report by 
Dr. **NAME[ZZZ]: `Negative for malignancy by touch prep.' One 
lymph node is subsectioned in cassettes B1-B3 for special 
handling. 
The third specimen is designated 'left nipple-sparing 
mastectomy' and is received in formalin. It is a 670 gram 
(OR weight 662 gram) skin and nipple-sparing breast, 19.0 cm 
medial to lateral, 27.0 cm superior to inferior and 4.0 cm 
from superficial to deep. Eccentrically placed in the 
anterior aspect is a concavity rim with metal clips, 2.5 x 
2.0 cm which is the former site of the nipple and areola. 
3.5 cm superolateral to the edge of the concavity, 3.5 cm 
superolateral to the edge of the concavity is a skin 
ellipse, 7.4 x 0.8 cm. Orientation is short suture superior 
and long lateral. The deep margin is without attached 
muscle. The specimen is inked: Non-marginal concavity red; 
2.0 cm band superior to concavity -green; 2.0 cm band 
inferior to concavity -yellow; remaining superoanterior 
margin -orange; remaining inferoanterior margin -blue; 
deep margin -black. The specimen is sectioned from medial 
to lateral into twenty-four slices. 
The cut surface has one gross finding in the upper outer 
quadrant at approximately 2:00-3:00, 4.0-5.0 cm from the 
center of the concavity in slices 10-13. This is a 
circumscribed mass with scalloped edges. It is 2.2 x 2.0 x 
2.0 cm. This mass is approximately 2.0 cm deep to the 
attached skin ellipse, 1.0 cm from the black deep margin and 
1.8 cm from the blue inferoanterior margin and 1.5 cm from 
the orange superoanterior margin. 

Summary of sections: 
C1 Slice 7, non-marginal red-inked concavity, former site 
of the nipple and areola 

 
PAGE 5 

<GROSS> (Continued) 
C2 Slice 7, green band superior to concavity, yellow band 
inferior to concavity 
C3 Slice 11, 2:00-3:00 upper outer quadrant mass, orange 
superoanterior 
C4 Slice 11, back deep\ 
C5 Slice 11, blue inferoanterior, blue seepage, only 
black over blue true inferoanterior margin 
C6 Slice 12, mass, no marginal ink, line adjoining with 
block C7, violet inked 
C7 Slice 12, mass line adjoining with C6, violet ink, no 
marginal ink 
C8 Slice 12, skin blue inferoanterior 
C9 Slice 5, upper inner quadrant, no marginal ink 
C10 Slice 5, lower inner quadrant black deep 
The fourth specimen is designated 'central milk duct right 
breast' and is received in formalin. It consists of an 
unoriented 1.7 gram ovoid tissue, 1.5 x 1.3 x 1.0 cm. It is 
inked and sectioned perpendicular to the long axis into six 
slices. The cut surface is a moderate white component with 
no grossly suspicious features. Entirely sequentially 
submitted in cassettes D1-D2 with three slices in each 
cassette. 
The fifth specimen is designated 'right breast 
nipple-sparing mastectomy' and is received in formalin. It 
consists of a 541 gram (OR weight 544 gram) skin and 
nipple-sparing breast without axillary content, 24.0 cm 
medial lateral, 22.0 cm superior inferior, 3.0 cm 
superficial deep. Eccentrically located anteriorly is a 2.8 
x 3.0 cm concavity rim with metal clips which is the former 
site of the nipple and areola. The deep margin has an area 
of puckering, 4.0 x 3.0 cm, but there is no attached muscle. 
Orientation is short suture superior and long lateral. The 
specimen is inked: Non-marginal concavity -red; 2.0 cm 
band superior concavity -green; 2.0 cm band inferior to 
concavity -yellow; remaining superoanterior margin orange; 
remaining inferoanterior margin -blue; deep margin 
-black. The specimen is then sectioned from lateral to 
medial into twenty-eight slices. 
The cut surface has one gross finding in slices 13-17, at 
approximately 9:00, at approximately 3.0 cm from the center 
of the concavity. This corresponds to the depressed area 
which was noted upon the deep margin which was without 
defect. This area is a white puckered area consistent with 
well-healed biopsy cavity. It is up to 4.0 x 1.7 cm. 
Slices 14 and 15 have a 1.0 x 0.7 cm smooth-lined cyst 
containing white friable material. Slice 15 also has two 
large clips. This puckered area consistent with former 
biopsy is within 0.2 cm of the black deep, 1.7 cm from the 
orange superoanterior margin, 1.5 cm from the blue 

 

<GROSS> (Continued) 
inferoanterior margin. 

Summary of sections: 
E1 Red-inked non-marginal concavity, former site of 
nipple and areola 
E2 Slice 13, green band superior to concavity, yellow 
band inferior to concavity 
E3 Slice 13, black deep puckered area consistent with a 
well-healed biopsy cavity 
E4 Slice 14, cystic portion of well-healed biopsy cavity, 
black deep 
E5 Slice 15, well-healed biopsy cavity, orange 
superoanterior 
E6 Slice 15, well-healed biopsy cavity, blue 
inferoanterior 
E7 Slice 17, well-healed biopsy cavity, black deep 
E8 Slice 5, upper outer quadrant, black deep 
E9 Slice 5, lower outer quadrant, black deep 
E10 Slice 20, upper inner quadrant, no marginal ink 
E11 Slice 20, lower inner quadrant, blue inferoanterior 
**INITIALS 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis.",,,,,
REG3,BREAST,0,PAT-00571392,1,REC-5000778762,,,,"CASE: HS-11-03868
PATIENT: **NAME[AAA BBB]


<GROSS>
The core biopsies are evaluated for adequacy using touch preparations on site in the CT Department by Dr. **NAME[ZZZ M. YYY].  One specimen is received in a container of formalin labeled **NAME[BBB, AAA] F.  The specimen is designated ""right upper lobe"" per the accompanying requisition and consists of multiple irregular needle core fragments and needle cores of gray-pale red soft tissue measuring less than 0.1 cm up to 0.6 x 0.1 cm.  This is filtered through a fine mesh and submitted in one cassette.  Also received are four fixed and stained slides prepared at the time of biopsy.  (**INITIALS **DATE[Jun 19 12])


<MICROSCOPIC>
The biopsies include alveolar lung tissue and fragments of a malignant epithelial neoplasm with sheet-like growth pattern.  Immunohistochemical evaluation is undertaken with the following results:
Marker                   Clone Type / Vendor      Species   Result
LungAd TTF1              8G7G3/1, BioCare         M Mono    Negative
LungAd **PLACE              BioCare             R Poly         Negative
GCDFP-15            D6,BioCare               M Mono    Negative
Mammaglobin              31A5,BioCare             R Mono         Negative
ER                  SP1, Ventana             R Mono         Negative
p63                 4A4, Dako           M Mono    Positive
Using an automated stainer, sections of formalin-fixed, paraffin embedded- tissue are incubated with the designated antibody which is then localized by a non-biotin, dual polymer detection system. The case is reviewed and interpreted in the context of appropriate internal and external controls.  These tests have been optimized and validated for use at Northwest Pathology.
ER/PR: Antibodies directed toward estrogen receptor (SP1, Biocare) and progesterone receptor (1AG, Vector) are applied to the test tissue along with appropriate controls. The tumor is scored in a manner that reflects the percentage of cells staining and the level of intensity.
The immunohistochemical findings are most compatible with squamous carcinoma, likely of lung origin.
1A-1: Sheet like growth
1A-2: p63 Pos
**NAME[ZZZ M. YYY], MD
Pathologist
Electronically signed **DATE[Jun 21 2012] 12:54:31PM


<FINAL DX>
Right upper lobe lung mass, CT directed core biopsies:  Poorly differentiated, nonkeratinizing squamous cell carcinoma.
TISSUE CODE 0
**NAME[ZZZ M. YYY], MD
Pathologist
**INITIALS **DATE[Jun 21 12]
INTRAOPERATIVE CONSULTATON:
Quick read, CT directed core biopsies (touch preparations):  Adequate specimen, malignant.  (JWH)


<CLINICAL INFO>
Smoker, breast cancer.",,,,,
REG3,BREAST,0,PAT-00725016,1,REC-5000779619,,,,"<CLINICAL INFO>
Left breast cancer.

<GROSS>
Received in formalin labeled with the patient's name and without a specimen source designation is an oriented modified left radical mastectomy consisting of the axillary tail measuring 15.0 x 13.3 x 3.3 cm and the left breast weighing 1,046.0 gm and measuring 26.7 cm medial to lateral, 21.5 cm superior to inferior, and up to 4.2 cm anterior to posterior.  The specimen has been received oriented per the surgeon with a short suture designating the superior resection margin and a long suture designating the lateral resection margin.  The overlying ellipse of lightly pigmented skin is 26.7 cm medial to lateral x 16.2 cm superior to inferior.  The nipple-areolar complex is 9.0 cm in diameter.  The everted nipple is 1.0 x 1.0 x 0.5 cm.  The skin surface is remarkable for a 7.0 cm in length x 0.1 cm in average diameter well-healed surgical scar involving the upper outer quadrant.  Additional skin masses or lesions are not grossly identified.  The specimen is differentially inked in order to allow for the microscopic evaluation of surgical resection margins in the following manner:  superior-anterior blue, inferior-anterior green, and posterior black.  Sectioning of the mastectomy reveals a 5.5 x 2.5 x 1.5 cm mass within the upper outer quadrant.  This mass comes to within 2.0 cm of the overlying skin, 4.0 cm of the posterior resection margin, 4.0 cm of the nearest superior-anterior resection margin, and 9.0 cm from the nearest inferior-anterior resection margin.  Present within the central aspect of the mass is a metallic clip.  Additional distinct breast masses, lesions or prior biopsy sites are not grossly identified.  The remainder of the mastectomy grossly appears to be comprised of approximately 75% yellow glistening adipose tissue and 25% white to pink fibrous tissue.  Dissection of the axillary tail reveals fifteen lymph node candidates ranging in greatest dimension from 0.6 cm to 3.0 cm.  The largest lymph node candidate which represents the highest lymph node within the axillary tail has a cut surface which is remarkable for a white to gray gritty cut surface as well as hemorrhage and necrosis.  This lymph node grossly appears to have been previously biopsied.  The identified lymph nodes are submitted in their entirety.  SUMMARY OF SECTIONS:  A1 nipple, A2 skin scar found on upper outer quadrant, A3-A6 mass from upper outer quadrant, A7 mass from upper outer quadrant with overlying skin, A8 superior-anterior resection margin of breast mass, A9 inferior-anterior resection margin of breast mass, A10 posterior resection margin of breast mass, A11 uninvolved breast tissue from upper inner quadrant, A12 uninvolved breast tissue from lower inner quadrant, A13 uninvolved breast tissue from lower outer quadrant, A14 uninvolved breast tissue from upper outer quadrant, A15 six intact lymph nodes, A16 six intact lymph nodes, A17 one lymph node bisected, A18-A19 largest and highest lymph node within axillary tail serially sectioned.
**INITIALS  **DATE[Jun 12 12]

<MICROSCOPIC>
H&E-stained sections examined.  Slide A18 shows an involved lymph node, 1.7 cm in greatest dimension.  Tumor is identified outside of the lymph node capsule.  This may represent extracapsular lymph node extension, tumor tracking along the previous biopsy site, or direct tumor extension into the lymph node. 
This case has undergone prospective intradepartmental quality assurance review prior to verification.
AK/cs  **DATE[Jun 13 12]


<FINAL DX>
BREAST, LEFT, RADICAL MASTECTOMY, INCLUDING SKIN, NIPPLE AND AXILLARY TAIL:
  INVASIVE DUCTAL CARCINOMA WITH THE FOLLOWING FEATURES:
  1.  TUMOR SITE:  UPPER OUTER QUADRANT.
  2.  TUMOR SIZE:  5.5 X 2.5 X 1.5 CM.
  3.  TUMOR FOCALITY:  SINGLE FOCUS OF INVASIVE CARCINOMA.
  4.  HISTOLOGIC GRADE:  NOTTINGHAM GRADE 2 OF 3 (DERIVED AS FOLLOWS:
    TUBULE FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY-1, 
    TOTAL SCORE 7 OF 9).
  5.  MACROSCOPIC AND MICROSCOPIC EXTENT TO TUMOR:  
    a.  SKIN AND NIPPLE:  INVASIVE CARCINOMA DOES NOT INVOLVE THE
      DERMIS, EPIDERMIS, OR NIPPLE.
    b.  SKELETAL MUSCLE:  NO SKELETAL PRESENT.
  6.  DUCTAL CARCINOMA IN SITU (DCIS):  NOT IDENTIFIED.
  7.  LOBULAR CARCINOMA IN SITU (LCIS):  NOT IDENTIFIED.
  8.  LYMPHOVASCULAR INVASION:  PRESENT.
  9.  MARGINS:  UNINVOLVED BY INVASIVE CARCINOMA AND DCIS; INVASIVE 
    CARCINOMA IS >1.0 CM FROM ALL MARGINS.
  10. ADDITIONAL PATHOLOGIC FINDINGS:  PRIOR BIOPSY SITE CHANGES, SKIN WITH
    DERMAL SCAR.
  11. LYMPH NODES:  
    a.  THREE OF 14 LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA 
      (3/14).
    b.  SIZE OF LARGEST METASTATIC DEPOSIT:  1.7 CM (EXTRACAPSULAR
      EXTENSION IDENTIFIED).
  12. ANCILLARY STUDIES:  HORMONE RECEPTOR STUDIES WERE PERFORMED ON THE 
    OUTSIDE PRIOR CORE BIOPSY SPECIMEN (PER REPORT, ER+, PR+, HER2 
    NEGATIVE).
  13. PATHOLOGIC STAGE:  pT3 N1a.",,,,,
REG3,BREAST,0,PAT-00749457,1,REC-5000780924,,,,"Right breast cancer.



The tissue block (""C3"") was sent for HER2 FISH study.



FISH RESULTS:  NEGATIVE FOR AMPLIFICATION OF HER2 NEU.



Please see the FISH report from LabCorp dated **DATE[Mar 13 2012].





This invasive breast carcinoma (""C3"" and ""C4"") was

immunostained for E-Caderin.  Despite the growth pattern of

lobular carcinoma, the infiltrating nests, cords and cells

are strongly positive for this marker.  Controls stain

appropriately.  Therefore this carcinoma is a ductal

carcinoma, not lobular carcinoma.  This case was seen in

consultation with Dr. **NAME[ZZZ].





CHANGE IN TYPE OF CARCINOMA: THIS IS AN INVASIVE DUCTAL CARCINOMA.







































          













   A.  SENTINEL LYMPH NODE #1:  NEGATIVE FOR CARCINOMA.

   

   B.  SENTINEL LYMPH NODE #2:  NEGATIVE FOR CARCINOMA.

   

   C.  RIGHT SIMPLE MASTECTOMY:  INVASIVE CARCINOMA OF THE BREAST WITH THE FOLLOWING FEATURES:

        1.  SPECIMEN AND PROCEDURE:  SIMPLE MASTECTOMY INCLUDING NIPPLE AND SKIN.

        2.  LYMPH NODE SAMPLING:  SENTINEL LYMPH NODES (SEE PARTS ""A"" AND ""B"" ABOVE).

        3.  SPECIMEN INTEGRITY:  SINGLE INTACT SPECIMEN (MARGINS CAN BE EVALUATED)

        4.  SPECIMEN SIZE:  12.5 X 12 X 4.5 CM.

        5.  SPECIMEN LATERALITY:  RIGHT.

        6.  TUMOR SITE:  7 O'CLOCK POSITION.

        7.  TUMOR SIZE:  1.5 CM IN GREATEST DIMENSION.

        8.  TUMOR FOCALITY:  SINGLE FOCUS OF INVASIVE CARCINOMA.

        9.  MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR:  SKIN, NIPPLE AND SKELETAL MUSCLE ARE NEGATIVE FOR CARCINOMA.

       10.  DUCTAL CARCINOMA IN SITU:  NOT IDENTIFIED.

       12.  LOBULAR CARCINOMA IN SITU:  NOT IDENTIFIED.

       13.  HISTOLOGIC TYPE OF INVASIVE CARCINOMA:  INVASIVE CARCINOMA WITH FEATURES OF LOBULAR CARCINOMA.

       14.  HISTOLOGIC GRADE:  NOTTINGHAM GRADE I (BLOOM-RICHARDSON SCORE 5/9 (TUBULE FORMATION - 3, NUCLEAR PLEOMORPHISM - 1, MITOSES - 1)).

       15.  SURGICAL MARGINS:

              a.  ALL SURGICAL MARGINS ARE NEGATIVE FOR CARCINOMA.

              b.  CLOSEST SURGICAL MARGIN IS THE DEEP MARGIN WHICH LIES 5 MM FROM THE TUMOR.

       16.  LYMPHOVASCULAR INVASION:  NOT IDENTIFIED.

       17.  PATHOLOGIC STAGING:  pT1c, pN0(sn) (STAGE IA).

       18.  ANCILLARY STUDIES:

              a.  ER/PR IMMUNOSTAINS WERE PERFORMED ON THE CORE BIOPSY (11S-4835) AND NOTED HERE FOR CONVENIENCE:  ER - 100% OF TUMOR CELLS STAIN  STRONGLY POSITIVE, PR - 90% OF TUMOR CELLS STAIN WEAKLY TO STRONGLY POSITIVE,  HER2 IMMUNOSTAINS - EQUIVOCAL.

              b.  HER2 FISH STUDY WILL BE PERFORMED ON BLOCK ""C3"" AND REPORT APPENDED.

       19.  ADDITIONAL PATHOLOGIC FINDINGS:  EXTENSIVE FIBROCYSTIC CHANGES INCLUDING FIBROSIS, DUCT ECTASIA, CYST FORMATION AND CHRONIC INFLAMMATION.





   

   Dr. **NAME[YYY] was consulted. To try to support the impression of lobular carcinoma immunosta

   in

   for E-Cadherin will be performed and report appended.







          













   A.  Received fresh in the OR is a 0.7 cm blue-stained lymph node which is bisected and touch

   preps are prepared.  TOUCH PREP DIAGNOSIS:  NEGATIVE FOR CARCINOMA ON TOUCH PREP AND GROSS

   EXAMINATION (KAR).  Submitted entirely.

   

   B.  Received fresh in the OR is 0.9 cm fatty lymph node with one end having blue stained

   tissue.  It is bisected and touch preps are prepared.  TOUCH PREP DIAGNOSIS:  NEGATIVE FOR

   CARCINOMA ON TOUCH PREP AND GROSS EXAMINATION (KAR).  Submitted entirely.

   

   C.  The discoid right simple mastectomy measures 12.5 x 12 x 4.5 cm and has an ellipse of

   skin attached on its surface which measures 11.3 x 6 cm.  The skin has a central normal

   nipple 0.5 cm in diameter in the middle of a 3 cm areola and with patches of blue staining

   around the areola.  The skin is unremarkable.  The specimen has orientation sutures as

   follows:  long lateral, short superior.  The superficial surgical margins consist of grossly

   unremarkable fat.  The deep surface is a flat fascial plane with tiny strands of attached

   skeletal muscle.  The specimen is inked as follows:  superior-superficial blue,

   inferior-superficial green, and deep black.  Sagital sections of the nipple are placed in

   cassette ""C1"".  Breadloafing reveals an ill-defined firm area at the 7 o'clock position

   measuring 3.5 x 2.5 x 2 cm at the deep aspect of which there is a 1.5 cm irregular stellate

   mass.  The edges of this mass are discrete and lie 5 mm from the deep margin, 3 cm from the

   inferior-superficial margin, and 2.5 cm deep to the skin ellipse.  There is a second 3 cm

   region of fibronodular tissue at the approximate 5 o'clock position.  Otherwise the  breast

   contains lobular adipose tissue.  The 7 o'clock lesion is sectioned and submitted entirely

   in cassettes ""C2"" through ""C10"".  Representative sections of the fibronodular area are

   submitted in cassettes ""C11"" through ""C16"".",,,,,
REG2,PROSTATE,0,PAT-40090596,1,REC-100000929911,"ClinicalHistory:
  Rule out carcinoma of prostate; ICD9 790.93; Elevated PSA.",,"FinalDiagnosis:
1.  Prostate, Core Biopsies x5 from Left Lobe:
Portions (5) of Prostatic Parenchyma Showing Extensive Involvement by Prostatic Adenocarcinoma, Gleason Histologic Score 7 of 10 (Major Pattern 4, Minor Pattern 3) Involving all Biopsy Cores (Approximately 50% of the Sample) with a Maximum Tumor Length of Approximately 1.3cm. 
Extensive Perineural Invasion is Present. 
High Grade Prostatic Intraepithelial Neoplasia (PIN III is Noted). 

2.  Prostate, Core Biopsies x5 from Right Lobe:
Portions of Prostatic Parenchyma Showing High Grade Prostatic Intraepithelial Neoplasia (PIN III). 
Negative for Carcinoma.

Note:
  This case is reviewed at the Departmental Surgical Pathology Conference on **DATE[Apr 8 2013] and a consensus diagnosis is rendered.",,"GrossDescription:
  Container 1:  Received in formalin labeled left lobe five cores are five cylindrical portions of tan to white, soft tissue ranging from 0.8 x 0.1cm to 1.6 x 0.1cm.  The specimen is submitted in toto as 1A and 1B.

  Container 2:  Received in formalin labeled right lobe five cores are seven cylindrical portions of tan to white, soft tissue ranging from 0.3 x 0.1cm to 1.8 x 0.1cm.  The specimen is submitted in toto as 2A and 2B.
AC:lefb **DATE[Apr 7 2013].","MicroscopicDescription:
  Slides reviewed.",1: Prostate biopsy2: Prostate biopsy,,
REG4,LUNG,0,PAT-01529478,2,REC-3000636469,"ClinicalHistory:
H/O cancer of vulva.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same 
FinalDiagnosis:
Left lung mass, biopsy:
  SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED.
DiagnosisComment:
Specimen signed out at **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.\X0A|",,"GrossDescription:
Received in formalin, labeled with the patient's name and birthdate but without specimen type are nine soft tan-white to gray cores ranging from 0.2 to 1.5 cm in length by 0.1 cm in width.  The entire specimen is submitted in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Large (L) lung mass 18g core bx,,
REG4,LUNG,0,PAT-10033963,1,REC-3000636833,,,"FinalDiagnosis:

Right upper lung lobe, bronchial biopsy:  POSITIVE FOR NON-SMALL CELL CARCINOMA
            (please see Comments)

Comments:
The morphological and immunophenotypic features are not entirely specific, however, a poorly differentiated adenocarcinoma is favored.  The possibility of squamous differentiation cannot be entirely excluded.  Immunohistochemical stains for CK7 and TTF-1 are strongly positive in cells of interest.  The tumor cells are also partially positive with MOC-31 and Ber-EP4, and focally positive with p63 and CK5/6.  CK20 is negative.  The preliminary results of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Aug 20 2011].    \X0A|",,"GrossDescription:
Received labeled with the patient's name are multiple tiny pieces of tan-pink and soft tissue measuring 0.7 x 0.7 x 0.2 cm in aggregate.  Entirely submitted in one cassette.","MicroscopicDescription:
Confirmed.",A: # 2 RUL bronchial biopsy R upper lobe for histopathology,,"AddendumComment:

Please see attached EGFR Mutation analysis report from Clarient (***PATH-NUMBER[1])."
REG4,LUNG,0,PAT-01622711,5,REC-3000637068,"ClinicalHistory:

V10.01 786.2 172.9
Procedure:->Needle Aspiration
Examine for:->Cancer
History/Clinical Impressions:->pleural effusion and RLL positive PET scan; h/o SCC tongue and melanoma./r/n","CytologyReview:
NEGATIVE FOR MALIGNANT CELLS
Blood and leukocytes present./r/n
NEGATIVE FOR MALIGNANT CELLS
Blood and leukocytes present.
See comment./r/n","FinalDiagnosis:
NEGATIVE FOR MALIGNANT CELLS
Blood and leukocytes present.
See comment./r/nDiagnosisComment:
The patient s clinical history is noted.  Immunohistochemical stains for S-100 and Melan-A (both markers associated with melanoma) are performed on sections from the cell blocks.  The Melan-A is negative, and there is only patchy nonspecific staining of histiocyte cytoplasm with the S-100 stain; no melanoma tumor cells are identified.

Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Jul 2 12]./r/n",,"GrossDescription:
70cc of cloudy amber colored fluid with clot
Preparation:
2 cytospins:     1 giemsa stain, 1 papanicolaou stain
2 pull smears:  1 giemsa stain, 1 papanicolaou stain
2 cell block./r/n",,A: Pleural fluid,,
REG4,LUNG,0,PAT-10013810,1,REC-3000637202,"ClinicalHistory:
History of lung carcinoma, type unspecified; S/P chemoradiation; now presenting with right upper lobe lung mass, increasing in size.","Other Case Numbers: #**ID-NUM/**ID-NUM/AA777546

.","IntraoperativeDiagnosis:
Touch Prep Diagnosis:     Necrotic material, suggest additional tissue if possible/SK
FinalDiagnosis:
Lung mass, core needle biopsy, clinically right upper lobe:
  Poorly differentiated NON-small cell carcinoma with necrosis
DiagnosisComment:
The patient reportedly has a previous biopsy diagnosis of carcinoma and is post-chemoradiation treatment.  The biopsy was apparently performed to retrieve tumor tissue for treatment protocol studies.

Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM|",,"GrossDescription:
Received fresh labeled ""XXXXXX"" are three cores of tan tissue measuring up to 1.3 cm in length and less than 0.1 cm in diameter.  Air-dried, Diff-Quik stained tissue imprints are prepared for intraoperative consultation.  Submitted in toto in one cassette, following formalin fixation.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right upper lobe lung mass (central),,
REG4,LUNG,0,PAT-10029487,1,REC-3000637597,"ClinicalHistory:
Right pleural effusion, pneumothorax, lung CA.",,"FinalDiagnosis:
RIGHT PLEURAL FLUID:  POSITIVE FOR MALIGNANT CELLS, COMPATIBLE WITH LUNG PRIMARY.",,"GrossDescription:
Received:  10 ml of cloudy light red fluid.
Prepared:  2 cytospin slides for Pap and DQ staining (treated with NH4Cl x 1).
Submitted: 1 cm x 1 cm cell button for cell block.",,A: RIGHT PLEURAL FLUID,,
REG4,LUNG,0,PAT-10040255,1,REC-3000637825,"ClinicalHistory:
Left pleural effusion.",,"FinalDiagnosis:
LEFT PLEURAL FLUID:  METASTATIC ADENOCARCINOMA, CONSISTENT WITH LUNG PRIMARY.
DiagnosisComment:
Tumor cells are immunopositive for CK 7, TTF-1, and Napsin-A; they are negative for CK 5/6, CK 20, CDX-2, and the prostate-associated markers p501s, PSA, and PSMA.  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Sep 11 2011].",,"GrossDescription:
Received:  980 cc. cloudy red fluid.
Prepared:  2 cytospin slides for Pap and DQ stains (treated with NH4Cl x 3).
Submitted:  1 cm x 1 cm cell button for a cell block.","MicroscopicDescription:
Cytologic preparations and cell block sections demonstrate numerous enlarged tumor cells with hyperchromatic and vesicular nuclei with marked pleomorphism, moderate amount of pale staining cytoplasm, and intracytoplasmic vacuoles.",A: LEFT PLEURAL FLUID,,
REG4,LUNG,0,PAT-10021272,1,REC-3000638342,"ClinicalHistory:
Right pleural effusion.",,"FinalDiagnosis:
RIGHT PLEURAL FLUID:  METASTATIC LUNG ADENOCARCINOMA.
DiagnosisComment:
The case was evaluated in conjunction with patient s previous right upper and middle lung biopsies (***PATH-NUMBER[1], **DATE[Jun 11 2009]), which demonstrated lung adenocarcinoma and appears morphologically identical.",,"GrossDescription:
Received:  950 cc. turbid red fluid.
Prepared:  2 cytospin slides for Pap and DQ stains (treated with NH4Cl x 1).
Submitted:  A 0.8 cm. diameter cell pellet for a cell block.","MicroscopicDescription:
Cytologic preparations show abundant cohesive clusters of tumor cells with enlarged, hyperchromatic nuclei, prominent nucleoli, and intracytoplasmic mucin with occasional gland formation.",A: RIGHT PLEURAL FLUID,,
REG4,LUNG,0,PAT-01076322,3,REC-3000638626,"ClinicalHistory:
Procedure:->Wash
Examine for:->Cancer
History/Clinical Impressions:->LLL mass and left pleural effusion./r/n","CytologyReview:
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with squamous cell carcinoma./r/n
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with squamous cell carcinoma.  Reviewed at staff conference.  Dr. **NAME[ZZZ] s office notified **DATE[Jun 15 12].  See also biopsy ***PATH-NUMBER[1]./r/n","FinalDiagnosis:
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with squamous cell carcinoma.  Reviewed at staff conference.  Dr. **NAME[ZZZ] s office notified **DATE[Jun 15 12].  See also biopsy ***PATH-NUMBER[1]./r/n",,"GrossDescription:
12cc of bloody, mucoid fluid
Preparation:
2 pull smears:  2 papanicolaou stain
1 cell block./r/n",,A: Bronchial Lavage/Washing left,,
REG4,LUNG,0,PAT-10016017,2,REC-3000638811,"ClinicalHistory:
Right side lung mass, history of left breast cancer, R/O metastasis, CT guided biopsy of right lung mass
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Right Lung mass, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Positive for non-small cell carcinoma.


Right Lung mass, CT-guided fine needle aspiration biopsy

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Non-small cell pulmonary adenocarcinoma (see comment).","FinalDiagnosis:

Right Lung mass, CT-guided fine needle aspiration biopsy

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Non-small cell pulmonary adenocarcinoma (see comment)

   

DiagnosisComment:
The malignant cells are positive for TTF-1 and cytokeratin 7, consistent with pulmonary adenocarcinoma. Cytokeratin 20, cytokeratin 5/6 and estrogen receptor show focal non-specific reactivity. The cells are non-reactive to p63, Brst-2 and mammoglobin (squamous and breast markers).\X0A|",,"GrossDescription:
Specimen consists of 7cc of grossly bloody, fixed fluid containing small particles.

2 CLH/PPPL prepped slide(s): 1 Pap stained,    1 Cell block
0 Review(s) by Pathologist.",,"A: Right Lung mass, FNA",,"AddendumComment:
Please see attached Clarient report for EGFR and IHC. Test ordered by Dr. **NAME[ZZZ YYY]."
REG4,LUNG,0,PAT-10037032,1,REC-3000638897,"ClinicalHistory:
Procedure->Biopsy
Procedure->Excision
Clinical History/Diagnosis/Condition->Left lung cancer./r/n",,"FinalDiagnosis:
A. Left upper lobe segment: Poorly differentiated squamous cell carcinoma, margins free in the sections examined. (see microscopic description for tumor information).

  Lymphatic invasion present.

  Emphysematous changes

B. Left pulmonary artery lymph nodes: Anthracotic lymph nodes x2, negative for metastasis.

C. Hilar lymph nodes: Anthracotic lymph nodes x3, negative for metastasis.

D. Subcarinal lymph node: Anthracotic lymph node x1, negative for metastasis./r/nDiagnosisComment:
Immunohistochemical stains for the squamous markers p63 is positive and CK 5/6 is focally positive. The adenocarcinoma markers CEA and B72.3 as well as TTF1 are negative. The immunohistochemical profile supports the diagnosis if squamous cell carcinoma. Intradepartmental consultation with Dr. **NAME[ZZZ]./r/n",,"GrossDescription:
A.  Labeled:        Patient name and medical record number, designated left upper lobe segment
Specimen:      Left upper lobe segment  
Size:        11.5 x 6.5 x 3 cm  
Weight:        65 grams  
Description:      Pleura appears unremarkable    
Tumor:        
      Location:      Peripheral    
      Size:         1.8 x 1.4 x 0.8 cm  
      Description:      Irregular firm mass.
    Extent of invasion:  
      Bronchial involvement:    None
      Visceral pleural involvement:  None    
      Mediastinal pleural involvement:  None  
      Interlobar fissure extension:  None    
      Blood vessel invasion:    None
      Invasion of attached tissues:  None  
  Additional tumors:    None
Margins:            Bronchial:      4 cm
      Vascular:      4 cm  
      Parenchymal surfaces:    4 cm
    Other tissues:      None
Additional findings:    Tumor 0.3 cm away from visceral pleura
Lymph nodes:      None
Section code:    
      Block A1:      Vascular margin
      Block A2:      Bronchial margin
    Blocks A3-5:      Tumor
      Block A6:      Uninvolved lung parenchyma
      Block A7:      Possible segmental lymph node

B.  Labeled:        Patient name and medical record number, designated left pulmonary artery lymph
          node   Specimen:      Two, dark-tan pieces of tissue (formalin)
  Findings:      Two, lymph nodes measuring up to 1.7 x 1.7 x 0.8 cm
  Submitted/Blocks:    Bisected 2 lymph node/2
  
C.  Labeled:        Patient name and medical record number, designated hilar lymph node
  Specimen:      Single, dark tan piece of tissue (formalin)
  Findings:      Three, lymph node identified measuring up to 1.8 x 1 x 0.7 cm
  Submitted/Block:      Entirely/1

D.  Labeled:        Patient name and medical record number, designated subcarinal lymph node
  Specimen:      Single, tan dark piece of tissue (formalin)
  Findings:      One, lymph node measuring up to 0.7 x 0.6 x 0.3 cm
   Submitted/Block:      Entirely/1./r/n","MicroscopicDescription:
A-D.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.

Lung Cancer Information (Based on AJCC/UICC TNM, 7th edition)

Tumor Size: 1.8 x 1.4 x 0.8 cm
Tumor Focality: Single focus
Histologic Type: Squamous cell carcinoma
Histologic Grade: Poorly differentiated
Visceral Pleura Invasion: Absent
Tumor Extension: Not identified
Margins: Uninvolved, the tumor comes to within 4 cm of the bronchial, vascular, and parenchymal margins
Treatment Effect (if applicable): Not applicable
Lymph-Vascular Invasion: Present
Pathologic Staging:
  Primary Tumor: pT1a 
  Regional Lymph Nodes: pN0 (parts B, C and D)
    Number examined: 6
    Number involved: 0
  Distant Metastasis: Not applicable
Additional Pathologic Findings: Emphysematous changes./r/n","A: A2 Left upper lobe segment, excision
B: A1 Left pulmonary artery lymph node, biopsy
C: A3 Hilar lymph node, biopsy
D: A4 Subcarinal lymph node, biopsy",,
REG4,LUNG,0,PAT-10033817,1,REC-3000638945,"ClinicalHistory:
170.9
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Right shoulder, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Sep 15 11])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  High grade malignancy.
? Melanoma.


Right shoulder, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Sep 15 11])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  High grade malignancy.
? Melanoma.","FinalDiagnosis:

Right shoulder, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Sep 15 11])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  Malignant neoplasm
Immunostain pending and addendum report to follow \X0A|",,"GrossDescription:
Specimen consists of 2 passes = 3 air-dried slides prepared by physician along with 30cc of clear, colorless, formalin fixed fluid containing cores.

3 Physician prepped slide(s):    3 Air-dried (Diff-quik stained)
2 CLH/PPPL prepped slide(s):    1 Pap stained,    1 Cell block
1 Review(s) by Pathologist:

Adequacy evaluation #1 (pass #    1     ) = _X_  Adequate
88172                 ___  Insufficient.",,"A: Right shoulder, FNA",,"AddendumDiagnosis:
The tumor cells are positive for pankeratin AE1/AE3, CK7, TTF1, CK19; negative for Ck20, CDX2, ER, CA19-9, S100, Melan A and HMB45. The immunostaining pattern is suggestive of metastatic carcinoma from lung or thyroid primary. Clinical and radiological correlation is recommended.  Dr. **NAME[YYY] concurs."
REG4,LUNG,0,PAT-10034389,1,REC-3000638959,"ClinicalHistory:
Right lung mass.","Other Case Numbers: cc:  **NAME[ZZZ M YYY], MD
.","IntraoperativeDiagnosis:
Touch Prep Diagnosis:     Adequate/OC/TM
FinalDiagnosis:
Mass, right lung, core biopsy:    POORLY DIFFERENTIATED ADENOCARCINOMA (see Comment)
DiagnosisComment:
The histologic and immunohistochemical data support a lung origin.  Please correlate clinically and with the radiographic findings.\X0A|",,"GrossDescription:
Received fresh labeled ""XXXXXX"" are approximately seven cores of tan-white tissue measuring up to 1.0 cm in length and <0.1 cm in diameter.  Air-dried, Diff-Quik stain imprints are prepared for intraoperative consultation.  A portion of the specimen is saved for possible cultures.  The remaining tissue is placed in formalin, and submitted in toto for light microscopy evaluation in one cassette.","MicroscopicDescription:
The Hematoxylin and Eosin-stained sections demonstrates thin cores of lung parenchyma infiltrated by numerous tumor cells found singly or in nests.  The tumor cells are variable in size and shape and generally have abundant eosinophilic cytoplasm with indistinct cytoplasmic boarders and hyperchromatic large nuclei.  A few associated mitotic figures are seen.  The tumor lacks a glanular pattern and no intercellular bridges are seen.  The tumor cells are found in association with acute inflammation and background fibrosis.  No granulomas or necrosis is seen.  Focal benign cartilage and focal benign respiratory mucosa are present.  The Diff-Quik touch prep stains demonstrate numerous large abnormal cells with pleomorphic hyperchromatic nuclei and abundant eosinophilic cytoplasm.  In the background, there are numerous macrophages, neutrophils and fewer small lymphocytes.  Immunohistochemical stains were conducted.  The tumor labels with cytokeratin 7, cytokeratin 20 (focal), p63 (rare), cytokeratin 5/6 (rare, weak), and TTF-1.  The tumor does not label with CDX2 or PSA (positive controls intact). 

NOTES:  Dr. **NAME[XXX] has reviewed this case and concurs with the diagnosis.  Results were discussed with Dr. **NAME[M. WWW] on **DATE[May 19 2012]. 


References:
1.  Rekhtman N, Ang DC, Sima CS, **NAME[VVV] WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and   squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011
2.  Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2,   S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung. J Thorac Oncol. 2011.",A: Right lung mass,,
REG4,LUNG,0,PAT-10006129,1,REC-3000639062,"ClinicalHistory:
Free air.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Colon, segmental colectomy, clinically sigmoid colon:            PAS 9
  1.   NEUROENDOCRINE CARCINOMA, POORLY DIFFERENTIATED (SEE COMMENT)
  2.   CARCINOMA PRESENT THROUGH MUSCULARIS PROPRIA INTO SUBSEROSAL SOFT TISSUE
  3.   AT LEAST ONE OF FOURTEEN LYMPH NODES POSITIVE FOR METASTASIS; SIZE: 1.3 MM  
  4.   RESECTION MARGINS VIABLE AND NEGATIVE FOR MALIGNANCY
  5.   ACUTE DIVERTICULITIS WITH SEROSITIS

Tumor Information:
Specimen:        Sigmoid colon
Procedure:        Colectomy
Specimen integrity:      Intact
Specimen size:      See gross
Tumor site:        Colon, within a diverticulum
Tumor size:        0.8 cm
Tumor focality:      Single tumor
Histologic type:      Neuroendocrine carcinoma
Histologic grade:      High grade
Mitotic rate:        Twenty mitotic figures per ONE hpf
Microscopic tumor extension:    Through MP and into subserosal soft tissue.  Serosa not involved
          (Tumor extends to within < 0.1 MM of serosal surface)
Margins:        All negative
Lymphovascular invasion:    Presumed positive due to nodal involvement
Perineural invasion:      Not identified
Pathologic Staging:      If tumor is primary in colon: pT3, pN1
Regional lymph nodes:    At least 1 of 12 nodes positive for metastasis (1/12)
Distant metastasis:      Cannot assess
  
DiagnosisComment:
While this is favored to be a primary neoplasm in the colon, the possibility of this lesion representing metastasis is not entirely ruled out.  The tumor in the current biopsy does not resemble the well differentiation pulmonary adenocarcinoma that was seen in the lung in prior cases ***PATH-NUMBER[1] and ***PATH-NUMBER[2].  Clinical correlation is suggested.

The focally inflamed and necrotic diverticulum that is favored to be responsible for the perforation is not associated with the tumor.

Immunohistochemistry stains show positive tumor staining for synaptophysin, CD56, TTF-1 and CK7.  Stains are negative for CK20 and CDX2.  PCK stain shows weak and patchy staining.  

Stains of nodal tissue show staining for synaptophysin, with surrounding lymphoid cells staining for LCA.  

Findings discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jul 19 12].  This case will be for routine intradepartmental review.   \X0A|",,"GrossDescription:
Received in formalin, labeled ""sigmoid colon"" is a segment of large bowel (9 cm in length by 2.7 cm in diameter).  The proximal resection margin is stapled and the distal resection margin is left open.  The proximal resection margin is inked black, the distal resection margin is inked red and the mesenteric resection margin is inked green.  The specimen is opened to reveal multiple diverticuli.  No obvious masses are grossly identified.  A semi-firm and possibly calcified tan-brown nodule (0.5 x 0.4 x 0.3 cm) is attached to a piece of epiploicae.  Representative sections are submitted as follows:

Block summary:
1.  -  Perpendicular section of proximal resection margin with diverticulum.
2.  -  Perpendicular section of distal resection margin with diverticulum.
3.  -  Perpendicular section of mesenteric resection margin.
4-12.  -  Sections of diverticuli.
13.  -  Section of nodule, bisected.
14.  -  Additional section of possible tumor/slightly firm area within wall.
15-35.  -  Sections of fat, entirely submitted.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Sigmoid colon-staple line is proximal,,
REG4,LUNG,0,PAT-10034389,1,REC-3000639065,"ClinicalHistory:
Right lung mass.","Other Case Numbers: cc:  **NAME[ZZZ M YYY], MD
.","IntraoperativeDiagnosis:
Touch Prep Diagnosis:     Adequate/OC/TM
FinalDiagnosis:
Mass, right lung, core biopsy:    POORLY DIFFERENTIATED ADENOCARCINOMA (see Comment)
DiagnosisComment:
The histologic and immunohistochemical data support a lung origin.  Please correlate clinically and with the radiographic findings.\X0A|",,"GrossDescription:
Received fresh labeled ""XXXXXX"" are approximately seven cores of tan-white tissue measuring up to 1.0 cm in length and <0.1 cm in diameter.  Air-dried, Diff-Quik stain imprints are prepared for intraoperative consultation.  A portion of the specimen is saved for possible cultures.  The remaining tissue is placed in formalin, and submitted in toto for light microscopy evaluation in one cassette.","MicroscopicDescription:
The Hematoxylin and Eosin-stained sections demonstrates thin cores of lung parenchyma infiltrated by numerous tumor cells found singly or in nests.  The tumor cells are variable in size and shape and generally have abundant eosinophilic cytoplasm with indistinct cytoplasmic boarders and hyperchromatic large nuclei.  A few associated mitotic figures are seen.  The tumor lacks a glanular pattern and no intercellular bridges are seen.  The tumor cells are found in association with acute inflammation and background fibrosis.  No granulomas or necrosis is seen.  Focal benign cartilage and focal benign respiratory mucosa are present.  The Diff-Quik touch prep stains demonstrate numerous large abnormal cells with pleomorphic hyperchromatic nuclei and abundant eosinophilic cytoplasm.  In the background, there are numerous macrophages, neutrophils and fewer small lymphocytes.  Immunohistochemical stains were conducted.  The tumor labels with cytokeratin 7, cytokeratin 20 (focal), p63 (rare), cytokeratin 5/6 (rare, weak), and TTF-1.  The tumor does not label with CDX2 or PSA (positive controls intact). 

NOTES:  Dr. **NAME[XXX] has reviewed this case and concurs with the diagnosis.  Results were discussed with Dr. **NAME[M. WWW] on **DATE[Mar 19 2012]. 


References:
1.  Rekhtman N, Ang DC, Sima CS, **NAME[VVV] WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and   squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011
2.  Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2,   S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung. J Thorac Oncol. 2011.",A: Right lung mass,,"AddendumComment:
This Addendum is created to incorporate additional staining results. 

Microscopic Description:
The Mucicarmine histochemical stain demonstrates focal mucin production, confirming the diagnosis of adenocarcinoma.  The Glypican-3 immunohistochemical stain does not label the tumor (positive control intact).  


These additional results confirm the original diagnosis of poorly differentiated adenocarcinoma.  The original results remain unchanged.  



Reference:
1.   Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2,   S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung. J Thorac Oncol. 2011."
REG4,LUNG,0,PAT-10029008,1,REC-3000639359,"ClinicalHistory:
Right lung mass - 8 cm.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
Bronchial biopsy:  POORLY-DIFFERENTIATED ADENOCARCINOMA, see Comment
DiagnosisComment:
Immunohistochemical stains show that the tumor cells are positive for CK7 and TTF-1 while negative for CK5/6, CK20 and synaptophysin, compatible with the diagnosis.  The lung primary is favored.  Please correlate clinically.  Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnosis.  Please also refer to the concurrent bronchial washing/ brushing [***PATH-NUMBER[1].  The result was communicated to Dr. **NAME[XXX].\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, bronchial biopsies"" are multiple fragments of tan-red blood clot and small fragments of mucosa, measuring in aggregate 0.5 x 0.5 x 0.2 cm.  Entirely one block.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Bronchial biopsy,,
REG4,LUNG,0,PAT-10033877,1,REC-3000639360,,"CytologyReview:

Endobronchial Lung Biopsies, Right Middle Lobe, Cytology and Cell Block:  

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy.","FinalDiagnosis:

Endobronchial Lung Biopsies, Right Middle Lobe, Cytology and Cell Block:  

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
DiagnosisComment:
Features are consistent with a moderately differentiated squamous cell carcinoma. \X0A|",,"GrossDescription:

Received labeled ""RML biopsy"" is 25.0 mL of pinkish and slightly turbid fluid with seven white-tan and pink fragments of soft material measuring up to 0.2 cm.  The fluid is centrifuged and the resulting cell pellet is submitted for Pap stain and Diff-Quik stain.  The seven fragments of tan-pink and soft material are submitted for cell block. 

4 PPPL prepared cytospin slides (2 Pap stained, 2 Diff-Quik stained)
1 Cell block.",,"A: Endobronchial lung biopsies, (R) middle lobe",,
REG4,LUNG,0,PAT-10042218,1,REC-3000639469,"ClinicalHistory:
793.1
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Left adrenal mass

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Feb 18 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  METASTATIC Adenocarcinoma.


Left adrenal mass

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Feb 18 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  METASTATIC Adenocarcinoma.","FinalDiagnosis:

Left adrenal mass

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Feb 18 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  METASTATIC Adenocarcinoma
DiagnosisComment:
The tumor cells are positive for CK7, CDX2 and CK19; focally positive for CK20; negative for TTF1 and CA19-9. The immunostaining pattern is suggestive of upper GI, biliopancreatic or urinary bladder primary.  Clinical and radiological correlation is recommended.\X0A|",,"GrossDescription:
Specimen consists of 3 ""passes"" = 1 air-dried slide prepared by physician along with 50cc of clear, colorless, fixed fluid with cores.

1 Physician prepped slide(s):    1 Air-dried (Diff-quik stained)
2 CLH/PPPL prepped slide(s):   1 Pap stained,    1 Cell block
1 Review(s) by Pathologist:

Adequacy evaluation #1 (pass #   1       ) = _X_  Adequate
88172                 ___  Insufficient.",,A: Left adrenal mass,,"AddendumDiagnosis:
Dr. **NAME[YYY] concurs."
REG4,LUNG,0,PAT-10028110,2,REC-3000639551,"ClinicalHistory:
786.6
Result to  **NAME[ZZZ YYY]
Procedure->Biopsy
Clinical History/Diagnosis/Condition->RUL lung mass former smoker./r/n",,"FinalDiagnosis:
Lung, right upper lobe:  Moderately differentiated adenocarcinoma./r/nDiagnosisComment:
H\T\E-stained sections demonstrate sclerotic tissue with malignant tumor cells forming variably discernible glandular structures.  Immunohistochemical stains are performed; all controls react appropriately.  The tumor cells are positive for cytokeratin 7 and TTF-1, and are negative for cytokeratin 20, cytokeratin 5/6, and p63.  The morphologic and immunophenotypic features are those of a moderately differentiated adenocarcinoma and they are further consistent with a lung primary.  

Case reviewed in Pathology Staff Conference on **DATE[Mar 22 12].  The findings were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Mar 22 12] at 4:08 p.m./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated lung biopsy per requisition
Specimen:    Four, cores and several fragmented cores (formalin)
Size:           Up to 0.4 x 0.1 x 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic finding./r/n","A: Lung RUL, core biopsy",,
REG4,LUNG,0,PAT-10028144,2,REC-3000639603,"ClinicalHistory:
Right neck supraclavicular lymph node (level 4) 1.7 x 1.5 x 1 cm / Hx of liver cancer (as per patient).",,"IntraoperativeDiagnosis:
Lymphoid tissue present; sample submitted for flow cytometry at the request of Dr. **NAME[ZZZ], assessed by **NAME[M. YYY] MD/**INITIALS.
FinalDiagnosis:
ULTRASOUND-GUIDED FNA AND CORE NEEDLE BIOPSY, RIGHT NECK SUPRACLAVICULAR LYMPH NODE (LEVEL 4):  POORLY DIFFERENTIATED NON-SMALL CELL CARCINOMA (SEE COMMENT).
DiagnosisComment:
Immunohistochemical stains were positive for cytokeratin 7 and TTF-1.  Negative stains include cytokeratin 20, liver markers (HepPar-1 and Glypican), squamous cell markers (CK 5/6 and p63), and Napsin-A.  This staining profile is suggestive of a pulmonary adenocarcinoma. 

Flow cytometric studies show no evidence of an abnormal lymphoid population.",,"GrossDescription:
Received:  5 DQ stained smears.
        Tissue fragments in formalin solution.
Submitted:  2 tissue fragments measuring up to 5 mm in length for a cell block.","MicroscopicDescription:
The cytologic smears and core needle biopsy sections show rare irregular nests of large, pleomorphic tumor cells with a high nuclear to cytoplasmic ratios.  There is also a polymorphous population of lymphoid cells.",A: RIGHT NECK SUPRACLAVICULAR LYMPH NODE (LEVEL 4) US-GUIDED FNA AND CNB,,"Interpretation:
RIGHT NECK SUPRACLAVICULAR LYMPH NODE:  
- NO MONOCLONAL B-CELL OR IMMUNOPHENOTYPICALLY ABNORMAL T-CELL POPULATION IDENTIFIED.

                         IMMUNOPHENOTYPIC ANALYSIS
%POS  MARKER   CLONE              EXPRESSION
--------------------------------------------------------------------
 81   CD3     (UCHT1)  T-cell antigen receptor associated,
                       immunocompetent T-cells.
 22   CD4      (T4)    T-helper cells, receptor for Class II and HIV
                       antigens.
 60   CD8      (T8)    T-suppressor/cytotoxic cells, receptor for 
                       HLA Class I.
  3   CD10    (ALB1)   Common acute lymphoblastic leukemia antigen 
                       (CALLA), granulocytes.
 15   CD19   (J3-119)  Pan B-cell, pre-B ALL.
 11   CD20    (B9E9)   Pan B-cell.
  9   CD22  (SJ10.1H11)Pan B-cell.
100***CD45    (J.33)   Pan leukocytes, LCA.
  1   CD3-56+ (NKH-1)  Natural killer cells (CD3-).
  8   Kappa            Kappa light chain.
  5   Lambda           Lambda light chain.
***strong intensity

POPULATION REPORTED:  CD45-BRIGHT LYMPHOID POPULATION

COMMENT:  Flow cytometric evaluation performed on a sparsely cellular sample with a limited number of markers shows a predominance of T-lymphocytes with both CD4 and CD8 subsets (CD4:CD8 ratio=0.4).  There is no obvious evidence of B-monoclonality.  Sampling is not optimal.

This test has not been cleared or approved by the U.S. Food and Drug Administration, but the FDA does not require this test to go through premarket FDA review.  **INSTITUTION Pathology Laboratory, which is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing, has developed this test's performance characteristics.  This test should be used for clinical purposes and should not be regarded as investigational or research."
REG4,LUNG,0,PAT-10037087,1,REC-3000639843,"ClinicalHistory:
Pneumonia, Bronchoscopy
  C) Specimen processed using ThinPrep monolayer technology.
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

A)Brushing at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Large cell adenocarcinoma of the lung.
  

B)Biopsy at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Atypical
Cytology: Reactive bronchial cells.
Cell block is pending.

   

C)Washing at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology: Large cell adenocarcinoma.
Cell block is pending.


A)Brushing at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Adenocarcinoma
  

B)Biopsy at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Atypical
Cytology and cell block: Reactive bronchial cells

   

C)Washing at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Adenocarcinoma.","FinalDiagnosis:

A)Brushing at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Adenocarcinoma
  

B)Biopsy at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Atypical
Cytology and cell block: Reactive bronchial cells

   

C)Washing at right upper lobe

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Adenocarcinoma
   
\X0A|",,"GrossDescription:
A)  Specimen consists of 2 fixed slides prepared by physician.

2 Physician prepped slide(s):    2 Fixed (Pap stained)

0 Review(s) by Pathologist:

B)  Specimen consists of 10cc of hazy, pink, unfixed fluid with small particles.

3 CLH/PPPL prepped slide(s):    1 Diff-quik stained,    1 Pap stained,    1 Cell block
0 Review(s) by Pathologist:


C)  Specimen consists of 5cc of cloudy, red, unfixed mucoid fluid.

2 CLH/PPPL prepped slide(s):    1 Pap stained,    1 Cell block
0 Review(s) by Pathologist:.",,"A: Brushing at right upper lobe
B: Biopsy at right upper lobe
C: Washing at right upper lobe",,
REG4,LUNG,0,PAT-10013228,1,REC-3000639885,"ClinicalHistory:
Right lung CA./r/n",,"FinalDiagnosis:
A.  Lung, right lower lobe: Adenocarcinoma (see template below).

B.  Lymph node, inferior pulmonary ligament: Negative for tumor (1).

C.  Lymph node, pulmonary artery: Metastatic adenocarcinoma (1)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ] on **DATE[Sep 18 08]./r/n",,"GrossDescription:
A.  Labeled:      patient name and medical record number, designated right lower lobe of lung
Specimen:    lower lobe of lung  
Size:      18.5 x 12 .5 x 3.0 cm  
Weight:      281.5 grams  
Description:    dusky brown gray smooth to partly shaggy  
Orientation:    none given  
Tumor:        
    Location:    superior segment, close to hilum  
    Size:      1.0 x 1.0 x 0.7 cm  
    Description:    tan-white slightly firm area
    Extent of invasion:
        Visceral pleural involvement:  none    
        Mediastinal pleural involvement:  none
        Interlobar fissure extension:  none    
        Blood vessel invasion:    none
        Invasion of attached tissues:  no attached tissue  
Margins:            Bronchial:    greater than 12 cm
      Vascular:    greater than 10 cm    

Section code:    
       Block 1:    bronchial margin
    Block 2:    vessel margins
    Block 3:    tumor
    Blocks 4-30:    entire superior segment, anterolateral area including fibrotic area
    Blocks 31-33:    representative sections of normal appearing lung tissue 

B.  Labeled:      patient name and medical record number, designated inferior pulmonary ligament lymph node 
  Specimen:    tan-gray smooth nearly ovoid lymph node (formalin)
  Size:      0.6 x 0.5 x 0.4 cm
  Submitted/Block:    entirely/1

C.  Labeled:      patient name and medical record number, designated pulmonary artery lymph node
  Specimen:    tan to dark gray firm ovoid lymph node (formalin)
  Size:      1.2 x 1.0 x 0.7 cm
  Submitted/Block:    entirely 1./r/n","MicroscopicDescription:
A. CANCER INFORMATION

Tumor size:  1.0 x 1.0 x 0.7 cm
Histologic type:  Adenocarcinoma
Histologic grade:     G2: Moderately differentiated
Pathologic Staging:  
  Primary Tumor:  pT1
  Regional Lymph Nodes:  pN1
    Number examined:  2 (parts B and C)
    Number involved:  1 (part C., pulmonary artery lymph node)
  Distant Metastasis:  pMX
Margins:  Uninvolved by invasive carcinoma          
Direct Extension of Tumor:  None identified
Venous (Large vessel) invasion:  None identified
Arterial (Large vessel) invasion:  None identified
Additional pathologic findings:  Focal fibrosis, emphysematous changes, and anthracotic pigmentation 

B-C.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Right lower lobe of lung
B: Inferior pulmonary ligament lymph node
C: Pulmonary artery lymph node",,"AddendumDiagnosis:
Lung Right Lower Lobe Tissue S08-14336-A3:  No EGFR alteration detected./r/n
Lung, right lower lobe tissue S08-14336-A3:  ALK gene rearrangement by FISH:  Not Detected./r/nAddendumComment:
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA, and reported by **NAME[YYY XXX], M.D., on **DATE[Aug 22 2011].


Comment:  ALK rearrangement was not detected using the ALK dual color, break-apart rearrangement assay from **INSTITUTION 
    (**NAME[WWW] Molecular).  The absence of an ALK rearrangement suggest that the patient may not respond to ALK 
    inhibitors.  Clinical correlation is suggested.

    Reference range:
    Not Detected:  Less than or equal to 15% of cells with split signals (3  ALK and 5  ALK signals apart by greater 
    than 2 times signal size or single 3  ALK signal) in 50 cells scored.
    Detected:  Greater than 15% of cells with split signals (3  ALK and 5  ALK signals apart by greater than 2 times 
    signal size or single 3  ALK signal) in 50 cells scored.

    Methodology:
    After deferring the tumor area on an H\T\E slide form this formalin-fixed paraffin-embedded (FFPE) patient 
    specimen, ALK gene rearrangement was assessed utilizing the LSI ALK Dual Color, Break Apart Probe assay 
    (**NAME[WWW] Molecular).  The identification probes for LSI ALK 5  probe (SpectrumGreen) and LSI ALK 3  probe 
    (SpectrumOrange) were hybridized according to the manufacturer s guidelines.  At least 50 non-overlapping 
    nuclei were analyzed and the localization of the LSI ALK 5  probe (green) and LSI ALK 3  probe (orange) signals 
    were recorded and interpreted.

    Intended Use:
    The LSI ALK (Anaplastic Lymphoma Kinase) dual Color, Break Apart Rearrangement Probe (Abbot Molecular) is 
    designed to detect rearrangements of the ALK gene.  Fusion of the ALK gene with the echinoderm microtubule-
    associated protein-like 4 gene (EML4-ALK) can be detected in a subset of non-small cell lung cancers (NSCLC).  
    EML4-ALK fusion is observed primarily in lung adenocarcinoma.  Patient s who harbor this mutation may 
    respond to ALK inhibitors.  Nature 448, 561-566 (2 **DATE[Sep 2007]).  Identification of the transforming EMBL4-ALK 
    fusion gene in non-small-cell lung cancer./r/n"
REG4,LUNG,0,PAT-10040251,1,REC-3000640185,"ClinicalHistory:
Lung CA, possible brain metastasis, assess for abnormal cells.",,"FinalDiagnosis:
A.  CSF CYTOLOGY TUBE #1:  NEGATIVE FOR MALIGNANT CELLS.
 
B.  CSF CYTOLOGY TUBE #2:  NEGATIVE FOR MALIGNANT CELLS.",,"GrossDescription:
Received:  A) 1.5 ml of clear colorless fluid.
       B) 2 ml of clear colorless fluid.
Prepared:  A) 2 cytospin slides for DQ/Pap stain.
       B) 2 cytospin slides for DQ/Pap stain.",,"A: CEREBROSPINAL FLUID CYTOLOGY-TUBE #1
B: CEREBROSPINAL FLUID CYTOLOGY-TUBE #2",,
REG4,LUNG,0,PAT-10040210,1,REC-3000640302,"ClinicalHistory:
Mediastinal mass, rule out malignancy.",,"FinalDiagnosis:
ENDOBRONCHIAL BIOPSY OF LEFT MAINSTEM BRONCHUS MASS:  SMALL CELL CARCINOMA.",,"GrossDescription:
Specimen:  Soft tan tissue, received in saline.
Number of segments:  2.    
Size:  Up to 0.4 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.","MicroscopicDescription:
The tumor cells are immunoreactive for CD56, synaptophysin, chromogranin, cytokeratin AE1/AE3 and TTF-1.  A study for CD45 is negative.",A: ENDOBRONCHIAL BIOPSY OF LEFT MAINSTEM BRONCHUS MASS,,
REG4,LUNG,0,PAT-10038777,1,REC-3000640637,"ClinicalHistory:


Procedure:->Wash
Examine for:->Cancer
History/Clinical Impressions:->**AGE[in 60s] y/o male with newly diagnosed adenoca of lung./r/n","CytologyReview:
NEGATIVE FOR MALIGNANT CELLS
Admixture of ciliated columnar cells, macrophages, and few leukocytes./r/n
NEGATIVE FOR MALIGNANT CELLS
Admixture of ciliated columnar cells, macrophages, and few leukocytes./r/n","FinalDiagnosis:
NEGATIVE FOR MALIGNANT CELLS
Admixture of ciliated columnar cells, macrophages, hemosiderin laden macrophages, red blood cells and few leukocytes./r/n",,"GrossDescription:
5cc bloody fluid
Preparation:
2 pull smears:  2 papanicolaou stain
1 cell block./r/n",,A: Bronchial Lavage/Washing,,
REG4,LUNG,0,PAT-10036620,1,REC-3000640732,"ClinicalHistory:
Right mainstem mass.",,"FinalDiagnosis:
BRONCHIAL WASHING CYTOLOGY:  
- ATYPICAL DEGENERATING CELLS CONSISTENT WITH SQUAMOUS CELL CARCINOMA.",,"GrossDescription:
Received:  15 ml of cloudy reddish fluid.
Prepared:  1 ThinPrep slide for Pap stain, treated with CytoLyt x1.
Submitted:  5 mm in diameter cell pellet for a cell block.",,A: BRONCHIAL WASHING CYTOLOGY,,
REG4,LUNG,0,PAT-01331412,2,REC-3000653501,"ClinicalHistory:
Lung cancer.",,"FinalDiagnosis:
PLEURAL FLUID CYTOLOGY:  METASTATIC POORLY DIFFERENTIATED CARCINOMA.
DiagnosisComment:
The cytologic preparations show crowded clusters of pleomorphic tumor cells, devoid of keratinization or gland formation.  Immunohistochemical staining of the tumor is positive with cytokeratin 7 and cytokeratin 20.  Staining is negative with TTF-1, Napsin-A, CDX-2, and villin.  The findings are compatible with metastatic non-small cell lung cancer.",,"GrossDescription:
Received:  800 cc. turbid red-orange colored fluid.
Prepared:  2 cytospin slides for Pap and DQ stains (treated with NH4Cl x 2).
Submitted:  cell button for a cell block, measuring up to 1 cm.",,A: PLEURAL FLUID,,
REG4,LUNG,0,PAT-10041807,1,REC-3000653664,"ClinicalHistory:
Lung bx ***PATH-NUMBER[1].
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSES:

A.  Lung biopsy, clinically ""left lower lobe mass"":
  MODERATELY DIFFERENTIATED ADENOCARCINOMA          PAS 9

B.  Lung biopsy, clinically ""right main bronchus biopsy"":
  MODERATELY DIFFERENTIATED ADENOCARCINOMA          PAS 9
DiagnosisComment:
Immunohistochemistry stains are positive for PCK/OSCAR, CK7 and TTF-1 (part B).  Stains are negative for CK20, CDX2, p63, keratin 5/6 and synaptophysin (part B).  CK7 and TTF-1 stains are also positive for part A.  

The findings are most compatible with adenocarcinoma of lung origin.  


Preliminary findings were discussed with Dr. **NAME[ZZZ YYY] and Dr. **NAME[XXX WWW] on **DATE[Aug 15 11].\X0A|",,"GrossDescription:
Specimen A:  Received in formalin, labeled ""LLL lung biopsy"" are multiple irregular pieces of soft to rubbery tan-red tissue (0.7 x 0.6 x 0.3 cm in aggregate).  The entire specimen is submitted in A.

Specimen B:  Received in formalin, labeled ""right main bronch biopsy"" are multiple irregular pieces of soft to rubbery tan-red tissue (0.7 x 0.5 x 0.2 cm in aggregate).  The entire specimen is submitted in B.","MicroscopicDescription:
A-B:  The microscopic findings support the diagnoses.","A: LLL mass bx
B: Right main bronc bx",,
REG4,LUNG,0,PAT-10042219,1,REC-3000653830,,,"FinalDiagnosis:
SPUTUM CYTOLOGY#2 OF 3:  CLUSTERS OF ATYPICAL CELLS CONSISTENT WITH ADENOCARCINOMA.
DiagnosisComment:
The ThinPrep slide shows clusters of atypical cells consistent with an adenocarcinoma. They are difficult to identify on the cell block preparation.",,"GrossDescription:
Received:  2.5 ml of cloudy yellow viscous specimen.
Prepared:  1 ThinPrep slide for Pap stain, treated with Sputasol and CytoLyt x1.
       2 mm in diameter cell pellet for a cell block.",,A: SPUTUM CYTOLOGY#2 OF 3,,
REG4,LUNG,0,PAT-10037087,1,REC-3000654028,"ClinicalHistory:
Pericardial effusion
  Specimen processed using ThinPrep monolayer technology.
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Pericardial fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Metastatic adenocarcinoma, lung primary.


Pericardial fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Metastatic adenocarcinoma, consistent with lung primary.","FinalDiagnosis:

Pericardial fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Metastatic adenocarcinoma, consistent with lung primary.
   
\X0A|",,"GrossDescription:
Specimen consists of 30cc of opaque, bright yellow, unfixed fluid.

3 CLH/PPPL prepped slide(s):    1 Diff-quik stained,    1 Pap stained,    1 Cell block.",,A: Pericardial fluid,,
REG4,LUNG,0,PAT-01544642,2,REC-3000654128,"ClinicalSummary:
Decedent has a history of lung cancer.  Found on back in bed.",,"FinalDiagnosis:
I.  Cardiac Arrest
  A.  Cardiomegaly, 525 grams
  B.  Severe coronary artery disease
  C.  Early acute pneumonitis
  D.  Pulmonary congestion and edema

II.  History of Lung Cancer\X0A|",,"GrossDescription:
AUTOPSY REPORT PROTOCOL


An autopsy was performed on the body of XXXXXX. XXXXXX at **INSTITUTION on **DATE[Apr 27 2012].  The body is identified by a right toe tag.



EXTERNAL EXAMINATION


The body is that of a well-developed, well-nourished adult male.  The body is partially clothed in black underwear, white shirt and blue sweatpants.  The body weighs an estimated 150 pounds, measures approximately 68 inches and appears compatible with the reported age of **AGE[in 80s] years.  The body is cold.  Rigor is present to an equal degree in all extremities.  Lividity is present and fixed on the posterior surface of the body except in areas exposed to pressure.  The scalp hair is gray.  Facial hair is absent.  The irides are brown.  The corneae are partially opacified.  The conjunctivae are hazy.  The sclerae are white.  Pupils appear equal and 0.5 cm in diameter bilaterally.  The external auditory canals, external nares and oral cavity are free of foreign material and abnormal secretions.  The mouth is edentulous with upper and lower dentures.  The neck is symmetrical and the trachea is palpable in the midline.  The chest diameter is within normal limits and symmetrical.  The abdomen is flat.  The upper extremities are symmetrical bilaterally.  No needle tracts or tattoos are noted.  Two scars of the right lower thorax measure 8 inches and 2 inches in length.  The hands, fingers and fingernails are intact.  The external genitalia are those of a normal adult male.  The lower extremities are symmetrical bilaterally.  The back and posterior body surfaces reveal no abnormalities.


INTERNAL EXAMINATION


Body Cavities:  The body is opened by the usual thoraco-abdominal incision, and the chest plate is removed.  Approximately 50 cc's of clear serous fluid is noted in the right pleural cavity along with apical adhesions.  All body organs are present in their normal anatomic position.  The subcutaneous fat layer of the abdominal wall measures 0.6 cm in thickness.  There is no internal evidence of blunt force or penetrating injury to the thoraco-abdominal region.

Head:  The head is normocephalic and atraumatic.

Neck:  Examination of the soft tissues of the neck, including strap muscles and large vessels, reveals no abnormalities.  

Cardiovascular System:  The pericardial surfaces are smooth and glistening.  The pericardial sac is free of significant fluid and adhesions.  The coronary arteries arise in their normal anatomic positions and follow a left dominant distribution.  The right coronary is approximately 20% occluded by atheroma.  The left circumflex is approximately 30% occluded by atheroma.  And the left anterior descending is 100% occluded by atheroma.  The chambers and valves exhibit the usual size-position relationship and are unremarkable.  The atrial and ventricular septa are intact.  The myocardium is dark-red brown, firm and unremarkable.  The left ventricle measures 2 cm in thickness and the right measures 0.5 cm in thickness.  The aorta and its major branches arise normally, follow the usual course and are widely patent.  The aortic valve is calcified.  There is no significant arteriosclerosis or other abnormality.  The vena cava and pulmonary arteries are free of thrombi.  The heart weighs 525 grams.

Respiratory System:  The upper airway contains thick mucous.  The mucosal surfaces are smooth and yellow-tan.  Mucosal plaques are noted in the right mainstem bronchus.  The pleural surfaces are smooth and glistening with increased amounts of anthracotic pigment, bilaterally.  The pulmonary parenchyma is red-brown exuding slight to moderate amounts of blood and frothy fluid.  No focal lesions are noted.  The pulmonary arteries are normally developed, patent and without thrombus or embolus.  The right lung weighs 975 grams, and the left lung weighs 560 grams.

Liver and Biliary System:  The hepatic capsule is smooth, glistening and intact, covering red-brown, moderately congested parenchyma with no focal lesions noted.  The gallbladder contains green-brown mucoid bile.  The extrahepatic biliary tree is patent without evidence of calculi.  The liver is normal in size and shape.

Alimentary Tract:  The tongue is without evidence of recent injury.  The gastro-intestinal tract is normal to external examination.  The pancreas has a normal pink-tan appearance and the ducts are clear.  The appendix is not identified.

Genitourinary System:  The renal capsules are smooth and thin, semi-transparent and strip with ease forming the underlying finely granular, red-brown cortical surfaces.  The cortices are slightly congested and sharply delineated from the medullary pyramids which are red-purple and unremarkable.  The calices, pelves and ureters are unremarkable.  

Reticuloendothelial System:  The regional lymph nodes are grossly unremarkable.  The spleen has a smooth, intact capsule covering red-purple, moderately firm parenchyma.  The spleen weighs an estimated 75 grams.

Musculoskeletal System:  Muscle development is normal.  No bone or joint abnormalities are noted.","MicroscopicDescription:
Heart:  Myocardial fibers are interrupted by patchy areas of fibrosis.  Some of the residual fibers have enlarged box-like nuclei.  

Lungs:  Sections are congested with emphysematous changes and increased amounts of anthracotic pigment.  Carcinoma is not noted within the sections examined.  Acute inflammation is focally noted within air spaces.

Liver:  Sections are histologically unremarkable.

Spleen:  Sections are histologically unremarkable.

Pancreas:  Sections are autolyzed.  

Kidney:  Sections demonstrate interstitial inflammation.",A: Autopsy Anatomic/Neuro Body,,
REG4,LUNG,0,PAT-10040725,1,REC-3000654482,"ClinicalHistory:
786.6
Procedure:->Wash
Examine for:->Cancer
History/Clinical Impressions:->LUL lung mass and bilaterally focal consolidation/lung nodules./r/n","CytologyReview:
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with adenocarcinoma./r/n
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with adenocarcinoma.  Please refer to case ***PATH-NUMBER[1]./r/n","FinalDiagnosis:
POSITIVE FOR MALIGNANT CELLS.
Malignant cells present consistent with adenocarcinoma.  Please refer to case ***PATH-NUMBER[1]./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[Jul 12 2012].  The preliminary diagnosis was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jul 12 2012] at 4:40 P.M.  Dr. **NAME[ZZZ YYY] was notified of the final pathologic diagnosis on **DATE[Jul 13 2012] at 9:21 A.M. via email message./r/n",,"GrossDescription:
10cc of bloody fluid
Preparation:
2 pull smears: 2 papanicolaou stain
1 cell block./r/n",,A: Bronchial Lavage/Washing,,
REG4,LUNG,0,PAT-01282144,2,REC-3000654658,"ClinicalHistory:
Left lung mass.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
Left lung:  POORLY DIFFERENTIATED NON-SMALL CELL CARCINOMA(see comment)
      
DiagnosisComment:
The tumor stains uniformly strongly positive for CK7, Napsin A and TTF-1, and focally positive for p63 and CK20.  Most of the tumor is negative for p63 and about half is negative for CK20.  This is most consistent with adenocarcinoma of lung origin.  
\X0A|",,"GrossDescription:
Specimen received in fixative labeled with the patient's name and ""left lung"" consists of three grayish soft tissue cores, measuring from 3 mm to 7 mm in maximum length and <1 mm in diameter.  The entire tissue is submitted in one cassette.","MicroscopicDescription:
The biopsy reveals poorly differentiated non-small cell carcinoma.  The tumor has enlarged and hyperchromatic nuclei with prominent nucleoli present.  There is fair amount of eosinophilic cytoplasm; otherwise, there is no further differentiation appreciated.",A: Left lung biopsy,,
REG4,LUNG,0,PAT-10040725,1,REC-3000654720,"ClinicalHistory:
786.6
Procedure->Biopsy
Clinical History/Diagnosis/Condition->LUL lung mass with bilateral focal consolidation/lung nodule./r/n",,"FinalDiagnosis:
Lung, left upper lobe:  Adenocarcinoma./r/nDiagnosisComment:
Immunoperoxidase stains show that the tumor cells expresses TTF-1 and Cytokeratin 7 and are negative for Cytokeratin 20.  The histologic and immunohistochemical findings support that this neoplasm is of lung origin.  Dr. **NAME[ZZZ YYY] was notified of the preliminary diagnosis on **DATE[Oct 12 2011] at 4:40 P.M.  Case reviewed in Pathology Staff Conference on **DATE[Oct 12 2011].  Intradepartmental consultation with Dr. **NAME[XXX WWW] on **DATE[Oct 13 2011].  Dr. **NAME[ZZZ YYY] was notified of the final pathologic diagnosis on **DATE[Oct 13 2011] at 9:21 A.M. via email message./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated left upper lobe transbronchial lung biopsy per requisition 
Specimen:    Multiple, tan pieces of tissue (formalin)
Aggregate:    0.7 x 0.5 x 0.2 cm
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left upper lobe transbronchial lung, biopsy",,"AddendumComment:
A paraffin block was sent to Clarient for EGFR analysis on **DATE[Oct 16 2011] and results will be reported in an addendum./r/n"
REG4,LUNG,0,PAT-10037087,1,REC-3000654736,"ClinicalHistory:
Lung cancer
Please do EGFR analysis.",,"FinalDiagnosis:

A.  PLEURA:  METASTATIC ADENOCARCINOMA.
 
B.  PERICARDIUM:  NEGATIVE FOR MALIGNANT CELLS.
DiagnosisComment:
Specimen shows scattered clusters of adenocarcinoma cells in a 
desmoplastic pleura. EGFR analysis will be attempted and 
reported in an addendum.",,"GrossDescription:

A. Specimen:  Irregular segments of tan-brown soft tissue, received in formalin.  
Weight:  Less than 1 gm.
Number of segments:  3.  
Size:  Up to 0.8 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segment of fatty tissue, received in formalin.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.3 x 1.5 x 1.0 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2.",,"A: PLEURA
B: PERICARDIUM",,
REG4,LUNG,0,PAT-10036652,1,REC-3000654742,"ClinicalHistory:
Abnormal chest CT, lung mass.",,"FinalDiagnosis:
COLD BIOPSY LUL LUNG:  POORLY DIFFERENTIATED MALIGNANCY WITH EXTENSIVE NECROSIS.
DiagnosisComment:
Small sections of lung tissue show small foci of tumor with extensive necrosis. The tumor cells are large, pleomorphic epithelioid and show scattered mitoses. On immunostaining, the tumor cells are positive for vimentin, and negative for lymphoma markers (LCA, CD30), epithelial markers (CK AE1/AE3, CK 7, CK 20, p63, TTF-1, Napsin A), and S-100. It is difficult to make a more specific diagnosis. The findings were discussed with Dr. **NAME[ZZZ] on **DATE[Nov 16 11].",,"GrossDescription:
Specimen:  Soft tan tissue.
Number of segments:  Multiple.    
Size:  Up to 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,A: COLD BIOPSY LUL LUNG,,
REG4,LUNG,0,PAT-10039985,1,REC-3000654763,"ClinicalHistory:
Mediastinal lymph nodes.",,"IntraoperativeDiagnosis:

A.  FROZEN SECTION DIAGNOSIS:  POSITIVE FOR ADENOCARCINOMA.  (BS)
FinalDiagnosis:

A.  Mediastinal lymph node, 2R mass, 
     biopsy:                 METASTATIC ADENOCARCINOMA (please see Comments)

B.  Additional mediastinal lymph node, 
     2R mass, biopsy:           METASTATIC ADENOCARCINOMA (please see Comments)

Comments:
The histological and immunophenotypic features are consistent with a lung primary.  Immunohistochemical stains strongly highlight the tumor cells with CK7 and TTF-1.  CK20 is negative.  The results of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 8 2012].    \X0A|",,"GrossDescription:
(A)  Received fresh labeled ""station 2 R mass (mediastinal)"" are multiple red-tan, pink and slightly firm lymph nodes measuring 
1.4 x 1.4 x 0.3 cm in aggregate (ranges in size from 0.2 - 0.7 cm in greatest dimension).  Entirely submitted for frozen section.  Entirely submitted in cassette AFS.

(B)  Received fresh labeled ""additional station 2 R mass (mediastinal)"" are multiple red-tan, pink and slightly firm lymph nodes measuring 2.0 x 2.0 x 0.3 cm in aggregate (ranges in size from 0.4 - 0.8 cm in greatest dimension).  Entirely submitted in one cassette.","MicroscopicDescription:

A, B.  Microscopic findings support the diagnosis.","A: Station 2R mass (mediastinal)
B: Additional Station 2R mass (mediastinal)",,"AddendumComment:

See attached ALK gene rearrangement and EGFR Mutation Analysis reports from Clarient."
REG4,LUNG,0,PAT-10034389,1,REC-3000654791,"ClinicalHistory:
Lung cancer.",,"IntraoperativeDiagnosis:
A)  Touch Prep and Frozen Section Diagnosis:  Malignant/OC/TM
B)  Touch Prep Diagnosis:  Malignant/OC/TM
FinalDiagnosis:
A.  Lymph node, superior mediastinal, biopsy:  Metastatic poorly differentiated 
              adenocarcinoma (see Comment)

B.  Subcarina, biopsy:          Metastatic poorly differentiated 
              adenocarcinoma (see Comment)
DiagnosisComment:
The tumor has a similar morphology and TTF-1 immunopositivity as identified in the previous specimen (***PATH-NUMBER[1]), being consistent with a lung primary.  Please correlate clinically and with the radiographic findings.  \X0A|",,"GrossDescription:
A.  Received fresh labeled ""XXXXXX, superior mediastinal lymph node"" are two irregular portions of yellow soft tissue, the smaller measuring up to 1.2 x 1.0 x 0.3 cm and the larger measuring up to 4.0 x 1.9 x 0.7 cm.  Embedded within the smaller fragment is a slightly firm, gray white nodule measuring up to 0.7 x 0.5 x 0.3 cm.  The cut surface of the larger fragment is unremarkable.  A portion of the nodule from the smaller fragment is submitted for frozen section with the residual tissue submitted in one cassette labeled ""AFS"".  Submitted in toto.  

  Key to cassettes: 
  1  -  Remainder of nodule from smaller fragment
  2  -  Remainder of smaller fragment
  3-4  -  Larger fragment

B.  Received fresh labeled ""XXXXXX, sub carina"" are approximately four irregular fragments of tan to pink tan tissue measuring 1.0 x 0.7 x 0.2 cm in aggregate dimension.  Air dried, Diff Quik stained tissue imprints are prepared for intraoperative consultation.  Submitted in toto in one cassette.","MicroscopicDescription:
A.  The hematoxylin and eosin-stained sections demonstrate fibroadipose tissue infiltrated by patchy areas of tumor cells.  The tumor cells are found in scattered, large irregularly shaped patches with a fibrotic background.  The tumor cells are poorly-differentiated, having irregularly shaped syncytial-like aggregates.  The tumor cells have variably shaped and sized nuclei and occasionally form gland-like structures.  The tumor cells are also found as scattered single cells or cells in small clusters.  The Diff Quik-stained touch prep demonstrates abundant, large, pleomorphic tumor cells with hyperchromatic nuclei and ample cytoplasm.  Immunostains were conducted.  The tumor has nuclear labeling with TTF-1.

B.  The hematoxylin and eosin-stained sections demonstrate small fragments of adipose tissue, dense fibroconnective tissue, and tumor cells.  The tumor cells have morphology as described in part A.  The tumor cells are also present in a background of fibrosis.  The Diff Quik-stained touch prep shows abundant tumor cells as described previously in part A.  Immunostains were conducted.  The tumor has nuclear labeling with TTF-1.

Notes:  The touch prep and hematoxylin and eosin-stained frozen section control for part A and touch prep for part B confirm the intraoperative consultation diagnoses.  This case has been referred for internal concurrence.","A: Superior mediastinal lymph node
B: Subcarina",,"AddendumDiagnosis:
A.  Lymph node, superior mediastinal, biopsy:  
  1. METASTATIC POORLY-DIFFERENTIATED ADENOCARCINOMA (SEE ADDENDUM COMMENT)
  2. Benign thymic tissue

B.  Subcarina, biopsy:
  METASTATIC POORLY-DIFFERENTIATED ADENOCARCINOMA.
AddendumComment:
This Addendum is created to incorporate additional immunostaining results.

The immunohistochemical findings provide additional support for the diagnosis of a poorly-differentiated adenocarcinoma, and this diagnosis remains unchanged.  This Addendum also reports the presence of benign thymic tissue (uninvolved by the metastatic adenocarcinoma), which was not previously included in the original diagnosis.

Microscopic Description
For part A, the tumor does not label with cytokeratin 5/6 (positive controls intact).  p63 stains few of the tumor nuclei.  

Note:  This case was also reviewed by Dr. **NAME[ZZZ] and Dr. **NAME[YYY], who favor the diagnosis of adenocarcinoma.  


Reference:
1. Rekhtman N, Ang DC, Sima CS, **NAME[XXX] WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011."
REG4,LUNG,0,PAT-10039797,1,REC-3000655134,"ClinicalHistory:
Mass; R/O malignancy; **AGE[in 70s]-year-old gentleman with large lung mass and FX 6 cm arm mass.  Mass causing neurologic compromise (cannot extend wrist).",,"FinalDiagnosis:
Mass, right arm, needle biopsy:    METASTATIC ADENOCARCINOMA, consistent with metastatic lung 
          adenocarcinoma.
DiagnosisComment:
Material will be submitted for EGFR gene mutation (Clarient Laboratory).\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, right arm"" are multiple cores of yellowish-white pieces of tissue measuring up to 1.3 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.","MicroscopicDescription:
Needle biopsies of fibrofatty soft tissue demonstrate a metastatic adenocarcinoma of moderate differentiation.  A histochemical stain for mucin demonstrates focal intracytoplasmic mucin staining.  Immunostains (TTF-1, Napsin, CK7, CK20) are evaluated and demonstrate positive staining for Napsin, weak positive staining for TTF-1, strong CK7 staining and negative CK20 staining.  This staining profile is supportive of metastatic lung adenocarcinoma.","A: Mass, right arm",,"AddendumComment:
Please see attached Clarient EGFR report #***PATH-NUMBER[1]."
REG4,LUNG,0,PAT-10038742,1,REC-3000655203,"ClinicalHistory:
Right malignant pleural effusion.
Post-OperativeDiagnosis:
Same, pending pathology.
Pre-OperativeDiagnosis:
Right thoracoscopy and talc pleurodesis.",,"PreOperativeDiagnosis:
Right thoracoscopy and talc pleurodesis
PostOperativeDiagnosis:
Same, pending pathology
FinalDiagnosis:
Right pleura/exudate, pleurodesis:  Positive for non-small cell carcinoma
          (additional stains pending).\X0A|",,"GrossDescription:
Received in formalin labeled ""right pleural exudate RO pleural tumor"" are numerous fragments of tan-pink to white soft tissue and tan-red hemorrhagic material measuring, in aggregate, 10.5 x 7.5 x 3.0 cm.  Representative sections are submitted in blocks 1-4.","MicroscopicDescription:
Sections contain fragments of fibrinopurulent material and thin fragments of pleura exhibiting reactive fibrosis.  In one fragment of soft tissue, there is a minute focus of malignant-appearing glands.  Immunostains (TTF-1, Napsin, p63, CD56, mesothelin) are pending.","A: Right pleural exudate, R/O pleural tumor",,
REG4,LUNG,0,PAT-10039756,1,REC-3000655400,"ClinicalHistory:
Left vocal cord paralysis secondary to probable neoplasm with metastasis, supraclavicular lymphadenopathy.",,"IntraoperativeDiagnosis:

A.  FROZEN SECTION DIAGNOSIS:  CARCINOMA.  (BS)

B.  FROZEN SECTION DIAGNOSIS:  CARCINOMA.  (BS)
FinalDiagnosis:

A, B.  Lymph nodes, supraclavicular #1 and #2, excisional biopsy:  
        FOUR LYMPH NODES POSITIVE FOR METASTATIC POORLY DIFFERENTIATED CARCINOMA.
     


Comment:  The tumor is positive for CK7, CK5/6, p63, and B72.3 stains; negative for CK20, ER, mammoglobin, TTF-1, Napsin-A, and thrombomodulin stains.  Tumor shows focal areas of intercellular bridges.  Favor metastatic squamous cell carcinoma.  History of lung mass is noted.  Clinical correlation is required to determine the origin of this tumor.  The stains performed cannot distinguish squamous cell carcinoma arising from different sites. 

Preliminary findings discussed with Dr. **NAME[ZZZ YYY] on **DATE[Dec 18 2011].     \X0A|",,"GrossDescription:
(A)  Received fresh labeled ""supraclavicular node #1"" are two tan-white and pink lymph nodes measuring 1 x 0.8 x 0.8 cm and 
0.6 x 0.5 x 0.4 cm.  The large lymph node is inked black and one-half of the large lymph node is submitted for frozen section in cassette AFS.  The remaining half and small lymph node (submitted as whole) are both submitted in cassette A1 for permanents.

(B)  Received fresh labeled ""supraclavicular node #2"" are two tan-yellow, pink and firm lymph nodes measuring 1.1 x 0.9 x 0.8 cm and 0.8 x 0.6 x 0.6 cm.  Both lymph nodes are each bisected.  A representative section of the large lymph node is submitted for frozen section in cassette BFS.  The remaining half of the large lymph node and  the bisected small lymph node are both submitted in cassette B1 for permanents.","MicroscopicDescription:
A, B.  Microscopic findings support the diagnosis.","A: Supraclavicular node #1
B: Supraclavicular node #2",,
REG4,LUNG,0,PAT-01331412,2,REC-3000655580,"ClinicalHistory:
Right lung mass.
Post-OperativeDiagnosis:
Same, pending pathology.",,"PostOperativeDiagnosis:
Same, pending pathology
FinalDiagnosis:
Right lung biopsy:    MODERATELY-DIFFERENTIATED ADENOCARCINOMA (see comment) 
DiagnosisComment:
Immunostains will be peformed to determine the origin of this tumor.  The patient has a history of carcinoma of the breast.

The tumor is CK7+/CK20-.  Stains for BRST-2 and mammaglobin are negative making a breast origin unlikely.  The patient had a DCIS in 2000 (***PATH-NUMBER[1]).  The tumor is also positive for MOC31 and CEA.  Stains for the following are negative   calretinin, TTF-1, CA125 and CA19-9.  This staining pattern is not definitive however it is consistent with a lung origin although the TTF-1 is negative.  An endocervical origin is also a possibility.  

Specimen reviewed at the **INSTITUTION **STREET-ADDRESS., **ROOM, **PLACE, HI **ZIP-CODE. \X0A|",,"GrossDescription:
Received in fixative labeled ""lung mass"" are four cores of tissue measuring up to 1.5 cm in length and 0.1 cm in diameter.  Submitted in toto in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right lung mass,,"AddendumComment:
Please see the attached Clarient EGFR report for results (***PATH-NUMBER[2]; **DATE[Dec 15 11])."
REG4,LUNG,0,PAT-10036511,1,REC-3000655586,"ClinicalHistory:
L lung mass and mediastinal adenopathy, R/O malignancy.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Lung biopsy, clinically left lower lobe mass:
  FAVOR NON-SMALL CELL CARCINOMA (SEE COMMENT)
DiagnosisComment:
Please see attached outside consultation report ***PATH-NUMBER[1] from Clarient.  The outside consultation diagnosis is NON-SMALL CELL CARCINOMA; POSSIBLY ADENOSQUAMOUS CARCINOMA.

The sections contain core biopsies of lung tissue.  Most of the core fragments are comprised of benign lung tissue, however, at the end of one core is a small focus of a CK7-positive epithelial proliferation which is favored to be non-small cell carcinoma.  The staining pattern present is not definitively specific for further characterization.  This case will be sent for pulmotype study to attempt to further characterize the process.  The findings will be reported in an addendum report.  

This case has been amended.  The initial diagnosis was ""focal atypical proliferation, favor non-small cell carcinoma"".  The amended diagnosis is ""favor non-small cell carcinoma"". 

Specimen signed out at **STREET-ADDRESS, **PLACE, HI  **ZIP-CODE.\X0A|",,"GrossDescription:
Received in formalin, labeled ""XXXXXX, XXXXXX"" and ""LLL mass"" are multiple cylindrical pieces of soft red and white tissue (1.6 x 0.3 x 0.1 cm in aggregate, 0.1 to 1.6 cm greatest dimension).  The entire specimen is submitted in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis.   Immunohistochemistry stains are positive for PCK, CK7, and CK5/6.  Stains are negative for CK20, CDX2, p63, and CD163.  TTF-1 shows non-specific staining.  This case has also been reviewed by Dr. **NAME[ZZZ YYY].","A: LLL mass, 18 g core bx",,
REG4,LUNG,0,PAT-10038643,1,REC-3000655691,,,"IntraoperativeDiagnosis:
Imprint   Positive for tumor; assessed by TN.
FinalDiagnosis:
LLL LUNG MASS CT-GUIDED CNB:  MODERATELY DIFFERENTIATED ADENOCARCINOMA.",,"GrossDescription:
Received:  1 DQ stained smear.
       Tissue fragments in formalin soln.
Submitted:  5 tissue fragments measuring up to 1.1 cm in length 
           for a cell block.",,A: LLL LUNG CT-GUIDED CNB,,
REG4,LUNG,0,PAT-10036381,1,REC-3000655895,"ClinicalHistory:
RLL mass.",,"IntraoperativeDiagnosis:

A.  FROZEN SECTION DIAGNOSIS:  ADENOCARCINOMA.  (BS)

D.  FROZEN SECTION DIAGNOSIS:  POSITIVE FOR ADENOCARCINOMA.  (**INITIALS)

E.  FROZEN SECTION DIAGNOSIS:  BRONCHIAL MARGIN NEGATIVE.  (BS)
FinalDiagnosis:

A.  Right lower lobe mass:               ADENOCARCINOMA.

Tumor information:
Type of specimen:    Lobectomy
Tumor location:    Right lower lobe
Tumor size:    2 cm
Tumor focality    Single focus
Histologic type:    Adenocarcinoma
Histologic grade:    Moderately differentiated
Main bronchus involvement:    Not involved
Visceral pleural involvement:    Not involved
Atelectasis/obstructive pneumonitis:    Not identified
Invasion of contiguous structures:    Not identified
Lymph vascular invasion:    Not identified
Resection margins:    Not involved on lobectomy specimen E.
Other findings:    N/A
Pathologic staging:    pT1a  pN1  Mx

B.  Level 9 lymph node, biopsy:    One benign lymph node.

C.  Level 10 lymph node, biopsy:    ADENOCARCINOMA, METASTATIC.

D.  Level 10 lymph node, biopsy:    ADENOCARCINOMA, METASTATIC.

E.  Right lower lobe, lobectomy:    Negative bronchial margins.
            Benign lung parenchyma and peri-bronchial lymph node.

F.  4R lymph node, biopsy:      One benign lymph node.

G.  Level 7 lymph node, biopsy:    One benign lymph node.\X0A|",,"GrossDescription:
(A)  Received fresh labeled ""right lower lobe mass"" is a lung wedge biopsy measuring 8 x 7 x 2 cm.  The staple line measures 
8 cm.  The pleural surfaces are inked black.  

Sections reveal a tan-white and firm circumscribed nodule measuring up to 2 cm in greatest dimension, and is within less than 0.5 cm from the nearest staple line.  Upon removal of staple line, the tumor is immediately adjacent and identified at the margin.  Adjacent sections are tan-gray with black tumor tissues, which grossly appears to be at the resection margin.  The mass does not appear to be grossly involving the pleural surface, however there appears to a torn or lacerated area adjacent the tumor.  The pleural parenchyma adjacent to the mass is predominantly tan-red and soft with scattered gray pigmentation.  No other firm masses or circumscribed lesions noted.  

A representative section of the nodule is submitted for frozen section in one cassette.  All tumor sections submitted in cassettes A1 - A7, with the section of tumor nearest staple line in cassette A4.  Random sections in cassettes A8 - A10.

(B)  Received in formalin labeled ""level 9 lymph node"" is a tan-red, brown and soft tissue fragment measuring 0.9 x 0.7 x 0.5 cm.  All in one cassette.

(C)  Received in formalin labeled ""level 10 lymph node"" is a tan-red, brown and soft tissue fragment measuring 1.1 x 0.7 x 0.5 cm.  All in one cassette.

(D)  Received fresh labeled ""level 10 lymph node"" is a 1 x 0.5 x 0.3 cm tan-red, brown and soft tissue fragment.  The specimen is bisected and submitted entirely for frozen section in one cassette.

(E)  Received fresh labeled ""right lower lobe (for bronchial margin)"" is a lung lobectomy specimen measuring 18 x 10 x 3 cm.  There are three staple lines measuring up to 12 cm.  The pleural surfaces are purple-red with scattered black and white pigmentation.  The surfaces are generally smooth.  On one edge of the lobe is a tan-white and soft unremarkable pleural parenchyma measuring 7 x 1.5 cm.  The stapled resection margins are inked black.  Sections reveal a predominantly maroon-red and soft pleural parenchyma with scattered gray-black and white spicules.  Areas along the staple line are predominantly dark maroon-red and homogeneous.  No circumscribed masses or lesions noted.  

The bronchial margins appear grossly unremarkable.  

Representative sections are submitted in eleven cassettes, with the bronchial margin submitted for frozen section in cassette EFS.  Random sections from staple line in cassettes E1 and E2, random pleural parenchyma E3 - E9, and sections from bronchial margin in cassette E10. 

(F)  Received in formalin labeled ""4R lymph node"" are two red-brown, black and soft tissue fragments measuring 0.6 x 0.5 x 0.3 cm and 1.4 x 0.8 x 0.5 cm.  The large fragment is bisected.  Submitted entirely in one cassette.

(G)  Received in formalin labeled ""level 7 lymph node"" is a red-brown, black and soft tissue fragment measuring 1.3 x 0.7 x 0.5 cm.  All in one cassette.","MicroscopicDescription:
A - G.  Confirmed.","A: FS - Right lower lobe mass, lung
B: Level 9 lymph node, lung - permanent
C: Level 10 lymph node, lung - permanent
D: FS - Level 10 lymph node, lung - R/O malignancy
E: FS - Right lower lobe (for bronchial margins)
F: 4R lymph node
G: level 7 lymph node",,"AddendumComment:
Please see attached Clarient KRAS report (***PATH-NUMBER[1]) and Clarient EGFR report (***PATH-NUMBER[2])."
REG4,LUNG,0,PAT-00358077,3,REC-3000655929,,,"FinalDiagnosis:
LEFT PLEURAL EFFUSION:  FEW ATYPICAL CELLS PRESENT, CONSISTENT WITH ADENOCARCINOMA (see ***PATH-NUMBER[1]).",,,,A: LEFT PLEURAL EFFUSION,,
REG4,LUNG,0,PAT-10034805,1,REC-3000656240,"ClinicalHistory:
Lung mass.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Lung mass, bronchoscopy.",,"PreOperativeDiagnosis:
Lung mass, bronchoscopy
PostOperativeDiagnosis:
Same
FinalDiagnosis:
Right upper lobe biopsies:  Moderately differentiated squamous cell carcinoma
DiagnosisComment:
Dr. **NAME[ZZZ YYY] notified on **DATE[Mar 30 12] at 1000 hrs.  Dr. **NAME[XXX WWW] concurs.

Specimen signed out at **STREET-ADDRESS, **ROOM, **PLACE, HI   **ZIP-CODE.\X0A|",,"GrossDescription:
Received in fixative labeled ""right upper lobe"" are three cores of tissue measuring up to 0.4 cm.  Submitted entirely in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.","A: RUL cold biopsy, lung",,
REG4,LUNG,0,PAT-10042219,1,REC-3000656321,"ClinicalHistory:
Lung mass, pneumonia.  H/O adeno CA lung, R/O bronchoalveolar (***PATH-NUMBER[1]).
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Lung biopsy, clinically ""left lower lobe mass"":            PAS 9
  ADENOCARCINOMA, WELL TO MODERATELY DIFFERENTIATED (SEE COMMENT)
DiagnosisComment:
The sections contain a well to moderately differentiated adenocarcinoma.  The immunohistochemistry staining pattern is not specific and not typical.  The differential includes primary vs. metastasis.  

Immunohistochemistry stains are positive for CK7, CDX2 and CEA.  Stains are negative for TTF-1, and CK20.  A Ki67 stain shows an increased proliferation index in the tumor cells.   

Findings were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Dec 19 11].  This case will be sent for routine interdepartmental consensus review.   \X0A|",,"GrossDescription:
Received in formalin, labeled ""biopsy left lower lobe"" are multiple irregular pieces of soft to rubbery tan-red tissue (0.7 x 0.4 x 0.2 cm in aggregate, 0.1 to 0.3 cm in greatest dimension).  The entire specimen is submitted in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Biopsy left lower lobe,,
REG4,LUNG,0,PAT-10040532,1,REC-3000656459,"ClinicalHistory:

511.9.","CytologyReview:

Pleural fluid, cytology and cell block:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy.","FinalDiagnosis:

Pleural fluid, cytology and cell block:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
DiagnosisComment:

The tumor cells are positive for TTF-1 and CK7 stains, and negative for CK20 and calretinin stains.  The findings are consistent with involvement of pleural fluid by pulmonary adenocarcinoma.  Discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 1 2012].\X0A|",,"GrossDescription:
Received unlabeled is an 875.0 mL brown and turbid fluid.  The fluid is centrifuged and the resulting cell pellet is submitted for cytology and cell block (one cassette).
4 PPPL prepared cytospin slides (2 Pap stained, 2 Diff-Quik stained) and 1cell block

*Note:  Specimen received unlabeled.  Called **NAME[XXX] / MMG Radiology and verified sample belongs to patient.",,A: Pleural fluid,,
REG4,LUNG,0,PAT-01465699,2,REC-3000659195,"ClinicalHistory:
Lung CA.",,"FinalDiagnosis:
REMOVED MEDIPORT (GROSS IDENTIFICATION).",,"GrossDescription:
Specimen:  Purple plastic Mediport with a single port and attached 23.5 cm plastic tubing.
Weight:  6 gm.
Size:  2.7 x 2.3 x 1.4 cm. 
Inscriptions:  BARD 2819.
Submitted:  None, object will be saved for storage.",,A: REMOVED MEDIPORT,,
REG4,LUNG,0,PAT-10030889,1,REC-3000659524,"ClinicalHistory:
Pathologic right humerus fracture.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
IM rod right humerus.",,"PreOperativeDiagnosis:
IM rod right humerus
PostOperativeDiagnosis:
Same
FinalDiagnosis:
Intramedullary tissue, right humerus fracture, reamings:  Metastatic poorly differentiated carcinoma.

Comment:  Immunostain evaluation of the metastatic carcinoma is pending.\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, right humerus intramedullary reamings"" is soft tan tissue, 1.0 gm, aggregate 4.3 x 1.0 x 0.3 cm.  Submitted entirely in one cassette.","MicroscopicDescription:
Sections contain fragments of bone, blood clot, hematopoietic marrow and multiple fragments of a poorly differentiated metastatic carcinoma.  Immunostains are pending.",A: Right humerus intramedullary reamings,,
REG4,LUNG,0,PAT-10036381,1,REC-3000659528,"ClinicalHistory:
L hip METS, R/O malignancy.",,"FinalDiagnosis:

Left hip, biopsy:  POSITIVE FOR ADENOCARCINOMA (please see Comments)

Comments:  
The morphological and immunophenotypic features are consistent with a lung primary.  A recent history of pulmonary adenocarcinoma is noted (***PATH-NUMBER[1]).  Immunohistochemical stains for TTF-1 strongly highlight the tumor cells.  PSA and PSAP are negative.  The results of this case were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jun 6 2012].    \X0A|",,"GrossDescription:
Received in formalin labeled with the patient's name is a single tan-pink core of bone measuring 0.3 x 0.1 x 0.1 cm.  Entirely submitted in cassette 1 after decalcification.  Also present is a 0.8 x 0.8 x 0.2 cm aggregate of dark red and soft material.  Entirely submitted in cassette 2.","MicroscopicDescription:
Confirmed.",A: L hip (acetabulum),,
REG4,LUNG,0,PAT-10041632,2,REC-3000665275,"ClinicalHistory:
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Left upper lobe mass./r/n",,"IntraoperativeDiagnosis:
A.  Adenocarcinoma, favor lung primary.  (CR/**INITIALS)./r/nFinalDiagnosis:
A.  Lung, left upper lobe:  Adenocarcinoma with areas with bronchoalveolar pattern.  

B.  Lung, left upper lobe:  Adenocarcinoma with areas with bronchoalveolar pattern, margins free. 

                                         Pulmonary lymph nodes with anthracosis, negative (0/2).

                                          Focal emphysematous changes with subpleural blebs and focal fibrosis.

C.  Lymph node, pulmonary artery region:  Lymph node with anthracosis, negative (0/1).

D.  Lymph nodes, inferior pulmonary ligament:  Lymph nodes with anthracosis, negative (0/2).

E.  Lymph nodes, hilar:  Lymph nodes with anthracosis, negative (0/2).

F.  Lymph node, AP window:  Lymph node with anthracosis, negative (0/1).

G.  Lymph node, left bronchial:  Lymph node with anthracosis, negative (0/1)./r/nDiagnosisComment:
Case reviewed at Pathology Staff Conference on **DATE[Dec 06 2011].  The tumor has an irregular contour which extends in the subpleural lung parenchyma in part A to part B. The tumor size estimation is complicated by parts of the tumor being in parts A and B with the tumor greatest dimension appearing 3.2 cm in a subpleural direction with lesser other dimensions./r/n",,"GrossDescription:
A.  Labeled:        Patient name and medical record number, designated left upper lobe, wedge
  Specimen:      Pale gray-pink spongy soft staple excision of lung tissue (fresh)
  Size:        5.7 x 2.7 x 1.8 cm Weight:        11.9 grams Colors:  
     Black:        Stapled margin   Blue:        Pleural surface
  Findings:      1.6 x 1.3 x 0.4 cm pale irregular gray lesion possible 0.3 cm from the stapled 
          Margin after removal of staple line (0.7 cm with stapled margin), lesion nearly abuts 
          the pleural surface 
          Representative portion submitted for frozen section
Section Code:  Block A1:      Frozen section residue
     Blocks A2- A6:      Representative sections of lesion
B.  Labeled:        Patient name and medical record number, designated left upper lobe
  Specimen:      Left upper lung lobe (fresh)  
  Size:        19.5 x 15 x 3 cm  
  Weight:        188.8 grams  
  Description:      Pale gray-pink spongy soft anthracotically pigmented excision of lung tissue  
  Orientation:      None provided  
  Lesion:        
    Location:      Left upper lobe more toward the apex at the end of the stapled margin  
    Size:        2 x 1.7 x 0.8 cm  
    Description:      Pale gray-tan firm irregular subpleural lesion
  Extent of invasion:  
    Bronchial involvement:    None
      Visceral pleural involvement:  None    
    Mediastinal pleural involvement:  None  
    Interlobar fissure extension:  None    
    Blood vessel invasion:    Does not grossly appear to involve blood vessels
    Invasion of attached tissues:  None  
  Additional tumors:    None
  Margins:            Bronchial:      8 cm
      Vascular:      7 cm
  Additional findings:    Previous wedge resection margin inked black, pleural surface in proximity to lesion 
          inked blue.  There are scattered emphysematous changes including a subpleural 
          emphysematous area 
  Lymph nodes:      Two, dark brown lymph nodes identified:  1 x 0.8 x 0.3 cm and 2.2 x 0.7 x 0.4 cm
  Section code:    
      Block B1:      Bronchial margin
      Block B2:      Hilar vessel margin
      Blocks B3-B10:      Lesion entirely serially sectioned from superior to more inferior 
    Blocks B11-B13      Representative sections
      Block B14:      Lymph nodesC.  Labeled:        Patient name and medical record number, designated pulmonary artery lymph node
  Specimen:      Gray-brown rubbery piece of tissue (formalin)
  Size:        1.4 x 1 x 0.4 cm
  Findings:      None
  Submitted/Block:      Entirely bisected/1  
D.  Labeled:        Patient name and medical record number, designated inferior pulmonary ligament 
          lymph node
  Specimen:      Two, yellow-gray pieces of tissue (formalin)
  Size:        0.5 x 0.4 x 0.4 cm and 0.9 x 0.4 x 0.4 cm 
  Findings:      None
  Submitted/Block:      Entirely/1

E.  Labeled:        Patient name and medical record number, designated hilar lymph node
  Specimen:      Two, dark red-brown pieces of tissue (formalin)
  Size:        Aggregating 3.4 x 1.3 x 0.6 cm
  Findings:      None
  Submitted/Block:      Larger specimen bisected; smaller specimen submitted entirely/1    
F.  Labeled:        Patient name and medical record number, designated window lymph node
  Specimen:      Gray-yellow ovoid piece of tissue (formalin)
  Size:        1 x 0.7 x 0.4 cm
  Findings:      None
  Submitted/Block:      Entirely bisected/1  
G.  Labeled:        Patient name and medical record number, designated left bronchial lymph node
  Specimen:      Gray-brown ovoid piece of tissue (formalin)
  Size:        1.2 x 0.6 x 0.5 cm
  Findings:      None
  Submitted/Block:      Entirely bisected/1./r/n","MicroscopicDescription:
A\T\B.  The lung mass has an irregular contour involving the subpleural lung parenchyma with areas of deeper lung parenchymal extension without involvement of the visceral pleura with an elastic stain examined to delineate the pleura (block B7).  There are malignant glandular formations with many parts of the tumor particularly in part B with a partly bronchoalveolar pattern of growth with lepidic spread along thicken alveolar septae with other areas with a more fibrotic background and focally more irregular malignant gland formations and focal background anthracotic pigment .  The neoplasm expresses TTF-1 (done on blocks A5 and B7) consistent with a lung primary.  The tumor expresses cytokeratin 7 and appears negative for cytokeratin 20 (block B7) also consistent with a lung primary.  There are scattered emphysematous changes with subpleural larger emphysematous spaces and focal limited subpleural fibrosis.  The neoplasm is seen in part B adjoining the staple line of the initial wedge biopsy suggesting contiguous tumor from the wedge biopsy portion to the part B specimen.  The bronchial and vascular margins are without tumor with two lymph nodes identified (block B14) with anthracosis without metastasis.  Focal limited subpleural poorly expanded alveoli are seen (block B13). 

C-G.  These parts have focally anthracotic pigment in the lymph node tissue with reactive sinus histiocytes without metastasis.


Lung Cancer Information (Based on AJCC/UICC TNM, 7th edition)

Tumor Size:  Greatest dimension:  Approximately 3.2 cm, accounting for the portions of tumor present in both parts A and B
Tumor Focality:  Unifocal 
Histologic Type:  Adenocarcinoma with focal bronchoalveolar pattern 
Histologic Grade:  G1:  Well differentiated 
Visceral Pleura Invasion:  Not identified 
Tumor Extension:  Not identified
Margins:  Final bronchial, vascular and parenchymal margins of part B:  Uninvolved by invasive carcinoma
Treatment Effect (if applicable):  Not applicable 
Lymph-Vascular Invasion:  Not identified
Pathologic Staging:
  Primary Tumor:  pT2a:  Tumor greater than 3 cm but  5 cm or less in greatest dimension surrounded by lung or visceral 
                        pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e. not in the main 
                        bronchus)
  Regional Lymph Nodes:  pN0:  No regional lymph node metastasis 
    Number examined:  9
    Number involved:  0
  Distant Metastasis:  Not applicable
Additional Pathologic Findings:  Focal emphysematous changes./r/n","A: A1 Left upper lobe wedge (frozen)
B: A7 Left upper lobe, excision
C: A2 Pulmonary artery lymph node, biopsy
D: A3 Inferior pulmonary ligament lymph node, biopsy
E: A4 Hilar lymph node, biopsy
F: A5 AP window lymph node, biopsy
G: A6 Left bronchial lymph node, biopsy",,
REG4,LUNG,0,PAT-10036609,1,REC-3000665284,"ClinicalHistory:
Right lung mass.",,"IntraoperativeDiagnosis:
A.  Malignant, per HS/MDB/NW

B.  Atypical cells present, per HS/MDB/NW

      assessed by, HS/MDB/NW
      supervised by, HS.
FinalDiagnosis:
A.  LUNG, RIGHT LOWER LOBE, ENDOSCOPICALLY GUIDED CNB:  SQUAMOUS CELL CARCINOMA. 
 
B.  LUNG, CARINA, ENDOSCOPICALLY GUIDED CNB:  SQUAMOUS CELL CARCINOMA.
DiagnosisComment:
Tumor cells are immunopositive for cytokeratin AE1/AE3 and squamous cell markers (p63 and cytokeratin 5/6); they are negative for TTF-1, Napsin-A, chomogranin, and synaptophysin.  There is focal immunopositive staining for CD56.  The immunophenotype and morphology is indicative of a squamous cell carcinoma. This case was discussed with Dr. **NAME[ZZZ] on **DATE[Apr 6 2012].",,"GrossDescription:
A.  Received:  4 DQ stained smears.
               5 red and tan colored tissue fragments in formalin up to approx. 
               0.5 cm. in length.
    Submitted:  All tissue fragments for a cell block (A1).


B.  Received:  4 DQ stained smears.","MicroscopicDescription:
A.  Cytologic preparations and cell block shows nests of pleomorphic tumor cells with high N:C ratio and hyperchromatic nuclei.

B.  Cytologic preparations show nests of pleomorphic tumor cells with high N:C ratio and hyperchromatic nuclei.","A: RIGHT LOWER LOBE LUNG CNB-ENDOSCOPICALLY GUIDED
B: LUNG CARINA FNA-ENDOSCOPICALLY GUIDED",,
REG4,LUNG,0,PAT-10042219,1,REC-3000671264,"ClinicalHistory:
Lung mass, pneumonia.  H/O adeno CA lung, R/O bronchoalveolar (***PATH-NUMBER[1]).
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Lung biopsy, clinically ""left lower lobe mass"":            PAS 9
  ADENOCARCINOMA, WELL TO MODERATELY DIFFERENTIATED (SEE COMMENT)
DiagnosisComment:
The sections contain a well to moderately differentiated adenocarcinoma.  The immunohistochemistry staining pattern is not specific and not typical.  The differential includes primary vs. metastasis.  

Immunohistochemistry stains are positive for CK7, CDX2 and CEA.  Stains are negative for TTF-1, and CK20.  A Ki67 stain shows an increased proliferation index in the tumor cells.   

Findings were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Dec 19 11].  This case will be sent for routine interdepartmental consensus review.   \X0A|",,"GrossDescription:
Received in formalin, labeled ""biopsy left lower lobe"" are multiple irregular pieces of soft to rubbery tan-red tissue (0.7 x 0.4 x 0.2 cm in aggregate, 0.1 to 0.3 cm in greatest dimension).  The entire specimen is submitted in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Biopsy left lower lobe,,
REG4,LUNG,0,PAT-10034763,1,REC-3000671274,,,"FinalDiagnosis:
Right lower lung, biopsy:    POSITIVE FOR MALIGNANCY, pending immunostains to further characterize the process
DiagnosisComment:
Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnosis.\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, **NAME[AAA]"" are multiple pieces of tan tissue measuring up to 0.5 x 0.1 cm in greatest dimension.  Submitted in toto in one cassette.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Right lower lung biopsy,,"AddendumDiagnosis:
Right lower lung, biopsy:         CONSISTENT WITH SQUAMOUS CELL CARCINOMA (see Comments).
AddendumComment:
The tumor is positive for p63 and Keratin 5/6, and negative for TTF-1, CK7, and Napsin A, supporting the above diagnosis."
REG4,LUNG,0,PAT-10033811,1,REC-3000671280,"ClinicalHistory:
511.9
  Specimen processed using ThinPrep monolayer technology.
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Left pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Metastatic small cell carcinoma.


Left pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block:  Favor small cell carcinoma (see Comments).","FinalDiagnosis:

Left pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Morphologically compatible with small cell carcinoma (see Comments).

   

DiagnosisComment:
Confirmatory immunohistochemical stains will be performed and reported separately.  Dr. **NAME[ZZZ YYY] concurs with the diagnosis.\X0A|",,"GrossDescription:
Specimen consists of 500cc of slightly hazy, yellow, unfixed fluid containing large fibrin clots.

3 CLH/PPPL prepped slide(s):    1 Diff-quik stained,    1 Pap stained,   1 Cell block.",,A: Left pleural fluid,,"AddendumComment:
Immunohistochemical stains show that the tumor cells are positive for synaptophysin, CD56, AE1, pankeratin, CK7, and TTF-1 while negative for CK20, napsin-A, and chromogranin.  This immunoprofile is compatible with a small cell carcinoma.  Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnosis."
REG4,LUNG,0,PAT-10029692,1,REC-3000671461,"ClinicalHistory:
Small bowel obstruction.
Post-OperativeDiagnosis:
Pending.",,"PostOperativeDiagnosis:
Pending
FinalDiagnosis:
Small bowel, resection:  METASTATIC ADENOCARCINOMA (see Comments)
DiagnosisComment:
Sections show a high-grade, infiltrative adenocarcinoma involving the bowel wall and serosa, within the area of fibrosis measuring 4.7 x 2.8 x 2.5 cm.  No in-situ carcinoma is identified.  The infiltrative morphology is compatible with metastatic adenocarcinoma.  The proximal and distal bowel resection margins are free of tumor.  The patient's history of lung carcinoma is noted.  Immunohistochemical stains are being performed to further characterize this tumor.  The result will be reported separately.  Dr. **NAME[ZZZ YYY] concurs with the diagnosis.\X0A|",,"GrossDescription:
Received in formalin labeled ""XXXXXX, small bowel"" is an unoriented segment of purplish-gray intestinal tissue measuring up to 17.0 cm in length x 3.3 cm in greatest diameter.  The specimen is received previously opened at one end.  The specimen is inked blue at the previously opened end, and orange on the opposite stapled margin.  Within the central portion of the segment of intestinal tissue, there is an extensive amount of fibrosis measuring up to 4.7 x 2.8 x 2.5 cm.  The area of fibrosis has been previously opened.  The area is inked black.  The fibrotic area is approximately 3.5 cm from the orange margin, and approximately 2.0 cm from the blue margin.  Further opening of the specimen reveals no masses.  

  KEY TO CASSETTES:  
  1  -  Blue margin
  2  -  Orange margin
  3-9  -  Representative, areas of fibrosis
  10  -  Normal intestinal tissue.","MicroscopicDescription:
The microscopic findings support the above diagnosis.",A: Small bowel,,"AddendumComment:
Immunohistochemical stains show that the tumor cells are positive for CK7 and negative for CK20, CDX-2, TTF-1, and Napsin-A.  Although this immunoprofile is non-specific, the morphology and immunoprofile is compatible with the known history of metastatic lung carcinoma.  Dr. **NAME[ZZZ YYY] concurs with the diagnosis."
REG4,LUNG,0,PAT-01450287,2,REC-3000671465,"ClinicalHistory:
Liver mass, lung mass.
Post-OperativeDiagnosis:
Same.",,"PostOperativeDiagnosis:
Same
FinalDiagnosis:
MICROSCOPIC DIAGNOSIS:

Ultrasound guided liver biopsy:                PAS 9
  SMALL CELL CARCINOMA, CONSISTENT WITH A POSSIBLE LUNG PRIMARY
  THE TUMOR STAINS POSITIVE FOR CD56, SYNAPTOPHYSIN, TTF-1, AND MOC-31
  THE TUMOR IS NEGATIVE FOR LEUKOCYTE COMMON ANTIGEN AND CK5/6
  TRICHROME AND RETICULIN STAINS SHOW MILD NON-SPECIFIC PORTAL FIBROSIS \X0A|",,"GrossDescription:
Received in formalin, labeled ""liver core biopsy"" are three soft tan-yellow to white cores, ranging from 1.7 to 2.1 cm in length by 0.1 cm in width.  The entire specimen is submitted in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: US guided liver bx,,
REG4,LUNG,0,PAT-10039099,1,REC-3000671555,"ClinicalHistory:
LUL mass, hemoptysis with bilateral pulmonary masses on CT.",,"IntraoperativeDiagnosis:
A.  Non-small cell carcinoma, favor adeno, per CF

C.  Non-small cell carcinoma, favor adeno, per CF

   assessed by, CF
   supervised by, CF.
FinalDiagnosis:
A.  LUNG, LEFT UPPER LOBE MASS, BRONCHIAL BRUSHING (ON-SITE EVALUATION):
- PULMONARY ADENOCARCINOMA, POORLY DIFFERENTIATED.
 
B.  LUNG, LEFT UPPER LOBE, BRONCHIAL BRUSHING:  
- PULMONARY ADENOCARCINOMA, POORLY DIFFERENTIATED.
 
C.  LUNG, LEFT UPPER LOBE, TRANSBRONCHIAL BIOPSY:  
- PULMONARY ADENOCARCINOMA, POORLY DIFFERENTIATED.
 
D.  LUNG, LEFT UPPER LOBE, RONCHIAL BRUSHING TIP:  
- PULMONARY ADENOCARCINOMA, POORLY DIFFERENTIATED.
DiagnosisComment:
At the request of the clinician, stains for AFB and fungus will be performed and reported in an addendum.",,"GrossDescription:
A.  Received:  1 DQ stained smear.

B.  Received:  1 DQ stained smear.
                  3 smears in alcohol for Pap stain. 
                  2 white tissue fragments in formalin up to approx. 0.3 cm. in length.
       Submitted:  All tissue fragments for a cell block (B1).

C.  Received:  3 DQ stained smears.
               3 white and red tissue fragments in formalin up to approx. 0.3 cm.
               in length.
    Submitted:  All tissue fragments for a cell block (C1).

D.  Received:  1 brushing tip in formalin.
       Submitted:  Multiple tissue fragments up to approx. 0.5 cm. in length for 
                   a cell block (D1).",,"A: ENDOSCOPIC BRONCHIAL BRUSHING-LEFT UPPER LOBE MASS (ON-SITE EVALUATION)
B: BRONCHIAL BRUSHING-LEFT UPPER LOBE
C: TRANSBRONCHIAL BIOPSY-LEFT UPPER LOBE
D: BRONCHIAL BRUSHING TIP-LEFT UPPER LOBE",,"AddendumDiagnosis:
D.  Kinyoun and GMS-F stained sections show no evidence of acid-fast bacilli or fungal organisms, respectively.  The final diagnosis remains unchanged.
Interpretation:
NEGATIVE (NO EGFR ALTERATION DETECTED).
ResultsComments:
Specimen  request made on B1 on **DATE[Jun 2 12].
By:  **NAME[ZZZ YYY], MD
Request:  EGFR Mutation Analysis-Sent to Clarient."
REG4,LUNG,0,PAT-10036609,1,REC-3000671660,"ClinicalHistory:
Right liver mass \R\ 4.2 cm solid, multiple liver masses, possible metastatic disease.  Patient with pulmonary squamous cell carcinoma and features of a small cell component.",,"IntraoperativeDiagnosis:
Malignant, lymphoma vs small cell carcinoma; assessed and supervised by CF/RF.
FinalDiagnosis:
RIGHT LIVER MASS, US-GUIDED FINE AND CORE NEEDLE BIOPSY:
- METASTATIC SMALL CELL CARCINOMA CONSISTENT WITH PULMONARY PRIMARY (SEE COMMENT).
DiagnosisComment:
The patient's previous endoscopic lung biopsy (***PATH-NUMBER[1]) demonstrated a squamous cell carcinoma with neuroendocrine component exhibiting prominent mechanical distortion and CD56 expression.  In light of this, the overall pathology represents a composite pulmonary squamous cell and small cell carcinoma (***PATH-NUMBER[1]) with metastatic small cell carcinoma to the liver.  Case discussed with Dr. **NAME[ZZZ] on **DATE[Jun 10 12].

The following stains were performed in the evaluation of this case (see microscopic description for complete details): cytokeratin AE1/AE3, CD56, NSE, TTF-1, synaptophysin, chromogranin A, p63 and cytokeratin 5/6.",,"GrossDescription:
Received:  4 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  5 tissue fragments measuring up to 7 mm in length for a cell block.","MicroscopicDescription:
Cytologic preparations and needle biopsy demonstrates a poorly differentiated carcinoma with scant cytoplasm, nuclear molding and mechanical distortion.  Immunoreactivity is noted with cytokeratin AE1/AE3, CD56 and NSE (focal).  TTF-1, synaptophysin, chromogranin A, p63 and cytokeratin 5/6 are negative.",A: RIGHT LIVER MASS US-GUIDED FNA AND CNB,,
REG4,LUNG,0,PAT-10030584,1,REC-3000671773,,,,,"GrossDescription:
Specimen request made on ***PATH-NUMBER[1] A1 from **DATE[Sep 24 10].
By:  **NAME[ZZZ YYY], MD (QCC)
Request: ALK Rearrangement to Clarient
DIAGNOSIS: LEFT UPPER LOBE NODULE, WEDGE RESECTION:
- POORLY DIFFERENTIATED ADENOCARCINOMA (1.0 CM), MARGINS FREE.",,"A: LEFT UPPER LOBE NODULE, WEDGE RESECTION",,"Interpretation:
ALK GENE REARRANGEMENT BY FISH:  NOT DETECTED (CLARIENT ***PATH-NUMBER[2])."
REG4,LUNG,0,PAT-10033024,1,REC-3000672066,,,"FinalDiagnosis:
Soft tissue, left neck, core needle biopsy: Poorly differentiated adenocarcinoma (see comment)./r/nDiagnosisComment:
Immunohistochemical stains are performed on sections of the formalin fixed, paraffin embedded material (block A1). The controls react appropriately. The tumor cells are positive for cytokeratin 7 and TTF-1, and are negative for cytokeratin 20 and cytokeratin 5/6. The results are consistent with a poorly differentiated adenocarcinoma of lung primary. 

Case reviewed in Pathology Staff Conference on **DATE[Jun 18 11].  Dr. **NAME[ZZZ YYY] notified of results via e-mail correspondence on **DATE[Jun 18 11]./r/n",,"GrossDescription:
Labeled:      patient name and medical record number, designated left neck
Specimen:    cylindrical, thin, friable cores of tissue (formalin)
Number:      2
Size:           up to 2.2 x 0.1 x 0.1 cm 
Submitted/Block:    entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left supraclavicular, biopsy",,"AddendumDiagnosis:
Left supraclavicular neck tissue ***PATH-NUMBER[1]:    No EGFR Alteration Detected.

Genotype Result:  Wild-type (No EGFR alteration detected)
Reference Range:  Alteration Detected   See Table
      Alteration Not Detected./r/n
Left Supraclavicular Neck Tissue ***PATH-NUMBER[1]:  ALK gene rearrangement:  Not Detected./r/nAddendumComment:
These results were reported by **NAME[XXX WWW], **INSTITUTION. on **DATE[Jun 27 2011].

Exon 19 deletionIncreased responsiveness to TKIsDeletions in exon 19 confer ligand independent activation and increase the duration and activation of receptor signaling after ligand binding.  These deletions result in the modified receptors being approximately 100-fold more sensitive than wild-type receptors to inhibition with TKIs. Reference (1).G719S, G719A, G719CIncreased responsiveness to TKIsMutations at codon 719 in exon 18 are associated with response of NSCLC to gefitinib or erlotinib monotherapy (slightly more than 50%), although they are not as responsive as those with deletions in exon 19 or point mutations of codon 858 in exon 21. Reference (1)L858RIncreased responsiveness to TKIsThe missense mutation L858R in exon 21 confers ligand independent activation and increases the duration and activation or receptor signaling after ligand binding.  This mutation results in the modified receptors being more sensitive than wild-type receptors to inhibition with TKIs. Reference (1)L861QIncreased  responsiveness to TKIsThe missense mutation L861Q in exon 21 confers ligand independent activation and increases the duration and activation of receptor signaling after ligand binding.  This mutation results in a modified receptor that has been reported to be more sensitive than wild-type receptor to inhibition with TKIs. Reference (1)S768ILack of responsiveness to TKIsMutations at codon 768 in exon 20 are associated with less responsiveness of NSCLC to gefitinib or erlotinib monotherapy. Reference (2)T790MLack of responsiveness to TKIsT790M point mutation in exon 20 is a frequent cause of secondary resistance to TKIs.  It appears that TKI administration may select for a pre-existing T790M resistance clone. Reference (3)Exon 20 InsertionLack of responsiveness to TKIsInsertions in exon 20 have been associated with lack of clinical response of NSCLC to gefitinib or erlotinib monotherapy both in vitro and in patients despite the fact that they seem to activate EGFR to a similar degree as deletions in exon 19 or exon 21 mutations.  This is a rare mutation, however, and robust clinical data is lacking. Reference (2)References:(1)  **NAME[VVV, UUU M]. et al.  N Engl J Med 350(21): 2129, 2004.
(2  )Wu, Jenn-Yu et al.  Cl.n Cancer Res 14(15): 4877, 2008.
(3)  Kobayashi, Susumu et al.  N Engl J Med 352(8): **PHONE.

Methodology:  Tumor areas of interest were identified, selectively microdissected from the paraffin-embedded tissue section.  The collected cells were lysed, and the genomic DNA was purified from the sample.  The DNA yield was determined, and the samples were brought to an optimal concentration.  Real-time PCR was used to evaluate specific mutations, deletions and insertions in the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene.  Eight reactions containing 30 primer and probe sets were used to target specific regions of exons 18-21 as well as the wild-type sequence.  

Intended Use:  The EGFR mutation analysis be real-time PCR is able to detect the wild-type sequence and 29 known mutations, deletions and insertions found in exons 18-21 of the EGFR tyrosine kinase domain.  The results of this study are to be interpreted in context with other clinical findings in patient care management.  The intended use of this assay is to aid the treating physician in the selection of the appropriate therapy for the patient.  There is a significant association between EGFR mutation, especially exon 19 deletion, and response to TKI' s.  This assay is capable of detecting a mutation of 1% in a background of wild-type alleles.  The intended use of this assay is to aid the treating physician in the selection of the appropriate therapy for the patient.  These mutations are linked to clinical responsiveness to EGFR inhibitors, such as gefitinib (Iressa) and erlotinib (Tarceva).

Prognostic and predictive testing should be interpreted in the context of additional clinical and/or histopathological findings.

This assay was developed and its performance characteristics were determined by **INSTITUTION.  Pursuant to the requirements of CLIA  88, this laboratory has established the test s accuracy and precision.  It has not been cleared or approved by the U.S. Food and Drug Administration, as the FDA has determined that such approval is not necessary.  This test is used for clinical purposes.  The results of this study are to be interpreted in the context of all other clinical findings./r/n
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA and reported by **NAME[XXX WWW], M.D. on **DATE[Apr 14 2012].   

Comment:  ALK rearrangement was not detected using the ALK dual color, break-apart rearrangement assay from **INSTITUTION (**NAME[TTT] Molecular).  The absence of an ALK rearrangement suggests that the patient may not respond to ALK inhibitors.  Clinical correlation is suggested.

    Reference range:  Not Detected:  Less than or equal to 15% of cells with split signals (3  ALK and 5  ALK signals apart by greater than 2 times signal size or single 3  ALK signal) in 50 cells scored.  Detected:  Greater than 15% of cells with split signals (3  ALK and 5  ALK signals apart by greater than 2 times signal size or single 3  ALK signal) in 50 cells scored.

    Methodology:  After determining the tumor area on an H\T\E slide from this formalin-fixed paraffin-embedded (FFPE) patient specimen, ALK gene rearrangement was assessed utilizing the LSI ALK Dual Color, Break Apart Probe assay (**NAME[TTT] Molecular).  The identification probes for LSI ALK 5  probe (SpectrumGreen) and LSI ALK 3  probe (SpectrumOrange) were hybridized according to the manufacturer s guidelines.  At least 50 non?overlapping nuclei were analyzed and the localization of the LSI ALK 5  probe (green) and LSI ALK 3  probe (orange) signals were recorded and interpreted.

    Intended Use:  The LSI ALK (Anaplastic Lymphoma Kinase) Dual Color, Break Apart Rearrangement Probe (**NAME[TTT] Molecular) is designed to detect rearrangements of the ALK gene.  Fusion of the ALK gene with the echinoderm microtubule-associated protein-like 4 gene (EML4   ALK) can be detected in a subset of non-small cell lung cancers (NSCLC).  EML4-ALK fusion is observed primarily in lung adenocarcinoma.  Patients who harbor this mutation may respond to ALK inhibitors.  Reference:  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.  Nature 448, 561-566 (2 **DATE[Mar 2008])./r/n"
REG4,LUNG,0,PAT-10036769,2,REC-3000672145,"ClinicalHistory:
Clinical Indications: HX of lung cancer resected 2003, new RUL spiculated mass suspicious for lung cancer.
Procedure->Core
Clinical History/Diagnosis/Condition->RUL spiculated mass, HX Lung CA resected 2003./r/n",,"FinalDiagnosis:
Lung, right upper lobe mass:  Moderately differentiated adenocarcinoma (see comment)./r/nDiagnosisComment:
The patient s previous history of right lower lobe moderately differentiated acinar carcinoma is noted.  The H\T\E-stained sections from that case (***PATH-NUMBER[1], **DATE[Apr 27 03]) are reviewed in conjunction with the current right upper lobe biopsy.  Immunohistochemical stains (performed on block A1; controls react appropriately) show the upper lobe tumor cells are positive for TTF-1 (a marker associated with tumors of lung primary) and cytokeratin 7, and they are negative for cytokeratin 20.  Other than being an adenocarcinoma, the morphologic features of the current case do not closely resemble those of the 2003 case, thus a second lung primary is a consideration.  Clinical correlation is recommended.

Case reviewed in Pathology Staff Conference on **DATE[May 18 11].  Dr. **NAME[ZZZ YYY] notified of the findings via e-mail communication on **DATE[May 18 11] at 4:35 p.m./r/n",,"GrossDescription:
Labeled:      patient name and medical record number, designated right lung mass biopsy
Specimen:    tan-white cylindrical segments of tissue (formalin)
Size:      up to 1.7 x 0.1 x 0.1 cm
Submitted/Block:    entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Lung, core biopsy",,"AddendumDiagnosis:
Lung, Right Upper Lobe Tissue ***PATH-NUMBER[2]:  No EGFR Alteration Detected./r/n
Lung, Right Upper Lobe Tissue S11-5210-A1:  ALK gene rearrangement:  Not Detected./r/nAddendumComment:
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA and reported by **NAME[XXX WWW], M.D. on **DATE[Nov 16 2011].   

FISH STUDY

Comment:  ALK rearrangement was not detected using the ALK dual color, break-apart rearrangement assay from **INSTITUTION (**NAME[VVV] Molecular).  The absence of an ALK rearrangement suggests that the patient may not respond to ALK inhibitors.  Clinical correlation is suggested.  

    Reference range:  
    Not Detected:  Less than or equal to 15% of cells with split signals (3  ALK and 5  ALK signals apart by greater than 2 times signal size or single 3  ALK signal) in 50 cells scored.  Detected:  Greater than 15% of cells with split signals (3  ALK and 5  ALK signals apart by greater than 2 times signal size or single 3  ALK signal) in 50 cells scored.

    Methodology:  
    After determining the tumor area on an H\T\E slide from this formalin-fixed paraffin-embedded (FFPE) patient specimen, ALK gene rearrangement was assessed utilizing the LSI ALK Dual Color, Break Apart Probe assay (**NAME[VVV] Molecular).  The identification probes for LSI ALK 5  probe (SpectrumGreen) and LSI ALK 3  probe (SpectrumOrange were hybridized according to the manufacturer s guidelines.  At least 50 non-overlapping nuclei were analyzed and the localization of the LSI ALK 5  probe (green) and LSI ALK 3  probe (orange) signals were recorded and interpreted.

Intended Use:  
The LSI ALK (Anaplastic Lymphoma Kinase) Dual Color, Break Apart Rearrangement Probe (**NAME[VVV] Molecular) is designed to detect rearrangements of the ALK gene.  Fusion of the ALK gene with the echinoderm microtubule-associated protein-like 4 gene (EML4-ALK) can be detected in a subset of non-small cell lung cancers (NSCLC).  EML4-ALK fusion is observed primarily in lung adenocarcinoma.  Patients who harbor this mutation may respond to ALK inhibitors.  Nature 448, 561-566 (2 **DATE[Oct 2007]).  Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer./r/n"
REG4,LUNG,0,PAT-10012339,3,REC-3000672188,"ClinicalHistory:
Left lower lobe lung mass, history of right lower lobe lung resection for CA.",,"IntraoperativeDiagnosis:
A. FROZEN SECTION:  Malignant (adenocarcinoma). 
GROSS:  0.6 cm from margin.  Assessed by **NAME[M. ZZZ] MD/KC.
FinalDiagnosis:
LEFT LOWER LOBE, WEDGE RESECTION:  MUCINOUS ADENOCARCINOMA, WELL DIFFERENTIATED, (1.1 X 0.8 X 0.8 CM), MARGIN FREE (BY 0.6 CM).",,"GrossDescription:
A. Specimen:  Lung wedge with attached staple line, received fresh.  
Weight:  5 gm.
Number of segments:  1.  
Size:  6.2 x 2.3 x 2.3 cm.
Gross findings:  Sectioning reveals a tan, soft, well-circumscribed nodule measuring 1.1 x 0.8 x 0.8 cm, 0.6 cm away from the surgical margin (inked green).
Submitted for microscopic evaluation:  Representative.  
Cassettes:  3, (1 - frozen section, 2 - tumor with adjacent surgical margin, 3 - uninvolved lung).",,A: LEFT LOWER LOBE,,"Interpretation:
ALK Gene Rearrangement (FISH Study):  NEGATIVE (NOT DETECTED)."
REG4,LUNG,0,PAT-10039737,1,REC-3000672215,,,"IntraoperativeDiagnosis:
Adenocarcinoma; assessed and supervised by **INITIALS.
FinalDiagnosis:
LEFT UPPER LOBE LUNG, CT-GUIDED CORE NEEDLE BIOPSY:  MODERATELY 
DIFFERENTIATED PRIMARY PULMONARY ADENOCARCINOMA (SEE COMMENT).
DiagnosisComment:
There is sufficient material in the specimen for EGFR 
analysis if required.",,"GrossDescription:
Received:  4 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  4 tissue fragments measuring up to 5 mm in length for a cell block.",,A: LEFT UPPER LOBE LUNG CT-GUIDED CNB,,
REG4,LUNG,0,PAT-00773051,2,REC-3000672563,"ClinicalHistory:
511.9
  Specimen processed using ThinPrep monolayer technology.
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Right Pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block:  Adenocarcinoma.


Right Pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block:  Adenocarcinoma.","FinalDiagnosis:

Right Pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block:  
Metastatic Adenocarcinoma from lung primary

Comment
The tumor cells are positive for BER-EP4, TTF1 and CK7; weakly positive for MOC-31; negative for CK20, Calretinin and D2-40, supporting the above diagnosis. Dr. **NAME[ZZZ] and **NAME[YYY] have been notified.\X0A|",,"GrossDescription:
Specimen consists of 1000cc of grossly bloody, unfixed fluid.

3 CLH/PPPL prepped slide(s):    1 Diff-quik stained,    1 Pap stained,    1 Cell block.",,A: Right Pleural fluid,,
REG4,LUNG,0,PAT-10039473,1,REC-3000672864,"ClinicalHistory:
Right lung nodule.",,"IntraoperativeDiagnosis:
A. FROZEN SECTION:  Malignant (adenocarcinoma).  Assessed by **NAME[M. ZZZ] MD/KT.
B. FROZEN SECTION:  Bronchial margin clear.  Assessed by **NAME[M. ZZZ] MD/**INITIALS.
FinalDiagnosis:
A.  RIGHT LOWER LOBE SOLITARY PULMONARY NODULE:  PULMONARY ADENOCARCINOMA
 
B.  RIGHT LOWER LUNG LOBE:
1.  PULMONARY ADENOCARCINOMA
2.  11 LYMPH NODES NEGATIVE FOR METASTASIS
 
Lung cancer information
Operative procedure:  Right lower lobectomy
Tumor-histologic type:  Pulmonary adenocarcinoma
Histologic grade:  Well to moderately differentiated
Anatomic site:  Right lower lobe of lung 
Size:  1.3 x 1.2 x 1.1 cm
Extent of involvement of main bronchus:  None
Invasion of pleura:  None
Separate tumor nodules in same lobe:  None
Tumor associated obstructive pneumonitis or atelectasis:  None
Invasion of adjacent structures:  None
Lymphatic invasion:  None
Arterial or venous invasion:  None
Resection margins:  Bronchial margin clear by 6.0 cm
Regional lymph nodes:  11 lymph nodes negative for metastasis
Distant metastasis:  Unknown
Ancillary studies:  Immunohistochemical staining of the tumor is positive with cytokeratin 7, TTF-1, and Napsin-A; staining is negative with cytokeratin 20 and thyroglobulin
Treatment effect: None
Pleural effusion cytology:  None submitted
Pathologic grade and stage:  G1-2 pT1a pN0 (Stage IA, if M0).",,"GrossDescription:
A. Specimen:  Soft tan-pink tissue, received fresh.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  0.5 x 0.5 x 0.4 cm.
Submitted for microscopic evaluation:  All, as frozen section.  
Cassettes:  1.

B. Specimen:  Right lower lobectomy, received fresh.
Weight:  203 gm.
Measurements:  15.0 x 11.0 x 4.0 cm.
Appearance of pleura (inked green):  Retracted over tumor.
Tumor
   Location:  Peripheral.
   Size:  1.3 x 1.2 x 1.1 cm.
   Relationship to bronchi:  Grossly not involved.
   Distance from bronchial margin:  6.0 cm.
   Relationship to pleura:  Abuts pleura.
   Appearance:  Irregular, tan-white and soft.
Uninvolved lung parenchyma:  Reddish to pale, spongy; no other lesions grossly identified.
Other findings:  None.
Lymph nodes:  Multiple anthracotic lymph nodes measuring up to 3.4 x 1.6 x 0.7 cm.  Largest lymph nodes appear matted.
Description of blocks for microscopic description:
1  shaved bronchial margin, frozen section
2-4  tumor
5  uninvolved lung
6-9  lobar lymph nodes (7 - single bisected node; 8 and 9 - single bisected node)
10-11  segmental lymph nodes.",,"A: RIGHT LOWER LOBE SOLITARY PULMONARY NODULE
B: RIGHT LOWER LUNG LOBE",,
REG4,LUNG,0,PAT-10040073,1,REC-3000673160,"ClinicalHistory:
Lung tumor.",,"IntraoperativeDiagnosis:
25G x 3 FNA
23G x 1 FNA

Malignant per **INITIALS

assessed by **INITIALS
supervised by **INITIALS.
FinalDiagnosis:
RIGHT SUPRACLAVICULAR LYMPH NODE FNA:  METASTATIC PULMONARY ADENOCARCINOMA.
DiagnosisComment:
Sections show tumor cells with enlarged, hyperchromatic and eccentric nuclei.  Immunohistochemical studies show positive staining in tumor cells with TTF-1 and Napsin A.  The morphologic and immunophenotypic features are consistent with adenocarcinoma of lung primary.  The paraffin block has been sent for EGFR/K-ras mutation analysis.  Case discussed with Dr. **NAME[ZZZ] on **DATE[Apr 1 12].",,"GrossDescription:
Received:  9 DQ stained smears.
       1 air dried smear for DQ staining.
       3 smears in alcohol for Pap staining.
       Multiple dark red circular tissue fragments up to 4 mm in diameter in 
     formalin.
Submitted: All tissue fragments for cell block.",,A: RIGHT SUPRACLAVICULAR LYMPH NODE FNA,,"Interpretation:
EGFR MUTATION ANALYSIS: NEGATIVE (NO EGFR ALTERATION DETECTED).

KRAS MUTATION ANALYSIS: NEGATIVE (KRAS Mutation Not Detected).

FISH STUDY: POSITIVE (ALK GENE REARRANGEMENT BY FISH DETECTED)."
REG4,LUNG,0,PAT-10034034,1,REC-3000673181,"ClinicalHistory:
786.6
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Mediastinal mass, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Aug 21 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  Small cell tumor.


Mediastinal mass, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Aug 21 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  Small cell tumor.","FinalDiagnosis:

Mediastinal mass, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Aug 21 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Cytology and cell block:  Small cell Carcinoma

Comment
The tumor cells are positive for pankeratin, synaptophysin, chromogranin, CD56 and TTF1; negative for LCA; supporting the above diagnosis. Dr. **NAME[YYY] concurs. Dr. **NAME[XXX] has been notified.",,"GrossDescription:
Specimen consists of 3 ""passes"" = 1 air-dried slides prepared by physician along with 45cc of clear, colorless, formalin, fixed fluid containing cores.

1 Physician prepped slide(s):    1 Air-dried (Diff-quik stained)
2 CLH/PPPL prepped slide(s):    1 Pap stained,    1 Cell block
1 Review(s) by Pathologist:

Adequacy evaluation #1 (pass #     1    ) = _X_  Adequate
88172                 ___  Insufficient.",,"A: Mediastinal mass, FNA",,
REG4,LUNG,0,PAT-10039992,1,REC-3000673205,"ClinicalHistory:
FNA right upper lobe lung lesion.","CytologyReview:

Right upper lobe lung lesion needle biopsy

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Adenocarcinoma of lung.","FinalDiagnosis:

Right upper lobe lung lesion needle biopsy

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Adenocarcinoma of lung.
DiagnosisComment:
Two adequacy evaluations are performed.  Adequate cellularity noted on second group of samplings.  The cellblock, direct smears, and concentrated cytospins demonstrate similar findings.  This consists of cohesive nests of large cells without keratin production.  Nuclei are large and atypical and mitotically active. 

Dr. **NAME[ZZZ]'s office was notified of the findings of a non-small cell carcinoma on **DATE[Oct 21 11].

TTF1 is positive.  Napsin A appears positive.  CK20 appears negative.  CK5 appears negative.  Special stains and controls worked appropriately.  The findings are consistent with primary adenocarcinoma of the lung.

EGFR by PCR and EML4-ALK have been requested.",,"GrossDescription:
Adequacy x 2, cell block.",,A: Right upper lobe lung lesion needle biopsy,,
REG4,LUNG,0,PAT-10016585,1,REC-3000675811,,"CytologyReview:

Cerebrospinal fluid, cytology and cell block:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy.","FinalDiagnosis:

Cerebrospinal fluid, cytology and cell block:

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy.
DiagnosisComment:

Single and small clusters of highly atypical cells present.  The findings are consistent with involvement of CSF by carcinoma.  Cell blocks have insufficient diagnostic cells for immunohistochemical stains.

Case discussed with Dr. **NAME[ZZZ YYY] on **DATE[Aug 23 2012].",,"GrossDescription:
Received labeled with the patient s name (in Tube # 4) is 3.5 mL of light yellow and clear fluid.  The fluid is centrifuged and the resulting cell pellet is submitted for cytology and cell block (one cassette).  Additional fluid in tube #1 is also submitted for cell block.  

2 PPPL prepared cytospin slides (2 Pap stained) and 2 cell blocks (Tubes # 4 and # 1).",,A: Cerebrospinal fluid # 4,,
REG4,LUNG,0,PAT-10036640,1,REC-3000675847,,,"FinalDiagnosis:
LEFT PLEURAL EFFUSION:  ATYPICAL CELLS, SUSPICIOUS FOR ADENOCARCINOMA.",,,,A: LEFT PLEURAL EFFUSION,,
REG4,LUNG,0,PAT-10039483,1,REC-3000675884,"ClinicalHistory:
LUL lung mass; history of smoking.",,"IntraoperativeDiagnosis:
Non-small cell carcinoma; assessed and supervised by **INITIALS.
FinalDiagnosis:
LEFT UPPER LOBE LUNG MASS, CT-GUIDED CORE NEEDLE BIOPSY:  SQUAMOUS CELL CARCINOMA.
DiagnosisComment:
Tumor cells are immunopositive for p63, and negative for TTF-1 and Napsin A.  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Sep 27 2012].",,"GrossDescription:
Received:  3 DQ stained smears.
       tissue fragments in formalin.
Submitted:  tissue fragments for a cell block.",,A: LUL LUNG MASS CT-GUIDED CNB,,
REG4,LUNG,0,PAT-10036651,1,REC-3000676199,"ClinicalHistory:
Lung cancer, non-smoker.",,"FinalDiagnosis:
PLEURAL FLUID:  METASTATIC ADENOCARCINOMA, CONSISTENT WITH LUNG PRIMARY.
DiagnosisComment:
EGFR mutation analysis and ALK (EML4) rearrangement studies are ordered (Clarient Diagnostic Services).",,"GrossDescription:
Received:  1000 cc of hazy, yellow fluid.
Prepared:  2 cytospin slides for Pap and DQ staining (treated with NH4Cl x 1).
Submitted:  cell button for a cell block.",,A: PLEURAL FLUID,,"Interpretation:
ALK GENE REARRANGEMENT BY FISH:  NOT DETECTED.

NEGATIVE (NO EGFR ALTERATION DETECTED)."
REG4,LUNG,0,PAT-00040212,2,REC-3000676238,"ClinicalHistory:
Left supraclavicular adenopathy.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Left supraclavicular node biopsy.",,"PreOperativeDiagnosis:
Left supraclavicular node biopsy.
PostOperativeDiagnosis:
Same, Pending pathology.
IntraoperativeDiagnosis:
Frozen Section:  Lymph node with metastatic adenocarcinoma/MP.
FinalDiagnosis:
Lymph node, left supraclavicular, biopsy:  Lymph node with metastatic adenocarcinoma, 
            poorly-differentiated, consistent with lung primary.
DiagnosisComment:
Material will be submitted for EGFR Gene Mutation and ALK Mutation by FISH (Clarient Labs, pending).",,"GrossDescription:
Received fresh for intraoperative consultation, labeled ""left supraclavicular node,"" is an excision of tan-pink to yellow, lymphoid soft tissue measuring 1.2 x 1.0 x 1.0 cm.  A portion is submitted for a frozen section and subsequently submitted in block 1.  The remainder of the specimen is submitted in block 2.","MicroscopicDescription:
Sections of lymph node demonstrate metastatic, poorly-differentiated carcinoma, consistent with adenocarcinoma.  A histochemical stain for mucin demonstrates focal equivocal intracytoplasmic staining.  An immunostain (TTF-1) demonstrates positive staining in tumor cells, supporting primary pulmonary adenocarcinoma origin.",A: Left supraclavicular node,,
REG4,LUNG,0,PAT-10039665,1,REC-3000676379,"ClinicalHistory:
Aspiration, Lt TVC paralysis, lung mass, thyroid masses.",,"FinalDiagnosis:

Right upper lobe bronchi, biopsy:  Poorly differentiated carcinoma.

Comment:  The biopsy shows small aggregates of malignant neoplasm in the sub-bronchial lymphatics.  These are not present in levels or staining with TTF-1.  These aggregates are consistent with a poorly differentiated carcinoma (non-small cell).   The bronchial cytology is positive.",,"GrossDescription:
Received in formalin labeled ""right upper lobe bronchi"" is a single tan and soft tissue fragment  measuring 0.2 cm.  Entirely submitted in one cassette.","MicroscopicDescription:
Confirmed.",A: Rt upper lobe bronchi,,
REG4,LUNG,0,PAT-01563337,2,REC-3000677793,,,"IntraoperativeDiagnosis:
Atypical cells present; assessed and supervised by PBG/RP.
Specimen submitted to micro for cultures.
FinalDiagnosis:
RIGHT UPPER LOBE LUNG, CT-GUIDED CORE NEEDLE BIOPSY:  MODERATELY 
DIFFERENTIATED LUNG ADENOCARCINOMA.
DiagnosisComment:
The biopsy specimen is adequate for EGFR testing if clinically indicated.",,"GrossDescription:
Received:  2 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  5 tissue fragments measuring up to 3 mm in length for a cell block.","MicroscopicDescription:
Cytologic preparations and cell-block demonstrate tumor cells forming 
glands within a background of desmoplastic fibrosis.",A: RIGHT UPPER LOBE LUNG CT-GUIDED CNB,,
REG4,LUNG,0,PAT-10022062,2,REC-3000677819,"ClinicalHistory:
RLL Lung Mass, CT Guided Lung Biopsy, Suspicious for malignancy
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS, **ROOM.","CytologyReview:

Right posterior lung mass, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Atypical
Cytology and cell block:  Atypical cells, rule out neoplastic process.


Right posterior lung mass, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block:  Carcinoma, favor squamous cell carcinoma, additional stains pending.","FinalDiagnosis:

Right posterior lung mass, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block:  Carcinoma, favor squamous cell carcinoma, additional stains pending.",,"GrossDescription:
Specimen consists of 2 air-dried slides prepared by physician along with 10cc of slightly hazy, colorless, fixed fluid containing minute particles.

2 Physician prepped slide(s):    2 Air-dried (Diff-quik stained)
2 CLH/PPPL prepped slide(s):    1 Pap stained,    1 Cell block
0 Review(s) by Pathologist:.",,"A: Right posterior lung mass, FNA",,
REG4,LUNG,0,PAT-10039155,1,REC-3000678037,"ClinicalHistory:
LLL lung mass.","PhysicianNotification:
Findings discussed with Dr. **NAME[ZZZ] on **DATE[Sep 4 12] at 10:40 am.","IntraoperativeDiagnosis:
Malignant cells present; assessed and supervised by AOL/MDB.
FinalDiagnosis:
LEFT LOWER LOBE OF LUNG MASS, CT-GUIDED CORE NEEDLE BIOPSY:  LUNG ADENOCARCINOMA.
DiagnosisComment:
Immunohistochemical studies show positive staining for TTF-1 and cytokeratin 7. Staining with cytokeratin 20 and CDX-2 is negative.  The morphologic and immunophenotypic features support the above diagnosis.",,"GrossDescription:
Received:  2 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  5 tissue fragments measuring up to 3 mm in length for a cell block.",,A: LLL LUNG MASS CT-GUIDED CNB,,
REG4,LUNG,0,PAT-10037717,1,REC-3000678179,,,"IntraoperativeDiagnosis:
Atypical cells present, per **INITIALS

assessed by, **INITIALS
supervised by, KK.
FinalDiagnosis:
RIGHT UPPER LOBE LUNG, CT-GUIDED CORE NEEDLE BIOPSY:  LUNG ADENOCARCINOMA.
DiagnosisComment:
Tumor cells are immunopositive for cytokeratin 7, TTF-1 and Napsin-A; they are negative for cytokeratin 20, p63, CDX-2, and GCDFP-15. The immunoprofile in combination with the morphology is indicative of a lung adenocarcinoma.  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Apr 5 12].",,"GrossDescription:
Received:  1 DQ stained smear.
           8 red and white colored tissue fragments in formalin up to approx. 0.3 cm.
           in length (A1).
           Approx. 0.75 cc. turbid red material in a syringe (A2).
Submitted:  All tissue fragments for a cell block (A1).
            A 0.4 cm. diameter cell pellet for a cell block (A2).","MicroscopicDescription:
Cytologic preparations and cell block show clusters of tumor cells with increased N:C ratio, pleomorphic nuclei, and focal gland formation.",A: RIGHT UPPER LOBE LUNG CNB-CT GUIDED,,
REG4,LUNG,0,PAT-10038721,1,REC-3000678498,"ClinicalHistory:
Right shoulder nodule, proximal humerus.",,"IntraoperativeDiagnosis:
25G FNA x 2

Malignant per KK/CF

assessed by KK/CF
supervised by KK/CF.
FinalDiagnosis:
RIGHT SHOULDER NODULE PROXIMAL HUMERUS FNA:  
- MODERATELY DIFFERENTIATED ADENOCARCINOMA.
DiagnosisComment:
The tumor is positive for cytokeratin 7, cytokeratin 20 and villin.  The tumor is negative for PAX-8, GCDFP-15, CDX-2, Napsin A, TTF-1, ER, Mammaglobin and p63.  The immunohistochemical profile raises the possibility of an upper gastrointestinal tract primary.  The report has been faxed to Dr. **NAME[ZZZ YYY]'s office on **DATE[Nov 7 11].",,"GrossDescription:
Received:  6 DQ stained smears.
       1 air dried smear for DQ staining.
       6 circular dark red tissue fragments of up to 5 mm in diameter in formalin. 
     (A1)
       Multiple elongated dark red tissue fragments of up to 7 mm in length in 
     formalin. (A2)
Submitted: All tissue fragments for cell block.","MicroscopicDescription:
The cytologic preparations show a gland forming tumor with eosinophilic cytoplasm and focal goblet cells.  Scattered mitotic figures are present.",A: RIGHT SHOULDER NODULE PROXIMAL HUMERUS FNA,,
REG4,LUNG,0,PAT-10038449,1,REC-3000678564,,,"IntraoperativeDiagnosis:
Malignant; assessed and supervised by PBG/RP.
FinalDiagnosis:
PLEURAL BASED EXPANSILE RIB MASS, CT-GUIDED CORE NEEDLE BIOPSY:  
-CONSISTENT WITH POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.
DiagnosisComment:
Confirmatory immunohistochemical studies will be performed and 
reported in an addendum.",,"GrossDescription:
Received:  2 DQ stained smears.
       2 air dried smears for DQ stain.
       Tissue fragments in formalin soln.
Submitted:  7 tissue fragments measuring up to 6 mm in length for a cell block.","MicroscopicDescription:
Cytologic preparations and cell-block demonstrate sheets of tumor 
cells with eosinophilic cytoplasm, intercellular bridging, and 
irregular hyperchromatic nuclei.",A: PLEURAL BASED EXPANSILE RIB MASS CT-GUIDED CNB,,"Interpretation:
Immunohistochemical studies show tumor cells staining positive 
for CK5/6, P63 and negative for Napsin A and TTF-1. Morphology 
and immunophenotype are diagnostic for poorly differentiated 
squamous cell carcinoma."
REG4,LUNG,0,PAT-10040073,1,REC-3000678691,,,,,"GrossDescription:
Specimen request made on ***PATH-NUMBER[1] A1 from **DATE[Jul 31 2011].
By:  **NAME[ZZZ YYY] MD (PALI MOMI)  
Request:  ALK- Sent to Clarient
DIAGNOSIS:  RIGHT SUPRACLAVICULAR LYMPH NODE FNA:  METASTATIC PULMONARY ADENOCARCINOMA.",,A: RIGHT SUPRACLAVICULAR LYMPH NODE FNA,,"Interpretation:
FISH STUDY: POSITIVE (ALK GENE REARRANGEMENT BY FISH DETECTED).
This was also reported in Surgical case number ***PATH-NUMBER[1]."
REG4,LUNG,0,PAT-10040446,1,REC-3000679113,"ClinicalHistory:
793.11
Procedure->Core
Clinical History/Diagnosis/Condition->Left pleural nodule./r/n",,"FinalDiagnosis:
Left total nodule: Small cell carcinoma consistent with lung primary./r/nDiagnosisComment:
The biopsy reveals infiltrating small cell carcinoma. The carcinoma cells are positive for TTF1, CD56 and focally positive for CK 7, chromogranin and synaptophysin. Negative for CD21. Findings are consistent with small cell carcinoma of lung. Dr. **NAME[ZZZ YYY] notified of the biopsy findings (via e-mail) on **DATE[Jul 13 2012]. Case reviewed in Pathology Staff Conference on **DATE[Jul 12 2012]./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated left pleural nodule
Specimen:    Cylindrical gray-white thread-like cores (formalin)
Number:      Multiple
Size:           Aggregating to 0.8 x 0.4 x less than 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left pleural nodule, core biopsy",,
REG4,LUNG,0,PAT-00645333,2,REC-3000679115,"ClinicalHistory:
Result to **NAME[ZZZ YYY]
Procedure->Biopsy
Clinical History/Diagnosis/Condition->LUL cavitary lesion lung./r/n",,"FinalDiagnosis:
Lung, left upper lobe:  Poorly differentiated adenocarcinoma consistent with lung primary (see comment)./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[Dec 16 11].  The  H\T\E-stained sections demonstrate sclerotic tissue with infiltrating malignant tumor cells, rarely forming vague glandular configurations.  Immunohistochemical stains are performed; all controls react appropriately.  The tumor cells are positive for cytokeratin 7, TTF-1, and p63 (focally), and they are negative for cytokeratin 20 and cytokeratin 5/6.  The morphologic features and immunophenotypic findings are those of a poorly differentiated adenocarcinoma consistent with lung primary.  

The findings were discussed with Dr. **NAME[ZZZ YYY] on **DATE[Dec 16 11] at 4:36 p.m./r/n",,"GrossDescription:
Labeled:      patient name and medical record number, designated lung biopsy
Specimen:    cylindrical (formalin)
Number:      two
Size:           up to 1.1 x 0.1 x 0.1 cm 
Submitted/Block:    entirely/1./r/n","MicroscopicDescription:
Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Lung LUL, biopsy",,"AddendumDiagnosis:
Lung Left Upper Lobe tissue ***PATH-NUMBER[1]:  NO EGFR ALTERATION DETECTED

Genotype Result:  Wild-type (No EGFR alteration detected)
Reference Range:  Alteration Detected:  See Table
      Alteration Not Detected./r/n
Lung left upper lobe tissue ***PATH-NUMBER[1]:  ALK Gene Rearrangement   Not Detected./r/nAddendumComment:
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA and reported by **NAME[XXX WWW], M.D. on **DATE[Jul 12 2012].


Comment:  ALK rearrangement was not detected using the ALK dual color, break-apart rearrangement assay from **INSTITUTION 
    Abbot Molecular).  The absence of an ALK rearrangement suggests that the patient may not respond to ALK 
    inhibitors.  Clinical correlation is suggested. 

    Reference range:
    Not Detected:  Less than or equal to 15% of cells with split signals (3  ALK and 45  ALK signals apart by greater 
    than 2 times signal size or single 3  ALK signal) in 50 cells scored.
    Detected:  Greater than 15% of cells with split signals (3  ALK and 45  ALK signals apart by greater than 2 times 
    signal size or single 3  ALK signal) in 50 cells scored.

    Methodology:
    After determining the tumor area on the H\T\E slide form this formalin-fixed paraffin-embedded (FFPE) patient 
    specimen, ALK gene rearrangement was assessed utilizing the LIS ALK Dual Color, Break Apart Probe assay 
    (Abbot Molecular).  The identification probes for LSI ALK 5  probe (SpectrumGreen) and LSI ALK 3  probe 
    (SpectrumOrange) were hybridized according to the manufacturer s guidelines.  At least 50 non-overlapping 
    nuclei were analyzed and the localization of the LSI ALK 5  probe (green) and LSI ALK 3  probe (orange) signals 
    were recorded and interpreted.

    Intended Use:
    The LSI ALK (anaplastic Lymphoma Kinase) Dual Color, Break Apart Rearrangement Probe (Abbot Molecular) is 
    designed to detect rearrangements of the ALK gene Fusion of the ALK gene with the echinoderm microtubule-
    associated protein-like 4 gene (EML4-ALK) can be detected in a subset of non-small cell lung cancers (NSCLC).  
    EML4-ALK fusion is observed primarily in lung adenocarcinoma.  Patients who harbor this mutation may respond 
    to ALK inhibitors.  Nature 448, 561-566 (2 **DATE[May 2008]).  Identification of the transforming EML4-ALK fusion 
    gene in the non-small-cell lung cancer.

    Prognostic and predictive testing should be interpreted in the context of additional clinical and/or 
    histopathological findings.

    Some tests use Analyte Specific Reagents (ASR s).  The performance characteristics of these ASR s were 
    determined by Clarient.  They have not been cleared or approved by the U.S. Food and Drug Administration 
    (FDA).  The FDA has determined that such clearance or approval is not necessary.  Clarient is certified under the 
    Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to performing high complexity 
    clinical laboratory testing./r/n
The following results were performed at Clarient Diagnostic Services, Aliso Viejo, CA and reported by **NAME[XXX WWW], M.D. on **DATE[Jan 29 2012].   

EGFR Mutation Analysis

Exon 19 deletionIncreased responsiveness to TKIsDeletions in exon 19 confer ligand independent activation and increase the duration and activation of receptor signaling after ligand binding.  These deletions result in the modified receptors being approximately 100-fold more sensitive than wild-type receptors to inhibition with TKIs. Reference (1).G719S, G719A, G719CIncreased responsiveness to TKIsMutations at codon 719 in exon 18 are associated with response of NSCLC to gefitinib or erlotinib monotherapy (slightly more than 50%), although they are not as responsive as those with deletions in exon 19 or point mutations of codon 858 in exon 21. Reference (1)L858RIncreased responsiveness to TKIsThe missense mutation L858R in exon 21 confers ligand independent activation and increases the duration and activation or receptor signaling after ligand binding.  This mutation results in the modified receptors being more sensitive than wild-type receptors to inhibition with TKIs. Reference (1)L861QIncreased  responsiveness to TKIsThe missense mutation L861Q in exon 21 confers ligand independent activation and increases the duration and activation of receptor signaling after ligand binding.  This mutation results in a modified receptor that has been reported to be more sensitive than wild-type receptor to inhibition with TKIs. Reference (1)S768ILack of responsiveness to TKIsMutations at codon 768 in exon 20 are associated with less responsiveness of NSCLC to gefitinib or erlotinib monotherapy. Reference (2)T790MLack of responsiveness to TKIsT790M point mutation in exon 20 is a frequent cause of secondary resistance to TKIs.  It appears that TKI administration may select for a pre-existing T790M resistance clone. Reference (3)Exon 20 InsertionLack of responsiveness to TKIsInsertions in exon 20 have been associated with lack of clinical response of NSCLC to gefitinib or erlotinib monotherapy both in vitro and in patients despite the fact that they seem to activate EGFR to a similar degree as deletions in exon 19 or exon 21 mutations.  This is a rare mutation, however, and robust clinical data is lacking. Reference (2)References:(1)  **NAME[VVV, UUU M]. et al.  N Engl J Med 350(21): 2129, 2004.
(2  )Wu, Jenn-Yu et al.  Cl.n Cancer Res 14(15): 4877, 2008.
(3)  Kobayashi, Susumu et al.  N Engl J Med 352(8): **PHONE.

Methodology:  Tumor areas of interest were identified and selectively microdissected from the paraffin-embedded tissue section.  The collected cells were lysed, and the genomic DNA was purified from the sample.  Real-time PCR was used to evaluate specific mutations, deletions and insertions in the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene.  Eight reactions containing 30 primer and probe sets were used to target specific regions of exons 18-21 as well as the wild-type sequence.  

Intended Use:  The EGFR mutation analysis be real-time PCR is able to detect the wild-type sequence and 29 known mutations, deletions and insertions found in exons 18-21 of the EGFR tyrosine kinase domain.  The results of this study are to be interpreted in context with other clinical findings in patient care management.  The intended use of this assay is to aid the treating physician in the selection of the appropriate therapy for the patient.  There is a significant association between EGFR mutation, especially exon 19 deletion, and response to TKI' s.  This assay is capable of detecting a mutation of 1% in a background of wild-type alleles.  These mutations are linked to clinical responsiveness to EGFR inhibitors, such as gefitinib (Iressa) and erlotinib (Tarceva)./r/n"
REG4,LUNG,0,PAT-10037473,1,REC-3000679133,"ClinicalHistory:
518.89
  Specimen processed at the **INSTITUTION, **STREET-ADDRESS., **ROOM.","CytologyReview:

Left lung nodule, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Non-small cell carcinoma (see Comment).


Left lung nodule, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Non-small cell carcinoma (see Comment).","FinalDiagnosis:

Left lung nodule, FNA

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:
Positive for malignancy
Cytology and cell block: Non-small cell carcinoma (see Comment).
DiagnosisComment:
The tumor cells are poorly differentiated with some squamous features, supported by immunoreactivity for p63 and CK5/6. The tumor cells are also positive for CK7 and CD56 but negative for synaptophysin, chromogranin, TTF1 and Napsin A. Dr. **NAME[ZZZ] and **NAME[YYY] concur. Dr. **NAME[XXX] has been notified.",,"GrossDescription:
Specimen consists of 3 air-dried and 1 fixed slides prepared by physician along with 55cc of cloudy, blood tinged, formalin fixed fluid.

4 Physician prepped slide(s):    3 Air-dried (Diff-quik stained),    1 Fixed (Pap stained)   
2 CLH/PPPL prepped slide(s):    1 Pap stained,    1 Cell block  
0 Review(s) by Pathologist.",,"A: Left lung nodule, FNA",,
REG4,LUNG,0,PAT-10034033,1,REC-3000679219,"ClinicalHistory:
786.60.","CytologyReview:

RUL, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Apr 14 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Malignant cell present, favor adenocarcinoma.


RUL, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Apr 14 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
Malignant cell present, favor adenocarcinoma.","FinalDiagnosis:

RUL, FNA

  Specimen Adequacy:
Adequacy/preliminary assessment delivered by Dr. **NAME[ZZZ] (**DATE[Apr 14 12])
Specimen adequate for diagnosis

  Interpretation:
Positive for malignancy
ADENOCARCINOMA.",,"GrossDescription:
Specimen consists of 1 fixed and 1 air-dried slides prepared **NAME[YYY] MD, along with 40cc of clear formalin fixed fluid containing minute particles.

2 Physician prepped slide(s):  1  Air-dried (Diff-quik stained),  1  Fixed (Pap stained)
CLH/PPPL prepped slide(s):    QNS for Cell block
1 Review(s) by Pathologist:

Adequacy evaluation #1 (pass #   1   ) = __X_  Adequate
88172                 ___   Insufficient.",,"A: RUL, FNA",,
REG4,LUNG,0,PAT-10008780,1,REC-3000679274,"ClinicalHistory:
Recurrent pleural effusion.",,"FinalDiagnosis:
PLEURAL FLUID CYTOLOGY:  POSITIVE FOR MALIGNANT CELLS.",,"GrossDescription:
Received:  5 cc. turbid red fluid in syringe.
Prepared:  2 cytospin slides for Pap and DQ stains (treated with NH4Cl x 2).
Submitted:  cell button for a cell block, measuring up to .5 cm.",,A: PLEURAL FLUID,,
REG4,LUNG,0,PAT-00658054,2,REC-3000679331,"ClinicalHistory:
H/O Malignant effusion, ?cell types.","CytologyReview:

Pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:  Smear:  Rare atypical cells(see comment)                    Cell Block:  Rare atypical cells(see comment).","FinalDiagnosis:

Pleural fluid

  Specimen Adequacy:
Satisfactory for evaluation

  Interpretation:  Smear:  Rare atypical cells(see comment)                    Cell Block:  Rare atypical cells(see comment).
DiagnosisComment:
Although definitively malignant cells are not present in this specimen, the prior pleural fluid(***PATH-NUMBER[1]) shows malignant cells(lung carcinoma) consistent with small cell carcinoma.",,"GrossDescription:
Received:  35 cc opaque grossly bloody unfixed viscous fluid with large clot
Prepared:  1 Pap-stained mega funnel slide
    1 DQ mega funnel slide
    2 cell blocks.",,A: Pleural fluid,,
REG4,LUNG,0,PAT-10041611,1,REC-3000679758,"ClinicalHistory:
793.1 785.6
Procedure:->Needle Aspiration
Examine for:->Cancer
History/Clinical Impressions:->RUL mas with mediastinal adenopathy
History/Clinical Impressions:->Sample A best aspiration; sample B bloody aspiration; same sites./r/n","CytologyReview:
POSITIVE FOR MALIGNANT CELLS.
Malignant, NOS./r/n
POSITIVE FOR MALIGNANT CELLS.
Few atypical cells present consistent with carcinoma (see comment)./r/n","FinalDiagnosis:
POSITIVE FOR MALIGNANT CELLS.
Few atypical cells present consistent with carcinoma (see comment)./r/nDiagnosisComment:
A few atypical cells are seen.  On immunohistochemical staining the cells are positive for CEA and B72.3.  Stains for p63, TTF-1, CK5/6, chromogranin and synaptophysin are negative.  There are specimen limitations as the representative atypical cells are scant but the findings are consistent with a non-small cell carcinoma and an adenocarcinoma is favored given the staining pattern.  Clinical correlation is recommended.  Case reviewed in Pathology Staff Conference on **DATE[Feb 26 12].  Case discussed with Dr. **NAME[ZZZ] notified on **DATE[Feb 27 12]./r/n",,"GrossDescription:
2 vials received labeled as A and B processed separately
A vial- 4cc of bloody fluid with small clot
Preparation:
2 cytospins:     1 giemsa stain, 1 papanicolaou stain
2 pull smears:  1 giemsa stain, 1 papanicolaou stain
2 cell block  
B vial- 4.5cc of bloody fluid with small clot
Preparation:
2 cytospins:     1 giemsa stain, 1 papanicolaou stain
2 pull smears:  1 giemsa stain, 1 papanicolaou stain
2 cell block./r/n",,"**NAME[M: YYY] needle, fine needle aspiration  right paratracheal node vial A",,"AddendumDiagnosis:
Right Paratracheal Node Tissue ***PATH-NUMBER[1]:  No EGFR Alteration Detected./r/n"
REG4,LUNG,0,PAT-10028118,2,REC-3000696826,"ClinicalHistory:
Right lower lobe mass, rule out metastasis.",,"FinalDiagnosis:
A.  RUL TISSUE/ CLOT:  POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.
 
B.  BIOPSY, RUL:  POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.
DiagnosisComment:
Immunohistochemical stains show the tumor is positive for p63, Cytokeratin 5/6, Cytokeratin 7 and Cytokeratin AE1/AE3.  Villin, CEA, Cytokeratin 20, TTF-1, Napsin and CDX-2 are negative.  The previous brain metastasis case (***PATH-NUMBER[1]) has been reviewed and shows different morphologic and immunohistochemical features.  The case was discussed with Dr. **NAME[ZZZ YYY] on **DATE[Jan 9 12].",,"GrossDescription:

A. Specimen:  Irregular, elongated segment of scant tan tissue and clotted blood.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  1.9 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Soft tan tissue.
Number of segments:  4.    
Size:  Up to 0.1 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1.",,"A: RUL TISSUE/ CLOT
B: BIOPSY, RUL",,
REG3,LUNG,0,PAT-00742224,1,REC-5000713332,,,,"<CLINICAL INFO>
 Patient to be seen at **INSTITUTION by Dr. **NAME[ZZZ YYY]
  on 6/20.<FINAL DX>
 **PLACE, WA; AS-11-15374 (**DATE[Dec 1 11])
  A)  Lung, left lower lobe, biopsy:  Poorly differentiated pulmonary
  adenocarcinoma; see Comment.<DIAGNOSIS COMMENT(S)> Slides reviewed demonstrate neoplastic cells which
  express TTF-1 and napsin A.  The morphologic and immunohistochemical findings
  support the above diagnosis.
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 Received 7 slides labeled AS11-15374.MATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[1]  0B,7S  Left lower lobe lung mass",,,,,
REG3,LUNG,0,PAT-00742915,1,REC-5000713557,,,,"<CLINICAL INFO>
 Patient to be seen at **INSTITUTION by Dr. **NAME[ZZZ YYY].<FINAL DX>
 **INSTITUTION, **PLACE, WA; 11S-3608
  (**DATE[Apr 4 12])
  Left axillary lymph node, excision (A, B): 2 lymph nodes positive for
  metastatic adenocarcinoma consistent with pulmonary origin; see Comment.<DIAGNOSIS COMMENT(S)> Slides reviewed for A, B) demonstrate neoplastic cells
  which are positive for CK7 and TTF-1 and are negative for CK20, p63, and CDX-
  2.  All immunohistochemistry performed at Dynacare is reviewed at **INSTITUTION.  A (micro)papillary pattern is conspicuous in areas of this
  neoplasm, raising consideration of a thyroid epithelial neoplasm.  Hence,
  although the morphologic and immunophenotypic findings support the diagnosis
  of metastatic adenocarcinoma consistent with pulmonary origin, correlation
  with clinical findings may be of additional value.
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 Received 12 slides labeled 11S-3608.MATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A 11 3608  0B,12S  Left axillary lymph node",,,,,
REG3,LUNG,0,PAT-00746291,1,REC-5000713999,,,,"<CLINICAL INFO>
 History of NSCLC and new RLL nodule that is
  growing.<FINAL DX>
 A)  Lung, right lower lobe, biopsy:  Invasive
  adenocarcinoma with extensive lepidic growth pattern with intra-alveolar
  mucin.
  Procedures used to establish the diagnosis:
  RoutineADDENDUM REASON:   This addendum is to report results of EGFR
  mutational analysis.
  EGFR Mutations Results:  NEGATIVE for L858R mutation and exon 19 deletions
  EGFR Block Tested:  A1
  EGFR Interpretation:
  The sample tested is negative for the L858R mutation in exon 21 and for
  deletion mutations in exon 19 of the EGFR gene, which together account for
  about 90% of the somatic mutations in the EGFR gene in patients with lung
  cancer. If clinically indicated, DNA sequence analysis can be performed
  separately to detect other rare mutations in the EGFR gene (EGFR Level 2
  test). This test can normally detect a heterozygous mutation when it is
  present in more than about 10% (for L858R) or 2% (for deletions) of the cells
  in the sample.
  For further information on test methods and interpretation, see
  **WEB-LOC or call lab at **PHONE. Test results
  reviewed by **NAME[ZZZ YYY], Ph.D., **NAME[XXX WWW] VVV], Ph.D., or **NAME[UUU]
  **NAME[TTT], VVV], Ph.D., Laboratory Directors.<GROSS>
 A) Received in formalin labeled ""**NAME[BBB,
  AAA]"" designated ""lung RLL"" are four tan-red core-like fragments of soft
  tissue ranging from 0.2 to 0.4 cm in length.  The specimen is wrapped and
  submitted in toto in cassette A1.  (**INITIALS)",,,,,
REG3,LUNG,0,PAT-00552576,2,REC-5000714793,,,,"Pathology Department (C6-PTH)
**STREET-ADDRESS
**PLACE, WA **ZIP-CODE
REPORT
MOLECULAR (PCR) REPORT
INTERPRETATION:
**INSTITUTION ***PATH-NUMBER[1], B1 
Lung, left lower lobe, biopsy: Positive for an exon 19 Deletion EGFR mutation
by real time PCR (see Comments).

<DIAGNOSIS COMMENTS>
In this case an epidermal growth factor receptor (EGFR) exon 19 deletion
mutation was detected by Qiagen/DxS real time PCR. In non-small cell lung
cancer, this type of activating EGFR mutation is reported to correlate with
responsiveness to anti-EGFR tyrosine kinase therapy. This real time PCR assay
has been validated to identify the most common EGFR tyrosine kinase domain
mutations that involve exons 18-21. This test is validated for non-small cell
lung carcinoma. The clinical significance and use of this assay in other tumor
types is not well characterized. Note that this assay is not intended to
diagnose any particular type of cancer, but as an aid to clinicians, is
intended to be used as an adjunct to other prognostic factors to select
eligible patients for therapy. (**NAME[ZZZ:YYY] et al., NEJM 2004;**ID-NUM, Mok
et al., NEJM 2009; **ID-NUM, Pao et al., JClinOnc 2005; **ID-NUM).
MATERIAL RECEIVED
A1 = ***PATH-NUMBER[1], B1, 1 Block (**DATE[Apr 10 2012])
PROCEDURE DATE
**DATE[Apr 09 2012]
CLIENT REQUEST / CLINICAL HISTORY
EGFR by PCR 
EGFR PCR METHODS
This real time PCR test (Qiagen/DxS) detects the most common activating
mutations in EGFR, which have been identified in human lung non-small cell
cancer involving codons 18-21, and leading to the following types of
mutations: exon 19 deletions (detects any of 19 deletions but does not
distinguish between the types), L858R, L861Q, G719X (detects G719S, G719A, and
G719C, but does not distinguish between the types), S768I, and exon 20
insertions (detects any of 3 insertions but does not distinguish between the
types). These mutations account for the vast majority of all activating EGFR
mutations. Using control materials that contain the L858R and exon 19
deletions, which account for ~86% of known EGFR activating mutations, this
assay has been validated to detect these mutations at a level of 1%. Purified
genomic DNA is extracted from microdissected tumor specimen, is analyzed by
low volume spectrophotometry, and then used as sample DNA in a real time PCR
assay using fluorescently labeled and non-labeled primers to detect wild-type
and mutated EGFR. Sample delta Ct values for mutant and control reactions are
calculated and compared against threshold delta Ct values in each mutant
reaction to determine the presence of each individual mutation type. Negative
and positive controls are assayed with each sample. The assay sensitivity is
estimated to be ~1% tumor involvement for each mutation type detected. 
METHOD LIMITATIONS: Tumor samples are non-homogeneous and data from a sample
of tumor may not be concordant with data from other sections of the same
tumor. Tumor samples may also contain non-tumor tissue, and DNA from these
areas would not be expected to contain a EGFR mutation. Although this assay
produces short PCR products, it may not work on heavily fragmented DNA. In
instances where the frequency of a target mutation is very low with respect to
the wild-type background (<1%), this assay may fail to detect the mutation,
leading to a false-negative result.     
    Electronically signed **DATE[Apr 14 2012]: **NAME[XXX WWW], MD-Pathologist
 M.D., Pathologist
Per CMS regulations, the pathologist's signature above indicates that this
case has been reviewed and the diagnosis made or confirmed by said
pathologist.
Note: Some of the tests reported here may have been developed and performance
characteristics determined by PhenoPath Laboratories. They have not been
cleared or approved by the U.S. Food and Drug Administration (FDA). However,
the FDA has determined that such clearance or approval is not necessary.
Pursuant to the requirements of CLIA, this laboratory has established and
verified the accuracy and precision of all tests, and additional information
about these tests is available upon request. PhenoPath Laboratories is
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
as qualified to perform high complexity clinical laboratory testing.",,,,,
REG3,LUNG,0,PAT-00744207,1,REC-5000718439,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  LUNG, LEFT LOWER, MASS, NEEDLE CORE BIOPSY: ADENOCARCINOMA, MUCINOUS TYPE
WITH LEPIDIC PATTERN, CONSISTENT WITH LUNG PRIMARY, (SEE MICROSCOPIC EXAMINA
TION).
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. CYTOKERATIN 7 (OV-TL12/30): STRONGLY POSITIVE
2. CYTOKERATIN 20 (Ks20.8): NEGATIVE
3. GCDFP-15 (EP1582Y): NEGATIVE
4. ESTROGEN RECEPTOR (SP1): NEGATIVE
5. PROGESTERONE RECEPTOR (IE2): NEGATIVE
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY]          Electronically Signed: **DATE[Dec 20 2011]
<SPECIMEN(S)>
  A) Left lower lung mass core bx
<GROSS>
  Received in a container labeled with the patient's name and ""left lower
lung tissue sample"" are two wispy fragmented tan tissue cores with a 3.0
cm aggregate length, AE/(2).
<MICROSCOPIC>
  Sections are composed of multiple needle fragments of tissue containing
neoplastic proliferation of well differentiated appearing, mucinous
epithelial cells forming glandular like structures and having lepidic
pattern.  The malignant cells are cytokeratin 7 positive and negative for
estrogen, progesterone, cytokeratin 20 and GCDFP-15 by IHC antibody
studies. Morphologically and immunohistochemically, the findings are
consistent with a lung primary.",,,,,
REG3,LUNG,0,PAT-00743621,1,REC-5000719173,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Cytology, Fine Needle Aspiration, Lung:
  Small cell carcinoma.

<CLINICAL INFO>
Right middle lobe lung mass.

INTRAPROCEDURAL EVALUATION:
Mediastinal lung mass (fine needle aspirate): ""Positive for tumor,
possible small cell. Additional sample for a cytofix requested"".
Performed by:  **NAME[ZZZ M. YYY], M.D.

<GROSS>
A specimen labeled ""**NAME[BBB, AAA]"", and designated ""lung FNA"" per
requisition, is received in 30 ml of CytoLyt collection fluid on
**DATE[May 07 2012]. Prepared is one cell block. Also received on **DATE[May 07 2012] is
one alcohol-fixed direct smear labeled ""**NAME[BBB]"", and designated ""lung
FNA"" per requisition. The alcohol-fixed smear is Papanicolaou stained.
One air-dried smear was kept in Olympia. (lw/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
Pan CK    Positive
Synaptophysin       Rare cells positive.
Chromogranin   Negative

Impression:
Interpreted by:  **NAME[M. XXX WWW] M.D.
Comment:  Cell block examined; above studies carried out on cell block
preparation.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[VVV M. UUU], M.D.

**NAME[M. XXX WWW], M.D.  Electronically signed **DATE[May 11 2012]",,,,,
REG3,LUNG,0,PAT-00744922,2,REC-5000719209,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Lung, Right Lower Lobe, CT-Guided Core Needle Biopsy:
Squamous cell carcinoma.

B.  Lung, Right Lower Lobe, CT-Guided Fine Needle Aspiration with Cell
Block Preparation:
Squamous cell carcinoma.

<COMMENT>
The patient has a history of squamous cell carcinoma of the tongue and a
subsequent lung mass. Strong p16 staining in the lung mass favors that
the lung tumor represents metastatic disease, but is not definitive and
should be interpreted within the clinical context.  If the primary
tongue tumor is not p16 positive, then it is likely that the lung tumor
represents a synchronous malignancy.

<CLINICAL INFO>
Patient with history of  squamous cell carcinoma of the tongue and a
lung mass.

INTRAPROCEDURAL EVALUATION:
A1.  Lung (core biopsy touch preps):  ""Nonsmall cell carcinoma"".
B1. Lung (fine needle aspirate preparation):  ""Nonsmall cell carcinoma"".
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A.  Received from Dr. **NAME[XXX] in Interventional Radiology labeled with the
patient's name and date of birth are two cores of tan tissue (0.2 x 0.2
x 0.1 cm and 0.2 x 0.3 x 0.1 cm), from which one air-dried touch prep
and one alcohol-fixed touch prep are made. The air-dried touch prep is
Diff-Quik stained and submitted for intraprocedural evaluation. The
alcohol-fixed touch prep is Papanicolaou-stained. The biopsy tissue is
formalin fixed and submitted for histologic processing. A1, core biopsy
right lower lobe lung.

B.  Additionally received labeled part B are one air-dried direct smear,
one alcohol direct smear and material in 10 ml of CytoLyt from the left
lower lobe lesion. The air-dried direct smear is Diff-Quik, stained and
submitted for intraprocedural evaluation. The alcohol-fixed direct smear
is Papanicolaou-stained. The material in CytoLyt is prepared into a cell
block. B1, left lower lung, cell block preparation from FNA.  **INITIALS

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
p16  Positive

Block B1

Antibody  Result    Comment
p63  Positive
p16  Variably positive

Impression:  p16 staining in the tumor in the cell block is variably
positive but is strongly positive in the core biopsy material.
Interpreted by:  **NAME[ZZZ M YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
Cellnetix pathologist Dr. **NAME[M. WWW] also reviewed this case and concurs
with nonsmall cell carcinoma.

**NAME[ZZZ M YYY], M.D.  Electronically signed **DATE[Nov 11 2011]
**EMAIL   **PHONE  (Physician to Physician Only)",,,,,
REG3,LUNG,0,PAT-00524089,2,REC-5000719474,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Left Upper Lobe Lung Mass, Fine Needle Aspirate for Cytology:
  Positive for malignancy, adenocarcinoma.

<CLINICAL INFO>
Left upper lung mass.  History of lung cancer; prostate cancer.

<GROSS>
Received on **DATE[Nov 11 2011] are five alcohol-fixed direct smears labeled
""**NAME[BBB, AAA]"", and designated ""left upper lobe mass"" per requisition.
The alcohol-fixed smears are Papanicolaou stained. (lw/nd)

<MICROSCOPIC>
Five Papanicolaou-stained direct smears examined. Please see diagnosis.

INTRADEPARTMENTAL CONSULTATION:
**NAME[ZZZ M. YYY], M.D.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Nov 12 2011]",,,,,
REG3,LUNG,0,PAT-00392209,4,REC-5000724248,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Liver, Core Biopsy:
Metastatic non-small cell carcinoma, consistent with pulmonary
adenocarcinoma.

<COMMENT>
Although very limited to no material is remaining in the paraffin block,
an EGFR assay will be attempted at the request of Dr. **NAME[ZZZ].

<CLINICAL INFO>
Liver lesion. Follicular lymphoma. ICD-9 Code(s): 202.00

INTRAPROCEDURAL EVALUATION:
Liver core biopsy (touch prep): ""Adequate. Need material in RPMI.""
Performed by: **NAME[YYY M. XXX], M.D.

FLOW CYTOMETRY:

<FINAL DX>

Liver (core biopsy):  Hypocellular specimen with no immunophenotypic
evidence of B-cell lymphoma.

COMMENT:
The viability is 50%. Lymphocytes comprise 4.18% of the total WBC
(89.06% T cells; 15.84% B cells; 9.52% NK cells). CD19-positive B cell
comprise approximately 1.39% of the total WBC and show a nonspecific
staining pattern. A light chain restricted B-cell population is not
present. The majority of the lymphocytes are T cells with no
immunophenotypic aberrancy. Due to low B-cell recovery, this assay is
somewhat limited.

Flow cytometry histograms interpreted by **NAME[YYY M. XXX], M.D.

Flow Cytometry Images

Antibodies tested: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD16, CD19, CD20,
CD23, CD25, CD38, CD45, CD56, CD57, Kappa and Lambda.

These tests were developed and the performance characteristics
determined by Cellnetix Pathology and Laboratories. They have not been
cleared or approved by the US Food and Drug Administration. The FDA has
determined that such clearance or approval is not necessary. This
laboratory is certified under CLIA-88 and is qualified to perform high
complexity clinical testing. Prognostic and predictive testing should be
interpreted in the context of additional clinical and/or
histopathological findings.

<GROSS>
A.  Received on **DATE[Jul 14 2012] is one alcohol-fixed direct smear labeled
""**NAME[BBB, M]"" and designated ""liver core biopsy"" per requisition. The
alcohol-fixed smear is Papanicolaou stained. One air-dried smear kept in
Olympia. (rc/gdb)

B.  Received in formalin, labeled ""**NAME[AAA BBB]"" and designated ""liver
biopsy"" per the requisition, are two 1 cm needle biopsies, which are
submitted in one cassette. (ke/vlb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
CD20/L26  Negative  No staining.
PAX-5     Negative  No staining.
BCL6 Positive  In cells of interest.
CD3       Highlights few T-cells.
MIB1 (Ki-67)s       Moderate index in cells of interest.
Pan CK    Positive  In hepatocytes and positive in foci of interest.

TTF-1     Positive
Napsin A  Negative
Synaptophysin  Negative
Chromogranin   Negative

Impression:
Interpreted by:  **NAME[YYY M. XXX] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

PHYSICIAN NOTIFICATION:
Dr. **NAME[ZZZ] was notified of the final diagnosis by Dr. **NAME[YYY XXX] on
**DATE[Jul 20 2012].

INTRADEPARTMENTAL CONSULTATION:
**NAME[WWW M. VVV], M.D. and **NAME[UUU M. TTT], M.D.

**NAME[YYY M. XXX], M.D.  Electronically signed **DATE[Jul 20 2012]",,,,,
REG3,LUNG,0,PAT-00710337,2,REC-5000726205,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Left Buttock Mass, Core Biopsies:
  Poorly differentiated carcinoma infiltrating fibrofatty tissue and
skeletal muscle.
 (see comment).

<COMMENT>
The patient has a history of poorly differentiated rectal carcinoma and
more recently left upper lobe lung and left pelvic lymph node lesions.
The left upper lobe lung core biopsy (***PATH-NUMBER[2]) was extensively
evaluated with immunocytochemistry and the current neoplasm is
histologically similar. At this time, additional immunocytochemistry to
evaluate for the possibility of melanoma or a lymphoreticular lesion was
pursued; however, all of these studies are negative. Clinical
correlation would be helpful.

<CLINICAL INFO>
History of rectal cancer.

INTRAPROCEDURAL EVALUATION:
Left buttock mass (touch preps): ""Atypical cells suspicious for
neoplasm. Definitive diagnosis pending permanent section"".
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
Received in alcohol, labeled ""**NAME[BBB, AAA]"", and designated ""left
buttock mass"", are three slides stained for rapid interpretation.

Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""left
buttock mass"", are seven delicate, less than 0.1 cm diameter, elongated
portions of tissue from 0.2 cm to 0.8 cm in lengths. The specimen is
entirely submitted in A1.  (rg/jkb)

<MICROSCOPIC>
Reviewed are three Diff-Quik-stained touch prep smears and one
HE-stained slide. Please see diagnosis.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Specimen A

Antibody  Result    Comment
Pan CK    Positive
HMB45     Negative
MelA/Mart-1    Negative
CD45 Negative
CD3  Negative
CD20/L26  Negative

Block A1

Antibody  Result    Comment
CD138     Positive
KAPPA     Negative
LAMBDA    Negative
CD79a     Negative

Impression:   These results support a diagnosis of carcinoma and are not
supportive of melanoma or  a lymphoreticular neoplasm.
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[VVV M. UUU], TTT], Ph.D.  (select slides).

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Jul 25 2012]",,,,,
REG3,LUNG,0,PAT-00744637,1,REC-5000728842,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Special Stains

<FINAL DX>     

A.  Bronchus Intermedius, Bronchial Biopsies:
     Well to moderately differentiated squamous cell carcinoma.
     Silver stain is pending and will be issued as an addendum.

B.  Bronchus Intermedius, Brushing:
     Non-diagnostic material composed predominately of blood.
     Silver stain is pending and will be issued as an addendum.

<CLINICAL INFO>
Right lower lobe mass. Obstructed bronchus intermedius. ICD-9 Code(s):
518.89-other lung disease NEC.

<GROSS>
A. Received in formalin, labeled ""**NAME[BBB, AAA M]"" and designated
""bronchial tissue biopsy in formalin from BI"", is a 0.7 x 0.4 x 0.2 cm
aggregate of soft pink-red tissue biopsies and clot. It is entirely
submitted in A1. (kjh/gdb)

B. Received on **DATE[Mar 27 2012] is 5 ml of clear colorless fluid containing
one brush labeled ""**NAME[BBB, AAA]"" and designated ""BI bronchial brushing""
per requisition. Prepared is one cell block. Also received on **DATE[Mar 27 2012]
are two alcohol-fixed direct smears labeled ""**NAME[BBB]"" and designated ""BI
bronchial brushing"" per requisition. One of the alcohol smears is
Papanicolaou stained and the other alcohol-fixed smear was given to
special stains. (lw/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

INTRADEPARTMENTAL CONSULTATION:
Dr. **NAME[ZZZ YYY] agrees with the diagnosis of squamous cell carcinoma.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Mar 28 2012]
**PHONE  (Physician to Physician Only)

<ADDENDUM> #1
Silver stains performed on parts A and B are negative for fungal
organisms.

Addendum #1 performed by **NAME[XXX M. WWW], M.D.  Electronically signed
**DATE[Mar 28 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,LUNG,0,PAT-00382059,2,REC-5000732387,,,,"Pathology Department
**STREET-ADDRESS SE
**PLACE, WA **ZIP-CODE
REPORT
MOLECULAR (PCR) REPORT
INTERPRETATION:
**INSTITUTION ***PATH-NUMBER[1], 1A 
Left lung mass, needle biopsy: Negative for an EGFR mutation by real time PCR
(see Comments).

<DIAGNOSIS COMMENTS>
In this case no epidermal growth factor receptor (EGFR) mutations were
identified by Qiagen/DxS real time PCR. This real time PCR assay has been
validated to identify the most common EGFR tyrosine kinase domain mutations
that involve exons 18-21. This test is validated for non-small cell lung
carcinoma. The clinical significance and use of this assay in other tumor
types is not well characterized. Note that this assay is not intended to
diagnose any particular type of cancer, but as an aid to clinicians, is
intended to be used as an adjunct to other prognostic factors to select
eligible patients for therapy. (**NAME[ZZZ:YYY] et al., NEJM 2004;**ID-NUM, Mok
et al., NEJM 2009; **ID-NUM, Pao et al., JClinOnc 2005; **ID-NUM).
MATERIAL RECEIVED
A1 = ***PATH-NUMBER[1], 1A, 1 Block (**DATE[Sep 19 2011])
PROCEDURE DATE
**DATE[Sep 14 2011]
CLIENT REQUEST / CLINICAL HISTORY
EGFR by PCR. Lung adenocarcinoma
EGFR PCR METHODS
This real time PCR test (Qiagen/DxS) detects the most common activating
mutations in EGFR, which have been identified in human lung non-small cell
cancer involving codons 18-21, and leading to the following types of
mutations: exon 19 deletions (detects any of 19 deletions but does not
distinguish between the types), L858R, L861Q, G719X (detects G719S, G719A, and
G719C, but does not distinguish between the types), S768I, and exon 20
insertions (detects any of 3 insertions but does not distinguish between the
types). These mutations account for the vast majority of all activating EGFR
mutations. Using control materials that contain the L858R and exon 19
deletions, which account for ~86% of known EGFR activating mutations, this
assay has been validated to detect these mutations at a level of 1%. Purified
genomic DNA is extracted from microdissected tumor specimen, is analyzed by
low volume spectrophotometry, and then used as sample DNA in a real time PCR
assay using fluorescently labeled and non-labeled primers to detect wild-type
and mutated EGFR. Sample delta Ct values for mutant and control reactions are
calculated and compared against threshold delta Ct values in each mutant
reaction to determine the presence of each individual mutation type. Negative
and positive controls are assayed with each sample. The assay sensitivity is
estimated to be ~1% tumor involvement for each mutation type detected. 
METHOD LIMITATIONS: Tumor samples are non-homogeneous and data from a sample
of tumor may not be concordant with data from other sections of the same
tumor. Tumor samples may also contain non-tumor tissue, and DNA from these
areas would not be expected to contain a EGFR mutation. Although this assay
produces short PCR products, it may not work on heavily fragmented DNA. In
instances where the frequency of a target mutation is very low with respect to
the wild-type background (<1%), this assay may fail to detect the mutation,
leading to a false-negative result.     
    Electronically signed **DATE[Sep 21 2011]: 
**NAME[XXX WWW], MD-Pathologist, IHC Fellow, Pathologist
Per CMS regulations, the pathologist's signature above indicates that this
case has been reviewed and the diagnosis made or confirmed by said
pathologist.
Note: Some of the tests reported here may have been developed and performance
characteristics determined by PhenoPath Laboratories. They have not been
cleared or approved by the U.S. Food and Drug Administration (FDA). However,
the FDA has determined that such clearance or approval is not necessary.
Pursuant to the requirements of CLIA, this laboratory has established and
verified the accuracy and precision of all tests, and additional information
about these tests is available upon request. PhenoPath Laboratories is
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
as qualified to perform high complexity clinical laboratory testing.",,,,,
REG3,LUNG,0,PAT-00746523,1,REC-5000732506,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Needle Biopsy, Paraspinal Mass:
  Metastatic adenocarcinoma, poorly differentiated.

<COMMENT>
The differential diagnosis includes lung, upper gastrointestinal tract
and pancreatobiliary primaries, among others; the immunophenotype is
nonspecific (CK7 positive, CD20 negative, TTF-1/Napsin A negative, PSA
negative, CDX-2 negative). The morphologic appearance is somewhat
suggestive of lung primary.

<CLINICAL INFO>
Paraspinal mass.

INTRAPROCEDURAL EVALUATION:
Bone, paraspinous mass biopsy (touch prep): ""Consistent with plasmacytic
neoplasm consistent with myeloma.""
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
Received in formalin, labeled ""**NAME[AAA BBB]"" and designated ""bone
biopsy, paraspinal mass"", are two needle biopsies of soft tissue and
bone which are 0.9 and 2 cm long. All tissue is submitted for brief
decalcification in one cassette. (ke/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
CK7  Positive
CK20 Negative
TTF-1     Negative
Napsin A  Negative
PSA  Negative
CDX-2     Negative

Impression:
Interpreted by:  **NAME[M. XXX WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[ZZZ M. YYY], M.D.

**NAME[M. XXX WWW], M.D.  Electronically signed **DATE[Aug 02 2012]",,,,,
REG3,LUNG,0,PAT-00753906,1,REC-5000732545,,,,"CASE: HS-11-02842
PATIENT: **NAME[AAA BBB]


SPECIMEN:
1. LEFT CHEST FLUID


<GROSS>
One specimen is received fresh in a container labeled **NAME[BBB, AAA] and is designated ""pleural thoracentesis fluid"".  The specimen consists of approximately 30 ml of hazy yellow pleural fluid.  The specimen is submitted to the cytology department for double dot cytospin resulting in one fixed slide and one air-dried slide.  One cell block is produced.  (**INITIALS **DATE[Oct 1 11])


<MICROSCOPIC>
Concentrated cytospin smears and cell block preparation harbor a mixed population of benign reactive cells.  The majority of cells represent macrophages with scattered reactive mesothelial cells and moderate numbers of mixed neutrophils and lymphocytes.  No significant cytologic atypia, aberrant epithelium or coagulation necrosis is apparent.
**NAME[ZZZ YYY], MD
Pathologist
Electronically signed **DATE[Oct 2 2011] 3:59:09PM


<FINAL DX>
Left pleural effusion:
     A.  Negative for malignancy.
     B.  Reactive exudative effusion with significant acute inflammation.
TISSUE CODE 0
**NAME[M. ZZZ YYY], MD
Pathologist
**INITIALS **DATE[Oct 2 11]


<CLINICAL INFO>
Left pleural fluid.  Left pleural effusion.  Recurrent left lower lobe pneumonia.  History of myelodysplasia with pancytopenia since 2009.",,,,,
REG3,LUNG,0,PAT-00736052,1,REC-5000733282,,,,"PART / DESCRIPTION - SEQ 
Lymph node/ 4L- A
PART / DESCRIPTION - SEQ 
Lymph node/ 4R- C
PART / DESCRIPTION - SEQ 
Lymph node/ STATION 7- B
INTRAOPERATIVE DX:
NONE
FINAL DX:

A. 4L lymph node, excision: -Fragments of anthracotic lymph node with no evidence of carcinoma.

B. Station 7 lymph node, excision: -Fragments of anthracotic lymph node with no evidence of carcinoma.

C. 4R lymph node, excision: -Fragments of anthracotic lymph node with no evidence of carcinoma.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''4L'', is a 1 x 0.8 x 0.6 cm aggregate of black-tan lymphoid tissue. Specimen is submitted entirely in cassette A1. 
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''station 7'', is a 2 x 1.4 x 0.8 cm aggregate of multiple fragments of black-red lymphoid tissue. The specimen is submitted entirely in cassette B1. 
C. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''4R'', is a 2 x 1.1 x 0.6 cm aggregate of multiple fragments of black-tan lymphoid tissue and adipose tissue. The specimen is submitted entirely in cassette C1. (**INITIALS:cmc94 279452)
CLINICAL INFO:
Malignant neoplasm of bronchus and lung unspecified site.
ICD-9 code: 162.9.
PATHOLOGIST:
**NAME[ZZZ YYY M]. 

SNOMED Code(s)",,,,,
REG3,LUNG,0,PAT-00525329,3,REC-5000734018,,,,"PART / DESCRIPTION - SEQ# 
Lymph node, biopsy/ LEVEL 7 LYMPH NODE- 4
PART / DESCRIPTION - SEQ# 
Lymph node, biopsy/ LEVEL 9 LYMPH NODE- 2
PART / DESCRIPTION - SEQ# 
Lymph node, biopsy/ LEVEL 2 AND 4 LYMPH NODE- 3
PART / DESCRIPTION - SEQ# 
Lymph node, biopsy/ LEVEL 8 LYMPH NODE- 5
PART / DESCRIPTION - SEQ# 
Biopsy, NOS/ RIGHT LOWER LOBE LUNG- 1<CLINICAL INFO>
Right lower lobe lung carcinoma.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
PART 1: RIGHT LOWER LOBE LUNG
RAPID DIAGNOSIS:
FROZEN SECTION: NO TUMOR IDENTIFIED AT BRONCHIAL MARGIN.
**NAME[ZZZ M. YYY], M.D. 2:25 PM **DATE[Sep 19 2011]<GROSS>
PART 1: RIGHT LOWER LOBE LUNG 
(GF:ab) Received fresh from the operating room labeled """"**NAME[AAA BBB],"""" designated """"right lower lobe lung,"""" is a lung lobectomy specimen weighing 258 grams and measuring 18 x 11 x 2.8 cm in its unfixed state. The hilum is traversed by heavily stapled surgical lines. A section of the bronchial margin is taken and a frozen section is performed, as requested by the surgeon. Also noted adjacent to the bronchial margin are two anthracotic lymph nodes measuring 0.4 and 1.1 cm in greatest dimensions. The hilar vascular margins are heavily stapled and appear grossly unremarkable. The pleural surface is purple-brown, smooth and intact. No pleural retractions are grossly appreciated. Sectioning the lung reveals a well-circumscribed, solid, malignant-appearing mass which is noted in the inferior aspect of the lobe. The lesion measures 3 x 2.1 cm. It is approximately 2 cm from the bronchial margin and approximately 1 cm from the pleural surface. The lesion has a solid, smooth, yellow-red cut surface. The airways appear grossly uninvolved. The nonlesional lung tissue parenchyma is red-maroon, smooth, soft and spongy. 

Summary of sections: 1a-bronchial margin frozen section control; 1b-representative shaved sections hilar vascular margins; 1c-anthracotic lymph nodes x 2 adjacent to bronchial margins, each submitted intact; 1d through 1f-representative sections lung mass; 1g, 1h-sections nonlesional lung tissue parenchyma
 
PART 2: LEVEL 9 LYMPH NODE
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"level 9 lymph node,"""" is an anthracotic nodule measuring 1.7 x 0.5 cm. It is bisected. Entirely submitted in cassette 2a.
 
PART 3: LEVEL 2 AND 4 LYMPH NODE 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"level 2 and 4 lymph node,"""" is a yellow-brown fatty and lymphoid tissue portion measuring 4.5 x 2.5 x 0.6 cm. Trimming of the soft fatty tissue reveals several anthracotic lymph nodes ranging from 0.2 up to 1.1 cm in greatest dimension. All of the lymph nodes are submitted.

Summary of sections: 3a-multiple intact nodes; 3b-two bisected nodes
 
PART 4: LEVEL 7 LYMPH NODE
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"level 7 lymph node,"""" is an anthracotic nodule measuring 1.5 cm in greatest dimension. Entirely submitted in cassette 4a.
 
PART 5: LEVEL 8 LYMPH NODE 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"level 8 lymph node,"""" is an anthracotic tissue portion measuring 0.5 cm. Embedded as is in cassette 5a.<FINAL DX>

1) LUNG, RIGHT LOWER LOBE, LOBECTOMY: A. MODERATE TO POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA OF THE LUNG WITH THE FOLLOWING FEATURES: 1. TUMOR SIZE: 3 X 2.1 CM.
 2. TUMOR FOCALITY: UNIFOCAL.
 3. VISCERAL PLEURAL INVASION: NOT IDENTIFIED.
 4. TUMOR EXTENSION: TUMOR APPEARS LIMITED TO THE LUNG.
 5. SURGICAL MARGINS: ALL MARGINS FREE OF CARCINOMA.
 6. LYMPH-VASCULAR INVASION: NOT IDENTIFIED.
 7. LYMPH NODES:  NO METASTATIC CARCINOMA IDENTIFIED IN TWO   PARABRONCHIAL LYMPH NODES.

8. ADDITIONAL PATHOLOGIC FINDINGS: PERITUMORAL INFLAMMATORY CHANGES.  MILD EMPHYSEMATOUS CHANGES.

2) LEVEL 9 LYMPH NODE, BIOPSY: NO METASTATIC CARCINOMA IDENTIFIED IN 1 LYMPH NODE.

3) LEVEL 2 AND 4 LYMPH NODES, BIOPSIES: NO METASTATIC CARCINOMA IDENTIFIED IN 10 TEN LYMPH NODES.

4) LEVEL 7 LYMPH NODE, BIOPSY: NO METASTATIC CARCINOMA IDENTIFIED IN 1 LYMPH NODE.

5) LEVEL 8 LYMPH NODE, BIOPSY: NO METASTATIC CARCINOMA IDENTIFIED IN 1 LYMPH NODE.
Minimum pathologic stage based on the above findings is:
7th Edition AJCC Grade 2-3; pT1b pN0
**INITIALS<MICROSCOPIC>
PART 1: RIGHT LOWER LOBE LUNG 
Multiple representative sections through the right lower lung lobe are reviewed. See diagnosis. 
 
PART 2: LEVEL 9 LYMPH NODE
Sections through the level 9 lymph node are reviewed. See diagnosis. 
 
PART 3: LEVEL 2 AND 4 LYMPH NODE 
Sections through the level 2 and level 4 lymph nodes are reviewed. See diagnosis. 
 
PART 4: LEVEL 7 LYMPH NODE
Sections through the level 7 lymph node are reviewed. See diagnosis. 
 
PART 5: LEVEL 8 LYMPH NODE 
Sections through the level 8 lymph node are reviewed. See diagnosis.PATHOLOGIST:
**NAME[YYY ZZZ M.",,,,,
REG3,LUNG,0,PAT-00745534,1,REC-5000734032,,,,"PART / DESCRIPTION - SEQ# 
Biopsy, NOS/ RIGHT UPPER LOBE- 2
PART / DESCRIPTION - SEQ# 
aspiration, other/ RIGHT PRETRACHEAL- 3
PART / DESCRIPTION - SEQ# 
Biopsy, NOS/ LEFT LOWER LOBE- 1<FINAL DX>

1) LUNG, LEFT LOWER LOBE, BIOPSIES: MODERATE TO POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA (SEE COMMENT).

2) LUNG, RIGHT UPPER LOBE, BIOPSIES: SMALL CELL NEUROENDOCRINE CARCINOMA.

3) RIGHT PRETRACHEAL LYMPH NODE, ASPIRATE: MALIGNANT CELLS PRESENT, CONSISTENT WITH METASTATIC SMALL CELL NEUROENDOCRINE CARCINOMA.
**INITIALS<GROSS>
PART 1: LEFT LOWER LOBE 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"left lower lobe biopsy,"""" are several portions of pink-white soft tissue ranging from 0.1 up to 0.2 cm. Wrapped and entirely submitted in cassette 1a.
 
PART 2: RIGHT UPPER LOBE
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"right upper lobe biopsy,"""" are several off-white soft tissue pieces ranging up to 0.2 cm. Wrapped and entirely submitted in cassette 2a.
 
PART 3: RIGHT PRETRACHEAL 
(cr) Identified as """"**NAME[AAA BBB]"""" and slip labeled """"right pretracheal lymph node aspirate."""" Received is one slide and material in CytoLyt from which one ThinPrep slide and a cell block are prepared for cytologic examination. A cytotechnologist assisted with the procedure to determine specimen adequacy.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONEComment
The tumors in the left lower lobe and the right upper lobe appear to represent two separate malignancies. The tumor from the left lower lobe demonstrates hstologic and immunohistochemical features which are diagnostic of squamous cell carcinoma, whereas the tumor from the right upper lobe is compatible with a small cell neuroendocrine carcinoma. The slides from parts 1 and 2 of this case were reviewed by Dr. **NAME[ZZZ YYY], who concurs the diagnoses.<MICROSCOPIC>
PART 1: LEFT LOWER LOBE
Sections through the left lower lobe biopsies demonstrate the presence of a malignant epithelioid neoplasm with squamoid features. The tumor is comprised of large, highly atypical cells arranged I variably sized solid nests and expansile sheets. The tumor elicits a mild desmoplastic and inflammatory host response. The neoplastic cells are large, with a moderate to marked degree of nuclear pleomorphism and abundant amounts of deeply eosinophilic cytoplasm. In some areas, the tumor appears to demonstrate intercellular bridge formation. No definite gland formations are noted. Mitotic figures are easily identified. Some areas of tumor necrosis are present.

IMMUNOHISTOCHEMICAL DATA:
 Antibodies Specific To:  Results: Pankeratin    Strongly positive Cytokeratin 7     Variably positive Cytokeratin 20    Negative (with no internal positive control) Cytokeratin 5/6   Strongly positive p63     Positive Synaptophysin    Negative (with no internal positive control) Chromogranin    Negative (with no internal positive control) 

PART 2: RIGHT UPPER LOBE 
Sections through the lung biopsies from the right upper lobe are reviewed on two levels. The sections demonstrate the presence the presence of an epithelioid neoplasm most consistent with small cell neuroendocrine carcinoma. The neoplastic cells are present in variably sized solid nests, and are comprised or relatively small cells with rounded to oval nuclei. Diffuse chromatin with inconspicuous nucleoli, and scant to moderate amounts of amphophilic cytoplasm. No definite gland formations or intracellular bridges are noted. Mitotic figures are easily identified. Some portions of the tumor demonstrate prominent streaming nuclear artifact. Foci of tumor necrosis are present.

IMMUNOHISTOCHEMICAL DATA:
 Antibodies Specific To:  Results: 
  Pankeratin     Positive Cytokeratin 7    Variably positive Cytokeratin 20    Negative (with internal internal positive control) Cytokeratin 5/6   Negative (with positive internal control) p63     Negative (with positive internal control) Synaptophysin    Diffuely positive Chromogranin    Negative (with no internal positive control)


NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing. 

PART 3: RIGHT PRETRACHEAL 
One smear, one ThinPrep slide and multiple sections through two levels of a cell block are reviewed. The cell block slides demonstrate clusters of atypical epithelioid cells compatible with the malignant neoplasm described in Part 2. The smear and ThinPrep slide likewise demonstrates scattered small clusters of similar appearing atypical epithelioid cells.<CLINICAL INFO>
Lung mass.PATHOLOGIST:
**NAME[XXX WWW M.",,,,,
REG3,LUNG,0,PAT-00742646,1,REC-5000734495,,,,"<SPECIMEN(S)>
      
MUSCLE BIOPSY


<GROSS> 
Labeled **NAME[AAA BBB] and CT guided biopsy right psoas muscle mass tissue.  Received in
formalin after initial touch preparation are five to six cores and fragments of pink white
soft tissue measuring from 0.1 to 0.5 cm in length and measuring less than 0.1 cm in width.
The cores are collected in a fine mesh filter bag and submitted entirely in one cassette
INTRAOPERATIVE TOUCH PREP DIAGNOSIS:  UNDIFFERENTIATED MALIGNANT TUMOR, MELANOMA VERSUS
MYELOMA VERSUS UNDIFFERENTIATED CARCINOMA.  OBTAIN MORE CORES FOR HISTOLOGY, FOR FLOW AND
CYTOGENETICS WITH FISH (JCZ).

SENT OUT FOR CONSULTATION 
IMMUNOHISTOCHEMISTRY RESULTS HAVE BEEN RECEIVED AND ARE INCLUDED IN THIS COPY OF THE
REPORT.  
FLOW CYTOMETRY RESULTS HAVE BEEN RECEIVED AND ARE INCLUDED IN THIS COPY OF THE REPORT.
<MICROSCOPIC> 
One H & E slide and four Diff-quik stained touch preparations examined.  Soft tissue as
well as striated muscle infiltrated by a malignant tumor that is of intermediate to large
cell in size composed of discohesive cells with  foci of necrosis.  The cells have
moderately abundant eosinophilic cytoplasm with an eccentric nucleus, some of the cells
being binucleated.  Mitoses are infrequent.  Nuclear vacuolations, and definite cytoplasmic
pigmentation, clock-faced nuclear chromatin or perinuclear hof are not seen.  Focally tumor
appears to be within thin walled vessels, possibly lymphatics.
The touch preparations reveal a nonsmall cell tumor with poorly cohesive cells having an
eccentric nucleus and moderately abundant cytoplasm, some of which has fine cytoplasmic
vacuolations.  Very fine pigment granules are identified in some of the cells.  


<FINAL DX> 
CT GUIDED RIGHT PSOAS MUSCLE MASS NEEDLE BIOPSY: ADENOCARCINOMA, POORLY DIFFERENTIATED,
FAVOR PULMONARY PRIMARY. (PLEASE REFER TO CONSULT REPORT FROM DR. **NAME[ZZZ YYY] OF
NORTHWEST PATHOLOGY)
NOTE:  PRELIMINARY RESULTS WERE DISCUSSED WITH DR. **NAME[XXX WWW] **DATE[Jul 8 12] AT 10:00 AM BY JCZ.
CYTOGENETIC STUDIES ARE PENDING.",,,,,
REG3,LUNG,0,PAT-00744532,1,REC-5000749420,,,,"<CLINICAL INFO>
 Patient to be seen by Dr. **NAME[ZZZ YYY] on **DATE[Aug 10 2012].<FINAL DX>
 **PLACE, WA; ***PATH-NUMBER[1]
  (**DATE[Jul 18 2012])
  Mediastinal/AP window mass, needle core biopsies:  Adenocarcinoma; see
  comment.<DIAGNOSIS COMMENT(S)> Small needle cores contain carcinoma cells in a
  background of fibrosis and plasma cell infiltrate.  Touch preparation cotnain
  multiple cohesive groups of cells with polarized nuclei consistent with
  adenocarcinoma.  Per report, molecular (PCR) studies for EGFR mutation
  performed at **PLACE, WA; ***PATH-NUMBER[2]) were
  negative for EGFR mutation by real time PCR.
  **INITIALS
  Procedures used to establish the diagnosis:
  RoutineMATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[1]  0B,4S  Mediastinal/AP window mass needle core biopsies",,,,,
REG3,LUNG,0,PAT-00731958,1,REC-5000749570,,,,"<CLINICAL INFO>
 **AGE[in 50s]-year-old male with 2-day-history of pruritic
  papules of B) UE R>L, in a linear confluent shape, also positive involvement
  of scalp.  Patient has metastatic SCC of lung.  Differential diagnosis:  Drug
  eruption, Sweets, cutaneous malignancy, infection.<FINAL DX>
 A) Skin, right arm, 6mm punch biopsy:  Interface
  dermatitis and small vessel vasculopathy.  See comment.
  B) Skin, left arm, 6mm punch biopsy:  Interface dermatitis and small vessel
  vasculopathy.  See comment.<DIAGNOSIS COMMENT(S)>
  In this clinical context, a drug reaction is a leading consideration.
  Characteristic findings of Sweet's syndrome are not appreciated.  Clinical
  correlation is necessary.
  Procedures used to establish the diagnosis:
  A    Periodic acid-Schiff stain for fungus e<GROSS>
 A) Received in formalin labeled ""**NAME[BBB,
  AAA], right arm"" is a 0.7 x 0.6 cm tan skin punch excised to a depth of 0.7
  cm.  The specimen is inked at its resected surface, bisected, wrapped, and
  entirely submitted in cassette A1.  (**INITIALS)
  B) Received in formalin labeled ""**NAME[BBB, AAA], left arm"" is a 0.6 x 0.6 cm
  tan skin punch excised to a depth of 0.5 cm.  The specimen is inked at its
  resected surface, bisected, wrapped, and entirely submitted in cassette B1.
  (**INITIALS)<MICROSCOPIC>
 A) Sections show skin with basket weave
  orthokeratosis.  Epidermis contains mild irregular psoriasiform hyperplasia
  and spongiosis.  Basal layer vacuolization is appreciated.  Superficial dermis
  with edema and interstitial and perivascular lymphohistiocytic inflammation.
  Prominent erythrocyte extravasation is seen.  No increase in dermal
  eosinophils is appreciated.  No neutrophilic infiltrates are seen.  Additional
  step sections were examined.  No fungal organisms were seen on PAS stain.
  B) Sections show skin with basket weave orthokeratosis.  Epidermis contains
  focal basal layer vacuolization.  Superficial dermis with minimal edema and
  interstitial and no notable inflammation.  Prominent erythrocyte extravasation
  is seen.  No increase in dermal eosinophils is appreciated.  No neutrophilic
  infiltrates are seen.   Additional step sections were examined.",,,,,
REG3,LUNG,0,PAT-00408994,2,REC-5000750095,,,,"<CLINICAL INFO>
SQUAMOUS CELL CARCINOMA, RIGHT LUNG


<GROSS>
The specimen, labeled on container as **NAME[BBB], designated exophytic mass, right colon, is four formalin-fixed, irregular, tan soft tissue fragments ranging from 0.1 to 0.2 cm in greatest dimension. The specimen is inked. All embedded, one block. (nh)


<MICROSCOPIC>
See diagnosis.


<FINAL DX>
EXOPHYTIC MASS, RIGHT COLON: 
 FRAGMENTS OF VILLOUS ADENOMA. 


<DX COMMENT>
The endoscopic impression (of exophytic mass) is noted. An invasive malignancy is not identified within these superficial biopsy fragments but an underlying carcinoma cannot be excluded. This case was also reviewed by Dr. **NAME[ZZZ], who agrees with the diagnosis.",,,,,
REG3,LUNG,0,PAT-00747821,1,REC-5000750970,,,,"<FINAL DX>
  LEFT PLEURAL FLUID, CYTOLOGY AND CELL BLOCK: INCONCLUSIVE. RARE ATYPICAL
CELLS SUSPICIOUS  FOR MALIGNANCY.

<PATHOLOGIST>
   **NAME[ZZZ] MD, Uma              Electronically Signed: **DATE[Jul 29 2012]
<SPECIMEN(S)>
  A) thoracentesis
<CLINICAL INFO>
  skin cancer; r/o metastasis
<GROSS>
  Fluid received from which a cell block and a SurePath slide are prepared.
<MICROSCOPIC>
  The cell block demonstrates predominately blood with entrapped lymphocytes
and some neutrophils. The SurePath slide demonstrates in a background of
abundant lymphocytes rare single atypical cells that are binucleate and
trinucleate and have prominent nucleoli. The cells seen on the SurePath
slide are highly suspicious for malignancy but too scant for additional
studies for  classification.",,,,,
REG3,LUNG,0,PAT-00748625,1,REC-5000751018,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  LUNG, RIGHT, NEEDLE BIOPSY: POORLY DIFFERENTIATED NON-SMALL CELL
CARCINOMA, IMMUNOPROFILE MOST CONSISTENT WITH POORLY DIFFERENTIATED
ADENOCARCINOMA

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Apr 03 2012]
<SPECIMEN(S)>
  A) Right lung mass 
<GROSS>
  Received in a container labeled with the patient's name and ""right lung
mass"" are three tan tissue core fragments with a 1.8 cm aggregate length,
AE/(3).
<MICROSCOPIC>
  Sections show fragmented pieces of lung tissue that are nearly completely
replaced by a non-small cell carcinoma. Neoplastic cells grow in sheet
like groups and are composed of cells with enlarged nuclei often with a
prominent nucleolus. Several mitotic figures are noted. The cell borders
are not well defined. Some cells have a slightly spindled appearance. 
The epithelial nature of these cells is confirmed with an
immunohistochemical stain showing diffuse and strong positive
immunoreactivity for cytokeratin 7. There is variable but strong positive
immunoreactivity for TTF-1 which is typical for tumors primary to the
lung. The cells are negative with stains for p63 and cytokeratin 5&6. This
pattern would favor adenocarcinoma over squamous cell carcinoma. An
immunostain for S-100 protein is negative excluding melanoma. The
histology does not suggest a specific lineage of differentiation. 
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. CYTOKERATIN 7 (OV-TL12/30): POSITIVE
2. CYTOKERATIN 20 (Ks20.8): NEGATIVE 
3. TTF-1 (8G7G3/1): POSITIVE (VARIABLE) 
4. p63 (BC4A4): NEGATIVE 
5. CYTOKERATIN 5/6 (D5&16B4): NEGATIVE
6. S100 (4C4.9): NEGATIVE  
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.",,,,,
REG3,LUNG,0,PAT-00526447,2,REC-5000751133,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  LUNG, RIGHT POSTERIOR, CORE BIOPSY: POORLY DIFFERENTIATED SQUAMOUS CELL
CARCINOMA.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Feb 15 2012]
<SPECIMEN(S)>
  A) Right lung mass tissue posterior core bx
<GROSS>
  Received in a container labeled with the patient's name and ""right
posterior lung mass"" is a 1.7 cm white-tan wispy tissue core, AE/(1).
<MICROSCOPIC>
  Sections show a core of pulmonary parenchyma infiltrated by a poorly
differentiated squamous cell carcinoma. Tumor cells grow in nested sheets
like groups and are composed of cells with enlarged moderate pleomorphic
nuclei often with one or more prominent nucleolus. The cells have variable
amounts of amphophilic cytoplasm. In some areas there is a suggestion of
intercellular bridges between some cells. Areas of the tumor are necrotic.
Other areas are surrounded by dense fibrous tissues. 
A panel of immunohistochemical marker stains has been performed. This
confirms a squamous phenotype for this neoplasm. The neoplastic cells show
diffuse and strong positive immunoreactivity for cytokeratin 5/6. There is
positive nuclear immunoreactivity for p63. These same cells are negative
with stains for cytokeratin 7, cytokeratin 20, TTF-1 and CDX2. Appropriate
internal controls are preset on some of these negative stains. 
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1.   CYTOKERATIN 7 (OV-TL12/30): NEGATIVE.
2.  CYTOKERATIN 20 (Ks20.8): NEGATIVE.
3.  CYTOKERATIN 5/6 (D5&16B4): POSITIVE.
4.  p63 (BC4A4): POSITIVE. 
5. CDX2 (CDX2-88): NEGATIVE. 
6. TTF-1 (8G7G3/1): NEGATIVE. 
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.",,,,,
REG3,LUNG,0,PAT-00747325,1,REC-5000751290,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  LEFT ILIAC BONE, BIOPSY:  METASTATIC ADENOCARCINOMA CONSISTENT WITH LUNG **NAME[ZZZ
YYY].
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. CYTOKERATIN 7 (OV-TL12/30): POSITIVE
2. CYTOKERATIN 20 (Ks20.8): NEGATIVE
3. TTF-1 (8G7G3/1): POSITIVE
4. ESTROGEN RECEPTOR (SP1): NEGATIVE

Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.

<PATHOLOGIST>
   **NAME[XXX] MD, **NAME[WWW]               Electronically Signed: **DATE[Aug 29 2012]
<SPECIMEN(S)>
  A) L. iliac bone
<GROSS>
  Received in a container labeled with the patient's name and ""left iliac""
is a 2.0 x 0.2 by less than 0.1 cm aggregate of multiple scanty red and
yellow soft tissue fragments which are filtered and submitted entirely in
one cassette, AE/(m). 
<MICROSCOPIC>
  Sections show fragmented pieces of delicate bony spicules and floating
fragments and tiny cores of fibrotic connective tissue involved by
metastatic adenocarcinoma. The tumor forms tight clusters and poorly
formed glands.  There may be extracellular mucin.  The tumor cells are
strongly positive for CK7, negative for CK 20 and positive for TTF-1.  The
tumor is ER negative. The clinical history, radiographic findings,
histologic appearance and immunohistochemical profile are consistent with
metastatic adenocarcinoma of lung origin.",,,,,
REG3,LUNG,0,PAT-00748522,1,REC-5000751749,,,,"<CLINICAL INFO>
The patient has a left hilar mass and a left frontal lobe mass suspicious for a metastasis.  On **DATE[Jan 01 2012], the patient underwent a craniotomy and resection of the left frontal mass which showed metastatic poorly differentiated carcinoma.

<GROSS>
A.  Received in formalin labeled with the patient's name and per the requisition designated 'endobronchial biopsy' are six pale tan-pink tissue fragments ranging from less than 0.1 to 0.1 cm in maximum dimension.  The specimen is sectioned in hematoxylin, wrapped and entirely submitted in one cassette.
**INITIALS  **DATE[Jan 2 12]
B.  Designated 'bronchial brushing' is a specimen in two parts.  The first consists of 25 cc of clear fluid in CytoLyt fixative which is used to make a monolayer slide.  Also received are two direct smears fixed in alcohol which are stained with a Pap stain.
C.  Designated 'bronchial washing' is 25 cc of cloudy orange fluid which is used to make a monolayer slide and a cell block.

<MICROSCOPIC>
A.  Sections show multiple fragments of bronchial tissue in which the mucosa and submucosa are well represented.  A nonspecific chronic inflammatory infiltrate is present within the submucosa.  No granulomas or neoplastic infiltrates are identified.
B.  The monolayer slide from the bronchial brushing as well as the direct smears show mostly bronchial epithelium and few inflammatory cells.  No malignant cells are identified.
C.  The monolayer slide and a section from the cell block show clusters of atypical epithelial cells with enlarged nuclei, multiple nucleoli and moderate cytoplasm.  The cells within the cell clusters exhibit pleomorphism and crowding.  Definite features of malignancy are not present.
**INITIALS  **DATE[Jan 2 12]


<FINAL DX>
A.  ENDOBRONCHIAL BIOPSY FROM LEFT SUPERIOR SEGMENT, LEFT UPPER LOBE AND LEFT 
  LOWER LOBE:
  1.  BRONCHIAL TISSUE WITH MILD NONSPECIFIC CHRONIC INFLAMMATION.
  2.  NEGATIVE FOR MALIGNANCY.
B.  BRONCHIAL BRUSHING:  NEGATIVE FOR MALIGNANCY.
C.  BRONCHIAL WASHING: 
  ATYPICAL CELLS SUSPICIOUS FOR NON-SMALL CELL CARCINOMA.",,,,,
REG3,LUNG,0,PAT-00748427,1,REC-5000751898,,,,"PART / DESCRIPTION - SEQ# 
Lung Bx/ Lung Biopsy- 1
<PROCEDURE INTERP>
Results-Comments
ANTIBODIES TO:    CLONE:    RESULTS:

CYTOKERATIN 7    OV-TL **DATE[Aug 31]    positive
CYTOKERATIN 20    KS20.8     negative
CYTOKERATIN 5/6    D5+16B4    negative
P63      4A4     negative
TTF-1      8G7G3/1    negative
SURFACTANT PROTEIN A   AB49566    negative
VILLIN      CWWB1    negative
CDX2      CDX2-88    negative
PSA      ER-PR8    negative

DIAGNOSIS:
Right lung lesion, needle core biopsy: Poorly differentiated non-small cell, non-squamous cell carcinoma, primary site indeterminate.

Comment: This tumor marks as a carcinoma however no additional positive markers for organ specific differentiation are present. Clinicopathologic correlation is suggested.

**DATE[Apr 25 2012] SMCInterpretation
Deparaffinized sections of formalin fixed tissue (along with appropriate positive and negative controls) are incubated with the following antibody(s). Using the automated Ventana stainer, tissue is incubated with the designated antibody which is then localized by a non-biotin, dual polymer detection system. The controls are reviewed for appropriate reactivity and found to be adequate. Results on the target cell population are indicated below:
Some of the immunohistochemistry stains reported below were developed and their performance characteristics determined by Skagit Pathology. They have not been cleared or approved by the U.S. Food and Drug Administration, although such approval is not required for analyte-specific reagents of this type.

<INTRAOPERATIVE DX>
NONE
<MICROSCOPIC>
NONE
<DIAGNOSIS COMMENTS>
Additional immunohistochemical stains will be performed in an attempt to further define this lesion. A separate report will be issued with the results.
<FINAL DX>
Right lung lesion, needle core biopsy: Invasive poorly differentiated non-small cell, non-squamous cell carcinoma, primary site indeterminate by immunohistochemistry.

**DATE[Apr 24 2012] SMC
<GROSS>
The specimen is received in one formalin filled container labeled with the patient's name, is without sublabeling, and consists of multiple serpiginous fragments of light tan tissue aggregating to 1.2 x 0.2 x 0.1 cm. The specimen is filtered through a tissue bag and submitted as cassette A. **DATE[Apr 24 2012] SMC/AO
<CLINICAL INFO>
right lung lesion, history of TB
1). Right lung<PATHOLOGIST>
**NAME[ZZZ YYY M] 

<SNOMED Code(s)>
T28100P1143M801033",,,,,
REG3,LUNG,0,PAT-00542924,2,REC-5000752721,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A, B. Left Deep Cervical Lymph Node, Excision:
     Metastatic adenocarcinoma consistent with lung primary.

<CLINICAL INFO>
ICD-9 Codes: 171.9, 569.69. Lung mass, multiple metastatic nodules.
History of rectal CA.

<GROSS>
A. Received fresh, labeled ""**NAME[BBB, AAA]"" and designated ""left deep
cervical lymph node"", is a 1.2 x 0.7 x 0.6 cm pink-tan lymph node. It is
bisected and the cut surfaces have central yellow-tan discoloration. It
is entirely submitted in A1. Two touch preps are made. (kjh/gdb)

B. Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""left
deep cervical lymph node"", is a 1.2 x 1 x 0.7 cm piece of rubbery,
pink-tan tissue, bisected and entirely submitted in B1.  (kjh/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block B1

Antibody  Result    Comment
CK7  Positive
CK20 Negative
TTF-1     Positive
Napsin A  Positive
Villin    Negative
CDX-2     Negative
PSA  Negative
CEA-P     Positive

Impression:  The immunophenotype is most compatible with lung primary,
arguing strongly against colorectal or prostatic origin.
Interpreted by:  **NAME[ZZZ M. YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Sep 07 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,LUNG,0,PAT-00746309,1,REC-5000752792,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Lung, Left Upper Lobe, Wedge Excision:
   Carcinoma of the lung with the following features:
      Histologic type:   Poorly differentiated neuroendocrine carcinoma
(small cell
      carcinoma).
      Tumor size:   1.5 x 1.5 x 1.3 cm. 
      Histologic grade:  G 4 of 4.
      Sites of invasion:
         Lung parenchyma invasion: Present. 
         Pleural invasion:    Tumor involves the visceral pleura to
outer surface (PL2).
         Main bronchus invasion:   Not applicable.
         Chest wall invasion: Unknown.
         Diaphragm invasion:  Unknown.
         Lymph-vascular invasion:  Present.
      Margins:
         Bronchial margin:    Not applicable.
         Parenchymal margin:  Tumor extends to within 2 mm from the
staple line.
         Vascular margin:     Not applicable.
      Regional lymph nodes:   Not included.
      Non-Neoplastic Lung:    Emphysematous changes, subpleural
interstitial fibrosis, and
       chronic inflammation.
      Distant metastasis:     Unknown.
      Pathological stage:     pT2, pNX (AJCC 7th edition).

<CLINICAL INFO>
Left lung CA.

INTRAPROCEDURAL EVALUATION:
Left lung wedge resection (frozen section): ""Poorly differentiated
carcinoma with necrosis extending close to the staple line"".
Performed by:  **NAME[ZZZ YYY], M.D.

<GROSS>
Received fresh, labeled ""**NAME[AAA BBB]"", and designated ""left lung
wedge resection"", is a wedge of lung tissue, 10 x 2 x 2 cm. The pleural
surface is relatively smooth with a 1.5 cm linear ragged defect. The
pleura is marked with blue dye and the specimen is sectioned, exposing a
gray nodule immediately beneath the pleural defect which is
approximately 1.5 x 1.3 x 1.5 cm. The surgical staple line is removed
and this non-true margin is marked with red dye. The specimen is
sectioned and representative tissue is submitted as follows:
Block Key:
A1.       Frozen section.
A2-A10.   Additional tissue including remaining tumor and adjacent
parenchyma. (ke/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A7

Antibody  Result    Comment
Chromogranin   Positive  Subset of cells.
Synaptophysin  Positive
p63  Negative
CAM5.2    Positive
High MW CK     Negative
MIB1 (Ki-67)s  Positive  Increased proliferative activity in
approximately 80% of cells.

Impression:  The results support the diagnosis.
Interpreted by:  **NAME[ZZZ YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

PHYSICIAN NOTIFICATION:
The case was discussed with Dr. **NAME[XXX] by Dr. **NAME[YYY] on **DATE[May 07 2012]

INTRADEPARTMENTAL CONSULTATION:
**NAME[WWW M. VVV], M.D.

**NAME[ZZZ YYY], M.D.  Electronically signed **DATE[May 07 2012]",,,,,
REG3,LUNG,0,PAT-00748106,1,REC-5000752945,,,,"PART / DESCRIPTION - SEQ 
Lung, Fine Needle Aspiration/ RIGHT LUNG MASS FNA/ FLUID AND SMEARS- A
PART / DESCRIPTION - SEQ 
Lung Bx/ RIGHT LUNG MASS BIOPSY AND TOUCH PREPS- BConsult
**NAME[ZZZ YYY], M.D. (QA)
FINAL DX:

a. Right lung mass, fine needle aspiration cytology:
-Positive for malignant cells consistent with squamous cell carcinoma.

B. Right lung mass, core biopsy:
-Positive for squamous cell carcinoma.
INTRAOPERATIVE DX:
A. right lung mass, immediate interpretation of fine needle aspiration: Diagnostic material obtained. (DCW)
B. right lung mass, immediate interpretation of core biopsy touch preparations: Diagnostic material obtained. (DCW)
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
A. A fine needle aspiration is performed on the ''right lung mass'' of patient ''**NAME[BBB, CCC]' with accompanying 
 requisition by Dr. **NAME[XXX]. One pass is made. Prepared in CT are one wet-fixed smear and one fast-stained 
 smear labeled ''**NAME[BBB, AAA (M])''. Also prepared is one ThinPrep slide from the sample collected in CT and 
 labeled ''**NAME[BBB, AAA (M])''. (DCW:ra)
B. Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''right lung'' per requisition, are five 0.1 cm in 
 diameter elongated, cylindrical portions of tissue, 0.2, 0.3, 0.5, 1.0, 1.3 cm in length, entirely submitted in cassette 
 B1. (**INITIALS:cmc20 22434) A core biopsy-touch preparation is performed on the ''right lung mass'' of patient 
 ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[XXX]. Four passes are made. Prepared in CT are 
 three fast-stained smears labeled ''**NAME[BBB, AAA (M])''. (DCW:ra) (DCW/cmc78 288327)
CLINICAL INFO:
Right lung mass.
PATHOLOGIST:
**NAME[WWW VVV M]. 

SNOMED Code(s)
T28100P1140M80703T28100P1149M80703",,,,,
REG3,LUNG,0,PAT-00604876,2,REC-5000753567,,,,"PART / DESCRIPTION - SEQ 
Bronchial Washings-Cytology/ RIGHT LOWER LOBE LUNG LAVAGE/ FLUID- D
PART / DESCRIPTION - SEQ 
Lymph Node, Fine Needle Aspiration/ 4R LYMPH NODE TBNA/ FLUID AND SMEARS- A
PART / DESCRIPTION - SEQ 
Lymph Node, Fine Needle Aspiration/ STATION 7 LYMPH NODE TBNA/ FLUID AND SMEARS- B
PART / DESCRIPTION - SEQ 
Lung Bx/ RIGHT LOWER LOBE LUNG BIOPSY- CConsult
**NAME[ZZZ M. YYY], M.D. - part A and B.
DIAGNOSIS COMMENTS:
The neoplastic cells are arranged as dyscohesive cells and small nests of cells. They appear mildly enlarged with hyperchromatic nuclei with irregular nuclear contours and indistinct nucleoli. The cells have minimal cytoplasm and show areas of molding and occasional mitoses. The neoplastic cells show moderate staining for pankeratin and very focal staining for synaptophysin. They fail to react with CD45 or TTF1. Flow cytometry studies fail to show a clonal B cell polulation; please see separate flow cytometry report (***PATH-NUMBER[1]). While small cell carcinomas are typically positive for TTF-1, the cytologic and immunohistochemical stains are otherwise very consistent with a small cell carcinoma.
FINAL DX:

a. 4R lymph node, fine needle aspiration and cell block:
-Poorly differentiated carcinoma consistent with small cell carcinoma (see Comment). 

b. Station 7 lymph node, fine needle aspiration and cell block:
-Poorly differentiated carcinoma consistent with small cell carcinoma (see Comment). 

c. Right lower lobe transbronchial biopsy:
-Upper respiratory tract mucosa with chronic inflammation, squamous metaplasia and pulmonary
 parenchyma; no evidence of granulomas or malignancy. 

d. Right lower lobe lung lavage, ThinPrep slide and cell block:
-Respiratory epithelium and alveolar histiocytes, negative for malignant cells.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.
INTRAOPERATIVE DX:
A. 4R lymph node, immediate interpretation of TBNA: Diagnostic material present; atypical probable lymphoid population. 
B. Station 7 lymph node, immediate interpretation of TBNA: Diagnostic material present; atypical probable lymphoid population. Material obtained for flow cytometry.GROSS:
A. A TBNA is performed on the ''4R lymph node'' of patient ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[XXX]. Five passes are made. Prepared in OR are two wet-fixed smears and two fast-stained smears labeled ''**NAME[BBB, AAA (M])''. Also prepared is one cell block from the sample collected in saline and labeled ''**NAME[BBB, AAA (M])''. 
B. A TBNA is performed on the ''station 7 lymph node'' of patient ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[XXX]. Eight passes are made. Prepared in OR are one wet-fixed smear and one fast-stained smear labeled ''**NAME[BBB, AAA (M])''. Also prepared is one cell block from the sample collected in saline and labeled ''**NAME[BBB, AAA (M])''. (DPM:ra)
C. Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''right lower lobe transbronchial biopsy'', is a 0.8 x 0.6 x 0.2 cm aggregate of multiple fragments of tan-white soft tissue. The specimen is submitted entirely in cassette C1. (**INITIALS:cmc31 295516) 
D. Received fresh on **DATE[Oct 31 2011] is approximately 30 cc of cloudy hemorrhagic mucoid fluid, labeled ''**NAME[BBB, AAA M. (M]) right lower lobe lung lavage''. Prepared are one cell block and one ThinPrep slide. (DPM:**NAME[WWW]) (DPM:cmc131 295684)
CLINICAL INFO:
Swelling, mass, or lump in chest.ICD-9 code: 786.6. History of breast cancer.
PATHOLOGIST:
**NAME[VVV UUU M]. 

SNOMED Code(s)
T28400T28010T05120P1251M09450T28000T26400T26200T26010P1140M73220M43000M09450T08000P1149M804133T08000P1149M804133",,,,,
REG3,LUNG,0,PAT-00742916,1,REC-5000753845,,,,"Right hilar mass, right main stem mass.  R/o carcinoma.



        A.  LUNG, RIGHT MAIN STEM, BRONCHIAL WASHINGS (CYTOSPIN PREPARATION AND CELL BLOCK):  SMALL CELL CARCINOMA.

        

        B.  LUNG, RIGHT MAIN STEM, BRONCHIAL BIOPSIES:  SMALL CELL CARCINOMA.

        

        C.  LUNG, MAIN CARINA, NEEDLE ASPIRATE X 4:  SMALL CELL CARCINOMA.

        

        D.  LUNG, RIGHT MAIN STEM, BRUSHINGS:  SMALL CELL CARCINOMA.





        This case was seen in consultation with Dr. **NAME[ZZZ].  Drs. **NAME[YYY], Jackson and **PLACE notified on **DATE[Nov 18 11].





        A.  Received is a plastic container with 20 mls of reddish fluid.  Submitted for cytology processing.

        

        B.  Multiple pink fragments of tissue measuring from 0.1 - 0.4 cm.  Submitted in ""B"".

        

        C.  Received in four containers without alcohol fixative and two slides each.  These are stained in the frozen section suite.

        

        D.  Received is a plastic container with alcohol fixative and two slides.  These are stained in the frozen section suite.





        A.  The specimen consists of atypical cells with minimal cytoplasm and powdery chromatin intermixed with unremarkable macrophages and respiratory epithelial cells.

        

        B.  Sections show normal connective tissue, necrosis and small groups of atypical cells,

          













        some of which are crushed, with minimal cytoplasm and dark nuclei.

        C.  In a background of blood, the specimen consists of abundant atypical cells with a high

        nuclear to cytoplasmic ratio, moderate pleomorphism and powdery chromatin.

        

        D.  The specimen consists predominantly of blood with rare atypical cells similar to those

        seen in specimen ""C"".",,,,,
REG3,LUNG,0,PAT-00744493,1,REC-5000754049,,,,"PART / DESCRIPTION - SEQ# 
Brain, biopsy/ BRAIN TUMOR- 1<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
<GROSS>
BRAIN TUMOR: 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"brain tumor,"""" is a Telfa pad from which several irregular portions of soft friable gray-white tissue aggregating to 4 x 3 x 1 cm are retrieved. Entirely submitted in cassettes 1a-1c.Addendum Diagnosis
<FINAL DX>

BRAIN TUMOR: HIGH GRADE SPINDLE CELL NEOPLASM CONSISTENT WITH METASTATIC SPINDLE CELL CARCINOMA FROM THE LUNG. IMMUNOHISTOCHEMICAL STUDIES BY PHENOPATH LABORATORIES PENDING, ADDENDUM REPORT WILL FOLLOW.
**INITIALS<CLINICAL INFO>
Brain tumor.<ADDENDUM COMMENTS>
This case was sent to PhenoPath Laboratories in **PLACE, Washington. Their results are as follows:

BRAIN TUMOR: METASTATIC SARCOMATOID CARCINOMA, CONSISTENT WITH ORIGIN FROM LUNG (SEE COMMENTS).

COMMENTS:
The results of the immunohistochemistry panel for this poorly differentiated mixed sarcomatoid and epithelioid malignancy confirm the suspicion of a metastatic carcinoma (uniformly positive with pancytokeratins OSCAR), and given the provided clinical history, are considered consistent with a metastasis from the patient's known lung carcinoma. Spindle cell carcinomas of the lung typically show no expression of lung organ-specific markers (such as TTF-1), as exemplified in this particular case. Otherwise, there is no evidence for a melanoma (negative S100/HMB45), myogenic sarcoma (negative desmin), vascular sarcoma (negative CD34), or an astrocytic malignancy (negative GFAP).

Reference is made to their complete report (***PATH-NUMBER[1]).
(**INITIALS **DATE[Feb 15 2012])
<MICROSCOPIC>
BRAIN TUMOR: 
All of the tissue is examined on three slides. It shows a partially necrotic high grade spindle cell tumor composed of pleomorphic tumor cells with intervening neutrophils and areas of geographic tumor necrosis. The tumor is similar to the patient's prior lung mass (***PATH-NUMBER[2]). The case will be sent in follow-up to PhenoPath Laboratories for additional immunohistochemical studies and an addendum report will follow.PATHOLOGIST:
Insalaco S J",,,,,
REG3,LUNG,0,PAT-00763087,1,REC-5000754361,,,,"<CLINICAL HX>
Lung ca, left.  

<HISTOLOGY COMMENT>




<GROSS>
A.  Received fresh for intraoperative consultation labeled ""aorto-pulmonary window node"" is one lymph node measuring 2.0 x 1.5 x 1.3 cm. The node is bisected and an intraoperative touch preparation is performed. The bisected lymph node is submitted entirely for intraoperative consultation, and the contents of the cryoblock are transferred to cassette A1.
B.  Received fresh for intraoperative consultation labeled ""left lung for margins please"" is a 442 gm left lung pneumonectomy specimen. A shave of the bronchial margin is submitted fresh for intraoperative consultation, and the contents of the cryoblock are transferred to cassette B1.  The left pulmonary artery and vein margins are identified, closed with suture.  The pneumonectomy specimen also demonstrates two stapled parenchymal/vascular margins, one at the lower lobe and one in the upper lobe, measuring 7.0 and 4.0 cm in length, respectively. The stapled parenchymal/vascular margin on the upper lobe is removed and the underlying parenchyma is inked yellow. The stapled parenchymal/vascular margin of the lower lobe is removed, and the immediate underlying parenchyma is inked green. Located within the upper lobe, centrally and adjacent to the left pulmonary artery, is a nodular firm white lesion measuring 3.5 x 3.0 x 3.0 cm. The lesion appears to arise from a main bronchus and appears to erode into a large segmental vessel that connects to the left pulmonary artery. The lesion closely approaches the overlying pleura but does not appear to invade into it.  The pleura overlying this mass is inked blue.  An second mass, measuring 3.0 x 3.0 x 2.5 cm, consisting of an ill-defined nodular white lesion within the periphery of the upper lobe is identified measuring approximately 3.0 cm from the centrally located mass. The pleura overlying the second mass is inked orange. The lesion closely approaches but does not involve the overlying pleura. The remaining upper lobe is unremarkable. The lower lobe demonstrates emphesematous changes and is otherwise without discrete mass or lesion. Multiple hilar and segmental lymph nodes are identified ranging from 0.5 up to 2.0 cm in greatest dimension. Representative sections are submitted as follows: B1 - bronchial margin; B2 - left pulmonary artery and left pulmonary vein margins; B3 - vascular margins at surgical staples; B4 - first mass arising from bronchus; B5  B6 - first mass adjacent to large segmental artery; B7 - first mass adjacent to lymph node; B8 - first mass nearest pleura; B9 - first mass adjacent to stapled parenchymal margin; B10 - first mass adjacent to unremarkable lung tissue; B11-B13 - representative second mass in relation to overlying pleura; B14 - representative unremarkable left upper lobe; B15 - representative left lower lobe; B16 - five hilar lymph nodes, whole; B17 - two hilar lymph nodes, bisected (one is inked blue); B18 - two hilar lymph nodes, bisected (one is inked blue); B19 - two hilar lymph nodes, bisected (one is inked blue); B20 - two hilar lymph nodes, bisected (one is inked blue); B21 - two hilar lymph nodes, bisected (one is inked blue); B22 - one hilar lymph node, trisected; B23 - one upper lobe segmental lymph node, fragmented; B24 - one upper lobe segmental lymph node, serially sectioned; B25 - one segmental upper lobe lymph node, serially sectioned; B26 - one segmental upper lobe lymph node, fragmented; B27 - four lower lobe segmental lymph nodes, whole (one fragmented node is inked blue).


<COMMENT>


<MICROSCOPIC>
Slide A1, which contains an aorto-pulmonary window lymph node, shows recognizable lymph node architecture with a moderate number of lymphoid follicles having active germinal centers.  There is sinus histiocytosis with dust deposits and there are an increased number of eosinophils in the lymph node.  No primary or metastatic neoplasm is observed.  Slide B1 represents the bronchial margin of resection.  This slide contains the bronchial margin of resection.  There is focal sloughing of  respiratory epithelium.  There is no significant inflammation.  No neoplasm is observed.  Slide B2 contains the left pulmonary artery and left pulmonary vein margins.  The vessels show recognizable architecture with no neoplasm and no inflammation.  There is some blood clot in the vessel lumens.  Slide B3 contains tissue from the vascular margin at surgical staples.  This slide shows vessels and bronchi.  Neither shows neoplasm.  There are focal artifactual changes.  Slide B4 was stated to contain the mass arising from the bronchus.  The tumor is arising in or from the bronchus and is composed of nests of neoplastic epithelioid cells and some neoplastic spindle cells.  There are areas of inflammation and focal areas of degeneration and necrosis.  There are a few areas where the tumor appears to be forming glandular structures.  These findings would suggest an adenosquamous carcinoma or an adenocarcinoma showing variable differentiation.  The bronchus that is intact adjacent to the tumor shows mild inflammation in the lamina propria of the bronchial mucosal tissue.  It is otherwise essentially normal.  Slides B5 and B6 were stated to contain the first mass adjacent to the large segmental artery.  These slides contain tumor tissue adjacent to bronchi and pulmonary arteries.  The tumor shows large areas of degeneration and necrosis.  There are areas where the tumor appears to be forming glandular structures and probably producing mucus.  In other areas the tumor is in fairly solid sheets and could represent squamous carcinoma.  In slide B5, the tumor appears to show more of a squamoid pattern but does show areas of glandular differentiation.  There are areas of degeneration and necrosis and the tumor is adjacent to vessels, bronchi, and lung parenchyma.  Slide B7 was stated to contain the first mass adjacent to a lymph node.  This slide shows a vessel, a pulmonary artery, lymph nodes, and tumor.  The tumor is fairly poorly differentiated and shows large areas of degeneration and necrosis.  There are areas where the tumor cells appear to be forming tubular structures.  There may be areas where the tumor cells are forming glandular structures, producing lumens.  Slide B8 was stated to contain the first mass nearest pleura. This slide contains three pieces of peripheral lung tissue in which the pleura is identified. The adjacent tumor, in areas, appears to be within the lumen of a dilated bronchus. There are areas where the tumor cells are spindle shaped.  Slide B9 was stated to contain the first mass adjacent to the stapled parenchymal margin. The tumor is composed of nodules that are adjacent to lung tissue and pleura. The tumor is poorly differentiated and shows epithelioid and some spindle cells. There is prominent lymphoid tissue, which might raise the possibility of this tumor being within a lymph node, although that cannot be determined for certain. The adjacent lung tissue shows inflammation and contains dust.  Slide B10 was stated to contain the first nodule adjacent to normal lung tissue. The tumor is similar to that seen in most of the other sections, being composed of epithelioid and spindle cells. There is bronchial cartilage which would suggest the tumor is involving a bronchus. The adjacent lung tissue shows extensive congestion and hemorrhage and areas of acute inflammation.  Slides B11 through B13 were stated to contain tissue from the second mass in relation to the overlying pleura. These slides contain tumor that has the features of an adenocarcinoma.  Slide B14 was stated to contain tissue from an unremarkable section from the left upper lobe. There are two pieces of lung tissue on this slide. There is a fair amount of congestion with some hemorrhage. There are a couple of areas of ossification in the tissue. There are areas of dust. The other piece of tissue shows compressive atelectasis with dust and carbonaceous material. There ae areas suggestive of mild centrilobular emphysema. No neoplasm is observed.  Slide B15 was stated to contain lung tissue from the left lower lobe. These two pieces of lung tissue show congestion, focal compressive atelectasis, carbonaceous dust deposits in a bronchovascular distribution, and nonspecific inflammation. No primary or metastatic neoplasm is observed. There are areas of centrilobular emphysema.  Slide B16 was stated to contain five hilar lymph nodes. These are all relatively small lymph nodes and measure from about 2-3 mm up to about 5-6 mm in diameter. There is adjacent hemorrhagic tissue. These lymph nodes show sinus histiocytosis with dust. No primary or metastatic neoplasm.  Slide B17 was stated to contain two hilar lymph nodes that had been bisected, one of which was inked blue. There are four or five pieces of lymphoid tissue on the slide. These lymph nodes show no primary or metastatic tumor. There is sinus histiocytosis with dust deposits.  Slide B18 was stated to contain two hilar lymph nodes that were bisected, one of which was inked blue. There are five pieces of lymphoid tissue on the slide. These lymph nodes show a fair amount of congestion and hemorrhage, which is probably a result of the biopsy. There are lymphoid nodules with germinal centers. There is sinus histiocytosis with dust deposits within macrophages. This is fairly extensive. There is one silicotic-like nodule in one lymph node and it contains birefringent silicates. No primary or metastatic tumor is identified in these lymph nodes.  Slide B19 contains two hilar lymph nodes that were bisected, one of which was inked blue. There are four pieces of tissue on this slide. These lymph nodes show recognizable architecture with mild lymphoid hyperplasia and a fair amount of hemorrhage in the tissue, which is probably a result of the biopsy. There is mild to moderate sinus histiocytosis with dust deposits. No primary or metastatic tumor is observed.  Slide B20 contains two hilar lymph nodes that have been bisected, one of which was inked blue. There are four pieces of lymph node on the slide. These show recognizable architecture with mild lymphoid hyperplasia and a fair amount of congestion and hemorrhage in the nodal tissue. There are areas of sinus histiocytosis with dust deposits. No primary or metastatic tumor is observed.  Slide B21 was stated to contain two hilar lymph nodes that were bisected, one of which was inked blue. This slide contains two larger pieces of lymphoid tissue and two smaller pieces. These slides show mild lymphoid hyperplasia with sinus histiocytosis. There is a fair amount of hemorrhage in the lymph nodes and surrounding tissue. This probably is secondary to compression. One of the lymph node fragments contains a significant number of macrophages and large amounts of dust. No primary or metastatic tumor is identified.  Slide B22 was stated to represent one hilar lymph node that was trisected. This slide contains three pieces of lymph node. The lymph node shows recognizable architecture with fairly prominent lymphoid nodules. There is sinus histiocytosis with a significant amount of dust, most of which is carbonaceous. No primary or metastatic tumor is identified.  Slide B23 was stated to contain tissue from one upper lobe segmental lymph node that was fragmented. There are several smaller pieces of lymph node on this slide. It shows fairly prominent lymphoid nodules with active germinal centers. There is hemorrhage in the tissue. There is dust in the tissue and there is mild sinus histiocytosis. No primary or metastatic tumor is identified.  Slide B24 was stated to contain one upper lobe segmental lymph node that was serially sectioned. There are four pieces of lymph node on this slide. This slide shows recognizable lymphoid architecture with occasional prominent lymphoid nodules. There is some adjacent lung tissue. There is mild sinus histiocytosis with dust deposits. No primary or metastatic tumor is observed.  Slide B25 was stated to contain one segmental upper lobe lymph node that was serially sectioned. There are five pieces of lymph node and adjacent fibrofatty tissue surrounding it. These slides contain pieces of lymph node that show lymphoid hyperplasia, sinus histiocytosis, and dust deposits. No primary or metastatic tumor is observed.  Slide B26 was stated to contain one fragmented segmental upper lobe lymph node. This slide shows lymphoid hyperplasia, sinus histiocytosis, and dust deposits. There is some congestion. There is some hemorrhage in the adjacent tissue. No primary or metastatic tumor is identified.  Slide B27 was stated to contain four lower lobe segmental lymph nodes that were whole, one of which was fragmented and inked blue. There are three larger fragments of lymphoid tissue and one smaller lymph node. The lymph nodes show mild lymphoid hyperplasia and fairly prominent sinus histiocytosis with dust deposits. No primary or metastatic tumor is observed. The surrounding tissue does not contain tumor.

<FINAL DX>
A. AORTOPULMONARY LYMPH NODE:  LYMPHOID TISSUE SHOWING MILD LYMPHOID HYPERPLASIA AND  SINUS HISTIOCYTOSIS WITH NO PRIMARY OR METASTATIC TUMOR.  B. LEFT LUNG (PNEUMONECTOMY SPECIMEN):  1.  3.5 x 3.0 x 3.0 CM MALIGNANCY PREDOMINANTLY IN A BRONCHIAL DISTRIBUTION.  2.  THE TUMOR ADJACENT TO THE BRONCHUS HAS THE HISTOLOGIC, HISTOCHEMICAL, AND IMMUNOHISTOCHEMICAL FEATURES OF AN ADENOSQUAMOUS CARCINOMA.  3.  SECOND LEFT UPPER LOBE NEOPLASM IS IN A SUBPLEURAL DISTRIBUTION, MEASURING 3.0 X 3.0 X 2.5 CM, AND HAS THE FEATURES OF AN ADENOCARCINOMA SHOWING VARIABLE DIFFERENTIATION.  SPECIMEN: LUNG PROCEDURE: PNEUMONECTOMY SPECIMEN INTEGRITY: INTACT SPECIMEN LATERALITY:  LEFT TUMOR SITE:  BOTH IN LUL  TUMOR SIZE:  TUMOR #1)  3.5 X 3.0 X 3.0 CM  TUMOR #2)  3.0 X 3.0 X 2.5 CM TUMOR FOCALITY:  TUMOR #1)  LUL, CENTRALLY AND ADJACENT TO THE LEFT PULMONARY ARTERY  TUMOR #2)  LUL PERIPHERY RELATIVELY CLOSE TO PLEURA HISTOLOGIC TYPE:  TUMOR #1) ADENOSQUAMOUS CARCINOMA  TUMOR #2)  ADENOCARCINOMA WITH VARIABLE DIFFERENTIATION HISTOLOGIC GRADE:  TUMOR #1)  G2-G3  TUMOR #2)  G1-G2 VISCERAL PLEURAL INVASION:  NOT IDENTIFIED TUMOR EXTENSION:  NOT APPLICABLE MARGINS:  Bronchial:  Uninvolved by invasive carcinoma  Vascular:  Uninvolved by invasive carcinoma  Parenchymal:  Uninvolved by invasive carcinoma  Parietal Pleural:  Uninvolved by invasive carcinoma  Chest Wall:  Uninvolved by invasive carcinoma  Other (specify):  N/A TREATMENT EFFECT:  NOT APPLICABLE LYMPH-VASCULAR INVASION:  NOT IDENTIFIED LYMPH NODES:  NO METASTATIC TUMOR IN NUMEROUS LYMPH NODES PATHOLOGIC STAGING (pTNM):  BOTH TUMORS pT2a, N0, M0 (ANATOMIC STAGE IB)  

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>


<NOTIFICATION>


<PRELIM DX>
Frozen section diagnoses by Dr. **NAME[ZZZ:  M].  ""One lymph node negative for metastatic carcinoma (0/1)."" Results called back to Dr. **NAME[YYY] at 17:43 p.m. on **DATE[Nov 26 2011].  
B.  ""Bronchial margin is negative for carcinoma."" Results called back to Dr. **NAME[YYY] at 18:11 p.m. on **DATE[Nov 26 2011].

<CHECKLIST>


<IMMUNOHISTOCHEMISTRY>
Immunostains are performed in our laboratory on sections from block B6.  There are positive controls that show the expected staining results.  The section stained for CK5/6 shows areas of immunostaining of the epithelioid and spindle cells.  The section stained for CK7 shows intense cytoplasmic and cell membrane staining of most epithelioid cells and some neoplastic spindle cells.  The section stained for TTF-1 shows no staining of neoplastic cells. There is built-in control staining of alveolar lining cells.  The section stained for p63 shows nuclear staining of a majority of the neoplastic spindle cells.  Additional immunostains are performed in our laboratory on sections from block B5 and B6 for CEA. There are focal areas of intracytoplasmic and cell membrane staining.

<INDICATIORS>


<SPECIAL STAINS>
A mucicarmine stain is done in our laboratory on sectios from blocks B5 and B6. It shows prominent areas of mucicarmine staining in individual cells and in glandular lumens.",,,,,
REG3,LUNG,0,PAT-00588495,2,REC-5000755548,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Lung, CT-Guided Core Biopsies:
Moderately to poorly differentiated squamous cell carcinoma.

<COMMENT>
This case was reviewed with Dr. **NAME[ZZZ M. YYY], as part of our
quality assurance policy, and he concurs with the diagnosis.

<CLINICAL INFO>
History of right lung lobectomy for squamous cell carcinoma, new right
lung mass.

INTRAPROCEDURAL EVALUATION:
Right lung biopsy (touch prep): ""Adequate.""
Performed by: **NAME[XXX M. WWW], M.D. on **DATE[Nov 09 2011] at 11:40 a.m.

<GROSS>
The specimen is obtained under CT guidance by Dr. **NAME[VVV UUU],
**INSTITUTION. Four core biopsies
are obtained, each of which is about 15 mm in length x 1 mm diameter.
From those core biopsies, four air-dried Diff-Quik-stained touch
imprints are made. The core biopsies are then placed in formalin and
resubmitted in cassettes A1 and A2. (acb/jmk)

<MICROSCOPIC>
Examination of the touch imprints reveals a cellular specimen with
numerous atypical cells present in generally large somewhat cohesive
clusters. Occasional individual and small groups of tumor cells are
present. The cells show cytologic atypia with large nuclei containing
dark chromatin and sometimes prominent nucleoli. The cells contain
moderate amounts of cytoplasm. There is a pavement-type architecture to
the epithelial cells in the large groups. Extensive tissue necrosis is
present in the background.  The core biopsies reveal fragments of dense
fibrous stroma with necrosis and nests of malignant cells. The cells
show similar cytologic features with some indication of individual cell
keratinization. The findings are compatible with a squamous cell
carcinoma.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Nov 12 2011]",,,,,
REG3,LUNG,0,PAT-00746722,1,REC-5000755740,,,,"<CLINICAL INFO>
162.9 LUNG CANCER.
A) RECEIVED ARE 5 SLIDES IN 95% ALCOHOL AND 30 ML PINK CYTOLYT. B) RECEIVED ARE 4 SLIDES IN 95% AND 30 ML CYTLYT.
<SPECIMEN(S)>
A. 7 NEEDLE
B. 4L
<GROSS>
The specimen consists of two parts.
A. Designated ""7 needle"" are seven slides in 95% alcohol. Two are stained by rapid H&E stain for quick stain interpretation: ATYPICAL CELLS PRESENT. BACKGROUND OF PLUMP RESPIRATORY CELLS. Also received are 30 ml pink CytoLyt solution which is submitted for a concentrated smear and cell block preparation. 
B. Designated ""4L"" are four slides in 95% alcohol and 30 ml CytoLyt solution. The slides are submitted for Papanicolaou staining and the solution submitted for a Thin prep concentrated smear and cell block preparation. 
<MICROSCOPIC>
A. The aspiration smears show varying cellularity and clusters of cells some of which show neoplastic features as they contain moderate amounts of cytoplasm and a large, hyperchromatic and irregular nuclei. The background contains red blood cells and columnar respiratory epithelial cells. The atypical cells present in the slides stained for quick stain interpretation are consistent with neoplastic cells upon review of the Papanicolaou stained slides. The Thin prep concentrated smear also contains neoplastic cells with vesicular nuclei containing clumped chromatin and small nucleoli as well as moderate amounts of cytoplasm. The cell block contains a few groups of neoplastic cells as well. 
B. These smears contain red blood cells, peripheral blood white cells and a few columnar respiratory epithelial cells. The Thin prep smear is of low cellularity and contains small groups of benign columnar epithelial cells. The cell block also contains columnar epithelial cells, bronchial mucous glands and a small amount of adipose tissue. No neoplastic cells are present. 
<FINAL DX>
A. ""7 needle"" aspirate: Positive for non-small cell carcinoma. 
B. ""4L"" aspiration: Negative for neoplasia. 
Comment: The neoplastic cells are similar to those seen in the recent left lung mass biopsy (***PATH-NUMBER[1]). Representative slides of the ""7 needle"" specimen reviewed by Dr. **NAME[ZZZ]. 
 
<PATHOLOGIST>
**NAME[YYY XXX], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,LUNG,0,PAT-00735145,1,REC-5000755760,,,,"<CLINICAL INFO>
RT PLEURAL EFFUSION. Hx LUNG CA AND PNEUMONIA.
RECEIVED ARE 45 ML RED FLUID IN A SYRINGE.
<SPECIMEN(S)>
RT PLEURAL
<GROSS>
Received fresh is a syringe with approximately 45 ml of cloudy red fluid labeled with the patient's name and VC number. Two concentrated cytospins and one cell block are prepared. 
<FINAL DX>
Pleural fluid, right, concentrated cytospins and cell block: Positive for malignancy, consistent with metastatic non-small cell carcinoma. 
See comment. 
Comment: Slides from previous surgical biopsy from the right upper lobe (***PATH-NUMBER[1]) are reviewed. The malignant cells present in the pleural fluid show similar features to those malignant cells present in the lung biopsy. 
Internal consult performed by Dr. **NAME[ZZZ], who concurs with the above diagnosis.
 
<PATHOLOGIST>
**NAME[YYY XXX], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,LUNG,0,PAT-00747262,2,REC-5000757903,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Left Lung, Upper Lobe, CT-Guided Core Biopsies (5):
  Poorly differentiated pulmonary adenocarcinoma with focal squamous
differentiation (see
     diagnosis comments).

DIAGNOSIS COMMENTS:
1.  As part of our quality assurance policy for the confirmation of new
cancers, the histologic sections of the specimen have been reviewed by
another pathologist, Dr. **NAME[ZZZ M. YYY], who agrees with the
diagnosis of a poorly differentiated nonsmall cell carcinoma that is
microscopically different from the poorly differentiated adenocarcinoma
in the patient's right upper lobe bronchoscopic biopsies obtained on
**DATE[Apr 15 2012] (pathology case ***PATH-NUMBER[2]). He and I both feel that the two
carcinomas are two separate synchronous lung cancers.

2.  The carcinoma in the current left upper lobe core biopsies has an
immunophenotype of a primary lung adenocarcinoma. It contains a small
number of scattered cells with squamous differentiation. The number of
cells with squamous differentiation is too small for a diagnosis of an
adenosquamous carcinoma.

<CLINICAL INFO>
1.7 cm left upper lobe pulmonary mass in female smoker with prior right
upper lobe pulmonary adenocarcinoma. ICD-9 Code(s): 162.9

INTRAPROCEDURAL EVALUATION:
Touch imprints of first three pulmonary left upper lobe core biopsies:
""Positive for carcinoma.""
Performed by: Pathologist **NAME[XXX M. WWW], M.D.

<GROSS>
A CT-guided thin core biopsy procedure of a left upper lobe pulmonary
mass was performed by interventional radiologist Dr. **NAME[VVV UUU]. The
radiology CT staff identified the patient as ""**NAME[AAA BBB]"", birth date
**DATE[Oct 19 1941], and Dr. **NAME[UUU] indicated that the patient had a recent right
upper lobe biopsy containing cancer. Initially, three biopsies were
obtained, yielding short slivers of white-tan tissue. One
Diff-Quik-stained air-dried imprint smear was prepared from each biopsy
and all three imprint smears were immediately examined by pathologist
Dr. **NAME[XXX M. WWW], who stated that the biopsies contained a
carcinoma. Dr. **NAME[WWW] also requested additional biopsies to optimally
compare with the patient's carcinoma in the right upper lobe. Therefore,
two additional similar biopsies were obtained by Dr. **NAME[UUU], neither of
which was utilized to prepare imprint smears. All five biopsies were
fixed in formalin and submitted for histologic processing in one
cassette labeled A1.

<MICROSCOPIC>
The histologic HE sections show scant cartilage, scant benign bronchial
mucosa, and fragments of variably anthracotic reactive fibrous tissue
with chronic inflammation and admixed with a poorly differentiated
nonsmall carcinoma. The carcinoma is composed of groups of polyhedral
malignant epithelial cells that are generally medium in size but include
very few large cells. The malignant cells have well defined cell borders
and have amphophilic or eosinophilic cytoplasm. Some malignant cells
have dense eosinophilic cytoplasm and questionable intercellular bridges
but no definite keratinization is seen. In addition, no definite
malignant glands are seen. The nuclei of the malignant cells are
round-oval, variable in size, and are either very hyperchromatic or
moderately hyperchromatic. The latter nuclei have small nucleoli.
Selected immunohistochemical stains show staining results of the
malignant cells that are consistent with a pulmonary adenocarcinoma.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
p63  Focally positive
CK 5/6    Focally positive
CK7  Positive  A positive internal control is identified.
CK20 Negative
TTF-1     Positive  A positive internal control is identified.
Napsin A  Positive  A positive internal control is identified.

Impression:  Poorly differentiated adenocarcinoma with a pulmonary
immunophenotype.
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:  The adenocarcinoma contains a very small number of scattered
cells that are p63 and cytokeratin 5/6 positive.  This feature is not
quantitatively significant and is not sufficient to classify the
adenocarcinoma as an adenosquamous carcinoma.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[May 17 2012]",,,,,
REG3,LUNG,0,PAT-00096119,3,REC-5000759901,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

L1 Spinous Process Core Biopsy:
  Positive for metastatic poorly differentiated adenocarcinoma.
  IHC stains performed, see Diagnosis Comment.

<COMMENT>
The IHC staining pattern (CK7 positive, CK20 negative, CDX-2 negative)
is evidence against a colon primary.  Despite the negative TTF-1 and
negative ER, PR, and GCDFP, lung and breast remain potential sites of
primary tumor.  Correlation with clinical information and imaging
studies is recommended.

<CLINICAL INFO>
History of colon cancer. L1 spinous process mass.

INTRAPROCEDURAL EVALUATION:
Bone, L1 spinous mass (touch preps): ""Positive for carcinoma"".
Performed by: **NAME[ZZZ M. YYY], XXX], Ph.D., consult by: **NAME[WWW M].
**NAME[VVV], M.D.

<GROSS>
Received in alcohol, labeled ""**NAME[BBB, AAA]"", designated ""L1 spinous
process"", are two slides stained for rapid interpretation. Received in
formalin, labeled ""**NAME[BBB, AAA]"", designated ""L1 spinous process"", are
five 0.1 cm diameter elongated portions of tissue from 0.9-1.8 cm in
lengths. They are entirely submitted in A1.  (rkg/cm)

<MICROSCOPIC>
Two touch prep cytology slides and one section of tissue core biopsy are
examined. These show carcinoma with focal features of gland formation
and marked fibrotic stromal response.

Immunohistochemical stains are performed to further characterize the
tumor.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
CK7  Positive
CK20 Negative
TTF-1     Negative
CDX-2     Negative
ER   Negative
PR   Negative
GCDFP-15  Negative

Impression:  This pattern of IHC staining (CK7 positive, CK20 and CDX-2
negative)  is evidence against a colon primary.  Despite negative TTF-1
and ER/PR/GCDFP stains, lung and breast are still potential sites of
primary tumor.
Interpreted by:  **NAME[UUU M. TTT] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[UUU M. TTT], M.D.  Electronically signed **DATE[Sep 20 2012]",,,,,
REG3,LUNG,0,PAT-00746717,1,REC-5000764683,,,,"CASE: HS-11-03592
PATIENT: **NAME[AAA BBB]


<GROSS>
Four specimens are received, each in containers labeled ""**NAME[BBB, AAA M].""
1.  The first specimen is received without fixative for frozen section diagnosis in a container designated ""1 right upper lobe lung,"" and consists of a 207 gram right upper lung lobectomy measuring 11.4 cm from inferior to superior, 10.5 cm from right lateral to medial and 5.2 cm from anterior to posterior surface.  The bronchial margin is identified, grossly found to be free of tumor, and sampled for frozen section diagnosis (1A).  The stapled vascular margins are identified and grossly found to be free of tumor.
A palpable central lesion measures 2.7 x 2.5 x 2.0 cm.  On section the indurated and gritty black-gray lesion is retracted at the cut surface and has focal anthracotic stippling.  The stellate lesion is poorly demarcated from the adjacent uninvolved lung parenchyma and has spiculated borders.  The lesion is focally hemorrhagic, but no necrosis or central cavity is grossly identified.  The lesion abuts multiple large vessels, but no vascular invasion is grossly identified.  The corresponding pleural surface is smooth and glistening with no evidence of invasion.  The indurated mass is approximately 2.7 cm from the bronchial margin.  The lesion is 3.0 cm from a staple line at the inferoposterior aspect that grossly resembles an interlobar fissure.  The staple line is scythed away, orange inked for identification and represented in 1H.
The red-tan and glistening pleural surface has no evidence of perforation, exudate or adhesions.  Sections of the uninvolved parenchyma reveal a congested, deep red and boggy parenchyma.  The superior/apical parenchyma has extensive emphysematous change, as represented in 1I.  Two anthracotic pigmented intralobar lymph nodes range in size from 0.6 cm up to 0.7 cm, and are submitted in 1J.  One anthracotic pigmented hilar node measuring 0.4 cm in maximum surface dimension is represented in 1F.  Representative sections are submitted in ten cassettes.
Summary of section: 1A-bronchial margin (frozen section control); 1B-vascular margin; 1C and 1D-lesion with adjacent uninvolved parenchyma; 1E-lesion with closest approach to blue inked pleural surface; 1F and 1G-each has one longitudinal section of hilum; 1H-two sections of orange inked putative interlobar fissure; 1I-two sections of uninvolved parenchyma; 1J-uninvolved parenchyma with two interlobar nodes.
2.  The second specimen is received in formalin designated ""2 subcarinal lymph node,"" and consists of three ill defined and hemorrhagic fatty fragments ranging in size from 0.8 cm up to 2.1 x 1.0 cm.  The smallest fragment has a single stainless surgical clip attached, but the two smallest fragments are otherwise grossly unremarkable.  The largest fragment contains one anthracotic pigmented lymph node measuring 1.9 cm in maximum surface dimension.  The individual node is bivalved and the specimen is submitted in toto in two cassettes.
Summary of section: 2A-two small fatty fragments; 2B-largest fragment/bivalved node.
3.  The third specimen is received in formalin designated ""3 hilar lymph node,"" and consists of an ill defined and hemorrhagic fatty fragment measuring 2.1 cm in maximum surface dimension and found to contain three anthracotic pigmented lymph nodes ranging in size from 0.6 cm up to 1.5 cm.  The specimen is submitted in toto in casette three.
4.  The fourth specimen is received in formalin designated ""4 inferior pulmonary ligament lymph node,"" and consists of one tan-gray lymph node measuring 0.6 x 0.4 cm, and submitted in toto in cassette four. (**INITIALS **DATE[May 28 12])


<MICROSCOPIC>
1. First of all, in specimen one the bronchial margins are confirmed negative for tumor, as is a vascular margin.  The tumor described grossly is confirmed to be infiltrating malignant epithelial neoplasm comprising gland forming tumor.  Glands are tubular to multiacinar and sometimes the cells form more solid nests.  The neoplastic cells frequently have clear cytoplasm and nuclei are large vesicular structures varying by a factor of 4 or 5 in size and having prominent nucleoli.  Extensive necrosis and reactive fibrosis is present.  Tumor invades the wall of large pulmonary vein but does not gain access to the lumen.  Focally lymphatic space invasion is suspected.  Tumor is remote from the pleura and does not invade pleura.  With the exception of sections 1D-1E of the tumor, all of the other sections from lung and hilum are devoid of malignancy. Peribronchial lymph nodes are sampled in 1J and are negative.
2. Specimen two is sections of lymph node with no metastatic malignancy identified.
3. Specimen three is sections of lymph node with no metastatic malignancy identified.
4. Specimen four is a lymph node with no metastatic malignancy identified.
1D-1: Adenocarcinoma
1D-1: Suspected lymphatic invasion
R. Mark **NAME[ZZZ] YYY] PhD
Pathologist
Electronically signed **DATE[May 29 2012] 3:19:20PM


<FINAL DX>
1.  Right upper lobe of lung, excision:  Moderately differentiated bronchogenic adenocarcinoma.
     A.  Histologic type:  Adenocarcinoma.
     B.  Histologic grade:  Moderately differentiated.
     C.  Size of tumor:  2.7 cm.
     D.  Location of tumor:  Centrally located in right upper lobe.
     E.  Tumor focality:  Unifocal.
     F.  Tumor extension:  No adjacent structures invaded.
     G.  Vascular space invasion:  Lymphatic invasion suspected.
     H.  Visceral pleura:  Not invaded.
     I.  Margins:
          1.  Bronchial - clear.
          2.  Vascular - clear.
          3.  Parenchymal - clear.
          4.  Chest wall/other - N/A.
     J.  Lymph node status:  Multiple negative regional nodes, specimens 1-4.
     K.  Treatment effect:  N/A.
     L.  TNM classification (AJCC, 7th edition):  pT1b pN0 pMX.
2.  Subcarinal lymph node, excision:
     A.  No metastatic malignancy identified.
3.  Hilar lymph node, excision:
     A.  No metastatic malignancy identified.
4.  Inferior pulmonary lymph node, excision:
     A.  No metastatic malignancy identified.
TISSUE CODE 0
R. Mark **NAME[ZZZ], YYY] PhD
Pathologist
RMO/dp **DATE[May 29 12]
INTRAOPERATIVE CONSULTATION:
1.  Right upper lobe.  Frozen section-bronchial margins negative. (RMO)


<CLINICAL INFO>
Right lung cancer.",,,,,
REG3,LUNG,0,PAT-00749823,1,REC-5000765097,,,,"<CLINICAL INFO>
Left Pleural Effusion 
<GROSS>
1100cc amber-colored fluid, 1 liquid based slide and 1 cell block prepared.

<MICROSCOPIC SECTION>

<FINAL DX>

Pleural Fluid (Left): Final Cytology Diagnosis
MALIGNANT EPITHELIAL CELLS PRESENT.
Scattered malignant cells present in an inflammatory background, consistent with a lung adenocarcinoma by IHC (BEREP4, B72.3 and TTF1 positive).
Dr. **NAME[ZZZ] was notified of this diagnosis on **DATE[Jul 20 12] at 9:30 am.  
Specimen Adequacy
Satisfactory for interpretation.







<SPECIMEN(S)>
Pleural Fluid",,,,,
REG3,LUNG,0,PAT-00395943,2,REC-5000765118,,,,"<CLINICAL INFO>
20 pack per year history; right lung biopsy
<GROSS>


<MICROSCOPIC SECTION>

<FINAL DX>
RIGHT LUNG, CORE NEEDLE BIOPSY (***PATH-NUMBER[1]; **DATE[Dec 17 11]):
Positive for moderately differentiated adenocarcinoma; see comment.

The adenocarcinoma shows papillary features.  Immunohistochemical studies performed at the referring institution and evaluated at VMMC show that the tumor cells are positive for cytokeratin 7, TTF-1, surfactant A protein, CEA, and negative for CK20, villin, CDX2, WT-1, and thyroglobulin.  The findings are consistent with a lung primary.
In addition, by report, studies performed at US Labs demonstrate the following:
1.     Negative for ALK specific gene rearrangement.
2.     Negative for mutation of EGFR gene by PCR.




Received from:  **INSTITUTION, P.S., 409 **PLACE, WA **ZIP-CODE:
(12) Slides and Surgical Pathology report, ***PATH-NUMBER[2], **DATE[Dec 17 11] (Right lung, needle core biopsies)

Outside pathologist:  Dr. **NAME[ZZZ M. YYY]  **PHONE
<SPECIMEN(S)>
Slides, Outside",,,,,
REG3,LUNG,0,PAT-00749810,1,REC-5000765554,,,,"<CLINICAL INFO>
 **AGE[in 50s]-year-old man
  with right upper lobe mass, hemoptysis.
<SPECIMEN(S)>
 A) Bronchial Wash (RUL);B) Bronchial brush (RIGHT
  MAIN);C) Needle aspirate (SUBCARINAL NODE);D) Needle aspirate (RUL MASS
  BIOPSY)
  SPECIMEN DESCRIPTION:
  (A) 45 ML GROSSLY HEMORRHAGIC FLUID (B) 2 ML SLT HEMORRHAGIC FLUID WITH BRUSH
  (C) 10 ML SLT HEMORRHAGIC FLUID (D) 5 ML SLT HEMORRHAGIC FLUID
  CYTOPREPARATION:
  (A) 2 SMEARS (B) 2 CCF (C) 2 CCF (D) 2 CCF, 1 CELL BLOCKCYTOLOGIC IMPRESSION: A) Right upper lobe, bronchial wash:
  Cytologically malignant cells suggest non-small cell carcinoma.  See comment.
                                                                Histologic
  confirmation is required for definitive diagnosis (please see SH-11-4575)
  B) Right upper lobe, bronchial brush:  Rare cytologically malignant cells
  present.  See comment.
  C) Subcarinal lymph node, FNA:  No lymphoid component is included; non-
  diagnostic sample.  See comment.
  D) Biopsy fluid from mass:  Scant mostly necrotic highly atypical cells.  See
  comment.<DIAGNOSIS COMMENT(S)> A) 45 mls grossly hemorrhagic fluid is received from
  which two Papanicolaou-stained smears are prepared.  Slides contain markedly
  atypical cells characterized by nuclear pleomorphism, hyperchromasia,
  irregular nuclear membranes, variably prominent nucleoli, and pale staining
  cytoplasm where discernible.  The background consists of blood and pigmented
  pulmonary alveolar macrophages.  Occasional cohesive clusters of markedly
  atypical cells are noted most consistent with non-small cell carcinoma.
  Histologic confirmation is required for definitive diagnosis; please refer to
  the concurrent forceps biopsy results (SH-11-4575).
  B) 2 ml of slightly hemorrhagic fluid is received from with bronchial brush
  from which two Papanicolaou-stained cytocentrifuged slides are prepared.  Rare
  atypical cells are present.  Atypical cells have high nuclear-to-cytoplasmic
  ratios, hyperchromasia, and irregular nuclear contours.  The atypical cells
  are suggestive of malignancy.
  C) 10 ml of slightly hemorrhagic fluid is received from which 5 ml is sent for
  flow cytometric analysis; the remaining fluid is then cytocentrifuged and
  Papanicolaou-stained.  Slides contain very scant, air-dried cells suggestive
  of macrophages.  No lymphoid component is identified.  Please see the
  concurrent flow cytometry report (***PATH-NUMBER[1]) which revealed no abnormal B- or
  T-cell population.
  D) 5 mls slightly hemorrhagic fluid is received from which two Papanicolaou-
  stained cytocentrifuged slides and one hematoxylin- and eosin-stained slide
  are prepared.  Slides contain morphologically similar highly atypical cells as
  noted in part A that are associated with necrosis.  The cell block is
  acellular.
  MS/mlb",,,,,
REG3,LUNG,0,PAT-00749526,1,REC-5000766191,,,,"<CLINICAL INFO>
 Stage 4 non-small
  cell lung cancer (adenocarcinoma).  Cytology sent for EGFR and ALK mutation
  testing.<DIAGNOSIS COMMENT(S)> 200 mls dark yellow fluid is received from which 1000 mls
  are spun to prepare two Papanicolaou-stained smears and one cell block with
  hematoxylin and eosin stained slide.  The slides contain highly atypical
  groups of epithelioid cells with high nuclear to cytoplasmic ratios, irregular
  nuclear outlines, and hyperchromatic, large pleomorphic nuclei with ample pale
  staining cytoplasm.  The cell block consists of clusters of malignant cells
  with high-grade cytology, consistent with the patient's history of poorly
  differentiated adenocarcinoma.  Unstained slides are sent to the Genetics
  Laboratory at the **INSTITUTION for EGFR and ALK fish mutational
  analysis; results will be issued in an addendum report.
  **INITIALS
<SPECIMEN(S)>
 A) Pleural Fluid (RIGHT)
  SPECIMEN DESCRIPTION:
  1200 ML DARK YELLOW FLUID
  CYTOPREPARATION:
  2 SMEARS,1 CELL BLOCKCYTOLOGIC IMPRESSION:
  Right pleural effusion:  Positive for malignancy.  See comment.",,,,,
REG3,LUNG,0,PAT-00750826,1,REC-5000767435,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Left Paratracheal, Fine Needle Aspiration:
Positive for malignancy.
Adenocarcinoma, consistent with pulmonary primary.

B.  Subcarinal, Fine Needle Aspiration:
Positive for malignancy.

C.  Right Bronchoalveolar Lavage (BAL):
Positive for malignancy (rare positive cells).

<COMMENT>
Flow cytometry is judged noncontributory and not performed.

<CLINICAL INFO>
ILD.

INTRAPROCEDURAL EVALUATION:
A.  Left paratracheal FNA (touch preps): Pass #1: ""Predominantly
bronchial epithelium"". Pass #2: ""Nonsmall cell malignancy"".
Performed by: **NAME[ZZZ M. YYY], M.D. on **DATE[Mar 29 2012] at 8:10 AM (pass #1),
8:12 AM (pass #2).

<GROSS>
A.  A specimen labeled ""**NAME[BBB, AAA]"", and designated ""left paratracheal
FNA"" per requisition, is received in 20 ml of CytoLyt collection fluid
on **DATE[Mar 29 2012]. Prepared is one cell block. Also received on **DATE[Mar 29 2012]
are three alcohol-fixed direct smears labeled ""**NAME[BBB, M]"", and designated
""left paratracheal FNA"" per requisition. The alcohol-fixed smears are
Papanicolaou-stained. Four air-dried smears were kept in Olympia.

B.  A specimen labeled ""**NAME[BBB, AAA]"", and designated ""subcarinal FNA""
per requisition, is received in 10 ml of CytoLyt collection fluid on
**DATE[Mar 29 2012]. Prepared are one cell block and one alcohol-fixed
cytocentrifuged Papanicolaou-stained slide. Also received on **DATE[Mar 29 2012]
are two alcohol-fixed direct smears and two air-dried direct smears,
labeled ""**NAME[BBB, M]"", and designated ""subcarinal FNA"" per requisition. The
alcohol-fixed smears are Papanicolaou-stained and the air-dried smears
are Diff-Quik-stained.

C.  Received on **DATE[Mar 29 2012] is 4 ml of colorless mucoid fluid labeled
""**NAME[BBB, AAA]"", and designated ""right BAL"" per requisition. Prepared are
one air-dried cytocentrifuged Diff-Quik-stained slide and one ThinPrep
Papanicolaou-stained slide. (lw/nd)

D.  A portion of the specimen from part B is submitted for flow
cytometric analysis - ""Hold for flow"".

<MICROSCOPIC>
A.  Direct smears and a cell block are reviewed.

B.  Direct smears, a cytocentrifuged, and a cell block are reviewed.

C.  A monolayer prep and cytocentrifuged are reviewed.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
TTF-1     Positive
p63  Negative

Impression:
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[VVV UUU], M.D.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Apr 03 2012]",,,,,
REG3,LUNG,0,PAT-00746579,1,REC-5000767915,,,,"<CLINICAL INFO>
 Patient to be seen by Dr **NAME[ZZZ YYY] on **DATE[Jul 14 2012].<FINAL DX>
 **PLACE, WA; ***PATH-NUMBER[1]
  (**DATE[Jun 5 2012])
  Lung, right upper lobe, CT-guided needle core biopsies: Poorly differentiated
  carcinoma. See Comment.
  **PLACE, WA; ***PATH-NUMBER[2] (**DATE[Jun 25 2012])
  Lymph node, precarinal, endobronchial ultrasound-guided FNA (part A): No
  definite carcinoma; lymphoid cells and rare epithelial cells consistent with
  contaminate from bronchial lining cells.
  Lymph node, 4R, 4L, 4R-B, level 7 and precarinal, biopsies (part B-F):
  Multiple lymph node fragments with no carcinoma identified.<DIAGNOSIS COMMENT(S)> Fragments of scar and lung tissue are infiltrated by
  poorly diffentiated carcinoma forming nests and single cells without specific
  glandular or squamous differentiation. Immunohistochemistry performed at
  Cellnetix and reviewed at UWMC demonstrates diffuse expression of CK7 by the
  neoplastic cells (confirming epithelial differentiation). No immunoreactivity
  for P63, Napsin A, TTF-1, CK20 and CDX2 is identified. The immunohistochemical
  profile is consistent with a poorly differentiated carcinoma and is not
  specific for site but is certainly consistent with lung origin.
  The FNA from the precarinal lymph node contains rare epithelial cells which
  are interpreted as contaminate although it is difficult to exclude metastatic
  caricnoma; clinical correlation is recommended.
  Procedures used to establish the diagnosis:
  RoutineMATERIALS RECEIVED:
  Label Consult Accession No Blocks/Slides Description
   A ***PATH-NUMBER[3]  0B,11S  Lung
   B ***PATH-NUMBER[4]  0B,20S  Lymph Nodes",,,,,
REG3,LUNG,0,PAT-00747023,1,REC-5000768400,,,,"<CLINICAL INFO>
 Presumed left lung cancer with prominent left
  supraclavicular lymph node.  IHC and histology including ALK and EGFR testing<CLINICAL INFO>
 Presumed left lung cancer with prominent left
  supraclavicular lymph node.  IHC and histology including ALK and EGFR testing<CLINICAL INFO>
 Presumed left lung cancer with prominent left
  supraclavicular lymph node.  IHC and histology including ALK and EGFR testing<CLINICAL INFO>
 Presumed left lung cancer with prominent left
  supraclavicular lymph node.  IHC and histology including ALK and EGFR testing<FINAL DX>
 A)  Left supraclavicular lymph node, biopsy:
  Moderate to poorly differentiated squamous cell carcinoma involving fibrotic
  tissue.  See comment.<FINAL DX>
 A)  Left supraclavicular lymph node, biopsy:
  Moderate to poorly differentiated squamous cell carcinoma involving fibrotic
  tissue.  See comment.<FINAL DX>
 A)  Left supraclavicular lymph node, biopsy:
  Moderate to poorly differentiated squamous cell carcinoma involving fibrotic
  tissue.  See comment.<FINAL DX>
 A)  Left supraclavicular lymph node, biopsy:
  Moderate to poorly differentiated squamous cell carcinoma involving fibrotic
  tissue.  See comment.<DIAGNOSIS COMMENT(S)> Results were discussed with Dr. **NAME[ZZZ YYY] who agrees that
  ALK and EGFR are not indicated given the clearly squamous growth pattern.
  Procedures used to establish the diagnosis:
  Routine<DIAGNOSIS COMMENT(S)> Results were discussed with Dr. **NAME[ZZZ YYY] who agrees that
  ALK and EGFR are not indicated given the clearly squamous growth pattern.
  Procedures used to establish the diagnosis:
  Routine<DIAGNOSIS COMMENT(S)> Results were discussed with Dr. **NAME[ZZZ YYY] who agrees that
  ALK and EGFR are not indicated given the clearly squamous growth pattern.
  Procedures used to establish the diagnosis:
  Routine<DIAGNOSIS COMMENT(S)> Results were discussed with Dr. **NAME[ZZZ YYY] who agrees that
  ALK and EGFR are not indicated given the clearly squamous growth pattern.
  Procedures used to establish the diagnosis:
  RoutineADDENDUM REASON:   This addendum is to report results of EGFR
  sequencing analysis.
  EGFR Results:  Negative for mutations in exons 18 to 21
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for mutations in exons 18,
  19, 20, and 21 of the EGFR gene, which together account for about 99% of the
  somatic mutations in the EGFR gene in patients with lung cancer. This test can
  normally detect a heterozygous mutation present in more than 20% to 40% of the
  cells in the specimen.  
  For further information on test methods and interpretation, see
  **WEB-LOC call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON:   This addendum is to report results of EGFR
  sequencing analysis.
  EGFR Results:  Negative for mutations in exons 18 to 21
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for mutations in exons 18,
  19, 20, and 21 of the EGFR gene, which together account for about 99% of the
  somatic mutations in the EGFR gene in patients with lung cancer. This test can
  normally detect a heterozygous mutation present in more than 20% to 40% of the
  cells in the specimen.  
  For further information on test methods and interpretation, see
  **WEB-LOC call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON:   This addendum is to report results of EGFR
  sequencing analysis.
  EGFR Results:  Negative for mutations in exons 18 to 21
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for mutations in exons 18,
  19, 20, and 21 of the EGFR gene, which together account for about 99% of the
  somatic mutations in the EGFR gene in patients with lung cancer. This test can
  normally detect a heterozygous mutation present in more than 20% to 40% of the
  cells in the specimen.  
  For further information on test methods and interpretation, see
  **WEB-LOC call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON:   This addendum is to report results of EGFR
  sequencing analysis.
  EGFR Results:  Negative for mutations in exons 18 to 21
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for mutations in exons 18,
  19, 20, and 21 of the EGFR gene, which together account for about 99% of the
  somatic mutations in the EGFR gene in patients with lung cancer. This test can
  normally detect a heterozygous mutation present in more than 20% to 40% of the
  cells in the specimen.  
  For further information on test methods and interpretation, see
  **WEB-LOC call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON: This addendum is issued to report the results of
  ALK FISH testing.
  FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS:
  (Interpreted by: **NAME[QQQ PPP] VVV], PhD)
  Deparaffinized sections from the indicated specimen and control tissues are
  hybridized with the ALK Break Apart Rearrangement Probe kit (Vysis LSI; **PLACE, IL), following the manufacturers directions.  The kit
  includes two FISH DNA probes. The first probe, an ~250 kb probe for the
  telomeric (3') side of the ALK breakpoint is labeled in SpectrumOrange .  A
  second probe, labeled in SpectrumGreen , is approximately ~300kb in length and
  lies centromeric (5') to the breakpoint. Fifty interphase signals are scored. 
  FISH-positive occurrences are defined as greater than 10% of tumor cells with
  split signals.
  Block (Original Label): A
  Population: Neoplastic cells

  Sample % Split-Apart Signals Special Notes/Comments
  Negative Control 0
  Positive Control 22
  ALK Sample 0
  Chromosomal rearrangements involving the ALK gene are characteristic of
  anaplastic large cell lymphoma and have also been reported in other tumors,
  including a minority of adenocarcinomas arising in lung, breast and colon
  (1,2).  Disruption of the ALK gene, as detected by this assay, is consistent
  with a chromosomal translocation or rearrangement involving ALK at 2p23, but
  does not identify the specific partner gene.
  1. Amin HM; Lai R.  Blood. 2007 **DATE[Apr 02];**ID-NUM. Epub 2007 **DATE[Nov 22].
  2. **NAME[OOO M, NNN M, MMM M, LLL M, KKK] CS, **NAME[JJJ M, III M, HHH] J,
  Modrusan Z.  Mol Cancer Res. 2009 **DATE[Mar];**ID-NUM.ADDENDUM REASON: This addendum is issued to report the results of
  ALK FISH testing.
  FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS:
  (Interpreted by: **NAME[QQQ PPP] VVV], PhD)
  Deparaffinized sections from the indicated specimen and control tissues are
  hybridized with the ALK Break Apart Rearrangement Probe kit (Vysis LSI; **PLACE, IL), following the manufacturers directions.  The kit
  includes two FISH DNA probes. The first probe, an ~250 kb probe for the
  telomeric (3') side of the ALK breakpoint is labeled in SpectrumOrange .  A
  second probe, labeled in SpectrumGreen , is approximately ~300kb in length and
  lies centromeric (5') to the breakpoint. Fifty interphase signals are scored. 
  FISH-positive occurrences are defined as greater than 10% of tumor cells with
  split signals.
  Block (Original Label): A
  Population: Neoplastic cells

  Sample % Split-Apart Signals Special Notes/Comments
  Negative Control 0
  Positive Control 22
  ALK Sample 0
  Chromosomal rearrangements involving the ALK gene are characteristic of
  anaplastic large cell lymphoma and have also been reported in other tumors,
  including a minority of adenocarcinomas arising in lung, breast and colon
  (1,2).  Disruption of the ALK gene, as detected by this assay, is consistent
  with a chromosomal translocation or rearrangement involving ALK at 2p23, but
  does not identify the specific partner gene.
  1. Amin HM; Lai R.  Blood. 2007 **DATE[Apr 02];**ID-NUM. Epub 2007 **DATE[Nov 22].
  2. **NAME[OOO M, NNN M, MMM M, LLL M, KKK] CS, **NAME[JJJ M, III M, HHH] J,
  Modrusan Z.  Mol Cancer Res. 2009 **DATE[Mar];**ID-NUM.ADDENDUM REASON: This addendum is issued to report the results of
  ALK FISH testing.
  FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS:
  (Interpreted by: **NAME[QQQ PPP] VVV], PhD)
  Deparaffinized sections from the indicated specimen and control tissues are
  hybridized with the ALK Break Apart Rearrangement Probe kit (Vysis LSI; **PLACE, IL), following the manufacturers directions.  The kit
  includes two FISH DNA probes. The first probe, an ~250 kb probe for the
  telomeric (3') side of the ALK breakpoint is labeled in SpectrumOrange .  A
  second probe, labeled in SpectrumGreen , is approximately ~300kb in length and
  lies centromeric (5') to the breakpoint. Fifty interphase signals are scored. 
  FISH-positive occurrences are defined as greater than 10% of tumor cells with
  split signals.
  Block (Original Label): A
  Population: Neoplastic cells

  Sample % Split-Apart Signals Special Notes/Comments
  Negative Control 0
  Positive Control 22
  ALK Sample 0
  Chromosomal rearrangements involving the ALK gene are characteristic of
  anaplastic large cell lymphoma and have also been reported in other tumors,
  including a minority of adenocarcinomas arising in lung, breast and colon
  (1,2).  Disruption of the ALK gene, as detected by this assay, is consistent
  with a chromosomal translocation or rearrangement involving ALK at 2p23, but
  does not identify the specific partner gene.
  1. Amin HM; Lai R.  Blood. 2007 **DATE[Apr 02];**ID-NUM. Epub 2007 **DATE[Nov 22].
  2. **NAME[OOO M, NNN M, MMM M, LLL M, KKK] CS, **NAME[JJJ M, III M, HHH] J,
  Modrusan Z.  Mol Cancer Res. 2009 **DATE[Mar];**ID-NUM.ADDENDUM REASON: This addendum is issued to report the results of
  ALK FISH testing.
  FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS:
  (Interpreted by: **NAME[QQQ PPP] VVV], PhD)
  Deparaffinized sections from the indicated specimen and control tissues are
  hybridized with the ALK Break Apart Rearrangement Probe kit (Vysis LSI; **PLACE, IL), following the manufacturers directions.  The kit
  includes two FISH DNA probes. The first probe, an ~250 kb probe for the
  telomeric (3') side of the ALK breakpoint is labeled in SpectrumOrange .  A
  second probe, labeled in SpectrumGreen , is approximately ~300kb in length and
  lies centromeric (5') to the breakpoint. Fifty interphase signals are scored. 
  FISH-positive occurrences are defined as greater than 10% of tumor cells with
  split signals.
  Block (Original Label): A
  Population: Neoplastic cells

  Sample % Split-Apart Signals Special Notes/Comments
  Negative Control 0
  Positive Control 22
  ALK Sample 0
  Chromosomal rearrangements involving the ALK gene are characteristic of
  anaplastic large cell lymphoma and have also been reported in other tumors,
  including a minority of adenocarcinomas arising in lung, breast and colon
  (1,2).  Disruption of the ALK gene, as detected by this assay, is consistent
  with a chromosomal translocation or rearrangement involving ALK at 2p23, but
  does not identify the specific partner gene.
  1. Amin HM; Lai R.  Blood. 2007 **DATE[Apr 02];**ID-NUM. Epub 2007 **DATE[Nov 22].
  2. **NAME[OOO M, NNN M, MMM M, LLL M, KKK] CS, **NAME[JJJ M, III M, HHH] J,
  Modrusan Z.  Mol Cancer Res. 2009 **DATE[Mar];**ID-NUM.ADDENDUM REASON:   This addendum is to report results of EGFR
  mutational analysis.
  EGFR Results: NEGATIVE for L858R mutation and exon 19 deletions
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for the L858R mutation in
  exon 21 and for deletion mutations in exon 19 of the EGFR gene, which together
  account for about 90% of the somatic mutations in the EGFR gene in patients
  with lung cancer. If clinically indicated, DNA sequence analysis can be
  performed separately to detect other rare mutations in the EGFR gene. This
  test can normally detect a heterozygous mutation when it is present in more
  than about 10% (for L858R) or 2% (for deletions) of the cells in the sample.
  For further information on test methods and interpretation, see
  **WEB-LOC or call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON:   This addendum is to report results of EGFR
  mutational analysis.
  EGFR Results: NEGATIVE for L858R mutation and exon 19 deletions
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for the L858R mutation in
  exon 21 and for deletion mutations in exon 19 of the EGFR gene, which together
  account for about 90% of the somatic mutations in the EGFR gene in patients
  with lung cancer. If clinically indicated, DNA sequence analysis can be
  performed separately to detect other rare mutations in the EGFR gene. This
  test can normally detect a heterozygous mutation when it is present in more
  than about 10% (for L858R) or 2% (for deletions) of the cells in the sample.
  For further information on test methods and interpretation, see
  **WEB-LOC or call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON:   This addendum is to report results of EGFR
  mutational analysis.
  EGFR Results: NEGATIVE for L858R mutation and exon 19 deletions
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for the L858R mutation in
  exon 21 and for deletion mutations in exon 19 of the EGFR gene, which together
  account for about 90% of the somatic mutations in the EGFR gene in patients
  with lung cancer. If clinically indicated, DNA sequence analysis can be
  performed separately to detect other rare mutations in the EGFR gene. This
  test can normally detect a heterozygous mutation when it is present in more
  than about 10% (for L858R) or 2% (for deletions) of the cells in the sample.
  For further information on test methods and interpretation, see
  **WEB-LOC or call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.ADDENDUM REASON:   This addendum is to report results of EGFR
  mutational analysis.
  EGFR Results: NEGATIVE for L858R mutation and exon 19 deletions
  Block tested: A1
  EGFR Interpretation:  The sample tested is negative for the L858R mutation in
  exon 21 and for deletion mutations in exon 19 of the EGFR gene, which together
  account for about 90% of the somatic mutations in the EGFR gene in patients
  with lung cancer. If clinically indicated, DNA sequence analysis can be
  performed separately to detect other rare mutations in the EGFR gene. This
  test can normally detect a heterozygous mutation when it is present in more
  than about 10% (for L858R) or 2% (for deletions) of the cells in the sample.
  For further information on test methods and interpretation, see
  **WEB-LOC or call lab at **PHONE. Test results
  reviewed by **NAME[XXX WWW], VVV], PhD, **NAME[UUU TTT], PhD, or **NAME[SSS RRR],
  **NAME[VVV], PhD, Laboratory Directors.<GROSS>
 A) Received in formalin labeled ""**NAME[BBB, AAA]"",
  designated ""left supraclavicular lymph node x 3"" are multiple gray-tan to pink
  cores and core-like fragments of soft tissue ranging from <0.1 to 0.8 cm in
  length.  The specimen is wrapped and submitted in toto in cassette A1.
  (**INITIALS)<GROSS>
 A) Received in formalin labeled ""**NAME[BBB, AAA]"",
  designated ""left supraclavicular lymph node x 3"" are multiple gray-tan to pink
  cores and core-like fragments of soft tissue ranging from <0.1 to 0.8 cm in
  length.  The specimen is wrapped and submitted in toto in cassette A1.
  (**INITIALS)<GROSS>
 A) Received in formalin labeled ""**NAME[BBB, AAA]"",
  designated ""left supraclavicular lymph node x 3"" are multiple gray-tan to pink
  cores and core-like fragments of soft tissue ranging from <0.1 to 0.8 cm in
  length.  The specimen is wrapped and submitted in toto in cassette A1.
  (**INITIALS)<GROSS>
 A) Received in formalin labeled ""**NAME[BBB, AAA]"",
  designated ""left supraclavicular lymph node x 3"" are multiple gray-tan to pink
  cores and core-like fragments of soft tissue ranging from <0.1 to 0.8 cm in
  length.  The specimen is wrapped and submitted in toto in cassette A1.
  (**INITIALS)NOTE:   The performance characteristics of the FISH studies cited
  in this report were determined by the Immunohistochemistry Laboratory at the
  **INSTITUTION, as part of
  an ongoing quality assurance program and in compliance with federally mandated
  regulations drawn from the Clinical Laboratory Improvement Amendments of 1988
  (CLIA  88).  FISH tests may rely on the use of ""analyte specific reagents"" and
  are subject to specific labeling requirements by the US Food and Drug
  Administration.  Such diagnostic tests may only be performed in a facility
  that is certified by the Centers for Medicare and Medicaid Services (formerly
  HCFA) as a high complexity laboratory under CLIA  88.  These tests need not be
  cleared or approved by the FDA prior to their use.  Nevertheless, federal
  rules concerning the medical use of analyte specific reagents require that the
  following disclaimer be attached to this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.
  FISH INTERPRETATION:
  There is no evidence of translocation or rearrangement of the ALK gene.  The
  above diagnosis is otherwise unchanged.NOTE:   The performance characteristics of the FISH studies cited
  in this report were determined by the Immunohistochemistry Laboratory at the
  **INSTITUTION, as part of
  an ongoing quality assurance program and in compliance with federally mandated
  regulations drawn from the Clinical Laboratory Improvement Amendments of 1988
  (CLIA  88).  FISH tests may rely on the use of ""analyte specific reagents"" and
  are subject to specific labeling requirements by the US Food and Drug
  Administration.  Such diagnostic tests may only be performed in a facility
  that is certified by the Centers for Medicare and Medicaid Services (formerly
  HCFA) as a high complexity laboratory under CLIA  88.  These tests need not be
  cleared or approved by the FDA prior to their use.  Nevertheless, federal
  rules concerning the medical use of analyte specific reagents require that the
  following disclaimer be attached to this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.
  FISH INTERPRETATION:
  There is no evidence of translocation or rearrangement of the ALK gene.  The
  above diagnosis is otherwise unchanged.NOTE:   The performance characteristics of the FISH studies cited
  in this report were determined by the Immunohistochemistry Laboratory at the
  **INSTITUTION, as part of
  an ongoing quality assurance program and in compliance with federally mandated
  regulations drawn from the Clinical Laboratory Improvement Amendments of 1988
  (CLIA  88).  FISH tests may rely on the use of ""analyte specific reagents"" and
  are subject to specific labeling requirements by the US Food and Drug
  Administration.  Such diagnostic tests may only be performed in a facility
  that is certified by the Centers for Medicare and Medicaid Services (formerly
  HCFA) as a high complexity laboratory under CLIA  88.  These tests need not be
  cleared or approved by the FDA prior to their use.  Nevertheless, federal
  rules concerning the medical use of analyte specific reagents require that the
  following disclaimer be attached to this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.
  FISH INTERPRETATION:
  There is no evidence of translocation or rearrangement of the ALK gene.  The
  above diagnosis is otherwise unchanged.NOTE:   The performance characteristics of the FISH studies cited
  in this report were determined by the Immunohistochemistry Laboratory at the
  **INSTITUTION, as part of
  an ongoing quality assurance program and in compliance with federally mandated
  regulations drawn from the Clinical Laboratory Improvement Amendments of 1988
  (CLIA  88).  FISH tests may rely on the use of ""analyte specific reagents"" and
  are subject to specific labeling requirements by the US Food and Drug
  Administration.  Such diagnostic tests may only be performed in a facility
  that is certified by the Centers for Medicare and Medicaid Services (formerly
  HCFA) as a high complexity laboratory under CLIA  88.  These tests need not be
  cleared or approved by the FDA prior to their use.  Nevertheless, federal
  rules concerning the medical use of analyte specific reagents require that the
  following disclaimer be attached to this report.
  This test was developed and its performance characteristics determined by the
  Immunohistochemistry Laboratory of the **INSTITUTION.  It has not been cleared or approved by the
  U. S. Food and Drug Administration.
  FISH INTERPRETATION:
  There is no evidence of translocation or rearrangement of the ALK gene.  The
  above diagnosis is otherwise unchanged.",,,,,
REG3,LUNG,0,PAT-00749287,1,REC-5000768459,,,,"PART / DESCRIPTION - SEQ# 
Lung, Fine Needle Aspiration/ LUNG MASS- 1<MICROSCOPIC>
LUNG MASS: 
A smear, ThinPrep, and two slides of cell core are examined. The smear shows adequate cellularity. The ThinPrep slide shows cohesive groups of non-small cells having uniform nuclear features. The cell block slides show cores of tissue largely effaced by an adenocarcinoma with a lipidic growth pattern, invasive component cannot be excluded. Immunohistochemistry performed by Laboratories Northwest shows the lesional cells expressing cytokeratin 7 and TTF-1 and not expressing cytokeratin 20. The immunohistochemical profile is consistent with a pulmonary adenocarcinoma. This case was reviewed by Dr. **NAME[ZZZ] who agrees with the diagnosis. 



NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.<CLINICAL INFO>
Abnormal finding of lung field.<FINAL DX>

LUNG MASS, FINE NEEDLE ASPIRATION: ADENOCARCINOMA WITH LIPIDIC PATTERN, INVASIVE COMPONENT CANNOT BE EXCLUDED. 
SJI:cr<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONE<GROSS>
LUNG MASS: 
(ll) Identified as **NAME[AAA BBB] and designated ""lung mass."" Received is one slide and material in formalin from which one ThinPrep slide and a cell block are prepared for cytologic examination.PATHOLOGIST:
Insalaco S J",,,,,
REG3,LUNG,0,PAT-00749803,2,REC-5000768576,,,,"PART / DESCRIPTION - SEQ# 
aspiration, other/ STATION 4 R- 4
PART / DESCRIPTION - SEQ# 
aspiration, other/ STATION 7- 2
PART / DESCRIPTION - SEQ# 
Biopsy, NOS/ RIGHT UPPER LOBE- 1
PART / DESCRIPTION - SEQ# 
aspiration, other/ STATION 10 R- 3Addendum Diagnosis
NONE<ADDENDUM COMMENTS>
#2
Real time PCR performed at PhenoPath Laboratories was negative for an EGFR mutation. Reference is made to the PhenoPath consultation report (***PATH-NUMBER[1]).
(**INITIALS **DATE[Sep 28 2012])
____________________________________________________________________________________

<ADDENDUM COMMENTS>
#1
Florescence in situ hybridization (FISH) performed at PhenoPath Laboratories was negative for a translocation involving the ALK-gene. Reference is made to the PhenoPath consultation report (***PATH-NUMBER[2]).
(**INITIALS **DATE[Sep 26 2012])<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
NONEComment
This case was reviewed by Dr. **NAME[ZZZ], who agrees with the diagnosis.<FINAL DX>

1) RIGHT LOWER LOBE OF THE LUNG BRONCHIAL BIOPSY: POORLY DIFFERENTIATED ADENOCARCINOMA. 

2) STATION 7 FINE NEEDLE ASPIRATION BIOPSY: POSITIVE FOR MALIGNANT TUMOR CELLS CONSISTENT WITH POORLY DIFFERENTIATED ADENOCARCINOMA. 

3) STATION 10 R FINE NEEDLE ASPIRATION BIOPSY: POSITIVE FOR MALIGNANT TUMOR CELLS CONSISTENT WITH POORLY DIFFERENTIATED ADENOCARCINOMA. 

4) STATION 4 R FINE NEEDLE ASPIRATION BIOPSY: POSITIVE FOR MALIGNANT TUMOR CELLS CONSISTENT WITH POORLY DIFFERENTIATED ADENOCARCINOMA OF THE LUNG. 
RRR:cr<MICROSCOPIC>
PART 1: RIGHT UPPER LOBE 
The bronchial mucosa is denuded. Within the lamina propria there are nests of large polygonal neoplastic epithelial cells with anaplastic nuclei containing coarse darkly staining chromatin. Some contain prominent nucleoli. 
 
PART 2: STATION 7 
Examination of a single Pap stained ThinPrep and two H&E stained sections of cell block prepared from a station 7 fine needle aspiration biopsy shows loosely cohesive clusters of large neoplastic epithelial cells with the same cytologic features as those described above in part 1. 
 
PART 3: STATION 10 R 
Examination of a single Pap stained ThinPrep and two H&E stained sections of cell block prepared from a station 10 R fine needle aspiration biopsy shows loosely cohesive clusters of large neoplastic epithelial cells with the same cytologic features as those described above in part 1. 
 
PART 4: STATION 4 R 
Examination of a single Pap stained ThinPrep and two H&E stained sections of cell block prepared from a station 4 R fine needle aspiration biopsy shows loosely cohesive clusters of large neoplastic epithelial cells with the same cytologic features as those described above in part 1. 

IMMUNOHISTOCHEMICAL DATA:
Immunohistochemistries performed at Laboratories Northwest showed the following: 
 Antibodies Specific To:  Results: Cytokeratin 5/6   Negative Cytokeratin 7     Strongly positive Cytokeratin 20    Negative p63     Rare cells positive CEA     Diffusely positive TTF-1     Strongly positive 

All controls showed the expected positive results. The morphologic and immunophenotypic features of these malignant tumor cells are most consistent with a poorly differentiated adenocarcinoma of the lung. 



NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.<CLINICAL INFO>
Lung mass.<GROSS>
PART 1: RIGHT UPPER LOBE 
(GF:ab) Received in formalin labeled """"**NAME[AAA BBB],"""" designated """"right upper lobe lung biopsy,"""" is a 0.2 cm yellow-tan soft tissue fragment accompanied by friable filmy pale-tan mucoid tissue. Wrapped and entirely submitted in cassette 1a.
 
PART 2: STATION 7
(ll) Identified as **NAME[AAA BBB] and designated """"station 7."""" Received is material in formalin from which one ThinPrep slide and a cell block are prepared for cytologic examination. 
 
PART 3: STATION 10 R 
(ll) Identified as **NAME[AAA BBB] and designated """"station 10R."""" Received is material in formalin from which one ThinPrep slide and a cell block are prepared for cytologic examination. 
 
PART 4: STATION 4 R 
(ll) Identified as **NAME[AAA BBB] and designated """"station 4R."""" Received is material in formalin from which one ThinPrep slide and a cell block are prepared for cytologic examination.PATHOLOGIST:
**NAME[YYY XXX]",,,,,
REG3,LUNG,0,PAT-00750817,1,REC-5000769388,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Sputum:
Negative for malignancy.

<CLINICAL INFO>
GI bleed; PNA; anemia; lung CA.

<GROSS>
Received on **DATE[Aug 03 2012] is 2 ml of pale yellow mucoid fluid labeled
""**NAME[BBB, AAA]"", and designated ""sputum"" per requisition. Prepared is
one ThinPrep Papanicolaou-stained slide. (lw/nd)

<MICROSCOPIC>
A monolayer prep is reviewed. Macrophages are present.

INTRADEPARTMENTAL CONSULTATION:
**NAME[M. ZZZ YYY], M.D.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Aug 04 2012]",,,,,
REG3,LUNG,0,PAT-00749724,1,REC-5000769642,,,,"PART / DESCRIPTION - SEQ 
Lymph Node, Fine Needle Aspiration/ STATION 7 LYMPH NODE TBNA, FLUID AND SMEARS- B
PART / DESCRIPTION - SEQ 
Lung Bx/ RIGHT LOWER LOBE BIOPSIES- D
PART / DESCRIPTION - SEQ 
Lymph Node, Fine Needle Aspiration/ 4 R LYMPH NODE TBNA, FLUID AND SMEARS- A
PART / DESCRIPTION - SEQ 
Bronchial Washings-Cytology/ RIGHT LOWER LOBE BAL- C
INTERPRETATION:

Sent to LabCorp for EGFR by FISH, EGFR-Mutation, and Abbot ALK by FISH.
PHYSICIAN NOTIFICATION:
Telephone preliminary results to Dr. **NAME[ZZZ], **DATE[Mar 13 2012], 10:15 a.m.
DIAGNOSIS COMMENTS:
Immunohistochemical studies are performed on both parts B and D (station 7 lymph node transbronchial needle aspiration and right lower lobe endobronchial biopsies), and the tumor cells are uniformly positive for TTF-1 and Napsin A, and negative for CK5/6 and P63. This immunoprofile supports the histologic impression of adenocarcinoma.Consult
**NAME[YYY M. XXX], MD
FINAL DX:

a. 4R lymph node, transbronchial needle aspiration (smears and cell block reviewed):
-Positive for malignant cells, consistent with non-small cell carcinoma (adenocarcinoma).

b. Station 7 lymph node, transbronchial needle aspiration (smears and cell block sections reviewed):
-Positive for malignant cells, consistent with non-small cell carcinoma (adenocarcinoma).

c. Right lower lobe, lung, lavage (one ThinPrep slide and cell block sections reviewed):
-Positive for malignant cells, consistent with non-small cell carcinoma (adenocarcinoma).

d. Lung, right lower lobe, endobronchial biopsies:
-Fragments of bronchial mucosa admixed with blood and fibrin showing focal non-small cell
 carcinoma (adenocarcinoma); please see comment. 
-Focal erosion with associated acute and chronic inflammation.
INTRAOPERATIVE DX:
A. 4R lymph node, fine needle aspiration (immediate interpretation of one smear): Numerous bronchial epithelial cells and a few scattered atypical cells, significance uncertain. 
B. Station 7 lymph node, fine needle aspiration (immediate interpretation of three smears): Atypical cells present admixed with numerous bronchial epithelial cells and lymphocytes, suspicious for non- small cell carcinoma.

Consultation: **NAME[YYY M. XXX], M.D.
MICROSCOPIC:
Part A - One wet-fixed smear, one fast-stained smear and cell block sections are reviewed. The aspiration contains numerous bronchial epithelial cells, many ciliated. Scattered within are clusters of atypical epithelial cells with relatively fine nuclear chromatin, round and smooth nuclear membrane and conspicuous nucleoli. Occasional large atypical cells with more clumpy chromatin and prominent nucleoli are focally present. These cells are consistent with non-small cell carcinoma. 

Part B - Three wet-fixed smears, three fast-stained smears and cell block sections are reviewed. The aspiration is cellular and contains many clusters and individually scattered malignant epithelial cells, some with nuclear hyperchromasia, irregular nuclear membranes and prominent nucleoli, consistent with non-small cell carcinoma. Numerous ciliated bronchial epithelial cells and a moderate number of lymphocytes are present in the background. 

Part C - One ThinPrep slide and cell block sections are reviewed. The ThinPrep slide is hypocellular, while the cell block sections show rare clusters of atypical epithelial cells with large hyperchromatic and vesicular nuclei and occasionally prominent nucleoli; the later are consistent with rare groups of non-small cell carcinoma.

Parts B and D:
Immunohistochemistry Study:
Deparaffinized sections of formalin-fixed tissue and the appropriate controls are incubated with a panel of antibodies. Localization is via one or all of the following three systems: Alkaline Phosphatase multimer-based method, indirect biotin streptavidin immunoperoxidase method, and biotin free multimer immunoperoxidase method. Results are outlined in the table below:

Antibodies: Results:
Cytokeratin 5/6 Negative. 
P63 Negative. 
TTF-1 Positive. 
Napsin A Positive. 


Impression: Immunoprofile consistent with adenocarcinoma of lung. 

The immunohistochemical tests reported were developed and performance characteristics determined by Dynacare Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests may be used for clinical purposes. They should not be regarded as investigational or for research use only. Dynacare Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988(CLIA) as qualified to perform high complexity clinical laboratory testing.GROSS:
A. TBNA is performed on the ''4 R lymph node'' of patient ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[ZZZ]. Seven passes are made. Prepared in N-2 OR are one wet-fixed smear and one fast-stained smear labeled ''**NAME[BBB, AAA (M])''. Also prepared is one cell block from the sample collected in saline and labeled ''**NAME[BBB, AAA (M)''. 
M. DDD] is performed on the ''station 7 lymph node'' of patient ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[ZZZ]. Seven passes are made. Prepared in N-2 OR are three wet-fixed smears and three fast-stained smears labeled ''**NAME[BBB, AAA (M])''. Also prepared is one cell block from the sample collected in saline and labeled ''**NAME[BBB, AAA (M])''. 
C. Received fresh on **DATE[Mar 9 12] is approximately 25 cc of hemorrhagic mucoid fluid, labeled ''**NAME[BBB, AAA (M])''. Prepared are one cell block and one ThinPrep slide. (NPW:id) 
Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''right lower lobe lung endobronchial biopsies'', is a 2.5 x 1 x 0.8 cm aggregate of multiple fragments of red-tan soft tissue and blood clot. Specimen is submitted entirely in cassette D1. (**INITIALS:cmc10 297881) (NPW:cmc131 298002) 



CLINICAL INFO:
Swelling mass or lump in chest. Lung mass and mediastinal lymphadenopathy (per Dr. **NAME[ZZZ]). 
ICD-9 code: 786.6.
PATHOLOGIST:
**NAME[WWW VVV UUU]   

SNOMED Code(s)
T28400T26400T26010T0X000P1140M80103M43000M42101T28400P1250M81403M80103T08330P1144M81403M80103T08330P1144M81403M80103",,,,,
REG3,LUNG,0,PAT-00749580,1,REC-5000770352,,,,"<FINAL DX>
  RIGHT UPPER LOBE:  SQUAMOUS CELL CARCINOMA WITH MODERATE DIFFERENTIATION.
TUMOR SIZE: 2.8 X 2.8 X 2.4 CM. 
TUMOR LOCATION PERIPHERAL: DISTANCE TO BRONCHIAL MARGIN 2.8 CM.
BRONCHIAL MARGIN STATUS: NEGATIVE FOR TUMOR AND CIS.
OTHER RESECTION MARGINS: NEGATIVE
VISCERAL PLEURAL INVASION: NOT PRESENT. 
PERIBRONCHIAL LYMPH NODE STATUS:  TWO LYMPH NODES IDENTIFIED. NEGATIVE
LYMPHATIC/VASCULAR INVASION: NOT IDENTIFIED. 
IN-SITU COMPONENT NOT IDENTIFIED. 
OTHER PULMONARY CHANGES: PNEUMONITIS INVOLVING PORTIONS OF THE LOBE.
PATHOLOGIC STAGE: pT1b, pNO, pMX

<PATHOLOGIST>
   **NAME[ZZZ] MD, Uma              Electronically Signed: **DATE[Mar 13 2012]
<SPECIMEN(S)>
  A) Right upper lobe
<GROSS>
  Received in a container labeled with the patient's name and ""1"" is a 14.4
x 11.5 x 5.5 cm right upper lobe with lung, which is received deflated and
is profuse with formalin and further fixed. The pleural is pink with
patchy areas of hemorrhage toward the apex, anterior and inferior aspects.
The hilum demonstrates a 0.6 cm length of bronchus, as well as sutured and
stapled ill-defined length of blood vessel margins.  An 8.0 cm staple line
is present at the anterior-most point and leads to the hilum. Two 1.6 x
0.5 x 0.5 cm and 2.0 x 1.5 x 0.7 cm lymph node candidates are identified;
the thinner is easily fragmented and is consistent with more than one
lymph node candidate in a lymph node chain.  The specimen is serially
sectioned from posterior to anterior. A 2.8 x 2.8 x 2.4 cm tan and
glistening, ovoid and moderately delineated focally cavitated lesion
within the apex, which is 0.3 cm from the pleura and 2.8 cm from the
bronchial margin. This lesion does not grossly involve the adjacent
pleura, but there is an area of thickening and fibrosis at the apex
measuring 3.5 x 2.0 x 0.5 cm, which is consistent with fibrosis or
additional tumor, and appears to be 0.7 cm from the nearest tumor.  This
fibrotic area of the pleural apex is associated with the aforementioned
pleural patchy hemorrhage. The remaining cut surfaces are pink-tan,
crepitant and focally anthracotic parenchyma, with no additional mass
lesions identified. There is a darkened, black and erythematous area of
thickened pleura at the lateral surface, which is 3.5 cm from the lesion
and is well-sampled. 
Representative sections are submitted as follows: 
1) vascular and bronchial margins
2) fragmented elongated portion of lymphoid tissue
3) 2.0 cm bisected hilar lymph node
4) section of the lesion to the nearest pleura
5,6) one section bisected of the lesion to the thickened apical pleura
7) additional thickened apical pleura
8) darkened and thickened lateral pleura
9) uninvolved parenchyma.
<MICROSCOPIC>
  Bronchial and vascular margins of resection are clear.  Microscopic
sections are of anthracotic lymph nodes without evidence of metastatic
carcinoma. Sections of lung parenchyma demonstrate a cavitary squamous
cell carcinoma associated with marked acute and chronic inflammation with
organization. Interweaving between the inflammatory cells  are small nests
of atypical squamous epithelium. Immunohistochemical stains for CK5/6 and
P63 are done on blocks 5 and 6 and highlight the tumor cells. Pleura is
fibrotic with scarring of the subpleural lung parenchyma but there is no
evidence of tumor involvement.",,,,,
REG3,LUNG,0,PAT-00734047,2,REC-5000770353,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  A) LUNG, RIGHT UPPER LOBE, WEDGE RESECTION:  
1. CONSISTENT WITH METASTATIC LEIOMYOSARCOMA MEASURING 2.6 X 1.8 X 1.7 CM.
2. LEIOMYOSARCOMA INVOLVES THE PLEURAL SURFACE.
3. RESECTION MARGIN: FREE OF TUMOR
4. CAPILLARY LYMPHATIC SPACE INVASION: NOT IDENTIFIED.
5. NON-NEOPLASTIC LUNG TISSUE; NO SPECIFIC PATHOLOGIC DIAGNOSIS.
B) LUNG, RIGHT LOWER LOBE, WEDGE RESECTION:  
1. GRADE I NEUROENDOCRINE CARCINOMA (FORMERLY CALLED ""CLASSIC CARCINOID"").
2. TUMOR SIZE: 1.0 X 0.9 X 0.4 CM.
3. RESECTION MARGIN: NEGATIVE FOR TUMOR (SEE MICROSCOPIC DESCRIPTION).
4. PLEURAL INVASION: NO PLEURAL INVASION IDENTIFIED.
5. LYMPHOVASCULAR INVASION: NOT IDENTIFIED (SEE MICROSCOPIC DESCRIPTION).
6. NO LYMPH NODES SAMPLED.
7. NO EVIDENCE OF METASTATIC LEIOMYOSARCOMA. 
8. PATHOLOGIC STAGE: pT1a,pNX, pMX.
COMMENT: The patient's previous history of uterine leiomyosarcoma
diagnosed in **DATE[Jan 2012] is noted in EPIC.
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. PANCYTOKERATIN (AE1/AE3): POSITIVE (DIFFUSE AND DOT-LIKE)
2. CYTOKERATIN 7 (OV-TL12/30): NEGATIVE
3. CYTOKERATIN 20 (Ks20.8): NEGATIVE
4. TTF-1 (8G7G3/1): POSITIVE (WEAK, VERY FOCAL)
5. SYNAPTOPHYSIN (SP11): STRONGLY POSITIVE
6. CHROMOGRANIN A (LK2H10): POSITIVE (FOCAL STRONG)

Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY]               Electronically Signed: **DATE[Jul 14 2012]
<SPECIMEN(S)>
  A) Right upper lobe wedge
B) Right lower lobe wedge
<GROSS>
  A) Received in a container labeled with the patient's name and ""#1""
requisition additionally stating ""right upper lobe wedge"" is a 33 gram
(formalin weight) 6.4 x 5.5 x 3.5 cm irregular portion of lung with
multiple complicated staple lines. The pleura is purple-tan, smooth,
glistening and remarkable for a 2.5 x 1.5 cm yellow-tan glistening
subpleural plaque.  This plaque-like lesion comes to within 1.0 cm of the
closest parenchymal resection margin and is marked with silver nitrate.
The staple lines are removed and the underlying parenchyma is inked blue
and the specimen is serially sectioned to demonstrate a moderately
delineated 2.6 x 1.8 x 1.7 cm mass lesion with homogenous white-tan
glistening and focally hemorrhagic cut surfaces. This mass lesion abuts,
distends the pleura at the aforementioned plaque-like lesion and comes to
with 0.3 cm of the closest inked parenchymal margin.  The remaining,
uninvolved lung parenchyma is brown-red, mottled, focally compressed but
otherwise grossly unremarkable.  Representative sections submitted in
blocks A1-A5. 
B) Received in a container labeled with the patient's name and ""#2""
requisition additionally stating ""right lower lobe wedge"" is a 2 gram
(formalin weight) 4.8 x 1.8 x 0.8 cm wedge of lung with a 5.5 cm simple
staple line. The pleural is brown-tan, smooth, glistening and focally
ragged with membranous adhesions. No discrete lesions however are grossly
noted. The staple lines are removed, the underlying parenchyma is inked
blue, and the specimen is serially sectioned perpendicular to the long
axis to demonstrate an irregular 1.0 x 0.9 x 0.4 cm indurated focus with
white-tan glistening cut surfaces. This lesion grossly abuts possible
vascular and bronchial structures and comes to with 0.2 cm of the
blue-inked parenchymal margin.  Additionally, the lesion extends to, abuts
but does not grossly involve the pleura.  The remaining, uninvolved lung
parenchyma is brown-tan, soft, spongy throughout. The specimen is
submitted entirely in blocks B1-B3.
<MICROSCOPIC>
  A) Sections show a fairly well circumscribed vesicular, cellular
proliferation of spindled cells which have elongated oval nuclei and
indistinct cytoplasmic borders.  The tumor is highly mitotically active
with up to 42 mitotic figures per high power fields.  Centrally there is a
fairly broad region of hemorrhage and necrosis. The tumor involves the
pleural surface but does not appear to involve the inked previously
stapled resection margin.  The non-neoplastic lung parenchyma is
atelectatic, shows vascular congestion and is otherwise unremarkable. 
B) Section show a polypoid bronchial proliferation of cohesive, monotonous
cells which have uniform stippled chromatin, small nucleoli and a modest
amount of light pink cytoplasm with some cells appearing plasmacytoid. The
tumor cells are arranged in sheets and trabeculae.  The polypoid
proliferation distorts the cartilage containing airspaces and incorporates
the adjacent alveolar tissue as well.  There tumor has a low mitotic rate,
no evidence of necrosis and no evidence of cellular pleomorphism. There
are areas of microcalcification. The immunohistochemical stains for
chromogranin and synaptophysin decorate the tumor cells and show floating
cells within alveolar spaces adjacent to the tumor and in a cross section
of an blood vessel.  This finding probably reflects tumor carry over. The
resection margin is negative for tumor (tumor is 0.2 cm from the resection
margin). The tumor does not involve the pleura (0.1 cm from the pleura).
The non-neoplastic lung tissue shows atelectasis, focal mucus plugging and
vascular congestion. The hyaline cartilage is focally calcified. There are
pleural adhesions. There is no evidence of metastatic leiomyosarcoma. No
lymph nodes are identified.",,,,,
REG3,LUNG,0,PAT-00750344,1,REC-5000771899,,,,"<CLINICAL INFO>
H/O Breast Cancer; ?Metastatic vs Primary Lung Ca

<GROSS>
A.  RUL Mass FNA:  12 direct smears and 1 cell block are prepared.
 
B.  Bronchial Washing:  Approximately10 cc of cloudy, red fluid are received. 1 liquid based slide is prepared.
 


<MICROSCOPIC SECTION>

<FINAL DX>

A: RUL Mass FNA: Final Cytology Diagnosis
MALIGNANT EPITHELIAL CELLS PRESENT.  
Specimen Adequacy
Satisfactory for interpretation.
B: Bronchial Washing: Final Cytology Diagnosis
MALIGNANT EPITHELIAL CELLS PRESENT.  
Specimen Adequacy
Satisfactory for interpretation.

A and B: 
Malignant cells present consistent with adenocarcinoma. Please see concurrent biopsy (***PATH-NUMBER[1]) for further classification.





<SPECIMEN(S)>
Transbronchial Needle, FNA
<SPECIMEN(S)>
Bronchial Washing",,,,,
REG3,LUNG,0,PAT-00750742,1,REC-5000772149,,,,"<CLINICAL INFO>
Lung cancer.

<GROSS>
Received fresh from the CAT scan suite, labeled with the patient's name and designated 'lung biopsy' per the requisition, are four cylindrical tan tissue fragments measuring 0.2 to 0.9 cm in length and up to 0.1 cm in diameter.  The specimen is inked with hematoxylin, wrapped and entirely submitted in cassette 
A1. 
Three core passes are obtained and produce three slides that are H&E stained for rapid interpretations:  Diagnosis:  ATP:  Positive for non-small cell carcinoma per Dr. **NAME[M. ZZZ].
RT/cs  **DATE[Oct 03 12]

<MICROSCOPIC>
Sections of the formalin-fixed paraffin embedded material reveal clusters of atypical epithelioid cells characterized by moderate nuclear size, nuclear hyperchromasia, and increased nuclear to cytoplasmic ratios.  Focal gland formation and focal intracytoplasmic mucin is suggested on H&E stains.  By immunohistochemistry, the neoplasm is variably positive for both TTF-1 and Napsin-A.  It is negative for CK5/6.  Occasional scattered neoplastic cells are positive for p63.  
**INITIALS **DATE[Oct 4 12]

<INTRAOPERATIVE CONSULT>
Intraoperative evaluation:  Positive for non-small cell carcinoma,

<FINAL DX>
LUNG, CT-GUIDED BIOPSY:
  MODERATELY TO POORLY DIFFERENTIATED ADENOCARCINOMA (SEE COMMENT).

<DX COMMENT>
The combination of histopathologic and immunophenotypic features is diagnostic of a primary pulmonary adenocarcinoma.  EGFR testing is pending and the results will be reported in an addendum.",,,,,
REG3,LUNG,0,PAT-00751117,1,REC-5000773221,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

AB.  Lung, Left Lower Lobe, Radiologically-Guided Core Biopsy and FNA
with Cell Block:
     Adenocarcinoma.

<COMMENT>
The adenocarcinoma in this small sample has a low nuclear grade and a
predominantly lepidic pattern of growth.

<CLINICAL INFO>
Left lower lobe lung mass

INTRAPROCEDURAL EVALUATION:
A.  Touch Preparation Smear:  Non-diagnostic.
B.  FNA Smears:  Adequate material present.

<GROSS>
A.  Received from Dr. **NAME[ZZZ] in the CT Suite and identified as ""left lower
lung lobe mass"" are 3 cores of red tan tissue measuring (9 x 2 x 2 mm in
aggregate) from which 1 air-dried and 1 alcohol fixed touch preparations
are prepared.  Immediate interpretation of the air-dried smear by Dr.
**NAME[YYY] yields the above diagnosis.  The cores are submitted between
sponges in one cassette.

B.  Received from Dr. **NAME[ZZZ] in the CT Suite and identified as ""left lower
lung lobe mass"" is a syringe with a scant amount of bloody material from
which 1 air-dried and 1 alcohol fixed smears are prepared.  Immediate
interpretation of the air-dried smear by Dr. **NAME[YYY] yields the above
diagnosis.  The syringe is washed into Cytolyt solution for cell block
preparation.

<MICROSCOPIC>
The final diagnoses for each specimen are based upon microscopic
examinations of the tissues / cells.

INTRADEPARTMENTAL CONSULTATION:
CellNetix pathologist, **NAME[M. YYY], M.D., has reviewed and concurs with
adenocarcinoma.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Jun 10 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,LUNG,0,PAT-00750101,1,REC-5000773252,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Biopsy Left Main:
     Scant bronchial epithelium, fibrin and blood.
     No malignancy identified.

B.  Left Mainstem Biopsy:
Small portion of  malignant neoplasm consistent with nonsmall cell
carcinoma, underlying bronchial epithelium and associated with moderate
chronic inflammation and fibrin clot (limited   tissue).

C.  Cytology, Left Mainstem Brushing:
     No malignant cells identified.

D.  Cytology, Left Lung Bronchioalveolar Lavage Fluid:
     Rare atypical cells noted.
     No diagnostic carcinoma identified.

<CLINICAL INFO>
Hemoptysis.  4 cm malignant mass eroding through bronchus. Technically
difficult biopsies due to bleeding.

INTRAPROCEDURAL EVALUATION:
A. Left mainstem biopsy (frozen section): ""Representative tissue shows
benign bronchial epithelium blood and apparent mucus. No diagnostic
neoplasm identified (artifactually distorted).  Touch prep: ""Blood and
few poorly preserved bronchial epithelial cells"".
C. Left mainstem brushings (touch preps): ""Blood and benign bronchial
epithelial cells"".
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A. Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated
""left mainstem"", are four fragments of hemorrhagic material and possible
tan tissue, 0.1-0.2 cm in greatest dimension. All are submitted for
touch prep evaluation. Two are submitted for frozen section evaluation.
Following formalin fixation, the unfrozen tissue is inked blue. All
fragments are entirely submitted in A1.

B. Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated
""left mainstem biopsy"", are five 0.1-0.3 cm hemorrhagic biopsies,
entirely submitted in B1.  (rkg/nd)

C. A specimen labeled ""**NAME[BBB, AAA]"" and designated as ""left
mainstem brushing"" per requisition, is received in 15 ml of alcohol
containing one brush on **DATE[Oct 07 2012]. Prepared is one cell block.  (lw/dg)
The two direct smears also received with the specimen were previously
rapid stained.

D. Received on **DATE[Oct 07 2012] is 11 ml of hemorrhagic, orange mucoid fluid
labeled ""**NAME[BBB, AAA]"" and designated as ""left lung BAL"" per
requisition. Prepared are one cell block, one air-dried cytocentrifuge
preparation Diff-Quik-stained slide, and one ThinPrep Pap-stained slide.
(lw/dg)

<MICROSCOPIC>
A. Reviewed is one HE-stained slide. Please see diagnosis.

B. Reviewed is one HE-stained slide. Please see diagnosis.

C. Reviewed are two direct smears and one cell block preparation. Please
see diagnosis.

D. Reviewed is one HE cell block preparation, one Diff-Quik-stained
cytocentrifuge preparation, and one ThinPrep Pap-stained slide. Please
see diagnosis.

INTRADEPARTMENTAL CONSULTATION:
**NAME[XXX M. WWW], M.D.(B).

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Oct 10 2012]",,,,,
REG3,LUNG,0,PAT-00748627,1,REC-5000773404,,,,"**** THIS IS AN AMENDED REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Amendment ****

Reason for Amendment #1: Additional Physician

<FINAL DX>     

A. Azygous Nodes, Excision:
     Lymph node tissue (four fragments) with no evidence of metastatic
carcinoma.

B. Lung, Right Upper Lobe, Lobectomy:
     Carcinoma of the lung with the following features:
             Histologic type:           Adenocarcinoma.
             Histologic subtype:   Mixed acinar and papillary, with foci
of lipidic growth pattern.
             Tumor size:                1.7 x 1.1 x 1 cm.
             Tumor focality:            Focal.
             Histologic grade:               Moderately differentiated,
G 2 of 4.
             Specimen integrity:             Intact.
             Hilar extending pneumonia:           Absent.
             Lung parenchyma invasion:       Present.
             Pleural invasion:               Absent.
             Main bronchus invasion:              Absent.
             Chest wall invasion:            Absent.
             Lymph-vascular invasion:        No definite invasion.
             Margins:
                Bronchial margin:            Negative, 4.5 cm.
                Parenchymal margin:          Not applicable.
                Vascular margin:             Negative.
             Regional lymph nodes:
                Three peribronchial lymph nodes with no evidence of
metastatic carcinoma (0/3).
        Non-Neoplastic Lung:       Emphysematous changes.
             Distant metastasis:             Unknown.
             Pathological stage:             pT1a (AJCC 7th edition)
                              pN0, pMX (AJCC 7th edition).
C. Lymph Node, Peribronchial, Excision:
     One lymph node with no evidence of metastatic carcinoma.

<CLINICAL INFO>
Right upper lobe lung CA.

INTRAPROCEDURAL EVALUATION:
A. Azygous lymph nodes (frozen section): ""Negative for carcinoma.""
B. Right upper lobe lung mass (2 frozen sections): ""Bronchial margins
negative for high-grade dysplasia.
    Negative for malignancy.""
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A. Received fresh, labeled ""**NAME[AAA BBB]"" and designated ""azygous
nodes"", are four 0.1 to 1.1 cm anthracotic fragments. All material is
used for frozen section and entirely submitted in one cassette.

B. Received fresh, labeled ""**NAME[AAA BBB]"" and designated ""right upper
lobe mass"", is a lobe of lung 18 x 13 x 5.5 cm. The pleural surface is
gray-brown and wrinkled. There is a 5 cm surgical staple line which
extends adjacent to the bronchial margin. There is a firm, tan-gray,
parenchymal mass in the superior portion of the lobe which is 1.7 x 1 x
1.1 cm. The mass is 1.3 cm from the closest pleural surface and is at
least 4.5 cm from the bronchus margin. The remaining parenchyma is
red-brown and spongy with extensive emphysematous change. Representative
tissue is submitted as follows:
     Block Key:
     B1        frozen section of bronchus margin
     B2        vascular margins
     B3-B5     tumor
     B6        superior parenchyma at least 3 cm from lesion
     B7        inferior parenchyma
     B8        two peribronchial lymph nodes.

C. Received in formalin, labeled ""**NAME[AAA BBB]"" and designated
""peribronchial node"", is a 1 cm nodule, which is submitted as received
in one cassette. (ke/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block B4

Antibody  Result    Comment
TTF-1     Positive
Napsin A  Positive

Block B8

Antibody  Result    Comment
Pan CK    Negative

Impression:  The results support the diagnosis.
Interpreted by:  **NAME[XXX WWW] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[XXX WWW], M.D.  Electronically signed **DATE[May 23 2012]
Amendment #1 performed by **NAME[XXX WWW], M.D.  Electronically signed
**DATE[Jun 11 2012]",,,,,
REG3,LUNG,0,PAT-00508722,2,REC-5000775807,,,,"<CLINICAL INFO>
LT LUNG MASS.
**NAME[M. ZZZ], MD            **NAME[M. YYY], XXX], PhD                 **NAME[M. WWW], MD
**NAME[M. VVV], MD       D.D. **NAME[UUU], MD                  
<SPECIMEN(S)>
LT LUNG MASS BX.
<GROSS>
Received in formalin labeled with the patient's name and ""lt lung mass Bx"" are eight tan to pink needle core tissue fragments ranging from 0.3 to 0.7 cm in length and 0.1 cm in diameter. Wrapped and entirely submitted in one cassette. Touch prep slides for quick stains are prepared. QUICK STAIN INTERPRETATION: LEFT LUNG MASS, QUICK STAIN: SATISFACTORY FOR EVALUATION (Dr. **NAME[WWW]). LS/VT:pro **DATE[Aug 11 12]
<FINAL DX>
Lung, left, biopsy of mass: Positive for malignancy, consistent with carcinoma. 
See comment. 
Internal consult performed by Dr. **NAME[TTT].
Comment: Immunohistochemical studies are pending to further characterize this malignant neoplasm, addendum to follow. 
 
<PATHOLOGIST>
**NAME[CCC WWW], M.D.
**INSTITUTION
**STREET-ADDRESS                                
PO Box 50010                                            
**PLACE, WA **ZIP-CODE                                          **PHONE
(**PHONE fax",,,,,
REG3,LUNG,0,PAT-00750993,1,REC-5000778692,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Molecular results
Reason for Addendum #2:  Reference Laboratory Results

<FINAL DX>     

A.  Subcarinal Fine Needle Aspirate:
Non-small cell carcinoma, consistent with primary lung adenocarcinoma.

B.  Precarinal Fine Needle Aspirate:
Non-small cell carcinoma, consistent with primary lung adenocarcinoma.

C.  Right Hilar Fine Needle Aspirate:
Negative for malignancy.
Lymph node tissue present.

D.  Bronchial Brush:
Negative for malignancy.
Bronchial epithelium, macrophages, and mixed inflammation.

<COMMENT>
Per clinical request, molecular testing for EGFR mutation with reflex
testing for EML4-ALK rearrangement (if no EGFR mutation is identified)
will be performed and the results reported in an addendum.

<CLINICAL INFO>
Smoker, lung mass, adenopathy.

INTRAPROCEDURAL EVALUATION:
A. Subcarinal (fine needle aspirate): ""Nonsmall cell carcinoma"".
B. Pre-carinal (fine needle aspirate): ""Nonsmall cell carcinoma"".
Performed by:  **NAME[ZZZ M. YYY], M.D.

<GROSS>
A.  A specimen labeled ""**NAME[BBB, AAA]"" and designated as ""subcarinal FNA""
per requisition is received in 30 ml of PreservCyt on **DATE[Aug 07 2012].
Prepared is one cell block. Also received on **DATE[Aug 07 2012] are three
alcohol-fixed direct smears and one air-dried direct smear labeled
""**NAME[BBB, M]"" and designated as ""subcarinal FNA"" per requisition. The
alcohol-fixed smears are Papanicolaou-stained and the air-dried smear is
Diff-Quik-stained. Two additional air-dried smears were kept in Olympia.

B.   A specimen labeled ""**NAME[BBB, AAA]"" and designated as ""pre-carinal
FNA"" per requisition is received in 50 ml of PreservCyt on **DATE[Aug 07 2012].
Prepared is one cell block. Also received on **DATE[Aug 07 2012] are two
alcohol-fixed direct smears labeled ""**NAME[BBB, M]"" and designated as
""pre-carinal FNA"" per requisition. The alcohol-fixed smears are
Papanicolaou-stained and two air-dried smears were kept in Olympia.

C.  A specimen labeled ""**NAME[BBB, AAA]"" and designated as ""right hilar""
per requisition is received in 20 ml of PreservCyt on **DATE[Aug 07 2012].
Prepared are one ThinPrep Pap-stained slide and one cell block. Also
received on **DATE[Aug 07 2012] are one alcohol-fixed direct smear and one
air-dried direct smear labeled ""**NAME[BBB, M]"" and designated as ""right
hilar"" per requisition. The alcohol-fixed smear is Papanicolaou-stained
and the air-dried smear is Diff-Quik-stained.

D.  A specimen labeled ""**NAME[BBB, AAA]"" and designated as ""bronchial
brush"" per requisition is received in 10 ml of PreservCyt with brush on
**DATE[Aug 07 2012]. Prepared is one ThinPrep Pap-stained slide.  (rc/dg)

<MICROSCOPIC>
A.  Six cytology smears and one cell block preparation are reviewed for
final diagnosis.

B.  Four cytology smears and one cytospin preparation are reviewed for
final diagnosis.

C.  Two cytology smears, one cytospin preparation, and one cell block
preparation are reviewed for the final diagnosis.

D.  A single cytospin preparation is reviewed for final diagnosis.

   INTRADEPARTMENTAL CONSULTATION:
**NAME[M. XXX WWW], M.D.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
p63  Negative
CK 5/6    Negative
Napsin A  Positive
TTF-1     Positive

Impression:  These findings support the diagnosis.
Interpreted by:  **NAME[VVV M UUU] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[VVV M UUU], M.D.  Electronically signed **DATE[Aug 11 2012]

<ADDENDUM> #1

EGFR MUTATION MOLECULAR (PCR) STUDY:
Testing performed by: **PLACE, WA **ZIP-CODE, report
***PATH-NUMBER[2].
Interpreted by: **NAME[TTT SSS], M.D., issued: **DATE[Aug 17 2012].

Result:  Subcarinal Fine Needle Aspirate:  NEGATIVE for an EGFR mutation
by real time PCR.

Comment:  In this case no epidermal growth factor receptor (EGFR)
mutations were identified by Qiagen/DxS real time PCR. This real time
PCR assay has been validated to identify the most common EGFR tyrosine
kinase domain mutations that involve exons 18-21. This test is validated
for non-small cell lung carcinoma. The clinical significance and use of
this assay in other tumor types is not well characterized. Note that
this assay is not intended to diagnose any particular type of cancer,
but as an aid to clinicians, is intended to be used as an adjunct to
other prognostic factors to select eligible patients for therapy. (**NAME[RRR:
QQQ] et al., NEJM 2004; **ID-NUM, Mok et al., NEJM 2009; **ID-NUM,
Pao et al., JClinOnc 2005; 23: 2556-68).

ALK FISH analysis has been initiated as requested, and the results will
be reported separately.

Addendum #1 performed by **NAME[PPP M. OOO], M.D.  Electronically signed
**DATE[Aug 17 2012]

<ADDENDUM> #2

ALK GENE by FLUORESCENCE IN SITU HYBRIDIZATION (FISH):
Testing performed by: **PLACE, WA **ZIP-CODE, report
***PATH-NUMBER[3].
Interpreted by: **NAME[TTT SSS], M.D., issued: **DATE[Aug 19 2012].

Result:  Subcarinal, Fine Needle Aspirate:
     NEGATIVE for a translocation involving the ALK gene by FISH.

Comment:  Translocations involving the anaplastic lymphoma kinase (ALK)
gene have been described in a small subset of nonsmall cell lung cancers
and typically involve the echinoderm microtubule-associated protein-like
4 (EML4) gene, resulting in an EML4-ALK fusion gene containing the ALK
tyrosine kinase domain. The presence of an ALK translocation in a
nonsmall cell lung cancer tumor specimen predicts possible tumor
responsiveness to ALK tyrosine kinase inhibitor drug therapy. This assay
is not intended to diagnose a specific type of cancer but is instead
intended to provide information to help guide potential therapy. (**NAME[RRR:
CCC] et al., AJP 2009; 174 (2):661, Soda et al., Nature 2007;
448:561, Kwak et al., NEJM 2010; **PHONE).

Addendum #2 performed by **NAME[VVV M UUU], M.D.  Electronically signed
**DATE[Aug 20 2012]",,,,,
REG3,LUNG,0,PAT-00747050,1,REC-5000780675,,,,"<CLINICAL INFO>
H/O Lung Cancer (Squamous cell)
<GROSS>
7.5cc red fluid received, 1 liquid based slide prepared.

<MICROSCOPIC SECTION>

<FINAL DX>

Pericardial Fluid: Final Cytology Diagnosis
ATYPICAL CELLS PRESENT, NOT DIAGNOSTIC OF MALIGNANCY.  
Specimen Adequacy
Satisfactory for interpretation.

Atypical cells are rare.





<SPECIMEN(S)>
Pericardial Fluid",,,,,
REG3,LUNG,0,PAT-00737949,1,REC-5000781020,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Cerebrospinal Fluid (Cytology):
Malignant cells present (see comment).

<COMMENT>
There are scattered malignant cells present with degenerative changes.
Some of these cells are loosely cohesive, whereas others are detached.
The findings are compatible with the patient's history of metastatic
adenocarcinoma in the brain.  There is also a background of acute and
chronic inflammation.

<CLINICAL INFO>
N/V in patient with brain mets from poorly differentiated lung cancer.

<GROSS>
Received on **DATE[Jun 25 2012] is 2 ml of clear yellow fluid labeled ""**NAME[BBB, AAA]""
and designated ""cerebrospinal fluid"" per requisition. Prepared are one
alcohol-fixed cytocentrifuged Pap-stained slide and one air-dried
cytocentrifuged Diff-Quik-stained slide. (rc/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

PHYSICIAN NOTIFICATION:
-Mark **NAME[ZZZ], MD, **DATE[Jun 26 12].

**NAME[YYY M XXX], M.D.  Electronically signed **DATE[Jun 26 2012]",,,,,
REG3,LUNG,0,PAT-00753040,1,REC-5000781042,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Lower Lobe of Lung, Fine Needle Aspirate Cytology:
  Poorly differentiated carcinoma.
  Please see comment.

<COMMENT>
The immunostaining profile on this case does not define a specific
primary site, but the fact that CK7 is focally positive and CK20 is
negative suggests that this is a lung, breast, or upper GI tract,
pancreatobiliary tree primary. Melanoma is essentially excluded. Breast
cancer is essentially excluded. Markers supporting a lung adenocarcinoma
(TTF-1 and Napsin) are both negative in this case. Further, markers
supporting squamous differentiation from any site (p63 and CK5/6) are
also both negative. The tumor does not show a small cell carcinoma
morphology.

<CLINICAL INFO>
Smoker; lung mass.

INTRAPROCEDURAL EVALUATION:
Right lower lobe lung (fine needle aspirate): ""Positive for nonsmall
cell carcinoma"".
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A specimen labeled ""**NAME[BBB, AAA]"", and designated ""right lower lobe
lung FNA"" per requisition, is received in 30 ml of CytoLyt collection
fluid on **DATE[Dec 20 2011]. Prepared is one cell block. Also received on
**DATE[Dec 20 2011] is one alcohol-fixed direct smear labeled ""**NAME[BBB, M]"", and
designated ""right lower lobe lung FNA"" per requisition. The
alcohol-fixed smear is Papanicolaou stained. One air-dried smear was
kept in Olympia.  (lw/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
TTF-1     Negative
p63  Negative
Napsin A  Negative
Mammoglobin    Negative
ER   Negative
CK7  Positive
CK20 Negative
CK 5/6    Negative
Pan CK    Positive
MelA/Mart-1    Negative
CAM5.2    Positive

Impression:
Interpreted by:  **NAME[ZZZ M. YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[XXX M. WWW], M.D.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Dec 26 2011]",,,,,
REG3,LUNG,0,PAT-00752022,1,REC-5000787559,,,,"<CLINICAL INFO>
Smaller; lung mass

<GROSS>
Received in formalin, labeled **NAME[BBB, AAA], biopsy RLL, is a 0.4 x 0.4 x 0.1 cm aggregate of tan-red tissue fragments.  SECTIONS:  A1 = in total.


<MICROSCOPIC SECTION>
Immunohistochemical studies demonstrate the following phenotype in tumor cells:
Positive:  p63, CK5/6
Negative:  TTF1, CK7, napsin
The findings support the diagnosis of moderately to poorly differentiated squamous cell carcinoma.  The fragments are superficial and consistent with at least squamous cell carcinoma in situ.  Correlation with radiologic findings is needed.  

<FINAL DX>
     
RIGHT LOWER LOBE OF LUNG BIOPSY:
Positive for superficial fragments of moderately to poorly differentiated squamous cell carcinoma.







<SPECIMEN(S)>
Lung/Bronchial/Pleural Biopsy",,,,,
REG3,LUNG,0,PAT-00750312,1,REC-5000788528,,,,"PART / DESCRIPTION - SEQ 
Lymph node/ 2R LYMPH NODES- D
PART / DESCRIPTION - SEQ 
Lymph node/ 4R LYMPH NODES- B
PART / DESCRIPTION - SEQ 
Lymph node/ STATION 7 LYMPH NODES- C
PART / DESCRIPTION - SEQ 
Lymph node/ 4L LYMPH NODES- A
INTRAOPERATIVE DX:
NONE
FINAL DX:

A-D: Lymph nodes, 4R (A and B), station 7 (C) and 2R (D), biopsy: - Fragments of lymph nodes with anthracosis and reactive changes. - No malignancy identified.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''4R lymph nodes'', is a 2.2 x 1.4 x 0.8 cm aggregate of multiple fragments of black lymphoid tissue. The specimen is submitted entirely in cassette A1.
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''4R lymph nodes'', is a 2.7 x 2.2 x 0.8 cm aggregate of multiple fragments of black lymphoid tissue. The specimen is submitted entirely in cassette B1.
C. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''station 7 lymph nodes'', is a 2.4 x 2 x 0.8 cm aggregate of multiple fragments of black lymphoid tissue. The specimen is submitted entirely in cassette C1.
D. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''2R lymph nodes'', is a 1 x 0.6 x 0.4 cm aggregate of two fragments of black lymphoid tissue with adherent adipose tissue. The specimen is submitted entirely in cassette D1. (**INITIALS:cmc40 205710)
CLINICAL INFO:
Malignant neoplasm of bronchus and lung, unspecified site.
ICD-9 code: 162.9.
INTRAOPERATIVE DX:
NONE
FINAL DX:

A-D: Lymph nodes, 4R (A and B), station 7 (C) and 2R (D), biopsy: - Fragments of lymph nodes with anthracosis and reactive changes. - No malignancy identified.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''4R lymph nodes'', is a 2.2 x 1.4 x 0.8 cm aggregate of multiple fragments of black lymphoid tissue. The specimen is submitted entirely in cassette A1.
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''4R lymph nodes'', is a 2.7 x 2.2 x 0.8 cm aggregate of multiple fragments of black lymphoid tissue. The specimen is submitted entirely in cassette B1.
C. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''station 7 lymph nodes'', is a 2.4 x 2 x 0.8 cm aggregate of multiple fragments of black lymphoid tissue. The specimen is submitted entirely in cassette C1.
D. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''2R lymph nodes'', is a 1 x 0.6 x 0.4 cm aggregate of two fragments of black lymphoid tissue with adherent adipose tissue. The specimen is submitted entirely in cassette D1. (**INITIALS:cmc40 205710)
CLINICAL INFO:
Malignant neoplasm of bronchus and lung, unspecified site.
ICD-9 code: 162.9.
PATHOLOGIST:
Ranguelov Rostislav D  

SNOMED Code(s)",,,,,
REG3,LUNG,0,PAT-00749577,1,REC-5000788603,,,,"PART / DESCRIPTION - SEQ 
Lymph node/ 10L ANTERIOR NODE- F
PART / DESCRIPTION - SEQ 
Skin, biopsy/ LEFT ANTERIOR CHEST WALL NEVUS- A
PART / DESCRIPTION - SEQ 
Lymph node/ 12 NODE PERI-TUMORAL LINGULA/BRONCHUS- H
PART / DESCRIPTION - SEQ 
Lymph node/ LN #5- J
PART / DESCRIPTION - SEQ 
Lymph node/ 7 NODE- C
PART / DESCRIPTION - SEQ 
Lymph node/ 7 NODE- G
PART / DESCRIPTION - SEQ 
Lung, resection/ LINGULA- K
PART / DESCRIPTION - SEQ 
Bronchus, biopsy/ REVISED BRONCHIAL STUMP- L
PART / DESCRIPTION - SEQ 
Lymph node/ LN #12- I
PART / DESCRIPTION - SEQ 
Lymph node/ 4R NODES- B
PART / DESCRIPTION - SEQ 
Lymph node/ 9 NODE- E
PART / DESCRIPTION - SEQ 
Lymph node/ 4L (3 NODES)- DConsult
**NAME[M. ZZZ], MD (part K, QA).
FINAL DX:

a. Skin, left anterior chest wall, nevus, excision:
-Seborrheic keratosis. 
-No malignancy identified. 

b. Lymph node, 4R (2 nodes), excision:
-Two fragments of lymph nodes with anthracosis (one of the fragments seen only on the frozen sections). 
-No carcinoma identified. 

c. Lymph node, L7 (1 node), excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

d. Lymph node, 4L (3 nodes), excision:
-Fragments of lymph nodes with anthracosis. 
-No carcinoma identified. 

e. Lymph node, 9 node (1 node), excision:
-Fragment of lymph node with anthracosis. 
-No carcinoma identified. 

f. Lymph node, 10L anterior, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

g. Lymph node, 7 node, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

h. Lymph node, 12 node peritumoral lingular/bronchus, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

i. Lymph node, 12 superior aspect lingular bronchus, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

j. Lymph node, #5, excision:
-Fragment of lymph node with anthracosis. 
-No carcinoma identified. 

K. Lung, lingula, excision: Carcinoma of the lung with the following features:  Histologic type:  Mucoepidermoid carcinoma (of submucosal salivary glands of          bronchus).  Tumor size:   0.8 cm.  Tumor focality:  Unifocal.  Histologic grade:  Low to intermediate grade G 1-2 of 3.  Specimen integrity:  Intact.  Sites of invasion:  Tumor restricted to bronchial submucosa.   Lung parenchyma invasion: Not identified.   Pleural invasion:  Not identified.   Main bronchus invasion: Not identified.  Lymph-vascular invasion: Not identified. Margins:  Bronchial margin:  The tumor is present at the bronchial margin of the specimen;         The revised bronchial margin (part L) shows no carcinoma.  Parenchymal margin:  Uninvolved.  Vascular margin:  Uninvolved. Regional lymph nodes:   Three N1 lymph nodes identified. 
Zero N1 lymph nodes with metastatic carcinoma (0/3).  Seven N2 lymph nodes identified. 
Zero N2 lymph nodes with metastatic carcinoma (0/7).  Two N3 lymph nodes identified.
Zero N3 lymph nodes with metastatic carcinoma (0/3). Non-Neoplastic Lung:  Emphysematous changes. Pathological stage:  pT1a, pN0 (AJCC 7th edition).

l. Bronchus, ''revised bronchial stump'', excision:
-Bronchial wall with chronic inflammation. 
-No carcinoma identified, multiple levels through the block are examined.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.

Mucicarmine histochemical stain was performed and highlights the areas of extracellular and intracellular mucin. Oncocytic features are noted.
INTRAOPERATIVE DX:
B. 4R nodes (frozen section): No evidence of malignancy.
C. 7 node (frozen section): No evidence of malignancy.
D. 4L lymph node (frozen section): No evidence of malignancy.
E. 9 node (frozen section): No evidence of malignancy.
F. 10L anterior node (frozen section): No evidence of malignancy. 
G. 7 node (frozen section): No evidence of malignancy. 
H. 12 node peritumoral lingula/bronchus (frozen section): No evidence of malignancy. 
Left lymph node No. 12 superior aspect lingular bronchus (frozen section): No evidence of malignancy.
J and L., lymph node designated '''' and lingular bronchial margin (frozen sections): No evidence of malignancy.
GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''A. left anterior chest wall nevus'', is a 1.1 x 0.6 cm unoriented skin ellipse with a depth of 0.2 cm. There is a 0.5 x 0.5 cm hyperpigmented area. The tips are submitted in A1 and the remaining specimen submitted in A2.
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''B. 4R nodes (2)'', are two 0.3-0.5 cm tan-gray possible lymph nodes, which are frozen and entirely submitted in B1.
C. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''C. L7 node'', are multiple tan, pink-to-gray, fragmented portions of soft tissue, collectively 1.5 x 1.3 x 0.2 cm. The specimen is frozen and entirely submitted in C1.
D. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''D. 4L (3 nodes)'', are multiple fragmented tan, pink-to-gray portions of soft tissue, collectively 1.5 x 1 x 0.1 cm. The specimen is frozen and entirely submitted in D1.
E. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''E. 9 node (1 node)'', is a 1.2 x 0.5 x 0.1 cm tan-gray portion of possible lymph node, frozen and entirely submitted in E1.
F. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''F. 10L anterior'', are two 0.6 and 1 cm gray-black portions of possible lymph node, which are frozen and entirely submitted in F1. (**INITIALS:cmc78 306605)
G. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''G. 7 node'', is a 1.7 x 1.7 x 0.4 cm aggregate of multiple fragments of black lymphoid tissue with adherent adipose tissue. The specimen was previously frozen and submitted in G1. 
H. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''H. 12 node peritumoral lingular/bronchus'', is a 1.1 x 0.7 x 0.4 cm aggregate of multiple fragments of black lymphoid tissue with adherent adipose tissue. The specimen was previously frozen and submitted in H1.
I. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''I. 12 superior aspect lingular bronchus'', is a 1 x 0.6 x 0.4 cm aggregate of multiple fragments of black lymphoid tissue with adherent adipose tissue. The specimen was previously frozen and submitted in I1. 
J. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''J. lymph node No. 5'', is a 0.6 x 0.4 x 0.2 cm fragment of black lymphoid tissue. The specimen was previously frozen and submitted in J1.
K. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''K. lingula'', is a 33-gram, 10 x 9.5 x 3.5 cm lingulectomy specimen received with a staple line, which is removed, and the underlying parenchyma is inked blue. There is a 0.8 cm in diameter, tan-white mass within the bronchus less than 0.1 cm from the bronchial margin, 0.4 cm from the surgical margin and 0.7 cm from the overlying pleura. There is also a moderate amount of mucus plugging within the adjacent vasculature and airways. The remainder of the specimen consists of red-brown, spongy soft tissue. Representative sections are submitted as follows: K1 - vascular and bronchial margins, en face; K2 - remainder of mass in bronchus, bisected; K3 - representative sections of mucus plugging; K4 - normal central and peripheral parenchyma. 
L. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''L. revised bronchial stump'', is a 1 cm diameter by 0.2 cm thick portion of bronchus. The specimen was previously frozen and submitted in L1. (**INITIALS:cmc94 306783) (RDR:cmc131 307765)
CLINICAL INFO:
Malignant neoplasm of bronchus and lung, unspecified site.
ICD-9 code: 162.9.Consult
**NAME[M. ZZZ], MD (part K, QA).
FINAL DX:

a. Skin, left anterior chest wall, nevus, excision:
-Seborrheic keratosis. 
-No malignancy identified. 

b. Lymph node, 4R (2 nodes), excision:
-Two fragments of lymph nodes with anthracosis (one of the fragments seen only on the frozen sections). 
-No carcinoma identified. 

c. Lymph node, L7 (1 node), excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

d. Lymph node, 4L (3 nodes), excision:
-Fragments of lymph nodes with anthracosis. 
-No carcinoma identified. 

e. Lymph node, 9 node (1 node), excision:
-Fragment of lymph node with anthracosis. 
-No carcinoma identified. 

f. Lymph node, 10L anterior, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

g. Lymph node, 7 node, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

h. Lymph node, 12 node peritumoral lingular/bronchus, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

i. Lymph node, 12 superior aspect lingular bronchus, excision:
-Fragments of lymph node with anthracosis. 
-No carcinoma identified. 

j. Lymph node, #5, excision:
-Fragment of lymph node with anthracosis. 
-No carcinoma identified. 

K. Lung, lingula, excision: Carcinoma of the lung with the following features:  Histologic type:  Mucoepidermoid carcinoma (of submucosal salivary glands of          bronchus).  Tumor size:   0.8 cm.  Tumor focality:  Unifocal.  Histologic grade:  Low to intermediate grade G 1-2 of 3.  Specimen integrity:  Intact.  Sites of invasion:  Tumor restricted to bronchial submucosa.   Lung parenchyma invasion: Not identified.   Pleural invasion:  Not identified.   Main bronchus invasion: Not identified.  Lymph-vascular invasion: Not identified. Margins:  Bronchial margin:  The tumor is present at the bronchial margin of the specimen;         The revised bronchial margin (part L) shows no carcinoma.  Parenchymal margin:  Uninvolved.  Vascular margin:  Uninvolved. Regional lymph nodes:   Three N1 lymph nodes identified. 
Zero N1 lymph nodes with metastatic carcinoma (0/3).  Seven N2 lymph nodes identified. 
Zero N2 lymph nodes with metastatic carcinoma (0/7).  Two N3 lymph nodes identified.
Zero N3 lymph nodes with metastatic carcinoma (0/3). Non-Neoplastic Lung:  Emphysematous changes. Pathological stage:  pT1a, pN0 (AJCC 7th edition).

l. Bronchus, ''revised bronchial stump'', excision:
-Bronchial wall with chronic inflammation. 
-No carcinoma identified, multiple levels through the block are examined.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.

Mucicarmine histochemical stain was performed and highlights the areas of extracellular and intracellular mucin. Oncocytic features are noted.
INTRAOPERATIVE DX:
B. 4R nodes (frozen section): No evidence of malignancy.
C. 7 node (frozen section): No evidence of malignancy.
D. 4L lymph node (frozen section): No evidence of malignancy.
E. 9 node (frozen section): No evidence of malignancy.
F. 10L anterior node (frozen section): No evidence of malignancy. 
G. 7 node (frozen section): No evidence of malignancy. 
H. 12 node peritumoral lingula/bronchus (frozen section): No evidence of malignancy. 
Left lymph node No. 12 superior aspect lingular bronchus (frozen section): No evidence of malignancy.
J and L., lymph node designated '''' and lingular bronchial margin (frozen sections): No evidence of malignancy.
GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''A. left anterior chest wall nevus'', is a 1.1 x 0.6 cm unoriented skin ellipse with a depth of 0.2 cm. There is a 0.5 x 0.5 cm hyperpigmented area. The tips are submitted in A1 and the remaining specimen submitted in A2.
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''B. 4R nodes (2)'', are two 0.3-0.5 cm tan-gray possible lymph nodes, which are frozen and entirely submitted in B1.
C. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''C. L7 node'', are multiple tan, pink-to-gray, fragmented portions of soft tissue, collectively 1.5 x 1.3 x 0.2 cm. The specimen is frozen and entirely submitted in C1.
D. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''D. 4L (3 nodes)'', are multiple fragmented tan, pink-to-gray portions of soft tissue, collectively 1.5 x 1 x 0.1 cm. The specimen is frozen and entirely submitted in D1.
E. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''E. 9 node (1 node)'', is a 1.2 x 0.5 x 0.1 cm tan-gray portion of possible lymph node, frozen and entirely submitted in E1.
F. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''F. 10L anterior'', are two 0.6 and 1 cm gray-black portions of possible lymph node, which are frozen and entirely submitted in F1. (**INITIALS:cmc78 306605)
G. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''G. 7 node'', is a 1.7 x 1.7 x 0.4 cm aggregate of multiple fragments of black lymphoid tissue with adherent adipose tissue. The specimen was previously frozen and submitted in G1. 
H. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''H. 12 node peritumoral lingular/bronchus'', is a 1.1 x 0.7 x 0.4 cm aggregate of multiple fragments of black lymphoid tissue with adherent adipose tissue. The specimen was previously frozen and submitted in H1.
I. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''I. 12 superior aspect lingular bronchus'', is a 1 x 0.6 x 0.4 cm aggregate of multiple fragments of black lymphoid tissue with adherent adipose tissue. The specimen was previously frozen and submitted in I1. 
J. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''J. lymph node No. 5'', is a 0.6 x 0.4 x 0.2 cm fragment of black lymphoid tissue. The specimen was previously frozen and submitted in J1.
K. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''K. lingula'', is a 33-gram, 10 x 9.5 x 3.5 cm lingulectomy specimen received with a staple line, which is removed, and the underlying parenchyma is inked blue. There is a 0.8 cm in diameter, tan-white mass within the bronchus less than 0.1 cm from the bronchial margin, 0.4 cm from the surgical margin and 0.7 cm from the overlying pleura. There is also a moderate amount of mucus plugging within the adjacent vasculature and airways. The remainder of the specimen consists of red-brown, spongy soft tissue. Representative sections are submitted as follows: K1 - vascular and bronchial margins, en face; K2 - remainder of mass in bronchus, bisected; K3 - representative sections of mucus plugging; K4 - normal central and peripheral parenchyma. 
L. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''L. revised bronchial stump'', is a 1 cm diameter by 0.2 cm thick portion of bronchus. The specimen was previously frozen and submitted in L1. (**INITIALS:cmc94 306783) (RDR:cmc131 307765)
CLINICAL INFO:
Malignant neoplasm of bronchus and lung, unspecified site.
ICD-9 code: 162.9.
PATHOLOGIST:
Ranguelov Rostislav D  

SNOMED Code(s)
P1100M09450D7610T26000P1100M43000M09450TY2130T28000M32800T08000M80106T40000T26000T00100M80001M09400T29000T02424TX6110T28000P1100M84303M80103T08000P1100M09450D7610T08330P1100T08000P1100D7610T08330T08000P1100M09450M09450D7610T08000M87200P1100M09450D7610T08000P1100M09450D7610T08000P1100M09450M72750D7610T08000P1100M09450D7610T08000P1100M09450D7610T08000M09450",,,,,
REG3,LUNG,0,PAT-00749293,2,REC-5000789154,,,,"<CLINICAL INFO>
Right lung cancer.

<GROSS>
A.  Received in formalin labeled with the patient's name and designated 'A, bronchus intermedius tumor', are multiple tan-pink to pink-red friable soft tissue fragments ranging from 0.1 to 0.2 cm in greatest dimension and aggregating to 0.5 x 0.5 x 0.2 cm.  The specimen is wrapped and submitted entirely in cassette A1.
B.  Received in formalin labeled with the patient's name and designated 'B, 4R', are four pink-gray lymph node candidates ranging from 0.4 to 0.5 cm in greatest dimension which are submitted entirely in cassette B1.
C.  Received in formalin labeled with the patient's name and designated 'C, 2R', is a single pink-gray lymph node candidate measuring 1.0 x 0.5 x 0.5 cm which is submitted entirely in cassette C1.
D.  Received in formalin labeled with the patient's name and designated 'D, 4L', are four tan-pink to pink-gray lymph node candidates ranging from 0.2 to 0.4 cm in greatest dimension which are submitted entirely in cassette D1.
E.  Received in formalin labeled with the patient's name and designated 'E, station 7', are three pink-gray lymph node candidates ranging from 0.2 to 0.5 cm in greatest dimension which are wrapped and submitted entirely in cassette E1.
**INITIALS  **DATE[Oct 11 12]

<MICROSCOPIC>
A.  The lung biopsy contains an infiltrate of poorly differentiated non-small cell carcinoma with focal gland formation.  In order to further characterize the neoplastic population, immunohistochemical stains for TTF1, napsin, CK5/6, p63, and CK7 are performed on block A1.  The neoplastic cells are diffusely and strongly positive for CK7, focally and weakly positive for CK5/6 and p63, and negative for TTF1 and napsin.  This immunophenotype is not specific, however the diffuse staining for CK7 and the focal gland formation favors an adenocarcinoma.  
B-E.  H&E-stained sections are examined.
This case has undergone prospective intradepartmental quality assurance review prior to verification.  
**INITIALS  **DATE[Oct 12 12]


<FINAL DX>
A.  LUNG, BRONCHUS INTERMEDIUS TUMOR, BIOPSY:  
  NON-SMALL CELL CARCINOMA, NOT OTHERWISE SPECIFIED (SEE COMMENT).  
B.  LYMPH NODE, 4R, BIOPSY: 
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA.  
C.  LYMPH NODE, 2R, BIOPSY:  
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA.  
D.  LYMPH NODE, 4L, BIOPSY:  
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA. 
E.  LYMPH NODE, STATION 7, BIOPSY:  
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA.

<DX COMMENT>
The immunophenotype (diffusely CK7 positive, focally and weakly CK5/6 and p63 positive, and negative for TTF-1 and napsin) is non-specific, although the diffuse CK7 staining favors an adenocarcinoma.  The tissue block A1 will be forwarded for EGFR analysis and if negative, ALK studies will be performed.


<ADDENDUM>
This addendum is issued to report the results of EGFR mutation analysis.
EGFR Mutation Analysis by real time PCR is performed at PhenoPath Laboratories.  Per report, the results are NEGATIVE.  Please refer to PhenoPath case #***PATH-NUMBER[1] for complete report details.
**INITIALS  **DATE[Oct 19 12], ALK gene rearrangement studies by FISH were performed through PhenoPath Laboratories at Cynogen/Plus Diagnostics.  Per report, the results are NEGATIVE for ALK rearrangement.  Please refer to PhenoPath Laboratories case #***PATH-NUMBER[2] for complete report details.
**INITIALS  **DATE[Oct 31 12],",,,,,
REG3,LUNG,0,PAT-00750827,1,REC-5000789227,,,,"<CLINICAL INFO>
Left lower lobe lung cancer.

<GROSS>
A.  Received in formalin, labeled with the patient's name and designated as '4R' are multiple fragments of anthracotically pigmented lymphoid tissue ranging in greatest dimension from 0.2 cm to 2.0 cm.  These fragments of lymphoid tissue are wrapped and submitted in their entirety in cassette A1.  
B.  Received in formalin, labeled with the patient's name and designated as '4L' are four fragments of anthracotically pigmented lymphoid tissue ranging in greatest dimension from 0.2 cm to 0.6 cm.  These fragments are wrapped and submitted in their entirely in cassette B1.  
C.  Received in formalin, labeled with the patient's name and designated as 'station 7' are two fragment of anthracotically pigmented lymphoid tissue measuring 1.0 x 1.5 cm in greatest dimension.  These fragments are wrapped and submitted in their entirety in cassette C1.  
**INITIALS  **DATE[Nov 01 12]

<MICROSCOPIC>
A.-C.  H&E-stained sections examined.
**DATE[Nov 2 12]


<FINAL DX>
A.  LYMPH NODE, 4R, BIOPSY:
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA.
B.  LYMPH NODE, 4L, BIOPSY:
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA.
C.  LYMPH NODE, STATION 7, BIOPSY:
  BENIGN ANTHRACOTIC LYMPH NODE; NEGATIVE FOR CARCINOMA.",,,,,
REG3,LUNG,0,PAT-00752828,1,REC-5000789491,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  A) RIGHT LUNG, LOWER LOBE MASS, CT-GUIDED NEEDLE BIOPSY: ADENOCARCINOMA
(see comment).
B) RIGHT LUNG, LOWER LOBE MASS, CT-GUIDED FNA: NON-DIAGNOSTIC FOR
MALIGNANCY (very scant).
COMMENT:A) Invasive adenocarcinoma with mucinous features.  Its
morphology and immunophenotype (CK7-positive, CK20-negative,
TTF1-negative, CDX2-negative) are not specific for primary site but
compatible with primary pulmonary origin (also can be seen in upper GI and
pancreato-biliary primary sites; while colorectal primary site is
unlikely). Please correlate clinically and radiographically.

<PATHOLOGIST>
   **NAME[ZZZ, YYY]             Electronically Signed: **DATE[Feb 11 2012]
<SPECIMEN(S)>
  A) RLL mass core bx
B) RLL mass aspirate in CytoRich red
<GROSS>
  A) Received in a container labeled with the patient's name and ""RLL mass""
is a 0.6 cm fine/slim white needle core, AE/(1). 
B) Received is CytoRich red vial for one pap SurePath and one H&E
cellblock slide.
<MICROSCOPIC>
  A) Slim core of fibrous stroma with invasive adenocarcinoma with mucinous
features.  
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES RESULTS (carcinoma cells, A1): 
1. CYTOKERATIN 20 (Ks20.8): NEGATIVE 
2. CYTOKERATIN 7 (OV-TL12/30): POSITIVE (uniformly)
3. TTF-1 (8G7G3/1): NEGATIVE (positive internal control)
4. CDX2 (CDX2-88): NEGATIVE 
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.
B) Scant cellularity, some necrosis; no diagnostic carcinoma cell
population identified.",,,,,
REG3,LUNG,0,PAT-00356767,2,REC-5000790233,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Right Lung, Lower Lobe, CT-Guided Core Biopsies (6):
Moderately differentiated pulmonary adenocarcinoma.

<COMMENT>
As part of our quality assurance policy for the confirmation of new
cancers, the histologic sections of the specimen have been reviewed by
another pathologist, Dr. **NAME[ZZZ M. YYY], who agrees with the
presence of an adenocarcinoma with a pulmonary immunophenotype.

<CLINICAL INFO>
Newly identified mass in the gastroesophageal recess and right lower
lobe lung lesion. .

INTRAPROCEDURAL EVALUATION:
Right lower lobe lung, core biopsies 1-3 (touch prep): ""Malignant cells
seen.""
Performed by: **NAME[XXX M. WWW], M.D

<GROSS>
A CT-guided 20-gauge core biopsy procedure of a right lower lobe
pulmonary nodule was performed by interventional radiologist Dr. **NAME[VVV
UUU]. The patient was identified as ""**NAME[AAA BBB]"", birth date
**DATE[Aug 01 1938] by the radiology staff. Initially, three core biopsies were
performed, yielding slivers of pale tan tissue. One Diff-Quik-stained
air-dried imprint smear was prepared from each biopsy and the three
imprint smears were immediately examined by pathologist Dr. **NAME[XXX M.
WWW], who rendered the stat diagnosis listed above. To end the
procedure, additional core biopsies were obtained, none of which were
utilized to prepare imprint smears. The biopsies were fixed in formalin
and submitted for histologic processing in cassettes A1-A3. (ehk/jmk)

<MICROSCOPIC>
Histologic HE sections at different levels of the specimen show thin
pieces of tissue that do not include normal pulmonary alveolar tissue.
Instead, the sections show fibrous tissue with many elastic fibers and
with scattered malignant glands lined by single layers of cuboidal or
low columnar malignant epithelial cells. The malignant glandular
epithelium contains moderately large round hyperchromatic nuclei.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A2

Antibody  Result    Comment
CK7  Diffusely positive
CK20 Negative
TTF-1     Diffusely positive
Napsin A  Diffusely positive
CDX-2     Negative

Impression:  Adenocarcinoma with a pulmonary immunophenotype.
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:  Reviewed by pathologist **NAME[ZZZ M. YYY], M.D.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[Mar 07 2012]",,,,,
REG3,LUNG,0,PAT-00753198,1,REC-5000793100,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Right Bronchoalveolar Lavage, Cytology With Cell Block:
Malignant cells present, consistent with adenocarcinoma.

B.  Bronchial Washing, Cytology With Cell Block:
Malignant cells present, consistent with adenocarcinoma.

C.  Right Lower Lobe, Bronchial Brushing, Cytology:
Malignant cells present, consistent with adenocarcinoma.

D.  Right Middle Lobe, Bronchial Brushing, Cytology:
Malignant cells present, consistent with adenocarcinoma.

E.  Right Middle Lobe and Right Lower Lobe, Endobronchial Biopsies:
Adenocarcinoma, poorly differentiated (see comment).

F.  Transbronchial Biopsies:
Adenocarcinoma, poorly differentiated (see comment).

<COMMENT>
Although the morphologic features are compatible with lung origin, the
immunohistochemical findings (negative TTF-1 and napsin A) are
nonspecific. Metastasis from other sites should be excluded clinically.

Per clinician request (Dr. **NAME[ZZZ YYY]), molecular studies (EGFR mutational
analysis and, if negative, ALK FISH) will be performed and reported in
an addendum.

<CLINICAL INFO>
Right lung mass.

<GROSS>
A.  Received on **DATE[May 04 2012] is 10 ml of clear, light orange, mucoid fluid
labeled ""**NAME[BBB, AAA]"", designated ""right bronchial lavage"" per
requisition. Prepared are one ThinPrep Pap-stained slide, one air-dried
cytocentrifuged Diff-Quik-stained slide and one cell block.

B.  Received on **DATE[May 04 2012] is 10 ml of hemorrhagic mucoid fluid labeled
""**NAME[BBB, AAA]"", designated ""bronchial wash"" per requisition. Prepared
are one ThinPrep Pap-stained slide, one air-dried cytocentrifuged
Diff-Quik-stained slide and one cell block.

C.  A specimen labeled ""**NAME[BBB, AAA]"", designated ""right lower lobe
bronchial brush"" per requisition is received in 20 ml of PreservCyt with
brush on **DATE[Jul 04 2011]. Prepared is one ThinPrep Pap-stained slide.

D.  A specimen labeled ""**NAME[BBB, AAA]"", designated ""right mid lobe
bronchial brush"" per requisition is received in 20 ml of PreservCyt with
brush on **DATE[May 04 2012]. Prepared is one ThinPrep Pap-stained slide.
(rc/gdb)

E.  Received in formalin, labeled ""**NAME[AAA BBB]"", designated ""three
endobronchial biopsies RML and RLL in formalin"", are three 0.1-0.2 cm
biopsies, which are submitted in one cassette.

F.  Received in formalin, labeled ""**NAME[AAA BBB]"", designated ""four
transbronchial biopsies in formalin"", are four 0.2 cm biopsies, which
are submitted in one cassette. (ke/jmk)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

SPECIAL STAINS:
A mucin stain confirms the presence of numerous tumor cells with
intracytoplasmic mucin (greater than 5 tumor cells per high-power
field), supporting the diagnosis of adenocarcinoma.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block F1

Antibody  Result    Comment
TTF-1     Negative
p63  Focally positive    Rare cells weakly staining.
Napsin A  Negative
CDX-2     Negative

Impression:  The immunohistochemical results support the diagnosis.
Interpreted by:  **NAME[XXX M. WWW] MD
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

PHYSICIAN NOTIFICATION:
Case discussed with Dr. **NAME[ZZZ YYY] on **DATE[May 07 2012].

INTRADEPARTMENTAL CONSULTATION:
**NAME[VVV M. UUU], M.D.

**NAME[XXX M. WWW], MD.  Electronically signed **DATE[May 09 2012]",,,,,
REG3,LUNG,0,PAT-00753346,1,REC-5000793106,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Lung Mass, Fine Needle Aspiration with Cell Block:
  Positive for malignancy.
  Adenocarcinoma, consistent with lung origin.

<CLINICAL INFO>
Smoker; PET-positive lung mass.

INTRAPROCEDURAL EVALUATION:
Lung mass (fine needle aspiration): ""Non-small cell carcinoma. Need
material in fixative"".
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A specimen labeled ""**NAME[BBB, AAA]"", and designated ""lung mass FNA""
per requisition, is received in 30 ml of CytoLyt collection fluid on
**DATE[Jan 07 2012]. Prepared is one cell block. Also received on **DATE[Jan 07 2012] are
two alcohol-fixed direct smears labeled ""**NAME[BBB, M]"", and designated
""lung mass FNA"" per requisition. The alcohol-fixed smears are
Papanicolaou stained. Two air-dried smears were kept in Olympia.
(lw/nd)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
p63  Negative
TTF-1     Positive

Impression:  The immunohistochemical results support the diagnosis.
Interpreted by:  **NAME[XXX M. WWW] MD
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[M. VVV UUU], M.D.

**NAME[XXX M. WWW], MD.  Electronically signed **DATE[Jan 09 2012]",,,,,
REG3,LUNG,0,PAT-00753651,1,REC-5000795130,,,,"PART / DESCRIPTION - SEQ# 
Lung Bx/ Lung Biopsy- 1
<INTRAOPERATIVE DX>
NONE
<MICROSCOPIC>
NONEInterpretation
Deparaffinized sections of formalin fixed tissue (along with appropriate positive and negative controls) are incubated with the following antibody(s). Using the automated Ventana stainer, tissue is incubated with the designated antibody which is then localized by a non-biotin, dual polymer detection system. The controls are reviewed for appropriate reactivity and found to be adequate. Results on the target cell population are indicated below:
Some of the immunohistochemistry stains reported below were developed and their performance characteristics determined by Skagit Pathology. They have not been cleared or approved by the U.S. Food and Drug Administration, although such approval is not required for analyte-specific reagents of this type.
 
ANTIBODIES TO:    CLONE:    RESULTS:

CYTOKERATIN 7    OV-TL **DATE[Jun 31]    positive
CYTOKERATIN 20    KS20.8     negative
TTF-1      8G7G3/1    positive
SURFACTANT PROTEIN A   AB49566    negative
VILLIN      CWWB1    negative
CDX2      CDX2-88    negative

**DATE[Apr 25 2012] PNM
<FINAL DX>
Right lung lesion, biopsy: Bronchial mucosa with invasive moderate to poorly differentiated PULMONARY adenocarcinoma

**DATE[Apr 24 2012] PNM
<GROSS>
The specimen is received in one formalin filled container labeled with the patient's name, sublabeled ""biopsy right lung lesion"", and consists of multiple irregularly shaped fragment(s) of pale tan tissue aggregating to 1.1 x 0.3 x 0.2 cm. The specimen is filtered through a tissue bag and submitted as cassette A. **DATE[Apr 21 2012] AO
<CLINICAL INFO>
Abnormal CT showing lung lesion
1). Biopsy right lung lesion<PATHOLOGIST>
**NAME[ZZZ YYY M].

<SNOMED Code(s)>
T28100T28000T26010P1140M814033",,,,,
REG3,LUNG,0,PAT-00390689,2,REC-5000796757,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Molecular results

<FINAL DX>     

Left Lung Core Biopsy:
Adenocarcinoma.
Immunohistochemical stains are consistent with lung primary.
EGFR studies pending, addendum to follow.

<CLINICAL INFO>
Lung mass.

INTRAPROCEDURAL EVALUATION:
Lung mass (touch prep): ""Diagnosis deferred to sections"".
Performed by:  **NAME[ZZZ M YYY], M.D.

<GROSS>
Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""L
lung"", are five 0.1 cm in diameter elongated portions of tissue, 0.3-1
cm in length, entirely submitted in A1.  (rtb/dg)

<MICROSCOPIC>
Two touch preps, cytology slides, and one permanent HE slide are
examined. The core biopsy has groups of atypical cells arranged in
glandular configurations, with hyperchromatic vesicular enlarged nuclei.
The background is fibrotic and has a lymphoid infiltrate.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
TTF-1     Positive
CK7  Positive
CK20 Positive

Impression:  This staining pattern is consistent with a lung primary.
This pattern is most often associated with a mixed bronchoalveolar or
mucinous adenocarcinoma.
Interpreted by:  **NAME[XXX M. WWW] M.D.
Comment:  Immunohistochemical stains are performed to further
characterize the tumor.

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[ZZZ M. YYY], M.D.

PHYSICIAN NOTIFICATION:
The finding of adenocarcinoma in this biopsy was reported to Dr. **NAME[VVV] by
telephone on **DATE[May 15 12] at 2:25 p.m. by Dr. **NAME[WWW].

**NAME[XXX M. WWW], M.D.  Electronically signed **DATE[May 15 2012]

<ADDENDUM>  #1

EGFR MUTATION ANALYSIS; MOLECULAR (PCR) REPORT:
Testing performed by: **PLACE, WA **ZIP-CODE, report
***PATH-NUMBER[2],
issued **DATE[May 17 2012].
Interpreted by: **NAME[UUU TTT], M.D.

Result: Left Lung Mass, Core Biopsy:  Negative for an EGFR mutation by
real time PCR (see Comments).

Comment: In this case no epidermal growth factor receptor (EGFR)
mutations were identified by Quigen/DxS real time PCR. This real time
PCR assay has been validated to identify the most common EGFR tyrosine
kinase domain mutations that involve exons 18-21. This test is validated
for non-small cell lung carcinoma. The clinical significance and use of
this assay in other tumor types is not well characterized. Note that
this assay is not intended to diagnose any particular type of cancer,
but as an aid to clinicians, is intended to be used as an adjunct to
other prognostic factors to select eligible patients for therapy. (refs:
**NAME[SSS] et al., NEJM 2004;**ID-NUM, Mok et al., NEJM 2009; **ID-NUM,
Pao et al., JClinOnc 2005; **ID-NUM).

Addendum #1 performed by **NAME[XXX M. WWW], M.D.  Electronically
signed **DATE[May 18 2012]",,,,,
REG3,LUNG,0,PAT-00753457,1,REC-5000798387,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Immunohistochemistry results

<FINAL DX>     

A.  Liver, Fine Needle Aspiration with Cell Block Preparation:
     High grade carcinoma; additional immunohistochemical stains will be
performed for
        further subtyping.

B.  Liver, Core Biopsies:
     High grade carcinoma; additional immunohistochemical stains will be
performed for
        further subtyping.

<COMMENT>
The initial battery of immunohistochemical stains showing negative CK20
and CDX-2 results would seem to indicate that a metastatic colonic
carcinoma is unlikely.  The negative synaptophysin and chromogranin
stains would suggest against a neuroendocrine tumor, but there is a
proportion of neuroendocrine tumors that could be negative for both
markers.  The positive pankeratin and CK7 would be compatible with a
carcinoma.  Additional immunohistochemical staining for squamous cell
carcinoma will be attempted (CK 5/6 and p63) and the results issued as
an addendum to this report.  These results have been reviewed with Dr.
**NAME[ZZZ] on **DATE[Nov 23 12] at 3 PM.

<CLINICAL INFO>
Liver mass with a lung mass.

INTRAPROCEDURAL EVALUATION:
A.  Fine Needle Aspiration Smears:  Adequate material present.
B.  Touch Preparation Smears:  Adequate material present.
Prepared by:  Dr. **NAME[YYY XXX]

<GROSS>
A.  Received from Dr. **NAME[WWW] in the CT Suite and identified as ""FNA liver""
is a scant amount of bloody material in a syringe from which one
air-dried and one alcohol fixed smear are prepared.  Immediate
interpretation of the air-dried smear by Dr. **NAME[XXX] is as above.  The
material remaining in the syringe is submitted in CytoLyt solution for
concentrated smear and cell block preparation.

B.  Received from Dr. **NAME[WWW] in the CT Suite and identified as ""Core
Liver"" are three cores of white-tan tissue ranging up to 0.7 cm. in
length, from which 2 air-dried smears and 2 alcohol fixed smears are
prepared.  Immediate interpretation of the air-dried smears by Dr. **NAME[XXX]
is as above.  The cores are submitted for processing in one cassette.

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block B1

Antibody  Result    Comment
Synaptophysin  Negative
Chromogranin   Negative
Pan CK    Positive
TTF-1     Negative
CDX-2     Negative
CK7  Positive
CK20 Negative

Impression:
Interpreted by:  **NAME[YYY M. XXX] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONULTATION:
Dr. **NAME[VVV UUU] agrees with the diagnosis of high grade carcinoma.

**NAME[YYY M. XXX], M.D.  Electronically signed **DATE[Nov 23 2012]
**PHONE  (Physician to Physician Only)

<ADDENDUM>  #1

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block B1

Antibody  Result    Comment
CK 5/6    Positive
p63  Positive

Impression:
The tumor is focally strongly positive for both CK5/6 and p63.  These
positive results indicate a poorly differentiated squamous phenotype for
the carcinoma.
cdsmd
Interpreted by:  **NAME[VVV M. UUU] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

Addendum #1 performed by **NAME[VVV M. UUU], M.D.  Electronically signed
**DATE[Nov 25 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,LUNG,0,PAT-00753352,1,REC-5000799598,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Reference Laboratory Results

<FINAL DX>     

A.  Lung, Right Lower Lobe, Radiologically Guided Core Biopsy:
     Non-small cell carcinoma, favor adenosquamous carcinoma.

B.  Lung, Right Lower Lobe, Radiologically Guided Fine Needle
Aspiration:
     Non small cell carcinoma, favor adenosquamous carcinoma.

<COMMENT>
The slides confirm a moderately differentiated non-small cell carcinoma
with a predominantly sheet-like growth pattern.  Immunohistochemical
studies (see below) confirm a squamous phenotype with uniform CK5/6
positivity.  Focal areas appear to show some intracytoplasmic mucin and
vacuoles, and the lesional cells in one area of the tumor are positive
for Napsin A and TTF-1, suggesting a partial glandular differentiation,
based upon this small sample an intermediate grade adenosqaumous
carcinoma is favored.

<CLINICAL INFO>
Patient is a former smoker who presents now with shortness of breath and
is found to have a 4.5 cm right paratracheal mass and a 5.3 cm inferior
right hilar mass encasing the right bronchus intermedius and associated
artery on chest CT.  ICD-9 Code(s): 766.6, 511.9, 496

INTRAPROCEDURAL EVALUATION:
A. Lower lung, right (touch prep): ""Nonsmall cell carcinoma.""  Based on
1 slide read at 3:11 on **DATE[Mar 15 12].
B. Lower lung, right (FNA): ""Nonsmall cell carcinoma.""   Based on 1
slide read at 3:13 on **DATE[Mar 15 12].
Performed by: **NAME[ZZZ M. YYY], M.D.

<GROSS>
A. Received in formalin, labeled ""**NAME[BBB, AAA]"" and designated ""right
lower lung"", are three 0.1 cm in diameter elongated portions of tissue
0.2-0.3 cm in length, entirely submitted in A1. Prior to placing the
cores in formalin, one air-dried and one alcohol-fixed touch preparation
are made.  The air-dried slide is Diff-Quik stained.  The alcohol-fixed
slide is Papanicolaou stained.(pcs/gdb/jmk/cds)

B. The specimen is designanted right lower lung and consists of one
air-dried direct smear, one alcohol-fixed direct smear and one 10 ml
blood tinged needle rinsing fluid collection.  The air-dried smear is
Diff-Quik stained.  The alcohol-fixed direct smear is Papanicolaou
stained.  The fluid is used to create a single alcohol-fixed and
Papanicolaou stained cytospin slide.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
TTF-1     Focally positive
Napsin A  Focally positive
p63  Focally positive
CK 5/6    Uniformly positive

Impression:
Interpreted by:  **NAME[ZZZ M. YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

<MICROSCOPIC>
The final diagnoses for each specimen are based on microscopic
examinations of the tissues and cells.

INTRADEPARTMENTAL CONSULTATION:
CellNetix pathologist, **NAME[M. XXX], M.D., has reviewed and concurs with the
diagnosis of non-small cell carcinoma.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Mar 17 2012]
**PHONE  (Physician to Physician Only)

ADDENDUM #1:

EGFR MUTATION MOLECULAR (PCR) STUDIES:
Testing performed by: **PLACE, WA **ZIP-CODE, report
***PATH-NUMBER[2].
Interpreted by: **NAME[WWW VVV], M.D., issued: **DATE[Mar 29 2012].

Result:  Lung, Right Lower Lobe:  NEGATIVE for an EGFR mutation by real
time PCR.

Comment:  In this case no epidermal growth factor receptor (EGFR)
mutations were identified by Qiagen/DxS real time PCR. This real time
PCR assay has been validated to identify the most common EGFR tyrosine
kinase domain mutations that involve exons 18-21. This test is validated
for non-small cell lung carcinoma. The clinical significance and use of
this assay in other tumor types is not well characterized. Note that
this assay is not intended to diagnose any particular type of cancer,
but as an aid to clinicians, is intended to be used as an adjunct to
other prognostic factors to select eligible patients for therapy. (**NAME[UUU:
TTT] et al., NEJM 2004; **ID-NUM, Mok et al., NEJM 2009; **ID-NUM,
Pao et al., JClinOnc 2005; 23: 2556-68).

ALK FISH analysis has been initiated as requested, and the results will
be reported separately.

Addendum #1 performed by **NAME[ZZZ M. YYY], M.D.  Electronically signed
**DATE[Mar 29 2012]
**PHONE  (Physician to Physician Only)",,,,,
REG3,LUNG,0,PAT-00754289,1,REC-5000801853,,,,"PART / DESCRIPTION - SEQ# 
Pleural Fluid/ PLEURAL FLUID- 1<MICROSCOPIC>
PLEURAL FLUID: 
H&E stained slides from a cell block and cytologic preparations including a ThinPrep are examined.
Immunohistochemistry for CD56 shows reactivity in cohesive groups of atypical cells.





NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.<GROSS>
PLEURAL FLUID: 
(ll) Identified as **NAME[AAA BBB] and designated """"pleural fluid."""" Received is approximately 850 cc of reddish fluid from which one ThinPrep slide, two smears and a cell block are prepared for cytologic examination.<FINAL DX>

PLEURAL FLUID FOR CYTOLOGY: POSITIVE FOR NEUROENDOCRINE CARCINOMA
**INITIALS<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::
Comment
Dr. **NAME[ZZZ] agrees.PATHOLOGIST:
Love **NAME[YYY M.",,,,,
REG3,LUNG,0,PAT-00738431,1,REC-5000802189,,,,"PART / DESCRIPTION - SEQ# 
CT Guided Needle Biopsy (GSH)/ Liver biopsy- 1Comment
Dr. **NAME[ZZZ YYY] has reviewed this case and is in agreement.
**INITIALS<FINAL DX>

NEEDLE BIOPSY WITH TOUCH PREPARATIONS, LIVER MASS - METASTATIC SMALL CELL CARCINOMA OF PULMONARY ORIGIN.<MICROSCOPIC>
Needle biopsy sections and touch preparations are examined. The needle biopsies show mostly core biopsies of liver tissue, however, there are two core biopsies of a malignant tumor with features suggestive of small cell carcinoma. The uninvolved liver parenchyma is unremarkable.

Immunohistochemical stains are applied at Laboratories Northwest with positive controls with the following results:
 TTF-1:     Positive. Synaptophysin:   Positive. LCA:     Negative.

NOTE: Some of the tests reported here may have been developed and performance characteristics determined by Laboratories Northwest. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined the such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. Laboratories Northwest is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.<DIAGNOSIS COMMENTS>
Intraoperative Consult Dx::

NEEDLE BIOPSY WITH TOUCH PREPARATIONS, LIVER MASS: SCANT ATYPICAL CELLULAR MATERIAL. (EWA)<GROSS>
Received in formalin labeled, """"**NAME[AAA BBB]"""" and designated, """"liver biopsy"""" are multiple needle core biopsies of yellow-tan, granular tissue ranging up to 1.6 cm in length and each measuring 0.1 cm in diameter. Entirely submitted in a single cassette. Also submitted to Cytology for further evaluation are four H&E-stained smears and four air-dried smears. 
**INITIALS<CLINICAL INFO>
162.9 - malignant neoplasm of bronchus and lung, unspecified
Right lobe lesion (series 3 image 67 supine).PATHOLOGIST:
**NAME[XXX WWW M]",,,,,
REG3,LUNG,0,PAT-00754395,1,REC-5000804606,,,,"1001 Klickitat Way SW #205
**PLACE, WA **ZIP-CODE
REPORT
HEMATOPATHOLOGY CONSULTATION: FLOW CYTOMETRY REPORT
INTERPRETATION:
**INSTITUTION of Pathology (PSIP) ***PATH-NUMBER[1] (Collection date:
**DATE[Jul 07 2012]) (Collection time: Not Provided)
Bone, right hip lytic lesion, biopsy: 
1. Findings consistent with involvement by a non-hematopoietic neoplasm (see
Comments)
2. No abnormal B-cell, T-cell, or NK-cell populations identified
COMMENTS
The presence of occasional atypical cohesive cell clusters on our
cytocentrifuge preparation, coupled with the flow cytometric identification of
a population of large, CD45-negative cells with uniform expression of the
epithelial cell adhesion (EpCAM) molecule (colored black in the first row of
flow histograms below), is consistent with involvement by a non-hematopoietic
neoplasm. The neoplastic cells represent ~1% of the viable cells analyzed in
this study. The neoplastic cells also express CD56, suggesting neuroendocrine
derivation; however, histologic and immunohistochemical evaluation will be
required for definitive classification of this process. There is no evidence
of a lymphoid neoplasm.
CLIENT REQUEST / CLINICAL HISTORY
Right hip lytic lesion - bone biopsy. Flow cytometry to rule out lymphoma.
(Per a telephone conversation with Dr. **NAME[ZZZ] on **DATE[Jul 9 12], the H&E and IHC
studies on the corresponding tissue are consistent with involvement by a small
cell carcinoma.)
RESULTS
Flow cytometric immunophenotyping after lysis of the erythroid cells reveals
that the viable leukocytes include 16% lymphocytes, 7.2% monocytes, 74%
maturing granulocytes, 2.5% blasts/basophils (1.4% CD34+ blasts), and <0.1%
plasma cells. The lymphocytes consist of 27% B cells (CD19+), 61% T cells
(CD5+), and 8.1% NK cells (CD5-, CD38+, CD56+). The mature B cells have a
mildly reversed kappa:lambda ratio of 41:56 in two separate assays, but do not
have a distinctly aberrant immunophenotype. The T cells have a normal CD4:CD8
ratio of 64:34. The NK cells have a normal immunophenotype.
Antibodies used: CD10: CD11c: CD19: CD2: CD20: CD22: CD3: CD34: CD38: CD4:
CD45: CD5: CD56: CD7: CD8: CD90: CD99: EpCAM (CD236): HLA-DR: Kappa (surface):
Lambda (surface)
Antibodies: 21
    Electronically signed **DATE[Jul 09 2012]: **NAME[YYY M. XXX], M.D., Pathologist
Per CMS regulations, the pathologist's signature above indicates that this
case has been reviewed and the diagnosis made or confirmed by said
pathologist.
Note: Some of the tests reported here may have been developed and performance
characteristics determined by PhenoPath Laboratories. They have not been
cleared or approved by the U.S. Food and Drug Administration (FDA). However,
the FDA has determined that such clearance or approval is not necessary.
Pursuant to the requirements of CLIA, this laboratory has established and
verified the accuracy and precision of all tests, and additional information
about these tests is available upon request. PhenoPath Laboratories is
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
as qualified to perform high complexity clinical laboratory testing.",,,,,
REG3,LUNG,0,PAT-00737685,1,REC-5000804846,,,,"<CLINICAL INFO>
Lung cancer.

<GROSS>
A.  Received in formalin, labeled with the patient's name and designated '4R,' is a single gray-pink lymph node candidate measuring 0.5 cm in greatest dimension.  It is wrapped and submitted entirely in A1.
B.  Received in formalin, labeled with the patient's name and designated 'station 7,' are four pink-gray lymph node candidates, which range in greatest dimension from 0.5 cm to 1 cm.  Lymph node candidates are wrapped and submitted entirely in B1.
C.  Received in formalin, labeled with the patient's name and designated '4L,' are four gray-pink lymph node candidates, which range in greatest dimension from 0.3 cm to 0.8 cm in greatest dimension.  The tissue was wrapped and submitted in its entirety in C1.
RA/cs  **DATE[May 29 12]

<MICROSCOPIC>
A-C.  Sections examined.
**INITIALS  **DATE[May 30 12]


<FINAL DX>
A.  LYMPH NODE, 4R:
  ONE LYMPH NODE NEGATIVE FOR MALIGNANCY.
B.  LYMPH NODE, #7:
  LYMPH NODE(S) NEGATIVE FOR MALIGNANCY.
C.  LYMPH NODE, 4L:
  LYMPH NODE(S) NEGATIVE FOR MALIGNANCY.",,,,,
REG3,LUNG,0,PAT-00755115,1,REC-5000804903,,,,"<CLINICAL INFO>
Right upper lobe mass on CXR and CT, tumor including right upper lobe.

<GROSS>
**INITIALS  **DATE[Jun 1 12]
C.  Received labeled with the patient's name and designated 'bronchial washings' is 25 cc of turbid bloody mucoid fluid which is used to make a monolayer slide and a cell block.
**INITIALS  **DATE[Jun 2 12]

<MICROSCOPIC>
A.  Sections show inflamed bronchial mucosa with scattered aggregates of highly atypical epithelial cells of intermediate to large size with frequent mitoses and single cell necrosis.  Some of the atypical cells have a squamoid appearance, but significant keratin production is not identified.  Most of the abnormal cells are either detached from the mucosa or are loosely associated within the mucosa.  An infiltrative growth pattern is suggested where the abnormal cells are surrounded by fibromyxoid stroma.
B.  The bronchial brushings contain clusters of ciliated columnar epithelial cells which are distributed in a background of mucus infiltrated by a acute inflammatory cells.  No malignant cells are identified.
C.  The monolayer slide shows inflammatory cells and few epithelial cells.  No malignant cells are identified.  However, a cell block prepared from the washings contains clusters of malignant cells of large size with some detached cells appearing to exhibit keratinization.
**INITIALS  **DATE[Jun 2 12]

<INTRAOPERATIVE CONSULT>

<FINAL DX>
A.  LUNG, RIGHT MAINSTEM BRONCHUS AND RIGHT UPPER LOBE, BRONCHIAL BIOPSY:
  POORLY DIFFERENTIATED NONSMALL CELL CARCINOMA WITH SQUAMOUS
  FEATURES; SEE COMMENT.
B.  BRONCHIAL BRUSHINGS:
  NEGATIVE FOR MALIGNANT CELLS.
C.  BRONCHIAL WASHINGS:
  POSITIVE FOR MALIGNANT CELLS.

<DX COMMENT>
The diagnoses were conveyed to Drs. **NAME[ZZZ] and **NAME[YYY] on **DATE[Jun 2 12].  While squamous differentiation is suggested in both specimens A and C, immunohistochemistry is pending for confirmation and definitive subclassification.  These results will be reported in an Addendum.",,,,,
REG3,LUNG,0,PAT-00753460,1,REC-5000805292,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Pleural Fluid, Left, Thoracentesis:
   Positive for small numbers of malignant cells,
     pleomorphic non-small cell carcinoma.

<CLINICAL INFO>
Lung cancer.

<GROSS>
Received on **DATE[Apr 04 2012] is 1000 ml of hazy orange clotted fluid labeled
""**NAME[BBB, AAA M]"", and designated ""left pleural"" per requisition. Prepared
are one ThinPrep Papanicolaou-stained slide, one air-dried
cytocentrifuged Diff-Quik-stained slide and one cell block. (clr/nd)

<MICROSCOPIC>
Histologic HE sections at different levels of the cell block are
prepared and microscopically examined.  The cytologic slide preparations
are also reviewed. The results of the microscopic examination are as
reported in the above final diagnosis.

**NAME[ZZZ M. YYY], M.D.  Electronically signed **DATE[Apr 05 2012]",,,,,
REG3,LUNG,0,PAT-00470641,3,REC-5000805708,,,,"PART / DESCRIPTION - SEQ 
Lung, Fine Needle Aspiration/ LEFT UPPER LOBE LUNG FNA, FLUID AND SMEARS- A
PART / DESCRIPTION - SEQ 
Core BX NOS/ LEFT UPPER LOBE LUNG CORE BIOSPY WITH TOUCH PREP- B
CLINICAL INFO:
Smoker. Diagnosis: Left upper lobe lung mass. 
ICD-9 code: None.
FINAL DX:

A-B. Lung, left upper lobe, fine needle aspiration cytology and core biopsy:
-Poorly differentiated non-small cell carcinoma consistent with poorly differentiated squamous cell 
 carcinoma. See comment.Consult
**NAME[ZZZ M. YYY], M.D.
INTRAOPERATIVE DX:
A. Necrotic material and atypical cells. 
B. Atypical cells present.
MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
A. A fine needle aspiration is performed on the ''Left upper lobe lung'' of patient ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[XXX]. One pass is made. Prepared in CT are one wet-fixed and one fast-stained smear labeled ''**NAME[BBB, AAA (M])''. Also prepared is one cell block from the sample collected in saline and labeled ''**NAME[BBB, AAA (M])''. (DCW: jm/hsk) 
B. Received in formalin, labeled ''**NAME[BBB, CCC]' and designated ''core biopsy'', are four 0.1 cm in diameter elongated, cylindrical portions of tissue, 0.2, 0.4, 0.4, 0.8 cm in length, entirely submitted in cassette B1. Core biopsy-touch preparations are performed on the ''Left upper lobe lung'' of patient ''**NAME[BBB, CCC]' with accompanying requisition by Dr. **NAME[XXX]. Four passes are made. Prepared in CT are three fast-stained smears labeled ''**NAME[BBB, AAA (M])''. (DCW: jm/hsk) (**INITIALS:cmc94 316447) (DCW/cmc78 317296
DIAGNOSIS COMMENTS:
Sections show extensively necrotic tumor cells, which are positive for pankeratin and p63, and negative for TTF-1 on immunostain. These findings are consistent with a poorly differentiated squamous cell carcinoma.

The immunohistochemical tests reported were developed and performance characteristics determined by Dynacare Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests may be used for clinical purposes. They should not be regarded as investigational or for research use only. Dynacare Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988(CLIA) as qualified to perform high complexity clinical laboratory testing.
PATHOLOGIST:
**NAME[WWW VVV M]. 

SNOMED Code(s)
T28600P1149M807033",,,,,
REG3,LUNG,0,PAT-00543960,2,REC-5000805734,,,,"PART / DESCRIPTION - SEQ 
Lymph Node, Fine Needle Aspiration/ STATION 7 LYMPH NODE FNA, FLUID AND SMEARS- A
PART / DESCRIPTION - SEQ 
Lung Bx/ RIGHT UPPER LOBE EBBX- C
PART / DESCRIPTION - SEQ 
Bronchial Washings-Cytology/ RIGHT LOWER LOBE BAL- B
FINAL DX:

a. Station 7 lymph node, endobronchial ultrasound-guided fine needle aspiration (smears, ThinPrep and cell block):
-Metastatic adenocarcinoma, consistent with patient's known lung primary (see comment).
-Scattered lymphocytes and bronchial cells in background. 

b. Right lower lobe of lung, bronchoalveolar lavage (ThinPrep and cell block):
-Rare lung adenocarcinoma cells. 

c. Right upper lobe of lung, endobronchial biopsy:
-Bronchial mucosa with no evidence of malignancy.
MICROSCOPIC:
The final diagnosis for each specimen is based on the microscopic examination of the tissues/cells.
INTRAOPERATIVE DX:
A. Station 7 lymph node, immediate interpretation of fine needle aspiration smear: Positive for carcinoma.GROSS:
A. An endobronchial ultrasound-guided fine needle aspiration is performed on the 'station 7 lymph node' of patient '**NAME[BBB, AAA]' with accompanying requisition by Dr. **NAME[ZZZ]. Five passes are made. Prepared in the operating room are two fast-stained smears labeled ''**NAME[BBB, AAA (M])''. Also prepared are one ThinPrep slide and one cell block from the sample collected in saline and labeled ''**NAME[BBB, AAA (M])''. 
B. Received fresh on **DATE[Jul 17 12] is approximately 20 cc of cloudy, pink fluid, labeled ''**NAME[BBB, AAA (M])''. Prepared are one cell block and one ThinPrep slide. (NPR:jm/jca/hsk)
C. Received in formalin, labeled ''**NAME[BBB, CCC]' designated ''endobronchial biopsy right upper lobe'', is a 1 x 0.8 x 0.4 cm white soft tissue and blood clot. The specimen is submitted entirely in cassette C1. (**INITIALS)
DIAGNOSIS COMMENTS:
The patient's previous metastatic lung adenocarcinoma to the 4R and station 7 lymph nodes (***PATH-NUMBER[1], **DATE[May 9 11]) is reviewed for comparison and the morphologic features are identical.
CLINICAL INFO:
Lung mass. History of metastatic lung adenocarcinoma to 4R and station 7 lymph nodes (***PATH-NUMBER[1], **DATE[May 09 2011]). 
ICD-9 code: 786.6.
PATHOLOGIST:
Perez-Reyes Nuria   

SNOMED Code(s)
P1250M82503M69760T28000T26000T08330T05230P1149T28200T26200P1140T28400T28000M81409",,,,,
REG3,LUNG,0,PAT-00755495,1,REC-5000806158,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  A & B) PRETRACHEAL AND SUB CARINA, EBUS, FNA: POSITIVE FOR MALIGNANCY,
MODERATELY DIFFERENTIATED ADENOCARCINOMA, IMMUNOPHENOTYPE CONSISTENT WITH
PULMONARY PRIMARY

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Nov 14 2012]
<SPECIMEN(S)>
  A) Pre tracheal
B) Sub carina
<GROSS>
  A) Received are two smear slides. 
B) Received are two smear slides. Material in CytoRich red fluid (combined
from specimens A and B) is prepared for a cell block.
<MICROSCOPIC>
  A & B) Both samples are abundantly cellular with groups of malignant
epithelial cell present forming sheet-like and ball-like structures. The
cells have enlarged mildly irregular nuclei. Occasional mitotic figures
are seen. On the cell block sections the neoplastic cells clearly from
gland-like structures. A few cells show cytoplasmic mucin with a
mucicarmine stain. 
A panel of immunohistochemical stains has been performed. The neoplastic
cells show an immunoprofile consistent with a primary pulmonary
adenocarcinoma. 
IMMUNOHISTOCHEMISTRY (IHC) REPORT:
ANTIBODIES:RESULTS: 
1. CYTOKERATIN 7 (OV-TL12/30): POSITIVE 
2. CYTOKERATIN 20 (Ks20.8): NEGATIVE 
3. TTF-1 (8G7G3/1): POSITIVE 
4. p63 (BC4A4): NEGATIVE 
5. CYTOKERATIN 5/6 (D5&16B4): NEGATIVE 
Formalin-fixed, deparaffinized tissue sections (along with appropriate
positive controls) are incubated with the following monoclonal and/or
polyclonal antibodies. Localization is via a biotin-free multimer-based
immunoperoxidase technique according to an optimized protocol. The
controls are reviewed for the appropriate positive and negative reactivity
and found to be satisfactory. Results on the population(s) of interest are
as indicated above. 
 
These tests were developed and their performance characteristics were
determined by the Department of Anatomic Pathology at Group Health
Cooperative.  The Laboratory is certified under CLIA-88 and is qualified
to perform high complexity testing.  These tests have not been cleared or
approved by the U.S. Food and Drug Administration. However, the FDA has
determined that such clearance or approval is not necessary.",,,,,
REG3,LUNG,0,PAT-00755853,1,REC-5000808549,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

Medullary Tumor, Biopsy:
Metastatic adenocarcinoma, see comment.

<COMMENT>
Metastatic adenocarcinoma involves approximately 5% of the bone marrow
space. There are areas of signet ring-type differentiation. The
immunophenotype is unusual for conventional adenocarcinoma, however, can
be seen with mucinous lung adenocarcinomas (Reference: **NAME[ZZZ M]. et. al.,
Primary mucinous (so-called colloid) carcinoma of the lung. The clinical
pathologic and immunohistochemical study with special reference to CDX-2
and MOC-2 expression. American Journal of Surgical Pathology 2004.
**ID-NUM). Mucinous lung adenocarcinoma is further supported due to
the lack of CDX-2 expression.

<CLINICAL INFO>
Hilar mass. No parenchymal lung lesions. Pathologic fracture right
femur.

<GROSS>
Received in formalin, labeled ""**NAME[AAA BBB]"", and designated
""medullary tumor"" is a 3.5 cm aggregate of brown soft tissue, bone and
clotted blood. Representative tissue is submitted for brief
decalcification in one cassette.  ke/ct

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A3

Antibody  Result    Comment
Pan CK    Positive
CK7  Negative
CK20 Positive
TTF-1     Positive
Napsin A  Negative
p63  Negative
CK 5/6    Negative
Mammoglobin    Negative
ER   0 % of tumor cells positive
CDX-2     Negative

Impression:
Interpreted by:  **NAME[YYY M. XXX] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

PHYSICIAN NOTIFICATION:
The results were discussed with Dr. **NAME[WWW] by Dr. **NAME[XXX] on **DATE[Jul 08]/29011 and
**DATE[Jul 08 2012].

INTRADEPARTMENTAL CONSULTATION:
**NAME[VVV M. UUU], M.D.

**NAME[YYY M. XXX], M.D.  Electronically signed **DATE[Jul 08 2012]",,,,,
REG3,LUNG,0,PAT-00737685,1,REC-5000808757,,,,"<CLINICAL INFO>
A **AGE[in 60s]-year-old female status post chemotherapy and radiation for Stage 3B non-small cell carcinoma.

<GROSS>
B.  Received fresh labeled with the patient's name and designated 'subcarinal lymph node #2' is a 1.8 x 1.5 x 0.5 cm pink-gray lymph node candidate which is frozen entirely.  Intraoperative frozen section diagnosis:  Lymph node negative for carcinoma (LDB).  The lymph node candidate is submitted entirely for permanent in cassette B1.  
C.  Received fresh labeled with the patient's name and designated 'right upper lobe' is a 255 gram, 15 x 9 x 4 cm intact right upper lobectomy specimen with attached third and fourth ribs on the lateral surface of the lung which in total measure 5.5 x 5.2 x 2.9 cm.  The parenchymal, bronchial and vascular resection margins are all intact with staple lines.  The pleural surface is pink-purple and dull.  The ribs and surrounding soft tissue and muscle are focally adherent to the lung by a thin and delicate strand of fibrous tissue.  The third rib measures 3.8 cm in length x 1.1 cm in average diameter and the fourth rib measures 5.0 cm in length and ranges in diameter from 1.3 to 2.0 cm.  A firm palpable nodule is present on the pleural surface deep to the attached ribs.  The ribs and surrounding soft tissue are differentially inked to allow for the microscopic evaluation of the surgical resection margins as follows:  Medial bone resection margin   black, lateral bone resection margin   orange, and surrounding soft tissue resection margin   blue.  The bronchial resection margin, representative section of pericostal soft tissue and representative section of underlying mass are frozen in two blocks.  Intraoperative frozen section diagnoses: C1)Pericostal muscle: Negative for carcinoma; Subpleural mass: No residual carcinoma in representative section frozen. C2)Bronchial margin: Negative for carcinoma (LDB).  The staple lines at the lung resection margin are removed and the underlying parenchyma marked with blue ink.  Sectioning reveals a 3.0 x 2.1 x 0.7 cm tan-white firm subpleural nodule located at the previously mentioned palpable nodule deep to the attached ribs.  The nodule is located 7.0 cm from the bronchial resection margin and 5.5 cm from the blue inked parenchymal resection margin.  The remaining lung parenchyma is purple-red, slightly consolidated with no other discrete lesions or masses identified.  The ribs and surrounding soft tissue are placed in decal and will be gross and dictated later.  A single 0.5 cm in diameter pink-gray lymph node candidate is identified adjacent to the bronchus.  Sectioning through the ribs and soft tissue reveals unremarkable pink-red bony cut surface with surrounding tan-pink fibrous tissue and skeletal muscle.  Representative sections are submitted as follows:  C1   remaining frozen section of nodule and pericostal soft tissue resection margin, C2   remaining frozen section tissue of bronchial resection margin, C3   vascular resection margins, C4 through C6   subpleural nodule submitted entirely, C7   uninvolved lung parenchyma, C8   single lymph node candidate, C9 full thickness section through third rib, C10 perpendicular section through lateral end of third rib, C11 perpendicular section through medial end of third rib, C12 full-thickness section through fourth rib, C13 perpendicular sections through medial and lateral ends of fourth rib. 
 
D.  Received in formalin, labeled with the patient's name and designated as 'fifth rib' is a 5.1 cm in length x 1.3 cm in average diameter portion of rib with attached 1.5 x 1.5 x 1.0 cm soft tissue on the anterior/superior aspect of the rib.  The rib is differentially inked to allow for the microscopic evaluation of surgical resection margins as follows:  Anterior surface of rib and soft tissue resection margin-blue, posterior surface of rib and soft tissue resection margin-green, medial end of rib-orange, and lateral end of rib-black.  Sectioning reveals tan-pink unremarkable soft tissue and skeletal muscle, with underlying unremarkable bone.  Representative sections are submitted as follows:  D1 and D2 full-thickness sections through fifth rib, D3 perpendicular sections through medial and lateral ends of rib.  
E.  Received in formalin labeled with the patient's name and designated 'posterior margin' are two fragments of bone measuring 1.3 x 0.7 x 0.5 cm and 2.1 x 1.3 x 0.9 cm.  The fragments are entirely marked with blue ink and sectioned showing unremarkable bony cut surface with hemorrhagic marrow.  The fragments of bone are submitted entirely after decal with the bisected smaller fragment in E1 and larger fragment in E2 through E4.
**INITIALS:ldk  **DATE[Apr 6 12]:**DATE[Apr 7 12]

<MICROSCOPIC>
A-B.  Sections are examined.  
C.  The grossly described subpleural nodule is entirely submitted in blocks C5 through C6.  Rare residual tumor cells are identified in microscopic foci best seen in slides C4 and C5, which are further evaluated by broad spectrum cytokeratin immunohistochemical stains.  In C5, one of tumor foci is present within a medium-sized vessel. Tumor is also identified in the decalcified sections of the 3rd rib (slide C9) with evidence of tumor extending beyond the visceral pleura as seen on an elastic tissue stain. Viable tumor in block C9 is also confirmed by a cytokeratin immunohistochemical stain. It is difficult to determine if the viable tumor cells extend into the parietal pleura, as the tissue planes have been obliterated by fibrosis. Elastic tissue stains are also performed on tumor blocks C4, C5, and C6.
D-E.  Sections are examined.  
**INITIALS  **DATE[Apr 07 12]

<INTRAOPERATIVE CONSULT>
B.  Intraoperative frozen section diagnosis:  Lymph node negative for carcinoma (LDB).  
C.  Intraoperative frozen section diagnoses (two blocks frozen):
C1: Pericostal muscle: Negative for carcinoma. Subpleural mass: No residual carcinoma in representative section frozen. (LDB).
C2: Bronchial margin: Negative for carcinoma. (LDB).

<FINAL DX>
A.  SUBCARINAL LYMPH NODE:  
    LYMPH NODE, ONE; NEGATIVE FOR METASTATIC CARCINOMA. 
B.  SUBCARINAL LYMPH NODE #2:  
    LYMPH NODE, ONE; NEGATIVE FOR METASTATIC CARCINOMA. 
C.  RIGHT UPPER LOBE OF LUNG WITH SECOND, THIRD, AND FOURTH RIBS 
  (RIGHT UPPER LOBE LOBECTOMY WITH EN BLOC RESECTION OF 
  SECOND THROUGH FOURTH RIBS):  
    NON-SMALL CELL CARCINOMA, STATUS POST NEOADJUVANT 
    THERAPY SHOWING THE FOLLOWING FEATURES:  
    1.  TUMOR SITE:  SUPERIOR SULCUS OF RIGHT UPPER LOBE 
      OF LUNG (PANCOAST TUMOR).  
    2.  TUMOR SIZE:  SCATTERED MICROSCOPIC TUMOR FOCI RANGING 
      IN SIZE FROM UP 0.1 UP TO 0.4 CM.  
    3.  TUMOR FOCALITY:  UNIFOCAL AREA WITH PROMINENT 
      FIBROSIS AND CALCIFICATION STATUS POST NEOADJUVANT 
      THERAPY. 
    4.  HISTOLOGIC TYPE:  NON-SMALL CELL CARCINOMA, SUBTYPE 
      CANNOT BE DETERMINED.  
    5.  HISTOLOGIC GRADE:  POORLY DIFFERENTIATED (G3).  
    6.  VISCERAL PLEURAL INVASION:  PRESENT, AT LEAST PL2.  
    7.  TUMOR EXTENSION:  SUSPECTED EXTENSION TO PARIETAL PLEURA
      (SEE COMMENT).
    8.  MARGINS:  UNINVOLVED BY INVASIVE CARCINOMA; INCLUDES 
      BRONCHIAL, VASCULAR, AND CHEST WALL MARGINS.  
    9.  TREATMENT EFFECT:  LESS THAN 10% RESIDUAL VIABLE 
      TUMOR.  
    10.  LYMPH-VASCULAR INVASION:  PRESENT.  
    11.  BRONCHIAL LYMPH NODE, ONE; NEGATIVE FOR METASTATIC 
      CARCINOMA.  
    12.  THIRD AND FOURTH RIBS:  NEGATIVE FOR MALIGNANCY.  
    13.  TNM STAGE:  AT LEAST ypT2a, ypN0 (SEE COMMENT).  
D.  FIFTH RIB:  PORTION OF RIB WITH SKELETAL MUSCLE; NEGATIVE FOR
       MALIGNANCY.
E.  POSTERIOR MARGIN:  PORTION OF RIB AND SKELETAL MUSCLE; NEGATIVE
           FOR MALGINANCY.

<DX COMMENT>
 Tumor extends through the visceral pleura in the region of the third rib and may involve parietal pleura (ypT3), but the tissue planes are obscured by fibrosis secondary to neoadjuvant therapy.",,,,,
REG3,LUNG,0,PAT-00755111,1,REC-5000809587,,,,"<CLINICAL INFO>
The patient has ascites and a CT scan of the abdomen showing an omental cake.

<GROSS>
Designated 'ascites' is 200 cc of processed cloudy yellowish fluid, which is used to make a monolayer and a cell block.
**INITIALS  **DATE[Oct 9 12]

<MICROSCOPIC>
The monolayer slide and a section from the cell block show malignant cells that are present as individual cells, small cell groups, and rare glandular structures.  
**INITIALS  **DATE[Oct 9 12]


<FINAL DX>
ASCITES FLUID:
POSITIVE FOR MALIGNANT CELLS CONSISTENT WITH ADENOCARCINOMA; SEE COMMENT.

<DX COMMENT>
Immunohistochemistry is pending to provide a better subclassification for the adenocarcinoma.  These results will be reported in an Addendum.",,,,,
REG3,LUNG,0,PAT-00753345,1,REC-5000811325,,,,"**** THIS IS AN ADDENDUM REPORT ****
CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

**** Addendum ****

Reason for Addendum #1:  Reference Laboratory Results
Reason for Addendum #2:  Reference Laboratory Results

<FINAL DX>     

Core Biopsy, Right Upper Lobe, Lung:
  Adenocarcinoma.
  Immunophenotype consistent with lung primary.

<CLINICAL INFO>
Right upper lobe lung biopsy.

INTRAPROCEDURAL EVALUATION:
Right upper lobe lung biopsy (touch prep): ""Nonsmall cell carcinoma.""
Performed by:  **NAME[M. ZZZ YYY], M.D.

<GROSS>
Received in formalin, labeled ""**NAME[AAA BBB]"" and designated ""right upper
lobe lung biopsy"", per requisition, are three 0.1 to 0.3 cm needle
biopsies, which are submitted in one cassette. (ke/do)

Received on **DATE[May 01 2012] is one air-dried direct smears labeled ""**NAME[BBB, M]""
and designated ""right upper lobe lung biopsy"" per requisition. The
air-dried smear is Diff-Quik stained. One alcohol-fixed smear kept in
Olympia. (rc/gdb)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

IMMUNOHISTOCHEMISTRY STUDY:
Deparaffinized sections of formalin-fixed tissue and the appropriate
controls are incubated with a panel of antibodies or a specific
fluorescein-labeled (oligo)nucleotide probe.  Localization is via one or
all of the following three systems: Alkaline Phosphatase multimer-based
method, indirect biotin streptavidin immunoperoxidase method, and biotin
free multimer immunoperoxidase method.  Results are outlined in the
table below:
Block A1

Antibody  Result    Comment
TTF-1     Positive
CDX-2     Negative
CK7  Positive
CK20 Negative

Impression:
Interpreted by:  **NAME[M. ZZZ YYY] M.D.
Comment:

The immunohistochemical tests reported were developed and performance
characteristics determined by CellNetix Labs, LLC.  Some tests have not
been cleared or approved by the U.S. Food and Drug Administration.  The
FDA has determined that such clearance or approval is not necessary.
These tests may be used for clinical purposes.  They should not be
regarded as investigational or for research use only.  CellNetix Labs,
LLC is certified under the Clinical Laboratory Improvement Amendments of
1988 (CLIA) as qualified to perform high complexity clinical laboratory
testing.

INTRADEPARTMENTAL CONSULTATION:
**NAME[XXX M. WWW], M.D.

**NAME[M. ZZZ YYY], M.D.  Electronically signed **DATE[May 03 2012]

<ADDENDUM>  #1

MOLECULAR (PCR) REPORT; EGFR MUTATION ANALYSIS:
Testing performed by: **PLACE, WA **ZIP-CODE, report
***PATH-NUMBER[2], issued **DATE[Jun 08 2012].
Interpreted by: **NAME[VVV UUU], M.D.

Result: Lung, Right Upper Lobe, Core Biopsy:  Negative for an EGFR
mutation by real time PCR (see Comments).

Comment: In this case no epidermal growth factor receptor (EGFR)
mutations were identified by Quigen/DxS real time PCR. This real time
PCR assay has been validated to identify the most common EGFR tyrosine
kinase domain mutations that involve exons 18-21. This test is validated
for non-small cell lung carcinoma. The clinical significance and use of
this assay in other tumor types is not well characterized. Note that
this assay is not intended to diagnose any particular type of cancer,
but as an aid to clinicians, is intended to be used as an adjunct to
other prognostic factors to select eligible patients for therapy. (refs:
**NAME[TTT] et al., NEJM 2004;**ID-NUM, Mok et al., NEJM 2009; **ID-NUM,
Pao et al., JClinOnc 2005; **ID-NUM).

ALK FISH analysis has been initiated as requested, and the results will
be reported separately.

Addendum #1 performed by **NAME[M. ZZZ YYY], M.D.  Electronically signed
**DATE[Jun 09 2012]

<ADDENDUM> #2

ALK by FLUORESCENCE IN SITU HYBRIDIZATION (FISH) REPORT:
Testing performed by: **PLACE, WA **ZIP-CODE, report
***PATH-NUMBER[3], issued **DATE[Jun 12 2012].
Interpreted by: **NAME[VVV UUU], M.D.

Result: Lung, Right Upper Lobe, Core Biopsy:
     Negative for a translocation involving the ALK gene by FISH

Comments: Translocations involving the anaplastic lymphoma kinase (ALK)
gene have been described in a small subset of nonsmall cell lung cancers
and typically involve the echinoderm microtubule-associated protein-like
4 (EML4) gene resulting in an EML4-ALK fusion gene containing the ALK
tyrosine kinase domain. The presence of an ALK translocation in a
nonsmall cell lung cancer tumor specimen predicts possible tumor
responsiveness to ALK tyrosine kinase inhibitor drug therapy. This assay
is not intended to diagnose a specific type of cancer but is instead
intended to provide information to help guide potential therapy (Ref:
Martelli et al. AJP 2009; 174 (2):661, Soda et al. Nature 2007; 448:561,
Kwak et al.NEJM 2010; **PHONE.)

Addendum #2 performed by **NAME[XXX M. WWW], MD.  Electronically signed
**DATE[Jun 14 2012]",,,,,
REG3,LUNG,0,PAT-00574746,2,REC-5000813980,,,,"<CLINICAL INFO>
Pulmonary nodule

<GROSS>
Received in formalin, labeled **NAME[BBB, AAA], #1, are multiple 0.1 to 0.2 cm, tan-red, soft tissue fragments.  SECTIONS:  A1 = in total.


<MICROSCOPIC SECTION>

<FINAL DX>
RIGHT UPPER LOBE, BIOPSY:
Invasive poorly differentiated squamous cell carcinoma.  Please see concurrent cytology (***PATH-NUMBER[1]).







<SPECIMEN(S)>
Lung/Bronchial/Pleural Biopsy",,,,,
REG1,COLON,0,54010,5,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\LEFT COLON MASS\X0D\\X0A\,"SURGEON            \X0D\\X0A\\X0D\\X0A\DR. **NAME[ZZZ YYY] WALKER\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:\X0D\\X0A\    LEFT COLON, SEGMENTAL RESECTION.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\    LEFT COLON, NOS.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\    1.0 X 0.8 CM.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\    ADENOCARCINOMA, LOW GRADE (MODERATELY DIFFERENTIATED).\X0D\\X0A\DEEPEST INVASION:\X0D\\X0A\    TUMOR EXTENDS INTO BUT NOT THROUGH MUSCLE WALL.\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:\X0D\\X0A\    NOT IDENTIFIED.\X0D\\X0A\MARGINS:\X0D\\X0A\    ALL NEGATIVE.\X0D\\X0A\    TUMOR IS 4.5 CM FROM THE NEARER PREVIOUSLY OPENED MARGIN (PROXIMAL\X0D\\X0A\    VERSUS DISTAL NOT DESIGNATED).\X0D\\X0A\LYMPHATIC/VASCULAR INVASION:\X0D\\X0A\    NOT IDENTIFIED.\X0D\\X0A\PERINEURAL INVASION:\X0D\\X0A\    NOT IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\    SIX LYMPH NODES RECOVERED, ALL BENIGN. SEE COMMENT.\X0D\\X0A\DISCONTINUOUS EXTRAMURAL EXTENSION:\X0D\\X0A\    NOT IDENTIFIED.\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\    NO PRIOR TREATMENT.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\    IMMUNOHISTOCHEMISTRY FOR MICROSATELLITE INSTABILITY WILL BE PERFORMED\X0D\\X0A\COPIES TO:\X0D\\X0A\   Choudry,Muneeb A\X0D\\X0A\   2355 Poplar Level Rd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX],Mark R\X0D\\X0A\   4500 Churchman Ave\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   Walker,**NAME[ZZZ YYY]\X0D\\X0A\   **STREET-ADDRESS Dr #450\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88309GS, 88342GS/4\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[WWW M VVV] MD **DATE[Oct 29 11]                \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Nov 01 11]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\CARCINOMA OF COLON SYNOPTIC REPORT AJCC/UICC TNM, 7th edition\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:\X0D\\X0A\LEFT COLON, SEGMENTAL RESECTION.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\LEFT COLON, NOS.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\1.0 X 0.8 CM.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\ADENOCARCINOMA, LOW GRADE (MODERATELY DIFFERENTIATED).\X0D\\X0A\DEEPEST INVASION:\X0D\\X0A\TUMOR EXTENDS INTO BUT NOT THROUGH MUSCLE WALL.\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\MARGINS:\X0D\\X0A\ALL NEGATIVE.\X0D\\X0A\TUMOR IS 4.5 CM FROM THE NEARER PREVIOUSLY OPENED MARGIN (PROXIMAL\X0D\\X0A\VERSUS DISTAL NOT DESIGNATED).\X0D\\X0A\LYMPHATIC/VASCULAR INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\PERINEURAL INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\SIX LYMPH NODES RECOVERED, ALL BENIGN. SEE COMMENT.\X0D\\X0A\DISCONTINUOUS EXTRAMURAL EXTENSION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\NO PRIOR TREATMENT.\X0D\\X0A\ANCILLARY STUDIES:\X0D\\X0A\IMMUNOHISTOCHEMISTRY FOR MICROSATELLITE INSTABILITY WILL BE PERFORMED\X0D\\X0A\ON BLOCK 5 AND REPORTED AS AN ADDENDUM.\X0D\\X0A\AJCC PATHOLOGIC STAGE:\X0D\\X0A\pT2 pN0 Mn/a.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Additional lymph nodes will be submitted and an addendum will follow.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin designated ""left colon"" is a segment of colon with an ample amount of\X0D\\X0A\attached pericolonic and mesenteric adipose tissue along with omentum.  The adipose tissue\X0D\\X0A\is adhesed causing the colon to loop.  The specimen is received closed at both ends by a\X0D\\X0A\line of surgical staples without designation as to proximal versus distal.  The specimen has\X0D\\X0A\been previously opened on one end.  The colon segment measures 35.0 cm in length and up to\X0D\\X0A\5.5 cm in diameter.  The visible serosal surface is pink-tan and glistening.  Approximately\X0D\\X0A\75% of the colon is adipose wrapped.\X0D\\X0A\\X0D\\X0A\The specimen is opened longitudinally to reveal a pink-tan button-like tumor mass measuring\X0D\\X0A\1.0 x 0.8 cm.  The tumor is located 4.5 cm from the staple line of the previously opened\X0D\\X0A\margin.  The soft tissue corresponding to the area of tumor is indurated and discolored by\X0D\\X0A\black injection dye.  The tumor is located on the mesenteric side of the colon, 4.5 cm from\X0D\\X0A\the opened margin, 30.0 cm from the opposite stapled margin and 5.0 cm from the closest\X0D\\X0A\mesenteric soft tissue margin.  The serosal surface associated with the tumor is marked with\X0D\\X0A\blue ink.  Sectioning through the tumor reveals invasion into but not grossly through the\X0D\\X0A\wall.  Focal bright yellow fat necrosis is noted associated with the tumor mass.\X0D\\X0A\\X0D\\X0A\There are no additional nodules or masses identified within the colon segment.\X0D\\X0A\\X0D\\X0A\The attached adherent omentum measures 48.0 x 16.0 x up to 1.8 cm.  Sectioning of the\X0D\\X0A\omentum reveals unremarkable nodular yellow-tan adipose tissue and vascular structures.\X0D\\X0A\\X0D\\X0A\Sectioning of the surrounding attached adipose tissue reveals rare lymph node candidates\X0D\\X0A\measuring up to 0.3 cm in greatest dimension.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\1.    surgical margin closer to tumor\X0D\\X0A\2.    surgical margin further from tumor\X0D\\X0A\3.    soft tissue mesenteric margin\X0D\\X0A\4-7.    entire tumor and adjacent adipose tissue\X0D\\X0A\8.    omentum\X0D\\X0A\9.    five intact lymph node candidates\X0D\\X0A\10.    five intact lymph node candidates\X0D\\X0A\11.    three intact lymph node candidates        **INITIALS\X0D\\X0A\12.    possible additional lymph nodes            **INITIALS\X0D\\X0A\\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\LEFT COLON\X0D\\X0A\,,"ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #2              Entered: **DATE[Oct 31 11]-1333\X0D\\X0A\\X0D\\X0A\GROSS DESCRIPTION:\X0D\\X0A\\X0D\\X0A\Following microscopic examination, additional samples from the specimen are submitted as\X0D\\X0A\follows:\X0D\\X0A\13.    one possible lymph node candidate\X0D\\X0A\14-18.    representative sections of adipose tissue with vascular structures adjacent to\X0D\\X0A\area of\X0D\\X0A\tumor        **INITIALS\X0D\\X0A\\X0D\\X0A\ADDENDUM DIAGNOSIS:\X0D\\X0A\The specimen has been placed in revealing solution, and searched for additional lymph nodes.\X0D\\X0A\Only one additional lymph node is recovered and is benign.  Total lymph nodes = 7, all\X0D\\X0A\benign.  No change in AJCC pathologic stage.  **INITIALS\X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Oct 29 11]-0941\X0D\\X0A\\X0D\\X0A\MSI IHC Testing\X0D\\X0A\\X0D\\X0A\INTERPRETATION: These results show no deficiency of the mismatch repair proteins tested.\X0D\\X0A\\X0D\\X0A\NOTE:  As clinically indicated, this tumor would be appropriate for additional BRAF and KRAS\X0D\\X0A\testing.\X0D\\X0A\\X0D\\X0A\COMMENT: Microsatellite instability (MSI) due to defective mismatch repair genes has been\X0D\\X0A\reported in a subset of sporadic colorectal adenocarcinomas, as well as in adenocarcinomas\X0D\\X0A\arising in patients with Lynch syndrome (hereditary non-polyposis colorectal cancer, or\X0D\\X0A\HNPCC). As a consequence of this alteration, these adenocarcinomas are all associated with\X0D\\X0A\high-level `microsatellite instability' (MSI), the most common mechanism of which is loss of\X0D\\X0A\function of one or more of the mismatch repair (MMR) proteins known as MLH1, MSH2, MHS6, and\X0D\\X0A\PMS2. Molecular testing for MSI or immunohistochemical studies looking for loss of\X0D\\X0A\expression of the MMR proteins are thus effective methods of screening for this unique\X0D\\X0A\subset of colorectal adenocarcinomas. IHC, particularly with the use of antibodies to all\X0D\\X0A\four major MMR proteins, can identify MSI adenocarcinomas with extremely high sensitivity\X0D\\X0A\and specificity. Furthermore, IHC analysis of the four MMR proteins can provide a highly\X0D\\X0A\sensitive strategy for the identification of MMR gene mutation-carrying, early-onset\X0D\\X0A\colorectal adenocarcinoma patients, many of whom might be missed by using clinical criteria\X0D\\X0A\(e.g., the **PLACE Criteria) alone. IHC analysis has several advantages over MSI testing,\X0D\\X0A\as the latter is more difficult to perform, and does not provide gene-specific information.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Identification of this important subset of adenocarcinomas is important, as published data\X0D\\X0A\suggest that sporadic colorectal adenocarcinomas with MSI have a significantly better\X0D\\X0A\prognosis compared with those with intact MMR. In addition, several studies have suggested\X0D\\X0A\that MSI adenocarcinomas may be resistant to 5-FU-based chemotherapy.\X0D\\X0A\\X0D\\X0A\Antibody/Clone            Marker For                    Results\X0D\\X0A\MLH-1/G168-728            MMR, Mismatch Repair         Protein Expressed\X0D\\X0A\MSH-2/G219-1129            MMR, Mismatch Repair         Protein Expressed 002\X0D\\X0A\MSH-6/44                                   MMR, Mismatch Repair         Protein Expressed 0\X0D\\X0A\PMS2/MRQ-28                MMR, Mismatch Repair         Protein Expressed **ID-NUM\X0D\\X0A\\X0D\\X0A\Detection System - Polymer\X0D\\X0A\\X0D\\X0A\NOTE: Genetic counseling may be appropriate to explain the implication of this test results.\X0D\\X0A\A positive result, indicating loss of one or more MMR proteins, should be confirmed by\X0D\\X0A\sequencing that particular protein. MLH1 promoter methylation should be ruled out by\X0D\\X0A\appropriate testing, in cases which show loss of only MLH1 protein. A negative result,\X0D\\X0A\indicating no loss of any MMR proteins, does not rule out MSI which may be due to non-MMR\X0D\\X0A\related pathway.\X0D\\X0A\\X0D\\X0A\Reference ranges for DNA Mismatch Repair Protein Expression by IHC:\X0D\\X0A\MLH-1, MSH-2, MSH-6 and PMS2 protein expressed: Preserved DNA Mismatch Repair Function.\X0D\\X0A\MLH-1, MSH-2, MSH-6 and PMS2 protein not expressed: Likely Deficient DNA Mismatch Repair\X0D\\X0A\Function.\X0D\\X0A\\X0D\\X0A\This analysis is an adjunct to the evaluation of the referring physician and does not\X0D\\X0A\represent a final diagnosis.\X0D\\X0A\\X0D\\X0A\Known positive tissues are tested with each IHC antibody, examined to ensure positivity, and\X0D\\X0A\returned with each case.\X0D\\X0A\\X0D\\X0A\REFERENCES:\X0D\\X0A\Ruczkiewicz AR and Jass JR. Pathol Case Rev 9:163-72, 2004.\X0D\\X0A\Popat S et al J Clin Oncol **ID-NUM, 2005.\X0D\\X0A\Southey MC et al., J Clin Oncol **ID-NUM, 2005.\X0D\\X0A\\X0D\\X0A\""These results are not, in and of themselves, diagnostic, but should be interpreted in the\X0D\\X0A\context of the clinical findings and the histopathologic diagnosis.""  This test was\X0D\\X0A\developed and its performance characteristics determined by CPA Lab.  It has not been\X0D\\X0A\cleared or approved by the U.S. Food and Drug Administration.  The FDA has determined that\X0D\\X0A\such clearance or approval is not necessary.  This test is used for clinical purposes.  It\X0D\\X0A\should not be regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the clinical Laboratory Improvement Amendments of 1988 (""CLIA"") as qualified to\X0D\\X0A\perform high-complexity clinical testing.""\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\ON BLOCK 5 AND REPORTED AS AN ADDENDUM.\X0D\\X0A\AJCC PATHOLOGIC STAGE:\X0D\\X0A\pT2 pN0 Mn/a.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS    \X0D\\X0A\\X0D\\X0A\Additional lymph nodes will be submitted and an addendum will follow.\X0D\\X0A\\X0D\\X0A\CLINICAL HISTORY       \X0D\\X0A\\X0D\\X0A\LEFT COLON MASS\X0D\\X0A\\X0D\\X0A\SPECIMEN INFORMATION     \X0D\\X0A\\X0D\\X0A\LEFT COLON\X0D\\X0A\\X0D\\X0A\GROSS DESCRIPTION       \X0D\\X0A\\X0D\\X0A\Received in formalin designated ""left colon"" is a segment of colon with an ample amount of\X0D\\X0A\attached pericolonic and mesenteric adipose tissue along with omentum.  The adipose tissue\X0D\\X0A\is adhesed causing the colon to loop.  The specimen is received closed at both ends by a\X0D\\X0A\line of surgical staples without designation as to proximal versus distal.  The specimen has\X0D\\X0A\been previously opened on one end.  The colon segment measures 35.0 cm in length and up to\X0D\\X0A\5.5 cm in diameter.  The visible serosal surface is pink-tan and glistening.  Approximately\X0D\\X0A\75% of the colon is adipose wrapped.\X0D\\X0A\\X0D\\X0A\The specimen is opened longitudinally to reveal a pink-tan button-like tumor mass measuring\X0D\\X0A\1.0 x 0.8 cm.  The tumor is located 4.5 cm from the staple line of the previously opened\X0D\\X0A\margin.  The soft tissue corresponding to the area of tumor is indurated and discolored by\X0D\\X0A\black injection dye.  The tumor is located on the mesenteric side of the colon, 4.5 cm from\X0D\\X0A\the opened margin, 30.0 cm from the opposite stapled margin and 5.0 cm from the closest\X0D\\X0A\mesenteric soft tissue margin.  The serosal surface associated with the tumor is marked with\X0D\\X0A\blue ink.  Sectioning through the tumor reveals invasion into but not grossly through the\X0D\\X0A\wall.  Focal bright yellow fat necrosis is noted associated with the tumor mass.\X0D\\X0A\\X0D\\X0A\There are no additional nodules or masses identified within the colon segment.\X0D\\X0A\\X0D\\X0A\The attached adherent omentum measures 48.0 x 16.0 x up to 1.8 cm.  Sectioning of the\X0D\\X0A\omentum reveals unremarkable nodular yellow-tan adipose tissue and vascular structures.\X0D\\X0A\\X0D\\X0A\Sectioning of the surrounding attached adipose tissue reveals rare lymph node candidates\X0D\\X0A\measuring up to 0.3 cm in greatest dimension.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\1.    surgical margin closer to tumor\X0D\\X0A\2.    surgical margin further from tumor\X0D\\X0A\3.    soft tissue mesenteric margin\X0D\\X0A\4-7.    entire tumor and adjacent adipose tissue\X0D\\X0A\8.    omentum\X0D\\X0A\9.    five intact lymph node candidates\X0D\\X0A\10.    five intact lymph node candidates\X0D\\X0A\11.    three intact lymph node candidates        **INITIALS\X0D\\X0A\12.    possible additional lymph nodes            **INITIALS\X0D\\X0A\\X0D\\X0A\Choudry,Muneeb A\X0D\\X0A\2355 Poplar Level Rd\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\**NAME[XXX],Mark R\X0D\\X0A\4500 Churchman Ave\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\Walker,**NAME[ZZZ YYY]\X0D\\X0A\**STREET-ADDRESS Dr #450\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88309GS, 88342GS/4\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[WWW M VVV] MD **DATE[Oct 29 11]\X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Nov 01 11]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\"
REG1,COLON,0,76154,3,,PREOP DIAGNOSIS:               HX OF COLON CANCER,"**NAME[BBB,AAA]                                ACCT #: **ID-NUM     LOC:  SDS    U #: 032061\X0D\\X0A\410 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 71/F       ROOM:         REG: **DATE[Nov 06 11]\X0D\\X0A\DOB: **DATE[Nov 07 40]    BED:         DIS:\X0D\\X0A\STATUS: REG SDC    TLOC:","FINAL DIAGNOSIS\X0D\\X0A\PART A: MID ASCENDING COLON POLYP, BIOPSY:\X0D\\X0A\.....ADENOMATOUS POLYP, TUBULAR TYPE.\X0D\\X0A\PART B: RECTAL MUCOSAL ELEVATION, BIOPSY:\X0D\\X0A\SQUAMOUS CELL CARCINOMA IN SITU WITH PROBABLE FOCAL SUBMUCOSAL\X0D\\X0A\.....INVASION.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ **NAME[ZZZ,YYY] XXX] MD  **DATE[Nov 07 11]",,"GROSS DESCRIPTION\X0D\\X0A\Part A: Received in a formalin container labeled with the patient's name\X0D\\X0A\and medical record number and designated as ""mid ascending colon polyp""\X0D\\X0A\includes multiple fragments of tan-pink to red-tan tissue with the single\X0D\\X0A\largest biopsy fragment measuring 0.7 x 0.4 x 0.3 cm. The remaining\X0D\\X0A\fragments measure 1 to 3 mm in greatest dimension. This specimen is\X0D\\X0A\submitted in toto in block A.\X0D\\X0A\Part B: Received in a formalin container labeled with the patient's name\X0D\\X0A\and medical record number and designated as ""mucosal elevation/rectal\X0D\\X0A\polyp"" includes 2 polypoid fragments both of which are red-brown and\X0D\\X0A\measure 0.5 x 0.3 x 0.3 and 0.3 x 0.3 x 0.3 cm. The specimen is submitted\X0D\\X0A\in toto in block B.\X0D\\X0A\D: **DATE[Nov 06 2011] - 1354 hours\X0D\\X0A\T: **DATE[Nov 06 2011] - 1554 hours","MICROSCOPIC EXAMINATION\X0D\\X0A\Part A: Sections of the submitted mid ascending colon polyp reveal\X0D\\X0A\adenomatous changes of the surface mucosal tissue with relative\X0D\\X0A\preservation of the colonic crypt contours.  There is a mild glandular\X0D\\X0A\atypia.  High-grade atypia or malignancy is not seen.\X0D\\X0A\Part B: Sections of the biopsy of rectal polyp reveal a fragment of\X0D\\X0A\acutely inflamed granulation tissue.  The second biopsy fragment also\X0D\\X0A\displays ulceration, acute inflammation, and granulation tissue\X0D\\X0A\proliferation. However, there is a proliferation of atypical squamous\X0D\\X0A\epithelial cells with associated parakeratosis. Thee are round edged nests\X0D\\X0A\extending from the surface mucosa which appear to be carcinoma in situ.\X0D\\X0A\These squamous cells display a marked epithelial atypia and display a\X0D\\X0A\marked increase in mitotic activity with 7 and 8 mitotic figures in a\X0D\\X0A\single high-powered field. There is also one focus in which there appears\X0D\\X0A\to be submucosal invasion with small irregular nests separate from the\X0D\\X0A\overlying malignant surface epithelium.  Lymphatic invasion is not seen.\X0D\\X0A\Glandular differentiation is not seen.\X0D\\X0A\D: **DATE[Nov 07 2011] - 0922 hours\X0D\\X0A\T: **DATE[Nov 07 2011] - 1016 hours","TISSUES:\X0D\\X0A\Colon, NOS (MID.ASCENDING POLYP BX)\X0D\\X0A\Rectum, NOS (MUCOSAL ELEVATION RECTAL POL)",,
REG1,COLON,0,125417,3,,"Clinical History:\X0D\\X0A\Rectal Cancer, Chemo, Radiation",CPT Code(s):   88309.26.\X0D\\X0A\KCA:jlj\X0D\\X0A\Dct:Trs:  **DATE[Dec 13 2011]\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Dec 14 2011],"Pre-Operative Diagnosis:\X0D\\X0A\Rectal Cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Colon and rectum, segmental resection:\X0D\\X0A\  -  Residual adenocarcinoma with therapy effect, present in submucosa.\X0D\\X0A\  -  Metastatic adenocarcinoma, one of eighteen regional lymph nodes\X0D\\X0A\(1/18).\X0D\\X0A\  -  Margins of resection free of tumor.\X0D\\X0A\  -  Tubular adenoma (0.7 cm).\X0D\\X0A\  -  See description and template.",,"Gross Description:\X0D\\X0A\One container is labeled ""colon and rectum"".  The specimen is received\X0D\\X0A\in fixative and consists of an unopened 27 cm segment of bowel with a\X0D\\X0A\moderate amount of attached pericolonic fat.  A surgical glove is\X0D\\X0A\attached to the proximal aspect of the specimen.  The serosa is pink and\X0D\\X0A\has dense adhesions.  The proximal margin is closed with a staple line\X0D\\X0A\and measures 4.7 cm in circumference.  The distal margin surrounded with\X0D\\X0A\anal mucosa is sutured shut and measures 8 cm in circumference.  A 0.5 x\X0D\\X0A\0.3 cm ill-defined slightly invaginated area is located 4.5 cm from the\X0D\\X0A\distal surgical margin and 1.2 cm from the dentate line.  The tissue\X0D\\X0A\subjacent to this area is cauterized.  The invaginated area does not\X0D\\X0A\appear to extend into the bowel wall.  The radial margin is located\X0D\\X0A\approximately 0.3 cm from the bowel.  Dilated blood-filled submucosal\X0D\\X0A\vessels are present between the dentate line and the distal surgical\X0D\\X0A\margin.  A 0.7 x 0.4 x 0.3 cm red polypoid structure is located 8 cm\X0D\\X0A\from the proximal surgical margin.  The polyp moves with ease over the\X0D\\X0A\muscularis.\X0D\\X0A\Additionally received in the same container is a 2 x 2 x 0.9 cm annular\X0D\\X0A\piece of tissue partially covered with mucosa.  There is a small amount\X0D\\X0A\of attached fat.  One margin is closed with a staple line.  No discrete\X0D\\X0A\mass lesions are present.\X0D\\X0A\Additionally received in the same container is a 2.5 x 1.5 cm ellipse of\X0D\\X0A\tan skin excised to a depth of 2.5 cm.  The surface of the skin is\X0D\\X0A\unremarkable.  Representative sections are submitted as follows:\X0D\\X0A\1 - perpendicular proximal margin;\X0D\\X0A\2 - perpendicular distal margin;\X0D\\X0A\3 and 4 - entire invaginated area;\X0D\\X0A\5 - dilated blood-filled vessels;\X0D\\X0A\6 - polyp;\X0D\\X0A\7 - annular piece of tissue;\X0D\\X0A\8 - separately received piece of skin and underlying soft tissue;\X0D\\X0A\9 through 11 - multiple lymph nodes.\X0D\\X0A\JMM:jck","Microscopic Description:\X0D\\X0A\Sections show focal residual adenocarcinoma, present within the\X0D\\X0A\submucosal at its deepest point, and demonstrating features consistent\X0D\\X0A\with therapy effect.  There is no significant extracellular mucin\X0D\\X0A\production.  The focus of residual tumor measures less than 0.6 cm in\X0D\\X0A\greatest dimension.\X0D\\X0A\CASE SUMMARY FOR PRIMARY COLON CARCINOMA\X0D\\X0A\Specimen:  segmental resection\X0D\\X0A\Procedure:  same\X0D\\X0A\Tumor site:  rectum\X0D\\X0A\Tumor size:  0.6 cm greatest dimension (post therapy)\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Histologic grade:  moderately differentiated (with treatment effect),\X0D\\X0A\low grade\X0D\\X0A\Microscopic tumor extension:  submucosa\X0D\\X0A\Macroscopic tumor perforation:  not seen\X0D\\X0A\Margins:\X0D\\X0A\Proximal margin:  negative\X0D\\X0A\Distal margin:  negative\X0D\\X0A\Circumferential radial margin:  at least 1 cm\X0D\\X0A\Distance of invasive carcinoma from closest margin:  at least 1 cm\X0D\\X0A\Lymph-vascular invasion:  presumed\X0D\\X0A\Perineural invasion:  yes\X0D\\X0A\Peritumor lymphocytic response (Crohn's-like response):  nil\X0D\\X0A\Treatment effect:  yes\X0D\\X0A\Extent of resection:  R0\X0D\\X0A\Regional lymph nodes:  1/18 involved\X0D\\X0A\Pathologic staging:\X0D\\X0A\     ypT1   tumor invades submucosal\X0D\\X0A\     ypN1a   metastasis in one regional lymph node\X0D\\X0A\     ypMX\X0D\\X0A\Tissue Code:  T1.",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Colon and Rectum,,
REG1,COLON,0,131103,3,,Clinical History:\X0D\\X0A\Colon Cancer,,"Pre-Operative Diagnosis:\X0D\\X0A\Colon Cancer\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Left colon, resection:\X0D\\X0A\       Poorly differentiated signet ring cell adenocarcinoma with mucinous\X0D\\X0A\differentiation.\X0D\\X0A\       Tumor invades through muscularis propria into the pericolic soft\X0D\\X0A\tissue.\X0D\\X0A\       Extensive angio-lymphatic space invasion is present.\X0D\\X0A\       Metastatic adenocarcinoma is present in one of sixteen (1/16)\X0D\\X0A\regional lymph nodes.\X0D\\X0A\       Surgical resection margins are free of tumor.\X0D\\X0A\       See template.",,"Gross Description:\X0D\\X0A\One container is labeled ""left colon"".  The specimen is received in\X0D\\X0A\fixative and consists of an unopened, unoriented 24 cm segment of bowel\X0D\\X0A\with an abundant amount of attached perienteric fat.  The surface of the\X0D\\X0A\bowel has focal dense adhesions.  One margin is closed with staple\X0D\\X0A\lines; the opposite margin is unstapled.  At the margin, luminal\X0D\\X0A\circumference is 3.5 cm.  Centrally the bowel dilates to 5 cm in\X0D\\X0A\circumference.  The bowel wall measures up to 0.3 cm.  A 2.0 x 1.0 x 1.1\X0D\\X0A\cm tumor is located 6 cm from the unstapled surgical margin.  The tumor\X0D\\X0A\is bosselated and appears polypoid.  The tumor does not appear to\X0D\\X0A\penetrate the fat.  The radial margin is located 7 cm from the bowel\X0D\\X0A\wall.  Multiple diverticula are present along the length of the\X0D\\X0A\specimen.  No sites of perforation are present.  No additional mass\X0D\\X0A\lesions are identified.  The pericolonic fat contains multiple apparent\X0D\\X0A\lymph nodes.\X0D\\X0A\Additionally received in the same container are two anastomotic rings,\X0D\\X0A\each measuring approximately 2.0 x 2.0 x 1.0 cm.  One ring contains\X0D\\X0A\sutures; the other contains staples.  Each piece of tissue is surfaced\X0D\\X0A\with unremarkable mucosa.  The sutured piece of tissue is inked.\X0D\\X0A\Representative sections are submitted as follows:\X0D\\X0A\1     proximal margin,\X0D\\X0A\2     distal margin,\X0D\\X0A\3     mesenteric radial margin,\X0D\\X0A\4-6     entire tumor,\X0D\\X0A\7     apparent diverticula,\X0D\\X0A\8, 9 \T\ 10     multiple lymph nodes,\X0D\\X0A\11     additional diverticula,\X0D\\X0A\12     anastomotic ring.\X0D\\X0A\**INITIALS","Microscopic Description:\X0D\\X0A\CASE SUMMARY FOR PRIMARY COLORECTAL CARCINOMA\X0D\\X0A\Specimen:  Left colon.\X0D\\X0A\Procedure:  Left hemicolectomy.\X0D\\X0A\Tumor site:  Left colon.\X0D\\X0A\Tumor size:  2 x 1 x 1.1 cm.\X0D\\X0A\Histologic type:  Signet ring cell carcinoma with component of mucinous\X0D\\X0A\carcinoma.\X0D\\X0A\Histologic grade:  Poorly differentiated.\X0D\\X0A\Microscopic tumor extension:  Tumor invades through the muscularis\X0D\\X0A\propria into the subserosal adipose tissue but does not extend to the\X0D\\X0A\serosal surface.\X0D\\X0A\Macroscopic tumor perforation:  Not identified.\X0D\\X0A\Margins:\X0D\\X0A\Proximal margin:  Negative for tumor.\X0D\\X0A\Distal margin:  Negative for tumor.\X0D\\X0A\Mesenteric margin:  Negative for tumor.\X0D\\X0A\Serosal (peritoneal) surface:  Negative for tumor.\X0D\\X0A\Distance of invasive carcinoma from closest margin:  6 cm from nearest\X0D\\X0A\mucosal margin.\X0D\\X0A\Lymph-vascular invasion:  Present.\X0D\\X0A\Perineural invasion:  Not identified.\X0D\\X0A\Peritumor lymphocytic response (Crohn-like response):  Not identified.\X0D\\X0A\Treatment effect:  No known prior therapy.\X0D\\X0A\Extent of resection:  Complete resection (R0) - margins histologically\X0D\\X0A\negative, no residual tumor left after resection.\X0D\\X0A\Regional lymph nodes:  1 positive/16 total.\X0D\\X0A\Tumor deposits:  Not identified.\X0D\\X0A\Additional pathologic findings:  Diverticular disease.\X0D\\X0A\Pathologic staging:\X0D\\X0A\pT3  Tumor invades through the muscularis propria into pericolorectal\X0D\\X0A\tissues.\X0D\\X0A\pN1a Metastasis in one regional lymph node.\X0D\\X0A\MX\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\CPT Code:  88309.26\X0D\\X0A\DBC:jck\X0D\\X0A\Dct:Trs:  **DATE[Dec 30 2011]\X0D\\X0A\**NAME[ZZZ YYY:  XXX WWW VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Dec 30 2011]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Left Colon,,
REG1,COLON,0,147920,3,,HISTORY: GI bleed,"ICD9 CODES: 153.9, , \X0D\\X0A\COMMENTS: The slides were seen in consultation with Dr. **NAME[ZZZ YYY], who agrees with the above diagnosis.","DIAGNOSIS: COLON, BIOPSY AT 55 CM:         MODERATELY TO POORLY DIFFERENTIATED ADENOCARCINOMA WITH         EXTENSIVE NECROSIS.",,"GROSS: Received in formalin and labeled with patient's name as ""biopsy at 65 cm"" and consists of multiple tan and gray fragments of tissue with the largest measuring up to 0.3 cm. Specimen is submitted for TE. DT: **DATE[Feb 12 2012]","MICRO: Microscopic examination was performed.  DT:  **DATE[Feb 15 12] (DRB, bsp)",PROCEDURE: Colonoscopy with biopsy\X0D\\X0A\SPECIMEN(S): biopsy at 65 cm,,
REG1,COLON,0,200867,4,,Clinical Diagnosis and History\X0D\\X0A\The working history is anal cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Anal - Rectal Resection\X0D\\X0A\2: Anal - Rectal Resection","Final Diagnosis\X0D\\X0A\RECTUM, SIGMOID COLON AND ANUS, ABDOMINAL PERINEAL RESECTION: \X0D\\X0A\     Moderately differentiated ano-rectal adenocarcinoma, tumor size 3.1 x 1.8 x\X0D\\X0A\1.8 cm, \X0D\\X0A\Deep radial margin negative, however, exceedingly close within 0.1 cm;\X0D\\X0A\Proximal and distal margin of resection negative for tumor. \X0D\\X0A\Lymphvascular and perineural invasion identified. \X0D\\X0A\2 of 13 mesenteric lymph nodes positive for metastatic carcinoma. \X0D\\X0A\EXTENDED LATERAL MARGIN:\X0D\\X0A\     Mature fibro-adipose, no tumor seen. \X0D\\X0A\COLON AND RECTUM \X0D\\X0A\DIAGNOSIS:  Ulcerated and infiltrating adenocarcinoma of the ano-rectal\X0D\\X0A\junction. \X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  A-P resection\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\TUMOR SITE:  Ano-Rectal junction. \X0D\\X0A\TUMOR SIZE (greatest dimension):  3.1 x 1.8 x 1.8 cm. \X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  No. \X0D\\X0A\TUMOR CONFIGURATION:   ulcerated and infiltrating. \X0D\\X0A\HISTOLOGIC TYPE:  Adenocarcinoma. \X0D\\X0A\HISTOLOGIC GRADE:  2. \X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION:  Tumor invades into and nearly\X0D\\X0A\through muscularis propria. \X0D\\X0A\PERITONEAL INVOLVEMENT:  No. \X0D\\X0A\LYMPH/VASCULAR INVASION:  Present. \X0D\\X0A\PERINEURAL INVASION:   Present. \X0D\\X0A\SURGICAL MARGINS:  Negative, however radial deep margin very close within less\X0D\\X0A\than 0.1 cm. \X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  Distal margin 0.5 cm,\X0D\\X0A\proximal margin approximately 26 cm. \X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  Radial margin less\X0D\\X0A\than 0.1 cm. \X0D\\X0A\DISTANCE FROM DENTATE LINE (RECTAL TUMOR ONLY):  0 mm. \X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  None. \X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED): 13 lymph nodes\X0D\\X0A\total, 2 positive for metastatic carcinoma (2/13). \X0D\\X0A\EXTRANODAL EXTENSION:  Present. \X0D\\X0A\TREATMENT EFFECT:  none\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  None. \X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  None. \X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=2  \X0D\\X0A\pN=1   \X0D\\X0A\pM=Indeterminate    \X0D\\X0A\AJCC PATHOLOGIC STAGE: IIIA\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 labeled rectum, sigmoid colon and anus, received fresh for frozen\X0D\\X0A\section, consists of a portion of colon and anus measuring 31 cm in length with\X0D\\X0A\the colon segment averaging 2.5 cm in diameter. Near the distal margin, located\X0D\\X0A\0.3 cm from the distal mucosa, is an indurated area of neoplasm. This measures\X0D\\X0A\3.1x1.8x1.8 cm. This invades deeply into the musculature and is 0.2 cm from the\X0D\\X0A\radial margin. Located 1 cm from the main tumor mass is a submucosal nodule\X0D\\X0A\which will be sampled. Additionally, 2.5 cm from the proximal margin is a small\X0D\\X0A\0.5 cm sessile polypoid lesion. No other lesions are identified. Serially\X0D\\X0A\sectioning through the mesenteric and perirectal adipose tissue shows several\X0D\\X0A\lymph nodes which are submitted. Sections are submitted as follows: AFS \X0D\\X0A\previously frozen tissue; B  distal mucosa margin; C-D  area corresponding to\X0D\\X0A\stitch representing lateral margins; E-H  representative tumor including deep\X0D\\X0A\margin; I  submucosal nodule and small sessile polyp; J-L  lymph nodes. \X0D\\X0A\Specimen 2 labeled additional lateral margins, received fresh for frozen\X0D\\X0A\section, consists of multiple fragments of fibrofatty tissue measuring\X0D\\X0A\3.0x1.0x1.0 cm in aggregate. Serially sectioning shows no gross nodules.\X0D\\X0A\Representative portions previously frozen and resubmitted as 2AFS. The remainder\X0D\\X0A\is entirely submitted in 2B-2D. \X0D\\X0A\JFJ/mbc","Microscopic Description\X0D\\X0A\Sections of the anorectal and sigmoid colon resection show a neoplastic mass\X0D\\X0A\arising at the anorectal junction. The tumor surface is ulcerated and is deeply\X0D\\X0A\invasive; it appears moderately differentiated. It is invading through into and\X0D\\X0A\nearly through the muscularis propria. The deep radial margin is negative for\X0D\\X0A\tumor; however, exceedingly close and within 0.1 cm.  Lymphvascular and\X0D\\X0A\perineural infiltration is also noted. A total of 13 mesenteric lymph nodes are\X0D\\X0A\identified, 2 of which are positive for metastatic carcinoma.  The proximal and\X0D\\X0A\distal margins of excision are negative.\X0D\\X0A\The extended lateral margin is comprised of mature fibro-adipose tissue that is\X0D\\X0A\free of tumor.",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,COLON,0,200983,3,,"CLINICAL HISTORY:  NONE GIVEN\X0D\\X0A\PRE-OP DIAGNOSIS:  MID TRANSVERSE COLON MASS WITH MILD MESENTERIC\X0D\\X0A\THICKENING OF SMALL BOWEL\X0D\\X0A\POST-OP DIAGNOSIS:  SAME, PLUS MULTIPLE ADHESIONS","CASE: SUR-11-13384\X0D\\X0A\PATIENT: **NAME[AAA BBB]\X0D\\X0A\PROCEDURE:  LAPAROSCOPIC EXAM, LAPAROSCOPIC TRANSVERSE RIGHT COLON\X0D\\X0A\RESECTION\X0D\\X0A\COMMENT:\X0D\\X0A\In the planes of section, much of this tumor appears to invade into the\X0D\\X0A\muscularis propria with only a small focus of invasion through the\X0D\\X0A\muscle into the pericolonic fatty tissues.  Marked acute inflammation is\X0D\\X0A\associated with this invasive carcinoma.","FINAL DIAGNOSIS:\X0D\\X0A\A. RIGHT TRANSVERSE COLON:\X0D\\X0A\TUMOR SITE:    Transverse colon\X0D\\X0A\HISTOLOGIC TYPE:    Adenocarcinoma\X0D\\X0A\HISTOLOGIC GRADE:   Low-grade (well to moderately differentiated)\X0D\\X0A\TUMOR SIZE:    4.5cm x 3.5cm\X0D\\X0A\DEPTH OF INVASION:  Invades through the muscle propria into\X0D\\X0A\pericolorectal soft tissue\X0D\\X0A\VISCERAL PERITONEAL PENETRATION:   Absent\X0D\\X0A\ANGIOLYMPHATIC INVASION: Not identified\X0D\\X0A\PERINEURAL INVASION:     Not identified\X0D\\X0A\MARGINS:\X0D\\X0A\-Proximal Margin:   Free of neoplasm\X0D\\X0A\-Distal Margin:     Free of neoplasm\X0D\\X0A\Tumor located 6.0 cm from distal margin.\X0D\\X0A\-Circumferential (Radial) Margin:  Cannot be assessed\X0D\\X0A\REGIONAL LYMPH NODES:    Total number examined:   22\X0D\\X0A\-Positive lymph nodes:   0\X0D\\X0A\METASTATIC DISEASE: Cannot be assessed\X0D\\X0A\TUMOR DEPOSITS:     Not identified\X0D\\X0A\EGFR, p53, K-ras:   To follow as separate report\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:    Unremarkable appendix and terminal\X0D\\X0A\ileum mucosa.\X0D\\X0A\PATHOLOGIC STAGING (pTNM):\X0D\\X0A\-Primary Tumor (pT):     pT3a/b\X0D\\X0A\-Regional Lymph Nodes (pN):   pN0\X0D\\X0A\-Distant Metastasis (pM):     Cannot be assessed",,"GROSS:\X0D\\X0A\Received designated right transverse colon is a 37 cm segment of colon\X0D\\X0A\with attached pericolonic fat. The specimen is opened in the usual\X0D\\X0A\fashion revealing a maximum circumference of 11.1 cm and a maximum wall\X0D\\X0A\thickness of 5 mm. The mucosa is pink and tan and remarkable for a\X0D\\X0A\circumferential polypoid lesion that is 4.5 x\X0D\\X0A\3.5 cm. This lesion is located \R\6 cm to the distal margin.\X0D\\X0A\INTRAOPERATIVE CONSULTATION DX:  Margins clear.        (DSG)\X0D\\X0A\The serosal surface is marked with ink and the neoplasm is sectioned\X0D\\X0A\revealing extension into and through the muscle wall, but not grossly\X0D\\X0A\extending to the inked margin. The remainder of the mucosa is\X0D\\X0A\unremarkable. There is an unremarkable 3.9 cm attached appendix and a\X0D\\X0A\3.6 cm segment of terminal ileum. The pericolonic fat is removed and\X0D\\X0A\placed in lymph node revealing solution. Representative sections of\X0D\\X0A\distal margin are submitted as A1, neoplasm and inked serosal surface\X0D\\X0A\A2, 3, 4 and 5, appendix A6, random sections through colon A7, terminal\X0D\\X0A\ileum A8, and lymph nodes A9-A12.                           (LDA)\X0D\\X0A\Final Diagnosis performed by\X0D\\X0A\**NAME[M. ZZZ YYY], M.D.\X0D\\X0A\Electronically signed **DATE[Aug 7 2012] 11:00AM",,SPECIMEN:  A. RIGHT TRANSVERSE COLON,,
REG1,COLON,0,204980,4,,Clinical Diagnosis and History\X0D\\X0A\GI Bleed.  Post-op diagnosis: Polyp.,"Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Colon, polyp 20 cm\X0D\\X0A\2: Rectal polyp\X0D\\X0A\3: Colon, polyp 10 cm","Final Diagnosis\X0D\\X0A\1.     Polyp at 20 cm:  \X0D\\X0A\     A.     Stalk invasion by moderately differentiated adenocarcinoma.  \X0D\\X0A\     B.     Tubulovillous adenoma with moderate to severe dysplasia seen.  \X0D\\X0A\2.     Large flat rectal polyp:       Tubulovillous adenoma. \X0D\\X0A\3.     Polyp at 10 cm:            Adenomatous polyp, tubular type, with moderate\X0D\\X0A\to severe dysplasia \X0D\\X0A\                         seen.  \X0D\\X0A\                    1\X0D\\X0A\Surgical Pathology Cancer Case Summary (Checklist)\X0D\\X0A\Protocol web posting date: **DATE[Aug 2010]\X0D\\X0A\     COLON AND RECTUM: Excisional Biopsy (Polypectomy)\X0D\\X0A\Select a single response unless otherwise indicated.\X0D\\X0A\Tumor Site (Note A)\X0D\\X0A\___ Cecum\X0D\\X0A\___ Right (ascending) colon\X0D\\X0A\___ Hepatic flexure\X0D\\X0A\___ Transverse colon\X0D\\X0A\___ Splenic flexure\X0D\\X0A\___ Left (descending) colon\X0D\\X0A\___ Sigmoid colon\X0D\\X0A\___ Rectum\X0D\\X0A\_x_ Other (specify): 20 cm\X0D\\X0A\___ Not specified\X0D\\X0A\*Specimen Integrity\X0D\\X0A\*_x_ Intact\X0D\\X0A\     *___ Fragmented\X0D\\X0A\*Polyp Size\X0D\\X0A\*Greatest dimension: 1.1 cm\X0D\\X0A\*Additional dimensions: ___ x ___ cm\X0D\\X0A\*___ Cannot be determined (see Comment)\X0D\\X0A\*Polyp Configuration n/a\X0D\\X0A\*___ Pedunculated with stalk     *Stalk length: ___ cm\X0D\\X0A\*___ Sessile\X0D\\X0A\Size of Invasive Carcinoma \X0D\\X0A\Greatest dimension: 0.25 cm\X0D\\X0A\*Additional dimensions: ___x ___ cm\X0D\\X0A\___ Cannot be determined (see Comment)\X0D\\X0A\Histologic Type (Note B)\X0D\\X0A\_x_ Adenocarcinoma\X0D\\X0A\___ Mucinous adenocarcinoma \X0D\\X0A\___ Signet-ring cell carcinoma \X0D\\X0A\___ Small cell carcinoma \X0D\\X0A\___ Squamous cell carcinoma \X0D\\X0A\___ Adenosquamous carcinoma\X0D\\X0A\___ Medullary carcinoma\X0D\\X0A\___ Undifferentiated carcinoma\X0D\\X0A\___ Other (specify): __________________________\X0D\\X0A\___ Carcinoma, type cannot be determined\X0D\\X0A\Histologic Grade (Note C)\X0D\\X0A\___ Not applicable\X0D\\X0A\___ Cannot be determined\X0D\\X0A\_x_ Low-grade (well-differentiated to moderately differentiated)\X0D\\X0A\___ High-grade (poorly differentiated to undifferentiated)\X0D\\X0A\Microscopic Tumor Extension (Note D) \X0D\\X0A\_x_ Cannot be determined\X0D\\X0A\Invasion (deepest):\X0D\\X0A\___ Lamina propria\X0D\\X0A\___ Muscularis mucosae\X0D\\X0A\___ Submucosa\X0D\\X0A\___ Muscularis propria\X0D\\X0A\Margins (select all that apply)\X0D\\X0A\Deep Margin (Stalk Margin)\X0D\\X0A\_x_ Cannot be assessed\X0D\\X0A\___ Uninvolved by invasive carcinoma\X0D\\X0A\     Distance of invasive carcinoma from margin: ___ mm\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\Mucosal/Lateral Margin \X0D\\X0A\___ Not applicable\X0D\\X0A\_x_ Cannot be assessed\X0D\\X0A\___ Uninvolved by invasive carcinoma\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\___ Involved by adenoma\X0D\\X0A\Lymph-Vascular Invasion (Notes D and E)\X0D\\X0A\___ Not identified\X0D\\X0A\___ Present\X0D\\X0A\_x_ Indeterminate\X0D\\X0A\*Type of Polyp in Which Invasive Carcinoma Arose (Note F)\X0D\\X0A\*___ Tubular adenoma\X0D\\X0A\*___ Villous adenoma\X0D\\X0A\*_x_ Tubulovillous adenoma\X0D\\X0A\*___ Traditional serrated adenoma\X0D\\X0A\*___ Sessile serrated adenoma\X0D\\X0A\*___ Hamartomatous polyp\X0D\\X0A\*___ Indeterminate\X0D\\X0A\*Additional Pathologic Findings (select all that apply)\X0D\\X0A\*___ None identified\X0D\\X0A\*___ Inflammatory bowel disease\X0D\\X0A\     *___ Active\X0D\\X0A\     *___ Quiescent\X0D\\X0A\*___ Other (specify): ___________________________\X0D\\X0A\*Ancillary Studies \X0D\\X0A\*Specify: ___________________________________\X0D\\X0A\*___ Not performed\X0D\\X0A\*Comment(s)\X0D\\X0A\*  Data elements with asterisks are not required. However, these elements may be\X0D\\X0A\clinically important but are not yet validated or regularly used in patient\X0D\\X0A\management. \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.",,"Gross Description\X0D\\X0A\1. Specimen #1 is received in formalin, labeled with the patient's name and\X0D\\X0A\""polyp at 20 cm.""  The specimen consists of two tan-pink soft tissue polyps\X0D\\X0A\measuring 0.7 x 0.4 x 0.3 cm and 1.1 x 1.0 x 0.8 cm.  Each resection margin is\X0D\\X0A\inked and sectioned.  The masses are both submitted in (block 1A).  \X0D\\X0A\2. Specimen #2 is received in formalin, labeled with the patient's name and\X0D\\X0A\""large flat rectal polyp.""  The specimen consists of six yellow-tan soft tissue\X0D\\X0A\fragments aggregating to 0.6 x 0.4 x 0.2 cm, totally submitted in (block 2A). \X0D\\X0A\3. Specimen #3 is received in formalin, labeled with the patient's name and\X0D\\X0A\""polyp at 10 cm.""  The specimen consists of four tan-pink soft tissue polyps\X0D\\X0A\ranging from 0.1 cm in greatest dimension to 0.5 x 0.5 x 0.3 cm.  The resection\X0D\\X0A\margin of the largest polyp is inked black and the polyp is trisected.  The\X0D\\X0A\entire specimen is submitted in (block 3A). \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\     1.     The sections are of a colonic polyp with villous and adenomatous\X0D\\X0A\glandular differentiation.  Moderate to severe surface dysplasia is present. \X0D\\X0A\Superficial infiltration into the stalk is identified.  Cautery artifact is\X0D\\X0A\present at the margins of excision.  The infiltrative tumor does not extend to\X0D\\X0A\the ink in any of the sections examined.  The inked margins, however, do show\X0D\\X0A\villous and adenomatous glandular differentiation.  Focally, a moderate level of\X0D\\X0A\cytologic dysplasia is present along the inked surface.  \X0D\\X0A\2.     The sections show villous and adenomatous glandular differentiation with\X0D\\X0A\no significant level of cytologic dysplasia seen.  The findings are consistent\X0D\\X0A\with a tubulovillous adenoma.  \X0D\\X0A\3.     The sections are of highly inflamed colonic tissue with adenomatous\X0D\\X0A\glandular differentiation showing moderate to severe dysplasia present, and no\X0D\\X0A\stalk invasion is identified in this instance.  \X0D\\X0A\**INITIALS",,,
REG1,COLON,0,208443,3,,Clinical Diagnosis and History\X0D\\X0A\The working history is intestinal bleeding; colon cancer.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: BPSC Endoscopy \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Colon, polyp\X0D\\X0A\Previous Pertinent History\X0D\\X0A\**DATE[Feb 09 2008] **ID-NUM  Tubular adenoma \X0D\\X0A\**DATE[Oct 16 2007] **ID-NUM Mild chronic gastritis Negative for Helicobacter",Final Diagnosis\X0D\\X0A\COLON POLYP:\X0D\\X0A\     Tubulovillous adenoma with focal surface adenocarcinoma in situ.\X0D\\X0A\MHB/mbc,,"Gross Description\X0D\\X0A\The specimen, labeled colon polyp, received in formalin, consists of a\X0D\\X0A\0.6x0.5x0.5 cm tan/pink polyp with is submitted entirely in one cassette.\X0D\\X0A\HM/mbc",Microscopic Description\X0D\\X0A\Sections including deeper sections show adenomatous change involving tubular and\X0D\\X0A\elongated glands.  Focal back to back atypical glands are seen along the surface\X0D\\X0A\of the polyp.  No stromal invasion is seen.,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,236208,4,,PREOP DIAGNOSIS:               RECTAL MASSES,"**NAME[BBB,AAA] L                            ACCT #: **ID-NUM     LOC:  5NO    U #: 050422\X0D\\X0A\339 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 76/F       **ROOM    REG: **DATE[Nov 01 12]\X0D\\X0A\DOB: **DATE[Feb 22 36]    BED: 01      DIS: **DATE[Nov 02 12]\X0D\\X0A\STATUS: DIS INo    TLOC: 5NO","FINAL DIAGNOSIS\X0D\\X0A\SUBMITTED RECTAL MASS:\X0D\\X0A\.....1....VILLOUS ADENOMA WITH A MICROSCOPIC FOCUS OF WELL-DIFFERENTIATED\X0D\\X0A\..........ADENOCARCINOMA, WHICH IS INTRAMUCOSAL.\X0D\\X0A\.....2....THE ADENOCARCINOMA MEASURES 2.4 MM IN GREATEST DIMENSION.\X0D\\X0A\.....3....THE ADENOCARCINOMA MEASURES 2.9 MM FROM THE CLOSEST SUBMUCOSAL\X0D\\X0A\..........LINE OF EXCISION.\X0D\\X0A\.....4....THE VILLOUS ADENOMATOUS CHANGES EXTEND TO THE MARGINS OF\X0D\\X0A\..........EXCISION.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ **NAME[ZZZ,YYY] XXX] MD  **DATE[Nov 05 12]",,"GROSS DESCRIPTION\X0D\\X0A\Received in a formalin container labeled with the patient's name and\X0D\\X0A\medical record number and designated as ""rectal masses"" are 2 polypoid,\X0D\\X0A\soft, slightly firm masses without identifiable stalk. Both are partially\X0D\\X0A\covered by red-purple thrombus. These polypoid fragments measure 2.2 x 1.4\X0D\\X0A\x 1.4 cm and 2.0 x 1.4 x 1.3 cm. The polypoid masses display a villous\X0D\\X0A\surface in part. There is friability of the mucosal aspect. The first\X0D\\X0A\polypoid segment is serially sectioned in submitted in blocks 1 and 2. The\X0D\\X0A\remaining polyp is serially sectioned and submitted in block 3 and 4,\X0D\\X0A\noting the greater friability of this segment.\X0D\\X0A\D: **DATE[Nov 02 2012] - 1142 hours\X0D\\X0A\T: **DATE[Nov 04 2012] - 1657 hours","MICROSCOPIC EXAMINATION\X0D\\X0A\Sections through the first polypoid fragment reveal villous adenomatous\X0D\\X0A\change within the polyp. There are finger-like mucosal projections lined\X0D\\X0A\by adenomatous epithelium, which for the most part displays a mild to\X0D\\X0A\moderate glandular atypia. There are areas of mucosal hemorrhage seen\X0D\\X0A\along the surface of the adenoma. There is well-differentiated\X0D\\X0A\adenocarcinoma seen arising within the polyp in which there is formation\X0D\\X0A\of complex gland-within-gland forms forming a cribriform architecture.\X0D\\X0A\This area measures 2.5 x less than 1 mm. There is also high-grade\X0D\\X0A\dysplasia seen in the superficial aspects of the villous adenoma, with the\X0D\\X0A\nuclei seen extending to the mucosal surface. The second polypoid segment\X0D\\X0A\shows identical features of villous adenoma. As noted in the first\X0D\\X0A\segment, there is surface mucosal erosion and hemorrhage. There is\X0D\\X0A\high-grade dysplasia seen along the surface of the adenoma, with nuclei\X0D\\X0A\extending to the surface mucosa and nuclear enlargement with occasional\X0D\\X0A\distinct nucleoli. The muscularis mucosa is readily identified in both\X0D\\X0A\polypoid fragments. Tumor does not extend beyond the muscularis mucosa.\X0D\\X0A\The adenocarcinoma measures 2.9 mm from the presumed submucosal line of\X0D\\X0A\resection.\X0D\\X0A\D: **DATE[Nov 05 2012] - 1123 hours\X0D\\X0A\T: **DATE[Nov 05 2012] - 1300 hours","TISSUES:\X0D\\X0A\Rectum, NOS (RECTAL MASSES)",,
REG1,COLON,0,329891,3,,Clinical Diagnosis and History\X0D\\X0A\OPER:   EGD AND COLONOSCOPY,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY M]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: DUODENUM rd\X0D\\X0A\2: RANDOM GASTRIC BX's rd\X0D\\X0A\3: CECAL POLYP rd","Final Diagnosis\X0D\\X0A\1:  DUODENUM, BIOPSIES \X0D\\X0A\     NO VILLOUS BLUNTING OR CRYPT HYPERPLASIA.\X0D\\X0A\     NO INCREASE OF INTRAEPITHELIAL LYMPHOCYTES.\X0D\\X0A\     NO ULCERS, GRANULOMAS OR PARASITES.\X0D\\X0A\2:  RANDOM GASTRIC BIOPSIES \X0D\\X0A\     MINIMAL FOCAL CHRONIC INFLAMMATION, NONSPECIFIC.\X0D\\X0A\     NO IDENTIFIED HELICOBACTER ORGANISMS WITH A SPECIAL STAIN.\X0D\\X0A\3:  CECUM, BIOPSIES \X0D\\X0A\     FRAGMENTS OF TUBULAR ADENOMA WITH HIGH GRADE DYSPLASIA / CARCINOMA IN    \X0D\\X0A\             SITU.\X0D\\X0A\MER/in\X0D\\X0A\IHC/a/THM\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\1: Received in formalin designated ""duodenum"" are fragments of tan tissue 0.7\X0D\\X0A\x0.2 x 0.2 cm in aggregate. Submitted labeled 1A.\X0D\\X0A\2: In formalin labeled ""random gastric biopsy"" are fragments of tan tissue 0.6 x\X0D\\X0A\0.3 x 0.2 cm in aggregate. Submitted labeled 2A.\X0D\\X0A\3: In formalin labeled ""cecal polyp"" are fragments of tan tissue 0.5 x 0.3 x 0.2\X0D\\X0A\cm in aggregate. Submitted labeled 3A.\X0D\\X0A\MER/cb",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,COLON,0,386095,4,,Clinical Diagnosis and History\X0D\\X0A\The working history is rectal cancer/small bowel obstruction.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Spermatic Cord\X0D\\X0A\2: Colon, seg resection for tumor (incl. lymph nodes)\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Dec 10 11]:  1. BIOPSIES OF RECTAL LESION: Invasive moderately\X0D\\X0A\differentiated adenocarcinoma. 2. BIOPSIES OF RIGHT COLON POLYP: Tubulovillous\X0D\\X0A\adenoma.  (MHB) \X0D\\X0A\***PATH-NUMBER[2], **DATE[Aug 23 09]: ANASTOMOTIC GRANULATION BIOPSY: Inflamed granulation tissue\X0D\\X0A\with inflammatory pseudopolyp formation. (MHB) \X0D\\X0A\***PATH-NUMBER[3], **DATE[Sep 13 08]:  RIGHT PELVIC WALL:  Dense fibrosis and adipose tissue, no\X0D\\X0A\tumor seen.  TISSUE SUBMITTED AS RECTUM:  Infiltrating moderately differentiated\X0D\\X0A\adenocarcinoma with penetration of outer longitudinal of muscularis propria;\X0D\\X0A\tumor size = 1.0 x 0.8 x 0.3cm.  No lymphvascular invasion identified, margins\X0D\\X0A\free of tumor. See Template. Lymph nodes x 2, no tumor seen. (DGD) \X0D\\X0A\***PATH-NUMBER[4], **DATE[Jan 5 08]:  1. APPENDIX, APPENDECTOMY:  Appendix with no significant\X0D\\X0A\histopathologic change. 2. LEFT COLON, HEMICOLECTOMY: Adenocarcinoma (see\X0D\\X0A\Template). 3. GALLBLADDER, CHOLECYSTECTOMY: Chronic cholecystitis and\X0D\\X0A\cholelithiasis. Benign lymph node.  (PCC)","Final Diagnosis\X0D\\X0A\1.  SPECIMEN SUBMITTED AS RIGHT SPERMATIC CORD AND INTERNAL ILIAC LYMPH NODE: \X0D\\X0A\     Recurrent moderately differentiated adenocarcinoma surrounding the\X0D\\X0A\spermatic cord. No lymph node identified.\X0D\\X0A\2.  RECTUM AND LEFT COLON, SEGMENTAL RESECTION: \X0D\\X0A\     Subserosal involvement with recurrent moderately differentiated mucinous\X0D\\X0A\adenocarcinoma. No mucosal tumor or mucosal marginal involvement identified.\X0D\\X0A\Radial margin involved by tumor.  Eight lymph nodes negative for metastasis. \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 labeled right spermatic cord and internal iliac node consists of a\X0D\\X0A\segment of spermatic cord measuring 6.0cm in length and 25.0cm in diameter which\X0D\\X0A\shows no abnormalities.  It also consists of an irregular fragment of yellow\X0D\\X0A\tissue measuring 3.0 x 2.0 x 1.0cm which on sectioning shows no definite lymph\X0D\\X0A\node.  This is submitted in toto after sectioning in B. \X0D\\X0A\Specimen 2 consists of a segment of bowel measuring 16.0 x 3.2cm.  The serosal\X0D\\X0A\surface shows dense fibrosis with a somewhat nodular area located 3.0cm from the\X0D\\X0A\anal margin.  There is a 2.5cm in length of anal skin and an area of ulcer with\X0D\\X0A\a defect extending through the wall in the rectoanal margin.  No obvious tumor\X0D\\X0A\mass is seen.  The serosal firm nodule measures 3.0 x 3.0 x 2.8cm.  The radial\X0D\\X0A\margin in this region is inked and on sectioning the firm mass has a variegated\X0D\\X0A\appearance which is suspicious for tumor.  Sections are submitted as follows:\X0D\\X0A\margin  A-B, sections from the subserosal mass including the inked radial margin\X0D\\X0A\ C, D, E; sections from the defect and mucosa in the area of defect in F-G. \X0D\\X0A\Intact lymph nodes in H and I.  **INITIALS",Microscopic Description\X0D\\X0A\Specimen 1 shows spermatic cord but also shows nests of tumor surrounding the\X0D\\X0A\cord. No lymph node is identified.\X0D\\X0A\The anal and colonic mucosal margins are free of tumor. The subserosal nodule\X0D\\X0A\shows extensive involvement with a mucinous adenocarcinoma. The tumor appears to\X0D\\X0A\extend to the inked radial margin of resection. There is additional portion of\X0D\\X0A\spermatic cord present within this mass of tissue which is surrounded by\X0D\\X0A\fibrosis and tumor. No mucosal tumor is seen.  Eight lymph nodes are identified\X0D\\X0A\and none of these show metastasis. **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,402927,3,,Clinical Diagnosis and History\X0D\\X0A\Rectal bleeding.\X0D\\X0A\Post-op polyps.,"Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Cecum polyp\X0D\\X0A\2: Colon, polyp descending\X0D\\X0A\3: Distal sigmoid colon, polyp","Final Diagnosis\X0D\\X0A\1.     Cecal polyp:    Fragments of hyperplastic polyp.  \X0D\\X0A\     2.     Descending colon polyp:    Polypoid fragment of benign colonic\X0D\\X0A\mucosa demonstrating mild active inflammation, non-specific. \X0D\\X0A\Comment:   Histologic changes of an adenomatous polyp or hyperplastic polyp are\X0D\\X0A\not identified.  \X0D\\X0A\3.     Distal sigmoid colon polyp:  \X0D\\X0A\          A.     Well-differentiated adenocarcinoma arising in a tubulovillous\X0D\\X0A\adenoma with focal submucosal stalk invasion.\X0D\\X0A\     B.     Foci of adenocarcinoma in situ. \X0D\\X0A\     C.     The inked base of the polyp stalk at the margin of excision is\X0D\\X0A\negative for malignancy and negative for adenomatous change.  \X0D\\X0A\AJCC stage:   pT1 pNX.  \X0D\\X0A\               2\X0D\\X0A\Comment:   This report is faxed to the office of Dr. **NAME[ZZZ YYY] on Tuesday,\X0D\\X0A\**DATE[May 22 2012].   \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX M. WWW], MD\X0D\\X0A\Surgical Pathology Cancer Case Summary (Checklist)\X0D\\X0A\Protocol web posting date: **DATE[Apr 2010]\X0D\\X0A\     COLON AND RECTUM: Excisional Biopsy (Polypectomy)\X0D\\X0A\Select a single response unless otherwise indicated.\X0D\\X0A\Tumor Site (Note A)\X0D\\X0A\___ Cecum\X0D\\X0A\___ Right (ascending) colon\X0D\\X0A\___ Hepatic flexure\X0D\\X0A\___ Transverse colon\X0D\\X0A\___ Splenic flexure\X0D\\X0A\___ Left (descending) colon\X0D\\X0A\_X__ Sigmoid colon\X0D\\X0A\___ Rectum\X0D\\X0A\___ Other (specify): ________________________\X0D\\X0A\___ Not specified\X0D\\X0A\*Specimen Integrity\X0D\\X0A\*___ Intact\X0D\\X0A\     *___ Fragmented\X0D\\X0A\*Polyp Size\X0D\\X0A\*Greatest dimension: ___ cm\X0D\\X0A\*Additional dimensions: ___ x ___ cm\X0D\\X0A\*___ Cannot be determined (see Comment)\X0D\\X0A\*Polyp Configuration \X0D\\X0A\*___ Pedunculated with stalk     *Stalk length: ___ cm\X0D\\X0A\*___ Sessile\X0D\\X0A\Size of Invasive Carcinoma \X0D\\X0A\Greatest dimension: 0.5___ cm\X0D\\X0A\*Additional dimensions: ___x ___ cm\X0D\\X0A\___ Cannot be determined (see Comment)\X0D\\X0A\Histologic Type (Note B)\X0D\\X0A\_X__ Adenocarcinoma\X0D\\X0A\___ Mucinous adenocarcinoma \X0D\\X0A\___ Signet-ring cell carcinoma \X0D\\X0A\___ Small cell carcinoma \X0D\\X0A\___ Squamous cell carcinoma \X0D\\X0A\___ Adenosquamous carcinoma\X0D\\X0A\___ Medullary carcinoma\X0D\\X0A\___ Undifferentiated carcinoma\X0D\\X0A\___ Other (specify): __________________________\X0D\\X0A\___ Carcinoma, type cannot be determined\X0D\\X0A\Histologic Grade (Note C)\X0D\\X0A\___ Not applicable\X0D\\X0A\___ Cannot be determined\X0D\\X0A\_X__ Low-grade (well-differentiated to moderately differentiated)\X0D\\X0A\___ High-grade (poorly differentiated to undifferentiated)\X0D\\X0A\Microscopic Tumor Extension (Note D) \X0D\\X0A\___ Cannot be determined\X0D\\X0A\Invasion (deepest):\X0D\\X0A\___ Lamina propria\X0D\\X0A\___ Muscularis mucosae\X0D\\X0A\_X__ Submucosa\X0D\\X0A\___ Muscularis propria\X0D\\X0A\Margins (select all that apply)\X0D\\X0A\Deep Margin (Stalk Margin)\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\__X_ Uninvolved by invasive carcinoma\X0D\\X0A\     Distance of invasive carcinoma from margin: ___ mm  CANNOT BE DETERMINED.\X0D\\X0A\INVASIVE MALIGNANCY NOT PRESENT IN SECTION OF STALK MARGIN.\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\Mucosal/Lateral Margin \X0D\\X0A\_X__ Not applicable\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\___ Uninvolved by invasive carcinoma\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\___ Involved by adenoma\X0D\\X0A\Lymph-Vascular Invasion (Notes D and E)\X0D\\X0A\_X__ Not identified\X0D\\X0A\___ Present\X0D\\X0A\___ Indeterminate\X0D\\X0A\*Type of Polyp in Which Invasive Carcinoma Arose (Note F)\X0D\\X0A\*___ Tubular adenoma\X0D\\X0A\*___ Villous adenoma\X0D\\X0A\*___ Tubulovillous adenoma\X0D\\X0A\*___ Traditional serrated adenoma\X0D\\X0A\*___ Sessile serrated adenoma\X0D\\X0A\*___ Hamartomatous polyp\X0D\\X0A\*___ Indeterminate\X0D\\X0A\*Additional Pathologic Findings (select all that apply)\X0D\\X0A\*___ None identified\X0D\\X0A\*___ Inflammatory bowel disease\X0D\\X0A\     *___ Active\X0D\\X0A\     *___ Quiescent\X0D\\X0A\*___ Other (specify): ___________________________\X0D\\X0A\*Ancillary Studies \X0D\\X0A\*Specify: ___________________________________\X0D\\X0A\*___ Not performed\X0D\\X0A\*Comment(s)\X0D\\X0A\*  Data elements with asterisks are not required. However, these elements may be\X0D\\X0A\clinically important but are not yet validated or regularly used in patient\X0D\\X0A\management.",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin and labeled with the patient name and\X0D\\X0A\""cecal"". The specimen consists of two red-tan soft tissue fragments aggregating\X0D\\X0A\to 0.7 x 0.5 x 0.2 cm, totally submitted in (block 1A).\X0D\\X0A\Specimen #2 is received in formalin and labeled with the patient name and\X0D\\X0A\""descending"". The specimen consists of one red-brown soft tissue polyp measuring\X0D\\X0A\0.5 x 0.4 x 0.2 cm, totally submitted in (block 2A).\X0D\\X0A\Specimen #3 is received in formalin and labeled with the patient name and\X0D\\X0A\""distal sigmoid"". The specimen consists of a red-brown, lobular polyp measuring\X0D\\X0A\2.5 x 2.1 x 1.8 cm.  The polyp appears slightly pedunculated.  The stalk\X0D\\X0A\measures 0.5 cm in length x 0.7 cm in diameter. The resection margin is inked\X0D\\X0A\blue.  The cut surface is lobulated and friable. The specimen is totally\X0D\\X0A\submitted in (blocks 3A-3D).\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\     1.     Sections of the cecal polyp reveal fragments of hyperplastic polyp. \X0D\\X0A\Serrated glands are seen.  There is no evidence of malignancy.  \X0D\\X0A\2.     Sections of the descending colon polyp reveal a polypoid fragment of\X0D\\X0A\colonic mucosa demonstrating a mild amount of non-specific active inflammation. \X0D\\X0A\There is a mild increase in eosinophils in the lamina propria.  PMN leukocytes\X0D\\X0A\may also be seen in the lamina propria.  The collagen table is not thickened. \X0D\\X0A\Crypt abscesses or granulomata are not identified and intraepithelial\X0D\\X0A\lymphocytes are not increased.  Histologic changes of an adenomatous polyp or\X0D\\X0A\hyperplastic polyp are not seen.  There is no evidence of malignancy. \X0D\\X0A\3.     Sections of the distal sigmoid colon polyp reveal well-differentiated\X0D\\X0A\adenocarcinoma arising in a tubulovillous adenoma.  The tumor forms complex and\X0D\\X0A\back-to-back glandular structures with high-grade cytologic atypia.  Lamina\X0D\\X0A\propria invasion is seen and focal submucosal stalk invasion is seen.  Foci of\X0D\\X0A\adenocarcinoma in situ are identified.  Otherwise, the tubulovillous adenoma\X0D\\X0A\demonstrates moderate atypia. The inked base of the polyp at the margin of\X0D\\X0A\resection is negative for malignancy.  \X0D\\X0A\**INITIALS",,,
REG1,COLON,0,458476,3,,,,,,,,,,
REG1,COLON,0,459136,3,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is anal ulcer. Operative procedure: anal lesion\X0D\\X0A\biopsies. \X0D\\X0A\\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Feb 14 1977] (Age: **AGE[in 30s])  MW\X0D\\X0A\Collect Date: **DATE[May 15 2012] 12:35\X0D\\X0A\Receipt Date: **DATE[May 15 2012] 12:35\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD: J.S. **NAME[YYY], MD     Service: SGG     Location: CAS\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 19 2012] 12:39\X0D\\X0A\RESIDENTS(S): S.R. **NAME[WWW], MD\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\LEFT PERIANAL, BIOPSY (A):\X0D\\X0A\   - SEVERE SQUAMOUS DYSPLASIA (AIN III).\X0D\\X0A\\X0D\\X0A\RIGHT PERIANAL, RIGHT, BIOPSY (B):\X0D\\X0A\   - SEVERE SQUAMOUS DYSPLASIA (AIN III).\X0D\\X0A\\X0D\\X0A\INTRA-ANAL, BIOPSY (C):\X0D\\X0A\   - ACUTELY INFLAMED CONDYLOMA ACUMINATUM WITH MILD SQUAMOUS DYSPLASIA.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 19 2012] **NAME[VVV M. UUU], MD\X0D\\X0A\ \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M74008 P1140\X0D\\X0A\B: M74008 P1140\X0D\\X0A\C: M40000 M7400 \X0D\\X0A\\X0D\\X0A\F: A: 88305\X0D\\X0A\B: 88305\X0D\\X0A\C: 88305 \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  three\X0D\\X0A\Specimen label:   A) left perianal biopsy                \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces:  one \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): red tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.3 x 0.2 x less than 0.1 cm \X0D\\X0A\The skin surface is white and no lesions are seen grossly \X0D\\X0A\Cassette summary: entirely submitted in screened A1. \X0D\\X0A\\X0D\\X0A\Specimen label:  B) right perianal biopsy                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.4 x 0.4 x 0.2 cm\X0D\\X0A\The skin surface is white tan. No lesions are seen grossly. \X0D\\X0A\Cassette summary: entirely submitted in screened B1. \X0D\\X0A\\X0D\\X0A\Specimen label:  C) intraanal rectal biopsies            \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces:  four \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): range from 1 x 0.7 x 0.7 cm to 0.4 x 0.3 x 0.2 cm \X0D\\X0A\Cassette summary: entirely submitted in screened C1.  \X0D\\X0A\\X0D\\X0A\rgc/**DATE[May 18 2012] S.R. **NAME[WWW], MD\X0D\\X0A\J.G. Combs  \X0D\\X0A\\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left perianal biopsy\X0D\\X0A\B: Right perianal biopsy\X0D\\X0A\C: Intraanal rectal biopsies\X0D\\X0A\,,
REG1,COLON,0,476136,1,,Clinical Diagnosis and History\X0D\\X0A\Screening colon,"Copy To: **NAME[ZZZ YYY], M.D. \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Colon, polyp 45 cm","Final Diagnosis\X0D\\X0A\Colon, polypectomy at 45 cm:  \X0D\\X0A\A.     Moderately differentiated adenocarcinoma arising in a tubulovillous\X0D\\X0A\adenoma.  \X0D\\X0A\B.     Lesion extends to within 0.9 cm of polyp base. \X0D\\X0A\C.     Negative for evidence of definitive stalk invasion.  \X0D\\X0A\D.     Base of polyp negative for evidence of dysplasia.  \X0D\\X0A\E.     Separate foci of at least high grade glandular dysplasia in a separately\X0D\\X0A\grossly described tubulovillous adenoma, base of polyp negative for evidence of\X0D\\X0A\dysplasia.\X0D\\X0A\Comment:    It is not clear whether the lesions represent two separate polyps at\X0D\\X0A\the same location or one single fragmented polyp.  No area of carcinoma or high\X0D\\X0A\grade dysplasia in either polyp is closer than 0.9 cm from the respective bases\X0D\\X0A\of excision.  Clinical correlation is suggested.  \X0D\\X0A\                    1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX M. WWW], M.D.",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin and labeled with the patient name and ""colon\X0D\\X0A\polyp 45 cm"". The specimen consists of two red-tan pediculated polyps. The first\X0D\\X0A\polyp measures 2.4 x 2 x 1.8 cm.  The polyp sets on a stalk measuring 1 cm in\X0D\\X0A\length x 0.8 cm in diameter. The surface of the polyp is red-pink, lobular and\X0D\\X0A\friable. The resection margin is inked black. Sectioning reveals a villous\X0D\\X0A\appearance and is markedly friable. The second polyp measures 1.8 x 1.5 x 1.3\X0D\\X0A\cm. The polyp sets on a stalk measuring 0.4 cm in length x 0.6 cm in diameter.\X0D\\X0A\The resection margin is inked blue.  The external surface of the polyp is\X0D\\X0A\red-tan and slightly granular. The cut surface is red-pink, slightly hemorrhagic\X0D\\X0A\and solid. A small amount of mucin material is identified.  The first described\X0D\\X0A\polyp is totally submitted in (blocks A-D). The second polyp is totally\X0D\\X0A\submitted in (blocks E-F).\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Microscopic examination reveals sections of polypoid colonic lesions\X0D\\X0A\demonstrating a focal villiform architecture and pseudostratified columnar\X0D\\X0A\lining epithelium with elongated hyperchromatic nuclei.  Multiple foci of the\X0D\\X0A\smaller grossly described polyp demonstrate cribriform gland formation with\X0D\\X0A\rounded atypical nuclei with high nuclear-to-cytoplasmic ratios also noted.  The\X0D\\X0A\atypical nuclei demonstrate coarse chromatin and occasional nucleoli. \X0D\\X0A\Definitive stalk invasion is not identified.  The lesion extends to within 0.9\X0D\\X0A\cm of the polyp base and no evidence of obvious dysplasia is noted at the polyp\X0D\\X0A\excision base.  The larger grossly described polyp also demonstrates foci of at\X0D\\X0A\least high grade glandular dysplasia which do not demonstrate evidence of stalk\X0D\\X0A\invasion.  The base of the larger polyp is also negative for dysplasia.\X0D\\X0A\CBG/js,,,
REG1,COLON,0,477064,1,,"Clinical Diagnosis and History\X0D\\X0A\RECTAL TUMOR, HEME+ STOOL\X0D\\X0A\OPER:   C-SCOPE","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RECTAL TUMOR BX lg","Final Diagnosis\X0D\\X0A\RECTUM, BIOPSIES:\X0D\\X0A\     FRAGMENTS OF INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA WITH\X0D\\X0A\        EVIDENCE OF ULCERATION.\X0D\\X0A\COMMENT: The total depth of invasion cannot be determined with certainty in this\X0D\\X0A\material.\X0D\\X0A\MER/cb \X0D\\X0A\IHC/a/CLS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\In formalin designated ""rectal tumor biopsy"" is tan gray soft tissue in\X0D\\X0A\aggregate measuring 7 x 3 x 3 mm.  Block 1A.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,COLON,0,477240,1,,"Clinical Diagnosis and History\X0D\\X0A\ASCENDING COLON MASS\X0D\\X0A\OPER:  EXPLORATORY LAPAROTOMY, RIGHT COLECTOMY","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[XXX]\X0D\\X0A\**NAME[YYY], M.D., U. GEETHA\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RIGHT COLON. jl","Final Diagnosis\X0D\\X0A\RIGHT COLON:\X0D\\X0A\     SPECIMEN: RIGHT COLON, APPENDIX, TERMINAL ILEUM.\X0D\\X0A\     PROCEDURE: RIGHT HEMICOLECTOMY.\X0D\\X0A\     TUMOR SITE: CECUM.\X0D\\X0A\     TUMOR SIZE: 10.7 X 9.3 X 5.3 CM.\X0D\\X0A\     MACROSCOPIC TUMOR PERFORATION: PRESENT.\X0D\\X0A\     HISTOLOGIC TYPE: ADENOCARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: HIGH GRADE (POORLY DIFFERENTIATED).\X0D\\X0A\     MICROSCOPIC TUMOR EXTENSION: TUMOR PENETRATES THE SURFACE OF THE \X0D\\X0A\         VISCERAL PERITONEUM (CANNOT BE DETERMINED IN THIS MATERIAL WHETHER\X0D\\X0A\         TUMOR INFILTRATES ADJACENT STRUCTURES OR NOT. TUMOR IS PRESENT AT \X0D\\X0A\          INKED MARGIN IN THE AREA OF PERFORATION AT THE CECUM). \X0D\\X0A\     MARGINS: \X0D\\X0A\     PROXIMAL MARGIN UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\DISTAL MARGIN UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\CIRCUMFERENTIAL RADIAL (MESENTERIC MARGIN): UNINVOLVED BY \X0D\\X0A\    INVASIVE CARCINOMA.\X0D\\X0A\     LYMPH/VASCULAR INVASION: NOT IDENTIFIED.\X0D\\X0A\     PERINEURAL INVASION: NOT IDENTIFIED.\X0D\\X0A\     TUMOR DEPOSITS: NOT IDENTIFIED.\X0D\\X0A\     PATHOLOGIC STAGING:\X0D\\X0A\          T4a (IF TUMOR DIRECTLY INVADES OR WAS ADHERENT TO OTHER ORGAN\X0D\\X0A\              STRUCTURES THEN THIS TUMOR IS T4b).\X0D\\X0A\          REGIONAL LYMPH NODES: N0 (TWENTY-FOUR BENIGN MESENTERIC LYMPH\X0D\\X0A\              NODES).\X0D\\X0A\          DISTANT METASTASES:  NOT APPLICABLE.\X0D\\X0A\     ADDITIONAL PATHOLOGIC FINDINGS: SUBMUCOUS LIPOMAS (TWO).\X0D\\X0A\     ADDITIONALLY SUBMITTED SEGMENT OF BOWEL CONSISTS OF BOTH SMALL\X0D\\X0A\         INTESTINE AND COLON WITH ANASTOMOSIS LINE. THIS TISSUE IS FREE OF\X0D\\X0A\TUMOR.\X0D\\X0A\**INITIALS \X0D\\X0A\**INITIALS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[WWW], M.D., **PLACE",,"Gross Description\X0D\\X0A\Received in formalin labeled ""right colon"" is a right colectomy specimen which\X0D\\X0A\includes the terminal ileum, cecum with appendix, proximal colon and a moderate\X0D\\X0A\amount of attached mesentery.  The proximal and distal bowel margins are closed\X0D\\X0A\with metal sutures.  The specimen is 14 cm from the ileal margin of resection to\X0D\\X0A\the ileocecal valve and 31 cm from the ileocecal valve to the distal margin. \X0D\\X0A\Filling the cecum and involving the ileocecal valve, there is a 10.7 x 9.3 x up\X0D\\X0A\to 5.3 cm firm tan neoplastic-appearing lesion, having raised friable and\X0D\\X0A\granular edges and a firm central portion.  Within this firm central portion,\X0D\\X0A\there is an irregular 4.3 x 4.0 cm full-thickness defect in the bowel wall.  The\X0D\\X0A\serosa adjacent to the defect is granular and this area is marked with India\X0D\\X0A\ink.  The adjacent appendix is 5.5 cm in length, 0.7cm in diameter.  This\X0D\\X0A\appears uninvolved.  The lesion is 5.5 cm from the partially shredded disrupted\X0D\\X0A\mesenteric apex margin.  This margin appears uninvolved by tumor.  The bowel\X0D\\X0A\distal to the lesion shows two submucosal nodules of fat which are 1.1 and 1.4\X0D\\X0A\cm in greatest dimension.  These are located 8.5 and 15.7 cm from the\X0D\\X0A\unremarkable appearing distal bowel margin.  No other bowel lesions are seen. \X0D\\X0A\The attached fat is found to contain multiple grossly benign pink tan lymph\X0D\\X0A\nodes to 1.7 cm in greatest dimension.  Detached but within the same container\X0D\\X0A\is a 6.3 x 2.1 x 1.5 cm irregular piece of intestinal tissue, distorted by black\X0D\\X0A\silk and metal sutures.  This shows no lesions.  Sections are submitted as\X0D\\X0A\follows: \X0D\\X0A\A:  A shave adjacent to each sutured bowel margin.\X0D\\X0A\B:  Ileocecal valve including tumor involvement.\X0D\\X0A\C though E:  Tumor with ink on edges of defect.\X0D\\X0A\F, G:  Additional representative sections of lesion.\X0D\\X0A\H:  Appendix.\X0D\\X0A\I, J:  Submucosal masses of fat.\X0D\\X0A\K:  Mesenteric apex soft tissue margin.\X0D\\X0A\L:  One serially sectioned mesenteric lymph node.\X0D\\X0A\M:  One serially sectioned lymph node.\X0D\\X0A\N:  One serially sectioned lymph node.\X0D\\X0A\O:  One serially sectioned lymph node.\X0D\\X0A\P:  One serially sectioned lymph node.\X0D\\X0A\Q through U:  Intact mesenteric lymph node candidates.\X0D\\X0A\V:  Representative sections, detached piece of intestine.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,COLON,0,479921,1,,Clinical Diagnosis and History\X0D\\X0A\CIRCUMFRENTIAL (SIC) MASS IN PROXIMAL TRANSVERSE COLON\X0D\\X0A\OPER:   LAPAROSCOPIC RIGHT HEMICOLECTOMY AND LIVE (SIC) BIOPSY,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LIVER BIOPSY (MOPHOLOGY (sic) OF CIRRHOSIS ON CT SCAN) lg\X0D\\X0A\2: TRANSVERSE COLON lg","Final Diagnosis\X0D\\X0A\1: LIVER, NEEDLE BIOPSY:\X0D\\X0A\     MILD CHRONIC TRIADITIS.\X0D\\X0A\     NO HEPATOCELLULAR NECROSIS.\X0D\\X0A\     TRICHOME, RETICULIN STAINS: MILD PERI-PORTAL FIBRROSIS WITHOUT ARCHI-\X0D\\X0A\          TECHURAL DISTORTION.\X0D\\X0A\     IRON STAIN: NO STAINABLE IRON.\X0D\\X0A\2: ""TRANSVERSE COLON"":\X0D\\X0A\        CAP TUMOR REPORTING PROTOCOL:\X0D\\X0A\     PROCEDURE: LAPAROSCOPIC HEMICOLECTOMY.\X0D\\X0A\     TUMOR SITE: PROXIMAL TRANSVERSE COLON.\X0D\\X0A\     TUMOR SIZE: 3.7 X 3.0 X 0.9 CM.\X0D\\X0A\     MACROSCOPIC TUMOR PERFORATION: NOT IDENTIFIED.\X0D\\X0A\     MICROSCOPIC TUMOR EXTENSION: FULL THICKNESS TUMOR EXTENSION THROUGH THE \X0D\\X0A\          MUSCULARIS PROPRIA INTO PERICOLONIC FAT.\X0D\\X0A\     SEROSA: UNINVOLVED.\X0D\\X0A\     HISTOLOGIC TYPE: MUCINOUS ADENOCARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: HIGH GRADE (POORLY DIFFERENTIATED).\X0D\\X0A\     LYMPH-VASCULAR INVASION: PRESENT (VENOUS INVASION WITH VENOUS TUMOR \X0D\\X0A\          THROMBUS).\X0D\\X0A\     PERINEURAL INVASION: NOT IDENTIFIED.\X0D\\X0A\     TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION): PRESENT.\X0D\\X0A\     PROXIMAL MARGIN: UNINVOLVED.\X0D\\X0A\     DISTAL MARGIN: UNINVOLVED.\X0D\\X0A\     CIRCUMFERENTIAL RADIAL MESENTERIC MARGIN: UNINVOLVED.\X0D\\X0A\     DISTANCE OF INVASIVE CARCINOMA FROM CLOSEST MARGIN: 5 CM (CIRCUMFERENTIAL \X0D\\X0A\          RADIAL MESENTERIC MARGIN).\X0D\\X0A\     REGIONAL LYMPH NODES: \X0D\\X0A\          NUMBER EXAMINED: 12.\X0D\\X0A\          NUMBER INVOLVED: 1 - WITH EVIDENCE OF EXTRANODAL TUMOR\X0D\\X0A\     EXTENSION.\X0D\\X0A\     PATHOLOGIC STAGING: pT3, N1a, MX.  CLINICAL AND RADIOGRAPHIC CORRELATION \X0D\\X0A\          REQUIRED FOR FINAL STAGING AS DETERMINED BY THE TREATING PHYSICIAN.\X0D\\X0A\     ADDITIONAL PATHOLOGIC FINDINGS: TUBULOVILLOUS ADENOMA (1).\X0D\\X0A\**INITIALS IHC/a/CLS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D., **NAME[WWW]",,"Gross Description\X0D\\X0A\1: Received in formalin labeled ""liver biopsy"" are two strips of tan brown\X0D\\X0A\tissue which are 0.3 and 0.9 cm in length.  These are submitted uncut as 1.\X0D\\X0A\2: Received in formalin labeled ""transverse colon"" is a 22 cm long unopened\X0D\\X0A\segment of large intestine which includes a moderate amount of attached\X0D\\X0A\mesentery and a 13.1 x 11.3 x 1.1 cm aggregate of contiguous omentum.  The\X0D\\X0A\omentum shows a few remnants of adhesions near one edge.  It is otherwise\X0D\\X0A\unremarkable.  When the bowel segment is opened, a 3.7 x 3.0 x 0.9 cm neoplastic\X0D\\X0A\appearing lesion is identified paracentral within the colonic segment 8.5 cm\X0D\\X0A\from the closest surgical margin.  This lesion involves 75% of the circumference\X0D\\X0A\of the bowel at this point.  The lesion involves the full thickness of the bowel\X0D\\X0A\wall and superficially invades the adjacent soft tissues.  The lesion is 5 cm\X0D\\X0A\from the sutured mesenteric apex soft tissue margin.  Although the margin is\X0D\\X0A\grossly uninvolved, there is a 1.7 cm suspicious appearing lymph node adjacent\X0D\\X0A\to the margin.  Sectioning of the remainder of the mesentery shows additional\X0D\\X0A\lymph nodes to 1.3 cm in greatest dimension.  The proximal and distal bowel\X0D\\X0A\margins are grossly uninvolved.  The bowel between the lesion and the closest\X0D\\X0A\margin shows a 0.3 cm sessile polyp.  This is 3.5 cm from the margin and the\X0D\\X0A\only additional lesion seen.  Sections are submitted as follows:\X0D\\X0A\2A  shave adjacent to each bowel margin\X0D\\X0A\2B  small sessile polyp\X0D\\X0A\2C through 2F  representative sections of tumor\X0D\\X0A\2G  shave mesenteric apex soft tissue margin\X0D\\X0A\2H  representative section lymph node adjacent to mesenteric apex soft tissue\X0D\\X0A\margin\X0D\\X0A\2I  two bisected mesenteric lymph node candidates, one inked black \X0D\\X0A\2J through 2L  intact mesenteric lymph node candidates\X0D\\X0A\2M and 2N  representative sections omentum\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Performed, not dictated.",,,
REG1,COLON,0,479924,1,,"Clinical Diagnosis and History\X0D\\X0A\STRICTURE AT PROXIMAL SIGMOID COLON, TUBULOVILLOUS ADENOMA WITH DYSPLASIA\X0D\\X0A\OPER:   SIGMOID COLECTOMY","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: SIGMOID COLON lg","Final Diagnosis\X0D\\X0A\SIGMOID COLON, RESECTION SPECIMEN:\X0D\\X0A\     INVASIVE, MODERATELY DIFFERENTIATED ADENOCARCINOMA, \X0D\\X0A\     725 CM MAXIMUM DIMENSION.\X0D\\X0A\     TUMOR EXTENDS THROUGH MUSCULAR PROPRIA INTO SUBSEROSAL FAT.\X0D\\X0A\     ASSOCIATED PERITUMORAL ABSCESS FORMATION.\X0D\\X0A\     NO IDENTIFIED ANGIOLYMPHATIC OR PERINEURAL INVASION.\X0D\\X0A\     NEGATIVE PROXIMAL AND DISTAL MUCOSAL MARGINS. \X0D\\X0A\     NEGATIVE SEROSAL SURFACE.\X0D\\X0A\     CHRONIC DIVERTICULITIS.\X0D\\X0A\     NEGATIVE MESENTERIC ROOT MARGIN.\X0D\\X0A\     NEGATIVE MESENTERIC LYMPH NODES (28 TOTAL).\X0D\\X0A\     ADDITIONAL COLONIC TISSUE WITH NO MICROSCOPIC ABNORMALITY.\X0D\\X0A\IHC/a/CMK\X0D\\X0A\MER/ap \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\Received in formalin labeled ""sigmoid colon, suture at proximal sigmoid colon""\X0D\\X0A\is a 20 cm long partially opened segment of colon with a moderate amount of\X0D\\X0A\attached fat.  One margin is closed with metal sutures and the opposite margin\X0D\\X0A\is unsutured.  There is a white silk suture adjacent to the sutured margin\X0D\\X0A\indicating the sutured margin to be proximal.  8.5 cm from the proximal margin\X0D\\X0A\of resection there is a 7.5 x 5.8 x 2.8 cm circumferential partially polypoid\X0D\\X0A\neoplastic appearing lesion which involves the full thickness of the bowel wall\X0D\\X0A\and focally infiltrates into the adjacent pericolonic soft tissues.  The serosa\X0D\\X0A\is hyperemic but remains smooth.  The lesion is 8 cm from the ligated and\X0D\\X0A\grossly uninvolved mesenteric apex margin.  Proximal to the lesion the bowel\X0D\\X0A\shows a few diverticula.  Distal to the lesion the bowel shows no focal lesions.\X0D\\X0A\ No polyps or other masses are identified.  The proximal and distal margins are\X0D\\X0A\grossly uninvolved.  The attached fat is found to contain multiple grossly\X0D\\X0A\benign appearing lymph nodes ranging from 0.2 to 1.2 cm in greatest dimension. \X0D\\X0A\Detachable within the same container is a 5.3 x 0.5 x 0.5 cm strip of soft\X0D\\X0A\tissue containing numerous metal sutures and a 2.1 x 1.3 x 0.7 cm irregular\X0D\\X0A\piece of yellow and tan tissue.  The origin of these is unclear.  Sections are\X0D\\X0A\submitted as follows:\X0D\\X0A\A  shave adjacent to sutured proximal margin\X0D\\X0A\B  shave at distal margin \X0D\\X0A\C and D  lesion with ink on serosa \X0D\\X0A\E through G  additional representative sections of lesion \X0D\\X0A\H  representative diverticula \X0D\\X0A\I  shave mesenteric apex soft tissue margin\X0D\\X0A\J  two bisected mesenteric lymph nodes, one inked black\X0D\\X0A\K  two bisected lymph nodes, one inked black\X0D\\X0A\L  two bisected lymph nodes, one inked black\X0D\\X0A\M through Q  intact mesenteric lymph node candidates\X0D\\X0A\R  entire smaller detached piece of tissue and sampling of segment of tissue\X0D\\X0A\containing numerous sutures\X0D\\X0A\LW/USO/MER/jsh","Microscopic Description\X0D\\X0A\Incorporated in diagnosis.\X0D\\X0A\CAP CANCER CASE SUMMARY:\X0D\\X0A\     SPECIMEN:  Sigmoid colon.\X0D\\X0A\     PROCEDURE:  Sigmoidectomy.\X0D\\X0A\     TUMOR SITE:  Sigmoid colon.\X0D\\X0A\     TUMOR SIZE:  Greatest dimension  7.5 cm.\X0D\\X0A\     MACROSCOPIC TUMOR PERFORATION:  Not identified.\X0D\\X0A\     HISTOLOGIC TYPE:  Adenocarcinoma.\X0D\\X0A\     HISTOLOGIC GRADE:  Moderately differentiated (low grade).\X0D\\X0A\     MICROSCOPIC TUMOR EXTENSION:  Tumor invades through the muscular propria\X0D\\X0A\into subserosal adipose tissue.\X0D\\X0A\     MARGINS:  Proximal, distal, circumferential and serosal margins negative.\X0D\\X0A\     TREATMENT EFFECT:  Not known.\X0D\\X0A\     LYMPH/VASCULAR INVASION: Not identified.\X0D\\X0A\     PERINEURAL INVASION:  Not identified.     \X0D\\X0A\     TUMOR DEPOSITS:  Not identified.\X0D\\X0A\     PATHOLOGIC STAGING:\X0D\\X0A\          PRIMARY TUMOR:  pT3.\X0D\\X0A\          REGIONAL LYMPH NODES:  pN0.\X0D\\X0A\          NUMBER OF NODES EXAMINED: 28.\X0D\\X0A\          NUMBER INVOLVED: 0.\X0D\\X0A\          DISTANT METASTASES:  Not applicable.\X0D\\X0A\MER/ap",,,
REG1,COLON,0,481337,3,,PREOP DIAGNOSIS:               SCREENING,"**NAME[BBB,AAA] M                          ACCT #: **ID-NUM     LOC:  SURGIC U #: 025894\X0D\\X0A\250 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 85/F       ROOM:         REG: **DATE[Dec 26 11]\X0D\\X0A\DOB: **DATE[Apr 12 26]    BED:         DIS:\X0D\\X0A\STATUS: REG REF    TLOC:","FINAL DIAGNOSIS\X0D\\X0A\BIOPSY OF COLON MASS:\X0D\\X0A\.....1....MODERATELY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\.....2....NECRO-INFLAMMATORY DEBRIS, CONSISTENT WITH ULCERATION AND\X0D\\X0A\..........DEGENERATION.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ **NAME[ZZZ,YYY] XXX] MD  **DATE[Dec 28 11]",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is received in a single container in formalin labelled\X0D\\X0A\""biopsy colon mass"" and consists of 3 gray-tan soft tissue fragments which\X0D\\X0A\aggregate to 0.5 x 0.5 x 0.2 cm. The entire specimen is submitted in a\X0D\\X0A\single cassette after being marked with hematoxylin.\X0D\\X0A\D: **DATE[Dec 27 2011] - 1046 hours\X0D\\X0A\T: **DATE[Dec 27 2011] - 1508 hours\X0D\\X0A\INTRADEPARTMENTAL CONSULT\X0D\\X0A\Intradepartmental consultation was sought with Dr. **NAME[WWW], who agrees\X0D\\X0A\with this diagnosis.\X0D\\X0A\D: **DATE[Dec 28 2011] - 0942 hours\X0D\\X0A\T: **DATE[Dec 28 2011] - 0954 hours",MICROSCOPIC EXAMINATION\X0D\\X0A\The sections are of colonic tissue with necro-inflammatory debris present\X0D\\X0A\and with a neoplasm composed of moderately differentiated glandular\X0D\\X0A\elements showing nuclear hyperchromasia and increased mitoses.  The\X0D\\X0A\findings are consistent with moderately differentiated adenocarcinoma.\X0D\\X0A\D: **DATE[Dec 28 2011] - 0942 hours\X0D\\X0A\T: **DATE[Dec 28 2011] - 0951 hours,"TISSUES:\X0D\\X0A\Colon, NOS (BIOPSY COLON MASS)",,
REG1,COLON,0,481587,1,,CLINICAL HISTORY:\X0D\\X0A\Colon mass.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   COLON, RIGHT HEMICOLECTOMY/RESECTION:  INVASIVE MODERATE TO POORLY\X0D\\X0A\DIFFERENTIATED COLONIC ADENOCARCINOMA\X0D\\X0A\1.   TUMOR SIZE:  6.2 cm. maximally.\X0D\\X0A\2.   HISTOLOGIC FEATURES:\X0D\\X0A\a.   INTRATUMORAL LYMPHOCYTIC RESPONSE:  None.\X0D\\X0A\b.   PERITUMORAL LYMPHOCYTIC RESPONSE:  Mild.\X0D\\X0A\3.   MARGINS AND EXTENT:\X0D\\X0A\a.   Tumor invades into the muscularis propria.\X0D\\X0A\b.   All margins of excision are free of tumor.\X0D\\X0A\c.   LYMPH VASCULAR SPACE INVASION:  Not identified.\X0D\\X0A\d.   PERINEURAL INVASION:  Not identified.\X0D\\X0A\e.   TUMOR DEPOSITS:  Not identified.\X0D\\X0A\4.   LYMPH NODES:  Thirty-one lymph nodes negative for metastatic\X0D\\X0A\carcinoma (0/31).\X0D\\X0A\5.   PATHOLOGIC STAGE:  pT2N0MXG3.\X0D\\X0A\6.   ADDITIONAL PATHOLOGIC FINDINGS:\X0D\\X0A\a.   Four tubulovillous adenomas without high-grade dysplasia or\X0D\\X0A\malignancy.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (MC/kd)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Mar 22 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Received fresh for intraoperative consultation designated 'right colon'\X0D\\X0A\is a right hemicolectomy specimen consisting of 6 cm of ileum with\X0D\\X0A\attached 17 cm of colon and a 5.9 cm in length attached appendix without\X0D\\X0A\gross abnormality. The serosal surface is purple-tan without evidence of\X0D\\X0A\mass lesion or tumor nodularity.  Both aspects of the specimen are\X0D\\X0A\closed by lines of staples.  The specimen is opened to reveal a 6.2 x\X0D\\X0A\4.1 cm fungating polypoid tumor mass in the mid portion of the colon\X0D\\X0A\located 6 cm from the distal margin.  Aside from the mass several other\X0D\\X0A\small polyps are identified.  No other tumor is seen. INTRAOPERATIVE\X0D\\X0A\**INSTITUTION DOWNTOWN, CLIA ID# 18D0320857 (DR. **NAME[XXX]):\X0D\\X0A\MASS IDENTIFIED, 6 CM FROM CLOSEST DISTAL MARGIN.  The results are\X0D\\X0A\reported via intercom directly to Dr. **NAME[WWW].  The proximal margin is\X0D\\X0A\submitted in A1.  The distal margin is submitted in A2.  the tumor\X0D\\X0A\appears to be invasive into and focally through the muscularis propria.\X0D\\X0A\Multiple representative sections of tumor are submitted in A3-A6.\X0D\\X0A\Multiple separately identified polyps measuring up to 1 cm maximally are\X0D\\X0A\sampled and submitted in A7. The appendix is sampled in A8 to include a\X0D\\X0A\longitudinal section of the tip.  The adipose is dissected from the\X0D\\X0A\bowel wall.  It is serially sectioned and carefully palpated.  All\X0D\\X0A\identified nodal material is submitted in A9-A15.  There is a bit of\X0D\\X0A\attached omentum serially sectioned and carefully palpated.  No\X0D\\X0A\nodularity is identified.  (MC/cm)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 15\X0D\\X0A\ \X0D\\X0A\Colon and Rectum\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: COLON SEGMENTAL\X0D\\X0A\ \X0D\\X0A\Tumor Configuration:     Exophytic (polypoid)\X0D\\X0A\Tumor Size:    Greatest dimension: 6.2cm\X0D\\X0A\Histologic Type:    Adenocarcinoma\X0D\\X0A\Histologic Grade:   High-grade (poorly differentiated to\X0D\\X0A\undifferentiated)\X0D\\X0A\Primary Tumor (pT): pT2\X0D\\X0A\Regional Lymph Nodes (pN):    pN0\X0D\\X0A\Specify: Number examined:     31\X0D\\X0A\Number involved:    0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Margins not involved:    by invasive carcinoma\X0D\\X0A\Lymphatic [small vessel] Invasion  (L): Absent\X0D\\X0A\Venous [large vessel] Invasion (V):     Absent\X0D\\X0A\Perineural invasion:     Absent\X0D\\X0A\Tumor Board Configuration:    Pushing\X0D\\X0A\Intratumoral/Peritumoral Lymphocytic Response:    None\X0D\\X0A\Additional Pathological Findings:  Include:: Other polyps\X0D\\X0A\type[s]:\X0D\\X0A\Tubulovillous adenomas X 4",,SPECIMEN(S): A COLON SEGMENTAL,,
REG1,COLON,0,481678,1,,CLINICAL HISTORY:\X0D\\X0A\Adenocarcinoma left colon,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'LEFT COLON RESECTION':  INVASIVE ADENOCARCINOMA\X0D\\X0A\1.   TUMOR SIZE:  3.5 x 3.5 x 0.7 cm. grossly.\X0D\\X0A\2.   TUMOR GRADE:  Invasive moderately differentiated adenocarcinoma.\X0D\\X0A\3.   MARGINS OF EXCISION AND EXTENT:  ALL MARGINS OF EXCISION ARE\X0D\\X0A\NEGATIVE FOR INVOLVEMENT BY CARCINOMA\X0D\\X0A\a.   Proximal and distal surgical margins are negative for involvement\X0D\\X0A\by carcinoma.\X0D\\X0A\b.   Radial shave margin is negative for involvement by carcinoma.\X0D\\X0A\c.   Carcinoma invades deeply through muscularis propria and focally\X0D\\X0A\into pericolic soft tissue/fat.\X0D\\X0A\d.   No definitive capillary lymphatic space invasion by carcinoma\X0D\\X0A\identified.\X0D\\X0A\e.   No large vessel invasion by carcinoma identified.\X0D\\X0A\4.   LYMPH NODES:  SIXTEEN LYMPH NODES/LYMPH NODE AGGREGATES IDENTIFIED.\X0D\\X0A\NEGATIVE FOR METASTATIC CARCINOMA (0/16)\X0D\\X0A\5.   ADDITIONAL FINDINGS:  Benign appendix with fibrous obliteration of\X0D\\X0A\the terminal portion.\X0D\\X0A\6.   PATHOLOGIC STAGE:  pT3a/b, N0, MX (G2).\X0D\\X0A\ \X0D\\X0A\Colon and Rectum\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: LEFT COLON\X0D\\X0A\ \X0D\\X0A\Specimen Type: Left hemicolectomy\X0D\\X0A\Tumor Site:    Left (descending) colon\X0D\\X0A\Tumor Size:    Greatest dimension: 3.5cm x 3.5cm x 0.7cm\X0D\\X0A\Histologic Type:    Adenocarcinoma\X0D\\X0A\Histologic Grade:   Low-grade (well to moderately differentiated)\X0D\\X0A\Primary Tumor (pT): pT3a/b\X0D\\X0A\Regional Lymph Nodes (pN):    pN0\X0D\\X0A\Specify: Number examined:     16\X0D\\X0A\Number involved:    0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Proximal Margin:    Uninvolved by invasive carcinoma\X0D\\X0A\Distal Margin: Uninvolved by invasive carcinoma\X0D\\X0A\Circumferential (Radial) Margin:   Uninvolved by invasive carcinoma\X0D\\X0A\Mesenteric Margin:  Uninvolved by invasive carcinoma\X0D\\X0A\Margins not involved:    by invasive carcinoma\X0D\\X0A\Lymphatic [small vessel] Invasion  (L): Absent\X0D\\X0A\Venous [large vessel] Invasion (V):     Absent\X0D\\X0A\Perineural invasion:     Absent\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (JT)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Oct 18 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received in formalin and designated 'left colon' is a 112.0\X0D\\X0A\cm. in length segment of colon and small intestine.  The segment of\X0D\\X0A\small intestine attached to the cecum measures 7.0 cm. in length and has\X0D\\X0A\a maximum diameter of 3.0 cm.  The segment of colon has a diameter of\X0D\\X0A\6.5 cm.  The specimen has been partially opened along the antimesenteric\X0D\\X0A\border disclosing a circumferential centrally ulcerated sessile mass\X0D\\X0A\measuring 9.0 cm. from the distal margin.  The margins are grossly\X0D\\X0A\viable and appear free of mass lesion.  Representative sections of\X0D\\X0A\margins are submitted in cassettes A1 and A2.  The lesion is confined to\X0D\\X0A\the mucosal surface and does not grossly extend to involve the radial\X0D\\X0A\margin.  The radial shave margin is submitted in cassette A3.  The\X0D\\X0A\previously described tumor mass measures 3.5 x 3.5 cm. and involves the\X0D\\X0A\entire thickness of the wall measuring up to 0.7 cm. in maximum\X0D\\X0A\thickness.  Representative sections of tumor are submitted in cassettes\X0D\\X0A\A4-A6.  Examination of the cecum discloses a vermiform appendix with\X0D\\X0A\attached mesoappendix.  The appendix measures 8.5 cm. in length and has\X0D\\X0A\a diameter that measures up to 0.5 cm.  No grossly discernible masses\X0D\\X0A\are identified.  Sections of appendix are submitted in cassette A7.\X0D\\X0A\Examination of the pericolic surface discloses a relatively large amount\X0D\\X0A\of omental tissue attached to the serosal surface.  The omental tissue\X0D\\X0A\measures 28.5 x 17.5 x 1.0 cm.  Careful palpation and examination of the\X0D\\X0A\omental fat discloses no discrete mass lesions.  A random representative\X0D\\X0A\section of omental fat is submitted in cassette A8. Careful palpation of\X0D\\X0A\pericolic fat discloses multiple indurated nodes measuring up to 0.8 cm.\X0D\\X0A\in diameter.  All nodules are submitted in cassette A9-A12.  (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 12,,SPECIMEN(S): A LEFT COLON,,
REG1,COLON,0,482205,1,,,"Patient Age: **AGE[in 60s].\X0A\ PATHOLOGY CODES: **INITIALS  88305 (x 4); 88313 COMMENT: Diagnosis called and report faxed to Dr. **NAME[ZZZ]' office (**NAME[YYY]) on **DATE[Apr 18 12] at 11:50 a.m. ** Original Signature on File ** **NAME[M. XXX WWW], MD **ID-NUM  **NAME[BBB,AAA M] **DATE[Apr 14 2012]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ DUODENUM, BIOPSY: \X0D\\X0A\ Focal metaplasia compatible with peptic ulcer disease \X0D\\X0A\ GASTROESOPHAGEAL JUNCTION BIOPSY: \X0D\\X0A\ Reactive squamous mucosa \X0D\\X0A\ CECUM, TUMOR, BIOPSIES: \X0D\\X0A\ Invasive moderately differentiated adenocarcinoma \X0D\\X0A\ COLON, POLYP AT 35.0 CM, BIOPSY: \X0D\\X0A\ Tubular adenoma",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is severe anemia. \X0D\\X0A\ Specimen 1 consists of: \X0D\\X0A\ Pieces:  One \X0D\\X0A\ Aggregate dimensions:  0.3 x 0.2 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. \X0D\\X0A\ Specimen 2 consists of: \X0D\\X0A\ Pieces:  One \X0D\\X0A\ Aggregate dimensions:  0.4 x 0.2 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. \X0D\\X0A\ Specimen 3 consists of: \X0D\\X0A\ Pieces:  Two \X0D\\X0A\ Aggregate dimensions:  0.4 x 0.3 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. \X0D\\X0A\ Specimen 4 consists of a tan soft polypoid tissue fragment measuring \X0D\\X0A\ 1.0 x 1.0 x 0.8 cm. The surgical margins are inked blue. The specimen \X0D\\X0A\ is trisected with fragments upon sectioning and submitted in its \X0D\\X0A\ entirety in a single cassette. **INITIALS","MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Sections of the first specimen, labeled duodenum, shows small bowel \X0D\\X0A\ mucosa with prominent Brunner's glands and a normal villous \X0D\\X0A\ architecture with a normal crypt to villous ratio.  The lamina propria \X0D\\X0A\ exhibits the normal complement of mononuclear cells.  Focally the \X0D\\X0A\ epithelium shows gastric metaplasia.  There is no increase in \X0D\\X0A\ intraepithelial lymphocytes and the collagen table is of normal \X0D\\X0A\ thickness.  No granulomas or parasites are seen.  There is no evidence \X0D\\X0A\ of dysplasia or carcinoma. \X0D\\X0A\ Sections of the second specimen, labeled gastroesophageal junction, \X0D\\X0A\ shows squamous mucosa with reactive changes, including elongation of \X0D\\X0A\ papillae and basal zone hyperplasia.  No eosinophils are seen.  No \X0D\\X0A\ glandular epithelium is present.  There is no evidence of dysplasia or \X0D\\X0A\ carcinoma.  Special stain is negative for fungal organisms and \X0D\\X0A\ intestinal mucin with adequate control. \X0D\\X0A\ Sections of the third specimen, labeled cecal tumor, shows \X0D\\X0A\ desmoplastic and fibrotic stroma infiltrated by irregular angulated \X0D\\X0A\ glands and acini composed of cells with enlarged hyperchromatic \X0D\\X0A\ irregular atypical round to oval nuclei.  Scattered glands show \X0D\\X0A\ luminal dirty necrosis.  The surface appears to be lined by \X0D\\X0A\ adenomatous epithelium. \X0D\\X0A\ Sections of the fourth specimen, labeled polyp at 45 cm, shows \X0D\\X0A\ polypoid fragments of colonic mucosa with a tubular proliferation of \X0D\\X0A\ crypts lined by adenomatous epithelium.  There is no evidence of high \X0D\\X0A\ grade dysplasia or carcinoma. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:",TISSUE SUBMITTED: \X0D\\X0A\ 1.  Duodenum biopsy \X0D\\X0A\ 2.  GE junction biopsy \X0D\\X0A\ 3.  Cecal tumor \X0D\\X0A\ 4.  Polyp at 35 cm,,
REG1,COLON,0,482362,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\ADENOCARCINOMA CECUM\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE:   RIGHT HEMICOLON, RESECTION.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:  INVASIVE ADENOCARCINOMA.\X0D\\X0A\TUMOR GRADE:  LOW GRADE\X0D\\X0A\TUMOR SITE:  ASCENDING COLON.\X0D\\X0A\TUMOR SIZE:   4 CM IN GREATEST DIMENSION.\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M (XXX])\X0D\\X0A\   315 E **PLACE\X0D\\X0A\   **PLACE, Ky **ZIP-CODE\X0D\\X0A\   **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[WWW,VVV M] MD\X0D\\X0A\   10821 Plantside Dr\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88302GS, 88307GS, 88309GS, 88313GS/2, 88342GS/4\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.  CARCINOMA OF COLON AND RECTUM: SYNOPTIC REPORT AJCC/UICC TNM, 7th edition\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:   RIGHT HEMICOLON, RESECTION.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:  INVASIVE ADENOCARCINOMA.\X0D\\X0A\TUMOR GRADE:  LOW GRADE\X0D\\X0A\TUMOR SITE:  ASCENDING COLON.\X0D\\X0A\TUMOR SIZE:   4 CM IN GREATEST DIMENSION.\X0D\\X0A\MICROSCOPIC TUMOR EXTENSION:  CARCINOMA INVADES INTO THE SUBMUCOSA.\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  NOT IDENTIFIED.\X0D\\X0A\MARGINS:   ALL MARGINS ARE FREE OF TUMOR.  CARCINOMA IS 9.5 CM FROM THE PROXIMAL\X0D\\X0A\MARGIN, 6.5 CM FROM THE DISTAL MARGIN, AND 2.5 CM FROM THE RADIAL\X0D\\X0A\MARGIN.\X0D\\X0A\LYMPHATIC/VASCULAR INVASION:   NOT IDENTIFIED.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\PERINEURAL INVASION:   NOT IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\Number of Lymph Nodes Examined:  13.\X0D\\X0A\Number of Lymph Nodes Involved:  0.\X0D\\X0A\\X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  NOT IDENTIFIED.\X0D\\X0A\TREATMENT EFFECT:  NO KNOWN PRIOR TREATMENT.\X0D\\X0A\ADDITIONAL FINDINGS:  UNREMARKABLE APPENDIX.\X0D\\X0A\ANCILLARY STUDIES\X0D\\X0A\IHC for mismatch repair testing to be performed and reported as an addendum.\X0D\\X0A\PATHOLOGIC STAGING (pT1 pN0 pMX)\X0D\\X0A\\X0D\\X0A\B.  LIVER BIOPSY:\X0D\\X0A\CHRONIC HEPATITIS WITH MODERATE ACTIVITY(GRADE 3) AND CIRRHOSIS (STAGE 4).\X0D\\X0A\NEGATIVE FOR MALIGNANCY.\X0D\\X0A\SEE COMMENT.\X0D\\X0A\\X0D\\X0A\C.  HERNIA SAC:\X0D\\X0A\BENIGN FIBROADIPOSE TISSUE.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\The liver biopsy shows chronic hepatitis with moderate activity and well developed\X0D\\X0A\cirrhosis.\X0D\\X0A\Recommend further clinical evaluation, including studies for viral hepatitis.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A. Received in formalin labeled ""right hemicolon"" is a segment of colon with contiguous\X0D\\X0A\terminal ileum.  The colon segment measures 14 cm in length.  The terminal ileum segment\X0D\\X0A\measures 12 cm in length.  The proximal and distal circumferential margins are 8 cm and 9.4\X0D\\X0A\cm, respectively.    The serosa is gray pink with severe scattered adhesions.  There is some\X0D\\X0A\attached pericolic fat and some attached omental tissue along the entire length of the\X0D\\X0A\segment.  There is a 4 x 2 x 1 cm firm broad based exophytic pink tan lesion within the\X0D\\X0A\ascending colon segment, 3 cm from the ileocecal valve, 9.5 cm from the proximal margin of\X0D\\X0A\resection, 6.5 cm from the distal margin of resection and 2.5 cm from the external soft\X0D\\X0A\tissue margin of resection.  Sectioning through the lesion shows possible involvement of the\X0D\\X0A\corresponding muscularis propria however involvement of the corresponding adipose tissue\X0D\\X0A\cannot be ascertained grossly.  The remaining mucosa of the colon segment is mostly\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\flattened and pink tan.  The mucosa of the terminal ileum segment is tan with normal folds.\X0D\\X0A\\X0D\\X0A\The appendix measures 5 x 0.7 cm and is grossly unremarkable.\X0D\\X0A\\X0D\\X0A\Eleven possible lymph nodes are identified.  The fatty tissue is trimmed and placed in a\X0D\\X0A\lymph node revealing solution for further gross lymph node evaluation.\X0D\\X0A\\X0D\\X0A\The entire lesion is submitted.  All possible lymph nodes are submitted.  Additional lymph\X0D\\X0A\nodes will be submitted following gross evaluation after lymph node revealing solution\X0D\\X0A\fixative.\X0D\\X0A\\X0D\\X0A\Cassette Summary:\X0D\\X0A\\X0D\\X0A\A1.  proximal margin\X0D\\X0A\A2.  distal margin\X0D\\X0A\A3.  external soft tissue margin of resection\X0D\\X0A\A4-9.  entire lesion\X0D\\X0A\A10.  appendix\X0D\\X0A\A11.  three possible lymph nodes\X0D\\X0A\A12.  one possible lymph node\X0D\\X0A\A13.  one possible lymph node\X0D\\X0A\A14.  one possible lymph node\X0D\\X0A\A15.  three possible lymph nodes\X0D\\X0A\A16.  one lymph node bisected\X0D\\X0A\A17.  one lymph node bisected\X0D\\X0A\A18.  one possible tiny lymph node (<0.1 cm)\X0D\\X0A\\X0D\\X0A\Sectioning through the pericolic fat after lymph node revealing solution fixation reveals\X0D\\X0A\three more possible lymph nodes. The lymph nodes are entirely submitted.\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\\X0D\\X0A\A19. - one whole lymph node\X0D\\X0A\A20. - two whole lymph nodes\X0D\\X0A\\X0D\\X0A\B. Received in formalin labeled ""liver biopsy"" are two soft tan cylindrical cores of tissue\X0D\\X0A\which measure 2 x 0.1 cm each.  The specimen is entirely submitted in a cassette labeled B.\X0D\\X0A\\X0D\\X0A\C. Received in formalin labeled ""hernia sac"" are two saccular gray brown fibromembranous\X0D\\X0A\tissue fragments with some attached fatty tissue.  They measure 5 x 2.5 x 1 cm and 3.5 x 3.5\X0D\\X0A\x 1 cm.  Representative sections are submitted in a cassette labeled C.  /st/as\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\Sections of the liver biopsy show benign liver tissue.  Distortion of the normal\X0D\\X0A\architecture is present with the formation of nodules.  Trichrome stain confirms fibrosis\X0D\\X0A\with a nodular architecture.  Chronic hepatitis is present with moderate activity.  The\X0D\\X0A\inflammatory infiltrate consists mostly of lymphocytes. There is some **NAME[UUU] hyaline\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\identified.  Mild steatosis is present.  Special stain for iron reveals no stainable iron.\X0D\\X0A\,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A.  RIGHT HEMICOLON\X0D\\X0A\B.  LIVER BIOPSY\X0D\\X0A\C.  HERNIA SAC\X0D\\X0A\,,"ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Jun 03 12]-0835\X0D\\X0A\\X0D\\X0A\MSI IHC Testing\X0D\\X0A\\X0D\\X0A\INTERPRETATION: These results show a deficiency of the mismatch protein (MLH1, PMS2) tested.\X0D\\X0A\\X0D\\X0A\Note:  Given the absence of MLH1 expression, further DNA (PCR BRAF mutation) testing is\X0D\\X0A\advised to exclude the possibility of somatic hypermethylation of the MLH1 gene as this\X0D\\X0A\immunostaining pattern may be seen in inherited as well as sporadic forms of colon cancer.\X0D\\X0A\This test may be performed on tumor (paraffin block) tissue.\X0D\\X0A\\X0D\\X0A\COMMENT: Microsatellite instability (MSI) due to defective mismatch repair genes has been\X0D\\X0A\reported in a subset of sporadic colorectal adenocarcinomas, as well as in adenocarcinomas\X0D\\X0A\arising in patients with Lynch syndrome (hereditary non-polyposis colorectal cancer, or\X0D\\X0A\HNPCC). As a consequence of this alteration, these adenocarcinomas are all associated with\X0D\\X0A\high-level `microsatellite instability' (MSI), the most common mechanism of which is loss of\X0D\\X0A\function of one or more of the mismatch repair (MMR) proteins known as MLH1, MSH2, MHS6, and\X0D\\X0A\PMS2. Molecular testing for MSI or immunohistochemical studies looking for loss of\X0D\\X0A\expression of the MMR proteins are thus effective methods of screening for this unique\X0D\\X0A\subset of colorectal adenocarcinomas. IHC, particularly with the use of antibodies to all\X0D\\X0A\four major MMR proteins, can identify MSI adenocarcinomas with extremely high sensitivity\X0D\\X0A\and specificity. Furthermore, IHC analysis of the four MMR proteins can provide a highly\X0D\\X0A\sensitive strategy for the identification of MMR gene mutation-carrying, early-onset\X0D\\X0A\colorectal adenocarcinoma patients, many of whom might be missed by using clinical criteria\X0D\\X0A\(e.g., the **PLACE Criteria) alone. IHC analysis has several advantages over MSI testing,\X0D\\X0A\as the latter is more difficult to perform, and does not provide gene-specific information.\X0D\\X0A\Identification of this important subset of adenocarcinomas is important, as published data\X0D\\X0A\suggest that sporadic colorectal adenocarcinomas with MSI have a significantly better\X0D\\X0A\prognosis compared with those with intact MMR. In addition, several studies have suggested\X0D\\X0A\that MSI adenocarcinomas may be resistant to 5-FU-based chemotherapy.\X0D\\X0A\\X0D\\X0A\Antibody/Clone            Marker For             Results\X0D\\X0A\MLH-1/G168-728        MMR, Mismatch Repair         Protein Not Expressed\X0D\\X0A\MSH-2/G219-1129        MMR, Mismatch Repair         Protein Expressed 00224\X0D\\X0A\MSH-6/44                     MMR, Mismatch Repair         Protein Expressed 00225\X0D\\X0A\PMS2/MRQ-28            MMR, Mismatch Repair         Protein Not Expressed **ID-NUM\X0D\\X0A\\X0D\\X0A\Detection System - Polymer\X0D\\X0A\\X0D\\X0A\NOTE: Genetic counseling may be appropriate to explain the implication of this test results.\X0D\\X0A\A positive result, indicating loss of one or more MMR proteins, should be confirmed by\X0D\\X0A\sequencing that particular protein. MLH1 promoter methylation should be ruled out by\X0D\\X0A\appropriate testing, in cases which show loss of only MLH1 protein. A negative result,\X0D\\X0A\indicating no loss of any MMR proteins, does not rule out MSI which may be due to non-MMR\X0D\\X0A\related pathway.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Reference ranges for DNA Mismatch Repair Protein Expression by IHC:\X0D\\X0A\MLH-1, MSH-2, MSH-6 and PMS2 protein expressed: Preserved DNA Mismatch Repair Function.\X0D\\X0A\MLH-1, MSH-2, MSH-6 and PMS2 protein not expressed: Likely Deficient DNA Mismatch Repair\X0D\\X0A\Function.\X0D\\X0A\\X0D\\X0A\This analysis is an adjunct to the evaluation of the referring physician and does not\X0D\\X0A\represent a final diagnosis.\X0D\\X0A\\X0D\\X0A\Known positive tissues are tested with each IHC antibody, examined to ensure positivity, and\X0D\\X0A\returned with each case.\X0D\\X0A\\X0D\\X0A\REFERENCES:\X0D\\X0A\Ruczkiewicz AR and Jass JR. Pathol Case Rev 9:163-72, 2004.\X0D\\X0A\Popat S et al J Clin Oncol **ID-NUM, 2005.\X0D\\X0A\Southey MC et al., J Clin Oncol **ID-NUM, 2005.\X0D\\X0A\\X0D\\X0A\""These results are not, in and of themselves, diagnostic, but should be interpreted in the\X0D\\X0A\context of the clinical findings and the histopathologic diagnosis.""  This test was\X0D\\X0A\developed and its performance characteristics determined by CPA Lab.  It has not been\X0D\\X0A\cleared or approved by the U.S. Food and Drug Administration.  The FDA has determined that\X0D\\X0A\such clearance or approval is not necessary.  This test is used for clinical purposes.  It\X0D\\X0A\should not be regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the clinical Laboratory Improvement Amendments of 1988 (""CLIA"") as qualified to\X0D\\X0A\perform high-complexity clinical testing.""\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\"
REG1,COLON,0,483825,1,,"CLINICAL HISTORY:\X0D\\X0A\Abnormal CT, abdomen pain.",AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'SIGMOID COLON POLYP':\X0D\\X0A\1.    TUBULOVILLOUS ADENOMA WITH FOCAL HIGH GRADE\X0D\\X0A\   GLANDULAR DYSPLASIA/INTRAEPITHELIAL\X0D\\X0A\   ADENOCARCINOMA (pTis).\X0D\\X0A\2.    No invasive carcinoma identified.\X0D\\X0A\3.    Cauterized margin with benign hyperplastic\X0D\\X0A\   change, negative for dysplasia or malignancy.\X0D\\X0A\ \X0D\\X0A\COMMENT:   Sections are of tubulovillous adenoma with focal high grade\X0D\\X0A\glandular dysplasia/intra-epithelial adenocarcinoma (pTis).  No\X0D\\X0A\definitive invasive carcinoma is identified.  The polyp stalk margin\X0D\\X0A\appears negative for dysplasia or malignancy.  Continued clinical\X0D\\X0A\surveillance is recommended.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jun 23 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'sigmoid colon polyp' is a 1.0 x 0.9 x\X0D\\X0A\0.6 cm. red-tan pedunculated tissue fragment.  The specimen is bisected\X0D\\X0A\and submitted en toto in a single cassette.   (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 1,,SPECIMEN(S): A SIGMOID COLON BX,,
REG1,COLON,0,483899,1,,"CLINICAL HISTORY:\X0D\\X0A\Anemia, rule out celiac disease, gastric polyps, sigmoid polyp mass.",AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   SMALL BOWEL, BIOPSY: BENIGN SMALL INTESTINAL MUCOSA WITH:\X0D\\X0A\1.   Normal intact villous surface.\X0D\\X0A\2.   No significant inflammation, no granulomas.\X0D\\X0A\3.   No viral inclusions or other organisms on routinely stained\X0D\\X0A\sections.\X0D\\X0A\B.   STOMACH, BIOPSY: BENIGN GASTRIC MUCOSA WITH:\X0D\\X0A\1.   Hyperplastic polyp.\X0D\\X0A\2.   Extensive chronic inflammation.\X0D\\X0A\3.   Acute inflammation.\X0D\\X0A\4.   Focal dysplastic changes, low grade.\X0D\\X0A\C.   COLON, SIGMOID, BIOPSY: INVASIVE MODERATELY DIFFERENTIATED\X0D\\X0A\ADENOCARCINOMA.\X0D\\X0A\D.   COLON, SIGMOID, BIOPSY: TUBULAR ADENOMAS\X0D\\X0A\Dr. **NAME[ZZZ] has seen parts B and C in an internal consult and concurs.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[YYY:  XXX M. WWW] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 31 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'small bowel biopsy'. The specimen\X0D\\X0A\consists of several tan fragments measuring in aggregate 1.2 x 0.3 x 0.3\X0D\\X0A\cm.  The specimen is submitted en toto in a single cassette.\X0D\\X0A\Specimen (B) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'gastric polyp biopsy'. The specimen\X0D\\X0A\consists of a tan polypoid fragment measuring 2.1 x 0.7 x 0.5 cm. The\X0D\\X0A\specimen is sectioned and submitted en toto in a single cassette.\X0D\\X0A\Specimen (C) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'sigmoid mass'. The specimen consists of\X0D\\X0A\several tan fragments measuring in aggregate 1.1 x 0.5 x 0.3 cm. The\X0D\\X0A\specimen is submitted en toto in a single cassette.\X0D\\X0A\Specimen (D) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'sigmoid polyp'. The specimen consists of\X0D\\X0A\three polypoid fragments measuring in aggregate 0.8 x 0.4 x 0.3 cm. The\X0D\\X0A\specimen is submitted en toto in a single cassette.  (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 4,,SPECIMEN(S): A SMALL BOWEL BIOPSY\X0D\\X0A\SPECIMEN(S): B GASTRIC POLYP\X0D\\X0A\SPECIMEN(S): C SIGMOID COLON BX\X0D\\X0A\SPECIMEN(S): D SIGMOID POLYP,,
REG1,COLON,0,484846,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is colonic mass. This is a **AGE[in 50s] year old gentlemen with\X0D\\X0A\abnormal imaging suggestive of rectosigmoid thickening and a liver mass\X0D\\X0A\suggestive of metastatic colon cancer for biopsies and stent placement\X0D\\X0A\(patient having obstructive symptoms). Operative findings: fungating\X0D\\X0A\infiltrative sessile ulcerated, completely obstructing large mass was found\X0D\\X0A\in the rectosigmoid colon. The mass was circumferential. The mass measures 9\X0D\\X0A\cm in length. The distal margin of the mass was at 5 cm from the anal verge.\X0D\\X0A\The proximal margin of the mass was at 14 cm from the anal verge. No bleeding\X0D\\X0A\was present. This was biopsied with cold forceps for histology.  Operative\X0D\\X0A\procedure: flexible sigmoidoscopy. \X0D\\X0A\\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Jan 18 1955] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[Jan 6 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Jan 7 2012] 07:41\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], MD     Service: GAS     Location: 3IR\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jan 11 2012] 12:56\X0D\\X0A\RESIDENTS(S): C.M. **NAME[WWW], MD\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\RECTUM, MASS, BIOPSY:\X0D\\X0A\   - INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jan 11 2012] Y.M. **NAME[VVV], MD\X0D\\X0A\ \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: **ID-NUM P114 \X0D\\X0A\\X0D\\X0A\F: A: 88305 \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) rectal mass                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 7 \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): red tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): range from 0.2 to 0.7 cm in largest dimension\X0D\\X0A\Specimen entirely submitted with three pieces in screened A1 and four pieces\X0D\\X0A\in screened A2. \X0D\\X0A\\X0D\\X0A\rgc/**DATE[Jan 8 2012] C.M. **NAME[WWW], MD\X0D\\X0A\J.W. **NAME[UUU], MD  \X0D\\X0A\\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Rectal mass\X0D\\X0A\,,
REG1,COLON,0,484985,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is pelvic mass, leukocytosis, ascites. Intra-operative\X0D\\X0A\findings: pelvic mass. Operative procedure: Exploratory laparotomy, total\X0D\\X0A\abdominal hysterectomy, bilateral salpingo oophorectomy, possible staging,\X0D\\X0A\colon resection.  \X0D\\X0A\\X0D\\X0A\ \X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1A-B:  ""LARGELY NECROTIC HIGH GRADE ADENOCARCINOMA,\X0D\\X0A\CANNOT EXCLUDE EXTRA OVARIAN MALIGNANCY""---RK. \X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  ""HIGH GRADE ADENOCARCINOMA; CANNOT EXCLUDE\X0D\\X0A\EXTRA OVARIAN MALIGNANCY""---RK. \X0D\\X0A\ \X0D\\X0A\     R.G. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[May 8 1960] (Age: **AGE[in 50s])  F\X0D\\X0A\Collect Date: **DATE[Jun 1 2012] 15:44\X0D\\X0A\Receipt Date: **DATE[Jun 1 2012] 15:44\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\\X0D\\X0A\**NAME[YYY] MD: **NAME[M. XXX], MD     Service: GYO     Location: 2OR\X0D\\X0A\**NAME[WWW] MD(**NAME[M): VVV UUU], MD     Reported: **DATE[Jun 8 2012] 18:28\X0D\\X0A\RESIDENTS(S): S.R. **NAME[TTT], MD\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\SPECIMEN SUBMITTED AS ABDOMINAL MASS, EXCISION (A):\X0D\\X0A\  -  ORGANIZING HEMATOMA, NO TUMOR SEEN. \X0D\\X0A\\X0D\\X0A\LEFT FALLOPIAN TUBE AND LEFT OVARY, SALPINGO-OOPHORECTOMY (B):\X0D\\X0A\   - ADENOCARCINOMA CONSISTENT WITH METASTASIS FROM COLON PRIMARY, OVARY.\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, FALLOPIAN TUBE.\X0D\\X0A\\X0D\\X0A\RIGHT FALLOPIAN TUBE AND RIGHT OVARY, SALPINGO-OOPHORECTOMY (C):\X0D\\X0A\   - ADENOCARCINOMA CONSISTENT WITH METASTASIS FROM COLON PRIMARY, OVARY.\X0D\\X0A\   - GRANULATION TISSUE AND ORGANIZING HEMATOMA WITH RARE FOCUS OF\X0D\\X0A\ADENOCARCINOMA\X0D\\X0A\    IDENTIFIED IN SEROSA OF FALLOPIAN TUBE. \X0D\\X0A\\X0D\\X0A\UTERUS, SUPRACERVICAL HYSTERECTOMY (D):\X0D\\X0A\   - METASTATIC ADENOCARCINOMA INVOLVING LEFT PARAMETRIAL TISSUE.\X0D\\X0A\   - NO TUMOR SEEN, RIGHT PARAMETRIAL TISSUE.\X0D\\X0A\   - ATROPHIC ENDOMETRIUM.\X0D\\X0A\   - LEIOMYOMA, MYOMETRIUM.\X0D\\X0A\\X0D\\X0A\COLON, TRANSVERSE, COLECTOMY (E):\X0D\\X0A\   - TRANSMURAL NECROSIS WITH PERFORATION, NO TUMOR SEEN.\X0D\\X0A\   - MARGIN OF RESECTION VIABLE..\X0D\\X0A\   - SUTURE GRANULOMA.\X0D\\X0A\   - NO TUMOR SEEN IN TWO LYMPH NODES (0/2).\X0D\\X0A\\X0D\\X0A\SMALL BOWEL, RESECTION (F):\X0D\\X0A\   - ACUTE SEROSITIS, NO TUMOR SEEN. (CLINICAL HISTORY OF ENTEROCUTANEOUS\X0D\\X0A\FISTULA.)\X0D\\X0A\   - MARGINS OF RESECTION VIABLE.\X0D\\X0A\   - NO TUMOR SEEN IN ONE MESENTERIC LYMPH NODE (0/1).\X0D\\X0A\\X0D\\X0A\SPECIMEN SUBMITTED AS ABDOMINAL TUMOR, EXCISION (G):\X0D\\X0A\   - ORGANIZING HEMATOMA WITH ACUTE INFLAMMATION, GRANULATION TISSUE, AND\X0D\\X0A\SMALL \X0D\\X0A\     FOCI OF ADENOCARCINOMA.\X0D\\X0A\\X0D\\X0A\COLON, SIGMOID, COLECTOMY (H):\X0D\\X0A\   - INVASIVE MODERATELY TO POORLY DIFFERENTIATED ADENOCARCINOMA EXTENDING TO\X0D\\X0A\THE SEROSAL \X0D\\X0A\     SURFACE, pT4a, pN2b, pM1b. (SEE TEMPLATE AND COMMENT)\X0D\\X0A\   - RADIAL MARGIN INVOLVED BY TUMOR.\X0D\\X0A\   - PROXIMAL AND DISTAL RESECTION MARGINS FREE OF TUMOR. \X0D\\X0A\   - LYMPHVASCULAR AND PERINERUAL INVASION PRESENT.\X0D\\X0A\   - METASTATIC ADENOCARCINOMA IN ELEVEN OF NINETEEN LYMPH NODES (**DATE[Oct 20]).    \X0D\\X0A\\X0D\\X0A\RIGHT COLON AND TERMINAL ILEUM, ILEOCECECTOMY (I):\X0D\\X0A\   - SEROSAL ADHESIONS WITH FOCUS OF METASTATIC ADENOCARCINOMA AND ACUTE\X0D\\X0A\SEROSITIS.\X0D\\X0A\   - NO TUMOR SEEN IN TWO LYMPH NODES (0/2).\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jun 6 2012] Y.M. **NAME[SSS], MD\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Nine specimens are received. \X0D\\X0A\\X0D\\X0A\Specimen A is received fresh and placed in formalin labeled abdominal mass\X0D\\X0A\and consists of a brown tan soft tissue fragment measuring 9.5 x 5.5 x 2.5\X0D\\X0A\cm. The specimen is unoriented. The external surfaces are inked black. The\X0D\\X0A\specimen is serially sectioned to reveal a multiloculated cystic mass with\X0D\\X0A\clear fluid. Representative sections are submitted in A1  A7. \X0D\\X0A\\X0D\\X0A\Specimen B is received fresh for frozen section labeled left tube and ovary\X0D\\X0A\and consists of the aforementioned which weigh 2400    g fresh.  \X0D\\X0A\\X0D\\X0A\The fallopian tube has an identifiable fimbriated end. No paratubal cysts are\X0D\\X0A\noted. There are no excrescences along its serosal surface.  The tube is\X0D\\X0A\serially sectioned to reveal a pinpoint lumen.  \X0D\\X0A\\X0D\\X0A\The ovary is yellow tan and distorted with a disrupted surface.  It is\X0D\\X0A\received disrupted without excrescences on its surface.  It is serially\X0D\\X0A\sectioned to reveal a solid yellow tan mass with areas of hemorrhage and\X0D\\X0A\necrosis. There are no residual grossly unremarkable ovary.\X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 4.1 cm length x 0.5 cm diameter\X0D\\X0A\Ovary:    26.0 x 18.0 x 13.0 cm (entire ovary replaced by mass)\X0D\\X0A\\X0D\\X0A\Inking: none (disrupted)\X0D\\X0A\\X0D\\X0A\Representative sections:\X0D\\X0A\B1  FS1A\X0D\\X0A\B2  FS1B\X0D\\X0A\B3  fallopian tube with fimbria\X0D\\X0A\B4  B10  representative ovarian mass\X0D\\X0A\\X0D\\X0A\Specimen C is received fresh for frozen section labeled right tube and ovary\X0D\\X0A\and consists of the aforementioned which weigh 201  g fresh.  \X0D\\X0A\\X0D\\X0A\There is no identifiable fallopian tube. \X0D\\X0A\\X0D\\X0A\The ovary is pink tan.  It is received intact without excrescences on its\X0D\\X0A\surface.  It is serially sectioned to reveal a cystic mass with two solid\X0D\\X0A\areas that measure 3.0 x 2.0 x 1.0 cm and 0.5 x 0.5 x 0.5 cm.  The solid\X0D\\X0A\areas are representatively frozen as FS2. \X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Ovary:    9.0 x 7.0 x 4.0 cm\X0D\\X0A\Largest solid area: 2.0 x 2.0 x 1.0 cm\X0D\\X0A\Second solid area measures: 0.5 x 0.5 x 0.5 cm    \X0D\\X0A\\X0D\\X0A\Inking\X0D\\X0A\Serosa: blue\X0D\\X0A\\X0D\\X0A\Representative sections:\X0D\\X0A\C1  FS2\X0D\\X0A\C2  C5  representative ovary \X0D\\X0A\\X0D\\X0A\Specimen D is received fresh and placed in formalin labeled uterus and fundus\X0D\\X0A\and consists of a supra-cervical uterus which weighs 44 grams and measures\X0D\\X0A\4.5 cm from superior to inferior x 6.5 cm cornu to cornu x 2.5 cm from\X0D\\X0A\anterior to posterior. The serosal surface is red tan with multiple\X0D\\X0A\adhesions. The uterus is opened to reveal an endometrial cavity that has a\X0D\\X0A\depth of 3.0 cm. The endometrium is pink yellow with no discrete lesion. The\X0D\\X0A\uterus is serially sectioned to reveal an average endometrium thickness of\X0D\\X0A\0.1 cm and an average myometrial thickness of 1.6 cm. No myometrial lesions\X0D\\X0A\are identified. The myometrium is pink tan with a small tan whorled nodule\X0D\\X0A\that measures 0.5 cm in greatest dimension. \X0D\\X0A\\X0D\\X0A\Representative sections: \X0D\\X0A\D1  right parametrium\X0D\\X0A\D2  left parametrium\X0D\\X0A\D3  anterior endomyometrium with possible leiomyoma\X0D\\X0A\D4  posterior endomyometrium \X0D\\X0A\\X0D\\X0A\Specimen E is received in formalin labeled transverse colon and consists of a\X0D\\X0A\short segment of bowel measuring 3.5 cm in length x 2.9 cm in diameter.  The\X0D\\X0A\specimen is unoriented with two staple margins.  There is a 1.5 cm diameter\X0D\\X0A\area of disruption.  The external surface is partially covered by yellow/tan\X0D\\X0A\mesentery. The serosa is pink/tan and smooth except for the aforementioned\X0D\\X0A\disruption.  The bowel is opened to reveal a yellow/tan mildly edematous\X0D\\X0A\mucosa but otherwise normally rugated. There is an umbilicated area that 0.5\X0D\\X0A\cm in diameter across from the mural disruption.  \X0D\\X0A\\X0D\\X0A\Representative sections: \X0D\\X0A\E1  one staple margin\X0D\\X0A\E2  second staple margin\X0D\\X0A\E3  representative sections of mural disruption\X0D\\X0A\E4-E5  umbilicated lesion entirely submitted\X0D\\X0A\E6  representative sections of unremarkable bowel mucosa\X0D\\X0A\\X0D\\X0A\Specimen F is received in formalin labeled small intestine and consists of a\X0D\\X0A\length of unoriented small bowel measuring 20.5 cm in length x 3.7 cm in\X0D\\X0A\circumference.  It is received previously open.  There is yellow/tan\X0D\\X0A\mesentery running the entire length of the bowel segment and extending 1 cm\X0D\\X0A\from the serosal surface. The bowel serosa is pink/tan and rough with\X0D\\X0A\irregular white and red nodular areas ranging from 0.5cm up to 2.2cm in\X0D\\X0A\greatest dimension. The mucosa is yellow/tan with edematous rugae but without\X0D\\X0A\masses or ulceration.  \X0D\\X0A\\X0D\\X0A\Representative sections:  \X0D\\X0A\F1  one staple margin\X0D\\X0A\F2  second staple margin\X0D\\X0A\R3-F5  representative sections of serosal nodules\X0D\\X0A\F6  representative sections of unremarkable mucosa.\X0D\\X0A\\X0D\\X0A\Specimen G is received in formalin labeled abdominal tumor and consists of\X0D\\X0A\multiple irregular pink/tan to yellow hemorrhagic fragments of tissue that\X0D\\X0A\are 10.5 x 5.8 x 3.2 cm in aggregate.  Sectioning reveals variegated\X0D\\X0A\hemorrhagic, cystic, fleshy, and necrotic cut surface.  Cassette summary: \X0D\\X0A\G1-G4  representative sections.\X0D\\X0A\\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\An immunohistochemical stain for CK7 was performed on the tumor in the\X0D\\X0A\sigmoid colon.  The stain is negative, supporting a diagnosis of primary\X0D\\X0A\colon adenocarcinoma.  \X0D\\X0A\\X0D\\X0A\COLORECTAL CANCER (template #5)\X0D\\X0A\(NOT for sarcoma, lymphoma, carcinoid tumor, and anal canal tumor) \X0D\\X0A\Last update **DATE[Aug 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Part of bowel resected or procedure:  colectomy\X0D\\X0A\\X0D\\X0A\Tumor site:  sigmoid\X0D\\X0A\\X0D\\X0A\Tumor size:  4.5 x 3.5 x 3.5 cm / cannot be determined\X0D\\X0A\\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\                                      \X0D\\X0A\\X0D\\X0A\Histologic grade:  high grade (moderate to poorly differentiated)\X0D\\X0A\          \X0D\\X0A\Margins:         proximal margin:  negative\X0D\\X0A\         distal margin:  negative  \X0D\\X0A\         radial (mesenteric) margin: positive \X0D\\X0A\             \X0D\\X0A\Macroscopic tumor perforation:  absent\X0D\\X0A\\X0D\\X0A\Extramural venous invasion:  no definite\X0D\\X0A\\X0D\\X0A\Intramural venous invasion:  no definite\X0D\\X0A\\X0D\\X0A\Lymph-vascular invasion:  present\X0D\\X0A\\X0D\\X0A\Perineural invasion:  present\X0D\\X0A\\X0D\\X0A\Peritumoral lymphoid response (Crohn-like response):  minimal to mild\X0D\\X0A\\X0D\\X0A\Intratumoral lymphocytic response (tumor-infiltrating lymphocytes):  none\X0D\\X0A\\X0D\\X0A\Depth of invasion:  pericolonic fat     \X0D\\X0A\\X0D\\X0A\Regional lymph node metastasis:  11 positive/ 23 total  \X0D\\X0A\   \X0D\\X0A\Tumor deposits (discontinuous extramural extension without histologic\X0D\\X0A\evidence of residual lymph node tissue or venous invasion):     present      \X0D\\X0A\  \X0D\\X0A\\X0D\\X0A\Pathologic Staging (pTNM) (y: post-treatment, r: recurrent)\X0D\\X0A\\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\\X0D\\X0A\     pT4a      Tumor penetrates to the surface of the visceral peritoneum\X0D\\X0A\          \X0D\\X0A\Regional lymph nodes (pN): (If fewer than 13 lymph nodes, second search is\X0D\\X0A\required)\X0D\\X0A\\X0D\\X0A\     pN2b       Metastasis in 7 or more lymph nodes\X0D\\X0A\\X0D\\X0A\Distant metastasis (pM):\X0D\\X0A\\X0D\\X0A\     pM1b     Metastasis to more than one organ/site or the peritoneum\X0D\\X0A\(specify site(s):  right ovary, left ovary, left uterine \X0D\\X0A\                    parametrial tissue                 \X0D\\X0A\     \X0D\\X0A\Extent of resection (residual tumor; R):\X0D\\X0A\\X0D\\X0A\     (X )     Incomplete resection, margins involved or gross disease remains\X0D\\X0A\after resection (R2)\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: abdominal mass\X0D\\X0A\B: left tube and ovary\X0D\\X0A\C: right tube and ovary\X0D\\X0A\D: Uterus and cervix\X0D\\X0A\E: tranverse colon\X0D\\X0A\F: small intestine\X0D\\X0A\G: abdominal tumor\X0D\\X0A\H: sigmoid colon\X0D\\X0A\I: right colon and terminal ileum\X0D\\X0A\,,
REG1,COLON,0,485974,1,,Clinical Diagnosis and History\X0D\\X0A\RECTAL MASS\X0D\\X0A\OPER: FLEX SIG WITH HOT BIOPSY\X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX: INVASIVE ADENOCARCINOMA. (CLS) (REPORTED TO DR. **NAME[ZZZ] AT 8:02 A.M.),"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RECTAL MASS -FS-ag","Final Diagnosis\X0D\\X0A\RECTAL ""MASS"", ENDOSCOPIC BIOPSY:\X0D\\X0A\     INVASIVE LOW GRADE / MODERATELY DIFFERENTIATED ADENOCARCINOMA ARISING IN \X0D\\X0A\          ASSOCIATION WITH A TUBULOVILLOUS ADENOMA.\X0D\\X0A\**INITIALS \X0D\\X0A\IHC/MER\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **NAME[XXX]",,"Gross Description\X0D\\X0A\Received fresh for frozen section evaluation labeled  ""rectal mass"" is an\X0D\\X0A\aggregate of small tan soft tissue fragments ranging up to 2.-3 mm in aggregate\X0D\\X0A\measuring 1.0 x 0.5 x 0.3 cm.  The entire specimen is frozen in one block with\X0D\\X0A\control submitted as FSC1A.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,COLON,0,486014,1,,Clinical Diagnosis and History\X0D\\X0A\COLON CA\X0D\\X0A\OPER: OPEN LOW ANTERIOR COLON RESECTION,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: SIGMOID \E\T\E\ UPPER RECTUM   bb\X0D\\X0A\2: CUL DE SAC NODULE   bb\X0D\\X0A\3: COLON, RESECTION MARGIN","Final Diagnosis\X0D\\X0A\1: SIGMOID COLON AND UPPER RECTUM, RESECTION SPECIMEN: \X0D\\X0A\     INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\     MAXIMUM TUMOR DIMENSION 3.5 CM.\X0D\\X0A\     TUMOR EXTENDS THROUGH MUSCULARIS PROPRIA INTO PERICOLONIC FAT.\X0D\\X0A\     ASSOCIATED MUCOSAL ULCERATION.\X0D\\X0A\     NEGATIVE MUCOSAL MARGINS.\X0D\\X0A\     NEGATIVE RADIAL SOFT TISSUE MARGIN.\X0D\\X0A\     HYPERPLASTIC POLYP.\X0D\\X0A\     DIVERTICULOSIS.\X0D\\X0A\     METASTATIC CARCINOMA IN TWO OF TWENTY-FOUR LYMPH NODES.\X0D\\X0A\     SINGLE DISCONTINUOUS TUMOR DEPOSIT IN MESENTERIC FAT.\X0D\\X0A\2: CUL DE SAC, BIOPSY:\X0D\\X0A\     REFRACTILE FOREIGN MATERIAL CONSISTENT WITH SUTURE.\X0D\\X0A\     FOCAL FIBROSIS.\X0D\\X0A\     NO IDENTIFIED MALIGNANCY.\X0D\\X0A\3: ""DONUTS OF ANASTOMOSIS"":\X0D\\X0A\     UNREMARKABLE BOWEL TISSUE.\X0D\\X0A\MER/cb\X0D\\X0A\IHC/a/CMK \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\1: Received in formalin designated ""sigmoid and upper rectum"" is a segment of\X0D\\X0A\colon measuring 19 cm in length and approximately 3.8 cm in diameter.  There is\X0D\\X0A\complete resection of the surrounding mesorectum.  The serosa is tan gray.  On\X0D\\X0A\opening the specimen  located 13.5 cm from the proximal margin and extending to\X0D\\X0A\within 3.0 cm of the distal margin is a circumferential 3.5 x 2.8 cm tan red\X0D\\X0A\raised and centrally ulcerated tumor mass.  The radial soft tissue margin is\X0D\\X0A\inked in blue.  On sectioning the tumor involves the entire bowel wall and has a\X0D\\X0A\maximum thickness of 1.5 cm.  Tumor is clear of the closest radial margin by\X0D\\X0A\approximately 4.0 cm.  The remaining mucosa is tan pink with no additional\X0D\\X0A\nodules or masses identified.  There are several diverticuli noted which extend\X0D\\X0A\into an area through the bowel wall into the immediate adjacent adipose tissue. \X0D\\X0A\No abscess cavities are grossly identified.  Sections are submitted as follows:\X0D\\X0A\1A  proximal resection margin \X0D\\X0A\1B  distal resection margin\X0D\\X0A\1C through 1 E  representative full thickness sections of tumor\X0D\\X0A\1F through 1H  perpendicular sections of closest inked radial soft tissue margin\X0D\\X0A\1I  1K  representative sections of diverticuli\X0D\\X0A\1L-1R  four possible lymph nodes in each cassette\X0D\\X0A\1S  a bisected possible node\X0D\\X0A\1T  trisected node containing an area suspicious for tumor\X0D\\X0A\1U  trisected possible node\X0D\\X0A\1V  bisected possible node\X0D\\X0A\1W  four possible nodes\X0D\\X0A\2: Received in formalin designated ""cul de sac nodule"" is a firm yellow gray 7 x\X0D\\X0A\5 x 3 mm tissue fragment submitted in toto in block 2A.\X0D\\X0A\3: Received in formalin designated ""donuts of anastomosis"" are two rings of\X0D\\X0A\bowel which are covered by glistening tan mucosa.  Each averages 1.5 x 1.0 x 0.6\X0D\\X0A\cm.  Each ring has a few attached metal staples.  A cross section from each ring\X0D\\X0A\is submitted in 3A and 3B.\X0D\\X0A\DH/**INITIALS \X0D\\X0A\/cb","Microscopic Description\X0D\\X0A\Incorporated in diagnosis. \X0D\\X0A\CAP REPORTING:\X0D\\X0A\Specimen: Sigmoid colon and upper rectum\X0D\\X0A\Procedure: Rectosigmoid colon resection (low anterior)\X0D\\X0A\Tumor site: Rectosigmoid\X0D\\X0A\Tumor size, greatest dimension: 3.5 cm\X0D\\X0A\Macroscopic tumor perforation: Not identified\X0D\\X0A\Histologic type: Adenocarcinoma\X0D\\X0A\Histologic grade: Low grade (moderately differentiated)\X0D\\X0A\Microscopic tumor extension: Tumor invades through muscularis propria into\X0D\\X0A\pericolonic fat\X0D\\X0A\Margins: \X0D\\X0A\     Proximal and distal margins - negative\X0D\\X0A\     Circumferential radial margin  negative\X0D\\X0A\     Distance from closest margin  3 cm (distal margin)\X0D\\X0A\Treatment effect: Not applicable\X0D\\X0A\Lymph / vascular invasion: Not identified\X0D\\X0A\Perineural invasion: Not identified\X0D\\X0A\Tumor deposits: Present (1)\X0D\\X0A\Pathologic staging: \X0D\\X0A\     Primary tumor: pT3\X0D\\X0A\     Regional lymph nodes: pN1b\X0D\\X0A\          Number of nodes involved: 2\X0D\\X0A\          Number examined: 24\X0D\\X0A\     Distant metastasis: Not applicable",,,
REG1,COLON,0,486361,1,,CLINICAL HISTORY: Preop diagnosis rectal bleeding.,"Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX M WWW], VVV] PhD **DATE[Mar 27 12]",FINAL DIAGNOSIS: POLYPS OF RECTUM (LARGER POLYP BLOCK 1) INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA EXTENDING THROUGH MUSCULARIS MUCOSA INTO SUBMUCOSA. SEE COMMENT. (SMALLER POLYP) VILLOGLANDULAR ADENOMATOUS POLYP WITH MODERATE ATYPIA. SEE COMMENT.,,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and ""rectal polyps.""  The specimen is received in formalin.  The first, and largest, is reddish-pink, lobulated, measuring 1.8 x 1.5 cm.  The base is inked and the specimen is serially sectioned.  The tissue is friable, glistening tan-pink throughout.  This portion of the specimen is totally submitted in Block 1.  The second portion is tan-pink, lobulated, measuring 1 cm. in greatest dimensions.  The base is inked, the specimen is serially sectioned and totally submitted in Block 2.","COMMENT WORD: The microscopic sections of the larger polyp submitted in Block 1 shows evidence of an adenomatous villous lesion.  There is easily identified adenocarcinoma in-situ as well as superficially invasive carcinoma. Within focal areas the neoplasm extends through the muscularis mucosa into submucosa.  Lymphovascular invasion is not identified.  It is noted that there is a peripheral rim of cauterized normal colonic mucosa, possibly indicating the lesion is totally excised.  The following staging criteria will be modified if additional specimens are received: T1 possible Stage I.  Histopathologic grade: G2, moderately differentiated.  Residual tumor, favoring R0, margins histologically negative. Histopathologic type: adenocarcinoma. The microscopic sections of the smaller polyp submitted in Block 2 shows evidence of a villoglandular adenomatous polyp.  There is moderate nuclear atypia with nuclei beginning to show evidence of prominent nucleoli.  There is nuclear crowding due to hypercellularity and pseudostratification of nuclei.  These findings are felt to indicate the presence of a high-grade lesion.  This polyp also shows evidence of a peripheral rim of cauterized normal colonic mucosa and, therefore, may be totally excised.   These findings should be correlated with clinical history and symptomatology.",Specimen Number: ***PATH-NUMBER[1]. Tissues: Rectum. Specimen Comments:,,
REG1,COLON,0,486382,1,,HISTORY: partially obstructing sigmoid mass,"ICD9 CODES: 153.9, 789.30, \X0D\\X0A\COMMENTS: The slides were seen in consultation with Dr. **NAME[ZZZ YYY] who agrees with the above diagnosis.","DIAGNOSIS: COLON, BIOPSY AT 10 CM:         POORLY DIFFERENTIATED MUCINOUS (COLLOID) ADENOCARCINOMA.",,"GROSS: Received in formalin and labeled with patient's name as ""biopsy of mass at 10 cm"" and consists of multiple tan fragments of tissue with the largest measuring up to 0.3 cm. Specimen is submitted for TE. DT: **DATE[Feb 18 2012]",MICRO: Microscopic examination was performed.   DT:  **DATE[Feb 19 2012]  (DRB/bab),PROCEDURE: Colonoscopy with biopsy\X0D\\X0A\SPECIMEN(S): biopsy of mass at 10 cm,,
REG1,COLON,0,486683,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA]                     DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\COPIES TO:       **NAME[YYY]  **NAME[XXX], MD\X0D\\X0A\COMMENT:  This case was shown at the intradepartmental consensus\X0D\\X0A\conference and all in attendance concurred with this diagnosis (dmp,\X0D\\X0A\drw).\X0D\\X0A\                                <Sign Out Dr. **NAME[WWW]>\X0D\\X0A\                                **NAME[VVV UUU], M.D., Pathologist\X0D\\X0A\CLINICAL           ABDOMINAL PAIN, ABNORMAL CT, ACUTE BLOOD LOSS\X0D\\X0A\INFORMATION:\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\Part B: 88305 x 2,  88312 x 1\X0D\\X0A\  ICD9: 535.10     153.9\X0D\\X0A\PATIENT:  **NAME[BBB, AAA]                        **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cNQjMrPpj3jWAGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zGjUN2YDAuxxqXXxDnoSGNZ\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\(A)  Gastric antrum biopsy:\X0D\\X0A\ Mild chronic gastritis.\X0D\\X0A\ Giemsa stain negative for Helicobacter pylori organisms.\X0D\\X0A\(B)  Colon biopsy at 16 cm.:\X0D\\X0A\ Invasive, moderately differentiated adenocarcinoma.",,"GROSS DESCRIPTION:\X0D\\X0A\The following specimens are received in prefilled formalin containers:\X0D\\X0A\(A) Labeled ""antrum biopsy, rule out H. pylori"" is one piece of tan\X0D\\X0A\soft tissue measuring 0.4 cm. in greatest dimension.  Entirely\X0D\\X0A\submitted.\X0D\\X0A\(B) Labeled ""colon mass at 16 cm."" are multiple pieces of tan soft\X0D\\X0A\tissue measuring 0.2 up to 0.4 cm. in greatest dimension.  Entirely\X0D\\X0A\submitted./AKC,SXH","MICROSCOPIC DESCRIPTION:\X0D\\X0A\(A)  The sections demonstrate a small fragment of gastric mucosa with\X0D\\X0A\mild chronic inflammation.  No evidence of high-grade dysplasia. The\X0D\\X0A\above findings are nonspecific and correlation with clinical findings\X0D\\X0A\is suggested.\X0D\\X0A\(B)  The sections demonstrate multiple fragments of colonic mucosa\X0D\\X0A\involved by an infiltrating, moderately differentiated adenocarcinoma.\X0D\\X0A\No definitive lymphvascular invasion is identified within the submitted\X0D\\X0A\material.","TISSUE SUBMITTED:  (A) ANTRAL BIOPSY, RULE OUT H. PYLORI\X0D\\X0A\                   (B) COLON BIOPSY, MASS AT 16 CM",,
REG1,COLON,0,486687,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA M]                 DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\COMMENT:  This case was discussed in the intradepartmental consensus\X0D\\X0A\conference (dmp. sxh).\X0D\\X0A\                                <Sign Out Dr. **NAME[YYY]>\X0D\\X0A\                                **NAME[XXX WWW], M.D., Pathologist\X0D\\X0A\CLINICAL           COLON CANCER\X0D\\X0A\INFORMATION:\X0D\\X0A\                                                    Trans ID:  RVL, K9P\X0D\\X0A\                                                         Trans ID: AA\X0D\\X0A\Part B: 88309 x 1,  3260F x 1\X0D\\X0A\ ICD9: 153.6     153.4     211.3\X0D\\X0A\PATIENT:  **NAME[BBB, AAA M]                    **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cGI3Azh4LeJiAGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zGd9BfpgeciO7HwcFTScgni\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\Terminal ileum, cecum with attached appendix, ascending colon, right\X0D\\X0A\hemicolectomy:\X0D\\X0A\ Invasive, moderately differentiated adenocarcinoma.\X0D\\X0A\    Specimen:\X0D\\X0A\  Terminal ileum\X0D\\X0A\  Cecum\X0D\\X0A\  Appendix\X0D\\X0A\  Ascending colon\X0D\\X0A\ Procedure:\X0D\\X0A\  Right hemicolectomy\X0D\\X0A\ Specimen Length:\X0D\\X0A\  26.5 cm.\X0D\\X0A\ Tumor Site:\X0D\\X0A\  Cecum\X0D\\X0A\  Right (ascending) colon\X0D\\X0A\ Tumor Size:\X0D\\X0A\  7.0 x 6.3 x 3.0 cm.\X0D\\X0A\ Macroscopic Tumor Perforation:\X0D\\X0A\  Not identified\X0D\\X0A\ Histologic Type:\X0D\\X0A\  Adenocarcinoma\X0D\\X0A\ Histologic Grade:\X0D\\X0A\  Low-grade (well-differentiated to moderately differentiated)\X0D\\X0A\ Microscopic Tumor Extension:\X0D\\X0A\  Tumor penetrates to the surface of the visceral peritoneum\X0D\\X0A\ Margins:\X0D\\X0A\  Proximal Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  Distal Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  Circumferential (Radial) or Mesenteric Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  All margins uninvolved by invasive carcinoma:\X0D\\X0A\   Distance of invasive carcinoma from closest margin:  0.3 cm.\X0D\\X0A\   Specify margin:  Radial\X0D\\X0A\ Treatment Effect:\X0D\\X0A\  No prior treatment\X0D\\X0A\ Lymph-Vascular Invasion:\X0D\\X0A\  Not identified\X0D\\X0A\ Perineural Invasion:\X0D\\X0A\  Not identified\X0D\\X0A\ Tumor Deposits:\X0D\\X0A\  Not identified\X0D\\X0A\ Pathologic Staging (pTNM)\X0D\\X0A\-      Primary Tumor (pT)\X0D\\X0A\  pT4a\X0D\\X0A\      Regional Lymph Nodes (pN)\X0D\\X0A\  pN1a\X0D\\X0A\  Number of Lymph Nodes Examined:  18\X0D\\X0A\  Number of Lymph Nodes Involved:  1\X0D\\X0A\      Distant Metastasis (pM)\X0D\\X0A\  Not applicable\X0D\\X0A\ Additional findings:\X0D\\X0A\  Adenoma(s) with focus of high-grade dysplasia\X0D\\X0A\  Other polyps:  Hyperplastic",,"GROSS DESCRIPTION:\X0D\\X0A\Received labeled only with the patient's name is a right hemicolectomy\X0D\\X0A\specimen closed with two stapled margins, including terminal ileum (2.5\X0D\\X0A\cm. in length x 3.0 cm. in diameter), appendix (9.5 cm. in length x 0.7\X0D\\X0A\cm. in diameter), and cecum and ascending colon (24.0 cm. in length and\X0D\\X0A\ranging from 3.5 to 6.5 cm. in diameter).  The serosa is tan to\X0D\\X0A\hemorrhagic and displays a centrally located area of black possible\X0D\\X0A\surgical tattooing, measuring 12.0 cm. from the terminal ileum margin\X0D\\X0A\and 11.0 cm. from the opposing margin. Measuring approximately 5.5 cm.\X0D\\X0A\proximal to the possible surgical tattooing there is an area of the\X0D\\X0A\colon and serosa that is firm, focally adhesed and puckered around the\X0D\\X0A\entire circumference of the specimen.  The attached yellow to focally\X0D\\X0A\hemorrhagic, lobulated adipose tissue is up to 10.0 cm. in thickness.\X0D\\X0A\The wall of the appendix averages 0.2 cm. in thickness and the lumen\X0D\\X0A\has a diameter that averages 0.3 cm. and is filled with tan-brown fecal\X0D\\X0A\material.  The bisected tip is tan and unremarkable.  No abnormalities\X0D\\X0A\are identified within the appendix.  The wall of the terminal ileum is\X0D\\X0A\0.3 cm. in thickness and the mucosa is tan-pink with abundant folds and\X0D\\X0A\focal raised areas within the mucosa measuring 0.1 cm. in greatest\X0D\\X0A\dimension.  The ileo-cecal valve is tan-pink and unremarkable.  The\X0D\\X0A\wall of the colon averages 0.4 cm. in thickness and the mucosa is\X0D\\X0A\tan-pink with abundant folds and focal hemorrhagic areas.  The mucosa\X0D\\X0A\in the central aspect and previous area of possible surgical tattooing\X0D\\X0A\on the serosa displays black discoloration consistent with tattooing\X0D\\X0A\underlying the mucosa.  An irregular, indurated tan to hemorrhagic mass\X0D\\X0A\with central ulceration and markedly heaped-up borders is present and\X0D\\X0A\measures 7.0 x 6.3 x 1.2 cm.  The mass is circumferential, narrows the\X0D\\X0A\lumen to approximately 0.8 cm. and is present in the previously\X0D\\X0A\mentioned circumferential puckered firm area.  A small portion of the\X0D\\X0A\mass is grossly present towards the cecum and the majority of the mass\X0D\\X0A\is present in the ascending colon.  The mass measures 4.0 cm. from the\X0D\\X0A\terminal ileum margin and 17.0 cm. from the opposing margin.  The mass\X0D\\X0A\is located 2.0 cm. distal to the ileocecal valve. The serosa\X0D\\X0A\surrounding the mass is inked black and the radial margin is inked\X0D\\X0A\green.  The radial margin is confirmed with Dr. **NAME[VVV] and upon\X0D\\X0A\sectioning the mass, it is located 0.3 cm. from the closest portion of\X0D\\X0A\the mass.  The mass is tan-white and irregular on cut section and\X0D\\X0A\grossly extends through the wall into the adipose tissue.  The mass\X0D\\X0A\abuts areas of the inked serosa and possible extension through the\X0D\\X0A\serosa is possible, consistent with the previously mentioned puckering\X0D\\X0A\on the serosa.  The mass is up to 3.0 cm. in thickness on cut section.\X0D\\X0A\There are two tan-pink sessile polyps within the ascending colon\X0D\\X0A\measuring 0.4 x 0.2 x 0.1 cm. and 1.0 x 0.5 x 0.4 cm.  The sessile\X0D\\X0A\polyps measure 5.5 and 3.5 cm. (respectively) distal to the mass.  The\X0D\\X0A\sessile polyps come to within 9.0 and 12.0 cm. from the stapled margins\X0D\\X0A\and are both located within the area of black tattooing.  Dissection of\X0D\\X0A\the adipose tissue reveals nineteen tan-pink possible lymph nodes\X0D\\X0A\ranging from 0.3 x 0.2 x 0.2 cm. to 1.1 x 0.8 x 0.5 cm.  One of the\X0D\\X0A\possible lymph nodes is present abutting the mass.  One possible lymph\X0D\\X0A\node abuts the radial margin.\X0D\\X0A\An additional portion of bowel closed with two stapled margins is\X0D\\X0A\present within the container, measuring 8.0 cm. in length x 10.0 cm. in\X0D\\X0A\diameter.  The serosa is tan-pink and the attached yellow lobulated\X0D\\X0A\adipose tissue is up to 3.0 cm. in thickness.  The wall averages 0.4\X0D\\X0A\cm. in thickness and the mucosa is tan-pink with abundant folds and\X0D\\X0A\numerous raised possible polypoid areas ranging from 0.1 to 0.2 cm. in\X0D\\X0A\greatest dimension and coming to within 0.3 and 2.0 cm. from the\X0D\\X0A\stapled margins.  Dissection of the adipose tissue attached to the\X0D\\X0A\additional portion of bowel reveals one tan-pink possible lymph node\X0D\\X0A\measuring 0.3 cm. in greatest dimension.\X0D\\X0A\Representative sections are submitted as follows: cassette ""1"" -\X0D\\X0A\terminal ileum margin; ""2"" - distal colon margin, enface; ""3"" -\X0D\\X0A\appendix; ""4"" - terminal ileum mucosa; ""5"" - ileocecal valve; ""6-7"" -\X0D\\X0A\one full thickness section of mass (bisected)including adjacent\X0D\\X0A\unremarkable mucosa, invasion into adipose tissue, and radial margin;\X0D\\X0A\""8"" - mass to radial margin; ""9-11"" - mass to closest inked serosa;\X0D\\X0A\""12"" - mass invading adipose tissue; ""13"" - mass surrounding one\X0D\\X0A\possible lymph node; ""14"" - larger sessile polyp; ""15"" - smaller\X0D\\X0A\sessile polyp and mucosa within tattooed area; ""16"" - unremarkable\X0D\\X0A\mucosa; ""17"" - one possible lymph node abutting radial margin\X0D\\X0A\(perpendicular); ""18""- six possible lymph nodes; ""19"" - six possible\X0D\\X0A\lymph nodes; ""20"" - three possible lymph nodes; ""21"" - one possible\X0D\\X0A\lymph node, bisected; ""22"" - one possible lymph node, trisected; ""23"" -\X0D\\X0A\additional portion of small bowel margin, enface; ""24"" - opposing\X0D\\X0A\additional portion of small bowel margin, enface; ""25"" - unremarkable\X0D\\X0A\mucosa and possible lymph node of additional portion of small\X0D\\X0A\bowel./HAH,MRJ","MICROSCOPIC DESCRIPTION:\X0D\\X0A\Sections of the grossly recognized tumor mass within the resected\X0D\\X0A\portion of the cecum and ascending colon display an invasive,\X0D\\X0A\moderately differentiated adenocarcinoma. Some areas show a mucinous\X0D\\X0A\differentiation, but this is not a predominant feature.  The tumor\X0D\\X0A\extends through the entire thickness of the muscularis propria and\X0D\\X0A\penetrates the serosa with the ink being seen on neoplastic glands on\X0D\\X0A\the serosal surface (slice ""10"").  Vascular or perineural invasion were\X0D\\X0A\not appreciated.  One of eighteen mesenteric lymph nodes showed\X0D\\X0A\evidence of metastatic disease.  This node also displays extranodal\X0D\\X0A\extension (slide ""13"").  The tumor is located 3 mm. away from the\X0D\\X0A\radial margin. The distal and proximal margins are distanced from the\X0D\\X0A\tumor.  The additional grossly recognized polypoid mucosal region in\X0D\\X0A\the resected colon shows a hyperplastic polyp (slide ""15) and a tubular\X0D\\X0A\adenoma with a focus of high-grade dysplasia (slide ""14"").  The\X0D\\X0A\appendix did not show clinically significant histologic changes. The\X0D\\X0A\additional bowel segment histologically corresponds to a portion of\X0D\\X0A\small bowel.  It is without clinically significant histological\X0D\\X0A\alterations.","TISSUE SUBMITTED:   RIGHT COLON, AND TERMINAL ILEUM",,
REG1,COLON,0,486688,3,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA] J                      DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\                                                         Trans ID:  K9P\X0D\\X0A\Part B: 88305 x 1\X0D\\X0A\ ICD9: 211.3\X0D\\X0A\PATIENT:  **NAME[BBB, AAA] J                         **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cIiv0RYRwtHDAGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zHIy5S+BYwKRnzgpXn/NCAg\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\Rectal mass biopsy:  At least intramucosal adenocarcinoma arising in a\X0D\\X0A\background of villous adenoma.\X0D\\X0A\Comment:  This case was shown at the intradepartmental consensus\X0D\\X0A\conference and all in attendance concurred with this diagnosis (hay,\X0D\\X0A\dmp, drw).\X0D\\X0A\                                <Sign Out Dr. **NAME[YYY]>\X0D\\X0A\                                **NAME[XXX WWW], M.D., Pathologist\X0D\\X0A\CLINICAL           RECTAL MASS WITH DYSPLASIA\X0D\\X0A\INFORMATION:",,"GROSS DESCRIPTION:\X0D\\X0A\Received in a prefilled formalin container labeled ""rectal mass biopsy""\X0D\\X0A\are multiple pieces of tan-pink soft tissue measuring 0.1 to 0.7 cm.\X0D\\X0A\Entirely submitted./HAH,MRJ","MICROSCOPIC DESCRIPTION:\X0D\\X0A\Step sections demonstrate fragments of a villous adenoma.  Focally the\X0D\\X0A\villous adenoma shows small irregularly shaped adenomatous glands with\X0D\\X0A\high-grade dysplasia infiltrating into the mucosa. Due to the\X0D\\X0A\superficial and fragmented nature of the biopsy material, invasive\X0D\\X0A\adenocarcinoma if present cannot be entirely excluded.","TISSUE SUBMITTED:   RECTAL BIOPSY, MASS",,
REG1,COLON,0,486857,1,,CLINICAL HISTORY:  NONE GIVEN\X0D\\X0A\PRE-OP DIAGNOSIS:  IRON DEF ANEMIA\X0D\\X0A\POST-OP DIAGNOSIS:  COLON POLYPS,CASE: SUR-11-10117\X0D\\X0A\PATIENT: **NAME[AAA BBB]\X0D\\X0A\PROCEDURE:  COLONOSCOPY,FINAL DIAGNOSIS:\X0D\\X0A\COLON BIOPSY AT 15 CM:\X0D\\X0A\Adenocarcinoma.\X0D\\X0A\-Histologic grade:  G2\X0D\\X0A\-Angiolymphatic invasion:  Not identified.\X0D\\X0A\-Perineural invasion:  Not identified.\X0D\\X0A\-Other:  The tumor appears to be arising in a polyp.,,GROSS:\X0D\\X0A\Received designated colon biopsy at 15 cm are multiple fragments of tan\X0D\\X0A\tissue that are <1-3 mm and are entirely submitted as A1.\X0D\\X0A\(AEE),"MICROSCOPIC:\X0D\\X0A\See final diagnosis.\X0D\\X0A\Final Diagnosis performed by\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\Electronically signed **DATE[Jun 8 2012] 1:21PM",SPECIMEN:  A. COLON BIOPSY @ 15 CM,,
REG1,COLON,0,487221,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA] F                      DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\COMMENT:  This case was discussed with Dr. **NAME[YYY] on **DATE[May 12 12] and\X0D\\X0A\presented at the intradepartmental consensus conference (SXH, JBU).\X0D\\X0A\                                <Sign Out Dr. **NAME[XXX]>\X0D\\X0A\                                **NAME[WWW VVV], D.O., Pathologist\X0D\\X0A\CLINICAL           ANAL STENOSIS, CONSTIPATION, RECTAL INCONTINENCE\X0D\\X0A\INFORMATION:\X0D\\X0A\                                                         Trans ID:  RVL\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\Part B: 88305 x 1\X0D\\X0A\ ICD9: 564.0\X0D\\X0A\PATIENT:  **NAME[BBB, AAA] F                         **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cJMhQ0/xxEOPAGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zFyq+ZmtGi/0byNCCR6J6Fu\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\Colon, ""rectum"", biopsy:\X0D\\X0A\ AT LEAST HIGH GRADE adenomatous-type epithelium with underlying lamina\X0D\\X0A\propria fibrosis,\X0D\\X0A\  suspicious for carcinoma (see microscopic description).",,"GROSS DESCRIPTION:\X0D\\X0A\Received in a prefilled formalin container labeled ""rectal biopsy"" are\X0D\\X0A\four pieces of tan-pink soft tissue measuring 0.1 to 0.4 cm.  Entirely\X0D\\X0A\submitted./HAH,LAE","MICROSCOPIC DESCRIPTION:\X0D\\X0A\Histologic sections demonstrate colonic-type epithelium.  The surface\X0D\\X0A\epithelium shows hyperchromasia and stratification.  One of the\X0D\\X0A\fragments shows prominent fibrosis within the lamina propria.  Although\X0D\\X0A\no definitive invasive carcinoma is identified; given the overall\X0D\\X0A\features, malignancy cannot be entirely excluded. Please correlate with\X0D\\X0A\endoscopic findings and additional evaluation is recommended.",TISSUE SUBMITTED:   RECTAL BIOPSY,,
REG1,COLON,0,487850,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is colon mass, necrotizing infection, left pelvis.\X0D\\X0A\Intraoperative procedure: exploratory laparotomy, possible bowel, possible\X0D\\X0A\stoma. I\T\D hip, possible disarticulation. \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Nov 31 1952] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[Feb 3 2012] 14:36\X0D\\X0A\Receipt Date: **DATE[Feb 3 2012] 14:36\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], MD.     Service: SGB     Location: A07J\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Feb 9 2012] 18:45\X0D\\X0A\RESIDENTS(S): K.K. **NAME[WWW], DO","DIAGNOSIS\X0D\\X0A\RIGHT COLON, EXCISION:\X0D\\X0A\   - INVASIVE MUCINOUS ADENOCARCINOMA (8.5 CM, pT3, pN1c, pM1, SEE TEMPLATE).\X0D\\X0A\   - SURGICAL MARGINS FREE OF TUMOR.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Feb 5 2012] M.S. **NAME[VVV], M.D.\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09400 M8480 \X0D\\X0A\F: A: 88309",,"GROSS DESCRIPTION\X0D\\X0A\Received fresh, then placed in formalin, is a colectomy specimen labeled\X0D\\X0A\""right colon"". Two fragments are received; fragment 1, is a portion of small\X0D\\X0A\and large bowel encompassing the IC valve and fragment 2 is a portion of\X0D\\X0A\small bowel.\X0D\\X0A\Fragment 1 grossly shows a circumferential mass which constricts the lumen of\X0D\\X0A\the ascending colon, just beyond the IC valve.  Upon opening, an ulcerated\X0D\\X0A\area is noted along the corresponding mass, which appears to invade the\X0D\\X0A\mucosa, submucosa, muscularis propria.  Perforation is absent. Ulceration is\X0D\\X0A\yellow tan with areas of necrosis and has a serpentine raised border along\X0D\\X0A\the mucosa. A staple line was found along the terminal ileum which measures 4\X0D\\X0A\cm. There is also an appendix attached with no gross lesions which measures\X0D\\X0A\7.5 cm and 0.4 cm in diameter.  No fecalith is identified in the appendix on\X0D\\X0A\sectioning.\X0D\\X0A\Fragment 2, is an unoriented small bowel fragment which measures 15 x 4 x 2\X0D\\X0A\cm. The small bowel is grossly unremarkable with a pink serosal surface and\X0D\\X0A\pink tan mucosa. \X0D\\X0A\The remainder of the mucosal surface is unremarkable.  \X0D\\X0A\\X0D\\X0A\MEASUREMENTS:\X0D\\X0A\Length of bowel segment: 18 cm\X0D\\X0A\Average bowel circumference: in the colon is 10 cm and in the terminal ileum\X0D\\X0A\is 6 cm \X0D\\X0A\Mass dimensions: 8.5 x 3.5 x 4 cm\X0D\\X0A\Mass distance to:\X0D\\X0A\     proximal margin: 9 cm\X0D\\X0A\     ileocecal valve (if applicable): 3 cm\X0D\\X0A\     distal margin: 5.5 cm\X0D\\X0A\     radial/mesenteric margin: 3 cm\X0D\\X0A\Size of attached mesentery/mesorectum: 8 x 5 x 1.5 cm\X0D\\X0A\Size of the largest lymph nodes: 1.5 cm x 1 x 1 cm \X0D\\X0A\Number of candidate lymph nodes dissected: possible 16\X0D\\X0A\Serosal surface is inked blue\X0D\\X0A\Gross images are taken, both fragments\X0D\\X0A\REPRESENTATIVE SECTIONS:\X0D\\X0A\A1  proximal margin\X0D\\X0A\A2  distal margin\X0D\\X0A\A3  representative terminal ileum \X0D\\X0A\A4  representative terminal ileum \X0D\\X0A\A5  representative IC valve\X0D\\X0A\A6  representative IC valve\X0D\\X0A\A7  proximal IC valve to mass\X0D\\X0A\A8  proximal IC valve to mass\X0D\\X0A\A9  A10  representative mass and excrescences\X0D\\X0A\A11  A12  distal mass and normal colon\X0D\\X0A\A13  representative distal colon\X0D\\X0A\A14  appendix and tip with associated mesoappendix\X0D\\X0A\A15  representative omentum\X0D\\X0A\A16  largest node\X0D\\X0A\A17  four possible nodes\X0D\\X0A\A18  four possible nodes\X0D\\X0A\A19  three possible nodes\X0D\\X0A\A20  the small bowel staple line margins\X0D\\X0A\A21  representative small bowel\X0D\\X0A\A22 A37  possible lymph nodes\X0D\\X0A\rgc/**DATE[Feb 4 2012] K.K. **NAME[WWW], DO\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\COLORECTAL CANCER (template #5)\X0D\\X0A\(NOT for sarcoma, lymphoma, carcinoid tumor, and anal canal tumor) \X0D\\X0A\Last update **DATE[Mar 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Part of bowel resected or procedure:  right hemicolectomy\X0D\\X0A\Tumor site:  proximal ascending colon\X0D\\X0A\Tumor size:  8.5 x 3.5 x 4 cm\X0D\\X0A\Histologic type:      mucinous adenocarcinoma (>50% mucinous)\X0D\\X0A\Histologic grade:  not applicable (medullary, mucinous)\X0D\\X0A\\X0D\\X0A\Margins:         proximal margin:  negative\X0D\\X0A\         distal margin:  negative\X0D\\X0A\         radial (mesenteric) margin (circumferential radial margin for rectal\X0D\\X0A\cancer):  less than 1 mm from inked serosal\X0D\\X0A\             surface\X0D\\X0A\\X0D\\X0A\Macroscopic tumor perforation:    absent \X0D\\X0A\Extramural venous invasion:  macroscopic vascular invasion (V2)\X0D\\X0A\Intramural venous invasion:  present \X0D\\X0A\Lymph-vascular invasion:  present\X0D\\X0A\Perineural invasion:  not identified\X0D\\X0A\Peritumoral lymphoid response (Crohn-like response):  none \X0D\\X0A\Intratumoral lymphocytic response (tumor-infiltrating lymphocytes):  none \X0D\\X0A\Depth of invasion:  into subserosal soft tissue   \X0D\\X0A\Regional lymph node metastasis:  0 positive/6 total (only 6 nodes are\X0D\\X0A\identified with additional search and section submitted)  \X0D\\X0A\\X0D\\X0A\Tumor deposits (discontinuous extramural extension without histologic\X0D\\X0A\evidence of residual lymph node tissue or venous invasion):     present      \X0D\\X0A\\X0D\\X0A\Pathologic Staging (pTNM) (y: post-treatment, r: recurrent)\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\\X0D\\X0A\     pT3     Tumor invades through the muscularis propria into the\X0D\\X0A\pericolorectal  tissues\X0D\\X0A\\X0D\\X0A\Regional lymph nodes (pN): (If fewer than 13 lymph nodes, second search is\X0D\\X0A\required)\X0D\\X0A\         pN1c    Tumor deposit(s) in the subserosa, mesentery, or\X0D\\X0A\non-peritonealized pericolic or \X0D\\X0A\                              perirectal tissue without regional lymph node\X0D\\X0A\metastasis\X0D\\X0A\Distant metastasis (pM):\X0D\\X0A\            pM1     Distant metastasis (specify site(s), if known:  omentum \X0D\\X0A\***PATH-NUMBER[2])\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right colon,,
REG1,COLON,0,487886,1,,CLINICAL HISTORY\X0D\\X0A\Preop diagnosis:  colon cancer.  Intraoperative findings:  colon mass/cancer.\X0D\\X0A\ Procedure:  left colon resection.\X0D\\X0A\\X0D\\X0A\,"**INSTITUTION \X0D\\X0A\310 S. LIMESTONE\X0D\\X0A\**PLACE, KY  **ZIP-CODE\X0D\\X0A\ MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jul 3 1934] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Aug 12 2011] 00:00\X0D\\X0A\Receipt Date: **DATE[Aug 13 2011] 11:24\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE Fax:  **PHONE          ***PATH-NUMBER[1]\X0D\\X0A\Email:      \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY], MD     Service: SSG     Location: S4E\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Aug 14 2011] 14:18\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\SPLENIC FLEXURE, COLON, RESECTION:\X0D\\X0A\   - 4.7 CM ULCERATING MUCINOUS ADENOCARCINOMA EXTENDING THROUGH MUSCULARIS\X0D\\X0A\PROPRIA INTO\X0D\\X0A\    SUPERFICIAL SUBMUSCULAR FAT.\X0D\\X0A\   - PROXIMAL AND DISTAL LINES OF EXCISION NEGATIVE FOR TUMOR.\X0D\\X0A\   - INCIDENTAL 0.5 CM ADENOMATOUS POLYP.\X0D\\X0A\   - THIRTEEN LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/13).\X0D\\X0A\   - NO ANGIOLYMPHATIC OR PERINEURAL INVASION IDENTIFIED.\X0D\\X0A\   - STAGING:  pT3, N0.\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Aug 14 2011] **NAME[M. WWW], MD\X0D\\X0A\ \X0D\\X0A\Addendum:  A second search for lymph nodes after fixation in alcohol is\X0D\\X0A\conducted. Additional possible lymph nodes are submitted in A11 and A12 with\X0D\\X0A\additional sections of mesenteric fat for possible nodes in A13-A20.\X0D\\X0A\\X0D\\X0A\dlf/**DATE[Aug 14 2011] **NAME[M. WWW], MD\X0D\\X0A\  \X0D\\X0A\\X0D\\X0A\ \X0D\\X0A\ICD 9:   SNOMED CODES:\X0D\\X0A\A: M82100 M8480 \X0D\\X0A\\X0D\\X0A\F: A: 88309 \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled splenic flexure colon\X0D\\X0A\resection and consists of a grayish pink segment of large bowel measuring\X0D\\X0A\19.5 cm in length and ranging from 2.5 to 4 cm in diameter.  There are\X0D\\X0A\adhesions over the surface.  Yellow mesenteric and omental fat is adherent to\X0D\\X0A\one portion of the specimen measuring 20.5 x 4.5-5.5 x 3-4 cm.  It is\X0D\\X0A\unoriented as to distal or proximal.  It is opened to reveal a large\X0D\\X0A\fungating mass measuring 4.7 x 4.5 cm, approximately 1.5 cm in depth.  A\X0D\\X0A\metallic cylindrical object is present attached to the mucosa approximately 1\X0D\\X0A\cm from the mass measuring 1.5 x 0.2 cm.  The mass is 7.2 cm from one margin\X0D\\X0A\and 7.5 cm from another margin. On sectioning, the tumor shows a glistening\X0D\\X0A\mucoid appearance.  A 0.5 cm mucosal polyp is present approximately 3 cm from\X0D\\X0A\the tumor toward one margin.  No other mucosal lesions are identified.  On\X0D\\X0A\sectioning, the tumor appears to fill the muscularis propria with possible\X0D\\X0A\invasion into fat.  The closest radial mesenteric margin is 4 cm. The\X0D\\X0A\mesenteric fat and omentum is sectioned with relatively lymph nodes\X0D\\X0A\identified. It is set aside for alcohol formalin fixation with additional\X0D\\X0A\sections to be submitted. Summary of sections:  first margin  A1; second\X0D\\X0A\margin  A2; tumor sections  A3-A5; lymph nodes and polyp  A6; representative\X0D\\X0A\mesenteric fat for possible lymph nodes  A7-A10.  \X0D\\X0A\","MICROSCOPIC DESCRIPTION/COMMENT\X0D\\X0A\COLORECTAL CANCER (template #5)\X0D\\X0A\(NOT for sarcoma, lymphoma, carcinoid tumor, and anal canal tumor) \X0D\\X0A\Last update **DATE[Oct 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Part of bowel resected or procedure:  splenic flexure\X0D\\X0A\\X0D\\X0A\Tumor site:  splenic flexure\X0D\\X0A\\X0D\\X0A\Tumor size:  4.7 x 4.5 x 1.5 cm\X0D\\X0A\\X0D\\X0A\Histologic type:  mucinous adenocarcinoma (>50% mucinous)\X0D\\X0A\\X0D\\X0A\Histologic grade:  low grade \X0D\\X0A\          \X0D\\X0A\Margins:         proximal margin:  negative\X0D\\X0A\         distal margin:  negative\X0D\\X0A\         radial (mesenteric) margin (circumferential radial margin for rectal\X0D\\X0A\cancer): negative\X0D\\X0A\            If not involved, tumor distance to closest radial margin:  40 mm\X0D\\X0A\             \X0D\\X0A\Macroscopic tumor perforation:  absent \X0D\\X0A\\X0D\\X0A\Extramural venous invasion:  absent\X0D\\X0A\\X0D\\X0A\Intramural venous invasion:  absent\X0D\\X0A\\X0D\\X0A\Lymph-vascular invasion:  absent \X0D\\X0A\\X0D\\X0A\Perineural invasion:  absent \X0D\\X0A\\X0D\\X0A\Peritumoral lymphoid response (Crohn-like response):  mild to moderate\X0D\\X0A\\X0D\\X0A\Intratumoral lymphocytic response (tumor-infiltrating lymphocytes):  none\X0D\\X0A\\X0D\\X0A\Depth of invasion:  superficially into submuscular fat   \X0D\\X0A\\X0D\\X0A\Regional lymph node metastasis:  0 positive / 13 total  \X0D\\X0A\   \X0D\\X0A\Tumor deposits (discontinuous extramural extension without histologic\X0D\\X0A\evidence of residual lymph node tissue or venous invasion):     absent       \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Additional pathologic findings:  0.5 cm tubular adenoma\X0D\\X0A\\X0D\\X0A\Pathologic Staging (pTNM) (y: post-treatment, r: recurrent)\X0D\\X0A\\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\     \X0D\\X0A\     pT3     Tumor invades through the muscularis propria into the\X0D\\X0A\pericolorectal tissues\X0D\\X0A\\X0D\\X0A\Regional lymph nodes (pN): (If fewer than 13 lymph nodes, second search is\X0D\\X0A\required)\X0D\\X0A\\X0D\\X0A\     pN0     No regional lymph node metastasis\X0D\\X0A\     \X0D\\X0A\Distant metastasis (pM):\X0D\\X0A\\X0D\\X0A\          Not applicable     \X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: splenic flexure colon resection\X0D\\X0A\,,
REG1,COLON,0,487895,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is colon cancer. Operative findings: colon cancer.\X0D\\X0A\Operative procedure: laparoscopic possible open, total colectomy, possible\X0D\\X0A\ostomy.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\TP 1/FROZEN SECTION DIAGNOSIS #1:  ""POSITIVE FOR METASTATIC MUCINOUS\X0D\\X0A\ADENOCARCINOMA""---EYL.\X0D\\X0A\\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jul 27 1961] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[Aug 26 2012] 14:49\X0D\\X0A\Receipt Date: **DATE[Aug 26 2012] 14:49\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: H.D. **NAME[YYY], MD     Service: SGG     Location: 3MCC\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Aug 30 2012] 17:05\X0D\\X0A\RESIDENTS(S): J.D. **NAME[WWW], MD","DIAGNOSIS\X0D\\X0A\OMENTUM, EXCISION:\X0D\\X0A\   - METASTATIC ADENOCARCINOMA WITH MUCINOUS FEATURES.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Aug 30 2012] Y.M. **NAME[VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M84806 P1100 \X0D\\X0A\F: A: 88331 FS1, 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) omentum                \X0D\\X0A\Fixation: fresh for frozen\X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: fatty to firm\X0D\\X0A\Size(s): 3 x 3 x 0.8 cm.  It is palpated to reveal multiple firm nodules\X0D\\X0A\ranging from 0.6 to 1 cm in diameter. Touch prep is performed and the\X0D\\X0A\specimen representatively frozen as FS1.\X0D\\X0A\Cassette summary: entirely submitted frozen portion biowrapped A1, unfrozen\X0D\\X0A\portion A2  \X0D\\X0A\ksl/**DATE[Aug 29 2012] J.D. **NAME[WWW], MD\X0D\\X0A\J.G. Combs",MICROSCOPIC DESCRIPTION\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Omentum,,
REG1,COLON,0,488076,4,,Clinical Diagnosis and History\X0D\\X0A\The working history is colorectal cancer; abdominal pain. On exam: 1.5 cm flat\X0D\\X0A\pole polyp.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: BPSC Endoscopy\X0D\\X0A\GOODIN, C. DALE\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Colon, polyp\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[May 13 1987]. Distal ileum and right colon: Invasive moderately\X0D\\X0A\differentiated adenocarcinoma of the right colon with transmural invasion into\X0D\\X0A\the surrounding fat. Three small adenomatous polyps. (LDD)\X0D\\X0A\***PATH-NUMBER[2], **DATE[May 06 1987]. Biopsies polyp ascending colon-hepatic flexure:\X0D\\X0A\Adenocarcinoma. (JMc)",Final Diagnosis\X0D\\X0A\TRANSVERSE COLON POLYP:\X0D\\X0A\     Adenocarcinoma in situ involving a tubulovillous adenoma. Excisional\X0D\\X0A\margins free of adenomatous change.\X0D\\X0A\MHB/mbc,,"Gross Description\X0D\\X0A\The specimen, labeled transverse polyp, received in formalin, consists of a\X0D\\X0A\1.4x1.0x0.6 cm red/tan polyp. The resection margin is inked black, the specimen\X0D\\X0A\is bisected and submitted entirely in one cassette.\X0D\\X0A\HM/mbc",Microscopic Description\X0D\\X0A\Sections show adenomatous change involving tubular elongated glands with areas\X0D\\X0A\of carcinoma in situ. No definite stromal invasion is seen. The inked margins\X0D\\X0A\are free of adenomatous change or CIS.\X0D\\X0A\MHB/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488093,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is colon polyps.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY\X0D\\X0A\GENETIC COUNSELOR \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Appendix, other than incidental\X0D\\X0A\2: Colon,  Neoplasm of Uncertain Behavior","Final Diagnosis\X0D\\X0A\1.          VERMIFORM APPENDIX:\X0D\\X0A\     No significant histopathologic abnormalities.\X0D\\X0A\2.          RECTOSIGMOID COLON, SEGMENTAL RESECTION:\X0D\\X0A\     Polypectomy site without residual carcinoma. Metastatic adenocarcinoma in\X0D\\X0A\one of fourteen lymph nodes.\X0D\\X0A\MHB/mbc \X0D\\X0A\     COLON AND RECTUM \X0D\\X0A\DIAGNOSIS:  Adenocarcinoma per outside plolypectomy\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  segmental resection\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\TUMOR SITE:         rectosigmoid\X0D\\X0A\TUMOR SIZE (greatest dimension):  microscopic in a polyp per outside biopsy\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  n/a\X0D\\X0A\TUMOR CONFIGURATION:   polypoid per outside biopsy\X0D\\X0A\HISTOLOGIC TYPE:  adenocarcinoma\X0D\\X0A\HISTOLOGIC GRADE:  moderately differentiated\X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION:  into stalk of polyp and\X0D\\X0A\submucosa per outside biopsy\X0D\\X0A\PERITONEAL INVOLVEMENT:  n/a\X0D\\X0A\LYMPH/VASCULAR INVASION:   suspicious per outside biopsy\X0D\\X0A\PERINEURAL INVASION:   none seen\X0D\\X0A\SURGICAL MARGINS:  free\X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  4.5 and 8 cm\X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  at least 5.5 cm\X0D\\X0A\DISTANCE FROM DENTATE LINE (RECTAL TUMOR ONLY):  n/a\X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  no\X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED):  1/14\X0D\\X0A\EXTRANODAL EXTENSION: n/a  \X0D\\X0A\TREATMENT EFFECT:  n/a\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  n/a\X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  no deficiency of the mismatch repair proteins\X0D\\X0A\tested per outside report\X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 1 \X0D\\X0A\pN= 1a \X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIIA",,"Gross Description\X0D\\X0A\Specimen 1 labeled appendix, received in formalin, consists of a 7 cm in length\X0D\\X0A\by 0.9 cm in diameter tan tubular appendix with attached mesoappendix. The\X0D\\X0A\serosa is tan smooth and glistening with prominent vasculature. The resection\X0D\\X0A\margin is inked blue. Sectioning reveals a central lumen averaging 0.2 cm in\X0D\\X0A\diameter. The mucosa is tan and glistening. No masses or perforations are\X0D\\X0A\appreciated. Representative sections to include the inked resection margin,\X0D\\X0A\bisected tip and additional random cross sections are submitted in cassette 1. \X0D\\X0A\Specimen 2 labeled rectosigmoid colon, received in formalin, consists of a 14.5\X0D\\X0A\cm in length segment of colon with an abundant amount of attached tan/yellow\X0D\\X0A\lobular mesenteric fat. The colon is opened to reveal a 0.5 cm area of slightly\X0D\\X0A\firm bowel wall and an umbilicated area of mucosa consistent with the probable\X0D\\X0A\previous polypectomy site. This area is 8.0 and 4.5 cm from the surgical\X0D\\X0A\resection margins. Sectioning reveals black submucosal dye. No invasive tumor or\X0D\\X0A\polypoid lesions are identified. The remaining mucosa is tan and glistening with\X0D\\X0A\normal folds. This area is 5.5 cm from the closest radial resection margin.\X0D\\X0A\Representative sections are submitted. Summary of sections: 2A-2B  surgical\X0D\\X0A\resection margins taken en face; 2C  representative section of radial resection\X0D\\X0A\margin; 2D-2H  previous polypectomy site; 2I-2K  intact lymph nodes.  \X0D\\X0A\HM/mbc",Microscopic Description\X0D\\X0A\The appendix shows no inflammatory change or neoplasm. The mucosal and radial\X0D\\X0A\margins are free of tumor. Sections from the polypectomy site show black pigment\X0D\\X0A\within the submucosa and extending into the subserosal adipose tissue. No\X0D\\X0A\residual tumor is seen at the site. Fourteen lymph nodes are identified and one\X0D\\X0A\of these shows metastasis without extracapsular extension. \X0D\\X0A\MHB/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\PREVIOUS HISTORY     Date Ordered:     **DATE[Dec 17 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Dec 17 2011]     By:  **NAME[XXX WWW VVV]\X0D\\X0A\     Date Reported:     **DATE[Dec 17 2011]         \X0D\\X0A\Interpretation\X0D\\X0A\SEE SCANNED REFERENCE REPORT.  \X0D\\X0A\mbc\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[ZZZ, YYY M."
REG1,COLON,0,488133,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is obstructing colon tumor.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Colon, seg resection for tumor (incl. lymph nodes)","Final Diagnosis\X0D\\X0A\RIGHT COLON AND ILEUM, SEGMENTAL RESECTION:\X0D\\X0A\     Invasive moderately differentiated adenocarcinoma transmural extension.\X0D\\X0A\Excisional margins free of tumor. Eighteen lymph nodes negative for metastasis.\X0D\\X0A\See Template.\X0D\\X0A\COLON AND RECTUM \X0D\\X0A\DIAGNOSIS:  Adenocarcinoma\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Segmental resection.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact\X0D\\X0A\TUMOR SITE:         Right colon.\X0D\\X0A\TUMOR SIZE (greatest dimension):  3.5x3.0x0.6 cm.\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  Transmural.\X0D\\X0A\TUMOR CONFIGURATION:  Circumferential                    \X0D\\X0A\HISTOLOGIC TYPE:  Adenocarcinoma.\X0D\\X0A\HISTOLOGIC GRADE:  Moderately differentiated.\X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION:  Into the subserosal fat.\X0D\\X0A\PERITONEAL INVOLVEMENT:  No.\X0D\\X0A\LYMPH/VASCULAR INVASION:  None seen.\X0D\\X0A\PERINEURAL INVASION:   None seen.\X0D\\X0A\SURGICAL MARGINS:  Free.\X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  6 cm from distal\X0D\\X0A\margin.\X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  5.3 cm.\X0D\\X0A\DISTANCE FROM DENTATE LINE (RECTAL TUMOR ONLY):  N/A.\X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  N/A.\X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED):  0/18.\X0D\\X0A\EXTRANODAL EXTENSION:  N/A.\X0D\\X0A\TREATMENT EFFECT:  N/A.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  N/A.\X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  N/A.\X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  N/A.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 3\X0D\\X0A\pN= 0   \X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIA\X0D\\X0A\MHB/mbc",,"Gross Description\X0D\\X0A\Received in formalin labeled right colon and ileum is a right colectomy specimen\X0D\\X0A\including 4 cm of terminal ileum, cecal pouch, and 27 cm of right colon. There\X0D\\X0A\is an abundant amount of attached tan/yellow lobular mesenteric fat. The radial\X0D\\X0A\resection margin is inked black. The appendix is not present. The colon is\X0D\\X0A\opened to reveal a 3.5 x 3.0 x 0.6 cm circumferential mass, 21 cm from the\X0D\\X0A\proximal resection margin and 6 cm from the distal resection margin. The mass is\X0D\\X0A\5.3 cm from the closest radial resection margin. No definitive invasion into the\X0D\\X0A\underlying fat is identified. The bowel proximal to the mass is slightly\X0D\\X0A\dilated. The remaining mucosa is tan and glistening with normal folds. No other\X0D\\X0A\masses or suspicious lesions are appreciated. Representative sections are\X0D\\X0A\submitted. Summary of sections: A  proximal resection margin taken en face; B \X0D\\X0A\distal resection margin taken en face; C  representative section of radial\X0D\\X0A\resection margin; D-F  representative sections of mass to include points of\X0D\\X0A\deepest invasion; G-H  intact mesenteric nodes.  **INITIALS",Microscopic Description\X0D\\X0A\The mucosal and radial margins are free of tumor. The tumor extends through the\X0D\\X0A\wall into the surrounding fat. No definite vascular space invasion is seen.\X0D\\X0A\Eighteen lymph nodes are identified and none of these show metastasis. \X0D\\X0A\MHB/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488138,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is colon cancer and gallstones.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Colon,  Neoplasm of Uncertain Behavior\X0D\\X0A\2: Gallbladder","Final Diagnosis\X0D\\X0A\RIGHT COLON, SEGMENTAL RESECTION: \X0D\\X0A\     Invasive signet ring cell adenocarcinoma with extension through the\X0D\\X0A\muscularis propria. Margins free of tumor. Unremarkable vermiform appendix.\X0D\\X0A\Metastatic adenocarcinoma involving two of twenty lymph nodes. \X0D\\X0A\GALLBLADDER: \X0D\\X0A\     Chronic cholecystitis with cholelithiasis. \X0D\\X0A\COLON AND RECTUM \X0D\\X0A\DIAGNOSIS:  Invasive signet ring cell adenocarcinoma. \X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Right colectomy with cholecystectomy. \X0D\\X0A\SPECIMEN INTEGRITY:  Intact. \X0D\\X0A\TUMOR SITE:         Right colon. \X0D\\X0A\TUMOR SIZE (greatest dimension):  2.8 x 2.5 x 0.8 cm. \X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  To serosa.\X0D\\X0A\TUMOR CONFIGURATION:   Flattened and polypoid. \X0D\\X0A\HISTOLOGIC TYPE:  Signet ring cell adenocarcinoma. \X0D\\X0A\HISTOLOGIC GRADE:  Poorly differentiated. \X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION:  Through muscularis propria. \X0D\\X0A\PERITONEAL INVOLVEMENT:  No. \X0D\\X0A\LYMPH/VASCULAR INVASION:  Present. \X0D\\X0A\PERINEURAL INVASION:   None seen. \X0D\\X0A\SURGICAL MARGINS:  Free. \X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  11.5 cm from distal\X0D\\X0A\margin. \X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  5 cm. \X0D\\X0A\DISTANCE FROM DENTATE LINE (RECTAL TUMOR ONLY):  N/A. \X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION): N/A. \X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED):  2/20. \X0D\\X0A\EXTRANODAL EXTENSION:  No. \X0D\\X0A\TREATMENT EFFECT:  N/A. \X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  N/A. \X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  N/A. \X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  N/A \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=3 \X0D\\X0A\pN=1b   \X0D\\X0A\AJCC PATHOLOGIC STAGE: IIIB \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled right colon and umbilical hernia for\X0D\\X0A\permanent is a right colectomy specimen including 6 cm of terminal ileum, cecal\X0D\\X0A\pouch, and 20 cm of right colon. There is an abundant amount of attached\X0D\\X0A\tan/yellow lobular mesenteric fat. The appendix is present and measures 4 cm in\X0D\\X0A\length by 0.7 cm in diameter. The colon is opened to reveal a 2.8 x 2.5 x 0.8 cm\X0D\\X0A\flattened polypoid mass, 9 cm from the proximal resection margin and 11.5 cm\X0D\\X0A\from the distal resection margin. Sectioning reveals invasion into the\X0D\\X0A\underlying muscle. The mass is greater than 5 cm from the radial resection\X0D\\X0A\margin. The remaining mucosa is tan and glistening with normal folds. No other\X0D\\X0A\masses or suspicious lesions are appreciated. There is no hernia sac identified.\X0D\\X0A\Several lymph nodes are identified in the fat. Representative sections are\X0D\\X0A\submitted. Summary of sections: A  proximal resection margin taken en face; B \X0D\\X0A\distal resection margin taken en face; C  radial resection margin; D  appendix;\X0D\\X0A\E-G  mass to include points of deepest invasion; H  bisected lymph node; I-J \X0D\\X0A\multiple intact lymph nodes. \X0D\\X0A\Specimen 2 received in formalin labeled gallbladder for permanent is a 9.5 x 4.0\X0D\\X0A\x 3.0 cm intact gallbladder with attached cystic duct. The serosa is tan/purple\X0D\\X0A\and wrinkled with prominent vasculature. The lumen contains a moderate amount of\X0D\\X0A\dark green viscid bile and several yellow multifaceted choleliths averaging 1.5\X0D\\X0A\cm in greatest dimension. The mucosa is dark green and trabecular and the wall\X0D\\X0A\thickness averages 0.3 cm. No masses are appreciated. Representative sections to\X0D\\X0A\include the cystic duct margin, neck, body and fundus are submitted in cassette\X0D\\X0A\2.  **INITIALS",Microscopic Description\X0D\\X0A\The mucosal and radial margins are free of tumor. The appendix shows no active\X0D\\X0A\inflammatory change or tumor. The tumor is a signet ring type adenocarcinoma. It\X0D\\X0A\infiltrates through the muscular wall and focal transmural extension is seen.\X0D\\X0A\Twenty lymph nodes are identified and two of these show metastasis without\X0D\\X0A\extracapsular extension. \X0D\\X0A\The gallbladder shows muscular hypertrophy with mild chronic inflammation. No\X0D\\X0A\tumor is seen. **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488178,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is positive hemoccult.  On endoscopic examination, Dr.\X0D\\X0A\**NAME[ZZZ] found for specimen 1 sessile polyp and for specimen 2 circumferential\X0D\\X0A\mass in splenic flexure consistent with adenocarcinoma.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: BPSC Endoscopy\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Colon, polyp\X0D\\X0A\2: Colon, biopsy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Mar 13 05]: SIGMOID COLON POLYP: Tubular adenoma.  (JFJ)",Final Diagnosis\X0D\\X0A\1.  DESCENDING COLON POLYP: \X0D\\X0A\     Tubular adenoma. \X0D\\X0A\2.  HEPATIC FLEXURE MASS: \X0D\\X0A\     Invasive moderately differentiated adenocarcinoma. See Comment. \X0D\\X0A\COMMENT: This diagnosis was called to **NAME[YYY XXX] in Dr. **NAME[ZZZ]'s office on\X0D\\X0A\**DATE[May 10 12] at 10:28 a.m. by **NAME[WWW VVV]. \X0D\\X0A\**INITIALS,,Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled descending polyp is a 0.6 x 0.3 x 0.3cm\X0D\\X0A\tan polyp which is submitted in toto in cassette 1.\X0D\\X0A\Specimen 2 received in formalin labeled splenic flexure mass biopsy are multiple\X0D\\X0A\tan soft tissue fragments aggregating 1.0 x 0.8 x 0.2cm which are submitted in\X0D\\X0A\toto in cassette 2.  **INITIALS,Microscopic Description\X0D\\X0A\Sections show adenomatous change involving tubular glands without high grade\X0D\\X0A\dysplasia. \X0D\\X0A\Sections show an invasive adenocarcinoma. The tumor shows infiltrating malignant\X0D\\X0A\glands within a desmoplastic and inflamed stroma. **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[UUU, TTT M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488184,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is invasive adenocarcinoma.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Colon,  Neoplasm of Uncertain Behavior","Final Diagnosis\X0D\\X0A\RIGHT COLON RESECTION:\X0D\\X0A\     Invasive moderately differentiated adenocarcinoma with extension into the\X0D\\X0A\submucosa.  \X0D\\X0A\     No muscularis propria involvement or marginal involvement is seen.  \X0D\\X0A\     Thirteen lymph nodes negative for metastasis.\X0D\\X0A\     See TEMPLATE.\X0D\\X0A\**INITIALS\X0D\\X0A\COLON AND RECTUM TEMPLATE:\X0D\\X0A\DIAGNOSIS: adenocarcinoma  \X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE: segmental resection  \X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\TUMOR SITE:         right colon     \X0D\\X0A\TUMOR SIZE (greatest dimension):  1.0 x 1.0 x 0.7 cm\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  minimal\X0D\\X0A\TUMOR CONFIGURATION:   ulcerated and flat\X0D\\X0A\HISTOLOGIC TYPE:  adenocarcinoma\X0D\\X0A\HISTOLOGIC GRADE:  moderately differentiated\X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION: into submucosa  \X0D\\X0A\PERITONEAL INVOLVEMENT:  no\X0D\\X0A\LYMPH/VASCULAR INVASION:  none seen\X0D\\X0A\PERINEURAL INVASION:   none seen\X0D\\X0A\SURGICAL MARGINS:  free\X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  7cm from proximal\X0D\\X0A\margin\X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  5 cm\X0D\\X0A\DISTANCE FROM DENTATE LINE (RECTAL TUMOR ONLY):  n/a\X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  n/a\X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED):  0/13\X0D\\X0A\EXTRANODAL EXTENSION:  n/a\X0D\\X0A\TREATMENT EFFECT:  n/a\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS: n/a \X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  n/a\X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 1 \X0D\\X0A\pN= 0  \X0D\\X0A\AJCC PATHOLOGIC STAGE:  I\X0D\\X0A\MHB",,Gross Description\X0D\\X0A\Received in formalin labeled right colon is a right colectomy specimen including\X0D\\X0A\4 cm of terminal ileum and 23 cm of attached right colon. There is an abundant\X0D\\X0A\amount of attached tan/yellow lobular mesenteric fat. The appendix is not\X0D\\X0A\present. The colon is opened to reveal a 0.5 cm in greatest dimension mucosa\X0D\\X0A\defect surrounded by black ink. This area is consistent with the previous\X0D\\X0A\polypectomy site. This area is 12.5 cm from the proximal resection margin and 15\X0D\\X0A\cm from the distal resection margin. No polyp or invasive tumor is identified\X0D\\X0A\grossly in this area. There is a second area of submucosal ink 3 cm from the\X0D\\X0A\polypectomy site. No invasive tumor is identified in this area. The second area\X0D\\X0A\is greater than 10 cm from both the proximal and distal resection margins. Both\X0D\\X0A\of the areas are greater than 5 cm from the radial/mesenteric resection margin.\X0D\\X0A\There is a 1.0 x 1.0 x 0.4 cm flattened centrally ulcerated mass identified 2 cm\X0D\\X0A\from the two previously described polypectomy site. This area is consistent with\X0D\\X0A\an area of invasive tumor and is located 7 cm from the proximal resection margin\X0D\\X0A\and greater than 15 cm from the distal resection margin. No invasion into the\X0D\\X0A\underlying fat is identified and the area is greater than 5 cm from the radial\X0D\\X0A\resection margin. The remaining mucosa is tan and glistening with normal folds.\X0D\\X0A\No other masses or suspicious lesions are appreciated. Representative sections\X0D\\X0A\are submitted. Summary of sections: A  proximal resection margin taken en face;\X0D\\X0A\B  distal resection margin taken en face; C  radial resection margin; D-E \X0D\\X0A\invasive tumor; F-H  polypectomy sites; I-J  intact lymph nodes.  **INITIALS,Microscopic Description\X0D\\X0A\The mucosal and radial margins are free of tumor.  The lesion in blocks D and E\X0D\\X0A\shows an invasive adenocarcinoma which extends into the submucosa only.  No deep\X0D\\X0A\invasion is seen.  Sections from the additional biopsy sites show some pigment\X0D\\X0A\within the submucosal stroma with some reactive changes but no adenomatous\X0D\\X0A\change or invasive tumor is seen.  Thirteen lymph nodes are identified and none\X0D\\X0A\of these show metastasis.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488310,1,,CLINICAL HISTORY:\X0D\\X0A\Colonic perforation.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   SEGMENTAL COLON RESECTION WITH OMENTUM:  POORLY DIFFERENTAITED\X0D\\X0A\ADENOCARCINOMA\X0D\\X0A\1.   TUMOR SIZE:  8.5 x 7.5 x 6.0 cm. grossly.\X0D\\X0A\2.   TUMOR GRADE:  Poorly differentiated mucin producing adenocarcinoma\X0D\\X0A\with clear cell and signet ringed cell features (G3).\X0D\\X0A\3.   MARGINS OF EXCISION AND EXTENT:  Adenocarcinoma extends to the\X0D\\X0A\margins of excision.\X0D\\X0A\a.   Adenocarcinoma extends through perforated viscous deeply into\X0D\\X0A\perinephric fat and soft tissues.\X0D\\X0A\b.   Adenocarcinoma extends to involve the radial shave margin.\X0D\\X0A\c.   Adenocarcinoma extensively involves the serosal fat extending to\X0D\\X0A\the peripheral fatty soft tissue margin of excision.\X0D\\X0A\d.   The proximal and distal epithelial margins of excision are negative\X0D\\X0A\for involvement by carcinoma.\X0D\\X0A\e.   Extensive capillary lymphatic space invasion by carcinoma is\X0D\\X0A\identified.\X0D\\X0A\f.   Focal perineural invasion by carcinoma is identified.\X0D\\X0A\4.   LYMPH NODES:  Thirteen of nineteen (13/19) lymph nodes/lymph node\X0D\\X0A\aggregates involved by metastatic carcinoma.\X0D\\X0A\a.   Extensive perinodal extension is identified.\X0D\\X0A\b.   Extramural tumor nodules are identified grossly and microscopically\X0D\\X0A\(v2).\X0D\\X0A\5.   ADDITIONAL FINDINGS:\X0D\\X0A\a.   Omental tissue with foci of metastatic poorly differentiated\X0D\\X0A\adenocarcinoma.\X0D\\X0A\6.   PATHOLOGIC STAGE:  pT4a, N2b, M1 (G3).\X0D\\X0A\B. 'SPLEEN':\X0D\\X0A\     1. Benign congested splenic tissue with gross splenomegaly,\X0D\\X0A\246-grams.\X0D\\X0A\     2. Focal capsular perforation/rupture with\X0D\\X0A\        extravasated red cells with focal pericapsular\X0D\\X0A\        hemorrhage.\X0D\\X0A\     3. No definitive metastatic carcinoma identified by\X0D\\X0A\        routine staining.\X0D\\X0A\     4. Two perihilar lymph node aggregates identified,\X0D\\X0A\        negative for metastatic carcinoma (0/2).\X0D\\X0A\ \X0D\\X0A\Colon and Rectum\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: COLON, SEGMENTAL\X0D\\X0A\ \X0D\\X0A\Specimen Type: Not specified\X0D\\X0A\Tumor Size:    Greatest dimension: 8.5cm x 7.5cm x 6cm\X0D\\X0A\Histologic Type:    Adenocarcinoma\X0D\\X0A\Histologic Grade:   High-grade (poorly differentiated to\X0D\\X0A\undifferentiated)\X0D\\X0A\Primary Tumor (pT): pT4a\X0D\\X0A\Regional Lymph Nodes (pN):    pN2\X0D\\X0A\Specify: Number examined:     19\X0D\\X0A\Number involved:    13\X0D\\X0A\Distant Metastasis (pM): pM1\X0D\\X0A\site(s):  omental tissue\X0D\\X0A\Margins:  Circumferential (Radial) Margin:\X0D\\X0A\Involved by invasive carcinoma (tumor present 0-1 mm from CRM)\X0D\\X0A\Mesenteric Margin:  Involved by invasive carcinoma\X0D\\X0A\Lymphatic [small vessel] Invasion  (L): Present\X0D\\X0A\Venous [large vessel] Invasion (V):     Present\X0D\\X0A\Perineural invasion:     Present\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (JT)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Aug 05 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received in formalin designated 'colonic perforation/mass'\X0D\\X0A\is an unoriented segment of large bowel with attached mass of omental\X0D\\X0A\tissue with dense fibrous adhesions.  A gross perforation is identified\X0D\\X0A\along the length of the specimen.  As previously mentioned no\X0D\\X0A\orientation is provided.  The more narrow stapled end of the specimen\X0D\\X0A\measures up to 4.0 cm in diameter.  The opposing end is dilated and\X0D\\X0A\ischemic appearing measuring 9.0 cm in diameter.  The site of\X0D\\X0A\perforation is located 13.0 cm from the more viable smaller surgical\X0D\\X0A\margin.  The site of perforation measures up to 2.5 cm in single\X0D\\X0A\greatest dimension.  Surrounding necrosis and induration with potential\X0D\\X0A\mass extends to the radial margin of excision.  Representative sections\X0D\\X0A\from the smaller diameter surgical margin are submitted in cassette A1\X0D\\X0A\and a larger diameter surgical margin submitted in cassette A2.\X0D\\X0A\Representative sections from the site of perforation are submitted in\X0D\\X0A\cassettes A3 and A4.  The relatively large segment of omental tissue\X0D\\X0A\measures 25.5 x 17.5 x 2.0 cm.  Sectioning through the omental tissue\X0D\\X0A\discloses no discrete mass.  A random representative section of apparent\X0D\\X0A\benign appearing omental tissue is submitted in cassette A5.  The\X0D\\X0A\specimen is opened in a longitudinal fashion disclosing a markedly\X0D\\X0A\edematous mucosal surface. There is a large perforated centrally\X0D\\X0A\necrotic and ulcerated colon mass identified. The circumferential mass\X0D\\X0A\measures approximately 8.5 cm in circumference by 6.0 cm by 7.5 cm.  The\X0D\\X0A\lesion extends deeply through the wall of the colon and extends to the\X0D\\X0A\site of perforation and adjacent radial margin. The tumor grossly\X0D\\X0A\extends into the pericolic fat. Tumor is submitted in cassettes A6-A9.\X0D\\X0A\No other discrete mass lesions are identified.  Careful palpation\X0D\\X0A\through the pericolic fat discloses indurated white nodules measuring up\X0D\\X0A\to 1.0 cm in single greatest dimension.  All potential lymph nodes are\X0D\\X0A\submitted in cassettes A10 through A17.\X0D\\X0A\Specimen (B) Received in formalin designated 'spleen' is a 246 gram\X0D\\X0A\spleen. There is some clotted blood adherent to the hilum of the spleen.\X0D\\X0A\There is focal disruption of the capsule near one edge of the specimen.\X0D\\X0A\The capsule disruption measures approximately 2.5 x 0.5 cm and is\X0D\\X0A\associated with subcapsular hemorrhage.  Representative sections from\X0D\\X0A\the hilum margin are submitted in cassette B3.  Representative sections\X0D\\X0A\from the small site of perforation are submitted in cassette B3. The\X0D\\X0A\spleen measures 12.0 x 9.3 x 3.0 cm.  Sectioning through the remainder\X0D\\X0A\portion of the spleen discloses homogenous maroon cut surface without\X0D\\X0A\hemorrhage, necrosis or discrete mass lesion.  Additional representative\X0D\\X0A\sections of the spleen are submitted in cassettes B3 and B4.  (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 21",,"SPECIMEN(S): A COLON, SEGMENTAL\X0D\\X0A\SPECIMEN(S): B Spleen",,
REG1,COLON,0,488432,1,,"CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\CA OF RECTUM, MENORRHAGIA\X0D\\X0A\","SURGEON            \X0D\\X0A\\X0D\\X0A\DR. **NAME[ZZZ] WALKER\X0D\\X0A\\X0D\\X0A\SPECIMEN/PROCEDURE:\X0D\\X0A\    SIGMOID COLON, RECTUM AND ANUS, ABDOMINAL PERINEAL RESECTION.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\    RECTUM (TWO TUMORS).\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\    5.5 X 5.0 CM(LARGER TUMOR)\X0D\\X0A\    A SECOND RECTAL SQUAMOUS CELL CARCINOMA INVOLVES THE RIGHT LOWER\X0D\\X0A\RECTUM TO THE LEVEL OF THE SQUAMOCOLUMNAR JUNCTION DISTALLY. THE\X0D\\X0A\    SECOND TUMOR MEASURES 11 MM (BLOCK 8).\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:\X0D\\X0A\    NOT IDENTIFIED.\X0D\\X0A\HISTOLOGIC TYPE:\X0D\\X0A\    SQUAMOUS CELL CARCINOMA, TWO TUMORS.\X0D\\X0A\HISTOLOGIC GRADE:\X0D\\X0A\    LOW-GRADE (MODERATELY DIFFERENTIATED).\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[YYY,XXX M]\X0D\\X0A\   1169 Eastern Pkwy\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 29 12]                 **PLACE Clinical Associates                    PAGE:   5\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA] L               DOB: **DATE[Jan 20 1959]   Sex: F\X0D\\X0A\Add:1222 **PLACE,KY **ZIP-CODE  **PHONE                                                              \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  ADM IN    Location:  D.3ES      D.3215-1    \X0D\\X0A\Reg:   **DATE[Jun 15 12]     Disch:           SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[CCC:YYY,XXX] B          Submit:**NAME[YYY,XXX] B               MDPhone:  **PHONE     \X0D\\X0A\Address: 1169 Eastern Pkwy               **PLACE                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:  (Continued)\X0D\\X0A\\X0D\\X0A\   **NAME[WWW,VVV M]\X0D\\X0A\   3425 Stoney Spring Circle\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   Walker,**NAME[DDD ZZZ]\X0D\\X0A\   **STREET-ADDRESS Dr #450\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS, 88309GS\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\CARCINOMA OF COLON AND RECTUM SYNOPTIC REPORT AJCC/UICC TNM, 7th edition\X0D\\X0A\\X0D\\X0A\SPECIMEN/PROCEDURE:\X0D\\X0A\SIGMOID COLON, RECTUM AND ANUS, ABDOMINAL PERINEAL RESECTION.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\RECTUM (TWO TUMORS).\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\5.5 X 5.0 CM(LARGER TUMOR)\X0D\\X0A\A SECOND RECTAL SQUAMOUS CELL CARCINOMA INVOLVES THE RIGHT LOWER\X0D\\X0A\RECTUM TO THE LEVEL OF THE SQUAMOCOLUMNAR JUNCTION DISTALLY. THE\X0D\\X0A\SECOND TUMOR MEASURES 11 MM (BLOCK 8).\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\HISTOLOGIC TYPE:\X0D\\X0A\SQUAMOUS CELL CARCINOMA, TWO TUMORS.\X0D\\X0A\HISTOLOGIC GRADE:\X0D\\X0A\LOW-GRADE (MODERATELY DIFFERENTIATED).\X0D\\X0A\MICROSCOPIC TUMOR EXTENSION:\X0D\\X0A\TUMOR INVADES THROUGH MUSCULARIS PROPRIA AND INTO NON-PERITONEALIZED\X0D\\X0A\PERIRECTAL SOFT TISSUE AND EXTENDS ANTERIORLY TO THE VAGINAL WALL\X0D\\X0A\(LARGER TUMOR).\X0D\\X0A\THE SECOND SMALLER TUMOR EXTENDS INTO BUT NOT THROUGH MUSCLE WALL.\X0D\\X0A\MARGINS:\X0D\\X0A\PROXIMAL MARGIN IS NEGATIVE FOR INVASIVE AND IN SITU CARCINOMA.\X0D\\X0A\DISTAL MARGIN IS NEGATIVE FOR INVASIVE AND IN SITU CARCINOMA.\X0D\\X0A\CIRCUMFERENTIAL (RADIAL) MARGIN IS NEGATIVE FOR CARCINOMA. TUMOR IS 4 MM\X0D\\X0A\FROM THE NEAREST RADIAL MARGIN (BLOCK 31).\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\NO PRIOR TREATMENT.\X0D\\X0A\LYMPHATIC/VASCULAR INVASION:\X0D\\X0A\PRESENT (IN A LYMPH NODE CAPSULE).\X0D\\X0A\PERINEURAL INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\DISCONTINUOUS EXTRAMURAL EXTENSION:\X0D\\X0A\PRESENT.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\MICROMETASTATIC CARCINOMA (0.25 MM) TO ONE OF FOURTEEN LYMPH NODES,\X0D\\X0A\INVOLVING CAPSULAR LYMPHATIC SPACE AND SINUS.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  mpT4b pN1a Mn/a.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:\X0D\\X0A\ADENOMA OF DISTAL RECTAL MUCOSA.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\UTERUS AND CERVIX WITH BILATERAL FALLOPIAN TUBES AND OVARIES:\X0D\\X0A\BENIGN CERVIX AND ENDOCERVIX.\X0D\\X0A\BENIGN SECRETORY ENDOMETRIUM WITH ADENOMYOSIS.\X0D\\X0A\BENIGN FALLOPIAN TUBES AND OVARIES BILATERALLY WITH ENDOMETRIOSIS\X0D\\X0A\I            NVOLVING THE LEFT FALLOPIAN TUBE.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Reviewed for QA (GK).\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received fresh designated ""TAH, BSO, abdominal perineal resection"" are two separate\X0D\\X0A\specimens in the container; first is a uterus with cervix and bilateral fallopian tubes and\X0D\\X0A\ovaries weighing 300 grams.  Also received is an **DATE[Mar] specimen including colon, rectum and\X0D\\X0A\anus.  Attached vagina is present anteriorly.  Dr. **NAME[UUU] demonstrated the connection\X0D\\X0A\between the two specimens and the anterior portion of the uterus is inked blue for\X0D\\X0A\orientation.  The segment of bowel, including anus, measures 45 cm in length.  The proximal\X0D\\X0A\portion consists of colon and is closed with a staple line.  The distal end is anus\X0D\\X0A\consisting of skin closed with a suture.  The distal portion of the specimen is\X0D\\X0A\retroperitoneal. Anteriorly, located 9.0 cm from the distal margin is a 5.2 x 5.2 cm diamond\X0D\\X0A\shaped area of attached vagina with staple lines.  It has been somewhat torn but appears to\X0D\\X0A\entirely cover the underlying rectum and tumor.  A palpable mass is identified beginning\X0D\\X0A\approximately 8 cm from the distal margin with possible thickening of the distal rectal\X0D\\X0A\portion for a length of approximately 2.0 cm beginning 3 cm from the anal margin.  The\X0D\\X0A\specimen is placed in formalin for fixation and further dictation.\X0D\\X0A\\X0D\\X0A\Following fixation, the specimen is re-examined.  The fixed abdominal perineal resection\X0D\\X0A\specimen including anus, rectum and sigmoid colon in the fixed state measures 38.0 cm.  The\X0D\\X0A\distal 11.4 cm consist of lower rectum and anus which is totally non-peritonealized.  Near\X0D\\X0A\the lower end of the peritoneal reflection 12.0 cm from the distal margin, the peritoneum\X0D\\X0A\has been torn for a length of 3.5 cm.  As previously described, the anterior rectum is\X0D\\X0A\partially covered by an irregular roughly diamond shaped of piece of vagina.  The upper\X0D\\X0A\portion of this piece of vaginal wall is torn and contains sutures.  Posteriorly, the\X0D\\X0A\peritoneal reflection is identified and the distal 18.0 cm posteriorly are retroperitoneal.\X0D\\X0A\The mesorectum is identified posteriorly 7.0 cm from the distal margin of resection and\X0D\\X0A\appears intact.\X0D\\X0A\\X0D\\X0A\The margins are inked as follows:  anterior deep margin with vaginal mucosa - black;\X0D\\X0A\corresponding lower uterine segment and cervix - black; proximal peritoneum - blue; distal\X0D\\X0A\adventitia including mesorectum - green. The specimen is opened and the squamocolumnar\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\junction is 3 cm from the distal margin. The tumor measures 5.5 x 5.0 x 2.4 cm.  It is\X0D\\X0A\pink-red and firm, has an irregular shape and it is entirely circumferential in the rectum.\X0D\\X0A\It is grossly located above the squamocolumnar junction.  It grossly extends through muscle\X0D\\X0A\wall, and possibly to the deep margin.  The distal margin is located 5.5 cm from the tumor.\X0D\\X0A\The proximal margin is 25.5 cm from the tumor.  The peritoneal margin is 7.0 cm from the\X0D\\X0A\tumor.  Proximal to the squamocolumnar junction the rectal mucosa appears somewhat\X0D\\X0A\redundant.\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\1.        proximal margin\X0D\\X0A\2.        distal margin with anal skin\X0D\\X0A\3.        peritoneal margin\X0D\\X0A\4\T\5.        soft tissue proximal to vaginal wall\X0D\\X0A\Representative sections distal to the gross tumor from anus to rectum are submitted by\X0D\\X0A\quadrants in cassettes 6-29 as follows:\X0D\\X0A\6\T\7.        12-9:00 distal (anterior to right side)\X0D\\X0A\8\T\9.        12-9:00 mid\X0D\\X0A\10\T\11.        12-9:00 upper\X0D\\X0A\12\T\13.        9-6:00 distal (right to posterior)\X0D\\X0A\14\T\15.        9-6:00 mid\X0D\\X0A\16\T\17.        9-6:00 upper\X0D\\X0A\18\T\19.        12-3:00 distal (anterior to left)\X0D\\X0A\20\T\21.        12-3:00 mid\X0D\\X0A\22\T\23.        12-3:00 upper\X0D\\X0A\24\T\25.        3-6:00 distal (left to posterior)\X0D\\X0A\26\T\27.        3-6:00 mid\X0D\\X0A\28\T\29.        3-6:00 upper\X0D\\X0A\The remainder of the specimen is sectioned as follows:\X0D\\X0A\30.        redundant colonic mucosa\X0D\\X0A\31.        full thickness section to include radial margin\X0D\\X0A\32\T\33.        tumor and vaginal mucosa\X0D\\X0A\34.        partially detached vaginal mucosa\X0D\\X0A\35-37.        tumor with radial margins\X0D\\X0A\38.        random proximal colon\X0D\\X0A\\X0D\\X0A\Fourteen possible nodes are identified ranging in size from 0.5 up to 2.3 cm in greatest\X0D\\X0A\dimension.\X0D\\X0A\\X0D\\X0A\They are submitted as follows:\X0D\\X0A\39.        four small nodes\X0D\\X0A\40.        four small nodes\X0D\\X0A\41.        bisected nodes\X0D\\X0A\42.        one node\X0D\\X0A\43.        one sectioned node\X0D\\X0A\44.        two nodes\X0D\\X0A\45\T\46.        largest node sectioned\X0D\\X0A\\X0D\\X0A\Received is a round detached uterus with a smooth shiny serosa with a few adhesions.  The\X0D\\X0A\uterus measures 9.0 x 7.5 x 5.5 cm.  The cervix is unremarkable and measures 3.5 x 3.0 cm.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\It has a 0.3 cm slit-like os.  The os is slightly stenotic.  The ovaries and fallopian tubes\X0D\\X0A\are attached.  The uterus is opened to reveal a tan, triangular endometrium measuring 3.5 x\X0D\\X0A\5.0 cm with a maximum endometrial thickness of 0.2 cm.  The myometrium is sectioned and has\X0D\\X0A\a maximum thickness of 4.3 cm.  The endocervical canal is unremarkable.\X0D\\X0A\\X0D\\X0A\The right ovary and fallopian tube weigh 12.0 grams.  The ovary has a dusky, gray-purple\X0D\\X0A\appearance and multiple serosal cysts ranging in size from 0.5 to 1.3 cm in greatest\X0D\\X0A\dimension.  They all contain clear fluid and smooth shiny walls.  The ovary measures 2.0 x\X0D\\X0A\2.0 x 1.5 cm.  It is sectioned and the cut surfaces are unremarkable.  The attached\X0D\\X0A\fimbriated fallopian tube measures 6.0 cm in length with a diameter ranging in size from 0.5\X0D\\X0A\to 0.7 cm.\X0D\\X0A\\X0D\\X0A\The left ovary weighs 18.0 grams.  The ovary has a dusky, purple-blue appearance and\X0D\\X0A\measures 1.6 x 1.4 x 1.0 cm.  The ovary is sectioned and the cut surfaces reveal two cystic\X0D\\X0A\areas and possible corpora lutea.  The smaller measures 1.3 cm in diameter and the larger\X0D\\X0A\measures 1.5 cm in diameter.  The attached fimbriated fallopian tube measures 5.0 cm in\X0D\\X0A\length with a diameter ranging in size from 0.4 up to 0.6 cm.\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\47.        anterior cervix\X0D\\X0A\48.        posterior cervix\X0D\\X0A\49.        anterior myometrium\X0D\\X0A\50\T\51.        posterior myometrium, bisected\X0D\\X0A\52.        anterior lower uterine segment\X0D\\X0A\53.        posterior lower uterine segment\X0D\\X0A\54.        right ovary and tube\X0D\\X0A\55.        left ovary and tube            **INITIALS\X0D\\X0A\\X0D\\X0A\Upon re-examination of the specimen, tumor is identified on the right side of the lower\X0D\\X0A\rectum, distal to the larger tumor.  Further sectioning reveals tumor located at the\X0D\\X0A\squamocolumnar junction, 3.0 cm from the distal proximal margin.  There is also a possible 5\X0D\\X0A\mm tan-white tumor nodule identified along one cauterized edge of the specimen.  Violet ink\X0D\\X0A\is placed on the cauterized surface for identification.\X0D\\X0A\\X0D\\X0A\The remaining anus is identified.\X0D\\X0A\\X0D\\X0A\Additional representative sections from the specimen are submitted as follows:\X0D\\X0A\\X0D\\X0A\56\T\57.        described possible nodule, lower rectum\X0D\\X0A\58.        tumor at squamo-columnar junction\X0D\\X0A\59.        unremarkable squamo-columnar junction         **INITIALS\X0D\\X0A\",,"SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\TAH, BSO, ABDOMINAL PERINEAL RESECTION\X0D\\X0A\",,
REG1,COLON,0,488711,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is colon CA.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Colon,  Neoplasm of Uncertain Behavior\X0D\\X0A\2: Omentum, resection other than for tumor\X0D\\X0A\Previous Pertinent History\X0D\\X0A\S11022358, **DATE[Oct 18 11]. GASTRIC BIOPSIES: Mild chronic gastritis. CFV stain -\X0D\\X0A\Negative for Helicobacter. (JLB)\X0D\\X0A\S06013179, **DATE[Jul 12 06]. GASTRIC BIOPSIES: Partially necrotic esophageal squamous\X0D\\X0A\epithelium. Negative for malignancy. (JLB)","Final Diagnosis\X0D\\X0A\1. RIGHT COLON WITH TERMINAL ILEUM:\X0D\\X0A\     Infiltrating moderately differentiated adenocarcinoma.\X0D\\X0A\     Gross tumor size 10.0 x 5.5 x 4.0cm.\X0D\\X0A\     Tumor infiltrates through entire wall thickness to serosal radial margin.\X0D\\X0A\     Extensive angiolymphatic permeation by neoplasm present.\X0D\\X0A\     Perineural invasion by neoplasm present.\X0D\\X0A\     Metastatic carcinoma involving six of fourteen pericolic lymph nodes with\X0D\\X0A\extracapsular extension.\X0D\\X0A\     See TEMPLATE.\X0D\\X0A\    OMENTUM: Negative for tumor\X0D\\X0A\**INITIALS\X0D\\X0A\COLON AND RECTUM CARCINOMA TEMPLATE:\X0D\\X0A\DIAGNOSIS:  Poorly differentiated adenocarcinoma with focal neuroendocrine\X0D\\X0A\features\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE:  Right hemicolectomy\X0D\\X0A\SPECIMEN INTEGRITY: Intact \X0D\\X0A\TUMOR SITE:  Cecum\X0D\\X0A\TUMOR SIZE (greatest dimension):  10.5 x 5.5 x 4.0cm\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  No\X0D\\X0A\TUMOR CONFIGURATION:  Circumferential lesion\X0D\\X0A\HISTOLOGIC TYPE:  Adenocarcinoma with focal neuroendocrine features\X0D\\X0A\HISTOLOGIC GRADE:  Grade 3\X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION:  To serosa\X0D\\X0A\PERITONEAL INVOLVEMENT:  Yes\X0D\\X0A\LYMPH/VASCULAR INVASION:  Yes\X0D\\X0A\PERINEURAL INVASION:  Yes\X0D\\X0A\SURGICAL MARGINS:  Free of neoplasm\X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  9.0cm from proximal\X0D\\X0A\margin\X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  Margin involved\X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  Yes\X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED):  6/14 positive for\X0D\\X0A\metastatic carcinoma\X0D\\X0A\EXTRANODAL EXTENSION:  Yes\X0D\\X0A\TREATMENT EFFECT:  No\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  None\X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  N/A\X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  Not requested\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  4a\X0D\\X0A\pN=  2a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIIC\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Received in formalin labeled right colon and omentum is a right colectomy\X0D\\X0A\specimen including 8.0cm of terminal ileum, cecal pouch, and 17.0cm of right\X0D\\X0A\colon.  The radial resection margin is inked black.  The appendix is not\X0D\\X0A\identified.  The bowel is opened to reveal a large circumferential obstructing\X0D\\X0A\mass with overall dimensions of 10.0 x 5.5 x 4.0cm.  The mass involves the\X0D\\X0A\ileocecal valve and has essentially completely obliterated the cecal pouch.  The\X0D\\X0A\mass is 9.0cm from the proximal resection margin and 13.0cm from the distal\X0D\\X0A\resection margin.  Sectioning reveals invasion into the underlying muscle and\X0D\\X0A\fat.  The mass abuts the closest black-inked radial resection margin. \X0D\\X0A\Sectioning through the cecal fat reveals numerous and large, matted lymph nodes.\X0D\\X0A\ Due to the extensive tumor infiltration, the lymph nodes cannot be separated\X0D\\X0A\into individual nodes.  Several smaller lymph nodes are identified.  Also\X0D\\X0A\received in the same container is a 13.0 x 10.0 x 5.0cm portion of yellow,\X0D\\X0A\lobular, omental fat.  No masses or definitive areas of caking are identified in\X0D\\X0A\the omentum.  Representative sections are submitted.  Summary of Sections: A \X0D\\X0A\proximal resection margin, B  distal resection margin, C-D  mass to include\X0D\\X0A\radial margin, E  ileocecal valve, F  representative section of omentum, G \X0D\\X0A\large abnormal lymph node, H  representative section from abnormal matted lymph\X0D\\X0A\nodes, I  one bisected lymph node, J  smaller intact lymph nodes.  **INITIALS",Microscopic Description\X0D\\X0A\Sections from proximal and distal margins of resection show no evidence of\X0D\\X0A\neoplasm.  Sections through the main tumor mass to include the radial resection\X0D\\X0A\margin show an infiltrating neoplasm composed of a mass of fused glands lined by\X0D\\X0A\cells with large rounded vesicular nuclei with multiple nucleoli and frequent\X0D\\X0A\mitotic figures.  The tumor is grossly present at the radial margin.  There is\X0D\\X0A\evidence of angiolymphatic permeation and perineural invasion by neoplasm.  Some\X0D\\X0A\sections show extensive angiolymphatic involvement by neoplasm.  Sections\X0D\\X0A\through fourteen lymph nodes show metastatic carcinoma in six of fourteen lymph\X0D\\X0A\nodes (6/14).  Some are simply micrometastases.  Sections through the omentum\X0D\\X0A\show no metastasis.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488712,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is colon polyps.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Colon,  Neoplasm of Uncertain Behavior","Final Diagnosis\X0D\\X0A\RIGHT COLON, SEGMENTAL RESECTION: \X0D\\X0A\     Minimal lamina proprial invasion with well-differentiated adenocarcinoma\X0D\\X0A\arising in a large tubulovillous adenoma. 17 lymph nodes negative for\X0D\\X0A\metastasis. Margins free. Unremarkable vermiform appendix. See TEMPLATE. \X0D\\X0A\COLON AND RECTUM \X0D\\X0A\DIAGNOSIS:  adenocarcinoma\X0D\\X0A\TYPE OF SPECIMEN/PROCEDURE: segmental resection \X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\TUMOR SITE  right colon\X0D\\X0A\TUMOR SIZE (greatest dimension):  approximately 5mm of invasive tumor in a polyp\X0D\\X0A\MACROSCOPIC TUMOR PERFORATION:  none seen\X0D\\X0A\TUMOR CONFIGURATION:   polypoid\X0D\\X0A\HISTOLOGIC TYPE:  adenocarcinoma\X0D\\X0A\HISTOLOGIC GRADE:  well differentiated\X0D\\X0A\MICROSCOPIC DEPTH OF TUMOR INVASION/EXTENSION:  lamina propria only\X0D\\X0A\PERITONEAL INVOLVEMENT:  no\X0D\\X0A\LYMPH/VASCULAR INVASION:  none seen\X0D\\X0A\PERINEURAL INVASION:   none seen\X0D\\X0A\SURGICAL MARGINS:  free\X0D\\X0A\DISTANCE FROM CLOSEST MUCOSAL MARGINS (PROXIMAL/DISTAL):  4 cm\X0D\\X0A\DISTANCE FROM CIRCUMFERENTIAL (radial) or MESENTERIC MARGIN:  5 cm\X0D\\X0A\DISTANCE FROM DENTATE LINE (RECTAL TUMOR ONLY):  n/a\X0D\\X0A\TUMOR DEPOSITS (DISCONTINUOUS EXTRAMURAL EXTENSION):  n/a\X0D\\X0A\REGIONAL LYMPH NODE STATUS (NUMBER INVOLVED/NUMBER EXAMINED):  0/17\X0D\\X0A\EXTRANODAL EXTENSION:  n/a\X0D\\X0A\TREATMENT EFFECT:  n/a\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  n/a\X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  n/a\X0D\\X0A\OTHER ANCILLARY STUDIES (BRAF, KRAS, ETC.):  \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  is\X0D\\X0A\pN=  0\X0D\\X0A\AJCC PATHOLOGIC STAGE: 0  \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Received in formalin labeled right colon is a right colectomy specimen including\X0D\\X0A\3.5 cm of terminal ileum, cecal pouch and 14 cm of right colon. The appendix is\X0D\\X0A\present and measures 4 cm in length by 0.2 cm in diameter. Sectioning through\X0D\\X0A\the appendix reveals a fibrotic, obliterated lumen. The bowel is opened to\X0D\\X0A\reveal a 2.5 x 1.7 x 0.8 cm flattened polypoid lesion within the cecal pouch. No\X0D\\X0A\involvement of the ileocecal valve or appendiceal orifice is identified. The\X0D\\X0A\mass is 4 cm from the proximal resection margin and 14 cm from the distal\X0D\\X0A\resection margin. No definitive invasion into the underlying muscle or fat is\X0D\\X0A\identified. The remaining mucosa is tan and glistening with normal folds. There\X0D\\X0A\are two additional small sessile polyps identified averaging 0.8 cm in greatest\X0D\\X0A\dimension. The cecal polyp is greater than 5 cm from the closest radial\X0D\\X0A\resection margin. Several small lymph nodes are identified in the surrounding\X0D\\X0A\fat. Representative sections are submitted. Summary of sections: A  proximal\X0D\\X0A\resection margin; B  distal resection margin; C  appendix; D  representative\X0D\\X0A\section of radial resection margin; E-G  cecal polyp; H  smaller sessile polyps;\X0D\\X0A\I-J  intact lymph nodes.  **INITIALS",Microscopic Description\X0D\\X0A\The margins are viable and free of inflammatory change or polyps. The radial\X0D\\X0A\margin shows no tumor. The appendix shows fibrous obliteration of the lumen but\X0D\\X0A\shows no neoplasm or active inflammatory change. The polyp shows adenomatous\X0D\\X0A\change involving tubular and elongated glands. Minimal superficial lamina\X0D\\X0A\proprial invasion is seen. Seventeen lymph nodes are identified and none of\X0D\\X0A\these show metastasis. **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,COLON,0,488761,1,,"PREVIOUS HISTORY FROM FILES \X0D\\X0A\ **DATE[Nov 11 2011] ; S11018865 \X0D\\X0A\ RIGHT COLON BIOPSIES: \X0D\\X0A\ Infiltrating carcinoma present, see microscopic description and \X0D\\X0A\ comment \X0D\\X0A\ COLON POLYP AT 20 CM: \X0D\\X0A\ Hyperplastic polyp","Patient Age: **AGE[in 60s].\X0A\ CODES: **INITIALS 88305 88307 88309 PROGNOSTIC INFORMATION ANATOMIC LOCATION:  Left colon. HISTOLOGIC TYPE:  Adenocarcinoma. HISTOLOGIC GRADE:  Poorly differentiated. DEPTH OF INVASION:  Into pericolic fat. TYPE OF SPECIMEN:  Resection (Length 29.5 cm). TUMOR SIZE: 3 x 3 x 3 cm. TUMOR CONFIGURATION: Serrated. PERITONEAL INVOLVEMENT: None. LYMPH/VASCULAR INVASION: Present. SURGICAL MARGINS: Free. DISTANCE TO CLOSEST MUCOSAL MARGIN: 7.5 cm. DISTANCE TO RADIAL SOFT TISSUE OR SEROSAL MARGIN: 3.0 cm. REGIONAL LYMPH NODE STATUS: 10 of 11 total mesenteric lymph nodes involved EXTRANODAL EXTENSION OF METASTATIC DISEASE: Present. ADDITIONAL PATHOLOGICAL FINDINGS:  None. AJCC pathologic stage:  pT3, pN2b, pM1, stage IV A ** Original Signature on File ** **NAME[ZZZ M. YYY], M.D. **ID-NUM  **NAME[BBB,AAA M] **DATE[Dec 05 2011]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ LEFT COLON: \X0D\\X0A\ Invasive poorly differentiated adenocarcinoma \X0D\\X0A\ Invasion into pericolonic fat present \X0D\\X0A\ Multiple lymph node metastases \X0D\\X0A\ Proximal, distal and radial margins free \X0D\\X0A\ See template for prognostic information \X0D\\X0A\ SEGMENT OF OMENTUM: \X0D\\X0A\ Negative for tumor \X0D\\X0A\ WEDGE BIOPSY OF LIVER: \X0D\\X0A\ Metastatic poorly differentiated colonic adenocarcinoma",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is liver mass/colon mass. \X0D\\X0A\ **PLACE, KY **ZIP-CODE \X0D\\X0A\ Specimen 1 consists of a grossly apparent segment of colon measuring \X0D\\X0A\ 29.5 cm in length and up to 2.5 cm in diameter.  The serosal surface \X0D\\X0A\ is pink/tan and glistening and there is a moderate amount of attached \X0D\\X0A\ fat.  On opening, 7.5 cm from the closest margin there is a serrated \X0D\\X0A\ mass with raised and rolled borders measuring 3.0 x 3.0 x ___ cm and \X0D\\X0A\ up to 1.5 cm in thickness.  This grossly infiltrates the pericolic \X0D\\X0A\ adipose and comes to within 3 cm of the inked radial margin.  It \X0D\\X0A\ focally appears to infiltrate to the serosal surface.  The remainder \X0D\\X0A\ of the mucosa shows a normal mucosal fold pattern with scattered small \X0D\\X0A\ polyps.  The pericolic adipose is trimmed and searched for lymph \X0D\\X0A\ nodes.  Sections are submitted as follows:  1A,B - margins, 1C-F - \X0D\\X0A\ tumor, 1G - small polyp, 1H,I-presumptive peritumoral lymph nodes. \X0D\\X0A\ Specimen 2 consists of apparent golden yellow omentum measuring 23.5 x \X0D\\X0A\ 13.5 x 3.0 cm in greatest dimensions.  On sectioning no gross lesions \X0D\\X0A\ are seen.  Representative sections are submitted in two cassettes. \X0D\\X0A\ Specimen 3 consists of multiple gray/tan and gray/white irregular \X0D\\X0A\ fragments measuring 1.8 x 1.5 x 0.4 cm in greatest aggregate.  The \X0D\\X0A\ specimen is entirely submitted in one cassette for microscopic \X0D\\X0A\ examination.  **INITIALS","MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Sections taken through the margins of resection show no evidence of \X0D\\X0A\ tumor.  The colonic tumor is poorly differentiated adenocarcinoma with \X0D\\X0A\ focal areas showing mucin production with pools of mucus surrounded by \X0D\\X0A\ neoplastic cells which are cuboidal to columnar showing large \X0D\\X0A\ hyperchromatic nuclei, many with small nucleoli and vacuolated \X0D\\X0A\ cytoplasm.  Other areas show sheet like proliferation of cells with \X0D\\X0A\ similar nuclei and scant eosinophilic cytoplasm.  Occasional glandular \X0D\\X0A\ lumens are identified.  These focally show dirty necrosis and resemble \X0D\\X0A\ neuroendocrine differentiation.  In addition, focal areas show a \X0D\\X0A\ squamoid appearance.  The tumor invades through the muscular wall into \X0D\\X0A\ pericolonic fat.  There is marked lymphatic invasion in the \X0D\\X0A\ peritumoral areas.  The small polyp recognized grossly is a benign \X0D\\X0A\ lymphoid nodule.  At least 12 lymph nodes have been recovered from the \X0D\\X0A\ pericolonic fat.  Eleven show complete replacement with extension of \X0D\\X0A\ tumor into the fat. \X0D\\X0A\ **PLACE, KY **ZIP-CODE \X0D\\X0A\ Specimen 2 is omental tissue with foci of hemorrhage and congestion. \X0D\\X0A\ Tumor is not recognized. \X0D\\X0A\ The liver biopsy shows almost total replacement by tumor similar to \X0D\\X0A\ that described in the colon above. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:",TISSUE SUBMITTED: \X0D\\X0A\ 1.  Left colon \X0D\\X0A\ 2.  Omentum \X0D\\X0A\ 3.  Liver wedge biopsy,,
REG1,COLON,0,489042,2,,HISTORY: colon polyps,"ICD9 CODES: 153.9, 211.3, 569.82\X0D\\X0A\COMMENTS: Due to the somewhat tangential sectioning of the malignant polyp (specimen 6), the depth of invasion is difficult to determine.  Favor intramucosal carcinoma.  It is not possible to evaluate the polyp for complete excision.  Endoscopic correlation is necessary.  The slides are seen in consultation with Dr.  **NAME[ZZZ YYY] who agrees with the above diagnoses.","DIAGNOSIS: 1 - DISTAL TRANSVERSE COLON, POLYPECTOMY:             TUBULAR ADENOMA.  2 - MID TRANSVERSE COLON, POLYPECTOMY:             TUBULAR ADENOMA.  3 - PROXIMAL ASCENDING COLON, POLYPECTOMY:             TUBULAR ADENOMA.  4 - MID ASCENDING COLON, POLYPECTOMY:             TUBULAR ADENOMAS.  5 - PROXIMAL TRANSVERSE COLON, POLYPECTOMY:             TUBULAR ADENOMAS.  6 - POLYP AT 20 CM AND POLYP AT 25 CM:             MODERATELY DIFFERENTIATED ADENOCARCINOMA (WITH             ULCERATION) ARISING IN A TUBULAR ADENOMA.             TUBULAR ADENOMAS.             SEE COMMENT.",,"GROSS: Received in formalin and labeled with patient's name are six specimens. First is labeled ""polyp distal transverse"" and consists of multiple tan fragments of tissue with the largest measuring up to 0.2 cm. Specimen is submitted for TE as #1. Second specimen labeled ""polyp mid transverse"" consists of a single tan polyp shaped structure measuring up to 0.3 cm. Specimen is bisected and submitted for TE as #2. Third specimen is labeled ""proximal ascending colon polyp"" and consists of three tan fragments of tissue with the largest measuring up to 0.3 cm.  Specimen is submitted for TE as #3. Fourth specimen is labeled ""polyp mid ascending colon x3"" and consists of multiple tan fragments of tissue with the largest measuring up to 0.3 cm. Specimen is submitted for TE as #4. Fifth specimen labeled ""polyp proximal transverse colon x3"" consists of multiple tan polyp shaped structure with the largest measuring up to 0.4 cm. Specimen is submitted for TE as #5. Sixth specimen is labeled ""polyp at 20 cm and 25 cm x2"" and consists of two polyp shaped structures with the largest measuring up to 1.3 x 1 x up to 0.5 cm.  The polyps are serially sectioned and submitted for TE along with multiple tan fragments of tissue with the largest measuring up to 0.3 cm submitted as #6. DT: **DATE[Dec 15 2011]",MICRO: Microscopic examination was performed.  No high grade dysplasia is identified in specimens #1 through #5.    DT:  **DATE[Dec 16 2011]  (DRB/bab),PROCEDURE: Colonoscopy with polypectomy\X0D\\X0A\SPECIMEN(S): 1) polyp distal transverse  2) polyp mid transverse  3) polyp proximal ascending colon 4) polyp mid ascending colon x3  5) polyp proximal transverse colon x3 6) polyp at 20 cm and 25 cm x2,,
REG1,COLON,0,489111,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA CCC]              DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\COMMENT:  The invasive tumor was detected microscopically in a\X0D\\X0A\background of tubulovillous adenoma.  The microscopic measurement is\X0D\\X0A\approximately 2 mm.  Additional dimensions cannot be precisely obtained\X0D\\X0A\due to the sectioning and fragmentation of the specimen.\X0D\\X0A\Dr. **NAME[YYY] was notified with the above findings on **DATE[Apr 08 2012] at 5:40\X0D\\X0A\pm by telephone conversation.\X0D\\X0A\This case was presented at the intradepartmental consensus conference\X0D\\X0A\(MRJ, LAE, SXH).\X0D\\X0A\                                <Sign Out Dr. **NAME[XXX]>\X0D\\X0A\                                **NAME[WWW VVV], MD\X0D\\X0A\CLINICAL           RECTAL POLYP\X0D\\X0A\INFORMATION:\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\Part B: 88309 x 1\X0D\\X0A\  ICD9: 154.1\X0D\\X0A\PATIENT:  **NAME[BBB, AAA CCC]                 **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cMKDRI5ql4tuAGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zEUWLW+bKCzXOmYi2IM0xiy\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\Rectum, polyp, resection:\X0D\\X0A\ Invasive, well to moderately differentiated adenocarcinoma.\X0D\\X0A\ The carcinoma extends into the submucosa.\X0D\\X0A\ No definitive lymphvascular invasion identified.\X0D\\X0A\ No perineural invasion identified.\X0D\\X0A\ The resection margins are negative of tumor.\X0D\\X0A\    Specimen:\X0D\\X0A\  Rectum\X0D\\X0A\  Anus\X0D\\X0A\ Procedure:\X0D\\X0A\  Transanal disk excision (local excision)\X0D\\X0A\ Specimen Length:\X0D\\X0A\  2.2 cm.\X0D\\X0A\ Tumor Site:\X0D\\X0A\  Rectum\X0D\\X0A\ Tumor Size:\X0D\\X0A\  Greatest dimension:  2 mm. approximately\X0D\\X0A\  Additional dimensions: Cannot be determined (see comment)\X0D\\X0A\ Macroscopic Tumor Perforation:\X0D\\X0A\  Cannot be determined\X0D\\X0A\ Macroscopic Intactness of Meso-rectum:\X0D\\X0A\  Not applicable\X0D\\X0A\ Histologic Type:\X0D\\X0A\  Adenocarcinoma\X0D\\X0A\ Histologic Grade:\X0D\\X0A\  Low-grade (well-differentiated to moderately differentiated)\X0D\\X0A\ Histologic Features Suggestive of Microsatellite Instability (Note I)\X0D\\X0A\   Intratumoral Lymphocytic Response (tumor-infiltrating lymphocytes)\X0D\\X0A\   Marked\X0D\\X0A\  Peritumor Lymphocytic Response (Crohn-like response)\X0D\\X0A\   None\X0D\\X0A\ Microscopic Tumor Extension:\X0D\\X0A\  Tumor invades submucosa\X0D\\X0A\ Margins:\X0D\\X0A\  Proximal Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  Distal Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\   Intramucosal carcinoma/adenoma not identified at distal margin\X0D\\X0A\Present within 2 mm. from distant margin\X0D\\X0A\  Circumferential (Radial) or Mesenteric Margin\X0D\\X0A\   Not applicable\X0D\\X0A\  Lateral Margin (for non-circumferential transanal disk excision)\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\    Distance of invasive carcinoma from closest lateral margin: 2 mm.\X0D\\X0A\ Treatment Effect:\X0D\\X0A\  No prior treatment\X0D\\X0A\ Lymph-Vascular Invasion:\X0D\\X0A\  Not identified\X0D\\X0A\ Perineural Invasion:\X0D\\X0A\  Not identified\X0D\\X0A\ Tumor Deposits:\X0D\\X0A\  Not identified\X0D\\X0A\  Type of Polyp in Which Invasive Carcinoma Arose (Note F)\X0D\\X0A\  Tubulovillous adenoma\X0D\\X0A\ Pathologic Staging (pTNM)\X0D\\X0A\      Primary Tumor (pT)\X0D\\X0A\  pT1\X0D\\X0A\      Regional Lymph Nodes (pN)\X0D\\X0A\  pNX\X0D\\X0A\      Distant Metastasis (pM)\X0D\\X0A\  Not applicable",,"GROSS DESCRIPTION:\X0D\\X0A\Received in a prefilled formalin container labeled ""rectal polyp"" is an\X0D\\X0A\irregular, unoriented portion of tan to hemorrhagic, polypoid,\X0D\\X0A\irregular soft tissue measuring 2.2 x 1.6 x 0.5 cm.  The underlying\X0D\\X0A\soft tissue is tan to hemorrhagic and cauterized. The underlying soft\X0D\\X0A\tissue is inked blue.  The specimen is serially sectioned to display\X0D\\X0A\tan to pink, membranous soft tissue. The specimen is entirely submitted\X0D\\X0A\in three cassettes./**NAME[UUU,TTT",MICROSCOPIC DESCRIPTION:\X0D\\X0A\The specimen consists of sections of junctional anal-rectal mucosa\X0D\\X0A\showing a tubulovillous adenoma with high-grade dysplasia.  Arising\X0D\\X0A\from the adenoma is a well to moderately differentiated carcinoma\X0D\\X0A\invading into the submucosa. The tumor does not extend into the\X0D\\X0A\muscularis propria. There is no definitive lymphvascular invasion or\X0D\\X0A\perineural invasion identified.  The anal squamous mucosa shows acute\X0D\\X0A\inflammation with atypical cytologic changes. These changes are not\X0D\\X0A\present on the resection margin. The invasive carcinoma is present\X0D\\X0A\within 2.0 mm from the lateral resection margin. The tubulovillous\X0D\\X0A\adenoma is present within 2.0 mm from the distal resection margin.,TISSUE SUBMITTED:   RECTAL POLYP,,
REG1,COLON,0,489146,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA] D                DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\COMMENT:  The tumor invades into the serosal surface. Althought the\X0D\\X0A\area of the tumor present on the serosal surface does not show rupture\X0D\\X0A\of the serosa, an adjacent area with extravasated mucin shows rupture\X0D\\X0A\of the serosa with mucin extending outside the serosal surface.\X0D\\X0A\This case was presented at the intradepartmental consensus conference\X0D\\X0A\(DRW, KZK, SXH).\X0D\\X0A\                                <Sign Out Dr. **NAME[YYY]>\X0D\\X0A\                                **NAME[XXX WWW], MD\X0D\\X0A\CLINICAL           COLON OBSTRUCTION\X0D\\X0A\INFORMATION:\X0D\\X0A\                                                         Trans ID:  RVL\X0D\\X0A\                                                          Trans ID: AA\X0D\\X0A\Part B: 88309 x 1 88342 x 1,  3260F x 1\X0D\\X0A\  ICD9: 153.9\X0D\\X0A\PATIENT:  **NAME[BBB, AAA] D                   **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cKwkAy0nOl89AGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zFpGSDjsV2Oz2iAD0QlXx9e\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\Colon, transverse and splenic flexure, partial colectomy:\X0D\\X0A\ Invasive, moderately differentiated mucinous adenocarcinoma.\X0D\\X0A\ Please see template below.\X0D\\X0A\    Specimen:\X0D\\X0A\  Transverse colon\X0D\\X0A\  Splenic flexure\X0D\\X0A\ Procedure:\X0D\\X0A\  Transverse colectomy\X0D\\X0A\ Specimen Length:\X0D\\X0A\  31 cm.\X0D\\X0A\ Tumor Site:\X0D\\X0A\  Transverse colon\X0D\\X0A\ Tumor Size:\X0D\\X0A\  Greatest dimension:  2.2 cm.\X0D\\X0A\  Additional dimensions:  1.8 x 0.9 cm.\X0D\\X0A\ Macroscopic Tumor Perforation:\X0D\\X0A\  Not identified\X0D\\X0A\ Histologic Type:\X0D\\X0A\  Mucinous adenocarcinoma\X0D\\X0A\ Histologic Grade:\X0D\\X0A\  Low-grade (well-differentiated to moderately differentiated)\X0D\\X0A\ Microscopic Tumor Extension:\X0D\\X0A\  Tumor penetrates to the surface of the visceral peritoneum (serosa),\X0D\\X0A\(see comment)\X0D\\X0A\ Margins:\X0D\\X0A\  Proximal Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  Distal Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  Circumferential (Radial) or Mesenteric Margin\X0D\\X0A\   Uninvolved by invasive carcinoma\X0D\\X0A\  All margins uninvolved by invasive carcinoma:\X0D\\X0A\   Distance of invasive carcinoma from closest margin: Approximately 2\X0D\\X0A\cm.\X0D\\X0A\   Specify margin: Radial\X0D\\X0A\ Treatment Effect:\X0D\\X0A\  No prior treatment\X0D\\X0A\ Lymph-Vascular Invasion:\X0D\\X0A\  Not identified\X0D\\X0A\ Perineural Invasion:\X0D\\X0A\  Not identified\X0D\\X0A\ Tumor Deposits:\X0D\\X0A\  Not identified\X0D\\X0A\ Pathologic Staging (pTNM)\X0D\\X0A\-      Primary Tumor (pT)\X0D\\X0A\  pT4a (see comment)\X0D\\X0A\      Regional Lymph Nodes (pN)\X0D\\X0A\  pN0\X0D\\X0A\  Number of Lymph Nodes Examined:  15\X0D\\X0A\  Number of Lymph Nodes Involved:  0\X0D\\X0A\      Distant Metastasis (pM)\X0D\\X0A\  Not applicable\X0D\\X0A\ Additional findings:\X0D\\X0A\  Tubulovillous adenoma with high grade dysplasia.",,"GROSS DESCRIPTION:\X0D\\X0A\The specimen is labeled only with the patient's name.  Received in\X0D\\X0A\formalin is a 31 in length x 9.5 cm. in circumference portion of\X0D\\X0A\unopened colon with one end closed with staples.  The serosal surface\X0D\\X0A\is tan-pink and is focally hemorrhagic near the opened end.  There is a\X0D\\X0A\moderate amount of attached fat that measures up to 9.5 cm. in length.\X0D\\X0A\There is a small attached sheath of omentum that measures 9.3 cm. in\X0D\\X0A\length and up to 13 cm. in diameter.  Opening shows a moderate amount\X0D\\X0A\of brown to green thickened fecal material.  There are mostly irregular\X0D\\X0A\tan to pink mucosal folds with multiple scattered diverticula.  Located\X0D\\X0A\10.5 cm. away from the stapled end there is a narrowed area that shows\X0D\\X0A\a somewhat thickened, pink to hemorrhagic possible mass measuring 1.8 x\X0D\\X0A\2.2 cm.  This mass is located 21.2 cm. away from the opposite opened\X0D\\X0A\end and less than 2 cm. away from the radial margin.  Located 3.2 cm.\X0D\\X0A\away from the opened end there is a slightly raised tan nodule\X0D\\X0A\measuring 0.5 x 0.5 cm.  It is entirely submitted.  The serosal surface\X0D\\X0A\at the area of the mass is inked black and the radial margin is inked\X0D\\X0A\green.  This mass is entirely submitted.  Sectioning through the\X0D\\X0A\attached fat shows fifteen tan to pink possible lymph nodes measuring\X0D\\X0A\from 0.2 up to 0.6 cm.  Representative sections are submitted as\X0D\\X0A\follows: ""1"" - stapled end; ""2"" - opposite opened end; ""3"" -\X0D\\X0A\diverticula; ""4"" - irregular mucosa; ""5"" - nodule near the opened end;\X0D\\X0A\""6-7"" - radial margin; ""8-13"" - mass; ""14"" - three possible nodes; ""15""\X0D\\X0A\- six possible nodes; ""16"" - six possible nodes; ""17"" -\X0D\\X0A\omentum./AKC,MRJ","MICROSCOPIC DESCRIPTION:\X0D\\X0A\The specimen consists of a section of colon showing invasive,\X0D\\X0A\moderately differentiated adenocarcinoma composed of irregular glands\X0D\\X0A\lined by columnar epithelium with elongated hyperchromatic nuclei. The\X0D\\X0A\tumor exhibits large areas of mucin lakes. The tumor appears to be\X0D\\X0A\arising from a tubulovillous adenoma with high-grade dysplasia. The\X0D\\X0A\tumor invades into the the pericolonic fat and present focally on the\X0D\\X0A\serosal surface. Immunohistochemical stain (AE1/3) with appropriately\X0D\\X0A\working controls was performed on the specimen (A9) for qualitative\X0D\\X0A\impression and it highlight the tumor on the serosal surface.\X0D\\X0A\Althought the area where the tumor is present on the serosa does not\X0D\\X0A\show rupture, an adjacent area shows extravasated mucin protruding\X0D\\X0A\outside the serosal surface through a ruptured area. No lymphvascular\X0D\\X0A\invasion is identified.  Resection margins, as well as the radial\X0D\\X0A\margin, are negative for carcinoma.  Sections from the omentum reveal\X0D\\X0A\no evidence of invasive carcinoma.  There are fifteen lymph nodes\X0D\\X0A\identified with no evidence of invasive carcinoma.","TISSUE SUBMITTED:   COLECTOMY, PARTIAL, TRANSVERSE AND SPLENIC FLEXURE",,
REG1,COLON,0,490114,1,,,"Patient Age: **AGE[in 50s].\X0A\ PATHOLOGY CODES: **INITIALS  88307 (x 2); 88309 PROGNOSTIC INFORMATION ANATOMIC LOCATION:  Right colon. HISTOLOGIC TYPE:  Mucinous adenocarcinoma. HISTOLOGIC GRADE:  Moderately differentiated. DEPTH OF INVASION:  Tumor invades pericolic adipose. TYPE OF SPECIMEN:  Right colectomy. (Length 18.0 cm of colon and 3.5 cm of ileum) TUMOR SIZE: 4.0 X 2.5 X 1.0 cm. TUMOR CONFIGURATION: Circumferential, ulcerated. PERITONEAL INVOLVEMENT: Present. LYMPH/VASCULAR INVASION: Not identified. SURGICAL MARGINS: Free. DISTANCE TO CLOSEST MUCOSAL MARGIN: 6.5 cm from proximal margin. DISTANCE TO RADIAL SOFT TISSUE OR SEROSAL MARGIN: 1.5 cm from radial margin and 2.0 cm from the mesenteric margin. REGIONAL LYMPH NODE STATUS: 4 of 10 total mesenteric lymph nodes involved EXTRANODAL EXTENSION OF METASTATIC DISEASE: Not identified. AJCC STAGING:  pT3, pN2, pM1b/Stage IVb ADDITIONAL PATHOLOGIC FINDINGS:  Acute and chronic serositis, two tubular adenomas ** Original Signature on File ** **NAME[M. ZZZ YYY], MD **ID-NUM  **NAME[BBB,AAA] **DATE[May 08 2012]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ RIGHT AND LEFT OVARY AND FALLOPIAN TUBES, BILATERAL \X0D\\X0A\ SALPINGO-OOPHORECTOMY: \X0D\\X0A\ Metastatic colonic mucinous adenocarcinoma (pM1b) \X0D\\X0A\ Benign fallopian tubes \X0D\\X0A\ COLON, MASS, SEGMENTAL RESECTION: \X0D\\X0A\ Moderately differentiated mucinous adenocarcinoma \X0D\\X0A\ Tumor invades pericolic adipose (pT3) \X0D\\X0A\ Surgical margins free \X0D\\X0A\ Tumor invades omentum by direct extension and involves omental serosal \X0D\\X0A\ surface \X0D\\X0A\ Four of 10 pericolic lymph nodes (4/10, pN2) \X0D\\X0A\ Tumor arises within a serrated adenoma \X0D\\X0A\ Acute periappendiceal serositis \X0D\\X0A\ SEE TUMOR TEMPLATE",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is bowel obstruction. \X0D\\X0A\ Specimen 1 consists of a 169 gram, 9.0 x 7.5 x 5.0 cm ovary having an \X0D\\X0A\ attached 4.5 x 0.5 x 0.5 cm fallopian tube. \X0D\\X0A\ The ovary has a 6.0 x 6.0 cm brown hemorrhagic opened possible \X0D\\X0A\ ruptured cyst.  Sectioning reveals the entirety of the ovarian \X0D\\X0A\ parenchyma to be replaced with a tan, partially hemorrhagic, partially \X0D\\X0A\ structured mucoid material.  No discrete mass lesions or areas of \X0D\\X0A\ nodularity are grossly identified. \X0D\\X0A\ The segment of fallopian tube is grossly unremarkable. \X0D\\X0A\ Representative sections are submitted in seven cassettes as follows: \X0D\\X0A\ 1A-1F - ovary; 1G-fallopian tube. \X0D\\X0A\ Specimen 2 consists of a 287 gram, 10.0 x 7.5 x 6.5 cm ovary having an \X0D\\X0A\ attached 3.5 cm in length x 0.6 cm in diameter segment of fallopian \X0D\\X0A\ tube. \X0D\\X0A\ The ovary has a tan, wrinkled, gray, glistening serosal surface. \X0D\\X0A\ There is a 7.0 x 5.0 x 2.0 cm mucoid area protruding from a 5.0 x 5.0 \X0D\\X0A\ cm opened portion of the ovary.  Sectioning reveals the entirety of \X0D\\X0A\ the ovarian parenchyma to be replaced with a tan, partially \X0D\\X0A\ hemorrhagic, partially structured mucoid material.  No discrete mass \X0D\\X0A\ lesions or areas of nodularity are grossly identified. \X0D\\X0A\ The segment of fallopian tube is grossly unremarkable. \X0D\\X0A\ Representative sections are submitted in eight cassettes as follows: \X0D\\X0A\ 2A-2G - ovary; 2H-fallopian tube. \X0D\\X0A\ Specimen 3 consists of a portion of right colon (18.0 cm in length x \X0D\\X0A\ 4.0 cm in diameter) having an attached portion of ileum (3.5 cm in \X0D\\X0A\ length x 2.2 cm in diameter) and an attached intact vermiform appendix \X0D\\X0A\ (3.2 x 0.8 x 0.7 cm).  There is also an attached portion of soft \X0D\\X0A\ yellow adipose tissue measuring 11.0 x 5.0 x 2.0 cm in aggregate. \X0D\\X0A\ There is a separate detached portion of omental fat (13.0 x 9.0 x 2.0 \X0D\\X0A\ cm). \X0D\\X0A\ The appendix has a tan, smooth, and glistening serosal surface.  No \X0D\\X0A\ perforations are grossly identified.  No tumor is grossly identified. \X0D\\X0A\ There is no fecalith present in the lumen of the appendix.  There are \X0D\\X0A\ no hemorrhagic or necrotic appearing areas. \X0D\\X0A\ Sectioning of the portion of right colon reveals a 4.0 x 2.5 x 1.0 cm \X0D\\X0A\ brown, circumferential, raised, roughened mass lesion measuring 6.5 cm \X0D\\X0A\ from the proximal margin.  The mass lesion grossly appears to invade \X0D\\X0A\ into and through the bowel wall and into the surrounding layer of fat \X0D\\X0A\ and measures 1.5 cm from the radial margin and 2.0 cm from the \X0D\\X0A\ mesenteric margin.  Sectioning through the remainder of the colon \X0D\\X0A\ reveals a 1.0 x 0.8 x 0.5 cm pink soft polyp measuring 1.0 cm from the \X0D\\X0A\ mass lesion and 10.5 cm from the distal margin.  There is also a 1.2 x \X0D\\X0A\ 0.6 x 0.3 cm pink flattened polyp located 1.2 cm from the distal \X0D\\X0A\ margin.  The remainder of the mucosal surface is tan, wrinkled, and \X0D\\X0A\ edematous.  The ileocecal valve appears lipomatous.  No discrete mass \X0D\\X0A\ lesions or areas of nodularity are grossly identified. \X0D\\X0A\ Sectioning through the attached portion of adipose tissue reveals \X0D\\X0A\ seven possible lymph nodes ranging in size from 0.3 x 0.3 x 0.3 cm to \X0D\\X0A\ 0.5 x 0.5 x 0.5 cm. \X0D\\X0A\ Sectioning of the portion of omental fat reveals yellow adipose cut \X0D\\X0A\ surfaces.  No infarcts, discrete mass lesions, or areas of nodularity \X0D\\X0A\ are grossly identified. \X0D\\X0A\ Representative sections are submitted in 13 cassettes as follow: \X0D\\X0A\ 3A-proximal margin; 3B-distal margin; 3C-representative longitudinal \X0D\\X0A\ sections representing the entire length of the appendix; 3D-3G - \X0D\\X0A\ mass lesion; 3H-polyp nearest mass lesion; 3I-distal polyp; \X0D\\X0A\ 3J-representative sections from ileum and colon; 3K-3L - lymph nodes \X0D\\X0A\ with four possible lymph nodes in cassette 3K and three possible lymph \X0D\\X0A\ nodes in cassette 3L; 3M-omental fat.  **INITIALS","MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Sections of the first specimen, labeled left ovary and tube, show \X0D\\X0A\ ovarian stroma infiltrated and virtually replaced with large dilated \X0D\\X0A\ glands with focally serpiginous and irregular contours distended by \X0D\\X0A\ mucin and lined by an atypical pseudostratified mucinous epithelium \X0D\\X0A\ showing variable cytologic atypia.  The intervening stroma is fibrotic \X0D\\X0A\ and desmoplastic and focally infiltrated by small irregular angulated \X0D\\X0A\ glands lined by similar appearing epithelium.  The epithelium appears \X0D\\X0A\ decidedly bland, while in others it appears overtly malignant and \X0D\\X0A\ similar to that seen within the colonic specimen.  A cross section of \X0D\\X0A\ the fallopian tube is unremarkable. \X0D\\X0A\ Sections of the second specimen, labeled right ovary, again shows an \X0D\\X0A\ ovary replaced and infiltrated by dilated glands with little \X0D\\X0A\ intervening stroma distended by mucin and lined by atypical mucinous \X0D\\X0A\ epithelium showing variable stratification.  In areas, this epithelium \X0D\\X0A\ forms micropapillae and in areas the intervening stroma is \X0D\\X0A\ desmoplastic and infiltrated by small irregular angulated acini.  The \X0D\\X0A\ tumor is comprised of the ovarian stroma and does not appear to \X0D\\X0A\ involve the surface.  A cross section of the fallopian tube is \X0D\\X0A\ unremarkable. \X0D\\X0A\ Sections of the third specimen, labeled right colon mass, shows \X0D\\X0A\ carcinoma with ulceration and an underlying tumor showing irregular \X0D\\X0A\ angulated glands and acini and cribriform sheets infiltrating a \X0D\\X0A\ desmoplastic and fibrotic stroma extending through the muscularis \X0D\\X0A\ propria to involve the pericolic adipose.  The tumor shows abundant \X0D\\X0A\ mucin with mucin pools containing free floating strips of atypical \X0D\\X0A\ colonic epithelium.  Focal residual adenoma shows a serrated contour \X0D\\X0A\ lined by an atypical adenomatous epithelium with high grade cytology. \X0D\\X0A\ The tumor and mucin infiltrate into the omental adipose where it \X0D\\X0A\ involved the serosa.  The additional polyps show a tubular \X0D\\X0A\ proliferation of crypts lined by adenomatous epithelium.  Four of 10 \X0D\\X0A\ pericolic lymph nodes show metastatic carcinoma (4/10).  The serosal \X0D\\X0A\ surface of the omentum and appendix show a chronic inflammatory cell \X0D\\X0A\ infiltrate with markedly reactive mesothelial cells. The appendiceal \X0D\\X0A\ mucosa is unremarkable. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:",TISSUE SUBMITTED: \X0D\\X0A\ 1. Left ovary and tube \X0D\\X0A\ 2. Right ovary and tube \X0D\\X0A\ 3. Right colon mass,,
REG1,COLON,0,490407,1,,"PREVIOUS HISTORY FROM FILES \X0D\\X0A\ **DATE[May 20 2012] ; S11019786 \X0D\\X0A\ SIGMOID COLON, MASS, BIOPSIES: \X0D\\X0A\ Moderately differentiated adenocarcinoma \X0D\\X0A\ RECTUM, POLYP, BIOPSIES: \X0D\\X0A\ Hyperplastic polyp \X0D\\X0A\ ---------------------------------------------------------------------- \X0D\\X0A\ **PLACE, KY **ZIP-CODE","Patient Age: **AGE[in 50s].\X0A\ DATE OF ORIGINAL REPORT: **DATE[Jun 06 12] CODES: **INITIALS  88309 PROGNOSTIC INFORMATION ANATOMIC LOCATION:  Sigmoid colon. HISTOLOGIC TYPE:  Adenocarcinoma. HISTOLOGIC GRADE:  Moderately differentiated. DEPTH OF INVASION:  Into pericolonic fat. TYPE OF SPECIMEN:  Resection (Length 14.0 cm) TUMOR SIZE: 5.5 X 4.5 X 1.3 cm. TUMOR CONFIGURATION: Circumferential. PERITONEAL INVOLVEMENT: None. LYMPH/VASCULAR INVASION: None. SURGICAL MARGINS: Free. DISTANCE TO CLOSEST MUCOSAL MARGIN: 3.7 cm. DISTANCE TO RADIAL SOFT TISSUE OR SEROSAL MARGIN: 0.5 cm. REGIONAL LYMPH NODE STATUS: 0 of 11 total mesenteric lymph nodes involved EXTRANODAL EXTENSION OF METASTATIC DISEASE: N/A. AJCC PATHOLOGIC STAGE: pT3, pN0, pMX, Stage IIA ** Original Signature on File ** **NAME[ZZZ M. YYY], M.D. **ID-NUM  **NAME[BBB,AAA] **DATE[Jun 04 2012]  *** FINAL REPORT ***",PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ SEGMENT OF SIGMOID COLON \X0D\\X0A\ Invasive moderately differentiated adenocarcinoma \X0D\\X0A\ Invasion through muscular wall into pericolonic fat identified \X0D\\X0A\ Eleven regional lymph nodes - negative for malignancy (0/11) \X0D\\X0A\ Proximal distal and radial margins free of tumor \X0D\\X0A\ See TEMPLATE for prognostic information,,"GROSS EXAMINATION: \X0D\\X0A\ The working history is colon cancer and liver mass. \X0D\\X0A\ Specimen 1 is received in formalin and labeled with the patient's name \X0D\\X0A\ ""sigmoid colon"".  It is a 14.0 cm in length segment of colon measuring \X0D\\X0A\ up to 6.0 cm in diameter.  There is an abundant amount of attached \X0D\\X0A\ tan-yellow lobular mesenteric fat.  The radial resection margin is \X0D\\X0A\ inked blue.  The previously opened bowel shows a large circumferential \X0D\\X0A\ mass measuring 5.5 x 4.5 x 1.3 cm.  The mass is 3.7 cm from the distal \X0D\\X0A\ resection margin and 5.0 cm from the proximal resection margin.  The \X0D\\X0A\ mass is 0.5 cm from the closest blue inked radial resection margin. \X0D\\X0A\ Sectioning reveals invasion into the underlying muscle and fat.  The \X0D\\X0A\ surrounding mucosa is tan and glistening with normal folds.  Several \X0D\\X0A\ enlarged lymph nodes are identified in the surrounding fat, measuring \X0D\\X0A\ up to 1.8 cm in greatest dimension.  Representative sections are \X0D\\X0A\ submitted. \X0D\\X0A\ Summary of section:  1A - proximal resection margin; 1B - distal \X0D\\X0A\ resection margin; 1C and 1D - mass to include inked radial resection \X0D\\X0A\ margin; 1E - additional representative section of mass to include \X0D\\X0A\ adjacent mucosa; 1F-1H - intact lymph nodes; 1I - one bisected lymph \X0D\\X0A\ node. \X0D\\X0A\ Specimen 2 is received in formalin and labeled with the patient's name \X0D\\X0A\ and ""distal sigmoid donut"".  It is a 2.0 x 1.5 x 1.5 cm intact, \X0D\\X0A\ annular portion of bowel with tan-pink glistening, focally congested \X0D\\X0A\ mucosa.  No invasive tumor is identified.  The specimen is submitted \X0D\\X0A\ entirely in cassette 2. \X0D\\X0A\ Specimen 3 is received in formalin and labeled with the patient's name \X0D\\X0A\ and ""proximal sigmoid donut"".  It is a 2.5 x 1.5 x 1.5 cm intact \X0D\\X0A\ annular  portion of bowel with several blue sutures.  The mucosa is \X0D\\X0A\ tan and focally hemorrhagic.  No invasive tumor is identified.  The \X0D\\X0A\ specimen is submitted entirely in cassettes 3A-3B.  **INITIALS",MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Tissue blocks are prepared and slides are examined microscopically. \X0D\\X0A\ See diagnosis for details. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:,"TISSUE SUBMITTED: \X0D\\X0A\ 1. Sigmoid colon segment \X0D\\X0A\ 2. Distal sigmoid donut \X0D\\X0A\ **PLACE, KY **ZIP-CODE \X0D\\X0A\ 3. Proximal sigmoid donut",,ADDENDUM: \X0D\\X0A\ Attached is a copy of the Oncotype DX Colon Cancer Assay indicating a \X0D\\X0A\ colon cancer recurrence score of 22 with a 13% recurrent rate at three \X0D\\X0A\ years. \X0D\\X0A\ **INITIALS \X0D\\X0A\ PATHOLOGY
REG1,COLON,0,490666,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\HX OF POLYPS\X0D\\X0A\,"COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY]\X0D\\X0A\   9342 **INSTITUTION Way\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[May 10 12]                 **PLACE Clinical Associates                    PAGE:   **ID-NUM\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA] L                DOB: **DATE[Jan 12 1962]   Sex: F\X0D\\X0A\Add:8101 WENDAMOOR DR,**NAME[XXX],KY **ID-NUM  **PHONE                                                           \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  REG SDC   Location:  D.ENDO                 \X0D\\X0A\Reg:   **DATE[May 07 12]     Disch:           SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[WWW:VVV,UUU] B       Submit:**NAME[VVV,UUU] B            MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS Dr #530         **NAME[XXX]                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:  (Continued)\X0D\\X0A\\X0D\\X0A\   **NAME[VVV,UUU M]\X0D\\X0A\   **STREET-ADDRESS Dr #530\X0D\\X0A\   **NAME[XXX], KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS, 88342GS/3\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[TTT M SSS] MD **DATE[May 09 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[May 10 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\RECTAL POLYPS, ENDOSCOPIC BIOPSY:\X0D\\X0A\POLYPOID FRAGMENT OF COLONIC-TYPE MUCOSA WITH CARCINOID TUMOR (PLEASE\X0D\\X0A\SEE COMMENT).\X0D\\X0A\ADDITIONALLY, THERE IS A HYPERPLASTIC POLYP.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\IMMUNOHISTOCHEMISTRY REPORT\X0D\\X0A\\X0D\\X0A\Using appropriate positive and negative controls, sections from the rectal polyps specimen\X0D\\X0A\are submitted for immunoreactive synaptophysin, chromogranin, and CD56 via an\X0D\\X0A\immunohistochemical technique.  Tumor cells stain strongly and diffusely positive for\X0D\\X0A\synaptophysin and moderately and diffusely positive for CD56.  Tumor cells are negative for\X0D\\X0A\chromogranin.  All internal and external controls react appropriately.\X0D\\X0A\\X0D\\X0A\INTERPRETATION:  This staining pattern is supportive of a carcinoid tumor.\X0D\\X0A\\X0D\\X0A\Case discussed with Dr. **NAME[UUU VVV] on **DATE[May 9 2012] at approximately 9:40 a.m.\X0D\\X0A\\X0D\\X0A\Reviewed for QA(LK).\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin designated ""rectal polyps"" are two ovoid pale pink-tan polyps measuring\X0D\\X0A\3 to 4 mm in greatest dimension.  The specimens are submitted in a single cassette.  **INITIALS\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\3 H\T\E, synaptophysin, chromogranin, CD56.\X0D\\X0A\",SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\RECTAL POLYPS\X0D\\X0A\,,
REG1,COLON,0,490949,1,,PREOP DIAGNOSIS:               COLON MASS,"COMMENT\X0D\\X0A\Adenocarcinoma is identified in three of the original lymph nodes.\X0D\\X0A\D: **DATE[Aug 02 2012] - 1041 hours\X0D\\X0A\T: **DATE[Aug 02 2012] - 1101 hours\X0D\\X0A\.....7....SEE COMMENT.\X0D\\X0A\**NAME[BBB,AAA] C                            ACCT #: **ID-NUM     LOC:  5NO    U #: 303858\X0D\\X0A\2030 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 48/M       **ROOM    REG: **DATE[Jul 31 12]\X0D\\X0A\DOB: **DATE[Jun 05 64]    BED: 01      DIS:\X0D\\X0A\STATUS: ADM IN     TLOC:","FINAL DIAGNOSIS\X0D\\X0A\RECTOSIGMOID:\X0D\\X0A\.....1....THREE OF NINE LYMPH NODES POSITIVE FOR METASTATIC MODERATELY\X0D\\X0A\..........DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\.....2....TUMOR SHOWS PREDOMINANTLY VILLOUS ADENOMATOUS ARCHITECTURE.\X0D\\X0A\.....3....MINOR ELEMENT OF TUBULOVILLOUS ADENOMA IDENTIFIED.\X0D\\X0A\.....4....SUPERFICIALLY INVASIVE MALIGNANCY IDENTIFIED IN EXTRA SECTIONS.\X0D\\X0A\.....5....NO ADDITIONAL SIGNIFICANT CHANGES NOTED.\X0D\\X0A\.....6....AJCC T1N1MX.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ **NAME[ZZZ,YYY] XXX] MD  **DATE[Aug 03 12]",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is submitted fixed in a container labeled with the patient\X0D\\X0A\name and designated ""rectosigmoid."" Within the container is a partial\X0D\\X0A\resection of colonic tissue measuring approximately 15 cm in length. There\X0D\\X0A\is a fungating, very papillary mass lesion present, focally extending (it\X0D\\X0A\appears grossly) to the margin of excision nearest the tumor (no\X0D\\X0A\designation as proximal and distal is present). The mass lesion begins\X0D\\X0A\10.5 cm from the clear margin of excision, and the margin of excision very\X0D\\X0A\near the lesion is 1 cm from the main mass, but appears to be thickened\X0D\\X0A\and irregular. The mass itself is circumferential and measures 7.5 cm in\X0D\\X0A\greatest length circumferentially. The tumor extends 3.5 cm in length\X0D\\X0A\along the colonic length. The margin of excision that is free of the tumor\X0D\\X0A\is submitted in cassette 1. The margin of excision showing possible\X0D\\X0A\involvement is submitted in cassette 2. The radial margin of excision is\X0D\\X0A\inked blue.  Sections from the radial margin are submitted in cassette 3.\X0D\\X0A\Sections of the mass to include the basilar layers along the colonic\X0D\\X0A\muscle tissue are submitted in cassettes 4 through 8. No invasion is\X0D\\X0A\identified grossly. A cross-section of essentially normal colonic mucosal\X0D\\X0A\tissue is submitted in cassette 9. The surrounding soft tissue is then\X0D\\X0A\sectioned and examined for lymph nodes, few of which are seen.  Sections\X0D\\X0A\from potential lymphoid structures are submitted in cassettes 10 through\X0D\\X0A\12.\X0D\\X0A\D: **DATE[Aug 01 2012] - 1516 hours\X0D\\X0A\T: **DATE[Aug 01 2012] - 1544 hours\X0D\\X0A\INTRADEPARTMENTAL CONSULT\X0D\\X0A\Dr. **NAME[WWW] has reviewed this and agrees.","MICROSCOPIC EXAMINATION\X0D\\X0A\The section from the margin of excision away from the exophytic tumor\X0D\\X0A\shows no evidence of malignancy present. Fresh hemorrhage is seen and is\X0D\\X0A\likely procedural in origin.\X0D\\X0A\The sections from the margin of excision near the neoplasm show villous\X0D\\X0A\and adenomatous gland forms present, consistent with tubulovillous\X0D\\X0A\adenoma. No significant level of cytologic dysplasia is present.\X0D\\X0A\The sections from the radial margin of excision show no evidence of\X0D\\X0A\malignancy present. The specimen also shows additional tubulovillous\X0D\\X0A\adenoma.\X0D\\X0A\The original sections from the mass lesion proper show no infiltrative\X0D\\X0A\malignancy present. The tumor shows predominantly villous glandular\X0D\\X0A\architecture with a minor element of adenomatous gland forms present. The\X0D\\X0A\tissue away from the villous adenoma shows no significant pathologic\X0D\\X0A\changes present.\X0D\\X0A\The sections from the potential lymph nodes show adipose tissue, blood\X0D\\X0A\vessels, and 6 lymph nodes, 3 of which are positive for metastatic\X0D\\X0A\moderately differentiated adenocarcinoma.\X0D\\X0A\After initial examination, additional sections of the mass are submitted\X0D\\X0A\in cassettes 13 through 16.  Additional sections from potential lymph\X0D\\X0A\nodes are submitted in cassettes 17 through 19. The additional sections\X0D\\X0A\from the colon show superficially infiltrative moderately differentiated\X0D\\X0A\adenocarcinoma.  No invasion of the deep muscle is seen.  The\X0D\\X0A\sections from the lymph nodes show 3 additional lymph nodes, all\X0D\\X0A\negative for metastatic carcinoma.\X0D\\X0A\D: **DATE[Aug 02 2012] - 1041 hours\X0D\\X0A\T: **DATE[Aug 02 2012] - 1058 hours","TISSUES:\X0D\\X0A\Colon, NOS (RECTO SIGMOID COLON SEGMENT)",,
REG1,COLON,0,491682,1,,,"Patient Age: **AGE[in 70s].\X0A\ PATHOLOGY CODES: **INITIALS  88305 (x 2) COMMENT: Diagnosis called and report faxed to **NAME[YYY] in Dr. **NAME[ZZZ]'s office on **DATE[Dec 28 11] at 1:35. ** Original Signature on File ** **NAME[M. XXX WWW], MD **ID-NUM  **NAME[BBB,AAA M] **DATE[Dec 27 2011]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ ASCENDING COLON POLYP, BIOPSIES: \X0D\\X0A\ Tubular adenoma \X0D\\X0A\ ASCENDING COLON POLYP NO.2, BIOPSIES: \X0D\\X0A\ Invasive, moderately differentiated adenocarcinoma with mucinous \X0D\\X0A\ features \X0D\\X0A\ Tumor arises in a tubular adenoma with high grade dysplasia",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is screening, polyps. \X0D\\X0A\ Specimen 1 consists of: \X0D\\X0A\ Pieces:  Multiple \X0D\\X0A\ Aggregate dimensions:  1.0 x 0.7 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. \X0D\\X0A\ Specimen 2 consists of: \X0D\\X0A\ Pieces:  Multiple \X0D\\X0A\ Aggregate dimensions:  1.0 x 0.8 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. **INITIALS","MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Sections of the first specimen, labeled ascending colon polyp, shows \X0D\\X0A\ multiple fragments of colonic mucosa with a tubular proliferation of \X0D\\X0A\ crypts lined by adenomatous epithelium.  There is no evidence of high \X0D\\X0A\ grade dysplasia or carcinoma. \X0D\\X0A\ Sections of the second specimen, labeled ascending colon polyp No.2, \X0D\\X0A\ shows multiple fragments of colonic mucosa, one of which shows \X0D\\X0A\ irregular angulated glands and acini infiltrating fibrotic and \X0D\\X0A\ desmoplastic stroma and lining and floating in pools of mucin.  The \X0D\\X0A\ overlying epithelium shows a tubular proliferation of crypts lined by \X0D\\X0A\ adenomatous epithelium showing increased cytologic atypia and a \X0D\\X0A\ cribriform architecture. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:",TISSUE SUBMITTED: \X0D\\X0A\ 1.  Ascending colon polyp \X0D\\X0A\ 2.  Ascending colon polyp,,
REG1,COLON,0,492132,1,,,"Patient Age: **AGE[in 70s].\X0A\ PATHOLOGY CODES: **INITIALS  88305 COMMENT: Report called and faxed to Dr. **NAME[ZZZ]'s office (**NAME[YYY]) on **DATE[Mar 17 12] at 12:10. ** Original Signature on File ** **NAME[XXX M. WWW], M.D. **ID-NUM  **NAME[BBB,AAA M] **DATE[Mar 16 2012]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ COLON POLYP AT 18.0 CM: \X0D\\X0A\ Adenocarcinoma, arising within a tubulovillous adenoma \X0D\\X0A\ Polyp size 2.0 cm \X0D\\X0A\ Invasive component 4.0 mm in diameter \X0D\\X0A\ Inked polyp margin clear by at least 4.0 mm \X0D\\X0A\ No lymphovascular invasion identified \X0D\\X0A\ SEE COMMENT",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is change in bowel habits, history of polyps. \X0D\\X0A\ Specimen consists of a tan soft polypoid tissue fragment and multiple \X0D\\X0A\ tan soft tissue fragments with the polypoid fragment measuring 2.0 x \X0D\\X0A\ 1.5 x 1.5 cm, and the tissue fragments measuring 1.2 x 1.0 x 0.2 cm in \X0D\\X0A\ aggregate. The surgical margins of the polypoid fragment is inked \X0D\\X0A\ blue. The polypoid fragment is serially sectioned with fragments upon \X0D\\X0A\ sectioning and the remaining tissue fragments have been filtered. The \X0D\\X0A\ specimen is submitted in its entirety in three cassettes with the \X0D\\X0A\ polypoid fragment in cassettes A and B, and the tissue fragments in \X0D\\X0A\ cassette C. **INITIALS",MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Tissue blocks are prepared and slides are examined microscopically. \X0D\\X0A\ See diagnosis for details. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:,TISSUE SUBMITTED: \X0D\\X0A\ Colon biopsy at 18 cm,,
REG1,COLON,0,492612,1,,,"Patient Age: **AGE[in 80s].\X0A\ PATHOLOGY CODES: **INITIALS  88305 COMMENT: Fragments of the tissue show ulceration and fibrinopurulent exudate. Other fragments show adenomatous epithelium with high grade dysplasia. In other areas, there is a desmoplastic stromal response with embedded atypical glands compatible with invasive carcinoma.  Due to the orientation and nature of these fragments it is not felt possible to definitively assess the depth of invasion. Diagnosis called and report faxed to Dr. **NAME[ZZZ]'s office (**NAME[YYY]) on **DATE[Sep 21 12] at 11:15 a.m. ** Original Signature on File ** **NAME[XXX M. WWW], M.D. **ID-NUM  SPEAR,VIOLET **DATE[Sep 20 2012]  *** FINAL REPORT ***",PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ RECTOSIGMOID MASS BIOPSY: \X0D\\X0A\ Invasive moderately differentiated adenocarcinoma,,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is rectal bleeding. \X0D\\X0A\ Specimen consists of: \X0D\\X0A\ Pieces:  Multiple \X0D\\X0A\ Aggregate dimensions:  0.5 x 0.5 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. **INITIALS",MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Tissue blocks are prepared and slides are examined microscopically. \X0D\\X0A\ See diagnosis for details. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:,TISSUE SUBMITTED: \X0D\\X0A\ Rectosigmoid mass biopsy,,
REG1,COLON,0,493157,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\THICKENING OF DISTAL ILEUM AND CECUM\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE:\X0D\\X0A\    ILEUM, APPENDIX AND CECUM, ILEOCOLIC RESECTION.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\    INTACT.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:\X0D\\X0A\    MIXED GOBLET CELL CARCINOID - ADENOCARCINOMA (CONSIDERED HIGH GRADE\X0D\\X0A\        MALIGNANT POTENTIAL).\X0D\\X0A\    PLEASE SEE COMMENT.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\    TUMOR INVOLVES MID PORTION AND BASE OF APPENDIX.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\    TUMOR INVOLVES BASE AND MID PORTION, ESTIMATED 5.0 CM.\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   **STREET-ADDRESS Dr #530\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX,WWW M]\X0D\\X0A\   **STREET-ADDRESS #208\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88309GS, 88342GS/7\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[VVV M UUU] MD **DATE[Nov 08 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Nov 09 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\CARCINOMA OF APPENDIX SYNOPTIC REPORT AJCC/UICC TNM, 7TH EDITION\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:\X0D\\X0A\ILEUM, APPENDIX AND CECUM, ILEOCOLIC RESECTION.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\INTACT.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:\X0D\\X0A\MIXED GOBLET CELL CARCINOID - ADENOCARCINOMA (CONSIDERED HIGH GRADE\X0D\\X0A\MALIGNANT POTENTIAL).\X0D\\X0A\PLEASE SEE COMMENT.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\TUMOR INVOLVES MID PORTION AND BASE OF APPENDIX.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\TUMOR INVOLVES BASE AND MID PORTION, ESTIMATED 5.0 CM.\X0D\\X0A\MICROSCOPIC TUMOR EXTENT:\X0D\\X0A\TUMOR INVADES THROUGH THE MUSCULARIS PROPRIA INTO\X0D\\X0A\SUBSEROSA/MESOAPPENDIX AND TUMOR FOCALLY DIRECTLY EXTENDS INTO\X0D\\X0A\ADJACENT COLON.\X0D\\X0A\NO INVOLVEMENT OF SEROSAL SURFACE IDENTIFIED.\X0D\\X0A\MARGINS:\X0D\\X0A\PROXIMAL AND DISTAL RESECTION MARGINS ARE NEGATIVE FOR TUMOR.\X0D\\X0A\SOFT TISSUE MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\DISTANCE FROM TUMOR TO CLOSEST (SOFT TISSUE) MARGIN IS APPROXIMATELY\X0D\\X0A\5.0 MM.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\NO DEFINITE ANGIOLYMPHATIC INVASION IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\THREE LYMPH NODES RECOVERED, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\SATELLITE PERITUMORAL NODULES (TUMOR DEPOSITS):\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\OTHER FINDINGS:\X0D\\X0A\THE DISTAL APPENDIX (TIP) DISPLAYS LOW GRADE MUCINOUS APPENDICEAL\X0D\\X0A\NEOPLASM, NON RUPTURED, NO EXTRAVASATED MUCIN.\X0D\\X0A\PATHOLOGIC STAGE:\X0D\\X0A\pT4b pN0 pMn/a.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual seventh edition\X0D\\X0A\guidelines.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\The appendix tumor displays features of goblet cell carcinoid, additionally there are\X0D\\X0A\features of frank adenocarcinoma (i.e. linear single-file growth, a mucin lake containing\X0D\\X0A\fused glands and a rare focus of infiltrating glands resembling typical colorectal\X0D\\X0A\adenocarcinoma).\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Using appropriate positive and negative controls, sections from the appendix are submitted\X0D\\X0A\for immunoreactive cytokeratin (AE1/3), synaptophysin, chromogranin, CD56 and cytokeratin 20\X0D\\X0A\via an immunohistochemical technique.  Tumor cells stain moderate to strongly and diffusely\X0D\\X0A\positive for cytokeratin (AE1/3), synaptophysin, CD56 and cytokeratin 20.  Tumor cells are\X0D\\X0A\negative for chromogranin.  All internal and external controls react appropriately.\X0D\\X0A\\X0D\\X0A\INTERPRETATION:  This staining pattern supports neuroendocrine differentiation for this\X0D\\X0A\tumor.\X0D\\X0A\\X0D\\X0A\Note:  The specimen is re-examined, no additional lymph nodes are identified.\X0D\\X0A\\X0D\\X0A\Reviewed for QA (LK).\X0D\\X0A\\X0D\\X0A\Case discussed with Dr. **NAME[ZZZ] on **DATE[Nov 08 12] at approximately 11:00 a.m.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin designated ""ileum, appendix and cecum"" is a segment of ileum with\X0D\\X0A\attached adhesed appendix and cecum.  The specimen is received closed at both ends by a line\X0D\\X0A\of surgical staples.  The serosal surface of the specimen is covered by fibrinous\X0D\\X0A\hemorrhagic adhesion.  The terminal ileum measures 8.5 cm in length and up to 5.5 cm in\X0D\\X0A\diameter.  The attached colon segment measures 6.5 cm in length and up to 9.0 cm in\X0D\\X0A\circumference.  The specimen is opened longitudinally to reveal unremarkable mucosal folding\X0D\\X0A\throughout the terminal ileum and colon.  The ileocecal valve is unremarkable and patent.\X0D\\X0A\There are no polyps or masses identified.  The mucosal surface at the level of the\X0D\\X0A\appendiceal orifice is slightly erythematous in appearance.\X0D\\X0A\\X0D\\X0A\The adhesed appendix measures 9.0 cm in length and up to 1.8 cm in diameter.  The serosal\X0D\\X0A\surface associated with the appendix is marked with black ink.  Sectioning the appendix\X0D\\X0A\reveals a dilated lumen filled with clear mucoid fluid.\X0D\\X0A\\X0D\\X0A\Sectioning of the surrounding attached limited adipose tissue reveals a single possible\X0D\\X0A\lymph node candidate measuring 0.5 cm in greatest dimension.\X0D\\X0A\\X0D\\X0A\Please note:  95-100% of the appendix is submitted for microscopic examination.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\\X0D\\X0A\Cassette(s):        1.    proximal margin\X0D\\X0A\2.    distal margin\X0D\\X0A\3\T\4.    bisected tip of the appendix\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\5-7.    representative sections of appendix and adhesed bowel\X0D\\X0A\8.    appendix and colon at orifice\X0D\\X0A\9\T\10.    bisected appendix at area of adhesion between the colon and small\X0D\\X0A\bowel\X0D\\X0A\11.    one lymph node candidate\X0D\\X0A\12.    additional sections of adjacent colon\X0D\\X0A\13.    additional intact lymph node candidates        **INITIALS\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\13 H\T\E, synaptophysin, chromogranin, CD56, cytokeratin 20, 3 cytokeratin (AE1/3).\X0D\\X0A\","SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\ILEUM, APPENDIX AND CECUM\X0D\\X0A\",,
REG1,COLON,0,493198,1,,"CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RUQ PAIN, SCREENING\X0D\\X0A\","COPIES TO:\X0D\\X0A\   Dwivedi,Sunita A\X0D\\X0A\   **STREET-ADDRESS Dr\X0D\\X0A\   **PLACE, Ky **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   **STREET-ADDRESS Dr #530\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS/3, 88342GS\X0D\\X0A\\X0D\\X0A\           DISCLAIMER          \X0D\\X0A\\X0D\\X0A\This test, H. pylori, was developed and its performance characteristics determined by\X0D\\X0A\Clinical Associates.  It has not been cleared or approved by the US Food and Drug\X0D\\X0A\Administration. The FDA has determined that such clearance or approval is not necessary.\X0D\\X0A\This test is used for clinical purposes only.  It should not be regarded as investigational\X0D\\X0A\or for research. This laboratory is certified under Clinical Improvement Amendments of 1988\X0D\\X0A\(CLIA) as qualified to perform high complexity testing.\X0D\\X0A\\X0D\\X0A\",FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.    BIOPSY GASTRIC ANTRUM:\X0D\\X0A\MILD CHRONIC GASTRITIS.\X0D\\X0A\NO INTESTINAL METAPLASIA OR DYSPLASIA.\X0D\\X0A\AN IMMUNOSTAIN FOR H. PYLORI IS NEGATIVE; THE EXTERNAL CONTROLS\X0D\\X0A\STAIN APPROPRIATELY.\X0D\\X0A\\X0D\\X0A\B.    POLYP TRANSVERSE COLON:\X0D\\X0A\TUBULAR ADENOMA.\X0D\\X0A\\X0D\\X0A\C.    DESCENDING COLON POLYP:\X0D\\X0A\MODERATELY DIFFERENTIATED INVASIVE ADENOCARCINOMA ARISING IN A\X0D\\X0A\VILLOUS ADENOMA.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Specimen C - Reviewed for QA(LWF).\X0D\\X0A\\X0D\\X0A\The presence of malignancy in this patient has been reported to **NAME[XXX] in Dr. **NAME[ZZZ]'s\X0D\\X0A\office on **DATE[Jan 4 12] at 2:38 PM.\X0D\\X0A\,,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  Received in formalin designated ""biopsy antrum"" is an ovoid fragment of pink-tan soft\X0D\\X0A\tissue measuring 3.5 mm in greatest dimension.  The specimen is entirely submitted in\X0D\\X0A\cassette A.\X0D\\X0A\\X0D\\X0A\B.  Received in formalin designated ""polyp transverse colon"" are two ovoid fragments of\X0D\\X0A\red-tan, polypoid, soft tissue measuring 4.5 to 7 mm in greatest dimension.  The larger\X0D\\X0A\specimen is marked with black ink and trisected.  The smaller specimen is bisected.  Both\X0D\\X0A\specimens are entirely submitted in cassette B.\X0D\\X0A\\X0D\\X0A\C.  Received in formalin designated ""descending colon polyp"" is an ovoid, pink-tan,\X0D\\X0A\pedunculated polyp measuring 2.5 x 2.0 x 1.8 cm.  The specimen is inked, sectioned, and\X0D\\X0A\entirely submitted in cassettes C1-C3.  **INITIALS\X0D\\X0A\\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A.  BIOPSY ANTRUM\X0D\\X0A\B.  POLYP TRANSVERSE COLON\X0D\\X0A\C.  DESCENDING COLON POLYP\X0D\\X0A\,,
REG1,COLON,0,493698,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is for therapy of adenomatous polyps in the colon. The\X0D\\X0A\operative findings: are one 40 mm polyp in the rectosigmoid colon. Incomplete\X0D\\X0A\resection. Resected tissue retrieved. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Apr 15 1956] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Jan 28 2012] 15:35\X0D\\X0A\Receipt Date: **DATE[Jan 28 2012] 15:35\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY], MD     Service: SRG     Location: ENDO\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jan 30 2012] 15:54\X0D\\X0A\RESIDENTS(**NAME[M): WWW VVV], DO","DIAGNOSIS\X0D\\X0A\RECTOSIGMOID COLON, BIOPSY:\X0D\\X0A\     INVASIVE ADENOCARCINOMA, WELL TO MODERATELY DIFFERENTIATED, ARISING IN\X0D\\X0A\TUBULOVILLOUS ADENOMA\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jan 30 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 154.0     MALIGNANT NEOPLASM RECTOSIGMOID JUNCTION\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M82633 P1140 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) rectosigmoid polyp                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 10 \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): red tan\X0D\\X0A\Consistency: soft and friable \X0D\\X0A\Size(s): 1.9 x 1.6 x 0.7 cm to 0.3 x 0.2 x 0.1 cm \X0D\\X0A\The largest fragment has no obvious point of attachment identified grossly.\X0D\\X0A\This large fragment is serially sectioned. \X0D\\X0A\Cassette summary: entirely submitted in screened A1  A4.   \X0D\\X0A\rgc/**DATE[Jan 29 2012] **NAME[WWW VVV], DO\X0D\\X0A\**NAME[SSS M. RRR",MICROSCOPIC DESCRIPTION\X0D\\X0A\A resident has participated in this service.  The electronic signature\X0D\\X0A\denotes the pathologist performing and responsible for the pathologic\X0D\\X0A\evaluation.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: recto-sigmoid polyp,,
REG1,COLON,0,493774,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is screening for colorectal malignant neoplasm.\X0D\\X0A\Operative procedure: colonoscopy. Intraoperative findings: one large 2 cm\X0D\\X0A\polyp in the rectosigmoid colon. Resected and retrieved. One 3 mm polyp in\X0D\\X0A\the sigmoid colon. Complete resection. Polyp tissue not retrieved. The\X0D\\X0A\examined portion of the ileum was normal. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Oct 20 1960] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Jun 10 2012] 11:34\X0D\\X0A\Receipt Date: **DATE[Jun 10 2012] 11:34\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], M.D.     Service: GAS     Location: ENDO\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Jun 12 2012] 16:32\X0D\\X0A\RESIDENTS(S): K.K. **NAME[WWW], DO","DIAGNOSIS\X0D\\X0A\LARGE INTESTINE, RECTOSIGMOID COLON, BIOPSY:\X0D\\X0A\  - INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA ARISING IN A\X0D\\X0A\TUBULOVILLOUS CARCINOMA\X0D\\X0A\   (SEE COMMENT).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jun 12 2012] **NAME[VVV UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M80103 M8140 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) rectosigmoid polyp                \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1  \X0D\\X0A\Shape(s): polypoid   \X0D\\X0A\Color(s): red \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 1.5 x 1 x 0.7 cm polypoid tissue fragment\X0D\\X0A\It is inked black\X0D\\X0A\It is serially sectioned and submitted in screened A1.  \X0D\\X0A\rgc/**DATE[Jun 11 2012] K.K. **NAME[WWW], DO\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections show a tubulovillous adenoma with invasive moderately differentiated\X0D\\X0A\adenocarcinoma.  The tumor extends to the submucosa but there is no evidence\X0D\\X0A\of lymphvascular invasion. The resected (cauterized margin) is clearly free\X0D\\X0A\of tumor involvement. Therefore, the patient does NOT need further resection\X0D\\X0A\(colectomy) and only close follow-up is recommended.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Recto-sigmoid polyp,,
REG1,COLON,0,493939,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is appendicitis.  Findings: not provided. Operative\X0D\\X0A\procedure: laparoscopic appendectomy.\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Jul 22 1990] (Age: **AGE[in 20s])  MW\X0D\\X0A\Collect Date: **DATE[Apr 31 2012] 11:52\X0D\\X0A\Receipt Date: **DATE[Apr 31 2012] 11:52\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: J.S. **NAME[YYY], MD     Service: SGB     Location: REC\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 7 2012] 16:25\X0D\\X0A\RESIDENTS(S): E.A. Pirruccello, DO","DIAGNOSIS\X0D\\X0A\APPENDIX, APPENDECTOMY:\X0D\\X0A\   - CARCINOID TUMOR, 0.7 CM (pT1a, pNX; SEE TEMPLATE AND COMMENT).\X0D\\X0A\   - MARGINS CANNOT BE ASSESSED (SEE COMMENT).\X0D\\X0A\   - ACUTE APPENDICITIS.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 3 2012] D.L. **NAME[WWW], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M82401 P1100 \X0D\\X0A\F: A: 88304, 67042 IMHC 1, S 88342 (PROF)",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled appendix and consists of a\X0D\\X0A\tan vermiform appendix with attached mesoappendix. The serosal surface is\X0D\\X0A\smooth and glistening.  A fecalith is not identified, however there is a\X0D\\X0A\yellow tan area in the lumen measuring up to 0.7 x 0.5 x 0.2 cm and this\X0D\\X0A\portion is submitted.\X0D\\X0A\Appendix measurement: 7 cm in length x 0.8 cm in diameter\X0D\\X0A\Lumen diameter: up to 0.5 cm \X0D\\X0A\Perforation: no\X0D\\X0A\The specimen is entirely submitted in A1-A5.\X0D\\X0A\ksl/**DATE[May 1 2012] E.A. Pirruccello, DO\X0D\\X0A\J.G. Combs","MICROSCOPIC DESCRIPTION\X0D\\X0A\     Per the technician who grossed the specimen, the lesion was located\X0D\\X0A\about three centimeters from the proximal surgical margin (although an exact\X0D\\X0A\measurement was not given).  The margin was not submitted separately, and\X0D\\X0A\therefore the true margins cannot be assessed.\X0D\\X0A\     A Ki-67 immunohistochemical stain was performed, and is positive in less\X0D\\X0A\than 2% of tumor cells.  This case was reviewed at the Intradepartmental\X0D\\X0A\Consensus Conference.\X0D\\X0A\     The case was discussed with Dr. **NAME[VVV UUU] by Dr. **NAME[WWW] on\X0D\\X0A\**DATE[May 7 12].\X0D\\X0A\APPENDIX:  Excision (Appendectomy) or Resection (template adapted from CAP",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Appendix\X0D\\X0A\Specimen \X0D\\X0A\Appendix\X0D\\X0A\Procedure\X0D\\X0A\ Appendectomy\X0D\\X0A\Specimen Integrity\X0D\\X0A\             Intact\X0D\\X0A\Tumor Site \X0D\\X0A\     Mid portion of appendix\X0D\\X0A\Tumor Size \X0D\\X0A\Greatest dimension: 0.7 cm\X0D\\X0A\Histologic Type \X0D\\X0A\Carcinoid \X0D\\X0A\Histologic Grade\X0D\\X0A\          G1: Low grade\X0D\\X0A\Mitotic Rate (Note D)\X0D\\X0A\Specify:  <1/10 high-power fields (HPF)\X0D\\X0A\Microscopic Tumor Extension  \X0D\\X0A\      Tumor invades muscularis propria\X0D\\X0A\\X0D\\X0A\Margins: \X0D\\X0A\Proximal Margin\X0D\\X0A\     Cannot be assessed\X0D\\X0A\Lymph-Vascular Invasion \X0D\\X0A\Not identified\X0D\\X0A\Pathologic Staging (pTNM) \X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\          pT1a:       Tumor 1 cm or less in greatest dimension\X0D\\X0A\Regional Lymph Nodes  \X0D\\X0A\     pNX      No nodes submitted or found\X0D\\X0A\Distant Metastasis \X0D\\X0A\     Not applicable \X0D\\X0A\Ancillary Studies (select all that apply) \X0D\\X0A\     Ki-67 index: =2%\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,,
REG1,COLON,0,494111,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is acute appendicitis. Intraoperative findings: acute\X0D\\X0A\appendicitis. Operative procedure: laparoscopic appendectomy [converted to\X0D\\X0A\open right hemicolectomy].\X0D\\X0A\Per op note:  .... very mobile right colon with enlarged retrocecal appendix\X0D\\X0A\.... mucus at the tip of the appendix .... \X0D\\X0A\omentum did not have any gross metastatic disease .... liver did not have any\X0D\\X0A\gross metastatic disease .... peritoneum had some\X0D\\X0A\exudative-type material particularly up around the liver .... biopsied and\X0D\\X0A\sent to pathology [sic] .... pelvis did not appear to have any metastatic\X0D\\X0A\disease\X0D\\X0A\Cf. ***PATH-NUMBER[1] (inguinal, hernia sac, bilateral inguinal hernia repair with\X0D\\X0A\removal of possible left spermatic cord lipoma):  Dissecting and extravasated\X0D\\X0A\mucin, vascularization, old hemorrhage and calcification  /  Comment  In\X0D\\X0A\addition to hydrocele sac, hernia sac findings .... unexplained abundant\X0D\\X0A\extravasated mucus .... no definite lipoma recognized .... findings worrisome\X0D\\X0A\for pseudomyxoma material from the peritoneal space occurring within a hernia\X0D\\X0A\sac \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Dec 11 1987] (Age: **AGE[in 20s])  MW\X0D\\X0A\Collect Date: **DATE[Nov 23 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Nov 25 2012] 08:28\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[2]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: SGB     Location: 8S\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Nov 29 2012] 16:09\X0D\\X0A\RESIDENTS(S): D.J. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\RIGHT COLON AND APPENDIX, RESECTION:\X0D\\X0A\     LOW-GRADE APPENDICEAL MUCINOUS NEOPLASM WITH LOW RISK OF RECURRENCE\X0D\\X0A\(pTis / NX / M1a) \X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Nov 29 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M80001 P1100 \X0D\\X0A\F: A: 88307",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received fresh and placed in formalin labeled appendix\X0D\\X0A\and right colon and consists of a fragment of cecum with attached appendix\X0D\\X0A\and small portion of attached terminal ileum. The margins appear viable;\X0D\\X0A\however, the serosa of the cecum is predominantly gray to dark red in\X0D\\X0A\appearance. The specimen measures 17.5 cm in length x 10 cm in average\X0D\\X0A\circumference. The cecal mucosa appears flattened. The appendix measures 8.5\X0D\\X0A\cm in length x 1.7 cm in diameter. The serosa is white and hemorrhagic in\X0D\\X0A\some areas. On sectioning, the lumen of the appendix is dilated and filled\X0D\\X0A\with tan-white mucoid material. The diameter of the lumen is 1.5 cm. Upon\X0D\\X0A\sectioning, in the tip of the appendix there appears to be a perforation. The\X0D\\X0A\perforation measures 0.4 cm. Prior to sectioning, the appendix serosal\X0D\\X0A\surface is inked blue. Cassette  A1  A2  appendix tip bisected with\X0D\\X0A\perforation; A3  proximal appendix sectioned; A4  terminal ileum staple\X0D\\X0A\margin shaved en face; A5  representative colon into IC valve; A6  distal\X0D\\X0A\staple margin shaved en face; A7-A17  remainder of appendix.  \X0D\\X0A\rgc/**DATE[Nov 25 2012] D.J. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\Appendiceal tumors (template #44)\X0D\\X0A\(Applies to all carcinomas arising in the vermiform appendix, including\X0D\\X0A\goblet-cell carcinoid tumor; not including other carcinoid tumors)\X0D\\X0A\Last updated **DATE[Sep 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Specimen or procedure:  right hemicolectomy\X0D\\X0A\Tumor site (proximal half / distal half / diffuse involvement / cannot be\X0D\\X0A\determined):  diffuse involvement \X0D\\X0A\Tumor size:  8.5 x 1.7 cm (size of appendix)\X0D\\X0A\Histologic type:  low-grade mucinous neoplasm with low risk of recurrence\X0D\\X0A\    - Cytologically low grade; flattened or villous architecture\X0D\\X0A\  - Extra-appendiceal acellular mucin present (cf. ***PATH-NUMBER[1]; left inquinal\X0D\\X0A\hernia sac containing extensive dissecting mucin) \X0D\\X0A\  - No extra-appendiceal neoplastic epithelium or invasion (multiple deeper\X0D\\X0A\sections examined of ***PATH-NUMBER[1]  block A1)\X0D\\X0A\Margins:    negative\X0D\\X0A\Pseudomyxoma peritonei (presence of mucinous material on the peritoneal\X0D\\X0A\surface; not localized to right lower quadrant): \X0D\\X0A\     Present in left inguinal hernia sac (cf. ***PATH-NUMBER[1]) without demonstrated\X0D\\X0A\neoplastic epithelium (either adenomatous or \X0D\\X0A\     carcinomatous)\X0D\\X0A\Regional lymph-node metastasis (ratio of positive to total number):  not\X0D\\X0A\excised\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\Tis:  Carcinoma in situ:  intraepithelial or invasion of lamina propria\X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\NX:  Cannot be assessed\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\\X0D\\X0A\M1a:  Intraperitoneal metastasis beyond the right lower quadrant, including\X0D\\X0A\pseudomyxoma peritonei (i.e., as defined above, \X0D\\X0A\          presence of mucinous material on the peritoneal surface; not\X0D\\X0A\localized to right lower quadrant)\X0D\\X0A\A resident has participated in this service.  A pathologist has performed and\X0D\\X0A\is responsible for the reported pathologic evaluation.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Appendix and colon,,
REG1,COLON,0,494193,3,,"Clinical Diagnosis and History\X0D\\X0A\LIKELY SQUAMOUS CARCINOMA OF THE PERINEUM AND ANAL CANAL\X0D\\X0A\OPER: PERINEAL BX, PERIANAL BX, EUA","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: PERINEAL LESION-aG\X0D\\X0A\2: ANAL WART-ag","Final Diagnosis\X0D\\X0A\1: PERINEAL LESION:\X0D\\X0A\     MULTIPLE FRAGMENTS OF SKIN / SQUAMOUS MUCOSA WITH MODERATELY \X0D\\X0A\    DIFFERENTIATED INVASIVE SQUAMOUS CELL CARCINOMA ARISING IN A\X0D\\X0A\         BACKGROUND OF EXTENSIVE SQUAMOUS CARCINOMA IN-SITU.\X0D\\X0A\ANGIOLYMPHATIC INVASION NOT IDENTIFIED.\X0D\\X0A\COMMENT: There is lack of optimal orientation of the fragments and it is\X0D\\X0A\difficult to ascertain the exact depth of invasion.   In one of the more well\X0D\\X0A\oriented fragments which has skin adnexal structures, the greatest depth of\X0D\\X0A\invasion is focally into fatty tissue to a depth of approximately 2.5 mm from\X0D\\X0A\the surface.  Because the specimen was received as multiple fragments the\X0D\\X0A\margins cannot be ascertained. \X0D\\X0A\2: ANAL WART:\X0D\\X0A\     SQUAMOUS CELL CARCINOMA IN-SITU WITH FOCUS OF POSSIBLE INVASION AND \X0D\\X0A\        ULCERATION.\X0D\\X0A\**INITIALS \X0D\\X0A\IHC/MER \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **PLACE",,"Gross Description\X0D\\X0A\1: Received in formalin designated ""perineal lesions"" are six highly irregular\X0D\\X0A\fragments of pink tan rubbery tissue each which appears to be partially covered\X0D\\X0A\by skin or mucosa.  They form an aggregate 22 x up to 15 x up to 6 mm.  totally\X0D\\X0A\submitted in A.  **INITIALS \X0D\\X0A\2: Received in formalin designated ""anal wart"" is telfa with two bits of\X0D\\X0A\irregular pink tan tissue each measuring approximately 3 mm in greatest\X0D\\X0A\dimension. \X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,COLON,0,494527,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\gastritis\X0D\\X0A\,"ENDOC EGD\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3062 - SUR PATH IV\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH IV/5, SPEC STAIN GR1/3, SPEC STAIN GR2/2\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH IV (**DATE[May 19 12]-1249)\X0D\\X0A\SPEC STAIN GR1 (**DATE[May 19 12]-1249)\X0D\\X0A\SPEC STAIN GR2 (**DATE[May 19 12]-1249)\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\A.  ESOPHAGEAL BIOPSY:\X0D\\X0A\ACTIVE ESOPHAGITIS CONSISTENT WITH REFLUX.\X0D\\X0A\B.  PROXIMAL STOMACH BIOPSY:\X0D\\X0A\CHRONIC GASTRITIS.\X0D\\X0A\C.  GASTRIC BIOPSY:\X0D\\X0A\GASTRIC ANTRAL MUCOSA WITH CHRONIC GASTRITIS.\X0D\\X0A\D.  RECTAL MASS BIOPSY:\X0D\\X0A\MODERATELY DIFFERENTIATED INFILTRATING ADENOCARCINOMA.\X0D\\X0A\E.  CECAL BIOPSY:\X0D\\X0A\NO HISTOPATHOLOGIC ABNORMALITY.\X0D\\X0A\ \X0D\\X0A\88305 x5, 88312 x3, 88313 x2\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\The specimen is received in five containers.  The first container is received designated as\X0D\\X0A\""esophageal biopsy"" and consists of a single small fragment of gray soft tissue.  The\X0D\\X0A\specimen measures 0.1 cm. in greatest dimension.  It is submitted in toto in cassette A.\X0D\\X0A\ \X0D\\X0A\The second container is received designated as ""proximal stomach biopsy"" and consists of a\X0D\\X0A\single irregularly-shaped fragment of gray to red soft tissue.  The specimen measures 0.3\X0D\\X0A\cm. in greatest dimension.  It is submitted in toto in cassette B.\X0D\\X0A\ \X0D\\X0A\The third container is received designated as ""gastric biopsy"" and consists of a single\X0D\\X0A\small fragment of gray to red soft tissue.  The specimen measures 0.2 cm. in greatest\X0D\\X0A\dimension.  It is submitted in toto in cassette C.\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\GROSS DESCRIPTION          (Continued)\X0D\\X0A\ \X0D\\X0A\The fourth container is received designated as ""rectal mass biopsy"" and consists of three\X0D\\X0A\(3) irregularly-shaped fragments of gray soft tissue.  The fragments vary in size from 0.2\X0D\\X0A\to 0.3 cm. in greatest dimension.  The specimen is submitted in toto in cassette D.\X0D\\X0A\ \X0D\\X0A\The remaining container is received designated as ""cecal polyp biopsy"" and consists of a\X0D\\X0A\single small fragment of gray soft tissue.  The specimen measures less than 0.1 cm. in\X0D\\X0A\greatest dimension.  It is submitted in toto in cassette E.\X0D\\X0A\",MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\A.  Section A consists of segments of esophageal mucosa lined by stratified squamous\X0D\\X0A\nonkeratinizing epithelium.  Occasional eosinophils are seen within the epithelium.  PAS\X0D\\X0A\staining shows marked decreased in staining of the epithelium and no fungal organisms seen.\X0D\\X0A\ \X0D\\X0A\B.  Section B consists of segments of gastric fundal mucosa.  The lamina propria is\X0D\\X0A\infiltrated with moderate numbers of chronic inflammatory cells.  Small chronic inflammatory\X0D\\X0A\aggregates are noted.  PAS stain reveals no infiltrative signet ring cells.  The Giemsa\X0D\\X0A\stain reveals no organisms.\X0D\\X0A\ \X0D\\X0A\C.  Section C consists of segments of gastric antral mucosa.  The lamina propria is\X0D\\X0A\infiltrated with moderate numbers of chronic inflammatory cells.  PAS stain reveals no\X0D\\X0A\infiltrative signet ring cells.  The Giemsa stain reveals no organisms.\X0D\\X0A\ \X0D\\X0A\D.  Section D consists of segments of colonic mucosa.  Beneath the mucosa are seen malignant\X0D\\X0A\glands with numerous mitoses.\X0D\\X0A\ \X0D\\X0A\E.  Section E consists of segments of colonic mucosa with no histopathologic abnormality.\X0D\\X0A\,SPECIMEN\X0D\\X0A\ \X0D\\X0A\A.  ESOPHAGEAL BIOPSY\X0D\\X0A\B.  PROXIMAL STOMACH BIOPSY\X0D\\X0A\C.  GASTRIC BIOPSY\X0D\\X0A\D.  RECTAL MASS BIOPSY\X0D\\X0A\E.  CECAL POLYP\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT,,
REG1,COLON,0,494553,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\hepatic flexure mass\X0D\\X0A\,"CP\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[ZZZ,YYY M], M.D.\X0D\\X0A\**STREET-ADDRESS, **ROOM **PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\**NAME[XXX,WWW M].\X0D\\X0A\**INSTITUTION\X0D\\X0A\201 PARK STREET\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\MOGARALA,INDRANEEL\X0D\\X0A\COMMONWEALTH MEDICAL PLAZA\X0D\\X0A\720 SECOND STREET, **ROOM **PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\MORSI,NAGY H.\X0D\\X0A\1701 **NAME[VVV UUU]\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI, PT CATEGORY\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI (**DATE[Aug 14 12]-1156)\X0D\\X0A\PT CATEGORY (**DATE[Aug 14 12]-1156)\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\TERMINAL ILEUM AND RIGHT COLON, RIGHT HEMICOLECTOMY:\X0D\\X0A\INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA ARISING IN\X0D\\X0A\ASCENDING COLON, 5.5 CM. IN GREATEST DIMENSION.\X0D\\X0A\TUMOR INVADES THROUGH THE MUSCULARIS PROPRIA AND INTO ADHERENT\X0D\\X0A\ADIPOSE TISSUE ALONG THE SEROSAL ASPECT (pT4b).\X0D\\X0A\PROXIMAL AND DISTAL MARGINS NEGATIVE FOR TUMOR.\X0D\\X0A\MULTIPLE SYNCHRONOUS TUBULAR ADENOMAS/TUBULOVILLOUS ADENOMAS.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\DIAGNOSIS              (Continued)\X0D\\X0A\ \X0D\\X0A\MESENTERIC LYMPH NODES (22):\X0D\\X0A\ONE OF TWENTY-TWO LYMPH NODES INVOLVED BY METASTATIC\X0D\\X0A\ADENOCARCINOMA SIMILAR TO COLON PRIMARY (1/22).\X0D\\X0A\AFFECTED NODE IS PRESENT AT MESENTERIC MARGIN.\X0D\\X0A\CAP CHECKLIST:\X0D\\X0A\ \X0D\\X0A\Specimen:  Terminal ileum and right colon\X0D\\X0A\Procedure:  Right hemicolectomy\X0D\\X0A\Tumor Site:  Ascending colon\X0D\\X0A\Tumor Size:  5.5 cm. in greatest dimension\X0D\\X0A\Macroscopic Tumor Perforation:  Not identified\X0D\\X0A\Histologic Type:  Adenocarcinoma\X0D\\X0A\Histologic Grade:  Low grade (moderately differentiated)\X0D\\X0A\Microscopic Tumor Extension:  Tumor penetrates to the surface of the visceral peritoneum\X0D\\X0A\(serosa) and directly invades adjacent structures (adherent adipose tissue)\X0D\\X0A\Margins:\X0D\\X0A\Proximal Margin:  Uninvolved by invasive carcinoma\X0D\\X0A\Distal Margin:  Uninvolved by invasive carcinoma\X0D\\X0A\Mesenteric Margin:  Involved by invasive carcinoma (in a positive lymph node)\X0D\\X0A\Treatment Effect:  No prior treatment\X0D\\X0A\Lymph-Vascular Invasion:  Not identified\X0D\\X0A\Perineural Invasion:  Not identified\X0D\\X0A\Tumor Deposits:  Not identified\X0D\\X0A\Type of Polyp in which Invasive Carcinoma Arose:  Tubulovillous adenoma\X0D\\X0A\Pathologic Staging (pTNM):\X0D\\X0A\Primary Tumor (pT):  pT4b\X0D\\X0A\Regional Lymph Nodes (pN):  pN1a\X0D\\X0A\Distant Metastasis (pM):  Not applicable\X0D\\X0A\ \X0D\\X0A\88309, 3260F\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\Received in formalin designated as ""right colon"" are two (2) segments of bowel. The larger\X0D\\X0A\is a right hemicolectomy specimen consisting of a 9 cm. segment of terminal ileum and 20 cm.\X0D\\X0A\segment of large bowel. The terminal ileum has a maximum diameter of 2 cm. The large bowel\X0D\\X0A\has a maximum diameter of 3.9 cm. There is a palpable mass present with puckering of the\X0D\\X0A\overlying serosal surface approximately 7 cm. from the distal margin. There are serosal\X0D\\X0A\adhesions. No appendix is present. There are staple lines at the proximal and distal\X0D\\X0A\margins. They are removed, and the specimen is opened showing a nearly circumferential tumor\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\GROSS DESCRIPTION          (Continued)\X0D\\X0A\ \X0D\\X0A\in the apparent proximal ascending colon. The tumor measures 5.5 cm. in maximum dimension.\X0D\\X0A\It has rolled borders and central ulceration. Sections of the tumor show no obvious\X0D\\X0A\extension into the mesenteric adipose. On the antimesenteric surface there is focal possible\X0D\\X0A\minimal extension into adherent adipose tissue. There are also multiple additional polyps\X0D\\X0A\ranging in size from 0.2 to 1.5 cm. in diameter. They are all located at least 5 cm. from\X0D\\X0A\the proximal and distal margins. The mesentery measures up to 8 cm. in length. The\X0D\\X0A\mesenteric margin is greater than 10 cm. from the tumor. There is a grossly positive node at\X0D\\X0A\the mesenteric margin. All identified lymph nodes are submitted.\X0D\\X0A\ \X0D\\X0A\There is also a separate segment of small bowel in the specimen container measuring up to 4\X0D\\X0A\cm. in length x 2 cm. in diameter. There are staple lines at either end. They are removed.\X0D\\X0A\The specimen is lined by  homogenous folded light tan mucosa. There is very little mesentery\X0D\\X0A\attached to the specimen. Sections show no vascular lesions or lymphadenopathy. Multiple\X0D\\X0A\representative sections are submitted.\X0D\\X0A\ \X0D\\X0A\SUMMARY OF SECTIONS:\X0D\\X0A\ \X0D\\X0A\A.    Proximal margin.\X0D\\X0A\B.    Distal margin.\X0D\\X0A\C-D.    Tumor with deepest invasion, antimesenteric.\X0D\\X0A\E.    Tumor with deepest invasion, mesenteric.\X0D\\X0A\F.    Small polyps.\X0D\\X0A\G.    Two polyps, one inked black.\X0D\\X0A\H.    Largest polyp.\X0D\\X0A\I.     Mesenteric margin.\X0D\\X0A\J.    Additional sections of grossly positive node at mesenteric margin.\X0D\\X0A\K.    Additional small lymph nodes immediately adjacent to mesenteric margin.\X0D\\X0A\L.    Sections from separate segment of small bowel.\X0D\\X0A\M-Q.    Lymph nodes for count\X0D\\X0A\R.    Lymph nodes not for count\X0D\\X0A\","MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\Sections of the tumor show an invasive moderately differentiated adenocarcinoma arising in a\X0D\\X0A\background of a preexisting tubulovillous adenoma.  The tumor invades both as well-formed\X0D\\X0A\glands and in fused glandular arrays.  The tumor invades through the muscularis propria and\X0D\\X0A\into adherent fibroadipose tissue along the antimesenteric aspect consistent with a T4\X0D\\X0A\designation.  There is minimal mucinous differentiation.  No lymphovascular or perineural\X0D\\X0A\invasion is seen in the representative sections.  The proximal and distal margins are\X0D\\X0A\negative for tumor.  A total of twenty-two lymph nodes are examined microscopically, and one\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\MICROSCOPIC EXAMINATION       (Continued)\X0D\\X0A\ \X0D\\X0A\is involved by metastatic adenocarcinoma similar to the colon primary.  The positive node is\X0D\\X0A\located at the mesenteric margin (blocks I-J).  The separate polyps are a mixture of tubular\X0D\\X0A\adenomas, tubulovillous adenomas, and lymphoid aggregates.\X0D\\X0A\ \X0D\\X0A\Sections of the separate segment of small bowel show no significant histopathologic change.\X0D\\X0A\",SPECIMEN\X0D\\X0A\ \X0D\\X0A\RIGHT COLON\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT,,
REG1,COLON,0,494639,1,,"CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\perforation colon and free air, splenic flexure mass and cecal perforation\X0D\\X0A\","N/V\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3063 - SUR PATH V\X0D\\X0A\ \X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[WWW,VVV M].\X0D\\X0A\**INSTITUTION\X0D\\X0A\**STREET-ADDRESS, **ROOM **PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\**NAME[ZZZ,YYY M]. M.D.\X0D\\X0A\**INSTITUTION\X0D\\X0A\201 PARK STREET\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\HURT,**NAME[XXX M]. M.D.\X0D\\X0A\**INSTITUTION\X0D\\X0A\**STREET-ADDRESS, FIRST FLOOR\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\**NAME[UUU,TTT M]\X0D\\X0A\MEDICAL ARTS BUILDING\X0D\\X0A\**STREET-ADDRESS, **ROOM **PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\WENTWORTH,RANCE R.\X0D\\X0A\**STREET-ADDRESS, **INSTITUTION\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI, SUR PATH V\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH VI (**DATE[Jul 01 12]-1555)\X0D\\X0A\SUR PATH V (**DATE[Jul 01 12]-1555)\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\TERMINAL ILEUM AND COLON, SUBTOTAL COLECTOMY WITH PORTION OF DISTAL PANCREAS:\X0D\\X0A\INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA ARISING AT\X0D\\X0A\SPLENIC FLEXURE WITH INVASION THROUGH THE BOWEL WALL AND DIRECT\X0D\\X0A\EXTENSION INTO DISTAL PANCREAS.\X0D\\X0A\TUMOR MEASURES 5 CM. IN GREATEST DIMENSION.\X0D\\X0A\TUMOR EXTENDS TO SOFT TISSUE MARGINS IN PERIPANCREATIC SOFT TISSUE.\X0D\\X0A\LYMPHOVASCULAR AND PERINEURAL INVASION IDENTIFIED.\X0D\\X0A\PROXIMAL PANCREAS MARGIN NEGATIVE FOR TUMOR.\X0D\\X0A\TERMINAL ILEUM AND DISTAL COLONIC MARGINS NEGATIVE FOR TUMOR.\X0D\\X0A\MESENTERIC MARGIN NEGATIVE FOR TUMOR\X0D\\X0A\SEPARATE TUBULAR ADENOMAS x3.\X0D\\X0A\DILATION OF PROXIMAL COLON AND TERMINAL ILEUM CONSISTENT WITH\X0D\\X0A\OBSTRUCTION.\X0D\\X0A\CECAL DEFECT CONSISTENT WITH PERFORATION WITH ASSOCIATED ACUTE\X0D\\X0A\PERITONITIS.\X0D\\X0A\DIVERTICULOSIS.\X0D\\X0A\MESENTERIC/PERIPANCREATIC LYMPH NODES (34):\X0D\\X0A\SEVEN OF 34 LYMPH NODES INVOLVED BY METASTATIC ADENOCARCINOMA\X0D\\X0A\WITH AREAS OF EXTRACAPSULAR EXTENSION.\X0D\\X0A\SCATTERED TUMOR DEPOSITS IN MESENTERY.\X0D\\X0A\APPENDIX:\X0D\\X0A\ACUTE SEROSITIS.\X0D\\X0A\NEGATIVE FOR TUMOR.\X0D\\X0A\OMENTUM, PARTIAL OMENTECTOMY:\X0D\\X0A\NEGATIVE FOR TUMOR.\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CAP CHECKLIST:\X0D\\X0A\ \X0D\\X0A\Specimen:  Terminal ileum, cecum, appendix, ascending colon, transverse colon, descending\X0D\\X0A\colon, and sigmoid\X0D\\X0A\Procedure:  Subtotal colectomy\X0D\\X0A\Tumor Site:  Splenic flexure\X0D\\X0A\Tumor Size:  5.0 cm. in greatest dimension\X0D\\X0A\Macroscopic Tumor Perforation:  Not identified\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\DIAGNOSIS              (Continued)\X0D\\X0A\ \X0D\\X0A\Histologic Type:  Adenocarcinoma\X0D\\X0A\Histologic Grade:  Low grade (moderately differentiated)\X0D\\X0A\Microscopic Tumor Extension:  Tumor penetrates to the surface of the visceral peritoneum\X0D\\X0A\(serosa) and directly invades adjacent structures (pancreas)\X0D\\X0A\Margins\X0D\\X0A\Proximal Margin:  Uninvolved by invasive carcinoma\X0D\\X0A\Distal Margin:  Uninvolved by invasive carcinoma\X0D\\X0A\Mesenteric margin:  Uninvolved by invasive carcinoma\X0D\\X0A\Peripancreatic soft tissue margin:  Involved by invasive carcinoma\X0D\\X0A\Treatment Effect:  No prior treatment\X0D\\X0A\Lymph-Vascular Invasion:  Present\X0D\\X0A\Perineural Invasion:  Present\X0D\\X0A\Tumor Deposits:  Present\X0D\\X0A\Pathologic Staging (pTNM)\X0D\\X0A\Primary Tumor:  pT4b\X0D\\X0A\Regional Lymph Nodes:  pN2b\X0D\\X0A\Number examined:  34, number involved: 7\X0D\\X0A\Distant Metastasis (pM):  Not applicable\X0D\\X0A\ \X0D\\X0A\88309, 88307, 3260F\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\Received in formalin designated ""colon and distal pancreas"" is a subtotal colectomy specimen\X0D\\X0A\with attached short segment of terminal ileum.  The terminal ileum measures 12.0 cm. in\X0D\\X0A\length and is slightly dilated up to 4.0 cm. in diameter.  The large bowel consists of\X0D\\X0A\cecum, ascending, transverse, descending, and probable portion of sigmoid colon.  It\X0D\\X0A\measures approximately 100.0 cm. in length.  Approximately two-thirds of the colonic portion\X0D\\X0A\of the specimen is dilated with dilation up to 12.0 cm. in the cecum.  Immediately distal to\X0D\\X0A\the area of dilatation, there is a mass, oriented by the surgeon as at the splenic flexure,\X0D\\X0A\with puckering of the overlying serosa, adherent adipose tissue, and with a small amount of\X0D\\X0A\adherent pancreatic tissue.  Beyond this, the colon has an approximate normal diameter of\X0D\\X0A\2.0 cm. for a distance measuring approximately 30 cm.  The bowel segment is opened and is\X0D\\X0A\shown to contain abundant yellow-green liquid stool proximal to the mass and a small amount\X0D\\X0A\of formed dark green stool distal to the mass.  The mass itself consists of an intraluminal\X0D\\X0A\tumor which is nearly circumferential measuring 4.0 x 3.0 cm. on its surface.  It has\X0D\\X0A\central ulceration and rolled borders and is located approximately 30 cm. from the distal\X0D\\X0A\margin and approximately 100 cm. from the proximal margin.  The attached portion of pancreas\X0D\\X0A\and adjacent soft tissue contains a staple line at its margin.  The staple line is removed\X0D\\X0A\showing no obvious tumor.  This margin is located 6.0 cm. from the intraluminal tumor.  The\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\GROSS DESCRIPTION          (Continued)\X0D\\X0A\ \X0D\\X0A\closest mesenteric margin is located 7.0 cm. from the intraluminal tumor and also shows no\X0D\\X0A\obvious involvement by tumor.  The serosal tissues and adherent adipose tissues in the area\X0D\\X0A\of the tumor are puckered.  These margins are inked with black ink.  Sections of the tumor\X0D\\X0A\show extension through the wall of the bowel into the adjacent mesenteric adipose tissue and\X0D\\X0A\pancreas.  The tumor extends to within 0.1 cm. of the inked soft tissue margins in these\X0D\\X0A\areas.  The tumor is approximately flask-shaped measuring up to 5 cm. in thickness.\X0D\\X0A\ \X0D\\X0A\There is a large polyp in the ascending colon measuring up to 1.0 cm. in diameter.  Two (2)\X0D\\X0A\smaller similar-appearing polyps are noted in the descending colon measuring 0.5 cm. and 0.3\X0D\\X0A\cm. in diameter.  The remainder of the mucosa is folded and light tan.  In the cecum, there\X0D\\X0A\is a defect which has been closed with sutures measuring up to 1.5 cm. in length.  It is\X0D\\X0A\surrounded by hemorrhage on the serosal surface and is suggestive of perforation.  Scattered\X0D\\X0A\diverticula are noted.\X0D\\X0A\ \X0D\\X0A\There is an appendix at the cecum measuring 5.5 cm. in length by 0.6 cm. diameter.  Sections\X0D\\X0A\show no focal lesions.\X0D\\X0A\ \X0D\\X0A\There is a small amount of omental tissue adherent near the tumor measuring up to 10.0 x 8.0\X0D\\X0A\x 1.5 cm.  Serial sections show no tumor nodules.\X0D\\X0A\ \X0D\\X0A\The mesentery is dissected, showing several prominent nodes near the tumor and areas of\X0D\\X0A\stellate tumor within the mesentery suggestive of vascular invasion/tumor deposits.  After\X0D\\X0A\initial search, the remainder of the mesentery is placed in a fat-clearing solution after\X0D\\X0A\which it is dissected and all identified lymph nodes submitted. Multiple representative\X0D\\X0A\sections are submitted for the remainder of the specimen.\X0D\\X0A\ \X0D\\X0A\Summary of Sections:\X0D\\X0A\A.        Proximal margin.\X0D\\X0A\B.        Distal margin.\X0D\\X0A\C.        Appendix.\X0D\\X0A\D.          Cecal defect.\X0D\\X0A\E.          Colon polyps x3, largest bisected.\X0D\\X0A\F.          Pancreatic/adjacent soft tissue margins.\X0D\\X0A\G.         Mesenteric margin.\X0D\\X0A\H.        Tumor with mesentery/adherent adipose.\X0D\\X0A\I-K.         Cross-section of tumor with deepest invasion including adjacent pancreas,\X0D\\X0A\trisected.\X0D\\X0A\L-N.        Cross-section of tumor with deepest invasion including adjacent pancreas,\X0D\\X0A\sequential sections.\X0D\\X0A\O-P:        Omentum.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\GROSS DESCRIPTION          (Continued)\X0D\\X0A\ \X0D\\X0A\Q.        Mesenteric nodule near tumor, possible tumor deposit.\X0D\\X0A\R.         Firm mesenteric tissue, possible tumor deposits.\X0D\\X0A\S.        Prominent lymph nodes near tumor x4.\X0D\\X0A\T-W.        Lymph nodes identified after fixation in Dissect-Aid.\X0D\\X0A\","MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\Sections of the tumor show an invasive moderately differentiated adenocarcinoma.  There are\X0D\\X0A\areas of adenocarcinoma in-situ on the surface with sharp transition to normal mucosa.  The\X0D\\X0A\tumor invades through the muscularis propria and into adherent adipose tissue with direct\X0D\\X0A\extension into the pancreas.  The tumor extends to soft tissue margins in the\X0D\\X0A\mesenteric/peripancreatic regions in some sections.  Lymphovascular invasion is identified,\X0D\\X0A\and there are foci of perineural invasion.  The pancreatic and mesenteric margins are\X0D\\X0A\negative for tumor.  The proximal and distal margins are negative for tumor.  There are\X0D\\X0A\multiple foci of tumor deposits in the mesentery.  A total of 34 mesenteric/peripancreatic\X0D\\X0A\lymph nodes are confirmed microscopically, and 7 are involved by metastatic adenocarcinoma.\X0D\\X0A\Foci of extracapsular extension are seen.\X0D\\X0A\ \X0D\\X0A\Sections of the cecum show changes consistent with perforation with associated acute\X0D\\X0A\peritonitis.  Sections of the other polypoid lesions in the colon show tubular adenomas.\X0D\\X0A\Sections of the appendix show acute serositis.  Sections of the omentum are negative for\X0D\\X0A\tumor.\X0D\\X0A\",SPECIMEN\X0D\\X0A\ \X0D\\X0A\COLON AND DISTAL PANCREAS\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT,,
REG1,COLON,0,494909,1,,CLINICAL HISTORY: Preop diagnosis left colon carcinoma.,"Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX M WWW], VVV] PhD **DATE[Jan 04 12]","FINAL DIAGNOSIS: LEFT COLON, RESECTION INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA EXTENDING THROUGH MUSCULARIS PROPRIA INTO SUBSEROSA. EVIDENCE OF LYMPHOVASCULAR INVASION. NO METASTATIC CARCINOMA IDENTIFIED IN 16 LYMPH NODES. SURGICAL MARGINS FREE OF TUMOR. SEE COMMENT.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and ""left colon and doughnuts.""  The specimen is received in formalin and consists of a previously opened colon segment, measuring 29.5 x 4 cm.  Within the middle of the specimen is a circumferential mass, centrally ulcerated with peripheral heaped-up margins.  The mass measures 5.5 x 4 cm.  The serosa is tan-pink and within the area of the mass there is indentation.  Grossly the mass is variegated tan-white, moderately firm and is grossly suspicious for extending into the subserosa.  Representative sections of the mass are placed in Blocks 1-6.  The mass is well removed from the proximal and distal colonic margins which are grossly viable and represented in Block 7.  The remaining colonic mucosa is uniform tan-pink with normal rugal pattern.  No additional masses or areas suspicious for malignancy are identified.  The pericolonic adipose tissues are removed, serially sectioned and placed in lymph node revealing solution.  Also received in the container are two portions of mucosa, measuring 4 x 0.5 cm. and 2 x 1.2 cm.  These are uniform tan-pink and representative sections are placed in Block 8.  The pericolonic adipose tissues are examined and possible lymph nodes removed and placed in Blocks 9 and 10.","COMMENT WORD: The left colon is found to contain a mass, measuring 5.5 x 4 cm.  Microscopically this mass is composed of invasive moderately differentiated adenocarcinoma.  The neoplasm extends through the muscularis propria into the subserosa.  There is no evidence of metastatic carcinoma in the 16 examined lymph nodes.  The surgical margins are free of tumor.  Staging criteria: T3, N0 probable Stage IIA.  Histopathologic grade: G2, moderately differentiated. Residual tumor, R0, margins histologically negative.  Histopathologic type: adenocarcinoma (minor component of mucinous carcinoma, less than 50%).",Specimen Number: ***PATH-NUMBER[1]. Tissues: Left colon. Specimen Comments:,,
REG1,COLON,0,494928,1,,"CLINICAL HISTORY: ***PATH-NUMBER[1] Polyp ascending colon: Villous adenoma with moderate architectural atypia, no invasion is identified.  Preop diagnosis h/o colon adenoma.   Postop diagnosis colon polyp and mass.","Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX WWW], MD **DATE[Oct 21 12]","FINAL DIAGNOSIS: A.    POLYP OF CECUM HYPERPLASTIC POLYP. B.    MASS ASCENDING COLON, BIOPSY INFILTRATING MODERATELY DIFFERENTIATED ADENOCARCINOMA WITH ADJACENT INTENSE INFLAMMATION. LESION IS BEST SEEN ON THE LEVEL 2 SLIDE. PLEASE EVALUATE FURTHER.",,"GROSS DESCRIPTION: A.    The specimen is received in a container labeled with the patient's name, number, date and ""polyp of cecum.""  The specimen is received in formalin and consists of a single 3 mm. grayish-tan tissue fragment.  The specimen is totally submitted in Block A. B.    The specimen is received in a container labeled with the patient's name, number, date and ""biopsy ascending colon mass.""  The specimen is received in formalin and consists of three 2-3 mm. pale tan mucosal fragments.  The specimen is totally submitted in Block B.",,"Specimen Number: ***PATH-NUMBER[2]. Tissues: A. Cecum - Polyp B. Ascending colon - Mass, Biopsy. Specimen Comments:",,
REG1,COLON,0,495138,3,,PRE-OPERATIVE DIAGNOSIS: SPLENIC FLEXURE MASS.,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,MARK I. Status: SOUT","MICROSCOPIC INTERPRETATION: #1 - SIGMOID COLON POLYPS: TUBULAR ADENOMA OF LARGE INTESTINE MUCOSA. NEGATIVE FOR SEVERE DYSPLASIA OR MALIGNANCY. #2 - STALK OF SIGMOID COLON POLYP: STALK OF TUBULAR ADENOMA OF LARGE INTESTINE MUCOSA. NEGATIVE FOR SEVERE DYSPLASIA OR MALIGNANCY. STALK MARGIN NEGATIVE FOR DYSPLASIA. #3 - COLON POLYP AT 30 CM.: SEVERE GLANDULAR DYSPLASIA/INTRAMUCOSAL COLONIC ADENOCARCINOMA. NEGATIVE FOR DEFINITIVE INVASIVE TUMOR. SURGICAL STALK MARGIN NEGATIVE FOR TUMOR (SEE NOTE). NOTE:  The pedunculated large intestine mucosal polyp demonstrates severe glandular dysplasia/intramucosal colonic adenocarcinoma within its distal tip.  Tumor is located 7 mm. from the closest cauterized stalk margin.. Final Signout: **NAME[YYY XXX], MD **DATE[Dec 14 11]",,GROSS DESCRIPTION: The specimens are received within formalin in three separate containers. Specimen #1 - is labeled sigmoid colon polyps and consists of four tan portions of soft tissue which range from 4-8 mm. in diameter.  The largest fragment is bisected and the specimen is entirely submitted in one block. Specimen #2 - is labeled sigmoid polyp stalk and consists of a tan soft tissue fragment measuring 6 x 5 x 4 mm.  It is bisected and entirely submitted in one block. Specimen #3 - is labeled colon polyp at 30 cm. and consists of a pedunculated mucosal polyp which is brown-tan and measures 16 mm. long and up to 8 mm. in diameter.  It is bisected perpendicular to the stalk margin and entirely submitted in one block.,,Tissues: 1. COLON BIOPSY - SIGMOID POLYPS 2. COLON BIOPSY - SIGMOID POLYP STALK 3. COLON BIOPSY - POLYP AT 30 CM. Specimen Comments: CPT CODES: 88305 x 3,,
REG1,COLON,0,495225,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA] R                        DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\COMMENT:  This case was discussed with Dr. **NAME[YYY] on **DATE[Dec 25 11] at 9:45\X0D\\X0A\am and presented at the intradepartmental consensus conference (SXH,\X0D\\X0A\**NAME[XXX]).\X0D\\X0A\                                <Sign Out Dr. **NAME[WWW]>\X0D\\X0A\                                **NAME[VVV UUU], D.O., Pathologist\X0D\\X0A\CLINICAL           MELENA, LOWER ABDOMINAL PAIN\X0D\\X0A\INFORMATION:\X0D\\X0A\                                                         Trans ID:  RVL\X0D\\X0A\                                                          Trans ID: AA\X0D\\X0A\Part B: 88305 x 2\X0D\\X0A\ ICD9: 789.0     211.3\X0D\\X0A\PATIENT:  **NAME[BBB, AAA] R                           **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cATL6lRrlwj7AGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zHibVju/lZipRYqnezYzbys\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\(A)  Colon, ""cecum"", endoscopic biopsy:\X0D\\X0A\ Tubular adenoma.\X0D\\X0A\ Sessile serrated polyp.\X0D\\X0A\ See microscopic description.\X0D\\X0A\(B)  Colon, ""50-55 cm."", endoscopic biopsy:\X0D\\X0A\ Ulcerated, detached fragments of colonic mucosa with at least high\X0D\\X0A\grade dysplasia/carcinoma in-situ (see    microscopic description).",,"GROSS DESCRIPTION:\X0D\\X0A\The following specimens are received in prefilled formalin containers:\X0D\\X0A\(A) Labeled ""cecal polyp"" are multiple pieces of tan-pink soft tissue\X0D\\X0A\measuring 0.2 up to 0.6 cm. in greatest dimension.  Entirely submitted.\X0D\\X0A\(B) Labeled ""ulcerative segment of colon, 50-55 cm. biopsy"" are\X0D\\X0A\multiple pieces of tan-pink soft tissue measuring 0.1 up to 0.5 cm. in\X0D\\X0A\greatest dimension.  Entirely submitted./AKC,SXH","MICROSCOPIC DESCRIPTION:\X0D\\X0A\(A)  Histologic sections demonstrate multiple fragments of colonic\X0D\\X0A\mucosa. Some of the fragments show hyperchromasia and stratification\X0D\\X0A\consistent with a tubular adenoma.  Other fragments show serrated\X0D\\X0A\glands.  No high-grade dysplasia identified.\X0D\\X0A\(B)  Histologic sections demonstrate fragments of colonic mucosa. Some\X0D\\X0A\of the fragments are essentially ulcerated with underlying granulation\X0D\\X0A\tissue. Adjacent to these ulcerative areas is adenomatous colonic\X0D\\X0A\mucosa with crowded glands and marked epithelial atypia, consistent\X0D\\X0A\with at least high grade dysplasia/carcinoma in-situ.  The depth of\X0D\\X0A\invasion cannot be determined due to the ulceration and superficial\X0D\\X0A\nature of the biopsy and invasion can't be excluded.  As such,\X0D\\X0A\additional evaluation is recommended.","TISSUE SUBMITTED:  (A) CECAL POLYP\X0D\\X0A\                   (B) COLON BIOPSY, ULCERATIVE SEGMENT AT 50-55 CM",,
REG1,COLON,0,495257,1,,,"SEE BELOW\X0D\\X0A\                                            **NAME[ZZZ]'s\X0D\\X0A\PATIENT  **NAME[BBB, AAA]                   DAUGHTERS\X0D\\X0A\:\X0D\\X0A\ACCESSI  **ID-NUM-SUR                       **INSTITUTION\X0D\\X0A\ON#\X0D\\X0A\                                            2201 **PLACE AVENUE,\X0D\\X0A\                                            **PLACE, KY **ZIP-CODE\X0D\\X0A\                                            TELEPHONE:  **PHONE,\X0D\\X0A\                                             **PHONE\X0D\\X0A\                                                         Trans ID:  K9P\X0D\\X0A\                                                          Trans ID:  AA\X0D\\X0A\Part B: 88305 x 3,  88312 x 1\X0D\\X0A\ ICD9: 285.9     578.1     V76.51     153.9\X0D\\X0A\PATIENT:  **NAME[BBB, AAA]                      **NAME[ZZZ]'s DAUGHTERS\X0D\\X0A\                                                **INSTITUTION\X0D\\X0A\ACCESSIO  **ID-NUM-SUR                          PAGE 1 OF 1\X0D\\X0A\N #\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cKmI8HAWFJRmAGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DlJJwComQ5zHv9vz2RArDmxHt9njSOMdO\S\REPORT","FINAL DIAGNOSIS:\X0D\\X0A\(A)  Stomach, antrum and body, biopsy:\X0D\\X0A\             Suggestive of chemical gastritis (see comment).\X0D\\X0A\             Giemsa stain NEGATIVE for Helicobacter pylori.\X0D\\X0A\(B)  Duodenum, biopsy:\X0D\\X0A\             WITHOUT diagnostic abnormality.\X0D\\X0A\             NO morphologic support for Celiac disease, dysplasia or\X0D\\X0A\carcinoma.\X0D\\X0A\(C)  Colon, proximal mass, biopsy:\X0D\\X0A\               ADENOCARCINOMA (see comment).\X0D\\X0A\COMMENT (""A""):  Chemical gastropathies result from surface-damaging\X0D\\X0A\agents in the gastric lumen. NSAIDs and alkaline reflux are its\X0D\\X0A\commonest causes. Suggest clinical correlation.\X0D\\X0A\COMMENT (""C""):  Extent of invasion CANNOT be determined in this\X0D\\X0A\superficial biopsy material showing infiltrative ADENOCARCINOMA.  As\X0D\\X0A\such, recommend follow-up investigation/intervention as indicated.\X0D\\X0A\Dr. **NAME[YYY] notified of the above findings on **DATE[Aug 11 12] at 9:45 a.m. per\X0D\\X0A\telephone correspondence.\X0D\\X0A\This case (""C"") reviewed in consensus conference:  DRW, MRJ.\X0D\\X0A\                                <Sign Out Dr. **NAME[XXX]>\X0D\\X0A\                                **NAME[WWW VVV], D.O., Pathologist\X0D\\X0A\CLINICAL           ACUTE BLOOD LOSS ANEMIA, GI BLEED\X0D\\X0A\INFORMATION:",,"GROSS DESCRIPTION:\X0D\\X0A\The following specimens are received in prefilled formalin containers:\X0D\\X0A\(A) Labeled ""antrum/body, rule out H. pylori"" is one piece of tan soft\X0D\\X0A\tissue measuring 0.6 cm. in greatest dimension.   Entirely submitted.\X0D\\X0A\(B) Labeled ""duodenum, rule out Celiac"" is one piece of yellow-tan soft\X0D\\X0A\tissue measuring 0.6 cm. in greatest dimension.  Entirely submitted.\X0D\\X0A\(C) Labeled ""proximal transverse colon mass biopsy"" are four pieces of\X0D\\X0A\tan soft tissue measuring from 0.2 to 0.5 cm. in greatest dimension.\X0D\\X0A\Entirely submitted./AKC,KZK","MICROSCOPIC DESCRIPTION:\X0D\\X0A\(A)  Histologic sections show antral and fundic-type gastric mucosa\X0D\\X0A\with prominent foveolar hyperplasia and focal denudation of the surface\X0D\\X0A\mucosal epithelium. Mild patchy fibrosis is revealed. Focal muscle\X0D\\X0A\fibers extending into the mucosa from the muscularis mucosa are\X0D\\X0A\appreciated.  Focal luminal ectasia is noted. Mixed inflammatory cells\X0D\\X0A\can be seen within the lamina propria, but inflammation per se is\X0D\\X0A\minimal. Dysplasia is NOT a feature. A giemsa stain, with appropriately\X0D\\X0A\working controls performed for qualitative impression, shows NO\X0D\\X0A\organisms morphologically consistent with Helicobacter pylori.\X0D\\X0A\(B)  Histologic sections demonstrate small bowel mucosa with normal\X0D\\X0A\villiform configuration of the surface epithelium.  Mixed inflammatory\X0D\\X0A\cells, including lymphocytes and plasma cells, can be seen within the\X0D\\X0A\lamina propria, as well as portions of Brunner glands. There is NO\X0D\\X0A\morphologic support of Celiac disease, dysplasia or carcinoma.\X0D\\X0A\(C)  Histologic sections show colonic mucosa involved focally by\X0D\\X0A\ADENOCARCINOMA with a back-to-back glandular/cribriform growth pattern.\X0D\\X0A\The biopsy is superficial; therefore, the extent of invasion CANNOT be\X0D\\X0A\reliably assessed.","TISSUE SUBMITTED:  (A) ANTRUM AND BODY, RULE OUT H. PYLORI\X0D\\X0A\                   (B) DUODENAL BIOPSY, RULE OUT CELIAC DISEASE\X0D\\X0A\                   (C) TRANSVERSE COLON BIOPSY, PROXIMAL MASS",,
REG1,COLON,0,495419,1,,Clinical History\X0D\\X0A\Same.\X0D\\X0A\Pre-Operative Diagnosis\X0D\\X0A\Nearly obstructive  distal transverse  colon cancer.  Abnormal CT.  Blood\X0D\\X0A\loss.  Renal hematoma versus abscess.\X0D\\X0A\Post-Operative Diagnosis\X0D\\X0A\Same.,"Bon Secours Kentucky Health System\X0D\\X0A\**INSTITUTION\X0D\\X0A\St. **PLACE Drive\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\Tel:  **PHONE    Fax:  **PHONE\X0D\\X0A\**NAME[ZZZ M. YYY], MD, Director\X0D\\X0A\Patient Name: **NAME[BBB, AAA]          Specimen #:***PATH-NUMBER[1]\X0D\\X0A\Patient ID: **ID-NUM          Account #:**ID-NUM\X0D\\X0A\DOB/Gender: **DATE[Jun 1 1946] (Age: **AGE[in 60s])/M          Location: 2C (OLB)\X0D\\X0A\Collect: **DATE[Apr 21 2012]   Rec'd: **DATE[Apr 21 2012]   Reported: **DATE[Apr 25 2012]\X0D\\X0A\Physician(s):\X0D\\X0A\PACK, MARK **NAME[M]., MD\X0D\\X0A\ABU AL RUB, **NAME[XXX] M.D.\X0D\\X0A\**NAME[WWW, VVV] MD\X0D\\X0A\SURGICAL PATHOLOGY REPORT","FINAL PATHOLOGIC DIAGNOSIS\X0D\\X0A\A.  Left kidney parenchyma, biopsies:     1.   Fat necrosis with fibrosis,\X0D\\X0A\acute and chronic inflammation, hemosiderin ladened macrophages and\X0D\\X0A\hemorrhage (see comment).\X0D\\X0A\2.          Negative for malignancy.\X0D\\X0A\B.  Distal transverse and sigmoid colon, segmental resection:     1.\X0D\\X0A\Moderately differentiated adenocarcinoma, circumferential.\X0D\\X0A\a.  Extent of invasion:  Invades through the muscularis propria\X0D\\X0A\and into the pericolonic adipose\X0D\\X0A\tissue.            b.  Blood/lymphatic\X0D\\X0A\invasion:  Suspicious.                           c.  Perineural invasion:\X0D\\X0A\Not identified.\X0D\\X0A\d.  Extramural venous invasion:  Not identified.           e.\X0D\\X0A\Peritumoral/intratumoral lymphocytic response:  Moderate.\X0D\\X0A\f.  Pattern of growth at tumor periphery:  Infiltrating.\X0D\\X0A\2.  Surgical resection margins:          a.  Proximal resection\X0D\\X0A\margin:  Free of tumor.           b.  Distal resection margin:  Free of\X0D\\X0A\tumor.           c.  Radial resection margin:  Free of tumor.\X0D\\X0A\3.   Regional lymph nodes:                      a.  Thirteen\X0D\\X0A\pericolonic lymph nodes identified.\X0D\\X0A\b.  One lymph node positive for metastatic\X0D\\X0A\adenocarcinoma (1/13).      4.  Additional pathologic findings:\X0D\\X0A\a.  Tubular adenomas with mild dysplasia and hyperplastic polyps\X0D\\X0A\(multiple).\X0D\\X0A\b.  Diverticulosis.           c.  Focal mucosal, submucosal and\X0D\\X0A\superficial muscularis necrosis and degeneration consistent\X0D\\X0A\with ischemic changes.\X0D\\X0A\d.  Omentum without significant histopathologic abnormalities.\X0D\\X0A\C.  Colon polyp, polypectomy:\X0D\\X0A\1.  Tubulovillous adenoma with moderate dysplasia.\X0D\\X0A\2.  Negative for severe dysplasia or malignancy.\X0D\\X0A\D.  Colon mucosal donut, incisional biopsy:       Colon tissue without\X0D\\X0A\evidence of malignancy.\X0D\\X0A\TNM CLASSIFICATION AND PATHOLOGIC STAGE:\X0D\\X0A\1.          pT3, pN1, pMX.\X0D\\X0A\2.     Stage IIIB.\X0D\\X0A\CPT: 88305 (x2), 88307 (x1), **ID-NUMF (x1), 88331 (x1)\X0D\\X0A\ls1/**DATE[Apr 25 2012]\X0D\\X0A\***Electronically Signed Out By **NAME[UUU, TTT M]., M.D.***",,"Gross Description\X0D\\X0A\A.          Submitted fresh specimen A is labeled LEFT KIDNEY PARENCHYMA\X0D\\X0A\FS and consists of two pieces of yellow maroon tissue measuring 2.0 x 0.5\X0D\\X0A\x 0.4 cm.  The resubmitted frozen section tissue is totally embedded in\X0D\\X0A\cassette A.\X0D\\X0A\B.     Submitted in formalin specimen B is labeled COLON and consists of a\X0D\\X0A\colon segment 73 cm in length x a diameter ranging from 2.5 up to 3.5 cm.\X0D\\X0A\The serosal area is light tan  pink maroon with a small area of serosal\X0D\\X0A\fibrosis.  Opening the colon displays an ulcerating and polypoid\X0D\\X0A\circumferential mass measuring 3.5 x 3.5 x 1.5 cm and extends to within\X0D\\X0A\4.5 cm of the nearest margin.  Prior to sectioning of the mass the serosal\X0D\\X0A\margin is inked in black.    Sections display the mass to extend through\X0D\\X0A\the muscularis propria and focally into pericolonic adipose tissue.  On\X0D\\X0A\the antimesenteric side the tumor appears to focally extend to the\X0D\\X0A\subserosa without definitive serosal involvment.  The remaining colon\X0D\\X0A\displays approximately the five small polyps ranging from 0.3 up to 0.5 cm\X0D\\X0A\in greatest dimension.  In addition a central mucosal area with green\X0D\\X0A\discoloration is identified measuring 0.9 cm in dimension.  Small\X0D\\X0A\diverticula are also grossly seen.  No additional masses are grossly\X0D\\X0A\identified.  An additional portion of omentum is identified in the\X0D\\X0A\specimen container measuring 19.5 x 8.0 x 1.5 cm.  Sectioning shows no\X0D\\X0A\gross abnormalities.    Sections of the tumor mass are submitted in\X0D\\X0A\cassettes B1  B4, a section of the nearest margin is submitted in cassette\X0D\\X0A\B5, sections of the additional mucosal polyps are submitted in cassette\X0D\\X0A\B6, sections of diverticula and green gangrenous area are submitted in\X0D\\X0A\cassette B7, section of omentum is submitted in cassette B8, three\X0D\\X0A\possible lymph nodes are submitted in cassette B9, a single piece of\X0D\\X0A\fibroadipose tissue with associated vascular structures and possible\X0D\\X0A\positive lymph nodes is submitted in cassette B10, and additional possible\X0D\\X0A\lymph nodes are submitted in cassettes B11- B14.\X0D\\X0A\C.     Submitted in formalin specimen C is labeled COLON POLYP and\X0D\\X0A\consists of a large mucosal polyp measuring 2.5 x 2.4 x 2.3 cm.\X0D\\X0A\Sectioning shows a friable polyp without definitive evidence of gross\X0D\\X0A\invasion.  Specimen is totally embedded in cassettes C1  C4.\X0D\\X0A\D.     Submitted in formalin specimen D is labeled COLON DONUT and\X0D\\X0A\consists of two pieces of focally sutured colon segments measuring 3.0 x\X0D\\X0A\2.0 x 1.3 cm.  Sections are submitted in cassette D.\X0D\\X0A\GAR\X0D\\X0A\Intraoperative Consultation(s)\X0D\\X0A\Frozen section diagnosis:\X0D\\X0A\A. Adipose tissue with fibrosis, inflammation and histiocytes.  Negative\X0D\\X0A\for malignancy. (GAR).","Microscopic Description\X0D\\X0A\A.          Permanent sections of the resubmitted frozen section tissue\X0D\\X0A\shows adipose tissue with areas of fat necrosis, fibrosis, mild to\X0D\\X0A\moderate acute and chronic inflammation with hemosiderin ladened\X0D\\X0A\macrophages and associated blood.  No evidence of malignancy is seen.\X0D\\X0A\B.     Sections of the submitted colon tumor shows irregular tortuous,\X0D\\X0A\cystically dilated and cribriforming malignant glands showing significant\X0D\\X0A\nuclear pleomorphism with enlarged vesicular nuclei showing occasional\X0D\\X0A\inconspicuous nucleoli, minimal pseudostratification and areas of central\X0D\\X0A\necrosis consistent with a moderately differentiated adenocarcinoma.  The\X0D\\X0A\tumor is seen extending through the muscularis propria and into the\X0D\\X0A\pericolonic adipose tissue and elicits a minimal to moderate lymphocytic\X0D\\X0A\response.  Occasional areas suspicious for lymphovascular invasion are\X0D\\X0A\seen.  The serosal margins are free of involvement. A section of the\X0D\\X0A\nearest proximal margin is negative for malignancy.  Sections of the\X0D\\X0A\additional mucosal polyps display additional tubular adenomas with mild\X0D\\X0A\dysplasia and hyperplastic polyps.  No evidence of additional evidence of\X0D\\X0A\malignancy is seen.  Sections of the diverticuli display a single\X0D\\X0A\diverticulus with associated adipose tissue showing a benign lymphoid\X0D\\X0A\aggregate.  Additionally, an area of green discoloration shows associated\X0D\\X0A\necrosis with significant acute inflammation, edema and muscularis\X0D\\X0A\degeneration.  No evidence of malignancy is seen. A section of the omentum\X0D\\X0A\shows no significant histopathologic abnormalities.  Sections of the\X0D\\X0A\submitted lymph nodes display the palpable lymph node to be replaced by\X0D\\X0A\malignant glands consistent with metastatic colonic adenocarcinoma.\X0D\\X0A\Sections of the remaining lymph nodes display an additional twelve lymph\X0D\\X0A\nodes negative for metastatic carcinoma.\X0D\\X0A\C.     Sections of the totally embedded mucosal polyps show the polyp to\X0D\\X0A\display a tubular and villous architectural pattern with surface\X0D\\X0A\epithelium showing nuclear hyperchromasia, pseudostratification and\X0D\\X0A\moderate loss of basal nuclear orientation.  Mild stroma edema with\X0D\\X0A\chronic inflammatory cells is seen.  No evidence of invasive malignancy is\X0D\\X0A\seen.  The stalk and cauterized resected margin shows hyperplastic changes\X0D\\X0A\without evidence of adenomatous dysplasia or malignancy.\X0D\\X0A\D.     Sections of the specimen designated colon donut shows portions of\X0D\\X0A\colon with areas of hyperplastic mucosa.  Minimal vascular congestion,\X0D\\X0A\mild stroma edema is seen.  No evidence of malignancy is identified.","Specimen Source: \X0D\\X0A\ \S\kidney bx left parenchema\T\Colon, segmental resection: for tumor.\T\Colon, polyp.\T\Colon, biopsy:donut\S\\S\0 \X0D\\X0A\",,
REG1,COLON,0,495624,1,,CLINICAL INFORMATION\X0D\\X0A\PRE-OP DIAGNOSIS:  Family history of colon cancer.  POST-OP DIAGNOSIS:\X0D\\X0A\Mass at 5 cm.,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       **NAME[ZZZ YYY]    SIGN OUT DATE:   **DATE[Aug 15 2012]\X0D\\X0A\COPIES TO:          **NAME[ZZZ YYY,"FROZEN SECTION DIAGNOSIS\X0D\\X0A\BIOPSY AT 5 CM, (1FS-1):  POORLY DIFFERENTIATED INVASIVE\X0D\\X0A\ADENOCARCINOMA.\X0D\\X0A\FROZEN SECTION REPORT CALLED TO DR. **NAME[YYY] **DATE[Aug 11 12] AT 1:24 PM.\X0D\\X0A\**NAME[XXX M. WWW], M.D\X0D\\X0A\DIAGNOSIS\X0D\\X0A\1. COLON BIOPSY AT 5 CM:  INVASIVE ADENOCARCINOMA.\X0D\\X0A\2. COLON BIOPSY AT 5 CM:  INVASIVE ADENOCARCINOMA.\X0D\\X0A\CPT4 88331, 88305 x2 / ICD9 153.2 / MORPHOLOGY CODE: M81403",,"GROSS DESCRIPTION\X0D\\X0A\Specimen one is received fresh for frozen section diagnosis labeled\X0D\\X0A\""biopsy at 5 cm"" and consists of three fragments of red-tan tissue\X0D\\X0A\measuring 0.2 to 0.1 cm.  The specimen is entirely submitted as 1FS-1.\X0D\\X0A\The previously frozen 1FS-1 is entirely resubmitted in cassette labeled\X0D\\X0A\1FS-1 for permanent section evaluation.\X0D\\X0A\Specimen two is labeled ""colon biopsy at 5 cm"" and consists of four\X0D\\X0A\fragments of tan tissue measuring 0.2 to 0.4 cm.  The specimen is\X0D\\X0A\entirely submitted in cassette 2.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Review of the frozen section 1FS-1 shows two significant fragments one\X0D\\X0A\showing poorly differentiated invasive adenocarcinoma and the other\X0D\\X0A\showing some glandular structures with reactive nuclei.  Permanent\X0D\\X0A\sections show adenocarcinoma occurring in the colonic mucosal surface.\X0D\\X0A\Invasive carcinoma is present.\X0D\\X0A\Section 2A of the colon biopsy at 5 cm shows fragments of\X0D\\X0A\adenocarcinoma with intact segments of adjacent colonic mucosa.  Glands\X0D\\X0A\with full thickness dysplastic change and invasive adenocarcinoma\X0D\\X0A\fragments scattered throughout the fragments of the biopsied material.\X0D\\X0A\<Sign Out Dr. **NAME[VVV]>\X0D\\X0A\**NAME[XXX WWW], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  (1) COLON BIOPSY, SURGICAL BIOPSY\X0D\\X0A\5 cm.\X0D\\X0A\(2) COLON BIOPSY,\X0D\\X0A\SURGICAL BIOPSY\X0D\\X0A\5 cm.",,
REG1,COLON,0,495625,1,,"CLINICAL INFORMATION\X0D\\X0A\PRE-OP DIAGNOSIS:  Rectal bleeding             POST-OP DIAGNOSIS:\X0D\\X0A\Polyps left colon, polyp @ lower left colon, polyp @ rectum, rectal\X0D\\X0A\cancer 17 cm",FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       OON LEEDHANACHO  SIGN OUT DATE:   **DATE[Dec 14 2011]\X0D\\X0A\COPIES TO:          OON\X0D\\X0A\LEEDHANACHO\X0D\\X0A\COMMENT\X0D\\X0A\I noticed a diagnosis of rectal cancer 17 cm and the polyp that is\X0D\\X0A\adjacent to that is at the rectum and shows severe dysplasia and focal\X0D\\X0A\carcinoma in situ.  Clinical correlation recommended.  No material was\X0D\\X0A\received from the rectal cancer at 17 cm.,"DIAGNOSIS\X0D\\X0A\1. POLYPS AT LEFT COLON:  TUBULAR ADENOMA WITH LOW-GRADE DYSPLASIA.\X0D\\X0A\NO IN SITU AND NO INVASIVE CHANGE SEEN.\X0D\\X0A\2. POLYP AT LOWER LEFT COLON:  TUBULAR ADENOMA WITH LOW-GRADE\X0D\\X0A\DYSPLASIA WITH VILLOUS TRANSFORMATION AND MILD PORTIONS OF\X0D\\X0A\DYSPLASTIC CHANGE.  NO IN SITU AND NO INVASIVE CHANGE SEEN.\X0D\\X0A\3. POLYP AT RECTUM:  TUBULAR ADENOMA WITH SEVERE DYSPLASIA WITH\X0D\\X0A\ADENOCARCINOMA IN SITU.  NO INVASIVE FEATURES IDENTIFIED.  CLINICAL\X0D\\X0A\CORRELATION RECOMMENDED.  (SEE COMMENT).\X0D\\X0A\CPT4 88305 x3 / ICD9 211.3, 230.4 / MORPHOLOGY CODE: M81402",,"GROSS DESCRIPTION\X0D\\X0A\Specimen one is labeled ""polyps at left colon"" and consists of five\X0D\\X0A\fragments of tan mucosa measuring 0.3 to 0.7 cm.  The entire specimen\X0D\\X0A\is submitted in cassette 1.\X0D\\X0A\Specimen two is labeled ""polyp at lower left colon"" and consists of a\X0D\\X0A\single fragment of tan mucosa measuring 0.8 cm.  The specimen is\X0D\\X0A\bisected and entirely submitted in cassette 2.\X0D\\X0A\Specimen three is labeled ""polyp at rectum"" and consists of a single\X0D\\X0A\fragment of tan mucosa measuring 0.4 cm with five red-tan soft tissue\X0D\\X0A\fragments each measuring less than 0.1 cm.  The entire specimen is\X0D\\X0A\submitted in cassette 3.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of the polyps at left colon show a fairly large segment of\X0D\\X0A\polypoid material with tubular adenoma, low-grade dysplasia, and\X0D\\X0A\villous transformation.  No in situ and no invasive change is seen.\X0D\\X0A\Deeper sections show similar features.\X0D\\X0A\Sections of the polyp at lower left colon show multiple fragments of\X0D\\X0A\polypoid material with tubular adenomatous variety of architecture with\X0D\\X0A\some villous transformation appreciated, mild to moderate.  Congestion\X0D\\X0A\is present in the stroma. Inflammation is chronic.   No malignant\X0D\\X0A\features are seen.  No in situ and no invasive change is identified.\X0D\\X0A\Deeper sections show similar features.\X0D\\X0A\Sections of the polyp at rectum show a tubular adenoma with\X0D\\X0A\medium-grade dysplasia.  No in situ and no invasive change is seen.\X0D\\X0A\Some focal areas of mild to moderate dysplasia are present on the\X0D\\X0A\surface of this polypoid structure.  No in situ and no invasive\X0D\\X0A\carcinoma is seen.  Deeper sections show fragments with superficial\X0D\\X0A\severe dysplasia.  Carcinoma in situ in this fragment of polypoid\X0D\\X0A\tissue from the rectum is present.  These are one the small fragments\X0D\\X0A\near the superficial layer of the mucosa.  Hyperchromatism and\X0D\\X0A\irregular nuclear membranes are present with mitotic activity.  No\X0D\\X0A\invasive features are identified.\X0D\\X0A\<Sign Out Dr. **NAME[ZZZ]>\X0D\\X0A\**NAME[YYY XXX], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  (1) POLYP, SURGICAL EXCISION\X0D\\X0A\Left colon polyps\X0D\\X0A\(2) POLYP, SURGICAL\X0D\\X0A\EXCISION\X0D\\X0A\Polyp @ lower left\X0D\\X0A\colon\X0D\\X0A\(3) POLYP, SURGICAL\X0D\\X0A\EXCISION\X0D\\X0A\Polyp @ rectum",,
REG1,COLON,0,496904,1,,Clinical History:\X0D\\X0A\Colon mass,,"Pre-Operative Diagnosis:\X0D\\X0A\Colon mass\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Colon segment, rectosigmoid:  Colonic adenocarcinoma, moderately\X0D\\X0A\differentiated, 5.0 x 3.5 x 2.2 cm, infiltrating through the muscularis\X0D\\X0A\propria into pericolonic and subserosal soft tissue.  Colonic\X0D\\X0A\diverticulosis with mild chronic diverticulitis.  Benign serosal\X0D\\X0A\surface.  Benign proximal colonic, distal colonic, and radial soft\X0D\\X0A\tissue resection margins.  Benign attached mesenteric lymph nodes (38).\X0D\\X0A\Benign detached colon wall tissue (donuts) x 2.",,"Gross Description:\X0D\\X0A\Received in formalin designated ""rectosigmoid"" is a 20 cm in length x\X0D\\X0A\2.5 cm in average diameter portion of large bowel which is received with\X0D\\X0A\both ends stapled.  There is an abundant amount of attached pericolic\X0D\\X0A\fat.  The serosa is pink-tan and the central portion of the specimen is\X0D\\X0A\notable for dense fibrous adhesions.  There are no overlying fibrinous\X0D\\X0A\exudates.  The area of fibrous adhesions is inked blue.  Opening the\X0D\\X0A\specimen reveals a 5 x 3.5 x 2.2 cm dark red exophytic mass lesion\X0D\\X0A\within the central portion of the specimen beneath the aforementioned\X0D\\X0A\area of fibrous adhesions.  The mass is dark red with a broad-based\X0D\\X0A\sessile polypoid appearance.  The lesion is grossly 6.5 cm from the\X0D\\X0A\nearest surgical margin and 9.5 cm from the opposing surgical margin.\X0D\\X0A\Sectioning through the lesion reveals full thickness involvement of the\X0D\\X0A\bowel wall with possible focal extension into the pericolic fat.  The\X0D\\X0A\lesion is 11 cm from the mesenteric radial margin.  There are no\X0D\\X0A\additional polyps or masses seen.  There are multiple diverticula\X0D\\X0A\throughout the entire length of the specimen, all of which appear to be\X0D\\X0A\intact with no evidence of perforation.  There are no pseudomembranes,\X0D\\X0A\sites of ulceration, or areas of stricturing.  A thorough search of the\X0D\\X0A\pericolic fat reveals  lymph nodes.  Additionally received in the same\X0D\\X0A\container is a metallic device onto which are threaded two anastomotic\X0D\\X0A\donuts which are each 1.5 x 1.5 x 1 cm.  The anastomotic donuts are\X0D\\X0A\surfaced as pink-tan unremarkable mucosa.  Representative sections are\X0D\\X0A\submitted.\X0D\\X0A\Summary of sections:  1 - shaved surgical margin closest to tumor; 2 -\X0D\\X0A\shaved surgical margin furthest from tumor; 3 - perpendicular section of\X0D\\X0A\mesenteric radial margin (blue ink on margin); 4- 7 - sections of tumor\X0D\\X0A\to inked overlying serosa; 8\T\9 - representative sections of\X0D\\X0A\diverticula;\X0D\\X0A\10-12 - multiple whole lymph nodes; 13 - two lymph nodes bisected, one\X0D\\X0A\is inked blue; 14 - two lymph nodes bisected, one is inked blue; 15 -\X0D\\X0A\one lymph node trisected; 16 - one lymph node trisected; 17 -\X0D\\X0A\representative sections of anastomotic donut.  JAB:vsg","Microscopic Description:\X0D\\X0A\The colon mass is growing as interanastomosing glandular structures.\X0D\\X0A\Many of the lumina contain necrotic debris while others show complicated\X0D\\X0A\cribriform-type architectures.  The individual tumor cells have moderate\X0D\\X0A\amounts of columnar cytoplasm surrounding very large vesicular nuclei\X0D\\X0A\with variably prominent nucleoli.  The neoplasm has extended completely\X0D\\X0A\through the submucosa into and just barely focally through the\X0D\\X0A\muscularis propria.  There is a marked amount of chronic active\X0D\\X0A\inflammation at the advancing edge of the tumor.  No definite\X0D\\X0A\lymphvascular invasion can be identified.  The remainder of the colon\X0D\\X0A\shows several diverticula present.  They are not perforated and do not\X0D\\X0A\show significant acute inflammation but do show some chronic\X0D\\X0A\inflammation along their advancing edges.  The proximal and distal\X0D\\X0A\resection margins are benign.  The radial mesenteric margin is also\X0D\\X0A\benign. The attached mesenteric lymph nodes (38) show mild reactive\X0D\\X0A\changes but no evidence of primary or metastatic neoplasm.  The detached\X0D\\X0A\colon tissue (donuts) x 2 both show benign colon wall.  Tissue Code:  T1\X0D\\X0A\Synoptic Template for Primary Colorectal Carcinoma:\X0D\\X0A\Specimen:  Colon segment.\X0D\\X0A\Procedure:  Rectosigmoid colon.\X0D\\X0A\Tumor site:  Rectosigmoid colon.\X0D\\X0A\Tumor size:  5.0 x 3.5 x 2.2 cm.\X0D\\X0A\Histologic type:  Adenocarcinoma.\X0D\\X0A\Histologic grade:  Moderately differentiated.\X0D\\X0A\Microscopic tumor extension:  Through muscularis propria into subserosal\X0D\\X0A\and mesenteric soft tissue.\X0D\\X0A\Macroscopic tumor perforation:  Not identified.\X0D\\X0A\Margins:\X0D\\X0A\Proximal margin:  Negative.\X0D\\X0A\Distal margin:  Negative.\X0D\\X0A\Mesenteric margin:  Negative.\X0D\\X0A\Circumferential radial margin:  Negative.\X0D\\X0A\Serosal (peritoneal) surface:  Negative.\X0D\\X0A\Lateral margin:  Not applicable\X0D\\X0A\Distance of invasive carcinoma from closest margin:  6.5 cm from nearest\X0D\\X0A\colonic margin.\X0D\\X0A\Lymphvascular invasion:  Not identified.\X0D\\X0A\Perineural invasion:  Not identified.\X0D\\X0A\Peritumor lymphocytic response (Crohn's-like reaction):  Marked.\X0D\\X0A\Treatment effect:  Unknown.\X0D\\X0A\Extent of resection:  R0 = complete resection, all margins negative.\X0D\\X0A\Regional lymph nodes:  0 positive / 38 total.\X0D\\X0A\Tumor deposits:  Not identified.\X0D\\X0A\Additional pathologic findings:  Colonic diverticulosis with mild\X0D\\X0A\chronic diverticulitis.\X0D\\X0A\Pathologic staging:  pT3 pN0 MX\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 01 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Rectosigmoid,,
REG1,COLON,0,497083,1,,"Clinical Diagnosis and History\X0D\\X0A\Bowel obstruction secondary colon cancer, cholelithiasis, need for IV access.",Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: right colon\X0D\\X0A\2: Gallbladder,"Final Diagnosis\X0D\\X0A\1.     Right hemicolectomy specimen:  \X0D\\X0A\          A.     Moderately differentiated adenocarcinoma arising in the right\X0D\\X0A\colon (4.5 cm in greatest dimension). \X0D\\X0A\     B.     The tumor invades through the muscularis propria into the subjacent\X0D\\X0A\fibroadipose tissue. \X0D\\X0A\     C.     The proximal, distal and inked radial margins of surgical resection\X0D\\X0A\are negative for malignancy.  \X0D\\X0A\     D.     Twenty-three (23) out of twenty-three (23) lymph nodes, including\X0D\\X0A\microscopic lymph nodes, are negative for metastatic adenocarcinoma.  \X0D\\X0A\     E.     Adenomatous polyps (four), proximal cecum (ranging up to 0.5 cm in\X0D\\X0A\greatest dimension).  \X0D\\X0A\     F.     Chronic serositis and focal reactive mesothelial hyperplasia.  \X0D\\X0A\     G.     Mucosal glandular hyperplastic changes, vermiform appendix.  \X0D\\X0A\AJCC stage:   pT3 pN0.  \X0D\\X0A\2.     Gallbladder:  \X0D\\X0A\     A.     Chronic active cholecystitis.  \X0D\\X0A\     B.     Cholelithiasis. \X0D\\X0A\     C.     Benign sentinel (cystic duct) lymph node demonstrating\X0D\\X0A\lipogranulomata.  \X0D\\X0A\               1 \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD\X0D\\X0A\Surgical Pathology Cancer Case Summary (Checklist)\X0D\\X0A\Based on AJCC/UICC TNM, 7th Edition     \X0D\\X0A\Protocol web posting date: **DATE[Dec 1 2011]\X0D\\X0A\     COLON AND RECTUM: Resection, Including Transanal Disk Excision of Rectal\X0D\\X0A\Neoplasms\X0D\\X0A\Select a single response unless otherwise indicated.\X0D\\X0A\Specimen (select all that apply) (Note A)\X0D\\X0A\_X__ Terminal ileum\X0D\\X0A\__X_ Cecum\X0D\\X0A\__X_ Appendix\X0D\\X0A\_X__ Ascending colon\X0D\\X0A\___ Transverse colon\X0D\\X0A\___ Descending colon\X0D\\X0A\___ Sigmoid colon\X0D\\X0A\___ Rectum\X0D\\X0A\___ Anus\X0D\\X0A\___ Other (specify): __________________________________\X0D\\X0A\___ Not specified\X0D\\X0A\Procedure \X0D\\X0A\___ Right hemicolectomy\X0D\\X0A\___ Transverse colectomy\X0D\\X0A\___ Left hemicolectomy\X0D\\X0A\___ Sigmoidectomy\X0D\\X0A\___ Rectal/rectosigmoid colon (low anterior resection)\X0D\\X0A\___ Total abdominal colectomy\X0D\\X0A\___ Abdominoperineal resection\X0D\\X0A\___ Transanal disk excision (local excision)\X0D\\X0A\___ Other (specify): ____________________________\X0D\\X0A\___ Not specified\X0D\\X0A\Tumor Site (select all that apply) (Note A)\X0D\\X0A\___ Cecum\X0D\\X0A\_X__ Right (ascending) colon\X0D\\X0A\___ Hepatic flexure\X0D\\X0A\___ Transverse colon\X0D\\X0A\___ Splenic flexure\X0D\\X0A\___ Left (descending) colon\X0D\\X0A\___ Sigmoid colon\X0D\\X0A\___ Rectosigmoid \X0D\\X0A\___ Rectum\X0D\\X0A\___ Colon, not otherwise specified\X0D\\X0A\___ Cannot be determined (see Comment)\X0D\\X0A\Tumor Size\X0D\\X0A\Greatest dimension: _4.5__ cm\X0D\\X0A\___ Cannot be determined (see Comment)\X0D\\X0A\Macroscopic Tumor Perforation (Note G)\X0D\\X0A\___ Present\X0D\\X0A\_X__ Not identified\X0D\\X0A\___ Cannot be determined\X0D\\X0A\Histologic Type (Note B)\X0D\\X0A\_X__ Adenocarcinoma\X0D\\X0A\___ Mucinous adenocarcinoma \X0D\\X0A\___ Signet-ring cell carcinoma \X0D\\X0A\___ Small cell carcinoma \X0D\\X0A\___ Squamous cell carcinoma \X0D\\X0A\___ Adenosquamous carcinoma\X0D\\X0A\___ Medullary carcinoma\X0D\\X0A\___ Undifferentiated carcinoma\X0D\\X0A\___ Other (specify): __________________________\X0D\\X0A\___ Carcinoma, type cannot be determined\X0D\\X0A\Histologic Grade (Note C)\X0D\\X0A\___ Not applicable\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\___ Low-grade (well-differentiated to moderately differentiated)\X0D\\X0A\___ High-grade (poorly differentiated to undifferentiated)\X0D\\X0A\___ Other (specify): ____________________________\X0D\\X0A\Microscopic Tumor Extension\X0D\\X0A\     ___ Cannot be assessed\X0D\\X0A\___ No evidence of primary tumor\X0D\\X0A\___ Intramucosal carcinoma, invasion of lamina propria\X0D\\X0A\___ Tumor invades submucosa\X0D\\X0A\___ Tumor invades muscularis propria\X0D\\X0A\     _X__ Tumor invades through the muscularis propria into the subserosal\X0D\\X0A\adipose tissue or the nonperitonealized pericolic or perirectal soft tissues but\X0D\\X0A\does not extend to the serosal surface\X0D\\X0A\     ___ Tumor penetrates to the surface of the visceral peritoneum (serosa) \X0D\\X0A\___ Tumor is adherent to other organs or structures (specify: _________________)\X0D\\X0A\___ Tumor directly invades adjacent structures (specify: __________________)\X0D\\X0A\     ___ Tumor penetrates to the surface of the visceral peritoneum (serosa) and\X0D\\X0A\directly invades adjacent structures (specify: _____________________)\X0D\\X0A\Margins (select all that apply) (Note J)\X0D\\X0A\Proximal Margin\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\_X__ Uninvolved by invasive carcinoma\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\___ Intramucosal carcinoma /adenoma not identified at proximal margin\X0D\\X0A\___ Intramucosal carcinoma/adenoma present at proximal margin\X0D\\X0A\Distal Margin\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\_X__ Uninvolved by invasive carcinoma\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\___ Intramucosal carcinoma/adenoma not identified at distal margin\X0D\\X0A\___ Intramucosal carcinoma /adenoma present at distal margin\X0D\\X0A\Circumferential (Radial) or Mesenteric Margin \X0D\\X0A\___ Not applicable\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\___ Uninvolved by invasive carcinoma\X0D\\X0A\___ Involved by invasive carcinoma (tumor present 0-1 mm from margin)\X0D\\X0A\If all margins uninvolved by invasive carcinoma:\X0D\\X0A\Distance of invasive carcinoma from closest margin: _7__ mm or ___ cm\X0D\\X0A\     Specify margin: ________RADIAL__________________\X0D\\X0A\Lateral Margin (for non-circumferential transanal disk excision)\X0D\\X0A\___ Cannot be assessed\X0D\\X0A\___ Uninvolved by invasive carcinoma\X0D\\X0A\     Distance of invasive carcinoma from closest lateral margin: ___ mm\X0D\\X0A\___ Involved by invasive carcinoma\X0D\\X0A\___ Uninvolved by adenoma \X0D\\X0A\___ Involved by adenoma\X0D\\X0A\Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy)\X0D\\X0A\(Note K)\X0D\\X0A\_X__ No prior treatment\X0D\\X0A\___ Present\X0D\\X0A\     *____ No residual tumor (complete response, grade 0)\X0D\\X0A\     *____ Moderate response (grade 1, minimal residual cancer)\X0D\\X0A\     *____ Minimal response (grade 2) \X0D\\X0A\___ No definite response identified (grade 3, poor response)\X0D\\X0A\___ Not known\X0D\\X0A\Lymph-Vascular Invasion (Note E)\X0D\\X0A\_X__ Not identified\X0D\\X0A\___ Present\X0D\\X0A\___ Indeterminate\X0D\\X0A\Perineural Invasion (Note E)\X0D\\X0A\__X_ Not identified\X0D\\X0A\___ Present\X0D\\X0A\___ Indeterminate\X0D\\X0A\     Tumor Deposits (discontinuous extramural extension) (Note L)\X0D\\X0A\_X__ Not identified\X0D\\X0A\___ Present (specify number of deposits: ____)\X0D\\X0A\___ Indeterminate\X0D\\X0A\Pathologic Staging (pTNM) (Note M)\X0D\\X0A\TNM Descriptors (required only if applicable) (select all that apply)\X0D\\X0A\___ m (multiple primary tumors)\X0D\\X0A\___ r (recurrent)\X0D\\X0A\___ y (post-treatment)\X0D\\X0A\Primary Tumor (pT) \X0D\\X0A\     ___ pTX:     Cannot be assessed\X0D\\X0A\___ pT0:     No evidence of primary tumor\X0D\\X0A\___ pTis:     Carcinoma in situ, intraepithelial (no invasion)\X0D\\X0A\___ pTis:     Carcinoma in situ, invasion of lamina propria\X0D\\X0A\___ pT1:     Tumor invades submucosa\X0D\\X0A\___ pT2:     Tumor invades muscularis propria\X0D\\X0A\_X__ pT3:     Tumor invades through the muscularis propria into pericolorectal\X0D\\X0A\tissues\X0D\\X0A\___ pT4a:     Tumor penetrates the visceral peritoneum\X0D\\X0A\___ pT4b:     Tumor directly invades or is adherent to other organs or\X0D\\X0A\structures \X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\     ___ pNX:     Cannot be assessed\X0D\\X0A\__X_ pN0:     No regional lymph node metastasis\X0D\\X0A\___ pN1a:     Metastasis in 1 regional lymph node\X0D\\X0A\___ pN1b:     Metastasis in 2 to 3 regional lymph nodes\X0D\\X0A\___ pN1c:     Tumor deposit(s) in the subserosa, or non-peritonealized pericolic\X0D\\X0A\or perirectal tissues without regional lymph node metastasis\X0D\\X0A\___ pN2a:     Metastasis in 4 to 6 regional lymph nodes\X0D\\X0A\___ pN2b:     Metastasis in 7 or more regional lymph nodes\X0D\\X0A\___ No nodes submitted or found\X0D\\X0A\     Number of Lymph Nodes Examined\X0D\\X0A\Specify: _23__\X0D\\X0A\___ Number cannot be determined (explain): ______________________\X0D\\X0A\Number of Lymph Nodes Involved\X0D\\X0A\Specify: ___0_\X0D\\X0A\___ Number cannot be determined (explain): ______________________\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\     _X__ Not applicable \X0D\\X0A\___ pM1:     Distant metastasis\X0D\\X0A\     ___ pM1a: Metastasis to single organ or site (eg, liver, lung, ovary,\X0D\\X0A\nonregional lymph node)\X0D\\X0A\     ___ pM1b: Metastasis to more than one organ/site or to the peritoneum",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin, labeled with the patient's name and ""right\X0D\\X0A\colon."" The specimen consists of a segment of colon with attached terminal ileum\X0D\\X0A\and appendix.  The segment of colon measures, from ileocecal valve to distal\X0D\\X0A\resection margin, 44.5 cm in length and averages 4.8 cm in diameter.  The\X0D\\X0A\segment of terminal ileum received measures, from ileocecal valve to proximal\X0D\\X0A\resection margin, 2.5 cm in length x 2.1 cm in diameter.  The external surface\X0D\\X0A\of the distal colon reveals tightly adhesed mesocolon and omentum with puckered\X0D\\X0A\serosa.  The remaining external surface is tan-pink and smooth.  The serosal\X0D\\X0A\surface of the small bowel appears unremarkable.  The segment of colon is opened\X0D\\X0A\to reveal an annular exophytic and infiltrative mass measuring 4.5 x 4.3 cm. \X0D\\X0A\The mass extends to within 3.7 cm of the stapled distal resection margin.  The\X0D\\X0A\serosa and fatty tissue surrounding the mass are inked black. Sectioning through\X0D\\X0A\the mass shows extension through the serosa and into the surrounding fatty\X0D\\X0A\tissue.  The mass appears to abut the serosal margin where no soft tissue is\X0D\\X0A\present.  \X0D\\X0A\The lumen proximal to the mass appears dilated with slightly flattened folds. \X0D\\X0A\The wall in this area appears thickened.  Five tan-pink soft polyps are noted in\X0D\\X0A\the proximal cecum.  The polyps measure up to 0.5 cm in greatest dimension.  The\X0D\\X0A\closest polyp to the ileocecal valve measures 0.5 cm lateral to the valve. The\X0D\\X0A\polyp closest to the mass measures 16.5 cm proximal to the mass.  Sectioning\X0D\\X0A\through each polyp reveals fatty submucosal tissue with no extension through the\X0D\\X0A\mucosa. \X0D\\X0A\The appendix measures 8.0 cm in length x 0.8 cm in diameter.  The serosal\X0D\\X0A\surface is tan-brown, smooth and glistening.  Sectioning reveals a fecal-filled\X0D\\X0A\lumen and is otherwise unremarkable.  \X0D\\X0A\The omentum and surrounding fatty tissue are dissected and reveals multiple\X0D\\X0A\lymph node candidates measuring up to 1.2 cm in greatest dimension.  The cut\X0D\\X0A\surface of the lymph node candidates are diffusely gray-white and otherwise\X0D\\X0A\unremarkable.  \X0D\\X0A\The proximal resection margin is submitted in (block 1A).  The distal resection\X0D\\X0A\margin is submitted in (blocks 1B and 1C).  Representative sections of the mass\X0D\\X0A\are submitted in (blocks 1D through 1H). Representative section of mass with\X0D\\X0A\adjacent unremarkable colon is submitted in (block 1I).  Representative sections\X0D\\X0A\of cecal polyps are submitted in (blocks 1J and 1K). Representative section of\X0D\\X0A\unremarkable colon is submitted in (block 1L).  Representative section of\X0D\\X0A\unremarkable small bowel is submitted in (block 1M). Representative sections of\X0D\\X0A\proximal appendix, mid appendix and the distal resection margin are submitted in\X0D\\X0A\(block 1N).  Representative sections of lymph nodes are submitted in (blocks 1O\X0D\\X0A\through 1S). \X0D\\X0A\Specimen #2 is received in formalin, labeled with the patient's name and\X0D\\X0A\designated ""gallbladder.""  The specimen consists of an intact gallbladder\X0D\\X0A\measuring 12.0 x 4.2 x 3.2 cm.  Serosal surface is green-gray, smooth and\X0D\\X0A\glistening.  The cystic duct appears patent.  Adjacent to the cystic duct is a\X0D\\X0A\well-defined nodule measuring 0.8 cm in greatest dimension.  The gallbladder\X0D\\X0A\wall averages 0.2 cm in thickness, the mucosa is yellow-green and granular.\X0D\\X0A\Within the lumen is a single round to oval yellow-black stone measuring 3.0 cm\X0D\\X0A\in greatest dimension.  Representative sections of gallbladder wall, soft tissue\X0D\\X0A\nodule, and the cystic duct resection margin are submitted in (block 2A). \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\     1.     Section of the proximal margin of surgical resection reveals viable\X0D\\X0A\small intestinal tissue.  The villi are not atrophic.  Lymphoid aggregates are\X0D\\X0A\seen consistent with Peyer's patches. They demonstrate germinal centers. \X0D\\X0A\Adenomatous changes are not seen.  There is no evidence of malignancy.  \X0D\\X0A\     Sections of the distal margin of surgical resection reveal viable large\X0D\\X0A\intestinal tissue.  Adenomatous changes are not seen.  There is no evidence of\X0D\\X0A\malignancy.  \X0D\\X0A\     Sections of the right colon mass reveal moderately differentiated\X0D\\X0A\adenocarcinoma.  The tumor forms complex glandular structures. Nuclear\X0D\\X0A\stratification is seen and the nuclei are hyperchromatic.  The tumor invades\X0D\\X0A\through the muscularis propria into the subjacent fibroadipose tissue.  The\X0D\\X0A\tumor elicits a desmoplastic response.  The serosa demonstrates chronic\X0D\\X0A\inflammation and focal changes of reactive mesothelial hyperplasia are seen.  \X0D\\X0A\Four out of the five polypoid segments of tissue noted in the proximal cecum\X0D\\X0A\reveal adenomatous polyps which are predominantly of the tubular type.  The\X0D\\X0A\fifth polypoid fragment of tissue is consistent with a polypoid excrescence. \X0D\\X0A\Adipose tissue is seen within the submucosa.  \X0D\\X0A\A random section of large intestine reveals viable large intestinal tissue. \X0D\\X0A\Adenomatous changes are not seen.  There is no evidence of malignancy.  \X0D\\X0A\A random section of small intestine reveals autolytic changes within the small\X0D\\X0A\intestinal mucosa.  The villi do not appear to be atrophic.  There is no\X0D\\X0A\evidence of malignancy.  \X0D\\X0A\Sections of the vermiform appendix reveal no transmural inflammation.  The\X0D\\X0A\mucosa of the distal vermiform appendix demonstrates glandular hyperplastic\X0D\\X0A\changes.  The mucosa has a serrated appearance and is lined by tall columnar\X0D\\X0A\epithelial cells with abundant mucin.  Fecal material is seen in the appendiceal\X0D\\X0A\lumen including vegetable fibers.  There is no evidence of malignancy.  \X0D\\X0A\Twenty-three out of twenty-three pericolic lymph nodes, including microscopic\X0D\\X0A\lymph nodes, are negative for metastatic adenocarcinoma.  \X0D\\X0A\     2.     Sections of the gallbladder reveal no significant atypia of the\X0D\\X0A\mucosal epithelium.  There is chronic active inflammation.  There is no evidence\X0D\\X0A\of malignancy in the sections examined.  \X0D\\X0A\     Section of the nodule adjacent to the cystic duct reveals a lymph node. \X0D\\X0A\Lipogranulomata are seen.  Lymphoid follicles with germinal centers are\X0D\\X0A\identified.  There is no evidence of primary or metastatic malignancy.   \X0D\\X0A\**INITIALS",,,
REG1,COLON,0,499896,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RECTAL BLEED\X0D\\X0A\,PROCEDURES: 88305GS\X0D\\X0A\\X0D\\X0A\,"FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\RECTAL POLYP, BIOPSY:\X0D\\X0A\WELL DIFFERENTIATED ENDOCRINE NEOPLASM.\X0D\\X0A\IMMUNOHISTOCHEMICAL STAINING PROFILE SUPPORTS THIS DIAGNOSIS,\X0D\\X0A\SEE MICROSCOPIC DESCRIPTION.\X0D\\X0A\THE NEOPLASM IS PRESENT AT BIOPSY EDGES, SEE COMMENT.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\A well-differentiated endocrine neoplasm is also known as carcinoid tumor.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin labeled ""rectal polyp"" is a 0.5 x 0.4 x 0.1 cm, soft, tan, ovoid\X0D\\X0A\portion of tissue. It is bisected and entirely submitted in a single cassette./st/sk\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\4 H\T\E, 1 Synaptophysin, 1 CD56 and 1 Chromogranin-A\X0D\\X0A\Appropriate positive and negative controls are reviewed. The immunohistochemical staining\X0D\\X0A\profile is as follows:\X0D\\X0A\\X0D\\X0A\Synaptophysin: positive\X0D\\X0A\CD56: positive\X0D\\X0A\Chromogranin-A: negative\X0D\\X0A\\X0D\\X0A\This immunohistochemical staining profile supports the diagnosis of well-differentiated\X0D\\X0A\endocrine neoplasm.\X0D\\X0A\",SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\RECTAL POLYP\X0D\\X0A\,,
REG1,COLON,0,500314,1,,CLINICAL HISTORY\X0D\\X0A\Gastrointestinal bleeding.\X0D\\X0A\\X0D\\X0A\PREOP DIAGNOSIS:               GI BLEED,"COMMENT\X0D\\X0A\The patient's clinical history is noted. It is not possible to\X0D\\X0A\definitively exclude a more significant adjacent lesion in specimen D.\X0D\\X0A\Clinical correlation is suggested.\X0D\\X0A\**NAME[BBB,AAA]                                ACCT #: **ID-NUM     LOC:  ICU    U #: 054388\X0D\\X0A\840 STATE ROUTE 408 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 74/M       **ROOM    REG: **DATE[Jul 28 12]\X0D\\X0A\DOB: **DATE[Jul 15 38]    BED: 01      DIS:\X0D\\X0A\STATUS: ADM IN     TLOC:","FINAL DIAGNOSIS\X0D\\X0A\A. COLON, BIOPSY OF HEPATIC FLEXURE MASS:\X0D\\X0A\.....MODERATELY DIFFERENTIATED COLONIC ADENOCARCINOMA.\X0D\\X0A\B. COLON, POLYPECTOMY AT 110 CM:\X0D\\X0A\.....TUBULAR ADENOMA, NEGATIVE FOR EVIDENCE OF HIGH-GRADE DYSPLASIA.\X0D\\X0A\C. COLON, PROXIMAL TRANSVERSE COLONIC POLYPECTOMY:\X0D\\X0A\.....TUBULAR ADENOMA, NEGATIVE FOR EVIDENCE OF HIGH-GRADE DYSPLASIA.\X0D\\X0A\D. COLON, BIOPSY OF MASS AT 70 CM:\X0D\\X0A\.....TUBULAR ADENOMA, NEGATIVE FOR EVIDENCE OF HIGH-GRADE DYSPLASIA.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ GREEN,**NAME[ZZZ] YYY] MD  **DATE[Jul 31 12]",,"GROSS DESCRIPTION\X0D\\X0A\Part A is designated as ""biopsy of colon mass at hepatic flexure"" consists\X0D\\X0A\of 3 friable brown-tan tissue fragments ranging from 1 x 1 mm to 3 x 3 mm\X0D\\X0A\in size. They are submitted in toto for embedding in block A.\X0D\\X0A\Part B is designated as ""biopsy of colon polyp of mid transverse colon at\X0D\\X0A\110 cm"" is received in a single container of formalin labeled with the\X0D\\X0A\patient's name and consists of 3 irregular velvety glistening tissue\X0D\\X0A\fragments no more than 3 x 2 mm in size. Submitted in toto for embedding\X0D\\X0A\in block B.\X0D\\X0A\Part C is designated as ""polyp of proximal transverse colon"" is received\X0D\\X0A\in a single container in formalin labeled with the patient's name and\X0D\\X0A\consists of multiple velvety pink-tan glistening tissue fragments no more\X0D\\X0A\than 2 x 2 mm in size. Approximately 8 tissue fragments are present and\X0D\\X0A\are submitted in toto for embedding in block C.\X0D\\X0A\Part D is designated as ""biopsy of mass at 70 cm"" consists of a single 4 x\X0D\\X0A\4 x 3 mm brown-tan glistening tissue fragment submitted in toto for\X0D\\X0A\embedding in block D.\X0D\\X0A\D: **DATE[Jul 30 2012] - 1545 hours\X0D\\X0A\T: **DATE[Jul 31 2012] - 0737 hours","MICROSCOPIC EXAMINATION\X0D\\X0A\A. Microscopic examination reveals sections of fragments of colonic-type\X0D\\X0A\mucosa demonstrating an infiltrative epithelial lesion comprised of\X0D\\X0A\irregularly shaped to oval glands lined by pseudostratified to rounded\X0D\\X0A\columnar epithelium with enlarged mildly pleomorphic hyperchromatic\X0D\\X0A\nuclei.Focal areas of possible stromal desmoplasia are identified as well\X0D\\X0A\as focal infiltration of muscle bundles. Malorientation of the fragments\X0D\\X0A\precludes a more definitive assessment of invasion.\X0D\\X0A\B. Microscopic examination reveals sections of polypoid fragments of\X0D\\X0A\colonic-type mucosa demonstrating pseudostratified columnar lining\X0D\\X0A\epithelium with elongated hyperchromatic nuclei overlying colonic crypts,\X0D\\X0A\which are focally crowded and irregular in shape, and also lined by\X0D\\X0A\atypical columnar epithelium. No evidence of high-grade dysplasia is\X0D\\X0A\identified.\X0D\\X0A\C. Microscopic examination reveals sections of polypoid fragments of\X0D\\X0A\colonic-type mucosa demonstrating pseudostratified columnar lining\X0D\\X0A\epithelium with elongated hyperchromatic nuclei overlying colonic crypts,\X0D\\X0A\which are focally crowded and irregular in shape, and also lined by\X0D\\X0A\atypical columnar epithelium. No evidence of high-grade dysplasia is\X0D\\X0A\identified.\X0D\\X0A\D. Microscopic examination reveals sections of polypoid fragments of\X0D\\X0A\colonic-type mucosa demonstrating pseudostratified columnar lining\X0D\\X0A\epithelium with elongated hyperchromatic nuclei overlying colonic crypts,\X0D\\X0A\which are focally crowded and irregular in shape, and also lined by\X0D\\X0A\atypical columnar epithelium. No evidence of high-grade dysplasia is\X0D\\X0A\identified.\X0D\\X0A\D: **DATE[Jul 31 2012] - 1407 hours\X0D\\X0A\T: **DATE[Jul 31 2012] - 1631 hours","TISSUES:\X0D\\X0A\Colon, NOS (HEP FLEX MASS BX)\X0D\\X0A\Colon, NOS (110CM MID TRANSVERSE BX)\X0D\\X0A\Colon, NOS (PROX TRANSVERSE POLYP)\X0D\\X0A\Colon, NOS (70CM MASS BX)",,
REG1,COLON,0,500430,1,,"PRE-OPERATIVE DIAGNOSIS: CONSTIPATION, ANEMIA.","Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,MARK A. Status: SOUT","MICROSCOPIC INTERPRETATION: ADENOCARCINOMA.. Final Signout: **NAME[YYY], MD **DATE[May 14 12]",,"GROSS DESCRIPTION: Submitted in a single container of formalin are tan tissue pieces, in aggregate, 0.7 x 0.6 x 0.3 cm., which are totally submitted in one cassette.",,Tissues: COLON BIOPSY. Specimen Comments: CPT CODES: 88305 X 1,,
REG1,COLON,0,503023,1,,PRE-OPERATIVE DIAGNOSIS: GI BLEED.,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,MARK A. Status: SOUT","MICROSCOPIC INTERPRETATION: #1 - HEPATIC FLEXURE MASS, BIOPSY: INVASIVE ADENOCARCINOMA, MODERATELY DIFFERENTIATED. NOTE:  Dr. **NAME[YYY XXX] has reviewed the case and agrees with the diagnosis. #2 - COLON, POLYP SNARE AT 10 CM, BIOPSY: TUBULOVILL0US ADENOMA. NEGATIVE FOR SEVERE DYSPLASIA OR MALIGNANCY.. Final Signout: **NAME[WWW VVV], MD **DATE[Jan 21 12]",,"GROSS DESCRIPTION: The specimens are received within formalin in two containers. Specimen #1 - is labeled hepatic flexure mass biopsy and consists of multiple fragments of soft tan tissue, ranging from 0.2 to 0.4 cm. in greatest dimension.  The specimen is filtered and entirely submitted in mesh cassette ""1"". Specimen #2 - is labeled colon polyp snare at 10 cm. and consists of a polypoid piece of soft tan glistening tissue that measures 0.7 x 0.4 x 0.3 cm.  The specimen is submitted in mesh cassette ""2"".",,Tissues: 1. COLONIC BIOPSY - HEPATIC FLEXURE MASS 2. COLONIC BIOPSY - POLYP SNARE AT 10. Specimen Comments: CPT CODES: 88305 X 2,,
REG1,COLON,0,504840,1,,"HISTORY: Mass in right colon moderately differentiated adenocarcinoma\X0D\\X0A\OR CONSULT: INTRAOPERATIVE CONSULTATION (performed at **INSTITUTION, **STREET-ADDRESS, **PLACE, KY **ZIP-CODE):   Tumor present in proximal right colon, mucosal margins wide and negative      (gross only).                     **NAME[ZZZ M. YYY], M.D.","ICD9 CODES: 153.6, 196.2, 543.9\X0D\\X0A\LAB_COMM: rc's to see serosal surface better to determine if penetrated by tumor, which would increase stage from T3 to T4a.  Dr **NAME[XXX]/JSMC","CANCER CHECKLIST: SPECIMEN          Specimen              Terminal ileum              Cecum              Appendix              Ascending colon          Procedure              Right hemicolectomy          Specify Specimen Length (cm) (if applicable): 22          Tumor Site              Right (ascending) colon          Macroscopic Tumor Perforation              Not Identified      TUMOR          Histologic Type              Adenocarcinoma          Histologic Grade              High-grade (poorly differentiated to undifferentiated)          Histologic Features Suggestive of Microsatellite Instability              Intratumoral Lymphocytic Response (tumor-infiltrating lymphocytes)                  Mild to moderate (0-2 per high-power [X400] field)              Peritumor Lymphocytic Response (Crohn-like response)                  Mild to moderate              Tumor Subtype and Differentiation                  High histologic grade (poorly differentiated)      EXTENT          Tumor Size              Greatest dimension (cm): 3.5                Additional Dimension (cm): 3.0                Additional Dimension (cm): 0.8          Microscopic Tumor Extension              Tumor invades through the muscularis propria into the subserosal adipose tissue or the nonperitonealized pericolic or perirectal soft tissues but does not extend to the serosal surface      MARGINS          Proximal Margin                    Uninvolved by invasive carcinoma          Distal Margin                    Uninvolved by invasive carcinoma          Circumferential (Radial) or Mesenteric Margin              Uninvolved by invasive carcinoma      ACCESSORY FINDINGS          Lymph-Vascular Invasion              Not identified          Perineural Invasion              Not identified          Tumor Deposits (Discontinuous Extramural Extension)              Not identified          Type of Polyp in Which Invasive Carcinoma Arose              None identified      STAGE  (pTNM)          Primary Tumor (pT)              pT3:  Tumor invades through the muscularis propria into pericolorectal tissues          Regional Lymph Nodes (pN)              pN1b:  Metastasis in 2 to 3 regional lymph nodes              Number Examined: 13              Number Involved: 2          Distant Metastasis (pM)              Not applicable\X0D\\X0A\DIAGNOSIS: Terminal ileum, appendix, cecum, and right colon \X0D\\X0A\laparoscopic right hemicolectomy:     Moderately and focally poorly differentiated adenocarcinoma of proximal right         colon, with invasion through muscularis propria into subserosal tissue, focally         abutting serosal surface (with associated reactive mesothelial changes) without         penetrating serosal surface \X0D\\X0A\no lymphovascular space invasion identified \X0D\\X0A\        proximal ileal and distal right colon margins, negative for malignancy.     Unremarkable terminal ileum and cecum.     Fibrous obliteration of appendix.     Metastatic adenocarcinoma identified in two of thirteen (2/13) lymph nodes \X0D\\X0A\        largest lymph node metastasis measures 0.7 cm.  AJCC stage:  IIIB (pT3  pN1b)",,"GROSS: The specimen is received fresh in the operating room labeled ""right colon"". It consists of a right hemicolectomy specimen that is stapled closed at both ends. Two smaller pieces of tan mucosa and some maroon soft tissue measure 0.8 and 3.0 x 1.0 x 1.0 cm each.  The hemicolectomy specimen has a portion of terminal ileum that measures 6 cm in length.  The colon segment including cecum measures 16 cm in length.  The terminal ileum is associated with up to 3 cm of adjacent adipose tissue.  A long, thin appendix extends from the base of cecum, measures 7.2 x 0.3-0.4 cm.  Up to 1.8 cm of adipose tissue is associated with the appendix. The colon segment is associated with up to 2-2.5 cm of adjacent adipose tissue. Upon opening, the terminal ileum has a circumference of 3.5 cm and shows unremarkable tan folds. The appendix measures 4.0 x 4.0 cm and shows unremarkable tan folds. The right colon segment measures 12 cm from base of ileocecal valve to distal margin. At 1.8 cm from the base of ileocecal valve, a tan-pink, ulcerated, plaque--like oval mucosal lesion is noted, measuring 3.0 cm in length, 3.5 cm in circumference where the colon circumference is 6.6 cm, and 0.4 cm in thickness. The distal margin measures approximately 9 cm in length.  A 1.5 x 3.0 cm area of gray coloration of colonic mucosa is noted just distal to the tumor mass. No additional mucosal lesions are noted within the colon segment.  The gross pathology is reviewed with Dr.  J.  **NAME[WWW].  The specimen is then fixed in formalin for several additional hours prior to further sectioning.  After fixation in formalin for several hours, the specimen is re-examined. Sectioning of ileocecal valve shows slight lipomatous hyperplasia, up to 1 cm thick. A-terminal ileum, ileocecal valve \X0D\\X0A\B-bisected tip and four cross sections of appendix (6). Serial sectioning the proximal right colon tumor mass reveals a maximum thickness of 0.6 cm. The tumor appears to invade into the wall and shows focal full thickness invasion in the muscularis propria without any deep subserosal invasion. Colon tumor is sampled in cassettes 1C-1F (1 each).  A portion of cecum and distal right colon margin are submitted in cassette 1G. Subserosal adipose tissue is removed, and the specimen is dissected for lymph nodes. Approximately fifteen candidate lymph nodes are noted, ranging from 0.2-1.2 cm each. No obviously suspicious lymph nodes are identified. Lymph nodes are sampled with a single section each in cassettes 1H-J. Total ten cassettes.","MICRO: The proximal right colon contains an invasive adenocarcinoma that is predominantly moderately differentiated, with approximately 10-15% of the tumor showing poorly differentiated tumor with single cells and marked nuclear pleomorphism. Tattoo pigment is noted adjacent to the infiltrating carcinoma. All slides except 1B required reprocessing to allow adequate fixation.",PROCEDURE: Laparoscopic colon resection\X0D\\X0A\SPECIMEN(S): Right colon segment with ORC,,
REG1,COLON,0,504891,1,,"PREOP DIAGNOSIS:               ANEMIA, HEME + STOOL","**NAME[BBB,AAA M]                            ACCT #: **ID-NUM     LOC:  SURGIC U #: 317073\X0D\\X0A\448 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 68/F       ROOM:         REG: **DATE[May 06 12]\X0D\\X0A\DOB: **DATE[Feb 29 44]    BED:         DIS:\X0D\\X0A\STATUS: REG REF    TLOC:","FINAL DIAGNOSIS\X0D\\X0A\A. BX AT SMALL BOWEL:\X0D\\X0A\.....1....NO EVIDENCE OF SYSTEMIC DISORDERS SUCH AS CELIAC DISEASE.\X0D\\X0A\.....2....ESSENTIALLY WITHIN NORMAL LIMITS TISSUE.\X0D\\X0A\B. SN POLYP AT ASCENDING X7:\X0D\\X0A\.....ADENOMATOUS POLYPS, TUBULAR TYPE.\X0D\\X0A\C. SN POLYP AT TRANSVERSE X13:\X0D\\X0A\.....ADENOMATOUS POLYPS WITH FOCAL HIGH-GRADE DYSPLASIA AND\X0D\\X0A\.....INTRAMUCOSAL CARCINOMA SEEN (SEE MICROSCOPIC DESCRIPTION).\X0D\\X0A\D. SN POLYP AT DESCENDING:\X0D\\X0A\.....ADENOMATOUS POLYP, TUBULAR TYPE.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ **NAME[ZZZ,YYY] XXX] MD  **DATE[May 07 12]",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is submitted fixed in 4 containers, each labeled with the\X0D\\X0A\patient name.\X0D\\X0A\A. Designated ""bx at small bowel"" are 5 tan to brown biopsy specimens\X0D\\X0A\averaging approximately 0.3 to 0.4 cm in greatest dimension. All are\X0D\\X0A\submitted in cassette A.\X0D\\X0A\B. Designated ""sn polyp at ascending x7"", the specimen consists of\X0D\\X0A\multiple large and small tan to brown biopsy specimens, all of which are\X0D\\X0A\filtered and submitted in cassette B.\X0D\\X0A\C. Designated ""sn polyp at transverse x13"", the specimen consists of\X0D\\X0A\multiple tan to brown biopsy specimens, all of which are filtered and\X0D\\X0A\submitted in cassettes C1 and C2.\X0D\\X0A\D. Designated ""sn polyp at descending"", the specimen consists of 7 gray to\X0D\\X0A\tan biopsy specimens, averaging approximately 0.3 to 0.4 cm in greatest\X0D\\X0A\dimension. All are submitted in cassette D.\X0D\\X0A\D: **DATE[May 06 2012] - 1445 hours\X0D\\X0A\T: **DATE[May 06 2012] - 1643 hours\X0D\\X0A\INTRADEPARTMENTAL CONSULT\X0D\\X0A\DR. **NAME[WWW] HAS REVIEWED THE CASE AND AGREES.","MICROSCOPIC EXAMINATION\X0D\\X0A\A. The sections are of small intestinal tissue and show 5 consecutive\X0D\\X0A\normal-height villous structures with no increased number of\X0D\\X0A\intraepithelial lymphocytes, effectively ruling out systemic disorders\X0D\\X0A\such as celiac disease. The biopsies are essentially unremarkable.\X0D\\X0A\B. The sections are of colonic tissue and show adenomatous\X0D\\X0A\glands consistent with adenomatous polyps. No significant\X0D\\X0A\level of cytologic dysplasia is seen. No evidence of\X0D\\X0A\malignancy is seen.\X0D\\X0A\C. The sections show colonic tissue with adenomatous glands, consistent\X0D\\X0A\with adenomatous polyps. In this instance, the specimen also shows\X0D\\X0A\high-grade dysplasia and intramucosal carcinoma present in multiple\X0D\\X0A\sections.\X0D\\X0A\D. The sections are of colonic tissue and show adenomatous\X0D\\X0A\glands consistent with adenomatous polyp. No significant\X0D\\X0A\level of cytologic dysplasia is seen. No evidence of\X0D\\X0A\malignancy is seen.\X0D\\X0A\D: **DATE[May 07 2012] - 1406 hours\X0D\\X0A\T: **DATE[May 07 2012] - 1414 hours","TISSUES:\X0D\\X0A\Small intestine, NOS (BX AT SMALL BOWEL)\X0D\\X0A\Colon, NOS (SN.POLYP AT ASCENDING X7 BX)\X0D\\X0A\Colon, NOS (SN.POLYP AT TRANSVERSE X13 B)\X0D\\X0A\Colon, NOS (SN.POLYP AT DESCENDING BX)",,
REG1,COLON,0,508363,1,,Clinical History:\X0D\\X0A\No Family History Polyps or Colon CA,,"Pre-Operative Diagnosis:\X0D\\X0A\Rectal Bleeding, Mucous in Stool\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Sigmoid Polyp 25 cm Tattooed Large\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A) Sigmoid colon, polyp at 25 cm, polypectomy:\X0D\\X0A\-    Intramucosal and focally invasive moderately differentiated\X0D\\X0A\adenocarcinoma extending into the polyp stalk, with high grade\X0D\\X0A\dysplasia/adenocarcinoma in situ extending to the cauterized base\X0D\\X0A\resection margin (see microscopic description).\X0D\\X0A\B) Sigmoid colon, polyp stalk, polypectomy:\X0D\\X0A\-    Intramucosal and focally invasive moderately differentiated\X0D\\X0A\adenocarcinoma arising within a tubulovillous adenoma; cauterized stalk\X0D\\X0A\base resection margin appears benign.\X0D\\X0A\C) Rectum, polyp, biopsy:\X0D\\X0A\-    Hyperplastic polyp.",,"Gross Description:\X0D\\X0A\Received are three separate formalin-filled containers, each labeled\X0D\\X0A\with the patient's name.\X0D\\X0A\Part A is additionally labeled ""sigmoid polyp at 25 cm"".  The specimen\X0D\\X0A\consists of three irregular pink-tan polypoid tissue fragments, which\X0D\\X0A\are 0.7, 0.5, and 2.2 x 1.4 x 1.4 cm.  The largest tissue fragment has\X0D\\X0A\its base inked blue and is sectioned.  The two smaller tissue fragments\X0D\\X0A\are submitted in toto in cassette A1.  The largest tissue fragment is\X0D\\X0A\sectioned and submitted entirely in cassettes A2 through A3.\X0D\\X0A\Part B is additionally labeled ""sigmoid polyp stalk"".  The specimen\X0D\\X0A\consists of a 2 x 1.7 x 0.8 cm pink-tan pedunculated polypoid tissue\X0D\\X0A\fragment.  The base is inked blue, and the specimen is sectioned and\X0D\\X0A\submitted entirely in cassettes B1 and B2.\X0D\\X0A\Part C is additionally labeled ""rectal polyp"".  The specimen consists of\X0D\\X0A\a single 0.2-cm white-tan irregular tissue fragment submitted in toto in\X0D\\X0A\cassette C.\X0D\\X0A\JAB:jg","Microscopic Description:\X0D\\X0A\A)   The two smallest described fragments show portions of tubulovillous\X0D\\X0A\adenoma with focal high grade dysplasia.  The remaining blocks\X0D\\X0A\containing the two larger portions of polypoid tissue, demonstrate a\X0D\\X0A\large tubulovillous adenoma with a transition to zones of intramucosal\X0D\\X0A\adenocarcinoma appearing moderately differentiated.  Focally invasive\X0D\\X0A\moderately differentiated adenocarcinoma is noted within the polyp\X0D\\X0A\stalk, with the high grade dysplastic changes and zones of intramucosal\X0D\\X0A\adenocarcinoma appearing to extend to the inked and cauterized base\X0D\\X0A\resection margin for these fragments.  Correlation with the colonoscopic\X0D\\X0A\impression is recommended.\X0D\\X0A\B)   Sections show a serially divided polypoid fragment of colonic\X0D\\X0A\mucosa again demonstrating changes of a tubulovillous adenoma with zones\X0D\\X0A\of high grade adenomatous dysplasia transitioning to intramucosal\X0D\\X0A\adenocarcinoma, with a small focus compatible with at least superficial\X0D\\X0A\invasion into the polyp stalk.  The inked and partially cauterized\X0D\\X0A\apparent stalk base resection margin as noted in block 2, and appears\X0D\\X0A\free of dysplasia and invasive carcinoma.\X0D\\X0A\C)   The rectal biopsy represents changes of an early hyperplastic\X0D\\X0A\polyp.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\DRJ:vsg\X0D\\X0A\D\T\T:  **DATE[Apr 19 2012].\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 19 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Sigmoid Polyp at 25 cm\X0D\\X0A\SOURCE OF SPECIMEN: B Sigmoid Polyp Stalk\X0D\\X0A\SOURCE OF SPECIMEN: C Rectal Polyp,,
REG1,COLON,0,508865,3,,"Clinical Diagnosis and History\X0D\\X0A\Anemia, rectal bleeding.",Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Biopsy colon mass at 100 cm,"Final Diagnosis\X0D\\X0A\Colon mass at 100 cm, biopsy:\X0D\\X0A\Invasive moderately differentiated adenocarcinoma.\X0D\\X0A\                                             1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin and labeled with the patient name and\X0D\\X0A\""biopsy of colon mass at 100 cm"". The specimen consists of multiple pink-gray\X0D\\X0A\soft tissue fragments aggregating to 1.5 x 1.1 x 0.2 cm. The specimen is totally\X0D\\X0A\submitted in (block A).\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Sections of the biopsy of colon mass at 100 cm reveal an invasive moderately\X0D\\X0A\differentiated adenocarcinoma.  There are complex glandular forms coursing\X0D\\X0A\through the mucosal tissue associated with desmoplastic fibrous response.  Gland\X0D\\X0A\within gland forms are seen.  There is brisk mitotic activity.  A pre-existing\X0D\\X0A\adenomatous lesion is not identified.\X0D\\X0A\**INITIALS,,,
REG1,COLON,0,526202,1,,CLINICAL HISTORY:\X0D\\X0A\Screening,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   COLON BIOPSY, 20 CM:\X0D\\X0A\1.   Tubulovillous colonic polyp, 1.4 cm. with multifocal\X0D\\X0A\intraepithelial carcinoma in-situ.\X0D\\X0A\2.   Negative for invasive neoplasm.\X0D\\X0A\3.   The stalk margin of excision appears free of intraepithelial\X0D\\X0A\atypia.\X0D\\X0A\ \X0D\\X0A\COMMENT: Tis\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (DA/dkv)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Mar 20 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received in formalin and designated 'colon polyp 20 cm' is\X0D\\X0A\a red-tan polypoid irregular tissue fragment measuring 1.4 x 1.1 x 0.8\X0D\\X0A\cm.  The specimen is sectioned and entirely submitted in a single\X0D\\X0A\cassette.  (MC/dkv)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 1,,SPECIMEN(S): A COLON POLYP @ 20 CM,,
REG1,COLON,0,532219,1,,Clinical History:\X0D\\X0A\Polyps,,"Pre-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Colonic mucosal biopsies, cecum:  Tubular adenomas.\X0D\\X0A\B)  Colonic mucosal biopsies, ascending:  Tubular adenomas.\X0D\\X0A\C)  Colonic mucosal biopsy, sigmoid at 40 cm:  Tubulovillous adenoma.\X0D\\X0A\D)  Rectal mucosal biopsy:  Tubular adenoma with focal carcinoma in\X0D\\X0A\situ.",,"Gross Description:\X0D\\X0A\A)  Received in formalin designated ""cecum polyp"" are five white-tan\X0D\\X0A\irregular tissue fragments, ranging in size from 0.1 to 0.4 cm.  The\X0D\\X0A\specimen is submitted in toto in cassette A.\X0D\\X0A\B)  Received in formalin designated ""ascending colon polyp"" are four\X0D\\X0A\white-tan irregular tissue fragments, ranging in size from 0.1 to 0.7 cm\X0D\\X0A\in greatest dimension.  The largest tissue fragment has a space inked\X0D\\X0A\blue and is bisected.  The specimen is submitted entirely in cassette B.\X0D\\X0A\C)  Received in formalin designated ""polyp sigmoid 40 cm"" is a single\X0D\\X0A\0.4 cm white-tan irregular tissue fragment.  The specimen is totally\X0D\\X0A\submitted in cassette C.\X0D\\X0A\D)  Received in formalin designated ""rectum polyp"" is a 1 x 0.7 x 0.7 cm\X0D\\X0A\pink-tan sessile polyp.  The base is inked blue, and the polyp is\X0D\\X0A\trisected and submitted entirely in cassette D.  JAB:jck","Microscopic Description:\X0D\\X0A\A)  These specimens all show distortion of the usual mucosal\X0D\\X0A\architecture by a proliferation of tubular structures lined by a mildly\X0D\\X0A\atypical columnar epithelium.  There is no evidence of any cribriforming\X0D\\X0A\or invasive process present.\X0D\\X0A\B)  These specimens all show distortion of the usual mucosal\X0D\\X0A\architecture by a proliferation of tubular structures lined by a mildly\X0D\\X0A\atypical columnar epithelium.  There is no evidence of any cribriforming\X0D\\X0A\or invasive process present.\X0D\\X0A\C)  This specimen shows distortion of the usual mucosal architecture by\X0D\\X0A\a proliferation of tubular and villous structures with the tubular\X0D\\X0A\structures somewhat predominating.  Both types of structures are lined\X0D\\X0A\by columnar cells showing mild cytologic atypia.  There is no evidence\X0D\\X0A\of any cribriforming or invasive process present.\X0D\\X0A\D)  This specimen shows distortion of the usual rectal mucosal\X0D\\X0A\architecture by a proliferation of tubular structures.  They are\X0D\\X0A\predominantly lined by mildly to moderately atypical columnar epithelium\X0D\\X0A\but there is focally marked cytologic atypia present in association with\X0D\\X0A\a cribriforming architecture.  In some of these very atypical areas the\X0D\\X0A\lumina contain eosinophilic necrosis.  No definite invasion can be\X0D\\X0A\identified.  In the plane of section, the inked stalk margin is free of\X0D\\X0A\the neoplasm although quite close (approximately 0.1 cm).  Tissue Code:\X0D\\X0A\T1.\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Oct 03 2011]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Polyp cecum x 3\X0D\\X0A\SOURCE OF SPECIMEN: B Ascending colon polyp x 4\X0D\\X0A\SOURCE OF SPECIMEN: C Sigmoid polyp 40 cm x 1\X0D\\X0A\SOURCE OF SPECIMEN: D Rectum polyp,,
REG2,BREAST,0,PAT-40159759,1,REC-100000926558,"ClinicalHistory:
  Left breast mass 6 o?clock; Solid suspicious mass.",,"FinalDiagnosis:
  Breast, Left, 6 O'clock, Ultrasound Guided Core Biopsy:
    Invasive Ductal Carcinoma, Nuclear Grade 3 Over 3, Poorly Differentiated.",,"GrossDescription:
  Received in formalin labeled left breast core biopsy 6 o?clock per the container and left breast core biopsy 6 o?clock 4.0cm from nipple per the requisition are seven cylindrical portions of tan to yellow, soft tissue ranging from 0.2 x 0.1cm to 1.0 x 0.2cm.  The specimen is submitted in toto as 1A and 1B.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[May 4 2013].","MicroscopicDescription:
  The core biopsies from the left breast at 6 o'clock consist of cores of mammary tissue with extensive involvement by a poorly differentiated mammary duct carcinoma. The tumor is of nuclear grade 3 over 3 and is poorly differentiated (B R score of 8). In situ ductal carcinoma component is not seen. Focal areas of necrosis are seen within the tumor. 

ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)     
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin-fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin-free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 

The Estrogen Receptor (VECTOR-CLONE 6F11) is negative in 100% of the tumor cells showing 0 staining. The Progesterone Receptor (DAKO-Clone PgR 636) is negative in 100% of the tumor cells showing 0 staining. The Herceptest (DAKO) shows negative (0) staining, after evaluation of membrane staining intensity and pattern on the standardized  0-3+ scale.

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO/CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO/CAP scoring criteria for HER2 protein over-expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.


PQRS CODE: 3394F.",1: Left breast core biopsy,,
REG2,BREAST,0,PAT-40160149,1,REC-100000926565,"ClinicalHistory:
  Calcification right breast posterior.",,"FinalDiagnosis:
1.  Breast, Right Breast with Calcifications Posterior, Core Biopsy:
Lobular Carcinoma in Situ (LCIS); See Comment.
Atypical Ductal Hyperplasia (ADH) Noted; No DCIS Identified.
     Background of Blunt Duct Adenosis, Columnar Cell Change and Dilatation of Ducts.
    Calcifications Seen in Benign Ducts.
    No Evidence of Invasive Carcinoma.

2.  Breast, Right Breast without Calcifications Posterior, Core Biopsy:
Benign Fatty Breast Tissue; Few Ductal Elements Identified.
No Evidence of Malignancy.

Comment:
  An E Cadherin stain is performed on part 1.  No DCIS is identified.  The lobular carcinoma appears both classic and pleomorphic type.  There is no evidence of invasive carcinoma.  

  This case is reviewed at the Daily Departmental Conference.",,"GrossDescription:
  Container 1:  Received in formalin labeled right breast biopsy with calcifications posterior are four cylindrical portions of tan to yellow, soft and delicate tissue ranging from 1.0 x 0.2cm to 3.8 x 0.2cm.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled right breast without calcifications posterior are six cylindrical portions of tan to yellow, soft and delicate tissue ranging from 0.8 x 0.2cm to 3.0 x 0.2cm.  The specimen is submitted in toto as 2A and 2B.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Oct 29 2013].","MicroscopicDescription:
  Slides Reviewed.",1: Right breast core biopsy2: Right breast core biopsy,,
REG2,BREAST,0,PAT-40060345,2,REC-100000926825,"ClinicalHistory:
Mets breast cancer ,carcinomatous meningitis.","CytologyReview:
 Atypical cells seen.

 Atypical cells seen.","FinalDiagnosis:
Rare atypical degenerated cells showing cytomorphologic features similar to the previous metastatic breast carcinoma to cerebrospinal fluid (please see N12 3216, N12 3025, N12 2842, N12 2653, N12 2621 and N12 2569).  Note is also made of the left breast carcinoma, S07 7741 and S07 7367.

Case reviewed at the pathology departmental conference.",,"GrossDescription:

Received  2 cc clear fluid  cc  fluid for ThinPrep.",,A: Cerebrospinal Fluid,,
REG2,BREAST,0,PAT-40160165,1,REC-100000926834,"ClinicalHistory:
  Right breast microcalcifications; Rule out malignancy.",,"FinalDiagnosis:
1.  Breast, Right Breast Tissue with Calcifications at 12 O'clock, Posterior Site, Mammotome Biopsy:
Ductal Carcinoma In Situ (DCIS), Solid and Cribriform Types, High Grade with Comedonecrosis and Associated Calcifications; See Comment.
Cancerization of Lobules Noted.
Calcifications Also Noted in Benign Ducts and Stroma.

2.  Breast, Right Breast Tissue without Calcifications at 12 O'clock, Posterior Site, Mammotome Biopsy:
DCIS, Solid and Cribriform Types, High Grade, with Focal Necrosis.
No Evidence of Invasive Carcinoma.

3.  Breast, Right Breast Tissue with Calcifications at 12 O'clock, Anterior Site, Mammotome Biopsy:
DCIS, Solid, Cribriform, and Papillary Types with Comedonecrosis and Associated Calcifications; See Comment.
Cancerization of Lobules Noted.

4.  Breast, Right Breast Tissue without Calcifications at 12 O'clock, Anterior Site, Mammotome Biopsy:
DCIS, Solid and Cribriform Types, High Grade with Comedonecrosis; See Comment.
Cancerization of Lobules Noted.


Comment: There is extensive high grade DCIS. Focally, there is a lymphoid and stromal response, however, no definite invasion is seen on H and E. Immunohistochemical stains are pending to rule out microinvasion and  results will follow as an addendum. Receptor studies pending also and results will follow. This case is reviewed with Dr. **NAME[ZZZ YYY], who agrees with the diagnosis.",,"GrossDescription:
  Container 1:  Received in formalin labeled right breast tissue with calcifications at 12 o?clock, posterior site are seven cylindrical, white, yellow fibrofatty soft tissue cores ranging from 0.5 x 0.2cm to 2.8 x 0.2cm, which are submitted in toto as 1A and 1B.

  Container 2:  Received in formalin labeled right breast tissue without calcifications at 12 o?clock posterior site are seven cylindrical, white, yellow fibrofatty soft tissue cores ranging from 0.3 x 0.2cm to 2.0 x 0.2cm, which are submitted in toto as 2A and 2B.

  Container 3:  Received in formalin labeled right breast tissue with calcifications at 12 o?clock, anterior site are six cylindrical, white to yellow fibrofatty soft tissue cores averaging from 2.8 x 0.2cm, which are submitted in toto as 3A and 3B.

  Container 4:  Received in formalin labeled right breast tissue without calcifications at 12 o?clock anterior site are two cylindrical, white to yellow fibrofatty soft tissue cores measuring 3.0 x 2.5cm and 2.6 x 0.2cm, which are submitted in toto as 4A. 
EB:lefb, **DATE[Sep 20 2013].","MicroscopicDescription:
  Slides Reviewed.",1: Right breast core biopsy2: Right breast core biopsy3: Right breast core biopsy4: Right breast core biopsy,,
REG2,BREAST,0,PAT-40160154,1,REC-100000926848,"ClinicalHistory:
  Left breast microcalcifications at 12:30; Rule out malignancy.",,"FinalDiagnosis:
1.  Breast, Left, 12:30, With Calcifications, Needle Core Biopsy (Mammotome):
Intraductal Carcinoma (Ductal Carcinoma In Situ), Solid and Comedo Carcinoma Type, Intermediate to High Grade, with Associated Microcalcifications. 
No Invasive Carcinoma Identified. 
See Note. 

2.  Breast, Left, 12:30, Without Calcifications, Needle Core Biopsy (Mammotome):
Intraductal Carcinoma (Ductal Carcinoma In Situ), Solid and Comedo Carcinoma Type, Intermediate to High Grade. 
No Invasive Carcinoma Identified. 
See Note. 

NOTE: 
  The supplied clinical information is noted.

  In specimen #1, left breast, 12:30, with calcifications, needle core biopsy specimen, intraductal carcinoma (ductal carcinoma in situ) involves an estimated three (3) needle core biopsy tissue cores in the sections examined.  In specimen #2, left breast, 12:30, without calcifications, needle core biopsy specimen, intraductal carcinoma (ductal carcinoma in situ) involves an estimated two (2) needle core biopsy tissue cores in the sections examined.  

  Intraductal carcinoma (ductal carcinoma in situ) has solid and comedo carcinoma architectural patterns and a nuclear grade ranging from grade 2 of 3 to grade 3 of 3, and would be considered an intermediate to high grade intraductal carcinoma (ductal carcinoma in situ).  Focal microcalcifications are associated with the intraductal carcinoma (ductal carcinoma in situ) in specimen #1.  

  No invasive carcinoma is identified in any portion of the present needle core biopsy specimen of the left breast at 12:30 in any section examined.; 

  Immunohistochemical stains for estrogen receptor and progesterone receptor (quantitative) will be performed on this specimen (on block 1A) and the results will be reported separately in an addendum.",,"GrossDescription:
  Container 1:  Received in formalin labeled A left breast tissue with calcifications at 12:30 are three yellow to white cores of soft tissue ranging from 2.0 x 0.2cm to 2.7 x 0.2cm, which are submitted in toto as 1A.

  Container 2:  Received in formalin labeled B left breast tissue without calcifications at 12:30 are eight yellow to white cores of soft tissue ranging from 0.4 x 0.2cm to 1.8 x 0.2cm, which are submitted in toto as 2A and 2B.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
CH:lefb **DATE[Feb 15 2013].","MicroscopicDescription:
  Slides reviewed.",1: Left breast core biopsy2: Left breast core biopsy,,"AddendumComment:
ER/PR (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis are performed on formalin fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is positive in 80% to 90% of the tumor cells showing 1 to 2+ staining intensity.  The Progesterone Receptor (DAKO Clone PgR 636) is positive in 70% to 80% of the tumor cells showing 1 to 3+ staining intensity.

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

PQRS CODE: 3394F"
REG2,BREAST,0,PAT-40171681,1,REC-100000926876,"ClinicalHistory:
Pericardial effusion, breast cancer.","CytologyReview:
 Malignant cells noted c/w patient?s known breast carcinoma.

 Malignant cells noted c/w patient?s known breast carcinoma.","FinalDiagnosis:
 Malignant cells present, consistent with patient?s history of mammary carcinoma.

Note
 Immunoperoxidase stains, show the malignant cells to be positive for CK7, Ber EP4, and BCA 225, and weakly and negative for GCDFP, CK20, mamoglobin, calretinin and WT1. 

ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
      
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on cytolyt-fixed paraffin embedded tissue (cell block) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin-free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 

The Estrogen Receptor (VECTOR-CLONE 6F11) is positive in 20% of the tumor cells showing 1+ to 2+ staining intensity. The Progesterone Receptor (DAKO-Clone PgR 636) is negative in 100% of the tumor cells. The Herceptest (DAKO) shows positive (2+ to 3+) staining, after evaluation of membrane staining intensity and pattern on the standardized  0-3+ scale. FISH is pending.

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO/CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO/CAP scoring criteria for HER2 protein over-expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.




PQRS CODE: 3394F.",,"GrossDescription:
Received    60cc bloody fluid for ThinPrep and Cell Block.",,A: Pericardial Fluid,,
REG2,BREAST,0,PAT-40160209,1,REC-100000926959,"ClinicalHistory:
  Suspicious mass; Suspicious lymph node.",,"FinalDiagnosis:
1.  Breast, Right Breast Biopsy at 12 O'Clock, Core Biopsy:
Invasive Ductal Adenocarcinoma, Nuclear Grade 3, Histologic Grade 3 (Poorly Differentiated). 
Tumor is Present in Three of Three (3 of 3) Tissue Cores, the Largest Fragment Measuring Approximately 1.8cm; Clinical Correlation Recommended. 

2.  Lymph Node, Right Axillary Lymph Node, Biopsy:
Invasive Ductal Adenocarcinoma, Identical to That Seen in Part #1, Present in One (1) Core (No Lymph Node Tissue).
Two (2) Other Core Biopsy Fragments of Lymph Node Without Evidence of Metastatic Carcinoma; Clinical Correlation Recommended. 

COMMENT: 
  This case is reviewed at the Daily Departmental Conference. Receptor studies pending and results will follow as an addendum.",,"GrossDescription:
  Container 1:  Received in formalin labeled right breast biopsy 12 o?clock per the container and right breast biopsy 12 o?clock 2.0cm from nipple per the requisition are three cylindrical portions of tan to pink, soft tissue ranging from 0.4 x 0.1cm to 1.8 x 0.2cm.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled right axilla lymph node are three cylindrical portions of tan to pink, soft tissue ranging from 0.8 x 0.2cm to 1.5 x 0.2cm.  The specimen is submitted in toto as 2A.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Mar 4 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy2: Right lymph node core biopsy,,"AddendumComment:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is negative in >99% of the tumor cells.  The Progesterone Receptor (DAKO Clone PgR 636) is negative in 100% of the tumor cells.  The Herceptest (DAKO) shows 2+ indeterminate staining, after evaluation of membrane staining intensity and pattern on the standardized  0 to 3+ scale.  FISH for Her2neu will be performed.

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE:   ASCO/CAP scoring criteria for HER2 protein over expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3).  Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1).  Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.  

PQRS CODE: 3394F"
REG2,BREAST,0,PAT-40160228,1,REC-100000927007,"ClinicalHistory:
  Right breast mass.",,"FinalDiagnosis:
Breast, Right, 10 O'Clock, ""Mass,"" Needle Core Biopsy (Imaging Guided):
Infiltrating Duct Carcinoma, Well Differentiated.
See Note. 

NOTE: 
  The supplied clinical information is noted. 

  In the present needle core biopsy specimen of the right breast at 10 o'clock, infiltrating duct carcinoma involves three (3) needle core biopsy tissue cores, with a maximum dimension measured microscopically on the slides of approximately 0.6cm in greatest dimension.  Clinical and imaging correlation should be considered.  

  Infiltrating duct carcinoma has an architectural grade of grade 2 of 3, a nuclear grade ranging from grade 1 of 3 to grade 2 of 3, and relatively few mitotic figures (grade 1 of 3) for a Nottingham score of 2+2+1 = 5 of 9; ""well differentiated"" (also termed ""grade 1 of 3"").  No definite lymphatic invasion, blood vessel invasion, or perineural invasion by carcinoma is identified in the sections examined.  No definite in situ carcinoma component is identified in the sections examined. 

  Immunohistochemical stains for estrogen receptor, progesterone receptor and Herceptest (quantitative) will be performed on the present specimen and will be reported separately in an addendum.",,"GrossDescription:
  Received in formalin labeled right breast biopsy 10 o?clock per the requisition and on the container with only the patient?s name are three cylindrical portions of tan to yellow, soft tissue ranging from 0.6 x 0.2cm to 1.2 x 0.2cm.  The specimen is submitted in toto as 1A.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Dec 12 2012].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy,,"AddendumDiagnosis:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
      
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin-fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin-free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 

The Estrogen Receptor (VECTOR-CLONE 6F11) is positive in over 95% of the tumor cells showing 2 to 3+  staining intensity. The Progesterone Receptor (DAKO-Clone PgR 636) is positive in over 90% of the tumor cells showing 2 to 3+ staining intensity. The Herceptest (DAKO) shows equivocal staining (1 to 2+ in 40 to 50% of the tumor cells), after evaluation of membrane staining intensity and pattern on the standardized  0-3+ scale. Therefore, this specimen will be sent for evaluation of HER2neu by FISH. When the final results are completed, an addendum will be added to the report.

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO/CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO/CAP scoring criteria for HER2 protein over-expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.





PQRS CODE: 3394F."
REG2,BREAST,0,PAT-40160251,1,REC-100000927012,"ClinicalHistory:
  Right breast mass.",,"FinalDiagnosis:
Right Breast, Ultrasound Guided Needle Core Biopsy at 9:30:
Infiltrating Mammary Carcinoma with Mixed Ductal and Lobular Features, Histologic Grade 2 out of 3, Nuclear Grade 3 out of 3. 
See Note. 

NOTE: 
  The right breast ultrasound guided needle core biopsy is composed of multiple needle core biopsy fragments of tissue showing extensive involvement by infiltrating mammary carcinoma diffusely permeating the fibrous and adipose stroma.  Tumor forms solid nests and exhibits a single cell pattern of infiltration.  Individual tumor cells are pleomorphic, with cytoplasmic vacuoles and occasional signet ring cells.  No in situ carcinoma component is identified.  No definite lymphovascular invasion is seen.  The tissue fragments with tumor range in size from 0.2 to 0.6cm.  

  E cadherin immunohistochemical stain is performed.  Some tumors cells are immunoreactive with E cadherin and others are negative.  This pattern is supportive of infiltrating mammary carcinoma with mixed ductal and lobular features. 

  This case was reviewed at the Pathology Departmental Conference and was also reviewed intradepartmentally with Dr. **NAME[ZZZ YYY].  Dr. **NAME[M. XXX] was notified of these findings on **DATE[Jan 7 2013] at 10:15 AM.

ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is positive in 99% of the tumor cells showing strong (3+) staining intensity.  The Progesterone Receptor (DAKO Clone PgR 636) is positive in 99% of the tumor cells showing strong (3+) staining intensity.  The Herceptest (DAKO) shows equivocal (1+ to 2+) staining, after evaluation of membrane staining intensity and pattern on the standardized  0 to 3+ scale.  Her2 neu by fluorescence in situ hybridization (FISH) will be performed on the tissue block and reported in an addendum.

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE:   ASCO/CAP scoring criteria for HER2 protein over expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3).  Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1).  Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.  

PQRS CODE: 3394F",,"GrossDescription:
  Received in formalin labeled ultrasound guided right breast core biopsy at 9:30 are 10 cylindrical, tan, white to yellow, fibrofatty tissues ranging from 0.2 x 0.2cm to 1.5 x 0.2cm.  The specimen is submitted in its entirety as 1A and 1B.

Fixation of specimen reviewed and assured to be 6 to 48 hours. 
MM:lefb **DATE[Jan 6 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy,,
REG2,BREAST,0,PAT-40072116,2,REC-100000927071,"ClinicalHistory:
  Left breast carcinoma.
IntraoperativeDiagnosis:
  Touch Prep Diagnosis:
1.  Left breast sentinel node, hot, not blue: No carcinoma identified on touch prep (JS). Report given to Dr. **NAME[ZZZ]. 
2.  Left breast sentinel node, hot, not blue: No carcinoma identified on touch prep (JS). Report given to Dr. **NAME[ZZZ].",,"FinalDiagnosis:
1.  Left Axilla, Sentinel Node, Hot, Not Blue, Biopsy:
One (1) Lymph Node with Sinus Histiocytosis and Fatty Change; No Evidence of Metastatic Carcinoma (Touch Preparation Smear, H and E Sections and Cytokeratin Immunohistochemical Stain). 

2.  Left Axilla, Sentinel Node #2, Hot, Not Blue, Biopsy:
One (1) Lymph Node with Sinus Histiocytosis and Fatty Change; No Evidence of Metastatic Carcinoma (Touch Preparation Smear, H and E Sections and Cytokeratin Immunohistochemical Stain). 

3.  Left Breast, Excision with Wire Guided Localization:
Previous Biopsy Site Identified, with Gross Metallic Clip. 
Invasive Tubular Carcinoma, Histologic Grade 1 out of 3, Nuclear Grade 1 out of 3, with Microcalcifications (0.8 x 0.6 x 0.4cm). 
No Ductal Carcinoma In Situ Identified. 
No Lymphovascular Invasion Present. 
Focal Fibrocystic Change with Apocrine Cysts, Adenosis, Occasional Lobular Microcalcifications, and Vascular Calcifications. 
Surgical Resection Margins Negative for Carcinoma. 
All Margins are Greater Than 10mm from Invasive Tubular Carcinoma.

4.  Left Breast, True Posterior Margin:
Portion of Fibrofatty Tissue and Skeletal Muscle.
No Carcinoma Identified.
True Posterior Margin Negative. 

NOTE: 
  Please see previous left breast ultrasound guided needle core biopsy at 10 o'clock, S12 19123, showing infiltrating carcinoma with extensive infiltrating tubular carcinoma features and with associated microcalcification, with positive estrogen receptor in over 99% of the tumor cells, showing 3+ staining intensity, positive progesterone receptor in over 95% of the tumor cells, showing 2+ to 3+ staining intensity, and negative Herceptest (1+ in 10% to 20% of tumor cells).

   

SYNOPTIC REPORT:
INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy With or Without Axillary Contents) and Mastectomy (Total, Modified Radical, Radical With or Without Axillary Contents)

Procedure   :  Excision with wire guided localization
Lymph Node Sampling   :  Sentinel lymph nodes (2) 
Specimen Laterality  :  Left

Tumor Site: Invasive Carcinoma)  :  Position: 10 o'clock, based on the ultrasound guided needle core biopsy, S12 19123

Histologic Type of Invasive Carcinoma  :  Invasive tubular carcinoma

Tumor Size: Size of Largest Invasive Carcinoma  :  Greatest dimension of largest focus of invasion >1mm: 8mm 
      Additional dimensions: 6 x 4mm
Histologic Grade: Nottingham Histologic Score
  Glandular (Acinar)/Tubular Differentiation  :  Score 1: >75 of tumor area forming glandular/tubular structures
  Nuclear Pleomorphism  :  Score 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size
  Mitotic Count  :  Score 1 (<3 mitoses per mm2)
  Overall Grade  :  Grade1 (score of 3)

Tumor Focality  :  Single focus of invasive carcinoma

Ductal Carcinoma In Situ (DCIS)  :  No DCIS is present

Margins
  Invasive Carcinoma  :  Margins uninvolved by invasive carcinoma
        Distance from closest margin: >10mm (all margins)

Lymph Nodes (required only if lymph nodes are present in the specimen):
    :  Number of sentinel lymph nodes examined: 2
      Number of lymph nodes with macrometastases (>2mm): 0
      Number of lymph nodes with micrometastases (>0.2mm to 2mm and/or >200 cells): 0
      Number of lymph node with isolated tumor cells (<0.2mm and <200 cells): 0
      Total number of lymph node without tumor cells identified: 2
Method of Evaluation of Sentinel Lymph Nodes
    :  H and E, multiple levels
      Immunohistochemistry

Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy
  In the Breast  :  No known presurgical therapy
  In the Lymph Nodes  :  No known presurgical therapy

Lymph Vascular Invasion   :  Not identified 
Dermal Lymph Vascular Invasion  :  Not skin present

Pathologic Staging (based on information available to the pathologist) (pTNM)
  Primary Tumor (Invasive Carcinoma)(pT)  :  pT1b  Tumor >5mm but <10mm in greatest dimension  
  Regional Lymph Nodes (pN)
       Modifiers  :  (sn)  Only sentinel nodes evaluated (2)
       Category  :  pN0(i-)  No regional lymph node metastases histologically, negative IHC  
  Distant Metastasis (M)    :  Not applicable

Ancillary Studies
  Estrogen Receptor  :  Performed on the needle core biopsy, S12 19123
       Results  :  Positive (>99% of tumor  cells with nuclear positivity)
        Average intensity of tumor cell nuclei staining: Strong
      
  Progesterone Receptor  :  Performed on the needle core biopsy, S12 19123
       Results  :  Positive (>95% of tumor  cells with nuclear positivity)
        Average intensity of tumor cell nuclei staining: Moderate to Strong
  HER2/neu
  Immunoperoxidase Studies  :  Performed on the needle core biopsy, S12 19123
       Results  :  Negative (score 1+)

Microcalcifications   :  Present in both carcinoma and non neoplastic tissue 

CPT Code: 3260-F.",,"GrossDescription:
  Container 1. Received fresh labeled ""left breast sentinel node, hot, not blue"" is a 1.2 x 0.8 x 0.3cm tan to yellow lymph node. The cut surface is smooth. No blue dye is identified. The lymph node is bisected and a touch prep is performed (see touch prep diagnosis #1). The specimen is entirely submitted as 1A. 

  Container 2. Received fresh labeled ""left breast sentinel node #2, hot, not blue"" is a 0.8 x 0.6 x 0.3cm portion of yellow adipose tissue, within which a 0.5cm in greatest dimension tan lymph node is identified. The cut surface is smooth. No blue dye is identified. The lymph node is bisected and a touch prep is performed (see touch prep diagnosis #2). The lymph node is entirely submitted as 2A. 

  Container 3. Received fresh on a radiographic grid labeled ""left breast mass"" is a fibrofatty portion of breast tissue oriented by sutures (single suture superior, double suture medial), measuring 8.2cm from superior to inferior, 7.8cm from medial to lateral and 2.3cm from anterior to posterior. There is a needle localization wire extending out of the medial aspect of the specimen. The specimen radiograph localizes a paracentric clip surrounded by a soft tissue density without associated microcalcifications. The margins are marked with silver nitrate prior to sectioning and additionally inked as follows: superior blue, inferior green, lateral yellow, anterior orange, posterior black. The specimen is serially sectioned to reveal a 0.8 x 0.6 x 0.4cm hemorrhagic biopsy site with an embedded metallic clip corresponding to the soft tissue density localized on the radiograph. The biopsy site is located 0.9cm from the nearest margin (posterior), 1.1cm from the anterior margin, 1.8cm from the medial margin and greater than 4.0cm from the remaining margins. A discrete residual mass lesion is not grossly appreciated. The remaining parenchyma consists of predominantly yellow glistening lobular adipose tissue intermixed with lacy white fibrous tissue. The fibrous tissue represents approximately 5% of the parenchyma. Sections are submitted from inferior to superior as follows: 3A, inferior margin; 3B, biopsy site to include posterior margin (location of clip); 3C, anterior margin nearest clip; 3D, remaining biopsy site to include anterior margin; 3E, lateral margin; 3F, medial margin; 3G, random superior section; 3H, superior margin. All margins are represented.

  Container 4. Received in formalin labeled ""left breast true posterior margin"" is a 3.8 x 2.8 x 0.8cm irregular portion of fibrofatty breast tissue with a black suture denoting ""true posterior margin"". The new true posterior margin is inked blue prior to sectioning. Sectioning reveals predominantly yellow glistening lobular adipose tissue intermixed with scant delicate white lacy fibrous tissue. The fibrous tissue represents less than 5% of the parenchyma.  A discrete mass lesion is not grossly identified. The specimen is serially sectioned and entirely submitted sequentially as 4A thru 4F.  

Fixation of specimen reviewed and assured to be between 6 to 48 hours. 
CH:fmg **DATE[May 05 2013].","MicroscopicDescription:
  Slides reviewed.",1: Left sentinal lymph node(s)2: Left sentinal lymph node(s)3: NL- Left breast biopsy requiring evaluation of surgical  margins4: Left breast biopsy requiring evaluation of surgical  margins,,
REG2,BREAST,0,PAT-40160128,1,REC-100000927423,"ClinicalHistory:
Right Breast Mass.","CytologyReview:
 Malignant  cells consistent with Ductal Cell Carcinoma.

 Atypical cells seen.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
 Atypical cells highly suspicious for malignancy.
This case was seen in the Pathology Departmental Conference.

Note: Case discussed with Dr. **NAME[M. ZZZ].",,"GrossDescription:
Received: 30cc bloody CytoLyt for ThinPrep and Cell Block.",,"A: Right Breast, Fine Needle Aspiration",,
REG2,BREAST,0,PAT-40099297,2,REC-100000927586,"ClinicalHistory:
  Right chest wall lesion.",,"FinalDiagnosis:
  Skin and Soft Tissue, Right Chest Wall, Excision of Lesion:
    Poorly Differentiated Carcinoma, Consistent with Recurrent Mammary Ductal
      Carcinoma from the Patient's Known Primary (S09 13161).
    Please See Comment and Results of Hormone Receptor Studies Below.

Comment: Note is made of the provided clinical information and the patient's previous specimen, S09 13161, which is reviewed.  The patient's previous invasive poorly differentiated mammary ductal carcinoma is morphologically similar to the tumor seen in the current right chest wall excision and is, therefore, interpreted as recurrence of the patient's previous carcinoma. The current chest wall excision shows infiltrating poorly differentiated carcinoma extending to all inked visualized surgical resection margins and is seen infiltrating skeletal muscle and adipose tissue. 

This case was reviewed at the Daily Intradepartmental Conference for consensus diagnosis on **DATE[Apr 30 2013]. This case was discussed with Dr. **NAME[ZZZ] via phone by Dr. **NAME[M. YYY] on **DATE[Apr 31 2013].


ER, PR, HERCEPTEST (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin-fixed paraffin embedded tissue (Block 1L) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin-free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR-CLONE 6F11) is POSITIVE in 100% of the tumor cells showing 3+ staining intensity. The Progesterone Receptor (DAKO-Clone PgR 636) is POSITIVE in 98% of the tumor cells showing 3+ staining intensity. The Herceptest (DAKO) shows EQUIVOCAL (2+) staining, after evaluation of membrane staining intensity and pattern on the standardized  0-3+ scale. Fluorescent in situ hybridization (FISH) for HER2 will be performed and reported in an addendum. 

[Herceptest reviewed with Dr. **NAME[M. XXX] on **DATE[Apr 31 2013].]

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO/CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO/CAP scoring criteria for HER2 protein over-expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.",,"GrossDescription:
  Received in formalin labeled right chest wall lesion is a 6.7cm (medial to lateral) by 3.2cm (superior to inferior) elliptical portion of white skin, excised to a depth of 2.0cm.  The skin surface displays a 2.5 x 2.4cm tan to pink, ulcerated and granular area, coming to within 0.3cm of the superior margin.  In addition, 1.7cm medial to the aforementioned lesion, there is a 1.0 x 1.0cm tan to pink, finely granular area approaching the soft tissue margin (medial and superior aspects).  The specimen is marked with a short suture designating superior and a long suture designating lateral.  The specimen is inked black along the superior aspect and blue along the inferior aspect.  On sectioning, underlying the larger lesion, the cut surfaces are tan, rubbery to indurated and glistening to finely granular.  The indurated area comes to within 0.3cm of the deep aspect and approaches both the superior and inferior margins.  The specimen is serially sectioned and submitted in its entirety as follows:  1A, cruciate medial tip; 1B and 1C, smaller lesion; 1D through 1I, sections between both lesions (1E and 1F, 1G and 1H represents bisected tissue portions); 1J through 1U, indurated area with overlying skin lesion (1J and 1K, 1L and 1M, 1N and 1O, 1P and 1Q, 1R and 1S, represents bisected tissue portions, respectively); 1V, cruciate lateral tip.  Please see diagram on the back of the requisition.          AC:lefb **DATE[Apr 28 2013].","MicroscopicDescription:
  Slides Reviewed.",1:  Wide excision of skin,,
REG2,BREAST,0,PAT-40146872,1,REC-100000927723,"ClinicalHistory:
  Left breast CA.
IntraoperativeDiagnosis:
Touch Prep Diagnosis:
TP1.  Sentinel lymph node 750CPS, left breast:  Negative for metastatic carcinoma on Touch Prep.  Report given to Dr. **NAME[ZZZ].  (ER)
TP2.  Sentinel lymph node level 1 400CPS, left breast:  Negative for metastatic carcinoma on Touch Prep.  Report given to Dr. **NAME[ZZZ].  (ER).",,"FinalDiagnosis:
1.  Lymph Node, Sentinel Lymph Node, Left, 750CPS:
Intraoperative Touch Preparation: Lymphoid Cells Present; No Tumor Cells Seen. 
Light Microscopic Examination: One Lymph Node Showing Reactive Changes with Sinus Histiocytosis; No Histologic Evidence of Micrometastatic Carcinoma Identified. 
Immunohistochemical Stain with Cytokeratin AE1 and AE3: No Immunohistochemical Evidence of Micrometastatic Disease.

2.  Lymph Node, Sentinel Lymph Node, Level 1, 400CPS:
Intraoperative Touch Preparation: Lymphoid Cells Present; No Tumor Cells Seen. 
Light Microscopic Examination: One Lymph Node Showing Reactive Changes with Sinus Histiocytosis; No Histologic Evidence of Micrometastatic Carcinoma Identified. 
Immunohistochemical Stain with Cytokeratin AE1 and AE3: No Immunohistochemical Evidence of Micrometastatic Disease.

3.  Breast, Left, Partial Mastectomy with Needle Localization Specimen:
Infiltrating Ductal Carcinoma, Nuclear Grade 2 of 3, Histologic Score 2 of 3; Maximum Tumor Dimension 15.0mm. 
Ductal Carcinoma In Situ, Nuclear Grade 2 of 3, Cribriform Type with Colonization of Lobules and Focal Comedoform Pattern Seen; 
Radiographic Clip Identified (See Surgical Pathology Case Number S12 16097). 
Extensive Proliferative Fibrocystic Changes with Extensive Sclerosing Adenosis. 
All the Surgical Margins are Clear. 


Please See Synoptic Report for Case Summary. 



INVASIVE CARCINOMA OF THE BREAST: SYNOPTIC REPORT



Procedure        : Excision with wire guided localization
Lymph Node Sampling     : Sentinel lymph nodes
Specimen Laterality      : Left
Tumor Site: Invasive Carcinoma  : Not specified

Histologic Type of Invasive Carcinoma: 
Invasive ductal carcinoma (no special type or not otherwise specified). 
Tumor Size: Size of Largest Invasive Carcinoma: 
Greatest dimension of largest focus of invasion >1 mm: 15 mm 
Additional dimensions: 12 x 10 mm
Histologic Grade: Nottingham Histologic Score:
Glandular (Acinar)/Tubular Differentiation
Score 2: 10% to 75% of tumor area forming glandular/tubular structures
Nuclear Pleomorphism
Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape
Mitotic Rate
Score 2 (4-7 mitoses per mm2)
Overall Grade
Grade 2: scores of 6 
Tumor Focality      : Single focus of invasive carcinoma
Ductal Carcinoma In Situ (DCIS)  : DCIS is present.
Positive for Extensive Intraductal Component (EIC).
Number of blocks with DCIS  : 3
Number of blocks examined  : 9

Architectural Patterns    : Comedo, cribriform
Nuclear Grade      : Grade II (intermediate)
Necrosis         : Focally present, central necrosis seen
Lobular Carcinoma In Situ (LCIS)  : Not identified
Margins        :
Invasive Carcinoma
Margins uninvolved by invasive carcinoma
Distance from closest margin: 3 mm
Specify margin: Anterior
DCIS
Margins uninvolved by DCIS 
Distance from closest margin: 3 mm
Specify margin: Anterior

Lymph Nodes
Number of sentinel lymph nodes examined: 2
Total number of lymph nodes examined (sentinel and nonsentinel): 2
Number of lymph nodes with macrometastases (>2 mm):  0
Number of lymph nodes with micrometastases (>0.2 mm to 2 mm and/or >200cells):0
\E\Number of lymph nodes with isolated tumor cells (?0.2 mm and ?200 cells): 0
Number of lymph nodes without tumor cells identified: 2
Size of largest metastatic deposit (if present): Not applicable
Method of Evaluation of Sentinel Lymph Nodes :
H\F\E, multiple levels
Immunohistochemistry (Cytokeratin AE1 and AE3)

Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy
In the Breast
No known presurgical therapy
In the Lymph Nodes
No known presurgical therapy
Lymph-Vascular Invasion
Not identified

Dermal Lymph-Vascular Invasion
No skin present

Pathologic Staging (based on information available to the pathologist) (pTNM)

Primary Tumor (Invasive Carcinoma) (pT) 
pT1c:  Tumor >10 mm but ?20 mm in greatest dimension

Regional Lymph Nodes (pN) 
Modifier (required only if applicable)
(sn):  Only sentinel node(s) evaluated.  
Category (pN)
pN0 (i-): No regional lymph node metastases histologically, negative IHC..

Distant Metastasis (pM) : Not applicable

Additional Pathologic Findings:

Ancillary Studies (Please see case report S12 16097)

Estrogen Receptor (ER) 
Results and interpretation:
Positive (essentially 100 % of tumor cells with nuclear positivity)
Average intensity of tumor cell nuclei staining: strong

Progesterone Receptor (PgR) 
Results and interpretation:
Positive (essentially 100 % of tumor cells with nuclear positivity)
Average intensity of tumor cell nuclei staining: strong

HER2 (results for invasive carcinoma performed on this specimen or a prior core needle biopsy or incisional biopsy) 

Immunoperoxidase Studies
Results:
Negative (Score 0 to 1+)

Microcalcifications    : Present in both carcinoma and nonneoplastic tissue

Note: This case is reviewed at the departmental surgical pathology conference on **DATE[Nov 6 2012] and a consensus diagnosis is rendered. 

CPT Code: 3260-F.",,"GrossDescription:
  Container 1:  Received fresh labeled sentinel lymph node left 750CPS is a 1.0 x 0.8 x 0.8cm tan to pink lymph node with minimal adherent adipose tissue.  The cut surface is pink and smooth, focally replaced by adipose tissue.  No blue dye is identified.  Touch Preps are performed.  (See Touch Prep Diagnosis #1).  The lymph node is bisected and entirely submitted as 1A.

  Container 2:  Received fresh labeled sentinel lymph node level 1 400CPS is a 1.0 x 1.0 x 0.6cm pink lymph node with a minimal amount of adherent yellow adipose tissue.  The cut surface is pink to red and smooth.  Touch Preps are performed.  (See Touch Prep Diagnosis #2).  The lymph node is trisected and entirely submitted as 2A.

  Container 3:  Received fresh labeled cancer left breast needle local is a fibrofatty portion of breast tissue oriented by marker clips measuring 5.5cm from cranial to caudal, 5.5cm from medial to lateral and 2.8cm from anterior to posterior.  There is a needle localization wire extending out of the anterior aspect of the specimen.  The specimen radiograph localizes a soft tissue density without associated microcalcifications and an adjacent mammotome clip.  The margins are marked with silver nitrate prior to sectioning and additionally inked as follows:  cranial blue, caudal green, lateral yellow, anterior orange, posterior black.  Sectioning reveals a 1.5 x 1.2 x 1.0cm white, firm, gritty mass, corresponding to the soft tissue density localized on the radiograph.  The mass is identified 0.3cm from the nearest margin (anterior), 0.6cm from the cranial margin, 1.5cm from the caudal margin and greater than 1.8cm from the remaining margins.  There is a mammotome clip embedded within the mass, consistent with a previous site of biopsy.  The remaining breast parenchyma consists of a moderate amount of dense, white, cystic, fibrous tissue, admixed with yellow, lobular, glistening, adipose tissue.  The fibrous tissue represents approximately 80% of the parenchyma.  The identified cysts measure up to 0.2cm in diameter and contains light brown fluid.  No additional lesions are identified.  The breast tissue is reradiographed and representative sequential sections are submitted from lateral to medial as follows:  3A, lateral margin; 3B through 3E, entire mass to include the anterior margin (mammotome clip localized in cassette 3D); 3F, posterior margin; 3G, cranial margin; 3H, caudal margin; 3I, medial margin.  All margins are represented.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
CH:lefb **DATE[Nov 4 2012].","MicroscopicDescription:
  Slides reviewed.",1: Left sentinal lymph node(s)2: Left sentinal lymph node(s)3: NL- Left breast biopsy requiring evaluation of surgical  margins,,
REG2,BREAST,0,PAT-40160196,1,REC-100000927747,"ClinicalHistory:
  Left breast mass; LIQ 6 to 7 o?clock; Abnormal lymph node left axilla.",,"FinalDiagnosis:
1.  Breast, Left, Ultrasound Guided Core Biopsy:  Invasive Ductal Carcinoma, Nuclear Grade 2 to 3 over 3, Poorly Differentiated.

2.  Soft Tissue, Left Axilla, Ultrasound Guided Core Biopsy:  Fibroadipose Tissue with 
  Invasive Ductal Carcinoma, Nuclear Grade 2 to 3 over 3, Poorly Differentiated.",,"GrossDescription:
  Container 1:  Received in formalin labeled left breast biopsy LIQ 6 to 7 o?clock are two tan, yellow, , fibrofatty tissues, which measure 0.6 x 0.2cm and 0.9 x 0.2cm.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin labeled left breast axilla biopsy is a tan, yellow, cylindrical, fibrofatty tissue, which measures 1.5 x 0.2cm.  The specimen is submitted in toto as 2A.
Fixation of the specimen is reviewed and assured to be between 6 and 48 hours.
MD:lefb **DATE[Apr 18 2013].","MicroscopicDescription:
  The specimen from the left breast consists of fibroadipose tissue with a malignant neoplasm with features of invasive ductal carcinoma.  The tumor is of nuclear grade 2 to 3 over 3 and is poorly differentiated (BR score of 8).  Benign mammary epithelial elements are not seen.  No in situ ductal carcinoma component is seen. 

  The specimen from the left axilla consists of fibroadipose tissue with a invasive ductal carcinoma with similar features with the specimen from the left breast.  Foci of necrosis are seen.  Lymph node parenchyma is not included.",1: Left breast core biopsy2: Left lymph node core biopsy,,"AddendumComment:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin fixed paraffin embedded tissue (Blocks 1A and 2A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is positive in 100% of the tumor cells in both blocks, showing 3+ staining intensity.  The Progesterone Receptor (DAKO Clone PgR 636) is positive in 40% of the tumor cells in block 1A and in 80% of tumor cells in block 2A, showing 3+ staining intensity.  The Herceptest (DAKO) is negative with 1+ staining in both blocks, after evaluation of membrane staining intensity and pattern on the standardized  0 to 3+ scale.

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE:   ASCO/CAP scoring criteria for HER2 protein over expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3).  Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1).  Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.  

PQRS CODE: 3394F"
REG2,BREAST,0,PAT-06908632,2,REC-100000927999,"ClinicalHistory:
  Right breast mass.",,"FinalDiagnosis:
  Breast, Right, Ultrasound Guided Core Biopsy at Retroareolar Position:
    Fragments of Blood Clot,  Portion of Adipose Tissue and Portion of Breast Tissue       Showing Focus of Crushed Markedly Atypical Cells, High Suspicious for
      Carcinoma.
    See Comment.

Comment:
  The specimen consists largely of fresh blood clot.  A small portion of adipose tissue is seen.  A portion of breast parenchyma is sampled which shows a focus of markedly atypical epithelial cells with extensive crush artifact.  The specimen is not diagnostic but is highly suspicious for carcinoma.
Immediate follow up is recommended.  

  This case is reviewed at the Departmental Surgical Pathology Conference and a consensus diagnosis is rendered on **DATE[May 1 2013].  The case is discussed with the attending radiologist, Dr. **NAME[ZZZ YYY].",,"GrossDescription:
  Received in formalin labeled ultrasound guided right breast core biopsy at retroareolar are two cylindrical portions of tan to yellow, soft tissue, displaying a moderate amount of adherent dark red clotted blood.  The tissue portions average 0.7 x 0.2cm.  

Also received in the same container is a 0.6 x 0.6 x 0.3cm aggregate of dark red clotted blood.  The specimen is submitted in toto as 1A.

Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Apr 31 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy,,
REG2,BREAST,0,PAT-40060345,2,REC-100000928011,"ClinicalHistory:
Breast cancer.","CytologyReview:
 Atypical cells seen.

 Atypical cells seen.","FinalDiagnosis:
 Rare malignant cells present, consistent with metastatic poorly differentiated mammary carcinoma and previous history.",,"GrossDescription:

Received  10  cc clear   fluid for ThinPrep.",,A: Cerebrospinal Fluid,,
REG2,BREAST,0,PAT-40060345,2,REC-100000928023,"ClinicalHistory:
Metastatic breast cancer.","CytologyReview:
 Atypical cells seen.

 Atypical cells seen.","FinalDiagnosis:
Rare Atypical cells seen showing degenerative changes, consistent with poorly differentiated carcinoma, in a patient with a history of metastatic mammary carcinoma.

NOTE: Note is made of the provided clinical information and the patient?s previous specimens (N12 2299, N12 2236, N12 2208, and N12 2168). The previous specimens were reviewed for morphologic comparison. 

This case was reviewed at the daily intradepartmental conference for consensus diagnosis on **DATE[Nov 1 2012].",,"GrossDescription:
Received:  4cc clear fluid for ThinPrep.",,A: Cerebrospinal Fluid,,
REG2,BREAST,0,PAT-40152322,1,REC-100000928059,"ClinicalHistory:
History of Breast cancer, same side.","CytologyReview:
  No Evidence of Malignancy.
Reactive mesothelial cells noted.

  No Evidence of Malignancy.
Reactive mesothelial cells noted.","FinalDiagnosis:
  No Evidence of Malignancy.
Reactive mesothelial cells noted.",,"GrossDescription:

Received:  800cc bloody fluid for ThinPrep and Cell Block.",,A: Left Pleural Fluid,,
REG2,BREAST,0,PAT-40145770,1,REC-100000928112,"ClinicalHistory:
  Left breast mass.",,"FinalDiagnosis:
Breast, Left, Left Simple Mastectomy:
Ductal Carcinoma In Situ (DCIS), Solid, Cribriform, and Apocrine Types with Focal Comedo Necrosis and Associated Microcalcifications.
No Invasive Carcinoma Identified.
DCIS Present in 7 of 20 Blocks; The Largest Focus 2.3cm.
Two Biopsy Sites Associated with Clips Noted.
Background of Usual Type Ductal Epithelial Hyperplasia, Columnar Cell Change, Intraductal Papilloma, and Fibroadenomatoid Change.
Please See CAP Synoptic Report.

DCIS OF THE BREAST:  Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy; With or Without Axillary Contents) and Mastectomy (Total, Modified Radical, Radical; With or Without Axillary Contents)


Specimen      :Total breast (including nipple and skin)
Procedure       :Total mastectomy (including nipple and skin)
Lymph Node Sampling  :No lymph nodes present
Specimen Integrity    :Single intact specimen (margins can be evaluated)
Specimen Laterality    :Left
Tumor Site      :Upper outer quadrant
        :Lower outer quadrant
Size (Extent) of DCIS    :
Estimated size (extent) of DCIS (greatest dimension using gross and 
Microscopic evaluation)  :At least: 2.3cm 
Number of blocks with DCIS  :7
Number of blocks e3xamined  :20
Histologic Type     :Ductal carcinoma in situ; classified as Tis (DCIS) or Tis (Paget)
Architectural Patterns    :Cribriform; solid, apocrine
Nuclear Grade      :Grade III (high)(
Necrosis      :Present, central (expansive ""comedo"" necrosis)
Margins       :Margin(s) uninvolved by DCIS
Distance from closest margin :? 10mm
Treatment Effect: Response to Presurgical 
(Neoadjuvant) Therapy  :No known  presurgical therapy
Pathologic Staging (pTNM) 
Primary Tumor (pT)     :pTis (DCIS): Ductal carcinoma in situ
Regional Lymph Nodes (pN)  :pNX: Regional lymph nodes cannot be assessed 
Distant Metastasis (M)    :Not applicable
Ancillary Studies    :
Estrogen Receptor     :Immunoreactive tumor cells present, weak staining in
        :5 to 10% of cells
Progesterone Receptor   :no immunoreactive tumor cells present
Microcalcifications    :Present in both DCIS and non neoplastic tissue.",,"GrossDescription:
  Received in formalin labeled left breast mass is a 770 gram, 16.0 x 16.0 x 5.5cm simple mastectomy specimen, which is partially surfaced by a 13.5 x 3.2cm elliptical portion of white skin.  The skin displays a 1.3cm in diameter everted nipple surrounded by a 3.0cm in diameter subtle area with complex.  The specimen is inked blue along the posterior aspect and black along the anterior aspect.  The specimen is sectioned to reveal a bowtie clip centrally located within a 1.0 x 0.5 x 0.5 x 0.5cm tan, finely granular, rubbery to indurated lesion with surrounding, rubbery to indurated, nodular fibrous tissue.  The lesion and surrounding fibrous tissue is located between two and 3 o'clock and comes to within 2.0cm of the posterior margin and 3.3cm of the overlying skin.  There is a second cylindrical, metallic clip located 7.0cm inferomedial to the aforementioned bowtie clip at 4 o'clock.  Surrounding the clip, the cut surfaces are tan to red, focally congested and focally nodular.  There is no definitively identified lesion.  The clip comes to within 1.5cm of the anterior margin and 6.0cm of the posterior margin.  The remaining cut surfaces are composed of 40% tan, rubbery to nodular fibrous tissue and 60% yellow, lobulated adipose tissue.  Representative tissue is submitted as follows:  1A, posterior margin closest to site of bowtie clip; 1B and 1C, site of bowtie clip and surrounding tissue; 1D, skin closest to bowtie clip; 1E, random section of both clips; 1F, posterior margin closest to cylindrical clip; 1G, site of cylindrical clip and closest anterior margin; 1H, fibrous tissue surrounding cylindrical clip; 1I and 1J, random sections of upper outer quadrant (3 to 12 o'clock) to include area corresponding to radiographic density; 1K and 1L, random sections from upper inner quadrant (9 to 12 o'clock); 1M and 1N, lower inner quadrant from 6 to 9 o'clock; 1O and 1P, lower outer quadrant from 3 to 6 o'clock; 1Q through 1S, nipple, submitted in its entirety; 1T, uninvolved skin.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Jun 26 2013].","MicroscopicDescription:
  Slides Reviewed.",1: Left simple or total mastectomy,,
REG2,BREAST,0,PAT-40107473,1,REC-100000928126,"ClinicalHistory:
  Abdominal pain.",,"FinalDiagnosis:
  Small Bowel:
    Full Thickness Involvement of Largest Segment of Small Bowel by Metastatic
      Carcinoma Consistent with Patient?s Known Breast Primary (See Gross
      Description).
    Tumor Extensively Present in Lymphatic Spaces.
    Resection Margins Negative for Metastatic Carcinoma.

Comment;
  The tumor cells are positive for pan Keratin, CK7, ER, and focally for Mammoglobin.  They are negative for PR, GCDFP15, CK20, and CDX2.  The findings are supportive of the diagnosis. 

  This case was reviewed at the Daily Departmental Conference.",,"GrossDescription:
  Received in formalin labeled ""small bowel"" is a 5.2cm in length x 6.7cm in circumference segment of small bowel. The stapled surgical margins are removed and differentially inked black and blue and the radial margin is inked green. The serosal surface is tan to pink and smooth and is marked with silver nitrate. Opening of the lumen reveals a 3.0 x 1.0cm indurated tan to brown tumor with two depressed areas. The tumor measures 1.3cm from the margin inked blue and 1.4cm from the margin inked black, measures 0.5cm in thickness and grossly appears to invade the serosal wall. The remaining mucosa is tan and displays unremarkable mucosal folds. Sectioning of the attached adipose tissue reveals a yellow, lobulated cut surface. Also received is a 2.9cm in length x 7.9cm in circumference portion of small bowel. The stapled surgical margins are differentially inked black and blue. The serosal surface is tan to pink and smooth and there is a moderate amount of attached yellow, lobulated adipose tissue. The mucosal surface is tan and displays unremarkable mucosal folds with a wall thickness averaging 0.1cm. Sectioning of the attached adipose tissue reveals a yellow lobulated cut surface. Also received is a 5.0 x 1.0 x 0.5cm portion of small bowel. The serosal surface is tan and smooth, the mucosa is tan and displays unremarkable mucosal folds. Representative sections are submitted as follows: 1A, largest bowel segment inked surgical margins; 1B thru 1F, largest bowel segment tumor entirely submitted; 1G, en face radial margin; 1H and 1I, adipose tissue; 1J, middle sized bowel segment inked margins; 1K, middle sized bowel segment representative mucosa; 1L and 1M, middle sized bowel segment adipose tissue; 1N, smallest sized bowel segment representative sections. 
GH:fmg **DATE[Aug 16 2012].","MicroscopicDescription:
  Slides Reviewed.",1: Small bowel resection other than for tumor,,"Interpretation:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
      
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin-fixed paraffin embedded tissue (Block B) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin-free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 

The Estrogen Receptor (VECTOR-CLONE 6F11) is positive in 20 to 30% of the tumor cells showing 1 to 2+ staining intensity. The Progesterone Receptor (DAKO-Clone PgR 636) is negative in 100% of the tumor cells. The Herceptest (DAKO) shows 0 to 2+ indeterminate staining, after evaluation of membrane staining intensity and pattern on the standardized  0-3+ scale. FISH for Her2Neu will be performed. See comment. 

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO/CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO/CAP scoring criteria for HER2 protein over-expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.

COMMENT: The staining pattern of the tumor cells; both for ER and Hercept is heterogeneous, with some areas totally negative and other areas showing distinct staining."
REG2,BREAST,0,PAT-40107473,1,REC-100000928808,"ClinicalHistory:
  Abdominal pain.",,"FinalDiagnosis:
  Small Bowel:
    Full Thickness Involvement of Largest Segment of Small Bowel by Metastatic
      Carcinoma Consistent with Patient?s Known Breast Primary (See Gross
      Description).
    Tumor Extensively Present in Lymphatic Spaces.
    Resection Margins Negative for Metastatic Carcinoma.

Comment;
  The tumor cells are positive for pan Keratin, CK7, ER, and focally for Mammoglobin.  They are negative for PR, GCDFP15, CK20, and CDX2.  The findings are supportive of the diagnosis. 

  This case was reviewed at the Daily Departmental Conference.",,"GrossDescription:
  Received in formalin labeled ""small bowel"" is a 5.2cm in length x 6.7cm in circumference segment of small bowel. The stapled surgical margins are removed and differentially inked black and blue and the radial margin is inked green. The serosal surface is tan to pink and smooth and is marked with silver nitrate. Opening of the lumen reveals a 3.0 x 1.0cm indurated tan to brown tumor with two depressed areas. The tumor measures 1.3cm from the margin inked blue and 1.4cm from the margin inked black, measures 0.5cm in thickness and grossly appears to invade the serosal wall. The remaining mucosa is tan and displays unremarkable mucosal folds. Sectioning of the attached adipose tissue reveals a yellow, lobulated cut surface. Also received is a 2.9cm in length x 7.9cm in circumference portion of small bowel. The stapled surgical margins are differentially inked black and blue. The serosal surface is tan to pink and smooth and there is a moderate amount of attached yellow, lobulated adipose tissue. The mucosal surface is tan and displays unremarkable mucosal folds with a wall thickness averaging 0.1cm. Sectioning of the attached adipose tissue reveals a yellow lobulated cut surface. Also received is a 5.0 x 1.0 x 0.5cm portion of small bowel. The serosal surface is tan and smooth, the mucosa is tan and displays unremarkable mucosal folds. Representative sections are submitted as follows: 1A, largest bowel segment inked surgical margins; 1B thru 1F, largest bowel segment tumor entirely submitted; 1G, en face radial margin; 1H and 1I, adipose tissue; 1J, middle sized bowel segment inked margins; 1K, middle sized bowel segment representative mucosa; 1L and 1M, middle sized bowel segment adipose tissue; 1N, smallest sized bowel segment representative sections. 
GH:fmg **DATE[Jul 16 2013].","MicroscopicDescription:
  Slides Reviewed.",1: Small bowel resection other than for tumor,,
REG2,BREAST,0,PAT-40121755,3,REC-100000928964,"ClinicalHistory:
  Breast cancer.",,"FinalDiagnosis:
1.  Breast, Right, Additional Resection Superior to Previous Anterior Margin:
Predominantly Fatty Breast Parenchyma Showing Fibrosis with Fat Necrosis and Lymphohistiocytic Inflammation Consistent with Previous Excision Procedure.
All Inked Visualized Surgical Margins of Excision Negative for Malignancy.

2.  Breast, Right, Additional Anterior Margin (Inferior to Previous Excision):
Partially Fatty Breast Parenchyma Showing Fibrocystic Alterations and Areas of Fibroadenomatous Change with Fibrosis, Fat Necrosis and Lymphohistiocytic Inflammation Consistent with Previous Excision Procedure.
No Diagnostic Histologic Evidence of Malignancy.
Surgical Margins of Excision Negative for Malignancy.

3.  Breast, Left, Additional Resectional for Inferior Margin:
Predominantly Fatty Breast Parenchyma Showing Fibrosis with Fat Necrosis and Lymphohistiocytic Inflammation Consistent with Previous Excision Procedure.
All Inked Visualized Surgical Margins of Excision Negative for Malignancy.

Comment: The additional right (specimens #1 and #2) and left (specimen #3) breast resections for margins show features consistent with previous excision procedure including fat necrosis, healing fibrosis and lymphohistiocytic inflammation with suture granulomas. Background fibrocystic changes are noted with fibroadenomatous change in specimen #2. There is no diagnostic histologic evidence of significant residual, in situ or invasive carcinoma. Comparison is made with the previous sample (S11 11815) and this case is reviewed for consensus diagnosis through Intradepartmental Consultation on **DATE[Aug 3 2012].",,"GrossDescription:
  Container 1:  Received in formalin labeled right breast tissue anterior margin superior to incision is a 5.0 x 2.5 x 2.0cm irregular portion of tan to yellow, fibrofatty breast tissue, which is marked with an undesignated suture.  The specimen is marked with silver nitrate and the sutured surface is overinked blue.  The specimen is serially sectioned to reveal focally congested to hemorrhagic cut surfaces with focal chalky areas.  The remaining cut surfaces are yellow and lobulated with scant, fine fibrous tissue.  There are no noted lesions.  The specimen is submitted in its entirety sequentially as 1A through 1H.

  Container 2:  Received in formalin labeled right breast tissue anterior margin inferior to incision is a 6.3 x 3.0 x 2.3cm irregular portion of yellow, lobulated adipose tissue.  The specimen is marked with an undesignated suture.  The specimen is marked with silver nitrate and the sutured surface is overinked blue.  The specimen is serially sectioned to reveal cut surfaces composed of less than 10% tan, fine to rubbery, fibrous tissue, focally chalky cut surfaces and greater than 90% yellow, lobulated adipose tissue.  There are no definitively identified lesions.  The specimen is submitted in its entirety sequentially as 2A through 2N (2D, 2E, 2F, 2F, 2H, 2I represents contiguous sections respectively).

  Container 3:  Received in formalin labeled left breast inferior margin is a 3.5 x 2.5 x 2.0cm irregular portion of tan to yellow, fibrofatty tissue, which is marked with an undesignated black suture.  The specimen is marked with silver nitrate and the sutured surface is overinked blue.  The specimen is serially sectioned to reveal yellow, focally chalky and lobulated cut surfaces with no definitively identified lesions or fibrous tissue.  The specimen is submitted in its entirety sequentially as 3A through 3H.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Aug 2 2012].","MicroscopicDescription:
  Slides Reviewed.",1: Right breast biopsy requiring evaluation of surgical  margins2: Right breast biopsy requiring evaluation of surgical  margins3: Left breast biopsy requiring evaluation of surgical  margins,,
REG2,BREAST,0,PAT-40145524,1,REC-100000929068,"ClinicalHistory:
  Right breast mass.",,"FinalDiagnosis:
Right Breast, Ultrasound Guided Needle Core Biopsy at 3 to 4 O'Clock:
Infiltrating Mammary Ductal Carcinoma, Poorly Differentiated, Histologic Grade 3 out of 3, Nuclear Grade 3 out of 3.
See Note. 

NOTE: 
  The ultrasound guided biopsy of right breast at 3 to 4 o'clock shows several cores of tissue extensively involved by infiltrating mammary ductal carcinoma with poorly differentiated features, histologic grade 3 (score of 3+3+3), nuclear grade 3 out of 3.  No ductal carcinoma in situ component is identified and no nonneoplastic breast tissue is seen.  Small zones of fibroadipose stroma are present.  Focal areas are suggestive, but not definitively diagnostic, of lymphovascular invasion.  Invasive carcinoma demonstrates focal necrosis.  The tissue cores with tumor range in size from 0.4 to 0.6cm.  

  This case was reviewed intradepartmentally with Dr. **NAME[M. ZZZ] and also reviewed at the Pathology Departmental Conference.  Dr. **NAME[M. YYY] was notified of these findings on **DATE[Mar 6 2013] at 8:55 AM.

  Estrogen receptor, progesterone receptor, and Herceptest will be performed on the tissue block (1A) and the results will be reported in an addendum.",,"GrossDescription:
  Received in formalin labeled ultrasound guided right breast core biopsy at 3 to 4 o'clock are four cylindrical portions of tan to pink to yellow, soft and delicate tissue ranging from 0.6 x 0.2cm to 1.3 x 0.2cm.  The specimen is submitted in toto as 1A.

  Fixation of specimen reviewed and assured to be 6 to 48 hours.
AC:lefb **DATE[Mar 5 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy,,"Interpretation:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
      
Estrogen and Progesterone Receptor analysis and the HercepTest (DAKO) for HER2 protein overexpression are performed on formalin fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 

The Estrogen Receptor (VECTOR CLONE 6F11) is positive in 25% of the tumor cells showing weak to
moderate (1+ to 2+) staining intensity. The Progesterone Receptor (DAKO Clone PgR 636) is negative
(very weak staining in less than 1% of the tumor cells). The HercepTest (DAKO) shows equivocal 1+ to
2+ staining.  Her2neu by fluorescence in situ hybridization will be performed on the tissue block and
reported in another addendum. 

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO CAP scoring criteria for HER2 protein over expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells."
REG2,BREAST,0,PAT-40145604,1,REC-100000929097,"ClinicalHistory:
  Invasive ductal carcinoma left breast; Submucosal myoma.
IntraoperativeDiagnosis:
Touch Prep Diagnosis:
  TP1.  Sentinel lymph node, left:  Negative on Touch Prep; diagnosis given to Dr. **NAME[ZZZ].  (ASJ)
TP2.  Sentinel lymph node, left, hot and blue:  Negative on Touch Prep; diagnosis given to Dr. **NAME[ZZZ].  (ASJ).",,"FinalDiagnosis:
1.  Lymph Nodes, Two Sentinel, Biopsy:
Two (2) Lymph Nodes (One (1) Blue) Negative for Metastatic Carcinoma on Touch Prep, H and E, and Immunohistochemistry (Blocks 1A and 1B and 1C).

2.  Lymph Nodes, Two Sentinel, Hot and Blue, Biopsy:
Lymph Node, Negative on Touch Prep, H and E and Immunohistochemistry (Block 2A). 

3.  Leiomyoma, Prolapse Myoma Uterus, Biopsy:
Benign Leiomyoma with Overlying Benign Endometrium with Compression Atrophy and Acute and Chronic Inflammation. 

4.  Endometrium, Polyp, Biopsy:
Fragments of Smooth Muscle Consistent with Leiomyoma and Scant Fragments of Benign Endometrium with Compression Atrophy. 

5.  Breast, Left, Mastectomy:
DCIS, Cribriform and Micropapillary Types, Low Grade with Microcalcifications Associated with Biopsy Site x 2 (Blocks 5I and 5R)
Additional Foci of DCIS in Areas Between Biopsy Sites (Blocks 5S thru 5U). 
Three Biopsy Sites Not Associated with DCIS (Blocks 5C, 5V, and 5Y). 
DCIS Present in 5 of 31 Blocks; The Largest Area Measures Approximately 0.9 cm.
DCIS Present Approximately 3 mm from Deep (Posterior) Margin (Block 5Z); Other Margins Widely Negative. 
Lobular Carcinoma In Situ (LCIS) Present. 
Background of Epithelial Hyperplasia, Flat Epithelial Atypia, Blunt Duct Adenosis, Apocrine Metaplasia, Columnar Cell Change, Duct Ectasia, and Fibrosis. 
Calcifications Also Seen Associated with Benign Ducts and Fat Necrosis. 
Negative Skin Including Nipple. 
No Evidence of Invasive Carcinoma. 
Please See CAP Synoptic Report.

6.  Breast, Inframammary Ridge Tissue, Biopsy:
Benign Connective Tissue. 

COMMENT: 
  This case is reviewed at the Daily Departmental Conference. Five biopsy sites are identified. Receptor studies pending and results will follow as an addendum.


DCIS OF THE BREAST:  Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy; With or Without Axillary Contents) and Mastectomy (Total, Modified Radical, Radical; With or Without Axillary Contents)


Specimen      : Total breast (including nipple and skin)
Lymph Node Sampling  : Sentinel lymph node(s)
Specimen Laterality    : Left
Size (Extent) of DCIS  
Estimated size (extent) of DCIS (greatest dimension using gross and microscopic evaluation): at least 0.9cm (block 5S). 
Number of blocks with DCIS: 5
Number of blocks examined: 31
Histologic Type     : Ductal carcinoma in situ
Architectural Patterns  : Cribriform, micropapillary
Nuclear Grade    : Grade I (low)
Necrosis      : Not identified
Margins       : Margin(s) uninvolved by DCIS
          Distance from closest margin 3.0mm
          Distance from deep (posterior) margin 3.0mm
Method of Evaluation of Sentinel Lymph Nodes: H\F\E, multiple levels, immunohistochemistry
Pathologic Staging (pTNM) 

Primary Tumor (pT)     : pTis (DCIS) Ductal carcinoma in situ
Regional Lymph Nodes (pN): pN0 (i-): No regional lymph node metastases histologically, negative IHC
Distant Metastasis (M)    : Not applicable.",,"GrossDescription:
  Container 1:  Received fresh labeled two sentinel lymph nodes is a 2.5 x 1.5 x 1.2cm portion of yellow adipose tissue, within which a 1.0cm in greatest dimension blue lymph node is identified and a 0.5cm in greatest dimension tan, lymph node is identified.  The cut surfaces of both of the lymph nodes are tan with focal blue dye and smooth.  Touch Preps are performed.  (See Touch Prep Diagnosis #1).  The nodal tissue is entirely submitted as follows:  1A and 1B, larger lymph node; 1C, smaller lymph node.

  Container 2:  Received fresh labeled two sentinel lymph node hot and blue is a 0.8 x 0.8 x 0.7cm tan, blue lymph node.  The cut surface is tan, smooth with focal blue dye.  Touch Preps are performed.  (See Touch Prep Diagnosis #2).  The lymph node is serially sectioned and entirely submitted as2A.
CH:lefb **DATE[Mar 23 2013]

  Container 3:  Received in formalin labeled prolapsed myoma is a 56 gram, 5.5 x 4.5 x 3.5cm white to pink, rubbery nodule, which is sectioned to reveal white to pink, whorled cut surfaces with no noted areas of hemorrhage or necrosis.  Representative tissue is submitted as 3A through 3D.

  Container 4:  Received in formalin labeled polyp is a 3.0 x 3.0 x 0.8cm aggregate of tan to pink, rubbery tissue and dark red clotted blood.  The specimen is submitted in toto as 4A through 4C. 

Container 5:  Received in formalin labeled left breast silk suture on axillary tail is a 738 gram, 14.0 x 13.5 x 6.0cm simple mastectomy, which is marked with a silk suture on the axillary tail.  Please note, a true axillary tail is not identified.  The specimen is partially surfaced by a 13.5 x 5.0cm irregular portion of white skin.  The everted to flattened nipple measures 1.5cm in diameter and is surrounded by a 4.0cm in diameter areolar complex.  There are no noted skin lesions.  The posterior aspect is inked blue and sectioned to reveal cut surfaces composed of 50% tan, rubbery and focally nodular, fibrocystic tissue with a metallic clip identified at approximately 8 o'clock (Lower inner quadrant).  There is no definitively identified lesion surrounding the clip.  The remaining specimen is reradiographed to reveal four additional clips located within the upper inner quadrant and between the lower and upper outer quadrants. There are no definitively identified lesions surrounding the additionally identified clips. However, there is a radiographic area of density associated with the most laterally identified clip. The remaining 50% of the cut surfaces are composed of yellow, lobulated adipose tissue.

Also received in the same container are two irregular portions of white skin, ranging from 3.5 x 1.0 x 1.0cm to 5.5 x 2.0 x 1.0cm.  On sectioning, there are no noted lesions.  Representative tissue is submitted as follows:  5A, additionally received skin; 5B, posterior margin closest to site of clip; 5C, site of clip; 5D and 5E, fibrous tissue immediately surrounding clip; 5F, anterior margin closest to site of clip (inked black); 5G and 5H, upper outer quadrant; 5I and 5J, upper inner quadrant (5I to include clip); 5K and 5L, lower inner quadrant; 5M through 5O, lower outer quadrant; 5P and 5Q, nipple submitted in its entirety and uninvolved skin, 5R, most laterally identified clip located within lower outer quadrant; 5S and 5T, area of radiographic density adjacent to most laterally identified clip; 5U random section between most lateral clip and second lateral clip; 5V and 5W, site of second lateral clip located between lower and upper outer quadrants (5V to include site of clip); 5X, random section between second lateral clip and third lateral clip; 5Y, site of third lateral clip located between lower and upper outer quadrants; 5Z, anterior and posterior margins closest to most lateral clip; 5AA, anterior and posterior margins closest to second lateral clip; 5AB, anterior and posterior margins closest to third lateral clip. Please see radiographic images.

Container 6: Received in formalin labeled inframammary ridge tissue is a 3.0 x 2.5 x 1.0cm aggregate of tan to yellow, fibrofatty tissue.  The tissue portions are sectioned to reveal cut surfaces composed of less than 5% tan, fine to rubbery, fibrous tissue and greater than 95% yellow, lobulated adipose tissue.  There are no definitively identified lesions.  The specimen is submitted in its entirety as 6A through 6C.

Fixation of specimen reviewed and assured to be 6 to 48 hours.
AC:lefb **DATE[Mar 23 2013].","MicroscopicDescription:
  Slides reviewed.","1: sentinal lymph node(s)2: sentinal lymph node(s)3: Leiomyoma / myoma / uterine myomectomy/fibroids4: Endometrial Biopsy5: Left modified radical mastectomy with lymph nodes6: Portion of fat for inflamation,necrosis or other",,"AddendumComment:
ER/PR (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis are performed on formalin fixed paraffin embedded tissue (Block 5S) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is positive in 90% of the tumor cells showing 3+ staining intensity.  The Progesterone Receptor (DAKO Clone PgR 636) is positive in 90% of the tumor cells showing 2 to 3+ staining intensity.

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong."
REG2,BREAST,0,PAT-40116430,2,REC-100000929159,"ClinicalHistory:
  Right breast carcinoma.
IntraoperativeDiagnosis:
Touch Prep Diagnosis:
TP1.  Right sentinel node, blue and hot:  No definitive malignant cells seen.  Report given to Dr. **NAME[ZZZ].  (AB).",,"FinalDiagnosis:
1.  Right Axilla, Sentinel Node, Blue and Hot, Biopsy:
Touch Preparation Smear: No Malignant Cells Seen. 
H and E Sections: One (1) Lymph Node with Sinus Histiocytosis and Sinusoidal Pigment; No Evidence of Metastatic Carcinoma. 
Cytokeratin Immunohistochemical Stain: No Evidence of Metastatic Carcinoma.

2.  Right Breast, Excision with Needle Wire Localization:
Previous Biopsy Site Present, with Gross Metallic Clip, Characterized by Organizing Hemorrhage, Fat Necrosis, Abundant Hemosiderin Pigment, Inflammatory Reaction, Fibrosis and Histiocytic Infiltrate. 
No Residual Carcinoma Identified. 
Breast Tissue with Stromal Fibrosis and Focal Fibrocystic Change with Apocrine Cysts and Focal Sclerosing Adenosis. 
Surgical Resection Margins Negative. 

NOTE: 
  No residual carcinoma is identified in the right breast excision, specimen #2, which shows the previous biopsy site with a gross metallic clip.  The previous biopsy site demonstrates organizing hemorrhage, fat necrosis, abundant hemosiderin pigment, fibrosis, inflammatory reaction and histiocytic infiltrates.  No residual carcinoma is identified.  The surgical resection margins are negative.  The breast tissue demonstrates stromal fibrosis with focal fibrocystic change, occasional apocrine cysts and focal sclerosing adenosis.  

  Specimen #1, representing the sentinel lymph node, shows sinus histiocytosis and abundant sinusoidal pigment.  No metastatic carcinoma is identified with cytokeratin AE1 AE3 immunohistochemical stain.  No clip is grossly identified.  Please see gross description.  

  The clinical history of preoperative neoadjuvant chemotherapy is noted.  

  Please see previous right breast needle core biopsy at 10 o'clock, showing infiltrating ductal carcinoma, poorly differentiated, with focal necrosis, specimen #1 and metastatic carcinoma involving one (1) lymph node in specimen #2, with negative estrogen receptor, negative progesterone receptor, equivocal Herceptest and negative (non amplified) Her2neu by FISH.  The previous biopsy, S11 22091, specimens #1 and #2, are reviewed and confirmed. 

Comment:
  The sentinel lymph node in specimen #1 does not show a definite previous biopsy site.    

  This case was discussed with Dr. **NAME[M. ZZZ] on **DATE[May 6 2013] at 5:10 PM. 



SYNOPTIC REPORT:
INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy With or Without Axillary Contents) and Mastectomy (Total, Modified Radical, Radical With or Without Axillary Contents)

Specimen  :  Partial breast
Procedure   :  Excision with wire guided localization
Lymph Node Sampling   :  Sentinel lymph node only (1)
Specimen Integrity   :  Single intact specimen (margins can be evaluated) 
Specimen Size  :  Greatest dimension: 13cm 
      Additional dimensions: 10 x 4 cm
Specimen Laterality  :  Right
Tumor Site:  Invasive Carcinoma  :  Position: 10 o'clock, based on the needle core biopsy, S11 22091
Tumor Size: 
  Size of Largest Invasive Carcinoma  :  No residual carcinoma after presurgical (neoadjuvant) therapy
Macroscopic and Microscopic Extent of Tumor
  Skin  :  Skin is not present
  Skeletal Muscle  :  No skeletal muscle present

Ductal Carcinoma In Situ (DCIS)  :  No DCIS is present

Lobular Carcinoma In Situ (LCIS)  :  Not identified  

Histologic Type of Invasive Carcinoma  :  No residual invasive carcinoma after presurgical (neoadjuvant) therapy 

Margins  :  Margins uninvolved by carcinoma (no residual carcinoma)

Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy
  In the Breast  :  No residual invasive carcinoma is present in the breast after presurgical therapy
  In the Lymph Nodes  :  No residual lymph node metastasis and no prominent fibrous scarring in the sentinel node

Lymph Nodes (required only if lymph nodes are present in the specimen):
    :  Number of sentinel lymph nodes examined: 1
      Number of lymph nodes with macrometastases (>0.2cm): 0
      Number of lymph nodes with micrometastases (>0.2mm to 0.2cm and/or >200 cells): 0
      Number of lymph node with isolated tumor cells (<0.2mm and <200 cells): 0
Method of Evaluation of Sentinel Lymph Nodes
    :  H and E, multiple levels;
      Immunohistochemistry

Pathologic Staging (based on information available to the pathologist) (pTNM)
  TNM Descriptors   :  y    (post treatment)
  Primary Tumor (Invasive Carcinoma)(pT):  ypT0  No evidence of primary tumor    
  Regional Lymph Nodes (pN)
       Modifiers  :  (sn)  Only sentinel node evaluated
       Category  :  pN0 (i-)  No regional lymph node metastases histologically, negative IHC   
  Distant Metastasis (M)    :  Not applicable

Ancillary Studies
  Estrogen Receptor  :  Immunohistochemical results on invasive carcinoma performed on a prior core needle biopsy:
      Performed on another specimen, see S11 22091
       Results  :  No immunoreactive tumor cells present

  Progesterone Receptor  :  Immunohistochemical results for invasive carcinoma performed on a prior core needle biopsy:
      Performed on another specimen, see S11 22091
       Results  :  No immunoreactive tumor cells present 

  HER2/neu
  Immunoperoxidase Studies  :  Results for invasive carcinoma performed on a prior core needle biopsy)
      Performed on another specimen, see S11 22091
       Results  :  Equivocal (Score 2+)

  Fluorescence In Situ Hybridization 
  (FISH) for HER2/neu  :  Performed on another specimen, see S11 22091
       Results  :  Not amplified (HER2 gene copy <4.0 or ratio <1.8)

Microcalcifications   :  Not identified 

CPT Code: 3260-F.",,"GrossDescription:
  Container 1:  Received fresh for Touch Prep diagnosis and subsequently placed in formalin labeled right axillary sentinel node is a 2.0 x 1.3 x 1.0cm tan, rubbery lymph node with a moderate amount of attached yellow, lobulated adipose tissue.  The node is bisected and Touch Preps are performed.  (See Touch Prep Diagnosis #1). A clip is not identified grossly or upon radiographing the tissue block. The lymph node is submitted in its entirety as 1A.

  Container 2:  Received fresh on a radiographic grid labeled right breast mass needle localization is a 13.0cm (medial to lateral) by 10.0cm (cephalad to caudad) by 4.0cm (anterior to posterior) irregular portion of tan to yellow, fibrofatty breast tissue, which is marked with a long suture designating lateral, a midsized suture designating medial, a short suture designating cephalad and clips designating the posterior aspect.  There is a needle localization wire extending from the superior aspect.  The specimen is marked with silver nitrate and additionally overinked as follows:  cephalad aspect blue, caudal aspect green, anterior aspect orange, posterior aspect black, lateral aspect yellow.  The specimen is serially sectioned and reradiographed to reveal a metallic clip, centrally located within a 0.3 x 0.3 x 0.3cm tan, indurated area. The area comes to within 1.5cm of the posterior margin and is greater than 2.0cm from all additional margins.  The cut surfaces immediately associated with the clip site are congested.  The remaining cut surfaces are composed of 80% tan, rubbery, fibrous tissue and 20% tan, yellow lobulated adipose tissue.  There are no additionally noted lesions.  Sections are submitted as follows:  2A, perpendicular sections of lateral margin; 2B and 2C, fibrous tissue between lateral margin and site of clip; 2D, caudal margin closest to site of clip; 2E and 2F, contiguous section (2E to include site of clip and lesion with posterior margin, 2F to include anterior margin); 2G, cephalad margin closest to site of clip; 2H and 2I, fibrous tissue adjacent to site of clip; 2J, remaining lesion, associated congested tissue and posterior margin; 2K and 2L, fibrous tissue adjacent to lesion (2K to include anterior margin and 2L to include margin); 2M through 2O, random sections between lesion and medial margin; 2P, perpendicular sections of medial margin.  Please see diagram.

  Fixation of specimen reviewed and assured to be 6 to 48 hours.
AC:lefb **DATE[May 2 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right sentinal lymph node(s)2: NL-Right breast biopsy requiring evaluation of surgical  margins,,
REG2,BREAST,0,PAT-40147136,1,REC-100000929215,"ClinicalHistory:
Left breast lump 12:30.","CytologyReview:
 Atypical cells seen.

 Malignant Cells Consistent with Mammary Carcinoma.
This case was seen in the Pathology Departmental Conference.","FinalDiagnosis:
 Malignant Cells Consistent with Mammary Carcinoma.
This case was seen in the Pathology Departmental Conference.",,"GrossDescription:

Received: 30 cc pink  cytolyt for ThinPrep and Cell Block.",,"A: Left Breast 12:30, Fine Needle Aspiration",,
REG2,BREAST,0,PAT-40145141,1,REC-100000929423,"ClinicalHistory:
  Possible malignancy.",,"FinalDiagnosis:
1.  Right Breast, Needle Core Biopsy at 12 O'Clock, 4cm from Nipple:
Infiltrating Mammary Ductal Carcinoma, Histologic Grade 3 out of 3, Nuclear Grade 3 out of 3. 
See Note.

2.  Right Breast, Needle Core Biopsy at 2 O'Clock, 4cm from Nipple:
Infiltrating Mammary Ductal Carcinoma. 
See Note. 

NOTE: 
  In specimen #1, the right breast needle core biopsy at 12 o'clock, 4cm from nipple, shows infiltrating mammary ductal carcinoma involving multiple tissue cores.  Invasive carcinoma lacks tubule formation and is embedded within a fibrous, focally myxoid stroma containing occasional microcalcifications.  No ductal carcinoma in situ component is identified.  No definite lymphovascular invasion is noted.  Invasive carcinoma in the tissue fragments ranges from 0.6 to 1.2cm.  

  Specimen #2 shows fibroadipose tissue with a small zone of infiltrating mammary ductal carcinoma, which is histomorphologically similar to the invasive ductal carcinoma identified in specimen #1.  Clinical correlation is recommended.  

  This case was reviewed at the Pathology Departmental Conference and Dr. **NAME[M. ZZZ] was notified of these findings are **DATE[Nov 22 2012] at 5:04 PM. 

Estrogen receptor, progesterone receptor and Herceptest will be performed on tissue block 1A and reported in an addendum.",,"GrossDescription:
  Container 1:  Received in formalin labeled right breast 12 o'clock 4.0cm from nipple per the requisition and right breast 12 o'clock per the container are four cylindrical portions of tan to yellow, soft and delicate tissue with scant, adherent, dark red clotted blood.  The tissue portions range from 0.9 x 0.2cm to 1.3 x 0.2cm and are submitted in toto as 1A.

  Container 2:  Received in formalin labeled right breast 2 o'clock 4.0cm from nipple per the requisition and right breast 2 o'clock per the container are three cylindrical portions of yellow, soft and delicate tissue ranging from 0.3 x 0.2cm to 2.2 x 0.2cm.  The specimen is submitted in toto as 2A.

  Fixation of specimen reviewed and assured to be 6 to 48 hours.
AC:lefb **DATE[Nov 21 2012].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy2: Right breast core biopsy,,"AddendumComment:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin fixed paraffin embedded tissue (Block 1A) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is positive in 98% of the tumor cells showing strong (3+) staining intensity.  The Progesterone Receptor (DAKO Clone PgR 636) is positive in 80% of the tumor cells showing strong (3+) staining intensity.  The Herceptest (DAKO) shows equivocal (2+) staining, after evaluation of membrane staining intensity and pattern on the standardized  0 to 3+ scale.  Her2eu by fluorescence in situ hybridization (FISH) will be performed on the tissue block and reported in another addendum. 

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE:   ASCO/CAP scoring criteria for HER2 protein over expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3).  Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1).  Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells."
REG2,BREAST,0,PAT-40058245,1,REC-100000929435,"ClinicalHistory:
  Right breast mass.",,"FinalDiagnosis:
  Breast, Right, Excision of Mass:
Infiltrating Ductal Carcinoma, Nuclear Grade 2 of 3, Recurrent,
with Perineural Invasion Seen; 
(The Nodule Measures Approximately 1.0cm in Maximum Dimension);
The Surgical Margins are Involved. 

Note:
  The patients previous invasive ductal carcinoma of the right breast (2.3cm in maximum dimension) with sentinel lymph node sampling (S08 1340) is noted. A re excision of the area (S10 8160) showed suture granulomata and remote fat necrosis. The previous diagnostic specimen is retrieved and reviewed.  The current material is similar in appearance histologically. Estrogen receptor, Progesterone receptor, and the Herceptest for Her 2 overexpression with be performed on this specimen and the results will be subsequently appended to this surgical pathology report. 

NOTE:  This case is reviewed at the Departmental Surgical Pathology Conference and a consensus diagnosis is rendered. 

Comment: This case is discussed with the attending surgeon, Dr. **NAME[ZZZ], on **DATE[May 14 2013].",,"GrossDescription:
  Received in formalin, labeled ""right breast mass,"" is a 2 x 1.6 x 1.3cm, irregular, tan white to yellow, fibrofatty tissue.  Sectioning of the specimen reveals a 1.0 x 1.0 x 0.7cm, irregular, tan white to tan pink, fibrous area, which extends grossly to the inked surgical resection margins.  The remaining cut surface is yellow, homogeneous, lobulated adipose tissue.  The specimen is entirely marked with silver nitrate and overinked blue.  The specimen is submitted in its entirety in 1A to 1D. 

  Note: Fixation of specimen reviewed and assured to be between 6 and 48 hours. 
MM:jaa, **DATE[May 12 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right breast biopsy not requiring surgical  margins,,"AddendumComment:
ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin fixed paraffin embedded tissue (Block 1B) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is strongly and diffusely immunoreactive in essentially 100% of the tumor cells showing 3+ immunoreactivity.  The Progesterone Receptor (DAKO Clone PgR 636) is strongly and diffusely immunoreactive in greater than 95% of the tumor cells showing 3+ immunoreactivity.  The Herceptest (DAKO) shows equivocal staining, after evaluation of membrane staining intensity and pattern on the standardized  0 to 3+ scale.  The specimen will be sent for FISH studies and the results will be subsequently appended to this Surgical Pathology report. 


NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.
Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 
NOTE:   ASCO/CAP scoring criteria for HER2 protein over expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3).  Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1).  Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.   

Comment: All positive and negative controls show appropriate immunoreactivity."
REG2,BREAST,0,PAT-40145141,1,REC-100000929462,"ClinicalHistory:
  Possible malignancy.",,"FinalDiagnosis:
1.  Right Breast, Needle Core Biopsy at 12 O'Clock, 4cm from Nipple:
Infiltrating Mammary Ductal Carcinoma, Histologic Grade 3 out of 3, Nuclear Grade 3 out of 3. 
See Note.

2.  Right Breast, Needle Core Biopsy at 2 O'Clock, 4cm from Nipple:
Infiltrating Mammary Ductal Carcinoma. 
See Note. 

NOTE: 
  In specimen #1, the right breast needle core biopsy at 12 o'clock, 4cm from nipple, shows infiltrating mammary ductal carcinoma involving multiple tissue cores.  Invasive carcinoma lacks tubule formation and is embedded within a fibrous, focally myxoid stroma containing occasional microcalcifications.  No ductal carcinoma in situ component is identified.  No definite lymphovascular invasion is noted.  Invasive carcinoma in the tissue fragments ranges from 0.6 to 1.2cm.  

  Specimen #2 shows fibroadipose tissue with a small zone of infiltrating mammary ductal carcinoma, which is histomorphologically similar to the invasive ductal carcinoma identified in specimen #1.  Clinical correlation is recommended.  

  This case was reviewed at the Pathology Departmental Conference and Dr. **NAME[M. ZZZ] was notified of these findings are **DATE[Oct 22 2012] at 5:04 PM. 

Estrogen receptor, progesterone receptor and Herceptest will be performed on tissue block 1A and reported in an addendum.",,"GrossDescription:
  Container 1:  Received in formalin labeled right breast 12 o'clock 4.0cm from nipple per the requisition and right breast 12 o'clock per the container are four cylindrical portions of tan to yellow, soft and delicate tissue with scant, adherent, dark red clotted blood.  The tissue portions range from 0.9 x 0.2cm to 1.3 x 0.2cm and are submitted in toto as 1A.

  Container 2:  Received in formalin labeled right breast 2 o'clock 4.0cm from nipple per the requisition and right breast 2 o'clock per the container are three cylindrical portions of yellow, soft and delicate tissue ranging from 0.3 x 0.2cm to 2.2 x 0.2cm.  The specimen is submitted in toto as 2A.

  Fixation of specimen reviewed and assured to be 6 to 48 hours.
AC:lefb **DATE[Oct 21 2012].","MicroscopicDescription:
  Slides reviewed.",1: Right breast core biopsy2: Right breast core biopsy,,
REG2,BREAST,0,PAT-40145154,1,REC-100000929465,"ClinicalHistory:
  Carcinoma left breast.",,"FinalDiagnosis:
Breast, Left, Reexcision:
Breast Parenchyma Showing Cystic Cavity with Organizing Hemorrhage, Healing Fibrosis, Lymphohistiocytic Inflammation, Fat Necrosis, and Suture Granulomata Consistent with Previous Surgical (Excision) Procedure. 
No Diagnostic Histologic Evidence of Malignancy. 
Surgical Margins of Excision Negative for Malignancy.

COMMENT: 
  This reexcision consists of predominantly fatty breast parenchyma showing a prior excision cavity (status post partial mastectomy with needle localization) exhibiting healing fibrosis, organizing hemorrhage, lymphohistiocytic inflammation, fat necrosis, and suture granulomata. There is no overt histologic evidence of malignancy and the surgical margins of excision appear negative for malignancy. 

  This case was reviewed for consensus diagnosis through intradepartmental consultation on **DATE[May 22 2013].",,"GrossDescription:
  Received in formalin labeled left breast tissue reexcision anterior margin is a 6.0cm (medial to lateral) by 4.0cm (superior to inferior) by 3.0cm (anterior to posterior) irregular portion of tan to yellow, fibrofatty breast tissue, which is marked with a long suture designating lateral, a short suture designating superior and a midsized suture designating inferior.  The specimen is marked with silver nitrate and additionally overinked as follows:  superior aspect blue, inferior aspect green, anterior aspect black, posterior aspect orange, lateral aspect yellow.  On sectioning, there is a 2.0 x 2.0 x 2.0cm cavitary defect extending to the anterior and posterior margins, comes to within 0.5cm of the superior margin, 0.5cm of the medial margin, 1.0cm of the inferior and lateral margins.  The cut surfaces of the cystic lesion are red and roughened with surrounding tan to yellow, chalky and rubbery areas.  The remaining cut surfaces are yellow with fine fibrous tissue.  There are no additionally noted lesions.  Representative tissue is submitted as follows:  1A, perpendicular sections of lateral margin; 1B through 1I, random sections of cystic area to surrounding margins; 1J, perpendicular sections of cystic lesion to medial margin.  Please see diagram.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[May 21 2013].","MicroscopicDescription:
  Slides reviewed.",1: Left breast biopsy requiring evaluation of surgical  margins,,
REG2,BREAST,0,PAT-40014243,1,REC-100000929487,"ClinicalHistory:
  Right breast cancer, metastatic to axillary nodes.",,"FinalDiagnosis:
Lymph Nodes, Right Axillary, Axillary Node Dissection:
Six of Ten (6 of 10) Lymph Nodes Showing Metastatic Adenocarcinoma Consistent with Metastatic Mammary Carcinoma. 

COMMENT: 
  Six of the excised ten axillary lymph nodes reveal features of metastatic mammary adenocarcinoma. 

  This case was reviewed for consensus diagnosis through intradepartmental consultation on **DATE[Apr 29 2013].",,"GrossDescription:
  Received in formalin labeled right axillary contents is a 6.5 x 5.0 x 3.5cm aggregate of yellow, lobulated adipose tissue.  Dissection of the adipose tissue reveals multiple, tan, white to tan, pink, rubbery lymph nodes ranging from 0.8cm to 3.0cm in greatest dimension.  Sectioning of the nodules reveal some of the nodules grossly positive for metastatic disease.  Representative sections are submitted as follows:  1A, two large lymph nodes; 1B, four single lymph nodes; 1C, two single lymph nodes; 1D, two single lymph nodes submitted in their entirety, each bisected.
MM:lefb **DATE[Apr 25 2013].","MicroscopicDescription:
  Slides reviewed.",1: Right axillary lymph node dissection,,
REG2,BREAST,0,PAT-40145770,1,REC-100000929674,"ClinicalHistory:
  Suspicious calcifications left.",,"FinalDiagnosis:
1.  Breast, Left, 2 O'clock, Calcifications, Needle Core Biopsy (Stereotactic):
Intraductal Carcinoma (Ductal Carcinoma In Situ), Comedocarcinoma and Solid Type, High Grade, with Associated Microcalcifications.
No Invasive Carcinoma Identified.
See Note.

2.  Breast, Left, 2 O'clock, No Calcifications, Needle Core Biopsy (Stereotactic):
Intraductal Carcinoma (Ductal Carcinoma In Situ), Solid Type, High Grade, with Associated Focal Microcalcifications.
No Invasive Carcinoma Identified.
See Note.

NOTE: The supplied clinical information and imaging findings are noted.

In specimen #1, left breast, 2 o'clock, calcifications, needle core biopsy, intraductal carcinoma (ductal carcinoma in situ) involves one needle core biopsy tissue core, and in specimen #2, left breast, 2 o'clock, no calcifications, needle core biopsy, intraductal carcinoma (ductal carcinoma in situ) involves four needle core biopsy tissue cores, in the sections examined.

Intraductal carcinoma (ductal carcinoma in situ) has a solid and comedocarcinoma architectural pattern and a nuclear grade of predominantly grade 3 of 3, and would be considered a high grade intraductal carcinoma (ductal carcinoma in situ). Focal punctate necrosis is identified in the area of intraductal carcinoma (ductal carcinoma in situ), in addition to comedo pattern necrosis. No invasive carcinoma is identified in any portion of the present needle core biopsy specimen of the left breast at 2 o'clock in any section examined.

Immunohistochemical stains for Estrogen receptor and Progesterone receptor (quantitative) will be performed on this specimen (on block 2C) and will be reported separately in an addendum.",,"GrossDescription:
  Container 1:  Received in formalin in a container labeled calcifications left 2 o'clock are two cylindrical portions of yellow to tan, soft tissue ranging from 0.4 x 0.2cm to 3.5 x 0.2cm.  The specimen is submitted in toto as 1A.

  Container 2:  Received in formalin in a container labeled no calcifications left 2 o'clock are 12 cylindrical portions of tan to yellow, soft and delicate tissue ranging from 0.4 x 0.3cm to 2.5 x 0.2cm.  The specimen is submitted in toto as 2A through 2C.

  Fixation of specimen reviewed and assured to be 6 to 48 hours.
AC:lefb **DATE[Jun 18 2012].","MicroscopicDescription:
  Slides Reviewed.",1: Left breast core biopsy2: Left breast core biopsy,,"AddendumComment:
ER/PR (QUANTITATIVE INTERPRETATION)
Estrogen and Progesterone Receptor analysis are performed on formalin fixed paraffin embedded tissue (Block 2C) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls.  Localization is via a biotin free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody.  The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 
The Estrogen Receptor (VECTOR CLONE 6F11) is focally weakly positive in 5% to 10% of the tumor cells showing 1+ staining intensity.  The Progesterone Receptor (DAKO Clone PgR 636) is negative in 100% of the tumor cells showing 0 staining intensity.

NOTE:   Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells.  Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO CAP scoring criteria.  If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong."
REG2,BREAST,0,PAT-30451329,1,REC-100000929706,"ClinicalHistory:
  Deleterious BRCA mutation; Breast CA.
IntraoperativeDiagnosis:
Gross OR Consultation:
1.  Right tube and ovary:  No gross lesions seen.  Report given to Dr. **NAME[ZZZ YYY].  (TM)
2.   Left tube and ovary:  No gross lesions seen.  Report given to Dr. **NAME[ZZZ YYY].  (TM).",,"FinalDiagnosis:
1.  Right Fallopian Tube and Ovary, Laparoscopic SalpingoOophorectomy Specimen:
Physiologic Ovary Showing Involuting Corpus Luteum, Corpora Albicantia, and Follicles, Minute Fibrous Cortical Nodules and Walthard Rest. 
Unremarkable Fallopian Tube. 
There is No Evidence of Malignancy in the Entirely Submitted Specimen. 

2.  Left Fallopian Tube and Ovary, Laparoscopic SalpingoOophorectomy Specimen:
Physiologic Ovary Showing Hemorrhagic Corpus Luteum, Corpora Albicantia, Cystic Follicles, and Germinal Inclusion Cysts. 
Unremarkable Fallopian Tube. 
There is No Evidence of Malignancy in the Entirely Submitted Specimen.",,"GrossDescription:
  Container 1:  Received fresh labeled right tube and ovary is an 8 gram, 3.9 x 2.0 x 1.0cm intact, tan, lobular ovary with an attached 6.8cm in length fimbriated fallopian tube measuring up to 0.5cm in diameter.  The external surface is marked with silver nitrate prior to sectioning.  There are two white, firm nodules identified on the ovarian capsule measuring 0.15cm and 0.2cm in greatest dimension. Sectioning of the ovary reveals a 0.6cm in greatest dimension clear, serous fluid filled cyst and a few corpora lutea measuring up to 0.5cm in greatest dimension. No papillary excrescences are identified. The surrounding stroma is tan and smooth. A discrete lesion is not identified. Sectioning of the fallopian tube reveals a stellate lumen.  (See Gross OR Consultation #1).  Sections are submitted as follows:  1A through 1I, entire ovary step sectioned; 1J through 1L, entire fallopian tube and fimbriae submitted proximal to distal.

  Container 2:  Received fresh labeled left tube and ovary is a 12 gram, 3.8 x 2.2 x 1.5cm intact, tan, lobular ovary with an attached 5.5cm in length fimbriated fallopian tube measuring up to 0.5cm in diameter.  The external surface of the specimen is marked with silver nitrate prior to sectioning.  Sectioning of the ovary reveals a 0.5cm in greatest dimension clear, serous fluid filled cyst and a 1.3cm in greatest dimension hemorrhagic corpora luteum. No papillary excrescences are identified. The surrounding stroma is tan and smooth. A discrete lesion is not identified. Sectioning of the fallopian tube reveals a stellate lumen.  (See Gross OR Consultation #2).  Sections are submitted as follows:  2A through 2G, entire ovary step sectioned; 2H through 2K, entire fallopian tube and fimbriae submitted proximal to distal.
CH:lefb **DATE[Jun 16 2012].","MicroscopicDescription:
  Slides reviewed.","1: Right ovary +/- tube, non-neoplastic2: Left ovary+/- tube, non-neoplastic",,
REG2,BREAST,0,PAT-40145489,1,REC-100000929784,"ClinicalHistory:
  Left breast DCIS; Left breast true posterior margin.",,"FinalDiagnosis:
1.  Breast, Left Breast Mass, Excisional Biopsy with Needle Localization:
Benign Breast Tissue with Evidence of Previous Biopsy (Mammotome Clip Identified). 
No Residual Ductal Carcinoma In Situ (DCIS) Identified.  
No Evidence of Invasive Carcinoma.

2.  Breast, Left Breast True Posterior Margin, Biopsy:
Benign Connective Tissue with Lymphoid Aggregate.
No Evidence of Malignancy.

SYNOPTIC REPORT:
DCIS OF THE BREAST:  Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy; With or Without Axillary Contents) and Mastectomy (Total, Modified Radical, Radical; With or Without Axillary Contents)

Specimen  :  Partial breast 
Procedure   :  Excision with wire guided localization
Lymph Node Sampling  :  No lymph nodes present
Specimen Integrity  :  Single intact specimen (margins can be evaluated)
Specimen Size  :  Greatest dimension: 7.5cm      Additional dimensions: 6 x 2.1cm
Specimen Laterality  :  Left
Size (Extent) of DCIS  :  Only seen in Mammotome biopsy  (***PATH-NUMBER[1])
Architectural Patterns  :  Cribriform; Solid
Nuclear Grade  :  Grade II (intermediate) to Grade III (high)
Necrosis  :  Present, focal (small foci or single cell necrosis)
      Present, central (expansive ""comedo"" necrosis)
Margins   :  Margins uninvolved by DCIS

Pathologic Staging (pTNM) 
  Primary Tumor (pT)   :  pTis (DCIS)  Ductal carcinoma in-situ 
  Regional Lymph Nodes (pN)  :  pNX    Regional lymph nodes cannot be assessed 
  Distant Metastasis (pM)    :  Not applicable

Ancillary Studies
  Estrogen Receptor   :  Immunoreactive tumor cells present
  Progesterone Receptor   :  Immunoreactive tumor cells present
Microcalcifications  :  Present in DCIS
Comment(s)  :  Synoptic based on Mammotome biopsy findings (***PATH-NUMBER[1]).  No residual DCIS or evidence of invasive carcinoma is identified in the present excisional biopsy.",,"GrossDescription:
  Container 1:  Received fresh on a radiographic grid labeled left breast mass is a fibrofatty portion of breast tissue oriented by sutures (single suture superior, double suture medial), measuring 7.5cm from medial to lateral, 6.0cm from superior to inferior and 2.1cm from anterior to posterior.  There is a needle localization wire extending out of the lateral aspect of the specimen.  The specimen radiograph localizes a central soft tissue density without associated microcalcifications, containing a mammotome clip.  The margins are marked with silver nitrate prior to sectioning and additionally inked as follows:  superior blue, inferior green, lateral yellow, anterior orange, posterior black.  Sectioning reveals a 0.7 x 0.6 x 0.5cm healing biopsy site containing a mammotome clip, located 0.5cm from the nearest margin (anterior), 1.1cm from the inferior margin, 1.1cm from the posterior margin and greater than 3.0cm from the remaining margins.  A discrete mass lesion is not appreciated.  The remaining breast parenchyma consists of predominantly yellow, glistening, lobular adipose tissue, intermixed with scant, delicate, white lacy fibrous tissue.  Representative sequential sections are submitted from lateral to medial as follows:  1A, lateral margin; 1B, section just lateral to biopsy site; 1C and 1D, entire biopsy site to include the anterior and posterior margins (1D represents location of mammotome clip); 1E, inferior margin nearest biopsy site; 1F, superior margin nearest biopsy site; 1G, section just medial to biopsy site; 1H, medial margin.  All margins are represented. Additional tissue submitted 1I through 1M

  Container 2:  Received in formalin labeled left breast true posterior margin is a 4.2 x 3.5 x 1.5cm yellow portion of fibrofatty breast tissue with a black suture denoting true posterior margin.  The true posterior margin is inked black prior to sectioning.  Sectioning reveals predominantly yellow to red, focally congested adipose tissue, intermixed with white, lacy, fibrous tissue.  The fibrous tissue represents approximately 2% of the parenchyma.  A discrete lesion is not grossly visualized.  The specimen is sequentially submitted as 2A through 2J.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
CH:lefb **DATE[Nov 28 2012].","MicroscopicDescription:
  Slides reviewed.",1: NL- Left breast biopsy requiring evaluation of surgical  margins2: Left breast biopsy requiring evaluation of surgical  margins,,
REG2,BREAST,0,PAT-40160160,1,REC-100000930545,"ClinicalHistory:
  Left breast cancer.",,"FinalDiagnosis:
1.  Breast, Left, Excision:
Organizing Previous Biopsy Site (See Previous S12 22417) and Residual In Situ Ductal Carcinoma, Nuclear Grade 3 Over 3, with Two Foci of Invasive Ductal Carcinoma, Size 0.2 and 0.1cm, Nuclear Grade 3 Over 3, Poorly Differentiated.
In Situ Ductal Carcinoma Present at Anterior, Superior, Inferior and Medial Margins.
Invasive Carcinoma Present Less than 0.1cm Away from Closest Anterior Margin.
Breast Tissue with Fibrocystic Mastopathy with Duct Ectasia with Minute Microcalcifications.

2.  Soft Tissue, Left Axillary Contents:
Benign Vascular Fibroadipose Tissue.
No Lymphoid Tissue Seen.
No Evidence of Malignancy.

Comment: The specimen shows residual in situ ductal carcinoma, solid type, nuclear grade 3 over 3 adjacent to the biopsy site and focally present at medial, superior, inferior, and anterior margins. The posterior and lateral margins are negative for carcinoma. Two foci of invasive ductal carcinoma are seen which are adjacent to the biopsy site and measure 0.2cm (slide 1H) and 0.1cm (slide 1F). The margins are negative for invasive carcinoma, however, invasive ductal carcinoma is focally present less than 1mm away from the anterior margin (slide 1F). Immunoperoxidase stains for Actin and Myosin performed in two blocks, confirm the presence of invasive ductal carcinoma.

ER/PR HERCEPTEST (QUANTITATIVE INTERPRETATION)
      
Estrogen and Progesterone Receptor analysis and the Herceptest (DAKO) for HER2 protein overexpression are performed on formalin-fixed paraffin embedded tissue (Block 1H) using immunohistochemical techniques.

IMMUNOHISTOCHEMISTRY TECHNICAL INFORMATION: 
Deparaffinized sections of tissue are incubated with the following panel of monoclonal antibodies, along with appropriate positive controls. Localization is via a biotin-free, EnVision Flex + immunoperoxidase system with pretreatment (heat induced epitope retrieval) according to laboratory optimization for each antibody. The control slides for each test are reviewed for appropriate positive and negative reactivity and found to be satisfactory.

SUMMATION OF FINDINGS: 

The Estrogen Receptor (VECTOR-CLONE 6F11) is negative (less than 1% of the tumor cells show 1+ staining intensity). The Progesterone Receptor (DAKO-Clone PgR 636) is negative in 100% of the tumor cells showing 0 staining intensity. The Herceptest (DAKO) shows positive 3+ staining, after evaluation of membrane staining intensity and pattern on the standardized  0-3+ scale.

NOTE: Positive Estrogen Receptor is defined as positive staining of greater than or equal to 1% of tumor cells. Positive Progesterone receptor is defined as positive staining of greater than or equal to 1% of tumor cells.

Immunohistochemical estrogen receptor and progesterone receptor test results are reported using the ASCO/CAP scoring criteria. If positive, staining intensity may be reported numerically 1, 2, 3+ or descriptively as weak, moderate or strong. 

NOTE: ASCO/CAP scoring criteria for HER2 protein over-expression by immunohistochemistry are as stated: Positive cases show strong and complete membrane staining in greater than 30% of invasive cancer cells (score 3). Negative cases are defined as those with no staining (score 0) or weak, incomplete membrane staining in any proportion of cells (score 1). Equivocal or indeterminate cases show strong staining in less than or equal to 30% of cells or less than strong but complete staining in any proportion of cells.





PQRS CODE: 3394F

INVASIVE CARCINOMA OF THE BREAST: SYNOPTIC REPORT

Procedure        :Excision with wire guided localization
Specimen Laterality      :Left
Tumor Site: Invasive Carcinoma  :
Position        :6 o'clock from previous biopsy (S12 22417)
Histologic Type of Invasive 
Carcinoma        :Invasive ductal carcinoma (no special type or not 
          :otherwise specified)
Tumor Size: Size of Largest Invasive Carcinoma:
Greatest dimension of largest focus of invasion >1 mm: 2mm (on slide 1H)
Histologic Grade: Nottingham Histologic Score:
Glandular (Acinar)/Tubular Differentiation
Score 3: <10% of tumor area forming glandular/tubular structures

Nuclear Pleomorphism
Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms

Mitotic Rate
Score 2 (4-7 mitoses per mm2) (see Table 1)

Overall Grade
Grade 3: score 8 

Tumor Focality      :Multiple foci of invasive carcinoma
Number of Foci      :2
Size of individual foci      :Smaller second focus 0.1cm
Ductal Carcinoma In Situ (DCIS)  :Positive for EIC
Size (Extent) of DCIS       :
Estimated size (extent) of DCIS (greatest dimension using gross and microscopic evaluation):at least 30mm
Number of blocks with DCIS    :7
Number of blocks examined    :14

Architectural Patterns      :Solid
Nuclear Grade        :Grade III (high)
Necrosis         :Not identified
Lobular Carcinoma In Situ (LCIS)  :Not identified

Margins        :
Invasive Carcinoma
Margins uninvolved by invasive carcinoma
  Distance from closest margin: <1mm
  Specify margin    :Anterior
DCIS
Margins uninvolved by DCIS 
  Distance from closest margin  :10mm
   Specify margin    :Posterior
Margin(s) positive for DCIS
  Specify margin(s)    :Anterior, superior, inferior, medial

For positive margins, specify extent (focal, minimal, moderate, or extensive):
  Anterior:   focal
  Superior:   focal
  Inferior:  focal
Medial:   focal
   
Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy

In the Breast
No known presurgical therapy

 Lymph Vascular Invasion
Not identified

Dermal Lymph Vascular Invasion
 No skin present

Pathologic Staging (based on information available to the pathologist) (pTNM)

TNM Descriptors (required only if applicable)
M (2) (multiple foci of invasive carcinoma)

Primary Tumor (Invasive Carcinoma) (pT) 
mpT1a:  Tumor >1 mm but ?5 mm in greatest dimension

Category (pN)
pNX:  Regional lymph nodes cannot be assessed (not removed for pathologic study)

Distant Metastasis (pM) (required only if present)
Not applicable

Ancillary Studies (required only if available at time of report completion) 

Estrogen Receptor (ER) 
Other (specify): See above

Progesterone Receptor (PgR) 
Other (specify): See above

HER2 (results for invasive carcinoma performed on this specimen or a prior core needle biopsy or incisional biopsy) 

Immunoperoxidase Studies
Results:
Other 
  Specify: See above

Microcalcifications    :Present in non neoplastic tissue

CPT Code: 3260-F.",,"GrossDescription:
  Container 1:  Received fresh on a radiographic grid labeled left breast mass is a 6.5cm (medial to lateral) by 4.0cm (superior to inferior) by 1.5cm (anterior to posterior) irregular portion of tan to yellow, fibrofatty breast tissue, which is marked with a long suture designating lateral and a short suture designating superior.  There is a needle localization wire extending from the lateral anterior aspect.  The specimen is marked with silver nitrate and additionally overinked as follows:  superior aspect blue, inferior aspect green, anterior aspect orange, posterior aspect black, lateral aspect yellow.  The specimen is serially sectioned and reradiographed to reveal a metallic clip, located within a 1.5 x 0.9 x 0.6cm ill defined, red, finely granular to indurated area, which extends to the posterior margin, comes to within 0.5cm of both the superior and anterior margins and is greater than 1.5cm from all additional margins.  The remaining cut surfaces are composed of predominantly yellow, lobulated adipose tissue with scant, fine, fibrous tissue.  Representative tissue is submitted as follows:  1A, medial margin; 1B and 1C, random sections between medial margin and lesion; 1D and 1E, contiguous section (1D to include superior, anterior and posterior margins, 1E to include anterior, posterior and inferior margins); 1F and 1G, contiguous section of lesion (1F to include anterior, posterior and superior margins, 1G to include anterior, posterior and inferior margins); 1H and 1I, contiguous section (1H to include lesion, site of clip, anterior, posterior and superior margins, 1I to include anterior, posterior and inferior margins); 1J and 1K, contiguous section of remaining lesion (1J to include lesion, anterior, posterior and superior margins, 1K to include inferior margin); 1L and 1M, random sections between lesion and lateral margin; 1N, perpendicular sections of lateral margin.  Please note:  90% of the specimen is submitted.  All fibrous tissue is submitted.  Please see diagram.

  Container 2:  Received in formalin labeled left axillary contents is a 5.5 x 4.5 x 2.0cm aggregate of yellow, lobulated adipose tissue, which is sectioned to reveal yellow, well vascularized cut surfaces.  There are no definitively identified lymph nodes.  The specimen is submitted in its entirety as 2A through 2I.

  Fixation of specimen reviewed and assured to be 6 to 48 hours. 
AC:lefb **DATE[Sep 11 2013].","MicroscopicDescription:
  Slides Reviewed.",1: NL- Left breast biopsy requiring evaluation of surgical  margins2: Left axillary lymph node dissection,,
REG3,PROSTATE,0,PAT-00602583,2,REC-5000713683,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

<FINAL DX>     

A.  Right and Left Testicles, Bilateral Orchiectomy:
     First-described testis without diagnostic histopathology.
     Second-described testis with old infarct.

B.  Prostate Tissue, Transurethral Resection:
     Nodular hyperplasia and patchy chronic inflammation.
     Adenocarcinoma is not identified in representative submitted
sections.

<CLINICAL INFO>
TURP, bilateral orchiectomy. Prostate adenocarcinoma.

<GROSS>
A.  Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated ""R
and L testicles"", are two testicles. The first testicle is 38 grams, 5.2
x 3.8 x 3 cm with an attached 1 cm in length spermatic cord. The
spermatic cord margin is inked orange and the remaining tissue is inked
blue. The tunica vaginalis is not present. The tunica albuginea is
smooth and unremarkable. The epididymis is slightly firm. The testicular
parenchyma is grossly unremarkable. The second testicle is 13 grams, 2.5
x 1.9 x 1.5 cm with an attached 1.5 cm in length spermatic cord. The
spermatic cord margin is inked orange and the remaining tissue is inked
blue. The tunica vaginalis is not present. The tunica albuginea is
smooth and unremarkable. The epididymis has a few 0.2-0.5 cm cysts
containing clear, watery fluid. There is a 1.2 cm slightly thickened,
firm, fibrotic area of parenchyma underlying the tunica albuginea. The
remaining parenchyma is grossly unremarkable. Representative sections
are submitted as follows:
Block Key:
A1-A3.    First described testicle (A1- spermatic cord with margin; A2,
A3- sections of testicular parenchyma and epididymis;
A4-A6.    Second described testicle (A4- spermatic cord with margin; A5,
A6- testis and epididymis including cysts involving epididymis and
slightly thick, fibrotic area of parenchyma).

B.  Received in formalin, labeled ""**NAME[BBB, AAA]"", and designated
""prostate"", is a 22 gram, 7.5 x 6.5 x 2 cm aggregate of irregular tan
tissue fragments. Representative sections are submitted in B1-B8.
(axp/cm)

<MICROSCOPIC>
Unless 'gross exam' is specified, the final diagnosis for each specimen
is based on a microscopic examination of the tissue(s)/cells.

**NAME[ZZZ M YYY], M.D.  Electronically signed **DATE[Dec 30 2011]",,,,,
REG3,PROSTATE,0,PAT-00704990,1,REC-5000714142,,,,"<CLINICAL INFO>
 Prostate cancer.  Radical prostatectomy and pelvic
  lymph node dissection, robotic.<CLINICAL INFO>
 Prostate cancer.  Radical prostatectomy and pelvic
  lymph node dissection, robotic.<FINAL DX>
 A) Prostate, prostatectomy: Prostatic
  adenocarcinoma, Gleason score 4+3=7, involving right side only, confined to
  prostate; see Comment and Summary Cancer Data below.
  B) Lymph node, right pelvic, excisions: 2 lymph nodes with no metastatic
  carcinoma.
  C) Lymph node, left pelvic, excisions: 5 lymph nodes with no metastatic
  carcinoma.<FINAL DX>
 A) Prostate, prostatectomy: Prostatic
  adenocarcinoma, Gleason score 4+3=7, involving right side only, confined to
  prostate; see Comment and Summary Cancer Data below.
  B) Lymph node, right pelvic, excisions: 2 lymph nodes with no metastatic
  carcinoma.
  C) Lymph node, left pelvic, excisions: 5 lymph nodes with no metastatic
  carcinoma.<DIAGNOSIS COMMENT(S)> Additional sections are pending to evaluate the surgical
  margins; an addendum report will follow.<DIAGNOSIS COMMENT(S)> Additional sections are pending to evaluate the surgical
  margins; an addendum report will follow.SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Prostate, radical resection
  B: Lymph node, pelvic right
  C: Lymph node, pelvic left
  Specimen and Tumor Location
  Specimen type: Radical Prostatectomy
  Specimen weight: 27g
  Specimen weight includes: Prostate and no seminal vesicles
  Characteristics and Extent of Neoplasm
  Histologic type: Adenocarcinoma, NOS (81403)
  Histologic (Gleason) Grade: Primary: 4  +  Secondary: 3   = Total: 7
  Estimated volume (in cc): 3.2
  Involved quadrants: Right anterior
  Right posterior
  Extraprostatic extension: Absent
  Seminal vesicle invasion: Left S.V. present; negative for invasion
  Right S.V. present; negative for invasion
  Angiolymphatic invasion: Not identified
  Extensive perineural invasion: Not identified
  Therapy prior to surgery: Unknown/History not provided
  Final Surgical Resection Margins
  Prostatic apex: Cannot assess presence of carcinoma
  Bladder neck: Carcinoma is absent (bladder neck margin is negative)
  Circumferential margins: Carcinoma abuts margin(s)
  Margin(s) abutted (but not involved) by carcinoma:
  Right postero-lateral (neurovascular bundle)
  Comment about surgical margins:
  Carcinoma is present in a section from the apex.  Final evaluation of the
  apical and right posterolateral surgical margins are pending additional
  sections and will be reported separately.
  Lymph Node Status
  Node summary: Nodes with carcinoma: 0    / Total nodes examined: 7
  Minimum Pathologic Stage (AJCC, 7th ed., 2010)
  Primary tumor (pT): pT2: Organ-confined
  pT2 Substage:
  pT2b: Organ-confined, unilateral involving more than one-half of 1 side
  (lobe), but not both sides
  Regional lymph nodes (pN): pN0
  Procedures used to establish the diagnosis:
  RoutineSUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Prostate, radical resection
  B: Lymph node, pelvic right
  C: Lymph node, pelvic left
  Specimen and Tumor Location
  Specimen type: Radical Prostatectomy
  Specimen weight: 27g
  Specimen weight includes: Prostate and no seminal vesicles
  Characteristics and Extent of Neoplasm
  Histologic type: Adenocarcinoma, NOS (81403)
  Histologic (Gleason) Grade: Primary: 4  +  Secondary: 3   = Total: 7
  Estimated volume (in cc): 3.2
  Involved quadrants: Right anterior
  Right posterior
  Extraprostatic extension: Absent
  Seminal vesicle invasion: Left S.V. present; negative for invasion
  Right S.V. present; negative for invasion
  Angiolymphatic invasion: Not identified
  Extensive perineural invasion: Not identified
  Therapy prior to surgery: Unknown/History not provided
  Final Surgical Resection Margins
  Prostatic apex: Cannot assess presence of carcinoma
  Bladder neck: Carcinoma is absent (bladder neck margin is negative)
  Circumferential margins: Carcinoma abuts margin(s)
  Margin(s) abutted (but not involved) by carcinoma:
  Right postero-lateral (neurovascular bundle)
  Comment about surgical margins:
  Carcinoma is present in a section from the apex.  Final evaluation of the
  apical and right posterolateral surgical margins are pending additional
  sections and will be reported separately.
  Lymph Node Status
  Node summary: Nodes with carcinoma: 0    / Total nodes examined: 7
  Minimum Pathologic Stage (AJCC, 7th ed., 2010)
  Primary tumor (pT): pT2: Organ-confined
  pT2 Substage:
  pT2b: Organ-confined, unilateral involving more than one-half of 1 side
  (lobe), but not both sides
  Regional lymph nodes (pN): pN0
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received fresh in a container labeled
  ""**NAME[BBB], prostate"" is a 33 g (with attached seminal vesicles) prostate with
  intact bilateral seminal vesicles, measuring 4.6 SI x 4.1 ML x 4.2 cm AP.
  After inking the right side black, the right rectal surface green, the left
  side blue and the left rectal surface orange, transverse sections are made
  revealing moderate bilateral hypertrophy and no grossly apparent cancer.  The
  prostate minus the seminal vesicles weighs 27 g.  The gland is fixed in
  formalin and embedded as follows:  apex - A1; base - A2-A3; A4 - most distal
  transverse section; A5-A6 - next transverse section; A7-A8 - next transverse
  section; A9-A10 - next transverse section; A11-A13 - next transverse section;
  A14-A15 - next transverse section; A16-A19 - next transverse section; A20-A22
  - next transverse section; A23-A24 - next transverse section; most proximal
  transverse section which includes the seminal vesicles is in cassette A25.
  (DZ/pwt)
  B) Received in formalin labeled ""**NAME[BBB]"", and designated ""right pelvic lymph
  nodes"" are two tan-yellow, fatty lymph nodes measuring 1.3 cm in greatest
  dimension and 5.0 cm in greatest dimension.  The lymph nodes are entirely
  submitted as follows:  Cassette B1 - smaller bisected node; B2-B5 - larger
  serially sectioned lymph node.  (CR/pwt)
  C) Received in formalin labeled ""**NAME[BBB]"", and designated ""left pelvic lymph
  nodes"" are five tan-yellow, fatty lymph nodes ranging from 0.6 cm in greatest
  dimension to 2.0 cm in greatest dimension.  The lymph nodes are entirely
  submitted as follows:  Cassette C1 - two whole nodes; C2 - one bisected node;
  C3 - one trisected node; C4-C5 - one serially sectioned lymph node.  (CR/pwt)<GROSS>
 A) Received fresh in a container labeled
  ""**NAME[BBB], prostate"" is a 33 g (with attached seminal vesicles) prostate with
  intact bilateral seminal vesicles, measuring 4.6 SI x 4.1 ML x 4.2 cm AP.
  After inking the right side black, the right rectal surface green, the left
  side blue and the left rectal surface orange, transverse sections are made
  revealing moderate bilateral hypertrophy and no grossly apparent cancer.  The
  prostate minus the seminal vesicles weighs 27 g.  The gland is fixed in
  formalin and embedded as follows:  apex - A1; base - A2-A3; A4 - most distal
  transverse section; A5-A6 - next transverse section; A7-A8 - next transverse
  section; A9-A10 - next transverse section; A11-A13 - next transverse section;
  A14-A15 - next transverse section; A16-A19 - next transverse section; A20-A22
  - next transverse section; A23-A24 - next transverse section; most proximal
  transverse section which includes the seminal vesicles is in cassette A25.
  (DZ/pwt)
  B) Received in formalin labeled ""**NAME[BBB]"", and designated ""right pelvic lymph
  nodes"" are two tan-yellow, fatty lymph nodes measuring 1.3 cm in greatest
  dimension and 5.0 cm in greatest dimension.  The lymph nodes are entirely
  submitted as follows:  Cassette B1 - smaller bisected node; B2-B5 - larger
  serially sectioned lymph node.  (CR/pwt)
  C) Received in formalin labeled ""**NAME[BBB]"", and designated ""left pelvic lymph
  nodes"" are five tan-yellow, fatty lymph nodes ranging from 0.6 cm in greatest
  dimension to 2.0 cm in greatest dimension.  The lymph nodes are entirely
  submitted as follows:  Cassette C1 - two whole nodes; C2 - one bisected node;
  C3 - one trisected node; C4-C5 - one serially sectioned lymph node.  (CR/pwt)ADDENDUM: Additional sections were taken to evaluate the apical
  and right postero-lateral margins; adenocarcinoma abuts (< 0.1 cm), but is not
  present at, the inked apical and right posterolateral resection margins.  The
  above diagnosis remains unchanged.ADDENDUM: Additional sections were taken to evaluate the apical
  and right postero-lateral margins; adenocarcinoma abuts (< 0.1 cm), but is not
  present at, the inked apical and right posterolateral resection margins.  The
  above diagnosis remains unchanged.",,,,,
REG3,PROSTATE,0,PAT-00737624,1,REC-5000714213,,,,"<CLINICAL INFO>
 Malignant neoplasm of prostate.  Gen-Probe study.<FINAL DX>
 A) Lymph nodes, left iliac obturator, excision:
  6 lymph nodes negative for carcinoma.
  B) Lymph nodes, right iliac obturator, excision:  6 lymph nodes negative for
  carcinoma.
  C) Prostate (34 gm), prostatectomy:  Prostatic adenocarcinoma.  Please see
  summary cancer data.SUMMARY CANCER DATA: Specimens Included in This Summary
  Specimens: A: Lymph node, sampling
  B: Lymph node, sampling
  C: Prostate, radical resection
  Specimen and Tumor Location
  Specimen type: Radical Prostatectomy
  Specimen weight: 34g
  Specimen weight includes: Prostate and both seminal vesicles
  Characteristics and Extent of Neoplasm
  Histologic type: Adenocarcinoma, NOS (81403)
  Histologic (Gleason) Grade: Primary: 3  +  Secondary: 4   = Total: 7
  Grade comment(s): Secondary pattern represents less than 10% of cancer
  Estimated volume (in cc): 2.4
  Tumor diameters: Greatest diameter: 1.2cm
  Involved quadrants: Left anterior
  Left posterior
  Right anterior
  Right posterior
  Extraprostatic extension: Absent
  Seminal vesicle invasion: Left S.V. present; negative for invasion
  Right S.V. present; negative for invasion
  Angiolymphatic invasion: Not identified
  Extensive perineural invasion: Present
  Therapy prior to surgery: Unknown/History not provided
  Final Surgical Resection Margins
  Prostatic apex: Carcinoma is present but not at margin
  Bladder neck: Carcinoma is absent (bladder neck margin is negative)
  Circumferential margins: All circumferential margins are free of carcinoma
  Lymph Node Status
  Node summary: Nodes with carcinoma: 0    / Total nodes examined: 12
  Minimum Pathologic Stage (AJCC, 7th ed., 2010)
  Primary tumor (pT): pT2: Organ-confined
  pT2 Substage: pT2c: Organ-confined, bilateral disease
  Regional lymph nodes (pN): pN0
  Procedures used to establish the diagnosis:
  Routine<GROSS>
 A) Received in a container of formalin labeled
  ""**NAME[BBB], left iliac obturator lymph nodes"" is a 9.0 x 3.0 x 1 cm yellow,
  lobulated, congested, nonoriented portion of fibrofatty tissue.  There are
  fatty cut surfaces admixed with a few lymph node candidates ranging in size
  from 0.1 to 3 cm.  Representative sections are submitted labeled:  A1 - one
  bisected lymph node; A2 - one bisected lymph node; A3 - four individual lymph
  node candidates.  (**INITIALS)
  B) Received in a container of formalin labeled ""**NAME[BBB], right iliac obturator
  lymph nodes"" is a 6.0 x 3.0 x 1 cm yellow, lobulated, nonoriented portion of
  fibrofatty tissue.  There are fatty cut surfaces admixed with numerous lymph
  node candidates ranging from 0.2 to 2 cm.  Representative sections are
  submitted labeled:  B1 - one bisected lymph node; B2 - one individual lymph
  node candidate; B3 - one individual lymph node candidate; B4-B5 - one
  trisected lymph node candidate; B6 - two individual lymph node candidates.
  (**INITIALS)
  C) Received fresh in a container labeled ""**NAME[BBB], prostate"" is 34 g prostate
  minus the intact bilateral seminal vesicles and vas deferentia.  After inking
  the right side black, right rectal surface green, left side blue, and left
  rectal surface orange, transverse section are made revealing medium bilateral
  periurethral nodular hypertrophy, and no grossly apparent cancer.
  Approximately 8.2 g of tissue are removed/dissected for potential further
  investigative studies as follows:  RA, LA, RM, LM, RB and LB.  The gland is
  fixed in formalin and embedded as follows:  apex -1, base - 2, and serial
  sections from distal to proximal as follows:  most distal transverse section -
  blocks 3 and 4 and RA, LA; next transverse section - blocks 5 and 6 and RM,
  LM; next transverse section - blocks 7-10; next transverse next transverse
  section - blocks 11 and 12 and RB, LB; next transverse section - blocks 13-16;
  next transverse section - blocks 17-18; next transverse section - blocks 19-
  20.  The most proximal transverse section which includes seminal vesicles -
  blocks 21-22.  (**INITIALS)",,,,,
REG3,PROSTATE,0,PAT-00415489,2,REC-5000716234,,,,"**NAME[ZZZ,YYY] L.  (JLG7504)
                               <FINAL DX>
PROSTATE, PROSTATECTOMY:
   - TUMOR TYPE: PROSTATIC ADENOCARCINOMA, ACINAR.
     - HISTOLOGIC GRADE (GLEASON PATTERN):
       - PRIMARY PATTERN: 3.
       - SECONDARY PATTERN: 3.
       - TOTAL GLEASON SCORE: 6/10.
     - PROPORTION OF PROSTATE INVOLVED BY TUMOR: 10%, BILATERAL.
     - PROSTATE SIZE:
       - WEIGHT: 36.3 GM.
       - SIZE: 4.3 X 3.8 X 3.5 CM.
     - EXTRAPROSTATIC EXTENSION: NOT IDENTIFIED.
     - SEMINAL VESICLE INVASION: NOT IDENTIFIED.
     - MARGINS: INVOLVED BY INVASIVE CARCINOMA.
       - TUMOR PRESENT AT ANTERIOR APICAL MARGIN.
     - TREATMENT EFFECT ON CARCINOMA: NOT IDENTIFIED.
     - LYMPHATIC/VASCULAR INVASION: NOT IDENTIFIED.
     - PERINEURAL INVASION: PRESENT.
     - PATHOLOGIC STAGING: pT2c NX (AJCC, 7th Edition).

This case received prospective Quality Control review.
                             
<GROSS>
""**NAME[BBB], prostate,"" submitted in formalin is a 36.3 gram radical
prostatectomy specimen consisting of prostate gland (4.3 x 3.8 x 3.5
cm), left seminal vesicle (2.8 x 1.3 x 0.9 cm), left vas deferens
(3.5 cm in length; 0.6 cm in diameter), right vas deferens (3.0 x 1.5
x 1.4 cm), and right vas deferens (3.5 cm in length; 0.6 cm in
diameter).  The prostate is bisected into left and right halves and
each half is serially sectioned from apex to base.  Sectioning
reveals a tan-pink to pale yellow, prostatic parenchyma with moderate
periurethral nodularity.  No discrete lesions, masses, or nodules can
be appreciated grossly.

Ink code:
Black - posterior.
Orange - left lateral.
Yellow - right lateral.
Blue - anterior and base.

Slide key:
1-5 - apex perpendicularly sectioned.
6-10 - base/bladder neck margin perpendicularly sectioned.
11 - representative section of left vas deferens and left seminal
vesicle with prostate.
12 - right vas deferens and right seminal vesicle junction with
prostate.
13-17 - representative alternating sections of left prostate
submitted from apex to base as follows:
  - 13 - one section.
  - 14-15 - one contiguous section.
  - 16-17 - one contiguous section.
18-24 - representative alternating sections of right prostate
submitted from apex to base as follows:
  - 18 - one section.
  - 19-20 - one contiguous section.
  - 21-22 - one contiguous section.
  - 23-24 - one contiguous section.  24SS.",,,,,
REG3,PROSTATE,0,PAT-00730521,1,REC-5000716664,,,,"PART / DESCRIPTION - SEQ 
Prostate, radical resection/ PROSTATE GLAND- D
PART / DESCRIPTION - SEQ 
Prostate, other/ LEFT LEVATOR- C
PART / DESCRIPTION - SEQ 
Prostate, other/ ANTERIOR APEX, RIGHT- A
PART / DESCRIPTION - SEQ 
Prostate, other/ ANTERIOR APEX, LEFT- BConsult
**NAME[ZZZ YYY XXX], M.D. (selected slides).
FINAL DX:

A. Right anterior apex:
-Fibrovascular tissue and skeletal muscle showing no diagnostic abnormalities.
-No evidence of malignancy.

B. Left anterior apex:
-Fibrovascular tissue and skeletal muscle showing no diagnostic abnormalities.
-No evidence of malignancy.

C. Left levator:
-Fibrovascular adipose tissue showing no diagnostic abnormalities.
-No evidence of malignancy.

D. Prostate (radical prostatectomy): Invasive adenocarcinoma of prostate with the following features:  Histologic type:   Acinar type.  Gleason's Grade: Total Score 7 of 10.
Primary pattern 3.
Secondary pattern 4.  Extent of invasion:  Focal extraprostatic extension identified left anterior prostate towards     apex, established.
Seminal vesicle is free of neoplasm.  Estimated tumor volume: 4.5 cc.  Margins:   Negative (see comment).  Lymph-vascular invasion:  Not identified.  Pathologic stage:    pT2c, pNX (AJCC 7th edition).  Additional findings:       Focal high grade prostatic intraepithelial neoplasia present.    Focal glandular hyperplasia and focal chronic active inflammation.    Seminal vesicles showing no diagnostic abnormalities.
DIAGNOSIS COMMENTS:
There is a focal area of extraprostatic extension by carcinoma in the left anterior prostate towards the apex in slice 3 (slide D9). This focus of extraprostatic carcinoma involves the green inked surface which corresponds to the staple line which was removed and does not represent a true surgical margin.
MICROSCOPIC:
The final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.
INTRAOPERATIVE DX:
A. Right anterior apex biopsy (frozen section): No evidence of malignancy. 
B. Left anterior apex biopsy (frozen section): No evidence of malignancy. 
C. Left levator biopsy (frozen section): No evidence of malignancy.GROSS:
A. Received fresh, labeled ''**NAME[BBB, AAA] W'' and designated ''A. anterior apex right'', is a 0.7 x 0.4 x 0.2 cm portion of red-tan tissue, submitted entirely for frozen section in A1. 
B. Received fresh, labeled ''**NAME[BBB, AAA] W'' and designated ''B. anterior apex left'', is a 0.6 x 0.3 x 0.2 cm portion of red-tan tissue, submitted entirely for frozen section in B1. 
C. Received fresh, labeled ''**NAME[BBB, AAA] W'' and designated ''C. left levator'', are two 0.5 and 0.8 cm portions of red-tan partially cauterized tissue, submitted entirely for frozen section in C1. (**INITIALS:cmc94 276933) 
D. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''D. prostate gland'', is a 30 g radical prostatectomy specimen. The specimen is 3.7 cm vertically with coronal and sagittal cross-sectional diameters of 4.7 x 3.5 cm and includes a 2.3 x 1 x 0.5 cm left seminal vesicle and a 3 x 0.5 cm left vas; a 2.5 x 1.5 x 0.5 cm right seminal vesicle and a 3.2 x 0.5 cm right vas. The surface is inked as follows: anterior - blue, posterior - black, right lateral -orange, left lateral - yellow. There is an anterior 2.5 cm staple line which is inked green. The specimen is sectioned from apex to base into 12 slices numbered respectively (apex=slice 1). There is moderate periurethral nodularity as well as moderate diffuse cystic change. Discrete lesions or masses are not identified. A photograph is taken and representative sections are submitted as follows: D1 - right and left seminal vesicles and vas deferens; D2 - right bladder neck margin, radially sectioned; D3 - left bladder neck margin, radially sectioned; D4 - right apical margin, radially sectioned; D5 - left apical margin, radially sectioned; D6-D7 - composite slice 2; D8-D9 - composite slice 3; D10-D11 - posterior slice 4; D12-D13 - posterior slice 5; D14-D15 - posterior slice 6; D16 - anterior slice 6; D17-D18 - posterior slice 7; D19-D20 - posterior slice 8; D21-D22 - posterior slice 9; D23-D24 - posterior slice 10; D25-D26 - anterior slice 10; D27-D28 - posterior slice 11; D29-D30 - posterior slice 12 and D31 anterior slice 12. Additional cassettes: D32 - anterior slice 4; D33 - anterior slice 5; D34 - anterior slice 7, bisected; D35 - anterior slice 8, bisected. (RJT/ ks:cmc40 277162) (RJT:cmc31 277509) (RJT:cmc10 277471)
CLINICAL INFO:
Malignant neoplasm of prostate. ICD-9 code: 185.
PATHOLOGIST:
**NAME[WWW VVV M]. 

SNOMED Code(s)
T77500M72421M43005M43001M74001T77230T77102T00100M80001T77100P1100M85503M81403T1X010M09450T13000M09450T13000M09450",,,,,
REG3,PROSTATE,0,PAT-00496774,2,REC-5000718226,,,,"1 ST HISALERT^ALERT   
<FINAL DX>
  A,B) PROSTATE, RIGHT AND LEFT LOBES, NEEDLE BIOPSIES: ADENOCARCINOMA,
GLEASON SCORE 4+3=7.

<PATHOLOGIST>
   **NAME[ZZZ] MD, **NAME[YYY] D.       Electronically Signed: **DATE[Dec 01 2011]
<SPECIMEN(S)>
  A) R prostate
B) L prostate
<CLINICAL INFO>
  Elevated PSA
<GROSS>
  A) Received in a container labeled with the patient's name and ""R"" are
five yellow-tan soft tissue needle cores, 6.0 cm in aggregate length,
AE/(5). 
B) Received in a container labeled with the patient's name and ""L"" are
four yellow-tan soft tissue needle cores, 6.0 cm in aggregate length, AE/(4)
.
<MICROSCOPIC>
  A,B) Biopsies from both lobes of the prostate show foci of an invasive
adenocarcinoma. On the right side there is a small focus of tumor on one
of five cores. Tumor occupies approximately 5% of the sampled tissues and
has predominantly a Gleason pattern 3 histologic appearance. In other
areas glands have a hyperplastic appearance. No perineural or
lymphovascular invasion is seen. 
On the left side invasive carcinoma is present on one of four cores and
occupies approximately 15% of the total sampled tissues on this side. Most
of the tumor shows Gleason pattern 4 histologic features with a few glands
showing a Gleason 3 pattern. No lymphovascular or perineural invasion is
noted. 
Overall, with the two sides combined a Gleason score of 4+3=7 is the
architectural pattern.",,,,,
REG3,PROSTATE,0,PAT-00735108,1,REC-5000733489,,,,"PART / DESCRIPTION - SEQ 
Prostate, radical resection/ PROSTATE- A
INTRAOPERATIVE DX:
NONEConsult
Dr. **NAME[ZZZ] (QA)
FINAL DX:

Prostate, 40 grams, radical prostectomy: Invasive adenocarcinoma of prostate with the following features:  Histologic type:   Acinar.  Gleason's Grade: Total Score 7 of 10.
Primary pattern 3.
Secondary pattern 4.  Extent of invasion:  Bilateral. (See photo)
Extraprostatic involvement: Negative 
Bilateral seminal vesicles negative for carcinoma.  Estimated tumor volume: 6 cc (including dominant nodule, 2 x 1.1 x 1.9 cm)  Margins:   Carcinoma is present in the tissue submitted from the apex and measures 0.3 mm to the anterior and 1 mm to the posterior inked apical margin.       Tissue from the prostatic base is negative for carcinoma.       Lateral margins are all negative for carcinoma.  Lymph-vascular invasion:  Not identified.  Perineurial invasion:   Present, focal.  Pathologic stage:   pT2c, pNX (AJCC 7th edition).  Additional findings:   High grade prostatic intraepithelial neoplasia. 

MICROSCOPIC:
Unless 'gross exam' is specified, the final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.GROSS:
Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''A. prostate gland'', is a 40 g radical prostatectomy specimen. The specimen is 4.0 cm vertically with coronal and sagittal cross-sectional diameters of 4.5 x 3.5 cm and includes a 1.5 x 1.5 x 0.7 cm left seminal vesicle and a 3.5 x 0.5 cm left vas; a 2.6 x 1.5 x 1.3 cm right seminal vesicle and a 4.5 x 0.5 cm right vas. The surface is inked as follows: anterior - blue, posterior - black, right lateral -orange, left lateral - yellow. There is a 2 cm anterior staple line which is inked green. The specimen is sectioned from apex to base into 12 slices numbered respectively (apex equals slice 1). There is mild periurethral nodularity with no discrete lesions or masses identified. A photograph is taken and representative sections are submitted as follows: A1 - right and left seminal vesicles and vas deferens; A2 - right bladder neck margin, radially sectioned; A3 - left bladder neck margin, radially sectioned; A6 and A7 - composite slice 2; A8 and A9 - composite slice 3; A10 and A11 - posterior slice 4; A12 and A13 - posterior slice 5; A14 and A15 - posterior slice 6; A16 - anterior slice 6; A17 and A18 - posterior slice 7; A19 and A20 - posterior slice 8; A21 and A22 - posterior slice 9; A23 - anterior slice 9; A24 and A25 - posterior slice 10; A26 and A27 - posterior slice 11; A28 and A29 - posterior slice 12; and A30 - anterior slice 12. (**INITIALS:cmc20 281736)
CLINICAL INFO:
Malignant neoplasm of prostate.
ICD-9 code: 185.
PATHOLOGIST:
**NAME[YYY XXX] D  

SNOMED Code(s)",,,,,
REG3,PROSTATE,0,PAT-00730428,1,REC-5000741409,,,,"<PATHOLOGIST>

**NAME[ZZZ YYY], M.D.

<CPT CODE(S)>

88305

<FINAL DX>

 PROSTATIC ADENOCARCINOMA. GLEASON's SCORE 7 (GRADES 3 + 4). PERINEURAL INVASION IS PRESENT.

PROSTATIC ADENOCARCINOMA. GLEASON's SCORE 7 (GRADES 3 + 4). PERINEURAL INVASION IS PRESENT.

PROSTATIC ADENOCARCINOMA. GLEASON's SCORE 7 (GRADES 3 + 4). PERINEURAL INVASION IS PRESENT.

PROSTATIC ADENOCARCINOMA. GLEASON's SCORE 6 (GRADES 3 + 3).

PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN), HIGH GRADE.

PROSTATIC ADENOCARCINOMA. GLEASON's SCORE 6 (GRADES 3 + 3). PERINEURAL INVASION IS PRESENT.

<CLINICAL INFO>

PATIENT RACE: CAUCASIAN
PSA 5.69, DRE Normal

<SPECIMEN(S)>

A Prostate Left Base B Prostate Left Mid C Prostate Left Apex D Prostate Right Base E Prostate Right Mid F Prostate Right Apex


<MICROSCOPIC>

 Sections show focal basophilic glands composed of crowded epithelial cells with enlarged nuclei, pleomorphism, hyperchromasia, and prominent nucleoli. 

 


**DATE[Jul 07 12]",,,,,
REG3,PROSTATE,0,PAT-00730237,1,REC-5000741536,,,,"<CLINICAL INFO>

Prostate carcinoma.

<FINAL DX>
A. RIGHT PELVIC LYMPH NODE: ONE BENIGN NODE (0/1).
B. LEFT PELVIC LYMPH NODES: SIX BENIGN NODES (0/6).
C. TISSUE DESIGNATED ""POSTERIOR MARGIN APEX"": FRAGMENTS OF PROSTATE GLAND FOCALLY POSITIVE FOR ADENOCARCINOMA, GLEASON GRADE 3 + 3 = 6 CARCINOMA EXTENDS TO EDGE OF ONE OF THE PIECES.
D. PROSTATE GLAND: ADENOCARCINOMA.
1. PROCEDURE: RADICAL PROSTATECTOMY.
2. PROSTATE SIZE: 54 GRAMS.
3. LYMPH NODE SAMPLING: PELVIC LYMPH NODE DISSECTION (PARTS A AND B),
4. HISTOLOGIC TYPE: ADENOCARCINOMA (ACINAR, NOT OTHERWISE SPECIFIED).
5. HISTOLOGIC GRADE: GLEASON PATTERN 3 + 3 = TOTAL GLEASON SCORE 6.
6. TUMOR QUANTITATION: PORTION OF PROSTATE INVOLVED BY TUMOR: LESS THAN 5%
7. EXTRAPROSTATIC EXTENSION: NOT IDENTIFIED IN PROSTATECTOMY SPECIMEN,
8. SEMINAL VESICLE INVASION: NOT IDENTIFIED.
9. MARGINS: MARGIN FOCALLY INVOLVED BY INVASIVE CARCINOMA IN REGION OF RIGHT APEX.
10. TREATMENT EFFECT ON CARCINOMA: NOT IDENTIFIED.
11. LYMPH-VASCULAR INVASION: NOT IDENTIFIED.
12. PERINEURAL INVASION: NOT IDENTIFIED.
13. PATHOLOGIC STAGING:
PRIMARY TUMOR: pT2c (BILATERAL).
REGIONAL LYMPH NODES: pN0
METASTASES: NOT APPLICABLE
14. ADDITIONAL PATHOLOGIC FINDINGS: EXTENSIVE INVOLVEMENT BY HIGH GRADE PROSTATE INTRAEPITHELIAL NEOPLASIA.
15. ANATOMIC STAGE: 11B

<DIAGNOSIS COMMENTS>
This case was seen in consultation with Dr. **NAME[ZZZ].

<GROSS>
A. A 2 cm fatty lymph node is sectioned in one cassette.
B. About 5 ml of fat containing three or four possible small nodes. The nodes are submitted in ""B1"" while the remainder of the fat is submitted in ""B2"".
C. Four irregular fragments of tan brown tissue range up to 1 cm in greatest size. The pieces are sectioned and submitted in one cassette.
D. This is a prostate gland with attached bilateral seminal vesicles. A suture marks the right posterior lobe. The right seminal vesicle is sampled in ""Dl"" while the left seminal vesicle is sampled in ""D2"". The gland alone weighs 54 grams and externally appears normal. The right side is inked blue and the left side green. Perpendicular samples from the apex are submitted in ""D3"" and ""D4"". Samples perpendicular to the bladder neck are submitted in ""D5"" and ""D6"". Sectioning the gland shows pronounced fibroglandular nodular hyperplasia centrally while the periphery is slightly firmer but no discrete tumor nodules are evident. Samples predominantly from the posterior peripheral zone are submitted in ""D7"" through ""D17"" from apex through base.

<MICROSCOPIC>
A. Levels through the right pelvic lymph node show no evidence of malignancy.
B. Levels through the left pelvic lymph node tissues show 6 small benign lymph nodes.
C. The posterior margin apex tissue shows portions of prostate gland with chronic inflammation, fibrosis and a 3 mm focus of Gleason grade 3 adenocarcinoma which extends to an edge of one of the pieces. The tumor consists of well formed acini lined by a single layer of cells with round nuclei with pale chromatin and distinct nucleoli.
D. Samples from the prostate gland show numerous foci of high grade prostate intraepithelial neoplasia throughout the gland. In addition are a few small foci of invasive carcinoma of Gleason pattern ""C"" consisting of well formed circular and slightly angulated acini lined by a single layer of cells with enlarged round nuclei with nucleoli. The carcinoma is confined to the apical half of the gland in the posterior portion. Tumor focally is seen in a sample of the right apical margin with extension to the inked surface. The largest focus of carcinoma is 0.4 cm. Invasive tumor occupies less than 5% of the sampled gland volume. Seminal vesicles are free of tumor. No definite extraprostatic extension is seen.",,,,,
REG3,PROSTATE,0,PAT-00559793,2,REC-5000741644,,,,"CASE: ***PATH-NUMBER[1]
PATIENT: **NAME[AAA BBB]

Final Diagnosis:
[A] Prostate, Left Base, Needle Core Biopsy:  Benign prostatic tissue.
[B] Prostate, Left Mid, Needle Core Biopsy:  Adenocarcinoma. Gleason
score 3 + 4 = 7, involving 1 core(s) with area(s) of involvement
measuring 1 mm representing 4% of the biopsy tissue.  No perineural
invasion identified. Negative for high - grade prostatic intraepithelial
neoplasia.
[C] Prostate, Left Apex, Needle Core Biopsy:  Benign prostatic tissue.
[D] Prostate, Right Base, Needle Core Biopsy:  Adenocarcinoma. Gleason
score 3 + 3 = 6, involving 3 core(s) with area(s) of involvement
measuring 10 mm representing 42% of the biopsy tissue.  No perineural
invasion identified. Negative for high - grade prostatic intraepithelial
neoplasia.
[E] Prostate, Right Mid, Needle Core Biopsy:  Adenocarcinoma. Gleason
score 3 + 4 = 7, involving 2 core(s) with area(s) of involvement
measuring 9 mm representing 43% of the biopsy tissue.  No perineural
invasion identified. Negative for high - grade prostatic intraepithelial
neoplasia.
[F] Prostate, Right Apex, Needle Core Biopsy:  Adenocarcinoma. Gleason
score 3 + 3 = 6, involving 1 core(s) with area(s) of involvement
measuring 3 mm representing 14% of the biopsy tissue.  No perineural
invasion identified. Negative for high - grade prostatic intraepithelial
neoplasia.

Prostate Diagram    Images

Unlabeled sections indicate no sample received.   Microscopic Image(s)

A1-1: E. Right mid prostate

Final Diagnosis for each specimen is based on microscopic examination.

Additional Comments

Specimen Summary
Specimen  Pieces    Spec Length [cm]    Gross Description   Receipt
Notes
[A] Prostate, Left Base, Needle Core Biopsy  4    0.3-1.1   tan-white
Specimen received in formalin with two identifiers.
[B] Prostate, Left Mid, Needle Core Biopsy   3    0.6-1.3   tan-white
Specimen received in formalin with two identifiers.
[C] Prostate, Left Apex, Needle Core Biopsy  2    0.6, 1    tan-white
Specimen received in formalin with two identifiers.
[D] Prostate, Right Base, Needle Core Biopsy      4    0.5-1
tan-white Specimen received in formalin with two identifiers.
[E] Prostate, Right Mid, Needle Core Biopsy  2    1.3, 1.5  tan-white
Specimen received in formalin with two identifiers.
[F] Prostate, Right Apex, Needle Core Biopsy      2    1, 1.3
tan-white Specimen received in formalin with two identifiers.

<CLINICAL INFO>
ICD-9 Code(s): 790.93 - elevated PSA.  (ke/cm)

INTRADEPARTMENTAL CONSULT:
**NAME[M. ZZZ], M.D.

**NAME[M. YYY XXX], M.D.  Electronically signed **DATE[Aug 19 2012]",,,,,
REG3,PROSTATE,0,PAT-00263726,1,REC-5000747325,,,,"<CLINICAL HX>
**AGE[in 80s] year old male. Hx prostate CA. Lung mass.  

<HISTOLOGY COMMENT>



<GROSS>
In formalin labeled ""R lung"" are approximately six 1 mm in diameter and 2-4 mm in length needle biopsy cores. Entirely submitted in cassette A1. as


<COMMENT>
 

<MICROSCOPIC>
 

<FINAL DX>
LUNG, RIGHT, ""MASS"", NEEDLE BIOPSY:  INVASIVE, MODERATELY DIFFERENTIATED NON-SMALL CELL, SQUAMOUS CARCINOMA  SEE IMMUNOHISTOCHEMISTRY

<ANCILLARY STUDIES>
 

<EXTERNAL CONSULTATION>
 

<INTRADEPARTMENTAL CONSULTATION>
 

<NOTIFICATION>
 

<PRELIM DX>
 

<CHECKLIST>
 

<IMMUNOHISTOCHEMISTRY>
A panel of immunohistochemical stains were performed on the paraffin-embedded tissue in block A, and the results of this analysis are presented in the table below.  INTERPRETATION: This staining profile is diagnostic of invasive, non-small cell, squamous carcinoma.

<INDICATIORS>
 

<SPECIAL STAINS>",,,,,
REG3,PROSTATE,0,PAT-00721275,1,REC-5000753400,,,,"PART / DESCRIPTION - SEQ 
Prostate, other/ APICAL MARGIN #2- C
PART / DESCRIPTION - SEQ 
Prostate, other/ APICAL MARGIN- B
PART / DESCRIPTION - SEQ 
Prostate, radical resection/ PROSTATE- D
PART / DESCRIPTION - SEQ 
Prostate, other/ LEFT POSTERIOR BORDER OF PROSTATE- AConsult
**NAME[ZZZ YYY XXX], WWW], Ph.D. (QA)
FINAL DX:

a. Left posterior border of prostate, biopsy:
-Fibrovascular tissue with nerve fibers.
-No glandular prostate tissue identified.
-No evidence of malignancy.

b. Apical margin:
-Skeletal muscle and fibroglandular prostate tissue.
-No evidence of malignancy.

c. Apical margin No. 2:
-Skeletal muscle showing no diagnostic abnormalities.
-No prostate tissue identified.
-No evidence of malignancy.

d. Prostate (radical prostatectomy): Invasive adenocarcinoma of prostate with the following features:  Histologic type:   Acinar type.  Gleason's Grade: Total Score 7 of 10.
Primary pattern 3.
Secondary pattern 4.  Extent of invasion:  Predominantly involving left posterior lateral gland with single      microscopic focus in posterior right lobe (see photo).
Extraprostatic involvement: Absent
Seminal vesicle involvement: Absent.  Estimated tumor volume: 0.5. cc.  Margins:   Free of neoplasm.  Lymph-vascular invasion:  Not identified.  Pathologic stage:   pTc, pNX (AJCC 7th edition).  Additional findings:   Focal high grade prostatic intraepithelial neoplasia.       Fibroglandular hyperplasia and chronic active prostatitis.       Posterior periprostatic tissue showing fibrosis with hemosiderin      pigment deposition.       Seminal vesicles showing no diagnostic abnormalities.
MICROSCOPIC:
The final diagnosis for each specimen is based on a microscopic examination of the tissue(s)/cells.
INTRAOPERATIVE DX:
A. Left posterior border of prostate (frozen section): Fibrovascular tissue with nerve fibers. No glandular prostate tissue and no evidence of malignancy.
B. Apical margin (frozen section): Skeletal muscle and fibroglandular prostate tissue. No malignancy identified.
Apical margin No. 2 (frozen section): Sections of tissue from margin surface reveal skeletal muscle without glandular prostate tissue.GROSS:
A. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''A. left posterior border of prostate'', is a 0.7 x 0.5 x 0.1 cm, tan-yellow portion of soft tissue which is frozen and submitted entirely in A1.
B. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''B. apical margin'', is a 0.5 x 0.5 x 0.1 cm, tan-yellow portion of soft tissue which is frozen and submitted entirely in B1.
C. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''C. apical margin No. 2'', is a 0.7 x 0.5 x 0.2 cm, tan-pink portion of soft tissue which is frozen and submitted entirely in C1.
D. Received fresh, labeled ''**NAME[BBB, CCC]' and designated ''D. prostate'', is a 48-g radical prostatectomy specimen. The specimen is 4.5 cm vertically with coronal and sagittal cross-sectional diameters of 5.3 x 4.3 cm and includes a 3.2 x 1.2 x 0.8 cm left seminal vesicle and a 3.2 x 0.5 cm left vas; a 3.5 x 1.4 x 1.0 cm right seminal vesicle and a 3.5 x 0.5 cm right vas. The surface is inked as follows: anterior - blue, posterior - black, right lateral -orange, left lateral - yellow. The specimen is sectioned from apex to base into 15 slices numbered respectively (apex = slice 1). There is marked periurethral nodularity as well as minimal diffuse cystic change. Discrete lesions or masses are not identified. A photograph is taken and representative sections are submitted as follows: D1 - right and left seminal vesicles and vas deferens; D2 - right bladder neck margin, radially sectioned; D3 - left bladder neck margin, radially sectioned; D4 - right apical margin, radially sectioned; D5 - left apical margin, radially sectioned; D6-D7 - composite slice 2; D8-D9 - posterior slice 3; D10-D11 - posterior slice 5; D12-D13 - posterior slice 6; D14-D15 - anterior slice 6; D16-D17 - posterior slice 8; D18-D20 - posterior slice 9; D21-D22 - anterior slice 9; D23-D25 - posterior slice 11; D26-D27 - posterior slice 12; D28-D29 - anterior slice 12; D30-D31 - posterior slice 14; D32-D33 - composite slice 15. An additional representative section is submitted as follows: D34 - left posterior two-thirds of slice 4. (**INITIALS:cmc10 293930) (RJT/cmc40 294313) (**INITIALS:cmc40 294341)
CLINICAL INFO:
Malignant neoplasm of prostate. ICD-9 code: 185.
PATHOLOGIST:
**NAME[VVV UUU M]. 

SNOMED Code(s)
T13000T00100M09450TX9001T77230T77100P1140T77580T77500M72000M57500M55000M49000M43005M74001M09400M80001M09450T77100P1100M85503M81403T13000T00100M09450M09070T77102T77100M09070",,,,,
REG3,PROSTATE,0,PAT-00738840,1,REC-5000754909,,,,"<CLINICAL INFO>
Elevated PSA

<GROSS>
Received in 24 GI fixative-containing bottles, labeled # , are 0.1 cm in diameter core biopsy fragments, submitted in total as follows: 
1.     Right apex anterior:  one core, 2.6 cm in length.  SECTIONS:  A1.
2.     Right apex anterior lateral:  one core, 2.4 cm in length.  SECTIONS:  B1.
3.     Right apex posterior lateral:  one core, 1.9 cm in length.  SECTIONS:  C1.
4.     Right apex posterior:  one core, 1.9 cm in length.  SECTIONS:  D1.
5.     Left apex posterior:  one core, 2.1 cm in length.  SECTIONS:  E1.
6.     Left apex posterior lateral:  one core, 1.6 cm in length.  SECTIONS:  F1.
7.     Left apex anterior lateral:  one core, 2.2 cm in length.  SECTIONS:  G1.
8.     Left apex anterior:  one core, 2.2 cm in length.  SECTIONS:  H1.
9.     Right mid anterior:  one core, 2.2 cm in length.  SECTIONS:  I1.
10.     Right mid anterior lateral:  one core, 1.7 cm in length.  SECTIONS:  J1.
11.     Right mid posterior lateral:  two cores, 0.2 and 1.2 cm in length.  SECTIONS:  K1.
12.     Right mid posterior:  one core, 2.0 cm in length.  SECTIONS:  L1.
13.     Left mid posterior:  one core, 2.1 cm in length.  SECTIONS:  M1.
14.     Left mid posterior lateral:  one core, 2.0 cm in length.  SECTIONS:  N1.
15.     Left mid anterior lateral:  one core, 1.9 cm in length.  SECTIONS:  O1.
16.     Left mid anterior:  one core, 1.8 cm in length.  SECTIONS:  P1.
17.     Right base anterior:  one core, 1.7 cm in length.  SECTIONS:  Q1.
18.     Right base anterior lateral:  one core, 2.0 cm in length.  SECTIONS:  R1.
19.     Right base posterior lateral:  two cores, 0.4 and 1.4 cm in length.  SECTIONS:  S1.
20.     Right base posterior:  one core, 2.2 cm in length.  SECTIONS:  T1.
21.     Left base posterior:  one core, 2.0 cm in length.  SECTIONS:  U1.
22.     Left base posterior lateral:  one core, 2.0 cm in length.  SECTIONS:  V1.
23.     Left base anterior lateral:  one core, 2.1 cm in length.  SECTIONS:  W1.
24.     Left base anterior:  one core, 1.5 cm in length.  SECTIONS:  X1.


<MICROSCOPIC SECTION>

<FINAL DX>
     1.     PROSTATE, RIGHT APEX ANTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 60% of the submitted core.
     A.     The linear amount of cancer is 11 mm.
     B.     Perineural invasion is not present.
2.     PROSTATE, RIGHT APEX ANTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 30% of the submitted core.
     A.     The linear amount of cancer is 5 mm.
     B.     Perineural invasion is present.
5.     PROSTATE, LEFT APEX POSTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 74% of the submitted core.
     A.     The linear amount of cancer is 10 mm.
     B.     Perineural invasion is not present.
6.     PROSTATE, LEFT APEX POSTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 95% of the submitted core.
     A.     The linear amount of cancer is 15 mm.
     B.     Perineural invasion is not present.
7.     PROSTATE, LEFT APEX ANTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 8 (3+5), involving approximately 95% of the submitted core.
     A.     The linear amount of cancer is 12 mm.
     B.     Perineural invasion is not present.
8.     PROSTATE, LEFT APEX ANTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 85% of the submitted core.
     A.     The linear amount of cancer is 15 mm.
     B.     Perineural invasion is not present.
9.     PROSTATE, RIGHT MID ANTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 40% of the submitted core.
     A.     The linear amount of cancer is 7.5 mm.
     B.     Perineural invasion is present.
10.     PROSTATE, RIGHT MID ANTERIOR LATERAL, CORE NEEDLE BIOPSY:
     A small focus of prostatic adenocarcinoma, Gleason score 7 (3+4), involving less than 5% of the submitted core.
     A.     The linear amount of cancer is 0.5 mm.
     B.     Perineural invasion is not present.
     11.     PROSTATE, RIGHT MID POSTERIOR LATERAL, CORE NEEDLE BIOPSY:
     A small focus of prostatic adenocarcinoma that is too small to grade, involving less than 5% of the submitted core.
     A.     The linear amount of cancer is 0.2 mm.
     B.     Perineural invasion is not present.
13.     PROSTATE, LEFT MID POSTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 8 (4+4), involving approximately 90% of the submitted core.
     A.     The linear amount of cancer is 15 mm.
     B.     Perineural invasion is not present.
14.     PROSTATE, LEFT MID POSTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 95% of the submitted core.
     A.     The linear amount of cancer is 15 mm.
     B.     Perineural invasion is present.
15.     PROSTATE, LEFT MID ANTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 95% of the submitted core.
     A.     The linear amount of cancer is 15 mm.
     B.     Perineural invasion is not present.
     16.     PROSTATE, LEFT MID ANTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 80% of the submitted core.
     A.     The linear amount of cancer is 12 mm.
     B.     Perineural invasion is not present.
17.     PROSTATE, RIGHT MID ANTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 80% of the submitted core.
     A.     The linear amount of cancer is 11 mm.
     B.     Perineural invasion is not present.
18.     PROSTATE, RIGHT BASE ANTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 7 (4+3), involving approximately 40% of the submitted core discontinuously.
     A.     The linear amount of cancer is 8 mm.
     B.     Perineural invasion is not present.
21.     PROSTATE, LEFT BASE POSTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 80% of the submitted core.
     A.     The linear amount of cancer is 14.5 mm.
     B.     Perineural invasion is not present.
22.     PROSTATE, LEFT BASE POSTERIOR LATERAL, CORE NEEDLE BIOPSY:
          Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 95% of the submitted core.
     A.     The linear amount of cancer is 17 mm.
     B.     Perineural invasion is not present.
     23.     PROSTATE, LEFT BASE ANTERIOR LATERAL, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 60% of the submitted core discontinuously.
     A.     The linear amount of cancer is 11 mm.
     B.     Perineural invasion is not present.
     
     24.     PROSTATE, LEFT BASE ANTERIOR, CORE NEEDLE BIOPSY:
     Prostatic adenocarcinoma, Gleason score 9 (4+5), involving approximately 95% of the submitted core.
     A.     The linear amount of cancer is 14 mm.
     B.     Perineural invasion is not present.
     
     3.     PROSTATE, RIGHT APEX POSTEROLATERAL, CORE NEEDLE BIOPSY:
     Focal high-grade prostatic intraepithelial neoplasia (PIN).
4,12,
19-20.     PROSTATE, SITES AS DESIGNATED BELOW, CORE NEEDLE BIOPSIES:
          Benign prostatic tissue.







<SPECIMEN(S)>
rmal
<SPECIMEN(S)>
rbp
<SPECIMEN(S)>
rma
<SPECIMEN(S)>
rbpl
<SPECIMEN(S)>
rbal
<SPECIMEN(S)>
laa
<SPECIMEN(S)>
raa
<SPECIMEN(S)>
rmpl
<SPECIMEN(S)>
lbp
<SPECIMEN(S)>
rba
<SPECIMEN(S)>
lmp
<SPECIMEN(S)>
lbal
<SPECIMEN(S)>
rmp
<SPECIMEN(S)>
lbpl
<SPECIMEN(S)>
raal
<SPECIMEN(S)>
rapl
<SPECIMEN(S)>
rap
<SPECIMEN(S)>
lmal
<SPECIMEN(S)>
lap
<SPECIMEN(S)>
lmpl
<SPECIMEN(S)>
lba
<SPECIMEN(S)>
lma
<SPECIMEN(S)>
lapl
<SPECIMEN(S)>
laal",,,,,
REG3,PROSTATE,0,PAT-00493307,3,REC-5000762470,,,,"<SPECIMEN(S)> 
A. Ureter -Left ureteral margin 
B. Ureter -Right ureteral margin 
C. Bladder -Bladder and prostate 
D. Pelvic Lymph Nodes -Right pelvic lymph node 
E. Pelvic Lymph Nodes -Left pelvic lymph node 
F. Ureter -Left terminal ureter 
G. Ureter -Right terminal ureter 

 
<CLINICAL INFO> 
Bladder cancer 188.9, 189.2 

<FINAL DX> 
A. Left ureteral margin: 
Cross-section of ureter negative for malignancy. 
B. Right ureteral margin: 
Cross-section of ureter negative for malignancy. 
C. Urinary bladder with attached prostate gland: 
Urothelial carcinoma 
Specimen: Distal ureters in continuity with urinary bladder and attached prostate 
gland. 
Procedure: Radical cystectomy, prostatectomy and bilateral pelvic node 
dissection. 
Tumor size: 2.5 cm in greatest dimension. 
Histologic type: Papillary urothelial carcinoma. 
Associated epithelial lesions: Adjacent urothelial carcinoma in situ. 
Histologic grade: High-grade. 
Microscopic tumor extension: Tumor confined to mucosa. 
Margins: All margins free of involvement. 
Lymph-vascular invasion: Not identified. 
Other: Single focus of prostatic adenocarcinoma (C26); grade 3 + 4, score 7. 
AJCC (7th ed.) pathologic stage: pTa pN0. 
D. Right pelvic lymph node: 
One node negative for metastatic carcinoma. 
E. Left pelvic lymph nodes: 
Four nodes negative for metastatic carcinoma. 
F. Left terminal ureter: 
Negative for malignancy. 
G. Right terminal ureter: 
Negative for malignancy. 
This case has been subjected to review by a second pathologist per departmental quality 
assurance (QA) policy. 
DN/dh 

 

<FINAL DX> (Continued) 

<GROSS> 
Received are seven containers labeled `**NAME[BBB, AAA M]. H000795112' with requisition `**NAME[BBB, 
AAA M]. H000795112'. 
The first is designated `left ureteral margin' and is received without fixative. It is a 
red-yellow tissue 1.0 x 0.8 x 0.4 cm which contains a white 0.2 cm tissue consistent with 
ureter, which has a less than 0.1 cm lumen. Intraoperative frozen section report by Dr. **NAME[ZZZ] 
of: `Negative for carcinoma'. All tissue in AFS. 
The second is designated `right ureteral margin' and is received without fixative. It is a 
0.5 cm red tissue which is marked with ink and has a 0.1 cm lumen. Intraoperative frozen 
section report by Dr. **NAME[ZZZ] of: `Proximal aspect negative for carcinoma'. All tissue in BFS. 
The third is designated `bladder and prostate' and is received in formalin with the 
specimen subsequently inflated with formalin and allowed to fix. It consists of a bladder 
which after formalin inflation is 11.0 x 9.0 x 5.0 cm and a prostate which is 4.5 cm from 
right to left, 5.0 cm from anterior to posterior and 3.8 cm from superior to inferior. 
The bladder is opened anteriorly and at 5.0 cm from the urethral margin surrounding the 
right ureteral orifice, is an exophytic papillated mass 1.5 x 1.0 cm. The cut surface of 
this appears grossly invasive and partially fills the lumen of the right ureter in a 1.5 cm 
zone. The more distal portion of the ureter appears grossly unremarkable. The remaining 
bladder muocsa has scattered diverticula but no areas of redness. The prostate is inked 
blue on the right and black on the left. The cut surface of the prostate is tan-pink tissue 
without grossly suspicious feature. 
No lymph nodes are identified in the attached adipose tissue. 
Summary of Sections: 
C1-C2 Urethral margin 
C3-C7 Exophytic papillated mass surrounding right ureteral orifice 
C8 Possible right ureter 
C9 Possible left ureter, ink is non-marginal seepage 
C10 Bladder diverticula on right side, approximately 10:00 
C11 Superficial sections of bladder mucosa, approximately 12:00 
C12 Superficial sections of bladder mucosa, approximately 3:00, left side 
C13 Superficial sections of bladder mucosa, approximately 5:00, left side 
C14 Intersection right seminal vesicle and prostate 
C15-C20 Right side prostate sequentially submitted from anterior to posterior 
C21 Intersection left seminal vesicle and prostate 
C22-C26 Left side prostate sequentially submitted from anterior to posterior 
The fourth is designated `right pelvic lymph node' and is yellow adipose tissue in aggregate 
6.0 x 5.5 x 3.0 cm. This has tentatively identified lymph nodes up to 1.5 cm. One lymph 
node subsectioned in D1 through D3. 
The fifth is designated `left pelvic lymph node' and is yellow-red adipose tissue 8.0 x 6.5 
x 3.0 cm. This has tentatively identified lymph nodes up to 3.0 x 1.5 cm. 

 

<GROSS> (Continued) 
Summary of Sections: 
E1-E6 One lymph node subsectioned 
E7 One lymph node subsectioned 
E8 One lymph node subsectioned 
E9-E20 One lymph node subsectioned 
The sixth is designated `left terminal ureter' and is a 0.8 cm in length grey-tan 
cylindrical tissue with a diameter of 0.3 cm. There is a stitch at one end and this end is 
inked violet. The opposite end is inked orange. The tissue is sectioned and submitted in 
F. 
The seventh is designated `right terminal ureter' and is a cylindrical grey-tan tissue 0.6 
cm in length with a diameter of 0.4 cm. One end has a suture and this end is inked violet; 
the opposite end is inked black. It is sectioned and entirely submitted in G. 
JR/ab 

<MICROSCOPIC> 
Microscopic examination supports the final diagnosis.",,,,,
REG3,PROSTATE,0,PAT-00617539,1,REC-5000770230,,,,"<FINAL DX>
  A) PELVIC LYMPH NODES:  FIBROADIPOSE SOFT TISSUE
COMMENT: Lymphoid tissue is not present in the histologic sections examined.
B) R. PELVIC LYMPH NODES: FIBROADIPOSE SOFT TISSUE
COMMENT:  Lymphoid tissue is not present in the histologic sections examined
C) PROSTATE AND SEMINAL VESICLES:  ADENOCARCINOMA OF PROSTATE, GLEASON
SCORE 3+3=6
1. SIZE: ADENOCARCINOMA IS PRESENT IN 5 OF 16 TISSUE SECTIONS. THE LARGEST
FOCUS MEASURES APPROXIMATELY 0.8CM IN GREATEST DIMENSION.
2. EXTRAPROSTATIC EXTENSION: NOT IDENTIFIED
3. SEMINAL VESICLE INVASION: NOT PRESENT
4. MARGINS: NEGATIVE FOR MALIGNANCY
5. LYMPH VASCULAR INVASION: NOT IDENTIFIED
6. PERINEURAL INVASION: NOT IDENTIFIED
7. TNM: pT2c pN0 pMx

<PATHOLOGIST>
   **PLACE, Sony               Electronically Signed: **DATE[May 02 2012]
<SPECIMEN(S)>
  A) L. PELVIC LYMPH NODES
B) R. PELVIC LYMPH NODES
C) PROSTATE & Seminal vesicles
<GROSS>
  A) Received in formalin is an aggregate of tan yellow adipose tissues
measuring 1.0 cm in greatest dimension.  No obvious lymph node material is
noted grossly.  The tissues are all embedded in cassette A. 
B) Received is an aggregate of tan yellow adipose tissues measuring 2.2 x
2.0 x 0.4 cm.  No obvious lymph node material is noted grossly. All
embedded cassette B1.
C) Received in formalin is a 33 gram prostate with attached seminal
vesicles and segments of vas deferens.  The right side is inked black and
the left side is inked blue. Sections through the prostate parenchyma show
nodular tan yellow tissues throughout.  Discrete mass lesions are not
evident. Representative sections submitted as follows:
C1) right apical margin
C2-C6) right apex to base
C7) right bladder neck margin
C8) left apex margin
C9-C13) left apex to left base
C14) left bladder neck margin
C15) right vas and seminal vesicle.
C16) left vas and seminal vesicle.
<MICROSCOPIC>
  Sections examined",,,,,
REG3,PROSTATE,0,PAT-00714449,2,REC-5000775193,,,,"PART / DESCRIPTION - SEQ# 
Prostate, needle bx,LA/ Prostate, Left Apex- 1
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,RMS/ Prostate, Right Mid Sagittal- 6
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,RL/ Prostate, Right Lateral- 8
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,RA/ Prostate, Right Apex- 5
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,LMS/ Prostate, Left Mid Sagittal- 2
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,RB/ Prostate, Right Base- 7
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,LB/ Prostate, Left Base- 3
PART / DESCRIPTION - SEQ# 
Prostate, needle bx,LL/ Prostate, Left Lateral- 4
<INTRAOPERATIVE DX>
NONE
<MICROSCOPIC>
NONE
<DIAGNOSIS COMMENTS>
Immunohistochemistry for p63, 334betaE12, and AMACR was performed on specimens 1 and 8.
<FINAL DX>
1). Left Apex prostate, needle biopsies: Prostatic tissue with moderately differentiated prostatic adenocarcinoma, Gleason score 3+3 = 6, involving 1 of 2 cores or a total length of 0.1 cm of 1.8 cm cores
2). Left mid sagittal prostate, needle biopsies: Prostatic tissue with no specific pathologic changes, negative for malignancy
3). Left base prostate, needle biopsies: Prostatic tissue with no specific pathologic changes, negative for malignancy
4). Left lateral prostate, needle biopsies: Prostatic tissue with no specific pathologic changes, negative for malignancy
5). Right Apex prostate, needle biopsies: Prostatic tissue with no specific pathologic changes, negative for malignancy
6). Right mid sagittal prostate, needle biopsies: Prostatic tissue with no specific pathologic changes, negative for malignancy
7). Right prostate, needle biopsies: Prostatic tissue with no specific pathologic changes, negative for malignancy
8). Right lateral prostate, needle biopsies: Prostatic tissue with moderately differentiated prostatic adenocarcinoma, Gleason score 3+3 = 6, involving 1 of 2 cores for a total length of 0.1 cm of 2.0 cm cores

**DATE[Jul 9 2012] PNM
<GROSS>
The specimen is received in eight formalin filled containers labeled with the patient's name.

1). The specimen is sublabeled ""left apex"" and consists of two serpentine fragment(s) of light tan tissue measuring up to 1.3 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 1A.

2). The specimen is sublabeled ""left mid sagittal"" and consists of one serpentine fragment(s) of light tan tissue measuring 1.7 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 2A.

3). The specimen is sublabeled ""left base"" and consists of one serpentine fragment(s) of light tan tissue measuring 1.2 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 3A.

4). The specimen is sublabeled ""left lateral"" and consists of two serpentine fragment(s) of light tan tissue measuring up to 1.6 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 4A.

5). The specimen is sublabeled ""right apex"" and consists of two serpentine fragment(s) of light tan tissue measuring up to 1.4 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 5A.

6). The specimen is sublabeled ""right mid sagittal"" and consists of one serpentine fragment(s) of light tan tissue measuring 2.2 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 6A.

7). The specimen is sublabeled ""right base"" and consists of one serpentine fragment(s) of light tan tissue measuring 1.6 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 7A.

8). The specimen is sublabeled ""right lateral"" and consists of two serpentine fragment(s) of light tan tissue measuring up to 1.7 x 0.1 cm. The specimen is entirely submitted between sponges as cassette 8A. **DATE[Jul 9 2012] PNM/AO
<CLINICAL INFO>
Elevated PSA 4.5
790.93<PATHOLOGIST>
**NAME[ZZZ YYY M].

<SNOMED Code(s)>
T77220P1143M814032T77100M09450T77230T77102P1143T77101M09450T77230P1143",,,,,
REG3,PROSTATE,0,PAT-00737374,1,REC-5000775486,,,,"<CLINICAL HX>
Malignant neoplasm of Prostate gland. Benign Prostatic Hypertrophy with urinary obstruction.  

<HISTOLOGY COMMENT>








<GROSS>
A.  In formalin labeled ""periprostatic fat"" is a 4.3 x 3.3 x 1.4 cm aggregate of pale yellow fibrofatty tissue. Submitted entirely in cassettes A1-A3.
B.  In formalin labeled ""prostate gland"" is a 60 gm prostate that measures 4.6 cm right to left, 4.5 cm anterior to posterior, and 5.0 cm superior to inferior. The right seminal vesicle measures 1.2 x 1.0 x 2.0 cm and the left, 2.3 x 0.4 x 2.5 cm. The right vas deferens measures 3.8 cm in length and the left measures 7-8 mm in diameter and 4.7 cm in length. The left side of the prostate is inked green and the right, yellow. The external surface of the prostate is tan to red-brown, smooth, and glistening. Cassette summary: B1 - left apical margin; B2 - right apical margin; B3-B6 - one cross-section: B3 - 1 LA, B4 - 1 LP, B5 - 1 RA, B6 - 1 RP; B7-B10 - second cross-section: B7 - 2 LA, B8 - 2 LP, B9 - 2 RP, B10 - 2 RA; B11-B14 - fifth cross-section: B11 - 5 LA, B12 - 5 LP, B13 - 5 RP, B14 - 5 RA; B15-B18 - sixth cross-section: B15 - 6 LA, B16 - 6 LP, B17 - 6 RP, B18 - 6 RA; B19-B22 - ninth cross-section: B19 - 9 LA, B20 - 9 LP, B21 - 9 RP, B22 - 9 RA; B23 - base margin; B24 - left seminal vesicle and vas deferens margin and representative section of mid vas deferens and seminal vesicles; B25 - right seminal vesicle and vas deferens margin and a cross-section of the mid vas deferens and seminal vesicle.
C.  In formalin labeled ""Rt external iliac"" are two 1.1 and 1.3 cm yellow-white fibrofatty pieces of tissue with candidate nodes. One of the candidate nodes is inked green and bisected and the other is submitted whole. Entirely submitted in cassette C.
D.  In formalin labeled ""right obturator hypogastric"" is one 3.3 x 2.0 x 0.5 cm fragment of yellow-white fibrofatty tissue. The specimen is bisected revealing one to three possible nodes. Submitted entirely in cassette D.
E.  In formalin labeled ""left external iliac"" are three 7-13 mm yellow-white fibrofatty tissue pieces and candidate nodes. The two larger nodes are inked green and the other yellow. The smaller node remains uninked and submitted whole. The larger inked nodes are bisected. Entirely submitted in cassette E.
F.  In formalin labeled ""left obturator hypogastric"" are two 1.9 and 2.0 cm yellow-white pieces of fatty tissue and possible candidate nodes. The smaller piece is inked yellow and the other green. The specimens are bisected and submitted as follows: Yellow bisected piece in F1 and the green bisected piece in F2.


<COMMENT>


<MICROSCOPIC>


<FINAL DX>
A) SOFT TISSUE, ""PERI-PROSTATIC FAT"", EXCISION:  BENIGN FIBROADIPOSE TISSUE WITH NO SIGNIFICANT HISTOPATHOLOGIC CHANGES  NEGATIVE FOR MALIGNANCY 
B) PROSTATE, SEMINAL VESICLES AND VASA DEFERENTIA, RIGHT AND LEFT, RADICAL  PROSTATECTOMY:  PROSTATIC ADENOCARCINOMA, GLEASON PATTERN 4+5=9  THE CARCINOMA INVOLVES THE LEFT AND RIGHT SIDES OF THE GLAND, AND IS  ORGAN-CONFINED  THE PROXIMAL URETHRAL MARGIN, APICAL MARGIN AND ALL LATERAL MARGINS  ARE NEGATIVE FOR MALIGNANCY  THE SEMINAL VESICLES AND VASA DEFERENTIA ARE NEGATIVE FOR MALIGNANCY  SEE CANCER CHECKLIST. 
C) LYMPH NODES, RIGHT EXTERNAL ILIAC, EXCISION:  TWO (2) LYMPH NODES AND ASSOCIATED FIBROADIPOSE TISSUE SHOWING NO EVIDENCE  OF PRIMARY OR METASTATIC MALIGNANCY  D) LYMPH NODES, RIGHT OBTURATOR HYPOGASTRIC, EXCISION:  THREE (3) LYMPH NODES AND ASSOCIATED FIBROADIPOSE TISSUE SHOWING NO EVIDENCE  OF PRIMARY OR METASTATIC MALIGNANCY  E) LYMPH NODES, LEFT EXTERNAL ILIAC, EXCISION:  THREE (3) LYMPH NODES AND ASSOCIATED FIBROADIPOSE TISSUE SHOWING NO EVIDENCE  OF PRIMARY OR METASTATIC MALIGNANCY  F) LYMPH NODES, LEFT OBTURATOR HYPOGASTRIC, EXCISION:  NINE (9) LYMPH NODES AND ASSOCIATED FIBROADIPOSE TISSUE SHOWING NO EVIDENCE  OF PRIMARY OR METASTATIC MALIGNANCY

<ANCILLARY STUDIES>


<EXTERNAL CONSULTATION>


<INTRADEPARTMENTAL CONSULTATION>


<NOTIFICATION>


<PRELIM DX>


<CHECKLIST>
CANCER CHECKLIST:  PROSTATE GLAND, RADICAL PROSTATECTOMY  AJCC 7TH ED.  PROCEDURE:  RADICAL PROSTATECTOMY PROSTATE SIZE:  Weight: 60 gm.  Size: 4.6 x 4.5 x 5.0 cm LYMPH NODE SAMPLING:  RIGHT EXTERNAL ILIAC (2): NEGATIVE FOR MALIGNANCY  RIGHT OBTURATOR HYPOGASTRIC (3): NEGATIVE FOR MALIGNANCY  LEFT EXTERNAL ILIAC (3): NEGATIVE FOR MALIGNANCY  LEFT OBTURATOR HYPOGASTRIC (9): NEGATIVE FOR MALIGNANCY HISTOLOGIC TYPE:  PROSTATIC ADENOCARCINOMA HISTOLOGIC GRADE:  Primary Gleason Pattern:  4  Secondary Gleason Pattern:  5  Tertiary Pattern:  3  Total Gleason Score:  9 TUMOR QUANTITATION:  Proportion of Prostate Involved by Tumor:  50%  EXTRA-PROSTATIC EXTENSION:  NOT PRESENT SEMINAL VESICLE INVASION:  NOT PRESENT  MARGINS:  NEGATIVE FOR MALIGNANCY TREATMENT EFFECT:  NONE IDENTIFIED LYMPH-VASCULAR INVASION:  NONE IDENTIFIED PERINEURAL INVASION:  PRESENT PATHOLOGIC STAGING (pTNM):  Primary Tumor:  pT2c  Regional Lymph Nodes:  pN0  Distant Metastasis (pM):  pMX  ADDITIONAL PATHOLOGIC FINDINGS: ACUTE AND CHRONIC INFLAMMATION WITH FOCI OF GLANDULAR ATROPHY

<IMMUNOHISTOCHEMISTRY>


<INDICATIORS>


<SPECIAL STAINS>",,,,,
REG1,OTHER,0,39763,3,,"Clinical Diagnosis and History\X0D\\X0A\BLADDER TUMOR\X0D\\X0A\OPER:  CYSTO, TURBT","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: BLADDER TUMOR, LEFT TRIGONE-ls","Final Diagnosis\X0D\\X0A\BLADDER, LEFT TRIGONE, TURBT PROCEDURE:\X0D\\X0A\     HIGH GRADE PAPILLARY UROTHELIAL CARCINOMA.\X0D\\X0A\     NO DEFINITE INVASION OF THE LAMINA PROPRIA IS IDENTIFIED.\X0D\\X0A\    SMALL NARROW BAND OF MUSCULARIS IS INCLUDED AND NOT INVOLVED BY TUMOR.\X0D\\X0A\CLS/in/IHC/MER \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\Received in formalin labeled \""bladder tumor left trigone\"" is a 2.1 x 1.8 x 0.3\X0D\\X0A\cm aggregate of red tan tissue fragments which are totally submitted in one\X0D\\X0A\cassette.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,OTHER,0,58084,3,,"HISTORY: bladder tumor, history of uterine cancer","ICD9 CODES: 188.4, , \X0D\\X0A\COMMENTS: This case also reviewed by Dr. **NAME[ZZZ YYY], who concurs with the diagnosis.","DIAGNOSIS: SPECIMEN SUBMITTED AS \""LEFT POSTERIOR BLADDER WALL TUMOR NEAR BLADDER NECK, TURBT\"":         PAPILLARY UROTHELIAL CARCINOMA, HIGH GRADE.         NO EVIDENCE OF INVASION.         MUSCLE IS PRESENT IN THE BIOPSY.",,"GROSS: Single specimen labeled \""bladder tumor, left posterior bladder wall near bladder neck, TURBT\"" consists of multiple soft tissues up to 2 cm aggregate all in one cassette. DT: **DATE[Jun 05 2012]",MICRO: Sections demonstrate multiple fragments of urothelial tissue.  Papillary urothelial carcinoma is present.  The tumor is high grade.  There is no evidence of invasion. Muscle is present in the biopsy.  DT:  **DATE[Jun 06 2012] (**INITIALS),PROCEDURE: TURBT\X0D\\X0A\SPECIMEN(S): tumor left posterior bladder wall near bladder neck,,
REG1,OTHER,0,160650,4,,Clinical History:\X0D\\X0A\None Given,,"Pre-Operative Diagnosis:\X0D\\X0A\Left Renal Mass\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Left kidney, nephrectomy:\X0D\\X0A\-    Papillary renal cell carcinoma, 9.0 cm, with extensive hemorrhagic\X0D\\X0A\degenerative changes, Fuhrman nuclear grade 3, appearing confined to the\X0D\\X0A\kidney (see synoptic and microscopic description).\X0D\\X0A\-    Renovascular, ureteral, and perinephric soft tissue resection\X0D\\X0A\margins are benign.\X0D\\X0A\-    No lymph nodes identified.\X0D\\X0A\-    Pathologic Stage:  pT2a; pNx.",,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled \""left kidney\"".  The specimen consists of a 575 gram\X0D\\X0A\left kidney with attached perinephric fat and an 8.5 cm in length x 0.4\X0D\\X0A\cm in diameter segment of ureter.  The adrenal gland is not present.\X0D\\X0A\The kidney is 16 x 8.5 x 8 cm.  There is a large bulging mass noted\X0D\\X0A\within the superior pole of the kidney.  The perinephric fat and fascia\X0D\\X0A\overlying the mass are inked blue.  Sectioning the kidney reveals a 9 x\X0D\\X0A\8 x 8 cm well-circumscribed mass lesion which completely replaces the\X0D\\X0A\superior pole of the kidney.  The edges of the lesion are yellowish-tan\X0D\\X0A\and focally densely calcified.  The cut surface of the lesion is dark\X0D\\X0A\reddish-brown and friable and appears completely necrotic.  The lesion\X0D\\X0A\abuts the overlying renal capsule, but does not appear to extend into or\X0D\\X0A\through it.  The lesion does not extend into the overlying perinephric\X0D\\X0A\fat.  The lesion has a cortical location and does not involve the renal\X0D\\X0A\sinus or hilar vascular structures.  There are no other lesions\X0D\\X0A\identified.  The uninvolved renal parenchyma is red-brown with a\X0D\\X0A\well-delineated corticomedullary junction.  The average renal cortical\X0D\\X0A\thickness is 0.7 cm.  The collecting system, renal pelvis, and ureter\X0D\\X0A\are all lined by pink-tan smooth urothelium with no papillary\X0D\\X0A\excrescences.  There are no lymph nodes identified within the hilar fat.\X0D\\X0A\Representative sections are submitted as follows:\X0D\\X0A\1     vascular surgical margins\X0D\\X0A\2     representative sections of lesion through inked overlying\X0D\\X0A\perinephric fat and fascia\X0D\\X0A\3 through 9     additional representative sections of tumor\X0D\\X0A\10     uninvolved kidney from inferior pole\X0D\\X0A\11     representative sections of ureter, renal pelvis, and renal calyx.\X0D\\X0A\NOTE:  Cassettes 2 through 5 and cassette 9 are submitted following\X0D\\X0A\decalcification.\X0D\\X0A\JAB:jg","Microscopic Description:\X0D\\X0A\The renovascular and ureteral margins are benign, with sections through\X0D\\X0A\the renal pelvis showing no atypia.  The inked perirenal fat and fascial\X0D\\X0A\plane relative to the mass is benign.  Sections of the tumor show\X0D\\X0A\extensive hemorrhagic degenerative changes with a compressed and\X0D\\X0A\fibrotic renal cortex and outer renal capsule in relation to the mass.\X0D\\X0A\Zones of marked dystrophic calcification are also present.  Zones of\X0D\\X0A\viable tumor demonstrate a predominant overall papillary architecture.\X0D\\X0A\The lining cells of the papillae show generally mildly to moderately\X0D\\X0A\enlarged vesiculated nuclei, some with prominent nucleoli.  Relatively\X0D\\X0A\voluminous and abundant eosinophilic cytoplasm is noted along with some\X0D\\X0A\cells demonstrating cytoplasmic clearing.  The background lamina propria\X0D\\X0A\shows numerous clusters of foamy macrophages and mixed chronic active\X0D\\X0A\inflammation.  These features suggest a type 2 variant of papillary\X0D\\X0A\renal cell carcinoma (Fuhrman nuclear grade 3).  No sarcomatoid features\X0D\\X0A\are appreciated, and no vascular invasion is identified.  The adjacent\X0D\\X0A\kidney shows compression/mass effect with patchy zones of mild chronic\X0D\\X0A\inflammation.  The tumor appears organ confined.\X0D\\X0A\Tissue Code:  T1.\X0D\\X0A\CASE SUMMARY FOR INVASIVE CARCINOMA OF THE KIDNEY\X0D\\X0A\OF RENAL TUBULAR ORIGIN\X0D\\X0A\Procedure:  Nephrectomy\X0D\\X0A\Specimen laterality:  Left\X0D\\X0A\Tumor size:  9 x 8 x 8 cm\X0D\\X0A\Tumor focality:  Unifocal\X0D\\X0A\Histologic type:  Papillary renal cell carcinoma - Type 2\X0D\\X0A\Sarcomatoid features:  Not identified\X0D\\X0A\Histologic grade (Fuhrman nuclear grade):  3\X0D\\X0A\Tumor extension:  Confined to kidney\X0D\\X0A\Renal vein invasion:  Not identified\X0D\\X0A\Margins:\X0D\\X0A\Renal parenchymal margin:  Benign\X0D\\X0A\Renal capsular margin:  Benign\X0D\\X0A\Perinephric fat margin:  Benign\X0D\\X0A\Gerota's fascial margin:  Benign\X0D\\X0A\Renal vein margin:  Benign\X0D\\X0A\Ureteral margin:  Benign\X0D\\X0A\Hilar soft tissue margin:  Benign\X0D\\X0A\Regional lymph nodes:  Not identified\X0D\\X0A\Size of largest nodal metastasis:\X0D\\X0A\Extranodal extension:\X0D\\X0A\Adrenal gland:  N/A\X0D\\X0A\Additional pathologic findings:  N/A\X0D\\X0A\Pathologic Staging:  pT2a; pNx; pM (N/A).\X0D\\X0A\DRJ:jck\X0D\\X0A\D\T\T:  **DATE[Apr 03 2012].\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 03 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Left Kidney,,
REG1,OTHER,0,165386,3,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  endometrial cancer.  Intraoperative findings: \X0D\\X0A\endometrial cancer.  Operative procedure:  total abdominal\X0D\\X0A\hysterectomy/bilateral salpingo-oophorectomy, possible lymph node sampling.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""NO MYOMETRIAL INVASION IN FROZEN SECTION\"" \X0D\\X0A\KJA.\X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Jun 7 1936] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Nov 1 2012] 10:34\X0D\\X0A\Receipt Date: **DATE[Nov 1 2012] 10:34\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: F.R. **NAME[WWW], M.D.     Service: GYO     Location: REC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Nov 2 2012] 19:11\X0D\\X0A\RESIDENTS(S): V.V. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\UTERUS, HYSTERECTOMY (A):\X0D\\X0A\     INVASIVE ENDOMETRIAL ADENOCARCINOMA (endometrioid type), LOW GRADE (pT1a\X0D\\X0A\/ N0) (FIGO IA) \X0D\\X0A\     MYOMETRIAL LEIOMYOMATA\X0D\\X0A\     UNREMARKABLE CERVIX\X0D\\X0A\RIGHT AND LEFT OVARIES AND FALLOPIAN TUBES, RESECTION (B):\X0D\\X0A\     NO PATHOLOGIC ABNORMALITY\X0D\\X0A\LYMPH NODE(S), RIGHT PELVIS (C):     NO TUMOR SEEN (0/5)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dw/**DATE[Nov 2 2012] **NAME[TTT SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M83803 M8890\X0D\\X0A\B: M00100 P1100\X0D\\X0A\C: M09450 T0860 \X0D\\X0A\F: A: 88331 FS1, 88309\X0D\\X0A\C: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Specimen A is received fresh and placed in formalin labeled \""uterus and\X0D\\X0A\cervix\"" and consists of the aforementioned.\X0D\\X0A\Sectioning of the endomyometrium reveals markedly thickened endometrium.  The\X0D\\X0A\lesion grossly does not appear to invade the myometrium.  The lesion does not\X0D\\X0A\extend into the endocervical canal.  The uninvolved myometrium appears\X0D\\X0A\trabeculated. Four intramural nodules are identified. They have solid white\X0D\\X0A\whorled cut surface.   \X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight:  129 grams\X0D\\X0A\Dimensions of uterus:  9 cm (length) x 6.5 cm (width) x 4 cm (ant-post) \X0D\\X0A\Depth of endometrial cavity:  7.0 cm\X0D\\X0A\Tumor/Polyp dimensions:  entire endometrium is involved\X0D\\X0A\Depth of invasion:  grossly does not invade the myometrium\X0D\\X0A\Distance to internal os:  0.5 cm\X0D\\X0A\     Percent of endometrial surface involvement: 100%\X0D\\X0A\Uninvolved endometrial thickness:  not applicable\X0D\\X0A\Uninvolved myometrial thickness:  1.5 to 2.0 cm\X0D\\X0A\Os diameter:  0.9 cm\X0D\\X0A\Endocervical canal length:  2.0 cm\X0D\\X0A\Cassette summary:\X0D\\X0A\A1  right parametrium\X0D\\X0A\A2  left parametrium\X0D\\X0A\A3  tissue from frozen sections\X0D\\X0A\A4  anterior cervix\X0D\\X0A\A5  posterior cervix\X0D\\X0A\A6  anterior lower uterine segment\X0D\\X0A\A7  posterior lower uterine segment\X0D\\X0A\A8-A14  anterior endometrium shaved (entirely submitted)\X0D\\X0A\A15-A16  endometrium in the area of the fundus\X0D\\X0A\A17-A25  posterior endometrium shaved (entirely submitted)\X0D\\X0A\A26  representative sections of the nodules\X0D\\X0A\Specimen B is received in formalin labeled bilateral tubes and ovaries and\X0D\\X0A\consists of the aforementioned.  The bilateral ovaries are white/tan,\X0D\\X0A\almond-shaped, and normally bosselated.  They are intact with no excrescences\X0D\\X0A\on their surfaces.  They are serially sectioned to reveal an unremarkable\X0D\\X0A\white/tan cut surface.  One of the fallopian tubes have an identifiable\X0D\\X0A\fimbriated end.  Multiple paratubal cysts are noted.  They range in size from\X0D\\X0A\0.1 to 0.5 cm.  They are serially sectioned to reveal a pinpoint lumen.  \X0D\\X0A\Measurements:\X0D\\X0A\First Fallopian tube:  4.0 cm length x 0.6 cm diameter\X0D\\X0A\First Ovary:  2 x 1.5 x 1.0 cm\X0D\\X0A\Second Fallopian tube:  3.5 cm length x 0.7 cm diameter\X0D\\X0A\Second Ovary:  2 x 1.5 x 0.7 cm\X0D\\X0A\Representative sections:\X0D\\X0A\B1  first fallopian tube (no fimbriated end and ovary)\X0D\\X0A\B2  second fallopian tube\X0D\\X0A\B3  second ovary representative sections\X0D\\X0A\Specimen label:  C) right pelvic lymph nodes\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s):  irregular\X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: adipose tissue\X0D\\X0A\Size(s): in aggregate 6.0 x 5.0 x 2.5 cm\X0D\\X0A\Five fragments of fatty replaced lymph nodes are identified.  \X0D\\X0A\Cassette summary:  submitted in five cassettes\X0D\\X0A\dlf/**DATE[Nov 2 2012] V.V. **NAME[UUU], MD\X0D\\X0A\J.P. **NAME[RRR], MD",MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Jul 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery:  hysterectomy; bilateral adnexectomy; right pelvic\X0D\\X0A\lymphadenectomy\X0D\\X0A\Weight of uterus:   129 grams\X0D\\X0A\Dimensions of uterus:   9 cm (length) x 6.5 cm (width) x 4 cm (ant-post)\X0D\\X0A\Tumor size:  indeterminate (entire endometrium abnormal in gross appearance;\X0D\\X0A\entire endometrium is not involved by carcinoma \X0D\\X0A\    microscopically        \X0D\\X0A\Distance from internal os:  0.5 cm\X0D\\X0A\Histologic type:  endometrioid\X0D\\X0A\Tumor grade (FIGO grade I/II/III):  1\X0D\\X0A\Confined to endometrium:  \X0D\\X0A\Depth of invasion (% of myometrium):  33%\X0D\\X0A\     Depth of invasion from EM junction (mm.) [approximate]:  5 mm\X0D\\X0A\     Thickness of myometrium (mm.) [approximate]:  15 mm\X0D\\X0A\\X0D\\X0A\Nontumorous endometrium:  marked inflammation; metaplasia; apparent\X0D\\X0A\progestogenic changes \X0D\\X0A\Serosal involvement:  not demonstrated\X0D\\X0A\\X0D\\X0A\Adnexal involvement:  no\X0D\\X0A\Parametrial soft tissues:  negative  \X0D\\X0A\Cervical stromal involvement:  no\X0D\\X0A\Lymphvascular invasion:  yes (A12)\X0D\\X0A\Lymph node involvement:  no    \X0D\\X0A\Other sites of involvement (list):  none known or demonstrated\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\T              FIGO\X0D\\X0A\T1a             IA            Tumor limited to endometrium or invades < 1/2\X0D\\X0A\of the myometrium\X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\N0                                No regional lymph node metastasis\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\Not applicable\X0D\\X0A\A resident has participated in this service.  A pathologist has performed and\X0D\\X0A\is responsible for the reported pathologic evaluation.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Uterus and cervix (for depth of invasion)\X0D\\X0A\B: bilateral tubes and ovaries\X0D\\X0A\C: right pelvic lymph nodes,,
REG1,OTHER,0,272491,4,,CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis: small bladder tumor. Operative procedure: saline\X0D\\X0A\transurethral resection of bladder tumor (small) and left retrograde\X0D\\X0A\pyelogram.\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Dec 14 1945] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Jun 11 2012] 10:30\X0D\\X0A\Receipt Date: **DATE[Jun 11 2012] 10:30\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: ORN\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Jun 16 2012] 16:38\X0D\\X0A\RESIDENTS(S): K.K. **NAME[VVV], DO","DIAGNOSIS\X0D\\X0A\URINARY BLADDER, BLADDER TUMOR, BIOPSY:\X0D\\X0A\   - HIGH-GRADE UROTHELIAL PAPILLARY CARCINOMA INVADING INTO LAMINA PROPRIA.\X0D\\X0A\   - MUSCULARIS PROPRIA IDENTIFIED BUT NOT INVOLVED.\X0D\\X0A\   - SEE COMMENT.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jun 15 2012] **NAME[M. UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M80503 P1140 \X0D\\X0A\F: A: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A)   bladder tumor              \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: two\X0D\\X0A\Shape(s):  irregular  \X0D\\X0A\Color(s): red tan with area of white tan discoloration measuring 0.4 cm in\X0D\\X0A\greatest dimension\X0D\\X0A\Consistency: firm\X0D\\X0A\Size(s): ranging from 0.5 x 0.2 x 0.2 cm up to 0.5 x 0.5 x 0.5 cm\X0D\\X0A\Cassette summary: submitted in its entirety in screened A1 \X0D\\X0A\ksl/**DATE[Jun 12 2012] K.K. **NAME[VVV], DO\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\The case was prospectively reviewed in the intradepartmental consensus\X0D\\X0A\conference with the agreement to the above diagnosis.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Bladder tumor,,
REG1,OTHER,0,287931,3,,"CLINICAL HISTORY: ***PATH-NUMBER[1] Papillary transitional cell carcinoma, Grade I of IV.  ***PATH-NUMBER[2] Urothelial tissue with evidence of dysplasia.  Preop diagnosis microhematuria.","Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX M WWW], VVV] PhD **DATE[Apr 21 12]",FINAL DIAGNOSIS: RIGHT PERIURETHRAL DIVERTICULUM INVASIVE TRANSITIONAL CELL CARCINOMA. SEE COMMENT.,,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and \""right periurethral diverticulum.\""  The specimen is received in formalin on Telfa pad and consists of fragments of soft tan-pink tissue, measuring 7 x 5 x 3 mm.  The specimen is totally submitted in one block.","COMMENT WORD: The microscopic sections of the biopsy reveal a proliferation of atypical epithelial cells forming solid masses.  The cells contain moderately pleomorphic hyperchromatic nuclei with irregular outlines, variably clumped chromatin patterns and variably sized nucleoli.  Within focal areas there are downward projections with irregular borders and without identifiable basement membrane felt to indicate the presence of invasion.  There is also underlying inflammation.  The depth of invasion cannot be assessed on the current biopsy.  Staging criteria: at least T1 Stage I neoplasm.  Histopathologic grade: G2, moderately differentiated.  Histopathologic type: urothelial (transitional cell) carcinoma.  Further assessment for depth of invasion and grading of tumor will be conducted if additional tissue is received.",Specimen Number: ***PATH-NUMBER[3]. Tissues: Urethra. Specimen Comments:,,
REG1,OTHER,0,331866,3,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\HEMORRHAGIC CYSTITIS\X0D\\X0A\,PROCEDURES: 88305GS\X0D\\X0A\\X0D\\X0A\,"FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\TRANSURETHRAL RESECTION OF BLADDER TUMOR:\X0D\\X0A\UROTHELIAL CARCINOMA, HIGH GRADE (SEE COMMENT).\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\The tumor tissue is poorly preserved.  No invasion is identifiable in this material.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin labeled \""bladder tumor\"" on the requisition only are multiple irregular\X0D\\X0A\soft tan tissue fragments which measure in aggregate 1.5 x 0.7 x 0.1 cm.  The specimen is\X0D\\X0A\entirely submitted in a single cassette. /st/as\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\BLADDER TUMOR\X0D\\X0A\,,
REG1,OTHER,0,338266,4,,Clinical Diagnosis and History\X0D\\X0A\DYSPHAGIA\X0D\\X0A\OPER: EGD WITH BIOPSIES,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: STOMACH BODY  rd\X0D\\X0A\2: FUNDUS rd\X0D\\X0A\3: G.E.JUNCTION rd","Final Diagnosis\X0D\\X0A\1: \""STOMACH BODY\"":\X0D\\X0A\     BENIGN GASTRIC MUCOSAL BIOPSIES \X0D\\X0A\          NO SIGNIFICANT HISTOLOGIC ABNORMALITY.\X0D\\X0A\     NO INTESTINAL METAPLASIA.\X0D\\X0A\     DIFF-QUICK STAIN:  NO HELICOBACTER SEEN.\X0D\\X0A\2: \""FUNDUS\"":\X0D\\X0A\     FOCAL CYSTIC GLANDULAR DILATATION SUGGESTIVE OF EARLY FUNDIC GLAND\X0D\\X0A\          POLYP FORMATION.\X0D\\X0A\     NO INTESTINAL METAPLASIA.\X0D\\X0A\     DIFF-QUICK STAIN:  NO HELICOBACTER SEEN.\X0D\\X0A\3: \""GE JUNCTION\"":\X0D\\X0A\     INVASIVE ADENOCARCINOMA WITH PROMINENT SIGNET RING FEATURES\X0D\\X0A\          (SIGNET RING ADENOCARCINOMA)  HIGH GRADE.\X0D\\X0A\**INITIALS IHC/a/CLS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D., **NAME[WWW]",,"Gross Description\X0D\\X0A\1: In formalin labeled \""stomach body\"" are fragments of tan soft tissue 0.2 cm in\X0D\\X0A\aggregate. Block 1A.\X0D\\X0A\2: In formalin labeled \""fundus\"" are fragments of tan soft tissue 0.2 cm in\X0D\\X0A\aggregate. Block 2A.\X0D\\X0A\3: In formalin labeled \""GE junction\"" are fragments of tan soft tissue 0.4 cm in\X0D\\X0A\aggregate. Block 3A.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,OTHER,0,404880,3,,Clinical History:\X0D\\X0A\Graves Disease\X0D\\X0A\Pre-Operative Diagnosis:\X0D\\X0A\Thyroid Nodule\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given,,"Final Diagnosis:\X0D\\X0A\A)  Right thyroid lobe, lobectomy:  Hyperplastic thyroid consistent with\X0D\\X0A\Grave's disease with patchy lymphocytic thyroiditis, and papillary\X0D\\X0A\microcarcinoma, (0.3 cm in greatest dimensions).\X0D\\X0A\B)  Left thyroid lobe, lobectomy:  Multifocal papillary carcinoma (\X0D\\X0A\largest focus 1.1 x 0.3 cm), in a background of hyperplastic thyroid,\X0D\\X0A\consistent with Grave's disease with patchy lymphocytic thyroiditis.",,"Gross Description:\X0D\\X0A\Two containers.\X0D\\X0A\A)  Container A is labeled \""right thyroid lobe\"".  The specimen is\X0D\\X0A\received in fixative and consists of a 24 gram, 7 x 4 x 3 cm lobulated\X0D\\X0A\lobe of thyroid.  The specimen is inked.  A 1.5 x 1.3 x 1 cm nodule is\X0D\\X0A\attached to the edge of the thyroid lobe.  The cut surface is deep red\X0D\\X0A\and has a 0.4 x 0.3 x 0.3 cm white nodule.  The remaining cut surface\X0D\\X0A\has no discrete mass lesions.  Representative sections are submitted as\X0D\\X0A\follows:\X0D\\X0A\A1 - entire nodule attached to the thyroid gland;\X0D\\X0A\A2 - entire small white nodule;\X0D\\X0A\A3 through A8 - representative sections.\X0D\\X0A\B)  Specimen B is labeled \""left thyroid lobe\"".  The specimen is received\X0D\\X0A\in fixative and consists of a 23 gram, 6.5 x 4 x 3 cm lobulated tan-gray\X0D\\X0A\lobe of thyroid.  The specimen is inked.  The cut surface is vaguely\X0D\\X0A\nodular and ranges from pink to red.  A single 0.4 cm solid white nodule\X0D\\X0A\is present.  No additional mass lesions are identified.  Representative\X0D\\X0A\sections are submitted as follows:\X0D\\X0A\B1 - entire nodule;\X0D\\X0A\B2 through B6 - random sections of thyroid.\X0D\\X0A\JMM:jck","Microscopic Description:\X0D\\X0A\A \T\ B)  Right and left lobes, lobectomies:  Sections from both thyroid\X0D\\X0A\lobes reveal similar findings demonstrating numerous thyroid follicles\X0D\\X0A\of varying sizes and shapes containing varying amounts of colloid.\X0D\\X0A\Patchy areas of lymphoid aggregates are noted, consistent with focal\X0D\\X0A\lymphocytic thyroiditis.  There are small Hurthle cell nodules noted\X0D\\X0A\also.  Some of the follicles demonstrate pseudopapillary projections\X0D\\X0A\within the follicles.  However, additionally, there are several foci of\X0D\\X0A\demonstrating nuclear features of papillary thyroid carcinoma with\X0D\\X0A\enlarged, hypochromatic nuclei with occasional nuclear grooves, nuclear\X0D\\X0A\overlapping, and an occasional intranuclear inclusion.  Two benign lymph\X0D\\X0A\nodes are noted.  For further details, see case summary below.\X0D\\X0A\CASE SUMMARY FOR PRIMARY CARCINOMA OF THE THYROID\X0D\\X0A\Procedure:  Right and left thyroid lobectomies.\X0D\\X0A\Specimen size:  Right - 24 grams, 7 x 4 x 3 cm; left - 23 grams, 6.5 x 4\X0D\\X0A\x 3 cm.\X0D\\X0A\Specimen integrity: Each separate lobe is intact.\X0D\\X0A\Tumor focality:  Multifocal, bilateral.\X0D\\X0A\Location of tumor(s):  Right and left lobes.\X0D\\X0A\Tumor size:  Largest focus 1.1 x 0.3 cm.\X0D\\X0A\Histologic type:  Papillary carcinoma, classic and follicular variant.\X0D\\X0A\Histologic grade: Well differentiated\X0D\\X0A\Tumor encapsulation:  None.\X0D\\X0A\Tumor capsule invasion:  Cannot be assessed.\X0D\\X0A\Lymph-vascular invasion:  Not identified.\X0D\\X0A\Extrathyroidal extension:  Not identified.\X0D\\X0A\Margins:  Negative for malignancy.\X0D\\X0A\Lymph nodes:  No lymph nodes identified.\X0D\\X0A\Additional pathologic findings:  Diffuse thyroid hyperplasia (consistent\X0D\\X0A\with Grave's disease), lymphocytic thyroiditis.\X0D\\X0A\Pathologic staging:  pT1b; pN0; pMX.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\CPT Code:  88307.26 x 2\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jun 20 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right Thyroid Lobe\X0D\\X0A\SOURCE OF SPECIMEN: B Left Thyroid Lobe,,
REG1,OTHER,0,427968,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\LEFT RENAL MASS\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\    LEFT KIDNEY, PARTIAL NEPHRECTOMY.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\    LOWER POLE (PER IMAGING STUDIES AND OPERATIVE NOTE).\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\    RENAL CELL CARCINOMA, CONVENTIONAL CLEAR CELL TYPE, FUHRMAN NUCLEAR             GRADE 2.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\    GREATEST TUMOR DIMENSION IS 2.8 CM.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\    UNIFOCAL.\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   101 Hospital Blvd\X0D\\X0A\   **PLACE, IN **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX,WWW M]\X0D\\X0A\   2355 Poplar Level Rd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS, 88331GS\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[VVV M UUU] MD **DATE[May 03 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[May 04 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FROZEN SECTION DIAGNOSIS\X0D\\X0A\\X0D\\X0A\PARENCHYMAL MARGIN NEGATIVE FOR TUMOR.  REPORTED TO DR. **NAME[ZZZ] ON **DATE[May 1 12] AT APPROXIMATELY 6:43\X0D\\X0A\P.M.  LWF\X0D\\X0A\\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\CARCINOMA OF THE KIDNEY SYNOPTIC REPORT AJCC/UICC TNM, 7TH EDITION\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\LEFT KIDNEY, PARTIAL NEPHRECTOMY.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\LOWER POLE (PER IMAGING STUDIES AND OPERATIVE NOTE).\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\RENAL CELL CARCINOMA, CONVENTIONAL CLEAR CELL TYPE, FUHRMAN NUCLEAR             GRADE 2.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\GREATEST TUMOR DIMENSION IS 2.8 CM.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\MACROSCOPIC AND MICROSCOPIC TUMOR EXTENT:\X0D\\X0A\TUMOR LIMITED TO KIDNEY.\X0D\\X0A\SARCOMATOID FEATURES:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\MARGINS:\X0D\\X0A\RENAL PARENCHYMAL MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\PERINEPHRIC FAT MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\PATHOLOGIC CHANGES IN NON-NEOPLASTIC KIDNEY:\X0D\\X0A\FOCAL GLOBAL GLOMERULOSCLEROSIS AND FOCAL INTERSTITIAL INFLAMMATION AND\X0D\\X0A\FIBROSIS.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  pT1a pNX pMn/a.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received fresh for frozen section diagnosis designated \""partial left kidney\"" is a partial\X0D\\X0A\nephrectomy specimen which is composed of an elliptical shaped fragment of kidney tissue as\X0D\\X0A\well as a large amount of attached perinephric adipose tissue.  The specimen weighs 175\X0D\\X0A\grams.  The kidney portion measures 5.5 x 3.5 x 2 cm.  The adipose tissue measures 14.0 x\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\11.5 x up to 2.0 cm.  The cut surface of the kidney is reddish brown, glistening and\X0D\\X0A\displays normal cortical and medullary markings.  The parenchymal margin is inked green.\X0D\\X0A\Sectioning reveals an ovoid, 2.8 x 2.5 x 1.6 yellow-tan, hemorrhagic mass.  The mass extends\X0D\\X0A\to within 0.2 cm from the parenchymal margin.  The parenchymal margin is inked green.  A\X0D\\X0A\representative section, to include the closest parenchymal margin, is submitted on a single\X0D\\X0A\block for frozen section.  The tumor does not appear to extend into the overlying adipose\X0D\\X0A\tissue.  The non-involved kidney is light brown and glistening and displays no additional\X0D\\X0A\lesions.  Sectioning through the attached perinephric adipose tissue reveals glistening,\X0D\\X0A\yellow-tan, adipose tissue.  No focal lesions are identified.  No lymph node candidates are\X0D\\X0A\identified.\X0D\\X0A\\X0D\\X0A\Representative sections of the specimen are submitted as follows:\X0D\\X0A\\X0D\\X0A\FSC.    representative section of tumor and closest parenchymal margin\X0D\\X0A\1.    tumor section with inked parenchymal margin and small portion of surrounding\X0D\\X0A\adipose tissue\X0D\\X0A\2\T\3.    one complete cross-section of tumor with inked parenchymal margin and overlying\X0D\\X0A\perinephric adipose tissue\X0D\\X0A\4\T\5.    cross-section of tumor with closest parenchymal margin and surrounding\X0D\\X0A\perinephric\X0D\\X0A\adipose tissue\X0D\\X0A\6\T\7.    additional sections of tumor with inked parenchymal margin and surrounding\X0D\\X0A\perinephric\X0D\\X0A\adipose tissue\X0D\\X0A\8\T\9.    sections of perinephric adipose tissue immediately overlying tumor\X0D\\X0A\10.    representative section of non-neoplastic kidney\X0D\\X0A\11\T\12.    representative sections of overlying perinephric adipose tissue margin\X0D\\X0A\**INITIALS\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\13 H\T\E\X0D\\X0A\,"SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\PARTIAL LEFT KIDNEY, FROZEN\X0D\\X0A\",,
REG1,OTHER,0,434581,3,,CLINICAL HISTORY\X0D\\X0A\Preop diagnosis:  bladder tumor.  Operative procedure: TUR bladder tumor.  \X0D\\X0A\,"**INSTITUTION \X0D\\X0A\310 S. LIMESTONE\X0D\\X0A\**PLACE, KY  **ZIP-CODE\X0D\\X0A\ MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Dec 19 1939] (Age: **AGE[in 70s])  MW\X0D\\X0A\Collect Date: **DATE[Aug 12 2012] 14:32\X0D\\X0A\Receipt Date: **DATE[Aug 12 2012] 14:32\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE Fax:  **PHONE          ***PATH-NUMBER[1]\X0D\\X0A\Email:      \X0D\\X0A\**NAME[ZZZ] MD: P.L. **NAME[YYY], MD     Service: URO     Location: SPCU\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Aug 13 2012] 16:25","DIAGNOSIS\X0D\\X0A\BLADDER TUMOR, TRANSURETHRAL RESECTION:\X0D\\X0A\   - PAPILLARY UROTHELIAL CARCINOMA, HIGH-GRADE, WITH LAMINA PROPRIA\X0D\\X0A\INVASION, NO LYMPHVASCULAR \X0D\\X0A\    INVASION NOTED.\X0D\\X0A\   - FLAT CIS PRESENT.\X0D\\X0A\   - NO MUSCULARIS PROPRIA SEEN.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Aug 13 2012] **NAME[M. WWW], MD\X0D\\X0A\\X0D\\X0A\ICD 9:   SNOMED CODES:\X0D\\X0A\A: M80503 P1100 \X0D\\X0A\F: A: 88304, 88304 <CR>, 88307",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled bladder tumor and consists\X0D\\X0A\of eight papillary pink tissue fragments in aggregate measuring 1 x 0.8 x 0.4\X0D\\X0A\cm.  It is submitted in its entirety in screened A1 and A2.\X0D\\X0A\dlf/**DATE[Aug 12 2012] **NAME[M. WWW], MD\X0D\\X0A\\X0D\\X0A\",MICROSCOPIC DESCRIPTION/COMMENT\X0D\\X0A\Consensus conference review with agreement is obtained.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: bladder tumor,,
REG1,OTHER,0,481128,3,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is endometrial cancer. Intraoperative findings:\X0D\\X0A\endometrial cancer. Operative procedure: robotic laparoscopic total\X0D\\X0A\hysterectomy, bilateral salpingo-oophorectomy, lymph node sampling. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""INNER HALF INVASION ON REPRESENTATIVE\X0D\\X0A\SECTION\""---WOC. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Aug 16 1949] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[May 22 2012] 06:48\X0D\\X0A\Receipt Date: **DATE[May 22 2012] 06:48\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: R.W. **NAME[WWW], MD     Service: GYO     Location: 3MCC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[May 25 2012] 12:02\X0D\\X0A\RESIDENTS(S): E.A. Pirruccello, DO","DIAGNOSIS\X0D\\X0A\UTERUS, CERVIX, FALLOPIAN TUBES, AND OVARIES, TOTAL ABDOMINAL HYSTERECTOMY\X0D\\X0A\WITH BILATERAL SALPHINGO-OOPHORECTOMY (A \T\ B):\X0D\\X0A\   - WELL DIFFERENTIATED ENDOMETRIOID TYPE ADENOCARCINOMA WITH MYOMETRIAL\X0D\\X0A\INVASION INTO INNER \X0D\\X0A\    HALF (FIGO GRADE I, pT1a, pNX), ENDOMETRIUM (SEE TEMPLATE).   -\X0D\\X0A\LEIOMYOMAS, MYOMETRIUM.\X0D\\X0A\   - CHRONIC CYSTIC CERVICITIS, CERVIX.\X0D\\X0A\  - NO TUMOR SEEN, RIGHT AND LEFT PARAMETRIA.\X0D\\X0A\  - NO PATHOLOGIC ABNORMLITIES, RIGHT AND LEFT FALLOPIAN TUBES.\X0D\\X0A\  - NO PATHOLOGIC ABNORMLITIES, RIGHT AND LEFT OVARIES.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[May 25 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09400 M4380 \X0D\\X0A\F: A: 88331 FS1, 88309",,"GROSS DESCRIPTION\X0D\\X0A\Two specimens are received. \X0D\\X0A\Specimen A is received fresh for frozen section labeled \""uterus and cervix\""\X0D\\X0A\and consists of the aforementioned.\X0D\\X0A\Sectioning of the endomyometrium reveals an large friable endometrial mass\X0D\\X0A\involving the anterior and posterior endometrial.  It measures 3 x 2.5 x 1.2\X0D\\X0A\cm.  The lesion grossly invades the inner     of the myometrium.  The lesion\X0D\\X0A\does not appear to extend into the endocervical canal but does appear to\X0D\\X0A\cover the entire endometrial surface on both the anterior and posterior\X0D\\X0A\aspects of the endometrium. There is a single white whorled nodule in the\X0D\\X0A\anterior myometrium which measures 0.5 cm in greatest dimension.\X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight  69.3 g post fixation\X0D\\X0A\Dimensions of uterus  8.5 cm (length) x 4.7 cm (width) x 3.5 cm (ant-post) \X0D\\X0A\Depth of endometrial cavity - 3 cm\X0D\\X0A\Tumor/Polyp dimensions - 3 cm (greatest) x 2.5 cm (smaller) x 1.2 cm (max\X0D\\X0A\thickness)\X0D\\X0A\Depth of invasion  inner    , 0.5 cm from endomyometrium\X0D\\X0A\Distance to internal os  0.2 cm on the posterior side\X0D\\X0A\     Tumor location  posterior and anterior walls\X0D\\X0A\     Uninvolved endometrial thickness  0.3 cm\X0D\\X0A\Uninvolved myometrial thickness  1.5 cm\X0D\\X0A\Os diameter  0.5 cm\X0D\\X0A\Endocervical canal length - 3 cm\X0D\\X0A\Cassette summary:\X0D\\X0A\A1  FS1 entirely resubmitted (posterior endomyometrium full thickness deepest\X0D\\X0A\invasion)\X0D\\X0A\A2  right parametrium\X0D\\X0A\A3  left parametrium\X0D\\X0A\A4  anterior cervix at 12:00\X0D\\X0A\A5  posterior cervix at 12:00\X0D\\X0A\A6  anterior lower uterine segment\X0D\\X0A\A7  posterior lower uterine segment\X0D\\X0A\A8  anterior endomyometrium full thickness greatest depth of invasion\X0D\\X0A\A9  anterior endomyometrium full thickness area of least invasion and\X0D\\X0A\possibly uninvolved area\X0D\\X0A\A10  posterior endomyometrium area of least invasion, no uninvolved\X0D\\X0A\endomyometrium present\X0D\\X0A\A11  anterior endomyometrium with white whorled nodule entirely submitted\X0D\\X0A\Specimen B is received in formalin labeled bilateral tubes and ovaries and\X0D\\X0A\consists of two ovary and fallopian tube pieces that are unoriented.  The\X0D\\X0A\fallopian tube has an identifiable fimbriated end.  No paratubal cysts are\X0D\\X0A\noted. The tube is serially sectioned to reveal a pinpoint lumen.  \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\Measurements:\X0D\\X0A\#1 fallopian tube weight: 7.3 grams\X0D\\X0A\#1 fallopian tube: 3 cm length x 0.5 cm diameter\X0D\\X0A\#1 ovary: 2.1 cm x 1.6 x 1.3 cm\X0D\\X0A\#2 fallopian tube weight: 8.2 grams\X0D\\X0A\#2 fallopian tube: 4.5 cm in length x 0.8 cm in diameter\X0D\\X0A\#2 ovary: 2 x 1 x 0.8 cm \X0D\\X0A\Representative sections:\X0D\\X0A\B1: #1 representative sections of tube and ovary  \X0D\\X0A\B2: #2 representative sections of tube and ovary\X0D\\X0A\rgc/**DATE[May 22 2012] E.A. Pirruccello, DO\X0D\\X0A\R.K. **NAME[SSS], MD",MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Feb 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery:  robotic hysterectomy with bilateral salpingo-oophorectomy\X0D\\X0A\Weight of uterus:  69.3 grams\X0D\\X0A\Dimensions of uterus:  8.5cm (length) x 4.7 cm (width) x 3.5 cm\X0D\\X0A\(anterior-posterior dimension)\X0D\\X0A\Histologic type of the tumor:  endometrioid type adenocarcinoma\X0D\\X0A\Tumor grade of differentiation (FIGO grade I/II/III):  I\X0D\\X0A\Tumor size:   3cm (greatest dimension) x 2.5 cm (smaller dimension) x 1.2 cm\X0D\\X0A\(maximum thickness) \X0D\\X0A\Distance from internal os:  0.2 cm\X0D\\X0A\Confined to endometrium:  no\X0D\\X0A\Myometrial invasion:  yes (inner 1/2) \X0D\\X0A\Depth of invasion:   40% of myometrial involvement \X0D\\X0A\                     (8 mm from EM junction/20 mm myometrial thickness) *   \X0D\\X0A\Nontumorous endometrium:  atypical complex hyperplasia\X0D\\X0A\Serosal involvement:  no\X0D\\X0A\Adnexal involvement (specify):  no\X0D\\X0A\Parametrial soft tissues:   no\X0D\\X0A\Cervical involvement:  no\X0D\\X0A\Lymphvascular invasion:  not seen\X0D\\X0A\Lymph node involvement (specify):    lymph nodes not submitted\X0D\\X0A\Other sites of involvement (list):\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\pT      FIGO\X0D\\X0A\pT1a    IA            Tumor limited to endometrium or invades < 1/2 of the\X0D\\X0A\myometrium\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\pNX                   Regional lymph nodes cannot be assessed\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\                       Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Uterus/cervix\X0D\\X0A\B: Bilateral tubes and ovaries,,
REG1,OTHER,0,483516,1,,"CLINICAL HISTORY\X0D\\X0A\Preop diagnosis:  MEN 2A.  Operative procedure:  parathyroidectomy, modified\X0D\\X0A\radical neck dissection thyroidectomy with limited node dissection.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1A and 1B:  \""SEVEN LYMPH NODES, NEGATIVE FOR\X0D\\X0A\TUMOR\"", RBV-CHERYL/SES.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""NORMOCELLULAR PARATHYROID\"", TO **NAME[ZZZ]\X0D\\X0A\WAINSCOTT/SES.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #3:  \""HYPERCELLULAR PARATHYROID\"", TO **NAME[ZZZ]\X0D\\X0A\WAINSCOTT/SES.\X0D\\X0A\\X0D\\X0A\     **NAME[M. YYY], MD","**INSTITUTION \X0D\\X0A\310 S. LIMESTONE\X0D\\X0A\**PLACE, KY  **ZIP-CODE\X0D\\X0A\ MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jun 2 1958] (Age: **AGE[in 50s])  MW\X0D\\X0A\Collect Date: **DATE[Apr 19 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Apr 22 2012] 12:45\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE Fax:  **PHONE          ***PATH-NUMBER[1]\X0D\\X0A\Email:      \X0D\\X0A\**NAME[XXX] MD: **NAME[WWW VVV], MD     Service: SSG     Location: S6E\X0D\\X0A\**NAME[UUU] MD(S):      Reported: **DATE[Apr 23 2012] 15:18","DIAGNOSIS\X0D\\X0A\RIGHT LEVEL II NODES, EXCISION (A):\X0D\\X0A\  - ELEVEN BENIGN LYMPH NODES, NO TUMOR SEEN (0/11).\X0D\\X0A\REIMPLANTED RIGHT INFERIOR PARATHYROID, BIOPSY (B):\X0D\\X0A\   - NORMOCELLULAR PARATHYROID TISSUE.\X0D\\X0A\ENLARGED LEFT SUPERIOR PARATHYROID, SUBTOTAL RESECTION (C):\X0D\\X0A\   - 0.334 GRAM HYPERCELLULAR PARATHYROID.\X0D\\X0A\\""CYST OVERLYING RIGHT CLAVICLE\"", EXCISIONAL BIOPSY (D):\X0D\\X0A\   - BENIGN ECCRINE SPIRADENOMA, EXCISED WITH NEGATIVE MARGINS.\X0D\\X0A\RIGHT LEVEL VI NODES, EXCISION (E):\X0D\\X0A\   - FIVE BENIGN LYMPH NODES, NO TUMOR SEEN (0/5).\X0D\\X0A\UPPER LEVEL VII NODES (RIGHT), EXCISION (F):\X0D\\X0A\   - BENIGN THYMIC TISSUE, NO LYMPH NODES IDENTIFIED.\X0D\\X0A\CONTENTS OF RIGHT NECK, LEVELS II, IV AND V, EXCISION (G):\X0D\\X0A\   - TWENTY-NINE LYMPH NODES NEGATIVE FOR TUMOR (0/29).\X0D\\X0A\LEFT LEVEL VI NODES, EXCISION (H):\X0D\\X0A\   - FOUR LYMPH NODES, NEGATIVE FOR TUMOR (0/4).\X0D\\X0A\TOTAL THYROID WITH CENTRAL NODES AND STRAP MUSCLE, EXCISION (I):\X0D\\X0A\   - BILATERAL MEDULLARY CARCINOMAS WITH PROMINENT AMYLOID STROMA (0.8 CM\X0D\\X0A\RIGHT AND 0.7 CM\X0D\\X0A\    LEFT).\X0D\\X0A\   - MARGINS NEGATIVE FOR CARCINOMA.\X0D\\X0A\   - SIX PERITHYROIDAL AND EIGHT CENTRAL LYMPH NODES NEGATIVE FOR TUMOR (0/6,\X0D\\X0A\0/8).\X0D\\X0A\   - NO LYMPHVASCULAR INVASION IDENTIFIED.\X0D\\X0A\   - MODERATELY CELLULAR PARATHYROID IDENTIFIED.\X0D\\X0A\HIGHEST LEFT LEVEL II NODE, EXCISION (J):\X0D\\X0A\   - SINGLE HYPERPLASTIC LYMPH NODE, NEGATIVE FOR TUMOR (0/1).\X0D\\X0A\CONTENTS OF LEFT NECK, LEVELS II, IV, AND V, EXCISION (K):\X0D\\X0A\   - FOURTEEN LYMPH NODES, NEGATIVE FOR TUMOR (0/14).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 23 2012] **NAME[M. YYY], MD\X0D\\X0A\\X0D\\X0A\ICD 9:   SNOMED CODES:\X0D\\X0A\A: M09450 P1100\X0D\\X0A\B: M00100 P1140\X0D\\X0A\C: M76020 P1100\X0D\\X0A\D: M09400 M3340\X0D\\X0A\E: M09450 P1100\X0D\\X0A\F: P1100 T98000\X0D\\X0A\G: M09450 P1100\X0D\\X0A\H: M09450 P1100\X0D\\X0A\I: M55100 M85103 P11 \X0D\\X0A\F:  88331 FS1(3)\X0D\\X0A\A: 88307, 88307 <CR>\X0D\\X0A\A,E,F,G: 88307\X0D\\X0A\B: 88305\X0D\\X0A\C: 88305\X0D\\X0A\D: 88305\X0D\\X0A\E: 88307, 88307 <CR>\X0D\\X0A\F: 88307, 88307 <CR>\X0D\\X0A\G: 88307, 88307 <CR>\X0D\\X0A\H: 88307, 88307 <CR>\X0D\\X0A\H,J,K: 88307\X0D\\X0A\I: 88307\X0D\\X0A\J: 88307, 88307 <CR>\X0D\\X0A\K: 88307, 88307 <CR>",,"GROSS DESCRIPTION\X0D\\X0A\Eleven specimens are received.  Specimen A is received fresh for frozen\X0D\\X0A\section labeled right level II nodes and consists of an aggregate of yellow\X0D\\X0A\fibrofatty tissue measuring 2.8 x 1.5 x 0.3 cm.  Lymph nodes are dissected\X0D\\X0A\free from the surrounding soft tissue and resubmitted from FS1A and 1B in\X0D\\X0A\screened A1 and A2.  The remainder of the tissue is submitted in screened A3.\X0D\\X0A\Specimen B is received fresh for frozen section labeled biopsy of reimplanted\X0D\\X0A\right inferior parathyroid and consists of a yellow 0.2 x 0.2 x 0.1 cm tissue\X0D\\X0A\fragment, entirely resubmitted form FS2 in screened B1.\X0D\\X0A\Specimen C is received fresh for frozen section labeled subtotal resection of\X0D\\X0A\large left superior parathyroid  frozen and weigh and consists of a 0.334\X0D\\X0A\gram, 1.5 x 1.0 x 0.4 cm tissue fragment resubmitted from FS3 in C1.\X0D\\X0A\The remaining specimens are submitted in formalin.  \X0D\\X0A\Specimen D is labeled cyst overlying right clavicle and consists of an\X0D\\X0A\ellipse brownish gray skin measuring 2.2 x 1.5 x 0.5 cm with an underlying\X0D\\X0A\firm nodule measuring 1.5 x 1 x 1 cm.  On sectioning the nodule is rather\X0D\\X0A\thick walled showing a pink interior measuring 0.8 x 0.6 x 0.5 cm that is\X0D\\X0A\firm and white.  It is sectioned and entirely submitted in D1.\X0D\\X0A\Specimen E is labeled right level VI nodes and consists of five tissue\X0D\\X0A\fragments, firm, pink and yellow.  They are submitted in their entirety in\X0D\\X0A\E1.\X0D\\X0A\Specimen F is labeled upper level VII nodes (right) and consists of a single\X0D\\X0A\yellow adipose tissue fragment measuring 2.2 x 1.7 x 0.5 cm.  It is submitted\X0D\\X0A\in its entirety in F1.\X0D\\X0A\Specimen G is labeled contents of right neck levels II, IV, V, white marks\X0D\\X0A\II, black marks IV, and blue marks V.  It consists of an irregularly shaped\X0D\\X0A\yellow and brown adipose tissue fragment measuring 8.8 x 6.5 x 1.-1.8 cm. \X0D\\X0A\There is included skeletal muscle measuring 2.5 x 1.2 x 0.5 cm.  Level II\X0D\\X0A\nodes are submitted in G1-G4, level IV nodes are G5-G8, and level V in\X0D\\X0A\G9-G11.  G10 contains a sample of skeletal muscle.\X0D\\X0A\Specimen H is labeled left level VI nodes and consists of two fragments of\X0D\\X0A\yellow adipose tissue with focal brownish nodules. The tissue in aggregate\X0D\\X0A\measures 1.3 x 1.1 x 0.2 cm and is entirely submitted in H1.\X0D\\X0A\Specimen I is labeled total thyroidectomy with central nodes and strap\X0D\\X0A\muscle, suture marks right superior pole.  It consists of a U-shaped brown\X0D\\X0A\parenchymal organ.  The right lobe measures 5.8 x 3.1 x 1.5 cm.  The isthmus\X0D\\X0A\measures 0.8 x 1.1 x 0.5 cm and the left lobe measures 5.2 x 2.8 x 1.7 cm. \X0D\\X0A\Adipose tissue is present subjacent to the isthmus measuring 3.8 x 2 x 1 cm.\X0D\\X0A\The left lobe is partially disrupted.  Staples are removed and the specimen\X0D\\X0A\is inked for margins.  On sectioning the right lobe a 0.8 x 0.4 x 0.3 cm\X0D\\X0A\nodule is present toward the inferior pole. The isthmus is unremarkable.  On\X0D\\X0A\sectioning the left lobe a 0.7 x 0.6 x 0.5 cm nodule is present toward the\X0D\\X0A\mid portion. The fat is serially sectioned with only a few nodules grossly\X0D\\X0A\identified. Summary of sections:  right lobe in its entirety from superior to\X0D\\X0A\inferior in I1-I10; isthmus  I11; left lobe in its entirety from superior to\X0D\\X0A\inferior  - I12-I19; fat in its entirety in I20-I23.\X0D\\X0A\Specimen J is labeled highest left level II node and consists of a single\X0D\\X0A\yellow fragment measuring 1.2 x 1.1 x 0.5 cm.  It is bisected to reveal a\X0D\\X0A\firm white interior, entirely submitted in J1.\X0D\\X0A\Specimen K is labeled contents of left neck, levels II, IV, V, white marks\X0D\\X0A\II, black marks IV, and blue marks V.  It consists of a oriented yellow/brown\X0D\\X0A\tissue fragment fibrofatty measuring 7 x 5.5 x 0.5-1.2 cm.  Sutures are\X0D\\X0A\present as denoted.  Additional yellow fatty fragments are found free\X0D\\X0A\floating in the container measuring 2.2 x 1.8 x 0.3 cm.  It is serially\X0D\\X0A\sectioned, notable for numerous firm whitish nodules.  Summary of sections: \X0D\\X0A\level II  K1-K3; level IV  K4-K8; level V  K9-K12.  The additional free\X0D\\X0A\tissue is in K13.  \X0D\\X0A\dlf/**DATE[Apr 22 2012] **NAME[M. YYY], MD\X0D\\X0A\\X0D\\X0A\","MICROSCOPIC DESCRIPTION/COMMENT\X0D\\X0A\The frozen section diagnoses are confirmed.  Consensus conference review with\X0D\\X0A\agreement is obtained.  An additional 4 lymph nodes were identified in the\X0D\\X0A\right level II nodes (specimen A). Interdepartmental review with agreement is\X0D\\X0A\obtained on specimen D (MSP).\X0D\\X0A\THYROID NEOPLASM (template #22)                                     \X0D\\X0A\Last updated **DATE[May 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of procedure or specimen:  total thyroidectomy with limited node\X0D\\X0A\dissection\X0D\\X0A\Location of tumors:  right and left lobes\X0D\\X0A\Histologic type:  medullary thyroid carcinoma\X0D\\X0A\\X0D\\X0A\Tumor grade:  well-differentiated \X0D\\X0A\Size of tumors:  0.8 x 0.4 x 0.3 cm (right) and 0.7 x 0.6 x 0.5 cm (left)\X0D\\X0A\Encapsulation of tumor:  no\X0D\\X0A\Centricity:  multicentric\X0D\\X0A\Lymphvascular invasion:  no\X0D\\X0A\Extension beyond the capsule of the thyroid:  no\X0D\\X0A\Margins:  negative\X0D\\X0A\Non-neoplastic thyroid:  unremarkable\X0D\\X0A\Number of parathyroids excised:  2\X0D\\X0A\Number of parathyroids biopsied:  1\X0D\\X0A\Lymph nodes (site, number, number involved):  right:  level II  0/23, level\X0D\\X0A\IV  0/8, level V  0/9, level VI  0/5 and level VII  0/0\X0D\\X0A\                                        left:  level II  0/5, level IV  0/4,\X0D\\X0A\level V  0/6, level VI  0/4\X0D\\X0A\                                                 parathyroidal  0/6 and\X0D\\X0A\central  0/8\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT)\X0D\\X0A\   Note: All categories may be subdivided:  s) solitary tumor and m)\X0D\\X0A\multifocal tumor (the largest one \X0D\\X0A\             determines T stage).\X0D\\X0A\pT1a(s)       Tumor 1 cm or less, limited to the thyroid\X0D\\X0A\REGIONAL LYMPH NODES (pN) \X0D\\X0A\pNO         No regional lymph node metastasis\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                Not applicable","DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: right level 2 nodes\X0D\\X0A\B: biopsy of reimplanted right inferior parathyroid\X0D\\X0A\C: subtotala resection enlarged left superior parathyroid\X0D\\X0A\D: cyst overlying right clavicle\X0D\\X0A\E: right level 6 nodes\X0D\\X0A\F: upper level 7 nodes- right\X0D\\X0A\G: contents of right neck level 2,4,5- white marks 2, blacks marks 4, blue\X0D\\X0A\marks 5\X0D\\X0A\H: left level 6 nodes\X0D\\X0A\I: total thyroidectomy with central nodes and strap muscle- suture marks\X0D\\X0A\right superior pole\X0D\\X0A\J: highest left level 2 node\X0D\\X0A\K: contents of left neck lvevls 2,4,5- white marks 2, black marks 4, blue\X0D\\X0A\marks 5",,
REG1,OTHER,0,483639,1,,PREOP DIAGNOSIS:               RIGHT VOCAL CORD LESION,"**NAME[BBB,AAA] L                         ACCT #: **ID-NUM     LOC:  SDS    U #: 324100\X0D\\X0A\1036 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 54/M       ROOM:         REG: **DATE[May 04 12]\X0D\\X0A\DOB: **DATE[Jul 02 57]    BED:         DIS:\X0D\\X0A\STATUS: REG SDC    TLOC:","FINAL DIAGNOSIS\X0D\\X0A\A. LARYNX, RIGHT TRUE VOCAL CORD BIOPSY:\X0D\\X0A\.....INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.\X0D\\X0A\B. LARYNX, RIGHT TRUE VOCAL CORD BIOPSY:\X0D\\X0A\.....INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.\X0D\\X0A\\X0D\\X0A\FROZEN SECTION DIAGNOSIS\X0D\\X0A\LARYNX, RIGHT TRUE VOCAL CORD BIOPSY:\X0D\\X0A\.....SQUAMOUS CELL CARCINOMA.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ GREEN,**NAME[ZZZ] YYY] MD  **DATE[May 05 12]",,"GROSS DESCRIPTION\X0D\\X0A\Part A: A specimen labeled with the patient's name and designated \""right\X0D\\X0A\true vocal cord lesion\"" is received fresh for intraoperative consultation\X0D\\X0A\and consists of an irregularly shaped fragment of gray-tan rubbery tissue\X0D\\X0A\measuring 0.7 x 0.4 x 0.2 cm. The specimen is bisected and entirely\X0D\\X0A\submitted for frozen section evaluation and then resubmitted for permanent\X0D\\X0A\section in block A.\X0D\\X0A\Part B: A specimen labeled with the patient's name and designated \""right\X0D\\X0A\true vocal cord\"" is received fresh and consists of 3 irregularly shaped\X0D\\X0A\fragments of tan-pink soft tissue ranging in size from 0.5 down to 0.2 cm.\X0D\\X0A\The specimens are entirely submitted in block B.\X0D\\X0A\D: **DATE[May 04 2012] - 0829 hours\X0D\\X0A\T: **DATE[May 04 2012] - 9043 hours","MICROSCOPIC EXAMINATION\X0D\\X0A\A. Microscopic examination reveals sections of fragments of stratified\X0D\\X0A\squamous mucosa demonstrating an infiltrative epithelial lesion comprised\X0D\\X0A\of nests and interlacing trabeculae of atypical keratinocytic cells\X0D\\X0A\demonstrating moderately increased nuclear to cytoplasmic ratios and\X0D\\X0A\moderately pleomorphic angular nuclei with coarse chromatin and occasional\X0D\\X0A\nucleoli. Occasional atypical mitotic figures are also noted. Focal\X0D\\X0A\stromal desmoplasia and edema are identified as well as severe chronic\X0D\\X0A\inflammation. Malorientation of some fragments imposes limitations upon\X0D\\X0A\the assessment of invasion depth.\X0D\\X0A\B. Microscopic examination reveals sections of fragments of stratified\X0D\\X0A\squamous mucosa demonstrating an infiltrating epithelial lesion comprised\X0D\\X0A\of nests of atypical squamous epithelial cells with moderately increased\X0D\\X0A\nuclear to cytoplasmic ratios and moderately pleomorphic angular nuclei\X0D\\X0A\with coarse chromatin and prominent nucleoli. Keratin pearls are noted in\X0D\\X0A\some areas as well as severe chronic stromal inflammation. The supporting\X0D\\X0A\stroma demonstrates severe chronic inflammation, however focal areas of\X0D\\X0A\possible stromal desmoplasia are noted.\X0D\\X0A\D: **DATE[May 05 2012] - 0813 hours\X0D\\X0A\T: **DATE[May 05 2012] - 0839 hours","TISSUES:\X0D\\X0A\Vocal cord, NOS (RIGHT TRUE VOCAL CORD FOR FR)\X0D\\X0A\Vocal cord, NOS (RT TRUE VOCAL CORD BX)",,
REG1,OTHER,0,483972,1,,CLINICAL HISTORY:\X0D\\X0A\Hilar mass. No known primary.  Cholangiocarcinoma vs. hepatoma vs.\X0D\\X0A\metastasis.,"AP SPECI\X0D\\X0A\**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\ADDENDUM I\X0D\\X0A\**DATE[Mar 14 2012]\X0D\\X0A\ \X0D\\X0A\SPECIAL STAINS:\X0D\\X0A\ \X0D\\X0A\A panel of immunoperoxidase stains were attempted on the fibrous cores\X0D\\X0A\with minimally represented atypical epithelial cells including\X0D\\X0A\cytokeratin (MCK), CK7, CK20, CDX2, CEA, CAM 5.2 and HepPar 1. The\X0D\\X0A\atypical epithelioid cells are positive for cytokeratin (MCK) and CAM\X0D\\X0A\5.2 and focally positive for CK7 and CEA, but judged negative for all\X0D\\X0A\other markers including HepPar1, CK20 and CDX2 (excluding hepatocellular\X0D\\X0A\and colorectal origins from the differential). Staining was performed on\X0D\\X0A\minimally represented carcinoma primarily at the edge of the biopsy. The\X0D\\X0A\overall findings appear most consistent with minimally represented\X0D\\X0A\cholangiocarcinoma.  This case was shared in an internal consultation\X0D\\X0A\with Drs. **NAME[ZZZ] and **NAME[YYY], who concurred.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Mar 16 12] 15:31\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Mar 16 12] 15:31\X0D\\X0A\\X0D\\X0A\The previous value **NAME[XXX:  WWW M VVV] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Mar 11 21] was corrected by IF on **DATE[Mar 16 12] 15:31","GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   HILAR MASS, NEEDLE BIOPSY:  CORE OF HYALINIZED TISSUE WITH\X0D\\X0A\1.   Focal atypical glandular epithelium consistent with minimally\X0D\\X0A\represented adenocarcinoma.\X0D\\X0A\ \X0D\\X0A\COMMENT: Immunohistochemical work-up will be attempted to further\X0D\\X0A\classify this adenocarcinoma.  Results will follow in an addendum.  This\X0D\\X0A\case is shared in an internal consultation with Dr. **NAME[YYY], who\X0D\\X0A\concurs.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (MC)\X0D\\X0A\**NAME[XXX:  WWW M VVV] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\**NAME[XXX:  CCC M. DDD] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Mar 16 2012]",,GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'liver mass' are two core-like fragments\X0D\\X0A\of gray tissue measuring 0.3 and 1.2 cm in length each with an average\X0D\\X0A\tubal diameter of less than 0.1 cm. The specimen is submitted en toto as\X0D\\X0A\received in a single cassette.  (MC/cm)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 1,,"SPECIMEN(S): A Liver bx, needle",,
REG1,OTHER,0,484407,1,,"Clinical Diagnosis and History\X0D\\X0A\ABNORMAL LESION IN THE RIGHT PARIETAL AREA\X0D\\X0A\OPER:   RIGHT SIDE STEREOTACTIC CRANIOTOMY FOR TUMOR\X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX: HIGH GRADE GLIOMA, POSSIBLE GBM.  **INITIALS\X0D\\X0A\#2FSDX: GLIAL TISSUE WITH NEURONS.  NO TUMOR IDENTIFIED.  **INITIALS","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., RENATO\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RIGHT PARIETAL MASS  jy\X0D\\X0A\2: RIGHT PARIETAL MASS  jy\X0D\\X0A\3: RIGHT PARIETAL MASS. jl","Final Diagnosis\X0D\\X0A\1: RIGHT PARIETAL MASS BIOPSY:\X0D\\X0A\     HIGH GRADE GLIOMA.\X0D\\X0A\2: RIGHT PARIETAL MASS BIOPSY:\X0D\\X0A\     GLIAL TISSUE WITH NEURONS.\X0D\\X0A\     NO TUMOR IDENTIFIED.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **PLACE",,"Gross Description\X0D\\X0A\1: Received fresh for frozen diagnosis designated \""right parietal mass\"" are bits\X0D\\X0A\of pink gray tissue forming in aggregate 3 x 3 x 1 mm.  Crush preparation is\X0D\\X0A\made and the remainder submitted for frozen diagnosis.\X0D\\X0A\2: Received fresh for frozen diagnosis designated \""right parietal mass\"" are two\X0D\\X0A\bits of gray white tissue each measuring 1 and 2 mm.  Crush preparation is made\X0D\\X0A\and the remainder submitted for frozen diagnosis.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 3 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 3 2012]     By:  **NAME[XXX, WWW]\X0D\\X0A\     Date Reported:     **DATE[Apr 6 2012]         \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\3: BRAIN, RIGHT PARIETAL REGION, BIOPSIES:\X0D\\X0A\     GLIOBLASTOMA MULTIFORME.\X0D\\X0A\COMMENT: This lesion is WHO grade IV.  \X0D\\X0A\IHC/a/CMK\X0D\\X0A\MER/cb\X0D\\X0A\CAP REPORTING (SURGICAL PATHOLOGY CANCER CASE SUMMARY):\X0D\\X0A\     SPECIMEN TYPE:  Biopsy, not otherwise stated.\X0D\\X0A\     SPECIMEN HANDLING:  Squash/smear/touch preparation.\X0D\\X0A\     FROZEN SECTION:  Unfrozen for routine permanent paraffin sections.\X0D\\X0A\     LATERALITY:  Right.\X0D\\X0A\     TUMOR SITE: Brain, parietal lobe.\X0D\\X0A\     HISTOLOGIC TYPE:  Glioblastoma (WHO grade IV).\X0D\\X0A\     HISTOLOGIC GRADE: WHO grade IV.\X0D\\X0A\MER/ap  \X0D\\X0A\Addendum Comment\X0D\\X0A\GROSS, CONTINUED:\X0D\\X0A\3: Received in formalin labeled \""right parietal mass\"" is a 4.0 x 3.0 x 2.0 cm\X0D\\X0A\aggregate of soft tan red tissue fragments admixed with blood clot.  The entire\X0D\\X0A\specimen is submitted in blocks 3A through 3J.  DH/**INITIALS\X0D\\X0A\CLINICAL DIAGNOSIS AND HISTORY:\X0D\\X0A\RIGHT PARIETAL MASS\X0D\\X0A\OPER:   RIGHT STEREOTACTIC CRANIOTOMY WITH RESECTION OF RIGHT PARIETAL MASS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 10 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 10 2012]     By:  **NAME[UUU, TTT]\X0D\\X0A\     Date Reported:     **DATE[Apr 10 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Vitro\X0D\\X0A\Molecular Laboratories regarding EGFR FISH studies.\X0D\\X0A\Their report, in part:\X0D\\X0A\Positive for amplification of EGFR.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[SSS], M.D., **NAME[RRR]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 20 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 20 2012]     By:  **NAME[QQQ,PPP]\X0D\\X0A\     Date Reported:     **DATE[Apr 20 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Vitro Molecular Laboratories in the\X0D\\X0A\electronic medical records file regarding MGMT promoter methylation.   /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[SSS], M.D., **NAME[RRR]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Aug 3 2013]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 3 2013]     By:  **NAME[XXX, WWW]\X0D\\X0A\     Date Reported:     **DATE[Aug 3 2013]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned EGFRvIII Real-time PCR Assay report from\X0D\\X0A\Integrated Oncology in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\EGFRvIII DETECTED.\X0D\\X0A\Signed: **NAME[OOO NNN], M.D. \X0D\\X0A\See the complete scanned report for additional details  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D.,  MARK E."
REG1,OTHER,0,485363,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is right thyroid goiter.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Thyroid, throidectomy","Final Diagnosis\X0D\\X0A\RIGHT THYROID, LOBECTOMY:\X0D\\X0A\     Well differentiated follicular carcinoma.  See TEMPLATE and COMMENT.\X0D\\X0A\     One benign parathyroid gland identified.\X0D\\X0A\COMMENT:  I have discussed this with Dr. **NAME[ZZZ] on **DATE[Sep 13 11].\X0D\\X0A\**INITIALS     \X0D\\X0A\THYROID TEMPLATE:\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  right lobectomy\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\SPECIMEN SIZE:  5.8 x 4.0 x 2.6 cm\X0D\\X0A\TUMOR FOCALITY:  unifocal\X0D\\X0A\TUMOR LATERALITY:  unilateral\X0D\\X0A\TUMOR SITE:  right lobe\X0D\\X0A\TUMOR SIZE (greatest dimension):  4 cm\X0D\\X0A\HISTOLOGIC TYPE:  follicular\X0D\\X0A\HISTOLOGIC GRADE:  well differentiated\X0D\\X0A\MARGINS:  free by 1mm\X0D\\X0A\TUMOR CAPSULE:  focally penetrated by tumor\X0D\\X0A\TUMOR CAPSULAR INVASION:  present\X0D\\X0A\LYMPH-VASCULAR INVASION:  none seen\X0D\\X0A\PERINEURAL INVASION:  none seen\X0D\\X0A\EXTRATHYROIDAL EXTENSIONS:  into perithyroid fat\X0D\\X0A\NUMBER OF PARATHYROID(S) REMOVED:  1\X0D\\X0A\LYMPH NODE STATUS:  n/a\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  n/a\X0D\\X0A\OTHER STUDIES:  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 3 \X0D\\X0A\pN= x \X0D\\X0A\AJCC PATHOLOGIC STAGE:  I\X0D\\X0A\MHB",,"Gross Description\X0D\\X0A\Received in formalin labeled right thyroid consists of a lobectomy specimen that\X0D\\X0A\weighs 25.9 grams and measures 5.8 x 4.0 x 2.6 cm. There is a large nodule\X0D\\X0A\present protruding from the surface of the right lobe that measures 4.0 x 2.8 x\X0D\\X0A\2.0 cm. The specimen is inked, serially sectioned and submitted in toto in A-O.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\The thyroid shows a nodule with hypercellular appearance with some residual\X0D\\X0A\follicular pattern.  No papillary architecture or nuclear clearing is seen.  No\X0D\\X0A\definite vascular space invasion is identified.  The lesion does infiltrate\X0D\\X0A\through the capsule into the surrounding fat in block H.  The surrounding\X0D\\X0A\thyroid tissue shows variably sized colloid filled follicles without additional\X0D\\X0A\foci of neoplasm.  A single parathyroid gland is identified in blocks N and O. \X0D\\X0A\**INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY, XXX M].\X0D\\X0A\Procedures/Addenda"
REG1,OTHER,0,486355,1,,CLINICAL HISTORY: Preop diagnosis dysphagia.  Postop diagnosis esophageal mass.,"Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX WWW], MD **DATE[May 13 12]","FINAL DIAGNOSIS: ESOPHAGUS @ 30 CM., BIOPSY INFILTRATING MODERATELY DIFFERENTIATED ADENOCARCINOMA, SEE COMMENT.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and \""biopsy esophageal 30 cm.\""  The specimen is received in formalin and consists of multiple papillomatous-appearing viable pale tan tissue fragments and blood, measuring in toto 9 mm. The specimen is totally submitted in one block.",COMMENT WORD: Multiple sections of the esophageal mass at 30 cm. show the presence of an infiltrating moderately differentiated adenocarcinoma composed of large tubular-to-cribriform side budded glands lined by tall columnar cells with anaplastic hyperchromatic overlapping nuclei. Tumor is seen infiltrating smooth muscle.  An acute ulceration covered with a layer of fibrinous debris and containing numerous filamentous bacterial forms is present. Further evaluation of this patient is advised.,Specimen Number: ***PATH-NUMBER[1]. Tissues: Esophagus. Specimen Comments:,,
REG1,OTHER,0,486425,1,,"Clinical Diagnosis and History\X0D\\X0A\ABNORMAL CT, HEME + STOOL\X0D\\X0A\OPER: EGD, C-SCOPE","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: DISTAL ESOPHAGEAL TUMOR-ls\X0D\\X0A\2: SIGMOID POLYP-ls","Final Diagnosis\X0D\\X0A\1:  DISTAL ESOPHAGUS, BIOPSIES \X0D\\X0A\     FRAGMENTS OF GASTRIC TYPE MUCOSA WITH POORLY DIFFERENTIATED\X0D\\X0A\          MALIGNANT TUMOR, FAVOR CARCINOMA.\X0D\\X0A\     ADDITIONAL MARKER STUDIES PENDING.\X0D\\X0A\2:  SIGMOID COLON, BIOPSY \X0D\\X0A\     HYPERPLASTIC POLYP.\X0D\\X0A\MER/in\X0D\\X0A\IHC/a/THM\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\1: In formalin labeled \""distal esophageal tumor\"" are fragments of tan soft\X0D\\X0A\tissue 0.3 cm in aggregate. Block 1A.\X0D\\X0A\2: In formalin labeled \""sigmoid polyp\"" is a single 0.5 cm pink polyp which is\X0D\\X0A\bisected through the apparent base and all submitted in block 2A.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Aug 2 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Aug 2 2012]     By:  **NAME[XXX], M.D.,  MARK E.\X0D\\X0A\     Date Reported:     **DATE[Aug 2 2012]     * Amended *    \X0D\\X0A\Addendum Comment\X0D\\X0A\                              AMENDED REPORT:\X0D\\X0A\This amendment reflects the addition of the outside Genzyme Laboratory report\X0D\\X0A\which was inadvertently omitted.\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding immunostains. \X0D\\X0A\Their, report in part:\X0D\\X0A\INTERPRETATION: \X0D\\X0A\These results support a moderately to poorly differentiated adenocarcinoma of\X0D\\X0A\primary upper gastrointestinal tract.\X0D\\X0A\Signed: **NAME[WWW VVV], M.D.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D.,  MARK E.\X0D\\X0A\Amendments for SUPPLEMENTAL REPORT (**DATE[Aug 2 2012])\X0D\\X0A\Amended:  **DATE[Aug 2 2012] by **NAME[UUU, TTT]\X0D\\X0A\Reason:     ATTACHMENT INADVERTENTLY NOT ADDED TO SUPPLEMENTAL REPORT\X0D\\X0A\     This amendment reflects the attachment of the outside Genzyme report.\X0D\\X0A\Previous Signout Date:  **DATE[Aug 2 2012]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Sep 1 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Sep 1 2012]     By:  **NAME[SSS,RRR]\X0D\\X0A\     Date Reported:     **DATE[Sep 2 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding immunohistochemical analysis.   /ap\X0D\\X0A\INTERPRETATION, in part, reads:  These results support a moderately to poorly\X0D\\X0A\differentiated adenocarcinoma of primary upper gastrointestinal tract.  Signed: \X0D\\X0A\**NAME[WWW VVV], MD     /ap \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D.,  MARK E."
REG1,OTHER,0,486502,3,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is renal mass. Operative findings: not provided.\X0D\\X0A\Operative procedure: laparoscopic, renal cryoblation/oncura system versus\X0D\\X0A\laparoscopic partial nephrectomy. \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Apr 23 1956] (Age: **AGE[in 50s])  MB\X0D\\X0A\Collect Date: **DATE[Jan 12 2012] 11:58\X0D\\X0A\Receipt Date: **DATE[Jan 12 2012] 11:58\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: URO     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Jan 15 2012] 17:35\X0D\\X0A\RESIDENTS(S): V.V. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\LEFT KIDNEY, BIOPSY (B):\X0D\\X0A\   - RENAL CELL CARCINOMA WITH PAPILLARY FEATURES (see comment).\X0D\\X0A\PERITUMOR FAT, LEFT KIDNEY, BIOPSY (A):\X0D\\X0A\   - NO TUMOR SEEN.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Jan 14 2012] R.G. **NAME[UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09450 P1140\X0D\\X0A\B: M80503 M8312 \X0D\\X0A\F: A: 88305\X0D\\X0A\B: 88305, 67042 IMHC 1, S 88342 (PROF), 67042 IMHC 1, S 88342 (PROF), 67042\X0D\\X0A\IMHC 1, S 88342 (PROF)",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  two\X0D\\X0A\Specimen label:   A) peri-tumor fat               \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): brown tan\X0D\\X0A\Consistency: fatty\X0D\\X0A\Size(s): in aggregate 3.5 x 3.5 x 1 cm \X0D\\X0A\Cassette summary: entirely submitted in A1  A3.  \X0D\\X0A\Specimen label:  B) left renal mass biopsy                \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 2 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): red tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.2 x less than 0.1 x less than 0.1 cm and 0.1 x 0.1 x less than 0.1\X0D\\X0A\cm \X0D\\X0A\Cassette summary: entirely submitted in screened B1.  \X0D\\X0A\rgc/**DATE[Jan 13 2012] V.V. **NAME[VVV], MD\X0D\\X0A\J.G. Combs","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of this renal biopsy show a renal cell carcinoma (RCC) with\X0D\\X0A\papillary architectural pattern. The tumor cells demonstrate cuboidal to\X0D\\X0A\columnar cytomorphology, eosinophilic to clear cytoplasm, and a low nuclear\X0D\\X0A\grade. The columnar cells that show clear cytoplasm also exhibit reversely\X0D\\X0A\polarized nuclei which can be seen in a special subtype/entity called clear\X0D\\X0A\cell papillary RCC. In addition, the immunostains have been performed, and\X0D\\X0A\the tumor cells are diffusely positive for CK7 and show weak incomplete\X0D\\X0A\positivity for CD10. Therefore, while the overall features are consistent\X0D\\X0A\with a papillary RCC, the possibility of a component of clear cell papillary\X0D\\X0A\RCC cannot be excluded. The positivity for vimentin is also noted. This case\X0D\\X0A\has been reviewed at the daily Departmental Consensus Conference.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Peritumor fat\X0D\\X0A\B: Left renal mass biopsy,,
REG1,OTHER,0,486933,1,,"CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Ovarian mass, abdominal pain","FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\RE      011\X0D\\X0A\PHYSICIAN:       HOLLY GALLION    SIGN OUT DATE:   **DATE[Nov 11 2011]\X0D\\X0A\COPIES TO:          HOLLY GALLION\X0D\\X0A\**NAME[YYY XXX]\X0D\\X0A\COMMENT\X0D\\X0A\The frozen section portion of this report is called to the attention of\X0D\\X0A\Dr. **NAME[ZZZ] in the OR at 2:33 p.m. on **DATE[Oct 26 2011].\X0D\\X0A\ADDITIONAL COMMENT\X0D\\X0A\Both ovaries and tubes are involved by this ovarian neoplasm which has\X0D\\X0A\endometroid features as well as papillary serous cyst adenocarcinoma.\X0D\\X0A\Consultation and immunohistochemical stains is being obtained to see\X0D\\X0A\what there opinion is in regard to the exact cytological features as\X0D\\X0A\endometroid and papillary serous cyst adenocarcinoma are hard to\X0D\\X0A\differentiate.  This is a high-grade ovarian neoplasm, papillary\X0D\\X0A\characteristics with extension to the omentum and the anterior\X0D\\X0A\abdominal wall.","FROZEN SECTION DIAGNOSIS\X0D\\X0A\1. LEFT TUBE AND OVARY (1FS-1):  ENDOMETROID ADENOCARCINOMA.\X0D\\X0A\2. RIGHT TUBE AND OVARY (2FS-1):  ENDOMETROID ADENOCARCINOMA.\X0D\\X0A\DIAGNOSIS\X0D\\X0A\1. LEFT TUBE AND OVARY (FROZEN AND PERMANENT SECTIONS): PAPILLARY\X0D\\X0A\SEROUS CYST ADENOCARCINOMA VERSES ENDOMETRIOD ADENOCARCINOMA WITH\X0D\\X0A\INVASION AND HIGH-GRADE CHANGE.\X0D\\X0A\2. RIGHTTUBE AND OVARY (FROZEN AND PERMANENT SECTIONS):  PAPILLARY\X0D\\X0A\SEROUS CYST ADENOCARCINOMA WITH INVASION AND HIGH-GRADE CHANGE.\X0D\\X0A\3. ANTERIOR ABDOMINAL WALL, BIOPSY:  METASTATIC PAPILLARY SEROUS CYST\X0D\\X0A\ADENOCARCINOMA / ENDOMETRIOD ADENOCARCINOMA.\X0D\\X0A\4. OMENTUM:  INVOLVEMENT BY PAPILLARY SEROUS CYST ADENOCARCINOMA /\X0D\\X0A\ENDOMETRIOD CHANGE.  ADDITIONAL COMMENT.\X0D\\X0A\CPT4 88331 X2, 88305 X4 / ICD9 183.0, 199.0, M84713, M84716\X0D\\X0A\OUTSIDE CONSULTATION (Reviewed by Dr. **NAME[M. WWW VVV] at P\T\C\X0D\\X0A\Laboratories) See outside report.\X0D\\X0A\CONSULTANT's DIAGNOSIS:\X0D\\X0A\- RIGHT AND LEFT TUBE AND OVARY, SALPINGOOOPHORECTOMY (SPECIMENS 1\X0D\\X0A\AND 2):  High grade papillary\X0D\\X0A\serous adenocarcinoma. Invasive implant of left mesosalpinx.\X0D\\X0A\-     ANTERIOR ABDOMINAL WALL, BIOPSY:  Invasive implants of high\X0D\\X0A\grade papillary serous adenocarcinoma.\X0D\\X0A\-     OMENTUM, OMENTECTOMY:  Invasive implants of high grade\X0D\\X0A\papillary serous adenocarcinoma.",,"MACROSCOPIC\X0D\\X0A\SPECIMEN: Right ovary, left ovary, right fallopian tube, left\X0D\\X0A\fallopian tube, omentum, peritoneum, anterior abdominal wall\X0D\\X0A\PROCEDURE: Right \T\ Left oophorectomy, Right \T\ Left\X0D\\X0A\salpingo-oophorectomy, Omentectomy, Peritoneal biopsies\X0D\\X0A\LYMPH NODE SAMPLING: Not performed\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\RIGHT OVARY:  Covered with tumor\X0D\\X0A\LEFT OVARY:  Covered with tumor\X0D\\X0A\PRIMARY TUMOR SITE: Right ovary, Left ovary, Bilateral ovarian\X0D\\X0A\involvement\X0D\\X0A\OVARIAN SURFACE INVOLVEMENT: Present\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\RIGHT OVARY: 8 x 7 x 3.5 cm\X0D\\X0A\LEFT OVARY:  4 x 3 x 1.5 cm\X0D\\X0A\GROSS DESCRIPTION\X0D\\X0A\Specimen one is received fresh for frozen section diagnosis labeled\X0D\\X0A\\""left tube and ovary\"" and consists of same which weighs 14.1 grams and\X0D\\X0A\measures 4 x 3 x 1.5 cm.  On the dorsal aspect of this ovary adjacent\X0D\\X0A\to the fallopian tube is a purple tan irregular mass measuring 3 cm in\X0D\\X0A\diameter.  Representative sections are submitted as 1FS-1.  The left\X0D\\X0A\tube and ovary are submitted in formalin for better fixation prior to\X0D\\X0A\permanent sections.  After adequate fixation sections of the papillary\X0D\\X0A\mass is submitted in cassettes 1A-1C.\X0D\\X0A\Specimen two is received fresh for frozen section diagnosis labeled\X0D\\X0A\\""right tube and ovary\"" and consists of a cluster of tissue which\X0D\\X0A\includes an ovary.  This specimen weighs 77.1 grams and has a papillary\X0D\\X0A\process extending over the surface of this ovary.  The specimen\X0D\\X0A\measures 8 x 7 x 3.5 cm.  A section of this is submitted as 2FS-1.  It\X0D\\X0A\has a similar composition to that submitted as 1FS-1.  The right tube\X0D\\X0A\and ovary is placed into formalin for better sections for permanent.\X0D\\X0A\Sections through the right tube and ovary show a gray papillary soft\X0D\\X0A\process of malignancy which appears to be primary in the ovarian\X0D\\X0A\architecture.  Representative sections of this mass is submitted in\X0D\\X0A\cassettes 2A-2C.\X0D\\X0A\Specimen three is labeled \""anterior abdominal wall\"" and consists of a\X0D\\X0A\fibro-fatty irregular nodular mass with similar composition to that of\X0D\\X0A\the ovarian tumors.  This specimen measures 3 x 2 x 1.5 cm.\X0D\\X0A\Representative sections are submitted in cassettes 3A and 3B.\X0D\\X0A\Specimen four is labeled \""omentum\"" and consists of a triangular shaped\X0D\\X0A\omentum weighing 173.3 grams and measuring 13 x 7 x 3 cm.  This\X0D\\X0A\triangular shaped segment of fat and tumor is scattered throughout.\X0D\\X0A\Sections through the omentum show fibro-fatty tissue. From one end the\X0D\\X0A\narrow piece of the process shows mostly fat covered by this\X0D\\X0A\hemorrhagically discolored papillary process on the surface.  Sections\X0D\\X0A\through this entire process shows fatty tissue that has a surface\X0D\\X0A\involvement by this discolored gray-black process.  Representative\X0D\\X0A\sections of the fat with these applications on the surface are\X0D\\X0A\submitted in cassette 4A.  As one approaches the broad based end of the\X0D\\X0A\triangular segment a little more involvement by tumor is appreciated.\X0D\\X0A\This surrounds collars of fatty tissue and hemorrhagically discolored\X0D\\X0A\nodules arranging in size and shape from 0.1 to 0.3 cm and have\X0D\\X0A\confluence.  All of these are submitted in cassette 4B-4D.","MICROSCOPIC\X0D\\X0A\HISTOLOGIC TYPE: Serous, carcinoma\X0D\\X0A\HISTOLOGIC GRADE: G2, moderately differentiated\X0D\\X0A\TWO-TIER GRADING SYSTEM:  High grade\X0D\\X0A\IMPLANTS\X0D\\X0A\INVASIVE IMPLANT(S): Present  (Omentum and anterior abdominal wall)\X0D\\X0A\EXTENT OF INVOLVMENT OF OTHER TISSUES/ORGANS\X0D\\X0A\RIGHT OVARY: Involved\X0D\\X0A\RIGHT FALLOPIAN TUBE: Involved\X0D\\X0A\LEFT FALLOPIAN TUBE: Involved\X0D\\X0A\OMENTUM: Involved\X0D\\X0A\UTERUS: Not applicable\X0D\\X0A\PERITONEUM: Involved\X0D\\X0A\LYMPH-VASCUARL INVASION: Present\X0D\\X0A\PATHOLOGIC STAGING (pT3cpN0pm1)\X0D\\X0A\PRIMARY TUMOR: pT3c\X0D\\X0A\REGIONAL LYMPH NODES: pN0\X0D\\X0A\DISTANT METASTASIS: pm1\X0D\\X0A\MICROSCOPIC DESCRIPTION\X0D\\X0A\FROZEN SECTION SLIDE REVIEW\X0D\\X0A\Section 1FS-1 of the left ovary and tube shows a malignant tumor with\X0D\\X0A\glandular characterization favoring endometroid variety.  Additional\X0D\\X0A\sections will be submitted to determine that this is not mucinous cyst\X0D\\X0A\adenocarcinoma.  Very little mucin is seen in the frozen section\X0D\\X0A\portion.\X0D\\X0A\Section 2FS-1 of the right ovary and tube shows endometroid malignant\X0D\\X0A\tumor which is much larger than the opposite side.  Features are\X0D\\X0A\similar to that of 1FS-1.\X0D\\X0A\PERMANENT SLIDE REVIEW\X0D\\X0A\Section 1FS-1 of the left ovary and tube shows papillary tumor of\X0D\\X0A\ovarian origin with features compatible with endometroid variety,\X0D\\X0A\adenocarcinoma with invasive features (high-grade).  Section 1FS-1\X0D\\X0A\level 2 shows a papillary process with solid areas and extension of the\X0D\\X0A\process down into the ovarian stroma which is an endometroid variety\X0D\\X0A\adenocarcinoma verses a mucinous cyst adenocarcinoma.  I favor\X0D\\X0A\endometroid characteristics predominate the scenario.  Section 1A shows\X0D\\X0A\a papillary serous cyst adenocarcinoma verses endometroid\X0D\\X0A\adenocarcinoma.  This is a high-grade invasive malignant process.\X0D\\X0A\Adjacent ovarian stroma shows fibroblastic proliferation of the stroma.\X0D\\X0A\Section 1B shows more of the tumor with similar features.  Section 1C\X0D\\X0A\also shows similar features.\X0D\\X0A\Section 2FS-1 of the right ovary and tube show an identical lesion of\X0D\\X0A\serous cyst adenocarcinoma, papillary variety.  Invasion is\X0D\\X0A\appreciated.  High-grade changes are present.  Section 2FS-1 level 2\X0D\\X0A\shows a serous cyst adenocarcinoma with some endometroid features\X0D\\X0A\present.  Section 2A shows a papillary serous cyst adenocarcinoma.\X0D\\X0A\Necrosis is present.  Invasive features are present.  This is a\X0D\\X0A\high-grade malignant ovarian neoplasm, primary.  Sections 2B and 2C\X0D\\X0A\show similar histology.  More necrosis and invasion is present.\X0D\\X0A\Section 3A of the anterior abdominal wall shows a metastatic foci of\X0D\\X0A\this ovarian tumor in a dense desmoplastic stroma.  The process is\X0D\\X0A\compatible with a papillary serous cyst adenocarcinoma.  Psammoma\X0D\\X0A\bodies are present and calcified spherules are seen in this process as\X0D\\X0A\well.  Section 3B shows similar features.\X0D\\X0A\Sections 4A and 4D of the omentum show invasive papillary serous cyst\X0D\\X0A\adenocarcinoma extending into the omentum.  This is a high-grade\X0D\\X0A\invasive malignant neoplasm of ovarian origin, serous cyst\X0D\\X0A\adenocarcinoma variety.\X0D\\X0A\<Sign Out Dr. **NAME[UUU]>\X0D\\X0A\**NAME[TTT SSS], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  (1) OVARY AND TUBE , LEFT, SURGICAL EXCISION\X0D\\X0A\(2) OVARY AND TUBE,\X0D\\X0A\RIGHT, SURGICAL EXCISION\X0D\\X0A\(3) ABDOMEN BX,\X0D\\X0A\SURGICAL BIOPSY\X0D\\X0A\Anterior abdominal\X0D\\X0A\wall\X0D\\X0A\(4) OMENTUM,\X0D\\X0A\SURGICAL EXCISION",,
REG1,OTHER,0,486936,3,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Bladder cancer,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\RE      011\X0D\\X0A\PHYSICIAN:       MARK SWOFFORD    SIGN OUT DATE:   **DATE[Feb 02 2012]\X0D\\X0A\COPIES TO:          MARK SWOFFORD,DIAGNOSIS\X0D\\X0A\URINARY BLADDER;  PAPILLARY TRANSITIONAL CELL CARCINOMA\X0D\\X0A\PATHOLOGIC STAGING\X0D\\X0A\PRIMARY TUMOR: pT1\X0D\\X0A\REGIONAL LYMPH NODES:  Not applicable\X0D\\X0A\DISTANT METASTASIS: Not applicable,,"MACROSCOPIC\X0D\\X0A\PROCEDURE:  TURBT\X0D\\X0A\GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled \""bladder biopsy, left\X0D\\X0A\wall\"" and consists of multiple red and yellow-tan irregular soft tissue\X0D\\X0A\fragments measuring in aggregate 2 x 1.5 x 0.5 cm.  The specimen is\X0D\\X0A\entirely submitted in cassette A.","MICROSCOPIC\X0D\\X0A\HISTOLOGIC TYPE:  Urothelial (transtitional cell carcinoma)\X0D\\X0A\ASSOCIATED EPITHELIAL LESIONS: None identified\X0D\\X0A\HISTOLOGIC GRADE: II/III\X0D\\X0A\TUMOR CONFIGURATION: Papillary\X0D\\X0A\ADEQUACY OF MATERIAL: Muscularis propria\X0D\\X0A\LYMPH-VASCULAR INVASION:  Present\X0D\\X0A\MICROSCOPIC EXTENT OF TUMOR: Tumor invades subepithelial tissue\X0D\\X0A\(lamina propria)\X0D\\X0A\MICROSCOPIC DESCRIPTION\X0D\\X0A\Microscopic description performed.\X0D\\X0A\<Sign Out Dr. **NAME[ZZZ]>\X0D\\X0A\**NAME[YYY XXX], PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  URINARY BLADDER TUMOR, SURGICAL EXCISION\X0D\\X0A\Bladder biopsy left\X0D\\X0A\wall",,
REG1,OTHER,0,487679,1,,Clinical Diagnosis and History\X0D\\X0A\Post menopausal bleeding,Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Endocervical\X0D\\X0A\2: Endometrial,"Final Diagnosis\X0D\\X0A\     .     Submitted endocervical curettings:     Fragment of lower uterine\X0D\\X0A\segment endometrial mucosa with   focal involvement by well differentiated\X0D\\X0A\endometrial adenocarcinoma.\X0D\\X0A\2.          Endometrial curettings:  Endometrial adenocarcinoma, endometrioid\X0D\\X0A\type with extensive mucinous differentiation, grade 1.\X0D\\X0A\Comment: The endometrial adenocarcinoma shows prominent mucinous\X0D\\X0A\differentiation. Differential diagnosis is endometrioid adenocarcinoma with\X0D\\X0A\mucinous differentiation versus mucinous adenocarcinoma. The behavior of the two\X0D\\X0A\tumors is essentially the same. Endocervical adenocarcinoma is ruled out by the\X0D\\X0A\strong vimentin positivity within the adenocarcinoma.\X0D\\X0A\                                   1\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], MD",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin labeled with the patient's name and\X0D\\X0A\designated \""endocervical\"".  The specimen consists of a tan-pink soft tissue\X0D\\X0A\fragment admixed with tan-red gelatinous material. The tissue fragment measures\X0D\\X0A\0.3 x 0.2 x 0.2 cm.  The gelatinous material aggregates to 1.1 x 0.8 x 0.1 cm. \X0D\\X0A\The specimen is totally submitted in (block 1A).\X0D\\X0A\Specimen #2 is received in formalin labeled with the patient's name and\X0D\\X0A\designated \""endometrial\"".  The specimen consists of multiple yellow-tan soft\X0D\\X0A\\""beefy\"" tissue fragments admixed with pink-brown soft material and blood clot.\X0D\\X0A\The fragments aggregate to 6.8 x 6.3 x 0.6 cm.  The specimen is totally\X0D\\X0A\submitted in (blocks 2A-2E).\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Sections of the endocervical curettings reveal a fragment of benign lower\X0D\\X0A\uterine segment endometrial mucosal tissue. There is focal involvement by the\X0D\\X0A\endometrial adenocarcinoma described below.  \X0D\\X0A\Sections of the endometrial curettings reveal a well differentiated\X0D\\X0A\adenocarcinoma. The tumor forms complex glandular forms throughout. The glands\X0D\\X0A\have a complex characteristic with large dilated glands many containing\X0D\\X0A\intraluminal papillary tufting.  There is associated abundant basophilic mucus\X0D\\X0A\within the center of the dilated glandular spaces.  There is an associated\X0D\\X0A\marked acute inflammation with neutrophils seen infiltrating the neoplastic\X0D\\X0A\glandular walls and seen within the glandular lumina. The adenocarcinoma\X0D\\X0A\demonstrates areas of mucinous differentiation as well as endometrioid\X0D\\X0A\differentiation. Mucicarcmine stain is performed along with appropriate positive\X0D\\X0A\control. There is abundant mucin positivity with the large glandular spaces.\X0D\\X0A\There are scattered foci displaying intracytoplasmic positivity, but the number\X0D\\X0A\of cells are less than ten percent.   Vimentin stain(positive control 3+) and\X0D\\X0A\CEA(positive control 3+) are performed along with appropriate negative control.\X0D\\X0A\There is strong positivity within the tumor cells with vimentin confirming an\X0D\\X0A\endometrial primary over endocervical primary. CEA stain is a characteristic of\X0D\\X0A\a mucinous adenocarcinoma. \X0D\\X0A\**INITIALS",,,
REG1,OTHER,0,487813,1,,CLINICAL INFORMATION:\X0D\\X0A\,"**INSTITUTION          MR #: **ID-NUM\X0D\\X0A\**INSTITUTION          **NAME[BBB, AAA]\X0D\\X0A\**PLACE, KENTUCKY  **ZIP-CODE          **DATE[Nov 7 1972] (Age: **AGE[in 30s])   MO\X0D\\X0A\          Collect Date: **DATE[Jul 28 2012] 00:00\X0D\\X0A\          Receipt Date: **DATE[Jul 28 2012] 14:50\X0D\\X0A\          Page 1\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND  LABORATORY MEDICINE\X0D\\X0A\CYTOPATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax: **PHONE\X0D\\X0A\Email: **EMAIL          ***PATH-NUMBER[1]     \X0D\\X0A\     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD/Practitioner:  **NAME[YYY XXX], MD     Service: PUL     Location:\X0D\\X0A\1MED\X0D\\X0A\OTHER  MD(**NAME[M): WWW VVV], MD     Reported: **DATE[Jul 29 2012] 15:53\X0D\\X0A\     Collected: **DATE[Jul 28 2012] 00:00\X0D\\X0A\\X0D\\X0A\COMMENT\X0D\\X0A\In view of the retroperitoneal adenopathy, gastric bleeding, and possible\X0D\\X0A\pancreatic lesion, the differential diagnosis includes, but is not limited\X0D\\X0A\to, non-intestinal type adenocarcinoma and pancreatic adenocarcinoma. \X0D\\X0A\Although a good cell block was obtained, no immunohistochemical panel is\X0D\\X0A\available to definitively distinguish between these two neoplasms. \X0D\\X0A\Correlation with serum tumor markers and all imaging studies is recommended. \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ Y.M. **NAME[UUU], MD\X0D\\X0A\DLR \X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ULTRASOUND GUIDED FNA, LEFT NECK LYMPH NODES (SMEARS AND CELL BLOCK): \X0D\\X0A\  - POSITIVE FOR MALIGNANCY, POORLY DIFFERENTIATED ADENOCARCINOMA.  (SEE\X0D\\X0A\COMMENT)\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\CLINICAL DIAGNOSIS\X0D\\X0A\Abdominal mass retroperitoneal\X0D\\X0A\Enlarged neck nodes\X0D\\X0A\\X0D\\X0A\Medicine ICU / FNA performed by: Dr. **NAME[M. VVV]\X0D\\X0A\\X0D\\X0A\Immediate evaluation performed by: Dr. **NAME[M. UUU]\X0D\\X0A\PASS # 1: tumor \X0D\\X0A\     2: necrosis\X0D\\X0A\     3: viable\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\ICD-9: 196.0     LYMPH NODES OF HEAD, FACE, AND NECK, SECONDARY AND\X0D\\X0A\UNSPECIFIED MALIGNANT NEOPLASM\X0D\\X0A\ F: A: 88173 ASP INTER, 67605, 88305, 88172, 88177(2) SNOMED CODES: A:\X0D\\X0A\M814033 T08200 TY0609 P1149 T03300\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\",,GROSS DESCRIPTION:\X0D\\X0A\\X0D\\X0A\Cell block made by resident (formalin)\X0D\\X0A\,,"SPECIMEN DESCRIPTION:\X0D\\X0A\A:  FNA LEFT NECK LYMPH NODES\X0D\\X0A\     DIFF-QUIK x 5, PAP STAIN x 7, CELL BLOCK x 1\X0D\\X0A\",,
REG1,OTHER,0,487819,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is endometrial cancer. Intraoperative findings: not\X0D\\X0A\given. Operative procedure: robotic laparoscopic, total hysterectomy,\X0D\\X0A\bilateral salpingo-oophorectomy, pelvic lymph node sampling. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""GRADE 1 ENDOMETRIOID WITH SUPERFICIAL INVASION\X0D\\X0A\AND ONE REPRESENTATIVE FROZEN SECTION\""---YMB. \X0D\\X0A\\X0D\\X0A\     Y.M. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 27 1948] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Nov 19 2011] 00:00\X0D\\X0A\Receipt Date: **DATE[Nov 20 2011] 07:22\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: **NAME[M. XXX], MD     Service: GYO     Location: 2MCC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Nov 22 2011] 15:59\X0D\\X0A\RESIDENTS(S): J.P. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\OMENTUM, OMENTECTOMY (A):   - NO TUMOR SEEN.LEFT FALLOPIAN TUBE AND OVARY,\X0D\\X0A\SALPINGO-OOPHORECTOMY (B):   - OVARY WITH CORTICAL STROMAL HYPERPLASIA AND\X0D\\X0A\BENIGN EPITHELIAL INCLUSIN CYSTS.   - DILATED FALLOPIAN TUBE WITH DYSTROPHIC\X0D\\X0A\CALCIFICATION AND PARATUBAL CYST. RIGHT FALLOPIAN TUBE AND OVARY,\X0D\\X0A\SALPINGO-OOPHORECTOMY (C):   - OVARY WITH CORTICAL STROMAL HYPERPLASIA AND\X0D\\X0A\BENIGN EPITHELIAL INCLUSIN CYSTS.   - DILATED FALLOPIAN TUBE WITH PARATUBAL\X0D\\X0A\CYST AND WALTHARD RESTS.UTERINE FUNDUS, LAPAROSCOPIC ROBOTIC HYSTERECTOMY\X0D\\X0A\(D):   - INVASIVE WELL DIFFERENTIATED ENDOMETRIOID CARCINOMA WITH FOCAL\X0D\\X0A\SQUAMOUS DIFFERENTIATION (FIGO     GRADE I) (pT1a, pNX, SEE TEMPLATE).   -\X0D\\X0A\TUMOR CONFINED TO INNER ONE HALF.   - MARGINS OF RESECTION FREE OF TUMOR.   -\X0D\\X0A\PARAMETRIUM WITH NO TUMOR SEEN.   - LEIOMYOMATA, LARGEST 3.0 CM.\X0D\\X0A\CERVIX, EXCISION (E):   - CHRONIC CYSTIC CERVICITIS, NO TUMOR SEEN.\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Nov 22 2011] **NAME[M. UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09450 M2635 \X0D\\X0A\F: A: 88305\X0D\\X0A\D: 88331 FS1, 88309",,"GROSS DESCRIPTION\X0D\\X0A\Five specimens are received. \X0D\\X0A\Specimen label:  A) omentum                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color: pink tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 23.5 x 13.4 x 0.7 cm \X0D\\X0A\The specimen is palpated and serially sectioned and does not reveal any gross\X0D\\X0A\masses or lesions. Cut surface of the specimen reveals pink tan glistening\X0D\\X0A\adipose tissue.\X0D\\X0A\Cassette summary: the specimen is representatively submitted in A1  A3. \X0D\\X0A\Specimen B is received in formalin labeled left tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 18.7 g post fixation.  The fallopian tube\X0D\\X0A\has an identifiable fimbriated end.  No paratubal cysts are noted. The tube\X0D\\X0A\is serially sectioned to reveal a dilated lumen.  \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 4.7 cm length x 1.1 cm diameter\X0D\\X0A\Ovary: 3.7 x 2.3 x 1.4 cm\X0D\\X0A\Representative sections:\X0D\\X0A\B1  B2  fallopian tube \X0D\\X0A\B3  ovary\X0D\\X0A\Specimen C is received in formalin labeled right tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 17.6 g post fixation.  The fallopian tube\X0D\\X0A\has an identifiable fimbriated end.  No paratubal cysts are noted.  The tube\X0D\\X0A\is serially sectioned to reveal a dilated lumen.  \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 4.5 cm length x 1.2 cm diameter\X0D\\X0A\Ovary: 3.5 x 1.7 x 1.6 cm\X0D\\X0A\Representative sections:\X0D\\X0A\C1  fallopian tube and fimbria\X0D\\X0A\C2  representative ovary and fallopian tube\X0D\\X0A\C3 - ovary\X0D\\X0A\Specimen D is received fresh for frozen section labeled \""uterine fundus\"" and\X0D\\X0A\consists of the aforementioned.\X0D\\X0A\Sectioning of the endomyometrium reveals a markedly thickened friable\X0D\\X0A\endometrial tumor involving the anterior and posterior      endometrium.  It\X0D\\X0A\measures 4.5 x 4.5 x 1.1 cm.  The lesion grossly does invade the endometrium\X0D\\X0A\in the inner one-half.  The lesion grossly does not extend into the\X0D\\X0A\endocervical canal. Polypoid nodules are not present in the subserosal\X0D\\X0A\posterior myometrium. These measure 3.0 and 2.1 cm in diameter. There is also\X0D\\X0A\an intramural nodule measuring 1.0 cm.  \X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight - 188 g\X0D\\X0A\Dimensions of uterus  7.0 cm (length) x 8.5 cm (width) x 4.5 cm (ant-post) \X0D\\X0A\Depth of endometrial cavity  4.5 cm\X0D\\X0A\Tumor/Polyp dimensions  4.5 cm (greatest) x 4.5 cm (smaller) x 1.0 cm (max\X0D\\X0A\thickness) involving the entire endometrial cavity\X0D\\X0A\Depth of invasion  1.1 cm tumor/0.3 cm endomyometrium\X0D\\X0A\Distance to internal os  0.6 cm from resection margin\X0D\\X0A\     Tumor location  (fundus, posterior and anterior)\X0D\\X0A\     Percent of endometrial surface involvement: 95%\X0D\\X0A\Uninvolved endometrial thickness  not identified\X0D\\X0A\Uninvolved myometrial thickness  2.3 cm\X0D\\X0A\Os diameter  0.8 cm\X0D\\X0A\Cassette summary: \X0D\\X0A\D1  FS1A\X0D\\X0A\D2  FS1B\X0D\\X0A\D3  right parametrium\X0D\\X0A\D4  left parametrium\X0D\\X0A\D5  anterior resection margin\X0D\\X0A\D6  posterior resection margin\X0D\\X0A\D7  D8  anterior full thickness, endometrium in D7; serosa in D8; serosa is\X0D\\X0A\inked black\X0D\\X0A\D9  D10  posterior full thickness endomyometrium bisected\X0D\\X0A\D9  endometrium\X0D\\X0A\D10  serosa inked black\X0D\\X0A\Representative sections of the nodules are submitted in D11  D13\X0D\\X0A\D11  largest nodule\X0D\\X0A\D12  second largest nodule\X0D\\X0A\D13  two intramural nodules\X0D\\X0A\Specimen label:  E) cervix                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: firm\X0D\\X0A\Size(s): 3.3 cm in length x 3.1 x 3.2 cm\X0D\\X0A\The os measures 0.8 cm \X0D\\X0A\The specimen is received unoriented. The ectocervix is pink tan and grossly\X0D\\X0A\unremarkable.\X0D\\X0A\Cassette summary: it is bisected to reveal a grossly unremarkable endocervix.\X0D\\X0A\The specimen is submitted as follows: E1  proximal resection margin; E2  E3 \X0D\\X0A\representative presumed 12 and 6:00 sections of cervix.  \X0D\\X0A\rgc/**DATE[Nov 21 2011] J.P. **NAME[VVV], MD\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Oct 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery: robotic laparoscopic total abdominal hysterectomy with\X0D\\X0A\bilateral salpingo-oophorectomy \X0D\\X0A\Weight of uterus: 188 grams\X0D\\X0A\Dimensions of uterus: 7 cm (length) x 8.5 cm (width) x 4.5 cm\X0D\\X0A\(anterior-posterior dimension)\X0D\\X0A\Histologic type of the tumor: endometrioid\X0D\\X0A\Tumor grade of differentiation (FIGO grade I/II/III):  I \X0D\\X0A\Tumor size:   4.5 x 4.5 x 1 cm \X0D\\X0A\Distance from internal os: 0.6 cm from resection margin\X0D\\X0A\Confined to endometrium:   no\X0D\\X0A\Myometrial invasion:  yes (inner    ) \X0D\\X0A\Depth of invasion:   % of myometrial involvement  24%\X0D\\X0A\                                (7 mm from EM junction/29 mm myometrial\X0D\\X0A\thickness) *   \X0D\\X0A\Nontumorous endometrium: not present\X0D\\X0A\Serosal involvement: no\X0D\\X0A\Adnexal involvement (specify): no\X0D\\X0A\Parametrial soft tissues:   no\X0D\\X0A\Cervical involvement:\X0D\\X0A\     Endocervical epithelium no\X0D\\X0A\     Stroma no\X0D\\X0A\Lymphvascular invasion: no\X0D\\X0A\Lymph node involvement (specify):    not applicable\X0D\\X0A\Other sites of involvement (list): none\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\         pT1a    IA            Tumor limited to endometrium or invades < 1/2\X0D\\X0A\of the myometrium\X0D\\X0A\\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\pNX                               Regional lymph nodes cannot be assessed\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\                                       Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Omentum\X0D\\X0A\B: Left tube and ovary\X0D\\X0A\C: Right tube and ovary\X0D\\X0A\D: Uterine fundus\X0D\\X0A\E: Cervix,,
REG1,OTHER,0,487951,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is pelvic mass. Intraoperative findings: pelvic mass.\X0D\\X0A\Operative procedure: total abdominal hysterectomy, bilateral\X0D\\X0A\salpingo-oophorectomy, possible lymphadenectomy, omentectomy and staging. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""RIGHT TUBE AND OVARY CONSISTENT WITH SEROUS\X0D\\X0A\CYSTADENOMAFIBROMA ON REPRESENTATIVE SECTIONS\""---MP.\X0D\\X0A\IOC: \""ON CUT AND LOOK NO ENDOMETRIAL THICKENING WAS OBSERVED.\""MP.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""ENDOMETRIUM, NO TUMOR SEEN ON REPRESENTATIVE\X0D\\X0A\SECTIONS\""---MP. \X0D\\X0A\\X0D\\X0A\     M.S. **NAME[ZZZ], M.D.","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Nov 2 1938] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Nov 15 2011] 10:40\X0D\\X0A\Receipt Date: **DATE[Nov 15 2011] 10:40\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: J.R. **NAME[CCC DDD] XXX]., MD     Service: GYO     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Nov 20 2011] 16:34\X0D\\X0A\RESIDENTS(**NAME[M): VVV UUU], DO\X0D\\X0A\COMMENT:  The entire endometrium is submitted for microscopic evaluation due\X0D\\X0A\to the presence of complex hyperplasia with atypia noted on the initial\X0D\\X0A\representative sections.  On additional sections, focal well differentiated\X0D\\X0A\endometrioid adenocarcinoma is noted.  This focus of tumor was not present in\X0D\\X0A\the representative section submitted for frozen section. \X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\RIGHT OVARY AND FALLOPIAN TUBE (A), RIGHT SALPINGO-OOPHORECTOMY:   - SEROUS\X0D\\X0A\CYSTADENOFIBROMA.LEFT OVARY AND FALLOPIAN TUBE (B), LEFT\X0D\\X0A\SALPINGO-OOPHORECTOMY:   - NO PATHOLOGIC ABNORMALITY.UTERUS (C),\X0D\\X0A\SUPRACERVICAL HYSTERECTOMY:   - ENDOMETRIUM: FOCAL WELL DIFFERENTIATED\X0D\\X0A\ENDOMETRIOID ADENOCARCINOMA ARISING IN THE SETTING OF \X0D\\X0A\       COMPLEX HYPERPLASIA WITH ATYPIA (FIGO pT1a, pNX), SEE TEMPLATE.\X0D\\X0A\   - MYOMETRIUM: NO PATHOLOGIC ABNORMALITIES.   - PARAMETRIUM: NO TUMOR SEEN.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Nov 19 2011] **NAME[TTT M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\\X0D\\X0A\F: A: 88307\X0D\\X0A\A,C: 88331 FS1(2)\X0D\\X0A\C: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Three specimens are received.\X0D\\X0A\Specimen A is received fresh for frozen section labeled right tube and ovary\X0D\\X0A\and consists of the aforementioned which weigh 356     g fresh.  \X0D\\X0A\The fallopian tube has an identifiable fimbriated end.  No paratubal cysts\X0D\\X0A\are noted.  There are no excrescences along its serosal surface.  The tube is\X0D\\X0A\serially sectioned to reveal a pinpoint lumen.  \X0D\\X0A\The ovary measured 12.4 x 7.8 x 6.1 cm prior to opening. It had multiple\X0D\\X0A\cystic structures that were filled with serous fluid.  It is received intact\X0D\\X0A\without excrescences on its surface.  It is serially sectioned to reveal\X0D\\X0A\multiple cystic compartments filled with serous fluid and small minute\X0D\\X0A\excrescences were seen inside of the one cyst. There is no residual grossly\X0D\\X0A\unremarkable ovary.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 4 cm length x 0.5 cm diameter\X0D\\X0A\Ovary:  12.4 x 7.8 x 6.1 cm pre-fixation\X0D\\X0A\Representative sections:\X0D\\X0A\A1  frozen section resubmitted\X0D\\X0A\A2  entire fallopian tube including fimbria \X0D\\X0A\A3  representative sections of ovary\X0D\\X0A\A4  representative sections of ovary \X0D\\X0A\Specimen B is received in formalin labeled left tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 5.25 g post fixation.  The fallopian tube\X0D\\X0A\has an identifiable fimbriated end.  No paratubal cysts are noted.  The tube\X0D\\X0A\is serially sectioned to reveal a pinpoint lumen.  \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 3.5 cm length x 0.6 cm diameter\X0D\\X0A\Ovary: 2 x 1.5 x 1 cm\X0D\\X0A\Representative sections:\X0D\\X0A\B1  sections of fallopian tube with fimbriated end \X0D\\X0A\B2  rest of fallopian tube and two representatives sections of the ovary\X0D\\X0A\Specimen C is received fresh for cut and look and frozen labeled \""uterus and\X0D\\X0A\cervix\"" and consists of the aforementioned. \X0D\\X0A\There are no nodules located in the serosa or mucosal. The uterus itself is\X0D\\X0A\characterized by a whorled appearance with no gross hemorrhage or necrosis on\X0D\\X0A\sectioning. \X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight  45.6 g\X0D\\X0A\Uterus dimensions  6.5 cm (length) x 5 cm (width) x 2 cm (ant-post)\X0D\\X0A\Os diameter  0.2 cm\X0D\\X0A\Endocervical canal length  0.9 cm\X0D\\X0A\Myometrial thickness  1 cm\X0D\\X0A\Endometrial thickness  0.2 cm\X0D\\X0A\Representative sections:\X0D\\X0A\C1  FS1 resubmitted with consists of the anterior and posterior endometrium.\X0D\\X0A\Anterior is inked blue.\X0D\\X0A\C2  representative section of anterior and posterior cervix, posterior inked\X0D\\X0A\black \X0D\\X0A\C3  representative section of anterior endometrium to myometrium to serosa\X0D\\X0A\C4  representative section of posterior endometrium to myometrium to serosa \X0D\\X0A\C5  parametrium on the left \X0D\\X0A\C6  parametrium on the right\X0D\\X0A\C7- residual resection margin anteriorly\X0D\\X0A\C8- left anterior endometrium\X0D\\X0A\C9- Left endometrial cavity anterior endometrium\X0D\\X0A\C10- Right endometrial cavity anterior endometrium\X0D\\X0A\C11- anterior endometrium\X0D\\X0A\C12- anterior endometrium\X0D\\X0A\C13- anterior endometrium\X0D\\X0A\C14- anterior fundic endometrium\X0D\\X0A\C15- posterior resection margin\X0D\\X0A\C16- right posterior endometrium\X0D\\X0A\C17- left posterior endometrium\X0D\\X0A\C18-C21- posterior endometrium\X0D\\X0A\C22- posterior fundic endometrium\X0D\\X0A\rgc/**DATE[Nov 16 2011] **NAME[VVV UUU], DO\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Oct 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery: supracervical hysterectomy / bilateral salpingo-oophorectomy\X0D\\X0A\Weight of uterus: 45.6 grams\X0D\\X0A\Dimensions of uterus:  6.5 cm (length) x 5 cm (width) x 2 cm\X0D\\X0A\(anterior-posterior dimension)\X0D\\X0A\Histologic type of the tumor: well differentiated endometrioid adenocarcinoma\X0D\\X0A\arising in the setting of complex hyperplasia with atypia\X0D\\X0A\Tumor grade of differentiation (FIGO grade I/II/III): FIGO I  \X0D\\X0A\Tumor size:   microscopic \X0D\\X0A\Distance from internal os: not applicable\X0D\\X0A\Confined to endometrium:  yes \X0D\\X0A\Myometrial invasion:   no \X0D\\X0A\Depth of invasion:   not applicable \X0D\\X0A\Nontumorous endometrium: complex hyperplasia with atypia\X0D\\X0A\Serosal involvement: no\X0D\\X0A\Adnexal involvement (specify): no\X0D\\X0A\Parametrial soft tissues:  no\X0D\\X0A\Cervical involvement: not applicable\X0D\\X0A\Lymphvascular invasion: not identified\X0D\\X0A\Lymph node involvement (specify):    not applicable, not received\X0D\\X0A\\X0D\\X0A\Other sites of involvement (list): none\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\pT              FIGO\X0D\\X0A\         pT1a    IA            Tumor limited to endometrium or invades < 1/2\X0D\\X0A\of the myometrium\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\pNX                               Regional lymph nodes cannot be assessed\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\                                       Not applicable",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right tube and ovaries\X0D\\X0A\B: Left tube and ovary\X0D\\X0A\C: Uterus,,
REG1,OTHER,0,487975,1,,CLINICAL INFORMATION:\X0D\\X0A\,"**INSTITUTION          MR #: **ID-NUM\X0D\\X0A\**INSTITUTION          **NAME[BBB, AAA M].\X0D\\X0A\**PLACE, KENTUCKY  **ZIP-CODE          **DATE[May 21 1951] (Age: **AGE[in 60s])   FW\X0D\\X0A\          Collect Date: **DATE[Jul 15 2012] 00:00\X0D\\X0A\          Receipt Date: **DATE[Jul 15 2012] 09:32\X0D\\X0A\          Page 1\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND  LABORATORY MEDICINE\X0D\\X0A\CYTOPATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax: **PHONE\X0D\\X0A\Email: **EMAIL          ***PATH-NUMBER[1]     \X0D\\X0A\     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD/Practitioner:  **NAME[M. YYY], MD     Service: MT1     Location: S2W\X0D\\X0A\OTHER  MD(**NAME[M]): P.A. **NAME[XXX], MD\X0D\\X0A\S.P. **NAME[WWW], MD\X0D\\X0A\**NAME[M. VVV], MD     Reported: **DATE[Jul 15 2012] 17:47\X0D\\X0A\     Collected: **DATE[Jul 15 2012] 00:00\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ENDOSCOPIC ULTRASOUND GUIDED FNA, HEAD OF PANCREAS: POSITIVE FOR MALIGNANCY,\X0D\\X0A\ADENOCARCINOMA.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ L.M. **NAME[UUU], MD\X0D\\X0A\LMS \X0D\\X0A\\X0D\\X0A\CLINICAL DIAGNOSIS\X0D\\X0A\**AGE[in 60s] y/o with obstructive jaundice 3.3x2.5 cm mass HOP FNA \S\\S\ Ca. 19-9\X0D\\X0A\\X0D\\X0A\Laboratory staff and/or housestaff attended procedure to prepare cytology\X0D\\X0A\aspirate slides.\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\ICD-9: 157.0     MALIGNANT NEOPLASM PANCREAS HEAD\X0D\\X0A\ F: A: 88173 ASP INTER, 62997 SNOMED CODES: A: M81403 T59100 P1149 T59000\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\",,GROSS DESCRIPTION:\X0D\\X0A\\X0D\\X0A\Hold needle rinse fluid.\X0D\\X0A\,,"SPECIMEN DESCRIPTION:\X0D\\X0A\A:  FNA HEAD OF PANCREAS, ENDOSCOPIC ULTRASOUND GUIDED\X0D\\X0A\     DIFF-QUIK x 3, PAP STAIN x 5\X0D\\X0A\",,
REG1,OTHER,0,488061,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is non-allopathic lesions pelvic region (739.5),\X0D\\X0A\dysfunctional or function uterine hemorrhage NOS (626.8).","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Endometrium, biopsy","Final Diagnosis\X0D\\X0A\ENDOMETRIAL CURETTINGS: \X0D\\X0A\     Poorly differentiated adenocarcinoma with probable squamous component. See\X0D\\X0A\comment:\X0D\\X0A\COMMENT:  I have discussed this with Dr. **NAME[ZZZ] on **DATE[Nov 27 11].  The tumor is\X0D\\X0A\poorly differentiated, but shows some features suggesting endocervical rather\X0D\\X0A\than endometrial origin.\X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled endometrial is a 2.0 x 1.5 x 0.4 cm aggregate of\X0D\\X0A\tan soft tissue which is wrapped and submitted in toto in one cassette.  **INITIALS,"Microscopic Description\X0D\\X0A\The curettings show sheets and nests of malignant cells, some of which appear to\X0D\\X0A\show a cribriform-like configuration while others show somewhat polypoid\X0D\\X0A\fragments lined by an in situ carcinoma suggesting a squamous component. No\X0D\\X0A\vascular space invasion is seen.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY, XXX M].\X0D\\X0A\Procedures/Addenda"
REG1,OTHER,0,488251,1,,CLINICAL HISTORY:\X0D\\X0A\Thyroid nodules,"AP SPECI\X0D\\X0A\**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\ADDENDUM I\X0D\\X0A\**DATE[Feb 24 12]\X0D\\X0A\ \X0D\\X0A\ADDITIONAL CLINICAL INFORMATION\X0D\\X0A\The previous value GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'LEFT LOBE THYROID, RESECTION' was corrected by IF on **DATE[Feb 24 12]\X0D\\X0A\11:25\X0D\\X0A\\X0D\\X0A\The previous value GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'neck thyroid left lobe' is  was\X0D\\X0A\corrected by IF on **DATE[Feb 24 12] 11:25\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Feb 24 12] 11:25\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Feb 24 12] 11:25\X0D\\X0A\\X0D\\X0A\The previous value **NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 24]/ was corrected by IF on **DATE[Feb 24 12] 11:25","GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'LEFT LOBE THYROID, RESECTION':\X0D\\X0A\1.   Mixed macro and microfollicular adenoma, 2.0 cm.\X0D\\X0A\2.   Hemorrhagic cystic degeneration, capsular fibrosis and entrapment\X0D\\X0A\of benign follicular structure suggesting previous needle biopsy effect.\X0D\\X0A\ \X0D\\X0A\3.   Associated benign adenomatoid hyperplasia.\X0D\\X0A\4.   No parathyroid tissue identified.\X0D\\X0A\5.   Scattered inflammation consistent with mild chronic Hashimoto's\X0D\\X0A\thyroiditis.\X0D\\X0A\6.   No malignancy identified.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\B.   RIGHT THYROID LOBECTOMY (11.7 GRAMS):\X0D\\X0A\1.   SINGLE MICROSCOPIC FOCUS OF OCCULT MICROPAPILLARY THYROID\X0D\\X0A\CARCINOMA, 2 MM IN GREATEST DIMENSION.\X0D\\X0A\2.   No evidence of angiolymphatic nor capsular invasion is identified.\X0D\\X0A\3.   All surgical margins of excision are widely free of tumor.\X0D\\X0A\4.   Single benign lymph node.\X0D\\X0A\5.   Negative for parathyroid parenchyma.\X0D\\X0A\ \X0D\\X0A\COMMENT:  T1a, NO, MX.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (DA/cm)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\**NAME[ZZZ:  CCC M DDD] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 24 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated 'neck thyroid left lobe' is a 20.2 gram\X0D\\X0A\distorted lobe of thyroid tissue.  The distorted lobe measures 5.0 x 3.0\X0D\\X0A\cm.  The specimen is inked and sectioned discloses a circumscribed\X0D\\X0A\cystic hemorrhagic mass measuring 2.0 cm in single greatest dimension\X0D\\X0A\and an adjacent multinodular solid component measuring up to 2.5 cm in\X0D\\X0A\single greatest dimension. No other discrete mass lesions are\X0D\\X0A\identified.  Multiple representative sections are placed in cassettes A1\X0D\\X0A\through A5.  Cassettes A1 and A2 cystic portion, cassettes A3 through A5\X0D\\X0A\solid portion.  (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 5\X0D\\X0A\GROSS DESCRIPTION:\X0D\\X0A\Specimen (B) Submitted in formalin is an intact 11.7 gram 4.2 x 3.4 x\X0D\\X0A\2.8 cm right thyroid lobectomy including isthmus. The overlying capsule\X0D\\X0A\is intact. No gross evidence of parathyroid tissue is identified.\X0D\\X0A\Serial sectioning reveals an irregular nodularity throughout with focal\X0D\\X0A\colloid cyst formation.  No evidence of calcification nor scarring is\X0D\\X0A\identified.  Representative sections including the bulk of the lobe are\X0D\\X0A\submitted in B1 through B4.  (DA/cm)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted:  9",,"SPECIMEN(S): B Thyroid, R(TOTAL THYROIDECTOMY)\X0D\\X0A\SPECIMEN(S): A NECK THYROID (TOTAL THYROIDECTOMY)",,
REG1,OTHER,0,488721,1,,CLINICAL HISTORY:\X0D\\X0A\Non-toxic multinodular goiter.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'RIGHT THYROID LOBECTOMY':\X0D\\X0A\1.   PAPILLARY CARCINOMA, FOLLICULAR VARIANT, 1.0 CM.\X0D\\X0A\2.   Incidental benign perithyroidal lymph node, negative for metastatic\X0D\\X0A\carcinoma (0/1).\X0D\\X0A\3.   No capillary lymphatic space invasion by tumor identified.\X0D\\X0A\4.   No parathyroid tissue identified.\X0D\\X0A\B.   'LEFT LOBE, SUPERFICIAL NODULE BIOPSY':\X0D\\X0A\1.   PAPILLARY CARCINOMA, MIXED FOLLICULAR VARIANT AND CLASSIC PAPILLARY\X0D\\X0A\CARCINOMA, 6 MM.\X0D\\X0A\2.   No capillary lymphatic space invasion by tumor identified.\X0D\\X0A\C.   'LEFT THYROID LOBECTOMY (COMPLETION THYROIDECTOMY)':\X0D\\X0A\1.   Mixed micro and macrofollicular adenoma, 4 mm.\X0D\\X0A\2.   No parathyroid tissue identified.\X0D\\X0A\3.   No malignancy identified.\X0D\\X0A\D.   'CENTRAL COMPARTMENT NODE THYROID':\X0D\\X0A\1.   Predominantly benign fatty tissue with three benign lymph nodes,\X0D\\X0A\negative for metastatic carcinoma (0/3).\X0D\\X0A\2.   Separately identified benign parathyroid tissue 0.5 mm.\X0D\\X0A\3.   No malignancy identified.\X0D\\X0A\ \X0D\\X0A\PATHOLOGIC STAGE:  mpT1, N0, MX (G1).\X0D\\X0A\m=(multifocal disease)\X0D\\X0A\Thyroid Gland\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: Thyroid, R\X0D\\X0A\B: Thyroid, L SUPERFICIAL NODULE\X0D\\X0A\C: Thyroid, L\X0D\\X0A\D: CENTRAL COMPARTMENT NODE, THYROID\X0D\\X0A\ \X0D\\X0A\THYROID: Resection\X0D\\X0A\MACROSCOPIC\X0D\\X0A\Specimen Type: Total thyroidectomy\X0D\\X0A\Tumor Focality:     Multifocal\X0D\\X0A\Tumor Size (largest nodule):  Greatest dimension: 1cm\X0D\\X0A\MICROSCOPIC\X0D\\X0A\Histologic Type:    Papillary carcinoma, follicular variant\X0D\\X0A\Pathologic Staging (pTNM)\X0D\\X0A\Primary Tumor (pT): pT1a\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\Regional Lymph Nodes (pN):    pN0\X0D\\X0A\Specify:  Number examined:    4\X0D\\X0A\Number involved:    0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Margins uninvolved by carcinoma\X0D\\X0A\Venous/Lymphatic (Large/Small Vessel) Invasion (V/L):\X0D\\X0A\ (Venous vessels outside tumor or in capsule)\X0D\\X0A\Absent\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jul 23 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received fresh for frozen section designated 'right\X0D\\X0A\thyroid' is a 6.0 x 2.5 x 1.3 cm. lobe of thyroid tissue and weighing\X0D\\X0A\12-grams in total aggregate weight.  The specimen is inked and sectioned\X0D\\X0A\disclosing a discrete circumscribed solid 1.0 cm. in diameter nodule.\X0D\\X0A\Scrape prep and frozen section are performed on this nodule.  SCRAPE\X0D\\X0A\PREP AND FROZEN SECTION DIAGNOSIS (DR. **NAME[XXX, WWW] HOSPITAL\X0D\\X0A\**PLACE, CLIA ID# 18D0320857):  PAPILLARY CARCINOMA, FOLLICULAR\X0D\\X0A\VARIANT. The frozen section control is resubmitted in a single cassette.\X0D\\X0A\The frozen section diagnosis is given directly to Dr. **NAME[VVV] by Dr.\X0D\\X0A\**NAME[XXX].  The remaining non-frozen nodule is sectioned and submitted in\X0D\\X0A\cassettes (A2-A3) respectively.  Further sectioning discloses no other\X0D\\X0A\discrete masses.  Additional random representative sections are placed\X0D\\X0A\in cassettes (A4-A5).\X0D\\X0A\Specimen (B) Received fresh for frozen section designated 'left lobe\X0D\\X0A\superficial nodule' is a 1.3 x 1.0 x 0.6 cm. nodule of maroon-tan\X0D\\X0A\tissue.  Sectioning discloses a circumscribed 0.6 cm. in greatest\X0D\\X0A\diameter nodule.  The entire bisected specimen is submitted for frozen\X0D\\X0A\section.  FROZEN SECTION DIAGNOSIS (DR. **NAME[XXX, WWW] HOSPITAL\X0D\\X0A\**PLACE, CLIA ID# 18D0320857):  THYROID TISSUE POSITIVE FOR PAPILLARY\X0D\\X0A\CARCINOMA. The frozen section control is entirely resubmitted in a\X0D\\X0A\single cassette.  The frozen section diagnosis is given directly to Dr.\X0D\\X0A\**NAME[VVV] by Dr. **NAME[XXX].\X0D\\X0A\Specimen (C) Received in formalin designated 'left lobe thyroid' is a\X0D\\X0A\lobe of thyroid and a small separately identified nodule of thyroid\X0D\\X0A\tissue.  The nodule measures 1.0 x 0.4 x 0.4 cm.  This specimen is\X0D\\X0A\bisected and submitted in cassette (C1).  The primary specimen measures\X0D\\X0A\4.4 x 2.6 x 1.8 cm.  The specimen is inked and sectioned disclosing a\X0D\\X0A\small 4.0 mm. in diameter solid nodule and vague nodularity.  The small\X0D\\X0A\nodule is entirely submitted in cassettes (C1-C2).  Random\X0D\\X0A\representative sections of thyroid tissue are submitted in cassettes\X0D\\X0A\(C3-C4) respectively.\X0D\\X0A\Specimen (D) Received in formalin designated 'central compartment node\X0D\\X0A\thyroid' is a fragment of fatty tissue with focal indurated nodules.\X0D\\X0A\The entire specimen measures 5.0 x 2.0 x 0.4 cm. with nodules measuring\X0D\\X0A\up to 0.3 cm. identified.  The specimen is bisected and entirely\X0D\\X0A\submitted in two cassettes.     (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 6",,"SPECIMEN(S): A Thyroid, R\X0D\\X0A\SPECIMEN(S): B Thyroid, L SUPERFICIAL NODULE\X0D\\X0A\SPECIMEN(S): C Thyroid, L\X0D\\X0A\SPECIMEN(S): D CENTRAL COMPARTMENT NODE, THYROID",,
REG1,OTHER,0,488799,1,,"Clinical Diagnosis and History\X0D\\X0A\BILATERAL THYROID MASSES\X0D\\X0A\OPER:  TOTAL THYROIDECTOMY\X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX#1: PARATHYROID TISSUE IS IDENTIFIED.  **INITIALS \X0D\\X0A\FSDX#2:  FOLLICULAR NEOPLASM, FURTHER CLASSIFICATION PENDING EVALUATION OF THE\X0D\\X0A\REMAINING NODULE AND ADJACENT CAPSULE.  (CLS)","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: BIOPSY THYROID VERSUS PARATHYROID-FS-ls\X0D\\X0A\2: PARTIAL RIGHT THYROID LOBE-FS-STITCH ON SUPERIOR MARGIN-ls\X0D\\X0A\3: THYROID","Final Diagnosis\X0D\\X0A\1:  BIOPSY THYROID VERSUS PARATHYROID:\X0D\\X0A\     BENIGN PARATHYROID.\X0D\\X0A\2:  PARTIAL RIGHT THYROID LOBE:\X0D\\X0A\     MICROFOLLICULAR ADENOMA.\X0D\\X0A\3:  THYROID:\X0D\\X0A\     FOLLICULAR NEOPLASM WITH ATYPICAL FEATURES.\X0D\\X0A\COMMENT:  I feel the microfollicular lesion in specimen 3 has a focally\X0D\\X0A\incomplete capsule, which raises the suspicion of minimally invasive follicular\X0D\\X0A\carcinoma.  The case will be seen in consultation at **INSTITUTION.\X0D\\X0A\**INITIALS \X0D\\X0A\**INITIALS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **PLACE",,"Gross Description\X0D\\X0A\1: Received fresh designated \""biopsy thyroid vs parathyroid\"" is a 0.2 cm piece\X0D\\X0A\of tan tissue totally frozen in one block with control submitted as FSC1A.\X0D\\X0A\**INITIALS \X0D\\X0A\2: Received fresh for frozen section evaluation labeled  \""partial right lobe\X0D\\X0A\(stitch on superior margin) is a 41 gm 7.5 x 5.5 x 5.0 cm portion of thyroid\X0D\\X0A\tissue with a suture as indicated.  Sutures ligate vessels on the external\X0D\\X0A\surface, which appears to be covered by an intact capsule.  The lobe is expanded\X0D\\X0A\by a nodule measuring approximately 4.5 cm as measured from the external\X0D\\X0A\surface.  After removing all of the sutures, the external surface is inked\X0D\\X0A\black.  Sectioning reveals that the majority of the specimen is involved by a\X0D\\X0A\4.5 x 4.0 x 3.0 cm nodule with a fairly uniform solid light brown cut surface. \X0D\\X0A\Representative sections are frozen in one block with control submitted as FSC1A.\X0D\\X0A\ The remainder of the thyroid tissue is submitted in blocks 2A  2T.  **INITIALS\X0D\\X0A\3:  Received in formalin designated \""thyroid\"" is a 10-gram, 4.3 x 3.0 x 2.6 cm\X0D\\X0A\portion of thyroid tissue which is covered by a capsule over 80% of the external\X0D\\X0A\surface.  Sutures ligate small vessels on the external surface.  The external\X0D\\X0A\surface is otherwise unremarkable and is inked black after removal of the\X0D\\X0A\sutures.  Sectioning reveals a discrete 1.5 x 1.2 x 1.5 cm nodule with a solid\X0D\\X0A\tan cut surface.  The surrounding thyroid tissue is unremarkable.  The entire\X0D\\X0A\specimen is submitted in blocks 3A-3G.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 30 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 30 2012]     By:  **NAME[YYY,XXX]\X0D\\X0A\     Date Reported:     **DATE[Jan 31 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from **INSTITUTION (Dr. **NAME[WWW VVV]) in the\X0D\\X0A\electronic medical records file regarding consultation.  /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 31 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 31 2012]     By:  **NAME[UUU, TTT]\X0D\\X0A\     Date Reported:     **DATE[Jan 31 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Dr. **NAME[VVV] of the **INSTITUTION has made a\X0D\\X0A\diagnosis of 'Follicular Variant Of Papillary Thyroid Carcinoma, Encapsulated\X0D\\X0A\Type' on specimen #3 which was received as 'Thyroid'.  He has also made a\X0D\\X0A\diagnosis of 'Hurthle Cell Adenoma of the lesion involving the partial right\X0D\\X0A\thyroid lobe (specimen 2).  The following is a synoptic report based on the\X0D\\X0A\findings in specimen 3.\X0D\\X0A\SYNOPTIC REPORT\X0D\\X0A\Procedure:  Not specified.\X0D\\X0A\Specimen integrity:  Intact.\X0D\\X0A\Specimen size:  Specimen 3 measures 4.3 x 3.0 x 2.6 cm.\X0D\\X0A\Tumor focality:  Unifocal.\X0D\\X0A\Tumor laterality:  Not specified.\X0D\\X0A\Tumor size:  1.5 cm in maximum gross dimension.\X0D\\X0A\Histologic type:  Follicular variant of papillary thyroid carcinoma,\X0D\\X0A\encapsulated type, with oncocytic features.\X0D\\X0A\Margins:  Margins uninvolved by Invasive carcinoma.\X0D\\X0A\Tumor capsule:  Largely encapsulated.\X0D\\X0A\Tumor capsular invasion:  Present.\X0D\\X0A\Lymph-vascular invasion:  Not identified.\X0D\\X0A\Extrathyroidal extension:  Not identified.\X0D\\X0A\Pathologic stating:  Primary tumor T1b.\X0D\\X0A\Regional lymph nodes: NX.\X0D\\X0A\Distant metastases:  Not applicable.\X0D\\X0A\CMK/in \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **PLACE"
REG1,OTHER,0,488847,3,,Clinical Diagnosis and History\X0D\\X0A\INGUINAL LYMPH NODE MASS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **PLACE\X0D\\X0A\**NAME[YYY], M.D., **NAME[XXX]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: CT GUIDED R INGUINAL LYMPH NODE BX  bb","Final Diagnosis\X0D\\X0A\\""CT-GUIDED RIGHT INGUINAL LYMPH NODE BIOPSY\"":\X0D\\X0A\     HIGH GRADE NON-SMALL CELL CARCINOMA INVOLVING FIBROADIPOSE TISSUE \X0D\\X0A\     (SEE COMMENT).\X0D\\X0A\COMMENT:  Immunostains, with appropriate controls, show: CK5/6 ( focal +), CK7\X0D\\X0A\(focal +), p63 (focal +), CK20 (-), PSA (-). This immunoprofile supports\X0D\\X0A\transitional cell/squamous phenotype (bladder origin ?). The negative PSA is\X0D\\X0A\against prostate origin. Additional more specific immunomarkers for urothelial\X0D\\X0A\origin are pending. A supplemental report will follow. \X0D\\X0A\**INITIALS IHC/a/CMK\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[WWW], M.D., **NAME[VVV",,"Gross Description\X0D\\X0A\In formalin, designated \""CT-guided right inguinal lymph node biopsy\"" are\X0D\\X0A\thread-like fragments of tan white and brown soft tissue ranging up to 1.4 cm in\X0D\\X0A\length.  Block 1A.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 15 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 15 2011]     By:  **NAME[TTT, SSS]\X0D\\X0A\     Date Reported:     **DATE[Oct 15 2011]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding flow cytometry analysis.\X0D\\X0A\Their report, in part:\X0D\\X0A\INTERPRETATION:\X0D\\X0A\INGUINAL LYMPH NODE:\X0D\\X0A\1: In the sample analyzed, there is no evidence of a B-cell or T-cell lymphoma.\X0D\\X0A\2: A CD45(-), CD56 (+) cell population is present (67%) suggesting a\X0D\\X0A\nonhematopoietic neoplasm.\X0D\\X0A\Signed: **NAME[RRR QQQ], M.D.\X0D\\X0A\See the complete report.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 22 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 22 2011]     By:  **NAME[TTT, SSS]\X0D\\X0A\     Date Reported:     **DATE[Oct 22 2011]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding immunostains. \X0D\\X0A\Their report, in part:\X0D\\X0A\INTERPRETATION:\X0D\\X0A\These results support a poorly differentiated large cell carcinoma with\X0D\\X0A\neuroendocrine differentiation (CD56 diffuse, strong+/TTF-1 focal + / KI-67,\X0D\\X0A\>90% / pancytokeratin+).\X0D\\X0A\Signed **NAME[PPP OOO], M.D.\X0D\\X0A\See the complete report including immunostains.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV"
REG1,OTHER,0,489019,1,,"CLINICAL HISTORY: ***PATH-NUMBER[1] Right thyroid, FNA: Atypical, but not suggestive of malignancy: cellular specimen with microfragments of follicular cells, no evidence of nuclear clearing or intranuclear cytoplasmic inclusions, fragments of mature fat and skeletal muscle within blood.  Preop diagnosis thyroid mass.","Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX M WWW], VVV] PhD **DATE[Jan 16 12]","FINAL DIAGNOSIS: RIGHT THYROID GLAND FOLLICULAR CARCINOMA OF THYROID. SEE COMMENT. FOLLICULAR MASS OF THYROID SUSPICIOUS FOR CARCINOMA, FINAL DIAGNOSIS DEFERRED TO PARAFFIN-EMBEDDED TISSUE SECTIONS.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and \""right thyroid lobe.\""  The specimen is received in the fresh state and consists of an enlarged encapsulated reddish-tan structure consistent with thyroid, measuring 7 x 5.5 x 3 cm.  The specimen weighs 66 grams.  The capsule, although intact, shows evidence of probable fibrovascular adhesions.  The outer surface is inked with black.  The specimen is serially sectioned.  A portion of the mass is solid tan-red and representative sections of this including the nearest surgical margins are placed in Blocks 1-8.  A significant portion of the mass is more friable, hemorrhagic, showing evidence of probable cystic degeneration. This area is represented in Blocks 9-12.  A representative section of the more solid appearing area is also placed in Block FS.","COMMENT WORD: The right thyroid is found to be replaced by large 7 x 5.5 x 3 cm. mass.  The mass is predominantly solid with focal evidence of degeneration and hemorrhage.  Microscopically the mass consists of variably sized follicular structures usually containing colloid.  There is mild nuclear pleomorphism with cells having enlarged nuclei with open chromatin patterns. Cytoplasm is moderately abundant and eosinophilic.  The mitotic rate is low.  Although no definite desmoplastic reaction is identified in the capsule, within multiple sites extension into vascular structures is found.  These protrusions or plugs into the blood vessels are lined by endothelial cells.  This finding of vascular extension is felt to indicate the presence of follicular carcinoma.  The follicular mass appears to be confined to the thyroid gland.  Staging criteria: T3 possible Stage II.  Histopathologic grade: G2, moderately differentiated.  Histopathologic type: follicular carcinoma.  Due to the unusual nature of the lesion, the case will be forwarded to **INSTITUTION **INSTITUTION for consultation and special studies as needed.",Specimen Number: ***PATH-NUMBER[2]. Tissues: Thyroid gland. Specimen Comments:,,
REG1,OTHER,0,489028,1,,"HISTORY: Mass, polypoid lesions.","ICD9 CODES: 151.9, 535.00, \X0D\\X0A\COMMENTS: Results called to Dr. **NAME[ZZZ YYY] at 9:50 a.m. on **DATE[Jul 02 12].\X0D\\X0A\LAB_COMM: HER/2 TO BE PERFORMED ON STOMACH PATH. COPY OF ORIGINAL ENCLOSED WITH BLOCK.","DIAGNOSIS: 1 -  MASS FROM GASTRIC BODY, BIOPSY:             POORLY DIFFERENTIATED ADENOCARCINOMA WITH SIGNET RING             FEATURES.             HELICOBACTER PYLORI ARE NOT IDENTIFIED (GIEMSA STAIN             PERFORMED).             NUMEROUS FUNGAL HYPHAE ARE IDENTIFIED.  2 -  GASTRIC ANTRUM, BIOPSY:             ACUTE GASTRITIS WITH ULCERATION.             NEGATIVE FOR MALIGNANCY.             HELICOBACTER PYLORI ARE NOT IDENTIFIED (GIEMSA STAIN             PERFORMED).",,"GROSS: Received in formalin and labeled with the patient's name are two specimens.  The first is labeled \""biopsy, mass in stomach (body)\"" and consists of four gray to tan fragments of tissue measuring up to 0.3 cm.  Submitted for TE as #1.  The second specimen is labeled \""biopsy, antrum\"" and consists of two tan to red fragments of tissue measuring up to 0.2 cm.  Submitted for TE as #2.  DT: **DATE[Jul 01 12]","MICRO: Microscopic examination was performed.  DT:  **DATE[Jul 02 12] (DRB, bsp)","PROCEDURE: Esophagogastroduodenoscopy with biopsy.\X0D\\X0A\SPECIMEN(S): 1) Biopsy, mass in stomach (body).  2) Biopsy, antrum.",,ADDENDUM: An immunohistochemical for Her-2/neu is performed on block 1A with appropriate controls.  Neoplastic cells are POSITIVE for Her-2/neu (patchy strong complete membranous staining).
REG1,OTHER,0,489269,1,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Thyroid nodule,EVA G                            #:\X0D\\X0A\FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\RE      011\X0D\\X0A\PHYSICIAN:       **NAME[ZZZ] BLAND      SIGN OUT DATE:   **DATE[Feb 16 2012]\X0D\\X0A\COPIES TO:          **NAME[ZZZ] BLAND,FROZEN SECTION DIAGNOSIS\X0D\\X0A\RIGHT THYROID AND ISTHMUS (1FS-1):  PAPILLARY THYROID CARCINOMA (0.6\X0D\\X0A\CM).\X0D\\X0A\DIAGNOSIS\X0D\\X0A\THYROID: PAPILLARY CARCINOMA\X0D\\X0A\PATHOLOGIC STAGING\X0D\\X0A\PRIMARY TUMOR: pT1a\X0D\\X0A\REGIONAL LYMPH NODES:  Not applicable\X0D\\X0A\DISTANT METASTASIS: Not applicable,,"MACROSCOPIC\X0D\\X0A\PROCEDURE: Total Thyroidectomy\X0D\\X0A\SPECIMEN INTEGRITY: Intact (lobes receieved separately\X0D\\X0A\SPECIMEN SIZE:  Left lobe:\X0D\\X0A\SPECIMEN WEIGHT:  Right lobe -7.7 grams- fresh - Left lobe 8.4 grams\X0D\\X0A\fixed.\X0D\\X0A\TUMOR FOCALITY: Unifocal\X0D\\X0A\TUMOR LATERALITY: Right\X0D\\X0A\TUMOR SIZE:  0.6 cm.\X0D\\X0A\GROSS DESCRIPTION\X0D\\X0A\Specimen one is received fresh for frozen section diagnosis labeled\X0D\\X0A\\""right thyroid and isthmus\"" and consists of the aforementioned weighing\X0D\\X0A\7.7 grams and measuring 3.5 x 2.5 x 1 cm in greatest dimensions.  The\X0D\\X0A\surgical margins are inked in black and the specimen is serially\X0D\\X0A\sectioned to reveal a yellow-tan nodular lesion measuring 0.6 cm in\X0D\\X0A\diameter.  A representative section is submitted as 1FS-1.  The\X0D\\X0A\previously frozen 1FS-1 is entirely resubmitted as such and sections\X0D\\X0A\from the unfrozen tissue are submitted in cassettes A-D with D\X0D\\X0A\containing the isthmus margin.\X0D\\X0A\Specimen two is received in formalin labeled \""left thyroid lobe\"" and\X0D\\X0A\consists of two red-tan irregular soft tissue fragments weighing\X0D\\X0A\together 8.4 grams. The largest fragment measures 3 x 1.8 x 0.7 cm in\X0D\\X0A\greatest dimensions and the smallest  measures  2.8 x 1.5 x 0.5 cm in\X0D\\X0A\greatest dimensions.  The specimen is sectioned to reveal a small\X0D\\X0A\yellow-tan pale ill defined area near one surface measuring 0.5 x 0.2 x\X0D\\X0A\0.2 cm.  Representative sections are submitted in cassettes A-C.","MICROSCOPIC\X0D\\X0A\HISTOLOGIC TYPE: Papillary carcinoma\X0D\\X0A\VARIANT:  Classical (usual)\X0D\\X0A\ARCHITECTURE: Classical (papillary)\X0D\\X0A\CYTOMORPHOLOGY: Classical\X0D\\X0A\MARGINS: Uninvolved by carcinoma\X0D\\X0A\TUMOR CAPSULE: Totally encapsulated\X0D\\X0A\TUMOR CAPSULAR INVASION:  Present, minimal\X0D\\X0A\LYMPH-VASCULAR INVASION:  Present, focal less than 4 vessels\X0D\\X0A\EXTRATHYROIDAL EXTENSION:  Not identified\X0D\\X0A\MICROSCOPIC DESCRIPTION\X0D\\X0A\Microscopic examination performed.\X0D\\X0A\<Sign Out Dr. **NAME[YYY]>\X0D\\X0A\**NAME[XXX WWW], PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  (1) THYROID, RIGHT LOBE, SURGICAL EXCISION\X0D\\X0A\Right thyroid and\X0D\\X0A\isthmus\X0D\\X0A\(2) THYROID, LEFT\X0D\\X0A\LOBE, SURGICAL EXCISION",,
REG1,OTHER,0,489498,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  endometrial cancer.  Operative procedure:  total\X0D\\X0A\abdominal hysterectomy, bilateral salpingo-oophorectomy, lymph node sampling.\X0D\\X0A\ Intraoperative findings:  not given.  \X0D\\X0A\\X0D\\X0A\ \X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FS#1:  \""TUMOR INVADES OUTER ONE HALF\""...KA.\X0D\\X0A\ \X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Aug 15 1941] (Age: **AGE[in 70s])  F\X0D\\X0A\Collect Date: **DATE[Nov 28 2011] 11:40\X0D\\X0A\Receipt Date: **DATE[Nov 28 2011] 11:40\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\\X0D\\X0A\**NAME[XXX] MD: F.R. **NAME[WWW], M.D.     Service: GYO     Location: REC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Nov 29 2011] 16:33\X0D\\X0A\RESIDENTS(S): K.K. **NAME[UUU], DO\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\LEFT OVARY AND FALLOPIAN TUBE (A), LEFT SALPINGO-OOPHORECTOMY:\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, NO TUMOR SEEN.\X0D\\X0A\\X0D\\X0A\RIGHT OVARY AND FALLOPIAN TUBE (B), RIGHT SALPINGO-OOPHORECTOMY:\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, NO TUMOR SEEN.\X0D\\X0A\\X0D\\X0A\UTERUS AND CERVIX (C), TOTAL ABDOMINAL HYSTERECTOMY:\X0D\\X0A\   - ENDOMETRIUM:  HIGH-GRADE CARCINOSARCOMA (MALIGNANT MIXED MULLERIAN\X0D\\X0A\TUMOR) (pT1b, pN0),\X0D\\X0A\    SEE TEMPLATE.\X0D\\X0A\   - MYOMETRIUM:  TUMOR EXTENDS TO OUTER ONE HALF.\X0D\\X0A\   - CERVIX:  CHRONIC CYSTIC CERVICITIS.\X0D\\X0A\   - PARAMETRIUM:  NO TUMOR SEEN.\X0D\\X0A\\X0D\\X0A\VAGINAL MUCOSA, VAGINAL MARGIN (D), EXCISION:\X0D\\X0A\   - SQUAMOUS MUCOSA, NO TUMOR SEEN.\X0D\\X0A\\X0D\\X0A\LYMPH NODES, LEFT PELVIC (E), EXCISION:\X0D\\X0A\   - NO TUMOR SEEN IN SIX LYMPH NODES (0/6).\X0D\\X0A\\X0D\\X0A\LYMPH NODES, LEFT COMMON ILIAC (F), EXCISION:\X0D\\X0A\   - NO TUMOR SEEN IN SIX LYMPH NODES (0/6).\X0D\\X0A\\X0D\\X0A\LYMPH NODES, LEFT PERIAORTIC (G), EXCISION:\X0D\\X0A\   - NO TUMOR SEEN IN FIVE LYMPH NODES (0/5)\X0D\\X0A\\X0D\\X0A\LYMPH NODES, RIGHT COMMON ILIAC (H), EXCISION:\X0D\\X0A\   - NO TUMOR SEEN IN NINE LYMPH NODES (0/9)\X0D\\X0A\\X0D\\X0A\LYMPH NODE, RIGHT PERIAORTIC (I), EXCISION:\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\\X0D\\X0A\LYMPH NODES, RIGHT PELVIC (J), EXCISION:\X0D\\X0A\   - NO TUMOR SEEN IN THREE LYMPH NODES (0/3).\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Nov 29 2011] **NAME[ZZZ M. YYY], MD\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Specimen A is received in formalin labeled left tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 8 grams.  The fallopian tube does not have\X0D\\X0A\an identifiable fimbriated end.  There is evidence of tubal ligation.  No\X0D\\X0A\paratubal cysts are noted.   The tube is serially sectioned to reveal a\X0D\\X0A\pinpoint lumen.  \X0D\\X0A\\X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube:  3 cm length x 0.6 cm diameter\X0D\\X0A\Ovary:  3 x 2 x 0.6 cm\X0D\\X0A\\X0D\\X0A\Representative sections:\X0D\\X0A\A1:   representative fallopian tube without fimbria\X0D\\X0A\A2:   representative ovary\X0D\\X0A\\X0D\\X0A\Specimen B is received in formalin labeled right tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 5.88 grams.  The fallopian tube does not\X0D\\X0A\have an identifiable fimbriated end.  There is evidence of tubal ligation. \X0D\\X0A\No paratubal cysts are noted.  The tube is serially sectioned to reveal a\X0D\\X0A\pinpoint lumen.  \X0D\\X0A\\X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube:  1.5 cm length x 0.4 cm diameter\X0D\\X0A\Ovary:  3 x 1.7 x 1 cm\X0D\\X0A\\X0D\\X0A\Representative sections:\X0D\\X0A\B1:  representative fallopian tube without fimbria\X0D\\X0A\B2:  representative ovary\X0D\\X0A\\X0D\\X0A\Specimen C is received fresh for frozen section labeled \""uterus and cervix,\X0D\\X0A\cut and look\"" and consists of the aforementioned.   \X0D\\X0A\Sectioning of the endomyometrium reveals an ulcerated mass involving the\X0D\\X0A\anterior and posterior right aspect of the endometrium.  It measures 4.5 cm\X0D\\X0A\in diameter and 1.2 cm in thickness.  The lesion grossly invades the\X0D\\X0A\myometrium outer one half.  The lesion does not extend into the endocervical\X0D\\X0A\canal.  \X0D\\X0A\\X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight:  151 g\X0D\\X0A\Dimensions of uterus: from superior to inferior is 10 cm, from right to left\X0D\\X0A\is 7 cm and from anterior to posterior is 4.5 cm \X0D\\X0A\Depth of endometrial cavity:  6 cm\X0D\\X0A\Tumor/Polyp dimensions:  4.5 cm in diameter and 1.2 cm in thickness\X0D\\X0A\Depth of invasion:  1.2 cm of tumor over 1 cm of endomyometrium\X0D\\X0A\Distance to internal os:  2.5 cm\X0D\\X0A\     Tumor location:  anterior and posterior\X0D\\X0A\     Percent of endometrial surface involvement:  65 %\X0D\\X0A\Uninvolved endometrial thickness:  2 mm\X0D\\X0A\Uninvolved myometrial thickness:  1 cm\X0D\\X0A\Os diameter: 0.4 cm\X0D\\X0A\Endocervical canal length: 3 cm\X0D\\X0A\\X0D\\X0A\Representative sections:\X0D\\X0A\C1 FS1\X0D\\X0A\C2 right parametrium\X0D\\X0A\C3 left parametrium\X0D\\X0A\C4 anterior cervix\X0D\\X0A\C5 posterior cervix\X0D\\X0A\C6 anterior lower uterine segment\X0D\\X0A\C7 posterior lower uterine segment\X0D\\X0A\C8-C18 anterior tumor\X0D\\X0A\C19-C23 posterior mass\X0D\\X0A\\X0D\\X0A\Specimen label:  D) vaginal margin               \X0D\\X0A\Fixation:  formalin\X0D\\X0A\Number of pieces:  two\X0D\\X0A\Shape(s):  irregular\X0D\\X0A\Color(s):  white tan\X0D\\X0A\Consistency:  soft and rubbery\X0D\\X0A\Size(s):  0.6 x 0.5 x 0.2 cm up to 1 x 1 x 0.5 cm.  The tissue fragments are\X0D\\X0A\serially sectioned.\X0D\\X0A\Cassette summary:  submitted in cassette D1.\X0D\\X0A\\X0D\\X0A\Specimen label:  E) left pelvic lymph node                 \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces:  multiple \X0D\\X0A\Shape(s):    irregular\X0D\\X0A\Color(s):  red tan\X0D\\X0A\Consistency:  soft\X0D\\X0A\Size(s):  0.2 x 0.2 x 0.2 cm up to1 x 1 x 0.5 cm.  Serially sectioned.\X0D\\X0A\Cassette summary:  submitted in cassettes E1-3\X0D\\X0A\\X0D\\X0A\Specimen label:  F) left common iliac lymph nodes                   \X0D\\X0A\Fixation:  formalin\X0D\\X0A\Number of pieces:   one\X0D\\X0A\Shape(s):    irregular\X0D\\X0A\Color(s):  red tan\X0D\\X0A\Consistency:  soft and rubbery\X0D\\X0A\Size(s):  3 x 1 x 0.5 cm.  Serially sectioned.\X0D\\X0A\Cassette summary: submitted in F1 and 2.\X0D\\X0A\\X0D\\X0A\Specimen label:  G) left periaortic lymph nodes  \X0D\\X0A\Fixation:  formalin\X0D\\X0A\Number of pieces:  one\X0D\\X0A\Shape(s):    irregular\X0D\\X0A\Color(s):  red tan\X0D\\X0A\Consistency:  soft and rubbery\X0D\\X0A\Size(s):  2 x 0.7 x 0.6 cm\X0D\\X0A\Cassette summary:  submitted in G1 and 2.\X0D\\X0A\\X0D\\X0A\Specimen label:  H) right common iliac lymph nodes                   \X0D\\X0A\Fixation:  formalin\X0D\\X0A\Number of pieces:  four\X0D\\X0A\Shape(s):    irregular\X0D\\X0A\Color(s):  red tan\X0D\\X0A\Consistency:  soft\X0D\\X0A\Size(s):  1 x 0.7 x 0.5 cm up to 1.2 x 0.6 x 0.5 cm.  Serially sectioned.\X0D\\X0A\Cassette summary:  submitted in H1, 2 and 3.\X0D\\X0A\\X0D\\X0A\Specimen label:  I) right periaortic lymph nodes \X0D\\X0A\Fixation:   formalin\X0D\\X0A\Number of pieces:  five\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s):  red tan\X0D\\X0A\Consistency:   soft and rubbery\X0D\\X0A\Size(s):  0.4 x 0.3 x 0.2 cm up to 1.5 x 1 x 0.5 cm.  Serially sectioned.\X0D\\X0A\Cassette summary:  submitted in I1 to 3.\X0D\\X0A\\X0D\\X0A\Specimen label:  J)  right pelvic lymph nodes\X0D\\X0A\Fixation:  formalin\X0D\\X0A\Number of pieces:  multiple\X0D\\X0A\Shape(s):  irregular\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Dec 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\\X0D\\X0A\Type of surgery: total abdominal hysterectomy with bilateral\X0D\\X0A\salpingo-oophorectomy and lymph node sampling\X0D\\X0A\\X0D\\X0A\Weight of uterus:  151 grams\X0D\\X0A\\X0D\\X0A\Dimensions of uterus:  10 cm (length) x 7 cm (width) x 4.5 cm\X0D\\X0A\(anterior-posterior dimension)\X0D\\X0A\\X0D\\X0A\Histologic type of the tumor:  poorly differentiated endometrioid\X0D\\X0A\adenocarcinoma with homologous sarcomatoid areas consistent with\X0D\\X0A\carcinosarcoma (malignant mixed mullerian tumor) (blocks C14, C16 and C17)\X0D\\X0A\\X0D\\X0A\Tumor grade of differentiation (FIGO grade I/II/III):  III\X0D\\X0A\\X0D\\X0A\Tumor size:  4.5 cm (greatest dimension) x 1.3 cm (maximum thickness) \X0D\\X0A\\X0D\\X0A\Distance from internal os:  2.5 cm\X0D\\X0A\\X0D\\X0A\Confined to endometrium:  no\X0D\\X0A\\X0D\\X0A\Myometrial invasion:  yes (outer 1/2) \X0D\\X0A\\X0D\\X0A\Depth of invasion:   87% of myometrial involvement \X0D\\X0A\                                (13 mm from EM junction / 15 mm myometrial\X0D\\X0A\thickness) *   \X0D\\X0A\\X0D\\X0A\Nontumorous endometrium:   weakly proliferative and complex atypical\X0D\\X0A\hyperplasia\X0D\\X0A\\X0D\\X0A\Serosal involvement:  not identified\X0D\\X0A\\X0D\\X0A\Adnexal involvement (specify):  no\X0D\\X0A\\X0D\\X0A\Parametrial soft tissues:  no\X0D\\X0A\\X0D\\X0A\Cervical involvement:  \X0D\\X0A\     Endocervical epithelium:  no\X0D\\X0A\     Stroma:  no\X0D\\X0A\\X0D\\X0A\Lymphvascular invasion:  no definite invasion identified\X0D\\X0A\\X0D\\X0A\Lymph node involvement (specify):   0 positive / 34 total\X0D\\X0A\     Left pelvic:  0/6\X0D\\X0A\     Left common iliac:  0/6\X0D\\X0A\     Left periaortic:  0/5\X0D\\X0A\     Right common iliac:  0/9\X0D\\X0A\     Right periaortic:  0/1\X0D\\X0A\     Right pelvic:  0/3\X0D\\X0A\     \X0D\\X0A\     Size of largest positive lymph node:  not applicable\X0D\\X0A\\X0D\\X0A\Other sites of involvement (list):  none\X0D\\X0A\\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\pT              FIGO\X0D\\X0A\\X0D\\X0A\pT1b    IB            Tumor invades = 1/2 of the myometrium\X0D\\X0A\\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\\X0D\\X0A\pN0                                No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\\X0D\\X0A\                                       Not applicable\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\  \X0D\\X0A\",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Fallopian tube \T\ ovary-left\X0D\\X0A\B: Fallopian tube \T\ ovary-right\X0D\\X0A\C: Uterus and cervix\X0D\\X0A\D: Vaginal margin\X0D\\X0A\E: left pelvic lymph node\X0D\\X0A\F: Left common iliac lymph nodes\X0D\\X0A\G: left peri-aortic iliac lymph nodes\X0D\\X0A\H: right common iliac lymph nodes\X0D\\X0A\I: right peri-aortic lymph nodes\X0D\\X0A\J: right pelvic lymph nodes\X0D\\X0A\,,
REG1,OTHER,0,490229,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is not provided. Operative procedure: cystoscopy,\X0D\\X0A\bilateral stent placement. \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Aug 18 1940] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Mar 19 2012] 14:58\X0D\\X0A\Receipt Date: **DATE[Mar 19 2012] 14:58\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: P.L. **NAME[YYY], MD     Service: NEU     Location: A06J\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Mar 21 2012] 17:12\X0D\\X0A\RESIDENTS(**NAME[M): M. WWW], MD","DIAGNOSIS\X0D\\X0A\SPECIMEN SUBMITTED AS BLADDER TUMOR BIOPSY:\X0D\\X0A\   - HIGH GRADE UROTHELIAL CARCINOMA WITH EXTENSIVE NECROSIS AND LAMINA\X0D\\X0A\PROPRIA INVASION; NO DEEP \X0D\\X0A\    MUSCLE PRESENT IN SPECIMEN.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Mar 21 2012] Y.M. **NAME[VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M54000 M8010 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) bladder tumor biopsy                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple  \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): red to tan\X0D\\X0A\Consistency: soft, spongy and friable \X0D\\X0A\Size(s): in aggregate 1.5 x 1.5 x 0.3 cm \X0D\\X0A\Cassette summary: entirely submitted in screened A1.   \X0D\\X0A\rgc/**DATE[Mar 20 2012] **NAME[M. WWW], MD\X0D\\X0A\**NAME[UUU M. TTT",MICROSCOPIC DESCRIPTION\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Bladder tumor biopsy,,
REG1,OTHER,0,490254,1,,CLINICAL INFORMATION:,"**INSTITUTION          MR #: **ID-NUM\X0D\\X0A\**INSTITUTION          **NAME[BBB, AAA M].\X0D\\X0A\**PLACE, KENTUCKY  **ZIP-CODE          **DATE[Apr 1 1954] (Age: **AGE[in 50s])   FW\X0D\\X0A\          Collect Date: **DATE[Feb 15 2012] 00:00\X0D\\X0A\          Receipt Date: **DATE[Feb 15 2012] 11:36\X0D\\X0A\          Page 1\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND  LABORATORY MEDICINE\X0D\\X0A\CYTOPATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax: **PHONE\X0D\\X0A\Email: **EMAIL          ***PATH-NUMBER[1]     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD/Practitioner:  N.J. **NAME[YYY], MD     Service: GAS     Location:\X0D\\X0A\ENDO\X0D\\X0A\     Reported: **DATE[Feb 15 2012] 16:33\X0D\\X0A\     Collected: **DATE[Feb 15 2012] 00:00","DIAGNOSIS\X0D\\X0A\ENDOSCOPIC ULTRASOUND GUIDED FNA, PANCREAS: \X0D\\X0A\     - POSITIVE FOR MALIGNANCY, ADENOCARCINOMA. \X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ R.G. **NAME[XXX], MD\X0D\\X0A\YMM \X0D\\X0A\CLINICAL DIAGNOSIS\X0D\\X0A\HOP mass, stent in situ\X0D\\X0A\Endo / FNA performed by: Dr. **NAME[M. YYY]\X0D\\X0A\Immediate evaluation performed by: Dr. **NAME[M. XXX]\X0D\\X0A\PASS # 1: atypical groups, suspicious for malignancy\X0D\\X0A\     2-3: inflammatory cells \T\ atypical groups\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\ICD-9:  F: A: 88173 ASP INTER, 88172, 88177, 62997 SNOMED CODES: A: M81403\X0D\\X0A\P1149 T59000",,GROSS DESCRIPTION:\X0D\\X0A\Hold needle rinse fluid.,,"SPECIMEN DESCRIPTION:\X0D\\X0A\A:  FNA PANCREAS, ENDOSCOPIC ULTRASOUND GUIDED\X0D\\X0A\     DIFF-QUIK x 3, PAP STAIN x 3",,
REG1,OTHER,0,490434,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is atypical right thyroid nodule.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Thyroid, lobectomy",Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS: \X0D\\X0A\RIGHT THYROID LOBE AND ISTHMUS: \X0D\\X0A\     H rthle cell carcinoma with vascular and capsular invasion. \X0D\\X0A\Remainder of the thyroid shows benign colloid nodules and chronic lymphocytic\X0D\\X0A\thyroiditis. \X0D\\X0A\This diagnosis was rendered by Dr. **NAME[ZZZ YYY] at the **INSTITUTION.\X0D\\X0A\**INITIALS \X0D\\X0A\PROVISIONAL DIAGNOSIS PENDING CONSULTATION:\X0D\\X0A\RIGHT THYROID LOBE AND ISTHMUS:\X0D\\X0A\     Multinodular thyroid with suspicious H rthle cell nodule and lymphocytic\X0D\\X0A\thyroiditis.\X0D\\X0A\DGD/mbc,,"Gross Description\X0D\\X0A\Received fresh for frozen section labeled right thyroid lobe and isthmus is a\X0D\\X0A\7.3 gram, 4.5 x 3.5 x 1.8 cm intact hemithyroidectomy specimen. The capsule is\X0D\\X0A\inked black and sectioning reveals a few well-circumscribed tan/pink nodules\X0D\\X0A\ranging from 1.0 to 1.5 cm in greatest dimension. No invasion through the\X0D\\X0A\capsule or into the surrounding thyroid tissue is identified. A representative\X0D\\X0A\section is submitted for frozen section, now resubmitted in cassette A. The\X0D\\X0A\remaining thyroid is submitted in its entirety sequentially in cassettes B-G. \X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Sections of the thyroid show it to be comprised of multiple nodules with one of\X0D\\X0A\the nodules showing it to be comprised entirely of H rthle cells. There is an\X0D\\X0A\area suspicious for invasion of the capsule. The remainder of the thyroid\X0D\\X0A\nodules are separated by fibrous septae of variable thickness. Also noted are\X0D\\X0A\lymphoid germinal centers and a lymphocytic infiltrate scattered randomly\X0D\\X0A\through the gland. No evidence of parathyroid tissue is identified.  The case is\X0D\\X0A\forwarded to Dr.**NAME[ZZZ YYY] for consultation. \X0D\\X0A\DGD/mbc,,,Amendments:\X0D\\X0A\Amended:  **DATE[Feb 1 2012] by **NAME[XXX WWW]\X0D\\X0A\Reason: OUTSIDE CONSULTATION RESULTS\X0D\\X0A\     Previous Signout Date:  **DATE[Jan 29 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\External Consultation     Date Ordered:     **DATE[Feb 1 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Feb 2 2012]     By:  **NAME[XXX WWW]\X0D\\X0A\     Date Reported:     **DATE[Feb 2 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,OTHER,0,490504,1,,"CLINICAL HISTORY:\X0D\\X0A\Hepatitis C, end-stage liver disease, end-stage renal disease.",AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   EXPLANTED LIVER (1382 GRAMS) AND ADJOINING GALLBLADDER:\X0D\\X0A\1.   MICROSCOPIC FOCI OF RESIDUAL MODERATE TO WELL DIFFERENTIATED (GRADE\X0D\\X0A\II) HEPATOCELLULAR CARCINOMA IN THE MID RIGHT HEPATIC LOBE, 1.8 X 1.6 X\X0D\\X0A\1.4 CM.\X0D\\X0A\2.   Greater than 95% of the tumor is necrotic consistent with\X0D\\X0A\successful chemo-embolization.\X0D\\X0A\3.   End stage macronodular cirrhosis.\X0D\\X0A\4.   Ongoing piecemeal necrosis consistent with active hepatitis-C.\X0D\\X0A\5.   Moderate microvesicular and macrovesicular steatosis.\X0D\\X0A\6.   Chronic cholecystitis.\X0D\\X0A\B.   DONOR GALLBLADDER:\X0D\\X0A\1.   Intact benign gallbladder with no significant histopathology.\X0D\\X0A\C.   DONOR LIVER BIOPSY:\X0D\\X0A\1.   Moderate centrilobular ischemia consistent with preservation\X0D\\X0A\injury.\X0D\\X0A\2.   Minimal nonspecific chronic triaditis.\X0D\\X0A\3.   Negative for active hepatitis.\X0D\\X0A\4.   Negative for steatosis.\X0D\\X0A\5.   Special stains are negative for increased portal fibrosis.\X0D\\X0A\6.   Special stains are negative for increased iron stores.\X0D\\X0A\ypT1,Nx,Mx,G2\X0D\\X0A\Pathology #**ID-NUM (DA/lap)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Aug 01 2013]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Submitted in formalin is an intact 1,382.0 gram, 22.2 x\X0D\\X0A\16.8 x 7.8 cm. hepatectomy specimen with an adjoining markedly\X0D\\X0A\attenuated 7.8 x 5.2 x 4.8 cm. gallbladder with an opaque serosal\X0D\\X0A\surface.  The gallbladder is transected along the longitudinal axis\X0D\\X0A\revealing a fundal cavity filled with a thick black bile.  The mucosal\X0D\\X0A\surface is intact with no gross evidence of ulceration nor tumor\X0D\\X0A\nodularity.  The fundal wall approximates 2.0 mm. in thickness.  A\X0D\\X0A\representative section of the mid fundal wall is submitted in A1.  The\X0D\\X0A\normal hepatic lobation is present.  An adjoining 10.8 x 6.4 x 1.2 cm.\X0D\\X0A\falciform ligament appears grossly unremarkable.  The overlying hepatic\X0D\\X0A\capsule is intact.  Serial sectioning through the hepatic parenchyma\X0D\\X0A\reveals a patent hepatic venous system with no gross evidence of\X0D\\X0A\thrombosis.  An irregular nodularity is noted throughout consistent with\X0D\\X0A\end-stage micronodular cirrhosis.  A central necrotic appearing\X0D\\X0A\circumscribed yellow 1.8 x 1.6 x 1.4 cm. nodule is noted in the mid\X0D\\X0A\right hepatic lobe.  This entire lesion with surrounding hepatic\X0D\\X0A\parenchyma is submitted in A2-A4.  No other grossly discernible tumor\X0D\\X0A\nodularity is identified.  A representative section of right hepatic\X0D\\X0A\lobe is submitted in A5 with left hepatic lobe in A6.\X0D\\X0A\Specimen (B) Submitted in formalin is an intact non-attenuated 5.2 x 3.4\X0D\\X0A\x 3.3 cm. gallbladder with an opaque serosal surface.  The specimen is\X0D\\X0A\transected along the longitudinal axis revealing a fundal cavity filled\X0D\\X0A\with a thick green bile.  No grossly discernible stone formation is\X0D\\X0A\identified.  The mucosal surface is intact with no gross evidence of\X0D\\X0A\ulceration nor tumor nodularity.  The fundal wall approximates 3.0 mm.\X0D\\X0A\in average thickness.  A representative section of the mid fundal wall\X0D\\X0A\is submitted in B.  (DA/dkv)\X0D\\X0A\Specimen (C) Submitted in formalin and designated 'donor liver biopsy'\X0D\\X0A\is a firm brown 9 x 1 mm core biopsy embedded in toto in (C).  Iron and\X0D\\X0A\Trichrome stains are ordered.\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 8\X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: Liver\X0D\\X0A\ \X0D\\X0A\LIVER: Resection\X0D\\X0A\Specimen Type: Explanted liver\X0D\\X0A\Tumor Size:    Greatest dimension: 1.8cm x 1.6cm x 1.4cm\X0D\\X0A\Histologic Type:    Hepatocellular carcinoma\X0D\\X0A\Histologic Grade:   GII\X0D\\X0A\Primary Tumor (pT): pT1\X0D\\X0A\Regional Lymph Nodes (pN):    pNX\X0D\\X0A\Number examined:    0\X0D\\X0A\Number involved:    0\X0D\\X0A\Bile Duct Margin:   Uninvolved by invasive carcinoma\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Additional Pathologic Findings:    Extensive tumor necrosis c/w TACE",,"SPECIMEN(S): C Liver bx, needle\X0D\\X0A\SPECIMEN(S): A Liver\X0D\\X0A\SPECIMEN(S): B GALLBLADDER",,
REG1,OTHER,0,490671,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\LEFT RENAL MASS\X0D\\X0A\,"PROCEDURE/SPECIMEN/LATERALITY:\X0D\\X0A\    LEFT KIDNEY, RADICAL NEPHRECTOMY.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\    UNIFOCAL.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:\X0D\\X0A\    CLEAR CELL RENAL CELL CARCINOMA.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\    15.0 CM.\X0D\\X0A\HISTOLOGIC GRADE (FUHRMAN NUCLEAR GRADE):\X0D\\X0A\    GRADE 3.\X0D\\X0A\SARCOMATOID FEATURES:\X0D\\X0A\    NOT IDENTIFIED.\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   2355 Poplar Level Rd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX,WWW M]\X0D\\X0A\   101 Hospital Blvd\X0D\\X0A\   **PLACE, IN **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS/2\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\RENAL TUBULAR CARCINOMA SYNOPTIC REPORT AJCC/UICC TNM, 7TH EDITION\X0D\\X0A\\X0D\\X0A\PROCEDURE/SPECIMEN/LATERALITY:\X0D\\X0A\LEFT KIDNEY, RADICAL NEPHRECTOMY.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\TUMOR HISTOLOGIC TYPE:\X0D\\X0A\CLEAR CELL RENAL CELL CARCINOMA.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\15.0 CM.\X0D\\X0A\HISTOLOGIC GRADE (FUHRMAN NUCLEAR GRADE):\X0D\\X0A\GRADE 3.\X0D\\X0A\SARCOMATOID FEATURES:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR:\X0D\\X0A\TUMOR EXTENDS INTO PERINEPHRIC ADIPOSE TISSUE.\X0D\\X0A\TUMOR EXTENDS INTO RENAL SINUS.\X0D\\X0A\TUMOR EXTENDS INTO RENAL VEIN.\X0D\\X0A\MARGINS:\X0D\\X0A\TUMOR IS PRESENT IN A VASCULAR SPACE AT THE URETERAL MARGIN.\X0D\\X0A\TUMOR IS PRESENT AT THE RENAL VEIN MARGIN.\X0D\\X0A\PERIPHERAL SOFT TISSUE MARGINS AND RENAL ARTERY MARGINS ARE NEGATIVE.\X0D\\X0A\ADRENAL GLAND:\X0D\\X0A\BENIGN ADRENAL GLAND.\X0D\\X0A\THE ADRENAL NODULE WILL BE REPORTED AS AN ADDENDUM.\X0D\\X0A\LYMPH  NODES:\X0D\\X0A\ONE BENIGN LYMPH NODE.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  pT3a at least pN0(one lymph node) Mn/a.\X0D\\X0A\PATHOLOGIC FINDINGS IN NON-NEOPLASTIC KIDNEY:\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\MILD ARTERIO-ARTERIOLONEPHROSCLEROSIS.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Reviewed for QA(LWF).\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin designated \""left kidney\"" is a 1,775 gram nephrectomy specimen measuring\X0D\\X0A\24.0 x 15.0 x 10.0 cm.  There is a 2.5 opened vascular margin (vein) exuding yellow-tan\X0D\\X0A\friable tumor.  The surface of the specimen consists of yellow-tan perinephric adipose\X0D\\X0A\tissue with focal Gerota's fascia.\X0D\\X0A\\X0D\\X0A\The previously mentioned vascular margin is shaved.  The renal artery is identified and\X0D\\X0A\appears free of tumor.  The ureter is identified and the margin is shaved.  The ureter\X0D\\X0A\measures 9.0 cm in length and is 0.5 cm in diameter and is dissected to the level of the\X0D\\X0A\renal pelvis and fails to reveal distinct tumor involvement.\X0D\\X0A\\X0D\\X0A\The specimen is marked with black ink and bivalved to reveal the kidney to measure 19.0 x\X0D\\X0A\12.0 x 10.0 cm.  There is a bulky, yellow-tan, partially gelatinous, hemorrhagic tumor mass\X0D\\X0A\identified within the kidney.  The tumor completely replaces the lower pole and extends into\X0D\\X0A\the upper pole of the kidney.  The tumor measures 15.0 x 10.5 x 10.0 cm.  Tumor grossly\X0D\\X0A\appears to involve the renal sinus adipose tissue and fills the calyceal system of the\X0D\\X0A\kidney, with tumor calyceal extension noted in the upper pole.  The tumor is located to\X0D\\X0A\within less than 0.1 cm of the overlying inked surface.\X0D\\X0A\\X0D\\X0A\The uninvolved kidney parenchyma is tan and unremarkable.\X0D\\X0A\\X0D\\X0A\The adrenal gland is identified and measures 6.8 x 3.0 x up to 1.0 cm.  There is a 1.1 x 0.9\X0D\\X0A\x 0.9 cm cortical nodule.  The adrenal gland does not appear to be involved by the tumor.\X0D\\X0A\\X0D\\X0A\Two possible lymph node candidates are identified within the renal pelvis measuring 0.8 cm\X0D\\X0A\in greatest dimension.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\1.        renal vein margin with tumor\X0D\\X0A\2.        renal artery and ureter margin\X0D\\X0A\3-5.        tumor and renal sinus adipose tissue\X0D\\X0A\6-9.        multiple representative sections of tumor and overlying inked\X0D\\X0A\peripheral surface\X0D\\X0A\10\T\11.        representative sections of tumor and adherent perinephric adipose tissue\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\12\T\13.        representative sections of tumor within calyx\X0D\\X0A\14.        unremarkable kidney parenchyma\X0D\\X0A\15.        two lymph node candidates\X0D\\X0A\16.        adrenal gland\X0D\\X0A\17.        section of adrenal cortical nodule    **INITIALS\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\LEFT KIDNEY\X0D\\X0A\,,"ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Feb 19 12]-1002\X0D\\X0A\\X0D\\X0A\The purpose of this addendum is to report findings on additional sections submitted from an\X0D\\X0A\adrenal nodule.  Sections from the adrenal nodule are consistent with an adrenal cortical\X0D\\X0A\adenoma.\X0D\\X0A\\X0D\\X0A\Reviewed for QA (MN).\X0D\\X0A\\X0D\\X0A\THE ADRENAL NODULE WILL BE REPORTED AS AN ADDENDUM.\X0D\\X0A\LYMPH  NODES:\X0D\\X0A\ONE BENIGN LYMPH NODE.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  pT3a at least pN0(one lymph node) Mn/a.\X0D\\X0A\PATHOLOGIC FINDINGS IN NON-NEOPLASTIC KIDNEY:\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\MILD ARTERIO-ARTERIOLONEPHROSCLEROSIS.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS    \X0D\\X0A\\X0D\\X0A\Reviewed for QA(LWF).\X0D\\X0A\\X0D\\X0A\CLINICAL HISTORY       \X0D\\X0A\\X0D\\X0A\LEFT RENAL MASS\X0D\\X0A\\X0D\\X0A\SPECIMEN INFORMATION     \X0D\\X0A\\X0D\\X0A\LEFT KIDNEY\X0D\\X0A\\X0D\\X0A\GROSS DESCRIPTION       \X0D\\X0A\\X0D\\X0A\Received in formalin designated \""left kidney\"" is a 1,775 gram nephrectomy specimen measuring\X0D\\X0A\24.0 x 15.0 x 10.0 cm.  There is a 2.5 opened vascular margin (vein) exuding yellow-tan\X0D\\X0A\friable tumor.  The surface of the specimen consists of yellow-tan perinephric adipose\X0D\\X0A\tissue with focal Gerota's fascia.\X0D\\X0A\\X0D\\X0A\The previously mentioned vascular margin is shaved.  The renal artery is identified and\X0D\\X0A\appears free of tumor.  The ureter is identified and the margin is shaved.  The ureter\X0D\\X0A\measures 9.0 cm in length and is 0.5 cm in diameter and is dissected to the level of the\X0D\\X0A\renal pelvis and fails to reveal distinct tumor involvement.\X0D\\X0A\\X0D\\X0A\The specimen is marked with black ink and bivalved to reveal the kidney to measure 19.0 x\X0D\\X0A\12.0 x 10.0 cm.  There is a bulky, yellow-tan, partially gelatinous, hemorrhagic tumor mass\X0D\\X0A\identified within the kidney.  The tumor completely replaces the lower pole and extends into\X0D\\X0A\the upper pole of the kidney.  The tumor measures 15.0 x 10.5 x 10.0 cm.  Tumor grossly\X0D\\X0A\appears to involve the renal sinus adipose tissue and fills the calyceal system of the\X0D\\X0A\kidney, with tumor calyceal extension noted in the upper pole.  The tumor is located to\X0D\\X0A\within less than 0.1 cm of the overlying inked surface.\X0D\\X0A\\X0D\\X0A\The uninvolved kidney parenchyma is tan and unremarkable.\X0D\\X0A\\X0D\\X0A\The adrenal gland is identified and measures 6.8 x 3.0 x up to 1.0 cm.  There is a 1.1 x 0.9\X0D\\X0A\x 0.9 cm cortical nodule.  The adrenal gland does not appear to be involved by the tumor.\X0D\\X0A\\X0D\\X0A\Two possible lymph node candidates are identified within the renal pelvis measuring 0.8 cm\X0D\\X0A\in greatest dimension.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\1.        renal vein margin with tumor\X0D\\X0A\2.        renal artery and ureter margin\X0D\\X0A\3-5.        tumor and renal sinus adipose tissue\X0D\\X0A\6-9.        multiple representative sections of tumor and overlying inked\X0D\\X0A\peripheral surface\X0D\\X0A\10\T\11.        representative sections of tumor and adherent perinephric adipose tissue\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\12\T\13.        representative sections of tumor within calyx\X0D\\X0A\14.        unremarkable kidney parenchyma\X0D\\X0A\15.        two lymph node candidates\X0D\\X0A\16.        adrenal gland\X0D\\X0A\17.        section of adrenal cortical nodule    **INITIALS\X0D\\X0A\\X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[ZZZ,YYY M]\X0D\\X0A\2355 Poplar Level Rd\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\**NAME[XXX,WWW M]\X0D\\X0A\101 Hospital Blvd\X0D\\X0A\**PLACE, IN **ZIP-CODE\X0D\\X0A\ **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS/2\X0D\\X0A\\X0D\\X0A\Signed __________(signature on file)___________ **NAME[VVV M UUU] MD **DATE[Feb 16 12]\X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Feb 20 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\"
REG1,OTHER,0,491737,1,,Clinical History:\X0D\\X0A\Papillary Thyroid Cancer,"Frozen Section:\X0D\\X0A\A) Cervical lymph node (TP and FS):\X0D\\X0A\- Benign lymph node, no tumor seen.\X0D\\X0A\- RBV by **NAME[ZZZ].  (DRJ)","Pre-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A) Cervical lymph node, excision:\X0D\\X0A\-    Benign lymph node; no tumor seen.\X0D\\X0A\B) Thyroid, total thyroidectomy:\X0D\\X0A\-    Two foci of well-differentiated papillary carcinoma, 0.3 and 2.0\X0D\\X0A\cm, appearing confined to the right thyroid lobe (see synoptic and\X0D\\X0A\microscopic description).\X0D\\X0A\-    Four benign perithyroidal lymph nodes, free of tumor.\X0D\\X0A\-    Pathologic Stage:  pT1b;  pN0.\X0D\\X0A\-    Background nodular thyroid with Hurthle cell change, chronic\X0D\\X0A\lymphocytic thyroiditis, and focal granulomatous inflammation.\X0D\\X0A\-    One benign parathyroid gland, and small portions of benign thymic\X0D\\X0A\tissue.\X0D\\X0A\-    GMS and acid-fast stains are negative for microorganisms.",,"Gross Description:\X0D\\X0A\Two containers.\X0D\\X0A\Container A is labeled \""cervical lymph node\"".  The specimen is received\X0D\\X0A\fresh and consists of a 0.5 x 0.3 x 0.1 cm soft tan-pink piece of\X0D\\X0A\tissue.  Touch preps are made and tissue is submitted for frozen\X0D\\X0A\section.  The frozen section residual is resubmitted for permanent\X0D\\X0A\sections in block AFSc.\X0D\\X0A\Specimen B is labeled \""total thyroid\"".  The specimen is received in\X0D\\X0A\fixative and consists of a 17 gram thyroid.  The right lobe is 5.0 x 2.0\X0D\\X0A\x 1.0 cm.  The isthmus 2.0 x 1.3 x 0.8 cm, and the left lobe 4.5 x 2.0 x\X0D\\X0A\1.0 cm.  The left lobe is partially disrupted.  The specimen is inked.\X0D\\X0A\A 2.0 x 1.8 x 1.5 cm solid white ill-defined nodule is present in the\X0D\\X0A\lower right thyroid extending into the isthmus.  A 0.3 z 0.3 x 0.2 cm\X0D\\X0A\solid white nodule is located in the left superior aspect of the\X0D\\X0A\thyroid.  The remaining cut surface is red and nodular.  No additional\X0D\\X0A\mass lesions are evident.  Representative sections are submitted as\X0D\\X0A\follows:\X0D\\X0A\1 through 6     entire large nodule in right lower lobe of thyroid\X0D\\X0A\7     solid nodule extending into the isthmus\X0D\\X0A\8 and 9     additional sections of right thyroid\X0D\\X0A\10     left thyroid nodule\X0D\\X0A\11 and 12     additional sections of left thyroid.\X0D\\X0A\JMM:dar","Microscopic Description:\X0D\\X0A\A)   Review of the touch preparation, frozen, and permanent section\X0D\\X0A\slides shows a single benign lymph node with minimal sinus\X0D\\X0A\histiocytosis, and no atypia.\X0D\\X0A\B)   Sections through the right lower lobe thyroid nodule demonstrate at\X0D\\X0A\least two foci of organ-confined papillary carcinoma of the thyroid,\X0D\\X0A\demonstrating a conventional true papillary architecture which\X0D\\X0A\predominates, and smaller zones of partial follicular variant\X0D\\X0A\differentiation within the largest nodule.  The smaller nodule measures\X0D\\X0A\approximately 0.3 cm.  The larger nodule extends to within one high\X0D\\X0A\power field of the inked outer capsule of the thyroid, and neither\X0D\\X0A\demonstrates convincing extrathyroidal extension into the surrounding\X0D\\X0A\soft tissues (deeper levels obtained on blocks B3 and B5).  The\X0D\\X0A\background thyroid shows nodular hyperplastic changes with a moderate\X0D\\X0A\chronic lymphocytic thyroiditis noted along with small foci of Hurthle\X0D\\X0A\cell change.  These features may suggest Hashimoto's thyroiditis.  The\X0D\\X0A\nodular adenomatous hyperplastic changes extend into the thyroid region.\X0D\\X0A\Sections of the additional right lobe tissue show similar benign nodular\X0D\\X0A\thyroid changes in the background along with chronic lymphocytic\X0D\\X0A\thyroiditis.  At least two separate fragments of benign thymic tissue\X0D\\X0A\are noted with Hassall's corpuscles, showing focal degenerative changes\X0D\\X0A\along with dystrophic calcifications.  No atypia is seen within this\X0D\\X0A\tissue which also shows the constituent background lymphoid components\X0D\\X0A\and admixed mature adipose tissue.\X0D\\X0A\Sections of the left lobe show similar benign nodular changes as seen in\X0D\\X0A\the right lobe, with the exception of a small focus of granulomatous\X0D\\X0A\inflammation with central degeneration, and palisaded bland appearing\X0D\\X0A\histiocytes at the periphery including rare multinucleated giant cells.\X0D\\X0A\Both GMS and acid-fast stains are performed on block B10, and show no\X0D\\X0A\associated microorganisms within this focus (adequate special stain\X0D\\X0A\controls).  In total, there are four benign perithyroidal lymph nodes\X0D\\X0A\recovered in association with the right lobe, and one benign parathyroid\X0D\\X0A\gland identified with the left lobe (slide ***PATH-NUMBER[1]).\X0D\\X0A\Tissue Code:  T1.\X0D\\X0A\CASE SUMMARY FOR PRIMARY CARCINOMA OF THE THYROID\X0D\\X0A\Procedure:  Total thyroidectomy\X0D\\X0A\Specimen size:  17 grams, left lobe 4.5 x 2.0 x 1.0 cm; right lobe 5.0 x\X0D\\X0A\2.0 x 1.0 cm\X0D\\X0A\Specimen integrity:  Single intact specimen, margins can be assessed\X0D\\X0A\Tumor focality:  Two foci within the right lobe\X0D\\X0A\Location of tumor(s):   Right lower lobe pole\X0D\\X0A\Tumor size:  0.3 and 2.0 cm\X0D\\X0A\Histologic type:  Papillary carcinoma (conventional)\X0D\\X0A\Histologic grade:   Well-differentiated\X0D\\X0A\Tumor encapsulation:  Partial encapsulation\X0D\\X0A\Tumor capsule invasion:   N/A\X0D\\X0A\Lymph-vascular invasion:  Not identified\X0D\\X0A\Extra thyroidal extension:  Not identified\X0D\\X0A\Margins:   Free of tumor\X0D\\X0A\Lymph nodes:   Four benign perithyroidal lymph nodes\X0D\\X0A\Additional pathologic findings:  Background nodular thyroid with Hurthle\X0D\\X0A\cell change and chronic lymphocytic thyroiditis\X0D\\X0A\Pathologic Staging:  pT1b; pN0; pM(N/A).\X0D\\X0A\DRJ:jlj\X0D\\X0A\D\T\T:  **DATE[Jan 22 2012].\X0D\\X0A\**NAME[YYY XXX:  WWW M VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jan 22 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Cervical Lymph Node\X0D\\X0A\SOURCE OF SPECIMEN: B Total Thyroid,,
REG1,OTHER,0,491742,1,,Clinical History:\X0D\\X0A\Followed For A Multinodular Goiter For Approx 15 Years With Development\X0D\\X0A\Of Localized Pain.,,"Pre-Operative Diagnosis:\X0D\\X0A\Papillary Thyroid Cancer In The Bilateral  Nodularity\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Left thyroid nodule:\X0D\\X0A\  -   0.9 cm papillary carcinoma, follicular variant, focally\X0D\\X0A\approaching (less than 0.1 cm from) cauterized margin.\X0D\\X0A\B)  Right thyroid nodule:\X0D\\X0A\  -   0.7 cm papillary carcinoma, follicular variant, margins of\X0D\\X0A\resection free of involvement within the planes of section.",,"Gross Description:\X0D\\X0A\Two containers:\X0D\\X0A\Specimen A is labeled \""left thyroid nodule\"".  The specimen is received\X0D\\X0A\in fixative and consists of a 5 gram, 3.3 x 2.3 x 1.4 cm lobulated\X0D\\X0A\tan-brown piece of tissue.  The specimen is inked.  The cut surface has\X0D\\X0A\a 0.9 x 0.8 x 0.6 cm encapsulated tan nodule.  The capsule is focally\X0D\\X0A\calcified.  The remaining cut surface is deep red and the tissue is\X0D\\X0A\entirely submitted as follows:\X0D\\X0A\A1 and A2 - nodules, decalcified;\X0D\\X0A\A3 through A5 - remaining tissue.\X0D\\X0A\Specimen B is labeled \""right thyroid nodule\"".  The specimen is received\X0D\\X0A\in fixative and consists of an 11 gram, 5.5 x 4 x 2 cm lobated red-brown\X0D\\X0A\piece of thyroid.  The specimen is inked.  The cut surface is dark red\X0D\\X0A\with a firm white well-circumscribed homogeneous nodule.  The remaining\X0D\\X0A\cut surface is deep red without additional mass lesions.  Representative\X0D\\X0A\sections are submitted as follows:\X0D\\X0A\B1 and B2 - entire nodule;\X0D\\X0A\B3 through B5 - random sections of remaining tissue.\X0D\\X0A\JMM:jlj","Microscopic Description:\X0D\\X0A\CASE SUMMARY FOR PRIMARY CARCINOMA OF THE THYROID\X0D\\X0A\Procedure:  Apparent right and left thyroid lobectomies, specimens\X0D\\X0A\submitted as \""left thyroid nodule\"" and \""right thyroid nodule\"".\X0D\\X0A\Specimen size:\X0D\\X0A\     A:  3.3 x 2.3 x 1.4 cm.\X0D\\X0A\     B:  5.5 x 4 x 2 cm.\X0D\\X0A\Specimen integrity: Intact\X0D\\X0A\Tumor focality:  Two foci of tumor present.\X0D\\X0A\Location of tumor(s):  Right and left lobes.\X0D\\X0A\Tumor size:\X0D\\X0A\     A:  3.3 x 2.3 x 1.4 cm.\X0D\\X0A\     B:  5.5 x 4 x 2 cm.\X0D\\X0A\Histologic type:  Papillary carcinoma.\X0D\\X0A\Lymph-vascular invasion:  Not identified.\X0D\\X0A\Extrathyroidal extension:  Not identified.\X0D\\X0A\Margins:\X0D\\X0A\A:  The tumor very closely approaches (less than 0.1 cm) the cauterized\X0D\\X0A\left thyroid margin.\X0D\\X0A\B:  Margins of right thyroid free of involvement within the planes of\X0D\\X0A\section.\X0D\\X0A\Lymph nodes:  N/A\X0D\\X0A\Additional pathologic findings:  Multinodular goiter.\X0D\\X0A\Pathologic staging:  pT1a; pN0; MX.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\CPT Code:  88307.26 x 2\X0D\\X0A\JES:jck\X0D\\X0A\Dct:Trs: **DATE[Jun 07 2012]\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jun 08 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Left Thyroid Nodule\X0D\\X0A\SOURCE OF SPECIMEN: B Right Thyroid Nodule,,
REG1,OTHER,0,491818,1,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,MARK I. Status: SOUT","MICROSCOPIC INTERPRETATION: BIOPSY OF STOMACH BODY MASS: INVASIVE POORLY DIFFERENTIATED GASTRIC ADENOCARCINOMA. EXTENT OF INVASION:  TUMOR INVADES SUBMUCOSA. LYMPHOVASCULAR INVASION:  NOT IDENTIFIED. ASSOCIATED COAGULATIVE TUMOR NECROSIS. BACKGROUND CHRONIC ACTIVE GASTRITIS. POSITIVE FOR H. PYLORI MICROORGANISMS. NOTE:  Dr. **NAME[M. YYY XXX] agrees with the diagnosis.. Final Signout: **NAME[WWW VVV], MD **DATE[Jan 19 12]",,"GROSS DESCRIPTION: The specimen is received within formalin in one container labeled biopsy of stomach body mass.  It consists of four pink-tan soft tissue fragments, ranging from 2 to 4 mm. in diameter.  The specimen is entirely submitted in one block.",,Tissues: STOMACH BIOPSY. Specimen Comments: CPT CODES: 88305 X 1,,
REG1,OTHER,0,491959,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is left thyroid nodule; benign FNA.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\**INSTITUTION\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Thyroid, lobectomy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\C11081224 (***PATH-NUMBER[1]), **DATE[Feb 09 12]. LEFT THYROID LOBE: Negative for malignant\X0D\\X0A\cells. Benign thyroid nodule. There are between 6-10 groups of follicular cells\X0D\\X0A\identified in this sample. (PCC)","Final Diagnosis\X0D\\X0A\LEFT THYROID LOBE:\X0D\\X0A\     Encapsulated unifocal follicular carcinoma 2.4 x 2.0 x 2.0cm., \X0D\\X0A\     vascular invasion present, surgical margins of resection negative for\X0D\\X0A\tumor.\X0D\\X0A\     Normal parathyroid x 1\X0D\\X0A\**INITIALS\X0D\\X0A\NOTE: Dr. **NAME[ZZZ YYY] was called and the case discussed by Dr. **NAME[XXX] on **DATE[Apr]\X0D\\X0A\4, ***PHONE at 11:10am.  **INITIALS\X0D\\X0A\THYROID TEMPLATE:\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  left thyroid lobectomy\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\SPECIMEN SIZE:  8.4 gram, 3.7 x 3.0 x 2.5cm intact hemithyroidectomy\X0D\\X0A\TUMOR FOCALITY:  unifocal\X0D\\X0A\TUMOR LATERALITY:  left\X0D\\X0A\TUMOR SITE:  nodule comprises most of left lobe\X0D\\X0A\TUMOR SIZE (greatest dimension):  2.4 x 2.0 x 2.0cm\X0D\\X0A\HISTOLOGIC TYPE:  follicular carcinoma\X0D\\X0A\HISTOLOGIC GRADE:  grade I\X0D\\X0A\MARGINS:  free of tumor\X0D\\X0A\TUMOR CAPSULE: encapsulated,  invaded by tumor\X0D\\X0A\TUMOR CAPSULAR INVASION:  capsule invaded\X0D\\X0A\LYMPH-VASCULAR INVASION:  yes\X0D\\X0A\PERINEURAL INVASION:  no\X0D\\X0A\EXTRATHYROIDAL EXTENSIONS:  no\X0D\\X0A\NUMBER OF PARATHYROID(S) REMOVED:  1\X0D\\X0A\LYMPH NODE STATUS:  no nodes submitted\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  none\X0D\\X0A\OTHER STUDIES:  none\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  T2\X0D\\X0A\pN=   NX\X0D\\X0A\pM=   MX\X0D\\X0A\AJCC PATHOLOGIC STAGE:  STAGE I",,"Gross Description\X0D\\X0A\Received in formalin labeled left thyroid lobe is an 8.4 gram, 3.7 x 3.0 x 2.5cm\X0D\\X0A\intact hemithyroidectomy specimen.  The capsule is inked black and sectioning\X0D\\X0A\reveals a 2.4 x 2.0 x 2.0cm well-circumscribed tan nodule which abuts the black\X0D\\X0A\inked capsule.  No invasion through the capsule or into the surrounding thyroid\X0D\\X0A\tissue is identified.  A representative section is submitted for frozen section,\X0D\\X0A\now resubmitted in cassette A.  The remaining thyroid tissue is submitted in its\X0D\\X0A\entirety sequentially in cassette B-F.  **INITIALS","Microscopic Description\X0D\\X0A\Sections of the entire left thyroid lobe show an encapsulated follicular\X0D\\X0A\proliferation that in several foci invades the tumor's fibrous capsule.  In\X0D\\X0A\addition, there is a small focus of vascular invasion.  The neoplasm measures\X0D\\X0A\2.4 x 2.0 x 2.0cm and is completely contained within the thyroid parenchyma. \X0D\\X0A\The nodule focally shows hemorrhage and some fibrous sclerosis.  Inked margins\X0D\\X0A\of excision are free of tumor.  A single parathyroid was also identified (block\X0D\\X0A\D), appears to have a normal complement of adipose and is not hypercellular. \X0D\\X0A\**INITIALS",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC XXX]\X0D\\X0A\Procedures/Addenda
REG1,OTHER,0,491975,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is right renal mass and right lung mass.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY M].\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Fine Needle Aspiration Performed by Radiologist","Final Diagnosis\X0D\\X0A\RIGHT RENAL MASS, FNA WITH CELL BLOCK:\X0D\\X0A\     Renal cell carcinoma. SEE COMMENT.\X0D\\X0A\COMMENT: Dr. **NAME[XXX] discussed this case with Dr. **NAME[ZZZ] at 10:10 am. on **DATE[Feb 29 12].\X0D\\X0A\JFJ/mbc",,"Gross Description\X0D\\X0A\Received in formalin labeled right renal mass FNA consists of two containers\X0D\\X0A\designated as A and B. The A container has a 2.0x2.0x0.4 cm aggregate of\X0D\\X0A\red/pink clot which is filtered, wrapped and submitted entirely in cassette A.\X0D\\X0A\The B container has a 2.8x2.5x0.6 cm aggregate of dark red clot which is\X0D\\X0A\filtered, wrapped and submitted entirely in cassette B.    HM/mbc","Microscopic Description\X0D\\X0A\Examination of smears shows clusters of tumor cells with nuclear enlargement\X0D\\X0A\showing prominent nucleoli and granular cytoplasm. Sections through the cell\X0D\\X0A\block show groups of tumor cells with large rounded nuclei, nucleoli, and\X0D\\X0A\variable clear to eosinophilic granular cytoplasm. Areas of necrosis are\X0D\\X0A\evident.    JFJ/mbc",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. XXX], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,OTHER,0,492010,2,,Clinical Diagnosis and History\X0D\\X0A\The working history is gallstones and endometrial cancer.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY\X0D\\X0A\GENETIC COUNSELOR \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Gallbladder\X0D\\X0A\2: Uterus +/- tubes/ovaries, Neoplastic\X0D\\X0A\3: Lymph node, regional resection\X0D\\X0A\4: Lymph node, regional resection\X0D\\X0A\5: Lymph node, biopsy\X0D\\X0A\6: Lymph node, regional resection\X0D\\X0A\7: Omentum, resection other than for tumor","Final Diagnosis\X0D\\X0A\ADDENDUM COMMENT: No involvement of the lower uterine segment noted. **INITIALS \X0D\\X0A\Amended to reflect MSI testing results. **INITIALS \X0D\\X0A\1.  GALLBLADDER AND CONTENTS: \X0D\\X0A\     Chronic cholecystitis and cholelithiasis with focal intramural\X0D\\X0A\calcification. \X0D\\X0A\2.  UTERUS WITH CERVIX, BILATERAL TUBES AND OVARIES: \X0D\\X0A\     Moderately differentiated endometrioid adenocarcinoma with focal papillary\X0D\\X0A\architecture and squamous metaplasis, tumor size 5 x 5 x 1.8 cm, \X0D\\X0A\4 mm of myometrial invasion with a total myometrial thickness of 22 mm, \X0D\\X0A\No lymphvascular invasion identified, no extrauterine tumor spread identified.\X0D\\X0A\Parametrial tissue is negative for tumor. See Template. \X0D\\X0A\Endosalpingiosis in left ovary, right and left ovaries atrophic, right and left\X0D\\X0A\fallopian tubes unremarkable. \X0D\\X0A\Cervix, endocervix and posterior endocervical zone uninvolved.\X0D\\X0A\Benign leiomyoma. \X0D\\X0A\3.  RIGHT PELVIC LYMPH NODES:\X0D\\X0A\     Lymph nodes x3, sinus histiocytosis and fatty replacement of nodal\X0D\\X0A\parenchyma, no granulomatous inflammation or metastatic disease identified. \X0D\\X0A\4.  LEFT PELVIC LYMPH NODES:  \X0D\\X0A\     Lymph nodes x3, no tumor or granulomatous inflammation identified.\X0D\\X0A\5.  RIGHT PERIAORTIC LYMPH NODE: \X0D\\X0A\     Lymph node x1, no tumor or granulomatous inflammation identified.\X0D\\X0A\6.  RIGHT COMMON LYMPH NODE: \X0D\\X0A\     Lymph nodes x11, no tumor or granulomatous inflammation identified.  \X0D\\X0A\7.  OMENTUM: \X0D\\X0A\     Mature adipose consistent with omentum, no tumor identified.  \X0D\\X0A\UTERUS ENDOMETRIUM\X0D\\X0A\SPECIMEN TYPE/ PROCEDURE: Robotic total laparoscopic hysterectomy and bilateral\X0D\\X0A\salpingo-oophorectomy with lymph node dissection. \X0D\\X0A\LYMPH NODE SAMPLING: Yes. \X0D\\X0A\SPECIMEN INTEGRITY:  Intact. \X0D\\X0A\TUMOR SITE:  Endometrium. \X0D\\X0A\TUMOR SIZE (greatest dimension):  5 x 5 x 1.8 cm. \X0D\\X0A\HISTOLOGIC TYPE:  Endometrioid. \X0D\\X0A\HISTOLOGIC GRADE:  Grade 2 \X0D\\X0A\MYOMETRIAL INVASION:  4 mm with total myometrial thickness of 22 mm. \X0D\\X0A\INVOLVEMENT OF CERVIX:  No. \X0D\\X0A\EXTENT OF INVOLVEMENT OF OTHER ORGANS:  No. \X0D\\X0A\MARGINS:  Negative. \X0D\\X0A\LYMPH-VASCULAR INVASION:  Negative. \X0D\\X0A\MSI TESTING (under age **AGE[in 60s]):  ABNORMAL.  \X0D\\X0A\REGIONAL LYMPH NODE STATUS:  All regional nodes negative for tumor. \X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Leiomyomas of myometrium and endosalpingiosis\X0D\\X0A\of left ovary. \X0D\\X0A\OTHER STUDIES:  None. \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=1a\X0D\\X0A\pN=0    \X0D\\X0A\pM=0\X0D\\X0A\AJCC PATHOLOGIC STAGE:   I \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled gallbladder and contents is a 10.0 x 7.0\X0D\\X0A\x 3.0 cm previously opened gallbladder. The cystic duct resection margin cannot\X0D\\X0A\definitively be identified. The serosa is tan/gray and fibrotic. The lumen\X0D\\X0A\contains a moderate amount of yellowish tan mucoid bile and a single large\X0D\\X0A\cholelith measuring 3.5 cm in greatest dimension. The mucosa is tan trabecular\X0D\\X0A\and focally calcified and the wall thickness averages 0.3 cm. No masses are\X0D\\X0A\appreciated. Representative sections to include the neck, body and fundus are\X0D\\X0A\submitted in cassette 1 following decalcification.\X0D\\X0A\Specimen 2 received fresh for frozen section labeled uterus with cervix,\X0D\\X0A\bilateral tubes and ovaries is an intact hysterectomy specimen with attached\X0D\\X0A\cervix and bilateral adnexa. The uterine body and cervix have a combined weight\X0D\\X0A\of 155.9 grams. The uterine body measures 6.0 x 6.0 x 5.5 cm, the attached\X0D\\X0A\cervix measures 4.5 x 3.5 x 3.0 cm. The serosa is tan/pink smooth and\X0D\\X0A\glistening. The ectocervical mucosa is tan and wrinkled and the cervical os is\X0D\\X0A\patent. The cervix and uterine body are bivalved to reveal a 3 cm in length tan,\X0D\\X0A\corrugated endocervical canal. The anterior and posterior endomyometrium is\X0D\\X0A\involved by a 5.0 x 5.0 x 1.8 cm tan friable mass with probable involvement of\X0D\\X0A\the posterior lower uterine segment. Sectioning reveals invasion into the\X0D\\X0A\myometrium. The invasion is grossly confined to the upper one-half of the\X0D\\X0A\myometrial thickness. The remaining myometrium is tan and trabecular with a\X0D\\X0A\single well-circumscribed tan intramural nodule measuring 1.5 cm in greatest\X0D\\X0A\dimension. The bilateral ovaries average 2.5 x 2.5 x 2.0 cm and sectioning of\X0D\\X0A\each reveals a tan predominantly solid cut surface. No suspicious cysts or\X0D\\X0A\nodules are identified. Sectioning through the fallopian tubes reveals a central\X0D\\X0A\lumen averaging 0.1 cm in diameter. A representative section of the endometrial\X0D\\X0A\mass is submitted for frozen section. Summary of sections: 2A  frozen section\X0D\\X0A\residue; 2B  anterior and posterior cervix; 2C  anterior lower uterine segment;\X0D\\X0A\2D  posterior lower uterine segment; 2E-2F  anterior endomyometrium to include\X0D\\X0A\mass; 2G-2H  posterior endomyometrium to include mass; 2I  intramural nodule; 2J\X0D\\X0A\ right parametrial soft tissue; 2K  left parametrial soft tissue; 2L  right tube\X0D\\X0A\and ovary; 2M  left tube and ovary.  \X0D\\X0A\Specimen 3 received in formalin labeled right pelvic lymph node is a 5.0 x 5.0 x\X0D\\X0A\3.0 cm aggregate of fatty soft tissue. Three probable lymph nodes are identified\X0D\\X0A\averaging 1.5 cm in greatest dimension which are submitted separately in\X0D\\X0A\cassettes 3A-3C. \X0D\\X0A\Specimen 4 received in formalin labeled left pelvic lymph node is a 6.0 x 5.0 x\X0D\\X0A\1.8 cm aggregate of fatty soft tissue. Three probable lymph nodes are identified\X0D\\X0A\averaging 1.5 cm in greatest dimension which are submitted entirely in cassettes\X0D\\X0A\4A-4C. \X0D\\X0A\Specimen 5 received in formalin labeled right periaortic lymph node is a 1.5 x\X0D\\X0A\1.5 x 0.6 cm fatty soft tissue which is submitted in toto in cassette 5. \X0D\\X0A\Specimen 6 received in formalin labeled right common lymph node is a 4.0 x 3.0 x\X0D\\X0A\1.0 cm aggregate of fatty soft tissue. No definitive lymph node is identified.\X0D\\X0A\The specimen is submitted entirely in cassette 6A-6B. \X0D\\X0A\Specimen 7 received in formalin labeled omentum is a 6.5 x 4.5 x 2.5 cm portion\X0D\\X0A\of yellow lobular omental fat. No masses, suspicious lesions or areas of caking\X0D\\X0A\are appreciated. Representative sections are submitted in cassettes 7A-7C. \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Sections of the gallbladder show very flattened mucosal epithelium with rare\X0D\\X0A\Aschoff-Rokitansky sinuses. The gallbladder wall is quite fibrotic and focally\X0D\\X0A\shows early dystrophic calcification. A number of small lymphocystic aggregates\X0D\\X0A\are seen in the gallbladder wall. A single cholelith was noted grossly. \X0D\\X0A\Sections of the uterine cervix show no evidence of squamous epithelial dysplasia\X0D\\X0A\or HPV change. The endocervical zone shows cystically dilated endocervical\X0D\\X0A\glands filled with inspissated mucus. There is mild chronic inflammation in the\X0D\\X0A\endocervical submucosa. The endometrium displays an endometrioid adenocarcinoma\X0D\\X0A\with focal papillary features and squamous metaplasia. the tumor grade is grade\X0D\\X0A\2 with no evidence of lymphvascular invasion. Sections show a total of\X0D\\X0A\approximately 4 mm myometrial invasion with a total myometrial thickness of 22\X0D\\X0A\mm. The myometrium is otherwise notable for a small benign leiomyoma. Sections\X0D\\X0A\of the parametrial tissues are free of tumor and there is no evident spread of\X0D\\X0A\the tumor outside the uterine endometrial cavity. The left ovary shows a small\X0D\\X0A\focus of endosalpingiosis, otherwise the right and left ovary show changes of\X0D\\X0A\atrophy. The right and left fallopian tubes are histologically unremarkable.\X0D\\X0A\Sections of the three right pelvic lymph nodes and three left pelvic lymph nodes\X0D\\X0A\(specimens 3 and 4) show nodal parenchyma with sinus histiocytosis and no\X0D\\X0A\granulomatous inflammation or metastatic disease. \X0D\\X0A\Sections of the right periaortic lymph node includes a single small lymph node\X0D\\X0A\and associated perinodal soft tissues all of which are negative for tumor or\X0D\\X0A\granulomatous inflammation. \X0D\\X0A\Sections of the tissue submitted as right common lymph node include 11 very\X0D\\X0A\small lymph nodes all of which are negative for metastatic carcinoma. \X0D\\X0A\Sections of the omentum show mature adipose tissue without evidence of tumor. \X0D\\X0A\**INITIALS",,,Amendments:\X0D\\X0A\Amended:  **DATE[Oct 24 2012] by **NAME[ZZZ YYY]\X0D\\X0A\Reason: Additional tissue or stains available after sign out\X0D\\X0A\     Previous Signout Date:  **DATE[Oct 12 2012]\X0D\\X0A\Amended:  **DATE[Nov 3 2012] by **NAME[ZZZ YYY]\X0D\\X0A\Reason: Pathologist Request\X0D\\X0A\     Previous Signout Date:  **DATE[Oct 24 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda\X0D\\X0A\ARUP Laboratory     Date Ordered:     **DATE[Oct 13 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 25 2012]     By:  **NAME[ZZZ YYY]\X0D\\X0A\     Date Reported:     **DATE[Oct 25 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\MMR IHC RESULT: \X0D\\X0A\     Abnormal.  SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\DARON **PLACE
REG1,OTHER,0,493277,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\NOT PROVIDED\X0D\\X0A\,"PROCEDURES: 88300GS, 88305GS\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.  BLADDER TUMOR:\X0D\\X0A\SMALL FRAGMENTS OF PAPILLARY, UROTHELIAL (TRANSITIONAL CELL) CARCINOMA,\X0D\\X0A\LOW-GRADE.\X0D\\X0A\NO INVASION INTO LAMINA PROPRIA IDENTIFIED.\X0D\\X0A\MUSCULARIS PROPRIA IS NOT IDENTIFIED IN THIS BIOPSY MATERIAL.\X0D\\X0A\\X0D\\X0A\B.  RENAL STONES:\X0D\\X0A\RENAL LITHIASIS, MULTIPLE STONES IDENTIFIED (GROSS DIAGNOSIS).\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A. Received in formalin labeled \""bladder tumor\"" is a 0.2 cm, soft, tan, ovoid portion of\X0D\\X0A\tissue which is entirely submitted in a cassette labeled A.\X0D\\X0A\\X0D\\X0A\B. Received fresh labeled \""renal stones\"" are multiple irregular, brown calculi ranging in\X0D\\X0A\size from less than 0.1 cm through 0.1 cm. The specimen is entirely submitted for chemical\X0D\\X0A\analysis only./st/sk\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A. BLADDER TUMOR\X0D\\X0A\B. RENAL STONES\X0D\\X0A\,,
REG1,OTHER,0,493514,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is penile cancer, squamous cell carcinoma; scrotal swelling;\X0D\\X0A\cellulitis.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Penis, radical penectomy","Final Diagnosis\X0D\\X0A\PENIS, RADICAL PENECTOMY:\X0D\\X0A\     Extensively infiltrating moderately to poorly differentiated squamous\X0D\\X0A\carcinoma with extensive lymphvascular invasion and carcinoma at the surgical\X0D\\X0A\margin of excision. The urethral margin is negative. See Template.\X0D\\X0A\PENIS\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  radical penectomy\X0D\\X0A\LYMPH NODE SAMPLING:  none\X0D\\X0A\SPECIMEN SIZE:  16cm in length, varying 2.5cm to 4.8cm in diameter\X0D\\X0A\TUMOR SITE:  glans with spread via corpora cavernosa to involve entire penile\X0D\\X0A\length\X0D\\X0A\TUMOR SIZE:  tumor is 4.8cm diameter in the glans and tracks entire 16cm length\X0D\\X0A\of the penile shaft\X0D\\X0A\TUMOR FOCALITY (UNIFOCAL OR MULTIFOCAL):  unifocal\X0D\\X0A\MACROSCOPIC EXTENT OF TUMOR:  entire penile specimen\X0D\\X0A\HISTOLOGIC TYPE:  squamous carcinoma\X0D\\X0A\HISTOLOGIC GRADE:  grade 2 to 3\X0D\\X0A\MICROSCOPIC TUMOR EXTENSION:  tumor is present at the surgical margin\X0D\\X0A\RESECTION MARGINS:\X0D\\X0A\     URETHERAL +/- : negative\X0D\\X0A\     PERIURETHRAL CORPUS SPONGIOSUM +/-  : positive\X0D\\X0A\     CORPUS CAVERNOSUM+/- : positive\X0D\\X0A\     SKIN +/- : no skin at margin\X0D\\X0A\     BUCKS FASCIA +/-: positive \X0D\\X0A\LYMPHVASCULAR INVASION:  extensive\X0D\\X0A\PERINEURAL INVASION:   present\X0D\\X0A\STAGING\X0D\\X0A\pT=  T3 tumor invades urethra\X0D\\X0A\pN=  Nx no nodes submitted\X0D\\X0A\pM=  M0, unknown\X0D\\X0A\AJCC STAGE GROUP:  STAGE II\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:    \X0D\\X0A\DGD/mbc",,"Gross Description\X0D\\X0A\The specimen, labeled penis radical penectomy, received in formalin, consists of\X0D\\X0A\a mass of soft tissue grossly consistent with a penis. The specimen measures 16\X0D\\X0A\cm in length and appears to harbor a fungating neoplasm on the glans penis. The\X0D\\X0A\penile shaft measures 2.5 cm in diameter at the point of amputation and at a\X0D\\X0A\point 4.5 cm from the glans the shaft becomes enlarged measuring at that point 3\X0D\\X0A\cm; and from there to the glans the shaft is swollen to 4.8 cm. In breadloaf\X0D\\X0A\sectioning the penile shaft at a distant 11 cm from the glans, there is a white\X0D\\X0A\nodule in the left corpora cavernosa that appears to be tumor. The tumor\X0D\\X0A\essentially replaces approximately 75% of the left corpora cavernosa. This\X0D\\X0A\nodule is visible in the left corpora cavernosa for a distance of approximately\X0D\\X0A\1.2 cm. Continuing to breadloaf the penile shaft reveals a similar white nodule\X0D\\X0A\present in the right corpora cavernosa a distance of 7 cm from the tip of the\X0D\\X0A\glans penis. Starting at approximately 5.5 cm, tumor is grossly noted to\X0D\\X0A\encircle both corpora cavernosa and the urethra and to essentially envelop all\X0D\\X0A\of the anatomic structures. From approximately 4.8 cm, the tumor is necrotic.\X0D\\X0A\The breadloaf sectioning is stopped approximately 3 cm from the tip of the glans\X0D\\X0A\and the glans sectioned parallel to the plane of the shaft. The tissue in the\X0D\\X0A\glans appears to be essentially replaced by necrotic tumor. A small amount of\X0D\\X0A\the foreskin is visible and appears grossly uninvolved. In cassette A is\X0D\\X0A\submitted the amputation margin of the penis. In cassette B-C a full thickness\X0D\\X0A\section through the glans. In cassette D-E is submitted complete cross section\X0D\\X0A\through the penile shaft where the tumor appears to start replacing the corpora\X0D\\X0A\cavernosa. In cassette F-G is a cross section of the penile shaft where the\X0D\\X0A\tumor was noted in the left corpora cavernosa. The section is bisected and\X0D\\X0A\submitted in cassettes F-G with the left corpora cavernosa in F and right in\X0D\\X0A\cassette G. \X0D\\X0A\DGD/mbc",Microscopic Description\X0D\\X0A\Sections of the penis show a very large moderately to poorly differentiated\X0D\\X0A\squamous carcinoma arising the glans and virtually filling the shaft of the\X0D\\X0A\penis with marked necrosis. The corpora cavernosa are extensively involved all\X0D\\X0A\the way to the margin of excision; periurethral corpus spongiosum is also\X0D\\X0A\notable for tumor in the vascular spaces at the surgical margin. Lymphvascular\X0D\\X0A\invasion is quite extensive. Perineural infiltration is also prominent. The\X0D\\X0A\urethra is obliterated distally by the tumor however the urethra is abutted by\X0D\\X0A\but not invaded by tumor along the proximal penile shaft and is negative for\X0D\\X0A\tumor at the surgical margin.\X0D\\X0A\DGD/mbc,,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,OTHER,0,493621,1,,,"Patient Age: **AGE[in 70s].\X0A\ CODES: **INITIALS 88305 x 6 ** Original Signature on File ** **NAME[ZZZ M. YYY], M.D. **ID-NUM  **NAME[BBB,AAA] **DATE[Oct 02 2011]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ BIOPSIES OF POSTERIOR WALL, RIGHT LATERAL WALL AND LEFT LATERAL WALL \X0D\\X0A\ OF BLADDER (SPECIMENS 1,2 AND 3): \X0D\\X0A\ Chronic follicular cystitis \X0D\\X0A\ BIOPSY DOME OF BLADDER: \X0D\\X0A\ Papillary transitional cell carcinoma, grade II of III \X0D\\X0A\ No invasion identified \X0D\\X0A\ No muscularis propria present \X0D\\X0A\ Chronic follicular cystitis \X0D\\X0A\ BIOPSIES OF BLADDER TUMOR: \X0D\\X0A\ Papillary transitional cell carcinoma, grade II of III \X0D\\X0A\ No invasion identified \X0D\\X0A\ Muscularis propria not present \X0D\\X0A\ Chronic follicular cystitis \X0D\\X0A\ POSTERIOR URETHRA BIOPSIES: \X0D\\X0A\ Chronic follicular urethritis \X0D\\X0A\ Negative for tumor",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is bladder lesion. \X0D\\X0A\ Specimen 1 received in formalin and labeled with the patient name and \X0D\\X0A\ \""posterior wall biopsy\"" is a 0.2 x 0.2 x 0.1 cm tan soft tissue \X0D\\X0A\ fragment which is submitted in toto in cassette 1. \X0D\\X0A\ Specimen 2 received in formalin and labeled with the patient name and \X0D\\X0A\ \""right lateral wall biopsy\"" is a 0.2 x 0.2 x 0.2 cm tan soft tissue \X0D\\X0A\ fragment which is submitted in toto in cassette 2. \X0D\\X0A\ Specimen 3 recevied in formalin and labeled with the patient name and \X0D\\X0A\ **PLACE, KY **ZIP-CODE \X0D\\X0A\ \""left lateral wall biopsy\"" is a 0.3 x 0.2 x 0.2 cm tan soft tissue \X0D\\X0A\ framgent which is submitted in toto in cassette 3. \X0D\\X0A\ Specimen 4 received in formalin and labeled with the patient name and \X0D\\X0A\ \""dome of the bladder\"" are a few tan soft tissue fragments aggregating \X0D\\X0A\ 0.6 x 0.6 x 0.2 cm which are submitted in toto in cassette 4. \X0D\\X0A\ Specimen 5 received in formalin and labeled with the patient name and \X0D\\X0A\ \""bladder tumor\"" are multiple pieces of tan soft tissue aggregating 1.2 \X0D\\X0A\ x 1.0 x 0.3 cm which are submitted in toto in cassette 5. \X0D\\X0A\ Specimen 6 received in formalin and labeled with the patient name and \X0D\\X0A\ \""prostatic urethra\"" is a 1.0 x 0.6 x 0.4 cm tan soft tissue which is \X0D\\X0A\ sectioned and submitted entirely in cassette 6.   **INITIALS",MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Tissue blocks are prepared and slides are examined microscopically. \X0D\\X0A\ See diagnosis for details. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:,TISSUE SUBMITTED: \X0D\\X0A\ 1.  Posterior wall biopsy \X0D\\X0A\ 2.  Right lateral wall biopsy \X0D\\X0A\ 3.  Left lateral wall biopsy \X0D\\X0A\ 4.  Dome of the bladder \X0D\\X0A\ 5.  Bladder tumor \X0D\\X0A\ 6.  Posterior urethra,,
REG1,OTHER,0,493701,1,,"CLINICAL HISTORY\X0D\\X0A\Working diagnosis:  endometrial carcinoma.  Intraoperative findings: \X0D\\X0A\endometrial cancer.  Operative procedure:  robotic laparoscopic total\X0D\\X0A\hysterectomy, bilateral salpingo-oophorectomy, possible lymph node sampling. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FS1A (FULL THICKNESS ANTERIOR ENDOMYOMETRIUM):  \""NO MYOMETRIAL INVASION ON\X0D\\X0A\REPRESENTATIVE SECTIONS\""---MC.\X0D\\X0A\FS1B (ANTERIOR LOWER UTERINE SEGMENT): \""NO CERVICAL INVOLVEMENT\""---MC.\X0D\\X0A\FS1C (POSTERIOR LOWER UTERINE SEGMENT): \""NO CERVICAL INVOLVEMENT\""---MC.\X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Mar 13 1960] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Apr 21 2012] 12:16\X0D\\X0A\Receipt Date: **DATE[Apr 21 2012] 12:16\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: R.W. **NAME[WWW], MD     Service: GYO     Location: REC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Apr 23 2012] 14:12\X0D\\X0A\RESIDENTS(S): R.G. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\INVASIVE MODERATELY DIFFERENTIATED ENDOMETRIOID TYPE ENDOMETRIAL\X0D\\X0A\ADENOCARCINOMA, FIGO GRADE II, CONFINED TO ENDOMETRIUM, UTERUS, HYSTERECTOMY\X0D\\X0A\SPECIMEN. \X0D\\X0A\PERMANENT SECTIONS CONFIRM FROZEN SECTION DIAGNOSIS #1A, 1B AND 1C.\X0D\\X0A\TUMOR STAGE IS pT1a, FIGO IA.\X0D\\X0A\NO TUMOR SEEN, UTERINE CERVIX.\X0D\\X0A\UNREMARKABLE RIGHT AND LEFT FALLOPIAN TUBES AND OVARIES.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Apr 23 2012] **NAME[TTT M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: **ID-NUM P110\X0D\\X0A\C: M09450 T8300\X0D\\X0A\D: M80001 \X0D\\X0A\F: A: 88331 FS1, 88332 ADD'L FS(2), 88309",,"GROSS DESCRIPTION\X0D\\X0A\Two specimens are received.\X0D\\X0A\Specimen A is received fresh for frozen section diagnosis labeled \""uterus and\X0D\\X0A\cervix\"" and consists of the aforementioned.  A pink tan firm tumor appears to\X0D\\X0A\involve the entire endometrial cavity and appears to extend grossly to the\X0D\\X0A\lower uterine segment.  Grossly, no cervical involvement is noted.  \X0D\\X0A\All other previously mentioned parts of the specimen are grossly\X0D\\X0A\unremarkable. \X0D\\X0A\                                                         or\X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight:  100 g\X0D\\X0A\Uterus dimensions:  10 cm (length) x 8 cm (width) x 4.5 cm (ant-post)\X0D\\X0A\Os diameter:  0.9 cm\X0D\\X0A\Endocervical canal length:  2.3 cm\X0D\\X0A\Myometrial thickness:  2.2 cm in maximum thickness\X0D\\X0A\Endometrial thickness:  1.4 cm\X0D\\X0A\Representative sections:\X0D\\X0A\A1:  anterior cervix (12:00)\X0D\\X0A\A2:  posterior cervix (6:00)\X0D\\X0A\A3:  full thickness, anterior endomyometrium frozen as FS1A\X0D\\X0A\A4:  anterior lower uterine segment frozen as FS1B.\X0D\\X0A\A5:  posterior lower uterine segment frozen as FS1C\X0D\\X0A\A6:  representative section of anterior lower uterine segment and cervix\X0D\\X0A\A7:  full thickness, anterior endomyometrium\X0D\\X0A\A8:  full thickness, posterior endomyometrium\X0D\\X0A\A9:  possible area of invasion in anterior lower uterine segment\X0D\\X0A\A10:  full thickness, anterior lower uterine segment just adjacent to the\X0D\\X0A\possible area of invasion\X0D\\X0A\A11:  representative section of posterior lower uterine segment and uterus\X0D\\X0A\***PATH-NUMBER[2]:  partial thickness endometrium submitted entirely.  \X0D\\X0A\A19:  right parametrium\X0D\\X0A\A20:  left parametrium\X0D\\X0A\Specimen B is received labeled bilateral tubes and ovaries. The bilateral\X0D\\X0A\ovaries are white/tan, almond-shaped, and normally bosselated.  They are\X0D\\X0A\intact with no excrescences on their surfaces.  They are serially sectioned\X0D\\X0A\to reveal an unremarkable heterogeneous yellow/tan cut surface.  \X0D\\X0A\The fallopian tubes have identifiable fimbriated ends.  No paratubal cysts\X0D\\X0A\are noted.  They are serially sectioned to reveal pinpoint         lumens.\X0D\\X0A\Measurements:\X0D\\X0A\Right Fallopian tube:  2.5 cm length x 0.5 cm diameter\X0D\\X0A\Right Ovary:  2.3 x 1.5 x 0.7 cm\X0D\\X0A\Left Fallopian tube:  4.2 cm length x 0.5 cm diameter\X0D\\X0A\Left Ovary:  2.5 x 1.5 x 0.5 cm\X0D\\X0A\Representative sections:\X0D\\X0A\B1:  representative right fallopian tube with fimbria\X0D\\X0A\B2:  representative right ovary\X0D\\X0A\B3:  representative left fallopian tube with fimbria\X0D\\X0A\B4:  representative left ovary\X0D\\X0A\blm/**DATE[Apr 22 2012] R.G. **NAME[UUU], MD\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Dec 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery: robotically assisted total laparoscopic hysterectomy and\X0D\\X0A\bilateral salpingo-oophorectomy\X0D\\X0A\Weight of uterus: 100 grams\X0D\\X0A\Dimensions of uterus:  10 cm (length) x 8 cm (width) x 4.5 cm\X0D\\X0A\(anterior-posterior dimension)\X0D\\X0A\Histologic type of the tumor: endometrioid adenocarcinoma\X0D\\X0A\Tumor grade of differentiation (FIGO grade I/II/III):  FIGO II\X0D\\X0A\Tumor size:   6.5 cm (greatest dimension) x 6.5 cm (smaller dimension) x 1.4\X0D\\X0A\cm (maximum thickness) \X0D\\X0A\Distance from internal os: 1 mm\X0D\\X0A\Confined to endometrium:  yes \X0D\\X0A\Myometrial invasion:  no \X0D\\X0A\Nontumorous endometrium: simple and complex hyperplasia with atypia\X0D\\X0A\Serosal involvement: no\X0D\\X0A\Adnexal involvement (specify): no\X0D\\X0A\Parametrial soft tissues:  no\X0D\\X0A\Cervical involvement: no\X0D\\X0A\Lymphvascular invasion: no\X0D\\X0A\Lymph node involvement (specify):  none submitted\X0D\\X0A\\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\pT              FIGO\X0D\\X0A\         pT1a    IA            Tumor limited to endometrium \X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\pNX                               Regional lymph nodes cannot be assessed\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Uterus/cervix\X0D\\X0A\B: Bilateral tubes and ovaries,,
REG1,OTHER,0,493749,1,,CLINICAL INFORMATION:,"**INSTITUTION          MR #: **ID-NUM\X0D\\X0A\**INSTITUTION          **NAME[BBB, AAA]\X0D\\X0A\**PLACE, KENTUCKY  **ZIP-CODE          **DATE[Jun 11 1942] (Age: **AGE[in 60s])   MW\X0D\\X0A\          Collect Date: **DATE[May 23 2012] 00:00\X0D\\X0A\          Receipt Date: **DATE[May 23 2012] 11:32\X0D\\X0A\          Page 1\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND  LABORATORY MEDICINE\X0D\\X0A\CYTOPATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax: **PHONE\X0D\\X0A\Email: **EMAIL          ***PATH-NUMBER[1]     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD/Practitioner:  **NAME[M. YYY], MD     Service: GAS     Location: ENDO\X0D\\X0A\     Reported: **DATE[May 23 2012] 16:17\X0D\\X0A\     Collected: **DATE[May 23 2012] 00:00","DIAGNOSIS\X0D\\X0A\TAIL OF PANCREAS , ENDOSCOPIC ULTRASOUND-GUIDED FNA:\X0D\\X0A\      - POSITIVE FOR MALIGNANCY, ADENOCARCINOMA WITH MUCINOUS FEATURES.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ D.L. **NAME[XXX], MD\X0D\\X0A\MSP \X0D\\X0A\CLINICAL DIAGNOSIS\X0D\\X0A\Mass tail of pancreas 3.5 cm cystic \T\ solid \X0D\\X0A\FNA performed by: Dr. **NAME[YYY]\X0D\\X0A\Immediate evaluation personally performed by: **NAME[WWW XXX], MD.\X0D\\X0A\PASS # 1-4: Mucinous neoplasm\X0D\\X0A\                 5: Suspicious for malignancy\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\ICD-9:  F: A: 88173 ASP INTER, 88172, 88177, 62997 SNOMED CODES: A: M81403\X0D\\X0A\P1149 T59000",,GROSS DESCRIPTION:\X0D\\X0A\Hold needle rinse fluid.,,"SPECIMEN DESCRIPTION:\X0D\\X0A\A:  FNA TAIL OF PANCREAS , ENDOSCOPIC ULTRASOUND GUIDED\X0D\\X0A\     DIFF-QUIK x 8, PAP STAIN x 7",,
REG1,OTHER,0,493798,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is endometrial cancer. Intraoperative findings:\X0D\\X0A\endometrial cancer. Operative procedure: robotic laparoscopic total\X0D\\X0A\hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\IOC #1: \""DIFFUSELY HYPERPLASTIC AND FOCALLY POLYPOID WITH NO DISCRETE\X0D\\X0A\LESIONS\""---RK.\X0D\\X0A\\X0D\\X0A\     R.G. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 21 1944] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Jun 19 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Jun 20 2012] 07:13\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: **NAME[M. XXX], MD     Service: GYO     Location: 3N\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Jun 21 2012] 17:18\X0D\\X0A\RESIDENTS(S): V.V. **NAME[VVV], MD\X0D\\X0A\Comment: The histologic sections from the endometrium show endometrial\X0D\\X0A\adenocarcioma, endometrioid type, FIGO grade I to II, with extensive\X0D\\X0A\involvement of foci of endometriosis. No definitive myometrial invasion is\X0D\\X0A\identified.\X0D\\X0A\The case was prospectively reviewed with Dr. **NAME[UUU] and **NAME[TTT] who\X0D\\X0A\concur to the above diagnosis.\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\A) UTERUS AND CERVIX, HYSTERECTOMY:   - ENDOMETRIAL ENDOMETRIOID\X0D\\X0A\ADENOCARCINOMA, FIGO GRADE I TO II, WITH EXTENSIVE INVOLVEMENT OF\X0D\\X0A\ADENOMYOSIS, PATHOLOGIC STAGING pT1,pN0,pMx   - ADENOMYOSIS.   - INTRAMURAL\X0D\\X0A\LEIOMYOMA.   - ADENOMYOMA.   - LEFT PARAMETRIUM WITH BENIGN MULLERIAN\X0D\\X0A\INCLUSION.\X0D\\X0A\    - SEE SYNOPTIC REPORT NAD COMMENT.\X0D\\X0A\B) LEFT LYMPH NODE, DISSECTION:   - THREE LYMPH NODES NEGATIVE FOR METASTATIC\X0D\\X0A\CARCINOMA (0/3).   - ONE LYMPH NODE WITH BENIGN MULLERIAN INCLUSION.C) RIGHT\X0D\\X0A\PELVIC LYMPH NODE, DISSECTION:   - THREE LYMPH NODES NEGATIVE FOR METASTATIC\X0D\\X0A\CARCINOMA (0/3).D) RIGHT TUBE AND OVARY, OOPHORECTOMY:   - OVARY WITH CORPORA\X0D\\X0A\ALBICANTIA AND BENIGN EPITHELIAL INCLUSION CYST.    - UNREMARKABLE FALLOPIAN\X0D\\X0A\TUBE.\X0D\\X0A\   - NEGATIVE FOR MALIGNANCY.E) LEFT TUBE AND OVARY, OOPHORECTOMY:   - OVARY\X0D\\X0A\WITH CORPORA ALBICANTIA AND BENIGN EPITHELIAL INCLUSION CYST.   -\X0D\\X0A\UNREMARKABLE FALLOPIAN TUBE.\X0D\\X0A\   - NEGATIVE FOR MALIGNACY.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Jun 21 2012] **NAME[M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M76510 M8380\X0D\\X0A\B: M09450 M3341 \X0D\\X0A\F: A: 88329 SURG CONS, 88309\X0D\\X0A\B: 88305\X0D\\X0A\C: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Five specimens are received. \X0D\\X0A\Specimen A is received fresh then placed in formalin labeled \""uterus and\X0D\\X0A\cervix\"" and consists of the aforementioned.\X0D\\X0A\Sectioning of the endomyometrium reveals a diffusely thickened endometrium.\X0D\\X0A\The process appears to be superficial and confined to the endometrium. It\X0D\\X0A\does not extend into the endocervical canal. Two white well-circumscribed\X0D\\X0A\nodules are identified. One is located subserosally, the other is located\X0D\\X0A\intramurally. They have solid whorled white tan cut surface. The serosal\X0D\\X0A\nodule measures 1.0 cm in greatest dimension, the intramurally nodule\X0D\\X0A\measures 0.7 cm in greatest dimension.  \X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight - 52 g\X0D\\X0A\Dimensions of uterus - 6 cm (length) x 4.5 cm (width) x 2.9 cm (ant-post) \X0D\\X0A\Depth of endometrial cavity  4.0 cm\X0D\\X0A\Diffusely thickened endometrium\X0D\\X0A\Depth of invasion  appears to be confined to the endometrium\X0D\\X0A\Distance to internal os -    cm\X0D\\X0A\Uninvolved endometrial thickness  entire endometrium involved\X0D\\X0A\Uninvolved myometrial thickness  1.3 cm\X0D\\X0A\Os diameter  0.5 cm\X0D\\X0A\Endocervical canal length  1.0 cm\X0D\\X0A\Cassette summary:\X0D\\X0A\A1  right parametrium\X0D\\X0A\A2  left parametrium\X0D\\X0A\A3  anterior cervix\X0D\\X0A\A4  posterior cervix\X0D\\X0A\A5  A8  anterior endometrium entirely submitted (A5  full thickness section)\X0D\\X0A\A9  A12  fundus\X0D\\X0A\A13- A15  posterior endometrium shaved entirely submitted\X0D\\X0A\A16  representative sections of nodule\X0D\\X0A\Specimen label:  B) left pelvic lymph node                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: adipose tissue\X0D\\X0A\Size(s): 4.5 x 2.0 x 1.0 cm \X0D\\X0A\Cassette summary: it is entirely submitted in B1 and B2. \X0D\\X0A\Specimen label:  C) right pelvic lymph node                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 2 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow tan \X0D\\X0A\Consistency: adipose tissue \X0D\\X0A\Size(s): 3.0 x 2.0 x 1.5 cm and 4.0 x 3.0 x 1.5 cm \X0D\\X0A\Three probable lymph nodes are identified\X0D\\X0A\Cassette summary: it is entirely submitted in C1  C2. \X0D\\X0A\Specimen D is received in formalin labeled right tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 9.3 g post fixation.      The fallopian\X0D\\X0A\tube has an identifiable fimbriated end.  Multiple paratubal cysts are noted\X0D\\X0A\ranging in size up to 3.0 cm.  The tube is serially sectioned to reveal a\X0D\\X0A\pinpoint lumen.  \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 1.0 cm length x 0.5 cm diameter\X0D\\X0A\Ovary: 2.5 x 0.7 x 0.5 cm\X0D\\X0A\Representative sections:\X0D\\X0A\Representatively submitted in D1. \X0D\\X0A\Specimen E is received in formalin labeled left tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 20 grams post fixation.  The fallopian tube\X0D\\X0A\has an identifiable fimbriated end.  A single large paratubal cyst is noted.\X0D\\X0A\It measures 4.5 cm in greatest dimension. It is filled with clear fluid. No\X0D\\X0A\excrescences are identified on the internal or external surface of the cyst.\X0D\\X0A\The tube is serially sectioned to reveal a pinpoint lumen.  \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 2.5 cm length x 0.3 cm diameter\X0D\\X0A\Ovary: 2.0 x 1.0 x 0.5 cm\X0D\\X0A\Representative sections:\X0D\\X0A\Representatively submitted in E1. \X0D\\X0A\rgc/**DATE[Jun 21 2012] V.V. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\ENDOMETRIAL TUMOR (template #2)\X0D\\X0A\Last updated **DATE[Apr 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery: hysterectomy with oophorectomy\X0D\\X0A\Weight of uterus: 52 grams\X0D\\X0A\Dimensions of uterus:  6 cm (length) x 4.5 cm (width) x 2.9 cm\X0D\\X0A\(anterior-posterior dimension)\X0D\\X0A\Histologic type of the tumor: endometrioid adenocarcinoma with focal squamous\X0D\\X0A\differentiation.\X0D\\X0A\Tumor grade of differentiation (FIGO grade I/II/III):  I-II\X0D\\X0A\Tumor size:   tumor involves entire endometrium, 4 cm (greatest dimension) \X0D\\X0A\Distance from internal os: cannot be determined\X0D\\X0A\Confined to endometrium:  yes \X0D\\X0A\Myometrial invasion:   no \X0D\\X0A\Nontumorous endometrium: entire endometrium involved by neoplastic process\X0D\\X0A\Serosal involvement: not identified\X0D\\X0A\Adnexal involvement (specify): not identified\X0D\\X0A\Parametrial soft tissues:    not involved.\X0D\\X0A\Cervical involvement:\X0D\\X0A\     Endocervical epithelium: not identified\X0D\\X0A\     Stroma: not identified\X0D\\X0A\Lymphvascular invasion: not identified.\X0D\\X0A\Lymph node involvement (specify):   0 positive / 6 total\X0D\\X0A\\X0D\\X0A\     Size of largest positive lymph node: not applicable\X0D\\X0A\     Size of largest metastasis: not applicable\X0D\\X0A\     Extranodal extension: not applicable\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\pT              FIGO\X0D\\X0A\         pT1a    IA            Tumor limited to endometrium or invades < 1/2\X0D\\X0A\of the myometrium\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\pN0                                No regional lymph node metastasis\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\                                       Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Uterus/cervix\X0D\\X0A\B: Left pelvic lymph nodes\X0D\\X0A\C: Right pelvic lymph nodes\X0D\\X0A\D: Right tube and ovary\X0D\\X0A\E: Left tube and ovary,,
REG1,OTHER,0,493862,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis: renal mass, from SCM. Arterially enhancing left renal\X0D\\X0A\lesion with multiple arterial enhancing liver lesions. Liver lesions are\X0D\\X0A\suspicious for hypovascular metastasis. Left renal mass suspicious for\X0D\\X0A\primary renal cell carcinoma.  Kidney on radiology measures 2.6 x 2.3 cm.\X0D\\X0A\Liver lesions measure 2.3 x 1.4 cm in left hepatic lobe. Operative procedure:\X0D\\X0A\laparoscopic nephrectomy hand assisted (left). Intraoperative findings: renal\X0D\\X0A\mass.\X0D\\X0A\AMENDMENTS\X0D\\X0A\Amended:  **DATE[Sep 8 2012] by **NAME[ZZZ YYY XXX]\X0D\\X0A\Reason:     Data entry error.\X0D\\X0A\     Incorrect date of service\X0D\\X0A\Previous Signout Date:  **DATE[Aug 31 2012]\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Apr 16 1977] (Age: **AGE[in 30s])  FW\X0D\\X0A\Collect Date: **DATE[Aug 24 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Aug 25 2012] 07:50\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\* Amended *\X0D\\X0A\**NAME[WWW] MD: **NAME[VVV UUU], MD     Service: URO     Location: 2MCC\X0D\\X0A\**NAME[TTT] MD(S):      Reported: **DATE[Aug 31 2012] 11:20\X0D\\X0A\RESIDENTS(S): K.K. **NAME[SSS], DO","DIAGNOSIS\X0D\\X0A\KIDNEY, LEFT, NEPHRECTOMY:\X0D\\X0A\   - CLEAR CELL RENAL CELL CARCINOMA, FUHRMAN NUCLEAR GRADE II, PATHOLOGIC\X0D\\X0A\STAGING:  pT1a, pN0,\X0D\\X0A\     pMX.\X0D\\X0A\   - SURGICAL RESECTION MARGINS NEGATIVE FOR MALIGNANCY.\X0D\\X0A\   - SEE TEMPLATE.\X0D\\X0A\NOTE\X0D\\X0A\This amendment corrects date of service only.  Diagnosis and template remain\X0D\\X0A\unchanged.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Aug 27 2012] **NAME[M. RRR], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 189.0     MALIGNANT NEOPLASM KIDNEY, EXCEPT PELVIS\X0D\\X0A\583.9     NEPHRITIS NOS / NEPHROPATHY NOS\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M09400 M8310 \X0D\\X0A\F: A: 88307",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received fresh and placed in formalin labeled left\X0D\\X0A\kidney and consists of the aforementioned.  The adrenal gland is not received\X0D\\X0A\with the specimen. There is a well circumscribed mass noted in the mid aspect\X0D\\X0A\of the kidney.  It has a yellow tan cut surface with focal areas of tan\X0D\\X0A\discoloration.  The mass measures 3 x 2 x 2 cm.  A tumor capsule is present. \X0D\\X0A\The tumor does not appear to extend through the kidney capsule grossly, with\X0D\\X0A\no extension into the perirenal fat.  The mass approaches the renal pelvis\X0D\\X0A\and does not involve the renal sinus.  Tumor is not noted in the vasculature.\X0D\\X0A\ No perirenal lymph nodes are identified.  \X0D\\X0A\Remaining parts of the specimen are grossly unremarkable.\X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight  304.8 g\X0D\\X0A\Specimen measurement (including perirenal fat)  19 x 10 x 5 cm\X0D\\X0A\Kidney measurement11.5 x 7 x 4 cm\X0D\\X0A\Mass measurement  3 x 2 x 2 cm\X0D\\X0A\Tumor distance to:\X0D\\X0A\kidney capsule -- abuts\X0D\\X0A\soft tissue margin -- abuts\X0D\\X0A\ureter margin --  8 cm\X0D\\X0A\vascular margin -- 7 cm\X0D\\X0A\renal pelvis --  0.5 cm\X0D\\X0A\renal sinus --  4 cm\X0D\\X0A\Inking:\X0D\\X0A\Soft tissue margins inked: blue\X0D\\X0A\Representative sections:\X0D\\X0A\A1ureter margin\X0D\\X0A\A2vascular margin\X0D\\X0A\A3tumor to soft tissue margin\X0D\\X0A\A4tumor to kidney capsule\X0D\\X0A\A5-tumor to pelvis\X0D\\X0A\A6-tumor to approaching vessel\X0D\\X0A\A7--tumor to renal sinus\X0D\\X0A\A8-A9- representative tumor\X0D\\X0A\A10grossly uninvolved parenchyma\X0D\\X0A\ksl/**DATE[Aug 26 2012] K.K. **NAME[SSS], DO\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\NEPHRECTOMY FOR NON-WILM' S MALIGNANCY (template #15)\X0D\\X0A\(EXCLUDING SARCOMAS, RENAL PELVIS TUMOR AND URETERAL TUMORS)      \X0D\\X0A\Last updated **DATE[Jun 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen: Left Kidney, nephrectomy\X0D\\X0A\Tumor site: midcentral\X0D\\X0A\Tumor size: 3x2x2\X0D\\X0A\Tumor focality:   unifocal\X0D\\X0A\Histologic type:  (If sarcomatoid dedifferentiation, specify %) Renal Cell\X0D\\X0A\Carcinoma\X0D\\X0A\Nuclear grade (Fuhrman grade: 2\X0D\\X0A\Tumor necrosis:    1-50%\X0D\\X0A\Lymphvascular invasion: no\X0D\\X0A\Renal vein involvement (specify if invasion of wall or attachment to wall):\X0D\\X0A\no\X0D\\X0A\Vena caval invasion: no\X0D\\X0A\Perinephric fat invasion:   no\X0D\\X0A\Renal sinus invasion: no\X0D\\X0A\Cancer at resected margin: no\X0D\\X0A\              If yes, location(s):\X0D\\X0A\Regional lymph node metastasis (renal hilar):  0 positive / 1 total   )\X0D\\X0A\     Size of the largest nodal metastasis: N/A\X0D\\X0A\               Perinodal extension: N/A\X0D\\X0A\     Size of extranodal metastasis: N/A\X0D\\X0A\\X0D\\X0A\Other (non-regional) lymph node metastasis (m1):  0 positive / 0 total \X0D\\X0A\Adrenal gland: not submitted\X0D\\X0A\Other pathologic findings in nonneoplastic kidney (list): minimal, focal\X0D\\X0A\lymphoplasmacytic inflammatory infiltrate.\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT)\X0D\\X0A\     pT1a     Tumor 4 cm or less in greatest dimension, limited to the kidney\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\    pNO      No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\    Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left kidney,,
REG1,OTHER,0,493932,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  thyroid cancer.  Operative procedure:  total\X0D\\X0A\thyroidectomy with limited node dissection.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""PARATHYROID TISSUE IDENTIFIED\"", RBV-DAN D'\X0D\\X0A\HANIS/MDT.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""SCANT TISSUE, FAVOR LYMPHOID\"", RBV-DAN D'\X0D\\X0A\HANIS/MDT.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #3:  \""PARATHYROID TISSUE IDENTIFIED\"", RBV-DAN D'\X0D\\X0A\HANIS/MDT.\X0D\\X0A\\X0D\\X0A\     M.M. **NAME[ZZZ], MD.","**INSTITUTION \X0D\\X0A\310 S. LIMESTONE\X0D\\X0A\**PLACE, KY  **ZIP-CODE\X0D\\X0A\ MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 4 1966] (Age: **AGE[in 40s])  FW\X0D\\X0A\Collect Date: **DATE[Feb 5 2012] 14:24\X0D\\X0A\Receipt Date: **DATE[Feb 5 2012] 14:24\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE Fax:  **PHONE          ***PATH-NUMBER[1]\X0D\\X0A\Email:      \X0D\\X0A\**NAME[YYY] MD: **NAME[XXX WWW], MD     Service: SGO     Location: SPCU\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Feb 6 2012] 15:02\X0D\\X0A\Comment:\X0D\\X0A\The frozen section diagnoses are confirmed.  Intradepartmental consultation\X0D\\X0A\with agreement is obtained in this case (SES).","DIAGNOSIS\X0D\\X0A\REIMPLANTED RIGHT INFERIOR PARATHYROID, BIOPSY (A):\X0D\\X0A\   - MINUTE FRAGMENT OF NORMOCELLULAR PARATHYROID TISSUE.\X0D\\X0A\REIMPLANTED POSSIBLE LEFT INFERIOR PARATHYROID, BIOPSY (B):\X0D\\X0A\  - MINUTE FRAGMENT OF FIBROADIPOSE AND LYMPHOID TISSUE, NO PARATHYROID\X0D\\X0A\TISSUE IDENTIFIED.\X0D\\X0A\TISSUE ADJACENT TO LEFT INFERIOR PARATHYROID, BIOPSY (C):\X0D\\X0A\   - MINUTE FRAGMENT OF NORMOCELLULAR PARATHYROID TISSUE.\X0D\\X0A\THYROID, TOTAL THYROIDECTOMY WITH LEVEL VI NODES (D):\X0D\\X0A\   - MULTIFOCAL PAPILLARY THYROID CARCINOMA (pT1b, pN1a).  SEE TEMPLATE AND\X0D\\X0A\COMMENT.\X0D\\X0A\   - LYMPHVASCULAR INVASION IDENTIFIED.\X0D\\X0A\   - MARGINS OF EXCISION NEGATIVE FOR TUMOR.\X0D\\X0A\   - METASTATIC PAPILLARY THYROID CARCINOMA IDENTIFIED IN FIVE OF TEN LEVEL\X0D\\X0A\VI LYMPH NODES (5/10).\X0D\\X0A\   - BENIGN THYMIC TISSUE, NO TUMOR SEEN.\X0D\\X0A\LYMPH NODE, RIGHT LEVEL VI, EXCISION (E):\X0D\\X0A\   - METASTATIC PAPILLARY THYROID CARCINOMA IDENTIFIED IN ONE OF TWO LYMPH\X0D\\X0A\NODES (1/2).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Feb 6 2012] M.M. **NAME[ZZZ], MD.\X0D\\X0A\\X0D\\X0A\ICD 9:   SNOMED CODES:\X0D\\X0A\A: M00100 P1140\X0D\\X0A\B: M09070 P1140\X0D\\X0A\C: M00100 P1140\X0D\\X0A\D: M09400 M8050\X0D\\X0A\E: M80506 P1100 \X0D\\X0A\F:  88331 FS1(3)\X0D\\X0A\A: 88305\X0D\\X0A\B: 88305\X0D\\X0A\C: 88305\X0D\\X0A\D: 88307\X0D\\X0A\E: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Five specimens are received.  Specimen A is received fresh and submitted for\X0D\\X0A\frozen section labeled reimplanted right inferior parathyroid and consists of\X0D\\X0A\a single red/tan soft tissue fragment measuring 0.3 x 0.2 x 0.2 cm.  It is\X0D\\X0A\entirely frozen as FS1.  FS1 is entirely resubmitted in A1.\X0D\\X0A\Specimen B is received fresh and submitted for frozen section labeled biopsy\X0D\\X0A\reimplanted possible left inferior parathyroid and consists of a single\X0D\\X0A\yellow/tan soft tissue fragment measuring 0.4 x 0.3 x 0.2 cm.  It is entirely\X0D\\X0A\frozen as FS2.  FS2 is entirely resubmitted in B1.\X0D\\X0A\Specimen C is received fresh and submitted for frozen section labeled biopsy\X0D\\X0A\tissue adjacent to left inferior parathyroid and consists of a single red/tan\X0D\\X0A\soft tissue fragment measuring 0.4 x 0.3 x 0.2 cm.  It is entirely frozen as\X0D\\X0A\FS3. FS3 is entirely resubmitted in C1.\X0D\\X0A\Specimen D is received in formalin labeled total thyroid with level VI nodes\X0D\\X0A\and consists of the aforementioned maroon/red butterfly-shaped partially\X0D\\X0A\disrupted thyroid gland weighing 21 grams.  The right lobe measures 4.2 x 2.3\X0D\\X0A\x 1.5 cm.  The largely disrupted left lobe measures 5.1 x 2.5 x 1.5 cm.  The\X0D\\X0A\isthmus measures 3.3 x 1.0 x 0.5 cm.  There is a small amount of attached\X0D\\X0A\fatty level VI tissue measuring 2.2 x 1.4 x 0.4 cm.  The specimen is inked\X0D\\X0A\blue. The right lobe is serially sectioned to reveal a maroon spongy cut\X0D\\X0A\surface.  In the mid to inferior portion of the lobe there are two well\X0D\\X0A\circumscribed nodules. The larger is tan and focally hemorrhagic.  No capsule\X0D\\X0A\is noted.  It measures 1.5 x 1.0 x 1.0 cm.  There is a smaller adjacent\X0D\\X0A\nodule which is somewhat less well circumscribed measuring 1.2 x 0.8 x 0.6\X0D\\X0A\cm.  This nodule is white/tan and has a firm consistency.  No other lesions\X0D\\X0A\are noted grossly.  The left lobe is serially sectioned to reveal a maroon\X0D\\X0A\heterogenous cut surface.  There are two small well circumscribed nodules\X0D\\X0A\measuring 0.5 cm in greatest dimension and 0.2 cm in greatest dimension.  The\X0D\\X0A\larger nodule has a tan cut surface.  It is soft to palpation. The smaller\X0D\\X0A\nodule is white and firm.  The isthmus is sectioned to reveal a uniform\X0D\\X0A\maroon spongy cut surface.  There is a single well circumscribed tan soft\X0D\\X0A\nodule measuring 0.6 cm in greatest dimension.  No other lesions are noted\X0D\\X0A\grossly.  The right lobe is submitted from superior to inferior in D1-D6. The\X0D\\X0A\left lobe is submitted from superior to inferior in D7-D11. The isthmus is\X0D\\X0A\submitted in D12 to D13.  Possible lymph nodes are submitted in D14.\X0D\\X0A\Specimen E is received in formalin labeled right level VI nodes and consists\X0D\\X0A\of multiple yellow/tan fatty soft tissue fragments measuring in aggregate 1.6\X0D\\X0A\x 1.5 x 0.5 cm.  It is entirely submitted in E1.\X0D\\X0A\dlf/**DATE[Feb 6 2012] M.M. **NAME[ZZZ], MD.\X0D\\X0A\\X0D\\X0A\","MICROSCOPIC DESCRIPTION/COMMENT\X0D\\X0A\THYROID NEOPLASM (template #22)                                     \X0D\\X0A\Last updated **DATE[Jan 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of procedure or specimen:  total thyroidectomy\X0D\\X0A\Location of tumors:  right lobe and isthmus\X0D\\X0A\Histologic type:  papillary carcinoma\X0D\\X0A\\X0D\\X0A\Tumor grade:  well-differentiated \X0D\\X0A\Size of tumor:  largest focus  1.2 x 0.8 x 0.6 cm, smaller foci  4 mm and 2\X0D\\X0A\mm\X0D\\X0A\Encapsulation of tumor:  partial\X0D\\X0A\Centricity:  multicentric\X0D\\X0A\Lymphvascular invasion:  present\X0D\\X0A\Extension beyond the capsule of the thyroid:  no\X0D\\X0A\Margins:  negative\X0D\\X0A\Non-neoplastic thyroid:  nodular adenomatous hyperplasia\X0D\\X0A\Number of parathyroids excised: none\X0D\\X0A\Number of parathyroids biopsied: two\X0D\\X0A\Lymph nodes (site, number, number involved):  6/12 level VI\X0D\\X0A\      Size of largest positive lymph node:  0.4 cm\X0D\\X0A\      Extracapsular extension:  not identified\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT)\X0D\\X0A\   Note: All categories may be subdivided:  s) solitary tumor and m)\X0D\\X0A\multifocal tumor (the largest one \X0D\\X0A\             determines T stage).\X0D\\X0A\pT1b(m)      Tumor more than 1 cm but not more than 2 cm in greatest\X0D\\X0A\dimension, limited to the thyroid\X0D\\X0A\REGIONAL LYMPH NODES (pN) \X0D\\X0A\    pN1a   Metastasis to level VI (pretracheal, paratracheal, and\X0D\\X0A\prelaryngeal/Delphian lymph nodes)\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                Not applicable","DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: re-implanted right inferior parathyroid\X0D\\X0A\B: biopsy re-implanted possible left inferior parathyroid\X0D\\X0A\C: biopsy tissue adjacent to left inferior parathyroid\X0D\\X0A\D: total thyroid with level 6 nodes, suture marks right superior pole\X0D\\X0A\E: right level 6 nodes",,
REG1,OTHER,0,493987,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is left temporal brain tumor  191.2. Operative\X0D\\X0A\procedure: craniotomy for left temporal brain tumor.\X0D\\X0A\Previous pathology\X0D\\X0A\***PATH-NUMBER[1] (left temporal lobe stereotactic biopsy): infiltrative glioma\X0D\\X0A\Imaging\X0D\\X0A\- MRI head (**DATE[Mar 20 12]): \""....masslike expansion of the left temporal lobe\X0D\\X0A\involving primarily the medial aspect with cortical thickening of the mesial\X0D\\X0A\temporal lobe and hippocampus . There is elevated T2 hyperintense signal\X0D\\X0A\involving the temporal lobe extending through the white matter tracts\X0D\\X0A\cephalad to the left basal ganglia and above the left occipital trigone and\X0D\\X0A\medial aspect of the left occipital lobe. The inferomedial left frontal lobe\X0D\\X0A\and anterior commissure also shows T2 hyperintense signal and there is\X0D\\X0A\cortical thickening of the left frontal lobe. There is no evidence for\X0D\\X0A\enhancement within this region although a number of enhancing prominent\X0D\\X0A\medullary vessels course through the above area. ... Findings are concerning\X0D\\X0A\for encephalitis or infiltrating glioma...\""\X0D\\X0A\-MRI head (**DATE[Apr 14 12]): \""...IMPRESSION: 1. Study obtained for stereotactic\X0D\\X0A\localization of lesion centered within the left temporal lobe. This lesion\X0D\\X0A\has not significantly changed since the prior studies. This is likely a\X0D\\X0A\glioma.\""  \X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jan 26 1989] (Age: **AGE[in 20s])  MW\X0D\\X0A\Collect Date: **DATE[Apr 15 2012] 14:26\X0D\\X0A\Receipt Date: **DATE[Apr 15 2012] 14:26\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[2]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY XXX], MD     Service: NS     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Apr 20 2012] 18:50\X0D\\X0A\RESIDENTS(S): D.J. **NAME[VVV], MD\X0D\\X0A\Comment\X0D\\X0A\Ancillary immunohistochemical studies are pending.  Their results will be\X0D\\X0A\issued in an addendum.\X0D\\X0A\A resident has participated in this service.  The electronic signature\X0D\\X0A\denotes the pathologist performing and responsible for the pathologic\X0D\\X0A\evaluation.","DIAGNOSIS\X0D\\X0A\CEREBRUM, LEFT TEMPORAL, RESECTION OF MASS (A; B):\X0D\\X0A\     DIFFUSE FIBRILLARY ASTROCYTOMA (WHO grade 2 to 3)\X0D\\X0A\NOTE\X0D\\X0A\On the basis of focal increased cellularity and atypia, increased mitotic\X0D\\X0A\activity (at least three high-power-fields containing two mitoses each are\X0D\\X0A\noted), focal perivascular macrophages, and focal minor/rudimentary\X0D\\X0A\microvascular proliferation, it is felt that the tumor may be more aggressive\X0D\\X0A\than is usual for grade 2 astrocytomas.   \X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\jhn/**DATE[Apr 16 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\The immunostain results (positive R132H IDH1 staining, clonal p53 positivity,\X0D\\X0A\and negative EGFR expression) are consistent with the diagnosis of a diffuse\X0D\\X0A\fibrillary astrocytoma.\X0D\\X0A\Addendum Comment\X0D\\X0A\The following immunostain results were obtained on B14:\X0D\\X0A\      - p53: strong clonal staining in tumor cells.\X0D\\X0A\      - IDH1 (R132H): strongly positive in tumor cells\X0D\\X0A\      - EGFR: negative in tumor cells.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jhn/**DATE[Apr 28 2012] C.M. **NAME[SSS], MD \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M94203 P1100 \X0D\\X0A\F: A: 88307\X0D\\X0A\B: 88307, S 67674, S 88342 (PROF), 67042 IMHC 1, S 88342 (PROF), 67042 IMHC\X0D\\X0A\1, S 88342 (PROF)",,"GROSS DESCRIPTION\X0D\\X0A\Three specimens are received. Specimen A is received in formalin labeled CUSA\X0D\\X0A\contents and consists of 450 ml of red fluid with small fragments of tissue.\X0D\\X0A\These are filtered and submitted and reveals numerous white tan soft\X0D\\X0A\fragments of tissue measuring in aggregate approximately 3.5 x 3 x 0.2 cm.\X0D\\X0A\The specimen is entirely submitted in biowrap in screened A1. \X0D\\X0A\Specimen B is received in formalin labeled left temporal tumor and consists\X0D\\X0A\of a fragment of brain cortex measuring 4.5 x 4.2 x 2.1 cm. The specimen\X0D\\X0A\weighs 19 grams. The specimen is serially sectioned to reveal gray white cut\X0D\\X0A\surfaces with identifiable gray and white matter demarcations. The specimen\X0D\\X0A\is entirely submitted in B1  B16. \X0D\\X0A\Specimen C is received fresh and used entirely for tumor bank.  \X0D\\X0A\rgc/**DATE[Apr 16 2012] D.J. **NAME[VVV], MD\X0D\\X0A\",MICROSCOPIC DESCRIPTION,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: CUSA contents\X0D\\X0A\B: Left temporal tumor,,PROCEDURES/ADDENDA
REG1,OTHER,0,494035,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is complex right ovarian tumor, elevated serum CA-125.\X0D\\X0A\Intraoperative findings: none given. Operative procedure: total abdominal\X0D\\X0A\hysterectomy, bilateral salpingo-oophorectomy, possible staging. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""POORLY DIFFERENTIATED CARCINOMA\""---MLC. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Sep 23 1951] (Age: **AGE[in 60s])  FW\X0D\\X0A\Collect Date: **DATE[Feb 15 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Feb 16 2012] 07:31\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: J.R. **NAME[CCC DDD] WWW]., MD     Service: GYO     Location: 1ER\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Feb 21 2012] 15:28\X0D\\X0A\RESIDENTS(S): R.K. **NAME[UUU], MD\X0D\\X0A\COMMENT:  Immunohistochemical stains for P63 and CEA polyclonal are performed\X0D\\X0A\and the tumor is negative for both of these immunohistochemical stains. This\X0D\\X0A\pattern argues against transitional carcinoma. A second panel of\X0D\\X0A\immunohistochemical stains including cytokeratin, inhibin, calretinin, ER,\X0D\\X0A\and P53 are performed to confirm a diagnosis of carcinoma and to exclude a\X0D\\X0A\sex cord-stromal tumor. The tumor is negative for inhibin and calretinin and\X0D\\X0A\is strongly positive for ER, cytokeratin and P53. While the tumor does not\X0D\\X0A\have the morphology of a typical serous tumor, some of the foci show nuclear\X0D\\X0A\clearing, particularly in the diaphragmatic and liver capsule metastases.\X0D\\X0A\However, P53 positivity is rare in clear cell and endometriod ovarian tumors.\X0D\\X0A\The findings are most consistent with an undifferentiated carcinoma. Since a\X0D\\X0A\large portion of the tumor is seen within the right ovary, it will be staged\X0D\\X0A\as an ovarian primary although the ipsilateral fallopian tube also shows\X0D\\X0A\considerable tumor. This case was shown in Consensus Conference.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\OVARIAN TUMOR (template #29)\X0D\\X0A\Last updated **DATE[Nov 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)     \X0D\\X0A\Growth involving:   right ovary \X0D\\X0A\Histologic type:  undifferentiated carcinoma\X0D\\X0A\Tumor grade of differentiation:  high-grade\X0D\\X0A\Main tumor dimensions:  approximately 3 cm in ovary. Multiple tumor nodules\X0D\\X0A\(largest measuring 10 cm in omentum) are found throughout the pelvis,\X0D\\X0A\peritoneum, diaphragm and liver capsule.\X0D\\X0A\Lymphvascular invasion:  yes\X0D\\X0A\Capsular involvement:   surface extension noted\X0D\\X0A\Pelvic extension:  the right fallopian tube and right parametrial tissue are\X0D\\X0A\involved by carcinoma, the uterine serosa and cervical serosa are both\X0D\\X0A\involved by tumor\X0D\\X0A\Peritoneal implants:   invasive inside and outside pelvis\X0D\\X0A\Lymph node involvement (specify): 0 positive / 1 intact lymph node identified\X0D\\X0A\in sigmoid mesenteric nodule specimen (L). However some nodules may represent\X0D\\X0A\completely replaced lymph nodes with extracapsular extension\X0D\\X0A\Metastasis (specify if present):  extensive metastases identified throughout\X0D\\X0A\pelvic, peritoneum, diaphragm, and liver capsule\X0D\\X0A\\X0D\\X0A\Residual ovary present:    yes \X0D\\X0A\Findings in residual ovary:  unremarkable\X0D\\X0A\Contralateral ovary findings:  no pathologic abnormality\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT)\X0D\\X0A\pT         FIGO\X0D\\X0A\     At least  pT3c      IIIC    Peritoneal metastasis beyond pelvis more\X0D\\X0A\than 2 cm in greatest dimension and/or regional  \X0D\\X0A\                            lymph node metastasis\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\pNO          No regional lymph node metastasis ( see above comment in\X0D\\X0A\template regarding lymph node involvement )\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\Not applicable\X0D\\X0A\Note:  Liver capsule metastasis T3/Stage III; liver parenchymal metastasis\X0D\\X0A\M1/Stage IV.  Pleural  \X0D\\X0A\                         effusion must have positive cytology for M1/Stage\X0D\\X0A\IV.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\OMENTUM, OMENTECTOMY (A):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA WITH EXTENSIVE NECROSIS.  \X0D\\X0A\TISSUE FROM LEFT PELVIC PERITONEUM, EXCISION (B):\X0D\\X0A\   - FIBROFATTY TISSUE WITH METASTATIC UNDIFFERENTIATED CARCINOMA.\X0D\\X0A\RIGHT PELVIC PERITONEAL IMPLANT, EXCISION (C):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA WITH NECROSIS.\X0D\\X0A\LEFT FALLOPIAN TUBE AND LEFT OVARY, SALPINGO-OOPHORECTOMY (D):\X0D\\X0A\   - SUBSEROSAL LEIOMYOMA, FALLOPIAN TUBE.\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, OVARY.\X0D\\X0A\TUMOR NODULE, LEFT PELVIC WALL, EXCISION (E):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA WITH NECROSIS.\X0D\\X0A\UTERUS, CERVIX, RIGHT OVARY, AND RIGHT FALLOPIAN TUBE, TOTAL ABDOMINAL\X0D\\X0A\HYSTERECTOMY WITH BILATERAL SALPINGO-OOPHORECTOMY (F):\X0D\\X0A\   - UNDIFFERENTIATED CARCINOMA INVOLVING SURFACE AND PARENCHYMA OF RIGHT\X0D\\X0A\OVARY, pT3c,\X0D\\X0A\     FIGO STAGE IIIC (SEE TEMPLATE AND COMMENT).\X0D\\X0A\   - UNDIFFERENTIATED CARCINOMA IDENTIFIED IN RIGHT FALLOPIAN TUBE EPITHELIUM\X0D\\X0A\AND STROMA.\X0D\\X0A\   - BENIGN WEAKLY PROLIFERATIVE ENDOMETRIUM.\X0D\\X0A\   - EXTENSIVE ADENOMYOSIS, MYOMETRIUM.\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA, POSTERIOR CERVIX SEROSA.\X0D\\X0A\   - CHRONIC CERVICITIS AND SQUAMOUS METAPLASIA.\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA IDENTIFIED IN UTERINE SEROSA AND\X0D\\X0A\RIGHT PARAMETRIAL\X0D\\X0A\     TISSUE.  NO TUMOR SEEN IN LEFT PARAMETRIAL TISSUE.\X0D\\X0A\SIGMOID SEROSA #1, BIOPSY (G):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA AND MINUTE FOCUS OF ENDOMETRIOSIS.\X0D\\X0A\SIGMOID SEROSA #2, BIOPSY (H):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.\X0D\\X0A\RIGHT PELVIC PERITONEUM, BIOPSY (I):\X0D\\X0A\  - METASTATIC UNDIFFERENTIATED ADENOCARCINOMA AND FOCUS OF ENDOMETRIOSIS.\X0D\\X0A\POSTERIOR CUL DE SAC, BIOPSIES (J):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\PERICOLIC GUTTER, LEFT, BIOPSY (K):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.\X0D\\X0A\SIGMOID MESENTERIC NODULE, BIOPSY (L):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.  NO TUMOR SEEN IN ONE INTACT\X0D\\X0A\LYMPH NODE.\X0D\\X0A\SIGMOID EPIPLOIC, BIOPSY (M):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.\X0D\\X0A\LEFT PERICOLIC GUTTER, BIOPSY (N):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.\X0D\\X0A\TRANSVERSE COLON MARGIN, BIOPSY (O):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.\X0D\\X0A\RETROPERITONEAL NODULE, EXCISION (P):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA WITH EXTENSIVE NECROSIS.\X0D\\X0A\DIAPHRAGMATIC PERITONECTOMY (Q):\X0D\\X0A\   - EXTENSIVE METASTATIC UNDIFFERENTIATED CARCINOMA WITH NECROSIS.\X0D\\X0A\LIVER CAPSULE (R):\X0D\\X0A\   - METASTATIC UNDIFFERENTIATED CARCINOMA.  DETACHED FRAGMENT OF LIVER\X0D\\X0A\PARENCHYMA ARE \X0D\\X0A\     IDENTIFIED WITH NO TUMOR SEEN.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Feb 21 2012] Y.M. **NAME[TTT], MD\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  eighteen\X0D\\X0A\Specimen A is received fresh for frozen section labeled omentum and consists\X0D\\X0A\of a single piece of omentum which measures 47 x 13.3 x 2.4 cm. The specimen\X0D\\X0A\reveals multiple white nodules, the largest of which measures 10.1 x 5.6 x\X0D\\X0A\2.4 cm. The omentum is serially sectioned to reveal multiple\X0D\\X0A\well-circumscribed white nodules which range in size from 10.1 x 5.6 x 2.4 cm\X0D\\X0A\to 0.7 x 0.9 x 0.5 cm. The specimen is representatively frozen as FS1. The\X0D\\X0A\specimen is submitted as follows: A1  FS1 entirely resubmitted; A2  A3 \X0D\\X0A\representative sections.\X0D\\X0A\Specimen label:  B) left pelvic peritoneum                  \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow pink \X0D\\X0A\Consistency: rubbery\X0D\\X0A\Size(s): 5 x 3.6 x 0.8 cm \X0D\\X0A\One of the sides of the specimen is pink and white and maybe involved by\X0D\\X0A\tumor. \X0D\\X0A\The specimen is serially sectioned to reveal a single possible lymph node\X0D\\X0A\which measures 0.4 x 0.4 x 0.8 cm. \X0D\\X0A\Cassette summary: it is entirely submitted in B1  B4.  \X0D\\X0A\Specimen label:  C) right pelvic peritoneal implant                   \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): purple tan \X0D\\X0A\Consistency: firm \X0D\\X0A\Size(s): 5 x 1.5 x 1.8 cm \X0D\\X0A\It is inked entirely in black and serially sectioned to reveal multiple white\X0D\\X0A\nodules which range in size from 1.1 cm in greatest dimension to 1.5 cm in\X0D\\X0A\greatest dimension. There is a cystic structure filled with yellow fluid\X0D\\X0A\which measures 0.7 cm in greatest dimension. The specimen is representatively\X0D\\X0A\submitted in C1. \X0D\\X0A\Specimen D is received in formalin labeled left tube and ovary and consists\X0D\\X0A\of the aforementioned which weigh 8.2 grams post fixation.  The fallopian\X0D\\X0A\tube has an identifiable fimbriated end. Two paratubal cysts are noted which\X0D\\X0A\range in size from 0.2 cm to 0.3 cm in greatest dimension.  The tube is\X0D\\X0A\serially sectioned to reveal a pinpoint lumen. There is a hard nodule next to\X0D\\X0A\the fallopian tube which measures 1.8 cm x 1 x 0.5 cm. The nodule is cut to\X0D\\X0A\reveal a white mass with hemorrhage in the center. \X0D\\X0A\The ovary is white/tan, almond-shaped, and normally bosselated.  It is intact\X0D\\X0A\with no excrescences on its surface.  It is serially sectioned to reveal an\X0D\\X0A\unremarkable heterogeneous yellow/tan cut surface.\X0D\\X0A\The specimen is inked entirely in black.\X0D\\X0A\Measurements:\X0D\\X0A\Fallopian tube: 5 cm length x 0.9 cm diameter\X0D\\X0A\Ovary: 2.2 cm x 0.9 x 0.7 cm\X0D\\X0A\Representative sections:\X0D\\X0A\D1  D2: fallopian tube entirely submitted \X0D\\X0A\D3: nodule entirely submitted \X0D\\X0A\D4  D5  ovary entirely submitted \X0D\\X0A\Specimen label:  E) tumor nodule left pelvic wall                   \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): pink yellow\X0D\\X0A\Consistency: firm\X0D\\X0A\Size(s): 6.4 x 2.8 x 0.7 cm\X0D\\X0A\It is palpated to reveal multiple hard nodules\X0D\\X0A\It is serially sectioned to reveal multiple white nodules ranging in size\X0D\\X0A\from 1.5 cm in greatest dimension to 1.1 cm in greatest dimension. There is a\X0D\\X0A\cyst attached to one of the tumor nodules which measures 0.5 cm in greatest\X0D\\X0A\dimension and is filled with yellow clear fluid. \X0D\\X0A\Cassette summary: it is representatively submitted in E1. \X0D\\X0A\Specimen F is received fresh and placed in formalin labeled \""uterus, cervix,\X0D\\X0A\and right ovary and fallopian tube\"" and consists of the aforementioned.\X0D\\X0A\Sectioning of the endomyometrium reveals nodular areas involving anterior and\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.",MICROSCOPIC DESCRIPTION,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Omentum\X0D\\X0A\B: Left pelvic peritoneum\X0D\\X0A\C: Right pelvic peritoneal implant\X0D\\X0A\D: Left tube and ovary\X0D\\X0A\E: Tumor nodule left pelvic wall\X0D\\X0A\F: Uterus/cervix/righ fallopian tube/ovary/mass\X0D\\X0A\G: Sigmoid serosa #1\X0D\\X0A\H: Sigmoid serosa #2\X0D\\X0A\I: Right pelvic peritoneum\X0D\\X0A\J: Posterior cul de sac\X0D\\X0A\K: Left pericolic gutter\X0D\\X0A\L: Sigmoid mesentery nodule\X0D\\X0A\M: Sigmoid epiploic\X0D\\X0A\N: Left paracolic gutter\X0D\\X0A\O: Transverse colon margin\X0D\\X0A\P: Retroperitoneal nodule\X0D\\X0A\Q: Diaphragmatic peritonectomy\X0D\\X0A\R: Liver capsule,,
REG1,OTHER,0,494047,4,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  bladder and kidney mass.  Intraoperative findings: \X0D\\X0A\bladder and kidney mass.  Operative procedure:  left hand assisted\X0D\\X0A\laparoscopic nephroureterectomy and abdominal cystectomy with ileal loop.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""NO TUMOR SEEN\"" --- MLC.\X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jan 31 1949] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Dec 15 2011] 00:00\X0D\\X0A\Receipt Date: **DATE[Dec 16 2011] 07:43\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: **NAME[M. WWW], MD     Service: URO     Location: 2MCC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Dec 21 2011] 17:19\X0D\\X0A\RESIDENTS(S): R.K. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\RIGHT DISTAL URETER, BIOPSY FOR FROZEN SECTION (A):\X0D\\X0A\   - NO TUMOR SEEN.\X0D\\X0A\LYMPH NODES, LEFT ILIAC AND OBTURATOR, EXCISION (B):\X0D\\X0A\   - NO TUMOR SEEN IN NINE LYMPH NODES (O/9).\X0D\\X0A\LYMPH NODES, RIGHT ILIAC AND OBTURATOR, EXCISION (C):\X0D\\X0A\   - NO TUMOR SEEN IN TWELVE LYMPH NODES (0/12).\X0D\\X0A\LEFT KIDNEY WITH ATTACHED LEFT URETER, BLADDER, PROSTATE AND RIGHT AND LEFT\X0D\\X0A\SEMINAL VESICLES, LEFT LAPAROSCOPIC NEPHROURETERECTOMY AND ABDOMINAL\X0D\\X0A\CYSTOPROSTATECTOMY (D):\X0D\\X0A\   - LEFT KIDNEY: RENAL CELL CARCINOMA, FUHRMAN GRADE III, pT2a, NX. (SEE\X0D\\X0A\TEMPLATE)\X0D\\X0A\   - BLADDER: HIGH-GRADE PAPILLARY UROTHELIAL CARCINOMA, pT1, N0. \X0D\\X0A\    NO TUMOR SEEN IN ONE PERIVESICULAR LYMPH NODE (0/1). (SEE TEMPLATE AND\X0D\\X0A\COMMENT)\X0D\\X0A\   - PROSTATE AND SEMINAL VESICLES: PROSTATIC ADENOCARCINOMA, GLEASON GRADE 3\X0D\\X0A\+ 4, pT3, N0.\X0D\\X0A\    TUMOR PRESENT AT RIGHT LATERAL INKED MARGIN OF EXCISION. (SEE TEMPLATE)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Dec 18 2011] Y.M. **NAME[TTT], MD\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Four specimens are received.\X0D\\X0A\Specimen A is received fresh for frozen section labeled right distal ureter \X0D\\X0A\cut side opposite stitch and consists of a soft red/tan tubular structure\X0D\\X0A\measuring 1 cm in length x 0.6 cm in diameter.  The specimen is divided into\X0D\\X0A\two halves, half opposite to the stitch is submitted for frozen section.  The\X0D\\X0A\entire specimen is submitted as follows:  A1  frozen section resubmitted; A2 \X0D\\X0A\half with the stitch.\X0D\\X0A\Specimen B is received in formalin labeled left iliac and obturator lymph\X0D\\X0A\node and consists of a fragment of tan/yellow adipose tissue measuring 5.5 x\X0D\\X0A\4 x 2 cm.  Multiple lymph nodes are identified ranging in size from 0.4 cm to\X0D\\X0A\3.8 cm in greatest dimension. All the lymph nodes are submitted as follows: \X0D\\X0A\B1  largest lymph node serially sectioned; B2  second largest lymph node\X0D\\X0A\bisected; B3  one lymph node serially sectioned; B4  one lymph node bisected;\X0D\\X0A\B5  multiple lymph nodes not modified.\X0D\\X0A\Specimen C is received in formalin labeled right iliac and obturator lymph\X0D\\X0A\nodes and consists of a two fragments of tan/yellow adipose tissue measuring\X0D\\X0A\in aggregate 6 x 5 x 1.8 cm.  Multiple lymph nodes are identified ranging in\X0D\\X0A\size from 0.6 to 3.5 cm in greatest dimension. All of the lymph nodes are\X0D\\X0A\submitted entirely as follows:  C1-C2  largest lymph node serially sectioned,\X0D\\X0A\entirely; C3  one lymph node bisected; C4  two bisected lymph nodes; C5  four\X0D\\X0A\lymph nodes not modified; C6  five lymph nodes not modified; C7  multiple\X0D\\X0A\lymph nodes not modified.\X0D\\X0A\Specimen D is received fresh and placed in formalin labeled left kidney,\X0D\\X0A\bladder, prostate and seminal vesicles and ureter and consists of a\X0D\\X0A\cystoprostatectomy with bilateral seminal vesicles and vas deferens and\X0D\\X0A\attached to his left nephroureterectomy.  \X0D\\X0A\The bladder is opened to reveal a large polypoid mass located on the entire\X0D\\X0A\posterior wall involving both lateral walls.  The tumor does not  appear to\X0D\\X0A\extend into the prostatic urethra grossly. Otherwise the mucosa is white/tan\X0D\\X0A\and rugated.  The ureters are probe patent and appropriately enter into the\X0D\\X0A\bladder in the region of the trigone.     \X0D\\X0A\The prostate has a dull red-brown external surface.  The cut surface varies\X0D\\X0A\from firm to rubbery and is nodular, light tan to yellow.  No discrete masses\X0D\\X0A\or lesions are noted.  The vas deferens and seminal vesicle are unremarkable\X0D\\X0A\and grossly free of tumor.   The tumor is present at right and left\X0D\\X0A\vesicoureteral junction. Tumor is not seen at right ureter margin.  The\X0D\\X0A\remaining portion of the specimen is grossly unremarkable.\X0D\\X0A\Measurements\X0D\\X0A\Total specimen weight:  1400 grams\X0D\\X0A\Kidney:  780 grams\X0D\\X0A\Bladder with prostate:  620 grams\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.","MICROSCOPIC DESCRIPTION\X0D\\X0A\NEPHRECTOMY FOR NON-WILM' S MALIGNANCY (template #15)\X0D\\X0A\(EXCLUDING SARCOMAS, RENAL PELVIS TUMOR AND URETERAL TUMORS)      \X0D\\X0A\Last updated **DATE[Sep 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  left nephrectomy with attached cystoprostatectomy\X0D\\X0A\Tumor site:  inferior pole of left kidney\X0D\\X0A\Tumor size:  8.5 x 8.5 x 8 cm\X0D\\X0A\Tumor focality:   unifocal \X0D\\X0A\Histologic type:   clear cell with pseudopapillary features\X0D\\X0A\Nuclear grade (Fuhrman grade):  III \X0D\\X0A\Tumor necrosis:   50-95%\X0D\\X0A\Lymphvascular invasion:  not identified\X0D\\X0A\Renal vein involvement (specify if invasion of wall or attachment to wall): \X0D\\X0A\no definite renal vein invasion seen\X0D\\X0A\Vena caval invasion:  no\X0D\\X0A\Perinephric fat invasion:  no   \X0D\\X0A\Renal sinus invasion: no definite\X0D\\X0A\Cancer at resected margin:  no\X0D\\X0A\Regional lymph node metastasis (renal hilar, caval, interaortocaval and\X0D\\X0A\aortic):  none submitted\X0D\\X0A\\X0D\\X0A\Other (non-regional) lymph node metastasis (m1):   0 positive / 21 (right and\X0D\\X0A\left iliac and obturator lymph nodes)\X0D\\X0A\Adrenal gland:  not submitted\X0D\\X0A\Other pathologic findings in nonneoplastic kidney (list):   extensive chronic\X0D\\X0A\pyelonephritis with glomerulosclerosis\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT)\X0D\\X0A\        pT2a     Tumor more than 7 cm and less than 10 cm  in greatest\X0D\\X0A\dimension, limited to the kidney\X0D\\X0A\\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\     pNX      Regional lymph nodes cannot be assessed\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\    Not applicable\X0D\\X0A\CYSTECTOMY FOR URINARY BLADDER CANCER (template #18)\X0D\\X0A\Last updated **DATE[Sep 13 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  cystoprostatectomy with attached left ureter and left\X0D\\X0A\kidney\X0D\\X0A\Histologic type : papillary urothelial\X0D\\X0A\Grade (WHO/ISUP):   high grade \X0D\\X0A\\X0D\\X0A\Carcinoma in situ:  not identified\X0D\\X0A\Lymph-vascular invasion:  not seen\X0D\\X0A\Invasion: Into lamina propria. The tumor is bulky and friable and in many\X0D\\X0A\sections appears interposed between bundles of the inner deep muscle layer;\X0D\\X0A\however, no definite invasion into deep muscle per se is identified. The\X0D\\X0A\bladder sections were shown in Consensus Conference. \X0D\\X0A\Tumor site:  posterolateral wall on right and left sides and region of\X0D\\X0A\trigone\X0D\\X0A\Prostate (use prostate protocol for prostatic adenocarcinoma): \X0D\\X0A\      CIS of prostatic ducts:  no\X0D\\X0A\      Direct stromal invasion:  no\X0D\\X0A\\X0D\\X0A\Involvement of adjacent organs (list):  no\X0D\\X0A\Urethral margin:   negative\X0D\\X0A\Ureteral margins:   Right:  negative;   Left: not applicable (left ureter\X0D\\X0A\submitted attached to left kidney and bladder)\X0D\\X0A\Lymph nodes:   Right pelvic: 0 positive / 12;  Left pelvic: 0 positive / 9 ; \X0D\\X0A\0 positive /1 in perivesicular fat        \X0D\\X0A\Pathologic Staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT)\X0D\\X0A\At least pT1      Tumor invades subepithelial connective tissue.  (See above\X0D\\X0A\comment in template under \""Invasion\"")\X0D\\X0A\\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\      pNO      No lymph node metastasis\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\     Not applicable\X0D\\X0A\PROSTATECTOMY (template #6)\X0D\\X0A\Last updated **DATE[Sep 2010] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of specimen:  cystoprostatectomy with attached left kidney and left\X0D\\X0A\ureter\X0D\\X0A\Type of procedure:  abdominal cystoprostatectomy\X0D\\X0A\Weight of prostate:  not applicable (resection en bloc)\X0D\\X0A\Histologic type: prostatic adenocarcinoma\X0D\\X0A\Gleason Grade:     \X0D\\X0A\              Primary (most prevalent) 3/5\X0D\\X0A\              Secondary (next most prevalent) 4/5\X0D\\X0A\              Score 7/10\X0D\\X0A\Tumor location:  right and left sides\X0D\\X0A\Tumor amount (percentage):  approximately 5%\X0D\\X0A\Size of largest tumor nodule:  15 mm\X0D\\X0A\Involvement of seminal vesicle:   no\X0D\\X0A\Extension into soft tissue:  focal extension beyond capsule into\X0D\\X0A\periprostatic adipose tissue (see below)\X0D\\X0A\Extracapsular extension:  focal (shown at Consensus Conference)\X0D\\X0A\Surgical margins:\X0D\\X0A\     Bladder neck:   negative\X0D\\X0A\     Apical (inferior):  negative\X0D\\X0A\Inked surgical margins:  positive \X0D\\X0A\    If inked surgical margins are positive, the length of the invasive focus\X0D\\X0A\abutting the inked margin is 2 mm.\X0D\\X0A\    Gleason grade of tumor at inked margin:  3 + 3\X0D\\X0A\Vascular invasion:  no\X0D\\X0A\Perineural invasion:  extensive perineural invasion seen\X0D\\X0A\High grade PIN:  present (quantity: moderate in both right and left lobes)\X0D\\X0A\Lymph node involvement:  0 positive / 21 total\X0D\\X0A\                    Right pelvic:  0/12\X0D\\X0A\                    Left pelvic:  0/9\X0D\\X0A\Additional pathologic findings (list):  chronic active prostatitis\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\PRIMARY TUMOR (pT) \X0D\\X0A\       pT3:  Tumor extends through the prostate capsule\X0D\\X0A\REGIONAL LYMPH NODES (pN)\X0D\\X0A\        pNO:     No regional lymph node metastasis\X0D\\X0A\\X0D\\X0A\DISTANT METASTASIS (pM)\X0D\\X0A\                     Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right distal ureter\X0D\\X0A\B: Left iliac/obturator lymph nodes\X0D\\X0A\C: Right iliac/obturator lymph nodes\X0D\\X0A\D: Left kidney/bladder/prostate/seminal vessicles/ureter,,
REG1,OTHER,0,494077,1,,CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  cervical cancer. Operative procedure:  radical\X0D\\X0A\hysterectomy and pelvic lymphadenectomy.\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Oct 17 1982] (Age: **AGE[in 20s])  FW\X0D\\X0A\Collect Date: **DATE[May 17 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[May 18 2012] 07:25\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: J.R. **NAME[CCC DDD] YYY]., MD     Service: GYO     Location: 2MCC\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 22 2012] 15:05\X0D\\X0A\RESIDENTS(S): D.J. **NAME[WWW], MD","DIAGNOSIS\X0D\\X0A\UTERUS AND CERVIX, TOTAL ABDOMINAL HYSTERECTOMY (I):\X0D\\X0A\   - INVASIVE POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA (pT1b1, pN0),\X0D\\X0A\CERVIX\X0D\\X0A\    (SEE TEMPLATE AND COMMENT).\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, ENDOEMTRIUM.\X0D\\X0A\   - NO PATHOLOGIC ABNORMALITY, MYOMETRIUM.\X0D\\X0A\   - NO TUMOR SEEN, RIGHT AND LEFT PARAMETRIA.\X0D\\X0A\LYMPH NODE, RIGHT EXTERNAL ILIAC, EXCISION (A):\X0D\\X0A\   - NO TUMOR SEEN (0/1).\X0D\\X0A\LYMPH NODE, RIGHT COMMON ILIAC, EXCISION (B):\X0D\\X0A\   - NO TUMOR SEEN (0/1).\X0D\\X0A\LYMPH NODE, RIGHT OBTURATOR, EXCISION (C):\X0D\\X0A\   - NO TUMOR SEEN (0/4).\X0D\\X0A\LYMPH NODE, RIGHT PARAMETRIAL, EXCISION (D):\X0D\\X0A\   - NO TUMOR SEEN (0/1).\X0D\\X0A\SOFT TISSUE, LEFT EXTERNAL ILIAC, EXCISION (E):\X0D\\X0A\   - NO TUMOR SEEN; NO LYMPHOID TISSUE IDENTIFIED.\X0D\\X0A\LYMPH NODE, LEFT INTERNAL, EXCISION (F):\X0D\\X0A\   - NO TUMOR SEEN (0/2).\X0D\\X0A\LYMPH NODE, LEFT OBTURATOR, EXCISION (G):\X0D\\X0A\   - NO TUMOR SEEN (0/3).\X0D\\X0A\LYMPH NODE, LEFT COMMON ILIAC, EXCISION (H):\X0D\\X0A\   - NO TUMOR SEEN (0/1).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 22 2012] **NAME[VVV UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09450 P1100\X0D\\X0A\B: M09450 P1100\X0D\\X0A\C: M09450 P1100\X0D\\X0A\D: M09450 P1100\X0D\\X0A\E: P1100 T08610\X0D\\X0A\F: M09450 P1100\X0D\\X0A\G: M09450 P1100\X0D\\X0A\H: M09450 P1100\X0D\\X0A\I: **ID-NUM P110 \X0D\\X0A\F: A: 88305\X0D\\X0A\B: 88305\X0D\\X0A\C: 88305\X0D\\X0A\D: 88305\X0D\\X0A\E: 88305\X0D\\X0A\F: 88305\X0D\\X0A\G: 88305\X0D\\X0A\H: 88305\X0D\\X0A\I: 88309",,"GROSS DESCRIPTION\X0D\\X0A\Nine specimens are received. \X0D\\X0A\Specimen label:  A) right external iliac lymph node            \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 3.5 x 1.2 x 1.1 cm\X0D\\X0A\A single possible node is identified measuring 2.2 cm in greatest dimension.\X0D\\X0A\Cassette summary:  A1  one possible node; A2  additional tissue with possible\X0D\\X0A\node\X0D\\X0A\Specimen label:  B) right common iliac lymph node                \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): yellow/gray\X0D\\X0A\Consistency: rubbery\X0D\\X0A\Size(s): 2.5 x 0.7 x 0.6 cm\X0D\\X0A\Cassette summary: entirely submitted in cassette B1\X0D\\X0A\Specimen label:  C) right obturator node                 \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): in aggregate 4.5 x 2 x 1.1 cm\X0D\\X0A\Three possible nodes are identified measuring up to 1.5 cm in greatest\X0D\\X0A\dimension.\X0D\\X0A\Cassette summary: C1  one possible node; C2  three possible nodes\X0D\\X0A\Specimen label:  D) right parametrial lymph node\X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): white/tan\X0D\\X0A\Consistency: rubbery\X0D\\X0A\Size(s): 0.8 cm in greatest dimension\X0D\\X0A\Cassette summary: the specimen is bisected and submitted entirely in D1\X0D\\X0A\Specimen label:  E) left external iliac lymph nodes                  \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: single\X0D\\X0A\Shape(s):  irregular\X0D\\X0A\Color(s): yellow to gray\X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): 2 cm in greatest dimension\X0D\\X0A\A single node is identified measuring 0.6 cm in greatest dimension.\X0D\\X0A\Cassette summary: entirely submitted in cassette E1\X0D\\X0A\Specimen label:  F) left internal iliac lymph node\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): gray to yellow\X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): in aggregate 3 x 2.5 x 1.4 cm\X0D\\X0A\Four possible nodes are identified measuring up to 1.2 cm in greatest\X0D\\X0A\dimension\X0D\\X0A\Cassette summary: F1  two possible nodes; F2  two possible nodes\X0D\\X0A\Specimen label:  G) left obturator lymph node\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s):  yellow/gray\X0D\\X0A\Consistency: rubbery\X0D\\X0A\Size(s): in aggregate 4 x 3 x 1.3 cm\X0D\\X0A\Three possible nodes are identified measuring up to 2.6 cm in greatest\X0D\\X0A\dimension\X0D\\X0A\Cassette summary: G1  two possible nodes; G2  representative sections of\X0D\\X0A\largest node\X0D\\X0A\Specimen label:  H) left common iliac lymph node\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s):  gray/tan\X0D\\X0A\Consistency: soft \X0D\\X0A\Size(s): 1.5 cm in greatest dimension\X0D\\X0A\Cassette summary: entirely submitted in H1\X0D\\X0A\Specimen I is received fresh and placed in formalin labeled uterus, cervix,\X0D\\X0A\and parametria and consists of the aforementioned. There are no subserosal\X0D\\X0A\nodules. The external and resectioned surface is inked blue.  The specimen is\X0D\\X0A\bivalved to reveal a lesion in the anterior and posterior cervix.  It appears\X0D\\X0A\to be ulcerated and invasive.  It is difficult to determine grossly the\X0D\\X0A\extent of invasion of this tumor.  \X0D\\X0A\Measurements:\X0D\\X0A\Specimen weight:  109 grams\X0D\\X0A\Uterus dimensions:  7 cm (length) x 5.5 cm (width) x 3.6 cm (ant-post)\X0D\\X0A\Os diameter:  0.5 cm\X0D\\X0A\Endocervical canal length:  2.5 cm\X0D\\X0A\Representative sections:\X0D\\X0A\I1-I9  anterior cervix from 3 o' clock to 9 o' clock\X0D\\X0A\I10-I15  posterior cervix from 3 o' clock to 9 o' clock\X0D\\X0A\I16  anterior lower uterine segment and left parametrium\X0D\\X0A\I17  posterior lower uterine segment\X0D\\X0A\I18  anterior endomyometrium full thickness\X0D\\X0A\I19  posterior endomyometrium full thickness\X0D\\X0A\I20  right parametrium\X0D\\X0A\dlf/**DATE[May 18 2012] D.J. **NAME[WWW], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\The tumor is very poorly differentiated (almost undifferentiated) in some\X0D\\X0A\areas.  There is no evidence of gland formation.  Although the tumor provokes\X0D\\X0A\marked lymphoid reaction, the findings are not those of lymphoepithelioma or\X0D\\X0A\glassy cell carcinoma.  The case was discussed at the consensus conference.\X0D\\X0A\CERVICAL TUMOR (template #1)\X0D\\X0A\Last updated **DATE[Feb 2011] (AJCC 7th Edition \T\ 2009 CAP checklist)\X0D\\X0A\Type of surgery:  total abdominal hysterectomy\X0D\\X0A\Histologic type of tumor:  squamous cell carcinoma (see comment)\X0D\\X0A\Tumor dimensions:\X0D\\X0A\   Maximal thickness of cervical stromal invasion:  5 mm/thickness of\X0D\\X0A\cervical wall: 12 mm\X0D\\X0A\   Maximum superficial (horizontal) spread of tumor:   at least 2.5 cm\X0D\\X0A\Tumor grade of differentiation (I/II/III):  poorly differentiated\X0D\\X0A\Tumor multicentricity (multicentric foci of invasive carcinoma):  no\X0D\\X0A\Lymphvascular invasion:  not identified\X0D\\X0A\Perineural invasion:  not identified\X0D\\X0A\Premalignant changes:    not identified\X0D\\X0A\Non-neoplastic cervix:   unremarkable\X0D\\X0A\Surgical margins:   negative\X0D\\X0A\Vaginal cuff involvement:  no\X0D\\X0A\Uterine corpus involvement (endometrial vs stromal):  tumor invades\X0D\\X0A\myometrium of the lower uterine segment\X0D\\X0A\Parametrial soft tissues:  uninvolved \X0D\\X0A\Other pelvic organs involved (specify):  not submitted\X0D\\X0A\Lymph node involvement (specify):  0 positive / 13 total\X0D\\X0A\\X0D\\X0A\Pathologic stage (pTNM)\X0D\\X0A\Primary Tumor (pT)\X0D\\X0A\pT               FIGO\X0D\\X0A\        pT1b1    IB1    Clinically visible lesion 4.0 cm or less in greatest\X0D\\X0A\dimension\X0D\\X0A\Regional Lymph Nodes (pN)\X0D\\X0A\        pN0              No regional lymph node metastasis\X0D\\X0A\Distant Metastasis (pM)\X0D\\X0A\                          Not applicable \X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right external iliac lymph nodes\X0D\\X0A\B: Right common iliac lymph nodes\X0D\\X0A\C: Right obturator node\X0D\\X0A\D: Right parametrial lymph nodes\X0D\\X0A\E: Left external lymph nodes\X0D\\X0A\F: Left internal iliac lymph nodes\X0D\\X0A\G: Left obturator lymph nodes\X0D\\X0A\H: Left common iliac lymph node\X0D\\X0A\I: Uterus/cervix/parametria,,
REG1,OTHER,0,494117,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  bladder tumor.  Intraoperative findings:  not\X0D\\X0A\listed.  Operative procedure:  TUR, bladder tumor.\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[May 24 1949] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[May 22 2012] 10:34\X0D\\X0A\Receipt Date: **DATE[May 22 2012] 10:34\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: J.R. **NAME[YYY], MD     Service: URO     Location: ORN\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 28 2012] 14:10\X0D\\X0A\RESIDENTS(S): R.G. **NAME[WWW], MD\X0D\\X0A\Comment: The histology sections show high grade papillary urothelial\X0D\\X0A\carcinoma with extensive crushing artifacts, making the assessment of\X0D\\X0A\invasion component very difficult. No muscularis propria is identified.\X0D\\X0A\The case was prospectively reviewed in the intradepartmental consensus\X0D\\X0A\conference with the agreement to the above diagnosis.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\URINARY BLADDER TUMOR, TRANSURETHRAL BIOPSY:\X0D\\X0A\   - HIGH-GRADE PAPILLARY UROTHELIAL CARCINOMA.\X0D\\X0A\   - NO DEFINITIVE INVASION IS IDENTIFIED.\X0D\\X0A\   - MUSCULARIS PROPRIA IS NOT PRESENT.\X0D\\X0A\   - SEE COMMENT.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 27 2012] **NAME[M. VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M80502 P1140 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A)   bladder tumor              \X0D\\X0A\Fixation:  formalin\X0D\\X0A\Number of pieces:  multiple\X0D\\X0A\Shape(s):    irregular\X0D\\X0A\Color(s):  brown tan\X0D\\X0A\Consistency:  firm\X0D\\X0A\Size(s):  2.5 x 1.5 x 0.2 cm in aggregate\X0D\\X0A\Cassette summary:  \X0D\\X0A\Submitted entirely in a single screened cassette A1.\X0D\\X0A\blm/**DATE[May 23 2012] R.G. **NAME[WWW], MD\X0D\\X0A\",MICROSCOPIC DESCRIPTION,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Bladder biopsy,,
REG1,OTHER,0,494166,1,,CLINICAL HISTORY\X0D\\X0A\Retinoblastoma\X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Feb 19 2009] (Age: **AGE[birth-12])  MW\X0D\\X0A\Collect Date: **DATE[Feb 15 2012] 12:58\X0D\\X0A\Receipt Date: **DATE[Feb 15 2012] 12:58\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. M. YYY],MD     Service: OPH     Location: CAS\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Feb 22 2012] 15:24\X0D\\X0A\RESIDENTS(S):","DIAGNOSIS\X0D\\X0A\EYE, RIGHT, ENUCLEATION  \X0D\\X0A\A.          RETINOBLASTOMA, 19 x 16 x 12 MM, ARISING IN THE POSTERIOR POLE.\X0D\\X0A\B.     SUPERFICIAL INVASION INTO THE OPTIC NERVE HEAD (GRADE I)\X0D\\X0A\C.     OPTIC NERVE MARGIN OF RESECTION FREE OF TUMOR.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\cmh/**DATE[Feb 22 2012] C.M. **NAME[WWW], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M09400 M9510 \X0D\\X0A\F: A: 88307, S 88313, 67642, S 88313, 67642 <CR>",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is received in fixative, with the patient' s name (initials XS),\X0D\\X0A\medical record number, and \""right eye\"" labeling the container. It consists of\X0D\\X0A\a globe identified as the right eye by the inferior oblique insertion. It\X0D\\X0A\measures 22 mm superior-inferior, 23 mm nasal to temporal, and 22 mm\X0D\\X0A\anterior-posterior. The cornea is free of abrasions and measures 13x12 mm.\X0D\\X0A\The optic nerve is 7x3 mm. The sclera is unremarkable, the iris is brown, and\X0D\\X0A\the pupil is dilated at 8x9mm. On transillumination, the tumor fills the\X0D\\X0A\posterior pole of the eye and wraps around the entire globe except from\X0D\\X0A\**ID-NUM. Based on this, the globe is sectioned vertically, revealing a 19\X0D\\X0A\x 12 x 16 mm soft, friable, white-yellow mass that is attached to the\X0D\\X0A\posterior pole. The tumor is submitted nasal side down in cassette A1. A\X0D\\X0A\fragment of tumor from the nasal aspect is retained for archival use if\X0D\\X0A\needed.\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections show an intraocular neoplasm composed of small round blue cells with\X0D\\X0A\scattered Flexner-Wintersteiner and **NAME[VVV UUU] rosettes, frequent mitoses\X0D\\X0A\and apoptotic bodies, and abundant necrosis. The tumor has a mostly\X0D\\X0A\endophytic growth pattern and wraps around the retinal vein, but shows no\X0D\\X0A\unequivocal evidence of intravascular invasion. Choroidal invasion is also\X0D\\X0A\not prominent, nor is tumor invasion into the lamina cribrosa. \X0D\\X0A\PAS stain shows normal membranous pattern. This service has been rendered in\X0D\\X0A\part by a resident.  A pathologist has personally reviewed the slides/tissue\X0D\\X0A\and has rendered and is responsible for the diagnosis that appears on the\X0D\\X0A\report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right eye,,
REG1,OTHER,0,494213,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT UPPER POLE RENAL MASS\X0D\\X0A\OPER:   LAPAROSCOPIC LEFT PARTIAL NEPHRECTOMY \X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX: ONCOCYTIC NEOPLASM (ONCOCYTOMA VS VARIANT CELL CARCINOMA).  **INITIALS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RENAL MASS (LEFT) FOR FROZEN SECTION. jl\X0D\\X0A\2: LEFT RENAL MASS   tb","Final Diagnosis\X0D\\X0A\1: \""RENAL MASS (LEFT) FOR FROZEN SECTION\"":\X0D\\X0A\     ONCOCYTIC NEOPLASM (SEE COMMENT).\X0D\\X0A\COMMENT: Report on part 2 to follow separately.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\1: Received fresh for frozen section evaluation labeled \""left renal mass\"" is an\X0D\\X0A\irregular partially fragmented portion of friable tan gray soft tissue 1.4 x 1.3\X0D\\X0A\x 1.2 cm.  Inked, divided and all submitted as frozen section.  **INITIALS","Microscopic Description\X0D\\X0A\Performed, not dictated.",,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 17 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 17 2011]     By:  **NAME[XXX, WWW]\X0D\\X0A\     Date Reported:     **DATE[Oct 19 2011]         \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\2: \""LEFT RENAL MASS\"", PARTIAL NEPHRECTOMY SPECIMEN:\X0D\\X0A\     FRAGMENTS OF ONCOCTYIC RENAL NEOPLASM.\X0D\\X0A\     ADDITIONAL MARKER STUDIES PENDING.\X0D\\X0A\     RENAL AND SOFT TISSUE MARGINS INDETERMINATE.\X0D\\X0A\COMMENT: The specimen has been received in multiple fragments, and evaluation\X0D\\X0A\for margins of resection is not possible with certainty.  Marker studies are\X0D\\X0A\being performed at Genzyme lLabs, report to follow.\X0D\\X0A\MER/jsh \X0D\\X0A\IHC/a/THM\X0D\\X0A\Addendum Comment\X0D\\X0A\MICROSCOPIC DESCRIPTION:\X0D\\X0A\Incorporated in diagnosis. \X0D\\X0A\GROSS, CONTINUED:\X0D\\X0A\2: Received in formalin labeled \""left renal mass\"" is a multi-fragmented\X0D\\X0A\aggregate of red brown apparent renal tissue.  The fragments vary from 0.5 cm up\X0D\\X0A\to 5.5 cm with the larger fragments having a small amount of attached fat.  Also\X0D\\X0A\received is an additional 6.5 cm aggregate of soft firm yellow portions of\X0D\\X0A\adipose tissue which measure up to 4.5 cm in greatest dimension.  The entire\X0D\\X0A\periphery of all of the fragments which appear to represent renal tissue are\X0D\\X0A\inked in blue and, on sectioning, these fragments have a tan brown to red\X0D\\X0A\appearance.  Some of the fragments appear to be partially covered by capsule. \X0D\\X0A\On sectioning through the remaining tissue which grossly appears to represent\X0D\\X0A\entirely fatty fragments, the cut surfaces are yellow with no areas of obvious\X0D\\X0A\tissue noted.  Sections are submitted as follows:\X0D\\X0A\2A through 2J  sections of the inked renal tissue fragments\X0D\\X0A\2K through 2O  representative sections of the additional fatty tissue\X0D\\X0A\DH/**INITIALS\X0D\\X0A\CLINICAL HISTORY AND DIAGNOSIS:\X0D\\X0A\LEFT UPPER POLE RENAL MASS\X0D\\X0A\OPER:   LAPAROSCOPIC LEFT PARTIAL NEPHRECTOMY \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 22 2011]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 22 2011]     By:  **NAME[UUU,TTT]\X0D\\X0A\     Date Reported:     **DATE[Oct 22 2011]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding immunohistochemical analysis.\X0D\\X0A\INTERPRETATION, in part, reads:  These results support chromophobe renal cell\X0D\\X0A\carcinoma, eosinophillic variant.\X0D\\X0A\Signed:  **NAME[SSS RRR], Ph.D.    /ap\X0D\\X0A\Based on these staining results, the following CAP cancer case summary is\X0D\\X0A\provided:\X0D\\X0A\PROCEDURE: Partial nephrectomy\X0D\\X0A\SPECIMEN LATERALITY: Left\X0D\\X0A\TUMOR SIZE, GREATEST DIMENSION: Cannot be estimated with certainty, specimen\X0D\\X0A\received in multiple fragments.\X0D\\X0A\Correlation with clinical and radiology studies required.\X0D\\X0A\TUMOR FOCALITY: Unifocal\X0D\\X0A\MACROSCOPIC EXTENT OF TUMOR: No evidence of extension beyond kidney in these\X0D\\X0A\fragments (tumor limited to kidney at least).\X0D\\X0A\HISTOLOGIC TYPE: Renal cell carcinoma, chromophobe type\X0D\\X0A\HISTOLOGIC GRADE: Fuhrman nuclear grade 3.\X0D\\X0A\MICROSCOPIC TUMOR EXTENSION: Tumor limited to kidney\X0D\\X0A\MARGINS: Cannot assessed based on pathologic staging  \X0D\\X0A\     Primary tumor: pT1 (at least, dimension of tumor cannot be estimated with\X0D\\X0A\certainty and margins also indeterminate).\X0D\\X0A\     Regional lymph nodes: pNX\X0D\\X0A\     Distant metastases: not applicable\X0D\\X0A\PATHOLOGIC FINDINGS IN NON-NEOPLASTIC KIDNEY: Insufficient tissue\X0D\\X0A\MER/cb \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D.,  MARK E."
REG1,OTHER,0,494265,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT RENAL MASS\X0D\\X0A\OPER:   RIGHT PARTIAL NEPHRECTOMY \X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX: CLEAR CELL RENAL CELL CARCINOMA  RENAL PARENCHYMAL MARGIN CLEAR. \X0D\\X0A\**INITIALS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RIGHT RENAL LESION (FROZEN SECTION)   tb\X0D\\X0A\2: FAT OVER RENAL TUMOR   bb","Final Diagnosis\X0D\\X0A\1:      PROCEDURE:  KIDNEY: PARTIAL NEPHRECTOMY (WEDGE RESECTION).\X0D\\X0A\     SPECIMEN LATERALITY:  RIGHT.\X0D\\X0A\     TUMOR SIZE:  2.2 CM IN MAXIMUM GROSS DIMENSION.\X0D\\X0A\     TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\     MACROSCOPIC EXTENT OF TUMOR:  TUMOR LIMITED TO KIDNEY.\X0D\\X0A\     HISTOLOGIC TYPE:  CLEAR CELL RENAL CELL CARCINOMA.\X0D\\X0A\     SARCOMATOID FEATURES:  NOT IDENTIFIED. \X0D\\X0A\     HISTOLOGIC GRADE (FUHRMAN NUCLEAR GRADE): GRADE 2.\X0D\\X0A\     MICROSCOPIC TUMOR EXTENSION: TUMOR LIMITED TO KIDNEY.\X0D\\X0A\     MARGINS:  MARGINS UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\     LYMPH/VASCULAR INVASION:  NOT IDENTIFIED. \X0D\\X0A\     PATHOLOGIC STAGING: \X0D\\X0A\          PRIMARY TUMOR:  T1a.\X0D\\X0A\          REGIONAL LYMPH NODES:  NX.\X0D\\X0A\          DISTANT METASTASES:  NOT APPLICABLE.\X0D\\X0A\2:  FAT OVER RENAL TUMOR:\X0D\\X0A\     BENIGN FIBROADIPOSE TISSUE.\X0D\\X0A\**INITIALS\X0D\\X0A\IHC/MER\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **PLACE",,"Gross Description\X0D\\X0A\1: Received fresh for frozen section evaluation labeled \""right renal lesion\"" is\X0D\\X0A\a hemispherical nodular portion of gray brown soft tissue 4.8 x 3.9 x 3.5 cm. \X0D\\X0A\One surface contains tags of yellow fatty tissue consistent with perinephric\X0D\\X0A\fat.  The opposite surface contains tan apparent renal parenchyma.  A 4.5 cm\X0D\\X0A\incision 1.8 cm in depth is present near the base.  Sectioning reveals a\X0D\\X0A\somewhat circumscribed yellow gray nodule 2.0 x 2.2 x 1.7 cm which focally\X0D\\X0A\extends to within approximately 0.3 cm of the closest renal parenchymal margin. \X0D\\X0A\The overlying renal capsule appears attenuated (less than 1 mm focally) but\X0D\\X0A\intact without evidence of extracapsular extension.  Representative section to\X0D\\X0A\include tumor and closest parenchymal margin submitted as frozen section.  The\X0D\\X0A\previously noted incision extends into the base of the tumor.  The tumor\X0D\\X0A\demonstrates broad areas of hemorrhage with areas of yellow white apparent\X0D\\X0A\necrosis.  Blocks 1A through E  multiple representative sections to include all\X0D\\X0A\margins.\X0D\\X0A\**INITIALS\X0D\\X0A\2:  Received in formalin labeled 'fat over renal tumor' is a 17.3 x 11.3 x up to\X0D\\X0A\2.2 cm 126 gram unoriented piece of fatty tissue.  One broad surface is inked\X0D\\X0A\black and the opposite broad surface is inked blue.  The specimen is serially\X0D\\X0A\sectioned showing no focal abnormalities.  Representative sections are submitted\X0D\\X0A\as 2A through 2D.  LW/USO/CMK/in",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,OTHER,0,494277,1,,Clinical Diagnosis and History\X0D\\X0A\RIGHT RENAL CA\X0D\\X0A\OPER:  RIGHT NEPHRECTOMY RADICAL,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RT KIDNEY  rd\X0D\\X0A\2: RECTROPERITONEAL (SIC)  PRE-CAVA MASS rd","Final Diagnosis\X0D\\X0A\1: RIGHT KIDNEY:\X0D\\X0A\     PROCEDURE: RADICAL NEPHRECTOMY.\X0D\\X0A\     SPECIMEN LATERALITY: RIGHT.\X0D\\X0A\     TUMOR SIZE: 7.1 CM IN MAXIMUM GROSS DIMENSION.\X0D\\X0A\     TUMOR FOCALITY: UNIFOCAL.\X0D\\X0A\     MACROSCOPIC EXTENT OF TUMOR: TUMOR EXTENDS INTO MAJOR VEINS AND INTO\X0D\\X0A\         PELVOCALYCEAL SYSTEM.\X0D\\X0A\     HISTOLOGIC TYPE: CLEAR CELL RENAL CELL CARCINOMA.\X0D\\X0A\     SARCOMATOID FEATURES: NOT IDENTIFIED.\X0D\\X0A\     HISTOLOGIC GRADE (FUHRMAN NUCLEAR GRADE): GRADE 4\X0D\\X0A\     MICROSCOPIC TUMOR EXTENSION: TUMOR EXTENDS INTO RENAL SINUS AND INTO\X0D\\X0A\         MAJOR VEINS.\X0D\\X0A\     MARGINS: TUMOR PRESENT AT RENAL VEIN MARGIN.\X0D\\X0A\     PATHOLOGIC STAGING: \X0D\\X0A\          PRIMARY TUMOR: T3a (tumor invades renal vein and renal sinus fat).\X0D\\X0A\          REGIONAL LYMPH NODES: N1 METASTASIS IN REGIONAL LYMPH NODES.\X0D\\X0A\          DISTANT METASTASES: NOT APPLICABLE.\X0D\\X0A\COMMENT: Specimen 1 also had additional fragments of adipose tissue lying free\X0D\\X0A\in the container.  One of these fragments had an 8 mm nodule of tissue which is\X0D\\X0A\tumor.  Without knowing the exact site of origin for this tissue its\X0D\\X0A\significance is uncertain.\X0D\\X0A\2: RETROPERITONEAL PRECAVAL MASS:\X0D\\X0A\     METASTATIC RENAL CELL CARCINOMA PRESENT IN MATTED LYMPH NODES FOCALLY\X0D\\X0A\        GROWING WITH ADIPOSE TISSUE.\X0D\\X0A\**INITIALS \X0D\\X0A\IHC/MER \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **PLACE",,"Gross Description\X0D\\X0A\1:  Received in formalin labeled \""right kidney\"" is an 11.3 x 7.1 x 6.5 cm kidney\X0D\\X0A\with a contiguous 2.1 cm-long segment of mildly dilated ureter.  The kidney is\X0D\\X0A\devoid of fat over the upper pole.  The remainder of the kidney is covered by a\X0D\\X0A\0.3 to 3.1 cm-thick layer of fat.  Detached but within the same container are\X0D\\X0A\multiple shredded fragments of fat which are 7.3 x 5.3 x 3.1 cm in aggregate. \X0D\\X0A\The entire specimen, including the detached pieces of fat, weigh 398 grams.  The\X0D\\X0A\central portion of the kidney is replaced by a multinodular 7.1 x 6.3 x 5.0 cm\X0D\\X0A\partially necrotic-appearing white tan tumor.  The tumor obliterates a portion\X0D\\X0A\of the calyces and displaces the pelvis.  Tumor invades renal pelvic sinus\X0D\\X0A\adipose tissue. The lesion appears to be confined by the capsule and comes to\X0D\\X0A\within 0.1 cm of the peripheral soft tissue margin.  This margin is inked black\X0D\\X0A\for lateral identification. The lesion appears to involve the renal vein and the\X0D\\X0A\process extends into the vein to the ligated margin.  The kidney away from the\X0D\\X0A\lesion shows no other abnormalities.  Within the detached fragments of fat,\X0D\\X0A\there is a 0.8 cm nodule of granular white tissue suggestive of tumor.  No\X0D\\X0A\adrenal gland is included.  Sections are submitted as follows: \X0D\\X0A\1A:  Ureteral and vascular margins.\X0D\\X0A\1B:  Tumor in vein adjacent to margin.\X0D\\X0A\1C:  Periphery of tumor with ink on soft tissue margin.\X0D\\X0A\1D through 1G:  Additional sections of tumor.\X0D\\X0A\1H: section of tumor in renal pelvic adipose tissue\X0D\\X0A\1I:  Kidney away from tumor.\X0D\\X0A\1J:  Nodule from detached pieces of fat.\X0D\\X0A\2;  Received in formalin labeled \""retroperitoneal precava mass\"" is an 8.7 x 5.9\X0D\\X0A\x 4.3 cm, 84-gram multinodular mass, partially covered by membrane, and having\X0D\\X0A\tags of fat and metal sutures attached.  Within the attached soft tissues, there\X0D\\X0A\is a 2.1 cm in length and 0.5 cm in diameter tubal structure, having multiple\X0D\\X0A\clamps along its length.  The surface of the nodular mass is inked and the\X0D\\X0A\specimen is then serially sectioned.  This shows coalescing nodules of partially\X0D\\X0A\necrotic-appearing tumor with the individual nodules ranging from 1.2 to 4.5 cm\X0D\\X0A\in greatest dimension.  This tumor may represent tumor within multiple matted\X0D\\X0A\lymph nodes. Individual lymph nodes are not distinguishable.  Representative\X0D\\X0A\sections are submitted as follows: \X0D\\X0A\2A through 2E:  Nodular components of specimen.\X0D\\X0A\2F:  Sampling of cylindrical tubal structure.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,OTHER,0,494285,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT TESTICULAR CANCER\X0D\\X0A\OPER: LEFT RADICAL ORCHECTOMY,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT TESTICLE    tb\X0D\\X0A\2: LEFT INGUINAL LYMPH NODE   tb","Final Diagnosis\X0D\\X0A\1:  LEFT TESTICLE, RADICAL ORCHIECTOMY:\X0D\\X0A\     CAP TUMOR PROTOCOL\X0D\\X0A\     TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\     TUMOR SIZE:  2.7 X 2.2 X 2.0 CM.\X0D\\X0A\     MACROSCOPIC EXTENT OF TUMOR:  CONFINED TO THE TESTIS.\X0D\\X0A\     HISTOLOGIC TYPE:  SEMINOMA, CLASSIC TYPE.\X0D\\X0A\     MARGINS:  SPERMATIC CORD AND ALL OTHER MARGINS ARE UNINVOLVED BY TUMOR.\X0D\\X0A\     MACROSCOPIC TUMOR EXTENT:  \X0D\\X0A\          TUMOR EXTENDS INTO RETE TESTES.\X0D\\X0A\          NEGATIVE EPIDIDYMIS, HILAR FAT, SPERMATIC CORD AND TUNICA VAGINALIS.\X0D\\X0A\     VASCULAR INVASION:  ABSENT.\X0D\\X0A\2:  LEFT INGUINAL LYMPH NODE, EXCISION:\X0D\\X0A\     METASTATIC SEMINOMA TO A LYMPH NODE.\X0D\\X0A\     METASTATIC DEPOSIT MEASURES 3.0 CM.\X0D\\X0A\COMMENT:  AJCC PATHOLOGIC TUMOR STAGE: T1 N2 MX.\X0D\\X0A\CLS/in/**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\1: Received in formalin designated \""left testicle\"" is a 48 gm radical\X0D\\X0A\orchiectomy specimen which includes a testis encircled by visceral and parietal\X0D\\X0A\tunica and having the adjacent adnexal structures and a contiguous 7.5 cm in\X0D\\X0A\length and up to 2.0 cm in diameter segment of spermatic cord.  The spermatic\X0D\\X0A\cord and the peri-testicular tissues are fatty.  The testis is 3.2 x 3.0 x 2.6\X0D\\X0A\cm.  There are adhesions between the visceral and the parietal tunica. \X0D\\X0A\Sectioning of the testis reveals a well circumscribed 2.7 x 2.2 x 2.0 cm soft\X0D\\X0A\tan mass.  The adjacent testicular parenchyma is atrophic appearing.  The lesion\X0D\\X0A\appears to be confined to the testis and does not grossly involved the adjacent\X0D\\X0A\structures or the spermatic cord.  Sections are submitted as follows:\X0D\\X0A\1A through 1P- entire testis sequentially submitted\X0D\\X0A\1Q and 1R  representative sections spermatic cord close to testis\X0D\\X0A\1S and 1T  representative sections of remainder of spermatic cord\X0D\\X0A\1U  spermatic cord margin\X0D\\X0A\2: Received in formalin designated \""left inguinal lymph node\"" is a 3.3 x 3.2 x\X0D\\X0A\2.2 cm well circumscribed nodule of soft to firm tan tissue rimmed in fat.\X0D\\X0A\Representative sections are submitted as 2A through 2C.\X0D\\X0A\**INITIALS \X0D\\X0A\/cb",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,
REG1,OTHER,0,494316,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT RENAL MASS\X0D\\X0A\OPER:  LEFT PARTIAL NEPHRECTOMY LAPAROSCOPIC WITH DA VINCI,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: PERITUMOR FAT    tb\X0D\\X0A\2: LEFT RENAL MASS    tb","Final Diagnosis\X0D\\X0A\1: SUBMITTED AS \""PERITUMOR FAT\"":\X0D\\X0A\     BENIGN ADIPOSE TISSUE.\X0D\\X0A\     NEGATIVE FOR MALIGNANCY. \X0D\\X0A\2: LEFT KIDNEY, LEFT PARTIAL NEPHRECTOMY:\X0D\\X0A\     TUMOR SIZE: 1.5 X 1.3 X 1.3 CM.\X0D\\X0A\     TUMOR FOCALITY: UNIFOCAL.\X0D\\X0A\     MACROSCOPIC EXTENT OF TUMOR: TUMOR LIMITED TO KIDNEY.\X0D\\X0A\     HISTOLOGIC TYPE: CLEAR CELL RENAL CELL CARCINOMA.\X0D\\X0A\     SARCOMATOID FEATURES: NOT IDENTIFIED.\X0D\\X0A\     TUMOR NECROSIS: NOT IDENTIFIED.\X0D\\X0A\     HISTOLOGIC GRADE: FUHRMAN NUCLEAR GRADE 2 OUT OF 4.\X0D\\X0A\     MICROSCOPIC TUMOR EXTENT: TUMOR LIMITED TO KIDNEY\X0D\\X0A\     MARGIN STATUS: MARGINS UNINVOLVED BY INVASIVE CARCINOMA.\X0D\\X0A\     LYMPH/VASCULAR INVASION: NOT IDENTIFIED.\X0D\\X0A\     AJCC PATHOLOGIC TUMOR STAGE: T1a.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\1:  Received in formalin labeled \""peritumor fat\"" is an unoriented partially torn\X0D\\X0A\portion of yellow pink adipose tissue measuring 4.5 x 4.0 x 1.5 cm.  Located\X0D\\X0A\along one surface of the fat is a thin membranous pink 2.0 x 1.0 cm area,\X0D\\X0A\possibly representing an area of the renal capsule.  All of the fatty border is\X0D\\X0A\inked in blue and the entire specimen is serially sectioned perpendicular to the\X0D\\X0A\membranous edge.  There are no nodules or masses and the cut surface is firm,\X0D\\X0A\yellow and homogenous throughout.  The entire specimen is submitted in blocks 1A\X0D\\X0A\through 1E.\X0D\\X0A\2:  Received in formalin labeled \""left renal mass\"" is a 4-gram, 2.5 x 2.3 x 1.5\X0D\\X0A\cm wedge of renal tissue.  One surface is covered by a centrally bulging area of\X0D\\X0A\capsule.  This surface will be inked in blue and the opposite parenchymal margin\X0D\\X0A\will be inked in yellow. On sectioning, extending to within less than 1 mm of\X0D\\X0A\the capsular edge and to within less than 1 mm of the parenchymal margin is a\X0D\\X0A\well-defined soft hemorrhagic red brown to slightly orange-appearing variegated\X0D\\X0A\1.5 x 1.3 x 1.3 cm tumor mass which has distinct borders.  The entire specimen\X0D\\X0A\is submitted in blocks 2A through 2E.  DH/**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis,,,
REG1,OTHER,0,494372,1,,Clinical Diagnosis and History\X0D\\X0A\MULTINODULAR GOITER\X0D\\X0A\OPER:  TOTAL THYROIDECTOMY\X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX:  FOLLICULAR LESION WITH FEATURES WORRISOME FOR MINIMALLY INVASIVE\X0D\\X0A\CARCINOMA.  CMK/in/IHC/MER/CLS\X0D\\X0A\#2FSDX:  FAVOR ABNORMAL THYROID TISSUE.  NO DEFINITE PARATHYROID IDENTIFIED. \X0D\\X0A\CMK/in IHC/MER,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RT.THYROID CHECK FOR PARATHYROID FROZEN lg\X0D\\X0A\2: R/O PARATHYROID LEFT THYROID FROZEN lg\X0D\\X0A\3: LEFT THYROID lg","Final Diagnosis\X0D\\X0A\1: RIGHT THYROID:     ENCAPSULATED FOLLICULAR LESION (4.7 CM) WITH FEATURES\X0D\\X0A\WORRISOME FOR ENCAPSULATED FOLLICULAR CARCINOMA WITH MULTIFOCAL ANGIOINVASION\X0D\\X0A\AND FOCI OF CAPSULAR INVASION.\X0D\\X0A\2: RULE OUT PARATHYROID, LEFT THYROID:\X0D\\X0A\     THYROID TISSUE WITH ADENOMATOUS CHANGE.\X0D\\X0A\3: LEFT THYROID:\X0D\\X0A\     PROCEDURE: LEFT HEMITHYROIDECTOMY.\X0D\\X0A\     SPECIMEN INTEGRITY: INTACT.\X0D\\X0A\     SPECIMEN SIZE: 3.7 X 2.4 X 1.7 CM WITH ISTHMUS 1.2 X 1.0 X 0.5 CM.\X0D\\X0A\     SPECIMEN WEIGHT: 7 GRAMS.\X0D\\X0A\     TUMOR FOCALITY: UNIFOCAL.\X0D\\X0A\     TUMOR SIZE: 3.5 MM IN MAXIMUM MICROSCOPIC DIMENSION.\X0D\\X0A\     HISTOLOGIC TYPE: PAPILLARY CARCINOMA, CLASSICAL TYPE.\X0D\\X0A\     MARGINS: MARGINS UNINVOLVED BY PAPILLARY CARCINOMA.\X0D\\X0A\     TUMOR CAPSULE: PARTIALLY ENCAPSULATED.\X0D\\X0A\     LYMPH-VASCULAR INVASION: NOT IDENTIFIED.\X0D\\X0A\     EXTRATHYROIDAL EXTENSION: NOT IDENTIFIED.\X0D\\X0A\     PATHOLOGIC STAGING:\X0D\\X0A\          PRIMARY TUMOR: T1a.\X0D\\X0A\          REGIONAL LYMPH NODES: NX (NO LYMPH NODES IDENTIFIED).\X0D\\X0A\          DISTANT METASTASES: NOT APPLICABLE.\X0D\\X0A\COMMENT: The criteria for diagnosis of minimally invasive follicular carcinoma\X0D\\X0A\are not universally agreed upon. This case will be seen in consultation by Dr.\X0D\\X0A\**NAME[ZZZ YYY], an expert in thyroid pathology.  Pathologic staging of the tumor in\X0D\\X0A\specimen 1 (right thyroid) will take place after receiving the consultation.\X0D\\X0A\**INITIALS\X0D\\X0A\IHC/MER/CLS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D., **PLACE",,"Gross Description\X0D\\X0A\1:  Received fresh for frozen diagnosis designated 'right thyroid' is an\X0D\\X0A\unoriented portion of lobulated red tan purple tissue consistent with lobe of\X0D\\X0A\thyroid measuring 6.8 x up to 4.3 x up to 4.5 cm.  The specimen weighs 49 grams.\X0D\\X0A\ Present about one surface which is felt to possibly be the posterior surface\X0D\\X0A\the capsule is shredded and a nodule protrudes through this area.  The nodule\X0D\\X0A\has been ruptured over an area measuring 3.0 x 1.5 cm.  No definite parathyroid\X0D\\X0A\identified.  Ink is placed about the margin with an attempt to avoid inking the\X0D\\X0A\area of capsular rupture and the shredded nodule.  The nodule is pink tan\X0D\\X0A\measuring 4.7 x 4.0 x 3.8 cm.  In most areas it has a thin gray white capsule\X0D\\X0A\measuring up to 1 mm in thickness.  A questionable calcification is noted on\X0D\\X0A\sectioning in a few areas.  At one pole there is red purple thyroid tissue with\X0D\\X0A\a somewhat more normal appearance.  The nodule is well demarcated from adjacent\X0D\\X0A\thyroid tissue.  Sections submitted on two blocks to include the nodule for\X0D\\X0A\frozen diagnosis. The remainder of the specimen is totally submitted for\X0D\\X0A\permanent sections in 1A through 1AJ.  CMK/in \X0D\\X0A\2:  Received fresh for frozen diagnosis designated \""rule out parathyroid\"" is\X0D\\X0A\pink tan tissue 3 x 2 x 1 mm.  It weighs 0.014 grams.  Totally submitted for\X0D\\X0A\frozen diagnosis.  **INITIALS\X0D\\X0A\3: Received in formalin labeled \""left thyroid\"" is a 3.7 x 2.4 x 1.7 cm lobe of\X0D\\X0A\thyroid tissue having a 1.2 x 1.0 x 0.5 cm isthmus attached.  The specimen\X0D\\X0A\weighs 7 grams and is externally unremarkable.  The specimen is almost entirely\X0D\\X0A\covered by capsule.  No parathyroid tissue is seen.  The margins are inked and\X0D\\X0A\the specimen is serial sectioned.  This shows a beefy red brown cut surface with\X0D\\X0A\two distinct lesions within.  At the upper pole, there is a 0.5 cm\X0D\\X0A\intraparenchymal nodule of tan tissue.  Within the mid portion of the left lobe,\X0D\\X0A\there is a 0.4 cm well-circumscribed nodule of white tan tissue.  The entire\X0D\\X0A\specimen is submitted as follows:\X0D\\X0A\3A  isthmus\X0D\\X0A\3B through 3K  remainder of specimen submitted inferior to superior \X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Feb 10 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Feb 10 2012]     By:  **NAME[WWW, VVV]\X0D\\X0A\     Date Reported:     **DATE[Feb 10 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned consultation report from Dr. **NAME[ZZZ YYY] from Genzyme\X0D\\X0A\Laboratories in electronic medical file.\X0D\\X0A\Their report, in part:\X0D\\X0A\FINAL DIAGNOSIS (FORMAL LETTER TO FOLLOW):\X0D\\X0A\- \""MIXED\"" CARCINOMA (FOLLICULAR, ONCOCYTIC AND PAPILLARY) (1A-1X).\X0D\\X0A\- PORTION OF THYROID \""MIXED\"" CARCINOMA (NOT) PARATHYROID) (SLIDE 2).\X0D\\X0A\- PAPILLARY MICROCARCINOMA (SLIDE 3D).\X0D\\X0A\Signed: **NAME[ZZZ YYY], M.D.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[UUU], M.D., **NAME[TTT]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Feb 14 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Feb 14 2012]     By:  **NAME[SSS, RRR]\X0D\\X0A\     Date Reported:     **DATE[Feb 14 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\For complete details see the scanned outside consultation report from Dr. **NAME[ZZZ]\X0D\\X0A\**NAME[YYY] in the electronic medical records file.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Feb 14 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Feb 15 2012]     By:  **NAME[XXX], M.D., **PLACE\X0D\\X0A\     Date Reported:     **DATE[Feb 15 2012]     * Amended *    \X0D\\X0A\Addendum Comment\X0D\\X0A\AMENDED REPORT  Typographical Error:  Amendment reflects the change of the word\X0D\\X0A\\""simple\"" to \""single\"" under the Synoptic Report header. (/pkm)\X0D\\X0A\A synoptic type report has already been issued for findings in the left thyroid\X0D\\X0A\(specimen #3).  The following represents synoptic findings on specimens 1 and 2\X0D\\X0A\based on Dr. **NAME[YYY]'s letter of consultation.  Because Dr. **NAME[YYY] felt specimen 2\X0D\\X0A\also represented portions of tumor largest represented in specimen 1, margins\X0D\\X0A\cannot be stated with certainty regarding the tumor in specimen 1. \X0D\\X0A\SYNOPTIC REPORT:\X0D\\X0A\     THYROID GLAND: RESECTION.\X0D\\X0A\     PROCEDURE: TOTAL THYROIDECTOMY.\X0D\\X0A\     SPECIMEN INTEGRITY: FRAGMENTED (TUMOR PRESENT IN BOTH SPECIMENS 1 AND 2).\X0D\\X0A\     SPECIMEN SIZE: RIGHT LOBE: 6.8 X 4.3 X 4.5 CM.\X0D\\X0A\     TUMOR FOCALITY: SINGLE FOCUS OF TUMOR IN RIGHT LOBE.\X0D\\X0A\     TUMOR SIZE: TUMOR IN RIGHT LOBE MEASURES 4.7 X 4.0 X 3.8 CM.\X0D\\X0A\     HISTOLOGIC TYPE: OTHER (MIXED CARCINOMA, FOLLICULAR WITH FOCAL ONCOCYTIC\X0D\\X0A\CHANGES \X0D\\X0A\          AND PAPILLARY).\X0D\\X0A\     MARGINS: CANNOT BE ASSESSED (SEE COMMENT).\X0D\\X0A\     TUMOR CAPSULE: PARTIALLY ENCAPSULATED.\X0D\\X0A\     TUMOR CAPSULAR INVASION: PRESENT, EXTENSIVE.\X0D\\X0A\     LYMPH-VASCULAR INVASION: PRESENT, EXTENSIVE.\X0D\\X0A\     EXTRA THYROIDAL EXTENSION: NOT IDENTIFIED.\X0D\\X0A\     PATHOLOGIC TUMOR STAGING FOR RIGHT LOBE ONLY: \X0D\\X0A\          PRIMARY TUMOR: T3 (TUMOR MORE THAN 4 CM).\X0D\\X0A\          REGIONAL LYMPH NODES: Nx (NO LYMPH NODES IDENTIFIED).\X0D\\X0A\          DISTANT METASTASES: NOT APPLICABLE.\X0D\\X0A\COMMENT: Although tumor is not identified at an inked margin, there was\X0D\\X0A\shredding of the capsule of the right lobe in one area and tissue submitted as\X0D\\X0A\specimen 2 is felt to represent tumor by Dr. **NAME[YYY].  Without knowing the exact\X0D\\X0A\site of origin of specimen 2 I do not feel a definitive statement can be made\X0D\\X0A\regarding the margins for this tumor.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **PLACE\X0D\\X0A\Amendments for SUPPLEMENTAL REPORT (**DATE[Feb 14 2012])\X0D\\X0A\Amended:  **DATE[Feb 15 2012] by **NAME[QQQ, PPP OOO]\X0D\\X0A\Reason:     TYPOGRAPHICAL  ERROR\X0D\\X0A\     Amendment reflects the change of the word \""simple\"" to \""single\"" under the\X0D\\X0A\Synoptic Report header. (/pkm)\X0D\\X0A\Previous Signout Date:  **DATE[Feb 14 2012]"
REG1,OTHER,0,494378,1,,Clinical Diagnosis and History\X0D\\X0A\PELVIC MASS\X0D\\X0A\OPER: TAH BSO\X0D\\X0A\FROZEN SECTION\X0D\\X0A\Intraoperative Consult\X0D\\X0A\FS: POORLY DIFFERENTIATED CARCINOMA FAVOR SEROUS (CLS) REPORTED AT 8:47 AM,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT TUBE AND OVARY-FS-ls\X0D\\X0A\2: UTERUS, R TUBE AND OVARY-ls\X0D\\X0A\3: SIGMOID COLON NODULE-ls\X0D\\X0A\4: RT PELVIC LYMPH NODES-ls\X0D\\X0A\5: LT PELVIC LYMPH NODES-ls\X0D\\X0A\6: RIGHT PERI AORTIC LYMPH NODES-ls\X0D\\X0A\7: LEFT PERIAORTIC LYMPH NODES-ls\X0D\\X0A\8: LT PERA COLIC GUTTER-ls\X0D\\X0A\9: RT PERA COLIC GUTTER-ls\X0D\\X0A\10: OMENTUM-ls\X0D\\X0A\11: LT HEMI DIAPHRAGM-ls\X0D\\X0A\12: RT HEMI DIAPHRAGM-ls","Final Diagnosis\X0D\\X0A\1: LEFT OVARY AND FALLOPIAN TUBE, LEFT SALPINGO-OOPHORECTOMY:\X0D\\X0A\     TUMOR SIZE: 479 GRAMS, 15 X 10 X 6 CM.\X0D\\X0A\     TUMOR SITE: OVARY AND FALLOPIAN TUBE.\X0D\\X0A\     HISTOLOGIC TYPE: SEROUS CARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: LOW-GRADE.\X0D\\X0A\     EXTENT OF TUMOR INVOLVEMENT: BOTH OVARY AND FALLOPIAN TUBE.\X0D\\X0A\     OVARIAN SURFACE INVOLVEMENT: PRESENT.\X0D\\X0A\     LEFT OVARY CAPSULE: NOT INTACT.\X0D\\X0A\2: UTERUS WITH RIGHT OVARY AND FALLOPIAN TUBE, HYSTERECTOMY WITH RIGHT \X0D\\X0A\    SALPINGO-OOPHORECTOMY:\X0D\\X0A\     TUMOR SIZE: 150 GRAMS, 12 X 10 X 5 CM.\X0D\\X0A\     TUMOR SITE: OVARY AND FALLOPIAN TUBE.\X0D\\X0A\     HISTOLOGIC TYPE: SEROUS CARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: LOW-GRADE.\X0D\\X0A\     EXTENT OF TUMOR INVOLVEMENT: BOTH OVARY AND FALLOPIAN TUBE.\X0D\\X0A\     OVARIAN SURFACE INVOLVEMENT: PRESENT.\X0D\\X0A\     RIGHT OVARY CAPSULE: NOT INTACT.\X0D\\X0A\     UTERINE FINDINGS:\X0D\\X0A\         METASTATIC SEROUS CARCINOMA TO ENDOCERVIX FORMING A 1.5 CM POLYPOIDAL\X0D\\X0A\MASS.\X0D\\X0A\         UTERINE SEROSAL TUMOR IMPLANTS. \X0D\\X0A\         INACTIVE BASALIS TYPE ENDOMETRIUM.\X0D\\X0A\         TWO UTERINE LEIOMYOMAS MEASURING UP TO 1.4 CM.\X0D\\X0A\3: SIGMOID COLON NODULE:\X0D\\X0A\     METASTATIC SEROUS CARCINOMA.\X0D\\X0A\4: RIGHT PELVIC LYMPH NODES:\X0D\\X0A\     BENIGN LYMPH NODES, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\5: LEFT PELVIC LYMPH NODES:\X0D\\X0A\     BENIGN LYMPH NODES, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\6: RIGHT PERIAORTIC LYMPH NODES:\X0D\\X0A\     BENIGN LYMPH NODES, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\7: LEFT PERIAORTIC LYMPH NODES:\X0D\\X0A\     BENIGN LYMPH NODES, NEGATIVE FOR MALIGNANCY.\X0D\\X0A\8: LEFT PARACOLIC GUTTER:\X0D\\X0A\     CHRONIC SEROSITIS WITH MICROCALCIFICATIONS, NO MALIGNANCY IDENTIFIED.\X0D\\X0A\9: RIGHT PARACOLIC GUTTER:\X0D\\X0A\     CHRONIC SEROSITIS, NO MALIGNANCY IDENTIFIED.\X0D\\X0A\10: OMENTUM: \X0D\\X0A\     METASTATIC SEROUS CARCINOMA, 3.5 CM DEPOSIT.\X0D\\X0A\11: LEFT HEMIDIAPHRAGM:\X0D\\X0A\     BENIGN FIBROMUSCULAR TISSUE, NO MALIGNANCY IDENTIFIED.\X0D\\X0A\12: RIGHT HEMIDIAPHRAGM:\X0D\\X0A\      BENIGN FIBROADIPOSE TISSUE, NO MALIGNANCY IDENTIFIED.\X0D\\X0A\COMMENT: See microscopic section below for Summary of CAP Tumor Reporting\X0D\\X0A\Protocol and AJCC Pathologic Tumor Stage.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D., **NAME[WWW]",,"Gross Description\X0D\\X0A\1: Received fresh for frozen section evaluation labeled \""left tube and ovary\"" is\X0D\\X0A\a 479 gm 15.0 x 10.0 x 6.0 cm focally disrupted encapsulated soft tissue mass\X0D\\X0A\designated \""left tube and ovary\"".  Draped over the external surface focally\X0D\\X0A\there is a partially sutured somewhat tubular structure reminiscent of fallopian\X0D\\X0A\tube without a fimbriated end.  The external surface demonstrates prominent\X0D\\X0A\vessels, focal attached blood clot and areas reminiscent of tan exudate. \X0D\\X0A\Opening up the specimen reveals a partially cystic cavity with attached\X0D\\X0A\partially necrotic nodules with a fleshy tan cut surface.  Also included\X0D\\X0A\separate from the specimen are small pieces of fleshy tan tumor nodules ranging\X0D\\X0A\up to 2.0 cm.  Representative sections including the fallopian tube are\X0D\\X0A\submitted in blocks 1A-1P. A single frozen section control block submitted as\X0D\\X0A\FSC1A.\X0D\\X0A\**INITIALS\X0D\\X0A\2: In formalin is a uterus with attached right ovary and fallopian tube.  The\X0D\\X0A\right tubo-ovarian complex is overgrown with tan pink tumor forming confluent\X0D\\X0A\nodules with overall dimensions of 12.0 x 10.0 x 5.0 cm.  A fimbriated\X0D\\X0A\trumpet-shaped fallopian tube measures up to 7.0 cm in length and 1.9 cm in\X0D\\X0A\diameter toward the distal one-half portion of the specimen.  Sectioning through\X0D\\X0A\the ovary reveals a cystic space filled with brown blood clot material.  The\X0D\\X0A\cystic space measures up to 2.0 cm in length.  Tumor extensively involves the\X0D\\X0A\external surface. Approximate weight of this tumor mass is 150 gm. Note also\X0D\\X0A\that there is a detached 7.0 x 6.0x 2.0 cm portion of blood clot.  Without the\X0D\\X0A\tumor and attached right ovary and fallopian tube the uterus weighs 87 gm and\X0D\\X0A\measures 9.5 cm in fundic to cervical length, 6.5 cm in fundic lateral dimension\X0D\\X0A\and 3.8 cm in fundic thickness.  The serosal surface shows patchy areas of\X0D\\X0A\hemorrhage and has a few fibrous adhesions.  The attached cervix measures 4.5 x\X0D\\X0A\4.0 cm in cross dimension and is covered by a tan focally hemorrhagic but smooth\X0D\\X0A\ectocervical mucosa.  The cervical os probes patent and the uterine cavity\X0D\\X0A\sounds to a depth of 7.5 cm.  The transformation zone is well demarcated.  The\X0D\\X0A\endocervical mucosa appears mucoid with a 1.0 cm polypoidal elevation.  The\X0D\\X0A\endometrium measures 0.2 cm.  The adjacent myometrium measures up to 2.5 cm in\X0D\\X0A\thickness and contains a single well demarcated nodule with a white whorled cut\X0D\\X0A\surface characteristic of leiomyoma.  It measures 1.4 cm.  No other discrete\X0D\\X0A\focal lesion is identified. Summary of sections:\X0D\\X0A\2A  2F  right tubo-ovarian complex\X0D\\X0A\2G  2H  cervix / endocervix\X0D\\X0A\2I  2J  endocervix/polypoidal area\X0D\\X0A\2K  2L  endomyometrium and leiomyoma\X0D\\X0A\2M  uterine serosa\X0D\\X0A\**INITIALS\X0D\\X0A\3: In formalin designated \""sigmoid colon\"" is soft tissue measuring 2.2 x 1.5 x\X0D\\X0A\1.0 cm bisected and entirely submitted block 3A.\X0D\\X0A\4: In formalin designated \""right pelvic lymph nodes\"" are several pieces of fatty\X0D\\X0A\tissue containing nodules consistent with lymph nodes ranging up to 2.5 cm. \X0D\\X0A\Separate areas of nodularity are submitted in blocks 4A  4C.\X0D\\X0A\5: In formalin designated \""left pelvic lymph nodes\"" are three portions of fatty\X0D\\X0A\tissue containing separate areas of nodularity ranging up to 3.0 x 2.0 x 1.0 cm.\X0D\\X0A\ Separate areas of nodularity are submitted in blocks 5A and 5B.  The bisected\X0D\\X0A\area of nodularity is submitted in block 5C.\X0D\\X0A\6: In formalin designated \""right periaortic lymph nodes\"" is fat containing an\X0D\\X0A\area of nodularity ranging up to 3.0 x 1.0 x 1.0 cm.  Entirely submitted in\X0D\\X0A\blocks 6A and 6B.\X0D\\X0A\7: In formalin designated \""left periaortic lymph nodes\"" are two somewhat nodular\X0D\\X0A\pieces of soft tissue measuring 3.0 x 2.0 x 1.0 cm and 2.5 x 1.5 x 1.5 cm. \X0D\\X0A\After removing staples the entire specimen is submitted in block 7A and 7B.  \X0D\\X0A\8: In formalin designated \""left pericolic gutter\"" is a 2.0 x 1.0 x 0.6 cm\X0D\\X0A\portion of tan and fatty tissue.  Sectioned and entirely submitted in block 8A.\X0D\\X0A\9: In formalin designated \""right pericolic gutter\"" is a piece of tan and fatty\X0D\\X0A\tissue measuring 1.6 x 1.0 x 0.3 cm.  Sectioned and entirely submitted in block\X0D\\X0A\9A.\X0D\\X0A\10: In formalin designated \""omentum\"" is a 159 gram apron of omental fat with\X0D\\X0A\overall dimensions of approximately 45.0 x 15.0 x 1.0 cm.  Sectioning reveals\X0D\\X0A\focal nodularity in an area measuring 3.5 x 1.5 x 1.0 cm.  Representative\X0D\\X0A\sections are submitted in blocks 10A  10E.\X0D\\X0A\11: In formalin designated \""left hemidiaphragm\"" is a 1.0 x 0.5 x 0.5 cm piece of\X0D\\X0A\tan gray soft tissue bisected and entirely submitted 11A.\X0D\\X0A\12: In formalin designated \""right hemidiaphragm\"" is a tan pink soft tissue\X0D\\X0A\fragment measuring 1.5 x 1.0 x 0.5 cm.  entirely submitted block 12A.   **INITIALS","Microscopic Description\X0D\\X0A\Incorporated in diagnosis.\X0D\\X0A\CAP SUMMARY TUMOR REPORTING PROTOCOL:\X0D\\X0A\Specimens: Uterus, cervix, right and left ovaries and fallopian tubes.\X0D\\X0A\Procedure: Hysterectomy with bilateral salpingo-oophorectomy, peritoneal\X0D\\X0A\biopsies.\X0D\\X0A\Lymph Node Sampling: Performed.\X0D\\X0A\Specimen Integrity: Right and left ovaries- Fragmented and non-intact capsules.\X0D\\X0A\Primary Tumor Site: Right and left ovaries and fallopian tubes.\X0D\\X0A\Ovarian Surface Involvement: Present.\X0D\\X0A\Tumor Size: Right ovary and fallopian tube-150 grams, 12 x 10 x 5 cm; Left ovary\X0D\\X0A\and fallopian tube-479 grams, 15 x 10 x 6 cm.\X0D\\X0A\Histologic Type: Serous carcinoma.\X0D\\X0A\Histologic Grade: Low-grade.\X0D\\X0A\Serosal Implants: Present (uterine and omental).\X0D\\X0A\Extent of Involvement of Other Tissue/Organs: Endocervix, omentum (3.5 cm\X0D\\X0A\deposit) and uterine serosa.\X0D\\X0A\Regional Lymph Nodes: No regional lymph node metastasis identified.\X0D\\X0A\AJCC Pathologic Tumor Stage: mT3cN0Mx.\X0D\\X0A\**INITIALS",,,
REG1,OTHER,0,494674,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\bladder tumor\X0D\\X0A\,"CYSTOSCOPY TURBT WITH FULGERATION\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3062 - SUR PATH IV\X0D\\X0A\P3063 - SUR PATH V\X0D\\X0A\ \X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[ZZZ,YYY M]\X0D\\X0A\**INSTITUTION\X0D\\X0A\201 PARK STREET\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\TRAVELSTED,MELISSA APRN\X0D\\X0A\CLUBMD\X0D\\X0A\1065 **NAME[XXX] ST, **ROOM **PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH IV, SUR PATH V\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH IV (**DATE[Dec 11 11]-1159)\X0D\\X0A\SUR PATH V (**DATE[Dec 11 11]-1159)\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\A.  URINARY BLADDER, TRANSURETHRAL RESECTION:\X0D\\X0A\HIGH-GRADE NON-INVASIVE PAPILLARY UROTHELIAL CARCINOMA.\X0D\\X0A\B.  URINARY BLADDER, TUMOR BASE, BIOPSY:\X0D\\X0A\NEGATIVE FOR TUMOR.\X0D\\X0A\NO SIGNIFICANT HISTOPATHOLOGIC CHANGE.\X0D\\X0A\MUSCULARIS PROPRIA PRESENT.\X0D\\X0A\ \X0D\\X0A\88307, 88305\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\The specimen is received in two (2) containers.\X0D\\X0A\ \X0D\\X0A\A.  The first container is received designated as \""bladder tumor\"" and consists of a 1.5 x\X0D\\X0A\0.8 x 0.3 cm. aggregate of tannish-pink soft tissue.  The aggregate is submitted in toto in\X0D\\X0A\cassette A.\X0D\\X0A\ \X0D\\X0A\B.  The remaining container is received designated as \""bladder tumor base\"" and consists of\X0D\\X0A\two single irregularly-shaped fragments of gray soft tissue.  Each measures 0.3 cm. in\X0D\\X0A\greatest dimension.  They are submitted in toto in cassette B.\X0D\\X0A\",MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\A-B.  Microscopic review was performed.\X0D\\X0A\,SPECIMEN\X0D\\X0A\ \X0D\\X0A\A.  BLADDER TUMOR\X0D\\X0A\B.  BLADDER TUMOR BASE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT,,
REG1,OTHER,0,494960,1,,"HISTORY: Right (UPJ) ureteral calculus, bladder cancer, hydronephrosis.","ICD9 CODES: 188.9, ,""","DIAGNOSIS: BLADDER TUMOR, TURBT:         PAPILLARY UROTHELIAL CARCINOMA, LOW-GRADE.         NO EVIDENCE OF INVASION.         MUSCLE IS NOT PRESENT IN THE BIOPSY.",,"GROSS: Received in formalin and labeled with the patient's name is \""bladder tumor\"" and consists of a tan fragment of tissue measuring 1.2 x 1 x up to 0.3 cm.  The specimen is submitted for TE.  DT:  **DATE[Jan 04 12]","MICRO: Sections demonstrate papillary urothelial carcinoma.  The tumor is low-grade.  There is no evidence of lamina propria invasion.  Muscle is not present in the biopsy.  DT: **DATE[Jan 07 12] (KSB, bsp)","PROCEDURE: Cystoscopy, TURBT, stent (R), ESWL (R).\X0D\\X0A\SPECIMEN(S): Bladder tumor.",,
REG1,OTHER,0,495087,1,,CLINICAL HISTORY\X0D\\X0A\ \X0D\\X0A\nodule x2 right lobe thyroid\X0D\\X0A\,"THYROID LOBECTOMY\X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\CODES: P3063 - SUR PATH V\X0D\\X0A\ \X0D\\X0A\COPIES TO:\X0D\\X0A\**NAME[ZZZ,YYY]\X0D\\X0A\411 **NAME[M M XXX WWW] BLVD\X0D\\X0A\**PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\**NAME[VVV,UUU M].\X0D\\X0A\MEDICAL ARTS BUILDING\X0D\\X0A\**STREET-ADDRESS, **ROOM **PLACE, KY **ZIP-CODE\X0D\\X0A\**PHONE\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH V\X0D\\X0A\ \X0D\\X0A\PROCEDURES: SUR PATH V (**DATE[Apr 20 12]-0909)\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\ \X0D\\X0A\THYROID LOBE, RIGHT:\X0D\\X0A\PAPILLARY THYROID CARCINOMA.\X0D\\X0A\MAXIMUM TUMOR DIAMETER 1 CM.\X0D\\X0A\TUMOR EXTENDS TO WITHIN LESS THAN 1 MM OF THE SURGICAL MARGIN.\X0D\\X0A\HURTHLE CELL ADENOMA.\X0D\\X0A\FOLLICULAR ADENOMA.\X0D\\X0A\ \X0D\\X0A\CAP PROTOCOL:\X0D\\X0A\ \X0D\\X0A\Specimen Type:  Thyroid gland resection\X0D\\X0A\Procedure:  Partial thyroidectomy\X0D\\X0A\Specimen Laterality:  Right, received in formalin\X0D\\X0A\Specimen Integrity:  Fragmented\X0D\\X0A\Specimen Size:  Right lobe - 4.2 x 2.5 x 2.1 cm.\X0D\\X0A\Specimen Weight:  5 grams\X0D\\X0A\Tumor Focality:  Unifocal\X0D\\X0A\Tumor Laterality:  Right lobe\X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\DIAGNOSIS              (Continued)\X0D\\X0A\ \X0D\\X0A\Tumor Size:  1 cm.\X0D\\X0A\Histologic Type:  Papillary carcinoma\X0D\\X0A\Variant:  Classical\X0D\\X0A\Architecture:  Classical\X0D\\X0A\Cytomorphology:  Classical\X0D\\X0A\Histologic Grade:  G1, well-differentiated\X0D\\X0A\Margins:  Margins uninvolved by carcinoma\X0D\\X0A\Distance of Invasive Carcinoma to the Closest Margin:  Less than 1 mm\X0D\\X0A\Tumor Capsule:  Partially encapsulated\X0D\\X0A\Tumor Capsular Invasion:  Present\X0D\\X0A\Extent:  Widely invasive\X0D\\X0A\Lymph-Vascular Invasion:  Not identified\X0D\\X0A\Perineural Invasion:  Not identified\X0D\\X0A\Extrathyroidal Extension:  Not identified\X0D\\X0A\Pathologic Staging (pTNM):\X0D\\X0A\Primary Tumor (pT):  pT1a\X0D\\X0A\Regional Lymph Nodes (pN):  pNX\X0D\\X0A\Distant Metastasis (pM):  Not applicable\X0D\\X0A\Additional Pathologic Findings:\X0D\\X0A\Hurthle cell adenoma\X0D\\X0A\Follicular adenoma\X0D\\X0A\ \X0D\\X0A\88307\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\ \X0D\\X0A\Received in formalin is a segment of thyroid gland labeled \""right\"" and a small tan nodule.\X0D\\X0A\The nodule measures approximately 1.2 x 0.7 x 0.6 cm. in greatest dimensions.  The external\X0D\\X0A\surface is marked with black ink.  The specimen is sectioned and submitted in toto in A.\X0D\\X0A\The thyroid lobe weighs 5 grams and measures 4.2 x 2.5 x 1.2 cm. in greatest dimensions.\X0D\\X0A\There is a defect near one pole.  The external surface is brown-gray and slightly irregular.\X0D\\X0A\On sectioning, near the opposite pole of the defect is seen a round white oval structure\X0D\\X0A\measuring approximately 0.7 cm. in diameter.  The remainder of the cut surface of the\X0D\\X0A\thyroid is reddish-brown and granular.  Representative sections are submitted in B-E with\X0D\\X0A\the white nodule in B-D.\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT\X0D\\X0A\ \X0D\\X0A\\T\a9.3L\X0D\\X0A\ \X0D\\X0A\",MICROSCOPIC EXAMINATION\X0D\\X0A\ \X0D\\X0A\Sections consist of segments of thyroid gland within which is seen a focus of classical type\X0D\\X0A\papillary thyroid carcinoma.  Tumor cells in papillary-like formations and have enlarged\X0D\\X0A\round nuclei with nuclear clearing and numerous linear grooves.  The tumor extends through a\X0D\\X0A\thick capsule into the surrounding benign thyroid tissue.  In one area is seen a small\X0D\\X0A\individual malignant acini several millimeters from the tumor.  The tumor extends to within\X0D\\X0A\less than 1 mm of the surgical margin focally.  Maximum tumor size is 1 cm.  Lymphovascular\X0D\\X0A\invasion is not identified.  Extrathyroidal extension is not noted.\X0D\\X0A\ \X0D\\X0A\A second smaller 3 mm diameter tumor is noted in the thyroid consisting of a Hurthle cell\X0D\\X0A\adenoma.\X0D\\X0A\ \X0D\\X0A\The second separately received segment of thyroid gland appears to be that of a benign\X0D\\X0A\adenoma.\X0D\\X0A\,SPECIMEN\X0D\\X0A\ \X0D\\X0A\RIGHT LOBE THYROID\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\PATHOLOGY REPORT,,
REG1,OTHER,0,495149,1,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,**NAME[YYY M]. Status: SOUT","MICROSCOPIC INTERPRETATION: BLADDER TUMOR: PAPILLARY UROTHELIAL CARCINOMA IN SITU. WHO HISTOLOGIC GRADE:  LOW-GRADE. PATTERN OF GROWTH:  PURELY PAPILLARY NON-INVASIVE. EXTENT OF INVASION:  CONFINED TO UROTHELIUM (NON-INVASIVE). BACKGROUND EOSINOPHILIC CYSTITIS. NOTE:  Dr. **NAME[M. XXX WWW] agrees with the diagnosis.. Final Signout: **NAME[VVV UUU], MD **DATE[Sep 10 11]",,"GROSS DESCRIPTION: The specimen is received within formalin in one container labeled bladder tumor.  It consists of lobulated portions of pink-tan soft tissue, which measure 2.5 x 1.5 x 0.4 cm. in aggregate.  The specimen is entirely submitted in one block.",,Tissues: BLADDER BIOPSY. Specimen Comments: CPT CODES: 88307 x 1,,
REG1,OTHER,0,495467,3,,"CLINICAL HISTORY:  NONE GIVEN\X0D\\X0A\PRE-OP DIAGNOSIS:  RIGHT THYROID MASS, LEFT INTRANASAL LESION\X0D\\X0A\POST-OP DIAGNOSIS:","CASE: SUR-11-12253\X0D\\X0A\PATIENT: **NAME[AAA BBB]\X0D\\X0A\PROCEDURE:  RIGHT THYROID LOBECTOMY POSSIBLE TOTAL, LEFT NASAL ENDOSCOPY\X0D\\X0A\WITH EXCISION OF NASAL SEPTAL LESION","FINAL DIAGNOSIS:\X0D\\X0A\A.  RIGHT THYROID LOBE:\X0D\\X0A\Two lesions:\X0D\\X0A\Papillary microcarcinoma, see note #1.\X0D\\X0A\- Tumor size:  0.90 mm.\X0D\\X0A\- Extent of invasion:  Tumor appears confined to the thyroid.\X0D\\X0A\- Angiolymphatic invasion:  Not identified.\X0D\\X0A\- Margins:  Clear.\X0D\\X0A\Follicular adenoma, see note #2.\X0D\\X0A\- Tumor size:  2.8 cm.\X0D\\X0A\- Capsular invasion:  Not identified.\X0D\\X0A\- Vascular invasion:  Not identified.\X0D\\X0A\B.  SKIN OF LEFT NOSE, EXCISION:\X0D\\X0A\Mildly acanthotic squamous epithelium, see note #3.\X0D\\X0A\Mild chronic inflammation.\X0D\\X0A\Note #1:  In additional tissue submitted for permanent sections there is\X0D\\X0A\a single, very small focus of papillary microcarcinoma that is centrally\X0D\\X0A\located and represents an incidental finding.  In the planes of section,\X0D\\X0A\this focus confined to the thyroid and is approximately 4 mm from the\X0D\\X0A\margin of resection.\X0D\\X0A\Note #2:  The entire primary lesion was submitted for histologic\X0D\\X0A\examination.  It is thinly encapsulated and consists of thyroid\X0D\\X0A\follicular epithelial cells arranged into small microfollicles\X0D\\X0A\containing a small amount of luminal colloid.  Unequivocal light\X0D\\X0A\microscopic evidence for malignancy (capsular/vascular invasion) are not\X0D\\X0A\appreciated in the planes of section.\X0D\\X0A\Note #3:  Confirmatory immunohistochemical stains are pending.",,"GROSS:\X0D\\X0A\A.  Received fresh for intraoperative consultation labeled with the\X0D\\X0A\patient's name. It is additionally labeled right thyroid lobe with mass.\X0D\\X0A\It consists of a 4.4 x \R\4.0 cm thyroid lobectomy specimen remarkable for\X0D\\X0A\an \R\2.4 cm well circumscribed lesion. The resection margin is entirely\X0D\\X0A\inked black. The specimen is sectioned revealing a well circumscribed\X0D\\X0A\thinly encapsulated \R\2.2 cm tan colored lesion. A portion is submitted\X0D\\X0A\for a frozen section and smear.\X0D\\X0A\INTRAOPERATIVE CONSULTATION DX: Follicular lesion, defer to permanent\X0D\\X0A\sections.      (CJM)\X0D\\X0A\The residual tissue from frozen section is submitted into Cassette A1.\X0D\\X0A\The entire lesion is subsequently submitted into Cassettes A2-A5, and\X0D\\X0A\unremarkable thyroid parenchyma in A6.\X0D\\X0A\B.  Received designated left nasal lesion is a 1 mm fragment of pink and\X0D\\X0A\tan tissue which is entirely submitted as B1.               (AEE)","MICROSCOPIC:\X0D\\X0A\A microscopic examination has been performed.\X0D\\X0A\IMMUNOHISTOCHEMISTRY REPORT\X0D\\X0A\Using formalin fixed paraffin embedded tissue with the appropriate\X0D\\X0A\positive and negative controls, the specimen designated skin of left\X0D\\X0A\nose (block B1) is stained for immunoreactive epithelial membrane\X0D\\X0A\antigen, S100, CD-34 using an automated immunohistochemical technique.\X0D\\X0A\All internal and external controls react appropriately.\X0D\\X0A\INTERPRETATION:  Cytoplasmic immunoreactivity for the epithelial\X0D\\X0A\membrane antigen stain is noted in unremarkable epithelium only.  The\X0D\\X0A\S100 stain is negative in the planes of interest.  The CD-34 stain shows\X0D\\X0A\cytoplasmic immunoreactivity in benign endothelial cells.  Overall,\X0D\\X0A\there is no light microscopic/immunohistochemical evidence for neoplasm.\X0D\\X0A\These findings support the final diagnosis.\X0D\\X0A\Preliminary Diagnosis performed by\X0D\\X0A\**NAME[M. ZZZ YYY], M.D.\X0D\\X0A\Electronically signed **DATE[Aug 4 2012] 12:24PM Final Diagnosis performed by\X0D\\X0A\**NAME[M. ZZZ YYY], M.D.\X0D\\X0A\Electronically signed **DATE[Aug 7 2012] 1:52PM",SPECIMEN:  A. RIGHT THYROID LOBE; B. LEFT NASAL LESION,,
REG1,OTHER,0,495644,1,,CLINICAL INFORMATION\X0D\\X0A\PRE-OP DIAGNOSIS:  Bradycardia          POST-OP DIAGNOSIS:  Gastric\X0D\\X0A\tumor,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       OON LEEDHANACHO  SIGN OUT DATE:   **DATE[May 10 2012]\X0D\\X0A\COPIES TO:          OON\X0D\\X0A\LEEDHANACHO,"DIAGNOSIS\X0D\\X0A\STOMACH, BIOPSY:  INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received in formalin labeled \""gastric biopsy\"" and\X0D\\X0A\consists of six yellow tan irregular soft tissue fragments  measuring\X0D\\X0A\0.3 to 0.4 cm.  The entire specimen is submitted in cassette A.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections demonstrate infiltrating adenocarcinoma.  The tumor has a\X0D\\X0A\glandular architecture with  acinar structures lined by  neoplastic\X0D\\X0A\cells with oval to round nuclei and a scant amount of cytoplasm.  The\X0D\\X0A\surrounding parenchyma contains a marked acute and chronic inflammatory\X0D\\X0A\infiltrate.\X0D\\X0A\<Sign Out Dr. **NAME[ZZZ]>\X0D\\X0A\**NAME[YYY XXX], PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  GASTRIC BIOPSY, SURGICAL BIOPSY",,
REG1,OTHER,0,495716,1,,"CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Endometrial cancer, bleeding","REVISED SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       HOLLY GALLION    SIGN OUT DATE:   **DATE[Apr 16 2012]\X0D\\X0A\COPIES TO:          HOLLY GALLION\X0D\\X0A\REVISED DATE: **DATE[Apr 30 2012]\X0D\\X0A\NOTE:  The revised report reflects the addition of the synoptic staging\X0D\\X0A\template.  No other changes were made.\X0D\\X0A\NOTE:  The second revised report reflects change in the depth of\X0D\\X0A\invasion and addition of the P\T\C consultation.  No other changes were\X0D\\X0A\made.\X0D\\X0A\<Sign Out Dr. **NAME[ZZZ]>\X0D\\X0A\**NAME[YYY XXX], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","FROZEN SECTION DIAGNOSIS\X0D\\X0A\OVARY AND TUBE, RIGHT (1FS-1):   DENSE FIBROSIS AND STROMAL EDEMA WITH\X0D\\X0A\MULTIPLE FOLLICULAR CYSTS.\X0D\\X0A\FROZEN SECTION REPORT CALLED TO DR. **NAME[WWW] **DATE[Apr 10 12].\X0D\\X0A\**NAME[VVV UUU], M.D\X0D\\X0A\DIAGNOSIS\X0D\\X0A\1. OVARY AND TUBE, RIGHT:  DENSE FIBROSIS AND STROMAL EDEMA WITH\X0D\\X0A\MULTIPLE FOLLICULAR CYSTS, NO MALIGNANT FEATURES ARE PRESENT.\X0D\\X0A\2. OBTURATOR LYMPH NODE:  NEGATIVE FOR TUMOR.\X0D\\X0A\3. LYMPH NODES, EXTERNAL COMMONS:  NEGATIVE FOR TUMOR.\X0D\\X0A\4. LYMPH NODES, RIGHT COMMON AND PARA-AORTIC:  NEGATIVE FOR TUMOR.\X0D\\X0A\5. OBTURATOR LYMPH NODE, LEFT INTERNAL OBTURATOR:  NEGATIVE FOR\X0D\\X0A\TUMOR.\X0D\\X0A\6. LYMPH NODES, LEFT COMMON AND PARA-AORTIC:  NEGATIVE FOR TUMOR.\X0D\\X0A\7. LYMPH NO DES, LEFT EXTERNAL ILIAC COMMONS:  NEGATIVE FOR TUMOR.\X0D\\X0A\8. OMENTUM:  NEGATIVE FOR TUMOR.\X0D\\X0A\9. UTERUS, CERVIX:  NO EVIDENCE OF TUMOR.\X0D\\X0A\LEFT OVARY AND FALLOPIAN TUBE:  NO EVIDENCE OF TUMOR.\X0D\\X0A\UTERUS, ENDOMETRIUM:  WELL-DIFFERENTIATED ADENOCARCINOMA WITH\X0D\\X0A\NECROSIS AND SIZE OF TUMOR MEASURING 1.5 CM GREATEST DIMENSION.\X0D\\X0A\EXTENSION OF THIS TUMOR IS 0.2 CM FROM THE SEROSAL SURFACE OF THE\X0D\\X0A\BODY OF THE UTERUS.  THICKNESS OF THE BODY OF THE UTERUS IS 3.7 CM\X0D\\X0A\FROM THE ENDMETRIUM TO THE BASE TO THE SEROSAL SURFACE.  FOCAL\X0D\\X0A\RESIDUAL INVOLVEMENT OF THE MYOMETRIUM IS 1.2 CM.\X0D\\X0A\CPT4 88331, 88332, 88305 X 5, 88307 x 3, 88302 x 1/ ICD9 182.0 /\X0D\\X0A\PC:  684, 665.1, 665.2,M81403",,"MACROSCOPIC\X0D\\X0A\SPECIMEN: Uterine corpus, cervix, right and left ovary, right and left\X0D\\X0A\fallopian tube\X0D\\X0A\PROCEDURE: Radical hysterectomy\X0D\\X0A\LYMPH NODE SAMPLING: Performed\X0D\\X0A\Pelvic lymph nodes\X0D\\X0A\Para-aortic lymph nodes\X0D\\X0A\External iliac, omentum\X0D\\X0A\SPECIMEN INTEGRITY: Intact hysterectomy specimen\X0D\\X0A\TUMOR SITE: Posterior endometrium\X0D\\X0A\TUMOR SIZE:  1.5 x 0.5 x 0.7 cm\X0D\\X0A\GROSS DESCRIPTION\X0D\\X0A\Nine specimens are received.  Specimen one is received fresh for frozen\X0D\\X0A\section diagnosis and is labeled \""right fallopian tube and ovary\"" and\X0D\\X0A\consists of the aforementioned weighing 60.5 grams and measuring 7 x 4\X0D\\X0A\x 6 cm in greatest dimension.  There is a purple-tan cystic structure\X0D\\X0A\extruding from a more firm pink-tan area measuring 3 cm in diameter and\X0D\\X0A\another pedunculated area of small cystic structures and firm areas\X0D\\X0A\extends on a thread of connective tissue which is 3 cm long and\X0D\\X0A\measures itself 3 x 2 x 1 cm.  An attached portion of fallopian tube is\X0D\\X0A\present measuring 8 cm in length by 1.5 cm in greatest diameter.  The\X0D\\X0A\serosal surface is inked in black and the specimen is sectioned to\X0D\\X0A\reveal a firm yellow-tan parenchyma containing multiple simple cystic\X0D\\X0A\spaces without excrescences and some hemorrhagic-filled cystic\X0D\\X0A\structures as well.  Representative sections are submitted from the\X0D\\X0A\varying architectural areas as 1FS-1 and 1FS-2.  The previously frozen\X0D\\X0A\1FS-1 and 1FS-2 are entirely resubmitted as such and sections from the\X0D\\X0A\unfrozen tissue are submitted in cassettes A-C.\X0D\\X0A\Specimen two is labeled \""right internal iliac obturator\"" and consists\X0D\\X0A\of a cluster of fibro-fatty tissue.  The total cluster measures 3 x 2.5\X0D\\X0A\x 0.3 cm.  The entire cluster is fibro-fatty.  No true lymph nodes are\X0D\\X0A\seen.  The entire cluster is submitted in cassettes labeled 2A and 2B.\X0D\\X0A\Specimen three is labeled \""external commons\"" and consists of two\X0D\\X0A\clusters of fibro-fatty rubbery tissue.  The total cluster measures 3 x\X0D\\X0A\2 x 0.3 cm.  The specimen is sectioned and shows more fat.  Very little\X0D\\X0A\lymphoid material is identified, if any.  All of the tissue is\X0D\\X0A\submitted in one cassette labeled 3.\X0D\\X0A\Specimen four is labeled \""right common and periaortic\"" and consists of\X0D\\X0A\a red-tan fragment of tissue.  The total cluster measures 2.5 x 1 x 0.3\X0D\\X0A\cm.  The cluster of tissue is submitted in one cassette labeled 4.\X0D\\X0A\Specimen five is labeled \""left internal opturator\"" and consists of a\X0D\\X0A\triangle of fibro-fatty rubbery tissue measuring 3 x 2.5 x 0.3 cm.  The\X0D\\X0A\specimen is sectioned and shows lymphoid material.  The entire cluster\X0D\\X0A\of lymphoid material and adjacent structures are submitted in one\X0D\\X0A\cassette labeled 5A.\X0D\\X0A\Specimen six is labeled \""left common and periaortic\"" and consists of a\X0D\\X0A\cluster of fatty tissue.  No lymphoid material is seen.  The total\X0D\\X0A\cluster measures 2.5 x 2 x 0.3 cm.  All fragments are submitted in one\X0D\\X0A\cassette labeled 6A.\X0D\\X0A\Specimen seven is labeled \""left external iliac commons\"" and consists of\X0D\\X0A\fibro-fatty irregular rubbery tissue.  The total cluster in two parts\X0D\\X0A\with one measuring 0.5 cm and the other measuring 1 x 0.3 cm.  Both\X0D\\X0A\fragments are submitted in one cassette labeled 7A.\X0D\\X0A\Specimen eight is labeled \""omentum\"" and consists of a lace-like pattern\X0D\\X0A\of fatty tissue compatible with omentum which has a measurement of 8 x\X0D\\X0A\4 x 0.5 cm.  Sections made perpendicular to the longitudinal axis of\X0D\\X0A\this portion of omentum show lobules of fatty tissue.  No lymph nodes\X0D\\X0A\are seen by gross inspection.  Representative sections are submitted in\X0D\\X0A\one cassette labeled 8A.\X0D\\X0A\Specimen nine is labeled \""cervix, uterus, left tube and left ovarie\""\X0D\\X0A\and consists of a uterus with attached ovary, left.  The uterus\X0D\\X0A\includes endocervical canal and a portion of the cervix.  The specimen\X0D\\X0A\weighs 370 grams and has a measurement of 13 cm and a width of 10 cm\X0D\\X0A\and a thickness of 7.2 cm.  The left ovary is tubular and cylindrical\X0D\\X0A\shaped and measures 6 x 2 x 2.2 cm.  The fallopian tube measures 6 cm.\X0D\\X0A\Greatest diameter of the ovary 5 cm.  The fimbriated end appears\X0D\\X0A\satisfactory.  The uterus is sectioned from the anterior posterior\X0D\\X0A\plane sagittally and shows a thickening and mass effect of the\X0D\\X0A\posterior central portion of the body of uterus.  The specimen is\X0D\\X0A\allowed adequate fixation prior to further section in order to preserve\X0D\\X0A\the tumor and the extent of tumor that might be present and degree of\X0D\\X0A\invasion.  The serosal surface of both these portions of the uterus is\X0D\\X0A\intact, smooth and uninvolved by tumor. The uterus is sectioned\X0D\\X0A\sagittally and now shows a satisfactory fixation process.  The left\X0D\\X0A\ovary and fallopian tube measures 5 x 2 cm.  The ovary is sectioned and\X0D\\X0A\shows well-fixed pink-tan stromal process.  Cystic follicles are\X0D\\X0A\present along the subcordical surface of this process.  A section of\X0D\\X0A\this ovary is submitted in one cassette.  A section of the fimbriated\X0D\\X0A\fallopian tube segment measures 5 x 1 cm.  Section is submitted in\X0D\\X0A\cassette labeled 9B.  No tumor is seen in these sections.  Sections of\X0D\\X0A\the site of the attachment of the ovary and the fallopian tube are\X0D\\X0A\submitted in\X0D\\X0A\one cassette labeled 9C.  No tumor is seen by gross inspection at this\X0D\\X0A\focus.  The sagittally sectioned body of the uterus is now sectioned\X0D\\X0A\perpendicular to the transverse axis and shows a superficial process of\X0D\\X0A\tumor on the endometrial surface.  A section of this process is\X0D\\X0A\submitted in cassette labeled 9D.  The process extends into the lower\X0D\\X0A\uterine segment.  A section from the lower uterine segment of the body\X0D\\X0A\of the uterus is submitted in cassette labeled 9E.  The process does\X0D\\X0A\not extend to the cervix.  Sections of the anterior and posterior lip\X0D\\X0A\of the cervix are submitted in cassette labeled 9F.  No tumor is seen\X0D\\X0A\in this extension either.  The opposite half of the body of the uterus\X0D\\X0A\is sectioned perpendicular to the longitudinal axis and shows the tumor\X0D\\X0A\size to be 1.5 cm.  The body of the uterus measures 3.7 cm from the\X0D\\X0A\base of the tumor.  A section showing the tumor and this involvement of\X0D\\X0A\the superficial portion of the endometrium reveal an extension of the\X0D\\X0A\tumor.  A section showing the superficial area of the tumor is\X0D\\X0A\submitted in cassette labeled 9G.  A section of the extent of tumor\X0D\\X0A\into the wall of the uterus is submitted in cassette labeled 9H.  The\X0D\\X0A\tumor extends on this particular focus a distance of 3 cm and the\X0D\\X0A\myometrium residual without tumor involvement is 1.2 cm at this focus.\X0D\\X0A\The serosal surface is free of metastatic disease.  Another section of\X0D\\X0A\the tumor that is well fixed showing the deep margin of resection of\X0D\\X0A\this tumor adjacent to a portion of the softened poorly fixed area is\X0D\\X0A\submitted in cassettes labeled 9I and 9J.","MICROSCOPIC\X0D\\X0A\HISTOLOGIC TYPE: Endometrioid adenocarcinoma, not otherwise\X0D\\X0A\characterized\X0D\\X0A\HISTOLOGIC GRADE: FIGO grade 1\X0D\\X0A\MYOMETRIAL INVASION: Present\X0D\\X0A\Depth of invasion: 0.2 cm\X0D\\X0A\Myometrial thickness: 3.7 cm\X0D\\X0A\INVOLVEMENT OF CERVIX: Not involved\X0D\\X0A\EXTENT OF INVOLVEMENT OF OTHER ORGANS\X0D\\X0A\RIGHT OVARY: Not involved\X0D\\X0A\LEFT OVARY: Not involved\X0D\\X0A\RIGHT FALLOPIAN TUBE: Not involved\X0D\\X0A\LEFT FALLOPIAN TUBE: Not involved\X0D\\X0A\MARGINS: Uninvolved by invasive carcinoma\X0D\\X0A\LYMPH-VASCULAR INVASION: Not identified\X0D\\X0A\PATHOLOGIC STAGING (pT1apN0)\X0D\\X0A\PRIMARY TUMOR: pT1a\X0D\\X0A\REGIONAL LYMPH NODES: pN0\X0D\\X0A\Pelvic lymph nodes\X0D\\X0A\Number examined: 7\X0D\\X0A\Number involved: 0\X0D\\X0A\Para-aortic lymph nodes:\X0D\\X0A\Number examined: 2\X0D\\X0A\Number involved: 0\X0D\\X0A\DISTANT METASTASIS: Not applicable\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS\X0D\\X0A\Complex hyperplasia\X0D\\X0A\CLINICAL HISTORY\X0D\\X0A\Stein-Leventhal Syndrome\X0D\\X0A\ANCILLARY STUDIES (Cytology performed in interpreted at P\T\C\X0D\\X0A\Laboratories)\X0D\\X0A\CYTOLOGY RESULTS (11-PM-25) See separate outside report\X0D\\X0A\PELVIC WASHING:  Negative for malignant cells.\X0D\\X0A\OUTSIDE CONSULTATION (Sent to P\T\C Laboratories)  See separate outside\X0D\\X0A\report.\X0D\\X0A\CONSULTANT's DIAGNOSIS:  UTERUS, CERVIX, LEFT OVARY AND FALLOPIAN TUBE:\X0D\\X0A\Focal endometriod adenocarcinoma, villoglandular variant, FIGO grade\X0D\\X0A\1, with superficial invasion.  Benign ovary, fallopian tube and cervix.\X0D\\X0A\Extensive adenomyosis.\X0D\\X0A\SYNOPTIC STAGING TEMPLATE COMPLETED **DATE[Apr 18 2012]\X0D\\X0A\**NAME[YYY M. XXX], M.D.\X0D\\X0A\MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of the right tube and ovary, 1FS-1, show dense fibrosis,\X0D\\X0A\stromal edema with multiple follicular cysts.  Permanent sections show\X0D\\X0A\similar features.  Permanent sections of the frozen section portion\X0D\\X0A\show benign ovarian stroma, follicles and no evidence of endometrial\X0D\\X0A\cancer seen in the permanent sections of the frozen section of this\X0D\\X0A\ovary.   Section 1FS-2 shows more ovarian stroma and no evidence of\X0D\\X0A\endometrial adenocarcinoma.  Mucinous structures are present.  No\X0D\\X0A\malignant features are seen.  Permanent sections of frozen section\X0D\\X0A\1FS-2 show benign tubular structures and cystic structures and ovarian\X0D\\X0A\stroma.  The margins are marked satisfactory and no tumor is seen.\X0D\\X0A\Permanent section labeled 1A shows benign serosal surface of what\X0D\\X0A\appears to be ovary and no malignant features present.  Cystic\X0D\\X0A\structures are present and no malignant features are seen.  Section 1B\X0D\\X0A\shows ovary with multiple follicles scattered throughout the\X0D\\X0A\subcortical layer of the ovary.  No tumor is present.  Clotted blood is\X0D\\X0A\present in some of the follicles.  Section 1C shows ovary with dense\X0D\\X0A\stroma, follicles and no malignant features seen.\X0D\\X0A\Sections of the obturator lymph node, 2A-1, show benign lymphoid\X0D\\X0A\structures and no tumor seen.  Section 2B shows four lymph node\X0D\\X0A\structures with benign lymphoid structures, sinus histiocytosis and no\X0D\\X0A\tumor seen.\X0D\\X0A\Sections of the lymph nodes, external common, 3A-1, show benign\X0D\\X0A\lymphoid structures, congestion and no malignant features seen.\X0D\\X0A\Negative lymphoid structures present.\X0D\\X0A\Sections of the lymph nodes, right common and para-aortic, 4A-1, show\X0D\\X0A\benign lymphoid structures, reactive changes, sinus histiocytosis.  No\X0D\\X0A\metastatic tumor is identified.  Multiple sections of lymph nodes are\X0D\\X0A\present.  A total of six (6) lymph nodes are present and no tumor is\X0D\\X0A\seen.\X0D\\X0A\Sections of the left internal obturator, 5A-1, show a total of seven\X0D\\X0A\(7) lymph node fragments are present and show benign lymphoid\X0D\\X0A\structures with no tumor present.  Sinus histiocytosis is noted.  No\X0D\\X0A\malignant features are seen.\X0D\\X0A\Sections of the left common and para-aortic node, 6A-1, show benign\X0D\\X0A\fibro-fatty tissue.  No lymphoid structures are present.\X0D\\X0A\Sections of the left external iliac commons, 7A-1, show benign lymphoid\X0D\\X0A\structures with sinus histiocytosis.  No metastatic tumor is\X0D\\X0A\identified.  Vessels, fatty tissue and clotted blood are present.  No\X0D\\X0A\tumor is seen.  A total of one (1) lymph node is present in levels\X0D\\X0A\present.  No tumor is seen.\X0D\\X0A\Sections of the omentum, 8A-1, show benign fibro-fatty tissue\X0D\\X0A\compatible with omentum.\X0D\\X0A\Sections of the uterus, left ovary and tube, 9A-1, show benign ovarian\X0D\\X0A\structures and no tumor seen.  No malignant features are present.\X0D\\X0A\Section 9B-1 shows a fallopian tube with no tumor seen.  Section 9C-1\X0D\\X0A\shows a round ligament, associated tissue and a portion of the\X0D\\X0A\fallopian tube with no evidence of tumor present in this focus.  This\X0D\\X0A\is near the attachment site of the ovary and fallopian tube.  Section\X0D\\X0A\9D-1 shows ovarian stroma and benign strands of endometrial glands and\X0D\\X0A\stroma scattered throughout the nodular process of myometrium.  Some\X0D\\X0A\focal cytological atypia is seen but no adenocarcinoma is seen in this\X0D\\X0A\section.  Section 9E-1 shows lower uterine segment of the body of the\X0D\\X0A\uterus.   This shows endometrial glands and stroma with simple cystic\X0D\\X0A\hyperplasia , branching complexity appreciated.  No cytological atypia\X0D\\X0A\is seen in this focus.  Section 9F-1 shows cervical epithelium with no\X0D\\X0A\tumor present.  Endocervical glands are also present showing\X0D\\X0A\hyperplasia with no atypical features identified.  Section 9G-1 shows a\X0D\\X0A\well-differentiated endometrioid adenocarcinoma.  Some necrosis is\X0D\\X0A\present.  Back-to-back glands with tubular structures and glandular\X0D\\X0A\structures showing necrosis and also well-differentiated\X0D\\X0A\adenocarcinoma, endometrioid variety, arising in the endometrial\X0D\\X0A\surface with extension into the wall.  Section\X0D\\X0A\9H-1 shows extent of the tumor into the wall of the uterus.  This\X0D\\X0A\specimen shows proliferation of endometrium, glandular structures and\X0D\\X0A\no malignant features seen.  Section 9I-1 shows back-to-back glands,\X0D\\X0A\well differentiated nodules of endometrial tissue with tumor present.\X0D\\X0A\Minimal necrosis is noted.  Section 9J-1 shows clusters of well\X0D\\X0A\differentiated tumor scattered throughout the entire section.  Poor\X0D\\X0A\fixation is appreciated as well.","TISSUE SUBMITTED:  (1) OVARY AND TUBE, RIGHT, SURGICAL EXCISION\X0D\\X0A\(2) OBTURATOR LYMPH\X0D\\X0A\NODE(S), SURGICAL EXCISION\X0D\\X0A\Right internal iliac\X0D\\X0A\obturator\X0D\\X0A\(3) LYMPH NODES,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\External commons\X0D\\X0A\(4) LYMPH NODES,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Right commons and\X0D\\X0A\para-aortic\X0D\\X0A\(5) OBTURATOR LYMPH\X0D\\X0A\NODE(S), SURGICAL EXCISION\X0D\\X0A\Left internal\X0D\\X0A\obturator\X0D\\X0A\(6) LYMPH NODES,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Left commons and\X0D\\X0A\para-aortic\X0D\\X0A\(7) LYMPH NODES,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Left external iliac\X0D\\X0A\commons\X0D\\X0A\(8) OMENTUM,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\(9) UTERUS, LEFT\X0D\\X0A\OVARY AND TUBE, SURGICAL EXCISION",,
REG1,OTHER,0,496226,2,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Vocal cord neoplasm,FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       **NAME[ZZZ YYY] SIGN OUT DATE:   **DATE[Aug 27 2012]\X0D\\X0A\COPIES TO:          **NAME[ZZZ]\X0D\\X0A\HAZELETT,"DIAGNOSIS\X0D\\X0A\1. RIGHT FALSE VOCAL CORD BIOPSY:  ATYPICAL LYMPHOID INFILTRATE IN\X0D\\X0A\THE SOFT TISSUE BENEATH AN INTACT SQUAMOUS EPITHELIUM COMPATIBLE\X0D\\X0A\WITH LYMPHOMA VERSES SMALL CELL CARCINOMA.\X0D\\X0A\2. LEFT TRUE VOCAL CORD BIOPSY:  ATYPICAL LYMPHOID INFILTRATE BENEATH\X0D\\X0A\THE MUCOSA WHICH IS BENIGN SQUAMOUS SHOWING AN ATYPICAL LYMPHOID\X0D\\X0A\INFILTRATE COMPATIBLE WITH LYMPHOMA VERSES SMALL CELL CARCINOMA.\X0D\\X0A\3. ANTERIOR COMMISSURE:  INTACT SQUAMOUS EPITHELIUM WITH A SUBMUCOSAL\X0D\\X0A\EXPRESSION OF LYMPHOID CELLS COMPATIBLE WITH A LYMPHOMA VERSES\X0D\\X0A\SMALL CELL CARCINOMA.\X0D\\X0A\CPT4 88305 x3 / ICD9 200.10 / MORPHOLOGY CODE: M96303\X0D\\X0A\OUTSIDE CONSULTATION (Reviewed by Dr. **NAME[XXX WWW] at P\T\C\X0D\\X0A\Laboratories)  See separate outside report.\X0D\\X0A\CONSULTANT's DIAGNOSIS:\X0D\\X0A\RIGHT FALSE VOCAL CORD, LEFT TRUE VOCAL CORD, AND ANTERIOR\X0D\\X0A\COMMISSURE, MULTIPLE BIOPSIES (SPECIMENS 1 - 3):  Poorly\X0D\\X0A\differentiated small cell neuroendocrine carcinoma.\X0D\\X0A\SPECIAL STAINS:  Five immunohistochemical stains were performed at\X0D\\X0A\P\T\C Laboratories.  The tumor cells are strongly immunoreactive to\X0D\\X0A\Pankeratin, Chromogranin, CEA-56 and Synaptophysin.  They are\X0D\\X0A\non-immunoreactive to CD45.",,"GROSS DESCRIPTION\X0D\\X0A\Specimen one is labeled \""right false vocal cord\"" and consists of\X0D\\X0A\red-tan-pink fragments of rubbery tissue measuring 0.1 to 0.4 cm\X0D\\X0A\diameter.  The specimen is entirely submitted in cassette 1.\X0D\\X0A\Specimen two is labeled \""left true vocal cord\"" and consists of pink-tan\X0D\\X0A\irregular fragments of tissue measuring 0.1 to 0.3 cm.  The specimen is\X0D\\X0A\entirely submitted in cassette 2.\X0D\\X0A\Specimen three is labeled \""anterior commissure\"" and consists of red-tan\X0D\\X0A\fragments of tissue measuring 0.1 to 0.3 cm.  The specimen is entirely\X0D\\X0A\submitted in cassette 3.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of the right false vocal cord show intact squamous epithelium\X0D\\X0A\on the surface.  Beneath this surface there are nodules of cells having\X0D\\X0A\features compatible with and diagnostic of lymphocyte origin and\X0D\\X0A\probable lymphoma in a nodular expression scattered throughout the\X0D\\X0A\submucosal expressions verses small cell carcinoma.  Deeper sections\X0D\\X0A\show similar features.\X0D\\X0A\Sections of the left true vocal cord show an identical process of a\X0D\\X0A\polypoid structure with lymphoid structures creating destruction of the\X0D\\X0A\subcutaneous tissue.  The lymph node structures have a medium to\X0D\\X0A\intermediate cell sized characterization with alteration of the\X0D\\X0A\chromatin pattern suggestive of a lymphoma verses small cell carcinoma.\X0D\\X0A\Sections of the anterior commissure show intact squamous epithelium\X0D\\X0A\with a submucosal expression of lymphoid cells compatible with a\X0D\\X0A\lymphoma verses small cell carcinoma.\X0D\\X0A\<Sign Out Dr. **NAME[VVV]>\X0D\\X0A\**NAME[UUU TTT], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  (1) VOCAL CORD BIOPSY, RIGHT, SURGICAL BIOPSY\X0D\\X0A\Right false vocal\X0D\\X0A\cord\X0D\\X0A\(2) VOCAL CORD\X0D\\X0A\BIOPSY, LEFT, SURGICAL BIOPSY\X0D\\X0A\Left true vocal cord\X0D\\X0A\(3) NECK AREA,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Anterior commissure",,
REG1,OTHER,0,499187,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is right temporal lobe brain tumor. Operative findings:\X0D\\X0A\brain tumor. Operative procedure: right crani for tumor.\X0D\\X0A\Imaging:  lesion involving the right anteroinferior sylvian region, in the\X0D\\X0A\region of the temporal operculum, involving cortex and \X0D\\X0A\subcortical white matter .... a more discrete 9 mm nodule within ....\X0D\\X0A\probably mildly larger than on the prior study .... raises concern for a\X0D\\X0A\neoplasm such as a DNET\X0D\\X0A\[contrast] mass involving the anterior right operculum / temporal lobe ....\X0D\\X0A\shows some elevated T1 and T2 signal on precontrast imaging .... no definite\X0D\\X0A\enhancement .... restricted diffusion in the nodular portion of the mass \X0D\\X0A\likely from hypercellularity .... may represent low-grade glioma or other\X0D\\X0A\neuroepithelial neoplasm \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\Frozen-section diagnosis #1:  \""NO TUMOR SEEN\""---DW.\X0D\\X0A\Frozen-section diagnosis #2:  \""HYPERCELLULAR ASTROCYTOMA WITH FOCAL\X0D\\X0A\NECROSIS\""---DW.\X0D\\X0A\\X0D\\X0A\ksl/**DATE[Oct 17 2012]     **NAME[ZZZ YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Mar 3 2004] (Age: **AGE[birth-12])  MW\X0D\\X0A\Collect Date: **DATE[Oct 13 2012] 13:04\X0D\\X0A\Receipt Date: **DATE[Oct 13 2012] 13:04\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: **NAME[WWW VVV], MD     Service: NS     Location: REC\X0D\\X0A\**NAME[UUU] MD(S):      Reported: **DATE[Oct 17 2012] 13:22\X0D\\X0A\RESIDENTS(**NAME[M): M. TTT], MD","DIAGNOSIS\X0D\\X0A\CEREBRUM, RIGHT TEMPORAL, RESECTION OF MASS (B; C):\X0D\\X0A\     PLEOMORPHIC XANTHOASTROCYTOMA (WHO grade 1)\X0D\\X0A\CEREBRUM, RIGHT TEMPORAL, BIOPSY (A):\X0D\\X0A\     NO TUMOR SEEN (unremarkable cerebral cortex)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dw/**DATE[Oct 17 2012] **NAME[ZZZ YYY], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 237.5     UNCERTAIN BEHAVIOR NEOPLASM BRAIN SPINAL\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M80001 P1100\X0D\\X0A\B: M09450 P1140 \X0D\\X0A\F: A: 88307\X0D\\X0A\A,B: 88331 FS1(2)\X0D\\X0A\B: 88307\X0D\\X0A\C: 88307",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  three\X0D\\X0A\Specimen label:   A) brain tumor              \X0D\\X0A\Fixation: fresh for frozen\X0D\\X0A\Number of pieces:  three\X0D\\X0A\Shape(s):  irregular  \X0D\\X0A\Color(s): pale\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): in aggregate in greatest dimension 6 to 7 mm; specimen\X0D\\X0A\representatively frozen as FS1.\X0D\\X0A\Cassette summary: specimen biowrapped and entirely submitted frozen portion\X0D\\X0A\A1, unfrozen portion A2.\X0D\\X0A\Specimen label:  B) brain tumor\X0D\\X0A\Fixation: fresh for frozen\X0D\\X0A\Number of pieces: three\X0D\\X0A\Shape(s):  irregular  \X0D\\X0A\Color(s): pale\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): in aggregate in greatest dimension 6 to 7 mm; specimen is\X0D\\X0A\representatively frozen as FS2.\X0D\\X0A\Cassette summary: specimen is entirely submitted frozen portion biowrapped\X0D\\X0A\B1, unfrozen portion biowrapped B2.\X0D\\X0A\Specimen label:  C) cusa contents\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s):  irregular  \X0D\\X0A\Color(s): white pink\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): in aggregate 2 x 2 x 0.5 cm\X0D\\X0A\Cassette summary:  entirely submitted in screened C1\X0D\\X0A\Note  tissue is also banked on this patient\X0D\\X0A\ksl/**DATE[Oct 17 2012] **NAME[M. TTT], MD\X0D\\X0A\J.G. Combs","MICROSCOPIC DESCRIPTION\X0D\\X0A\The focus appearing to have necrotic features in the cryostat section\X0D\\X0A\(frozen-section #2) is not evident in the corresponding routinely processed\X0D\\X0A\section, nor is there evident necrosis in the remaining sections.  This may\X0D\\X0A\be attributable to artifact in the cryostat section, or, alternatively, to\X0D\\X0A\markedly limited focality of necrosis.       \X0D\\X0A\A resident has participated in this service.  A pathologist has performed and\X0D\\X0A\is responsible for the reported pathologic evaluation.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Brain tumor\X0D\\X0A\B: Brain tumor\X0D\\X0A\C: CUSA contents,,
REG1,OTHER,0,499230,1,,Clinical History:\X0D\\X0A\None Given,"Frozen Section:\X0D\\X0A\A)  TP \T\ FS DX:  Metastatic high grade non-small cell carcinoma. \X0D\\X0A\(DBC).\X0D\\X0A\Results given directly to Dr. **NAME[ZZZ].\X0D\\X0A\CPT Code(s):   **ID-NUM (x2), 88331.26 (x2), **ID-NUM (x4)\X0D\\X0A\DBC/dar\X0D\\X0A\Dct \T\ Trs **DATE[Mar 07 2012]\X0D\\X0A\**NAME[YYY XXX:  WWW VVV UUU] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Mar 08 2012]","Pre-Operative Diagnosis:\X0D\\X0A\Ascites, SOB, Abd. Distention\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Peritoneal implant:  Metastatic high grade papillary serous\X0D\\X0A\carcinoma.\X0D\\X0A\B)  Omental mass:  Metastatic high grade papillary serous carcinoma.\X0D\\X0A\Note:  The histologic and immunophenotypic findings are most in keeping\X0D\\X0A\with metastasis from a gynecologic primary or, alternatively, metastasis\X0D\\X0A\from primary peritoneal carcinoma (serous surface papillary carcinoma).",,"Gross Description:\X0D\\X0A\Received are two parts, each labeled with the patient's name.\X0D\\X0A\Part A is received fresh for frozen section additionally labeled\X0D\\X0A\\""peritoneal implant\"".  The specimen consists of a 1 x 0.6 x 0.5 cm\X0D\\X0A\yellow-tan soft tissue fragment.  The surface of the tissue fragment is\X0D\\X0A\notable for a 0.6 x 0.2 cm irregular indurated whitish area.  The\X0D\\X0A\specimen is entirely inked blue and serially sectioned.  Touch preps are\X0D\\X0A\obtained and the specimen is submitted entirely for frozen section in\X0D\\X0A\one block.  The specimen is now resubmitted in toto for permanents in\X0D\\X0A\Cassette A-FSC.\X0D\\X0A\Part B is received in formalin additionally labeled \""omentum mass\"".  The\X0D\\X0A\specimen consists of a 4.5 x 3 x 1 cm irregular portion of omentum.  The\X0D\\X0A\specimen is entirely inked blue.  Sectioning the specimen reveals a 3.5\X0D\\X0A\x 1.7 x 1 cm ill-defined lesion which has a solid white-tan to bright\X0D\\X0A\yellow cut surface.  The lesion extends to the inked outer margins.\X0D\\X0A\Representative sections are submitted in Cassette B.  JAB:jlj","Microscopic Description:\X0D\\X0A\Sections from both the peritoneal implant and partial resection of\X0D\\X0A\omentum demonstrate metastatic high-grade adenocarcinoma with associated\X0D\\X0A\calcifications with tumor infiltrating through desmoplastic stroma.\X0D\\X0A\The tumor displays immunoreactivity with cytokeratin 7, CA-125, PAX-8,\X0D\\X0A\and estrogen receptor.  The histologic and immunophenotypic findings\X0D\\X0A\support the above diagnosis.  Tissue Code:  T1",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Peritoneal Implant\X0D\\X0A\SOURCE OF SPECIMEN: B Omentum Mass,,
REG1,OTHER,0,499898,1,,"CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\? MET PANC CA, PANC MASS WITH LIVER LESIONS\X0D\\X0A\","COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY XXX]\X0D\\X0A\   4003 Kresge Way\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[WWW,VVV]\X0D\\X0A\   **STREET-ADDRESS, **ROOM\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   Tuong,Hieu T\X0D\\X0A\   2619 **PLACE Wynde\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\   **PHONE (Pager)\X0D\\X0A\\X0D\\X0A\PROCEDURES: ***PHONEGS, ***PHONEGS/9\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\RIGHT LOBE, LIVER, NEEDLE BIOPSY:\X0D\\X0A\ADENOCARCINOMA.\X0D\\X0A\IMMUNOHISTOCHEMICAL WORKUP SUPPORTS PANCREATOBILIARY ORIGIN.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\This case discussed with Dr. **NAME[XXX ZZZ] **DATE[Dec 29 12] @\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin labeled \""right lobe liver\"" are two pink tan soft thread-like cores of\X0D\\X0A\tissue which measure 1.5 cm and 0.7 cm.  Also received are touch imprints which are H\T\E\X0D\\X0A\stained.  The soft tissue is submitted for histologic examination in a single cassette.\X0D\\X0A\/st/as\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\2 H\T\E, 1 CK7, 1 CK19, 1 CK20, 1 CEA(monoclonal), CA1-125, HCC, 1 CAM5.2, 1 CA19.9 and 1 AFP.\X0D\\X0A\Using appropriate positive and negative controls, the malignant neoplasm is stained for\X0D\\X0A\immunoreactive CK7, CK19, CK20, CEA(monoclonal), CA-125, HCC, CAM5.2, CA19.9 and AFP.  All\X0D\\X0A\internal and external controls react appropriately.  The malignant neoplasm stains positive\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\for CK7, CK19, CK20, CEA(monoclonal), CAM5.2 and CA19.9.  The malignant neoplasm stains\X0D\\X0A\negative for CK20, CA-125, HCC and AFP.   This staining pattern in conjunction with\X0D\\X0A\histology supports pancreatobiliary origin.\X0D\\X0A\",SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\RIGHT LOBE LIVER - 18 G\X0D\\X0A\,,ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Mar 01 13]-0852\X0D\\X0A\\X0D\\X0A\Please see scanned report under Pathology EMR from **INSTITUTION **INSTITUTION\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\
REG1,OTHER,0,501208,1,,Clinical History:\X0D\\X0A\Right renal mass\X0D\\X0A\Pre-Operative Diagnosis:\X0D\\X0A\Same as above\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Same as above,,"Final Diagnosis:\X0D\\X0A\Renal core needle biopsies, right:  Renal cell carcinoma, clear cell\X0D\\X0A\type, Fuhrman grade 3.",,"Gross Description:\X0D\\X0A\Received in formalin designated \""right kidney tissue\"" are multiple\X0D\\X0A\fragments of approximately six brown tissues.  The largest measures less\X0D\\X0A\than 0.1 x 0.1 cm.  The tissue is filtered and all of it is submitted in\X0D\\X0A\one cassette.  **INITIALS","Microscopic Description:\X0D\\X0A\This specimen shows a somewhat fibrotic capsule lined on one side by a\X0D\\X0A\proliferation of clear epithelial cells.  They are growing in small\X0D\\X0A\glandular structures or small solid aggregates and show very clear\X0D\\X0A\cytoplasm surrounding nuclei that vary from fairly small, dark, and\X0D\\X0A\round up to larger vesicular nuclei with rare nucleoli visible at medium\X0D\\X0A\power magnification (Fuhrman grade 3).  Tissue Code:  T1.\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Sep 02 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Right renal tissue,,
REG1,OTHER,0,512336,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  larynx cancer.  History of T3 supraglottic carcinoma\X0D\\X0A\with paralysis of the left vocal cord one year ago.  Treated with\X0D\\X0A\chemoradiation therapy.  Tumor returned.  CT and PET scan did not show\X0D\\X0A\evidence of regional or distant disease.  Intraoperative findings:  larynx\X0D\\X0A\cancer.  Operative procedure:  total laryngectomy and bilateral neck\X0D\\X0A\dissection and skin graft.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\TOUCH PREP/FROZEN SECTION DIAGNOSIS #1:  ' NO TUMORSEEN\"" ---RGK/PR\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""NO TUMOR SEEN\"" --- **INITIALS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #3:  \""NO TUMOR SEEN\"" --- **INITIALS\X0D\\X0A\\X0D\\X0A\     R.G. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Dec 7 1947] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[May 20 2013] 00:00\X0D\\X0A\Receipt Date: **DATE[May 21 2013] 07:11\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: R.K. **NAME[XXX], MD     Service: ENT     Location: A07J\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[May 25 2013] 19:34\X0D\\X0A\RESIDENTS(S): D.J. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\LARYNX, TOTAL LARYNGECTOMY (s/p supraglottic laryngectomy rypT3 / NX) (L):\X0D\\X0A\     INVASIVE SQUAMOUS-CELL CARCINOMA  (rypT4a / N0)\X0D\\X0A\PHARYNX (left wall) (J):     NO TUMOR SEEN \X0D\\X0A\TONGUE (base) (K):\X0D\\X0A\     NO TUMOR SEEN\X0D\\X0A\LYMPH NODES, LEFT NECK, LYMPHADENECTOMY (A through D):\X0D\\X0A\     NO TUMOR SEEN (0/18) \X0D\\X0A\LYMPH NODES, RIGHT NECK, LYMPHADENECTOMY (E through I):\X0D\\X0A\     NO TUMOR SEEN (0/13)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[May 25 2013] **NAME[UUU TTT], MD\X0D\\X0A\",,GROSS DESCRIPTION\X0D\\X0A\Twelve specimens are received.\X0D\\X0A\Total specimen number:  twelve\X0D\\X0A\Specimen label:  A) left level IIA              \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): 4 cm in greatest dimension\X0D\\X0A\No nodes are identified as the specimen consists predominantly of skeletal\X0D\\X0A\muscle.\X0D\\X0A\Cassette summary:  entirely submitted in A1-A4 \X0D\\X0A\Specimen label:  B) left neck level III                \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): brown/tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 4 cm in greatest dimension\X0D\\X0A\No nodes are identified as the specimen consists predominantly of skeletal\X0D\\X0A\muscle.\X0D\\X0A\Cassette summary: entirely submitted in B1-B2\X0D\\X0A\Specimen label:  C) left neck level IV                  \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): 4 cm in greatest dimension\X0D\\X0A\A single possible node is identified measuring 0.4 cm.\X0D\\X0A\Cassette summary: C1  one possible node; C2-C5  remainder of specimen \X0D\\X0A\Specimen label:  D)  left neck level IIB \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: soft to rubbery\X0D\\X0A\Size(s): 2.5 cm in greatest dimension\X0D\\X0A\No definite nodes are identified.\X0D\\X0A\Cassette summary: specimen is quadrisected and entirely submitted in D1-D2\X0D\\X0A\Specimen label:  E) right level IV node                  \X0D\\X0A\Fixation: fresh for frozen section\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): red/tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.5 x 0.5 x 0.2 cm\X0D\\X0A\Touch prep 1 is made and the specimen is entirely frozen as FS1.\X0D\\X0A\Cassette summary: FS1 is entirely resubmitted in biowrapped cassette E1\X0D\\X0A\Specimen label:  F) right level II\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): brown/tan\X0D\\X0A\Consistency: soft \X0D\\X0A\Size(s):4.5 cm in greatest dimension\X0D\\X0A\No definite nodes are identified.  The specimen is predominantly skeletal\X0D\\X0A\muscle.\X0D\\X0A\Cassette summary: entirely submitted F1-F3 \X0D\\X0A\Specimen label:  G) right level III\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces:  one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s):  brown/tan\X0D\\X0A\Consistency:  soft\X0D\\X0A\Size(s):  4.3 cm in greatest dimension\X0D\\X0A\No definite nodes are identified.  The specimen is predominantly skeletal\X0D\\X0A\muscle.\X0D\\X0A\Cassette summary: entirely submitted G1-G4\X0D\\X0A\Specimen label:  H) right neck level IV\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s):  yellow/brown\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): measures 3.7 cm in greatest dimension\X0D\\X0A\One possible node is identified measuring 0.3 cm.\X0D\\X0A\Cassette summary: H1  one possible node; H2-H4  remainder of specimen\X0D\\X0A\Specimen label: I)  right neck level V\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): yellow/tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 4 cm in greatest dimension\X0D\\X0A\No definite nodes are identified.\X0D\\X0A\Cassette summary: entirely submitted in cassettes I1-I3\X0D\\X0A\Specimen label: J) left pharyngeal wall\X0D\\X0A\Fixation: fresh for frozen section\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s):  pink/tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.6 x 0.1 x 0.1 cm\X0D\\X0A\Entirely frozen as FS2\X0D\\X0A\Cassette summary: entirely resubmitted in biowrap cassette J1\X0D\\X0A\Specimen label:   K) base of tongue               \X0D\\X0A\Fixation: fresh for frozen section\X0D\\X0A\Number of pieces: two\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): red/tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.7 cm in greatest dimension\X0D\\X0A\Entirely frozen as FS3.\X0D\\X0A\Cassette summary:  entirely resubmitted in biowrapped cassette K1\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.,"MICROSCOPIC DESCRIPTION\X0D\\X0A\LARYNGECTOMY FOR TUMOR \X0D\\X0A\Type of specimen or procedure:  total laryngectomy\X0D\\X0A\Tumor location:\X0D\\X0A\          Site                        \X0D\\X0A\          supraglottis           \X0D\\X0A\Histologic type:  squamous-cell carcinoma\X0D\\X0A\Grade:  s/p adjuvant therapy\X0D\\X0A\In-situ carcinoma:  not identified\X0D\\X0A\Tumor size:   2.5 cm in greatest dimension\X0D\\X0A\Multicentricity:  no\X0D\\X0A\Thyroid-cartilage involvement (if positive, minor [inner cortex] or major\X0D\\X0A\[outer cortex]):  yes  through thyroid cartilage (L6)\X0D\\X0A\Pre-epiglottic space invasion:  yes\X0D\\X0A\Involvement of soft tissues in neck:  yes (e.g., L5; L11)\X0D\\X0A\Thyroid-gland involvement:  not submitted\X0D\\X0A\Muscle invasion:  not identified\X0D\\X0A\Subglottic involvement (if positive, extent in cm):  no\X0D\\X0A\Lymph-vascular invasion:  not identified\X0D\\X0A\Perineurial invasion:  not identified\X0D\\X0A\Margins (if negative, distance to closest): negative ( 0.5 cm from closest\X0D\\X0A\soft-tissue margin)\X0D\\X0A\Lymph nodes (positive/total number / cf. lymph-node template):  0/32\X0D\\X0A\Photographs taken:  yes\X0D\\X0A\Primary tumor (pT)\X0D\\X0A\SUPRAGLOTTIS\X0D\\X0A\\X0D\\X0A\T4a       Moderately advanced local disease\X0D\\X0A\                Tumor invades through thyroid cartilage and/or invades\X0D\\X0A\tissues beyond the larynx (e.g., trachea, soft  tissues of neck \X0D\\X0A\                 including deep extrinsic muscle of the tongue, strap\X0D\\X0A\muscles, thyroid, or  esophagus)\X0D\\X0A\Lymph node (pN)\X0D\\X0A\N0           No regional lymph node metastasis\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\Not applicable\X0D\\X0A\M1           Distant metastasis\X0D\\X0A\Residual tumor (R)\X0D\\X0A\R0     No residual tumor\X0D\\X0A\LYMPH NODE DISSECTION, NECK\X0D\\X0A\Type of dissection (radical vs. modified radical vs. selective node\X0D\\X0A\dissection):  modified radical\X0D\\X0A\Site and type of primary neoplasm:  supraglottic larynx\X0D\\X0A\Number positive / total number:  0/32\X0D\\X0A\Left\X0D\\X0A\ Level 2A (A):  0/6\X0D\\X0A\ Level 3 (B:  0/3\X0D\\X0A\ Level 4 (C):  0/5 \X0D\\X0A\ Level 2B (D): 0/5 \X0D\\X0A\Right\X0D\\X0A\ Level 4 (E):  0/1\X0D\\X0A\ Level 2 (F):  0/3\X0D\\X0A\ Level 3 (G):  0/4\X0D\\X0A\ Level 4 (H):  0/2\X0D\\X0A\ Level 5 (I):   0/3\X0D\\X0A\Size of largest positive node:  not applicable\X0D\\X0A\Extracapsular nodal extension:  not applicable\X0D\\X0A\Other structures received (submandibular gland, jugular vein, muscle, etc): \X0D\\X0A\none\X0D\\X0A\Other structures involved:  n/a\X0D\\X0A\A resident has participated in this service.  A pathologist has performed and\X0D\\X0A\is responsible for the reported pathologic evaluation.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left neck level 2A\X0D\\X0A\B: Left neck level 3\X0D\\X0A\C: Left neck level 4\X0D\\X0A\D: Left neck level 2B\X0D\\X0A\E: Right neck level 4\X0D\\X0A\F: Right neck level 2\X0D\\X0A\G: Right neck level 3\X0D\\X0A\H: Right neck level 4\X0D\\X0A\I: Right neck level 5\X0D\\X0A\J: Left pharyngeal wall\X0D\\X0A\K: Base of tongue\X0D\\X0A\L: Larynx,,
REG1,LUNG,0,18267,3,,,"**NAME[BBB, AAA] B             ***PATH-NUMBER[1]         **NAME[ZZZ YYY], MD","FINAL DIAGNOSIS:\X0D\\X0A\LEFT UPPER LOBE LUNG MASS, CT GUIDED CORE BIOPSY:\X0D\\X0A\ POSITIVE FOR MALIGNANCY, CONSISTENT WITH SQUAMOUS CELL CARCINOMA.\X0D\\X0A\Reviewed for QA(LK).\X0D\\X0A\PATHOLOGIST COMMENTS:\X0D\\X0A\See ***PATH-NUMBER[2].\X0D\\X0A\                                                <Sign Out Dr. **NAME[XXX]>\X0D\\X0A\                                                    **NAME[WWW VVV], MD\X0D\\X0A\                                       Signed out on **DATE[Feb 17 2013] at 15:16\X0D\\X0A\                                                      Transcribed by JEN",,"GROSS DESCRIPTION:\X0D\\X0A\Received in formalin designated \""left upper lobe lung mass\"" are\X0D\\X0A\multiple irregular fragments of pink-tan soft tissue measuring up to 2\X0D\\X0A\mm in greatest dimension.  The specimens are entirely submitted in a\X0D\\X0A\single cassette.\X0D\\X0A\Note:  Due to the size of the fragments some may not survive\X0D\\X0A\processing.   **INITIALS","MICROSCOPIC DESCRIPTION:\X0D\\X0A\Microscopic examination performed.\X0D\\X0A\1 H\E\T\E\E.\X0D\\X0A\ CC: **NAME[ZZZ YYY], MD ;   **NAME[UUU TTT], MD\X0D\\X0A\Final Report            **NAME[SSS RRR], M.D.    Page 1 of 1\X0D\\X0A\                         Medical Director",SPECIMEN INFORMATION:\X0D\\X0A\LUL LUNG MASS\X0D\\X0A\CLINICAL HISTORY:\X0D\\X0A\Left upper lobe lung mass,,
REG1,LUNG,0,48678,3,,Clinical Diagnosis and History\X0D\\X0A\The working history is left apical lung mass with lung lesions suspicious for\X0D\\X0A\metastatic disease.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: PADMANABHAN, ARI\X0D\\X0A\**NAME[ZZZ, YYY]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Fine Needle Aspiration Performed by Radiologist\X0D\\X0A\Previous Pertinent History\X0D\\X0A\C11088304, **DATE[Oct 10 12]. LT PLEURAL EFFUSION, (***PATH-NUMBER[1]) PLEURAL FLUID Left Lower\X0D\\X0A\Lobe: Negative for malignant cells. (PCL)","Final Diagnosis\X0D\\X0A\LEFT APICAL LUNG MASS, FINE NEEDLE ASPIRATION BY RADIOLOGIST WITH CELL BLOCK:\X0D\\X0A\     Positive for poorly differentiated carcinoma, non-small cell.\X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\A single specimen is received labeled FNA left apical lung mass and consists of\X0D\\X0A\tiny fragments of pink soft tissue less than 1.0mm in diameter.  It is submitted\X0D\\X0A\in toto.  **INITIALS,"Microscopic Description\X0D\\X0A\Sections of the cell block only a mucoid mixture of mucus, inflammatory cells,\X0D\\X0A\and some highly atypical large cells having pleomorphic nuclei and prominent\X0D\\X0A\nucleoli.  Review of the smears prepared at the time of FNA shows a cellular\X0D\\X0A\linear aggregate of highly atypical cells with pleomorphic nuclei, prominent\X0D\\X0A\macronucleoli, and appears compatible with a non-small cell carcinoma.  **INITIALS",,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,LUNG,0,73460,3,,CLINICAL HISTORY:  NONE GIVEN\X0D\\X0A\PRE-OP DIAGNOSIS:  RIGHT UPPER LOBE NODULAR LUNG CANCER\X0D\\X0A\POST-OP DIAGNOSIS:  SAME,"CASE: SUR-11-09235\X0D\\X0A\PATIENT: **NAME[AAA BBB]\X0D\\X0A\PROCEDURE:  BRONCHOSCOPY, MEDIAD","FINAL DIAGNOSIS:\X0D\\X0A\PRE-CARINAL SOFT TISSUE, BIOPSY:\X0D\\X0A\Mature adipose tissue with associated lymphoid aggregate.\X0D\\X0A\LYMPH NODES, RIGHT LOWER PARATRACHEAL, BIOPSY:\X0D\\X0A\Fragments of unremarkable lymph node and associated perinodal soft\X0D\\X0A\tissue, see note #1.\X0D\\X0A\LYMPH NODE, RIGHT PULMONARY ARTERY ADJACENT TO RIGHT UPPER LOBE\X0D\\X0A\BRONCHUS, BIOPSY:\X0D\\X0A\Fragmented portions of unremarkable lymph node and associated\X0D\\X0A\perinodal soft tissue, see note #1.\X0D\\X0A\LYMPH NODE, RIGHT UPPER LOBE BRONCHUS, BIOPSY:\X0D\\X0A\Fragmented portions of unremarkable lymph node and associated\X0D\\X0A\perinodal soft tissue, see note #1.\X0D\\X0A\LYMPH NODE, AZYGOUS, BIOPSY:\X0D\\X0A\Fragmented portions of unremarkable lymph node and associated\X0D\\X0A\perinodal soft tissue, see note #1.\X0D\\X0A\LYMPH NODE, ADJACENT TO RIGHT UPPER LOBE, BIOPSY:\X0D\\X0A\Fragmented portions of unremarkable lymph node and associated\X0D\\X0A\perinodal soft tissue, see note #1.\X0D\\X0A\LYMPH NODE, RIGHT MIDDLE LOBE, BIOPSY:\X0D\\X0A\Fragmented portions of unremarkable lymph node and associated\X0D\\X0A\perinodal soft tissue, see note #1.\X0D\\X0A\NERVE, UPPER BRONCHUS, BIOPSY;\X0D\\X0A\Unremarkable lymph node and associated perinodal soft tissue, see\X0D\\X0A\note #1.\X0D\\X0A\LYMPH NODE, RIGHT MIDDLE LOBE, BIOPSY:\X0D\\X0A\Fragmented portions of unremarkable lymph node and associated\X0D\\X0A\perinodal soft tissue, see note #1.\X0D\\X0A\LUNG, RIGHT UPPER LOBE, LOBECTOMY:\X0D\\X0A\HISTOLOGIC TYPE:    Squamous cell carcinoma\X0D\\X0A\HISTOLOGIC GRADE:   G2\X0D\\X0A\TUMOR SIZE:    2.9cm\X0D\\X0A\ANGIOLYMPHATIC INVASION: Not identified\X0D\\X0A\PERINEURAL INVASION:     Not identified\X0D\\X0A\PLEURAL INVOLVEMENT:     Tumor invades visceral pleura (PL2)\X0D\\X0A\BRONCHIAL MARGIN:   Free of neoplasm\X0D\\X0A\-Distance from bronchial margin:   2cm\X0D\\X0A\NON-BRONCHIAL MARGINS:   Free of neoplasm\X0D\\X0A\-Distance from nearest non-bronchial margin: <0.10 mm\X0D\\X0A\INVASION OF OTHER ORGANS/STRUCTURES:    Tumor invades:\X0D\\X0A\-Parietal pericardium.\X0D\\X0A\LYMPH NODES, LOBAR/INTERLOBAR:     Cannot be assessed\X0D\\X0A\REGIONAL LYMPH NODES:    (see parts A, B, C, D, E, F, G, H, I)\X0D\\X0A\-Number examined:   8\X0D\\X0A\-Number involved:   0\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:    None identified\X0D\\X0A\PATHOLOGIC STAGING (pTNM)\X0D\\X0A\-Primary Tumor (pT):     pT3\X0D\\X0A\-Regional Lymph Nodes (pN):   pN0\X0D\\X0A\-Distant Metastasis (pM):     Unknown\X0D\\X0A\PERICARDIAL SAC, RIGHT ATRIUM AT SUPERIOR VENA CAVA ATRIAL JUNCTION,\X0D\\X0A\BIOPSY:  Malignant.\X0D\\X0A\     HISTOLOGIC TYPE:  Squamous cell carcinoma.\X0D\\X0A\     HISTOLOGIC GRADE:  G2\X0D\\X0A\     TUMOR SIZE:  \R\12 mm\X0D\\X0A\NOTE #1:  There is no light microscopic and/or immunohistochemical\X0D\\X0A\evidence of metastatic carcinoma in the examined planes of section (see\X0D\\X0A\accompanying immunohistochemistry report).",,"GROSS:\X0D\\X0A\The first part received labeled precarinal node contains several\X0D\\X0A\fragments of yellow fatty tissue measuring approximately 8 mm in\X0D\\X0A\aggregate.  The specimens are entirely frozen as one block.\X0D\\X0A\FROZEN SECTION DIAGNOSIS:  Aggregate of unremarkable lymphoid parenchyma\X0D\\X0A\and associated fibrofatty soft tissue; no tumor seen.     (BEW)\X0D\\X0A\The frozen material is entirely submitted as A1.\X0D\\X0A\The second part received labeled right lower paratracheal lymph nodes\X0D\\X0A\contains multiple variably sized fragments of dark brown anthracotic\X0D\\X0A\lymph node and associated yellow adipose tissue measuring approximately\X0D\\X0A\2.2 cm in aggregate.  The specimens are entirely frozen as one block.\X0D\\X0A\FROZEN SECTION DIAGNOSIS:  Unremarkable lymph nodes and associated\X0D\\X0A\fibrofatty perinodal soft tissue; negative for malignancy.      (BEW)\X0D\\X0A\The frozen material is entirely submitted as B1.\X0D\\X0A\The third part received labeled lymph node of right pulmonary artery\X0D\\X0A\adjacent to right upper lobe bronchus are multiple fragments of red and\X0D\\X0A\tan tissue that are 3-8 mm and are entirely submitted as C1.\X0D\\X0A\The fourth part received labeled right upper lobe bronchus is a 1.4 cm\X0D\\X0A\fragment of red and tan tissue which is entirely submitted as D1.\X0D\\X0A\The fifth part received labeled azygous node are three fragments of red\X0D\\X0A\and tan tissue that are 9 mm up to 1.5 cm. The larger fragments are\X0D\\X0A\bisected revealing two lymph nodes that are 4 and 5 mm. The specimen is\X0D\\X0A\entirely submitted as E1.\X0D\\X0A\The sixth part received labeled additional right upper lobe is a 1.1 cm\X0D\\X0A\piece of red and tan tissue which is bisected and entirely submitted as\X0D\\X0A\F1.\X0D\\X0A\The seventh part received labeled right middle lobe are three fragments\X0D\\X0A\of red and tan tissue that are 5 mm up to\X0D\\X0A\1.5 cm. The specimens are bisected and entirely submitted as G1.\X0D\\X0A\The eighth part received labeled upper bronchus nerve is a 1.5 cm\X0D\\X0A\fragment of red and tan tissue which is bisected and entirely submitted\X0D\\X0A\as H1.\X0D\\X0A\The ninth part received labeled middle lobe node are two fragments of\X0D\\X0A\red and tan tissue that are 5 and 7 mm which are each bisected and\X0D\\X0A\entirely submitted as I1.\X0D\\X0A\The tenth part received labeled right upper lobe is a 143 gram 11.9 x\X0D\\X0A\8.4 x 4.4 cm lobectomy specimen. The pleura is pink and tan. Of note is\X0D\\X0A\an area of pleural retraction that is 2.5 cm. This area is marked with\X0D\\X0A\ink and the specimen is sectioned revealing a 2.9 cm firm necrotic tan\X0D\\X0A\neoplasm which is in direct association with the area of pleural\X0D\\X0A\retraction and comes to within 1 mm of the pleural surface. The lesion\X0D\\X0A\also comes to within 1.5 cm of the bronchial margin. The remainder of\X0D\\X0A\the specimen is unremarkable. There are no grossly identifiable\X0D\\X0A\parabronchial lymph nodes. Representative sections of bronchial margin\X0D\\X0A\are submitted as J1, lesion and inked pleural surface J2, 3 and 4, and\X0D\\X0A\random sections through the remainder of the specimen as J5\X0D\\X0A\The eleventh part received labeled pericardial sac from right atrium off\X0D\\X0A\superior vena cava atrial junction is a 2.6 x 2 x 0.3 cm fragment of\X0D\\X0A\pink and tan tissue. Representative sections are submitted as K1.\X0D\\X0A\(LDA)\X0D\\X0A\IMMUNOHISTOCHEMISTRY REPORT\X0D\\X0A\Using formalin fixed paraffin embedded tissue with the appropriate\X0D\\X0A\positive and negative controls, the specimens designated right lower\X0D\\X0A\paratracheal nodes, lymph node right pulmonary artery adjacent to right\X0D\\X0A\upper lobe bronchus, right upper lobe bronchus, azygous node, lymph node\X0D\\X0A\adjacent to right upper lobe, lymph node right middle lobe, upper\X0D\\X0A\bronchus biopsy, right middle lobe node (blocks B1, C1, D1, E1, F1, G1,\X0D\\X0A\H1, I1) are stained for immunoreactive pankeratin using an automated\X0D\\X0A\immunohistochemical technique.  The examined preparations are\X0D\\X0A\interpreted as negative; all external controls react appropriately.\X0D\\X0A\INTERPRETATION:  Unremarkable lymph nodes and associated perinodal soft\X0D\\X0A\tissue without light microscopic and/or immunohistochemical evidence of\X0D\\X0A\metastatic squamous cell carcinoma.\X0D\\X0A\Preliminary Diagnosis performed by\X0D\\X0A\**NAME[M. M. ZZZ], M.D.\X0D\\X0A\Electronically signed **DATE[Aug 18 2012] 1:49PM  Final Diagnosis performed by\X0D\\X0A\**NAME[M. M. ZZZ], M.D.\X0D\\X0A\Electronically signed **DATE[Aug 19 2012] 12:31PM",,SPECIMEN:  A. PRE CARINAL NODES; B. RIGHT LOWER PARATRACHEAL NODES; C.\X0D\\X0A\LYMPH NODE RT PULMONARY ARTERY ADJACENT TO RT UPPER LOBE BRONCHUS; D. RT\X0D\\X0A\UPPER LOBE BRONCHUS; E. AZYGOS NODE; F. ADDITIONAL TO RT UPPER LOBE; G.\X0D\\X0A\RIGHT MIDDLE LOBE; H. RIGHT UPPER BRONCHUS NERVE; I. RT MIDDLE LOBE\X0D\\X0A\NODE; J. RIGHT UPPER LOBE; K. PERICARDIAL SAC FROM RT ATRIUM OFF OF\X0D\\X0A\SUPERIOR VENA CAVA ATRIAL JUNCTION,,
REG1,LUNG,0,144431,3,,"CLINICAL HISTORY:\X0D\\X0A\Suspected malignancy left upper and lower lobe nodules, PET  active.","AP SPECI\X0D\\X0A\**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\ADDENDUM I\X0D\\X0A\**DATE[Aug 29 2012]\X0D\\X0A\ \X0D\\X0A\SPECIAL STUDY:  ALK gene rearrangement by FISH.\X0D\\X0A\ \X0D\\X0A\Tissue is sent to Genzyme for ALK gene rearrangement studies by FISH.\X0D\\X0A\The result:\X0D\\X0A\ \X0D\\X0A\INTERPRETATION:  NEGATIVE FOR A REARRANGEMENT INVOLVING THE ALK GENE.\X0D\\X0A\ \X0D\\X0A\The outside consultant's report is on file with this department and can\X0D\\X0A\be requested if desired.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (MC/kd)\X0D\\X0A\ADDENDUM II\X0D\\X0A\**DATE[Sep 01 2012]\X0D\\X0A\ \X0D\\X0A\SPECIAL STUDY - EGFR MUTATION BY PCR PERFORMED AT GENZYME:\X0D\\X0A\ \X0D\\X0A\RESULTS: NO EGFR MUTATION DETECTED\X0D\\X0A\ \X0D\\X0A\The report is on file with our department and can be requested if\X0D\\X0A\desired.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (MC/dkv)\X0D\\X0A\AMENDMENT\X0D\\X0A\**DATE[Jul 31 2012]   correction of visceral pleural invasion on specimen A.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (MC/dkv)\X0D\\X0A\The previous value GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   LUNG, LEFT UPPER LOBE, WEDGE R was corrected by IF on **DATE[Jul 31 12]\X0D\\X0A\09:33\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Jul 31 12] 09:33\X0D\\X0A\\X0D\\X0A\The previous value **** THIS IS AN AMENDED REPORT **** was corrected by\X0D\\X0A\IF on **DATE[Aug 30 12] 09:02\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Aug 30 12] 09:02\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Sep 01 12] 13:27\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Jul 31 12] 09:33\X0D\\X0A\\X0D\\X0A\The previous value **NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jul 31 21] was corrected by IF on **DATE[Aug 30 12] 09:02\X0D\\X0A\\X0D\\X0A\The previous value **NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Aug 30 21] was corrected by IF on **DATE[Sep 01 12] 13:27","GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   LUNG, LEFT UPPER LOBE, WEDGE RESECTION: MODERATE TO POORLY\X0D\\X0A\DIFFERENTIATED ADENOCARCINOMA WITH PERIPHERAL LEPIDIC GROWTH.\X0D\\X0A\1.   TUMOR SIZE: 1.7 cm. maximally.\X0D\\X0A\2.   TUMOR FOCALITY: Unifocal\X0D\\X0A\3.   HISTOLOGIC GRADE: Moderate to poorly differentiated (G3).\X0D\\X0A\4.   VISCERAL PLEURAL INVASION: Not identified by elastin stain.\X0D\\X0A\5.   TUMOR EXTENSION: Not identified.\X0D\\X0A\6.   MARGINS AND EXTENT:\X0D\\X0A\a.   Margin of excision free of tumor.\X0D\\X0A\b.   Lymphovascular invasion: Not identified.\X0D\\X0A\7.   PATHOLOGIC STAGE: mpT1aNXMXG1\X0D\\X0A\B.   LUNG, LEFT LOWER LOBE, WEDGE RESECTION: POSITIVE FOR MODERATELY\X0D\\X0A\DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\1.   TUMOR SIZE: 1.0 cm.\X0D\\X0A\2.   TUMOR FOCALITY: Unifocal\X0D\\X0A\3.   HISTOLOGIC GRADE: Moderately differentiated (G2).\X0D\\X0A\4.   VISCERAL PLEURAL INVASION:  Not identified.\X0D\\X0A\5.   TUMOR EXTENSION: Not identified.\X0D\\X0A\6.   MARGINS AND EXTENT:\X0D\\X0A\a.   Parenchymal margin is free of tumor, tumor comes to within 1.5 mm.\X0D\\X0A\of the inked margin.\X0D\\X0A\b.   Lymphovascular invasion: not identified.\X0D\\X0A\7.   PATHOLOGIC STAGE: mpT1aNXMXG2\X0D\\X0A\ \X0D\\X0A\COMMENT: The tumors have a different morphologic appearance with\X0D\\X0A\carcinoma-in-situ.  No evidence of lymphovascular space invasion is\X0D\\X0A\identified.  Status of nodes is unknown, thus these tumors are staged as\X0D\\X0A\synchronous primaries.  Clinical correlation is required.\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Sep 01 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received fresh for frozen section designated 'left upper\X0D\\X0A\lobe wedge' is an 11.4 x 4.2 x 2.2 cm. wedge resection specimen closed\X0D\\X0A\by a line of staples, which has been previously incised to reveal a 1.7\X0D\\X0A\cm. gray-white firm subpleural nodule located 2.7 cm. from the margin.\X0D\\X0A\The staple line is removed.  A representative section of the tumor and\X0D\\X0A\the margin are submitted in a single cassette for frozen section\X0D\\X0A\analysis.  FROZEN SECTION DIAGNOSIS (DR. **NAME[XXX, WWW] HOSPITAL\X0D\\X0A\**PLACE, CLIA ID# 18D0320857):  ADENOCARCINOMA.  MARGIN FREE OF\X0D\\X0A\TUMOR. The frozen section remnant is submitted in cassettes (AFS).  The\X0D\\X0A\results are called directly to Dr. **NAME[VVV].  The overlying pleural\X0D\\X0A\surface is puckered.  There is pleural anthracosis.  The remaining\X0D\\X0A\tissue is serially sectioned and carefully palpated.  No additional\X0D\\X0A\tumor is identified in the wedge resection specimen.  Additional\X0D\\X0A\sections of tumor are submitted in cassettes (A2-A4).\X0D\\X0A\Specimen (B) Received fresh for frozen section designated 'left lower\X0D\\X0A\lobe pulmonary nodule' is a 4.5 x 1.8 x 0.8 cm. pulmonary wedge\X0D\\X0A\resection specimen, which has been previously incised to reveal a 1 cm.\X0D\\X0A\nodule grossly located 0.2 cm. from the stapled parenchymal margin.  A\X0D\\X0A\section is submitted for frozen section analysis.  FROZEN SECTION\X0D\\X0A\DIAGNOSIS (DR. **NAME[XXX, WWW] HOSPITAL **PLACE, CLIA ID# 18D0320857):\X0D\\X0A\ADENOCARCINOMA.  The frozen section remnant is submitted in cassette\X0D\\X0A\(BFS).  The results are called directly to Dr. **NAME[VVV].  The staple\X0D\\X0A\line is removed.  The margin is inked. Additional sections of tumor are\X0D\\X0A\submitted in cassette (B2).  The remaining tissue is sectioned and\X0D\\X0A\carefully palpated.  No additional tumor nodularity is identified.\X0D\\X0A\(MC/kd)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 6\X0D\\X0A\ \X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: LEFT UPPER LUNG, WEDGE\X0D\\X0A\B: LEFT LOWER PULMONARY NODULE\X0D\\X0A\ \X0D\\X0A\LUNG: Resection\X0D\\X0A\Specimen Type: Wedge resection\X0D\\X0A\Laterality:    Left\X0D\\X0A\Tumor Site:    Upper and lower\X0D\\X0A\Histologic Type:    Adenocarcinoma, not otherwise characterized\X0D\\X0A\Histologic Grade:   G3\X0D\\X0A\Visceral Pleural Invasion:    Indeterminant\X0D\\X0A\Pathologic Staging (pTNM)\X0D\\X0A\Primary Tumor (pT): pT1a\X0D\\X0A\Regional Lymph Nodes (pN):    pNX\X0D\\X0A\Number examined:    0\X0D\\X0A\Number involved:    0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Margins uninvolved by invasive carcinoma\X0D\\X0A\Direct Extension of Tumor:    None identified\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Arterial (Large Vessel) Invasion:  Absent\X0D\\X0A\Lymphatic (Small Vessel) Invasion (L):  Absent\X0D\\X0A\Comment(s):    Multiple tumor nodules",,"SPECIMEN(S): A LEFT UPPER LUNG, WEDGE\X0D\\X0A\SPECIMEN(S): B LEFT LOWER PULMONARY NODULE",,
REG1,LUNG,0,299733,4,,Clinical Diagnosis and History\X0D\\X0A\MEDIASTINAL MASS\X0D\\X0A\OPER: MEDIASTINOSCOPY\X0D\\X0A\FROZEN SECTION\X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX#1: POORLY DIFFERENTIATED MALIGNANT NEOPLASM. (CLS) (REPORTED TO DR. **NAME[ZZZ]\X0D\\X0A\AT 8:39 A.M.)\X0D\\X0A\TOUCH PREP AND FSDX#2: POORLY DIFFERENTIATED MALIGNANT NEOPLASM.  (CLS)\X0D\\X0A\(REPORTED TO DR. **NAME[ZZZ] \X0D\\X0A\  AT 8:39 A.M.),"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: R4 -FS-ag-SENT FOR FLOW\X0D\\X0A\2: ANTERIOR MEDIASTINAL MASS -FS-aG\X0D\\X0A\3: MEDIASTINAL MASS -FRESH SENT TO PRECISION-ag\X0D\\X0A\4: MEIDIASTINAL MASS -ag","Final Diagnosis\X0D\\X0A\1:  R4 LYMPH NODE:\X0D\\X0A\     FAVOR SMALL CELL NEUROENDOCRINE CARCINOMA, SEE COMMENT.\X0D\\X0A\2:  ANTERIOR MEDIASTINUM, BIOPSY:\X0D\\X0A\     FAVOR SMALL CELL NEUROENDOCRINE CARCINOMA, SEE COMMENT.\X0D\\X0A\3:  MEDIASTINAL, BIOPSY:\X0D\\X0A\     PRECISION STUDY RESULTS PENDING; SEPARATE REPORT TO FOLLOW.\X0D\\X0A\4:  MEDIASTINUM, BIOPSY:\X0D\\X0A\     FAVOR SMALL CELL NEUROENDOCRINE CARCINOMA, SEE COMMENT.\X0D\\X0A\Comment:  Immunohistochemical studies show strong diffuse staining with\X0D\\X0A\neuroendocrine markers. In addition, there is equivocal immunoreactivity for p63\X0D\\X0A\and CK 5/6, markers typically seen in association with squamous cell carcinoma.\X0D\\X0A\These latter studies will be repeated. Results to follow.\X0D\\X0A\NOTE: See microscopic section for details regarding immunohistochemical studies\X0D\\X0A\that have been performed.\X0D\\X0A\CLS/in /**INITIALS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **NAME[XXX",,"Gross Description\X0D\\X0A\1: Received fresh designated \""R4\"" are two irregular fragments of soft tan tissue\X0D\\X0A\measuring 0.8 x 0.4 x 0.3 cm and 1.5 x 1.0 x 0.7 cm.  The larger fragment is\X0D\\X0A\bisected.  Touch preps are performed.  A representative portion is frozen in one\X0D\\X0A\block with control submitted as FSC1A.  A portion of the remaining tissue is\X0D\\X0A\submitted for flow cytometric analysis.  What remains is submitted in block 1A.\X0D\\X0A\2: Received fresh designated \""anterior mediastinal mass\"" is a 0.7 x 0.7 x 0.4 cm\X0D\\X0A\piece of soft tan tissue.  Touch preps are performed and the entire specimen is\X0D\\X0A\frozen in one block with control submitted as FSC2A.  **INITIALS\X0D\\X0A\3: Received fresh for frozen section evaluation labeled  \""mediastinal mass\"" is\X0D\\X0A\an aggregate of tan red soft tissue in aggregate measuring 1.5 x 1.0 x 0.5 cm.\X0D\\X0A\Entirely submitted to Precision as requested by the surgeon.\X0D\\X0A\**INITIALS\X0D\\X0A\4: Received in formalin designated \""mediastinal mass\"" are pieces of yellow tan\X0D\\X0A\to pink tan tissue on a small telfa pad.  These range from 0.2 to 0.8 cm in\X0D\\X0A\greatest dimension and are 1.3 x 1.0 x0 .4 cm in aggregate. The entire specimen\X0D\\X0A\is submitted as 4.\X0D\\X0A\**INITIALS \X0D\\X0A\/cb","Microscopic Description\X0D\\X0A\Incorporated in diagnosis.\X0D\\X0A\Results of immunohistochemical studies:\X0D\\X0A\Using appropriate positive and negative controls, the following antibodies (with\X0D\\X0A\results) are performed: Synaptophysin (+), \X0D\\X0A\CD56 (+), P63 (equivocal), CK5/6 (equivocal), CD45 (-), TTF1 (-), CK7 (-),\X0D\\X0A\Napsin (-).  Immunohistochemical studies in correlation with the morphologic\X0D\\X0A\findings  favor small cell neuroendocrine carcinoma.  Cannot completely exclude\X0D\\X0A\an intermixed squamous cell carcinoma component. See comment above under\X0D\\X0A\Diagnosis section.",,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jul 2 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jul 2 2012]     By:  **NAME[VVV,UUU]\X0D\\X0A\     Date Reported:     **DATE[Jul 2 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding flow cytometry analysis.\X0D\\X0A\INTERPRETATION, in part, reads:\X0D\\X0A\ANTERIOR MEDIASTINUM:\X0D\\X0A\- B- and T-cells are essentially absent, see comment.\X0D\\X0A\- CD56(+), CD45(-) cells are observed suggesting a possible nonhematopoietic\X0D\\X0A\neoplasm, see comment.\X0D\\X0A\COMMENT:  Given the low viability, the results of this study should be\X0D\\X0A\interpreted with caution. Correlation with morphologic evaluation of the\X0D\\X0A\original tissue sections and immunohistochemical study is recommended.  Signed: \X0D\\X0A\**NAME[TTT SSS], MD    /ap \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[YYY], M.D., **NAME[XXX]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jul 7 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jul 7 2012]     By:  **NAME[RRR, QQQ]\X0D\\X0A\     Date Reported:     **DATE[Jul 7 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report regarding Immunohistochemistry Analysis from\X0D\\X0A\Genzyme Laboratories in electronic medical file.\X0D\\X0A\Their report, in part:\X0D\\X0A\These results support small cell carcinoma.\X0D\\X0A\Signed: **NAME[PPP OOO M. NNN], M.D.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[YYY], M.D., **NAME[XXX]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jul 30 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jul 30 2012]     By:  **NAME[RRR, QQQ]\X0D\\X0A\     Date Reported:     **DATE[Jul 30 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\For details see the complete separately scanned ChemoFx report from Precision\X0D\\X0A\Therapeutics in the electronic medical records file.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[YYY], M.D., **NAME[XXX"
REG1,LUNG,0,303187,3,,Clinical Diagnosis and History\X0D\\X0A\Left lung mass.,Copy To:  \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Biopsy left lung mass,"Final Diagnosis\X0D\\X0A\Fine needle core biopsy left lung mass;   \X0D\\X0A\     A.     Moderately differentiated adenocarcinoma.\X0D\\X0A\     B.     Dense reactive fibrosis of background stroma with mild anthracosis. \X0D\\X0A\Comment:      An immunohistochemical staining panel is performed, and reveals\X0D\\X0A\the tumor to demonstrate strong nuclear immunoreactivity to TTF-1 immunostains,\X0D\\X0A\strong cytoplasmic immunoreactivity to CK7 immunostains and only weak focal\X0D\\X0A\immunoreactivity to stains for CK20.  This staining pattern would be consistent\X0D\\X0A\with lung primary.  Clinical correlation recommended.  \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\Ben **NAME[M. ZZZ], MD",,"Gross Description\X0D\\X0A\Specimen #1 is received in formalin, labeled with the patient's name and \""left\X0D\\X0A\lung mass.\""  The specimen consists of two gray-white soft tissue core biopsies\X0D\\X0A\ranging from 0.5 cm in length x less than 0.1 cm in diameter to 0.8 cm in length\X0D\\X0A\x less than 0.1 cm in diameter.  The cores are inked with hematoxylin and are\X0D\\X0A\totally submitted in (block A). \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Serial step sections of fine needle core biopsy of lung mass reveal a moderately\X0D\\X0A\differentiated adenocarcinoma infiltrating a densely fibrotic stroma replacing\X0D\\X0A\pulmonary parenchyma.  A small amount of anthracotic pigment is present within\X0D\\X0A\the background stroma.  The tumor demonstrates irregular serpiginous nests and\X0D\\X0A\ribbons of cells with occasional gland formations.  Tumor cells are enlarged\X0D\\X0A\with plump mildly pleomorphic nuclei, enlarged round nucleoli and varying\X0D\\X0A\amounts of pale pinkish-gray cytoplasm.  Increased numbers of mitotic figures\X0D\\X0A\are identified.  The presence of discrete glands, and large cell size would tend\X0D\\X0A\to rule out a metastatic breast carcinoma in this patient with a known clinical\X0D\\X0A\history of lobular carcinoma of the breast.  \X0D\\X0A\BHT/js",,,
REG1,LUNG,0,401283,3,,"Clinical Diagnosis and History\X0D\\X0A\LEFT LOWER LOBE MASS\X0D\\X0A\OPER:  L VAT\X0D\\X0A\FROZEN SECTION AND BRONCHIAL VASCULAR MARGINS\X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX#1 (4 BLOCKS):  BRONCHIAL AND VASCULAR MARGINS (A, B)  BENIGN.  **INITIALS \X0D\\X0A\                   SHAVE STAPLE LINE MARGIN (C)  BENIGN.  **INITIALS \X0D\\X0A\                   TUMOR (D)  ADENOCARCINOMA.  **INITIALS","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT LOWER LOBE FOR FROZEN SECTION AND BRONCHIAL VACULAR MARGINS. jl  (SENT\X0D\\X0A\TO PRECISION)\X0D\\X0A\2: L8 rd\X0D\\X0A\3: STATION 7 rd\X0D\\X0A\4: L10 rd","Final Diagnosis\X0D\\X0A\1: LUNG \""LEFT LOWER LOBE\"":\X0D\\X0A\       CAP TUMOR REPORTING PROTOCOL:\X0D\\X0A\     SPECIMEN: LOBE.\X0D\\X0A\     PROCEDURE: LOBECTOMY.\X0D\\X0A\     SPECIMEN INTEGRITY: INTACT.\X0D\\X0A\     SPECIMEN LATERALITY: LEFT.\X0D\\X0A\     TUMOR SITE: LOWER LOBE.\X0D\\X0A\     TUMOR SIZE: 2.9 X 2.0 X 1.7 CM.\X0D\\X0A\     TUMOR FOCALITY: UNIFOCAL.\X0D\\X0A\     HISTOLOGIC TYPE: ADENOCARCINOMA WITH BRONCHOALVEOLAR FEATURES.\X0D\\X0A\     HISTOLOGIC GRADE: MODERATELY DIFFERENTIATED (GRADE 2).\X0D\\X0A\     VISCERAL PLEURA INVASION: NOT IDENTIFIED.\X0D\\X0A\     MARGINS: \X0D\\X0A\          BRONCHIAL MARGIN: UNINVOLVED.\X0D\\X0A\          VASCULAR MARGIN: UNINVOLVED.\X0D\\X0A\          PARENCHYMAL MARGIN: UNINVOLVED.\X0D\\X0A\     DISTANCE OF INVASIVE CARCINOMA FROM CLOSEST MARGIN:  APPROXIMATELY 1.0 CM\X0D\\X0A\          (STAPLE LINE PARENCHYMAL MARGIN).\X0D\\X0A\     TREATMENT EFFECT: NOT APPLICABLE.\X0D\\X0A\     LYMPHOVASCULAR INVASION: PRESENT.\X0D\\X0A\     LYMPH NODES: \X0D\\X0A\          ATTACHED LYMPH NODES: 4.\X0D\\X0A\          LYMPH NODES with METASTATIC CARCINOMA: 1.\X0D\\X0A\          ADDITIONALLY SUBMITTED LYMPH NODES: 2 (SPECIMENS 3 AND 4).\X0D\\X0A\          TOTAL LYMPH NODES SAMPLED: 6.\X0D\\X0A\     ADDITIONAL PATHOLOGIC FINDINGS: FOCAL SUBPLEURAL OSSEOUS METAPLASIA.\X0D\\X0A\     ANCILLARY TESTING: PORTION SUBMITTED TO PRECISION LABORATORY FOR\X0D\\X0A\          CHEMOSENSITIVITY TESTING AS REQUESTED.\X0D\\X0A\2: \""L8\"":\X0D\\X0A\     BENIGN FIBROADIPOSE TISSUE.\X0D\\X0A\3: \""STATION 7\"":\X0D\\X0A\     BENIGN ANTHRACOTIC LYMPHOID TISSUE.\X0D\\X0A\4: \""L10\"":\X0D\\X0A\     BENIGN ANTHRACOTIC LYMPHOID TISSUE.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\1:  Received fresh for frozen section evaluation labeled \""left lower lobe\"" is a\X0D\\X0A\21.5 x 10.5 x 5.7 cm lobe of lung.  The pleural surface is smooth, gray and\X0D\\X0A\glistening.  Multiple staple lines are present ranging to 15.5 cm in length. \X0D\\X0A\Shave bronchial and vascular margins are submitted as frozen section blocks 1A\X0D\\X0A\and B.  Sectioning reveals a subpleural firm tan tumor, 2.9 x 2.0 x 1.7 cm,\X0D\\X0A\which extends to within 0.2 cm of the overlying pleura and to within 1.0 cm of\X0D\\X0A\the closest staple line margin.  The closest staple line margin is shaved and\X0D\\X0A\submitted as frozen section 1C.  Representative sections of tumor are submitted\X0D\\X0A\as frozen section 1D.  Several anthracotic peribronchial lymph nodes are\X0D\\X0A\present.  The remainder of the lung demonstrates the usual spongy gray cut\X0D\\X0A\surface.  There is patchy hemorrhage adjacent to the staple line.  A 0.1-cm\X0D\\X0A\possibly calcified subpleural nodule is present, located approximately 3 cm from\X0D\\X0A\the tumor.  No additional abnormalities are noted.  A representative portion of\X0D\\X0A\tumor is submitted to Precision Labs for testing as requested.\X0D\\X0A\SUMMARY OF SECTIONS:\X0D\\X0A\1A:  Smaller peribronchial anthracotic lymph node, submitted intact.\X0D\\X0A\1B:  Additional possible peribronchial lymph node.\X0D\\X0A\1C, D, E:  Tumor with overlying pleura.\X0D\\X0A\1F, G:  Lung tissue away from tumor.\X0D\\X0A\1H:  Subpleural nodule, submitted intact.\X0D\\X0A\**INITIALS\X0D\\X0A\2: Received in formalin labeled \""L8\"" is a 0.9 x 0.4 x 0.3 cm piece of\X0D\\X0A\hemorrhagic tissue which is submitted uncut as 2.\X0D\\X0A\3: Received in formalin labeled \""station 7\"" are three strips and pieces of black\X0D\\X0A\and red tissue which range from 0.6 to 1.0 cm in greatest dimension.  These are\X0D\\X0A\submitted uncut as 3.\X0D\\X0A\4: Received in formalin labeled \""L10\"" are several irregular pieces of black and\X0D\\X0A\red tissue which are 1.2 x 1.0 x 0.5 cm in aggregate.  A single small metal clip\X0D\\X0A\is identified within the specimen.  This is removed and the remainder of the\X0D\\X0A\specimen is submitted as 4.  **INITIALS","Microscopic Description\X0D\\X0A\Performed, not dictated.",,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 20 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 20 2012]     By:  **NAME[XXX,WWW]\X0D\\X0A\     Date Reported:     **DATE[Apr 21 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Precision Therapeutics in the electronic\X0D\\X0A\medical records file regarding in vitro response summary.    /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **NAME[YYY"
REG1,LUNG,0,425996,3,,Clinical Diagnosis and History\X0D\\X0A\The working history is lung nodule.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\4: Lymph node, biopsy","Final Diagnosis\X0D\\X0A\1.          LEFT UPPER LOBE OF LUNG, LOBECTOMY:\X0D\\X0A\     Infiltrating moderately differentiated squamous cell carcinoma.\X0D\\X0A\Gross tumor size = 3.4x2.5x2.8 cm.\X0D\\X0A\Invasive tumor 0.8 cm from bronchial margin with squamous cell carcinoma in situ\X0D\\X0A\present at bronchial margin.\X0D\\X0A\Angiolymphatic permeation by neoplasm present.\X0D\\X0A\Metastatic carcinoma present in two of eight level 12 lymph nodes. See Template.\X0D\\X0A\2.          LEVEL 5 LYMPH NODE:\X0D\\X0A\     One lymph node negative for metastatic carcinoma.\X0D\\X0A\3.          LEVEL 9 LYMPH NODE:\X0D\\X0A\     One lymph node negative for metastatic carcinoma.\X0D\\X0A\4.          LEVEL 7 LYMPH NODE:\X0D\\X0A\     One lymph node negative for metastatic carcinoma. \X0D\\X0A\LUNG CARCINOMA \X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  Lobectomy.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\LATERALITY:  Left.\X0D\\X0A\TUMOR FOCALITY:  Unifocal.\X0D\\X0A\TUMOR SITE:  Left upper lobe.\X0D\\X0A\TUMOR SIZE (greatest dimension):  3.4x2.8x2.5 cm.\X0D\\X0A\HISTOLOGIC TYPE:  Squamous carcinoma.\X0D\\X0A\HISTOLOGIC GRADE:  2.\X0D\\X0A\VISCERAL PLEURA INVASION:  No.\X0D\\X0A\TUMOR EXTENSION:  Confined within the lobe.\X0D\\X0A\     BRONCHIAL MARGIN:  Squamous carcinoma in situ present at margin; invasive\X0D\\X0A\tumor 0.8 cm from bronchial margin.\X0D\\X0A\VASCULAR MARGIN:  Negative.\X0D\\X0A\LYMPHVASCULAR INVASION:  Yes\X0D\\X0A\CHEST WALL MARGIN:  Not involved.\X0D\\X0A\OTHER TISSUE MARGIN:  Not involved.\X0D\\X0A\     REGIONAL LYMPH NODE STATUS:  2/8 level 12 lymph nodes positive for\X0D\\X0A\metastatic carcinoma, 0/1 level 5, 0/1 level 7, 0/1 level 9.\X0D\\X0A\EXTRANODAL TUMOR SPREAD: No\X0D\\X0A\TREATMENT EFFECT:  None.\X0D\\X0A\OTHER METASTATIC SITES:  Unknown.\X0D\\X0A\OTHER NEOPLASM SITES: Unknown.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Respiratory bronchiolitis.\X0D\\X0A\OTHER STUDIES:  Not requested.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  2a\X0D\\X0A\pN=  1\X0D\\X0A\AJCC PATHOLOGIC STAGE:    IIA.\X0D\\X0A\JFJ/mbc",,"Gross Description\X0D\\X0A\Specimen 1 labeled left upper lobe with bronchial margins, received fresh for\X0D\\X0A\frozen section, consists of 286 gram lobectomy specimen that measures\X0D\\X0A\18.0x10.2x4.0 cm. At a distance of approximately 8 mm from the bronchial margin\X0D\\X0A\is a tan tumor mass that measures 3.4x2.5x2.8 cm. The tumor extends to the\X0D\\X0A\pleural surface of this region but no extension through the pleura is seen. It\X0D\\X0A\also abuts some parabronchial nodes but no definite nodal involvement is\X0D\\X0A\identified. No additional masses are seen on sectioning through the lung.\X0D\\X0A\Sections are submitted as follows: frozen section resubmitted as A and B;\X0D\\X0A\arteriole margin with parabronchial nodes in C; sections of tumor in D-F; random\X0D\\X0A\section of lung away from mass in G. \X0D\\X0A\Specimen 2 labeled lymph node 5, received in formalin, consists of an 8 mm gray\X0D\\X0A\lymph node with two additional tan fragments of tissue. The aggregate\X0D\\X0A\measurement is 1.5x1.5x0.8 cm. This is submitted in toto. \X0D\\X0A\Specimen 3 labeled lymph node 9, received in formalin, consists of a single 6 mm\X0D\\X0A\gray nodule; submitted in toto. \X0D\\X0A\Specimen 4 labeled lymph node 7, received in formalin, consists of a single 1 cm\X0D\\X0A\gray nodule; submitted in toto. \X0D\\X0A\MHB/mbc",Microscopic Description\X0D\\X0A\Sections from the bronchial margin show benign respiratory epithelium which in\X0D\\X0A\focal areas show immature atypical squamous metaplasia as well as a focal area\X0D\\X0A\of high-grade dysplasia/carcinoma in situ composed of cells with enlarged\X0D\\X0A\hyperchromatic nuclei and displaying mitotic activity. The process extends into\X0D\\X0A\adjacent peribronchial glands. Sections through the invasive tumor show a\X0D\\X0A\squamous cell carcinoma characterized as large groups of malignant cells with\X0D\\X0A\enlarged hyperchromatic nuclei and background eosinophilic cytoplasm with\X0D\\X0A\keratinization. Angiolymphatic permeation by neoplasm is present. Perineural\X0D\\X0A\invasion by neoplasm is not identified. Sections through eight peribronchial\X0D\\X0A\lymph nodes show metastatic carcinoma in two of eight.\X0D\\X0A\Sections through level 5 lymph node show anthracosis and sinus histiocytosis\X0D\\X0A\without evidence of metastatic carcinoma.\X0D\\X0A\Sections from level 9 lymph node show similar findings without evidence of\X0D\\X0A\metastatic carcinoma.\X0D\\X0A\Sections from level 7 lymph node show similar findings without evidence of\X0D\\X0A\metastatic carcinoma.\X0D\\X0A\JFJ/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ M. YYY], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,460059,3,,"HISTORY: right lung nodule, malignant pleural effusion, history right breast CA **DATE[Jul 2011]","ICD9 CODES: 162.9, , \X0D\\X0A\LAB_COMM: SEND BLOCK FOR GCDFP-15, TTF-1, CK7, ER, PR, AND MUCICARMINE ON FRIDAY **DATE[Nov 13 12]","DIAGNOSIS: RIGHT LUNG, CLINICALLY HILAR NODULE \X0D\\X0A\CT GUIDED NEEDLE CORE BIOPSY:     MODERATELY DIFFERENTIATED ADENOCARCINOMA MOST CONSISTENT     WITH PRIMARY PULMONARY ADENOCARCINOMA.     DIFFERENTIAL IMMUNOHISTOCHEMICAL STAIN (ESTROGEN AND     PROGESTERONE RECEPTORS AND GCD-15): NEGATIVE.     IMMUNOHISTOCHEMICAL STAINS (CYTOKERATIN 7, TTF-1): POSITIVE.     HISTOCHEMICAL STAIN (MUCICARMINE): FOCALLY POSITIVE FOR     INTRACYTOPLASMIC MUCIN SUBSTANCES.     SEE DESCRIPTION.",,"GROSS: Single specimen received in Radiology labeled \""CT guided needle biopsies, right lung nodule\"". Clinically malignant pleural effusion, history of right breast cancer in **DATE[Jul 2011].  Specimen consists of multiple variegated needle biopsies varying from white to dark red, the longest 1.7 cm and the smallest 0.3 cm all in one double sponged cassette.  Touch preps are prepared both air dried and alcohol fixed. Adequate for evaluation (**NAME[ZZZ]).  TP DX 1:\""CARCINOMA\"" (**NAME[ZZZ]).  NOTE: Differential immunohistochemical stains will be performed including TTF-1, CK7, ER, PR and mucicarmine stain as well.  DT: **DATE[Nov 12 2012]","MICRO: The CT guided needle core biopsies, right lung nodule, clinically hilar nodule are evaluated in the context of history of infiltrating poorly differentiated mixed ductal and lobular breast carcinoma, right breast and now with right-sided malignant pleural effusion.  The needle core biopsy shows adenocarcinoma.  Pulmonary parenchyma is infiltrated by malignant glandular epithelial cells focally forming malignant glandular lumina.  There is stromal desmoplasia in the background in reaction to this. Focal areas of cohesive cellular infiltrate are identified, in the minority pattern.  Most of the malignant cells are organized into nests with large malignant gland formation. \""Indian file\"" patterns are not observed.  There is a background of stromal desmoplasia and probably a background of parenchymal scar in the lung tissue.  Differential immunohistochemical stains are performed.  The CK7, TTF-1 immunostains are strongly positive in malignant glandular epithelial cells and the mucicarmine stain shows focal cytoplasmic mucin substance positivity. Immunostains ER, PR and GCD-15 are all negative.  It is noted that the patient's previous breast cancer (10-TC-3691) was ER positive at 4+ and PR positive at 1+.  In summary, the right lung nodule is most consistent with a new primary pulmonary adenocarcinoma, this supported by the immunohistochemical staining pattern and histologic evidence of a background pulmonary parenchymal \""scar\"".  Called to Dr. **NAME[YYY] **DATE[Nov 18 12].  DT: **DATE[Nov 18 2012] (**NAME[ZZZ], tlb)",PROCEDURE: CT guided right hilar lung biopsy\X0D\\X0A\SPECIMEN(S): CT guided needle biopsy right lung nodule,,
REG1,LUNG,0,463374,3,,"PREVIOUS HISTORY FROM FILES \X0D\\X0A\ **DATE[Jul 06 2011] ; S10021983 \X0D\\X0A\ RIGHT PROSTATE, APEX, CORE BIOPSY: \X0D\\X0A\ Benign prostate \X0D\\X0A\ Negative for carcinoma \X0D\\X0A\ RIGHT PROSTATE, MID, CORE BIOPSIES: \X0D\\X0A\ Prostatic adenocarcinoma, Gleason score 3 + 3 \X0D\\X0A\ Tumor involves one of one core and approximately 38% of the total \X0D\\X0A\ cores' volume \X0D\\X0A\ Negative for perineural invasion \X0D\\X0A\ **PLACE, KY **ZIP-CODE \X0D\\X0A\ RIGHT PROSTATE, BASE, CORE BIOPSIES: \X0D\\X0A\ Prostatic adenocarcinoma, Gleason score 3 + 3 \X0D\\X0A\ Tumor involves two of two cores and approximately 57% of the total \X0D\\X0A\ cores' volume \X0D\\X0A\ Negative for perineural invasion \X0D\\X0A\ LEFT PROSTATE, APEX, CORE BIOPSIES: \X0D\\X0A\ Benign prostate \X0D\\X0A\ Negative for carcinoma \X0D\\X0A\ LEFT PROSTATE, MID, CORE BIOPSIES: \X0D\\X0A\ Prostatic adenocarcinoma, Gleason score 3 + 3 \X0D\\X0A\ Tumor involves one of two cores and approximately 26% of total cores' \X0D\\X0A\ volume \X0D\\X0A\ Negative for perineural invasion \X0D\\X0A\ LEFT PROSTATE, BASE, CORE BIOPSIES: \X0D\\X0A\ Prostatic adenocarcinoma, Gleason score 3 + 4 \X0D\\X0A\ Tumor involves two or two cores and approximately 55% of the total \X0D\\X0A\ cores' volume \X0D\\X0A\ Negative for perineural invasion \X0D\\X0A\ ---------------------------------------------------------------------- \X0D\\X0A\ **DATE[Jul 06 2011] ; S10021983 \X0D\\X0A\ YES","Patient Age: **AGE[in 50s].\X0A\ CODES: APM/mmm88305  88342x4 COMMENT: The tumor cells show areas of positivity in the immunostains that mark for squamous carcinoma (CK5/P63) and for adenocarcinoma (TTF/Napsin) Because of this, final determination of final tumor type is deferred to further sampling of the tumor (presumed resection specimen). Final report called and faxed to **NAME[YYY] at Dr. **NAME[ZZZ]'s office on **DATE[Aug 13 12] at 9:40 p.m. ** Original Signature on File ** **NAME[XXX M. WWW], M.D. **ID-NUM  **NAME[BBB,AAA] **DATE[Aug 08 2012]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ FINAL DIAGNOSIS: \X0D\\X0A\ RIGHT UPPER LOBE OF LUNG BIOPSIES: \X0D\\X0A\ Invasive non-small cell carcinoma, see COMMENT and IMMUNOSTAINING \X0D\\X0A\ RESULTS \X0D\\X0A\ No vascular space invasion is identified in these small biopsies",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is right lung mass. \X0D\\X0A\ Specimen consists of: \X0D\\X0A\ Pieces:  Multiple \X0D\\X0A\ Aggregate dimensions:  0.4 x 0.3 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. **INITIALS","MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Sections through the submitted right upper lobe of lung biopsies show \X0D\\X0A\ invasive non-small cell carcinoma. There are nests of tumor that show \X0D\\X0A\ enlarged nuclei and nucleoli.  The individual cells appear to show \X0D\\X0A\ intercellular bridge formation suggestive of a squamous carcinoma.  In \X0D\\X0A\ some areas there is extension of the tumor cells into the submucosa of \X0D\\X0A\ the bronchial wall. No vascular space invasion is seen in these small \X0D\\X0A\ biopsies. \X0D\\X0A\ IMMUNOSTAINING RESULTS: \X0D\\X0A\ The tumor cells show areas of positivity for CK5, P63, TTF, and \X0D\\X0A\ Napsin.  These stains have been performed with appropriate control \X0D\\X0A\ slides. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:",TISSUE SUBMITTED: \X0D\\X0A\ Right upper lobe of lung biopsies,,
REG1,LUNG,0,470052,4,,"CLINICAL HISTORY:\X0D\\X0A\Lung nodule, right upper lobe bronchus.",AP SPECI\X0D\\X0A\**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\ADDENDUM I\X0D\\X0A\**DATE[Apr 22 12]\X0D\\X0A\ \X0D\\X0A\SPECIAL STAINS (Cytokeratin AE1/AE3 and synaptophysin)\X0D\\X0A\ \X0D\\X0A\Several special stains are performed including cytokeratin AE1/AE3 and\X0D\\X0A\synaptophysin. The controls stain appropriately.  Synaptophysin is\X0D\\X0A\strongly positive in the cells and the AE1/AE3 cytokeratin has some\X0D\\X0A\dot-like positivity.  This helps confirm that this is a small cell\X0D\\X0A\carcinoma.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (**INITIALS)\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Apr 22 12] 09:47\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Apr 22 12] 09:47\X0D\\X0A\\X0D\\X0A\The previous value **NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 20]/ was corrected by IF on **DATE[Apr 22 12] 09:47,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   RIGHT UPPER LOBE LYMPH NODE: BENIGN ANTHRACOTIC LYMPH NODE.\X0D\\X0A\B.   R4 NODES: BENIGN ANTHRACOTIC LYMPH NODES.\X0D\\X0A\C.   R10 NODES: BENIGN ANTHRACOTIC LYMPH NODES.\X0D\\X0A\D.   LUNG, RIGHT UPPER LOBE SUPERIOR SEGMENT, WEDGE: SMALL CELL\X0D\\X0A\CARCINOMA (HIGH GRADE NEUROENDOCRINE CARCINOMA).\X0D\\X0A\1.   HISTOLOGIC FEATURES:\X0D\\X0A\a.   Histologic type: small cell carcinoma.\X0D\\X0A\b.   Grade: high grade neuroendocrine carcinoma (grade III)\X0D\\X0A\(undifferentiated carcinoma G4).\X0D\\X0A\2.   TUMOR SIZE: Tumor measures 0.9 cm.\X0D\\X0A\3.   MARGINS AND EXTENT:\X0D\\X0A\a.   The specimen is intact.\X0D\\X0A\b.   The tumor is unifocal.\X0D\\X0A\c.   No visceral pleural invasion is identified.\X0D\\X0A\d.   No tumor extension beyond the lung is identified.\X0D\\X0A\e.   The parenchymal margin is uninvolved.\X0D\\X0A\f.   No definitive lymphovascular invasion is identified.\X0D\\X0A\E.   INFERIOR PULMONARY LIGAMENT LYMPH NODE: BENIGN ANTHRACOTIC LYMPH\X0D\\X0A\NODE.\X0D\\X0A\F.   R4 LYMPH NODES: BENIGN ANTHRACOTIC LYMPH NODES.\X0D\\X0A\G.   R10 LYMPH NODES: BENIGN ANTHRACOTIC LYMPH NODES.\X0D\\X0A\H.   LOWER HALF OF RIGHT UPPER LOBE, LOBECTOMY: BENIGN LOBE OF LUNG WITH\X0D\\X0A\NO RESIDUAL TUMOR AND BENIGN BRONCHIAL MARGIN.\X0D\\X0A\ \X0D\\X0A\COMMENT: The overall pathologic staging is pT1a,N0,MX,G4.  A short panel\X0D\\X0A\of immunostains will be performed to confirm this is small cell.  The\X0D\\X0A\results will be reported in an addendum.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Apr 22 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received fresh labeled with the patient's name and\X0D\\X0A\designated 'right upper lobe lung bronchial lymph node'.  FROZEN SECTION\X0D\\X0A\**INSTITUTION DOWNTOWN, CLIA ID# 18D0320857 (DR. **NAME[WWW]):\X0D\\X0A\BENIGN.  The result to Dr. **NAME[VVV]. The specimen consists of several\X0D\\X0A\tan fragments measuring 2.5 x 1.1 x 0.1 cm.  The specimen is submitted\X0D\\X0A\en toto in a single cassette.\X0D\\X0A\Specimen (B) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'R4 lymph node'. The specimen consists of\X0D\\X0A\anthracotic lymph node measuring in aggregate 1.5 x 1.1 x 0.4 cm. The\X0D\\X0A\specimen is submitted en toto in a single cassette.\X0D\\X0A\Specimen (C) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'R10 lymph node'. The specimen consists of\X0D\\X0A\an anthracotic lymph node measuring 1.9 x 1.1 x 0.4 cm. The specimen is\X0D\\X0A\submitted en toto in a single cassette.\X0D\\X0A\Specimen (D) Received fresh labeled with the patient's name and\X0D\\X0A\designated 'right upper lobe superior segment'.  FROZEN SECTION\X0D\\X0A\**INSTITUTION DOWNTOWN, CLIA ID# 18D0320857 (DR. **NAME[WWW]):\X0D\\X0A\NEUROENDOCRINE CARCINOMA CONSISTENT WITH SMALL CELL CARCINOMA.  The\X0D\\X0A\results to Dr. **NAME[VVV].  The frozen section in D1 and D2.  Examination\X0D\\X0A\of the frozen section reveals a gray nodule measuring up to 0.9 cm.\X0D\\X0A\There are two halves of a lobe of lung, the larger half measuring 7.1 x\X0D\\X0A\6.1 x 3.5 cm with the stapled margin and the other measuring 4.5 x 3.9 x\X0D\\X0A\2.5 cm.  Both appear to be wedges.  Sectioning through the lung reveals\X0D\\X0A\no additional tumor masses.  Both halves appear to be wedges.  Sections\X0D\\X0A\of lung without mass in D3 through D6.\X0D\\X0A\Specimen (E) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'inferior pulmonary ligament lymph node'.\X0D\\X0A\The specimen consists of a tan fragment measuring 0.5 x 0.5 x 0.5 cm.\X0D\\X0A\The specimen is submitted en toto in a single cassette.\X0D\\X0A\Specimen (F) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'R4 lymph node'. The specimen consists of\X0D\\X0A\a fragment of lymph node measuring 3.1 x 2.1 x 0.5 cm.  It is submitted\X0D\\X0A\in two cassettes.\X0D\\X0A\Specimen (G) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'R10 lymph node'. The specimen consists of\X0D\\X0A\a tan lymph node measuring 0.5 x 0.5 x 0.6 cm. The specimen is submitted\X0D\\X0A\en toto in a single cassette.\X0D\\X0A\Specimen (H) The specimen is received in formalin labeled with the\X0D\\X0A\patient's name and designated 'lower half of right upper lobe'. The\X0D\\X0A\specimen consists of a lobe of lung weighing 204 grams.  The bronchial\X0D\\X0A\margin in H1.  Potential lymph node and vascular margin in H2.  No\X0D\\X0A\residual tumor mass is identified.  Additional sections of lung in H3\X0D\\X0A\and H4.  (**INITIALS)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 17\X0D\\X0A\ \X0D\\X0A\ \X0D\\X0A\LUNG: Resection\X0D\\X0A\Specimen Type: Lobectomy\X0D\\X0A\Laterality:    Right\X0D\\X0A\Tumor Site:    Upper lobe\X0D\\X0A\Tumor Size:    Greatest dimension: 0.9cm\X0D\\X0A\Histologic Type:    Small cell carcinoma\X0D\\X0A\Histologic Grade:   G4\X0D\\X0A\Visceral Pleural Invasion:    Not Identified\X0D\\X0A\Pathologic Staging (pTNM)\X0D\\X0A\Primary Tumor (pT): pT1a\X0D\\X0A\Regional Lymph Nodes (pN):    pN0\X0D\\X0A\Number examined:    14\X0D\\X0A\Number involved:    0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Margins uninvolved by invasive carcinoma\X0D\\X0A\Margin:   bronchial margin\X0D\\X0A\Direct Extension of Tumor:    None identified\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Arterial (Large Vessel) Invasion:  Absent\X0D\\X0A\Lymphatic (Small Vessel) Invasion (L):  Absent",,"SPECIMEN(S): D RT UPPER LOBE, SUPERIOR SEGMENT\X0D\\X0A\SPECIMEN(S): E INFERIOR PULMONARY LIGAMENT LYMPH NODE\X0D\\X0A\SPECIMEN(S): F R4 LYMPH NODES\X0D\\X0A\SPECIMEN(S): G R10 LYMPH NODES\X0D\\X0A\SPECIMEN(S): H LOWER HALF OF RT UPPER LOBE\X0D\\X0A\SPECIMEN(S): A RT UPPER LOBE BRONCHIOLE\X0D\\X0A\SPECIMEN(S): B R4 NODES\X0D\\X0A\SPECIMEN(S): C R10 NODES",,
REG1,LUNG,0,480903,5,,Clinical Diagnosis and History\X0D\\X0A\The working history is bladder cancer.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, Wedge or Bleb\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\4: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[May 22 2012]. 1. RIGHT LUNG NODULE, FINE NEEDLE ASPIRATE WITH CELL\X0D\\X0A\BLOCK #1: Poorly differentiated non-small cell carcinoma. 2. RIGHT LUNG NODULE,\X0D\\X0A\FINE NEEDLE ASPIRATE WITH CELL BLOCK #2: Poorly differentiated non-small cell\X0D\\X0A\carcinoma. See COMMENT. (JFJ)\X0D\\X0A\S11007392, **DATE[Aug 14 2011]. TRANSURETHRAL RESECTION OF THE URINARY BLADDER TUMOR:\X0D\\X0A\Papillary transitional cell carcinoma, low-grade. No invasion of submucosa.\X0D\\X0A\Scant muscularis propria (detrusor muscle) identified. Negative for cancer\X0D\\X0A\involvement. SEE COMMENT. (MSG)","Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\1. RIGHT UPPER LOBE WEDGE: \X0D\\X0A\     Poorly differentiated non-small cell neoplasm with marked tumor necrosis\X0D\\X0A\and perivascular tumoral sparing; staple line of excision free of tumor; no\X0D\\X0A\lymphvascular invasion identified. **INITIALS  \X0D\\X0A\PROVISIONAL DIAGNOSIS\X0D\\X0A\1. RIGHT UPPER LOBE WEDGE:\X0D\\X0A\     Poorly differentiated non-small cell neoplasm with marked tumor necrosis\X0D\\X0A\and perivascular tumoral sparing; staple line of excision free of tumor; no\X0D\\X0A\lymphvascular invasion identified.  \X0D\\X0A\2. L7 LYMPH NODE:\X0D\\X0A\     Sinus histiocytosis and anthracosis; no tumor identified; small granuloma\X0D\\X0A\in perinodal tissue.\X0D\\X0A\3. L4 LYMPH NODE:\X0D\\X0A\     Sinus histiocytosis and anthracosis; no tumor identified.\X0D\\X0A\4. RIGHT UPPER LOBE:\X0D\\X0A\     Focal organizing pneumonitis and intraalveolar hemorrhage; no tumor\X0D\\X0A\identified; bronchial and vascular margins of excision free of tumor; three\X0D\\X0A\hilar nodes negative for tumor with scattered hyalinized granulomata. \X0D\\X0A\     LUNG CARCINOMA \X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  Right upper lobe wedge excision with completion right\X0D\\X0A\upper lobe lobectomy.\X0D\\X0A\SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\LATERALITY:  Right.\X0D\\X0A\TUMOR FOCALITY:  Unifocal.\X0D\\X0A\TUMOR SITE:  right upper lobe\X0D\\X0A\TUMOR SIZE (greatest dimension):  1.8x1.8x1.5 cm.\X0D\\X0A\HISTOLOGIC TYPE:  Poorly differentiated neoplasm, immunohistochemistry pending.\X0D\\X0A\HISTOLOGIC GRADE:  Grade 3.\X0D\\X0A\VISCERAL PLEURA INVASION: None. \X0D\\X0A\TUMOR EXTENSION:  None.\X0D\\X0A\BRONCHIAL MARGIN:  Negative for tumor.\X0D\\X0A\VASCULAR MARGIN:  Negative for tumor.\X0D\\X0A\LYMPHVASCULAR INVASION:  Absent.\X0D\\X0A\PARENCHYMAL MARGIN:  Negative.\X0D\\X0A\CHEST WALL MARGIN:  Negative.\X0D\\X0A\OTHER TISSUE MARGIN:  Unknown.\X0D\\X0A\     REGIONAL LYMPH NODE STATUS:   One level 7 lymph node, one level 4 lymph\X0D\\X0A\node, and three hilar nodes all negative for tumor.\X0D\\X0A\EXTRANODAL TUMOR SPREAD:  N/A.\X0D\\X0A\TREATMENT EFFECT:  None.\X0D\\X0A\OTHER METASTATIC SITES: Unknown. \X0D\\X0A\OTHER NEOPLASM SITES: Unknown.\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Changes compatible with aspiration and foreign\X0D\\X0A\body giant cell reaction.\X0D\\X0A\OTHER STUDIES:  None.\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  1a\X0D\\X0A\pN=  X \X0D\\X0A\pM=  X \X0D\\X0A\AJCC PATHOLOGIC STAGE:    IA.\X0D\\X0A\DGD/mbc",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled right upper lobe wedge\X0D\\X0A\consists of a 25.4 gram, 11.0x4.0x4.0 cm tan/purple lung wedge biopsy.\X0D\\X0A\Sectioning reveals a 1.8x1.8x1.5 cm ill defined tan firm nodule, 1.7 cm from the\X0D\\X0A\closest stapled resection margin. The nodule is at the periphery of the wedge\X0D\\X0A\and grossly involves the pleura. The remaining lung parenchyma is dark purple\X0D\\X0A\and spongy. No other masses are appreciated. A representative section of the\X0D\\X0A\mass is submitted for frozen section. Summary of sections: 1A - frozen section\X0D\\X0A\residue; 1B - stapled resection margin taken en face; 1C-1E - additional\X0D\\X0A\representative sections of mass.\X0D\\X0A\Specimen 2 received in formalin labeled L7 lymph node consists of a 1.5 cm in\X0D\\X0A\greatest dimension black anthracotic lymph node which is submitted in toto in\X0D\\X0A\cassette 2.\X0D\\X0A\Specimen 3 received in formalin labeled L4 lymph node consists of a few pieces\X0D\\X0A\of black anthracotic soft tissue aggregating 0.4 cm in greatest dimension which\X0D\\X0A\are submitted in toto in cassette 3.\X0D\\X0A\Specimen 4 received in formalin labeled right upper lobe consists of a 127.7\X0D\\X0A\gram, 12.0x8.0x5.0 cm intact lobectomy specimen. There is a 7 cm in length\X0D\\X0A\staple line identified consistent with the previous wedge biopsy site. The\X0D\\X0A\staple line is 3.5 cm from the bronchial resection margin. No invasive tumor is\X0D\\X0A\identified along the staple line. Sectioning reveals dark red congested slightly\X0D\\X0A\firm lung parenchyma. No suspicious nodules or invasive tumor is identified. A\X0D\\X0A\few lymph nodes are identified around the hilum. Representative sections are\X0D\\X0A\submitted. Summary of sections: 4A - bronchial resection margin taken en face;\X0D\\X0A\4B - vascular resection margin taken en face; 4C-4D - staple line; 4E - hilar\X0D\\X0A\lymph node.\X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections of the wedge biopsy show a very poorly differentiated non-small cell\X0D\\X0A\neoplasm that is highly necrotic with sparing of viable tumor cells\X0D\\X0A\predominantly seen only around small blood vessels. The tumor has a high degree\X0D\\X0A\of nuclear pleomorphism, prominent macronucleoli and there is a hint of\X0D\\X0A\pigmentation in some of the cytoplasm within the tumor. Immunohistochemistry for\X0D\\X0A\P63, CK5/6, TTF, Napsin, and melanin A mart 1 are pending. \X0D\\X0A\Sections of the node show extensive sinus histiocytosis and anthracosis with no\X0D\\X0A\evidence of metastatic tumor identified. There is a small granuloma in the\X0D\\X0A\adjacent perilymph nodal adipose.\X0D\\X0A\Sections of the entirely submitted lymph nodal tissue show sinus histiocytosis\X0D\\X0A\and anthracosis without evidence of metastatic tumor.\X0D\\X0A\Sections of the bronchial and vascular margins of the right upper lobe resection\X0D\\X0A\show no evidence of tumor. The lung lobe from which the prior wedge excision was\X0D\\X0A\made is also free of tumor, however, it shows acute intraalveolar hemorrhage and\X0D\\X0A\some old focal areas of organizing pneumonitis with scattered foreign body giant\X0D\\X0A\cell which are associated with what appears to be vegetable matter consistent\X0D\\X0A\with aspiration materials. A total of three hilar nodes are seen and these show\X0D\\X0A\sinus histiocytosis and anthracosis with a number of small noncaseating\X0D\\X0A\granulomas some of which are hyalinized.\X0D\\X0A\DGD/mbc\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: Immunohistochemistry for pankeratin is\X0D\\X0A\strongly positive in the tumor cells. There is weak p63 immunostaining and\X0D\\X0A\negative MART-1, TTF1, Napsin, and CK5/6. The tumor is compatible with a poorly\X0D\\X0A\differentiated carcinoma. **INITIALS",,,Amendments:\X0D\\X0A\Amended:  **DATE[Jun 20 2012] by **NAME[ZZZ YYY]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Jun 19 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,LUNG,0,481688,2,,CLINICAL HISTORY:\X0D\\X0A\Bronchoalveolar ca.,"AP SPECI\X0D\\X0A\**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\ADDENDUM I\X0D\\X0A\**DATE[Sep 23 2012]\X0D\\X0A\ \X0D\\X0A\SPECIAL STAINS: (p63, CK7, TTF1)\X0D\\X0A\ \X0D\\X0A\Immunostains were performed on representative material from Specimen C\X0D\\X0A\including p63, CK7 and TTF1.  The tumor cells appear diffusely and\X0D\\X0A\strongly positive for CK7 and the majority of the tumor also appears\X0D\\X0A\positive for p63.  TTF1 staining is judged negative; an unusual finding\X0D\\X0A\with bronchioloalveolar carcinoma.  The results of immunostaining are\X0D\\X0A\somewhat equivocal, but are consistent with metastatic nonsmall cell\X0D\\X0A\carcinoma.  Results of immunostaining favor adenosquamous cell\X0D\\X0A\carcinoma.  Given the history of lung mass, a pulmonary primary is\X0D\\X0A\strongly favored.  Head and neck primaries could also give similar\X0D\\X0A\results.  Clinical correlation is required.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Sep 23 12] 10:11\X0D\\X0A\\X0D\\X0A\The previous value no value was corrected by IF on **DATE[Sep 23 12] 10:11\X0D\\X0A\\X0D\\X0A\The previous value **NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Sep 22]/ was corrected by IF on **DATE[Sep 23 12] 10:11",GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   'LOWER RIGHT PARATRACHEAL LYMPH NODES': FRAGMENTS OF LYMPH NODE\X0D\\X0A\WITH SINUS HISTIOCYTOSIS AND ANTHRACOSIS AND MINIMALLY REPRESENTED\X0D\\X0A\METASTATIC ADENOCARCINOMA (BEST SEEN IN PERMANENT SECTION MATERIAL).\X0D\\X0A\1.   Focus of metastasis measures less than 0.3 mm.\X0D\\X0A\2.   Carcinoma located primarily within subcapsular region and lymphatic\X0D\\X0A\spaces.\X0D\\X0A\B.   'LOWER RIGHT PARATRACHEAL LYMPH NODES': FRAGMENTS OF LYMPH NODE\X0D\\X0A\WITH METASTATIC ADENOCARCINOMA.\X0D\\X0A\1.   Foci of metastasis measures up to 7.0 mm. in single greatest\X0D\\X0A\aggregate dimension.\X0D\\X0A\2.   Focal extranodal extension is identified.\X0D\\X0A\3.   Focal capillary lymphatic space invasion is identified.\X0D\\X0A\C.   'RIGHT LOWER PARATRACHEAL LYMPH NODES': FRAGMENTS OF LYMPH NODE\X0D\\X0A\WITH METASTATIC ADENOCARCINOMA.\X0D\\X0A\1.   Foci of metastatic carcinoma measure up to 6.0 mm. in single\X0D\\X0A\greatest aggregate dimension.\X0D\\X0A\2.   Focal extranodal extension is identified.\X0D\\X0A\3.   Focal capillary lymphatic space invasion by carcinoma is\X0D\\X0A\identified.\X0D\\X0A\ \X0D\\X0A\COMMENT: The frozen section control from Specimen A is reviewed showing\X0D\\X0A\no evidence of malignancy.  Deeper permanent sectioning disclosed a\X0D\\X0A\microscopic focus of adenocarcinoma representing sampling error.  A\X0D\\X0A\short panel of immunoperoxidase stains will be attempted on Specimen C\X0D\\X0A\and reported separately in an addendum.\X0D\\X0A\ \X0D\\X0A\PATHOLOGY #**ID-NUM (**INITIALS)\X0D\\X0A\**NAME[ZZZ:  YYY M. XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Sep 23 2012],,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received fresh for frozen section designated 'lower right\X0D\\X0A\paratracheal nodes' are multiple fragments of indurated maroon, gray and\X0D\\X0A\focally black tissue measuring 1.3 x 0.8 x 0.4 cm. in total aggregate\X0D\\X0A\dimension.  The entire specimen is submitted for frozen section.  FROZEN\X0D\\X0A\SECTION DIAGNOSIS (DR. **NAME[XXX, WWW] HOSPITAL **PLACE, CLIA ID#\X0D\\X0A\18d0320857) NEGATIVE FOR METASTATIC CARCINOMA.  The frozen section\X0D\\X0A\diagnosis is given directly to Dr. **NAME[VVV] by Dr. **NAME[XXX].  The frozen\X0D\\X0A\section control is entirely resubmitted in a single cassette.\X0D\\X0A\Specimen (B) Received fresh for frozen section designated 'lower right\X0D\\X0A\paratracheal lymph node' are multiple fragments of maroon, gray, tan and\X0D\\X0A\black tissue measuring 1.7 x 1.0 x 0.4 cm. in total aggregate dimension.\X0D\\X0A\The entire specimen is submitted for frozen section.  FROZEN SECTION\X0D\\X0A\DIAGNOSIS (DR. **NAME[XXX, WWW] HOSPITAL **PLACE, CLIA ID# 18d0320857)\X0D\\X0A\LYMPH NODE: POSITIVE FOR METASTATIC CARCINOMA.  The frozen section\X0D\\X0A\diagnosis is given directly to Dr. **NAME[VVV] by Dr. **NAME[XXX].  The frozen\X0D\\X0A\section control is resubmitted in a single cassette.\X0D\\X0A\Specimen (C) Received in formalin and designated 'right lower\X0D\\X0A\paratracheal lymph node' are additional fragments of black, pink and\X0D\\X0A\gray soft tissue measuring 2.0 x 1.0 x 0.3 cm. in total aggregate\X0D\\X0A\dimension.  The specimen is filtered and entirely submitted in a single\X0D\\X0A\cassette.\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 3",,SPECIMEN(S): A LOWER RT PARATRACHEAL NODES\X0D\\X0A\SPECIMEN(S): B LOWER RT PARATRACHEAL LYMPH NODES\X0D\\X0A\SPECIMEN(S): C RIGHT LOWER PARATRACHEAL LYMPH NODE,,
REG1,LUNG,0,483878,1,,CLINICAL HISTORY:\X0D\\X0A\Non-small cell lung cancer.,AP SPECI,"GROSS AND MICROSCOPIC PATHOLOGIC DIAGNOSIS:\X0D\\X0A\A.   ANTERIOR SEGMENT LEFT UPPER LOBE LYMPH NODE:\X0D\\X0A\1.   Reactive anthracotic lymph node, negative for metastatic carcinoma.\X0D\\X0A\B.   LEFT UPPER LOBE LYMPH NODE STATION 11:\X0D\\X0A\1.   Fragments of reactive anthracotic lymph node, negative for\X0D\\X0A\metastatic carcinoma.\X0D\\X0A\C.   LUNG, LEFT UPPER LOBE ANTERIOR SEGMENT, WEDGE RESECTION:  WELL\X0D\\X0A\DIFFERENTIATED KERATINIZING SQUAMOUS CELL CARCINOMA\X0D\\X0A\1.   TUMOR SIZE:  0.9 cm.\X0D\\X0A\2.   VISCERAL PLEURAL INVASION:  Not identified by elastin stain.\X0D\\X0A\3.   TUMOR EXTENSION:  Not identified.\X0D\\X0A\4.   MARGINS AND EXTENT:\X0D\\X0A\a.   Parenchymal margin free of tumor.\X0D\\X0A\b.   Lymph vascular space invasion:  Not identified.\X0D\\X0A\5.   PATHOLOGIC STAGE:  pT1a, N0, MX, G1.\X0D\\X0A\ \X0D\\X0A\Pathology #**ID-NUM (MC/cm)\X0D\\X0A\**NAME[ZZZ:  YYY M XXX] M.D.\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 11 2012]",,"GROSS DESCRIPTION:\X0D\\X0A\Specimen (A) Received fresh for frozen section designated 'anterior\X0D\\X0A\segment left upper lobe lymph node' is a 0.7 x 0.5 x 0.4 cm anthracotic\X0D\\X0A\nodal fragment submitted en toto for frozen section analysis.  FROZEN\X0D\\X0A\**INSTITUTION DOWNTOWN, CLIA ID# 18D0320857 (DR.\X0D\\X0A\**NAME[XXX]):  BENIGN LYMPH NODE.  The results are called directly to Dr.\X0D\\X0A\Bousamra. The frozen section remnant is submitted in AFS.\X0D\\X0A\Specimen (B) Received fresh for frozen section designated 'left upper\X0D\\X0A\lobe lymph node station 11' are fragments of anthracotic nodal material\X0D\\X0A\aggregately measuring 1.5 x 1.1 x 0.4 cm submitted en toto for frozen\X0D\\X0A\section analysis.  **INSTITUTION DOWNTOWN,\X0D\\X0A\CLIA ID# 18D0320857 (DR. **NAME[XXX]):  BENIGN LYMPH NODE.  The frozen section\X0D\\X0A\remnant is submitted in BFS. The results are called directly to Dr.\X0D\\X0A\Bousamra.\X0D\\X0A\Specimen (C) Received fresh for frozen section designated 'left upper\X0D\\X0A\lobe lung anterior segment' is a 14.5 x 6.1 x 1.5 cm wedge resection\X0D\\X0A\specimen. The specimen has been previously incised to reveal a\X0D\\X0A\subpleural 0.9 x 0.8 x 0.8 cm nodule. The overlying pleural surface is\X0D\\X0A\smooth. The staple line is removed. The margin is inked. A shaved\X0D\\X0A\section from the margin and a section from the tumor are submitted for\X0D\\X0A\frozen section analysis.  **INSTITUTION\X0D\\X0A\DOWNTOWN, CLIA ID# 18D0320857 (DR. **NAME[XXX]):  C1FS:  MARGIN FREE OF TUMOR.\X0D\\X0A\C2FS:  KERATINIZING SQUAMOUS CELL CARCINOMA.  The results are called\X0D\\X0A\directly to Dr. **NAME[WWW].\X0D\\X0A\The frozen section remnants are submitted in C1 and C2FS respectively.\X0D\\X0A\The remaining half of the tumor is sectioned and submitted in C3. The\X0D\\X0A\remaining parenchyma is serially sectioned and carefully palpated.  No\X0D\\X0A\additional nodularity is identified.  (MC/cm)\X0D\\X0A\ \X0D\\X0A\Total Blocks Submitted: 5\X0D\\X0A\ \X0D\\X0A\Specimens Involved\X0D\\X0A\Specimens:     A: ANTERIOR SEGMENT LUL LYMPH NODE\X0D\\X0A\B: LUL LYMPH NODE STATION 11\X0D\\X0A\C: LUL ANTERIOR SEGMENT WITH LUNG CANCER\X0D\\X0A\ \X0D\\X0A\LUNG: Resection\X0D\\X0A\Specimen Type: Wedge resection\X0D\\X0A\Laterality:    Left\X0D\\X0A\Tumor Site:    Upper lobe\X0D\\X0A\Tumor Size:    Greatest dimension: 0.9cm\X0D\\X0A\Histologic Type:    Squamous cell carcinoma\X0D\\X0A\Histologic Grade:   G1\X0D\\X0A\Pathologic Staging (pTNM)\X0D\\X0A\Primary Tumor (pT): pT1a\X0D\\X0A\Regional Lymph Nodes (pN):    pN0\X0D\\X0A\Number examined:    2\X0D\\X0A\Number involved:    0\X0D\\X0A\Distant Metastasis (pM): pMX\X0D\\X0A\Margins:  Margins uninvolved by invasive carcinoma\X0D\\X0A\Direct Extension of Tumor:    None identified\X0D\\X0A\Venous (Large Vessel) Invasion (V):     Absent\X0D\\X0A\Arterial (Large Vessel) Invasion:  Absent\X0D\\X0A\Lymphatic (Small Vessel) Invasion (L):  Absent",,SPECIMEN(S): B LUL LYMPH NODE STATION 11\X0D\\X0A\SPECIMEN(S): C LUL ANTERIOR SEGMENT WITH LUNG CANCER\X0D\\X0A\SPECIMEN(S): A ANTERIOR SEGMENT LUL LYMPH NODE,,
REG1,LUNG,0,485346,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is left lung mass.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **PLACE DOSSETT\X0D\\X0A\ONCOLOGY PATHWAY\X0D\\X0A\**NAME[ZZZ, YYY] \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Fine Needle Aspiration Performed by Radiologist","Final Diagnosis\X0D\\X0A\LEFT LUNG, MASS, CT GUIDED FNA:\X0D\\X0A\     Scant necroinflammatory debris with admixed rare atypical large cells\X0D\\X0A\compatible with non-small cell carcinoma. SEE COMMENT.\X0D\\X0A\COMMENT: The diagnosis is based on a rare number of cells. Nothing remains for\X0D\\X0A\immunohistochemical workup to further define the type of neoplasm. Dr. **NAME[XXX]\X0D\\X0A\discussed this case with Dr. **NAME[ZZZ] at 11:50 AM on **DATE[Sep 1 11].   JFJ/mbc",,Gross Description\X0D\\X0A\Received in formalin labeled left lung mass FNA are a few cc of tannish gray\X0D\\X0A\cloudy formalin. The formalin is filtered and no definitive tissue is\X0D\\X0A\identified. Any possible tissue is wrapped and submitted entirely in one\X0D\\X0A\cassette.  **INITIALS,Microscopic Description\X0D\\X0A\Sections show scant necroinflammatory debris with admixed  rare degenerating\X0D\\X0A\atypical cells with an enlarged hyperchromatic nucleus with a moderate amount of\X0D\\X0A\cytoplasm. \X0D\\X0A\FLP/mbc,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. XXX], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,486054,2,,"Clinical Diagnosis and History\X0D\\X0A\L LUNG MASS\X0D\\X0A\LEFT UPPER LOBE PULMONARY NODULE\X0D\\X0A\OPER:  L VAT WITH L UPPER LOBECTOMY POSSIBLE LEFT THORACOTOMY\X0D\\X0A\L VAT L LOWER LOBECTOMY \X0D\\X0A\FROZEN SECTION  \X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX#1:  CARCINOMA, NON-SMALL CELL.  TUMOR IS 2 MM FROM STAPLE LINE MARGIN. \X0D\\X0A\**INITIALS  IHC/MER/ap\X0D\\X0A\FSDX#3:  SHAVE BRONCHIAL AND VASCULAR MARGINS FREE OF TUMOR.  **INITIALS","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[YYY M].\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LEFT UPPER LOBE PULMONARY NODULE-FS-ls\X0D\\X0A\2: LEFT UPPER LOBE PULMONARY NODULE-FRESH FOR PRECISION-ls\X0D\\X0A\3: LEFT UPPER LOBE-FS-ls\X0D\\X0A\4: STATION 7-ls\X0D\\X0A\5: L 10-ls\X0D\\X0A\6: AP WINDOW-ls","Final Diagnosis\X0D\\X0A\1:  LEFT UPPER LOBE WEDGE RESECTION:\X0D\\X0A\     ADENOCARCINOMA, MODERATELY WELL-DIFFERENTIATED (GRADE 2).\X0D\\X0A\     MAXIMUM GROSS DIMENSION OF TUMOR IS 15 MM.\X0D\\X0A\     TUMOR UNIFOCAL.\X0D\\X0A\     VISCERAL PLEURAL INVASION NOT IDENTIFIED. \X0D\\X0A\     VASCULAR INVASION:  NOT IDENTIFIED. \X0D\\X0A\     MARGIN OF WEDGE FREE OF TUMOR.\X0D\\X0A\COMMENT:  Tumor appears to be arising in association with scar.  I feel tumor on\X0D\\X0A\routing histology is consistent with origin from lung.  However,\X0D\\X0A\immunoperoxidase stains will be performed in an effort to support this\X0D\\X0A\impression.\X0D\\X0A\2:  LEFT UPPER LOBE WEDGE:\X0D\\X0A\     SUBMITTED TO PRECISION THERAPEUTICS.\X0D\\X0A\3:  LEFT UPPER LOBE:\X0D\\X0A\     RESIDUAL CARCINOMA NOT IDENTIFIED. \X0D\\X0A\     METASTATIC CARCINOMA PRESENT IN 1 OF 7 PARABRONCHIAL LYMPH NODES.\X0D\\X0A\     SHAVE BRONCHIAL AND VASCULAR MARGINS FREE OF TUMOR.\X0D\\X0A\4:  STATION 7:\X0D\\X0A\     BENIGN LYMPH NODE.\X0D\\X0A\5:  L10:\X0D\\X0A\     FRAGMENTS OF BENIGN LYMPH NODE.\X0D\\X0A\6:  AP WINDOW LYMPH NODE:\X0D\\X0A\     FRAGMENTS OF BENIGN LYMPH NODE.\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX], M.D., **PLACE",,"Gross Description\X0D\\X0A\1:  Received fresh for frozen diagnosis designated \""left upper lobe pulmonary\X0D\\X0A\nodule\"" is a wedge resection of lung, 10.5 x up to 5.7 x up to 2.9 cm.  Staple\X0D\\X0A\line of closure is present.  One centimeter from the staple line, the specimen\X0D\\X0A\has been previously incised over a distance of 2 cm.  Pleura is gray pink black.\X0D\\X0A\ In the area of prior incision, there is firm pink tan lesion 15 x 10 x 10 mm. \X0D\\X0A\This lesion is within 3 mm of the staple line margin.  Ink is placed about the\X0D\\X0A\staple line margin.  Sections of the lesion are submitted on two blocks for\X0D\\X0A\frozen diagnosis.  The remainder of the mass is submitted for permanent sections\X0D\\X0A\as A through D and sections obtained at least 1 cm from the mass are submitted\X0D\\X0A\in E and F.  Tissue submitted in cassettes and formalin at 8:37AM.\X0D\\X0A\2:  Received fresh designated \""left upper lobe wedge\"" is a highly irregular\X0D\\X0A\fragment of pink tan tissue 7 x 5 x 4 mm.  This tissue has been submitted for\X0D\\X0A\Precision Therapeutics.\X0D\\X0A\**INITIALS\X0D\\X0A\3:  Received fresh for frozen diagnosis designated \""left upper lobe\"" is a lobe\X0D\\X0A\of lung 13.8 x 8.7 x 3.5 cm.  Extensive staple lines of closure extend outward\X0D\\X0A\from the hilum.  One of these is associated with extensive recent hemorrhage and\X0D\\X0A\is felt to represent site of prior wedge resection and extends 8 cm from the\X0D\\X0A\hilum.  Bronchial margin and vessels at the hilum have staple lines of closure. \X0D\\X0A\Shave bronchial margin submitted on block A for frozen diagnosis and shave\X0D\\X0A\vascular margin on block B.  No residual carcinoma identified at the site of\X0D\\X0A\prior wedge biopsy.  No focal abnormal marking or mass lesion identified within\X0D\\X0A\the parenchyma.  There appears to be a metastatic tumor within a gray black\X0D\\X0A\rubbery peribronchial lymph node which measures 1.8 cm.  Five additional\X0D\\X0A\possible peribronchial lymph nodes are recovered.  \X0D\\X0A\SUMMARY OF SECTIONS:\X0D\\X0A\A and B  parenchyma staple of prior wedge biopsy site\X0D\\X0A\C and D  lymph node with metastatic tumor sectioned and totally submitted \X0D\\X0A\E  four possible lymph nodes\X0D\\X0A\F  one possible lymph node, bisected\X0D\\X0A\G and H  random sections of non-tumorous lung\X0D\\X0A\**INITIALS\X0D\\X0A\4: Received in formalin designated \""station 7\"" is lobulated gray black rubbery\X0D\\X0A\tissue 8 x 5 x 5 mm.  \X0D\\X0A\5: Received in formalin designated \""L10\"" are two fragments of gray black rubbery\X0D\\X0A\tissue measuring 6 and 9 mm respectively.  \X0D\\X0A\6: Received in formalin designated \""AP window\"" are two irregular portions of\X0D\\X0A\lobulated rubbery tan yellow black tissue measuring 8 mm.  Each is bisected. \X0D\\X0A\The specimen is totally submitted in A.  **INITIALS","Microscopic Description\X0D\\X0A\Incorporated in diagnosis. \X0D\\X0A\SYNOPTIC:\X0D\\X0A\     SPECIMEN:  Wedge biopsy and subsequent lobectomy, left upper lobe.\X0D\\X0A\     SPECIMEN INTEGRITY:  Intact.\X0D\\X0A\     SPECIMEN LATERALITY:  Left.\X0D\\X0A\     TUMOR SITE:  Left upper lobe.\X0D\\X0A\     TUMOR SIZE:  15 mm.\X0D\\X0A\     TUMOR FOCALITY:  Unifocal.\X0D\\X0A\     HISTOLOGIC TYPE:  Adenocarcinoma.\X0D\\X0A\     HISTOLOGIC GRADE:  Grade 2 (moderately differentiated).\X0D\\X0A\     VISCERAL PLEURAL INVASION:  Not identified.\X0D\\X0A\     TUMOR EXTENSION:  Not identified.\X0D\\X0A\     MARGINS:  Bronchial margin uninvolved by invasive carcinoma.\X0D\\X0A\                Vascular margin uninvolved by invasive carcinoma.\X0D\\X0A\     PATHOLOGIC STAGING:\X0D\\X0A\          PRIMARY TUMOR:  T1a.\X0D\\X0A\          REGIONAL LYMPH NODES:  N1.  Metastatic carcinoma present in 1 of a\X0D\\X0A\total of 10 nodes (specimen 3).\X0D\\X0A\          DISTANT METASTASES:  Not applicable.\X0D\\X0A\**INITIALS\X0D\\X0A\IHC/MER (1)",,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 3 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 3 2012]     By:  **NAME[WWW, VVV]\X0D\\X0A\     Date Reported:     **DATE[Jan 3 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Using appropriate controls, immunoperoxidase stains for TTF1, surfactant,\X0D\\X0A\Napsin, Ck20 and CK7 have been performed.  Tumor cells are negative for CK20. \X0D\\X0A\Tumor cells are positive for CK7, TTF1, Surfactant and Napsin.  These finding\X0D\\X0A\support the diagnosis of primary adenocarcinoma of lung.  CMK/in \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 16 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 16 2012]     By:  **NAME[UUU, TTT]\X0D\\X0A\     Date Reported:     **DATE[Jan 16 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report in the electronic medical file from Genzyme\X0D\\X0A\Laboratories regarding KRAS Mutation Analysis.\X0D\\X0A\Their report, in part:\X0D\\X0A\RESULTS: Positive for a p.G12V (c.35G>T) mutation in codon 12 of the KRAS gene.\X0D\\X0A\Signed: **NAME[SSS M. RRR] Ph.D.\X0D\\X0A\See the complete report.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 18 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 18 2012]     By:  **NAME[QQQ, PPP]\X0D\\X0A\     Date Reported:     **DATE[Jan 18 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report regarding EGFR Mutation Analysis from Genzyme\X0D\\X0A\Laboratories in electronic medical file.\X0D\\X0A\Their report, in part, reads:\X0D\\X0A\INTERPRETATION: No mutations were identified; however 18-20% of patients with\X0D\\X0A\non-small-cell lung cancer and without identifiable mutations are reported to be\X0D\\X0A\responsive to EGFR tyrosine kinase inhibitor therapies.\X0D\\X0A\Reviewing Pathologist: **NAME[OOO NNN], Ph.D.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[MMM], M.D., **NAME[LLL]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 24 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 24 2012]     By:  **NAME[KKK, JJJ III]\X0D\\X0A\     Date Reported:     **DATE[Jan 24 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned FISH report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Negative for a rearrangement involving the ALK gene.  Three and four copies of\X0D\\X0A\ALK were observed in 72.0% of cells, suggesting the presence of a neoplastic\X0D\\X0A\cell population with gains of chromosome 2 or 2p.\X0D\\X0A\Signed: **NAME[HHH GGG], M.D.\X0D\\X0A\MER/pkm\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[FFF], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jan 30 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 30 2012]     By:  **NAME[EEE,DDD]\X0D\\X0A\     Date Reported:     **DATE[Jan 31 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Precision Therapeutics in the electronic\X0D\\X0A\medical records file regarding in vitro response summary.   /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[XXX], M.D., **PLACE"
REG1,LUNG,0,486363,1,,CLINICAL HISTORY: Preop diagnosis left hilar mass.  See also ***PATH-NUMBER[1] same-day cytology.,"Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX M WWW], VVV] PhD **DATE[Oct 29 11]","FINAL DIAGNOSIS: LEFT UPPER LOBE BRONCHUS, BIOPSY SQUAMOUS CELL CARCINOMA. SEE COMMENT.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and \""bronchial biopsy left upper lobe.\""  The specimen is received in formalin on Telfa pad and consists of fragments of pink-white tissue, measuring 2 mm. in aggregate.  The specimen is totally submitted in one block.","COMMENT WORD: The microscopic sections of bronchial biopsy from the left upper lobe reveal an atypical squamous cell proliferation.  Nuclei are enlarged, hyperchromatic with irregular outlines and variably clumped chromatin patterns.  There is decreased maturation and mitoses are easily identified.  There is evidence of desmoplastic reaction and inflammation.  The findings are felt to indicate the presence of squamous cell carcinoma consistent with a lung primary.  The findings should be correlated with clinical history and symptomatology.",Specimen Number: ***PATH-NUMBER[2]. Tissues: Left upper lobe of lung. Specimen Comments:,,
REG1,LUNG,0,487717,1,,CLINICAL HISTORY\X0D\\X0A\Left hilar lung tumor with pulmonary and bony metastases.\X0D\\X0A\\X0D\\X0A\PREOP DIAGNOSIS:               LEFT LUNG MASS,"COMMENT\X0D\\X0A\The tumor will be evaluated for EGFR mutation, KRAS, and ALK.\X0D\\X0A\**NAME[BBB,AAA]                              ACCT #: **ID-NUM     LOC:  5NO    U #: 153691\X0D\\X0A\4405 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 58/F       **ROOM    REG: **DATE[Sep 14 12]\X0D\\X0A\DOB: **DATE[May 25 54]    BED: 01      DIS:\X0D\\X0A\STATUS: ADM IN     TLOC:","FINAL DIAGNOSIS\X0D\\X0A\A. LEFT HILAR LUNG MASS, BIOPSY WITH FROZEN SECTION:\X0D\\X0A\.....INFILTRATING MODERATELY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\B. LEFT HILAR LUNG MASS, BIOPSY:\X0D\\X0A\.....INFILTRATING POORLY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\\X0D\\X0A\FROZEN SECTION DIAGNOSIS\X0D\\X0A\A. LUNG, BIOPSY OF LEFT HILAR LUNG MASS:\X0D\\X0A\.....NON-SMALL CELL CARCINOMA.\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ GREEN,**NAME[ZZZ] YYY] MD  **DATE[Sep 15 12]",,"GROSS DESCRIPTION\X0D\\X0A\A. A specimen labelled with the patient's name and designated \""biopsy left\X0D\\X0A\hilar lung mass\"" is received fresh for intraoperative consultation and\X0D\\X0A\consists of 3 irregularly shaped fragments of reddish-tan soft tissue\X0D\\X0A\measuring 1.1, 1.0 and 0.5 cm in greatest dimension respectively. The\X0D\\X0A\largest fragment is bisected and submitted with the unaltered smaller\X0D\\X0A\fragments for frozen section evaluation and then resubmitted for permanent\X0D\\X0A\section in block A.\X0D\\X0A\B. A specimen labelled with the patient's name and designated \""left hilar\X0D\\X0A\lung mass\"" is received fresh and consists of 2 irregularly shaped\X0D\\X0A\fragments of reddish-tan soft tissue measuring 1.0 x 0.5 x 0.4 and 0.8 x\X0D\\X0A\0.5 x up to 0.3 cm. The specimens are entirely submitted after appropriate\X0D\\X0A\fixation in block B.\X0D\\X0A\D: **DATE[Sep 14 2012] - 1425 hours\X0D\\X0A\T: **DATE[Sep 14 2012] - 1649 hours",MICROSCOPIC EXAMINATION\X0D\\X0A\A. An infiltrating adenocarcinoma. There are nests of malignant epithelial\X0D\\X0A\cells at least focally displaying distinct gland lumen formation. There is\X0D\\X0A\an associated desmoplastic fibrous response. Tumor cells have a moderate\X0D\\X0A\to abundant amount of eosinophilic cytoplasm. The tumor cells have\X0D\\X0A\enlarged pleomorphic nuclei. Keratinization is not readily identified\X0D\\X0A\within the tumor. Small cell differentiation is not seen. The lung tissue\X0D\\X0A\through which the tumor infiltrates displays a prominent interstitial\X0D\\X0A\fibrosis.\X0D\\X0A\B. Sections of the additional biopsy of left hilar lung mass reveal\X0D\\X0A\similar findings of an infiltrating adenocarcinoma.\X0D\\X0A\D: **DATE[Sep 15 2012] - 1143 hours\X0D\\X0A\T: **DATE[Sep 15 2012] - 1327 hours,"TISSUES:\X0D\\X0A\Lung, NOS (LEFT HILAR LUNG MASS BX)\X0D\\X0A\Lung, NOS (LEFT HILAR LUNG MASS)",,
REG1,LUNG,0,487833,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is right lower lobe mass, hilar lymphadenopathy of\X0D\\X0A\right side, mediastinal adenopathy.  **AGE[in 60s] year old male with right lower lobe\X0D\\X0A\masses, suspicious for malignancy.  Operative findings: hilar lymphadenopathy\X0D\\X0A\of right side. Mediastinal adenopathy. The examination was normal.\X0D\\X0A\Endobronchial biopsy was performed. Transbronchial biopsies were performed. \X0D\\X0A\Brushings were obtained. Fluoroscopically guided transbronchial brushings\X0D\\X0A\were obtained. Right middle lobe endobronchial lesion. Right lower lobe\X0D\\X0A\external compression with abnormal mucosa.  Operative procedure: bronchoscopy\X0D\\X0A\with transbronchial endobronchial biopsies.\X0D\\X0A\\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Aug 25 1948] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Apr 7 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Apr 8 2012] 07:27\X0D\\X0A\Page 1\X0D\\X0A\ \X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD: J.R. **NAME[YYY], M.D.     Service: PUL     Location: PULM\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Apr 12 2012] 15:12\X0D\\X0A\RESIDENTS(**NAME[M): M. WWW], MD\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\LUNG, RIGHT LOWER LOBE, BIOPSY (A):\X0D\\X0A\   - POORLY DIFFERENTIATED NON SMALL CELL CARCINOMA (SEE COMMENT).\X0D\\X0A\\X0D\\X0A\LUNG, RIGHT MIDDLE LOBE, BIOPSY (B):\X0D\\X0A\   - POORLY DIFFERENTIATED NON SMALL CELL CARCINOMA. (SEE COMMENT)\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 12 2012] **NAME[VVV M. UUU], MD\X0D\\X0A\ \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: **ID-NUM P114\X0D\\X0A\B: **ID-NUM P114 \X0D\\X0A\\X0D\\X0A\F: A: 88305\X0D\\X0A\B: 88305 \X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  two\X0D\\X0A\Specimen label:   A) right lower lobe biopsy              \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: five\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): red to tan\X0D\\X0A\Consistency: soft friable\X0D\\X0A\Size(s): 0.3 x 0.2 x 0.1 cm to 0.1 cm in all dimensions\X0D\\X0A\Cassette summary:  entirely submitted screened A1\X0D\\X0A\\X0D\\X0A\Specimen label:  B) right middle lobe biopsy\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: five \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): tan to brown\X0D\\X0A\Consistency: soft friable\X0D\\X0A\Size(s): 0.1 to less than 0.1 cm in all dimensions each\X0D\\X0A\Cassette summary: entirely submitted screened B1 \X0D\\X0A\\X0D\\X0A\ksl/**DATE[Apr 11 2012] **NAME[M. WWW], MD\X0D\\X0A\**NAME[TTT M. SSS]  \X0D\\X0A\\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\After discussion with Dr. **NAME[YYY], we will not proceed with further testing\X0D\\X0A\to determine exact tumor type due to the very limited amount of tumor present\X0D\\X0A\in this material. If additional testing is required please contact surgical\X0D\\X0A\pathology. \X0D\\X0A\Thiscase was reviewed at the daily consensus conference.\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right lower lobe biopsies\X0D\\X0A\B: Right middle lobe biopsies\X0D\\X0A\,,
REG1,LUNG,0,487905,1,,CLINICAL INFORMATION:\X0D\\X0A\,"**INSTITUTION          MR #: **ID-NUM\X0D\\X0A\**INSTITUTION          **NAME[BBB, AAA]\X0D\\X0A\**PLACE, KENTUCKY  **ZIP-CODE          **DATE[Sep 16 1955] (Age: **AGE[in 50s])   FW\X0D\\X0A\          Collect Date: **DATE[Aug 14 2011] 00:00\X0D\\X0A\          Receipt Date: **DATE[Aug 14 2011] 11:37\X0D\\X0A\          Page 1\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND  LABORATORY MEDICINE\X0D\\X0A\CYTOPATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax: **PHONE\X0D\\X0A\Email: **EMAIL          ***PATH-NUMBER[1]     \X0D\\X0A\     \X0D\\X0A\\X0D\\X0A\**NAME[ZZZ] MD/Practitioner:  T.W. **NAME[YYY], MD     Service: HO     Location:\X0D\\X0A\GILR\X0D\\X0A\     Reported: **DATE[Aug 15 2011] 17:46\X0D\\X0A\     Collected: **DATE[Aug 14 2011] 00:00\X0D\\X0A\","DIAGNOSIS\X0D\\X0A\FNA, LEFT SUPRACLAVICULAR LYMPH NODE (SMEARS AND CELL BLOCK):  POSITIVE FOR\X0D\\X0A\MALIGNANCY, METASTATIC SMALL CELL CARCINOMA.  \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ L.M. **NAME[XXX], MD\X0D\\X0A\DLR \X0D\\X0A\\X0D\\X0A\CLINICAL DIAGNOSIS\X0D\\X0A\Pt noticed enlarged supraclavicular lymph node on **DATE[Aug 4]th, the nodule has\X0D\\X0A\enlarged and it is not tender, pt is a smoker, no personal history of cancer.\X0D\\X0A\\X0D\\X0A\Hem/ Onc / FNA performed by staff pathologist: Dr. **NAME[M. XXX]\X0D\\X0A\\X0D\\X0A\A time out procedure was performed by our service for patient and site\X0D\\X0A\verification.\X0D\\X0A\\X0D\\X0A\Patient tolerated 5 needle passes well without injected anesthesia or known\X0D\\X0A\complications.\X0D\\X0A\\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\ICD-9: 196.0     LYMPH NODES OF HEAD, FACE, AND NECK, SECONDARY AND\X0D\\X0A\UNSPECIFIED MALIGNANT NEOPLASM\X0D\\X0A\ F: A: 88173 ASP INTER, 67605, 88305, 10021 FNA PATHO SNOMED CODES: A: M80413\X0D\\X0A\M80416 T08220 P1149\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\",,GROSS DESCRIPTION:\X0D\\X0A\\X0D\\X0A\Needle rinse fluid for cell block processing.\X0D\\X0A\,,"SPECIMEN DESCRIPTION:\X0D\\X0A\A:  FNA LEFT SUPRACLAVICULAR LN\X0D\\X0A\     DIFF-QUIK x 4, PAP STAIN x 4, CELL BLOCK x 1\X0D\\X0A\",,
REG1,LUNG,0,487965,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is **AGE[in 80s] year old male, 3.5 cm RUL lung mass. Operative\X0D\\X0A\procedure: not provided. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\TP #1: \""LYMPHOID APPEARING CELLS WITH CRUSH ARTIFACT/NECROSIS, REQUEST\X0D\\X0A\ADDITIONAL MATERIAL FOR HISTOLOGY/FLOW CYTOMETRY\""---LC. \X0D\\X0A\\X0D\\X0A\     L.M. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Oct 20 1929] (Age: **AGE[in 80s])  MW\X0D\\X0A\Collect Date: **DATE[Apr 15 2012] 09:42\X0D\\X0A\Receipt Date: **DATE[Apr 15 2012] 09:42\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: T.W. **NAME[XXX], MD     Service: HO     Location: 3IR\X0D\\X0A\**NAME[WWW] MD(**NAME[M): VVV UUU], MD     Reported: **DATE[Apr 17 2012] 17:44\X0D\\X0A\RESIDENTS(S): R.K. **NAME[TTT], MD","DIAGNOSIS\X0D\\X0A\LUNG, RIGHT UPPER LOBE, CT GUIDED CORE BIOPSY:\X0D\\X0A\  - PREDOMINANTLY NECROTIC TISSUE WITH MINUTE FOCI OF VIABLE TUMOR CONSISTENT\X0D\\X0A\WITH SMALL CELL\X0D\\X0A\    CARCINOMA (SEE COMMENT).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Apr 17 2012] **NAME[M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M54000 M8002 \X0D\\X0A\F: A: C 88333, 67405, 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) right upper lobe lung mass                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 6 \X0D\\X0A\Shape(s): irregular to core   \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft and friable \X0D\\X0A\Size(s): 0.2 x 0.1 x 0.1 cm to less than 0.1 cm in all dimensions\X0D\\X0A\A touch prep is performed by cytology as TP1. \X0D\\X0A\Cassette summary: entirely submitted in screened A1  A2. \X0D\\X0A\rgc/**DATE[Apr 16 2012] R.K. **NAME[TTT], MD\X0D\\X0A\**NAME[RRR M. QQQ",MICROSCOPIC DESCRIPTION\X0D\\X0A\Recommend correlation with concurrent flow cytometry findings (***PATH-NUMBER[2]).\X0D\\X0A\The case was prospectively reviewed in the intradepartmental consensus\X0D\\X0A\conference with the agreement to the above diagnosis.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right upper lobe lung mass,,
REG1,LUNG,0,487970,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is left lung lesion with positive history of\X0D\\X0A\adenocarcinoma right adrenal. 66 arrow pointing to the right suspected\X0D\\X0A\primary. Operative findings: same as above. Operative procedure: CT guided\X0D\\X0A\core biopsy, left lung x 2. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\TP #1: \""POSITIVE FOR MALIGNANCY; \""NON-SMALL CELL CARCINOMA\""---YMB. \X0D\\X0A\\X0D\\X0A\     Y.M. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[May 18 1937] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[May 22 2012] 10:52\X0D\\X0A\Receipt Date: **DATE[May 22 2012] 10:52\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: J.B. **NAME[XXX], MD     Service: HO     Location: 3IR\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[May 24 2012] 15:34\X0D\\X0A\RESIDENTS(S): R.K. **NAME[VVV], MD","DIAGNOSIS\X0D\\X0A\LUNG, LEFT, CT GUIDED NEEDLE CORE BIOPSY:\X0D\\X0A\   - INVASIVE MODERATELY TO POORLY DIFFERENTIATED ADENOCARCINOMA (SEE\X0D\\X0A\COMMENT).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 24 2012] **NAME[UUU TTT], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\BORDERLINE ADEQUATE TUMOR FOR MOLECULAR ANALYSIS\X0D\\X0A\Addendum Comment\X0D\\X0A\Per request from Dr. **NAME[SSS], slides and blocks are pulled from the archive\X0D\\X0A\and reviewed for molecular analysis. Block A1 is selected and unstained\X0D\\X0A\slides are prepared for EGFR mutation analysis (charged, 5 microns, made with\X0D\\X0A\PCR precautions). A follow up H\T\E shows that the tissue in the block is\X0D\\X0A\beginning to be cut through, but there are still several tumor glands present\X0D\\X0A\in a fibrous stroma. These are marked, and the slides will be sent **NAME[RRR] MD\X0D\\X0A\**PLACE for analysis. A set of 5 regular cut and mount slides is also\X0D\\X0A\available from this block. If the EGFR mutation analysis is negative, these\X0D\\X0A\will be used for ALK break-apart FISH probe testing. RRM1 normalized\X0D\\X0A\quantitative gene expression analysis was also requested and will be\X0D\\X0A\performed on Block A2 (separate addendum). \X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jfp/**DATE[Jun 8 2012] **NAME[QQQ M. PPP], MD SG \X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\BORDERLINE ADEQUATE TUMOR FOR MOLECULAR ANALYSIS, SEE COMMENT.\X0D\\X0A\Addendum Comment\X0D\\X0A\Per request from Dr. **NAME[SSS], slides and blocks are pulled from the archive\X0D\\X0A\and reviewed. Block A1 with tumor is used for EGFR mutation analysis **NAME[RRR] MD\X0D\\X0A\**PLACE (see previous addendum). Block A2 is used for RRM1. Unstained slides\X0D\\X0A\are prepared with the Response Genetics protocol for small biopsies\X0D\\X0A\(non-charged, 7 microns, made with PCR precautions). A follow up H\T\E shows\X0D\\X0A\the tissue is beginning to be cut through, but there are still several tumor\X0D\\X0A\glands available for analysis (and the first sections have more tissue).\X0D\\X0A\Microdissection may be required to increase the percentage of tumor cell RNA.\X0D\\X0A\Slides will be sent to Response Genetics for RRM1 normalized quantitation.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jfp/**DATE[Jun 9 2012] **NAME[QQQ M. PPP], MD SG \X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\BORDERLINE ADEQUATE TUMOR FOR FISH ANALYSIS\X0D\\X0A\Addendum Comment\X0D\\X0A\This addendum is a follow up to the request from Dr. **NAME[OOO SSS]. EGFR\X0D\\X0A\mutation analysis in exons 19-21 was negative, therefore the regular cut and\X0D\\X0A\mount slides from block A1 will be sent for ALK rearrangement analysis by\X0D\\X0A\FISH. No H\T\E slide was prepared; however, these cut and mount slides were\X0D\\X0A\sandwiched by H\T\E slides showing tumor. There is fibrosis and chronic\X0D\\X0A\inflammation in the sections with intermixed tumor glands and care will be\X0D\\X0A\needed to avoid counting these cells; therefore the block is considered to be\X0D\\X0A\borderline adequate for FISH analysis. Slides will be sent to the University\X0D\\X0A\of **PLACE for ALK rearrangement testing.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jfp/**DATE[Jul 26 2012] **NAME[QQQ M. PPP], MD SG \X0D\\X0A\ICD 9: 162.9     MALIGNANT NEOPLASM BRONCHUS AND LUNG NOS\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M81403 P1140 \X0D\\X0A\F: A: C 88333, 67405, 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) CT guided core biopsy left lung x 2                \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 4 \X0D\\X0A\Shape(s): core   \X0D\\X0A\Color(s): red tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): range from 0.5 to 0.2 cm in length x less than 0.1 cm in diameter \X0D\\X0A\TP is performed by cytology\X0D\\X0A\Cassette summary: it is entirely submitted in screened A1  A2.  \X0D\\X0A\rgc/**DATE[May 23 2012] R.K. **NAME[VVV], MD\X0D\\X0A\J.G. Combs",MICROSCOPIC DESCRIPTION\X0D\\X0A\Block A1 and A2 both contain tumor tissue which can be used for additional\X0D\\X0A\molecular studies if desired.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: CT guided core biopsy left lung x2,,PROCEDURES/ADDENDA
REG1,LUNG,0,488232,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RIGHT LOWER LOBE MASS\X0D\\X0A\,"A.    SPECIMEN TYPE/PROCEDURE:  LOBECTOMY, (RIGHT LOWER LOBE).\X0D\\X0A\TUMOR HISTOLOGIC TYPE:  INVASIVE (NON-MUCINOUS) ADENOCARCINOMA.\X0D\\X0A\HISTOLOGIC GRADE:  HIGH GRADE (MODERATE TO POORLY DIFFERENTIATED).\X0D\\X0A\TUMOR SITE:  LOWER LOBE.\X0D\\X0A\LATERALITY:  RIGHT.\X0D\\X0A\TUMOR SIZE:  2.4 X 2.0 X 2.0 CM.\X0D\\X0A\TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\VISCERAL PLEURAL INVASION:  NOT IDENTIFIED.\X0D\\X0A\MARGINS:  ALL MARGINS ARE FREE OF LESION (TUMOR IS WITHIN 1 CM FROM\X0D\\X0A\BRONCHIAL\X0D\\X0A\    MARGIN AND 0.5 CM FROM VASCULAR MARGIN OF RESECTION).\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  NOT DEFINITIVELY IDENTIFIED.\X0D\\X0A\ADDITIONAL FINDINGS:  PLEURAL FIBROSIS WITH CALCIFICATION, PULMONARY\X0D\\X0A\CONGESTION AND EDEMA WITH HEMORRHAGE.\X0D\\X0A\LYMPH NODES:  BENIGN  PERIBRONCHIAL LYMPH NODES WITH HYALINIZED\X0D\\X0A\GRANULOMA.\X0D\\X0A\\X0D\\X0A\B.      RIGHT LUNG LYMPH NODES (N1):\X0D\\X0A\    NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\\X0D\\X0A\C.     RIGHT LYMPH NODES (N2):\X0D\\X0A\    NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\    CALCIFIED GRANULOMA.\X0D\\X0A\\X0D\\X0A\AJCC Stage:  pT1b  NO MX\X0D\\X0A\\X0D\\X0A\As required by the American College of Surgeons, the American Joint Cancer Committee Staging\X0D\\X0A\is included in this report.  However, this stage should only be considered preliminary and\X0D\\X0A\incomplete; final staging can only be accomplished by the oncologist/surgeon after\X0D\\X0A\evaluation of all clinical and surgical/pathologic information.\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Dec 16 12]                 **PLACE Clinical Associates                    PAGE:   3\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA M]                  DOB: **DATE[Sep 28 1948]   Sex: M\X0D\\X0A\Add:1550 **PLACE,KY **ZIP-CODE  **PHONE                                                               \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS IN    Location:  M.CCU      M.CCU-2     \X0D\\X0A\Reg:   **DATE[Nov 16 12]     Disch: **DATE[Nov 24 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\Attend:Cagata,Ardel C            Submit:Cagata,Ardel C                 MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS., **ROOM      **PLACE                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88307GS/2, 88309GS, 88311GS/2, 88331GS, 88332GS\X0D\\X0A\\X0D\\X0A\","FROZEN SECTION DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A. BRONCHIAL MARGINS ARE CLEAR AS REPORTED TO DR. **NAME[ZZZ] BY DR. **NAME[YYY] AT 11:10 A.M.\X0D\\X0A\\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.    SPECIMEN TYPE/PROCEDURE:  LOBECTOMY, (RIGHT LOWER LOBE).\X0D\\X0A\TUMOR HISTOLOGIC TYPE:  INVASIVE (NON-MUCINOUS) ADENOCARCINOMA.\X0D\\X0A\HISTOLOGIC GRADE:  HIGH GRADE (MODERATE TO POORLY DIFFERENTIATED).\X0D\\X0A\TUMOR SITE:  LOWER LOBE.\X0D\\X0A\LATERALITY:  RIGHT.\X0D\\X0A\TUMOR SIZE:  2.4 X 2.0 X 2.0 CM.\X0D\\X0A\TUMOR FOCALITY:  UNIFOCAL.\X0D\\X0A\VISCERAL PLEURAL INVASION:  NOT IDENTIFIED.\X0D\\X0A\MARGINS:  ALL MARGINS ARE FREE OF LESION (TUMOR IS WITHIN 1 CM FROM\X0D\\X0A\BRONCHIAL\X0D\\X0A\MARGIN AND 0.5 CM FROM VASCULAR MARGIN OF RESECTION).\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:  NOT DEFINITIVELY IDENTIFIED.\X0D\\X0A\ADDITIONAL FINDINGS:  PLEURAL FIBROSIS WITH CALCIFICATION, PULMONARY\X0D\\X0A\CONGESTION AND EDEMA WITH HEMORRHAGE.\X0D\\X0A\LYMPH NODES:  BENIGN  PERIBRONCHIAL LYMPH NODES WITH HYALINIZED\X0D\\X0A\GRANULOMA.\X0D\\X0A\\X0D\\X0A\B.      RIGHT LUNG LYMPH NODES (N1):\X0D\\X0A\NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\\X0D\\X0A\C.     RIGHT LYMPH NODES (N2):\X0D\\X0A\NEGATIVE FOR METASTATIC DISEASE.\X0D\\X0A\CALCIFIED GRANULOMA.\X0D\\X0A\\X0D\\X0A\AJCC Stage:  pT1b  NO MX\X0D\\X0A\\X0D\\X0A\As required by the American College of Surgeons, the American Joint Cancer Committee Staging\X0D\\X0A\is included in this report.  However, this stage should only be considered preliminary and\X0D\\X0A\incomplete; final staging can only be accomplished by the oncologist/surgeon after\X0D\\X0A\evaluation of all clinical and surgical/pathologic information.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Molecular panel will be performed.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A. Received fresh for frozen section labeled \""right lower lobe\"" is a 310 gram lobe of lung\X0D\\X0A\measuring 28.0 x 14.5 x 3.0 cm. The bronchial margin is closed by a line of staples, they\X0D\\X0A\are removed and the bronchial margin is submitted as block FSC1. The lung is sectioned to\X0D\\X0A\reveal a tan-grey, irregularly shaped firm nodule measuring 2.4 x 2.0 x 2.0 cm. A cross\X0D\\X0A\section of this is submitted as block FSC2 and a portion will be sent to Precision for\X0D\\X0A\analysis. The tumor is located 0.5 cm from the vascular margin and 1.0 cm from the bronchial\X0D\\X0A\margin. The pleural surface overlying the tumor is inked black for identification. The\X0D\\X0A\remaining parenchyma is black to pink and dark red and mottled. The remaining lung tissue is\X0D\\X0A\serially sectioned and reveals two firm irregularly shaped grey-tan nodules in the distal\X0D\\X0A\portion of the lung. They measure 0.6 and 0.7 cm in greatest dimension. Seven hilar lymph\X0D\\X0A\nodes are identified. They are anthracotic and range in size from 0.5 up to 0.7 cm in\X0D\\X0A\greatest dimension.\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\A1        Vascular margin\X0D\\X0A\A2        Tumor and inked pleural margin\X0D\\X0A\A3\T\4        Tumor\X0D\\X0A\A5        Firm area in lung\X0D\\X0A\A6\T\7        Additional lung tissue\X0D\\X0A\A8-10        Lymph nodes/sbp\X0D\\X0A\\X0D\\X0A\B. Received in formalin labeled \""N1 lymph node, right lung\"" are fifteen tan anthracotic\X0D\\X0A\lymph nodes ranging in size from 0.5 up to 0.9 cm in greatest dimension. They are entirely\X0D\\X0A\submitted in cassettes B1-3.\X0D\\X0A\\X0D\\X0A\C. Received in formalin labeled \""N2 lymph node, right lung\"" are seven tan anthracotic and\X0D\\X0A\slightly calcified lymph nodes ranging in size from 0.5 up to 1.4 cm in greatest dimension.\X0D\\X0A\The lymph nodes are entirely submitted in cassettes C1-3 with cassette 3 retained for\X0D\\X0A\decalcification./sbp/sk\X0D\\X0A\",,"SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A. RIGHT LOWER LOBE BRONCHIAL MARGINS\X0D\\X0A\B. N1 LYMPH NODE, RIGHT LUNG\X0D\\X0A\C. N2 LYMPH NODE, RIGHT LUNG\X0D\\X0A\",,ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #3              Entered: **DATE[Dec 15 12]-1009\X0D\\X0A\\X0D\\X0A\Please see scanned report from Precision Therapeutics under Pathology EMR\X0D\\X0A\\X0D\\X0A\Addendum #2              Entered: **DATE[Nov 27 12]-1623\X0D\\X0A\\X0D\\X0A\KRAS MUTATION ANALYSIS\X0D\\X0A\\X0D\\X0A\INTERPRETATION:\X0D\\X0A\\X0D\\X0A\KRAS MUTATION NOT DETECTED\X0D\\X0A\\X0D\\X0A\COMMENT:\X0D\\X0A\Please refer to case MO12-104 in Carelink for a complete report.\X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Nov 20 12]-1128\X0D\\X0A\\X0D\\X0A\FISH Analysis ALK Rearrangement\X0D\\X0A\(MO12-104 / ***PATH-NUMBER[1])\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\Interpretation\X0D\\X0A\\X0D\\X0A\NEGATIVE FOR ALK REARRANGEMENT\X0D\\X0A\SEE REPORT #MO12-104 FOR FURTHER DETAILS.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\
REG1,LUNG,0,488705,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is right pleural effusion.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY] :36A \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, Wedge or Bleb\X0D\\X0A\2: Lung, Wedge or Bleb\X0D\\X0A\Previous Pertinent History\X0D\\X0A\C11062549, **DATE[Oct 21 11]. 1 OF 2 BRONCH BRUSH RIGHT MIDDLE LOBE: Malignant. COMMENT:\X0D\\X0A\Adenocarcinoma. 2 OF 2 RIGHT MIDDLE LOBE: Negative for malignant cells. (FLP)\X0D\\X0A\S11019891, **DATE[Oct 21 11]. RIGHT LUNG, MIDDLE LOBE, BRONCHIAL BIOPSY: Moderately\X0D\\X0A\differentiated adenocarcinoma within lymphatics. (FLP)\X0D\\X0A\C11061161, **DATE[Oct 16 11]. PLEURAL Malignant. Adenocarcinoma. (FLP)","Final Diagnosis\X0D\\X0A\VISCERAL AND PARIETAL PLEURA BIOPSIES (#1-#2):\X0D\\X0A\     Extensive lymphatic permeation by malignant neoplasm compatible with poorly\X0D\\X0A\differentiated \X0D\\X0A\      adenocarcinoma.\X0D\\X0A\     See COMMENT.\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT:  The biopsies show malignant neoplasm within lymphatic channels.  Given\X0D\\X0A\the cytologic diagnosis of adenocarcinoma per the cytologies specimens\X0D\\X0A\referenced below, this is felt to represent a metastatic adenocarcinoma. \X0D\\X0A\Correlation with other clinical and operative findings is suggested.  **INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled right lung pleural implant\X0D\\X0A\consists of a sheet of red/pink fibrovascular connective tissue measuring 1.2 x\X0D\\X0A\0.5 x 0.2cm, previously frozen and now entirely resubmitted in one block.\X0D\\X0A\Specimen 2 received in formalin labeled right lung pleural biopsy consists of\X0D\\X0A\several fragments of red, yellow, and pink soft tissue measuring in aggregate\X0D\\X0A\2.4 x 1.5 x 0.5cm.  Entirely submitted in one block.  **INITIALS","Microscopic Description\X0D\\X0A\Sections from both specimens appear similar.  These show a neoplastic infiltrate\X0D\\X0A\composed of cords and focal glandular structures.  The constituent cells show\X0D\\X0A\large vesicular nuclei, some with prominent nucleoli.  Much of this is located\X0D\\X0A\within lymphatic channels.  Sections from specimen 2 show portions of parietal\X0D\\X0A\pleura with underlying adipose and skeletal muscle, also containing malignant\X0D\\X0A\epithelial cell groups similar to those described above.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX M. WWW], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,488854,1,,Clinical Diagnosis and History\X0D\\X0A\FOREIGN BODY\X0D\\X0A\OPER: BRONCHOSCOPY,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., MELISSA T\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: LLL BX-ls","Final Diagnosis\X0D\\X0A\LEFT LOWER LOBE OF LUNG, BRONCHIAL BIOPSY:\X0D\\X0A\     UNDIFFERENTIATED SMALL CELL CARCINOMA (OAT CELL CARCINOMA).\X0D\\X0A\CLS/in \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **NAME[XXX]",,"Gross Description\X0D\\X0A\In formalin labeled \""LLL biopsy\"" is tan tissue in aggregate measuring 1.0 x 0.5 \X0D\\X0A\x 0.3 cm. Block 1A.\X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Incorporated in diagnosis.\X0D\\X0A\Using appropriate positive and negative controls, immunohistochemical studies\X0D\\X0A\for the following antibodies (with results) are performed:  pancytokeratin\X0D\\X0A\(positive), synaptophysin (positive), CD56 (positive), TTF1 (negative), CD45\X0D\\X0A\(negative).  The morphologic findings in correlation with the\X0D\\X0A\immunohistochemical studies are consistent with undifferentiated small cell/oat\X0D\\X0A\cell carcinoma.   **INITIALS  **INITIALS",,,
REG1,LUNG,0,489038,1,,HISTORY: Mass.,"ICD9 CODES: 786.6, 162.3, 162.0\X0D\\X0A\COMMENTS: The slides were seen in consultation with Dr. **NAME[ZZZ YYY], who agrees with the above diagnosis.  The slides were seen in consultation with Dr. **NAME[XXX WWW], who agrees with the above diagnosis.  A panel of immunohistochemical stains was performed with the following results: CD56 positive, synaptophysin moderately positive, scattered TTF-1 positive cells, LCA negative.  Results given to **NAME[UUU] Green in Dr. **NAME[VVV]'s office by Dr. **NAME[ZZZ YYY] at 8:45 a.m. on **DATE[Aug 08 12].  Results discussed with Dr.  **NAME[VVV] at 9:05 a.m.  on **DATE[Aug 08 12].  Immunohistochemistry stains performed by:  Anatomic Pathology Laboratory of **PLACE (Division of Pathgroup **PLACE), 658 **PLACE, Tennessee **ZIP-CODE.  CLIA # 44D0934312.\X0D\\X0A\LAB_COMM: Bringing block to you now - thanks! EIH **DATE[Aug 8 12] returned block and slides (las)","DIAGNOSIS: 1 -  BRONCHIAL WASHINGS FROM RIGHT UPPER LOBE, CYTOLOGY:             RARE ALVEOLAR MACROPHAGES AND BENIGN MIXED             INFLAMMATORY CELLS.  2 -  BRUSHINGS FROM TRACHEAL LESION, CYTOLOGY:             SMALL CELL CARCINOMA.  3 -  BRONCHIAL BRUSHINGS FROM RIGHT UPPER LOBE, CYTOLOGY:             SMALL CELL CARCINOMA.  4 -  TRACHEAL LESION, BIOPSY:             EMPTY SPECIMEN CONTAINERS, QUANTITY NOT SUFFICIENT FOR             DIAGNOSIS.  5 -  RIGHT LUNG, UPPER LOBE, TRANSBRONCHIAL BIOPSY:             MALIGNANT NEOPLASM WITH EXTENSIVE CRUSH ARTIFACT.             CONSISTENT WITH SMALL CELL CARCINOMA.",,"GROSS: Received in formalin and labeled with the patient's name are eight containers. Specimen #1 is labeled \""RUL washings\"" and consists of two containers with a total volume of 15 cc of red, mucoid-like fluid.  Cell block and cytospins are submitted as #1.  The second is labeled as \""brushings, tracheal lesion\"" and consists of a single slide in alcohol submitted as #2.  The third specimen is labeled \""brushing RUL\"" and consists of a single slide in alcohol labeled #3.  The fourth specimen consists of two containers, both labeled \""biopsy, tracheal lesion\"".  No specimen is identified in either container.  The fifth specimen is labeled \""biopsy RUL\"" and consists of two containers.  A single white fragment of tissue is identified in one, measuring up to 0.1 cm.  This specimen is submitted for TE as #5.  DT: **DATE[Aug 02 12]","MICRO: Microscopic examination was performed.  DT:  **DATE[Aug 03 12] (DRB, bsp)","PROCEDURE: Bronchoscopy with biopsy, brushing, and washing.\X0D\\X0A\SPECIMEN(S): 1) RUL washing.  2) Brushing tracheal lesion.  3) Brushing RUL.  4) Biopsy tracheal lesion.  5) Biopsy RUL.",,
REG1,LUNG,0,489322,1,,,,,,,,,,
REG1,LUNG,0,490086,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is left upper lobe lung cancer, small cell.\X0D\\X0A\Intraoperative findings: lung cancer. Operative procedure: video-assisted\X0D\\X0A\thoracoscopy, left upper lobectomy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""NO TUMOR SEEN\""---KJA\X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Feb 25 1951] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Oct 20 2011] 00:00\X0D\\X0A\Receipt Date: **DATE[Oct 21 2011] 07:39\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: T.W. **NAME[WWW], MD     Service: CVT     Location: 2PAC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Oct 23 2011] 18:25\X0D\\X0A\RESIDENTS(**NAME[M): UUU TTT], DO\X0D\\X0A\Comment: Sections through the lung demonstrate an undifferentiated\X0D\\X0A\neuroendocrine carcinoma consistent with small cell carcinoma.  In the region\X0D\\X0A\of the tumor, a small focus of necrotizing granulomatous inflammation is\X0D\\X0A\identified.  A GMS stain for fungal organisms is negative.  A fite stain for\X0D\\X0A\acid fast organisms is pending and will be issued as an addendum.  Whether\X0D\\X0A\this represents a granulomatous reaction to tumor or infection cannot be\X0D\\X0A\determined.  Clinical correlation is recommended.  \X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\LUNG, LEFT UPPER LOBE (A), VIDEO ASSISTED THORASCOPIC LEFT UPPER LOBECTOMY:  \X0D\\X0A\- SMALL CELL CARCINOMA (pT1b, pN0), SEE TEMPLATE.\X0D\\X0A\   - SURGICAL MARGINS FREE OF TUMOR.   - EMPHYSEMATOUS / SMOKING RELATED\X0D\\X0A\CHANGES.   - FOCAL NECROTIZING GRANULOMATOUS INFLAMMATION ADJACENT TO TUMOR,\X0D\\X0A\SEE COMMENT.  \X0D\\X0A\   - HYALINIZED CALCIFIED NODULE, NO TUMOR SEEN IN TWO LYMPH NODES (0/2).\X0D\\X0A\LYMPH NODES, AP WINDOW (B), EXCISION:     - ANTHRACOSIS, NO TUMOR SEEN IN\X0D\\X0A\THREE LYMPH NODES (0/3).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Oct 23 2011] **NAME[ZZZ M. YYY], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\FITE STAIN:  \X0D\\X0A\   - NO ACID FAST ORGANISMS IDENTIFIED ON FITE STAIN.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\ksl/**DATE[Oct 26 2011] **NAME[ZZZ M. YYY], MD \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: E4000 M09400 \X0D\\X0A\F: A: 88331 FS1, 88309, S 88312, 67636, S 88312, 67203, S 88312, 67636, S\X0D\\X0A\88312, 67203, S 88312, 67636 <CR>, S 88312, 67203 <CR>\X0D\\X0A\B: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Two specimens are received.\X0D\\X0A\Specimen A is received fresh for frozen section labeled left upper lobe and\X0D\\X0A\consists of the aforementioned.\X0D\\X0A\\X0D\\X0A\The pleural surface shows a possible area of puckering in the left lower\X0D\\X0A\lobe. The uninvolved lung parenchyma is congested with emphysematous changes.\X0D\\X0A\ The bronchi and airways are predominantly unremarkable. Few show mucous\X0D\\X0A\plugging. No post-obstructive changes are identified.\X0D\\X0A\There is a large calcified hilar lymph node identified. This node measures\X0D\\X0A\1.6 x 1.3 x 1.2 cm. Staple lines are present on the specimen; however, no\X0D\\X0A\wedge was sent. The pleural surface of the specimen is inked blue. \X0D\\X0A\Ink Code: Pleura Blue, green ink where staples removed (parenchymal margin).\X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen: 20 x 11.5 x 2.5 cm\X0D\\X0A\Specimen weight: 315 gm\X0D\\X0A\Mass size: 2.9 x 2.3 x 1.9 cm \X0D\\X0A\Mass to pleura distance: 0.5 cm \X0D\\X0A\Mass to bronchial margin: 6.3 cm \X0D\\X0A\Number of candidate hilar lymph nodes: 2\X0D\\X0A\Sections:\X0D\\X0A\A1  FS1\X0D\\X0A\A2  vascular margin\X0D\\X0A\A3  one hilar lymph node\X0D\\X0A\A4  calcified hilar lymph node\X0D\\X0A\A5  A6  tumor closest to pleura\X0D\\X0A\A7  additional tumor\X0D\\X0A\A8  bronchus to tumor, no tumor present in section\X0D\\X0A\A9  A10  representative sections of lung\X0D\\X0A\Specimen label:  B) AP window node                 \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 3 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): black pink tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): ranges in size from 0.4 x 0.2 x 0.1 cm to 0.7 x 0.6 x 0.4 cm \X0D\\X0A\Cassette summary: it is submitted in its entirety in B1.  \X0D\\X0A\rgc/**DATE[Oct 22 2011] **NAME[UUU TTT], DO\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\LUNG CARCINOMA (template #12)\X0D\\X0A\(including non-small cell, small cell, and carcinoid tumors) \X0D\\X0A\Last updated **DATE[Feb 2010] (AJCC 7th Edition \T\ 2009 AJCC checklist)\X0D\\X0A\Type of surgery:   left upper lobectomy  \X0D\\X0A\Weight:  315 grams\X0D\\X0A\Dimensions of lung: 20 x 11.5 x 2.5 cm\X0D\\X0A\Location (lobe / segment): left upper lobe\X0D\\X0A\Tumor size:   2.9 x 2.3 x 1.9 cm\X0D\\X0A\Tumor focality (unifocal, separate nodules - same or different lobe):\X0D\\X0A\unifocal\X0D\\X0A\Histologic type: small cell carcinoma\X0D\\X0A\Histologic grade (if applicable): poorly differentiated / undifferentiated\X0D\\X0A\Margins:\X0D\\X0A\     bronchial:  negative\X0D\\X0A\     parenchymal (if applicable):  not applicable\X0D\\X0A\     vascular: negative\X0D\\X0A\    chest wall (if applicable): not applicable\X0D\\X0A\Pleural invasion:  no\X0D\\X0A\Other organs / structures involved: none\X0D\\X0A\Tumor distance from bronchial margin:    6.3 cm\X0D\\X0A\Tumor distance from pleural surface:     3 mm\X0D\\X0A\Lymphvascular invasion:  indeterminate\X0D\\X0A\Vascular (venous) invasion:  not identified\X0D\\X0A\Lymph nodes (positive / total) [list by site]: 0/5\X0D\\X0A\     Peribronchial          0/2\X0D\\X0A\     AP window          0/3\X0D\\X0A\Description of nontumorous lung: emphysematous/smoking related changes\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\Primary tumor (pT) (all dimensions refer to greatest dimension)\X0D\\X0A\\X0D\\X0A\pT (AJCC/CAP)                                                                \X0D\\X0A\                                       (Subgroups by IASLC)\X0D\\X0A\   pT1b         Tumor >2 cm but <3 cm                                        \X0D\\X0A\                                   (T1b)\X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\pN0               No regional node metastasis\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\                       Not applicable",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left upper lobe\X0D\\X0A\B: AP window node,,PROCEDURES/ADDENDA
REG1,LUNG,0,490088,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis: lung mass. Operative procedure:\X0D\\X0A\bronchoscopy/mediastinoscopy with biopsy and left **PLACE drain.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\TOUCH PREP/FROZEN SECTION DIAGNOSIS #1:  \""CRUSHED ATYPICAL CELLS WITH CAUTERY\X0D\\X0A\ARTIFACT, POSSIBLY SMALL CELL UNDIFFERENTIATED CARCINOMA BUT DEFER TO\X0D\\X0A\PERMANENT SECTIONS\""---YMB.\X0D\\X0A\\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 17 1943] (Age: **AGE[in 60s])  M\X0D\\X0A\Collect Date: **DATE[Mar 30 2012] 11:47\X0D\\X0A\Receipt Date: **DATE[Mar 30 2012] 11:47\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: Sibu. **NAME[YYY], MD     Service: SGB     Location: REC\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Mar 31 2012] 12:39\X0D\\X0A\RESIDENTS(S): K.K. **NAME[WWW], DO","DIAGNOSIS\X0D\\X0A\UNDIFFERENTIATED SMALL CELL CARCINOMA; PERMANENT SECTIONS CONFIRM FROZEN\X0D\\X0A\SECTION DIAGNOSIS, BRONCHIAL BIOPSIES FROM CARINA (A AND B).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Mar 31 2012] **NAME[VVV M. UUU], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M80203 M8041 \X0D\\X0A\F: A: 88305, 88331 FS1\X0D\\X0A\B: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Two specimens are received.  Specimen A is received fresh for frozen section\X0D\\X0A\and placed in formalin labeled biopsy from carina and consists of two red tan\X0D\\X0A\soft tissue fragments measuring from 0.1 x 0.1 x 0.1 cm up to 0.2 x 0.2 x 0.2\X0D\\X0A\cm.  The specimen is entirely frozen as FS1 and entirely resubmitted in\X0D\\X0A\screened A1.\X0D\\X0A\Specimen label:  B) biopsy from carina                 \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: two\X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): white tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.2 x 0.2 x 0.2 cm for both\X0D\\X0A\Cassette summary: submitted entirely in screened B1\X0D\\X0A\Note  this case is for rush diagnosis  \X0D\\X0A\ksl/**DATE[Mar 31 2012] K.K. **NAME[WWW], DO\X0D\\X0A\R.G. **NAME[TTT], MD","MICROSCOPIC DESCRIPTION\X0D\\X0A\Permanent sections show typical small cell undifferentiated carcinoma with\X0D\\X0A\hyperchromatic cells, prominent apoptosis, and mitosis as well as nuclear\X0D\\X0A\streaming artifact.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: biopsy from carina\X0D\\X0A\B: biopsy from carina,,
REG1,LUNG,0,490166,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis is left upper lobe mass.  Intraoperative findings:\X0D\\X0A\left hilar mass.  Operative procedure: left video assisted thoracoscopy\X0D\\X0A\pneumonectomy.  \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""NO TUMOR SEEN\""---KA.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""NO TUMOR SEEN\""---KA\X0D\\X0A\FROZEN SECTION DIAGNOSIS #3:  \""FOCAL ATYPIA IN A BACKGROUND OF INFLAMMATION\X0D\\X0A\AND REACTIVE CHANGES\""---KA\X0D\\X0A\FROZEN SECTION DIAGNOSIS #4:  \""ORGANIZATION AND INFLAMMATION\""---KA.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #5A:  \""INTRALUMINAL TUMOR, NO DEFINITIVE BRONCHIAL\X0D\\X0A\WALL INVASION\""---**INITIALS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #5B:  \""SQUAMOUS CELL CARCINOMA\""---KA.\X0D\\X0A\\X0D\\X0A\ksl/**DATE[May 29 2012]     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Aug 13 1948] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[May 27 2012] 13:30\X0D\\X0A\Receipt Date: **DATE[May 27 2012] 13:30\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: T.W. **NAME[WWW], MD     Service: CVT     Location: ORN\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[May 29 2012] 15:47\X0D\\X0A\RESIDENTS(**NAME[M): UUU TTT], DO\X0D\\X0A\Comment:\X0D\\X0A\The bronchial margin has tumor protruding in the lumen, but the tumor is not\X0D\\X0A\attached at the margin. There is some squamous metaplasia with mild atypia at\X0D\\X0A\the bronchial margin, however.  The tumor is very close to the bronchial\X0D\\X0A\margin, as the subsequent section shows invasive tumor within the bronchial\X0D\\X0A\wall.  Permanent sections confirm the frozen section diagnoses.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\LEFT UPPER LOBE, LOBECTOMY (J):\X0D\\X0A\   - INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA (pT2b, pN0).\X0D\\X0A\   - MARGINS OF RESECTION NEGATIVE FOR TUMOR (TUMOR IS 1-2 MM FROM BOTH\X0D\\X0A\BRONCHIAL AND\X0D\\X0A\    VASCULAR MARGINS).\X0D\\X0A\   - SEE TEMPLATE AND COMMENT.\X0D\\X0A\AP WINDOW NODES, EXCISION (A):\X0D\\X0A\   - NO TUMOR SEEN IN THREE LYMPH NODES (0/3).\X0D\\X0A\AP WINDOW LYMPH NODE, EXCISION (B):\X0D\\X0A\   - UNREMARKABLE SKELETAL MUSCLE; NO TUMOR SEEN, NO LYMPH NODE IDENTIFIED.\X0D\\X0A\LEFT HILAR LYMPH NODE, EXCISION (C):\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\LEFT INFERIOR PULMONARY LIGAMENT LYMPH NODE, EXCISION (D):\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\LEFT POSTERIOR HILAR LYMPH NODE, EXCISION (E):\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\SUBCARINAL LYMPH NODE, EXCISION (F):\X0D\\X0A\  - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\INTERLOBAR LYMPH NODE, EXCISION (G):\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\LEFT UPPER LOBE MASS, CORE BIOPSY (H):\X0D\\X0A\   - INFLAMMATION AND REACTIVE ATYPIA; NO TUMOR SEEN.\X0D\\X0A\LEFT UPPER LOBE MASS #2, BIOPSY (I):\X0D\\X0A\   - ORGANIZATION AND FOCAL FIBROSIS; NO TUMOR SEEN.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 29 2012] M.V. **NAME[SSS], MD\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\Ten specimens are submitted.\X0D\\X0A\Total specimen number:  four\X0D\\X0A\Specimen label:  A) AP window node                  \X0D\\X0A\Fixation: fresh for frozen section then resubmitted in formalin \X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s):    irregular\X0D\\X0A\Color(s): black tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 2 x 2 x 0.5 cm. It is palpated to reveal lymph node the largest of\X0D\\X0A\which measures 1.5 x 0.8 x 0.5 cm. \X0D\\X0A\Cassette summary:  FS1 is resubmitted in A1.  The remaining fibrofatty tissue\X0D\\X0A\is submitted in A2.\X0D\\X0A\Specimen label:  B)  AP window lymph node\X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s):   irregular \X0D\\X0A\Color(s): red tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 1 x 0.5 x 0.5 cm. \X0D\\X0A\Cassette summary: entirely submitted in B1\X0D\\X0A\Specimen label:  C) left hilar lymph node\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: four \X0D\\X0A\Shape(s):     \X0D\\X0A\Color(s):\X0D\\X0A\Consistency: \X0D\\X0A\Size(s): 2.5 x 2 x 1 cm. It is palpated to reveal a possible candidate lymph\X0D\\X0A\node measuring 1.5 x 0.6 x 0.5 cm\X0D\\X0A\Cassette summary: candidate lymph node is submitted in C1; remainder of\X0D\\X0A\fibrofatty tissue in C2.\X0D\\X0A\Specimen label:  D) left inferior pulmonary ligament lymph node              \X0D\\X0A\\X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 2.5 x 2 x 1.5 cm. \X0D\\X0A\Cassette summary:  submitted in D1.\X0D\\X0A\Specimen label:  E) left inferior pulmonary ligament lymph node              \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one \X0D\\X0A\Shape(s):  irregular\X0D\\X0A\Color(s): yellow tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s):  2.5 x 1.5 x 0.5 cm. It is palpated to reveal a candidate lymph node\X0D\\X0A\measuring 1 x 0.5 x 0.5 cm\X0D\\X0A\Cassette summary: lymph node and associated fibrofatty tissue are submitted\X0D\\X0A\in E1 \X0D\\X0A\Specimen label:  F) subcarinal lymph node                 \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: one\X0D\\X0A\Shape(s):   irregular \X0D\\X0A\Color(s): red brown\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 2 x 1.5 x 1 cm.  \X0D\\X0A\Cassette summary: bisected and submitted in F1\X0D\\X0A\Specimen label:  G) interlobar lymph node  \X0D\\X0A\Fixation: fresh for frozen section FS2\X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s):  irregular  \X0D\\X0A\Color(s): red brown\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 2.5 x 1.5 x 0.6 cm. \X0D\\X0A\Cassette summary: FS2 is resubmitted entirely in G1\X0D\\X0A\Specimen label:  H)  left upper lobe mass\X0D\\X0A\Fixation: fresh for frozen section FS3\X0D\\X0A\Number of pieces: three \X0D\\X0A\Shape(s): core   \X0D\\X0A\Color(s): pink tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): ranging in length from 1.6 to 1.9 cm and less than 0.1 cm in\X0D\\X0A\diameter.\X0D\\X0A\Cassette summary: FS3 is completely resubmitted biowrapped in H1\X0D\\X0A\Specimen label:  I) left upper lobe mass #2 (biopsy) \X0D\\X0A\Fixation: fresh for frozen section FS4\X0D\\X0A\Number of pieces: three\X0D\\X0A\Shape(s):  core \X0D\\X0A\Color(s): pink tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): ranging from 1.6 to 1.8 cm and less than 0.1 cm in diameter\X0D\\X0A\Cassette summary: resubmitted entirely in I1 biowrap\X0D\\X0A\Specimen J is received fresh for frozen section labeled left upper lobe\X0D\\X0A\(diagnosis in bronchial margins) and consists of the aforementioned.  The\X0D\\X0A\pleural surface is intact and slightly puckered.  Cut surface shows partly\X0D\\X0A\circumscribed mass, measurements below.  The uninvolved lung parenchyma is\X0D\\X0A\consolidative changes with plugging.  The bronchi and airways are mucous\X0D\\X0A\plugging.  Some post-obstructive changes are noted.\X0D\\X0A\Ink Code: Pleura Blue, green ink where staples removed (parenchymal margin).\X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen: 19.5 x 15 x 6 cm\X0D\\X0A\Specimen weight: 640 gm\X0D\\X0A\Mass size: 6 x 5.2 x 4.5 cm \X0D\\X0A\Mass to pleura distance:0.5 cm \X0D\\X0A\Mass to bronchial margin: mass extends into bronchus, however is not\X0D\\X0A\connected to the bronchial mucosa \X0D\\X0A\Number of candidate hilar lymph nodes: 5\X0D\\X0A\Sections:\X0D\\X0A\J1 is FS5A resubmitted \X0D\\X0A\J2 is FS5B is resubmitted \X0D\\X0A\J3 vascular margin\X0D\\X0A\J4 bronchus to tumor\X0D\\X0A\J5 representative section of bronchus to tumor\X0D\\X0A\J6 tumor to pleura\X0D\\X0A\J7 representative section of tumor to ink\X0D\\X0A\J8 representative section of tumor to pleura\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.","MICROSCOPIC DESCRIPTION\X0D\\X0A\LUNG CARCINOMA (template #12)\X0D\\X0A\(including non-small cell, small cell, and carcinoid tumors) \X0D\\X0A\Last updated **DATE[Sep 2010] (AJCC 7th Edition \T\ 2009 AJCC checklist)\X0D\\X0A\Type of surgery:  lobectomy\X0D\\X0A\Weight:  640 grams\X0D\\X0A\Dimensions of lung:  19.5 x 15 x 6 cm\X0D\\X0A\Location (lobe / segment):  left upper lobe\X0D\\X0A\Tumor size:  6 x 5.2 x 4.5 cm\X0D\\X0A\Tumor focality (unifocal, separate nodules - same or different lobe): \X0D\\X0A\unifocal\X0D\\X0A\Histologic type:  squamous cell carcinoma\X0D\\X0A\Histologic grade (if applicable):  moderately differentiated\X0D\\X0A\Margins:\X0D\\X0A\     bronchial:  negative; intraluminal tumor is present but it is not\X0D\\X0A\attached. The subsequent section does\X0D\\X0A\      show invasive tumor such that the bronchial margin is probably only 1-2\X0D\\X0A\mm at most from the invasive carcinoma.\X0D\\X0A\     vascular:  negative, but tumor within 1 mm \X0D\\X0A\Pleural invasion:  no\X0D\\X0A\Other organs / structures involved:  no\X0D\\X0A\Tumor distance from bronchial margin:  1-2mm\X0D\\X0A\Tumor distance from pleural surface:  approximately 8mm\X0D\\X0A\Lymphvascular invasion:  not identified\X0D\\X0A\Vascular (venous) invasion:  not identified\X0D\\X0A\Lymph nodes (positive / total) [list by site]: 0/17\X0D\\X0A\     AP window -  0/3\X0D\\X0A\     Hilar  0/11\X0D\\X0A\     Left inferior pulmonary ligament lymph node  0/1\X0D\\X0A\     Subcarinal lymph node  0/1\X0D\\X0A\     Interlobar lymph node  0/1\X0D\\X0A\Description of nontumorous lung:  emphysematous and smoking related changes;\X0D\\X0A\extensive post obstructive change/necrotizing pneumonia with organization\X0D\\X0A\distal to tumor\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\Primary tumor (pT) (all dimensions refer to greatest dimension)\X0D\\X0A\\X0D\\X0A\pT (AJCC/CAP)                                                                \X0D\\X0A\                                       (Subgroups by IASLC)\X0D\\X0A\pT2b       Tumor >5 but <7 cm                                                \X0D\\X0A\  (T2b)\X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\pN0               No regional node metastasis\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\                       Not applicable",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: AP window node\X0D\\X0A\B: AP window lymph node\X0D\\X0A\C: Left hilar lymph node\X0D\\X0A\D: Left inferior pulmonary ligament lymph node\X0D\\X0A\E: Left posterior hilar lymph node\X0D\\X0A\F: Subcarinal lymph node\X0D\\X0A\G: Interlobar lymph node\X0D\\X0A\H: Left upper lobe mass\X0D\\X0A\I: Left upper lobe mass #2 biopsy\X0D\\X0A\J: Left upper lobe (diagnosis and bronchial margin),,
REG1,LUNG,0,490253,1,,CLINICAL HISTORY\X0D\\X0A\The working diagnosis is history of right upper lobe lung nodule. Operative\X0D\\X0A\findings: mainstem right bronchus with narrowing. Operative procedure:\X0D\\X0A\bronchoscopy with right mainstem/right upper lobe endobronchial biopsies. \X0D\\X0A\,"**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Jul 19 1953] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Apr 30 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[May 3 2012] 09:16\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], MD     Service: PUL     Location: ENDO\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[May 6 2012] 11:31\X0D\\X0A\RESIDENTS(S): M.H. **NAME[WWW], MD\X0D\\X0A\Comment: The histologic sections show a invasive, non-small cell carcinoma\X0D\\X0A\with glandular and squamous features. The amount of tumor tissue is limited;\X0D\\X0A\however there is enough tumoral tissue for immunohistochemical stains (and\X0D\\X0A\eventually for molecular studies) for further tumor categorization if\X0D\\X0A\clinically indicated.  The case was prospectively reviewed in the\X0D\\X0A\intradepartmental consensus conference with the agreement to the above\X0D\\X0A\diagnosis.\X0D\\X0A\This case has been reviewed at the daily departmental consensus conference.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.","DIAGNOSIS\X0D\\X0A\LUNG, RIGHT MAINSTEM/RIGHT UPPER LOBE, ENDOBRONCHIAL BIOPSIES:\X0D\\X0A\   - NON-SMALL CELL CARCINOMA, SEE COMMENT.\X0D\\X0A\\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[May 5 2012] **NAME[M. VVV], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M80103 P1140 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) right mainstem/right upper lobe endobronchial biopsies   \X0D\\X0A\\X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 12 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): black tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): range from 0.2 to less than 0.1 cm in greatest dimension \X0D\\X0A\Cassette summary: entirely submitted in screened A1  A3.  \X0D\\X0A\rgc/**DATE[May 4 2012] M.H. **NAME[WWW], MD\X0D\\X0A\J.G. Combs",MICROSCOPIC DESCRIPTION,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Endobronchial biopsies right mainstem/right upper lobe,,
REG1,LUNG,0,490435,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is ex-smoker and new left upper lobe mass.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Lung, bronchial biopsy","Final Diagnosis\X0D\\X0A\LEFT UPPER LOBE BIOPSIES: \X0D\\X0A\     Detached fragments of poorly differentiated non-small cell carcinoma. \X0D\\X0A\NOTE: Dr.**NAME[ZZZ]'s nurse (**NAME[YYY XXX]) was contacted and the case discussed\X0D\\X0A\(DGD, 11am **DATE[Jul 18 12]).\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Received in formalin labeled left upper lobe biopsy are a multiple tan soft\X0D\\X0A\tissue fragments aggregating 0.5 x 0.5 x 0.1 cm which are filtered, wrapped and\X0D\\X0A\submitted entirely in one cassette.  **INITIALS",Microscopic Description\X0D\\X0A\Sections of the biopsy show fragments of bronchial epithelium and subbronchial\X0D\\X0A\tissues. The subbronchial tissues are mildly chronically inflamed. There are\X0D\\X0A\several detached fragments of tumor having pleomorphic nuclei with ample\X0D\\X0A\cytoplasm and a modicum of intercellular cohesiveness.  **INITIALS,,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,LUNG,0,490900,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is lung mass.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\2: Soft tissue mass, biopsy\X0D\\X0A\3: Lung, Wedge or Bleb\X0D\\X0A\4: Bone Biopsy\X0D\\X0A\5: Bone Biopsy\X0D\\X0A\6: Lymph node, biopsy\X0D\\X0A\7: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\8: Lymph node, biopsy\X0D\\X0A\9: Lymph node, biopsy","Final Diagnosis\X0D\\X0A\1.  RIGHT UPPER LOBE WITH ADJACENT SOFT TISSUE AND RIB, WEDGE RESECTION: \X0D\\X0A\     Moderately differentiated squamous cell carcinoma with extension into chest\X0D\\X0A\wall and adjacent rib. \X0D\\X0A\Extensive necrosis evident. \X0D\\X0A\Angiolymphatic permeation by neoplasm present. \X0D\\X0A\2.  RIGHT CHEST WALL, RESECTION: \X0D\\X0A\     Portions of soft tissue and rib with extensive poorly differentiated\X0D\\X0A\squamous cell carcinoma with extensive necrosis. \X0D\\X0A\Gross tumor size equal 8.0 x 5.0 x 2.5 cm. \X0D\\X0A\Soft tissue margin 3 mm. \X0D\\X0A\3.  SUBMITTED RIGHT CHEST WALL MASS, BIOPSY: \X0D\\X0A\     Poorly differentiated squamous cell carcinoma with involvement of soft\X0D\\X0A\tissue and bone, margin positive.\X0D\\X0A\4.  HEAD OF 4TH RIB, RESECTION: \X0D\\X0A\     Infiltrating poorly differentiated squamous cell carcinoma with involvement\X0D\\X0A\of marrow space; margin positive.  \X0D\\X0A\5.  HEAD OF 3RD RIB: \X0D\\X0A\     Bone with reactive marrow; negative for neoplasm. \X0D\\X0A\6.  LEVEL 10 LYMPH NODE, BIOPSY: \X0D\\X0A\     Lymph node with sinus histiocytosis and anthracosis; negative for neoplasm.\X0D\\X0A\7.  RIGHT UPPER LOBE, COMPLETION LOBECTOMY: \X0D\\X0A\     No residual tumor identified. \X0D\\X0A\Bronchial margin free of neoplasm. \X0D\\X0A\One level 12 lymph node negative for metastatic carcinoma. \X0D\\X0A\8.  RIGHT LEVEL 4 LYMPH NODE: \X0D\\X0A\     Negative for metastatic carcinoma (0/1). \X0D\\X0A\9.  RIGHT LEVEL 9 LYMPH NODES, BIOPSY: \X0D\\X0A\     Two lymph nodes negative for metastatic carcinoma. (0/2). See Template and\X0D\\X0A\Comment. \X0D\\X0A\LUNG CARCINOMA \X0D\\X0A\SPECIMEN TYPE/PROCEDURE: Wedge resection with completion lobectomy. \X0D\\X0A\SPECIMEN INTEGRITY:  Received in multiple specimens. \X0D\\X0A\LATERALITY:  Right. \X0D\\X0A\TUMOR FOCALITY:  Unifocal. \X0D\\X0A\TUMOR SITE:  Right upper lobe. \X0D\\X0A\TUMOR SIZE (greatest dimension):  8.0 x 5.0 x 2.5 cm. \X0D\\X0A\HISTOLOGIC TYPE:  Squamous carcinoma. \X0D\\X0A\HISTOLOGIC GRADE:  3. \X0D\\X0A\VISCERAL PLEURA INVASION:  Yes. \X0D\\X0A\TUMOR EXTENSION:  Into chest wall, involving soft tissue and rib. \X0D\\X0A\BRONCHIAL MARGIN:  Free of neoplasm. \X0D\\X0A\VASCULAR MARGIN: Negative. \X0D\\X0A\LYMPHVASCULAR INVASION:  Yes. \X0D\\X0A\PARENCHYMAL MARGIN:  N/A\X0D\\X0A\CHEST WALL MARGIN:  Positive at rib; negative by 3 mm. at soft tissue\X0D\\X0A\OTHER TISSUE MARGIN:  Unknown. \X0D\\X0A\REGIONAL LYMPH NODE STATUS:  0/1 level 4, 0/2 level 9, 0/1 level 10, 0/1 level\X0D\\X0A\12. \X0D\\X0A\EXTRANODAL TUMOR SPREAD:  N/A. \X0D\\X0A\TREATMENT EFFECT:  None. \X0D\\X0A\OTHER METASTATIC SITES:  Unknown. \X0D\\X0A\OTHER NEOPLASM SITES: Unknown. \X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Emphysema, pleural fibrosis. \X0D\\X0A\OTHER STUDIES:  Not requested. \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=3\X0D\\X0A\pN=0  \X0D\\X0A\AJCC PATHOLOGIC STAGE:    IIB\X0D\\X0A\COMMENT: Dr. **NAME[ZZZ] discussed this case with Dr. **NAME[YYY] on **DATE[Oct 23 11] at 2:50 p.m. \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled right upper lobe erosion into chest wall\X0D\\X0A\and consists of a wedge resection of lung and a very short segment of rib. The\X0D\\X0A\wedge of lung measures 10 cm in length by 2.5 cm in width by 2.5 cm in\X0D\\X0A\thickness. There is an obvious tumor eroding through the pleural surface on this\X0D\\X0A\wedge and this area of ulceration measures 3.1 cm in diameter. Cut surface of\X0D\\X0A\the pulmonary wedge reveals a whitish what is suspected to be tumor mass\X0D\\X0A\measuring 2.1 x 0.7 cm. Representative sections of this mass are submitted in\X0D\\X0A\cassettes 1A-1C and in cassettes 1D-1F are submitted the entirety of the segment\X0D\\X0A\of rib after decalcification.  \X0D\\X0A\Specimen 2 received fresh for frozen section labeled right chest wall margins is\X0D\\X0A\a 139.8 gram, 15.0 x 6.0 x 3.0 cm gray/white soft tissue mass including three\X0D\\X0A\segments of rib. The outer surface of the ribs are inked black and sectioning\X0D\\X0A\reveals a gray/white soft cut surface. The soft tissue mass has overall\X0D\\X0A\dimensions of 8.0 x 5.0 x 2.5 cm and appears to invade through the rib and abuts\X0D\\X0A\the black inked resection margin. No lung tissue is identified. A representative\X0D\\X0A\section is submitted for frozen section, now resubmitted in cassette 2A.\X0D\\X0A\Additional representative sections of the mass to include the rib and black\X0D\\X0A\inked soft tissue resection margin are submitted in cassettes 2B-2I following\X0D\\X0A\decalcification.  \X0D\\X0A\Specimen 3 received in formalin labeled chest right mass for permanent and\X0D\\X0A\consists of a small mass of tissue with an apparent muscular and adipose\X0D\\X0A\component. The tissue measures 2 x 1 x 0.8 cm. It is sectioned sequentially and\X0D\\X0A\submitted in toto in cassette 3A. \X0D\\X0A\Specimen 4 received in formalin labeled head of fourth rib for permanent and\X0D\\X0A\consists of three masses of bony tissue having an aggregate dimension of 4 x 3 x\X0D\\X0A\1 cm. It is representatively submitted after decalcification in cassette 4.  \X0D\\X0A\Specimen 5 received in formalin labeled head of third rib for permanent and\X0D\\X0A\consists of a segment of rib measuring 2.1 cm in length by 2 cm in width by 1.1\X0D\\X0A\cm in thickness. The specimen is decalcified and submitted in toto in cassette\X0D\\X0A\5. \X0D\\X0A\Specimen 6 received in formalin labeled level 10 lymph node for permanent and\X0D\\X0A\consists of a small mass of soft tissue grossly consistent with an anthracotic\X0D\\X0A\node. It measures 1.1 cm in width by 1.5 cm in length by 0.3 cm in thickness.\X0D\\X0A\The specimen is submitted in toto in a single cassette 6.  \X0D\\X0A\Specimen 7 received fresh for frozen section labeled right upper lobe and\X0D\\X0A\consists of a 100 gram mass of soft tissue grossly consistent with a right upper\X0D\\X0A\lobe with multiple staple lines. The bronchial margin has been previously\X0D\\X0A\submitted. The lobe is breadloaf sectioned thoroughly and no residual tumor is\X0D\\X0A\seen within it. Representative sections of the vascular margin are submitted in\X0D\\X0A\cassette 7B and representative sections of random areas of the lung lobe\X0D\\X0A\submitted in cassettes C-E. \X0D\\X0A\Specimen 8 received in formalin labeled level 4R lymph node and consists of a\X0D\\X0A\very tiny mass of soft tissue that has what appears to be a small tiny palpable\X0D\\X0A\node within it measuring approximately 3 mm in diameter. The specimen is\X0D\\X0A\submitted in a single cassette 8. \X0D\\X0A\Specimen 9 received in formalin labeled level 9R lymph node and consists of a\X0D\\X0A\small fragment of adipose with what appears to be a gross node measuring\X0D\\X0A\approximately 4 mm in diameter and is submitted in toto in a single cassette 9. \X0D\\X0A\**INITIALS","Microscopic Description\X0D\\X0A\Sections from the right upper lobe wedge biopsy show infiltrating poorly\X0D\\X0A\differentiating neoplasm with extensive necrosis. The neoplastic cells vary from\X0D\\X0A\epithelioid to spindled with large vesicular nuclei with prominent nucleoli.\X0D\\X0A\Focal keratinization is observed. The tumor extends into the chest wall,\X0D\\X0A\involving the visceral and parietal pleura. Angiolymphatic permeation by\X0D\\X0A\neoplasm is noted. Sections through the rib show neoplasm within soft tissue\X0D\\X0A\proper. \X0D\\X0A\Sections through specimen 2 show the frozen section control to be free of\X0D\\X0A\neoplasm. Sections which include rib and surrounding soft tissue show evidence\X0D\\X0A\of neoplasm extending through the soft tissue and into the rib. The margin of\X0D\\X0A\resection is approximately 3-5 mm from the inked surgical margin. Again, areas\X0D\\X0A\of angiolymphatic permeation by neoplasm are noted. \X0D\\X0A\Sections from specimen 3 show infiltrating neoplasm similar to that described\X0D\\X0A\above within soft tissue. There is a 1 mm margin as can be best discerned. \X0D\\X0A\Sections through specimen 4 designated head of fourth rib show an area of\X0D\\X0A\reactive marrow containing neoplasm with background reactive marrow which\X0D\\X0A\includes some small lymphoid aggregates. \X0D\\X0A\Sections through specimen 5, designated head of third rib show reactive\X0D\\X0A\appearing bone with marrow which is normocellular and contains some small\X0D\\X0A\lymphoid aggregates. This is free of neoplasm. \X0D\\X0A\Sections from specimen 6 show a lymph node with anthracotic pigmentation and\X0D\\X0A\sinus histiocytosis. There is no evidence of metastatic neoplasm. \X0D\\X0A\Sections from the bronchial margin show no evidence of neoplasm. The additional\X0D\\X0A\sections of lung submitted show areas of pleural fibrosis and emphysematous\X0D\\X0A\change. There is no evidence of neoplasm. A single lymph node identified shows\X0D\\X0A\no evidence of neoplasm. \X0D\\X0A\Sections through specimen 8 show lymph node with anthrasilicosis and without\X0D\\X0A\evidence of neoplasm. \X0D\\X0A\Sections from specimen 9 show two lymph nodes without evidence of metastatic\X0D\\X0A\carcinoma.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. ZZZ], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,491804,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is not provided.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, Wedge or Bleb\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\4: Lymph node, biopsy\X0D\\X0A\5: Lymph node, biopsy\X0D\\X0A\6: Lymph node, biopsy","Final Diagnosis\X0D\\X0A\1. LEFT UPPER LOBE, WEDGE BIOPSY:\X0D\\X0A\     Infiltrating poorly differentiated adenocarcinoma arising within extensive\X0D\\X0A\background acute and chronic inflammation including granulomatous inflammation. \X0D\\X0A\Estimated gross tumor size = 1.5x1.2x0.8 cm.\X0D\\X0A\Stapled margin free of neoplasm by 1.1cm.\X0D\\X0A\Neither angiolymphatic nor perineural invasion by tumor identified.\X0D\\X0A\GMS stain negative for fungus.\X0D\\X0A\1.          LEVEL 7 LYMPH NODE:\X0D\\X0A\     One lymph node negative for metastatic carcinoma (0/1).\X0D\\X0A\2.          LEVEL 8 LYMPH NODE:\X0D\\X0A\     One lymph node negative for metastatic carcinoma (0/1).\X0D\\X0A\3.          LEVEL 10 LYMPH NODE:\X0D\\X0A\     Two lymph nodes negative for metastatic carcinoma (0/2).\X0D\\X0A\4.          LEVEL 5 LYMPH NODE:\X0D\\X0A\     Two lymph nodes negative for metastatic carcinoma (0/2).\X0D\\X0A\5.          LEVEL 6 LYMPH NODE:\X0D\\X0A\     One lymph node negative for metastatic carcinoma (0/1).\X0D\\X0A\JFJ/mbc\X0D\\X0A\COMMENT:  See immunohistochemistry result details in microscopic description. \X0D\\X0A\Dr. **NAME[ZZZ] discussed the final diagnosis on this case with Dr. **NAME[YYY XXX] on\X0D\\X0A\**DATE[Jul 21 2012] at 12:20pm.  **INITIALS\X0D\\X0A\LUNG CARCINOMA \X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  Wedge resection\X0D\\X0A\SPECIMEN INTEGRITY:  Intact\X0D\\X0A\LATERALITY:  Left\X0D\\X0A\TUMOR FOCALITY:  Unifocal\X0D\\X0A\TUMOR SITE:  Left upper lobe\X0D\\X0A\TUMOR SIZE (greatest dimension):  1.5 x 1.2 x 0.8cm\X0D\\X0A\HISTOLOGIC TYPE:  Adenocarcinoma\X0D\\X0A\HISTOLOGIC GRADE:  Grade 3\X0D\\X0A\VISCERAL PLEURA INVASION:  No\X0D\\X0A\TUMOR EXTENSION:  Confined to lobe\X0D\\X0A\BRONCHIAL MARGIN:  N/A\X0D\\X0A\VASCULAR MARGIN:  Negative\X0D\\X0A\LYMPHVASCULAR INVASION:  Not identified\X0D\\X0A\PARENCHYMAL MARGIN:  Negative by 1.1cm\X0D\\X0A\CHEST WALL MARGIN:  Not involved\X0D\\X0A\OTHER TISSUE MARGIN:  N/A\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  0/1 level 7, 0/1 level 8, 0/2 level 10, 0/2 level\X0D\\X0A\5, 0/1 level 6\X0D\\X0A\EXTRANODAL TUMOR SPREAD:  N/A\X0D\\X0A\TREATMENT EFFECT:  None\X0D\\X0A\OTHER METASTATIC SITES:  Unknown\X0D\\X0A\OTHER NEOPLASM SITES:  Unknown\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  Respiratory bronchiolitis, parenchymal fibrosis\X0D\\X0A\OTHER STUDIES:  Not requested\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  1a\X0D\\X0A\pN=  0\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IA\X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 labeled left upper lobe wedge, received fresh for frozen section,\X0D\\X0A\consists of a 30.4 gram, 8.0x4.8x3.0 cm intact lung wedge biopsy. The pleura is\X0D\\X0A\red/pink and wrinkled with a moderate amount of black anthracotic pigment.\X0D\\X0A\Sectioning reveals a 2.8x2.0x2.0 cm area if ill defined gray/white firm lung\X0D\\X0A\tissue. No definitive invasive tumor is identified. A representative section of\X0D\\X0A\the firm lung tissue is submitted for frozen section. Summary of sections: 1A \X0D\\X0A\frozen section residue; 1B  resection margin taken en face; 1C-1E  remainder of\X0D\\X0A\firm lung tissue. \X0D\\X0A\Specimen 2 labeled level 7 lymph node, received in formalin, consists of a 1 cm\X0D\\X0A\in greatest dimension black anthracotic lymph node which is submitted entirely\X0D\\X0A\in cassette 2. \X0D\\X0A\Specimen 3 labeled level 8 lymph node, received in formalin, consists of two\X0D\\X0A\pieces of black anthracotic soft tissue aggregating 1.3x1.3x0.3 cm which are\X0D\\X0A\submitted in toto in cassette 3. \X0D\\X0A\Specimen 4 labeled level 10 lymph node, received in formalin, consists of a\X0D\\X0A\1.5x1.5x0.5 cm aggregate of black anthracotic soft tissue which is submitted in\X0D\\X0A\toto in cassette 4. \X0D\\X0A\Specimen 5 labeled level 5 lymph node, received in formalin, consists of several\X0D\\X0A\pieces of black anthracotic soft tissue with attached fat aggregating\X0D\\X0A\2.5x2.2x0.6 cm which is submitted in toto in cassette 5. \X0D\\X0A\Specimen 6 labeled level 6 lymph node, received in formalin, consists of a 1.3\X0D\\X0A\cm in greatest dimension black anthracotic lymph node which is submitted in toto\X0D\\X0A\in cassette 6. \X0D\\X0A\HM/mbc","Microscopic Description\X0D\\X0A\Sections from the wedge biopsy show a central area adjacent to a bronchus\X0D\\X0A\showing marked mixed acute and chronic inflammation but also showing evidence of\X0D\\X0A\a neoplasm composed of cells with enlarged hyperchromatic nuclei including focal\X0D\\X0A\large bizarre cells. Cells vary from epithelioid to spindled with enlarged\X0D\\X0A\hyperchromatic to vesicular nuclei. Occasional mitotic figures are observed.\X0D\\X0A\These are present in a desmoplastic stroma. Background areas of granulomatous\X0D\\X0A\inflammation are noted including histiocytes and focal giant cells. Tumor is not\X0D\\X0A\present in any margin of resection. There is no evidence of angiolymphatic or\X0D\\X0A\perineural invasion by tumor. With appropriate control, GMS stain shows staining\X0D\\X0A\of inflammatory cells and nuclear debris.  No fungi are identified.  \X0D\\X0A\Sections through specimens 2 and 3 show anthracotic lymph nodes with sinus\X0D\\X0A\histiocytosis and without evidence of metastatic carcinoma. \X0D\\X0A\Sections from specimens 4, 5, and 6 overall appear similar, again showing\X0D\\X0A\extensive anthracosis and sinus histiocytosis. There is a well circumscribed\X0D\\X0A\fibrous nodule compatible with an old granuloma. None of the lymph nodes show\X0D\\X0A\evidence of metastatic carcinoma.  JFJ/mbc\X0D\\X0A\With appropriate control, five immunohistochemical stains are performed.  The\X0D\\X0A\area of putative neoplasm stains strongly with antibody CK7.  It also shows\X0D\\X0A\strong positive staining with antibodies to Napsin and TTF with cytoplasmic and\X0D\\X0A\nuclear patterns respectively.  There is absolutely no staining with antibody\X0D\\X0A\P63 or CK5/6.  All controls stain appropriately including external positive,\X0D\\X0A\internal negative and external negative controls as required. **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[CCC M. ZZZ], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,491812,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is weight loss of 9 pounds over past six months, history of\X0D\\X0A\smoking (1 ppd x40 years).","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY M]\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Fine Needle Aspiration Performed by Radiologist","Final Diagnosis\X0D\\X0A\RIGHT LUNG MASS FINE NEEDLE ASPIRATE: \X0D\\X0A\     Fragments of poorly differentiated carcinoma, non-small cell. \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled right lung mass FNA is a 0.6 x 0.4 x 0.2 cm\X0D\\X0A\aggregate of red/pink clot which is wrapped and submitted in toto in one\X0D\\X0A\cassette.  **INITIALS,Microscopic Description\X0D\\X0A\Sections of the cell block show blood and fragments of necrotic material and a\X0D\\X0A\small fragment of tumor. The tumor cells display high nuclear to cytoplasmic\X0D\\X0A\ratio. There are modest amounts of cytoplasm associated with the large nuclei.\X0D\\X0A\No keratin pleural formation or evidence of glandular differentiation is\X0D\\X0A\apparent. **INITIALS,,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\DARON **PLACE\X0D\\X0A\Procedures/Addenda
REG1,LUNG,0,491814,1,,Clinical Diagnosis and History,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\FNA CYTOLOGY","Final Diagnosis\X0D\\X0A\LUNG FNA: \X0D\\X0A\     Malignant. See Comment. \X0D\\X0A\COMMENT: Neoplastic cells consistent with squamous cell carcinoma are present. \X0D\\X0A\Pathology and Cytology Labs Accession No.: **ID-NUM\X0D\\X0A\Testing Performed at Pathology and **INSTITUTION.\X0D\\X0A\290 Big Run Road\X0D\\X0A\**PLACE, Kentucky  **ZIP-CODE\X0D\\X0A\Phone **PHONE  \X0D\\X0A\Slides reviewed and diagnosis rendered by Dr. **NAME[ZZZ YYY].  /sk",,,,,,Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[XXX WWW]\X0D\\X0A\Procedures/Addenda
REG1,LUNG,0,491826,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is lung mass and hemoptysis.,"**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Lung, bronchial biopsy",Final Diagnosis\X0D\\X0A\ENDOBRONCHIAL BIOPSIES LEFT UPPER LOBE: \X0D\\X0A\     Squamous cell carcinoma. See Comment. \X0D\\X0A\COMMENT:  Diagnosis called to **NAME[XXX WWW] at Dr. **NAME[ZZZ YYY]'s office on\X0D\\X0A\**DATE[Jan 6 12] at 9:19 a.m. by **NAME[VVV UUU]. \X0D\\X0A\**INITIALS,,"Gross Description\X0D\\X0A\Received in formalin labeled endobronchial biopsy left upper lobe are numerous\X0D\\X0A\tan soft tissue fragments aggregating 1.0 x 0.8 x 0.1 cm which are filtered,\X0D\\X0A\wrapped and submitted in toto in one cassette. **INITIALS",Microscopic Description\X0D\\X0A\The bronchial biopsies show involvement with squamous carcinoma. The tumor shows\X0D\\X0A\infiltrating nests of malignant cells with hyperchromatic and pleomorphic nuclei\X0D\\X0A\and abundant eosinophilic cytoplasm. Some intercellular bridge formation is\X0D\\X0A\seen. **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[TTT, SSS M].\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,491898,2,,"Clinical Diagnosis and History\X0D\\X0A\The working history is persistent nodular infiltrate, positive hemoptysis, and\X0D\\X0A\positive cigarette smoking.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, bronchial biopsy\X0D\\X0A\2: Lung, bronchial biopsy","Final Diagnosis\X0D\\X0A\1.          LEFT LOWER LOBE TRANSBRONCHIAL BIOPSY:\X0D\\X0A\     Benign bronchus and peribronchial alveoli.\X0D\\X0A\Negative for granulomatous inflammation and neoplasm.\X0D\\X0A\2.          LEFT LOWER LOBE ENDOBRONCHIAL BIOPSY:\X0D\\X0A\     Superficial fragments of squamous cell carcinoma. JFJ/mbc\X0D\\X0A\COMMENT: This diagnosis was called and the report faxed to **NAME[ZZZ YYY], RN, at\X0D\\X0A\Dr. **NAME[XXX]'s office on **DATE[Aug 01 2012] by **NAME[WWW VVV UUU].",,"Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled transbronchial biopsy left lower lobe\X0D\\X0A\are a few tan/red soft tissue fragments aggregating 0.4 x 0.4 x 0.2cm which are\X0D\\X0A\filtered, wrapped, and submitted in toto in cassette 1. \X0D\\X0A\Specimen 2 received in formalin labeled endobronchial biopsy left lower lobe are\X0D\\X0A\a few tan/pink soft tissue fragments aggregating 0.6 x 0.6 x 0.2cm which are\X0D\\X0A\wrapped and submitted in toto in cassette 2.  **INITIALS","Microscopic Description\X0D\\X0A\Sections show bronchial wall and peribronchial alveoli. There is a minimal\X0D\\X0A\degree of interstitial fibrous stroma within the alveoli. There is no evidence\X0D\\X0A\of vasculitis, granulomatous inflammation, or neoplasm.\X0D\\X0A\Sections from specimen 2 show superficial malignant appearing squamous cells\X0D\\X0A\showing nuclear enlargement and hyperchromatism with evidence of keratinization.\X0D\\X0A\These are focally seen invading into the underlying stroma. Angiolymphatic\X0D\\X0A\permeation by neoplasm is not identified.     JFJ/mbc",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[TTT M. SSS], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,491931,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is right-sided chest pain, pleural effusion (recurrent).","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY\X0D\\X0A\**PLACE, **PLACE \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Pleura, biopsy\X0D\\X0A\2: Pleura, biopsy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Dec 14 11]. RIGHT LOWER LOBE BRONCH BRUSH: Negative for malignant\X0D\\X0A\cells. COMMENT: Reactive bronchial cells are present. Numerous benign bronchial\X0D\\X0A\epithelial cells are present. (PCL)\X0D\\X0A\***PATH-NUMBER[2], **DATE[Dec 14 11]. BRONCH WASH:  Negative for malignant cells.  COMMENT:\X0D\\X0A\Bronchial cells and pulmonary macrophages are present. (PCL)",Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS:\X0D\\X0A\RIGHT PLEURAL TISSUES (#s 1 AND 2):\X0D\\X0A\     Metastatic poorly differentiated carcinoma involving pleura.  No specific\X0D\\X0A\origin is suggested by an      immunophenotype performed at **INSTITUTION Arizona.\X0D\\X0A\ The overall immunomorphology does not      support a diagnosis of malignant\X0D\\X0A\mesothelioma (polyclonal CEA positive).\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT:  The diagnosis above was rendered by Dr. **NAME[ZZZ M. YYY] at **NAME[XXX] Clinic\X0D\\X0A\in Scottsdale Arizona.  Report will scanned into PIM and also Medical Records. \X0D\\X0A\Dr. **NAME[WWW] has discussed this diagnosis with Dr. **NAME[VVV] on **DATE[Jan 17 12]. **INITIALS\X0D\\X0A\PROVISIONAL\X0D\\X0A\ADDENDUM COMMENT:  The immunostains are inconclusive. The case will be sent for\X0D\\X0A\outside consultation prior to issuing a final report. I have discussed this with\X0D\\X0A\**NAME[TTT] in Dr. **NAME[UUU]'s office on **DATE[Jan 10 12]. **INITIALS \X0D\\X0A\RIGHT PLEURAL TISSUES (#s 1 AND 2):\X0D\\X0A\     Malignant neoplasm.  Further characterization pending immunostains.\X0D\\X0A\**INITIALS,,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled pleural tissue is a 2.0 x\X0D\\X0A\1.5 x 0.5cm aggregate of tan/pink soft tissue which is submitted entirely for\X0D\\X0A\frozen section, now resubmitted in cassette 1.\X0D\\X0A\Specimen 2 received in formalin labeled right pleural tissue are a few pieces of\X0D\\X0A\tan/pink soft tissue aggregating 2.0 x 1.8 x 0.3cm which are submitted in toto\X0D\\X0A\in cassette 2.  **INITIALS","Microscopic Description\X0D\\X0A\Sections show nests of malignant cells within a reactive fibrotic background\X0D\\X0A\with some chronic inflammation.  Rare groups are seen in the original frozen\X0D\\X0A\section block.  **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: All controls stain appropriately including\X0D\\X0A\external positive, internal negative and external negative controls as required.\X0D\\X0A\ The CK7 is strongly positive in the tumor cells while the CK20, TTF, and Napsin\X0D\\X0A\are all negative. The calretinin shows positive staining the background spindle\X0D\\X0A\cell component but also appears to show some weak cytoplasmic staining in the\X0D\\X0A\tumor cells. For this reason, the findings are somewhat inconclusive.  **INITIALS\X0D\\X0A\**INSTITUTION CONSULTATION: The tumor cells are\X0D\\X0A\strongly positive for polyclonal CEA and express cytokeratin 5/6.  EMA is\X0D\\X0A\diffusely positive within the tumor cytoplasm.  These immunohistochemical\X0D\\X0A\findings support a diagnosis of metastatic carcinoma to pleura.  TTF-1 and CD15\X0D\\X0A\are negative in the tumor cells, as are calretinin, WT-1, and D2-40. \X0D\\X0A\Pancytokeratin nicely outlines the infiltrative malignant tumor cells.  **INITIALS",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Jan 10 2012] by **NAME[SSS RRR]\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Jan 8 2012]\X0D\\X0A\Amended:  **DATE[Jan 17 2012] by Ruthanne Walker\X0D\\X0A\Reason: OUTSIDE CONSULTATION RESULTS\X0D\\X0A\     Previous Signout Date:  **DATE[Jan 10 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[WWW, CCC M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\External Consultation     Date Ordered:     **DATE[Jan 17 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 17 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Jan 17 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\**INSTITUTION EXTERNAL REPORT.  SEE SCANNED REFERENCE REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[WWW, CCC M].\X0D\\X0A\External Consultation     Date Ordered:     **DATE[Jan 17 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jan 17 2012]     By:  Ruthanne Walker\X0D\\X0A\     Date Reported:     **DATE[Jan 17 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\**INSTITUTION:  SEE SCANNED REFERENCE\X0D\\X0A\REPORT.  /rw\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[WWW, CCC M."
REG1,LUNG,0,491958,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is left neck mass with adenopathy, left arm neuropathy, and\X0D\\X0A\negative history for cancer.","**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]\X0D\\X0A\WEST, **PLACE R\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Fine Needle Aspiration Performed by Radiologist\X0D\\X0A\2: Fine Needle Core Biopsy Performed by Radiologist","Final Diagnosis\X0D\\X0A\FINAL DIAGNOSIS:\X0D\\X0A\1. LEFT NECK MASS, FINE NEEDLE ASPIRATE WITH CELL BLOCK AND NEEDLE CORE BIOPSIES\X0D\\X0A\(SPECIMENS 1 AND 2):\X0D\\X0A\     Poorly differentiated malignant neoplasm compatible with poorly\X0D\\X0A\differentiated squamous cell \X0D\\X0A\      carcinoma.\X0D\\X0A\     See COMMENT.\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT: The tumor cells show an immunohistochemical profile compatible with a\X0D\\X0A\poorly differentiated squamous cell carcinoma.  Dr. **NAME[XXX] discussed the final\X0D\\X0A\diagnosis on this case with Dr. **NAME[ZZZ] on **DATE[Oct 19 2012] at 2:05pm.  **INITIALS\X0D\\X0A\1.  LEFT NECK MASS, FINE NEEDLE ASPIRATE WITH CELL BLOCK: \X0D\\X0A\     Poorly differentiated malignant neoplasm. \X0D\\X0A\2.  LEFT NECK, MASS, NEEDLE CORE BIOPSIES: \X0D\\X0A\     Poorly differentiated malignant neoplasm. \X0D\\X0A\Immunohistochemical stains pending. See Comment. \X0D\\X0A\COMMENT: The biopsy material shows a poorly differentiated malignant neoplasm.\X0D\\X0A\Immunohistochemical stains will be performed and a finalized diagnosis will be\X0D\\X0A\issued upon review of those stains.  \X0D\\X0A\**INITIALS",,Gross Description\X0D\\X0A\Specimen 1 received in formalin labeled left neck mass fine needle aspirate with\X0D\\X0A\cell block is clotted bloody material measuring 1.2 x 0.5 x 0.1cm.  Smears are\X0D\\X0A\previously prepared.  Entirely submitted in one block.  \X0D\\X0A\Specimen 2 received in formalin labeled left neck medial core biopsies consists\X0D\\X0A\of multiple small fragments of tan to red soft tissue 0.1 to 0.3cm in size. \X0D\\X0A\Entirely submitted in one block.  **INITIALS\X0D\\X0A\NOTE:  A portion was placed in flow cytometry media and will be sent for\X0D\\X0A\evaluation.  **INITIALS,"Microscopic Description\X0D\\X0A\Examination of smears shows very loosely associated malignant cells with high\X0D\\X0A\nuclear to cytoplastic ratios with large atypical nuclei showing nucleoli.\X0D\\X0A\Sections through the cell block show a blood clot with intermixed similar very\X0D\\X0A\loosely cohesive malignant cell groups. These show pleomorphic nuclei, some\X0D\\X0A\being very large and pleomorphic with vesicular chromatin with prominent\X0D\\X0A\nucleoli. There are some suggestions of intercellular bridges. Also noted are\X0D\\X0A\cytoplasmic vacuoles. \X0D\\X0A\Sections from the needle core biopsies show cores of tissue composed of\X0D\\X0A\malignant cells with similar appearance. **INITIALS\X0D\\X0A\ADDITIONAL MICROSCOPIC DESCRIPTION: With appropriate control, five\X0D\\X0A\immunohistochemical stains are examined.  These show the tumor cells to stain\X0D\\X0A\strongly with antibody CK5/6.  The tumor cells do not stain with antibodies CK7,\X0D\\X0A\CK20, Napsin, or CD45 (leukocyte common antigen).  All controls stain\X0D\\X0A\appropriately including external positive, internal negative and external\X0D\\X0A\negative controls as required.  **INITIALS",,,"Amendments:\X0D\\X0A\Amended:  **DATE[Oct 19 2012] by Ruthanne Walker\X0D\\X0A\Reason: Immunohistochemical Results\X0D\\X0A\     Previous Signout Date:  **DATE[Oct 18 2012]\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY M. XXX], M.D.\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Flow Cytometry - Tissue - UK     Date Ordered:     **DATE[Oct 17 2012]     Status: \X0D\\X0A\Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 21 2012]     By:  **NAME[WWW VVV UUU]\X0D\\X0A\     Date Reported:     **DATE[Oct 21 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\TISSUE FROM LEFT NECK MASS:\X0D\\X0A\     Predominantly CD45 negative events in the debris region with no viable\X0D\\X0A\lymphocytes. SEE SCANNED REFERENCE REPORT.  \X0D\\X0A\mbc\X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[YYY M. XXX], M.D."
REG1,LUNG,0,491977,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is lung mass.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, regional resection\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Aug 16 12]: LEFT LUNG MASS, FNA: Adenocarcinoma compatible with lung\X0D\\X0A\primary. (JFJ) \X0D\\X0A\***PATH-NUMBER[2], **DATE[Aug 15 12]: CT GUIDED FNA OF LEFT LUNG MASS: No tumor seen.  (MHB) \X0D\\X0A\***PATH-NUMBER[3], **DATE[Aug 9 12]: LEFT UPPER LOBE BRONCHIAL BIOPSY: Benign bronchial tissue.\X0D\\X0A\No tumor or granulomas identified. (MHB) \X0D\\X0A\***PATH-NUMBER[4], **DATE[Aug 9 12]: BRONCH BRUSH: Negative for malignant cells.  See comment.\X0D\\X0A\(MSG)\X0D\\X0A\***PATH-NUMBER[5], **DATE[Aug 9 12]; BRONCH WASHING: Negative for malignant cells.  See comment. \X0D\\X0A\(MSG)","Final Diagnosis\X0D\\X0A\1.  LEFT UPPER LOBE, LOBECTOMY: \X0D\\X0A\     Large (5.5 cm) poorly differentiated adenocarcinoma with separate (1.7 cm)\X0D\\X0A\focus of well differentiated adenocarcinoma. Bronchial margin free of tumor. No\X0D\\X0A\metastasis to peribronchial lymph nodes. See Template. \X0D\\X0A\2.  L5 LYMPH NODE: \X0D\\X0A\     No metastasis identified (0/2). \X0D\\X0A\3.  L7 LYMPH NODE: \X0D\\X0A\     No metastasis identified (0/3). \X0D\\X0A\LUNG CARCINOMA \X0D\\X0A\SPECIMEN TYPE/PROCEDURE: Lobectomy with lymph node sampling. \X0D\\X0A\SPECIMEN INTEGRITY:  Intact. \X0D\\X0A\LATERALITY:  Unilateral. \X0D\\X0A\TUMOR FOCALITY:  Bifocal. \X0D\\X0A\TUMOR SITE:  Left upper lobe. \X0D\\X0A\TUMOR SIZE (greatest dimension):  5.5cm and 1.7 cm (per glass slide measurement)\X0D\\X0A\HISTOLOGIC TYPE:  Adenocarcinoma. \X0D\\X0A\HISTOLOGIC GRADE:  Poorly differentiated and well differentiated. \X0D\\X0A\VISCERAL PLEURA INVASION:  No. \X0D\\X0A\TUMOR EXTENSION:  Confined within the lobe. \X0D\\X0A\BRONCHIAL MARGIN:  Free. \X0D\\X0A\VASCULAR MARGIN:  Free. \X0D\\X0A\LYMPHVASCULAR INVASION:  None seen.\X0D\\X0A\PARENCHYMAL MARGIN:  N/A. \X0D\\X0A\CHEST WALL MARGIN:  N/A. \X0D\\X0A\OTHER TISSUE MARGIN:  N/A. \X0D\\X0A\REGIONAL LYMPH NODE STATUS:  Peribronchial, L5 and L7 nodes negative. \X0D\\X0A\EXTRANODAL TUMOR SPREAD:  N/A\X0D\\X0A\TREATMENT EFFECT:  No. \X0D\\X0A\OTHER METASTATIC SITES: Unknown.   \X0D\\X0A\OTHER NEOPLASM SITES: Unknown. \X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  N/A. \X0D\\X0A\OTHER STUDIES:  N/A. \X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT= 3 \X0D\\X0A\pN= 0     \X0D\\X0A\AJCC PATHOLOGIC STAGE:   IIB",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled left upper lobe is a 219.3\X0D\\X0A\gram, 21.0 x 10.0 x 5.5 cm intact lobectomy specimen. The bronchial resection\X0D\\X0A\margin is taken en face and submitted entirely for frozen section. Sectioning\X0D\\X0A\through the hilum reveals a 5.5 x 4.0 x 4.0 cm ill-defined tan/yellow firm mass,\X0D\\X0A\1 cm from the bronchial resection margin. The mass surrounds the bronchus and is\X0D\\X0A\2.8 cm from the pleura. The remaining lung parenchyma is red/tan and spongy and\X0D\\X0A\there is a cystic mass in the superior aspect of the lobe measuring 3.0 x 3.0 x\X0D\\X0A\2.8 cm. the cystic area is surrounded by slightly firm tan lung parenchyma. No\X0D\\X0A\other masses are appreciated. Representative sections are submitted for frozen\X0D\\X0A\section. Summary of sections: 1A-1B  frozen section residue; 1C  vascular\X0D\\X0A\margins taken en face; 1D-1G  hilar mass to include bronchus; 1H-1I  cystic mass\X0D\\X0A\to include surrounding lung parenchyma; 1J  intact hilar lymph nodes. \X0D\\X0A\Specimen 2 received in formalin labeled L5 lymph node is a 2.0 x 2.0 x 0.5 cm\X0D\\X0A\aggregate of black anthracotic soft tissue which is submitted in toto in\X0D\\X0A\cassette 2. \X0D\\X0A\Specimen 3 received in formalin labeled L7 lymph node are a few black\X0D\\X0A\anthracotic lymph nodes averaging 0.7 cm in greatest dimension which are\X0D\\X0A\submitted in toto in cassette 3.  **INITIALS","Microscopic Description\X0D\\X0A\The bronchial margin is free of tumor as is the pulmonary artery margin. A\X0D\\X0A\peribronchial lymph node shows no metastasis. The tumor shows sheets and nests\X0D\\X0A\of malignant cells with hyperchromatic and pleomorphic nuclei and frequent\X0D\\X0A\mitosis. Areas of necrosis and inflammation are also seen. Away from the main\X0D\\X0A\tumor, in some areas of fibrotic lung, there is a separate component of more\X0D\\X0A\obvious adenocarcinoma within the fibrous scar. Some emphysematous changes are\X0D\\X0A\also seen. The peribronchial lymph nodes are also free of tumor. \X0D\\X0A\The level 5 and level 7 lymph nodes show no metastasis.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,491996,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is lung nodule.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY\X0D\\X0A\PADMANABHAN, ARI \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, Wedge or Bleb\X0D\\X0A\2: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\4: Lymph node, biopsy\X0D\\X0A\5: Lymph node, biopsy","Final Diagnosis\X0D\\X0A\1. LEFT UPPER LOBE, WEDGE RESECTION:\X0D\\X0A\     Well differentiated adenocarcinoma.  Margin free.\X0D\\X0A\2. LEFT UPPER LOBE, LOBECTOMY:\X0D\\X0A\     Separate focus of poorly differentiated adenocarcinoma.  Bronchial margin\X0D\\X0A\free of tumor.\X0D\\X0A\     No metastasis to four peribronchial lymph nodes.\X0D\\X0A\     See COMMENT and TEMPLATE.\X0D\\X0A\3. LEVEL 4 LYMPH NODE:\X0D\\X0A\     No metastasis identified in one lymph node (0/1).\X0D\\X0A\4. LEVEL 5 LYMPH NODE:\X0D\\X0A\     No metastasis identified in one lymph node (0/1).\X0D\\X0A\5. LEVEL 7 LYMPH NODE:\X0D\\X0A\     No metastasis identified in one lymph node (0/1).\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT: At Dr. **NAME[ZZZ]'s request, the tumor will be submitted for ERCC1 and\X0D\\X0A\RRMI testing and these results will be reported as an addendum.  **INITIALS\X0D\\X0A\LUNG CARCINOMA TEMPLATE:\X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  wedge resection with completion lobectomy and node\X0D\\X0A\sampling\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\LATERALITY:  unilateral\X0D\\X0A\TUMOR FOCALITY:  bifocal\X0D\\X0A\TUMOR SITE:  left upper lobe\X0D\\X0A\TUMOR SIZE (greatest dimension):  1.3 and 2.0 cm\X0D\\X0A\HISTOLOGIC TYPE:  adenocarcinoma\X0D\\X0A\HISTOLOGIC GRADE:  well and poorly differentiated\X0D\\X0A\VISCERAL PLEURA INVASION:  no\X0D\\X0A\TUMOR EXTENSION:  confined to lobe\X0D\\X0A\BRONCHIAL MARGIN:  free by 1 cm\X0D\\X0A\VASCULAR MARGIN:  free\X0D\\X0A\LYMPHVASCULAR INVASION: none seen  \X0D\\X0A\PARENCHYMAL MARGIN:  free\X0D\\X0A\CHEST WALL MARGIN:  free\X0D\\X0A\OTHER TISSUE MARGIN:  free\X0D\\X0A\REGIONAL LYMPH NODE STATUS: level 4, 5, and 7 and parabronchial nodes negative \X0D\\X0A\EXTRANODAL TUMOR SPREAD:  no\X0D\\X0A\TREATMENT EFFECT:  n/a\X0D\\X0A\OTHER METASTATIC SITES:  unknown\X0D\\X0A\OTHER NEOPLASM SITES: unknown\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS: n/a \X0D\\X0A\OTHER STUDIES:  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=    3\X0D\\X0A\pN=   0\X0D\\X0A\AJCC PATHOLOGIC STAGE:  IIB \X0D\\X0A\MHB",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled left upper lobe is a 9.8\X0D\\X0A\gram, 4.5 x 2.8 x 2.5cm intact lung wedge biopsy.  The pleura is red/pink and\X0D\\X0A\glistening.  There is a moderate amount of anthracotic pigment.  Sectioning\X0D\\X0A\reveals a 1.3 x 1.0 x 1.0cm ill-defined tan firm mass, 1.0cm from the pleura and\X0D\\X0A\1.2cm from the stapled resection margin.  The remaining lung parenchyma is\X0D\\X0A\red/pink and spongy.  A representative section of the nodule submitted for\X0D\\X0A\frozen section, now resubmitted in cassette 1A.  The remaining nodule is\X0D\\X0A\submitted in cassette 1B.\X0D\\X0A\Specimen 2 received fresh for frozen section labeled left upper lobe margins and\X0D\\X0A\second tumor within is a 178.5gram, 24.0 x 11.0 x 6.0cm intact lobectomy\X0D\\X0A\specimen.  There is a 15.0cm in length staple line present consistent with the\X0D\\X0A\previous wedge biopsy site.  The staple line is 4.0cm from the bronchial\X0D\\X0A\resection margin.  Sectioning along the staple line reveals red/tan focally\X0D\\X0A\congested lung parenchyma.  No definitive invasive tumor is identified.  There\X0D\\X0A\is a second tan firm nodule identified measuring 2.0 x 1.5 x 1.5cm.  This nodule\X0D\\X0A\is 1.0cm from the bronchial resection margin and 0.8cm from the black-inked\X0D\\X0A\pleura.  The remaining lung parenchyma is pale tan and spongy with a moderate\X0D\\X0A\amount of black anthracotic pigment.  Representative sections of the bronchial\X0D\\X0A\resection margin and the second tumor are submitted for frozen section.  Summary\X0D\\X0A\of Sections: 2A-2B  frozen section residue, 2C  vascular margin taken en face,\X0D\\X0A\2D  staple line, 2E-2G  second mass to include pleura and adjacent bronchus, 2H \X0D\\X0A\lung parenchyma away from mass, 2I  intact hilar lymph nodes.  \X0D\\X0A\Specimen 3 received in formalin labeled level 4 lymph node is a 1.5cm in\X0D\\X0A\greatest dimension black anthracotic lymph node which is bisected and submitted\X0D\\X0A\entirely in cassette 3.\X0D\\X0A\Specimen 4 received in formalin labeled level 5 lymph node is a 0.4cm in\X0D\\X0A\greatest dimension black anthracotic lymph node which is submitted in toto in\X0D\\X0A\cassette 4.\X0D\\X0A\Specimen 5 received in formalin labeled level 7 lymph node is a 1.0cm in\X0D\\X0A\greatest dimension black anthracotic lymph node with attached fat which is\X0D\\X0A\submitted in toto in cassette 5.  **INITIALS","Microscopic Description\X0D\\X0A\The wedge biopsy shows involvement with adenocarcinoma.  There is a central area\X0D\\X0A\of scar with well differentiated tumor extending out from the scar with a\X0D\\X0A\bronchioalveolar pattern.  \X0D\\X0A\The bronchial and pulmonary artery margins are free of tumor.  The second tumor\X0D\\X0A\also shows adenocarcinoma, but this tumor shows a more poorly differentiated\X0D\\X0A\pattern with some clear cell characteristics.  No pleural involvement or\X0D\\X0A\vascular space invasion is seen.  The four parabronchial lymph nodes show no\X0D\\X0A\metastasis.  \X0D\\X0A\Specimen 3 shows a single lymph node without metastasis.  Specimen 4 shows a\X0D\\X0A\single lymph node without metastasis.  Specimen 5 shows a single lymph node\X0D\\X0A\without metastasis.  **INITIALS",,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY, XXX M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\ARUP Laboratory     Date Ordered:     **DATE[Jul 5 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jul 15 2012]     By:  **NAME[WWW VVV]\X0D\\X0A\     Date Reported:     **DATE[Jul 16 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\RESPONSE-DX/LUNG: \X0D\\X0A\SEE SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[YYY, XXX M."
REG1,LUNG,0,492001,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is lung cancer.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\1: Lung, resection or Lobe or Segment or Entire Lung\X0D\\X0A\2: Lymph node, biopsy\X0D\\X0A\3: Lymph node, biopsy\X0D\\X0A\Previous Pertinent History\X0D\\X0A\***PATH-NUMBER[1], **DATE[Apr 7 12]: RIGHT LUNG MASS, FNA WITH CELL BLOCK: Non-small cell\X0D\\X0A\neoplasm suggestive of carcinoid tumor. (JFJ)","Final Diagnosis\X0D\\X0A\1.  RIGHT MIDDLE LOBE, LOBECTOMY: \X0D\\X0A\     Carcinoid tumor (low grade neuroendocrine carcinoma). Margin free. No lymph\X0D\\X0A\node metastasis identified. See Template. \X0D\\X0A\2.  LEVEL 7 LYMPH NODE: \X0D\\X0A\     No metastasis identified (0/1). \X0D\\X0A\3.  LEVEL 4 LYMPH NODE: \X0D\\X0A\     No metastasis identified (0/1). \X0D\\X0A\LUNG CARCINOMA \X0D\\X0A\SPECIMEN TYPE/PROCEDURE:  lobectomy with node sampling\X0D\\X0A\SPECIMEN INTEGRITY:  intact\X0D\\X0A\LATERALITY:  unilateral\X0D\\X0A\TUMOR FOCALITY:  unifocal\X0D\\X0A\TUMOR SITE:  right middle lobe\X0D\\X0A\TUMOR SIZE (greatest dimension):  2.3 x 1.8 x 1.8 cm\X0D\\X0A\HISTOLOGIC TYPE:  neuroendocrine\X0D\\X0A\HISTOLOGIC GRADE:  low grade\X0D\\X0A\VISCERAL PLEURA INVASION:  no\X0D\\X0A\TUMOR EXTENSION:  confined to lobe\X0D\\X0A\BRONCHIAL MARGIN:  free\X0D\\X0A\VASCULAR MARGIN:  free\X0D\\X0A\LYMPHVASCULAR INVASION:  none seen\X0D\\X0A\PARENCHYMAL MARGIN:  n/a\X0D\\X0A\CHEST WALL MARGIN:  n/a\X0D\\X0A\OTHER TISSUE MARGIN:  n/a\X0D\\X0A\REGIONAL LYMPH NODE STATUS:  parabronchial, level 7 and 4 nodes negative\X0D\\X0A\EXTRANODAL TUMOR SPREAD:  n/a\X0D\\X0A\TREATMENT EFFECT:  n/a\X0D\\X0A\OTHER METASTATIC SITES:  unknown\X0D\\X0A\OTHER NEOPLASM SITES: unknown\X0D\\X0A\ADDITIONAL PATHOLOGIC FINDINGS:  n/a\X0D\\X0A\OTHER STUDIES:  n/a\X0D\\X0A\AJCC PATHOLOGIC STAGE:  (COMPLETED BY PATHOLOGIST, BASED ONLY ON TISSUE\X0D\\X0A\FINDINGS, MORE EXTENSIVE DISEASE MAY NOT BE KNOWN TO THE PATHOLOGIST)\X0D\\X0A\pT=  1b\X0D\\X0A\pN=  0  \X0D\\X0A\AJCC PATHOLOGIC STAGE:  IA  \X0D\\X0A\**INITIALS",,"Gross Description\X0D\\X0A\Specimen 1 received fresh for frozen section labeled right middle lobe is a 38\X0D\\X0A\gram, 11.0 x 7.0 x 3.5 cm intact lobectomy specimen. The pleura is tan/pink and\X0D\\X0A\wrinkled with a moderate amount of black anthracotic pigment. The pleura is\X0D\\X0A\inked black and sectioning reveals a 2.3 x 1.8 x 1.8 cm well-circumscribed tan\X0D\\X0A\glistening focally hemorrhagic nodule 1 cm from the pleura and 1.2 cm from the\X0D\\X0A\bronchial resection margin. No involvement of the bronchus is identified. The\X0D\\X0A\remaining lung parenchyma is pale pink and spongy. The bronchial and vascular\X0D\\X0A\resection margins are taken en face and submitted entirely for frozen section.\X0D\\X0A\There is a single small black anthracotic lymph node identified around the\X0D\\X0A\hilum. Representative sections are submitted. Summary of sections: 1A-1B  frozen\X0D\\X0A\section residue; 1C-1E  tumor mass to include pleura; 1F  small hilar lymph\X0D\\X0A\node.  \X0D\\X0A\Specimen 2 received in formalin labeled level 7 is a 0.7 cm in greatest\X0D\\X0A\dimension black anthracotic lymph node which is submitted in toto in cassette 2.\X0D\\X0A\Specimen 3 received in formalin labeled level 4 is a 1.2 cm in greatest\X0D\\X0A\dimension black anthracotic lymph node which is bisected and submitted entirely\X0D\\X0A\in cassette 3.  **INITIALS",Microscopic Description\X0D\\X0A\The tumor shows a somewhat circumscribed nodule with cells with intermediate\X0D\\X0A\sized nuclei and some nucleoli. Mitotic activity is not prominent.  The tumor is\X0D\\X0A\arranged in an organoid like pattern. The bronchial margin is free of tumor. A\X0D\\X0A\single small lymphoid is seen without metastasis. \X0D\\X0A\Specimen 2 shows a single lymph node without metastasis. \X0D\\X0A\Specimen 3 shows a single lymph node without metastasis. An occasional\X0D\\X0A\hyalinized granuloma is seen in the nodes.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ, YYY M].\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,492027,1,,Clinical Diagnosis and History\X0D\\X0A\The working history is not provided.,"**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Lung, bronchial biopsy","Final Diagnosis\X0D\\X0A\RIGHT UPPER LOBE, ENDOBRONCHIAL BIOPSIES:\X0D\\X0A\     Small cell undifferentiated carcinoma.\X0D\\X0A\**INITIALS\X0D\\X0A\COMMENT:  This diagnosis was called to **NAME[XXX WWW] in Dr. **NAME[ZZZ YYY]' office\X0D\\X0A\on **DATE[Nov 23 2012] by Ruthanne Walker, Pathology Secretary.  **INITIALS",,Gross Description\X0D\\X0A\Received in formalin labeled right upper lobe is three fragments of tan to red\X0D\\X0A\soft tissue 0.1 to 0.3cm in greatest dimension.  Entirely submitted in one\X0D\\X0A\block.  **INITIALS,Microscopic Description\X0D\\X0A\Sections show bronchial mucosa with an underlying neoplasm showing high nuclear\X0D\\X0A\to cytoplasmic ratios with enlarged nuclei showing coarsely stippled chromatin\X0D\\X0A\with prominent nuclear molding and streaming.  There is evidence of single cell\X0D\\X0A\necrosis.  **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[VVV M. UUU], M.D.\X0D\\X0A\Procedures/Addenda"
REG1,LUNG,0,492043,1,,"Clinical Diagnosis and History\X0D\\X0A\The working history is right lung mass, history of COPD, smoker and dyspnea.","**INSTITUTION\X0D\\X0A\**STREET-ADDRESS **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: BADIN, FIRAS\X0D\\X0A\ONCOLOGY PATHWAY \X0D\\X0A\Specimen(s) Received:\X0D\\X0A\Fine Needle Aspiration Performed by Radiologist\X0D\\X0A\Previous Pertinent History\X0D\\X0A\C11064850, **DATE[Dec 27 11]: BRONCH WASH LINGULA AREA: Suspicious. Atypical cells\X0D\\X0A\suspicious for a non-small cell neoplasm are seen. BRONCH BRUSH: Negative for\X0D\\X0A\malignant cells. Numerous benign bronchial epithelial cells are present. RIGHT\X0D\\X0A\LOWER LOBE BRONCH WASH: Suspicious. Atypical cells suspicious for a non-small\X0D\\X0A\cell neoplasm are seen. RIGHT LOWER LOBE BRONCH BRUSH: Suspicious. Rare group of\X0D\\X0A\atypical cells suspicious for a non-small cell neoplasm are seen. (APM)",Final Diagnosis\X0D\\X0A\CT GUIDED FNA OF RIGHT LUNG MASS: \X0D\\X0A\     Adenocarcinoma.  See Comment. \X0D\\X0A\COMMENT:  This diagnosis was called to Sherry **PLACE in Dr. **NAME[ZZZ]'s office on\X0D\\X0A\**DATE[May 6 12] at 11:03 a.m. by **NAME[YYY XXX]. \X0D\\X0A\**INITIALS,,"Gross Description\X0D\\X0A\Received in formalin labeled right lung mass FNA is a 0.1 x 0.1 x 0.1 cm\X0D\\X0A\aggregate of red/pink clot which is filtered, wrapped and submitted entirely in\X0D\\X0A\one cassette.  **INITIALS",Microscopic Description\X0D\\X0A\The cell block and smears are similar showing involvement with adenocarcinoma.\X0D\\X0A\The tumor shows variably sized small glandular groups with moderate nuclear\X0D\\X0A\pleomorphism. **INITIALS,,,"Amendments:\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[WWW, VVV M].\X0D\\X0A\Procedures/Addenda\X0D\\X0A\Genzyme Testing     Date Ordered:     **DATE[May 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 23 2012]     By:  **NAME[CCC XXX]\X0D\\X0A\     Date Reported:     **DATE[May 23 2012]         \X0D\\X0A\Interpretation\X0D\\X0A\EGFR MUTATION ANALYSIS: \X0D\\X0A\     No mutation detected. \X0D\\X0A\INTERPRETATION: \X0D\\X0A\     No mutations were identified in the sample provided for analysis. Fewer\X0D\\X0A\than 5% of non-small cell lung carcinoma patients without identifiable mutations\X0D\\X0A\are reported to be responsive to EGFR tyrosine kinase inhibitor therapies. SEE\X0D\\X0A\SCANNED REFERENCE REPORT.  /sk \X0D\\X0A\Results-Comments\X0D\\X0A\{Not Entered}\X0D\\X0A\**NAME[WWW, VVV M."
REG1,LUNG,0,492626,1,,,"Patient Age: **AGE[in 70s].\X0A\ CODES: **INITIALS  88305 COMMENT: Diagnosis called and report faxed to Dr. **NAME[ZZZ]'s office on Monday, **DATE[Dec 26 11]. ** Original Signature on File ** **NAME[M. YYY XXX], MD **ID-NUM  **NAME[BBB,AAA M] **DATE[Dec 23 2011]  *** FINAL REPORT ***","PATHOLOGICAL DIAGNOSIS: \X0D\\X0A\ LEFT LUNG, UPPER LOBE MASS, BIOPSIES: \X0D\\X0A\ Moderate differentiated squamous cell carcinoma",,"GROSS EXAMINATION: \X0D\\X0A\ The working diagnosis is left upper lobe mass. \X0D\\X0A\ Specimen consists of: \X0D\\X0A\ Pieces:  Multiple \X0D\\X0A\ Aggregate dimensions:  0.4 x 0.4 x 0.1 cm. \X0D\\X0A\ Cassettes:  One, entirely submitted. **INITIALS","MICROSCOPIC DESCRIPTION: \X0D\\X0A\ Sections show no mucosa, alveolated lung, and fragments of tumor.  The \X0D\\X0A\ tumor is composed of irregular lobulated sheets of atypical squamous \X0D\\X0A\ cells that is focally lined by benign bronchial epithelium, while in \X0D\\X0A\ other areas infiltrates the underlying stroma.  The alveolated lung \X0D\\X0A\ shows thickened fibrotic alveolar septae within an associated mixed \X0D\\X0A\ inflammatory cell infiltrate.  The alveoli also are lined by reactive \X0D\\X0A\ pneumocytes.  The bronchial mucosa shows increased chronic \X0D\\X0A\ inflammatory cell infiltrate. No angiolymphatic or perineural invasion \X0D\\X0A\ is seen. \X0D\\X0A\ DICTATION  DIAGNOSIS BY:",TISSUE SUBMITTED: \X0D\\X0A\ Left upper lobe biopsy,,
REG1,LUNG,0,493144,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RIGHT UPPER LOBE MASS\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\        LUNG, RIGHT UPPER LOBE, WEDGE RESECTION FOLLOWED BY LOBECTOMY.\X0D\\X0A\    TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\        ADENOCARCINOMA, MODERATELY DIFFERENTIATED.\X0D\\X0A\    TUMOR SITE:\X0D\\X0A\        RIGHT UPPER LOBE NOS.\X0D\\X0A\    TUMOR SIZE:\X0D\\X0A\        GREATEST TUMOR DIMENSION IS 2.3 CM.\X0D\\X0A\    TUMOR FOCALITY:\X0D\\X0A\        UNIFOCAL.\X0D\\X0A\    VISCERAL PLEURAL INVASION:\X0D\\X0A\        IDENTIFIED.\X0D\\X0A\    DIRECT EXTENSION OF TUMOR:\X0D\\X0A\        NON APPLICABLE.\X0D\\X0A\    MARGINS:\X0D\\X0A\        BRONCHIAL RESECTION MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\        VASCULAR RESECTION MARGINS ARE NEGATIVE FOR TUMOR.\X0D\\X0A\        DISTANCE FROM TUMOR TO CLOSEST (BRONCHIAL) MARGIN IS 2.5 CM.\X0D\\X0A\    VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\        NOT IDENTIFIED.\X0D\\X0A\    LYMPH NODES:\X0D\\X0A\        EIGHT PERIBRONCHIAL LYMPH NODES RECOVERED, ALL NEGATIVE FOR\X0D\\X0A\METASTATIC TUMOR.\X0D\\X0A\        SEE SPECIMENS C AND D FOR ADDITIONAL LYMPH NODES.\X0D\\X0A\    TREATMENT EFFECT:\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 14 12]                 **PLACE Clinical Associates                    PAGE:   **ID-NUM\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA]                     DOB: **DATE[May 11 1947]   Sex: F\X0D\\X0A\Add:1180 **PLACE,KY **ZIP-CODE  **PHONE                                                                 \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS IN    Location:  D.5WS      D.5125-1    \X0D\\X0A\Reg:   **DATE[May 22 12]     Disch: **DATE[May 27 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[ZZZ:YYY,XXX M] MD         Submit:**NAME[YYY,XXX M] MD              MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS Dr              **PLACE                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[YYY,XXX M] MD\X0D\\X0A\   **STREET-ADDRESS Dr\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 14 12]                 **PLACE Clinical Associates                    PAGE:   4\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA]                     DOB: **DATE[May 11 1947]   Sex: F\X0D\\X0A\Add:1180 **PLACE,KY **ZIP-CODE  **PHONE                                                                 \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS IN    Location:  D.5WS      D.5125-1    \X0D\\X0A\Reg:   **DATE[May 22 12]     Disch: **DATE[May 27 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[ZZZ:YYY,XXX M] MD         Submit:**NAME[YYY,XXX M] MD              MDPhone:  **PHONE     \X0D\\X0A\**STREET-ADDRESS Dr              **PLACE                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:  (Continued)\X0D\\X0A\\X0D\\X0A\   Movania,Jawed M\X0D\\X0A\   700 W **PLACE Trail Blvd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS/2, 88307GS, 88309GS, 88313GS, 88331GS/2\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[WWW M VVV] MD **DATE[May 23 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jun 14 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FROZEN SECTION DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.  POSITIVE FOR ADENOCARCINOMA.  REPORTED TO DR. **NAME[YYY] ON **DATE[May 22 12] AT 9:48 A.M.  LWF\X0D\\X0A\B.  BRONCHIAL MARGIN IS NEGATIVE FOR TUMOR.  REPORTED TO DR. **NAME[YYY] ON **DATE[May 22 12] AT 10:32 A.M.\X0D\\X0A\LWF\X0D\\X0A\\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A\T\B.    LUNG SYNOPTIC REPORT AJCC/UICC TNM, 7th edition\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\LUNG, RIGHT UPPER LOBE, WEDGE RESECTION FOLLOWED BY LOBECTOMY.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\ADENOCARCINOMA, MODERATELY DIFFERENTIATED.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\RIGHT UPPER LOBE NOS.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\GREATEST TUMOR DIMENSION IS 2.3 CM.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\VISCERAL PLEURAL INVASION:\X0D\\X0A\IDENTIFIED.\X0D\\X0A\DIRECT EXTENSION OF TUMOR:\X0D\\X0A\NON APPLICABLE.\X0D\\X0A\MARGINS:\X0D\\X0A\BRONCHIAL RESECTION MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\VASCULAR RESECTION MARGINS ARE NEGATIVE FOR TUMOR.\X0D\\X0A\DISTANCE FROM TUMOR TO CLOSEST (BRONCHIAL) MARGIN IS 2.5 CM.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\EIGHT PERIBRONCHIAL LYMPH NODES RECOVERED, ALL NEGATIVE FOR\X0D\\X0A\METASTATIC TUMOR.\X0D\\X0A\SEE SPECIMENS C AND D FOR ADDITIONAL LYMPH NODES.\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\NO PRIOR TREATMENT.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\RECEIVED AS TWO SEPARATE SPECIMENS.\X0D\\X0A\ADDITIONAL FINDINGS:\X0D\\X0A\THE NON NEOPLASTIC LUNG DISPLAYS FOCALLY DILATED AIR SPACES AND\X0D\\X0A\FOCAL PLEURAL FIBROSIS.\X0D\\X0A\PATHOLOGIC STAGE:\X0D\\X0A\PLEASE SEE COMMENT.\X0D\\X0A\\X0D\\X0A\C.    N2 LYMPH NODE, EXCISION:\X0D\\X0A\ONE LYMPH NODE, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\\X0D\\X0A\D.    N1 LYMPH NODES, EXCISION:\X0D\\X0A\FRAGMENTS OF LYMPH NODE TISSUE, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Pathologic stage:  pT2a pN0 pMn/a.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  Received fresh for frozen section designated \""right upper lobe\"" is a 72 gram wedge of\X0D\\X0A\red-tan lung parenchyma measuring 13.0 x 5.5 x 4.3 cm.  A staple line closes the specimen\X0D\\X0A\along one edge.  Pleural puckering is noted, 2.2 cm from the stapled margin.  The pleural\X0D\\X0A\surface is marked with black ink and the specimen is serially sectioned.  Sectioning reveals\X0D\\X0A\a well circumscribed gray-tan tumor mass measuring 2.3 x 1.8 x 2.0 cm.  The tumor abuts the\X0D\\X0A\inked pleural surface and is located 1.9 cm from the stapled margin.  A touch prep is\X0D\\X0A\prepared and a representative section of the tumor is submitted on a single block for frozen\X0D\\X0A\section.  Following frozen section, the specimen is submitted in cassette A-FSC.\X0D\\X0A\\X0D\\X0A\Additional representative sections from the specimen are submitted as follows:\X0D\\X0A\A1.    representative lung parenchyma immediately adjacent to tumor\X0D\\X0A\A2-A5.    tumor and overlying inked pleural surface\X0D\\X0A\A6.    additional representative section of tumor and unremarkable lung parenchyma\X0D\\X0A\A7.    representative section of non involved lung parenchyma\X0D\\X0A\\X0D\\X0A\Note:  A representative portion of the tumor is sent to Precision Therapeutics per Dr.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\**NAME[XXX YYY].\X0D\\X0A\\X0D\\X0A\B.  Received fresh for frozen section designated \""right upper lobe\"" is a 144 gram lobectomy\X0D\\X0A\specimen measuring 16.0 x 9.0 x up to 4.0 cm.  The stapled bronchial margin is identified\X0D\\X0A\and is located 2.5 cm from the previous staple line of the concurrent wedge resection.  The\X0D\\X0A\staple line is removed and the margin is shaved and submitted on a single block for frozen\X0D\\X0A\section.  Following frozen section, the specimen is submitted in cassette B-FSC.\X0D\\X0A\\X0D\\X0A\The pleural surface is smooth and glistening with focal spongy pale pink-tan lung parenchyma\X0D\\X0A\noted.  Opening the bronchial structure fails to reveal the presence of distinct tumor.  All\X0D\\X0A\vascular margins are shaved and submitted.  The vascular structures display unremarkable\X0D\\X0A\red-tan, smooth, shiny endothelium without tumor involvement.  Further sectioning fails to\X0D\\X0A\reveal additional nodules or masses within the lung parenchyma.\X0D\\X0A\\X0D\\X0A\Multiple peribronchial lymph node candidates are identified measuring up to 0.8 cm in\X0D\\X0A\greatest dimension.\X0D\\X0A\\X0D\\X0A\Multiple representative sections from the specimen are submitted as follows:\X0D\\X0A\B1.    shaved vascular margins\X0D\\X0A\B2-B4.    representative sections of lung parenchyma\X0D\\X0A\B5.    four intact lymph node candidates\X0D\\X0A\B6.    four intact lymph node candidates\X0D\\X0A\B7.    two intact lymph node candidates\X0D\\X0A\\X0D\\X0A\C.  Received fresh designated \""N2 lymph node\"" is a single brown-tan lymph node candidate\X0D\\X0A\measuring 2.3 x 0.9 x 0.4 cm.  The specimen is sectioned and entirely submitted in cassette\X0D\\X0A\C.\X0D\\X0A\\X0D\\X0A\D.  Received fresh designated \""N1 lymph nodes\"" are multiple irregular fragments of brown-tan\X0D\\X0A\to black soft tissue ranging in size from 0.5 to 1.5 cm.  The specimens are entirely\X0D\\X0A\submitted in cassettes D1 and D2.  **INITIALS\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  8 H\T\E, 2 elastic stains - elastic stains are utilized to assist in evaluation of\X0D\\X0A\visceral pleura for tumor invasion, control reacts appropriately.\X0D\\X0A\B.  7 H\T\E.\X0D\\X0A\C.  1 H\T\E.\X0D\\X0A\D.  2 H\T\E.\X0D\\X0A\","SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A.  RIGHT UPPER LOBE - FROZEN\X0D\\X0A\B.  RIGHT UPPER LOBE - FROZEN\X0D\\X0A\C.  N2 LYMPH NODE, FRESH\X0D\\X0A\D.  N1 LYMPH NODES, FRESH\X0D\\X0A\",,ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Jun 13 12]-1505\X0D\\X0A\\X0D\\X0A\Please see scanned report in EMR (WT266075) from Precision Therapeutics for chemotherapy\X0D\\X0A\sensitivity assay results.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\
REG1,LUNG,0,493146,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\LEFT LOWER LOBE LUNG MASS\X0D\\X0A\,"SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\        LUNG, LEFT LOWER LOBECTOMY.\X0D\\X0A\    TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\        ADENOCARCINOMA, MODERATE TO POORLY DIFFERENTIATED.\X0D\\X0A\    TUMOR SIZE:\X0D\\X0A\        GREATEST TUMOR DIMENSION IS 2.0 CM.\X0D\\X0A\    TUMOR SITE:\X0D\\X0A\        LEFT LOWER LOBE, NOS.\X0D\\X0A\    TUMOR FOCALITY:\X0D\\X0A\        UNIFOCAL.\X0D\\X0A\    VISCERAL PLEURAL INVASION:\X0D\\X0A\        NOT IDENTIFIED.\X0D\\X0A\    DIRECT TUMOR EXTENSION:\X0D\\X0A\        NOT APPLICABLE.\X0D\\X0A\    MARGINS:\X0D\\X0A\        BRONCHIAL RESECTION MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\        VASCULAR RESECTION MARGINS ARE NEGATIVE FOR TUMOR.\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Sep 16 12]                 **PLACE Clinical Associates                    PAGE:   **ID-NUM\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA M]                DOB: **DATE[Jun 09 1937]   Sex: F\X0D\\X0A\Add:2835 DESHLER DR,**NAME[ZZZ],KY **ID-NUM  **PHONE                                                             \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS IN    Location:  D.5WS      D.5127-1    \X0D\\X0A\Reg:   **DATE[Aug 20 12]     Disch: **DATE[Aug 28 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[YYY:XXX,WWW] MD         Submit:**NAME[XXX,WWW] MD              MDPhone:  **PHONE     \X0D\\X0A\Address: 200 **NAME[M. VVV]                 **NAME[ZZZ]                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\COPIES TO:\X0D\\X0A\   Brown,Julia A\X0D\\X0A\   4950 **PLACE Healthcare Blvd\X0D\\X0A\   **NAME[ZZZ], KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[UUU,TTT M] MD\X0D\\X0A\   **STREET-ADDRESS Dr\X0D\\X0A\   **NAME[ZZZ], KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS, 88307GS, 88309GS, 88331GS\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Sep 16 12]                 **PLACE Clinical Associates                    PAGE:   4\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA M]                DOB: **DATE[Jun 09 1937]   Sex: F\X0D\\X0A\Add:2835 DESHLER DR,**NAME[ZZZ],KY **ID-NUM  **PHONE                                                             \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  DIS IN    Location:  D.5WS      D.5127-1    \X0D\\X0A\Reg:   **DATE[Aug 20 12]     Disch: **DATE[Aug 28 12]  SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[YYY:XXX,WWW] MD         Submit:**NAME[XXX,WWW] MD              MDPhone:  **PHONE     \X0D\\X0A\Address: 200 **NAME[M. VVV]                 **NAME[ZZZ]                     KY **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[SSS M RRR] MD **DATE[Aug 21 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Sep 16 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FROZEN SECTION DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A1-FSC:  BRONCHIAL MARGIN IS NEGATIVE FOR TUMOR.  REPORTED TO DR. **NAME[UUU] ON **DATE[Aug 20 12] AT 9:46\X0D\\X0A\A.M.  LWF\X0D\\X0A\A2-FSC:  POSITIVE FOR NON SMALL CELL CARCINOMA FAVOR ADENOCARCINOMA.  REPORTED TO DR. **NAME[UUU]\X0D\\X0A\ON **DATE[Aug 20 12] AT 9:56 A.M.  LWF\X0D\\X0A\\X0D\\X0A\FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\A.    LUNG SYNOPTIC REPORT AJCC/UICC TNM, 7TH EDITION\X0D\\X0A\\X0D\\X0A\SPECIMEN TYPE/PROCEDURE/LATERALITY:\X0D\\X0A\LUNG, LEFT LOWER LOBECTOMY.\X0D\\X0A\TUMOR HISTOLOGIC TYPE/GRADE:\X0D\\X0A\ADENOCARCINOMA, MODERATE TO POORLY DIFFERENTIATED.\X0D\\X0A\TUMOR SIZE:\X0D\\X0A\GREATEST TUMOR DIMENSION IS 2.0 CM.\X0D\\X0A\TUMOR SITE:\X0D\\X0A\LEFT LOWER LOBE, NOS.\X0D\\X0A\TUMOR FOCALITY:\X0D\\X0A\UNIFOCAL.\X0D\\X0A\VISCERAL PLEURAL INVASION:\X0D\\X0A\NOT IDENTIFIED.\X0D\\X0A\DIRECT TUMOR EXTENSION:\X0D\\X0A\NOT APPLICABLE.\X0D\\X0A\MARGINS:\X0D\\X0A\BRONCHIAL RESECTION MARGIN IS NEGATIVE FOR TUMOR.\X0D\\X0A\VASCULAR RESECTION MARGINS ARE NEGATIVE FOR TUMOR.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\DISTANCE FROM TUMOR TO CLOSEST (BRONCHIAL) MARGIN IS 2.5 CM.\X0D\\X0A\VASCULAR/LYMPHATIC INVASION:\X0D\\X0A\IDENTIFIED.\X0D\\X0A\LYMPH NODES:\X0D\\X0A\FIVE PERIBRONCHIAL LYMPH NODES, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\SEE SPECIMENS B AND C FOR ADDITIONAL LYMPH NODES.\X0D\\X0A\TREATMENT EFFECT:\X0D\\X0A\NO PRIOR TREATMENT.\X0D\\X0A\SPECIMEN INTEGRITY:\X0D\\X0A\INTACT.\X0D\\X0A\ADDITIONAL FINDINGS:\X0D\\X0A\FOCAL DILATED AIR SPACES AND FOCAL FIBROSIS / SCAR.\X0D\\X0A\PATHOLOGIC STAGE:\X0D\\X0A\PLEASE SEE COMMENT.\X0D\\X0A\\X0D\\X0A\COMMENT:  The pathologic stage is based upon the AJCC cancer staging manual seventh\X0D\\X0A\edition guidelines.\X0D\\X0A\\X0D\\X0A\B.    N2 LEVEL LYMPH NODE, EXCISION:\X0D\\X0A\FRAGMENTS OF LYMPH NODE TISSUE, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\\X0D\\X0A\C.    N1 LEVEL LYMPH NODES, EXCISION:\X0D\\X0A\FRAGMENTS OF LYMPH NODE TISSUE, NEGATIVE FOR METASTATIC TUMOR.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Pathologic stage:  pT1a pN0 pMn/a.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  Received fresh for frozen section designated \""left lower lobe, cancer bronchial margin\""\X0D\\X0A\is a 250 gram portion of lung tissue, it is intact and measures 19.5 x 10.2 x 3.0 cm.  It\X0D\\X0A\has a pink-dark red and black streaked mottled surface.  The bronchial margin is closed by a\X0D\\X0A\line of staples.  The staples are removed and measures 2.0 cm in diameter.  A cross section\X0D\\X0A\of the bronchial margin is submitted on one block.  Following frozen section, the section is\X0D\\X0A\submitted in cassette A1-FSC.  The pleura overlying the nodule is slightly puckered and the\X0D\\X0A\area is inked green.  It is incised and reveals a 2.0 x 1.5 x 1.8 cm nodule.  The cut\X0D\\X0A\surface is firm and has a mottled tan-gray appearance.  It is oval in shape.  It is located\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\2.5 cm from the bronchial margin and 2.9 cm from the vascular margin.  It is grossly 0.5 cm\X0D\\X0A\from the pleural surface.  A representative section of the nodule is submitted on a single\X0D\\X0A\block for frozen section.  Following frozen section, the section is submitted in cassette\X0D\\X0A\A2-FSC.  The remaining lung is serially sectioned and the cut surfaces reveal unremarkable\X0D\\X0A\pink-tan tissue.  No additional nodules are identified.  Five possible hilar lymph nodes are\X0D\\X0A\identified.  They range in size from 0.2 to 0.7 cm.  They are all anthracotic and oval in\X0D\\X0A\appearance.\X0D\\X0A\\X0D\\X0A\Cassette summary:\X0D\\X0A\A1-FSC.    bronchial margin\X0D\\X0A\A2-FSC.    representative section of nodule\X0D\\X0A\A1.        additional bronchus\X0D\\X0A\A2.        vascular margin\X0D\\X0A\A3.        excision site\X0D\\X0A\A4\T\A5.        one complete cross section with pleural surface margin and excision site\X0D\\X0A\margin\X0D\\X0A\A6-A8.        complete cross sections with pleural surface\X0D\\X0A\A9.        random lung\X0D\\X0A\A10.        lymph nodes\X0D\\X0A\\X0D\\X0A\Note:  A portion of lung tumor was for Precision Therapeutics.\X0D\\X0A\\X0D\\X0A\B.  Received in formalin designated \""N2 level lymph node\"" are four oval, lymph node\X0D\\X0A\fragments, three are anthracotic and range in size from 0.2 to 0.7 cm.  One is pink-tan and\X0D\\X0A\measures 0.5 x 0.4 x 0.3 cm.  The specimens are entirely submitted in cassette B.\X0D\\X0A\\X0D\\X0A\C.  Received in formalin designated \""N1 level lymph nodes\"" are ten oval, pink-tan to\X0D\\X0A\anthracotic lymph node fragments  ranging in size from 0.5 up to 0.9 cm in greatest\X0D\\X0A\dimensions.  The specimens are entirely submitted in cassettes C1 and C2.  **INITIALS\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\A.  12 H\T\E.\X0D\\X0A\B.  1 H\T\E.\X0D\\X0A\C.  2 H\T\E.\X0D\\X0A\,"SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\A.  LEFT LOWER LOBE, CANCER BRONCHIAL MARGIN - PRECISION / FROZEN\X0D\\X0A\B.  N2 LEVEL LYMPH NODE, PERMANENT\X0D\\X0A\C.  N1 LEVEL LYMPH NODES, PERMANENT\X0D\\X0A\",,ADDENDUM           \X0D\\X0A\\X0D\\X0A\Addendum #1              Entered: **DATE[Sep 15 12]-1641\X0D\\X0A\\X0D\\X0A\REPORT FROM PRECISION THERAPEUTICS\X0D\\X0A\\X0D\\X0A\TERMINATION REPORT\X0D\\X0A\\X0D\\X0A\Case terminated due to unsuccessful cell culture.\X0D\\X0A\\X0D\\X0A\No final report will be issued.\X0D\\X0A\Specimen has been disposed of properly.\X0D\\X0A\\X0D\\X0A\\X0D\\X0A\
REG1,LUNG,0,493657,1,,"CLINICAL HISTORY\X0D\\X0A\History:  2 cm nodule left lung.  Procedure:  CT guided FNA biopsy.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\IMMEDIATE EVALUATION #1:  \""FAVOR TUMOR\"", TO DR. **NAME[ZZZ/YYY].\X0D\\X0A\\X0D\\X0A\","**INSTITUTION \X0D\\X0A\310 S. LIMESTONE\X0D\\X0A\**PLACE, KY  **ZIP-CODE\X0D\\X0A\ MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Dec 5 1938] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Jun 13 2012] 12:16\X0D\\X0A\Receipt Date: **DATE[Jun 13 2012] 12:16\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE Fax:  **PHONE          ***PATH-NUMBER[1]\X0D\\X0A\Email:      \X0D\\X0A\**NAME[XXX] MD: P.X. **NAME[WWW], MD     **NAME[VVV]: MD2     Location: S4W\X0D\\X0A\**NAME[UUU] MD(S): H.T. **NAME[ZZZ], MD     Reported: **DATE[Jun 17 2012] 15:21","DIAGNOSIS\X0D\\X0A\LUG, LEFT LOWER LOBE, CT GUIDED FNA ( (SMEARS AND CELL BLOCK):\X0D\\X0A\-          POSITIVE FOR MALIGNANCY, POORLY DIFFERENTIATED SQUAMOUS CELL\X0D\\X0A\CARCINOMA (SEE COMMENT)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\msp/**DATE[Jun 17 2012] M.S. **NAME[TTT], M.D.\X0D\\X0A\\X0D\\X0A\ICD 9:   SNOMED CODES:\X0D\\X0A\A: M81403 P1149 \X0D\\X0A\F:  88173 ASP INTER, 88172, 67417, 88305\X0D\\X0A\A: S 67238, S 88342 (PROF), 67043 IMHC2, S 88342 (PROF), 67042 IMHC 1, S\X0D\\X0A\88342 (PROF), S 67240, S 88342 (PROF)",,"GROSS DESCRIPTION\X0D\\X0A\The procedure is performed in the ultrasound suite by Dr. **NAME[ZZZ].  A single\X0D\\X0A\dried dif quik stained smear is reviewed for immediate evaluation with a\X0D\\X0A\spray fixed smear retained for PAP staining.  Needle rinsings consisting\X0D\\X0A\mainly of thrombus measuring 1 x 0.8 x 0.2 cm are submitted in screened A1\X0D\\X0A\for cell block.\X0D\\X0A\dlf/**DATE[Jun 14 2012] **NAME[M. SSS], MD\X0D\\X0A\\X0D\\X0A\",MICROSCOPIC DESCRIPTION/COMMENT\X0D\\X0A\Immunohistochemical staining of the cell block shows the tumor is positive\X0D\\X0A\for CK 5/6 and p63 and negative for TTF1.  Focal positive staining for\X0D\\X0A\Napsin-A is noted in what are possibly pulmonary macrophages with no definite\X0D\\X0A\staining of tumor cells.\X0D\\X0A\Interdepartmental review with agreement is obtained (MDT).\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: ct guided fna-2 cm nodule left lung,,
REG1,LUNG,0,493671,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is lung nodule. Intraoperative findings: lung nodule.\X0D\\X0A\Operative procedure: video-assisted thorascoscopy, wedge, possible lobectomy.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\IOC #1:  \""NO DEFINITIVE LESION IDENTIFIED\""---VC.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""NON-SMALL CELL CARCINOMA\""---VC. \X0D\\X0A\FROZEN SECTION DIAGNOSIS #3:  \""NEGATIVE FOR MALIGNANCY\""---VC.\X0D\\X0A\\X0D\\X0A\     **NAME[M. ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 2 1934] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Aug 23 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Aug 25 2012] 08:43\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: T.W. **NAME[XXX], MD     Service: CVT     Location: 6S\X0D\\X0A\**NAME[WWW] MD(**NAME[M): M. VVV], MD.     Reported: **DATE[Aug 29 2012] 17:53\X0D\\X0A\RESIDENTS(S): D.J. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\RIGHT LUNG (upper and middle lobes), WEDGE EXCISION (A):     ADENOCARCINOMA,\X0D\\X0A\WELL TO MODERATELY DIFFERENTIATED\X0D\\X0A\           Present at stapled margin\X0D\\X0A\     SCATTERED SMALL INTERSTITIAL NONNECROTIZING GRANULOMAS*\X0D\\X0A\RIGHT LUNG (middle lobe), WEDGE EXCISION (B):\X0D\\X0A\     ADENOCARCINOMA, WELL TO MODERATELY DIFFERENTIATED  [pT1a / N0]\X0D\\X0A\            Present at stapled margin\X0D\\X0A\     SCATTERED SMALL INTERSTITIAL NONNECROTIZING GRANULOMAS*\X0D\\X0A\RIGHT LUNG, MIDDLE LOBE, COMPLETION LOBECTOMY (C):\X0D\\X0A\     NO TUMOR SEEN\X0D\\X0A\     SCATTERED SMALL INTERSTITIAL NONNECROTIZING GRANULOMAS*\X0D\\X0A\LYMPH NODE (subcarinal), BIOPSY (D):     NO TUMOR SEEN (0/1)\X0D\\X0A\LYMPH NODE (inferior pulmonary ligament), BIOPSY (E):     NO TUMOR SEEN (0/1)\X0D\\X0A\NOTE\X0D\\X0A\*Further evaluation in process (addendum will follow)\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dw/**DATE[Aug 29 2012] **NAME[TTT SSS], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Comment\X0D\\X0A\ GMS stain:  no fungi identified\X0D\\X0A\ Fite stain:  no mycobacteria identified\X0D\\X0A\Note:  Infection is not excluded on the basis of negative tissue stains.\X0D\\X0A\Result of immunostain\X0D\\X0A\ CD1a:  negative\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\dw/**DATE[Sep 2 2012] **NAME[TTT SSS], MD \X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\A: M44200 M8140\X0D\\X0A\B: M44200 M8140\X0D\\X0A\C: M09450 P1100\X0D\\X0A\D: M09450 P1140\X0D\\X0A\E: M09450 P1140 \X0D\\X0A\F: A: 88329 SURG CONS, 88309, 67043 IMHC2, S 88342 (PROF), S 88312, 67636, S\X0D\\X0A\88312, 67203\X0D\\X0A\B: 88309\X0D\\X0A\B,C: 88331 FS1(2)\X0D\\X0A\C: 88309\X0D\\X0A\D: 88305\X0D\\X0A\E: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  five\X0D\\X0A\Specimen A is received fresh for frozen section labeled right upper and\X0D\\X0A\middle lobe and consists of the aforementioned. \X0D\\X0A\\X0D\\X0A\The pleural surface is smooth and intact. Cut surfaces show unremarkable lung\X0D\\X0A\parenchyma with no discrete mass or other lesions noted. The uninvolved lung\X0D\\X0A\parenchyma is unremarkable. The bronchi and airways are unremarkable. No\X0D\\X0A\post-obstructive changes are noted.\X0D\\X0A\Ink Code: Pleura Blue, staple line is inked green \X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen: 13.1 x 5.7 x 2.2 cm\X0D\\X0A\Specimen weight: 70 gm\X0D\\X0A\Sections:\X0D\\X0A\A1  A3  staple line en face\X0D\\X0A\A4  A7  horizontal sections 2 cm from inferior specimen\X0D\\X0A\A8  A10  horizontal sections 2.2 cm from inferior\X0D\\X0A\A11  A12  sections 2.5 cm from inferior \X0D\\X0A\Specimen B is received fresh for frozen section labeled middle lobe/upper\X0D\\X0A\lobe extended edge, stitch is area of concern in middle lobe and consists of\X0D\\X0A\the aforementioned. \X0D\\X0A\The pleural surface is smooth and intact.  Cut surfaces show a gray/white\X0D\\X0A\mass. The uninvolved lung parenchyma is unremarkable.  The bronchi and\X0D\\X0A\airways are unremarkable.  No post-obstructive changes are noted.\X0D\\X0A\Ink Code: Pleura Blue, green ink where staples removed (parenchymal margin).\X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen: 8.5 x 8.2 x 1.6 cm\X0D\\X0A\Specimen weight: 60 gm\X0D\\X0A\Mass size: 0.7 x 0.5 x 0.5 cm \X0D\\X0A\Length of staple line(s): 4.5, 8.6 x 7.3 and 9.1 cm  \X0D\\X0A\Mass to staple line distance: 2 mm\X0D\\X0A\Mass to stitched distance: 0.7 cm  \X0D\\X0A\Sections:\X0D\\X0A\B1  FS2 entirely resubmitted in biowrap\X0D\\X0A\B2  B4  mass to closest staple line (staple end inked black)\X0D\\X0A\B5  B7  representative uninvolved parenchyma \X0D\\X0A\Specimen label:  C) completion middle lobectomy                   \X0D\\X0A\Fixation: fresh for frozen  stitch superior, final margin frozen section on\X0D\\X0A\bronchial margins\X0D\\X0A\Number of pieces: 1\X0D\\X0A\Shape(s): wedge \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 4 x 1.7 x 1.1 cm\X0D\\X0A\Weight: 2.97 grams\X0D\\X0A\The bronchial margin is frozen en face as FS3\X0D\\X0A\It has numerous staple lines. The staple lines are removed and the specimen\X0D\\X0A\is entirely submitted in C1  C2. C1  FS3 in biowrap. \X0D\\X0A\Specimen label:  D) subcarinal lymph node  \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): pink tan with some red areas\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 1.5 x 1 x 0.7 cm \X0D\\X0A\Cassette summary: one possible lymph node bisected and entirely submitted in\X0D\\X0A\D1.  \X0D\\X0A\Specimen label:  E) inferior pulmonary ligament node                  \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): pink tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.5cm\X0D\\X0A\Cassette summary: entirely submitted in E1 unaltered \X0D\\X0A\rgc/**DATE[Aug 28 2012] D.J. **NAME[UUU], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\LUNG CARCINOMA (template #12)\X0D\\X0A\(including non-small-cell, small-cell, and carcinoid tumors) \X0D\\X0A\Last updated **DATE[Oct 2010] (AJCC 7th Edition \T\ 2009 AJCC checklist)\X0D\\X0A\Type of surgery:  wedge excision; middle lobectomy \X0D\\X0A\Weight:  70 grams (specimen A); 60 grams (specimen B); 2.97 grams (specimen\X0D\\X0A\C)\X0D\\X0A\Dimensions of lung:  13.1 x 5.7 x 2.2 cm (specimen A); 8.5 x 8.2 x 1.6 cm\X0D\\X0A\(specimen B); 4 x 1.7 x 1.1 cm (specimen C)\X0D\\X0A\Location (lobe / segment):  middle lobe\X0D\\X0A\Tumor size:  1.6 cm    \X0D\\X0A\Tumor focality (unifocal  /  separate nodules - same or different lobe): \X0D\\X0A\unifocal\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Histologic grade (if applicable):  1 to 2\X0D\\X0A\Margins:\X0D\\X0A\     bronchial:  negative\X0D\\X0A\     parenchymal (if applicable):  negative (According to intraoperative\X0D\\X0A\diagram provided by Dr. **NAME[XXX], final parenchymal margin is \X0D\\X0A\       represented in specimen C; no tumor is demonstrated in the entirely\X0D\\X0A\processed specimen C.)\X0D\\X0A\     vascular:  unknown\X0D\\X0A\     chest wall (if applicable):  not applicable\X0D\\X0A\Pleural invasion (visceral / parietal):  no  \X0D\\X0A\Other organs / structures involved:  none known or demonstrated\X0D\\X0A\Tumor distance from bronchial margin:   1.1 cm    \X0D\\X0A\Tumor distance from pleural surface:  \R\ 1 mm. (section B2)        \X0D\\X0A\Lymph-vascular invasion:  not identified\X0D\\X0A\Vascular (venous) invasion:  not identified\X0D\\X0A\Lymph nodes (positive / total) [list by site]:  0/2 (subcarinal; inferior\X0D\\X0A\pulmonary ligament)\X0D\\X0A\Description of nontumorous lung:  anthracosilicosis; focal interstitial\X0D\\X0A\fibrosis; small interstitial nonnecrotizing granulomas; incidental \X0D\\X0A\    tumorlet (A12)\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\Primary tumor (pT) (all dimensions refer to greatest dimension)\X0D\\X0A\\X0D\\X0A\     AJCC/CAP   /   Subgroups (IASLC)\X0D\\X0A\\X0D\\X0A\    T1a     Tumor 2 cm. or less   (T1a) \X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\N0     No regional node metastasis\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\Not applicable\X0D\\X0A\A resident has participated in this service.  A pathologist has performed and\X0D\\X0A\is responsible for the reported pathologic evaluation.","DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right upper and middle lung\X0D\\X0A\B: Middle lobe / upper lobe extended edge, stitch area of concern in middle\X0D\\X0A\lobe\X0D\\X0A\C: Completion middle lobectomy - stitch superior final margin\X0D\\X0A\D: Subcarinal lymph node\X0D\\X0A\E: Inferior pulmonary ligament node",,PROCEDURES/ADDENDA
REG1,LUNG,0,493730,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is history of COPD, tobacco abuse. Left upper lobe\X0D\\X0A\bronchus occlusion. Operative findings: left mainstem and left upper lobe\X0D\\X0A\occlusion. Operative procedure: bronchoscopy with endobronchial biopsies of\X0D\\X0A\left upper lobe.\X0D\\X0A\","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Mar 4 1959] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Sep 12 2012] 15:57\X0D\\X0A\Receipt Date: **DATE[Sep 12 2012] 15:57\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[ZZZ] MD: **NAME[M. YYY], MD     Service: MT3     Location: 7E\X0D\\X0A\**NAME[XXX] MD(S):      Reported: **DATE[Sep 13 2012] 16:24\X0D\\X0A\RESIDENTS(**NAME[M): WWW VVV], DO","DIAGNOSIS\X0D\\X0A\LUNG, LEFT UPPER LOBE, ENDOBRONCHIAL BIOPSY:\X0D\\X0A\   - MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Sep 13 2012] M.S. **NAME[UUU], M.D.\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\B: **ID-NUM P114 \X0D\\X0A\F: A: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total number of specimens:  one \X0D\\X0A\Specimen label:  A) left lung                \X0D\\X0A\Fixation: formalin\X0D\\X0A\Number of pieces: five\X0D\\X0A\Shape(s):  irregular  \X0D\\X0A\Color(s): red tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): 0.1 cm in greatest dimension each\X0D\\X0A\Cassette summary: entirely submitted in screened A1 to be rushed for\X0D\\X0A\Wednesday AM \X0D\\X0A\ksl/**DATE[Sep 13 2012] **NAME[WWW VVV], DO\X0D\\X0A\J.G. Combs",MICROSCOPIC DESCRIPTION\X0D\\X0A\Results were called to Dr. **NAME[TTT] on **DATE[Sep 13 2012] at 10:30 a.m.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left lung,,
REG1,LUNG,0,493735,1,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is left upper lung nodule. Operative findings: not\X0D\\X0A\given. Operative procedure: left video-assisted thoracoscopy of biopsy of\X0D\\X0A\lung and mediastinal mass with possible thoracotomy, bronchoscopy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""SQUAMOUS CELL CARCINOMA\""----MLC.\X0D\\X0A\FROZEN SECTION DIAGNOSIS #2:  \""METASTATIC SQUAMOUS CELL CARCINOMA\""---MLC. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Oct 31 1945] (Age: **AGE[in 60s])  MW\X0D\\X0A\Collect Date: **DATE[Nov 22 2011] 15:01\X0D\\X0A\Receipt Date: **DATE[Nov 22 2011] 15:01\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: H.K. **NAME[WWW], MD     Service: CVT     Location: REC\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Nov 25 2011] 21:47\X0D\\X0A\RESIDENTS(S): J.P. **NAME[UUU], MD","DIAGNOSIS\X0D\\X0A\LEFT LUNG (upper lobe), BIOPSY OF MASS (A; C):\X0D\\X0A\     SQUAMOUS-CELL CARCINOMA, LOW GRADE \X0D\\X0A\LYMPH NODE(S), AP WINDOW (B):\X0D\\X0A\     METASTATIC SQUAMOUS-CELL CARCINOMA\X0D\\X0A\LYMPH NODE(S), INFERIOR PULMONARY LIGAMENT (D):     NO TUMOR SEEN\X0D\\X0A\RIGHT LUNG (lower lobe), BIOPSY OF NODULE (E):     ANTHRACOSILICOTIC NODULE\X0D\\X0A\     NO TUMOR SEEN\X0D\\X0A\TISSUE, AP WINDOW (F):     METASTATIC SQUAMOUS-CELL CARCINOMA\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dw/**DATE[Nov 25 2011] **NAME[TTT SSS], MD\X0D\\X0A\\X0D\\X0A\Addendum     \X0D\\X0A\Addendum Comment\X0D\\X0A\GMS stain (calcified nodule  section E2):  no fungi identified\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\dw/**DATE[Nov 29 2011] **NAME[TTT SSS], MD \X0D\\X0A\ICD 9: 162.3     MALIGNANT NEOPLASM UPPER LOBE, BRONCHUS OR  LUNG\X0D\\X0A\196.1     INTRATHORACIC LYMPH NODES, SECONDARY AND UNSPECIFIED MALIGNANT\X0D\\X0A\NEOPLASM\X0D\\X0A\500     ANTHRACOSILICOSIS\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M80703 P1140\X0D\\X0A\B: M80706 T0800\X0D\\X0A\C: M09450 T0831\X0D\\X0A\D: D7612 M09450\X0D\\X0A\E: M80706 \X0D\\X0A\F: A: 88305\X0D\\X0A\A,B: 88331 FS1(2)\X0D\\X0A\B: 88305\X0D\\X0A\C: 88305\X0D\\X0A\D: 88305\X0D\\X0A\E: 88307, S 88311 DECAL, S 88311 DECAL, S 88312, 67636, S 88311 DECAL <CR>\X0D\\X0A\F: 88305",,"GROSS DESCRIPTION\X0D\\X0A\Total specimen number:  six\X0D\\X0A\Specimen label:  A) left upper lobe mass              \X0D\\X0A\Fixation: fresh for frozen section \X0D\\X0A\Number of pieces: 3\X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): tan brown \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): ranges in size from 0.2 x 0.2 x 0.3 cm to 0.2 x 0.5 x 0.5 cm \X0D\\X0A\Cassette summary: it is entirely frozen as FS1. FS1 is entirely resubmitted\X0D\\X0A\in screened A1.   \X0D\\X0A\Specimen label:  B) AP window node                 \X0D\\X0A\Fixation: fresh for frozen section \X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): brown tan \X0D\\X0A\Consistency: irregular\X0D\\X0A\Size(s): measures in aggregate 0.4 x 1.5 x 2.5 cm \X0D\\X0A\Cassette summary: representative portion of the specimen is frozen as FS2.\X0D\\X0A\FS2 is entirely resubmitted in B1. Remainder of the tissue is submitted in\X0D\\X0A\B2.  \X0D\\X0A\Specimen label:  C) left upper lobe mass                   \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple  \X0D\\X0A\Shape(s): irregular    \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): in aggregate 2.2 x 2.0 x 0.3 cm \X0D\\X0A\Cassette summary: submitted entirely in screened C1.  \X0D\\X0A\Specimen label:  D) inferior pulmonary ligament node \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft and firm \X0D\\X0A\Size(s): 2.3 x 2.2 x 0.5 cm \X0D\\X0A\Cassette summary: it is submitted entirely in screened D1. \X0D\\X0A\Specimen label:  E) right lower lobe nodule                  \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: 1 \X0D\\X0A\Shape(s): irregular   \X0D\\X0A\Color(s): pink tan \X0D\\X0A\Consistency: soft and firm \X0D\\X0A\Size(s): 4.5 x 1.0 x 0.6 cm\X0D\\X0A\The specimen is a lung wedge with a staple line measuring 4 cm. There is a\X0D\\X0A\firm nodule measuring 1.0 cm which is 0.3 cm from the staple line. The nodule\X0D\\X0A\is firm and feels calcific in nature. Due to the small size of the wedge, the\X0D\\X0A\staple line is trimmed and blue marks where the staple line is removed. The\X0D\\X0A\specimen is serially sectioned and submitted in its entirety in E1  E1. E1\X0D\\X0A\contains lung; E2  hard calcified nodule for decal.  \X0D\\X0A\Specimen label:  F) AP window tissue \X0D\\X0A\Fixation: formalin \X0D\\X0A\Number of pieces: multiple\X0D\\X0A\Shape(s): irregular\X0D\\X0A\Color(s): pink tan\X0D\\X0A\Consistency: soft\X0D\\X0A\Size(s): in aggregate 1.6 x 1.3 x 0.3 cm \X0D\\X0A\Cassette summary: submitted in its entirety in screened F1. \X0D\\X0A\rgc/**DATE[Nov 23 2011] J.P. **NAME[UUU], MD\X0D\\X0A\**NAME[M. RRR], MD",MICROSCOPIC DESCRIPTION\X0D\\X0A\A resident has participated in this service.  The electronic signature\X0D\\X0A\denotes the pathologist performing and responsible for the pathologic\X0D\\X0A\evaluation.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left upper lobe mass\X0D\\X0A\B: AP window node\X0D\\X0A\C: Left upper lobe mass\X0D\\X0A\D: Inferior pulmonary ligament node\X0D\\X0A\E: Right lower lobe nodule\X0D\\X0A\F: AP window tissue,,PROCEDURES/ADDENDA
REG1,LUNG,0,493833,1,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis:  lung cancer.  Intraoperative findings:  none\X0D\\X0A\provided.  Operative procedure:  left upper video-assisted thoroscopy\X0D\\X0A\lobectomy.  \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FS1A (LEFT UPPER LOBE BRONCHIAL MARGIN): \""POSITIVE FOR ADENOCARCINOMA\""---DLR\X0D\\X0A\FS1B (LEFT UPPER LOBE MASS): \""ADENOCARCINOMA\""---DLR  \X0D\\X0A\\X0D\\X0A\     D.L. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA M].\X0D\\X0A\**DATE[Sep 31 1940] (Age: **AGE[in 70s])  FW\X0D\\X0A\Collect Date: **DATE[Jan 28 2012] 00:00\X0D\\X0A\Receipt Date: **DATE[Jan 29 2012] 08:14\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: T.W. **NAME[XXX], MD     Service: CVT     Location: 1CV\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Feb 3 2012] 14:13\X0D\\X0A\RESIDENTS(S): R.K. **NAME[VVV], MD","Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\ADEQUATE TUMOR FOR MOLECULAR ANALYSIS, SEE COMMENT\X0D\\X0A\Addendum Comment\X0D\\X0A\Per request from Dr. **NAME[UUU], slides and blocks are pulled from the archive\X0D\\X0A\and reviewed. Block G1 (one of four lymph nodes completely replaced by tumor)\X0D\\X0A\is selected and unstained slides are prepared (charged, 5 microns, made with\X0D\\X0A\PCR precautions). A follow up H\T\E shows a similar distribution and\X0D\\X0A\percentage of tumor as the initial H\T\E. The lymph node replaced with tumor\X0D\\X0A\is marked for macrodissection, and a portion of the slides will be sent **NAME[TTT] MD\X0D\\X0A\**PLACE Molecular Diagnostics for EGFR mutation analysis. Should the EGFR\X0D\\X0A\analysis be negative, remaining slides will be sent to **INSTITUTION for ALK\X0D\\X0A\rearrangement analysis by FISH.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jfp/**DATE[May 16 2012] **NAME[SSS M. RRR], MD SG \X0D\\X0A\Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\ADEQUATE TUMOR FOR FISH ANALYSIS, SEE COMMENT\X0D\\X0A\Addendum Comment\X0D\\X0A\This is a follow-up to the previous addendum. The EGFR mutation analysis is\X0D\\X0A\negative; therefore remaining slides (unstained) will be sent to **INSTITUTION for ALK\X0D\\X0A\rearrangement analysis by FISH. In slide \""4\"" the portion with tumor is\X0D\\X0A\marked.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jfp/**DATE[May 27 2012] **NAME[SSS M. RRR], MD SG \X0D\\X0A\DIAGNOSIS\X0D\\X0A\LEFT LUNG, UPPER LOBE, LOBECTOMY (A):\X0D\\X0A\   - INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA (pT3, pN2), SEE\X0D\\X0A\COMMENT AND TEMPLATE.\X0D\\X0A\   - BRONCHIAL MARGIN POSITIVE FOR TUMOR (SEE ALSO SPECIMEN G, COMPLETION\X0D\\X0A\PNEUMONECTOMY).\X0D\\X0A\LEFT LUNG, COMPLETION PNEUMONECTOMY (G):\X0D\\X0A\   - MILD EMPHYSEMATOUS CHANGE, NO TUMOR SEEN.\X0D\\X0A\   - BRONCHIAL AND VASCULAR MARGINS NEGATIVE FOR TUMOR.\X0D\\X0A\   - METASTATIC ADENOCARCINOMA IN ONE OF FOUR HILAR LYMPH NODES (1/4).\X0D\\X0A\INFERIOR PULMONARY LIGAMENT LYMPH NODE, EXCISION (B):\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\INTERLOBAR LYMPH NODES, EXCISION (C):\X0D\\X0A\   - METASTATIC ADENOCARCINOMA IN TWO LYMPH NODES (2/2).\X0D\\X0A\ANTERIOR HILAR LYMPHATIC TISSUE, EXCISION (D):\X0D\\X0A\   - NO TUMOR SEEN, NO LYMPH NODE IDENTIFIED.\X0D\\X0A\SUBCARINAL LYMPH NODES (E):\X0D\\X0A\  - METASTATIC ADENOCARCINOMA IN TWO OF FIVE LYMPH NODES (2/5).\X0D\\X0A\PERIBRONCHIAL LYMPH NODE, EXCISION (F):\X0D\\X0A\   - NO TUMOR SEEN IN ONE LYMPH NODE (0/1).\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\dlf/**DATE[Feb 3 2012] M.V. **NAME[QQQ], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 162.3     MALIGNANT NEOPLASM UPPER LOBE, BRONCHUS OR  LUNG\X0D\\X0A\196.1     INTRATHORACIC LYMPH NODES, SECONDARY AND UNSPECIFIED MALIGNANT\X0D\\X0A\NEOPLASM\X0D\\X0A\492.8     EMPHYSEMA NOS/NEC\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: **ID-NUM P110\X0D\\X0A\B: M09400 M3280\X0D\\X0A\C: M09450 P1100\X0D\\X0A\D: M81406 P1100\X0D\\X0A\E: M09450 P1100\X0D\\X0A\F: M81406 T0800\X0D\\X0A\G: M09450 P1100 \X0D\\X0A\F: A: 88331 FS1, 88332 ADD'L FS, 88309\X0D\\X0A\Result information is incomplete.\X0D\\X0A\Please see patient chart for complete information.",,"GROSS DESCRIPTION\X0D\\X0A\Seven specimens are received.\X0D\\X0A\Specimen A is received fresh for frozen section labeled left upper lobe and\X0D\\X0A\consists of the aforementioned. The pleural surface is smooth and tan pink to\X0D\\X0A\tan purple with an area of tan white pleural thickening with puckering.  The\X0D\\X0A\area of pleural thickening with puckering measures 7.5 x 6.5 cm.  Cut surface\X0D\\X0A\shows a tan white fairly circumscribed mass with large areas of necrosis,\X0D\\X0A\measurements below.  The uninvolved lung parenchyma is tan red. The bronchi\X0D\\X0A\and airways are involved by tumor 0.5 cm away from bronchial margin.  The\X0D\\X0A\airways are unremarkable.  No post-obstructive changes are noted.  The\X0D\\X0A\remaining tissue is grossly unremarkable.\X0D\\X0A\Ink Code: pleura black.\X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen:  14 x 9 x 3 cm\X0D\\X0A\Specimen weight:  250 gm\X0D\\X0A\Mass size: 8 x 7.5 x 4 cm \X0D\\X0A\Mass to pleura distance: abuts the pleural surface with puckering \X0D\\X0A\Mass to bronchial margin: 0.5 cm \X0D\\X0A\Length of staple line(s):  4.5 cm and 3 cm \X0D\\X0A\Number of candidate hilar lymph nodes:  1 (1 x 0.6 x 0.5 cm)\X0D\\X0A\Sections:\X0D\\X0A\A1:  FS1A resubmitted (bronchial margin)\X0D\\X0A\A2:  FS1B resubmitted (mass)\X0D\\X0A\A3-4:  tumor with closest to pleural surface and pleural puckering\X0D\\X0A\A5:  mass filling the main bronchus\X0D\\X0A\A6:  mass with bronchus and branches of pulmonary vessels\X0D\\X0A\A7:  tumor additional sections\X0D\\X0A\A8:  vascular margin\X0D\\X0A\A9:  tumor additional section with branches of pulmonary vessels\X0D\\X0A\A10:  uninvolved lung, representative\X0D\\X0A\Specimen B is received in formalin labeled inferior pulmonary ligament lymph\X0D\\X0A\node and consists of a single fragment of dark red to dark gray soft tissue\X0D\\X0A\measuring 1 x 0.4 x 0.3 cm.  Entire specimen submitted in cassette B1.\X0D\\X0A\Specimen C is received in formalin labeled interlobar lymph node and consists\X0D\\X0A\of two fragments of tan red to tan gray soft tissue measuring 0.9 and 1 cm in\X0D\\X0A\greatest dimension.  One fragment is inked black.  Both fragments are\X0D\\X0A\bisected and submitted entirely in cassette C1.\X0D\\X0A\Specimen D is received in formalin labeled anterior hilar lymphatic tissue\X0D\\X0A\and consists of an irregular fragment of tan red to tan brown soft tissue\X0D\\X0A\measuring 3 x 1.5 x 0.5 cm.  Entire specimen submitted in cassette D1.\X0D\\X0A\Specimen E is received in formalin labeled subcarinal lymph node and consists\X0D\\X0A\of three fragments of tan pink to tan red soft tissue measuring, in\X0D\\X0A\aggregate, 2.5 x 2 x 1 cm.  The largest fragment measures 2.5 cm in greatest\X0D\\X0A\dimension.  Five possible lymph nodes are identified ranging in size from 0.5\X0D\\X0A\cm to 1 cm in greatest dimension.  All five lymph nodes are submitted in\X0D\\X0A\cassette E1, not modified.\X0D\\X0A\Specimen F is received in formalin labeled peribronchial lymph node and\X0D\\X0A\consists of a fragment of tan pink to tan gray soft tissue measuring 0.5 x\X0D\\X0A\0.4 x 0.1 cm.  Entire specimen submitted in cassette F1.\X0D\\X0A\Specimen G is received fresh and inflated with formalin labeled left lower\X0D\\X0A\lobe completion pneumonectomy and consists of the aforementioned.  The\X0D\\X0A\pleural surface is tan pink, smooth, and unremarkable without puckering.  Cut\X0D\\X0A\surface is tan pink to tan red without any gross mass or lesion.  The\X0D\\X0A\uninvolved lung parenchyma is unremarkable.  The bronchi and airways are\X0D\\X0A\unremarkable.  No post-obstructive changes are noted.  All remaining portions\X0D\\X0A\of the specimen are grossly unremarkable.\X0D\\X0A\Ink Code: pleura black\X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen:  17 x 9 x 4 cm\X0D\\X0A\Specimen weight:  200 gm\X0D\\X0A\Mass size: no mass identified \X0D\\X0A\Number of candidate hilar lymph nodes:  four ranging in size from 0.5 cm to\X0D\\X0A\1.2 cm in greatest dimension\X0D\\X0A\Staple line:  4.5 cm, 2 cm, 1.5 cm and 1.4 cm\X0D\\X0A\Sections:\X0D\\X0A\G1:  four perihilar lymph nodes, not modified\X0D\\X0A\G2:  parenchymal stapled margin, shaved, en face with one pulmonary vessel\X0D\\X0A\G3:  stapled vascular margins, shaved\X0D\\X0A\G4:  bronchial margin, shaved\X0D\\X0A\G5 to G7:  lung parenchyma, representative\X0D\\X0A\blm/**DATE[Jan 29 2012] R.K. **NAME[VVV], MD\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\LUNG CARCINOMA (template #12)\X0D\\X0A\(including non-small cell, small cell, and carcinoid tumors) \X0D\\X0A\Last updated **DATE[Feb 2010] (AJCC 7th Edition \T\ 2009 AJCC checklist)\X0D\\X0A\Type of surgery:   lobectomy\X0D\\X0A\Weight:  250 grams\X0D\\X0A\Dimensions of lung:  14 x 9 x 3 cm\X0D\\X0A\Location (lobe / segment):  left upper lobe\X0D\\X0A\Tumor size:  8 x 7.5 x 4 cm\X0D\\X0A\Tumor focality (unifocal, separate nodules - same or different lobe): \X0D\\X0A\unifocal\X0D\\X0A\Histologic type:  adenocarcinoma\X0D\\X0A\Histologic grade (if applicable):  moderately differentiated\X0D\\X0A\Margins:\X0D\\X0A\     bronchial:  positive on initial lobectomy (final bronchial margin,\X0D\\X0A\specimen G, negative)\X0D\\X0A\     vascular:  negative\X0D\\X0A\Pleural invasion:  \X0D\\X0A\       Visceral:  yes\X0D\\X0A\Tumor distance from bronchial margin:   tumor present at initial bronchial\X0D\\X0A\margin\X0D\\X0A\Tumor distance from pleural surface:    less than 1 mm\X0D\\X0A\Lymphvascular invasion:  possible\X0D\\X0A\Vascular (venous) invasion:  not identified\X0D\\X0A\Lymph nodes (positive / total) [list by site]: \X0D\\X0A\     Inferior pulmonary ligament:  0/1\X0D\\X0A\     Interlobar:  2/2\X0D\\X0A\     Subcarinal:  2/5\X0D\\X0A\     Peribronchial:  0/1\X0D\\X0A\     Perihilar:  1/4\X0D\\X0A\Description of nontumorous lung:  emphysematous changes and perivascular\X0D\\X0A\chronic inflammation\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\Primary tumor (pT) (all dimensions refer to greatest dimension)\X0D\\X0A\\X0D\\X0A\pT (AJCC/CAP)                                                                \X0D\\X0A\                                       (Subgroups by IASLC)\X0D\\X0A\pT3              Tumor >7 cm;                                                \X0D\\X0A\                                                     (T3>7)       \X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\pN2               Metastasis in ipsilateral mediastinal and/or subcarinal\X0D\\X0A\lymph nodes\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\                       Not applicable\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Left upper lobe\X0D\\X0A\B: Inferior pulmonary ligament lymph node\X0D\\X0A\C: Interlobar lymph node\X0D\\X0A\D: Anterior hilar lymphatic tissue\X0D\\X0A\E: Subcarinal lymph node\X0D\\X0A\F: Peribronchial lymph node\X0D\\X0A\G: Left lower lobe; completion pneumonectomy,,PROCEDURES/ADDENDA
REG1,LUNG,0,493836,2,,"CLINICAL HISTORY\X0D\\X0A\Preoperative diagnosis: lung mass. Intraoperative findings: not given.\X0D\\X0A\Operative procedure: chest node biopsy.\X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS:  \""ADENOCARCINOMA WITH MUCINOUS FEATURES\""---RK.\X0D\\X0A\\X0D\\X0A\     R.G. **NAME[ZZZ], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Oct 6 1954] (Age: **AGE[in 50s])  FW\X0D\\X0A\Collect Date: **DATE[Jan 2 2012] 14:04\X0D\\X0A\Receipt Date: **DATE[Jan 2 2012] 14:04\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[YYY] MD: T.W. **NAME[XXX], MD     Service: CVT     Location: REC\X0D\\X0A\**NAME[WWW] MD(S):      Reported: **DATE[Jan 6 2012] 15:37\X0D\\X0A\RESIDENTS(S): E.A. Pirruccello, DO","Addendum     \X0D\\X0A\Addendum Diagnosis\X0D\\X0A\ADEQUATE TUMOR FOR FISH ANALYSIS\X0D\\X0A\Addendum Comment\X0D\\X0A\Per request from Dr. **NAME[VVV], slides and blocks are pulled from the archive\X0D\\X0A\and evaluated for FISH analysis. Block A2 is selected and unstained slides\X0D\\X0A\are prepared (charged, 5 microns). The follow up H\T\E shows tumor in a\X0D\\X0A\similar distribution and frequency as the initial H\T\E. Slides will be sent\X0D\\X0A\to **INSTITUTION for ALK rearrangement analysis by FISH.\X0D\\X0A\A resident has participated in this service.  A pathologist has performed and\X0D\\X0A\is responsible for the reported pathologic evaluation.\X0D\\X0A\     ***Electronically Signed Out***\X0D\\X0A\jfp/**DATE[Jan 13 2013] **NAME[UUU M. TTT], MD SG \X0D\\X0A\DIAGNOSIS\X0D\\X0A\LYMPH NODE, INTERNAL JUGULAR, EXCISION:\X0D\\X0A\ - METASTATIC ADENOCARCINOMA WITH MUCINOUS FEATURES INVOLVING ONE LYMPH NODE\X0D\\X0A\(1/1), SEE \X0D\\X0A\  COMMENT.\X0D\\X0A\ - LYMPHVASCULAR INVASION AND EXTRACAPSULAR EXTENSION IDENTIFED.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\rgc/**DATE[Jan 6 2012] **NAME[M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9: 196.0     LYMPH NODES OF HEAD, FACE, AND NECK, SECONDARY AND\X0D\\X0A\UNSPECIFIED MALIGNANT NEOPLASM\X0D\\X0A\ SNOMED CODES:\X0D\\X0A\A: M84806 P1100 \X0D\\X0A\F: A: 88331 FS1, 88305",,"GROSS DESCRIPTION\X0D\\X0A\A single specimen is received fresh for lymphoma work up and frozen and\X0D\\X0A\labeled internal jugular lymph node/molecular marker. The specimen consists\X0D\\X0A\of a single yellow tan fragment of tissue measuring 3.5 x 2.6 x 1.2 cm. The\X0D\\X0A\specimen is palpated to reveal three possible lymph nodes, the largest of\X0D\\X0A\which measures 1.1 cm in greatest dimension. Tissue is taken for lymphoma\X0D\\X0A\work up and a frozen section is performed. Cassette summary: A1 FS1 entirely\X0D\\X0A\resubmitted, A2-A4 remaining tissue entirely submitted.\X0D\\X0A\ksl/**DATE[Jan 5 2012] E.A. Pirruccello, DO\X0D\\X0A\J.P. **NAME[RRR], MD",MICROSCOPIC DESCRIPTION\X0D\\X0A\The tumor is morphologically similar to the tumor in the paratracheal and\X0D\\X0A\subcarinal lymph nodes (***PATH-NUMBER[2]). The frozen section diagnosis is\X0D\\X0A\confirmed.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.,DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Internal jugular lymph node,,PROCEDURES/ADDENDA
REG1,LUNG,0,494147,3,,"CLINICAL HISTORY\X0D\\X0A\The working diagnosis is lung mass. Intraoperative findings: lung mass.\X0D\\X0A\Operative procedure: right upper lobe wedge resection with possible\X0D\\X0A\lobectomy. \X0D\\X0A\\X0D\\X0A\INTRAOPERATIVE CONSULT DIAGNOSIS\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1:  \""NO TUMOR SEEN\""---MLC. \X0D\\X0A\\X0D\\X0A\     **NAME[ZZZ M. YYY], MD","**INSTITUTION\X0D\\X0A\**INSTITUTION\X0D\\X0A\**PLACE, KENTUCKY **ZIP-CODE MR #: **ID-NUM\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\**DATE[Nov 23 1941] (Age: **AGE[in 70s])  MW\X0D\\X0A\Collect Date: **DATE[Feb 21 2012] 14:25\X0D\\X0A\Receipt Date: **DATE[Feb 21 2012] 14:25\X0D\\X0A\Page 1\X0D\\X0A\\X0D\\X0A\DEPARTMENT OF PATHOLOGY\X0D\\X0A\AND LABORATORY MEDICINE\X0D\\X0A\SURGICAL PATHOLOGY REPORT\X0D\\X0A\Phone: **PHONE    Fax:  **PHONE     ***PATH-NUMBER[1]\X0D\\X0A\Email: **EMAIL     \X0D\\X0A\**NAME[XXX] MD: J.B. **NAME[WWW], MD     Service: CVT     Location: 2OR\X0D\\X0A\**NAME[VVV] MD(S):      Reported: **DATE[Feb 23 2012] 13:55\X0D\\X0A\RESIDENTS(S): V.V. **NAME[UUU], MD\X0D\\X0A\Comment: Histologically the tumor shows extensive hyalinization and focal\X0D\\X0A\necrosis. Occasional abortive gland formation is seen. However, many areas\X0D\\X0A\show a plate like growth pattern with some clearing of the cell cytoplasm\X0D\\X0A\raising the possibility of a significant squamous component.  No small cell\X0D\\X0A\component identified.  In order to further work up this specimen immunostains\X0D\\X0A\are performed on A8. They consist of CK56, P63, TTF1, CK7 and CK20 and these\X0D\\X0A\are pending.\X0D\\X0A\This service has been rendered in part by a resident.  A pathologist has\X0D\\X0A\personally reviewed the slides/tissue and has rendered and is responsible for\X0D\\X0A\the diagnosis that appears on the report.\X0D\\X0A\The immunohistochemical test(s) were developed and the performance\X0D\\X0A\characteristics determined by the **INSTITUTION\X0D\\X0A\Pathology.  It has not been cleared or approved by the U.S. Food and Drug\X0D\\X0A\Administration.  The FDA has determined that such clearance or approval is\X0D\\X0A\not necessary.  This test is used for clinical purposes.  It should not be\X0D\\X0A\regarded as investigational or for research.  This laboratory is certified\X0D\\X0A\under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as\X0D\\X0A\qualified to perform high complexity clinical laboratory testing.","DIAGNOSIS\X0D\\X0A\INVASIVE POORLY DIFFERENTIATED ADENOCARCINOMA, MASS INVOLVING RIGHT UPPER\X0D\\X0A\LUNG LOBE, LOBECTOMY SPECIMEN. \X0D\\X0A\TUMOR STAGE pT2a.\X0D\\X0A\IMMUNOSTAIN POSITIVE FOR TTF1 AND CK7; IMMUNOSTAINS NEGATIVE FOR P63, CK5/6,\X0D\\X0A\AND CK20.\X0D\\X0A\   NO TUMOR SEEN, RIGHT UPPER BRONCHIAL MARGIN; PERMANENT SECTIONS CONFIRM\X0D\\X0A\FROZEN SECTION DIAGNOSIS #1.\X0D\\X0A\NO TUMOR SEEN, FIVE PERIBRONCHIAL LYMPH NODES.\X0D\\X0A\     ***Electronically Signed Out***       \X0D\\X0A\ksl/**DATE[Feb 23 2012] **NAME[TTT M. SSS], MD\X0D\\X0A\\X0D\\X0A\ICD 9:  SNOMED CODES:\X0D\\X0A\\X0D\\X0A\F: A: 88331 FS1, 88309, S 67240, S 88342 (PROF), 67043 IMHC2, S 88342 (PROF),\X0D\\X0A\S 67238, S 88342 (PROF), 67042 IMHC 1, S 88342 (PROF), 67042 IMHC 1, S 88342\X0D\\X0A\(PROF)",,"GROSS DESCRIPTION\X0D\\X0A\Specimen A is received fresh for frozen section diagnosis labeled right upper\X0D\\X0A\bronchial margins and consists of the aforementioned. \X0D\\X0A\The pleural surface is focally puckered.  Cut surface shows an\X0D\\X0A\poorly-circumscribed gray mass, measurements below.  The uninvolved lung\X0D\\X0A\parenchyma is grossly unremarkable. The bronchi and airways are unremarkable.\X0D\\X0A\ No post-obstructive changes are noted. Additionally, plaque-like areas are\X0D\\X0A\identified on the pleural surface. It measures 3.5 x 3.0 cm. No definitive\X0D\\X0A\lesion is noted on sectioning of that area.\X0D\\X0A\Ink Code: Pleura Blue\X0D\\X0A\Measurements:\X0D\\X0A\Dimensions of specimen: 18.5 x 17 x 2.8 cm\X0D\\X0A\Specimen weight: 484 gm\X0D\\X0A\Mass size: 3.1 x 3.0 x 2.8 cm\X0D\\X0A\Mass to pleura distance: 0.3 cm \X0D\\X0A\Mass to bronchial margin: 2.0 cm \X0D\\X0A\Length of staple line(s): 10.0 cm\X0D\\X0A\Mass to staple line distance: 8.5 cm \X0D\\X0A\Sections:\X0D\\X0A\A1  FS1\X0D\\X0A\A2  vascular margin\X0D\\X0A\A3  A4  staple line\X0D\\X0A\A5  tumor to pleura\X0D\\X0A\A6  A8  additional sections of the tumor\X0D\\X0A\A9  sections of the plaque-like area\X0D\\X0A\A10  unremarkable lung and peribronchial lymph nodes\X0D\\X0A\rgc/**DATE[Feb 22 2012] V.V. **NAME[UUU], MD\X0D\\X0A\R.G. **NAME[RRR], MD","MICROSCOPIC DESCRIPTION\X0D\\X0A\LUNG CARCINOMA (template #12)\X0D\\X0A\(including non-small cell, small cell, and carcinoid tumors) \X0D\\X0A\Last updated **DATE[Mar 2010] (AJCC 7th Edition \T\ 2009 AJCC checklist)\X0D\\X0A\Type of surgery:   lobectomy \X0D\\X0A\Weight:  484 grams\X0D\\X0A\Dimensions of lung: 18.5 x 17 x 2.8 cm\X0D\\X0A\Location (lobe / segment): right upper lobe\X0D\\X0A\Tumor size:   3.1 x 3 x 2.8 cm\X0D\\X0A\Tumor focality (unifocal, separate nodules - same or different lobe):\X0D\\X0A\unifocal\X0D\\X0A\Histologic type: adenocarcinoma\X0D\\X0A\Histologic grade (if applicable): poorly differentiated\X0D\\X0A\Margins:\X0D\\X0A\     bronchial:  negative\X0D\\X0A\     parenchymal (if applicable): negative  \X0D\\X0A\     vascular: negative\X0D\\X0A\    chest wall (if applicable): not applicable\X0D\\X0A\Pleural invasion:  no\X0D\\X0A\Other organs / structures involved: not applicable\X0D\\X0A\Tumor distance from bronchial margin:    2 cm\X0D\\X0A\Tumor distance from pleural surface:     3 mm\X0D\\X0A\Lymphvascular invasion:  yes\X0D\\X0A\Vascular (venous) invasion:  yes\X0D\\X0A\Lymph nodes (positive / total) [list by site]:  0/5 peribronchial\X0D\\X0A\Description of nontumorous lung: emphysema and small airway smoking related\X0D\\X0A\disease\X0D\\X0A\Pathologic staging (pTNM)\X0D\\X0A\Primary tumor (pT) (all dimensions refer to greatest dimension)\X0D\\X0A\\X0D\\X0A\pT (AJCC/CAP)                                                                \X0D\\X0A\                                       (Subgroups by IASLC)\X0D\\X0A\     pT2a       Tumor >3 but < 5 cm                                          \X0D\\X0A\\X0D\\X0A\Regional lymph nodes (pN)\X0D\\X0A\pN0               No regional node metastasis\X0D\\X0A\Distant metastasis (pM)\X0D\\X0A\                       Not applicable",DESCRIPTION OF SPECIMEN:\X0D\\X0A\A: Right upper lobe,,
REG1,LUNG,0,494235,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT LOWER LUNG MASS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[XXX M].\X0D\\X0A\**NAME[YYY], M.D., LEELA\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: CT GUIDED LT LUNG BX-1 CONTAINER, 3 CORES","Final Diagnosis\X0D\\X0A\\""CT GUIDED LEFT LUNG BIOPSY\"", NEEDLE BIOPSIES:\X0D\\X0A\     POORLY DIFFERENTIATED NON-SMALL CELL CARCINOMA (SEE COMMENT).\X0D\\X0A\COMMENT:  A limited panel of immunostains with appropriate controls show tumor\X0D\\X0A\cells with\X0D\\X0A\The following: TTF1 (+), AE1/3 (+), CK7 (+), p63 (focal weak +), Napsin (+),\X0D\\X0A\CK5/6 (diffuse weak +), surfactant (+). This immunoprofile is supportive of lung\X0D\\X0A\primary non-small cell carcinoma with immunophenotypic evidence of both squamous\X0D\\X0A\(p63, CK5/6) and glandular (napsin/surfactant) differentiation. \X0D\\X0A\**INITIALS IHC/a/CLS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[WWW], M.D., **NAME[XXX]\X0D\\X0A\Results:  Positive for a p.G12C (c.34>T) mutation in codon 12 of the KRAS gene.\X0D\\X0A\Interpretation:  Mutations in the KRAS gene are reported to correlate with poor\X0D\\X0A\prognosis and resistance to tyrosine kinase inhibitor therapies in patients with\X0D\\X0A\non-small-cell lung cancer.\X0D\\X0A\Signed:   **NAME[VVV M. UUU], Ph.D. FACMG    /ap\X0D\\X0A\See the complete scanned report for additional details.  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[TTT], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 28 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 28 2012]     By:  **NAME[SSS, RRR]\X0D\\X0A\     Date Reported:     **DATE[Oct 28 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned Fluorescence In Situ Hybridization (FISH)\X0D\\X0A\report from Genzyme Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:  \X0D\\X0A\Interpretation:  Negative for a rearrangement involving the ALK gene\X0D\\X0A\Signed:  **NAME[QQQ PPP], Ph.D.\X0D\\X0A\See the complete scanned report for additional details \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[XXX]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 29 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 29 2012]     By:  **NAME[OOO, NNN]\X0D\\X0A\     Date Reported:     **DATE[Oct 29 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned EGFR Mutation Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Results: No mutation detected.\X0D\\X0A\Interpretation: No mutations were identified in the sample provided for\X0D\\X0A\analysis.  Fewer than 5% of non-small cell lung carcinoma patients without\X0D\\X0A\identifiable mutations are reported to be responsive to EGFR tyrosine kinase\X0D\\X0A\inhibitor therapies.  \X0D\\X0A\Signed: **NAME[M. MMM LLL], Ph.D.\X0D\\X0A\See the complete scanned report for additional details \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[XXX",,"Gross Description\X0D\\X0A\Received in formalin labeled \""left lung biopsy\"" are strips and fragments of\X0D\\X0A\white tan tissue ranging to 1.1 cm in length.  These are 1.3 x 0.3 x 0.1 cm in\X0D\\X0A\aggregate and totally submitted in one cassette.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 21 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 21 2012]     By:  **NAME[KKK, JJJ]\X0D\\X0A\     Date Reported:     **DATE[Oct 21 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned ERCC1 Immunohistochemistry Analysis report\X0D\\X0A\from Genzyme Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Interpretation: Positive          \X0D\\X0A\Signed: **NAME[III M. HHH], M.D.\X0D\\X0A\See the complete scanned report for additional details  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[GGG], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 21 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 21 2012]     By:  **NAME[FFF,EEE]\X0D\\X0A\     Date Reported:     **DATE[Oct 21 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned EGFR FISH Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\EGFR/CEP7:  Positive.\X0D\\X0A\Signed:  Moscyr Da **NAME[DDD], M.D.    /ap\X0D\\X0A\See the complete scanned report for additional details  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[GGG], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 23 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 23 2012]     By:  **NAME[FFF,EEE]\X0D\\X0A\     Date Reported:     **DATE[Oct 23 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned KRAS Mutation Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report, in part:"
REG1,LUNG,0,494356,1,,Clinical Diagnosis and History\X0D\\X0A\INFORMATION NOT PROVIDED ON SURGICAL REQUISITION,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[XXX M].\X0D\\X0A\**NAME[YYY], M.D., **NAME[WWW]\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: COMPUTERIZED TOMOGRAPHYBONE  BIOPSY rd","Final Diagnosis\X0D\\X0A\BONE, CT GUIDED BIOPSY:\X0D\\X0A\     POORLY DIFFERENTIATED MALIGNANT NEOPLASM, SEE COMMENT.\X0D\\X0A\COMMENT: Would favor metastatic poorly differentiated adenocarcinoma. However,\X0D\\X0A\in order to further classify and determine tumor origin, additional\X0D\\X0A\immunohistochemical studies will be performed with results to follow as a\X0D\\X0A\supplemental report.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[VVV], M.D., **NAME[UUU]\X0D\\X0A\Results: Positive for a p.G12A  (c.35G>C)mutation in codon 12 of the KRAS gene.\X0D\\X0A\Interpretation: Mutations in the KRAS gene are reported to correlate with poor\X0D\\X0A\prognosis and resistance to tyrosin kinase inhibitor therapies in patients with\X0D\\X0A\non-small cell lung cancer.\X0D\\X0A\Signed: **NAME[TTT SSS], Ph.D.\X0D\\X0A\See the complete scanned report for additional details  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[RRR], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[May 7 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 7 2012]     By:  **NAME[QQQ, PPP]\X0D\\X0A\     Date Reported:     **DATE[May 7 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned Fluorescence In Situ Hybridization (FISH)\X0D\\X0A\report from Genzyme Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Interpretation:  Negative for a rearrangement involving the ALK gene.\X0D\\X0A\Signed:   **NAME[OOO NNN], Ph.D.\X0D\\X0A\See the complete scanned report for additional details \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[MMM], M.D., **NAME[LLL]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[May 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 9 2012]     By:  **NAME[QQQ, PPP]\X0D\\X0A\     Date Reported:     **DATE[May 9 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned EGFR Mutation Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Results:\X0D\\X0A\Interpretation: No mutations were identified in the sample provided for\X0D\\X0A\analysis.  Fewer than 5% of non-small cell lung carcinoma patients without\X0D\\X0A\identifiable mutations are reported to be responsive to EGFR tyrosine kinase\X0D\\X0A\inhibitor therapis.\X0D\\X0A\Signed:  Narasimhan Nagan, Ph.D, FACMG, DABCC\X0D\\X0A\See the complete scanned report for additional details \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[RRR], M.D.,  MARK E.",,"Gross Description\X0D\\X0A\Received in formalin designated \""bone biopsy\"" are cores of red purple tan tissue\X0D\\X0A\forming an aggregate 15 x 7 x 3 mm.  No definite bone identified.  Submitted in\X0D\\X0A\A.\X0D\\X0A\**INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 25 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 25 2012]     By:  **NAME[KKK, JJJ III]\X0D\\X0A\     Date Reported:     **DATE[Apr 25 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Results of immunohistochemical studies:\X0D\\X0A\Using appropriate positive and negative controls, the following antibodies (with\X0D\\X0A\results) are performed:  TTF-1 (positive), napsin (positive), CK7 (positive),\X0D\\X0A\CK5/6 (rare positive cell), p63 (negative), CD56 (negative), synaptophysin\X0D\\X0A\(negative).  The immunohistochemical studies in correlation with the morphologic\X0D\\X0A\findings are consistent with adenocarcinoma and metastasis from lung primary\X0D\\X0A\site.  \X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D., **NAME[UUU]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[May 2 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 2 2012]     By:  **NAME[HHH, GGG]\X0D\\X0A\     Date Reported:     **DATE[May 2 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Request received for KRAS / EGFR Mutation Analysis and ALK molecular testing\X0D\\X0A\from CBC.  Archived slides retrieved and reviewed with Block 1A selected and\X0D\\X0A\sent for testing (Genzyme Laboratories).\X0D\\X0A\CPT:  88363\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D., **NAME[UUU]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[May 6 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 6 2012]     By:  **NAME[HHH, GGG]\X0D\\X0A\     Date Reported:     **DATE[May 6 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned KRAS Mutation Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:"
REG1,LUNG,0,494455,1,,Clinical Diagnosis and History\X0D\\X0A\LUNG NODULE SUPERIOR SEGMENT LEFT LOWER LOBE\X0D\\X0A\OPER:  LEFT VAT\X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\#1FSDX:  NON-SMALL CELL CARCINOMA AT MARGIN.  **INITIALS \X0D\\X0A\#2FSDX (3 BLOCKS):  NO NEOPLASM SEEN.  **INITIALS,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: SUPERIOR SEGMENT LEFT LOWER LOBE-FS-CHECK MARGINS-ALSO NEED\X0D\\X0A\EGFR/ALK1/KRAS-PORTION SENT TO PRECISION-ls\X0D\\X0A\2: ADDITION RESECTION STAPLE LINE-FS-LOOK AT FIRST-ls\X0D\\X0A\3: HILAR LYMPH NODE-ag","Final Diagnosis\X0D\\X0A\1: \""SUPERIOR SEGMENT LEFT LOWER LOBE\"":\X0D\\X0A\     CAP TUMOR REPORTING PROTOCOL:\X0D\\X0A\     SPECIMEN/PROCEDURE: LEFT LOWER LOBE SEGMENTECTOMY.\X0D\\X0A\     SPECIMEN INTEGRITY: INTACT.\X0D\\X0A\     SPECIMEN LATERALITY: LEFT.\X0D\\X0A\     TUMOR SITE: LOWER LOBE.\X0D\\X0A\     TUMOR SIZE: 2.9 X 2.0 X 1.7 CM.\X0D\\X0A\     TUMOR FOCALITY: UNIFOCAL.\X0D\\X0A\     HISTOLOGIC TYPE: SQUAMOUS CARCINOMA.\X0D\\X0A\     HISTOLOGIC GRADE: MODERATE TO POORLY DIFFERENTIATED (GRADE 2-3).\X0D\\X0A\     VISCERAL PLEURAL INVASION: FOCALLY PRESENT  CONFIRMED ON ELASTIN STAINS.\X0D\\X0A\     MARGINS: SHAVE RESECTION MARGIN FOCALLY INVOLVED (SEE SPECIMEN #2 FOR \X0D\\X0A\        FINAL NEW MARGIN).\X0D\\X0A\     VASCULAR MARGIN: NOT APPLICABLE.\X0D\\X0A\     BRONCHIAL MARGIN: NOT APPLICABLE.\X0D\\X0A\     TREATMENT EFFECT: NOT APPLICABLE.\X0D\\X0A\     LYMPHOVASCULAR INVASION: NOT IDENTIFIED.\X0D\\X0A\     LYMPH NODES: PRESENT (ONE SITE SAMPLED  SPECIMEN #3)  UNINVOLVED.\X0D\\X0A\     PATHOLOGIC STAGING: T1b, N0 Mx.  Clinical and radiographic correlation\X0D\\X0A\required for final staging as\X0D\\X0A\         determined by the treating physician.\X0D\\X0A\2: \""ADDITIONAL RESECTION STAPLE LINE\"":\X0D\\X0A\     BENIGN LUNG TISSUE.\X0D\\X0A\     NO NEOPLASM IDENTIFIED AFTER REMOVAL OF STAPLE LINES.\X0D\\X0A\3: \""HILAR LYMPH NODE\"":\X0D\\X0A\     BENIGN ANTHRACOTIC LYMPHOID TISSUE.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[ZZZ], M.D., **NAME[YYY]",,"Gross Description\X0D\\X0A\1:  Received fresh for frozen section evaluation labeled \""superior segment left\X0D\\X0A\lower lobe\"" is a portion of gray lung tissue, 13.5 x 5.5 cm, ranging to 2.9 cm\X0D\\X0A\in thickness.  Multiple staple lines are present.  Focally abutting the margin\X0D\\X0A\is a portion of tan white tumor, 0.5 cm in diameter.  Sectioning reveals\X0D\\X0A\underlying this focus of tumor abutting the margin, the remainder of the tumor,\X0D\\X0A\measuring 2.9 x 2.0 x 1.7 cm which abuts the overlying pleura, which is puckered\X0D\\X0A\and dimpled in this area. The remainder of the lung is congested; however, no\X0D\\X0A\additional suspicious areas are seen.  Shaved section of the margin is submitted\X0D\\X0A\as frozen section.  \X0D\\X0A\SUMMARY OF SECTIONS: \X0D\\X0A\1A, B, C:  Representative sections of tumor with overlying pleura.\X0D\\X0A\1D, E, F:   Additional lung tissue.\X0D\\X0A\NOTE:  Fresh tissue is submitted to Precision Laboratories for chemosensitivity\X0D\\X0A\studies and as per request from Dr. **NAME[XXX].  Additional tissue is also submitted\X0D\\X0A\for EGFR, ALK1 and KRAS.  **INITIALS  \X0D\\X0A\2: Received fresh for frozen section evaluation labeled \""additional resection\X0D\\X0A\staple line\"" is a portion of red tan lung tissue 7.0 x 1.7 cm ranging to 0.8 cm\X0D\\X0A\in thickness containing multiple staple lines.  The pleural surface where\X0D\\X0A\recognizable is smooth and glistening.  The staple lines are removed with\X0D\\X0A\difficulty and the remaining lung tissue serially sectioned revealing a\X0D\\X0A\congested, slightly firm cut surface.  No discrete focal abnormalities are seen.\X0D\\X0A\ All submitted as frozen section (3 blocks).  **INITIALS\X0D\\X0A\3: In formalin labeled \""hilar lymph node\"" are multiple angulated fragments of\X0D\\X0A\gray black soft tissue 2.5 x 1.5 x 0.6 cm.  The larger fragments are divided. \X0D\\X0A\All submitted in block 3A.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 30 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 30 2012]     By:  **NAME[WWW,VVV]\X0D\\X0A\     Date Reported:     **DATE[Apr 30 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Additional data elements as requested by cancer registry personell:\X0D\\X0A\     TUMOR EXTENSION:  Not applicable.\X0D\\X0A\     PARIETAL PLEURAL MARGIN:  Not applicable.\X0D\\X0A\     CHEST WALL MARGIN:  Not applicable.\X0D\\X0A\     OTHER ATTACHED TISSUE MARGIN:  Not applicable.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[May 5 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[May 5 2012]     By:  **NAME[WWW,VVV]\X0D\\X0A\     Date Reported:     **DATE[May 6 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\For details see the complete separately scanned ChemoFx report from Precision\X0D\\X0A\Therapeutics in the electronic medical records file.   /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **NAME[YYY]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Jun 15 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Jun 15 2012]     By:  **NAME[WWW,VVV]\X0D\\X0A\     Date Reported:     **DATE[Jun 15 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\For details see the complete separately scanned BioSpeciFx report from Precision\X0D\\X0A\Therapeutics Laboratories in the electronic medical records file.   /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[ZZZ], M.D., **NAME[YYY"
REG1,LUNG,0,494940,1,,CLINICAL HISTORY: **AGE[in 60s] year old female with recurrent left upper lobe pneumonia. CT shows left hilar mass. Bronchoscopy shows narrowing of apical posterior segment.  See also ***PATH-NUMBER[1] same-day cytology.,"Submitting Physician: KOIRALA, KANCHAN. Status: SOUT. Final Signout: **NAME[ZZZ M YYY], XXX] PhD **DATE[Dec 04 11]","FINAL DIAGNOSIS: LEFT UPPER LOBE OF LUNG, BIOPSY BRONCHIAL BIOPSY WITH FEATURES OF ADENOCARCINOMA. SEE COMMENT.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and \""biopsy left upper lobe.\""  The specimen is received in formalin and consists of a fragment of white-tan tissue, measuring less than 1 mm. in greatest dimensions.  The specimen is totally submitted in one block.","COMMENT WORD: The microscopic sections of biopsy from the left upper lobe of the lung reveal a proliferation of epithelial cells demonstrating mild atypia and forming gland-like structures.  The cells contain slightly enlarged, hyperchromatic nuclei with punctuate, variably sized nucleoli.  There is cellular crowding with occasional mitotic figures.  The findings are felt to indicate the presence of adenocarcinoma consistent with a lung primary. The findings should be correlated with clinical history and symptomatology.",Specimen Number: ***PATH-NUMBER[2]. Tissues: Left upper lobe of lung. Specimen Comments:,,
REG1,LUNG,0,494957,1,,HISTORY: Pneumonia.,"ICD9 CODES: 162.9, ,""",,,"GROSS: Received and labeled with the patient's name are two containers.  Container #1 is labeled \""brushing, left lung\"" and consists of four slides in alcohol.  Submitted for cytology stain as #1.  The second specimen is labeled \""biopsy, left lung\"" and consists of multiple tan fragments of tissue measuring less than 0.1 cm.  The specimen is filtered and submitted for TE as #2.  DT:  **DATE[Aug 08 12]","MICRO: Microscopic examination was performed.  DT:  **DATE[Aug 10 12] (DRB, bsp)","PROCEDURE: Cytology bronchial brushing.\X0D\\X0A\SPECIMEN(S): 1) Bronchial brushings, left lung  2) Biopsy, left lung.",,
REG1,LUNG,0,495052,1,,"Clinical Diagnosis and History\X0D\\X0A\MALIGNANT PLEURAL EFFUSION \X0D\\X0A\OPER:   LEFT VAT\X0D\\X0A\Intraoperative Consult\X0D\\X0A\#2FSDX:  MALIGNANT TUMOR, FAVOR ADENOCARCINOMA.  CMK/in","4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ, YYY]., M.D., H. DALE\X0D\\X0A\**NAME[XXX], M.D., **NAME[WWW M].\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: PLEURA SEND FOR BIOMARKERS SENT TO PRECISION lg\X0D\\X0A\2: PLEURA FROZEN lg\X0D\\X0A\3: VISCERAL PLEURAL ls","Final Diagnosis\X0D\\X0A\1:  PLEURA \X0D\\X0A\     ENTIRE SPECIMEN FORWARDED TO PRECISION THERAPEUTICS.\X0D\\X0A\2:  PLEURA \X0D\\X0A\     ADENOCARCINOMA.\X0D\\X0A\3:  VISCERAL PLEURA \X0D\\X0A\     LUNG WITH ADENOCARCINOMA IN VISCERAL PLEURA.\X0D\\X0A\Comment: I do not see carcinoma within pulmonary parenchyma.  It is about the\X0D\\X0A\pleural surface only.   Immunoperoxidase stains were performed at Genzyme\X0D\\X0A\Laboratories on a prior cytology specimen (***PATH-NUMBER[1]).  Their report on that\X0D\\X0A\specimen states that the results are consistent with metastatic adenocarcinoma\X0D\\X0A\of lung primary.  If additional stains are desired on the current pleural\X0D\\X0A\biopsy, please contact the laboratory.\X0D\\X0A\CMK/in \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[VVV], M.D., **PLACE",,"Gross Description\X0D\\X0A\1:  Received fresh on Telfa for submission to Precision Therapeutics designated\X0D\\X0A\'pleura' are fragments of somewhat firm rubbery gray white pink tissue forming\X0D\\X0A\an aggregate 35 x 33 x up to 9 mm.  A portion of the specimen is submitted in a\X0D\\X0A\vial designated 'chemofix', the remainder is submitted in a container designated\X0D\\X0A\PATH-TECH which is stated to contain 10% neutrobuffered formalin.\X0D\\X0A\2:  Received fresh for frozen diagnosis designated 'pleura' are fragments of\X0D\\X0A\rubbery somewhat firm pink tan focally yellow tissue forming an aggregate 17 x\X0D\\X0A\17 x up to 7 mm.  The remainder is submitted in cassettes A and B at 2:20 pm. \X0D\\X0A\CMK/in \X0D\\X0A\3:  Received in formalin labeled \""visceral pleura\"" is an irregular piece of pink\X0D\\X0A\tan tissue, 2.5 x 1.6 x 0.6 cm in overall dimension.  This shows no focal\X0D\\X0A\lesions.  This is sectioned and totally submitted as 3.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 12 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 12 2012]     By:  **NAME[UUU,TTT]\X0D\\X0A\     Date Reported:     **DATE[Mar 12 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding KRAS mutation analysis.\X0D\\X0A\RESULTS:  Wild-type gene.\X0D\\X0A\INTERPRETATION:  No mutations were identified at codons 12 and 13 of the KRAS\X0D\\X0A\gene.\X0D\\X0A\Signed:  **NAME[M. SSS RRR], Ph.D., FACMG  /ap \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 13 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 13 2012]     By:  **NAME[UUU,TTT]\X0D\\X0A\     Date Reported:     **DATE[Mar 13 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report from Genzyme Laboratories in the electronic\X0D\\X0A\medical records file regarding ALK by FISH. \X0D\\X0A\INTERPRETATION, in part, reads:\X0D\\X0A\Negative for a rearrangement involving the ALK gene.\X0D\\X0A\Signed:  **NAME[QQQ PPP], Ph.D.    /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 15 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 15 2012]     By:  **NAME[OOO, NNN]\X0D\\X0A\     Date Reported:     **DATE[Mar 15 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned report regarding EGFR Mutation Analysis from Genzyme\X0D\\X0A\Laboratories in electronic medical file.\X0D\\X0A\Their report, in part:\X0D\\X0A\INTERPRETATION: No mutations were identified; however 18-20% of patients with\X0D\\X0A\non-small-cell lung cancer and without identifiable mutations are reported to be\X0D\\X0A\responsive to EGFR tyrosine kinase inhibitor therapies.\X0D\\X0A\Signed: **NAME[MMM LLL], Ph.D.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[KKK], M.D., **NAME[JJJ]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 28 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 28 2012]     By:  **NAME[III, HHH GGG]\X0D\\X0A\     Date Reported:     **DATE[Mar 28 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned ChemoFx report from Precision Therapeutics in the\X0D\\X0A\electronic medical records file. \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[VVV], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Apr 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Apr 9 2012]     By:  **NAME[OOO, NNN]\X0D\\X0A\     Date Reported:     **DATE[Apr 9 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See separately scanned BioSpeciFx report from Precision Therapeutics in\X0D\\X0A\electronic medical file.\X0D\\X0A\**INITIALS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[KKK], M.D., **NAME[JJJ"
REG1,LUNG,0,495077,1,,Clinical Diagnosis and History\X0D\\X0A\RT LUNG NODULE\X0D\\X0A\OPER:   BIOPSY,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: **NAME[ZZZ], M.D., **NAME[XXX]\X0D\\X0A\**NAME[YYY], M.D., KHALID Z.\X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: RT LUNG BIOPSY-3 CORES-ls","Final Diagnosis\X0D\\X0A\\""RIGHT LUNG BIOPSY\"", NEEDLE BIOPSIES:\X0D\\X0A\     NON-SMALL CELL CARCINOMA (SEE COMMENT).\X0D\\X0A\COMMENT: Immunostains are pending for further characterization.  A supplemental\X0D\\X0A\report will follow.\X0D\\X0A\**INITIALS \X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[WWW], M.D., **NAME[VVV]\X0D\\X0A\Results:  Wild-type gene.\X0D\\X0A\Interpretation:  No mutations were identified at codons 12 and 13 of the KRAS\X0D\\X0A\gene.\X0D\\X0A\Signed:   **NAME[M. UUU TTT], Ph.D., FACMG  /ap \X0D\\X0A\See the complete scanned report for additional details.  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Nov 9 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Nov 9 2012]     By:  **NAME[SSS, RRR]\X0D\\X0A\     Date Reported:     **DATE[Nov 9 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned EGFR Mutation Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Results: No mutation detected.\X0D\\X0A\Interpretation: No mutations were identified in the sample provided for\X0D\\X0A\analysis.  Few than 5% of non-small lung carcinoma patients without identifiable\X0D\\X0A\mutations are reported to be responsive to EGFR tyrosine kinase inhibitor\X0D\\X0A\therapies.\X0D\\X0A\Signed:  **NAME[QQQ PPP] Ph.D.\X0D\\X0A\See the complete scanned report for additional details\X0D\\X0A\**INITIALS  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Nov 13 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Nov 13 2012]     By:  **NAME[OOO, NNN]\X0D\\X0A\     Date Reported:     **DATE[Nov 13 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned ALK FISH report from Genzyme Laboratories in\X0D\\X0A\the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Interpretation: Negative for a rearrangement  involving the ALK gene.\X0D\\X0A\Signed: **NAME[MMM LLL], M.D., FACMG\X0D\\X0A\See the complete scanned report for additional details\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV",,"Gross Description\X0D\\X0A\Received in formalin, site not designated on container, are three cores of tan\X0D\\X0A\tissue measuring up to 18 mm in length.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 27 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 27 2012]     By:  **NAME[KKK,JJJ]\X0D\\X0A\     Date Reported:     **DATE[Oct 27 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\Immunostains with appropriate controls show tumor cells to be diffusely and\X0D\\X0A\strongly positive for TTF1, napsin, CK7, and pancytokeratin, with negative\X0D\\X0A\staining for CK20, CK5-6, mammaglobin and gross cystic disease fluid protein. \X0D\\X0A\Tumor cells are focally positive for surfactant with only rare nuclear staining\X0D\\X0A\for P63.  \X0D\\X0A\This immunoprofile is supportive of a diagnosis of lung primary adenocarcinoma. \X0D\\X0A\**INITIALS IHC/a/CLS \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Oct 31 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Oct 31 2012]     By:  **NAME[III, HHH]\X0D\\X0A\     Date Reported:     **DATE[Oct 31 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned ERCC1 Immunohistochemistry Analysis report\X0D\\X0A\from Genzyme Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\Interpretation: Negative.\X0D\\X0A\Signed:  **NAME[DDD M EEE], GGG]., M.D.\X0D\\X0A\See the complete scanned report for additional details  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[FFF], M.D.,  MARK E.\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Nov 3 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Nov 3 2012]     By:  **NAME[EEE, zzz yyy]\X0D\\X0A\     Date Reported:     **DATE[Nov 3 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned EGFR FISH Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report in part:\X0D\\X0A\EGFR/CEP7:  Negative.\X0D\\X0A\Signed: **NAME[xxx www], M.D.\X0D\\X0A\See the complete scanned report for additional details.  \X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[WWW], M.D., **NAME[VVV]\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Nov 5 2012]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Nov 5 2012]     By:  **NAME[KKK,JJJ]\X0D\\X0A\     Date Reported:     **DATE[Nov 6 2012]         \X0D\\X0A\Addendum Comment\X0D\\X0A\See the complete separately scanned KRAS Mutation Analysis report from Genzyme\X0D\\X0A\Laboratories in the electronic medical records file.\X0D\\X0A\Their report, in part:"
REG1,LUNG,0,495123,1,,HISTORY: left lung mass,"ICD9 CODES: 162.8, , \X0D\\X0A\COMMENTS: The slides were seen in consultation with Dr. **NAME[ZZZ YYY], who agrees with the above diagnosis.  Results called to Dr. **NAME[XXX] on **DATE[Nov 21 12] at 12:50 pm.","DIAGNOSIS: 1 -  BRONCHIAL WASHINGS FROM LEFT LINGULA:             ATYPICAL CELLS ARE PRESENT \X0D\\X0A\SUSPICIOUS FOR MALIGNANCY.  2 -  BRONCHIAL BRUSHINGS FROM LEFT LINGULA:             SQUAMOUS CARCINOMA.  3 -  LEFT LUNG, LINGULA, TRANSBRONCHIAL BIOPSY:             MODERATELY DIFFERENTIATED SQUAMOUS CARCINOMA.",,"GROSS: Received with patient's name are three specimens. First is labeled \""washings left lingula\"" and consists of approximately 60 cc of red hazy fluid. Cell block and cytospins are submitted as #1. Second specimen is labeled \""brushings left lingula\"" and consists of six slides submitted in alcohol fixative. Slides are submitted for cytology staining as #2. Third specimen is labeled \""biopsy left lingula\"" and consists of multiple tan fragments of tissue, the largest of which measures up to 0.2 cm. Specimen is submitted for TE as #3. DT: **DATE[Nov 20 2012]","MICRO: Microscopic examination was performed.  DT:  **DATE[Nov 21 12] (DRB, bsp)",PROCEDURE: Bronchoscopy\X0D\\X0A\SPECIMEN(S): 1) washings left lingula  2) brushings left lingula  3) biopsy left lingula,,
REG1,LUNG,0,495217,3,,,"SEE BELOW\X0D\\X0A\**INSTITUTION\X0D\\X0A\**STREET-ADDRESS, **PLACE Ky  **ZIP-CODE\X0D\\X0A\Department of Cytology\X0D\\X0A\**NAME[BBB, AAA]\X0D\\X0A\MRN:  **ID-NUM                        **ID-NUM-FNA\X0D\\X0A\COPIES TO:             **NAME[ZZZ]  **NAME[YYY], MD\X0D\\X0A\CLINICAL      HISTORY OF BREAST CANCER\X0D\\X0A\DATA:\X0D\\X0A\SPECIMEN:     FNA LUNG, RIGHT LOWER LOBE","FINAL DIAGNOSIS:\X0D\\X0A\Non-small cell carcinoma.\X0D\\X0A\The specimen shows malignant cells morphologically consistent with\X0D\\X0A\non-small cell carcinoma. Immunohistochemical stains (CK7, TTF-1,\X0D\\X0A\CK5/6, p63, ER and mammoglobin) wit appropriately working controls were\X0D\\X0A\performed on the cellblock for qualitative impression. The malignant\X0D\\X0A\cells are positive for CK7 and TTF-1, they show focal faint staining\X0D\\X0A\for CK5/6 and p63 and they are negative for ER and mammoglobin. The\X0D\\X0A\immnohistochemical pattern is consistent with carcinoma from lung\X0D\\X0A\origin and it favors adenocarcinoma.  No evidence of metastatic breast\X0D\\X0A\carcinoma is present.\X0D\\X0A\PEER: KZK, MRJ\X0D\\X0A\Adequacy of specimen was checked using the Diff-Quick staining\X0D\\X0A\technique.\X0D\\X0A\Preliminary diagnosis of rapid evaluation:  Passes one through three\X0D\\X0A\were reviewed and showed marginally adequate material./SXH\X0D\\X0A\REVISED COMMENT:  Per request of Dr. **NAME[XXX WWW], after this case was\X0D\\X0A\signed-out, archived block(s) and slide(s) were pulled and reviewed by\X0D\\X0A\the pathologist, along with review of the corresponding pathology\X0D\\X0A\report, in order to select appropriate slide(s)/block(s) for the\X0D\\X0A\requested EGFR mutation and ALK translocation  molecular studies.  This\X0D\\X0A\testing is now complete.  Please see the scanned reference laboratory's\X0D\\X0A\findings as the last page(s) of this KDMC report.\X0D\\X0A\ REVISION REASON:  This report is being issued to document the results\X0D\\X0A\of ancillary molecular testing on archived material.\X0D\\X0A\                                    <Sign Out Dr. **NAME[VVV]>\X0D\\X0A\Screened By : EMR                   **NAME[UUU TTT], MD\X0D\\X0A\                              Page 1 of 1\X0D\\X0A\http://kdlab1/LIVE.as/SoftImageWebApp_3.1/show/I4XkBmDlPzuDtHEemZt3cK8EtTFjfx34AGnTrX8RQ4MgU+8jgQuzXbJL0dtig//DzBW1q6E6nxMYYeb6H47Oex6epaoXQi4W\S\REPORT",,,,Specimen Description:            Materials Examined:\X0D\\X0A\Volume ................30 ml     Smear Slides .......... 10\X0D\\X0A\Consist.................fluid    Cell Blocks ..............1\X0D\\X0A\                                 Monolayers ............ 1\X0D\\X0A\Fixed ...................Y       Special Stains ........ 14\X0D\\X0A\Bloody..................Y\X0D\\X0A\Other: with red flecks,,
REG1,LUNG,0,495651,1,,"CLINICAL INFORMATION\X0D\\X0A\PRE-OP DIAGNOSIS:  Respiratory failure           POST-OP DIAGNOSIS:\X0D\\X0A\Endobroncho mass, endobronch atelectasis.",FINAL SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       RAMI **NAME[ZZZ]       SIGN OUT DATE:   **DATE[Jul 06 2012]\X0D\\X0A\COPIES TO:          RAMI **NAME[ZZZ,"DIAGNOSIS\X0D\\X0A\LUNG, ENDOBRONCHIAL LESION, RIGHT UPPER LOBE, BRONCHIAL BIOPSY:\X0D\\X0A\FEATURES COMPATIBLE WITH SMALL CELL CARCINOMA VERSES SQUAMOUS\X0D\\X0A\CARCINOMA.  SEE COMMENT. FAVOR NON-SMALL CELL CARCINOMA.\X0D\\X0A\CPT4 88305 / ICD9 162.3 / PC: 332.4 / MC: M80003\X0D\\X0A\OUTSIDE CONSULTATION (Reviewed by Dr. **NAME[YYY XXX] at P\T\C\X0D\\X0A\Laboratories) See separate outside report.\X0D\\X0A\CONSULTANT's DIAGNOSIS:\X0D\\X0A\LUNG, RIGHT UPPER LOBE, ENDOBRONCHIAL LESION, BIOPSY: Extensive\X0D\\X0A\necrosis with very focal areas of apparent non-small cell carcinoma.\X0D\\X0A\SPECIAL STAINS:  Immunoperoxidase studies were attempted for LEUM-1,\X0D\\X0A\TTF-1, CK5/6, P63, Chromogranin, and CD56 with appropriate controls.\X0D\\X0A\There is no significant staining of the limited tumor present on the\X0D\\X0A\immunostain levels for any of the tested markers.  Based upon the\X0D\\X0A\histologic findings and the reported cytology findings, which was\X0D\\X0A\again reviewed, this appears to be compatible with a non-small cell\X0D\\X0A\carcinoma. See outside report for further details.\X0D\\X0A\ANCILLARY STUDIES (Cytology specimens processed at P\T\C Laboratories and\X0D\\X0A\reviewed by Dr. **NAME[WWW VVV])\X0D\\X0A\CYTOLOGY RESULTS (11-PM-742 / SPECIMENS 1 THROUGH 6) See separate\X0D\\X0A\outside reports\X0D\\X0A\1.) BRONCH BRUSH, RIGHT: Malignant (Neoplastic cells consistent with\X0D\\X0A\poorly differentiated carcinoma, not small cell type, are present,\X0D\\X0A\favor squamous cell carcinoma.)\X0D\\X0A\2.) BRONCH WASH, LEFT: Malignant (Neoplastic cells consistent with\X0D\\X0A\poorly differentiated carcinoma, not small cell type, are present,\X0D\\X0A\favor squamous cell carcinoma.)\X0D\\X0A\3.) BRONCH WASH, RIGHT: Malignant (Neoplastic cells consistent with\X0D\\X0A\poorly differentiated carcinoma, not small cell type, are present,\X0D\\X0A\favor squamous cell carcinoma.)\X0D\\X0A\4.) BRONCH WASH, RIGHT (ALL LOBES): Negative for malignant cells.\X0D\\X0A\(Pulmonary macrophages and inflammatory cells are present.)\X0D\\X0A\5.) BRONCH WASH, RIGHT UPPER LOBE: Malignant (Neoplastic cells\X0D\\X0A\consistent with poorly differentiated carcinoma, not small cell\X0D\\X0A\type, are present, favor squamous cell carcinoma.)\X0D\\X0A\6.) PLEURAL FLUID:   Malignant (Neoplastic cells consistent with\X0D\\X0A\poorly differentiated carcinoma, not small cell type, are present,\X0D\\X0A\favor squamous cell carcinoma.)",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is labeled \""endobronchial lesion right upper lobe, biopsy\""\X0D\\X0A\and consists of grey tan irregular fragments of soft tissue, the total\X0D\\X0A\cluster measures 1 x 0.3 x 0.1 cm.  The entire specimen is submitted in\X0D\\X0A\one cassette.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Sections of the right upper lobe bronchial biopsy show cartilaginous\X0D\\X0A\material and portions of the bronchial mucosa and submucosa with\X0D\\X0A\fibrous connective tissue present along with an acute inflammatory\X0D\\X0A\infiltrate.  Debris is also present.  Bronchial and sub-bronchial\X0D\\X0A\tissue is present.  Muscle fibers are seen.  Clusters of epithelial\X0D\\X0A\cells are noted.  Cartilaginous bronchial structures are present as\X0D\\X0A\well.  Atypical features are present, cannot exclude a malignant\X0D\\X0A\process.  The features are compatible with small cell carcinoma verses\X0D\\X0A\squamous carcinoma.\X0D\\X0A\<Sign Out Dr. **NAME[UUU]>\X0D\\X0A\**NAME[TTT SSS], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","TISSUE SUBMITTED:  LUNG, BIOPSY, SURGICAL EXCISION\X0D\\X0A\Endobroncho lesion\X0D\\X0A\right upper lobe, bronch",,
REG1,LUNG,0,495683,1,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Right lung mass,"REVISED SURGICAL PATHOLOGY REPORT\X0D\\X0A\PHYSICIAN:       **NAME[ZZZ YYY]    SIGN OUT DATE:   **DATE[Nov 12 2012]\X0D\\X0A\COPIES TO:          **NAME[ZZZ YYY]\X0D\\X0A\REVISED DATE: **DATE[Nov 13 2012]\X0D\\X0A\NOTE:  The revised report reflects the addition of the cytology\X0D\\X0A\resultst.  No other changes were made to this report.\X0D\\X0A\<Sign Out Dr. **NAME[XXX]>\X0D\\X0A\**NAME[CCC ZZZ], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","FROZEN SECTION DIAGNOSIS\X0D\\X0A\MEDIASTINAL MASS, 1FS-1:  METASTATIC LARGE-CELL CARCINOMA,\X0D\\X0A\NON-KERATINIZING, SQUAMOUS VARIETY.\X0D\\X0A\FROZEN SECTION REPORT CALLED TO DR. **NAME[YYY] **DATE[Nov 11 12] AT 9:47AM.\X0D\\X0A\**NAME[CCC M. ZZZ], M.D\X0D\\X0A\DIAGNOSIS\X0D\\X0A\1. MEDIASTINAL MASS, 1FS-1:  METASTATIC TUMOR, LARGE-CELL,\X0D\\X0A\NON-KERATINIZING                     FEATURES.\X0D\\X0A\MEDIASTINAL MASS, PERMANENT:  LARGE-CELL EPIDERMOID CARCINOMA WITH\X0D\\X0A\KERATINIZATION SEEN.\X0D\\X0A\2. LUNG, RIGHT UPPER LOBE, BIOPSY:  COLLAPSE OF ALVEOLAR SPACES,\X0D\\X0A\DENSE FIBROUS CONNECTIVE TISSUE PROLIFERATION WITH A NODULE OF\X0D\\X0A\KERATINIZING SQUAMOUS CARCINOMA SCATTERED THROUGHOUT THE\X0D\\X0A\ARCHITECTURE WITH SOME ACUTE INFLAMMATION.\X0D\\X0A\3. LYMPH NODE, MEDIASTINAL LYMPH NODE:  MEDIASTINAL LYMPH  NODE\X0D\\X0A\FRAGMENTS TWO (2), SIX LEVELS , ALL NEGATIVE FOR TUMOR.\X0D\\X0A\4. MASS, MEDIASTINAL MASS:  METASTATIC LARGE-CELL CARCINOMA,\X0D\\X0A\KERATINIZING VARIETY.\X0D\\X0A\CPT4 88331 X 1, 88305 X 2, 88307 X 2 / ICD9 162.9, 162.3 / PC\X0D\\X0A\342.2, 342.5, 401.1, M80123, M80713\X0D\\X0A\ANCILLARY STUDIES (Processed at P\T\C Laboratories and reviewed by Dr.\X0D\\X0A\F. **PLACE Picklesimer)\X0D\\X0A\CYTOLOGY RESULTS (11-PM-32 / SPECIMENS 1\T\2) See separate outside\X0D\\X0A\reports.\X0D\\X0A\SPECIMEN SUBMITTED NAME:\X0D\\X0A\1. BAL FLUID, RIGHT UPPER LOBE:  Atypical.\X0D\\X0A\2. BRONCHIAL BRUSHING, RIGHT UPPER LOBE:  Malignant.",,"GROSS DESCRIPTION\X0D\\X0A\Specimen one is received for frozen section diagnosis labeled\X0D\\X0A\\""mediastinal mass\"" and consist of a 0.5 cm thin disc of red soft\X0D\\X0A\tissue.  The entire cluster is submitted for frozen section.  The\X0D\\X0A\frozen section portion is all of the tissue received and is submitted\X0D\\X0A\in one cassette labeled 1FS-1.\X0D\\X0A\Specimen two is labeled \""right upper lobe biopsy\"" and consists of\X0D\\X0A\minute fragments of tiny tan tissue measuring 0.1 to 0.2 cm.  The total\X0D\\X0A\cluster measures 0.3 cm. All are submitted in one cassette labeled 2.\X0D\\X0A\Specimen three is labeled \""right mediastinal lymph node\"" and consists\X0D\\X0A\of two tan-red nodes measuring 0.3 and 0.4 cm.  Both are submitted in\X0D\\X0A\one cassette labeled 3.\X0D\\X0A\Specimen four is labeled \""mediastinal mass\"" and consists of a red-tan\X0D\\X0A\fragment of tissue measuring 0.4 cm and another measuring 0.3 cm and\X0D\\X0A\some black tissue measuring 0.1 x 0.3 cm.  All tissue is submitted in\X0D\\X0A\one cassette labeled 4.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Review of the mediastinal mass, 1FS-1, show a metastatic tumor of\X0D\\X0A\epithelial origin, large-cell, non-keratinizing lesion present in\X0D\\X0A\bundles and clusters scattered throughout the entire mass submitted for\X0D\\X0A\frozen section.  After H\T\E staining, sections of the mediastinal mass,\X0D\\X0A\1FS-1, show malignant epithelial tumor in nodules and clusters within\X0D\\X0A\the frozen section portion.  Diffuse involvement of the mediastinal\X0D\\X0A\tissue by this tumor is noted.  Permanent section of the frozen section\X0D\\X0A\portion shows a malignant metastatic tumor, large-cell epithelial\X0D\\X0A\variety, non-keratinizing tumor present.\X0D\\X0A\Sections of the right upper lobe lung biopsy, 2A-1, show alveolar\X0D\\X0A\tissue, dense septal walls and a cellular infiltrate of cells having\X0D\\X0A\features compatible with large-cell squamous carcinoma with\X0D\\X0A\inflammation present.  Desmoplastic response and cells are free within\X0D\\X0A\the alveolar spaces.  The cells have large oval nuclei and prominent\X0D\\X0A\nucleoli with dense clumped chromatin.  Inflammation is also present.\X0D\\X0A\Sections of the right mediastinal lymph node, 3A-1, show more of the\X0D\\X0A\mediastinal lymph node architecture with diffuse hyperplasia in the\X0D\\X0A\residual fragments.  A nodular proliferation is noted.  The lymph node\X0D\\X0A\structure is sectioned serially and three levels are identified in this\X0D\\X0A\one block and is sectioned and no tumor is seen.\X0D\\X0A\Sections of the mediastinal mass, 4A-1, show metastatic large-cell,\X0D\\X0A\keratinizing, squamous carcinoma with irregular clusters and bundles\X0D\\X0A\streaming through the mediastinal mass.  Mitotic activity is plentiful.\X0D\\X0A\Individual cell keratinization is seen in small cells with keratin\X0D\\X0A\production present.  Deeper sections of the mediastinal mass show large\X0D\\X0A\cell carcinoma scattered throughout with individual cell\X0D\\X0A\keratinization.  Keratin pearl formation is present.  Dense pink\X0D\\X0A\cytoplasm is present in multiple clusters of this tumor.","TISSUE SUBMITTED:  (1) MASS, SURGICAL EXCISION\X0D\\X0A\Mediastinal mass\X0D\\X0A\(2) LUNG, BIOPSY,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Right upper lobe\X0D\\X0A\biopsy\X0D\\X0A\(3) LYMPH NODES,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Mediastinal lymph\X0D\\X0A\node\X0D\\X0A\(4) MASS, SURGICAL\X0D\\X0A\EXCISION\X0D\\X0A\Mediastinal mass",,
REG1,LUNG,0,495702,1,,CLINICAL INFORMATION\X0D\\X0A\PRE \T\ POST-OP DIAGNOSIS:  Cancer,"**NAME[ZZZ]\X0D\\X0A\REVISED SURGICAL PATHOLOGY REPORT\X0D\\X0A\**NAME[ZZZ]\X0D\\X0A\PHYSICIAN:       **NAME[YYY XXX]    SIGN OUT DATE:   **DATE[May 04 2012]\X0D\\X0A\COPIES TO:          **NAME[YYY XXX]\X0D\\X0A\**NAME[WWW VVV]\X0D\\X0A\REVISED DATE: **DATE[May 20 2012]\X0D\\X0A\Note:  The revised report reflects the addition of the consultant's\X0D\\X0A\diagnosis.  No other changes were made to this report.\X0D\\X0A\<Sign Out Dr. **NAME[UUU]>\X0D\\X0A\**NAME[CCC YYY], M.D, PATHOLOGIST\X0D\\X0A\Page 1 of 1","FROZEN SECTION DIAGNOSIS\X0D\\X0A\LYMPH NODES, ANTERIOR TRACHEAL LYMPH NODE (1FS-1):  METASTATIC LARGE\X0D\\X0A\CELL CARCINOMA COMPATIBLE WITH SQUAMOUS CELL CARCINOMA.  NO\X0D\\X0A\KERATINIZATION SEEN BY FROZEN SECTION.\X0D\\X0A\FROZEN SECTION REPORT CALLED TO DR. **NAME[XXX] ON **DATE[Apr 30 12] AT  11:22 AM.\X0D\\X0A\**NAME[CCC M. YYY], M.D\X0D\\X0A\DIAGNOSIS\X0D\\X0A\LYMPH NODES, ANTERIOR TRACHEAL LYMPH NODE (1FS-1):  MALIGNANT\X0D\\X0A\LARGE-CELL NEOPLASM, EPITHELIAL IN CHARACTER, NO KERATINIZATION SEEN.\X0D\\X0A\LYMPH NODES, ANTERIOR TRACHEAL LYMPH NODE, PERMANENT SECTION:\X0D\\X0A\MALIGNANT TUMOR, LARGE CELL VARIETY WITH NO KERATINIZATION IDENTIFIED.\X0D\\X0A\LYMPH NODES, ANTERIOR TRACHEAL LYMPH NODE:  CLUSTERS OF MALIGNANT\X0D\\X0A\TISSUE SCATTERED THROUGHOUT COMAPTIBLE WITH A LARGE CELL CARCINOMA,\X0D\\X0A\POOR DIFFERENTIATION, NO KERATINIZATION SEEN.\X0D\\X0A\CPT4 88331, 88305 X 2 / ICD9 96.0, M80726\X0D\\X0A\OUTSIDE CONSULTATION (Sent to P\T\C Laboratories, Dr. **NAME[TTT M. SSS])\X0D\\X0A\CONSULTANT's DIAGNOSIS:  ANTERIOR TRACHEAL LYMPH NODE BIOPSIES:\X0D\\X0A\Metastatic non-small cell carcinoma most consistent with poorly\X0D\\X0A\differentiated adenocarcinoma.\X0D\\X0A\ANCILLARY STUDIES (Processed at P\T\C Laboratories and reviewed by Dr.\X0D\\X0A\**NAME[TTT M. SSS])\X0D\\X0A\CYTOLOGY RESULTS (11-PM-821 / Specimen 1) See separate outside reports\X0D\\X0A\SPECIMEN SUBMITTED NAME:  **NAME[DDD] Washing, Left:  Negative for\X0D\\X0A\malignant cells.",,"GROSS DESCRIPTION\X0D\\X0A\Specimen one is received fresh for frozen section labeled \""anterior\X0D\\X0A\tracheal lymph node\"" and consists of two fragments of grey tan soft\X0D\\X0A\tissue measuring 0.9 x 0.2 and the smaller measuring 0.5 x 0.1 x 0.1\X0D\\X0A\cm.  Both are submitted in one cassette for frozen section as 1FS-1.\X0D\\X0A\The previously frozen 1FS-1 is entirely resubmitted as 1FS-1.\X0D\\X0A\Specimen two is labeled \""anterior tracheal lymph node\"" and consists of\X0D\\X0A\a tan fragment of tissue measuring 0.2 cm and another measuring 0.3 cm\X0D\\X0A\and another having a longitudinal segment measurement of 1.5 x 0.3 cm.\X0D\\X0A\All three fragments are submitted in cassette 2.","MICROSCOPIC DESCRIPTION\X0D\\X0A\Review of sections of the anterior tracheal lymph node, 1FS-1 shows\X0D\\X0A\invasive large cell carcinoma in both fragments submitted.  Features\X0D\\X0A\are compatible with a metastatic lesion to this lymph node.   After H\T\E\X0D\\X0A\staining, sections of the anterior tracheal lymph node, 1FS-1, show\X0D\\X0A\metastatic cancer, epithelial in character.  Clusters and bundles of\X0D\\X0A\tumor is present.  Permanent section of the anterior tracheal lymph\X0D\\X0A\node shows clusters and bundles of a large-cell epidermoid  or squamous\X0D\\X0A\carcinoma.  No keratinization is identified.  Clusters and bundles are\X0D\\X0A\rampant throughout the entire fragmented tissue submitted.  No typical\X0D\\X0A\lymph node architecture is appreciated.  Deeper sections of the frozen\X0D\\X0A\section show the same features.\X0D\\X0A\Sections of the anterior tracheal lymph node, 2A-1, show dense clusters\X0D\\X0A\of tumor, large-cell, squamous carcinoma variety with invasive features\X0D\\X0A\rampant.  Poor differentiation is appreciated. No keratinization is\X0D\\X0A\identified.  Back-to-back tumor clusters are present in nodules and\X0D\\X0A\bundles.  A deeper section of part two shows similar features\X0D\\X0A\throughout.   This is a large cell carcinoma, non-keratinizing variety.\X0D\\X0A\Primary site unknown.","TISSUE SUBMITTED:  (1) LYMPH NODES, SURGICAL EXCISION\X0D\\X0A\Anterior tracheal\X0D\\X0A\lymph node\X0D\\X0A\(2) LYMPH NODES,\X0D\\X0A\SURGICAL EXCISION\X0D\\X0A\Anterior tracheal\X0D\\X0A\lymph node",,
REG1,LUNG,0,497471,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\SACRAL MASS\X0D\\X0A\,"COPIES TO:\X0D\\X0A\   DeWeese,R **PLACE\X0D\\X0A\   4121 **NAME[ZZZ YYY]\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\   **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX,WWW VVV]\X0D\\X0A\   3991 **NAME[ZZZ CCC]\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS, 88342GS/4\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\SACRAL BIOPSY:\X0D\\X0A\METASTATIC SMALL CELL (NEUROENDOCRINE) CARCINOMA.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\Lung should be considered as the likely site of primary however other possible sites of\X0D\\X0A\primary include head and neck, GI tract, pancreas and genitourinary tract.  Clinical\X0D\\X0A\correlation is suggested.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin labeled \""sacral mass biopsies are multiple pink tan focally hemorrhagic\X0D\\X0A\irregular shaped tissue fragments that measure in aggregate 0.6 x 0.3 x 0.2 cm.  The tissue\X0D\\X0A\is submitted in toto in one cassette.  /pb/as\X0D\\X0A\",MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\Sections show fragments of hemorrhagic tissue mixed with fibrinous material and clusters of\X0D\\X0A\malignant cells showing scanty cytoplasm and round to oval to spindle hyperchromatic nuclei\X0D\\X0A\with inconspicuous nucleoli.  A few fragments of bone are identified.  Immunostains show\X0D\\X0A\positivity for thyroid transcription factor I and synaptophysin.  Immunostain for p63 and\X0D\\X0A\chromogranin is negative.\X0D\\X0A\,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\SACRAL MASS BIOPSY\X0D\\X0A\,,
REG1,LUNG,0,497500,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\RIGHT LUNG MASS\X0D\\X0A\,"SURGEON            \X0D\\X0A\\X0D\\X0A\DR. **NAME[ZZZ YYY]\X0D\\X0A\\X0D\\X0A\COPIES TO:\X0D\\X0A\   **NAME[YYY,ZZZ M]\X0D\\X0A\   **STREET-ADDRESS, **ROOM\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX,WWW M]\X0D\\X0A\   1169 Eastern Pkwy\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88333GS, 88305GS, 88342GS/5\X0D\\X0A\\X0D\\X0A\Signed ________________________________________ **NAME[VVV M UUU] MD **DATE[Mar 03 12]              \X0D\\X0A\\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Mar 04 12]                 **PLACE Clinical Associates                    \X0D\\X0A\\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\RIGHT LUNG MASS, CT GUIDED CORE BIOPSY:\X0D\\X0A\POSITIVE FOR NON-SMALL CELL CARCINOMA.\X0D\\X0A\TUMOR NECROSIS IS NOTED.\X0D\\X0A\PLEASE SEE COMMENT.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\IMMUNOHISTOCHEMISTRY REPORT\X0D\\X0A\\X0D\\X0A\Using appropriate positive and negative controls, sections from the right lung biopsy are\X0D\\X0A\submitted for immunoreactive thyroid transcription factor 1 (TTF-1), p63, cytokeratin 5/6,\X0D\\X0A\cytokeratin 7, and CAM5.2 via an immunohistochemical technique.  Most tumor cells stain\X0D\\X0A\strongly positive for cytokeratin 5/6.  Several tumor cells stain moderate to strongly\X0D\\X0A\positive for p63.  Tumor cells are negative for TTF-1 and cytokeratin 7.  CAM5.2 stain is\X0D\\X0A\non contributory.  All external controls react appropriately.\X0D\\X0A\\X0D\\X0A\INTERPRETATION:  This staining pattern is most supportive of a squamous cell carcinoma.\X0D\\X0A\\X0D\\X0A\Reviewed for QA (LK).\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin designated \""right lung biopsy\"" are multiple minute fragments of pale\X0D\\X0A\tan to white soft tissue measuring up to 0.3 cm in length.  All specimens are submitted in a\X0D\\X0A\single cassette.\X0D\\X0A\\X0D\\X0A\Touch preps are prepared in radiology for immediate evaluation.  **INITIALS\X0D\\X0A\\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\1 H\T\E, TTF-1, p63, cytokeratin 5/6, cytokeratin 7 and CAM5.2\X0D\\X0A\",SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\RIGHT LUNG BIOPSY\X0D\\X0A\,,
REG1,LUNG,0,497508,1,,"CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\ABDOMINAL PAIN, EMESIS, DIARRHEA, DIZZINESS, MILD PERSISTENT NON-PRODUCTIVE COUGH\X0D\\X0A\","COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY]\X0D\\X0A\   200 **NAME[M. XXX]\X0D\\X0A\   **PLACE, Ky **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[WWW,VVV M]\X0D\\X0A\   **STREET-ADDRESS #902\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[UUU,TTT (SSS])\X0D\\X0A\   935 **NAME[M RRR QQQ]\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS, 88342GS/3\X0D\\X0A\\X0D\\X0A\RUN DATE:**DATE[Jan 17 12]                 **PLACE Clinical Associates                    PAGE:   **ID-NUM\X0D\\X0A\RUN TIME:***PHONE\X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\Name:  **NAME[BBB,AAA] K                DOB: **DATE[Aug 05 1944]   Sex: M\X0D\\X0A\Add:175 **PLACE,KY **ZIP-CODE  **PHONE                                                                \X0D\\X0A\Acct#: **ID-NUM Unit#: **ID-NUM  Status:  ADM IN    Location:  D.4WS      D.4114-1    \X0D\\X0A\Reg:   **DATE[Jan 11 12]     Disch:           SS: **ID-NUM    Race: WH        \X0D\\X0A\**NAME[CCC:ZZZ,YYY]             Submit:**NAME[ZZZ,YYY]                  MDPhone:  **PHONE     \X0D\\X0A\Address: 200 **NAME[M. XXX]                 **PLACE                     Ky **ZIP-CODE     \X0D\\X0A\--------------------------------------------------------------------------------------------\X0D\\X0D\\X0A\\X0D\\X0A\",FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\LEFT LOWER LOBE LUNG BIOPSY:\X0D\\X0A\INVASIVE POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA.\X0D\\X0A\\X0D\\X0A\PATHOLOGIST's COMMENTS\X0D\\X0A\\X0D\\X0A\A panel of immunostains is performed with results as follows:\X0D\\X0A\Tumor cells are negative for TTF-1.\X0D\\X0A\Tumor cells are positive for CK5/6 and p63.\X0D\\X0A\All controls stain appropriately.\X0D\\X0A\\X0D\\X0A\This staining pattern is consistent with squamous cell carcinoma.\X0D\\X0A\\X0D\\X0A\See ***PATH-NUMBER[1] and 1113.\X0D\\X0A\,,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin designated \""left lower lobe lung biopsy\"" are multiple minute fragments\X0D\\X0A\of pink-tan soft tissue measuring up to 1.5 mm in greatest dimension.  The specimens are\X0D\\X0A\submitted in a single cassette. /tj-dj\X0D\\X0A\",,SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\LEFT LOWER LOBE LUNG BIOPSY\X0D\\X0A\,,
REG1,LUNG,0,497529,1,,CLINICAL HISTORY\X0D\\X0A\\X0D\\X0A\NOT PROVIDED\X0D\\X0A\,"COPIES TO:\X0D\\X0A\   **NAME[ZZZ,YYY M]\X0D\\X0A\   2355 Poplar Level Rd\X0D\\X0A\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\   **NAME[XXX,WWW]\X0D\\X0A\   **STREET-ADDRESS, **ROOM\   **PLACE, KY **ZIP-CODE\X0D\\X0A\    **PHONE\X0D\\X0A\\X0D\\X0A\PROCEDURES: 88305GS, 88342GS/6\X0D\\X0A\\X0D\\X0A\","FINAL DIAGNOSIS\X0D\\X0A\\X0D\\X0A\SUBCARINAL MASS, BIOPSY:\X0D\\X0A\NON-SMALL CELL CARCINOMA.\X0D\\X0A\IMMUNOHISTOCHEMICAL WORKUP MOST SUPPORTIVE OF SQUAMOUS ORIGIN.\X0D\\X0A\",,"GROSS DESCRIPTION\X0D\\X0A\\X0D\\X0A\Received in formalin labeled \""subcarinal mass biopsy\"" are four pink tan tissue cores, each\X0D\\X0A\with diameters of 0.1 cm that vary in length from 1.3 to 1.7 cm.  The tissue is submitted in\X0D\\X0A\toto in one cassette. /pb/as\X0D\\X0A\","MICROSCOPIC DESCRIPTION\X0D\\X0A\\X0D\\X0A\2 H\T\E, 1 CK7, 1 TTF-1, 1 p63, 1 PSA, 1 PSAP.\X0D\\X0A\Using appropriate positive and negative controls, the malignant neoplasm is stained for\X0D\\X0A\immunoreactive CK7, TTF-1, p63, PSA and PSAP.  All internal and external controls react\X0D\\X0A\appropriately.  The malignant neoplasm stains positive for TTF-1.  The malignant neoplasm\X0D\\X0A\stains negative for CK20, TTF-1, PSA and PSAP.  This staining pattern in conjunction with\X0D\\X0A\histology is most supportive of squamous origin.\X0D\\X0A\",SPECIMEN INFORMATION\X0D\\X0A\\X0D\\X0A\SUBCARINAL MASS\X0D\\X0A\,,
REG1,LUNG,0,497751,1,,Clinical Diagnosis and History\X0D\\X0A\LEFT UPPER LOBE LUNG NODULE\X0D\\X0A\OPER:   LEFT VAT\X0D\\X0A\FROZEN SECTION \X0D\\X0A\Intraoperative Consult\X0D\\X0A\FSDX: NON SMALL CELL CARCINOMA.  TUMOR AT INKED MARGIN.  **INITIALS \X0D\\X0A\Called to Dr. **NAME[ZZZ] at 1:30.,"4000 **PLACE, KY **ZIP-CODE\X0D\\X0A\Copy To: \X0D\\X0A\Specimen(s) Received\X0D\\X0A\1: WEDGE LEFT UPPER LOBE FROZEN, PORTIONS OF SPECIMEN SENT TO PRECISION\X0D\\X0A\BIOMARKERS AND CHEMOSENSITIVIY lg","Final Diagnosis\X0D\\X0A\LUNG: RESECTION - \X0D\\X0A\  SPECIMEN: LEFT UPPER LOBE BIOPSY.\X0D\\X0A\  PROCEDURE: WEDGE RESECTION.\X0D\\X0A\  SPECIMEN INTEGRITY: DISRUPTED.\X0D\\X0A\  SPECIMEN LATERALITY: LEFT.\X0D\\X0A\  TUMOR SITE: LEFT UPPER LOBE.\X0D\\X0A\  TUMOR SIZE: 15 MM.\X0D\\X0A\  TUMOR FOCALITY: UNIFOCAL.\X0D\\X0A\  HISTOLOGIC TYPE: SQUAMOUS CELL CARCINOMA.\X0D\\X0A\  HISTOLOGIC GRADE: GRADE II (MODERATELY DIFFERENTIATED).\X0D\\X0A\  VISCERAL PLEURAL INVASION: NOT IDENTIFIED.\X0D\\X0A\  TUMOR EXTENSION: NOT IDENTIFIED.\X0D\\X0A\  BRONCHIAL MARGIN: NOT APPLICABLE.\X0D\\X0A\  VASCULAR MARGIN: NOT APPLICABLE.\X0D\\X0A\  PARENCHYMAL MARGIN: TUMOR PRESENT FOCALLY AT PARENCHYMAL MARGIN AT STAPLE\X0D\\X0A\     LINE.\X0D\\X0A\  PARIETAL PLEURAL MARGIN: NOT APPLICABLE.\X0D\\X0A\  CHEST WALL MARGIN: NOT APPLICABLE.\X0D\\X0A\  OTHER ATTACHED TISSUE MARGIN: NOT APPLICABLE.\X0D\\X0A\  LYMPH-VASCULAR INVASION: NOT IDENTIFIED.\X0D\\X0A\  PATHOLOGIC STAGING: \X0D\\X0A\     PRIMARY TUMOR: T1a.\X0D\\X0A\     REGIONAL LYMPH NODES: NX (CANNOT BE ASSESSED).\X0D\\X0A\     DISTANT METASTASES: NOT APPLICABLE.\X0D\\X0A\**INITIALS\X0D\\X0A\Electronically Signed Out By\X0D\\X0A\**NAME[YYY], M.D., **PLACE",,"Gross Description\X0D\\X0A\Received fresh for frozen diagnosis designated \""wedge left upper lobe\"" is a\X0D\\X0A\wedge biopsy of lung 4.7 x 1.7 x 1.6 cm.  Staple line of closure is present. \X0D\\X0A\The specimen has been previously incised to reveal a pink tan purple mass which\X0D\\X0A\bulges above the cut surface.  The mass is 15 x 13 x 12 mm.  It appears to abut\X0D\\X0A\the staple line margin.  A section of this mass is submitted for frozen\X0D\\X0A\diagnosis with India ink at the staple line margin.  Tissue is retained for\X0D\\X0A\Precision Therapeutics.  The remainder is submitted for permanent sections in A\X0D\\X0A\and B.  Additional sections of the wedge are submitted in C.  **INITIALS",Microscopic Description\X0D\\X0A\Incorporated in diagnosis.,,,"Procedures/Addenda\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 1 2013]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 1 2013]     By:  **NAME[XXX, WWW]\X0D\\X0A\     Date Reported:     **DATE[Mar 1 2013]         \X0D\\X0A\Addendum Comment\X0D\\X0A\For details see the complete separately scanned ChemoFx report from Precision\X0D\\X0A\Therapeutics in the electronic medical records file.\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[YYY], M.D., **PLACE\X0D\\X0A\SUPPLEMENTAL REPORT     Date Ordered:     **DATE[Mar 7 2013]     Status:  Signed Out\X0D\\X0A\     Date Complete:     **DATE[Mar 7 2013]     By:  **NAME[VVV,UUU]\X0D\\X0A\     Date Reported:     **DATE[Mar 7 2013]         \X0D\\X0A\Addendum Comment\X0D\\X0A\For details see the complete separately scanned BioSpeciFx report from Precision\X0D\\X0A\Therapeutics Laboratories in the electronic medical records file.   /ap\X0D\\X0A\     This certifies that I have reviewed and   electronically signed this\X0D\\X0A\report.\X0D\\X0A\                                             **NAME[YYY], M.D., **PLACE"
REG1,LUNG,0,498050,1,,"CLINICAL HISTORY: Patient with lung mass, Mediastinal Lymphadenopathy and lytic lesion of left iliac wing. PET scan positive.  Spiculated right upper lobe mass.","Submitting Physician: **NAME[ZZZ, YYY M]. Status: SOUT. Final Signout: **NAME[XXX WWW], MD **DATE[Oct 23 12]","FINAL DIAGNOSIS: LEFT ILIAC WING, BIOPSY METASTATIC POORLY DIFFERENTIATED CARCINOMA, SEE COMMENT.",,"GROSS DESCRIPTION: The specimen is received in a container labeled with the patient's name, number, date and \""left iliac biopsy.\""  The specimen is received in formalin and consists of multiple longitudinal, cylindrically-shaped portion of glistening tan-white material, measuring 1 x < 0.1 cm. in aggregate.  The specimen is totally submitted in one block.","COMMENT WORD: Sections of the left iliac wing biopsy show the presence of a non-small cell type carcinoma, present in organoid sheets and nests with a faint pseudoglandular appearance.  The cells are large with abundant cytoplasm and centrally located ovoid nuclei with vesicular chromatin and prominent central nucleoli.  No attempts at keratinization are identified.  Tumor infiltrates within fibrous tissue and adjacent skeletal muscle fragments.  Tumor cells stain negatively with Napsin, TTF-1, and p63.  Although this does not exclude a lung primary, it makes it less likely.  Further immunostains are pending to include Mart-1 and S-100 and a separate report will follow.",Specimen Number: ***PATH-NUMBER[1]. Tissues: Ilium. Specimen Comments:,,
REG1,LUNG,0,500391,1,,PREOP DIAGNOSIS:               RIGHT UPPER LOBE OF LUNG NODULE,"**NAME[BBB,AAA] C                           ACCT #: **ID-NUM     LOC:  5NO    U #: 013936\X0D\\X0A\350 **PLACE,KY **ZIP-CODE  **PHONE\X0D\\X0A\Race: W           SSN: **ID-NUM\X0D\\X0A\AGE/SX: 87/F       **ROOM    REG: **DATE[May 28 12]\X0D\\X0A\DOB: **DATE[May 07 25]    BED: 02      DIS:\X0D\\X0A\STATUS: ADM IN     TLOC:","FINAL DIAGNOSIS\X0D\\X0A\A. RIGHT LUNG MASS:\X0D\\X0A\.....MODERATELY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\B. RIGHT LUNG MASS FOR BRONCHIAL MARGINS:\X0D\\X0A\.....1. BRONCHIAL MARGIN FREE OF MALIGNANCY.\X0D\\X0A\.....2. PERIBRONCHIAL LYMPH NODE NEGATIVE FOR MALIGNANCY.\X0D\\X0A\.....3. POSITIVE FOR MODERATELY DIFFERENTIATED ADENOCARCINOMA.\X0D\\X0A\.....4. TUMOR MEASURES 2.3 CM IN GREATEST DIMENSION.\X0D\\X0A\.....5. MODERATELY DIFFERENTIATED ADENOCARCINOMA WITH FOCAL LEPIDIC\X0D\\X0A\.....SPREAD.\X0D\\X0A\.....6. MODERATE EMPHYSEMATOUS CHANGES.\X0D\\X0A\C. STATION 4R LYMPH NODES:\X0D\\X0A\.....1. REACTIVE NODES (2).\X0D\\X0A\.....2. NO METASTATIC MALIGNANCY SEEN.\X0D\\X0A\.....3. FAT REPLACEMENT.\X0D\\X0A\\X0D\\X0A\FROZEN SECTION DIAGNOSIS\X0D\\X0A\A. RIGHT LUNG MASS:\X0D\\X0A\.....POSITIVE FOR MALIGNANCY, NON-SMALL CELL TYPE. GTW AND BHT\X0D\\X0A\B. RIGHT UPPER LOBE FOR BRONCHIAL MARGINS:\X0D\\X0A\.....\X0D\\X0A\.....NO TUMOR SEEN. GTW\X0D\\X0A\\X0D\\X0A\Signed  __________(signature on file)_ **NAME[ZZZ,YYY] XXX] MD  **DATE[May 29 12]",,"GROSS DESCRIPTION\X0D\\X0A\The specimen is submitted in 3 containers, each labelled with the patient\X0D\\X0A\name.\X0D\\X0A\A. Submitted fresh and designated \""right lung mass\"" are 2 very hemorrhagic\X0D\\X0A\reddish-brown biopsy specimens that are submitted for frozen sections and\X0D\\X0A\are now entirely submitted in cassette A.\X0D\\X0A\B. Submitted fresh and designated \""right lung mass for bronchial margins\"",\X0D\\X0A\the specimen consists of a lung lobectomy specimen with staple lines\X0D\\X0A\present. The specimen measures up to approximately 12 x 8 x 4 cm in\X0D\\X0A\greatest dimensions. The staple line is partially interrupted revealing\X0D\\X0A\bronchial margins. The bronchial margins are submitted for frozen sections\X0D\\X0A\and are now submitted in cassette B1. The additional lung tissue is then\X0D\\X0A\perfused prior to examination. Additional stapled tissue is removed prior\X0D\\X0A\to further examination. The pleural surface shows a roughly sutured area\X0D\\X0A\measuring 2.5 cm in greatest dimension which probably represents the prior\X0D\\X0A\biopsy site. Possible anthracotic peribronchial lymph node structures are\X0D\\X0A\identified and submitted in cassette B2. Also submitted in cassette B2 are\X0D\\X0A\probable vascular margins of excision. The specimen is sectioned with\X0D\\X0A\possible pulmonary edema identified; 1.5 cm from the margin of excision\X0D\\X0A\(the pleural surface) is a 2.3 cm in greatest dimension hemorrhagic and\X0D\\X0A\necrotic appearing mass lesion. This area is sectioned and submitted in\X0D\\X0A\cassettes B3 through B6, with pleural surface also submitted.  Sections\X0D\\X0A\away from tumor, of possible emphysematous and edematous tissue, are\X0D\\X0A\submitted in cassette B7.\X0D\\X0A\C. Submitted fresh and designated \""station 4R lymph nodes\"", the specimen\X0D\\X0A\consists of hemorrhagic and anthracotic red-brown soft tissue, with the\X0D\\X0A\smaller portion entirely submitted in cassette C1. The larger specimen\X0D\\X0A\measures up to 4 x 1.5 x 0.8 cm in greatest dimension. This is sectioned\X0D\\X0A\longitudinally and entirely submitted in cassettes C2 and C3.\X0D\\X0A\D: **DATE[May 28 2012] - 1637 hours\X0D\\X0A\T: **DATE[May 29 2012] - 0746 hours","MICROSCOPIC EXAMINATION\X0D\\X0A\A. The sections are of lung and show a moderately differentiated\X0D\\X0A\adenocarcinoma, with hyperchromatic nuclei, scant eosinophilic to\X0D\\X0A\amphophilic cytoplasm and focal mucoid production.\X0D\\X0A\B. The sections from the bronchial margin show bronchial tissue with the\X0D\\X0A\lung tissue surrounding the bronchus showing a moderate level of\X0D\\X0A\emphysematous change. No malignancy is seen. The sections from lymph nodes\X0D\\X0A\show anthracotic node and the blood vessel shows blood vessel with no\X0D\\X0A\tumor present. The multiple sections from the nodule show adenocarcinoma,\X0D\\X0A\moderately differentiated, with focal lepidic spread through the lung\X0D\\X0A\parenchyma. Fresh hemorrhage and emphysematous change are identified in\X0D\\X0A\the surrounding soft tissue. The pleural surfaces are uninvolved by tumor.\X0D\\X0A\Emphysematous changes are noted throughout the extra sections examined.\X0D\\X0A\C. The section show benign adipose tissue and fibrous tissue with benign\X0D\\X0A\reactive anthracotic lymph node identified. No evidence of metastatic\X0D\\X0A\malignancy is seen.\X0D\\X0A\D: **DATE[May 29 2012] - 1215 hours\X0D\\X0A\T: **DATE[May 29 2012] - 1234 hours","TISSUES:\X0D\\X0A\Lung, NOS (RIGHT UPPER LOBE OF LUNG BIO)\X0D\\X0A\Lung, NOS (RIGHT UPPER LOBE OF LUNG WIT)\X0D\\X0A\Lymph node, NOS (STATION 4 RIGHT LYMPH NODES)",,
REG1,LUNG,0,501158,1,,"Clinical History:\X0D\\X0A\Smoker x 39 Years, CT Scan **DATE[May 4 12] Shows Left Hilar Mass, Mediastinal\X0D\\X0A\Masses Which Are Hypermetabolic on the PET CT\X0D\\X0A\Pre-Operative Diagnosis:\X0D\\X0A\Mediastinal Mass\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given","CPT Code(s):  88305.26, 88333.26, 88342.26(x5).\X0D\\X0A\DBC:jg\X0D\\X0A\D\T\T:  **DATE[Jun 01 2012]\X0D\\X0A\**NAME[ZZZ YYY:  XXX WWW VVV] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Jun 02 2012]",Final Diagnosis:\X0D\\X0A\Posterior mediastinal mass biopsy:  Metastatic small cell neuroendocrine\X0D\\X0A\carcinoma.\X0D\\X0A\Note:  The tumor is strongly immunoreactive with TTF-1 which supports a\X0D\\X0A\pulmonary origin.,,"Gross Description:\X0D\\X0A\Received fresh as \""biopsy of posterior mediastinal mass\"" is a 1 x 0.6 x\X0D\\X0A\0.4 cm fragment of tan-pink tissue surrounded by fibroconnective tissue.\X0D\\X0A\The specimen is bisected and cytological touch imprints are obtained.\X0D\\X0A\Fresh tissue is submitted to an outside reference laboratory for flow\X0D\\X0A\cytometric studies.  The remaining tissue is submitted for routine\X0D\\X0A\processing in one tissue block.  DBC:vsg /jck\X0D\\X0A\Frozen Section Diagnosis:\X0D\\X0A\A)  TP DX:  Atypical.  Fresh tissue is to be submitted for flow\X0D\\X0A\cytometry.  (DBC).","Microscopic Description:\X0D\\X0A\Sections demonstrate cohesive sheets and clusters of small cells with\X0D\\X0A\scant cytoplasm and dense chromatin pattern.  Crush artifact is present.\X0D\\X0A\The tumor shows strong immunoreactivity with low molecular weight\X0D\\X0A\cytokeratin (CAM 5.2), TTF-1, and CD56.  Synaptophysin is exhibits\X0D\\X0A\diffuse weak immunostaining.  The tumor is negative for leukocyte common\X0D\\X0A\antigen (CD45).\X0D\\X0A\Flow cytometric studies have been performed by US Labs and the tissue\X0D\\X0A\sample shows an abnormal cell population which is CD45 negative and\X0D\\X0A\positive for CD56 and Ber-EP4.\X0D\\X0A\These histologic, immunohistochemical, and flow cytometric studies\X0D\\X0A\support the above diagnosis.\X0D\\X0A\Tissue Code:  T1.",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Biopsy of Posterior Mediastinal mass,,
REG1,LUNG,0,501217,1,,Clinical History:\X0D\\X0A\Right Lung Mass,"**** THIS IS AN ADDENDUM REPORT ****\X0D\\X0A\Frozen Section:\X0D\\X0A\A)  Lung wedge resection, right upper lobe - TP \T\ FS DX:\X0D\\X0A\  -   Carcinoma, non-small cell type.   (JLW / RBV **NAME[ZZZ YYY]).","Pre-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A)  Wedge resection, right upper lobe mass:\X0D\\X0A\  -   Poorly differentiated non-small cell carcinoma, most consistent\X0D\\X0A\with poorly differentiated adenocarcinoma.\X0D\\X0A\B)  Right main pulmonary artery lymph node:\X0D\\X0A\  -   Sinus histiocytosis with soot dust anthracosis (no evidence of\X0D\\X0A\metastatic carcinoma).\X0D\\X0A\C)  Right superior mediastinal lymph node:\X0D\\X0A\  -   Sinus histiocytosis with soot dust anthracosis (no evidence of\X0D\\X0A\metastatic carcinoma).\X0D\\X0A\D)  Right upper lobe of lung:\X0D\\X0A\  -   Bullous pulmonary emphysema, NOS.\X0D\\X0A\  -   Sinus histiocytosis with soot dust anthracosis, multiple\X0D\\X0A\peribronchial lymph nodes.\X0D\\X0A\E)  Subcarinal lymph node:\X0D\\X0A\  -   Sinus histiocytosis with soot dust anthracosis.\X0D\\X0A\F)  Right inferior lymph node:\X0D\\X0A\  -   Sinus histiocytosis with soot dust anthracosis, NOS.",,"Gross Description:\X0D\\X0A\A)  One container is labeled \""wedge resection, right upper lobe mass\"".\X0D\\X0A\The specimen is received fresh for frozen section and consists of a 14\X0D\\X0A\gram, 9 x 3.5 x 3 cm wedge excision of lung with a palpable 2.5 x 2.5 x\X0D\\X0A\2 cm subpleural mass.  The surgical margins are closed with a staple\X0D\\X0A\line.  The staple line is removed.  The specimen is inked and sectioned.\X0D\\X0A\The remaining cut surface is red and spongy without additional mass\X0D\\X0A\lesions.  Touch imprints are made and the tissue is submitted for frozen\X0D\\X0A\section.  Representative sections are submitted as follows:\X0D\\X0A\A1-FSC - frozen section residual resubmitted for permanent section;\X0D\\X0A\A2, 3 and 4 - additional sections of tumor;\X0D\\X0A\A5 - random section of lung.\X0D\\X0A\B)  Part B is labeled \""right main pulmonary artery lymph node\"".  The\X0D\\X0A\specimen is received in fixative and consists of a 2.6 x 1.5 x 1.2 cm\X0D\\X0A\red-black nodule.  The cut surface is anthracotic.  The specimen is\X0D\\X0A\entirely submitted in two cassettes.\X0D\\X0A\C)  Specimen C is labeled \""right superior mediastinal lymph node\"".  The\X0D\\X0A\specimen is received in fixative and consists of a 2.2 x 1.2 x 0.5 cm\X0D\\X0A\piece of soft tan tissue containing two gray-black nodules, 1.5 x 1 x\X0D\\X0A\0.4 cm., and 0.7 x 0.4 x 0.3 cm.  The cut surfaces of the nodules are\X0D\\X0A\anthracotic.  The tissue is entirely submitted in two cassettes.\X0D\\X0A\D)  Part D is labeled \""right upper lobe\"".  The specimen is received in\X0D\\X0A\fixative and consists of a 223 gram, 15 x 10.5 x 4 cm lobe of lung.  The\X0D\\X0A\pleura is gray and smooth without adhesions.  An 11 cm staple line is\X0D\\X0A\located along the edge of the lung.  The cut surface has focal areas\X0D\\X0A\containing dilated air filled spaces.  The remaining cut surface is deep\X0D\\X0A\red and spongy.  Multiple anthracotic lymph nodes are located\X0D\\X0A\surrounding the bronchi.  Representative sections are submitted as\X0D\\X0A\follows:\X0D\\X0A\D1 - en face bronchial margin;\X0D\\X0A\D2 - en face vascular margins;\X0D\\X0A\D3 - dilated air filled spaces;\X0D\\X0A\D4 - random section of lung;\X0D\\X0A\D5 - multiple lymph nodes;\X0D\\X0A\D6 - one trisected lymph node;\X0D\\X0A\D7 - fragmented lymph node.\X0D\\X0A\E)  Specimen E is labeled \""subcarinal lymph node\"".  The specimen is\X0D\\X0A\received in fixative and consists of a 3.5 x 2.5 x 1 cm lymph node.  The\X0D\\X0A\cut surface is anthracotic and focally calcified.  The tissue is\X0D\\X0A\entirely submitted as follows:\X0D\\X0A\E1 and E2 - calcified areas, decalcified;\X0D\\X0A\E3 and E4 - remaining tissue.\X0D\\X0A\F)  Specimen F is labeled \""right inferior pulmonary ligament\"".  The\X0D\\X0A\specimen is received in fixative and consists of a 1.9 x 1 x 0.6 cm\X0D\\X0A\gray-black nodule.  The cut surface is anthracotic.  The tissue is\X0D\\X0A\entirely submitted in two cassettes.\X0D\\X0A\JMM:jlj","Microscopic Description:\X0D\\X0A\A)  The frozen section block of the tumor and permanent sections of the\X0D\\X0A\wedge excision demonstrates the presence of an infiltrating tumor with a\X0D\\X0A\semicircumscribed but pushing margin with focal finger-like extensions.\X0D\\X0A\The tumor shows areas of necrosis within a relatively solid cohesive\X0D\\X0A\infiltrative mass.  Individual cells are noted with relatively abundant\X0D\\X0A\eosinophilic cytoplasm and variable sized enlarged nuclei possessing one\X0D\\X0A\or more nucleoli and frequent mitoses.  The nuclei are somewhat\X0D\\X0A\eccentric within the cytoplasm in many of the cells.  There is some\X0D\\X0A\suggestion of intercellular bridging.  The tumor appears entirely\X0D\\X0A\confined within the lung tissue resection margins.  Adjacent to the\X0D\\X0A\tumor, the lung appears more atelectatic focally.  One section shows\X0D\\X0A\tumor cells spilling out within adjacent alveolar airspaces.  The\X0D\\X0A\closest approach to an inked margin is 2 mm.  There is no evidence of\X0D\\X0A\vascular invasion.  Some emphysematous changes are observed within the\X0D\\X0A\adjacent lung.\X0D\\X0A\B)  The B specimen includes a main pulmonary artery lymph node in\X0D\\X0A\multiple cross-sections.  This shows prominent aggregates of sinus\X0D\\X0A\histiocytes within the parenchyma.  The latter are somewhat soot\X0D\\X0A\pigmented.  There is no evidence of metastatic tumor within the lymph\X0D\\X0A\node section.\X0D\\X0A\C)  The C specimen, from the right superior mediastinum, includes\X0D\\X0A\multiple cross-sections of an additional lymph node showing similar\X0D\\X0A\sinus histiocytosis and soot dust accumulation within histiocytes.\X0D\\X0A\There are a few hyalinized small blood vessels within the medullary\X0D\\X0A\center.  No evidence of metastatic carcinoma is observed within this\X0D\\X0A\lymph node as well.\X0D\\X0A\D)  The en face bronchial margin of the resected right upper lobe,\X0D\\X0A\submitted as D, demonstrates benign bronchial cartilage and columnar\X0D\\X0A\pseudostratified mucosa without atypia and with some seromucinous glands\X0D\\X0A\within the surrounding connective tissue.  The proximal vascular margins\X0D\\X0A\are free of tumor and show only some mild atherosclerotic changes within\X0D\\X0A\the pulmonary arterial vasculature.  The more dilated airspaces show\X0D\\X0A\some mild bronchiolar metaplasia and are otherwise without remarkable\X0D\\X0A\features.  There is fusion of adjacent alveolar air sacs to form large\X0D\\X0A\cystic spaces.  The remaining lung shows lesser emphysematous changes\X0D\\X0A\but with a somewhat generalized saccular dilatation of several adjacent\X0D\\X0A\fused alveoli.\X0D\\X0A\Six lymph nodes in block D5, one trisected lymph node in D6 and a\X0D\\X0A\fragmented lymph node in D7 demonstrate similar sinus histiocytosis\X0D\\X0A\changes.  There is no evidence of tumor metastasis in any of the lymph\X0D\\X0A\nodes.\X0D\\X0A\E)  The E portion includes a lymph node with similar sinus histiocytosis\X0D\\X0A\changes and a large area of calcification apparently representing an old\X0D\\X0A\calcified granuloma.  This has a thin fibrotic wall.  There is no tumor\X0D\\X0A\involvement.\X0D\\X0A\F)  The final lymph node, F, shows similar sinus histiocytosis and soot\X0D\\X0A\dust anthracosis changes.  There is no tumor within this lymph node as\X0D\\X0A\well.\X0D\\X0A\CASE SUMMARY FOR PRIMARY CARCINOMA OF THE LUNG:\X0D\\X0A\Specimen: Upper lobe, right lung.\X0D\\X0A\Procedure: Wedge resection, followed by lobectomy.\X0D\\X0A\Specimen integrity: Intact.\X0D\\X0A\Tumor location: Peripheral, subpleural.\X0D\\X0A\Tumor size: 2.5 x 2.5 x 2 cm.\X0D\\X0A\Tumor focality: Discrete mass.\X0D\\X0A\Histologic type: Adenocarcinoma.\X0D\\X0A\Histologic grade: Poorly differentiated.\X0D\\X0A\Visceral pleural invasion: No.\X0D\\X0A\Tumor extension: No.\X0D\\X0A\Margins:\X0D\\X0A\Bronchial:  Widely free.\X0D\\X0A\Parenchymal:    Free (closest approach 2 mm in wedge resection; no\X0D\\X0A\residual tumor in lobectomy.\X0D\\X0A\Vascular: Free.\X0D\\X0A\Parietal pleural: N/A\X0D\\X0A\Chest wall:    N/A\X0D\\X0A\Distance of invasive carcinoma from closest margin: >5 cm\X0D\\X0A\Treatment effect: No.\X0D\\X0A\Lymph-vascular invasion: No\X0D\\X0A\Lymph nodes:\X0D\\X0A\Peribronchial: Eight lymph nodes negative for metastasis.\X0D\\X0A\Non-tumorous lung:  Bullous emphysema.\X0D\\X0A\Pathologic staging:  pT1b, pN0, MX\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\CPT Code:\X0D\\X0A\A)  88331.26, 88334.26, 88307.26, 88342.26 x 4, 88313.26\X0D\\X0A\B)  88305.26\X0D\\X0A\C)  88305.26\X0D\\X0A\D)  88307.26\X0D\\X0A\E)  88305.26\X0D\\X0A\F)  88305.26\X0D\\X0A\ECW:jck\X0D\\X0A\Dct:Trs:  **DATE[Sep 13 2012]\X0D\\X0A\Addendum:\X0D\\X0A\The tumor is negative for CEA, CK5/6 and p63 and stains focally\X0D\\X0A\positively for mucicarmine.  The staining reactions for the controls are\X0D\\X0A\appropriate for positive and negative controls for immunoperoxidase\X0D\\X0A\stains and also appropriately reactive for mucicarmine.\X0D\\X0A\**NAME[XXX WWW:  VVV M UUU] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Sep 13 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: B Right main pulmonary Artery Lymph Node\X0D\\X0A\SOURCE OF SPECIMEN: C Right Superior Mediastinel\X0D\\X0A\SOURCE OF SPECIMEN: D Right Upper Lobe\X0D\\X0A\SOURCE OF SPECIMEN: E Subcarinao Lymph Node\X0D\\X0A\SOURCE OF SPECIMEN: F Right inferior Lymp Node\X0D\\X0A\SOURCE OF SPECIMEN: A Wedge resection Right Upper lobe Mass,,
REG1,LUNG,0,503211,1,,Clinical History:\X0D\\X0A\Right Brain Mass,"Frozen Section:\X0D\\X0A\TP \T\ FS Dx:  Malignant, extensively-necrotic, favor metastatic\X0D\\X0A\carcinoma.  Results called to **NAME[ZZZ].  **NAME[YYY XXX], M.D.","Pre-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\None Given\X0D\\X0A\p\X0D\\X0A\Final Diagnosis:\X0D\\X0A\A \T\ B)  Brain mass and CUSA contents:  Metastatic poorly\X0D\\X0A\differentiated\X0D\\X0A\neuroendocrine carcinoma, small cell type (small-cell carcinoma), with\X0D\\X0A\extensive necrosis consistent with pulmonary origin.",,"Gross Description:\X0D\\X0A\Two containers.\X0D\\X0A\Container A is labeled \""brain mass\"".  The specimen is received fresh and\X0D\\X0A\consists of a 1.1 x 0.8 x 0.3 cm piece of soft tan-gray tissue.  Squash\X0D\\X0A\preps are made and the remaining tissue is submitted for frozen section.\X0D\\X0A\The frozen section residual is resubmitted for permanent sections in\X0D\\X0A\block A-FSC.\X0D\\X0A\Specimen B is labeled \""CUSA contents\"".  The specimen is received in\X0D\\X0A\fixative and consists of a 7.5 x 5.0 x 0.5 cm aggregate of soft tan-pink\X0D\\X0A\diffluent tissue.  The tissue is entirely submitted in fourteen\X0D\\X0A\cassettes.  **INITIALS","Microscopic Description:\X0D\\X0A\A \T\ B)  Brain mass and CUSA contents:  Sections reveal an extensively\X0D\\X0A\necrotic neoplasm composed of sheets of markedly atypical epithelial\X0D\\X0A\cells with small, hyperchromatic nuclei and scant amounts of cytoplasm.\X0D\\X0A\\""Crush\"" artifact and some nuclear molding are noted.  Mitotic activity\X0D\\X0A\is brisk.  Small fragments of benign brain parenchyma are identified.\X0D\\X0A\Immunohistochemical stains are performed and reported as follows:\X0D\\X0A\Chromogranin:  Strongly positive.\X0D\\X0A\Synaptophysin:  Negative.\X0D\\X0A\TTF-1:  Positive.\X0D\\X0A\CK7:  Positive\X0D\\X0A\P63:  Negative\X0D\\X0A\Pankeratin:  Focally positive.  The associated controls performed as\X0D\\X0A\expected.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\CPT Code:\X0D\\X0A\A)  88307.26, 88331.26, 88334.26\X0D\\X0A\B)  88307.26, 88342.26 x 6\X0D\\X0A\**NAME[CCC DDD:  YYY M XXX] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Feb 29 2012]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A Brain Mass\X0D\\X0A\SOURCE OF SPECIMEN: B CUSA Contents,,
REG1,LUNG,0,508299,1,,Clinical History:\X0D\\X0A\Coughing/Right Hilar Mass,,Pre-Operative Diagnosis:\X0D\\X0A\Right Hilar Mass (lung Neoplasm)\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\Final Diagnosis:\X0D\\X0A\Right upper lobe biopsy:\X0D\\X0A\  -   Poorly differentiated non-small cell carcinoma favoring\X0D\\X0A\sarcomatoid squamous cell carcinoma.,,"Gross Description:\X0D\\X0A\The specimen is received in formalin labeled with the patient's name and\X0D\\X0A\additionally labeled \""right upper lobe biopsy\"".  The specimen consists\X0D\\X0A\of a single 0.2 cm white-tan irregular tissue fragment submitted in toto\X0D\\X0A\in a single cassette.  JAB:vsg","Microscopic Description:\X0D\\X0A\The right upper lobe biopsy consists of a single biopsy of a cellular\X0D\\X0A\neoplasm with somewhat plump and spindly cellular elements with\X0D\\X0A\irregular sized nuclei and relatively abundant eosinophilic cytoplasm.\X0D\\X0A\Because of the overall appearance of the tumor and the focal areas of\X0D\\X0A\somewhat stellate appearance of some of the cells, a battery of\X0D\\X0A\Immunoperoxidase stains has been performed including CEA, pankeratin,\X0D\\X0A\vimentin, LCA (CD45) and CD34.  The latter has been performed because of\X0D\\X0A\the appearance of unusual appearing vessels in a portion of the tumor.\X0D\\X0A\Strong positive staining for vimentin and pankeratin are noted with\X0D\\X0A\negative staining for CEA, CD45 and CD34, except for the normal vessels.\X0D\\X0A\Positive and negative controls are appropriately reactive.\X0D\\X0A\Tissue Code:  T1\X0D\\X0A\CPT Code:  88305.26, 88342.26 x 5\X0D\\X0A\ECW:jck\X0D\\X0A\Dct:Trs:  **DATE[Dec 07 2011]\X0D\\X0A\**NAME[ZZZ YYY:  XXX M WWW] MD\X0D\\X0A\Pathologist\X0D\\X0A\Electronically Signed **DATE[Dec 07 2011]",Specimen Source: \X0D\\X0A\ APSURG\T\AP SURGICAL SPECIMEN\S\\S\\S\\S\\S\OTHR\T\Miscellaneous \X0D\\X0A\ SOURCE OF SPECIMEN: A RUL Biopsy,,
REG1,LUNG,0,511776,1,,HISTORY: Large Necrotic Soft Tissue Mass Right Lower Lobe \X0D\\X0A\hip bone lesion consistent with metastasis \X0D\\X0A\long time smoker.,"ICD9 CODES: 162.5, V15.82, \X0D\\X0A\COMMENTS: The pathology is diagnostic of a poorly differentiated non-small cell carcinoma, and morphology and staining pattern have some features suggestive of adenocarcinoma. The carcinoma is compatible with but not entirely specific for a lung primary. Clinical correlation is required.\X0D\\X0A\LAB_COMM: cell block\X0D\\X0A\PRELIM: Lung, right lower, CT-guided FNA biopsy:     Positive for malignancy.     Non-small cell carcinoma with background necrosis, pending additional stains to            further characterize.  Comment:     Preliminary impression was given to Dr. **NAME[M. ZZZ] at the time of the FNA biopsy, and discussed with Dr. **NAME[M. YYY] at 4 p.m. on **DATE[Feb 1 12].","DIAGNOSIS: Lung, right lower lobe, CT-guided FNA biopsy:     Positive for malignancy.     Poorly differentiated non-small cell carcinoma with background necrosis.     See comment and microscopic description.\X0D\\X0A\TECH FINDINGS: Malignant cells present.  Favor adenocarcinoma.",,,"MICRO: One of three direct smears contains numerous irregular linear and anastomosing groups of polygonal tumor cells with moderate nuclear atypia and moderate amounts of pink cytoplasm.  A ThinPrep slide is low cellularity and noncontributory.  A cell block slide contains many groups of poorly differentiated carcinoma without discrete gland formation or keratin production, with a background of necrosis. Special stains are performed on the cell block. Mucicarmine stain is mostly negative, but a single cell with intracellular mucin is identified. Tumor cells are positive for cytokeratin 7 \X0D\\X0A\negative for cytokeratin 20, squamous markers p63 and cytokeratin 5/6, and TTF-1.","PROCEDURE: FNA-Right Lung  Adequacy  check performed by Dr. **NAME[XXX WWW]  Preliminary Impression: Positive for malignancy, favor adenocarcinoma.                                                        Dr. **NAME[XXX WWW]\X0D\\X0A\SPECIMEN(S): FNA-Right Lung     3 slides received stained w/     20 mls of red fluid in cytolyt",,
REG1,LUNG,0,512888,1,,Clinical History:\X0D\\X0A\Lung mass\X0D\\X0A\\X0D\\X0A\Pre-Operative Diagnosis:\X0D\\X0A\Same\X0D\\X0A\\X0D\\X0A\Post-Operative Diagnosis:\X0D\\X0A\Pending,"SMS-11-01654     **NAME[BBB, AAA] D             MRN: **ID-NUM          Sex: M  DOB:        **DATE[Dec 20 1949]\X0D\\X0A\SSN:         **ID-NUM\X0D\\X0A\Collected:   **DATE[Oct 13 2012]\X0D\\X0A\**NAME[ZZZ] MD: **NAME[YYY] MD,\X0D\\X0A\Pathologist: **NAME[XXX] MD, **NAME[WWW M]\X0D\\X0A\Signout Date:           **DATE[Oct 15 2012]","Final Diagnosis:\X0D\\X0A\Bronchial biopsy, right middle lobe:  Small cell undifferentiated carcinoma.",,"Gross Description:\X0D\\X0A\Received in formalin designated \""right middle lobe biopsy\"" are numerous red-tan tissue\X0D\\X0A\fragments measuring 0.3 x 0.3 x 0.1 cm in aggregate.  All tissue is submitted entirely in one\X0D\\X0A\cassette in a tea bag.  LEH:vsg",Microscopic Description:\X0D\\X0A\The biopsy specimens show a benign respiratory epithelium covering a subepithelial stroma\X0D\\X0A\which is being diffusely infiltrated by a small cell infiltrate.  The cells have small but\X0D\\X0A\very hyperchromatic nuclei which show nuclear molding and extensive crush artifact.  The\X0D\\X0A\nuclei are surrounded by very scanty rims of amphophilic cytoplasm.  There is no evidence of\X0D\\X0A\any glandular or squamous differentiation present.  Immunoperoxidase stains for pankeratin\X0D\\X0A\(epithelial marker) and chromogranin and synaptophysin (neuroendocrine markers) show positive\X0D\\X0A\staining of the tumor cells.  This pattern of staining is compatible with a small cell\X0D\\X0A\undifferentiated carcinoma.  Tissue Code:  T1,,,
REG1,LUNG,0,515801,1,,,"Specimen Number: ***PATH-NUMBER[1]. Submitting Physician: **NAME[ZZZ] MD,IMTIAZ. Status: SOUT. COMMENT::. CELL BLOCK: POSITIVE FOR MALIGNANCY (ADENOCARCINOMA). CPT CODES:. 88112; 88305. GENERAL CATEGORIZATION:. Epithelial, Other Cell Abnormalities: See Diagnoses/Comment","DESCRIPTIVE DIAGNOSES: Positive For Malignancy (Adenocarcinoma). Preliminary Signout: **NAME[M. YYY, XXX](ASCP) **DATE[Jan 16 12]. Final Signout: **NAME[WWW], MD **DATE[Jan 16 12]",,,,"Tissues: THORACOCENTESIS FLUID, TP ENHANCED. Specimen Comments:. SPECIMEN ADEQUACY: Satisfactory for Evaluation. SPECIMEN ADEQUACY (REASON): (Mesothelial Cells Present)",,
REG1,LUNG,0,517680,1,,HISTORY: Left Lower Lung Mass 3.5cm partially necrotic,"ICD9 CODES: 162.5, 786.6, \X0D\\X0A\COMMENTS: Fragments of tumor form sheets of irregular polygonal cells with moderate to marked nuclear atypia and moderate amounts of pink granular cytoplasm. No obvious gland formation or keratin production is seen. Mucicarmine stain is negative for mucin. Immunoperoxidase stains are performed. Tumor cells are strongly positive for cytokeratin 7, and focal tumor cells are positive for cytokeratin 5/6. The tumor is negative for p63, TTF-1, and cytokeratin 20. The pathology is compatible with but not specific for a lung primary. Clinical correlation is required.\X0D\\X0A\LAB_COMM: cell block","DIAGNOSIS: Lung mass, left lower, CT-guided FNA biopsy:     Positive for malignancy.     Poorly differentiated non-small cell carcinoma, with extensive background           necrosis.\X0D\\X0A\TECH FINDINGS: Poorly differentiated carcinoma.",,,"MICRO: Two direct smears, a ThinPrep slide, and a cell block are reviewed. Special stains are performed on the cell block.",PROCEDURE: FNA-Left Lung  Adequacy check performed by Dr.**NAME[ZZZ YYY]  Preliminary Impression: Non-small cell carcinoma                                                      Dr.**NAME[ZZZ YYY]\X0D\\X0A\SPECIMEN(S): FNA-Left Lung     2 slides received stained w/     30 mls of red fluid in cytolyt,,
REG1,LUNG,0,521754,1,,HISTORY: Cavitary area left upper lobe \X0D\\X0A\Nodular area right middle lobe \X0D\\X0A\Pleural effusion,"ICD9 CODES: 162.9, , \X0D\\X0A\LAB_COMM: Please Keep these slides at grassmere for me to read on Tuesday.  Thanks,  TTc\X0D\\X0A\MESSAGES: This diagnosis was reported by telephone to Dr. **NAME[ZZZ] in his office at 11:16 a.m. **DATE[Nov 12 12].\X0D\\X0A\PRELIM: Lung, left, fine needle aspiration, ThinPrep slide, smears, cell block:     Poorly differentiated non-small cell carcinoma.     See comment.  COMMENT: Cytologic changes are indicative of a poorly differentiated non-small cell carcinoma. A poorly differentiated squamous cell carcinoma is favored, but immunoperoxidase stains will be performed to better differentiate between poorly differentiated squamous cell carcinoma and poorly differentiated adenocarcinoma. Final report is pending those immunoperoxidase stains.  This diagnosis was reported by telephone to Dr. **NAME[ZZZ] in his office at 11:16AM, **DATE[Nov 12 12].","DIAGNOSIS: Lung, left, fine needle aspiration, smears, ThinPrep slide, cell block:     Poorly differentiated squamous cell carcinoma.\X0D\\X0A\TECH FINDINGS: Atypical cells present.  Suspicious.",,,"MICRO: Direct smears prepared at time of left lung fine needle aspiration contain abundant blood.  There are some thick clusters of atypical appearing epithelioid cells present which raise a high degree of suspicion for the presence of nonsmall cell carcinoma. These cell clusters are somewhat obscured by the large amount of blood present. These atypical cellular elements are somewhat better visualized on the ThinPrep specimen, and even better visualized on the cell block preparation.  Diagnostic changes of poorly differentiated nonsmall cell carcinoma are indicated. Immunoperoxidase stains are performed on the cell block. Tumor cells show some focal weak positivity for cytokeratin 7, but are strongly positive for cytokeratin 5/6. In addition, p63 stain is strongly positive and TTF-1 is negative. These phenotypic features are indicative of squamous cell carcinoma rather than adenocarcinoma.","PROCEDURE: CT Guided FNA Left Lung Mass  FNA Adequacy check performed by **NAME[YYY M. XXX], MD  Preliminary Impression:  Primarily blood.  Rare thick epithelial clusters.                                                                 **NAME[YYY]  **NAME[M. XXX], MD\X0D\\X0A\SPECIMEN(S): CT Guided FNA Left Lung Mass     4 stained slides received     30 mls of cloudy red fluid received in cytolyt",,
REG4,PROSTATE,0,PAT-10034567,1,REC-3000636477,"ClinicalHistory:
Prostate cancer.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
Bilateral scrotal orchiectomy.",,"PreOperativeDiagnosis:
Bilateral scrotal orchiectomy
PostOperativeDiagnosis:
Same 
FinalDiagnosis:
A-B.   Testicles, right and left, therapeutic orchiectomy:    Minimal atrophic changes; negative for malignancy.\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""left testicle"" is a tan-pink testis with attached epididymis, having overall dimensions of 5.7 x 3.4 x 2.5 cm.  Sectioning reveals a tan-brown, granular cut surface with no grossly identifiable masses or lesions.  Representative sections are submitted in block A.

B.  Received in formalin labeled ""right testicle"" is a tan-pink testis with attached epididymis, having overall dimensions of 6.0 x 4.5 x 2.5 cm.  Sectioning reveals a tan-brown, granular cut surface and no grossly identifiable masses or lesions.  A representative section is submitted in block B.","MicroscopicDescription:
A-B.   Sections of right and left testicles demonstrate areas of minimal atrophic changes.  There is no evidence of malignancy.","A: Left testicle
B: Right testicle",,
REG4,PROSTATE,0,PAT-10036975,1,REC-3000636839,"ClinicalHistory:

Elevated PSA = 8.8 ng/mL done on **DATE[Aug 2 11].  Rectal exam demonstrates prostate 4.0 x 3.5 cm, smooth, non-nodular.",,"FinalDiagnosis:
Prostate, core needle biopsy:

A. Right apex:      Prostatic adenocarcinoma, Gleason score 6(3+3), one focus 0.5 mm
        No perineural invasion present

B. Right mid gland:     Small focus of atypical glands

C. Right base:     Benign prostatic tissue

D. Right lateral:     Benign prostatic tissue

E. Right anterior:     Prostatic adenocarcinoma, Gleason score 6(3+3), one focus 1.5 mm
        No perineural invasion present

F. Left apex:       Benign prostatic tissue

G. Left mid gland:     Prostatic adenocarcinoma, Gleason score 6(3+3), one focus 0.2 mm
        No perineural invasion present

H. Left base:       Benign prostatic tissue

I. Left lateral:       Benign prostatic tissue

J. Left anterior:     Prostatic adenocarcinoma, Gleason score 6(3+3), one focus 1.0 mm
        No perineural invasion present

Comment
For part A, B, E, G and J, the immunostain for PIN4 supports the diagnosis. Dr. **NAME[ZZZ] concurs. Dr. **NAME[YYY] has been notified.

\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right apex"" is a core of white-tan soft tissue measuring 1.2 cm in length x <1.0 mm in
      outside diameter.  Submitted entirely in block A.

B.  Received in formalin labeled ""XXXXXX, right mid gland"" is a core of white-tan soft tissue measuring 1.6 cm in length x <1.0 mm
      in outside diameter.  Submitted entirely in block B.

C.  Received in formalin labeled ""XXXXXX, right base"" is a core of white-tan soft tissue measuring 1.3 cm in length x <1.0 mm in
      outside diameter.  Submitted entirely in block C.

D.  Received in formalin labeled ""XXXXXX, right lateral"" is a core of white-tan soft tissue measuring 1.5 cm in length x <1.0 mm in
      outside diameter.  Submitted entirely in block D.

E.  Received in formalin labeled ""XXXXXX, right anterior"" is a core of white-tan soft tissue measuring 1.2 cm in length x <1.0 mm in
      outside diameter.  Submitted in entirely in block E.

F.  Received in formalin labeled ""XXXXXX, left apex"" is a core of white-tan tissue soft tissue measuring 1.3 cm in length x <1.0 mm
     in outside diameter.  Submitted entirely in block F.

G.  Received in formalin labeled ""XXXXXX, left mid gland"" is a core of white-tan tissue measuring 1.4 cm in length x <1.0 mm in 
      outside diameter.  Submitted entirely in block G.

H.  Received in formalin labeled ""XXXXXX, left base"" is a core of white-tan tissue measuring 1.5 cm in length x <1.0 mm in outside
     diameter.  Submitted entirely in block H.

I.   Received in formalin labeled ""XXXXXX, left lateral"" is a core of white-tan soft tissue measuring 1.3 cm in length x <1.0 mm in 
     outside diameter.  Submitted entirely in block I.

J.  Received in formalin labeled ""XXXXXX, left anterior"" is a core of white-tan soft tissue measuring 0.8 cm in length x <1.0 mm in
     outside diameter.  Submitted entirely in block J.","MicroscopicDescription:
The microscopic findings support the diagnosis.","A: Right prostate core needle biopsy at apex
B: Right prostate core needle biopsy at midgland
C: Right prostate core needle biopsy at base
D: Right prostate core needle biopsy at lateral
E: Right prostate core needle biopsy at anterior
F: Left prostate core needle biopsy at apex
G: Left prostate core needle biopsy at midgland
H: Left prostate core needle biopsy at base
I: Left prostate core needle biopsy at lateral
J: Left prostate core needle biopsy at anterior",,
REG4,PROSTATE,0,PAT-10032005,1,REC-3000637099,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  PROSTATE GLAND:  SMALL FOCUS OF PROSTATIC ADENOCARCINOMA.
 
B.  RIGHT PELVIC LYMPH NODES:  1 LYMPH NODE NEGATIVE FOR
    METASTASIS.

C.  LEFT PELVIC LYMPH NODES:  4 LYMPH NODES NEGATIVE FOR
    METASTASIS.

Prostate cancer information
Operative procedure:  Radical prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Not identified.
Anatomic site (including status of apex):  Left mid prostate,
  apex not involved.
Anti-androgen therapy:  Given, by history.
Gleason score:  8 (4 + 4).
Percent Gleason grade 4 and/or 5:  100%.
Size (dominant nodule):  0.1 cm.
Percent of prostate involved by carcinoma:  Less than 1%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Not identified
Invasion of adjacent structures:  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes:  0/5.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
Pathologic grade and stage:  Gleason 8, yT2a N0, stage IIB.",,"GrossDescription:
Seven
A. Specimen:  Prostate with attached bilateral seminal vesicles and right vas deferens.
Fixative:  10% buffered neutral formalin.
Weight:  141 gm.
Size:
  Apex Base:  7 cm.
  Anterior Posterior:  4.9 cm.
  Right Left:  6.5 cm.
Gross findings:  Prostate markedly enlarged and deformed.  Nodular cut surface with focal hemorrhage.  No discrete lesions grossly identified.
Seminal vesicles
  Right:  3.9 x 1.6 x 0.4 cm; unremarkable.
  Left:  2 x 1.8 x 0.6 cm; unremarkable.
Vasa deferentia
  Right:  2.7 x 0.5 cm; unremarkable.
  Left:  0.5 x 0.4 cm possible stump.
Other findings:  Multiple small brown stones weighing less than 1 gm and measuring up to 0.1 cm.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-5  cross sections through bladder neck margin
6-7  cross sections through apical margin
8  right apex
9-11  right mid prostate
12-13  right posterior base
14  left apex
15-18  left mid prostate
19-20  left posterior base
21  right seminal vesicle and vas deferens
22  left seminal vesicle and possible vas deferens
23-25  right mid prostate
26-30  right base
31-34  left mid prostate
35-40  left base

B. Specimen:  Lymph node.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.1 x 1 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1, bisected.

C. Specimen:  Irregular segment of fatty tissue.  
Weight:  3 gm.
Number of segments:  1.  
Size:  3.5 x 2 x 0.8 cm.
Gross findings:  3 lymph nodes measuring up to 2.9 x 1.2 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks: 
1-2  lymph nodes (single node in 2)
3  fat.",,"A: PROSTATE
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE",,
REG4,PROSTATE,0,PAT-10036974,1,REC-3000637897,"ClinicalHistory:
Elevated PSA.","PhysicianNotification:
Notified and faxed report to **NAME[YYY] at Dr. **NAME[ZZZ] s office on **DATE[Jan 11 12].","FinalDiagnosis:
A.  LEFT APEX PROSTATE:  BENIGN PROSTATE TISSUE.

B.  LEFT MID PROSTATE:  BENIGN PROSTATE TISSUE.
 
C.  LEFT BASE PROSTATE:  BENIGN PROSTATE TISSUE.
 
D.  RIGHT APEX PROSTATE:  PROSTATIC ADENOCARCINOMA,
    GLEASON SCORE 7 (4 + 3).

E.  RIGHT MID PROSTATE:  BENIGN PROSTATE TISSUE.
 
F.  RIGHT BASE PROSTATE:  BENIGN PROSTATE TISSUE.
 
G.  CENTRAL:  NO SPECIMEN IDENTIFIED IN CONTAINER.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right apex.
Number of cores with carcinoma/total cores:  3/20.
Maximum size of carcinoma:  4 mm.
Percent of overall tissue involved by carcinoma:  10%.
Highest Gleason score at single site:  7 (4 + 3).
Overall Gleason score:  7 (4 + 3).
Percent of Gleason grade 4 and/or 5:  80%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  5. 
Size:  Up to 0.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  White top container filled with clear formalin.  The
Gross findings: No specimen grossly identified.","MicroscopicDescription:
ABCEF. Small, elongated sections of prostate tissue show benign glands and stroma. No malignancy is seen.

D. Small elongated sections of prostate show foci of adenocarcinoma consisting of infiltrating predominantly fused glands.","A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE
G: CENTRAL",,
REG4,PROSTATE,0,PAT-10037137,1,REC-3000638110,"ClinicalHistory:
Adenocarcinoma of the prostate.",,"FinalDiagnosis:
PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON 7 (3+4).

Prostate cancer information
Operative procedure:  Radical prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Right and left apex to base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  10-20%.
Size (dominant nodule):  Spans approximately 4.2 cm (microscopic with
                         comparison to gross photo).
Percent of prostate involved by carcinoma:  50%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:  Involved.
  Bladder neck (proximal) margin:  Uninvolved. 
  Apical (distal) margin:  Involved; Right apex and posteriorly.
  Circumferential (left and right) margins:  Left circumferential margin
                                             involved at the level of the apex. 
Regional lymph nodes:  None submitted.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  Gleason 7; pT2c NX (Stage IIB if N0 M0).",,"GrossDescription:
Specimen:  Prostate with attached seminal vesicles and vas deferens.
Fixative:  Formalin.
Weight:  35 gm.
Size:
  Apex Base:  4.2 cm.
  Anterior Posterior:  3.7 cm.
  Right Left:  4.7 cm.
Lesion(s): 
  Location:  Right and left apex.
  Size:  1.7 x 1.6 z 0.7 cm.
  Appearance:  Firm, tan-white.
  Distance to margins:  Abuts surgical margin at apex.
Seminal vesicles
  Right:  2.4 x 1.2 x 1.0 cm; unremarkable.
  Left:  3.0 x 1.7 x 0.7 cm; unremarkable.
Vasa deferentia
  Right:  3.0 x 0.6 cm; unremarkable.
  Left:  2.0 x 0.6 cm; unremarkable.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  distal apex
3-4  proximal base
5  tumor, left apex
6-7   left mid prostate
8     left anterior mid prostate
9  left posterior mid prostate
10  left anterior mid prostate
11  left posterior mid prostate
12  left anterior base
13  left posterior base
14  tumor, right apex
15-16 right mid prostate
17    right anterior mid prostate
18    right posterior mid prostate
19    right base
20    left base
21  right seminal vesicle and vas deferens
22  left seminal vesicle and vas deferens.",,A: PROSTATE,,
REG4,PROSTATE,0,PAT-01279256,3,REC-3000638163,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
AB. PROSTATE NEEDLE BIOPSIES (RIGHT BASE, MID):  
    BENIGN PROSTATIC TISSUE.

C.  PROSTATE NEEDLE BIOPSIES (RIGHT APEX):  
    NECROTIZING GRANULOMATOUS INFLAMMATION;
    NEGATIVE FOR MALIGNANCY.

D.  PROSTATE NEEDLE BIOPSIES (LEFT BASE):  
    BENIGN PROSTATIC TISSUE.

E.  PROSTATE NEEDLE BIOPSIES (LEFT MID):  
    NECROTIZING GRANULOMATOUS INFLAMMATION;
    NEGATIVE FOR MALIGNANCY.

F.  PROSTATE NEEDLE BIOPSIES (LEFT APEX):  
    BENIGN PROSTATIC TISSUE.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.7 to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.9 to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.2 to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.3 to 0.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
ABDF.  Small segments of prostatic tissue show mild patchy chronic inflammation with no evidence of malignancy.

CE.  Small segments of prostatic tissue show necrotizing granulomatous inflammation with no evidence of malignancy.","A: RIGHT BASE PROSTATE
B: RIGHT MID PROSTATE
C: RIGHT APEX PROSTATE
D: LEFT BASE PROSTATE
E: LEFT MID PROSTATE
F: LEFT APEX PROSTATE",,
REG4,PROSTATE,0,PAT-10037509,1,REC-3000638310,"ClinicalHistory:
790.93
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Elevated PSA./r/n",,"FinalDiagnosis:
A. Right prostate, core biopsy: Single small atypical gland.

B. Left prostate, core biopsy: Prostatic adenocarcinoma (Gleason score 4+5 = 9) (see microscopic description for tumor information)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ]. Dr. **NAME[YYY] contacted on **DATE[Jun 13 12] at 12:54 pm./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right prostate x6
  Specimen:    Cylindrical friable cores of tissue (formalin)
  Number:      Six
  Size:           Up to 1.5 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1

B.  Labeled:      Patient name and medical record number, designated left prostate x6
  Specimen:    Cylindrical friable cores of tissue (formalin)
  Number:      Six
  Size:           Up to 1.4 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A-B.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.

Prostate Cancer (Needle Biopsy) Information
Based on AJCC/UICC TNM, 7th edition

PART B
Histologic type: Adenocarcinoma
Histologic grade: 
    Primary (predominant) pattern: 4
    Secondary (worse remaining) pattern: 5
    Gleason score: 9
Tumor quantitation:
    Number of cores positive: 3
    Total number of cores: 7 core fragments
    Proportion (percent) of prostatic tissue involved by tumor: Approximately 15%
Periprostatic fat invasion: Not identified
Seminal vesicle invasion: Not identified./r/n","A: Right prostate, biopsy
B: Left prostate, biopsy",,
REG4,PROSTATE,0,PAT-10034943,1,REC-3000638502,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  BLADDER NECK:  BENIGN PROSTATIC TISSUE.
 
B.  APICAL MARGIN OF PROSTATE:  BENIGN PROSTATIC TISSUE.
 
C.  LEFT PELVIC LYMPH NODE: ONE LYMPH NODE NEGATIVE FOR METASTASIS (0/1). 
 
D.  RIGHT PELVIC LYMPH NODES: TWO LYMPH NODES NEGATIVE FOR METASTASIS (0/2). 
 
E.  PROSTATE:  PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Robot-assisted laparoscopic radical prostatectomy and bilateral pelvic lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Apex to mid (L>R).
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  30%.
Size (dominant nodule):  Up to 0.7 x 0.6 cm (microscopic measurement).
Percent of prostate involved by carcinoma:  5%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes: Negative for metastasis (0/3).
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
Pathologic stage:  pT2c, pN0, Stage IIB (if M0).",,"GrossDescription:
A. Specimen:  Irregular segments of tan rubbery tissue.  
Weight:  Less than 1 gm.
Number of segments:  2.  
Size:  Up to 0.8 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segments of tan-pink rubbery tissue.  
Weight:  Less than 1 gm.
Number of segments:  2.  
Size:  Up to 0.6 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.0 x 1.5 x 1.0 cm.
Gross findings: Single lymph node identified measuring 2.0 x 0.8 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  3 gm.
Number of segments:  1.  
Size:  3.0 x 2.0 x 1.4 cm.
Gross findings: Two lymph nodes identified measuring up to 3.0 x 1.1 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, (1-single bisected lymph node, 2-lymph node and fat).

E. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% buffered formalin solution.
Weight:  73 gm.
Size:
  Apex Base:  4.3 cm.
  Anterior Posterior:  4.5 cm.
  Right Left:  6.0 cm.
Lesion(s): No obvious mass/lesions grossly identified.  
Seminal vesicles
  Right:  3.4 x 2.0 x 1.2 cm, unremarkable.
  Left:  3.4 x 1.5 x 0.8 cm, unremarkable.
Vasa deferentia
  Right:  4.7 x 0.6 cm, unremarkable.
  Left:  4.1 x 0.5 cm, unremarkable.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross-sections through shaved distal, prostatic apical margin
2-3  cross-sections through shaved proximal, bladder neck margin
4-7  left apical prostate
8-11  left mid prostate
12-15  left base prostate
16  left seminal vesicle and vas deferens
17  right seminal vesicle and vas deferens
18-21  right base prostate
22-25  right mid prostate
26-27  right apical prostate.",,"A: BLADDER NECK
B: APICAL MARGIN OF PROSTATE
C: LEFT PELVIC LYMPH NODE
D: RIGHT PELVIC LYMPH NODES
E: PROSTATE",,
REG4,PROSTATE,0,PAT-10034928,1,REC-3000638557,"ClinicalHistory:
236.5.",,"FinalDiagnosis:
ABC. PROSTATE NEEDLE BIOPSIES (LEFT APEX, MID, BASE):  
     BENIGN PROSTATIC TISSUE.

D.   PROSTATE NEEDLE BIOPSIES (RIGHT APEX):
     PROSTATIC ADENOCARCINOMA, GLEASON's 8 (4+4),
     INVOLVING ONE OF THREE SEGMENTS.

EF.  PROSTATE NEEDLE BIOPSIES (RIGHT MID, BASE):  
     BENIGN PROSTATIC TISSUE.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right apex.
Number of cores with carcinoma/total cores in involved area:  1/3.
Maximum size of carcinoma:  0.3-cm.
Percent of overall tissue involved by carcinoma:  5%.
Highest Gleason score at single site:  8 (4+4).
Overall Gleason score:  8 (4+4).
Percent of Gleason grade 4 and/or 5:  100%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified. 
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
DiagnosisComment:
The case was discussed with Dr. **NAME[ZZZ] on **DATE[Oct 14 2011].",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  5. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
ABCEF.  Small segments of prostatic tissue show patchy acute and chronic inflammation with no evidence of malignancy.

D.  Small segments of prostatic tissue show partial replacement and invasion by fused glands that displays cells with prominent nucleoli.","A: PROSTATE LEFT APEX
B: PROSTATE LEFT MID
C: PROSTATE LEFT BASE
D: PROSTATE RIGHT APEX
E: PROSTATE RIGHT MID
F: PROSTATE RIGHT BASE",,
REG4,PROSTATE,0,PAT-10027790,1,REC-3000638754,"ClinicalHistory:
Prostate hypertrophy, prostate cancer.",,"FinalDiagnosis:
PROSTATE TISSUE, TUR:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 7 (3 + 4).

TURP/SUBTOTAL PROSTATECTOMY information
Operative procedure:  TURP.
Tumor-histologic type:  Prostatic adenocarcinoma.
Gleason score:  7 (3 + 4).
Percent Gleason grade 4:  15%.
Percent of tissue involved by tumor:  Less than 5%.
Other findings:  BPH.
DiagnosisComment:
The foci of atypical glands show absence of a basal cell layer (p63 immunoperoxidase stain), and are positive for p504s.",,"GrossDescription:
Specimen:  Multiple; irregular, pink-tan tissue fragments, received in formalin. 
Weight:  1 gm.
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,A: PROSTATE TISSUE,,
REG4,PROSTATE,0,PAT-10038289,1,REC-3000638979,,,"FinalDiagnosis:
SLIDE REVIEW ***PATH-NUMBER[1] (PALI MOMI)

AB.  PROSTATE BIOPSIES (BILATERAL WIDE):
     BENIGN PROSTATIC TISSUE.

C.   PROSTATE BIOPSIES (LEFT APEX):
     PROSTATIC ADENOCARCINOMA, GLEASON's 6 (3+3).

D-H. PROSTATE BIOPSIES (RIGHT APEX; BILATERAL MID, BILATERAL BASE): 
     BENIGN PROSTATIC TISSUE.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left apex.
Number of cores with carcinoma/total cores in involved area:  1/1.
Maximum size of carcinoma:  0.2-cm.
Percent of overall tissue involved by carcinoma:  5%.
Highest Gleason score at single site:  6 (3+3).
Overall Gleason score:  6 (3+3)
Percent of Gleason grade 4 and/or 5:  0%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified. 
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  Immunoperoxidase stains show that the neoplastic cells are weakly positive forp504s and negative for p63 and HMWK.",,"GrossDescription:
Specimen:  Case received for consultation.

Materials received:
Original pathology report no.:  ***PATH-NUMBER[1].
Name of laboratory:  **INSTITUTION.
Date of specimen:  **DATE[Jun 20 12].
Original diagnosis:  
  Prostate biopsies - left wide, right wide, right apex, right mid, left base, right base:  Benign prostate.
  Prostate, left apex, biopsy:  Prostate adenocarcinoma, Gleason 3+3=6; o.2 cm; no perineural invasion.
  Prostate, left mid, biopsy:  Focal high-grade prostatic intraepithelial neoplasia (PIN III).
Number of slides:  20 
   16 H/E: A1-H1 original and 1 recut
   4 ipox stains on C1: HMWK, p63, p504s, neg. control
Number of blocks:  0.",,"A: PROSTATE BIOPSIES: A) LEFT WIDE, B) RIGHT WIDE, C)  LEFT APEX, D)  RIGHT APEX,  E)  LEFT MID, F)  RIGHT MID, G) LEFT BASE, H) RIGHT BASE (SLIDE REVIEW ***PATH-NUMBER[1])",,
REG4,PROSTATE,0,PAT-10037153,1,REC-3000639041,"ClinicalHistory:
    Elevated PSA.",,"FinalDiagnosis:
Prostate, core needle biopsy:

A.  Right base:        Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus, 6.0 mm
          No perineural invasion present
 
B.  Right mid lateral:      Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus, 2.5 mm
          No perineural invasion present
 
C.  Right mid:        Benign prostatic tissue  
 
D.  Right mid transitional zone:  Benign prostatic tissue  
 
E.  Right apex:        Benign prostatic tissue
 
F.  Left base:        Benign prostatic tissue
 
G.  Left mid lateral:       Benign prostatic tissue 
 
H.  Left mid:        Benign prostatic tissue    
 
I.  Left mid transitional zone:    Benign prostatic tissue  
 
J.  Left apex:         Benign prostatic tissue \X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.5 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.    

B.  Received in formalin labeled ""XXXXXX, right mid lateral"" is a soft, tan core of tissue measuring up to 1.3 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

C.  Received in formalin labeled ""XXXXXX, right mid"" is a soft, tan core of tissue measuring up to 1.1 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

D.  Received in formalin labeled ""XXXXXX, right mid TZ"" is a soft, tan core of tissue measuring up to 1.0 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

E.  Received in formalin labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 0.8 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

F.  Received in formalin labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.1 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

G.  Received in formalin labeled ""XXXXXX, left mid lateral"" is a soft, tan core of tissue measuring up to 1.5 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

H.  Received in formalin labeled ""XXXXXX, left mid"" is a soft, tan core of tissue measuring up to 1.2 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

I.  Received in formalin labeled ""XXXXXX, left mid TZ"" is a soft, tan core of tissue measuring up to 1.4 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.  

J.  Received in formalin labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 0.7cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.   The microscopic findings support the above diagnoses.  Dr. **NAME[ZZZ] concurs. Dr. **NAME[YYY] has been notified.","A: Prostate core biopsy right base
B: Prostate core biopsy right mid lateral
C: Prostate core biopsy right mid
D: Prostate core biopsy right mid transitional zone
E: Prostate core biopsy right apex
F: Prostate core biopsy left base
G: Prostate core biopsy left mid lateral
H: Prostate core biopsy left mid
I: Prostate core biopsy left mid transitional zone
J: Prostate core biopsy left apex",,
REG4,PROSTATE,0,PAT-10041854,1,REC-3000639639,"ClinicalHistory:
790.93.",,"FinalDiagnosis:

A.  LEFT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 25% OF SAMPLE. 
 
B.  LEFT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
C.  LEFT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
D.  RIGHT BASE PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
E.  RIGHT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
F.  RIGHT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3),
    INVOLVING 10% OF SAMPLE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left base and right apex.
Number of cores with carcinoma:  4 of 18 core fragments.
Maximum size of carcinoma:  0.2 cm.
Percent of overall tissue involved by carcinoma:  5 to 10%.
Highest Gleason score at single site:  6 (3 + 3).
Overall Gleason score:  6 (3 + 3).
Percent of Gleason grade 4 and/or 5:  None.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT PROSTATE BASE
B: LEFT PROSTATE MID
C: LEFT PROSTAE APEX
D: RIGHT PROSTATE BASE
E: RIGHT PROSTATE MID
F: RIGHT PROSTATE APEX",,
REG4,PROSTATE,0,PAT-10037127,1,REC-3000639811,"ClinicalHistory:
Prostate adenocarcinoma.",,"FinalDiagnosis:
A.  POSTERIOR BLADDER NECK:  
- NEGATIVE FOR MALIGNANCY.
 
B.  POSTERIOR PROSTATE MARGIN:
- NEGATIVE FOR MALIGNANCY.  
 
C.  PROSTATE:  
- PROSTATIC ADENOCARCINOMA, GLEASON 7 (3 + 4).
 
D.  RIGHT BLADDER NECK:  
- NEGATIVE FOR MALIGNANCY.

Prostate cancer information
Operative procedure:  Robot-assisted laparoscopic radical prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:
- Left apex and left mid to base.
- Right mid.
Evidence of anti-androgen therapy:  Not applicable.
Gleason score:  7 (3 + 4).
Percent Gleason grade 4 and/or 5:  20-30%.
Size (dominant nodule):  2 x 0.6 x 0.3 cm (microscopic correlation with macroscopic findings).
Percent of prostate involved by carcinoma:  10%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Not definitively identified.
Invasion of adjacent structures:  Not applicable.
Lymph-Vascular invasion:  Not identified.
Margins:  Uninvolved by carcinoma. 
Regional lymph nodes:  Not applicable.
Distant metastasis:  Not applicable.
High grade prostatic intraepithelial neoplasia:  Present.
Distant metastasis:  Not applicable.
Other findings:  None identified.
Pathologic stage:  pT2c(m) NX (stage IIB if N0 M0).",,"GrossDescription:
A. Specimen:  Rubbery tan tissue, received in formalin.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  0.9 x 0.4 x 0.3 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Rubbery tan tissue, received in formalin.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  2.0 x 0.8 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Prostate with attached bilateral seminal vesicles and right vas deferens and separate fatty tissue, received in formalin.
Fixative:  10% buffered formalin.
Weight:  70 gm.
Size:
  Apex Base:  4.8 cm.
  Anterior Posterior:  4.2 cm.
  Right Left:  5.2 cm.
Gross findings:  No obvious lesion grossly identified. 
Seminal vesicles
  Right:  6.2 x 1.2 x 0.5 cm; unremarkable.
  Left:  4.2 x 1.2 x 0.4 cm; unremarkable.
Vasa deferentia
  Right:  1.5 x 0.7 cm; unremarkable.
  Left:  Absent.
Other findings:  Irregular fatty tissue measuring 5.5 by 2.E a 0.6 cm in no lesions grossly identified.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved proximal margin
2  cross sections through shaved distal margin
3  right apical prostate
4-7  right mid prostate
8-11  right base prostate
12  left apical prostate
13-16  left mid prostate
17-20  left base prostate
21  right seminal vesicle and vas deferens
22  left seminal vesicle
23  fatty tissue

D. Specimen:  Soft tan tissue, received in formalin.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  0.8 x 0.6 x 0.2 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.",,"A: POSTERIOR BLADDER NECK
B: POSTERIOR PROSTATE MARGIN
C: PROSTATE
D: RIGHT BLADDER NECK",,
REG4,PROSTATE,0,PAT-10040911,1,REC-3000639893,"ClinicalHistory:
790.93
Procedure->Biopsy
*** PROSTATE BIOPSY T ULTRASOUND
Clinical History/Diagnosis/Condition->ELEVATED PSA.   PSA=696.63./r/n",,"FinalDiagnosis:
A. Right prostate: Adenocarcinoma Gleason grade 4+4, Sum 8.

B. Left prostate: Adenocarcinoma Gleason grade 4+3, Sum 7./r/nDiagnosisComment:
Findings called to urology clinic at **NAME[ZZZ (YYY]) on **DATE[Mar 26 2012], 15:15. Case reviewed in Pathology Staff Conference on **DATE[Mar 26 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right prostate x2
  Specimen:    Cylindrical tan tissue cores (formalin)
  Number:      Three cores, one fragment
  Size:           Up to 1.6 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1  

B.  Labeled:      Patient name and medical record number, designated left prostate x2
  Specimen:    Cylindrical tan tissue cores (formalin)
  Number:      Two
  Size:           Up to 2.5 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A\T\B. Right and left prostate:
Tumor type: Adenocarcinoma
Gleason score: 4+4, sum 8 with minor component of 5 (right side), 4+3, sum 7 (left side)
Number of cores: 4 
Number with tumor: 3
Percent of tissue involved: 60%
Perineural invasion: Not identified./r/n","A: Right prostate x2, biopsy
B: Left prostate x2, biopsy",,
REG4,PROSTATE,0,PAT-10034879,1,REC-3000639960,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:

A.  LEFT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5), 
    INVOLVING 15% OF SAMPLE. 
 
B.  LEFT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5), 
    INVOLVING 40% OF SAMPLE.
 
C.  LEFT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5),
    INVOLVING 80% OF SAMPLE.
 
D.  RIGHT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5), 
    INVOLVING 50% OF SAMPLE.
 
E.  RIGHT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5), 
    INVOLVING 40% OF SAMPLE.
 
F.  RIGHT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5),
    INVOLVING 30% OF SAMPLE.
 
G.  CENTRAL ZONE PROSTATE BIOPSY:  ADENOCARCINOMA GS 9 (4 + 5),
    INVOLVING 90% OF SAMPLE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Left and right (apex to base, bilaterally) and
  central zone.
Number of cores with carcinoma:  16 of 29 core fragments.
Maximum size of carcinoma:  0.9 cm.
Percent of overall tissue involved by carcinoma:  50%.
Highest Gleason score at single site:  9 (4 + 5).
Overall Gleason score:  9 (4 + 5).
Percent of Gleason grade 4 and/or 5:  100%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Present.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 0.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Ranging from 0.2 to 0.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.1 to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE
G: CENTRAL ZONE",,
REG4,PROSTATE,0,PAT-10036396,1,REC-3000640044,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:
A.  PROSTATE NEEDLE BIOPSIES, RIGHT BASE:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 8(5+3),
    INVOLVING 1 OF 2 SEGMENTS.
 
B.  PROSTATE NEEDLE BIOPSIES, CENTRAL ZONE:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7(4+3),
    INVOLVING 1 OF 5 SEGMENTS.
 
C.  PROSTATE NEEDLE BIOPSIES, LEFT BASE:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7(4+3),
    INVOLVING 1 OF 2 SEGMENTS.
 
D.  PROSTATE NEEDLE BIOPSIES, LEFT MID:  
    BENIGN PROSTATIC TISSUE.

E.  PROSTATE NEEDLE BIOPSIES, LEFT APEX:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7(3+4),
    INVOLVING 2 OF 5 SEGMENTS.
 
F.  PROSTATE NEEDLE BIOPSIES, RIGHT MID:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7(4+3),
    INVOLVING 2 OF 3 SEGMENTS.
 
G.  PROSTATE NEEDLE BIOPSIES, RIGHT APEX:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 8(3+5),
    INVOLVING 3 OF 3 SEGMENTS.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Bilateral apex, base; right mid; central zone
Number of cores with carcinoma/total cores in involved area:  **DATE[Aug 21].
Maximum size of carcinoma:  1 cm (right apex).
Percent of overall tissue involved by carcinoma:  30-40%.
Highest Gleason score at single site:  8(5+3) and 8(3+5);
   right base, right apex.
Overall Gleason score:  9 (4+5)
Percent of Gleason grade 4 and/or 5:  50-60%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Present. 
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
DiagnosisComment:
Dr. **NAME[ZZZ] notified **DATE[May 27 2012].",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.9 to 1.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  5. 
Size:  Ranging from 0.3 to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 1.3 to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  5. 
Size:  Ranging from 0.2 to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.2 to 0.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.4 to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT BASE PROSTATE
B: CENTRAL ZONE PROSTATE BIOPSY
C: LEFT BASE PROSTATE
D: LEFT MID PROSTATE
E: LEFT APEX PROSTATE
F: RIGHT MID PROSTATE
G: RIGHT APEX PROSTATE",,
REG4,PROSTATE,0,PAT-01243898,1,REC-3000640167,"ClinicalHistory:
599.70 
790.93
Procedure->Biopsy
*** PROSTATE BIOPSY \T\ ULTRASOUND
Clinical History/Diagnosis/Condition->Prostate cancer \T\ elevated PSA.  PSA 13.66./r/n",,"FinalDiagnosis:
A.  Prostate, right:  Prostatic adenocarcinoma (Gleason 3 + 4, sum 7), with perineural invasion.
 
B.  Prostate, left:  Prostatic adenocarcinoma (Gleason 3 + 4, sum 7)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[Oct 28 2011].  Dr. **NAME[WWW VVV] was notified of the diagnosis via e-mail on **DATE[Oct 28 2011]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Two
  Size:           Up to 0.8 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1

B.  Labeled:      Patient name and medical record number, designated left prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Two
  Size:           Up to 1 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 4, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 80%
  Number of cores with tumor/total number of cores: 2 of 2
Lymphatic invasion: Not identified
Perineural invasion: Present
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

B.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 4, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 60%
  Number of cores with tumor/total number of cores: 2 of 2
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None./r/n","A: Right prostate x2, biopsy
B: Left prostate x2, biopsy",,
REG4,PROSTATE,0,PAT-10034522,1,REC-3000640317,"ClinicalHistory:
Prostate CA.",,"FinalDiagnosis:
A.  PRE PROSTATIC FAT:  
    1 LYMPH NODE NEGATIVE FOR METASTASIS (0/1).
 
B.  RIGHT PELVIC LYMPH NODE:  
    1 LYMPH NODE NEGATIVE FOR METASTASIS (0/1).
 
C.  SPECIMEN FROM LEFT PELVIC REGION:  
    ADIPOSE TISSUE; NEGATIVE FOR LYMPH NODES OR MALIGNANCY.
 
D.  PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON's 7 (3+4).

Prostate cancer information
Operative procedure:  Prostatectomy w/lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Bilateral, from base to apex.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4).
Percent Gleason grade 4 and/or 5:  10%.
Size (dominant nodule):  Estimate about 3 cm.
Percent of prostate involved by carcinoma:  20%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures: Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes:  0/2.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.

Pathologic grade and stage:
  Gleason's 7 (3+4), pT2c N0 (Stage II if M0).",,"GrossDescription:
A. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  3 gm.
Number of segments:  1.  
Size:  3.0 x 1.7 x 1.6 cm.
Gross findings: Single lymph node identified measuring 3.0 x 1.5 x 0.9 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1  single bisected lymph node
2  remaining fatty tissue

B. Specimen:  Single lymph node.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  1.1 x 0.7 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  3 gm.
Number of segments:  2.  
Size:  Up to 2.7 x 1.2 x 0.8 cm.
Gross findings: No lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% buffered formalin solution.
Weight:  67 gm.
Size:
  Apex Base:  4.5 cm.
  Anterior Posterior:  4.1 cm.
  Right Left:  7.0 cm.
Lesion(s): 
  Location:  Right apical to mid prostate.
  Size:  # cm.
  Appearance:  Firm, tan-white, ill-defined.
  Distance to margins:  Abutting right circumferential margin.
Seminal vesicles
  Right:  4.2 x 1.8 x 1.1 cm; unremarkable.
  Left:  3.0 x 2.0 x 1.1 cm; unremarkable.
Vasa deferentia
  Right:  2.4 x 0.7 cm; unremarkable.
  Left:  3.2 x 0.6 cm; unremarkable.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal (bladder neck) margin
3  cross sections through shaved distal (apical) margin
4-14  right apical to base prostate, respectively (lesion in cassettes 4 through 10)
15-25  left apical to base prostate, respectively
26  right seminal vesicle and vas deferens
27  left seminal vesicle and vas deferens.",,"A: PRE PROSTATIC FAT
B: RIGHT PELVIC LYMPH NODES
C: LEFT PELVIC LYMPH NODES
D: PROSTATE",,
REG4,PROSTATE,0,PAT-10034939,1,REC-3000640523,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 7 (4 + 3).
 
B.  RIGHT PELVIC LYMPH NODE(S):  2 LYMPH NODES NEGATIVE FOR METASTASIS.

Prostate cancer information
Operative procedure:  Radical prostatectomy and right pelvic lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site (including status of apex):  Right and left prostate, apex to base.
Evidence of anti-androgen therapy:  None.
Gleason score:  7 (4 + 3).
Percent Gleason grade 4 and/or 5:  60%.
Size (dominant nodule):  3.4 cm, right apex to base.
Percent of prostate involved by carcinoma:  60-70%.
Involvement of seminal vesicle:  None.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  None.
Lymph-Vascular invasion:  None.
Margins (focal/extensive involvement):
   Bladder neck (proximal) margin:  Negative. 
   Apical (distal) margin:  Negative; tumor is less than 0.1 cm from right margin.
   Circumferential (left and right) margins:  Negative. 
Regional lymph nodes (including number of nodes):  2 negative, right.
Distant metastasis:  Unknown.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  GS 7; pT3a N0 (Stage III).",,"GrossDescription:
A.  Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens, and 
       separate segment of vas deferens.
Fixative:  10% buffered formalin.
Weight:  48 gm.
Size:
   Apex Base:  3.4 cm.
   Anterior Posterior:  4.1 cm.
   Right Left:  4.8 cm.
Inking of margins:  Right - orange; left - blue; posterior - black.
Lesion(s): 
   Location:  Right posterior mid to base.
   Size:  0.8 x 0.6 x 0.6 cm.
   Appearance:  Ill-defined, firm white-tan.
   Distance to margins:  0.3 cm from the posterior margin, and 0.6 cm from the right 
      lateral margin.
Seminal vesicles
   Right:  3.4 x 1.5 x 0.6 cm; unremarkable.
   Left:  3.6 x 1.6 x 0.6 cm; unremarkable.
Vasa deferentia
   Right:  3.3 x 0.6 cm; unremarkable.
   Left:  4.9 x 0.5 cm; unremarkable.
   Separate segment:  3.4 x 0.5 cm; unremarkable.
Other findings:  None.
Photograph:  Taken.
Description of blocks submitted for microscopic evaluation:
     1,2  cross-sections through bladder neck (proximal) margin
       3  cross-sections through apical (distal) margin
       4  right apex
    5-10  right mid prostate (lesion in 10)
   11,12  right base (lesion in 12)
      13  left apex
   14-19  left mid prostate
   20,21  left base
      22  right seminal vesicle and vas deferens
      23  left seminal vesicle and vas deferens
      24  separate segment of vas deferens.

B.  Specimen:  Irregular segment of fatty tissue.  
Weight:  3 gm.
Number of segments:  1.  
Size:  6.5 x 1.9 x 0.8 cm.
Gross findings:  2 lymph nodes, up to 3.5 x 1 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
   1,2  lymph nodes (single lymph node in 1)
     3  fat.",,"A: PROSTATE
B: RIGHT PELVIC LYMPH NODE",,
REG4,PROSTATE,0,PAT-10037113,1,REC-3000640879,"ClinicalHistory:
CA prostate.",,"FinalDiagnosis:
A.  RIGHT PELVIC LYMPH NODE: ONE LYMPH NODE NEGATIVE FOR METASTASIS (0/1).
 
B.  LEFT PELVIC LYMPH NODES:  SIX LYMPH NODES NEGATIVE FOR METASTASIS (0/6).
 
C.  PROSTATE: PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Robotic radical prostatectomy and bilateral pelvic lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Bilateral, apex to mid.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  30%.
Size (dominant nodule): 1.5 x 1.0 cm (microscopic measurement, mid apex).
Percent of prostate involved by carcinoma:  10%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Focally involved (right apex).
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes: Negative for metastasis (0/7).
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic stage: pT2c, pN0, Stage IIB (if M0).",,"GrossDescription:

A. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  4 gm.
Number of segments:  1.  
Size:  5.0 x 2.5 x 0.8 cm.
Gross findings: Single lymph node identified measuring up to 3.5 x 2.0 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1-2  single lymph node, halved
3   remaining fatty tissue

B. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  4 gm.
Number of segments:  3.  
Size:  Up to 2.7 x 1.2 x 1.2 cm.
Gross findings: Two lymph nodes identified measuring up to 2.1 x 1.2 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1  lymph nodes
2  remaining fatty tissue

C. Specimen:  Prostate with attached bilateral seminal vesicles and vasa deferentia.
Fixative:  10% buffered formalin solution.
Weight:  117 gm.
Size:
  Apex Base:  5.2 cm.
  Anterior Posterior:  5.8 cm.
  Right Left:  7.6 cm.
Gross findings: Homogeneous tan, nodular cut surface. No obvious mass/lesions grossly identified. 
Seminal vesicles
  Right:  2.2 x 1.7 x 0.8 cm; unremarkable.
  Left:  3.2 x 2.0 x 1.4 cm; unremarkable.
Vasa deferentia
  Right:  2.2 x 0.6 cm; unremarkable.
  Left:  1.7 x 0.5 cm; unremarkable.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-3  cross sections through shaved proximal (bladder neck) margin
4  cross sections through shaved distal (apical) margin
5-22  right apical to base prostate as per photograph
23-40  left apical to base prostate as per photograph
41  right seminal vesicle and vas deferens
42  left seminal vesicle and vas deferens.",,"A: RIGHT PELVIC LYMPH NODES
B: LEFT PELVIC LYMPH NODES
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10034040,1,REC-3000640883,"ClinicalHistory:
Prostate CA.",,"FinalDiagnosis:
A.  RIGHT PELVIC LYMPH NODES:  FOUR LYMPH NODES NEGATIVE FOR METASTASIS (0/4).
 
B.  LEFT PELVIC LYMPH NODES:  TWO LYMPH NODES NEGATIVE FOR METASTASIS (0/2).
 
C.  PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON 7 (4+3).

Prostate cancer information
Operative procedure:  Robotic assisted prostatectomy with bilateral lymph nodes.
Tumor-histologic type:  Prostate adenocarcinoma.
Multicentricity:  Not identified.
Anatomic site:  Left and right apex to base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (4+3).  10% tertiary component of Gleason 5.
Percent Gleason grade 4 and/or 5:  80%.
Size (dominant nodule):  4.7 cm (microscopic with comparison to gross photo).
Percent of prostate involved by carcinoma:  85%.
Involvement of seminal vesicle:  Present.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Uninvolved. 
  Apical (distal) margin:  Uninvolved.
  Circumferential (left and right) margins:  Focally involves the right mid
                                             posterior margin. 
Regional lymph nodes (including number of nodes):  0/6.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  Gleason 7; pT3b N0 (Stage III if M0).",,"GrossDescription:

A. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  6 gm.
Number of segments:  1.  
Size:  3.5 x 2.8 x 1.7 cm.
Gross findings: Multiple lymph nodes identified measuring up to 2.3 x 0.5 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  3, (1-2 lymph nodes, 3-fat).

B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  5 gm.
Number of segments:  1.  
Size:  4.0 x 3.2 x 1.5 cm.
Gross findings: Two lymph nodes identified measuring up to 1.6 x 0.9 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, (1-lymph nodes, 2-fat).

C. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% buffered formalin solution.
Weight:  57 gm.
Size:
  Apex Base:  4.7 cm.
  Anterior Posterior:  4.8 cm.
  Right Left:  5.5 cm.
Lesion(s): 
  Location:  Left and right apex-base prostate.
  Size:  4.1 x 2.8 x 2.5 cm.
  Appearance:  Ill-defined, firm tan lesion.
  Distance to margins:  Grossly abutting the posterior margin, and 0.2-cm away from the left and right circumferential margins.
Seminal vesicles
  Right:  2.5 x 1.4 x 1.4 cm, unremarkable.
  Left:  2.3 x 1.5 x 1.3 cm, unremarkable.
Vasa deferentia
  Right:  3.5 x 0.6 cm, unremarkable.
  Left:  3.7 x 0.6 cm, unremarkable.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved distal, prostatic apical margin
2  cross sections through shaved proximal, bladder neck margin3-4  lesion, left apical prostate
5-8  lesion, left mid prostate
9-11  left base prostate (10-lesion)
12  left seminal vesicle and vas deferens
13  right seminal vesicle and vas deferens
14-16  right base prostate (15-lesion)
17-20  lesion, right mid prostate
21-22  lesion, right apical prostate.",,"A: RIGHT PELVIC LYMPH NODES
B: LEFT PELVIC LYMPH NODES
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10033760,1,REC-3000653616,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  PROSTATE:  
- PROSTATIC ADENOCARCINOMA, GLEASON SCORE 7 (3+4), WITH EXTRAPROSTATIC EXTENSION 
  INVOLVING THE RIGHT SEMINAL VESICLE; EXTENDING TO THE RIGHT CIRCUMFERENTIAL BASE AND 
  LEFT APICAL MARGIN.
 
B.  RIGHT AND LEFT PELVIC LYMPH NODES:  
- BENIGN LYMPHOID TISSUE; NO MALIGNANCY IDENTIFIED (0/5). 

Prostate cancer information
Operative procedure:  Prostatectomy and lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Not identified.
Anatomic site:  
Bilateral prostatic lobes, including the apex and right seminal vesicle.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  Grade 4, 30%.
Size (dominant nodule):  4.6 cm.
Percent of prostate involved by carcinoma:  40%.
Involvement of seminal vesicle:  Involving the right seminal vesicle.
Extraprostatic extension:  Identified.
Perineural invasion:  Identified.
Invasion of adjacent structures (bladder, rectum):  Not assessed.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear of tumor. 
  Apical (distal) margin:  Focally involving the left apical margin.
  Circumferential margins:  Involving the right seminal vesicle and soft tissue. 
Regional lymph nodes:  No malignancy identified (0/5).
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Identified.
Other findings:  None.
Pathologic grade and stage:  G7 pT3bpN0 (Stage III).",,"GrossDescription:
A. Specimen:  Prostate with attached bilateral seminal vesicles and right vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  44 gm.
Size:
  Apex Base:  3.3 cm.
  Anterior Posterior:  3.7 cm.
  Right Left:  4.6 cm.
Lesion(s): 
  Location:  Right mid to base.
  Size:  1.4 x 1.3 x 0.7 cm.
  Appearance:  Irregular, tan-yellow.
  Distance to margins:  Abutting the right posterior prostate.
Seminal vesicles
  Right:  2.9 x 2.0 x 1.2 cm; unremarkable.
  Left:  2.2 x 1.2 x 0.5 cm; unremarkable.
Vasa deferentia
  Right:  2.5 x 0.5 cm.
  Left:  Absent.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross-sections through shaved proximal margin
2  cross-sections through shaved distal margin
3  right apical prostate
4  right mid prostate
5-8  right base prostate
9  left apical prostate
10  left mid prostate
11-14  left base prostate
15  right seminal vesicle and vas deferens
16  left seminal vesicle  

B. Specimen:  Lymph nodes with attached fat, received in formalin.  
Weight:  12 gm.
Number of segments:  3.  
Size:  Aggregating to 5.2 x 5.0 x 1.5 cm.
Gross findings: 3 apparent lymph nodes grossly identified measuring up to 2.4 x 1.2 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks for microscopic evaluation:
1-2  lymph nodes
3-6  remaining fatty tissue.",,"A: PROSTATE
B: RIGHT AND LEFT PELVIC LYMPH NODES",,
REG4,PROSTATE,0,PAT-10034934,1,REC-3000655535,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON 7.

Prostate cancer information
Operative procedure:  Radical prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:
- Right apex to base.
- Left mid to base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3 + 4).
Percent Gleason grade 4 and/or 5:  10%.
Size (dominant nodule):  2.2 x 1.5 x 0.8 cm (right and left mid to base).
Percent of prostate involved by carcinoma:  20%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not applicable.
Lymph-Vascular invasion:  Not identified.
Margins:  Uninvolved by carcinoma.
  Bladder neck (proximal) margin:  Uninvolved by carcinoma. 
  Apical (distal) margin:  Uninvolved by carcinoma.
  Circumferential (left and right) margins:  Uninvolved by carcinoma. 
Regional lymph nodes:  Not applicable.
Distant metastasis:  Not applicable.
High grade prostatic intraepithelial neoplasia:  Present.
Distant metastasis:  Not applicable.
Other findings:  None identified.
Pathologic grade and stage:  Gleason 7, pT2c(m) NX (stage IIB if N0 M0).",,"GrossDescription:
Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  42 gm.
Size:
  Apex Base:  3.5 cm.
  Anterior Posterior:  2.5 cm.
  Right Left:  4.3 cm.
Gross findings:  No discrete lesions grossly identified.
Seminal vesicles
  Right:  3.7 x 1.5 x 0.7 cm; unremarkable.
  Left:  3 x 1.3 x 1.2 cm; unremarkable.
Vasa deferentia
  Right:  4.4 x 0.6 cm.
  Left:  4.6 x 0.6 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through bladder neck margin
3  cross sections through apical margin
4  right apex
5-7  right mid prostate
8-11  right base
12  left apex
13-15  left mid prostate
16-19  left base
20  right seminal vesicle and vas deferens
21  left seminal vesicle and vas deferens.",,A: PROSTATE,,
REG4,PROSTATE,0,PAT-10034961,1,REC-3000655674,"ClinicalHistory:
Procedure->Excision
Clinical History/Diagnosis/Condition->BENIGN PROSTATIC HYPERTROPHY./r/n",,"FinalDiagnosis:
Prostatic urethral lesion:  Consistent with prostatic duct adenocarcinoma (see comment)./r/nDiagnosisComment:
Case reviewed in Pathology Staff Conference on **DATE[Dec 24 2011].  The clinical and histologic features are best in keeping with prostatic duct adenocarcinoma with a focal cribriform, Grade 4 pattern in addition to an apparent more exophytic papillary pattern.  Prostatic duct adenocarcinomas may more often have a course approximating a Gleason grade 4+4, sum 8 form of the much more common prostatic adenocarcinoma of prostatic acinar derivation.  Only limited non-neoplastic prostate tissue is represented without representation of seminal vesicle tissue without evidence of lymphovascular invasion or perineural invasion as sampled.  Findings reported to Dr. **NAME[ZZZ YYY] s office (**NAME[XXX]) on **DATE[Dec 24 2011] at 4:45 PM./r/n",,"GrossDescription:
Labeled:      Patient name and medical record number, designated prostatic urethral lesion Specimen:    Multiple, tan-gray to pink pieces of friable tissue (formalin)
Aggregate:    3 x 2 x 0.8 cm
Weight:      1.6 grams
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
The multiple fragments have features consistent with prostatic duct adenocarcinoma with part of the lesion having complex papillary formations with hyperchromatic nuclei with crowded papillary and glandular formations, likely associated with an exophytic portion. Other parts of the tumor have a focal cribriform back to back gland arrangement with glandular confluence and invasive features with general absence of immunoreactive cells for high molecular weight cytokeratin and p63 with only rare areas with some background non-neoplastic prostatic glands with some immunoreactive cells.  The lesion diffusely expresses prostatic specific antigen and in most areas expresses p504 (AMCAR) consistent with a prostate derived lesion.

Prostate Cancer Information
Based on AJCC/UICC TNM, 7th edition

Procedure:  Transurethral prostatic resection 
Specimen size:  Weight:  1.6 g
Histologic type:  Prostatic duct adenocarcinoma 
Histologic grade
    Total Gleason score:  4+4, sum 8
Tumor quantitation:  Proportion (percentage) of prostatic tissue involved by tumor:  Approximately 96%./r/n","A: PROSTATIC URETHRAL LESION, excision",,
REG4,PROSTATE,0,PAT-10042822,1,REC-3000655711,"ClinicalHistory:
Elevated PSA.
Post-OperativeDiagnosis:
To be determined by pathology.",,"PostOperativeDiagnosis:
To be determined by pathology
FinalDiagnosis:
Prostate core needle biopsies:

A.  Right base:      Benign prostatic tissue

B.  Right mid lat:    Atypical glands present (see Comments)

C.  Right mid:       Benign prostatic tissue with focal chronic prostatitis

D.  Right mid TZ:     Benign prostatic tissue 

E.  Right apex:     Benign prostatic tissue with focal chronic prostatitis

F.  Left base:      Benign prostatic tissue with focal chronic prostatitis

G.  Left mid lat:     Benign prostatic tissue

H.  Left mid:       Benign prostatic tissue with focal active chronic prostatitis

I.  Left mid tz:       Benign prostatic tissue

J.  Left apex:       Benign prostatic tissue with focal chronic prostatitis
DiagnosisComment:
B.  Consultation is pending; the result will be reported separately.

B,E,F, and H:  Immunohistochemical stains for PIN-4 (p63, 34BE12, and AMACR) support the diagnoses.

Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnoses. \X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.2 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

B.  Received in formalin labeled ""XXXXXX, right mid lat"" is a soft, tan core of tissue measuring up to 2.1 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

C.  Received in formalin labeled ""XXXXXX, right mid"" is a soft, tan core of tissue measuring up to 1.8 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

D.  Received in formalin labeled ""XXXXXX, right mid tz"" is a soft, tan core of tissue measuring up to 1.3 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

E.  Received in formalin labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 1.7 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

F.  Received in formalin labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.3 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

G.  Received in formalin labeled ""XXXXXX, left mid lat"" is a soft, tan core of tissue measuring up to 1.1 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

H.  Received in formalin labeled ""XXXXXX, left mid"" is a soft, tan core of tissue measuring up to 0.9 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

I.  Received in formalin labeled ""XXXXXX, left mid tz"" are two soft, tan cores of tissues measuring up to 1.5 cm in length x 0.1 cm in diameter.  The larger core is submitted in cassette I1.  The specimens are submitted entirely in cassettes I1 and I2.

J.  Received in formalin labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.6 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.   The microscopic findings support the above diagnoses.","A: Right prostate core needle biopsy at base
B: Right prostate core needle biopsy at mid lat
C: Right prostate core needle biopsy at mid
D: Right prostate core needle biopsy at mid tz
E: Right prostate core needle biopsy at apex
F: Left prostate core needle biopsy at base
G: Left prostate core needle biopsy at mid lat
H: Left prostate core needle biopsy at mid
I: Left prostate core needle biopsy at mid tz
J: Left prostate core needle biopsy at apex",,"AddendumDiagnosis:
The **NAME[XXX WWW] Reference Laboratories Consultation Report ***PATH-NUMBER[1], Dated **DATE[Dec 25 2011], reads:
  
  Prostate
  A. Benign prostatic tissue.

  B. Prostate tissue with small focus of atypical glands, suspicious for carcinoma. High-grade prostatic intraepithelial
       neoplasia cannot be excluded with certainty. See note.

    Note: Although these findings are atypical and suspicious for adenocarcinoma, there is insufficient cytologic
              and/or architectural atypia to establish a definitive diagnosis. Repeat biopsy is recommended with 
              relative increased sampling of the initial atypical site.
              By itself, negative staining for high molecular weight cytokeratin and p63 in a small focus of glands, as
              seen in this case, is not diagnostic of cancer. The immunohistochemical stain for alpha-methyacyl-CoA
              racemase (P504S) is positive. However, this marker is also found positive in the majority of high-grade
              prostatic intraepithelial neoplasia and occasional benign glands and mimickers of cancer. Therefore, a
              positive P504S staining does not equate to prostate cancer. Luo, et al, Cancer Res 2002, **ID-NUM.

  C-J. Benign prostatic tissue.

Signed
**NAME[VVV M. UUU], M.D.   JIE*.
AddendumComment:
See attached copy of The **NAME[XXX WWW] Reference Laboratories Report No. ***PATH-NUMBER[2], Dated **DATE[Dec 25 2011]."
REG4,PROSTATE,0,PAT-10038519,1,REC-3000655750,"ClinicalHistory:
790.93, elevated prostate specific antigen (PSA).",,"FinalDiagnosis:
A.  RIGHT APEX PROSTATE BIOPSY:  
- ADENOCARCINOMA GS 7 (4+3), INVOLVING 100% OF THE SAMPLE, GLEASON 4
  COMPONENT COMPRISING 60% OF THE TUMOR.
 
B.  RIGHT MID PROSTATE BIOPSY:  
- ADENOCARCINOMA GS 7 (4+3), INVOLVING 95% OF THE SAMPLE, GLEASON 4
  COMPONENT COMPRISING 80% OF THE TUMOR.
 
C.  RIGHT BASE PROSTATE BIOPSY:  
- ADENOCARCINOMA GS 7 (3+4), INVOLVING 75% OF THE SAMPLE, GLEASON 4
  COMPONENT COMPRISING 40% OF THE TUMOR, WITH PERINEURAL INVASION.
 
D.  LEFT APEX PROSTATE BIOPSY:  
- BENIGN PROSTATIC TISSUE. 
 
E.  LEFT MID PROSTATE BIOPSY:  
- BENIGN PROSTATIC TISSUE. 
 
F.  LEFT BASE PROSTATE BIOPSY:  
- ADENOCARCINOMA GS 7 (4+3), INVOLVING 5% OF THE SAMPLE, GLEASON 4 
  COMPONENT COMPRISING 60% OF THE TUMOR.
 
G.  MEDIAL ZONE PROSTATE BIOPSY:  
- ADENOCARCINOMA GS 7 (3+4), INVOLVING 20% OF THE SAMPLE, GLEASON 4
  COMPONENT COMPRISING 10% OF THE TUMOR.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right apex, mid and base; Left base; Medial zone.
Number of cores with carcinoma/total cores:  9/15.
Maximum size of carcinoma:  1.0 cm.
Percent of overall tissue involved by carcinoma:  40%.
Highest Gleason score at single site:  7 (4+3).
Overall Gleason score:  7 (4+3). 
Percent of Gleason grade 4 and/or 5:  60%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Present. 
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT APEX PROSTATE BIOPSY
B: RIGHT MID PROSTATE BIOPSY
C: RIGHT BASE PROSTATE BIOPSY
D: LEFT APEX PROSTATE BIOPSY
E: LEFT MID PROSTATE BIOPSY
F: LEFT BASE PROSTATE BIOPSY
G: MEDIAL ZONE PROSTATE BIOPSY",,
REG4,PROSTATE,0,PAT-10034932,1,REC-3000655849,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  RIGHT PELVIC TISSUE: 1 NODE NEGATIVE FOR METASTASIS (0/1).
 
B.  LEFT PELVIC TISSUE:  NEGATIVE FOR LYMPH NODE OR MALIGNANCY.
 
C.  PROSTATE:  PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Bilateral, extending from made to apex.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4)
Percent Gleason grade 4 and/or 5:  10%.
Size (dominant nodule):  0.5 cm.
Percent of prostate involved by carcinoma:  5-10%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Not identified.
Invasion of adjacent structures:  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes:  0/1.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  
  Gleason's 7 (3+4), pT2c N0 (Stage IIB if M0).",,"GrossDescription:
A. Specimen:  Irregular segment of fatty tissue.  
Weight:  2 gm.
Number of segments:  1.  
Size:  4.1 x 5 x 0.6 cm.
Gross findings:  Single lymph node measuring 2.3 x 0.9 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1  single bisected node; 2  fat

B. Specimen:  Irregular segment of fatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.2 x 1.2 x 0.5 cm.
Gross findings:  No lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  37 gm.
Size:
  Apex Base:  3.9 cm.
  Anterior Posterior:  4 cm.
  Right Left:  3.7 cm.
Gross findings:  No obvious lesions grossly identified.  Slightly nodular cut surface.
Seminal vesicles
  Right:  1.7 x 1.5 x 0.6 cm; unremarkable.
  Left:  1.8 x 1.6 x 0.6 cm; partially detached, unremarkable.
Vasa deferentia
  Right:  2.1 x 0.5 cm.
  Left:  2.1 x 0.5 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through bladder neck margin
3  cross sections through apical margin
4  right apex
5-7  right mid prostate
8-11  right base
12  left apex
13-15  left mid prostate
16-19  left base
20/21  right/left seminal vesicle and vas deferens.",,"A: RIGHT PELVIC LYMPH NODES
B: LEFT PELVIC LYMPH NODES
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10038322,1,REC-3000655985,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  PRE PROSTATIC FAT:  
- FIBROADIPOSE TISSUE; NO EVIDENCE OF MALIGNANCY.
 
B.  RIGHT PELVIC LYMPH NODE:  
- ONE (1) BENIGN LYMPH NODE.
 
C.  LEFT PELVIC LYMPH NODE:  
- FIBROADIPOSE TISSUE; NO LYMPHOID TISSUE OR MALIGNANCY IDENTIFIED.
 
D.  PROSTATE:
- PROSTATIC ADENOCARCINOMA, GLEASON 8.

Prostate cancer information
Operative procedure:  Robot-assisted prostatectomy with pelvic lymphadenectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Right apex to base with extension to left mid and base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  8 (4 + 4).
Percent Gleason grade 4 and/or 5:  100%.
Size (dominant nodule):  2.3 x 1.4 x 0.7 (macroscopic).
Percent of prostate involved by carcinoma:  20%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not applicable.
Lymph-Vascular invasion:  Not identified.
Margins:  Uninvolved by carcinoma.
  Bladder neck (proximal) margin:  Uninvolved by carcinoma. 
  Apical (distal) margin:  Uninvolved by carcinoma.
  Circumferential (left and right) margins:  Uninvolved by carcinoma. 
Regional lymph nodes:  0/1 (pN0).
Distant metastasis:  Not applicable.
High grade prostatic intraepithelial neoplasia:  Present.
Distant metastasis:  Not applicable.
Other findings:  None identified.
Pathologic stage:  pT3a(m) pN0 (stage III if M0).",,"GrossDescription:
A. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  5 gm.
Number of segments:  3.  
Size:  Aggregating to 3.0 x 2.8 x 1.5 cm.
Gross findings: No mass/lesions or lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.5 x 1.0 x 0.7 cm.
Gross findings: Single lymph node identified measuring 3.0 x 0.8 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  1.6 x 1.1 x 0.8 cm.
Gross findings: Single apparent lymph node measuring 0.6 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Prostate attached bilateral seminal vesicles and vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  54 gm.
Size:
  Apex Base:  4.3 cm.
  Anterior Posterior:  4.0 cm.
  Right Left:  5.2 cm.
Lesion(s): 
  Location:  Right apex-base prostate.
  Size:  0.7 x 2.3 x 1.4 cm.
  Appearance:  Ill-defined, irregular tan and firm.
  Distance to margins:  Grossly abutting the posterior and right circumferential margins.
Seminal vesicles
  Right:  3.8 x 1.6 x 0.9 cm; unremarkable.
  Left:  5.0 x 2.0 x 1.6 cm; unremarkable.
Vasa deferentia
  Right:  1.3 x 0.6 cm, unremarkable. 
  Left:  2.0 x 0.6 cm, unremarkable. 
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved distal, prostatic apical margin
2  cross sections through shaved proximal, bladder neck margin
3  left apical prostate
4-6  left mid prostate
7-9  left base prostate
10  left seminal vesicle and vas deferens
11  right seminal vesicle and vas deferens
12-14  lesion, right base prostate
15-17  lesion, right mid prostate
18  lesion, right apical prostate.",,"A: PRE PROSTATIC FAT
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE
D: PROSTATE",,
REG4,PROSTATE,0,PAT-10034075,1,REC-3000656051,"ClinicalHistory:
Elevated PSA 790.93.",,"FinalDiagnosis:

A.  LEFT LATERAL PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4),
    INVOLVING 15% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    10% OF THE TUMOR. 
 
B.  RIGHT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 5% OF SAMPLE.   
 
C.  LEFT LATERAL PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.   
 
D.  LEFT SEXTANT PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Left lateral and right sextant.
Number of cores with carcinoma:  3 of 19 core fragments.
Maximum size of carcinoma:  0.3 cm.
Percent of overall tissue involved by carcinoma:  5%.
Highest Gleason score at single site:  7 (3 + 4).
Overall Gleason score:  7 (3 + 4).
Percent of overall Gleason grade 4 and/or 5:  5 to 10%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 0.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT LATERAL
B: RIGHT SEXTANT
C: LEFT LATERAL
D: LEFT SEXTANT",,
REG4,PROSTATE,0,PAT-10034875,1,REC-3000656106,"ClinicalHistory:
Elevated PSA = 10.4 ng/mL.",,"FinalDiagnosis:
Prostate core needle biopsies:

A.  Right apex:      Benign prostatic tissue

B.  Right mid gland:     Benign prostatic tissue

C.  Right base:     Atypical glands highly suspicious for carcinoma present, see Comments

D.  Right lateral:     PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 
        core, measuring 0.4 mm, see Comments

E.  Right anterior:     Benign prostatic tissue

F.  Left apex:      Benign prostatic tissue

G. Left mid gland:     Benign prostatic tissue

H.  Left base:       Benign prostatic tissue

I.  Left lateral:       Benign prostatic tissue

J.  Left anterior:     Benign prostatic tissue
DiagnosisComment:
C.  A focus of atypical glands measures 0.5 mm in greatest dimension.
A-J:  Immunohistochemical stains for PIN-4 (p63, 34BE12, and AMACR) support the diagnosis.

Dr. **NAME[ZZZ YYY] has reviewed the case and concur with the diagnosis. \X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, #1"" is a core of tissue measuring 1.4 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

B.  Received in formalin labeled ""XXXXXX, #2"" is a core of tissue measuring 1.7 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

C.  Received in formalin labeled ""XXXXXX, #3"" is a core of tissue measuring 1.9 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

D.  Received in formalin labeled ""XXXXXX, #4"" is a core of tissue measuring 1.8 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

E.  Received in formalin labeled ""XXXXXX, #5"" is a core of tissue measuring 1.3 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

F.  Received in formalin labeled ""XXXXXX, #6"" is a core of tissue measuring 2.2 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

G.  Received in formalin labeled ""XXXXXX, #7"" is a core of tissue measuring 1.5 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

H.  Received in formalin labeled ""XXXXXX, #8"" is a core of tissue measuring 1.7 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

I.  Received in formalin labeled ""XXXXXX, #9"" is a core of tissue measuring 1.4 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.

J.  Received in formalin labeled ""XXXXXX, #10"" is a core of tissue measuring 1.6 cm in length x 0.1 cm in diameter.  Submitted in toto in one cassette.","MicroscopicDescription:
A-J.   The microscopic findings support the above diagnoses.","A: Right prostate core needle biopsy at apex
B: Right prostate core needle biopsy at midgland
C: Right prostate core needle biopsy at base
D: Right prostate core needle biopsy at lateral
E: Right prostate core needle biopsy at anterior
F: Left prostate core needle biopsy at apex
G: Left prostate core needle biopsy at midgland
H: Left prostate core needle biopsy at base
I: Left prostate core needle biopsy lateral
J: Left prostate core needle biopsy at anterior",,"AddendumComment:
Dr. **NAME[XXX WWW] and Dr. **NAME[VVV UUU] concur with the diagnoses for C (atypical) and D (adenocarcinoma).  Dr. **NAME[TTT SSS] has been notified. 

Note:  Although the findings in part C are atypical and may represent adenocarcinoma, there is insufficient cytologic and/or architectural atypia to establish a definitive diagnosis.  The negative staining for p63 and 34BE12 and positive staining for AMACR in a small focus of glands is not diagnostic of cancer by itself.  This pattern of staining can be seen in adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and occasional benign glands.  Repeat sampling maybe of help if clinically indicated.

Reference:  Luo, et al, Cancer Res 2002, **ID-NUM."
REG4,PROSTATE,0,PAT-10038420,1,REC-3000656461,"ClinicalHistory:
Elevated PSA/BPH with obstruction. PSA=4.51 (**DATE[Jul 7 11]).
Post-OperativeDiagnosis:
Pending.
Pre-OperativeDiagnosis:
TRUS/PBX.",,"PreOperativeDiagnosis:
TRUS/PBX
PostOperativeDiagnosis:
Pending
FinalDiagnosis:
A.  Prostate, left wide, biopsy:      Benign prostate   
 
B.  Prostate, right wide, biopsy:    Benign prostate 
 
C.  Prostate, left apex, biopsy:      Benign prostate 
 
D.  Prostate, right apex, biopsy:    Atypical small acinar proliferation (ASAP)     
 
E.  Prostate, left mid, biopsy:      Benign prostate 
 
F.  Prostate, right mid, biopsy:      Benign prostate 
 
G.  Prostate, left base, biopsy:      Benign prostate 
 
H.  Prostate, right base, biopsy:     PROSTATE ADENOCARCINOMA, Gleason's grade 3 + 3 = 6;
            0.5 mm focus; no perineural invasion evident   \X0A|",,"GrossDescription:
A.  Received in formalin labeled ""**NAME[BBB, AAA], left wide"" are two cores of tan-white soft tissue measuring up to 1.1 cm in length and 0.1 cm in diameter.  Submitted entirely in block A.

B.  Received in formalin labeled ""**NAME[BBB, AAA], right wide"" are two cores of tan-white tissue measuring up to 1.4 cm in length and 0.1 cm in diameter.  Submitted entirely in block B.

C.  Received in formalin labeled ""**NAME[BBB, AAA], left apex"" is one core of tan-white soft tissue measuring up to 1.3 cm in length and 0.1 cm in diameter.  Submitted entirely in block C.

D.  Received in formalin labeled ""**NAME[BBB, AAA], right apex"" is one core of tan-white tissue measuring up to 1.0 cm in length and 0.1 cm in diameter.  Submitted entirely in block D.

E.  Received in formalin labeled ""**NAME[BBB, AAA], left mid"" is one core of tan-white tissue measuring up to 1.4 cm in length and 0.1 cm in diameter.  Submitted entirely in block E.

F.  Received in formalin labeled ""**NAME[BBB, AAA], right mid"" is one core of tan-white tissue measuring up to 1.5 cm in length and 0.1 cm in diameter.  Submitted entirely in block F.

G.  Received in formalin labeled ""**NAME[BBB, AAA], left base"" is one core of tan-white soft tissue measuring up to 1.0 cm in length and 0.1 cm in diameter.  Submitted entirely in block G.

H.  Received in formalin labeled ""**NAME[BBB, AAA], right base"" is one core of tan-white soft tissue measuring up to 1.2 cm in length and 0.1 cm in diameter.  Submitted entirely in block H.","MicroscopicDescription:
A.  Sections contain benign prostate.

B.  Sections contain benign prostate.

C.  Sections contain benign prostate.

D.  Needle biopsies of prostate demonstrate a small focus of glands with mild cytologic and architectural atypia, present at a distal tip of the biopsy core.  Immunostains for basal cells (p63, HMWK) are evaluated and demonstrate focal loss of basal cells in this focus.  In the context of adjacent prostatic intraepithelial neoplasia (PIN), presence at the core tip, and small number of involved acini, this focus is interpreted as an atypical small acinar proliferation (ASAP), suspicious for carcinoma.

E.  Sections contain benign prostate.

F.  Sections contain benign prostate.

G.  Sections contain benign prostate.

H.  A core biopsy of prostate demonstrates a few glands with mild cytologic and architectural atypia, and focally prominent nucleoli.  Immunostains for basal cells (p63, HMWK) are evaluated and demonstrate focal loss of basal cells.  An immunostain (P504S) is positive in the small focus of atypical acini.  Step sections demonstrate several areas with prominent macronucleoli. Collectively, this small focus is consistent with prostate adenocarcinoma of Gleason's grade 3 + 3 = 6, measuring 0.5 mm in greatest dimension.  No perineural invasion is evident.","A: Prostate biopsy, left wide
B: Prostate biopsy, right wide
C: Prostate biopsy, left apex
D: Prostate biopsy, right apex
E: Prostate biopsy, left mid
F: Prostate biopsy, right mid
G: Prostate biopsy, left base
H: Prostate biopsy, right base",,
REG4,PROSTATE,0,PAT-10034936,1,REC-3000659096,"ClinicalHistory:
Prostate cancer, PSA 0.89.",,"FinalDiagnosis:
A.  LEFT PELVIC LYMPH NODE:  
    - THREE LYMPH NODES NEGATIVE FOR METASTASIS (0/3).
 
B.  RIGHT PELVIC LYMPH NODE:  
    - THREE LYMPH NODES NEGATIVE FOR METASTASIS (0/3).
 
C.  PROSTATE: PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Robotic radical prostatectomy and bilateral pelvic lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Unifocal.
Anatomic site:  Left posterior apex to mid.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  20%.
Size (dominant nodule): 1.5 x 1.5 x 0.7 cm (macroscopic measurement).
Percent of prostate involved by carcinoma:  10%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes: Negative for metastasis (0/6).
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
Pathologic stage:  pT2a, pN0, Stage IIA (if M0).",,"GrossDescription:
A. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  7 gm.
Number of segments:  2.  
Size:  Up to 4.2 x 1.6 x 1.1 cm.
Gross findings: Two lymph nodes identified measuring up to 4.2 x 1.1 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1  single lymph node, halved
2  single lymph node
3  remaining fatty tissue


B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  6 gm.
Number of segments:  1.  
Size:  4.5 x 3.0 x 1.0 cm.
Gross findings: Single lymph node identified measuring 4.2 x 2.0 x 1.0 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1-2  lymph node, bisected (green lymph node is separate in 2)
3  remaining fatty tissue

C. Specimen:  Prostate with attached bilateral seminal vesicles and vasa deferentia.
Fixative:  10% neutral buffered formalin.
Weight:  47 gm.
Size:
  Apex Base:  4.1 cm.
  Anterior Posterior:  3.5 cm.
  Right Left:  5.0 cm.
Lesion(s): 
  Location:  Left apical to mid prostate.
  Size:  1.5 x 1.5 x 0.7 cm.
  Appearance:  abutting left posterior margin.
  Distance to margins:  Abutting left posterior margin.
Seminal vesicles
  Right:  3.7 x 1.7 x 0.6 cm; unremarkable.
  Left:  3.0 x 1.8 x 0.6 cm; unremarkable.
Vasa deferentia
  Right:  3.6 x 0.5 cm.
  Left:  2.2 x 0.6 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal (bladder neck) margin
3  cross sections through shaved distal (apical) margin
4-11  right apical to base prostate, respectively
12-19  left apical to base prostate, respectively
20  right seminal vesicle and vas deferens
21  left seminal vesicle and vas deferens.",,"A: LEFT PELVIC LYMPH NODE
B: RIGHT PELVIC LYMPH NODE
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10034935,1,REC-3000659141,"ClinicalHistory:
Prostate CA.",,"IntraoperativeDiagnosis:
FROZEN SECTION: Neurovascular tissue; negative for malignancy.  Assessed by **NAME[M. ZZZ]/**INITIALS.
FinalDiagnosis:
A.  RIGHT NEUROVASCULAR BUNDLE:  NEGATIVE FOR MALIGNANCY.
 
B.  RIGHT PELVIC LYMPH NODES:  TWO LYMPH NODES NEGATIVE FOR METASTASIS (0/2).
 
C.  LEFT PELVIC LYMPH NODE: ONE LYMPH NODE NEGATIVE FOR METASTASIS (0/1). 
 
D.  PROSTATE: PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Robotic radical prostatectomy and bilateral pelvic lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Bilateral (R>>L), apex to base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  20-30%.
Size (dominant nodule):  1.5 x 0.7 cm (microscopic measurement).
Percent of prostate involved by carcinoma:  15%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes: Negative for metastasis (0/3).
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic stage: pT2c, pN0, Stage IIB (if M0).",,"GrossDescription:

A. Specimen:  Reddish soft tan tissue, received fresh.
Number of segments:  1.    
Size:  0.4 x 0.3 x 0.3 cm.
Submitted for microscopic evaluation:  All.    
Cassettes:  1, frozen section.

B. Specimen:  Single lymph node.  
Weight:  2 gm.
Number of segments:  1.  
Size:  3.7 x 1.3 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, lymph node is bisected and halved.

C. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.7 x 1.2 x 0.5 cm.
Gross findings: Single lymph node identified measuring 2.4 x 1.0 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Prostate with attached bilateral seminal vesicles and vasa deferentia.
Fixative:  10% neutral buffered formalin.
Weight:  36 gm.
Size:
  Apex Base:  3.8 cm.
  Anterior Posterior:  4.2 cm.
  Right Left:  4.3 cm.
Lesion(s): 
  Location:  Right posterior mid to base prostate.
  Size:  1.5 x 1.0 x 0.7 cm.
  Appearance:  Firm, ill-defined, tan-yellow.
  Distance to margins:  Abutting right posterior margin.
Seminal vesicles
  Right:  1.1 x 0.7 x 0.7 cm; unremarkable.
  Left:  1.5 x 1.2 x 0.8 cm; unremarkable.
Vasa deferentia
  Right:  1.3 x 0.5 cm.
  Left:  2.0 x 0.7 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved proximal (bladder neck) margin
2  cross sections through shaved distal (apical) margin
3-10  right apical to base prostate, respectively (lesion in 7, 9, 10)
11-19  left apical to base prostate, respectively
20  right seminal vesicle and vas deferens
21  left seminal vesicle and vas deferens.",,"A: RIGHT NEUROVASCULAR BUNDLE
B: RIGHT PELVIC LYMPH NODES
C: LEFT PELVIC LYMPH NODES
D: PROSTATE",,
REG4,PROSTATE,0,PAT-10038247,1,REC-3000659231,"ClinicalHistory:
790.93 Elevated PSA - 6.6, R/O malignancy.",,"FinalDiagnosis:

A.  Left prostate, biopsy:    Benign prostate parenchyma.

B.  Right prostate, biopsy:    Adenocarcinoma, Gleason grade 3+3.

Comment:  The adenocarcinoma focus measures less than 2 mm and less than 10% of biopsy volume.   \X0A|",,"GrossDescription:
(A)  Received in formalin labeled ""biopsy of prostate, left"" are five white-tan, soft and cylindrical tissue fragments that range in size from 0.6 - 1.5 cm in length by less than 0.1 cm in diameter.   Entirely submitted in two cassettes. 

(B)  Received in formalin labeled ""biopsy of prostate, right "" are five white-tan, soft and cylindrical tissue fragments that range in size from 1.2 - 1.8 cm in length by less than 0.1 cm in diameter.   Entirely submitted in two cassettes.","MicroscopicDescription:
A, B.  Confirmed.  Multiple levels.","A: Prostate, needle biopsy, Lt
B: Prostate, needle biopsy, Rt",,"AddendumComment:

Stains for high molecular weight keratin 34bE12 show absence of the basement membranes in the adenocarcinomatous areas."
REG4,PROSTATE,0,PAT-10037140,1,REC-3000659313,"ClinicalHistory:
Prostate Cancer.",,"FinalDiagnosis:
A.  PRE PROSTATIC FAT:  NEGATIVE FOR MALIGNANCY.
 
BC. LEFT AND RIGHT PELVIC LYMPH NODES:
    2 NODES NEGATIVE FOR METASTASIS (0/2).

D.  PROSTATE:  PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Prostatectomy w/bilateral pelvic node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Not identified.
Anatomic site:  Bilateral, base to apex
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (4+3), with Gleason's 5 component present (about 10%).
Percent Gleason grade 4 and/or 5:  60-70%.
Size (dominant nodule):  Estimate 5 cm.
Percent of prostate involved by carcinoma:  60-70%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures:  Tumor involves bladder neck margin.
Lymph-Vascular invasion:  Lymphatic invasion present.
Margins:
  Bladder neck (proximal) margin:  Extensively involved. 
  Apical (distal) margin:  Clear.
  Circumferential margins:  Anterior circumferential margin focally involved. 
Regional lymph nodes:  0/2
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.

Pathologic grade and stage:
  Gleason's 7 (4+3), pT3a N0 (Stage III if M0).",,"GrossDescription:
A. Specimen:  Irregular segments of fibrofatty tissue.  
Weight:  7 gm.
Number of segments:  2.  
Size:  Up to 4.0 x 3.4 x 1.8 cm.
Gross findings: No lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  2.

B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.4 x 1.5 x 1.2 cm.
Gross findings: Single lymph node identified measuring 1.5 x 1.0 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  2 gm.
Number of segments:  1.  
Size:  1.8 x 1.6 x 1.0 cm.
Gross findings: Single lymph node identified measuring 1.8 x 1.0 x 0.7 cm.  All
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Prostate with attached bilateral seminal vesicles and vasa differentia.
Fixative:  10% neutral buffered formalin.
Weight:  58 gm.
Size:
  Apex Base:  4.7 cm.
  Anterior Posterior:  4.0 cm.
  Right Left:  5.5 cm.
Lesion(s): 
  Location:  Right and left apical to base prostate.
  Size:  4.4 x 2.7 x 1.5  cm.
  Appearance:  Rubbery, tan-yellow, irregular.
  Distance to margins:  Abutting left circumferential margin.
Seminal vesicles
  Right:  3.4 x 1.2 x 0.7 cm; unremarkable.
  Left:  2.2 x 0.8 x 0.7 cm; unremarkable.
Vasa deferentia
  Right:  2.8 x 0.5 cm.
  Left:  1.8 x 0.6 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-3  cross-sections through shaved proximal (bladder neck) margin
4  cross-sections through shaved distal (apical) margin
5-13  lesion, right apical to base prostate, respectively
14-23  lesion, left apical to base prostate, respectively
24  right seminal vesicle and vas deferens
25  left seminal vesicle and vas deferens.",,"A: PRE PROSTATIC FAT
B: LEFT PELVIC LYMPH NODE
C: RIGHT PELVIC LYMPH NODE
D: PROSTATE GLAND",,
REG4,PROSTATE,0,PAT-10015753,2,REC-3000659371,"ClinicalHistory:
Elevated PSA, 790.93.",,"FinalDiagnosis:
A.  PROSTATE NEEDLE BIOPSY (LEFT APEX):  
    BENIGN PROSTATIC TISSUE.
 
B.  PROSTATE NEEDLE BIOPSIES (LEFT MID):  
    SMALL FOCI OF PROSTATIC ADENOCARCINOMA, GLEASON's 6 (3+3),
    INVOLVING 2 OF MULTIPLE SEGMENTS.
 
C.  PROSTATE NEEDLE BIOPSIES (LEFT BASE):  
    BENIGN PROSTATIC TISSUE.

D.  PROSTATE NEEDLE BIOPSIES (RIGHT APEX):  
    BENIGN PROSTATIC TISSUE.
 
E.  PROSTATE NEEDLE BIOPSIES (RIGHT MID):  
    SMALL FOCI OF PROSTATIC ADENOCARCINOMA, GLEASON's 6 (3+3),
    INVOLVING 2 OF MULTIPLE SEGMENTS.
 
F.  PROSTATE NEEDLE BIOPSIES (RIGHT BASE):  
    SMALL FOCI OF PROSTATIC ADENOCARCINOMA, GLEASON's 6 (3+3),
    INVOLVING 3 OF 4.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left mid; Right mid, base.
Number of cores with carcinoma/total cores in involved area:  
  7/multiple.
Maximum size of carcinoma:  0.1 cm.
Percent of overall tissue involved by carcinoma:  < 5%.
Highest Gleason score at single site:  6 (3+3).
Overall Gleason score:  6 (3+3)
Percent of Gleason grade 4 and/or 5:  0%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
DiagnosisComment:
Dr. **NAME[ZZZ]'s office notified and report faxed **DATE[Jun 2 2012].",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
ACD.  Small segments of prostatic tissue show patchy chronic inflammation with no evidence of malignancy.

BEF.  Small segments of prostatic tissue show small foci of single separate variable glands lined by cells with prominent nucleoli.  PIN is noted.","A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE",,
REG4,PROSTATE,0,PAT-10041334,1,REC-3000659393,"ClinicalHistory:
790.93 elevated PSA.",,"FinalDiagnosis:
A.  LEFT APEX PROSTATE:  ADENOCARCINOMA GS 6 (3+3), INVOLVING 5% OF THE SAMPLE.

B.  LEFT MID PROSTATE:  BENIGN PROSTATIC TISSUE.

C.  LEFT BASE PROSTATE:  BENIGN PROSTATIC TISSUE.

D.  RIGHT APEX PROSTATE:  BENIGN PROSTATIC TISSUE.

E.  RIGHT MID PROSTATE:  BENIGN PROSTATIC TISSUE.

F.  RIGHT BASE PROSTATE:  BENIGN PROSTATIC TISSUE.

G.  MEDIAL ZONE PROSTATE:  ATYPICAL SMALL ACINAR PROLIFERATION.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left apex.
Number of cores with carcinoma/total cores:  1/15.
Maximum size of carcinoma:  0.2 cm.
Percent of overall tissue involved by carcinoma:  5%.
Highest Gleason score at single site:  6 (3+3).
Overall Gleason score:  6 (3+3). 
Percent of Gleason grade 4 and/or 5:  0%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Lymph-Vascular invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  None.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 0.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE
G: MEDIAL ZONE PROSTATE",,
REG4,PROSTATE,0,PAT-10042650,1,REC-3000665370,"ClinicalHistory:
Elevated PSA 790.93.",,"FinalDiagnosis:
A.  PROSTATE NEEDLE BIOPSIES, RIGHT BASE:  
    BENIGN PROSTATIC TISSUE.
 
B.  PROSTATE NEEDLE BIOPSIES, RIGHT MID:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7 (4+3),
    INVOLVING 1 OF 2 SEGMENTS.
 
C.  PROSTATE NEEDLE BIOPSIES, RIGHT APEX:  
    BENIGN PROSTATIC TISSUE.
 
D.  PROSTATE NEEDLE BIOPSIES, LEFT BASE:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7 (3+4),
    INVOLVING 2 OF 2 SEGMENTS.
 
E.  PROSTATE NEEDLE BIOPSIES, LEFT MID:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7 (4+3),
    INVOLVING 2 OF 3 SEGMENTS.
 
F.  PROSTATE NEEDLE BIOPSIES, LEFT APEX:  
    PROSTATIC ADENOCARCINOMA, GLEASON's 7 (3+4),
    INVOLVING 2 OF 2 SEGMENTS.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right mid; Left base, mid apex
Number of cores with carcinoma/total cores in involved area:  7/9.
Maximum size of carcinoma:  0.7 cm. (left mid).
Percent of overall tissue involved by carcinoma:  20-30%.
Highest Gleason score at single site:  7 (4+3); bilateral mid.
Overall Gleason score:  Gleason's 7 (4+3)
Percent of Gleason grade 4 and/or 5:  50-60%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Present. 
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
AC. Small segments of prostatic tissue show no evidence of malignancy.

BDEF. Small segments of prostatic tissue show partial replacement and invasion by fused glands and single separate variable glands lined by cells with prominent nucleoli.  Perineural invasion is noted.","A: RIGHT BASE PROSTATE
B: RIGHT MID PROSTATE
C: RIGHT APEX PROSTATE
D: LEFT BASE PROSTATE
E: LEFT MID PROSTATE
F: LEFT APEX PROSTATE",,
REG4,PROSTATE,0,PAT-10034172,1,REC-3000671232,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:

A.  PROSTATE:  ADENOCARCINOMA, GS 8 (4 + 4), WITH EXTRAPROSTATIC
    EXTENSION, MARGINS FREE.
 
B.  RIGHT PELVIC LYMPH NODES:  7 NODES WITHOUT METASTASIS (0/7).
 
C.  LEFT PELVIC LYMPH NODES:  9 NODES WITHOUT METASTASIS (0/9).

PROSTATE CANCER INFORMATION
Operative procedure:  Robotic laparoscopic radical prostatectomy
  with bilateral pelvic lymph node dissection. 
Tumor-histologic type:  Adenocarcinoma.
Multicentricity:  Absent.
Anatomic site:  Right peripheral zone.
Evidence of anti-androgen therapy:  Absent.
Gleason score:  8 (4 + 4).
Percent Gleason grade 4:  100%.
Size (dominant nodule):  3.0 cm.
Percent of prostate involved by carcinoma:  
Involvement of seminal vesicle:  Absent.
Extraprostatic extension:  Present (microscopic).
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Absent.
Lymph-Vascular invasion:  Present.
Margins (Bladder neck, apical, circumferential):  Clear.
Regional lymph nodes:  Pelvic nodes uninvolved (0/16).
Distant metastasis:  Not applicable.
PSA value:  5.76 ng/ml (from history).
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  GS 8; pT3a N0 (Stage III).",,"GrossDescription:
Specimen:  Prostate with attached bilateral seminal vesicles and 
  vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  52 gm.
Size:
  Apex Base:  4.3 cm.
  Anterior Posterior:  4.5 cm.
  Right Left:  5.7 cm.
Lesion(s): 
  Location:  Primarily right mid, posterior lateral, extending to
    upper apex.
  Size:  Approximately 1.9 x 1.9 x 0.7 cm.
  Appearance:  Firm tan-white lesion with ill-defined borders.
  Distance to margins:  Abuts right lateral posterior margin.
Seminal vesicles
  Right:  2.6 x 1.2 x 0.7 cm; unremarkable.
  Left:  2.7 x 1.4 x 0.7 cm; unremarkable.
Vasa deferentia
  Right:  2 x 0.7 cm.
  Left:  1.5 x 0.7 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior -
  black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2    shaved proximal (bladder neck) margin
3    cross sections through coned distal (apical) margin
4    right prostate, apex
5-6    right prostate, upper apex anterior and posterior
            respectively (lesion in 6)
7-8    right prostate, lower mid, anterior and posterior
            respectively (lesion in 8)
9-10    right prostate, upper mid, anterior and posterior
            respectively (lesion in 10)
11-12    right prostate, lower base, anterior and posterior
            respectively
13-14    right prostate, upper base, anterior and posterior
            respectively
15    left prostate, apex
16-17    left prostate, upper apex
18-19    left prostate, upper mid
20-21    left prostate, upper base (21 includes seminal
            vesicle)
22    right seminal vesicle and vas deferens
23    left seminal vesicle and vas deferens

B. Specimen:  Irregular segments of fatty tissue, received in 
  formalin.  
Weight:  5 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 3 x 2.5 x 1.5 cm.
Gross findings: Separation of fatty tissue reveals two tan 
  rubbery to firm lymph nodes up to 2.2 x 0.7 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  3, largest node bisected in 1.

C. Specimen:  Irregular segment of fatty tissue, received in
  formalin.  
Weight:  5 gm.
Number of segments:  1.  
Size:  3.9 x 3 x 1.2 cm.
Gross findings: Separation of fatty tissue reveals multiple tan
  rubbery to firm lymph nodes up to 2.5 x 0.9 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  3.",,"A: PROSTATE
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE",,"AddendumDiagnosis:
Percent of prostate involved by carcinoma:  5 to 10%."
REG4,PROSTATE,0,PAT-10038473,1,REC-3000671286,"ClinicalHistory:
Elevated PSA. PSA= 18.85 H (**DATE[Dec 8 2011]).
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
TRUS/PBx.",,"PreOperativeDiagnosis:
TRUS/PBx
PostOperativeDiagnosis:
Same, Pending pathology
FinalDiagnosis:
A.   Prostate, left wide, biopsy:  Focal high-grade prostatic intraepithelial neoplasia (PIN III).

B.   Prostate, right wide, biopsy:  Atypical small acinar proliferation (ASAP)

C.   Prostate, left apex, biopsy:  PROSTATE ADENCARCINOMA, Gleason's grade 3 + 3 = 6; 0.1 cm; 
          no perineural invasion evident

D.   Prostate, right apex, biopsy:  Focal high-grade prostatic intraepithelial neoplasia (PIN III)

E.   Prostate, left mid, biopsy:    Benign prostate

F.   Prostate, right mid, biopsy:  Benign prostate

G.  Prostate, left base, biopsy:    Benign prostate

H.  Prostate, right base, biopsy:  Benign prostate\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""**NAME[BBB, AAA], left wide"" are two cores of tan-white soft tissue measuring up to 0.9 x 0.1 cm.  Submitted entirely in block A.

B.  Received in formalin labeled ""**NAME[BBB, AAA], right wide"" are two cores of tan-white soft tissue measuring up to 1.1 x 0.1 cm.  Submitted entirely in block B.

C.  Received in formalin labeled ""**NAME[BBB, AAA], left apex"" is one core of tan-white soft tissue measuring 1.5 x 0.1 cm.  Submitted entirely in block C.

D.  Received in formalin labeled ""**NAME[BBB, AAA], right apex"" is one core of tan-white soft tissue measuring 1.2 x 0.1 cm.  Submitted entirely in block D.

E.  Received in formalin labeled ""**NAME[BBB, AAA], left mid"" is one core of tan-white soft tissue measuring 1.3 x 0.1 cm.  Submitted entirely in block E.

F.  Received in formalin labeled ""**NAME[BBB, AAA], right mid"" is one core of tan-white soft tissue measuring 1.1 x 0.1 cm.  Submitted entirely in block F.

G.  Received in formalin labeled ""**NAME[BBB, AAA], left base"" is one core of tan-white soft tissue measuring 1.3 x 0.1 cm.  Submitted entirely in block G.

H.  Received in formalin labeled ""**NAME[BBB, AAA], right base"" is one minute fragment of tan-white soft tissue measuring 0.2 x 0.1 cm.  Submitted entirely in block H.","MicroscopicDescription:
A.  Needle biopsies of prostate exhibit areas of high-grade prostatic intraepithelial neoplasia (PIN III).  A few scattered glands with mild atypia are evaluated for basal cells (p63, HMWK), which demonstrate an intact basal cell layer.

B.  Needle biopsies of prostate demonstrate a small focus of glands with minimal cytologic architectural atypia, including mild prominence of nucleoli.  Immunostains (p63, HMWK) are evaluated and demonstrate rare glands lacking a basal cell layer by p63, however focally equivocal by HMWK.  These few glands, in the absence of more definitive criteria for malignancy, are interpreted as an atypical small acinar proliferation.

C.  Sections of prostate demonstrate a small focus of glands with mild cytologic and architectural atypia, present at the partially fragmented tip of one core.  Immunostains (p63, HMWK) are evaluated and demonstrate this small cluster of glands to lack a basal cell layer, and to exhibit positive staining for P504S, supporting a small focus of prostate adenocarcinoma of Gleason's grade 3 + 3 = 6; measuring 1.0 mm in greatest dimension.  No perineural invasion is evident.

D.  Sections of prostate exhibit focal high-grade prostatic intraepithelial neoplasia (CIN III). 

E.  Sections contain benign prostate.

F.  Sections of prostate demonstrate a few glands with mild cytologic and architectural atypia.  Immunostains (p63, HMWK) are evaluated and demonstrate an intact basal cell layer.

G.  Sections contain benign prostate.

H.  Sections contain benign prostate.","A: Left wide
B: Right wide
C: Left apex
D: Right apex
E: Left mid
F: Right mid
G: Left base
H: Right base",,
REG4,PROSTATE,0,PAT-01560101,1,REC-3000671445,"ClinicalHistory:
Phimosis, Prostate cancer, bladder obstruction.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Circumcision, bilateral orchiectomy.",,"PreOperativeDiagnosis:
Circumcision, bilateral orchiectomy
PostOperativeDiagnosis:
Same, Pending pathology
FinalDiagnosis:
A.  Bilateral testicles, therapeutic orchiectomy:  Testes with atrophic changes
 
B.  Foreskin, phimosis/circumcision:      Foreskin with focal chronic inflammation\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""testicles-bilateral"" are two tan-pink to white testes with attached epididymis measuring in aggregate 6.0 x 3.6 x 2.4 cm.  Sectioning reveals a tan-brown, granular cut surface.  No masses or lesions are grossly identified.  Representative sections are submitted in blocks A1-A2.
 
B.  Received in formalin labeled ""foreskin"" is an excision of tan-pink to white skin measuring 5.5 x 2.4 x 0.5 cm.  Representative sections are submitted in block B.","MicroscopicDescription:
A.  Sections of testes exhibit mild atrophic changes.  There is no evidence of malignancy.

B.  Sections of foreskin exhibit areas of chronic inflammation.","A: Testicles-bilateral
B: Foreskin",,
REG4,PROSTATE,0,PAT-10035151,1,REC-3000671554,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:

A.  RIGHT SEMINAL VESICLE:  NEGATIVE FOR TUMOR.
 
B.  LEFT SEMINAL VESICLE:  NEGATIVE FOR TUMOR.
 
C.  RIGHT PELVIC TISSUE:  NEGATIVE FOR LYMPH NODES (0/0).
 
D.  LEFT PELVIC LYMPH NODES:  NEGATIVE FOR TUMOR (0/2).
 
E.  PROSTATE:  ADENOCARCINOMA, GS 6 (3 + 3), MARGINS CLEAR.
DiagnosisComment:
PROSTATE CANCER INFORMATION
Operative procedure:  Robotic laparoscopic radical prostatectomy.
Tumor-histologic type:  Adenocarcinoma.
Multicentricity:  Absent.
Anatomic site:  Right apex.
Evidence of anti-androgen therapy:  Absent.
Gleason score:  6 (3 + 3).
Percent Gleason grade 4 and/or 5:  None.
Size (dominant nodule):  0.1 cm.
Percent of prostate involved by carcinoma:  <5%.
Involvement of seminal vesicle:  Absent.
Extraprostatic extension:  Absent.
Perineural invasion:  Absent.
Invasion of adjacent structures:  Absent.
Lymph-Vascular invasion:  Absent.
Margins (Bladder neck, apical, circumferential):  Clear.
Regional lymph nodes:  Uninvolved.
Distant metastasis:  Not applicable.
PSA value:  2.49.
High grade prostatic intraepithelial neoplasia:  Absent.
Other findings:  None.
Pathologic grade and stage:  GS 6; pT2a N0 (Stage I).",,"GrossDescription:
A. Specimen:  Seminal vesicle and attached vas deferens.  
Weight:  4 gm.
Number of segments:  1.  
Seminal vesicle:  3.3 x 1.5 x 0.8 cm; unremarkable.
Vas deferens:  4.4 x 0.5 cm.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  1.

B. Specimen:  Seminal vesicle and separate vas deferens.  
Weight:  2 gm.
Number of segments:  2.  
Seminal vesicle:  2.4 x 1.3 x 0.7 cm; unremarkable.
Vas deferens:  2.6 x 0.5 cm.
Submitted for microscopic evaluation:  Representative.  
Cassettes:  1.

C. Specimen:  Irregular segment of fatty tissue.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  2.9 x 1.2 x 0.5 cm.
Gross findings:  No lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Irregular segment of fatty tissue.  
Weight:  2 gm.
Number of segments:  1.  
Size:  3.2 x 1.2 x 1 cm.
Gross findings:  2 lymph nodes measuring up to 2.5 x 0.8 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1  single bisected lymph node
2  single bisected lymph node and remaining fat

E. Specimen:  Prostate.
Fixative:  10% neutral buffered formalin.
Weight:  36 gm.
Size:
  Apex Base:  3.5 cm.
  Anterior Posterior:  3.7 cm.
  Right Left:  5 cm.
Gross findings:  No lesions grossly identified.
Seminal vesicles:  Submitted separately.
Vasa deferentia:  Submitted separately.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - 
  black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross-sections through bladder neck margin
3-4  cross-sections through apical margin
5  right apex
6-8  right mid prostate
9-12  right base
13  left apex
14-16  left mid prostate
17-20  left base.",,"A: RIGHT SEMINAL VESICLE
B: LEFT SEMINAL VESICLE
C: RIGHT PELVIC LYMPH NODES
D: LEFT PELVIC LYMPH NODES
E: PROSTATE",,
REG4,PROSTATE,0,PAT-10038283,1,REC-3000671642,"ClinicalHistory:
790.93
Transrectal ultrasound biopsy of the prostate
Procedure->Biopsy
*** Right
*** Left
Clinical History/Diagnosis/Condition->Transrectal ultrasound biopsy of the prostate./r/n",,"FinalDiagnosis:
A.  Prostate, right:  Prostatic adenocarcinoma (Gleason 4 + 4, sum 8).  
 
B.  Prostate, left:  Prostatic adenocarcinoma (Gleason 4 + 4, sum 8)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Aug 10 2012].  Dr. **NAME[XXX WWW] was notified of the diagnosis via e-mail on **DATE[Aug 10 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right prostate   Specimen:    Nine, cylindrical pale gray pieces of tissue (formalin)
  Aggregate:    2 x 0.9 x 0.1 cm
  Submitted/Block:    Entirely/1  

B.  Labeled:      Patient name and medical record number, designated left prostate   Specimen:    Ten, cylindrical pale gray pieces of tissue (formalin)
  Aggregate:    1 x 0.9 x 0.1 cm
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 4 + 4, sum 8
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 10%
  Number of cores with tumor/total number of cores: 2 of multiple
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

B.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 4 + 4, sum 8
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 50%
Number of cores with tumor/total number of cores: Several cores involved (difficult to quantify due to specimen fragmentation)
Lymphatic invasion: Not identified
Perineural invasion: Present
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None./r/n","A: Right prostate, biopsy
B: Left prostate, biopsy",,
REG4,PROSTATE,0,PAT-10036381,2,REC-3000671678,"ClinicalHistory:
R/O malignancy
790.93 Elevated PSA (4.7)
Prostate lesion on MRI and PET Scan.",,"FinalDiagnosis:

A.  Prostate, right apex, core needle biopsy:        Benign prostatic tissue.

B.  Prostate, right mid, core needle biopsy:        Benign prostatic tissue.
  
C.  Prostate, right base, core needle biopsy:        1.  PROSTATIC ADENOCARCINOMA.
              2.  Gleason score 8 (3 + 5).
              3.  Representing 50% of the biopsy volume.

D.  Prostate, CZ, core needle biopsy:      Benign prostatic tissue.

E.  Prostate, TZ, core needle biopsy:      1.  PROSTATIC ADENOCARCINOMA.
              2.  Gleason score 7 (3 + 4).
              3.  Representing 20% of the biopsy volume.

F.  Prostate, left apex, core needle biopsy:    Benign prostatic tissue.

G.  Prostate, left mid, core needle biopsy:    1.  PROSTATIC ADENOCARCINOMA.
              2.  Gleason score 7 (3 + 4).
              3.  Representing 5% of the biopsy volume.


H.  Prostate, left base, core needle biopsy:    1.  PROSTATIC ADENOCARCINOMA.
              2.  Gleason score 8 (3 + 5).
              3.  Representing 60% of the biopsy volume.

Comment:  

Tumor is positive for PSA and PSAP, and negative for TTF-1 stains.  The findings are consistent with primary prostatic adenocarcinoma.  Slides from recently diagnosed lung adenocarcinoma (***PATH-NUMBER[1]) were reviewed.  Current tumor is morphologically different from the previously diagnosed pulmonary adenocarcinoma.

Dr. **NAME[ZZZ]'s office informed of preliminary findings on **DATE[Jan 8 2012].\X0A|",,"GrossDescription:
(A)  Received in formalin labeled ""R apex"" are six white-tan, soft and cylindrical tissue fragments that range in size from
0.2 - 1.5 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 

(B)  Received in formalin labeled ""R mid"" are  seven white-tan, soft and cylindrical tissue fragments that range in size from 
0.1 - 0.7 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 

(C)  Received in formalin labeled ""R base"" are four white-tan, soft and cylindrical tissue fragments that range in size from
0.2 - 1.1 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 

(D)  Received in formalin labeled ""CZ"" are six white-tan, soft and cylindrical tissue fragments that range in size from 0.1 - 0.6 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 

(E)  Received in formalin labeled ""TZ"" are four white-tan, soft and cylindrical tissue fragments that range in size from 0.2 - 0.8 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 
 
(F)  Received in formalin labeled ""L apex"" are five white-tan, soft and cylindrical tissue fragments that range in size from 
0.1 - 0.6 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 

(G)  Received in formalin labeled ""L mid "" are three white-tan, soft and cylindrical tissue fragments that range in size from
0.1 - 1.1 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette. 

(H)  Received in formalin labeled ""L base"" are three white-tan, soft and cylindrical tissue fragments that range in size from
0.1 - 1.4 cm in length by less than 0.1 cm in diameter.  Submitted in toto in one cassette.","MicroscopicDescription:
A - H.  Microscopic findings support the diagnosis.","A: R apex
B: R mid
C: R base
D: CZ
E: TZ
F: L apex
G: L mid
H: L base",,
REG4,PROSTATE,0,PAT-10041831,1,REC-3000671706,"ClinicalHistory:
Elevated PSA.
Pre-OperativeDiagnosis:
Prostate biopsy.",,"PreOperativeDiagnosis:
Prostate biopsy
FinalDiagnosis:
A.  Prostate, right:        PROSTATE ADENOCARCINOMA
      
Operative procedure:      Prostate needle biopsies
Tumor histological type:    Prostate adenocarcinoma, NOS
Anatomic site:        Right prostate
# of cores involved by carcinoma:  3 out of multiple core fragments involved
Maximum size of carcinoma:    2.2 mm
% tissue involved by carcinoma:  5%
Gleason score:      7 (3 + 4)
Perineal invasion:      Not seen
Lymphovascular invasion:    Not seen
High grade PIN:      Not seen
Other findings:        None
 
B.  Prostate, left:       PROSTATE ADENOCARCINOMA  
 
Operative procedure:      Prostate needle biopsies
Tumor histological type:    Prostate adenocarcinoma, NOS
Anatomic site:        Left prostate
# of cores involved by carcinoma:  1 out of multiple core fragments involved
Maximum size of carcinoma:    2.3 mm
% tissue involved by carcinoma:  5%
Gleason score:      6 (3 + 3)
Perineal invasion:      Present
Lymphovascular invasion:    Not seen
High grade PIN:      Not seen
Other findings:        None
DiagnosisComment:
Dr. **NAME[ZZZ] reviewed the slides and concurred with the diagnosis. \X0A|",,"GrossDescription:
Specimen is received in fixative, in two containers labeled ""XXXXXX, XXXXXX"":

Container A is labeled ""right prostate"" and consists of seven core biopsies of white soft tissue measuring up to 1.2 cm in maximum length.  Totally submitted in cassettes A1 and A2.

Container B is labeled ""left prostate"" and consists of six core biopsies of white soft tissue measuring up to 0.9 cm in maximum dimension.  Totally submitted in cassettes B1 and B2.","MicroscopicDescription:
A.  The microscopic findings support the above diagnosis. 

B.  The microscopic findings support the above diagnosis.","A: Prostate, right
B: Prostate, left",,
REG4,PROSTATE,0,PAT-10037893,1,REC-3000671955,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:

A.  PROSTATE:  
  -POORLY DIFFERENTIATED PROSTATIC ADENOCARCINOMA, GLEASON SCORE 7 (4+3).
 
B.  RIGHT PELVIC LYMPH NODES:  BENIGN FIBROVASCULAR TISSUE.
 
C.  LEFT PELVIC LYMPH NODES:  
-REACTIVE LYMPH NODE; NEGATIVE FOR MALIGNANCY (0/1)
 
Prostate cancer information
Operative procedure:  Prostatectomy with bilateral pelvic lymph node dissection.
Tumor-histologic type:  Adenocarcinoma.
Multicentricity:  Absent.
Anatomic site (including status of apex):  Left base.
Evidence of anti-androgen therapy:  None.
Gleason score:  7 (4+3).
Percent Gleason grade 4 and/or 5:  65% grade 4.
Size (dominant nodule):  2.7 x 2.4 x 1.7.
Percent of prostate involved by carcinoma:  15%.
Involvement of seminal vesicle:  Absent.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  None.
Lymph-Vascular invasion:  Present.
Margins (focal/extensive involvement):
  Bladder neck (proximal) margin:  > 1 cm. 
  Apical (distal) margin:  > 1 cm.
  Circumferential (left and right) margins:  < 1 mm (left posterior 
circumferential margin). 
Regional lymph nodes (including number of nodes):  0/1.
Distant metastasis:  Unknown.
High-grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  T3a N0 G3; Group III.",,"GrossDescription:
A. Specimen:  Prostate with attached bilateral seminal vesicles and vasa deferentia.
Fixative:  10% neutral buffered formalin.
Weight:  87 gm.
Size:
  Apex Base:  5.3 cm.
  Anterior Posterior:  4.5 cm.
  Right Left:  6.5 cm.
Lesion(s): 
  Location:  Left base prostate.
  Size:  1.8 x 1.3 x 0.7 cm.
  Appearance:  Rubbery to firm, tan-yellow.
  Distance to margins:  Abutting left posterior margin.
Seminal vesicles
  Right:  3.5 x 1.5 x 0.8 cm; unremarkable.
  Left:  3.2 x 2.0 x 0.8 cm; unremarkable.
Vasa deferentia
  Right:  2.6 x 0.6 cm.
  Left:  2.7 x 0.6 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal (bladder neck) margin
3  cross sections through shaved distal (apical) margin
4-11  right apical to base prostate, respectively
12-22  left apical to base prostate, respectively
23  right seminal vesicle and vas deferens
24  left seminal vesicle and vas deferens

B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  2 gm.
Number of segments:  1.  
Size:  2.5 x 1.6 x 1.2 cm.
Gross findings: No lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  3.1 x 1.7 x 0.4 cm.
Gross findings: One lymph node identified measuring 2.0 x 1.1 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.",,"A: PROSTATE
B: RIGHT PELVIC LYMPH NODES
C: LEFT PELVIC LYMPH NODES",,
REG4,PROSTATE,0,PAT-10038516,1,REC-3000672347,"ClinicalHistory:
Elevated PSA= 8.9 ng/ml done on **DATE[May 1 12]; Abnormal prostate exam
Rectal exam demonstrates prostate slightly enlarged at 5.0 x 4.5 cm smooth, firm, non-tender prostate with a question of a nodule at the left base.",,"FinalDiagnosis:
Prostate, core needle biopsies:    

A. Right apex:      Benign prostatic tissue

B. Right midgland:     Benign prostatic tissue

C. Right base:     Benign prostatic tissue

D. Right lateral:    Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 0.8 mm
        No perineural invasion

E. Right anterior:     Benign prostatic tissue

F. Left apex:       Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 5.0 mm
        No perineural invasion

G. Left midgland:     Benign prostatic tissue

H. Left base:       Benign prostatic tissue

I. Left lateral:       Prostatic adenocarcinoma, Gleason score 6 (3+3), 
        Three focus 2.0 mm, 2.0 mm and 0.8 mm, no perineural invasion

J. Left anterior:    Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 1.0 mm
        Perineural invasion identified\X0A|",,"GrossDescription:
A.  Received in formalin, labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 1.0 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

B.  Received in formalin, labeled ""XXXXXX, right mid gland"" are two soft, tan cores of tissue measuring up to 1.0 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes B1 and B2, with the larger core in B1.

C.  Received in formalin, labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.1 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.  

D.  Received in formalin, labeled ""XXXXXX, right lateral"" is a soft, tan core of tissue measuring up to 0.8 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes D1 and D2, with smaller fragments of tissue submitted in cassette D2.

E.  Received in formalin, labeled ""XXXXXX, right anterior"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes E1 and E2, with small additional fragments of tissue submitted in cassette E2.

F.  Received in formalin, labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

G.  Received in formalin, labeled ""XXXXXX, left mid gland"" is a soft, tan core of tissue measuring up to 0.5 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes G1 and G2, with small additional fragments of tissue submitted in G2.

H.  Received in formalin, labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 0.4 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes H1 and H2, with small additional fragments of tissue submitted in H2.

I.  Received in formalin, labeled ""XXXXXX, left lateral"" is a soft, tan core of tissue measuring up to 0.9 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes I1 and I2, with small additional fragments of tissue submitted in I2.

J.  Received in formalin, labeled ""XXXXXX, left anterior"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.  The microscopic description supports the above diagnoses. For D, F, I and J, the immunostain PIN4 support the diagnosis. 
Dr. **NAME[ZZZ] concurs with the diagnosis. Dr. **NAME[YYY] has been notified.","A: Right prostate core needle biopsy at apex
B: Right prostate core needle biopsy at midgland
C: Right prostate core needle biopsy at base
D: Right prostate core needle biopsy at lateral
E: Right prostate core needle biopsy at anterior
F: Left prostate core needle biopsy at apex
G: Left prostate core needle biopsy at midgland
H: Left prostate core needle biopsy at base
I: Left prostate core needle biopsy at lateral
J: Left prostate core needle biopsy at anterior",,
REG4,PROSTATE,0,PAT-10038416,1,REC-3000672561,"ClinicalHistory:
Elevated PSA; 5.08 **DATE[Sep 30 11].
Post-OperativeDiagnosis:
Pending.
Pre-OperativeDiagnosis:
TRUS/PBX.",,"PreOperativeDiagnosis:
TRUS/PBX
PostOperativeDiagnosis:
Pending
FinalDiagnosis:
A.  Prostate, left wide, biopsy:      Benign prostate  
 
B.  Prostate, right wide, biopsy:      Benign prostate
 
C.  Prostate biopsy, left apex, biopsy:    Benign prostate
 
D.  Prostate biopsy, right apex, biopsy:    Benign prostate
 
E.  Prostate biopsy, left mid, biopsy:      PROSTATE ADENOCARCINOMA, Gleason's 3+3=6; 0.1 cm; 
            no perineural invasion evident
 
F.  Prostate biopsy, right mid, biopsy:    Benign prostate
 
G.  Prostate biopsy, left base, biopsy:    Benign prostate
 
H.  Prostate biopsy, right base, biopsy:    Benign prostate\X0A|",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, **NAME[AAA], left wide"" are two cores of tan-white soft tissue measuring 1.6 x 0.1 cm, submitted entirely in block A.

B.  Received in formalin labeled ""XXXXXX, **NAME[AAA], right wide"" are two cores of tan-white soft tissue measuring up to 1.3 x 0.1 cm, submitted entirely in block B.

C.  Received in formalin labeled ""XXXXXX, **NAME[AAA], left apex"" is one core of tan-white soft tissue measuring 1.5 x 0.1 cm, submitted entirely in block C.

D.  Received in formalin labeled ""XXXXXX, **NAME[AAA], right apex"" is one core of tan-white soft tissue measuring 1.0 x 0.1 cm, submitted entirely in block D.

E.  Received in formalin labeled ""XXXXXX, **NAME[AAA], left mid"" is one core of tan-white soft tissue measuring 1.5 x 0.1 cm, submitted entirely in block E.

F.  Received in formalin labeled ""XXXXXX, **NAME[AAA], right mid"" is one core of tan-white soft tissue measuring 1.6 x 0.1 cm, submitted entirely in block F.

G.  Received in formalin labeled ""XXXXXX, **NAME[AAA], left base"" is one core of tan-white soft tissue measuring 1.3 x 0.1 cm, submitted entirely in block G.

H.  Received in formalin labeled ""XXXXXX, **NAME[AAA], right base"" is one core of tan-white soft tissue measuring 1.7 x 0.1 cm, submitted entirely in block H.","MicroscopicDescription:
A.  Sections contain benign prostate.

B.  Sections contain benign prostate.

C.  Sections contain benign prostate.

D.  Sections contain benign prostate.

E.  Sections of prostate demonstrate a small cluster of glands with mild cytologic and architectural atypia.  Immunostains (p63, HMWK, P504S) are evaluated and demonstrate an absence of basal cells and focal positive staining for P504S, supporting a small focus of prostate adenocarcinoma of Gleason's grade 3+3=6, measuring 1.0 mm in greatest dimension.  No perineural invasion is evident.

F.  Sections contain benign prostate.

G.  Sections contain benign prostate.

H.  Sections contain benign prostate.","A: Prostate, left wide
B: Prostate, right wide
C: Prostate biopsy, left apex
D: Prostate biopsy, right apex
E: Prostate biopsy, left mid
F: Prostate biopsy, right mid
G: Prostate biopsy, left base
H: Prostate biopsy, right base",,
REG4,PROSTATE,0,PAT-01163914,2,REC-3000672840,"ClinicalHistory:
790.93
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Elevated PSA./r/n",,"FinalDiagnosis:
A.  Prostate, left:  Benign prostatic tissue with chronic inflammation.

B.  Prostate, right:  Prostatic adenocarcinoma (Gleason 4 + 3, sum 7)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[May 20 2012].  Dr. **NAME[WWW VVV] was notified of the diagnosis via e-mail on **DATE[May 20 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left prostate x6
  Specimen:    Cylindrical thread-like cores of tissue (formalin)
  Number:      Six and fragments
  Size:           Measuring up to 0.8 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1  

B.  Labeled:      Patient name and medical record number, designated right prostate x4
  Specimen:    Cylindrical thread-like cores of tissue (formalin)
  Number:      Four
  Size:           Measuring up to 0.9 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.

B.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 4 + 3, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 75%
  Number of cores with tumor/total number of cores: 4 of 4
Lymphatic invasion: Not identified
Perineural invasion: Present
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None./r/n","A: Left prostate x6, biopsy
B: Right prostate x4, biopsy",,
REG4,PROSTATE,0,PAT-10035105,1,REC-3000672999,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  URETHRAL MARGIN:  
- PROSTATIC ADENOCARCINOMA.
 
B.  PROSTATE:  
- PROSTATIC ADENOCARCINOMA, GLEASON 9.

Prostate cancer information
Operative procedure:  Robot assisted radical prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Not identified.
Anatomic site:  Left and right apex to base.
Evidence of anti-androgen therapy:  Not applicable.
Gleason score:  9 (5 + 4).
Percent Gleason grade 4 and/or 5:  Nearly 100%.
Size:  4 x 3.8 x 2.8 cm.
Percent of prostate involved by carcinoma:  90%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not applicable.
Lymph-Vascular invasion:  Not identified.
Margins:  Involved by carcinoma - greatest focus spans 0.9 cm in length (left circumferential margin).
  Bladder neck (proximal) margin:  Involved by carcinoma. 
  Apical (distal) margin:  Involved by carcinoma.
  Circumferential (left and right) margins:  Involved by carcinoma. 
Regional lymph nodes:  Not applicable.
High grade prostatic intraepithelial neoplasia:  Present.
Distant metastasis:  Not applicable.
Other findings:  None identified.
Pathologic stage:  pT3a NX (stage III if N0 M0).",,"GrossDescription:
A. Specimen:  Rubbery tan-pink tissue.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  0.9 x 0.6 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Prostate with attached bilateral seminal and vasa deferentia.
Fixative:  10% neutral buffered formalin.
Weight:  65 gm.
Size:
  Apex Base:  4.8 cm.
  Anterior Posterior:  4.0 cm.
  Right Left:  6.0 cm.
Lesion(s): 
  Location:  Right and left apical to base prostate.
  Size:  4.0 x 3.8 x 2.8 cm.
  Appearance:  Firm, tan to yellow.
  Distance to margins:  Abutting right, left, anterior, and posterior prostate 
  margins.
Seminal vesicles
  Right:  3.0 x 1.4 x 0.6 cm; unremarkable.
  Left:  3.0 x 2.1 x 0.6 cm; unremarkable.
Vasa deferentia
  Right:  5.2 x 0.5 cm.
  Left:  4.1 x 0.5 cm.
Other findings:  None.
Staining of margins:  Right - blue; left - orange; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross-sections through shaved proximal (bladder neck) margin
3  cross-sections through shaved distal (apical) margin
4-13  lesion, right apical to base prostate, as per photo
14-23  lesion, left apical to base prostate, as per photo
24  right seminal vesicle and vas deferens
25  left seminal vesicle and vas deferens.",,"A: URETHRAL MARGIN
B: PROSTATE",,
REG4,PROSTATE,0,PAT-10034547,1,REC-3000673008,"ClinicalHistory:
Elevated PSA = 4.6ng/ml done on **DATE[Jul 15 12]
Rectal exam demonstrates prostate slightly enlarged to 3.5 x 4.0cm but is otherwise smooth, firm, non-nodular, non-tender, without masses or induration noted.",,"FinalDiagnosis:
Prostate core needle biopsies:  

A.   Right apex:  PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 1.9 mm

B.   Right mid gland:  PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 6.0 mm

C.   Right base:  PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 5.1 mm

D.   Right lateral:  PROSTATIC ADENOCARCINOMA, Gleason's score 7 (3+4), involving 1 of 1 core,
      measuring 6.7 mm

E.   Right anterior:  PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 1.3 mm

F.   Left apex:    Benign prostatic tissue

G.   Left mid gland:  PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 0.4 mm

H.   Left base:    PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 1.1 mm

I.     Left lateral:  PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 core,
      measuring 0.3 mm

J.    Left anterior:  Benign prostatic tissue.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] concurs with the diagnosis.  Dr. **NAME[XXX WWW] has been notified on **DATE[Sep 22 2012].",,"GrossDescription:
A.  Received in formalin, labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.  

B.  Received in formalin, labeled ""XXXXXX, right mid gland"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

C.  Received in formalin, labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.5 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

D.  Received in formalin, labeled ""XXXXXX, right lateral"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

E.  Received in formalin, labeled ""XXXXXX, right anterior"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

F.  Received in formalin, labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

G.  Received in formalin, labeled ""XXXXXX, left mid gland"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

H.  Received in formalin, labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

I.  Received in formalin, labeled ""XXXXXX, left lateral"" is a soft, tan core of tissue measuring up to 1.5 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

J.  Received in formalin, labeled ""XXXXXX, left anterior"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.   The microscopic findings support the above diagnoses.","A: Right prostate core needle biopsy at apex
B: Right prostate core needle biopsy at mid gland
C: Right prostate core needle biopsy at base
D: Right prostate core needle biopsy at lateral
E: Right prostate core needle biopsy at anterior
F: Left prostate core needle biopsy at apex
G: Left prostate core needle biopsy at mid gland
H: Left prostate core needle biopsy at base
I: Left prostate core needle biopsy at lateral
J: Left prostate core needle biopsy at anterior",,
REG4,PROSTATE,0,PAT-10034058,1,REC-3000673148,"ClinicalHistory:
Prostate CA.",,"FinalDiagnosis:
A.  RIGHT PELVIC LYMPH NODES:  
- ONE LYMPH NODE NEGATIVE FOR METASTASIS (0/1).
 
B.  LEFT PELVIC LYMPH NODES:  
- ONE LYMPH NODE NEGATIVE FOR METASTASIS (0/1).
 
C.  PROSTATE:  
- PROSTATE ADENOCARCINOMA, GLEASON 7 (3+4).

Prostate cancer information
Operative procedure:  Robotic radical prostatectomy with bilateral lymph nodes.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Unifocal.
Anatomic site:  Spans left and right apex to base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4). 
Percent Gleason grade 4 and/or 5:  20%.
Size (dominant nodule):  Approximately 3.9 cm (microscopic with comparison
                         to gross photo).
Percent of prostate involved by carcinoma:  85%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not identified.
Lymph-Vascular invasion:  Present.
Margins:
  Bladder neck (proximal) margin:  Uninvolved. 
  Apical (distal) margin:  Uninvolved.
  Circumferential (left and right) margins:  Involves right circumferential margin
                                             (towards apex of prostate) over an area
                                             of 0.8 cm. 
Regional lymph nodes:  0/2.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  Gleason 7; pT3a N0 (Stage III if M0).",,"GrossDescription:
A. Specimen:  Single lymph node.  
Weight:  2 gm.
Number of segments:  1.  
Size:  2.8 x 1.5 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, bisected.

B. Specimen:  Single lymph node.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.5 x 1.5 x 1.2 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1, bisected.

C. Specimen:  Prostate with attached bilateral seminal vesicles and vasa deferentia.
Fixative:  10% neutral buffered formalin.
Weight:  33 gm.
Size:
  Apex Base:  3.7 cm.
  Anterior Posterior:  3.5 cm.
  Right Left:  4.5 cm.
Lesion(s): 
  Location:  Left apical prostate.
  Size:  0.8 x 0.7 x 0.5 cm.
  Appearance:  Irregular tan-yellow.
  Distance to margins:  Abutting left circumferential margin.
Seminal vesicles
  Right:  2.3 x 1.1 x 1.0 cm; unremarkable.
  Left:  2.7 x 1.4 x 0.9 cm; unremarkable.
Vasa deferentia
  Right:  4.0 x 0.6 cm.
  Left:  3.6 x 0.6 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross-sections through shaved proximal (bladder neck) margin
3  cross-sections through shaved distal (apical) margin
4  lesion, right and left
5-9  right apical to base prostate, respectively
10-14  left apical to base prostate, respectively (lesion in 10)
15  right seminal vesicle and vas deferens
16  left seminal vesicle and vas deferens.",,"A: RIGHT PELVIC LYMPH NODES
B: LEFT PELVIC LYMPH NODES
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10041338,1,REC-3000673212,"ClinicalHistory:
790.93, 600.10.",,"FinalDiagnosis:

A.  LEFT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4), 
    INVOLVING 60% OF SAMPLE. 
 
B.  LEFT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4), 
    INVOLVING 80% OF SAMPLE.
 
C.  LEFT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4), 
    INVOLVING 100% OF SAMPLE.
 
D.  RIGHT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4), 
    INVOLVING 80% OF SAMPLE.
 
E.  RIGHT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4), 
    INVOLVING 20% OF SAMPLE.
 
F.  RIGHT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4),
    INVOLVING 15% OF SAMPLE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left and right (base to apex, bilaterally).
Number of cores with carcinoma:  18 of 21 cores fragments with 
  prostate tissue.
Maximum size of carcinoma:  1.0 cm.
Percent of overall tissue involved by carcinoma:  60%.
Highest Gleason score at single site:  8 (4 + 4).
Overall Gleason score:  8 (4 + 4).
Percent of Gleason grade 4 and/or 5:  100%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Present.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Ranging from 0.2 to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 0.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.2 to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.3 to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT BASE PROSTATE
B: LEFT MID PROSTATE
C: LEFT APEX PROSTATE
D: RIGHT BASE PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT APEX PROSTATE",,
REG4,PROSTATE,0,PAT-10042317,1,REC-3000673320,"ClinicalHistory:
History of prostate cancer.",,"IntraoperativeDiagnosis:
Rare mechanically distorted cells, no obvious malignancy; assessed and supervised by CF/MDB.
FinalDiagnosis:
LEFT POSTERIOR ACETABULUM, CT-GUIDED CORE NEEDLE BIOPSY:
- METASTATIC POORLY DIFFERENTIATED CARCINOMA CONSISTENT WITH PROSTATE PRIMARY.
DiagnosisComment:
Tumor cells are immunopositive for PSMA, p504s (focal and weak) and cytokeratin AE1/AE3.  They are negative for p501s and PSA.  The immunophenotype is consistent with a prostate primary.",,"GrossDescription:
Received: 3 DQ stained smears.
       Tissue fragments in formalin soln.
Submitted:  3 decalcified tissue fragments measuring up to 7 mm in length for a cell
    block.",,A: LEFT POSTERIOR ACETABULUM CT-GUIDED CNB,,
REG4,PROSTATE,0,PAT-10030666,1,REC-3000673324,"ClinicalHistory:
Adenocarcinoma of the prostate.",,"FinalDiagnosis:
A.  PRE-PROSTATIC FAT:  BENIGN FIBROADIPOSE TISSUE  
 
B.  RIGHT PELVIC LYMPH NODES:  NEGATIVE FOR METASTASIS (0/2)  
 
C.  LEFT PELVIC LYMPH NODE:  NEGATIVE FOR METASTASIS (0/1)  
 
D.  PROSTATE WITH BILATERAL SEMINAL VESICLES:  PROSTATIC ADENOCARCINOMA

Prostate cancer information
Operative procedure:  Resection of prostate and bilateral seminal vesicles
Tumor-histologic type:  Prostatic adenocarcinoma
Multicentricity:  Present
Anatomic site (including status of apex):  Right and left prostate, from base to apex
Evidence of anti-androgen therapy:  none
Gleason score:  3 + 4 equals 7
Percent Gleason grade 4 and/or 5:  20%
Size (dominant nodule):  At least 4.5 cm
Percent of prostate involved by carcinoma:  65-70%
Involvement of seminal vesicle:  Not identified
Extraprostatic extension:  Present
Perineural invasion:  Present
Invasion of adjacent structures (bladder, rectum):  Not identified
Lymphatic-vascular invasion:  Not identified
Margins:
  Bladder neck (proximal) margin:  Clear 
  Apical (distal) margin:  Clear
  Circumferential (left and right) margins:  Clear 
Regional lymph nodes (including number of nodes):  Negative for metastasis (0/3)
Distant metastasis:  Unknown
High grade prostatic intraepithelial neoplasia:  None
Other findings:  None
Pathologic grade and stage:  Gleason 7 pT3a pN0 (Stage III, if M0).",,"GrossDescription:
A. Specimen:  Irregular segments of fatty tissue.  
Weight:  3 gm.
Number of segments:  Multiple.  
Size:  Up to 2.0 x 1.5 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  4 gm.
Number of segments:  1.  
Size:  4.0 x 2.6 x 1.2 cm.
Gross findings:  Two lymph nodes identified measuring up to 2.7 x 2.3 x 1.1 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks:
1-2  single bisected lymph node
3  single lymph node and remaining fat

C. Specimen:  Single lymph node.  
Weight:  7 gm.
Number of segments:  1.  
Size:  5.1 x 2.2 x 1.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  4 (lymph node is bisected and halved).

D. Specimen:  Prostate with attached bilateral seminal vesicles and vasa differentia.
Fixative:  10% neutral buffered formalin.
Weight:  54 gm.
Size:
  Apex Base:  5.0 cm.
  Anterior Posterior:  4.8 cm.
  Right Left:  4.5 cm.
Gross findings:  Homogeneous tan cut surface; no definite lesion grossly identified.
Seminal vesicles
  Right:  2.0 x 1.8 x 1.1 cm; unremarkable.
  Left:  1.8 x 1.7 x 1.5 cm; unremarkable.
Vasa deferentia
  Right:  2.0 x 0.7 cm.
  Left:  2.3 x 0.7 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal (bladder neck) margin
3  cross sections through shaved distal (apical) margin
4  right and left apical prostate
5-12  right apical to base prostate, respectively
13-21  left apical to base prostate, respectively
22  right seminal vesicle and vas deferens
23  left seminal vesicle and vas deferens.",,"A: PRE- PROSTATIC FAT
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE
D: PROSTATE GLAND",,
REG4,PROSTATE,0,PAT-10035945,1,REC-3000673476,"ClinicalHistory:
Elevated PSA 790.93.",,"FinalDiagnosis:

A.  RIGHT LATERAL PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
B.  RIGHT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4), 
    INVOLVING 5% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING 
    20% OF THE TUMOR. 
 
C.  LEFT LATERAL PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
D.  LEFT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (4 + 3), 
    INVOLVING 10% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    80% OF THE TUMOR.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Right sextant and left sextant biopsies.
Number of cores with carcinoma:  3 of 20 core fragments.
Maximum size of carcinoma:  0.3 cm.
Percent of overall tissue involved by carcinoma:  <5%.
Highest Gleason score at single site:  7 (4 + 3).
Overall Gleason score:  7 (3 + 4).
Percent of Gleason grade 4 and/or 5:  40%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 2.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.",,"A: RIGHT LATERAL PROSTATE
B: RIGHT SEXTANT PROSTATE
C: LEFT LATERAL PROSTATE
D: LEFT SEXTANT PROSTATE",,
REG4,PROSTATE,0,PAT-10038493,1,REC-3000673479,"ClinicalHistory:
Elevated PSA, 790.93.",,"FinalDiagnosis:

A.  RIGHT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
B.  RIGHT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
C.  RIGHT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING <5% OF SAMPLE. 
 
D.  LEFT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
E.  LEFT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
F.  LEFT BASE PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right base.
Number of cores with carcinoma:  1 of 12 core fragments.
Maximum size of carcinoma:  <0.1 cm.
Percent of overall tissue involved by carcinoma:  <5%.
Highest Gleason score at single site:  6 (3 + 3).
Overall Gleason score:  6 (3 + 3).
Percent of Gleason grade 4 and/or 5:  None.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  Positive staining of the atypical glands for 
  P504S and negative staining for basal cell markers (p63 and 
  cytokeratin 5/6) confirms the diagnosis of prostatic 
  adenocarcinoma.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 1.0 to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 1.3 to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.9 to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT APEX
B: RIGHT MID
C: RIGHT BASE
D: LEFT APEX
E: LEFT MID
F: LEFT BASE",,
REG4,PROSTATE,0,PAT-10034062,1,REC-3000675795,"ClinicalHistory:
Prostate CA.",,"FinalDiagnosis:
A.  ANTERIOR PRE PROSTATIC FAT:  NEGATIVE FOR MALIGNANCY.
 
B.  PROSTATE:  PROSTATE ADENOCARCINOMA, GLEASON 7 (4+3).

Prostate cancer information
Operative procedure:  Robotic radical prostatectomy.
Tumor-histologic type:  Prostate adenocarcinoma.
Multicentricity:  Not identified.
Anatomic site:  Involves left mid to base.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (4+3). 
Percent Gleason grade 4 and/or 5:  60%.
Size (dominant nodule):  Approximately 2.8 cm (microscopic with comparison
                         to gross photo).
Percent of prostate involved by carcinoma:  10-15%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Uninvolved. 
  Apical (distal) margin:  Uninvolved.
  Circumferential (left and right) margins:  Uninvolved. 
Regional lymph nodes:  Not applicable.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:  Gleason 7; pT2a NX (Stage IIA if N0, M0, PSA<20).",,"GrossDescription:
A. Specimen:  Irregular segments of fatty tissue, received in formalin.  
Weight:  4 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 4.4 x 3.2 x 0.7 cm.
Gross findings: No lesion grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  4.

B. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens, received in formalin.
Fixative:  10% neutral buffered formalin.
Weight:  48 gm.
Size:
  Apex Base:  4.2 cm.
  Anterior Posterior:  3.6 cm.
  Right Left:  4.6 cm.
Lesion(s): 
  Location:  Left mid to base.
  Size:  2.2 x 1.5 x 1.0 cm.
  Appearance:  Irregular tan-white.
  Distance to margins:  0.1 cm away from the left lateral margin, 0.2 cm away from the left posterior margin.
Seminal vesicles
  Right:  3.9 x 1.5 x 1.0 cm; unremarkable.
  Left:  3.5 x 2.0 x 1.0 cm; unremarkable.
Vasa deferentia
  Right:  2.2 x 0.4 cm.
  Left:  2.5 x 0.4 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved proximal margin
2  cross-sections and shave distal margin
3  right and left apical prostate
4  right apical prostate
5-6  right mid prostate
7-10  right base prostate
11  left apical prostate
12-14  left mid prostate
15-18  left base prostate
19  right seminal vesicle and vas deferens
20  left seminal vesicle and vas deferens.",,"A: ANTERIOR PRE PROSTATIC FAT
B: PROSTATE",,
REG4,PROSTATE,0,PAT-10036955,1,REC-3000676319,"ClinicalHistory:
790.93
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Elevated PSA./r/n",,"FinalDiagnosis:
A.  Prostate, right:  Small focus of prostatic adenocarcinoma (Gleason 3 + 3, sum 6).

B.  Prostate, left:  Prostatic adenocarcinoma (Gleason 3 + 3, sum 6)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY] on **DATE[Sep 30 2012].  Dr. **NAME[XXX WWW] was notified of the diagnosis via e-mail on **DATE[Sep 30 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right prostate
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Six
  Size:           Up to 2.3 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1

B.  Labeled:      Patient name and medical record number, designated left prostate
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Six
  Size:           Up to 1.6 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 3, sum 6
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: Less than 5%
  Number of cores with tumor/total number of cores: 1 of 6
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: Immunostains for high molecular weight cytokeratin and p63 show an absence of staining in association with the atypical glands, supporting the diagnosis  


B.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 3, sum 6
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 10%
  Number of cores with tumor/total number of cores: 5 of 6
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: Immunostains for high molecular weight cytokeratin and p63 show an absence of staining in association with the atypical glands, supporting the diagnosis./r/n","A: Right prostate, biopsy
B: Left prostate, biopsy",,
REG4,PROSTATE,0,PAT-10036949,1,REC-3000677989,"ClinicalHistory:
Elevated PSA, 790.93.",,"FinalDiagnosis:

A.  RIGHT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 5% OF SAMPLE. 
 
B.  LEFT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
C.  RIGHT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
D.  LEFT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING <5% OF SAMPLE.
 
E.  RIGHT BASE PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
F.  LEFT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3),
    INVOLVING <5% OF SAMPLE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Right (apex) and left (mid, base).
Number of cores with carcinoma:  3 of 31 core fragments with 
  prostate tissue.
Maximum size of carcinoma:  0.1 cm.
Percent of overall tissue involved by carcinoma:  <5%.
Highest Gleason score at single site:  6 (3 + 3).
Overall Gleason score:  6 (3 + 3).
Percent of Gleason grade 4 and/or 5:  None.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  Positive staining of the atypical glands in 
  specimens A, D, and F for P504S and negative staining for basal
  cell markers (p63 and cytokeratin 5/6) confirms the diagnosis 
  of prostatic adenocarcinoma.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Ranging from 0.2 to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Ranging from 0.3 to 0.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Ranging from 0.2 to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Ranging from 0.2 to 2.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.2 to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  5. 
Size:  Ranging from 0.3 to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT APEX PROSTATE
B: LEFT APEX PROSTATE
C: RIGHT MID PROSTATE
D: LEFT MID PROSTATE
E: RIGHT BASE PROSTATE
F: LEFT BASE PROSTATE",,
REG4,PROSTATE,0,PAT-10038304,1,REC-3000678009,"ClinicalHistory:
790.93
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Elevated PSA./r/n",,"FinalDiagnosis:
A.  Prostate, left:  Prostatic adenocarcinoma (Gleason 3 + 3, sum 6).  
 
B.  Prostate, right:  Benign prostatic tissue./r/nDiagnosisComment:
Intradepartmental consultations with Dr. **NAME[ZZZ YYY] and Dr. **NAME[XXX WWW] on **DATE[Sep 4 2012].  Dr. **NAME[VVV UUU] was notified of the diagnosis via e-mail on **DATE[Sep 4 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left prostate x4
  Specimen:    Cylindrical cores of tissue (formalin)
  Number:      Four
  Size:           Up to 0.9 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1

B.  Labeled:      Patient name and medical record number, designated right prostate x6
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Six
  Size:           Up to 2 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left prostate
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 3, sum 6
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 5%
  Number of cores with tumor/total number of cores: 2 of 4
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

B.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left prostate  x4, biopsy
B: Right prostate  x6, biopsy",,
REG4,PROSTATE,0,PAT-10037906,1,REC-3000678279,"ClinicalHistory:
790.93
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Elevated PSA./r/n",,"FinalDiagnosis:
A.  Prostate, left base:  Prostatic adenocarcinoma (Gleason 3 + 4, sum 7).

B.  Prostate, left mid:  Prostatic adenocarcinoma (Gleason 3 + 4, sum 7).

C.  Prostate, left apex:  Benign prostatic tissue.

D.  Prostate, right base:  Prostatic adenocarcinoma (Gleason 3 + 3, sum 6).

E.  Prostate, right mid:  Prostatic adenocarcinoma (Gleason 3 + 3, sum 6), with perineural invasion.

F.  Prostate, right apex:  Benign prostatic tissue./r/nDiagnosisComment:
The overall Gleason score is 3 + 4, sum 7.  Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[Nov 6 2011].  Dr. **NAME[WWW VVV] was notified of the diagnosis via e-mail on **DATE[Nov 6 2011]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated left base prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Two
  Size:           Measuring up to 0.6 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1

B.  Labeled:      Patient name and medical record number, designated left mid prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Two
  Size:           Measuring up to 0.7 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1
C.  Labeled:      Patient name and medical record number, designated left apex prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Three
  Size:           Measuring up to 0.7 x 1 x 0.1 cm 
  Submitted/Block:    Entirely/1
D.  Labeled:      Patient name and medical record number, designated right base prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Three
  Size:           Measuring up to 1 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1
E.  Labeled:      Patient name and medical record number, designated right mid prostate x2
  Specimen:    Cylindrical threadlike cores of tissue (formalin)
  Number:      Two
  Size:           Measuring up to 0.7 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1
F.  Labeled:      Patient name and medical record number, designated right apex prostate x2
Specimen:    Cylindrical threadlike cores of tissue (formalin)
Number:      Two
Size:           Measuring up to 1.1 x 0.1 x 0.1 cm 
Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left base
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 4, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 40%
  Number of cores with tumor/total number of cores: 2 of 2
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

B.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left mid
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 4, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 10%
  Number of cores with tumor/total number of cores: 2 of 2
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

C.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings.

D.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right base
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 3, sum 6
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 5%
  Number of cores with tumor/total number of cores: 2 of 2
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

E.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right mid
Histologic type: Prostatic adenocarcinoma
Gleason score: 3 + 3, sum 6
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 20%
  Number of cores with tumor/total number of cores: 1 of 2
Lymphatic invasion: Not identified
Perineural invasion: Present
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

F.  Microscopic evaluation was performed.  Final diagnosis was rendered based on gross and microscopic findings./r/n","A: Left base prostate x2, biopsy
B: Left mid prostate x2, biopsy
C: Left apex prostate x2, biopsy
D: Right base prostate x2, biopsy
E: Right mid prostate x2, biopsy
F: Right apex prostate x2, biopsy",,
REG4,PROSTATE,0,PAT-10038415,1,REC-3000678399,"ClinicalHistory:
790.93, elevated PSA.",,"FinalDiagnosis:

A.  RIGHT LATERAL PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING <5% OF SAMPLE. 
 
B.  RIGHT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4),
    INVOLVING <5% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    20% OF THE TUMOR. 
 
C.  LEFT LATERAL PROSTATE BIOPSY:  FOCUS OF ATYPICAL GLANDS. 
 
D.  LEFT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (4 + 3), 
    INVOLVING <5% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    80% OF THE TUMOR.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right (lateral and sextant) and left (sextant).
Number of cores with carcinoma:  5 of 20 core fragments.
Maximum size of carcinoma:  <0.1 cm.
Percent of overall tissue involved by carcinoma:  <5%.
Highest Gleason score at single site:  7 (4 + 3).
Overall Gleason score:  7 (4 + 3).
Percent of overall Gleason grade 4 and/or 5:  50%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:
    In specimens A, B, and D, the positive staining of the 
  atypical glands for P504S and negative staining for basal cell
  marker (cytokeratin 5/6) confirms the diagnosis of prostatic
  adenocarcinoma.
    In specimen C, the focus with atypical glands do not contain 
  cells with P504s+ and ck 5/6- staining pattern.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Ranging from 0.2 to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Ranging from 0.1 to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 1.7 to 1.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Ranging from 1.4 to 2.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT LATERAL PROSTATE
B: RIGHT SEXTANT PROSTATE
C: LEFT LATERAL PROSTATE
D: LEFT SEXTANT PROSTATE",,
REG4,PROSTATE,0,PAT-10034064,1,REC-3000678526,"ClinicalHistory:
Elevated PSA, 790.93.",,"FinalDiagnosis:
AB. PROSTATE NEEDLE BIOPSIES (RIGHT BASE, MID):
    BENIGN PROSTATIC TISSUE.

C.  PROSTATE NEEDLE BIOPSIES (RIGHT APEX):  
    SMALL FOCUS OF PROSTATIC ADENOCARCINOMA, GLEASON's 6 (3+3),
    INVOLVING 1 OF 4 SEGMENTS.
 
D.  PROSTATE NEEDLE BIOPSIES (LEFT BASE):  
    PROSTATIC ADENOCARCINOMA, GLEASON's 8 (4+4),
    INVOLVING 2 OF 3 SEGMENTS.
 
E.  PROSTATE NEEDLE BIOPSIES (LEFT MID):  
    SMALL FOCUS OF PROSTATIC ADENOCARCINOMA, GLEASON's 6 (3+3),
    INVOLVING 1 OF MULTIPLE SEGMENTS.
 
F.  PROSTATE NEEDLE BIOPSIES (LEFT APEX):  
    PROSTATIC ADENOCARCINOMA, GLEASON's 8 (4+4),
    INVOLVING 2 OF 3 SEGMENTS.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right apex; left base, mid, apex.
Number of cores with carcinoma/total cores in involved area:  
  6/multiple.
Maximum size of carcinoma:  0.8 cm (left apex).
Percent of overall tissue involved by carcinoma:  10-15%.
Highest Gleason score at single site:  8 (4+4); left base and apex.
Overall Gleason score:  7 (4+3).
Percent of Gleason grade 4 and/or 5:  80%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified. 
Lymph-Vascular invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:

A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 0.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
AB.  Small segments of prostatic tissue show no evidence of malignancy.

CE.  Small segments of prostatic tissue show small foci of single separate variable glands lined by cells with prominent nucleoli.

DF.  Small segments of prostatic tissue show replacement and invasion by fused glands with prominent nucleoli.","A: RIGHT BASE PROSTATE
B: RIGHT MID PROSTATE
C: RIGHT APEX PROSTATE
D: LEFT BASE PROSTATE
E: LEFT MID PROSTATE
F: LEFT APEX PROSTATE",,
REG4,PROSTATE,0,PAT-10037131,1,REC-3000678681,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:

A.  PROSTATE GLAND:  ADENOCARCINOMA, GS 7 (4 + 3), WITH FOCAL 
    EXTRAPROSTATIC EXTENSION AND INVOLVED MARGINS.
 
B.  RIGHT PELVIC LYMPH NODES:  NEGATIVE FOR METASTASIS (0/9).
 
C.  LEFT PELVIC LYMPH NODE:  POSITIVE FOR METASTASIS (1/1).

PROSTATE CANCER INFORMATION
Operative procedure:  
  1. Robot-assisted laparoscopic radical prostatectomy. 
  2. Bilateral pelvic lymphadenectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Absent.
Anatomic site:  Peripheral zone, bilateral (L>R), apex to base.
Evidence of anti-androgen therapy:  Absent.
Gleason score:  7 (4 + 3).
Percent Gleason grade 4 and/or 5:  75%.
Size (dominant nodule):  Up to 4 cm.
Percent of prostate involved by carcinoma:  30%.
Involvement of seminal vesicle:  Absent.
Extraprostatic extension:  Present.
Perineural invasion:  Present.
Invasion of adjacent structures:  Absent.
Lymph-Vascular invasion:  Absent.
Margins:  Apical and circumferential margins focally involved.  
  Bladder margin clear.
Regional lymph nodes:  Left pelvic node involved, with 
  extracapsular extension.
Distant metastasis:  Not applicable.
PSA value:  32.33 ng/ml **DATE[Jul 4 2012] (from history).
High grade prostatic intraepithelial neoplasia:  Absent.
Other findings:  None.
Pathologic grade and stage:  GS 7; pT3a N1 (Stage IV).",,"GrossDescription:
A. Specimen:  Prostate with attached bilateral seminal vesicles 
  and vas deferens, received in formalin.
Fixative:  10% neutral buffered formalin.
Weight:  54 gm.
Size:
  Apex Base:  4.3 cm.
  Anterior Posterior:  3.8 cm.
  Right Left:  5.6 cm.
Lesion(s): 
  Location:  Right and left posterior prostate.
  Size:  3.7 x 2.9 x 1.7 cm.
  Appearance:  Irregular, ill-defined firm tan-white.
  Distance to margins:  Grossly abutting all margins.
Seminal vesicles
  Right:  3.4 x 1.2 x 0.8 cm; unremarkable.
  Left:  2.7 x 1.8 x 0.8 cm; unremarkable.
Vasa deferentia
  Right:  5.9 x 0.3 cm.
  Left:  3.1 x 0.4 cm.
Other findings:  Calcified nodule in the right base prostate 
  measuring 0.4 cm.
Staining of margins:  Right - orange; left - blue; posterior 
  - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal margin
3  cross sections through shave distal margin
4  right apical prostate
5-7  right mid prostate
8-11  right base prostate (8 includes calcified nodule, post 
      fixed in decal)
12  left apical prostate
13-15  left mid prostate
16-19  left base prostate
20  right seminal vesicle and vas deferens
21  left seminal vesicle and vas deferens

B. Specimen:  Lymph node with attached fat, received in formalin.  
Weight:  4 gm.
Number of segments:  1.  
Size:  3.7 x 2.1 x 0.9 cm.
Gross findings: Multiple apparent lymph nodes grossly identified
   measuring up to 2.3 x 0.9 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks for microscopic evaluation:
1-2  lymph nodes
3  remaining fatty tissue

C. Specimen:  Lymph nodes with attached fat, received in formalin.  
Weight:  4 gm.
Number of segments:  1.  
Size:  2.5 x 2.5 x 0.6 cm.
Gross findings: Single apparent lymph node grossly identified 
  measuring 2.5 x 1.0 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks for microscopic evaluation:
1  lymph node
2  remaining fatty tissue.",,"A: PROSTATE GLAND
B: RIGHT PELVIC LYMPH NODES
C: LEFT PELVIC LYMPH NODES",,
REG4,PROSTATE,0,PAT-10036319,1,REC-3000678696,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  ANTERIOR PRE PROSTATIC FAT:  NEGATIVE FOR MALIGNANCY.
 
B.  PROSTATE:  PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure: Prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Bilateral, with patchy foci from base to apex.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4)
Percent Gleason grade 4 and/or 5:  10%.
Size (dominant nodule):  Estimate spans 2.4-cm.
Percent of prostate involved by carcinoma:  10-20%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Focally present, left mid posterior.
Perineural invasion:  Present.
Invasion of adjacent structures: Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes (including number of nodes):  Not assessed.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:   
  Gleason's 7 (3+4), pT3a (Stage III if N0 M0).",,"GrossDescription:
A. Specimen:  Irregular segment of fatty tissue, received in formalin.  
Weight:  5 gm.
Number of segments:  Multiple.  
Size:  Aggregating to 4.0 x 3.2 x 0.7 cm.
Gross findings: No masses or lesions grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  3.

B. Specimen:  Prostate with attached seminal vesicle and vas deferens, received in formalin.
Fixative:  10% neutral buffered formalin.
Weight:  33 gm.
Size:
  Apex Base:  3.0 cm.
  Anterior Posterior:  3.2 cm.
  Right Left:  4.1 cm.
Lesion(s): 
  Location:  Left mid prostate.
  Size:  0.5 x 0.3 x 0.3 cm.
  Appearance:  Irregular, ill-defined flat tan yellow lesion.
  Distance to margins:  Grossly abutting the left mid posterior margin.
  Other findings: Firm to rubbery tan-white nodule in the left mid prostate measuring 0.6 x 0.6 x 0.4 cm
Seminal vesicles
  Right:  3.4 x 1.0 x 0.8 cm; unremarkable.
  Left:  2.9 x 1.5 x 0.4 cm; unremarkable.
Vasa deferentia
  Right:  2.9 x 0.4 cm.
  Left:  3.5 x 0.3 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved proximal margin
2  cross sections through shaved distal margin
3  left and right apical prostate
4-5  right mid prostate
6-8  right base prostate
9-10  left mid prostate
11-14  left base prostate
15  right seminal vesicle and vas deferens
16  left seminal vesicle and vas deferens.",,"A: ANTERIOR PRE PROSTATIC FAT
B: PROSTATE GLAND",,
REG4,PROSTATE,0,PAT-10036810,1,REC-3000678950,"ClinicalHistory:
Elevated PSA = 17.6 ng/mL done on **DATE[Oct 5 2012].",,"FinalDiagnosis:
Prostate core needle biopsies:

A.  Right apex:      PROSTATIC ADENOCARCINOMA, Gleason's score 8 (3+5), involving 1 of 1 
        core, measuring 1.3 mm
 
B.  Right mid gland:    Benign prostatic tissue
 
C.  Right base:      Benign prostatic tissue
 
D.  Right lateral:      Benign prostatic tissue
 
E.  Right anterior:      Benign prostatic tissue
 
F.  Left apex:      Benign prostatic tissue
 
G.  Left mid gland:      Benign prostatic tissue
 
H.  Left base:      Benign prostatic tissue
 
I.   Left lateral:      Benign prostatic tissue
 
J.  Left anterior:    Benign prostatic tissue.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnoses.  Dr. **NAME[XXX WWW] has been notified on **DATE[Oct 13 2012].",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right apex"" are two soft, tan core of tissue measuring up to 0.7 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes A1 and A2, with the larger core in cassette A1.

B.  Received in formalin labeled ""XXXXXX, right mid gland"" is a soft, tan core of tissue measuring up to 1.5 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

C.  Received in formalin labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.6 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

D.  Received in formalin labeled ""XXXXXX, right lateral"" is a soft, tan core of tissue measuring up to 1.6 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

E.  Received in formalin labeled ""XXXXXX, right anterior"" is a soft, tan core of tissue measuring up to 0.9 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

F.  Received in formalin labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

G.  Received in formalin labeled ""XXXXXX, left mid gland"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

H.  Received in formalin labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

I.  Received in formalin labeled ""XXXXXX, left lateral"" is a soft, tan core of tissue measuring up to 1.1 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

J.  Received in formalin labeled ""XXXXXX, left anterior"" is a soft, tan core of tissue measuring up to 1.0 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.  The microscopic description supports the above diagnoses.","A: Right prostate core needle biopsy at apex
B: Right prostate core needle biopsy at midgland
C: Right prostate core needle biopsy at base
D: Right prostate core needle biopsy at lateral
E: Right prostate core needle biopsy at anterior
F: Left prostate core needle biopsy at apex
G: Left prostate core needle biopsy at midgland
H: Left prostate core needle biopsy at base
I: Left prostate core needle biopsy at lateral
J: Left prostate core needle biopsy at anterior",,
REG4,PROSTATE,0,PAT-10034543,1,REC-3000678961,"ClinicalHistory:
Elevated PSA.
Post-OperativeDiagnosis:
To be determined by pathology.",,"PostOperativeDiagnosis:
To be determined by pathology.
FinalDiagnosis:
Prostate core needle biopsies:

A.  Right base:      Benign prostatic tissue 
 
B.  Right mid gland:    PROSTATIC ADENOCARCINOMA, Gleason's score 7 (3+4), involving 1 of 2 
        cores, measuring 4.9 mm
 
C.  Right mid:      Benign prostatic tissue
 
D.  Right mid tz:    Benign prostatic tissue
 
E.  Right apex:    PROSTATIC ADENOCARCINOMA, Gleason's score 6 (3+3), involving 1 of 1 
        core, measuring 1.1 mm
 
F.  Left base:      Benign prostatic tissue
 
G.  Left mid lat:      Benign prostatic tissue
 
H.  Left mid:        Benign prostatic tissue
 
I.   Left mid tz:      Benign prostatic tissue
 
J.  Left apex:      Benign prostatic tissue.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnoses.  Dr. **NAME[XXX WWW] has been notified on **DATE[Dec 13 2011].",,"GrossDescription:
A.  Received in formalin, labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.5 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

B.  Received in formalin, labeled ""XXXXXX, right mid lat"" are two soft, tan cores of tissue measuring up to 1.7 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes B1 and B2.  

C.  Received in formalin, labeled ""XXXXXX, right mid' are two soft, tan cores of tissue measuring up to 2.0 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes C1 and C2.

D.  Received in formalin, labeled ""XXXXXX, right mid TZ"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

E.  Received in formalin, labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 1.0 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

F.  Received in formalin, labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

G.  Received in formalin, labeled ""XXXXXX, left mid lat"" are two soft, tan cores of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes G1 and G2.

H.  Received in formalin, labeled ""XXXXXX, left mid"" are two soft, tan cores of tissue measuring up to 1.0 cm in length by 0.1 cm in diameter.  Submitted entirely in cassettes H1 and H2.

I.  Received in formalin, labeled ""XXXXXX, left mid TZ"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

J.  Received in formalin, labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.5 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.  The microscopic description supports the above diagnoses.","A: Right prostate core needle biopsy at base
B: Right prostate core needle biopsy at mid lat
C: Right prostate core needle biopsy at mid
D: Right prostate core needle biopsy at mid tz
E: Right prostate core needle biopsy at apex
F: Left prostate core needle biopsy at base
G: Left prostate core needle biopsy at mid lat
H: Left prostate core needle biopsy at mid
I: Left prostate core needle biopsy at mid tz
J: Left prostate core needle biopsy at apex",,
REG4,PROSTATE,0,PAT-10033753,1,REC-3000678971,"ClinicalHistory:
Elevated PSA = 6.1 ng/mL; abnormal prostate exam.  Rectal exam demonstrates prostate slightly enlarged at 3.5 x 4.0 cm, abnormal with a nodule at the left base noted.",,"FinalDiagnosis:
Prostate core needle biopsies:

A.  Right apex:      Benign prostatic tissue 
 
B.  Right mid gland:    Benign prostatic tissue
 
C.  Right base:      Benign prostatic tissue
 
D.  Right lateral:      Benign prostatic tissue
 
E.  Right anterior:      Benign prostatic tissue
 
F.  Left apex:      PROSTATIC ADENOCARCINOMA, Gleason's score 9 (5+4), involving 1 of 1 
        core, measuring 2.0 mm
 
G.  Left mid gland:      PROSTATIC ADENOCARCINOMA, Gleason's score 7 (4+3), involving 1 of 1 
        core, measuring 6.9 mm
 
H.  Left base:      PROSTATIC ADENOCARCINOMA, Gleason's score 9 (4+5), involving 1 of 1 
        core, measuring 4.7 mm

 
I.   Left lateral:      PROSTATIC ADENOCARCINOMA, Gleason's score 9 (4+5), involving 1 of 1 
        core, measuring 9.8 mm
 
J.  Left anterior:    PROSTATIC ADENOCARCINOMA, Gleason's score 7 (3+4), involving 1 of 1 
        core, measuring 0.9 mm.
DiagnosisComment:
Dr. **NAME[ZZZ YYY] has reviewed the case and concurs with the diagnoses.  Dr. **NAME[XXX WWW] has been notified on **DATE[Nov 13 2011].",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

B.  Received in formalin labeled ""XXXXXX, right mid gland"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

C.  Received in formalin labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 1.6 cm Iength by 0.1 cm in diameter.  Submitted entirely in one cassette.

D.  Received in formalin labeled ""XXXXXX, right lateral"" is a soft, tan core of tissue measuring up to 1.6 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

E.  Received in formalin labeled ""XXXXXX, right anterior"" is a soft, tan core of tissue measuring up to 2.0 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

F.  Received in formalin labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.4 cm in length by 0.1 in diameter.  Submitted entirely in one cassette.

G.  Received in formalin labeled ""XXXXXX, left mid gland"" is a soft, tan core of tissue measuring up to 1.2 cm in length by 0.1 cm diameter.  Submitted entirely in one cassette.

H.  Received in formalin labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

I.  Received in formalin labeled ""XXXXXX, left lateral"" is a soft, tan core of tissue measuring up to 1.3 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.

J.  Received in formalin labeled ""XXXXXX, left anterior"" is a soft, tan core of tissue measuring 1.0 cm in length by 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
A-J.  The microscopic description supports the above diagnoses.","A: Right prostate core needle biopsy at apex
B: Right prostate core needle biopsy at midgland
C: Right prostate core needle biopsy at base
D: Right prostate core needle biopsy at lateral
E: Right prostate core needle biopsy at anterior
F: Left prostate core needle biopsy at apex
G: Left prostate core needle biopsy at midgland
H: Left prostate core needle biopsy at base
I: Left prostate core needle biopsy at lateral
J: Left prostate core needle biopsy at anterior",,
REG4,PROSTATE,0,PAT-10036804,1,REC-3000679205,"ClinicalHistory:
Elevated PSA 4.5 ng/ ml on **DATE[Feb 17 2012]; Prostate enlarged, 50 grams, no induration and no nodules.",,"FinalDiagnosis:
A.  Prostate core needle biopsy, left base:    Prostatic adenocarcinoma, Gleason score 6 (3+3), two
              foci 0.5 mm and 0.3 mm, 5% of tissue volume, no 
              perineural invasion present      
 
B.  Prostate core needle biopsy, right base:    Benign prostatic tissue  
 
C.  Prostate core needle biopsy, left mid:    Benign prostatic tissue  
 
D.  Prostate core needle biopsy, right mid:     Prostatic adenocarcinoma, Gleason score 6 (3+3), one 
              focus 2.0 mm, 30% of tissue volume, no perineural 
              invasion present  
 
E.  Prostate core needle biopsy, left lateral:    Benign prostatic tissue  
 
F.  Prostate core needle biopsy, right lateral:    Benign prostatic tissue  
 
G.  Prostate core needle biopsy, right apex:    Benign prosrtatic tissue  
 
H.  Prostate core needle biopsy, left apex:    Prostatic adenocarcinoma, Gleason score 6 (3+3), two 
              foci 4.0 mm and 0.7 mm, 60 % of tissue volume, 
              no perineural invasion present.",,"GrossDescription:
A.  Received in fixative labeled ""XXXXXX, #1 (L) base"" are two cores of tan to white tissue measuring up to 1.9 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

B.  Received in fixative labeled ""XXXXXX, #2 (R) base"" are two cores of tan to white tissue measuring up to 1.7 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

C.  Received in fixative labeled ""XXXXXX, #3 (L) mid"" are two cores of tan to white tissue measuring up to 1.5 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

D.  Received in fixative labeled ""XXXXXX, #4 (R) mid"" are two cores of tan to white tissue measuring up to 1.5 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

E.  Received in fixative labeled ""XXXXXX, #5 (L) lateral"" are two cores of tan to white tissue measuring up to 1.8 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

F.  Received in fixative labeled ""XXXXXX, #6 (R) lateral"" are two cores of tan to white tissue measuring up to 1.8 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

G.  Received in fixative labeled ""XXXXXX, #7 (R) apex"" are two cores of tan to white tissue measuring up to 1.2 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.

H.  Received in fixative labeled ""XXXXXX, #8 (L) apex"" are two cores of tan to white tissue measuring up to 1.8 cm in length and 0.1 cm in diameter.  Submitted entirely in two cassettes.","MicroscopicDescription:
A-H.   The microscopic findings support the above diagnoses. For part A, D, F and H, the immunostain for PIN4 supports the diagnosis. Dr. **NAME[ZZZ] concurs. Dr. **NAME[YYY XXX] has been notified.","A: Left prostate core needle biopsy at base
B: Right prostate core needle biopsy at base
C: Left prostate core needle biopsy at mid
D: Right prostate core needle biopsy at mid
E: Left prostate core needle biopsy at lateral
F: Right prostate core needle biopsy at lateral
G: Right prostate core needle biopsy at apex
H: Left prostate core needle biopsy at apex",,
REG4,PROSTATE,0,PAT-10042286,1,REC-3000679354,"ClinicalHistory:
Abnormal digital rectal exam; Prostate 30 grams with apical nodule.",,"FinalDiagnosis:
Prostate, core needle biopsy:

A. Left base:    Benign prostate tissue

B. Right base:    Benign prostate tissue and seminal vesicle

C. Left mid:    Benign prostate tissue

D. Right mid:    Benign prostate tissue

E. Left lateral:    Benign prostate tissue

F. Right lateral:  Benign prostate tissue  

G. Left apex:    Atypical small acinar proliferation, suspicious for adenocarcinoma (see Comment) 
      Slide consultation pending and an addendum report to follow

H. Right apex:    Benign prostate tissue.
DiagnosisComment:
For part G, immunostain for PIN 4 support the diagnosis.  Dr. **NAME[ZZZ] concurs. Dr. **NAME[YYY] has been notified.",,"GrossDescription:
A.  Received in fixative labeled ""XXXXXX, #1 (L) base"" are 2 cores of tan to white tissue measuring up to 1.5 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.

B.  Received in fixative labeled ""XXXXXX, #2 (R) base"" are 2 cores of tan to white tissue measuring up to 2.2 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.

C.  Received in fixative labeled ""XXXXXX, #3 (L) mid"" are 2 cores of tan to white tissue measuring up to 1.3 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.

D.  Received in fixative labeled ""XXXXXX, #4 (R) mid"" are 2 cores of tan to white tissue measuring up to 1.6 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.

E.  Received in fixative labeled ""XXXXXX, #5 (L) lateral"" are 2 cores of tan to white tissue measuring up to 2.2 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.

F.  Received in fixative labeled ""XXXXXX, #6 (R) lateral"" are 2 cores of tan to white tissue measuring up to 2.4 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes. 

G.  Received in fixative labeled ""XXXXXX, #7 (L) apex"" are 2 cores of tan to white tissue measuring up to 2.0 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.

H.  Received in fixative labeled ""XXXXXX, #8 (R) apex"" are 2 cores of tan to white tissue measuring up to 1.8 cm in length and 0.1 cm in diameter.  Submitted in toto in two cassettes.","MicroscopicDescription:
The microscopic findings support the diagnosis.","A: Left prostate core needle biopsy at base
B: Right prostate core needle biopsy at base
C: Left prostate core needle biopsy at mid
D: Right prostate core needle biopsy at mid
E: Left prostate core needle biopsy at lateral
F: Right prostate core needle biopsy at lateral
G: Left prostate core needle biopsy at apex
H: Right prostate core needle biopsy at apex",,
REG4,PROSTATE,0,PAT-10038276,1,REC-3000679441,"ClinicalHistory:
790.93, elevated PSA.",,"FinalDiagnosis:
A.  CORE NEEDLE BIOPSY, LEFT APEX PROSTATE:  BENIGN PROSTATE TISSUE.
 
B.  CORE NEEDLE BIOPSY, LEFT MID PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE
    6 (3 + 3), INVOLVING 1 OF 6 CORES (LESS THAN 5% OF THE SPECIMEN).
 
C.  CORE NEEDLE BIOPSY, LEFT BASE PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE
    6 (3 + 3), INVOLVING 2 OF 3 CORES (LESS THAN 5% OF THE SPECIMEN).
 
D.  CORE NEEDLE BIOPSY, RIGHT APEX PROSTATE:  BENIGN PROSTATE TISSUE.
 
E.  CORE NEEDLE BIOPSY, RIGHT MID PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE
    6 (3 + 3), INVOLVING 1 OF 7 CORES (LESS THAN 5% OF THE SPECIMEN).
 
F.  CORE NEEDLE BIOPSY, RIGHT BASE PROSTATE:  BENIGN PROSTATE TISSUE.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left mid, base; right mid.
Number of cores with carcinoma/total cores:  Left - 3/10; right - 1/12.
Maximum size of carcinoma:  0.1 cm.
Percent of overall tissue involved by carcinoma:  Less than 5%.
Highest Gleason score at single site:  6 (3 + 3).
Overall Gleason score:  6 (3 + 3).
Percent of Gleason grade 4 and/or 5:  None. 
Extraprostatic or seminal vesicle invasion:  None.
Perineural invasion:  None. 
Lymph-Vascular invasion:  None. 
High grade prostatic intraepithelial neoplasia:  None.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

C.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  5. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  3. 
Size:  Up to 0.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

F.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE",,
REG4,PROSTATE,0,PAT-10038325,1,REC-3000679618,"ClinicalHistory:
790.93.",,"FinalDiagnosis:
A.  CORE NEEDLE BIOPSY, RIGHT BASE PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 
    7 (4 + 3), WITH PERINEURAL INVASION AND EXTRAPROSTATIC EXTENSION, INVOLVING 2 OF 2 
    CORES (95% OF THE SPECIMEN).
 
B.  CORE NEEDLE BIOPSY, RIGHT MID PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 
    7 (4 + 3), WITH PERINEURAL INVASION, INVOLVING 2 OF 2 CORES (90% OF THE SPECIMEN).
 
C.  CORE NEEDLE BIOPSY, RIGHT APEX PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 
    7 (4 + 3), INVOLVING 2 OF 2 CORES (50-60% OF THE SPECIMEN).
 
D.  CORE NEEDLE BIOPSY, LEFT BASE PROSTATE:  BENIGN PROSTATE TISSUE.
 
E.  CORE NEEDLE BIOPSY, LEFT MID PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 
    6 (3 + 3), INVOLVING 1 OF 2 CORES (10-20% OF THE SPECIMEN).
 
F.  CORE NEEDLE BIOPSY, LEFT APEX PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON SCORE 
    6 (3 + 3), INVOLVING 1 OF 2 CORES (60% OF THE SPECIMEN).

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right base, mid, apex; left mid, apex.
Number of cores with carcinoma/total cores:  Right - 6/6; left - 2/6.
Maximum size of carcinoma:  0.8 cm.
Percent of overall tissue involved by carcinoma:  50-60%.
Highest Gleason score at single site:  7 (4 + 3).
Overall Gleason score:  7 (4 + 3).
Percent of Gleason grade 4 and/or 5:  60-70%. 
Extraprostatic or seminal vesicle invasion:  Present, right base.
Perineural invasion:  Present. 
Lymph-Vascular invasion:  None. 
High grade prostatic intraepithelial neoplasia:  None.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  3. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  4. 
Size:  Up to 0.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  3. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT BASE PROSTATE
B: RIGHT MID PROSTATE
C: RIGHT APEX PROSTATE
D: LEFT BASE PROSTATE
E: LEFT MID PROSTATE
F: LEFT APEX PROSTATE",,
REG4,PROSTATE,0,PAT-10041431,1,REC-3000679755,"ClinicalHistory:
790.93
185
Procedure->Biopsy
Clinical History/Diagnosis/Condition->Elevated PSA   135.28./r/n",,"FinalDiagnosis:
A\T\B.  Prostate, right and left:  Prostatic adenocarcinoma (Gleason 4 +3, sum 7)./r/nDiagnosisComment:
Intradepartmental consultation with Dr. **NAME[ZZZ YYY XXX] on **DATE[Sep 18 2012].  Dr. **NAME[WWW] was notified of the diagnosis via e-mail on **DATE[Sep 18 2012]./r/n",,"GrossDescription:
A.  Labeled:      Patient name and medical record number, designated right prostate x4
  Specimen:    Cylindrical thread-like cores of tissue (formalin)
  Number:      Four and fragments
  Size:           Measuring up to 1.6 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1

B.  Labeled:      Patient name and medical record number, designated left prostate x4
  Specimen:    Cylindrical thread-like cores of tissue (formalin)
  Number:      Four
  Size:           Measuring up to 1.2 x 0.1 x 0.1 cm 
  Submitted/Block:    Entirely/1./r/n","MicroscopicDescription:
A.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Right lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 4 + 3, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 80%
  Number of cores with tumor/total number of cores: 4 of 4
Lymphatic invasion: Not identified
Perineural invasion: Not identified
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None

B.  PROSTATE CANCER INFORMATION
Specimen type: Prostate needle biopsy 
Biopsy site: Left lobe
Histologic type: Prostatic adenocarcinoma
Gleason score: 4 + 3, sum 7
Tumor quantitation:
  Proportion (percent) of prostatic tissue involved by tumor: 80%
  Number of cores with tumor/total number of cores: 4 of 4
Lymphatic invasion: Not identified
Perineural invasion: Present
Periprostatic fat invasion (extraprostatic extension): Not identified
Seminal vesicle invasion: Not identified (no seminal vesicle tissue present)
Additional pathologic findings: None./r/n","A: Right prostate x4, biopsy
B: Left prostate x4, biopsy",,
REG4,PROSTATE,0,PAT-10034591,1,REC-3000682840,"ClinicalHistory:

Elevated PSA.
Post-OperativeDiagnosis:
To be determined by pathology.",,"PostOperativeDiagnosis:
To be determined by pathology.
FinalDiagnosis:
Prostate, core needle biopsy:

A. Right base:        Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 0.04 cm
          No perineural invasion 

B. Right mid lateral:       Benign prostate tissue

C. Right mid:         Prostatic adenocarcinoma, Gleason score 6 (3+3), involves entire core, 
          1.0 cm, no perineural invasion

D. Right mid transitional:     Benign prostate tissue

E. Right apex:         Prostatic adenocarcinoma, Gleason score 6 (3+3), involves entire core, 
          1.0 cm, no perineural invasion

F. Left base:         Benign prostate tissue

G. Left mid lateral:       Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 0.6 cm, 
          No perineural invasion

H. Left mid:         Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 0.1 cm, 
          No perineural invasion

I. Left mid transitional:     Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 0.5 cm, 
          No perineural invasion

J. Left apex:        Prostatic adenocarcinoma, Gleason score 6 (3+3), one focus 0.3 cm, 
          No perineural invasion.",,"GrossDescription:
A.  Received in formalin labeled ""XXXXXX, right base"" is a soft, tan core of tissue measuring up to 0.9 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

B.  Received in formalin labeled ""XXXXXX, right mid lat"" is a soft, tan core of tissue measuring up to 1.2 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

C.  Received in formalin labeled ""XXXXXX, right mid"" is a soft, tan core of tissue measuring up to 1.4 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

D.  Received in formalin labeled ""XXXXXX, right mid tz"" is a soft, tan core of tissue measuring up to 1.6 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

E.  Received in formalin labeled ""XXXXXX, right apex"" is a soft, tan core of tissue measuring up to 1.5 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

F.  Received in formalin labeled ""XXXXXX, left base"" is a soft, tan core of tissue measuring up to 1.3 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

G.  Received in formalin labeled ""XXXXXX, left mid lat"" is a soft, tan core of tissue measuring up to 1.5 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

H.  Received in formalin labeled ""XXXXXX, left mid"" is a soft, tan core of tissue measuring up to 1.4 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

I.  Received in formalin labeled ""XXXXXX, left mid tz"" is a soft, tan core of tissue measuring up to 1.8 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.

J.  Received in formalin labeled ""XXXXXX, left apex"" is a soft, tan core of tissue measuring up to 1.4 cm in length x 0.1 cm in diameter.  Submitted entirely in one cassette.","MicroscopicDescription:
The microscopic findings support the diagnosis. Dr. **NAME[ZZZ] has been notified.","A: Right prostate core needle biopsy at base
B: Right prostate core needle biopsy at mid lat
C: Right prostate core needle biopsy at mid
D: Right prostate core needle biopsy at mid tz
E: Right prostate core needle biopsy at apex
F: Left prostate core needle biopsy at base
G: Left prostate core needle biopsy at mid lat
H: Left prostate core needle biopsy at mid
I: Left prostate core needle biopsy at mid tz
J: Left prostate core needle biopsy at apex",,"AddendumDiagnosis:
Dr. **NAME[YYY] concurs."
REG4,PROSTATE,0,PAT-10035947,1,REC-3000682976,"ClinicalHistory:
Increasing PSA.","PhysicianNotification:
Preliminary report faxed to Dr **NAME[ZZZ] on **DATE[Nov 11 11] (TN).","FinalDiagnosis:

A.  LEFT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
B.  LEFT MID PROSTATE PROSTATE BIOPSY:  HIGH GRADE PIN.
 
C.  LEFT BASE PROSTATE PROSTATE BIOPSY:  HIGH GRADE PIN.
 
D.  RIGHT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
E.  RIGHT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
F.  RIGHT BASE PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
G.  CENTRAL ZONE PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
DiagnosisComment:
B,C. The biopsy material was sent to Dr. **NAME[YYY] at **NAME[XXX WWW] for confirmation.  Additional recut slides of specimens from the previous biopsy (***PATH-NUMBER[1]) were also sent for review.  See separate consult report.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  2.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.0 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 0.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
A,D-G. Sections show core biopsy fragments of benign prostatic glands and stroma.  There is no evidence of malignancy or significant PIN. 

B,C. Sections show core biopsy fragments of prostate tissue with foci of glands lined by cells with variable nuclear enlargement and occasionally prominent nucleoli.  In specimen B, the amount of nuclear pleomorphism is pronounced but abnormal architectural changes (cribriform, papillary changes) are not identified.  Positive staining of the atypical glands for P504S and basal cell markers (p63 and cytokeratin 5/6) is compatible with high grade PIN.","A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE
G: CENTRAL ZONE",,"Interpretation:
JOHN **NAME[WWW] REFERENCE LABORATORIES:
***PATH-NUMBER[2] **NAME[CCC M YYY] MD

1) PROSTATE (***PATH-NUMBER[1]):

     B1) HIGH GRADE PIN WITH ADJACENT SMALL ATYPICAL GLANDS WHERE
         IT IS DIFFICULT TO DETERMINE WHETHER THESE ADJACENT 
         SMALL ATYPICAL GLANDS REPRESENT OUTPOUCHINGS FROM 
         ADJACENT HIGH GRADE PIN OR REPRESENT ASSOCIATED FOCAL
         INFILTRATING ADENOCARCINOMA.  FINDINGS ARE HIGHLY 
         SUSPICIOUS FOR CARCINOMA.  SEPARATE HIGH-GRADE PROSTATIC
         INTRAEPITHELIAL NEOPLASIA.  SEE NOTE.

         NOTE:  A stain for high molecular weight cytokeratin is
         noncontributory.  (Stains were performed at **NAME[XXX
         WWW].)

     C1) BENIGN PROSTATIC TISSUE.

     E1) BENIGN PROSTATIC TISSUE. SEE NOTE.

     NOTE:  There are foci, which may represent low grade PIN.
     However, we do not diagnose low grade PIN since its
     recognition is subjective and it lacks clinic relevance.

2) PROSTATE (***PATH-NUMBER[3]):

     B2) HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA.
         BENIGN PORTION OF SEMINAL VESICLE/EJACULATORY DUCT.

     C1) HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA."
REG4,PROSTATE,0,PAT-10038475,1,REC-3000683155,"ClinicalHistory:
Prostate CA, PSA 10.",,"FinalDiagnosis:
A.  PRE PROSTATIC FAT:  BENIGN FIBROADIPOSE TISSUE.
 
B.  RIGHT PELVIC LYMPH NODE: ONE LYMPH NODE NEGATIVE FOR METASTASIS (0/1). 
 
C.  LEFT PELVIC LYMPH NODE:  TWO LYMPH NODES NEGATIVE FOR METASTASIS (0/2).
 
D.  PROSTATE: PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Robotic radical retropubic prostatectomy and bilateral pelvic lymph node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site:  Bilateral, mid to base (posterior > anterior).
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (4+3). 
Percent Gleason grade 4 and/or 5:  60%.
Size (dominant nodule):  2.5 x 0.6 cm (microscopic measurement).
Percent of prostate involved by carcinoma:  20%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Focal extraprostatic extension present.
Perineural invasion:  Present.
Invasion of adjacent structures (bladder, rectum):  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes: Negative for metastasis (0/3).
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic stage:  pT3a, pN0, Stage III (if M0).",,"GrossDescription:

A. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  4 gm.
Number of segments:  1.  
Size:  3.7 x 2.3 x 1.4 cm.
Gross findings: No obvious lymph nodes grossly identified.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  2 gm.
Number of segments:  1.  
Size:  3.0 x 1.6 x 1.0 cm.
Gross findings: Single lymph node identified measuring 2.8 x 1.3 x 1.0 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, bisected.

C. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.0 x 1.4 x 1.2 cm.
Gross findings: Two lymph nodes identified grossly measuring up to 1.3 x 1.0 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

D. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  71 gm.
Size:
  Apex Base:  5.0 cm.
  Anterior Posterior:  4.4 cm.
  Right Left:  6.0 cm.
Lesion(s): 
  Location:  Right mid-base prostate.
  Size:  1.3 x 1.1 x 0.7 cm.
  Appearance:  Irregular, tan-yellow and firm.
  Distance to margins:  Grossly abuts the posterior margin and 0.4 cm away from the right circumferential margin.
Seminal vesicles
  Right:  4.2 x 1.2 x 0.5 cm; unremarkable.
  Left:  3.2 x 1.1 x 0.6 cm; unremarkable.
Vasa deferentia
  Right:  0.9 x 0.7 cm, unremarkable.
  Left:  1.9 x 0.8 cm, unremarkable. 
Other findings:  Multiple, well circumscribed tan nodules throughout entire specimen.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through shaved distal, prostatic apical margin
2  cross sections through shaved proximal, bladder neck margin
3  left apical prostate
4-7  left mid prostate
8-13  left base prostate
14  left seminal vesicle and vas deferens
15  right seminal vesicle and vas deferens
16-20  right base prostate (lesion in 18-20)
21-24  right mid prostate (lesion in 21)
25  right apical prostate.",,"A: PRE PROSTATIC FAT
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE
D: PROSTATE",,
REG4,PROSTATE,0,PAT-10024090,2,REC-3000685121,"ClinicalHistory:

Elevated PFA, urinary retention.
Post-OperativeDiagnosis:
Same pending results.",,"PostOperativeDiagnosis:
Same pending results.
FinalDiagnosis:
Prostate, TURP:    1. Prostatic adenocarcinoma, Gleason score 6 (3+3), 
           two foci 2.0 mm and 1.3 mm, less than 5% of tissue volume, no perineural 
           invasion 
        2. Granulomatous inflammation present.
DiagnosisComment:
PIN4 stains support the diagnosis. GMS and AFB stain are negative for fungus or acid-fast bacilli. Dr. **NAME[ZZZ] concurs.",,"GrossDescription:
Received in formalin labeled ""**NAME[BBB], prostate"" are multiple soft, pink-tan, rubbery pieces of tissue weighing up to 7.0 gm, measuring up to 6.0 x 3.0 x 1.0 cm in aggregate.  Submitted entirely in six cassettes.","MicroscopicDescription:
The microscopic findings support the diagnosis.",A: Prostate,,"AddendumDiagnosis:
Dr. **NAME[YYY] concurs with the diagnosis."
REG4,PROSTATE,0,PAT-01496579,1,REC-3000685198,"ClinicalHistory:
Procedure:->Other (Specify in Comments)
Examine for:->Cancer
History/Clinical Impressions:->metastatic prostate CA ,./r/n","CytologyReview:
SUSPICIOUS FOR MALIGNANCY
Atypical cells in clusters, suspicious for prostatic carcinoma./r/n
NEGATIVE FOR MALIGNANT CELLS
Admixture of reactive mesothelial cells, RBC's, lymphocytes and neutrophils. Minute fragment of benign appearing squamous epithelium present, possibly of skin surface origin./r/n","FinalDiagnosis:
NEGATIVE FOR MALIGNANT CELLS
Admixture of reactive mesothelial cells, RBC's, lymphocytes and neutrophils. Minute fragment of benign appearing squamous epithelium present, possibly of skin surface origin./r/nDiagnosisComment:
Immunohistochemical stain for PSA is negative on both cell blocks. A minute fragment of benign appearing squamous cells is present in one of the blocks, possibly of skin surface origin. Case reviewed in Pathology Staff Conference on **DATE[Mar 25 12]./r/n",,"GrossDescription:
675cc of cloudy yellow fluid with clot
Preparation:
2 cytospins:     1 giemsa stain, 1 papanicolaou stain
2 pull smears:  1 giemsa stain, 1 papanicolaou stain
2 cell block./r/n",,A: Pleural fluid right (per jar),,
REG4,PROSTATE,0,PAT-10041987,1,REC-3000697617,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:
A.  Right prostate:  PROSTATE ADENOCARCINOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Right prostate
  Number of cores involved by carcinoma:  Five out of nine core fragments involved
  Maximum size of carcinoma:      3.8 mm
  Percent of tissue involved by carcinoma:  45%
  Gleason's score:        7 (3+4)
  Perineural invasion:        Not seen
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None

B.  Left prostate:  PROSTATE ADENOCARCINOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Left prostate
  Number of cores involved by carcinoma:  Four out of seven core fragments involved
  Maximum size of carcinoma:      5 mm
  Percent of tissue involved by carcinoma:  35%
  Gleason's score:        7 (3+4)
  Perineural invasion:        Not seen
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None.
DiagnosisComment:
A, B.  Dr. **NAME[ZZZ] reviewed the slides and concurred with the diagnosis.",,"GrossDescription:
Two specimens are received in fixative labeled with the patient's name.
A.  Specimen labeled ""right prostate"" consists of six core biopsies of white soft tissue measuring up to 1.3 cm in maximum length.  Totally submitted in two cassettes.
  A1, A2)  Right prostate

B.  Specimen labeled ""left prostate"" consists of seven core biopsies of white soft tissue measuring up to 1.3 cm in maximum length.  Totally submitted in two cassettes.
  B1, B2)  Left prostate.","MicroscopicDescription:
A, B.  The microscopic findings support the above diagnosis.","A: Right prostate
B: Left prostate",,
REG4,PROSTATE,0,PAT-01596717,3,REC-3000697653,"ClinicalHistory:
790.93, elevated prostate specific antigen.",,"FinalDiagnosis:

A.  RIGHT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
B.  RIGHT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
C.  RIGHT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 5 to 10% OF SAMPLE. 
 
D.  LEFT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
E.  LEFT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
F.  LEFT BASE PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
G.  MEDIAL ZONES PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right base prostate.
Number of cores with carcinoma:  1 of 12 core fragments.
Maximum size of carcinoma:  0.15 cm.
Percent of overall tissue involved by carcinoma:  <5%.
Highest Gleason score at single site:  6 (3 + 3).
Overall Gleason score:  6 (3 + 3).
Percent of Gleason grade 4 and/or 5:  None.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  2.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: RIGHT APEX
B: RIGHT MID
C: RIGHT BASE
D: LEFT APEX
E: LEFT MID
F: LEFT BASE
G: MEDIAL ZONES",,
REG4,PROSTATE,0,PAT-10036965,1,REC-3000697911,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  ANTERIOR FAT OF PROSTATE:  BENIGN FIBROADIPOSE TISSUE
 
B.  RIGHT BLADDER NECK MARGIN:  CALCIFIED NODULE; NEGATIVE FOR MALIGNANCY
 
C.  PROSTATE AND BILATERAL SEMINAL VESICLES:  PROSTATIC ADENOCARCINOMA
Prostate cancer information
Operative procedure:  Resection of prostate and bilateral seminal vesicles
Tumor-histologic type:  Prostatic adenocarcinoma
Multicentricity:  Present
Anatomic site (including status of apex):  Right and left prostate, from apex to base
Evidence of anti-androgen therapy:  None
Gleason score:  3 + 4 equals 7
Percent Gleason grade 4 and/or 5:  10%
Size (dominant nodule):  At least 1.3 cm
Percent of prostate involved by carcinoma:  35%
Involvement of seminal vesicle:  None
Extraprostatic extension:  None
Perineural invasion:  Present
Invasion of adjacent structures (bladder, rectum):  None
Lymphatic-vascular invasion:  Not identified
Margins:
  Bladder neck (proximal) margin:  Clear 
  Apical (distal) margin:  Clear
  Circumferential (left and right) margins:  Clear 
Regional lymph nodes (including number of nodes):  None submitted
Distant metastasis:  Unknown
High grade prostatic intraepithelial neoplasia:  Present
Other findings:  None
Pathologic grade and stage:  Gleason 7 pT2c NX (Stage IIB, if N0 and M0).",,"GrossDescription:
A. Specimen:  Irregular segment of fatty tissue.  
Weight:  2 gm.
Number of segments:  1.  
Size:  4.3 x 1.7 x 0.5 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Irregular segment of soft tan tissue.  
Weight:  Less than 1 gm.
Number of segments:  1.  
Size:  0.8 x 0.6 x 0.4 cm.
Gross findings:  0.4 x 0.4 x 0.3 cm tan-yellow calcified nodule.
Submitted for microscopic evaluation:  All.  
Cassettes:  1, for decalcification.

C. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  46 gm.
Size:
  Apex Base:  2.8 cm.
  Anterior Posterior:  2.9 cm.
  Right Left:  4.6 cm.
Lesion(s): 
  Location:  Left anterior mid-prostate to base.
  Size:  1.4 x 1 x 1 cm.
  Appearance:  Tan-yellow firm mass with ill-defined borders.
  Distance to margins:  0.4 cm from the left anterior origin.
Seminal vesicles
  Right:  2.3 x 1.2 x 0.9 cm; unremarkable.
  Left:  2.1 x 1.5 x 0.5 cm; unremarkable.
Vasa deferentia
  Right:  3.3 x 0.6 cm.
  Left:  2.5 x 0.6 cm.
Other findings:  Multiple brown to black stones weighing less than 1 gm and measuring up to 0.1 cm.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross sections through bladder neck margin
2  cross sections through apical margin
3-12  right prostate, apex to base respectively
13-22  left prostate, apex to base respectively; lesion in 17 and 19
23  right seminal vesicle and vas deferens
24  left seminal vesicle and vas deferens.",,"A: ANTERIOR FAT OF PROSTATE
B: RIGHT BLADDER NECK MARGIN
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10036966,1,REC-3000698066,"ClinicalHistory:
Prostate cancer.",,"FinalDiagnosis:
A.  RIGHT PELVIC LYMPH NODES:  NEGATIVE FOR METASTASIS (0/4)  
 
B.  LEFT PELVIC LYMPH NODE:  NEGATIVE FOR METASTASIS (0/1)  
 
C.  PROSTATE AND BILATERAL SEMINAL VESICLES:  PROSTATIC ADENOCARCINOMA

Prostate cancer information
Operative procedure:  Resection of prostate and bilateral seminal vesicles with bilateral pelvic lymph node dissections
Tumor-histologic type:  Prostatic adenocarcinoma
Multicentricity:  Unifocal  
Anatomic site (including status of apex):  Predominantly left apex and mid prostate, with extension into right prostate
Evidence of anti-androgen therapy:  Present
Gleason score:  4 + 3 equals 7 (based on prior core needle biopsy specimen ***PATH-NUMBER[1], **DATE[Jan 16 12])
Percent Gleason grade 4 and/or 5:  70-80% (based on prior core needle biopsy specimen ***PATH-NUMBER[1], **DATE[Jan 16 12])
Size (dominant nodule):  At least 2.2 cm
Percent of prostate involved by carcinoma:  15%
Involvement of seminal vesicle:  None
Extraprostatic extension:  None
Perineural invasion:  Present
Invasion of adjacent structures (bladder, rectum):  None
Lymphatic-vascular invasion:  None
Margins:
  Bladder neck (proximal) margin:  Clear 
  Apical (distal) margin:  Clear
  Circumferential (left and right) margins:  Tumor extensively involves left anterior circumferential margin 
Regional lymph nodes:  Negative for metastasis (0/5)
Distant metastasis:  Unknown
High grade prostatic intraepithelial neoplasia:  Present  
Other findings:  None
Pathologic grade and stage:  Gleason 7 pT2c pN0 (Stage IIB, if M0).",,"GrossDescription:
A. Specimen:  Irregular segment of fibrofatty tissue.  
Weight:  3 gm.
Number of segments:  1.  
Size:  3.0 x 1.5 x 1.3 cm.
Gross findings:  Four lymph nodes identified measuring up to 2.7 x 1.0 x 0.6 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, (1-single bisected lymph node, 2-remaining lymph node and fat).

B. Specimen:  Lymph node.  
Weight:  1 gm.
Number of segments:  1.  
Size:  2.9 x 1.1 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

C. Specimen:  Prostate with attached bilateral seminal vesicles and vasa differentia.
Fixative:  10% neutral buffered formalin.
Weight:  31 gm.
Size:
  Apex Base:  3.8 cm.
  Anterior Posterior:  3.5 cm.
  Right Left:  4.7 cm.
Gross findings: Homogeneous tan cut surface. No obvious mass/lesions grossly identified.
Seminal vesicles
  Right:  2.5 x 1.4 x 0.7 cm; unremarkable.
  Left:  2.2 x 0.8 x 0.6 cm; unremarkable.
Vasa deferentia
  Right:  2.5 x 0.5 cm.
  Left:  2.2 x 0.5 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal (bladder neck) margin
3  cross sections through shaved distal (apical) margin
4  right and left apical prostate
5-9  right apical to base prostate, respectively
10-14  left apical to base prostate, respectively
15  right seminal vesicle and vas deferens
16  left seminal vesicle and vas deferens.",,"A: RIGHT PELVIC LYMPH NODE
B: LEFT PELVIC LYMPH NODE
C: PROSTATE",,
REG4,PROSTATE,0,PAT-10037907,1,REC-3000698081,"ClinicalHistory:
Benign prostate hypertrophy.
Post-OperativeDiagnosis:
Same, Pending pathology.
Pre-OperativeDiagnosis:
Cystoscopy, Transuretheral resection of prostate.",,"PreOperativeDiagnosis:
Cystoscopy, Transuretheral resection of prostate.
PostOperativeDiagnosis:
Same, Pending pathology.
FinalDiagnosis:
Prostate, TURP:  PROSTATE ADENOCARCINOMA, GLEASON's 3 + 3 =6; 
      0.4 cm focus; involving 1 of 50 submitted chips.",,"GrossDescription:
Received in formalin, labeled ""prostate chips"" are numerous irregular fragments of tan-pink to brown, rubbery soft tissue, measuring in aggregate 5.5 x 5.5 x 2.5 cm and weighing 15.0 gm.  Submitted entirely in blocks 1-6.","MicroscopicDescription:
Fragments of prostate exhibit glandular and stromal hyperplasia.  Areas of mild chronic lymphocytic inflammation are present.  In one chip (slide 4), there is mild cytologic and architectural atypia.  This area is evaluated for basal cells (p63, HMWK).  These studies demonstrate an absence of basal cells, supporting focal prostate adenocarcinoma of Gleason's grade 3 + 3, measuring 0.4 cm in greatest dimension and involving 1/50 submitted chips.  No perineural invasion is evident.",A: Prostate chips,,
REG4,PROSTATE,0,PAT-01450816,1,REC-3000698234,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:

A.  LEFT APEX PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 5% OF SAMPLE. 
 
B.  LEFT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (4 + 3),
    INVOLVING 30% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    75% OF THE TUMOR. 
 
C.  LEFT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 15% OF SAMPLE.   
 
D.  RIGHT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
E.  RIGHT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4), 
    INVOLVING 20% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    10% OF THE TUMOR.  
 
F.  RIGHT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4),
    INVOLVING 30% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    40% OF THE TUMOR.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Left (apex, mid, base) and right (mid, base).
Number of cores with carcinoma:  8 of 13 core fragments.
Maximum size of carcinoma:  0.3 cm.
Percent of overall tissue involved by carcinoma:  15 to 20%.
Highest Gleason score at single site:  7 (4 + 3).
Overall Gleason score:  7 (3 + 4).
Percent of overall Gleason grade 4 and/or 5:  35 to 40%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.8 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 0.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT APEX PROSTATE
B: LEFT MID PROSTATE
C: LEFT BASE PROSTATE
D: RIGHT APEX PROSTATE
E: RIGHT MID PROSTATE
F: RIGHT BASE PROSTATE",,
REG4,PROSTATE,0,PAT-10036200,1,REC-3000698579,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:

A.  LEFT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
B.  LEFT MID PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
C.  LEFT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4), 
    INVOLVING 55% OF SAMPLE, GLEASON GRADE 4 COMPONENT COMPRISING
    35% OF THE TUMOR. 
 
D.  RIGHT APEX PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE.
 
E.  RIGHT MID PROSTATE BIOPSY:  ADENOCARCINOMA GS 7 (3 + 4),
    INVOLVING 100% OF SAMPLE, GLEASON GRADE 4 COMPONENT 
    COMPRISING 10% OF THE TUMOR. 
 
F.  RIGHT BASE PROSTATE BIOPSY:  ADENOCARCINOMA GS 8 (4 + 4), 
    INVOLVING 100% OF SAMPLE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Left (base) and right (mid, base).
Number of cores with carcinoma:  7 of 12 core fragments.
Maximum size of carcinoma:  1.0 cm.
Percent of overall tissue involved by carcinoma:  40 to 45%.
Highest Gleason score at single site:  8 (4 + 4).
Overall Gleason score:  7 (4 + 3).
Percent of Gleason grade 4 and/or 5:  50%.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Present.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  0.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 0.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Up to 1.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: LEFT APEX
B: LEFT MID
C: LEFT BASE
D: RIGHT APEX
E: RIGHT MID
F: RIGHT BASE",,
REG4,PROSTATE,0,PAT-10035265,1,REC-3000698678,"ClinicalHistory:
Urinary obstruction with enlarged prostate.
Post-OperativeDiagnosis:
Same.
Pre-OperativeDiagnosis:
TURP.",,"PreOperativeDiagnosis:
TURP.
PostOperativeDiagnosis:
Same.
FinalDiagnosis:
Prostate chips:  POORLY DIFFERENTIATED CARCINOMA CONSISTENT WITH
      PROSTATE ADENOCARCINOMA

  Operative procedure:        TURP
  Tumor histologic type:        Prostate adenocarcinoma (poorly differentiated)
  Anatomic site:          Unknown
  Percent of tissue involved by carcinoma:  80%
  Gleason's score:        10 (5+5)
  Perineural invasion:        Present
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          Lining urothelium with high grade dysplasia.
DiagnosisComment:
Dr. **NAME[ZZZ] reviewed the slides and concurred with the diagnosis. Dr. **NAME[YYY] notified.",,"GrossDescription:
Specimen received in fixative labeled with the patient's name and ""prostate chips"" consists of 35 grams of firm tan rubbery tissue fragments measuring up to 2.5 cm in maximum dimension.  Specimen is totally submitted in eleven cassettes.
(1-11) Prostate chips.","MicroscopicDescription:
The microscopic findings support the above diagnosis.  The neoplastic cells show focal positive immunohistochemical reaction to PSAP, and negative immunohistochemical reaction to CK7, CK20, PSA, p63 and Uroplakin III.",A: Prostate chips,,
REG4,PROSTATE,0,PAT-10037826,1,REC-3000698814,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:

A.  RIGHT LATERAL PROSTATE BIOPSY:  BENIGN PROSTATIC TISSUE. 
 
B.  RIGHT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING 5% OF SAMPLE.   
 
C.  LEFT SEXTANT PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3), 
    INVOLVING <5% OF SAMPLE.

D.  LEFT LATERAL PROSTATE BIOPSY:  ADENOCARCINOMA GS 6 (3 + 3),
    INVOLVING <5% OF SAMPLE.
DiagnosisComment:
PROSTATE BIOPSY INFORMATION
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic sites:  Right (sextant) and left (sextant and lateral).
Number of cores with carcinoma:  3 of 24 core fragments.
Maximum size of carcinoma:  0.26 cm.
Percent of overall tissue involved by carcinoma:  <5%.
Highest Gleason score at single site:  6 (3 + 3).
Overall Gleason score:  6 (3 + 3).
Percent of Gleason grade 4 and/or 5:  None.
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified.
Blood/lymphatic vessel invasion:  Not identified.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 2.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: PROSTATE RIGHT LAT
B: PROSTATE RIGHT SEXT
C: PROSTATE LEFT SEXT
D: PROSTATE LEFT LAT",,
REG4,PROSTATE,0,PAT-10037714,1,REC-3000698905,"ClinicalHistory:
Prostate CA.",,"FinalDiagnosis:
A.  PROSTATE:  PROSTATIC ADENOCARCINOMA, GLEASON's 7 (3+4).
 
BC. RIGHT AND LEFT PELVIC LYMPH NODES:
    8 NODES NEGATIVE FOR METASTASIS (0/8).

Prostate cancer information
Operative procedure:  Prostatectomy w/bilateral pelvic node dissection.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site: Bilateral, spanning base to apex
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4)
Percent Gleason grade 4 and/or 5:  10%.
Size (dominant nodule):  Estimate about 3 cm.
Percent of prostate involved by carcinoma:  10-20%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes:  0/8.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
Pathologic grade and stage:
   Gleason's 7 (3+4), pT2c N0 (Stage IIB if M0).",,"GrossDescription:
A. Specimen:  Prostate with attached bilateral seminal vesicles and vas deferens.
Fixative:  10% neutral buffered formalin.
Weight:  40 gm.
Size:
  Apex Base:  3.4 cm.
  Anterior Posterior:  3.0 cm.
  Right Left:  4.4 cm.
Lesion(s): 
  Location:  Right apex to base, left mid to base.
  Size:  Lesion 1-2.3 x 2.3 x 1.0 cm.  Lesion 2-2.0 x 1.2 x 1.2 cm.
  Appearance:  Lesion 1-irregular firm to rubbery tan-yellow lesion.  Lesion 2-rubbery tan-white.
  Distance to margins:  Lesion 1-0.2 cm away from the left and right anterior margins.  Lesion 2-grossly abutting the left and right anterior margins.
Seminal vesicles
  Right:  2.7 x 1.3 x 0.4 cm; unremarkable.
  Left:  2.7 x 1.3 x 0.4 cm; unremarkable.
Vasa deferentia
  Right:  3.0 x 0.5 cm.
  Left:  4.5 x 0.5 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1  cross-sections through shave proximal margin
2  cross-sections through shave distal margin
3  right apex with lesion 1
4-6  right mid (4 and 5 includes lesion 1, 6 includes lesion 1 and 2)
7-10  right base (7, 9 includes lesion 2)
11  left apex
12-14  left mid (12-13 includes lesion 1, 14 includes lesion 1 and 2
15-18  left base (15, 17 includes lesion 2)
19  right seminal vessel and vas deferens
20  left seminal vesicle and vas deferens
21-40 remainder of specimen, per photo

B. Specimen:  Lymph node with attached fat, received in formalin.  
Weight:  4 gm.
Number of segments:  1.  
Size:  3.7 x 1.7 x 1.0 cm.
Gross findings: 2 apparent lymph nodes grossly identified measuring up to 2.7 x 1.3 x 0.4
Submitted for microscopic evaluation:  All.  
Description of blocks for microscopic evaluation:
1-2  single bisected lymph node
3  remaining lymph node
4-5  remaining fatty tissue

C. Specimen:  Lymph node with attached fat, received in formalin.  
Weight:  6 gm.
Number of segments:  1.  
Size:  4.0 x 2.5 x 1.0 cm.
Gross findings: 5 apparent lymph nodes grossly identified measuring up to 1.7 x 1.0 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Description of blocks for microscopic evaluation:
1  lymph nodes
2-3  each includes a single bisected lymph node
4-6  remaining fatty tissue.",,"A: PROSTATE
B: RIGHT PELVIC LYMPH NODES
C: LEFT PELVIC LYMPH NODES",,
REG4,PROSTATE,0,PAT-10029852,1,REC-3000704885,"ClinicalHistory:
Lesion by MRI at right mid rising PSA up to 2.19 S/P cryoablation **DATE[May 21 10].",,"FinalDiagnosis:
A.   PROSTATE NEEDLE BIOPSIES (LEFT APEX):  
     PROSTATIC ADENOCARCINOMA, GLEASON's 7 (3+4), 
     INVOLVING 1 OF 4 SEGMENTS.
 
B-H. PROSTATE NEEDLE BIOPSIES (BILATERAL MID, BASE, WIDE; 
     RIGHT APEX):  BENIGN PROSTATIC TISSUE.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Left Apex.
Number of cores with carcinoma/total cores in involved area:  1/4.
Maximum size of carcinoma:  0.4-cm.
Percent of overall tissue involved by carcinoma:  5%.
Highest Gleason score at single site:  7 (3+4).
Overall Gleason score:  7 (3+4)
Percent of Gleason grade 4 and/or 5:  30%. 
Extraprostatic or seminal vesicle invasion:  Not identified.
Perineural invasion:  Not identified. 
Lymph-Vascular invasion:  Not identified. 
High grade prostatic intraepithelial neoplasia:  Not identified.
Other findings:  None.
DiagnosisComment:
Dr. **NAME[ZZZ]'s office notified and report faxed **DATE[Jan 14 2012].",,"GrossDescription:
A.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  4. 
Size:  Ranging from 0.6 to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.7 to 1.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  1. 
Size:  2.2 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.9 to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 0.3 to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  3. 
Size:  Ranging from 1.1 to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.7 to 1.6 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

H. Specimen:  Elongated tan tissue received in formalin.
Number of segments:  2. 
Size:  Ranging from 0.9 to 2.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.","MicroscopicDescription:
A.  Small segments of prostatic tissue show replacement and invasion by single separate variable glands as well as by fused glands that displays cells with prominent nucleoli.

B-H. Small segments of prostatic tissue show no evidence of malignancy.","A: PROSTATE LEFT APEX
B: PROSTATE LEFT MID
C: PROSTATE LEFT BASE
D: PROSTATE LEFT WIDE
E: PROSTATE RIGHT APEX
F: PROSTATE RIGHT MID
G: PROSTATE RIGHT BASE
H: PROSTATE RIGHT WIDE",,
REG4,PROSTATE,0,PAT-10038271,1,REC-3000705073,"ClinicalHistory:
Prostate CA.",,"FinalDiagnosis:
A.  POSTERIOR BLADDER NECK:  BENIGN FIBROMUSCULAR TISSUE;
    NEGATIVE FOR PROSTATIC GLANDS OR MALIGNANCY.
 
BC. RIGHT AND LEFT PELVIC LYMPH NODES:  
    2 NODES NEGATIVE FOR METASTASIS (0/2).
 
D.  PROSTATE:  PROSTATIC ADENOCARCINOMA.

Prostate cancer information
Operative procedure:  Prostatectomy.
Tumor-histologic type:  Prostatic adenocarcinoma.
Multicentricity:  Present.
Anatomic site (including status of apex):  Primarily right mid, 
  w/small foci at right base and apex.
Evidence of anti-androgen therapy:  Not identified.
Gleason score:  7 (3+4)
Percent Gleason grade 4 and/or 5:  30%.
Size (dominant nodule):  Estimate tumor spans 1.8 cm.
Percent of prostate involved by carcinoma:  5%.
Involvement of seminal vesicle:  Not identified.
Extraprostatic extension:  Not identified.
Perineural invasion:  Present.
Invasion of adjacent structures:  Not identified.
Lymph-Vascular invasion:  Not identified.
Margins:
  Bladder neck (proximal) margin:  Clear. 
  Apical (distal) margin:  Clear.
  Circumferential (left and right) margins:  Clear. 
Regional lymph nodes (including number of nodes):  0/2.
Distant metastasis:  Not assessed.
High grade prostatic intraepithelial neoplasia:  Present.
Other findings:  None.
Pathologic grade and stage:
   Gleason's 7 (3+4), pT2a N0 (Stage IIA if M0, PSA < 20).",,"GrossDescription:
A. Specimen:  Irregular segments of rubbery tan-red cauterized tissue.  
Weight:  Less than 1 gm.
Number of segments:  2.  
Size:  Up to 0.7 x 0.5 x 0.4 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1.

B. Specimen:  Single lymph node.  
Weight:  1 gm.
Number of segments:  1.  
Size:  3.2 x 1.2 x 0.7 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  1, lymph node is halved.

C. Specimen:  Single lymph node.  
Weight:  2 gm.
Number of segments:  1.  
Size:  3.1 x 1.3 x 0.8 cm.
Submitted for microscopic evaluation:  All.  
Cassettes:  2, lymph node is bisected and halved.

D. Specimen:  Prostate with attached bilateral seminal vesicles and vasa differentia.
Fixative:  10% neutral buffered formalin.
Weight:  75 gm.
Size:
  Apex Base:  3.7 cm.
  Anterior Posterior:  5.0 cm.
  Right Left:  5.7 cm.
Lesion(s): 
  Location:  Right apical to mid prostate.
  Size:  1.4 x 0.8 x 0.8 cm.
  Appearance:  Firm, ill-defined tan-yellow.
  Distance to margins:  0.3 cm from right posterior margin.
Seminal vesicles
  Right:  4.2 x 1.3 x 0.6 cm; unremarkable.
  Left:  2.5 x 1.4 x 0.7 cm; unremarkable.
Vasa deferentia
  Right:  3.8 x 0.5 cm.
  Left:  1.8 x 0.5 cm.
Other findings:  None.
Staining of margins:  Right - orange; left - blue; posterior - black.
Photograph:  Photograph of slices, taken.
Description of blocks for microscopic evaluation:
1-2  cross sections through shaved proximal (bladder neck) margin
3  cross sections through shaved distal (apical) margin
4-14  right apical to base prostate, respectively (lesion in 6 and 8)
15-27  left apical to base prostate, respectively
28  right seminal vesicle and vas deferens
29  left seminal vesicle and vas deferens.",,"A: POSTERIOR BLADDER NECK PERMENANT
B: RIGHT PELVIC LYMPH NODE
C: LEFT PELVIC LYMPH NODE
D: PROSTATE",,
REG4,PROSTATE,0,PAT-10034613,1,REC-3000705096,"ClinicalHistory:
Elevated PSA (790.93), prostate nodule (600.10).",,"FinalDiagnosis:
A.  CORE NEEDLE BIOPSIES, PROSTATE RIGHT BASE:  BENIGN PROSTATE TISSUE.
 
B.  CORE NEEDLE BIOPSIES, PROSTATE RIGHT MID:  BENIGN PROSTATE TISSUE.
 
C.  CORE NEEDLE BIOPSIES, PROSTATE RIGHT APEX:  PROSTATIC ADENOCARCINOMA, GLEASON 
    SCORE 8 (4 + 4), INVOLVING 3 OF MULTIPLE CORES (20-30% OF THE SPECIMEN).
 
D.  CORE NEEDLE BIOPSIES, PROSTATE LEFT BASE:  BENIGN PROSTATE TISSUE.
 
E.  CORE NEEDLE BIOPSIES, PROSTATE LEFT MID:  BENIGN PROSTATE TISSUE.
 
F.  CORE NEEDLE BIOPSIES, PROSTATE LEFT APEX:  BENIGN PROSTATE TISSUE.
 
G.  CORE NEEDLE BIOPSIES, PROSTATE CENTRAL ZONE:  BENIGN PROSTATE TISSUE.

Prostate needle biopsy information
Operative procedure:  Prostate needle biopsies.
Tumor-histologic type:  Prostatic adenocarcinoma.
Anatomic site:  Right apex.
Number of cores with carcinoma/total cores:  Right - 3/multiple.
Maximum size of carcinoma:  0.8 cm.
Percent of overall tissue involved by carcinoma:  5-10%.
Highest Gleason score at single site:  8 (4 + 4).
Overall Gleason score:  8 (4 + 4).
Percent of Gleason grade 4 and/or 5:  100%. 
Extraprostatic or seminal vesicle invasion:  None.
Perineural invasion:  None. 
Lymph-Vascular invasion:  None. 
High grade prostatic intraepithelial neoplasia:  None.
Other findings:  None.",,"GrossDescription:
A.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  5. 
Size:  Up to 1.1 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

B.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  Multiple. 
Size:  Up to 0.7 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

C.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  Multiple. 
Size:  Up to 1.4 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

D.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.3 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

E.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  2. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

F.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  4. 
Size:  Up to 1.5 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.

G.  Specimen:  Elongated tan tissue, received in formalin.
Number of segments:  4. 
Size:  Up to 1.9 cm in length. 
Submitted for microscopic evaluation:  All.
Cassettes:  1.",,"A: PROSTATE RIGHT BASE
B: PROSTATE RIGHT MID
C: PROSTATE RIGHT APEX
D: PROSTATE LEFT BASE
E: PROSTATE LEFT MID
F: PROSTATE LEFT APEX
G: PROSTATE CENTRAL ZONE",,
REG4,PROSTATE,0,PAT-10038460,1,REC-3000705267,"ClinicalHistory:
Elevated PSA.",,"FinalDiagnosis:
A.      Prostate, right apex:        PROSTATE ADENOCARCNOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Right apex
  Number of cores involved by carcinoma:  One out of two core fragments involved
  Maximum size of carcinoma:      0.6 mm
  Percent of tissue involved by carcinoma:  10%
  Gleason's score:        6 (3+3)
  Perineural invasion:        Not seen
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None

B.     Prostate, right middle gland:      Benign prostatic tissue with focal atypical small 
                acinar proliferation (ASAP)

C.      Prostate, right base:        PROSTATE ADENOCARCNOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Right base
  Number of cores involved by carcinoma:  One out of one core fragment involved
  Maximum size of carcinoma:      0.3 mm
  Percent of tissue involved by carcinoma:  <5%
  Gleason's score:        6 (3+3)
  Perineural invasion:        Not seen
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None


D.      Prostate, left apex:        PROSTATE ADENOCARCNOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Left apex
  Number of cores involved by carcinoma:  One out of one core fragment involved
  Maximum size of carcinoma:      7 mm
  Percent of tissue involved by carcinoma:  80%
  Gleason's score:        7 (3+4)
  Perineural invasion:        Not seen
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None

E.     Prostate, left mid gland:        PROSTATE ADENOCARCINOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Left mid gland  
  Number of cores involved by carcinoma:  Two out of two core fragments involved
  Maximum size of carcinoma:      7.2 mm
  Percent of tissue involved by carcinoma:  70%
  Gleason's score:        7 (4+3)
  Perineural invasion:        Present
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None

F.  Prostate, left base:          PROSTATE ADENOCARCINOMA

  Operative procedure:        Prostate needle biopsies
  Tumor histologic type:        Prostate adenocarcinoma, NOS
  Anatomic site:          Left base
  Number of cores involved by carcinoma:  One out of one core fragment involved
  Maximum size of carcinoma:      1.6 mm
  Percent of tissue involved by carcinoma:  30%
  Gleason's score:        7 (3+4)
  Perineural invasion:        Not seen
  Lymphovascular invasion:      Not seen
  High grade PIN:        Not seen
  Other findings:          None.
DiagnosisComment:
A-F. Dr. **NAME[ZZZ] reviewed the slides and concurred with the above diagnosis.",,"GrossDescription:
Six specimens are received in fixative labeled with the patient's name.
A.  Specimen labeled ""right apex"" consists of two core biopsies of white soft tissue measuring up to 0.8 cm in maximum length.  Totally submitted in one cassette.
B.  Specimen labeled ""right mid gland"" consists of two core biopsies of white soft tissue measuring up to 1.5 cm in maximum length.  Totally submitted in one cassette.
C.  Specimen labeled ""right base"" consists of one core biopsy of white soft tissue measuring 1.3 cm in length.  Totally submitted in one cassette.
D.  Specimen labeled ""left apex"" consists of one core biopsy of white soft tissue measuring 1 cm in length.  Totally submitted in one cassette.
E.  Specimen labeled ""left mid gland"" consists of two core biopsies of white soft tissue measuring up to 1.1 cm in maximum length.  Totally submitted in one cassette.
F.  Specimen labeled ""left base"" consists of one core biopsy of white soft tissue measuring 1.2 cm in length.  Totally submitted in one cassette.","MicroscopicDescription:
A-F.  The microscopic findings support the above diagnosis. P63 immunostain is conducted in A, C and D.","A: Prostate biopsy, right apex
B: Prostate biopsy, right mid
C: Prostate biopsy, right base
D: Prostate biopsy, left apex
E: Prostate biopsy, left mid
F: Prostate biopsy, left base",,